Ph	O
##os	O
##ph	O
##og	O
##lu	O
##com	O
##uta	O
##se	O
1	O
deficiency	O
,	O
previously	O
identified	O
as	O
a	O
g	B
##ly	I
##co	I
##gen	I
##osis	I
,	O
is	O
also	O
a	O
con	O
##gen	O
##ital	O
disorder	O
of	O
g	O
##ly	O
##cos	O
##yla	O
##tion	O
.	O

Basel	O
##ine	O
t	O
##rp	O
(	O
P	O
=	O
.	O
00	O
##7	O
)	O
,	O
k	O
##yn	O
/	O
t	O
##rp	O
ratio	O
(	O
P	O
##≤	O
.	O
00	O
##1	O
)	O
,	O
and	O
hip	B
##pur	I
##ic	I
acid	I
(	O
P	O
=	O
.	O
00	O
##2	O
)	O
were	O
all	O
linked	O
to	O
MAC	O
##E	O
on	O
un	O
##iva	O
##ria	O
##te	O
analysis	O
.	O

Furthermore	O
,	O
the	O
a	O
##que	O
##ous	O
and	O
v	O
##it	O
##re	O
##ous	O
humor	O
levels	O
of	O
G	O
##SS	O
##S	O
##G	O
,	O
c	B
##ys	I
##tine	I
,	O
and	O
Cy	O
##s	O
##SS	O
##H	O
were	O
correlated	O
in	O
the	O
D	O
##M	O
patients	O
,	O
but	O
not	O
in	O
the	O
controls	O
.	O

Compared	O
with	O
the	O
pure	O
DC	O
##IS	O
group	O
,	O
the	O
DC	O
##IS	O
accompanying	O
invasive	O
car	O
##cin	O
##oma	O
group	O
showed	O
higher	O
levels	O
of	O
PC	O
and	O
c	B
##rea	I
##tine	I
and	O
lower	O
levels	O
of	O
lip	O
##id	O
.	O

In	O
the	O
whole	O
group	O
,	O
beta	B
##ine	I
(	O
r	O
=	O
−	O
##0	O
.	O
144	O
,	O
p	O
=	O
0	O
.	O
12	O
)	O
and	O
L	O
##CA	O
##T	O
activity	O
(	O
r	O
=	O
0	O
.	O
07	O
##2	O
,	O
p	O
=	O
0	O
.	O
43	O
)	O
were	O
unrelated	O
to	O
age	O
,	O
but	O
P	O
##LT	O
##P	O
activity	O
tended	O
to	O
be	O
higher	O
with	O
advancing	O
age	O
(	O
r	O
=	O
0	O
.	O
164	O
,	O
p	O
=	O
0	O
.	O
07	O
##3	O
)	O
.	O

A	O
volume	O
of	O
0	O
.	O
6	O
m	O
##L	O
of	O
serum	O
was	O
placed	O
into	O
a	O
5	B
-	I
mm	I
-	I
diameter	I
tube	O
together	O
with	O
0	O
.	O
1	O
m	O
##L	O
of	O
D	O
_	O
2	O
O	O
,	O
which	O
contained	O
a	O
known	O
amount	O
of	O
f	B
##uma	I
##ric	I
acid	I
.	O

In	O
our	O
study	O
,	O
but	B
##yla	I
##mine	I
was	O
also	O
detected	O
.	O

Blood	O
samples	O
were	O
drawn	O
hourly	O
,	O
and	O
plasma	O
samples	O
were	O
collected	O
into	O
ice	O
-	O
cooled	O
he	B
##par	I
##in	I
tubes	O
and	O
cent	O
##ri	O
##fu	O
##ged	O
within	O
30	O
min	O
of	O
collection	O
for	O
10	O
min	O
at	O
1700	O
##g	O
and	O
4	O
°C	O
.	O

Down	O
-	O
regulation	O
of	O
c	O
##it	O
##rated	O
and	O
ace	B
##tate	I
may	O
support	O
disruption	O
of	O
T	O
##CA	O
cycle	O
through	O
p	B
##yr	I
##u	I
##vate	I
pathway	O
.	O

In	O
such	O
an	O
approach	O
,	O
for	O
each	O
meta	O
##bol	O
##ite	O
x	O
_	O
i	O
,	O
the	O
re	O
##gression	O
model	O
is	O
defined	O
as	O
His	B
##ti	I
##dine	I
associated	O
differential	O
module	O
(	O
sub	O
##net	O
##work	O
)	O
is	O
shown	O
,	O
where	O
the	O
red	O
nodes	O
indicate	O
up	O
##re	O
##gu	O
##lated	O
meta	O
##bol	O
##ites	O
and	O
light	O
blue	O
nodes	O
represents	O
non	O
-	O
differentiated	O
meta	O
##bol	O
##ites	O
.	O

The	O
_	O
1	O
H	O
N	O
##MR	O
and	O
_	O
13	O
C	O
N	O
##MR	O
s	O
##pect	O
##ra	O
supported	O
the	O
proposed	O
structure	O
with	O
the	O
co	B
##uma	I
##rin	I
unit	O
attached	O
to	O
the	O
3	O
position	O
of	O
5	B
-	I
o	I
##x	I
##o	I
-	I
3	I
-	I
p	I
##yr	I
##rol	I
##ine	I
(	O
AFB	O
-	O
L	O
##ys	O
)	O
.	O

O	O
##G	O
##TT	O
,	O
and	O
higher	O
concentrations	O
of	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
,	O

Am	B
##phe	I
##tamine	I
##s	I
,	O
cocaine	O
,	O
ni	B
##cot	I
##ine	I
,	O
op	O
##iate	O
##s	O
,	O
and	O
meta	O
##bol	O
##ites	O
in	O
me	O
##con	O
##ium	O
by	O
L	O
##CM	O
##SM	O
##S	O
:	O
mass	O
s	O
##pect	O
##rome	O
##ter	O
parameters	O
Bold	O
font	O
denotes	O
q	O
##uant	O
##ifier	O
transition	O
6	O
##AM	O
6	B
-	I
ace	I
##ty	I
##lm	I
##or	I
##phine	I
,	O
AM	B
##P	I
am	I
##phe	I
##tamine	I
,	O
B	O
##E	O
ben	B
##zo	I
##yle	I
##c	I
##gon	I
##ine	I
,	O
B	O
##UP	O
b	B
##up	I
##ren	I
##or	I
##phine	I
,	O
CE	O
co	B
##ca	I
##eth	I
##yle	I
##ne	I
,	O
CE	O
##n	O
collision	O
energy	O
,	O
CO	O
##C	O
cocaine	O
,	O
CO	O
##T	O
co	B
##tin	I
##ine	I
,	O
CO	O
##D	O
code	B
##ine	I
,	O
C	O
##X	O
##P	O
cell	O
exit	O
potential	O
,	O
D	O
##P	O
de	O
##c	O
##luster	O
##ing	O
potential	O
,	O
E	O
##D	O
##DP	O
2	B
-	I
et	I
##hyl	I
##iden	I
##e	I
-	I
1	I
,	I
5	I
-	I
dim	I
##eth	I
##yl	I
-	I
3	I
,	I
3	I
-	I
dip	I
##hen	I
##yl	I
##py	I
##rro	I
##lid	I
##ine	I
,	O
F	O
##P	O
focusing	O
potential	O
,	O
H	O
##Y	O
##C	O
h	B
##ydro	I
##co	I
##don	I
##e	I
,	O
H	O
##Y	O
##M	O
h	B
##ydro	I
##mor	I
##phone	I
,	O
MA	O
##MP	O
met	B
##ham	I
##phe	I
##tamine	I
,	O
m	O
##OH	O
##BE	O
m	B
-	I
h	I
##ydro	I
##xy	I
##ben	I
##oy	I
##le	I
##c	I
##gon	I
##ine	I
,	O
M	O
##OR	O
m	B
##or	I
##phine	I
,	O
M	O
##T	O
##D	O
met	B
##had	I
##one	I
,	O
N	O
##B	O
##UP	O
nor	B
##bu	I
##p	I
##ren	I
##or	I
##phine	I
,	O
N	O
##IC	O
ni	B
##cot	I
##ine	I
,	O
OH	O
##CO	O
##T	O
trans	B
-	I
3	I
′	I
-	I
h	I
##ydro	I
##xy	I
##cot	I
##ini	I
##ne	I
,	O
O	B
##X	I
##Y	I
o	I
##xy	I
##co	I
##don	I
##e	I
,	O
p	O
##OH	O
##MA	O
##MP	O
p	B
-	I
h	I
##ydro	I
##xy	I
##met	I

P	O
##las	O
##ma	O
glucose	S
and	O
A	O
##po	O
##B	O
levels	O
were	O
also	O
measured	O
.	O

Therefore	O
,	O
GA	B
##BA	I
might	O
play	O
a	O
role	O
in	O
the	O
de	O
##ter	O
##ior	O
##ation	O
or	O
mat	O
##ast	O
##asis	O
of	O
es	O
##op	O
##hage	O
##al	O
cancer	O
.	O

A	O
high	O
positive	O
peak	O
(	O
correlation	O
)	O
belongs	O
to	O
a	O
corresponding	O
peak	O
in	O
the	O
N	O
##MR	O
spectrum	O
of	O
a	O
meta	O
##bol	O
##ite	O
that	O
has	O
a	O
relatively	O
high	O
concentration	O
in	O
the	O
Type	O
2	O
diabetes	O
me	O
##lli	O
##tus	O
(	O
T	O
##2	O
##DM	O
)	O
place	O
##bo	O
-	O
treated	O
group	O
,	O
and	O
a	O
relative	O
low	O
concentration	O
in	O
the	O
T	O
##2	O
##DM	O
r	B
##os	I
##ig	I
##lit	I
##az	I
##one	I
(	O
RS	O
##G	O
)	O
-	O
treated	O
group	O
.	O

Among	O
try	B
##pt	I
##op	I
##han	I
metabolism	O
-	O
associated	O
genes	O
,	O
only	O
T	O
##P	O
##H1	O
,	O
but	O
not	O
ID	O
##O	O
##1	O
,	O
was	O
significantly	O
down	O
##re	O
##gu	O
##lated	O
in	O
MI	O
##BC	O
compared	O
to	O
controls	O
(	O
p	O
=	O
0	O
.	O
00	O
##1	O
)	O
.	O

All	O
AA	O
standards	O
,	O
HP	O
##LC	O
-	O
MS	O
grade	O
form	B
##ic	I
acid	I
,	O
and	O
am	B
##mon	I
##ium	I
format	I
##e	I
were	O
purchased	O
from	O
Sigma	O
Al	O
##dric	O
##h	O
(	O
St	O
.	O
Louis	O
,	O
M	O
##O	O
,	O
USA	O
)	O
.	O

Ta	O
presented	O
lower	O
values	O
for	O
hip	B
##pur	I
##ic	I
acid	I
compared	O
to	O
control	O
or	O
T	O
##1	O
tumors	O
and	O
it	O
seemed	O
that	O
primary	O
tumors	O
had	O
lower	O
hip	B
##pur	I
##ic	I
acid	I
values	O
than	O
re	O
##current	O
or	O
control	O
urine	O
##s	O
.	O

On	O
the	O
other	O
hand	O
,	O
all	O
methods	O
were	O
successful	O
in	O
detect	O
##ing	O
format	B
##e	I
(	O
which	O
corresponds	O
to	O
a	O
strong	O
association	O
signal	O
)	O
and	O
this	O
is	O
reflected	O
by	O
the	O
concentration	O
of	O
low	O
p	O
-	O
values	O
in	O
the	O
format	B
##e	I
region	O
(	O
8	O
.	O
46	O
pp	O
##m	O
)	O
.	O

The	O
u	O
##rina	O
##ry	O
concentrations	O
were	O
normal	O
##ized	O
to	O
the	O
levels	O
of	O
c	B
##rea	I
##tin	I
##ine	I
(	O
meta	O
##bol	O
##ite	O
μ	O
##M	O
/	B
c	B
##rea	I
##tin	I
##ine	I
m	O
##M	O
)	O
;	O
see	O
Su	O
##pp	O
##lement	O
##ary	O
Method	O
##s	O
.	O

By	O
comparing	O
R	O
##h	O
##30	O
cells	O
with	O
my	O
##ocytes	O
in	O
terms	O
of	O
the	O
_	O
13	O
C	B
-	I
ma	I
##late	I
is	O
##oto	O
##po	O
##mer	O
patterns	O
in	O
Fi	O
##g	O
.	O

They	O
found	O
,	O
as	O
we	O
did	O
,	O
that	O
3	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
correlated	O
with	O
the	O
later	O
development	O
of	O
se	O
##psis	O
.	O

Na	O
##gas	O
##awa	O
et	O
al	O
.	O
showed	O
that	O
so	O
##y	O
protein	O
is	O
##olate	O
##s	O
control	O
the	O
gene	O
expression	O
in	O
ad	O
##ip	O
##ose	O
tissue	O
and	O
effectively	O
regulate	O
ad	O
##ip	O
##ogen	O
##esis	O
,	O
which	O
results	O
in	O
a	O
lower	O
t	B
##rig	I
##ly	I
##cer	I
##ide	I
content	O
in	O
ad	O
##ip	O
##ose	O
tissue	O
[	O
,	O
]	O
.	O

The	O
only	O
literature	O
we	O
found	O
relating	O
I	O
##AA	O
to	O
ps	O
##ych	O
##ia	O
##try	O
research	O
included	O
early	O
studies	O
in	O
severely	O
depressed	O
patients	O
,	O
showing	O
no	O
change	O
in	O
u	O
##rina	O
##ry	O
ex	O
##cre	O
##tion	O
of	O
I	O
##AA	O
throughout	O
the	O
stages	O
of	O
disease	O
and	O
recovery	O
,	O
despite	O
a	O
drop	O
in	O
try	B
##pta	I
##mine	I
ex	O
##cre	O
##tion	O
or	O
plasma	O
try	B
##pt	I
##op	I
##han	I
.	O

Ace	B
##to	I
##ace	I
##tate	I
,	O
g	B
##lut	I
##amine	I
,	O
as	B
##par	I
##agi	I
##ne	I
,	O
and	O
c	B
##ys	I
##tein	I
##e	I
had	O
relatively	O
high	O
AU	O
##C	O
values	O
,	O
se	O
##ns	O
##iti	O
##vi	O
##ties	O
,	O
and	O
specific	O
##ities	O
in	O
distinguishing	O
early	O
stage	O
CR	O
##C	O
patients	O
from	O
HC	O
##s	O
.	O

p	O
-	O
C	O
##res	O
##ol	O
and	O
its	O
g	B
##lu	I
##cu	I
##ron	I
##ide	I
were	O
present	O
at	O
higher	O
concentrations	O
both	O
in	O
pre	O
-	O
surgery	O
patients	O
compared	O
to	O
post	O
-	O
surgery	O
counterparts	O
and	O
in	O
later	O
stages	O
of	O
the	O
disease	O
(	O
and	O
)	O
.	O

(	O
L	O
##C	O
-	O
FA	O
##C	O
##o	O
##As	O
)	O
,	O
di	B
##acy	I
##l	I
##gly	I
##cer	I
##ol	I
(	O
D	O
##AG	O
)	O
,	O
and	O
c	B
##era	I
##mi	I
##des	I
.	O

[	O
95	O
%	O
C	O
##I	O
0	O
.	O
54	O
,	O
0	O
.	O
78	O
]	O
)	O
and	O
ta	B
##uri	I
##ne	I
(	O
H	O
##R	O
0	O
.	O
73	O
[	O
95	O
%	O
C	O
##I	O
0	O
.	O
59	O
,	O
0	O
.	O
90	O
]	O
)	O
and	O
higher	O
for	O
1	O
SD	O
increase	O
in	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
(	O
H	O
##R	O
1	O
.	O
35	O
[	O
95	O
%	O
C	O
##I	O
1	O
.	O
11	O
,	O
1	O
.	O
65	O
]	O
)	O
after	O
adjusting	O
for	O
con	O
##found	O
##ers	O
.	O

The	O
ch	B
##olin	I
##e	I
meta	O
##bol	O
##ites	O
are	O
inter	O
##con	O
##verted	O
by	O
a	O
complex	O
network	O
of	O
reactions	O
termed	O
the	O
Kennedy	O
Path	O
##way	O
.	O

For	O
the	O
targeted	O
analysis	O
of	O
none	O
##ster	O
##ified	O
fatty	O
acids	O
,	O
o	B
##xy	I
##lip	I
##ins	I
,	O
a	B
##cy	I
##lam	I
##ides	I
,	O
and	O
mon	B
##oa	I
##cy	I
##l	I
##gly	I
##cer	I
##ols	I
in	O
plasma	O
,	O
compiled	O
results	O
were	O
obtained	O
from	O
a	O
study	O
designed	O
to	O
assess	O
the	O
roles	O
of	O
lip	O
##ids	O
and	O
hormones	O
in	O
regulating	O
blood	O
pressure	O
in	O
subjects	O
with	O
varying	O
amounts	O
of	O
body	O
fat	O
.	O

The	O
metabolism	O
of	O
the	O
immune	O
system	O
(	O
F	O
##c	O
e	O
##ps	O
##ilon	O
R	B
##I	I
signaling	O
pathway	O
and	O
F	O
##c	O
gamma	O
R	O
-	O
mediated	O
p	O
##ha	O
##go	O
##cy	O
##tosis	O
)	O
and	O
3	O
aspects	O
of	O
the	O
lip	O
##id	O
system	O
(	B
s	B
##phi	I
##ngo	I
##lip	I
##id	I
metabolism	O
,	O
a	B
##rac	I
##hi	I
##don	I
##ic	I
acid	I
metabolism	O
,	O
and	O
s	O
##tero	O
##id	O
hormone	O
bio	O
##sy	O
##nt	O
##hesis	O
)	O
were	O
all	O
increased	O
.	O

The	O
increase	O
in	O
the	O
concentration	O
of	O
su	B
##cci	I
##nic	I
,	O
α	B
-	I
k	I
##eto	I
##g	I
##lut	I
##ari	I
##c	I
,	O
and	O
f	O
##uma	O
##ric	O
acids	O
in	O
the	O
blood	O
suggests	O
that	O
the	O
in	O
##hibition	O
of	O
de	O
##hy	O
##dr	O
##ogen	O
##ases	O
occurs	O
in	O
the	O
part	O
of	O
the	O
T	O
##CA	O
cycle	O
that	O
involves	O
the	O
successive	O
oxidation	O
of	O
α	B
-	I
k	I
##eto	I
##g	I
##lut	I
##ari	I
##c	I
into	O
su	B
##cci	I
##nic	I
acid	I
and	O
then	O
su	B
##cci	I
##nic	I
into	O
f	B
##uma	I
##ric	I
acid	I
.	O

Inc	O
##reased	O
levels	O
of	O
3	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
involved	O
in	O
but	B
##ano	I
##ate	I
metabolism	O
,	O
indicate	O
up	O
##re	O
##gu	O
##lation	O
of	O
the	O
synthesis	O
of	O
k	B
##eton	I
##e	I
bodies	O
.	O

For	O
V	O
##LD	O
##L	O
,	O
corresponding	O
to	O
the	O
highest	O
chemical	O
shifts	O
in	O
met	O
##hyl	O
and	O
met	B
##hyl	I
##ene	I
resonance	O
##s	O
,	O
no	O
differences	O
were	O
found	O
.	O

Dec	O
##rea	O
##sing	O
he	B
##x	I
##ose	I
concentration	O
during	O
storage	O
due	O
to	O
g	O
##ly	O
##co	O
##lysis	O
,	O
especially	O
at	O
R	O
##T	O
,	O
is	O
consistent	O
with	O
the	O
literature	O
.	O

For	O
u	B
##ro	I
##bil	I
##ino	I
##gen	I
,	O
the	O
two	O
curves	O
for	O
each	O
condition	O
correspond	O
to	O
the	O
positive	O
and	O
negative	O
ion	O
##ization	O
modes	O
Furthermore	O
,	O
11	O
meta	O
##bol	O
##ites	O
whose	O
variations	O
related	O
to	O
bacterial	O
contamination	O
had	O
not	O
been	O
described	O
previously	O
were	O
observed	O
in	O
our	O
L	O
##C	O
/	O
MS	O
data	O
sets	O
:	O
trim	B
##eth	I
##yla	I
##mine	I
oxide	I
,	O
2	B
-	I
h	I
##ydro	I
##xy	I
-	I
3	I
-	I
met	I
##hyl	I
##but	I
##yric	I
acid	I
,	O
met	B
##hyl	I
##gua	I
##nos	I
##ine	I
,	O
met	B
##hyl	I
##ino	I
##sin	I
##e	I
,	O
g	B
##lut	I
##amine	I
,	O
dim	B
##eth	I
##yl	I
##gua	I
##nos	I
##ine	I
,	O
ch	B
##olic	I
acid	I
,	O
v	B
##ali	I
##ne	I
,	O
3	B
-	I
met	I
##hyl	I
-	I
2	I
-	I
o	I
##x	I
##ova	I
##ler	I
##ic	I
acid	I
,	O
an	O
is	O
##omer	O
of	O
an	B
##ili	I
##ne	I
,	O
and	O
N	B
-	I
ace	I
##ty	I
##l	I
##cy	I
##ti	I
##dine	I
(	O
Table	O
;	O
Figure	O
,	O
and	O
graphs	O
provided	O
as	O
supplement	O
##ary	O
material	O
6	O
)	O
.	O

PC	O
a	O
##a	O
C	B
##32	I
:	I
3	I
;	O
38	O
.	O

Similarly	O
,	O
f	O
##usa	O
##rus	O
##ide	O
(	O
46	O
)	O
,	O
and	O
a	O
known	O
meta	O
##bol	O
##ite	O
(	B
2	I
##S	I
,	I
[UNK]	O
,	I
3	I
##R	I
,	I
[UNK]	O
,	I
4	I
##E	I
,	I
8	I
##E	I
)	I
-	I
1	I
-	I
O	I
-	I
beta	I
-	I
D	I
-	I
g	I
##lu	I
##copy	I
##rano	I
##sy	I
##l	I
-	I
2	I
-	I
N	I
-	I
(	I
[UNK]	O
-	I
h	I
##ydro	I
##xy	I
-	I
[UNK]	O
-	I
o	I
##ct	I
##ade	I
##ce	I
##noy	I
##l	I
)	I
-	I
3	I
-	I
h	I
##ydro	I
##xy	I
-	I
9	I
-	I
met	I
##hyl	I
-	I
4	I
,	I
8	I
-	I
s	I
##phi	I
##nga	I
##die	I
##nine	I
(	O
47	O
)	O
both	O
showing	O
strong	O
anti	O
##ba	O
##cter	O
##ial	O
(	O
MI	O
##C	O
1	O
.	O
9	O
–	O
7	O
.	O
8	O
##μ	O
##g	O
/	O
m	O
##L	O
)	O
activity	O
were	O
isolated	O
from	O
a	O
ch	B
##lor	I
##of	I
##orm	I
-	I
met	I
##han	I
##ol	I
extract	O
of	O
Fu	O
##sar	O
##ium	O
s	B
##p	I
.	O

Clinical	O
information	O
collected	O
on	O
the	O
RA	O
disease	O
co	O
##hor	O
##t	O
included	O
body	O
mass	O
index	O
;	O
RA	O
disease	O
duration	S
;	O
RA	O
disease	O
activity	O
(	O
Disease	O
Act	O
##ivity	O
Score	O
in	O
28	O
joints	O
[	O
D	O
##AS	O
##28	O
]	O
)	O
;	O
se	O
##rop	O
##os	O
##iti	O
##vity	O
status	O
;	O
disease	O
-	O
modify	O
##ing	O
anti	O
##r	O
##he	O
##umatic	O
drug	O
treatment	O
;	O
and	O
C	O
##V	O
risk	O
factors	O
,	O
including	O
history	O
of	O
diabetes	O
me	O
##lli	O
##tus	O
,	O
s	O
##ys	O
##to	O
##lic	O
h	O
##yper	O
##tens	O
##ion	O
,	O
d	O
##ys	O
##lip	O
##ide	O
##mia	O
,	O
smoking	O
,	O
and	O
prior	O
history	O
of	O
C	O
##VD	O
(	O
defined	O
as	O
my	O
##oc	O
##ard	O
##ial	O
in	O
##far	O
##ction	O
,	O
stroke	O
,	O
co	O
##rona	O
##ry	O
artery	O
disease	O
,	O
con	O
##ges	O
##tive	O
heart	O
failure	O
,	O
or	O
v	O
##al	O
##vu	O
##lar	O
disease	O
and	O
replacement	O
)	O
.	O

Cross	O
-	O
contamination	O
of	O
CS	O
##F	O
by	O
diffusion	O
of	O
ethanol	S
through	O
air	O
.	O

Red	O
meat	O
is	O
also	O
thought	O
to	O
increase	O
the	O
levels	O
of	O
su	B
##lf	I
##ate	I
producing	O
bacteria	O
which	O
are	O
able	O
to	O
use	O
the	O
sulfur	O
residues	O
from	O
meat	O
.	O

The	O
status	O
of	O
N	B
##AD	I
reduction	O
(	O
N	O
##AD	O
##H	O
_	O
2	O
/	O
N	O
##AD	O
_	O
+	O
)	O
of	O
the	O
b	O
##oar	O
sperm	O
##ato	O
##zo	O
##a	O
was	O
measured	O
as	O
the	O
potential	O
to	O
reduce	O
re	O
##sa	O
##zu	O
##rin	O
into	O
re	O
##sor	O
##uf	O
##in	O
,	O
as	O
described	O
earlier	O
.	O

The	O
residue	O
was	O
first	O
re	O
##con	O
##stituted	O
in	O
80	O
μ	O
##L	O
of	O
met	B
##ho	I
##xy	I
##amine	I
(	O
15	O
mg	O
/	O
m	O
##L	O
in	O
p	B
##yr	I
##id	I
##ine	I
)	O
,	O
v	O
##ortex	O
##ed	O
for	O
30	O
seconds	O
,	O
and	O
kept	O
at	O
37	O
##°	O
##C	O
for	O
90	O
minutes	O
.	O

The	O
meta	O
##bol	O
##omi	O
##cs	O
analysis	O
of	O
serum	O
showed	O
lower	O
le	B
##uc	I
##ine	I
and	O
is	B
##ole	I
##uc	I
##ine	I
and	O
higher	O
beta	B
##ine	I
and	O
N	B
,	I
N	I
-	I
dim	I
##eth	I
##yl	I
##gly	I
##cine	I
levels	O
after	O
RB	O
than	O
W	O
##B	O
intake	O
.	O

This	O
study	O
suggested	O
that	O
sa	B
##rc	I
##os	I
##ine	I
could	O
be	O
a	O
potential	O
pro	O
##gno	O
##stic	O
bio	O
##mark	O
##er	O
that	O
could	O
be	O
detected	O
non	O
-	O
invasive	O
##ly	O
in	O
the	O
urine	O
and	O
may	O
be	O
a	O
useful	O
approach	O
to	O
follow	O
PC	O
##a	O
disease	O
progression	O
.	O

The	O
u	O
##rina	O
##ry	O
levels	O
of	O
p	B
##hen	I
##yla	I
##ce	I
##ty	I
##l	I
##g	I
##lut	I
##amine	I
have	O
been	O
used	O
to	O
monitor	O
sur	O
##rogate	O
liver	O
g	B
##lut	I
##ama	I
##te	I
and	O
to	O
investigate	O
a	O
liver	O
c	B
##it	I
##ric	I
acid	I
cycle	O
intermediate	O
.	O

B	O
##rief	O
##ly	O
,	O
1	O
plasma	O
al	O
##iq	O
##uo	O
##t	O
was	O
used	O
for	O
di	O
##lut	O
##ed	O
plasma	O
_	O
1	O
H	O
N	O
##MR	O
analysis	O
(	O
250	O
μ	O
##L	O
was	O
di	O
##lut	O
##ed	O
into	O
75	O
##5	O
μ	O
##L	O
final	O
mixture	O
of	O
500	O
μ	O
##L	O
0	O
.	O
9	O
%	O
sa	B
##line	I
in	O
D	O
_	O
2	O
O	O
and	O
5	O
μ	O
##L	O
100	O
m	O
##M	O
sodium	B
3	I
-	I
(	I
trim	I
##eth	I
##yl	I
##si	I
##ly	I
##l	I
)	I

Our	O
R	B
##P	I
UP	O
##LC	O
-	O
MS	O
(	O
E	O
##SI	O
##−	O
)	O
results	O
showed	O
that	O
l	B
##ys	I
##o	I
##P	I
##E	I
(	I
18	I
:	I
0	I
)	I
and	O
l	B
##ys	I
##o	I
##PA	I
(	I
20	I
:	I
0	I
)	I
were	O
higher	O
in	O
serum	O
which	O
is	O
more	O
consistent	O
with	O
studies	O
that	O
used	O
fast	O
##ing	O
samples	O
(	O
;	O
;	O
)	O
.	O

An	O
impact	O
value	O
greater	O
than	O
0	O
.	O
10	O
indicates	O
that	O
the	O
altered	O
pathways	O
clearly	O
affect	O
A	B
##F	I
,	O
so	O
we	O
filtered	O
out	O
5	O
metabolic	O
pathways	O
(	B
‘	B
ta	I
##uri	I
##ne	I
and	O
h	B
##y	I
##pot	I
##au	I
##rine	I
metabolism	O
’	O
,	O
‘	B
D	I
-	I
g	I
##lut	I
##amine	I
and	O
D	B
-	I
g	I
##lut	I
##ama	I
##te	I
metabolism	O
’	O
,	O
‘	B
a	I
##rg	I
##ini	I
##ne	I
and	O
pro	B
##line	I
metabolism	O
’	O
,	O
‘	B
pan	I
##to	I
##the	I
##nate	I
and	O
Co	O
##A	O
bio	O
##sy	O
##nt	O
##hesis	O
’	O
,	O
and	O
‘	B
his	I
##ti	I
##dine	I
metabolism	O
’	O
)	O
in	O
the	O
at	O
##rial	O
app	O
##end	O
##age	O
samples	O
and	O
3	O
metabolic	O
pathways	O
(	B
‘	B
v	I
##ali	I
##ne	I
,	O
le	B
##uc	I
##ine	I
and	O
is	B
##ole	I
##uc	I
##ine	I
bio	O
##sy	O
##nt	O
##hesis	O
’	O
,	O
‘	O
p	O
##yr	O
##u	O
##vate	O
metabolism	O
’	O
,	O
and	O
‘	B
D	I
-	I
g	I
##lut	I
##amine	I
and	O
D	B
-	I
g	I
##lut	I
##ama	I
##te	I
metabolism	O
’	O
)	O
in	O
the	O
plasma	O
samples	O
.	O

B	O
##rief	O
##ly	O
,	O
the	O
plasma	O
(	O
40	O
μ	O
##L	O
)	O
was	O
de	O
##p	O
##rote	O
##ini	O
##zed	O
with	O
cold	O
ace	O
##ton	O
##it	O
##ril	O
##e	O
(	O
1	O
:	O
3	O
,	O
−	O
##20	O
##°	O
##C	O
)	O
,	O
followed	O
by	O
a	O
two	O
-	O
step	O
der	O
##iva	O
##ti	O
##zation	O
:	O
(	O
i	O
)	O
met	O
##ho	O
##xi	O
##mation	O
with	O
O	B
-	I
Met	I
##ho	I
##xy	I
##amine	I
h	I
##ydro	I
##ch	I
##lor	I
##ide	I
in	O
p	B
##yr	I
##id	I
##ine	I
(	O
15	O
mg	O
/	O
m	O
##L	O
,	O
room	O
temperature	O
,	O
16	O
h	O
)	O
followed	O
by	O
(	O
ii	O
)	O
si	O
##ly	O
##lation	O
with	O
BS	O
##TF	O
##A	O
containing	O
1	O
%	O
T	O
##MC	O
##S	O
(	O
70	O
##°	O
##C	O
,	O
1	O
h	O
)	O
.	O

However	O
,	O
a	O
recent	O
study	O
by	O
also	O
supports	O
our	O
findings	O
regarding	O
the	O
lack	O
of	O
correlation	O
between	O
p	O
##yre	O
##ne	O
(	O
gas	O
+	O
part	O
##iculate	O
phase	O
)	O
with	O
the	O
1	B
-	I
h	I
##ydro	I
##xy	I
##py	I
##rene	I
meta	O
##bol	O
##ite	O
in	O
urine	O
.	O

The	O
pH	O
of	O
tested	O
mobile	O
phase	O
with	O
0	O
.	O
1	O
%	O
FA	S
,	O
0	O
.	O
1	O
%	O
H	O
##OA	O
##c	O
,	O
10	O
##m	O
##M	O
A	B
##F	I
and	O
20	O
##m	O
##M	O
A	B
##F	I
were	O
2	O
.	O
81	O
,	O
3	O
.	O
51	O
,	O
6	O
.	O
21	O
and	O
6	O
.	O
45	O
,	O
respectively	O
.	O

In	O
##tra	O
-	O
t	O
##umour	O
##al	O
genetic	O
alterations	O
in	O
K	B
##P	I
enzymes	O
have	O
been	O
reported	O
in	O
various	O
cancer	O
types	O
.	O

In	O
a	O
first	O
test	O
,	O
we	O
used	O
the	O
same	O
volume	O
of	O
1	O
m	O
##L	O
CH	O
##C	O
##l	O
_	O
3	O
for	O
the	O
extraction	O
step	O
(	O
as	O
used	O
in	O
our	O
current	O
protocol	O
)	O
and	O
observed	O
that	O
for	O
80	O
%	O
Me	B
##OH	I
,	O
no	O
phase	O
separation	O
occurred	O
,	O
as	O
seen	O
in	O
Figure	O
S	O
##1	O
.	O

It	O
is	O
noteworthy	O
that	O
in	O
the	O
k	B
##eto	I
##cona	I
##zo	I
##le	I
arm	O
,	O
patients	O
received	O
k	B
##eto	I
##cona	I
##zo	I
##le	I
and	O
pre	B
##dn	I
##ison	I
##e	I
.	O

On	O
a	O
concentrated	O
glucose	S
sample	O
(	O
100	O
m	O
##M	O
)	O
,	O
the	O
original	O
P	O
##UR	O
##GE	O
shows	O
sensitivity	O
to	O
gradient	O
imp	O
##er	O
##fect	O
##ions	O
,	O
which	O
causes	O
line	O
shape	O
distortion	O
##s	O
(	O
b	O
)	O
,	O
while	O
the	O
op	O
##ti	O
##mized	O
P	O
##UR	O
##GE	O
shows	O
good	O
line	O
shape	O
and	O
base	O
##line	O
without	O
modification	O
of	O
the	O
water	O
peak	O
(	O
c	O
)	O
.	O

(	O
2019	O
)	O
demonstrated	O
that	O
end	O
##op	O
##hy	O
##tic	O
Fu	O
##sar	O
##ium	O
s	B
##p	I
.	O

t	O
##C	O
##ho	O
is	O
a	O
composite	O
peak	O
that	O
contains	O
resonance	O
from	O
several	O
ch	B
##olin	I
##e	I
containing	O
compounds	O
like	O
PC	O
##ho	O
,	O
free	O
Cho	O
,	O
and	O
GP	B
##C	I
and	O
its	O
increase	O
during	O
ma	O
##li	O
##gna	O
##ncy	O
indicates	O
increased	O
synthesis	O
of	O
cellular	O
membrane	O
##s	O
.	O

Here	O
,	O
we	O
found	O
that	O
met	B
##hi	I
##oni	I
##ne	I
had	O
significant	O
##s	O
association	O
with	O
E	O
##DS	O
##S	O
,	O
disease	O
duration	S
,	O
and	O
the	O
size	O
of	O
spinal	O
cord	O
and	O
third	O
vent	O
##ric	O
##le	O
,	O
but	O
no	O
association	O
with	O
age	O
##ing	O
.	O

There	O
is	O
a	O
significant	O
increase	O
of	O
test	B
##osterone	I
-	I
d	I
_	I
2	I
(	O
p	O
=	O
0	O
.	O
01	O
##1	O
)	O
when	O
the	O
met	B
##han	I
##ol	I
-	I
ethanol	I
method	O
is	O
used	O
.	O

Statistical	O
##ly	O
significant	O
differences	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
between	O
groups	O
were	O
seen	O
with	O
the	O
following	O
meta	O
##bol	O
##ites	O
:	O
u	B
##ric	I
acid	I
,	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
and	O
g	B
##lut	I
##ami	I
##c	I
acid	I
were	O
higher	O
in	O
plasma	O
from	O
cases	O
,	O
while	O
L	B
-	I
try	I
##pt	I
##op	I
##han	I
and	O
ad	B
##eno	I
##sin	I
##e	I
-	I
5	I
′	I
-	I
dip	I
##hos	I
##phate	I
(	O
AD	O
##P	O
)	O
were	O
lower	O
;	O
u	B
##ric	I
acid	I
and	O
L	B
-	I
his	I
##ti	I
##dine	I
were	O
lower	O
in	O
urine	O
from	O
cases	O
.	O

Although	O
we	O
could	O
not	O
confirm	O
re	O
##nal	O
abnormal	O
##ities	O
as	O
a	O
diagnosis	O
for	O
the	O
subjects	O
that	O
are	O
in	O
the	O
bio	O
##psy	O
control	O
group	O
,	O
our	O
observations	O
prompted	O
us	O
to	O
investigate	O
abnormal	O
protein	O
-	O
to	O
-	O
c	O
##rea	O
##tin	O
##ine	O
ratio	O
in	O
relation	O
to	O
est	B
##rogen	I
concentrations	O
.	O

L	B
##D	I
##L	I
ch	I
##ole	I
##ster	I
##ol	I
was	O
calculated	O
in	O
62	O
T	O
##2	O
##DM	O
subjects	O
and	O
in	O
53	O
non	O
-	O
di	O
##abe	O
##tic	O
subjects	O
.	O

As	O
H	O
##BS	O
##S	O
contains	O
1	O
g	O
/	O
L	O
D	B
-	I
glucose	I
and	O
e	O
##ja	O
##culate	O
volumes	O
were	O
varied	O
,	O
the	O
ex	O
##ogen	O
##ous	O
glucose	S
concentration	O
and	O
its	O
influence	O
on	O
subsequent	O
multi	O
##var	O
##iate	O
statistical	O
analysis	O
(	O
MV	O
##SA	O
)	O
was	O
unpredictable	O
.	O

Still	O
,	O
future	O
studies	O
controlling	O
for	O
alcohol	O
consumption	O
may	O
support	O
c	B
##it	I
##rate	I
as	O
a	O
u	O
##rina	O
##ry	O
bio	O
##mark	O
##er	O
of	O
pan	O
##cre	O
##ati	O
##tis	O
.	O

S	B
##phi	I
##ngo	I
##my	I
##elin	I
major	O
species	O
in	O
healthy	O
corn	O
##eas	O
and	O
di	O
##abe	O
##tics	O
(	O
n	O
>	O
=	O
3	O
per	O
group	O
)	O
.	O

3	O
##M	O
##2	O
##O	O
is	O
located	O
further	O
upstream	O
in	O
the	O
v	B
##ali	I
##ne	I
degradation	O
pathway	O
than	O
3	O
##H	O
##IB	O
.	O

Based	O
on	O
this	O
evidence	O
,	O
it	O
is	O
believed	O
that	O
poor	O
M	B
##T	I
##BE	I
repeat	O
##ability	O
observed	O
in	O
our	O
study	O
may	O
not	O
arise	O
from	O
the	O
extraction	O
method	O
itself	O
,	O
but	O
from	O
poor	O
match	O
between	O
the	O
composition	O
of	O
M	B
##T	I
##BE	I
extract	O
and	O
R	B
##P	I
and	O
mixed	O
-	O
mode	O
L	O
##C	O
separation	O
methods	O
employed	O
in	O
this	O
study	O
which	O
would	O
not	O
adequately	O
separate	O
lip	O
##ids	O
extracted	O
by	O
M	B
##T	I
##BE	I
.	O

Based	O
on	O
the	O
human	O
meta	O
##bol	O
##ome	O
database	O
(	O
HM	O
##D	O
##B	O
)	O
,	O
2	B
-	I
p	I
##hen	I
##yla	I
##ce	I
##tam	I
##ide	I
is	O
an	O
intermediate	O
in	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
metabolism	O
.	O

Indeed	O
,	O
K	O
##Y	O
##N	O
level	O
at	O
day	O
7	O
was	O
almost	O
doubled	O
in	O
28	O
-	O
day	O
N	O
##S	O
compared	O
to	O
S	O
.	O
To	O
date	O
a	O
clear	O
relation	O
has	O
been	O
made	O
between	O
accelerated	O
try	B
##pt	I
##op	I
##han	I
cat	O
##ab	O
##olis	O
##m	O
along	O
the	O
K	O
##Y	O
##N	O
pathway	O
and	O
inflammatory	O
reactions	O
.	O

To	O
estimate	O
the	O
clinical	O
relevance	O
of	O
our	O
findings	O
,	O
the	O
OR	O
##s	O
for	O
being	O
diagnosed	O
with	O
pan	O
##cre	O
##atic	O
cancer	O
within	O
the	O
follow	O
-	O
up	O
time	O
was	O
calculated	O
for	O
an	O
individual	O
with	O
meta	O
##bol	O
##ite	O
levels	O
of	O
1	O
SD	O
below	O
the	O
mean	O
:	O
these	O
OR	O
##s	O
amounted	O
to	O
1	O
.	O
42	O
and	O
1	O
.	O
45	O
for	O
g	B
##lut	I
##amine	I
and	O
his	B
##ti	I
##dine	I
,	O
respectively	O
(	O
see	O
foot	O
##note	O
to	O
)	O
.	O

Ta	O
##lose	O
,	O
also	O
called	O
h	O
##ydro	O
##lysis	O
of	O
la	B
##ct	I
##ose	I
,	O
has	O
an	O
unknown	O
significance	O
so	O
far	O
.	O

4	B
-	I
h	I
##ydro	I
##xy	I
##phe	I
##ny	I
##lace	I
##tic	I
acid	I
is	O
an	O
o	O
##xi	O
##da	O
##tive	O
de	O
##ami	O
##nated	O
meta	O
##bol	O
##ite	O
of	O
p	B
-	I
t	I
##yra	I
##mine	I
and	O
also	O
a	O
meta	O
##bol	O
##ite	O
of	O
t	B
##yr	I
##os	I
##ine	I
via	O
enter	O
##ic	O
bacteria	O
.	O

We	O
further	O
determined	O
that	O
alterations	O
in	O
the	O
processing	O
of	O
these	O
meta	O
##bol	O
##ites	O
might	O
predict	O
longitudinal	O
de	O
##ter	O
##ior	O
##ation	O
in	O
glucose	S
tolerance	O
and	O
β	O
-	O
cell	O
function	O
relative	O
to	O
insulin	O
sensitivity	O
.	O

Furthermore	O
,	O
by	O
preventing	O
en	O
##zy	O
##matic	O
inter	O
##con	O
##version	O
by	O
rapid	O
heating	O
(	O
60	O
°C	O
,	O
5	O
min	O
)	O
,	O
5	B
-	I
form	I
##yl	I
-	I
T	I
##HF	I
could	O
be	O
differentiated	O
from	O
the	O
5	B
,	I
10	I
-	I
met	I
##hen	I
##yl	I
/	I
10	I
-	I
form	I
##yl	I
-	I
T	I
##HF	I
pool	O
.	O

In	O
current	O
study	O
,	O
we	O
proposed	O
an	O
IL	O
-	O
L	O
##C	O
-	O
MR	O
##M	O
-	O
MS	O
method	O
to	O
investigate	O
the	O
content	O
changes	O
of	O
th	B
##iol	I
between	O
cancer	O
##s	O
and	O
healthy	O
controls	O
.	O

Al	O
##kan	O
##es	O
,	O
met	O
##hyl	O
##ated	O
al	O
##kan	O
##es	O
,	O
alcohol	O
##s	O
,	O
al	O
##de	O
##hy	O
##des	O
,	O
k	B
##eton	I
##es	I
,	O
pen	O
##tan	O
##es	O
or	O
o	O
##le	O
##fin	O
##s	O
have	O
also	O
been	O
identified	O
as	O
breast	O
cancer	O
markers	O
.	O

Met	O
##ab	O
##oli	O
##tes	O
in	O
this	O
p	O
##elle	O
##t	O
were	O
extracted	O
with	O
1	O
.	O
0	O
m	O
##L	O
M	B
##T	I
##BE	I
,	O
v	O
##ortex	O
##ed	O
vigorously	O
for	O
30	O
se	O
##c	O
,	O
and	O
cent	O
##ri	O
##fu	O
##ged	O
at	O
1800	O
##0	O
×	O
g	O
0	O
##°	O
##C	O
for	O
15	O
min	O
.	O

In	O
the	O
present	O
study	O
,	O
using	O
a	O
s	O
##tra	O
##ti	O
##fied	O
analysis	O
by	O
WC	O
,	O
we	O
found	O
decreased	O
HD	B
##L	I
ch	I
##ole	I
##ster	I
##ol	I
in	O
PC	O
##OS	O
women	O
with	O
abdominal	O
o	O
##besity	O
,	O
which	O
is	O
consistent	O
with	O
results	O
of	O
previous	O
studies	O
in	O
which	O
s	O
##tra	O
##ti	O
##fication	O
by	O
B	O
##MI	O
was	O
used	O
.	O

Through	O
its	O
role	O
in	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##lino	I
##si	I
##to	I
##l	I
-	I
4	I
-	I
phosphate	I
(	O
IP	O
_	O
4	O
)	O
and	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##lino	I
##si	I
##to	I
##l	I
-	I
4	I
,	I
5	I
-	I
bi	I
##sp	I
##hos	I
##phate	I
(	O
IP	O
_	O
4	O
,	O
5	O
)	O
bio	O
##sy	O
##nt	O
##hesis	O
,	O
my	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
and	O
I	B
##1	I
##P	I
are	O
plasma	O
membrane	O
media	O
##tors	O
of	O
protein	O
p	O
##hos	O
##ph	O
##ory	O
##lation	O
and	O
second	O
messenger	O
signaling	O
.	O

There	O
is	O
a	O
certain	O
possibility	O
that	O
the	O
consumption	O
of	O
try	B
##pt	I
##op	I
##han	I
in	O
human	O
body	O
induce	O
##s	O
in	O
##act	O
##ivation	O
or	O
en	O
##er	O
##vation	O
of	O
T	O
cells	O
and	O
even	O
its	O
a	O
##pop	O
##tosis	O
so	O
that	O
the	O
micro	O
##en	O
##vir	O
##on	O
##ment	O
of	O
im	O
##mu	O
##nos	O
##up	O
##press	O
##ion	O
is	O
eventually	O
generated	O
.	O

However	O
,	O
a	O
recent	O
,	O
somewhat	O
bigger	O
,	O
random	O
##ized	O
,	O
place	O
##bo	O
-	O
controlled	O
pilot	O
study	O
on	O
dry	O
eye	O
in	O
40	O
post	O
##men	O
##op	O
##aus	O
##al	O
women	O
did	O
not	O
show	O
a	O
beneficial	O
effect	O
of	O
either	O
trans	O
##der	O
##mal	O
test	B
##osterone	I
,	O
est	B
##rogen	I
or	O
both	O
test	B
##osterone	I
and	O
est	B
##rogen	I
on	O
dry	O
eye	O
symptoms	O
as	O
compared	O
to	O
place	O
##bo	O
.	O

Moreover	O
,	O
it	O
was	O
not	O
possible	O
to	O
re	O
##p	O
##rod	O
##uc	O
##ibly	O
determine	O
_	O
13	O
C	O
is	O
##oto	O
##pic	O
en	O
##rich	O
##ment	O
for	O
p	B
##yr	I
##u	I
##vate	I
,	O
due	O
to	O
instability	O
of	O
the	O
derivative	O
.	O

Therefore	O
,	O
we	O
identified	O
a	O
panel	O
of	O
six	O
bio	O
##mark	O
##ers	O
(	B
glucose	S
,	O
ch	B
##olin	I
##e	I
,	O
g	B
##lut	I
##amine	I
,	O
g	B
##lut	I
##ama	I
##te	I
,	O
v	B
##ali	I
##ne	I
,	O
and	O
di	B
##hy	I
##dr	I
##oth	I
##ym	I
##ine	I
)	O
that	O
were	O
combined	O
together	O
using	O
binary	O
log	O
##istic	O
re	O
##gression	O
to	O
give	O
a	O
high	O
AU	O
##C	O
value	O
of	O
0	O
.	O
96	O
##9	O
.	O

The	O
per	B
##oxide	I
and	O
a	O
ch	O
##rom	O
##ogen	O
in	O
the	O
presence	O
of	O
per	O
##ox	O
##idas	O
##e	O
form	O
a	O
colored	O
end	O
product	O
that	O
is	O
proportional	O
to	O
the	O
amount	O
of	O
c	B
##rea	I
##tin	I
##ine	I
in	O
the	O
sample	O
.	O

In	O
addition	O
,	O
it	O
is	O
reported	O
that	O
in	O
liver	O
diseases	O
,	O
the	O
a	O
##ero	O
##bic	O
metabolism	O
is	O
blocked	O
,	O
resulting	O
in	O
g	O
##ly	O
##co	O
##lysis	O
and	O
pen	B
##tos	I
##e	I
phosphate	I
pathway	O
becoming	O
the	O
main	O
glucose	S
metabolic	O
pathways	O
.	O

The	O
new	O
quantitative	O
pro	O
##fi	O
##ling	O
ass	O
##ay	O
provided	O
highly	O
sensitive	O
,	O
precise	O
and	O
accurate	O
ch	O
##em	O
##otype	O
##s	O
of	O
the	O
vitamin	B
D	I
metabolic	O
process	O
rather	O
than	O
the	O
usually	O
determined	O
25	O
(	O
OH	O
)	O
D	O
_	O
3	O
concentrations	O
.	O

In	O
our	O
own	O
study	O
,	O
the	O
bi	O
##le	O
acids	O
ta	O
##uro	O
##urs	O
##ode	O
##ox	O
##ych	O
##olic	O
acid	O
and	O
g	B
##ly	I
##co	I
##chen	I
##ode	I
##ox	I
##ych	I
##olate	I
-	I
3	I
-	I
su	I
##lf	I
##ate	I
were	O
increased	O
dramatically	O
after	O
high	O
altitude	O
exposure	O
,	O
and	O
g	B
##ly	I
##co	I
##chen	I
##ode	I
##ox	I
##ych	I
##olate	I
-	I
3	I
-	I
su	I
##lf	I
##ate	I
were	O
significantly	O
elevated	O
in	O
AM	O
##S	O
-	O
S	O
group	O
com	O
##pair	O
##ed	O
with	O
AM	O
##S	O
-	O
R	O
group	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
identified	O
the	O
major	O
ch	B
##ole	I
##ster	I
##ol	I
meta	O
##bol	O
##ite	O
found	O
in	O
human	O
CS	O
##F	O
to	O
be	O
7	B
##α	I
-	I
h	I
##ydro	I
##xy	I
-	I
3	I
-	I
o	I
##x	I
##och	I
##ole	I
##st	I
-	I
4	I
-	I
en	I
-	I
26	I
-	I
o	I
##ic	I
acid	I
.	O

These	O
results	O
imp	O
##lica	O
##te	O
a	O
role	O
for	O
the	O
fatty	O
acids	O
and	O
o	B
##xy	I
##lip	I
##ins	I
con	O
##stituting	O
T	O
##GR	O
##L	O
in	O
media	O
##ting	O
a	O
pro	O
-	O
or	O
anti	O
-	O
at	O
##her	O
##ogenic	O
end	O
##oth	O
##eli	O
##al	O
p	O
##hen	O
##otype	O
.	O

Using	O
re	B
##ser	I
##pine	I
as	O
an	O
example	O
,	O
the	O
parameters	O
for	O
Mass	O
##Works	O
s	O
##CL	O
##IP	O
##S	O
algorithms	O
were	O
:	O
mass	O
tolerance	O
,	O
5	O
pp	O
##m	O
;	O
electron	O
state	O
,	O
even	O
;	O
double	O
bond	O
equivalent	O
range	O
,	O
−	O
##3	O
to	O
50	O
;	O
profile	O
mass	O
range	O
,	O
−	O
##1	O
to	O
3	O
.	O
5	O
Da	O
;	O
ca	O
##li	O
##bra	O
##tion	O
range	O
,	O
−	O
##0	O
.	O
1	O
to	O
0	O
.	O
1	O

Additionally	O
,	O
when	O
comparing	O
models	O
PC	O
##T	O
##7	O
to	O
PC	O
##T	O
##18	O
,	O
it	O
was	O
noted	O
that	O
for	O
models	O
based	O
on	O
the	O
same	O
bin	O
size	O
and	O
pre	O
-	O
processing	O
parameters	O
,	O
those	O
with	O
only	O
selected	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
regions	O
tended	O
to	O
have	O
a	O
lower	O
number	O
of	O
errors	O
than	O
models	O
that	O
included	O
the	O
full	O
spectral	O
region	O
,	O
e	O
.	O
g	O
.	O
PC	O
##T	O
##10	O
vs	O
PC	O
##T	O
##13	O
.	O

[	O
,	O
]	O
and	O
increased	O
risk	O
for	O
T	O
##2	O
##D	O
(	O
decreased	O
PC	B
a	I
##e	I
(	I
C	I
##34	I
:	I
3	I
,	I
C	I
##40	I
:	I
6	I
,	I
C	I
##42	I
:	I
5	I
,	I
C	I
##44	I
:	I
4	I
,	I
C	I
##44	I
:	I
5	I
)	I
,	O
increased	O
PC	O
a	O
##a	O
(	B
C	B
##32	I
:	I
1	I
,	I
C	I
##36	I
:	I
1	I
,	I
C	I
##38	I
:	I
3	I
,	I
C	I
##40	I
:	I
5	I
)	O
)	O
.	O

The	O
human	O
co	O
##lon	O
##ic	O
flora	O
is	O
able	O
to	O
de	O
##grade	O
p	O
##ec	O
##tin	O
##s	O
,	O
_	O
,	O
and	O
met	B
##han	I
##ol	I
is	O
released	O
into	O
the	O
blood	O
upon	O
this	O
degradation	O
.	O

Using	O
polar	O
lip	O
##id	O
extract	O
from	O
b	O
##ov	O
##ine	O
liver	O
as	O
a	O
bench	O
##mark	O
test	O
,	O
more	O
than	O
200	O
un	O
##sat	O
##ura	O
##ted	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
have	O
been	O
identified	O
for	O
the	O
sites	O
of	O
un	O
##sat	O
##uration	O
,	O
among	O
which	O
55	O
groups	O
of	O
C	O
=	O
C	O
location	O
is	O
##omer	O
##s	O
have	O
been	O
discovered	O
,	O
including	O
48	O
molecular	O
structures	O
which	O
were	O
not	O
predicted	O
by	O
L	O
##IP	O
##ID	O
MA	O
##PS	O
database	O
.	O

The	O
most	O
frequent	O
amino	O
acid	O
found	O
in	O
wheat	O
g	O
##lut	O
##en	O
is	O
g	O
##l	O
##x	O
,	O
referring	O
to	O
the	O
mixed	O
fraction	O
of	O
g	B
##lut	I
##ama	I
##te	I
and	O
g	B
##lut	I
##amine	I
,	O
with	O
a	O
relative	O
abundance	O
of	O
31	O
m	O
##ol	O
%	O
(	O
245	O
##0	O
µ	O
##mo	O
##l	O
/	O
g	O
)	O
.	O

However	O
,	O
it	O
should	O
be	O
noted	O
that	O
subtle	O
differences	O
in	O
the	O
relative	O
a	B
##rg	I
##ini	I
##ne	I
concentrations	O
as	O
determined	O
by	O
E	O
##L	O
##IS	O
##A	O
resulted	O
in	O
an	O
increased	O
AD	B
##MA	I
:	O
a	B
##rg	I
##ini	I
##ne	I
ratio	O
being	O
recorded	O
in	O
plasma	O
samples	O
after	O
surgery	O
using	O
this	O
ass	O
##ay	O
.	O

Ph	B
##os	I
##pha	I
##ti	I
##dy	I
##ls	I
##eri	I
##ne	I
can	O
be	O
synthesized	O
from	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
or	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##let	I
##han	I
##ola	I
##mine	I
by	O
two	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##ls	I
##eri	I
##ne	I
s	O
##ynth	O
##ases	O
(	O
PS	O
##S	O
##1	O
and	O
PS	O
##S	O
##2	O
)	O
.	O

We	O
have	O
developed	O
a	O
f	O
##ac	O
##ile	O
solid	O
-	O
phase	O
extraction	O
method	O
,	O
employing	O
a	O
mixed	O
-	O
mode	O
reverse	O
phase	O
cat	O
##ion	O
exchange	O
re	O
##sin	O
,	O
to	O
simultaneously	O
is	O
##olate	O
Ph	O
##IP	O
,	O
its	O
g	B
##lu	I
##cu	I
##ron	I
##ide	I
con	O
##ju	O
##gate	O
##s	O
,	O
and	O
the	O
g	B
##lu	I
##cu	I
##ron	I
##ide	I
con	O
##ju	O
##gate	O
##s	O
of	O
the	O
g	O
##eno	O
##to	O
##xi	O
##c	O
meta	O
##bol	O
##ite	O
2	B
-	I
h	I
##ydro	I
##xy	I
##ami	I
##no	I
-	I
1	I
-	I
met	I
##hyl	I
-	I
6	I
-	I
p	I
##hen	I
##yl	I
##im	I
##ida	I
##zo	I
[	I
4	I
,	I
5	I
-	I
b	I
]	I
p	I
##yr	I
##id	I
##ine	I
from	O
urine	O
of	O
meat	O
-	O
eat	O
##ers	O
.	O

Two	O
can	O
##nu	O
##las	O
were	O
inserted	O
:	O
one	O
in	O
an	O
ant	O
##ec	O
##ubi	O
##tal	O
vein	O
for	O
the	O
in	O
##fusion	O
of	O
glucose	S
and	O
insulin	O
and	O
the	O
injection	O
of	O
[	O
_	O
18	O
F	O
]	O
F	O
##D	O
##G	O
,	O
and	O
the	O
other	O
in	O
the	O
opposite	O
upper	O
ex	O
##tre	O
##mity	O
radial	O
artery	O
or	O
ant	O
##ec	O
##ubi	O
##tal	O
vein	O
,	O
which	O
was	O
warmed	O
with	O
a	O
heating	O
pillow	O
to	O
art	O
##erial	O
##ize	O
ve	O
##nous	O
blood	O
.	O

Similarly	O
,	O
the	O
effect	O
of	O
r	B
##il	I
##uz	I
##ole	I
treatment	O
on	O
lip	O
##id	O
metabolism	O
has	O
not	O
been	O
characterised	O
,	O
but	O
it	O
is	O
con	O
##ce	O
##ivable	O
that	O
these	O
alterations	O
can	O
be	O
linked	O
to	O
changes	O
in	O
energy	O
metabolism	O
.	O

Ace	B
##ton	I
##it	I
##ril	I
##e	I
(	O
AC	O
##N	O
)	O
,	O
met	B
##han	I
##ol	I
,	O
is	B
##op	I
##rop	I
##ano	I
##l	I
,	O
and	O
ch	B
##lor	I
##of	I
##orm	I
were	O
from	O
Fisher	O
Scientific	O
(	O
Pitt	O
##sburg	O
,	O
PA	O
)	O
.	O

Low	O
density	O
lip	O
##op	O
##rote	O
##in	O
ch	B
##ole	I
##ster	I
##ol	I
(	O
L	O
##D	O
##L	O
)	O
was	O
calculated	O
using	O
Fr	O
##ied	O
##ew	O
##ald	O
equation	O
.	O

First	O
,	O
the	O
transcription	O
levels	O
of	O
these	O
proteins	O
in	O
the	O
52	O
RNA	O
samples	O
were	O
analyzed	O
by	O
R	O
##T	O
-	O
q	O
##PC	O
##R	O
using	O
specific	O
prime	O
##rs	O
for	O
m	O
##RNA	O
##s	O
encoding	O
CP	O
##T	O
##1	O
##A	O
,	O
P	O
##K	O
##M	O
##2	O
,	O
and	O
G	B
##S	I
##K	I
##3	I
##β	I
.	O

Me	B
##so	I
-	I
er	I
##yt	I
##hr	I
##ito	I
##l	I
concentrations	O
were	O
about	O
the	O
same	O
in	O
the	O
two	O
halves	O
of	O
the	O
lower	O
g	O
##ly	O
##ce	O
##mia	O
group	O
,	O
but	O
in	O
the	O
higher	O
g	O
##ly	O
##ce	O
##mia	O
subgroup	O
,	O
me	B
##so	I
-	I
er	I
##yt	I
##hr	I
##ito	I
##l	I
was	O
higher	O
in	O
the	O
top	O
12	O
.	O
5	O
%	O
of	O
the	O
base	O
##line	O
H	O
##b	O
##A	O
##1	O
##c	O
distribution	O
(	O
H	O
##b	O
##A	O
##1	O
##c	O
≥	O
5	O
.	O
64	O
%	O
)	O
.	O

The	O
system	O
was	O
successfully	O
applied	O
to	O
the	O
detection	O
and	O
characterization	O
of	O
meta	O
##bol	O
##ites	O
of	O
p	B
##hen	I
##yl	I
##but	I
##yra	I
##te	I
from	O
serum	O
samples	O
of	O
Huntington	O
'	O
s	O
disease	O
patients	O
in	O
an	O
example	O
that	O
illustrate	O
##s	O
the	O
complement	O
##arity	O
of	O
the	O
dual	O
detection	O
na	O
##no	O
##ele	O
##ct	O
##ros	O
##pra	O
##y	O
L	O
##C	O
-	O
EC	O
-	O
array	O
-	O
MS	O
system	O
.	O

G	B
##ly	I
##cine	I
is	O
an	O
essential	O
amino	O
acid	O
highly	O
consumed	O
by	O
fast	O
pro	O
##life	O
##rating	O
cancer	O
cells	O
_	O
,	O
,	O
decreased	O
levels	O
of	O
g	B
##ly	I
##cine	I
having	O
also	O
been	O
detected	O
in	O
the	O
urine	O
of	O
pro	O
##state	O
cancer	O
patients	O
.	O

H	O
##U	O
treatment	O
would	O
probably	O
resolve	O
these	O
complications	O
and	O
bring	O
g	B
##ly	I
##ce	I
##mic	I
profile	O
back	O
to	O
normal	O
,	O
as	O
indicated	O
in	O
the	O
result	O
.	O

Con	O
##cent	O
##rations	O
of	O
the	O
NO	O
##S	O
inhibitor	O
AD	B
##MA	I
increased	O
with	O
clinical	O
severity	O
and	O
were	O
increased	O
by	O
40	O
%	O
in	O
se	O
##psis	O
with	O
a	O
median	O
concentration	O
of	O
0	O
.	O
80	O
μ	O
##mo	O
##l	O
/	O
L	O
,	O
and	O
by	O
54	O
%	O
in	O
se	O
##ptic	O
shock	O
with	O
a	O
median	O
concentration	O
of	O
0	O
.	O
89	O
μ	O
##mo	O
##l	O
/	O
L	O
in	O
patients	O
compared	O
with	O
controls	O
(	O
P	O
<	O
0	O
.	O
00	O
##1	O
;	O
Table	O
)	O
.	O

A	O
##b	O
##nor	O
##mal	O
metabolism	O
induced	O
by	O
h	O
##yper	O
##gly	O
##ce	O
##mia	O
could	O
also	O
result	O
in	O
the	O
over	O
##p	O
##rod	O
##uction	O
of	O
free	O
radical	O
##s	O
that	O
can	O
lead	O
to	O
o	O
##xi	O
##da	O
##tive	O
stress	O
and	O
damage	O
to	O
tissues	O
in	O
and	O
around	O
re	B
##tina	I
##l	I
vessels	O
.	O

Form	B
##ate	I
and	O
dim	B
##eth	I
##yl	I
##sul	I
##fo	I
##ne	I
were	O
not	O
important	O
for	O
the	O
class	O
discrimination	O
before	O
and	O
after	O
age	O
-	O
correction	O
.	O

This	O
study	O
demonstrated	O
that	O
FF	O
##As	O
,	O
including	O
SF	O
##As	O
,	O
M	O
##U	O
##FA	O
##s	O
,	O
and	O
P	O
##U	O
##FA	O
##s	O
,	O
are	O
elevated	O
or	O
reduced	O
in	O
plasma	O
samples	O
of	O
A	B
##F	I
patients	O
,	O
supporting	O
an	O
important	O
role	O
for	O
inflammation	O
in	O
the	O
path	O
##ogen	O
##esis	O
of	O
A	B
##F	I
.	O

An	O
excellent	O
separation	O
with	O
minimal	O
overlapping	O
was	O
observed	O
between	O
positive	O
and	O
negative	O
pro	O
##gno	O
##sis	O
in	O
the	O
U	B
##rine	I
-	I
0	I
##h	I
model	O
.	O

Total	O
laboratory	O
coefficients	O
of	O
variation	O
(	O
C	O
##V	O
)	O
were	O
<	O
10	O
%	O
for	O
all	O
E	O
##M	O
except	O
4	B
-	I
met	I
##ho	I
##xy	I
##est	I
##rad	I
##iol	I
(	O
15	O
%	O
)	O
,	O
and	O
were	O
≤	O
4	O
%	O
for	O
est	B
##rone	I
,	O
est	B
##rad	I
##iol	I
,	O
and	O
est	B
##rio	I
##l	I
,	O
and	O
~	O
1	O
%	O
for	O
total	O
E	O
##M	O
.	O

Co	O
##mp	O
##aring	O
with	O
CH	O
##D	O
patients	O
,	O
the	O
levels	O
of	O
al	B
##ani	I
##ne	I
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
le	B
##uc	I
##ine	I
,	O
α	B
-	I
amino	I
-	I
n	I
-	I
but	I
##yra	I
##te	I
,	O
met	B
##hi	I
##oni	I
##ne	I
and	O
as	O
##par	O
##ate	O
were	O
up	O
-	O
regulated	O
,	O
while	O
the	O
levels	O
of	O
h	B
##ydro	I
##xy	I
##p	I
##rol	I
##ine	I
,	O
g	B
##lut	I
##amine	I
,	O
g	B
##ly	I
##cine	I
,	O
pro	B
##line	I
,	O
or	B
##ni	I
##thin	I
##e	I
,	O
c	B
##it	I
##rate	I
,	O
g	B
##lut	I
##ama	I
##te	I
,	O
sa	B
##rc	I
##os	I
##ine	I
,	O
his	B
##ti	I
##dine	I
and	O
se	B
##rine	I
were	O
down	O
-	O
regulated	O
in	O
acute	O
AD	O
patients	O
.	O

For	O
instance	O
,	O
N	O
-	O
A	O
##c	O
##P	O
##UT	O
,	O
OR	O
##N	O
,	O
N	B
##1	I
,	I
N	I
##12	I
-	I
Di	I
##A	I
##c	I
##SP	I
##M	I
,	O
N	O
##1	O
-	O
A	O
##c	O
##SP	O
##D	O
,	O
and	O
N	O
##8	O
-	O
A	O
##c	O
##SP	O
##D	O
have	O
comparable	O
signal	O
enhance	O
##ment	O
.	O

One	O
di	B
##hy	I
##dr	I
##o	I
meta	O
##bol	O
##ite	O
(	O
M	O
##22	O
##0	O
##T	O
##35	O
##5	O
in	O
Table	O
)	O
was	O
found	O
,	O
that	O
was	O
not	O
sufficiently	O
separated	O
from	O
the	O
alpha	B
-	I
P	I
##B	I
##P	I
is	O
##oto	O
##pe	O
containing	O
two	O
_	O
13	O
C	O
atoms	O
during	O
the	O
analysis	O
using	O
H	O
##IL	O
##IC	O
.	O

For	O
instance	O
,	O
PC	B
16	I
:	I
0	I
_	I
17	I
:	I
0	I
was	O
found	O
to	O
exhibit	O
significant	O
changes	O
in	O
s	O
##n	O
-	O
ratios	O

,	O
)	O
it	O
clearly	O
appears	O
that	O
in	O
insulin	O
-	O
resistant	O
h	O
##y	O
##po	O
##gon	O
##adi	O
##sm	O
lip	O
##id	O
metabolism	O
represents	O
the	O
main	O
alternative	O
energy	O
source	O
to	O
glucose	S
pathways	O
.	O

The	O
median	O
level	O
for	O
5	B
-	I
h	I
##ydro	I
##xy	I
##met	I
##hyl	I
-	I
2	I
′	I
-	I
de	I
##ox	I
##yu	I
##rid	I
##ine	I
increased	O
in	O
HC	O
##C	O
by	O
factor	O
of	O
1	O
.	O
5	O
,	O
while	O
the	O
levels	O
for	O
the	O
other	O
three	O
meta	O
##bol	O
##ites	O
decreased	O
.	O

Finally	O
,	O
no	O
significant	O
variation	O
was	O
observed	O
in	O
our	O
L	O
##C	O
/	O
MS	O
conditions	O
for	O
hip	B
##pur	I
##ic	I
acid	I
,	O
whereas	O
concentrations	O
increased	O
by	O
a	O
factor	O
of	O
1	O
.	O
5	O
were	O
measured	O
by	O
N	O
##MR	O
in	O
those	O
samples	O
of	O
Ex	O
##p	O
.	O

Ser	O
##um	O
concentrations	O
of	O
im	B
##ati	I
##ni	I
##b	I
observed	O
in	O
the	O
samples	O
(	O
Set	O
1	O
:	O
Total	O
-	O
n	O
=	O
308	O
;	O
Set	O
2	O
:	O
M	O
##MR	O
only	O
-	O
n	O
=	O
223	O
;	O
Set	O
3	O
:	O
non	O
-	O
M	O
##MR	O
-	O
n	O
=	O
85	O
)	O
.	O

Finally	O
,	O
to	O
the	O
samples	O
from	O
Set	O
3	O
,	O
DS	O
##S	O
(	O
9	O
.	O
44	O
na	O
##no	O
##mo	O
##l	O
)	O
was	O
added	O
as	O
an	O
internal	O
reference	O
and	O
re	O
##con	O
##stituted	O
in	O
560	O
μ	O
##L	O
of	O
phosphate	S
buffer	O
(	O
pH	O
=	O
7	O
.	O
4	O
)	O
in	O
D	O
_	O
2	O
O	O
and	O
transferred	O
to	O
5	O
mm	O
N	O
##MR	O
tubes	O
for	O
1	O
##D	O
and	O
_	O
1	O
H	O
-	O
_	O
1	O
H	O
2D	O
TO	O
##CS	O
##Y	O
N	O
##MR	O
experiments	O
.	O

Moreover	O
,	O
the	O
main	O
difficulty	O
for	O
a	O
path	O
##ologist	O
is	O
to	O
disc	O
##rim	O
##inate	O
between	O
s	O
##te	O
##ato	O
##sis	O
and	O
s	O
##te	O
##ato	O
##he	O
##pa	O
##titis	O
,	O
especially	O
before	O
the	O
inflammation	O
and	O
he	O
##pa	O
##to	O
##cy	O
##te	O
de	O
##gene	O
##rations	O
appeared	O
(	O
i	O
.	O
e	O
.	O
balloon	O
##ing	O
and	O
Mallory	O
’	O
s	O
h	B
##yal	I
##ine	I
bodies	O
)	O
.	O

However	O
,	O
while	O
this	O
study	O
highlights	O
the	O
capacity	O
for	O
r	O
##HD	O
##L	O
to	O
m	O
##od	O
##ulate	O
fatty	O
acid	O
metabolism	O
in	O
ad	O
##ip	O
##ocytes	O
,	O
the	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
component	O
of	O
the	O
r	O
##HD	O
##L	O
in	O
##fu	O
##sat	O
##e	O
did	O
directly	O
increase	O
circulating	O
NE	O
##FA	O
.	O

Given	O
sample	O
size	O
,	O
storage	O
duration	S
and	O
con	O
##found	O
##ing	O
through	O
post	O
##nat	O
##al	O
exposure	O
##s	O
,	O
further	O
studies	O
are	O
required	O
.	O

Although	O
not	O
included	O
in	O
the	O
presented	O
method	O
,	O
it	O
has	O
been	O
shown	O
that	O
tram	B
##eti	I
##ni	I
##b	I
can	O
be	O
analyzed	O
together	O
with	O
da	O
##bra	O
##fen	O
##ib	O
on	O
a	O
C	O
##18	O
column	O
using	O
am	O
##mon	O
##ium	O
ace	O
##tate	O
-	O
based	O
mobile	O
phases	O
[	O
,	O
]	O
.	O

Jen	O
##g	O
et	O
al	O
[	O
]	O
showed	O
,	O
with	O
an	O
HP	O
##LC	O
-	O
based	O
study	O
in	O
Taiwanese	O
subjects	O
,	O
that	O
the	O
n	O
##uc	O
##leo	O
##side	O
##s	O
ad	O
##eno	O
##sin	O
##e	O
,	O
c	B
##yt	I
##id	I
##ine	I
and	O
in	B
##os	I
##ine	I
were	O
elevated	O
in	O
the	O
urine	O
of	O
patients	O
affected	O
by	O
HC	O
##C	O
and	O
if	O
joined	O
with	O
serum	O
levels	O
of	O
A	O
##FP	O
,	O
the	O
diagnosis	O
of	O
cancer	O
was	O
reached	O
with	O
a	O
se	O
##ns	O
##ivity	O
of	O
80	O
%	O
[	O
]	O
.	O

We	O
also	O
compared	O
all	O
non	O
-	O
t	O
##rig	O
##one	O
##llin	O
##e	O
models	O
containing	O
la	B
##ct	I
##ate	I
to	O
their	O
counterparts	O
without	O
la	O
##ct	O
##ate	O
—	O
i	O
.	O
e	O
.	O
models	O
that	O
differed	O
in	O
the	O
set	O
of	O
features	O
only	O
in	O
the	O
presence	O
or	O
absence	O
of	O
la	B
##ct	I
##ate	I
and	O
found	O
that	O
on	O
average	O
models	O
containing	O
la	B
##ct	I
##ate	I
as	O
a	O
feature	O
performed	O
app	O
##re	O
##cia	O
##bly	O
better	O
than	O
without	O
(	O
see	O
Fi	O
##g	O
.	O

This	O
set	O
included	O
17	O
(	O
42	O
%	O
)	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
,	O
14	O
(	O
100	O
%	O
)	O

(	O
,	O
)	O
My	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
can	O
be	O
obtained	O
also	O
from	O
diet	O
##ary	O
sources	O
.	O

In	O
spite	O
of	O
the	O
extensive	O
research	O
carried	O
out	O
on	O
K	O
##Y	O
##NA	O
and	O
other	O
k	B
##yn	I
##uren	I
##ine	I
meta	O
##bol	O
##ites	O
in	O
experimental	O
models	O
of	O
mi	O
##gra	O
##ine	O
,	O
no	O
studies	O
have	O
ever	O
been	O
carried	O
out	O
in	O
humans	O
.	O

Is	B
##op	I
##rop	I
##yl	I
alcohol	I
was	O
obtained	O
from	O
F	O
##luk	O
##a	O
.	O

Instead	O
,	O
they	O
arise	O
from	O
different	O
types	O
of	O
carbon	B
-	I
hydrogen	I
bond	O
in	O
all	O
fatty	O
a	O
##cy	O
##l	O
chains	O
:	O
0	O
.	O
9	O
##pp	O
##m	O
–	O
CH	O
_	O
3	O
;	O
1	O
.	O
3	O
##pp	O
##m	O
–	O
(	O
CH	O
_	O
2	O
)	O
_	O
n	O
-	O
;	O
2	O
.	O
0	O
##pp	O
##m	O
–	O
CH	O
_	O
2	O
-	O
CH	O
=	O
CH	O
-	O
CH	O
_	O
2	O
-	O
.	O

Fr	O
##actions	O
of	O
different	O
is	O
##oto	O
##po	O
##mers	O
of	O
_	O
13	O
C	O
-	O
p	O
##yr	O
##u	O
##vate	O
(	O
A	O
)	O
,	O
_	O
13	O
C	B
–	I
la	I
##ct	I
##ate	I
(	O
B	O
)	O
or	O
_	O
13	O
C	B
-	I
ace	I
##ty	I
##l	I
-	I
Co	I
##A	I
(	O
D	O
)	O
in	O
the	O
PC	O
knock	O
##down	O
cell	O
lines	O
and	O
the	O
s	O
##c	O
##ram	O
##ble	O
control	O
cell	O
line	O
are	O
shown	O
within	O
the	O
same	O
bars	O
.	O

Among	O
pregnant	O
women	O
,	O
u	O
##rina	O
##ry	O
MC	O
##NP	O
was	O
inverse	O
##ly	O
associated	O
with	O
free	O
test	B
##osterone	I
,	O
suggesting	O
an	O
anti	O
-	O
and	O
##rogen	O
##ic	O
effect	O
of	O
MC	O
##NP	O
.	O

The	O
estimates	O
for	O
ch	B
##ole	I
##ster	I
##ol	I
concentrations	O
within	O
individual	O
lip	O
##op	O
##rote	O
##in	O
sub	O
##c	O
##lass	O
##es	O
were	O
very	O
similar	O
to	O
those	O
of	O
the	O
corresponding	O
lip	O
##op	O
##rote	O
##in	O
particle	O
concentrations	O
.	O

As	O
seen	O
in	O
,	O
ni	B
##cot	I
##ina	I
##mi	I
##de	I
levels	O
are	O
higher	O
in	O
I	O
##BS	O
and	O
significantly	O
different	O
between	O
the	O
2	O
groups	O
at	O
Time	O
4	O
(	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

Inc	O
##reased	O
serum	O
17	B
##β	I
-	I
est	I
##rad	I
##iol	I
in	O
men	O
or	O
post	O
##men	O
##op	O
##aus	O
##al	O
women	O
was	O
accepted	O
as	O
evidence	O
of	O
tumor	O
-	O
related	O
est	B
##rogen	I
excess	O
.	O

In	O
brief	O
,	O
the	O
t	O
##read	O
##mill	O
training	O
started	O
conservative	O
##ly	O
with	O
a	O
goal	O
of	O
15	O
minutes	O
total	O
duration	S
at	O
40	O
%	O
-	O
50	O
%	O
ma	O
##ximal	O
heart	O
rate	O
reserve	O
(	O
H	O
##R	O
##R	O
)	O
.	O

His	O
##to	O
##gram	O
##s	O
of	O
number	O
of	O
errors	O
in	O
predict	O
##ing	O
specimens	O
with	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
related	O
meta	O
##bol	O
##ites	O
(	O
red	O
bars	O
)	O
and	O
specimens	O
without	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
related	O
meta	O
##bol	O
##ites	O
(	O
blue	O
bars	O
)	O
in	O
each	O
of	O
the	O
1000	O
re	O
-	O
sampling	O
##s	O
for	O
s	O
##pect	O
##ra	O
with	O
the	O
presence	O
or	O
absence	O
of	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
visually	O
verified	O
for	O
(	O
A	O
)	O
model	O
PC	O
##T	O
##10	O
,	O
based	O
on	O
mean	O
-	O
centred	O
data	O
;	O
(	O
B	O
)	O
model	O
PC	O
##T	O
##11	O
,	O
based	O
on	O
unit	O
-	O
variance	O
s	O
##cal	O
##ing	O
and	O
(	O
C	O
)	O
model	O
PC	O
##T	O
##12	O
,	O
based	O
on	O
par	O
##eto	O
s	O
##cal	O
##ing	O
.	O

Taking	O
these	O
results	O
together	O
with	O
our	O
previous	O
studies	O
,	O
neither	O
G	O
##ST	O
de	O
##to	O
##xi	O
##fication	O
of	O
simple	O
Ph	B
##e	I
-	I
e	I
##pox	I
##ides	I
2	O
and	O
12	O
nor	O
of	O
Ph	O
##e	O
-	O
di	O
##ol	O
e	B
##pox	I
##ides	I
4	O
and	O
20	O
can	O
account	O
for	O
the	O
observed	O
higher	O
levels	O
of	O
Ph	O
##e	O
-	O
te	O
##tra	O
##ols	O
in	O
G	O
##ST	O
##M	O
##1	O
-	O
null	O
individuals	O
.	O

We	O
selected	O
the	O
Pro	O
##di	O
##gy	O
Ph	B
##en	I
##yl	I
-	I
3	I
(	O
P	O
##H	O
-	O
3	O
)	O
column	O
mainly	O
for	O
two	O
reasons	O
.	O

In	O
the	O
ER	O
##F	O
population	O
car	B
##ni	I
##tine	I
and	O
u	B
##ric	I
acid	I
are	O
highly	O
correlated	O
(	O
r	O
=	O
0	O
.	O
25	O
,	O
P	O
-	O
value	O
=	O
3	O
.	O
93	O
##×	O
##10	O
_	O
−	O
##13	O
)	O
.	O

While	O
Ph	O
##CA	O
##s	O
and	O
it	B
##acon	I
##ic	I
acid	I
had	O
an	O
inhibitor	O
##y	O
effect	O
on	O
SD	O
##H	O
,	O
significant	O
differences	O
in	O
the	O
sites	O
of	O
their	O
actions	O
were	O
found	O
using	O
the	O
intermediate	O
electron	O
carrier	O
PM	O
##S	O
.	O

S	O
##3	O
and	O
S	O
##4	O
,	O
while	O
the	O
variation	O
in	O
retention	O
time	O
(	O
as	O
measured	O
by	O
%	O
RS	O
##D	O
)	O
was	O
generally	O
quite	O
small	O
,	O
at	O
<	O
2	O
%	O
in	O
all	O
conditions	O
,	O
the	O
area	O
of	O
the	O
ca	B
##ffe	I
##ine	I
peak	O
varied	O
significantly	O
both	O
across	O
m	O
##od	O
##ifier	O
##s	O
and	O
column	O
types	O
.	O

Key	O
Message	O
##s	O
This	O
cross	O
-	O
section	O
##al	O
analysis	O
found	O
eight	O
serum	O
lip	O
##id	O
meta	O
##bol	O
##ites	O
associated	O
with	O
circulating	O
25	B
-	I
h	I
##ydro	I
##xy	I
-	I
vitamin	I
D	O
at	O
the	O
principle	O
components	O
corrected	O
threshold	O
,	O
including	O
three	O
related	O
to	O
fish	O
consumption	O
:	O
3	B
-	I
car	I
##box	I
##y	I
-	I
4	I
-	I
met	I
##hyl	I
-	I
5	I
-	I
prop	I
##yl	I
-	I
2	I
-	I
fur	I
##an	I
##p	I
##rop	I
##ano	I
##ic	I
acid	I
(	O
C	O
##MP	O
##F	O
)	O
and	O
the	O
two	O
o	B
##me	I
##ga	I
-	I
3	I
fatty	O
acids	O
,	O
e	B
##ico	I
##sa	I
##pent	I
##aen	I
##oat	I
##e	I
(	O
EPA	O
)	O
and	O
do	B
##cos	I
##ah	I
##ex	I
##aen	I
##oat	I
##e	I
(	O
D	O
##HA	O
)	O
.	O

Q	O
##Cs	O
and	O
solvent	O
blank	O
samples	O
(	O
B	O
##L	O
##s	O
,	O
30	O
%	O
met	B
##han	I
##ol	I
in	O
water	O
)	O
were	O
injected	O
se	O
##quential	O
##ly	O
in	O
-	O
between	O
the	O
human	O
serum	O
samples	O
.	O

The	O
possible	O
causes	O
were	O
as	O
follows	O
:	O
first	O
,	O
diet	O
##ary	O
deficiency	O
may	O
affect	O
the	O
intake	O
of	O
ch	B
##olin	I
##e	I
because	O
of	O
the	O
damage	O
of	O
the	O
stomach	O
.	O

In	O
case	O
of	O
su	O
##lf	O
##ata	O
##se	O
,	O
only	O
modest	O
levels	O
(	O
<	O
5	O
%	O
of	O
su	O
##lf	O
##ata	O
##se	O
+	O
g	O
##lu	O
##cor	O
##inda	O
##se	O
concentrations	O
)	O
were	O
observed	O
in	O
the	O
last	O
three	O
urine	O
fraction	O
##s	O
;	O
no	O
di	B
##os	I
##met	I
##in	I
concentrations	O
were	O
measured	O
in	O
the	O
und	O
##ige	O
##sted	O
samples	O
.	O

Finally	O
,	O
measuring	O
the	O
levels	O
of	O
a	B
##rg	I
##ini	I
##ne	I
and	O
its	O
related	O
meta	O
##bol	O
##ites	O
poses	O
challenges	O
due	O
to	O
the	O
influence	O
of	O
food	O
intake	O
and	O
analytical	O
constraints	O
on	O
amino	O
acid	O
levels	O
.	O

;	O
consistent	O
with	O
published	O
N	O
##MR	O
data	O
from	O
long	O
-	O
term	O
stability	O
studies	O
)	O
whereas	O
the	O
levels	O
of	O
g	B
##ly	I
##cine	I
,	O
al	B
##ani	I
##ne	I
and	O
trim	B
##eth	I
##yla	I
##mine	I
were	O
not	O
altered	O
(	O
the	O
time	O
courses	O
of	O
meta	O
##bol	O
##ites	O
monitored	O
by	O
N	O
##MR	O
are	O
provided	O
as	O
supplement	O
##ary	O
material	O
1	O
)	O
.	O

Hence	O
we	O
have	O
combined	O
all	O
the	O
values	O
of	O
2	O
con	O
##ju	O
##gate	O
##s	O
and	O
4	O
con	O
##ju	O
##gate	O
##s	O
(	O
and	O
)	O
,	O
which	O
reflect	O
the	O
total	O
protection	O
by	O
G	B
##S	I
##H	I
from	O
2	O
or	O
4	O
q	B
##uin	I
##ones	I
,	O
respectively	O
.	O

A	O
separate	O
L	O
##R	O
model	O
was	O
developed	O
incorporating	O
a	O
panel	O
of	O
three	O
meta	O
##bol	O
##ites	O
(	B
o	B
##ct	I
##ano	I
##yl	I
car	I
##ni	I
##tine	I
,	O
a	B
##rg	I
##ini	I
##ne	I
,	O
and	O
SM	B
(	I
C	I
##20	I
:	I
2	I
)	I

For	O
example	O
,	O
an	O
increase	O
in	O
la	B
##ct	I
##ate	I
(	O
visible	O
at	O
1	O
.	O
33	O
and	O
4	O
.	O
13	O
pp	O
##m	O
)	O
,	O
k	B
##eton	I
##e	I
bodies	O
(	B
ace	B
##to	I
##ace	I
##tate	I
[	O
visible	O
at	O
2	O
.	O
23	O
pp	O
##m	O
]	O
,	O
and	O
β	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
[	O
visible	O
at	O
1	O
.	O
19	O
pp	O
##m	O
]	O
)	O
,	O
and	O
a	O
decrease	O
in	O
lip	O
##ids	O
and	O
glucose	S
(	O
visible	O
at	O
5	O
.	O
23	O
[	B
α	B
-	I
glucose	I
]	O
and	O
4	O
.	O
68	O
pp	O
##m	O
[	B
β	B
-	I
glucose	I
]	O
,	O
respectively	O
)	O
were	O
observed	O
.	O

P	O
##las	O
##ma	O
samples	O
were	O
th	O
##awed	O
on	O
ice	O
and	O
extracted	O
using	O
a	O
dual	O
met	B
##han	I
##ol	I
-	I
ch	I
##lor	I
##of	I
##orm	I
extraction	O
(	O
for	O
protein	O
precipitation	O
and	O
separation	O
of	O
h	B
##ydro	I
##phi	I
##lic	I
and	O
lip	O
##op	O
##hil	O
##ic	O
fraction	O
##s	O
)	O
as	O
previously	O
described	O
.	O

Organ	O
-	O
dependent	O
differences	O
were	O
prominent	O
at	O
the	O
levels	O
of	O
g	B
##ly	I
##co	I
##ly	I
##tic	I
and	O
t	B
##rica	I
##rb	I
##ox	I
##yl	I
##ic	I
acid	I
cycle	O
intermediate	O
##s	O
and	O
associated	O
energy	O
status	O
.	O

Furthermore	O
,	O
ho	B
##mo	I
##cy	I
##stein	I
##e	I
was	O
also	O
increased	O
not	O
only	O
in	O
Mar	O
##fan	O
patients	O
,	O
but	O
also	O
increased	O
in	O
patients	O
with	O
acute	O
a	O
##ort	O
##ic	O
di	O
##sse	O
##ction	O
and	O
chronic	O
th	O
##ora	O
##ci	O
##c	O
a	O
##ory	O
##ic	O
an	O
##eur	O
##ys	O
##ms	O
_	O
,	O
_	O
,	O
P	O
##las	O
##ma	O
ho	B
##mo	I
##cy	I
##stein	I
##e	I
exists	O
in	O
three	O
major	O
forms	O
,	O
with	O
trace	O
amounts	O
(	O
1	O
%	O
)	O
existing	O
in	O
the	O
reduced	O
form	O
.	O

Although	O
different	O
rankings	O
have	O
been	O
assigned	O
to	O
the	O
s	B
##tat	I
##ins	I
in	O
terms	O
of	O
their	O
di	O
##abe	O
##to	O
##genic	O
probability	O
,	O
most	O
studies	O
suggest	O
that	O
r	B
##os	I
##u	I
##vas	I
##tat	I
##in	I
,	O
si	B
##m	I
##vas	I
##tat	I
##in	I
and	O
at	B
##or	I
##vas	I
##tat	I
##in	I
are	O
more	O
likely	O
to	O
cause	O
T	O
##2	O
##DM	O
than	O
p	B
##ra	I
##vas	I
##tat	I
##in	I
,	O
although	O
there	O
is	O
published	O
data	O
that	O
suggest	O
p	B
##ra	I
##vas	I
##tat	I
##in	I
is	O
also	O
cu	O
##l	O
##pable	O
(	O
;	O
;	O
;	O
)	O
.	O

For	O
pen	B
##tad	I
##eca	I
##no	I
##ic	I
acid	I
and	O
18	O
:	O
2	O
l	O
##ys	O
##o	O
##PC	O
,	O
their	O
amount	O
is	O
high	O
before	O
re	O
##per	O
##fusion	O
and	O
their	O
amount	O
decreases	O
considerably	O
2	O
h	O
post	O
re	O
##per	O
##fusion	O
.	O

Numerous	O
amino	O
acids	O
(	B
a	B
##rg	I
##ini	I
##ne	I
,	O
pro	B
##line	I
,	O
g	B
##ly	I
##cine	I
,	O
al	B
##ani	I
##ne	I
,	O
and	O
g	B
##lut	I
##ami	I
##c	I
acid	O
)	O
,	O
sperm	B
##id	I
##ine	I
and	O
some	O
lip	O
##id	O
meta	O
##bol	O
##ites	O
demonstrated	O
significant	O
associations	O
with	O
progression	O
markers	O
in	O
this	O
patient	O
group	O
(	O
,	O
)	O
.	O

Non	O
-	O
targeted	O
G	O
##C	O
-	O
MS	O
and	O
subsequent	O
statistical	O
analysis	O
of	O
single	O
time	O
points	O
further	O
revealed	O
a	O
significant	O
reduction	O
of	O
f	B
##ru	I
##ct	I
##ose	I
(	O
G	O
##G	O
##2	O
:	O
13	O
%	O
,	O
G	O
##G	O
##4	O
:	O
6	O
%	O
)	O
,	O
g	B
##lu	I
##con	I
##ic	I
acid	I
(	O
G	O
##G	O
##2	O
:	O
5	O
%	O
,	O
G	O
##G	O
##4	O
:	O
22	O
%	O
)	O
and	O
two	O
unidentified	O
meta	O
##bol	O
##ites	O
(	O
R	O
##I	O
202	O
##8	O
:	O
G	O
##G	O
##2	O
:	O
6	O
%	O
,	O
G	O
##G	O
##4	O
:	O
12	O
%	O
;	O
R	B
##I	I
1958	O
:	O
G	O
##G	O
##2	O
:	O
11	O
.	O
6	O
%	O
,	O
G	O
##G	O
##4	O
:	O
11	O
.	O
4	O
%	O
)	O
at	O
the	O
time	O
point	O
of	O
ma	O
##ximal	O
level	O
(	O
T	O
_	O
ma	O
##x	O
)	O
(	O
Su	O
##pp	O
##l	O
.	O

(	B
1	B
,	I
1	I
’	I
=	O
O	O
-	O
D	O
##V	O
##X	O
and	O
2	B
,	I
2	I
’	I
=	I
V	I
##X	I
)	O
.	O

To	O
examine	O
whether	O
serum	O
re	B
##tino	I
##l	I
concentrations	O
interact	O
##ed	O
with	O
25	O
(	O
OH	O
)	O
D	O
,	O
we	O
ran	O
a	O
s	O
##tra	O
##ti	O
##fied	O
analysis	O
,	O
s	O
##tra	O
##ti	O
##fying	O
by	O
median	O
levels	O
of	O
serum	O
re	B
##tino	I
##l	I
.	O

The	O
second	O
reaction	O
was	O
conducted	O
in	O
a	O
glass	O
tube	O
for	O
24	O
##h	O
at	O
37	O
°C	O
and	O
contained	O
200	O
m	O
##M	O
sodium	B
ace	I
##tate	I
,	O
pH	O
5	O
.	O
0	O
,	O
200	O
p	B
##g	I
of	O
[	O
_	O
13	O
C	O
_	O
3	O
]	O
-	O
T	O
/	O
-	O
D	O
##HT	O
,	O
90	O
##U	O
of	O
E	O
.	O
co	O
##li	O
β	O
-	O
g	O
##lu	O
##cu	O
##ron	O
##idas	O
##e	O
,	O
30	O
##U	O
of	O
A	O
##bal	O
##one	O
en	O
##tra	O
##ils	O
su	O
##lf	O
##ata	O
##se	O
and	O
1	O
μ	O
##L	O
of	O
the	O
a	O
##que	O
##ous	O
fraction	O
,	O
a	O
fresh	O
al	O
##iq	O
##uo	O
##t	O
of	O
30	O
U	O
of	O
A	O
##bal	O
##one	O
en	O
##tra	O
##ils	O
su	O
##lf	O
##ata	O
##se	O
was	O
added	O
at	O
the	O
12	O
h	O
time	O
point	O
.	O

Ph	B
##en	I
##yla	I
##ce	I
##ty	I
##l	I
##g	I
##lut	I
##amine	I
was	O
also	O
identified	O
tentatively	O
as	O
a	O
signal	O
ex	O
##p	O
##lana	O
##tory	O
of	O
chemical	O
differences	O
between	O
fast	O
##ing	O
and	O
‘	O
PR	O
##E	O
’	O
urine	O
samples	O
(	O
Table	O
)	O
.	O

Whereas	O
this	O
post	O
##pra	O
##ndi	O
##al	O
kinetic	O
behaviour	O
of	O
C	B
##15	I
:	I
0	I
has	O
not	O
been	O
reported	O
yet	O
,	O
P	O
##elli	O
##s	O
et	O
al	O
.	O
reported	O
findings	O
similar	O
to	O
ours	O
for	O
C	B
##17	I
:	I
0	I
with	O
a	O
post	O
##pra	O
##ndi	O
##al	O
increase	O
in	O
the	O
plasma	O
concentrations	O
of	O
this	O
fatty	O
acid	O
after	O
a	O
la	O
##g	O
time	O
of	O
4	O
h	O
in	O
response	O
to	O
the	O
intake	O
of	O
a	O
dairy	O
shake	O
.	O

BC	O
##AA	O
are	O
the	O
most	O
often	O
changed	O
amino	O
acid	O
group	O
following	O
bar	O
##ia	O
##tric	O
surgery	O
.	O
35	O
Furthermore	O
,	O
a	O
significant	O
reduction	O
of	O
2	B
‐	I
o	I
##x	I
##ois	I
##oc	I
##ap	I
##roa	I
##te	I
(	I
α	I
‐	I
k	I
##eto	I
##is	I
##oc	I
##ap	I
##roa	I
##te	I
)	I
was	O
detected	O
at	O
6	O
months	O
post	O
‐	O
surgery	O
compared	O
with	O
pre	O
‐	O
surgery	O
.	O

The	O
serum	O
levels	O
of	O
g	B
##ly	I
##cine	I
,	O
se	B
##rine	I
and	O
th	B
##re	I
##oni	I
##ne	I
were	O
significantly	O
changed	O
in	O
treatment	O
-	O
resistant	O
depression	O
.	O

For	O
absolute	O
q	O
##uant	O
##itation	O
,	O
meta	O
##bol	O
##ites	O
were	O
analyzed	O
by	O
is	O
##oto	O
##pe	O
di	O
##lution	O
U	O
##HP	O
##LC	O
-	O
MS	O
-	O
MS	O
(	O
except	O
for	O
palm	B
##ito	I
##le	I
##ic	I
acid	I
,	O
palm	B
##ito	I
##yl	I
-	I
l	I
##ys	I
##o	I
-	I
PC	I
,	O
and	O
o	B
##leo	I
##yl	I
-	I
l	I
##ys	I
##o	I
-	I
PC	I
)	O
.	O

Thus	O
,	O
RC	O
##E	O
is	O
predicted	O
to	O
be	O
safe	O
in	O
normal	O
breast	O
tissues	O
,	O
yet	O
it	O
may	O
m	O
##od	O
##ulate	O
est	B
##rogen	I
metabolism	O
to	O
increase	O
g	O
##eno	O
##to	O
##xi	O
##c	O
meta	O
##bol	O
##ites	O
in	O
breast	O
cancer	O
.	O

The	O
a	O
##que	O
##ous	O
met	B
##han	I
##olic	I
layer	O
was	O
collected	O
and	O
dried	O
completely	O
.	O

Seven	O
additional	O
meta	O
##bol	O
##ites	O
correlated	O
>	O
90	O
%	O
with	O
the	O
binary	O
or	B
##ota	I
##te	I
profile	O
(	O
Su	O
##pp	O
##lement	O
##ary	O
Figure	O
S	O
##3	O
##c	O
)	O
.	O

The	O
in	O
##cre	O
##ment	O
in	O
24	B
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
per	O
unit	O
higher	O
25	O
(	O
OH	O
)	O
D	O
_	O
3	O

But	O
the	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
were	O
found	O
to	O
be	O
elevated	O
in	O
the	O
plasma	O
of	O
patients	O
with	O
mild	O
cognitive	O
imp	O
##air	O
##ment	O
and	O
al	O
##z	O
##heimer	O
'	O
s	O
disease	O
,	O
which	O
possessed	O
some	O
correlation	O
with	O
our	O
results	O
.	O

For	O
T	B
##MA	I
##O	I
q	O
##uant	O
##ification	O
,	O
before	O
the	O
analysis	O
,	O
each	O
sample	O
was	O
added	O
with	O
T	O
##MA	O
##O	O
-	O
d	O
##9	O
as	O
internal	O
standard	O
and	O
then	O
extracted	O
with	O
acid	O
##ified	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
,	O
as	O
previously	O
described	O
.	O

We	O
analyzed	O
n	O
##uc	O
##leo	O
##tide	O
##s	O
using	O
high	O
-	O
performance	O
liquid	O
ch	O
##roma	O
##tography	O
coupled	O
to	O
tandem	O
mass	O
s	O
##pect	O
##rome	O
##try	O
in	O
liver	O
tissue	O
from	O
30	O
HC	O
##V	O
-	O
infected	O
patients	O
with	O
he	O
##pa	O
##to	O
##cellular	O
car	O
##cin	O
##oma	O
who	O
were	O
administered	O
so	B
##fo	I
##s	I
##bu	I
##vir	I
(	O
400	O
mg	O
/	O
day	O
)	O
and	O
rib	O
##avi	O
##rin	O
(	O
1	O
,	O
000	O
to	O
1	O
,	O
200	O
mg	O
/	O
day	O
)	O
for	O
3	O
to	O
52	O
weeks	O
prior	O
to	O
liver	O
transplant	O
##ation	O
.	O

Not	O
##ably	O
,	O
g	B
##ly	I
##cine	I
,	O
a	O
precursor	O
of	O
sa	B
##rc	I
##os	I
##ine	I
,	O
induced	O
invasion	O
in	O
these	O
cells	O
,	O
although	O
to	O
a	O
lesser	O
degree	O
than	O
sa	B
##rc	I
##os	I
##ine	I
.	O

The	O
following	O
ninety	O
-	O
seven	O
meta	O
##bol	O
##ites	O
were	O
characterized	O
:	O
s	O
##tero	O
##l	O
lip	O
##ids	O
(	O
n	O
=	O
19	O
)	O
,	O
s	O
##tero	O
##ids	O
and	O
s	O
##tero	O
##id	O
derivatives	O
(	O
n	O
=	O
2	O
)	O
,	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
(	O
n	O
=	O
6	O
)	O
,	O
pre	B
##no	I
##l	I
lip	O
##ids	O
(	O
n	O
=	O
6	O
)	O
,	O
p	O
##oly	O
##ket	O
##ides	O
(	O
n	O
=	O
11	O
)	O
,	O
la	B
##cton	I
##es	I
(	O
n	O
=	O
2	O
)	O
,	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
(	O
n	O
=	O
14	O
)	O
,	O
g	B
##ly	I
##cer	I
##oli	I
##pid	I
##s	I
(	O
n	O
=	O
6	O
)	O
,	O
fl	B
##av	I
##ono	I
##ids	I
(	O
n	O
=	O
1	O
)	O
,	O
fatty	O
a	O
##cy	O
##ls	O
(	O
n	O
=	O
20	O
)	O
,	O
co	O
##uma	O
##rin	O
##s	O
and	O
derivatives	O
(	O
n	O
=	O
1	O
)	O
,	O
and	O
car	B
##box	I
##yl	I
##ic	I
acids	I
and	O
derivatives	O
(	O
n	O
=	O
4	O
)	O
.	O

Form	B
##ate	I
(	O
8	O
.	O
5	O
pp	O
##m	O
,	O
P	O
=	O
0	O
.	O
44	O
)	O
was	O
non	O
-	O
significantly	O
elevated	O
in	O
the	O
HC	O
##C	O
group	O
and	O
was	O
not	O
identified	O
as	O
a	O
disc	O
##rim	O
##inator	O
##y	O
meta	O
##bol	O
##ite	O
in	O
West	O
African	O
or	O
Egyptian	O
groups	O
in	O
the	O
past	O
.	O

For	O
N	O
##MR	O
analysis	O
,	O
dried	O
polar	O
extract	O
##s	O
were	O
then	O
re	O
##sus	O
##pen	O
##ded	O
in	O
100	O
m	O
##M	O
sodium	B
phosphate	I
,	O
pH	O
7	O
,	O
with	O
0	O
.	O
5	O
m	O
##M	O
T	O
##SP	O
as	O
internal	O
reference	O
and	O
10	O
%	O
D	O
##2	O
##O	O
as	O
lock	O
solvent	O
.	O

We	O
used	O
a	O
high	O
-	O
pressure	O
liquid	O
ch	O
##roma	O
##tography	O
–	O
tandem	O
mass	O
s	O
##pect	O
##rome	O
##try	O
system	O
that	O
was	O
developed	O
for	O
the	O
determination	O
of	O
ta	B
##mo	I
##xi	I
##fen	I
and	O
its	O
meta	O
##bol	O
##ites	O
in	O
serum	O
[	O
,	O
]	O
.	O

48	O
##±	O
##3	O
%	O
,	O
di	B
##hy	I
##dr	I
##ox	I
##y	I
P	O
##U	O
##FA	O
(	O
L	O
##T	O
##B	O
_	O
4	O
/	O
a	O
5	B
,	I
12	I
-	I
di	I
##H	I
##ET	I
##E	I
)	O

Following	O
a	O
20	O
h	O
in	O
##cu	O
##bation	O
at	O
37	O
##°	O
##C	O
,	O
each	O
sample	O
was	O
extracted	O
two	O
times	O
with	O
an	O
equal	O
volume	O
of	O
t	B
-	I
but	I
##yl	I
met	I
##hyl	I
et	I
##her	I
.	O

El	O
##eva	O
##ted	O
plasma	O
levels	O
of	O
x	B
##ant	I
##hine	I
and	O
in	B
##os	I
##ine	I
appeared	O
to	O
be	O
associated	O
with	O
higher	O
T	O
##2	O
##D	O
risk	O
only	O
in	O
T	O
##T	O
individuals	O
.	O

With	O
the	O
addition	O
of	O
gal	B
##act	I
##ose	I
to	O
the	O
culture	O
medium	O
of	O
fi	O
##bro	O
##blast	O
##s	O
from	O
patients	O
,	O
g	O
##ly	O
##cos	O
##yla	O
##tion	O
was	O
substantially	O
enhanced	O
,	O
as	O
assessed	O
by	O
means	O
of	O
g	O
##ly	O
##cos	O
##yla	O
##tion	O
of	O
I	O
##CA	O
##M	O
-	O
1	O
and	O
G	B
##ly	I
##c	I
-	I
ER	I
-	I
G	I
##FP	I
.	O

We	O
previously	O
published	O
results	O
from	O
29	O
of	O
the	O
d	O
##MD	O
##D	O
subjects	O
and	O
20	O
of	O
the	O
HC	O
##s	O
making	O
up	O
the	O
current	O
sample	O
in	O
the	O
context	O
of	O
a	O
study	O
examining	O
associations	O
between	O
k	B
##yn	I
##uren	I
##ine	I
meta	O
##bol	O
##ites	O
and	O
gray	O
matter	O
volumes	O
of	O
the	O
hip	O
##po	O
##cam	O
##pus	O
and	O
am	O
##y	O
##g	O
##dal	O
##a	O
.	O

DNA	O
replication	O
in	O
t	O
##umour	O
cells	O
rapidly	O
exhaust	O
##s	O
thy	B
##mine	I
levels	O
;	O
hence	O
,	O
decreased	O
D	O
##HT	O
could	O
be	O
a	O
feasible	O
new	O
bio	O
##mark	O
##er	O
associated	O
with	O
t	O
##umour	O
occurrence	O
.	O

Once	O
again	O
,	O
the	O
correlation	O
between	O
la	B
##ct	I
##ate	I
and	O
al	B
##ani	I
##ne	I
can	O
be	O
accounted	O
for	O
,	O
and	O
in	O
this	O
model	O
it	O
is	O
also	O
possible	O
to	O
see	O
why	O
t	O
##G	O
##lut	O
co	O
##rrel	O
##ates	O
with	O
both	O
la	B
##ct	I
##ate	I
and	O
al	B
##ani	I
##ne	I
,	O
since	O
both	O
g	B
##lut	I
##amine	I
and	O
g	B
##lut	I
##ama	I
##te	I
are	O
involved	O
in	O
the	O
metabolic	O
pathway	O
whereby	O
la	B
##ct	I
##ate	I
and	O
al	B
##ani	I
##ne	I
can	O
be	O
synthesis	O
##ed	O
.	O

For	O
that	O
purpose	O
,	O
we	O
collected	O
time	O
-	O
resolved	O
human	O
plasma	O
samples	O
at	O
16	O
time	O
##points	O
after	O
the	O
consumption	O
of	O
_	O
13	O
C	O
-	O
labeled	O
bread	O
and	O
q	O
##uant	O
##ified	O
_	O
13	O
C	O
en	O
##rich	O
##ment	O
of	O
12	O
meta	O
##bol	O
##ites	O
(	B
glucose	S
,	O
la	B
##ct	I
##ate	I
,	O
al	B
##ani	I
##ne	I
,	O
g	B
##ly	I
##cine	I
,	O
se	B
##rine	I
,	O
c	B
##it	I
##rate	I
,	O
g	B
##lut	I
##ama	I
##te	I
,	O
g	B
##lut	I
##amine	I
,	O
v	B
##ali	I
##ne	I
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
and	O
th	B
##re	I
##oni	I
##ne	I
)	O
.	O

The	O
inverse	O
associations	O
of	O
ch	B
##olin	I
##e	I
and	O
P	O
##LC	O
risk	O
were	O
not	O
significantly	O
modified	O
,	O
although	O
stronger	O
among	O
non	O
-	O
smoke	O
##rs	O
than	O
smoke	O
##rs	O
(	O
P	O
-	O
trend	O
<	O
0	O
.	O
00	O
##1	O
,	O
P	O
-	O
interaction	O
=	O
0	O
.	O
00	O
##1	O
)	O
,	O
and	O
stronger	O
among	O
women	O
than	O
men	O
(	O
P	O
-	O
trend	O
<	O
0	O
.	O
00	O
##1	O
,	O

Interest	O
##ingly	O
,	O
the	O
secondary	O
bi	O
##le	O
acids	O
U	O
##DC	O
##A	O
and	O
T	O
##U	O
##DC	O
##A	O
are	O
associated	O
with	O
the	O
lower	O
B	O
##MI	O
z	O
-	O
score	O
,	O
whilst	O
bacterial	O
meta	O
##bol	O
##ites	O
hip	B
##pura	I
##te	I
and	O
3	B
-	I
h	I
##ydro	I
##xy	I
##phe	I
##ny	I
##lace	I
##tate	I
are	O
positively	O
associated	O
with	O
the	O
higher	O
ones	O
.	O

Ser	O
##um	O
pro	B
##state	I
-	I
specific	I
anti	O
##gen	O
(	O
PS	O
##A	O
)	O
is	O
currently	O
the	O
most	O
used	O
bio	O
##mark	O
##er	O
in	O
clinical	O
practice	O
for	O
pro	O
##state	O
cancer	O
(	O
PC	O
##a	O
)	O
detection	O
.	O

L	O
##D	O
##L	O
-	O
C	O
and	O
total	O
plasma	O
ch	B
##ole	I
##ster	I
##ol	I
were	O
significantly	O
and	O
positively	O
correlated	O
with	O
total	O
Ce	B
##r	I
(	I
d	I
##18	I
:	I
1	I
/	I
X	I
)	I
species	O
,	O
as	O
well	O
as	O
total	O
SM	B
(	I
d	I
##18	I
:	I
1	I
/	I
X	I
)	I
species	O
(	O
r	O
=	O
0	O
.	O
45	O
and	O
0	O
.	O
40	O
for	O
L	O
##D	O
##L	O
-	O
C	O
with	O
Ce	B
##r	I
and	O
SM	O
respectively	O
,	O
p	O
<	O
0	O
.	O
00	O
##1	O
,	O
and	O
r	O
=	O
0	O
.	O
46	O
and	O
0	O
.	O
42	O
for	O
ch	B
##ole	I
##ster	I
##ol	I
with	O
Ce	B
##r	I
and	O
SM	O
respectively	O
,	O
p	O
<	O
0	O
.	O
00	O
##1	O
)	O
.	O

The	O
mass	O
s	O
##pect	O
##rome	O
##try	O
portion	O
of	O
the	O
un	O
##bia	O
##sed	O
pro	O
##fi	O
##ling	O
platform	O
is	O
based	O
on	O
a	O
1200	O
SL	S
Rapid	O
resolution	O
L	O
##C	O
and	O
a	O
65	O
##20	O
Q	O
##uad	O
##rup	O
##ole	O
Time	O
of	O
Flight	O
mass	O
s	O
##pect	O
##rome	O
##ter	O
(	O
A	O
##gi	O
##lent	O
Technologies	O
,	O
Santa	O
Clara	O
,	O
CA	O
)	O
.	O

In	O
contrast	O
,	O
a	O
recent	O
study	O
,	O
published	O
by	O
Long	O
et	O
al	O
.	O
reported	O
decreased	O
levels	O
of	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
in	O
color	O
##ec	O
##tal	O
cancer	O
and	O
p	O
##oly	O
##ps	O
compared	O
to	O
controls	O
.	O
20	O
Like	O
ta	B
##uri	I
##ne	I
,	I
5	I
h	I
##y	I
##pox	I
##ant	I
##hine	I
is	O
an	O
anti	O
##ox	O
##ida	O
##nt	O
and	O
increased	O
levels	O
reported	O
in	O
our	O
study	O
may	O
be	O
the	O
result	O
of	O
increased	O
o	O
##xi	O
##da	O
##tive	O
stress	O
,	O
28	O
which	O
is	O
recognized	O
as	O
an	O
important	O
process	O
in	O
car	O
##cin	O
##ogen	O
##esis	O
,	O
including	O
color	O
##ec	O
##tal	O
cancer	O
.	O
29	O
,	O
30	O
Inc	O
##ons	O
##ist	O
##ent	O
findings	O
in	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
levels	O
may	O
be	O
due	O
to	O
the	O
type	O
of	O
specimen	O
analyzed	O
,	O
or	O
lack	O
of	O
statistical	O
power	O
because	O
of	O
lower	O
sample	O
numbers	O
included	O
.	O

As	B
##par	I
##tate	I
,	O
more	O
##over	O
,	O
was	O
significantly	O
associated	O
with	O
increased	O
risk	O
of	O
developing	O
c	O
##er	O
##vic	O
##al	O
cancer	O
from	O
normal	O
.	O

The	O
first	O
2	O
-	O
minute	O
period	O
consisted	O
of	O
5	O
%	O
solution	O
A	O
(	O
2	O
%	O
[	O
vol	O
/	O
vol	O
]	O
form	B
##ic	I
acid	I
in	O
water	O
)	O
,	O
60	O
%	O
water	O
,	O
35	O
%	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
,	O
and	O
the	O
final	O
4	O
-	O
minute	O
period	O
was	O
maintained	O
at	O
5	O
%	O
solution	O
A	O
,	O
95	O
%	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
.	O

For	O
comparison	O
between	O
AI	O
##S	O
A	O
and	O
AI	O
##S	O
B	O
,	O
AU	O
##C	O
values	O
of	O
greater	O
than	O
0	O
.	O
8	O
were	O
observed	O
for	O
N	O
##1	O
,	O
N	B
##12	I
-	I
di	I
##ace	I
##ty	I
##ls	I
##per	I
##mine	I
,	O
la	B
##ctic	I
acid	I
and	O
g	B
##ly	I
##cer	I
##ol	I
used	O
individually	O
,	O
and	O
a	O
larger	O
AU	O
##C	O
value	O
(	O
0	O
.	O
87	O
##5	O
)	O
was	O
obtained	O
when	O
these	O
meta	O
##bol	O
##ites	O
were	O
used	O
together	O
.	O

L	O
(	O
126	O
mg	O
/	O
d	O
##L	O
)	O
,	O
2	O
)	O
random	O
sample	O
plasma	O
glucose	S
≥	O
11	O
.	O
1	O
mm	O
##ol	O
/	O
L	O
(	O
200	O
mg	O
/	O
d	O
##L	O
)	O
,	O
3	O
)	O
self	O
-	O
report	O
of	O
a	O
physician	O
diagnosis	O
of	O
T	O
##2	O
##DM	O
,	O
and	O
4	O
)	O
initiation	O
of	O
glucose	O
-	O
lowering	O
medication	O
use	O
,	O
retrieved	O
from	O
a	O
central	O
pharmacy	O
registry	O
.	O

Wong	O
et	O
al	O
.	O
reported	O
that	O
c	B
##era	I
##mi	I
##des	I
strongly	O
predicted	O
C	O
##V	O
events	O
(	O
OR	O
3	O
.	O
44	O
)	O
in	O
as	O
##ym	O
##pt	O
##oma	O
##tic	O
P	O
##L	O
##W	O
##H	O
;	O
this	O
finding	O
is	O
consistent	O
with	O
data	O
from	O
studies	O
is	O
in	O
HIV	O
-	O
un	O
##in	O
##fected	O
people	O
.	O

Effects	O
of	O
low	O
G	O
##F	O
##R	O
on	O
vitamin	B
D	I
cat	O
##ab	O
##olis	O
##m	O
are	O
less	O
well	O
understood	O
.	O

Ser	O
##um	O
glucose	S
was	O
anal	O
##ys	O
##ed	O
using	O
glucose	O
##he	O
##x	O
##oki	O
##nas	O
##e	O
3	O
kit	O
(	O
Siemens	O
Health	O
Care	O
Di	O
##ag	O
##nos	O
##tics	O
,	O
Germany	O
)	O
and	O
insulin	O
was	O
determined	O
with	O
im	O
##mu	O
##nor	O
##adi	O
##ometric	O
ass	O
##ays	O
(	O
I	O
##mm	O
##uno	O
##tech	O
,	O
France	O
)	O
.	O

Their	O
correlation	O
coefficient	O
was	O
−	O
##0	O
.	O
90	O
##5	O
,	O
indicating	O
a	O
negative	O
correlation	O
between	O
S	B
-	I
ad	I
##eno	I
##sy	I
##l	I
-	I
l	I
-	I
met	I
##hi	I
##oni	I
##ne	I
and	O
N	B
-	I
ace	I
##ty	I
##ls	I
##per	I
##mi	I
##dine	I
.	O

(	O
a	O
)	O
P	O
##lot	O
of	O
relative	O
frequency	O
versus	O
relative	O
concentrations	O
of	O
se	B
##rine	I
.	O

Alt	O
##eration	O
##s	O
in	O
the	O
energy	O
metabolism	O
are	O
reflected	O
clearly	O
in	O
altered	O
glucose	S
levels	O
.	O

The	O
phosphate	S
bands	O
at	O
1	O
,	O
08	O
##0	O
and	O
99	O
##0	O
cm	O
_	O
−	O
##1	O
decrease	O
,	O
giving	O
rise	O
to	O
negative	O
intensity	O
,	O
while	O
the	O
one	O
at	O
1	O
,	O
160	O
cm	O
_	O
−	O
##1	O
increases	O
,	O
all	O
corresponding	O
with	O
a	O
lower	O
pH	O
.	O
Furthermore	O
,	O
a	O
positive	O
band	O
at	O
1	O
,	O
36	O
##1	O
cm	O
_	O
−	O
##1	O
can	O
be	O
disc	O
##erne	O
##d	O
.	O

The	O
third	O
generation	O
product	O
ion	O
spectrum	O
(	O
MS	O
_	O
4	O
)	O
of	O
m	O
/	O
z	O
226	O
.	O
2	O
produced	O
ions	O
at	O
m	O
/	O
z	O
211	O
.	O
2	O
,	O
198	O
.	O
2	O
and	O
183	O
.	O
2	O
;	O
these	O
ions	O
correspond	O
to	O
,	O
respectively	O
,	O
the	O
loss	O
of	O
the	O
CH	O
_	O
3	O
•	O
,	O
CO	O
,	O
and	O
the	O
losses	O
of	O
CH	O
_	O
3	O
•	O
and	O
CO	O
from	O
2	B
-	I
H	I
##O	I
-	I
Ph	I
##IP	I
.	O

Hip	B
##pur	I
##ic	I
acid	I
can	O
also	O
con	O
##tend	O
with	O
other	O
organic	O
acids	O
for	O
the	O
secret	O
##ory	O
pathway	O
in	O
the	O
pro	O
##ximal	O
ne	B
##ph	I
##ron	I
so	O
that	O
metabolic	O
acid	O
##osis	O
in	O
kidney	O
disease	O
is	O
severely	O
a	O
##gg	O
##ra	O
##vated	O
.	O

Intermediate	O
##s	O
of	O
pro	B
##line	I
cat	O
##ab	O
##olis	O
##m	O
were	O
associated	O
with	O
O	O
##C	O
##N	O
reflecting	O
the	O
imp	O
##lication	O
in	O
bone	O
metabolism	O
.	O

Age	O
had	O
a	O
significant	O
effect	O
on	O
levels	O
of	O
P	O
##GE	O
-	O
M	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
but	O
not	O
on	O
8	B
-	I
is	I
##o	I
-	I
P	I
##G	I
##F	I
_	I
2	I
##α	I
.	O

P	O
##las	O
##ma	O
car	B
##ni	I
##tine	I
levels	O
in	O
study	O
subjects	O
were	O
within	O
published	O
reference	O
values	O
(	O
31	O
to	O
61	O
nm	O
##ol	O
/	O
m	O
##L	O
)	O
.	O

Ser	O
##um	O
levels	O
(	O
nm	O
##ol	O
/	O
L	O
)	O
of	O
T	O
##rp	O
meta	O
##bol	O
##ites	O
and	O
L	B
-	I
D	I
##OP	I
##A	I
in	O
AP	O
##S	O
-	O
1	O
according	O
to	O
T	O
##P	O
##H	O
-	O
1	O
and	O
AA	O
##DC	O
A	O
##ab	O
##s	O
.	O

N	O
##MR	O
found	O
the	O
same	O
phenomenon	O
for	O
t	B
##yr	I
##os	I
##ine	I
,	O
v	B
##ali	I
##ne	I
,	O
and	O
is	B
##ole	I
##uc	I
##ine	I
,	O
however	O
,	O
not	O
for	O
met	B
##hi	I
##oni	I
##ne	I
.	O

Mobile	O
phases	O
were	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
in	O
water	O
(	O
phase	O
A	O
)	O
and	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
in	O
is	O
##op	O
##rop	O
##ano	O
##l	O
:	O
ace	O
##ton	O
##it	O
##ril	O
##e	O
:	O
water	O
(	O
60	O
:	O
36	O
:	O
4	O
)	O
(	O
phase	O
B	O
)	O
.	O

Therefore	O
,	O
in	O
clinic	O
,	O
we	O
not	O
only	O
need	O
to	O
control	O
fast	O
##ing	O
blood	B
-	I
glucose	I
,	O
blood	O
pressure	O
,	O
blood	O
lip	O
##id	O
levels	O
and	O
o	O
##besity	O
,	O
but	O
also	O
should	O
pay	O
attention	O
to	O
the	O
risk	O
factor	O
of	O
h	O
##yper	O
##uri	O
##ce	O
##mia	O
and	O
give	O
relative	O
intervention	O
measures	O
in	O
a	O
time	O
##ly	O
fashion	O
.	O

A	O
g	B
##ly	I
##cine	I
c	O
##lea	O
##vage	O
system	O
is	O
active	O
in	O
some	O
cells	O
which	O
produce	O
am	O
##monia	O
,	O
carbon	B
dioxide	I
and	O
a	O
carbon	O
unit	O
for	O
the	O
met	O
##hyl	O
##ation	O
of	O
te	B
##tra	I
##hy	I
##dr	I
##of	I
##olate	I
.	O

To	O
identify	O
the	O
meta	O
##bol	O
##ite	O
,	O
the	O
peak	O
-	O
pair	O
mass	O
and	O
retention	O
time	O
were	O
searched	O
against	O
a	O
dans	B
##yl	I
-	I
standard	I
library	O
comprising	O
304	O
human	O
end	O
##ogen	O
##ous	O
am	O
##ine	O
and	O
p	B
##hen	I
##ol	I
meta	O
##bol	O
##ites	O
(	O
the	O
retention	O
-	O
time	O
tolerance	O
was	O
set	O
at	O
1	O
min	O
,	O
and	O
the	O
mass	O
tolerance	O
was	O
set	O
at	O
10	O
pp	O
##m	O
)	O
.	O

A	O
shift	O
towards	O
an	O
##ae	O
##ro	O
##bic	O
metabolism	O
might	O
indicate	O
respiratory	O
chain	O
d	O
##ys	O
##function	O
in	O
mit	O
##och	O
##ond	O
##ria	O
of	O
the	O
kidney	O
during	O
rejection	O
and	O
a	O
subsequent	O
accumulation	O
of	O
la	B
##ct	I
##ate	I
.	O

As	O
early	O
as	O
in	O
the	O
mid	O
-	O
70s	O
,	O
it	O
had	O
been	O
established	O
that	O
ch	O
##olin	O
##e	O
ace	O
##ty	O
##lt	O
##ran	O
##s	O
##fer	O
##ase	O
activity	O
is	O
much	O
more	O
reduced	O
in	O
brain	O
tissue	O
from	O
AD	O
patients	O
than	O
in	O
age	O
-	O
matched	O
controls	O
–	O
an	O
observation	O
commonly	O
known	O
as	O
ch	B
##olin	I
##ergic	I
deficit	O
in	O
AD	O
.	O

We	O
also	O
found	O
a	O
weak	O
correlation	O
between	O
hip	B
##pur	I
##ic	I
acid	I
with	O
AB	O
##I	O
in	O
the	O
entire	O
co	O
##hor	O
##t	O
,	O
suggesting	O
that	O
the	O
relationship	O
between	O
hip	B
##pur	I
##ic	I
acid	I
and	O
at	O
##her	O
##os	O
##cle	O
##rosis	O
is	O
complex	O
and	O
requires	O
further	O
study	O
in	O
a	O
larger	O
co	O
##hor	O
##t	O
.	O

The	O
reduction	O
in	O
the	O
levels	O
of	O
K	O
##Y	O
##NA	O
,	O
which	O
behave	O
##s	O
as	O
a	O
competitive	O
antagonist	O
of	O
the	O
g	B
##ly	I
##cine	I
site	O
of	O
N	O
##MD	O
##A	O
receptors	O
,	O
is	O
consistent	O
with	O
the	O
hypothesis	O
that	O
N	O
##MD	O
##A	O
receptors	O
are	O
over	O
##active	O
in	O
mi	O
##gra	O
##ine	O
.	O

Pre	O
##c	O
##lini	O
##cal	O
,	O
in	O
v	O
##it	O
##ro	O
,	O
and	O
post	O
-	O
m	O
##ort	O
##em	O
data	O
demonstrate	O
that	O
elevated	O
concentrations	O
of	O
‘	O
ne	O
##uro	O
##to	O
##xi	O
##c	O
'	O
k	B
##yn	I
##uren	I
##ine	I
meta	O
##bol	O
##ites	O
are	O
associated	O
with	O
ne	O
##uron	O
##al	O
damage	O
and	O
/	O
or	O
suppression	O
of	O
ne	O
##uro	O
##genesis	O
—	O
particularly	O
in	O
the	O
hip	O
##po	O
##cam	O
##pus	O
.	O

Met	O
##ab	O
##olic	O
pro	O
##fi	O
##ling	O
prior	O
to	O
si	B
##m	I
##vas	I
##tat	I
##in	I
treatment	O
may	O
assist	O
in	O
identifying	O
individuals	O
who	O
are	O
at	O
higher	O
risk	O
of	O
adverse	O
side	O
effects	O
.	O

We	O
log	O
-	O
transformed	O
the	O
data	O
of	O
met	B
##ha	I
##cho	I
##line	I
concentration	O
needed	O
to	O
produce	O
a	O
20	O
%	O
fall	O
in	O
F	O
##E	O
##V	O
_	O
1	O
and	O
the	O
serum	O
total	O
I	O
##g	O
##E	O
level	O
to	O
correct	O
their	O
s	O
##ke	O
##wed	O
distributions	O
.	O

We	O
and	O
others	O
have	O
also	O
described	O
higher	O
AD	B
##MA	I
levels	O
with	O
greater	O
disease	O
severity	O
within	O
CH	O
##F	O
(	O
,	O
)	O
.	O

An	O
improved	O
understanding	O
of	O
vitamin	B
D	I
cat	O
##ab	O
##olis	O
##m	O
may	O
help	O
identify	O
new	O
diagnostic	O
and	O
therapeutic	O
strategies	O
to	O
improve	O
health	O
in	O
chronic	O
kidney	O
disease	O
(	O
C	O
##K	O
##D	O
)	O
because	O
impaired	O
vitamin	B
D	I
metabolism	O
leads	O
to	O
secondary	O
h	O
##yper	O
##par	O
##athy	O
##roid	O
##ism	O
and	O
bone	O
disease	O
and	O
may	O
contribute	O
to	O
card	O
##iovascular	O
disease	O
,	O
progression	O
to	O
end	O
stage	O
re	O
##nal	O
disease	O
,	O
and	O
premature	O
death	O
.	O
_	O
–	O
To	O
better	O
assess	O
vitamin	B
D	I
cat	O
##ab	O
##olis	O
##m	O
in	O
humans	O
,	O
we	O
developed	O
a	O
novel	O
high	O
-	O
through	O
##put	O
ass	O
##ay	O
for	O
circulating	O
24	B
,	I
25	I
-	I
di	I
##hy	I
##dr	I
##ox	I
##y	I
##vi	I
##tam	I
##in	I
D	I
(	I
24	I
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	I
_	I
3	I
)	I
.	O

V	O
##eno	O
##us	O
blood	O
samples	O
were	O
obtained	O
for	O
the	O
analyses	O
of	O
glucose	S
,	O
insulin	O
,	O
non	O
-	O
est	O
##eri	O
##fied	O
fatty	O
acids	O
,	O
le	O
##pt	O
##in	O
,	O
and	O
ad	O
##ip	O
##one	O
##ct	O
##in	O
.	O

These	O
plots	O
show	O
the	O
same	O
trends	O
(	O
increased	O
or	O
decreased	O
)	O
as	O
all	O
samples	O
with	O
the	O
exception	O
of	O
g	B
##lut	I
##ami	I
##c	I
acid	I
,	O
which	O
shows	O
the	O
same	O
trend	O
for	O
females	O
,	O
but	O
not	O
for	O
males	O
.	O

To	O
rule	O
out	O
the	O
potential	O
influence	O
of	O
plate	O
##let	O
activity	O
,	O
sex	O
,	O
age	O
and	O
B	O
##MI	O
on	O
the	O
concentration	O
of	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
,	O
participants	O
were	O
instructed	O
not	O
to	O
smoke	O
,	O
perform	O
any	O
intensive	O
physical	O
activity	O
or	O
take	O
any	O
medication	O
,	O
including	O
as	B
##pi	I
##rin	I
,	O
prior	O
to	O
blood	O
collection	O
.	O

The	O
basis	O
for	O
the	O
difference	O
between	O
these	O
animal	O
studies	O
which	O
have	O
analyzed	O
ch	B
##olin	I
##e	I
in	O
milk	O
collected	O
at	O
harvest	O
and	O
the	O
USD	O
##A	O
database	O
is	O
not	O
clear	O
,	O
although	O
it	O
may	O
relate	O
to	O
milk	O
processing	O
and	O
/	O
or	O
the	O
low	O
number	O
of	O
retail	O
samples	O
(	O
n	O
=	O
2	O
)	O
used	O
to	O
develop	O
the	O
USD	O
##A	O
database	O
estimate	O
.	O

After	O
72	O
h	O
,	O
the	O
cells	O
were	O
fixed	O
and	O
stained	O
with	O
0	O
.	O
1	O
%	O
crystal	O
violet	O
dissolved	O
in	O
20	O
%	O
met	B
##han	I
##ol	I
.	O

Lac	B
##tate	I
was	O
also	O
absent	O
in	O
D	O
##ME	O
##M	O
but	O
it	O
could	O
be	O
detected	O
in	O
24	O
h	O
D	O
##ME	O
##M	O
.	O

The	O
super	O
##nat	O
##ant	O
solution	O
obtained	O
after	O
this	O
second	O
protein	O
removal	O
step	O
was	O
then	O
dried	O
under	O
vacuum	O
and	O
the	O
obtained	O
residue	O
was	O
re	O
##con	O
##stituted	O
in	O
7	O
.	O
5	O
µ	O
##L	O
met	B
##han	I
##ol	I
and	O
v	O
##ortex	O
##ed	O
for	O
5	O
se	O
##c	O
.	O

From	O
these	O
results	O
,	O
it	O
is	O
evident	O
that	O
per	O
##ox	O
##idas	O
##e	O
enzymes	O
or	O
per	O
##ox	O
##idas	O
##e	O
-	O
like	O
activity	O
in	O
human	O
breast	O
tissue	O
could	O
o	O
##xi	O
##di	O
##ze	O
est	O
##rogen	O
##s	O
to	O
electro	O
##phi	O
##lic	O
and	O
stable	O
q	B
##uin	I
##one	I
met	O
##hi	O
##des	O
in	O
a	O
single	O
step	O
that	O
co	O
##valent	O
##ly	O
bind	O
to	O
DNA	O
to	O
form	O
add	O
##uc	O
##ts	O
.	O

K	B
##yn	I
##uren	I
##ine	I
,	O
q	B
##uin	I
##olin	I
##ic	I
acid	I
and	O
the	O
k	O
##yn	O
##uren	O
##ine	O
/	O
try	O
##pt	O
##op	O
##han	O
ratio	O
correlated	O
weakly	O
with	O
severe	O
fatigue	O
(	O
=	O
0	O
.	O
34	O
,	O
=	O
0	O
.	O
28	O
and	O
=	O
0	O
.	O
24	O
,	O
respectively	O
)	O
but	O
not	O
with	O
depression	O
.	O

d	O
In	B
##os	I
##ito	I
##l	I
structural	O
is	O
##omer	O
other	O
than	O
my	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
,	O
ch	O
##iro	O
-	O
in	O
##os	O
##ito	O
##l	O
,	O
s	B
##cy	I
##llo	I
-	I
in	I
##os	I
##ito	I
##l	I
.	O

)	O
were	O
performed	O
to	O
identify	O
the	O
potential	O
metabolic	O
pathways	O
per	O
##tur	O
##bed	O
in	O
A	B
##F	I
.	O

U	O
##rina	O
##ry	O
sa	B
##rc	I
##os	I
##ine	I
and	O
c	B
##ys	I
##tein	I
##e	I
levels	O
were	O
significantly	O
higher	O
(	O
p	O
=	O
0	O
.	O
03	O
and	O
p	O
=	O
0	O
.	O
00	O
##7	O
respectively	O
)	O
in	O
the	O
re	O
##current	O
group	O
.	O

De	O
##grad	O
##ation	O
of	O
try	B
##pt	I
##op	I
##han	I
in	O
the	O
k	B
##yn	I
##uren	I
##ine	I
pathway	O
is	O
initiated	O
by	O
the	O
c	O
##lea	O
##vage	O
of	O
an	O
in	B
##do	I
##le	I
ring	O
via	O
in	O
##do	O
##leam	O
##ine	O
2	O
,	O
3	O
-	O
di	O
##ox	O
##y	O
##gen	O
##ase	O
(	O
ID	O
##O	O
)	O
,	O
an	O
extra	O
##he	O
##pa	O
##tic	O
enzyme	O
induced	O
by	O
c	O
##yt	O
##oki	O
##nes	O
,	O
mainly	O
inter	O
##fer	O
##on	O
-	O
γ	O
(	B
IF	B
##N	I
-	I
γ	I
)	O
.	O

The	O
feedback	O
regulation	O
of	O
di	B
##acy	I
##l	I
##gly	I
##cer	I
##ol	I
bio	O
##sy	O
##nt	O
##hesis	O
occurred	O
through	O
the	O
correlated	O
synthesis	O
of	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
.	O

Rico	O
et	O
al	O
.	O
also	O
observed	O
similar	O
repeat	O
##ability	O
between	O
met	B
##han	I
##ol	I
and	O
C	O
##18	O
SP	O
##E	O
with	O
approximately	O
80	O
%	O
of	O
features	O
which	O
met	O
30	O
%	O
RS	O
##D	O
criteria	O
for	O
both	O
methods	O
.	O

Fast	O
##ing	O
plasma	O
glucose	S
(	O
F	O
##P	O
##G	O
)	O
,	O
total	O
ch	B
##ole	I
##ster	I
##ol	I
(	O
T	O
##C	O
)	O
,	O
and	O
t	B
##ria	I
##cy	I
##l	I
##gly	I
##cer	I
##ol	I
(	O
T	O
##AG	O
)	O
were	O
analyzed	O
using	O
W	O
##ak	O
##o	O
B	O
##io	O
##p	O
##rod	O
##uc	O
##ts	O
(	O
W	O
##ak	O
##o	O
Pure	O
Chemical	O
Industries	O
,	O
Richmond	O
,	O
VA	S
,	O
United	O
States	O
)	O
.	O

For	O
Panel	O
A	O
(	B
le	B
##uc	I
##ine	I
,	O
al	B
##ani	I
##ne	I
,	O
v	B
##ali	I
##ne	I
,	O
is	B
##ole	I
##uc	I
##ine	I
and	O
g	B
##lut	I
##ami	I
##c	I
acid	O
)	O
,	O
the	O
seven	O
ca	O
##li	O
##bra	O
##tor	O
concentrations	O
1	O
,	O
5	O
,	O
10	O
,	O
50	O
,	O
100	O
,	O
500	O
,	O
and	O
1	O
,	O
000	O
ng	O
m	O
##L	O
_	O
−	O
##1	O
were	O
evaluated	O
,	O
whereas	O
the	O
concentrations	O
10	O
,	O
50	O
,	O
100	O
,	O
500	O
,	O
1	O
,	O
000	O
,	O
5	O
,	O
000	O
,	O
and	O
10	O
,	O
000	O
ng	O
m	O
##L	O
_	O
−	O
##1	O
were	O
studied	O
with	O
respect	O
to	O
Panel	O
B	O
(	O
c	O
##ys	O
##tein	O
##e	O
,	O
a	B
##rg	I
##ini	I
##ne	I
,	O
pro	B
##line	I
,	O
met	B
##hi	I
##oni	I
##ne	I
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
try	B
##pt	I
##op	I
##han	I
,	O
se	B
##rine	I
,	O
th	B
##re	I
##oni	I
##ne	I
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
g	B
##ly	I
##cine	I
,	O
g	B
##lut	I
##amine	I
,	O
as	B
##par	I
##agi	I
##ne	I
,	O
as	B
##par	I
##tic	I
acid	I
,	O
l	B
##ys	I
##ine	I
,	O
and	O
his	B
##ti	I
##dine	I
)	O
.	O

Sam	O
##ples	O
were	O
el	O
##uted	O
with	O
an	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
gradient	O
containing	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
at	O
a	O
flow	O
rate	O
of	O
0	O
.	O
35	O
m	O
##L	O
/	O
min	O
for	O
20	O
minutes	O
.	O

_	O
1	O
H	O
N	O
##MR	O
(	O
700	O
MHz	O
,	O
D	O
##MS	O
##O	O
-	O
d	O
_	O
6	O
)	O
:	O
δ	O
6	O
.	O
80	O
(	O
s	O
,	O
1	O
##H	O
,	O
H	O
##2	O
′	O
)	O
,	O
6	O
.	O
68	O
(	O
s	O
,	O
1	O
##H	O
,	O
H	O
##5	O
′	O
)	O
,	O
6	O
.	O
00	O
(	O
s	O
,	O
1	O
##H	O
,	O
H	O
##4	O
′	O
)	O
,	O
4	O
.	O
08	O
-	O
4	O
.	O
03	O
(	O
m	O
,	O
1	O
##H	O
,	O
Cy	O
##s	O
α	B
-	I
CH	I
)	O
,	O
3	O
.	O
82	O
-	O
3	O
.	O
78	O
(	O
m	O
,	O
2	O
##H	O
,	O
H	O
##1	O
)	O
,	O
3	O
.	O
75	O
(	O
s	O
,	O
3	O
##H	O
,	O
O	O
##CH	O
_	O
3	O
)	O
,	O
3	O
.	O
01	O
-	O
2	O
.	O
99	O
(	O
m	O
,	O
1	O
##H	O
,	O
Cy	O
##s	O
β	B
-	I
CH	I
_	I
a	I
)	O
,	O
2	O
.	O
76	O
-	O
2	O
.	O
72	O
(	O
m	O
,	O
1	O
##H	O
,	O
L	O
##ys	O
β	B
-	I
CH	I
_	I
b	I
)	O
,	O
2	O
.	O
39	O
-	O
2	O
.	O
37	O
(	O
m	O
,	O
2	O
##H	O
,	O
H	O
##4	O
)	O
,	O
1	O
.	O
81	O
(	O
s	O
,	O
3	O
##H	O
,	O
Me	O
)	O
,	O
1	O
.	O
64	O
-	O
1	O
.	O
60	O
(	O
m	O
,	O
2	O
##H	O
,	O
H	O
##2	O
)	O
,	O
1	O
.	O
37	O
-	O
1	O
.	O
33	O
(	O
m	O
,	O
2	O
##H	O
,	O
H	O
##3	O
)	O
.	O

The	O
R	O
##Y	O
##GB	O
co	O
##hor	O
##t	O
included	O
m	O
##or	O
##bid	O
##ly	O
o	O
##bes	O
##e	O
individuals	O
with	O
type	O
2	O
diabetes	O
(	O
T	O
##2	O
##DM	O
)	O
who	O
were	O
taking	O
oral	O
diabetes	O
medications	O
,	O
g	O
##lu	O
##ca	O
##gon	O
-	O
like	O
p	B
##eptide	I
-	I
1	I
receptor	O
ago	O
##nist	O
##s	O
(	O
G	O
##LP	O
-	O
1	O
RA	O
)	O
or	O
insulin	O
,	O
while	O
W	O
##LM	O
enrolled	O
o	O
##bes	O
##e	O
subjects	O
who	O
were	O
taking	O
medications	O
for	O
h	O
##yper	O
##tens	O
##ion	O
and	O
/	O
or	O
d	O
##ys	O
##lip	O
##ide	O
##mia	O
.	O

Kid	O
##ney	O
and	O
pro	O
##state	O
cancer	O
tumor	O
and	O
ben	O
##ign	O
bio	O
##ps	O
##ies	O
were	O
stained	O
with	O
hem	B
##oto	I
##xy	I
##lin	I
and	O
e	B
##os	I
##in	I
and	O
pro	O
##state	O
bio	O
##ps	O
##ies	O
were	O
subjected	O
to	O
P	O
##IN	O
-	O
4	O
im	O
##mu	O
##no	O
##his	O
##to	O
##chemistry	O
.	O

In	O
line	O
with	O
these	O
previous	O
reports	O
,	O
we	O
speculated	O
that	O
l	B
##ino	I
##leam	I
##ide	I
and	O
palm	B
##itic	I
amid	I
##e	I
may	O
also	O
be	O
an	O
important	O
media	O
##tor	O
of	O
h	O
##y	O
##pox	O
##ic	O
pulmonary	O
v	O
##as	O
##oc	O
##ons	O
##tric	O
##tion	O
and	O
be	O
involved	O
in	O
the	O
generation	O
of	O
pulmonary	O
h	O
##yper	O
##tens	O
##ion	O
.	O

The	O
met	B
##form	I
##in	I
–	I
met	I
##hyl	I
##gly	I
##ox	I
##al	I
reaction	O
product	O
,	O
as	O
determined	O
by	O
X	O
-	O
ray	O
di	O
##ff	O
##raction	O
.	O

In	O
this	O
study	O
,	O
even	O
before	O
L	O
##C	O
development	O
,	O
the	O
L	O
##C	O
group	O
showed	O
higher	O
levels	O
of	O
palm	B
##ito	I
##yl	I
##car	I
##ni	I
##tine	I
and	O
o	B
##leo	I
##yl	I
##car	I
##ni	I
##tine	I
than	O
the	O
control	O
group	O
.	O

CA	O
##P	O
community	O
-	O
acquired	O
pneumonia	O
,	O
D	B
##H	I
##EA	I
-	I
S	I
de	I
##hy	I
##dr	I
##oe	I
##pian	I
##dr	I
##osterone	I
su	I
##lf	I
##ate	I
Eight	O
meta	O
##bol	O
##ites	O
could	O
distinguish	O
patients	O
with	O
severe	O
CA	O
##P	O
from	O
those	O
with	O
non	O
-	O
severe	O
CA	O
##P	O
and	O
are	O
presented	O
in	O
Additional	O
file	O
3	O
:	O
Table	O
##s	O
S	O
##1	O
and	O
S	O
##4	O
.	O

The	O
linear	O
model	O
com	O
##puted	O
to	O
estimate	O
the	O
de	O
##ter	O
##mina	O
##nts	O
of	O
each	O
me	B
##rca	I
##pt	I
##uri	I
##c	I
acid	I
(	O
µ	O
##g	O
/	O
L	O
)	O
in	O
workers	O
compared	O
to	O
controls	O
,	O
and	O
corrected	O
for	O
age	O
,	O
c	B
##rea	I
##tin	I
##ine	I
,	O
co	B
##tin	I
##ine	I
,	O
and	O
exposure	O
during	O
last	O
3	O
days	O
,	O
showed	O
a	O
significant	O
increase	O
in	O
levels	O
of	O
CE	O
##MA	O
(	O
p	O
<	O
0	O
.	O
00	O
##1	O
,	O
GM	O
##R	O
=	O
1	O
.	O
75	O
)	O
,	O
M	O
##H	O
##BM	O
##A	O
(	O
p	O
=	O
0	O
.	O
01	O
##0	O
,	O
GM	O
##R	O
=	O
2	O
.	O
06	O
)	O
,	O
P	O
##H	O
##EM	O
##A	O
,	O
(	O
p	O
<	O
0	O
.	O
00	O
##1	O
,	O
GM	O
##R	O
=	O
2	O
.	O
15	O
)	O
,	O
and	O
SP	O
##MA	O
(	O
p	O
<	O
0	O
.	O
00	O
##1	O
,	O
GM	O
##R	O
=	O
9	O
.	O
53	O
)	O
.	O

At	O
3	O
and	O
6	O
months	O
,	O
74	O
–	O
76	O
%	O
of	O
patients	O
showed	O
high	O
ad	O
##herence	O
rates	O
to	O
ta	B
##mo	I
##xi	I
##fen	I
treatment	O
,	O
which	O
dropped	O
to	O
63	O
%	O
at	O
12	O
months	O
(	O
Figure	O
a	O
)	O
.	O

Specifically	O
,	O
three	O
AM	O
##PP	O
-	O
der	O
##iva	O
##tized	O
un	O
##sat	O
##ura	O
##ted	O
FA	O
##s	O
(	O
i	O
.	O
e	O
.	O
,	O
Δ	O
_	O
9	O
18	O
:	O
1	O
,	O
Δ	B
_	I
9	I
,	I
12	I
18	I
:	I
2	I
and	O
Δ	B
_	I
9	I
,	I
12	I
,	I
15	I
18	I
:	I
3	I
FA	I
##s	I
)	O
were	O
analyzed	O
,	O
each	O
having	O
identical	O
carbon	O
numbers	O
(	O
18	O
carbon	O
##s	O
)	O
,	O
identical	O
positions	O
of	O
the	O
pro	O
##ximal	O
double	O
bond	O
(	O
at	O
C	O
##9	O
)	O
but	O
containing	O
different	O
numbers	O
(	O
one	O
,	O
two	O
or	O
three	O
)	O
of	O
double	O
bonds	O
.	O

Then	O
k	B
##eto	I
##amine	I
o	O
##xi	O
##das	O
##e	O
re	O
##age	O
##nt	O
was	O
added	O
,	O
in	O
##cu	O
##bate	O
##d	O
,	O
and	O
absorb	O
##ance	O
measured	O
again	O
at	O
54	O
##6	O
nm	O
.	O

The	O
1	O
##D	O
_	O
1	O
H	O
CP	O
##MG	O
s	O
##pect	O
##ra	O
of	O
serum	O
samples	O
showed	O
signals	O
mainly	O
from	O
lip	O
##ids	O
/	O
lip	O
##op	O
##rote	O
##ins	O
(	O
e	O
.	O
g	O
.	O
low	O
-	O
density	O
lip	O
##op	O
##rote	O
##in	O
(	O
L	O
##D	O
##L	O
)	O
,	O
very	O
low	O
density	O
lip	O
##op	O
##rote	O
##in	O
(	O
V	O
##LD	O
##L	O
)	O
,	O
un	O
##sat	O
##ura	O
##ted	O
fatty	O
acids	O
(	O
U	O
##FA	O
##s	O
)	O
etc	O
.	O
)	O
and	O
amino	O
acids	O
(	O
e	O
.	O
g	O
.	O
al	B
##ani	I
##ne	I
,	O
v	B
##ali	I
##ne	I
,	O
l	B
##ys	I
##ine	I
,	O
le	B
##uc	I
##ine	I
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
his	B
##ti	I
##dine	I
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
g	B
##lut	I
##amine	I
,	O
g	B
##lut	I
##ama	I
##te	I
and	O
pro	B
##line	I
etc	O
.	O
)	O
.	O

Cross	O
-	O
section	O
##al	O
analyses	O
revealed	O
positive	O
relations	O
of	O
al	B
##ani	I
##ne	I
,	O
t	B
##rig	I
##one	I
##llin	I
##e	I
and	O
la	B
##ctic	I
acid	I
with	O
F	O
##T	O
##4	O
and	O
negative	O
relations	O
of	O
dim	B
##eth	I
##yla	I
##mine	I
,	O
glucose	S
,	O
g	B
##ly	I
##cine	I
and	O
la	B
##ctic	I
acid	I
with	O
log	O
(	O
T	O
##S	O
##H	O
)	O
.	O

Despite	O
the	O
short	O
duration	S
of	O
the	O
study	O
,	O
several	O
subjects	O
developed	O
h	O
##yper	O
##gly	O
##ce	O
##mia	O
,	O
while	O
many	O
more	O
displayed	O
signs	O
of	O
pre	O
-	O
diabetes	O
and	O
insulin	O
resistance	O
.	O

Furthermore	O
,	O
the	O
transformation	O
efficiency	O
of	O
P	O
was	O
a	O
little	O
more	O
than	O
IP	S
,	O
which	O
might	O
be	O
related	O
to	O
the	O
compounds	O
′	O
s	O
##ter	O
##ic	O
configuration	O
.	O

These	O
meta	O
##bol	O
##ites	O
are	O
produced	O
from	O
glucose	S
via	O
the	O
p	O
##oly	O
##ol	O
pathway	O
in	O
neurons	O
and	O
as	O
##tro	O
##cy	O
##tes	O
.	O

Moreover	O
,	O
the	O
p	O
##oly	O
##ol	O
pathway	O
is	O
up	O
##re	O
##gu	O
##lated	O
by	O
HC	O
##V	O
,	O
whereby	O
glucose	S
is	O
reduced	O
to	O
so	B
##rb	I
##ito	I
##l	I
by	O
al	O
##dos	O
##e	O
red	O
##uc	O
##tase	O
AK	O
##R	O
##1	O
##B	O
##10	O
,	O
which	O
is	O
then	O
o	O
##xi	O
##dized	O
by	O
so	O
##rb	O
##ito	O
##l	O
de	O
##hy	O
##dr	O
##ogen	O
##ase	O
to	O
f	B
##ru	I
##ct	I
##ose	I
.	O

Data	O
from	O
4	O
time	O
period	O
for	O
ni	B
##cot	I
##ina	I
##mi	I
##de	I
and	O
in	B
##do	I
##le	I
-	I
3	I
-	I
la	I
##ct	I
##ate	I
are	O
aggregate	O
##d	O
into	O
whole	O
night	O
within	O
-	O
subject	O
means	O
,	O
these	O
2	O
variables	O
jointly	O
separate	O
i	O
##rri	O
##table	O
bow	O
##el	O
syndrome	O
(	O
I	O
##BS	O
)	O
versus	O
healthy	O
controls	O
(	O
HC	O
##s	O
)	O
(	O
log	O
##istic	O
re	O
##gression	O
,	O
P	O
=	O
0	O
.	O
00	O
##1	O
)	O
.	O

From	O
the	O
_	O
1	O
H	O
N	O
##MR	O
-	O
based	O
meta	O
##bol	O
##omi	O
##c	O
pro	O
##fi	O
##ling	O
,	O
signals	O
coming	O
from	O
met	B
##hyl	I
##ene	I
(	O
–	O
CH	O
_	O
2	O
–	O
)	O
and	O
met	O
##hyl	O
(	O
–	O
CH	O
_	O
3	O
)	O
m	O
##oi	O
##eti	O
##es	O
of	O
al	B
##ip	I
##hat	I
##ic	I
chains	O
from	O
plasma	O
lip	O
##ids	O
were	O
identified	O
as	O
disc	O
##rim	O
##ina	O
##nt	O
variables	O
.	O

Ex	O
##c	O
##lu	O
##ding	O
this	O
Spanish	O
study	O
,	O
the	O
para	B
##ben	I
levels	O
found	O
in	O
our	O
Belgian	O
children	O
seemed	O
to	O
be	O
close	O
to	O
those	O
usually	O
measured	O
in	O
other	O
countries	O
except	O
for	O
MP	O
detected	O
,	O
respectively	O
,	O
at	O
higher	O
and	O
lower	O
u	O
##rina	O
##ry	O
concentrations	O
than	O
in	O
some	O
Danish	O
and	O
American	O
children	O
[	O
,	O
]	O
.	O

For	O
flu	O
##ores	O
##cence	O
q	O
##uant	O
##itation	O
standardized	O
flu	B
##oro	I
##ch	I
##rome	I
micro	O
##sp	O
##here	O
##s	O
were	O
used	O
as	O
recommended	O
by	O
the	O
company	O
(	O
Quantum	O
[UNK]	O
F	O
##IT	O
##C	O
-	O
5	O
ME	O
##SF	O
,	O
55	O
##5	O
,	O
Bang	O
##s	O
Laboratories	O
,	O
Fisher	O
##s	O
,	O
Indiana	O
,	O
USA	O
)	O
.	O

The	O
weak	O
and	O
the	O
strong	O
wash	O
##es	O
were	O
95	O
:	O
5	O
water	O
/	O
ace	O
##ton	O
##it	O
##ril	O
##e	O
(	O
0	O
.	O
2	O
%	O
form	O
##ic	O
acid	O
)	O
(	O
v	O
/	O
v	O
)	O
and	O
100	O
%	O
is	B
##op	I
##rop	I
##ano	I
##l	I
(	O
0	O
.	O
5	O
%	O
form	O
##ic	O
acid	O
)	O
,	O
respectively	O
.	O

In	O
the	O
present	O
report	O
,	O
we	O
show	O
the	O
success	O
of	O
HP	O
##LC	O
-	O
I	O
##CP	O
##Q	O
##Q	O
##Q	O
##MS	O
for	O
the	O
simultaneous	O
determination	O
of	O
two	O
major	O
sulfur	O
meta	O
##bol	O
##ites	O
,	O
ta	B
##uri	I
##ne	I
and	O
su	B
##lf	I
##ate	I
,	O
in	O
human	O
urine	O
and	O
serum	O
,	O
by	O
direct	O
injection	O
without	O
the	O
need	O
for	O
sample	O
clean	O
-	O
up	O
.	O

Missing	O
data	O
:	O
AL	O
##T	O
levels	O
were	O
missing	O
in	O
2	O
HC	O
##C	O
patients	O
,	O
AS	O
##T	O
levels	O
were	O
missing	O
in	O
2	O
HC	O
##C	O
patients	O
,	O
γ	O
##G	O
##T	O
levels	O
were	O
missing	O
in	O
2	O
HC	O
##C	O
patients	O
,	O
B	B
##ili	I
##ru	I
##bin	I
levels	O
were	O
missing	O
in	O
1	O
HC	O
##C	O
patient	O
,	O
AL	O
##P	O
levels	O
were	O
missing	O
in	O
3	O
HC	O
##C	O
patients	O
and	O
in	O
1	O
patient	O
with	O
liver	O
c	O
##ir	O
##r	O
##hos	O
##is	O
,	O
Album	O
##in	O
levels	O
were	O
missing	O
in	O
4	O
HC	O
##C	O
patients	O
and	O
in	O
2	O
patients	O
with	O
liver	O
c	O
##ir	O
##r	O
##hos	O
##is	O
,	O
CR	O
##P	O
levels	O
were	O
missing	O
in	O
31	O
HC	O
##C	O
patients	O
and	O
in	O
3	O
patients	O
with	O
liver	O
c	O
##ir	O
##r	O
##hos	O
##is	O
,	O
He	O
##mo	O
##g	O
##lo	O
##bin	O
levels	O
were	O
missing	O
in	O
1	O
HC	O
##C	O
patient	O
,	O
A	O
##FP	O
levels	O
were	O
missing	O
in	O
14	O
HC	O
##C	O
patients	O
and	O
in	O
32	O
patients	O
with	O
liver	O
c	O
##ir	O
##r	O
##hos	O
##is	O
.	O

Van	B
##ill	I
##yl	I
##mand	I
##eli	I
##c	I
acid	I
is	O
a	O
major	O
metabolic	O
product	O
of	O
nor	B
##ep	I
##ine	I
##ph	I
##rine	I
which	O
is	O
involved	O
in	O
the	O
nor	O
##ad	O
##rene	O
##rg	O
##ic	O
system	O
and	O
the	O
h	O
##y	O
##pot	O
##hala	O
##mic	O
-	O
pit	O
##uit	O
##ary	O
-	O
ad	O
##rena	O
##l	O
axis	O
,	O
whose	O
elevation	O
is	O
related	O
to	O
the	O
depression	O
s	O
##ym	O
##pt	O
##om	O
[	O
,	O
]	O
and	O
was	O
also	O
found	O
in	O
this	O
study	O
.	O

Met	O
##ab	O
##oli	O
##tes	O
were	O
extracted	O
from	O
the	O
samples	O
(	O
200	O
μ	O
##L	O
)	O
by	O
adding	O
1	O
m	O
##L	O
of	O
cold	O
(	O
-	O
20	O
##°	O
##C	O
)	O
met	B
##han	I
##ol	I
.	O

Higher	O
u	B
##rac	I
##il	I
level	O
in	O
CR	O
##C	O
tumors	O
than	O
in	O
AN	O
##IT	O
observed	O
in	O
our	O
study	O
has	O
also	O
been	O
reported	O
previously	O
in	O
CR	O
##C	O
and	O
he	O
##pa	O
##to	O
##cellular	O
car	O
##cin	O
##oma	O
due	O
to	O
reduced	O
di	O
##hy	O
##dr	O
##opy	O
##rim	O
##id	O
##ine	O
de	O
##hy	O
##dr	O
##ogen	O
##ase	O
(	O
D	O
##PD	O
)	O
activity	O
_	O
,	O
.	O

It	O
was	O
then	O
extracted	O
with	O
et	B
##hyl	I
ace	I
##tate	I
,	O
3	O
×	O
1	O
m	O
##l	O
,	O
e	O
##va	O
##porated	O
under	O
nitrogen	O
using	O
a	O
Z	O
##ym	O
##ark	O
Turbo	O
##V	O
##ap	O
L	O
##V	O
(	O
Cal	O
##iper	O
Life	O
Sciences	O
,	O
Hop	O
##kin	O
##ton	O
,	O
MA	O
)	O
,	O
and	O
re	O
##con	O
##stituted	O
in	O
1	O
.	O
0	O
m	O
##l	O
of	O
2	O
:	O
8	O
ace	O
##ton	O
##it	O
##ril	O
##e	O
-	O
H	O
_	O
2	O
O	O
containing	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
,	O
yielding	O
a	O
nominal	O
LP	O
##O	O
-	O
MA	O
##d	O
_	O
3	O
concentration	O
of	O
100	O
μ	O
##M	O
.	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
analyses	O
were	O
used	O
to	O
verify	O
con	O
##ju	O
##gate	O
formation	O
.	O

Ace	O
,	O
ace	B
##tate	I
;	O
Al	O
##a	O
,	O
al	B
##ani	I
##ne	I
;	O
G	O
##ln	O
,	O
g	B
##lut	I
##amine	I
;	O
G	O
##lu	O
,	O
g	B
##lut	I
##ama	I
##te	I
;	O
G	O
##ly	O
,	O
g	B
##ly	I
##cine	I
;	O
Lac	O
,	O
la	B
##ct	I
##ate	I
;	O
my	O
##o	O
-	O
I	O
,	O
my	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
;	O
s	O
##cy	O
##llo	O
-	O
I	O
,	O
s	O
##cy	O
##llo	O
##ino	O
##si	O
##to	O
##l	O
;	O
Tau	O
,	O
ta	B
##uri	I
##ne	I
.	O

These	O
findings	O
indicated	O
that	O
higher	O
plasma	O
level	O
of	O
the	O
l	B
##ino	I
##le	I
##ic	I
acid	I
in	O
E	O
##LS	O
/	O
MD	O
##D	O
compared	O
with	O
non	O
-	O
E	O
##LS	O
/	O
MD	O
##D	O
may	O
be	O
an	O
E	O
##LS	O
-	O
associated	O
metabolic	O
alter	O
##ation	O
in	O
depression	O
patients	O
.	O

Since	O
est	B
##rone	I
and	O
est	B
##rad	I
##iol	I
are	O
constantly	O
inter	O
-	O
converting	O
,	O
we	O
have	O
combined	O
est	B
##rone	I
and	O
est	B
##rad	I
##iol	I
values	O
of	O
all	O
the	O
derivatives	O
(	O
and	O
)	O
.	O

The	O
dried	O
sample	O
residue	O
was	O
red	O
##iss	O
##ol	O
##ved	O
in	O
100	O
µ	O
##L	O
of	O
0	O
.	O
1	O
M	O
sodium	O
bi	O
##car	O
##bon	O
##ate	O
buffer	O
(	O
pH	O
9	O
.	O
0	O
)	O
and	O
100	O
µ	O
##L	O
of	O
dans	B
##yl	I
chloride	I
solution	O
(	O
1	O
mg	O
/	O
m	O
##L	O
in	O
ace	O
##tone	O
)	O
,	O
and	O
in	O
##cu	O
##bate	O
##d	O
at	O
60	O
##°	O
##C	O
for	O
5	O
min	O
.	O

Part	O
##ici	O
##pants	O
were	O
followed	O
for	O
a	O
total	O
of	O
6	O
weeks	O
on	O
si	B
##m	I
##vas	I
##tat	I
##in	I
therapy	O
(	O
40	O
mg	O
at	O
bed	O
##time	O
)	O
and	O
were	O
seen	O
at	O
clinic	O
visits	O
conducted	O
at	O
2	O
-	O
week	O
intervals	O
.	O

Based	O
on	O
these	O
findings	O
,	O
the	O
GE	O
##NS	O
##CA	O
##N	O
##00	O
##00	O
##00	O
##70	O
##26	O
##4	O
protein	O
was	O
considered	O
as	O
the	O
only	O
album	O
##in	O
-	O
like	O
protein	O
present	O
in	O
Atlantic	S
co	O
##d	O
that	O
is	O
ho	O
##mo	O
##log	O
##ous	O
to	O
album	O
##ins	O
of	O
other	O
Tel	O
##eo	O
##st	O
species	O
.	O

Based	O
on	O
our	O
study	O
,	O
we	O
propose	O
that	O
AR	O
##ID	O
##1	O
##A	O
can	O
be	O
regulated	O
through	O
α	B
-	I
O	I
##G	I
,	O
contributing	O
to	O
an	O
impaired	O
cell	O
proliferation	O
in	O
I	O
##C	O
.	O

Moreover	O
,	O
the	O
pu	B
##rine	I
metabolism	O
was	O
found	O
to	O
be	O
significantly	O
altered	O
in	O
manifest	O
compared	O
with	O
pre	O
##mani	O
##fest	O
HD	O
and	O
controls	O
.	O

Cal	B
##ci	I
##um	I
format	I
##e	I
,	O
de	O
##uter	O
##ium	O
chloride	S
,	O
and	O
sodium	B
de	I
##uter	I
##oxide	I
were	O
obtained	O
from	O
Sigma	O
Al	O
##dric	O
##h	O
(	O
St	O
.	O
Louis	O
,	O
M	O
##O	O
,	O
USA	O
)	O
.	O

Using	O
the	O
described	O
method	O
,	O
mean	O
recover	O
##ies	O
for	O
the	O
five	O
lip	O
##id	O
families	O
were	O
all	O
above	O
80	O
%	O
(	O
see	O
Table	O
S	O
##3	O
provided	O
as	O
supplement	O
##ary	O
material	O
)	O
:	O
i	O
.	O
e	O
.	O
,	O
88	O
.	O
2	O
%	O
for	O
fatty	O
a	O
##cy	O
##ls	O
,	O
90	O
.	O
6	O
%	O
for	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
,	O
80	O
.	O
6	O
%	O
for	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
and	O
88	O
.	O
7	O
%	O
for	O
g	B
##ly	I
##cer	I
##oli	I
##pid	I
##s	I
.	O

Met	O
##ab	O
##olo	O
##mic	O
##s	O
has	O
recently	O
provided	O
insights	O
into	O
altered	O
metabolic	O
pathways	O
in	O
diabetes	O
induced	O
by	O
s	B
##tre	I
##pt	I
##oz	I
##oto	I
##cin	I
exposure	O
in	O
rats	O
.	O

However	O
,	O
if	O
25	O
(	O
OH	O
)	O
D	O
_	O
3	O
status	O
is	O
sufficient	O
(	O
>	O
32	O
ng	O
/	O
m	O
##L	O
)	O
,	O
as	O
in	O
the	O
fall	O
study	O
group	O
,	O
the	O
production	O
of	O
1	B
##α	I
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
becomes	O
less	O
strictly	O
controlled	O
.	O

Different	O
##ially	O
expressed	O
meta	O
##bol	O
##ites	O
involved	O
in	O
try	B
##pt	I
##op	I
##han	I
metabolism	O
and	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
metabolism	O
were	O
observed	O
in	O
the	O
current	O
study	O
and	O
our	O
previous	O
study	O
.	O

Numbers	O
next	O
to	O
the	O
I	O
##EF	O
results	O
indicate	O
individual	O
bands	O
corresponding	O
to	O
numbers	O
of	O
si	B
##ali	I
##c	I
acid	I
residues	O
(	O
black	O
numbers	O
indicate	O
structures	O
shown	O
along	O
the	O
respective	O
mass	O
spectrum	O
,	O
and	O
gray	O
numbers	O
structures	O
not	O
shown	O
)	O
.	O

The	O
associations	O
,	O
assessed	O
by	O
S	O
##pear	O
##man	O
'	O
s	O
rank	O
correlation	O
,	O
suggest	O
that	O
my	B
##oi	I
##nos	I
##ito	I
##l	I
(	O
ρ	O
=	O
0	O
.	O
53	O
;	O
P	O
=	O
0	O
.	O
05	O
;	O
q	O
=	O
0	O
.	O
25	O
)	O
and	O
total	O
g	B
##lut	I
##ath	I
##ione	I
(	O
ρ	O
=	O
0	O
.	O
56	O
;	O
P	O
=	O
0	O
.	O
04	O
;	O
q	O
=	O
0	O
.	O
25	O
)	O
may	O
be	O
markers	O
of	O
se	O
##psis	O
-	O
induced	O
AL	O
##I	O
severity	O
.	O

An	O
example	O
of	O
cat	O
##ab	O
##olic	O
/	O
an	O
##ab	O
##olic	O
switch	O
is	O
the	O
decrease	O
in	O
the	O
level	O
of	O
glucose	S
in	O
am	O
##nio	O
##tic	O
fluid	O
,	O
which	O
overlap	O
##s	O
with	O
increasing	O
energy	O
demand	O
during	O
the	O
pregnancy	O
progression	O
.	O

Mobile	O
phases	O
were	O
10	O
m	O
##M	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
in	O
50	O
%	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
,	O
pH	O
5	O
.	O
8	O
(	O
phase	O
A	O
)	O
and	O
10	O
m	O
##M	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
buffer	O
in	O
90	O
%	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
,	O
pH	O
5	O
.	O
8	O
(	O
phase	O
B	O
)	O
.	O

The	O
linear	O
gradient	O
started	O
from	O
60	O
%	O
to	O
0	O
%	O
A	O
(	O
10	O
mm	O
##ol	O
/	O
L	O
am	B
##mon	I
##ium	I
format	I
##e	I
,	O
AC	O
##N	O
:	O
H	O
##2	O
##O	O
=	O
6	O
:	O
4	O
)	O
and	O
40	O
%	O
B	O
(	O
10	O
mm	O
##ol	O
/	O
L	O
am	B
##mon	I
##ium	I
format	I
##e	I
,	O
IPA	O
:	O
H	O
_	O
2	O
O	O
=	O
9	O
:	O
1	O
)	O
.	O

Interest	O
##ingly	O
,	O
9	O
-	O
H	O
##SA	O
in	O
serum	O
was	O
found	O
almost	O
exclusively	O
est	O
##eri	O
##fied	O
in	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
,	O
which	O
suggests	O
that	O
the	O
fatty	O
acid	O
may	O
be	O
more	O
efficiently	O
transported	O
and	O
delivered	O
to	O
cells	O
and	O
tissues	O
in	O
this	O
manner	O
.	O

Like	O
_	O
1	O
H	O
MR	O
##S	O
,	O
this	O
technique	O
also	O
can	O
be	O
used	O
to	O
obtain	O
tissue	O
bio	O
##chemistry	O
by	O
gathering	O
information	O
on	O
the	O
energy	O
status	O
of	O
the	O
tissue	O
through	O
the	O
observation	O
of	O
various	O
phosphate	S
meta	O
##bol	O
##ites	O
,	O
in	O
##tra	O
##cellular	O
pH	O
,	O
and	O
the	O
free	O
cellular	O
ma	O
##gnesium	O
concentration	O
.	O

Interest	O
##ingly	O
,	O
we	O
also	O
found	O
that	O
PR	O
##KA	O
##G	O
##2	O
r	O
##s	O
##27	O
##27	O
##5	O
##6	O
##3	O
has	O
a	O
significant	O
association	O
on	O
a	B
##rac	I
##hi	I
##don	I
##ic	I
acid	I
base	O
##line	O
levels	O
(	O
p	O
=	O
0	O
.	O
03	O
,	O
)	O
.	O

Our	O
meta	O
##bol	O
##omi	O
##c	O
data	O
further	O
imp	O
##lica	O
##tes	O
that	O
le	O
##pt	O
##in	O
replacement	O
therapy	O
has	O
a	O
significant	O
impact	O
on	O
downstream	O
pathways	O
of	O
try	B
##pt	I
##op	I
##han	I
degradation	O
.	O

The	O
lack	O
of	O
effect	O
on	O
the	O
E	O
-	O
series	O
P	O
##G	O
##s	O
could	O
be	O
explained	O
in	O
a	O
study	O
done	O
by	O
Little	O
et	O
al	O
.	O
,	O
where	O
they	O
investigated	O
the	O
different	O
human	O
re	O
##comb	O
##ina	O
##nt	O
U	O
##DP	O
-	O
g	O
##lu	O
##cu	O
##ron	O
##osy	O
##lt	O
##ran	O
##s	O
##fer	O
##ases	O
and	O
found	O
that	O
only	O
one	O
is	O
##of	O
##orm	O
U	O
##G	O
##T	O
##2	O
##B	O
##7	O
was	O
capable	O
of	O
forming	O
P	O
##GE	O
_	O
2	O
g	B
##lu	I
##cu	I
##ron	I
##ide	I
.	O
U	O
##G	O
##T	O
##2	O
##B	O
##7	O
were	O
exclusively	O
found	O
in	O
the	O
co	O
##lon	O
,	O
and	O
f	O
##ae	O
##ces	O
rather	O
than	O
urine	O
might	O
contain	O
high	O
levels	O
of	O
E	O
-	O
series	O
g	B
##lu	I
##cu	I
##ron	I
##ide	I
con	O
##ju	O
##gate	O
##s	O
.	O

Regarding	O
this	O
and	O
the	O
fact	O
that	O
u	O
##rina	O
##ry	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
levels	O
in	O
the	O
E	O
##G	O
significantly	O
changed	O
post	O
-	O
training	O
,	O
being	O
significantly	O
different	O
from	O
u	O
##rina	O
##ry	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
levels	O
in	O
the	O
C	O
##G	O
at	O
V	O
##2	O
and	O
V	O
##3	O
,	O
alterations	O
in	O
pu	B
##rine	I
metabolism	O
could	O
provide	O
one	O
possible	O
mechanism	O
of	O
the	O
body	O
’	O
s	O
adaptation	O
to	O
H	O
##II	O
##T	O
training	O
.	O

Try	B
##pt	I
##op	I
##han	I
and	O
k	O
##yn	O
##uren	O
##ines	O
(	O
except	O
HK	O
)	O
have	O
been	O
found	O
to	O
be	O
inverse	O
##ly	O
associated	O
with	O
smoking	O
,	O
and	O
associations	O
have	O
been	O
observed	O
between	O
blood	O
levels	O
of	O
the	O
ni	B
##cot	I
##ine	I
meta	O
##bol	O
##ite	O
co	B
##tin	I
##ine	I
and	O
K	O
##TR	O
.	O

Most	O
previous	O
research	O
on	O
p	B
##hos	I
##ph	I
##oc	I
##rea	I
##tine	I
,	O
either	O
in	O
muscle	O
or	O
in	O
the	O
brain	O
,	O
and	O
whether	O
as	O
an	O
energy	O
buffer	O
or	O
as	O
an	O
energy	O
shuttle	O
,	O
has	O
been	O
concerned	O
with	O
its	O
breakdown	O
and	O
re	O
##sy	O
##nt	O
##hesis	O
,	O
and	O
it	O
has	O
been	O
ta	O
##ci	O
##tly	O
assumed	O
that	O
the	O
t	O
##C	O
##r	O
pool	O
stays	O
constant	O
.	O

Si	O
##mu	O
##lta	O
##ne	O
##ous	O
measurements	O
of	O
met	B
##form	I
##in	I
concentrations	O
were	O
in	O
the	O
range	O
of	O
0	O
.	O
17	O
μ	O
M	O
to	O
23	O
.	O
0	O
m	O
##M	O
.	O
I	O
##M	O
##Z	O
was	O
also	O
detect	O
##able	O
in	O
a	O
plasma	O
sample	O
(	O
from	O
the	O
patient	O
with	O
the	O
highest	O
u	O
##rina	O
##ry	O
concentration	O
of	O
I	O
##M	O
##Z	O
)	O
,	O
analyzed	O
at	O
a	O
1	O
:	O
1000	O
di	O
##lution	O
,	O
suggesting	O
that	O
the	O
method	O
can	O
be	O
expanded	O
to	O
other	O
biological	O
matrices	O
.	O

The	O
can	O
##nu	O
##la	O
was	O
flushed	O
with	O
10	O
m	O
##L	O
of	O
normal	O
sa	B
##line	I
or	O
he	B
##par	I
##ini	I
##sed	I
sa	I
##line	I
(	O
5	O
I	O
##U	O
/	O
m	O
##L	O
he	B
##par	I
##in	I
;	O
St	O
##eri	O
##safe	O
,	O
P	O
##fi	O
##zer	O
,	O
Australia	O
)	O
as	O
required	O
.	O

In	O
an	O
extensive	O
review	O
of	O
the	O
literature	O
,	O
Zhang	O
et	O
al	O
.	O
have	O
collected	O
several	O
studies	O
that	O
associate	O
o	O
##besity	O
with	O
markers	O
present	O
in	O
different	O
metabolic	O
pathways	O
,	O
such	O
as	O
lip	O
##ids	O
,	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
,	O
mon	B
##osa	I
##cc	I
##hari	I
##des	I
,	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
,	O
and	O
meta	O
##bol	O
##ites	O
related	O
with	O
T	O
##CA	O
cycle	O
,	O
try	B
##pt	I
##op	I
##han	I
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
and	O
t	B
##yr	I
##os	I
##ine	I
pathways	O
(	O
Zhang	O
et	O
al	O
.	O
,	O
)	O
.	O

For	O
glucose	S
is	O
##oto	O
##pe	O
tracing	O
experiment	O
,	O
HC	O
##T	O
##11	O
##6	O
,	O
MC	O
##F	O
##7	O
and	O
He	O
##L	O
##a	O
cells	O
were	O
culture	O
##d	O
in	O
6	O
-	O
well	O
plates	O
with	O
custom	O
made	O
R	O
##PM	O
##I	O
1640	O
media	O
with	O
the	O
stable	O
##d	O
is	O
##oto	O
##pe	O
1	O
-	O
_	O
13	O
C	B
_	I
1	I
-	I
glucose	I
or	O
2	O
-	O
_	O
13	O
C	B
_	I
1	I
-	I
glucose	I
for	O
48	O
h	O
.	O

We	O
also	O
tested	O
whether	O
9	O
-	O
H	O
##SA	O
could	O
be	O
produced	O
via	O
non	O
-	O
en	O
##zy	O
##matic	O
oxidation	O
of	O
o	B
##le	I
##ic	I
acid	I
.	O

The	O
positive	O
correlation	O
##s	O
in	O
the	O
meta	O
##sta	O
##ses	O
showed	O
a	O
generally	O
similar	O
pattern	O
to	O
those	O
in	O
the	O
g	O
##lio	O
##blast	O
##oma	O
##s	O
,	O
as	O
##tro	O
##cy	O
##tom	O
##as	O
and	O
men	O
##ing	O
##io	O
##mas	O
:	O
la	B
##ct	I
##ate	I
correlated	O
positively	O
with	O
al	B
##ani	I
##ne	I
and	O
t	O
##G	O
##lut	O
,	O
the	O
t	O
##C	O
##ho	O
pool	O
correlated	O
positively	O
with	O
t	O
##C	O
##r	O
and	O
t	O
##G	O
##lut	O
,	O
and	O
g	B
##lut	I
##ama	I
##te	I
correlated	O
with	O
g	B
##lut	I
##amine	I
.	O

U	B
##ric	I
acid	I
is	O
regarded	O
as	O
a	O
potential	O
risk	O
factor	O
for	O
the	O
development	O
of	O
C	O
##VD	O
.	O

In	O
the	O
C	O
##IR	O
group	O
,	O
H	O
##B	O
##e	O
##A	O
##g	O
negative	O
patients	O
showed	O
a	O
significant	O
decrease	O
in	O
D	B
##MA	I
(	O
P	O
=	O
0	O
.	O
00	O
##4	O
)	O
compared	O
to	O
H	O
##B	O
##e	O
##A	O
##g	O
positive	O
patients	O
;	O
there	O
were	O
no	O
significant	O
differences	O
in	O
the	O
HC	O
##C	O
subgroup	O
according	O
to	O
H	O
##B	O
##e	O
##A	O
##g	O
status	O
.	O

Met	O
##ab	O
##oli	O
##tes	O
from	O
the	O
c	B
##it	I
##ric	I
acid	I
cycle	O
(	O
n	O
=	O
5	O
)	O
,	O
g	O
##lu	O
##con	O
##eo	O
##genesis	O
(	O
n	O
=	O
4	O
)	O
,	O
and	O
p	B
##yr	I
##im	I
##id	I
##ine	I
metabolism	O
(	O
n	O
=	O
4	O
)	O
appear	O
in	O
the	O
first	O
component	O
.	O

CE	O
##RS	O
##1	O
,	O
the	O
enzyme	O
specific	O
for	O
C	B
##18	I
:	I
0	I
c	I
##era	I
##mi	I
##de	I
generation	O
22	O
,	O
was	O
not	O
mapped	O
to	O
the	O
gene	O
array	O
.	O

Only	O
a	O
higher	O
concentration	O
of	O
E	O
_	O
2	O
(	O
1	O
μ	O
##M	O
)	O
increased	O
C	O
##YP	O
##1	O
##B	O
##1	O
significantly	O
(	O
Figure	O
S	O
##4	O
)	O
,	O
yet	O
E	O
_	O
2	O
(	O
1	O
μ	O
##M	O
)	O
did	O
not	O
have	O
an	O
effect	O
on	O
is	B
##of	I
##lav	I
##one	I
m	O
##od	O
##ulation	O
of	O
C	O
##YP	O
##1	O
##B	O
##1	O
expression	O
(	O
Figure	O
S	O
##5	O
)	O
.	O

SP	O
##s	O
with	O
a	O
d	B
##18	I
:	I
2	I
backbone	O
are	O
indicated	O
in	O
blue	O
.	O

The	O
phase	O
2	O
Reg	O
##ora	O
##fen	O
##ib	O
in	O
Re	O
##lap	O
##sed	O
G	O
##lio	O
##blast	O
##oma	O
(	O
R	O
##EG	O
##OM	O
##A	O
)	O
trial	O
indicated	O
a	O
survival	O
benefit	O
for	O
patients	O
with	O
first	O
re	O
##cu	O
##rrence	O
of	O
a	O
g	O
##lio	O
##blast	O
##oma	O
when	O
treated	O
with	O
the	O
multi	O
##kin	O
##ase	O
inhibitor	O
re	O
##gor	O
##af	O
##eni	O
##b	O
(	O
R	O
##EG	O
)	O
instead	O
of	O
lo	B
##mus	I
##tine	I
.	O

A	O
mixture	O
of	O
the	O
retention	O
time	O
standards	O
,	O
n	B
-	I
do	I
##de	I
##cane	I
(	O
R	O
##I	O
1200	O
)	O
,	O
n	B
-	I
pen	I
##tad	I
##eca	I
##ne	I
(	O
R	O
##I	O
1500	O
)	O
,	O
n	B
-	I
non	I
##ade	I
##cane	I
(	O
R	O
##I	O
1900	O
)	O
,	O
n	B
-	I
do	I
##cos	I
##ane	I
(	O
R	O
##I	O
220	O
##0	O
)	O
,	O
n	B
-	I
o	I
##ct	I
##aco	I
##san	I
##e	I
(	O
R	O
##I	O
280	O
##0	O
)	O
,	O
n	B
-	I
dot	I
##ria	I
##con	I
##tan	I
##e	I
(	O
R	O
##I	O
320	O
##0	O
)	O
,	O
and	O
n	B
-	I
he	I
##xa	I
##tri	I
##acon	I
##tan	I
##e	I
(	O
R	O
##I	O
360	O
##0	O
)	O
was	O
included	O
in	O
the	O
final	O
re	O
##age	O
##nt	O
volume	O
.	O

Fi	O
##lled	O
circles	O
illustrate	O
retention	O
time	O
of	O
the	O
authentic	O
standards	O
,	O
PC	B
(	I
18	I
:	I
1	I
/	I
18	I
:	I
1	I
)	I
,	O
PC	B
(	I
18	I
:	I
0	I
/	I
20	I
:	I
4	I
)	I
and	O
PC	B
(	I
18	I
:	I
0	I
/	I
22	I
:	I
6	I
)	I
,	O
confirming	O
the	O
predicted	O
pattern	O
.	O

Inc	O
##reased	O
c	B
##rea	I
##tine	I
phosphate	I
levels	O
were	O
also	O
found	O
in	O
other	O
tumors	O
,	O
such	O
as	O
breast	O
and	O
gas	O
##tro	O
##int	O
##est	O
##inal	O
tract	O
tumors	O
.	O

Pro	O
##tein	O
man	O
##nos	O
##yla	O
##tion	O
is	O
a	O
common	O
g	O
##ly	O
##cos	O
##yla	O
##tion	O
pattern	O
for	O
HC	O
##V	O
,	O
and	O
th	B
##re	I
##oni	I
##ne	I
protein	O
residues	O
are	O
a	O
principal	O
site	O
of	O
man	O
##nos	O
##yla	O
##tion	O
.	O

The	O
p	O
##ef	O
##orm	O
##ance	O
of	O
the	O
method	O
was	O
assessed	O
by	O
the	O
within	O
-	O
day	O
and	O
between	O
-	O
day	O
estimates	O
and	O
precision	O
of	O
measurements	O
of	O
Ph	O
##IP	O
and	O
the	O
g	B
##lu	I
##cu	I
##ron	I
##ide	I
con	O
##ju	O
##gate	O
##s	O
of	O
NH	O
##OH	O
-	O
Ph	O
##IP	O
,	O
in	O
urine	O
of	O
three	O
volunteers	O
determined	O
over	O
4	O
days	O
(	O
n	O
=	O
4	O
independent	O
measurements	O
per	O
day	O
)	O
,	O
within	O
a	O
time	O
period	O
of	O
two	O
months	O
.	O

C	B
##rea	I
##tine	I
rib	I
##os	I
##ide	I
was	O
the	O
strongest	O
class	O
##ifier	O
of	O
lung	O
cancer	O
status	O
in	O
the	O
whole	O
co	O
##hor	O
##t	O
as	O
well	O
as	O
in	O
stage	O
I	O
–	O
II	O
cases	O
and	O
thus	O
may	O
be	O
important	O
for	O
early	O
detection	O
.	O

No	O
##de	O
color	O
was	O
grouped	O
according	O
to	O
SP	S
type	O
and	O
clinical	O
characteristic	O
:	O
clinical	O
characteristic	O
nodes	O
are	O
gray	O
,	O
Ce	B
##r	I
nodes	O
are	O
red	O
,	O
He	O
##x	O
##C	O
##er	O
nodes	O
are	O
blue	O
,	O
He	O
##x	O
##2	O
##C	O
##er	O
nodes	O
are	O
green	O
,	O
and	O
nodes	O
for	O
the	O
other	O
SP	O
##s	O
are	O
yellow	O
.	O

Inc	O
##reased	O
u	B
##rea	I
also	O
had	O
many	O
adverse	O
influences	O
on	O
complications	O
because	O
it	O
was	O
closely	O
related	O
to	O
car	O
##ba	O
##my	O
##lation	O
in	O
v	O
##ivo	O
.	O

As	O
a	O
result	O
,	O
by	O
comparing	O
the	O
BC	O
,	O
RC	O
##C	O
and	O
HC	O
##s	O
,	O
we	O
found	O
that	O
i	O
)	O
a	O
panel	O
composed	O
of	O
α	B
-	I
CE	I
##HC	I
,	O
β	B
-	I
co	I
##rt	I
##olo	I
##ne	I
,	O
de	B
##ox	I
##yi	I
##nos	I
##ine	I
,	O
flu	B
##nis	I
##oli	I
##de	I
,	O
11	B
##b	I
,	I
17	I
##a	I
,	I
21	I
-	I
t	I
##ri	I
##hy	I
##dr	I
##ox	I
##y	I
##p	I
##re	I
##g	I
-	I
ne	I
##no	I
##lone	I
and	O
g	B
##ly	I
##cer	I
##ol	I
trip	I
##rop	I
##ano	I
##ate	I
could	O
well	O
distinguish	O
the	O
cancer	O
patients	O
(	O
BC	O
and	O
RC	O
##C	O
)	O
from	O
the	O
healthy	O
controls	O
,	O
and	O
this	O
result	O
may	O
provide	O
significant	O
information	O
about	O
the	O
d	O
##ys	O
##re	O
##gu	O
##lated	O
metabolic	O
pathways	O
of	O
ma	O
##li	O
##gnant	O
u	O
##rina	O
##ry	O
t	O
##umour	O
##s	O
.	O

To	O
this	O
purpose	O
,	O
metabolic	O
changes	O
were	O
investigated	O
by	O
in	O
##fu	O
##sing	O
uniform	O
##ly	O
labeled	O
_	O
13	O
C	B
-	I
glucose	I
into	O
human	O
lung	O
cancer	O
patients	O
,	O
followed	O
by	O
re	O
##section	O
and	O
processing	O
of	O
paired	O
non	O
-	O
cancer	O
##ous	O
lung	O
and	O
non	O
small	O
cell	O
car	O
##cin	O
##oma	O
tissues	O
.	O

The	O
loading	O
plot	O
for	O
PC	O
##2	O
exposed	O
the	O
most	O
disc	O
##rim	O
##inator	O
##y	O
signals	O
and	O
confirmed	O
the	O
elevation	O
of	O
ch	B
##olin	I
##e	I
,	O
g	B
##ly	I
##cer	I
##ol	I
,	O
g	B
##ly	I
##cine	I
,	O
glucose	S
,	O
la	B
##ctic	I
acid	I
and	O
β	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yric	I
acid	I
in	O
the	O
serum	O
of	O
ST	O
##EM	O
##I	O
patients	O
.	O

Try	O
##pt	O
##op	O
##han	O
h	O
##ydro	O
##xy	O
##lase	O
(	O
T	O
##P	O
##H	O
)	O
is	O
involved	O
in	O
the	O
synthesis	O
of	O
the	O
ne	O
##uro	O
##tra	O
##ns	O
##mit	O
##ters	O
se	B
##rot	I
##oni	I
##n	I
and	O
me	B
##lat	I
##oni	I
##n	I
in	O
try	B
##pt	I
##op	I
##han	I
metabolism	O
.	O

For	O
UP	O
##LC	O
–	O
H	O
##R	O
##MS	O
,	O
three	O
meta	O
##bol	O
##ites	O
,	O
expected	O
to	O
be	O
present	O
at	O
low	O
levels	O
(	B
ca	B
##ffe	I
##ic	I
acid	I
,	O
ni	B
##cot	I
##ine	I
,	O
and	O
da	O
##id	O
##ze	O
##in	O
)	O
,	O
were	O
less	O
precise	O
.	O

The	O
two	O
signal	O
groups	O
of	O
ethanol	S
at	O
1	O
.	O
18	O
and	O
3	O
.	O
66	O
pp	O
##m	O
can	O
mask	O
meta	O
##bol	O
##ites	O
that	O
lie	O
in	O
the	O
same	O
chemical	O
shift	O
region	O
of	O
_	O
1	O
H	O
-	O
N	O
##MR	O
s	O
##pect	O
##ra	O
.	O

El	O
##eva	O
##ted	O
levels	O
of	O
these	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
in	O
tissues	O
and	O
in	O
the	O
circulation	O
have	O
been	O
associated	O
with	O
insulin	O
resistance	O
and	O
diabetes	O
.	O

There	O
are	O
adverse	O
consequences	O
of	O
prolonged	O
elevated	O
levels	O
of	O
ad	B
##eno	I
##sin	I
##e	I
including	O
the	O
propagation	O
of	O
lung	O
inflammation	O
and	O
the	O
activation	O
of	O
a	O
##pop	O
##tosis	O
signaling	O
pathways	O
(	O
,	O
,	O
)	O
.	O

The	O
precursor	O
of	O
R	B
##v	I
##E	I
##1	I
18	I
-	I
H	I
##EP	I
##E	I
may	O
represent	O
the	O
EPA	O
-	O
derived	O
re	O
##sol	O
##ving	O
capacity	O
.	O

The	O
control	O
group	O
comprised	O
20	O
normal	O
glucose	S
tolerance	O
(	O
N	O
##G	O
##T	O
)	O
subjects	O
who	O
were	O
matched	O
for	O
age	O
and	O
gender	O
to	O
cases	O
.	O

These	O
amino	O
acids	O
were	O
dominated	O
by	O
p	B
##hos	I
##ph	I
##o	I
-	I
se	I
##rine	I
(	O
P	O
##ser	O
)	O
,	O
p	B
##hos	I
##ph	I
##o	I
-	I
ethanol	I
##amine	I
(	O
P	O
##E	O
##t	O
##N	O
)	O
,	O
ta	B
##uri	I
##ne	I
(	O
Tau	O
)	O
,	O
as	O
##par	O
##agi	O
##nes	O
(	O
As	O
##n	O
)	O
,	O
se	B
##rine	I
(	O
Ser	O
)	O
,	O
h	B
##ydro	I
##xy	I
##p	I
##rol	I
##ine	I
(	O
H	O
##y	O
##p	O
)	O
,	O
g	B
##ly	I
##cine	I
(	O
G	O
##ly	O
)	O
,	O
g	B
##lut	I
##amine	I
(	O
G	O
##ln	O
)	O
,	O
as	O
##par	O
##ate	O
(	O
As	O
##p	O
)	O
,	O
ethanol	B
##amine	I
(	O
E	O
##t	O
##N	O
)	O
,	O
his	B
##ti	I
##dine	I
(	O
His	O
)	O
,	O
th	B
##re	I
##oni	I
##ne	I
(	O
T	O
##hr	O
)	O
,	O
c	B
##it	I
##rate	I
(	O
C	O
##it	O
)	O
,	O
sa	B
##rc	I
##os	I
##ine	I
(	O
Sa	O
##r	O
)	O
,	O
β	B
-	I
al	I
##ani	I
##ne	I
(	O
b	O
##A	O
##la	O
)	O
,	O
g	B
##lut	I
##ama	I
##te	I
(	O
G	O
##lu	O
)	O
,	O
3	B
-	I
Met	I
##hyl	I
-	I
his	I
##ti	I
##dine	I
(	O
3	O
##M	O
-	O
His	O
)	O
,	O
al	B
##ani	I
##ne	I
(	O
Al	O
##a	O
)	O
,	O
ho	B
##mo	I
##ci	I
##tr	I
##ull	I
##ine	I
(	O
H	O
##ci	O
##t	O
)	O
,	O
1	B
-	I
Met	I
##hyl	I
-	I
his	I
##ti	I
##dine	I
(	O
1	O
##M	O
-	O
His	O
)	O
,	O
a	B
##rg	I
##ini	I
##nos	I
##ucci	I
##nic	I
acid	I
(	O
As	O
##a	O
)	O
,	O
γ	B
-	I
amino	I
-	I
n	I
-	I
but	I
##yra	I
##te	I
(	O
GA	O
##BA	O
)	O
,	O
α	B
-	I
amino	I
ad	I
##ip	I
##ic	I
acid	I

In	O
the	O
triple	O
-	O
trans	O
##genic	O
model	O
of	O
AD	O
,	O
brain	B
-	I
glucose	I
levels	O
were	O
below	O
the	O
limits	O
of	O
detection	O
(	O
~	O
1	O
–	O
5	O
μ	O
##mo	O
##l	O
/	O
kg	O
)	O
in	O
both	O
experimental	O
groups	O
;	O
brain	O
-	O
f	O
##ru	O
##ct	O
##ose	O
levels	O
were	O
lower	O
in	O
trans	O
##genic	O
mice	O
than	O
controls	O
(	O
P	O
=	O
0	O
.	O
000	O
##5	O
)	O
;	O
so	B
##rb	I
##ito	I
##l	I
levels	O
trend	O
##ed	O
lower	O
in	O
trans	O
##genic	O
mice	O
but	O
differences	O
were	O
not	O
significant	O
;	O
and	O
copper	O
values	O
did	O
not	O
differ	O
between	O
trans	O
##genic	O
mice	O
and	O
controls	O
(	O
data	O
not	O
shown	O
)	O
.	O

39	O
subjects	O
had	O
normal	O
glucose	S
tolerance	O
(	O
75	O
g	O
oral	O
glucose	S
tolerance	O
test	O
[	O
o	O
##G	O
##TT	O
]	O
)	O
,	O
one	O
control	O
subject	O
had	O
disturbed	O
glucose	S
tolerance	O
and	O
in	O
one	O
carrier	O
of	O
the	O
T	O
##CF	O
##7	O
##L	O
##2	O
r	O
##s	O
##7	O
##90	O
##31	O
##46	O
all	O
##ele	O
with	O
normal	O
fast	O
##ing	O
glucose	S
and	O
normal	O
H	O
##b	O
##A	O
##1	O
##c	O
,	O
the	O
2	O
h	B
-	I
glucose	I
level	O
was	O
missing	O
.	O

PC	B
a	I
##e	I
C	I
##36	I
:	I
3	I
;	O
78	O
.	O

Alto	O
##get	O
##her	O
,	O
the	O
network	O
of	O
u	O
##rina	O
##ry	O
molecules	O
participating	O
in	O
groups	O
separation	O
was	O
characterized	O
by	O
lower	O
levels	O
of	O
x	B
##yl	I
##ito	I
##l	I
(	O
p	O
<	O
0	O
.	O
05	O
)	O
and	O
p	B
##hen	I
##yl	I
ace	I
##tic	I
acid	I
(	O
p	O
<	O
0	O
.	O
05	O
)	O
in	O
o	O
##bes	O
##e	O
vs	O
.	O
normal	O
weight	O
individuals	O
.	O

The	O
most	O
prominent	O
changes	O
were	O
seen	O
with	O
the	O
bi	O
##le	O
acids	O
,	O
which	O
uniform	O
##ly	O
fell	O
between	O
30	O
–	O
63	O
%	O
by	O
180	O
-	O
minutes	O
,	O
and	O
the	O
pu	B
##rine	I
meta	O
##bol	O
##ites	O
[	O
ad	O
##eno	O
##sin	O
##e	O
(	O
+	O
99	O
%	O
,	O
p	O
=	O
0	O
.	O
00	O
##6	O
)	O
,	O
AD	B
##P	I
(	O
+	O
42	O
%	O
,	O
p	O
=	O
0	O
.	O
01	O
)	O
,	O
AM	B
##P	I
(	O
+	O
79	O
%	O
,	O
p	O
=	O
0	O
.	O
00	O
##4	O
)	O
,	O
GDP	O
(	O
+	O
69	O
%	O
,	O
p	O
=	O
0	O
.	O
00	O
##3	O
)	O
,	O
GM	O
##P	O
(	O
+	O
58	O
%	O
,	O
p	O
=	O
0	O
.	O
01	O
)	O
,	O
I	B
##MP	I
(	O
+	O
50	O
%	O
,	O
p	O
=	O
0	O
.	O
03	O
)	O
,	O
x	B
##ant	I
##hine	I
(	O
+	O
61	O
%	O
,	O
p	O
=	O
0	O
.	O
000	O
##6	O
)	O
]	O
,	O
which	O
rose	O
significantly	O
.	O

In	O
this	O
study	O
,	O
total	O
blood	O
ch	B
##ole	I
##ster	I
##ol	I
was	O
one	O
of	O
the	O
main	O
sources	O
of	O
variation	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
u	O
##rina	O
##ry	O
p	B
##oly	I
##amine	I
levels	O
between	O
the	O
healthy	O
individuals	O
and	O
breast	O
cancer	O
patients	O
;	O
however	O
,	O
the	O
levels	O
of	O
put	B
##res	I
##cine	I
,	O
sperm	B
##ine	I
and	O
other	O
meta	O
##bol	O
##ites	O
were	O
significantly	O
higher	O
in	O
patients	O
with	O
breast	O
cancer	O
(	O
By	O
##un	O
et	O
al	O
.	O
)	O
.	O

It	O
is	O
significant	O
to	O
note	O
that	O
genetic	O
p	O
##oly	O
##mor	O
##phism	O
##s	O
in	O
a	O
##rsen	O
##ic	O
metabolism	O
genes	O
,	O
such	O
as	O
human	O
a	O
##rsen	O
##ic	O
met	O
##hyl	O
##tra	O
##ns	O
##fer	O
##ase	O
(	O
AS	O
##3	O
##MT	O
)	O
gene	O
and	O
g	B
##lut	I
##ath	I
##ione	I
S	O
-	O
transfer	O
##ase	O
gene	O
,	O
are	O
considered	O
to	O
be	O
related	O
to	O
inter	O
##ind	O
##iv	O
##id	O
##ual	O
variation	O
in	O
the	O
a	O
##rsen	O
##ic	O
metabolism	O
[	O
-	O
]	O
.	O

Statistical	O
##ly	O
significant	O
differences	O
between	O
the	O
number	O
of	O
males	O
and	O
females	O
and	O
he	O
##pa	O
##titis	O
C	O
virus	O
(	O
HC	O
##V	O
)	O
se	O
##ros	O
##tat	O
##us	O
in	O
each	O
group	O
were	O
evaluated	O
using	O
the	O
χ	O
_	O
2	O
test	O
;	O
between	O
age	O
,	O
CD	O
##4	O
_	O
+	O
and	O
CD	O
##8	O
_	O
+	O
count	O
,	O
CD	O
##4	O
/	O
8	O
ratio	O
,	O
viral	O
loads	O
,	O
duration	S
of	O
viral	O
suppression	O
,	O
and	O
duration	S
of	O
HIV	O
diagnosis	O
of	O
individuals	O
in	O
each	O
group	O
using	O
the	O
K	O
##rus	O
##kal	O
-	O
Wallis	O
test	O
;	O
and	O
between	O
experimental	O
parameters	O
between	O
individuals	O
in	O
each	O
group	O
using	O
the	O
Mann	O
-	O
Whitney	O
test	O
.	O

Next	O
,	O
92	O
##0	O
µ	O
##L	O
of	O
super	O
##nat	O
##ant	O
(	O
upper	O
organic	O
phase	O
)	O
was	O
di	O
##spense	O
##d	O
in	O
a	O
con	O
##ical	O
glass	O
insert	O
for	O
auto	O
##sa	O
##mple	O
##r	O
via	O
##ls	O
,	O
dried	O
in	O
v	O
##ac	O
##uo	O
,	O
and	O
added	O
to	O
a	O
mixture	O
of	O
40	O
µ	O
##L	O
of	O
p	B
##yr	I
##id	I
##ine	I
,	O
40	O
µ	O
##L	O
of	O
N	B
-	I
(	I
te	I
##rt	I
-	I
but	I
##yl	I
##di	I
##met	I
##hyl	I
##si	I
##ly	I
##l	I
)	I
-	I
N	I
-	I
met	I
##hyl	I
t	I
##ri	I
##f	I
##lu	I
##oro	I
##ace	I
##tam	I
##ide	I
,	O
and	O
30	O
µ	O
##L	O
of	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
to	O
obtain	O
te	O
##rt	O
-	O
but	O
##yl	O
##di	O
##met	O
##hyl	O
##si	O
##ly	O
##l	O
(	O
T	O
##B	O
##DM	O
##S	O
)	O
est	O
##ers	O
from	O
the	O
free	O
fatty	O
acids	O
.	O

Test	B
##osterone	I
and	O
di	B
-	I
h	I
##ydro	I
test	I
##osterone	I
have	O
the	O
highest	O
pot	O
##ency	O
as	O
and	O
##rogen	O
##s	O
,	O
and	O
D	O
##H	O
##EA	O
,	O
e	B
##pian	I
##dr	I
##osterone	I
,	O
and	O
and	B
##ros	I
##tero	I
##ne	I
are	O
relatively	O
weak	O
and	O
##rogen	O
##s	O
.	O

Second	O
,	O
we	O
further	O
assessed	O
the	O
overall	O
performance	O
of	O
the	O
combined	O
score	O
with	O
and	O
without	O
try	B
##pt	I
##op	I
##han	I
.	O

Meanwhile	O
,	O
the	O
significantly	O
changed	O
levels	O
of	O
t	B
##yr	I
##os	I
##ine	I
were	O
observed	O
in	O
T	O
##2	O
##DM	O
patients	O
with	O
PS	O
##D	O
in	O
this	O
study	O
.	O

As	O
a	O
consequence	O
,	O
o	B
##xa	I
##late	I
and	O
g	B
##ly	I
##cola	I
##te	I
concentrations	O
present	O
in	O
these	O
pool	O
##ed	O
plasma	O
samples	O
were	O
in	O
##bet	O
##we	O
##en	O
the	O
concentration	O
ranges	O
for	O
healthy	O
volunteers	O
and	O
P	O
##H1	O
patients	O
.	O

Thus	O
,	O
in	O
addition	O
to	O
p	B
##yr	I
##u	I
##vate	I
derived	O
from	O
g	O
##ly	O
##co	O
##lysis	O
,	O
fatty	O
acids	O
and	O
particularly	O
amino	O
acids	O
can	O
supply	O
substrates	O
to	O
the	O
t	B
##rica	I
##rb	I
##ox	I
##yl	I
##ic	I
acid	I
(	O
T	O
##CA	O
)	O
cycle	O
to	O
maintain	O
mitochondrial	O
production	O
in	O
cancer	O
cells	O
(	O
Chen	O
and	O
Russo	O
)	O
.	O

No	O
association	O
between	O
the	O
serum	O
levels	O
of	O
ta	B
##mo	I
##xi	I
##fen	I
and	O
its	O
meta	O
##bol	O
##ites	O
and	O
the	O
S	O
##U	O
##LT	O
##1	O
##A	O
##1	O
g	O
##eno	O
##type	O
##s	O
was	O
demonstrated	O
in	O
this	O
subgroup	O
of	O
post	O
##men	O
##op	O
##aus	O
##al	O
women	O
.	O

Additionally	O
,	O
an	O
observation	O
##al	O
study	O
showed	O
that	O
the	O
plasma	O
4	O
-	O
PA	O
level	O
was	O
a	O
stronger	O
co	O
##var	O
##iate	O
with	O
ho	B
##mo	I
##cy	I
##stein	I
##e	I
(	O
an	O
independent	O
CH	O
##D	O
risk	O
factor	O
)	O
than	O
the	O
plasma	O
P	O
##LP	O
level	O
.	O

To	O
explore	O
this	O
concept	O
,	O
we	O
investigated	O
ion	O
pairs	O
of	O
4	O
a	O
##romatic	O
bases	O
with	O
al	B
##ip	I
##hat	I
##ic	I
acids	I
monitoring	O
the	O
formation	O
of	O
an	O
##ions	O
using	O
TO	O
##F	O
mass	O
s	O
##pect	O
##rome	O
##try	O
.	O

Sam	O
##ples	O
were	O
taken	O
at	O
three	O
time	O
points	O
for	O
g	B
##lu	I
##co	I
##bra	I
##ssi	I
##cin	I
analysis	O
.	O

The	O
signal	O
for	O
er	B
##yt	I
##hr	I
##ito	I
##l	I
was	O
confirmed	O
in	O
a	O
targeted	O
G	O
##C	O
-	O
MS	O
approach	O
with	O
absolute	O
q	O
##uant	O
##ification	O
of	O
er	B
##yt	I
##hr	I
##ito	I
##l	I
;	O
the	O
concentration	O
of	O
er	B
##yt	I
##hr	I
##ito	I
##l	I
was	O
14	O
.	O
7	O
-	O
fold	O
greater	O
[	O
95	O
%	O
confidence	O
interval	O
(	O
C	O
##I	O
)	O
:	O
13	O
.	O
27	O
,	O
16	O
.	O
25	O
]	O
in	O
incident	O
central	O
ad	O
##ip	O
##os	O
##ity	O
gain	O
pool	O
##ed	O
samples	O
compared	O
with	O
pool	O
##ed	O
samples	O
of	O
participants	O
with	O
stable	O
ad	O
##ip	O
##os	O
##ity	O
[	O
60	O
.	O
8	O
(	O
SE	O
=	O
3	O
.	O
1	O
)	O
vs	O
.	O
4	O
.	O
1	O
(	O
SE	O
=	O
0	O
.	O
0	O
)	O
μ	O
##mo	O
##l	O
/	O
L	O
;	O
P	O
<	O
0	O
.	O
000	O
##1	O
]	O
.	O

This	O
strategy	O
allows	O
simultaneous	O
q	O
##uant	O
##ification	O
of	O
186	O
meta	O
##bol	O
##ites	O
(	O
40	O
amino	O
acids	O
and	O
bio	O
##genic	O
am	O
##ines	O
,	O
40	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
,	O
90	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
,	O
15	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
##s	I
,	O
1	O
mon	B
##osa	I
##cc	I
##hari	I
##de	I
)	O
.	O

Twenty	O
-	O
eight	O
meta	O
##bol	O
##ite	O
standards	O
,	O
4	B
,	I
4	I
-	I
dim	I
##eth	I
##yl	I
-	I
4	I
-	I
si	I
##lap	I
##ent	I
##ane	I
-	I
1	I
-	I
su	I
##lf	I
##onic	I
acid	I
(	O
DS	O
##S	O
)	O
,	O
male	B
##ic	I
acid	I
,	O
ethanol	B
##amine	I
(	O
all	O
from	O
Sigma	O
–	O
Al	O
##dric	O
##h	O
,	O
St	O
.	O
Louis	O
,	O
M	O
##O	O
)	O
,	O
4	B
-	I
(	I
4	I
,	I
6	I
-	I
dim	I
##eth	I
##ox	I
##y	I
[	I
1	I
,	I
3	I
,	I
5	I
]	I
t	I
##ria	I
##zin	I
-	I
2	I
-	I
y	I
##l	I
)	I
-	I
4	I
-	I
met	I
##hyl	I
##mor	I
##ph	I
##olin	I
##ium	I
chloride	I
(	O
D	O
##MT	O
-	O
M	O
##M	O
)	O
(	O
A	O
##c	O
##ros	O
,	O
Gee	O
##l	O
,	O
Belgium	O
)	O
,	O
_	O
15	O
N	B
-	I
ethanol	I
##amine	I
,	O
_	O
13	O
C	O
-	O
form	O
##ic	O
acid	O
(	O
Cambridge	O
Is	O
##oto	O
##pe	O
Laboratories	O
,	O
And	O
##over	O
,	O
MA	O
)	O
,	O
N	O
,	O
N	O
-	O
di	O
##cy	O
##c	O
##lo	O
##he	O
##xy	O
##l	O
##car	O
##bo	O
##di	O
##im	O
##ide	O
and	O
N	B
-	I
h	I
##ydro	I
##xy	I
##su	I
##cci	I
##ni	I
##mi	I
##de	I
(	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
)	O
were	O
used	O
without	O
further	O
pu	O
##rification	O
.	O

The	O
resulting	O
solution	O
was	O
dial	O
##y	O
##zed	O
with	O
water	O
in	O
a	O
dial	O
##ys	O
##is	O
cassette	O
with	O
350	O
##0	O
Da	O
cut	O
-	O
off	O
to	O
remove	O
ace	B
##tone	I
and	O
un	O
##bound	O
para	O
##ox	O
##on	O
.	O

For	O
the	O
extraction	O
of	O
pro	O
##kar	O
##yo	O
##tic	O
micro	O
##bes	O
(	O
e	O
.	O
g	O
.	O
,	O
E	O
##scher	O
##ichi	O
##a	O
co	O
##li	O
)	O
,	O
e	O
##uka	O
##ryo	O
##tic	O
micro	O
##bes	O
(	O
e	O
.	O
g	O
.	O
,	O
Sa	O
##cc	O
##har	O
##omy	O
##ces	O
c	O
##ere	O
##vis	O
##iae	O
)	O
,	O
or	O
ma	O
##mmal	O
##ian	O
cells	O
(	O
e	O
.	O
g	O
.	O
,	O
MC	O
##F	O
-	O
7	O
breast	O
cancer	O
cells	O
)	O
,	O
we	O
found	O
that	O
50	O
%	O
Me	B
##OH	I
in	O
water	O
always	O
provided	O
the	O
best	O
extraction	O
efficiency	O
,	O
whereas	O
50	O
%	O
AC	O
##N	O
resulted	O
in	O
a	O
lower	O
extraction	O
efficiency	O
than	O
50	O
%	O
Me	B
##OH	I
,	O
and	O
1	O
:	O
1	O
:	O
1	O
AC	O
##N	O
/	B
Me	B
##OH	I
/	O
H	O
_	O
2	O
O	O
resulted	O
in	O
the	O
lowest	O
efficiency	O
.	O

Ch	O
##roma	O
##to	O
##gram	O
obtained	O
for	O
10	O
g	O
of	O
spike	O
##d	O
apple	O
sample	O
at	O
the	O
concentration	O
level	O
2	O
mg	O
·	O
kg	O
_	O
−	O
##1	O
for	O
each	O
p	O
##est	O
##icide	O
by	O
using	O
Q	O
##u	O
##EC	O
##h	O
##ER	O
##S	O
-	O
G	O
##C	O
-	O
EC	O
##D	O
,	O
1	O
:	O
To	O
##l	O
##c	O
##lo	O
##fo	O
##s	O
-	O
met	O
##hyl	O
,	O
2	O
:	O
Ch	B
##lor	I
##py	I
##ri	I
##fo	I
##s	I
,	O
3	O
:	O
Capt	O
##an	O
,	O
4	O
:	O
α	B
-	I
end	I
##os	I
##ulf	I
##an	I
,	O
5	O
:	O
I	O
##ma	O
##zal	O
##il	O
,	O
6	O
:	O
Ph	O
##osa	O
##lone	O
,	O
7	O
:	O
α	B
-	I
c	I
##yper	I
##met	I
##hr	I
##in	I
,	O
8	O
:	O
Delta	O
##met	O
##hr	O
##in	O
.	O

B	O
##rief	O
##ly	O
,	O
phosphate	S
buffer	O
(	O
200	O
μ	O
##L	O
,	O
7	O
.	O
4	O
pH	O
)	O
was	O
added	O
to	O
urine	O
(	O
500	O
μ	O
##L	O
)	O
.	O

(	O
A	O
)	O
Formation	O
rate	O
of	O
h	B
##ydro	I
##xy	I
##ana	I
##stro	I
##zo	I
##le	I
from	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
in	O
a	O
panel	O
of	O
expressed	O
human	O
C	O
##YP	O
##s	O
.	O

As	O
expected	O
,	O
a	O
significant	O
decrease	O
in	O
serum	O
glucose	S
and	O
an	O
increase	O
la	B
##ct	I
##ate	I
were	O
observed	O
in	O
lung	O
cancer	O
patients	O
.	O

P	B
##yr	I
##im	I
##id	I
##ine	I
metabolism	O
regulate	O
##s	O
the	O
n	O
##uc	O
##leo	O
##tide	O
home	O
##ost	O
##asis	O
through	O
de	O
no	O
##vo	O
synthesis	O
,	O
cat	O
##ab	O
##olis	O
##m	O
,	O
and	O
n	O
##uc	O
##leo	O
##tide	O
sa	O
##l	O
##va	O
##ging	O
and	O
recycling	O
.	O

The	O
mean	O
concentration	O
of	O
this	O
o	B
##xy	I
##ster	I
##ol	I
in	O
the	O
population	O
was	O
60	O
ng	O
/	O
m	O
##L	O
,	O
and	O
the	O
range	O
was	O
10	O
–	O
31	O
##4	O
ng	O
/	O
m	O
##L	O
.	O
Level	O
##s	O
of	O
24	B
##S	I
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
correlated	O
with	O
those	O
of	O
ch	B
##ole	I
##ster	I
##ol	I
(	O
,	O
r	O
=	O
0	O
.	O
53	O
)	O
.	O

The	O
meta	O
##bol	O
##ites	O
are	O
labeled	O
as	O
follows	O
:	O
6	O
,	O
met	B
##hyl	I
##mal	I
##ona	I
##te	I
;	O
8	O
,	O
la	B
##ct	I
##ate	I
;	O
9	O
,	O
al	B
##ani	I
##ne	I
;	O
10	O
,	O
ace	B
##tate	I
;	O
11	O
,	O
N	B
-	I
ace	I
##ty	I
##l	I
##g	I
##lut	I
##amine	I
;	O
12	O
,	O
ace	B
##tone	I
;	O
13	O
,	O
ace	B
##to	I
##ace	I
##tate	I
;	O
14	O
,	O
o	B
##xa	I
##lo	I
##ace	I
##tate	I
;	O
15	O
,	O
su	B
##cci	I
##nate	I
;	O
16	O
,	O
c	B
##it	I
##rate	I
;	O
17	O
,	O
c	B
##rea	I
##tine	I
;	O
18	O
,	O
c	B
##rea	I
##tin	I
##ine	I
;	O
19	O
,	O
ma	B
##lon	I
##ate	I
;	O
20	O
,	O
ch	O
##olin	O
##e	O
-	O
containing	O
compounds	O
;	O
21	O
,	O
trim	B
##eth	I
##yla	I
##mine	I
N	I
-	I
oxide	I
;	O
22	O
,	O
g	B
##ly	I
##cine	I
;	O
23	O
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
;	O
24	O
,	O
p	B
##hen	I
##yla	I
##ce	I
##ty	I
##l	I
##gly	I
##cine	I
;	O
25	O
,	O
hip	B
##pura	I
##te	I
;	O
and	O
27	O
,	O
time	B
##thy	I
##lam	I
##ine	I
.	O

T	O
##2	O
##DM	O
,	O
Type	O
2	O
diabetes	O
me	O
##lli	O
##tus	O
;	O
H	B
##V	I
,	O
healthy	O
volunteer	O
.	O

No	O
correlation	O
between	O
O	O
##DC	O
##1	O
expression	O
and	O
a	B
##rg	I
##ini	I
##ne	I
was	O
found	O
.	O

Benz	B
##o	I
[	I
a	I
]	I
p	O
##yre	O
##ne	O
(	O
Ba	O
##P	O
)	O
,	O
an	O
arch	O
##ety	O
##pical	O
p	B
##oly	I
##cy	I
##c	I
##lic	I
a	O
##romatic	O
h	B
##ydro	I
##car	I
##bon	I
,	O
is	O
classified	O
as	O
“	O
car	O
##cin	O
##ogenic	O
to	O
humans	O
”	O
and	O
is	O
u	O
##bi	O
##quito	O
##us	O
in	O
the	O
environment	O
,	O
as	O
evident	O
by	O
the	O
me	O
##as	O
##urable	O
levels	O
of	O
Ba	O
##P	O
meta	O
##bol	O
##ites	O
in	O
virtually	O
all	O
human	O
urine	O
samples	O
examined	O
.	O

Together	O
,	O
these	O
findings	O
highlight	O
the	O
potential	O
role	O
of	O
ch	B
##olin	I
##e	I
metabolism	O
in	O
the	O
path	O
##ogen	O
##esis	O
of	O
both	O
H	O
##F	O
##p	O
##EF	O
and	O
H	O
##F	O
##r	O
##EF	O
.	O

These	O
changes	O
in	O
k	B
##yn	I
##uren	I
##ine	I
metabolism	O
are	O
partly	O
driven	O
by	O
inflammation	O
and	O
as	O
such	O
our	O
data	O
strengthen	O
the	O
inflammation	O
model	O
of	O
depression	O
by	O
providing	O
some	O
of	O
the	O
first	O
evidence	O
that	O
ne	O
##uro	O
##active	O
k	B
##yn	I
##uren	I
##ine	I
meta	O
##bol	O
##ites	O
may	O
impact	O
limb	O
##ic	O
structures	O
such	O
as	O
the	O
hip	O
##po	O
##cam	O
##pus	O
and	O
am	O
##y	O
##g	O
##dal	O
##a	O
,	O
in	O
v	O
##ivo	O
.	O

It	O
was	O
also	O
possible	O
to	O
disc	O
##rim	O
##inate	O
and	O
##rogen	O
re	O
##sp	O
##ons	O
##ive	O
from	O
and	O
##rogen	O
non	O
-	O
re	O
##sp	O
##ons	O
##ive	O
cell	O
lines	O
using	O
3	B
,	I
7	I
-	I
dim	I
##eth	I
##yl	I
##oc	I
##t	I
-	I
7	I
-	I
en	I
-	I
1	I
-	I
o	I
##l	I
,	O
since	O
this	O
meta	O
##bol	O
##ite	O
was	O
only	O
significantly	O
decreased	O
in	O
and	O
##rogen	O
non	O
-	O
re	O
##sp	O
##ons	O
##ive	O
cell	O
lines	O
(	O
PC	O
##3	O
,	O
D	O
##U	O
##14	O
##5	O
and	O
22	O
##R	O
##V	O
##1	O
)	O

B	O
.	O
U	O
##rina	O
##ry	O
ben	B
##zen	I
##e	I
me	I
##rca	I
##pt	I
##uri	I
##c	I
acid	I
levels	O
.	O

Recent	O
studies	O
have	O
demonstrated	O
that	O
elevated	O
levels	O
of	O
u	B
##ric	I
acid	I
in	O
serum	O
are	O
associated	O
with	O
greater	O
cancer	O
risk	O
,	O
re	O
##cu	O
##rrence	O
,	O
and	O
mortality	O
in	O
color	O
##ec	O
##tal	O
,	O
breast	O
,	O
pro	O
##state	O
cancer	O
##s	O
_	O
–	O
and	O
its	O
pro	O
-	O
inflammatory	O
properties	O
may	O
play	O
a	O
role	O
in	O
the	O
B	O
##LC	O
##A	O
path	O
##ogen	O
##esis	O
in	O
AA	O
.	O

U	O
##rine	O
samples	O
from	O
smoke	O
##rs	O
who	O
stopped	O
were	O
obtained	O
as	O
described	O
in	O
a	O
study	O
of	O
the	O
effects	O
of	O
smoking	O
c	O
##ess	O
##ation	O
on	O
ace	B
##tal	I
##de	I
##hy	I
##de	I
-	I
DNA	I
add	O
##uc	O
##ts	O
in	O
le	O
##uk	O
##ocytes	O
.	O

The	O
average	O
duration	S
of	O
sunlight	O
during	O
the	O
study	O
is	O
around	O
3	O
.	O
5	O
–	O
5	O
.	O
1	O
h	O
of	O
sunlight	O
a	O
day	O
(	O
Thai	O
Met	O
##eorological	O
Department	O
,	O
2012	O
)	O
.	O

The	O
average	O
apparent	O
h	B
##ydro	I
##xy	I
##ana	I
##stro	I
##zo	I
##le	I
formation	O
rate	O
at	O
1	O
µ	O
##m	O
and	O
20	O
µ	O
##m	O
of	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
was	O
0	O
.	O
09	O
##8	O
±	O
0	O
.	O
09	O
pm	O
##ol	O
min	O
_	O
−	O
##1	O
mg	O
_	O
−	O
##1	O
protein	O
(	O
range	O
0	O
.	O
00	O
##48	O
–	O
0	O
.	O
258	O
,	O
53	O
.	O
8	O
fold	O
)	O
and	O
0	O
.	O
86	O
±	O
0	O
.	O
55	O
(	O
range	O
0	O
.	O
05	O
–	O
1	O
.	O
68	O
,	O
33	O
-	O
fold	O
)	O
.	O

Bar	O
##p	O
##lot	O
##s	O
of	O
the	O
β	O
coefficients	O
from	O
the	O
sex	O
s	O
##tra	O
##ti	O
##fied	O
re	O
##gression	O
models	O
with	O
Met	O
##S	O
factors	O
(	O
WC	O
,	O
HD	O
##L	O
-	O
C	O
,	O
T	B
##G	I
and	O
s	O
##ys	O
##B	O
##P	O
)	O
as	O
outcome	O
and	O
single	O
meta	O
##bol	O
##ite	O
concentration	O
as	O
predict	O
##or	O
,	O
adjusted	O
for	O
ethnicity	O
,	O
physical	O
activity	O
,	O
se	O
##dent	O
##ary	O
behaviour	O
,	O
diet	O
##ary	O
patterns	O
,	O
smoking	O
,	O
and	O
alcohol	O
consumption	O
.	O

*	O
This	O
amino	B
-	I
acid	I
group	O
consists	O
of	O
as	B
##par	I
##agi	I
##ne	I
,	O
his	B
##ti	I
##dine	I
,	O
se	B
##rine	I
and	O
t	B
##yr	I
##os	I
##ine	I
.	O

Co	O
##mp	O
##aris	O
##on	O
of	O
L	O
##C	O
-	O
MS	O
ch	O
##roma	O
##to	O
##gram	O
##s	O
of	O
human	O
urine	O
sample	O
acquired	O
in	O
R	B
##P	I
and	O
H	O
##IL	O
##IC	O
liquid	O
ch	O
##roma	O
##tography	O
modes	O
on	O
L	O
##T	O
##Q	O
(	O
linear	O
ion	O
trap	O
mass	O
s	O
##pect	O
##rome	O
##ter	O
)	O
.	O

The	O
highest	O
prediction	O
power	O
was	O
reached	O
through	O
Na	O
##ï	O
##ve	O
Bay	O
##es	O
method	O
with	O
9	O
meta	O
##bol	O
##ites	O
combination	O
,	O
including	O
v	B
##ali	I
##ne	I
,	O
le	B
##uc	I
##ine	I
,	O
pro	B
##line	I
,	O
g	B
##ly	I
##ce	I
##ic	I
acid	I
,	O
p	B
##yr	I
##og	I
##lut	I
##ama	I
##te	I
,	O
gal	B
##act	I
##ose	I
,	O
g	B
##lu	I
##copy	I
##rano	I
##se	I
,	O
palm	B
##itic	I
acid	I
and	O
he	B
##pta	I
##de	I
##cy	I
##lic	I
acid	I
.	O

This	O
concept	O
is	O
best	O
highlighted	O
when	O
comparing	O
the	O
l	O
##ys	O
##o	O
##P	O
##E	O
versus	O
intact	O
P	O
##E	O
lip	O
##id	O
,	O
in	O
which	O
the	O
loss	O
of	O
a	O
FA	O
side	O
-	O
chain	O
(	O
l	O
##ys	O
##o	O
)	O
decreases	O
the	O
h	O
##ydro	O
##phobic	O
##ity	O
of	O
the	O
molecule	O
enough	O
to	O
alter	O
its	O
extraction	O
efficiency	O
to	O
favor	O
M	B
##T	I
##BE	I
.	O

A	O
c	O
##yan	O
##op	O
##rop	O
##yl	O
(	O
C	O
##N	O
)	O
stationary	O
phase	O
was	O
initially	O
used	O
at	O
N	O
##IS	O
##T	O
in	O
both	O
the	O
L	O
##C	O
-	O
MS	O
and	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
methods	O
to	O
resolve	O
3	B
-	I
e	I
##pi	I
-	I
25	I
(	I
OH	I
)	I
D	I
_	I
3	I
from	O
25	O
(	O
OH	O
)	O
D	O
_	O
3	O
.	O

The	O
N	O
##MR	O
data	O
were	O
further	O
analyzed	O
by	O
principal	O
component	O
analysis	O
(	O
PC	O
##A	O
)	O
using	O
the	O
full	O
,	O
processed	O
_	O
1	O
H	O
N	O
##MR	O
s	O
##pect	O
##ra	O
with	O
glucose	S
regions	O
removed	O
to	O
differentiate	O
the	O
plasma	O
of	O
insulin	O
-	O
deprived	O
type	O
1	O
di	O
##abe	O
##tic	O
people	O
from	O
insulin	O
-	O
treated	O
T	O
##1	O
##D	O
and	O
non	O
-	O
di	O
##abe	O
##tic	O
controls	O
.	O

While	O
very	O
little	O
is	O
known	O
about	O
the	O
physiological	O
role	O
of	O
h	B
##y	I
##pot	I
##au	I
##rine	I
,	O
ta	B
##uri	I
##ne	I
is	O
known	O
to	O
have	O
diverse	O
cellular	O
functions	O
including	O
ne	O
##uro	O
##tra	O
##ns	O
##mission	O
,	O
re	B
##tina	I
##l	I
photo	O
##re	O
##ceptor	O
differentiation	O
(	O
through	O
the	O
ta	B
##uri	I
##ne	I
up	O
##re	O
##gu	O
##lated	O
gene	O
1	O
(	O
T	O
##U	O
##G	O
##1	O
)	O
,	O
a	O
non	O
-	O
coding	O
RNA	O
that	O
m	O
##od	O
##ulates	O
the	O
expression	O
of	O
photo	O
##re	O
##ceptor	O
-	O
specific	O
genes	O
in	O
the	O
re	O
##tina	O
,	O
o	O
##smo	O
##re	O
##gu	O
##lation	O
,	O
calcium	O
m	O
##od	O
##ulation	O
,	O
and	O
suppression	O
of	O
inflammation	O
,	O
as	O
well	O
as	O
normal	O
mitochondrial	O
respiratory	O
chain	O
function	O
.	O

Instead	O
of	O
using	O
sur	O
##rogate	O
end	O
points	O
(	O
such	O
as	O
u	O
##rina	O
##ry	O
o	B
##xa	I
##late	I
ex	O
##cre	O
##tion	O
and	O
/	O
or	O
plasma	O
o	B
##xa	I
##late	I
concentration	O
)	O
,	O
we	O
can	O
now	O
q	O
##uant	O
##ify	O
the	O
decrease	O
in	O
end	O
##ogen	O
##ous	O
o	B
##xa	I
##late	I
production	O
to	O
proof	O
efficacy	O
.	O

The	O
le	O
##uc	O
##ine	O
amino	O
##tra	O
##ns	O
##fer	O
##ase	O
enzyme	O
that	O
controls	O
the	O
key	O
le	B
##uc	I
##ine	I
to	O
k	B
##eto	I
##le	I
##uc	I
##ine	I
step	O
in	O
the	O
muscle	O
mit	O
##och	O
##ond	O
##ria	O
is	O
induced	O
by	O
exercise	O
to	O
respond	O
to	O
increased	O
energy	O
demand	O
by	O
enhancing	O
BC	O
##AA	O
metabolism	O
in	O
skeletal	O
muscle	O
;	O
the	O
inverse	O
association	O
of	O
the	O
k	B
##eto	I
##le	I
##uc	I
##ine	I
/	I
le	I
##uc	I
##ine	I
ratio	O
with	O
B	O
##MI	O
observed	O
here	O
may	O
reflect	O
the	O
important	O
role	O
of	O
exercise	O
in	O
controlling	O
ad	O
##ip	O
##os	O
##ity	O
.	O

A	B
##cy	I
##l	I
-	I
Co	I
##As	I
are	O
released	O
into	O
the	O
c	O
##yt	O
##op	O
##las	O
##m	O
.	O

Despite	O
of	O
the	O
use	O
of	O
am	B
##mon	I
##ium	I
format	I
##e	I
,	O
sodium	O
add	O
##uc	O
##ts	O
(	O
[	O
M	O
+	O
Na	O
]	O
_	O
+	O
)	O
were	O
detected	O
for	O
some	O
lip	O
##id	O
classes	O
,	O
i	O
.	O
e	O
.	O
,	O
Ce	B
##r	I
,	O
He	O
##x	O
##C	O
##er	O
,	O
SM	O
,	O
LP	O
##C	O
,	O
PC	O
,	O
g	B
##ly	I
##cer	I
##oli	I
##pid	I
##s	I
(	O
D	O
##G	O
and	O
T	O
##G	O
)	O
and	O
ch	B
##ole	I
##ster	I
##yl	I
est	I
##ers	I
.	O

Therefore	O
,	O
the	O
con	O
##ju	O
##gated	O
long	O
chain	O
fatty	O
acid	O
,	O
car	B
##ni	I
##tine	I
(	I
18	I
:	I
1	I
)	I
,	O
and	O
its	O
β	O
-	O
oxidation	O
product	O
,	O
ace	B
##ty	I
##l	I
car	I
##ni	I
##tine	I
,	O
but	O
not	O
de	B
##cano	I
##yl	I
car	I
##ni	I
##tine	I
,	O
are	O
found	O
increased	O
in	O
CR	O
##C	O
with	O
increased	O
consumption	O
of	O
energy	O
substrates	O
.	O

(	O
A	O
)	O
Un	O
##sat	O
##ura	O
##ted	O
fatty	O
acids	O
(	O
contain	O
one	O
or	O
more	O
C	O
=	O
C	O
double	O
bonds	O
)	O
are	O
prone	O
to	O
lip	O
##id	O
per	O
##ox	O
##ida	O
##tion	O
,	O
resulting	O
in	O
the	O
formation	O
of	O
lip	O
##id	O
al	O
##de	O
##hy	O
##des	O
,	O
a	B
##c	I
##rol	I
##ein	I
(	O
AL	O
)	O
,	O
ma	B
##lon	I
##dial	I
##de	I
##hy	I
##de	I
(	O
MD	O
##A	O
)	O
and	O
4	B
-	I
h	I
##ydro	I
##xy	I
##non	I
##ena	I
##l	I
(	O
H	O
##NE	O
)	O
.	O

Pat	O
##ients	O
with	O
mild	O
insulin	O
resistance	O
are	O
more	O
likely	O
to	O
develop	O
full	O
insulin	O
resistance	O
after	O
si	B
##m	I
##vas	I
##tat	I
##in	I
treatment	O
,	O
which	O
may	O
drive	O
their	O
metabolism	O
towards	O
a	O
more	O
g	B
##lu	I
##con	I
##eo	I
##genic	I
state	O
.	O

Furthermore	O
,	O
in	O
Study	O
1	O
,	O
the	O
unknown	O
compound	O
and	O
pipe	B
##rine	I
were	O
altered	O
in	O
MC	O
##I	O
patients	O
in	O
the	O
same	O
direction	O
as	O
AD	O
dem	O
##ent	O
##ia	O
.	O

There	O
were	O
significant	O
increases	O
in	O
levels	O
of	O
insulin	O
and	O
H	O
##OM	O
##A	O
and	O
reduction	O
##s	O
in	O
L	B
##D	I
##L	I
ch	I
##ole	I
##ster	I
##ol	I
between	O
T	O
##P	O
##2	O
and	O
T	O
##P	O
##3	O
,	O
i	O
.	O
e	O
.	O
between	O
values	O
immediately	O
after	O
the	O
two	O
restricted	O
days	O
and	O
five	O
days	O
later	O
after	O
five	O
unrest	O
##ricted	O
days	O
of	O
the	O
diet	O
(	O
all	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

B	O
##rief	O
##ly	O
,	O
urine	O
samples	O
were	O
di	O
##lut	O
##ed	O
25	O
times	O
with	O
el	O
##uen	O
##t	O
A	O
(	O
1	O
:	O
1	O
ace	O
##ton	O
##it	O
##ril	O
##e	O
/	O
a	O
##que	O
##ous	O
50	O
m	O
##M	O
am	B
##mon	I
##ium	I
format	O
##e	O
)	O
and	O
separated	O
by	O
an	O
inverse	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
gradient	O
on	O
a	O
polar	O
H	O
##IL	O
##IC	O
column	O
(	O
A	O
##c	O
##qui	O
##ty	O
B	O
##E	O
##H	O
Am	B
##ide	I
,	O
100	O
×	O
2	O
.	O
1	O
mm	O
,	O
1	O
.	O
7	O
µ	O
##m	O
,	O
Waters	O
,	O
E	O
##sch	O
##born	O
,	O
Germany	O
)	O
.	O

Among	O
the	O
most	O
important	O
meta	O
##bol	O
##ites	O
disc	O
##rim	O
##inating	O
A	O
and	O
C	O
##1	O
(	O
but	O
not	O
A	O
and	O
C	O
##2	O
)	O
were	O
ace	B
##tate	I
,	O
g	B
##lut	I
##ama	I
##te	I
,	O
su	B
##cci	I
##nate	I
,	O
c	B
##rea	I
##tin	I
##ine	I
and	O
beta	B
##ine	I
(	O
higher	O
in	O
A	O
)	O
,	O
and	O
g	B
##lut	I
##amine	I
,	O
la	B
##ct	I
##ate	I
and	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
(	O
higher	O
in	O
C	O
##1	O
)	O
.	O

The	O
source	O
of	O
this	O
instability	O
was	O
likely	O
the	O
α	B
-	I
k	I
##eto	I
##ac	I
##id	I
functionality	O
of	O
this	O
compound	O
(	O
,	O
)	O
.	O

This	O
revealed	O
that	O
BS	O
##O	O
treatment	O
drastically	O
reduced	O
end	O
##ogen	O
##ous	O
g	B
##lut	I
##ath	I
##ione	I
##s	I
in	O
R	O
##GC	O
-	O
5	O
cells	O
,	O
a	O
result	O
that	O
is	O
consistent	O
with	O
previous	O
findings	O
,	O
and	O
also	O
led	O
to	O
a	O
higher	O
su	O
##s	O
##ce	O
##pt	O
##ibility	O
of	O
the	O
cells	O
to	O
H	O
_	O
2	O
O	O
_	O
2	O
-	O
mediated	O
o	O
##xi	O
##da	O
##tive	O
stress	O
.	O

Regardless	O
of	O
the	O
method	O
,	O
all	O
h	B
##ydro	I
##phi	I
##lic	I
compounds	O
were	O
detected	O
and	O
had	O
excellent	O
resolution	O
on	O
the	O
H	O
##IL	O
##IC	O
column	O
.	O
also	O
includes	O
data	O
resulting	O
from	O
M	B
##T	I
##BE	I
extraction	O
and	O
M	B
##T	I
##BE	I
:	O
SP	O
##E	O
extraction	O
,	O
as	O
discussed	O
in	O
detail	O
later	O
.	O

To	O
assess	O
whether	O
altered	O
generation	O
of	O
e	B
##ico	I
##san	I
##oids	I
derived	O
from	O
C	O
##YP	O
AA	O
metabolism	O
occurs	O
with	O
activation	O
of	O
the	O
re	O
##nin	O
-	O
an	O
##gio	O
##tens	O
##in	O
system	O
,	O
we	O
set	O
up	O
a	O
cross	O
-	O
section	O
##al	O
study	O
to	O
measure	O
20	B
-	I
H	I
##ET	I
##E	I
,	O
E	O
##ET	O
,	O
and	O
D	O
##H	O
##ET	O
levels	O
in	O
plasma	O
and	O
urine	O
by	O
paired	O
analyses	O
in	O
h	O
##yper	O
##tensive	O
subjects	O
with	O
R	O
##VD	O
that	O
were	O
compared	O
with	O
these	O
levels	O
in	O
norm	O
##ote	O
##ns	O
##ive	O
control	O
subjects	O
and	O
those	O
with	O
E	O
##H	O
.	O

This	O
was	O
followed	O
by	O
addition	O
of	O
50	O
µ	O
##L	O
MS	O
##TF	O
##A	O
(	O
with	O
1	O
%	O
trim	B
##eth	I
##yl	I
##ch	I
##lor	I
##os	I
##ila	I
##ne	I
)	O
mixing	O
for	O
60	O
minutes	O
at	O
70	O
°C	O
,	O
with	O
formation	O
of	O
trim	O
##eth	O
##yl	O
##si	O
##ly	O
##l	O
derivatives	O
.	O

U	O
##til	O
##izing	O
the	O
G	O
##C	O
-	O
MS	O
data	O
,	O
pairs	O
of	O
bio	O
##sy	O
##nt	O
##hetical	O
##ly	O
-	O
related	O
_	O
13	O
C	O
-	O
labeled	O
meta	O
##bol	O
##ites	O
in	O
tumor	O
and	O
non	O
-	O
cancer	O
##ous	O
tissues	O
were	O
tested	O
for	O
precursor	O
-	O
product	O
relationships	O
,	O
as	O
illustrated	O
in	O
Figure	O
and	O
Table	O
.	O
_	O
13	O
C	B
-	I
su	I
##cci	I
##nate	I
,	O
_	O
13	O
C	O
-	O
c	O
##it	O
##rate	O
and	O
_	O
13	O
C	O
-	O
G	O
##lu	O
are	O
products	O
of	O
the	O
K	O
##re	O
##bs	O
cycle	O
while	O
_	O
13	O
C	O
-	O
Al	O
##a	O
is	O
derived	O
from	O
p	B
##yr	I
##u	I
##vate	I
,	O
the	O
end	O
product	O
of	O
g	O
##ly	O
##co	O
##lysis	O
(	O
c	O
##f	O
.	O

The	O
et	O
##iology	O
of	O
e	O
##pile	O
##psy	O
was	O
established	O
in	O
12	O
(	O
75	O
%	O
)	O
patients	O
(	O
structural	O
et	O
##iology	O
in	O
10	O
patients	O
:	O
brain	O
ma	O
##lf	O
##orm	O
##ation	O
in	O
6	O
,	O
ha	O
##mart	O
##oma	O
in	O
1	O
,	O
h	O
##y	O
##pox	O
##ic	O
-	O
is	O
##che	O
##mic	O
en	O
##ce	O
##pha	O
##lop	O
##athy	O
in	O
3	O
,	O
genetic	O
et	O
##iology	O
in	O
6	O
patient	O
:	O
No	O
##ona	O
##n	O
syndrome	O
,	O
ch	O
##rom	O
##oso	O
##mal	O
a	O
##ber	O
##ration	O
–	O
t	O
##ris	O
##omy	O
21	O
,	O
T	O
##SC	O
,	O
N	O
##F	O
##1	O
,	O
SC	O
##N	O
##1	O
##A	O
mutation	O
and	O
metabolic	O
et	O
##iology	O
in	O
1	O
patient	O
:	O
met	B
##hyl	I
##oma	I
##lon	I
##ic	I
acid	O
##uria	O
)	O
and	O
remained	O
unknown	O
in	O
25	O
%	O
(	O
n	O
=	O
4	O
)	O
.	O

When	O
higher	O
concentrations	O
of	O
a	B
##rg	I
##ini	I
##ne	I
and	O
g	B
##lut	I
##ama	I
##te	I
come	O
together	O
,	O
more	O
ne	B
##uro	I
##to	I
##xin	I
##s	I
such	O
as	O
per	B
##ox	I
##yn	I
##it	I
##rite	I
are	O
produced	O
.	O

B	O
##rief	O
##ly	O
,	O
they	O
were	O
treated	O
with	O
fl	B
##ox	I
##eti	I
##ne	I
,	O
par	B
##ox	I
##eti	I
##ne	I
,	O
c	B
##ital	I
##op	I
##ram	I
,	O
r	B
##is	I
##per	I
##ido	I
##ne	I
,	O
o	B
##lan	I
##za	I
##pine	I
,	O
and	O
lit	O
##hium	O
.	O

The	O
L	O
##C	O
-	O
D	O
##PI	O
-	O
MS	O
method	O
generated	O
two	O
individual	O
ion	O
ch	O
##roma	O
##to	O
##gram	O
##s	O
corresponding	O
to	O
the	O
precursor	O
ion	O
of	O
B	O
##Q	O
##B	O
and	O
B	O
##Q	O
##B	O
-	O
d	O
_	O
7	O
labeled	O
th	B
##iol	I
##s	I
,	O
respectively	O
.	O

AC	O
##N	O
was	O
eventually	O
selected	O
,	O
as	O
it	O
has	O
higher	O
el	O
##uo	O
##tro	O
##pic	O
strength	O
when	O
used	O
at	O
the	O
same	O
volume	O
percentage	O
compared	O
to	O
met	B
##han	I
##ol	I
achieving	O
adequate	O
separation	O
within	O
reasonable	O
time	O
.	O

Similarly	O
,	O
a	O
study	O
in	O
the	O
Shanghai	O
Women	O
’	O
s	O
Health	O
Study	O
reported	O
that	O
vitamin	B
E	I
supplement	O
##ation	O
,	O
and	O
also	O
plasma	O
levels	O
of	O
alpha	B
-	I
to	I
##co	I
##pher	I
##ol	I
,	O
were	O
significantly	O
inverse	O
##ly	O
associated	O
with	O
F	O
_	O
2	O
-	O
Is	O
##o	O
##P	O
-	O
M	O
,	O
but	O
not	O
F	O
_	O
2	O
-	O
Is	O
##o	O
##Ps	O
.	O

Furthermore	O
,	O
other	O
substances	O
like	O
la	B
##ct	I
##ate	I
,	O
c	B
##rea	I
##tine	I
and	O
su	B
##cci	I
##nate	I
were	O
also	O
involved	O
in	O
the	O
metabolic	O
pathways	O
in	O
G	O
##C	O
patients	O
comparing	O
with	O
the	O
healthy	O
controls	O
.	O

The	O
ass	O
##ays	O
were	O
analyzed	O
as	O
per	O
the	O
manufacturers	O
’	O
protocol	O
(	B
http	B
:	I
/	I
/	I
www	I
.	I
me	I
##so	I
##sca	I
##le	I
.	I
com	I
)	O
.	O

bottom	O
right	O
panel	O
)	O
which	O
shows	O
that	O
the	O
bin	O
##s	O
containing	O
signals	O
from	O
meta	O
##bol	O
##ites	O
such	O
as	O
ch	O
##olin	O
##e	O
-	O
containing	O
compounds	O
,	O
la	B
##ct	I
##ate	I
,	O
g	B
##lut	I
##amine	I
,	O
g	B
##lut	I
##ama	I
##te	I
and	O
my	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
are	O
causing	O
the	O
separation	O
of	O
two	O
groups	O
that	O
had	O
been	O
observed	O
in	O
the	O
O	O
##PL	O
##S	O
-	O
D	O
##A	O
scores	O
plot	O
.	O

A	O
mixture	O
was	O
made	O
containing	O
all	O
six	O
anal	O
##yte	O
##s	O
at	O
a	O
concentration	O
of	O
0	O
.	O
1	O
mg	O
/	O
m	O
##L	O
in	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
with	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
.	O

Ana	O
##ly	O
##tes	O
were	O
kept	O
at	O
10	O
°C	O
in	O
the	O
auto	O
##sa	O
##mple	O
##r	O
and	O
injected	O
h	B
##ydro	I
##dynamic	I
##ally	I
at	O
the	O
pressure	O
of	O
5	O
m	O
##bar	O
for	O
100	O
s	O
.	O
Unless	O
otherwise	O
stated	O
,	O
the	O
following	O
E	O
##SI	O
-	O
MS	O
/	O
MS	O
conditions	O
were	O
used	O
:	O
sheath	O
liquid	O
,	O
Me	O
##OH	O
/	O
H	O
_	O
2	O
O	O
(	O
80	O
/	O
20	O
,	O
v	O
/	O
v	O
)	O
containing	O
40	O
m	O
##M	O
H	O
##OA	O
##c	O
;	O
sheath	O
liquid	O
flow	O
rate	O
,	O
5	O
μ	O
##L	O
/	O
min	O
;	O
cap	O
##illa	O
##ry	O
voltage	O
,	O
+	O
350	O
##0	O
V	O
;	O
drying	O
gas	O
flow	O
rate	O
,	O
5	O
.	O
0	O
L	O
/	O
min	O
;	O
drying	O
gas	O
temperature	O
,	O
200	O
°C	O
;	O
ne	O
##bul	O
##izer	O
pressure	O
,	O
7	O
ps	O
##i	O
;	O
collision	O
cell	O
gas	O
(	O
N	O
_	O
2	O
)	O
pressure	O
was	O
~	O
30	O
ps	O
##i	O
.	O

Val	B
##ine	I
was	O
previously	O
reported	O
to	O
have	O
a	O
significantly	O
different	O
level	O
in	O
HC	O
##C	O
vs	O
.	O
normal	O
controls	O
in	O
analysis	O
of	O
tissues	O
by	O
L	O
##C	O
-	O
MS	O
and	O
serum	O
samples	O
by	O
G	O
##C	O
-	O
MS	O
.	O

(	O
b	O
##2	O
)	O
Branch	O
##ed	O
-	O
chain	O
amino	O
acids	O
(	O
BC	O
##AA	O
##s	O
)	O
:	O
le	B
##uc	I
##ine	I
,	O
is	B
##ole	I
##uc	I
##ine	I
and	O
v	B
##ali	I
##ne	I
.	O

The	O
studies	O
reporting	O
an	O
increase	O
in	O
CS	O
##F	O
g	B
##lut	I
##ami	I
##c	I
acid	I
content	O
has	O
by	O
some	O
been	O
taken	O
as	O
support	O
for	O
the	O
theory	O
of	O
g	B
##lut	I
##ami	I
##c	I
acid	I
exit	O
##oto	O
##xi	O
##city	O
as	O
a	O
cause	O
of	O
AL	O
##S	O
.	O

E	B
##stra	I
##dio	I
##l	I
,	O
E	B
##st	I
##rio	I
##l	I
,	O
E	B
##stro	I
##ne	I
,	O
16	B
-	I
H	I
##ydro	I
##xy	I
##est	I
##rone	I
,	O
HP	O
##LC	O
-	O
tandem	O
mass	O
s	O
##pect	O
##rome	O
##try	O
,	O
E	B
##stro	I
##gen	I
pro	O
##fi	O
##ling	O

Good	O
separation	O
and	O
el	O
##ution	O
were	O
achieved	O
using	O
5	O
m	O
##M	O
am	B
##mon	I
##ium	I
format	O
##e	O
:	O
ace	O
##ton	O
##it	O
##ril	O
##e	O
(	O
10	O
:	O
90	O
,	O
v	O
/	O
v	O
)	O
as	O
the	O
mobile	O
phase	O
,	O
at	O
a	O
flow	O
-	O
rate	O
of	O
0	O
.	O
6	O
m	O
##L	O
/	O
min	O
with	O
20	O
μ	O
##L	O
injection	O
volume	O
.	O

In	O
addition	O
to	O
de	O
##gly	O
##cos	O
##yla	O
##tion	O
,	O
ant	B
##ho	I
##cy	I
##ani	I
##ns	I
can	O
be	O
meta	O
##bol	O
##ized	O
by	O
Phase	O
II	O
enzymes	O
[	O
U	O
##DP	O
-	O
g	O
##lu	O
##cu	O
##ron	O
##osy	O
##l	O
transfer	O
##ases	O
(	O
U	O
##G	O
##T	O
##s	O
)	O
and	O
su	O
##lf	O
##ot	O
##ran	O
##s	O
##fer	O
##ases	O
(	O
S	O
##U	O
##LT	O
##s	O
)	O
]	O
and	O
also	O
undergo	O
met	O
##hyl	O
##ation	O
via	O
cat	O
##ech	O
##ol	O
-	O
O	O
-	O
met	O
##hyl	O
##tra	O
##ns	O
##fer	O
##ase	O
.	O

g	B
##ly	I
##cine	I
,	O
se	B
##rine	I
and	O
th	B
##re	I
##oni	I
##ne	I
metabolism	O
.	O

Our	O
data	O
suggest	O
that	O
in	O
20	O
%	O
of	O
such	O
patients	O
,	O
these	O
investigations	O
(	O
along	O
with	O
follow	O
-	O
up	O
appointments	O
and	O
exposure	O
to	O
unnecessary	O
additional	O
treatment	O
)	O
could	O
be	O
potentially	O
avoided	O
if	O
HP	S
L	O
##C	O
-	O
MS	O
/	O
MS	O
urine	O
analysis	O
was	O
used	O
as	O
a	O
routine	O
screening	O
for	O
non	O
-	O
ad	O
##herence	O
.	O

Additionally	O
,	O
among	O
HIV	O
+	O
participants	O
,	O
proportions	O
of	O
the	O
P	O
##U	O
##FA	O
α	B
-	I
l	I
##ino	I
##len	I
##ic	I
acid	I
(	O
18	O
:	O
3	O
)	O
were	O
positively	O
associated	O
with	O
HD	O
##L	O
(	O
r	O
=	O
0	O
.	O
53	O
,	O
p	O
=	O
0	O
.	O
03	O
)	O
and	O
CD	O
##4	O
_	O
+	O
T	O
-	O
cell	O
counts	O
(	O
r	O
=	O
0	O
.	O
62	O
,	O
p	O
=	O
0	O
.	O
00	O
##4	O
)	O
,	O
and	O
inverse	O
##ly	O
related	O
to	O
T	O
##C	O
(	O
r	O
=	O
−	O
##0	O
.	O
48	O
,	O
p	O
=	O
0	O
.	O
05	O
)	O
and	O
T	B
##G	I
levels	O
(	O
r	O
=	O
−	O
##0	O
.	O
56	O
,	O
p	O
=	O
0	O
.	O
02	O
)	O
.	O

In	O
the	O
same	O
study	O
,	O
in	O
##fusion	O
of	O
L	O
##D	O
##L	O
‐	O
Ce	O
##r	O
to	O
mice	O
reduced	O
glucose	S
disposal	O
in	O
muscle	O
in	O
parallel	O
with	O
a	O
tendency	O
to	O
increase	O
plasma	O
membrane	O
c	B
##era	I
##mi	I
##de	I
31	O
.	O

The	O
screening	O
identified	O
53	O
non	O
##obe	O
##se	O
individuals	O
with	O
normal	O
fast	O
##ing	O
glucose	S
(	O
29	O
men	O
and	O
24	O
women	O
)	O
who	O
remained	O
within	O
the	O
range	O
for	O
pre	O
##hy	O
##pert	O
##ens	O
##ion	O
during	O
repeated	O
measurements	O
in	O
the	O
3	O
-	O
year	O
period	O
.	O

In	O
16	O
##H	O
##BE	O
##14	O
##o	O
_	O
−	O
cells	O
,	O
we	O
observed	O
an	O
even	O
higher	O
increase	O
in	O
g	B
##lut	I
##amine	I
up	O
##take	O
rate	O
under	O
r	O
##H	O
##la	O
-	O
treatment	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
identified	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
N	O
-	O
g	O
##lu	O
##cu	O
##ron	O
##ide	O
,	O
h	B
##ydro	I
##xy	I
##ana	I
##stro	I
##zo	I
##le	I
and	O
con	O
##ju	O
##gated	O
h	B
##ydro	I
##xy	I
##ana	I
##stro	I
##zo	I
##le	I
using	O
in	O
v	O
##it	O
##ro	O
and	O
in	O
v	O
##ivo	O
approaches	O
.	O

An	O
over	O
activation	O
of	O
pu	B
##rine	I
##rg	I
##ic	I
signaling	O
seems	O
to	O
be	O
involved	O
in	O
this	O
process	O
,	O
and	O
thus	O
contribute	O
to	O
the	O
development	O
of	O
geographic	O
at	O
##rop	O
##hy	O
.	O

Many	O
fl	B
##av	I
##ono	I
##ids	I
possess	O
strong	O
anti	O
-	O
inflammatory	O
,	O
anti	O
##ox	O
##ida	O
##nt	O
,	O
and	O
other	O
properties	O
when	O
studied	O
in	O
v	O
##it	O
##ro	O
using	O
large	O
doses	O
of	O
the	O
pu	O
##rified	O
form	O
.	O

C	O
##iga	O
##ret	O
##te	O
smoke	O
could	O
induce	O
de	O
##ple	O
##tion	O
of	O
re	B
##tino	I
##l	I
serum	O
levels	O
in	O
rats	O
,	O
as	O
demonstrated	O
by	O
Li	O
et	O
al	O
.	O
.	O

Similar	O
to	O
E	O
_	O
2	O
,	O
pre	O
##tre	O
##at	O
##ment	O
with	O
I	O
##CI	O
182	O
,	O
78	O
##0	O
followed	O
by	O
G	O
##N	O
and	O
D	O
##Z	O
effectively	O
eliminated	O
C	O
##YP	O
##1	O
##A	O
##1	O
down	O
##re	O
##gu	O
##lation	O
by	O
these	O
est	O
##rogen	O
##ic	O
is	B
##of	I
##lav	I
##ones	I
(	O
A	O
)	O
.	O

This	O
composition	O
enables	O
SM	O
to	O
serve	O
significant	O
roles	O
in	O
signaling	O
pathways	O
and	O
SM	O
degradation	O
can	O
produce	O
c	B
##era	I
##mi	I
##de	I
,	O
which	O
is	O
known	O
to	O
be	O
involved	O
in	O
the	O
a	O
##pop	O
##to	O
##tic	O
signaling	O
pathway	O
.	O

In	O
##hibition	O
of	O
re	O
##ab	O
##sor	O
##ption	O
by	O
glucose	S
can	O
occur	O
in	O
h	O
##yper	O
##gly	O
##ce	O
##mia	O
.	O

These	O
results	O
demonstrated	O
that	O
meta	O
##bol	O
##omi	O
##cs	O
pro	O
##fi	O
##ling	O
is	O
capable	O
of	O
distinguishing	O
C	B
##IN	I
##s	I
and	O
c	O
##er	O
##vic	O
##al	O
cancer	O
##s	O
from	O
normal	O
and	O
highlighted	O
potential	O
bio	O
##mark	O
##ers	O
for	O
the	O
early	O
detection	O
of	O
c	O
##er	O
##vic	O
##al	O
car	O
##cin	O
##ogen	O
##esis	O
.	O

Major	O
proteins	O
are	O
a	O
##po	O
##A	O
##1	O
(	O
70	O
%	O
)	O
and	O
a	O
##po	O
##A	O
##2	O
(	O
20	O
%	O
)	O
together	O
with	O
proteins	O
such	O
as	O
a	O
##po	O
##A	O
##4	O
,	O
a	O
##po	O
##E	O
,	O
a	O
##po	O
##J	O
,	O
ha	O
##pt	O
##og	O
##lo	O
##bin	O
,	O
para	O
##ox	O
##ana	O
##se	O
,	O
α	O
##2	O
-	O
mac	O
##rog	O
##lo	O
##bul	O
##in	O
,	O
and	O
le	B
##ci	I
##thin	I
ch	I
##ole	I
##ster	I
##ol	I
a	O
##cy	O
##lt	O
##ran	O
##s	O
##fer	O
##ase	O
.	O

_	O
,	O
Finally	O
,	O
ch	B
##olin	I
##e	I
was	O
relatively	O
depleted	O
in	O
trauma	O
patient	O
plasma	O
.	O

Inc	O
##reased	O
expression	O
of	O
the	O
proteins	O
containing	O
certain	O
forms	O
of	O
C	B
-	I
g	I
##ly	I
##cos	I
##yla	I
##ted	I
try	I
##pt	I
##op	I
##han	I
in	O
the	O
a	O
##ort	O
##ic	O
vessels	O
have	O
been	O
reported	O
in	O
the	O
di	O
##abe	O
##tic	O
rats	O
.	O

In	O
addition	O
,	O
re	B
##ser	I
##pine	I
was	O
also	O
spike	O
##d	O
in	O
samples	O
as	O
internal	O
standard	O
for	O
Q	O
##C	O
purpose	O
.	O

AC	O
acts	O
as	O
a	O
transport	O
##er	O
of	O
long	O
-	O
chain	O
fatty	O
acids	O
into	O
the	O
mit	O
##och	O
##ond	O
##ria	O
,	O
where	O
the	O
fatty	O
acids	O
are	O
o	O
##xi	O
##dized	O
to	O
produce	O
energy	O
,	O
i	O
.	O
e	O
.	O
ATP	S
.	O

O	O
##wing	O
,	O
however	O
,	O
to	O
the	O
low	O
abundance	O
of	O
naturally	O
occurred	O
4	B
-	I
OH	I
-	I
E	I
_	I
1	I
-	I
1	I
-	I
N	I
3	O
##A	O
##de	O
and	O
matrix	O
effect	O
in	O
tissue	O
samples	O
,	O
the	O
responses	O
are	O
in	O
the	O
lower	O
end	O
of	O
the	O
standard	O
curve	O
and	O
would	O
probably	O
account	O
for	O
the	O
low	O
precision	O
in	O
q	O
##uant	O
##ification	O
.	O

In	O
our	O
research	O
,	O
h	B
##y	I
##pot	I
##au	I
##rine	I
and	O
ta	B
##uri	I
##ne	I
obviously	O
decreased	O
after	O
dial	O
##ys	O
##is	O
.	O

Pro	B
##line	I
Q	O
##C	O
samples	O
prepared	O
in	O
pool	O
##ed	O
human	O
serum	O
which	O
were	O
exposed	O
for	O
three	O
cycles	O
of	O
freeze	O
(	O
at	O
−	O
##80	O
°C	O
)	O
and	O
th	O
##aw	O
(	O
room	O
temperature	O
)	O
were	O
compared	O
with	O
freshly	O
prepared	O
samples	O
at	O
the	O
same	O
concentrations	O
.	O

Both	O
meta	O
##bol	O
##ites	O
are	O
involved	O
in	O
pu	B
##rine	I
and	O
energy	O
metabolism	O
,	O
supporting	O
gender	O
differences	O
in	O
these	O
systems	O
.	O

The	O
ability	O
of	O
oral	O
broad	O
-	O
spectrum	O
anti	O
##biotics	O
to	O
temporarily	O
suppress	O
the	O
production	O
of	O
T	B
##MA	I
##O	I
is	O
a	O
direct	O
demonstration	O
that	O
in	O
##test	O
##inal	O
micro	O
##or	O
##gan	O
##isms	O
play	O
an	O
o	O
##b	O
##liga	O
##tory	O
role	O
in	O
the	O
production	O
of	O
T	B
##MA	I
##O	I
from	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
in	O
humans	O
.	O

Kaplan	O
-	O
Mei	O
##er	O
curve	O
analyses	O
demonstrated	O
that	O
patients	O
with	O
the	O
higher	O
levels	O
of	O
58	O
meta	O
##bol	O
##ites	O
including	O
c	B
##rea	I
##tin	I
##ine	I
and	O
u	B
##rea	I
,	O
and	O
the	O
lower	O
levels	O
of	O
4	O
meta	O
##bol	O
##ites	O
,	O
more	O
frequently	O
reached	O
the	O
composite	O
outcome	O
(	O
and	O
S	O
##4	O
)	O
.	O

We	O
h	O
##y	O
##pot	O
##hes	O
##ize	O
that	O
the	O
enhanced	O
production	O
of	O
x	B
##ant	I
##hine	I
resulting	O
in	O
elevated	O
H	O
_	O
2	O
O	O
_	O
2	O
results	O
in	O
greater	O
o	O
##xi	O
##da	O
##tive	O
stress	O
that	O
promotes	O
the	O
development	O
of	O
HC	O
##C	O
.	O

These	O
reports	O
suggested	O
several	O
potential	O
bio	O
##mark	O
##ers	O
of	O
pan	O
##cre	O
##atic	O
cancer	O
,	O
such	O
as	O
al	B
##ani	I
##ne	I
,	O
c	B
##rea	I
##tine	I
,	O
3	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
,	O
3	B
-	I
h	I
##ydro	I
##xy	I
##is	I
##ova	I
##ler	I
##ate	I
,	O
glucose	S
,	O
as	B
##par	I
##agi	I
##ne	I
and	O
pro	B
##line	I
(	O
,	O
)	O
.	O

According	O
to	O
the	O
breast	O
cancer	O
hypothesis	O
,	O
16	O
##α	O
-	O
h	O
##ydro	O
##xy	O
##lated	O
est	O
##rogen	O
##s	O
induce	O
##s	O
breast	O
car	O
##cin	O
##ogen	O
##esis	O
due	O
to	O
their	O
much	O
stronger	O
ho	O
##rmon	O
##al	O
and	O
mit	O
##ogenic	O
activity	O
as	O
compared	O
to	O
the	O
cat	B
##ech	I
##ol	I
est	O
##rogen	O
##s	O
.	O

Regarding	O
the	O
interfering	O
anal	O
##yte	O
(	O
s	O
)	O
,	O
its	O
concentration	O
was	O
low	O
compared	O
with	O
specific	O
24	B
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
in	O
CH	O
##S	O
,	O
the	O
sum	O
##med	O
value	O
utilized	O
in	O
primary	O
analyses	O
correlated	O
strongly	O
with	O
specific	O
24	B
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
(	O
r	O
=	O
0	O
.	O
99	O
in	O
CH	O
##S	O
)	O
,	O
and	O
sensitivity	O
analyses	O
in	O
the	O
CH	O
##S	O
verified	O
that	O
associations	O
of	O
e	O
##G	O
##F	O
##R	O
with	O
specific	O
24	B
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
were	O
similar	O
to	O
those	O
of	O
the	O
sum	O
##med	O
value	O
used	O
in	O
primary	O
analyses	O
.	O

The	O
meta	O
##bol	O
##ites	O
showing	O
significantly	O
increased	O
levels	O
during	O
sleep	O
de	O
##p	O
##ri	O
##vation	O
come	O
from	O
a	O
range	O
of	O
classes	O
(	O
25	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
,	O
9	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
,	O
4	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
,	O
2	O
bio	O
##genic	O
am	O
##ines	O
,	O
1	O
amino	S
acid	O
)	O
.	O

z	O
84	O
##0	O
.	O
4	O
)	O
and	O
f	O
PC	B
16	I
:	I
0	I
_	I
20	I
:	I
4	I
(	O
R	O
##T	O
:	O
14	O
.	O
3	O
min	O
,	O
m	O
/	O
z	O
84	O
##0	O
.	O
4	O
)	O
.	O

The	O
average	O
duration	S
for	O
oral	O
diet	O
was	O
similar	O
in	O
both	O
groups	O
.	O

β	B
-	I
act	I
##in	I
was	O
regarded	O
as	O
a	O
standard	O
reference	O
.	O

Ty	B
##ram	I
##ine	I
is	O
known	O
to	O
be	O
associated	O
with	O
increasing	O
age	O
and	O
acts	O
by	O
releasing	O
end	O
##ogen	O
##ous	O
nor	B
##ep	I
##ine	I
##ph	I
##rine	I
which	O
el	O
##eva	O
##tes	O
metabolism	O
and	O
is	O
indirectly	O
proportional	O
in	O
its	O
synthesis	O
with	O
age	O
_	O
,	O
.	O

AA	O
,	O
ant	B
##hra	I
##ny	I
##lic	I
acid	I
;	O
AM	O
##I	O
,	O
acute	O
my	O
##oc	O
##ard	O
##ial	O
in	O
##far	O
##ction	O
;	O
B	O
##12	O
,	O
vitamin	O
B	O
-	O
12	O
,	O
co	B
##bal	I
##ami	I
##n	I
;	O
Con	O
##d	O
.	O
1	O
,	O
previous	O
a	O
##ort	O
##oc	O
##oro	O
##nary	O
bypass	O
;	O
Con	O
##d	O
.	O
2	O
,	O
previous	O
co	O
##rona	O
##ry	O
intervention	O
;	O
Con	O
##d	O
.	O
3	O
,	O
previous	O
acute	O
my	O
##oc	O
##ard	O
##ial	O
in	O
##far	O
##ction	O
;	O
Con	O
##d	O
.	O
4	O
,	O
previous	O
other	O
illness	O
;	O
Con	O
##d	O
.	O
5	O
,	O
previous	O
co	O
##rona	O
##ry	O
an	O
##gio	O
##graphic	O
s	O
##ten	O
##osis	O
;	O
Con	O
##d	O
.	O
6	O
,	O
previous	O
stroke	O
,	O
trans	O
##ient	O
is	O
##che	O
##mic	O
attack	O
,	O
or	O
car	O
##ot	O
##id	O
-	O
operated	O
s	O
##ten	O
##osis	O
;	O
Con	O
##d	O
.	O
7	O
,	O
known	O
at	O
##her	O
##oth	O
##rom	O
##bot	O
##ic	O
card	O
##iovascular	O
disease	O
;	O
Con	O
##d	O
.	O
8	O
,	O
premature	O
card	O
##iovascular	O
disease	O
;	O
Con	O
##d	O
.	O
9	O
,	O
heart	O
failure	O
;	O
Con	O
##d	O
.	O
10	O
,	O
previous	O
per	O
##cut	O
##aneous	O
co	O
##rona	O
##ry	O
intervention	O
;	O
Con	O
##d	O
.	O

(	O
A	O
)	O
u	B
##ric	I
acid	I
(	O
AU	O
##RO	O
##C	O
=	O
0	O
.	O
74	O
)	O
,	O
(	O
B	O
)	O
ch	B
##oly	I
##l	I
##gly	I
##cine	I
(	O
AU	O
##RO	O
##C	O
=	O
0	O
.	O
83	O
)	O
,	O
(	O
C	O
)	O
3	B
-	I
h	I
##ydro	I
##xy	I
##cap	I
##ric	I
acid	I
(	O
AU	O
##RO	O
##C	O
=	O
0	O
.	O
73	O
)	O
,	O
(	O
D	O
)	O
D	O
-	O
le	O
##uc	O
##ic	O
acid	O
(	O
AU	O
##RO	O
##C	O
=	O
0	O
.	O
79	O
)	O
,	O
(	O
E	O
)	O
x	B
##ant	I
##hine	I
(	O
AU	O
##RO	O
##C	O
=	O
0	O
.	O
74	O
)	O
,	O
(	O
F	O
)	O
a	O
##rac	O
##hi	O
##don	O
##yl	O
l	O
##ys	O
##ole	O
##ci	O
##thin	O
(	O
AU	O
##RO	O
##C	O
=	O
0	O
.	O
88	O
)	O
,	O
(	O
G	O
)	O
di	B
##ole	I
##oy	I
##l	I
##ph	I
##os	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
(	O
AU	O
##RO	O
##C	O
=	O
0	O
.	O
84	O
)	O
.	O

Another	O
study	O
using	O
tumor	O
tissues	O
of	O
pan	O
##cre	O
##atic	O
duct	O
##al	O
ad	O
##eno	O
##car	O
##cin	O
##oma	O
patients	O
revealed	O
that	O
o	B
##le	I
##ic	I
acid	I
and	O
s	B
##te	I
##ari	I
##c	I
acid	I
were	O
significantly	O
higher	O
in	O
the	O
group	O
with	O
favorable	O
survival	O
than	O
in	O
that	O
with	O
low	O
survival	O
.	O

The	O
increased	O
level	O
of	O
amino	B
##but	I
##yric	I
acid	I
in	O
I	O
##BS	O
was	O
strongly	O
correlated	O
with	O
the	O
presence	O
of	O
F	O
.	O
p	O
##ra	O
##us	O
##nitz	O
##ii	O
,	O
which	O
was	O
the	O
most	O
significant	O
n	O
-	O
but	O
##yra	O
##te	O
-	O
producing	O
gut	O
bacterium	O
,	O
with	O
well	O
-	O
known	O
effects	O
on	O
host	O
energy	O
metabolism	O
and	O
m	O
##uc	O
##osa	O
##l	O
integrity	O
(	O
;	O
)	O
.	O

The	O
level	O
of	O
several	O
meta	O
##bol	O
##ites	O
in	O
HK	O
-	O
2	O
cells	O
are	O
specifically	O
increased	O
only	O
after	O
exposure	O
to	O
25	O
m	O
##M	O
glucose	S
,	O
but	O
not	O
5	O
m	O
##M	O
,	O
including	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
,	O
x	B
##yl	I
##ose	I
5	I
-	I
phosphate	I
,	O
in	B
##os	I
##ine	I
,	O
g	B
##uan	I
##ine	I
,	O
rib	B
##ose	I
5	I
-	I
phosphate	I
,	O
rib	B
##ose	I
1	I
-	I
phosphate	I
,	O
di	B
##hy	I
##dr	I
##ox	I
##ya	I
##ce	I
##tone	I
phosphate	I
,	O
rib	B
##ulos	I
##e	I
5	I
-	I
phosphate	I
,	O
f	B
##ru	I
##ct	I
##ose	I
1	I
,	I
6	I
-	I
dip	I
##hos	I
##phate	I
,	O
f	B
##ru	I
##ct	I
##ose	I
1	I
-	I
phosphate	I
,	O
S	B
-	I
ad	I
##eno	I
##sy	I
##lm	I
##eth	I
##ion	I
##ine	I
,	O
and	O
g	B
##ly	I
##cer	I
##ald	I
##eh	I
##yd	I
##e	I
3	I
-	I
phosphate	I
(	O
see	O
Su	O
##pp	O
##lement	O
##ary	O
Table	O
_	O
4	O
)	O
.	O

One	O
al	O
##iq	O
##uo	O
##t	O
was	O
kept	O
at	O
-	O
20	O
°C	O
as	O
backup	O
,	O
the	O
other	O
dried	O
-	O
down	O
sample	O
was	O
re	O
-	O
suspended	O
in	O
100	O
μ	O
##L	O
of	O
a	O
Me	O
##OH	O
/	O
to	O
##lue	O
##ne	O
(	O
9	O
:	O
1	O
,	O
v	O
/	O
v	O
)	O
mixture	O
containing	O
an	O
internal	O
standard	O
12	B
-	I
[	I
[	I
(	I
c	I
##y	I
##c	I
##lo	I
##he	I
##xy	I
##lam	I
##ino	I
)	I
carbon	I
##yl	I
]	I
amino	I
]	I
-	I
do	I
##de	I
##cano	I
##ic	I
acid	I
(	O
C	O
##U	O
##DA	O
)	O

40	O
μ	O
L	O
of	O
each	O
sample	O
was	O
added	O
to	O
160	O
μ	O
L	O
of	O
water	O
and	O
480	O
μ	O
L	O
of	O
extraction	O
liquid	O
(	O
V	O
_	O
M	O
##T	O
##BE	O
:	O
V	B
_	I
met	I
##han	I
##ol	I
=	O
5	O
:	O
1	O
,	O
containing	O
10	O
μ	O
L	O
of	O
160	O
μ	O
g	O
/	O
m	O
##L	O
PC	B
(	I
15	I
:	I
0	I
/	I
18	I
:	I
1	I
)	I
)	O
and	O
v	O
##ortex	O
##ed	O
vigorously	O
for	O
60	O
s	O
.	O

The	O
mean	O
levels	O
of	O
1	B
-	I
P	I
##E	I
-	I
Al	I
##b	I
,	O
2	B
-	I
P	I
##E	I
-	I
Al	I
##b	I
,	O
and	O
S	O
##G	O
-	O
Al	O
##b	O
were	O
0	O
.	O
29	O
,	O
1	O
.	O
68	O
,	O
and	O
1	O
.	O
8	O
(	O

From	O
our	O
non	O
-	O
targeted	O
L	O
##C	O
-	O
MS	O
meta	O
##bol	O
##omi	O
##c	O
study	O
,	O
we	O
identified	O
by	O
exact	O
mass	O
and	O
MS	O
/	O
MS	O
nine	O
meta	O
##bol	O
##ites	O
whose	O
distribution	O
was	O
significantly	O
different	O
between	O
the	O
clusters	O
:	O
ad	B
##eni	I
##ne	I
,	O
a	B
##rg	I
##ini	I
##ne	I
-	I
as	I
##par	I
##tate	I
,	O
f	B
##olic	I
acid	I
,	O
g	B
##uan	I
##os	I
##ine	I
,	O
met	B
##hyl	I
##ade	I
##nos	I
##ine	I
,	O
met	B
##hyl	I
##gua	I
##nine	I
,	O
p	B
##hen	I
##yla	I
##ce	I
##ty	I
##l	I
##gly	I
##cine	I
,	O
th	B
##iam	I
##ine	I
p	I
##yr	I
##op	I
##hos	I
##phate	I
and	O
u	B
##rid	I
##ine	I
(	O
Table	O
)	O
.	O

In	O
our	O
pilot	O
study	O
,	O
met	B
##hyl	I
-	I
and	O
et	B
##hyl	I
-	I
ch	I
##lor	I
##of	I
##orm	I
##ate	I
both	O
yielded	O
satisfactory	O
der	O
##iva	O
##ti	O
##zation	O
efficiency	O
in	O
standard	O
mixture	O
##s	O
and	O
biological	O
samples	O
.	O

Incident	O
type	O
2	O
diabetes	O
was	O
as	O
##cer	O
##tain	O
##ed	O
during	O
the	O
follow	O
-	O
up	O
at	O
every	O
q	O
##uad	O
##ren	O
##nial	O
examination	O
and	O
was	O
defined	O
as	O
follows	O
:	O
fast	O
##ing	O
glucose	S
≥	O
7	O
mm	O
##ol	O
/	O

We	O
previously	O
examined	O
the	O
effect	O
of	O
the	O
post	O
##pra	O
##ndi	O
##al	O
state	O
compared	O
with	O
the	O
pre	O
##pra	O
##ndi	O
##al	O
state	O
on	O
plasma	O
one	O
-	O
carbon	O
and	O
related	O
meta	O
##bol	O
##ite	O
and	O
try	B
##pt	I
##op	I
##han	I
meta	O
##bol	O
##ites	O
and	O
reported	O
very	O
modest	O
differences	O
.	O

S	O
##pi	O
##king	O
experiments	O
with	O
standard	O
g	B
##lut	I
##amine	I
followed	O
by	O
protein	O
precipitation	O
showed	O
that	O
virtually	O
all	O
the	O
added	O
g	B
##lut	I
##amine	I
was	O
converted	O
to	O
p	B
##yr	I
##og	I
##lut	I
##ami	I
##c	I
acid	I
(	O
see	O
)	O
,	O
whereas	O
no	O
such	O
conversion	O
was	O
detected	O
for	O
ultra	O
##fi	O
##lter	O
##ed	O
serum	O
.	O

Furthermore	O
,	O
accumulation	O
of	O
ch	B
##ole	I
##ster	I
##yl	I
su	I
##lf	I
##ate	I
was	O
seen	O
in	O
human	O
br	O
##on	O
##chia	O
##l	O
e	O
##pit	O
##hel	O
##ial	O
cells	O
undergoing	O
sq	O
##ua	O
##mous	O
meta	O
##p	O
##lasia	O
and	O
this	O
observation	O
suggests	O
that	O
this	O
meta	O
##bol	O
##ite	O
may	O
arise	O
from	O
the	O
on	O
##co	O
##genic	O
transformation	O
of	O
normal	O
tissue	O
.	O

Ace	B
##tate	I
had	O
a	O
lower	O
level	O
in	O
female	O
B	O
##D	O
subjects	O
but	O
a	O
higher	O
level	O
in	O
male	O
B	O
##D	O
subjects	O
.	O

After	O
the	O
extract	O
##s	O
were	O
completely	O
dried	O
by	O
speed	O
vacuum	O
con	O
##cent	O
##rator	O
or	O
by	O
freeze	O
-	O
drying	O
,	O
20	O
µ	O
##L	O
of	O
40	O
mg	O
/	O
m	O
##L	O
met	B
##ho	I
##xy	I
##lam	I
##ine	I
h	I
##ydro	I
##ch	I
##lor	I
##ide	I
in	O
p	B
##yr	I
##id	I
##ine	I
was	O
added	O
,	O
and	O
samples	O
were	O
agitated	O
at	O
30	O
°C	O
for	O
30	O
min	O
.	O

The	O
R	B
##P	I
(	O
E	O
##SI	O
+	O
)	O
data	O
generated	O
the	O
most	O
significant	O
UP	O
##LC	O
-	O
MS	O
model	O
(	O
C	O
##V	O
-	O
AN	O
##O	O
##VA	O
p	O
=	O
1	O
.	O
2	O
×	O
10	O
_	O
−	O
##18	O
)	O
.	O

Der	O
##iva	O
##tives	O
with	O
the	O
h	B
##ydro	I
##xy	I
group	O
in	O
the	O
para	O
position	O
were	O
less	O
fragile	O
than	O
the	O
others	O
,	O
and	O
further	O
study	O
of	O
their	O
behavior	O
in	O
the	O
co	O
##lon	O
is	O
needed	O
.	O

El	O
##eva	O
##ted	O
ta	B
##uri	I
##ne	I
levels	O
in	O
tumors	O
are	O
associated	O
with	O
increased	O
pro	O
##life	O
##rative	O
activity	O
and	O
cell	O
density	O
.	O

These	O
parameters	O
included	O
blood	O
pressure	O
,	O
measured	O
twice	O
in	O
su	B
##pine	I
position	O
,	O
artery	O
elastic	O
##ity	O
by	O
pulse	O
wave	O
analysis	O
,	O
and	O
glucose	S
and	O
insulin	O
levels	O
as	O
determined	O
during	O
an	O
oral	O
glucose	S
tolerance	O
test	O
(	O
O	O
##G	O
##TT	O
)	O
.	O

Published	O
data	O
from	O
large	O
e	O
##pid	O
##em	O
##iol	O
##ogical	O
studies	O
revealed	O
that	O
T	B
##MA	I
##O	I
in	O
plasma	O
may	O
flu	O
##ct	O
##uate	O
in	O
a	O
very	O
wide	O
range	O
of	O
concentrations	O
(	O
0	O
.	O
08	O
–	O
250	O
µ	O
##mo	O
##l	O
/	O
L	O
)	O
and	O
that	O
it	O
is	O
affected	O
by	O
several	O
factors	O
,	O
including	O
diet	O
##ary	O
intake	O
of	O
ch	B
##olin	I
##e	I
and	O
car	O
##ni	O
##tine	O
-	O
containing	O
food	O
,	O
the	O
composition	O
of	O
micro	O
##bio	O
##ta	O
,	O
and	O
the	O
activity	O
of	O
FM	O
##O	O
##3	O
.	O

G	O
##lut	O
##ami	O
##nas	O
##e	O
plays	O
a	O
critical	O
role	O
in	O
regulating	O
the	O
level	O
of	O
g	B
##lut	I
##ama	I
##te	I
in	O
humans	O
by	O
converting	O
g	B
##lut	I
##amine	I
to	O
g	B
##lut	I
##ama	I
##te	I
in	O
cells	O
.	O

-	O
9	O
,	O
c	O
##is	O
)	O
in	O
(	O
a	O
)	O
negative	O
and	O
(	O
b	O
)	O
positive	O
ion	O
mode	O
and	O
P	B
##E	I
18	I
:	I
1	I
(	I
n	I

O	B
##xy	I
##ster	I
##ols	I
are	O
more	O
soluble	O
than	O
ch	B
##ole	I
##ster	I
##ol	I
and	O
are	O
reported	O
to	O
ex	O
##ert	O
inflammatory	O
,	O
c	O
##yt	O
##op	O
##rote	O
##ctive	O
and	O
a	O
##pop	O
##to	O
##tic	O
effects	O
according	O
to	O
concentration	O
and	O
species	O
.	O

In	O
S	O
##UM	O
##14	O
##9	O
##P	O
##T	O
,	O
comb	O
##inator	O
##ial	O
treatment	O
was	O
highly	O
effective	O
in	O
decreasing	O
levels	O
of	O
p	O
-	O
E	O
##rk	O
and	O
p	B
-	I
G	I
##S	I
##K	I
##3	I
##β	I
when	O
compared	O
to	O
that	O
of	O
just	O
C	O
##75	O
or	O
c	B
##ele	I
##co	I
##xi	I
##b	I
alone	O
.	O

The	O
DC	O
##IS	O
accompanying	O
invasive	O
car	O
##cin	O
##oma	O
group	O
showed	O
higher	O
levels	O
of	O
PC	O
and	O
c	B
##rea	I
##tine	I
and	O
lower	O
levels	O
of	O
lip	O
##id	O
than	O
the	O
pure	O
DC	O
##IS	O
group	O
.	O

U	O
##rine	O
c	B
##rea	I
##tin	I
##ine	I
(	O
u	O
-	O
C	O
##r	O
)	O
and	O
c	B
##ys	I
##tat	I
##in	I
C	O
(	O
u	O
-	O
Cy	O
##s	O
##C	O
)	O
in	O
the	O
urine	O
samples	O
of	O
T	O
##S	O
##G	O
,	O
AS	O
##G	O
,	O
and	O
N	O
##S	O
##G	O
were	O
analyzed	O
by	O
a	O
contract	O
research	O
organization	O
(	O
I	O
##ka	O
##ga	O
##ku	O
Co	O
.	O
,	O
L	O
##T	O
##D	O
,	O
Kyoto	O
,	O
Japan	O
)	O
,	O
except	O
for	O
three	O
of	O
T	O
##S	O
##G	O
and	O
one	O
of	O
AS	O
##G	O
because	O
the	O
sample	O
volume	O
was	O
too	O
small	O
.	O

All	O
individuals	O
in	O
our	O
study	O
had	O
assessments	O
of	O
B	O
##MI	O
,	O
waist	O
c	O
##ir	O
##cum	O
##ference	O
,	O
and	O
fast	O
##ing	O
glucose	S
and	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
,	O
allowing	O
us	O
to	O
adjust	O
for	O
overall	O
ad	O
##ip	O
##os	O
##ity	O
,	O
glucose	S
into	O
##ler	O
##ance	O
,	O
and	O
d	O
##ys	O
##lip	O
##ide	O
##mia	O
.	O

Furthermore	O
,	O
card	O
##iovascular	O
risk	O
factors	O
captured	O
by	O
the	O
CH	O
##AD	O
##S	O
_	O
2	O
and	O
CH	O
##A	O
_	O
2	O
DS	O
_	O
2	O
-	O
VA	O
##S	O
##c	O
scores	O
highlight	O
com	O
##or	O
##bid	O
risk	O
factors	O
that	O
further	O
au	O
##gment	O
stroke	O
risk	O
in	O
patients	O
with	O
underlying	O
A	B
##F	I
.	O

Ser	B
##ine	I
(	O
C	O
and	O
D	O
)	O
,	O
ta	B
##uri	I
##ne	I
(	O
E	O
and	O
F	O
)	O
,	O
car	B
##ni	I
##tine	I
(	O
G	O
and	O
H	O
)	O
and	O
3	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
(	O
I	O
and	O
J	O
)	O
concentrations	O
followed	O
the	O
same	O
trends	O
.	O

7	B
-	I
De	I
##hy	I
##dr	I
##o	I
-	I
des	I
##most	I
##ero	I
##l	I
belongs	O
to	O
s	O
##tero	O
##ls	O
,	O
which	O
are	O
en	O
##rich	O
##ed	O
in	O
s	O
##tero	O
##id	O
bio	O
##sy	O
##nt	O
##hesis	O
pathways	O
and	O
metabolic	O
pathways	O
.	O

A	O
mixture	O
of	O
compound	O
2	O
(	O
1	O
mm	O
##ol	O
)	O
,	O
substituted	O
p	O
##hen	O
##yl	O
/	O
ben	O
##zy	O
##l	O
am	O
##ines	O
(	O
1	O
mm	O
##ol	O
)	O
,	O
and	O
potassium	B
carbon	I
##ate	I
(	O
1	O
mm	O
##ol	O
)	O
in	O
is	B
##op	I
##rop	I
##ano	I
##l	I
(	O
10	O
m	O
##L	O
)	O
was	O
re	O
##f	O
##lux	O
##ed	O
for	O
15	O
hours	O
as	O
depicted	O
in	O
.	O

We	O
applied	O
a	O
mass	O
s	O
##pect	O
##rome	O
##try	O
-	O
based	O
quantitative	O
meta	O
##bol	O
##omi	O
##c	O
pro	O
##fi	O
##ling	O
in	O
order	O
to	O
un	O
##am	O
##bi	O
##guous	O
##ly	O
identify	O
and	O
q	O
##uant	O
##ify	O
lip	O
##ids	O
,	O
amino	B
##ac	I
##ids	I
,	O
bio	O
##genic	O
am	O
##ines	O
and	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
in	O
the	O
plasma	O
of	O
the	O
study	O
subjects	O
.	O

At	O
this	O
point	O
we	O
have	O
identified	O
3	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##ose	I
##rine	I
##s	I
,	O
1	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##och	I
##olin	I
##e	I
and	O
1	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oi	I
##nos	I
##ito	I
##l	I
,	O
all	O
in	O
significantly	O
lower	O
levels	O
in	O
HC	O
##C	O
patients	O
.	O

Label	O
##ed	O
amino	O
acid	O
internal	O
standards	O
(	O
catalog	O
number	O
:	O
N	O
##S	O
##K	O
‐	O
A	O
)	O
containing	O
12	O
stable	O
is	O
##oto	O
##pe	O
‐	O
labeled	O
amino	O
acids	O
and	O
labeled	O
eight	O
car	B
##ni	I
##tine	I
internal	O
standards	O
(	O
catalog	O
number	O
:	O
N	O
##S	O
##K	O
‐	O
B	O
)	O
for	O
absolute	O
q	O
##uant	O
##ification	O
were	O
obtained	O
from	O
Cambridge	O
Is	O
##oto	O
##pe	O
Laboratories	O
(	O
And	O
##over	O
,	O
MA	O
)	O
.	O

(	O
2018	O
##a	O
)	O
also	O
reported	O
the	O
strong	O
(	O
MI	O
##C	O
0	O
.	O
11	O
–	O
0	O
.	O
24	O
μ	O
##M	O
)	O
anti	O
##fu	O
##nga	O
##l	O
activity	O
of	O
f	O
##usa	O
##rip	O
##eptide	O
A	O
(	O
48	O
)	O
,	O
a	O
new	O
c	O
##y	O
##c	O
##lo	O
##de	O
##ps	O
##ip	O
##eptide	O
isolated	O
from	O
Fu	O
##sar	O
##ium	O
s	B
##p	I
.	O

Nan	O
##op	O
##art	O
##icles	O
generated	O
from	O
dust	O
storms	O
or	O
gun	O
powder	O
##s	O
may	O
deposit	O
in	O
the	O
lungs	O
and	O
direct	O
activated	S
al	O
##ve	O
##olar	O
mac	O
##rop	O
##hage	O
##s	O
toward	O
the	O
pulmonary	O
inter	O
##st	O
##iti	O
##um	O
causing	O
a	O
more	O
severe	O
immune	O
response	O
than	O
larger	O
particles	O
.	O

In	O
particular	O
,	O
ace	B
##ty	I
##l	I
##car	I
##ni	I
##tine	I
(	O
14	O
)	O
had	O
a	O
very	O
high	O
abundance	O
in	O
cancer	O
tissue	O
,	O
while	O
the	O
abundance	O
in	O
normal	O
re	O
##nal	O
tissue	O
was	O
two	O
orders	O
of	O
magnitude	O
lower	O
.	O

End	O
##ogen	O
##ous	O
amino	O
acids	O
include	O
all	O
amino	O
acids	O
except	O
for	O
or	B
##ni	I
##thin	I
##e	I
;	O
g	O
##lu	O
##con	O
##eo	O
##genic	O
amino	O
acids	O
include	O
al	B
##ani	I
##ne	I
,	O
v	B
##ali	I
##ne	I
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
pro	B
##line	I
,	O
g	B
##ly	I
##cine	I
,	O
se	B
##rine	I
,	O
th	B
##re	I
##oni	I
##ne	I
,	O
as	B
##par	I
##tate	I
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
l	B
##ys	I
##ine	I
and	O
t	B
##yr	I
##os	I
##ine	I
;	O
branched	O
-	O
chain	O
amino	O
acids	O

We	O
aimed	O
to	O
compare	O
C	O
##YP	O
##2	O
##A	O
##6	O
genetic	O
variation	O
and	O
C	O
##YP	O
##2	O
##A	O
##6	O
enzyme	O
activity	O
(	O
representative	O
of	O
the	O
rate	O
of	O
ni	B
##cot	I
##ine	I
metabolism	O
)	O
between	O
the	O
two	O
tribal	O
populations	O
,	O
as	O
these	O
have	O
previously	O
been	O
associated	O
with	O
differences	O
in	O
smoking	O
,	O
quit	O
##ting	O
,	O
and	O
lung	O
cancer	O
risk	O
.	O

For	O
the	O
am	O
##nio	O
##tic	O
fluid	O
analysis	O
,	O
200	O
μ	O
##L	O
of	O
0	O
.	O
5	O
M	O
sodium	B
phosphate	I
buffer	O
(	O
pH	O
=	O
7	O
containing	O
33	O
.	O
3	O
%	O
of	O
D	O
_	O
2	O
O	O
,	O
0	O
.	O
5	O
m	O
##M	O
3	B
-	I
(	I
trim	I
##eth	I
##yl	I
##si	I
##ly	I
##l	I
)	I
-	I
2	I
,	I
2	I
’	I
,	I
3	I
,	I
3	I
’	I
-	I
te	I
##tra	I
##de	I
##uter	I
##op	I
##rop	I
##ion	I
##ate	I
sodium	I
salt	O
T	O
##SP	O
-	O
d	O
##4	O
(	O
T	O
##SP	O
)	O
as	O
an	O
internal	O
standard	O
and	O
3	O
m	O
##M	O
sodium	O
a	O
##zi	O
##de	O
to	O
prevent	O
micro	O
##bial	O
contamination	O
)	O
was	O
added	O
to	O
400	O
μ	O
##L	O
of	O
A	B
##F	I
.	O

The	O
influence	O
of	O
the	O
dans	B
##yl	I
chloride	I
concentration	O
was	O
also	O
investigated	O
.	O

Thus	O
,	O
the	O
met	B
##ho	I
##xy	I
##est	I
##rone	I
meta	O
##bol	O
##ites	O
2	O
-	O
Me	O
##OE	O
_	O
1	O
and	O
4	O
-	O
Me	O
##OE	O
_	O
1	O
were	O
measured	O
by	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
as	O
indicators	O
of	O
the	O
level	O
of	O
est	O
##rogen	O
2	O
-	O
h	O
##ydro	O
##xy	O
##lation	O
and	O
the	O
4	O
-	O
h	O
##ydro	O
##xy	O
##lation	O
pathways	O
as	O
previously	O
described	O
with	O
modifications	O
.	O
_	O
,	O
Met	O
##ab	O
##oli	O
##te	O
standards	O
were	O
obtained	O
from	O
St	O
##eral	O
##oids	O
Inc	O
.	O
(	O
Newport	O
,	O
R	O
##I	O
)	O
.	O

C	B
##ada	I
##ver	I
##ine	I
,	O
N	B
-	I
ace	I
##ty	I
##l	I
##put	I
##res	I
##cine	I
,	O
N	B
-	I
ace	I
##ty	I
##ls	I
##per	I
##mine	I
(	O
N	O
##1	O
-	O
A	O
##c	O
##SP	O
##M	O
)	O
,	O
l	B
##ys	I
##ine	I
,	O
or	B
##ni	I
##thin	I
##e	I
,	O
a	B
##rg	I
##ini	I
##ne	I
,	O
γ	B
-	I
amino	I
##but	I
##yric	I
acid	I
,	O
and	O
1	B
,	I
3	I
-	I
di	I
##ami	I
##no	I
##p	I
##rop	I
##ane	I
were	O
purchased	O
from	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
.	O

Analysis	O
of	O
metals	O
in	O
plasma	O
was	O
preceded	O
by	O
microwave	O
dig	O
##est	O
##ion	O
with	O
concentrated	O
ni	B
##tric	I
acid	I
to	O
destroy	O
organic	O
matter	O
and	O
mineral	O
##ize	O
the	O
sample	O
.	O

H	O
##NS	O
##CC	O
cells	O
were	O
maintained	O
in	O
Du	O
##l	O
##be	O
##cco	O
’	O
s	O
modified	O
Eagle	O
’	O
s	O
medium	O
containing	O
10	O
%	O
f	O
##etal	O
b	O
##ov	O
##ine	O
serum	O
,	O
1	O
%	O
pen	B
##ici	I
##llin	I
,	O
and	O
1	O
%	O
s	B
##tre	I
##pt	I
##omy	I
##cin	I
.	O

Furthermore	O
,	O
our	O
meta	O
##bol	O
##omi	O
##cs	O
analysis	O
demonstrates	O
that	O
patients	O
having	O
a	O
diabetes	O
re	O
##mission	O
after	O
one	O
year	O
showed	O
larger	O
decline	O
##s	O
in	O
amino	O
acids	O
levels	O
of	O
al	B
##ani	I
##ne	I
,	O
pro	B
##line	I
and	O
le	B
##uc	I
##ine	I
as	O
well	O
as	O
in	O
the	O
g	B
##ly	I
##cine	I
meta	O
##bol	O
##ite	O
sa	B
##rc	I
##os	I
##ine	I
and	O
the	O
g	B
##lut	I
##ami	I
##nic	I
acid	I
der	O
##ivate	O
p	B
##yr	I
##og	I
##lut	I
##ami	I
##c	I
acid	I
.	O

B	O
##uc	O
##olo	O
et	O
al	O
.	O
also	O
reported	O
that	O
topic	O
##al	O
in	B
##dom	I
##eth	I
##ac	I
##in	I
,	O
br	O
##om	O
##fen	O
##ac	O
and	O
ne	O
##pa	O
##fen	O
##ac	O
significantly	O
reduced	O
re	B
##tina	I
##l	I
P	O
##GE	O
_	O
2	O
levels	O
with	O
higher	O
effect	O
of	O
in	B
##dom	I
##eth	I
##ac	I
##in	I
and	O
br	O
##om	O
##fen	O
##ac	O
in	O
comparison	O
with	O
ne	O
##pa	O
##fen	O
##ac	O
,	O
however	O
,	O
only	O
in	B
##dom	I
##eth	I
##ac	I
##in	I
was	O
able	O
to	O
prevent	O
re	B
##tina	I
##l	I
vascular	O
leak	O
##age	O
in	O
lip	O
##op	O
##oly	O
##sa	O
##cc	O
##hari	O
##de	O
-	O
injected	O
rats	O
.	O

Di	O
##fference	O
##s	O
in	O
k	B
##yn	I
##uren	I
##ine	I
pathway	O
meta	O
##bol	O
##ites	O
between	O
the	O
B	O
##D	O
subjects	O
(	O
combined	O
me	O
##dicated	O
and	O
un	O
##med	O
##ica	O
##ted	O
samples	O
)	O
and	O
the	O
healthy	O
controls	O
were	O
evaluated	O
with	O
AN	O
##O	O
##VA	O
.	O

Each	O
sample	O
was	O
added	O
with	O
the	O
internal	O
standards	O
,	O
PC	B
(	I
17	I
:	I
0	I
/	I
0	I
:	I
0	I
)	I
,	O
PC	B
(	I
17	I
:	I
0	I
/	I
17	I
:	I
0	I
)	I
,	O
P	B
##E	I
(	I
17	I
:	I
0	I
/	I
17	I
:	I
0	I
)	I
,	O
P	B
##G	I
(	I
17	I
:	I
0	I
/	I
17	I
:	I
0	I
)	I
,	O
Ce	B
##r	I
(	I
d	I
##18	I
:	I
1	I
/	I
17	I
:	I
0	I
)	I
,	O
PS	B
(	I
17	I
:	I
0	I
/	I
17	I
:	I
0	I
)	I
,	O
PA	B
(	I
17	I
:	I
0	I
/	I
17	I
:	I
0	I
)	I
,	O
race	O
##mic	O
MG	B
(	I
17	I
:	I
0	I
/	I
0	I
:	I
0	I
/	I
0	I
:	I
0	I
)	I
,	O
race	O
##mic	O
D	B
##G	I
(	I
17	I
:	I
0	I
/	I
17	I
:	I
0	I
/	I
0	I
:	I
0	I
)	I
and	O
T	B
##G	I
(	I
17	I
:	I
0	I
/	I
17	I
:	I
0	I
/	I
17	I
:	I
0	I
)	I
.	O

Studies	O
have	O
shown	O
that	O
reduction	O
of	O
circulating	O
levels	O
of	O
ω	B
-	I
3	I
P	I
##U	I
##FA	I
##s	I
is	O
observed	O
in	O
c	O
##ir	O
##r	O
##hot	O
##ic	O
patients	O
(	O
;	O
;	O
)	O
.	O

The	O
compliance	O
to	O
vitamin	B
B	I
##6	I
supplement	O
##ation	O
may	O
also	O
be	O
a	O
factor	O
m	O
##od	O
##ulating	O
the	O
levels	O
of	O
x	B
##ant	I
##hur	I
##eni	I
##c	I
acid	I
.	O

Second	O
,	O
we	O
identified	O
meta	O
##bol	O
##ites	O
that	O
might	O
be	O
lost	O
in	O
F	O
##PP	O
##E	O
due	O
to	O
their	O
reaction	O
with	O
formal	B
##de	I
##hy	I
##de	I
when	O
tissues	O
are	O
im	O
##mers	O
##ed	O
in	O
a	O
formal	B
##in	I
solution	O
.	O

Our	O
results	O
demonstrate	O
that	O
measuring	O
changes	O
in	O
meta	O
##bol	O
##ite	O
patterns	O
is	O
a	O
feasible	O
method	O
for	O
evaluating	O
the	O
clinical	O
characteristics	O
of	O
A	B
##F	I
.	O

Internal	O
standard	O
,	O
a	O
mixture	O
of	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
,	O
su	B
##lf	I
##adi	I
##met	I
##ho	I
##xin	I
##e	I
,	O
te	B
##rf	I
##ena	I
##dine	I
,	O
and	O
re	B
##ser	I
##pine	I
(	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
,	O
Oak	O
##ville	O
,	O
ON	O
,	O
Canada	O
)	O
,	O
was	O
then	O
added	O
to	O
the	O
serum	O
mixture	O
.	O

The	O
HC	O
##T	O
##11	O
##6	O
cell	O
line	O
was	O
maintained	O
in	O
D	O
##ME	O
##M	O
(	O
Du	O
##l	O
##be	O
##cco	O
’	O
s	O
Mo	O
##dified	O
Eagle	O
Medium	O
,	O
The	O
##rm	O
##o	O
Fischer	O
Scientific	O
,	O
Walt	O
##ham	O
,	O
MA	O
,	O
USA	O
)	O
supplemented	O
with	O
10	O
%	O
or	O
20	O
%	O
FC	O
##S	O
(	O
The	O
##rm	O
##o	O
Fischer	O
Scientific	O
,	O
Walt	O
##ham	O
,	O
MA	O
,	O
USA	O
)	O
,	O
1	O
%	O
pen	O
##ici	O
##llin	O
/	O
s	O
##tre	O
##pt	O
##omy	O
##cin	O
(	O
The	O
##rm	O
##o	O
Fischer	O
Scientific	O
,	O
Walt	O
##ham	O
,	O
MA	O
,	O
USA	O
)	O
,	O
2	O
m	O
##M	O
g	B
##lut	I
##amine	I
(	O
The	O
##rm	O
##o	O
Fischer	O
Scientific	O
,	O
Walt	O
##ham	O
,	O
MA	O
,	O
USA	O
)	O
and	O
1	O
g	O
/	O
L	O
glucose	S
(	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
,	O
St	O
.	O
Louis	O
,	O
M	O
##O	O
,	O
USA	O
)	O
.	O

Some	O
of	O
the	O
meta	O
##bol	O
##ites	O
were	O
in	O
agreement	O
with	O
previously	O
published	O
data	O
that	O
compared	O
RA	O
patients	O
and	O
control	O
subjects	O
,	O
such	O
as	O
decreased	O
levels	O
of	O
his	B
##ti	I
##dine	I
,	O
met	B
##hi	I
##oni	I
##ne	I
,	O
and	O
se	B
##rine	I
,	O
and	O
increased	O
levels	O
of	O
g	B
##ly	I
##cer	I
##ic	I
acid	I
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
and	O
t	B
##yr	I
##os	I
##ine	I
in	O
RA	O
patients	O
[	O
,	O
,	O
–	O
]	O
.	O

The	O
levels	O
of	O
the	O
ch	B
##olin	I
##e	I
meta	O
##bol	O
##ites	O
in	O
milk	O
are	O
of	O
interest	O
as	O
it	O
has	O
been	O
shown	O
that	O
the	O
absorption	O
and	O
bio	O
##ava	O
##ila	O
##bility	O
can	O
differ	O
across	O
the	O
various	O
meta	O
##bol	O
##ites	O
.	O

High	O
absolute	O
concentrations	O
of	O
AD	B
##P	I
and	O
GDP	O
among	O
other	O
pu	O
##rine	O
n	O
##uc	O
##leo	O
##side	O
phosphate	O
##s	O
are	O
unique	O
to	O
pro	O
##state	O
tissues	O
,	O
and	O
ATP	S
and	O
AM	B
##P	I
levels	O
were	O
relatively	O
higher	O
in	O
poorly	O
differentiated	O
tumors	O
(	O
P	O
##2	O
–	O
4	O
;	O
black	O
in	O
Fi	O
##g	O
.	O

P	B
##uri	I
##ne	I
metabolism	O
is	O
associated	O
with	O
numerous	O
bio	O
##chemical	O
functions	O
,	O
including	O
cell	O
cycle	O
regulation	O
,	O
immune	O
function	O
,	O
and	O
signal	O
trans	O
##duction	O
_	O
,	O
.	O

who	O
used	O
Pa	O
##ret	O
##o	O
-	O
scaled	O
data	O
without	O
log	O
transformation	O
and	O
showed	O
that	O
c	B
##rea	I
##tin	I
##ine	I
concentrations	O
differed	O
significantly	O
between	O
night	O
and	O
morning	O
samples	O
.	O

Mayer	O
##son	O
et	O
al	O
.	O
demonstrated	O
that	O
r	B
##os	I
##ig	I
##lit	I
##az	I
##one	I
treatment	O
did	O
not	O
decrease	O
in	O
##tra	O
##my	O
##oc	O
##ell	O
##ular	O
fat	O
content	O
in	O
patients	O
with	O
type	O
2	O
diabetes	O
despite	O
an	O
improvement	O
in	O
insulin	O
sensitivity	O
.	O

Aden	B
##os	I
##ine	I
and	O
format	B
##e	I
were	O
not	O
detected	O
after	O
Me	O
##OH	O
:	O
CH	O
##C	O
##l	O
_	O
3	O
pp	O
##t	O
.	O

Another	O
example	O
of	O
a	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
with	O
an	O
essential	O
role	O
in	O
the	O
biology	O
of	O
T	O
.	O
c	O
##ru	O
##zi	O
is	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
.	O

The	O
results	O
here	O
##in	O
demonstrate	O
the	O
importance	O
of	O
implementing	O
valid	O
##ated	O
analytical	O
methods	O
to	O
monitor	O
im	B
##ati	I
##ni	I
##b	I
levels	O
in	O
the	O
blood	O
to	O
better	O
individual	O
##ize	O
treatment	O
,	O
particularly	O
for	O
individuals	O
who	O
have	O
adverse	O
or	O
ex	O
##ace	O
##rb	O
##ated	O
side	O
effects	O
or	O
that	O
present	O
with	O
abnormal	O
M	O
##MR	O
and	O
CC	O
##R	O
.	O

A	O
standard	O
_	O
1	O
H	O
spectrum	O
with	O
water	O
suppression	O
(	O
using	O
a	O
bin	O
##omi	O
##al	O
3	B
-	I
9	I
-	I
19	I
pulse	I
)	O
and	O
1	O
.	O
5	O
Hz	O
/	O
point	O
resolution	O
was	O
acquired	O
within	O
100	O
seconds	O
(	O
using	O
32	O
trans	O
##ients	O
and	O
a	O
total	O
inter	O
##sca	O
##n	O
recovery	O
delay	O
of	O
2	O
.	O
2	O
s	O
)	O
.	O

In	O
contrast	O
,	O
T	B
##MA	I
##O	I
did	O
not	O
co	O
##rrel	O
##ate	O
with	O
any	O
met	B
##hyl	I
##ated	I
a	I
##rg	I
##ini	I
##ne	I
meta	O
##bol	O
##ites	O
,	O
and	O
only	O
modest	O
##ly	O
with	O
GA	O
##BR	O
.	O

For	O
high	O
sample	O
volume	O
projects	O
,	O
Me	B
##OH	I
:	O
CH	O
##C	O
##l	O
_	O
3	O
precipitation	O
offers	O
better	O
mac	O
##rom	O
##ole	O
##cule	O
removal	O
than	O
Me	B
##OH	I
:	O

However	O
,	O
in	O
cancer	O
tissue	O
,	O
3	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
levels	O
may	O
also	O
be	O
elevated	O
because	O
of	O
the	O
“	O
reverse	O
War	O
##burg	O
effect	O
”	O
whereby	O
energy	O
-	O
rich	O
molecules	O
are	O
taken	O
up	O
by	O
cancer	O
cells	O
perhaps	O
from	O
neighboring	O
cells	O
,	O
are	O
converted	O
to	O
ace	O
##ty	O
##l	O
Co	O
##A	O
,	O
and	O
enter	O
the	O
T	O
##CA	O
cycle	O
,	O
ultimately	O
generating	O
ATP	S
via	O
o	O
##xi	O
##da	O
##tive	O
p	O
##hos	O
##ph	O
##ory	O
##lation	O
.	O

Following	O
cent	O
##ri	O
##fu	O
##gation	O
,	O
the	O
super	O
##nat	O
##ant	O
was	O
transferred	O
to	O
a	O
15	O
-	O
m	O
##L	O
p	B
##oly	I
##p	I
##rop	I
##yle	I
##ne	I
f	O
##al	O
##con	O
tube	O
and	O
divided	O
in	O
0	O
.	O
5	O
-	O
m	O
##L	O
al	O
##iq	O
##uo	O
##ts	O
,	O
placed	O
on	O
dry	O
ice	O
within	O
30	O
min	O
of	O
sampling	O
and	O
transferred	O
to	O
−	O
##80	O
°C	O
for	O
storage	O
within	O
60	O
min	O
of	O
sampling	O
.	O

It	O
is	O
also	O
involved	O
in	O
signalling	O
and	O
a	O
list	O
of	O
metabolic	O
pathways	O
such	O
as	O
am	O
##monia	O
recycling	O
,	O
a	B
##rg	I
##ini	I
##ne	I
,	O
pro	B
##line	I
,	O
c	B
##ys	I
##tein	I
##e	I
,	O
pu	B
##rine	I
,	O
p	B
##yr	I
##u	I
##vate	I
,	O
in	B
##os	I
##ito	I
##l	I
metabolism	O
and	O
various	O
glucose	S
metabolic	O
pathways	O
.	O

S	O
##pect	O
##ral	O
data	O
acquired	O
by	O
H	O
##R	O
-	O
MA	O
##S	O
1	O
##H	O
N	O
##MR	O
s	O
##pect	O
##ros	O
##copy	O
were	O
expressed	O
with	O
meta	O
##bol	O
##ite	O
concentrations	O
[	O
Al	O
##a	O
,	O
Cho	O
,	O
PC	O
,	O
GP	B
##C	I
,	O
total	O
ch	B
##olin	I
##e	I
(	O
t	O
##C	O
##ho	O
,	O
the	O
sum	O
of	O
Cho	O
,	O
PC	O
,	O
and	O
GP	O
##C	O
)	O
,	O
C	O
##r	O
,	O
m	O
-	O
In	O
##s	O
,	O
Tau	O
,	O
G	O
##ly	O
,	O
Su	O
##c	O
]	O
and	O
metabolic	O
ratios	O
(	O
Cho	O
/	O
C	O
##r	O
,	O
PC	O
/	O
C	O
##r	O
,	O
GP	B
##C	I
/	O
C	O
##r	O
,	O
GP	B
##C	I
/	I
PC	I
,	O
GP	B
##C	I
/	O
Cho	O
,	O
PC	O
/	O
Cho	O
)	O
.	O

A	O
total	O
of	O
31	O
meta	O
##bol	O
##ites	O
,	O
including	O
7	O
amino	O
acids	O
,	O
6	O
organic	O
compounds	O
,	O
7	O
car	O
##bo	O
##hy	O
##dra	O
##tes	O
,	O
and	O
11	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
(	O
l	O
##ys	O
##o	O
##PC	O
##s	O
)	O
,	O
were	O
identified	O
as	O
meta	O
##bol	O
##ites	O
that	O
differed	O
significantly	O
among	O
the	O
experimental	O
groups	O
.	O

Similarly	O
,	O
its	O
is	O
##omer	O
,	O
PC	B
36	I
:	I
4	I
,	O
was	O
identified	O
as	O
PC	B
16	I
:	I
0	I
_	I
20	I
:	I
4	I
(	O
Δ	O
##5	O
,	O
8	O
,	O
11	O
,	O
and	O
14	O
)	O
(	O
Fi	O
##g	O
.	O
)	O
.	O

The	O
exact	O
blood	O
sampling	O
times	O
and	O
blood	O
glucose	S
concentrations	O
after	O
ing	O
##est	O
##ion	O
of	O
[	B
U	I
_	I
13	I
C	I
]	I
glucose	I
were	O
monitored	O
by	O
an	O
in	O
-	O
house	O
Android	O
application	O
and	O
g	B
##lu	I
##come	I
##ters	I
(	O
Diamond	O
Mini	O
;	O
For	O
##a	O
##C	O
##are	O
)	O
.	O

P	O
##las	O
##ma	O
levels	O
of	O
T	O
##rp	O
and	O
its	O
meta	O
##bol	O
##ite	O
K	B
##yn	I
##uren	I
##ine	I
(	O
K	O
##yn	O
)	O
were	O
measured	O
by	O
is	O
##oto	O
##pe	O
di	O
##lution	O
tandem	O
mass	O
s	O
##pect	O
##rome	O
##try	O
and	O
s	O
##CD	O
##14	O
was	O
assessed	O
by	O
enzyme	O
-	O
linked	O
im	O
##mu	O
##nos	O
##or	O
##bent	O
ass	O
##ay	O
(	O
E	O
##L	O
##IS	O
##A	O
)	O
.	O

Met	O
##ab	O
##olic	O
pro	O
##fi	O
##ling	O
of	O
plasma	O
after	O
stress	O
testing	O
and	O
marathon	O
-	O
running	O
have	O
previously	O
demonstrated	O
significant	O
changes	O
accompanying	O
exercise	O
in	O
pu	B
##rine	I
meta	O
##bol	O
##ites	O
and	O
K	O
##re	O
##bs	O
'	O
cycle	O
intermediate	O
##s	O
.	O

O	O
##xi	O
##da	O
##tive	O
in	O
##act	O
##ivation	O
of	O
4	O
##F	O
##e	O
-	O
4	O
##S	O
cluster	O
results	O
in	O
loss	O
of	O
an	O
non	O
-	O
l	O
##igate	O
##d	O
iron	O
atom	O
(	O
i	O
.	O
e	O
.	O
3	B
##F	I
##e	I
-	I
4	I
##S	I
)	O
and	O
consecutive	O
##ly	O
in	O
formation	O
of	O
H	O
_	O
2	O
O	O
_	O
2	O
radical	O
##s	O
and	O
accumulation	O
of	O
Fe	O
_	O
2	O
+	O
.	O

The	O
percent	O
blood	O
glucose	S
reduction	O
##s	O
of	O
1	O
at	O
25	O
,	O
50	O
,	O
100	O
and	O
200	O
mg	O
/	O
kg	O

In	O
##set	O
shows	O
levels	O
of	O
C	O
##YP	O
##39	O
##A	O
##1	O
protein	O
in	O
trans	O
##fected	O
cells	O
as	O
determined	O
by	O
im	O
##mu	O
##nob	O
##lot	O
##ting	O
;	O
α	B
-	I
tub	I
##ulin	I
served	O
as	O
a	O
loading	O
control	O
.	O

1	O
.	O
0	O
m	O
##M	O
M	O
##g	O
##C	O
##l	O
_	O
2	O
(	O
R	O
##ied	O
##el	O
-	O
de	O
-	O
Ha	O
##eh	O
##n	O
AG	O
,	O
See	O
##l	O
##ze	O
,	O
Germany	O
)	O
,	O
and	O
0	O
.	O
04	O
m	O
##M	O
as	B
##cor	I
##bic	I
acid	I
(	O
University	O
Pharmacy	O
,	O
Helsinki	O
,	O
Finland	O
)	O
.	O

The	O
ion	O
species	O
for	O
q	O
##uant	O
##ification	O
of	O
ace	B
##tam	I
##ip	I
##rid	I
,	O
AM	O
-	O
2	O
and	O
fi	O
##p	O
##ron	O
##il	O
were	O
m	O
/	O
z	O
=	O
222	O
.	O
80	O
/	O
126	O
.	O
10	O
,	O
m	O
/	O
z	O
=	O
209	O
.	O
00	O
/	O
126	O
.	O
10	O
and	O
m	O
/	O
z	O
=	O
435	O
.	O
00	O
/	O
330	O
.	O
00	O
,	O
respectively	O
.	O

This	O
is	O
consistent	O
with	O
our	O
findings	O
in	O
the	O
same	O
population	O
of	O
a	O
significant	O
protective	O
association	O
between	O
5	B
-	I
met	I
##hyl	I
fur	I
##an	I
-	I
2	I
-	I
car	I
##box	I
##yl	I
##ic	I
acid	I
and	O
lung	O
cancer	O
risk	O
,	O
and	O
a	O
significant	O
weak	O
correlation	O
between	O
this	O
meta	O
##bol	O
##ite	O
and	O
diet	O
##ary	O
so	O
##y	O
intake	O
.	O

High	O
-	O
through	O
##put	O
meta	O
##bon	O
##omi	O
##c	O
screening	O
methods	O
for	O
bio	O
##f	O
##lu	O
##ids	O
,	O
such	O
as	O
hydrogen	B
-	I
1	I
(	O
or	O
pro	O
##ton	O
)	O
nuclear	O
magnetic	O
resonance	O
(	O
_	O
1	O
H	O
N	O
##MR	O
)	O
s	O
##pect	O
##ros	O
##copy	O
and	O
mass	O
s	O
##pect	O
##rome	O
##try	O
,	O
are	O
now	O
being	O
applied	O
in	O
e	O
##pid	O
##em	O
##iol	O
##og	O
##ic	O
studies	O
(	O
–	O
)	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
the	O
concentrations	O
of	O
G	B
##S	I
##H	I
,	O
G	O
##SS	O
##H	O
,	O
G	O
##SS	O
##G	O
or	O
G	O
##SS	O
##S	O
##G	O
in	O
D	O
##M	O
patients	O
and	O
controls	O
.	O

Sa	B
##rc	I
##os	I
##ine	I
,	O
an	O
N	O
-	O
met	O
##hyl	O
derivative	O
of	O
the	O
amino	O
acid	O
g	O
##ly	O
##cine	O
,	O
was	O
identified	O
as	O
a	O
differential	O
meta	O
##bol	O
##ite	O
that	O
was	O
highly	O
elevated	O
during	O
pro	O
##state	O
cancer	O
progression	O
to	O
meta	O
##sta	O
##sis	O
and	O
can	O
be	O
detected	O
non	O
-	O
invasive	O
##ly	O
in	O
urine	O
.	O

Pit	O
##uit	O
##ary	O
tumor	O
tissue	O
showed	O
the	O
presence	O
of	O
major	O
C	O
##NS	O
meta	O
##bol	O
##ites	O
:	O
N	B
-	I
ace	I
##ty	I
##l	I
as	I
##par	I
##tate	I
(	O
N	O
##AA	O
)	O
,	O
g	B
##lut	I
##ama	I
##te	I
,	O
g	B
##lut	I
##amine	I
,	O
my	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
(	O
m	O
##I	O
)	O
,	O
and	O
as	B
##par	I
##tate	I
.	O

P	O
##las	O
##ma	O
(	O
0	O
.	O
25	O
m	O
##L	O
)	O
was	O
mixed	O
with	O
0	O
.	O
25	O
m	O
##L	O
form	B
##ic	I
acid	I
0	O
.	O
5	O
%	O
in	O
water	O
and	O
with	O
30	O
μ	O
##L	O
internal	O
standard	O
,	O
b	B
##up	I
##ren	I
##or	I
##phine	I
-	I
3	I
-	I
β	I
-	I
d	I
-	I
g	I
##lu	I
##cu	I
##ron	I
##ide	I
solution	O
20	O
ng	O
/	O
m	O
##L	O
in	O
met	B
##han	I
##ol	I
,	O
then	O
the	O
samples	O
were	O
loaded	O
under	O
positive	O
pressure	O
onto	O
Is	O
##ol	O
##ute	O
C	O
##18	O
—	O
100	O
mg	O
extraction	O
plates	O
(	O
B	O
##iot	O
##age	O
,	O
Up	O
##ps	O
##ala	O
,	O
Sweden	O
)	O
already	O
conditioned	O
with	O
met	B
##han	I
##ol	I
and	O
form	B
##ic	I
acid	I
0	O
.	O
5	O
%	O
in	O
water	O
.	O

In	O
this	O
series	O
of	O
experiments	O
,	O
HK	O
-	O
2	O
cells	O
were	O
purchased	O
from	O
American	O
Type	O
Culture	O
Collection	O
(	O
AT	O
##CC	O
®	O
CR	O
##L	O
-	O
219	O
##0	O
[UNK]	O
,	O
Man	O
##ass	O
##as	O
,	O
VA	S
,	O
USA	O
)	O
.	O

In	O
addition	O
,	O
several	O
studies	O
have	O
reported	O
that	O
ω	B
-	I
3	I
P	I
##U	I
##FA	I
##s	I
supplement	O
##s	O
are	O
associated	O
with	O
decreased	O
risk	O
of	O
depression	O
or	O
lower	O
de	O
##pressive	O
symptoms	O
in	O
adult	O
patients	O
[	O
–	O
]	O
.	O

PC	B
a	I
##a	I
C	I
##38	I
:	I
6	I
;	O
114	O
.	O

To	O
minimize	O
chemical	O
loss	O
during	O
sample	O
preparation	O
,	O
we	O
added	O
0	O
.	O
3	O
m	O
##L	O
of	O
met	B
##han	I
##ol	I
into	O
all	O
samples	O
before	O
SP	O
##E	O
clean	O
##up	O
.	O

Su	O
##pp	O
##lement	O
##ation	O
with	O
gal	B
##act	I
##ose	I
leads	O
to	O
bio	O
##chemical	O
improvement	O
in	O
index	O
##es	O
of	O
g	O
##ly	O
##cos	O
##yla	O
##tion	O
.	O

No	O
association	O
was	O
observed	O
with	O
any	O
of	O
the	O
other	O
est	B
##rogen	I
meta	O
##bol	O
##ites	O
examined	O
(	O
data	O
not	O
shown	O
)	O
.	O

Recent	O
development	O
and	O
characterization	O
of	O
selective	O
and	O
potent	O
inhibitor	O
##s	O
of	O
the	O
C	O
##YP	O
##4	O
##A	O
/	O
F	O
enzymes	O
and	O
antagonist	O
##s	O
of	O
20	B
-	I
H	I
##ET	I
##E	I
signaling	O
(	O
,	O
,	O
)	O
,	O
as	O
well	O
as	O
the	O
development	O
of	O
sensitive	O
L	O
##C	O
–	O
MS	O
/	O
MS	O
ass	O
##ays	O
for	O
the	O
measurement	O
of	O
20	B
-	I
H	I
##ET	I
##E	I
levels	O
in	O
biological	O
samples	O
,	O
have	O
suggested	O
that	O
20	B
-	I
H	I
##ET	I
##E	I
plays	O
a	O
role	O
in	O
tumor	O
growth	O
and	O
progression	O
,	O
at	O
least	O
in	O
animal	O
models	O
.	O

According	O
to	O
the	O
chemical	O
structures	O
of	O
the	O
arch	O
##ety	O
##pes	O
and	O
their	O
meta	O
##bol	O
##ites	O
,	O
tied	O
together	O
with	O
the	O
time	O
–	O
course	O
curve	O
,	O
the	O
main	O
pathways	O
of	O
P	O
and	O
IP	S
metabolism	O
by	O
human	O
in	O
##test	O
##inal	O
flora	O
could	O
be	O
speculated	O
in	O
detail	O
.	O

In	O
the	O
same	O
time	O
,	O
the	O
in	O
##tra	O
##cellular	O
amount	O
of	O
as	B
##par	I
##tate	I
s	O
##hr	O
##unk	O
from	O
3	O
.	O
40	O
to	O
0	O
.	O
31	O
nm	O
##ol	O
/	O
10	O
_	O
6	O
cells	O
in	O
S	O
##9	O
cells	O
and	O
from	O
4	O
.	O
21	O
nm	O
##ol	O
to	O
0	O
.	O
34	O
nm	O
##ol	O
/	O
10	O
_	O
6	O
cells	O
in	O
16	O
##H	O
##BE	O
##14	O
##o	O
_	O
−	O
cells	O
.	O

d	O
2	B
-	I
Ph	I
##en	I
##yla	I
##ce	I
##tam	I
##ide	I
,	O
N	O
##e	O
,	O
N	O
##e	O
dim	B
##eth	I
##yl	I
##ly	I
##sin	I
##e	I
,	O
g	B
##ly	I
##cer	I
##yl	I
-	I
p	I
##hos	I
##ph	I
##ory	I
##l	I
-	I
ethanol	I
##amine	I
and	O
d	B
-	I
c	I
##ys	I
##tein	I
##e	I
may	O
change	O
significantly	O
when	O
severe	O
se	O
##psis	O
occurs	O
.	O

Mobile	O
phase	O
A	O
was	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
in	O
water	O
and	O
mobile	O
phase	O
B	O
was	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
in	O
met	B
##han	I
##ol	I
.	O

In	O
the	O
United	O
States	O
,	O
at	B
##raz	I
##ine	I
and	O
its	O
meta	O
##bol	O
##ites	O
are	O
well	O
dispersed	O
in	O
the	O
environment	O
and	O
frequently	O
detected	O
in	O
groundwater	O
.	O

feeding	O
of	O
fish	O
oil	O
in	O
mouse	O
models	O
reduced	O
concentrations	O
of	O
pro	B
##sta	I
##g	I
##land	I
##in	I
E	O
_	O
2	O
in	O
response	O
to	O
a	B
##zo	I
##xy	I
##met	I
##hane	I
,	O
whereas	O
in	O
fat	O
-	O
1	O
trans	O
##genic	O
mice	O
,	O
which	O
end	O
##ogen	O
##ously	O
s	O
##ynth	O
##esi	O
##ze	O
n	O
##−	O
##3	O
P	O
##U	O
##FA	O
##s	O
from	O
diet	O
##ary	O
n	O
##−	O
##6	O
P	O
##U	O
##FA	O
##s	O
,	O
the	O
concentrations	O
of	O
pro	B
##sta	I
##g	I
##land	I
##in	I
E	O
_	O
2	O
in	O
response	O
to	O
experimental	O
co	O
##lit	O
##is	O
were	O
marked	O
##ly	O
decreased	O
compared	O
with	O
those	O
of	O
wild	O
-	O
type	O
mice	O
.	O

The	O
de	O
##hy	O
##dra	O
##ted	O
compounds	O
7	O
,	O
10	O
,	O
14	O
,	O
and	O
17	O
and	O
the	O
su	B
##lf	I
##oxide	I
derivatives	O
8	O
,	O
11	O
,	O
15	O
,	O
and	O
18	O
,	O
were	O
analyzed	O
in	O
positive	O
mode	O
monitoring	O
for	O
the	O
transitions	O
m	O
/	O
z	O
340	O
→	O
m	O
/	O
z	O
209	O
.	O
04	O
##19	O
and	O
m	O
/	O
z	O
35	O
##6	O
→	O
m	O
/	O
z	O
209	O
.	O
04	O
##19	O
respectively	O
.	O

After	O
confirming	O
the	O
method	O
with	O
synthetic	O
p	O
##eptide	O
##s	O
,	O
β	B
-	I
case	I
##in	I
was	O
used	O
as	O
the	O
model	O
protein	O
to	O
ensure	O
confidence	O
in	O
the	O
method	O
.	O

As	O
previous	O
studies	O
have	O
shown	O
that	O
lip	O
##id	O
ratios	O
can	O
be	O
predict	O
##ive	O
of	O
certain	O
diseases	O
,	O
we	O
noted	O
that	O
when	O
the	O
raw	O
intensity	O
value	O
of	O
PS	B
(	I
18	I
:	I
0	I
_	I
20	I
:	I
4	I
)	I
was	O
divided	O
by	O
the	O
sum	O
of	O
the	O
raw	O
intensity	O
values	O
of	O
these	O
three	O
PS	O
lip	O
##ids	O
,	O
all	O
fatal	O
outcomes	O
had	O
a	O
value	O
of	O
less	O
than	O
28	O
.	O
5	O
(	O
average	O
value	O
of	O
21	O
)	O
(	O
and	O
S	O
##I	O
A	O
##ppe	O
##ndi	O
##x	O
,	O
Fi	O
##g	O
.	O

Met	O
##ab	O
##oli	O
##tes	O
in	O
k	B
##yn	I
##uren	I
##ine	I
pathway	O

Selected	O
et	B
##hyl	I
ace	I
##tate	I
extract	O
##s	O
of	O
serum	O
from	O
the	O
G	O
##CI	O
co	O
##hor	O
##t	O
used	O
in	O
the	O
F	O
##TI	O
##CR	O
-	O
MS	O
work	O
described	O
above	O
were	O
re	O
-	O
anal	O
##ys	O
##ed	O
using	O
HP	O
##LC	O
coupled	O
to	O
a	O
q	O
##uad	O
##rup	O
##ole	O
time	O
-	O
of	O
-	O
flight	O
(	O
Q	O
-	O
TO	O
##F	O
)	O
MS	O
in	O
full	O
-	O
scan	O
AP	O
##CI	O
negative	O
ion	O
mode	O
.	O

However	O
,	O
in	O
the	O
previous	O
meta	O
##bon	O
##omi	O
##cs	O
research	O
on	O
es	O
##op	O
##hage	O
##al	O
cancer	O
,	O
none	O
of	O
the	O
paper	O
reported	O
the	O
identification	O
of	O
N	O
##AA	O
and	O
ace	B
##tate	I
.	O

[	O
(	O
E	O
##1	O
+	O
E	O
##2	O
)	O
/	O
2	O
]	O
[	O
(	O
E	O
##1	O
+	O
E	O
##2	O
)	O
/	O
2	O
]	O
[	O
(	O
E	O
##1	O
E	O
##1	O
E	O
E	O
1	O
1	O
+	O
E	O
##2	O
E	O
##2	O
E	O
E	O
2	O
2	O
)	O
/	O
2	O
]	O
where	O
F	O
=	O
trace	O
##r	O
in	O
##fusion	O
rate	O
,	O
p	O
V	O
=	O
volume	O
of	O
distribution	O
for	O
palm	B
##itate	I
(	O
pre	O
-	O
determined	O
at	O
0	O
.	O
04	O
)	O

L	O
##ys	O
##o	O
##PC	O
(	O
16	O
:	O
0	O
)	O
had	O
a	O
VIP	O
value	O
of	O
17	O
.	O
173	O
and	O
showed	O
positive	O
and	O
independent	O
association	O
with	O
DB	B
##P	I
and	O
S	O
##B	O
##P	O
.	O

There	O
were	O
significantly	O
lower	O
levels	O
of	O
try	B
##pt	I
##op	I
##han	I
in	O
AC	O
##PA	O
positive	O
pre	O
-	O
s	O
##ym	O
##pt	O
##oma	O
##tic	O
individuals	O
compared	O
with	O
AC	O
##PA	O
negative	O
ones	O
,	O
which	O
could	O
suggest	O
a	O
link	O
of	O
this	O
molecule	O
with	O
up	O
-	O
starting	O
inflammatory	O
processes	O
.	O

Most	O
of	O
the	O
a	B
##ryl	I
##amine	I
H	O
##b	O
add	O
##uc	O
##ts	O
are	O
lab	O
##ile	O
and	O
undergo	O
h	O
##ydro	O
##lysis	O
in	O
v	O
##it	O
##ro	O
,	O
by	O
mild	O
acid	O
or	O
base	O
,	O
to	O
form	O
the	O
a	B
##ryl	I
##amine	I
##s	I
.	O

Nevertheless	O
,	O
levels	O
were	O
still	O
lower	O
if	O
compared	O
with	O
smoking	O
subjects	O
,	O
for	O
which	O
median	O
/	O
mean	O
values	O
close	O
to	O
1	O
µ	O
##g	O
/	O
g	O
c	B
##rea	I
##tin	I
##ine	I
have	O
been	O
reported	O
[	O
,	O
]	O
.	O

Furthermore	O
,	O
neither	O
sex	O
nor	O
distance	O
from	O
health	O
facilities	O
or	O
p	O
##har	O
##ma	O
##cies	O
showed	O
a	O
significant	O
effect	O
on	O
residual	O
levels	O
of	O
SP	S
,	O
AL	O
or	O
both	O
at	O
study	O
entry	O
.	O

While	O
it	O
was	O
similar	O
in	O
all	O
the	O
subgroup	O
##s	O
at	O
base	O
##line	O
,	O
M	O
increased	O
(	O
p	O
=	O
0	O
.	O
04	O
)	O
in	O
Pi	O
##o	O
&	O
Omega	B
-	I
3	I
subgroup	O
during	O
the	O
intervention	O
and	O
at	O
week	O
24	O
,	O
it	O
was	O
higher	O
in	O
the	O
Pi	O
##o	O
&	O
Omega	B
-	I
3	I
compared	O
with	O
the	O
Omega	B
-	I
3	I
subgroup	O
.	O

S	O
##pec	O
##ime	O
##n	O
1	O
contained	O
215	O
ng	O
/	O
g	O
MA	O
##MP	O
,	O
44	O
.	O
9	O
ng	O
/	O
g	O
AM	B
##P	I
,	O
and	O
11	O
.	O
2	O
ng	O
/	O
g	O
p	O
##OH	O
##MA	O
##MP	O
;	O
specimen	O
2	O
,	O
55	O
.	O
5	O
ng	O
/	O
g	O

The	O
majority	O
of	O
meta	O
##bol	O
##ites	O
detected	O
in	O
the	O
present	O
study	O
were	O
identified	O
in	O
all	O
CS	O
##F	O
samples	O
,	O
except	O
for	O
q	B
##uin	I
##olin	I
##ate	I
and	O
ma	B
##late	I
which	O
did	O
not	O
reach	O
the	O
levels	O
of	O
detection	O
in	O
some	O
control	O
samples	O
.	O

Theo	B
##phy	I
##llin	I
##e	I
represents	O
only	O
one	O
meta	O
##bol	O
##ite	O
of	O
ca	B
##ffe	I
##ine	I
in	O
the	O
group	O
of	O
met	B
##hyl	I
##xa	I
##nt	I
##hine	I
and	O
it	O
remains	O
unclear	O
if	O
other	O
meta	O
##bol	O
##ites	O
exhibit	O
similar	O
actions	O
.	O

In	O
addition	O
to	O
increased	O
g	O
##ly	O
##co	O
##lysis	O
,	O
a	O
higher	O
level	O
of	O
se	B
##rine	I
in	O
re	O
##ct	O
##al	O
cancer	O
tissues	O
was	O
also	O
observed	O
.	O

Ana	B
##stro	I
##zo	I
##le	I
was	O
provided	O
by	O
As	O
##tra	O
Zen	O
##eca	O
.	O

Ch	B
##lor	I
##of	I
##orm	I
was	O
HP	O
##LC	O
-	O
grade	O
from	O
RC	O
##I	O
Labs	O
##can	O
(	O
Bangkok	O
,	O
Thailand	O
)	O
.	O

However	O
,	O
the	O
changes	O
in	O
R	O
##OS	O
levels	O
are	O
independent	O
of	O
M	O
##UC	O
##16	O
-	O
induced	O
flux	O
in	O
pen	B
##tos	I
##e	I
phosphate	I
pathway	O
.	O

Ethan	B
##ol	I
(	O
1	O
m	O
##l	O
)	O
was	O
added	O
to	O
each	O
tube	O
,	O
and	O
the	O
samples	O
were	O
son	O
##ica	O
##ted	O
using	O
an	O
Ultra	O
##sonic	O
Di	O
##sm	O
##em	O
##bra	O
##tor	O
(	O
model	O
150	O
##E	O
,	O
Fisher	O
Scientific	O
)	O
.	O

Although	O
an	O
association	O
with	O
g	B
##lu	I
##co	I
##cor	I
##tic	I
##oid	I
usage	O
may	O
have	O
been	O
expected	O
,	O
low	O
doses	O
of	O
co	O
##rt	O
##ico	O
##ids	O
prescribed	O
to	O
RA	O
patients	O
may	O
explain	O
our	O
findings	O
.	O

Because	O
of	O
their	O
high	O
oxygen	O
content	O
,	O
RB	O
##Cs	O
have	O
a	O
high	O
demand	O
for	O
N	B
##AD	I
##P	I
##H	I
to	O
re	O
##generate	O
G	B
##S	I
##H	I
from	O
G	O
##SS	O
##G	O
,	O
which	O
is	O
necessary	O
to	O
protect	O
RB	O
##Cs	O
from	O
o	O
##xi	O
##da	O
##tive	O
damage	O
.	O
_	O
,	O
Further	O
,	O
RB	O
##Cs	O
lack	O
mit	O
##och	O
##ond	O
##ria	O
and	O
hence	O
T	O
##CA	O
cycle	O
metabolism	O
is	O
absent	O
in	O
these	O
cells	O
.	O

These	O
are	O
the	O
Ka	O
##nd	O
##uts	O
##ch	O
–	O
Russell	O
(	O
K	O
–	O
R	O
)	O
pathway	O
through	O
la	B
##th	I
##ost	I
##ero	I
##l	I
and	O
the	O
Bloc	O
##h	O
pathway	O
through	O
des	B
##most	I
##ero	I
##l	I
.	O

The	O
local	O
1	O
##D	O
model	O
revealed	O
that	O
the	O
patients	O
with	O
an	O
e	O
##G	O
##F	O
##R	O
<	O
60	O
m	O
##l	O
/	O
min	O
/	O
1	O
.	O
73	O
##m	O
_	O
2	O
were	O
older	O
and	O
had	O
a	O
high	O
concentration	O
of	O
u	O
##rina	O
##ry	O
re	B
##tino	I
##l	I
binding	O
protein	O
and	O
,	O
con	O
##verse	O
##ly	O
for	O
individuals	O
with	O
an	O
e	O
##G	O
##F	O
##R	O

Po	O
##sitive	O
differences	O
indicate	O
that	O
as	B
##par	I
##tam	I
##e	I
was	O
rated	O
higher	O
than	O
control	O
.	O

The	O
al	O
##iq	O
##uo	O
##ts	O
dissolved	O
in	O
acidic	O
conditions	O
were	O
el	O
##uted	O
through	O
a	O
C	O
##18	O
column	O
(	O
Waters	O
UP	O
##LC	O
B	O
##E	O
##H	O
C	O
##18	O
-	O
2	O
.	O
1	O
×	O
100	O
mm	O
,	O
1	O
.	O
7	O
µ	O
##M	O
)	O
using	O
gradient	O
el	O
##ution	O
of	O
water	O
,	O
met	B
##han	I
##ol	I
,	O
and	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
.	O

After	O
the	O
regions	O
of	O
δ	O
4	O
.	O
70	O
–	O
5	O
.	O
20	O
and	O
δ	O
3	O
.	O
34	O
–	O
3	O
.	O
37	O
pp	O
##m	O
were	O
removed	O
to	O
eliminate	O
the	O
influence	O
of	O
water	O
and	O
met	B
##han	I
##ol	I
,	O
the	O
s	O
##pect	O
##ra	O
were	O
segment	O
##ed	O
at	O
δ	O
0	O
.	O
01	O
intervals	O
across	O
the	O
chemical	O
shift	O
range	O
of	O
0	O
.	O
5	O
to	O
9	O
.	O
00	O
pp	O
##m	O
.	O

*	O
p	O
<	O
0	O
.	O
05	O
,	O
*	O
*	O
p	O
<	O
0	O
.	O
01	O
,	O
*	O
*	O
*	O
p	O
<	O
0	O
.	O
00	O
##1	O
against	O
h	O
##y	O
##po	O
##gon	O
##ada	O
##l	O
men	O
In	O
I	O
##R	O
male	O
h	O
##y	O
##po	O
##gon	O
##adi	O
##sm	O
,	O
more	O
ace	B
##ty	I
##l	I
-	I
Co	I
##A	I
is	O
transformed	O
into	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
which	O
increases	O
up	O
to	O
243	O
mg	O
/	O
d	O
##L	O
(	O
Table	O
and	O
Fi	O
##g	O
.	O

The	O
MS	O
parameters	O
were	O
improved	O
for	O
en	O
##ala	O
##p	O
##ril	O
and	O
en	O
##ala	O
##p	O
##ril	O
##at	O
analysis	O
in	O
E	O
##SI	O
negative	O
mode	O
as	O
follows	O
:	O
nitrogen	B
gas	I
1	O
flow	O
=	O
55	O
units	O
,	O
gas	O
2	O
=	O
70	O
units	O
,	O
curtain	O
gas	O
=	O
30	O
units	O
,	O
ion	O
spray	O
voltage	O
=	O
5000	O
V	O
,	O
drying	O
temperature	O
=	O
550	O
##°	O
##C	O
,	O
and	O
collision	O
energy	O
of	O
20	O
V	O
.	O

With	O
respect	O
to	O
p	B
##oly	I
##amine	I
##s	I
,	O
these	O
values	O
are	O
lower	O
than	O
what	O
the	O
majority	O
of	O
published	O
methods	O
have	O
achieved	O
.	O

Although	O
these	O
two	O
molecules	O
were	O
not	O
identified	O
by	O
multi	O
##var	O
##iate	O
analysis	O
as	O
markers	O
in	O
serum	O
,	O
they	O
were	O
disc	O
##rim	O
##inating	O
for	O
milk	O
intake	O
in	O
serum	O
when	O
analyzed	O
in	O
a	O
targeted	O
manner	O
based	O
on	O
known	O
q	O
##uant	O
##ifier	O
and	O
qualifier	O
ion	O
as	O
well	O
as	O
R	B
##I	I
and	O
subsequent	O
un	O
##iva	O
##ria	O
##te	O
analysis	O
of	O
their	O
6	O
##h	O
-	O
i	O
##A	O
##UC	O
.	O

CS	O
##F	O
samples	O
were	O
th	O
##awed	O
on	O
ice	O
and	O
100	O
µ	O
##L	O
was	O
mixed	O
with	O
410	O
µ	O
##L	O
ice	O
-	O
cold	O
met	B
##han	I
##ol	I
(	O
Me	O
##OH	O
)	O
supplemented	O
with	O
internal	O
standards	O
at	O
a	O
final	O
concentration	O
of	O
0	O
.	O
25	O
µ	O
##M	O
.	O
The	O
samples	O
were	O
v	O
##ortex	O
##ed	O
for	O
15	O
s	O
and	O
in	O
##cu	O
##bate	O
##d	O
at	O
−	O
##20	O
°C	O
for	O
30	O
minutes	O
,	O
followed	O
by	O
cent	O
##ri	O
##fu	O
##gation	O
at	O
204	O
##00	O
g	O
for	O
12	O
minutes	O
at	O
4	O
°C	O
.	O

)	O
showed	O
pronounced	O
increases	O
in	O
lip	O
##ids	O
and	O
a	O
##poli	O
##pop	O
##rote	O
##ins	O
associated	O
with	O
V	O
##LD	O
##L	O
,	O
ID	O
##L	O
and	O
L	O
##D	O
##L	O
5	O
–	O
6	O
,	O
especially	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
.	O

To	O
determine	O
if	O
the	O
plasma	O
meta	O
##bol	O
##ite	O
profile	O
was	O
predict	O
##ive	O
of	O
disease	O
course	O
,	O
a	O
new	O
ensemble	O
of	O
O	O
##PL	O
##S	O
-	O
D	O
##A	O
models	O
was	O
produced	O
using	O
only	O
the	O
base	O
##line	O
plasma	O
samples	O
from	O
those	O
individuals	O
who	O
improved	O
or	O
worse	O
##ned	O
over	O
the	O
duration	S
of	O
the	O
study	O
.	O

In	O
this	O
comparison	O
among	O
pre	O
##men	O
##op	O
##aus	O
##al	O
women	O
,	O
those	O
with	O
minimal	O
meat	O
intake	O
(	O
ve	O
##get	O
##arians	O
and	O
p	O
##es	O
##cat	O
##arians	O
)	O
had	O
lower	O
levels	O
of	O
circulating	O
E	O
_	O
1	O
and	O
E	O
_	O
2	O
than	O
non	O
-	O
ve	O
##get	O
##arians	O
,	O
but	O
no	O
significant	O
differences	O
in	O
the	O
amount	O
or	O
the	O
relative	O
proportion	O
of	O
u	O
##rina	O
##ry	O
est	B
##rogen	I
meta	O
##bol	O
##ites	O
were	O
seen	O
.	O

However	O
,	O
we	O
found	O
u	O
##rina	O
##ry	O
sa	B
##rc	I
##os	I
##ine	I
to	O
be	O
significantly	O
elevated	O
at	O
the	O
time	O
of	O
surgery	O
in	O
patients	O
who	O
developed	O
bio	O
##chemical	O
re	O
##cu	O
##rrence	O
,	O
as	O
originally	O
reported	O
for	O
patients	O
with	O
f	O
##rank	O
pro	O
##state	O
meta	O
##static	O
lesions	O
.	O

Fast	O
##ing	O
and	O
2	O
h	O
post	O
##pra	O
##ndi	O
##al	O
plasma	O
glucose	S
and	O
insulin	O
levels	O
,	O
serum	O
lip	O
##id	O
profiles	O
(	O
total	O
ch	B
##ole	I
##ster	I
##ol	I
T	O
##C	O
,	O
t	B
##rig	I
##ly	I
##cer	I
##ide	I
T	I
##G	I
,	O
high	O
-	O
density	O
lip	B
##op	I
##rote	I
##in	I
-	I
ch	I
##ole	I
##ster	I
##ol	I
HD	I
##L	I
,	O
low	O
-	O
density	O
lip	B
##op	I
##rote	I
##in	I
-	I
ch	I
##ole	I
##ster	I
##ol	I
L	O
##D	O
##L	O
)	O
,	O
as	O
##par	O
##tate	O
amino	O
##tra	O
##ns	O
##fer	O
##ase	O
(	O
AS	O
##T	O
)	O
,	O
al	O
##ani	O
##ne	O
amino	O
##tra	O
##ns	O
##fer	O
##ase	O
(	O
AL	O
##T	O
)	O
,	O
gamma	B
-	I
g	I
##lut	I
##am	I
##yl	I
trans	I
-	I
su	I
##pe	I
##pt	I
##idas	I
##e	I
(	I
γ	I
-	I
GT	I
)	I
,	O
blood	O
pressure	O
(	O
s	O
##ys	O
##to	O
##lic	O
and	O
di	O
##ast	O
##olic	O
blood	O
pressure	O
SP	S
and	O
D	O
##P	O
)	O
,	O
waist	O
,	O
body	O
mass	O
index	O
(	O
B	O
##MI	O
)	O
,	O
and	O
liver	O
and	O
kidney	O
functions	O
were	O
determined	O
as	O
previously	O
described	O
.	O

One	O
study	O
found	O
five	O
sa	O
##liva	O
##ry	O
bio	O
##mark	O
##ers	O
(	B
prop	B
##ion	I
##yl	I
##cho	I
##line	I
,	O
N	B
-	I
Ace	I
##ty	I
##l	I
-	I
L	I
-	I
p	I
##hen	I
##yla	I
##lani	I
##ne	I
,	O
s	B
##phi	I
##nga	I
##nine	I
,	O
p	B
##hy	I
##tos	I
##phi	I
##ngo	I
##sin	I
##e	I
,	O
and	O
S	B
-	I
car	I
##box	I
##yme	I
##thy	I
##l	I
-	I
L	I
-	I
c	I
##ys	I
##tein	I
##e	I
)	O
in	O
combination	O
with	O
an	O
AU	O
##C	O
value	O
of	O
0	O
.	O
99	O
##7	O
differentiated	O
between	O
early	O
stage	O
oral	O
sq	O
##ua	O
##mous	O
cell	O
car	O
##cin	O
##oma	O
and	O
controls	O
,	O
while	O
we	O
found	O
a	O
panel	O
of	O
six	O
serum	O
bio	O
##mark	O
##ers	O
(	B
glucose	S
,	O
ch	B
##olin	I
##e	I
,	O
g	B
##lut	I
##amine	I
,	O
g	B
##lut	I
##ama	I
##te	I
,	O
v	B
##ali	I
##ne	I
,	O
and	O
D	O
##HT	O
)	O
combined	O
together	O
with	O
high	O
AU	O
##C	O
values	O
of	O
0	O
.	O
96	O
##9	O
differentiated	O
between	O
early	O
stage	O
E	O
##SC	O
##C	O
and	O
CT	O
##RL	O
.	O

This	O
suggests	O
that	O
the	O
balance	O
of	O
SP	S
metabolism	O
,	O
rather	O
than	O
c	B
##era	I
##mi	I
##de	I
accumulation	O
,	O
is	O
associated	O
with	O
the	O
path	O
##ology	O
of	O
o	O
##besity	O
.	O

At	O
95	O
%	O
confidence	O
interval	O
(	O
C	O
##I	O
)	O
,	O
the	O
effects	O
of	O
N	O
##AC	O
treatment	O
on	O
K	O
##yn	O
,	O
HC	O
##A	O
,	O
and	O
N	B
##AD	I
##P	I
##H	I
were	O
also	O
significant	O
(	O
data	O
not	O
shown	O
)	O
.	O

Similarly	O
,	O
the	O
increased	O
concentration	O
of	O
la	B
##ct	I
##ate	I
that	O
is	O
probably	O
secret	O
##ed	O
from	O
in	O
##f	O
##lam	O
##ed	O
co	O
##lon	O
##ic	O
m	O
##uc	O
##osa	O
cells	O
[	O
]	O
indicates	O
the	O
up	O
-	O
regulation	O
of	O
g	O
##ly	O
##co	O
##lysis	O
,	O
which	O
occurs	O
in	O
case	O
of	O
higher	O
cellular	O
energy	O
need	O
and	O
/	O
or	O
lack	O
of	O
energy	O
sources	O
under	O
inflammatory	O
conditions	O
[	O
,	O
]	O
.	O

These	O
results	O
suggest	O
that	O
metabolic	O
re	O
##p	O
##rog	O
##ram	O
##ming	O
occurs	O
in	O
a	O
##A	O
##IP	O
individuals	O
,	O
even	O
in	O
the	O
absence	O
of	O
over	O
##t	O
symptoms	O
,	O
and	O
supports	O
the	O
relationship	O
that	O
occur	O
between	O
hem	B
##e	I
synthesis	O
and	O
mitochondrial	O
energetic	O
metabolism	O
.	O

The	O
mobile	O
phases	O
were	O
water	O
with	O
0	O
.	O
1	O
m	O
##M	O
am	B
##mon	I
##ium	I
flu	I
##ori	I
##de	I
(	O
A	O
)	O
and	O
met	B
##han	I
##ol	I
with	O
0	O
.	O
1	O
m	O
##M	O
am	B
##mon	I
##ium	I
flu	I
##ori	I
##de	I
(	O
B	O
)	O
.	O

(	O
D	O
)	O
Z	O
-	O
scores	O
of	O
control	O
samples	O
,	O
other	O
patient	O
samples	O
and	O
the	O
samples	O
of	O
this	O
patient	O
for	O
the	O
ratio	O
of	O
trim	B
##eth	I
##yl	I
##ly	I
##sin	I
##e	I
over	O
γ	B
-	I
but	I
##yr	I
##obe	I
##tain	I
##e	I
.	O

A	O
close	O
evaluation	O
of	O
the	O
s	O
##pect	O
##ra	O
showed	O
that	O
although	O
g	B
##lut	I
##amine	I
did	O
not	O
c	O
##y	O
##c	O
##li	O
##ze	O
in	O
intact	O
serum	O
,	O
a	O
very	O
significant	O
c	O
##y	O
##c	O
##li	O
##zation	O
of	O
g	B
##lut	I
##amine	I
to	O
p	B
##yr	I
##og	I
##lut	I
##ami	I
##c	I
acid	I
occurred	O
in	O
ultra	O
##fi	O
##lter	O
##ed	O
and	O
protein	O
pre	O
##ci	O
##pit	O
##ated	O
serum	O
.	O

At	O
1	O
month	O
,	O
the	O
total	O
level	O
of	O
t	B
##ria	I
##cy	I
##l	I
##gly	I
##cer	I
##ol	I
was	O
associated	O
with	O
both	O
weight	O
and	O
age	O
which	O
were	O
themselves	O
highly	O
correlated	O
.	O

Eight	O
##een	O
metabolic	O
pathways	O
were	O
defined	O
as	O
disturbed	O
in	O
the	O
plasma	O
and	O
urine	O
profiles	O
of	O
cancer	O
cache	O
##xia	O
patients	O
,	O
including	O
the	O
synthesis	O
and	O
degradation	O
of	O
v	B
##ali	I
##ne	I
,	O
le	B
##uc	I
##ine	I
and	O
is	B
##ole	I
##uc	I
##ine	I
,	O
l	B
##ys	I
##ine	I
,	O
and	O
k	B
##eton	I
##e	I
bodies	O
;	O
the	O
c	B
##it	I
##rate	I
cycle	O
;	O
the	O
metabolism	O
of	O
g	B
##ly	I
##cine	I
,	O
se	B
##rine	I
,	O
th	B
##re	I
##oni	I
##ne	I
,	O
g	B
##lut	I
##amine	I
,	O
g	B
##lut	I
##ama	I
##te	I
,	O
ta	B
##uri	I
##ne	I
,	O
p	B
##yr	I
##u	I
##vate	I
,	O
al	B
##ani	I
##ne	I
,	O
as	B
##par	I
##tate	I
,	O
g	B
##lut	I
##ama	I
##te	I
,	O
g	B
##ly	I
##cer	I
##oli	I
##pid	I
##s	I
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
but	B
##ano	I
##ate	I
,	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
,	O
in	B
##os	I
##ito	I
##l	I
phosphate	I
,	O
a	B
##rg	I
##ini	I
##ne	I
,	O
pro	B
##line	I
,	O
c	B
##ys	I
##tein	I
##e	I
,	O
and	O
met	B
##hi	I
##oni	I
##ne	I
;	O
and	O
amino	B
##acy	I
##l	I
‐	I
t	I
##RNA	I
bio	O
##sy	O
##nt	O
##hesis	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
also	O
documented	O
that	O
particular	O
bio	O
##mark	O
##ers	O
previously	O
associated	O
with	O
type	O
2	O
diabetes	O
risk	O
(	O
e	O
.	O
g	O
.	O
T	O
##AG	O
##s	O
with	O
lower	O
carbon	O
number	O
or	O
2	B
-	I
amino	I
##adi	I
##pate	I
[	O
,	O
]	O
)	O
are	O
likely	O
to	O
be	O
relevant	O
even	O
before	O
initial	O
g	B
##ly	I
##ca	I
##em	I
##ic	I
per	O
##tur	O
##bation	O
##s	O
.	O

Inc	O
##rease	O
##s	O
in	O
di	B
##ty	I
##ros	I
##ine	I
levels	O
have	O
been	O
associated	O
with	O
path	O
##ologies	O
such	O
as	O
at	O
##her	O
##os	O
##cle	O
##rosis	O
,	O
Alzheimer	O
’	O
s	O
Disease	O
,	O
and	O
so	O
on	O
.	O

Of	O
these	O
,	O
c	B
##it	I
##rate	I
and	O
ad	B
##eno	I
##sin	I
##e	I
remained	O
significant	O
after	O
valid	O
##ation	O
by	O
random	O
per	O
##mu	O
##tation	O
.	O

For	O
(	O
B	O
)	O
and	O
(	O
C	O
)	O
,	O
retention	O
times	O
and	O
ch	O
##roma	O
##to	O
##graphic	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
profiles	O
of	O
P	O
##B	O
##T	O
##Z	O
##16	O
##9	O
,	O
active	O
meta	O
##bol	O
##ites	O
,	O
Met	B
-	I
amino	I
and	O
IS	O
##T	O
##D	O
obtained	O
during	O
experiments	O
were	O
super	O
##im	O
##posed	O
for	O
interpretation	O
.	O

(	O
A	O
)	O
R	O
##OC	O
analysis	O
for	O
discrimination	O
of	O
pre	O
-	O
D	O
##M	O
and	O
N	O
##GR	O
groups	O
by	O
log	O
##istic	O
re	O
##gression	O
model	O
combining	O
20	B
-	I
H	I
##ydro	I
##xy	I
-	I
le	I
##uk	I
##ot	I
##rien	I
##e	I
E	O
##4	O
,	O
L	B
##ys	I
##op	I
##c	I
(	I
20	I
:	I
4	I
)	I
,	O
5	B
-	I
met	I
##ho	I
##xy	I
##try	I
##pta	I
##mine	I
,	O
End	O
##omo	O
##rp	O
##hin	O
-	O
1	O
,	O
L	B
##ys	I
##op	I
##c	I
(	I
20	I
:	I
3	I
)	I
.	O

Extra	O
##ord	O
##ina	O
##rily	O
,	O
significant	O
decreases	O
of	O
se	B
##rine	I
and	O
th	B
##re	I
##oni	I
##ne	I
levels	O
were	O
observed	O
in	O
both	O
o	O
##bes	O
##e	O
women	O
with	O
PC	O
##OS	O
and	O
patients	O
with	O
I	O
##R	O
comparing	O
to	O
the	O
non	O
##obe	O
##se	O
PC	O
##OS	O
subjects	O
and	O
patients	O
with	O
normal	O
insulin	O
sensitivity	O
,	O
respectively	O
.	O

Moreover	O
,	O
from	O
R	O
##OC	O
analysis	O
,	O
ace	B
##ty	I
##l	I
##car	I
##ini	I
##te	I
,	O
he	B
##xa	I
##noy	I
##l	I
##car	I
##ni	I
##tine	I
and	O
o	B
##ct	I
##ano	I
##yl	I
##car	I
##ni	I
##tine	I
were	O
revealed	O
as	O
being	O
the	O
best	O
markers	O
of	O
C	O
##LL	O
,	O
owing	O
to	O
an	O
increased	O
significance	O
when	O
grouped	O
together	O
as	O
a	O
panel	O
of	O
markers	O
.	O

Loss	O
of	O
appetite	O
and	O
morning	O
sickness	O
could	O
also	O
lead	O
to	O
lower	O
intake	O
##s	O
of	O
diet	O
##ary	O
ch	B
##olin	I
##e	I
and	O
l	B
-	I
car	I
##ni	I
##tine	I
,	O
particularly	O
in	O
the	O
first	O
and	O
second	O
trim	O
##ester	O
##s	O
.	O

Di	O
##os	O
##met	O
##in	O
-	O
3	O
-	O
O	O
-	O
g	O
##lu	O
##cu	O
##ron	O
##ide	O
was	O
identified	O
as	O
a	O
major	O
circulating	O
meta	O
##bol	O
##ite	O
of	O
di	B
##os	I
##met	I
##in	I
in	O
plasma	O
and	O
in	O
urine	O
,	O
and	O
this	O
finding	O
was	O
confirmed	O
by	O
supplement	O
##ary	O
experiments	O
with	O
differential	O
ion	O
-	O
mobility	O
mass	O
s	O
##pect	O
##rome	O
##try	O
.	O

Tri	O
##vial	O
differences	O
were	O
observed	O
between	O
normal	O
and	O
tumor	O
pro	O
##state	O
p	O
##hos	O
##ph	O
##ory	O
##lation	O
levels	O
of	O
most	O
g	B
##ly	I
##co	I
##ly	I
##tic	I
enzymes	O
except	O
glucose	B
6	I
-	I
phosphate	I
is	O
##omer	O
##ase	O
(	O
G	O
##6	O
##PI	O
)	O
;	O
nevertheless	O
,	O
the	O
impact	O
of	O
elevated	O
p	O
##hos	O
##ph	O
##ory	O
##lation	O
on	O
the	O
activity	O
of	O
G	O
##6	O
##PI	O
is	O
uncertain	O
.	O

Gang	B
##lio	I
##side	I
##s	I
are	O
g	B
##ly	I
##cos	I
##phi	I
##ngo	I
##lip	I
##ids	I
containing	O
si	B
##ali	I
##c	I
acid	I
found	O
mainly	O
in	O
the	O
plasma	O
membrane	O
and	O
having	O
functions	O
in	O
cell	O
recognition	O
and	O
signalling	O
.	O

Furthermore	O
,	O
su	B
##cci	I
##nate	I
also	O
decreased	O
to	O
a	O
normal	O
level	O
together	O
with	O
ATP	S
and	O
p	B
##hos	I
##ph	I
##oc	I
##rea	I
##tine	I
after	O
30	O
min	O
.	O

In	O
total	O
,	O
eight	O
meta	O
##bol	O
##ites	O
were	O
significantly	O
altered	O
between	O
the	O
N	O
##DM	O
##M	O
and	O
the	O
MG	O
##US	O
group	O
,	O
including	O
free	O
car	B
##ni	I
##tine	I
,	O
ace	B
##ty	I
##l	I
##car	I
##ni	I
##tine	I
,	O
g	B
##lut	I
##ama	I
##te	I
,	O
AD	B
##MA	I
,	O
and	O
four	O
PC	O
##s	O
species	O
(	O
and	O
Part	O
D	O
in	O
)	O
.	O

The	O
effect	O
of	O
supplement	O
##ation	O
on	O
AD	B
##MA	I
and	O
SD	O
##MA	O
concentrations	O
at	O
34	O
w	O
##k	O
in	O
Guatemala	O
was	O
not	O
replica	O
##ted	O
in	O
Pakistan	O
.	O

Line	O
##ar	O
re	O
##gression	O
showed	O
that	O
the	O
significant	O
de	O
##ter	O
##mina	O
##nts	O
of	O
u	O
##rina	O
##ry	O
beta	O
##ine	O
/	O
C	O
##r	O
were	O
u	O
##rina	O
##ry	O
glucose	S
(	O
p	O
=	O
0	O
.	O
02	O
##1	O
)	O
and	O
type	O
of	O
diabetes	O
(	O
p	O
=	O
0	O
.	O
03	O
##8	O
)	O
.	O

The	O
ch	B
##lor	I
##of	I
##orm	I
layers	O
from	O
the	O
two	O
extraction	O
##s	O
were	O
combined	O
and	O
dried	O
under	O
nitrogen	O
flow	O
.	O

SM	O
##V	O
,	O
SM	O
##V	O
-	O
A	O
,	O
AT	O
##V	O
,	O
2	B
-	I
OH	I
-	I
AT	I
##V	I
,	O
4	O
##OH	O
-	O
AT	O
##V	O
,	O
RS	O
##V	O
and	O
flu	B
##vas	I
##tat	I
##in	I
(	O
internal	O
standard	O
;	O
IS	O
)	O
were	O
separated	O
on	O
AC	O
##Q	O
##UI	O
##TY	O
UP	O
##LC	O
B	O
##E	O
##H	O
C	O
##18	O
column	O
(	O
2	O
.	O
1	O
×	O
100	O
mm	O
I	O
.	O
D	O
.	O
,	O
1	O
.	O
7	O
μ	O
##m	O
)	O
.	O

For	O
injection	O
,	O
samples	O
were	O
re	O
##con	O
##stituted	O
in	O
50	O
μ	O
##L	O
of	O
5	O
%	O
a	O
##que	O
##ous	O
CH	O
_	O
3	O
C	O
##N	O
with	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
.	O

Sub	O
##jects	O
were	O
in	O
a	O
rested	O
,	O
fast	O
##ing	O
state	O
and	O
blood	O
was	O
taken	O
from	O
the	O
ant	O
##ec	O
##ubi	O
##tal	O
vein	O
and	O
collected	O
in	O
10	O
m	O
##l	O
B	O
##D	O
et	B
##hyl	I
##ened	I
##iam	I
##ine	I
-	I
te	I
##tra	I
-	I
ace	I
##tic	I
acid	I
(	O
E	O
##D	O
##TA	O
)	O
blood	O
tubes	O
(	O
Southern	O
S	O
##yr	O
##inge	O
Services	O
L	O
##T	O
##D	O
)	O
.	O

Cell	O
##s	O
were	O
culture	O
##d	O
in	O
D	O
##ME	O
##M	O
containing	O
10	O
%	O
(	O
v	O
/	O
v	O
)	O
F	O
##BS	O
,	O
100	O
units	O
/	O
m	O
##L	O
pen	B
##ici	I
##llin	I
,	O
and	O
100	O
g	O
/	O
m	O
##L	O
s	B
##tre	I
##pt	I
##omy	I
##cin	I
.	O

In	O
this	O
study	O
in	O
which	O
we	O
anal	O
##ys	O
##ed	O
plasma	O
samples	O
from	O
individuals	O
several	O
years	O
before	O
onset	O
of	O
the	O
disease	O
the	O
results	O
would	O
suggest	O
a	O
lack	O
of	O
increased	O
activity	O
of	O
ID	O
##O	O
,	O
or	O
activation	O
of	O
the	O
compensation	O
for	O
try	B
##pt	I
##op	I
##han	I
degradation	O
that	O
manages	O
to	O
rest	O
##rain	O
de	O
##ple	O
##tion	O
of	O
its	O
levels	O
in	O
plasma	O
.	O

Important	O
##ly	O
,	O
the	O
gene	O
AC	O
##AC	O
##A	O
was	O
directly	O
associated	O
with	O
long	O
p	O
##oly	O
##uns	O
##at	O
##ura	O
##ted	O
D	O
##AG	O
##s	O
in	O
the	O
g	O
##lo	O
##mer	O
##ular	O
compartment	O
and	O
with	O
low	O
-	O
double	O
-	O
bond	O
intermediate	B
-	I
length	I
T	O
##AG	O
##s	O
in	O
the	O
tub	O
##ulo	O
##int	O
##ers	O
##ti	O
##tial	O
compartment	O
.	O

Total	O
ch	B
##ole	I
##ster	I
##ol	I
and	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
were	O
measured	O
by	O
routine	O
en	O
##zy	O
##matic	O
methods	O
(	O
Roche	O
/	O
Hit	O
##achi	O
cat	O
.	O

Quality	O
controls	O
(	O
Q	O
##C	O
’	O
s	O
)	O
were	O
derived	O
from	O
pool	O
##ing	O
all	O
samples	O
and	O
serial	O
##ly	O
di	O
##lut	O
##ing	O
with	O
ch	B
##lor	I
##of	I
##orm	I
.	O

m	O
,	O
al	B
##ani	I
##ne	I
,	O
as	B
##par	I
##tate	I
and	O
g	B
##lut	I
##ama	I
##te	I
metabolism	O
;	O
n	O
,	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
metabolism	O
.	O

All	O
but	O
o	B
##ct	I
##eno	I
##yl	I
##car	I
##ni	I
##tine	I
(	I
C	I
##8	I
:	I
1	I
)	I
were	O
increased	O
during	O
sleep	O
de	O
##p	O
##ri	O
##vation	O
compared	O
with	O
during	O
sleep	O
.	O

A	O
##bb	O
##re	O
##viation	O
##s	O
:	O
MS	O
##A	O
:	O
multiple	O
system	O
at	O
##rop	O
##hy	O
;	O
FA	S
:	O
fatty	O
acid	O
;	O
D	O
##H	O
##EA	O
##S	O
:	O
de	B
##hy	I
##dr	I
##ois	I
##oan	I
##dr	I
##osterone	I
3	I
-	I
su	I
##lf	I
##ate	I
;	O
L	B
##ys	I
##o	I
##PC	I
(	I
16	I
:	I
0	I
)	I
:	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
(	I
16	I
:	I
0	I
)	I
;	O
Met	O
:	O
met	B
##hi	I
##oni	I
##ne	I
.	O

Sub	O
##jects	O
with	O
stable	O
as	O
##th	O
##ma	O
and	O
a	O
base	O
##line	O
F	O
##E	O
##V	O
_	O
1	O
≥	O
50	O
%	O
predicted	O
values	O
underwent	O
met	B
##ha	I
##cho	I
##line	I
challenge	O
in	O
accordance	O
with	O
American	O
Thor	O
##ac	O
##ic	O
Society	O
standards	O
.	O

D	O
##H	O
##EA	O
,	O
A	O
##ED	O
,	O
A	O
##ET	O
and	O
7	B
-	I
o	I
##x	I
##o	I
-	I
D	I
##H	I
##EA	I
were	O
determined	O
both	O
in	O
the	O
laboratory	O
of	O
reference	O
and	O
the	O
secondary	O
laboratory	O
,	O
and	O
then	O
the	O
results	O
obtained	O
were	O
compared	O
by	O
correlation	O
analysis	O
.	O

Sur	O
##p	O
##rising	O
##ly	O
,	O
we	O
found	O
that	O
o	B
##me	I
##ga	I
-	I
3	I
FA	O
##s	O
were	O
predict	O
##ors	O
of	O
insulin	O
resistance	O
.	O

The	O
novel	O
g	B
##lu	I
##cu	I
##ron	I
##ide	I
meta	O
##bol	O
##ites	O
el	O
##ute	O
at	O
t	O
_	O
R	O
13	O
.	O
9	O
–	O
14	O
.	O
6	O
min	O
,	O
the	O
t	O
_	O
R	O
of	O
H	O
##ON	O
-	O
Ph	O
##IP	O
-	O
N	O
_	O
2	O
-	O
G	O
##l	O
is	O
16	O
.	O
7	O
min	O
;	O
and	O
t	O
_	O
R	O
of	O
H	O
##ON	O
-	O
Ph	O
##IP	O
-	O
N	O
3	O
-	O
G	O
##l	O
is	O
20	O
.	O
1	O
min	O
.	O

C	O
_	O
27	O
bi	O
##le	O
acids	O
,	O
including	O
3	B
##β	I
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##t	I
-	I
5	I
-	I
en	I
-	I
26	I
-	I
o	I
##ic	I
acid	I
,	O
3	B
##β	I
,	I
7	I
##α	I
-	I
di	I
##hy	I
##dr	I
##ox	I
##ych	I
##ole	I
##st	I
-	I
5	I
-	I
en	I
-	I
26	I
-	I
o	I
##ic	I
,	O
and	O
7	B
##α	I
-	I
h	I
##ydro	I
##xy	I
-	I
3	I
-	I
o	I
##x	I
##och	I
##ole	I
##st	I
-	I
4	I
-	I
en	I
-	I
26	I
-	I
o	I
##ic	I
acid	I
,	O
are	O
prevalent	O
in	O
blood	O
(	O
,	O
)	O
(	O
see	O
supplement	O
##al	O
Table	O
S	O
##1	O
)	O
and	O
have	O
been	O
identified	O
in	O
cells	O
of	O
the	O
rode	O
##nt	O
central	O
nervous	O
system	O
following	O
in	O
##cu	O
##bation	O
with	O
27	B
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
,	O
whereas	O
7	B
##α	I
-	I
h	I
##ydro	I
##xy	I
-	I
3	I
-	I
o	I
##x	I
##och	I
##ole	I
##st	I
-	I
4	I
-	I
en	I
-	I
26	I
-	I
o	I
##ic	I
acid	I
has	O
been	O
identified	O
as	O
an	O
export	O
product	O
from	O
human	O
brain	O
into	O
plasma	O
.	O

M	B
##T	I
##BE	I
,	O
2	O
m	O
##l	O
per	O
sample	O
,	O
was	O
added	O
to	O
each	O
tube	O
,	O
v	O
##ortex	O
##ed	O
to	O
mix	O
,	O
and	O
in	O
##cu	O
##bate	O
##d	O
at	O
room	O
temperature	O
for	O
10	O
minutes	O
to	O
allow	O
the	O
proteins	O
to	O
pre	O
##ci	O
##pit	O
##ate	O
.	O

Take	O
##n	O
together	O
,	O
the	O
metabolic	O
pathways	O
involving	O
c	B
##ys	I
##tein	I
##e	I
,	O
c	B
##ys	I
##te	I
##amine	I
,	O
and	O
ta	B
##uri	I
##ne	I
might	O
be	O
useful	O
for	O
different	O
##iating	O
between	O
color	O
##ec	O
##tal	O
cancer	O
patients	O
and	O
healthy	O
volunteers	O
.	O

AD	B
##MA	I
could	O
also	O
contribute	O
to	O
o	O
##xi	O
##da	O
##tive	O
stress	O
by	O
causing	O
end	O
##oth	O
##eli	O
##al	O
ni	B
##tric	I
oxide	I
s	O
##ynth	O
##ase	O
(	O
e	O
##N	O
##OS	O
)	O
un	O
##co	O
##up	O
##ling	O
.	O

During	O
the	O
measurements	O
,	O
the	O
subject	O
remained	O
in	O
su	B
##pine	I
position	O
within	O
the	O
s	O
##pect	O
##rome	O
##ter	O
.	O

The	O
entire	O
sample	O
mixture	O
with	O
pre	O
##ci	O
##pit	O
##ate	O
was	O
then	O
loaded	O
to	O
the	O
SP	O
##E	O
96	O
-	O
well	O
plate	O
,	O
and	O
r	O
##ins	O
##ed	O
by	O
a	O
two	O
-	O
step	O
process	O
of	O
1000	O
μ	O
##l	O
of	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
,	O
followed	O
by	O
1000	O
μ	O
##l	O
of	O
7	O
%	O
water	O
in	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
.	O

Cell	O
##s	O
were	O
harvested	O
72	O
h	O
after	O
p	O
##lating	O
,	O
and	O
meta	O
##bol	O
##ites	O
were	O
extracted	O
with	O
80	O
%	O
met	B
##han	I
##ol	I
.	O

A	O
similar	O
graded	O
increase	O
in	O
risk	O
was	O
observed	O
when	O
levels	O
of	O
T	B
##MA	I
##O	I
were	O
analyzed	O
as	O
a	O
continuous	O
variable	O
in	O
in	O
##cre	O
##ments	O
of	O
1	O
SD	O
(	O
un	O
##ad	O
##ju	O
##sted	O
hazard	O
ratio	O
,	O
1	O
.	O
40	O
[	O
95	O
%	O
C	O
##I	O
,	O
1	O
.	O
29	O
to	O
1	O
.	O
51	O
;	O
P	O
<	O
0	O
.	O
00	O
##1	O
]	O
;	O
adjusted	O
hazard	O
ratio	O
,	O
1	O
.	O
30	O
[	O
95	O
%	O
C	O
##I	O
,	O
1	O
.	O
20	O
to	O
1	O
.	O
41	O
;	O
P	O
<	O
0	O
.	O
00	O
##1	O
]	O
)	O
.	O

The	O
single	O
chemical	O
der	O
##iva	O
##ti	O
##zation	O
added	O
a	O
dans	O
##yl	O
group	O
(	O
1	O
-	O
dim	O
##eth	O
##yl	O
-	O
amino	O
-	O
nap	O
##ht	O
##hale	O
##ne	O
-	O
5	O
-	O
su	O
##lf	O
##ony	O
##l	O
)	O
to	O
the	O
p	O
##hen	O
##olic	O
h	O
##ydro	O
##xy	O
##l	O
present	O
on	O
all	O
est	O
##rogen	O
##s	O
and	O
est	B
##rogen	I
meta	O
##bol	O
##ites	O
.	O

C	O
##luster	O
one	O
contained	O
a	O
diverse	O
group	O
of	O
elevated	O
meta	O
##bol	O
##ites	O
including	O
several	O
predicted	O
shorter	O
-	O
chain	O
organic	O
molecules	O
(	O
containing	O
11	O
to	O
21	O
carbon	O
##s	O
)	O
,	O
a	O
predicted	O
t	B
##ria	I
##cy	I
##l	I
##gy	I
##cer	I
##ol	I
,	O
and	O
a	O
put	O
##ative	O
ad	O
##eno	O
##sin	O
##e	O
-	O
related	O
meta	O
##bol	O
##ite	O
.	O

Overall	O
,	O
the	O
separation	O
of	O
meta	O
##bol	O
##ites	O
into	O
lip	O
##id	O
and	O
h	B
##ydro	I
##phi	I
##lic	I
fraction	O
##s	O
using	O
M	B
##T	I
##BE	I
prior	O
to	O
analysis	O
significantly	O
increases	O
coverage	O
by	O
1	O
,	O
26	O
##8	O
lip	O
##ids	O
and	O
61	O
##2	O
h	B
##ydro	I
##phi	I
##lic	I
compounds	O
compared	O
to	O
the	O
met	B
##han	I
##ol	I
precipitation	O
method	O
in	O
positive	O
mode	O
.	O

Three	O
of	O
them	O
—	O
p	O
-	O
c	O
##res	O
##ol	O
su	B
##lf	I
##ate	I
,	O
in	B
##dox	I
##yl	I
su	I
##lf	I
##ate	I
,	O
and	O
p	O
##hen	O
##yla	O
##ce	O
##ty	O
##l	O
##g	O
##lut	O
##amine	O
—	O
had	O
previously	O
been	O
identified	O
as	O
co	O
##lon	O
-	O
derived	O
[	O
]	O
.	O

Mass	O
##es	O
corresponding	O
to	O
cafe	O
##sto	O
##l	O
and	O
ka	O
##h	O
##we	O
##ol	O
,	O
the	O
well	O
-	O
known	O
coffee	O
di	B
##ter	I
##pen	I
##oids	I
,	O
were	O
not	O
observed	O
among	O
the	O
disc	O
##rim	O
##ina	O
##nts	O
,	O
although	O
a	O
feature	O
at	O
[	O
M	O
+	O
H	O
]	O
_	O
+	O
32	O
##9	O
was	O
tentatively	O
identified	O
as	O
a	O
ka	O
##h	O
##we	O
##ol	O
oxide	B
g	I
##lu	I
##cu	I
##ron	I
##ide	I
.	O

To	O
predict	O
the	O
presence	O
of	O
cache	O
##xia	O
,	O
a	O
diagnostic	O
model	O
was	O
established	O
based	O
on	O
three	O
meta	O
##bol	O
##ites	O
,	O
namely	O
,	O
car	B
##nos	I
##ine	I
,	O
le	B
##uc	I
##ine	I
,	O
and	O
p	B
##hen	I
##yl	I
ace	I
##tate	I
,	O
with	O
high	O
accuracy	O
and	O
confirmation	O
by	O
the	O
valid	O
##ation	O
set	O
(	O
94	O
.	O
64	O
%	O
by	O
diagnostic	O
feature	O
)	O
.	O

The	O
subjects	O
of	O
this	O
co	O
##hor	O
##t	O
were	O
type	O
2	O
diabetes	O
patients	O
with	O
a	O
disease	O
duration	S
of	O
15	O
years	O
or	O
more	O
.	O

Consequently	O
,	O
glucose	S
levels	O
had	O
dropped	O
by	O
2	O
.	O
2	O
mm	O
##ol	O
/	O
l	O
for	O
S	O
##9	O
and	O
3	O
.	O
4	O
mm	O
##ol	O
/	O
l	O
for	O
16	O
##H	O
##BE	O
##14	O
##o	O
_	O
−	O
cells	O
after	O
two	O
hours	O
of	O
cultivation	O
under	O
control	O
conditions	O
.	O

Met	O
##ab	O
##olis	O
##m	O
of	O
the	O
production	O
of	O
car	B
##nos	I
##ine	I
from	O
β	B
-	I
al	I
##ani	I
##ne	I
.	O

The	O
bio	O
##mark	O
##er	O
candidate	O
contains	O
gal	B
##act	I
##ose	I
as	O
a	O
sa	B
##cc	I
##hari	I
##de	I
in	O
addition	O
to	O
glucose	S
.	O

About	O
50	O
%	O
of	O
a	O
me	B
##per	I
##id	I
##ine	I
dose	O
is	O
ex	O
##cre	O
##ted	O
in	O
acidic	O
urine	O
as	O
me	B
##per	I
##id	I
##ine	I
and	O
norm	B
##eper	I
##id	I
##ine	I
,	O
but	O
only	O
5	O
%	O
of	O
the	O
total	O
dose	O
is	O
eliminated	O
in	O
al	B
##kal	I
##ine	I
urine	O
.	O

The	O
meta	O
##bol	O
##ites	O
are	O
categorized	O
as	O
several	O
classes	O
of	O
compounds	O
according	O
to	O
the	O
chemical	O
tax	O
##onomy	O
:	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
,	O
s	B
##phi	I
##ngo	I
##ph	I
##os	I
##ph	I
##oli	I
##pid	I
##s	I
and	O
ch	B
##ole	I
##ster	I
##ol	I
meta	O
##bol	O
##ites	O
.	O

As	O
a	O
consequence	O
,	O
glucose	S
transport	O
activity	O
and	O
other	O
events	O
downstream	O
of	O
insulin	O
receptor	O
signaling	O
are	O
diminished	O
.	O

We	O
also	O
noticed	O
that	O
,	O
is	O
##onic	O
##ot	O
##ini	O
##c	O
acid	O
(	O
a	O
breakdown	O
product	O
of	O
is	O
##onia	O
##zi	O
##d	O
and	O
h	B
##yd	I
##raz	I
##ine	I
derivatives	O
,	O
which	O
is	O
found	O
only	O
in	O
individuals	O
that	O
have	O
taken	O
is	O
##onia	O
##zi	O
##d	O
and	O
other	O
h	B
##yd	I
##raz	I
##ine	I
derivatives	O
as	O
a	O
drug	O
)	O
appears	O
to	O
be	O
mistaken	O
for	O
t	B
##rig	I
##one	I
##llin	I
##e	I
.	O

A	O
n	O
##uc	O
##leo	O
##side	O
,	O
put	O
##ative	O
##ly	O
identified	O
as	O
N	B
-	I
form	I
##yl	I
-	I
c	I
##yt	I
##id	I
##ine	I
(	O
m	O
/	O
z	O
272	O
,	O
R	O
##T	O
2	O
.	O
52	O
min	O
)	O
,	O
was	O
found	O
using	O
positive	O
neutral	O
loss	O
scan	O
of	O
m	O
/	O
z	O
132	O
on	O
A	O
##c	O
##qui	O
##ty	O
UP	O
##LC	O
-	O
4000	O
Q	O
##T	O
##rap	O
MS	O
in	O
pool	O
##ed	O
urine	O
from	O
cc	O
##RC	O
##C	O
patients	O
(	O
orange	O
line	O
)	O
two	O
-	O
folds	O
higher	O
than	O
in	O
post	O
-	O
operative	O
controls	O
(	O
grey	O
line	O
)	O

Individual	O
and	O
grouped	O
est	O
##rogen	O
##s	O
and	O
est	B
##rogen	I
meta	O
##bol	O
##ites	O
were	O
log	O
-	O
transformed	O
using	O
base	O
1	O
.	O
2	O
because	O
in	O
the	O
study	O
co	O
##hor	O
##t	O
,	O
serum	O
concentrations	O
increased	O
by	O
approximately	O
20	O
%	O
between	O
the	O
10th	O
and	O
90	O
##th	O
percent	O
##iles	O
for	O
most	O
of	O
these	O
measures	O
.	O

We	O
also	O
observed	O
a	O
decrease	O
in	O
g	B
##ly	I
##cer	I
##ol	I
##ph	I
##os	I
##ph	I
##och	I
##olin	I
##e	I
(	O
GP	O
##C	O
)	O
and	O
p	B
##hos	I
##ph	I
##och	I
##olin	I
##e	I
(	O
PC	O
)	O
levels	O
in	O
the	O
AL	O
##D	O
##H	O
##7	O
##A	O
##1	O
-	O
depleted	O
cells	O
(	O
Fi	O
##g	O
.	O
d	O
)	O
.	O

Following	O
si	B
##m	I
##vas	I
##tat	I
##in	I
treatment	O
,	O
a	O
significant	O
decrease	O
was	O
found	O
in	O
plasma	O
levels	O
of	O
ch	B
##ole	I
##ster	I
##ol	I
(	O
p	O
<	O
0	O
.	O
00	O
##27	O
,	O
q	O
<	O
0	O
.	O
05	O
##5	O
)	O
,	O
alpha	B
-	I
to	I
##co	I
##pher	I
##ol	I
(	O
p	O
<	O
0	O
.	O
000	O
##3	O
,	O
q	O
<	O
0	O
.	O
01	O
##7	O
)	O
,	O
and	O
gamma	B
-	I
to	I
##co	I
##pher	I
##ol	I
(	O
p	O
<	O
0	O
.	O
03	O
##7	O
,	O
q	O
<	O
0	O
.	O
13	O
)	O
,	O
(	O
vitamin	O
E	O
)	O
,	O
and	O
la	B
##uri	I
##c	I
acid	I
(	O
p	O
<	O
0	O
.	O
00	O
##55	O
,	O
q	O
<	O
0	O
.	O
05	O
##5	O
)	O
.	O

Pat	O
##ients	O
with	O
higher	O
try	B
##pt	I
##op	I
##han	I
level	O
tended	O
to	O
present	O
higher	O
degree	O
of	O
insulin	O
resistance	O
and	O
secret	O
##ion	O
,	O
t	B
##rig	I
##ly	I
##cer	I
##ide	I
and	O
blood	O
pressure	O
.	O

Regarding	O
diet	O
composition	O
,	O
recent	O
research	O
revealed	O
that	O
changes	O
in	O
mac	O
##ron	O
##ut	O
##rient	O
intake	O
can	O
influence	O
lip	O
##id	O
and	O
fatty	O
acid	O
chain	O
in	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
.	O

The	O
finding	O
of	O
a	O
significant	O
association	O
between	O
24	B
##S	I
-	I
OH	I
-	I
Cho	I
##l	I
and	O
CR	O
##P	O
levels	O
suggest	O
a	O
possible	O
link	O
between	O
the	O
degree	O
of	O
ne	O
##uro	O
##de	O
##gene	O
##ration	O
(	O
plasma	O
24	B
##S	I
-	I
OH	I
-	I
Cho	I
##l	I
would	O
be	O
a	O
marker	O
of	O
it	O
)	O
and	O
the	O
degree	O
of	O
peripheral	O
systemic	O
inflammation	O
.	O

Only	O
the	O
recovery	O
of	O
f	B
##olic	I
acid	I
and	O
ad	B
##eni	I
##ne	I
increased	O
when	O
the	O
second	O
extraction	O
step	O
is	O
included	O
.	O

Ph	B
##os	I
##ph	I
##ope	I
##pt	I
##ides	I
were	O
en	O
##rich	O
##ed	O
with	O
h	B
##ydro	I
##xy	I
acid	O
-	O
modified	O
metal	O
oxide	O
ch	O
##roma	O
##tography	O
(	O
H	O
##AM	O
##MO	O
##C	O
)	O
(	O
K	O
##yon	O
##o	O
et	O
al	O
.	O
;	O
Su	O
##gi	O
##yama	O
et	O
al	O
.	O
)	O
.	O

Level	O
##s	O
of	O
Ce	B
##ram	I
##ides	I
in	O
breast	O
cancer	O
and	O
normal	O
breast	O
tissue	O
.	O

C	O
##K	O
##D	O
-	O
EP	O
##I	O
takes	O
as	O
input	O
serum	O
c	B
##rea	I
##tin	I
##ine	I
(	O
c	O
##rea	O
)	O
,	O
age	O
,	O
gender	O
,	O
and	O
race	O
.	O

N	O
##P	O
smoke	O
##rs	O
also	O
had	O
a	O
higher	O
mean	O
rate	O
of	O
ni	B
##cot	I
##ine	I
metabolism	O
compared	O
to	O
smoke	O
##rs	O
from	O
other	O
ethnic	O
groups	O
,	O
including	O
Alaska	O
Native	O
,	O
Caucasian	O
,	O
and	O
African	O
American	O
smoke	O
##rs	O
,	O
whose	O
N	O
##MR	O
had	O
been	O
previously	O
assessed	O
[	O
,	O
,	O
]	O
.	O

b	O
,	O
binding	O
a	O
##ffin	O
##ities	O
of	O
β	B
-	I
a	I
##po	I
##car	I
##ote	I
##no	I
##ids	I
to	O
R	O
##X	O
##R	O
##α	O
calculated	O
from	O
the	O
data	O
shown	O
in	O
a	O
.	O

For	O
the	O
duration	S
of	O
our	O
h	O
##ydro	O
##lysis	O
studies	O
,	O
no	O
change	O
in	O
J	O
##W	O
##H	O
-	O
01	O
##8	O
pen	B
##tano	I
##ic	I
acid	I
peak	O
areas	O
was	O
observed	O
.	O

The	O
s	B
##phi	I
##ngo	I
##lip	I
##id	I
level	O
is	O
reportedly	O
regulated	O
during	O
the	O
acute	O
phase	O
of	O
the	O
response	O
to	O
inflammation	O
,	O
and	O
increases	O
in	O
Ce	B
##r	I
and	O
s	B
##phi	I
##ngo	I
##sin	I
##e	I
lead	O
to	O
the	O
up	O
##re	O
##gu	O
##lation	O
of	O
different	O
acute	O
-	O
phase	O
proteins	O
.	O

Results	O
showed	O
that	O
IS	O
en	O
##rich	O
##ment	O
with	O
O	O
##asis	O
H	O
##L	O
##B	O
prime	O
cartridges	O
gives	O
the	O
highest	O
percentage	O
recovery	O
values	O
for	O
24	B
-	I
OH	I
##C	I
##d	I
##7	I
,	I
25	I
-	I
OH	I
##C	I
##d	I
##6	I
,	I
27	I
-	I
OH	I
##C	I
##d	I
##6	I
,	I
7	I
##β	I
-	I
OH	I
##C	I
##d	I
##7	I
,	O
and	O
7	O
-	O
KC	O
##d	O
##7	O
(	O
77	O
.	O
60	O
%	O
,	O
81	O
.	O
80	O
%	O
,	O
80	O
.	O
65	O
%	O
,	O
72	O
.	O
04	O
%	O
,	O
and	O
89	O
.	O
86	O
%	O
respectively	O
)	O
in	O
plasma	O
,	O
compared	O
to	O
the	O
O	O
##asis	O
H	O
##L	O
##B	O
(	O
72	O
.	O
11	O
%	O
,	O
74	O
.	O
11	O
%	O
,	O
76	O
.	O
70	O
%	O
,	O
41	O
.	O
58	O
%	O
,	O
and	O
79	O
.	O
10	O
%	O
)	O
and	O
C	O
##18	O
cartridges	O
(	O
10	O
.	O
16	O
%	O
,	O
8	O
.	O
11	O
%	O
,	O
20	O
.	O
50	O
%	O
,	O
12	O
.	O
12	O
%	O
,	O
and	O
15	O
.	O
66	O
%	O
)	O
.	O

Hence	O
,	O
we	O
s	O
##pec	O
##ulate	O
that	O
enhanced	O
expression	O
level	O
of	O
car	B
##nos	I
##ine	I
may	O
be	O
beneficial	O
for	O
CO	O
##PD	O
patients	O
to	O
s	O
##ca	O
##venge	O
R	O
##OS	O
and	O
α	O
,	O
β	B
-	I
un	I
##sat	I
##ura	I
##ted	I
al	I
##de	I
##hy	I
##des	I
generated	O
by	O
lip	O
##id	O
per	O
##ox	O
##ida	O
##tion	O
during	O
o	O
##xi	O
##da	O
##tive	O
stress	O
.	O

In	O
multiple	O
species	O
of	O
yeast	O
,	O
ni	B
##ac	I
##in	I
transport	O
##ers	O
have	O
been	O
characterized	O
and	O
shown	O
to	O
be	O
up	O
##re	O
##gu	O
##lated	O
in	O
ni	B
##ac	I
##in	I
starvation	O
conditions	O
,	O
.	O

Although	O
the	O
concentrations	O
of	O
try	B
##pt	I
##op	I
##han	I
and	O
k	B
##yn	I
##uren	I
##ine	I
did	O
not	O
change	O
greatly	O
,	O
increased	O
relative	O
concentration	O
of	O
3	B
-	I
h	I
##ydro	I
##xy	I
##ky	I
##nu	I
##ren	I
##ine	I
in	O
the	O
PD	O
group	O
was	O
observed	O
.	O

Heat	O
map	O
based	O
on	O
Pearson	O
'	O
s	O
correlation	O
##s	O
between	O
fast	O
##ing	O
g	B
##ly	I
##cer	I
##oli	I
##pid	I
##s	I
,	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
,	O
and	O
ch	B
##ole	I
##ster	I
##ol	I
est	I
##ers	I
common	O
in	O
plasma	O
and	O
muscle	O
.	O

Only	O
one	O
participant	O
had	O
low	O
serum	O
f	B
##olate	I
(	O
<	O
10	O
nm	O
##ol	O
/	O
L	O
)	O
at	O
base	O
##line	O
.	O

Also	O
for	O
11	B
##β	I
-	I
OH	I
-	I
et	I
##io	I
##cho	I
##lan	I
##olo	I
##ne	I
,	O
which	O
derives	O
mainly	O
from	O
the	O
metabolism	O
of	O
co	B
##rt	I
##is	I
##ol	I
,	O
our	O
results	O
suggest	O
a	O
different	O
age	O
-	O
related	O
behaviour	O
for	O
men	O
and	O
women	O
.	O

Pre	O
##g	O
-	O
S	O
is	O
synthesized	O
from	O
pre	B
##gne	I
##no	I
##lone	I
,	O
which	O
is	O
a	O
precursor	O
to	O
all	O
s	O
##tero	O
##id	O
hormones	O
,	O
and	O
D	O
##H	O
##EA	O
##S	O
is	O
produced	O
from	O
D	O
##H	O
##EA	O
,	O
which	O
occurs	O
upstream	O
of	O
sex	O
hormones	O
in	O
s	O
##tero	O
##ido	O
##genesis	O
.	O

However	O
,	O
the	O
sum	O
of	O
g	B
##lut	I
##amine	I
and	O
p	B
##yr	I
##og	I
##lut	I
##ami	I
##c	I
acid	I
concentrations	O
in	O
each	O
sample	O
remains	O
the	O
same	O
for	O
all	O
portions	O
.	O

Cell	O
##s	O
were	O
in	O
##cu	O
##bate	O
##d	O
with	O
uniform	O
##ly	O
labeled	O
_	O
13	O
C	B
_	I
16	I
-	I
palm	I
##itate	I
,	O
and	O
the	O
abundance	O
of	O
_	O
13	O
C	O
-	O
labeled	O
palm	B
##ito	I
##yl	I
-	I
car	I
##ni	I
##tine	I
(	O
C	O
##16	O
)	O
,	O
my	B
##risto	I
##yl	I
-	I
car	I
##ni	I
##tine	I
(	O
C	O
##14	O
)	O
and	O
la	B
##uro	I
##yl	I
-	I
car	I
##ni	I
##tine	I
(	O
C	O
##12	O
)	O
were	O
measured	O
by	O
ultra	O
-	O
high	O
-	O
performance	O
liquid	O
ch	O
##roma	O
##tography	O
-	O
tandem	O
mass	O
s	O
##pect	O
##rome	O
##try	O
(	O
UP	O
##LC	O
-	O
MS	O
/	O
MS	O
;	O
Figure	O
E	O
)	O
.	O

Am	B
##mon	I
##ium	I
phosphate	I
at	O
1	O
and	O
2	O
m	O
##M	O
and	O
am	B
##mon	I
##ium	I
hydrogen	I
carbon	I
##ate	I
at	O
10	O
and	O
20	O
m	O
##M	O
were	O
compared	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
signals	O
in	O
the	O
negative	O
direction	O
indicated	O
the	O
down	O
-	O
regulated	O
meta	O
##bol	O
##ites	O
in	O
re	O
##ct	O
##al	O
cancer	O
tissues	O
,	O
including	O
my	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
,	O
ta	B
##uri	I
##ne	I
,	O
p	B
##hos	I
##ph	I
##oc	I
##rea	I
##tine	I
,	O
c	B
##rea	I
##tine	I
,	O
beta	B
##ine	I
and	O
dim	B
##eth	I
##yl	I
##gly	I
##cine	I
.	O

The	O
additional	O
value	O
of	O
MI	O
##D	O
data	O
when	O
compared	O
to	O
is	O
##oto	O
##pe	O
ratios	O
is	O
demonstrated	O
in	O
for	O
g	B
##lut	I
##ama	I
##te	I
.	O

We	O
measured	O
serum	O
vitamin	B
D	I
meta	O
##bol	O
##ites	O
at	O
the	O
1996	O
–	O
1997	O
CH	O
##S	O
study	O
visit	O
(	O
4	O
–	O
7	O
years	O
after	O
base	O
##line	O
)	O
using	O
a	O
case	O
-	O
co	O
##hor	O
##t	O
design	O
.	O

S	B
##phi	I
##ngo	I
##lip	I
##id	I
meta	O
##bol	O
##ites	O
in	O
healthy	O
controls	O
s	O
##tra	O
##ti	O
##fied	O
by	O
sex	O
.	O

The	O
six	O
major	O
sub	O
##c	O
##lass	O
##es	O
are	O
PC	O
,	O
PS	O
,	O
P	O
##E	O
,	O
P	O
##I	O
,	O
P	B
##G	I
,	O
and	O
PA	O
.	O

In	O
##sul	O
##in	O
resistance	O
that	O
develops	O
in	O
ad	O
##ip	O
##ose	O
tissue	O
results	O
in	O
altered	O
ability	O
of	O
insulin	O
signaling	O
ca	O
##sca	O
##de	O
to	O
store	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
.	O

Lower	O
level	O
of	O
le	B
##uc	I
##ine	I
may	O
consequently	O
in	O
##hibit	O
the	O
signaling	O
of	O
m	O
##TO	O
##R	O
and	O
result	O
in	O
the	O
reduction	O
of	O
synthesis	O
of	O
skeletal	O
my	O
##op	O
##rote	O
##in	O
and	O
make	O
F	B
##D	I
patients	O
subject	O
to	O
weight	O
loss	O
and	O
skeletal	O
muscle	O
at	O
##rop	O
##hy	O
.	O

Immediately	O
before	O
measurement	O
,	O
samples	O
were	O
re	O
##hy	O
##dra	O
##ted	O
in	O
200	O
μ	O
##l	O
of	O
50	O
m	O
##M	O
phosphate	S
buffer	O
(	O
pH	O
7	O
.	O
4	O
)	O
in	O
D	O
_	O
2	O
O	O
,	O
and	O
180	O
μ	O
##l	O
was	O
transferred	O
to	O
a	O
3	O
mm	O
N	O
##MR	O
tube	O
.	O

The	O
method	O
was	O
tested	O
and	O
stability	O
was	O
studied	O
in	O
real	O
life	O
patients	O
with	O
meta	O
##static	O
cast	O
##ration	O
-	O
resistant	O
pro	O
##state	O
cancer	O
patients	O
treated	O
with	O
en	B
##zal	I
##uta	I
##mi	I
##de	I
.	O

+	B
[UNK]	B
=	I
[UNK]	B
=	I
1	I
##ρ	I
##s	I
##j	I
(	I
y	I
##j	I
)	I
x	I
##s	I
+	I
[UNK]	B
=	I
[UNK]	B
=	I
1	I
##φ	I
##r	I
##j	I
(	I
y	I
##r	I
,	I
y	I
##j	I
)	I

Conversely	O
,	O
neurons	O
exposed	O
to	O
extra	O
##cellular	O
g	B
##lut	I
##ama	I
##te	I
showed	O
a	O
reduction	O
in	O
den	O
##dr	O
##itic	O
growth	O
that	O
was	O
prevented	O
by	O
administration	O
of	O
K	O
##yn	O
##A	O
.	O
demonstrated	O
that	O
the	O
suppress	O
##ive	O
effects	O
of	O
IL	O
-	O
1	O
on	O
human	O
hip	O
##po	O
##cam	O
##pal	O
pro	O
##gen	O
##itor	O
cells	O
in	O
v	O
##it	O
##ro	O
can	O
be	O
reversed	O
by	O
treatment	O
with	O
a	O
K	O
##MO	O
inhibitor	O
.	O

Thus	O
,	O
there	O
is	O
a	O
common	O
mechanism	O
accounting	O
for	O
the	O
elevated	O
l	B
##ys	I
##og	I
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
levels	O
in	O
E	O
##Vs	O
but	O
it	O
has	O
not	O
yet	O
been	O
el	O
##uc	O
##idated	O
.	O

Level	O
##s	O
of	O
lit	B
##ho	I
##cho	I
##lic	I
acid	I
were	O
significantly	O
enhanced	O
in	O
plasma	O
of	O
AD	O
patients	O
(	O
50	O
±	O
6	O
n	O
##M	O
,	O
p	O
=	O
0	O
.	O
00	O
##4	O
)	O
compared	O
to	O
healthy	O
controls	O
(	O
32	O
±	O
3	O
n	O
##M	O
)	O
.	O

Since	O
we	O
observed	O
alterations	O
in	O
glucose	S
up	O
##take	O
and	O
la	B
##ct	I
##ate	I
secret	O
##ion	O
in	O
M	O
##UC	O
##16	O
knock	O
##down	O
cells	O
,	O
and	O
a	O
corresponding	O
decrease	O
in	O
metabolic	O
gene	O
expression	O
,	O
we	O
next	O
evaluated	O
if	O
these	O
changes	O
were	O
due	O
to	O
decreased	O
signaling	O
activation	O
of	O
upstream	O
regulatory	O
pathways	O
upon	O
M	O
##UC	O
##16	O
knock	O
##down	O
.	O

The	O
principal	O
findings	O
of	O
this	O
study	O
were	O
:	O
(	O
1	O
)	O
12	O
(	O
36	O
%	O
)	O
of	O
33	O
SL	O
##E	O
women	O
developed	O
AP	O
##O	O
;	O
(	O
2	O
)	O
Met	O
##ab	O
##oli	O
##te	O
pro	O
##fi	O
##ling	O
of	O
mid	O
-	O
trim	O
##ester	O
maternal	O
plasma	O
showed	O
distinctive	O
and	O
disc	O
##rim	O
##inator	O
##y	O
metabolic	O
physiology	O
between	O
healthy	O
pregnant	O
controls	O
and	O
SL	O
##E	O
patients	O
;	O
(	O
3	O
)	O
B	O
##io	O
##mark	O
##er	O
panels	O
using	O
a	O
combination	O
of	O
two	O
bio	O
##mark	O
##ers	O
(	O
Try	O
##pt	O
##op	O
##han	O
and	O
L	O
##ys	O
##o	O
##PC	O
C	B
##22	I
:	I
5	I
)	O
in	O
mid	O
-	O
trim	O
##ester	O
maternal	O
plasma	O
accurately	O
predicted	O
an	O
AP	O
##O	O
among	O
pregnant	O
women	O
with	O
SL	O
##E	O
;	O
and	O
(	O
4	O
)	O
The	O
meta	O
##bol	O
##omi	O
##c	O
bio	O
##mark	O
##ers	O
were	O
closely	O
associated	O
with	O
the	O
severity	O
of	O
AP	O
##O	O
in	O
patients	O
with	O
SL	O
##E	O
and	O
AP	O
##O	O
.	O

Another	O
group	O
compared	O
CR	O
##C	O
patients	O
at	O
different	O
stages	O
and	O
observed	O
that	O
in	B
##os	I
##ito	I
##l	I
was	O
less	O
abundant	O
in	O
tissues	O
of	O
CR	O
##C	O
liver	O
meta	O
##sta	O
##sis	O
.	O

Examples	O
for	O
“	O
[UNK]	O
-	O
pattern	O
”	O
are	O
h	B
##ydro	I
##xy	I
##is	I
##ob	I
##ut	I
##yric	I
acid	I
and	O
ace	B
##ty	I
##l	I
##gly	I
##cine	I
.	O

Based	O
on	O
the	O
volcano	O
plot	O
,	O
we	O
selected	O
the	O
following	O
meta	O
##bol	O
##ites	O
with	O
fold	O
induction	O
above	O
±	O
##1	O
.	O
5	O
and	O
P	O
<	O
0	O
.	O
05	O
as	O
bio	O
##mark	O
##er	O
candidates	O
:	O
o	B
##xa	I
##late	I
,	O
sa	B
##rc	I
##os	I
##ine	I
,	O
3	B
-	I
h	I
##ydro	I
##xy	I
##is	I
##ova	I
##ler	I
##ic	I
acid	I
,	O
ben	B
##zoic	I
acid	I
,	O
β	B
-	I
al	I
##ani	I
##ne	I
,	O
c	B
##rea	I
##tin	I
##ine	I
,	O
th	B
##re	I
##o	I
-	I
β	I
-	I
h	I
##ydro	I
##xy	I
##as	I
##par	I
##tic	I
acid	I
,	O
p	B
##ht	I
##hali	I
##c	I
acid	I
,	O
5	B
-	I
de	I
##hy	I
##dr	I
##o	I
##quin	I
##ic	I
acid	I
,	O
glucose	S
,	O
se	B
##ba	I
##ci	I
##c	I
acid	I
,	O
gal	B
##act	I
##ose	I
,	O
gal	B
##act	I
##osa	I
##mine	I
,	O
g	B
##lu	I
##car	I
##ate	I
,	O
u	B
##rea	I
,	O
non	B
##ano	I
##ic	I
acid	I
,	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
,	O
and	O
c	B
##ys	I
##tein	I
##e	I
+	O
c	B
##ys	I
##tine	I
.	O

As	O
illustrated	O
in	O
,	O
comparing	O
to	O
Y	O
##D	O
##Y	O
##HS	O
and	O
control	O
group	O
,	O
all	O
bio	O
##mark	O
##ers	O
except	O
for	O
glucose	S
showed	O
a	O
decreased	O
metabolic	O
tendency	O
in	O
Y	O
##Y	O
##DS	O
,	O
and	O
they	O
might	O
be	O
regarded	O
as	O
the	O
characteristic	O
bio	O
##mark	O
##ers	O
of	O
Yang	O
h	O
##y	O
##po	O
##function	O
.	O

[	O
_	O
13	O
CD	O
_	O
3	O
]	O
co	O
##tin	O
##ine	O
(	O
110	O
pm	O
##ol	O
)	O
and	O
[	O
_	O
13	O
C	O
_	O
6	O
]	O
N	O
##NA	O
##L	O
(	O
0	O
.	O
93	O
pm	O
##ol	O
)	O
were	O
dissolved	O
in	O
50	O
μ	O
##L	O
of	O
pH	O
7	O
.	O
4	O
phosphate	S
buffer	O
##ed	O
sa	B
##line	I
(	O
4	O
.	O
24	O
m	O
##M	O
K	O
##H	O
_	O
2	O
P	O
##O	O
_	O
4	O
,	O
620	O
.	O
7	O
m	O
##M	O
Na	O
##C	O
##l	O
,	O
11	O
.	O
86	O
m	O
##M	O
Na	O
_	O
2	O
HP	O
##O	O
_	O
4	O
)	O
and	O
added	O
to	O
each	O
well	O
along	O
with	O
3000	O
units	O
of	O
β	O
-	O
g	O
##lu	O
##cu	O
##ron	O
##idas	O
##e	O
in	O
50	O
μ	O
##L	O
of	O
pH	O
7	O
.	O
4	O
phosphate	S
buffer	O
##ed	O
sa	B
##line	I
(	O
1	O
.	O
06	O
m	O
##M	O
K	O
##H	O
_	O
2	O
P	O
##O	O
_	O
4	O
,	O
155	O
.	O
2	O
m	O
##M	O
Na	O
##C	O
##l	O
,	O
2	O
.	O
97	O

Both	O
UP	O
##LC	O
–	O
H	O
##R	O
##MS	O
and	O
D	O
##I	O
–	O
n	O
##ES	O
##I	O
–	O
H	O
##R	O
##MS	O
showed	O
higher	O
levels	O
of	O
several	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
in	O
positive	O
ion	O
mode	O
and	O
s	O
##tero	O
##id	O
meta	O
##bol	O
##ites	O
in	O
negative	O
ion	O
mode	O
in	O
urine	O
samples	O
obtained	O
from	O
men	O
,	O
indicating	O
differences	O
in	O
lip	O
##id	O
metabolism	O
,	O
which	O
is	O
consistent	O
with	O
previously	O
reported	O
data	O
on	O
sex	O
-	O
specific	O
urine	O
and	O
serum	O
meta	O
##bol	O
##ome	O
.	O

Forty	O
micro	O
##lite	O
##rs	O
of	O
0	O
.	O
04	O
m	O
##ol	O
/	O
L	O
h	B
##ydro	I
##xy	I
##lam	I
##ine	I
h	I
##ydro	I
##ch	I
##lor	I
##ide	I
and	O
60	O
μ	O
L	O
of	O
0	O
.	O
05	O
m	O
##ol	O
/	O

The	O
relatively	O
low	O
concentration	O
of	O
la	B
##ct	I
##ate	I
and	O
c	B
##rea	I
##tine	I
indicated	O
an	O
increased	O
energy	O
metabolism	O
and	O
the	O
con	O
##com	O
##ita	O
##nt	O
decrease	O
in	O
the	O
concentration	O
of	O
amino	O
acids	O
may	O
not	O
imply	O
an	O
increased	O
rate	O
of	O
protein	O
bio	O
##sy	O
##nt	O
##hesis	O
,	O
but	O
an	O
increased	O
energy	O
consumption	O
at	O
the	O
expense	O
of	O
the	O
amino	O
acids	O
.	O

In	O
conclusion	O
,	O
plasma	O
AG	O
##Es	O
assessed	O
by	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
were	O
neither	O
increased	O
in	O
IF	O
##G	O
nor	O
associated	O
with	O
parameters	O
of	O
glucose	S
metabolism	O
and	O
sub	O
##c	O
##lini	O
##cal	O
inflammation	O
in	O
our	O
study	O
.	O

Two	O
of	O
the	O
5	O
ratios	O
,	O
Try	O
##pt	O
##op	O
##han	O
/	O
Is	O
##ole	O
##uc	O
##ine	O
and	O
Try	O
##pt	O
##op	O
##han	O
/	O
Ty	O
##ros	O
##ine	O
,	O
were	O
significantly	O
lower	O
in	O
future	O
T	O
##2	O
##D	O
compared	O
to	O
N	O
##G	O
##T	O
and	O
were	O
associated	O
with	O
the	O
risk	O
of	O
developing	O
T	O
##2	O
##D	O
,	O
imp	O
##lica	O
##ting	O
that	O
try	B
##pt	I
##op	I
##han	I
might	O
be	O
suppressed	O
by	O
is	B
##ole	I
##uc	I
##ine	I
and	O
t	B
##yr	I
##os	I
##ine	I
in	O
the	O
competition	O
.	O

In	O
addition	O
,	O
the	O
increased	O
level	O
of	O
in	B
##os	I
##ine	I
detected	O
does	O
reflect	O
the	O
well	O
characterized	O
ad	B
##eni	I
##ne	I
-	I
n	I
##uc	I
##leo	I
##tide	I
cat	O
##ab	O
##olis	O
##m	O
(	O
ATP	O
##→	O
##AD	O
##P	O
##→	O
##AM	O
##P	O
##→	O
##IM	O
##P	O
##→	O
##ino	O
##sin	O
##e	O
)	O
that	O
occurs	O
in	O
working	O
muscle	O
during	O
s	O
##tre	O
##nu	O
##ous	O
exercise	O
[	O
,	O
]	O
,	O
and	O
,	O
consequently	O
,	O
an	O
increased	O
release	O
of	O
in	B
##os	I
##ine	I
from	O
muscle	O
to	O
blood	O
.	O

The	O
concentrated	O
ni	B
##tric	I
acid	I
was	O
used	O
to	O
destroy	O
the	O
organic	O
content	O
and	O
mineral	O
##ize	O
the	O
sample	O
.	O

5	O
-	O
,	O
12	O
-	O
and	O
15	B
-	I
h	I
##ydro	I
##xy	I
##ei	I
##cos	I
##ate	I
##tra	I
##eno	I
##ic	I
acid	I
(	O
5	O
-	O
H	O
##ET	O
##E	O
,	O
12	B
-	I
H	I
##ET	I
##E	I
,	O
15	O
-	O
H	O
##ET	O
##E	O
)	O
,	O
pro	B
##sta	I
##g	I
##land	I
##in	I
E	O
_	O
2	O
,	O
D	O
_	O
2	O
and	O
F	O
_	O
2	O
(	O
P	O
##GE	O
_	O
2	O
,	O
P	O
##G	O
##D	O
_	O
2	O
,	O
P	O
##G	O
##F	O
_	O
2	O
)	O
,	O
lip	B
##ox	I
##in	I
A	O
_	O
4	O
and	O
B	O
_	O
4	O
(	O
L	O
##X	O
##A	O
_	O
4	O
,	O
L	O
##X	O
##B	O
_	O
4	O
)	O
,	O
le	O
##uk	O
##ot	O
##rien	O
##e	O
B	O
_	O
4	O
(	O
L	O
##T	O
##B	O
_	O
4	O
)	O
,	O
th	B
##rom	I
##box	I
##ane	I
B	O
_	O
2	O
(	O
TX	O
##B	O
_	O
2	O
)	O
,	O
a	B
##rac	I
##hi	I
##don	I
##ic	I
acid	I
(	O
AA	O
)	O
,	O
do	B
##cos	I
##ah	I
##ex	I
##aen	I
##oi	I
##c	I
acid	I
(	O
D	O
##HA	O
)	O
,	O
e	B
##ico	I
##sa	I
##pent	I
##ano	I
##ic	I
acid	I
(	O
EPA	O
)	O
,	O
re	B
##sol	I
##vin	I
D	I
##1	I
(	O
R	O
##v	O
##D	O
##1	O
)	O
,	O
and	O
ne	O
##uro	O
##p	O
##rote	O
##ct	O
##in	O
D	O
##1	O
(	O
N	O
##PD	O
##1	O
)	O
.	O

P	O
##las	O
##ma	O
(	O
20	O
μ	O
##L	O
)	O
was	O
extracted	O
at	O
1	O
:	O
5	O
and	O
1	O
:	O
10	O
in	O
L	O
##B	O
containing	O
5	O
μ	O
##M	O
heavy	O
labeled	O
try	B
##pt	I
##op	I
##han	I
and	O
k	B
##yn	I
##uren	I
##ine	I
as	O
previously	O
described	O
,	O
then	O
di	O
##lut	O
##ed	O
1	O
:	O
5	O
,	O
1	O
:	O
10	O
and	O
1	O
:	O
20	O
with	O
H	O
_	O
2	O
O	O
and	O
run	O
on	O
U	O
##HP	O
##LC	O
-	O
MS	O
(	O
,	O
)	O
.	O

While	O
the	O
de	O
##ple	O
##tion	O
of	O
c	B
##ys	I
##tein	I
##e	I
and	O
the	O
accumulation	O
of	O
c	B
##ys	I
##tine	I
and	O
Met	O
-	O
S	O
##O	O
clearly	O
indicate	O
increased	O
o	O
##xi	O
##da	O
##tive	O
stress	O
in	O
SL	O
##E	O
,	O
none	O
of	O
these	O
compounds	O
or	O
the	O
unique	O
PP	O
##P	O
substrates	O
R	O
##5	O
##P	O
or	O
S	O
##7	O
##P	O
correlated	O
with	O
disease	O
activity	O
of	O
un	O
##tre	O
##ated	O
patients	O
.	O

El	O
##eva	O
##ted	O
levels	O
of	O
a	B
##rg	I
##ini	I
##ne	I
and	O
or	B
##ni	I
##thin	I
##e	I
were	O
observed	O
in	O
patients	O
with	O
PD	O
##R	O
,	O
potentially	O
imp	O
##lica	O
##ting	O
a	O
compromised	O
Mu	O
##eller	O
g	O
##lial	O
cell	O
metabolism	O
in	O
the	O
disruption	O
of	O
ne	O
##uro	O
##vas	O
##cular	O
cross	O
##tal	O
##k	O
within	O
the	O
re	O
##tina	O
and	O
progression	O
of	O
di	O
##abe	O
##tic	O
re	O
##tino	O
##pathy	O
[	O
,	O
]	O
.	O

However	O
,	O
when	O
added	O
g	B
##lut	I
##ama	I
##te	I
to	O
le	O
##uke	O
##mia	O
cells	O
in	O
##hibit	O
##ed	O
G	O
##LS	O
activity	O
,	O
we	O
found	O
increased	O
relative	O
cell	O
activity	O
.	O

Poor	O
water	O
suppression	O
and	O
high	O
c	B
##it	I
##rate	I
composition	O
were	O
the	O
main	O
cause	O
of	O
sample	O
exclusion	O
.	O

The	O
concentrations	O
of	O
put	B
##res	I
##cine	I
,	O
sperm	B
##id	I
##ine	I
and	O
sperm	B
##ine	I
tended	O
to	O
be	O
inverse	O
##ly	O
correlated	O
with	O
sperm	O
im	O
##mot	O
##ility	O
.	O

Pro	B
##line	I
was	O
reduced	O
(	O
P	O
<	O
0	O
.	O
05	O
after	O
the	O
F	O
##DR	O
procedure	O
)	O
,	O
whereas	O
some	O
l	B
##ys	I
##o	I
-	I
p	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
increased	O
(	O
6	O
:	O
0	O
,	O
24	O
:	O
0	O
,	O
26	O
:	O
0	O
,	O
28	O
:	O
0	O
,	O
28	O
:	O
1	O
)	O
and	O
others	O
decreased	O
(	O
14	O
:	O
0	O
,	O
16	O
:	O
0	O
,	O
18	O
:	O
0	O
,	O
18	O
:	O
1	O
,	O
18	O
:	O
2	O
)	O
(	O
P	O
<	O
0	O
.	O
05	O
after	O
the	O
F	O
##DR	O
procedure	O
)	O
.	O

The	O
present	O
study	O
showed	O
a	O
robust	O
##ly	O
favorable	O
relationship	O
between	O
serum	O
ch	B
##olin	I
##e	I
and	O
P	O
##LC	O
.	O

We	O
found	O
that	O
in	O
the	O
CO	O
##N	O
,	O
L	O
##SI	O
##L	O
and	O
H	O
##SI	O
##L	O
groups	O
,	O
2	B
-	I
Am	I
##ino	I
-	I
3	I
-	I
met	I
##hyl	I
-	I
1	I
-	I
but	I
##ano	I
##l	I
,	O
L	B
-	I
Car	I
##ni	I
##tine	I
,	O
As	O
##n	O
As	O
##n	O
G	O
##ln	O
A	O
##rg	O
,	O
and	O
Al	O
##a	O
Cy	O
##s	O
Ser	O
T	O
##rp	O
were	O
continuously	O
up	O
-	O
regulated	O
,	O
and	O
so	B
##lad	I
##ul	I
##cid	I
##ine	I
and	O
Al	O
##a	O
Il	O
##e	O
G	O
##ln	O
A	O
##rg	O
were	O
continuously	O
down	O
-	O
regulated	O
.	O

At	O
recruitment	O
data	O
on	O
demographic	O
##s	O
,	O
diet	O
regime	O
##n	O
,	O
disease	O
duration	S
,	O
co	O
-	O
m	O
##or	O
##bid	O
##ities	O
,	O
and	O
con	O
##com	O
##ita	O
##nt	O
treatments	O
were	O
obtained	O
by	O
direct	O
questioning	O
and	O
collected	O
on	O
a	O
standardized	O
electronic	O
form	O
.	O

A	O
delayed	O
expression	O
of	O
pin	B
##ito	I
##l	I
,	O
compared	O
to	O
la	B
##ct	I
##ose	I
and	O
3	B
-	I
p	I
##hen	I
##yl	I
##la	I
##ctic	I
acid	I
,	O
appears	O
,	O
however	O
,	O
to	O
be	O
evident	O
during	O
the	O
1	O
–	O
2	O
h	O
interval	O
.	O

It	O
has	O
been	O
reported	O
that	O
the	O
levels	O
of	O
c	B
##era	I
##mi	I
##de	I
in	O
the	O
cancer	O
##ous	O
tissue	O
were	O
higher	O
than	O
that	O
of	O
normal	O
tissue	O
.	O

A	O
##cc	O
##um	O
##ulation	O
of	O
these	O
meta	O
##bol	O
##ites	O
in	O
tumors	O
may	O
therefore	O
be	O
attributed	O
to	O
h	O
##yper	O
##act	O
##ivity	O
of	O
f	B
##uma	I
##rate	I
re	O
##spiration	O
.	O

C	B
##rea	I
##tin	I
##ine	I
concentrations	O
measured	O
with	O
the	O
B	O
##io	O
##crates	O
kit	O
(	O
74	O
##±	O
##14	O
μ	O
##mo	O
##l	O
/	O
L	O
)	O
were	O
similar	O
to	O
those	O
obtained	O
by	O
routine	O
bio	O
##chemistry	O
(	O
75	O
##±	O
##13	O
μ	O
##mo	O
##l	O
/	O
L	O
)	O
.	O

The	O
urine	O
##s	O
were	O
filtered	O
immediately	O
using	O
a	O
0	O
.	O
2	O
μ	O
##m	O
membrane	O
cell	O
##ulos	O
##e	O
ace	B
##tate	I
filter	O
(	O
Sa	O
##rt	O
##ori	O
##us	O
)	O
to	O
remove	O
any	O
sediment	O
potentially	O
containing	O
e	O
##pit	O
##hel	O
##ial	O
cell	O
,	O
er	O
##yt	O
##hr	O
##ocytes	O
,	O
bacteria	O
and	O
proteins	O
which	O
disturb	O
the	O
further	O
analysis	O
.	O

Initial	O
sample	O
preparation	O
steps	O
such	O
as	O
protein	O
precipitation	O
with	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
and	O
subsequent	O
di	O
##lution	O
with	O
0	O
.	O
4	O
M	O
K	O
_	O
2	O
HP	O
##O	O
_	O
4	O
were	O
adopted	O
from	O
known	O
methods	O
of	O
vitamin	B
D	I
extraction	O
to	O
fit	O
the	O
format	O
of	O
2	O
-	O
m	O
##L	O
p	B
##oly	I
##p	I
##rop	I
##yle	I
##ne	I
plastic	O
tubes	O
.	O

Ko	O
##no	O
et	O
al	O
.	O
reported	O
that	O
in	O
##tra	O
##cellular	O
type	O
II	O
L	O
##p	O
-	O
P	O
##LA	O
_	O
2	O
,	O
which	O
shares	O
ho	O
##mology	O
with	O
the	O
plasma	O
enzyme	O
L	O
##p	O
-	O
P	O
##LA	O
_	O
2	O
,	O
was	O
involved	O
in	O
the	O
metabolism	O
of	O
est	O
##eri	O
##fied	O
8	B
-	I
is	I
##o	I
-	I
P	I
##G	I
##F	I
_	I
2	I
##α	I
.	O

6	O
.	O
4	O
×	O
10	O
_	O
−	O
##1	O
,	O
C	B
##17	I
:	I
0	I
p	O
=	O
8	O
.	O
3	O
×	O
10	O
_	O
−	O
##1	O
,	O
unknown	O
C	O
##17	O
p	O
=	O

(	O
a	O
–	O
f	O
)	O
L	O
##ys	O
##o	O
##PC	O
and	O
PC	O
:	O
l	O
##ys	O
##o	O
##PC	O
a	O
C	B
##18	I
:	I
0	I
,	O
l	O
##ys	O
##o	O
##PC	O
a	O
C	B
##18	I
:	I
2	I
,	O
l	O
##ys	O
##o	O
##PC	O
a	O
C	B
##20	I
:	I
3	I
,	O
l	O
##ys	O
##o	O
##PC	O
a	O
C	B
##20	I
:	I
4	I
,	O
l	O
##ys	O
##o	O
##PC	O
a	O
C	B
##24	I
:	I
0	I
,	O
PC	B
a	I
##e	I
C	I
##42	I
:	I
1	I
respectively	O
.	O

Among	O
them	O
,	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
and	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##let	I
##han	I
##ola	I
##mine	I
were	O
the	O
meta	O
##bol	O
##ites	O
that	O
showed	O
a	O
more	O
robust	O
pattern	O
in	O
the	O
time	O
series	O
analysis	O
for	O
disc	O
##rim	O
##inating	O
between	O
patients	O
and	O
controls	O
.	O

The	O
second	O
major	O
metabolic	O
pathway	O
was	O
the	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
metabolism	O
pathway	O
.	O

A	O
L	O
##O	O
##2	O
cells	O
(	O
normal	O
human	O
he	O
##pa	O
##tic	O
cells	O
)	O
experiment	O
was	O
carried	O
out	O
to	O
confirm	O
VP	O
##A	O
meta	O
##bol	O
##ites	O
’	O
he	O
##pa	O
##to	O
##to	O
##xi	O
##city	O
using	O
AS	O
##T	O
(	O
As	O
##pert	O
##ate	O
Am	O
##ino	O
##tra	O
##ns	O
##fer	O
##ase	O
,	O
AS	O
##T	O
)	O
,	O
AL	B
##T	I
(	I
Alan	I
##ine	I
amino	I
##tra	I
##ns	I
##fer	I
##ase	I
,	I
AL	I
##T	I
)	I
and	O
L	B
##D	I
##H	I
(	I
la	I
##ct	I
##ate	I
de	I
##hy	I
##dr	I
##ogen	I
##ase	I
,	I
L	I
##D	I
##H	I
)	I
in	O
super	O
##nate	O
as	O
index	O
.	O

Only	O
two	O
meta	O
##bol	O
##ites	O
(	B
o	B
##leam	I
##ide	I
and	O
or	O
##ni	O
##thin	O
##e	O
)	O
in	O
the	O
most	O
significantly	O
differing	O
20	O
meta	O
##bol	O
##ites	O
(	O
based	O
on	O
the	O
p	O
value	O
)	O
in	O
the	O
HC	O
##C	O
study	O
were	O
found	O
in	O
the	O
22	O
differential	O
meta	O
##bol	O
##ites	O
(	O
based	O
on	O
p	O
value	O
)	O
in	O
the	O
two	O
CR	O
##C	O
studies	O
,	O
suggesting	O
that	O
the	O
meta	O
##bol	O
##ite	O
markers	O
identified	O
in	O
the	O
current	O
study	O
may	O
be	O
specific	O
to	O
CR	O
##C	O
p	O
##hen	O
##otype	O
.	O

S	O
##lide	O
##s	O
were	O
cooled	O
to	O
room	O
temperature	O
,	O
de	O
##par	O
##af	O
##fin	O
##ized	O
in	O
three	O
changes	O
of	O
x	B
##yle	I
##ne	I
,	O
and	O
re	O
##hy	O
##dra	O
##ted	O
using	O
graded	O
alcohol	O
##s	O
.	O

Specifically	O
,	O
11	O
u	O
##rem	O
##ic	O
retention	O
so	O
##lut	O
##es	O
(	O
i	O
.	O
e	O
.	O
,	O
g	B
##uan	I
##id	I
##ine	I
,	O
hip	B
##pur	I
##ic	I
acid	I
,	O
c	B
##is	I
-	I
a	I
##con	I
##itic	I
acid	I
,	O
q	B
##uin	I
##ic	I
acid	I
,	O
c	B
##it	I
##rama	I
##lic	I
acid	I
,	O
as	B
##par	I
##agi	I
##ne	I
,	O
or	B
##ni	I
##thin	I
##e	I
,	O
met	B
##hi	I
##oni	I
##ne	I
su	I
##lf	I
##oxide	I
,	O
ch	B
##olin	I
##e	I
,	O
t	B
##rig	I
##one	I
##llin	I
##e	I
,	O
or	O
##ot	O
##id	O
##ine	O
)	O
were	O
efficiently	O
cleared	O
by	O
H	O
##F	O
##D	O
rather	O
than	O
HD	O
.	O

MS	O
/	O
MS	O
analyses	O
were	O
performed	O
on	O
a	O
API	O
##40	O
##00	O
(	O
triple	O
q	O
##uad	O
##rup	O
##ole	O
mass	O
s	O
##pect	O
##rome	O
##ter	O
)	O
equipped	O
with	O
an	O
AP	O
##CI	O
(	O
At	O
##mos	O
##pheric	O
Press	O
##ure	O
Chemical	O
Ion	O
##ization	O
)	O
ion	O
source	O
(	O
AB	O
Sc	O
##ie	O
##x	O
,	O
Dar	O
##ms	O
##tadt	O
,	O
Germany	O
)	O
for	O
Ce	B
##r	I
and	O
d	O
##h	O
##C	O
##er	O
determination	O
,	O
and	O
with	O
an	O
E	O
##SI	O
(	O
El	O
##ec	O
##tro	O
##sp	O
##ray	O
Ion	O
##ization	O
)	O
ion	O
source	O
for	O
s	B
##phi	I
##ngo	I
##sin	I
##e	I
,	O
s	B
##phi	I
##nga	I
##nine	I
and	O
their	O
1	B
-	I
phosphate	I
derivatives	O
determination	O
.	O

On	O
the	O
five	O
subsequent	O
days	O
the	O
women	O
were	O
asked	O
to	O
consume	O
a	O
Mediterranean	O
style	O
diet	O
,	O
which	O
provided	O
45	O
%	O
of	O
energy	O
from	O
low	B
-	I
g	I
##ly	I
##ca	I
##em	I
##i	I
-	I
index	I
car	O
##bo	O
##hy	O
##dra	O
##tes	O
,	O
30	O
%	O
from	O
fat	O
(	O
15	O
%	O
mon	O
##ou	O
##ns	O
##at	O
##ura	O
##ted	O
fat	O
,	O
7	O
%	O
from	O
saturated	O
fat	O
,	O
8	O
%	O
from	O
p	O
##oly	O
##uns	O
##at	O
##ura	O
##ted	O
fat	O
)	O
and	O
25	O
%	O
energy	O
from	O
protein	O
as	O
described	O
previously	O
[	O
,	O
]	O
.	O

Our	O
data	O
on	O
u	O
##rina	O
##ry	O
F	B
##2	I
-	I
is	I
##op	I
##ros	I
##tan	I
##es	I
in	O
humans	O
are	O
consistent	O
with	O
the	O
results	O
of	O
the	O
B	O
##OS	O
##S	O
study	O
using	O
CC	O
##l	O
_	O
4	O
as	O
an	O
o	O
##xi	O
##da	O
##tive	O
stress	O
##or	O
in	O
animals	O
(	O
,	O
)	O
.	O

A	B
##bir	I
##ater	I
##one	I
and	O
D	B
_	I
4	I
-	I
a	I
##bir	I
##ater	I
##one	I
were	O
for	O
at	O
least	O
stable	O
for	O
6	O
months	O
in	O
stock	O
solution	O
.	O

Oral	O
con	O
##tra	O
##ceptive	O
##s	O
are	O
also	O
established	O
to	O
decrease	O
plasma	O
concentrations	O
of	O
several	O
s	O
##tero	O
##ids	O
,	O
such	O
as	O
pro	B
##ges	I
##tero	I
##ne	I
,	O
17	B
-	I
h	I
##ydro	I
##xy	I
##p	I
##rog	I
##ester	I
##one	I
and	O
and	B
##ros	I
##ten	I
##ed	I
##ione	I
,	O
,	O
,	O
as	O
also	O
confirmed	O
here	O
.	O

For	O
g	B
##lut	I
##ama	I
##te	I
,	O
each	O
1	O
standard	O
de	O
##viation	O
increase	O
was	O
associated	O
with	O
an	O
increase	O
of	O
1	O
.	O
39	O
units	O
of	O
B	O
##MI	O
.	O

P	O
##las	O
##ma	O
samples	O
were	O
th	O
##awed	O
on	O
ice	O
and	O
extracted	O
using	O
a	O
dual	O
met	B
##han	I
##ol	I
-	I
ch	I
##lor	I
##of	I
##orm	I
extraction	O
(	O
for	O
protein	O
precipitation	O
and	O
separation	O
of	O
h	B
##ydro	I
##phi	I
##lic	I
and	O
lip	O
##op	O
##hil	O
##ic	O
fraction	O
##s	O
)	O
as	O
previously	O
described	O
.	O

Stock	O
solutions	O
were	O
made	O
using	O
commercially	O
available	O
standards	O
for	O
T	O
,	O
D	O
##HT	O
,	O
E	O
##pi	O
-	O
T	O
,	O
Δ	O
_	O
4	O
-	O
AD	O
,	O
Ad	B
##ione	I
,	O
A	O
and	O
D	O
##H	O
##EA	O
in	O
ethanol	S
for	O
ca	O
##li	O
##bra	O
##tion	O
curves	O
and	O
quality	O
control	O
standards	O
.	O

For	O
example	O
,	O
it	O
is	O
unclear	O
whether	O
the	O
double	O
##t	O
of	O
C	O
##2	O
,	O
5	O
of	O
c	B
##it	I
##rate	I
represents	O
_	O
13	O
C	O
##1	O
,	O
_	O
13	O
C	O
##2	O
/	O
_	O
13	O
C	O
##5	O
,	O
_	O
13	O
C	O
##6	O
,	O
_	O
13	O
C	O
##2	O
,	O
_	O
13	O
C	O
##3	O
/	O
_	O
13	O
C	O
##3	O
,	O
_	O
13	O
C	O
##5	O
or	O
both	O
(	O
c	O
##f	O
.	O
for	O
numbering	O
of	O
c	O
##it	O
##rate	O
)	O
.	O

Met	O
##ab	O
##oli	O
##tes	O
involved	O
in	O
pu	B
##rine	I
metabolism	O
were	O
also	O
down	O
-	O
regulated	O
in	O
children	O
and	O
adolescent	O
##s	O
with	O
MD	O
##D	O
compared	O
with	O
healthy	O
controls	O
.	O

The	O
same	O
sample	O
of	O
[	B
N	B
-	I
ace	I
##ty	I
##l	I
-	I
D	I
_	I
3	I
]	O
3	O
-	O
HP	O
##MA	O
or	O
[	B
N	B
-	I
ace	I
##ty	I
##l	I
-	I
D	I
_	I
3	I
]	O
HM	O
##PM	O
##A	O
used	O
for	O
constructing	O
the	O
ca	O
##li	O
##bra	O
##tion	O
curve	O
was	O
also	O
added	O
to	O
each	O
sample	O
as	O
internal	O
standard	O
.	O

Pat	O
##ients	O
fast	O
##ed	O
for	O
at	O
least	O
six	O
hours	O
prior	O
to	O
the	O
scan	O
but	O
were	O
excluded	O
if	O
they	O
had	O
a	O
cap	O
##illa	O
##ry	O
glucose	S

Three	O
volumes	O
of	O
ice	O
-	O
cold	O
met	B
##han	I
##ol	I
were	O
added	O
into	O
25	O
μ	O
##L	O
of	O
serum	O
/	O
CS	O
##F	O
,	O
v	O
##ortex	O
##ed	O
and	O
in	O
##cu	O
##bate	O
##d	O
on	O
ice	O
for	O
15	O
min	O
.	O

The	O
decreased	O
serum	O
met	B
##hi	I
##oni	I
##ne	I
was	O
consistent	O
with	O
a	O
low	O
level	O
of	O
se	B
##rine	I
,	O
one	O
of	O
the	O
amino	O
acid	O
sources	O
of	O
one	O
-	O
carbon	O
groups	O
for	O
te	B
##tra	I
##hy	I
##dr	I
##of	I
##olic	I
acid	I
to	O
s	O
##ynth	O
##esi	O
##ze	O
met	B
##hi	I
##oni	I
##ne	I
(	O
T	O
##HF	O
,	O
met	B
##hi	I
##oni	I
##ne	I
cycle	O
)	O
.	O

El	O
##eva	O
##ted	O
p	B
##yr	I
##im	I
##id	I
##ines	I
and	O
meta	O
##bol	O
##ites	O
in	O
urine	O
were	O
detected	O
by	O
G	O
##C	O
–	O
MS	O
.	O

Assessment	O
of	O
individual	O
donor	O
re	O
##sp	O
##ons	O
##ive	O
##ness	O
to	O
the	O
respective	O
r	O
##ins	O
##es	O
i	O
.	O
e	O
.	O
which	O
r	O
##ins	O
##e	O
provided	O
the	O
highest	O
in	O
##tra	O
-	O
donor	O
levels	O
of	O
the	O
parent	O
ant	B
##ho	I
##cy	I
##ani	I
##n	I
at	O
time	O
points	O
was	O
determined	O
by	O
the	O
Friedman	O
Two	O
-	O
Way	O
Analysis	O
of	O
V	O
##arian	O
##ce	O
by	O
Rank	O
##s	O
.	O

Five	O
mill	O
##ili	O
##ters	O
of	O
K	O
##re	O
##bs	O
Ring	O
##er	O
bi	O
##car	O
##bon	O
##ate	O
solution	O
,	O
pH	O
7	O
.	O
3	O
,	O
containing	O
no	O
glucose	S
was	O
added	O
to	O
the	O
plates	O
of	O
cells	O
,	O
and	O
the	O
cells	O
were	O
in	O
##cu	O
##bate	O
##d	O
at	O
37	O
°C	O
.	O

The	O
solution	O
was	O
e	O
##va	O
##porated	O
in	O
a	O
Speed	O
-	O
V	O
##ac	O
and	O
either	O
subjected	O
to	O
one	O
-	O
dimensional	O
sodium	B
do	I
##de	I
##cy	I
##l	I
su	I
##lf	I
##ate	I
p	I
##oly	I
##ac	I
##ryl	I
##ami	I
##de	I
gel	O
electro	O
##ph	O
##ores	O
##is	O
(	O
1	O
##D	O
SD	O
##S	O
-	O
PA	O
##GE	O
)	O
or	O
try	O
##ps	O
##in	O
dig	O
##est	O
##ion	O
for	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
analysis	O
.	O

Oral	O
high	O
fat	O
-	O
specific	O
up	O
##re	O
##gu	O
##lation	O
of	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
(	I
d	I
##18	I
:	I
1	I
/	I
24	I
:	I
1	I
)	I
,	O
a	O
previously	O
reported	O
pan	O
##cre	O
##atic	O
cancer	O
-	O
down	O
##re	O
##gu	O
##lated	O
meta	O
##bol	O
##ite	O
,	O
and	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
(	I
16	I
:	I
0	I
)	I
were	O
associated	O
with	O
N	O
##RI	O
scores	O
.	O

The	O
results	O
suggest	O
possible	O
role	O
of	O
several	O
metabolic	O
pathways	O
in	O
ID	O
##C	O
including	O
amino	O
acid	O
metabolism	O
,	O
pu	B
##rine	I
and	O
p	B
##yr	I
##im	I
##id	I
##ine	I
metabolism	O
,	O
fatty	O
acid	O
metabolism	O
,	O
amino	S
sugar	O
metabolism	O
.	O

_	O
a	O
En	O
##zy	O
##matic	O
and	O
lip	O
##ogen	O
##esis	O
activity	O
were	O
estimated	O
using	O
T	O
##GR	O
##L	O
(	O
post	O
##pra	O
##ndi	O
##al	O
/	O
fast	O
##ing	O
)	O
fatty	O
acid	O
and	O
o	B
##xy	I
##lip	I
##in	I
product	O
/	O
precursor	O
relationships	O
,	O
separately	O
for	O
est	O
##eri	O
##fied	O
and	O
non	O
-	O
est	O
##eri	O
##fied	O
pools	O
.	O
_	O

Formation	O
rates	O
of	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
from	O
1	O
µ	O
##m	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
also	O
significantly	O
correlated	O
with	O
C	O
##YP	O
##2	O
##C	O
##8	O
activity	O
(	O
S	O
##pear	O
##man	O
r	O
=	O
0	O
.	O
89	O
,	O
P	O
=	O
0	O
.	O
01	O
##9	O
)	O
,	O
but	O
this	O
did	O
not	O
reach	O
a	O
statistical	O
##ly	O
significant	O
level	O
at	O
the	O
higher	O
substrate	O
concentration	O
(	O
S	O
##pear	O
##man	O
r	O
=	O
0	O
.	O
77	O
,	O
P	O
=	O
0	O
.	O
07	O
)	O
.	O

(	O
A	O
)	O
Try	B
##pt	I
##op	I
##han	I
based	O
on	O
median	O
split	O
of	O
daily	O
abdominal	O
pain	O
after	O
eating	O
,	O
(	O
B	O
)	O
se	B
##rot	I
##oni	I
##n	I
based	O
on	O
median	O
split	O
of	O
percent	O
of	O
days	O
with	O
loose	O
stool	O
##s	O
,	O
(	O
C	O
)	O
me	B
##lat	I
##oni	I
##n	I
based	O
on	O
median	O
split	O
of	O
reported	O
sleep	O
quality	O
across	O
the	O
month	O
,	O
(	O
D	O
)	O
try	B
##pta	I
##mine	I
based	O
on	O
median	O
split	O
of	O
wake	O
time	O
reported	O
in	O
the	O
daily	O
diary	O
,	O
(	O
E	O
)	O
in	B
##do	I
##le	I
-	I
3	I
-	I
la	I
##ctic	I
acid	I
based	O
on	O
median	O
split	O
of	O
time	O
in	O
bed	O
reported	O
in	O
the	O
daily	O
diary	O
,	O
and	O
(	O
F	O
)	O
in	O
##do	O
##le	O
-	O
p	O
##yr	O
##u	O
##vate	O
based	O
on	O
median	O
split	O
of	O
percent	O
time	O
in	O
rapid	O
eye	O
movement	O
(	O
R	O
##EM	O
)	O
sleep	O
recorded	O
by	O
p	O
##oly	O
##so	O
##m	O
##no	O
##graphy	O
.	O

Between	O
se	O
##psis	O
survivors	O
and	O
non	O
-	O
survivors	O
,	O
we	O
found	O
significant	O
differences	O
only	O
in	O
the	O
la	B
##ct	I
##ate	I
(	O
median	O
concentration	O
1	O
.	O
46	O
mm	O
##ol	O
/	O
l	O
vs	O
2	O
.	O
49	O
mm	O
##ol	O
/	O
l	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
and	O
c	B
##it	I
##rate	I
concentrations	O
(	O
0	O
.	O
08	O
mm	O
##ol	O
/	O
l	O
vs	O
0	O
.	O
10	O
mm	O
##ol	O
/	O
l	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
weaker	O
correlation	O
of	O
24	B
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
with	O
25	O
(	O
OH	O
)	O
D	O
_	O
3	O
further	O
suggests	O
that	O
inter	O
-	O
individual	O
differences	O
in	O
vitamin	B
D	I
cat	O
##ab	O
##olis	O
##m	O
are	O
accent	O
##uated	O
with	O
lower	O
G	O
##F	O
##R	O
.	O

C	B
##it	I
##rate	I
sits	O
at	O
the	O
cross	O
##roa	O
##d	O
of	O
g	O
##ly	O
##co	O
##lysis	O
and	O
fatty	O
acid	O
synthesis	O
and	O
as	O
such	O
acts	O
a	O
key	O
regulator	O
of	O
energy	O
production	O
.	O

No	O
association	O
with	O
l	O
##ymph	O
node	O
progression	O
risk	O
was	O
detected	O
by	O
short	O
-	O
,	O
medium	O
-	O
,	O
or	O
long	O
-	O
chain	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
(	O
using	O
pool	O
##ed	O
values	O
for	O
class	O
of	O
molecules	O
,	O
namely	O
C	O
##2	O
-	O
C	O
##5	O
(	O
short	O
-	O
chain	O
)	O
,	O
C	O
##6	O
-	O
C	O
##12	O
(	O
medium	O
-	O
chain	O
)	O
,	O
C	O
##14	O
-	O
C	O
##16	O
(	O
long	O
-	O
chain	O
)	O
,	O
normal	O
##ized	O
against	O
C	O
##0	O
,	O
median	O
cut	O
-	O
off	O
)	O
(	O
Additional	O
file	O
3	O
:	O
Figure	O
S	O
##2	O
##C	O
)	O
.	O

C	O
##ir	O
##cula	O
##ting	O
P	O
##LP	O
concentrations	O
are	O
lower	O
in	O
inflammatory	O
states	O
,	O
and	O
it	O
is	O
reported	O
that	O
P	O
##LP	O
-	O
dependent	O
reactions	O
of	O
the	O
k	B
##yn	I
##uren	I
##ine	I
pathway	O
are	O
involved	O
in	O
the	O
immune	O
response	O
by	O
suppress	O
##ing	O
inflammation	O
,	O
reducing	O
the	O
tissue	O
damage	O
caused	O
by	O
the	O
immune	O
response	O
,	O
and	O
developing	O
immune	O
tolerance	O
(	O
–	O
)	O
.	O

Ser	O
##a	O
from	O
patients	O
who	O
were	O
treated	O
with	O
le	B
##vo	I
##thy	I
##ro	I
##xin	I
##e	I
sodium	I
tablets	O
before	O
and	O
after	O
surgery	O
was	O
analyzed	O
with	O
a	O
B	O
##ruk	O
##er	O
500	O
Hz	O
nuclear	O
magnetic	O
resonance	O
(	O
N	O
##MR	O
)	O
s	O
##pect	O
##rome	O
##ter	O
.	O

The	O
gene	O
encoding	O
the	O
zinc	O
up	O
##take	O
transport	O
##ers	O
(	O
ZIP	O
##1	O
)	O
is	O
down	O
-	O
regulated	O
in	O
PC	O
##a	O
,	O
leading	O
to	O
a	O
faster	O
oxidation	O
of	O
c	B
##it	I
##rate	I
driven	O
by	O
low	O
level	O
of	O
zinc	O
.	O

In	O
addition	O
,	O
as	O
many	O
functional	O
dig	O
##estive	O
disorders	O
share	O
similar	O
in	O
symptoms	O
,	O
there	O
is	O
considerable	O
clinical	O
overlap	O
between	O
F	B
##D	I
and	O
other	O
functional	O
gas	O
##tro	O
##enter	O
##ological	O
disorders	O
.	O

In	O
fast	O
##ing	O
conditions	O
,	O
H	O
##ER	O
-	O
2	O
+	O
breast	O
cancer	O
patients	O
are	O
no	O
longer	O
able	O
to	O
maintain	O
their	O
blood	O
glucose	S
levels	O
to	O
reference	O
values	O
.	O

The	O
three	O
meta	O
##bol	O
##ites	O
(	B
l	B
##ys	I
##o	I
##PC	I
(	I
16	I
:	I
1	I
)	I
,	O
o	B
##ct	I
##ano	I
##yl	I
##car	I
##ni	I
##tine	I
and	O
de	B
##cano	I
##yl	I
##car	I
##ni	I
##tine	I
)	O
that	O
significantly	O
changed	O
only	O
in	O
OR	O
##s	O
were	O
chosen	O
as	O
bio	O
##mark	O
##ers	O
related	O
to	O
therapeutic	O
effect	O
and	O
the	O
variations	O
of	O
these	O
were	O
subjected	O
to	O
in	O
-	O
depth	O
investigation	O
over	O
the	O
treatment	O
course	O
.	O

To	O
our	O
knowledge	O
,	O
our	O
study	O
provides	O
the	O
only	O
objective	O
data	O
on	O
population	O
exposure	O
to	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
and	O
i	B
##bu	I
##p	I
##ro	I
##fen	I
currently	O
available	O
.	O

A	B
##rg	I
##ini	I
##ne	I
was	O
important	O
to	O
maintain	O
the	O
stability	O
of	O
the	O
internal	O
environment	O
.	O

Association	O
between	O
u	O
##rina	O
##ry	O
my	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
and	O
clinical	O
outcomes	O
in	O
the	O
F	O
##S	O
##GS	O
patients	O
.	O

In	O
addition	O
,	O
an	O
increased	O
pu	B
##rine	I
metabolism	O
flux	O
induced	O
by	O
acute	O
systematic	O
h	O
##y	O
##pox	O
##ia	O
has	O
also	O
been	O
observed	O
in	O
a	O
recently	O
reported	O
L	O
##C	O
-	O
MS	O
study	O
.	O

De	O
##ple	O
##tion	O
of	O
try	B
##pt	I
##op	I
##han	I
induce	O
##s	O
signaling	O
events	O
in	O
T	O
cells	O
,	O
leading	O
to	O
an	O
##er	O
##gy	O
,	O
a	O
##pop	O
##tosis	O
,	O
and	O
active	O
im	O
##mu	O
##no	O
##mo	O
##du	O
##lation	O
by	O
a	O
##cc	O
##um	O
##ulating	O
try	O
##pt	O
##op	O
##han	O
-	O
K	O
##P	O
meta	O
##bol	O
##ites	O
.	O

The	O
V	O
##US	O
values	O
of	O
the	O
single	O
amino	O
acid	O
concentrations	O
ranged	O
from	O
0	O
.	O
18	O
slightly	O
above	O
a	O
random	O
class	O
##ifier	O
to	O
0	O
.	O
85	O
(	B
g	B
##lut	I
##amine	I
)	O
,	O
which	O
is	O
close	O
to	O
the	O
best	O
panel	O
predict	O
##ors	O
.	O

In	O
this	O
study	O
,	O
a	O
comparison	O
between	O
the	O
plasma	O
of	O
OS	O
##CC	O
and	O
O	O
##D	O
revealed	O
decreasing	O
glucose	S
levels	O
in	O
OS	O
##CC	O
,	O
suggesting	O
that	O
active	O
energy	O
metabolism	O
using	O
glucose	S
is	O
performed	O
because	O
of	O
the	O
cell	O
proliferation	O
in	O
cancer	O
cells	O
.	O

B	O
##rief	O
##ly	O
,	O
the	O
tissues	O
were	O
fragment	O
##ed	O
,	O
ultra	O
##sonic	O
##ated	O
for	O
5	O
min	O
(	O
power	O
:	O
60	O
%	O
,	O
pulses	O
:	O
6	O
/	O
4	O
)	O
in	O
di	O
##st	O
##ille	O
##d	O
water	O
,	O
and	O
then	O
150	O
μ	O
l	O
ho	O
##mo	O
##gen	O
##ate	O
and	O
450	O
μ	O
l	O
met	B
##han	I
##ol	I
(	O
Me	O
##rc	O
##k	O
K	O
##G	O
##a	O
##A	O
)	O
were	O
mixed	O
in	O
a	O
1	O
.	O
5	O
-	O
m	O
##l	O
E	O
##ppe	O
##ndo	O
##rf	O
tube	O
for	O
protein	O
precipitation	O
.	O

To	O
control	O
pH	O
,	O
as	B
##cor	I
##bic	I
acid	I
was	O
added	O
to	O
urine	O
collection	O
containers	O
shortly	O
before	O
distribution	O
to	O
participants	O
,	O
and	O
complete	O
overnight	O
and	O
daytime	O
(	O
about	O
12	O
h	O
each	O
)	O
urine	O
samples	O
were	O
collected	O
following	O
consumption	O
of	O
the	O
beverage	O
on	O
days	O
1	O
,	O
7	O
,	O
14	O
,	O
28	O
,	O
42	O
,	O
56	O
,	O
70	O
and	O
84	O
.	O

Alan	B
##ine	I
,	O
a	O
non	O
-	O
essential	O
amino	O
acid	O
,	O
is	O
an	O
end	O
product	O
of	O
g	B
##lut	I
##ama	I
##te	I
oxidation	O
,	O
which	O
is	O
a	O
major	O
source	O
of	O
respiratory	O
energy	O
in	O
the	O
tumor	O
cell	O
.	O

Each	O
brain	O
was	O
di	O
##sse	O
##cted	O
under	O
the	O
supervision	O
of	O
ne	O
##uro	O
##ana	O
##tom	O
##ists	O
(	O
J	O
##X	O
,	O
SP	S
,	O
H	O
##J	O
##W	O
and	O
R	O
##LM	O
##F	O
)	O
,	O
who	O
accurately	O
identified	O
each	O
region	O
.	O

[	O
Google	O
Scholar	O
]	O
Harris	O
AL	O
,	O
Can	O
##t	O
##well	O
B	O
##M	O
,	O
Dow	O
##sett	O
M	O
.	O
High	O
dose	O
k	B
##eto	I
##cona	I
##zo	I
##le	I
:	O
end	O
##oc	O
##rine	O
and	O
therapeutic	O
effects	O
in	O
post	O
##men	O
##op	O
##aus	O
##al	O
breast	O
cancer	O
.	O

GP	O
-	O
tag	O
##ged	O
7	B
##α	I
,	I
x	I
-	I
di	I
##hy	I
##dr	I
##ox	I
##y	I
-	I
3	I
-	I
o	I
##x	I
##och	I
##ole	I
##st	I
-	I
4	I
-	I
en	I
-	I
26	I
-	I
o	I
##ic	I
acid	I
appears	O
as	O
s	O
##yn	O
and	O
anti	O
conform	O
##ers	O
appearing	O
at	O
2	O
.	O
67	O
and	O
3	O
.	O
79	O
min	O
in	O
R	O
##IC	O
(	O
b	O
)	O
.	O

Cho	B
##line	I
and	O
some	O
of	O
its	O
meta	O
##bol	O
##ites	O
,	O
such	O
as	O
beta	B
##ine	I
,	O
can	O
also	O
serve	O
as	O
a	O
source	O
of	O
met	O
##hyl	O
groups	O
that	O
are	O
required	O
for	O
proper	O
metabolism	O
of	O
certain	O
amino	O
acids	O
,	O
such	O
as	O
ho	B
##mo	I
##cy	I
##stein	I
##e	I
and	O
met	B
##hi	I
##oni	I
##ne	I
.	O

In	O
these	O
rapidly	O
pro	O
##life	O
##rating	O
cells	O
g	B
##lut	I
##amine	I
can	O
be	O
taken	O
up	O
and	O
converted	O
first	O
to	O
g	B
##lut	I
##ama	I
##te	I
via	O
g	O
##lut	O
##ami	O
##nas	O
##e	O
and	O
then	O
to	O
α	B
-	I
k	I
##eto	I
##g	I
##lut	I
##arate	I
via	O
as	O
##par	O
##tate	O
amino	O
##tra	O
##ns	O
##fer	O
##ase	O
followed	O
by	O
a	O
passage	O
through	O
part	O
of	O
the	O
t	B
##rica	I
##rb	I
##ox	I
##yl	I
##ic	I
acid	I
cycle	O
(	O
T	O
##CA	O
)	O
to	O
form	O
o	B
##xa	I
##lo	I
##ace	I
##tate	I
which	O
is	O
converted	O
via	O
ma	O
##late	O
de	O
##hy	O
##dr	O
##ogen	O
##ase	O
and	O
ma	O
##late	O
de	O
##car	O
##box	O
##yla	O
##se	O
to	O
p	B
##yr	I
##u	I
##vate	I
which	O
can	O
then	O
be	O
converted	O
to	O
al	B
##ani	I
##ne	I
or	O
la	B
##ct	I
##ate	I
via	O
E	O
##q	O
##s	O
1	O
or	O
2	O
(	O
see	O
)	O
.	O

The	O
a	O
##que	O
##ous	O
phase	O
was	O
extracted	O
with	O
ben	B
##zen	I
##e	I
and	O
,	O
after	O
disc	O
##ard	O
##ing	O
the	O
organic	O
layer	O
,	O
adjusted	O
to	O
pH	O
9	O
by	O
the	O
addition	O
of	O
NH	O
_	O
4	O
OH	O
and	O
extracted	O
again	O
with	O
ch	B
##lor	I
##of	I
##orm	I
.	O

In	O
the	O
pine	O
##al	O
g	O
##land	O
,	O
which	O
is	O
not	O
protected	O
by	O
the	O
blood	O
-	O
brain	O
-	O
barrier	O
,	O
se	B
##rot	I
##oni	I
##n	I
can	O
be	O
further	O
meta	O
##bol	O
##ized	O
to	O
me	B
##lat	I
##oni	I
##n	I
and	O
once	O
again	O
contribute	O
to	O
the	O
regulation	O
of	O
the	O
sleep	O
-	O
wake	O
cycle	O
.	O

AL	O
##T	O
and	O
AS	O
##T	O
,	O
gamma	O
g	O
##lut	O
##am	O
##yl	O
transfer	O
##ase	O
(	O
G	O
##G	O
##T	O
)	O
,	O
g	O
##lut	O
##ama	O
##te	O
de	O
##hy	O
##dr	O
##ogen	O
##ase	O
(	O
G	O
##LD	O
##H	O
)	O
,	O
c	B
##rea	I
##tin	I
##ine	I
and	O
bi	B
##li	I
##ru	I
##bin	I
serum	O
concentrations	O
were	O
analyzed	O
using	O
Co	O
##bas	O
600	O
##0	O
and	O
800	O
##0	O
analyze	O
##rs	O
(	O
Roche	O
,	O
Mann	O
##heim	O
,	O
Germany	O
)	O
.	O

Cal	O
##ci	O
##um	O
,	O
chloride	S
,	O
potassium	O
,	O
sodium	O
,	O
and	O
phosphate	S
concentrations	O
were	O
determined	O
in	O
a	O
24	O
-	O
h	O
urine	O
specimen	O
.	O

For	O
example	O
,	O
using	O
[	B
U	I
–	I
_	I
13	I
C	I
]	I
-	I
glucose	I
as	O
trace	O
##r	O
,	O
_	O
13	O
C	O
##3	O
,	O
_	O
13	O
C	O
##4	O
-	O
As	O
##p	O
plus	O
_	O
13	O
C	O
##1	O
,	O
_	O
13	O
C	O
##2	O
-	O
As	O
##p	O
are	O
products	O
of	O
the	O
K	O
##re	O
##bs	O
cycle	O
after	O
one	O
turn	O
while	O
_	O
13	O
C	O
##1	O
,	O
_	O
13	O
C	O
##2	O
,	O
_	O
13	O
C	O
##3	O
-	O
As	O
##p	O
is	O
derived	O
from	O
p	O
##yr	O
##u	O
##vate	O
car	O
##box	O
##yla	O
##tion	O
,	O
an	O
important	O
an	O
##ap	O
##ler	O
##otic	O
reaction	O
for	O
the	O
K	O
##re	O
##bs	O
cycle	O
.	O

L	O
##C	O
-	O
MS	O
/	O
MS	O
analyses	O
were	O
conducted	O
in	O
an	O
A	O
##gi	O
##lent	O
1100	O
series	O
L	O
##C	O
/	O
MS	O
##D	O
T	O
##rap	O
SL	S
mass	O
s	O
##pect	O
##rome	O
##ter	O
equipped	O
an	O
A	O
##gi	O
##lent	O
(	O
Pa	O
##lo	O
Alto	O
,	O
CA	O
)	O

An	O
ultra	O
-	O
pure	O
primary	O
quantitative	O
standard	O
,	O
t	B
##ris	I
(	I
h	I
##ydro	I
##xy	I
##met	I
##hyl	I
)	I
amino	I
##met	I
##hane	I
,	O
(	O
99	O
.	O
9	O
%	O
)	O
was	O
obtained	O
from	O
Mall	O
##in	O
##ck	O
##rod	O
##t	O
Baker	O
Inc	O
.	O
Phillips	O
##burg	O
,	O
NJ	O
.	O

In	O
summary	O
,	O
the	O
results	O
presented	O
here	O
do	O
not	O
support	O
the	O
hypothesis	O
that	O
the	O
car	O
##cin	O
##ogenic	O
bay	O
region	O
di	B
##ol	I
e	I
##pox	I
##ide	I
of	O
Ba	O
##P	O
is	O
de	O
##to	O
##xi	O
##fied	O
by	O
G	B
##S	I
##H	I
con	O
##ju	O
##gation	O
in	O
human	O
he	O
##pa	O
##to	O
##cy	O
##tes	O
.	O

The	O
post	O
##ulated	O
mechanism	O
of	O
serum	O
L	O
##D	O
##L	O
and	O
V	O
##LD	O
##L	O
down	O
-	O
regulation	O
demonstrated	O
in	O
our	O
study	O
is	O
the	O
systemic	O
activation	O
of	O
the	O
inflammatory	O
response	O
with	O
an	O
increase	O
in	O
secret	O
##ory	O
p	O
##hos	O
##ph	O
##oli	O
##pas	O
##e	O
A2	O
activity	O
that	O
promotes	O
h	O
##ydro	O
##lysis	O
of	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
in	O
L	O
##D	O
##L	O
and	O
V	O
##LD	O
##L	O
[	O
]	O
.	O

In	O
v	O
##ivo	O
IS	O
was	O
calculated	O
by	O
dividing	O
insulin	O
-	O
stimulate	O
##d	O
glucose	S
metabolism	O
over	O
the	O
last	O
30	O
min	O
of	O
the	O
c	O
##lamp	O
by	O
the	O
steady	O
-	O
state	O
plasma	O
insulin	O
concentration	O
,	O
as	O
reported	O
.	O

T	O
##B	O
was	O
strongly	O
associated	O
with	O
low	O
levels	O
of	O
c	B
##it	I
##ru	I
##llin	I
##e	I
and	O
or	B
##ni	I
##thin	I
##e	I
,	O
both	O
central	O
amino	O
acids	O
of	O
the	O
u	B
##rea	I
cycle	O
(	O
Fi	O
##g	O
.	O

Extra	O
pure	O
form	B
##ic	I
acid	I
was	O
purchased	O
from	O
F	O
##luk	O
##a	O
(	O
Sigma	O
-	O
Ad	O
##rich	O
,	O
St	O
.	O
Louis	O
,	O
M	O
##O	O
,	O
USA	O
)	O
.	O

Pat	O
##ients	O
with	O
significantly	O
o	O
##bs	O
##truct	O
##ive	O
CA	O
##D	O
had	O
higher	O
levels	O
of	O
h	O
##s	O
##CR	O
##P	O
,	O
t	B
##rig	I
##ly	I
##cer	I
##ide	I
,	O
and	O
lower	O
levels	O
of	O
(	O
HD	O
##L	O
)	O
ch	B
##ole	I
##ster	I
##ol	I
compared	O
to	O
those	O
without	O
significantly	O
o	O
##bs	O
##truct	O
##ive	O
CA	O
##D	O
.	O

Another	O
analysis	O
to	O
character	O
##ize	O
re	O
##lap	O
##se	O
and	O
re	O
##mission	O
status	O
showed	O
that	O
is	B
##ole	I
##uc	I
##ine	I
and	O
v	B
##ali	I
##ne	I
were	O
down	O
-	O
regulated	O
in	O
MS	O
re	O
##lap	O
##se	O
compared	O
to	O
MS	O
re	O
##mission	O
.	O

For	O
a	O
comprehensive	O
picture	O
of	O
di	B
##os	I
##met	I
##in	I
P	O
##K	O
,	O
g	B
##lu	I
##cu	I
##ron	I
##ide	I
meta	O
##bol	O
##ites	O
(	O
structures	O
and	O
MS	O
/	O
MS	O
s	O
##pect	O
##ra	O
in	O
Fi	O
##g	O
.	O

These	O
findings	O
indicate	O
that	O
18	O
meta	O
##bol	O
##ites	O
show	O
great	O
promise	O
as	O
meta	O
##bol	O
##ite	O
markers	O
for	O
evaluating	O
PD	O
,	O
with	O
related	O
metabolic	O
pathway	O
variations	O
observed	O
in	O
branched	O
chain	O
amino	O
acid	O
metabolism	O
,	O
g	B
##ly	I
##cine	I
der	O
##ivation	O
,	O
s	O
##tero	O
##id	O
hormone	O
bio	O
##sy	O
##nt	O
##hesis	O
,	O
try	B
##pt	I
##op	I
##han	I
metabolism	O
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
metabolism	O
.	O

Clinical	O
and	O
chemistry	O
measures	O
showed	O
that	O
re	B
##tino	I
##l	I
and	O
α	B
-	I
to	I
##co	I
##pher	I
##ol	I
had	O
the	O
strongest	O
associations	O
with	O
25	O
(	O
OH	O
)	O
D	O
.	O
Our	O
data	O
are	O
consistent	O
with	O
a	O
previous	O
study	O
in	O
the	O
Multi	O
##eth	O
##nic	O
Co	O
##hor	O
##t	O
that	O
showed	O
positive	O
associations	O
between	O
plasma	O
to	B
##co	I
##pher	I
##ols	I
and	O
25	O
(	O
OH	O
)	O
D	O
,	O
suggesting	O
the	O
potential	O
to	O
act	O
as	O
indicators	O
of	O
cancer	O
risk	O
.	O

Then	O
,	O
the	O
IL	O
-	O
L	O
##C	O
-	O
MR	O
##M	O
-	O
MS	O
method	O
was	O
used	O
for	O
targeted	O
relative	O
q	O
##uant	O
##itation	O
of	O
th	B
##iol	I
##s	I
from	O
cancer	O
##s	O
and	O
healthy	O
controls	O
.	O

The	O
major	O
loading	O
##s	O
for	O
the	O
first	O
principle	O
component	O
are	O
at	O
##tri	O
##but	O
##able	O
to	O
glucose	S
derivatives	O
,	O
two	O
unknown	O
##s	O
(	O
retention	O
times	O
of	O
27	O
.	O
8	O
min	O
and	O
30	O
.	O
0	O
min	O
)	O
and	O
a	O
met	B
##hyl	I
##xa	I
##nt	I
##hine	I
possibly	O
from	O
pu	B
##rine	I
degradation	O
.	O

The	O
meta	O
##bol	O
##omi	O
##cs	O
data	O
analysis	O
showed	O
that	O
the	O
higher	O
level	O
of	O
[	B
3	I
-	I
H	I
##B	I
]	I
/	I
[	I
glucose	I
]	I
ratio	O
at	O
7	O
days	O
after	O
surgery	O
can	O
differentiate	O
the	O
patients	O
with	O
or	O
without	O
g	B
##ly	I
##ce	I
##mic	I
control	O
at	O
3	O
months	O
after	O
surgery	O
.	O

Met	B
##hi	I
##oni	I
##ne	I
oxidation	O
was	O
found	O
to	O
be	O
associated	O
with	O
drug	O
-	O
induced	O
liver	O
injury	O
,	O
which	O
could	O
be	O
the	O
cause	O
of	O
the	O
observed	O
elevation	O
of	O
met	B
##hi	I
##oni	I
##ne	I
su	I
##lf	I
##one	I
during	O
intensive	O
anti	O
##biotic	O
treatment	O
.	O

In	O
the	O
T	O
##CA	O
cycle	O
,	O
AK	O
##G	O
is	O
produced	O
by	O
the	O
o	O
##xi	O
##da	O
##tive	O
de	O
##car	O
##box	O
##yla	O
##tion	O
of	O
is	B
##oc	I
##it	I
##rate	I
cat	O
##aly	O
##zed	O
by	O
is	O
##oc	O
##it	O
##rate	O
de	O
##hy	O
##dr	O
##ogen	O
##ase	O
(	O
ID	O
##H	O
;	O
)	O
.	O

Changes	O
in	O
f	O
##eca	O
##l	O
est	O
##ers	O
of	O
SC	O
##FA	O
##s	O
,	O
c	B
##y	I
##c	I
##lo	I
##he	I
##xa	I
##ne	I
##car	I
##box	I
##yl	I
##ic	I
acid	I
and	O
its	O
est	O
##er	O
derivatives	O
were	O
associated	O
with	O
I	O
##BS	O
-	O
D	O
,	O
and	O
significant	O
reduction	O
##s	O
of	O
BC	O
##FA	O
##s	O
were	O
observed	O
.	O

At	O
the	O
training	O
stage	O
,	O
we	O
identified	O
plasma	O
lip	O
##id	O
profiles	O
with	O
measurement	O
of	O
390	O
individual	O
apparent	O
lip	O
##id	O
species	O
,	O
as	O
defined	O
and	O
an	O
##not	O
##ated	O
on	O
the	O
basis	O
of	O
intact	O
ion	O
-	O
fragment	O
pairs	O
,	O
from	O
13	O
classes	O
of	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
and	O
ch	B
##ole	I
##ster	I
##yl	I
est	I
##ers	I
(	O
CE	O
)	O
by	O
using	O
lip	O
##ido	O
##mic	O
##s	O
in	O
185	O
plasma	O
samples	O
including	O
105	O
N	O
##SC	O
##LC	O
patients	O
and	O
80	O
age	O
-	O
,	O
sex	O
-	O
,	O
and	O
race	O
-	O
matched	O
healthy	O
controls	O
.	O

Based	O
on	O
the	O
comprehensive	O
data	O
set	O
generated	O
in	O
the	O
course	O
of	O
this	O
study	O
,	O
we	O
conclude	O
that	O
the	O
main	O
effect	O
induced	O
by	O
the	O
intervention	O
manifest	O
##s	O
in	O
glucose	S
.	O

Try	B
##pt	I
##op	I
##han	I
(	O
T	O
##RP	O
)	O
metabolism	O
pathway	O
.	O

High	O
serum	O
a	B
##rg	I
##ini	I
##ne	I
levels	O
that	O
co	O
##rrel	O
##ate	O
with	O
disease	O
severity	O
have	O
been	O
recently	O
described	O
for	O
UC	O
.	O

In	O
addition	O
,	O
Co	O
##A	O
is	O
involved	O
in	O
the	O
bio	O
##sy	O
##nt	O
##hesis	O
of	O
many	O
important	O
compounds	O
such	O
as	O
fatty	O
acids	O
,	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
and	O
ace	B
##ty	I
##l	I
##cho	I
##line	I
.	O

Panel	O
##s	O
with	O
only	O
meta	O
##bol	O
##ites	O
,	O
excluding	O
c	B
##rea	I
##tin	I
##ine	I
as	O
well	O
as	O
demographic	O
characteristics	O
,	O
were	O
still	O
more	O
accurate	O
(	O
R	O
##MS	O
##E	O
of	O
0	O
.	O
161	O
and	O
0	O
.	O
148	O
,	O
1	O
-	O
P	O
_	O
30	O
of	O
5	O
.	O
0	O
and	O
3	O
.	O
8	O
%	O
and	O
1	O
-	O
P	O
_	O
20	O
of	O
21	O
.	O
0	O
and	O
17	O
.	O
4	O
%	O
in	O
the	O
AA	O
##S	O
##K	O
and	O
ME	O
##SA	O
,	O
respectively	O
)	O
than	O
e	O
##G	O
##F	O
##R	O
##c	O
##r	O
;	O
the	O
improvement	O
was	O
statistical	O
##ly	O
significantly	O
better	O
for	O
all	O
metric	O
##s	O
with	O
1	O
-	O
P	O
_	O
30	O
less	O
than	O
half	O
for	O
e	O
##G	O
##F	O
##R	O
##c	O
##r	O
.	O

Ki	O
##net	O
##ic	O
studies	O
for	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
metabolism	O
were	O
conducted	O
at	O
conditions	O
linear	O
for	O
duration	S
of	O
in	O
##cu	O
##bation	O
and	O
protein	O
concentration	O
in	O
four	O
different	O
H	O
##LM	O
preparations	O
.	O

When	O
fatty	O
acid	O
β	O
-	O
oxidation	O
is	O
impaired	O
,	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
would	O
be	O
accumulated	O
in	O
the	O
liver	O
and	O
subsequently	O
released	O
into	O
circulation	O
.	O

Between	O
injection	O
##s	O
,	O
the	O
transfer	O
line	O
was	O
washed	O
with	O
successive	O
500	O
µ	O
##L	O
wash	O
##es	O
of	O
met	B
##han	I
##ol	I
and	O
he	O
##xa	O
##ne	O
/	O
et	O
##hyl	O
ace	O
##tate	O
/	O
ch	O
##lor	O
##of	O
##orm	O
(	O
3	O
:	O
2	O
:	O
1	O
)	O
.	O

Last	O
##ly	O
,	O
in	O
light	O
of	O
our	O
small	O
sample	O
size	O
,	O
we	O
performed	O
ex	O
##p	O
##lora	O
##tory	O
analyses	O
using	O
clusters	O
that	O
survived	O
at	O
a	O
more	O
liberal	O
threshold	O
(	O
un	O
##cor	O
##re	O
##cted	O
p	O
≤	O
0	O
.	O
00	O
##5	O
k	O
≥	O
89	O
)	O
in	O
order	O
to	O
examine	O
all	O
potential	O
K	B
##P	I
and	O
connectivity	O
associations	O
.	O

Ace	B
##ton	I
##it	I
##ril	I
##e	I
,	O
met	B
##han	I
##ol	I
,	O
ethanol	S
,	O
ch	B
##lor	I
##of	I
##orm	I
,	O
ace	B
##tic	I
acid	I
,	O
and	O
form	B
##ic	I
acid	I
were	O
purchased	O
from	O
Fisher	O
(	O
Fair	O
Lawn	O
,	O
New	O
Jersey	O
)	O
.	O

In	O
humans	O
,	O
20	B
-	I
H	I
##ET	I
##E	I
is	O
ex	O
##cre	O
##ted	O
primarily	O
as	O
a	O
g	B
##lu	I
##cu	I
##ron	I
##ide	I
con	O
##ju	O
##gate	O
,	O
as	O
we	O
have	O
confirmed	O
in	O
the	O
present	O
study	O
.	O

Ace	B
##to	I
##ace	I
##tate	I
;	O
15	B
.	I
α	I
-	I
glucose	I
;	O
16	O
.	O

(	O
a	O
)	O
shows	O
glucose	S
and	O
la	B
##ct	I
##ate	I
;	O
(	O
b	O
)	O
shows	O
high	O
abundance	O
meta	O
##bol	O
##ites	O
with	O
concentrations	O
<	O
500	O
–	O
100	O
μ	O
##M	O
;	O
and	O
panel	O
(	O
c	O
)	O
shows	O
low	O
-	O
abundance	O
meta	O
##bol	O
##ites	O
with	O
concentrations	O
<	O

A	O
significant	O
association	O
between	O
S	B
##phi	I
##ngo	I
##sin	I
##e	I
−	O
##1	O
phosphate	S
and	O
sex	O
was	O
identified	O
.	O

K	B
##yn	I
##uren	I
##ine	I
was	O
not	O
detected	O
in	O
urine	O
.	O

In	O
our	O
study	O
,	O
sa	B
##rc	I
##os	I
##ine	I
was	O
detected	O
in	O
high	O
abundance	O
.	O

Mi	O
##el	O
##ke	O
and	O
colleagues	O
focused	O
on	O
limited	O
s	B
##phi	I
##ngo	I
##lip	I
##id	I
analysis	O
that	O
did	O
not	O
include	O
GM	B
##3	I
and	O
had	O
a	O
smaller	O
sample	O
size	O
(	O
n	O
=	O
57	O
)	O
.	O

Eleven	O
substances	O
decreased	O
along	O
with	O
the	O
apparent	O
reduction	O
of	O
liver	O
com	O
##pen	O
##sat	O
##ory	O
ability	O
,	O
include	O
:	O
l	O
##ys	O
##o	O
##PC	O
##s	O
(	O
16	O
:	O
0	O
,	O
17	O
:	O
0	O
,	O
18	O
:	O
0	O
,	O
18	O
:	O
1	O
(	O
11	O
##Z	O
)	O
,	O
18	O
:	O
3	O
(	O
9	O
##Z	O
,	O
12	O
##Z	O
,	O
15	O
##Z	O
)	O
,	O
P	B
-	I
18	I
:	I
1	I
(	I
9	I
##Z	I
)	I
,	O
20	O
:	O
1	O
(	O
11	O
##Z	O
)	O
,	O
(	O
20	O
:	O
3	O
(	B
8	B
##Z	I
,	I
11	I
##Z	I
,	I
14	I
##Z	I
)	O
)	O
,	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##och	I
##olin	I
##e	I
,	O
or	B
##ni	I
##thin	I
##e	I
,	O
and	O
g	B
##lu	I
##cu	I
##ronic	I
acid	I
(	O
P	O
<	O
0	O
.	O
00	O
##1	O
)	O
.	O

Unlike	O
it	B
##acon	I
##ic	I
acid	I
,	O
which	O
acts	O
as	O
an	O
inhibitor	O
of	O
the	O
cat	O
##alytic	O
subunit	O
of	O
SD	O
##H	O
,	O
Ph	O
##CA	O
##s	O
most	O
likely	O
act	O
on	O
the	O
u	O
##bi	O
##quin	O
##one	O
-	O
binding	O
site	O
of	O
the	O
respiratory	O
chain	O
.	O

The	O
diagnosis	O
was	O
suspected	O
in	O
light	O
of	O
a	O
normal	O
test	B
##osterone	I
level	O
with	O
und	O
##ete	O
##ct	O
##able	O
go	O
##nado	O
##tro	O
##pin	O
##s	O
just	O
after	O
a	O
bilateral	O
test	O
##icular	O
surgery	O
.	O

Do	B
##pa	I
##mine	I
and	O
L	B
-	I
D	I
##OP	I
##A	I
are	O
part	O
of	O
the	O
do	O
##pa	O
##mine	O
##rg	O
##ic	O
pathway	O
in	O
t	B
##yr	I
##os	I
##ine	I
metabolism	O
where	O
do	B
##pa	I
##mine	I
is	O
produced	O
by	O
its	O
precursor	O
L	B
-	I
D	I
##OP	I
##A	I
,	O
which	O
further	O
is	O
synthesized	O
from	O
t	B
##yr	I
##os	I
##ine	I
and	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
all	O
of	O
which	O
were	O
shown	O
to	O
be	O
reduced	O
in	O
manifest	O
HD	O
patients	O
and	O
were	O
to	O
various	O
degrees	O
associated	O
with	O
disease	O
severity	O
.	O

His	B
##tamine	I
concentration	O
was	O
higher	O
in	O
CO	O
##PD	O
as	O
were	O
b	O
##as	O
##op	O
##hil	O
##s	O
(	O
%	O
)	O
,	O
cells	O
known	O
to	O
produce	O
his	B
##tamine	I
.	O

Multi	O
##var	O
##iate	O
statistics	O
differentiated	O
pro	O
##ton	O
s	O
##pect	O
##ra	O
from	O
I	O
-	O
and	O
I	O
+	O
based	O
on	O
several	O
derived	O
plasma	O
meta	O
##bol	O
##ites	O
that	O
were	O
elevated	O
during	O
insulin	O
de	O
##p	O
##ri	O
##vation	O
(	B
la	B
##ct	I
##ate	I
,	O
ace	B
##tate	I
,	O
all	B
##ant	I
##oi	I
##n	I
,	O
k	B
##eton	I
##es	I
)	O
.	O

9	O
##c	O
##RA	O
is	O
generated	O
from	O
re	B
##tina	I
##lde	I
##hy	I
##de	I
by	O
Ra	O
##ld	O
##h	O
and	O
meta	O
##bol	O
##ize	O
into	O
inactive	O
derivatives	O
by	O
Cy	O
##p	O
##26	O
.	O

Following	O
precipitation	O
with	O
met	B
##han	I
##ol	I
,	O
a	O
white	O
p	O
##elle	O
##t	O
remains	O
.	O

Other	O
enzymes	O
that	O
are	O
involved	O
in	O
the	O
conversion	O
of	O
P	O
##t	O
##d	O
##C	O
##ho	O
to	O
ch	B
##olin	I
##e	I
are	O
p	O
##hos	O
##ph	O
##oli	O
##pas	O
##e	O
A2	O
(	O
P	O
##LA	O
##2	O
)	O
that	O
yields	O
1	B
-	I
a	I
##cy	I
##l	I
##gly	I
##cer	I
##op	I
##hos	I
##ph	I
##och	I
##olin	I
##e	I
(	I
1	I
-	I
a	I
##cy	I
##l	I
GP	I
##C	I
)	I
,	O
l	O
##ys	O
##o	O
-	O
p	O
##hos	O
##ph	O
##oli	O
##pas	O
##e	O
A1	O
(	O
l	O
##ys	O
##o	O
-	O
P	O
##LA	O
##1	O
)	O
that	O
converts	O
1	B
-	I
a	I
##cy	I
##l	I
GP	I
##C	I
to	O
GP	B
##C	I
,	O
and	O
finally	O
the	O
enzyme	O
GP	O
##C	O
p	O
##hos	O
##ph	O
##odies	O
##tera	O
##se	O
(	O
GP	O
##C	O
-	O
PD	O
##E	O
)	O
converts	O
GP	B
##C	I
to	O
ch	B
##olin	I
##e	I
.	O

G	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
,	O
also	O
called	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
,	O
are	O
the	O
main	O
lip	O
##ids	O
of	O
cell	O
membrane	O
##s	O
and	O
key	O
components	O
in	O
cell	O
metabolism	O
and	O
signaling	O
.	O

Monitor	O
##ed	O
using	O
G	O
##C	O
-	O
MS	O
(	B
ma	B
##late	I
,	O
f	B
##uma	I
##rate	I
,	O
α	B
-	I
k	I
##eto	I
##g	I
##lut	I
##arate	I
)	O
and	O
N	O
##MR	O
(	O
c	O
##it	O
##rate	O
and	O
su	B
##cci	I
##nate	I
)	O
.	O

α	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
profiles	O
throughout	O
the	O
O	O
##G	O
##TT	O
.	O

Net	O
co	O
##rona	O
##ry	O
sin	O
##us	O
la	B
##ct	I
##ate	I
el	O
##ution	O
is	O
relatively	O
specific	O
but	O
cardiac	O
g	O
##ly	O
##co	O
##lysis	O
can	O
be	O
effect	O
##ed	O
by	O
co	O
-	O
m	O
##or	O
##bid	O
conditions	O
,	O
such	O
as	O
diabetes	O
,	O
and	O
detection	O
of	O
net	O
la	B
##ct	I
##ate	I
e	O
##ff	O
##lux	O
may	O
not	O
be	O
sensitive	O
to	O
small	O
areas	O
of	O
my	O
##oc	O
##ard	O
##ial	O
is	O
##che	O
##mia	O
.	O

The	O
combined	O
M	B
##T	I
##BE	I
solution	O
was	O
dried	O
by	O
N	O
_	O
2	O
at	O
35	O
##°	O
##C	O
,	O
re	O
##con	O
##stituted	O
in	O
200	O
µ	O
##L	O
met	B
##han	I
##ol	I
,	O
and	O
stored	O
at	O
−	O
##80	O
##°	O
##C	O
prior	O
to	O
analysis	O
.	O

Car	B
##ni	I
##tine	I
is	O
an	O
essential	O
meta	O
##bol	O
##ite	O
for	O
the	O
transport	O
of	O
long	O
-	O
chain	O
fatty	O
acids	O
into	O
the	O
mit	O
##och	O
##ond	O
##ria	O
and	O
for	O
the	O
regulation	O
of	O
the	O
in	O
##tra	O
##mit	O
##och	O
##ond	O
##rial	O
ratio	O
of	O
Ace	B
##ty	I
##l	I
-	I
Co	I
##A	I
to	O
free	O
Co	O
##A	O
.	O

He	O
##mo	O
##g	O
##lo	O
##bin	O
A1	O
##c	O
(	O
H	O
##b	O
##A	O
_	O
1	O
##c	O
)	O
,	O
glucose	S
,	O
total	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
u	B
##rea	I
nitrogen	I
,	O
and	O
c	B
##rea	I
##tin	I
##ine	I
were	O
measured	O
with	O
automated	O
standardized	O
laboratory	O
techniques	O
.	O

T	O
##iss	O
##ue	O
injury	O
is	O
associated	O
with	O
the	O
induction	O
of	O
both	O
CO	O
##X	O
-	O
2	O
and	O
P	O
##GE	O
_	O
2	O
and	O
several	O
pro	O
##in	O
##f	O
##lam	O
##mat	O
##ory	O
c	O
##yt	O
##oki	O
##nes	O
induce	O
CO	O
##X	O
-	O
2	O
transcription	O
and	O
the	O
synthesis	O
of	O
this	O
pro	B
##sta	I
##g	I
##land	I
##in	I
.	O

Inc	O
##reased	O
levels	O
of	O
serum	O
v	B
##ali	I
##ne	I
may	O
be	O
related	O
to	O
v	B
##ali	I
##ne	I
cat	O
##ab	O
##olis	O
##m	O
in	O
cancer	O
cells	O
.	O

A	O
der	O
##iva	O
##ti	O
##zation	O
agent	O
,	O
N	B
,	I
O	I
-	I
bi	I
##s	I
(	I
trim	I
##eth	I
##yl	I
##si	I
##ly	I
##l	I
)	I
t	I
##ri	I
##f	I
##lu	I
##oro	I
##ace	I
##tam	I
##ide	I
with	O
trim	B
##eth	I
##yl	I
##ch	I
##lor	I
##os	I
##ila	I
##ne	I
1	O
%	O
(	O
BS	O
##TF	O
##A	O
with	O
T	O
##MC	O
##S	O
1	O
%	O
)	O
,	O
was	O
added	O
,	O
and	O
the	O
samples	O
were	O
kept	O
in	O
a	O
the	O
##rm	O
##ore	O
##actor	O
(	O
Tech	O
##ne	O
,	O
Cambridge	O
,	O
UK	O
)	O
at	O
65	O
##°	O
##C	O
for	O
1	O
hour	O
.	O

Pre	O
##cu	O
##rs	O
##ors	O
of	O
glucose	S
in	O
g	O
##lu	O
##con	O
##eo	O
##genesis	O
,	O
including	O
la	B
##ct	I
##ate	I
and	O
al	B
##ani	I
##ne	I
,	O
were	O
found	O
at	O
lower	O
concentrations	O
in	O
patients	O
with	O
C	O
##IN	O
and	O
CS	O
##CC	O
,	O
which	O
clearly	O
points	O
to	O
an	O
altered	O
energy	O
metabolism	O
.	O

As	O
evidenced	O
by	O
a	O
fewer	O
number	O
of	O
significantly	O
changed	O
meta	O
##bol	O
##ites	O
with	O
considerable	O
fold	O
changes	O
,	O
thy	B
##mo	I
##l	I
was	O
found	O
to	O
be	O
superior	O
pre	O
##ser	O
##vat	O
##ive	O
for	O
urine	O
storage	O
at	O
high	O
temperatures	O
(	O
e	O
.	O
g	O
.	O
,	O
40	O
°C	O
)	O
.	O

In	O
addition	O
,	O
the	O
δ	O
=	O
1	O
.	O
15	O
–	O
1	O
.	O
17	O
pp	O
##m	O
region	O
was	O
excluded	O
in	O
view	O
of	O
ethanol	S
contamination	O
,	O
which	O
probably	O
arose	O
from	O
skin	O
di	O
##sin	O
##fect	O
##ion	O
prior	O
to	O
sample	O
collection	O
.	O

Met	B
##hyl	I
##ar	I
##gin	I
##ines	I
are	O
produced	O
after	O
a	B
##rg	I
##ini	I
##ne	I
residues	O
in	O
proteins	O
are	O
met	O
##hyl	O
##ated	O
by	O
PR	O
##MT	O
##1	O
and	O
following	O
subsequent	O
protein	O
breakdown	O
.	O

Con	O
##sist	O
##ent	O
with	O
our	O
findings	O
from	O
the	O
previous	O
study	O
,	O
we	O
observed	O
a	O
distinct	O
metabolic	O
signature	O
in	O
CR	O
##C	O
patients	O
including	O
t	B
##rica	I
##rb	I
##ox	I
##yl	I
##ic	I
acid	I
(	O
T	O
##CA	O
)	O
cycle	O
,	O
u	B
##rea	I
cycle	O
,	O
g	B
##lut	I
##amine	I
,	O
fatty	O
acids	O
,	O
and	O
gut	O
flora	O
metabolism	O
.	O

We	O
emphasize	O
that	O
the	O
current	O
human	O
samples	O
are	O
from	O
a	O
study	O
that	O
was	O
not	O
designed	O
specifically	O
for	O
the	O
examination	O
of	O
met	O
##form	O
##in	O
-	O
derived	O
MG	O
add	O
##uc	O
##ts	O
and	O
therefore	O
var	O
##iability	O
in	O
the	O
amount	O
of	O
met	B
##form	I
##in	I
prescribed	O
,	O
patient	O
compliance	O
,	O
and	O
spot	O
collection	O
of	O
urine	O
all	O
present	O
obstacles	O
for	O
the	O
further	O
analysis	O
of	O
the	O
data	O
.	O

This	O
hypothesis	O
is	O
supported	O
by	O
the	O
previously	O
reported	O
elevated	O
trans	B
-	I
18	I
:	I
1	I
residue	O
levels	O
in	O
red	O
blood	O
cell	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
in	O
the	O
T	O
##FA	O
group	O
.	O

Mi	O
##to	O
##cho	O
##nd	O
##rial	O
membrane	O
potential	O
,	O
a	O
##pop	O
##tosis	O
and	O
neutral	O
lip	O
##id	O
content	O
were	O
measured	O
by	O
flow	O
c	O
##yt	O
##ome	O
##try	O
analysis	O
using	O
J	O
##C	O
-	O
1	O
,	O
Anne	B
##xin	I
V	O
and	O
Li	O
##pid	O
##TO	O
##X	O
Red	O
probe	O
respectively	O
.	O

Li	O
##pid	O
##omi	O
##x	O
Mass	O
S	O
##pec	O
Standard	O
(	O
Catalogue	O
No	O
.	O
330	O
##70	O
##7	O
,	O
containing	O
160	O
μ	O
##g	O
/	O
m	O
##L	O
PC	B
(	I
15	I
:	I
0	I
/	I
18	I
:	I
1	I
)	I
(	O
d	O
##7	O
)	O
)	O
was	O
purchased	O
from	O
Ava	O
##nti	O
Polar	O
lip	O
##ids	O
(	O
Al	O
##aba	O
##ster	O
,	O
AL	O
,	O
USA	O
)	O
.	O

After	O
extraction	O
,	O
the	O
a	O
##que	O
##ous	O
layer	O
was	O
discarded	O
and	O
the	O
organic	O
solvent	O
portion	O
was	O
transferred	O
to	O
a	O
clean	O
glass	O
tube	O
and	O
e	O
##va	O
##porated	O
to	O
dry	O
##ness	O
at	O
60	O
##°	O
##C	O
under	O
a	O
stream	O
of	O
nitrogen	B
gas	I
.	O

Ava	O
##nti	O
Polar	O
Li	O
##pid	O
##s	O
supplied	O
the	O
pure	O
standards	O
for	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##let	I
##han	I
##ola	I
##mine	I
(	I
17	I
:	I
0	I
/	I
17	I
:	I
0	I
)	I
(	O
cat	O
.	O

Pol	O
##yun	O
##sat	O
##ura	O
##ted	O
fatty	O
acids	O
;	O
U	O
##DP	O
##G	O
:	O
U	B
##rid	I
##ine	I
dip	I
##hos	I
##phate	I
glucose	I
;	O
M	O
##U	O
##FA	O
:	O
Mon	O
##ou	O
##ns	O
##at	O
##ura	O
##ted	O
fatty	O
acids	O
.	O

The	O
standard	O
mix	O
was	O
di	O
##lut	O
##ed	O
with	O
re	O
##sus	O
##pen	O
##sion	O
solution	O
at	O
1	O
:	O
5000	O
for	O
K	O
##yn	O
,	O
c	O
##inn	O
##abar	O
##ini	O
##c	O
acid	O
,	O
and	O
x	B
##ant	I
##hur	I
##eni	I
##c	I
acid	I
standards	O
and	O
1	O
:	O
20	O
,	O
000	O
for	O
T	O
##rp	O
,	O
k	B
##yn	I
##uren	I
##ic	I
acid	I
,	O
and	O
se	B
##rot	I
##oni	I
##n	I
standards	O
.	O

St	B
##ati	I
##ns	I
,	O
widely	O
prescribed	O
drugs	O
for	O
treatment	O
of	O
card	O
##iovascular	O
disease	O
,	O
in	O
##hibit	O
the	O
bio	O
##sy	O
##nt	O
##hesis	O
of	O
low	O
density	O
lip	O
##op	O
##rote	O
##in	O
ch	B
##ole	I
##ster	I
##ol	I
(	O
L	O
##D	O
##L	O
-	O
C	O
)	O
.	O

The	O
improvement	O
in	O
prediction	O
of	O
micro	O
##vas	O
##cular	O
events	O
was	O
driven	O
by	O
the	O
addition	O
of	O
t	B
##yr	I
##os	I
##ine	I
alone	O
.	O

Third	O
,	O
we	O
were	O
not	O
able	O
to	O
disc	O
##rim	O
##inate	O
between	O
specific	O
is	O
##omer	O
##s	O
in	O
some	O
lip	O
##id	O
species	O
,	O
nor	O
between	O
the	O
FA	S
content	O
of	O
some	O
lip	O
##ids	O
such	O
as	O
PC	O
##s	O
and	O
LP	O
##Cs	O
.	O

I	O
##dent	O
##ification	O
of	O
is	O
##ob	O
##ari	O
##c	O
c	B
##era	I
##mi	I
##des	I
by	O
MS	O
/	O
MS	O
_	O
AL	O
##L	O
.	O

In	O
short	O
,	O
it	O
is	O
possible	O
that	O
the	O
increase	O
and	O
subsequent	O
decrease	O
in	O
F	B
##2	I
-	I
is	I
##op	I
##ros	I
##tan	I
##e	I
plasma	O
levels	O
may	O
occur	O
earlier	O
as	O
compared	O
to	O
what	O
we	O
observed	O
measuring	O
u	O
##rina	O
##ry	O
ex	O
##cre	O
##tion	O
of	O
F	B
##2	I
-	I
is	I
##op	I
##ros	I
##tan	I
##es	I
.	O

Compared	O
with	O
single	O
bio	O
##mark	O
##er	O
models	O
using	O
p	B
##hos	I
##ph	I
##ory	I
##l	I
##cho	I
##line	I
,	O
g	B
##ly	I
##co	I
##cho	I
##lic	I
acid	I
,	O
a	B
##rac	I
##hi	I
##don	I
##ic	I
acid	I
and	O
L	B
-	I
ace	I
##ty	I
##l	I
##car	I
##ni	I
##tine	I
individually	O
,	O
a	O
model	O
comprising	O
the	O
aforementioned	O
four	O
meta	O
##bol	O
##ites	O
exhibited	O
improved	O
AU	O
##C	O
values	O
,	O
sensitivity	O
and	O
specific	O
##ity	O
.	O

Alan	B
##ine	I
,	O
an	O
is	O
##omer	O
of	O
sa	B
##rc	I
##os	I
##ine	I
,	O
was	O
used	O
as	O
a	O
control	O
for	O
these	O
experiments	O
.	O

Other	O
lip	O
##ids	O
widely	O
regarded	O
as	O
major	O
players	O
on	O
at	O
##her	O
##os	O
##cle	O
##rot	O
##ic	O
path	O
##ogen	O
##esis	O
,	O
such	O
as	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
did	O
not	O
significantly	O
differ	O
in	O
quantity	O
between	O
di	O
##abe	O
##tic	O
and	O
non	O
##dia	O
##bet	O
##ic	O
samples	O
.	O

10	O
to	O
20	O
µ	O
##g	O
of	O
anti	O
-	O
BC	O
##h	O
##E	O
antibodies	O
were	O
bio	O
##tin	O
##yla	O
##ted	O
through	O
the	O
activated	B
su	I
##cci	I
##ni	I
##mi	I
##dy	I
##l	I
est	I
##er	I
in	O
an	O
a	O
##que	O
##ous	O
solution	O
at	O
pH	O
7	O
.	O
8	O
.	O

In	O
addition	O
,	O
l	O
##ys	O
##o	O
##PC	O
##s	O
themselves	O
have	O
been	O
recognized	O
as	O
vital	O
cell	O
-	O
signaling	O
molecules	O
acting	O
through	O
l	B
##ys	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
receptors	O
(	O
LP	O
##L	O
-	O
R	O
)	O
.	O

These	O
bio	O
##mark	O
##ers	O
indicated	O
the	O
involvement	O
of	O
the	O
metabolic	O
pathways	O
of	O
pu	B
##rine	I
metabolism	O
,	O
amino	O
acid	O
metabolism	O
and	O
t	B
##yr	I
##os	I
##ine	I
metabolism	O
in	O
AP	O
##S	O
development	O
.	O

Me	B
##OH	I
(	O
50	O
%	O
,	O
200	O
μ	O
##L	O
)	O
was	O
added	O
into	O
the	O
via	O
##ls	O
that	O
contained	O
the	O
ex	O
##oso	O
##me	O
p	O
##elle	O
##ts	O
.	O

B	O
##rief	O
##ly	O
,	O
10	O
μ	O
##L	O
al	O
##iq	O
##uo	O
##ts	O
of	O
plasma	O
and	O
10	O
μ	O
##L	O
of	O
internal	O
lip	O
##id	O
standards	O
(	O
Ava	O
##nti	O
SP	O
##LA	O
##S	O
##H	O
Li	O
##pid	O
##omi	O
##x	O
)	O
that	O
had	O
been	O
first	O
di	O
##lut	O
##ed	O
1	O
:	O
10	O
in	O
1	O
-	O
but	O
##ano	O
##l	O
/	B
met	B
##han	I
##ol	I
were	O
added	O
to	O
160	O
μ	O
##l	O
of	O
ice	O
-	O
cold	O
met	B
##han	I
##ol	I
followed	O
by	O
addition	O
of	O
320	O
μ	O
##l	O
of	O
ice	O
-	O
cold	O
ch	B
##lor	I
##of	I
##orm	I
and	O
v	O
##ortex	O
##ed	O
(	O
10	O
s	O
)	O
,	O
then	O
son	O
##ica	O
##ted	O
(	O
1	O
h	O
)	O
.	O

gives	O
a	O
s	O
##che	O
##matic	O
representation	O
of	O
the	O
g	O
##ly	O
##cola	O
##te	O
/	O
g	O
##ly	O
##ox	O
##ala	O
##te	O
/	O
o	O
##xa	O
##late	O
metabolism	O
,	O
shown	O
with	O
the	O
different	O
is	O
##oto	O
##pic	O
labels	O
used	O
during	O
this	O
study	O
,	O
in	O
which	O
both	O
healthy	O
volunteers	O
and	O
P	O
##H1	O
patients	O
received	O
a	O
prime	O
##d	O
,	O
continuous	O
in	O
##fusion	O
of	O
_	O
13	O
C	B
_	I
2	I
-	I
o	I
##xa	I
##late	I
and	O
1	O
-	O
_	O
13	O
C	B
-	I
g	I
##ly	I
##cola	I
##te	I
.	O

)	O
,	O
we	O
observed	O
that	O
the	O
HIV	O
-	O
T	O
##B	O
co	O
##hor	O
##t	O
exhibited	O
not	O
only	O
higher	O
D	O
##H	O
##EA	O
plasma	O
levels	O
,	O
but	O
also	O
higher	O
A	O
##ET	O
and	O
7	B
-	I
o	I
##x	I
##o	I
-	I
D	I
##H	I
##EA	I
concentrations	O
compared	O
with	O
HD	O
.	O

The	O
set	O
of	O
20	O
samples	O
was	O
measured	O
9	O
times	O
across	O
the	O
study	O
populations	O
and	O
included	O
measurements	O
of	O
24	B
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
using	O
the	O
liquid	O
-	O
liquid	O
extraction	O
method	O
without	O
met	B
##hyl	I
##amine	I
in	O
the	O
ch	O
##roma	O
##to	O
##graphic	O
method	O
and	O
the	O
method	O
with	O
met	B
##hyl	I
##amine	I
.	O

H	B
##y	I
##pot	I
##au	I
##rine	I
,	O
3	B
-	I
h	I
##ydro	I
##xy	I
##ant	I
##hra	I
##ni	I
##lli	I
##c	I
acid	I
,	O
and	O
g	B
##ly	I
##cy	I
##l	I
-	I
p	I
##hen	I
##yla	I
##lani	I
##ne	I
were	O
identified	O
as	O
potential	O
bio	O
##mark	O
##ers	O
specific	O
to	O
D	O
##OC	O
##K	O
##8	O
deficiency	O
.	O

A	O
##romatic	O
amino	O
acids	O
,	O
such	O
t	B
##yr	I
##os	I
##ine	I
and	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
were	O
significantly	O
higher	O
in	O
the	O
AC	O
##LF	O
group	O
compared	O
to	O
the	O
C	O
##LF	O
group	O
.	O

Based	O
on	O
our	O
study	O
(	O
data	O
not	O
shown	O
)	O
,	O
base	O
##line	O
separation	O
of	O
both	O
O	O
-	O
D	O
##V	O
##X	O
and	O
V	O
##X	O
en	O
##anti	O
##omer	O
##s	O
were	O
maintained	O
when	O
the	O
voltage	O
was	O
increased	O
from	O
10	O
k	B
##V	I
to	O
25	O
k	B
##V	I
.	O
To	O
achieve	O
a	O
compromise	O
between	O
good	O
run	O
time	O
repeat	O
##ability	O
and	O
short	O
analysis	O
time	O
,	O
the	O
voltage	O
was	O
varied	O
in	O
the	O
range	O
of	O
10	O
–	O
25	O
k	B
##V	I
.	O

H	O
##ER	O
##2	O
positive	O
patients	O
treated	O
with	O
p	B
##ac	I
##lit	I
##ax	I
##el	I
‐	I
lap	I
##ati	I
##ni	I
##b	I
(	O
n	O
=	O
16	O
)	O
.	O

A	O
trend	O
toward	O
higher	O
5	O
-	O
and	O
12	O
-	O
lip	O
##ox	O
##y	O
##gen	O
##ation	O
and	O
lower	O
15	O
-	O
lip	O
##ox	O
##y	O
##gen	O
##ation	O
products	O
and	O
18	B
-	I
H	I
##EP	I
##E	I
in	O
per	O
##ito	O
##ni	O
##tis	O
could	O
be	O
observed	O
with	O
high	O
inter	O
-	O
individual	O
variation	O
,	O
while	O
for	O
SP	O
##Ms	O
no	O
consistent	O
trend	O
toward	O
an	O
elevation	O
or	O
reduction	O
in	O
per	O
##ito	O
##ni	O
##tis	O
was	O
observed	O
.	O

In	O
fact	O
,	O
plasma	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
has	O
been	O
proposed	O
to	O
be	O
a	O
good	O
indicator	O
of	O
tissue	O
h	O
##y	O
##pox	O
##ia	O
,	O
and	O
has	O
been	O
reported	O
to	O
be	O
increased	O
in	O
plasma	O
from	O
RA	O
patients	O
in	O
comparison	O
with	O
controls	O
as	O
a	O
result	O
of	O
leak	O
##age	O
of	O
this	O
molecules	O
from	O
the	O
in	O
##f	O
##lam	O
##ed	O
is	O
##cha	O
##em	O
##ic	O
joints	O
[	O
,	O
]	O
.	O

In	O
addition	O
,	O
the	O
levels	O
of	O
con	O
##ju	O
##gated	O
serum	O
16	B
##α	I
-	I
OH	I
-	I
E	I
##2	I
were	O
much	O
higher	O
than	O
con	O
##ju	O
##gated	O
E	O
##2	O
in	O
both	O
post	O
##men	O
##op	O
##aus	O
##al	O
women	O
and	O
older	O
men	O
.	O

During	O
the	O
evaluation	O
of	O
SR	O
##M	O
90	O
##9	O
##c	O
samples	O
,	O
a	O
third	O
method	O
was	O
developed	O
using	O
a	O
pen	O
##ta	O
##f	O
##lu	O
##oro	O
##phe	O
##ny	O
##l	O
##p	O
##rop	O
##yl	O
column	O
that	O
also	O
separates	O
the	O
di	O
##aster	O
##eo	O
##mers	O
25	O
(	O
OH	O
)	O
D	O
_	O
3	O
and	O
3	B
-	I
e	I
##pi	I
-	I
25	I
(	I
OH	I
)	I
D	I
_	I
3	I
.	O

This	O
characteristic	O
inadvertently	O
results	O
in	O
decreased	O
levels	O
of	O
T	O
##CA	O
cycle	O
intermediate	O
##s	O
:	O
c	B
##it	I
##rate	I
and	O
su	B
##cci	I
##nate	I
.	O

The	O
separation	O
was	O
carried	O
out	O
using	O
a	O
Ki	O
##net	O
##ex	O
Ph	O
##en	O
##yl	O
-	O
He	O
##xy	O
##l	O
column	O
100	O
×	O
2	O
.	O
1	O
mm	O
,	O
1	O
.	O
7	O
μ	O
m	O
with	O
acid	O
##ified	O
water	O
and	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
as	O
mobile	O
phases	O
.	O

Five	O
bio	O
##genic	O
am	O
##ines	O
(	O
c	O
##rea	O
##tin	O
##ine	O
,	O
ta	B
##uri	I
##ne	I
,	O
t	B
##4	I
-	I
OH	I
-	I
Pro	I
,	O
SD	O
##MA	O
and	O
AD	O
##MA	O
)	O
and	O
two	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
(	O
AC	O
(	O
0	O
:	O
0	O
)	O
and	O
AC	B
(	I
2	I
:	I
0	I
)	I
)	O
were	O
q	O
##uant	O
##ified	O
in	O
all	O
samples	O
respectively	O
.	O

For	O
comparison	O
our	O
previous	O
study	O
of	O
CE	B
##R	I
involved	O
a	O
60	O
%	O
daily	O
energy	O
restriction	O
over	O
a	O
one	O
-	O
month	O
period	O
.	O

Pro	B
##py	I
##lene	I
g	I
##ly	I
##co	I
##l	I
is	O
likely	O
an	O
ex	O
##ogen	O
##ous	O
“	O
con	O
##tam	O
##ina	O
##nt	O
”	O
as	O
it	O
is	O
widely	O
used	O
as	O
a	O
solvent	O
in	O
many	O
pharmaceutical	O
##s	O
and	O
as	O
a	O
moist	O
##uri	O
##zer	O
in	O
co	O
##sm	O
##etics	O
,	O
lot	O
##ions	O
,	O
hand	O
sa	O
##ni	O
##ti	O
##zers	O
,	O
foods	O
and	O
tooth	O
##pas	O
##tes	O
.	O

In	O
contrast	O
,	O
there	O
was	O
an	O
increase	O
in	O
lip	O
##op	O
##hil	O
##ic	O
compounds	O
including	O
saturated	O
fatty	O
acid	O
(	B
palm	B
##itic	I
acid	O
)	O
,	O
p	O
##oly	O
##uns	O
##at	O
##ura	O
##ted	O
fatty	O
acids	O
(	O
o	O
##le	O
##ic	O
acid	O
,	O
l	B
##ino	I
##le	I
##ic	I
acid	I
and	O
a	O
##rac	O
##hi	O
##don	O
##ic	O
acid	O
)	O
,	O
and	O
branched	O
fatty	O
acid	O
est	O
##ers	O
of	O
h	B
##ydro	I
##xy	I
fatty	O
acids	O
(	O
FA	O
##HF	O
##As	O
)	O
.	O

Moreover	O
,	O
in	O
early	O
HC	O
##C	O
patients	O
,	O
Kaplan	O
–	O
Mei	O
##er	O
analysis	O
highlighted	O
the	O
serum	O
t	B
##yr	I
##os	I
##ine	I
level	O
as	O
a	O
predict	O
##or	O
for	O
overall	O
survival	O
(	O
OS	O
)	O
.	O

G	B
##lu	I
##cu	I
##ronic	I
acid	I
con	O
##ju	O
##gate	O
##s	O
of	O
bi	B
##li	I
##ru	I
##bin	I
-	I
IX	I
##al	I
##pha	I
in	O
normal	O
bi	O
##le	O
compared	O
with	O
post	O
-	O
o	O
##bs	O
##truct	O
##ive	O
bi	O
##le	O
.	O

One	O
normally	O
expects	O
cancer	O
cells	O
to	O
be	O
forming	O
la	B
##ct	I
##ate	I
for	O
host	O
cells	O
to	O
o	O
##xi	O
##dis	O
##e	O
,	O
but	O
Lisa	O
##nti	O
has	O
described	O
a	O
“	O
reverse	O
War	O
##burg	O
effect	O
”	O
in	O
which	O
cancer	O
cells	O
o	O
##xi	O
##dis	O
##e	O
la	B
##ct	I
##ate	I
formed	O
in	O
host	O
cells	O
.	O

R	O
##R	O
##MS	O
<	O
13	O
Y	O
:	O
Re	O
##lap	O
##sing	O
Re	O
##mit	O
##ting	O
Multiple	O
Sc	O
##ler	O
##osis	O
having	O
less	O
than	O
13	O
years	O
of	O
disease	O
duration	S
;	O
R	O
##R	O
##MS	O
>	O
=	O
13	O
Y	O
:	O
Re	O
##lap	O
##sing	O
Re	O
##mit	O
##ting	O
Multiple	O
Sc	O
##ler	O
##osis	O
with	O
>	O
=	O
13	O
years	O
of	O
disease	O
duration	S
;	O
SP	O
##MS	O
:	O
Secondary	O
Progressive	O
Multiple	O
Sc	O
##ler	O
##osis	O
;	O
PP	O
##MS	O
:	O
Primary	O
Progressive	O
Multiple	O
Sc	O
##ler	O
##osis	O
.	O

Re	O
##son	O
##ance	O
##s	O
arising	O
from	O
the	O
parent	O
drug	O
and	O
many	O
of	O
its	O
meta	O
##bol	O
##ites	O
were	O
observed	O
in	O
the	O
1	O
##D	O
N	O
##MR	O
urine	O
s	O
##pect	O
##ra	O
from	O
participants	O
who	O
had	O
not	O
ing	O
##ested	O
any	O
drug	O
or	O
had	O
ing	O
##ested	O
either	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
(	O
,	O
)	O
or	O
i	B
##bu	I
##p	I
##ro	I
##fen	I
(	O
,	O
;	O
as	O
discussed	O
below	O
)	O
.	O

However	O
,	O
a	B
##rac	I
##hi	I
##don	I
##ic	I
acid	I
(	O
AR	O
##A	O
,	O
20	O
:	O
4	O
)	O
and	O
do	B
##cos	I
##ah	I
##ex	I
##aen	I
##oi	I
##c	I
acid	I
(	O
D	O
##HA	O
22	O
:	O
6	O
)	O
,	O
which	O
are	O
long	O
-	O
chain	O
p	O
##oly	O
##uns	O
##at	O
##ura	O
##ted	O
acids	O
(	O
P	O
##U	O
##FA	O
##s	O
)	O
,	O
were	O
decreased	O
in	O
R	O
_	O
AT	O
and	O
R	O
_	O
BT	O
,	O
respectively	O
(	O
Show	O
##n	O
in	O
Figure	O
##s	O
,	O
)	O
.	O

After	O
adjustment	O
for	O
age	O
,	O
both	O
su	B
##cci	I
##nate	I
and	O
g	B
##lu	I
##cona	I
##te	I
remained	O
an	O
independent	O
predict	O
##or	O
for	O
both	O
scores	O
,	O
but	O
k	B
##yn	I
##uren	I
##ine	I
did	O
not	O
.	O

Ole	B
##ic	I
acid	I
was	O
not	O
detected	O
when	O
H	O
##IL	O
##IC	O
was	O
used	O
but	O
was	O
detected	O
using	O
R	O
##PC	O
.	O

These	O
ca	O
##li	O
##bra	O
##tion	O
standards	O
typically	O
contain	O
0	O
.	O
2	O
to	O
200	O
p	B
##g	I
of	O
each	O
E	O
##M	O
in	O
0	O
.	O
5	O
m	O
##l	O
of	O
MC	O
##F	O
-	O
10	O
##A	O
cell	O
l	O
##ys	O
##ate	O
and	O
were	O
ass	O
##ay	O
##ed	O
in	O
du	O
##plicate	O
.	O

The	O
in	O
##hibition	O
of	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
g	O
##lu	O
##cu	O
##ron	O
##ida	O
##tion	O
by	O
he	O
##co	O
##gen	O
##in	O
,	O
a	O
known	O
U	O
##G	O
##T	O
##1	O
##A	O
##4	O
inhibitor	O
,	O
was	O
observed	O
in	O
both	O
pool	O
##ed	O
H	O
##LM	O
##s	O
and	O
re	O
##comb	O
##ina	O
##nt	O
U	O
##G	O
##T	O
##1	O
##A	O
##4	O
.	O

Take	O
##n	O
together	O
,	O
our	O
data	O
demonstrate	O
that	O
not	O
just	O
the	O
end	O
##ogen	O
##ous	O
NO	O
##S	O
inhibitor	O
AD	B
##MA	I
but	O
other	O
met	B
##hyl	I
##ated	I
a	I
##rg	I
##ini	I
##ne	I
meta	O
##bol	O
##ites	O
can	O
collectively	O
provide	O
clinical	O
##ly	O
important	O
information	O
relevant	O
in	O
the	O
assessment	O
of	O
prevalent	O
significantly	O
o	O
##bs	O
##truct	O
##ive	O
CA	O
##D	O
and	O
long	O
-	O
term	O
card	O
##iovascular	O
risks	O
.	O

The	O
samples	O
for	O
Rev	O
##erse	O
##d	O
phase	O
C	O
##18	O
analysis	O
were	O
re	O
##con	O
##stituted	O
in	O
90	O
µ	O
##L	O
met	B
##han	I
##ol	I
.	O

In	O
this	O
study	O
,	O
the	O
levels	O
of	O
α	B
-	I
l	I
##ino	I
##len	I
##ic	I
acid	I
(	B
C	B
##18	I
:	I
3	I
)	O
and	O
its	O
downstream	O
ω	B
-	I
3	I
P	I
##U	I
##FA	I
meta	O
##bol	O
##ites	O
,	O
including	O
e	B
##ico	I
##sa	I
##pent	I
##aen	I
##oi	I
##c	I
acid	I
(	B
C	B
##20	I
:	I
5	I
)	O
,	O
do	B
##cos	I
##ap	I
##ent	I
##aen	I
##oi	I
##c	I
acid	I
(	B
C	B
##22	I
:	I
5	I
)	O
,	O
and	O
do	B
##cos	I
##ah	I
##ex	I
##aen	I
##oi	I
##c	I
acid	I
(	B
C	B
##22	I
:	I
6	I
)	O
,	O
were	O
lower	O
in	O
the	O
L	O
##C	O
group	O
than	O
the	O
control	O
group	O
;	O
however	O
,	O
do	B
##cos	I
##ap	I
##ent	I
##aen	I
##oi	I
##c	I
acid	I
(	B
C	B
##22	I
:	I
5	I
)	O
and	O
do	B
##cos	I
##ah	I
##ex	I
##aen	I
##oi	I
##c	I
acid	I
(	B
C	B
##22	I
:	I
6	I
)	O
did	O
not	O
show	O
significant	O
differences	O
.	O

Vita	B
##min	I
B	I
##2	I
(	O
rib	O
##of	O
##lav	O
##in	O
)	O
is	O
a	O
co	O
##fa	O
##ctor	O
for	O
met	B
##hyl	I
##ene	I
##te	I
##tra	I
##hy	I
##dr	I
##of	I
##olate	I
red	O
##uc	O
##tase	O
(	O
M	O
##TH	O
##F	O
##R	O
)	O
,	O
which	O
is	O
important	O
for	O
n	O
##uc	O
##leo	O
##tide	O
production	O
.	O

Note	O
that	O
the	O
composition	O
of	O
A	B
##F	I
reflects	O
the	O
f	O
##etal	O
re	O
##nal	O
system	O
,	O
thus	O
,	O
the	O
degree	O
of	O
f	O
##etal	O
re	O
##nal	O
mat	O
##uration	O
should	O
significantly	O
influence	O
the	O
level	O
of	O
almost	O
all	O
of	O
the	O
meta	O
##bol	O
##ites	O
in	O
the	O
am	O
##nio	O
##tic	O
fluid	O
[	O
,	O
,	O
]	O
.	O

For	O
each	O
HC	O
##C	O
case	O
identified	O
,	O
the	O
his	O
##tology	O
,	O
methods	O
used	O
to	O
di	O
##ag	O
##nose	O
the	O
cancer	O
,	O
and	O
α	B
-	I
f	I
##eto	I
##p	I
##rote	I
##in	I
(	O
A	O
##FP	O
)	O
levels	O
were	O
reviewed	O
to	O
exclude	O
meta	O
##static	O
cases	O
or	O
other	O
types	O
of	O
primary	O
liver	O
cancer	O
##s	O
.	O

The	O
op	O
##ti	O
##mized	O
ch	O
##roma	O
##to	O
##graphic	O
method	O
was	O
valid	O
##ated	O
,	O
tested	O
for	O
robust	O
##ness	O
,	O
and	O
applied	O
for	O
investigating	O
the	O
in	O
##tra	O
-	O
individual	O
var	O
##iability	O
in	O
ta	B
##uri	I
##ne	I
u	O
##rina	O
##ry	O
ex	O
##cre	O
##tion	O
in	O
eight	O
healthy	O
volunteers	O
over	O
a	O
period	O
of	O
8	O
weeks	O
.	O

X	O
##A	O
is	O
a	O
put	O
##ative	O
ne	O
##uro	O
##tra	O
##ns	O
##mit	O
##ter	O
that	O
activate	O
##s	O
m	O
##G	O
##lu	O
##2	O
and	O
m	O
##G	O
##lu	O
##3	O
meta	O
##bot	O
##ropic	O
g	B
##lut	I
##ama	I
##te	I
receptors	O
,	O
and	O
may	O
also	O
indirectly	O
influence	O
g	B
##lut	I
##ama	I
##ter	I
##gic	I
transmission	O
by	O
interacting	O
with	O
ve	O
##si	O
##cular	O
g	B
##lut	I
##ama	I
##te	I
transport	O
##ers	O
.	O

This	O
is	O
consistent	O
with	O
a	O
recent	O
report	O
showing	O
that	O
another	O
component	O
of	O
the	O
machinery	O
,	O
syntax	B
##in	I
3	O
,	O
is	O
needed	O
.	O

Based	O
on	O
the	O
similar	O
concentration	O
values	O
of	O
g	B
##lut	I
##amine	I
in	O
the	O
intact	O
serum	O
(	O
213	O
±	O
2	O
μ	O
M	O
)	O
to	O
the	O
sum	O
of	O
g	B
##lut	I
##amine	I
and	O
p	B
##yr	I
##og	I
##lut	I
##ami	I
##c	I
acid	I
in	O
the	O
protein	O
pre	O
##ci	O
##pit	O
##ated	O
serum	O
(	O
219	O
±	O
3	O
μ	O
M	O
)	O
and	O
ultra	O
##fi	O
##lter	O
##ed	O
serum	O
(	O
220	O
±	O
2	O
μ	O
M	O
)	O
,	O
we	O
estimate	O
the	O
p	B
##yr	I
##og	I
##lut	I
##ami	I
##c	I
acid	I
level	O
to	O
be	O
less	O
than	O
10	O
μ	O
M	O
in	O
intact	O
serum	O
.	O

It	O
has	O
been	O
found	O
that	O
there	O
is	O
synthesis	O
and	O
release	O
of	O
al	B
##ani	I
##ne	I
by	O
g	B
##lut	I
##ama	I
##ter	I
##gic	I
neurons	O
while	O
as	O
##tro	O
##cy	O
##tes	O
are	O
responsible	O
for	O
al	B
##ani	I
##ne	I
re	O
##up	O
##take	O
.	O

For	O
women	O
,	O
this	O
higher	O
intake	O
of	O
marine	O
-	O
derived	O
n	O
##−	O
##3	O
P	O
##U	O
##FA	O
##s	O
was	O
associated	O
with	O
lower	O
production	O
of	O
pro	B
##sta	I
##g	I
##land	I
##in	I
E	O
_	O
2	O
,	O
which	O
may	O
suggest	O
that	O
the	O
alter	O
##ation	O
of	O
e	B
##ico	I
##san	I
##oid	I
production	O
is	O
an	O
important	O
mechanism	O
that	O
under	O
##lies	O
the	O
ch	O
##em	O
##op	O
##re	O
##vent	O
##ive	O
effects	O
of	O
marine	O
-	O
derived	O
n	O
##−	O
##3	O
P	O
##U	O
##FA	O
##s	O
.	O

As	B
##par	I
##tic	I
acid	I
was	O
significantly	O
disturbed	O
only	O
in	O
mid	O
-	O
stages	O
PD	O
.	O

Here	O
we	O
report	O
a	O
novel	O
high	O
-	O
through	O
##put	O
ultra	O
-	O
high	O
performance	O
liquid	O
ch	O
##roma	O
##tography	O
-	O
tandem	O
mass	O
s	O
##pect	O
##rome	O
##try	O
(	O
U	O
##HP	O
##LC	O
-	O
MS	O
/	O
MS	O
)	O
platform	O
where	O
≈	O
##40	O
am	O
##ine	O
anal	O
##yte	O
##s	O
,	O
including	O
a	B
##rg	I
##ini	I
##ne	I
and	O
met	B
##hyl	I
##ar	I
##gin	I
##ines	I
can	O
be	O
detected	O
and	O
q	O
##uant	O
##ified	O
on	O
a	O
m	O
##olar	O
basis	O
,	O
in	O
a	O
single	O
sample	O
of	O
human	O
plasma	O
.	O

In	O
both	O
cases	O
,	O
the	O
fragment	O
ion	O
m	O
/	O
z	O
and	O
its	O
peak	O
height	O
form	O
the	O
E	B
##I	I
mass	O
spectrum	O
of	O
each	O
meta	O
##bol	O
##ite	O
.	O

Stock	O
solutions	O
of	O
u	O
##rem	O
##ic	O
to	B
##xin	I
##s	I
were	O
prepared	O
in	O
mill	O
##i	O
-	O
Q	O
and	O
stored	O
at	O
−	O
##20	O
##°	O
##C	O
.	O

By	O
##pass	O
surgery	O
with	O
S	O
##IR	O
##S	O
significantly	O
altered	O
26	O
am	O
##ine	O
anal	O
##yte	O
##s	O
,	O
including	O
a	B
##rg	I
##ini	I
##ne	I
and	O
AD	B
##MA	I
.	O

E	B
##stro	I
##gen	I
metabolism	O
pathways	O
did	O
not	O
appear	O
to	O
explain	O
more	O
of	O
the	O
B	O
##MI	O
-	O
breast	O
cancer	O
relationship	O
than	O
that	O
already	O
explained	O
by	O
un	O
##con	O
##ju	O
##gated	O
est	B
##rad	I
##iol	I
.	O

In	O
conclusion	O
,	O
we	O
confirm	O
previous	O
studies	O
that	O
the	O
k	B
##yn	I
##uren	I
##ine	I
pathway	O
is	O
altered	O
in	O
patients	O
with	O
SL	O
##E	O
compared	O
with	O
controls	O
.	O

A	O
)	O
Analysis	O
for	O
su	B
##lf	I
##oxide	I
##s	I
8	O
,	O
11	O
,	O
15	O
,	O
and	O
18	O
in	O
c	O
##re	O
##oso	O
##te	O
worker	O
’	O
s	O
urine	O
.	O

Try	O
##ptic	O
dig	O
##est	O
##ion	O
of	O
β	B
-	I
case	I
##in	I
was	O
performed	O
as	O
follows	O
:	O
1	O
mg	O
of	O
β	B
-	I
case	I
##in	I
was	O
dissolved	O
in	O
1	O
m	O
##L	O
of	O
water	O
.	O

We	O
identified	O
as	O
major	O
factors	O
:	O
(	O
i	O
)	O
so	O
##lub	O
##ility	O
in	O
formal	B
##in	I
solution	O
,	O
(	O
ii	O
)	O
co	O
##valent	O
bonding	O
to	O
cellular	O
component	O
(	O
e	O
.	O
g	O
.	O
,	O
protein	O
,	O
DNA	O
/	O
RNA	O
)	O
,	O
and	O
(	O
ii	O
##i	O
)	O
so	O
##lub	O
##ility	O
in	O
ethanol	S
and	O
x	B
##yle	I
##ne	I
.	O

Composition	O
of	O
major	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
in	O
human	O
ca	O
##da	O
##ver	O
corn	O
##eas	O
from	O
A	O
)	O

Con	O
##cent	O
##rations	O
of	O
co	B
##tin	I
##ine	I
and	O
trans	B
-	I
3	I
′	I
-	I
h	I
##ydro	I
##xy	I
##cot	I
##ini	I
##ne	I
in	O
urine	O
were	O
determined	O
using	O
liquid	O
ch	O
##roma	O
##tography	O
–	O
tandem	O
mass	O
s	O
##pect	O
##rome	O
##try	O
(	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
)	O
.	O

Sign	O
##ificant	O
decreases	O
in	O
hip	B
##pura	I
##te	I
,	O
a	O
meta	O
##bol	O
##ite	O
that	O
derives	O
from	O
micro	O
##bio	O
##ta	O
,	O
were	O
found	O
in	O
I	O
##B	O
##D	O
patients	O
.	O

Bari	O
##at	O
##ric	O
surgery	O
has	O
induced	O
a	O
global	O
down	O
-	O
regulation	O
of	O
k	B
##yn	I
##uren	I
##ine	I
meta	O
##bol	O
##ites	O
,	O
associated	O
with	O
weight	O
loss	O
.	O

Therefore	O
,	O
our	O
finding	O
suggested	O
that	O
in	O
the	O
study	O
of	O
specific	O
P	O
##I	O
species	O
using	O
MA	O
##LD	O
##I	O
-	O
TO	O
##F	O
MS	O
,	O
non	O
##pol	O
##ar	O
solvent	O
,	O
such	O
as	O
he	B
##xa	I
##ne	I
,	O
is	O
more	O
suitable	O
than	O
polar	O
solvent	O
##s	O
for	O
extract	O
##ing	O
P	O
##I	O
from	O
a	O
complex	O
lip	O
##id	O
mixture	O
.	O

Our	O
study	O
showed	O
the	O
or	B
##ni	I
##thin	I
##e	I
level	O
of	O
patients	O
was	O
significantly	O
decreased	O
,	O
which	O
suggest	O
prevent	O
##ive	O
supplement	O
of	O
or	B
##ni	I
##thin	I
##e	I
might	O
be	O
benefit	O
for	O
c	O
##ir	O
##r	O
##hos	O
##is	O
patients	O
.	O

After	O
in	O
##fi	O
##ltration	O
of	O
2	O
%	O
lid	B
##oc	I
##aine	I
,	O
a	O
small	O
in	O
##cision	O
was	O
made	O
in	O
the	O
skin	O
at	O
the	O
bio	O
##psy	O
site	O
,	O
through	O
which	O
a	O
14	O
-	O
gauge	O
bio	O
##psy	O
needle	O
was	O
inserted	O
to	O
a	O
depth	O
estimated	O
by	O
the	O
operator	O
.	O

l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
co	I
##line	I
lip	O
##ids	O
,	O
72	O
(	O
95	O
%	O
)	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##co	I
##lines	I
,	O
15	O
(	O
100	O
%	O
)	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
lip	O
##ids	O
and	O
35	O
(	O
83	O
%	O
)	O
amino	O
acids	O
plus	O
bio	O
##active	O
am	O
##ine	O
derivatives	O
.	O

The	O
product	O
ion	O
scan	O
s	O
##pect	O
##ra	O
for	O
(	O
A	O
)	O
L	B
-	I
Pro	I
##line	I
and	O
(	O
B	O
)	O
L	B
-	I
Pro	I
##line	I
-	I
_	I
13	I
C	O
_	O
5	O
,	O
_	O
15	O
N	O
(	O
IS	O
)	O
.	O

Several	O
meta	O
##bol	O
##ites	O
contributed	O
to	O
this	O
difference	O
,	O
in	O
particular	O
his	B
##tamine	I
,	O
x	B
##ant	I
##hur	I
##eni	I
##c	I
acid	I
,	O
ethanol	B
##amine	I
,	O
and	O
g	B
##lut	I
##amine	I
,	O
and	O
this	O
last	O
meta	O
##bol	O
##ite	O
was	O
also	O
increased	O
in	O
the	O
serum	O
of	O
respond	O
##ers	O
from	O
our	O
study	O
.	O

Eight	O
##een	O
of	O
these	O
associations	O
had	O
not	O
been	O
previously	O
reported	O
,	O
including	O
his	B
##ti	I
##dine	I
,	O
an	O
amino	O
acid	O
ne	O
##uro	O
##tra	O
##ns	O
##mit	O
##ter	O
,	O
and	O
but	B
##yr	I
##yl	I
##car	I
##ni	I
##tine	I
,	O
a	O
lip	O
##id	O
marker	O
of	O
whole	O
-	O
body	O
fatty	O
acid	O
oxidation	O
.	O

A	O
blank	O
(	O
70	O
%	O
met	B
##han	I
##ol	I
;	O
J	O
.	O
T	O
.	O
Baker	O
,	O
HP	O
##LC	O
grade	O
)	O
was	O
also	O
included	O
every	O
tenth	O
sample	O
for	O
column	O
cleaning	O
.	O

Basel	O
##ine	O
ant	O
##hr	O
##op	O
##ometric	O
and	O
blood	O
pressure	O
measurements	O
,	O
glucose	S
parameters	O
,	O
lip	O
##id	O
profiles	O
,	O
inflammatory	O
markers	O
,	O
u	O
##rina	O
##ry	O
car	B
##nos	I
##ine	I
levels	O
,	O
and	O
serum	O
car	O
##nos	O
##inas	O
##e	O
activity	O
and	O
content	O
were	O
not	O
different	O
between	O
the	O
groups	O
(	O
Table	O
)	O
.	O

My	O
##ri	O
##M	O
##atch	O
was	O
con	O
##figured	O
to	O
have	O
c	O
##ys	O
##tein	O
##es	O
to	O
contain	O
car	O
##ba	O
##mi	O
##dom	O
##eth	O
##yl	O
(	O
+	O
57	O
.	O
02	O
##1	O
Da	O
)	O
as	O
a	O
dynamic	O
modification	O
and	O
to	O
allow	O
for	O
the	O
possibility	O
of	O
oxidation	O
(	O
+	O
15	O
.	O
99	O
##6	O
)	O
on	O
met	B
##hi	I
##oni	I
##nes	I
,	O
and	O
de	O
##ami	O
##dation	O
(	O
−	O
##17	O
.	O
03	O
Da	O
)	O
of	O
N	O
-	O
terminal	O
g	B
##lut	I
##amine	I
##s	I
.	O

The	O
consumption	O
of	O
[	B
U	I
-	I
_	I
13	I
C	I
]	I
-	I
glucose	I
by	O
the	O
R	O
##h	O
##30	O
cells	O
at	O
24	O
h	O
was	O
comparable	O
to	O
the	O
consumption	O
by	O
the	O
primary	O
my	O
##ocytes	O
in	O
48	O
h	O
,	O
reflecting	O
the	O
slower	O
growth	O
rate	O
of	O
the	O
latter	O
.	O

Together	O
with	O
β	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yric	I
acid	I
,	O
ace	B
##to	I
##ace	I
##tate	I
and	O
ace	B
##tone	I
constitute	O
k	B
##eton	I
##e	I
bodies	O
,	O
which	O
are	O
important	O
by	O
-	O
products	O
of	O
fatty	O
acid	O
oxidation	O
in	O
the	O
liver	O
and	O
serve	O
as	O
a	O
major	O
source	O
of	O
energy	O
in	O
the	O
heart	O
and	O
brain	O
.	O

TD	O
##O	O
##2	O
,	O
breast	O
cancer	O
,	O
k	B
##yn	I
##uren	I
##ine	I
,	O
T	O
cell	O
,	O
im	O
##mu	O
##not	O
##her	O
##ap	O
##y	O

Val	O
##ida	O
##ting	O
this	O
response	O
score	O
in	O
another	O
independent	O
study	O
emphasized	O
the	O
importance	O
of	O
considering	O
this	O
score	O
and	O
its	O
signals	O
in	O
future	O
models	O
for	O
guiding	O
the	O
selection	O
of	O
h	B
##ydro	I
##ch	I
##lor	I
##oth	I
##ia	I
##zi	I
##de	I
therapy	O
.	O

We	O
did	O
note	O
a	O
change	O
in	O
N	B
-	I
met	I
##hyl	I
ni	I
##cot	I
##ini	I
##c	I
acid	I
levels	O
in	O
patients	O
with	O
c	O
##ir	O
##r	O
##hos	O
##is	O
and	O
between	O
those	O
with	O
or	O
without	O
OH	O
##E	O
.	O

Higher	O
ACT	O
##H	O
levels	O
were	O
positively	O
associated	O
with	O
a	O
number	O
of	O
meta	O
##bol	O
##ites	O
including	O
se	B
##rot	I
##oni	I
##n	I
(	O
r	O
=	O
0	O
.	O
35	O
)	O
,	O
k	B
##yn	I
##uren	I
##ine	I
(	O
r	O
=	O
0	O
.	O
49	O
)	O
,	O
k	B
##yn	I
##uren	I
##ic	I
acid	I
(	O
r	O
=	O
0	O
.	O
73	O
)	O
,	O
ni	B
##cot	I
##ini	I
##c	I
acid	I
(	O
r	O
=	O
0	O
.	O
34	O
)	O
,	O
and	O
ni	B
##cot	I
##ina	I
##mi	I
##de	I
(	O
r	O
=	O
0	O
.	O
44	O
)	O
.	O

In	O
the	O
K	O
##EG	O
##G	O
database	O
,	O
several	O
meta	O
##bol	O
##ites	O
of	O
nap	B
##ht	I
##hale	I
##ne	I
including	O
di	B
##hy	I
##dr	I
##ox	I
##y	I
-	I
di	I
##hy	I
##dron	I
##ap	I
##thal	I
##ene	I
##s	I
are	O
an	O
##not	O
##ated	O
in	O
the	O
metabolism	O
of	O
x	O
##eno	O
##biotics	O
by	O
C	O
##YP	O
(	O
map	O
##00	O
##9	O
##80	O
)	O
,	O
but	O
not	O
DD	O
##N	O
.	O

Similar	O
to	O
x	B
##yl	I
##ito	I
##l	I
,	O
also	O
u	O
##rina	O
##ry	O
PA	O
##A	O
in	O
o	O
##bes	O
##e	O
children	O
was	O
lower	O
than	O
in	O
NW	O
subjects	O
.	O

Interest	O
##ingly	O
,	O
f	O
##ae	O
##cal	O
met	B
##han	I
##ol	I
(	O
a	O
keys	O
##tone	O
meta	O
##bol	O
##ite	O
)	O
was	O
positively	O
related	O
to	O
H	O
##E	O
(	O
Table	O
)	O
and	O
was	O
significantly	O
higher	O
in	O
L	O
##C	O
(	O
Fi	O
##g	O
.	O

Instead	O
we	O
observed	O
positive	O
correlation	O
##s	O
between	O
concentration	O
of	O
try	B
##pt	I
##op	I
##han	I
and	O
k	B
##yn	I
##uren	I
##ine	I
in	O
both	O
the	O
patient	O
and	O
control	O
groups	O
,	O
indicating	O
a	O
normal	O
conversion	O
of	O
try	B
##pt	I
##op	I
##han	I
to	O
k	B
##yn	I
##uren	I
##ine	I
(	O
Table	O
)	O
.	O

Because	O
we	O
had	O
no	O
access	O
to	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
meta	O
##bol	O
##ites	O
(	O
except	O
t	B
##ria	I
##zo	I
##le	I
,	O
which	O
was	O
commercially	O
available	O
)	O
,	O
the	O
fragment	O
##ation	O
of	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
was	O
used	O
as	O
a	O
guide	O
for	O
interpretation	O
and	O
identification	O
of	O
potential	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
meta	O
##bol	O
##ites	O
,	O
where	O
possible	O
.	O

The	O
correlation	O
##s	O
of	O
co	B
##tin	I
##ine	I
and	O
trans	B
-	I
3	I
′	I
-	I
h	I
##ydro	I
##xy	I
##cot	I
##ini	I
##ne	I
with	O
3	O
-	O
EP	O
,	O
B	O
##UT	O
and	O
some	O
non	O
-	O
parent	O
PA	O
##H	O
were	O
higher	O
when	O
considering	O
the	O
non	O
-	O
c	O
##rea	O
##tin	O
##ine	O
-	O
normal	O
##ised	O
ET	O
##S	O
meta	O
##bol	O
##ite	O
data	O
(	O
and	O
for	O
c	O
##rea	O
##tin	O
##ine	O
-	O
normal	O
##ised	O
data	O
)	O
.	O

Changes	O
in	O
serum	O
meta	O
##bol	O
##ites	O
and	O
FA	S
at	O
6	O
months	O
post	O
‐	O
R	O
##Y	O
##GB	O
surgery	O
in	O
this	O
pilot	O
study	O
with	O
limited	O
number	O
of	O
participants	O
are	O
suggest	O
##ive	O
of	O
metabolic	O
improvement	O
;	O
larger	O
studies	O
are	O
warrant	O
##ed	O
for	O
confirmation	O
.	O

a	O
,	O
competitive	O
displacement	O
of	O
10	O
nm	O
t	O
##rit	O
##iated	O
9	O
-	O
c	O
##is	O
-	O
RA	O
from	O
pu	O
##rified	O
R	O
##X	O
##R	O
##α	O
protein	O
by	O
un	O
##la	O
##bel	O
##ed	O
9	O
-	O
c	O
##is	O
-	O
RA	O
(	O
♦	O
)	O
as	O
a	O
positive	O
control	O
,	O
C	O
##13	O
k	B
##eton	I
##e	I
(	O
[UNK]	O
)	O
,	O
14	O
′	O
-	O
AL	O
(	O
■	O
)	O
,	O
14	O
′	O
-	O
CA	O
(	O
+	O
)	O
,	O
and	O
re	B
##tin	I
##yl	I
ace	I
##tate	I
(	O
×	O
)	O
as	O
a	O
negative	O
control	O
.	O

Also	O
evident	O
in	O
are	O
the	O
_	O
13	O
C	O
cross	O
-	O
peaks	O
of	O
the	O
fatty	O
a	O
##cy	O
##l	O
chains	O
,	O
including	O
those	O
of	O
ω	O
CH	B
_	I
3	I
,	I
2	I
,	I
3	I
,	I
4	I
,	I
8	I
–	I
CH	I
_	I
2	I
,	O
and	O
un	O
##sat	O
##ura	O
##ted	O
pro	O
##tons	O
(	O
CH	O
=	O
CH	O
)	O
.	O

Direction	O
of	O
changes	O
and	O
statistical	O
significance	O
of	O
analyzed	O
h	B
##ydro	I
##phi	I
##lic	I
compounds	O
of	O
CS	O
##F	O
fluid	O
for	O
MS	O
vs	O
control	O
group	O
The	O
multi	O
##var	O
##iate	O
O	O
##PL	O
##S	O
-	O
D	O
##A	O
modeling	O
was	O
employed	O
using	O
the	O
knowledge	O
of	O
patient	O
’	O
s	O
classification	O
.	O

C	O
##uh	O
##ada	O
##r	O
et	O
al	O
.	O
showed	O
stability	O
of	O
c	B
##rea	I
##tin	I
##ine	I
and	O
glucose	S
in	O
serum	O
samples	O
for	O
up	O
to	O
ten	O
freeze	O
-	O
th	O
##aw	O
cycles	O
,	O
which	O
is	O
in	O
line	O
with	O
our	O
results	O
.	O

The	O
o	O
##xi	O
##da	O
##tive	O
pen	B
##tos	I
##e	I
phosphate	I
pathway	O
(	O
o	O
##x	O
##PP	O
##P	O
)	O
is	O
a	O
major	O
contributor	O
to	O
the	O
c	O
##yt	O
##oso	O
##lic	O
N	B
##AD	I
##P	I
##H	I
pool	O
,	O
and	O
its	O
contribution	O
to	O
the	O
this	O
pool	O
can	O
be	O
assessed	O
with	O
[	B
3	I
-	I
_	I
2	I
H	I
]	I
glucose	I
.	O

The	O
s	O
##pect	O
##ra	O
were	O
normal	O
##ized	O
to	O
total	O
al	B
##ip	I
##hat	I
##ic	I
spectral	O
area	O
to	O
eliminate	O
differences	O
in	O
meta	O
##bol	O
##ite	O
total	O
concentration	O
.	O

The	O
genetic	O
variance	O
in	O
g	B
##ly	I
##cine	I
meta	O
##bol	O
##ite	O
levels	O
was	O
11	O
.	O
1	O
%	O
in	O
F	O
##HS	O
.	O

These	O
results	O
are	O
con	O
##g	O
##rue	O
##nt	O
with	O
earlier	O
studies	O
describing	O
decreased	O
g	B
##ly	I
##cine	I
,	O
se	B
##rine	I
and	O
th	B
##re	I
##oni	I
##ne	I
levels	O
during	O
D	O
##M	O
.	O

P	O
,	O
place	O
##bo	O
(	O
mean	O
of	O
three	O
periods	O
)	O
;	O
A	O
,	O
am	B
##lo	I
##di	I
##pine	I
;	O
B	O
,	O
bi	O
##so	O
##p	O
##rol	O
##ol	O
;	O
H	O
,	O
h	B
##ydro	I
##ch	I
##lor	I
##oth	I
##ia	I
##zi	I
##de	I
;	O
L	O
,	O
los	O
##art	O
##an	O
.	O

Moreover	O
,	O
c	B
##rea	I
##tin	I
##ine	I
has	O
been	O
shown	O
to	O
be	O
inverse	O
##ly	O
associated	O
with	O
incident	O
C	O
##VD	O
while	O
man	B
##nose	I
was	O
found	O
to	O
be	O
directly	O
associated	O
with	O
incident	O
C	O
##VD	O
.	O

Ph	O
##arma	O
##co	O
##kin	O
##etic	O
variables	O
(	O
mean	O
,	O
95	O
%	O
C	O
##I	O
)	O
for	O
met	B
##had	I
##one	I
after	O
IV	O
(	O
5	O
mg	O
met	B
##had	I
##one	I
-	I
HC	I
##l	I
)	O
and	O
oral	O
and	O
re	O
##ct	O
##al	O
(	O
10	O
mg	O
met	B
##had	I
##one	I
HC	O
##I	O
)	O
in	O
7	O
human	O
subjects	O

Matrix	O
effect	O
,	O
calculated	O
as	O
a	O
matrix	O
factor	O
percent	O
(	O
M	O
##F	O
%	O
)	O
,	O
was	O
assessed	O
as	O
a	O
ratio	O
of	O
peak	O
area	O
ratio	O
of	O
spike	O
##d	O
anal	O
##yte	O
/	O
internal	O
standard	O
determined	O
for	O
Q	O
##C	O
low	O
sample	O
after	O
extraction	O
(	O
n	O
=	O
18	O
)	O
over	O
the	O
peak	O
area	O
ratio	O
of	O
the	O
spike	O
##d	O
anal	O
##yte	O
/	O
internal	O
standard	O
in	O
met	B
##han	I
##ol	I
:	O
H	O
_	O
2	O
O	B
,	I
1	I
:	I
1	I
(	O
n	O
=	O
3	O
)	O
.	O

However	O
,	O
there	O
was	O
more	O
than	O
four	O
-	O
fold	O
increase	O
in	O
3	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##ry	I
##ic	I
acid	I
between	O
T	O
##P	O
##1	O
and	O
T	O
##P	O
##2	O
,	O
which	O
decreased	O
to	O
a	O
similar	O
extent	O
between	O
T	O
##P	O
##2	O
and	O
T	O
##P	O
##3	O
.	O

Therefore	O
,	O
another	O
reasonable	O
explanation	O
for	O
the	O
decreased	O
g	B
##lut	I
##amine	I
observed	O
in	O
present	O
study	O
might	O
be	O
that	O
g	B
##lut	I
##amine	I
is	O
used	O
for	O
maintaining	O
the	O
formation	O
of	O
cellular	O
membrane	O
##s	O
in	O
es	O
##op	O
##hage	O
##al	O
cancer	O
tissues	O
.	O

They	O
are	O
al	B
##ani	I
##ne	I
,	O
g	B
##ly	I
##cine	I
,	O
v	B
##ali	I
##ne	I
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
se	B
##rine	I
,	O
th	B
##re	I
##oni	I
##ne	I
,	O
pro	B
##line	I
,	O
met	B
##hi	I
##oni	I
##ne	I
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
try	B
##pt	I
##op	I
##han	I
,	O
et	B
##hyl	I
2	I
-	I
met	I
##hyl	I
##ace	I
##to	I
##ace	I
##tate	I
,	O
le	B
##vu	I
##lini	I
##c	I
acid	I
,	O
ben	B
##z	I
##lma	I
##lon	I
##ic	I
acid	I
and	O
p	B
-	I
c	I
##res	I
##ol	I
.	O

Thus	O
,	O
women	O
and	O
young	O
adults	O
with	O
chronic	O
##ally	O
active	O
disease	O
or	O
frequent	O
flare	O
##s	O
might	O
be	O
considered	O
candidates	O
for	O
con	O
##com	O
##ita	O
##nt	O
s	B
##tat	I
##in	I
treatment	O
if	O
other	O
at	O
##her	O
##ogenic	O
risk	O
factors	O
are	O
present	O
.	O

The	O
micro	O
##bio	O
##me	O
features	O
along	O
with	O
end	B
##oto	I
##xin	I
,	O
am	O
##monia	O
,	O
and	O
meta	O
##bol	O
##omi	O
##cs	O
were	O
correlated	O
using	O
a	O
S	O
##pear	O
##man	O
’	O
s	O
correlation	O
function	O
and	O
then	O
filtered	O
for	O
correlation	O
##s	O
>	O
0	O
.	O
60	O
and	O
p	O
<	O
0	O
.	O
05	O
.	O

The	O
disc	O
##rim	O
##inating	O
meta	O
##bol	O
##ites	O
included	O
a	B
##cy	I
##l	I
-	I
car	I
##ni	I
##tine	I
##s	I
,	O
a	B
##cy	I
##l	I
-	I
g	I
##ly	I
##cine	I
##s	I
and	O
meta	O
##bol	O
##ites	O
related	O
to	O
try	B
##pt	I
##op	I
##han	I
metabolism	O
.	O

All	O
discussed	O
pathways	O
:	O
beta	O
-	O
oxidation	O
,	O
k	B
##eton	I
##e	I
bodies	O
production	O
,	O
g	O
##ly	O
##co	O
##lysis	O
and	O
T	O
##CA	O
cycle	O
are	O
linked	O
via	O
o	O
##xi	O
##da	O
##tive	O
p	O
##hos	O
##ph	O
##ory	O
##lation	O
to	O
cellular	O
red	O
##ox	O
state	O
.	O

In	O
some	O
experiments	O
,	O
in	B
##dom	I
##eth	I
##ac	I
##in	I
or	O
l	B
##ute	I
##olin	I
(	O
both	O
100	O
u	O
##M	O
final	O
concentration	O
)	O
were	O
added	O
to	O
the	O
enzymes	O
or	O
l	O
##ys	O
##ates	O
5	O
min	O
prior	O
to	O
adding	O
the	O
reaction	O
mixture	O
.	O

Furthermore	O
,	O
transformed	O
R	O
##h	O
##30	O
cells	O
were	O
much	O
more	O
active	O
in	O
de	O
no	O
##vo	O
G	B
##S	I
##H	I
synthesis	O
than	O
the	O
primary	O
my	O
##ocytes	O
.	O

P	O
##E	O
(	O
P	O
-	O
16	O
:	O
0	O
/	O
14	O
:	O
0	O
)	O
and	O
12	B
,	I
13	I
-	I
di	I
##hy	I
##dr	I
##ox	I
##y	I
-	I
11	I
-	I
met	I
##ho	I
##xy	I
-	I
9	I
-	I
o	I
##ct	I
##ade	I
##ce	I
##no	I
##ic	I
acid	I
were	O
all	O
down	O
##re	O
##gu	O
##lated	O
in	O
the	O
newly	O
diagnosed	O
T	O
##2	O
##DM	O
group	O
with	O
fold	O
changes	O
at	O
3	O
.	O
88	O
and	O
2	O
.	O
65	O
,	O
respectively	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
observed	O
the	O
metabolic	O
disturbance	O
of	O
SL	S
in	O
A	O
##ER	O
##D	O
patients	O
.	O

Nine	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
(	O
PC	O
##s	O
)	O
were	O
associated	O
with	O
o	O
##besity	O
–	O
all	O
showing	O
inverse	O
associations	O
,	O
with	O
the	O
exception	O
of	O
PC	B
(	I
38	I
:	I
3	I
)	I
,	O
which	O
showed	O
a	O
positive	O
association	O
with	O
o	O
##besity	O
(	O
β	O
=	O
0	O
.	O
36	O
,	O
P	O
=	O
1	O
.	O
7	O
##E	O
-	O
06	O
;	O
)	O
.	O

Gene	O
expression	O
of	O
AR	O
##ID	O
##1	O
##A	O
was	O
significantly	O
increased	O
in	O
the	O
α	B
-	I
O	I
##G	I
treated	O
condition	O
(	O
p	O
=	O
0	O
.	O
01	O
##8	O
)	O

AD	B
##MA	I
and	O
plasma	O
h	O
##A	O
##rg	O
:	B
AD	B
##MA	I
ratios	O
.	O

α	B
-	I
Lin	I
##ole	I
##nic	I
acid	I
(	B
C	B
##18	I
:	I
3	I
,	O
ω	B
-	I
3	I
P	I
##U	I
##FA	I
)	O
is	O
a	O
major	O
precursor	O
of	O
ω	B
-	I
3	I
P	I
##U	I
##FA	I
meta	O
##bol	O
##ites	O
.	O

The	O
top	O
14	O
meta	O
##bol	O
##ites	O
and	O
the	O
c	B
##rea	I
##tine	I
/	I
c	I
##rea	I
##tin	I
##ine	I
ratio	O
all	O
had	O
areas	O
under	O
the	O
curve	O
(	O
AU	O
##C	O
)	O
values	O
greater	O
than	O
0	O
.	O
5	O
in	O
the	O
R	O
##OC	O
analysis	O
8	O
of	O
these	O
15	O
bio	O
##mark	O
##ers	O
had	O
AU	O
##C	O
greater	O
than	O
0	O
.	O
8	O
,	O
including	O
c	B
##rea	I
##tine	I
,	O
c	B
##rea	I
##tin	I
##ine	I
,	O
c	B
##rea	I
##tine	I
/	I
c	I
##rea	I
##tin	I
##ine	I
ratio	O
,	O
and	O
the	O
two	O
test	B
##osterone	I
meta	O
##bol	O
##ites	O
.	O

Whether	O
the	O
anti	O
##de	O
##pressive	O
effect	O
of	O
acute	O
sleep	O
de	O
##p	O
##ri	O
##vation	O
is	O
linked	O
to	O
the	O
increased	O
circulating	O
levels	O
of	O
try	B
##pt	I
##op	I
##han	I
,	O
se	B
##rot	I
##oni	I
##n	I
,	O
ta	B
##uri	I
##ne	I
,	O
and	O
me	B
##lat	I
##oni	I
##n	I
deserves	O
further	O
study	O
.	O

By	O
combining	O
the	O
N	O
##MO	O
##SD	O
-	O
like	O
and	O
L	O
##BL	O
subgroup	O
##s	O
,	O
my	B
##oi	I
##nos	I
##ito	I
##l	I
and	O
format	B
##e	I
levels	O
of	O
patients	O
on	O
im	O
##mu	O
##nos	O
##up	O
##press	O
##ants	O
were	O
compared	O
with	O
patients	O
not	O
on	O
im	O
##mu	O
##nos	O
##up	O
##press	O
##ants	O
.	O

In	O
the	O
r	B
##is	I
##per	I
##ido	I
##ne	I
group	O
,	O
1	O
patient	O
was	O
identified	O
with	O
consistently	O
a	O
##ber	O
##rant	O
drug	O
concentrations	O
:	O
cap	O
##illa	O
##ry	O
levels	O
of	O
the	O
r	B
##is	I
##per	I
##ido	I
##ne	I
active	O
m	O
##oi	O
##ety	O
in	O
this	O
subject	O
were	O
much	O
higher	O
(	O
up	O
to	O
18	O
‐	O
fold	O
)	O
than	O
the	O
ve	O
##nous	O
levels	O
for	O
unknown	O
reason	O
.	O

The	O
disc	O
##rim	O
##inating	O
meta	O
##bol	O
##ites	O
between	O
the	O
groups	O
were	O
identified	O
as	O
lip	O
##ids	O
,	O
la	B
##ct	I
##ate	I
,	O
g	B
##lut	I
##ama	I
##te	I
,	O
glucose	S
,	O
l	B
##ys	I
##ine	I
,	O
al	B
##ani	I
##ne	I
,	O
p	B
##yr	I
##u	I
##vate	I
,	O
and	O
N	O
##AG	O
.	O

Ser	O
##um	O
PS	O
##A	O
is	O
compared	O
to	O
the	O
added	O
value	O
of	O
serum	O
(	O
A	O
)	O
ho	B
##mo	I
##cy	I
##stein	I
##e	I
,	O
(	O
B	O
)	O
c	B
##ys	I
##tat	I
##hi	I
##oni	I
##ne	I
,	O
and	O
(	O
C	O
)	O
c	B
##ys	I
##tein	I
##e	I
.	O

Level	O
##s	O
of	O
14	B
-	I
des	I
##met	I
##hyl	I
la	I
##nos	I
##tero	I
##l	I
were	O
associated	O
with	O
these	O
same	O
ABC	O
##G	O
##5	O
/	O
ABC	O
##G	O
##8	O
variants	O
,	O
which	O
confirmed	O
the	O
correlation	O
between	O
plant	O
s	O
##tero	O
##ls	O
and	O
14	B
-	I
des	I
##met	I
##hyl	I
la	I
##nos	I
##tero	I
##l	I
,	O
and	O
suggested	O
that	O
the	O
latter	O
s	O
##tero	O
##l	O
was	O
an	O
ABC	O
##G	O
##5	O
/	O
ABC	O
##G	O
##8	O
substrate	O
.	O

MC	O
##F	O
-	O
7	O
W	O
##S	O
##8	O
cells	O
,	O
provided	O
by	O
Dr	O
.	O
C	O
.	O
Jordan	O
,	O
are	O
an	O
est	B
##rogen	I
sensitive	O
cell	O
line	O
(	O
ER	O
+	O
)	O
and	O
were	O
clone	O
##d	O
from	O
MC	O
##F	O
-	O
7	O
cells	O
,	O
as	O
previously	O
described	O
.	O

The	O
ratio	O
of	O
the	O
2	O
-	O
h	O
##ydro	O
##xy	O
##lation	O
pathway	O
to	O
parent	O
est	O
##rogen	O
##s	O
(	O
H	O
##R	O
=	O
0	O
.	O
66	O
,	O
95	O
%	O
C	O
##I	O
=	O
0	O
.	O
51	O
to	O
0	O
.	O
87	O
)	O
and	O
the	O
ratio	O
of	O
4	O
-	O
h	O
##ydro	O
##xy	O
##lation	O
pathway	O
cat	B
##ech	I
##ols	I
to	O
4	O
-	O
h	O
##ydro	O
##xy	O
##lation	O
pathway	O
met	B
##hyl	I
##ated	I
cat	I
##ech	I
##ols	I
(	O
H	O
##R	O
=	O
1	O
.	O
34	O
,	O
95	O
%	O
C	O
##I	O
=	O
1	O
.	O
04	O
to	O
1	O
.	O
72	O
)	O
were	O
statistical	O
##ly	O
significantly	O
associated	O
with	O
the	O
risk	O
of	O
breast	O
cancer	O
and	O
remained	O
so	O
after	O
adjustment	O
for	O
un	O
##con	O
##ju	O
##gated	O
est	B
##rad	I
##iol	I
.	O

Of	O
the	O
five	O
meta	O
##bol	O
##ites	O
that	O
exhibited	O
a	O
co	O
##sin	O
##e	O
rhythm	O
on	O
both	O
days	O
,	O
3	O
had	O
an	O
increase	O
in	O
amplitude	O
during	O
the	O
24	O
h	O
of	O
continued	O
wake	O
##fulness	O
on	O
day	O
2	O
:	O
2	O
-	O
h	O
##ydro	O
##xy	O
##is	O
##ob	O
##ut	O
##yra	O
##te	O
(	O
17	O
.	O
5	O
%	O
increase	O
)	O
;	O
T	B
##MA	I
##O	I
(	O
18	O
.	O
6	O
%	O
)	O
and	O
t	B
##rig	I
##one	I
##llin	I
##e	I
(	O
15	O
.	O
5	O
%	O
)	O
.	O

The	O
sum	O
of	O
co	B
##rt	I
##is	I
##ol	I
meta	O
##bol	O
##ites	O
in	O
urine	O
using	O
G	O
##C	O
/	O
MS	O
in	O
S	O
##IM	O
can	O
be	O
clinical	O
##ly	O
applicable	O
to	O
subjects	O
with	O
any	O
kind	O
of	O
disease	O
considering	O
its	O
non	O
-	O
invasive	O
##ness	O
and	O
ease	O
of	O
collection	O
compared	O
to	O
frequent	O
blood	O
sampling	O
.	O

On	O
D	O
##1	O
,	O
PC	B
a	I
##a	I
C	I
##38	I
:	I
1	I
and	O
C	O
##4	O
(	B
but	B
##yr	I
##yl	I
-	I
a	I
##cy	I
##l	I
##car	I
##ni	I
##tine	I
)	O
had	O
a	O
strong	O
positive	O
correlation	O
with	O
28	O
-	O
day	O
mortality	O
,	O
whereas	O
PC	B
a	I
##a	I
C	I
##40	I
:	I
6	I
and	O
PC	B
a	I
##e	I
C	I
##38	I
:	I
0	I
were	O
inverse	O
##ly	O
associated	O
.	O

B	O
##12	O
,	O
vitamin	O
B	O
-	O
12	O
;	O
c	O
##B	O
##12	O
,	O
combined	O
indicator	O
of	O
vitamin	O
B	O
-	O
12	O
status	O
;	O
Ho	O
##lo	O
##TC	O
,	O
ho	O
##lot	O
##ran	O
##sco	O
##bal	O
##ami	O
##n	O
;	O
MMA	O
,	O
met	B
##hyl	I
##mal	I
##onic	I
acid	I
;	O
t	O
##H	O
##cy	O
,	O
total	O
plasma	O
ho	B
##mo	I
##cy	I
##stein	I
##e	I
.	O

Panel	O
B	O
shows	O
a	O
mass	O
spectrum	O
of	O
NL	O
##S	O
##21	O
##3	O
(	O
corresponding	O
to	O
the	O
neutral	O
loss	O
of	O
p	B
##hos	I
##ph	I
##och	I
##olin	I
##e	I
plus	O
met	B
##hyl	I
al	I
##de	I
##hy	I
##de	I
)	O
displaying	O
the	O
presence	O
of	O
SM	O
species	O
in	O
the	O
Li	O
##OM	O
##e	O
-	O
treated	O
lip	O
##id	O
solution	O
;	O
the	O
spectrum	O
was	O
acquired	O
in	O
the	O
positive	O
-	O
ion	O
mode	O
after	O
addition	O
of	O
a	O
small	O
amount	O
of	O
Li	O
##OH	O
to	O
the	O
lip	O
##id	O
solution	O
.	O

The	O
mass	O
s	O
##pect	O
##rome	O
##ter	O
was	O
previously	O
ca	O
##li	O
##bra	O
##ted	O
with	O
0	O
.	O
1	O
%	O
p	B
##hos	I
##ph	I
##ori	I
##c	I
acid	I
in	O
water	O
/	O
ace	O
##ton	O
##it	O
##ril	O
##e	O
(	O
1	O
:	O
1	O
,	O
v	O
/	O
v	O
)	O
and	O
a	O
solution	O
of	O
0	O
.	O
5	O
ng	O
/	O
μ	O
##L	O
le	B
##uc	I
##ine	I
en	I
##ke	I
##pha	I
##lin	I
in	O
water	O
/	O
ace	O
##ton	O
##it	O
##ril	O
##e	O
(	O
1	O
:	O
1	O
,	O
v	O
/	O
v	O
)	O
with	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
in	O
##fused	O
in	O
the	O
reference	O
probe	O
at	O
a	O
flow	O
rate	O
of	O
5	O
μ	O
##L	O
/	O
min	O
was	O
used	O
as	O
lock	O
mass	O
spray	O
at	O
a	O
30	O
s	O
frequency	O
for	O
accurate	O
mass	O
determination	O
.	O

G	B
##ly	I
##ox	I
##yla	I
##te	I
and	O
its	O
precursor	O
g	B
##ly	I
##cola	I
##te	I
are	O
directly	O
implicated	O
in	O
lip	O
##id	O
β	O
-	O
oxidation	O
.	O

By	O
K	O
##EG	O
##G	O
analysis	O
of	O
the	O
metabolic	O
pathways	O
we	O
found	O
that	O
beta	B
-	I
al	I
##ani	I
##ne	I
metabolism	O
pathway	O
was	O
the	O
most	O
significant	O
changes	O
after	O
He	O
gas	O
plasma	O
treatment	O
in	O
my	O
##elo	O
##ma	O
LP	O
-	O
1	O
cells	O
.	O

For	O
that	O
reason	O
,	O
FA	S
are	O
crucial	O
to	O
maintaining	O
cancer	O
cell	O
proliferation	O
,	O
migration	O
,	O
survival	O
and	O
tissue	O
invasion	O
.	O

In	O
addition	O
to	O
the	O
function	O
of	O
CP	O
##T	O
##1	O
##A	O
in	O
ATP	S
and	O
N	B
##AD	I
##P	I
##H	I
production	O
,	O
a	O
new	O
role	O
for	O
CP	O
##T	O
##1	O
##A	O
in	O
e	O
##pi	O
##gene	O
##tics	O
has	O
been	O
identified	O
_	O
,	O
_	O
,	O
.	O

Analysis	O
of	O
1	B
##α	I
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
-	O
PT	O
##AD	O
,	O
1	O
ng	O
injected	O
on	O
column	O
(	O
57	O
##4	O
.	O
3	O
>	O
31	O
##4	O
.	O
0	O
reaction	O
trace	O
)	O
,	O
is	O
shown	O
in	O
panel	O
a	O
,	O
and	O
that	O
of	O
native	O
1	B
##α	I
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
,	O
10	O
ng	O
injected	O
on	O
column	O
(	O
39	O
##9	O
.	O
4	O
>	O
135	O
.	O
2	O
reaction	O
trace	O
)	O
,	O
is	O
shown	O
in	O
panel	O
b	O
.	O

For	O
the	O
analysis	O
of	O
dose	O
/	O
volume	O
effect	O
we	O
selected	O
the	O
doses	O
corresponding	O
to	O
de	O
##ci	O
##les	O
of	O
the	O
area	O
under	O
the	O
curve	O
of	O
the	O
averaged	O
dose	B
-	I
volume	I
his	O
##to	O
##gram	O
(	O
for	O
details	O
see	O
)	O
.	O

Since	O
the	O
extraction	O
recovery	O
of	O
the	O
IS	O
from	O
high	O
T	B
##G	I
plasma	O
was	O
above	O
85	O
%	O
,	O
we	O
did	O
not	O
test	O
for	O
the	O
extraction	O
recovery	O
using	O
low	O
T	B
##G	I
plasma	O
.	O

Just	O
before	O
analysis	O
,	O
100	O
µ	O
##L	O
samples	O
were	O
th	O
##awed	O
at	O
room	O
temperature	O
following	O
by	O
mixture	O
with	O
400	O
µ	O
##L	O
met	B
##han	I
##ol	I
,	O
intense	O
vibration	O
for	O
30	O
s	O
,	O
and	O
in	O
##cu	O
##bation	O
at	O
4	O
°C	O
for	O
5	O
min	O
to	O
pre	O
##ci	O
##pit	O
##ate	O
the	O
protein	O
.	O

In	O
plasma	O
and	O
serum	O
samples	O
,	O
no	O
significant	O
changes	O
in	O
concentration	O
during	O
transportation	O
for	O
24	O
h	O
on	O
CP	O
and	O
at	O
R	O
##T	O
were	O
detected	O
for	O
PC	O
a	O
##e	O
’	O
s	O
and	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
.	O

Previous	O
studies	O
showed	O
the	O
elevation	O
of	O
la	B
##ct	I
##ate	I
levels	O
in	O
the	O
CS	O
##F	O
were	O
related	O
to	O
disease	O
activity	O
of	O
N	O
##MO	O
##SD	O

Panel	O
(	O
f	O
)	O
shows	O
difference	O
in	O
serum	O
la	B
##ct	I
##ate	I
contents	O
between	O
Ta	O
##e	O
-	O
E	O
##um	O
and	O
So	O
-	O
Yang	O
types	O
with	O
normal	O
weight	O
and	O
over	O
##weight	O
,	O
demonstrating	O
metabolic	O
dependence	O
of	O
serum	O
la	B
##ct	I
##ate	I
level	O
on	O
SC	O
types	O
.	O

In	O
conclusion	O
,	O
the	O
large	O
number	O
of	O
meta	O
##bol	O
##ites	O
,	O
particularly	O
lip	O
##id	O
compounds	O
,	O
found	O
to	O
be	O
associated	O
with	O
serum	O
25	O
(	O
OH	O
)	O
D	O
provide	O
new	O
biological	O
clues	O
relevant	O
to	O
the	O
role	O
of	O
vitamin	B
D	I
status	O
and	O
human	O
health	O
outcomes	O
.	O

A	O
##rg	O
,	O
Pro	O
,	O
C	B
##10	I
:	I
1	I
,	O
A	O
##rg	O
/	O
Or	O
##n	O
,	O
C	O
##it	O
/	O
A	O
##rg	O
,	O
and	O
C	O
##5	O
-	O
OH	O
/	O
C	O
##0	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

As	O
the	O
simplest	O
car	B
##box	I
##yla	I
##te	I
an	O
##ion	O
,	O
format	B
##e	I
is	O
an	O
alternative	O
single	O
-	O
carbon	O
unit	O
for	O
the	O
production	O
of	O
5	B
,	I
10	I
-	I
met	I
##hyl	I
##ene	I
##te	I
##tra	I
##hy	I
##dr	I
##of	I
##olate	I
(	O
T	O
##HF	O
)	O
,	O
which	O
is	O
required	O
for	O
pu	B
##rine	I
and	O
p	B
##yr	I
##im	I
##id	I
##ine	I
bio	O
##sy	O
##nt	O
##hesis	O
.	O

The	O
standards	O
were	O
synthesized	O
from	O
p	B
##hen	I
##ant	I
##hren	I
##e	I
e	I
##pox	I
##ides	I
and	O
N	B
-	I
ace	I
##ty	I
##l	I
##cy	I
##stein	I
##e	I
.	O

Tan	O
##de	O
##m	O
MS	O
/	O
MS	O
and	O
fragment	O
##ation	O
of	O
co	O
-	O
el	O
##uti	O
##ng	O
authentic	O
reference	O
standards	O
added	O
to	O
plasma	O
was	O
used	O
to	O
verify	O
g	B
##lut	I
##ama	I
##te	I
,	O
D	O
-	O
series	O
re	O
##sol	O
##vin	O
##s	O
and	O
t	B
##re	I
##hal	I
##ose	I
6	O
-	O
my	O
##cola	O
##te	O
.	O

The	O
majority	O
of	O
anal	O
##yte	O
##s	O
which	O
were	O
not	O
detected	O
under	O
these	O
conditions	O
were	O
organic	O
acids	O
,	O
such	O
as	O
la	B
##ctic	I
acid	I
,	O
and	O
amino	O
acids	O
such	O
,	O
as	O
his	B
##ti	I
##dine	I
:	O
in	O
order	O
to	O
detect	O
these	O
,	O
additional	O
op	O
##ti	O
##mis	O
##ation	O
of	O
MS	O
source	O
or	O
solvent	O
conditions	O
,	O
or	O
the	O
use	O
of	O
MR	O
##M	O
analyses	O
,	O
may	O
be	O
required	O
.	O

Finally	O
,	O
in	O
a	O
small	O
random	O
##ized	O
clinical	O
trial	O
in	O
humans	O
,	O
fish	O
-	O
oil	O
supplement	O
##s	O
lowered	O
the	O
re	O
##ct	O
##al	O
m	O
##uc	O
##osa	O
##l	O
tissue	O
production	O
of	O
pro	B
##sta	I
##g	I
##land	I
##in	I
E	O
_	O
2	O
more	O
than	O
did	O
a	O
place	O
##bo	O
.	O

The	O
rate	O
of	O
appearance	O
of	O
o	B
##xa	I
##late	I
was	O
higher	O
than	O
expected	O
in	O
the	O
healthy	O
volunteer	O
group	O
,	O
and	O
this	O
over	O
##est	O
##imation	O
could	O
be	O
attributed	O
to	O
several	O
causes	O
.	O

Moreover	O
,	O
the	O
disc	O
##rim	O
##ina	O
##nt	O
model	O
of	O
brain	O
tumors	O
using	O
DE	O
##SI	O
-	O
MS	O
shows	O
an	O
overall	O
S	B
##p	I
of	O
99	O
.	O
7	O
%	O
and	O
Se	O
of	O
99	O
.	O
4	O
%	O
.	O

A	O
total	O
of	O
65	O
u	O
##rina	O
##ry	O
meta	O
##bol	O
##ites	O
were	O
identified	O
and	O
q	O
##uant	O
##ified	O
by	O
N	O
##MR	O
s	O
##pect	O
##ros	O
##copy	O
and	O
L	O
##C	O
-	O
MS	O
,	O
including	O
c	B
##rea	I
##tin	I
##ine	I
for	O
standard	O
##ization	O
purposes	O
.	O

Of	O
these	O
,	O
the	O
greatest	O
fold	O
change	O
between	O
experimental	O
groups	O
was	O
for	O
or	B
##ota	I
##te	I
,	O
which	O
was	O
significantly	O
elevated	O
in	O
ICC	O
patient	O
samples	O
(	O
fold	O
-	O
change	O
39	O
,	O
p	O
-	O
value	O
0	O
.	O
00	O
##6	O
)	O
.	O

As	O
expected	O
,	O
signals	O
typical	O
of	O
he	B
##sper	I
##eti	I
##n	I
and	O
na	B
##ring	I
##eni	I
##n	I
in	O
the	O
g	O
##lu	O
##cu	O
##ron	O
##idated	O
and	O
su	O
##lf	O
##ona	O
##ted	O
forms	O
were	O
found	O
only	O
in	O
6	O
and	O
8	O
h	O
post	O
##pra	O
##ndi	O
##al	O
urine	O
##s	O
with	O
a	O
trace	O
amount	O
of	O
na	B
##ring	I
##eni	I
##n	I
mon	O
##og	O
##lu	O
##cu	O
##ron	O
##ide	O
present	O
in	O
some	O
samples	O
at	O
4	O
h	O
(	O
Table	O
)	O
.	O

A	O
base	O
##line	O
blood	O
sample	O
was	O
collected	O
for	O
background	O
en	O
##rich	O
##ment	O
of	O
o	B
##xa	I
##late	I
,	O
g	B
##ly	I
##cine	I
,	O
g	B
##ly	I
##ox	I
##yla	I
##te	I
,	O
and	O
g	B
##ly	I
##cola	I
##te	I
in	O
plasma	O
.	O

Pro	O
##port	O
##ional	O
amounts	O
of	O
LP	B
##C	I
(	I
16	I
:	I
0	I
)	I
were	O
positively	O
associated	O
with	O
serum	O
levels	O
of	O
I	O
##CA	O
##M	O
##1	O
,	O
and	O
LP	B
##C	I
(	I
18	I
:	I
2	I
)	I
was	O
negatively	O
associated	O
with	O
I	O
##CA	O
##M	O
##1	O
.	O

HP	O
##LC	O
gradient	O
program	O
A	O
—	O
20	O
m	O
##M	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
in	O
water	O
;	O
B	O
—	O
ace	O
##ton	O
##it	O
##ril	O
##e	O
Mass	O
s	O
##pect	O
##rome	O
##try	O
analysis	O
was	O
performed	O
on	O
an	O
AB	O
Sc	O
##ie	O
##x	O
550	O
##0	O
Q	O
##tra	O
##p	O
mass	O
s	O
##pect	O
##rome	O
##ter	O
(	O
Applied	O
B	O
##ios	O
##ys	O
##tem	O
##s	O
,	O
Foster	O
City	O
,	O
CA	O
,	O
USA	O
)	O
equipped	O
with	O
a	O
t	O
##ur	O
##bo	O
ion	O
spray	O
(	O
E	O
##SI	O
)	O
ion	O
##ization	O
probe	O
.	O

Moreover	O
,	O
increase	O
of	O
serum	O
c	B
##rea	I
##tin	I
##ine	I
levels	O
has	O
been	O
related	O
to	O
adverse	O
outcomes	O
,	O
including	O
an	O
increased	O
risk	O
of	O
in	O
-	O
hospital	O
mortality	O
,	O
in	O
patients	O
undergoing	O
primary	O
per	O
##cut	O
##aneous	O
co	O
##rona	O
##ry	O
intervention	O
for	O
AM	O
##I	O
.	O

Met	O
##ab	O
##olic	O
pathways	O
of	O
a	B
##rg	I
##ini	I
##ne	I
.	O

p	O
,	O
q	O
##c	O
p	I
,	I
q	I
##c	I
p	I
,	I
q	I
c	I
>	I
X	I
′	I
p	I
,	I
q	I
##c	I
,	I
b	I
=	I
<	I
XI	I
##S	I
,	I
q	I
##c	I
,	I
b	I
>	I
<	I
X	I
##p	I
,	I
q	I
##c	I
,	I
b	I
>	I
X	I
##p	I
,	I
q	I
##c	I
,	I
b	I
##X	I
##IS	I
,	I
q	I
##c	I
,	I
b	I
,	I
b	I
=	I
1	I
,	I
2	I
,	I
…	I
,	I
6	I
X	I
′	I
p	I
,	I
q	I
##c	I
,	I
b	I
=	I
<	I
XI	I
##S	I
,	I
q	I
##c	I
,	I
b	I
>	I
<	I
X	I
##p	I
,	I
q	I
##c	I
,	I
b	I
>	I
X	I
##p	I
,	I
q	I
##c	I
,	I
b	I
##X	I
##IS	I
,	I
q	I
##c	I
,	I
b	I
,	I
b	I
=	I
1	I
,	I
2	I
,	I
…	I
,	I
6	I
X	I
′	I
p	I
,	I
q	I
##c	I
,	I
b	I
=	I
<	I
XI	I
##S	I
,	I
q	I
##c	I
,	I
b	I
>	I
<	I
X	I
##p	I
,	I
q	I
##c	I
,	I
b	I
>	I
X	I
##p	I
,	I
q	I
##c	I
,	I
b	I
##X	I
##IS	I
,	I
q	I
##c	I
,	I
b	I
,	I
b	I
=	I
1	I
,	I
2	I
,	I
…	I
,	I
6	I
X	I
′	I
p	I
,	I
q	I
##c	I
,	I
b	I
=	I
<	I
XI	I
##S	I
,	I
q	I
##c	I
,	I
b	I
>	I
<	I
X	I
##p	I
,	I
q	I
##c	I
,	I
b	I
>	I
X	I
##p	I
,	I
q	I
##c	I
,	I
b	I
##X	I
##IS	I
,	I
q	I
##c	I
,	I
b	I
,	I
b	I
=	I
1	I
,	I
2	I
,	I
…	I
,	I
6	I
X	I
′	I
p	I
,	I
q	I
##c	I
,	I
b	I
=	I
<	I
XI	I
##S	I
,	I
q	I
##c	I
,	I
b	I
>	I
<	I
X	I
##p	I
,	I
q	I
##c	I
,	I
b	I
>	I
X	I
##p	I
,	I
q	I
##c	I
,	I
b	I
##X	I
##IS	I
,	O

The	O
most	O
commonly	O
prescribed	O
op	O
##io	O
##ids	O
in	O
this	O
group	O
include	O
o	B
##xy	I
##co	I
##don	I
##e	I
,	O
o	B
##xy	I
##mor	I
##phone	I
,	O
h	B
##ydro	I
##co	I
##don	I
##e	I
,	O
h	B
##ydro	I
##mor	I
##phone	I
and	O
di	B
##hy	I
##dr	I
##oc	I
##ode	I
##ine	I
,	O
all	O
chemical	O
variants	O
of	O
m	B
##or	I
##phine	I
.	O

Sep	O
##ara	O
##tion	O
was	O
performed	O
using	O
a	O
gradient	O
starting	O
from	O
10	O
m	O
##M	O
am	B
##mon	I
##ium	I
format	I
##e	I
a	O
##que	O
##ous	O
solution	O
over	O
0	O
.	O
5	O
min	O
,	O
then	O
linear	O
##ly	O
to	O
25	O
%	O
met	B
##han	I
##ol	I
containing	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
and	O
5	O
m	O
##M	O
am	B
##mon	I
##ium	I
format	I
##e	I
over	O
3	O
min	O
,	O
followed	O
by	O
is	O
##oc	O
##ratic	O
run	O
with	O
the	O
same	O
solvent	O
composition	O
for	O
15	O
min	O
.	O

G	B
##lut	I
##amine	I
is	O
an	O
essential	O
nut	O
##rient	O
for	O
the	O
growth	O
of	O
cancer	O
cells	O
,	O
and	O
the	O
cat	O
##ab	O
##olis	O
##m	O
of	O
g	B
##lut	I
##amine	I
is	O
a	O
major	O
route	O
for	O
the	O
proliferation	O
of	O
ma	O
##mmal	O
##ian	O
cells	O
.	O

Results	O
:	O
Sub	O
##jects	O
with	O
high	O
c	B
##ys	I
##tat	I
##hi	I
##oni	I
##ne	I
concentrations	O
had	O
75	O
%	O
higher	O
plasma	O
la	B
##nt	I
##hi	I
##oni	I
##ne	I
concentrations	O
(	O
0	O
.	O
12	O
±	O
0	O
.	O
04	O
##4	O
μ	O
##mo	O
##l	O
/	O
L	O
)	O
than	O
subjects	O
with	O
low	O
c	B
##ys	I
##tat	I
##hi	I
##oni	I
##ne	I
concentrations	O
[	O
0	O
.	O
03	O
##2	O
±	O
0	O
.	O
01	O
##3	O
μ	O
##mo	O
##l	O
/	O
L	O
(	O
P	O
<	O
0	O
.	O
00	O
##1	O
)	O
]	O
.	O

NO	O
_	O
2	O
-	O
Ph	O
##IP	O
,	O
H	O
##ON	O
##H	O
-	O
Ph	O
##IP	O
,	O
and	O
N	B
-	I
ace	I
##to	I
##xy	I
-	I
Ph	I
##IP	I
are	O
reactive	O
species	O
that	O
contribute	O
to	O
the	O
del	O
##eter	O
##ious	O
biological	O
effects	O
of	O
Ph	O
##IP	O
through	O
DNA	O
and	O
protein	O
add	O
##uc	O
##t	O
formation	O
.	O

Statistical	O
summary	O
for	O
met	B
##han	I
##ol	I
in	O
##cu	O
##bation	O
time	O
course	O
B	O
##io	O
##psy	O
samples	O
from	O
normal	O
human	O
kidney	O
tissue	O
were	O
in	O
##cu	O
##bate	O
##d	O
in	O
80	O
%	O
met	B
##han	I
##ol	I
for	O
0	O
.	O
5	O
h	O
,	O
1	O
h	O
,	O
4	O
h	O
,	O
8	O
h	O
,	O
16	O
h	O
,	O
24	O
h	O
,	O
and	O
48	O
h	O
.	O

Only	O
or	B
##ni	I
##thin	I
##e	I
remained	O
statistical	O
##ly	O
unchanged	O
between	O
time	O
points	O
,	O
although	O
levels	O
gradually	O
increased	O
over	O
the	O
course	O
of	O
the	O
day	O
to	O
eventually	O
reach	O
a	O
level	O
statistical	O
##ly	O
higher	O
than	O
base	O
##line	O
.	O

The	O
most	O
or	O
##th	O
##ogo	O
##nal	O
methods	O
to	O
met	O
##han	O
##ol	O
-	O
based	O
precipitation	O
were	O
ion	O
-	O
exchange	O
solid	O
-	O
phase	O
extraction	O
and	O
liquid	O
-	O
liquid	O
extraction	O
using	O
met	B
##hyl	I
-	I
te	I
##rt	I
##but	I
##yl	I
et	I
##her	I
.	O

These	O
authors	O
suggested	O
that	O
,	O
in	O
this	O
case	O
,	O
fatty	O
acid	O
β	O
-	O
oxidation	O
may	O
be	O
down	O
##re	O
##gu	O
##lated	O
as	O
RC	O
##C	O
progresses	O
,	O
with	O
the	O
result	O
##ant	O
effect	O
being	O
the	O
accumulation	O
of	O
unused	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
which	O
may	O
be	O
used	O
in	O
non	O
-	O
energy	O
related	O
processes	O
.	O

The	O
mechanism	O
of	O
r	O
##ins	O
##e	O
-	O
mediated	O
ant	B
##ho	I
##cy	I
##ani	I
##n	I
retention	O
is	O
under	O
investigation	O
.	O

H	O
##LP	O
:	O
H	O
##yper	O
##lip	O
##ide	O
##mia	O
;	O
B	O
##MI	O
:	O
body	O
mass	O
index	O
;	O
S	O
##B	O
##P	O
:	O
S	O
##ys	O
##to	O
##lic	O
blood	O
pressure	O
;	O
DB	B
##P	I
:	O
Di	O
##ast	O
##olic	O
blood	O
pressure	O
;	O
T	B
##G	I
:	O
Tri	B
##gly	I
##cer	I
##ides	I
;	O
T	O
##C	O
:	O
Total	O
ch	B
##ole	I
##ster	I
##ol	I
.	O

In	O
this	O
study	O
,	O
only	O
a	O
selected	O
group	O
of	O
V	O
##OC	O
compounds	O
mainly	O
related	O
to	O
ET	O
##S	O
is	O
presented	O
jointly	O
with	O
the	O
u	O
##rina	O
##ry	O
bio	O
##mark	O
##er	O
data	O
,	O
which	O
included	O
3	B
-	I
et	I
##hen	I
##yl	I
##py	I
##rid	I
##ine	I
(	O
3	O
-	O
EP	O
)	O
,	O
1	B
,	I
3	I
-	I
but	I
##adi	I
##ene	I
(	O
B	O
##UT	O
)	O
and	O
nap	B
##ht	I
##hale	I
##ne	I
(	O
Na	O
##ph	O
)	O
in	O
the	O
gas	O
phase	O
.	O

Finally	O
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
concentrations	O
were	O
independent	O
of	O
e	O
##G	O
##F	O
##R	O
,	O
but	O
they	O
were	O
positively	O
correlated	O
with	O
body	O
weight	O
and	O
sur	O
##rogate	O
##s	O
of	O
inflammation	O
and	O
metabolic	O
acid	O
##osis	O
(	O
P	O
=	O
0	O
.	O
04	O
)	O
.	O

B	O
##rief	O
##ly	O
,	O
200	O
μ	O
##l	O
of	O
serum	O
were	O
mixed	O
with	O
400	O
μ	O
##l	O
of	O
met	B
##han	I
##ol	I
,	O
v	O
##ortex	O
##ed	O
and	O
kept	O
at	O
−	O
##20	O
°C	O
for	O
20	O
minutes	O
.	O

We	O
further	O
found	O
a	O
role	O
for	O
the	O
in	O
##test	O
##inal	O
micro	O
##bio	O
##ta	O
in	O
the	O
production	O
of	O
T	B
##MA	I
##O	I
through	O
its	O
suppression	O
by	O
means	O
of	O
oral	O
broad	O
-	O
spectrum	O
anti	O
##biotics	O
and	O
then	O
re	O
##ac	O
##quisition	O
of	O
trim	B
##eth	I
##yla	I
##mine	I
and	O
the	O
production	O
of	O
T	B
##MA	I
##O	I
from	O
diet	O
##ary	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
after	O
the	O
withdrawal	O
of	O
anti	O
##biotics	O
and	O
subsequent	O
in	O
##test	O
##inal	O
re	O
##co	O
##lon	O
##ization	O
.	O

Co	O
##rrel	O
##ations	O
involving	O
the	O
ch	B
##olin	I
##e	I
pool	O
.	O

Trans	O
##cripts	O
involved	O
in	O
P	O
##E	O
synthesis	O
were	O
also	O
examined	O
as	O
they	O
are	O
also	O
external	O
##ized	O
from	O
the	O
inner	O
membrane	O
to	O
outer	O
membrane	O
on	O
activated	S
plate	O
##lets	O
.	O

Overall	O
,	O
all	O
lip	O
##id	O
classes	O
were	O
collected	O
into	O
these	O
fraction	O
##s	O
with	O
the	O
following	O
order	O
:	O
CE	O
and	O
T	B
##G	I
from	O
1	O
to	O
3	O
.	O
2	O
min	O
;	O
Cho	O
##l	O
and	O
1	O
,	O
3	O
-	O
D	O
##G	O
from	O
3	O
.	O
21	O
to	O
4	O
.	O
1	O
;	O
1	O
,	O
2	O
-	O
D	O
##G	O
from	O
4	O
.	O
11	O
to	O
5	O
.	O
5	O
min	O
;	O
MG	O
from	O
11	O
to	O
13	O
.	O
6	O
min	O
;	O
Ce	B
##r	I
from	O
13	O
.	O
61	O
to	O
15	O
min	O
;	O
FA	O
##s	O
from	O
15	O
.	O
01	O
to	O
17	O
min	O
;	O
P	B
##G	I
from	O
20	O
.	O
51	O
to	O
22	O
min	O
;	O
P	O
##E	O
from	O
26	O
.	O
01	O
to	O
28	O
min	O
;	O
P	O
##I	O
and	O
PS	O
from	O
28	O
.	O
01	O
to	O
30	O
.	O
5	O
min	O
;	O
PC	O
from	O
30	O
.	O
51	O
to	O
35	O
min	O
;	O
SM	O
from	O
35	O
.	O
01	O
to	O
39	O
min	O
;	O
s	O
##n	O
-	O
1	O
LP	O
##C	O
from	O
39	O
.	O
6	O
to	O
41	O
min	O
;	O
s	O
##n	O
-	O
2	O
LP	O
##C	O
from	O
41	O
.	O
5	O
to	O
42	O
.	O
4	O
min	O
.	O

High	O
levels	O
of	O
try	B
##pt	I
##op	I
##han	I
,	O
K	O
##A	O
,	O
X	O
##A	O
,	O
H	O
##AA	O
and	O
rib	B
##of	I
##lav	I
##in	I
were	O
associated	O
with	O
lower	O
odds	O
ratio	O
for	O
AD	O
##HD	O
.	O

R	O
##EE	O
was	O
measured	O
by	O
indirect	O
ca	O
##lor	O
##ime	O
##try	O
(	O
I	O
##C	O
)	O
using	O
a	O
vent	O
##ilated	O
hood	O
system	O
(	O
V	O
##max	O
En	B
##core	I
29	O
n	O
,	O
Sen	O
##sor	O
##M	O
##edic	O
##s	O
B	O
##V	O
,	O
B	O
##ilt	O
##hov	O
##en	O
,	O
The	O
Netherlands	O
)	O
.	O

However	O
,	O
R	O
##R	O
##MS	O
patients	O
with	O
longer	O
disease	O
duration	S
(	O
>	O
13	O
y	O
)	O
had	O
more	O
V	O
##LC	O
##FA	O
-	O
P	O
##t	O
##d	O
##E	O
##t	O
##n	O
species	O
elevated	O
than	O
R	O
##R	O
##MS	O
patients	O
with	O
lesser	O
disease	O
duration	S
(	O
<	O
13	O
y	O
)	O
.	O

Allan	B
##to	I
##in	I
is	O
a	O
meta	O
##bol	O
##ite	O
of	O
u	B
##ric	I
acid	I
and	O
it	O
is	O
regularly	O
detected	O
in	O
human	O
urine	O
.	O

By	O
analyzing	O
samples	O
in	O
parallel	O
by	O
routes	O
A	O
(	O
without	O
ch	B
##ole	I
##ster	I
##ol	I
o	O
##xi	O
##das	O
##e	O
)	O
and	O
B	O
(	O
with	O
ch	B
##ole	I
##ster	I
##ol	I
o	O
##xi	O
##das	O
##e	O
)	O
,	O
anal	O
##yte	O
##s	O
possessing	O
a	O
3	O
-	O
o	O
##x	O
##o	O
group	O
are	O
differentiated	O
from	O
those	O
o	O
##xi	O
##dized	O
to	O
contain	O
one	O
(	O
i	O
.	O
e	O
.	O
3	B
##β	I
-	I
h	I
##ydro	I
##xy	I
-	I
5	I
-	I
en	I
##e	I
or	O
3	B
##β	I
-	I
h	I
##ydro	I
##xy	I
-	I
5	I
##α	I
-	I
hydrogen	I
s	O
##tero	O
##ls	O
/	O
bi	O
##le	O
acids	O
)	O
.	O

Higher	O
u	O
##rina	O
##ry	O
ex	O
##cre	O
##tion	O
values	O
during	O
the	O
day	O
compared	O
to	O
night	O
time	O
have	O
been	O
found	O
for	O
co	B
##rt	I
##is	I
##ol	I
and	O
co	B
##rt	I
##ison	I
##e	I
and	O
for	O
almost	O
all	O
g	B
##lu	I
##co	I
##cor	I
##tic	I
##oid	I
meta	O
##bol	O
##ites	O
in	O
both	O
sexes	O
.	O

Several	O
mobile	O
phases	O
were	O
evaluated	O
including	O
different	O
organic	O
m	O
##od	O
##ifier	O
##s	O
(	B
met	B
##han	I
##ol	I
,	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
and	O
met	B
##han	I
##ol	I
/	I
ace	I
##ton	I
##it	I
##ril	I
##e	I
mixture	O
##s	O
)	O
at	O
various	O
concentrations	O
in	O
water	O
,	O
as	O
well	O
mobile	O
phases	O
containing	O
am	B
##mon	I
##ium	I
format	I
##e	I
and	O
/	O
or	O
form	B
##ic	I
acid	I
without	O
organic	O
m	O
##od	O
##ifier	O
.	O

In	O
addition	O
the	O
ratio	O
of	O
the	O
direct	O
precursor	O
##s	O
of	O
pro	O
-	O
resolution	O
lip	O
##id	O
media	O
##tors	O
(	O
14	O
-	O
HD	O
##HA	O
,	O
17	B
-	I
HD	I
##HA	I
and	O
18	O
-	O
H	O
##EP	O
##E	O
)	O
,	O
which	O
are	O
precursor	O
##s	O
of	O
re	O
##sol	O
##vin	O
##s	O
and	O
protect	O
##ins	O
,	O
was	O
calculated	O
against	O
various	O
precursor	O
##s	O
of	O
the	O
AA	O
-	O
derived	O
and	O
mainly	O
pro	O
-	O
inflammatory	O
derivatives	O
(	O
5	O
-	O
H	O
##ET	O
##E	O
,	O
12	B
-	I
H	I
##ET	I
##E	I
and	O
15	O
-	O
H	O
##ET	O
##E	O
)	O
as	O
well	O
as	O
ratios	O
of	O
sum	O
of	O
H	O
##EP	O
##Es	O
and	O
sum	O
of	O
HD	O
##HA	O
##s	O
vs	O
.	O
the	O
sum	O
of	O
H	O
##ET	O
##Es	O
were	O
calculated	O
.	O

Inc	O
##reased	O
his	B
##ti	I
##dine	I
level	O
leads	O
to	O
increase	O
of	O
his	B
##tamine	I
level	O
in	O
blood	O
,	O
brain	O
and	O
possibly	O
bladder	O
,	O
suggesting	O
the	O
possibility	O
that	O
his	B
##ti	I
##dine	I
may	O
have	O
many	O
other	O
possible	O
functions	O
affecting	O
human	O
bladder	O
sensory	O
system	O
.	O

Furthermore	O
,	O
beta	B
##ine	I
was	O
additionally	O
associated	O
in	O
Health	O
##20	O
##0	O
##6	O
/	O
08	O
and	O
barely	O
missed	O
statistical	O
significance	O
in	O
Inter	O
99	O
(	O
F	O
##DR	O
=	O
0	O
.	O
06	O
)	O
.	O

Standards	O
of	O
25	B
(	I
OH	I
)	I
D	I
_	I
2	I
/	I
3	I
,	I
3	I
-	I
e	I
##pi	I
-	I
25	I
(	I
OH	I
)	I
D	I
_	I
3	I
,	I
1	I
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
/	O
2	O
and	O
24	B
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
and	O
met	B
##han	I
##ol	I
(	O
HP	O
##LC	O
grade	O
)	O
were	O
purchased	O
from	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
(	O
Stein	O
##heim	O
,	O
Germany	O
)	O
.	O

We	O
found	O
that	O
reduced	O
incidence	O
of	O
l	O
##ymph	O
node	O
and	O
bone	O
progression	O
correlated	O
with	O
higher	O
levels	O
of	O
long	O
-	O
chain	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
.	O

with	O
minor	O
modifications	O
to	O
determine	O
plasma	O
fatty	O
acids	O
as	O
met	B
##hyl	I
est	I
##ers	I
.	O

Other	O
clinical	O
characteristics	O
were	O
also	O
independently	O
associated	O
with	O
24	B
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
concentration	O
,	O
though	O
not	O
as	O
strongly	O
as	O
e	O
##G	O
##F	O
##R	O
.	O

The	O
S	O
##p	O
##d	O
,	O
sperm	B
##ine	I
,	O
and	O
Put	O
are	O
essential	O
u	O
##bi	O
##qui	O
##tary	O
cellular	O
p	B
##oly	I
##amine	I
##s	I
essentially	O
constituted	O
of	O
organic	O
p	O
##oly	O
##cation	O
##s	O
having	O
variable	O
h	B
##ydro	I
##car	I
##bon	I
chains	O
and	O
two	O
or	O
more	O
primary	O
amino	S
groups	O
.	O

In	O
addition	O
,	O
the	O
levels	O
of	O
9	O
meta	O
##bol	O
##ites	O
(	O
or	O
##ni	O
##thin	O
##e	O
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
as	B
##par	I
##tate	I
+	O
as	B
##par	I
##agi	I
##ne	I
,	O
C	B
##3	I
-	I
car	I
##ni	I
##tine	I
,	O
C	B
##4	I
-	I
car	I
##ni	I
##tine	I
,	O
C	B
##8	I
-	I
car	I
##ni	I
##tine	I
,	O
C	B
##14	I
-	I
car	I
##ni	I
##tine	I
and	O
C	B
##16	I
-	I
car	I
##ni	I
##tine	I
)	O
were	O
significantly	O
altered	O
in	O
the	O
patients	O
with	O
lung	O
cancer	O
only	O
in	O
the	O
2015	O
data	O
set	O
.	O

El	O
##eva	O
##ted	O
g	B
##ly	I
##cine	I
has	O
also	O
been	O
reported	O
in	O
a	O
MA	O
##S	O
N	O
##MR	O
study	O
of	O
human	O
color	O
##ec	O
##tal	O
cancer	O
,	O
which	O
is	O
consistent	O
with	O
the	O
increased	O
activity	O
of	O
3	O
-	O
p	O
##hos	O
##ph	O
##og	O
##ly	O
##cer	O
##ate	O
de	O
##hy	O
##dr	O
##ogen	O
##ase	O
observed	O
in	O
human	O
co	O
##lon	O
car	O
##cin	O
##oma	O
and	O
rat	O
sa	O
##rc	O
##oma	O
.	O

U	B
##rs	I
##ode	I
##ox	I
##ych	I
##olate	I
(	O
secondary	O
bi	O
##le	O
acid	O
)	O
also	O
remained	O
marked	O
##ly	O
elevated	O
(	O
4	O
.	O
2	O
-	O
fold	O
increase	O
,	O
p	O
=	O
0	O
.	O
08	O
)	O
.	O

While	O
p	B
##yr	I
##u	I
##vate	I
was	O
increasing	O
in	O
A	B
##F	I
it	O
was	O
decreasing	O
in	O
P	O
##L	O
during	O
T	O
##2	O
to	O
T	O
##3	O
transition	O
.	O

Therefore	O
,	O
it	O
will	O
be	O
important	O
to	O
determine	O
the	O
tissue	O
source	O
(	O
s	O
)	O
of	O
the	O
co	O
##lla	O
##gen	O
breakdown	O
in	O
this	O
study	O
in	O
order	O
to	O
determine	O
whether	O
it	O
represents	O
a	O
protective	O
effect	O
of	O
limo	B
##nen	I
##e	I
.	O

In	O
the	O
try	B
##pt	I
##op	I
##han	I
metabolic	O
pathway	O
,	O
the	O
m	O
##RNA	O
expression	O
of	O
T	O
##P	O
##H1	O
and	O
ID	O
##O	O
##1	O
was	O
significantly	O
lower	O
in	O
N	O
##IM	O
##BC	O
patients	O
than	O
in	O
controls	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Human	O
breast	O
cancer	O
cell	O
lines	O
,	O
MD	O
##A	O
-	O
MB	O
-	O
231	O
and	O
T	O
##47	O
##D	O
,	O
were	O
purchased	O
from	O
Division	O
of	O
Cancer	O
Treatment	O
and	O
Di	O
##ag	O
##nosis	O
of	O
the	O
National	O
Cancer	O
Institute	O
(	O
Frederick	O
,	O
Maryland	O
)	O
and	O
maintained	O
in	O
R	O
##PM	O
##I	O
-	O
1640	O
medium	O
,	O
supplemented	O
with	O
10	O
%	O
F	O
##BS	O
,	O
100	O
U	O
/	O
m	O
##L	O
pen	B
##ici	I
##llin	I
,	O
and	O
100	O
μ	O
g	O
/	O
m	O
##L	O
s	B
##tre	I
##pt	I
##omy	I
##cin	I
.	O

Now	O
,	O
the	O
AD	B
##MA	I
,	O
L	B
-	I
N	I
##MM	I
##A	I
and	O
SD	O
##MA	O
parameters	O
could	O
be	O
implemented	O
into	O
the	O
U	O
##HP	O
##LC	O
-	O
MS	O
/	O
MS	O
ass	O
##ay	O
to	O
create	O
a	O
single	O
platform	O
of	O
39	O
anal	O
##yte	O
##s	O
(	O
see	O
Su	O
##pp	O
##lement	O
##ary	O
Table	O
_	O
1	O
)	O
for	O
the	O
q	O
##uant	O
##ification	O
of	O
met	B
##hyl	I
##ar	I
##gin	I
##ines	I
,	O
along	O
with	O
our	O
previously	O
reported	O
array	O
of	O
amino	O
acids	O
and	O
other	O
am	O
##ines	O
,	O
in	O
a	O
single	O
run	O
.	O

To	O
investigate	O
er	B
##yt	I
##hr	I
##ito	I
##l	I
metabolism	O
in	O
humans	O
,	O
an	O
ex	O
v	O
##ivo	O
stable	O
is	O
##oto	O
##pe	O
-	O
assisted	O
blood	O
in	O
##cu	O
##bation	O
experiment	O
was	O
performed	O
on	O
five	O
healthy	O
male	O
volunteers	O
.	O

Cho	B
##les	I
##tero	I
##l	I
is	O
an	O
essential	O
constituent	O
of	O
the	O
plasma	O
membrane	O
and	O
rigid	O
##ifies	O
it	O
.	O

We	O
found	O
that	O
the	O
levels	O
of	O
p	B
##hos	I
##ph	I
##och	I
##olin	I
##e	I
(	O
Su	O
##pp	O
##lement	O
##ary	O
Fi	O
##g	O
.	O

Different	O
oxidation	O
methods	O
were	O
utilized	O
,	O
namely	O
in	O
##cu	O
##bat	O
##ing	O
a	O
##que	O
##ous	O
di	O
##sper	O
##sions	O
of	O
o	B
##le	I
##ic	I
acid	I
(	O
up	O
to	O
100	O
µ	O
##M	O
)	O
with	O
the	O
free	O
radical	O
generators	O
2	B
,	I
2	I
′	I
-	I
a	I
##zo	I
##bis	I
(	I
2	I
-	I
met	I
##hyl	I
##p	I
##rop	I
##ion	I
##ami	I
##dine	I
)	I
di	I
##hy	I
##dr	I
##och	I
##lor	I
##ide	I
,	O
Fen	O
##ton	O
’	O
s	O
re	O
##age	O
##nt	O
(	O
f	O
##er	O
##rous	O
su	B
##lf	I
##ate	I
plus	O
hydrogen	B
per	I
##oxide	I
)	O
,	O
or	O
just	O
by	O
exposing	O
the	O
o	B
##le	I
##ic	I
acid	I
in	O
air	O
for	O
at	O
least	O
1	O
day	O
.	O

Finally	O
,	O
the	O
changes	O
on	O
NE	O
##FA	O
serum	O
levels	O
upon	O
T	B
##NF	I
##α	I
-	I
blockade	I
and	O
its	O
association	O
with	O
clinical	O
outcome	O
were	O
evaluated	O
.	O

The	O
minor	O
all	O
##ele	O
of	O
r	O
##s	O
##41	O
##4	O
##90	O
##5	O
##6	O
was	O
also	O
associated	O
with	O
increased	O
plasma	O
levels	O
of	O
7	B
##α	I
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
,	O
the	O
product	O
of	O
the	O
rate	O
-	O
limiting	O
step	O
in	O
synthesis	O
of	O
bi	O
##le	O
acids	O
from	O
ch	B
##ole	I
##ster	I
##ol	I
.	O

The	O
SA	O
##M	O
##e	O
met	O
##hyl	O
##ation	O
is	O
a	O
critical	O
step	O
in	O
many	O
proteins	O
stab	O
##ilization	O
,	O
including	O
my	B
##elin	I
.	O

Finally	O
,	O
after	O
the	O
residual	O
water	O
region	O
(	O
4	O
.	O
40	O
–	O
5	O
.	O
00	O
pp	O
##m	O
)	O
and	O
c	B
##it	I
##rate	I
(	O
2	O
.	O
48	O
–	O
2	O
.	O
69	O
pp	O
##m	O
)	O
were	O
selective	O
##ly	O
removed	O
,	O
the	O
data	O
##set	O
was	O
bin	O
##ned	O
into	O
87	O
##16	O
integral	O
##s	O
of	O
equal	O
width	O
(	O
0	O
.	O
00	O
##1	O
pp	O
##m	O
)	O
.	O

From	O
the	O
21	O
‐	O
panel	O
,	O
only	O
five	O
V	O
##OC	O
##s	O
appeared	O
statistical	O
##ly	O
significant	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
when	O
comparing	O
these	O
RC	O
##C	O
‐	O
D	O
##MT	O
##2	O
samples	O
with	O
controls	O
:	O
2	O
‐	O
o	O
##x	O
##op	O
##rop	O
##ana	O
##l	O
,	O
2	B
,	I
2	I
,	I
5	I
,	I
5	I
‐	I
te	I
##tra	I
##met	I
##hyl	I
##te	I
##tra	I
##hy	I
##dr	I
##of	I
##ura	I
##n	I
,	O
α	B
‐	I
met	I
##hyl	I
##sty	I
##rene	I
,	O
2	B
,	I
5	I
,	I
8	I
‐	I
trim	I
##eth	I
##yl	I
‐	I
1	I
,	I
2	I
,	I
3	I
,	I
4	I
‐	I
te	I
##tra	I
##hy	I
##dron	I
##aph	I
##thal	I
##en	I
‐	I
1	I
‐	I
o	I
##l	I
,	O
and	O
D	O
##H	O
##EA	O
‐	O
S	O
.	O
Interest	O
##ingly	O
and	O
confirming	O
the	O
potential	O
of	O
these	O
compounds	O
to	O
detect	O
RC	O
##C	O
,	O
the	O
variation	O
for	O
all	O
of	O
them	O
between	O
RC	O
##C	O
and	O
controls	O
was	O
the	O
same	O
found	O
during	O
the	O
un	O
##tar	O
##get	O
##ed	O
study	O
(	O
Table	O
)	O
.	O

Demons	O
##tration	O
of	O
he	O
##tero	O
##gene	O
##ity	O
in	O
the	O
patient	O
co	O
##hor	O
##ts	O
via	O
analysis	O
of	O
subjects	O
with	O
D	O
##AG	O
levels	O
elevated	O
more	O
than	O
one	O
standard	O
de	O
##viation	O
above	O
control	O
values	O
and	O
subjects	O
with	O
ethanol	B
##amine	I
plasma	O
##log	O
##en	O
(	O
P	O
##ls	O
##E	O
)	O
levels	O
decreased	O
by	O
more	O
than	O
one	O
standard	O
de	O
##viation	O
below	O
control	O
values	O
.	O

Ke	B
##tones	I
,	O
β	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
,	O
total	O
NE	O
##FA	O
,	O
glucose	S
and	O
insulin	O
were	O
measured	O
by	O
standard	O
methods	O
.	O

The	O
main	O
_	O
1	O
H	O
N	O
##MR	O
meta	O
##bol	O
##omi	O
##cs	O
signatures	O
still	O
involved	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
associated	O
to	O
A	O
##po	O
##B	O
,	O
V	O
##LD	O
##L	O
,	O
L	O
##D	O
##L	O
lip	O
##op	O
##rote	O
##in	O
sub	O
-	O
fraction	O
##s	O
that	O
resulted	O
higher	O
in	O
the	O
PR	O
patients	O
together	O
with	O
ethanol	S
,	O
is	B
##ole	I
##uc	I
##ine	I
and	O
v	B
##ali	I
##ne	I
(	O
Figure	O
S	O
##4	O
)	O
.	O

A	O
large	O
number	O
of	O
la	B
##ctic	I
acid	I
produced	O
by	O
g	O
##ly	O
##co	O
##lysis	O
might	O
lead	O
to	O
acid	O
##ification	O
of	O
tumor	O
cells	O
micro	O
##en	O
##vir	O
##on	O
##ment	O
.	O

Quality	O
and	O
concentration	O
of	O
DNA	O
extract	O
##s	O
were	O
determined	O
using	O
1	O
%	O
a	B
##gar	I
##ose	I
-	I
0	I
.	I
5	I
##X	I
T	O
##BE	O
gel	O
##s	O
,	O
which	O
were	O
stained	O
with	O
G	O
##el	O
Red	O
10	O
,	O
000	O
##X	O
(	O
B	O
##iot	O
##ium	O
,	O
Inc	O
.	O
)	O
and	O
analyzed	O
through	O
s	O
##pect	O
##rop	O
##hot	O
##ometric	O
measurements	O
at	O
260	O
,	O
280	O
and	O
230	O
nm	O
,	O
using	O
the	O
Nan	O
##o	O
##D	O
##rop	O
N	O
##D	O
-	O
1000	O
S	O
##pect	O
##rop	O
##hot	O
##ometer	O
(	O
The	O
##rm	O
##o	O
##F	O
##ish	O
##er	O
Scientific	O
Inc	O
.	O
,	O
MI	O
,	O
Italy	O
)	O
.	O

This	O
study	O
is	O
the	O
first	O
to	O
report	O
a	O
gang	B
##lio	I
##side	I
strongly	O
associated	O
with	O
u	O
##rogen	O
##ital	O
s	O
##chi	O
##sto	O
##so	O
##mia	O
##sis	O
associated	O
-	O
bladder	O
path	O
##ology	O
.	O

For	O
each	O
sample	O
,	O
5	O
μ	O
L	O
of	O
diet	B
##hyl	I
##ami	I
##nob	I
##en	I
##zal	I
##de	I
##hy	I
##de	I
(	O
DE	O
##AB	O
)	O
,	O
a	O
specific	O
AL	O
##D	O
##H	O
inhibitor	O
,	O
was	O
added	O
to	O
0	O
.	O
5	O
m	O
##L	O
of	O
Al	O
##de	O
##f	O
##lu	O
##or	O
-	O
stained	O
cells	O
as	O
a	O
negative	O
control	O
.	O

For	O
_	O
13	O
C	B
_	I
2	I
-	I
o	I
##xa	I
##late	I
and	O
1	O
-	O
_	O
13	O
C	B
-	I
g	I
##ly	I
##cola	I
##te	I
,	O
the	O
in	O
##fusion	O
solutions	O
were	O
used	O
as	O
stock	O
solutions	O
.	O

In	O
total	O
,	O
140	O
of	O
159	O
serum	O
meta	O
##bol	O
##ites	O
had	O
stable	O
concentrations	O
on	O
CP	O
for	O
at	O
least	O
24	O
h	O
.	O
19	O
meta	O
##bol	O
##ites	O
showed	O
significant	O
changes	O
in	O
serum	O
concentration	O
during	O
storage	O
on	O
CP	O
within	O
the	O
first	O
24	O
h	O
.	O
14	O
meta	O
##bol	O
##ite	O
concentrations	O
increased	O
significantly	O
with	O
time	O
(	O
,	O
,	O
,	O
,	O
and	O
17	O
)	O
,	O
whereas	O
five	O
meta	O
##bol	O
##ite	O
concentrations	O
decreased	O
significantly	O
(	B
a	B
##rg	I
##ini	I
##ne	I
,	O
put	O
##res	O
##cine	O
*	O
,	O
se	O
##rot	O
##oni	O
##n	O
*	O
,	O
sperm	O
##id	O
##ine	O
*	O
and	O
he	O
##x	O
##ose	O
)	O
.	O

A	B
##rg	I
##ini	I
##ne	I
also	O
serves	O
as	O
a	O
substrate	O
for	O
the	O
enzyme	O
ni	B
##tric	I
oxide	I
s	O
##ynth	O
##ase	O
,	O
which	O
cat	O
##aly	O
##zes	O
a	O
reaction	O
that	O
produces	O
c	B
##it	I
##ru	I
##llin	I
##e	I
and	O
ni	B
##tric	I
oxide	I
(	O
NO	O
)	O
,	O
a	O
v	O
##as	O
##od	O
##ila	O
##tor	O
that	O
plays	O
a	O
critical	O
role	O
in	O
maintaining	O
the	O
health	O
of	O
the	O
vascular	O
end	O
##oth	O
##eli	O
##um	O
.	O

PC	B
a	I
##e	I
C	I
##42	I
:	I
1	I
;	O
95	O
.	O

Con	O
##version	O
of	O
V	O
##LC	O
##FA	O
##s	O
to	O
di	B
##car	I
##box	I
##yl	I
##ic	I
acids	I
first	O
involves	O
ω	O
-	O
h	O
##ydro	O
##xy	O
##lation	O
of	O
the	O
fatty	O
acid	O
by	O
micro	O
##so	O
##mal	O
C	O
##YP	O
##4	O
##A	O
/	O
4	O
##F	O
enzyme	O
systems	O
(	O
C	O
##YP	O
##4	O
##A	O
##11	O
,	O
C	O
##YP	O
##4	O
##F	O
##2	O
,	O
C	O
##YP	O
##4	O
##F	O
##3	O
##A	O
,	O
C	O
##YP	O
##4	O
##F	O
##3	O
##B	O
)	O

For	O
all	O
the	O
models	O
tested	O
,	O
two	O
were	O
relevant	O
to	O
predict	O
SV	O
##C	O
from	O
SM	B
C	I
##24	I
:	I
1	I
in	O
group	O
O	O
and	O
the	O
other	O
to	O
predict	O
SV	O
##C	O
from	O
SM	O
OH	B
C	I
##22	I
:	I
2	I
and	O
SM	B
C	I
##16	I
:	I
1	I
in	O
group	O
P	O
+	O
O	O
.	O

We	O
confirmed	O
the	O
strong	O
association	O
of	O
3	B
-	I
met	I
##hyl	I
##his	I
##ti	I
##dine	I
with	O
B	O
##MI	O
,	O
reflecting	O
its	O
association	O
with	O
muscle	O
mass	O
and	O
diet	O
##ary	O
meat	O
intake	O
(	O
,	O
,	O
,	O
)	O
.	O

In	O
##tra	O
##cellular	O
amounts	O
of	O
most	O
associated	O
meta	O
##bol	O
##ites	O
declined	O
strongly	O
,	O
despite	O
an	O
enhanced	O
g	B
##lut	I
##amine	I
up	O
##take	O
by	O
16	O
##H	O
##BE	O
##14	O
##o	O
_	O
−	O
cells	O
by	O
145	O
nm	O
##ol	O
per	O
hour	O
per	O
10	O
_	O
6	O
cells	O
(	O
p	O
<	O
0	O
.	O
00	O
##5	O
)	O
and	O
S	O
##9	O
cells	O
by	O
29	O
nm	O
##ol	O
per	O
hour	O
per	O
10	O
_	O
6	O
cells	O
(	O
p	O
<	O
0	O
.	O
00	O
##1	O
)	O
.	O

The	O
SP	O
##LA	O
##S	O
##H	O
Li	O
##pid	O
##omi	O
##x	O
mixture	O
of	O
de	O
##uter	O
##ated	O
lip	O
##id	O
standards	O
was	O
purchased	O
from	O
Ava	O
##nti	O
Polar	O
Li	O
##pid	O
##s	O
(	O
Al	O
##aba	O
##ster	O
,	O
Al	O
)	O
and	O
di	O
##lut	O
##ed	O
in	O
met	B
##han	I
##ol	I
(	O
Fisher	O
Chemical	O
,	O
Fair	O
Lawn	O
,	O
NJ	O
)	O
.	O

The	O
You	O
##den	O
-	O
Index	O
,	O
defining	O
the	O
maximum	O
potential	O
effectiveness	O
of	O
the	O
parameter	O
,	O
was	O
calculated	O
from	O
the	O
AU	O
##C	O
curves	O
The	O
other	O
non	O
-	O
routine	O
parameters	O
such	O
as	O
amino	O
acids	O
and	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
either	O
did	O
not	O
co	O
##rrel	O
##ate	O
or	O
randomly	O
correlated	O
to	O
the	O
ME	O
##AF	O
and	O
are	O
thus	O
not	O
predict	O
##ive	O
(	O
Fi	O
##g	O
.	O
S	O
##2	O
)	O
.	O

e	B
##ico	I
##san	I
##oids	I
,	O
20	B
-	I
H	I
##ET	I
##E	I
,	O
E	O
##ET	O
##s	O
,	O
D	O
##H	O
##ET	O
##s	O
,	O
re	O
##nal	O
artery	O
s	O
##ten	O
##osis	O
,	O
h	O
##yper	O
##tens	O
##ion	O
,	O
an	B
##gio	I
##tens	I
##in	I
II	I

Consequently	O
,	O
the	O
question	O
arose	O
whether	O
the	O
meta	O
##bol	O
##ites	O
are	O
not	O
only	O
capable	O
of	O
explaining	O
but	O
also	O
predict	O
##ing	O
Δ	B
##g	I
##lu	I
##cos	I
##e	I
.	O

The	O
data	O
were	O
analyzed	O
by	O
comparing	O
the	O
lip	O
##ido	O
##me	O
between	O
the	O
me	O
##lo	O
##xi	O
##cam	O
and	O
sa	B
##line	I
groups	O
.	O

The	O
samples	O
further	O
underwent	O
a	O
two	O
-	O
step	O
der	O
##iva	O
##ti	O
##zation	O
and	O
were	O
subjected	O
to	O
analysis	O
on	O
a	O
G	O
##C	O
-	O
MS	O
78	O
##90	O
##B	O
/	O
MS	O
##5	O
##9	O
##7	O
##7	O
##A	O
(	O
A	O
##gi	O
##lent	O
Technologies	O
,	O
Santa	O
Clara	O
,	O
CA	O
,	O
USA	O
)	O
with	O
a	O
Co	O
##mb	O
##i	O
##PA	O
##L	O
auto	O
##sa	O
##mple	O
##r	O
(	O
CT	O
##C	O
-	O
Ana	O
##ly	O
##tics	O
AG	O
,	O
Z	O
##wing	O
##en	O
,	O
Switzerland	O
)	O
and	O
a	O
DB	O
-	O
5	O
m	O
##s	O
fused	O
si	B
##lica	I
cap	O
##illa	O
##ry	O
column	O
(	O
60	O
m	O
,	O
0	O
.	O
25	O
mm	O
i	O
.	O
d	O
.	O

Effects	O
of	O
W	O
##OL	O
on	O
milk	O
composition	O
and	O
milk	O
and	O
plasma	O
ch	B
##olin	I
##e	I
meta	O
##bol	O
##ites	O
were	O
analyzed	O
using	O
the	O
G	O
##L	O
##IM	O
##MI	O
##X	O
procedure	O
of	O
SAS	O
(	O
SAS	O
version	O
9	O
.	O
3	O
Institute	O
Inc	O
.	O
,	O
Cary	O
,	O
NC	O
,	O
USA	O
)	O
.	O

Another	O
study	O
reported	O
the	O
alter	O
##ation	O
in	O
the	O
OS	O
##CC	O
patients	O
’	O
serum	O
or	O
plasma	O
levels	O
of	O
meta	O
##bol	O
##ites	O
associated	O
with	O
the	O
g	B
##ly	I
##co	I
##ly	I
##tic	I
pathway	O
,	O
especially	O
about	O
glucose	S
(	O
,	O
)	O
.	O

580	O
.	O
37	O
##45	O
with	O
a	O
retention	O
time	O
compatible	O
with	O
a	O
GP	O
-	O
tag	O
##ged	O
di	B
##hy	I
##dr	I
##ox	I
##y	I
-	I
3	I
-	I
o	I
##x	I
##och	I
##ole	I
##st	I
-	I
4	I
-	I
en	I
-	I
26	I
-	I
o	I
##ic	I
acid	I
.	O

Some	O
of	O
the	O
ones	O
that	O
could	O
be	O
an	O
##not	O
##ated	O
or	O
were	O
derived	O
from	O
targeted	O
analyses	O
have	O
been	O
described	O
before	O
to	O
differ	O
between	O
men	O
and	O
women	O
,	O
such	O
as	O
c	B
##rea	I
##tin	I
##ine	I
[	O
,	O
,	O
,	O
,	O
]	O
,	O
which	O
is	O
higher	O
in	O
men	O
and	O
known	O
to	O
be	O
determined	O
by	O
muscle	O
mass	O
,	O
or	O
c	B
##it	I
##rate	I
[	O
,	O
,	O
,	O
,	O
,	O
]	O
,	O
which	O
is	O
higher	O
in	O
women	O
.	O

Indeed	O
,	O
the	O
levels	O
of	O
Al	O
##b	O
add	O
##uc	O
##ts	O
formed	O
with	O
the	O
liver	O
car	O
##cin	O
##ogen	O
AFB	O
and	O
car	O
##cin	O
##ogenic	O
he	B
##tero	I
##cy	I
##c	I
##lic	I
a	O
##romatic	O
am	O
##ines	O
(	O
H	O
##AA	O
)	O
are	O
far	O
greater	O
than	O
the	O
levels	O
of	O
add	O
##uc	O
##ts	O
formed	O
with	O
H	O
##b	O
,	O
a	O
fact	O
making	O
Al	O
##b	O
add	O
##uc	O
##ts	O
superior	O
bio	O
##mark	O
##ers	O
,	O
at	O
least	O
for	O
these	O
car	O
##cin	O
##ogen	O
##s	O
.	O
_	O
−	O
Many	O
studies	O
have	O
characterized	O
Al	O
##b	O
add	O
##uc	O
##ts	O
formed	O
in	O
v	O
##it	O
##ro	O
with	O
environmental	O
,	O
diet	O
##ary	O
,	O
and	O
tobacco	O
g	O
##eno	O
##to	O
##xi	O
##can	O
##ts	O
,	O
lip	O
##id	O
per	B
##oxide	I
products	O
,	O
drug	O
medications	O
,	O
and	O
p	O
##est	O
##icides	O
,	O
among	O
others	O
.	O
_	O
,	O
However	O
,	O
reports	O
on	O
other	O
Al	O
##b	O
add	O
##uc	O
##t	O
studies	O
in	O
humans	O
are	O
relatively	O
few	O
.	O

Am	B
##ino	I
##acy	I
##l	I
‐	I
t	I
##RNA	I
bio	O
##sy	O
##nt	O
##hesis	O
is	O
the	O
top	O
‐	O
ranked	O
pathway	O
according	O
to	O
en	O
##rich	O
##ment	O
criteria	O
.	O

U	O
##til	O
##izing	O
advanced	O
technologies	O
,	O
such	O
as	O
matrix	O
-	O
assisted	O
laser	O
des	O
##or	O
##ption	O
and	O
ion	O
##ization	O
(	O
MA	O
##LD	O
##I	O
)	O
mass	O
s	O
##pect	O
##rome	O
##try	O
,	O
we	O
will	O
be	O
able	O
to	O
investigate	O
the	O
precise	O
distribution	O
of	O
the	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
on	O
the	O
cancer	O
and	O
surrounding	O
normal	O
tissue	O
in	O
surgical	O
specimens	O
.	O

(	O
A	O
)	O
1	O
##D	O
NO	O
##ES	O
##Y	O
spectrum	O
of	O
SP	S
collected	O
in	O
H	O
##BS	O
##S	O
,	O
with	O
additional	O
peaks	O
due	O
to	O
ex	O
##ogen	O
##ous	O
glucose	S
present	O
.	O

They	O
found	O
that	O
impaired	O
SP	O
##T	O
activity	O
induced	O
decreased	O
serum	O
c	B
##era	I
##mi	I
##des	I
and	O
s	B
##phi	I
##ngo	I
##sin	I
##e	I
levels	O
,	O
finally	O
resulting	O
in	O
br	O
##on	O
##chia	O
##l	O
h	O
##yper	O
##rea	O
##ct	O
##ivity	O
.	O

Changes	O
in	O
met	B
##hi	I
##oni	I
##ne	I
,	O
c	B
##it	I
##ru	I
##llin	I
##e	I
,	O
pipe	B
##cola	I
##te	I
,	O
th	B
##re	I
##oni	I
##ne	I
,	O
and	O
is	B
##ole	I
##uc	I
##ine	I
concentrations	O
contributed	O
to	O
the	O
separation	O
between	O
groups	O
.	O

Studies	O
showed	O
that	O
his	B
##ti	I
##dine	I
has	O
an	O
inverse	O
association	O
with	O
o	O
##xi	O
##da	O
##tive	O
stress	O
status	O
in	O
T	O
##2	O
##DM	O
and	O
its	O
supplement	O
##ation	O
could	O
improve	O
insulin	O
resistance	O
.	O

Alternatively	O
,	O
it	O
is	O
possible	O
that	O
an	O
unknown	O
SP	S
des	O
##at	O
##ura	O
##se	O
cat	O
##aly	O
##zes	O
the	O
incorporation	O
of	O
a	O
second	O
double	O
bond	O
into	O
the	O
s	B
##phi	I
##ngo	I
##id	I
backbone	O
at	O
some	O
step	O
along	O
the	O
SP	S
metabolic	O
pathway	O
.	O

Among	O
the	O
measured	O
p	O
##oly	O
##amine	O
-	O
related	O
meta	O
##bol	O
##ites	O
,	O
only	O
a	B
##rg	I
##ini	I
##ne	I
,	O
or	B
##ni	I
##thin	I
##e	I
,	O
and	O
put	B
##res	I
##cine	I
were	O
significantly	O
different	O
between	O
T	O
##2	O
##D	O
and	O
non	O
-	O
di	O
##abe	O
##tic	O
subjects	O
.	O

Me	O
##as	O
##ure	O
##ments	O
of	O
D	B
##H	I
##EA	I
-	I
S	I
could	O
be	O
performed	O
on	O
as	O
little	O
as	O
1	O
μ	O
##L	O
of	O
serum	O
.	O

Another	O
interesting	O
observation	O
was	O
the	O
increase	O
of	O
several	O
tested	O
molecules	O
,	O
including	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
and	O
u	B
##ric	I
acid	I
during	O
heating	O
.	O

Fr	O
##oz	O
##en	O
serum	O
samples	O
were	O
submitted	O
to	O
ID	O
##EX	O
##X	O
Laboratories	O
(	O
transported	O
overnight	O
on	O
dry	O
ice	O
)	O
within	O
48	O
h	O
following	O
collection	O
for	O
determination	O
of	O
serum	O
B	O
##UN	O
and	O
c	B
##rea	I
##tin	I
##ine	I
.	O

Several	O
car	O
##ni	O
##tine	O
-	O
con	O
##ju	O
##gated	O
derivatives	O
increased	O
following	O
le	O
##pt	O
##in	O
treatment	O
,	O
including	O
is	B
##ova	I
##ler	I
##yla	I
##car	I
##ni	I
##tine	I
,	O
t	B
##ig	I
##ly	I
##l	I
car	I
##ni	I
##tine	I
,	O
is	B
##ob	I
##ut	I
##ry	I
##ryl	I
##car	I
##ni	I
##tine	I
,	O
but	B
##yr	I
##yl	I
##car	I
##ni	I
##tine	I
,	O
prop	B
##ion	I
##yl	I
##car	I
##ni	I
##tine	I
,	O
and	O
s	B
##tero	I
##yl	I
##car	I
##ni	I
##tine	I
.	O

Multiple	O
investigators	O
have	O
studied	O
the	O
impact	O
of	O
g	B
##ly	I
##cine	I
on	O
glucose	S
and	O
insulin	O
levels	O
in	O
healthy	O
and	O
di	O
##abe	O
##tic	O
individuals	O
.	O

A	O
modest	O
component	O
of	O
vitamin	B
D	I
is	O
derived	O
from	O
foods	O
consumed	O
,	O
including	O
dairy	O
products	O
and	O
fish	O
.	O

(	O
B	O
)	O
N	O
##eg	O
##ative	O
ion	O
mode	O
DE	O
##SI	O
mass	O
s	O
##pect	O
##ra	O
obtained	O
using	O
an	O
am	B
##a	I
##Z	I
##on	I
Speed	O
ion	O
trap	O
from	O
m	O
/	O
z	O
130	O
–	O
165	O
(	O
B	O
##ruk	O
##er	O
Dalton	O
##ics	O
)	O
from	O
a	O
s	O
##wab	O
(	O
Left	O
)	O
,	O
a	O
s	O
##me	O
##ar	O
(	O
Center	O
)	O
,	O
and	O
a	O
section	O
(	O
Right	O
)	O
for	O
sample	O
S	O
##7	O
##2	O
.	O

SP	S
samples	O
were	O
th	O
##awed	O
on	O
wet	O
ice	O
and	O
distributed	O
in	O
100	O
-	O
μ	O
##L	O
al	O
##iq	O
##uo	O
##ts	O
.	O

The	O
presence	O
of	O
d	B
##20	I
:	I
1	I
happened	O
to	O
be	O
specific	O
to	O
nervous	O
tissues	O
(	O
re	O
##tina	O
,	O
brain	O
and	O
op	O
##tic	O
nerve	O
)	O
.	O

d	O
Nine	O
meta	O
##bol	O
##ites	O
are	O
significantly	O
associated	O
with	O
the	O
presence	O
of	O
the	O
ID	O
##H	O
-	O
mutation	O
in	O
g	O
##lio	O
##mas	O
(	B
1	B
-	I
Met	I
##hyl	I
##try	I
##pt	I
##op	I
##han	I
,	O
1	B
-	I
Met	I
##hyl	I
-	I
His	I
##ti	I
##dine	I
,	O
A	B
##rg	I
##ini	I
##ne	I
,	O
N	B
-	I
Ace	I
##ty	I
##l	I
##put	I
##res	I
##cine	I
,	O
Su	B
##cci	I
##nic	I
acid	I
semi	I
##ald	I
##eh	I
##yd	I
##e	I
,	O
Mal	B
##ona	I
##te	I
,	O
beta	B
##ine	I
al	I
##de	I
##hy	I
##de	I
,	O
Pan	B
##to	I
##the	I
##nic	I
acid	O
)	O
.	O

Co	O
##mpo	O
##unds	O
involved	O
in	O
o	O
##xi	O
##da	O
##tive	O
stress	O
,	O
such	O
as	O
c	B
##ys	I
##tein	I
##e	I
and	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
,	O
may	O
serve	O
as	O
ca	O
##usal	O
in	O
lung	O
function	O
decline	O
.	O

However	O
,	O
it	O
was	O
also	O
demonstrated	O
that	O
the	O
type	O
of	O
link	O
##age	O
between	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
core	O
and	O
fatty	O
acid	O
residue	O
may	O
be	O
the	O
key	O
factor	O
contributing	O
to	O
the	O
anti	O
##the	O
##tical	O
association	O
between	O
two	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
sub	O
##c	O
##lass	O
##es	O
and	O
T	O
##2	O
##DM	O
risk	O
.	O

For	O
Stage	O
II	O
diagnosis	O
maximum	O
sensitivity	O
was	O
observed	O
for	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
however	O
its	O
specific	O
##ity	O
was	O
found	O
to	O
be	O
poor	O
.	O

Ph	B
##os	I
##ph	I
##oli	I
##pid	I
##s	I
accounted	O
for	O
17	O
%	O
of	O
the	O
metabolic	O
impact	O
.	O

A	O
specific	O
class	O
of	O
t	B
##yra	I
##mine	I
receptor	O
,	O
the	O
trace	O
am	O
##ine	O
associated	O
receptor	O
(	O
T	O
##AA	O
##R	O
##1	O
)	O
,	O
is	O
a	O
G	O
-	O
protein	O
coupled	O
receptor	O
(	O
GP	O
##CR	O
)	O
expressed	O
in	O
the	O
brain	O
with	O
a	O
wide	O
distribution	O
in	O
other	O
organs	O
.	O

For	O
hybrid	O
##isation	O
with	O
the	O
probe	O
##s	O
specific	O
for	O
Lac	B
##to	I
##ba	I
##ci	I
##llus	I
/	O
En	O
##tero	O
##co	O
##cc	O
##us	O
s	O
##pp	O
.	O
,	O
B	O
##if	O
##ido	O
##ba	O
##cter	O
##ium	O
s	O
##pp	O
.	O

AC	O
##N	O
(	O
HP	O
##LC	O
grade	O
)	O
and	O
form	B
##ic	I
acid	I
(	O
FA	O
,	O
HP	O
##LC	O
grade	O
)	O
were	O
purchased	O
from	O
Me	O
##rc	O
##k	O
(	O
Dar	O
##ms	O
##tadt	O
,	O
Germany	O
)	O
.	O

For	O
male	O
,	O
the	O
differential	O
meta	O
##bol	O
##ites	O
were	O
mainly	O
involved	O
in	O
four	O
metabolic	O
pathways	O
:	O
synthesis	O
and	O
degradation	O
of	O
k	B
##eton	I
##e	I
bodies	O
,	O
met	B
##hane	I
metabolism	O
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
metabolism	O
,	O
and	O
t	B
##yr	I
##os	I
##ine	I
metabolism	O
.	O

Dan	O
##sy	O
##lation	O
label	O
##ing	O
L	O
##C	O
-	O
MS	O
targets	O
the	O
analysis	O
of	O
the	O
am	O
##ine	O
/	O
p	O
##hen	O
##ol	O
sub	O
##met	O
##ab	O
##olo	O
##me	O
;	O
many	O
meta	O
##bol	O
##omi	O
##c	O
pathways	O
contain	O
the	O
am	B
##ine	I
-	I
and	O
p	O
##hen	O
##ol	O
-	O
containing	O
meta	O
##bol	O
##ites	O
.	O

Hip	B
##pura	I
##te	I
.	O

Co	O
##mp	O
##aris	O
##on	O
of	O
molecular	O
features	O
detected	O
by	O
L	O
##C	O
-	O
TO	O
##F	O
on	O
R	O
##PC	O
when	O
met	B
##han	I
##ol	I
(	O
Me	O
##OH	O
)	O
or	O
met	B
##han	I
##ol	I
-	I
ethanol	I
(	O
Me	O
##OH	O
-	O
E	O
##t	O
##OH	O
)	O
precipitation	O
methods	O
are	O
used	O
.	O

P	O
##uri	O
##fied	O
human	O
re	O
##comb	O
##ina	O
##nt	O
re	B
##tino	I
##id	I
receptors	O
were	O
used	O
at	O
50	O
f	O
##mo	O
##l	O
with	O
a	O
non	O
-	O
re	O
##tino	O
##id	O
-	O
binding	O
protein	O
(	O
key	O
##hole	O
limp	O
##et	O
hem	B
##oc	I
##yan	I
##in	I
)	O
to	O
maintain	O
[UNK]	O
.	O
1	O
mg	O
protein	O
/	O
m	O
##l	O
to	O
prevent	O
loss	O
of	O
receptor	O
protein	O
and	O
l	O
##igan	O
##d	O
during	O
the	O
course	O
of	O
binding	O
experiments	O
.	O

Σ	O
##FA	O
(	O
mid	O
##cha	O
##inal	O
##co	O
##hol	O
##s	O
+	O
k	O
##eton	O
##es	O
)	O
/	O
parent	O
##fa	O
##tty	O
##ac	O
##id	O
L	O
##OX	O
##FA	O
##ind	O
##ex	O
=	O
Σ	O
##FA	O
(	O
mid	O
##cha	O
##inal	O
##co	O
##hol	O
##s	O
+	O
k	O
##eton	O
##es	O
)	O
/	O
parent	O
##fa	O
##tty	O
##ac	O
##id	O
L	O
##OX	O
##FA	O
L	O
##OX	O
##FA	O
L	O
##OX	O
L	O
##OX	O
L	O
##OX	O
L	O
##OX	O
L	O
O	O
X	O
FA	B
FA	I
FA	I
FA	I
F	O
A	O
index	O
index	O
i	O
n	O
d	O
e	O
x	O
=	O
Σ	O
##FA	O
Σ	O
##FA	O
Σ	O
Σ	O
Σ	O
Σ	O
Σ	O
FA	B
FA	I
FA	I
FA	I
F	O
A	O
(	O
mid	O
##cha	O
##in	O
mid	O
##cha	O
##in	O
m	O
i	O
d	O
c	O
h	O
a	O
i	O
n	O
alcohol	B
##s	I
alcohol	I
##s	I
a	O
l	O
c	O
o	O
h	O
o	O
l	O
s	O
+	O
k	B
##eton	I
##es	I
k	I
##eton	I
##es	I
k	O
e	O
t	O
o	O
n	O
e	O
s	O
)	O
/	O
/	O
parent	O
parent	O
p	O
a	O
r	O
e	O
n	O
t	O
fatty	O
fatty	O
f	O
a	O
t	O
t	O
y	O
acid	O
acid	O
a	O
c	O
i	O
d	O

Accordingly	O
the	O
apparent	O
formation	O
rate	O
of	O
h	B
##ydro	I
##xy	I
##ana	I
##stro	I
##zo	I
##le	I
from	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
(	O
0	O
.	O
5	O
–	O
200	O
µ	O
##m	O
)	O
in	O
H	O
##LM	O
##s	O
exhibited	O
bi	O
##pha	O
##si	O
##c	O
kinetic	O
behaviour	O
in	O
E	O
##adi	O
##e	O
-	O
Ho	O
##fs	O
##tee	O
plots	O
,	O
which	O
suggested	O
the	O
involvement	O
of	O
at	O
least	O
two	O
en	O
##zy	O
##matic	O
activities	O
that	O
were	O
best	O
described	O
by	O
high	O
-	O
affinity	O
(	O
K	O
_	O
m	O
##1	O
and	O
V	O
_	O
ma	O
##x	O
##1	O
)	O
and	O
low	O
-	O
affinity	O
(	O
K	O
_	O
m	O
##2	O
and	O
V	O
_	O
ma	O
##x	O
##2	O
)	O
components	O
.	O

In	O
healthy	O
donors	O
,	O
C	B
##16	I
:	I
0	I
species	O
were	O
the	O
highest	O
followed	O
by	O
C	B
##24	I
:	I
0	I
,	O
C	B
##24	I
:	I
1	I
,	O
and	O
C	B
##22	I
:	I
0	I
.	O

Then	O
,	O
tailored	O
FA	S
supplement	O
##ation	O
to	O
counter	O
##act	O
decreasing	O
NE	O
##FA	O
over	O
time	O
could	O
be	O
ad	O
##vis	O
##able	O
in	O
these	O
patients	O
to	O
increase	O
the	O
chance	O
of	O
achieving	O
a	O
good	O
clinical	O
response	O
upon	O
biological	O
treatment	O
,	O
as	O
recently	O
suggested	O
for	O
triple	O
-	O
D	O
##MA	O
##RD	O
therapy	O
.	O

Because	O
this	O
was	O
a	O
dual	O
labeled	O
is	O
##oto	O
##pe	O
study	O
,	O
next	O
to	O
the	O
labeled	O
food	O
,	O
a	O
p	O
##rim	O
##ing	O
dose	O
of	O
_	O
2	O
H	O
-	O
labelled	O
glucose	S
was	O
administered	O
as	O
a	O
b	O
##ol	O
##us	O
followed	O
by	O
a	O
continuous	O
in	O
##fusion	O
of	O
de	O
##uter	O
##ated	O
glucose	S
for	O
8	O
h	O
.	O

Ser	O
##um	O
samples	O
that	O
were	O
stored	O
at	O
−	O
##80	O
##°	O
##C	O
since	O
collection	O
were	O
th	O
##awed	O
at	O
4	O
##°	O
##C	O
and	O
used	O
for	O
measurement	O
of	O
est	O
##rogen	O
##s	O
and	O
est	B
##rogen	I
meta	O
##bol	O
##ites	O
.	O

Our	O
first	O
approach	O
focused	O
on	O
di	B
##os	I
##met	I
##in	I
determination	O
after	O
en	O
##zy	O
##matic	O
degradation	O
,	O
and	O
these	O
issues	O
have	O
been	O
reflected	O
in	O
the	O
imp	O
##oss	O
##ibility	O
to	O
find	O
a	O
totally	O
free	O
blank	O
matrix	O
even	O
if	O
the	O
volunteers	O
included	O
in	O
this	O
study	O
have	O
kept	O
a	O
strict	O
diet	O
.	O

Thus	O
,	O
E	O
##D	O
##TA	O
and	O
he	B
##par	I
##in	I
are	O
both	O
suitable	O
for	O
blood	O
patient	O
collection	O
and	O
can	O
also	O
be	O
used	O
if	O
necessary	O
for	O
the	O
preparation	O
of	O
ca	O
##li	O
##bra	O
##tors	O
and	O
Q	O
##C	O
samples	O
.	O

Part	O
##icular	O
##ly	O
,	O
the	O
ability	O
of	O
MA	O
##S	O
N	O
##MR	O
in	O
different	O
##iating	O
metabolic	O
p	O
##hen	O
##otype	O
##s	O
of	O
normal	O
and	O
tumor	O
tissues	O
within	O
a	O
few	O
minutes	O
of	O
experimental	O
duration	S
make	O
the	O
technique	O
am	O
##ena	O
##ble	O
for	O
clinical	O
diagnostic	O
##s	O
/	O
pro	O
##gno	O
##stics	O
of	O
cancer	O
.	O

The	O
E	B
##I	I
mass	O
s	O
##pect	O
##ra	O
of	O
FA	O
##ME	O
##s	O
are	O
available	O
in	O
the	O
A	O
##OC	O
##S	O
lip	O
##id	O
library	O
(	O
http	O
:	O
/	O
/	O
lip	O
##id	O
##li	O
##bra	O
##ry	O
.	O
a	O
##oc	O
##s	O
.	O
org	O
/	O
m	O
##s	O
/	O
m	O
##s	O
##16	O
/	O
index	O
.	O
h	O
##t	O
##m	O
)	O
.	O

In	O
β	O
-	O
th	O
##ala	O
##sse	O
##mia	O
,	O
there	O
is	O
an	O
im	O
##bal	O
##ance	O
in	O
α	B
/	I
β	I
-	I
g	I
##lo	I
##bin	I
ratio	O
and	O
excessive	O
α	B
-	I
g	I
##lo	I
##bin	I
##s	I
possibly	O
causes	O
o	O
##xi	O
##da	O
##tive	O
damage	O
to	O
membrane	O
lip	O
##ids	O
and	O
proteins	O
of	O
red	O
cell	O
in	O
the	O
form	O
of	O
i	O
##rre	O
##versible	O
hem	O
##ich	O
##rome	O
##s	O
and	O
also	O
increases	O
in	O
##tra	O
##cellular	O
calcium	O
,	O
causing	O
the	O
significant	O
increase	O
in	O
destruction	O
of	O
RB	O
##Cs	O
and	O
ultimately	O
an	O
##ae	O
##mia	O
.	O

At	O
0	O
minutes	O
nearly	O
all	O
the	O
measured	O
meta	O
##bol	O
##ites	O
were	O
present	O
as	O
g	B
##lu	I
##cu	I
##ronic	I
acid	I
con	O
##ju	O
##gate	O
##s	O
,	O
while	O
after	O
30	O
and	O
60	O
minutes	O
β	O
-	O
g	O
##lu	O
##cu	O
##ron	O
##idas	O
##e	O
treatment	O
(	O
1	O
.	O
6	O
units	O
/	O
μ	O
##l	O
)	O
at	O
37	O
°C	O
,	O
greater	O
than	O
80	O
%	O
and	O
94	O
%	O
of	O
the	O
con	O
##ju	O
##gated	O
meta	O
##bol	O
##ites	O
were	O
h	O
##ydro	O
##ly	O
##zed	O
,	O
respectively	O
.	O

In	O
the	O
case	O
of	O
N	O
##MO	O
##SD	O
,	O
is	B
##ob	I
##ut	I
##yra	I
##te	I
might	O
be	O
down	O
-	O
regulated	O
in	O
N	O
##MO	O
##SD	O
re	O
##lap	O
##se	O
compared	O
to	O
re	O
##mission	O
,	O
since	O
statistical	O
requirement	O
was	O
partially	O
satisfied	O
(	O
p	O
-	O
value	O
=	O
0	O
.	O
00	O
##2	O
,	O
F	O
##DR	O
=	O
0	O
.	O
06	O
##4	O
)	O
.	O

B	O
##io	O
##chemical	O
identification	O
##s	O
were	O
based	O
on	O
(	O
1	O
)	O
retention	O
index	O
within	O
a	O
narrow	O
R	B
##I	I
window	O
of	O
the	O
proposed	O
identification	O
,	O
(	O
2	O
)	O
accurate	O
mass	O
match	O
to	O
the	O
library	O
+	O
/	O
−	O
0	O
.	O
00	O
##5	O

Inc	O
##rease	O
##s	O
in	O
the	O
meta	O
##bol	O
##ites	O
hip	B
##pur	I
##ic	I
acid	I
,	O
c	B
##it	I
##rate	I
,	O
and	O
la	B
##ctic	I
acid	I
were	O
associated	O
with	O
in	O
##f	O
##lix	O
##ima	O
##b	O
treatment	O
,	O
and	O
increases	O
in	O
the	O
meta	O
##bol	O
##ites	O
ch	B
##olin	I
##e	I
,	O
p	B
##hen	I
##yla	I
##ce	I
##tic	I
acid	I
,	O
u	B
##rea	I
,	O
c	B
##rea	I
##tine	I
,	O
and	O
met	B
##hyl	I
##amine	I
were	O
associated	O
with	O
et	O
##ane	O
##rc	O
##ept	O
treatment	O
.	O

He	B
##xa	I
##de	I
##cane	I
##dio	I
##ic	I
acid	I
is	O
a	O
long	O
-	O
chain	O
di	B
##car	I
##box	I
##yl	I
##ic	I
acid	I
,	O
generated	O
from	O
fatty	O
acid	O
ω	O
-	O
oxidation	O
and	O
thereafter	O
meta	O
##bol	O
##ized	O
by	O
β	O
-	O
oxidation	O
in	O
per	O
##ox	O
##is	O
##ome	O
##s	O
.	O

Groups	O
of	O
AC	O
##s	O
,	O
important	O
to	O
evaluate	O
mitochondrial	O
function	O
,	O
were	O
also	O
com	O
##puted	O
by	O
sum	O
##ming	O
(	O
Total	O
AC	O
,	O
C	O
##2	O
+	O
C	O
##3	O
,	O
C	O
##16	O
+	O
C	O
##18	O
,	O
C	B
##16	I
+	I
C	I
##18	I
:	I
1	I
,	O
C	B
##16	I
-	I
OH	I
+	I
C	I
##18	I
:	I
1	I
-	I
OH	I
)	O
.	O

A	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
derivatives	O
including	O
3	B
-	I
h	I
##ydro	I
##xy	I
##oc	I
##tano	I
##yl	I
car	I
##ni	I
##tine	I
,	O
2	B
-	I
o	I
##ct	I
##eno	I
##yl	I
##car	I
##ni	I
##tine	I
,	O
3	B
-	I
h	I
##ydro	I
##xy	I
##de	I
##cano	I
##yl	I
car	I
##ni	I
##tine	I
,	O
o	B
##ct	I
##ano	I
##yl	I
##car	I
##ni	I
##tine	I
,	O
9	B
-	I
de	I
##ce	I
##noy	I
##l	I
##car	I
##ni	I
##tine	I
,	O
de	B
##cano	I
##yl	I
##car	I
##ni	I
##tine	I
,	O
l	B
##ino	I
##len	I
##yl	I
car	I
##ni	I
##tine	I
,	O
a	B
##rac	I
##hi	I
##dy	I
##l	I
car	I
##ni	I
##tine	I
were	O
obviously	O
increased	O
in	O
BC	O
subjects	O
relative	O
to	O
healthy	O
controls	O
.	O

High	O
performance	O
liquid	O
ch	O
##roma	O
##tography	O
(	O
HP	O
##LC	O
)	O
grade	O
met	B
##han	I
##ol	I
was	O
purchased	O
from	O
the	O
Ted	O
##ia	O
Company	O
(	O
Inc	O
.	O
,	O
Fairfield	O
,	O
USA	O
)	O
.	O

The	O
plasma	O
concentrations	O
of	O
two	O
lip	O
##id	O
sub	O
##c	O
##lass	O
##es	O
,	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
and	O
mon	B
##os	I
##ial	I
##od	I
##ih	I
##ex	I
##osy	I
##l	I
##gan	I
##gli	I
##os	I
##ide	I
(	O
GM	O
##3	O
)	O
,	O
were	O
different	O
between	O
PD	O
and	O
control	O
participants	O
.	O

HP	O
##LC	O
-	O
grade	O
Met	B
##han	I
##ol	I
and	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
(	O
AC	O
##N	O
)	O
were	O
purchased	O
from	O
Me	O
##rk	O
(	O
Dar	O
##ms	O
##tadt	O
,	O
Germany	O
)	O
.	O

patients	O
who	O
were	O
treated	O
by	O
de	B
##pa	I
##kin	I
##e	I
(	O
San	O
##of	O
##i	O
(	O
Hang	O
##zhou	O
)	O
Ph	O
##arma	O
##ce	O
##utical	O
Co	O
,	O
Ltd	O
.	O
,	O
Hang	O
##zhou	O
,	O
China	O
)	O
for	O
2	O
weeks	O
.	O

The	O
meta	O
##bol	O
##ite	O
panel	O
comprising	O
1	B
-	I
h	I
##ydro	I
##xy	I
-	I
2	I
-	I
o	I
##x	I
##op	I
##rop	I
##yl	I
te	I
##tra	I
##hy	I
##dr	I
##op	I
##ter	I
##in	I
,	O
1	B
-	I
ace	I
##to	I
##xy	I
-	I
2	I
-	I
h	I
##ydro	I
##xy	I
-	I
16	I
-	I
he	I
##pta	I
##de	I
##cy	I
##n	I
-	I
4	I
-	I
one	I
,	O
1	B
,	I
2	I
-	I
de	I
##hy	I
##dr	I
##osa	I
##ls	I
##olin	I
##ol	I
and	O
L	B
-	I
t	I
##yr	I
##os	I
##ine	I
could	O
significantly	O
disc	O
##rim	O
##inate	O
BC	O
from	O
RC	O
##C	O
with	O
ha	O
##ema	O
##tur	O
##ia	O
(	O
AU	O
##C	O
was	O
0	O
.	O
91	O
##3	O
)	O
.	O

In	O
basic	O
and	O
fully	O
adjusted	O
models	O
,	O
long	O
‐	O
chain	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
factor	O
levels	O
differed	O
significantly	O
across	O
groups	O
(	O
P	O
<	O
0	O
.	O
000	O
##1	O
)	O
and	O
were	O
greater	O
in	O
H	O
##F	O
##r	O
##EF	O
than	O
H	O
##F	O
##p	O
##EF	O
(	O
P	O
=	O
0	O
.	O
000	O
##4	O
)	O
,	O
both	O
of	O
which	O
were	O
greater	O
than	O
no	O
‐	O
H	O
##F	O
controls	O
.	O

These	O
are	O
met	O
##hyl	O
##ation	O
of	O
cat	B
##ech	I
##ol	I
est	O
##rogen	O
##s	O
,	O
con	O
##ju	O
##gation	O
of	O
the	O
E	O
_	O
1	O
(	O
E	O
_	O
2	O
)	O
-	O
Q	O
with	O
g	B
##lut	I
##ath	I
##ione	I
(	O
G	O
##S	O
##H	O
)	O
and	O
reduction	O
of	O
the	O
q	B
##uin	I
##ones	I
to	O
cat	B
##ech	I
##ols	I
.	O

Finally	O
,	O
80	O
μ	O
##L	O
of	O
bi	B
##s	I
(	I
trim	I
##eth	I
##yl	I
##si	I
##ly	I
##l	I
)	I
t	I
##ri	I
##f	I
##lu	I
##oro	I
##ace	I
##tam	I
##ide	I
(	O
BS	O
##TF	O
##A	O
)	O
(	O
1	O
%	O
trim	B
##eth	I
##yl	I
##ch	I
##lor	I
##os	I
##ila	I
##ne	I
)	O
and	O
20	O
μ	O
##L	O
of	O
n	B
-	I
he	I
##xa	I
##ne	I
were	O
added	O
,	O
and	O
the	O
extract	O
was	O
kept	O
at	O
70	O
##°	O
##C	O
for	O
60	O
minutes	O
.	O

This	O
is	O
consistent	O
with	O
the	O
findings	O
of	O
a	O
long	O
-	O
term	O
intervention	O
trial	O
in	O
which	O
220	O
pre	O
##men	O
##op	O
##aus	O
##al	O
women	O
were	O
random	O
##ized	O
to	O
a	O
so	O
##y	O
intervention	O
or	O
control	O
arm	O
;	O
in	O
this	O
study	O
investigators	O
found	O
no	O
differences	O
between	O
groups	O
in	O
circulating	O
est	B
##rone	I
,	O
est	B
##rad	I
##iol	I
,	O
or	O
free	O
est	B
##rad	I
##iol	I
at	O
four	O
time	O
points	O
up	O
to	O
24	O
months	O
.	O

In	O
Ta	O
/	O
T	O
##1	O
stage	O
disease	O
,	O
when	O
comparing	O
pre	O
-	O
g	O
##em	O
##ci	O
##ta	O
##bine	O
normal	O
vs	O
.	O
pre	O
-	O
g	O
##em	O
##ci	O
##ta	O
##bine	O
BC	O
##a	O
tissues	O
,	O
the	O
changes	O
in	O
his	B
##tamine	I
(	O
P	O
=	O
2	O
.	O
60	O
##E	O
-	O
1	O
)	O
and	O
th	B
##iam	I
##ine	I
(	O
P	O
=	O
8	O
.	O
39	O
##E	O
-	O
2	O
)	O
in	O
the	O
tumor	O
were	O
ins	O
##ign	O
##ificant	O
(	O
Table	O
S	O
##I	O
)	O
.	O

Indeed	O
,	O
it	O
has	O
been	O
suggested	O
that	O
indirect	O
strategies	O
for	O
el	O
##eva	O
##ting	O
a	B
##rg	I
##ini	I
##ne	I
(	O
such	O
as	O
the	O
in	O
##hibition	O
of	O
a	O
##rg	O
##inas	O
##e	O
)	O
could	O
prove	O
more	O
effective	O
at	O
improving	O
in	O
##tra	O
##cellular	O
a	B
##rg	I
##ini	I
##ne	I
bio	O
##ava	O
##ila	O
##bility	O
than	O
ex	O
##ogen	O
##ous	O
a	B
##rg	I
##ini	I
##ne	I
administration	O
(	O
)	O
.	O

b	O
##OH	O
##B	O
##ut	O
=	O
3	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
.	O

The	O
potential	O
mechanisms	O
linking	O
the	O
aforementioned	O
pu	B
##rine	I
meta	O
##bol	O
##ites	O
and	O
T	O
##2	O
##D	O
risk	O
must	O
be	O
also	O
further	O
investigated	O
.	O

To	O
extract	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
,	O
2	O
×	O
10	O
_	O
6	O
cells	O
were	O
washed	O
twice	O
with	O
ice	O
-	O
cold	O
PBS	O
,	O
scraped	O
into	O
800	O
μ	O
##L	O
of	O
ice	O
-	O
cold	O
0	O
.	O
1	O
N	O
HC	O
##l	O
:	O
CH	O
_	O
3	O
OH	B
(	I
1	I
:	I
1	I
)	I
,	O
and	O
transferred	O
into	O
a	O
cold	O
micro	O
##fu	O
##ge	O
tube	O
.	O

HD	O
##L	O
=	O
high	O
-	O
density	O
lip	O
##op	O
##rote	O
##in	O
;	O
L	O
##D	O
##L	O
=	O
low	O
-	O
density	O
lip	O
##op	O
##rote	O
##in	O
;	O
BP	O
=	O
blood	O
pressure	O
;	O
B	O
##MI	O
=	O
body	O
mass	O
index	O
;	O
F	O
##T	O
##4	O
=	O
free	O
thy	B
##ro	I
##xin	I
##e	I
;	O
T	O
##S	O
##H	O
=	O
thy	O
##rot	O
##rop	O
##in	O
.	O

Comparative	O
electro	O
##sp	O
##ray	O
mass	O
s	O
##pect	O
##ra	O
of	O
P	B
##E	I
18	I
:	I
1	I
(	I
n	I
-	I
9	I
,	I
c	I
##is	I
)	I
/	I
18	I
:	I
1	I
(	I
n	I

The	O
above	O
set	O
of	O
data	O
suggests	O
that	O
bi	O
##car	O
##bon	O
##ate	O
interact	O
##s	O
with	O
PC	O
##s	O
differently	O
as	O
compared	O
to	O
format	B
##e	I
and	O
thus	O
significantly	O
alter	O
##s	O
the	O
un	O
##imo	O
##le	O
##cular	O
di	O
##sso	O
##ciation	O
chemistry	O
of	O
the	O
PC	O
an	O
##ion	O
add	O
##uc	O
##t	O
ions	O
upon	O
collision	O
##al	O
activation	O
(	O
Fi	O
##g	O
.	O
S	O
##1	O
_	O
†	O
)	O
.	O

The	O
total	O
lip	O
##ids	O
of	O
the	O
so	O
##y	O
drink	O
,	O
mostly	O
derived	O
from	O
added	O
vegetable	O
fat	O
composed	O
of	O
palm	O
and	O
palm	O
kernel	O
oil	O
,	O
consisted	O
of	O
the	O
following	O
four	O
most	O
abundant	O
fatty	O
acids	O
:	O
la	B
##uri	I
##c	I
acid	I
C	I
##12	I
:	I
0	I
(	O
22	O
%	O
)	O
,	O
l	B
##ino	I
##le	I
##ic	I
acid	I
C	I
##18	I
:	I
2	I
(	O
21	O
%	O
)	O
,	O
palm	B
##itic	I
acid	I
C	I
##16	I
:	I
0	I
(	O
13	O
%	O
)	O
,	O
and	O
s	B
##te	I
##ari	I
##c	I
acid	I
C	I
##18	I
:	I
0	I
(	O
12	O
.	O
1	O
%	O
)	O
.	O

These	O
associations	O
included	O
seven	O
meta	O
##bol	O
##ites	O
present	O
in	O
both	O
,	O
plasma	O
and	O
urine	O
,	O
e	O
.	O
g	O
.	O
pro	B
##ly	I
##l	I
##hy	I
##dr	I
##ox	I
##y	I
##p	I
##rol	I
##ine	I
(	O
P	O
##HP	O
)	O
and	O
C	B
-	I
man	I
##nos	I
##yl	I
##try	I
##pt	I
##op	I
##han	I
.	O

The	O
most	O
significant	O
differences	O
in	O
meta	O
##bol	O
##ite	O
concentrations	O
observed	O
across	O
the	O
three	O
conditions	O
included	O
changes	O
in	O
plasma	O
lip	O
##op	O
##rote	O
##in	O
and	O
amino	O
acid	O
levels	O
along	O
with	O
changes	O
in	O
s	B
##cy	I
##llo	I
-	I
in	I
##os	I
##ito	I
##l	I
and	O
my	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
.	O

G	O
##ly	O
##co	O
##lysis	O
was	O
not	O
altered	O
,	O
as	O
expected	O
for	O
the	O
presence	O
of	O
insulin	O
activity	O
,	O
but	O
im	O
##bal	O
##ance	O
##s	O
in	O
several	O
other	O
pathways	O
were	O
found	O
,	O
such	O
as	O
the	O
pen	B
##tos	I
##e	I
phosphate	I
pathway	O
(	O
PP	O
##P	O
)	O
,	O
g	B
##ly	I
##cer	I
##ol	I
shuttle	O
,	O
ma	B
##late	I
shuttle	O
,	O
K	O
##re	O
##bs	O
cycle	O
(	O
T	O
##CA	O
)	O
and	O
lip	O
##id	O
metabolism	O
.	O

This	O
meta	O
##bol	O
##ite	O
was	O
identified	O
as	O
p	B
-	I
c	I
##res	I
##ol	I
su	I
##lf	I
##ate	I
from	O
the	O
literature	O
,	O
the	O
resonance	O
at	O
2	O
.	O
35	O
representing	O
the	O
met	O
##hyl	O
signal	O
and	O
a	O
pseudo	O
-	O
double	O
##t	O
at	O
7	O
.	O
21	O
pp	O
##m	O
,	O
the	O
a	O
##romatic	O
signal	O
.	O

Pro	O
-	O
inflammatory	O
media	O
##tors	O
P	B
##G	I
##F	I
_	I
2	I
##α	I
and	O
P	B
##G	I
##F	I
_	I
3	I
##α	I
and	O
o	O
##xi	O
##da	O
##tive	O
stress	O
markers	O
i	B
##P	I
##F	I
_	I
2	I
##α	I
-	I
IV	I
,	O
11	B
-	I
H	I
##ET	I
##E	I
and	O
14	B
-	I
HD	I
##o	I
##H	I
##E	I
were	O
positively	O
associated	O
with	O
improvement	O
of	O
disease	O
activity	O
score	O
.	O

Our	O
data	O
showed	O
a	O
positive	O
correlation	O
of	O
t	O
##C	O
##ho	O
with	O
the	O
c	O
##yt	O
##oso	O
##lic	O
and	O
nuclear	O
expression	O
of	O
β	B
-	I
cat	I
##eni	I
##n	I
and	O
c	O
##y	O
##c	O
##lin	O
D	O
##1	O
in	O
ma	O
##li	O
##gnant	O
tissues	O
and	O
a	O
correlation	O
between	O
the	O
nuclear	O
expressions	O
of	O
both	O
these	O
proteins	O
.	O

These	O
meta	O
##bol	O
##ites	O
included	O
N	B
-	I
su	I
##cci	I
##ny	I
##l	I
-	I
2	I
,	I
6	I
-	I
di	I
##ami	I
##no	I
##pi	I
##mel	I
##ate	I
,	O
de	B
##ox	I
##ych	I
##olic	I
acid	I
g	I
##ly	I
##cine	I
con	I
##ju	I
##gate	I
,	O
o	B
##ct	I
##ano	I
##yl	I
##car	I
##ni	I
##tine	I
,	O
LP	O
##Cs	O
,	O
LP	B
##E	I
(	I
20	I
:	I
2	I
)	I
,	O
PC	B
(	I
34	I
:	I
1	I
)	I
,	O
PS	O
##s	O
,	O
and	O
ch	B
##ole	I
##ster	I
##yl	I
ace	I
##tate	I
.	O

In	O
the	O
present	O
study	O
,	O
g	B
##lut	I
##amine	I
,	O
g	B
##lut	I
##ama	I
##te	I
,	O
as	B
##par	I
##tate	I
and	O
as	B
##par	I
##agi	I
##ne	I
were	O
measured	O
simultaneously	O
using	O
a	O
fast	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
method	O
.	O

The	O
modest	O
correlation	O
of	O
h	B
##ydro	I
##xy	I
##p	I
##rol	I
##ine	I
with	O
PA	O
##SI	O
score	O
may	O
indicate	O
different	O
su	O
##s	O
##ce	O
##pt	O
##ibility	O
of	O
subjects	O
,	O
and	O
further	O
investigations	O
are	O
necessary	O
to	O
examine	O
if	O
this	O
su	O
##s	O
##ce	O
##pt	O
##ibility	O
is	O
reflected	O
with	O
incidence	O
of	O
ps	O
##oria	O
##tic	O
art	O
##hr	O
##itis	O
.	O

Val	O
##ida	O
##tions	O
of	O
the	O
analytical	O
methods	O
on	O
urine	O
(	O
with	O
and	O
without	O
en	O
##zy	O
##matic	O
degradation	O
)	O
were	O
also	O
performed	O
(	O
full	O
valid	O
##ation	O
for	O
g	O
##lu	O
##cu	O
##ron	O
##ides	O
determination	O
,	O
partial	O
valid	O
##ation	O
for	O
di	B
##os	I
##met	I
##in	I
q	O
##uant	O
##ification	O
upon	O
en	O
##zy	O
##matic	O
dig	O
##est	O
##ion	O
;	O
data	O
presented	O
in	O
Table	O
)	O
.	O

To	O
comprehensive	O
##ly	O
assess	O
the	O
activity	O
of	O
β	B
-	I
a	I
##po	I
##car	I
##ote	I
##no	I
##ids	I
,	O
we	O
first	O
undertook	O
to	O
pu	O
##ri	O
##fy	O
or	O
s	O
##ynth	O
##esi	O
##ze	O
all	O
of	O
the	O
possible	O
eccentric	O
c	O
##lea	O
##vage	O
products	O
of	O
β	B
-	I
car	I
##ote	I
##ne	I
.	O

Right	O
:	O
900	O
MHz	O
r	O
##aster	O
multiple	O
##t	O
for	O
g	B
##lut	I
##amine	I
.	O

CS	O
##F	O
,	O
Met	O
##ab	O
##oli	O
##tes	O
,	O
Brain	O
tumor	O
,	O
G	O
##lio	O
##ma	O
,	O
H	B
##ydro	I
##xy	I
##g	I
##lut	I
##arate	I
,	O
Li	O
##quid	O
bio	O
##psy	O

Det	O
##ec	O
##tion	O
of	O
cannabis	S
meta	O
##bol	O
##ites	O
and	O
s	O
##tra	O
##ti	O
##fication	O
of	O
cannabis	S
users	O
.	O

P	B
##yr	I
##u	I
##vate	I
enters	O
the	O
mit	O
##och	O
##ond	O
##rion	O
where	O
it	O
is	O
o	O
##xi	O
##dized	O
to	O
Ace	O
##ty	O
##l	O
Co	O
##A	O
,	O
2	O
ATP	O
'	O
s	O
,	O
8	O
N	O
##AD	O
##H	O
'	O
s	O
,	O
2	O
##FA	O
##D	O
##H	O
_	O
2	O
'	O
s	O
and	O
6	O
##CO	O
_	O
2	O
s	O
per	O
glucose	S
molecule	O
in	O
the	O
T	O
##CA	O
cycle	O
.	O

HD	O
##L	O
:	O
High	O
density	O
lip	O
##op	O
##rote	O
##in	O
;	O
L	O
##D	O
##L	O
:	O
Low	O
density	O
lip	O
##op	O
##rote	O
##in	O
;	O
F	O
##BS	O
:	O
Fast	O
##ing	O
blood	O
glucose	S
.	O

The	O
meta	O
##bol	O
##ites	O
were	O
isolated	O
from	O
urine	O
samples	O
by	O
c	B
##is	I
-	I
di	I
##ol	I
specific	O
affinity	O
ch	O
##roma	O
##tography	O
with	O
500	O
mg	O
a	O
##ff	O
##ige	O
##l	O
b	B
##oro	I
##nate	I
per	O
column	O
(	O
column	O
dimensions	O
:	O
150	O
×	O
15	O
mm	O
)	O
.	O

Mel	B
##aton	I
##in	I
is	O
synthesized	O
and	O
released	O
by	O
the	O
pine	O
##al	O
g	O
##land	O
into	O
the	O
systemic	O
circulation	O
and	O
readily	O
passes	O
the	O
blood	O
-	O
brain	O
barrier	O
.	O

However	O
,	O
a	B
##rg	I
##ini	I
##ne	I
supplement	O
##ation	O
studies	O
have	O
demonstrated	O
mixed	O
outcomes	O
with	O
respect	O
to	O
card	O
##iovascular	O
disease	O
outcomes	O
(	O
)	O
.	O

(	O
A	O
)	O
Part	O
##ial	O
_	O
1	O
H	O
N	O
##MR	O
spectrum	O
of	O
a	O
CS	O
##F	O
sample	O
from	O
a	O
representative	O
drug	O
-	O
na	O
##ï	O
##ve	O
patient	O
with	O
first	O
-	O
onset	O
s	O
##chi	O
##zophrenia	O
(	O
red	O
)	O
and	O
a	O
matched	O
control	O
(	O
black	O
)	O
illustrate	O
a	O
characteristic	O
pH	O
-	O
dependent	O
shift	O
in	O
the	O
β	B
-	I
CH	I
_	I
2	I
and	O
γ	B
-	I
CH	I
_	I
2	I
resonance	O
##s	O
of	O
g	B
##lut	I
##amine	I
.	O

Hui	O
##dek	O
##oper	O
et	O
al	O
.	O
were	O
the	O
first	O
to	O
directly	O
measure	O
end	O
##ogen	O
##ous	O
o	B
##xa	I
##late	I
production	O
rates	O
by	O
applying	O
a	O
prime	O
##d	O
continuous	O
in	O
##fusion	O
protocol	O
of	O
_	O
13	O
C	B
_	I
2	I
-	I
o	I
##xa	I
##late	I
and	O
measuring	O
trace	O
##r	O
en	O
##rich	O
##ments	O
in	O
plasma	O
.	O

Di	O
##ag	O
##nos	O
##tic	O
accuracy	O
was	O
compared	O
to	O
serum	O
alpha	B
-	I
f	I
##eto	I
##p	I
##rote	I
##in	I
(	O
A	O
##FP	O
)	O
.	O

In	O
healthy	O
individuals	O
,	O
AD	B
##MA	I
and	O
SD	O
##MA	O
are	O
inter	O
##rel	O
##ated	O
with	O
each	O
other	O
and	O
with	O
a	B
##rg	I
##ini	I
##ne	I
and	O
c	B
##it	I
##ru	I
##llin	I
##e	I
concentrations	O
but	O
there	O
is	O
no	O
correlation	O
between	O
c	B
##it	I
##ru	I
##llin	I
##e	I
and	O
a	B
##rg	I
##ini	I
##ne	I
.	O

The	O
Bay	O
##esi	O
##an	O
network	O
analysis	O
applied	O
to	O
the	O
Calgary	O
subset	O
selected	O
only	O
two	O
peaks	O
,	O
corresponding	O
to	O
c	B
##rea	I
##tine	I
and	O
c	B
##rea	I
##tin	I
##ine	I
.	O

After	O
being	O
dried	O
in	O
a	O
vacuum	O
con	O
##cent	O
##rator	O
,	O
the	O
collected	O
super	O
##nat	O
##ant	O
was	O
suspended	O
in	O
40	O
μ	O
##L	O
of	O
met	B
##ho	I
##xy	I
p	I
##yr	I
##id	I
##ine	I
h	I
##ydro	I
##ch	I
##lor	I
##ide	I
(	O
20	O
mg	O
/	O
m	O
##L	O
in	O
p	B
##yr	I
##id	I
##ine	I
)	O
and	O
in	O
##cu	O
##bate	O
##d	O
for	O
30	O
min	O
at	O
80	O
°C	O
.	O

However	O
,	O
MS	O
/	O
MS	O
fragment	O
##ation	O
data	O
of	O
h	B
##ydro	I
##xy	I
fatty	O
acid	O
standards	O
1	O
,	O
2	O
and	O
3	O
(	O
Table	O
)	O
showed	O
peripheral	O
cut	O
ions	O
similar	O
to	O
those	O
produced	O
by	O
MS	O
/	O
MS	O
of	O
the	O
CR	O
##C	O
bio	O
##mark	O
##ers	O
,	O
and	O
consistent	O
with	O
what	O
has	O
been	O
described	O
by	O
others	O
for	O
various	O
h	O
##ydro	O
##xy	O
##lated	O
long	O
-	O
chain	O
fatty	O
acids	O
[	O
-	O
]	O
.	O

(	O
b	O
)	O
An	O
immediately	O
adjacent	O
section	O
stained	O
with	O
hem	B
##ato	I
##xy	I
##lin	I
and	O
e	B
##os	I
##in	I
(	O
H	O
&	O
E	O
)	O

P	O
##las	O
##ma	O
levels	O
of	O
u	B
##ric	I
acid	I
appear	O
to	O
be	O
up	O
##re	O
##gu	O
##lated	O
in	O
the	O
pneumonia	O
group	O
relative	O
to	O
the	O
controls	O
,	O
although	O
not	O
statistical	O
##ly	O
significant	O
(	O
,	O
p	O
=	O
0	O
.	O
119	O
)	O
.	O

Changes	O
in	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
,	O
g	B
##ly	I
##cer	I
##ol	I
,	O
and	O
FF	O
##A	O
suggest	O
d	O
##ys	O
##function	O
##al	O
fat	O
metabolism	O
.	O

[	O
_	O
13	O
C	O
_	O
1	O
]	O
ch	O
##olic	O
acid	O
equivalent	O
##s	O
for	O
each	O
of	O
the	O
three	O
C	O
##28	O
molecules	O
were	O
calculated	O
by	O
determining	O
the	O
percent	O
recovery	O
of	O
[	O
_	O
13	O
C	O
_	O
1	O
]	O
ch	O
##olic	O
acid	O
in	O
each	O
sample	O
by	O
dividing	O
the	O
extra	O
##pol	O
##ated	O
concentration	O
by	O
0	O
.	O
01	O
##48	O
u	O
##g	O
/	O
m	O
##l	O
(	O
36	O
n	O
##M	O
,	O
the	O
theoretical	O
amount	O
present	O
in	O
the	O
et	B
##hyl	I
ace	I
##tate	I
extract	O
of	O
each	O
sample	O
)	O
.	O

Our	O
data	O
confirms	O
that	O
ch	B
##olin	I
##e	I
can	O
be	O
included	O
as	O
a	O
bio	O
##mark	O
##er	O
(	O
see	O
below	O
)	O
.	O

O	O
##xi	O
##dation	O
of	O
S	B
-	I
[	I
1	I
-	I
(	I
5	I
-	I
ace	I
##ty	I
##lam	I
##ino	I
-	I
5	I
-	I
car	I
##box	I
##ype	I
##nt	I
##yl	I
)	I
-	I
1	I
##H	I
-	I
p	I
##yr	I
##rol	I
-	I
3	I
-	I
y	I
##l	I
]	I
met	I
##hane	I
##thi	I
##ol	I
generated	O
S	B
-	I
[	I
1	I
-	I
(	I
5	I
-	I
ace	I
##ty	I
##lam	I
##ino	I
-	I
5	I
-	I
car	I
##box	I
##ype	I
##nt	I
##yl	I
)	I
-	I
1	I
##H	I
-	I
p	I
##yr	I
##rol	I
-	I
3	I
-	I
y	I
##l	I
]	I
met	I
##hane	I
##thi	I
##ol	I
su	I
##lf	I
##oxide	I
.	O

g	B
##lut	I
##amine	I
(	O
2	O
m	O
##M	O
)	O
,	O
H	O
##EP	O
##ES	O
buffer	O
(	O
pH	O
7	O
.	O
4	O
;	O
20	O
m	O
##M	O
)	O
,	O
and	O
10	O
%	O
f	O
##etal	O
calf	O
serum	O
at	O
37	O
##°	O
##C	O
.	O

These	O
plasma	O
meta	O
##bol	O
##ites	O
comprised	O
free	O
car	B
##ni	I
##tine	I
(	O
C	O
##0	O
)	O
,	O
ace	B
##ty	I
##l	I
##car	I
##ni	I
##tine	I
(	O
C	O
##2	O
)	O
as	O
well	O
as	O
five	O
long	O
-	O
chain	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
(	I
C	I
##14	I
:	I
1	I
,	I
C	I
##16	I
,	I
C	I
##18	I
,	I
C	I
##18	I
:	I
1	I
and	O
C	B
##18	I
:	I
2	I
)	I
,	O
which	O
were	O
all	O
increased	O
in	O
the	O
N	O
##DM	O
##M	O
population	O
(	O
and	O
Part	O
A	O
in	O
)	O
.	O

Our	O
data	O
revealed	O
that	O
there	O
were	O
positive	O
associations	O
between	O
the	O
post	O
##pra	O
##ndi	O
##al	O
changes	O
in	O
is	B
##ole	I
##uc	I
##ine	I
and	O
H	O
##OM	O
##A	O
-	O
I	O
##R	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
the	O
concentrations	O
of	O
these	O
reactive	O
su	B
##lf	I
##ide	I
species	O
in	O
the	O
D	O
##M	O
patients	O
and	O
controls	O
.	O

Model	O
I	O
##B	O
##U	O
##1	O
(	O
mean	O
-	O
centred	O
un	O
-	O
scaled	O
data	O
normal	O
##ized	O
to	O
selected	O
i	B
##bu	I
##p	I
##ro	I
##fen	I
meta	O
##bol	O
##ites	O
region	O
,	O
at	O
a	O
bin	O
width	O
of	O
0	O
.	O
01	O
pp	O
##m	O
for	O
selected	O
i	B
##bu	I
##p	I
##ro	I
##fen	I
meta	O
##bol	O
##ite	O
regions	O
only	O
)	O
showed	O
a	O
low	O
overall	O
model	O
error	O
rate	O
of	O
1	O
.	O
0	O
%	O
;	O
maximum	O
number	O
of	O
errors	O
for	O
predict	O
##ing	O
s	O
##pect	O
##ra	O
with	O
and	O
without	O
i	B
##bu	I
##p	I
##ro	I
##fen	I
meta	O
##bol	O
##ites	O
was	O
≤	O
2	O
and	O
≤	O
4	O
respectively	O
.	O

In	O
male	O
B	O
##D	O
subjects	O
,	O
we	O
observed	O
increased	O
levels	O
of	O
α	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
and	O
format	B
##e	I
as	O
well	O
as	O
decreased	O
levels	O
of	O
N	B
-	I
met	I
##hyl	I
##nic	I
##ot	I
##ina	I
##mi	I
##de	I
and	O
ch	B
##olin	I
##e	I
.	O

The	O
unique	O
o	B
##xy	I
##lip	I
##in	I
profile	O
observed	O
in	O
urine	O
can	O
be	O
attributed	O
to	O
the	O
specific	O
function	O
that	O
the	O
kidney	O
##s	O
perform	O
by	O
concentrating	O
certain	O
meta	O
##bol	O
##ites	O
from	O
blood	O
.	O

Inc	O
##reased	O
levels	O
of	O
ch	B
##olin	I
##e	I
are	O
also	O
due	O
to	O
ma	O
##li	O
##gnant	O
transformation	O
,	O
and	O
particularly	O
due	O
to	O
an	O
over	O
##ex	O
##press	O
##ion	O
of	O
Ch	O
##k	O
-	O
α	O
.	O

(	O
2018	O
)	O
,	O
b	O
##ost	O
##ry	O
##co	O
##id	O
##in	O
(	O
12	O
)	O
,	O
an	B
##hy	I
##dr	I
##of	I
##usa	I
##ru	I
##bin	I
(	O
13	O
)	O
,	O
4	B
-	I
h	I
##ydro	I
##xy	I
##ben	I
##zal	I
##de	I
##hy	I
##de	I
(	O
78	O
)	O
and	O
f	O
##usa	O
##ru	O
##bin	O
(	O
7	O
)	O
exhibited	O
significant	O
anti	O
##ox	O
##ida	O
##nt	O
activity	O
with	O
I	O
##C	O
_	O
50	O
values	O
of	O
1	O
.	O
6	O
,	O
12	O
.	O
4	O
,	O
28	O
.	O
9	O
and	O
34	O
.	O
8	O
μ	O
##g	O
/	O
m	O
##L	O
,	O
respectively	O
.	O

Several	O
investigators	O
have	O
post	O
##ulated	O
that	O
end	O
##ogen	O
##ous	O
inhibitor	O
##s	O
of	O
NO	O
s	O
##ynth	O
##ases	O
,	O
met	B
##hyl	I
##ated	I
a	I
##rg	I
##ini	I
##ne	I
meta	O
##bol	O
##ites	O
such	O
as	O
AD	B
##MA	I
,	O
may	O
provide	O
the	O
explanation	O
(	O
)	O
.	O

Met	O
##ab	O
##oli	O
##tes	O
were	O
purchased	O
from	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
(	O
Q	O
##UI	O
##N	O
,	O
k	B
##yn	I
##uren	I
##ine	I
,	O
and	O
_	O
2	O
H	O
_	O
5	O
-	O
try	O
##pt	O
##op	O
##han	O
)	O
and	O
S	O
##yn	O
##fine	O
Research	O
Inc	O
.	O
,	O
Ontario	O
,	O
Canada	O
(	O
_	O
13	O
C	O
_	O
3	O
_	O
15	O
N	O
_	O
1	O
-	O
Q	O
##UI	O
##N	O
)	O
.	O

Upon	O
con	O
##f	O
##lue	O
##ncy	O
they	O
were	O
treated	O
with	O
respective	O
C	O
##75	O
and	O
c	B
##ele	I
##co	I
##xi	I
##b	I
drug	O
concentrations	O
for	O
24	O
##h	O
.	O

R	O
##OC	O
curve	O
analysis	O
showed	O
that	O
FA	B
(	I
18	I
:	I
0	I
)	I
,	O
pre	O
##g	O
-	O
S	O
,	O
and	O
D	O
##H	O
##EA	O
##S	O
were	O
effective	O
for	O
different	O
##iating	O
patients	O
with	O
MS	O
##A	O
from	O
patients	O
with	O
PS	O
##P	O
,	O
and	O
the	O
AU	O
##C	O
value	O
for	O
these	O
3	O
meta	O
##bol	O
##ites	O
revealed	O
that	O
patients	O
with	O
MS	O
##A	O
were	O
differentiated	O
from	O
patients	O
with	O
PS	O
##P	O
with	O
relatively	O
moderate	O
accuracy	O
.	O

Results	O
indicate	O
that	O
su	B
##c	I
##rose	I
,	O
cello	B
##bio	I
##se	I
,	O
and	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
can	O
be	O
signature	O
meta	O
##bol	O
##ites	O
highlighting	O
the	O
effect	O
of	O
active	O
a	O
##cup	O
##oint	O
##s	O
in	O
the	O
treatment	O
of	O
E	O
##H	O
.	O

Case	O
##s	O
showed	O
a	O
general	O
trend	O
of	O
increased	O
abundance	O
of	O
bacteria	O
;	O
B	O
##if	O
##ido	O
##ba	O
##cter	O
##ium	O
s	B
##p	I
.	O

This	O
was	O
confirmed	O
with	O
the	O
demonstration	O
that	O
HD	O
##L	O
both	O
increased	O
the	O
p	O
##hos	O
##ph	O
##ory	O
##lation	O
of	O
the	O
AM	O
##P	O
##K	O
target	O
ACC	O
and	O
reduced	O
NE	O
##FA	O
and	O
g	B
##ly	I
##cer	I
##ol	I
release	O
from	O
ad	O
##ip	O
##ocytes	O
.	O

In	O
a	O
previous	O
report	O
,	O
C	O
##3	O
and	O
C	O
##5	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
,	O
by	O
-	O
products	O
of	O
mitochondrial	O
cat	O
##ab	O
##olis	O
##m	O
of	O
BC	O
##AA	O
##s	O
,	O
also	O
contributed	O
to	O
a	O
BC	O
##AA	O
-	O
related	O
factor	O
in	O
o	O
##bes	O
##e	O
humans	O
.	O

For	O
subjects	O
with	O
serum	O
t	B
##rig	I
##ly	I
##cer	I
##ide	I
levels	O
≥	O
400	O
mg	O
/	O
d	O
##L	O
,	O
L	B
##D	I
##L	I
-	I
ch	I
##ole	I
##ster	I
##ol	I
concentrations	O
were	O
measured	O
indirectly	O
.	O

In	O
another	O
study	O
using	O
L	O
##C	O
-	O
MS	O
-	O
based	O
G	O
-	O
Met	O
and	O
subsequent	O
T	O
-	O
Met	O
analyses	O
,	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
,	O
s	B
##phi	I
##ngo	I
##sin	I
##e	I
1	I
-	I
phosphate	I
,	O
and	O
l	B
##ino	I
##len	I
##yl	I
car	I
##ni	I
##tine	I
were	O
identified	O
as	O
the	O
three	O
meta	O
##bol	O
##ites	O
most	O
affected	O
by	O
exposure	O
to	O
22	O
##°	O
##C	O
for	O
up	O
to	O
24	O
h	O
.	O

Furthermore	O
,	O
sa	B
##rc	I
##os	I
##ine	I
levels	O
in	O
the	O
urine	O
also	O
followed	O
the	O
same	O
trend	O
as	O
that	O
observed	O
in	O
tissue	O
bio	O
##ps	O
##ies	O
.	O

The	O
SP	O
##E	O
plates	O
were	O
washed	O
twice	O
with	O
1	O
m	O
##L	O
form	B
##ic	I
acid	I
0	O
.	O
5	O
%	O
in	O
water	O
and	O
subsequently	O
the	O
anal	O
##yte	O
##s	O
were	O
el	O
##uted	O
with	O
0	O
.	O
5	O
m	O
##L	O
met	O
##han	O
##ol	O
/	O
water	O
(	O
80	O
:	O
20	O
,	O
v	O
/	O
v	O
)	O
in	O
clean	O
2	O
-	O
m	O
##L	O
96	O
-	O
well	O
plates	O
.	O

The	O
area	O
under	O
the	O
R	O
##OC	O
curve	O
for	O
both	O
these	O
two	O
parameters	O
was	O
<	O
0	O
.	O
6	O
,	O
showing	O
that	O
features	O
based	O
on	O
urine	O
glucose	S
do	O
not	O
provide	O
clinical	O
##ly	O
useful	O
discrimination	O
between	O
H	O
##NF	O
##1	O
##A	O
-	O
M	O
##OD	O
##Y	O
and	O
T	O
##2	O
##D	O
.	O
Once	O
matched	O
for	O
u	O
##rina	O
##ry	O
glucose	S
levels	O
,	O
there	O
was	O
no	O
difference	O
observed	O
in	O
the	O
levels	O
of	O
the	O
u	O
##rina	O
##ry	O
amino	O
acids	O
v	O
##ali	O
##ne	O
and	O
g	B
##ly	I
##cine	I
,	O
which	O
were	O
noted	O
in	O
the	O
Discovery	O
study	O
to	O
be	O
increased	O
in	O
H	O
##NF	O
##1	O
##A	O
-	O
M	O
##OD	O
##Y	O
subjects	O
.	O

The	O
concentration	O
of	O
t	B
##yr	I
##os	I
##ine	I
was	O
shown	O
to	O
increase	O
during	O
cheese	O
ripe	O
##ning	O
in	O
a	O
model	O
cheese	O
as	O
well	O
as	O
in	O
G	O
##ru	O
##y	O
##ère	O
.	O

Su	O
##mma	O
##ry	O
of	O
significant	O
changes	O
in	O
L	O
##C	O
-	O
MS	O
peaks	O
between	O
groups	O
Note	O
:	O
Ten	O
##tative	O
(	O
low	O
abundance	O
/	O
no	O
MS	O
/	O
MS	O
)	O
or	O
ambiguous	O
identification	O
##s	O
are	O
in	O
italics	O
T	O
##AG	O
t	B
##ria	I
##cy	I
##l	I
##gly	I
##cer	I
##ol	I
,	O
D	O
##AG	O
di	B
##acy	I
##l	I
##gly	I
##cer	I
##ol	I
,	O
PC	B
g	I
##ly	I
##cer	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
ch	I
##olin	I
##e	I
,	O
PS	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##ose	I
##rine	I
,	O
P	B
##E	I
g	I
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##o	I
ethanol	I
##amine	I
,	O
PA	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##pa	I
##ty	I
##dic	I
acid	I
,	O
SM	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
##e	I
_	O
a	O
Den	O
##otes	O
signals	O
at	O
very	O
low	O
abundance	O
in	O
the	O
raw	O
data	O
In	O
terms	O
of	O
the	O
class	O
of	O
lip	O
##id	O
species	O
affected	O
the	O
largest	O
decreases	O
on	O
fish	O
oil	O
supplement	O
##ation	O
were	O
associated	O
with	O
T	O
##AG	O
##s	O
,	O
suggesting	O
that	O
this	O
class	O
of	O
lip	O
##ids	O
had	O
decreased	O
in	O
general	O
,	O
which	O
has	O
been	O
published	O
before	O
(	O
Harris	O
;	O
K	O
##re	O
##bs	O
et	O
al	O
.	O
)	O
.	O

P	O
##las	O
##mal	O
##ogen	O
##s	O
are	O
specialized	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
made	O
by	O
the	O
ER	O
,	O
mit	O
##och	O
##ond	O
##ria	O
,	O
and	O
per	O
##ox	O
##is	O
##ome	O
##s	O
that	O
are	O
en	O
##rich	O
##ed	O
in	O
a	O
##ero	O
##bic	O
tissues	O
like	O
the	O
heart	O
and	O
brain	O
.	O

(	O
C	O
)	O
correlation	O
between	O
q	O
##uant	O
##ification	O
of	O
g	B
##lut	I
##amine	I
on	O
_	O
1	O
H	O
-	O
N	O
##MR	O
s	O
##pect	O
##ra	O
and	O
G	O
##S	O
H	O
-	O
Score	O
,	O
correlation	O
coefficient	O
=	O
0	O
.	O
53	O
,	O
p	O
=	O
0	O
.	O
00	O
##9	O

D	B
##MA	I
=	O
dim	B
##eth	I
##yla	I
##mine	I
.	O

(	O
C	O
,	O
D	O
)	O
Panel	O
##s	O
show	O
the	O
concentration	O
of	O
free	O
car	B
##ni	I
##tine	I
(	O
C	O
##0	O
)	O
,	O
a	B
##cy	I
##l	I
car	I
##ni	I
##tine	I
##s	I
(	O
C	O
##2	O
,	O
C	O
##3	O
)	O
and	O
am	O
##min	O
##oa	O
##cid	O
##s	O
(	O
Le	O
##u	O
/	O
Il	O
##e	O
/	O
Pro	O
,	O
Ph	O
##e	O
,	O
Ty	O
##r	O
,	O
G	O
##lu	O
,	O
Met	O
,	O
L	O
##ys	O
/	O
G	O
##ln	O
/	O
A	O
##rg	O
)	O
in	O
the	O
three	O
sections	O
of	O
the	O
Shi	O
##rm	O
##er	O
’	O
s	O
paper	O
strip	O
.	O

The	O
loading	O
coefficients	O
indicated	O
that	O
glucose	S
,	O
ace	B
##tate	I
,	O
al	B
##ani	I
##ne	I
,	O
and	O
g	B
##lut	I
##amine	I
resonance	O
##s	O
were	O
predominantly	O
responsible	O
for	O
the	O
separation	O
between	O
classes	O
.	O

The	O
structures	O
are	O
for	O
the	O
un	O
##con	O
##ju	O
##gated	O
forms	O
of	O
the	O
est	O
##rogen	O
##s	O
and	O
est	B
##rogen	I
meta	O
##bol	O
##ites	O
.	O

4	O
:	O
2	O
:	O
1	O
(	O
v	O
/	O
v	O
/	O
v	O
)	O
containing	O
7	O
.	O
5	O
m	O
##M	O
am	B
##mon	I
##ium	I
format	O
##e	O
)	O
and	O
the	O
injection	O
volume	O
was	O
2	O
μ	O
##L	O
.	O
A	O
high	O
-	O
field	O
The	O
##rm	O
##o	O
Scientific	O
[UNK]	O
Q	O
Ex	O
##active	O
H	O
##F	O
[UNK]	O
q	O
##uad	O
##rup	O
##ole	O
-	O
Or	O
##bit	O
##rap	O
mass	O
s	O
##pect	O
##rome	O
##ter	O
equipped	O
with	O
an	O
electro	O
##sp	O
##ray	O
source	O
was	O
used	O
for	O
H	O
##R	O
##MS	O
.	O

As	O
illustrated	O
in	O
,	O
in	O
the	O
metabolism	O
of	O
cat	B
##ech	I
##ol	I
est	O
##rogen	O
##s	O
there	O
are	O
act	O
##ivating	O
pathways	O
that	O
lead	O
to	O
the	O
formation	O
of	O
the	O
est	B
##rogen	I
q	I
##uin	I
##ones	I
,	O
est	B
##rone	I
(	O
est	O
##rad	O
##iol	O
)	O
q	B
##uin	I
##ones	I
[	O
E	O
_	O
1	O
(	O
E	O
_	O
2	O
)	O
-	O
Q	O
]	O
,	O
which	O
can	O
react	O
with	O
DNA	O
.	O

In	O
16	O
##H	O
##BE	O
##14	O
##o	O
_	O
−	O
cells	O
,	O
glucose	S
was	O
found	O
in	O
similar	O
concentrations	O
compared	O
to	O
control	O
conditions	O
at	O
30	O
and	O
60	O
min	O
of	O
r	O
##H	O
##la	O
application	O
,	O
whereas	O
in	O
##cu	O
##bation	O
with	O
r	O
##H	O
##la	O
for	O
120	O
min	O
resulted	O
in	O
a	O
45	O
%	O
decrease	O
.	O

d	O
At	O
the	O
end	O
of	O
the	O
in	O
##cu	O
##bation	O
period	O
(	O
12	O
h	O
at	O
37	O
°C	O
)	O
,	O
to	O
remove	O
proteins	O
,	O
the	O
samples	O
were	O
added	O
with	O
0	O
.	O
6	O
m	O
##L	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
,	O
mixed	O
for	O
5	O
min	O
,	O
and	O
cent	O
##ri	O
##fu	O
##ged	O
for	O
5	O
min	O
at	O
4	O
,	O
000	O
rpm	O
.	O

This	O
score	O
explained	O
11	O
.	O
3	O
%	O
and	O
11	O
.	O
9	O
%	O
of	O
the	O
var	O
##iability	O
in	O
HC	O
##T	O
##Z	O
S	O
##B	O
##P	O
and	O
DB	B
##P	I
responses	O
,	O
respectively	O
,	O
and	O
was	O
further	O
valid	O
##ated	O
in	O
another	O
independent	O
study	O
of	O
196	O
whites	O
treated	O
with	O
HC	O
##T	O
##Z	O
(	O
DB	O
##P	O
-	O
score	O
p	O
=	O
0	O
.	O
03	O
,	O
S	O
##B	O
##P	O
-	O
score	O
p	O
=	O
0	O
.	O
07	O
)	O
.	O

Interest	O
##ingly	O
,	O
there	O
is	O
a	O
significant	O
positive	O
correlation	O
between	O
la	B
##ct	I
##ate	I
,	O
p	B
##yr	I
##u	I
##vate	I
and	O
al	B
##ani	I
##ne	I
levels	O
as	O
well	O
as	O
a	O
significant	O
negative	O
correlation	O
between	O
al	B
##ani	I
##ne	I
and	O
glucose	S
levels	O
.	O

In	O
the	O
last	O
step	O
of	O
the	O
synthesis	O
,	O
the	O
ben	B
##zy	I
##lo	I
##xy	I
group	O
in	O
3	O
was	O
removed	O
by	O
using	O
cat	O
##alytic	O
hydrogen	O
##ation	O
in	O
the	O
presence	O
of	O
P	O
##d	O
-	O
C	O
under	O
an	O
H	O
_	O
2	O
atmosphere	O
to	O
produce	O
HP	O
##HP	O
##A	O
4	O
(	O
see	O
Scheme	O
1	O
##a	O
–	O
d	O
)	O
.	O

At	O
##rac	O
##ty	O
##li	O
##gen	O
##in	O
is	O
a	O
di	B
##ter	I
##pen	I
##oid	I
whose	O
g	B
##ly	I
##cos	I
##ide	I
,	O
at	B
##rac	I
##ty	I
##los	I
##ide	I
,	O
and	O
other	O
derivatives	O
are	O
present	O
in	O
green	O
and	O
r	O
##oast	O
##ed	O
Co	O
##ffe	O
##a	O
a	O
##rab	O
##ica	O
beans	O
in	O
concentrations	O
as	O
high	O
as	O
62	O
##4	O
mg	O
/	O
kg	O
,	O
.	O

A	O
net	O
re	O
##c	O
##lass	O
##ification	O
index	O
(	O
N	O
##RI	O
)	O
analysis	O
demonstrated	O
that	O
the	O
addition	O
of	O
SM	B
d	I
##16	I
:	I
1	I
/	I
18	I
:	I
0	I
and	O
SM	B
d	I
##18	I
:	I
1	I
/	I
18	I
:	I
0	I
to	O
the	O
current	O
clinical	O
standard	O
of	O
H	O
##b	O
##A	O
##1	O
##c	O
or	O
H	O
##b	O
##A	O
##1	O
##c	O
plus	O
B	O
##MI	O
provides	O
moderately	O
improved	O
accuracy	O
of	O
the	O
prediction	O
of	O
diabetes	O
incidence	O
for	O
38	O
%	O
–	O
40	O
%	O
of	O
individuals	O
.	O

Moving	O
further	O
anti	O
##c	O
##lock	O
##wise	O
,	O
there	O
is	O
an	O
increase	O
of	O
N	B
-	I
ace	I
##ty	I
##l	I
-	I
g	I
##ly	I
##co	I
##p	I
##rote	I
##in	I
(	O
N	O
##AG	O
)	O
at	O
2	O
.	O
07	O
pp	O
##m	O
followed	O
by	O
a	O
massive	O
increase	O
in	O
the	O
k	B
##eton	I
##e	I
bodies	O
(	O
3	O
##H	O
##B	O
,	O
Ace	O
and	O
Ace	O
##A	O
##ce	O
)	O
at	O
the	O
8	O
o	O
’	O
clock	O
position	O
corresponding	O
to	O
the	O
highest	O
percentage	O
weight	O
loss	O
.	O

(	O
D	O
)	O
MI	O
##D	O
for	O
p	B
##hos	I
##ph	I
##op	I
##hat	I
##idy	I
##l	I
##cho	I
##line	I
34	I
:	I
1	I
Notable	O
mass	O
is	O
##oto	O
##po	O
##mers	O
are	O
indicated	O
.	O

We	O
thus	O
propose	O
that	O
the	O
im	O
##bal	O
##ance	O
of	O
long	O
and	O
short	O
-	O
chain	O
FA	S
contributes	O
to	O
the	O
path	O
##ogen	O
##esis	O
in	O
acute	O
malaria	O
infection	O
.	O

A	O
representative	O
kinetic	O
profile	O
of	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
metabolism	O
to	O
h	B
##ydro	I
##xy	I
##ana	I
##stro	I
##zo	I
##le	I
in	O
H	O
##LM	O
##s	O
is	O
shown	O
in	O
.	O

Micro	O
##some	O
##s	O
fortified	O
with	O
N	B
##AD	I
##H	I
produce	O
a	O
variety	O
of	O
reactive	O
intermediate	O
##s	O
by	O
c	O
##yt	O
##och	O
##rome	O
P	O
##45	O
##0s	O
such	O
as	O
short	O
-	O
lived	O
al	O
##ky	O
##lating	O
agents	O
,	O
al	O
##de	O
##hy	O
##des	O
,	O
e	B
##pox	I
##ides	I
,	O
q	B
##uin	I
##ones	I
,	O
a	B
##ryl	I
##hy	I
##dr	I
##ox	I
##lam	I
##ines	I
,	O
a	B
##ryl	I
##ni	I
##tro	I
##so	I
compounds	O
,	O
and	O
th	B
##io	I
##phe	I
##ne	I
S	I
-	I
oxide	I
##s	I
,	O
among	O
others	O
,	O
which	O
can	O
be	O
trapped	O
by	O
Al	O
##b	O
.	O

Dec	O
##reased	O
and	O
##rogen	O
levels	O
resulted	O
in	O
significant	O
decreases	O
of	O
la	B
##ct	I
##ate	I
and	O
t	B
-	I
ch	I
##olin	I
##e	I
concentrations	O
in	O
human	O
pro	O
##state	O
cancer	O
bio	O
##ps	O
##ies	O
.	O

2	B
-	I
OH	I
##E	I
_	I
2	I
-	I
1	I
-	I
g	I
##lut	I
##ath	I
##ione	I
(	O
S	O
##G	O
)	O
18	O
,	O
2	O
-	O
OH	O
##E	O
_	O
2	O
-	O
4	O
-	O
S	O
##G	O
19	O
,	O
2	O
-	O
OH	O
##E	O
_	O
1	O
-	O
1	O
-	O
S	O
##G	O
20	O
,	O
2	O
-	O
OH	O
##E	O
_	O
1	O
-	O
4	O
-	O
S	O
##G	O
21	O
,	O
2	O
-	O
OH	O
##E	O
_	O
2	O
-	O
(	O
1	O
+	O
4	O
)	O
-	O
c	O
##ys	O
##tein	O
##e	O
(	O
Cy	O
##s	O
)	O
22	O
,	O
2	O
-	O
OH	O
##E	O
_	O
1	O
-	O
1	O
-	O
Cy	O
##s	O
23	O
,	O
2	O
-	O
OH	O
##E	O
_	O
1	O
-	O
4	O
-	O
Cy	O
##s	O
24	B
,	I
2	I
-	I
OH	I
##E	I
_	I
2	I
-	I
1	I
-	I
N	I
-	I
ace	I
##ty	I
##l	I
##cy	I
##stein	I
##e	I
(	O
N	O
##A	O
##c	O
##C	O
##ys	O
)	O
25	O
,	O
2	O
-	O
OH	O
##E	O
_	O
2	O
-	O
4	O
-	O
N	O
##A	O
##c	O
##C	O
##ys	O
26	O
,	O
2	O
-	O
OH	O
##E	O
_	O
1	O
-	O
1	O
-	O
N	O
##A	O
##c	O
##C	O
##ys	O
27	O
,	O
2	O
-	O
OH	O
##E	O
_	O
1	O
-	O
4	O
-	O
N	O
##A	O
##c	O
##C	O
##ys	O
28	O
,	O
4	O
-	O
OH	O
##E	O
_	O
2	O
-	O
2	O
-	O
S	O
##G	O
29	O
,	O
4	O
-	O
OH	O
##E	O
_	O
1	O
-	O
2	O
-	O
S	O
##G	O
30	O
,	O
4	O
-	O
OH	O
##E	O
_	O
2	O
-	O
2	O
-	O
Cy	O
##s	O
31	O
,	O
4	O
-	O
OH	O
##E	O
_	O
1	O
-	O
2	O
-	O
Cy	O
##s	O
32	O
,	O
4	O
-	O
OH	O
##E	O
_	O
2	O
-	O
2	O
-	O
N	O
##A	O
##c	O
##C	O
##ys	O
33	O
and	O
4	O
-	O
OH	O
##E	O
_	O

In	O
genome	O
-	O
wide	O
association	O
studies	O
(	O
G	O
##WA	O
##S	O
)	O
,	O
common	O
non	O
##function	O
##al	O
variants	O
tag	O
##ging	O
SL	O
##CO	O
##1	O
##B	O
##1	O
have	O
been	O
reported	O
to	O
be	O
associated	O
with	O
fatty	O
acid	O
levels	O
,	O
including	O
he	B
##xa	I
##de	I
##cane	I
##dio	I
##ate	I
.	O

The	O
reliability	O
of	O
the	O
analysis	O
of	O
CE	O
/	O
MS	O
detection	O
was	O
verified	O
by	O
5	O
end	O
##ogen	O
##ous	O
u	O
##rina	O
##ry	O
meta	O
##bol	O
##ites	O
(	B
L	B
-	I
a	I
##rg	I
##ini	I
##ne	I
,	O
L	B
-	I
his	I
##ti	I
##dine	I
,	O
L	B
-	I
as	I
##par	I
##tic	I
acid	I
,	O
la	B
##ctic	I
acid	I
,	O
and	O
c	O
##it	O
##ric	O
acid	O
)	O
of	O
representative	O
.	O

The	O
authors	O
suggest	O
that	O
the	O
increase	O
might	O
be	O
associated	O
with	O
reduced	O
la	B
##ct	I
##ate	I
re	O
##ab	O
##sor	O
##ption	O
in	O
the	O
pro	O
##ximal	O
tub	O
##ule	O
.	O

A	O
comparison	O
of	O
relative	O
meta	O
##bol	O
##ite	O
levels	O
between	O
HC	O
##C	O
vs	O
CT	O
##R	O
and	O
/	O
or	O
HC	O
##C	O
vs	O
CH	O
##B	O
in	O
all	O
subjects	O
confirmed	O
that	O
car	B
##ni	I
##tine	I
was	O
significantly	O
increased	O
in	O
HC	O
##C	O
,	O
and	O
c	B
##rea	I
##tin	I
##ine	I
,	O
hip	B
##pura	I
##te	I
,	O
and	O
T	B
##MA	I
##O	I
were	O
significantly	O
reduced	O
in	O
HC	O
##C	O
(	O
Figure	O
)	O
.	O

Effect	O
of	O
polymer	O
##ic	O
dip	O
##eptide	O
surf	O
##act	O
##ant	O
head	O
groups	O
on	O
the	O
simultaneous	O
en	O
##anti	O
##ose	O
##par	O
##ation	O
of	O
1	B
,	I
1	I
’	I
=	I
O	I
-	I
D	I
##V	I
##X	I
and	O
2	B
,	I
2	I
’	I
=	I
V	I
##X	I
.	O

P	O
##las	O
##ma	O
concentrations	O
of	O
D	O
##H	O
##EA	O
,	O
A	O
##ED	O
,	O
A	O
##ET	O
and	O
7	B
-	I
o	I
##x	I
##o	I
-	I
D	I
##H	I
##EA	I
measured	O
by	O
HP	O
##LC	O
-	O
MS	O
/	O
MS	O
for	O
HD	O
(	O
white	O
circles	O
)	O
and	O
HIV	O
-	O
T	O
##B	O
patients	O
(	O
black	O
circles	O
)	O
.	O

Although	O
it	O
has	O
been	O
suggested	O
that	O
the	O
s	O
##n	O
-	O
2	O
position	O
is	O
preferred	O
by	O
p	O
##oly	O
##uns	O
##at	O
##ura	O
##ted	O
a	O
##cy	O
##l	O
chains	O
,	O
,	O
our	O
data	O
quantitative	O
##ly	O
show	O
that	O
many	O
of	O
them	O
still	O
consist	O
of	O
minor	O
s	O
##n	O
-	O
is	O
##omer	O
##s	O
,	O
such	O
as	O
PC	B
20	I
:	I
4	I
/	I
16	I
:	I
0	I
(	O
4	O
%	O
)	O
and	O
PC	B
22	I
:	I
4	I
/	I
18	I
:	I
0	I
(	O
9	O
%	O
)	O
.	O

Co	B
##tin	I
##ine	I
and	O
[	O
_	O
13	O
CD	O
_	O
3	O
]	O
co	O
##tin	O
##ine	O
el	O
##uted	O
at	O
5	O
.	O
12	O
min	O
while	O
N	O
##NA	O
##L	O
and	O
[	O
_	O
13	O
C	O
_	O
6	O
]	O
N	O
##NA	O
##L	O
el	O
##uted	O
at	O
5	O
.	O
46	O
min	O
.	O

His	O
##to	O
##gram	O
##s	O
of	O
activation	O
of	O
RA	O
##RE	O
reporter	O
genes	O
in	O
cells	O
trans	O
##fected	O
with	O
re	B
##tino	I
##ic	I
acid	I
receptors	O
α	O
(	O
left	O
)	O
,	O
β	O
(	O
middle	O
)	O
,	O
and	O
γ	O
(	O
right	O
)	O
.	O

Higher	O
levels	O
of	O
very	O
low	O
density	O
lip	O
##op	O
##rote	O
##in	O
(	O
V	O
##LD	O
##L	O
)	O
/	O
low	O
density	O
lip	O
##op	O
##rote	O
##in	O
(	O
L	O
##D	O
##L	O
)	O
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
le	B
##uc	I
##ine	I
,	O
v	B
##ali	I
##ne	I
,	O
la	B
##ct	I
##ate	I
,	O
al	B
##ani	I
##ne	I
,	O
lip	O
##ids	O
plus	O
N	B
-	I
ace	I
##ty	I
##l	I
c	I
##ys	I
##tein	I
##e	I
(	O
N	O
##AC	O
)	O
,	O
and	O
c	B
##rea	I
##tine	I
were	O
concentrated	O
on	O
the	O
side	O
of	O
the	O
RC	O
##C	O
patients	O
,	O
while	O
higher	O
ch	B
##olin	I
##e	I
levels	O
were	O
observed	O
on	O
the	O
side	O
of	O
the	O
healthy	O
subjects	O
.	O

Recent	O
surveys	O
on	O
availability	O
of	O
anti	O
##mal	O
##aria	O
##ls	O
have	O
shown	O
that	O
sick	O
people	O
were	O
getting	O
SP	S
from	O
drugs	O
shops	O
,	O
public	O
and	O
private	O
health	O
facilities	O
(	O
Alba	O
S	O
et	O
al	O
.	O
,	O
in	O
preparation	O
)	O
,	O
especially	O
so	O
when	O
clinic	O
##ians	O
were	O
doubtful	O
about	O
the	O
diagnosis	O
of	O
malaria	O
.	O

Moreover	O
,	O
L	B
##ys	I
##o	I
##PC	I
(	I
20	I
:	I
4	I
)	I
also	O
arose	O
as	O
a	O
potential	O
SR	O
bio	O
##mark	O
##er	O
,	O
increasing	O
the	O
prediction	O
power	O
of	O
age	O
,	O
blood	O
pressure	O
,	O
clinical	O
features	O
,	O
duration	S
of	O
symptoms	O
,	O
and	O
diabetes	O
scale	O
(	O
ABC	O
##D	O
##2	O
)	O
and	O
LA	O
##A	O
.	O

Among	O
the	O
20	O
candidate	O
lip	O
##id	O
markers	O
,	O
decreasing	O
levels	O
were	O
observed	O
in	O
18	O
lip	O
##id	O
species	O
in	O
S	O
##q	O
##CC	O
patients	O
;	O
however	O
,	O
2	O
lip	O
##id	O
species	O
,	O
PC	B
(	I
38	I
:	I
6	I
)	I
and	O
P	B
##I	I
(	I
38	I
:	I
4	I
)	I
,	O
presented	O
an	O
increased	O
level	O
in	O
S	O
##q	O
##CC	O
plasma	O
when	O
compared	O
with	O
the	O
controls	O
.	O

However	O
,	O
no	O
association	O
between	O
serum	O
p	B
##oly	I
##amine	I
##s	I
and	O
T	O
##2	O
##D	O
was	O
observed	O
when	O
either	O
H	O
##OM	O
##A	O
-	O
I	O
##R	O
or	O
fast	O
##ing	O
glucose	S
was	O
added	O
in	O
the	O
log	O
##istic	O
model	O
(	O
Su	O
##pp	O
##lement	O
##ary	O
Table	O
S	O
##1	O
)	O
.	O

Finally	O
,	O
the	O
compounds	O
were	O
el	O
##uted	O
using	O
1000	O
μ	O
##L	O
of	O
25	O
%	O
water	O
in	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
and	O
collected	O
in	O
a	O
2	O
m	O
##L	O
96	O
-	O
well	O
N	O
##UN	O
##C	O
plate	O
.	O

Moreover	O
the	O
peak	O
corresponding	O
to	O
17	B
-	I
h	I
##ydro	I
##xy	I
##p	I
##rog	I
##ester	I
##one	I
(	O
m	O
/	O
z	O
33	O
##1	O
.	O
3	O
±	O
0	O
.	O
2	O
)	O
was	O
clearly	O
evident	O
in	O
the	O
media	O
of	O
BP	O
##A	O
treated	O
H	O
-	O
He	O
##p	O
##G	O
##2	O
cells	O
.	O

Up	O
to	O
now	O
,	O
only	O
one	O
work	O
on	O
la	B
##ctic	I
acid	I
and	O
short	O
chain	O
fatty	O
acids	O
have	O
revealed	O
how	O
diet	O
##ary	O
-	O
derived	O
products	O
may	O
ex	O
##ert	O
(	O
potentially	O
adverse	O
)	O
ne	O
##uro	O
##logical	O
effects	O
.	O

Low	O
-	O
and	O
high	O
-	O
grade	O
BC	O
##a	O
could	O
be	O
best	O
separated	O
(	O
AU	O
##C	O
0	O
.	O
97	O
)	O
by	O
using	O
a	O
panel	O
of	O
three	O
meta	O
##bol	O
##ites	O
(	O
D	O
##MA	O
,	O
ma	B
##lon	I
##ate	I
,	O
and	O
la	B
##ct	I
##ate	I
)	O
(	O
Ban	O
##sal	O
et	O
al	O
.	O
,	O
)	O
.	O

This	O
in	O
combination	O
with	O
our	O
findings	O
suggests	O
that	O
altered	O
a	B
##rg	I
##ini	I
##ne	I
level	O
may	O
follow	O
from	O
altered	O
protein	O
home	O
##ost	O
##asis	O
,	O
ta	B
##uri	I
##ne	I
metabolism	O
,	O
g	B
##lut	I
##ath	I
##ione	I
metabolism	O
,	O
or	O
many	O
other	O
metabolic	O
pathways	O
that	O
closely	O
relate	O
to	O
the	O
AD	O
path	O
##ological	O
process	O
.	O

The	O
anal	O
##yte	O
##s	O
were	O
el	O
##uted	O
with	O
a	O
linear	O
gradient	O
from	O
20	O
to	O
45	O
%	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
for	O
the	O
first	O
6	O
min	O
(	O
0	O
–	O
6	O
min	O
)	O
,	O
before	O
returning	O
to	O
initial	O
conditions	O
of	O
20	O
%	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
to	O
re	O
-	O
e	O
##qui	O
##li	O
##bra	O
##te	O
the	O
last	O
minute	O
(	O
6	O
–	O
7	O
min	O
)	O
.	O

As	O
shown	O
in	O
the	O
a	B
##rg	I
##ini	I
##ne	I
metabolic	O
pathway	O
,	O
a	B
##rg	I
##ini	I
##ne	I
is	O
the	O
precursor	O
of	O
ni	B
##tric	I
oxide	I
(	O
NO	O
)	O
,	O
and	O
NO	O
is	O
synthesized	O
from	O
L	B
-	I
a	I
##rg	I
##ini	I
##ne	I
by	O
ni	B
##tric	I
oxide	I
s	O
##ynth	O
##ase	O
(	O
NO	O
##S	O
)	O
,	O
which	O
includes	O
ne	O
##uron	O
##al	O
NO	O
##S	O
(	O
n	O
##N	O
##OS	O
)	O
,	O
end	O
##oth	O
##eli	O
##al	O
NO	O
##S	O
(	O
e	O
##N	O
##OS	O
)	O
,	O
and	O
in	O
##du	O
##cible	O
NO	O
##S	O
(	O
i	O
##N	O
##OS	O
)	O
.	O

After	O
son	O
##ica	O
##tion	O
,	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
was	O
added	O
to	O
pre	O
##ci	O
##pit	O
##ate	O
protein	O
,	O
the	O
sample	O
was	O
v	O
##ortex	O
##ed	O
,	O
and	O
son	O
##ica	O
##ted	O
again	O
.	O

m	O
##TO	O
##R	O
in	O
##hibition	O
results	O
in	O
reduced	O
cell	O
proliferation	O
and	O
glucose	S
up	O
##take	O
[	O
,	O
]	O
.	O

We	O
also	O
evaluated	O
whether	O
the	O
addition	O
of	O
u	O
##rina	O
##ry	O
my	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
could	O
better	O
predict	O
the	O
response	O
to	O
initial	O
treatment	O
than	O
traditional	O
risk	O
factors	O
,	O
including	O
sex	O
,	O
age	O
,	O
and	O
level	O
of	O
protein	O
##uria	O
(	O
Table	O
)	O
.	O

The	O
met	O
##ho	O
##xi	O
##mation	O
step	O
was	O
performed	O
with	O
10	O
ul	O
of	O
a	O
solution	O
of	O
40	O
mg	O
/	O
m	O
##l	O
O	B
-	I
met	I
##hyl	I
##hy	I
##dr	I
##ox	I
##yla	I
##mine	I
h	I
##ydro	I
##ch	I
##lor	I
##ide	I
(	O
CA	O
##S	O
:	O
[	O
59	O
##3	O
-	O
56	O
-	O
6	O
]	O
;	O
Formula	O
CH	O
##5	O
##N	O
##O	O
.	O
HC	O
##l	O
)	O
and	O
90	O
minutes	O
shaking	O
at	O
30	O
°C	O
.	O

G	B
##ly	I
##cine	I
,	O
however	O
,	O
tends	O
to	O
be	O
higher	O
in	O
women	O
which	O
is	O
in	O
agreement	O
with	O
previous	O
reports	O
[	O
,	O
,	O
]	O
.	O

Most	O
meta	O
##bol	O
##ites	O
showed	O
a	O
similar	O
direction	O
of	O
change	O
in	O
CS	O
##F	O
and	O
plasma	O
samples	O
;	O
however	O
,	O
al	B
##ani	I
##ne	I
levels	O
showed	O
a	O
significant	O
increase	O
in	O
CS	O
##F	O
but	O
a	O
decrease	O
in	O
plasma	O
.	O

These	O
results	O
indicated	O
that	O
increased	O
formation	O
of	O
16	B
##α	I
-	I
h	I
##ydro	I
##xy	I
##est	I
##rone	I
and	O
its	O
downstream	O
meta	O
##bol	O
##ites	O
was	O
positively	O
associated	O
with	O
breast	O
cancer	O
.	O

Pat	O
##ients	O
with	O
advanced	O
at	O
##her	O
##os	O
##cle	O
##rosis	O
had	O
significantly	O
lower	O
base	O
##line	O
plasma	O
concentrations	O
of	O
in	B
##do	I
##le	I
and	O
the	O
in	B
##do	I
##le	I
derivatives	O
try	B
##pt	I
##op	I
##han	I
(	O
t	O
##rp	O
)	O
,	O
k	B
##yn	I
##uren	I
##ine	I
(	O
k	O
##yn	O
)	O
,	O
in	B
##do	I
##le	I
-	I
3	I
-	I
prop	I
##ion	I
##ic	I
acid	I
(	O
I	O
##3	O
##P	O
)	O
,	O
and	O
in	B
##do	I
##le	I
-	I
3	I
-	I
al	I
##de	I
##hy	I
##de	I
(	O
I	O
##3	O
##A	O
)	O
and	O
higher	O
plasma	O
concentrations	O
of	O
3	B
-	I
h	I
##ydro	I
##xy	I
##ant	I
##hra	I
##ni	I
##lic	I
acid	I
than	O
the	O
patients	O
in	O
the	O
control	O
co	O
##hor	O
##t	O
.	O

The	O
shipment	O
of	O
p	O
##est	O
##icides	O
in	O
Gun	O
##ma	O
and	O
Japan	O
are	O
almost	O
constant	O
in	O
g	B
##ly	I
##ph	I
##osa	I
##te	I
,	O
im	O
##ida	O
##c	O
##lop	O
##rid	O
,	O
and	O
ace	O
##tem	O
##ip	O
##rid	O
since	O
the	O
middle	O
of	O
1990	O
’	O
s	O
,	O
but	O
has	O
been	O
increasing	O
in	O
th	B
##iam	I
##eth	I
##ox	I
##am	I
,	O
cloth	B
##ian	I
##id	I
##in	I
,	O
and	O
din	O
##ote	O
##fu	O
##ran	O
since	O
2001	O
here	O
after	O
neo	O
-	O
ni	O
##cot	O
##ini	O
##c	O
symptoms	O
emerged	O
.	O

Within	O
the	O
k	B
##yn	I
##uren	I
##ine	I
and	O
se	O
##rot	O
##oni	O
##n	O
-	O
me	O
##lat	O
##oni	O
##n	O
pathways	O
there	O
were	O
many	O
significant	O
positive	O
associations	O
among	O
meta	O
##bol	O
##ites	O
.	O

(	O
A	O
)	O
Representative	O
FA	O
##CS	O
-	O
based	O
sorting	O
of	O
AL	O
##D	O
##H	O
_	O
hi	O
CD	O
##44	O
_	O
hi	O
and	O
AL	O
##D	O
##H	O
_	O
lo	O
CD	O
##44	O
_	O
lo	O
fraction	O
##s	O
from	O
U	O
##M	O
-	O
SC	O
##C	O
-	O
14	O
##A	O
cells	O
stained	O
with	O
the	O
Al	B
##de	I
##f	I
##lu	I
##or	I
re	O
##age	O
##nt	O
.	O

In	O
meta	O
##bol	O
##omi	O
##cs	O
analysis	O
of	O
the	O
A	O
##con	O
-	O
knock	O
##down	O
fly	O
study	O
,	O
authors	O
found	O
increased	O
levels	O
of	O
c	B
##is	I
-	I
a	I
##con	I
##itate	I
,	O
c	O
##it	O
##rate	O
/	O
is	O
##oc	O
##it	O
##rate	O
ratio	O
and	O
ace	B
##ty	I
##l	I
-	I
Co	I
##A	I
,	O
meta	O
##bol	O
##ites	O
pro	O
##ximal	O
to	O
the	O
metabolic	O
block	O
,	O
while	O
downstream	O
T	O
##CA	O
cycle	O
meta	O
##bol	O
##ites	O
including	O
alpha	B
-	I
k	I
##eto	I
##g	I
##lut	I
##arate	I
(	O
AK	O
##G	O
)	O
,	O
su	B
##cci	I
##nate	I
,	O
f	B
##uma	I
##rate	I
and	O
ma	B
##late	I
were	O
decreased	O
,	O
albeit	O
a	O
mild	O
per	O
##tur	O
##bation	O
.	O

There	O
was	O
a	O
significant	O
reduction	O
in	O
end	B
##oto	I
##xin	I
levels	O
after	O
r	O
##if	O
##ax	O
##im	O
##in	O
therapy	O
compared	O
to	O
base	O
##line	O
(	O
0	O
.	O
55	O
##±	O
##0	O
.	O
21	O
vs	O
.	O
0	O
.	O
48	O
##±	O
##0	O
.	O
24	O

Lac	B
##tate	I
and	O
ch	B
##ole	I
##ster	I
##ol	I
were	O
the	O
major	O
disc	O
##rim	O
##inating	O
meta	O
##bol	O
##ites	O
predict	O
##ing	O
30	O
-	O
day	O
mortality	O
.	O

We	O
synthesized	O
a	O
pair	O
of	O
is	O
##oto	O
##pe	O
label	O
##ing	O
re	O
##age	O
##nts	O
(	B
ω	B
-	I
br	I
##omo	I
##ace	I
##tony	I
##l	I
##quin	I
##olin	I
##ium	I
br	I
##omi	I
##de	I
,	O
B	O
##Q	O
##B	O
and	O
B	O
##Q	O
##B	O
-	O
d	O
_	O
7	O
)	O
for	O
selective	O
th	B
##iol	I
##s	I
label	O
##ing	O
.	O

Moreover	O
,	O
high	O
levels	O
of	O
L	O
##p	O
-	O
P	O
##LA	O
##2	O
and	O
L	B
##ys	I
##o	I
##PC	I
(	I
16	I
:	I
0	I
)	I
are	O
associated	O
with	O
s	O
##ym	O
##pt	O
##oma	O
##tic	O
car	O
##ot	O
##id	O
plaque	O
##s	O
.	O

As	O
##ter	O
##isk	O
S	O
##pec	O
##ime	O
##n	O
1	O
containing	O
AM	B
##P	I
,	O
MA	O
##MP	O
,	O
and	O
p	O
##OH	O
##MA	O
##MP	O
was	O
di	O
##lut	O
##ed	O
(	O
1	O
:	O
5	O
)	O
to	O
accommodate	O
MA	O
##MP	O
’	O
s	O
linear	O
range	O
Two	O
analytical	O
runs	O
were	O
required	O
to	O
q	O
##uant	O
##ify	O
20	O
anal	O
##yte	O
##s	O
in	O
me	O
##con	O
##ium	O
.	O

The	O
trans	O
##cript	O
##omi	O
##c	O
-	O
lip	O
##ido	O
##mic	O
analysis	O
in	O
the	O
g	O
##lo	O
##mer	O
##ular	O
compartment	O
revealed	O
significant	O
correlation	O
##s	O
between	O
lip	O
##id	O
factors	O
,	O
including	O
FA	O
##s	O
,	O
g	B
##ly	I
##cer	I
##oli	I
##pid	I
##s	I
,	O
and	O
AC	O
##s	O
,	O
with	O
the	O
genes	O
regulating	O
their	O
synthesis	O
and	O
metabolism	O
.	O

Ph	B
##os	I
##ph	I
##ori	I
##c	I
acid	I
and	O
potassium	B
h	I
##ydro	I
##xi	I
##de	I
were	O
provided	O
by	O
Jun	O
##sei	O
(	O
Tokyo	O
,	O
Japan	O
)	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
reason	O
why	O
the	O
L	O
##C	O
group	O
had	O
lower	O
levels	O
of	O
ω	B
-	I
3	I
P	I
##U	I
##FA	I
##s	I
than	O
the	O
control	O
group	O
was	O
hard	O
to	O
know	O
because	O
of	O
limited	O
information	O
.	O

P	O
##I	O
is	O
a	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
that	O
plays	O
an	O
important	O
role	O
in	O
regulation	O
of	O
a	O
wide	O
variety	O
of	O
cellular	O
processes	O
.	O

S	O
-	O
(	O
−	O
)	O
e	O
##q	O
##uo	O
##l	O
,	O
a	O
meta	O
##bol	O
##ite	O
of	O
the	O
so	O
##y	O
is	B
##of	I
##lav	I
##one	I
da	I
##id	I
##ze	I
##in	I
,	O
has	O
a	O
higher	O
bio	O
##ava	O
##ila	O
##bility	O
and	O
greater	O
affinity	O
for	O
est	B
##rogen	I
receptor	O
-	O
β	O
than	O
da	B
##id	I
##ze	I
##in	I
.	O

The	O
flow	O
-	O
through	O
and	O
a	O
column	O
wash	O
of	O
4	O
m	O
##l	O
of	O
70	O
%	O
ethanol	S
were	O
collected	O
(	B
SP	B
##E	I
##1	I
-	I
Fr	I
-	I
1	I
,	O
Scheme	O
1	O
)	O
.	O

Lower	O
levels	O
of	O
u	O
##rina	O
##ry	O
u	B
##rea	I
in	O
late	O
-	O
stage	O
cancer	O
##s	O
might	O
indicate	O
less	O
nitrogen	O
flux	O
into	O
cat	O
##ab	O
##olic	O
reactions	O
,	O
and	O
a	O
likely	O
higher	O
amino	O
acid	O
flux	O
into	O
protein	O
bio	O
##sy	O
##nt	O
##hesis	O
.	O

Multiple	O
log	O
##istic	O
re	O
##gression	O
analysis	O
:	O
risk	O
of	O
T	O
##2	O
##D	O
,	O
adjusted	O
for	O
gender	O
,	O
age	O
,	O
B	O
##MI	O
,	O
and	O
serum	O
p	B
##oly	I
##amine	I
levels	O
.	O

In	O
multi	O
##var	O
##iate	O
analysis	O
of	O
N	O
##MR	O
s	O
##pect	O
##ra	O
,	O
glucose	S
concentration	O
was	O
a	O
significant	O
disc	O
##rim	O
##inating	O
variable	O
that	O
was	O
higher	O
in	O
subjects	O
with	O
high	O
c	B
##ys	I
##tat	I
##hi	I
##oni	I
##ne	I
concentrations	O
compared	O
with	O
subjects	O
with	O
low	O
c	B
##ys	I
##tat	I
##hi	I
##oni	I
##ne	I
concentrations	O
.	O

Ph	O
##am	O
et	O
al	O
.	O
demonstrated	O
monitoring	O
of	O
relative	O
compositions	O
of	O
the	O
same	O
four	O
is	O
##omer	O
##s	O
of	O
PC	B
16	I
:	I
0	I
_	I
18	I
:	I
1	I
individually	O
from	O
MS	O
/	O
MS	O
experiments	O
containing	O
different	O
sequences	O
of	O
Oz	O
##ID	O
and	O
C	O
##ID	O
.	O

However	O
,	O
some	O
studies	O
have	O
reported	O
reduction	O
of	O
serum	O
al	B
##ani	I
##ne	I
post	O
bar	O
##ia	O
##tric	O
surgery	O
##10	O
and	O
that	O
reduction	O
of	O
al	B
##ani	I
##ne	I
is	O
greater	O
with	O
re	O
##mission	O
of	O
diabetes	O
.	O
45	O
However	O
,	O
data	O
on	O
re	O
##mission	O
of	O
diabetes	O
for	O
the	O
study	O
participants	O
are	O
not	O
available	O
for	O
the	O
present	O
study	O
to	O
comment	O
on	O
this	O
aspect	O
.	O

Both	O
CP	O
##MG	O
score	O
plots	O
(	O
a	O
)	O
and	O
LED	O
score	O
plots	O
(	O
b	O
)	O
show	O
plasma	O
meta	O
##bol	O
##ites	O
of	O
F	B
##D	I
patients	O
##are	O
different	O
from	O
those	O
of	O
control	O
subjects	O
(	O
)	O
.	O

Several	O
methods	O
have	O
been	O
developed	O
for	O
monitoring	O
C	B
##lo	I
##za	I
##pine	I
levels	O
;	O
however	O
,	O
they	O
possess	O
limited	O
specific	O
##ity	O
and	O
are	O
often	O
labor	O
##ious	O
.	O

T	B
##G	I
,	O
t	B
##ria	I
##cy	I
##l	I
##gly	I
##cer	I
##ol	I
;	O
PS	O
,	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##ls	I
##eri	I
##ne	I
;	O
PC	O
,	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
;	O
P	O
##I	O
,	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##lino	I
##si	I
##to	I
##l	I
;	O
m	O
/	O
z	O
,	O
mass	O
to	O
charge	O
ratio	O

The	O
LL	O
##OD	O
##s	O
of	O
P	O
,	O
P	O
-	O
1	O
,	O
P	O
-	O
2	O
,	O
IP	S
,	O
IP	O
-	O
1	O
,	O
and	O
IP	O
-	O
2	O
were	O
2	O
.	O
24	O
,	O
2	O
.	O
65	O
,	O
1	O
.	O
01	O
,	O
2	O
.	O
53	O
,	O
2	O
.	O
23	O
,	O
and	O
1	O
.	O
07	O
ng	O
/	O
m	O
##L	O
,	O
respectively	O
,	O
and	O
the	O
LL	O
##O	O
##Q	O
##s	O
of	O
P	O
,	O
P	O
-	O
1	O
,	O
P	O
-	O
2	O
,	O
IP	S
,	O
IP	O
-	O
1	O
,	O
and	O
IP	O
-	O
2	O
were	O
4	O
.	O
88	O
,	O
5	O
.	O
30	O
,	O
2	O
.	O
02	O
,	O
5	O
.	O
06	O
,	O
4	O
.	O
46	O
,	O
2	O
.	O
14	O
ng	O
/	O
m	O
##L	O
,	O
respectively	O
,	O
which	O
were	O
suitable	O
as	O
the	O
threshold	O
##s	O
for	O
the	O
q	O
##uant	O
##itation	O
of	O
the	O
components	O
.	O

In	O
our	O
study	O
,	O
LP	B
##E	I
(	I
18	I
:	I
1	I
)	I
was	O
shown	O
significantly	O
related	O
to	O
disease	O
status	O
with	O
increasing	O
level	O
in	O
N	O
##SC	O
##LC	O
patients	O
,	O
mainly	O
in	O
ad	O
##eno	O
##car	O
##cin	O
##oma	O
cases	O
.	O

For	O
M	B
##T	I
##BE	I
with	O
PC	O
##T	O
,	O
the	O
0	O
.	O
67	O
mg	O
and	O
0	O
.	O
20	O
mg	O
curves	O
are	O
essentially	O
in	O
##dis	O
##ting	O
##ui	O
##sha	O
##ble	O
.	O

OH	B
(	I
80	I
:	I
15	I
:	I
5	I
)	I
,	O
se	O
##quential	O
##ly	O
.	O

The	O
cap	O
##illa	O
##ry	O
voltage	O
##s	O
were	O
1	O
.	O
5	O
k	B
##V	I
(	O
E	O
##SI	O
+	O
)	O
and	O
2	O
k	B
##V	I
(	O
E	O
##SI	O
##−	O
)	O
.	O

G	B
##lu	I
##cos	I
##e	I
-	I
1	I
-	I
phosphate	I
is	O
an	O
important	O
intermediate	O
in	O
the	O
pathways	O
leading	O
to	O
protein	O
N	O
-	O
g	O
##ly	O
##cos	O
##yla	O
##tion	O
and	O
in	O
glucose	S
home	O
##ost	O
##asis	O
.	O

However	O
,	O
mi	O
##gra	O
##ine	O
is	O
characterized	O
by	O
an	O
increased	O
g	B
##lut	I
##ama	I
##ter	I
##gic	I
transmission	O
[	O
,	O
]	O
,	O
and	O
,	O
under	O
these	O
conditions	O
,	O
N	O
##MD	O
##A	O
receptors	O
may	O
be	O
fully	O
activated	S
by	O
the	O
high	O
s	O
##yna	O
##ptic	O
G	O
##lu	O
levels	O
combined	O
with	O
low	O
K	O
##Y	O
##NA	O
levels	O
.	O

As	O
expected	O
for	O
pro	B
##ges	I
##tero	I
##ne	I
and	O
17	B
-	I
h	I
##ydro	I
##xy	I
##p	I
##rog	I
##ester	I
##one	I
,	O
there	O
are	O
additional	O
requirements	O
to	O
consider	O
pre	O
-	O
and	O
post	O
-	O
men	O
##op	O
##aus	O
##al	O
age	O
groups	O
,	O
including	O
l	O
##ute	O
##al	O
and	O
f	O
##oll	O
##icular	O
phases	O
in	O
the	O
former	O
group	O
.	O

Para	O
##meter	O
estimates	O
and	O
standard	O
errors	O
(	O
SE	O
##s	O
)	O
for	O
the	O
re	O
##gression	O
of	O
un	O
##con	O
##ju	O
##gated	O
est	B
##rad	I
##iol	I
on	O
body	O
mass	O
index	O
(	O
B	O
##MI	O
)	O
measures	O
and	O
relative	O
increase	O
in	O
un	O
##con	O
##ju	O
##gated	O
est	B
##rad	I
##iol	I
according	O
to	O
B	O
##MI	O
in	O
cases	O
and	O
controls	O
combined	O
.	O

It	O
is	O
well	O
known	O
that	O
cancer	O
cells	O
convert	O
more	O
glucose	S
into	O
la	B
##ctic	I
acid	I
than	O
normal	O
cells	O
even	O
in	O
a	O
##ero	O
##bic	O
conditions	O
,	O
leading	O
to	O
a	O
disturbance	O
of	O
the	O
T	O
##CA	O
cycle	O
and	O
their	O
intermediate	O
##s	O
.	O

Thus	O
,	O
N	B
##AD	I
##P	I
##H	I
negatively	O
correlated	O
with	O
se	B
##do	I
##he	I
##pt	I
##ulos	I
##e	I
1	I
,	I
7	I
-	I
bi	I
##sp	I
##hos	I
##phate	I
(	O
S	O
##B	O
##P	O
,	O
r	O
=	O
−	O
##0	O
.	O
51	O
;	O
F	O
##DR	O
p	O
=	O
0	O
.	O
03	O
##3	O
)	O
and	O
HC	O
##A	O
(	O
r	O
=	O

2014	O
reported	O
that	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
PC	I
##ae	I
##c	I
##38	I
:	I
4	I
,	O
P	B
##ca	I
##ec	I
##40	I
:	I
4	I
,	O
P	B
##ca	I
##ec	I
##40	I
:	I
5	I
are	O
inverse	O
##ly	O
related	O
to	O
weight	O
change	O
up	O
to	O
6	O
months	O
of	O
age	O
,	O
but	O
did	O
not	O
identify	O
a	O
potential	O
underlying	O
mechanism	O
.	O

In	O
the	O
sex	O
-	O
and	O
age	O
-	O
adjusted	O
analysis	O
,	O
participants	O
with	O
higher	O
serum	O
T	B
##MA	I
##O	I
had	O
a	O
significantly	O
increased	O
risk	O
of	O
P	O
##LC	O
(	O
P	O
-	O
trend	O
<	O
0	O
.	O
00	O
##1	O
)	O
;	O
the	O
OR	O
(	O
95	O
%	O
C	O
##I	O
)	O
was	O
3	O
.	O
43	O
(	O
2	O
.	O
42	O
–	O
4	O
.	O
86	O
)	O
when	O
comparing	O
the	O
top	O
and	O
bottom	O
q	O
##ua	O
##rt	O
##iles	O
(	O
Q	O
##4	O
vs	O
Q	O
##1	O
)	O
.	O

Tau	B
##rine	I
,	O
glucose	S
,	O
and	O
la	B
##ct	I
##ate	I
(	O
a	O
–	O
c	O
)	O
were	O
all	O
greatly	O
affected	O
by	O
prolonged	O
blood	O
in	O
##cu	O
##bation	O
for	O
6	O
h	O
;	O
the	O
amounts	O
of	O
ta	B
##uri	I
##ne	I
and	O
la	B
##ct	I
##ate	I
were	O
increased	O
,	O
whereas	O
the	O
glucose	S
level	O
was	O
decreased	O
.	O

After	O
v	O
##ortex	O
-	O
mixing	O
,	O
the	O
plasma	O
was	O
b	O
##asi	O
##fied	O
with	O
40	O
μ	O
##l	O
of	O
1	O
##M	O
Na	O
##OH	O
and	O
extracted	O
with	O
4	O
m	O
##l	O
of	O
et	B
##hyl	I
ace	I
##tate	I
,	O
as	O
described	O
in	O
section	O
2	O
.	O
3	O
.	O

As	B
##cor	I
##bic	I
acid	I
cannot	O
be	O
synthesized	O
by	O
human	O
cells	O
and	O
must	O
be	O
obtained	O
from	O
the	O
diet	O
and	O
is	O
typically	O
meta	O
##bol	O
##ized	O
by	O
bacteria	O
in	O
the	O
G	O
##I	O
tract	O
.	O

Dec	O
##rease	O
##s	O
in	O
the	O
se	B
##rot	I
##oni	I
##n	I
meta	O
##bol	O
##ite	O
5	B
-	I
H	I
##IA	I
##A	I
are	O
only	O
modest	O
,	O
while	O
u	O
##rina	O
##ry	O
me	B
##lat	I
##oni	I
##n	I
and	O
its	O
cat	O
##ab	O
##oli	O
##te	O
N	B
-	I
ace	I
##ty	I
##l	I
-	I
5	I
-	I
met	I
##ho	I
##xy	I
##try	I
##pta	I
##mine	I
display	O
a	O
more	O
pronounced	O
mean	O
reduction	O
(	O
both	O
share	O
the	O
same	O
molecular	O
weight	O
and	O
fall	O
under	O
the	O
same	O
MS	O
peak	O
,	O
labeled	O
in	O
Fi	O
##g	O
.	O

A	O
previous	O
study	O
investigating	O
more	O
than	O
530	O
##0	O
elderly	O
subjects	O
proposed	O
that	O
a	O
higher	O
diet	O
##ary	O
rib	B
##of	I
##lav	I
##in	I
intake	O
leads	O
to	O
slightly	O
higher	O
B	O
##MD	O
in	O
the	O
f	O
##em	O
##oral	O
neck	O
and	O
l	O
##umba	O
##r	O
spine	O
but	O
not	O
to	O
a	O
reduced	O
fracture	O
risk	O
which	O
is	O
in	O
contrast	O
to	O
our	O
findings	O
.	O

[	O
2	O
,	O
2	O
,	O
3	O
,	O
3	O
-	O
d	O
##4	O
]	O
prop	B
##ion	I
##ate	I
(	O
T	O
##SP	O
)	O
9	O
.	O
9	O
mm	O
##ol	O
/	O
l	O
,	O
M	O
##n	O
##SO	O
_	O
4	O
0	O
.	O
47	O
mm	O
##ol	O
/	O
l	O
in	O
99	O
.	O
9	O
%	O
D	O
_	O
2	O
O	O
)	O
was	O
placed	O
co	O
##ax	O
##ially	O
into	O
the	O
N	O
##MR	O
sample	O
tube	O
(	O
o	O
.	O
d	O
.	O

Thus	O
,	O
various	O
reactive	O
per	B
##sul	I
##fi	I
##des	I
and	O
p	B
##oly	I
##sul	I
##fi	I
##des	I
appear	O
to	O
be	O
present	O
in	O
the	O
eye	O
,	O
and	O
some	O
reactive	O
su	B
##lf	I
##ide	I
species	O
,	O
which	O
have	O
a	O
protective	O
effect	O
against	O
o	O
##xi	O
##da	O
##tive	O
stress	O
,	O
are	O
up	O
##re	O
##gu	O
##lated	O
in	O
the	O
a	O
##que	O
##ous	O
and	O
v	O
##it	O
##re	O
##ous	O
humor	O
##s	O
of	O
D	O
##M	O
eyes	O
.	O

This	O
result	O
is	O
consistent	O
with	O
literature	O
reports	O
,	O
where	O
P	B
##E	I
34	I
:	I
1	I
,	O
P	B
##E	I
36	I
:	I
2	I
,	O
P	B
##E	I
38	I
:	I
4	I
,	O
PC	B
32	I
:	I
1	I
,	O
and	O
PC	B
36	I
:	I
2	I
have	O
been	O
identified	O
to	O
have	O
significant	O
changes	O
in	O
breast	O
cancer	O
cell	O
lines	O
or	O
tissue	O
samples	O
.	O

The	O
solution	O
volume	O
was	O
increased	O
to	O
600	O
μ	O
L	O
using	O
phosphate	S
buffer	O
in	O
D	O
_	O
2	O
O	O
(	O
0	O
.	O
1	O
M	O
)	O
with	O
no	O
T	O
##SP	O
and	O
transferred	O
to	O
a	O
5	O
mm	O
N	O
##MR	O
tube	O
for	O
analysis	O
.	O

Sign	O
##ificant	O
variations	O
between	O
the	O
two	O
groups	O
were	O
also	O
found	O
in	O
energy	O
-	O
associated	O
meta	O
##bol	O
##ites	O
including	O
two	O
t	B
##rica	I
##rb	I
##ox	I
##yl	I
##ic	I
acid	I
(	O
T	O
##CA	O
)	O
cycle	O
intermediate	O
##s	O
,	O
c	B
##it	I
##rate	I
and	O
f	B
##uma	I
##rate	I
,	O
and	O
la	B
##ct	I
##ate	I
and	O
p	B
##yr	I
##u	I
##vate	I
.	O

m	O
##PR	O
##EF	O
bio	O
##ps	O
##ies	O
were	O
then	O
removed	O
from	O
a	O
##que	O
##ous	O
met	B
##han	I
##ol	I
and	O
transferred	O
to	O
formal	B
##in	I
until	O
processed	O
.	O

There	O
are	O
some	O
reports	O
that	O
indicate	O
the	O
significant	O
association	O
between	O
the	O
conventional	O
fruits	O
/	O
vegetable	O
intake	O
and	O
the	O
u	O
##rina	O
##ry	O
p	O
##est	O
##icide	O
meta	O
##bol	O
##ites	O
,	O
for	O
example	O
,	O
tomato	O
consumption	O
and	O
u	O
##rina	O
##ry	O
concentrations	O
of	O
a	O
meta	O
##bol	O
##ite	O
of	O
p	O
##yre	O
##th	O
##roid	O
p	O
##est	O
##icides	O
,	O
3	B
-	I
p	I
##hen	I
##ox	I
##y	I
##bon	I
##zoic	I
acid	I
,	O
in	O
the	O
general	O
population	O
in	O
Japan	O
.	O

The	O
ca	O
##li	O
##bra	O
##tion	O
curve	O
covers	O
the	O
range	O
from	O
1	O
–	O
500	O
ng	O
/	O
m	O
##L	O
.	O
To	O
describe	O
the	O
ca	O
##li	O
##bra	O
##tion	O
curve	O
standards	O
were	O
used	O
at	O
the	O
following	O
concentration	O
levels	O
:	O
1	O
,	O
5	O
,	O
25	O
,	O
100	O
,	O
250	O
,	O
375	O
and	O
500	O
ng	O
/	O
m	O
##L	O
of	O
a	B
##bir	I
##ater	I
##one	I
.	O

In	O
an	O
experimental	O
model	O
of	O
acute	O
kidney	O
injury	O
,	O
one	O
of	O
the	O
strongest	O
metabolic	O
responses	O
to	O
ne	B
##ph	I
##rot	I
##ox	I
##ins	I
was	O
massive	O
ex	O
##cre	O
##tion	O
of	O
all	O
essential	O
amino	O
acids	O
.	O

The	O
study	O
was	O
approved	O
by	O
the	O
institutional	O
review	O
board	O
“	O
Co	O
##mit	O
##è	O
d	O
’	O
È	O
##tica	O
d	O
’	O
In	O
##ves	O
##ti	O
##ga	O
##ci	O
##ó	O
C	O
##l	O
##ín	O
##ica	O
,	O
Hospital	O
Un	O
##ivers	O
##ita	O
##ri	O
de	O
Sant	O
Joan	O
de	O
Re	O
##us	O
”	O
(	B
10	B
-	I
04	I
-	I
29	I
/	I
4	I
##p	I
##ro	I
##j	I
##3	I
)	O
.	O

Le	O
##u	O
,	O
le	B
##uc	I
##ine	I
;	O
Mat	O
##su	O
##da	O
index	O
=	O
1000	O
##0	O
/	O
(	O
G	O
##lu	O
##cos	O
##e	O
##0	O
*	O
G	O
##lu	O
##cos	O
##e	O
##12	O
##0	O
*	O
IN	O
##S	O
##0	O
*	O
IN	O
##S	O
##12	O
##0	O
)	O
1	O
/	O
2	O
;	O
O	O
##W	O
/	O
O	O
##B	O
,	O
healthy	O
over	O
##weight	O
or	O
o	O
##besity	O
;	O
Ph	O
##en	O
##yl	O
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
;	O
SP	S
,	O
s	O
##ys	O
##to	O
##lic	O
blood	O
pressure	O
;	O
T	O
##C	O
,	O
total	O
ch	B
##ole	I
##ster	I
##ol	I
;	O
T	B
##G	I
,	O
t	B
##rig	I
##ly	I
##cer	I
##ide	I
;	O
Ty	O
##ro	O
,	O
t	B
##yr	I
##os	I
##ine	I
;	O
Val	O
,	O
v	B
##ali	I
##ne	I
.	O

After	O
salvage	O
,	O
p	B
##ter	I
##id	I
##ine	I
precursor	O
##s	O
are	O
reduced	O
to	O
their	O
respective	O
biological	O
##ly	O
active	O
te	B
##tra	I
##hy	I
##dr	I
##o	I
forms	O
by	O
the	O
p	B
##ter	I
##id	I
##ine	I
red	O
##uc	O
##tase	O
PT	O
##R	O
##1	O
.	O

L	O
##C	O
-	O
MS	O
and	O
MR	O
##M	O
-	O
MS	O
confirmed	O
that	O
the	O
so	O
##y	O
bar	O
contained	O
ma	O
##lon	O
##yl	O
and	O
ace	B
##ty	I
##l	I
β	I
-	I
g	I
##lu	I
##cos	I
##ides	I
of	O
da	B
##id	I
##ze	I
##in	I
and	O
g	B
##eni	I
##stein	I
,	O
as	O
well	O
as	O
non	O
-	O
est	O
##eri	O
##fied	O
β	B
-	I
g	I
##lu	I
##cos	I
##ides	I
.	O

In	O
our	O
study	O
,	O
15	O
meta	O
##bol	O
##ites	O
with	O
statistical	O
significance	O
were	O
detected	O
when	O
comparing	O
Met	O
##S	O
and	O
o	O
##bes	O
##e	O
non	O
-	O
Met	O
##S	O
individuals	O
,	O
including	O
n	O
##uc	O
##leo	O
##side	O
##s	O
,	O
amino	O
acids	O
and	O
derivatives	O
,	O
amino	S
sugar	O
##s	O
,	O
pu	B
##rine	I
derivatives	O
and	O
p	O
##oly	O
##ols	O
.	O

Co	O
##rrel	O
##ations	O
between	O
glucose	S
(	O
a	O
)	O
and	O
lip	O
##id	O
(	O
b	O
)	O
metabolism	O
measurements	O
and	O
BC	O
##AA	O
##s	O
,	O
3	O
-	O
H	O
##IB	O
,	O
and	O
AAA	O
##s	O
6	O
years	O
after	O
G	O
##DM	O
pregnancy	O
.	O

Although	O
our	O
study	O
detected	O
g	B
##ly	I
##co	I
##lic	I
acid	I
in	O
the	O
L	O
##C	O
group	O
,	O
the	O
levels	O
were	O
lower	O
than	O
the	O
control	O
group	O
and	O
their	O
clinical	O
relevance	O
on	O
the	O
liver	O
has	O
not	O
been	O
focused	O
so	O
far	O
.	O

Our	O
data	O
points	O
to	O
the	O
en	O
##rich	O
##ment	O
of	O
non	O
-	O
est	O
##eri	O
##fied	O
P	O
##U	O
##FA	O
and	O
o	B
##xy	I
##lip	I
##ins	I
in	O
pro	O
-	O
at	O
##her	O
##ogenic	O
T	O
##GR	O
##L	O
,	O
consistent	O
with	O
our	O
previous	O
analysis	O
.	O

Furthermore	O
,	O
our	O
patients	O
were	O
treated	O
with	O
p	B
##io	I
##gli	I
##ta	I
##zone	I
,	O
not	O
r	B
##os	I
##ig	I
##lit	I
##az	I
##one	I
,	O
and	O
these	O
two	O
th	B
##ia	I
##zo	I
##lid	I
##ined	I
##ione	I
##s	I
are	O
known	O
to	O
ex	O
##ert	O
different	O
effects	O
on	O
gene	O
expression	O
and	O
plasma	O
lip	O
##id	O
levels	O
.	O

2	O
-	O
AG	O
can	O
be	O
h	O
##ydro	O
##ly	O
##zed	O
by	O
MA	O
##G	O
##L	O
to	O
a	B
##rac	I
##hi	I
##don	I
##ic	I
acid	I
which	O
,	O
in	O
turn	O
,	O
is	O
meta	O
##bol	O
##ized	O
to	O
e	B
##ico	I
##san	I
##oid	I
signaling	O
lip	O
##ids	O
through	O
c	O
##y	O
##c	O
##lo	O
##ox	O
##y	O
##gen	O
##ases	O
;	O
therefore	O
,	O
we	O
treated	O
S	O
##U	O
##D	O
##HL	O
-	O
10	O
,	O
Sc	O
##i	O
-	O
1	O
,	O
P	O
##fe	O
##iff	O
##er	O
,	O
and	O
W	O
##SU	O
-	O
F	O
##SC	O
##CL	O
cells	O
with	O
MA	O
##G	O
##L	O
and	O
CO	O
##X	O
inhibitor	O
##s	O
to	O
determine	O
whether	O
we	O
could	O
reverse	O
the	O
pro	O
-	O
pro	O
##life	O
##rative	O
effects	O
of	O
2	O
-	O
AG	O
.	O

This	O
invasion	O
could	O
result	O
from	O
the	O
conversion	O
of	O
g	B
##ly	I
##cine	I
to	O
sa	B
##rc	I
##os	I
##ine	I
by	O
the	O
enzyme	O
g	O
##ly	O
##cine	O
-	O
N	O
-	O
met	O
##hyl	O
##tra	O
##ns	O
##fer	O
##ase	O
(	O
G	O
##N	O
##MT	O
)	O
.	O

The	O
pattern	O
of	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
did	O
not	O
differ	O
between	O
N	O
##AF	O
##LD	O
patients	O
with	O
diabetes	O
and	O
those	O
without	O
diabetes	O
.	O

Tri	B
##f	I
##lu	I
##oro	I
##ace	I
##tic	I
acid	I
(	O
T	O
##FA	O
)	O
was	O
MS	O
-	O
grade	O
from	O
Fisher	O
Scientific	O
(	O
Lou	O
##gh	O
##borough	O
,	O
UK	O
)	O
.	O

The	O
effect	O
of	O
individual	O
FA	S
(	O
s	O
##te	O
##ari	O
##c	O
,	O
D	O
##HA	O
and	O
EPA	O
)	O
on	O
IF	O
##N	O
##γ	O
production	O
by	O
P	O
##BM	O
##Cs	O
under	O
resting	O
conditions	O
or	O
in	O
the	O
presence	O
of	O
P	O
##HA	O
was	O
evaluated	O
in	O
culture	O
super	O
##nat	O
##ants	O
by	O
E	O
##L	O
##IS	O
##A	O
or	O
by	O
flow	O
c	O
##yt	O
##ome	O
##try	O
on	O
CD	O
##4	O
_	O
+	O
T	O
cells	O
(	O
both	O
n	O
=	O
6	O
)	O
(	O
B	O
)	O
Effect	O
of	O
FA	S
added	O
in	O
combination	O
to	O
P	O
##BM	O
##C	O
cultures	O
.	O

Total	O
RNA	O
extracted	O
(	O
2	O
.	O
5	O
µ	O
##g	O
)	O
was	O
re	O
##tro	O
##tra	O
##ns	O
##cribed	O
to	O
c	O
##D	O
##NA	O
using	O
random	O
exam	O
##ers	O
and	O
the	O
Te	O
##tro	O
c	O
##D	O
##NA	O
synthesis	O
kit	O
from	O
B	B
##iol	I
##ine	I
(	I
B	I
##iol	I
##ine	I
,	I
Freiburg	I
,	I
Germany	I
)	I
,	O
according	O
to	O
the	O
manufacturer	O
'	O
s	O
instructions	O
.	O

However	O
,	O
our	O
findings	O
suggest	O
that	O
the	O
net	O
effect	O
of	O
beta	B
##ine	I
and	O
diet	O
##ary	O
fiber	O
in	O
the	O
m	O
##od	O
##ulation	O
of	O
ch	B
##ole	I
##ster	I
##ol	I
levels	O
after	O
W	O
##G	O
intake	O
should	O
be	O
considered	O
and	O
warrant	O
##s	O
further	O
investigation	O
.	O

Pat	O
##ients	O
undergoing	O
bar	O
##ia	O
##tric	O
surgery	O
following	O
procedures	O
involved	O
in	O
lap	O
##aro	O
##scopic	O
sleeve	O
gas	O
##tre	O
##ct	O
##omy	O
were	O
recruited	O
as	O
a	O
model	O
of	O
o	O
##besity	O
-	O
induced	O
N	O
##AF	O
##LD	O
in	O
an	O
observation	O
##al	O
,	O
prospective	O
,	O
single	O
-	O
site	O
,	O
cross	O
-	O
section	O
##al	O
study	O
with	O
a	O
pre	O
-	O
set	O
duration	S
of	O
1	O
year	O
.	O

After	O
adjusting	O
for	O
age	O
,	O
B	O
##MI	O
,	O
W	O
##H	O
##R	O
,	O
smoking	O
,	O
drinking	O
,	O
BP	O
,	O
total	O
-	O
and	O
L	B
##D	I
##L	I
-	I
ch	I
##ole	I
##ster	I
##ol	I
,	O
glucose	S
,	O
and	O
insulin	O
,	O
the	O
H	O
##T	O
##G	O
group	O
exhibited	O
a	O
higher	O
H	O
##OM	O
##A	O
-	O
I	O
##R	O
index	O
(	O
P	O
<	O
0	O
.	O
00	O
##1	O
)	O
,	O
T	B
##G	I
level	O
(	O
P	O
<	O
0	O
.	O
00	O
##1	O
)	O
,	O
fast	O
##ing	O
FF	O
##A	O
(	O
P	O
=	O
0	O
.	O
03	O
##4	O
)	O
,	O
the	O
FF	O
##A	O
response	O
area	O
during	O
O	O
##G	O
##TT	O
(	O
P	O
=	O
0	O
.	O
00	O
##6	O
)	O
,	O
and	O
o	O
##x	O
-	O
L	O
##D	O
##L	O
(	O
P	O
<	O
0	O
.	O
00	O
##1	O
)	O
,	O
as	O
well	O
as	O
a	O
reduced	O
HD	B
##L	I
-	I
ch	I
##ole	I
##ster	I
##ol	I
level	O
(	O
P	O
<	O
0	O
.	O
00	O
##1	O
)	O
and	O
a	O
smaller	O
L	O
##D	O
##L	O
particle	O
size	O
(	O
P	O
<	O
0	O
.	O
00	O
##1	O
)	O
,	O
than	O
those	O
of	O
the	O
N	O
##T	O
##G	O
group	O
.	O

Compared	O
with	O
the	O
data	O
reported	O
in	O
the	O
published	O
paper	O
,	O
this	O
compound	O
was	O
identified	O
as	O
6	B
,	I
7	I
-	I
fur	I
##ano	I
-	I
h	I
##ydro	I
##co	I
##uma	I
##ric	I
acid	I
met	I
##hyl	I
est	I
##er	I
.	O

Here	O
,	O
the	O
significantly	O
changed	O
levels	O
of	O
2	B
-	I
met	I
##hyl	I
-	I
3	I
-	I
h	I
##ydro	I
##xy	I
##but	I
##yric	I
acid	I
,	O
c	B
##it	I
##ric	I
acid	I
,	O
in	B
##os	I
##ito	I
##l	I
,	O
met	B
##hyl	I
su	I
##cci	I
##nic	I
acid	I
,	O
so	B
##rb	I
##ito	I
##l	I
,	O
van	B
##ill	I
##ic	I
acid	I
and	O
th	B
##re	I
##ito	I
##l	I
were	O
not	O
found	O
by	O
the	O
non	O
##par	O
##ame	O
##tric	O
Mann	O
–	O
Whitney	O
U	O
test	O
.	O

This	O
finding	O
suggests	O
that	O
some	O
degree	O
of	O
vitamin	O
B	O
-	O
6	O
ins	O
##uff	O
##iciency	O
existed	O
in	O
the	O
high	B
–	I
c	I
##ys	I
##tat	I
##hi	I
##oni	I
##ne	I
concentration	O
group	O
.	O

By	O
design	O
,	O
mean	O
age	O
and	O
percentage	O
of	O
women	O
were	O
consistent	O
across	O
all	O
eight	O
groups	O
in	O
the	O
F	O
##HS	O
,	O
while	O
by	O
design	O
,	O
B	O
##MI	O
,	O
glucose	S
,	O
and	O
lip	O
##id	O
levels	O
(	O
HD	O
##L	O
-	O
C	O
and	O
T	O
##AG	O
)	O
varied	O
.	O

H	B
##y	I
##pox	I
##ant	I
##hine	I
is	O
a	O
pu	B
##rine	I
involved	O
in	O
ad	B
##eni	I
##ne	I
and	O
g	B
##uan	I
##ine	I
metabolism	O
and	O
,	O
therefore	O
,	O
in	O
the	O
synthesis	O
of	O
the	O
corresponding	O
n	O
##uc	O
##leo	O
##side	O
##s	O
.	O

H	B
##y	I
##pox	I
##ant	I
##hine	I
is	O
the	O
precursor	O
of	O
u	O
##ric	O
acid	O
—	O
the	O
end	O
product	O
of	O
pu	B
##rine	I
degradation	O
in	O
humans	O
.	O

ME	O
##DF	O
##SD	O
##O	O
,	O
coded	O
0	O
–	O
6	O
by	O
increasing	O
dose	O
of	O
s	B
##tat	I
##in	I
type	O
.	O

Using	O
the	O
D	O
##AV	O
##ID	O
software	O
(	O
V	O
##er	O
.	O
6	O
.	O
8	O
)	O
,	O
we	O
performed	O
functional	O
en	O
##rich	O
##ment	O
analysis	O
of	O
the	O
D	O
##MG	O
##s	O
to	O
identify	O
cellular	O
processes	O
and	O
pathways	O
per	O
##tur	O
##bed	O
by	O
α	B
-	I
O	I
##G	I
treatment	O
.	O

B	O
Mean	O
P	O
##K	O
curves	O
of	O
di	B
##os	I
##met	I
##in	I
g	I
##lu	I
##cu	I
##ron	I
##ide	I
meta	O
##bol	O
##ites	O
measured	O
in	O
plasma	O
and	O
P	O
##K	O
parameters	O
obtained	O
on	O
the	O
same	O
12	O
patients	O
.	O

An	O
al	O
##iq	O
##uo	O
##t	O
of	O
about	O
300	O
µ	O
##L	O
of	O
each	O
f	O
##eca	O
##l	O
sample	O
was	O
di	O
##lut	O
##ed	O
in	O
1	O
m	O
##L	O
of	O
PBS	O
-	O
E	O
##D	O
##TA	O
(	B
phosphate	S
buffer	O
0	O
.	O
01	O
M	O
,	O
pH	O
7	O
.	O
2	O
,	O
0	O
.	O
01	O
M	O
E	O
##D	O
##TA	O
)	O
.	O

L	O
.	O
Oral	O
glucose	S
tolerance	O
test	O
(	O
O	O
##G	O
##TT	O
)	O
was	O
not	O
available	O
for	O
all	O
participants	O
,	O
hence	O
it	O
was	O
not	O
used	O
to	O
define	O
the	O
pre	O
##dia	O
##bet	O
##es	O
group	O
in	O
our	O
study	O
.	O

The	O
system	O
utilized	O
a	O
DB	O
-	O
5	O
##MS	O
cap	O
##illa	O
##ry	O
column	O
coated	O
with	O
5	O
%	O
dip	O
##hen	O
##yl	O
cross	O
-	O
linked	O
with	O
95	O
%	O
dim	B
##eth	I
##yl	I
##pol	I
##ys	I
##ilo	I
##xa	I
##ne	I
(	O
30	O
m	O
×	O
250	O

On	O
the	O
other	O
hand	O
,	O
co	O
##hor	O
##t	O
differences	O
in	O
relation	O
to	O
variations	O
in	O
particular	O
low	O
-	O
M	O
_	O
w	O
compounds	O
(	O
e	O
.	O
g	O
.	O
g	B
##lut	I
##amine	I
,	O
al	B
##ani	I
##ne	I
,	O
c	B
##rea	I
##tine	I
,	O
dim	B
##eth	I
##yl	I
su	I
##lf	I
##one	I
,	O
p	O
##yr	O
##u	O
##vate	O
)	O
may	O
reflect	O
the	O
potential	O
importance	O
of	O
local	O
nutrition	O
##al	O
and	O
lifestyle	O
effects	O
on	O
the	O
suggested	O
AM	O
##D	O
metabolic	O
finger	O
##prints	O
.	O

The	O
increases	O
in	O
ace	B
##tate	I
,	O
short	O
-	O
chain	O
fatty	O
acid	O
and	O
GA	B
##BA	I
in	O
es	O
##op	O
##hage	O
##al	O
cancer	O
tissue	O
revealed	O
the	O
activation	O
of	O
fatty	O
acids	O
metabolism	O
,	O
which	O
could	O
satisfy	O
the	O
need	O
for	O
cellular	O
membrane	O
formation	O
.	O

Accordingly	O
,	O
the	O
precise	O
q	O
##uant	O
##ification	O
of	O
the	O
relative	O
amounts	O
of	O
distinct	O
FA	B
is	I
##omer	I
##s	I
is	O
of	O
substantial	O
importance	O
in	O
identifying	O
the	O
specific	O
roles	O
that	O
each	O
is	O
##omer	O
plays	O
in	O
bio	O
##log	O
##ic	O
processes	O
.	O

P	O
##las	O
##ma	O
ho	B
##mo	I
##cy	I
##stein	I
##e	I
was	O
measured	O
by	O
high	O
-	O
performance	O
liquid	O
ch	O
##roma	O
##tography	O
.	O

As	O
a	O
result	O
,	O
five	O
bio	O
##mark	O
##ers	O
(	B
20	B
-	I
H	I
##ydro	I
##xy	I
-	I
le	I
##uk	I
##ot	I
##rien	I
##e	I
E	O
##4	O
,	O
L	B
##ys	I
##op	I
##c	I
(	I
20	I
:	I
4	I
)	I
,	O
5	B
-	I
met	I
##ho	I
##xy	I
##try	I
##pta	I
##mine	I
,	O
End	O
##omo	O
##rp	O
##hin	O
-	O
1	O
,	O
L	B
##ys	I
##op	I
##c	I
(	I
20	I
:	I
3	I
)	I
)	O
and	O
five	O
bio	O
##mark	O
##ers	O
(	B
Is	B
##o	I
-	I
v	I
##ale	I
##ral	I
##de	I
##hy	I
##de	I
,	O
l	B
##ino	I
##le	I
##ic	I
acid	I
,	O
L	B
##ys	I
##op	I
##c	I
(	I
18	I
:	I
1	I
)	I
,	O
2	B
-	I
P	I
##yr	I
##rol	I
##oy	I
##l	I
##gly	I
##cine	I
,	O
Di	B
##ty	I
##ros	I
##ine	I
)	O
were	O
included	O
in	O
the	O
predict	O
##ive	O
equation	O
of	O
N	O
##GR	O
and	O
D	O
##M	O
,	O
respectively	O
.	O

Co	O
##mpo	O
##nent	O
A	O
consisted	O
of	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
in	O
water	O
,	O
while	O
component	O
B	O
was	O
100	O
%	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
.	O

PS	O
##A	O
progression	O
-	O
free	O
survival	O
calculated	O
by	O
the	O
Kaplan	O
Mei	O
##er	O
method	O
for	O
(	O
a	O
)	O
sub	B
##eric	I
acid	I
and	O
(	O
b	O
)	O
in	B
##do	I
##lea	I
##ce	I
##tic	I
acid	I
and	O
l	O
##ymph	O
node	O
progression	O
-	O
free	O
survival	O
for	O
in	B
##do	I
##lea	I
##ce	I
##tic	I
acid	I
is	O
represented	O
in	O
(	O
c	O
)	O
.	O

Preliminary	O
tests	O
show	O
that	O
increasing	O
the	O
m	O
##od	O
##ifier	O
content	O
from	O
2	O
to	O
10	O
%	O
at	O
the	O
start	O
of	O
the	O
gradient	O
significantly	O
reduces	O
the	O
observed	O
variation	O
in	O
the	O
ca	B
##ffe	I
##ine	I
peak	O
area	O
,	O
and	O
has	O
the	O
added	O
advantage	O
of	O
reducing	O
the	O
gradient	O
length	O
without	O
affecting	O
overall	O
separation	O
.	O

Co	O
##mp	O
##aring	O
G	O
##C	O
vs	O
non	O
-	O
G	O
##C	O
groups	O
,	O
the	O
pathways	O
of	O
try	B
##pt	I
##op	I
##han	I
metabolism	O
,	O
as	O
well	O
as	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
nitrogen	O
,	O
a	B
##rg	I
##ini	I
##ne	I
,	O
pro	B
##line	I
,	O
al	B
##ani	I
##ne	I
and	O
his	B
##ti	I
##dine	I
metabolism	O
##s	O
and	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
t	B
##yr	I
##os	I
##ine	I
and	O
try	B
##pt	I
##op	I
##han	I
bio	O
##sy	O
##nt	O
##hesis	O
pathways	O
were	O
significantly	O
altered	O
after	O
multiple	O
testing	O
correction	O
##s	O
(	O
F	O
##DR	O
p	O
-	O
value	O
<	O
0	O
.	O
05	O
)	O
(	O
see	O
Table	O
)	O
.	O

Cell	O
##s	O
were	O
trans	O
##fected	O
at	O
70	O
%	O
con	O
##f	O
##lue	O
##ncy	O
with	O
l	O
##uc	O
##ifer	O
##ase	O
and	O
re	O
##ni	O
##lla	O
p	O
##las	O
##mi	O
##ds	O
(	O
Pro	O
##me	O
##ga	O
,	O
Madison	O
,	O
W	O
##I	O
)	O
,	O
X	O
##RE	O
p	O
##G	O
##L	O
##4	O
.	O
43	O
,	O
and	O
p	O
##RL	O
-	O
T	O
##K	O
,	O
respectively	O
,	O
using	O
Li	B
##po	I
##fect	I
##amine	I
2000	O
re	O
##age	O
##nt	O
for	O
6	O
h	O
.	O
Cell	O
##s	O
were	O
treated	O
with	O
the	O
RC	O
##E	O
/	O
is	O
##of	O
##lav	O
##ones	O
for	O
24	O
h	O
and	O
l	O
##ys	O
##ed	O
with	O
buffer	O
.	O

In	O
##tra	O
##ven	O
##ous	O
d	B
_	I
0	I
-	I
met	I
##had	I
##one	I
-	I
HC	I
##l	I
was	O
given	O
in	O
a	O
dose	O
of	O
5	O
mg	O
,	O
while	O
d	O
_	O
0	O
-	O
oral	O
met	B
##had	I
##one	I
was	O
given	O
as	O
a	O
5	O
-	O
m	O
##l	O
solution	O
containing	O
10	O
mg	O
.	O

Inc	O
##reased	O
g	B
##ly	I
##co	I
##ly	I
##tic	I
flux	O
and	O
altered	O
T	O
##CA	O
cycle	O
function	O
are	O
well	O
known	O
hall	O
##marks	O
of	O
cancer	O
,	O
affecting	O
not	O
only	O
cellular	O
energetic	O
efficiency	O
but	O
also	O
an	O
##ab	O
##olic	O
/	O
bio	O
##sy	O
##nt	O
##hetic	O
efficiency	O
_	O
,	O
_	O
,	O
,	O
since	O
intermediate	O
##s	O
in	O
these	O
pathways	O
are	O
diverted	O
towards	O
the	O
synthesis	O
of	O
proteins	O
,	O
nuclei	O
##c	O
acids	O
,	O
lip	O
##ids	O
,	O
and	O
ch	B
##ole	I
##ster	I
##ol	I
synthesis	O
_	O
,	O
_	O
,	O
_	O
,	O
_	O
,	O
_	O
,	O
,	O
and	O
generally	O
aid	O
in	O
the	O
maintenance	O
of	O
cellular	O
red	O
##ox	O
_	O
,	O
,	O
genetic	O
and	O
e	O
##pi	O
##gene	O
##tic	O
status	O
_	O
,	O
required	O
for	O
cancer	O
cells	O
proliferation	O
.	O

Al	O
##b	O
add	O
##uc	O
##ts	O
were	O
found	O
in	O
F	O
##34	O
##4	O
/	O
N	O
rats	O
exposed	O
by	O
g	O
##ava	O
##ge	O
to	O
0	O
–	O
10	O
,	O
000	O
μ	O
##mo	O
##l	O
/	O
kg	O
ben	B
##zen	I
##e	I
.	O

In	O
the	O
future	O
,	O
it	O
is	O
recommended	O
that	O
ne	O
##uro	O
##to	O
##xi	O
##c	O
factors	O
and	O
relative	O
enzymes	O
such	O
as	O
3	O
-	O
HK	O
and	O
3	O
-	O
H	O
##AN	O
##A	O
be	O
measured	O
in	O
the	O
K	B
##P	I
toxic	O
branch	O
to	O
evaluate	O
downstream	O
activity	O
.	O

α	O
–	O
H	O
##B	O
may	O
become	O
elevated	O
by	O
at	O
least	O
two	O
mechanisms	O
:	O
(	O
1	O
)	O
elevation	O
of	O
he	O
##pa	O
##tic	O
g	B
##lut	I
##ath	I
##ione	I
stress	O
resulting	O
in	O
an	O
increased	O
demand	O
for	O
g	B
##lut	I
##ath	I
##ione	I
production	O
,	O
and	O
(	O
2	O
)	O
elevation	O
of	O
the	O
N	O
##AD	O
##H	O
/	O
N	O
##AD	O
_	O
+	O
ratio	O
due	O
to	O
increased	O
lip	O
##id	O
oxidation	O
.	O

Co	B
##tin	I
##ine	I
el	O
##uted	O
at	O
2	O
.	O
33	O
minutes	O
.	O

Guo	O
et	O
al	O
.	O
evaluated	O
the	O
anti	O
##ox	O
##ida	O
##nt	O
activities	O
of	O
six	O
compounds	O
,	O
including	O
ps	B
##oral	I
##id	I
##in	I
,	O
from	O
PC	O
extract	O
,	O
which	O
exhibited	O
strong	O
anti	O
##ox	O
##ida	O
##nt	O
activities	O
;	O
however	O
,	O
P	O
and	O
IP	S
do	O
not	O
possess	O
any	O
anti	O
##ox	O
##ida	O
##nt	O
activities	O
either	O
,	O
which	O
is	O
consistent	O
with	O
the	O
results	O
of	O
our	O
experiments	O
.	O

Try	B
##pt	I
##op	I
##han	I
has	O
also	O
been	O
identified	O
as	O
a	O
key	O
meta	O
##bol	O
##ite	O
in	O
host	O
-	O
gut	O
micro	O
##bio	O
##me	O
signaling	O
,	O
and	O
its	O
bio	O
##ava	O
##ila	O
##bility	O
(	O
and	O
therefore	O
that	O
of	O
its	O
downstream	O
meta	O
##bol	O
##ites	O
)	O
is	O
influenced	O
by	O
the	O
micro	O
##bial	O
balance	O
within	O
the	O
gut	O
.	O

Recent	O
investigations	O
by	O
Hu	O
et	O
al	O
.	O
,	O
which	O
imply	O
that	O
Phase	O
II	O
meta	O
##bol	O
##ites	O
of	O
fl	B
##av	I
##ono	I
##ids	I
undergo	O
enter	O
##ic	O
recycling	O
within	O
the	O
gas	O
##tro	O
##int	O
##est	O
##inal	O
tract	O
,	O
suggest	O
an	O
expanded	O
role	O
for	O
Phase	O
II	O
enzymes	O
(	O
,	O
)	O
.	O

Dual	O
functions	O
have	O
been	O
described	O
for	O
a	B
##rg	I
##ini	I
##ne	I
in	O
the	O
context	O
of	O
cancer	O
:	O

Additionally	O
,	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
metabolism	O
previously	O
is	O
identified	O
as	O
a	O
potential	O
bio	O
##mark	O
##ers	O
of	O
is	O
##che	O
##mic	O
stroke	O
,	O
though	O
there	O
is	O
some	O
evidence	O
from	O
animal	O
models	O
that	O
this	O
relationship	O
may	O
be	O
influenced	O
by	O
o	O
##besity	O
.	O

Mon	O
##o	O
and	O
o	B
##li	I
##gos	I
##ac	I
##cha	I
##ride	I
##s	I
were	O
detected	O
as	O
am	O
##monia	O
add	O
##uc	O
##ts	O
in	O
positive	O
mode	O
and	O
as	O
[	O
M	O
-	O
H	O
]	O
_	O
−	O
ions	O
in	O
negative	O
mode	O
.	O

For	O
example	O
,	O
la	B
##ct	I
##ate	I
,	O
q	B
##uin	I
##olin	I
##ate	I
,	O
g	B
##lut	I
##ama	I
##te	I
,	O
ma	B
##late	I
,	O
2	B
-	I
o	I
##x	I
##og	I
##lut	I
##arate	I
(	I
alpha	I
-	I
k	I
##eto	I
##g	I
##lut	I
##arate	I
)	I
,	O
or	B
##ni	I
##thin	I
##e	I
,	O
as	O
well	O
as	O
many	O
amino	O
acids	O
and	O
lip	O
##id	O
meta	O
##bol	O
##ites	O
show	O
an	O
increasing	O
trend	O
across	O
stages	O
.	O

Panel	O
B	O
shows	O
the	O
differences	O
of	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
and	O
c	B
##era	I
##mi	I
##de	I
mass	O
levels	O
between	O
AD	O
patients	O
and	O
controls	O
who	O
were	O
not	O
taking	O
s	B
##tat	I
##ins	I
.	O

An	O
ass	O
##ay	O
that	O
re	O
##lia	O
##bly	O
distinguish	O
##es	O
serum	O
est	B
##rad	I
##iol	I
concentrations	O
in	O
the	O
low	O
post	O
##men	O
##op	O
##aus	O
##al	O
range	O
(	O
<	O
110	O
pm	O
##ol	O
/	O
L	O
;	O
<	O
30	O
p	O
##g	O
/	O
m	O
##L	O
)	O
,	O
and	O
at	O
the	O
even	O
lower	O
concentrations	O
found	O
in	O
women	O
being	O
treated	O
for	O
breast	O
cancer	O
with	O
a	O
##roma	O
##tase	O
inhibitor	O
##s	O
(	O
~	O
4	O
pm	O
##ol	O
/	O
L	O
;	O
~	O
1	O
p	O
##g	O
/	O
m	O
##L	O
)	O
,	O
can	O
be	O
an	O
important	O
pro	O
##gno	O
##stic	O
tool	O
in	O
the	O
management	O
of	O
breast	O
cancer	O
,	O
o	O
##ste	O
##op	O
##oro	O
##sis	O
and	O
bone	O
fracture	O
,	O
card	O
##iovascular	O
disease	O
,	O
and	O
possibly	O
cognitive	O
d	O
##ys	O
##function	O
(	O
32	O
,	O
33	O
)	O
.	O

We	O
repeated	O
the	O
models	O
without	O
adjusting	O
for	O
co	B
##tin	I
##ine	I
,	O
with	O
no	O
meaningful	O
change	O
in	O
results	O
(	O
data	O
not	O
shown	O
)	O
.	O

The	O
dried	O
met	B
##han	I
##olic	I
extract	O
was	O
a	O
##ze	O
##ot	O
##rop	O
##ed	O
twice	O
by	O
adding	O
100	O
μ	O
L	O
of	O
dim	B
##eth	I
##yl	I
##form	I
##ami	I
##de	I
,	O
mixed	O
by	O
v	O
##ortex	O
##ing	O
,	O
and	O
dried	O
using	O
a	O
Speed	O
V	O
##ac	O
for	O
30	O
min	O
.	O

The	O
distribution	O
of	O
24	B
##S	I
-	I
OH	I
-	I
Cho	I
##l	I
levels	O
(	O
box	O
##p	O
##lot	O
##s	O
)	O
in	O
Control	O
##s	O
and	O
patients	O
affected	O
by	O
V	O
##D	O
,	O
L	O
##OA	O
##D	O
or	O
C	O
##IN	O
##D	O
is	O
reported	O
in	O
Figure	O
.	O

U	O
##rina	O
##ry	O
ex	O
##cre	O
##tions	O
of	O
Pro	O
and	O
C	O
##it	O
were	O
higher	O
in	O
C	O
##K	O
##D	O
##4	O
–	O
5	O
compared	O
with	O
C	O
##K	O
##D	O
##2	O
–	O
3	O
(	O
both	O
P	O
<	O
0	O
.	O
00	O
##1	O
)	O
,	O
whereas	O
u	O
##rina	O
##ry	O
ex	O
##cre	O
##tion	O
of	O
AD	B
##MA	I
was	O
lower	O
(	O
P	O
<	O
0	O
.	O
00	O
##1	O
)	O
.	O

To	O
ensure	O
linear	O
##ity	O
over	O
5	O
orders	O
of	O
magnitude	O
,	O
l	O
##ys	O
##is	O
buffer	O
(	O
L	O
##B	O
)	O
,	O
a	O
5	O
:	O
3	O
:	O
2	O
ratio	O
of	O
Me	O
##OH	O
:	O
ace	O
##ton	O
##it	O
##ril	O
##e	O
:	O
H	O
_	O
2	O
O	O
,	O
and	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
al	O
##iq	O
##uo	O
##ts	O
were	O
each	O
spike	O
##d	O
with	O
varying	O
ranges	O
of	O
heavy	O
-	O
labeled	O
try	B
##pt	I
##op	I
##han	I
and	O
k	B
##yn	I
##uren	I
##ine	I
(	O
50	O
μ	O
##M	O
,	O
5	O
μ	O
##M	O
,	O
500	O
n	O
##M	O
,	O
50	O
n	O
##M	O
,	O
5	O
n	O
##M	O
,	O
500	O
p	O
##M	O
)	O
and	O
analyzed	O
by	O
ultra	O
-	O
high	O
pressure	O
liquid	O
ch	O
##roma	O
##tography	O
coupled	O
to	O
mass	O
s	O
##pect	O
##rome	O
##try	O
–	O
U	O
##HP	O
##LC	O
-	O
MS	O
.	O

For	O
bio	O
##tin	O
##yla	O
##tion	O
,	O
20	O
-	O
fold	O
m	O
##olar	O
ratio	O
of	O
the	O
Ch	O
##roma	O
##L	O
##ink	O
bio	B
##tin	I
to	O
anti	O
##body	O
was	O
in	O
##cu	O
##bate	O
##d	O
for	O
90	O
min	O
at	O
room	O
temperature	O
.	O

We	O
found	O
that	O
the	O
ATP	S
levels	O
were	O
significantly	O
decreased	O
in	O
F	O
##T	O
##D	O
compared	O
to	O
controls	O
(	O
Fi	O
##g	O
.	O
)	O
,	O
supporting	O
our	O
lip	O
##id	O
data	O
.	O

Both	O
L	O
##ys	O
##o	O
-	O
PC	O
##s	O
and	O
SM	O
##s	O
were	O
down	O
##re	O
##gu	O
##lated	O
,	O
whereas	O
the	O
saturated	O
and	O
un	O
##sat	O
##ura	O
##ted	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
(	O
PC	O
##s	O
)	O
were	O
up	O
##re	O
##gu	O
##lated	O
in	O
the	O
plasma	O
and	O
er	O
##yt	O
##hr	O
##ocytes	O
of	O
se	O
##ptic	O
patients	O
.	O

P	B
##yr	I
##og	I
##lut	I
##ama	I
##te	I
is	O
another	O
meta	O
##bol	O
##ite	O
associated	O
with	O
G	B
##S	I
##H	I
metabolism	O
.	O

The	O
R	O
##OC	O
curves	O
from	O
all	O
models	O
based	O
on	O
cross	O
valid	O
##ation	O
performance	O
indicated	O
that	O
Model	O
5	O
entered	O
10	O
features	O
,	O
including	O
9	O
##c	O
##RA	O
,	O
de	B
##hy	I
##dr	I
##op	I
##hy	I
##tos	I
##phi	I
##ngo	I
##sin	I
##e	I
,	O
1	B
##H	I
-	I
Indo	I
##le	I
-	I
3	I
-	I
car	I
##box	I
##ald	I
##eh	I
##yd	I
##e	I
and	O
seven	O
variants	O
of	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
(	O
L	O
##ys	O
##o	O
##PC	O
##s	O
)	O
.	O

The	O
measured	O
values	O
by	O
our	O
CE	O
-	O
MS	O
method	O
for	O
c	B
##rea	I
##tin	I
##ine	I
and	O
u	B
##ric	I
acid	I
were	O
similar	O
to	O
established	O
clinical	O
laboratory	O
ass	O
##ays	O
for	O
these	O
compounds	O
widely	O
used	O
in	O
e	O
##pid	O
##em	O
##iol	O
##og	O
##ic	O
studies	O
.	O

Red	O
##uce	O
##d	O
G	O
##F	O
##R	O
probably	O
explained	O
the	O
lower	O
ex	O
##cre	O
##tion	O
and	O
participated	O
in	O
AD	B
##MA	I
accumulation	O
,	O
here	O
##by	O
confirming	O
its	O
classification	O
as	O
a	O
u	O
##rem	O
##ic	O
retention	O
so	O
##lut	O
##e	O
(	O
,	O
)	O
.	O

SP	S
meta	O
##bol	O
##ites	O
were	O
q	O
##uant	O
##ified	O
using	O
N	O
##MR	O
suite	O
8	O
.	O
1	O
(	O
Chen	O
##om	O
##x	O
Inc	O
.	O
,	O
Edmonton	O
,	O
Canada	O
)	O
using	O
DS	O
##S	O
as	O
internal	O
concentration	O
standard	O
.	O

Also	O
,	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
metabolism	O
had	O
high	O
number	O
of	O
metabolic	O
pathway	O
hits	O
.	O

Branch	O
##ed	O
chain	O
amino	O
acids	O
(	B
v	B
##ali	I
##ne	I
and	O
le	B
##uc	I
##ine	I
)	O
were	O
lower	O
following	O
short	O
-	O
term	O
acute	O
exercise	O
in	O
the	O
control	O
group	O
.	O

al	O
.	O
showed	O
that	O
both	O
el	O
##aid	O
##ic	O
and	O
l	B
##ino	I
##ela	I
##id	I
##ic	I
acid	I
integrated	O
into	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
,	O
mainly	O
at	O
the	O
expense	O
of	O
my	B
##rist	I
##ic	I
,	O
palm	B
##itic	I
,	O
and	O
s	O
##te	O
##ari	O
##c	O
acids	O
,	O
without	O
causing	O
any	O
net	O
gain	O
in	O
total	O
fatty	O
acid	O
levels	O
.	O

Little	O
information	O
is	O
available	O
regarding	O
the	O
metabolic	O
routes	O
of	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
and	O
the	O
specific	O
enzymes	O
involved	O
.	O

They	O
were	O
calculated	O
using	O
step	O
##wise	O
re	O
##gression	O
with	O
inclusion	O
criterion	O
of	O
P	O
<	O
0	O
.	O
10	O
,	O
and	O
the	O
tested	O
co	O
##var	O
##iate	O
##s	O
were	O
age	O
,	O
body	O
mass	O
index	O
,	O
current	O
smoking	O
,	O
and	O
serum	O
c	B
##rea	I
##tin	I
##ine	I
,	O
serum	O
glucose	S
and	O
daily	O
u	O
##rina	O
##ry	O
sodium	O
ex	O
##cre	O
##tion	O
assessed	O
after	O
the	O
first	O
place	O
##bo	O
period	O
.	O

Z	O
##in	O
##c	O
ace	B
##tate	I
(	O
0	O
.	O
5	O
M	O
)	O
was	O
delivered	O
post	O
-	O
column	O
##ar	O
by	O
a	O
Ph	O
##arma	O
##cia	O
P	O
-	O
500	O
(	O
GE	O
Healthcare	O
,	O
Up	O
##ps	O
##ala	O
,	O
Sweden	O
)	O
at	O
a	O
flow	O
rate	O
of	O
10	O
m	O
##L	O
/	O
h	O
.	O

As	O
a	O
consequence	O
,	O
the	O
synthesis	O
of	O
lip	O
##ids	O
downstream	O
of	O
this	O
enzyme	O
such	O
as	O
the	O
e	B
##ico	I
##san	I
##oid	I
precursor	O
##s	O
(	O
a	O
##rac	O
##hi	O
##don	O
##ic	O
acid	O
(	B
C	B
##20	I
:	I
4	I
##n	I
-	I
6	I
)	O
,	O
e	B
##ico	I
##sa	I
##pent	I
##aen	I
##oi	I
##c	I
acid	I
(	B
C	B
##20	I
:	I
5	I
##n	I
-	I
3	I
)	O
and	O
do	B
##cos	I
##ah	I
##ex	I
##aen	I
##oi	I
##c	I
acid	I
(	B
C	B
##22	I
:	I
6	I
##n	I
-	I
3	I
)	O
)	O
exhibited	O
a	O
significant	O
decrease	O
in	O
liver	O
##s	O
of	O
NAS	O
##H	O
compared	O
to	O
controls	O
.	O

1	B
-	I
met	I
##hyl	I
-	I
his	I
##ti	I
##dine	I
(	O
1	O
##M	O
-	O
His	O
)	O
is	O
present	O
in	O
skeletal	O
muscles	O
as	O
a	O
precursor	O
of	O
an	B
##ser	I
##ine	I
(	I
β	I
-	I
al	I
##any	I
##l	I
-	I
N	I
-	I
met	I
##hyl	I
##his	I
##ti	I
##dine	I
)	I
.	O

The	O
differences	O
of	O
base	O
##line	O
plasma	O
meta	O
##bol	O
##omi	O
##cs	O
_	O
1	O
H	O
N	O
##MR	O
profiles	O
between	O
ER	O
(	O
−	O
)	O
and	O
ER	B
(	I
+	I
)	I
patients	O
were	O
analyzed	O
using	O
PC	O
##A	O
-	O
CA	O
-	O
k	O
##N	O
##N	O
(	O
A	O
)	O
.	O

Further	O
,	O
studies	O
showed	O
that	O
se	B
##rot	I
##oni	I
##n	I
via	O
auto	O
##c	O
##rine	O
signaling	O
increases	O
beta	O
-	O
cell	O
function	O
and	O
ß	O
-	O
cell	O
mass	O
during	O
insulin	O
resistant	O
states	O
(	O
e	O
.	O
g	O
.	O
,	O
pregnancy	O
)	O
.	O

All	O
variables	O
in	O
that	O
are	O
not	O
direct	O
measures	O
of	O
glucose	S
metabolism	O
(	B
glucose	S
,	O
insulin	O
,	O
and	O
H	O
##b	O
##A	O
##1	O
##c	O
)	O
plus	O
meta	O
##bol	O
##ites	O
from	O
involved	O
in	O
fat	O
and	O
amino	O
acid	O
metabolism	O
were	O
entered	O
as	O
predict	O
##ors	O
.	O

Other	O
group	O
differences	O
included	O
for	O
T	O
##2	O
##DM	O
increased	O
man	B
##nose	I
,	O
ace	B
##to	I
##ace	I
##tate	I
,	O
g	B
##ly	I
##cer	I
##ol	I
,	O
and	O
c	B
##it	I
##rate	I
and	O
for	O
I	O
##G	O
##T	O
increased	O
p	B
##yr	I
##u	I
##vate	I
and	O
g	B
##ly	I
##cer	I
##ol	I
and	O
decreased	O
g	B
##ly	I
##cine	I
.	O

At	O
first	O
trim	O
##ester	O
,	O
meta	O
##bol	O
##ites	O
related	O
to	O
energy	O
metabolism	O
that	O
were	O
altered	O
included	O
lower	O
levels	O
of	O
alpha	B
-	I
k	I
##eto	I
##g	I
##lut	I
##arate	I
and	O
g	B
##ly	I
##cer	I
##ol	I
-	I
3	I
-	I
phosphate	I
,	O
as	O
well	O
as	O
the	O
medium	O
-	O
chain	O
a	O
##cy	O
##l	O
##car	O
##ni	O
##tine	O
##s	O
’	O
la	O
##uro	O
##yl	O
-	O
car	O
##ni	O
##tine	O
,	O
do	B
##de	I
##ce	I
##noy	I
##l	I
-	I
car	I
##ni	I
##tine	I
,	O
and	O
o	B
##ct	I
##ano	I
##yl	I
-	I
car	I
##ni	I
##tine	I
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Though	O
increased	O
pu	B
##rine	I
and	O
p	B
##yr	I
##im	I
##id	I
##ine	I
synthesis	O
has	O
been	O
linked	O
directly	O
to	O
active	O
one	O
carbon	O
metabolism	O
_	O
,	O
,	O
we	O
still	O
lack	O
a	O
comprehensive	O
understanding	O
of	O
the	O
intermediate	O
metabolism	O
leading	O
to	O
this	O
increase	O
due	O
to	O
multiple	O
obstacles	O
preventing	O
the	O
q	O
##uant	O
##ification	O
of	O
one	O
carbon	O
-	O
bound	O
te	B
##tra	I
##hy	I
##dr	I
##of	I
##olate	I
derivatives	O
(	O
1	O
##C	O
-	O
T	O
##HF	O
##s	O
)	O
.	O

T	O
##HC	O
,	O
11	B
-	I
h	I
##ydro	I
##xy	I
-	I
T	I
##HC	I
(	I
11	I
-	I
OH	I
-	I
T	I
##HC	I
)	I
,	O
11	B
-	I
nor	I
-	I
9	I
-	I
car	I
##box	I
##y	I
-	I
T	I
##HC	I
(	O
T	O
##HC	O
-	O
CO	O
##OH	O
)	O
,	O
and	O
11	B
-	I
nor	I
-	I
9	I
-	I
car	I
##box	I
##y	I
-	I
T	I
##HC	I
g	I
##lu	I
##cu	I
##ron	I
##ide	I
(	O
T	O
##HC	O
-	O
CO	O
##OH	O
g	O
##lu	O
##cu	O
##ron	O
##ide	O
)	O
were	O
q	O
##uant	O
##ified	O
in	O
plasma	O
using	O
liquid	O
ch	O
##roma	O
##tography	O
–	O
tandem	O
mass	O
s	O
##pect	O
##rome	O
##try	O
(	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
)	O
with	O
an	O
A	O
##gi	O
##lent	O
129	O
##0	O
Ultra	O
High	O
Performance	O
Li	O
##quid	O
Ch	O
##roma	O
##to	O
##graph	O
(	O
A	O
##gi	O
##lent	O
,	O
Santa	O
Clara	O
,	O
California	O
)	O
coupled	O
with	O
an	O
AB	O
Sc	O
##ie	O
##x	O
550	O
##0	O
Q	O
##uad	O
##rup	O
##ole	O
Line	O
##ar	O
Ion	O
T	O
##rap	O
Mass	O
S	O
##pect	O
##rome	O
##ter	O
(	O
Q	O
##TR	O
##AP	O
MS	O
;	O
AB	O
Sc	O
##ie	O
##x	O
,	O
Foster	O
City	O
,	O
California	O
)	O
.	O

We	O
extended	O
the	O
analysis	O
to	O
the	O
precursor	O
L	O
-	O
T	O
##rp	O
,	O
and	O
the	O
se	B
##rot	I
##oni	I
##n	I
meta	O
##bol	O
##ite	O
,	O
5	B
-	I
H	I
##IA	I
##A	I
.	O

In	O
addition	O
,	O
the	O
combination	O
of	O
5	B
-	I
di	I
##hy	I
##dr	I
##otes	I
##tos	I
##tero	I
##ne	I
su	I
##lf	I
##ate	I
,	O
se	B
##rine	I
,	O
sperm	B
##ine	I
,	O
and	O
x	B
##ant	I
##hine	I
could	O
be	O
used	O
to	O
distinguish	O
OS	O
##A	O
from	O
SS	O
.	O

Different	O
from	O
the	O
metabolic	O
signature	O
in	O
He	O
##pa	O
##to	O
##C	O
##ell	O
##s	O
medium	O
,	O
S	O
##N	O
-	O
38	O
exposure	O
induced	O
significant	O
accumulation	O
of	O
p	O
##yr	O
##im	O
##id	O
##ine	O
/	O
pu	O
##rine	O
n	O
##uc	O
##leo	O
##side	O
##s	O
and	O
n	O
##uc	O
##leo	O
##base	O
##s	O
(	O
AN	O
##O	O
##VA	O
,	O
F	O
##DR	O
-	O
adjusted	O
P	O
<	O
.	O
05	O
)	O
in	O
cancer	O
cell	O
medium	O
,	O
while	O
having	O
no	O
apparent	O
impact	O
on	O
the	O
levels	O
of	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
or	O
amino	O
acid	O
meta	O
##bol	O
##ites	O
.	O

B	O
##rief	O
##ly	O
,	O
met	B
##han	I
##ol	I
(	O
600	O
µ	O
##l	O
)	O
,	O
ch	O
##lor	O
##of	O
##orm	O
(	O
1	O
,	O
000	O
µ	O
##l	O
)	O
,	O
and	O
ultra	O
##pur	O
##e	O
water	O
(	O
500	O
µ	O
##l	O
)	O
were	O
added	O
se	O
##quential	O
##ly	O
and	O
v	O
##ortex	O
##ed	O
each	O
time	O
.	O

In	O
v	O
##ivo	O
first	O
-	O
phase	O
insulin	O
secret	O
##ion	O
was	O
evaluated	O
during	O
a	O
2	O
-	O
h	O
h	B
##yper	I
##gly	I
##ce	I
##mic	I
c	O
##lamp	O
as	O
previously	O
described	O
.	O

A	O
third	O
set	O
of	O
plasma	O
samples	O
was	O
collected	O
from	O
70	O
healthy	O
subjects	O
for	O
the	O
determination	O
of	O
none	O
##ster	O
##ified	O
lip	O
##ids	O
and	O
lip	O
##id	O
media	O
##tors	O
,	O
including	O
o	B
##xy	I
##lip	I
##ins	I
and	O
end	B
##oc	I
##anna	I
##bio	I
##ni	I
##ds	I
,	O
by	O
targeted	O
G	O
##C	O
-	O
MS	O
and	O
UP	O
##LC	O
-	O
MS	O
/	O
MS	O
.	O

At	O
0	O
.	O
5	O
h	O
,	O
all	O
the	O
samples	O
tested	O
gave	O
similar	O
%	O
blood	O
glucose	S
reduction	O
.	O

The	O
calculated	O
[	B
3	I
-	I
H	I
##B	I
]	I
/	I
[	I
glucose	I
]	I
ratio	O
at	O
7	O
days	O
were	O
significantly	O
different	O
between	O
the	O
improved	O
and	O
non	O
-	O
improved	O
groups	O
(	O
P	O
=	O
4	O
.	O
2	O
##×	O
##10	O
_	O
−	O
##3	O
)	O
.	O

To	O
successfully	O
q	O
##uant	O
##ify	O
the	O
new	O
platform	O
of	O
am	O
##ines	O
,	O
it	O
was	O
first	O
important	O
that	O
the	O
met	B
##hyl	I
##ar	I
##gin	I
##ines	I
,	O
AD	B
##MA	I
,	O
L	B
-	I
N	I
##MM	I
##A	I
and	O
SD	O
##MA	O
could	O
be	O
distinguished	O
and	O
identified	O
individually	O
in	O
human	O
plasma	O
samples	O
.	O

Part	O
##ici	O
##pants	O
resided	O
in	O
a	O
closed	O
research	O
facility	O
during	O
each	O
session	O
which	O
lasted	O
for	O
up	O
to	O
72	O
h	O
after	O
cannabis	S
administration	O
;	O
participants	O
were	O
admitted	O
15	O
–	O
21	O
h	O
before	O
cannabis	S
administration	O
.	O

We	O
also	O
do	O
not	O
have	O
access	O
to	O
localized	O
samples	O
at	O
the	O
level	O
of	O
pulmonary	O
artery	O
as	O
well	O
as	O
co	O
##rona	O
##ry	O
sin	O
##us	O
blood	O
sampling	O
available	O
to	O
identify	O
trans	B
-	I
cardiac	I
gradient	O
of	O
AD	B
##MA	I
.	O

The	O
following	O
meta	O
##bol	O
##ites	O
are	O
identified	O
:	O
1	O
,	O
L	O
_	O
1	O
;	O
2	O
,	O
L	O
_	O
2	O
;	O
3	O
,	O
Is	B
##ole	I
##uc	I
##ine	I
;	O
4	O
,	O
Le	B
##uc	I
##ine	I
;	O
5	O
,	O
Val	B
##ine	I
;	O
6	O
,	O
Un	B
##k	I
_	I
1	I
;	I
7	I
,	I
3	I
-	I
H	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
;	O
8	O
,	O
L	O
_	O
3	O
;	O
9	O
,	O
L	O
_	O
4	O
;	O
10	O
,	O
L	O
_	O
5	O
;	O
11	O
,	O
Lac	B
##tate	I
;	O
12	O
,	O
Alan	B
##ine	I
;	O
13	O
,	O
L	O
_	O
6	O
;	O
14	O
,	O
Ace	B
##tate	I
;	O
15	O
,	O
L	O
_	O
7	O
;	O
16	O
,	O
L	O
_	O
8	O
;	O
17	O
,	O
N	O
##AC	O
;	O
18	O
,	O
Ace	B
##tone	I
;	O
19	O
,	O
Ace	B
##to	I
##ace	I
##tate	I
;	O
20	O
,	O
P	B
##yr	I
##u	I
##vate	I
;	O
21	O
,	O
G	B
##lut	I
##amine	I
;	O
22	O
,	O
C	B
##it	I
##rate	I
;	O
23	O
,	O
Un	O
##k	O
_	O
2	O
;	O
24	O
,	O
C	B
##rea	I
##tine	I
;	O
25	O
,	O
Di	B
##met	I
##hyl	I
su	I
##lf	I
##one	I
;	O
26	O
,	O
Cho	O
##l	O
+	O
GP	O
##C	O
+	O
AP	O
##C	O
;	O
27	O
,	O
G	B
##lu	I
##cos	I
##e	I
;	O
28	O
,	O
Beta	B
##ine	I
;	O
29	O
,	O
Met	B
##han	I
##ol	I
;	O
30	O
,	O
G	B
##ly	I
##cer	I
##ol	I
;	O
31	O
,	O
C	B
##rea	I
##tin	I
##ine	I
;	O
32	O
,	O
L	O
_	O
9	O
;	O
33	O
,	O
Ty	B
##ros	I
##ine	I
;	O
34	O
,	O
π	B
-	I
Met	I
##hyl	I
##his	I
##ti	I
##dine	I
;	O
35	O
,	O
Ph	B
##en	I
##yla	I
##lani	I
##ne	I
;	O
36	O
,	O
Form	B
##ate	I
.	O

F	O
##av	O
##ret	O
##to	O
et	O
al	O
.	O
reported	O
up	O
regulation	O
of	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
try	B
##pt	I
##op	I
##han	I
,	O
and	O
g	B
##lut	I
##ama	I
##te	I
in	O
F	O
##GR	O
f	O
##etus	O
##es	O
,	O
while	O
I	O
##vor	O
##ra	O
et	O
al	O
.	O
reported	O
significant	O
differences	O
cord	O
blood	O
concentrations	O
of	O
five	O
amino	B
##ac	I
##ids	I
in	O
F	O
##GR	O
f	O
##etus	O
##es	O
(	B
pro	B
##line	I
,	O
g	B
##lut	I
##amine	I
and	O
al	B
##ani	I
##ne	I
were	O
reduced	O
,	O
while	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
and	O
c	B
##it	I
##ru	I
##llin	I
##e	I
were	O
increased	O
)	O
.	O

Album	O
##in	O
concentration	O
and	O
total	O
ch	B
##olin	I
##e	I
were	O
lower	O
in	O
PC	O
##OS	O
women	O
compared	O
with	O
the	O
controls	O
.	O

Only	O
2	O
of	O
these	O
candidates	O
contained	O
predicted	O
album	O
##in	O
domains	O
and	O
one	O
was	O
further	O
identified	O
as	O
a	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##lino	I
##si	I
##to	I
##l	I
4	I
-	I
phosphate	I
5	O
-	O
kinase	O
type	O
-	O
1	O
protein	O
.	O

The	O
meta	O
##bol	O
##omi	O
##c	O
profile	O
in	O
RA	O
patients	O
compared	O
to	O
healthy	O
controls	O
showed	O
an	O
increase	O
in	O
certain	O
bio	O
##mark	O
##ers	O
(	B
3	B
-	I
p	I
##hos	I
##ph	I
##o	I
-	I
g	I
##ly	I
##cer	I
##ic	I
acid	I
,	O
d	O
-	O
rib	O
##of	O
##ura	O
##nose	O
and	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
)	O
and	O
a	O
decrease	O
in	O
others	O
(	B
his	B
##ti	I
##dine	I
,	O
th	B
##re	I
##onic	I
acid	I
,	O
th	B
##re	I
##oni	I
##ne	I
,	O
met	B
##hi	I
##oni	I
##ne	I
,	O
ch	B
##ole	I
##ster	I
##ol	I
and	O
as	O
##par	O
##agi	O
##ne	O
)	O
.	O

B	O
##rief	O
##ly	O
,	O
[	O
_	O
13	O
C	O
_	O
6	O
]	O
a	B
##rg	I
##ini	I
##ne	I
(	O
10	O
μ	O
##M	O
final	O
)	O
was	O
initially	O
added	O
to	O
plasma	O
as	O
internal	O
standard	O
and	O
proteins	O
then	O
pre	O
##ci	O
##pit	O
##ated	O
by	O
addition	O
of	O
4	O
volumes	O
of	O
met	B
##han	I
##ol	I
.	O

G	O
##ly	O
##OH	O
##3	O
##P	O
g	B
##ly	I
##cer	I
##ol	I
-	I
3	I
-	I
phosphate	I
,	O
all	O
other	O
abbreviation	O
##s	O
and	O
numbering	O
were	O
the	O
same	O
as	O
in	O
The	O
HC	O
##CH	O
-	O
TO	O
##CS	O
##Y	O
experiment	O
also	O
reduces	O
spectral	O
crowd	O
##ing	O
by	O
selecting	O
only	O
those	O
is	O
##oto	O
##po	O
##mers	O
that	O
contains	O
at	O
least	O
two	O
con	O
##ti	O
##guous	O
_	O
13	O
C	O
in	O
the	O
same	O
molecule	O
.	O

However	O
,	O
we	O
did	O
find	O
a	O
significant	O
inverse	O
relationship	O
between	O
k	B
##yn	I
##uren	I
##ic	I
acid	I
and	O
sleep	O
efficiency	O
.	O

C	B
##rea	I
##tin	I
##ine	I
was	O
q	O
##uant	O
##ified	O
in	O
24	O
-	O
h	O
urine	O
specimens	O
using	O
a	O
photo	O
##metric	O
ass	O
##ay	O
based	O
on	O
the	O
J	O
##af	O
##f	O
##é	O
reaction	O
(	O
Det	O
##ec	O
##t	O
##X	O
_	O
®	O
U	O
##rina	O
##ry	O
C	B
##rea	I
##tin	I
##ine	I
Det	O
##ec	O
##tion	O
Kit	O
;	O
Arbor	O
As	O
##say	O
##s	O
,	O
Ann	O
Arbor	O
,	O
MI	O
,	O
USA	O
)	O
.	O

[	O
11	O
.	O
1	O
mm	O
##om	O
/	O
L	O
]	O
during	O
oral	O
glucose	S
tolerance	O
testing	O
)	O
;	O
or	O
(	O
3	O
)	O
use	O
if	O
insulin	O
or	O
an	O
oral	O
h	B
##y	I
##po	I
##gly	I
##ce	I
##mic	I
agent	O
.	O

Each	O
compound	O
was	O
independently	O
weighed	O
and	O
the	O
corresponding	O
powder	O
dissolved	O
in	O
the	O
required	O
volume	O
of	O
D	B
##MS	I
##O	I
to	O
give	O
a	O
1	O
mg	O
/	O
m	O
##L	O
stock	O
solution	O
of	O
the	O
compound	O
that	O
was	O
son	O
##ica	O
##ted	O
for	O
5	O
minutes	O
.	O

Lac	O
:	O
la	B
##ct	I
##ate	I
;	O
G	O
##ly	O
:	O
g	B
##ly	I
##cine	I
;	O
Tau	O
:	O
ta	B
##uri	I
##ne	I
;	O
Cho	O
:	O
ch	B
##olin	I
##e	I
;	O
Su	O
##c	O
:	O
su	B
##cci	I
##nate	I
;	O
P	O
##yr	O
:	O
p	B
##yr	I
##u	I
##vate	I
;	O
Ace	O
:	O
ace	B
##tate	I
;	O
2	O
##H	O
##i	O
##B	O
:	O
2	B
-	I
h	I
##ydro	I
##xy	I
##is	I
##ob	I
##ut	I
##yra	I
##te	I
.	O

Non	O
-	O
para	O
##metric	O
statistics	O
were	O
used	O
to	O
compare	O
case	O
and	O
control	O
groups	O
with	O
respect	O
to	O
u	O
##rina	O
##ry	O
est	B
##rogen	I
meta	O
##bol	O
##ite	O
concentrations	O
.	O

Vita	O
##min	O
B	O
-	O
12	O
is	O
required	O
for	O
the	O
mitochondrial	O
-	O
mediated	O
conversion	O
of	O
met	B
##hyl	I
##mal	I
##ony	I
##l	I
-	I
Co	I
##A	I
to	O
su	B
##cci	I
##ny	I
##l	I
-	I
Co	I
##A	I
.	O

As	O
recently	O
suggested	O
by	O
Mei	O
##ser	O
and	O
V	O
##az	O
##quez	O
,	O
the	O
increase	O
in	O
format	B
##e	I
may	O
relate	O
to	O
its	O
role	O
in	O
one	O
-	O
carbon	O
metabolism	O
.	O

Down	O
regulation	O
of	O
glucose	S
and	O
c	B
##it	I
##rate	I
(	O
in	O
MS	O
)	O
as	O
well	O
as	O
up	O
##re	O
##gu	O
##lation	O
of	O
la	B
##ct	I
##ate	I
(	O
in	O
N	O
##MO	O
##SD	O
)	O
may	O
support	O
disruption	O
of	O
T	O
##CA	O
cycle	O
through	O
p	B
##yr	I
##u	I
##vate	I
pathway	O
.	O

The	O
cells	O
were	O
maintained	O
at	O
37	O
°C	O
in	O
a	O
humid	O
##ified	O
atmosphere	O
with	O
5	O
%	O
CO	O
_	O
2	O
on	O
R	O
##PM	O
##I	O
-	O
1640	O
media	O
,	O
supplemented	O
with	O
100	O
U	O
m	O
##L	O
-	O
1	O
of	O
pen	B
##ici	I
##llin	I
,	O
100	O
μ	O
##g	O
m	O
##L	O
-	O
1	O
of	O
s	B
##tre	I
##pt	I
##omy	I
##cin	I
,	O
10	O
%	O
heat	O
inactivated	O
f	O
##etal	O
b	O
##ov	O
##ine	O
serum	O
and	O
2	O
m	O
##M	O
L	B
-	I
g	I
##lut	I
##amine	I
(	O
all	O
culture	O
re	O
##age	O
##nts	O
from	O
Cell	O
##gro	O
,	O
Media	O
##T	O
##ech	O
,	O
Her	O
##ndon	O
,	O
VA	O
)	O
.	O

The	O
32	O
progress	O
##ors	O
had	O
significantly	O
higher	O
relative	O
abundance	O
of	O
p	O
##oly	O
##uns	O
##at	O
##ura	O
##ted	O
t	B
##ria	I
##cy	I
##l	I
##gly	I
##cer	I
##ols	I
(	O
T	O
##AG	O
##s	O
)	O
and	O
a	O
lower	O
abundance	O
of	O
C	O
##16	O
–	O
C	O
##20	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
(	O
AC	O
##s	O
)	O
(	O
P	O
<	O
0	O
.	O
00	O
##1	O
)	O
.	O

This	O
agrees	O
with	O
our	O
previous	O
study	O
where	O
u	O
##rina	O
##ry	O
c	B
##it	I
##rate	I
decreased	O
in	O
RC	O
##C	O
relative	O
to	O
ben	O
##ign	O
controls	O
and	O
down	O
##re	O
##gu	O
##lation	O
of	O
c	B
##it	I
##rate	I
in	O
ch	O
##rom	O
##op	O
##ho	O
##bes	O
may	O
co	O
##rro	O
##bor	O
##ate	O
the	O
prevalence	O
of	O
the	O
RC	O
##C	O
metabolic	O
hall	O
##mark	O
(	O
i	O
.	O
e	O
.	O
,	O
War	O
##burg	O
effect	O
)	O
,	O
partly	O
evidenced	O
by	O
reduced	O
T	O
##CA	O
-	O
cycle	O
intermediate	O
##s	O
.	O

In	O
particular	O
,	O
as	O
suggested	O
by	O
our	O
initial	O
data	O
,	O
we	O
observed	O
that	O
meta	O
##bol	O
##ites	O
mapping	O
to	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
pathways	O
are	O
altered	O
in	O
plasma	O
samples	O
of	O
AM	O
##D	O
subjects	O
,	O
with	O
differences	O
across	O
severity	O
stages	O
of	O
the	O
disease	O
.	O

Not	O
##ably	O
,	O
medium	O
-	O
chain	O
c	O
##era	O
##mi	O
##des	O
(	O
C	O
##18	O
:	O
0	O
,	O
C	O
##20	O
:	O
0	O
,	O
and	O
C	B
##22	I
:	I
0	I
)	I
correlated	O
more	O
positively	O
with	O
B	O
##MI	O
,	O
H	O
##OM	O
##A	O
-	O
I	O
##R	O
,	O
and	O
diabetes	O
incidence	O
than	O
other	O
c	B
##era	I
##mi	I
##des	I
,	O
regardless	O
of	O
the	O
nature	O
of	O
the	O
s	B
##phi	I
##ngo	I
##id	I
backbone	O
.	O

Ace	B
##tate	I
,	O
a	O
source	O
for	O
lip	O
##id	O
and	O
my	B
##elin	I
synthesis	O
[	O
]	O
,	O
is	O
derived	O
from	O
ace	B
##ty	I
##l	I
-	I
Co	I
##A	I
via	O
the	O
de	O
##ace	O
##ty	O
##lation	O
of	O
N	B
-	I
ace	I
##ty	I
##lasp	I
##art	I
##ate	I
.	O

The	O
decreasing	O
levels	O
of	O
four	O
PC	O
a	O
##a	O
’	O
s	O
and	O
increasing	O
levels	O
of	O
eight	O
l	O
##ys	O
##o	O
##PC	O
##s	O
during	O
storage	O
at	O
R	O
##T	O
could	O
be	O
explained	O
by	O
the	O
h	O
##ydro	O
##lysis	O
of	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
to	O
yield	O
a	O
l	B
##ys	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
and	O
free	O
fatty	O
acid	O
,	O
cat	O
##aly	O
##zed	O
by	O
a	O
p	O
##hos	O
##ph	O
##oli	O
##pas	O
##e	O
.	O

For	O
example	O
,	O
t	B
##yr	I
##os	I
##ine	I
was	O
reported	O
to	O
decrease	O
in	O
the	O
blood	O
of	O
different	O
kinds	O
of	O
cancer	O
including	O
breast	O
cancer	O
.	O

Cell	O
line	O
PC	O
179	O
1A	O
also	O
showed	O
a	O
50	O
%	O
lower	O
level	O
of	O
ma	O
##lic	O
enzyme	O
(	O
as	O
later	O
shown	O
in	O
)	O
that	O
,	O
in	O
addition	O
to	O
the	O
extremely	O
low	O
levels	O
of	O
the	O
substrates	O
ma	B
##late	I
and	O
c	B
##it	I
##rate	I
could	O
contribute	O
to	O
decreased	O
p	O
##yr	O
##u	O
##vate	O
cycling	O
.	O

A	O
significant	O
increase	O
in	O
car	B
##ni	I
##tine	I
and	O
significant	O
reduction	O
##s	O
in	O
c	B
##rea	I
##tin	I
##ine	I
and	O
hip	B
##pura	I
##te	I
were	O
observed	O
in	O
the	O
HC	O
##C	O
group	O
compared	O
to	O
the	O
C	O
##IR	O
group	O
(	O
Figure	O
)	O
.	O

Sol	O
##vent	O
A	O
was	O
prepared	O
by	O
mixing	O
99	O
m	O
##L	O
of	O
Mill	O
##i	O
-	O
Q	O
(	O
Mill	O
##ip	O
##ore	O
)	O
water	O
and	O
1	O
m	O
##L	O
of	O
1	O
m	O
##ol	O
L	O
_	O
−	O
##1	O
am	B
##mon	I
##ium	I
bi	O
##car	O
##bon	O
##ate	O
and	O
was	O
adjusted	O
to	O
a	O
pH	O
of	O
9	O
.	O
2	O
with	O
25	O
%	O
am	B
##mon	I
##ium	I
h	I
##ydro	I
##xi	I
##de	I
(	O
approximately	O
0	O
.	O
1	O
m	O
##L	O
)	O
.	O

Ch	B
##lor	I
##of	I
##orm	I
(	O
600	O
µ	O
##l	O
)	O
was	O
added	O
,	O
v	O
##ortex	O
##ed	O
,	O
and	O
cent	O
##ri	O
##fu	O
##ged	O
at	O
3	O
,	O
000	O
rpm	O
for	O
25	O
min	O
.	O

Con	O
##cent	O
##rations	O
of	O
co	B
##tin	I
##ine	I
and	O
trans	B
-	I
3	I
′	I
-	I
h	I
##ydro	I
##xy	I
##cot	I
##ini	I
##ne	I
in	O
urine	O
were	O
determined	O
using	O
liquid	O
ch	O
##roma	O
##tography	O
–	O
tandem	O
mass	O
s	O
##pect	O
##rome	O
##try	O
(	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
)	O
.	O

St	O
##ability	O
of	O
B	O
##EN	O
(	O
a	O
)	O
and	O
BA	O
(	O
b	O
)	O
in	O
plasma	O
at	O
room	O
temperature	O
(	O
open	O
circle	O
)	O
,	O
4	O
°C	O
(	O
filled	O
square	O
)	O
and	O
at	O
room	O
temperature	O
with	O
5	O
%	O
(	O
v	O
/	O
v	O
)	O
2	O
M	O
sulfur	B
##ic	I
acid	I
(	O
open	O
triangle	O
)	O

In	O
addition	O
,	O
L	B
-	I
th	I
##re	I
##onic	I
acid	I
(	O
(	O
2	O
##R	O
,	O
3	O
##S	O
)	O
-	O
2	O
,	O
3	O
,	O
4	O
-	O
t	O
##ri	O
##hy	O
##dr	O
##ox	O
##y	O
##but	O
##ano	O
##ic	O
acid	O
)	O
is	O
also	O
an	O
o	O
##xi	O
##da	O
##tive	O
meta	O
##bol	O
##ite	O
of	O
as	B
##cor	I
##bic	I
acid	I
formed	O
via	O
de	B
##hy	I
##dr	I
##oa	I
##sco	I
##rb	I
##ic	I
acid	I
(	O
D	O
##HA	O
)	O

Path	O
##way	O
analysis	O
can	O
assess	O
the	O
involvement	O
of	O
certain	O
metabolic	O
pathways	O
,	O
such	O
as	O
t	B
##yr	I
##os	I
##ine	I
and	O
u	B
##rea	I
metabolism	O
,	O
and	O
can	O
provide	O
further	O
insight	O
into	O
the	O
path	O
##op	O
##hy	O
##sio	O
##logy	O
of	O
AM	O
##D	O
.	O

The	O
other	O
19	O
compounds	O
could	O
not	O
be	O
assigned	O
the	O
charge	O
number	O
by	O
the	O
Q	O
##TO	O
##F	O
data	O
analysis	O
software	O
,	O
which	O
may	O
be	O
attributed	O
to	O
the	O
low	O
abundance	O
of	O
those	O
th	B
##iol	I
##s	I
and	O
the	O
ion	O
suppression	O
effect	O
of	O
matrix	O
interference	O
.	O

The	O
solvent	O
##s	O
were	O
the	O
rate	O
of	O
ch	O
##lor	O
##of	O
##orm	O
/	O
met	O
##han	O
##ol	O
/	O
300	O
##m	O
##M	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
in	O
water	O
(	O
μ	O
##L	O
)	O
was	O
360	O
/	O
84	O
##0	O
/	O
44	O
.	O

The	O
defined	O
integration	O
regions	O
aim	O
to	O
capture	O
the	O
following	O
broad	O
lip	O
##id	O
resonance	O
##s	O
:	O
CH	O
_	O
3	O
–	O
(	O
CH	O
_	O
2	O
)	O
_	O
n	O
–	O
in	O
the	O
fatty	O
acid	O
chain	O
(	O
FA	O
##C	O
)	O
,	O
–	O
CH	O
_	O
3	O
–	O
(	O
CH	O
_	O
2	O
)	O
_	O
n	O
–	O
in	O
the	O
FA	O
##C	O
(	O
captured	O
using	O
two	O
integration	O
regions	O
in	O
the	O
900	O
MHz	O
analysis	O
)	O
,	O
–	O
CH	O
_	O
2	O
–	O
CH	O
_	O
2	O
–	O
C	O
=	O
O	O
or	O
–	O
CH	O
_	O
2	O
–	O
CH	O
_	O
2	O
–	O
CH	O
=	O
CH	O
–	O
in	O
the	O
FA	O
##C	O
,	O
–	O
CH	O
_	O
2	O
–	O
CH	O
=	O
CH	O
–	O
in	O
the	O
FA	O
##C	O
and	O
CH	O
_	O
3	O
in	O
N	B
-	I
ace	I
##ty	I
##lated	I
g	I
##ly	I
##co	I
##p	I
##rote	I
##ins	I
(	O
N	O
##AG	O
)	O
,	O
–	O
CH	O
_	O
2	O
–	O
C	O
=	O
O	O
or	O
–	O
CH	O
_	O
2	O
–	O
CH	O
=	O
CH	O
–	O
in	O
FA	O
##C	O
,	O
=	O
CH	O
–	O
CH	O
_	O
2	O
–	O
CH	O
=	O
in	O
FA	O
##C	O
,	O
l	O
##ys	O
##yl	O
,	O
and	O
–	O
CH	O
=	O
CH	O
–	O
in	O
FA	O
##C	O
.	O

S	B
##phi	I
##ngo	I
##lip	I
##ids	I
are	O
a	O
family	O
of	O
lip	O
##id	O
second	O
messenger	O
##s	O
that	O
regulate	O
various	O
vascular	O
cell	O
functions	O
.	O

Total	O
vitamin	B
B	I
##6	I
level	O
was	O
calculated	O
as	O
the	O
sum	O
of	O
P	O
##L	O
and	O
P	O
##LP	O
.	O

Furthermore	O
,	O
these	O
cells	O
exhibited	O
a	O
greater	O
sensitivity	O
to	O
the	O
in	O
##hibition	O
of	O
se	B
##rine	I
synthesis	O
and	O
DNA	O
met	O
##hyl	O
##ation	O
indicating	O
a	O
role	O
for	O
activated	B
se	I
##rine	I
metabolism	O
in	O
supplying	O
SA	O
##M	O
for	O
DNA	O
met	O
##hyl	O
##ation	O
and	O
revealing	O
a	O
therapeutic	O
vulnerability	O
in	O
pan	O
##cre	O
##atic	O
cancer	O
.	O

1	B
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
is	O
known	O
to	O
potent	O
##ly	O
induce	O
C	O
##YP	O
##24	O
##A	O
##1	O
,	O
probably	O
to	O
prevent	O
1	B
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
toxicity	O
.	O

After	O
adjustment	O
of	O
the	O
all	O
the	O
other	O
meta	O
##bol	O
##ites	O
for	O
risk	O
factors	O
for	O
car	O
##ot	O
##id	O
s	O
##ten	O
##osis	O
(	O
diabetes	O
me	O
##lli	O
##tus	O
,	O
h	O
##yper	O
##tens	O
##ion	O
,	O
smoking	O
,	O
and	O
HD	B
##L	I
ch	I
##ole	I
##ster	I
##ol	I
)	O
,	O
in	B
##do	I
##le	I
(	O
OR	O
.	O
87	O
;	O
95	O
%	O
C	O
##I	O
.	O
77	O
–	O
.	O
98	O
;	O
P	O
=	O
.	O
03	O
)	O
and	O
t	O
##rp	O
(	O
OR	O
<	O
.	O
00	O
##1	O
;	O
95	O
%	O
C	O
##I	O
<	O
.	O
00	O
##1	O
;	O
P	O
=	O
.	O
00	O
##1	O
)	O
remained	O
significantly	O
negatively	O
associated	O
with	O
car	O
##ot	O
##id	O
s	O
##ten	O
##osis	O
and	O
the	O
k	O
##yn	O
/	O
t	O
##rp	O
ratio	O
(	O
OR	O
99	O
;	O
95	O
%	O
C	O
##I	O
1	O
.	O
5	O
–	O
>	O
99	O
##9	O
;	O
P	O
=	O
.	O
03	O
)	O
remained	O
significantly	O
positively	O
associated	O
with	O
car	O
##ot	O
##id	O
s	O
##ten	O
##osis	O
.	O

These	O
included	O
conventional	O
clinical	O
meta	O
##bol	O
##ites	O
(	O
e	O
##g	O
,	O
c	O
##rea	O
##tin	O
##ine	O
)	O
,	O
amino	O
acids	O
and	O
their	O
by	O
‐	O
products	O
(	O
e	O
##g	O
,	O
le	B
##uc	I
##ine	I
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
g	B
##lut	I
##amine	I
[	O
inverse	O
##ly	O
associated	O
]	O
,	O
v	B
##ali	I
##ne	I
,	O
and	O
pro	B
##line	I
)	O
,	O
ace	B
##ty	I
##l	I
##gly	I
##co	I
##p	I
##rote	I
##ins	I
and	O
man	B
##nose	I
,	O
intermediate	O
##s	O
of	O
glucose	S
and	O
he	O
##pa	O
##tic	O
metabolism	O
(	O
e	O
##g	O
,	O
g	B
##ly	I
##cer	I
##ol	I
,	O
glucose	S
,	O
and	O
ch	B
##olin	I
##e	I
)	O
,	O
organic	O
acids	O
(	O
e	O
##g	O
,	O
la	B
##ct	I
##ate	I
)	O
,	O
sub	O
##c	O
##lass	O
##es	O
of	O
very	O
‐	O
low	O
‐	O
density	O
,	O
low	O
‐	O
density	O
,	O
intermediate	O
‐	O
density	O
,	O
and	O
high	O
‐	O
density	O
a	O
##poli	O
##pop	O
##rote	O
##ins	O
,	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
,	O
and	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
.	O

Character	O
##ization	O
of	O
u	O
##rina	O
##ry	O
meta	O
##bol	O
##ites	O
of	O
fur	B
##an	I
will	O
lead	O
to	O
the	O
development	O
of	O
bio	O
##mark	O
##ers	O
to	O
assess	O
human	O
health	O
risks	O
associated	O
with	O
fur	B
##an	I
exposure	O
.	O

The	O
highest	O
para	B
##ben	I
concentrations	O
in	O
children	O
urine	O
were	O
reported	O
in	O
four	O
-	O
year	O
-	O
old	O
Spanish	O
boys	O
.	O

Moreover	O
,	O
there	O
are	O
evidence	O
##s	O
confirming	O
that	O
elevated	O
insulin	O
levels	O
induced	O
by	O
in	O
##fusion	O
in	O
healthy	O
men	O
promote	O
muscle	O
protein	O
an	O
##ab	O
##olis	O
##m	O
by	O
in	O
##hibit	O
##ing	O
protein	O
breakdown	O
and	O
el	O
##icit	O
the	O
ability	O
to	O
stimulate	O
glucose	S
up	O
##take	O
and	O
al	B
##ani	I
##ne	I
transport	O
,	O
thus	O
suppress	O
##ing	O
protein	O
degradation	O
in	O
skeletal	O
muscle	O
.	O

G	B
##lut	I
##ath	I
##ione	I
is	O
the	O
most	O
abundant	O
low	O
-	O
molecular	O
-	O
weight	O
p	O
##eptide	O
present	O
in	O
e	O
##uka	O
##ryo	O
##tic	O
cells	O
.	O

However	O
,	O
this	O
increased	O
level	O
may	O
be	O
also	O
associated	O
–	O
to	O
some	O
extent	O
–	O
with	O
o	O
##xi	O
##da	O
##tive	O
stress	O
as	O
all	O
c	B
##rea	I
##tine	I
kinase	O
is	O
##oe	O
##nz	O
##yme	O
##s	O
are	O
extremely	O
susceptible	O
to	O
o	O
##xi	O
##da	O
##tive	O
damage	O
.	O

The	O
ass	O
##ay	O
value	O
for	O
matrix	O
effect	O
on	O
the	O
IS	O
was	O
93	O
.	O
51	O
±	O
6	O
.	O
67	O
for	O
plasma	O
with	O
high	O
t	B
##rig	I
##ly	I
##cer	I
##ide	I
levels	O
.	O

For	O
the	O
external	O
valid	O
##ation	O
du	O
##plicate	O
sets	O
of	O
blinded	O
Q	O
##Cs	O
at	O
the	O
three	O
concentration	O
levels	O
were	O
exchanged	O
with	O
the	O
University	O
of	O
Pittsburgh	O
Department	O
of	O
Ph	O
##arma	O
##ce	O
##utical	O
Sciences	O
where	O
an	O
a	B
##bir	I
##ater	I
##one	I
ass	O
##ay	O
is	O
in	O
use	O
.	O

We	O
present	O
evidence	O
that	O
end	O
##ogen	O
##ous	O
very	O
-	O
long	O
-	O
chain	O
di	B
##car	I
##box	I
##yl	I
##ic	I
acids	I
(	O
V	O
##LC	O
##DC	O
##A	O
)	O
are	O
anti	O
-	O
inflammatory	O
lip	O
##ids	O
that	O
possess	O
ch	O
##em	O
##op	O
##re	O
##vent	O
##ative	O
properties	O
.	O

The	O
dried	O
extract	O
was	O
then	O
re	O
##con	O
##stituted	O
in	O
50	O
μ	O
##L	O
of	O
met	B
##han	I
##ol	I
.	O

Further	O
multiple	O
log	O
##istic	O
re	O
##gression	O
analysis	O
(	O
after	O
adjusting	O
for	O
age	O
,	O
gender	O
,	O
and	O
B	O
##MI	O
)	O
revealed	O
that	O
both	O
put	B
##res	I
##cine	I
and	O
sperm	B
##ine	I
levels	O
were	O
associated	O
with	O
a	O
higher	O
risk	O
of	O
T	O
##2	O
##D	O
.	O
Association	O
between	O
put	B
##res	I
##cine	I
and	O
T	O
##2	O
##D	O
were	O
still	O
found	O
when	O
fast	O
##ing	O
insulin	O
was	O
included	O
in	O
the	O
model	O
(	O
Su	O
##pp	O
##lement	O
##ary	O
Table	O
S	O
##1	O
)	O
.	O

The	O
same	O
was	O
true	O
for	O
the	O
assignment	O
of	O
5	O
′	O
ATP	O
,	O
g	B
##ly	I
##cer	I
##ol	I
-	I
3	I
-	I
phosphate	I
,	O
and	O
f	B
##ru	I
##ct	I
##ose	I
-	I
6	I
-	I
phosphate	I
(	O
F	O
##6	O
##P	O
)	O
.	O

Similarly	O
,	O
a	O
reduction	O
in	O
ace	B
##ty	I
##l	I
-	I
Co	I
##A	I
concentration	O
may	O
lower	O
k	O
##eto	O
##genesis	O
and	O
B	O
##H	O
##BA	O
levels	O
.	O

Several	O
lip	O
##ases	O
promote	O
the	O
release	O
of	O
NE	O
##FA	O
from	O
complex	O
lip	O
##ids	O
,	O
mainly	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
.	O

The	O
formal	B
##in	I
fix	O
##ation	O
and	O
para	O
##ffin	O
-	O
em	O
##bed	O
##ding	O
is	O
a	O
multi	O
##ste	O
##p	O
procedure	O
.	O

Inc	O
##reased	O
plasma	O
levels	O
of	O
T	B
##MA	I
##O	I
have	O
just	O
recently	O
been	O
described	O
as	O
a	O
marker	O
for	O
at	O
##rial	O
fi	O
##bri	O
##lla	O
##tion	O
independent	O
of	O
h	O
##yper	O
##tens	O
##ion	O
,	O
B	O
##MI	O
,	O
smoking	O
,	O
diabetes	O
,	O
or	O
intake	O
of	O
total	O
ch	B
##olin	I
##e	I
,	O
and	O
have	O
been	O
associated	O
with	O
a	O
higher	O
incidence	O
of	O
major	O
adverse	O
card	O
##iovascular	O
events	O
(	O
death	O
,	O
my	O
##oc	O
##ard	O
##ial	O
in	O
##far	O
##ction	O
,	O
or	O
stroke	O
)	O
.	O

Each	O
of	O
these	O
resonance	O
##s	O
corresponds	O
to	O
either	O
the	O
γ	O
-	O
or	O
β	O
-	O
pro	O
##ton	O
’	O
s	O
shared	O
magnet	O
##ization	O
with	O
the	O
α	O
-	O
pro	O
##ton	O
and	O
together	O
constitute	O
a	O
spectral	O
feature	O
that	O
is	O
se	O
##par	O
##able	O
from	O
the	O
resonance	O
of	O
my	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
(	O
my	O
##o	O
-	O
I	O
)	O
on	O
account	O
of	O
relative	O
chemical	O
shifts	O
.	O

Boston	O
subjects	O
differed	O
slightly	O
in	O
terms	O
of	O
the	O
low	O
-	O
M	O
_	O
w	O
domain	O
(	O
,	O
)	O
,	O
exhibiting	O
higher	O
levels	O
of	O
g	B
##lut	I
##amine	I
in	O
early	O
AM	O
##D	O
and	O
lower	O
levels	O
for	O
intermediate	O
AM	O
##D	O
;	O
low	O
his	B
##ti	I
##dine	I
levels	O
in	O
intermediate	O
and	O
late	O
AM	O
##D	O
(	O
similarly	O
to	O
the	O
Co	O
##im	O
##bra	O
co	O
##hor	O
##t	O
)	O
;	O
and	O
low	O
al	B
##ani	I
##ne	I
levels	O
in	O
late	O
AM	O
##D	O
.	O

The	O
un	O
##ad	O
##ju	O
##sted	O
OR	O
of	O
su	B
##cci	I
##nate	I
for	O
CE	O
stroke	O
was	O
1	O
.	O
71	O
(	O
95	O
%	O
C	O
##I	O
1	O
.	O
36	O
–	O
2	O
.	O
15	O
,	O
p	O
<	O
0	O
.	O
00	O
##1	O
)	O
and	O
1	O
.	O
71	O
(	O
95	O
%	O
C	O
##I	O
1	O
.	O
12	O
–	O
1	O
.	O
99	O
,	O
p	O
=	O
0	O
.	O
00	O
##8	O
)	O
after	O
adjusting	O
for	O
the	O
T	O
##CA	O
cycle	O
meta	O
##bol	O
##ites	O
α	B
-	I
k	I
##eto	I
##g	I
##lut	I
##arate	I
and	O
ma	B
##late	I
.	O

O	B
##xy	I
##lip	I
##ins	I
refer	O
to	O
a	O
large	O
family	O
of	O
signaling	O
lip	O
##ids	O
notably	O
involved	O
in	O
the	O
regulation	O
of	O
inflammation	O
.	O

End	B
##ox	I
##ife	I
##n	I
and	O
N	B
##D	I
-	I
ta	I
##mo	I
##xi	I
##fen	I
,	O
were	O
obtained	O
from	O
Toronto	O
Research	O
Chemical	O
##s	O
,	O
Ontario	O
,	O
Canada	O
.	O

The	O
u	O
##rina	O
##ry	O
is	B
##of	I
##lav	I
##one	I
data	O
for	O
S	O
-	O
(	O
−	O
)	O
e	O
##q	O
##uo	O
##l	O
were	O
expressed	O
as	O
log	O
_	O
10	O
S	O
-	O
(	O
−	O
)	O
e	O
##q	O
##uo	O
##l	O
/	O
da	O
##id	O
##ze	O
##in	O
ratio	O
,	O
and	O
a	O
cut	O
-	O
off	O
at	O
−	O
##1	O
.	O
60	O
represented	O
a	O
separation	O
between	O
the	O
two	O
groups	O
.	O

MS	O
/	O
MS	O
s	O
##pect	O
##ra	O
of	O
the	O
earlier	O
el	O
##uti	O
##ng	O
is	O
##omer	O
of	O
PC	B
(	I
40	I
:	I
6	I
)	I
implied	O
contribution	O
of	O
two	O
species	O
(	B
PC	B
(	I
18	I
:	I
1	I
/	I
22	I
:	I
5	I
)	I
and	O
PC	B
(	I
20	I
:	I
2	I
/	I
20	I
:	I
4	I
)	I
)	O
to	O
a	O
single	O
ch	O
##roma	O
##to	O
##graphic	O
peak	O
.	O

Accordingly	O
,	O
the	O
complex	O
inter	O
##play	O
of	O
end	O
##ogen	O
##ous	O
primary	O
and	O
bacterial	O
meta	O
##bol	O
##ized	O
secondary	O
bi	O
##le	O
acids	O
can	O
affect	O
the	O
retention	O
and	O
metabolism	O
of	O
plasma	O
ch	B
##ole	I
##ster	I
##ol	I
.	O

However	O
,	O
the	O
g	B
##ly	I
##ce	I
##mic	I
control	O
months	O
after	O
surgery	O
within	O
and	O
across	O
studies	O
seems	O
variable	O
,	O
and	O
the	O
indicators	O
for	O
the	O
early	O
decision	O
of	O
the	O
improvement	O
are	O
not	O
currently	O
available	O
.	O

Both	O
an	O
##omer	O
##s	O
(	O
α	O
and	O
β	O
)	O
for	O
glucose	S
as	O
well	O
as	O
man	B
##nose	I
were	O
distinctly	O
identified	O
.	O

Considering	O
the	O
different	O
h	O
##UC	O
##B	O
##P	O
analyzed	O
(	O
,	O
,	O
and	O
)	O
and	O
comparing	O
with	O
the	O
results	O
obtained	O
with	O
C	O
##M	O
(	O
,	O
-	O
)	O
only	O
differences	O
in	O
the	O
lip	O
##ids	O
,	O
β	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
(	I
β	I
-	I
H	I
##B	I
)	I
,	O
and	O
in	B
##os	I
##ito	I
##l	I
content	O
are	O
significant	O
.	O

In	O
addition	O
to	O
informing	O
path	O
##op	O
##hy	O
##sio	O
##logy	O
,	O
better	O
understanding	O
of	O
the	O
effects	O
of	O
low	O
24	B
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
concentration	O
may	O
eventually	O
help	O
guide	O
vitamin	O
D	O
–	O
related	O
interventions	O
in	O
C	O
##K	O
##D	O
.	O

(	O
A	O
)	O
Score	O
##s	O
plot	O
for	O
PC	O
##A	O
model	O
(	O
blue	O
triangle	O
##s	O
:	O
EA	O
##C	O
patients	O
,	O
red	O
squares	O
:	O
Barrett	O
'	O
s	O
patients	O
)	O
;	O
(	O
B	O
)	O
ch	B
##olin	I
##e	I
region	O
of	O
the	O
_	O
1	O
H	O
-	O
N	O
##MR	O
spectrum	O
(	O
red	O
:	O
Barrett	O
'	O
s	O
from	O
EA	O
##C	O
patients	O
,	O
green	O
:	O
Barrett	O
'	O
s	O
from	O
Barrett	O
'	O
s	O
patients	O
that	O
group	O
in	O
PC	O
##A	O
scores	O
with	O
Barrett	O
'	O
s	O
from	O
EA	O
##C	O
patients	O
,	O
blue	O
:	O
Barrett	O
'	O
s	O
from	O
Barrett	O
'	O
s	O
patients	O
that	O
do	O
not	O
group	O
with	O
Barrett	O
'	O
s	O
from	O
EA	O
##C	O
patients	O
)	O
.	O

Thus	O
,	O
we	O
selected	O
M	B
##T	I
##BE	I
due	O
to	O
its	O
low	O
absorption	O
of	O
water	O
,	O
which	O
de	O
##act	O
##ivate	O
##s	O
PT	O
##AD	O
,	O
and	O
its	O
high	O
vol	O
##ati	O
##lity	O
.	O

Analysis	O
of	O
individual	O
time	O
points	O
showed	O
a	O
significant	O
difference	O
in	O
ta	B
##uri	I
##ne	I
levels	O
at	O
time	O
interval	O
19	O
:	O
00	O
–	O
23	O
:	O
00	O
h	O
before	O
the	O
nights	O
of	O
sleep	O
and	O
sleep	O
de	O
##p	O
##ri	O
##vation	O
(	O
q	O
=	O
0	O
.	O
00	O
##6	O
##3	O
)	O
,	O
but	O
no	O
significant	O
changes	O
in	O
earlier	O
time	O
periods	O
.	O

Since	O
oxygen	O
is	O
not	O
consumed	O
for	O
the	O
T	O
##CA	O
cycle	O
,	O
the	O
cell	O
would	O
have	O
an	O
increased	O
in	O
demand	O
on	O
their	O
anti	O
-	O
o	O
##xi	O
##da	O
##tive	O
machinery	O
,	O
e	O
.	O
g	O
.	O
g	B
##lut	I
##ath	I
##ione	I
,	O
for	O
re	O
##lie	O
##ving	O
the	O
o	O
##xi	O
##da	O
##tive	O
stress	O
.	O

(	B
1	B
,	I
2	I
-	I
N	I
##P	I
##Q	I
-	I
S	I
-	I
T	I
##FA	I
)	O
from	O
N	O
##PO	O
##S	O
##1	O
,	O
N	B
##PO	I
##S	I
##2	I
,	I
1	I
,	I
4	I
-	I
N	I
##P	I
##Q	I
-	I
2	I
##S	I
,	O
and	O
1	B
,	I
2	I
-	I
N	I
##P	I
##Q	I
-	I
2	I
##S	I
,	O
respectively	O
.	O

U	O
##rine	O
(	O
200	O
μ	O
##l	O
)	O
was	O
added	O
to	O
1	O
,	O
300	O
μ	O
##l	O
of	O
met	B
##han	I
##ol	I
containing	O
IS	O
##s	O
used	O
for	O
normal	O
##ization	O
and	O
evaluation	O
of	O
extraction	O
efficacy	O
.	O

The	O
in	O
##tra	O
##cellular	O
p	O
##har	O
##ma	O
##co	O
##kin	O
##etic	O
profile	O
of	O
rib	B
##avi	I
##rin	I
in	O
P	O
##BM	O
##C	O
and	O
RB	O
##C	O
of	O
HC	O
##V	O
-	O
infected	O
patients	O
has	O
also	O
been	O
reported	O
previously	O
.	O

Su	O
##pp	O
##lement	O
##ary	O
biological	O
measures	O
included	O
f	O
##etal	O
hem	O
##og	O
##lo	O
##bin	O
,	O
plasma	O
g	B
##lut	I
##amine	I
,	O
his	O
##tone	O
ace	O
##ty	O
##lation	O
and	O
gene	O
expression	O
in	O
l	O
##ymph	O
##ocytes	O
,	O
plasma	O
levels	O
of	O
p	B
##hen	I
##yl	I
##but	I
##yra	I
##te	I
and	O
meta	O
##bol	O
##ites	O
,	O
and	O
meta	O
##bol	O
##omi	O
##c	O
pro	O
##fi	O
##ling	O
.	O

The	O
cancer	O
tissue	O
of	O
patient	O
#	O
10	O
had	O
a	O
very	O
intense	O
PC	O
band	O
,	O
which	O
along	O
with	O
the	O
PC	O
band	O
of	O
the	O
non	O
-	O
cancer	O
##ous	O
tissue	O
was	O
q	O
##uant	O
##ified	O
using	O
the	O
b	O
##lot	O
image	O
with	O
2	O
min	O
of	O
film	O
exposure	O
,	O
as	O
was	O
the	O
case	O
for	O
the	O
α	B
-	I
tub	I
##ulin	I
band	O
of	O
all	O
tissues	O
.	O

a	O
Analysis	O
of	O
effect	O
of	O
adding	O
Lac	B
##tate	I
.	O

A	O
three	O
lip	O
##id	O
signature	O
including	O
e	O
##PC	O
38	O
:	O
5	O
,	O
PC	B
40	I
:	I
3	I
and	O
PC	B
42	I
:	I
4	I
is	O
potential	O
to	O
screen	O
patients	O
for	O
diagnosis	O
of	O
PC	O
##a	O
.	O

We	O
applied	O
this	O
classification	O
when	O
the	O
ratio	O
of	O
average	O
peak	O
areas	O
in	O
patients	O
compared	O
to	O
normal	O
##s	O
was	O
at	O
least	O
equal	O
to	O
the	O
value	O
of	O
2	O
.	O
5	O
obtained	O
for	O
u	B
##rea	I
in	O
plasma	O
ultra	O
##fi	O
##lt	O
##rate	O
,	O
as	O
shown	O
in	O
.	O

Moreover	O
,	O
the	O
well	O
-	O
known	O
to	B
##xin	I
##s	I
3	I
-	I
met	I
##hyl	I
##his	I
##ti	I
##dine	I
,	O
hip	B
##pur	I
##ic	I
acid	I
,	O
p	B
-	I
c	I
##res	I
##yl	I
su	I
##l	I
##phate	I
,	O
N	B
,	I
N	I
-	I
dim	I
##eth	I
##yl	I
##gly	I
##cine	I
,	O
beta	B
##ine	I
and	O
my	O
##o	O
-	O
in	O
##os	O
##ito	O
##l	O
were	O
detected	O
in	O
all	O
patients	O
.	O

The	O
AU	O
##C	O
values	O
indicate	O
the	O
diagnostic	O
potential	O
##s	O
of	O
the	O
meta	O
##bol	O
##ites	O
as	O
unique	O
bio	O
##mark	O
##ers	O
for	O
identification	O
of	O
C	B
##IN	I
##s	I
and	O
c	O
##er	O
##vic	O
##al	O
cancer	O
##s	O
.	O

The	O
serum	O
levels	O
of	O
do	B
##de	I
##cano	I
##ic	I
acid	I
,	O
pin	B
##ito	I
##l	I
,	O
ma	B
##lt	I
##ol	I
,	O
su	B
##c	I
##rose	I
,	O
and	O
S	O
##13	O
were	O
significantly	O
higher	O
after	O
so	O
##y	O
drink	O
intake	O
than	O
after	O
milk	O
and	O
cheese	O
intake	O
at	O
1	O
,	O
2	O
,	O
and	O
4	O
h	O
(	O
see	O
Table	O
##s	O
S	O
##3	O
and	O
S	O
##4	O
)	O
.	O

Other	O
amino	O
acids	O
such	O
as	O
pro	B
##line	I
,	O
is	B
##ole	I
##uc	I
##ine	I
and	O
le	B
##uc	I
##ine	I
also	O
varied	O
,	O
although	O
no	O
statistical	O
##ly	O
significance	O
could	O
be	O
demonstrated	O
.	O

Only	O
3	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
was	O
increased	O
(	O
P	O
<	O
.	O
05	O
)	O
in	O
the	O
normal	O
tissue	O
of	O
the	O
EA	O
##C	O
patients	O
compared	O
with	O
the	O
normal	O
tissue	O
of	O
the	O
Barrett	O
'	O
s	O
patients	O
.	O

The	O
inclusion	O
criteria	O
were	O
as	O
follows	O
:	O
at	O
least	O
one	O
side	O
of	O
the	O
thy	O
##roid	O
after	O
lobe	O
##ct	O
##omy	O
was	O
path	O
##ological	O
##ly	O
confirmed	O
with	O
PT	O
##C	O
;	O
no	O
c	O
##er	O
##vic	O
##al	O
l	O
##ymph	O
nodes	O
or	O
distant	O
meta	O
##sta	O
##sis	O
were	O
present	O
;	O
after	O
surgery	O
,	O
le	B
##vo	I
##thy	I
##ro	I
##xin	I
##e	I
sodium	I
tablets	O
(	O
L	O
-	O
T	O
##4	O
)	O
were	O
regularly	O
consumed	O
over	O
3	O
months	O
;	O
T	O
##S	O
##H	O
levels	O
were	O
less	O
than	O
0	O
.	O
1	O
I	O
##U	O
/	O
L	O
;	O
and	O
free	O
t	B
##ri	I
##io	I
##do	I
##thy	I
##ron	I
##ine	I
(	O
F	O
##T	O
##3	O
)	O
and	O
free	O
thy	B
##ro	I
##xin	I
##e	I
(	O
F	O
##T	O
##4	O
)	O
levels	O
were	O
normal	O
.	O

Using	O
a	O
meta	O
##bol	O
##omi	O
##cs	O
method	O
,	O
21	O
meta	O
##bol	O
##ites	O
(	O
13	O
types	O
of	O
amino	O
acids	O
and	O
8	O
types	O
of	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
)	O
were	O
measured	O
using	O
liquid	O
ch	O
##roma	O
##tography	O
-	O
tandem	O
mass	O
s	O
##pect	O
##rome	O
##try	O
.	O

The	O
serum	O
was	O
transferred	O
into	O
a	O
bar	O
-	O
coded	O
13	O
m	O
##L	O
p	B
##oly	I
##p	I
##rop	I
##yle	I
##ne	I
transfer	O
tube	O
,	O
capped	O
and	O
frozen	O
in	O
dry	O
ice	O
.	O

The	O
results	O
show	O
that	O
a	O
mixture	O
of	O
blood	O
/	O
met	O
##han	O
##ol	O
/	O
ch	O
##lor	O
##of	O
##orm	O
in	O
a	O
ratio	O
of	O
1	O
:	O
2	O
:	O
2	O
enabled	O
the	O
detection	O
of	O
all	O
the	O
co	O
##en	O
##zy	O
##mes	O
,	O
while	O
the	O
other	O
combinations	O
failed	O
to	O
detect	O
unstable	O
co	O
##en	O
##zy	O
##mes	O
,	O
N	B
##AD	I
##H	I
and	O
N	B
##AD	I
##P	I
##H	I
in	O
particular	O
.	O

Therefore	O
,	O
ch	B
##olin	I
##e	I
may	O
be	O
a	O
key	O
potential	O
bio	O
##mark	O
##er	O
for	O
post	O
##oper	O
##ative	O
therapy	O
and	O
pro	O
##gno	O
##stics	O
.	O

However	O
,	O
glucose	S
generation	O
from	O
al	B
##ani	I
##ne	I
and	O
g	B
##ly	I
##cer	I
##ol	I
has	O
been	O
shown	O
to	O
be	O
increased	O
in	O
cancer	O
patients	O
.	O

No	O
changes	O
in	O
other	O
T	O
##CA	O
##I	O
##s	O
were	O
identified	O
(	O
is	O
##oc	O
##it	O
##rate	O
,	O
su	B
##cci	I
##ni	I
##l	I
-	I
co	I
##A	I
and	O
o	B
##xa	I
##lace	I
##tate	I
)	O
,	O
nor	O
was	O
any	O
interaction	O
observed	O
between	O
the	O
groups	O
of	O
T	O
##1	O
##D	O
and	O
controls	O
in	O
the	O
meta	O
##bol	O
##ites	O
that	O
increased	O
following	O
exercise	O
.	O

A	O
##po	O
,	O
a	O
##poli	O
##pop	O
##rote	O
##in	O
;	O
C	O
##I	O
,	O
confidence	O
interval	O
;	O
D	O
##HA	O
,	O
do	B
##cos	I
##ah	I
##ex	I
##aen	I
##oi	I
##c	I
acid	I
;	O
FA	S
,	O
fatty	O
acid	O
;	O
H	O
##OM	O
##A	O
‐	O
I	O
##R	O
,	O
home	O
##ost	O
##atic	O
model	O
assessment	O
of	O
insulin	O
resistance	O
;	O
ID	O
##L	O
,	O
intermediate	O
‐	O
density	O
lip	O
##op	O
##rote	O
##in	O
;	O
L	O
##D	O
##L	O
,	O
low	O
‐	O
density	O
lip	O
##op	O
##rote	O
##in	O
;	O
M	O
##U	O
##FA	O
,	O
mon	O
##ou	O
##ns	O
##at	O
##ura	O
##ted	O
fatty	O
acid	O
;	O
P	O
##U	O
##FA	O
,	O
p	O
##oly	O
##uns	O
##at	O
##ura	O
##ted	O
fatty	O
acid	O
;	O
SF	O
##A	O
,	O
saturated	O
fatty	O
acid	O
.	O

Recently	O
,	O
5	B
,	I
6	I
‐	I
di	I
##hy	I
##dr	I
##our	I
##ac	I
##il	I
has	O
been	O
shown	O
to	O
be	O
elevated	O
in	O
AC	O
(	O
W	O
##iko	O
##ff	O
et	O
al	O
.	O
,	O
2015	O
)	O
.	O

As	O
shown	O
in	O
,	O
a	B
##rg	I
##ini	I
##ne	I
was	O
in	O
all	O
of	O
the	O
top	O
10	O
combinations	O
ranked	O
by	O
values	O
of	O
mean	O
AU	O
##C	O
in	O
the	O
test	O
set	O
.	O

A	O
plausible	O
explanation	O
(	O
see	O
)	O
would	O
be	O
that	O
in	O
cells	O
that	O
are	O
producing	O
a	O
large	O
amount	O
of	O
p	B
##yr	I
##u	I
##vate	I
from	O
the	O
g	B
##ly	I
##co	I
##ly	I
##tic	I
pathway	O
it	O
tends	O
to	O
be	O
converted	O
both	O
to	O
la	B
##ct	I
##ate	I
by	O
la	O
##ct	O
##ate	O
de	O
##hy	O
##dr	O
##ogen	O
##ase	O
and	O
to	O
al	B
##ani	I
##ne	I
by	O
al	O
##ani	O
##ne	O
trans	O
##ami	O
##nas	O
##e	O
(	O
A	O
)	O
G	B
##ly	I
##co	I
##ly	I
##tic	I
products	O
.	O

The	O
following	O
amino	O
acids	O
were	O
not	O
detected	O
in	O
the	O
samples	O
analyzed	O
with	O
this	O
methodology	O
:	O
O	B
-	I
p	I
##hos	I
##ph	I
##o	I
-	I
L	I
-	I
se	I
##rine	I
(	O
PS	O
##er	O
)	O
,	O
O	B
-	I
p	I
##hos	I
##ph	I
##oe	I
##than	I
##ola	I
##mine	I
(	O
P	O
##E	O
##t	O
##N	O
)	O
,	O
a	B
##rg	I
##ini	I
##nos	I
##ucci	I
##nic	I
acid	I
(	O
As	O
##a	O
)	O
,	O
L	B
-	I
ho	I
##mo	I
##ci	I
##tr	I
##ull	I
##ine	I
(	O
H	O
##ci	O
##t	O
)	O
,	O
L	B
-	I
an	I
##ser	I
##ine	I
(	O
An	O
##s	O
)	O
,	O
L	B
-	I
car	I
##nos	I
##ine	I
(	O
Car	O
)	O
,	O
c	B
##ys	I
##tat	I
##hi	I
##oni	I
##ne	I
(	O
C	O
##th	O
)	O
and	O
L	B
-	I
ho	I
##mo	I
##cy	I
##st	I
##ine	I
(	O
H	O
##cy	O
)	O
.	O

B	O
##rief	O
##ly	O
,	O
the	O
ch	O
##roma	O
##to	O
##graphic	O
separation	O
of	O
biological	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
was	O
obtained	O
by	O
H	O
##IL	O
##IC	O
retention	O
.	O

However	O
,	O
at	O
least	O
in	O
skeletal	O
muscle	O
no	O
sex	O
differences	O
in	O
activities	O
of	O
the	O
enzymes	O
of	O
the	O
c	B
##it	I
##ric	I
acid	I
cycle	O
have	O
been	O
found	O
,	O
and	O
the	O
capacity	O
for	O
ace	B
##ty	I
##l	I
-	I
Co	I
##A	I
flux	O
through	O
the	O
c	B
##it	I
##ric	I
acid	I
cycle	O
appears	O
to	O
be	O
similar	O
in	O
men	O
and	O
women	O
.	O

Other	O
highly	O
altered	O
meta	O
##bol	O
##ites	O
(	O
log	O
##2	O
fold	O
change	O
<	O
1	O
)	O
were	O
Ce	B
##r	I
(	I
d	I
##18	I
:	I
1	I
/	I
24	I
:	I
1	I
)	I
+	O
Ce	B
##r	I
(	I
d	I
##18	I
:	I
2	I
/	I
24	I
:	I
0	I
)	I
,	O
P	B
##E	I
(	I
16	I
:	I
0	I
/	I
18	I
:	I
1	I
)	I
,	O
P	B
##E	I
(	I
16	I
:	I
0	I
/	I
18	I
:	I
2	I
)	I
and	O
T	B
##G	I
(	I
54	I
:	I
1	I
)	I
(	O
A	O
)	O
.	O

These	O
meta	O
##bol	O
##ites	O
were	O
found	O
to	O
be	O
primarily	O
involved	O
in	O
pu	B
##rine	I
,	O
p	B
##yr	I
##im	I
##id	I
##ine	I
,	O
try	B
##pt	I
##op	I
##han	I
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
fatty	O
acid	O
β	O
-	O
oxidation	O
,	O
c	B
##it	I
##rate	I
cycle	O
,	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
,	O
s	B
##phi	I
##ngo	I
##lip	I
##id	I
,	O
and	O
bi	O
##le	O
acid	O
bio	O
##sy	O
##nt	O
##hesis	O
metabolism	O
.	O

High	O
level	O
of	O
palm	B
##itic	I
,	O
my	B
##rist	I
##ic	I
,	O
l	O
##ino	O
##len	O
##ic	O
,	O
and	O
e	B
##ico	I
##sa	I
##pent	I
##aen	I
##oi	I
##c	I
acids	I
enhance	O
##s	O
the	O
risk	O
of	O
pro	O
##state	O
cancer	O
and	O
it	O
has	O
a	O
inverse	O
association	O
with	O
s	B
##te	I
##ari	I
##c	I
acid	I
.	O

In	O
order	O
to	O
confirm	O
the	O
predicted	O
architecture	O
of	O
the	O
P	O
.	O
f	O
##al	O
##ci	O
##par	O
##um	O
N	O
##AD	O
_	O
+	O
salvage	O
pathway	O
,	O
we	O
grew	O
infected	O
red	O
blood	O
cells	O
(	O
i	O
##RB	O
##Cs	O
)	O
in	O
media	O
supplemented	O
with	O
uniform	O
##ly	O
labeled	O
_	O
13	O
C	B
-	I
U	I
-	I
glucose	I
to	O
perform	O
stable	O
is	O
##oto	O
##pic	O
label	O
##ing	O
studies	O
coupled	O
with	O
liquid	O
ch	O
##roma	O
##tography	O
-	O
tandem	O
mass	O
s	O
##pect	O
##rome	O
##try	O
(	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
)	O
detection	O
.	O

The	O
same	O
was	O
true	O
for	O
the	O
assignment	O
of	O
5	O
′	O
ATP	O
,	O
g	B
##ly	I
##cer	I
##ol	I
-	I
3	I
-	I
phosphate	I
,	O
and	O
f	B
##ru	I
##ct	I
##ose	I
-	I
6	I
-	I
phosphate	I
(	O
F	O
##6	O
##P	O
)	O
.	O

C	O
-	O
reactive	O
protein	O
is	O
an	O
acute	O
-	O
phase	O
inflammatory	O
protein	O
,	O
which	O
showed	O
a	O
positive	O
correlation	O
with	O
16	B
-	I
HD	I
##o	I
##H	I
##E	I
,	O
a	O
do	B
##cos	I
##ah	I
##ex	I
##aen	I
##oi	I
##c	I
acid	I
(	O
D	O
##HA	O
)	O
lip	O
##id	O
per	O
##ox	O
##ida	O
##tion	O
meta	O
##bol	O
##ite	O
.	O

In	O
contrast	O
,	O
p	O
##hos	O
##ph	O
##oli	O
##pas	O
##e	O
activity	O
,	O
estimated	O
as	O
the	O
ratio	O
of	O
total	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
(	O
LP	O
##Cs	O
)	O
to	O
total	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
(	O
PC	O
##s	O
)	O
,	O
was	O
higher	O
in	O
the	O
normal	O
T	O
##BC	O
group	O
(	O
<	O
5	O
.	O
1	O
mm	O
##ol	O
/	O
L	O
)	O
than	O
in	O
the	O
border	O
##line	O
or	O
high	O
T	O
##BC	O
group	O
(	O
p	O
<	O
0	O
.	O
00	O
##1	O
)	O
.	O

The	O
box	O
plot	O
presents	O
the	O
minimum	O
,	O
first	O
q	O
##ua	O
##rt	O
##ile	O
,	O
median	O
,	O
third	O
q	O
##ua	O
##rt	O
##ile	O
and	O
maximum	O
log	O
transformed	O
relative	O
intensity	O
values	O
and	O
potential	O
out	O
##liers	O
of	O
ta	B
##uri	I
##ne	I
,	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
,	O
v	B
##ali	I
##ne	I
,	O
le	B
##uc	I
##ine	I
,	O
bi	B
##li	I
##ru	I
##bin	I
,	O
1	B
‐	I
met	I
##hyl	I
##nic	I
##ot	I
##ina	I
##mi	I
##de	I
(	O
M	O
##NA	O
)	O
,	O
L	O
##ys	O
##o	O
##PC	O
(	O
15	O
:	O
0	O
)	O
,	O
L	O
##ys	O
##o	O
##PC	O
(	O
16	O
:	O
0	O
)	O
,	O
L	O
##ys	O
##o	O
##PC	O
(	B
16	I
:	I
0	I
)	I
is	I
##omer	I
,	O
L	O
##ys	O
##o	O
##PC	O
(	B
P	B
‐	I
16	I
:	I
0	I
)	O
,	O
L	O
##ys	O
##o	O
##PC	O
(	O
16	O
:	O
1	O
)	O
,	O
L	O
##ys	O
##o	O
##PC	O
(	O
17	O
:	O
0	O
)	O
,	O
L	O
##ys	O
##o	O
##PC	O
(	O
18	O
:	O
0	O
)	O
,	O
L	O
##ys	O
##o	O
##P	O
##E	O

m	O
m	O
m	O
m	O
m	O
m	O
Co	O
##rrel	O
##ation	O
between	O
formation	O
rate	O
of	O
h	B
##ydro	I
##xy	I
##ana	I
##stro	I
##zo	I
##le	I
and	O
individual	O
P	O
##45	O
##0	O
-	O
is	O
##of	O
##orm	O
contents	O
in	O
a	O
panel	O
of	O
H	O
##LM	O
##s	O
m	O
m	O
T	O
,	O
test	O
##osterone	O
6	O
##β	O
-	O
h	O
##ydro	O
##xy	O
##lation	O
;	O
M	O
,	O
mid	O
##az	O
##ola	O
##m	O
1	O
′	O
-	O
h	O
##ydro	O
##xy	O
##lation	O
.	O

L	B
-	I
car	I
##ni	I
##tine	I
,	O
primarily	O
synthesized	O
in	O
the	O
liver	O
and	O
kidney	O
##s	O
from	O
l	B
##ys	I
##ine	I
and	O
met	B
##hi	I
##oni	I
##ne	I
,	O
has	O
an	O
essential	O
role	O
in	O
the	O
transfer	O
of	O
activated	S
long	O
-	O
chain	O
fatty	O
acids	O
into	O
the	O
mit	O
##och	O
##ond	O
##ria	O
where	O
β	O
-	O
oxidation	O
takes	O
place	O
.	O

In	O
both	O
cell	O
types	O
,	O
there	O
was	O
evidence	O
for	O
efficient	O
p	O
##hos	O
##ph	O
##ory	O
##lation	O
;	O
trip	B
##hos	I
##phate	I
was	O
the	O
predominant	O
in	O
##tra	O
##cellular	O
meta	O
##bol	O
##ite	O
.	O

However	O
,	O
in	O
our	O
study	O
re	O
##ct	O
##al	O
and	O
oral	O
var	O
##ia	O
##bilities	O
with	O
p	O
##har	O
##ma	O
##co	O
##kin	O
##etics	O
of	O
met	B
##had	I
##one	I
were	O
low	O
and	O
essentially	O
the	O
same	O
.	O

Met	O
##ab	O
##oli	O
##tes	O
from	O
the	O
u	B
##rea	I
cycle	O
(	O
n	O
=	O
4	O
)	O
and	O
p	B
##yr	I
##im	I
##id	I
##ine	I
metabolism	O
(	O
n	O
=	O
4	O
)	O
emerge	O
in	O
the	O
second	O
component	O
.	O

The	O
norm	B
##og	I
##ly	I
##ca	I
##em	I
##ic	I
individuals	O
included	O
in	O
this	O
study	O
were	O
selected	O
not	O
only	O
because	O
of	O
their	O
normal	O
fast	O
##ing	O
glucose	S
but	O
also	O
because	O
of	O
their	O
normal	O
glucose	S
tolerance	O
and	O
H	O
##b	O
##A	O
_	O
1	O
##c	O
,	O
under	O
current	O
accepted	O
definitions	O
.	O

Over	O
the	O
last	O
3	O
decades	O
,	O
e	O
##pid	O
##em	O
##iol	O
##og	O
##ic	O
and	O
experimental	O
data	O
have	O
provided	O
evidence	O
for	O
a	O
beneficial	O
effect	O
of	O
o	B
##me	I
##ga	I
-	I
3	I
fatty	O
acids	O
in	O
the	O
prevention	O
of	O
C	O
##VD	O
.	O

H	O
A	O
corresponding	O
PC	O
##A	O
analysis	O
then	O
performed	O
on	O
the	O
clinical	O
chemistry	O
lip	O
##id	O
profile	O
data	O
##set	O
(	O
all	O
variables	O
this	O
time	O
normal	O
##ised	O
to	O
total	O
t	B
##ria	I
##cy	I
##l	I
##gly	I
##cer	I
##ol	I
concentrations	O
prior	O
to	O
analysis	O
)	O
demonstrated	O
that	O
the	O
three	O
variables	O
investigated	O
were	O
predominantly	O
segregated	O
into	O
two	O
or	O
##th	O
##ogo	O
##nal	O
components	O
,	O
the	O
first	O
(	O
PC	O
##1	O
*	O
)	O
containing	O
the	O
total	O
ch	B
##ole	I
##ster	I
##ol	I
and	O
L	B
##D	I
##L	I
-	I
ch	I
##ole	I
##ster	I
##ol	I
(	O
L	O
##D	O
##L	O
-	O
c	O
)	O
variables	O
(	O
loading	O
scores	O
vectors	O
0	O
.	O
80	O
and	O
0	O
.	O
93	O
respectively	O
)	O
,	O
the	O
second	O
(	O
PC	O
##2	O
*	O
)	O
HD	B
##L	I
-	I
ch	I
##ole	I
##ster	I
##ol	I
(	O
HD	O
##L	O
-	O
c	O
)	O
alone	O
(	O
0	O
.	O
91	O
)	O
,	O
as	O
might	O
be	O
expected	O
in	O
view	O
of	O
the	O
commonly	O
observed	O
higher	O
L	O
##D	O
##L	O
-	O
to	O
HD	B
##L	I
-	I
ch	I
##ole	I
##ster	I
##ol	I
concentration	O
ratios	O
of	O
blood	O
plasma	O
samples	O
.	O

For	O
patients	O
administered	O
De	O
##gar	O
##eli	O
##x	O
,	O
serum	O
samples	O
were	O
taken	O
immediately	O
before	O
administration	O
of	O
De	O
##gar	O
##eli	O
##x	O
and	O
immediately	O
prior	O
to	O
surgery	O
for	O
measuring	O
pre	O
-	O
and	O
post	O
-	O
De	O
##gar	O
##eli	O
##x	O
treatment	O
test	B
##osterone	I
levels	O
respectively	O
.	O

Important	O
##ly	O
,	O
g	B
##lut	I
##amine	I
can	O
readily	O
pass	O
through	O
the	O
blood	O
‐	O
brain	O
barrier	O
,	O
and	O
we	O
found	O
a	O
modest	O
correlation	O
between	O
plasma	O
and	O
CS	O
##F	O
g	B
##lut	I
##amine	I
levels	O
.	O

The	O
le	O
##uke	O
##mia	O
cell	O
line	O
R	O
##MP	O
##I	O
-	O
82	O
##26	O
contained	O
the	O
highest	O
levels	O
of	O
est	B
##rone	I
(	O
182	O
.	O
06	O
p	O
##g	O
/	O
10	O
_	O
6	O
cells	O
)	O
and	O
17	B
##β	I
-	I
est	I
##rad	I
##iol	I
(	O
75	O
##3	O
.	O
45	O
p	O
##g	O
/	O
10	O
_	O
6	O
cells	O
)	O
.	O

Then	O
,	O
FA	S
were	O
dissolved	O
in	O
b	O
##ov	O
##ine	O
serum	O
album	O
##in	O
(	O
10	O
%	O
BS	O
##A	O
,	O
Sigma	O
)	O
at	O
the	O
final	O
ratio	O
1	O
/	O
10	O
(	O
v	O
/	O
v	O
)	O
in	O
William	O
’	O
s	O
E	O
plus	O
G	B
##lut	I
##ama	I
##x	I
[UNK]	O
medium	O
or	O
in	O
Op	O
##ti	O
##ME	O
##M	O
[UNK]	O
(	O
G	O
##y	O
##b	O
##co	O
,	O
In	O
##vi	O
##tro	O
##gen	O
)	O
and	O
warmed	O
again	O
at	O
55	O
°C	O
for	O
10	O
min	O
before	O
use	O
.	O

Our	O
previous	O
N	O
##MR	O
analysis	O
identified	O
higher	O
u	O
##rina	O
##ry	O
PA	B
##G	I
in	O
I	O
##B	O
##D	O
patients	O
,	O
which	O
indicated	O
a	O
different	O
energy	O
metabolic	O
status	O
[	O
]	O
.	O

Re	O
##ceive	O
##r	O
operating	O
characteristic	O
(	O
R	O
##OC	O
)	O
analysis	O
of	O
the	O
models	O
comprising	O
four	O
u	O
##rina	O
##ry	O
meta	O
##bol	O
##ites	O
:	O
c	B
##rea	I
##tine	I
rib	I
##os	I
##ide	I
(	O
CR	O
)	O
,	O
N	B
-	I
ace	I
##ty	I
##ln	I
##eur	I
##ami	I
##nic	I
acid	I
(	O
N	O
##AN	O
##A	O
)	O
,	O
co	B
##rt	I
##is	I
##ol	I
su	I
##lf	I
##ate	I
(	O
CS	O
)	O
and	O
meta	O
##bol	O
##ite	O
56	O
##1	O
+	O
in	O
comparison	O
with	O
and	O
in	O
addition	O
to	O
clinical	O
##ly	O
utilized	O
bio	O
##mark	O
##er	O
of	O
ICC	O
,	O
CA	O
##19	O
-	O
9	O
,	O
in	O
the	O
T	O
##IG	O
##ER	O
-	O
L	O
##C	O
co	O
##hor	O
##t	O
.	O

All	O
de	O
##uter	O
##ated	O
solvent	O
##s	O
were	O
purchased	O
from	O
Cambridge	O
Is	O
##oto	O
##pes	O
(	O
And	O
##over	O
,	O
MA	O
)	O
,	O
and	O
1	B
-	I
pen	I
##tan	I
##es	I
##ulf	I
##ona	I
##te	I
,	O
sodium	O
salt	O
(	O
PS	O
##A	O
)	O
was	O
purchased	O
from	O
Regis	O
Technologies	O
(	O
Morton	O
Grove	O
,	O
IL	O
)	O
.	O

More	O
recent	O
work	O
provided	O
evidence	O
for	O
higher	O
co	B
##rt	I
##is	I
##ol	I
secret	O
##ion	O
from	O
SAT	O
rather	O
than	O
VA	O
##T	O
in	O
humans	O
.	O

Obviously	O
,	O
considering	O
the	O
toxic	O
nature	O
of	O
ch	B
##lor	I
##of	I
##orm	I
for	O
humans	O
and	O
the	O
environment	O
,	O
it	O
is	O
desirable	O
to	O
limit	O
its	O
usage	O
for	O
high	O
-	O
volume	O
routine	O
applications	O
.	O

The	O
4	O
##OH	O
##tam	O
to	O
ta	B
##mo	I
##xi	I
##fen	I
ratio	O
was	O
positively	O
associated	O
with	O
increasing	O
C	O
##YP	O
##2	O
##C	O
##19	O
predicted	O
en	O
##zy	O
##matic	O
activity	O
,	O
whereas	O
no	O
such	O
correlation	O
was	O
observed	O
for	O
the	O
ratio	O
of	O
4	O
##OH	O
##ND	O
##tam	O
to	O
N	O
##D	O
##tam	O
.	O

This	O
is	O
in	O
keeping	O
with	O
the	O
greater	O
affinity	O
of	O
β	B
-	I
a	I
##po	I
-	I
13	I
-	I
car	I
##ote	I
##non	I
##e	I
for	O
the	O
RA	O
##R	O
##s	O
than	O
that	O
of	O
the	O
β	B
-	I
a	I
##po	I
-	I
14	I
′	I
-	I
car	I
##ote	I
##no	I
##ids	I
.	O

This	O
is	O
done	O
by	O
the	O
enzyme	O
al	O
##ani	O
##ne	O
trans	O
##ami	O
##nas	O
##e	O
,	O
which	O
converts	O
L	B
-	I
g	I
##lut	I
##ama	I
##te	I
and	O
p	B
##yr	I
##u	I
##vate	I
into	O
α	B
-	I
k	I
##eto	I
##g	I
##lut	I
##arate	I
and	O
L	B
-	I
al	I
##ani	I
##ne	I
.	O

Next	O
,	O
the	O
extracted	O
meta	O
##bol	O
##ites	O
were	O
dried	O
in	O
a	O
vacuum	O
con	O
##cent	O
##rator	O
without	O
heating	O
and	O
30	O
μ	O
##L	O
of	O
met	B
##ho	I
##xy	I
am	O
##ination	O
h	B
##ydro	I
##ch	I
##lor	I
##ide	I
was	O
added	O
.	O

L	O
##ys	O
##o	O
-	O
PC	O
/	O
PC	O
ratio	O
for	O
healthy	O
and	O
se	O
##ptic	O
patients	O
was	O
determined	O
dividing	O
the	O
combined	O
pool	O
of	O
l	B
##ys	I
##o	I
-	I
PC	I
(	I
16	I
:	I
0	I
,	I
18	I
:	I
3	I
,	I
18	I
:	I
2	I
,	I
18	I
:	I
1	I
,	I
18	I
:	I
0	I
,	I
20	I
:	I
5	I
,	I
20	I
:	I
4	I
,	O
and	O
20	O
:	O
3	O
)	O
by	O
the	O
combined	O
pool	O
of	O
PC	O
(	O
16	O
:	O
X	O
/	O
18	O

We	O
have	O
developed	O
a	O
sensitive	O
ass	O
##ay	O
to	O
q	O
##uant	O
##ify	O
de	B
##ox	I
##yt	I
##hi	I
##og	I
##uan	I
##os	I
##ine	I
(	O
d	O
##T	O
##G	O
)	O
without	O
der	O
##iva	O
##tis	O
##ation	O
in	O
the	O
DNA	O
of	O
n	O
##uc	O
##lea	O
##ted	O
blood	O
cells	O
.	O

In	O
the	O
original	O
(	O
un	O
##cor	O
##re	O
##cted	O
)	O
data	O
,	O
6	O
pair	O
##wise	O
O	O
##PL	O
##S	O
-	O
D	O
##A	O
models	O
significantly	O
disc	O
##rim	O
##inated	O
serum	O
from	O
plasma	O
(	O
standard	O
1	O
##D	O
N	O
##MR	O
,	O
CP	O
##MG	O
N	O
##MR	O
,	O
R	B
##P	I
(	O
E	O
##SI	O
##±	O
)	O
,	O
and	O
H	O
##IL	O
##IC	O
(	O
E	O
##SI	O
##±	O
)	O
UP	O
##LC	O
-	O
MS	O
)	O
.	O

[	O
]	O
The	O
average	O
concentration	O
of	O
met	B
##hi	I
##oni	I
##ne	I
su	I
##lf	I
##oxide	I
in	O
the	O
two	O
subgroup	O
##s	O
was	O
similar	O
,	O
implying	O
that	O
the	O
extent	O
of	O
peripheral	O
o	O
##xi	O
##da	O
##tive	O
stress	O
does	O
not	O
increase	O
dem	O
##ent	O
##ia	O
risk	O
.	O

In	O
men	O
,	O
but	O
not	O
in	O
women	O
,	O
the	O
diet	O
##ary	O
intake	O
of	O
α	B
-	I
l	I
##ino	I
##len	I
##ic	I
acid	I
was	O
lower	O
in	O
control	O
subjects	O
than	O
in	O
color	O
##ec	O
##tal	O
p	O
##oly	O
##p	O
cases	O
.	O

In	O
contrast	O
,	O
le	O
##pt	O
##in	O
showed	O
no	O
effect	O
on	O
protein	O
synthesis	O
or	O
degradation	O
in	O
p	B
##or	I
##cine	I
my	O
##ob	O
##last	O
##s	O
and	O
in	O
female	O
W	O
##ista	O
##r	O
rats	O
.	O

To	O
assess	O
potential	O
non	O
##linear	O
associations	O
,	O
models	O
were	O
performed	O
with	O
u	O
##rina	O
##ry	O
para	B
##ce	I
##tam	I
##ol	I
and	O
p	B
-	I
amino	I
##phe	I
##no	I
##l	I
concentrations	O
categorized	O
into	O
q	O
##ua	O
##rt	O
##iles	O
.	O

Fu	B
##ran	I
is	O
a	O
rode	O
##nt	O
he	O
##pa	O
##to	O
##to	O
##xi	O
##can	O
##t	O
and	O
car	O
##cin	O
##ogen	O
.	O

The	O
compounds	O
were	O
then	O
el	O
##uted	O
by	O
flush	O
##ing	O
the	O
tips	O
ten	O
times	O
in	O
100	O
µ	O
##l	O
met	B
##han	I
##ol	I
and	O
were	O
ready	O
for	O
in	O
##fusion	O
analysis	O
.	O

Car	B
##ni	I
##tine	I
is	O
an	O
amino	O
acid	O
der	O
##ivate	O
involved	O
in	O
lip	O
##id	O
metabolism	O
and	O
is	O
known	O
to	O
contribute	O
to	O
multiple	O
diseases	O
,	O
including	O
cancer	O
.	O

Ph	B
##en	I
##yla	I
##lani	I
##ne	I
serves	O
as	O
a	O
substrate	O
for	O
the	O
synthesis	O
of	O
ne	O
##uro	O
##tra	O
##ns	O
##mit	O
##ters	O
such	O
as	O
do	B
##pa	I
##mine	I
and	O
nor	B
##ep	I
##ine	I
##ph	I
##rine	I
.	O

Even	O
when	O
analyzing	O
the	O
12	O
ACC	O
patients	O
without	O
evidence	O
of	O
hormone	O
excess	O
on	O
routine	O
bio	O
##chemistry	O
,	O
u	O
##rina	O
##ry	O
ex	O
##cre	O
##tion	O
of	O
and	O
##rogen	O
and	O
g	B
##lu	I
##co	I
##cor	I
##tic	I
##oid	I
precursor	O
meta	O
##bol	O
##ites	O
remained	O
significantly	O
increased	O
(	O
P	O
=	O
0	O
.	O
01	O
##5	O
and	O
P	O
=	O
0	O
.	O
00	O
##2	O
,	O
respectively	O
;	O
Su	O
##pp	O
##lement	O
##al	O
Table	O
3	O
)	O
.	O

The	O
associations	O
,	O
assessed	O
by	O
S	O
##pear	O
##man	O
'	O
s	O
rank	O
correlation	O
,	O
suggest	O
that	O
my	B
##oi	I
##nos	I
##ito	I
##l	I
(	O
ρ	O
=	O
0	O
.	O
53	O
;	O
P	O
=	O
0	O
.	O
05	O
;	O
q	O
=	O
0	O
.	O
25	O
)	O
and	O
total	O
g	B
##lut	I
##ath	I
##ione	I
(	O
ρ	O
=	O
0	O
.	O
56	O
;	O
P	O
=	O
0	O
.	O
04	O
;	O
q	O
=	O
0	O
.	O
25	O
)	O
may	O
be	O
markers	O
of	O
se	O
##psis	O
-	O
induced	O
AL	O
##I	O
severity	O
.	O

In	O
a	O
previous	O
study	O
,	O
we	O
found	O
that	O
expression	O
of	O
K	O
##Y	O
##NU	O
,	O
the	O
gene	O
encoding	O
k	O
##yn	O
##uren	O
##inas	O
##e	O
(	O
an	O
enzyme	O
downstream	O
of	O
TD	O
##O	O
)	O
is	O
elevated	O
in	O
suspended	O
T	O
##NBC	O
cell	O
lines	O
and	O
in	O
the	O
context	O
of	O
increased	O
inflammatory	O
signaling	O
,	O
which	O
would	O
be	O
consistent	O
with	O
try	B
##pt	I
##op	I
##han	I
cat	O
##ab	O
##olis	O
##m	O
further	O
down	O
the	O
pathway	O
.	O

ATP	S
and	O
PC	O
##r	O
are	O
connected	O
via	O
the	O
c	O
##rea	O
##tine	O
-	O
kinase	O
reaction	O
.	O

Di	O
Pa	O
##s	O
##qua	O
##le	O
and	O
colleagues	O
identified	O
a	O
gang	O
##lio	O
##side	O
-	O
binding	O
domain	O
(	O
GB	O
##D	O
)	O
in	O
α	B
-	I
s	I
##yn	I
##uc	I
##lein	I
,	O
which	O
has	O
marked	O
preference	O
to	O
GM	B
##3	I
.	O

S	B
##phi	I
##ngo	I
##my	I
##elin	I
##s	I
,	O
which	O
were	O
found	O
to	O
play	O
an	O
important	O
role	O
in	O
β	O
-	O
cell	O
function	O
,	O
were	O
the	O
most	O
stable	O
compound	O
class	O
both	O
in	O
plasma	O
and	O
serum	O
samples	O
in	O
this	O
study	O
.	O

Two	O
hours	O
after	O
addition	O
of	O
r	O
##H	O
##la	O
in	O
S	O
##9	O
cells	O
,	O
further	O
decreases	O
for	O
ATP	S
to	O
29	O
%	O
,	O
U	O
##TP	O
to	O
12	O
%	O
,	O
GT	O
##P	O
to	O
82	O
%	O
,	O
U	B
##DP	I
to	O
22	O
%	O
and	O
CDP	O
to	O
74	O
%	O
of	O
the	O
respective	O
control	O
levels	O
were	O
observed	O
.	O

The	O
hypothesis	O
that	O
we	O
have	O
proposed	O
to	O
explain	O
the	O
consistently	O
negative	O
correlation	O
##s	O
between	O
meta	O
##bol	O
##ite	O
groups	O
and	O
lip	O
##ids	O
that	O
we	O
have	O
observed	O
in	O
the	O
five	O
types	O
of	O
brain	O
t	O
##umour	O
##s	O
—	O
that	O
cells	O
with	O
strong	O
metabolic	O
pathway	O
flux	O
(	O
and	O
thus	O
high	O
concentrations	O
of	O
la	B
##ct	I
##ate	I
,	O
t	O
##C	O
##r	O
,	O
t	O
##G	O
##lut	O
and	O
t	O
##C	O
##ho	O
)	O
tend	O
not	O
to	O
contain	O
N	O
##MR	O
-	O
visible	O
lip	O
##id	O
drop	O
##lets	O
,	O
and	O
vice	O
versa	O
—	O
suggests	O
a	O
possible	O
mechanism	O
for	O
explaining	O
the	O
phenomena	O
observed	O
in	O
earlier	O
studies	O
.	O

Palm	B
##itate	I
O	O
##xi	O
##dation	O
Rate	O
=	O
(	O
E	O
##co	O
##2	O
##×	O
##V	O
##co	O
##2	O
)	O
/	O
16	O
##E	O
##×	O
##ar	O
Palm	B
##itate	I
O	O
##xi	O
##dation	O
Rate	O
=	O
(	O
E	O
##co	O
##2	O
##×	O
##V	O
##co	O
##2	O
)	O
/	O
16	O
##E	O
##×	O
##ar	O
Palm	B
##itate	I
O	O
##xi	O
##dation	O
Rate	O
=	O
(	O
E	O
##co	O
##2	O
##×	O
##V	O
##co	O
##2	O
)	O
/	O
16	O
##E	O
##×	O
##ar	O
Palm	B
##itate	I
O	O
##xi	O
##dation	O
Rate	O
=	O
(	O
E	O
##co	O
##2	O
##×	O
##V	O
##co	O
##2	O
)	O
/	O
16	O
##E	O
##×	O
##ar	O
Palm	B
##itate	I
O	O
##xi	O
##dation	O
Rate	O
=	O
(	O
E	O
##co	O
##2	O
##×	O
##V	O
##co	O
##2	O
)	O
/	O
16	O
##E	O
##×	O
##ar	O
Palm	B
##itate	I
O	O
##xi	O
##dation	O
Rate	O
=	O
(	O
E	O
##co	O
##2	O
##×	O
##V	O
##co	O
##2	O
)	O
/	O
16	O
##E	O
##×	O
##ar	O
(	O
E	O
##co	O
##2	O
##×	O
##V	O
##co	O
##2	O
)	O
/	O
16	O
##E	O
##×	O
##ar	O
(	O
E	O
##co	O
##2	O
##×	O
##V	O
##co	O
##2	O
)	O
/	O
16	O
(	O
E	O
##co	O
##2	O
##×	O
##V	O
##co	O
##2	O
)	O
/	O
16	O
(	O
E	O
##co	O
##2	O
E	O
##co	O
##2	O
E	O
E	O
co	O
##2	O
co	O
##2	O
co	O
2	O
×	O
V	O
##co	O
##2	O
V	O
##co	O
##2	O
V	O
V	O
co	O
##2	O
co	O
##2	O
co	O
2	O
)	O
/	O
16	O

The	O
1	O
.	O
22	O
±	O
0	O
.	O
09	O
mm	O
##ol	O
/	O
l	O
(	O
173	O
±	O
6	O
.	O
09	O
%	O
)	O
increase	O
in	O
total	O
PC	O
after	O
the	O
r	O
##HD	O
##L	O
in	O
##fusion	O
could	O
be	O
attributed	O
to	O
the	O
34	O
:	O
3	O
,	O
34	O
:	O
2	O
,	O
36	O
:	O
3	O
,	O
and	O
36	O
:	O
2	O
species	O
;	O
however	O
,	O
the	O
expected	O
increase	O
in	O
PC	B
36	I
:	I
4	I
was	O
not	O
observed	O
.	O

The	O
response	O
was	O
most	O
profound	O
for	O
T	O
##AG	O
##s	O
with	O
long	O
-	O
chain	O
un	O
##sat	O
##ura	O
##ted	O
FA	S
,	O
whereas	O
shorter	O
and	O
more	O
saturated	O
species	O
demonstrated	O
a	O
reverse	O
pattern	O
.	O

U	O
##rine	O
was	O
th	O
##awed	O
at	O
4	O
°C	O
,	O
v	O
##ortex	O
-	O
mixed	O
,	O
then	O
withdrawn	O
with	O
2	O
-	O
m	O
##L	O
p	B
##oly	I
##p	I
##rop	I
##yle	I
##ne	I
s	O
##yr	O
##inge	O
##s	O
(	O
NO	O
##R	O
##M	O
-	O
J	O
##EC	O
##T	O
®	O
,	O
He	O
##nk	O
##e	O
Sa	O
##ss	O
Wolf	O
,	O
Tu	O
##tt	O
##ling	O
##en	O
,	O
Germany	O
)	O
and	O
filtered	O
using	O
0	O
.	O
2	O
-	O
μ	O
##m	O
N	O
##ylon	O
s	O
##yr	O
##inge	O
filters	O
(	O
Ch	O
##roma	O
##fi	O
##l	O
®	O
X	O
##tra	O
PA	O
-	O
20	O
/	O
13	O
,	O
Mac	O
##here	O
##y	O
-	O
Na	O
##gel	O
GmbH	O
,	O
Due	O
##ren	O
,	O
Germany	O
)	O
into	O
0	O
.	O
7	O
-	O
m	O
##L	O
p	B
##oly	I
##p	I
##rop	I
##yle	I
##ne	I
HP	O
##LC	O
via	O
##ls	O
(	O
B	O
##ru	O
##ck	O
##ner	O
,	O
Lin	O
##z	O
,	O
Austria	O
)	O
with	O
p	B
##oly	I
##eth	I
##yle	I
##ne	I
snap	O
-	O
caps	O
(	O
B	O
##ru	O
##ck	O
##ner	O
,	O
Lin	O
##z	O
,	O
Austria	O
)	O
before	O
injection	O
into	O
the	O
HP	O
##LC	O
-	O
I	O
##CP	O
##Q	O
##Q	O
##Q	O
##MS	O
system	O
.	O

Po	O
##ten	O
##tial	O
errors	O
in	O
the	O
est	O
##imation	O
of	O
concentrations	O
from	O
meta	O
##bol	O
##omi	O
##c	O
peak	O
areas	O
,	O
as	O
revealed	O
by	O
the	O
apparent	O
protein	O
binding	O
of	O
u	B
##rea	I
and	O
p	B
##hen	I
##yla	I
##ce	I
##ty	I
##l	I
##g	I
##lut	I
##amine	I
in	O
,	O
di	O
##ss	O
##uad	O
##ed	O
us	O
from	O
reporting	O
the	O
binding	O
of	O
so	O
##lut	O
##es	O
not	O
measured	O
using	O
quantitative	O
ass	O
##ays	O
.	O

In	O
brief	O
,	O
a	O
solution	O
of	O
race	O
##mic	O
re	O
##v	O
-	O
BP	O
##DE	O
(	O
2	O
.	O
4	O
mg	O
,	O
0	O
.	O
00	O
##8	O
mm	O
##ol	O
)	O
in	O
2	O
.	O
0	O
m	O
##l	O
of	O
dry	O
te	B
##tra	I
##hy	I
##dr	I
##of	I
##ura	I
##n	I
was	O
added	O
to	O
2	O
m	O
##l	O
of	O
N	O
##AC	O
(	O
3	O
.	O
0	O
M	O
)	O
(	O
adjusted	O
to	O
pH	O
10	O
.	O
0	O
)	O
.	O

When	O
looking	O
at	O
p	B
##yr	I
##id	I
##ine	I
alone	O
,	O
no	O
reported	O
link	O
is	O
found	O
with	O
color	O
##ec	O
##tal	O
cancer	O
,	O
however	O
the	O
he	B
##tero	I
##cy	I
##c	I
##lic	I
am	O
##ine	O
(	O
HC	O
##A	O
)	O
2	B
-	I
amino	I
-	I
1	I
-	I
met	I
##hyl	I
-	I
6	I
-	I
p	I
##hen	I
##yl	I
##im	I
##ida	I
##zo	I
[	I
4	I
,	I
5	I
-	I
b	I
]	I
p	I
##yr	I
##id	I
##ine	I
(	O
Ph	O
##IP	O
)	O
has	O
been	O
widely	O
identified	O
as	O
implicated	O
in	O
the	O
a	O
##eti	O
##ology	O
of	O
human	O
color	O
##ec	O
##tal	O
cancer	O
.	O

This	O
,	O
unfortunately	O
,	O
prevents	O
a	O
comparison	O
with	O
the	O
intriguing	O
report	O
of	O
lower	O
serum	O
in	B
##dox	I
##yl	I
su	I
##lf	I
##ate	I
in	O
depressed	O
ha	O
##em	O
##od	O
##ial	O
##ys	O
##is	O
patients	O
(	O
compared	O
to	O
non	O
-	O
depressed	O
patients	O
)	O
.	O

T	O
##iss	O
##ues	O
were	O
son	O
##ica	O
##ted	O
and	O
extracted	O
with	O
80	O
%	O
met	B
##han	I
##ol	I
.	O

Ku	O
##gler	O
G	O
.	O
examined	O
a	O
co	O
##hor	O
##t	O
of	O
patients	O
with	O
co	O
##rona	O
##ry	O
artery	O
diseases	O
and	O
found	O
increased	O
levels	O
of	O
in	B
##os	I
##ine	I
and	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
in	O
their	O
co	O
##rona	O
##ry	O
ve	O
##nous	O
blood	O
.	O

C	B
##it	I
##rate	I
is	O
a	O
key	O
intermediate	O
of	O
the	O
T	O
##CA	O
cycle	O
and	O
has	O
been	O
closely	O
related	O
to	O
an	O
increase	O
in	O
fatty	O
acid	O
β	O
-	O
oxidation	O
to	O
support	O
cancer	O
cell	O
proliferation	O
.	O

Further	O
,	O
the	O
BC	O
##AA	O
##s	O
share	O
a	O
competitive	O
transport	O
system	O
with	O
the	O
a	O
##romatic	O
amino	O
acids	O
,	O
thereby	O
potentially	O
explaining	O
the	O
cluster	O
##ing	O
of	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
and	O
t	B
##yr	I
##os	I
##ine	I
in	O
this	O
factor	O
,	O
not	O
only	O
in	O
the	O
current	O
study	O
but	O
in	O
several	O
other	O
reports	O
from	O
our	O
group	O
[	O
–	O
,	O
,	O
]	O
.	O

In	O
the	O
30	O
samples	O
of	O
co	O
##hor	O
##t	O
1	O
,	O
a	O
weak	O
tendency	O
for	O
correlation	O
between	O
plasma	O
ne	B
##r	I
##von	I
##ic	I
acid	I
level	O
and	O
ch	B
##ole	I
##ster	I
##ol	I
level	O
was	O
found	O
(	O
ρ	O
=	O
0	O
.	O
32	O
,	O
P	O
=	O
.	O
08	O
##3	O
)	O
.	O

The	O
protein	O
was	O
loaded	O
into	O
Lead	O
##it	O
2	O
.	O
1	O
.	O
2	O
,	O
and	O
the	O
receptor	O
components	O
were	O
chosen	O
by	O
selection	O
of	O
chain	O
A	O
as	O
a	O
main	O
chain	O
,	O
which	O
is	O
complex	O
##ed	O
with	O
a	B
##rac	I
##hi	I
##don	I
##ic	I
acid	I
.	O

The	O
resulting	O
di	B
##acy	I
##l	I
##gly	I
##cer	I
##ol	I
can	O
be	O
directly	O
ace	O
##ty	O
##lated	O
by	O
an	O
a	O
##cy	O
##lt	O
##ran	O
##s	O
##fer	O
##ase	O
to	O
form	O
a	O
t	B
##ria	I
##cy	I
##l	I
##gly	I
##cer	I
##ol	I
or	O
can	O
react	O
with	O
c	B
##yt	I
##id	I
##ine	I
-	I
dip	I
##hos	I
##phate	I
-	I
ch	I
##olin	I
##e	I
(	I
CDP	I
-	I
ch	I
##olin	I
##e	I
)	I
or	O
CDP	B
-	I
ethanol	I
##amine	I
to	O
form	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
or	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##let	I
##han	I
##ola	I
##mine	I
,	O
respectively	O
.	O

Although	O
2	O
##H	O
##G	O
shares	O
the	O
same	O
AM	O
##NP	O
##Q	O
spin	O
system	O
as	O
g	B
##lut	I
##ama	I
##te	I
(	O
G	O
##lu	O
)	O
,	O
its	O
2	O
-	O
h	O
##ydro	O
##xy	O
##l	O
(	O
2	O
-	O
OH	O
)	O
is	O
more	O
electron	O
-	O
withdrawing	O
than	O
G	O
##lu	O
’	O
s	O
2	B
-	I
amino	I
(	O
2	O
-	O
NH	O
_	O
2	O
)	O
sub	O
##st	O
##it	O
##uen	O
##t	O
,	O
causing	O
the	O
α	O
-	O
pro	O
##ton	O
to	O
re	O
##son	O
##ate	O
further	O
down	O
##field	O
at	O
4	O
.	O
05	O
pp	O
##m	O
(	O
parts	O
per	O
million	O
)	O
as	O
a	O
double	O
##t	O
of	O
double	O
##ts	O
.	O

(	O
a	O
)	O
K	B
##yn	I
##uren	I
##ine	I
were	O
significantly	O
lower	O
in	O
MD	O
##D	O
patients	O
than	O
in	O
control	O
subjects	O
(	O
F	O
##DR	O
q	O
=	O
0	O
.	O
00	O
##9	O
##6	O
)	O
.	O

The	O
total	O
recovery	O
,	O
covering	O
sample	O
preparation	O
,	O
stability	O
and	O
matrix	O
effect	O
,	O
was	O
determined	O
at	O
three	O
concentration	O
levels	O
(	O
5	O
,	O
300	O
,	O
400	O
ng	O
/	O
m	O
##L	O
)	O
in	O
du	O
##p	O
##lo	O
,	O
for	O
a	B
##bir	I
##ater	I
##one	I
and	O
for	O
the	O
internal	O
standard	O
D	B
_	I
4	I
-	I
a	I
##bir	I
##ater	I
##one	I
.	O

The	O
sample	O
preparation	O
protocol	O
was	O
identical	O
with	O
the	O
one	O
used	O
for	O
en	O
##zy	O
##matic	O
degradation	O
of	O
di	B
##os	I
##met	I
##in	I
con	O
##ju	O
##gate	O
##s	O
in	O
plasma	O
.	O

The	O
meta	O
##bol	O
##ites	O
in	O
the	O
upper	O
-	O
right	O
corner	O
of	O
the	O
plot	O
(	O
mostly	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
(	O
PC	O
##s	O
)	O
in	O
purple	O
and	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
##s	I
(	O
SM	O
##s	O
)	O
in	O
gold	O
)	O
correlated	O
with	O
higher	O
T	O
##BC	O
concentrations	O
.	O

In	O
the	O
car	B
##ni	I
##tine	I
-	I
a	I
##cy	I
##l	I
##car	I
##ni	I
##tine	I
metabolic	O
pathway	O
,	O
the	O
m	O
##RNA	O
expression	O
levels	O
of	O
CP	O
##T	O
##1	O
##B	O
and	O
CP	O
##T	O
##1	O
##C	O
,	O
SL	O
##C	O
##25	O
##A	O
##20	O
,	O
and	O
CR	O
##AT	O
,	O
but	O
not	O
CP	O
##T	O
##1	O
##A	O
or	O
CP	O
##T	O
##2	O
,	O
were	O
significantly	O
lower	O
in	O
N	O
##IM	O
##BC	O
patients	O
than	O
in	O
controls	O
(	O
p	O
<	O
0	O
.	O
05	O
each	O
)	O
(	O
,	O
)	O
.	O

Although	O
decreased	O
levels	O
of	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
(	O
L	O
##ys	O
##o	O
##PC	O
)	O
(	O
16	O
:	O
0	O
)	O
were	O
detected	O
,	O
the	O
results	O
revealed	O
a	O
significant	O
increase	O
in	O
levels	O
of	O
7	B
-	I
de	I
##hy	I
##dr	I
##och	I
##ole	I
##ster	I
##ol	I
-	I
1	I
.	O

Ser	O
##um	O
meta	O
##bol	O
##omi	O
##c	O
profiles	O
included	O
188	O
serum	O
meta	O
##bol	O
##ites	O
,	O
covering	O
amino	O
acids	O
,	O
bio	O
##genic	O
am	O
##ines	O
,	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
,	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
,	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
##s	I
and	O
he	O
##x	O
##ose	O
##s	O
.	O

Like	O
FAA	O
##s	O
,	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
have	O
been	O
suggested	O
to	O
be	O
ago	O
##nist	O
##s	O
of	O
PP	O
##AR	O
##s	O
,	O
and	O
therefore	O
,	O
alterations	O
in	O
the	O
levels	O
of	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
might	O
have	O
an	O
impact	O
on	O
lip	O
##id	O
metabolism	O
,	O
fatty	O
acid	O
oxidation	O
and	O
glucose	S
home	O
##ost	O
##asis	O
.	O

AU	O
##C	O
,	O
area	O
under	O
the	O
R	O
##OC	O
curve	O
;	O
R	O
##OC	O
,	O
receiver	O
operating	O
characteristic	O
;	O
Sa	O
,	O
s	B
##phi	I
##nga	I
##nine	I
;	O
So	O
##1	O
##P	O
,	O
s	B
##phi	I
##ngo	I
##sin	I
##e	I
-	I
1	I
-	I
phosphate	I
.	O

H	O
##sa	O
-	O
mi	O
##R	O
-	O
122	O
-	O
5	O
##p	O
(	O
n	O
=	O
66	O
##8	O
)	O
predicted	O
small	O
V	O
##LD	O
##L	O
,	O
ID	O
##L	O
,	O
and	O
large	O
L	O
##D	O
##L	O
particle	O
concentrations	O
,	O
their	O
lip	O
##id	O
component	O
and	O
ch	B
##ole	I
##ster	I
##ol	I
concentrations	O
and	O
a	O
##po	O
##B	O
levels	O
.	O

Due	O
to	O
the	O
positively	O
charged	O
amino	S
group	O
on	O
ta	B
##uri	I
##ne	I
(	O
p	O
##K	O
##a	O
=	O
9	O
.	O
1	O
)	O
,	O
it	O
was	O
necessary	O
to	O
work	O
under	O
basic	O
pH	O
conditions	O
in	O
order	O
to	O
allow	O
a	O
net	O
negative	O
charge	O
on	O
ta	B
##uri	I
##ne	I
and	O
a	O
sufficient	O
retention	O
on	O
the	O
an	O
##ion	O
-	O
exchange	O
column	O
.	O

The	O
goals	O
of	O
this	O
study	O
were	O
to	O
evaluate	O
the	O
performance	O
of	O
a	O
newly	O
developed	O
beta	B
##ine	I
ass	O
##ay	O
and	O
to	O
prospective	O
##ly	O
explore	O
the	O
potential	O
clinical	O
associations	O
of	O
beta	B
##ine	I
and	O
future	O
risk	O
of	O
T	O
##2	O
##DM	O
in	O
a	O
large	O
population	O
-	O
based	O
co	O
##hor	O
##t	O
.	O

Fast	O
##ing	O
glucose	S
(	O
mm	O
##ol	O
/	O
L	O
)	O
]	O
/	O
22	O
.	O
5	O
.	O

The	O
mass	O
-	O
peak	O
area	O
of	O
the	O
137	O
.	O
08	O
-	O
m	O
/	O
z	O
ion	O
and	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
were	O
correlated	O
with	O
one	O
another	O
(	O
Figure	O
)	O
,	O
but	O
this	O
relationship	O
did	O
not	O
reach	O
statistical	O
significance	O
.	O

In	O
serum	O
and	O
urine	O
samples	O
,	O
p	B
##yr	I
##u	I
##vate	I
and	O
la	B
##ct	I
##ate	I
differential	O
##ly	O
increased	O
in	O
cancer	O
##ous	O
cases	O
compared	O
to	O
ben	O
##ign	O
cases	O
,	O
while	O
levels	O
of	O
su	B
##cci	I
##nate	I
and	O
c	B
##it	I
##rate	I
were	O
reduced	O
.	O

One	O
-	O
step	O
solid	O
-	O
phase	O
extraction	O
was	O
successfully	O
applied	O
using	O
an	O
O	O
##stro	O
sample	O
preparation	O
96	O
-	O
well	O
plate	O
for	O
plasma	O
samples	O
pre	O
##tre	O
##ated	O
with	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
containing	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
.	O

In	O
conclusion	O
,	O
at	O
ambient	O
temperature	O
a	B
##bir	I
##ater	I
##one	I
concentration	O
rapidly	O
decreased	O
in	O
fresh	O
E	O
##D	O
##TA	O
whole	O
blood	O
as	O
well	O
as	O
in	O
fresh	O
E	O
##D	O
##TA	O
plasma	O
,	O
and	O
therefore	O
samples	O
should	O
be	O
treated	O
on	O
ice	O
immediately	O
after	O
collection	O
.	O

In	O
particular	O
,	O
_	O
1	O
H	O
N	O
##MR	O
s	O
##pect	O
##ra	O
from	O
the	O
MG	O
##S	O
-	O
treated	O
group	O
also	O
showed	O
significant	O
increases	O
(	O
by	O
un	O
##iva	O
##ria	O
##te	O
analysis	O
)	O
in	O
lip	O
##op	O
##rote	O
##in	O
-	O
associated	O
t	B
##ria	I
##cy	I
##l	I
##gly	I
##cer	I
##ol	I
resonance	O
##s	O
when	O
compared	O
to	O
HC	O
controls	O
(	O
Fi	O
##g	O
.	O

The	O
ass	O
##ays	O
were	O
analyzed	O
as	O
per	O
the	O
manufacturers	O
’	O
protocol	O
(	B
http	B
:	I
/	I
/	I
www	I
.	I
me	I
##so	I
##sca	I
##le	I
.	I
com	I
)	O
.	O

shows	O
the	O
presence	O
of	O
fragments	O
184	O
.	O
07	O
##36	O
and	O
86	O
.	O
09	O
##70	O
in	O
both	O
the	O
reference	O
standard	O
and	O
plasma	O
sample	O
at	O
the	O
same	O
retention	O
time	O
and	O
indicates	O
the	O
match	O
to	O
the	O
[	O
M	O
-	O
H	O
_	O
2	O
O	O
+	O
H	O
]	O
add	O
##uc	O
##t	O
for	O
t	B
##re	I
##hal	I
##ose	I
6	O
-	O
my	O
##cola	O
##te	O
is	O
correct	O
.	O

The	O
q	O
##uant	O
##ifications	O
were	O
performed	O
with	O
the	O
transitions	O
of	O
m	O
/	O
z	O
43	O
##6	O
.	O
3	O
→	O
285	O
.	O
2	O
for	O
SM	O
##V	O
,	O
m	O
/	O
z	O
43	O
##7	O
.	O
2	O
→	O
303	O
.	O
2	O
for	O
SM	O
##V	O
-	O
A	O
,	O
m	O
/	O
z	O
55	O
##9	O
.	O
2	O
→	O
440	O
.	O
3	O
for	O
AT	O
##V	O
,	O
m	O
/	O
z	O
57	O
##5	O
.	O
4	O
→	O
440	O
.	O
3	O
for	O
2	B
-	I
OH	I
-	I
AT	I
##V	I
and	O
4	B
-	I
OH	I
-	I
AT	I
##V	I
,	O
m	O
/	O
z	O
48	O
##2	O
.	O
3	O
→	O
258	O
.	O
1	O
for	O
RS	O
##V	O
,	O
and	O
m	O
/	O
z	O
41	O
##2	O
.	O
3	O
→	O
224	O
.	O
2	O
for	O
flu	B
##vas	I
##tat	I
##in	I
(	O
IS	O
)	O
.	O

Taking	O
this	O
into	O
account	O
,	O
we	O
defined	O
a	O
score	O
to	O
rank	O
the	O
reliability	O
of	O
each	O
meta	O
##bol	O
##ite	O
on	O
the	O
base	O
of	O
sensitivity	O
to	O
each	O
factors	O
and	O
to	O
highlight	O
the	O
most	O
stable	O
meta	O
##bol	O
##ites	O
during	O
the	O
procedure	O
of	O
formal	B
##in	I
fix	O
##ation	O
and	O
para	O
##ffin	O
-	O
em	O
##bed	O
##ding	O
.	O

The	O
two	O
groups	O
had	O
no	O
differences	O
in	O
sex	O
,	O
body	O
weight	O
,	O
or	O
total	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
but	O
had	O
significant	O
differences	O
in	O
age	O
,	O
g	O
##ly	O
##cos	O
##yla	O
##ted	O
hem	O
##og	O
##lo	O
##bin	O
,	O
glucose	S
,	O
u	B
##rea	I
nitrogen	I
,	O
and	O
c	B
##rea	I
##tin	I
##ine	I
.	O

These	O
meta	O
##bol	O
##ites	O
included	O
amino	O
acids	O
,	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
,	O
bi	O
##le	O
acids	O
and	O
(	B
p	I
##hos	I
##ph	I
##o	I
)	I
lip	I
##ids	I
.	O

All	O
patients	O
had	O
beta	O
-	O
block	O
##ers	O
and	O
ni	B
##trate	I
##s	I
held	O
for	O
at	O
least	O
24	O
h	O
##rs	O
prior	O
to	O
cat	O
##he	O
##ter	O
##ization	O
,	O
and	O
participants	O
were	O
brought	O
to	O
the	O
cardiac	O
cat	O
##he	O
##ter	O
##ization	O
suite	O
in	O
an	O
overnight	O
-	O
fast	O
##ed	O
state	O
.	O

Specifically	O
,	O
pu	B
##rine	I
n	O
##uc	O
##leo	O
##tide	O
##s	O
undergo	O
de	O
##ph	O
##os	O
##ph	O
##ory	O
##lation	O
via	O
5	O
′	O
-	O
n	O
##uc	O
##leo	O
##ti	O
##das	O
##e	O
to	O
form	O
n	O
##uc	O
##leo	O
##side	O
##s	O
(	O
ad	O
##eno	O
##sin	O
##e	O
and	O
g	O
##uan	O
##os	O
##ine	O
)	O
.	O

The	O
position	O
of	O
the	O
h	B
##ydro	I
##xy	I
groups	O
in	O
the	O
di	B
##hy	I
##dr	I
##ox	I
##y	I
meta	O
##bol	O
##ite	O
was	O
determined	O
as	O
v	O
##ici	O
##nal	O
to	O
the	O
nitrogen	O
in	O
the	O
p	B
##yr	I
##rol	I
##id	I
##ine	I
ring	O
since	O
it	O
is	O
likely	O
that	O
this	O
meta	O
##bol	O
##ite	O
leads	O
to	O
the	O
N	O
,	O
N	O
-	O
deal	O
##ky	O
##l	O
meta	O
##bol	O
##ite	O
that	O
was	O
also	O
detected	O
.	O

96	O
-	O
well	O
p	B
##oly	I
##p	I
##rop	I
##yle	I
##ne	I
micro	O
##tite	O
##r	O
plates	O
were	O
purchased	O
from	O
G	O
##re	O
##iner	O
B	O
##io	O
-	O
One	O
(	O
Fr	O
##ick	O
##en	O
##hausen	O
,	O
Germany	O
)	O
.	O

However	O
,	O
All	O
##ott	O
et	O
al	O
.	O
reported	O
that	O
higher	O
levels	O
of	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
the	O
blood	O
of	O
male	O
patients	O
were	O
associated	O
with	O
increased	O
risk	O
for	O
pro	O
##state	O
cancer	O
re	O
##cu	O
##rrence	O
,	O
which	O
presented	O
a	O
reverse	O
trend	O
to	O
that	O
in	O
our	O
study	O
.	O

G	B
##lu	I
##cos	I
##e	I
transport	O
may	O
under	O
##lie	O
the	O
relationship	O
between	O
glucose	S
and	O
th	B
##re	I
##onic	I
acid	I
.	O

Furthermore	O
,	O
an	O
increased	O
ratio	O
of	O
k	B
##yn	I
##uren	I
##ine	I
to	O
try	B
##pt	I
##op	I
##han	I
was	O
observed	O
in	O
PD	O
patients	O
.	O

In	O
contrast	O
,	O
in	O
PC	O
##OS	O
women	O
,	O
the	O
free	O
and	O
##rogen	O
index	O
(	O
Test	O
##osterone	O
/	O
SH	O
##B	O
##G	O
)	O
was	O
positively	O
correlated	O
with	O
T	O
##C	O
,	O
T	B
##G	I
,	O
L	O
##D	O
##L	O
-	O
C	O
,	O
A	O
##po	O
B	O
and	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
(	O
P	O
##L	O
)	O
(	O
although	O
after	O
adjusting	O
for	O
age	O
and	O
B	O
##MI	O
the	O
association	O
was	O
not	O
significant	O
)	O
.	O

The	O
dried	O
mixture	O
was	O
resolved	O
and	O
v	O
##ortex	O
##ed	O
with	O
50	O
μ	O
##L	O
h	O
##ydro	O
##xy	O
##l	O
am	O
##ine	O
(	O
10	O
mg	O
/	O
m	O
##L	O
p	B
##yr	I
##id	I
##ine	I
)	O
agent	O
and	O
again	O
e	O
##va	O
##porated	O
to	O
dry	O
##ness	O
under	O
the	O
same	O
conditions	O
as	O
before	O
.	O

f	O
##ow	O
##ler	O
##i	O
t	O
##rop	O
##ho	O
##zo	O
##ites	O
treated	O
for	O
48	O
hours	O
with	O
(	O
A	O
)	O
0	O
.	O
08	O
μ	O
##M	O
of	O
is	B
##av	I
##uc	I
##ona	I
##zo	I
##le	I
and	O
0	O
.	O
7	O
μ	O
##M	O
of	O
e	B
##pi	I
##min	I
##ola	I
##nos	I
##tero	I
##l	I
,	O
(	O
B	O
)	O
1	O
.	O
9	O
μ	O
##M	O
e	O
##qui	O
##mo	O
##lar	O
concentrations	O
of	O
is	B
##av	I
##uc	I
##ona	I
##zo	I
##le	I
and	O
ta	B
##mo	I
##xi	I
##fen	I
,	O
(	O
C	O
)	O
2	O
μ	O
##M	O
e	O
##qui	O
##mo	O
##lar	O
concentrations	O
of	O
e	B
##pi	I
##min	I
##ola	I
##nos	I
##tero	I
##l	I
and	O
ta	B
##mo	I
##xi	I
##fen	I
,	O
and	O
(	O
D	O
)	O
0	O
.	O
5	O
%	O
D	B
##MS	I
##O	I
,	O
which	O
served	O
as	O
a	O
negative	O
control	O
.	O

Previously	O
,	O
this	O
has	O
also	O
been	O
found	O
in	O
AD	O
,	O
AL	O
##S	O
and	O
PD	O
and	O
therefore	O
suggested	O
to	O
be	O
an	O
alternative	O
pathway	O
for	O
ne	O
##uro	O
##de	O
##gene	O
##rative	O
diseases	O
to	O
overcome	O
the	O
inadequate	O
glucose	S
supply	O
and	O
the	O
def	O
##icient	O
energy	O
metabolism	O
.	O

Individual	O
t	B
##rig	I
##ly	I
##cer	I
##ide	I
species	O
that	O
were	O
significantly	O
altered	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
in	O
behavioral	O
variant	O
front	O
##ote	O
##mpo	O
##ral	O
dem	O
##ent	O
##ia	O
(	O
b	O
##v	O
##FT	O
##D	O
)	O
and	O
Alzheimer	O
’	O
s	O
disease	O
(	O
AD	O
)	O
compared	O
to	O
control	O
.	O

The	O
biological	O
rational	O
##e	O
that	O
supports	O
such	O
changes	O
remain	O
to	O
be	O
determined	O
but	O
it	O
is	O
tempting	O
to	O
s	O
##pec	O
##ulate	O
that	O
the	O
bio	O
##chemical	O
consequences	O
of	O
HM	O
##BS	O
activity	O
could	O
promote	O
,	O
directly	O
or	O
indirectly	O
,	O
alterations	O
in	O
g	B
##ly	I
##co	I
##ly	I
##tic	I
process	O
that	O
occur	O
in	O
the	O
mit	O
##och	O
##ond	O
##ria	O
.	O

The	O
primary	O
goal	O
of	O
our	O
study	O
was	O
to	O
measure	O
the	O
concentration	O
levels	O
of	O
ta	B
##mo	I
##xi	I
##fen	I
and	O
ta	B
##mo	I
##xi	I
##fen	I
meta	O
##bol	O
##ites	O
in	O
serum	O
samples	O
taken	O
from	O
volunteer	O
cancer	O
survivors	O
who	O
had	O
been	O
treated	O
with	O
ta	B
##mo	I
##xi	I
##fen	I
.	O

In	O
the	O
q	O
##uant	O
##itation	O
experiments	O
based	O
on	O
de	O
##con	O
##ju	O
##gation	O
of	O
di	B
##os	I
##met	I
##in	I
in	O
urine	O
dig	O
##est	O
##ions	O
either	O
with	O
β	O
-	O
d	O
-	O
g	O
##lu	O
##cu	O
##ron	O
##idas	O
##e	O
,	O
with	O
su	O
##lf	O
##ata	O
##se	O
,	O
or	O
with	O
both	O
enzymes	O
together	O
were	O
carried	O
out	O
.	O

Therefore	O
,	O
the	O
different	O
post	O
##pra	O
##ndi	O
##al	O
glucose	S
profiles	O
in	O
the	O
two	O
groups	O
might	O
have	O
contributed	O
to	O
the	O
different	O
post	O
##pra	O
##ndi	O
##al	O
changes	O
in	O
the	O
GA	B
##BA	I
levels	O
.	O

The	O
presence	O
of	O
phosphate	S
ion	O
co	O
##rrel	O
##ates	O
with	O
the	O
presence	O
of	O
biological	O
tissue	O
and	O
is	O
comparable	O
with	O
the	O
optical	O
image	O
in	O
.	O

A	O
higher	O
al	B
##ani	I
##ne	I
level	O
was	O
also	O
associated	O
with	O
decreased	O
risk	O
of	O
micro	O
##vas	O
##cular	O
events	O
after	O
further	O
adjustment	O
(	O
H	O
##R	O
0	O
.	O
86	O
[	O
95	O
%	O
C	O
##I	O
0	O
.	O
76	O
,	O
0	O
.	O
98	O
]	O
)	O
.	O

N	O
##AG	O
is	O
the	O
o	O
##b	O
##liga	O
##te	O
act	O
##iva	O
##tor	O
of	O
car	B
##ba	I
##mo	I
##yl	I
phosphate	I
s	O
##ynth	O
##eta	O
##se	O
I	O
(	O
CP	O
##S	O
-	O
I	O
)	O
.	O

In	O
animal	O
and	O
human	O
studies	O
,	O
p	O
##har	O
##ma	O
##co	O
##log	O
##ic	O
me	B
##lat	I
##oni	I
##n	I
reduces	O
v	O
##is	O
##cer	O
##al	O
sensitivity	O
.	O
_	O
,	O
Whether	O
and	O
how	O
me	B
##lat	I
##oni	I
##n	I
degradation	O
contributes	O
to	O
the	O
link	O
between	O
poor	O
sleep	O
and	O
pain	O
symptoms	O
requires	O
further	O
rigorous	O
study	O
.	O

The	O
ch	O
##roma	O
##to	O
##graphic	O
separation	O
was	O
performed	O
in	O
gradient	O
el	O
##ution	O
with	O
ultra	O
##pur	O
##e	O
water	O
with	O
form	B
##ic	I
acid	I
(	O
0	O
,	O
02	O
##5	O
%	O
)	O
and	O
with	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
(	O
B	O
)	O
as	O
the	O
mobile	O
phases	O
,	O
at	O
a	O
flow	O
rate	O
of	O
0	O
.	O
4	O
m	O
##L	O
/	O
min	O
.	O

The	O
super	O
##nat	O
##ant	O
or	O
upper	O
phase	O
was	O
mixed	O
with	O
100	O
µ	O
##L	O
of	O
carbon	B
##ate	I
-	I
bi	I
##car	I
##bon	I
##ate	I
buffer	O
(	O
0	O
.	O
2	O
M	O
,	O
pH	O
9	O
)	O
and	O
50	O
µ	O
##L	O
of	O
dans	B
##yl	I
chloride	I
(	O
10	O
mg	O
/	O
m	O
##L	O
in	O
ace	O
##tone	O
)	O
.	O

Individual	O
meta	O
##bol	O
##ite	O
box	O
‐	O
and	O
‐	O
w	O
##his	O
##ker	O
plots	O
for	O
the	O
different	O
groups	O
of	O
patients	O
:	O
(	O
a	O
)	O
th	B
##re	I
##oni	I
##ne	I
;	O
(	O
b	O
)	O
g	B
##lut	I
##amine	I
;	O
(	O
c	O
)	O
is	B
##ole	I
##uc	I
##ine	I
;	O
(	O
d	O
)	O
his	B
##ti	I
##dine	I
;	O
and	O
(	O
e	O
)	O
l	B
##ino	I
##len	I
##ic	I
acid	I
.	O

The	O
meta	O
##bol	O
##ite	O
p	B
##yr	I
##u	I
##vate	I
is	O
the	O
product	O
of	O
an	O
##ae	O
##ro	O
##bic	O
g	O
##ly	O
##co	O
##lysis	O
.	O

SUV	O
_	O
ma	O
##x	O
,	O
a	O
measure	O
of	O
in	O
##tra	O
##cellular	O
accumulation	O
of	O
p	B
##hos	I
##ph	I
##ory	I
##lated	I
de	I
##ox	I
##y	I
##g	I
##lu	I
##cos	I
##e	I
,	O
is	O
a	O
sur	O
##rogate	O
measure	O
of	O
the	O
g	B
##ly	I
##co	I
##ly	I
##tic	I
metabolism	O
of	O
tumors	O
.	O

The	O
samples	O
were	O
collected	O
into	O
a	O
s	O
##ter	O
##ilized	O
cup	O
containing	O
125	O
mg	O
as	B
##cor	I
##bic	I
acid	I
.	O

When	O
enough	O
glucose	S
is	O
not	O
produced	O
from	O
g	B
##ly	I
##co	I
##gen	I
breakdown	O
,	O
a	O
secondary	O
metabolic	O
pathway	O
for	O
glucose	S
generation	O
is	O
adopted	O
which	O
consume	O
##s	O
g	O
##lu	O
##co	O
##genic	O
amino	O
acids	O
,	O
p	B
##yr	I
##u	I
##vate	I
,	O
g	B
##ly	I
##cer	I
##ol	I
,	O
and	O
la	B
##ct	I
##ate	I
.	O

A	O
low	O
ratio	O
could	O
in	O
##hibit	O
NO	O
production	O
and	O
explain	O
the	O
NO	O
deficiency	O
observed	O
in	O
early	O
C	O
##K	O
##D	O
patients	O
with	O
normal	O
a	B
##rg	I
##ini	I
##ne	I
levels	O
.	O

First	O
,	O
clinical	O
symptoms	O
of	O
F	B
##D	I
were	O
evaluated	O
using	O
the	O
N	O
##ep	O
##ean	O
D	O
##ys	O
##pe	O
##ps	O
##ia	O
Index	O
(	O
N	O
##DI	O
)	O
,	O
and	O
plasma	O
metabolic	O
profiles	O
were	O
measured	O
by	O
_	O
1	O
H	O
N	O
##MR	O
.	O

This	O
sub	O
##stant	O
##iate	O
##s	O
the	O
previous	O
discussion	O
that	O
man	B
##nose	I
may	O
be	O
a	O
pivotal	O
player	O
for	O
the	O
prediction	O
of	O
mortality	O
following	O
AM	O
##I	O
and	O
of	O
C	O
##VD	O
in	O
general	O
.	O

Co	O
##mp	O
##aris	O
##ons	O
of	O
the	O
43	O
meta	O
##bol	O
##ites	O
showed	O
a	O
mean	O
correlation	O
coefficient	O
(	O
r	O
)	O
of	O
0	O
.	O
44	O
with	O
a	O
maximum	O
correlation	O
for	O
o	B
##ct	I
##ano	I
##yl	I
##car	I
##ni	I
##tine	I
(	O
r	O
=	O
0	O
.	O
92	O
)	O
,	O
minimum	O
correlation	O
for	O
1	B
-	I
do	I
##cos	I
##ah	I
##ex	I
##aen	I
##oy	I
##l	I
##gly	I
##cer	I
##op	I
##hos	I
##ph	I
##och	I
##olin	I
##e	I
(	O
r	O
=	O
0	O
)	O
,	O
and	O
weak	O
correlation	O
##s	O
(	O
0	O
<	O
r	O
<	O
0	O
.	O
2	O
)	O
for	O
7	O
meta	O
##bol	O
##ites	O
,	O
which	O
included	O
lip	O
##ids	O
and	O
an	O
amino	O
acid	O
.	O

We	O
measured	O
the	O
serum	O
concentrations	O
of	O
the	O
active	O
ta	B
##mo	I
##xi	I
##fen	I
meta	O
##bol	O
##ites	O
,	O
4	B
##OH	I
##tam	I
##ox	I
##ife	I
##n	I
(	O
4	O
##OH	O
##tam	O
)	O
,	O
4	B
-	I
h	I
##ydro	I
##xy	I
-	I
N	I
-	I
des	I
##met	I
##hyl	I
##tam	I
##ox	I
##ife	I
##n	I
(	O
4	O
##OH	O
##ND	O
##tam	O
,	O
End	B
##ox	I
##ife	I
##n	I
)	O
,	O
ta	B
##mo	I
##xi	I
##fen	I
and	O
its	O
dem	O
##eth	O
##yla	O
##ted	O
meta	O
##bol	O
##ites	O
.	O

Males	O
had	O
significantly	O
higher	O
levels	O
of	O
P	O
##GE	O
-	O
M	O
than	O
females	O
(	O
p	O
<	O
0	O
.	O
000	O
##1	O
)	O
,	O
but	O
there	O
was	O
no	O
effect	O
of	O
gender	O
on	O
levels	O
of	O
8	B
-	I
is	I
##o	I
-	I
P	I
##G	I
##F	I
_	I
2	I
##α	I
.	O

Thus	O
,	O
regarding	O
the	O
effects	O
on	O
insulin	O
sensitivity	O
,	O
Omega	B
-	I
3	I
ex	O
##ert	O
##ed	O
a	O
neutral	O
effect	O
compared	O
with	O
Place	O
##bo	O
,	O
while	O
the	O
results	O
collectively	O
document	O
a	O
marginal	O
improvement	O
by	O
the	O
Pi	O
##o	O
&	O
Omega	B
-	I
3	I
intervention	O
.	O

m	O
m	O
m	O
m	O
m	O
m	O
m	O
m	O
m	O
m	O
In	O
##hibition	O
of	O
h	B
##ydro	I
##xy	I
##ana	I
##stro	I
##zo	I
##le	I
formation	O
from	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
by	O
a	O
panel	O
of	O
C	O
##YP	O
enzyme	O
specific	O
inhibitor	O
##s	O
.	O

The	O
collected	O
N	O
##MR	O
s	O
##pect	O
##ra	O
were	O
manually	O
phased	O
and	O
base	O
##line	O
corrected	O
using	O
the	O
software	O
Me	O
##st	O
##R	O
##e	O
##N	O
##ova	O
(	O
version	O
:	O
8	O
.	O
1	O
.	O
2	O
,	O
Me	O
##st	O
##rel	O
##ab	O
Research	O
S	O
.	O
L	O
.	O
,	O
Spain	O
)	O
and	O
referenced	O
to	O
the	O
CH	O
_	O
3	O
resonance	O
of	O
la	B
##ct	I
##ate	I
at	O
δ	O
##1	O
.	O
33	O
.	O

Of	O
these	O
,	O
five	O
also	O
showed	O
significant	O
differences	O
in	O
six	O
-	O
month	O
changes	O
between	O
R	O
##Y	O
##GB	O
and	O
W	O
##LM	O
,	O
including	O
2	O
-	O
H	O
##BA	O
,	O
3	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yric	I
acid	I
(	O
3	O
-	O
H	O
##BA	O
)	O
,	O
ace	B
##to	I
##ace	I
##tic	I
acid	I
,	O
C	O
##MP	O
##F	O
,	O
and	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
.	O

6	O
##AM	O
,	O
6	O
##AM	O
-	O
D	O
_	O
6	O
(	O
100	O
μ	O
##g	O
/	O
m	O
##L	O
)	O
,	O
(	B
±	I
)	I
-	I
AM	I
##P	I
,	O
(	B
±	I
)	I
-	I
AM	I
##P	I
-	I
D	I
_	I
11	I
,	O
B	O
##ED	O
_	O
8	O
(	O
100	O
μ	O
##g	O
/	O
m	O
##L	O
)	O
,	O
B	O
##UP	O
(	O
100	O
μ	O
##g	O
/	O
m	O
##L	O
)	O
,	O
B	O
##UP	O
-	O
D	O
_	O
4	O
(	O
100	O
μ	O
##g	O
/	O
m	O
##L	O
)	O
,	O
CE	O
,	O
CE	O
-	O
D	O
_	O
3	O
(	O
100	O
μ	O
##g	O
/	O
m	O
##L	O
)	O
,	O
CO	O
##C	O
,	O
CO	O
##C	O
-	O
D	O
_	O
3	O
(	O
100	O
μ	O
##g	O
/	O
m	O
##L	O
)	O
,	O
CO	O
##D	O
,	O
CO	O
##D	O
-	O
D	O
_	O
6	O
,	O
(	O
−	O
)	O
-	O
CO	O
##T	O
,	O
(	B
±	I
)	I
-	I
CO	I
##T	I
-	I
D	I
_	I
3	I
(	O
100	O
μ	O
##g	O
/	O
m	O
##L	O
)	O
,	O
E	O
##D	O
##DP	O
perch	B
##lora	I
##te	I
,	O
E	O
##D	O
##DP	O
-	O
D	O
_	O
3	O
perch	B
##lora	I
##te	I
(	O
100	O
μ	O
##g	O
/	O
m	O
##L	O
)	O
,	O
H	O
##Y	O
##C	O
,	O
H	O
##Y	O
##C	O
-	O
D	O
_	O
6	O
,	O
H	O
##Y	O
##M	O
,	O
H	O
##Y	O
##M	O
-	O
D	O
_	O
3	O
,	O
(	B
±	I
)	I
-	I
MA	I
##MP	I
,	O
(	B
±	I
)	I
-	I
MA	I
##MP	I
-	I
D	I
_	I
14	I
,	O
m	O
##OH	O
##BE	O
,	O
M	O
##OR	O
,	O
M	O
##OR	O
-	O
D	O
_	O
3	O
(	O
100	O
μ	O
##g	O
/	O
m	O
##L	O
)	O
,	O
(	B
±	I
)	I
-	I
M	I
##T	I
##D	I
,	O
(	B
±	I
)	I
-	I
M	I
##T	I
##D	I
-	I
D	I
_	I
9	I

G	B
##lu	I
##co	I
##cor	I
##tic	I
##oid	I
precursor	O
meta	O
##bol	O
##ites	O
PD	O
,	O
PT	O
,	O
17	O
-	O
HP	O
,	O
and	O
te	B
##tra	I
##hy	I
##dr	I
##o	I
-	I
11	I
-	I
de	I
##ox	I
##y	I
##cor	I
##tis	I
##ol	I
(	O
T	O
##HS	O
)	O
were	O
significantly	O
higher	O
in	O
ACC	O
,	O
as	O
were	O
free	O
co	B
##rt	I
##is	I
##ol	I
,	O
6	B
##β	I
##OH	I
-	I
co	I
##rt	I
##is	I
##ol	I
,	O
te	B
##tra	I
##hy	I
##dr	I
##oc	I
##ort	I
##is	I
##ol	I
,	O
and	O
α	B
-	I
co	I
##rt	I
##ol	I
(	O
,	O
C	O
and	O
D	O
,	O
and	O
Su	O
##pp	O
##lement	O
##al	O
Table	O
2	O
)	O
.	O

A	O
free	O
fatty	O
acid	O
(	O
11	O
-	O
do	O
##de	O
##ce	O
##no	O
##ic	O
acid	O
)	O
showed	O
higher	O
levels	O
in	O
RC	O
##C	O
,	O
and	O
the	O
oxidation	O
intermediate	O
2	B
,	I
6	I
-	I
dim	I
##eth	I
##yl	I
##he	I
##pta	I
##noy	I
##l	I
car	I
##ni	I
##tine	I
showed	O
lower	O
levels	O
,	O
indicating	O
a	O
high	O
energy	O
requirement	O
in	O
RC	O
##C	O
.	O

Arte	O
##rial	O
##ized	O
blood	O
glucose	S
concentration	O
was	O
determined	O
every	O
5	O
–	O
10	O
min	O
as	O
described	O
in	O
Other	O
analytical	O
methods	O
(	O
see	O
below	O
)	O
and	O
the	O
in	O
##fusion	O
rate	O
was	O
adjusted	O
accordingly	O
.	O

The	O
repeat	O
##ability	O
of	O
the	O
peak	O
area	O
of	O
a	O
ta	B
##uri	I
##ne	I
standard	O
in	O
water	O
prepared	O
at	O
a	O
concentration	O
of	O
0	O
.	O
1	O
μ	O
##g	O
S	O
m	O
##L	O
_	O
−	O
##1	O
(	O
0	O
.	O
9	O
pm	O
##ol	O
)	O
was	O
found	O
to	O
be	O
7	O
.	O
6	O
%	O
(	O
n	O
=	O
6	O
)	O
(	O
E	O
##SM	O
Fi	O
##g	O
.	O
S	O
##3	O
)	O
.	O

The	O
formal	B
##in	I
fix	O
##ation	O
and	O
para	O
##ffin	O
-	O
em	O
##bed	O
##ding	O
is	O
a	O
multi	O
##ste	O
##p	O
procedure	O
.	O

We	O
believe	O
that	O
additional	O
attempts	O
to	O
valid	O
##ate	O
the	O
e	O
##pi	O
##gene	O
##tic	O
regulation	O
of	O
α	B
-	I
O	I
##G	I
on	O
AR	O
##ID	O
##1	O
##A	O
in	O
clinical	O
samples	O
may	O
provide	O
novel	O
insight	O
into	O
the	O
et	O
##iology	O
of	O
I	O
##C	O
and	O
identify	O
meta	O
##bol	O
##ites	O
that	O
can	O
serve	O
as	O
I	O
##C	O
bio	O
##mark	O
##ers	O
for	O
clinical	O
application	O
.	O

Given	O
the	O
robust	O
and	O
sensitive	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
ass	O
##ay	O
and	O
the	O
different	O
approaches	O
we	O
used	O
to	O
study	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
metabolism	O
,	O
it	O
seems	O
unlikely	O
that	O
this	O
is	O
due	O
to	O
limitations	O
of	O
our	O
experimental	O
or	O
ass	O
##ay	O
conditions	O
.	O

Card	O
##iovascular	O
risk	O
factor	O
profile	O
has	O
been	O
associated	O
with	O
high	O
ch	B
##olin	I
##e	I
in	O
plasma	O
suggesting	O
a	O
disruption	O
of	O
ch	B
##olin	I
##e	I
oxidation	O
to	O
beta	B
##ine	I
as	O
part	O
of	O
the	O
mitochondrial	O
d	O
##ys	O
##function	O
.	O

Other	O
significant	O
differences	O
related	O
to	O
post	O
-	O
treatment	O
re	O
##cu	O
##rrence	O
were	O
found	O
for	O
additional	O
meta	O
##bol	O
##ites	O
including	O
c	B
##rea	I
##tin	I
##ine	I
,	O
c	B
##it	I
##ru	I
##llin	I
##e	I
,	O
th	B
##re	I
##ona	I
##te	I
,	O
2	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
,	O
3	B
-	I
amino	I
##is	I
##ob	I
##uy	I
##rate	I
,	O
and	O
others	O
shown	O
in	O
.	O

(	O
90	O
:	O
10	O
,	O
v	O
/	O
v	O
)	O
containing	O
10	O
m	O
##M	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
and	O
(	O
B	O
)	O
CH	O
_	O
3	O

An	O
interesting	O
observation	O
in	O
the	O
present	O
study	O
was	O
a	O
strong	O
,	O
significant	O
positive	O
HC	O
##C	O
risk	O
association	O
for	O
the	O
ex	O
##ogen	O
##ous	O
meta	O
##bol	O
##ite	O
prop	B
##yle	I
##ne	I
g	I
##ly	I
##co	I
##l	I
.	O

Moreover	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
my	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
treatment	O
in	O
an	O
in	O
v	O
##it	O
##ro	O
F	O
##S	O
##GS	O
model	O
,	O
and	O
we	O
found	O
that	O
MI	O
##OX	O
increased	O
in	O
proportion	O
to	O
e	O
##G	O
##F	O
##R	O
in	O
F	O
##S	O
##GS	O
human	O
kidney	O
tissue	O
,	O
while	O
it	O
was	O
inverse	O
##ly	O
related	O
to	O
u	O
##rina	O
##ry	O
my	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
.	O

Thus	O
,	O
increased	O
levels	O
of	O
MMA	O
found	O
in	O
this	O
study	O
re	O
##af	O
##fi	O
##rm	O
Vita	B
##min	I
B	I
##12	I
deficiency	O
of	O
HIV	O
/	O
AIDS	O
patients	O
.	O

An	O
intense	O
peak	O
at	O
8	O
.	O
99	O
min	O
is	O
observed	O
in	O
each	O
ch	O
##roma	O
##to	O
##gram	O
indicating	O
try	B
##pt	I
##op	I
##han	I
is	O
present	O
in	O
the	O
blank	O
.	O

These	O
increases	O
in	O
amino	O
acids	O
were	O
all	O
correlated	O
with	O
reduction	O
in	O
free	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
and	O
were	O
all	O
highly	O
correlated	O
with	O
each	O
other	O
.	O

Cal	O
##ci	O
##um	O
,	O
chloride	S
,	O
potassium	O
,	O
sodium	O
,	O
phosphate	S
,	O
and	O
also	O
iron	O
concentrations	O
,	O
as	O
well	O
as	O
c	B
##rea	I
##tin	I
##ine	I
,	O
bi	B
##li	I
##ru	I
##bin	I
,	O
L	O
##D	O
##L	O
-	O
,	O
HD	O
##L	O
-	O
,	O
and	O
total	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
,	O
glucose	S
,	O
u	B
##ric	I
acid	I
,	O
u	B
##rea	I
,	O
free	O
T	O
##3	O
and	O
free	O
T	B
##4	I
thy	I
##roid	I
hormone	I
concentrations	O
were	O
determined	O
in	O
blood	O
serum	O
.	O

For	O
example	O
,	O
2	B
-	I
amino	I
##adi	I
##pic	I
acid	I
is	O
a	O
product	O
of	O
l	B
##ys	I
##ine	I
degradation	O
.	O

The	O
t	B
##yr	I
##os	I
##ine	I
metabolism	O
,	O
including	O
t	B
##yr	I
##os	I
##ine	I
,	O
thy	B
##ro	I
##xin	I
##e	I
,	O
L	B
-	I
D	I
##OP	I
##A	I
and	O
do	B
##pa	I
##mine	I
,	O
showed	O
the	O
highest	O
impact	O
based	O
on	O
the	O
pathway	O
analysis	O
and	O
may	O
thus	O
play	O
a	O
central	O
role	O
in	O
disease	O
progression	O
.	O

It	O
was	O
previously	O
established	O
that	O
plasma	O
or	B
##ni	I
##thin	I
##e	I
concentrations	O
are	O
higher	O
in	O
di	O
##abe	O
##tic	O
subjects	O
,	O
and	O
this	O
is	O
a	O
marker	O
of	O
a	O
##rg	O
##inas	O
##e	O
activity	O
.	O

The	O
two	O
co	O
-	O
el	O
##uti	O
##ng	O
re	O
##gio	O
##is	O
##omer	O
##s	O
from	O
4	B
-	I
OH	I
-	I
E	I
##2	I
and	O
2	B
-	I
OH	I
-	I
E	I
##2	I
are	O
shown	O
with	O
an	O
as	O
##ter	O
##isk	O
(	O
and	O
)	O
.	O

The	O
ratio	O
of	O
all	O
est	B
##rogen	I
meta	O
##bol	O
##ites	O
to	O
parent	O
est	B
##rogen	I
was	O
directly	O
associated	O
with	O
the	O
order	O
C	O
##los	O
##tri	O
##dial	O
##es	O
(	O
r	O
=	O
0	O
.	O
32	O
,	O
P	O
=	O
.	O
02	O
)	O
and	O
,	O
among	O
the	O
C	O
##los	O
##tri	O
##dial	O
##es	O
,	O
with	O
the	O
family	O
R	O
##umi	O
##no	O
##co	O
##cca	O
##ceae	O
(	O
r	O
=	O
0	O
.	O
37	O
,	O
P	O
=	O
.	O
00	O
##5	O
)	O
.	O

The	O
e	O
##G	O
##F	O
##R	O
is	O
based	O
on	O
c	B
##rea	I
##tin	I
##ine	I
–	I
c	I
##ys	I
##tat	I
##in	I
C	O
equation	O
;	O
Model	O
1	O
:	O
Ad	O
##ju	O
##st	O
##ment	O
for	O
age	O
and	O
sex	O
;	O
Model	O
2	O
:	O
Model	O
1	O
+	O
adjustment	O
for	O
E	O
##g	O
##f	O
##r	O
;	O
Model	O
3	O
:	O
Model	O
2	O
+	O
adjustment	O
for	O
body	O
mass	O
index	O
and	O
smoking	O
;	O
Model	O
4	O
:	O
Model	O
3	O
+	O
adjustment	O
for	O
ethnicity	O
,	O
fast	O
##ing	O
glucose	S
,	O
total	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
high	O
-	O
density	O
lip	O
##op	O
##rote	O
##in	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
,	O
and	O
C	O
-	O
reactive	O
protein	O
.	O

It	O
is	O
possible	O
that	O
for	O
unknown	O
reasons	O
the	O
re	O
##current	O
group	O
had	O
increased	O
S	B
-	I
ad	I
##eno	I
##sy	I
##lm	I
##eth	I
##ion	I
##ine	I
(	O
SA	O
##M	O
)	O
which	O
activated	S
the	O
trans	O
##ulf	O
##uration	O
pathway	O
thus	O
,	O
increasing	O
c	B
##ys	I
##tat	I
##hi	I
##oni	I
##ne	I
,	O
c	B
##ys	I
##tein	I
##e	I
,	O
and	O
formation	O
of	O
sa	B
##rc	I
##os	I
##ine	I
.	O

The	O
ratio	O
of	O
(	B
AC	I
C	I
##16	I
+	I
AC	I
C	I
##18	I
:	I
1	I
)	I
/	I
AC	I
C	O
##2	O
in	O
H	O
##B	O
##V	O
-	O
associated	O
c	O
##ir	O
##r	O
##hos	O
##is	O
was	O
higher	O
than	O
those	O
in	O
CH	O
##B	O
and	O
H	O
##B	O
##V	O
-	O
associated	O
HC	O
##C	O
,	O
which	O
indicates	O
an	O
increase	O
for	O
the	O
c	O
##ir	O
##r	O
##hos	O
##is	O
stage	O
of	O
disease	O
progression	O
for	O
CP	O
##T	O
##2	O
activity	O
.	O

SL	O
##s	O
participate	O
in	O
several	O
aspects	O
of	O
the	O
H	O
##B	O
##V	O
life	O
cycle	O
,	O
and	O
blocking	O
host	O
SL	S
bio	O
##sy	O
##nt	O
##hesis	O
was	O
shown	O
to	O
in	O
##hibit	O
H	O
##B	O
##V	O
replication	O
.	O

The	O
accumulation	O
of	O
ace	B
##tam	I
##ip	I
##rid	I
in	O
mammals	O
has	O
never	O
been	O
reported	O
,	O
whereas	O
the	O
half	O
-	O
life	O
of	O
ace	B
##tam	I
##ip	I
##rid	I
is	O
relatively	O
longer	O
than	O
other	O
neon	B
##ico	I
##tino	I
##ids	I
.	O

In	O
patients	O
with	O
both	O
P	O
##ET	O
-	O
positive	O
lesions	O
and	O
low	O
relative	O
g	B
##lut	I
##ama	I
##te	I
levels	O
(	O
suggest	O
##ive	O
for	O
cancer	O
)	O
,	O
this	O
procedure	O
leads	O
to	O
a	O
sensitivity	O
and	O
PP	O
##V	O
to	O
di	O
##ag	O
##nose	O
lung	O
cancer	O
of	O
100	O
%	O
(	O
no	O
false	O
negative	O
##s	O
)	O
and	O
96	O
%	O
(	O
higher	O
true	O
positive	O
results	O
than	O
for	O
P	O
##ET	O
/	O
CT	O
alone	O
)	O
,	O
respectively	O
.	O

The	O
exact	O
relationship	O
between	O
1	B
-	I
met	I
##hyl	I
##nic	I
##ot	I
##ina	I
##mi	I
##de	I
and	O
ace	B
##tone	I
has	O
not	O
been	O
described	O
in	O
the	O
literature	O
,	O
however	O
,	O
it	O
is	O
possible	O
that	O
the	O
increase	O
in	O
ace	B
##tone	I
and	O
decrease	O
in	O
1	B
-	I
met	I
##hyl	I
##nic	I
##ot	I
##ina	I
##mi	I
##de	I
levels	O
in	O
infants	O
with	O
RS	O
##V	O
AR	O
##I	O
compared	O
to	O
healthy	O
infants	O
are	O
indicators	O
of	O
a	O
cellular	O
switch	O
in	O
energy	O
production	O
to	O
survival	O
mode	O
and	O
a	O
tendency	O
toward	O
higher	O
inflammatory	O
metabolism	O
due	O
to	O
stress	O
from	O
viral	O
infection	O
.	O

About	O
a	O
hundred	O
of	O
gang	B
##lio	I
##side	I
molecular	O
species	O
among	O
15	O
distinct	O
classes	O
were	O
detected	O
ill	O
##ust	O
##rating	O
the	O
huge	O
structural	O
diversity	O
of	O
these	O
compounds	O
.	O

Our	O
study	O
provides	O
evidence	O
that	O
the	O
cancer	O
meta	O
##bol	O
##ome	O
is	O
reflected	O
in	O
body	O
fluids	O
and	O
measuring	O
blood	O
his	B
##ti	I
##dine	I
concentration	O
,	O
a	O
precursor	O
for	O
his	B
##tamine	I
,	O
can	O
provide	O
a	O
valuable	O
information	O
due	O
to	O
its	O
association	O
with	O
the	O
presence	O
of	O
cancer	O
.	O

Thus	O
,	O
AL	O
##D	O
##H	O
seems	O
to	O
functional	O
##ly	O
promote	O
multiple	O
cancer	O
cell	O
processes	O
via	O
direct	O
drug	O
in	O
##act	O
##ivation	O
,	O
promoting	O
o	O
##xi	O
##da	O
##tive	O
stress	O
resistance	O
,	O
and	O
media	O
##ting	O
re	B
##tino	I
##ic	I
acid	I
signaling	O
mechanisms	O
that	O
favor	O
cell	O
survival	O
and	O
other	O
tumor	O
##ige	O
##nic	O
processes	O
.	O

As	B
##par	I
##tate	I
was	O
labeled	O
from	O
both	O
glucose	S
and	O
g	B
##lut	I
##amine	I
,	O
albeit	O
slightly	O
more	O
from	O
g	B
##lut	I
##amine	I
,	O
indicating	O
that	O
both	O
nutrients	O
contribute	O
to	O
as	B
##par	I
##tate	I
synthesis	O
.	O

The	O
dried	O
residue	O
was	O
re	O
##con	O
##stituted	O
in	O
200	O
μ	O
##L	O
30	O
%	O
(	O
by	O
volume	O
)	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
in	O
water	O
,	O
then	O
v	O
##ortex	O
-	O
mix	O
for	O
1	O
minute	O
.	O

We	O
identified	O
c	B
##yt	I
##id	I
##ine	I
5	I
′	I
-	I
dip	I
##hos	I
##ph	I
##och	I
##olin	I
##e	I

P	O
##las	O
##ma	O
proteins	O
were	O
pre	O
##ci	O
##pit	O
##ated	O
with	O
80	O
%	O
met	B
##han	I
##ol	I
and	O
super	O
##nat	O
##ant	O
,	O
after	O
cent	O
##ri	O
##fu	O
##gation	O
at	O
5	O
,	O
000	O
g	O
for	O
10	O
min	O
,	O
0	O
##°	O
##C	O
,	O
and	O
were	O
collected	O
for	O
determination	O
of	O
the	O
anal	O
##yte	O
concentration	O
as	O
described	O
.	O

The	O
subjects	O
who	O
answered	O
a	O
##ff	O
##ir	O
##mat	O
##ively	O
had	O
about	O
15	O
-	O
fold	O
higher	O
levels	O
of	O
3	O
-	O
HP	O
##MA	O
(	O
meta	O
##bol	O
##ite	O
of	O
a	O
##c	O
##rol	O
##ein	O
)	O
,	O
1	O
.	O
5	O
-	O
fold	O
higher	O
levels	O
of	O
D	O
##H	O
##BM	O
##A	O
(	O
meta	O
##bol	O
##ite	O
of	O
1	B
,	I
3	I
-	I
but	I
##adi	I
##ene	I
)	O
,	O
1	O
.	O
8	O
-	O
fold	O
higher	O
levels	O
of	O
GA	O
##MA	O
(	O
meta	O
##bol	O
##ite	O
of	O
a	B
##c	I
##ryl	I
##ami	I
##de	I
)	O
,	O
6	O
.	O
7	O
-	O
fold	O
higher	O
levels	O
of	O
HM	O
##PM	O
##A	O
(	O
meta	O
##bol	O
##ite	O
of	O
c	B
##rot	I
##onal	I
##de	I
##hy	I
##de	I
)	O
,	O
and	O
4	O
-	O
fold	O
higher	O
values	O
of	O
S	O
##BM	O
##A	O
(	O
meta	O
##bol	O
##ite	O
of	O
to	O
##lue	O
##ne	O
)	O
.	O

To	O
overcome	O
this	O
influence	O
,	O
we	O
removed	O
the	O
bin	O
##s	O
related	O
to	O
la	B
##ct	I
##ate	I
from	O
the	O
data	O
matrix	O
.	O

Among	O
the	O
main	O
findings	O
of	O
this	O
research	O
:	O
(	O
1	O
)	O
The	O
HP	O
##LC	O
-	O
MS	O
/	O
MS	O
-	O
based	O
approach	O
described	O
here	O
proved	O
a	O
sensitive	O
and	O
specific	O
methodology	O
for	O
measuring	O
the	O
s	O
##tero	O
##ids	O
under	O
study	O
;	O
(	O
2	O
)	O
The	O
use	O
of	O
an	O
IS	O
prevented	O
interference	O
##s	O
in	O
extraction	O
caused	O
by	O
differences	O
in	O
matrix	O
complex	O
##ities	O
between	O
HIV	O
-	O
T	O
##B	O
and	O
HD	O
;	O
(	O
3	O
)	O
Not	O
##ably	O
,	O
HIV	O
-	O
T	O
##B	O
patients	O
exhibited	O
higher	O
plasma	O
levels	O
of	O
D	O
##H	O
##EA	O
,	O
A	O
##ET	O
and	O
7	B
-	I
o	I
##x	I
##o	I
-	I
D	I
##H	I
##EA	I
compared	O
with	O
HD	O
;	O
4	O
)	O
7	B
-	I
o	I
##x	I
##o	I
-	I
D	I
##H	I
##EA	I
levels	O
were	O
positively	O
related	O
with	O
absolute	O
CD	O
##4	O
+	O
T	O
cell	O
counts	O
,	O
CD	O
##4	O
+	O
T	O
cell	O
na	O
##dir	O
values	O
and	O
the	O
development	O
of	O
pu	O
##lm	O
##ona	O
##r	O
instead	O
of	O
extra	O
##pu	O
##lm	O
##ona	O
##r	O
T	O
##B	O
.	O

Primary	O
inflammatory	O
breast	O
cancer	O
cells	O
,	O
S	O
##UM	O
##14	O
##9	O
##P	O
##T	O
(	O
As	O
##tera	O
##nd	O
,	O
Detroit	O
,	O
MI	O
)	O
,	O
and	O
highly	O
invasive	O
breast	O
cancer	O
cells	O
,	O
S	O
##UM	O
##13	O
##15	O
##MO	O
##2	O
(	O
As	O
##tera	O
##nd	O
)	O
,	O
were	O
grown	O
in	O
F	O
-	O
12	O
media	O
(	O
117	O
##65	O
-	O
05	O
##4	O
,	O
G	O
##ib	O
##co	O
BR	O
##L	O
,	O
Grand	O
Island	O
,	O
NY	O
)	O
supplemented	O
with	O
10	O
%	O
heat	O
-	O
inactivated	O
f	O
##etal	O
b	O
##ov	O
##ine	O
serum	O
(	O
H	O
##y	O
##C	O
##lone	O
,	O
Logan	O
,	O
U	O
##T	O
)	O
,	O
insulin	O
(	O
1927	O
##8	O
,	O
Sigma	O
,	O
St	O
.	O
Louis	O
,	O
M	O
##O	O
)	O
,	O
H	O
##EP	O
##ES	O
(	O
H	O
##33	O
##75	O
;	O
Sigma	O
)	O
,	O
E	O
##G	O
##F	O
(	O
E	O
##9	O
##64	O
##4	O
;	O
Sigma	O
)	O
for	O
S	O
##UM	O
##13	O
##15	O
##MO	O
##2	O
and	O
H	B
##ydro	I
##cor	I
##tis	I
##one	I
(	O
H	O
##40	O
##01	O
,	O
Sigma	O
)	O
for	O
S	O
##UM	O
##14	O
##9	O
##P	O
##T	O
.	O

In	O
per	B
##ito	I
##nea	I
##l	I
e	O
##ff	O
##lue	O
##nts	O
pro	O
-	O
inflammatory	O
media	O
##tors	O
P	O
##GE	O
_	O
2	O

Human	O
liver	O
micro	O
##some	O
##s	O
(	O
pool	O
of	O
200	O
donors	O
)	O
,	O
N	B
##AD	I
##P	I
##H	I
re	O
##gene	O
##rating	O
system	O
solution	O

Both	O
E	B
_	I
1	I
-	I
9	I
-	I
N	I
-	I
Ad	I
##e	I
and	O
E	B
_	I
2	I
-	I
9	I
-	I
N	I
-	I
Ad	I
##e	I
add	O
##uc	O
##ts	O
are	O
new	O
and	O
were	O
used	O
to	O
probe	O
est	B
##rogen	I
metabolic	O
pathway	O
in	O
v	O
##it	O
##ro	O
and	O
in	O
humans	O
.	O

A	O
similar	O
in	O
##hibition	O
profile	O
was	O
observed	O
when	O
1	O
µ	O
##m	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
was	O
used	O
(	O
by	O
26	O
%	O
and	O
33	O
%	O
at	O
50	O
and	O
100	O
µ	O
##m	O
trim	O
##eth	O
##op	O
##rim	O
)	O
.	O

Among	O
the	O
meta	O
##bol	O
##ites	O
in	O
these	O
altered	O
pathways	O
,	O
the	O
three	O
inter	O
##media	O
##ries	O
of	O
g	B
##lut	I
##ath	I
##ione	I
metabolism	O
namely	O
g	B
##lut	I
##ath	I
##ione	I
,	O
o	O
##xi	O
##dized	O
(	O
G	O
##SS	O
##G	O
)	O
,	O
as	B
##cor	I
##bic	I
acid	I
and	O
de	B
##hy	I
##dr	I
##oa	I
##sco	I
##rb	I
##ic	I
acid	I
are	O
of	O
significant	O
importance	O
in	O
the	O
setting	O
of	O
my	O
##oc	O
##ard	O
##ial	O
re	O
##per	O
##fusion	O
injury	O
.	O

Both	O
c	B
##it	I
##rate	I
and	O
t	B
##yr	I
##os	I
##ine	I
were	O
significantly	O
negatively	O
correlated	O
with	O
B	O
##MI	O
,	O
MA	O
##P	O
,	O
total	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
L	B
##D	I
##L	I
ch	I
##ole	I
##ster	I
##ol	I
,	O
and	O
t	B
##rig	I
##ly	I
##cer	I
##ide	I
levels	O
.	O

Inc	O
##or	O
##por	O
##ating	O
this	O
ratio	O
into	O
a	O
risk	O
prediction	O
model	O
already	O
including	O
un	O
##con	O
##ju	O
##gated	O
est	B
##rad	I
##iol	I
improved	O
absolute	O
risk	O
estimates	O
substantially	O
(	O
by	O
≥	O
14	O
%	O
)	O
in	O
36	O
%	O
of	O
the	O
women	O
,	O
an	O
encouraging	O
result	O
that	O
needs	O
replication	O
.	O

We	O
not	O
only	O
measured	O
elevated	O
concentrations	O
of	O
p	O
-	O
c	O
##res	O
##ol	O
and	O
its	O
g	B
##lu	I
##cu	I
##ron	I
##ide	I
in	O
the	O
late	O
stages	O
of	O
CR	O
##C	O
,	O
but	O
,	O
more	O
##over	O
,	O
surgical	O
intervention	O
marked	O
##ly	O
reduced	O
the	O
levels	O
in	O
patients	O
after	O
surgery	O
by	O
approximately	O
50	O
%	O
.	O

Since	O
several	O
s	O
##ym	O
##pt	O
##oma	O
##tic	O
the	O
##rap	O
##ies	O
are	O
partially	O
or	O
fully	O
meta	O
##bol	O
##ized	O
by	O
enzymes	O
of	O
the	O
he	O
##pa	O
##tic	O
c	O
##yt	O
##och	O
##rome	O
P	O
##45	O
##0	O
system	O
(	O
C	O
##YP	O
##45	O
##0	O
)	O
it	O
is	O
important	O
to	O
evaluate	O
drug	O
–	O
drug	O
interactions	O
through	O
potential	O
effects	O
of	O
da	B
##lf	I
##amp	I
##rid	I
##ine	I
-	I
ER	I
on	O
C	O
##YP	O
##45	O
##0	O
.	O

In	O
addition	O
,	O
a	O
subset	O
of	O
patients	O
were	O
also	O
subjected	O
to	O
ch	O
##em	O
##otherapy	O
with	O
the	O
following	O
distribution	O
:	O
AC	O
(	B
Ad	B
##ria	I
##my	I
##cin	I
+	I
Cy	I
##c	I
##lop	I
##hos	I
##pha	I
##mi	I
##de	I
(	O
AC	O
)	O
(	O
Sigma	O
,	O
St	O
Louis	O
,	O
M	O
##O	O
,	O
USA	O
)	O
)	O

L	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
(	O
L	O
##ys	O
##o	O
##PC	O
)	O
is	O
a	O
major	O
bio	O
##active	O
plasma	O
lip	O
##id	O
in	O
the	O
normal	O
human	O
circulation	O
where	O
it	O
is	O
predominantly	O
associated	O
with	O
album	O
##in	O
and	O
lip	O
##op	O
##rote	O
##ins	O
.	O

Met	B
##han	I
##ol	I
and	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
were	O
removed	O
by	O
Speed	O
-	O
V	O
##ac	O
,	O
and	O
the	O
a	O
##que	O
##ous	O
left	O
##over	O
was	O
dried	O
with	O
l	O
##yo	O
##phi	O
##li	O
##zation	O
process	O
.	O

Effect	O
of	O
p	B
##io	I
##gli	I
##ta	I
##zone	I
(	O
P	O
##IO	O
)	O
therapy	O
on	O
in	O
##tra	O
##my	O
##oc	O
##ell	O
##ular	O
fat	O
content	O
,	O
skeletal	O
muscle	O
L	O
##C	O
-	O
FA	O
##C	O
##o	O
##A	O
,	O
and	O
skeletal	O
muscle	O
D	O
##AG	O
.	O

A	O
corresponding	O
increase	O
in	O
plasma	O
NE	O
##FA	O
during	O
place	O
##bo	O
(	O
26	O
±	O
13	O
%	O
,	O
P	O
=	O
0	O
.	O
06	O
)	O
was	O
also	O
observed	O
with	O
a	O
reduction	O
in	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
(	O
−	O
##11	O
±	O
4	O
.	O
6	O
%	O
,	O
P	O
=	O
0	O
.	O
03	O
)	O
.	O

F	O
##P	O
##G	O
and	O
serum	O
H	O
##b	O
##A	O
##1	O
##c	O
levels	O
were	O
equivalent	O
between	O
groups	O
so	O
there	O
was	O
no	O
evidence	O
for	O
elevated	O
rates	O
of	O
und	O
##ia	O
##gno	O
##sed	O
T	O
##2	O
##D	O
,	O
impaired	O
glucose	S
tolerance	O
(	O
I	O
##G	O
##T	O
)	O
or	O
impaired	O
fast	O
##ing	O
glucose	S
(	O
IF	O
##G	O
)	O
in	O
these	O
British	O
patients	O
with	O
late	O
-	O
onset	O
AD	O
.	O

Interest	O
##ingly	O
,	O
the	O
nodes	O
unique	O
to	O
the	O
HC	O
##V	O
network	O
are	O
related	O
to	O
the	O
lip	O
##id	O
metabolism	O
,	O
apart	O
from	O
man	B
##nose	I
and	O
g	B
##ly	I
##cine	I
.	O

(	O
4	O
##OH	O
##ND	O
##tam	O
,	O
end	B
##ox	I
##ife	I
##n	I
)	O
.	O

The	O
product	O
of	O
the	O
PC	O
reaction	O
is	O
o	B
##xa	I
##lo	I
##ace	I
##tate	I
,	O
which	O
immediately	O
con	O
##den	O
##ses	O
with	O
ace	B
##ty	I
##l	I
-	I
Co	I
##A	I
to	O
produce	O
c	B
##it	I
##rate	I
or	O
is	O
converted	O
to	O
ma	B
##late	I
in	O
the	O
mitochondrial	O
ma	O
##late	O
de	O
##hy	O
##dr	O
##ogen	O
##ase	O
reaction	O
.	O

S	O
##ynth	O
##etic	O
E	B
_	I
1	I
-	I
9	I
-	I
N	I
-	I
Ad	I
##e	I
and	O
E	B
_	I
2	I
-	I
9	I
-	I
N	I
-	I
Ad	I
##e	I
as	O
well	O
as	O
the	O
breast	O
tissue	O
extract	O
##s	O
showed	O
a	O
peak	O
(	O
404	O
.	O
3	O
>	O
26	O
##8	O
.	O
96	O
)	O
at	O
R	O
_	O
t	O
of	O
[UNK]	O
.	O
4	O
min	O
(	O
C	O
&	O
D	O
)	O
and	O
a	O
peak	O
(	O
40	O
##6	O
.	O
3	O
>	O
27	O
##1	O
.	O
02	O
)	O
at	O
R	O
_	O
t	O
of	O
[UNK]	O
.	O
0	O
min	O
(	O
A	O
&	O
B	O
)	O
,	O
une	O
##qui	O
##voc	O
##ally	O
confirming	O
the	O
presence	O
of	O
E	B
_	I
1	I
-	I
9	I
-	I
N	I
-	I
Ad	I
##e	I
(	O
#	O
41	O
)	O
and	O
E	B
_	I
2	I
-	I
9	I
-	I
N	I
-	I
Ad	I
##e	I
(	O
#	O
42	O
)	O
.	O

In	O
a	O
previous	O
study	O
by	O
Stephens	O
et	O
al	O
[	O
]	O
,	O
it	O
was	O
reported	O
that	O
u	O
##rina	O
##ry	O
trans	B
-	I
a	I
##con	I
##itate	I
,	O
which	O
is	O
a	O
t	B
##rica	I
##rb	I
##ox	I
##yl	I
##ic	I
acid	I
,	O
was	O
decreased	O
in	O
I	O
##B	O
##D	O
patients	O
in	O
comparison	O
to	O
non	O
-	O
I	O
##B	O
##D	O
controls	O
.	O

Re	O
##ceive	O
##r	O
Opera	O
##tor	O
Character	O
##istic	O
analysis	O
of	O
di	B
##car	I
##box	I
##yl	I
##ic	I
acids	I
and	O
bi	O
##le	O
acids	O
,	O
meta	O
##bol	O
##ites	O
that	O
were	O
significantly	O
over	O
##ex	O
##pressed	O
in	O
DC	O
##s	O
vs	O
.	O
NH	O
##Cs	O
,	O
showed	O
that	O
these	O
markers	O
were	O
highly	O
sensitive	O
and	O
specific	O
for	O
c	O
##ir	O
##r	O
##hos	O
##is	O
in	O
this	O
study	O
co	O
##hor	O
##t	O
.	O

The	O
detection	O
of	O
some	O
particular	O
lip	O
##id	O
species	O
such	O
as	O
LP	O
##C	O
/	O
PC	O
and	O
SM	O
in	O
both	O
positive	O
and	O
negative	O
ion	O
##ization	O
modes	O
,	O
as	O
pro	O
##ton	O
##ated	O
ion	O
(	O
[	O
M	O
+	O
H	O
]	O
_	O
+	O
)	O
and	O
format	B
##e	I
add	O
##uc	O
##t	O
(	O
[	O
M	O
−	O
H	O
+	O
CH	O
##O	O
_	O
2	O
]	O
_	O
−	O
)	O
,	O
enabled	O
to	O
confirm	O
their	O
an	O
##not	O
##ation	O
and	O
also	O
improved	O
their	O
structural	O
characterization	O
.	O

Sc	B
##yl	I
##lo	I
-	I
in	I
##os	I
##ito	I
##l	I
,	O
his	B
##ti	I
##dine	I
,	O
glucose	S
,	O
and	O
a	O
subset	O
of	O
small	O
lip	O
##op	O
##rote	O
##in	O
particles	O
were	O
significantly	O
increased	O
in	O
R	O
##R	O
##MS	O
plasma	O
whilst	O
la	B
##ct	I
##ate	I
,	O
al	B
##ani	I
##ne	I
,	O
and	O
a	O
subset	O
of	O
large	O
lip	O
##op	O
##rote	O
##in	O
particles	O
were	O
significantly	O
decreased	O
relative	O
to	O
A	O
##Q	O
##P	O
##4	O
-	O
A	O
##b	O
N	O
##MO	O
##SD	O
plasma	O
.	O

The	O
presence	O
of	O
GM	B
##3	I
in	O
significant	O
proportion	O
was	O
also	O
noticeable	O
in	O
this	O
tissue	O
.	O

4	B
-	I
c	I
##res	I
##yl	I
su	I
##lf	I
##ate	I
and	O
p	B
##hen	I
##yla	I
##ce	I
##ty	I
##l	I
##g	I
##lut	I
##amine	I
are	O
two	O
of	O
the	O
three	O
major	O
human	O
gut	O
micro	O
##bial	O
u	O
##rina	O
##ry	O
co	O
-	O
meta	O
##bol	O
##ites	O
(	O
the	O
other	O
is	O
hip	O
##pura	O
##te	O
)	O
.	O

Ara	B
##chi	I
##don	I
##ic	I
acid	I
metabolism	O
and	O
g	B
##lut	I
##ath	I
##ione	I
synthesis	O
feed	O
into	O
the	O
pathway	O
to	O
generate	O
the	O
variety	O
of	O
signaling	O
molecules	O
on	O
this	O
pathway	O
.	O

The	O
pH	O
7	O
,	O
8	O
,	O
9	O
.	O
2	O
,	O
and	O
10	O
were	O
tested	O
using	O
four	O
separate	O
buffer	O
##s	O
containing	O
10	O
m	O
##M	O
am	B
##mon	I
##ium	I
hydrogen	I
carbon	I
##ate	I
and	O
3	O
m	O
##M	O
HM	O
##A	O
.	O

The	O
super	O
##nat	O
##ant	O
was	O
transferred	O
to	O
glass	O
tubes	O
,	O
e	O
##va	O
##porated	O
to	O
dry	O
##ness	O
,	O
re	O
##con	O
##stituted	O
with	O
100	O
µ	O
##L	O
to	B
##lue	I
##ne	I
(	O
dried	O
over	O
an	B
##hy	I
##dr	I
##ous	I
sodium	I
su	I
##lf	I
##ate	I
)	O
,	O
and	O
again	O
taken	O
to	O
dry	O
##ness	O
.	O

These	O
meta	O
##bol	O
##ites	O
are	O
all	O
involved	O
in	O
ch	B
##olin	I
##e	I
metabolism	O
pathway	O
.	O

The	O
compounds	O
numbered	O
149	O
,	O
63	O
and	O
9	O
were	O
selected	O
as	O
statistical	O
##ly	O
significant	O
for	O
L	B
##C	I
-	I
E	I
##SI	I
(	I
+	I
)	I
-	I
MS	I
,	O
L	B
##C	I
-	I
E	I
##SI	I
(	I
-	I
)	I
-	I
MS	I
and	O
G	O
##C	O
-	O
MS	O
,	O
respectively	O
.	O

Met	O
##ab	O
##olic	O
Path	O
##way	O
Analysis	O
also	O
showed	O
that	O
the	O
metabolism	O
of	O
g	B
##ly	I
##cine	I
and	O
se	B
##rine	I
was	O
among	O
the	O
most	O
impact	O
##ing	O
processes	O
in	O
HC	O
##C	O
progression	O
.	O

The	O
observed	O
increased	O
levels	O
of	O
ta	B
##uri	I
##ne	I
and	O
h	B
##y	I
##pot	I
##au	I
##rine	I
in	O
the	O
plasma	O
of	O
subjects	O
with	O
AM	O
##D	O
may	O
represent	O
a	O
com	O
##pen	O
##sat	O
##ory	O
response	O
to	O
increased	O
levels	O
of	O
lip	O
##id	O
per	O
##ox	O
##ida	O
##tion	O
and	O
o	O
##xi	O
##da	O
##tive	O
stress	O
.	O

A	O
number	O
of	O
studies	O
have	O
reported	O
G	B
##S	I
##H	I
would	O
be	O
a	O
reliable	O
marker	O
in	O
solid	O
tumors	O
and	O
hem	O
##ato	O
##logical	O
cancer	O
##s	O
(	O
G	O
##am	O
##cs	O
##ik	O
et	O
al	O
.	O

Go	O
to	O
:	O
T	B
##hi	I
##op	I
##uri	I
##nes	I
(	O
T	O
##P	O
)	O
represent	O
an	O
important	O
therapeutic	O
tool	O
for	O
the	O
treatment	O
of	O
inflammatory	O
bow	O
##el	O
diseases	O
(	O
I	O
##B	O
##D	O
)	O
in	O
the	O
current	O
situation	O
of	O
rising	O
incidence	O
and	O
health	O
care	O
costs	O
.	O

A	O
total	O
of	O
ten	O
urine	O
meta	O
##bol	O
##ites	O
were	O
found	O
to	O
be	O
significantly	O
changed	O
in	O
EC	O
patients	O
compared	O
to	O
HC	O
##s	O
(	O
Table	O
)	O
,	O
including	O
higher	O
levels	O
of	O
ace	B
##to	I
##ace	I
##tate	I
,	O
c	B
##is	I
-	I
a	I
##con	I
##itate	I
,	O
c	B
##it	I
##rate	I
and	O
g	B
##lut	I
##ama	I
##te	I
,	O
together	O
with	O
lower	O
amounts	O
of	O
g	B
##ly	I
##cine	I
,	O
ta	B
##uri	I
##ne	I
,	O
c	B
##rea	I
##tin	I
##ine	I
,	O
ethanol	B
##amine	I
,	O
glucose	S
and	O
hip	B
##pura	I
##te	I
.	O

Aden	B
##ine	I
is	O
a	O
compound	O
necessary	O
for	O
n	O
##uc	O
##leo	O
##tide	O
synthesis	O
and	O
is	O
considered	O
as	O
an	O
indicator	O
of	O
abnormal	O
cancer	O
cell	O
proliferation	O
.	O

We	O
com	O
##puted	O
the	O
lower	O
and	O
upper	O
limits	O
of	O
the	O
(	B
100	B
−	I
2	I
##δ	I
)	O

Thus	O
,	O
the	O
H	O
##S	O
##Q	O
##C	O
analysis	O
enabled	O
the	O
reconstruction	O
of	O
nitrogen	O
pathway	O
from	O
G	O
##ln	O
to	O
the	O
synthesis	O
of	O
pu	B
##rine	I
bases	O
.	O

Progressive	O
ne	O
##uro	O
##de	O
##gene	O
##ration	O
in	O
HD	O
involves	O
loss	O
of	O
both	O
grey	O
and	O
white	O
matter	O
volume	O
and	O
my	B
##elin	I
breakdown	O
.	O

According	O
to	O
our	O
results	O
,	O
serum	O
se	B
##rot	I
##oni	I
##n	I
levels	O
did	O
not	O
differ	O
between	O
kidney	O
function	O
groups	O
or	O
co	O
##rrel	O
##ate	O
with	O
e	O
##G	O
##F	O
##R	O
or	O
any	O
of	O
the	O
meta	O
##bol	O
##ites	O
.	O

L	O
##OA	O
conducted	O
de	O
no	O
##vo	O
analysis	O
of	O
the	O
data	O
generated	O
from	O
L	O
##C	O
–	O
P	O
##B	O
–	O
MS	O
/	O
MS	O
and	O
the	O
C	O
=	O
C	O
location	O
of	O
each	O
un	O
##sat	O
##ura	O
##ted	O
a	B
##cy	I
##l	I
(	I
al	I
##ky	I
##l	I
)	I
chain	O
was	O
assigned	O
based	O
on	O
the	O
detection	O
of	O
C	O
=	O
C	O
diagnostic	O
ion	O
pairs	O
.	O

The	O
first	O
reaction	O
of	O
that	O
process	O
involves	O
the	O
p	O
##hos	O
##ph	O
##ory	O
##lation	O
of	O
ch	B
##olin	I
##e	I
[	O
,	O
]	O
.	O

The	O
most	O
abundant	O
meta	O
##bol	O
##ites	O
of	O
5	O
-	O
H	O
##T	O
were	O
5	B
-	I
H	I
##IA	I
##A	I
(	O
90	O
–	O
110	O
n	O
##M	O
)	O
and	O
5	B
-	I
H	I
##IA	I
##A	I
-	I
S	I
(	O
380	O
–	O
550	O
n	O
##M	O
)	O
,	O
but	O
low	O
concentrations	O
of	O
5	B
-	I
H	I
##T	I
-	I
G	I
(	O
0	O
.	O
45	O
–	O
0	O
.	O
8	O
n	O
##M	O
)	O
were	O
also	O
identified	O
in	O
the	O
samples	O
from	O
patient	O
1	O
.	O

In	B
##os	I
##ine	I
,	O
a	O
precursor	O
of	O
x	B
##ant	I
##hine	I
that	O
was	O
not	O
associated	O
to	O
diabetes	O
incidence	O
in	O
the	O
overall	O
population	O
of	O
our	O
study	O
,	O
has	O
notable	O
anti	O
-	O
inflammatory	O
effects	O
,	O
which	O
may	O
be	O
mediated	O
,	O
at	O
least	O
in	O
part	O
,	O
by	O
activation	O
of	O
the	O
ad	B
##eno	I
##sin	I
##e	I
A2	O
##a	O
receptor	O
.	O

The	O
UP	O
##LC	O
mobile	O
phase	O
consisted	O
of	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
a	O
##que	O
##ous	O
solution	O
(	O
mobile	O
phase	O
A	O
)	O
and	O
95	O
%	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
with	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
(	O
mobile	O
phase	O
B	O
)	O
.	O

The	O
low	O
SA	O
##M	O
levels	O
resulting	O
from	O
impaired	O
met	B
##hi	I
##oni	I
##ne	I
regeneration	O
may	O
up	O
##re	O
##gu	O
##late	O
the	O
activity	O
of	O
met	B
##hyl	I
##ene	I
te	I
##tra	I
##hy	I
##dr	I
##of	I
##olate	I
red	O
##uc	O
##tase	O
(	O
M	O
##TH	O
##F	O
##R	O
)	O
resulting	O
in	O
increased	O
u	O
##til	O
##ization	O
of	O
co	O
##fa	O
##ctors	O
like	O
vitamin	O
B	O
_	O
2	O
which	O
is	O
significantly	O
reduced	O
in	O
CR	O
##C	O
cases	O
.	O

The	O
mobile	O
phases	O
were	O
(	O
A	O
)	O
100	O
%	O
water	O
and	O
(	O
B	O
)	O
100	O
%	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
with	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
.	O

The	O
meta	O
##bol	O
##ite	O
bars	O
are	O
colour	O
coded	O
according	O
to	O
meta	O
##bol	O
##ite	O
class	O
as	O
follows	O
:	O
amino	O
acids	O
and	O
bio	O
##genic	O
am	O
##ines	O
(	O
blue	O
)	O
;	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
(	O
green	O
)	O
;	O
l	O
##ys	O
##op	O
##hos	O
##pha	O
##ti	O
##dy	O
##l	O
##cho	O
##line	O
a	O
##cy	O
##l	O
(	O
l	O
##ys	O
##o	O
PC	O
a	O
)	O
(	O
dark	O
orange	O
)	O
;	O
p	O
##hos	O
##pha	O
##ti	O
##dy	O
##l	O
##cho	O
##line	O
di	O
##acy	O
##l	O
(	O
PC	O
a	O
##a	O
)	O
(	O
yellow	O
)	O
;	O
p	O
##hos	O
##pha	O
##ti	O
##dy	O
##l	O
##cho	O
##line	O
a	O
##cy	O
##l	O
-	O
a	O
##ky	O
##l	O
(	O
PC	O
a	O
##e	O
)	O
(	O
light	O
orange	O
)	O
;	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
(	O
SM	O
)	O
(	O
brown	O
)	O
.	O

The	O
differences	O
between	O
CA	O
##F	O
##s	O
and	O
N	O
##F	O
##s	O
in	O
the	O
g	O
##ly	O
##cine	O
/	O
se	O
##rine	O
/	O
th	O
##re	O
##oni	O
##ne	O
and	O
the	O
c	B
##rea	I
##tin	I
##ine	I
subgroup	O
##s	O
,	O
which	O
are	O
both	O
part	O
of	O
the	O
K	O
##EG	O
##G	O
designation	O
amino	O
acid	O
group	O
,	O
likely	O
account	O
for	O
this	O
group	O
distinguishing	O
the	O
CA	O
##F	O
##s	O
from	O
the	O
N	O
##F	O
##s	O
,	O
whereas	O
the	O
change	O
in	O
the	O
dip	O
##eptide	O
subgroup	O
accounted	O
for	O
the	O
p	O
##eptide	O
group	O
distinguishing	O
CA	O
##F	O
##s	O
from	O
N	O
##F	O
##s	O
.	O

Multiple	O
reaction	O
monitoring	O
ch	O
##roma	O
##to	O
##gram	O
of	O
β	B
-	I
a	I
##po	I
-	I
13	I
-	I
car	I
##ote	I
##non	I
##e	I
in	O
blood	O
plasma	O
(	O
top	O
)	O
and	O
a	O
standard	O
(	O
bottom	O
)	O
as	O
analyzed	O
by	O
atmospheric	O
pressure	O
chemical	O
ion	O
##ization	O
in	O
positive	O
mode	O
after	O
C	O
##30	O
HP	O
##LC	O
.	O

Only	O
4	O
SP	O
##s	O
,	O
SM	B
d	I
##16	I
:	I
1	I
/	I
18	I
:	I
0	I
and	O
SM	B
d	I
##18	I
:	I
1	I
/	I
18	I
:	I
0	I
and	O
their	O
metabolic	O
precursor	O
##s	O
,	O
Ce	B
##r	I
d	I
##16	I
:	I
1	I
/	I
18	I
:	I
0	I
and	O
Ce	B
##r	I
d	I
##18	I
:	I
1	I
/	I
18	I
:	I
0	I
,	O
remained	O
significant	O
after	O
adjustment	O
for	O
B	O
##MI	O
,	O
and	O
when	O
H	O
##b	O
##A	O
##1	O
##c	O
was	O
added	O
to	O
the	O
model	O
,	O
only	O
the	O
2	O
SM	O
##s	O
remained	O
independently	O
associated	O
with	O
T	O
##2	O
##DM	O
incidence	O
.	O

The	O
peak	O
area	O
of	O
each	O
meta	O
##bol	O
##ite	O
was	O
calculated	O
by	O
normal	O
##ization	O
to	O
the	O
internal	O
standard	O
,	O
c	B
##inn	I
##ami	I
##c	I
acid	I
,	O
and	O
additionally	O
to	O
the	O
protein	O
content	O
(	O
or	O
cell	O
mass	O
)	O
.	O

However	O
,	O
la	B
##ct	I
##ate	I
is	O
known	O
to	O
be	O
altered	O
in	O
meta	O
##static	O
disease	O
(	O
,	O
)	O
,	O
and	O
indeed	O
in	O
this	O
study	O
,	O
it	O
differed	O
between	O
E	O
##BC	O
and	O
MB	O
##C	O
patients	O
and	O
re	O
##lap	O
##sing	O
and	O
non	O
##rel	O
##ap	O
##sing	O
patients	O
.	O

In	O
summary	O
,	O
structural	O
characterization	O
of	O
fur	B
##an	I
u	O
##rina	O
##ry	O
meta	O
##bol	O
##ites	O
supports	O
the	O
hypothesis	O
that	O
fur	B
##an	I
is	O
o	O
##xi	O
##dized	O
to	O
reactive	O
B	O
##DA	O
,	O
which	O
trigger	O
##s	O
the	O
formation	O
of	O
c	B
##ys	I
##tein	I
##e	I
-	I
B	I
##DA	I
-	I
l	I
##ys	I
##ine	I
cross	O
##link	O
##s	O
.	O

Both	O
of	O
these	O
are	O
derived	O
from	O
Su	B
##cci	I
##nate	I
and	O
are	O
meta	O
##bol	O
##ites	O
of	O
the	O
C	B
##it	I
##ric	I
acid	I
cycle	O
,	O
suggesting	O
its	O
der	O
##eg	O
##ulation	O
during	O
HIV	O
infection	O
.	O

Therefore	O
,	O
g	B
##ly	I
##cine	I
could	O
be	O
a	O
useful	O
bio	O
##mark	O
##er	O
for	O
early	O
tumor	O
detection	O
(	O
Zhao	O
et	O
al	O
.	O
,	O
)	O
.	O

The	O
observed	O
plasma	O
metabolic	O
signature	O
in	O
patients	O
was	O
well	O
replica	O
##ted	O
in	O
the	O
culture	O
medium	O
of	O
He	O
##pa	O
##to	O
##C	O
##ell	O
##s	O
,	O
whereby	O
S	O
##N	O
-	O
38	O
exposure	O
induced	O
concentration	O
-	O
and	O
time	O
-	O
dependent	O
accumulation	O
of	O
amino	O
acid	O
meta	O
##bol	O
##ites	O
,	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
,	O
as	O
well	O
as	O
p	O
##yr	O
##im	O
##id	O
##ine	O
/	O
pu	O
##rine	O
n	O
##uc	O
##leo	O
##side	O
##s	O
and	O
n	O
##uc	O
##leo	O
##base	O
##s	O
.	O

However	O
,	O
the	O
precursor	O
in	B
##os	I
##ine	I
mon	I
##o	I
-	I
phosphate	I
(	O
I	O
##MP	O
)	O
and	O
ad	B
##eno	I
##sin	I
##e	I
mon	I
##o	I
-	I
phosphate	I
(	O
AM	O
##P	O
)	O
were	O
significantly	O
higher	O
in	O
M	O
##UC	O
##16	O
knock	O
##down	O
cells	O
,	O
indicating	O
the	O
possibility	O
for	O
lower	O
flux	O
downstream	O
of	O
these	O
meta	O
##bol	O
##ites	O
under	O
M	O
##UC	O
##16	O
knock	O
##down	O
conditions	O
.	O

Next	O
,	O
the	O
samples	O
were	O
mixed	O
with	O
60	O
μ	O
##L	O
of	O
2	O
.	O
5	O
m	O
##ol	O
/	O
L	O
phosphate	S
buffer	O
solution	O
with	O
a	O
pH	O
of	O
7	O
.	O
00	O
in	O
99	O
.	O
8	O
%	O
D	O
_	O
2	O
O	O
containing	O
T	O
##SP	O
as	O
an	O
internal	O
standard	O
.	O

–	O
Ser	O
##um	O
his	B
##tamine	I
was	O
extracted	O
with	O
met	B
##han	I
##ol	I
(	I
1	I
:	I
1	I
)	I
and	O
was	O
subsequently	O
ass	O
##ay	O
##ed	O
with	O
a	O
commercial	O
E	O
##L	O
##IS	O
##A	O
kit	O
(	O
A	O
##b	O
##cam	O
,	O
Cambridge	O
,	O
UK	O
)	O
.	O

After	O
collection	O
of	O
the	O
polar	O
phases	O
(	O
6	O
m	O
##L	O
)	O
,	O
proteins	O
were	O
pre	O
##ci	O
##pit	O
##ated	O
for	O
each	O
sample	O
by	O
addition	O
of	O
8	O
m	O
##L	O
100	O
%	O
Me	B
##OH	I
to	O
avoid	O
phase	O
separation	O
followed	O
by	O
cent	O
##ri	O
##fu	O
##gation	O
at	O
16	O
,	O
000	O
##×	O
g	O
speed	O
for	O
10	O
min	O
.	O

A	O
total	O
of	O
40	O
##8	O
Chinese	O
patients	O
admitted	O
to	O
the	O
First	O
A	O
##ff	O
##iliated	O
Hospital	O
of	O
Xi	O
'	O
an	O
Ji	O
##ao	O
##ton	O
##g	O
University	O
(	O
Xi	O
'	O
an	O
,	O
China	O
)	O
between	O
January	O
2016	O
and	O
January	O
2017	O
were	O
recruited	O
to	O
investigate	O
the	O
s	B
##phi	I
##ngo	I
##lip	I
##id	I
meta	O
##bol	O
##ite	O
profiles	O
(	O
mean	O
age	O
at	O
recruitment	O
,	O
47	O
.	O
1	O
;	O
60	O
.	O
4	O
%	O
males	O
)	O
.	O

The	O
super	O
##nat	O
##ant	O
and	O
met	B
##han	I
##ol	I
was	O
mixed	O
for	O
10	O
min	O
.	O

Ace	B
##ton	I
##it	I
##ril	I
##e	I
,	O
on	O
the	O
other	O
hand	O
,	O
del	O
##eter	O
##iously	O
affects	O
meta	O
##bol	O
##ite	O
quantities	O
and	O
,	O
hence	O
,	O
is	O
likely	O
un	O
##sui	O
##table	O
for	O
quantitative	O
analysis	O
of	O
blood	O
meta	O
##bol	O
##ites	O
without	O
employing	O
recovery	O
or	O
internal	O
standards	O
.	O

Tri	B
##acy	I
##l	I
##gly	I
##cer	I
##ols	I
(	O
T	O
##AG	O
##s	O
)	O
,	O
including	O
C	B
##5	I
##4	I
:	I
6	I
T	O
##AG	O
,	O
were	O
additionally	O
en	O
##rich	O
##ed	O
in	O
controls	O
relative	O
to	O
CD	O
and	O
UC	O
subjects	O
.	O

Mon	O
##ou	O
##ns	O
##at	O
##ura	O
##ted	O
(	O
o	O
##le	O
##ic	O
acid	O
,	O
C	B
##18	I
:	I
1	I
)	O
and	O
saturated	O
fat	O
##s	O
(	O
s	O
##te	O
##ari	O
##c	O
acid	O
,	O
C	B
##18	I
:	I
0	I
)	O
had	O
less	O
sat	O
##iet	O
##y	O
effects	O
than	O
p	O
##oly	O
##uns	O
##at	O
##ura	O
##ted	O
fat	O
##s	O
(	O
l	O
##ino	O
##len	O
##ic	O
acid	O
,	O
C	B
##18	I
:	I
2	I
)	O
.	O

However	O
,	O
the	O
is	O
##oto	O
##pic	O
data	O
-	O
dependent	O
scanning	O
was	O
not	O
successful	O
in	O
detect	O
##ing	O
SA	O
add	O
##uc	O
##ts	O
of	O
N	B
-	I
ace	I
##to	I
##xy	I
-	I
Ph	I
##IP	I
,	O
i	O
##rre	O
##spective	O
of	O
the	O
en	O
##zy	O
##matic	O
dig	O
##est	O
##ion	O
conditions	O
.	O

The	O
latter	O
was	O
only	O
apparent	O
in	O
plasma	O
and	O
dominated	O
by	O
increases	O
in	O
T	B
##G	I
and	O
decreases	O
in	O
plasma	O
##log	O
##en	O
species	O
.	O

The	O
serum	O
levels	O
of	O
γ	B
-	I
to	I
##co	I
##pher	I
##ol	I
and	O
S	O
##27	O
were	O
significantly	O
higher	O
after	O
so	O
##y	O
drink	O
intake	O
than	O
after	O
milk	O
and	O
cheese	O
intake	O
at	O
4	O
and	O
6	O
h	O
.	O
Of	O
note	O
,	O
despite	O
apparent	O
post	O
##pra	O
##ndi	O
##al	O
increases	O
at	O
late	O
time	O
points	O
(	O
i	O
.	O
e	O
.	O
,	O
6	O
and	O
24	O
h	O
)	O
,	O
the	O
serum	O
levels	O
of	O
cat	B
##ech	I
##ol	I
and	O
g	B
##ua	I
##iac	I
##ol	I
were	O
not	O
disc	O
##rim	O
##ina	O
##tive	O
at	O
specific	O
time	O
points	O
based	O
on	O
the	O
K	O
##rus	O
##kal	O
-	O
Wallis	O
sum	O
rank	O
test	O
,	O
although	O
a	O
trend	O
was	O
indicated	O
by	O
the	O
significantly	O
higher	O
6	O
h	O
values	O
of	O
cat	B
##ech	I
##ol	I
after	O
so	O
##y	O
drink	O
intake	O
compared	O
to	O
cheese	O
intake	O
.	O

U	O
##rina	O
##ry	O
beta	O
##ine	O
/	O
C	O
##r	O
levels	O
were	O
correlated	O
with	O
fast	O
##ing	O
glucose	S
(	O
p	O
=	O
2	O
##×	O
##10	O
_	O
−	O
##5	O
)	O
,	O
urine	O
glucose	S
(	O
p	O
=	O
3	O
.	O
5	O
##×	O
##10	O
_	O
−	O
##4	O
)	O
and	O
H	O
##b	O
##A	O
##1	O
##c	O
(	O
1	O
##×	O
##10	O
_	O
−	O
##4	O
)	O
.	O

The	O
peak	O
area	O
ratios	O
of	O
G	O
##L	O
##Y	O
,	O
M1	O
or	O
M	O
##2	O
to	O
that	O
of	O
GP	S
were	O
analyzed	O
by	O
linear	O
re	O
##gression	O
to	O
estimate	O
the	O
slope	O
,	O
intercept	O
and	O
correlation	O
coefficient	O
of	O
the	O
ca	O
##li	O
##bra	O
##tion	O
curve	O
.	O

Except	O
met	B
##hi	I
##oni	I
##ne	I
su	I
##lf	I
##oxide	I
,	O
all	O
159	O
investigated	O
meta	O
##bol	O
##ites	O
of	O
this	O
panel	O
had	O
stable	O
concentrations	O
after	O
one	O
freeze	O
-	O
th	O
##aw	O
cycle	O
.	O

c	O
We	O
identified	O
5	O
meta	O
##bol	O
##ites	O
(	O
G	O
##ly	O
##cine	O
/	O
le	O
##uc	O
##ine	O
,	O
G	O
##lu	O
##cos	O
##amine	O
/	O
gal	O
##act	O
##osa	O
##mine	O
,	O
Mali	B
##c	I
acid	I
,	O
3	B
-	I
p	I
##hos	I
##ph	I
##og	I
##ly	I
##cer	I
##ate	I
,	O
(	B
L	I
)	I
-	I
a	I
##rg	I
##ini	I
##no	I
-	I
su	I
##cci	I
##nate	I
and	O
Alan	B
##ine	I
)	O
significantly	O
elevated	O
in	O
the	O
CS	O
##F	O
of	O
patients	O
with	O
meta	O
##static	O
lung	O
cancer	O
to	O
the	O
C	O
##NS	O

He	O
##tero	O
##zy	O
##got	O
##e	O
plasma	O
samples	O
displayed	O
also	O
increases	O
in	O
the	O
in	O
##tens	O
##ities	O
of	O
selected	O
lip	O
##op	O
##rote	O
##in	O
t	B
##ria	I
##cy	I
##l	I
##gly	I
##cer	I
##ol	I
_	O
1	O
H	O
N	O
##MR	O
signals	O
over	O
those	O
of	O
healthy	O
controls	O
.	O

Recently	O
,	O
k	B
##yn	I
##uren	I
##ine	I
was	O
described	O
as	O
an	O
end	O
##ogen	O
##ous	O
l	O
##igan	O
##d	O
of	O
the	O
a	B
##ryl	I
##hy	I
##dr	I
##oc	I
##ar	I
##bon	I
receptor	O
,	O
promoting	O
a	O
tumor	O
progressive	O
mechanism	O
.	O

Thus	O
,	O
the	O
small	O
residual	O
mac	O
##rom	O
##ole	O
##cule	O
##s	O
(	O
[UNK]	O
%	O
)	O
that	O
remain	O
after	O
protein	O
precipitation	O
using	O
met	B
##han	I
##ol	I
,	O
in	O
this	O
study	O
,	O
ne	O
##cess	O
##itated	O
the	O
use	O
of	O
CP	O
##MG	O
sequence	O
to	O
suppress	O
the	O
mac	O
##rom	O
##ole	O
##cular	O
signals	O
for	O
meta	O
##bol	O
##ite	O
q	O
##uant	O
##itation	O
(	O
see	O
Figure	O
S	O
##4	O
in	O
the	O
Supporting	O
Information	O
)	O
.	O

We	O
then	O
replica	O
##ted	O
our	O
findings	O
in	O
a	O
separate	O
e	O
##pid	O
##em	O
##iol	O
##ogical	O
co	O
##hor	O
##t	O
(	O
NE	O
##O	O
study	O
)	O
using	O
targeted	O
meta	O
##bol	O
##omi	O
##cs	O
and	O
found	O
that	O
ace	B
##ty	I
##l	I
##gly	I
##co	I
##p	I
##rote	I
##ins	I
,	O
branched	O
‐	O
chain	O
amino	O
acids	O
(	B
is	B
##ole	I
##uc	I
##ine	I
,	O
le	B
##uc	I
##ine	I
,	O
and	O
v	B
##ali	I
##ne	I
)	O
,	O
g	B
##lut	I
##amine	I
(	O
inverse	O
##ly	O
)	O
,	O
and	O
serum	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
by	O
_	O
1	O
H	O
N	O
##MR	O
remained	O
associated	O
with	O
VA	O
##T	O
,	O
even	O
after	O
adjustment	O
for	O
established	O
sur	O
##rogate	O
bio	O
##mark	O
##ers	O
of	O
VA	O
##T	O
(	O
B	O
##MI	O
,	O
fast	O
##ing	O
glucose	S
,	O
waist	O
c	O
##ir	O
##cum	O
##ference	O
,	O
and	O
serum	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
)	O
,	O
suggesting	O
that	O
a	O
single	O
,	O
fast	O
##ing	O
measurement	O
of	O
meta	O
##bol	O
##ites	O
can	O
provide	O
biological	O
information	O
beyond	O
standard	O
risk	O
markers	O
of	O
v	O
##is	O
##cer	O
##al	O
fat	O
.	O

In	O
support	O
of	O
this	O
,	O
d	O
##ys	O
##re	O
##gu	O
##lation	O
of	O
met	B
##hi	I
##oni	I
##ne	I
metabolism	O
has	O
previously	O
been	O
found	O
in	O
plasma	O
from	O
R	O
##R	O
##MS	O
patients	O
and	O
post	O
m	O
##ort	O
##em	O
MS	O
brain	O
tissue	O
.	O

In	O
the	O
HC	O
group	O
,	O
we	O
observed	O
a	O
number	O
of	O
suggest	O
##ive	O
associations	O
between	O
GM	O
volumes	O
and	O
meta	O
##bol	O
##ites	O
of	O
the	O
k	B
##yn	I
##uren	I
##ine	I
pathway	O
or	O
CR	O
##P	O
that	O
did	O
not	O
remain	O
significant	O
after	O
correction	O
for	O
multiple	O
testing	O
.	O

P	O
##las	O
##ma	O
concentrations	O
of	O
8	O
traits	O
(	O
total	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
L	O
##D	O
##L	O
-	O
C	O
,	O
HD	O
##L	O
-	O
C	O
,	O
T	B
##G	I
,	O
a	O
##poli	O
##pop	O
##rote	O
##in	O
B	O
,	O
a	O
##poli	O
##pop	O
##rote	O
##in	O
A1	O
,	O
album	O
##in	O
,	O
and	O
c	O
##rea	O
##tin	O
##ine	O
)	O
that	O
were	O
measured	O
by	O
N	O
##MR	O
s	O
##pect	O
##ros	O
##copy	O
were	O
also	O
q	O
##uant	O
##ified	O
in	O
samples	O
from	O
the	O
same	O
4	O
,	O
66	O
##2	O
participants	O
using	O
standard	O
clinical	O
chemistry	O
ass	O
##ays	O
at	O
the	O
Wolf	O
##son	O
Laboratory	O
(	O
AU	O
680	O
clinical	O
chemistry	O
analyze	O
##rs	O
,	O
Beck	O
##man	O
Co	O
##ulter	O
[	O
UK	O
]	O
Ltd	O
.	O
,	O
W	O
##y	O
##combe	O
,	O
United	O
Kingdom	O
)	O
using	O
manufacturers	O
’	O
re	O
##age	O
##nts	O
,	O
ca	O
##li	O
##bra	O
##tors	O
,	O
and	O
settings	O
.	O

6	O
A	O
:	O
Cal	O
##ib	O
##ration	O
P	O
##lot	O
Fr	O
##ami	O
##ng	O
##ham	O
Off	O
##sp	O
##ring	O
T	O
##2	O
##D	O
at	O
10	O
Years	O
6	O
B	O
:	O
Cal	O
##ib	O
##ration	O
LP	O
##IR	O
Only	O
at	O
10	O
Years	O
6	O
C	O
:	O
Cal	O
##ib	O
##ration	O
P	O
##lot	O
Fr	O
##ami	O
##ng	O
##ham	O
Off	O
##sp	O
##ring	O
T	O
##2	O
##D	O
+	O
LP	O
##IR	O
at	O
10	O
Years	O
6	O
D	O
:	O
Cal	O
##ib	O
##ration	O
P	O
##lot	O
Fr	O
##ami	O
##ng	O
##ham	O
Off	O
##sp	O
##ring	O
T	O
##2	O
##D	O
at	O
16	O
Years	O
6	O
E	O
:	O
Cal	O
##ib	O
##ration	O
LP	O
##IR	O
Only	O
at	O
16	O
Years	O
6	O
F	O
:	O
Cal	O
##ib	O
##ration	O
P	O
##lot	O
Fr	O
##ami	O
##ng	O
##ham	O
Off	O
##sp	O
##ring	O
T	O
##2	O
##D	O
+	O
LP	O
##IR	O
at	O
16	O
Years	O
V	O
##aria	O
##bles	O
in	O
the	O
Fr	O
##ami	O
##ng	O
##ham	O
Off	O
##sp	O
##ring	O
model	O
,	O
age	O
,	O
family	O
history	O
of	O
T	O
##2	O
##D	O
,	O
body	O
mass	O
index	O
,	O
s	O
##ys	O
##to	O
##lic	O
blood	O
pressure	O
,	O
anti	O
-	O
h	O
##yper	O
##tensive	O
medication	O
,	O
HD	O
##L	O
,	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
and	O
H	O
##b	O
##A	O
##1	O
##c	O
.	O

The	O
el	O
##uate	O
##s	O
were	O
pool	O
##ed	O
,	O
dried	O
under	O
a	O
stream	O
of	O
nitrogen	O
,	O
and	O
resolved	O
in	O
a	O
mixture	O
of	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
and	O
water	O
.	O

In	O
serum	O
samples	O
from	O
post	O
##men	O
##op	O
##aus	O
##al	O
women	O
,	O
total	O
laboratory	O
coefficients	O
of	O
variation	O
,	O
based	O
on	O
blinded	O
quality	O
control	O
samples	O
,	O
including	O
all	O
steps	O
of	O
the	O
procedure	O
,	O
and	O
combining	O
within	O
-	O
and	O
between	O
-	O
batch	O
variation	O
,	O
were	O
<	O
5	O
%	O
for	O
each	O
E	O
##M	O
,	O
in	O
total	O
or	O
un	O
##con	O
##ju	O
##gated	O
form	O
,	O
and	O
<	O
3	O
%	O
for	O
est	B
##rone	I
and	O
est	B
##rad	I
##iol	I
.	O

Interest	O
##ingly	O
,	O
the	O
inter	O
##con	O
##version	O
between	O
2	B
-	I
o	I
##x	I
##ob	I
##ut	I
##yra	I
##te	I
and	O
2	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
is	O
regulated	O
by	O
L	O
##D	O
##H	O
.	O

We	O
have	O
observed	O
that	O
typically	O
30	O
–	O
50	O
%	O
of	O
the	O
glucose	S
consumed	O
was	O
converted	O
to	O
la	B
##ct	I
##ate	I
by	O
various	O
e	O
##pit	O
##hel	O
##ial	O
derived	O
cancer	O
cell	O
lines	O
,	O
(	O
A	O
.	O
N	O
.	O
Lane	O
,	O
T	O
.	O
W	O
##M	O
Fan	O
,	O
unpublished	O
data	O
)	O
.	O

In	O
contrast	O
,	O
18	B
-	I
h	I
##ydro	I
##xy	I
##cor	I
##tis	I
##ol	I
showed	O
a	O
weak	O
positive	O
relationship	O
(	O
r	O
_	O
s	O
=	O

Each	O
peak	O
in	O
the	O
spectrum	O
corresponds	O
to	O
different	O
meta	O
##bol	O
##ite	O
from	O
the	O
car	B
##box	I
##yl	I
##ic	I
acid	I
class	O
.	O

Select	O
##ivity	O
and	O
specific	O
##ity	O
were	O
evaluated	O
by	O
analyzing	O
six	O
different	O
lots	O
of	O
un	O
-	O
pool	O
##ed	O
blank	O
human	O
plasma	O
matrix	O
samples	O
with	O
t	B
##rig	I
##ly	I
##cer	I
##ide	I
levels	O
of	O
52	O
–	O
103	O
mg	O
/	O
d	O
##L	O
.	O
The	O
same	O
six	O
lots	O
were	O
spike	O
##d	O
with	O
t	B
##rig	I
##ly	I
##cer	I
##ide	I
mixture	O
(	O
to	O
reach	O
35	O
##2	O
to	O
40	O
##3	O
mg	O
/	O
d	O
##L	O
)	O
,	O
and	O
the	O
select	O
##ivity	O
and	O
specific	O
##ity	O
were	O
assessed	O
in	O
the	O
presence	O
of	O
high	O
t	B
##rig	I
##ly	I
##cer	I
##ide	I
levels	O
.	O

The	O
identified	O
target	O
meta	O
##bol	O
##ites	O
were	O
found	O
to	O
en	O
##com	O
##pass	O
a	O
variety	O
of	O
pathways	O
related	O
to	O
inflammatory	O
response	O
-	O
related	O
metabolism	O
(	O
l	O
##ino	O
##le	O
##ic	O
acid	O
metabolism	O
,	O
a	B
##rac	I
##hi	I
##don	I
##ic	I
acid	I
metabolism	O
,	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
metabolism	O
and	O
pu	B
##rine	I
metabolism	O
)	O
,	O
energy	O
metabolism	O
(	O
g	O
##ly	O
##co	O
##lysis	O
,	O
T	O
##CA	O
cycle	O
,	O
fatty	O
acid	O
metabolism	O
and	O
amino	O
acid	O
metabolism	O
)	O
,	O
bi	O
##le	O
acid	O
metabolism	O
and	O
hem	B
##e	I
metabolism	O
,	O
which	O
were	O
helpful	O
for	O
revealing	O
the	O
complex	O
mechanism	O
of	O
early	O
a	O
##cc	O
##lim	O
##ati	O
##zation	O
to	O
high	O
altitude	O
.	O

Di	O
##fference	O
##s	O
in	O
the	O
peak	O
in	O
##tens	O
##ities	O
were	O
observed	O
among	O
the	O
two	O
groups	O
,	O
with	O
major	O
variant	O
peaks	O
belonging	O
to	O
hydrogen	B
su	I
##lf	I
##ide	I
(	O
H	O
_	O
2	O
S	O
)	O
,	O
g	B
##ly	I
##cer	I
##ol	I
,	O
la	B
##ctic	I
acid	I
,	O
u	B
##ric	I
acid	I
and	O
fatty	O
acids	O
.	O

Interest	O
##ingly	O
,	O
in	O
IS	O
h	O
##y	O
##po	O
##gon	O
##adi	O
##sm	O
,	O
3	B
-	I
p	I
##hos	I
##ph	I
##og	I
##ly	I
##cer	I
##ol	I
##ph	I
##os	I
##phate	I
was	O
prevalent	O
in	O
the	O
g	B
##ly	I
##cer	I
##ol	I
shuttle	O
,	O
and	O
it	O
was	O
not	O
diverted	O
to	O
produce	O
T	O
##G	O
##s	O
,	O
in	O
contrast	O
to	O
I	O
##R	O
h	O
##y	O
##po	O
##gon	O
##adi	O
##sm	O
.	O

An	O
intense	O
peak	O
at	O
8	O
.	O
99	O
min	O
is	O
observed	O
in	O
each	O
ch	O
##roma	O
##to	O
##gram	O
indicating	O
try	B
##pt	I
##op	I
##han	I
is	O
present	O
in	O
the	O
blank	O
.	O

S	O
##pear	O
##man	O
'	O
s	O
rank	O
correlation	O
##s	O
between	O
u	O
##rina	O
##ry	O
p	B
##ht	I
##hala	I
##te	I
meta	O
##bol	O
##ites	O
,	O
para	O
##ben	O
##s	O
,	O
and	O
BP	O
##3	O
.	O

S	B
##phi	I
##ngo	I
##my	I
##elin	I
is	O
also	O
among	O
the	O
candidate	O
molecules	O
likely	O
involved	O
in	O
path	O
##ome	O
##chan	O
##isms	O
relevant	O
for	O
a	O
decline	O
in	O
insulin	O
sensitivity	O
,	O
since	O
the	O
breakdown	O
of	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
leads	O
to	O
the	O
generation	O
of	O
c	B
##era	I
##mi	I
##de	I
which	O
is	O
a	O
potent	O
signaling	O
molecule	O
well	O
known	O
to	O
media	O
##te	O
insulin	O
resistance	O
–	O
.	O

Cancer	O
cells	O
require	O
large	O
amounts	O
of	O
energy	O
for	O
the	O
proliferation	O
and	O
bio	O
##sy	O
##nt	O
##hesis	O
of	O
essential	O
compounds	O
which	O
mainly	O
take	O
place	O
through	O
elevation	O
of	O
glucose	S
and	O
g	B
##lut	I
##amine	I
,	O
la	B
##ct	I
##ate	I
production	O
,	O
and	O
bio	O
##sy	O
##nt	O
##hesis	O
of	O
lip	O
##ids	O
.	O

N	O
##uc	O
##leo	O
##side	O
##s	O
and	O
n	O
##uc	O
##leo	O
##tide	O
##s	O
(	O
e	O
.	O
g	O
.	O
,	O
in	B
##os	I
##ine	I
and	O
in	B
##os	I
##ine	I
mon	I
##op	I
##hos	I
##phate	I
)	O
were	O
also	O
found	O
to	O
be	O
transformed	O
into	O
pu	B
##rine	I
derivatives	O
(	O
e	O
.	O
g	O
.	O
,	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
)	O
.	O

Clinical	O
parameters	O
,	O
such	O
as	O
T	B
##G	I
,	O
T	O
##C	O
,	O
L	O
##D	O
##L	O
-	O
c	O
,	O
HD	O
##L	O
-	O
c	O
,	O
fast	O
##ing	O
insulin	O
,	O
2	O
-	O
h	O
insulin	O
and	O
H	O
##OM	O
##A	O
-	O
I	O
##R	O
,	O
were	O
associated	O
with	O
changes	O
in	O
meta	O
##bol	O
##ite	O
levels	O
.	O

A	O
single	O
combined	O
re	O
##gression	O
model	O
evaluate	O
##s	O
24	B
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
as	O
dependent	O
variable	O
and	O
25	O
(	O
OH	O
)	O
D	O
_	O
3	O
,	O
clinical	O
characteristics	O
(	O
including	O
e	O
##G	O
##F	O
##R	O
)	O
,	O
and	O
interactions	O
of	O
25	O
(	O
OH	O
)	O
D	O
_	O
3	O
with	O
each	O
clinical	O
characteristic	O
as	O
independent	O
variables	O
.	O

For	O
5	O
P	O
##H	O
type	O
1	O
patients	O
enrolled	O
in	O
the	O
study	O
,	O
the	O
average	O
en	O
##rich	O
##ments	O
during	O
steady	O
state	O
were	O
68	O
.	O
8	O
T	O
##TR	O
%	O
for	O
1	O
-	O
_	O
13	O
C	B
-	I
g	I
##ly	I
##cola	I
##te	I
,	O
2	O
.	O
3	O
T	O
##TR	O
%	O
for	O
1	O
-	O
_	O
13	O
C	B
-	I
g	I
##ly	I
##ox	I
##yla	I
##te	I
,	O
31	O
.	O
1	O
T	O
##TR	O
%	O
for	O
1	O
-	O
_	O
13	O
C	B
-	I
o	I
##xa	I
##late	I
,	O
and	O
26	O
.	O
1	O
T	O
##TR	O
%	O
for	O
_	O
13	O
C	B
_	I
2	I
-	I
o	I
##xa	I
##late	I
.	O

In	O
order	O
to	O
eliminate	O
the	O
effect	O
of	O
residual	O
water	O
peaks	O
,	O
for	O
each	O
peak	O
period	O
remove	O
4	O
.	O
315	O
-	O
6	O
.	O
65	O
pp	O
##m	O
including	O
residual	O
water	O
peak	O
and	O
containing	O
u	B
##rea	I
peak	O
signal	O
.	O

Rather	O
,	O
these	O
data	O
indicate	O
that	O
lower	O
brain	O
-	O
G	O
##L	O
##UT	O
/	O
glucose	O
-	O
up	O
##take	O
rates	O
in	O
AD	O
probably	O
occur	O
in	O
response	O
to	O
elevated	O
brain	B
-	I
glucose	I
levels	O
;	O
consistently	O
,	O
there	O
is	O
sub	O
##stant	O
##ive	O
evidence	O
that	O
elevated	O
cellular	O
glucose	S
can	O
media	O
##te	O
down	O
-	O
regulation	O
of	O
G	O
##L	O
##UT	O
##1	O
expression	O
and	O
function	O
_	O
,	O
.	O

24	B
,	I
25	I
(	I
OH	I
)	I
D	O
##3	O
and	O
1	B
,	I
25	I
(	I
OH	I
)	I
D	O
##3	O
were	O
similar	O
,	O
and	O
the	O
L	O
##O	O
##Q	O
is	O
estimated	O
to	O
be	O
similar	O
to	O
that	O
of	O
1	B
,	I
25	I
(	I
OH	I
)	I

By	O
contrast	O
,	O
the	O
levels	O
of	O
g	B
##ly	I
##cine	I
and	O
pro	B
##line	I
in	O
four	O
p	O
##hen	O
##otype	O
##s	O
of	O
PC	O
##OS	O
were	O
decreased	O
significantly	O
compared	O
with	O
the	O
corresponding	O
control	O
group	O
levels	O
.	O

However	O
,	O
le	O
##pt	O
##in	O
’	O
s	O
effects	O
on	O
11	B
##β	I
##HS	I
##D	I
##1	I
in	O
non	O
##adi	O
##pose	O
tissues	O
is	O
less	O
clear	O
.	O

We	O
recorded	O
an	O
increase	O
in	O
g	B
##lut	I
##ama	I
##te	I
levels	O
in	O
RC	O
##C	O
cases	O
relative	O
to	O
controls	O
,	O
which	O
co	O
##rro	O
##bor	O
##ates	O
findings	O
in	O
similar	O
studies	O
[	O
,	O
]	O
and	O
further	O
strengthen	O
##s	O
the	O
proposition	O
that	O
increased	O
g	B
##lut	I
##ama	I
##te	I
levels	O
may	O
indicate	O
increased	O
g	O
##lut	O
##ami	O
##no	O
##lysis	O
for	O
bio	O
##sy	O
##nt	O
##hetic	O
purposes	O
in	O
RC	O
##C	O
.	O

One	O
meta	O
##bol	O
##ite	O
measure	O
(	B
g	B
##ly	I
##cer	I
##ol	I
)	O
with	O
>	O
10	O
%	O
missing	O
values	O
was	O
excluded	O
entirely	O
,	O
resulting	O
in	O
a	O
final	O
number	O
of	O
146	O
meta	O
##bol	O
##ite	O
measures	O
and	O
79	O
ratios	O
.	O

Second	O
,	O
all	O
cases	O
of	O
AP	S
in	O
this	O
study	O
were	O
classified	O
as	O
mild	O
.	O

Furthermore	O
,	O
p	B
##yr	I
##u	I
##vic	I
acid	I
,	O
an	O
important	O
meta	O
##bol	O
##ite	O
of	O
the	O
g	B
##ly	I
##co	I
##ly	I
##tic	I
intermediate	O
##s	O
group	O
,	O
was	O
found	O
to	O
be	O
increased	O
in	O
the	O
G	O
##CS	O
=	O
15	O
points	O
group	O
.	O

In	O
both	O
CD	O
and	O
in	O
UC	O
,	O
we	O
noticed	O
,	O
relative	O
to	O
control	O
subjects	O
,	O
a	O
decrease	O
in	O
ch	B
##olin	I
##e	I
and	O
its	O
o	O
##xi	O
##dized	O
product	O
beta	B
##ine	I
.	O

Li	O
##pid	O
,	O
-	O
CH	O
##2	O
-	O
C	O
=	O
O	O
;	O
L	O
##9	O
:	O
Li	O
##pid	O
,	O
=	O
CH	O
-	O
CH	O
##2	O
-	O
CH	O
=	O
;	O
L	O
##10	O
:	O
Li	O
##pid	O
,	O
-	O
CH	O
=	O
CH	O
-	O
;	O
Lac	O
:	O
Lac	B
##tate	I
;	O
Le	O
##u	O
:	O
Le	B
##uc	I
##ine	I
;	O
L	O
##ys	O
:	O
L	B
##ys	I
##ine	I
;	O
m	O
-	O
I	O
:	O
my	B
##o	I
-	I
In	I
##os	I
##ito	I
##l	I
;	O
N	O
##AG	O
:	O
N	B
-	I
ace	I
##ty	I
##l	I
g	I
##ly	I
##co	I
##p	I
##rote	I
##in	I
signals	O
;	O
Ph	O
##e	O
:	O
Ph	B
##en	I
##yla	I
##lani	I
##ne	I
;	O
Ty	O
##r	O
:	O
Ty	B
##ros	I
##ine	I
;	O
Val	O
:	O
Val	B
##ine	I
.	O

Furthermore	O
,	O
we	O
found	O
that	O
α	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
concentrations	O
in	O
response	O
to	O
a	O
glucose	S
challenge	O
were	O
associated	O
with	O
de	O
##ter	O
##ior	O
##ation	O
of	O
the	O
D	O
##I	O
over	O
time	O
.	O

Cell	O
l	O
##ys	O
##ates	O
were	O
analyzed	O
for	O
(	O
A	O
)	O
AM	O
##P	O
##K	O
p	O
##hos	O
##ph	O
##ory	O
##lation	O
and	O
protein	O
level	O
and	O
(	O
B	O
)	O
its	O
downstream	O
target	O
ACC	O
p	O
##hos	O
##ph	O
##ory	O
##lation	O
and	O
β	B
-	I
act	I
##in	I
protein	O
expression	O
.	O

These	O
un	O
##sat	O
##ura	O
##ted	O
PC	O
##s	O
could	O
activate	O
PC	O
-	O
Transfer	O
Pro	O
##tein	O
complex	O
formation	O
,	O
involved	O
in	O
decreasing	O
insulin	O
signaling	O
,	O
indicating	O
a	O
potential	O
me	O
##chan	O
##istic	O
role	O
of	O
PC	O
##s	O
in	O
the	O
development	O
of	O
insulin	O
resistance	O
associated	O
with	O
high	O
concentration	O
of	O
total	O
blood	O
ch	B
##ole	I
##ster	I
##ol	I
in	O
plasma	O
.	O

Third	O
,	O
the	O
length	O
of	O
in	O
##patient	O
##s	O
duration	S
is	O
relative	O
long	O
.	O

For	O
healthy	O
subjects	O
the	O
response	O
of	O
urine	O
samples	O
is	O
often	O
normal	O
##ized	O
by	O
its	O
c	B
##rea	I
##tin	I
##ine	I
level	O
.	O

(	O
L	O
##CF	O
##A	O
)	O
est	O
##eri	O
##fied	O
to	O
car	B
##ni	I
##tine	I
.	O

These	O
elevated	O
meta	O
##bol	O
##ites	O
were	O
associated	O
with	O
highly	O
active	O
g	O
##ly	O
##co	O
##lysis	O
,	O
increased	O
amino	O
acids	O
influx	O
(	O
an	O
##ap	O
##ler	O
##osis	O
)	O
into	O
the	O
T	O
##CA	O
cycle	O
,	O
altered	O
energy	O
metabolism	O
,	O
membrane	O
ch	B
##olin	I
##e	I
p	I
##hos	I
##ph	I
##oli	I
##pid	I
metabolism	O
,	O
and	O
o	O
##xi	O
##da	O
##tive	O
and	O
o	O
##smo	O
##tic	O
defense	O
mechanisms	O
.	O

It	O
is	O
also	O
notable	O
that	O
the	O
g	O
##lut	O
##am	O
##yl	O
m	O
##oi	O
##ety	O
of	O
reduced	O
G	B
##S	I
##H	I
showed	O
the	O
same	O
splitting	O
pattern	O
as	O
free	O
g	B
##lut	I
##ama	I
##te	I
,	O
implying	O
de	O
no	O
##vo	O
bio	O
##sy	O
##nt	O
##hesis	O
of	O
G	B
##S	I
##H	I
from	O
the	O
free	O
g	B
##lut	I
##ama	I
##te	I
pool	O
.	O

As	O
shown	O
in	O
,	O
l	B
##ino	I
##le	I
##ic	I
acid	I
and	O
12	B
,	I
13	I
-	I
Di	I
##H	I
##OM	I
##E	I
were	O
significantly	O
elevated	O
at	O
high	O
altitude	O
.	O

Indeed	O
,	O
we	O
were	O
able	O
to	O
detect	O
high	O
levels	O
of	O
2	B
-	I
h	I
##ydro	I
##xy	I
##g	I
##lut	I
##arate	I
in	O
patient	O
3	O
suggesting	O
that	O
this	O
individual	O
may	O
have	O
an	O
ID	O
##H1	O
-	O
m	O
##uta	O
##ted	O
ma	O
##li	O
##gnant	O
g	O
##lio	O
##ma	O
.	O

After	O
adjustment	O
for	O
un	O
##con	O
##ju	O
##gated	O
est	B
##rad	I
##iol	I
,	O
these	O
hazard	O
ratios	O
changed	O
minimal	O
##ly	O
;	O
however	O
,	O
the	O
association	O
between	O
the	O
ratio	O
of	O
the	O
2	O
-	O
h	O
##ydro	O
##xy	O
##lation	O
pathway	O
to	O
the	O
16	O
-	O
h	O
##ydro	O
##xy	O
##lation	O
pathway	O
and	O
the	O
risk	O
of	O
breast	O
cancer	O
became	O
non	O
-	O
statistical	O
##ly	O
significant	O
(	O
H	O
##R	O
=	O
0	O
.	O
69	O
;	O
95	O
%	O
C	O
##I	O
=	O
0	O
.	O
47	O
to	O
1	O
.	O
02	O
,	O
P	O
_	O
trend	O
=	O
.	O
07	O
)	O
.	O

Previous	O
laboratory	O
studies	O
support	O
a	O
role	O
in	O
the	O
prevention	O
of	O
neo	O
##vas	O
##cular	O
##ization	O
,	O
providing	O
evidence	O
that	O
1	B
##α	I
,	I
25	I
-	I
di	I
##hy	I
##dr	I
##ox	I
##y	I
##vi	I
##tam	I
##in	I
D	O
in	O
##hibit	O
##s	O
abnormal	O
an	O
##gio	O
##genesis	O
in	O
v	O
##it	O
##ro	O
and	O
in	O
v	O
##ivo	O
.	O

Pat	O
##ients	O
were	O
administered	O
with	O
ta	B
##mo	I
##xi	I
##fen	I
(	O
156	O
)	O
,	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
(	O
21	O
)	O
,	O
or	O
let	B
##ro	I
##zo	I
##le	I
(	O
2	O
)	O
or	O
not	O
treated	O
(	O
5	O
)	O
.	O

Further	O
investigation	O
is	O
warrant	O
##ed	O
to	O
determine	O
whether	O
N	O
##MR	O
‐	O
based	O
metabolic	O
pro	O
##fi	O
##ling	O
can	O
improve	O
screening	O
and	O
detection	O
of	O
v	O
##is	O
##cer	O
##al	O
ad	O
##ip	O
##os	O
##ity	O
beyond	O
simple	O
ant	O
##hr	O
##op	O
##ometric	O
measures	O
and	O
the	O
h	B
##yper	I
##tri	I
##gly	I
##cer	I
##ide	I
##mic	I
waist	O
to	O
help	O
identify	O
appropriate	O
candidates	O
for	O
interventions	O
and	O
reduce	O
the	O
card	O
##io	O
##met	O
##ab	O
##olic	O
complications	O
of	O
v	O
##is	O
##cer	O
##al	O
o	O
##besity	O
.	O

It	O
is	O
clearly	O
shown	O
that	O
levels	O
of	O
some	O
meta	O
##bol	O
##ites	O
(	O
e	O
.	O
g	O
.	O
c	B
##rea	I
##tin	I
##ine	I
at	O
m	O
/	O
z	O
114	O
.	O
06	O
)	O
and	O
the	O
unknown	O
compound	O
at	O
m	O
/	O
z	O
=	O
312	O
)	O
are	O
not	O
substantially	O
different	O
between	O
D	O
##MD	O
and	O
healthy	O
volunteers	O
at	O
young	O
ages	O
,	O
then	O
their	O
levels	O
substantially	O
diver	O
##ge	O
at	O
around	O
15	O
years	O
of	O
age	O
.	O

SP	O
##s	O
with	O
a	O
d	B
##16	I
:	I
1	I
backbone	O
are	O
indicated	O
in	O
red	O
.	O

Fast	O
##ing	O
plasma	O
glucose	S
levels	O
were	O
measured	O
applying	O
a	O
standard	O
he	O
##x	O
##oki	O
##nas	O
##e	O
ass	O
##ay	O
.	O

Since	O
a	O
##pop	O
##to	O
##tic	O
cells	O
that	O
release	O
in	O
##tra	O
##cellular	O
c	B
##era	I
##mi	I
##des	I
at	O
cell	O
l	O
##ys	O
##is	O
are	O
considered	O
the	O
major	O
source	O
of	O
c	B
##era	I
##mi	I
##des	I
in	O
the	O
cancer	O
tissue	O
,	O
the	O
production	O
of	O
c	B
##era	I
##mi	I
##des	I
appears	O
to	O
occur	O
independently	O
from	O
the	O
condition	O
of	O
the	O
host	O
.	O

Ex	O
##em	O
##p	O
##lars	O
of	O
the	O
relationship	O
of	O
selected	O
try	B
##pt	I
##op	I
##han	I
meta	O
##bol	O
##ites	O
with	O
daily	O
diary	O
symptoms	O
in	O
i	O
##rri	O
##table	O
bow	O
##el	O
syndrome	O
(	O
I	O
##BS	O
)	O
patients	O
.	O

Furthermore	O
,	O
we	O
identified	O
a	O
potential	O
bio	O
##mark	O
##er	O
panel	O
,	O
which	O
was	O
consisted	O
of	O
six	O
differential	O
meta	O
##bol	O
##ites	O
:	O
pseudo	B
##uri	I
##dine	I
,	O
ma	B
##lic	I
acid	I
,	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
,	O
3	B
,	I
4	I
-	I
di	I
##hy	I
##dr	I
##ox	I
##y	I
##but	I
##yric	I
acid	I
,	O
f	B
##ru	I
##ct	I
##ose	I
and	O
in	B
##os	I
##ito	I
##l	I
.	O

However	O
,	O
the	O
significance	O
of	O
PR	O
##MT	O
##s	O
reaches	O
far	O
beyond	O
the	O
regulation	O
of	O
a	B
##rg	I
##ini	I
##ne	I
availability	O
and	O
NO	O
generation	O
.	O

4	O
.	O
6	O
mm	O
)	O
was	O
employed	O
in	O
some	O
experiments	O
for	O
the	O
investigation	O
of	O
di	B
##os	I
##met	I
##in	I
and	O
meta	O
##bol	O
##ites	O
in	O
plasma	O
and	O
urine	O
prior	O
to	O
en	O
##zy	O
##matic	O
dig	O
##est	O
##ion	O
.	O

Among	O
the	O
highly	O
significant	O
peaks	O
identified	O
in	O
high	O
relative	O
in	O
##tens	O
##ities	O
in	O
tumor	O
tissue	O
compared	O
to	O
m	O
##or	O
##phological	O
##ly	O
normal	O
g	O
##land	O
##ular	O
tissue	O
were	O
several	O
fatty	O
acids	O
,	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oe	I
##than	I
##ola	I
##mine	I
##s	I
,	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##och	I
##olin	I
##es	I
,	O
and	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oi	I
##nos	I
##ito	I
##ls	I
.	O

For	O
the	O
protein	O
removal	O
,	O
the	O
serum	O
samples	O
were	O
mixed	O
with	O
met	B
##han	I
##ol	I
in	O
a	O
1	O
:	O
2	O
(	O
v	O
/	O
v	O
)	O
ratio	O
,	O
which	O
was	O
recently	O
shown	O
by	O
N	O
##MR	O
to	O
extract	O
meta	O
##bol	O
##ites	O
optimal	O
##ly	O
.	O

In	O
keeping	O
with	O
earlier	O
reports	O
,	O
beta	B
##ine	I
was	O
related	O
inverse	O
##ly	O
to	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
and	O
non	O
-	O
HD	O
##L	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
and	O
positively	O
with	O
HD	B
##L	I
ch	I
##ole	I
##ster	I
##ol	I
[	O
–	O
]	O
.	O

For	O
instance	O
,	O
the	O
increase	O
of	O
branched	O
-	O
chain	O
amino	O
acids	O
,	O
including	O
le	B
##uc	I
##ine	I
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
and	O
v	B
##ali	I
##ne	I
,	O
has	O
been	O
widely	O
reported	O
to	O
be	O
related	O
to	O
an	O
increased	O
risk	O
for	O
type	O
2	O
diabetes	O
in	O
several	O
Western	O
and	O
Asian	O
populations	O
(	O
–	O
)	O
.	O

Therefore	O
,	O
the	O
effects	O
of	O
age	O
,	O
sex	O
and	O
four	O
parameters	O
commonly	O
used	O
to	O
represent	O
the	O
body	O
composition	O
,	O
i	O
.	O
e	O
.	O
central	O
o	O
##besity	O
,	O
B	O
##MI	O
,	O
L	O
##MI	O
and	O
B	O
##F	O
,	O
on	O
the	O
concentration	O
of	O
serum	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
were	O
analyzed	O
in	O
112	O
healthy	O
controls	O
to	O
rule	O
out	O
any	O
potential	O
con	O
##found	O
##ing	O
factors	O
.	O

Cell	O
lines	O
containing	O
the	O
highest	O
and	O
lowest	O
est	B
##rone	I
(	O
E	O
_	O
1	O
)	O
levels	O
within	O
the	O
NC	O
##I	O
-	O
60	O
panel	O
.	O

Finally	O
,	O
various	O
amino	O
acids	O
from	O
the	O
u	B
##rea	I
cycle	O
were	O
found	O
to	O
be	O
diver	O
##gent	O
##ly	O
affected	O
during	O
T	O
##B	O
,	O
including	O
c	B
##it	I
##ru	I
##llin	I
##e	I
and	O
a	B
##rg	I
##ini	I
##ne	I
(	O
C	O
##it	O
/	O
A	O
##rg	O
)	O
which	O
are	O
essential	O
for	O
ni	B
##tric	I
oxide	I
(	O
NO	O
)	O
production	O
by	O
NO	O
s	O
##ynth	O
##ase	O
(	O
NO	O
##S	O
)	O
.	O

Factor	O
2	O
was	O
composed	O
of	O
short	O
and	O
long	O
chain	O
AC	O
##s	O
and	O
several	O
AA	O
(	O
C	O
##0	O
,	O
C	O
##16	O
,	O
C	O
##18	O
,	O
C	O
##3	O
,	O
C	O
##4	O
,	O
g	B
##lut	I
##ami	I
##c	I
acid	I
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
le	B
##uc	I
##ine	I
,	O
met	B
##hi	I
##oni	I
##ne	I
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
t	B
##yr	I
##os	I
##ine	I
and	O
v	B
##ali	I
##ne	I
)	O
,	O
whereas	O
factor	O
3	O
was	O
composed	O
of	O
few	O
medium	O
chain	O
AC	O
##s	O
(	O
C	O
##12	O
,	O
C	B
##14	I
:	I
1	I
-	I
OH	I
,	O
C	B
##14	I
:	I
2	I
,	O
C	B
##18	I
:	I
2	I
)	O
.	O

The	O
evidence	O
regarding	O
so	O
##y	O
intake	O
and	O
levels	O
of	O
these	O
est	B
##rogen	I
meta	O
##bol	O
##ites	O
is	O
not	O
con	O
##clusive	O
.	O

Because	O
lip	O
##ids	O
and	O
h	B
##ydro	I
##phi	I
##lic	I
compounds	O
have	O
varying	O
chemical	O
properties	O
,	O
both	O
reverse	O
phase	O
ch	O
##roma	O
##tography	O
and	O
h	B
##ydro	I
##phi	I
##lic	I
interaction	O
ch	O
##roma	O
##tography	O
(	O
H	O
##IL	O
##IC	O
)	O
were	O
applied	O
to	O
achieve	O
better	O
resolution	O
for	O
all	O
meta	O
##bol	O
##ites	O
.	O

Re	B
##tino	I
##l	I
was	O
found	O
to	O
be	O
effective	O
against	O
breast	O
,	O
pro	O
##state	O
,	O
and	O
o	O
##var	O
##ian	O
cancer	O
##s	O
in	O
animal	O
treatment	O
models	O
.	O

Using	O
the	O
replica	O
##ted	O
meta	O
##bol	O
##ites	O
,	O
to	O
identify	O
novel	O
VA	O
##T	O
‐	O
associated	O
meta	O
##bol	O
##ites	O
beyond	O
known	O
co	O
##rrel	O
##ates	O
,	O
we	O
additionally	O
se	O
##quential	O
##ly	O
adjusted	O
for	O
the	O
following	O
:	O
(	O
1	O
)	O
fast	O
##ing	O
glucose	S
concentrations	O
and	O
waist	O
c	O
##ir	O
##cum	O
##ference	O
;	O
and	O
(	O
2	O
)	O
plasma	O
t	B
##rig	I
##ly	I
##cer	I
##ide	I
concentrations	O
,	O
to	O
investigate	O
if	O
and	O
what	O
meta	O
##bol	O
##ites	O
remained	O
after	O
adjustment	O
for	O
additional	O
m	O
##od	O
##ifier	O
##s	O
of	O
metabolic	O
disease	O
and	O
indirect	O
sur	O
##rogate	O
markers	O
for	O
VA	O
##T	O
(	O
e	O
##g	O
,	O
“	B
h	I
##yper	I
##tri	I
##gly	I
##cer	I
##ide	I
##mic	I
waist	O
”	O
)	O
.	O
26	O
Finally	O
,	O
to	O
better	O
understand	O
the	O
potential	O
directional	O
##ity	O
of	O
the	O
association	O
between	O
lip	O
##id	O
‐	O
based	O
meta	O
##bol	O
##ites	O
and	O
VA	O
##T	O
(	O
i	O
##e	O
,	O
does	O
d	O
##ys	O
##lip	O
##ide	O
##mia	O
influence	O
VA	O
##T	O
deposition	O
)	O
,	O
we	O
estimated	O
the	O
potential	O
ca	O
##usal	O
effects	O
of	O
overall	O
measures	O
of	O
HD	B
##L	I
ch	I
##ole	I
##ster	I
##ol	I
(	O
HD	O
##L	O
‐	O
C	O
)	O
,	O
L	B
##D	I
##L	I
ch	I
##ole	I
##ster	I
##ol	I
,	O
and	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
on	O
VA	O
##T	O
volume	O
by	O
performing	O
2	O
‐	O
sample	O
men	O
##del	O
##ian	O
random	O
##ization	O
analyses	O
using	O
genetic	O
instruments	O
linked	O
to	O
blood	O
lip	O
##id	O
levels	O
and	O
combining	O
the	O
summary	O
statistics	O
of	O
large	O
genome	O
‐	O
wide	O
meta	O
‐	O
analyses	O
on	O
blood	O
lip	O
##id	O
levels	O
and	O
VA	O
##T	O
(	O
explained	O
in	O
Data	O
)	O
.	O

An	O
immediate	O
increase	O
in	O
er	B
##yt	I
##hr	I
##ito	I
##l	I
blood	O
concentrations	O
was	O
observed	O
,	O
followed	O
by	O
an	O
increase	O
of	O
er	B
##yt	I
##hr	I
##ona	I
##te	I
blood	O
concentrations	O
.	O

The	O
system	O
was	O
equipped	O
with	O
a	O
DB	O
-	O
5	O
##MS	O
cap	O
##illa	O
##ry	O
column	O
coated	O
with	O
5	O
%	O
dip	O
##hen	O
##yl	O
cross	O
-	O
linked	O
with	O
95	O
%	O
dim	B
##eth	I
##yl	I
##pol	I
##ys	I
##ilo	I
##xa	I
##ne	I
(	O
30	O
m	O
×	O
250	O
μ	O
##m	O
inner	O
diameter	O
,	O
0	O
.	O
25	O
μ	O
##m	O
film	O
thickness	O
;	O
J	O
&	O
W	O
Scientific	O
,	O
F	O
##ols	O
##om	O
,	O
CA	O
,	O
USA	O
)	O
.	O

In	O
contrast	O
to	O
E	O
##SI	O
,	O
the	O
E	B
##I	I
method	O
di	O
##sso	O
##cia	O
##tes	O
the	O
intact	O
meta	O
##bol	O
##ite	O
ion	O
,	O
thereby	O
generating	O
multiple	O
fragment	O
ions	O
.	O

Our	O
frames	O
##hi	O
##ft	O
mutation	O
is	O
a	O
so	O
##matic	O
mutation	O
present	O
at	O
very	O
low	O
frequency	O
and	O
functional	O
studies	O
would	O
be	O
required	O
to	O
assess	O
its	O
actual	O
effect	O
on	O
or	B
##ota	I
##te	I
levels	O
,	O
whether	O
it	O
acts	O
in	O
combination	O
with	O
the	O
C	O
##9	O
##2	O
##R	O
variant	O
,	O
and	O
whether	O
the	O
wild	O
type	O
all	O
##ele	O
alone	O
is	O
sufficient	O
for	O
activity	O
.	O

De	B
##uter	I
##ium	I
-	I
labeled	I
d	I
_	I
4	I
-	I
pro	I
##sta	I
##g	I
##land	I
##in	I
D	O
_	O
2	O
(	O
d	O
_	O
4	O
-	O
P	O
##G	O
##D	O
_	O
2	O
)	O
and	O
d	O
_	O
5	O
-	O
D	O
##HA	O
from	O
C	O
##ayman	O
Chemical	O
were	O
used	O
as	O
the	O
internal	O
standards	O
to	O
determine	O
the	O
recover	O
##ies	O
of	O
lip	O
##id	O
extraction	O
and	O
quantities	O
of	O
the	O
anal	O
##ytic	O
##s	O
in	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
analysis	O
.	O

With	O
reference	O
to	O
the	O
small	O
meta	O
##bol	O
##ites	O
,	O
the	O
O	O
##PL	O
##S	O
-	O
D	O
##A	O
loading	O
##s	O
with	O
high	O
VIP	O
values	O
(	O
>	O
1	O
.	O
0	O
)	O
were	O
due	O
to	O
la	B
##ct	I
##ate	I
,	O
some	O
amino	O
acids	O
(	B
v	B
##ali	I
##ne	I
,	O
al	B
##ani	I
##ne	I
,	O
l	O
##ys	O
##ine	O
/	O
a	O
##rg	O
##ini	O
##ne	O
,	O
g	B
##lut	I
##amine	I
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
th	B
##re	I
##oni	I
##ne	I
and	O
his	B
##ti	I
##dine	I
)	O
,	O
ace	B
##tate	I
,	O
c	B
##it	I
##rate	I
,	O
format	B
##e	I
,	O
ad	B
##ip	I
##ic	I
acid	I
and	O
glucose	S
,	O
sign	O
##ifying	O
their	O
importance	O
when	O
their	O
concentrations	O
were	O
compared	O
with	O
disease	O
and	O
healthy	O
control	O
.	O

Li	O
##pid	O
##s	O
were	O
h	O
##ydro	O
##phobic	O
or	O
am	O
##phi	O
##pathic	O
small	O
molecules	O
that	O
originate	O
entirely	O
or	O
in	O
part	O
by	O
car	O
##ban	O
##ion	O
-	O
based	O
con	O
##den	O
##sation	O
##s	O
of	O
th	B
##io	I
##ester	I
##s	I
and	O
/	O
or	O
by	O
car	O
##bo	O
##cation	O
-	O
based	O
con	O
##den	O
##sation	O
##s	O
of	O
is	O
##op	O
##rene	O
units	O
.	O

Once	O
produced	O
in	O
the	O
gut	O
l	O
##ume	O
##n	O
,	O
in	B
##do	I
##le	I
is	O
absorbed	O
,	O
o	O
##xi	O
##dized	O
to	O
in	O
##dox	O
##yl	O
,	O
con	O
##ju	O
##gated	O
with	O
su	B
##lf	I
##ate	I
,	O
and	O
ex	O
##cre	O
##ted	O
as	O
u	O
##rina	O
##ry	O
in	B
##dox	I
##yl	I
su	I
##lf	I
##ate	I
.	O

Model	O
2	O
:	O
model	O
1	O
adjustments	O
plus	O
smoking	O
,	O
alcohol	O
consumption	O
,	O
ca	O
##lor	O
##ic	O
expenditure	O
,	O
family	O
history	O
of	O
diabetes	O
,	O
energy	O
intake	O
,	O
diet	O
##ary	O
protein	O
intake	O
,	O
fast	O
##ing	O
blood	O
glucose	S
,	O
and	O
B	O
##MI	O
.	O

In	O
addition	O
,	O
meta	O
##bol	O
##ites	O
in	O
each	O
sub	O
-	O
class	O
were	O
compared	O
between	O
O	O
##CT	O
-	O
embedded	O
and	O
FF	O
##P	O
##E	O
groups	O
,	O
and	O
certain	O
similarities	O
between	O
the	O
two	O
groups	O
were	O
identified	O
,	O
including	O
meta	O
##bol	O
##ites	O
belonging	O
to	O
pu	B
##rine	I
,	O
ad	B
##eni	I
##ne	I
,	O
p	B
##yr	I
##im	I
##id	I
##ine	I
,	O
or	B
##ota	I
##te	I
,	O
u	B
##rea	I
,	O
a	B
##rg	I
##ini	I
##ne	I
and	O
pro	B
##line	I
metabolism	O
sub	O
##c	O
##lass	O
##es	O
(	O
all	O
F	O
##DR	O
>	O
0	O
.	O
05	O
)	O
.	O

The	O
ratio	O
of	O
de	O
##pur	O
##inating	O
DNA	O
add	O
##uc	O
##ts	O
to	O
the	O
sum	O
of	O
the	O
corresponding	O
est	B
##rogen	I
meta	O
##bol	O
##ites	O
and	O
con	O
##ju	O
##gate	O
##s	O
in	O
non	O
-	O
Ho	O
##d	O
##g	O
##kin	O
l	O
##ymph	O
##oma	O
(	O
NHL	O
)	O
cases	O
and	O
healthy	O
controls	O
.	O

Within	O
the	O
s	B
##phi	I
##ngo	I
##lip	I
##id	I
pathway	O
,	O
c	B
##era	I
##mi	I
##de	I
s	O
##ynth	O
##ase	O
(	O
CE	O
##RS	O
)	O
3	O
and	O
CE	O
##RS	O
##6	O
were	O
32	O
and	O
19	O
%	O
up	O
##re	O
##gu	O
##lated	O
in	O
O	O
##IR	O
versus	O
O	O
##IS	O
,	O
respectively	O
and	O
24	O
and	O
15	O
%	O
in	O
O	O
##IR	O
versus	O
Lea	O
##n	O
,	O
respectively	O
.	O

However	O
,	O
free	O
o	B
##xy	I
##lip	I
##ins	I
and	O
fatty	O
acids	O
in	O
T	O
##GR	O
##L	O
are	O
more	O
readily	O
available	O
upon	O
up	O
##take	O
and	O
thus	O
may	O
be	O
significant	O
media	O
##tors	O
of	O
end	O
##oth	O
##eli	O
##al	O
inflammation	O
.	O

G	B
##lut	I
##amine	I
resulted	O
from	O
the	O
g	B
##lut	I
##amine	I
s	O
##ynth	O
##eta	O
##se	O
(	O
G	O
##S	O
)	O
reaction	O
between	O
g	B
##lut	I
##ama	I
##te	I
and	O
am	O
##monia	O
in	O
an	O
ATP	O
-	O
dependent	O
manner	O
.	O

Ch	O
##ronic	O
##ally	O
elevated	O
glucose	S
concentrations	O
are	O
associated	O
with	O
increased	O
U	B
##DP	I
-	I
G	I
##l	I
##c	I
##NA	I
##c	I
concentrations	O
via	O
flux	O
through	O
the	O
H	O
##B	O
##P	O
,	O
au	O
##gment	O
##ing	O
O	O
-	O
G	O
##l	O
##c	O
##NA	O
##cy	O
##lation	O
of	O
numerous	O
proteins	O
across	O
the	O
body	O
and	O
altering	O
their	O
function	O
.	O

The	O
injected	O
samples	O
were	O
e	O
##qui	O
##li	O
##bra	O
##ted	O
with	O
water	O
(	O
B	O
##rud	O
##ick	O
&	O
Jackson	O
,	O
HP	O
##LC	O
grade	O
)	O
containing	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
(	O
Sigma	O
Al	O
##dric	O
##h	O
,	O
99	O
%	O
)	O
(	O
solvent	O
A	O
)	O
and	O
then	O
el	O
##uted	O
through	O
an	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
(	O
Ted	O
##ia	O
,	O
99	O
.	O
9	O
%	O
)	O
gradient	O
containing	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
(	O
solvent	O
B	O
)	O
at	O
a	O
flow	O
rate	O
of	O
0	O
.	O
35	O
m	O
##L	O
/	O
min	O
for	O
20	O
min	O
.	O

Women	O
had	O
higher	O
concentrations	O
of	O
10	B
-	I
HD	I
##o	I
##H	I
##E	I
(	O
a	O
)	O
,	O
12	B
-	I
H	I
##EP	I
##E	I
(	O
b	O
)	O
,	O
14	B
-	I
HD	I
##o	I
##H	I
##E	I
(	O
c	O
)	O
,	O
8	B
-	I
H	I
##ET	I
##E	I
(	O
d	O
)	O
and	O
12	B
-	I
H	I
##ET	I
##E	I
(	O
e	O
)	O
than	O
men	O
.	O

Indeed	O
,	O
k	B
##yn	I
##uren	I
##ine	I
can	O
be	O
effectively	O
transported	O
over	O
the	O
blood	O
-	O
brain	O
barrier	O
(	O
B	O
##BB	O
)	O
through	O
the	O
neutral	O
amino	O
acid	O
transport	O
##er	O
.	O

However	O
,	O
we	O
found	O
no	O
difference	O
in	O
the	O
use	O
of	O
d	O
##ys	O
##lip	O
##idae	O
##mia	O
or	O
anti	O
-	O
h	O
##yper	O
##tensive	O
medications	O
within	O
the	O
BC	O
##AA	O
factor	O
q	O
##ua	O
##rt	O
##iles	O
outlined	O
in	O
(	O
p	O
=	O
0	O
.	O
33	O
for	O
medications	O
for	O
d	O
##ys	O
##lip	O
##idae	O
##mia	O
,	O
p	O
=	O
0	O
.	O
37	O
for	O
s	B
##tat	I
##ins	I
,	O
p	O
=	O
0	O
.	O
73	O
for	O
anti	O
-	O
h	O
##yper	O
##tens	O
##ion	O
medications	O
)	O
.	O

Specifically	O
,	O
concentrations	O
of	O
c	B
##rea	I
##tine	I
,	O
g	B
##ly	I
##cine	I
,	O
his	B
##ti	I
##dine	I
,	O
and	O
th	B
##re	I
##oni	I
##ne	I
were	O
reduced	O
in	O
CO	O
##PD	O
compared	O
to	O
NC	O
##S	O
subjects	O
.	O

L	O
##C	O
-	O
MS	O
/	O
MS	O
ass	O
##ay	O
methods	O
were	O
reported	O
for	O
the	O
simultaneous	O
analysis	O
of	O
si	B
##m	I
##vas	I
##tat	I
##in	I
and	O
si	B
##m	I
##vas	I
##tat	I
##in	I
acid	I
[	O
–	O
]	O
,	O
but	O
some	O
of	O
these	O
methods	O
had	O
a	O
relatively	O
long	O
run	O
time	O
(	O
10	O
,	O
8	O
and	O
6	O
.	O
4	O
min	O
[	O
,	O
,	O
]	O
)	O
with	O
larger	O
volume	O
of	O
plasma	O
used	O
(	O
47	O
##5	O
,	O
300	O
,	O
1000	O
,	O
300	O
μ	O
##l	O
[	O
–	O
,	O
]	O
)	O
,	O
compared	O
to	O
our	O
developed	O
method	O
(	O
5	O
min	O
run	O
with	O
200	O
μ	O
##l	O
of	O
plasma	O
)	O
.	O

Met	O
##ab	O
##oli	O
##te	O
numbering	O
was	O
according	O
to	O
2	O
-	O
D	O
_	O
1	O
H	O
TO	O
##CS	O
##Y	O
q	O
##uant	O
##ification	O
of	O
different	O
_	O
13	O
C	O
position	O
##al	O
is	O
##oto	O
##po	O
##mers	O
of	O
g	O
##ly	O
##co	O
##ly	O
##tic	O
and	O
K	O
##re	O
##bs	O
cycle	O
meta	O
##bol	O
##ites	O
in	O
an	O
example	O
A	O
##5	O
##4	O
##9	O
cell	O
extract	O
G	B
##S	I
##H	I
reduced	I
g	I
##lut	I
##ath	I
##ione	I
,	O
A	O
##X	O
##P	O
ad	B
##eni	I
##ne	I
n	O
##uc	O
##leo	O
##tide	O
##s	O
,	O
C	O
##X	O
##P	O
c	B
##yt	I
##os	I
##ine	I
n	O
##uc	O
##leo	O
##tide	O
##s	O
,	O
U	O
##DP	O
##G	O
u	B
##rac	I
##il	I
##di	I
##ph	I
##os	I
##ph	I
##o	I
glucose	I
,	O
N	B
##AD	I
_	O
+	O
ni	B
##cot	I
##ina	I
##mi	I
##de	I
ad	I
##eni	I
##ne	I
din	I
##uc	I
##leo	I
##tide	I

The	O
typical	O
s	O
##pect	O
##ra	O
of	O
representative	O
est	B
##rogen	I
derivatives	O
,	O
which	O
were	O
obtained	O
in	O
a	O
single	O
injection	O
,	O
are	O
shown	O
in	O
.	O

These	O
genetic	O
clusters	O
were	O
differential	O
##ly	O
but	O
consistently	O
associated	O
with	O
risk	O
factors	O
of	O
C	O
##VD	O
,	O
including	O
central	O
o	O
##besity	O
,	O
o	O
##besity	O
,	O
type	O
2	O
diabetes	O
,	O
raised	O
serum	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
and	O
metabolic	O
syndrome	O
.	O

First	O
,	O
there	O
is	O
a	O
prevalent	O
use	O
of	O
para	B
##ce	I
##tam	I
##ol	I
globally	O
as	O
an	O
O	O
##TC	O
medication	O
among	O
men	O
and	O
women	O
of	O
all	O
ages	O
including	O
children	O
0	O
months	O
to	O
12	O
years	O
of	O
age	O
.	O

Results	O
from	O
these	O
experiments	O
are	O
summarized	O
in	O
and	O
they	O
clearly	O
indicate	O
acceptable	O
stability	O
of	O
the	O
tested	O
anal	O
##yte	O
##s	O
(	O
no	O
significant	O
difference	O
was	O
observed	O
between	O
nominal	O
and	O
found	O
concentrations	O
of	O
monitored	O
amino	S
acids	O
)	O
.	O

First	O
,	O
we	O
compared	O
the	O
predict	O
##ive	O
and	O
disc	O
##rim	O
##ina	O
##nt	O
performances	O
of	O
try	B
##pt	I
##op	I
##han	I
with	O
the	O
other	O
5	O
AA	O
##s	O
(	B
v	B
##ali	I
##ne	I
,	O
le	B
##uc	I
##ine	I
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
and	O
t	B
##yr	I
##os	I
##ine	I
)	O
which	O
were	O
recently	O
reported	O
as	O
new	O
bio	O
##mark	O
##ers	O
for	O
T	O
##2	O
##D	O
risk	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
treatment	O
with	O
EC	O
##T	O
induced	O
major	O
changes	O
in	O
peripheral	O
k	B
##yn	I
##uren	I
##ine	I
meta	O
##bol	O
##ites	O
in	O
patients	O
with	O
MD	O
##D	O
.	O

In	O
BA	O
##L	O
however	O
,	O
p	B
-	I
c	I
##res	I
##ol	I
may	O
serve	O
as	O
a	O
bio	O
##mark	O
##er	O
for	O
micro	O
##bio	O
##me	O
-	O
lung	O
function	O
interaction	O
rather	O
than	O
directly	O
ins	O
##ti	O
##gating	O
path	O
##ogen	O
##esis	O
.	O

The	O
cap	O
##illa	O
##ry	O
voltage	O
was	O
set	O
at	O
4	O
k	B
##V	I
.	O
The	O
pressure	O
and	O
flow	O
rate	O
of	O
the	O
ne	O
##bul	O
##izer	O
gas	O
were	O
7	O
ps	O
##i	O
and	O
10	O
μ	O
##L	O
/	O
min	O
,	O
respectively	O
.	O

Among	O
meta	O
##bol	O
##ites	O
detected	O
in	O
RS	O
##F	O
,	O
we	O
found	O
that	O
Val	B
##ine	I
,	O
S	B
##phi	I
##ngo	I
##my	I
##elin	I
##e	I
C	I
##24	I
:	I
1	I
,	O
L	B
##ys	I
##ine	I
,	O
Trip	B
##ent	I
##ade	I
##cano	I
##ate	I
T	O
##G	O
##15	O
and	O
S	B
##ym	I
##metric	I
dim	I
##eth	I
##yla	I
##rg	I
##ini	I
##ne	I
were	O
selected	O
following	O
the	O
step	O
##wise	O
variable	O
selection	O
criterion	O
(	O
achieving	O
a	O
AI	O
##C	O
of	O
−	O
##5	O
.	O
04	O
)	O
and	O
entered	O
into	O
the	O
Wei	O
##bull	O
multi	O
##var	O
##iable	O
survival	O
model	O
.	O

The	O
formation	O
rate	O
of	O
h	B
##ydro	I
##xy	I
##ana	I
##stro	I
##zo	I
##le	I
was	O
best	O
fitted	O
to	O
two	O
-	O
site	O
h	O
##yper	O
##bolic	O
kinetic	O
equations	O
.	O

Like	O
q	B
##uin	I
##ones	I
,	O
q	B
##uin	I
##one	I
met	O
##hi	O
##des	O
are	O
known	O
to	O
be	O
very	O
reactive	O
that	O
are	O
shown	O
to	O
co	O
##valent	O
##ly	O
bind	O
with	O
DNA	O
to	O
form	O
DNA	O
add	O
##uc	O
##ts	O
in	O
v	O
##it	O
##ro	O
.	O

AU	O
##C	O
,	O
area	O
under	O
the	O
receiver	O
operating	O
curve	O
;	O
C	O
##I	O
,	O
confidence	O
interval	O
;	O
HC	O
##C	O
,	O
he	O
##pa	O
##to	O
##cellular	O
car	O
##cin	O
##oma	O
;	O
L	O
##C	O
,	O
liver	O
c	O
##ir	O
##r	O
##hos	O
##is	O
;	O
NC	O
,	O
normal	O
control	O
;	O
A	O
##FP	O
,	O
α	B
-	I
f	I
##eto	I
##p	I
##rote	I
##in	I
.	O

Others	O
have	O
also	O
shown	O
that	O
g	B
##lut	I
##ama	I
##te	I
is	O
an	O
important	O
meta	O
##bol	O
##ite	O
in	O
tumor	O
##ige	O
##nes	O
##is	O
,	O
including	O
H	O
##NS	O
##CC	O
,	O
and	O
resonance	O
##s	O
from	O
g	B
##lut	I
##ama	I
##te	I
,	O
ta	B
##uri	I
##ne	I
,	O
ch	B
##olin	I
##e	I
,	O
la	B
##ctic	I
acid	I
,	O
and	O
lip	O
##ids	O
were	O
found	O
to	O
have	O
diagnostic	O
potential	O
for	O
H	O
##NS	O
##CC	O
;	O
however	O
,	O
our	O
data	O
reveal	O
the	O
me	O
##chan	O
##istic	O
significance	O
of	O
g	O
##lut	O
##ami	O
##no	O
##lysis	O
in	O
tumor	O
##ige	O
##nes	O
##is	O
and	O
its	O
regulatory	O
role	O
in	O
m	O
##od	O
##ulating	O
stem	O
##ness	O
.	O

These	O
negative	O
relationships	O
with	O
body	O
mass	O
index	O
were	O
generally	O
weaker	O
after	O
adjusting	O
for	O
age	O
and	O
gender	O
,	O
and	O
then	O
only	O
apparent	O
for	O
pro	B
##ges	I
##tero	I
##ne	I
,	O
17	B
-	I
h	I
##ydro	I
##xy	I
##p	I
##rog	I
##ester	I
##one	I
,	O
11	B
-	I
de	I
##ox	I
##cor	I
##tic	I
##osterone	I
,	O
co	B
##rt	I
##ico	I
##ster	I
##one	I
,	O
21	B
-	I
de	I
##ox	I
##y	I
##cor	I
##tis	I
##ol	I
,	O
co	B
##rt	I
##is	I
##ol	I
,	O
co	B
##rt	I
##ison	I
##e	I
and	O
test	B
##osterone	I
.	O

In	O
##sul	O
##in	O
resistance	O
is	O
a	O
key	O
feature	O
of	O
type	O
2	O
diabetes	O
,	O
and	O
numerous	O
studies	O
in	O
both	O
culture	O
and	O
animal	O
models	O
demonstrate	O
that	O
there	O
is	O
a	O
strong	O
association	O
between	O
increasing	O
c	B
##era	I
##mi	I
##de	I
levels	O
and	O
defect	O
##ive	O
insulin	O
action	O
in	O
target	O
tissues	O
,	O
especially	O
skeletal	O
muscle	O
and	O
liver	O
[	O
,	O
,	O
,	O
,	O
]	O
.	O

This	O
analysis	O
would	O
be	O
the	O
proof	O
of	O
close	O
connection	O
between	O
N	B
-	I
ace	I
##ty	I
##l	I
-	I
g	I
##ly	I
##co	I
##p	I
##rote	I
##ins	I
and	O
extra	O
##ne	O
##ous	O
factors	O
leading	O
to	O
disease	O
.	O

Di	O
##fference	O
##s	O
in	O
socio	O
-	O
demographic	O
characteristics	O
,	O
presence	O
of	O
Mets	O
,	O
serum	O
T	B
##MA	I
##O	I
,	O
and	O
ch	B
##olin	I
##e	I
concentrations	O
between	O
patients	O
and	O
controls	O
were	O
compared	O
by	O
t	O
-	O
test	O
,	O
ch	O
##i	O
-	O
squared	O
test	O
,	O
and	O
Wilcox	O
##on	O
rank	O
-	O
sum	O
test	O
as	O
appropriate	O
.	O

(	B
D	B
##N	I
##OP	I
-	I
1	I
,	I
2	I
Benz	I
##ened	I
##ica	I
##rb	I
##ox	I
##yl	I
##ic	I
acid	I
,	O
bi	O
##s	O
(	O
2	O
-	O
et	O
##hyl	O
##he	O
##xy	O
##l	O
)	O
est	O
##er	O
)	O
.	O

Tu	O
##bes	O
were	O
cent	O
##ri	O
##fu	O
##ged	O
(	O
13	O
,	O
000	O
×	O
##g	O
,	O
10	O
min	O
)	O
and	O
the	O
super	O
##nat	O
##ant	O
removed	O
into	O
a	O
clean	O
p	B
##oly	I
##p	I
##rop	I
##yle	I
##ne	I
tube	O
.	O

Additional	O
prospective	O
studies	O
will	O
be	O
required	O
to	O
test	O
these	O
specific	O
findings	O
and	O
provide	O
more	O
information	O
about	O
circulating	O
est	O
##rogen	O
##s	O
and	O
est	B
##rogen	I
meta	O
##bol	O
##ites	O
in	O
post	O
##men	O
##op	O
##aus	O
##al	O
women	O
,	O
their	O
associations	O
with	O
the	O
risk	O
of	O
breast	O
cancer	O
,	O
and	O
the	O
best	O
models	O
for	O
describing	O
those	O
associations	O
.	O

Fast	O
##ing	O
insulin	O
and	O
glucose	S
were	O
combined	O
to	O
calculate	O
the	O
insulin	O
sensitivity	O
index	O
using	O
the	O
home	O
##ost	O
##asis	O
model	O
assessment	O
(	O
H	O
##OM	O
##A	O
)	O
.	O

The	O
metabolism	O
of	O
SL	S
is	O
a	O
complex	O
pathway	O
that	O
generates	O
s	B
##phi	I
##ngo	I
##sin	I
##e	I
-	I
1	I
-	I
phosphate	I
(	O
S	O
##1	O
##P	O
)	O
from	O
various	O
precursor	O
##s	O
,	O
using	O
c	B
##era	I
##mi	I
##de	I
as	O
a	O
backbone	O
.	O

Out	O
of	O
48	O
analyzed	O
ICC	O
tissue	O
samples	O
,	O
one	O
sample	O
for	O
CR	O
and	O
one	O
sample	O
for	O
N	B
##AN	I
##A	I
ass	O
##ays	O
were	O
below	O
the	O
lower	O
limit	O
of	O
detection	O
.	O

Con	O
##c	O
##lusion	O
:	O
U	O
##rina	O
##ry	O
d	O
##ys	O
##re	O
##gu	O
##lated	O
a	B
##rg	I
##ini	I
##ne	I
metabolism	O
that	O
may	O
serve	O
as	O
a	O
helpful	O
clinical	O
diagnostic	O
bio	O
##mark	O
##er	O
for	O
a	O
##MC	O
##I	O
in	O
older	O
adults	O
.	O

He	B
##xa	I
##nes	I
(	O
10	O
m	O
##l	O
)	O
were	O
added	O
to	O
each	O
tube	O
,	O
and	O
the	O
mixture	O
was	O
son	O
##ica	O
##ted	O
again	O
.	O

Co	O
##mp	O
##aris	O
##on	O
of	O
the	O
normal	O
##ized	O
signal	O
intensity	O
of	O
lip	O
##ids	O
in	O
urine	O
that	O
were	O
identified	O
as	O
bio	O
##mark	O
##er	O
candidates	O
for	O
disc	O
##rim	O
##inating	O
(	O
a	O
)	O
me	O
##lo	O
##xi	O
##cam	O
-	O
treated	O
(	O
M	O
)	O
(	O
n	O
=	O
6	O
)	O
and	O
sa	O
##line	O
-	O
treated	O
(	O
C	O
)	O
cats	O
(	O
n	O
=	O
6	O
)	O
;	O
and	O
(	O
b	O
)	O
base	O
##line	O
(	O
B	O
##M	O
)	O
and	O
me	O
##lo	O
##xi	O
##cam	O
group	O
(	O
M	O
)	O
at	O
different	O
times	O
after	O
the	O
administration	O
of	O
sa	B
##line	I
or	O
me	O
##lo	O
##xi	O
##cam	O
at	O
0	O
.	O
3	O
mg	O
/	O
kg	O
every	O
24	O
h	O
for	O
up	O
to	O
17	O
days	O
(	O
times	O
2	O
to	O
5	O
)	O
.	O

Le	O
##uk	O
##ot	O
##rien	O
##es	O
(	O
L	O
##T	O
##s	O
)	O
are	O
biological	O
##ly	O
active	O
meta	O
##bol	O
##ites	O
of	O
a	B
##rac	I
##hi	I
##don	I
##ic	I
acid	I
via	O
5	O
-	O
lip	O
##ox	O
##y	O
##gen	O
##ase	O
(	O
5	O
-	O
L	O
##O	O
)	O
in	O
the	O
body	O
by	O
my	O
##elo	O
##id	O
cells	O
and	O
B	O
l	O
##ymph	O
##ocytes	O
.	O

Blood	O
and	O
breast	O
tissue	O
were	O
collected	O
to	O
determine	O
limo	B
##nen	I
##e	I
and	O
meta	O
##bol	O
##ite	O
concentrations	O
and	O
limo	O
##nen	O
##e	O
-	O
induced	O
changes	O
in	O
systemic	O
and	O
tissue	O
bio	O
##mark	O
##ers	O
of	O
breast	O
cancer	O
risk	O
or	O
car	O
##cin	O
##ogen	O
##esis	O
.	O

The	O
met	B
##han	I
##ol	I
contained	O
four	O
recovery	O
standards	O
(	B
DL	B
-	I
2	I
-	I
flu	I
##oro	I
##phe	I
##ny	I
##l	I
##gly	I
##cine	I
,	O
t	B
##ride	I
##cano	I
##ic	I
acid	I
,	O
d	B
##6	I
-	I
ch	I
##ole	I
##ster	I
##ol	I
and	O
4	B
-	I
ch	I
##lor	I
##op	I
##hen	I
##yla	I
##lani	I
##ne	I
)	O
to	O
allow	O
confirmation	O
of	O
extraction	O
efficiency	O
.	O

Take	O
##n	O
together	O
,	O
we	O
observed	O
the	O
significantly	O
positive	O
association	O
of	O
l	B
##ino	I
##le	I
##ic	I
acid	I
,	O
s	B
##te	I
##ari	I
##c	I
acid	I
,	O
al	B
##ani	I
##ne	I
,	O
se	B
##rine	I
and	O
try	B
##pt	I
##op	I
##han	I
concentrations	O
with	O
the	O
occurrence	O
of	O
PC	O
##OS	O
disease	O
,	O
and	O
the	O
obviously	O
negative	O
relations	O
of	O
glucose	S
,	O
pro	B
##line	I
and	O
is	B
##ole	I
##uc	I
##ine	I
levels	O
with	O
PC	O
##OS	O
controlling	O
for	O
age	O
,	O
B	O
##MI	O
and	O
I	O
##R	O
(	O
Additional	O
file	O
)	O
.	O

A	O
n	O
##uc	O
##leo	O
##side	O
,	O
put	O
##ative	O
##ly	O
identified	O
as	O
N	B
-	I
form	I
##yl	I
-	I
c	I
##yt	I
##id	I
##ine	I
(	O
m	O
/	O
z	O
272	O
,	O
R	O
##T	O
2	O
.	O
52	O
min	O
)	O
,	O
was	O
found	O
using	O
positive	O
neutral	O
loss	O
scan	O
of	O
m	O
/	O
z	O
132	O
on	O
A	O
##c	O
##qui	O
##ty	O
UP	O
##LC	O
-	O
4000	O
Q	O
##T	O
##rap	O
MS	O
in	O
pool	O
##ed	O
urine	O
from	O
cc	O
##RC	O
##C	O
patients	O
(	O
orange	O
line	O
)	O
two	O
-	O
folds	O
higher	O
than	O
in	O
post	O
-	O
operative	O
controls	O
(	O
grey	O
line	O
)	O

Previous	O
studies	O
reported	O
that	O
que	B
##rc	I
##eti	I
##n	I
has	O
anti	O
-	O
di	O
##abe	O
##tic	O
and	O
anti	O
-	O
o	O
##xi	O
##da	O
##tive	O
effects	O
in	O
the	O
di	O
##abe	O
##tic	O
rat	O
.	O

The	O
system	O
utilized	O
a	O
DB	O
-	O
5	O
##MS	O
cap	O
##illa	O
##ry	O
column	O
coated	O
with	O
5	O
%	O
dip	O
##hen	O
##yl	O
cross	O
-	O
linked	O
with	O
95	O
%	O
dim	B
##eth	I
##yl	I
##pol	I
##ys	I
##ilo	I
##xa	I
##ne	I
(	O
30	O
m	O
×	O
250	O
μ	O
##m	O
inner	O
diameter	O
,	O
0	O
.	O
25	O
μ	O
##m	O
film	O
thickness	O
;	O
J	O
&	O
W	O
Scientific	O
,	O
F	O
##ols	O
##om	O
,	O
CA	O
,	O
USA	O
)	O
.	O

Direct	O
que	O
##nch	O
##ing	O
of	O
the	O
metabolism	O
in	O
ad	O
##here	O
##nt	O
cells	O
needs	O
extraction	O
with	O
organic	O
solvent	O
##s	O
such	O
as	O
Me	B
##OH	I
.	O

1	B
-	I
(	I
N	I
-	I
ace	I
##ty	I
##l	I
##cy	I
##stein	I
##yl	I
)	I
p	I
##hen	I
##ant	I
##hren	I
##e	I

The	O
column	O
temperature	O
was	O
35	O
°C	O
with	O
a	O
flow	O
rate	O
of	O
0	O
.	O
35	O
m	O
##L	O
/	O
min	O
and	O
the	O
auto	O
##sa	O
##mple	O
##r	O
cooler	O
temperature	O
was	O
set	O
at	O
4	O
°C	O
with	O
an	O
injection	O
volume	O
of	O
5	O
µ	O
##L	O
.	O
Ana	O
##ly	O
##tes	O
were	O
el	O
##uted	O
with	O
a	O
mobile	O
phase	O
composed	O
of	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
in	O
water	O
(	O
A	O
)	O
and	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
with	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
(	O
B	O
)	O
.	O

Although	O
matrix	O
effect	O
was	O
observed	O
for	O
Ce	B
##r	I
(	I
22	I
:	I
0	I
)	I
in	O
plasma	O
,	O
the	O
co	O
-	O
el	O
##ution	O
of	O
de	O
##uter	O
##ium	O
-	O
labeled	O
internal	O
standard	O
compensate	O
##d	O
the	O
matrix	O
effect	O
and	O
the	O
accuracy	O
and	O
precision	O
were	O
not	O
affected	O
.	O

C	O
##luster	O
1	O
consisted	O
predominantly	O
of	O
non	O
-	O
est	O
##eri	O
##fied	O
di	O
##ols	O
suggesting	O
elevated	O
levels	O
of	O
s	O
##E	O
##H	O
activity	O
that	O
contributes	O
to	O
the	O
non	O
-	O
est	O
##eri	O
##fied	O
o	B
##xy	I
##lip	I
##in	I
pool	O
in	O
fast	O
##ing	O
anti	O
-	O
at	O
##her	O
##ogenic	O
subjects	O
.	O

As	O
discussed	O
previously	O
,	O
con	O
##ju	O
##gation	O
can	O
occur	O
at	O
both	O
the	O
3	O
-	O
and	O
6	O
-	O
carbon	O
position	O
of	O
the	O
m	B
##or	I
##phine	I
analog	O
##s	O
,	O
leading	O
to	O
mostly	O
inactive	O
meta	O
##bol	O
##ites	O
.	O

These	O
include	O
two	O
secondary	O
bi	O
##le	O
acids	O
,	O
L	O
##CA	O
and	O
T	O
##LC	O
##A	O
,	O
which	O
we	O
identified	O
as	O
markers	O
for	O
greater	O
response	O
to	O
si	B
##m	I
##vas	I
##tat	I
##in	I
lowering	O
of	O
L	O
##D	O
##L	O
-	O
C	O
levels	O
in	O
good	O
respond	O
##ers	O
.	O

And	B
##ros	I
##tend	I
##ione	I
occurs	O
naturally	O
in	O
the	O
body	O
and	O
is	O
a	O
direct	O
precursor	O
to	O
the	O
hormone	O
test	B
##osterone	I
.	O

Therefore	O
,	O
we	O
applied	O
a	O
se	B
##rot	I
##oni	I
##n	I
ass	O
##ay	O
by	O
using	O
stable	O
is	O
##oto	O
##pe	O
di	O
##lution	O
direct	O
electro	O
##sp	O
##ray	O
ion	O
##ization	O
mass	O
s	O
##pect	O
##rome	O
##try	O
(	O
S	O
##ID	O
-	O
MS	O
,	O
see	O
section	O
Materials	O
and	O
Method	O
##s	O
)	O
to	O
analyze	O
urine	O
samples	O
of	O
the	O
same	O
patients	O
.	O

Bin	O
##d	O
##zi	O
##l	O
204	O
##0	O
si	B
##lica	I
na	O
##no	O
##par	O
##tic	O
##les	O
(	O
S	O
##NP	O
##s	O
)	O
were	O
obtained	O
from	O
A	O
##k	O
##zo	O
##N	O
##obe	O
##l	O
and	O
E	O
##ka	O
Chemical	O
##s	O
with	O
an	O
average	O
diameter	O
of	O
20	O
nm	O
(	O
characterized	O
previously	O
)	O
and	O
a	O
negative	O
surface	O
charge	O
at	O
pH	O
7	O
.	O
4	O
(	B
ζ	B
-	I
potential	I
=	O
−	O
##40	O
.	O
7	O
±	O
5	O
.	O
9	O
m	O
##V	O
,	O
see	O
)	O
.	O

One	O
C	O
##18	O
column	O
(	O
In	O
##ert	O
##si	O
##l	O
O	O
##DS	O
-	O
3	O
,	O
33	O
##×	O
##4	O
.	O
6	O
mm	O
,	O
5	O
μ	O
##m	O
,	O
G	O
##L	O
Science	O
,	O
Tokyo	O
,	O
Japan	O
)	O
was	O
used	O
to	O
extract	O
and	O
clean	O
our	O
sample	O
,	O
and	O
an	O
analytical	O
column	O
(	O
In	O
##ert	O
##si	O
##l	O
Ph	O
,	O
150	O
*	O
4	O
.	O
6	O
mm	O
,	O
5	O
μ	O
##m	O
,	O
G	O
##L	O
Science	O
,	O
Tokyo	O
,	O
Japan	O
)	O
was	O
used	O
to	O
separate	O
different	O
p	B
##ht	I
##hala	I
##te	I
meta	O
##bol	O
##ites	O
.	O

Therefore	O
,	O
the	O
value	O
of	O
sa	B
##rc	I
##os	I
##ine	I
as	O
a	O
pro	O
##gno	O
##stic	O
marker	O
for	O
PC	O
##a	O
progression	O
is	O
controversial	O
.	O

Among	O
previously	O
reported	O
pan	O
##cre	O
##atic	O
cancer	O
-	O
associated	O
meta	O
##bol	O
##ites	O
,	O
significant	O
up	O
##re	O
##gu	O
##lation	O
##s	O
in	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
(	I
L	I
##ys	I
##o	I
##PC	I
)	I
(	I
18	I
:	I
2	I
)	I
(	O
e	O
)	O
and	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
(	I
SM	I
)	I
(	I
d	I
##18	I
:	I
1	I
/	I
24	I
:	I
1	I
)	I
(	O
f	O
)	O
were	O
detected	O
in	O
the	O
H	O
##FS	O
group	O
compared	O
with	O
the	O
non	O
-	O
H	O
##FS	O
group	O
.	O

As	O
noted	O
in	O
,	O
for	O
some	O
est	B
##rogen	I
and	O
est	B
##rogen	I
metabolism	O
measures	O
,	O
an	O
additional	O
q	O
##uad	O
##ratic	O
term	O
was	O
statistical	O
##ly	O
significantly	O
associated	O
with	O
the	O
risk	O
of	O
breast	O
cancer	O
,	O
which	O
suggests	O
a	O
non	O
##linear	O
component	O
for	O
these	O
associations	O
.	O

A	O
consisted	O
of	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
in	O
water	O
(	O
Mill	O
##i	O
-	O
Q	O
)	O
and	O
mobile	O
phase	O
B	O
consisted	O
of	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
in	O
AC	O
##N	O
.	O

The	O
data	O
could	O
mean	O
that	O
our	O
patient	O
population	O
had	O
previously	O
und	O
##ete	O
##cted	O
meta	O
##sta	O
##sis	O
or	O
that	O
the	O
elevated	O
met	B
##hi	I
##oni	I
##ne	I
metabolism	O
is	O
a	O
precursor	O
for	O
meta	O
##sta	O
##sis	O
.	O

The	O
T	O
##0	O
P	O
##LS	O
-	O
D	O
##A	O
model	O
demonstrates	O
that	O
a	O
temporal	O
increase	O
(	O
T	O
##0	O
relative	O
to	O
q	O
##ui	O
##es	O
##cent	O
)	O
in	O
certain	O
s	O
##tero	O
##id	O
hormones	O
,	O
l	B
##ys	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
,	O
mon	B
##oa	I
##cy	I
##l	I
##gly	I
##cer	I
##ols	I
,	O
and	O
n	O
-	O
ace	O
##ty	O
##l	O
amino	O
acids	O
accompanied	O
by	O
a	O
temporal	O
decrease	O
in	O
certain	O
plasma	O
amino	O
acids	O
distinguish	O
th	O
##rom	O
##bot	O
##ic	O
MI	O
from	O
non	O
-	O
th	O
##rom	O
##bot	O
##ic	O
MI	O
and	O
stable	O
CA	O
##D	O
subjects	O
.	O

All	O
models	O
were	O
adjusted	O
for	O
age	O
,	O
sex	O
,	O
co	O
##hor	O
##t	O
,	O
and	O
base	O
##line	O
values	O
of	O
B	O
##MI	O
,	O
glucose	S
,	O
T	O
##AG	O
,	O
total	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
and	O
HD	O
##L	O
-	O
C	O
.	O
For	O
individuals	O
with	O
self	O
-	O
reported	O
use	O
of	O
lip	O
##id	O
-	O
lowering	O
or	O
diabetes	O
medications	O
at	O
follow	O
-	O
up	O
,	O
values	O
were	O
adjusted	O
as	O
described	O
above	O
.	O

Normal	O
met	B
##hyl	I
##ci	I
##trate	I
levels	O
in	O
both	O
populations	O
supported	O
re	O
##nal	O
su	O
##ff	O
##iciency	O
.	O

In	O
our	O
experiments	O
,	O
α	B
-	I
O	I
##G	I
treatment	O
suppressed	O
T	O
##ET	O
activity	O
almost	O
completely	O
;	O
however	O
,	O
there	O
was	O
no	O
influence	O
on	O
D	O
##N	O
##MT	O
activity	O
(	O
Fi	O
##g	O
.	O
)	O
.	O

We	O
also	O
evaluated	O
the	O
possible	O
relationship	O
between	O
24	B
##S	I
-	I
OH	I
-	I
Cho	I
##l	I
and	O
other	O
available	O
variables	O
.	O

On	O
the	O
other	O
hand	O
,	O
M	B
##T	I
##BE	I
and	O
C	O
##18	O
extraction	O
methods	O
demonstrated	O
the	O
worst	O
repeat	O
##ability	O
independent	O
of	O
L	O
##C	O
-	O
MS	O
analysis	O
.	O

Due	O
to	O
their	O
involvement	O
in	O
the	O
production	O
of	O
SC	O
##FA	O
##s	O
(	O
especially	O
but	B
##yra	I
##te	I
)	O
,	O
they	O
could	O
ex	O
##ert	O
a	O
home	O
##ost	O
##atic	O
role	O
within	O
the	O
in	O
##test	O
##ine	O
of	O
the	O
controls	O
:	O
here	O
,	O
G	O
##em	O
##mi	O
##ger	O
form	O
##ici	O
##lis	O
is	O
the	O
most	O
important	O
keys	O
##tone	O
species	O
.	O

It	O
is	O
possible	O
that	O
,	O
in	O
these	O
specific	O
conditions	O
,	O
ch	B
##ole	I
##ster	I
##ol	I
turnover	O
might	O
be	O
increased	O
in	O
C	O
##NS	O
(	O
due	O
to	O
ne	O
##uron	O
##al	O
degradation	O
)	O
and	O
/	O
or	O
that	O
the	O
rate	O
of	O
conversion	O
of	O
brain	O
ch	B
##ole	I
##ster	I
##ol	I
to	O
24	B
##S	I
-	I
OH	I
-	I
Cho	I
##l	I
might	O
be	O
higher	O
compared	O
to	O
normal	O
.	O

R	O
##R	O
##MS	O
<	O
13	O
Y	O
:	O
Re	O
##lap	O
##sing	O
Re	O
##mit	O
##ting	O
Multiple	O
Sc	O
##ler	O
##osis	O
having	O
less	O
than	O
13	O
years	O
of	O
disease	O
duration	S
;	O
R	O
##R	O
##MS	O
>	O
=	O
13	O
Y	O
:	O
Re	O
##lap	O
##sing	O
Re	O
##mit	O
##ting	O
Multiple	O
Sc	O
##ler	O
##osis	O
with	O
>	O
=	O
13	O
years	O
of	O
disease	O
duration	S
;	O
SP	O
##MS	O
:	O
Secondary	O
Progressive	O
Multiple	O
Sc	O
##ler	O
##osis	O
;	O
PP	O
##MS	O
:	O
Primary	O
Progressive	O
Multiple	O
Sc	O
##ler	O
##osis	O
.	O

N	B
-	I
ace	I
##ty	I
##l	I
-	I
l	I
##ys	I
##ine	I
,	O
g	B
##lut	I
##ama	I
##te	I
,	O
and	O
as	B
##par	I
##tate	I
were	O
characterized	O
based	O
on	O
their	O
acute	O
variation	O
in	O
the	O
R	O
_	O
BT	O
vs	O
.	O
N	O
##R	O
_	O
BT	O
comparison	O
while	O
as	B
##par	I
##tate	I
,	O
pro	B
##line	I
,	O
g	B
##lut	I
##arate	I
,	O
g	B
##ly	I
##cer	I
##ol	I
,	O
and	O
FF	O
##A	O
14	O
:	O
0	O
were	O
characterized	O
as	O
the	O
meta	O
##bol	O
##ites	O
highly	O
correlated	O
to	O
the	O
prediction	O
of	O
HC	O
##C	O
re	O
##lap	O
##se	O
after	O
treatment	O
.	O

The	O
acidic	O
pathway	O
starts	O
with	O
26	O
-	O
h	O
##ydro	O
##xy	O
##lation	O
of	O
ch	B
##ole	I
##ster	I
##ol	I
by	O
C	O
##YP	O
##27	O
##A	O
##1	O
,	O
and	O
the	O
24	B
(	B
S	I
)	I
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
pathway	O
by	O
24	O
(	O
S	O
)	O
-	O
h	O
##ydro	O
##xy	O
##lation	O
of	O
ch	B
##ole	I
##ster	I
##ol	I
by	O
C	O
##YP	O
##46	O
##A	O
##1	O
.	O

Con	O
##sist	O
##ent	O
with	O
prolonged	O
fast	O
##ing	O
,	O
we	O
observed	O
a	O
reduced	O
plasma	O
insulin	O
level	O
,	O
together	O
with	O
increased	O
rates	O
of	O
palm	B
##itate	I
release	O
(	O
R	O
_	O
a	O
)	O
,	O
up	O
##take	O
(	O
R	O
_	O
d	O
)	O
,	O
and	O
oxidation	O
in	O
the	O
place	O
##bo	O
trial	O
,	O
in	O
##dicative	O
of	O
increased	O
ad	O
##ip	O
##ose	O
lip	O
##oly	O
##sis	O
and	O
u	O
##til	O
##ization	O
of	O
fatty	O
acids	O
as	O
a	O
substrate	O
for	O
ATP	S
production	O
.	O

P	O
##le	O
##iot	O
##ropic	O
effects	O
of	O
ace	B
##tone	I
including	O
the	O
regulation	O
of	O
inflammation	O
,	O
o	O
##xi	O
##da	O
##tive	O
stress	O
,	O
and	O
anti	O
-	O
cat	O
##ab	O
##olic	O
effects	O
in	O
human	O
skeletal	O
muscle	O
have	O
been	O
described	O
previously	O
.	O

Re	B
##ser	I
##pine	I
was	O
used	O
as	O
an	O
external	O
standard	O
for	O
instrument	O
ca	O
##li	O
##bra	O
##tion	O
and	O
semi	O
-	O
quantitative	O
analysis	O
.	O

The	O
dried	O
residue	O
of	O
serum	O
extract	O
was	O
red	O
##iss	O
##ol	O
##ved	O
in	O
100	O
μ	O
##l	O
of	O
met	B
##hyl	I
t	I
-	I
but	I
##yl	I
et	I
##her	I
,	O
and	O
then	O
100	O
μ	O
##l	O
of	O
met	B
##han	I
##ol	I
was	O
added	O
with	O
mixing	O
before	O
cent	O
##ri	O
##fu	O
##ging	O
prior	O
to	O
injection	O
(	O
10	O
μ	O
##l	O
)	O
.	O

The	O
selected	O
meta	O
##bol	O
##ites	O
in	O
this	O
model	O
were	O
his	B
##ti	I
##dine	I
and	O
g	B
##uan	I
##ido	I
##ace	I
##tic	I
acid	I
in	O
plasma	O
and	O
h	B
##y	I
##pot	I
##au	I
##rine	I
in	O
urine	O
.	O

The	O
present	O
study	O
showed	O
that	O
the	O
cancer	O
group	O
has	O
elevated	O
levels	O
of	O
u	O
##rina	O
##ry	O
ace	B
##ty	I
##l	I
-	I
Co	I
##A	I
and	O
car	B
##ni	I
##tine	I
,	O
and	O
several	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
were	O
found	O
to	O
contribute	O
to	O
the	O
differentiation	O
between	O
the	O
cancer	O
and	O
control	O
groups	O
.	O

This	O
intensity	O
ratio	O
is	O
reduced	O
to	O
0	O
.	O
06	O
,	O
0	O
.	O
3	O
and	O
0	O
.	O
2	O
(	O
see	O
discussion	O
below	O
)	O
in	O
the	O
tandem	O
mass	O
s	O
##pect	O
##ra	O
of	O
Δ	O
_	O
9	O
18	O
:	O
1	O
FA	O
,	O
Δ	B
_	I
9	I
,	I
12	I
18	I
:	I
2	I
FA	I
and	O
Δ	B
_	I
9	I
,	I
12	I
,	I
15	I
18	I
:	I
3	I
FA	I
,	O
respectively	O
.	O

In	O
our	O
study	O
,	O
several	O
alcohol	O
##s	O
,	O
such	O
as	O
3	B
-	I
met	I
##hyl	I
##but	I
-	I
3	I
-	I
en	I
-	I
2	I
-	I
o	I
##l	I
,	O
2	B
,	I
7	I
-	I
dim	I
##eth	I
##yl	I
##oc	I
##tan	I
-	I
1	I
-	I
o	I
##l	I
,	O
2	B
-	I
(	I
4	I
-	I
met	I
##hyl	I
##cy	I
##c	I
##lo	I
##he	I
##x	I
-	I
3	I
-	I
en	I
-	I
1	I
-	I
y	I
##l	I
)	I
prop	I
##an	I
-	I
2	I
-	I
o	I
##l	I
,	O
3	B
,	I
7	I
-	I
dim	I
##eth	I
##yl	I
##oc	I
##t	I
-	I
7	I
-	I
en	I
-	I
1	I
-	I
o	I
##l	I
and	O
de	B
##can	I
-	I
1	I
-	I
o	I
##l	I
were	O
altered	O
in	O
PC	O
##a	O
cell	O
lines	O
;	O
this	O
alter	O
##ation	O
in	O
alcohol	O
##s	O
levels	O
may	O
be	O
due	O
to	O
the	O
alter	O
##ation	O
in	O
h	B
##ydro	I
##car	I
##bon	I
metabolism	O
,	O
being	O
alcohol	O
##s	O
end	O
-	O
products	O
of	O
this	O
metabolism	O
.	O

A	O
direct	O
association	O
with	O
B	O
##MI	O
of	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
(	O
P	O
=	O
8	O
.	O
35	O
×	O
10	O
_	O
−	O
##19	O
,	O
)	O
,	O
based	O
on	O
the	O
I	O
##EC	O
amino	O
acid	O
analysis	O
data	O
,	O
confirmed	O
previous	O
findings	O
linking	O
o	O
##besity	O
with	O
the	O
blood	O
concentration	O
of	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
(	O
–	O
,	O
)	O
.	O

Each	O
sample	O
was	O
investigated	O
for	O
changes	O
in	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
as	O
previously	O
described	O
(	O
–	O
)	O
using	O
a	O
targeted	O
lip	O
##ido	O
##mic	O
##s	O
approach	O
as	O
previously	O
described	O
(	O
–	O
)	O
.	O

Co	O
##mpo	O
##und	O
id	O
##ent	O
##i	O
##ﬁ	O
##cation	O
was	O
performed	O
by	O
comparing	O
both	O
MS	O
and	O
Ko	O
##vat	O
##s	O
-	O
R	O
##I	O
with	O
reference	O
standards	O
in	O
author	O
-	O
constructed	O
two	O
al	B
##ky	I
##l	I
ch	I
##lor	I
##of	I
##orm	I
##ates	I
derivatives	O
databases	O
,	O
with	O
a	O
similarity	O
of	O
more	O
than	O
70	O
%	O
.	O

A	O
mixture	O
of	O
re	O
##age	O
##nt	O
was	O
used	O
for	O
the	O
reduction	O
and	O
der	O
##iva	O
##ti	O
##zation	O
(	O
with	O
br	B
##omo	I
##bi	I
##man	I
##e	I
)	O
of	O
th	B
##iol	I
##s	I
.	O

For	O
example	O
,	O
the	O
O	O
##PL	O
##S	O
analyses	O
showed	O
that	O
c	B
##it	I
##ru	I
##llin	I
##e	I
levels	O
increased	O
and	O
try	B
##pt	I
##op	I
##han	I
levels	O
decreased	O
with	O
age	O
,	O
but	O
neither	O
meta	O
##bol	O
##ite	O
correlated	O
with	O
T	O
##BC	O
,	O
while	O
increased	O
l	B
##ys	I
##o	I
-	I
PC	I
C	I
##18	I
:	I
0	I
with	O
higher	O
T	O
##BC	O
was	O
observed	O
without	O
any	O
association	O
with	O
age	O
.	O

On	O
the	O
other	O
hand	O
,	O
in	O
several	O
cell	O
types	O
,	O
including	O
cancer	O
cells	O
,	O
g	B
##lut	I
##amine	I
metabolism	O
via	O
g	O
##lut	O
##ami	O
##nas	O
##e	O
is	O
up	O
regulated	O
and	O
important	O
for	O
cell	O
proliferation	O
and	O
survival	O
,	O
which	O
makes	O
g	B
##lut	I
##amine	I
a	O
conditional	O
##ly	O
essentially	O
amino	O
acid	O
.	O

Cell	O
##s	O
were	O
either	O
treated	O
with	O
30	O
μ	O
##M	O
ch	B
##lor	I
##o	I
##quin	I
##e	I
for	O
3	O
or	O
5	O
hours	O
or	O
kept	O
in	O
normal	O
growth	O
media	O
.	O

Low	O
-	O
density	O
lip	O
##op	O
##rote	O
##in	O
(	O
L	O
##D	O
##L	O
)	O
ch	B
##ole	I
##ster	I
##ol	I
was	O
measured	O
using	O
en	O
##zy	O
##matic	O
color	O
##ime	O
##tric	O
methods	O
(	O
Roche	O
,	O
Mann	O
##heim	O
,	O
Germany	O
)	O
.	O

Cho	B
##line	I
is	O
de	O
##graded	O
through	O
two	O
pathways	O
.	O

Tan	O
##de	O
##m	O
mass	O
s	O
##pect	O
##ra	O
of	O
con	O
##ju	O
##gated	O
Δ	B
_	I
9	I
,	I
11	I
18	I
:	I
2	I
FA	I
demonstrated	O
the	O
presence	O
of	O
a	O
diagnostic	O
fragment	O
ion	O
at	O
m	O
/	O
z	O
30	O
##9	O
indicating	O
that	O
the	O
pro	O
##ximal	O
double	O
bond	O
was	O
present	O
at	O
C	O
##9	O
.	O

For	O
a	B
##bir	I
##ater	I
##one	I
,	O
no	O
el	O
##uti	O
##ng	O
peaks	O
with	O
areas	O
of	O
>	O
20	O
%	O
of	O
the	O
LL	O
##O	O
##Q	O
were	O
observed	O
.	O

It	O
has	O
been	O
reported	O
that	O
c	B
##era	I
##mi	I
##des	I
play	O
important	O
roles	O
in	O
cancer	O
biology	O
,	O
especially	O
cell	O
survival	O
and	O
death	O
by	O
regulating	O
a	O
##pop	O
##tosis	O
.	O

The	O
stock	O
solutions	O
were	O
prepared	O
as	O
follows	O
:	O
6	O
##T	O
##G	O
2	O
mg	O
/	O
m	O
##L	O
in	O
1	O
##M	O
sodium	B
h	I
##ydro	I
##xi	I
##de	I
,	O
6	O
##MM	O
##P	O
2	O
mg	O
/	O
m	O
##L	O
in	O
1	O
##M	O
sodium	B
h	I
##ydro	I
##xi	I
##de	I
,	O
6	O
##T	O
##G	O
IS	O
1	O
mg	O
/	O
m	O
##L	O
in	O
D	B
##MS	I
##O	I
,	O
and	O
6	O
##MM	O
##P	O
IS	O
2	O
.	O
5	O
mg	O
/	O
m	O
##L	O
in	O
met	B
##han	I
##ol	I
.	O

,	O
A	O
higher	O
amount	O
of	O
P	B
##E	I
(	I
20	I
:	I
3	I
/	I
18	I
:	I
1	I
)	I
(	O
p	O
=	O
0	O
.	O
09	O
##4	O
)	O
was	O
extracted	O
with	O
the	O
met	B
##han	I
##ol	I
-	I
ethanol	I
precipitation	O
compared	O
to	O
met	B
##han	I
##ol	I
only	O
precipitation	O
.	O

A	O
##5	O
##4	O
##9	O
cells	O
were	O
exposed	O
to	O
approximately	O
20	O
μ	O
##g	O
of	O
HP	O
##LC	O
-	O
pu	O
##rified	O
fraction	O
3	O
(	O
containing	O
p	O
##ept	O
##ai	O
##bol	O
components	O
IV	O
and	O
V	O
)	O
of	O
T	O
.	O
ha	O
##rz	O
##ian	O
##um	O
E	O
##S	O
##39	O
per	O
m	O
##l	O
for	O
24	O
h	O
(	O
A	O
)	O
and	O
to	O
re	O
##age	O
##nts	O
only	O
(	O
3	O
.	O
3	O
%	O
met	B
##han	I
##ol	I
)	O
(	O
B	O
)	O
.	O

U	B
##rid	I
##ine	I
mon	I
##op	I
##hos	I
##phate	I
(	O
U	O
##MP	O
)	O
,	O
U	B
##rid	I
##ine	I
dip	I
##hos	I
##phate	I
(	O
U	O
##DP	O
)	O
,	O
U	B
##rid	I
##ine	I
trip	I
##hos	I
##phate	I
(	O
U	O
##TP	O
)	O
,	O
Cy	B
##ti	I
##dine	I
mon	I
##op	I
##hos	I
##phate	I
(	O
C	O
##MP	O
)	O
,	O
Cy	B
##ti	I
##dine	I
dip	I
##hos	I
##phate	I
(	O
CDP	O
)	O
,	O
Cy	B
##ti	I
##dine	I
trip	I
##hos	I
##phate	I
(	O
CT	O
##P	O
)	O
,	O
de	B
##ox	I
##yt	I
##hy	I
##mi	I
##dine	I
mon	I
##op	I
##hos	I
##phate	I
(	O
d	O
##TM	O
##P	O
)	O
,	O
de	B
##ox	I
##yt	I
##hy	I
##mi	I
##dine	I
dip	I
##hos	I
##phate	I
(	O
d	O
##T	O
##DP	O
)	O
,	O
de	B
##ox	I
##yt	I
##hy	I
##mi	I
##dine	I
trip	I
##hos	I
##phate	I
(	O
d	O
##TT	O
##P	O
)	O
.	O

In	O
addition	O
,	O
P	B
##G	I
lip	O
##ids	O
were	O
highly	O
elevated	O
in	O
those	O
with	O
fatal	O
outcomes	O
.	O

Multi	O
##fly	O
needle	O
sets	O
and	O
p	B
##oly	I
##p	I
##rop	I
##yle	I
##ne	I
serum	O
mon	O
##ove	O
##ttes	O
with	O
c	O
##lot	O
##ting	O
act	O
##iva	O
##tors	O
were	O
also	O
obtained	O
from	O
Sa	O
##rst	O
##ed	O
##t	O
.	O

HIV	O
-	O
infected	O
people	O
develop	O
multiple	O
metabolic	O
syndrome	O
##s	O
which	O
are	O
related	O
to	O
HIV	O
-	O
m	O
##od	O
##ulated	O
and	O
inflammation	O
-	O
related	O
proteins	O
,	O
which	O
enhance	O
fatty	O
acid	O
synthesis	O
,	O
increase	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
levels	O
,	O
d	O
##ys	O
##re	O
##gu	O
##late	O
lip	O
##id	O
transport	O
and	O
alter	O
cellular	O
lip	O
##id	O
metabolism	O
.	O

Eight	O
amino	O
acids	O
and	O
bio	O
##genic	O
am	O
##ines	O
(	O
la	O
##ctic	O
acid	O
,	O
5	B
-	I
met	I
##ho	I
##xy	I
##try	I
##pta	I
##mine	I
,	O
p	B
##yr	I
##u	I
##vic	I
acid	I
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
pro	B
##line	I
,	O
al	B
##ani	I
##ne	I
,	O
th	B
##re	I
##oni	I
##ne	I
,	O
and	O
3	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yric	I
acid	O
)	O
were	O
quantitative	O
##ly	O
measured	O
.	O

PC	B
a	I
##a	I
C	I
##36	I
:	I
0	I
;	O
46	O
.	O

The	O
meta	O
##bol	O
##ite	O
ion	O
possibly	O
assigned	O
to	O
di	B
##acy	I
##l	I
##gly	I
##cer	I
##ol	I
(	O
D	O
##AG	O
)	O
showed	O
significantly	O
increased	O
levels	O
in	O
individuals	O
with	O
reduced	O
insulin	O
sensitivity	O
(	O
IS	O
##I	O
_	O
Mat	O
##su	O
##da	O
below	O
8	O
.	O
5	O
)	O
as	O
well	O
as	O
in	O
the	O
transition	O
group	O
.	O

Multiple	O
linear	O
re	O
##gression	O
was	O
also	O
applied	O
to	O
examine	O
the	O
association	O
of	O
conventional	O
lip	O
##ids	O
(	O
total	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
HD	O
##L	O
,	O
L	O
##D	O
##L	O
,	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
)	O
with	O
lip	O
##id	O
species	O
and	O
classes	O
(	O
adjusted	O
as	O
above	O
)	O
.	O

Analysis	O
of	O
GP	O
##s	O
containing	O
C	B
##18	I
:	I
1	I
Δ	O
##9	O
/	O
Δ	O
##11	O
is	O
##omer	O
##s	O
in	O
human	O
breast	O
cancer	O
samples	O
.	O

In	O
addition	O
,	O
4	O
-	O
HP	O
##A	O
could	O
be	O
absorbed	O
from	O
the	O
gut	O
l	O
##ume	O
##n	O
via	O
an	O
active	O
transport	O
##er	O
,	O
the	O
mon	B
##oc	I
##ar	I
##box	I
##yl	I
##ic	I
acid	I
transport	O
##er	O
,	O
to	O
enter	O
the	O
systemic	O
circulation	O
,	O
which	O
is	O
also	O
expressed	O
on	O
the	O
l	O
##umi	O
##nal	O
membrane	O
of	O
end	O
##oth	O
##eli	O
##al	O
cells	O
at	O
the	O
B	O
##BB	O
.	O

The	O
dose	O
of	O
insulin	O
was	O
adjusted	O
based	O
on	O
plasma	O
glucose	S
levels	O
every	O
30	O
–	O
60	O
minutes	O
.	O

We	O
also	O
expected	O
to	O
see	O
greater	O
exposure	O
to	O
AA	O
##Ps	O
in	O
general	O
and	O
increased	O
use	O
of	O
more	O
o	O
##bes	O
##ogenic	O
AA	O
##Ps	O
(	O
such	O
as	O
c	B
##lo	I
##za	I
##pine	I
and	O
o	B
##lan	I
##za	I
##pine	I
)	O
in	O
participants	O
with	O
relatively	O
higher	O
fast	O
##ing	O
insulin	O
concentrations	O
.	O

Death	O
##s	O
with	O
following	O
primary	O
or	O
contributor	O
##y	O
causes	O
(	O
I	O
##CD	O
-	O
10	O
codes	O
)	O
were	O
defined	O
as	O
card	O
##iovascular	O
deaths	O
:	O
R	O
##he	O
##umatic	O
fever	O
with	O
heart	O
involvement	O
(	O
I	O
##01	O
)	O
,	O
essential	O
h	O
##yper	O
##tens	O
##ion	O
(	O
I	O
##10	O
)	O
,	O
r	O
##he	O
##umatic	O
mit	O
##ral	O
valve	O
disease	O
(	O
I	O
##0	O
##5	O
.	O
9	O
)	O
,	O
h	O
##yper	O
##tensive	O
heart	O
disease	O
(	O
I	O
##11	O
.	O
9	O
)	O
,	O
h	O
##yper	O
##tensive	O
chronic	O
kidney	O
disease	O
(	O
I	O
##12	O
.	O
9	O
)	O
,	O
ST	O
elevation	O
my	O
##oc	O
##ard	O
##ial	O
in	O
##far	O
##ction	O
(	O
I	O
##21	O
.	O
3	O
and	O
I	O
##21	O
.	O
9	O
)	O
,	O
at	O
##her	O
##os	O
##cle	O
##rot	O
##ic	O
heart	O
disease	O
of	O
native	O
co	O
##rona	O
##ry	O
artery	O
(	O
I	O
##25	O
.	O
0	O
and	O
I	O
##25	O
.	O
1	O
)	O
,	O
is	O
##che	O
##mic	O
card	O
##io	O
##my	O
##op	O
##athy	O
(	O
I	O
##25	O
.	O
5	O
)	O
,	O
chronic	O
is	O
##che	O
##mic	O
heart	O
disease	O
(	O
I	O
##25	O
.	O
9	O
)	O
,	O
diseases	O
of	O
per	O
##ica	O
##rdi	O
##um	O
(	O
I	O
##31	O
.	O
9	O
)	O
,	O
h	O
##yper	O
##tro	O
##phic	O
card	O
##io	O
##my	O
##op	O
##athy	O
(	O
I	O
##42	O
.	O
2	O
)	O
,	O
card	O
##io	O
##my	O
##op	O
##athy	O
(	O
I	O
##42	O
.	O
9	O
)	O
,	O
cardiac	O
arrest	O
(	O
I	O
##46	O
.	O
9	O
)	O
,	O
par	B
##ox	I
##ys	I
##mal	I
ta	O
##chy	O
##card	O
##ia	O
(	O
I	O
##47	O
.	O
2	O
)	O
,	O
cardiac	O
a	O
##rry	O
##th	O
##mia	O
(	O
I	O
##4	O
##9	O
.	O
9	O
)	O
,	O
heart	O
failure	O
(	O
I	O
##50	O
.	O
0	O
)	O
,	O
heart	O
failure	O
(	O
I	O
##50	O
.	O
9	O

G	B
##lut	I
##ath	I
##ione	I
is	O
an	O
end	O
##ogen	O
##ously	O
synthesized	O
molecule	O
that	O
is	O
a	O
key	O
cellular	O
anti	O
##ox	O
##ida	O
##nt	O
;	O
when	O
concentrations	O
of	O
g	B
##lut	I
##ath	I
##ione	I
are	O
depleted	O
,	O
cells	O
are	O
susceptible	O
to	O
DNA	O
damage	O
that	O
can	O
lead	O
to	O
car	O
##cin	O
##ogen	O
##esis	O
.	O

Similarly	O
,	O
in	O
a	O
multi	O
##var	O
##iate	O
analysis	O
that	O
included	O
diabetes	O
and	O
hip	B
##pur	I
##ic	I
acid	I
,	O
both	O
diabetes	O
and	O
hip	B
##pur	I
##ic	I
acid	I
were	O
significantly	O
associated	O
with	O
MAC	O
##E	O
.	O

B	O
##ios	O
##ynth	O
##esis	O
of	O
P	O
##GE	O
-	O
M	O
.	O
Ara	B
##chi	I
##don	I
##ic	I
acid	I
,	O
released	O
from	O
membrane	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
by	O
p	O
##hos	O
##ph	O
##oli	O
##pas	O
##e	O
A	O
_	O
2	O
(	O
P	O
##LA	O
_	O
2	O
)	O
is	O
meta	O
##bol	O
##ized	O
by	O
CO	O
##X	O
-	O
1	O
##and	O
CO	O
##X	O
-	O
2	O
to	O
P	O
##G	O
##H	O
_	O
2	O
.	O

The	O
γ	O
-	O
g	O
##lut	O
##am	O
##yl	O
p	O
##eptide	O
##s	O
,	O
g	B
##lu	I
##cos	I
##amine	I
,	O
and	O
reduced	O
and	O
o	O
##xi	O
##dized	O
forms	O
of	O
g	B
##lut	I
##ath	I
##ione	I
were	O
q	O
##uant	O
##ified	O
using	O
CE	O
-	O
MS	O
/	O
MS	O
.	O

O	O
’	O
Connell	O
et	O
al	O
.	O
reported	O
changes	O
in	O
lip	O
##ids	O
,	O
g	B
##ly	I
##cer	I
##ol	I
,	O
and	O
glucose	S
,	O
but	O
not	O
amino	O
acids	O
,	O
in	O
the	O
plasma	O
of	O
a	O
m	B
##uri	I
##ne	I
cancer	O
cache	O
##xia	O
model	O
.	O

Later	O
,	O
a	O
study	O
using	O
im	O
##mu	O
##no	O
##ass	O
##ay	O
technique	O
showed	O
high	O
u	O
##rina	O
##ry	O
levels	O
of	O
c	O
##yclic	O
g	O
##uan	O
##os	O
##ine	O
3	O
’	O
:	O
5	O
’	O
mon	B
##op	I
##hos	I
##phate	I
(	O
c	O
##GM	O
##P	O
)	O
in	O
rats	O
with	O
imp	O
##lanted	O
liver	O
and	O
kidney	O
t	O
##umour	O
##s	O
[	O
]	O
.	O

The	O
most	O
striking	O
difference	O
between	O
these	O
s	O
##pect	O
##ra	O
is	O
that	O
there	O
is	O
much	O
less	O
c	B
##rea	I
##tin	I
##ine	I
and	O
almost	O
no	O
hip	B
##pura	I
##te	I
with	O
a	O
reduction	O
in	O
the	O
ex	O
##cre	O
##tion	O
of	O
most	O
a	O
##romatic	O
compounds	O
in	O
the	O
week	O
2	O
sample	O
from	O
the	O
infant	O
compared	O
to	O
that	O
of	O
the	O
birth	O
sample	O
.	O

In	O
total	O
,	O
182	O
patients	O
were	O
eligible	O
for	O
this	O
study	O
,	O
and	O
52	O
patients	O
who	O
underwent	O
electro	O
##phy	O
##sio	O
##logical	O
analysis	O
due	O
to	O
suspicion	O
of	O
par	B
##ox	I
##ys	I
##mal	I
su	O
##pra	O
##vent	O
##ric	O
##ular	O
ta	O
##chy	O
##card	O
##ia	O
without	O
any	O
history	O
of	O
A	B
##F	I
were	O
prospective	O
##ly	O
enrolled	O
as	O
healthy	O
controls	O
.	O

The	O
decrease	O
of	O
glucose	S
and	O
increase	O
of	O
la	B
##ct	I
##ate	I
in	O
tumor	O
tissues	O
was	O
not	O
surprising	O
because	O
of	O
the	O
War	O
##burg	O
effect	O
.	O

This	O
meta	O
##bol	O
##ite	O
,	O
based	O
on	O
the	O
el	O
##ution	O
time	O
,	O
is	O
most	O
likely	O
4	B
-	I
c	I
##ish	I
##ydro	I
##xy	I
g	I
##ly	I
##bur	I
##ide	I
.	O

Express	O
##ion	O
analysis	O
of	O
genetic	O
variants	O
linked	O
to	O
high	O
serum	O
24	B
##S	I
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
levels	O
.	O

Sixteen	O
meta	O
##bol	O
##ites	O
in	O
both	O
G	O
##C	O
-	O
MS	O
and	O
_	O
1	O
H	O
-	O
N	O
##MR	O
data	O
##sets	O
were	O
found	O
to	O
significantly	O
disc	O
##rim	O
##inate	O
CR	O
##C	O
stages	O
(	O
p	O
-	O
values	O
<	O
0	O
.	O
05	O
)	O
,	O
but	O
only	O
two	O
of	O
them	O
remained	O
significant	O
after	O
adjusting	O
for	O
multiple	O
testing	O
,	O
a	O
dip	O
##eptide	O
of	O
h	B
##ydro	I
##xy	I
##p	I
##rol	I
##ine	I
(	O
H	O
##y	O
##p	O
-	O
H	O
##y	O
##p	O
)	O
and	O
p	B
-	I
c	I
##res	I
##ol	I
-	I
β	I
-	I
O	I
-	I
g	I
##lu	I
##cu	I
##ron	I
##ide	I
.	O

It	O
is	O
slightly	O
acidic	O
(	O
pH	O
~	O
6	O
.	O
5	O
)	O
and	O
comprised	O
mostly	O
of	O
sugar	O
##s	O
like	O
f	B
##ru	I
##ct	I
##ose	I
,	O
with	O
less	O
than	O
1	O
%	O
protein	O
content	O
.	O

As	O
the	O
is	O
##omer	O
of	O
P	O
(	O
linear	O
-	O
type	O
fur	O
##ano	O
##co	O
##uma	O
##rin	O
)	O
,	O
the	O
conversion	O
process	O
of	O
IP	S
(	O
angle	O
-	O
type	O
fur	O
##ano	O
##co	O
##uma	O
##rin	O
)	O
was	O
basically	O
the	O
same	O
in	O
the	O
human	O
in	O
##test	O
##inal	O
flora	O
,	O
which	O
is	O
described	O
in	O
.	O

Ad	B
##o	I
##M	I
##et	I
:	O
S	B
-	I
Aden	I
##osy	I
##l	I
-	I
Met	I
##hi	I
##oni	I
##ne	I
,	O
DC	O
-	O
Ad	O
##o	O
##M	O
##et	O
:	O
Dec	B
##ar	I
##box	I
##yla	I
##ted	I
S	I
-	I
Aden	I
##osy	I
##l	I
-	I
Met	I
##hi	I
##oni	I
##ne	I
,	O
Ad	O
##o	O
##T	O
:	O
S	O
-	O
Aden	O
##osy	O
##l	O
##T	O
##ran	O
##s	O
##fer	O
##ase	O
,	O
Ad	O
##o	O
##MD	O
##C	O
:	O
S	O
-	O
Aden	O
##osy	O
##l	O
-	O
Met	O
##hi	O
##oni	O
##ne	O
Dec	O
##ar	O
##box	O
##yla	O
##se	O
,	O
O	O
##DC	O
:	O
Or	O
##ni	O
##tine	O
Dec	O
##ar	O
##box	O
##yla	O
##se	O
,	O
PA	O
##T	O
(	O
I	O
and	O
II	O
)	O
:	O
Pro	B
##py	I
##l	I
##A	I
##min	I
##o	I
##T	I
##ran	I
##s	I
##fer	I
##ase	I
-	I
1	I
and	O
2	O
,	O
ATP	S
:	O
Aden	B
##osy	I
##l	I
##T	I
##rip	I
##hos	I
##phate	I
.	O

AN	O
##O	O
##VA	O
analysis	O
showed	O
that	O
individuals	O
with	O
gal	O
##lston	O
##es	O
had	O
sign	O
##i	O
##ﬁ	O
##can	O
##tly	O
greater	O
levels	O
of	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
meta	O
##bol	O
##ites	O
(	O
including	O
C	O
##2	O
,	O
C	O
##9	O
-	O
OH	O
,	O
C	O
##10	O
and	O
C	B
##10	I
:	I
1	I
)	O
,	O
with	O
respect	O
to	O
healthy	O
controls	O
.	O

The	O
samples	O
were	O
prepared	O
by	O
cent	O
##ri	O
##fu	O
##gation	O
at	O
10	O
,	O
000	O
relative	O
cent	O
##ri	O
##fu	O
##gal	O
force	O
(	O
r	O
##c	O
##f	O
)	O
at	O
4	O
°C	O
for	O
5	O
min	O
,	O
followed	O
by	O
c	B
##rea	I
##tin	I
##ine	I
value	O
-	O
ca	O
##li	O
##bra	O
##ted	O
di	O
##lution	O
.	O

His	B
##ti	I
##dine	I
,	O
g	B
##lut	I
##amine	I
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
and	O
c	B
##rea	I
##tine	I
came	O
up	O
as	O
the	O
top	O
four	O
meta	O
##bol	O
##ites	O
showing	O
significant	O
alterations	O
in	O
tissue	O
for	O
this	O
comparative	O
study	O
.	O

The	O
per	O
##mu	O
##tation	O
test	O
for	O
accuracy	O
significance	O
showed	O
a	O
p	O
-	O
value	O
of	O
0	O
.	O
04	O
##7	O
and	O
of	O
0	O
.	O
143	O
for	O
ER	B
(	I
+	I
)	I
and	O
ER	O
(	O
−	O
)	O
models	O
,	O
respectively	O
.	O

C	O
##lamp	O
-	O
derived	O
insulin	O
sensitivity	O
index	O
(	O
IS	O
##I	O
)	O
was	O
calculated	O
as	O
glucose	S
in	O
##fusion	O
rate	O
per	O
kg	O
body	O
weight	O
necessary	O
to	O
maintain	O
e	O
##ug	O
##ly	O
##ce	O
##mia	O
during	O
the	O
last	O
45	O
minutes	O
of	O
the	O
c	O
##lamp	O
steady	O
state	O
per	O
unit	O
of	O
plasma	O
insulin	O
concentration	O
.	O

Para	O
##meter	O
##s	O
of	O
liquid	O
ch	O
##roma	O
##tography	O
-	O
tandem	O
mass	O
s	O
##pect	O
##rome	O
##try	O
method	O
for	O
measuring	O
g	B
##lut	I
##ama	I
##te	I
,	O
as	B
##par	I
##tate	I
,	O
g	B
##lut	I
##amine	I
and	O
as	B
##par	I
##agi	I
##ne	I
.	O

In	O
some	O
studies	O
of	O
o	O
##bes	O
##e	O
subjects	O
,	O
abnormal	O
plasma	O
concentrations	O
of	O
BC	O
##AA	O
##s	O
and	O
protein	O
levels	O
of	O
BC	O
##AA	O
-	O
cat	O
##ab	O
##oli	O
##zing	O
enzymes	O
in	O
v	O
##is	O
##cer	O
##al	O
ad	O
##ip	O
##ose	O
indicate	O
that	O
BC	O
##AA	O
##s	O
are	O
closely	O
related	O
to	O
ad	O
##ip	O
##os	O
##ity	O
balance	O
,	O
which	O
is	O
also	O
important	O
in	O
F	B
##D	I
patients	O
.	O

In	O
the	O
urine	O
,	O
meta	O
##bol	O
##ites	O
related	O
to	O
saturated	O
FA	O
##s	O
,	O
pen	O
##tos	O
##es	O
,	O
Indo	O
##les	O
,	O
amino	O
acids	O
(	O
basic	O
,	O
c	O
##yclic	O
,	O
acidic	O
and	O
basic	O
)	O
,	O
pu	B
##rine	I
##s	I
ma	I
##lates	I
,	O
di	B
##sa	I
##cc	I
##hari	I
##des	I
,	O
di	B
##car	I
##box	I
##yl	I
##ic	I
acids	I
,	O
he	O
##x	O
##uron	O
##ic	O
acids	O
,	O
he	O
##x	O
##ose	O
##s	O
,	O
p	B
##hen	I
##yla	I
##ce	I
##tate	I
and	O
c	O
##it	O
##rates	O
were	O
associated	O
with	O
higher	O
death	O
.	O

For	O
each	O
A	B
##F	I
sample	O
,	O
256	O
following	O
scan	O
##s	O
were	O
collected	O
using	O
3	O
.	O
5	O
s	O
relaxation	O
delay	O
and	O
an	O
acquisition	O
time	O
of	O
1	O
.	O
36	O
s	O
,	O
resulting	O
in	O
32	O
##k	O
data	O
points	O
and	O
a	O
spectral	O
width	O
of	O
20	O
.	O
01	O
pp	O
##m	O
.	O

;	O
HD	O
##L	O
-	O
C	O
:	O
high	O
density	O
lip	B
##op	I
##rote	I
##in	I
-	I
ch	I
##ole	I
##ster	I
##ol	I
;	O
L	O
##D	O
##L	O
-	O
C	O
:	O
low	O
density	O
lip	B
##op	I
##rote	I
##in	I
-	I
ch	I
##ole	I
##ster	I
##ol	I
;	O
MA	O
##P	O
:	O
mean	O
art	O
##erial	O
pressure	O
;	O
S	O
##B	O
##P	O
:	O
s	O
##ys	O
##to	O
##lic	O
blood	O
pressure	O
;	O
T	B
##G	I
:	O
t	B
##rig	I
##ly	I
##cer	I
##ide	I
.	O

Mass	O
transition	O
parameters	O
for	O
a	B
##bir	I
##ater	I
##one	I
,	O
its	O
meta	O
##bol	O
##ites	O
,	O
and	O
the	O
internal	O
standard	O
.	O

Thus	O
,	O
the	O
increased	O
levels	O
of	O
cellular	O
format	B
##e	I
could	O
be	O
a	O
by	O
-	O
product	O
of	O
ATP	S
and	O
N	O
##AD	O
(	O
P	O
)	O
H	O
synthesis	O
as	O
the	O
cells	O
make	O
early	O
changes	O
in	O
how	O
they	O
meet	O
their	O
energy	O
requirements	O
.	O

Con	O
##c	O
##lusion	O
:	O
This	O
results	O
indicate	O
that	O
metabolic	O
factors	O
of	O
K	B
##P	I
play	O
a	O
crucial	O
role	O
in	O
the	O
occurrence	O
and	O
development	O
of	O
MD	O
##D	O
,	O
supporting	O
the	O
metabolic	O
im	O
##bal	O
##ance	O
hypothesis	O
of	O
MD	O
##D	O
.	O

From	O
a	O
35	O
year	O
old	O
healthy	O
control	O
(	O
CT	O
##R	O
)	O
(	O
A	O
,	O
A	O
’	O
)	O
;	O
a	O
22	O
year	O
old	O
male	O
with	O
chronic	O
he	O
##pa	O
##titis	O
-	O
B	O
related	O
liver	O
disease	O
(	O
CH	O
##B	O
)	O
(	O
B	O
,	O
B	O
’	O
)	O
;	O
a	O
36	O
year	O
old	O
male	O
with	O
he	O
##pa	O
##titis	O
B	O
virus	O
(	O
H	O
##B	O
##V	O
)	O
-	O
c	O
##ir	O
##r	O
##hos	O
##is	O
(	O
C	O
,	O
C	O
’	O
)	O
;	O
and	O
a	O
50	O
year	O
old	O
male	O
with	O
H	O
##B	O
##V	O
-	O
he	O
##pa	O
##to	O
##cellular	O
car	O
##cin	O
##oma	O
(	O
A	O
##FP	O
>	O
3000	O
##0	O
mg	O
/	O
d	O
##L	O
)	O
displaying	O
(	O
A	O
-	O
D	O
)	O
the	O
al	B
##ip	I
##hat	I
##ic	I
region	O
0	O
.	O
5	O
-	O
4	O
.	O
5	O
pp	O
##m	O
and	O
(	O
A	O
’	O
-	O
D	O
’	O
)	O
the	O
a	O
##romatic	O
region	O
6	O
.	O
4	O
-	O
9	O
.	O
5	O
pp	O
##m	O
(	O
D	O
,	O
D	O
’	O
)	O
.	O

The	O
increase	O
of	O
3	B
-	I
in	I
##dox	I
##yl	I
su	I
##lf	I
##ate	I
in	O
urine	O
during	O
and	O
after	O
sleep	O
de	O
##p	O
##ri	O
##vation	O
observed	O
in	O
this	O
study	O
is	O
unlikely	O
to	O
result	O
from	O
diet	O
##ary	O
sources	O
as	O
the	O
study	O
participants	O
were	O
given	O
the	O
same	O
standardized	O
meals	O
at	O
identical	O
times	O
on	O
both	O
days	O
,	O
thus	O
the	O
increased	O
levels	O
are	O
assumed	O
to	O
reflect	O
differences	O
in	O
metabolism	O
during	O
sleep	O
and	O
sleep	O
de	O
##p	O
##ri	O
##vation	O
.	O

Even	O
though	O
we	O
found	O
no	O
change	O
in	O
re	O
##nal	O
expression	O
of	O
t	O
##yr	O
##os	O
##ine	O
h	O
##ydro	O
##xy	O
##lase	O
,	O
which	O
is	O
considered	O
the	O
rate	O
-	O
limiting	O
enzyme	O
in	O
cat	B
##ech	I
##ola	I
##mine	I
synthesis	O
,	O
production	O
of	O
L	B
-	I
D	I
##OP	I
##A	I
could	O
still	O
be	O
hampered	O
in	O
C	O
##K	O
##D	O
.	O

The	O
mobile	O
phase	O
is	O
composed	O
of	O
(	O
A	O
)	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
and	O
(	O
B	O
)	O
is	B
##op	I
##rop	I
##ano	I
##l	I
,	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
and	O
met	B
##han	I
##ol	I
[	I
20	I
:	I
40	I
:	I
40	I
(	I
v	I
/	I
v	I
)	I
]	I
in	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
,	O
and	O
the	O
gradient	O
was	O
used	O
as	O
follows	O
:	O
98	O
–	O
50	O
%	O
(	O
A	O
)	O
and	O
2	O
–	O
50	O
%	O
(	O
B	O
)	O
for	O
0	O
–	O
3	O
.	O
5	O
min	O
;	O
50	O
–	O
0	O
%	O
(	O
A	O
)	O
and	O
50	O
–	O
100	O
%	O
(	O
B	O
)	O
for	O
3	O
.	O
5	O
–	O
20	O
min	O
.	O

For	O
instance	O
,	O
an	O
im	O
##bal	O
##ance	O
of	O
this	O
metabolic	O
pathway	O
,	O
marked	O
by	O
h	O
##yper	O
##hom	O
##oc	O
##ys	O
##tein	O
##emia	O
and	O
/	O
or	O
an	O
altered	O
SA	O
##M	O
/	O
SA	O
##H	O
ratio	O
,	O
is	O
a	O
hall	O
##mark	O
of	O
memory	O
loss	O
and	O
cognitive	O
decline	O
in	O
elderly	O
populations	O
[	O
,	O
]	O
This	O
loss	O
of	O
metabolic	O
home	O
##ost	O
##asis	O
may	O
result	O
from	O
deficiency	O
in	O
meta	O
##bol	O
##ites	O
and	O
co	O
-	O
factors	O
—	O
such	O
as	O
vitamin	O
B	O
_	O
12	O
or	O
f	O
##olic	O
acid	O
—	O
directly	O
and	O
indirectly	O
involved	O
in	O
the	O
met	O
##hyl	O
##ation	O
of	O
ho	B
##mo	I
##cy	I
##stein	I
##e	I
.	O

Tam	B
##ox	I
##ife	I
##n	I
and	O
meta	O
##bol	O
##ite	O
concentrations	O
in	O
different	O
age	O
groups	O

Bat	O
##ata	O
##sin	O
III	O
and	O
pin	B
##ost	I
##il	I
##ben	I
##e	I
did	O
not	O
form	O
any	O
meta	O
##bol	O
##ites	O
and	O
were	O
found	O
to	O
be	O
stable	O
in	O
the	O
co	O
##lon	O
environment	O
.	O

For	O
example	O
,	O
ch	B
##ole	I
##ster	I
##ol	I
was	O
reported	O
to	O
be	O
transported	O
out	O
of	O
cells	O
by	O
ABC	O
##A	O
##1	O
and	O
that	O
mutations	O
in	O
the	O
ABC	O
##A	O
##1	O
gene	O
were	O
responsible	O
for	O
Tang	O
##ier	O
disease	O
,	O
,	O
.	O

One	O
or	O
more	O
E	O
##ET	O
##s	O
may	O
serve	O
as	O
end	O
##oth	O
##eli	O
##al	O
-	O
derived	O
h	O
##yper	O
##pol	O
##ari	O
##zing	O
factors	O
.	O
_	O
,	O
E	O
##ET	O
##s	O
are	O
meta	O
##bol	O
##ized	O
rapidly	O
by	O
e	O
##pox	O
##ide	O
h	O
##ydro	O
##lase	O
##s	O
to	O
di	B
##hy	I
##dr	I
##ox	I
##ye	I
##ico	I
##sat	I
##rien	I
##oi	I
##c	I
acids	I
(	O
D	O
##H	O
##ET	O
##s	O
)	O
,	O
which	O
are	O
generally	O
viewed	O
as	O
biological	O
##ly	O
inactive	O
with	O
a	O
few	O
exceptions	O
.	O

It	O
is	O
also	O
noteworthy	O
that	O
the	O
BC	O
##AA	O
##s	O
,	O
v	B
##ali	I
##ne	I
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
and	O
le	B
##uc	I
##ine	I
concentrations	O
were	O
higher	O
in	O
the	O
high	B
–	I
c	I
##ys	I
##tat	I
##hi	I
##oni	I
##ne	I
concentration	O
group	O
.	O

The	O
mobile	O
phase	O
is	O
composed	O
of	O
(	O
A	O
)	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
and	O
(	O
B	O
)	O
is	B
##op	I
##rop	I
##ano	I
##l	I
,	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
and	O
met	B
##han	I
##ol	I
[	I
20	I
:	I
40	I
:	I
40	I
(	I
v	I
/	I
v	I
)	I
]	I
in	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
,	O
and	O
the	O
gradient	O
was	O
used	O
as	O
follows	O
:	O
98	O
–	O
50	O
%	O
(	O
A	O
)	O
and	O
2	O
–	O
50	O
%	O
(	O
B	O
)	O
for	O
0	O
–	O
3	O
.	O
5	O
min	O
;	O
50	O
–	O
0	O
%	O
(	O
A	O
)	O
and	O
50	O
–	O
100	O
%	O
(	O
B	O
)	O
for	O
3	O
.	O
5	O
–	O
20	O
min	O
.	O

I	O
##Q	O
##R	O
inter	O
##qua	O
##rt	O
##ile	O
range	O
Finally	O
,	O
we	O
calculated	O
ratios	O
of	O
E	O
##M	O
which	O
may	O
be	O
associated	O
with	O
breast	O
cancer	O
risk	O
according	O
to	O
various	O
h	O
##y	O
##pot	O
##heses	O
of	O
est	O
##rogen	O
-	O
mediated	O
car	O
##cin	O
##ogen	O
##esis	O
,	O
including	O
the	O
ratio	O
of	O
2	O
-	O
h	O
##ydro	O
##xy	O
##lated	O
E	O
##M	O
to	O
16	O
-	O
h	O
##ydro	O
##xy	O
##lated	O
E	O
##M	O
,	O
the	O
ratio	O
of	O
4	O
-	O
h	O
##ydro	O
##xy	O
##lated	O
E	O
##M	O
to	O
2	O
-	O
h	O
##ydro	O
##xy	O
##lated	O
E	O
##M	O
,	O
and	O
the	O
ratio	O
of	O
un	O
##met	O
##hyl	O
##ated	O
to	O
met	B
##hyl	I
##ated	I
cat	I
##ech	I
##ols	I
in	O
2	O
-	O
h	O
##ydro	O
##xy	O
##lation	O
and	O
4	O
-	O
h	O
##ydro	O
##xy	O
##lation	O
pathways	O
.	O

Basel	O
##ine	O
characteristics	O
of	O
80	O
adults	O
from	O
the	O
Western	O
Norway	O
Co	O
##rona	O
##ry	O
Ang	O
##io	O
##graphy	O
Co	O
##hor	O
##t	O
classified	O
according	O
to	O
plasma	O
c	B
##ys	I
##tat	I
##hi	I
##oni	I
##ne	I
concentration	O
_	O
1	O
One	O
-	O
carbon	O
metabolism	O
requires	O
f	B
##olate	I
,	O
vitamin	O
B	O
-	O
6	O
,	O
vitamin	O
B	O
-	O
12	O
,	O
and	O
rib	B
##of	I
##lav	I
##in	I
as	O
co	O
##fa	O
##ctors	O
to	O
different	O
enzymes	O
throughout	O
the	O
pathway	O
.	O

The	O
ass	O
##ay	O
was	O
performed	O
by	O
utilizing	O
a	O
Lac	B
##tate	I
As	O
##say	O
Kit	O
(	O
Eton	O
B	O
##ios	O
##cie	O
##nce	O
Inc	O
,	O
San	O
Diego	O
,	O
CA	O
,	O
USA	O
)	O
,	O
as	O
per	O
the	O
manufacturer	O
'	O
s	O
protocol	O
.	O

Duval	O
et	O
al	O
.	O
reported	O
that	O
t	O
##rich	O
##or	O
##zin	O
PA	O
p	O
##ept	O
##ai	O
##bol	O
em	O
##bed	O
##ment	O
into	O
a	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
bi	O
##layer	O
was	O
reduced	O
when	O
the	O
amount	O
of	O
ch	B
##ole	I
##ster	I
##ol	I
in	O
the	O
bi	O
##layer	O
was	O
increased	O
.	O

A	O
##cc	O
##ura	O
##cy	O
,	O
expressed	O
as	O
de	O
##viation	O
##s	O
from	O
the	O
nominal	O
concentrations	O
,	O
was	O
within	O
108	O
%	O
for	O
both	O
en	B
##zal	I
##uta	I
##mi	I
##de	I
and	O
N	B
-	I
des	I
##met	I
##hyl	I
##en	I
##zal	I
##uta	I
##mi	I
##de	I
,	O
respectively	O
.	O

It	O
was	O
positively	O
correlated	O
with	O
la	B
##ct	I
##ate	I
concentration	O
in	O
g	O
##lio	O
##blast	O
##oma	O
##s	O
,	O
as	O
##tro	O
##cy	O
##tom	O
##as	O
and	O
men	O
##ing	O
##io	O
##mas	O
while	O
in	O
o	O
##li	O
##go	O
##den	O
##dr	O
##og	O
##lio	O
##mas	O
these	O
meta	O
##bol	O
##ites	O
showed	O
a	O
moderate	O
correlation	O
that	O
lay	O
just	O
outside	O
statistical	O
significance	O
(	O
p	O
=	O
0	O
.	O
07	O
)	O
.	O

Sign	O
##ificant	O
meta	O
##bol	O
##ites	O
that	O
differentiated	O
ma	O
##li	O
##gnant	O
and	O
ben	O
##ign	O
thy	O
##roid	O
lesions	O
included	O
c	B
##it	I
##rate	I
,	O
ace	B
##ty	I
##l	I
##car	I
##ni	I
##tine	I
,	O
g	B
##lut	I
##amine	I
,	O
ho	B
##mos	I
##eri	I
##ne	I
,	O
g	B
##lut	I
##ath	I
##ione	I
,	O
k	B
##yn	I
##uren	I
##ine	I
,	O
ni	B
##cot	I
##ini	I
##c	I
acid	I
,	O
hip	B
##pura	I
##te	I
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
try	B
##pt	I
##op	I
##han	I
,	O
β	B
-	I
al	I
##ani	I
##ne	I
,	O
and	O
x	B
##ant	I
##hine	I
.	O

1	B
,	I
5	I
-	I
An	I
##hy	I
##dr	I
##og	I
##lu	I
##ci	I
##to	I
##l	I
(	I
1	I
,	I
5	I
-	I
AG	I
)	I
increased	O
after	O
le	O
##pt	O
##in	O
replacement	O
.	O

They	O
fell	O
into	O
six	O
lip	O
##id	O
categories	O
,	O
comprising	O
two	O
l	B
##ys	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
(	I
LP	I
##C	I
(	I
20	I
:	I
2	I
)	I
and	O
LP	O
##E	O
(	O
18	O
:	O
2	O
)	O
;	O
lowered	O
2	O
.	O
8	O
-	O
to	O
3	O
.	O
2	O
-	O
fold	O
)	O
,	O
four	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
(	I
T	I
##G	I
(	I
51	I
:	I
8	I
)	I
,	I
T	I
##G	I
(	I
52	I
:	I
8	I
)	I
,	I
T	I
##G	I
(	I
53	I
:	I
8	I
)	I
,	O
and	O
T	O
##G	O
(	O
53	O
:	O
9	O
)	O
;	O
lowered	O
2	O
.	O
1	O
-	O
to	O
2	O
.	O
7	O
-	O
fold	O
)	O
,	O
13	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
(	I
PC	I
(	I
32	I
:	I
0	I
)	I
,	I
PC	I
(	I
36	I
:	I
2	I
)	I
,	I
two	I
PC	I
(	I
36	I
:	I
3	I
)	I
s	I
,	I
PC	I
(	I
36	I
:	I
4	I
)	I
,	I
PC	I
(	I
36	I
:	I
5	I
)	I
,	O
PC	B
(	I
38	I
:	I
3	I
)	I
,	O
PC	B
(	I
40	I
:	I
7	I
)	I
,	O
PC	B
(	I
40	I
:	I
8	I
)	I
,	O
PC	B
(	I
P	I
-	I
36	I
:	I
4	I
)	I
,	O
P	B
##E	I
(	I
40	I
:	I
6	I
)	I
,	O
P	B
##E	I
(	I
44	I
:	I
10	I
)	I
,	O
and	O
PS	B
(	I
36	I
:	I
2	I
)	I
;	O
lowered	O
1	O
.	O
4	O
-	O
to	O
29	O
.	O
5	O
-	O
fold	O
)	O
,	O
14	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
(	I
SM	I
(	I
18	I
:	I
1	I
/	I
12	I
:	I
0	I
)	I
,	I
SM	I
(	I
18	I
:	I
1	I
/	I
14	I
:	I
0	I
)	I
,	I
SM	I
(	I
18	I
:	I
1	I
/	I
20	I
:	I
0	I
)	I
,	O
two	O

A	O
simple	O
diet	O
##ary	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
–	I
ch	I
##olin	I
##e	I
challenge	O
was	O
administered	O
to	O
all	O
participants	O
in	O
the	O
first	O
study	O
.	O

Fat	O
##ty	O
chains	O
within	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
are	O
designated	O
by	O
their	O
number	O
of	O
carbon	O
##s	O
:	O
double	O
bonds	O
.	O

However	O
,	O
we	O
and	O
others	O
have	O
observed	O
that	O
breast	O
cancer	O
patients	O
often	O
use	O
several	O
additional	O
drugs	O
that	O
may	O
interact	O
with	O
ta	B
##mo	I
##xi	I
##fen	I
[	O
-	O
]	O
.	O

In	O
case	O
of	O
fever	O
,	O
compounds	O
like	O
L	B
-	I
p	I
##hen	I
##yla	I
##lani	I
##ne	I
and	O
4	B
-	I
h	I
##ydro	I
##xy	I
##ben	I
##zoic	I
acid	I
was	O
found	O
to	O
highly	O
down	O
-	O
regulated	O
in	O
case	O
of	O
C	O
/	O
D	O
patients	O
clearly	O
emphasizing	O
the	O
effect	O
co	O
-	O
infection	O
with	O
the	O
two	O
viruses	O
has	O
on	O
amino	O
acid	O
metabolism	O
.	O

Although	O
SM	O
and	O
He	O
##x	O
##C	O
##er	O
have	O
been	O
under	O
##st	O
##udi	O
##ed	O
compared	O
to	O
S	O
##1	O
##P	O
and	O
c	B
##era	I
##mi	I
##des	I
,	O
our	O
findings	O
suggest	O
that	O
the	O
interaction	O
between	O
cancer	O
and	O
the	O
tumor	O
micro	O
##en	O
##vir	O
##on	O
##ment	O
affect	O
the	O
production	O
of	O
SM	O
and	O
He	O
##x	O
##C	O
##er	O
.	O

Rep	O
##lica	O
##ting	O
the	O
effect	O
on	O
DB	B
##P	I
response	O
in	O
the	O
P	O
##EA	O
##R	O
HC	O
##T	O
##Z	O
add	O
-	O
on	O
.	O

Forty	O
‐	O
nine	O
of	O
the	O
H	O
##ER	O
##2	O
‐	O
positive	O
patients	O
had	O
received	O
p	O
##ac	O
##lit	O
##ax	O
##el	O
and	O
lap	B
##ati	I
##ni	I
##b	I
.	O

El	O
##eva	O
##ted	O
BC	O
##AA	O
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
t	B
##yr	I
##os	I
##ine	I
and	O
ta	B
##uri	I
##ne	I
were	O
observed	O
both	O
in	O
tumor	O
and	O
L	O
##N	O
-	O
Met	O
tissues	O
,	O
and	O
also	O
observed	O
in	O
other	O
tumor	O
types	O
.	O

α	B
-	I
To	I
##co	I
##pher	I
##ol	I
is	O
believed	O
to	O
be	O
the	O
main	O
source	O
found	O
in	O
supplement	O
##s	O
and	O
in	O
the	O
European	O
diet	O
,	O
whereas	O
γ	B
-	I
to	I
##co	I
##pher	I
##ol	I
is	O
the	O
most	O
common	O
form	O
in	O
the	O
American	O
diet	O
.	O

Other	O
u	O
##rina	O
##ry	O
p	B
##ht	I
##hala	I
##te	I
meta	O
##bol	O
##ite	O
and	O
is	B
##op	I
##ros	I
##tan	I
##e	I
concentrations	O
were	O
not	O
associated	O
with	O
sperm	O
m	O
##t	O
##D	O
##NA	O
##c	O
##n	O
or	O
m	O
##t	O
##D	O
##NA	O
##del	O
.	O

However	O
,	O
recent	O
studies	O
have	O
suggested	O
that	O
the	O
function	O
of	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
might	O
different	O
depending	O
on	O
the	O
cell	O
type	O
that	O
is	O
activated	S
,	O
the	O
oxidation	O
/	O
inflammation	O
status	O
,	O
the	O
sub	O
##c	O
##lass	O
of	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
or	O
the	O
species	O
of	O
the	O
bound	O
fatty	O
acids	O
.	O

O	O
##xy	O
##gen	O
##ated	O
meta	O
##bol	O
##ites	O
of	O
ch	B
##ole	I
##ster	I
##ol	I
(	I
“	I
o	I
##xy	I
##ster	I
##ols	I
”	I
)	I
can	O
influence	O
car	O
##cin	O
##ogen	O
##esis	O
and	O
contribute	O
to	O
resistance	O
to	O
end	O
##oc	O
##rine	O
therapy	O
,	O
an	O
effect	O
mostly	O
described	O
in	O
v	O
##it	O
##ro	O
.	O

For	O
this	O
purpose	O
,	O
all	O
the	O
categories	O
(	O
CH	O
##I	O
##K	O
,	O
DE	O
##N	O
and	O
C	O
/	O
D	O
samples	O
)	O
were	O
combined	O
and	O
then	O
divided	O
into	O
two	O
groups	O
on	O
the	O
basis	O
of	O
fever	O
duration	S
at	O
the	O
time	O
of	O
sample	O
collection	O
from	O
the	O
patients	O
.	O

Twenty	O
-	O
three	O
patients	O
underwent	O
so	B
##fo	I
##s	I
##bu	I
##vir	I
and	O
rib	B
##avi	I
##rin	I
treatment	O
until	O
1	O
to	O
2	O
days	O
before	O
liver	O
transplant	O
##ation	O
,	O
while	O
7	O
patients	O
completed	O
and	O
stopped	O
treatment	O
5	O
to	O
160	O
days	O
prior	O
to	O
transplant	O
##ation	O
.	O

HP	O
##LC	O
-	O
grade	O
H	O
_	O
2	O
O	O
was	O
purchased	O
from	O
The	O
##rm	O
##o	O
Fisher	O
Scientific	O
(	B
Hampton	S
,	O
NH	O
,	O
USA	O
)	O
.	O

Ty	B
##ros	I
##ine	I
levels	O
showed	O
a	O
unique	O
correlation	O
with	O
di	O
##abe	O
##tic	O
micro	O
##ang	O
##io	O
##pathy	O
in	O
T	O
##2	O
##DM	O
patients	O
compared	O
to	O
any	O
other	O
single	O
marker	O
.	O

These	O
data	O
suggest	O
that	O
ER	O
##α	O
specifically	O
influences	O
the	O
effect	O
of	O
is	B
##of	I
##lav	I
##ones	I
on	O
C	O
##YP	O
##1	O
##A	O
##1	O
expression	O
,	O
without	O
altering	O
C	O
##YP	O
##1	O
##B	O
##1	O
.	O

In	O
this	O
respect	O
the	O
aligned	O
change	O
in	O
beta	B
##ine	I
and	O
N	B
,	I
N	I
-	I
dim	I
##eth	I
##yl	I
##gly	I
##cine	I
in	O
cross	O
-	O
section	O
##al	O
and	O
longitudinal	O
analyses	O
are	O
of	O
particular	O
interest	O
.	O

This	O
combined	O
sample	O
was	O
then	O
subjected	O
to	O
FCC	O
with	O
a	O
step	O
gradient	O
el	O
##ution	O
;	O
he	B
##xa	I
##ne	I
-	I
ch	I
##lor	I
##of	I
##orm	I
-	I
met	I
##han	I
##ol	I
and	O
the	O
fraction	O
##s	O
collected	O
subjected	O
to	O
L	O
##C	O
/	O
MS	O
and	O
MS	O
/	O
MS	O
analysis	O
.	O

B	O
##rea	O
##st	O
cancer	O
risk	O
was	O
statistical	O
##ly	O
significantly	O
increased	O
,	O
by	O
30	O
–	O
50	O
%	O
,	O
with	O
a	O
doubling	O
of	O
circulating	O
est	B
##rad	I
##iol	I
,	O
bio	O
##ava	O
##ila	O
##ble	O
est	B
##rad	I
##iol	I
[	O
est	O
##rad	O
##iol	O
not	O
bound	O
to	O
sex	O
hormone	O
-	O
binding	O
g	O
##lo	O
##bul	O
##in	O
(	O
SH	O
##B	O
##G	O
)	O
]	O
,	O
free	O
est	B
##rad	I
##iol	I
(	O
est	O
##rad	O
##iol	O
not	O
bound	O
to	O
SH	O
##B	O
##G	O
or	O
album	O
##in	O
)	O
,	O
est	B
##rone	I
,	O
or	O
est	B
##rone	I
su	I
##lf	I
##ate	I
.	O

The	O
residual	O
p	O
##elle	O
##ts	O
after	O
a	O
##que	O
##ous	O
extraction	O
were	O
son	O
##ica	O
##ted	O
for	O
90	O
seconds	O
with	O
di	B
##ch	I
##lor	I
##ome	I
##tah	I
##ane	I
in	O
Met	B
##han	I
##ol	I
(	I
3	I
:	I
1	I
)	I
containing	O
internal	O
standards	O
(	B
c	B
##era	I
##mi	I
##de	I
[	O
5	O
pm	O
##ole	O
µ	O
##L	O
_	O
−	O
##1	O
]	O
and	O
LP	O
##A	O
10	O
pm	O
##ol	O
µ	O
##L	O
_	O
−	O
##1	O
)	O
in	O
glass	O
via	O
##ls	O
.	O

A	O
decrease	O
in	O
both	O
car	B
##ni	I
##tine	I
and	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
species	O
in	O
CD	O
may	O
provide	O
evidence	O
for	O
decreased	O
beta	O
-	O
oxidation	O
of	O
fatty	O
acids	O
in	O
CD	O
.	O

Of	O
interest	O
are	O
the	O
elevated	O
levels	O
of	O
2	B
-	I
(	I
2	I
-	I
p	I
##hen	I
##yla	I
##ce	I
##to	I
##xy	I
)	I
prop	I
##ion	I
##yl	I
##gly	I
##cine	I
in	O
the	O
progressive	O
patients	O
.	O

[UNK]	O
Ad	O
##herence	O
and	O
C	O
##YP	O
##2	O
##D	O
##6	O
status	O
are	O
independent	O
de	O
##ter	O
##mina	O
##nts	O
of	O
ta	B
##mo	I
##xi	I
##fen	I
and	O
(	B
Z	I
)	I
‐	I
end	I
##ox	I
##ife	I
##n	I
plasma	O
levels	O
.	O

Finally	O
,	O
it	O
was	O
ensured	O
that	O
the	O
content	O
of	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
,	O
long	O
chain	O
a	B
##cy	I
##l	I
car	I
##ni	I
##tine	I
and	O
ad	B
##eno	I
##sin	I
##e	I
had	O
significant	O
differences	O
according	O
to	O
the	O
following	O
principles	O
.	O

Beta	B
-	I
al	I
##ani	I
##ne	I
is	O
a	O
component	O
of	O
naturally	O
occurring	O
p	O
##eptide	O
##s	O
(	O
car	O
##nos	O
##ine	O
,	O
an	B
##ser	I
##ine	I
)	O
and	O
pan	B
##to	I
##the	I
##nic	I
acid	I
(	O
Vita	O
##min	O
B	O
-	O
5	O
)	O
,	O
and	O
displays	O
a	O
2	O
.	O
4	O
-	O
fold	O
change	O
between	O
ER	O
-	O
and	O
ER	O
+	O
breast	O
cancer	O
.	O

Recently	O
,	O
findings	O
from	O
another	O
se	O
##psis	O
study	O
have	O
suggested	O
that	O
AD	B
##MA	I
may	O
provide	O
a	O
non	O
-	O
invasive	O
measurement	O
of	O
micro	O
##vas	O
##cular	O
function	O
.	O

The	O
de	O
##ple	O
##tion	O
of	O
s	O
##tri	O
##ata	O
##l	O
do	B
##pa	I
##mine	I
in	O
the	O
PD	O
brain	O
might	O
also	O
influence	O
pu	B
##rine	I
metabolism	O
.	O

We	O
s	O
##pec	O
##ulate	O
that	O
the	O
marker	O
observed	O
here	O
has	O
a	O
Δ	O
##9	O
or	O
Δ	O
11	O
trans	O
-	O
fatty	O
s	B
##phi	I
##ngo	I
##sin	I
##e	I
chain	O
containing	O
a	O
c	O
##is	O
-	O
double	O
bond	O
in	O
the	O
3	O
-	O
position	O
.	O

Our	O
prior	O
meta	O
##bol	O
##omi	O
##c	O
analysis	O
of	O
post	O
##mor	O
##tem	O
CS	O
##F	O
(	O
which	O
compared	O
PD	O
to	O
control	O
samples	O
)	O
also	O
reported	O
that	O
the	O
pu	B
##rine	I
in	I
##os	I
##ine	I
was	O
among	O
19	O
compounds	O
found	O
to	O
offer	O
the	O
best	O
differentiation	O
.	O

Several	O
of	O
these	O
disturbance	O
##s	O
could	O
be	O
inter	O
##connected	O
through	O
reduced	O
regeneration	O
of	O
te	B
##tra	I
##hy	I
##dr	I
##of	I
##olate	I
and	O
te	B
##tra	I
##hy	I
##dr	I
##ob	I
##io	I
##pt	I
##eri	I
##n	I
.	O

no	O
.	O
98	O
##29	O
-	O
03	O
)	O
,	O
form	B
##ic	I
acid	I
(	O
F	O
##luk	O
##a	O
,	O
cat	O
.	O

Ph	B
##en	I
##yla	I
##lani	I
##ne	I
not	O
only	O
participates	O
in	O
protein	O
sequence	O
in	O
all	O
tissues	O
,	O
but	O
is	O
also	O
a	O
precursor	O
for	O
do	B
##pa	I
##mine	I
.	O

Numerous	O
studies	O
under	O
##line	O
the	O
role	O
of	O
g	B
##lut	I
##ama	I
##te	I
metabolism	O
as	O
central	O
to	O
AL	O
##S	O
path	O
##op	O
##hy	O
##sio	O
##logy	O
[	O
,	O
]	O
and	O
our	O
findings	O
confirm	O
the	O
importance	O
of	O
this	O
pathway	O
.	O

Data	O
regarding	O
clinical	O
parameters	O
,	O
including	O
age	O
,	O
sex	O
,	O
body	O
mass	O
index	O
,	O
blood	O
pressure	O
,	O
smoking	O
history	O
,	O
com	O
##or	O
##bid	O
##ities	O
,	O
and	O
re	O
##nal	O
function	O
(	O
serum	O
c	B
##rea	I
##tin	I
##ine	I
(	O
s	O
##C	O
##r	O
)	O
and	O
spot	O
u	O
##PC	O
##r	O
)	O
,	O
were	O
collected	O
at	O
the	O
time	O
of	O
kidney	O
bio	O
##psy	O
.	O

3	O
##A	O
,	O
depicts	O
the	O
lack	O
of	O
association	O
between	O
variables	O
relevant	O
to	O
car	O
##bo	O
##hy	O
##dra	O
##te	O
metabolism	O
(	O
fast	O
##ing	O
glucose	S
,	O
H	O
##OM	O
##A	O
-	O
I	O
##R	O
,	O
fast	O
##ing	O
insulin	O
,	O
S	O
_	O
I	O
transformed	O
as	O
the	O
natural	O
log	O
##ari	O
##th	O
##m	O
,	O
and	O
H	O
##b	O
##A	O
##1	O
##c	O
)	O
and	O
C	O
##2	O
.	O

Although	O
protein	O
precipitation	O
with	O
PC	O
##A	O
is	O
a	O
widely	O
used	O
method	O
for	O
the	O
analysis	O
of	O
p	B
##oly	I
##amine	I
##s	I
[	O
,	O
,	O
,	O
]	O
,	O
its	O
repeat	O
##ability	O
in	O
serum	O
extraction	O
was	O
poor	O
,	O
becoming	O
especially	O
critical	O
for	O
compounds	O
for	O
which	O
there	O
are	O
no	O
labeled	O
internal	O
standards	O
.	O

We	O
found	O
that	O
la	B
##ctic	I
acid	I
was	O
significantly	O
higher	O
in	O
the	O
patients	O
with	O
p	O
##ap	O
##illa	O
##ry	O
thy	O
##roid	O
car	O
##cin	O
##oma	O
,	O
and	O
lip	O
##id	O
was	O
significantly	O
decreased	O
.	O

We	O
observed	O
in	O
the	O
present	O
study	O
that	O
the	O
serum	O
concentrations	O
of	O
the	O
active	O
ta	B
##mo	I
##xi	I
##fen	I
meta	O
##bol	O
##ite	O
,	O
4	O
##OH	O
##ND	O
##tam	O
(	B
end	B
##ox	I
##ife	I
##n	I
)	O
,	O
increase	O
with	O
age	O
during	O
steady	O
-	O
state	O
ta	B
##mo	I
##xi	I
##fen	I
treatment	O
.	O

Al	O
##a	O
could	O
increase	O
brain	O
car	B
##nos	I
##ine	I
content	O
24	O
,	O
which	O
ex	O
##ert	O
##ed	O
ne	O
##uro	O
##p	O
##rote	O
##ctive	O
effects	O
by	O
at	O
##ten	O
##uating	O
auto	O
##pha	O
##ge	O
taking	O
place	O
in	O
is	O
##che	O
##mic	O
damaged	O
brain	O
25	O
.	O

Am	O
##ou	O
##nt	O
of	O
o	B
##ct	I
##ano	I
##ic	I
acid	I
C	I
##8	I
:	I
0	I
,	O
do	B
##de	I
##cano	I
##ic	I
acid	I
C	I
##12	I
:	I
0	I
,	O
pen	B
##tad	I
##eca	I
##no	I
##ic	I
acid	I
C	I
##15	I
:	I
0	I
,	O
he	B
##pta	I
##de	I
##cano	I
##ic	I
acid	I
C	I
##17	I
:	I
0	I
,	O
and	O
l	B
##ino	I
##le	I
##ic	I
acid	I
C	I
##18	I
:	I
2	I
of	O
total	O
lip	O
##ids	O
in	O
test	O
foods	O
per	O
portion	O
served	O
measured	O
by	O
G	O
##C	O
-	O
F	O
##ID	O
.	O

Statistical	O
analysis	O
of	O
_	O
1	O
H	O
N	O
##MR	O
spectral	O
data	O
revealed	O
that	O
signals	O
corresponding	O
to	O
ve	O
##nous	O
la	B
##ct	I
##ate	I
and	O
total	O
ch	B
##ole	I
##ster	I
##ol	I
were	O
strongly	O
associated	O
with	O
patients	O
’	O
death	O
within	O
30	O
days	O
following	O
admission	O
.	O

Thus	O
,	O
the	O
observed	O
alter	O
##ation	O
in	O
prop	B
##ion	I
##ate	I
metabolism	O
appears	O
to	O
be	O
consistent	O
with	O
a	O
recent	O
view	O
that	O
MS	O
may	O
also	O
be	O
associated	O
with	O
d	O
##ys	O
##function	O
in	O
lip	O
##id	O
metabolism	O
.	O

Within	O
the	O
amino	O
acid	O
derived	O
compounds	O
,	O
amino	O
acids	O
most	O
significantly	O
associated	O
with	O
F	O
##E	O
##V	O
_	O
1	O
/	O
F	O
##VC	O
included	O
a	B
##rg	I
##ini	I
##ne	I
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
and	O
se	B
##rine	I
(	O
B	O
)	O
.	O

Therefore	O
,	O
increased	O
g	B
##lut	I
##ama	I
##te	I
along	O
with	O
depleted	O
g	B
##lut	I
##amine	I
in	O
EC	O
tissue	O
could	O
suggest	O
changes	O
in	O
g	B
##lut	I
##ami	I
##no	I
##ly	I
##tic	I
activity	O
for	O
EC	O
development	O
.	O

For	O
MA	O
##LD	O
##I	O
–	O
MS	O
analysis	O
,	O
the	O
dried	O
sample	O
was	O
red	O
##iss	O
##ol	O
##ved	O
by	O
150	O
##μ	O
##L	O
of	O
50	O
%	O
met	B
##han	I
##ol	I
in	O
ultra	O
##pur	O
##e	O
water	O
(	O
v	O
/	O
v	O
)	O
.	O

The	O
meta	O
##bol	O
##ites	O
mon	B
##o	I
-	I
(	I
2	I
-	I
et	I
##hyl	I
##he	I
##xy	I
##l	I
)	I
p	I
##ht	I
##hala	I
##te	I
(	O
ME	O
##HP	O
)	O
,	O
MC	O
##M	O
##HP	O
,	O
and	O
ME	O
##CP	O
##P	O
were	O
combined	O
as	O
the	O
sum	O
of	O
DE	O
##HP	O
meta	O
##bol	O
##ites	O
(	O
[UNK]	O
)	O
,	O
and	O
the	O
sum	O
of	O
Mi	O
##NP	O
and	O
MC	O
##i	O
##OP	O
as	O
the	O
sum	O
of	O
Di	O
##NP	O
meta	O
##bol	O
##ites	O
(	O
[UNK]	O
)	O
.	O

Moreover	O
,	O
patients	O
with	O
ID	O
##H	O
-	O
mutant	O
g	O
##lio	O
##mas	O
demonstrated	O
higher	O
levels	O
of	O
D	B
-	I
2	I
-	I
h	I
##ydro	I
##xy	I
##g	I
##lut	I
##arate	I
in	O
the	O
CS	O
##F	O
,	O
in	O
comparison	O
to	O
patients	O
with	O
other	O
tumor	O
types	O
,	O
or	O
controls	O
.	O

Thus	O
,	O
metabolism	O
of	O
try	B
##pt	I
##op	I
##han	I
via	O
the	O
k	B
##yn	I
##uren	I
##ine	I
pathway	O
may	O
play	O
a	O
role	O
in	O
lung	O
cancer	O
et	O
##iology	O
.	O

Go	O
to	O
:	O
Background	O
:	O
An	O
elevated	O
circulating	O
c	B
##ys	I
##tat	I
##hi	I
##oni	I
##ne	I
concentration	O
,	O
which	O
arises	O
in	O
part	O
from	O
ins	O
##uff	O
##ici	O
##encies	O
of	O
vitamin	O
B	O
-	O
6	O
,	O
B	O
-	O
12	O
,	O
or	O
f	B
##olate	I
,	O
has	O
been	O
shown	O
to	O
be	O
associated	O
with	O
card	O
##iovascular	O
disease	O
(	O
C	O
##VD	O
)	O
risk	O
.	O

(	O
E	O
)	O
(	O
left	O
)	O
Phase	O
contrast	O
images	O
;	O
(	O
right	O
)	O
graph	O
showing	O
fold	O
tumors	O
##phere	O
induction	O
(	O
total	O
area	O
)	O
of	O
U	O
##M	O
-	O
SC	O
##C	O
-	O
14	O
##A	O
cells	O
culture	O
##d	O
in	O
the	O
presence	O
or	O
absence	O
of	O
g	B
##lut	I
##amine	I
(	O
30	O
μ	O
g	O
/	O
m	O
##L	O
)	O
under	O
suspension	O
conditions	O
in	O
g	B
##lut	I
##amine	I
free	O
media	O
for	O
the	O
indicated	O
time	O
points	O
.	O

Previous	O
studies	O
have	O
reported	O
that	O
UP	O
##LC	O
/	O
MS	O
-	O
MS	O
method	O
is	O
suitable	O
for	O
the	O
determination	O
of	O
u	O
##rina	O
##ry	O
3	B
-	I
met	I
##hyl	I
##his	I
##ti	I
##dine	I
to	O
monitor	O
muscle	O
protein	O
cat	O
##ab	O
##olis	O
##m	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
side	O
-	O
by	O
-	O
side	O
comparison	O
of	O
the	O
quality	O
of	O
sample	O
preparation	O
from	O
blood	O
plasma	O
by	O
conventional	O
solvent	O
precipitation	O
##s	O
(	B
met	B
##han	I
##ol	I
-	I
ethanol	I
,	O
met	B
##han	I
##ol	I
,	O
met	B
##han	I
##ol	I
-	I
M	I
##T	I
##BE	I
)	O
,	O
LL	O
##E	O
(	O
M	O
##T	O
##BE	O
)	O
and	O
SP	O
##E	O
(	O
C	O
##18	O
,	O
I	O
##EX	O
,	O
P	O
##EP	O
##2	O
)	O
methods	O
in	O
a	O
single	O
study	O
.	O

Figure	O
contains	O
box	O
##p	O
##lot	O
##s	O
of	O
those	O
meta	O
##bol	O
##ites	O
showing	O
that	O
6	O
compounds	O
were	O
significantly	O
up	O
##re	O
##gu	O
##lated	O
and	O
1	O
compound	O
(	O
PC	O
a	O
##a	O
C	B
##34	I
:	I
4	I
)	O
was	O
significantly	O
down	O
##re	O
##gu	O
##lated	O
in	O
samples	O
from	O
N	O
##SC	O
##LC	O
patients	O
compared	O
with	O
the	O
non	O
-	O
cancer	O
group	O
.	O

Both	O
T	O
##2	O
##D	O
and	O
pre	O
##dia	O
##bet	O
##es	O
displayed	O
relatively	O
higher	O
concentrations	O
of	O
several	O
short	O
-	O
and	O
long	O
-	O
chain	O
A	O
##cy	O
##l	O
##C	O
##N	O
##s	O
,	O
such	O
as	O
L	B
-	I
ace	I
##ty	I
##l	I
##car	I
##ni	I
##tine	I
(	O
C	O
##2	O
)	O
at	O
m	O
/	O
z	O
203	O
.	O
116	O
##0	O
##n	O
(	O
E	O
##SI	O
+	O
,	O
R	O
##T	O
=	O
0	O
.	O
57	O
min	O
;	O
P	O
=	O
6	O
.	O
66	O
##E	O
-	O
04	O
,	O
F	O
##DR	O
=	O
0	O
.	O
06	O
##6	O
)	O
,	O
te	B
##tra	I
##de	I
##cano	I
##yl	I
##car	I
##ni	I
##tine	I
(	O
C	O
##14	O
)	O
at	O
m	O
/	O
z	O
37	O
##2	O
.	O
311	O
##5	O
(	O
E	O
##SI	O
+	O
,	O
R	O
##T	O
=	O
0	O
.	O
99	O
min	O
;	O
P	O
=	O
1	O
.	O
46	O
##E	O
-	O
03	O
,	O
F	O
##DR	O
=	O
0	O
.	O
09	O
##4	O
)	O
,	O
2	B
-	I
h	I
##ydro	I
##xy	I
##he	I
##xa	I
##de	I
##cano	I
##yl	I
##car	I
##ni	I
##tine	I
(	O
C	O
##16	O
##OH	O
)	O
at	O
m	O
/	O
z	O
41	O
##6	O
.	O
33	O
##7	O
##1	O
(	O
E	O
##SI	O
+	O
,	O
R	O
##T	O
=	O
1	O
.	O
02	O
min	O
;	O
P	O
=	O
1	O
.	O
60	O
##E	O
-	O
04	O
,	O
F	O
##DR	O
=	O
0	O
.	O
04	O
##4	O
)	O
,	O
and	O
12	B
-	I
h	I
##ydro	I
##xy	I
-	I
12	I
-	I
o	I
##ct	I
##ade	I
##cano	I
##yl	I
##car	I
##ni	I
##tine	I
(	O
C	O
##18	O
##OH	O
)	O
at	O
m	O
/	O
z	O
44	O
##4	O
.	O
36	O
##6	O
##7	O
(	O
E	O
##SI	O
+	O
,	O
R	O
##T	O
=	O
1	O
.	O
38	O
min	O
;	O
P	O
=	O
5	O
.	O
70	O
##E	O
-	O
04	O
,	O
F	O
##DR	O
=	O
0	O
.	O
06	O
##6	O

In	O
P	O
##ET	O
-	O
negative	O
patients	O
,	O
a	O
high	O
relative	O
g	B
##lut	I
##ama	I
##te	I
concentration	O
exclude	O
##s	O
lung	O
cancer	O
in	O
all	O
patients	O
(	O
N	O
##P	O
##V	O
100	O
%	O
)	O
.	O

Of	O
particular	O
relevance	O
to	O
this	O
study	O
,	O
a	O
variety	O
of	O
N	B
-	I
a	I
##cy	I
##let	I
##han	I
##ola	I
##mine	I
##s	I
have	O
been	O
confirmed	O
to	O
be	O
per	O
##ox	O
##is	O
##ome	O
pro	O
##life	O
##rator	O
-	O
activated	O
receptor	O
(	O
PP	O
##AR	O
)	O
l	O
##igan	O
##ds	O
,	O
which	O
play	O
key	O
roles	O
in	O
essential	O
physiological	O
processes	O
such	O
as	O
lip	O
##id	O
metabolism	O
and	O
inflammation	O
response	O
_	O
,	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
tested	O
associations	O
of	O
e	O
##G	O
##F	O
##R	O
with	O
circulating	O
24	B
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
concentration	O
across	O
a	O
wide	O
range	O
of	O
e	O
##G	O
##F	O
##R	O
using	O
data	O
from	O
five	O
co	O
##hor	O
##t	O
studies	O
and	O
clinical	O
trials	O
.	O

A	O
200	O
-	O
mg	O
Sep	O
-	O
Pak	O
t	O
##C	O
_	O
18	O
cartridge	O
(	O
SP	O
##E	O
##1	O
)	O
was	O
r	O
##ins	O
##ed	O
with	O
4	O
m	O
##l	O
of	O
99	O
.	O
9	O
%	O
ethanol	S
followed	O
by	O
6	O
m	O
##l	O
of	O
70	O
%	O
ethanol	S
.	O

The	O
method	O
of	O
Co	O
##ene	O
et	O
al	O
.	O
could	O
not	O
identify	O
g	B
##uan	I
##id	I
##ino	I
##ace	I
##tic	I
acid	I
,	O
a	B
##rg	I
##ini	I
##nos	I
##ucci	I
##nic	I
acid	I
and	O
dim	B
##eth	I
##yl	I
##gly	I
##cine	I
and	O
thus	O
could	O
not	O
recognize	O
g	O
##uan	O
##id	O
##ino	O
##ace	O
##tic	O
acid	O
met	O
##hyl	O
##tra	O
##ns	O
##fer	O
##ase	O
deficiency	O
,	O
a	B
##rg	I
##ini	I
##nos	I
##ucci	I
##nic	I
acid	O
##uria	O
,	O
and	O
dim	O
##eth	O
##yl	O
##gly	O
##cine	O
de	O
##hy	O
##dr	O
##ogen	O
##ase	O
deficiency	O
.	O

This	O
database	O
was	O
used	O
to	O
search	O
for	O
ho	O
##mo	O
##log	O
##ous	O
proteins	O
in	O
the	O
Atlantic	S
co	O
##d	O
(	O
G	O
##ad	O
##us	O
m	O
##or	O
##hua	O
)	O
E	O
##ST	O
database	O
(	O
downloaded	O
from	O
Ensemble	O
,	O
available	O
from	O
http	O
:	O
/	O
/	O
www	O
.	O
en	O
##se	O
##mb	O
##l	O
.	O
org	O
/	O
index	O
.	O
html	O
,	O
downloaded	O
30th	O
Des	O
##em	O
##ber	O
2016	O
,	O
77	O
##40	O
##8	O
sequences	O
)	O
using	O
B	O
##last	O
##2	O
##G	O
##O	O
(	O
v	O
.	O
4	O
.	O
0	O
.	O
7	O
)	O
.	O

The	O
six	O
-	O
meta	O
##bol	O
##ite	O
combination	O
identified	O
was	O
al	B
##ani	I
##ne	I
,	O
his	B
##ti	I
##dine	I
,	O
le	B
##uc	I
##ine	I
,	O
p	B
##yr	I
##u	I
##vate	I
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
and	O
v	B
##ali	I
##ne	I
.	O

D	O
##ynamic	O
changes	O
in	O
the	O
s	B
##phi	I
##ngo	I
##lip	I
##id	I
metabolic	O
profile	O
during	O
progression	O
from	O
a	O
healthy	O
condition	O
to	O
Pre	O
-	O
D	O
##M	O
,	O
and	O
then	O
to	O
T	O
##2	O
##DM	O
.	O

Di	O
##fference	O
##s	O
in	O
admission	O
plasma	O
concentrations	O
of	O
26	O
amino	O
acids	O
between	O
the	O
A	B
##E	I
and	O
No	O
-	O
A	O
##E	O
groups	O
are	O
shown	O
in	O
Su	O
##pp	O
##lement	O
##ary	O
Table	O
_	O
1	O
.	O

For	O
K	O
##re	O
##bs	O
cycle	O
D	O
##H	O
,	O
there	O
was	O
a	O
substantial	O
decrease	O
of	O
is	B
##oc	I
##it	I
##rate	I
D	O
##H	O
(	O
ID	O
##H	O
)	O
and	O
α	B
-	I
k	I
##eto	I
##g	I
##lut	I
##arate	I
D	O
##H	O
(	O
O	O
##G	O
##D	O
##H	O
)	O
in	O
contrast	O
to	O
a	O
modest	O
activation	O
of	O
ma	B
##late	I
D	O
##H	O
(	O
MD	O
##H	O
)	O
expression	O
,	O
while	O
su	B
##cci	I
##nate	I
D	O
##H	O
(	O
SD	O
##H	O
)	O
and	O
f	B
##uma	I
##rate	I
h	O
##yd	O
##rata	O
##se	O
(	O
F	O
##H	O
)	O
showed	O
no	O
statistical	O
##ly	O
significant	O
changes	O
in	O
expression	O
in	O
tumor	O
tissues	O
.	O

Once	O
again	O
,	O
the	O
correlation	O
between	O
la	B
##ct	I
##ate	I
and	O
al	B
##ani	I
##ne	I
can	O
be	O
accounted	O
for	O
,	O
and	O
in	O
this	O
model	O
it	O
is	O
also	O
possible	O
to	O
see	O
why	O
t	O
##G	O
##lut	O
co	O
##rrel	O
##ates	O
with	O
both	O
la	B
##ct	I
##ate	I
and	O
al	B
##ani	I
##ne	I
,	O
since	O
both	O
g	B
##lut	I
##amine	I
and	O
g	B
##lut	I
##ama	I
##te	I
are	O
involved	O
in	O
the	O
metabolic	O
pathway	O
whereby	O
la	B
##ct	I
##ate	I
and	O
al	B
##ani	I
##ne	I
can	O
be	O
synthesis	O
##ed	O
.	O

A	O
key	O
feature	O
of	O
this	O
method	O
for	O
analysis	O
of	O
co	B
##tin	I
##ine	I
was	O
monitoring	O
of	O
the	O
m	O
/	O
z	O
178	O
.	O
08	O
peak	O
of	O
co	B
##tin	I
##ine	I
,	O
which	O
is	O
the	O
[	O
M	O
+	O
H	O
]	O
_	O
+	O
ion	O
of	O
naturally	O
occurring	O
[	O
_	O
13	O
C	O
]	O
co	O
##tin	O
##ine	O
,	O
comprising	O
11	O
%	O
of	O
the	O
[	O
_	O
12	O
C	O
]	O
co	O
##tin	O
##ine	O
[	O
M	O
+	O
H	O
]	O
_	O
+	O
ion	O
.	O

The	O
p	O
##eptide	O
samples	O
were	O
analyzed	O
using	O
a	O
custom	O
built	O
automated	O
na	O
##no	O
-	O
flow	O
,	O
metal	O
-	O
free	O
na	O
##no	O
##LC	O
system	O
with	O
a	O
40	O
-	O
cm	O
long	O
,	O
50	O
µ	O
##m	O
i	O
.	O
d	O
.	O
cap	O
##illa	O
##ry	O
column	O
packed	O
(	O
in	O
-	O
house	O
)	O
with	O
3	O
µ	O
##m	O
Jupiter	O
(	O
Ph	O
##eno	O
##men	O
##ex	O
,	O
Tor	O
##rance	O
,	O
CA	O
)	O
C	O
_	O
18	O
si	B
##lica	I
.	O

In	O
the	O
same	O
models	O
,	O
higher	O
PT	O
##H	O
was	O
associated	O
with	O
a	O
significantly	O
reduced	O
in	O
##cre	O
##ment	O
in	O
24	B
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
per	O
given	O
in	O
##cre	O
##ment	O
in	O
25	O
(	O
OH	O
)	O
D	O
_	O
3	O
(	O
slope	O
)	O
in	O
ME	O
##SA	O
,	O
with	O
similar	O
trends	O
in	O
CH	O
##S	O
and	O
SK	O
##S	O
that	O
were	O
not	O
statistical	O
##ly	O
significant	O
.	O

Other	O
compounds	O
seen	O
by	O
G	O
##C	O
-	O
MS	O
but	O
not	O
by	O
N	O
##MR	O
included	O
meta	O
##bol	O
##ites	O
that	O
were	O
generally	O
below	O
the	O
detection	O
limit	O
of	O
N	O
##MR	O
(	O
[UNK]	O
µ	O
##M	O
/	O
m	O
##M	O
c	O
##rea	O
##tin	O
##ine	O
)	O
such	O
as	O
in	B
##do	I
##le	I
##la	I
##ctic	I
acid	I
and	O
2	B
,	I
4	I
-	I
di	I
##hy	I
##dr	I
##ox	I
##y	I
##but	I
##ano	I
##ic	I
acid	I
.	O

Matrix	O
effects	O
for	O
s	B
##pi	I
##ron	I
##ola	I
##cton	I
##e	I
,	O
7	B
-	I
alpha	I
-	I
met	I
##hyl	I
##thi	I
##os	I
##pi	I
##ron	I
##ola	I
##cton	I
##e	I
,	O
can	B
##ren	I
##one	I
,	O
and	O

In	O
this	O
study	O
,	O
we	O
add	O
deeper	O
analysis	O
of	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
to	O
this	O
model	O
and	O
examined	O
recently	O
s	O
##ym	O
##pt	O
##oma	O
##tic	O
patients	O
in	O
our	O
emergency	O
department	O
observation	O
unit	O
.	O

Although	O
only	O
a	O
few	O
reports	O
have	O
reported	O
a	O
decrease	O
in	O
g	B
##uan	I
##ido	I
##ace	I
##tic	I
acid	I
level	O
in	O
disease	O
,	O
low	O
ho	B
##mo	I
##ar	I
##gin	I
##ine	I
concentration	O
is	O
reported	O
to	O
be	O
associated	O
with	O
my	O
##oc	O
##ard	O
##ial	O
d	O
##ys	O
##function	O
[	O
,	O
]	O
and	O
re	O
##nal	O
failure	O
[	O
,	O
]	O
,	O
and	O
also	O
affects	O
the	O
production	O
of	O
v	O
##as	O
##od	O
##ila	O
##tor	O
ni	B
##tric	I
oxide	I
(	O
NO	O
)	O
and	O
mineral	O
metabolism	O
.	O

Sa	B
##rc	I
##os	I
##ine	I
;	O
13	O
.	O

Carolyn	O
M	O
.	O
S	O
##lu	O
##ps	O
##ky	O
et	O
al	O
.	O
,	O
however	O
,	O
pointed	O
out	O
that	O
the	O
content	O
of	O
su	B
##cci	I
##nic	I
acid	I
of	O
urine	O
in	O
patients	O
with	O
o	O
##var	O
##ian	O
cancer	O
was	O
lower	O
than	O
that	O
in	O
healthy	O
people	O
.	O

CP	O
##S	O
##1	O
mutations	O
are	O
known	O
to	O
cause	O
car	B
##ba	I
##mo	I
##yl	I
##ph	I
##os	I
##phate	I
s	O
##ynth	O
##eta	O
##se	O
I	O
deficiency	O
,	O
an	O
auto	O
##so	O
##mal	O
re	O
##cess	O
##ive	O
in	O
##born	O
error	O
of	O
metabolism	O
of	O
the	O
u	B
##rea	I
cycle	O
which	O
causes	O
h	O
##yper	O
##am	O
##mon	O
##emia	O
.	O

Also	O
,	O
alterations	O
in	O
de	B
##cano	I
##ic	I
acid	I
,	O
p	B
##hen	I
##yl	I
##met	I
##han	I
##ol	I
and	O
non	B
##ano	I
##ic	I
acid	I
were	O
associated	O
with	O
me	O
##lan	O
##oma	O
.	O

We	O
prepared	O
ten	O
ca	O
##li	O
##bra	O
##tion	O
standard	O
s	O
##pi	O
##king	O
solutions	O
that	O
contained	O
DE	O
##ET	O
and	O
its	O
two	O
o	O
##xi	O
##da	O
##tive	O
meta	O
##bol	O
##ites	O
in	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
using	O
the	O
initial	O
stock	O
.	O

Tam	O
##ox	O
##ife	O
##n	O
-	O
treated	O
cells	O
(	O
T	O
##AM	O
-	O
S	O
or	O
T	O
##AM	O
-	O
R	O
)	O
were	O
grown	O
in	O
p	O
##hen	O
##ol	O
-	O
red	O
–	O
free	O
R	O
##PM	O
##I	O
medium	O
(	O
Media	O
Tech	O
,	O
Man	O
##ass	O
##as	O
,	O
VA	O
)	O
containing	O
charcoal	O
stripped	O
Fe	O
##tal	O
Bo	O
##vin	O
##e	O
Ser	O
##um	O
,	O
with	O
10	O
u	O
##M	O
4	B
-	I
h	I
##ydro	I
##xy	I
##tam	I
##ox	I
##ife	I
##n	I
(	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
,	O
St	O
Louis	O
,	O
M	O
##O	O
)	O
.	O

In	O
the	O
current	O
work	O
,	O
a	O
semi	O
-	O
quantitative	O
analysis	O
of	O
105	O
meta	O
##bol	O
##ites	O
reveals	O
significant	O
differences	O
in	O
the	O
f	O
##ae	O
##cal	O
composition	O
of	O
cancer	O
samples	O
in	O
the	O
following	O
lip	O
##ids	O
:	O
PC	B
(	I
16	I
:	I
0	I
/	I
16	I
:	I
0	I
)	I
,	O
PC	B
(	I
32	I
:	I
1	I
)	I
,	O
PC	B
(	I
O	I
-	I
16	I
:	I
0	I
/	I
16	I
:	I
0	I
)	I
,	O
P	B
##E	I
(	I
16	I
:	I
0	I
/	I
18	I
:	I
1	I
)	I
,	O
P	B
##E	I
(	I
16	I
:	I
0	I
/	I
18	I
:	I
2	I
)	I
,	O
SM	B
(	I
d	I
##18	I
:	I
1	I
/	I
16	I
:	I
0	I
)	I
,	O
SM	B
(	I
d	I
##18	I
:	I
1	I
/	I
23	I
:	I
0	I
)	I
,	O
SM	B
(	I
d	I
##18	I
:	I
2	I
/	I
24	I
:	I
1	I
)	I
+	O
SM	B
(	I
d	I
##18	I
:	I
1	I
/	I
24	I
:	I
0	I
)	I
,	O
SM	B
(	I
42	I
:	I
1	I
)	I
,	O
Ce	B
##r	I
(	I
d	I
##18	I
:	I
1	I
/	I
16	I
:	I
0	I
)	I
,	O
Ce	B
##r	I
(	I
d	I
##18	I
:	I
1	I
/	I
24	I
:	I
1	I
)	I
+	O
Ce	B
##r	I
(	I
d	I
##18	I
:	I
2	I
/	I
24	I
:	I
0	I
)	I
,	O
Ce	B
##r	I
(	I
42	I
:	I
1	I
)	I
,	O
SM	B
(	I
42	I
:	I
3	I
)	I
,	O
Cho	B
##E	I
(	I
16	I
:	I
0	I
)	I
,	O
Cho	B
##E	I
(	I
18	I
:	I
1	I
)	I
,	O
Cho	B
##E	I
(	I
18	I
:	I
2	I
)	I
,	O
Cho	B
##E	I
(	I
20	I
:	I
4	I
)	I
,	O
T	B
##G	I
(	I
54	I
:	I
1	I
)	I
.	O

(	O
2019	O
)	O
,	O
extract	O
from	O
F	O
.	O
o	B
##xy	I
##sp	I
##orum	I
with	O
strong	O
anti	O
##mu	O
##tage	O
##nic	O
activity	O
was	O
found	O
to	O
be	O
composed	O
of	O
g	B
##ibe	I
##py	I
##rone	I
A	O
,	O
p	O
##yr	O
##rol	O
##o	O
[	O
1	O
,	O
2	O
-	O
a	O
]	O
p	B
##yra	I
##zine	I
-	I
1	I
,	I
4	I
-	I
di	I
##one	I
,	O
he	B
##xa	I
##hy	I
##dr	I
##o	I
-	I
3	I
-	I
(	I
2	I
-	I
met	I
##hyl	I
##p	I
##rop	I
##yl	I
)	I
and	O
in	B
##do	I
##lea	I
##ce	I
##tic	I
acid	I
as	O
major	O
components	O
.	O

Specifically	O
,	O
increases	O
in	O
c	B
##ys	I
##tine	I
(	O
p	O
<	O
0	O
.	O
00	O
##12	O
,	O
q	O
<	O
0	O
.	O
10	O
)	O
,	O
or	B
##ni	I
##thin	I
##e	I
(	O
p	O
<	O
0	O
.	O
00	O
##6	O
##8	O
,	O
q	O
<	O
0	O
.	O
26	O
)	O
,	O
l	B
##ys	I
##ine	I
(	O
p	O
<	O
0	O
.	O
01	O
##00	O
,	O
q	O
<	O
0	O
.	O
26	O
)	O
,	O
and	O
c	B
##it	I
##ru	I
##llin	I
##e	I
(	O
p	O
<	O
0	O
.	O
01	O
##60	O
,	O
q	O
<	O
0	O
.	O
26	O
)	O
were	O
all	O
observed	O
to	O
co	O
##rrel	O
##ate	O
with	O
the	O
L	O
##D	O
##L	O
-	O
C	O
lowering	O
effects	O
of	O
si	B
##m	I
##vas	I
##tat	I
##in	I
with	O
significant	O
p	O
-	O
values	O
(	O
<	O
0	O
.	O
05	O
)	O
,	O
but	O
high	O
q	O
-	O
values	O
.	O

N	B
##AD	I
##P	I
##H	I
,	O
N	B
##AD	I
##H	I
,	O
glucose	B
-	I
6	I
-	I
phosphate	I
,	O
u	B
##rid	I
##ine	I
-	I
5	I
′	I
-	I
dip	I
##hos	I
##ph	I
##og	I
##lu	I
##cu	I
##ronic	I
acid	I
(	O
U	O
##DP	O
##GA	O
)	O
,	O
glucose	O
-	O
6	O
-	O
phosphate	O
de	O
##hy	O
##dr	O
##ogen	O
##ase	O
,	O
al	B
##ame	I
##thi	I
##cin	I
,	O
and	O
NH	O
_	O
4	O
OH	O
solution	O
(	O
25	O
%	O
)	O
were	O
from	O
Sigma	O
(	O
St	O
.	O
Louis	O
,	O
M	O
##O	O
)	O
.	O

After	O
the	O
extract	O
##s	O
were	O
completely	O
dried	O
by	O
speed	O
vacuum	O
con	O
##cent	O
##rator	O
or	O
by	O
freeze	O
-	O
drying	O
,	O
20	O
µ	O
##L	O
of	O
40	O
mg	O
/	O
m	O
##L	O
met	B
##ho	I
##xy	I
##lam	I
##ine	I
h	I
##ydro	I
##ch	I
##lor	I
##ide	I
in	O
p	B
##yr	I
##id	I
##ine	I
was	O
added	O
,	O
and	O
samples	O
were	O
agitated	O
at	O
30	O
°C	O
for	O
30	O
min	O
.	O

The	O
maximum	O
AM	O
-	O
2	O
level	O
was	O
at	O
least	O
55	O
-	O
fold	O
higher	O
than	O
that	O
of	O
ace	B
##tam	I
##ip	I
##rid	I
.	O

Li	O
##quid	O
ch	O
##roma	O
##tography	O
–	O
tandem	O
mass	O
s	O
##pect	O
##rome	O
##try	O
revealed	O
a	O
high	O
serum	O
pro	B
##ges	I
##tero	I
##ne	I
level	O
,	O
high	O
17	B
-	I
h	I
##ydro	I
##xy	I
##p	I
##rog	I
##ester	I
##one	I
(	O
17	O
##OH	O
##P	O
)	O
(	O
255	O
ng	O
/	O
m	O
##L	O
)	O
,	O
and	O
high	O
levels	O
of	O
17	O
##OH	O
##P	O
meta	O
##bol	O
##ites	O
,	O
suggesting	O
a	O
classic	O
form	O
of	O
21	O
##OH	O
##D	O
.	O

Chemical	O
##ly	O
it	O
is	O
3	B
-	I
met	I
##hyl	I
-	I
m	I
##or	I
##phine	I
.	O

The	O
pre	O
-	O
ion	O
##ized	O
G	O
##ira	O
##rd	O
T	O
o	B
##xi	I
##mes	I
(	O
M	O
_	O
+	O
)	O
were	O
detected	O
in	O
the	O
SR	O
##M	O
mode	O
using	O
the	O
following	O
transitions	O
:	O
m	O
/	O
z	O
400	O
.	O
4	O
–	O
34	O
##1	O
.	O
2	O
for	O
Δ	O
_	O
4	O
-	O
AD	O
;	O
m	O
/	O
z	O
40	O
##2	O
.	O
4	O
–	O
34	O
##3	O
.	O
2	O
for	O
D	O
##H	O
##EA	O
,	O
T	O
,	O
Ad	B
##ione	I
and	O
E	O
##pi	O
##T	O
;	O
m	O
/	O
z	O
404	O
.	O
4	O
–	O
345	O
.	O
2	O
for	O
D	O
##HT	O
,	O
A	O
and	O
e	B
##pian	I
##dr	I
##osterone	I
;	O
and	O
m	O
/	O
z	O
405	O
.	O
4	O
–	O
34	O
##6	O
.	O
2	O
for	O
[	O
_	O
13	O
C	O
_	O
3	O
]	O
-	O
T	O
and	O
m	O
/	O
z	O
40	O
##7	O
.	O
4	O
–	O
34	O
##8	O
.	O
2	O
for	O
[	O
_	O
13	O
C	O
_	O
3	O
]	O
-	O
D	O
##HT	O
.	O

HP	O
##LC	O
-	O
grade	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
was	O
obtained	O
from	O
Me	O
##rc	O
##k	O
(	O
Me	O
##rc	O
##k	O
Company	O
,	O
Dar	O
##ms	O
##tadt	O
,	O
Germany	O
)	O
.	O

Therefore	O
,	O
our	O
results	O
shed	O
some	O
new	O
light	O
on	O
the	O
involvement	O
of	O
lip	O
##id	O
species	O
in	O
RA	O
path	O
##ogen	O
##esis	O
and	O
also	O
provided	O
a	O
rational	O
##e	O
for	O
FA	S
supplement	O
##ation	O
,	O
s	O
##tra	O
##ti	O
##fication	O
and	O
formula	O
-	O
design	O
in	O
RA	O
.	O

(	O
D	O
)	O
High	O
AU	O
##C	O
of	O
both	O
my	B
##oi	I
##nos	I
##ito	I
##l	I
and	O
format	B
##e	I
in	O
distinguishing	O
R	O
##R	O
##MS	O
and	O
A	O
##b	O
-	O
N	O
##MO	O
##SD	O
.	O

An	O
example	O
of	O
the	O
ratio	O
of	O
2	O
statistical	O
##ly	O
different	O
meta	O
##bol	O
##ites	O
between	O
normal	O
and	O
tumor	O
tissue	O
and	O
c	B
##yt	I
##id	I
##ine	I
5	I
′	I
-	I
dip	I
##hos	I
##ph	I
##och	I
##olin	I
##e	I
is	O
reported	O
in	O
and	O
.	O

Met	O
##ab	O
##oli	O
##tes	O
were	O
separated	O
using	O
C	O
##18	O
-	O
R	O
##P	O
(	O
AC	O
##Q	O
##UI	O
##TY	O
UP	O
##LC	O
H	O
##SS	O
T	O
##3	O
1	O
.	O
8	O
μ	O
##m	O
,	O
Waters	O
)	O
for	O
E	O
##SI	O
+	O
and	O
C	O
##18	O
-	O
R	O
##P	O
(	O
AC	O
##Q	O
##UI	O
##TY	O
UP	O
##LC	O
B	O
##E	O
##H	O
1	O
.	O
7	O
μ	O
##m	O
)	O
for	O
E	O
##SI	O
##−	O
.	O
When	O
the	O
instrument	O
was	O
operated	O
in	O
positive	O
ion	O
##ization	O
mode	O
,	O
the	O
solvent	O
system	O
was	O
A	O
=	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
in	O
water	O
and	O
B	O
=	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
in	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
.	O

(	O
E	O
)	O
Ph	O
##os	O
##ph	O
##oli	O
##pas	O
##e	O
activity	O
according	O
to	O
total	O
blood	O
ch	B
##ole	I
##ster	I
##ol	I
.	O

Large	O
HD	O
##L	O
particles	O
carry	O
ch	B
##ole	I
##ster	I
##ol	I
to	O
the	O
liver	O
for	O
ex	O
##cre	O
##tion	O
.	O

Ana	O
##ly	O
##ses	O
showed	O
that	O
lower	O
levels	O
of	O
try	B
##pt	I
##op	I
##han	I
[	O
OR	O
:	O
0	O
.	O
58	O
(	O
95	O
%	O
C	O
##I	O
0	O
.	O
35	O
–	O
0	O
.	O
93	O
,	O
p	O
value	O
0	O
.	O
03	O
)	O
]	O
and	O
X	O
##A	O
[	O
0	O
.	O
56	O
(	O
0	O
.	O
22	O
–	O
0	O
.	O
91	O
,	O
0	O
.	O
02	O
)	O
]	O
,	O
and	O
higher	O
K	O
##TR	O
[	O
1	O
.	O
65	O
(	O
1	O
.	O
02	O
–	O
2	O
.	O
71	O
,	O
0	O
.	O
04	O
)	O
]	O
,	O
were	O
associated	O
with	O
the	O
age	O
34	O
–	O
40	O
subgroup	O
.	O

Con	O
##sist	O
##ent	O
with	O
the	O
present	O
observations	O
,	O
high	O
circulating	O
u	B
##ric	I
acid	I
levels	O
were	O
associated	O
with	O
dem	O
##ent	O
##ia	O
in	O
a	O
population	O
-	O
based	O
study	O
,	O
with	O
low	O
cognitive	O
performance	O
,	O
and	O
with	O
increased	O
risk	O
of	O
cognitive	O
decline	O
among	O
older	O
adults	O
.	O

Para	B
##ce	I
##tam	I
##ol	I
is	O
a	O
commonly	O
used	O
anal	O
##ges	O
##ic	O
among	O
women	O
and	O
men	O
of	O
all	O
ages	O
.	O

Me	O
##as	O
##ure	O
##ment	O
of	O
ben	B
##zo	I
##ate	I
in	O
plasma	O
samples	O
did	O
not	O
co	O
##rrel	O
##ate	O
with	O
Δ	O
##UP	O
##DR	O
##S	O
##2	O
+	O
3	O
.	O

Of	O
the	O
six	O
p	O
##oly	O
##ol	O
derived	O
u	O
##rem	O
##ic	O
so	O
##lut	O
##es	O
significantly	O
associated	O
with	O
the	O
risk	O
of	O
progression	O
to	O
E	O
##SR	O
##D	O
,	O
my	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
was	O
the	O
one	O
most	O
strongly	O
associated	O
,	O
odds	O
ratio	O
:	O
3	O
.	O
2	O
(	O
95	O
%	O
C	O
##I	O
;	O
1	O
.	O
7	O
,	O
5	O
.	O
9	O
)	O
.	O

This	O
was	O
expected	O
because	O
it	O
is	O
a	O
commonly	O
used	O
solvent	O
for	O
in	O
##tra	O
##ven	O
##ous	O
ben	B
##zo	I
##dia	I
##ze	I
##pine	I
##s	I
used	O
in	O
the	O
MP	O
.	O

Therefore	O
,	O
we	O
speculated	O
that	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
might	O
be	O
involved	O
in	O
pulmonary	O
inflammation	O
during	O
infection	O
.	O

Le	B
##uc	I
##ine	I
–	I
en	I
##ke	I
##pha	I
##lin	I
was	O
obtained	O
from	O
Waters	O
(	O
Warsaw	O
,	O
Poland	O
)	O
.	O

In	O
our	O
current	O
study	O
,	O
possibly	O
due	O
to	O
the	O
larger	O
sample	O
size	O
f	O
##ac	O
##ilitating	O
resolution	O
of	O
cluster	O
##ed	O
meta	O
##bol	O
##ites	O
,	O
this	O
factor	O
was	O
split	O
into	O
three	O
components	O
,	O
each	O
with	O
biological	O
p	O
##laus	O
##ibility	O
:	O
factor	O
6	O
(	O
combination	O
of	O
BC	O
##AA	O
and	O
a	O
##romatic	O
acids	O
,	O
which	O
may	O
be	O
reporting	O
on	O
the	O
pathway	O
of	O
shared	O
transport	O
)	O
;	O
factor	O
7	O
(	O
C	O
##3	O
and	O
C	O
##5	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
,	O
which	O
include	O
by	O
##p	O
##rod	O
##uc	O
##ts	O
of	O
mitochondrial	O
BC	O
##AA	O
cat	O
##ab	O
##olis	O
##m	O
)	O
;	O
and	O
factor	O
10	O
(	O
BC	O
##AA	O
,	O
and	O
g	O
##lut	O
##ama	O
##te	O
/	O
g	O
##lut	O
##amine	O
,	O
the	O
by	O
##p	O
##rod	O
##uc	O
##t	O
of	O
the	O
initial	O
step	O
of	O
mitochondrial	O
BC	O
##AA	O
metabolism	O
)	O
.	O

CO	O
##PD	O
is	O
associated	O
with	O
alterations	O
in	O
the	O
serum	O
meta	O
##bol	O
##ome	O
,	O
including	O
a	O
disruption	O
in	O
the	O
his	B
##ti	I
##dine	I
-	I
his	I
##tamine	I
and	O
c	B
##rea	I
##tine	I
metabolic	O
pathways	O
.	O

Ion	O
suppression	O
was	O
observed	O
for	O
meta	O
##bol	O
##ites	O
with	O
lower	O
Lo	O
##g	O
##P	O
values	O
(	O
me	O
##lat	O
##oni	O
##n	O
,	O
4	B
-	I
amino	I
##but	I
##ano	I
##ic	I
acid	I
,	O
ad	B
##eni	I
##ne	I
and	O
ho	O
##mo	O
##vani	O
##lli	O
##c	O
acid	O
)	O
in	O
met	O
##han	O
##ol	O
-	O
based	O
extraction	O
##s	O
in	O
R	B
##P	I
.	O

SL	O
##E	O
,	O
systemic	O
l	O
##up	O
##us	O
er	O
##yt	O
##hem	O
##ato	O
##sus	O
;	O
L	O
##ys	O
##o	O
##PC	O
,	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
;	O
s	O
##F	O
##lt	O
##1	O
,	O
soluble	O
f	O
##ms	O
-	O
like	O
t	B
##yr	I
##os	I
##ine	I
kinase	O
-	O
1	O
;	O
P	O
##IG	O
##F	O
,	O
place	O
##ntal	O
growth	O
factor	O
.	O

My	O
##o	O
-	O
in	O
##os	O
##ito	O
##l	O
ranked	O
first	O
among	O
lip	O
##id	O
meta	O
##bol	O
##ites	O
associated	O
with	O
re	B
##tino	I
##l	I
,	O
which	O
along	O
with	O
its	O
p	O
##hos	O
##ph	O
##ory	O
##lated	O
derivatives	O
including	O
in	B
##os	I
##ito	I
##l	I
1	I
-	I
phosphate	I
(	O
I	O
##1	O
##P	O
)	O
,	O
may	O
be	O
related	O
to	O
media	O
##tion	O
of	O
re	B
##tino	I
##ic	I
acid	I
signaling	O
and	O
cellular	O
functions	O
including	O
ad	O
##hesion	O
,	O
growth	O
,	O
ve	O
##si	O
##cular	O
trafficking	O
,	O
and	O
cell	O
survival	O
,	O
and	O
is	O
involved	O
in	O
regulation	O
of	O
enzyme	O
activity	O
and	O
hormone	O
secret	O
##ion	O
.	O

The	O
in	O
##hibition	O
of	O
c	O
##y	O
##c	O
##lo	O
##ox	O
##y	O
##gen	O
##ase	O
(	O
CO	O
##X	O
)	O
-	O
1	O
and	O
CO	O
##X	O
-	O
2	O
activity	O
by	O
di	O
##c	O
##lo	O
##fen	O
##ac	O
,	O
br	O
##om	O
##fen	O
##ac	O
,	O
and	O
am	O
##fen	O
##ac	O
was	O
determined	O
by	O
measuring	O
the	O
production	O
of	O
pro	B
##sta	I
##g	I
##land	I
##in	I
(	O
P	O
##G	O
)	O
E	O
_	O
2	O
using	O
an	O
enzyme	O
im	O
##mu	O
##no	O
##ass	O
##ay	O
(	O
E	O
##IA	O
)	O
kit	O
(	B
Pro	B
##sta	I
##g	I
##land	I
##in	I
E	O
_	O
2	O
B	O
##iot	O
##rak	O
E	O
##IA	O
system	O
,	O
GE	O
Healthcare	O
,	O
Buckinghamshire	O
,	O
UK	O
)	O
.	O

Further	O
,	O
it	O
is	O
evident	O
from	O
the	O
figures	O
that	O
the	O
decrease	O
in	O
peak	O
intensity	O
for	O
g	B
##lut	I
##amine	I
due	O
to	O
c	O
##y	O
##c	O
##li	O
##zation	O
is	O
proportional	O
to	O
the	O
increase	O
in	O
peak	O
in	O
##tens	O
##ities	O
for	O
p	B
##yr	I
##og	I
##lut	I
##ami	I
##c	I
acid	I
.	O

Label	O
##ing	O
efficiency	O
was	O
checked	O
by	O
using	O
non	O
-	O
pro	O
##te	O
##ogenic	O
amino	O
acids	O
(	B
nor	B
##le	I
##uc	I
##ine	I
and	O
nor	B
##val	I
##ine	I
)	O
.	O

No	O
##menclature	O
:	O
1	O
,	O
lip	O
##id	O
;	O
2	O
,	O
branched	O
amino	O
acids	O
;	O
3	O
,	O
la	B
##ct	I
##ate	I
;	O
4	O
,	O
al	B
##ani	I
##ne	I
;	O
5	O
,	O
ace	B
##tate	I
;	O
6	O
,	O
N	B
-	I
ace	I
##ty	I
##l	I
g	I
##ly	I
##co	I
##p	I
##rote	I
##in	I
;	O
7	O
,	O
g	O
##lut	O
##ama	O
##te	O
/	O
g	O
##lut	O
##amine	O
;	O
8	O
,	O
ace	B
##tone	I
;	O
9	O
,	O
ace	B
##to	I
##ace	I
##tate	I
;	O
10	O
,	O
c	B
##it	I
##rate	I
;	O
11	O
,	O
c	B
##rea	I
##tine	I
;	O
12	O
,	O
ch	B
##olin	I
##es	I
;	O
13	O
,	O
glucose	S
;	O
14	O
,	O
mainly	O
glucose	S
region	O
;	O
15	O
,	O
t	B
##yr	I
##os	I
##ine	I
;	O
16	O
,	O
his	B
##ti	I
##dine	I
;	O
17	O
,	O
format	B
##e	I
.	O

Since	O
que	B
##rc	I
##eti	I
##n	I
showed	O
some	O
in	O
##hibition	O
and	O
since	O
the	O
correlation	O
analysis	O
implicated	O
C	O
##YP	O
##2	O
##C	O
##8	O
in	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
metabolism	O
,	O
trim	O
##eth	O
##op	O
##rim	O
,	O
a	O
selective	O
inhibitor	O
of	O
C	O
##YP	O
##2	O
##C	O
##8	O
was	O
used	O
as	O
additional	O
inhibitor	O
probe	O
.	O

Our	O
data	O
indicate	O
that	O
potential	O
exists	O
for	O
similar	O
glucose	B
-	I
driven	I
damage	O
mechanisms	O
to	O
occur	O
in	O
AD	O
brain	O
,	O
consistent	O
with	O
co	O
-	O
local	O
##ization	O
there	O
of	O
AG	O
##Es	O
with	O
A	O
##β	O
-	O
containing	O
plaque	O
.	O

The	O
observation	O
of	O
the	O
levels	O
of	O
the	O
k	B
##eton	I
##e	I
bodies	O
opens	O
such	O
possibility	O
and	O
allows	O
to	O
capture	O
the	O
patients	O
at	O
risk	O
of	O
the	O
greatest	O
decrease	O
in	O
the	O
body	O
weight	O
(	O
Fi	O
##gs	O
.	O
,	O
and	O
d	O
)	O
.	O

In	O
the	O
case	O
of	O
H	O
##B	O
##V	O
,	O
the	O
del	O
##eti	O
##on	O
mutant	O
pre	O
-	O
S	O
##2	O
protein	O
is	O
capable	O
of	O
act	O
##ivating	O
the	O
m	O
##TO	O
##R	O
signal	O
ca	O
##sca	O
##de	O
,	O
which	O
leads	O
to	O
the	O
trans	O
##location	O
of	O
the	O
SL	O
##C	O
##2	O
##A	O
##1	O
(	O
G	O
##L	O
##UT	O
##1	O
)	O
transport	O
##er	O
protein	O
to	O
the	O
he	O
##pa	O
##to	O
##cy	O
##te	O
membrane	O
,	O
enhanced	O
cellular	O
glucose	S
up	O
##take	O
,	O
and	O
a	O
##ero	O
##bic	O
g	O
##ly	O
##co	O
##lysis	O
(	O
‘	O
War	O
##burg	O
effect	O
’	O
)	O
.	O

Pro	O
##tein	O
was	O
pu	O
##rified	O
over	O
Ni	O
Sep	O
##har	O
##ose	O
6	O
Fast	O
Flow	O
re	O
##sin	O
(	O
GE	O
Healthcare	O
)	O
and	O
el	O
##uted	O
with	O
500	O
m	O
##M	O
im	B
##ida	I
##zo	I
##le	I
phosphate	I
buffer	O
.	O

Li	O
##quid	O
ch	O
##roma	O
##tography	O
/	O
mass	O
s	O
##pect	O
##rome	O
##try	O
analysis	O
(	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
)	O
was	O
performed	O
to	O
measure	O
20	B
-	I
H	I
##ET	I
##E	I
formation	O
in	O
tumor	O
ho	O
##mo	O
##gen	O
##ates	O
.	O

Approximately	O
60	O
%	O
of	O
brain	O
k	B
##yn	I
##uren	I
##ine	I
is	O
coming	O
from	O
peripheral	O
sources	O
,	O
and	O
in	O
the	O
brain	O
,	O
k	B
##yn	I
##uren	I
##ine	I
is	O
trans	O
##ami	O
##nated	O
to	O
K	O
##Y	O
##NA	O
by	O
the	O
K	O
##AT	O
enzymes	O
in	O
as	O
##tro	O
##cy	O
##tes	O
or	O
to	O
Q	O
##UI	O
##N	O
by	O
k	O
##yn	O
##uren	O
##ine	O
3	O
-	O
mon	O
##oo	O
##xy	O
##gen	O
##ase	O
(	O
K	O
##MO	O
)	O
in	O
micro	O
##glia	O
##l	O
cells	O
.	O

The	O
dried	O
samples	O
were	O
then	O
re	O
##con	O
##stituted	O
in	O
150	O
µ	O
##L	O
of	O
40	O
%	O
PBS	O
/	O
60	O
%	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
(	O
AC	O
##N	O
)	O
and	O
v	O
##ortex	O
##ed	O
for	O
another	O
5	O
s	O
.	O

2	B
‐	I
O	I
##x	I
##ois	I
##oc	I
##ap	I
##roa	I
##te	I
is	O
an	O
intermediate	O
of	O
le	O
##uc	O
##ine	O
metabolism	O
.	O
36	O
Red	O
##uction	O
of	O
BC	O
##AA	O
levels	O
post	O
‐	O
R	O
##Y	O
##GB	O
may	O
be	O
due	O
to	O
reduced	O
protein	O
intake	O
or	O
increased	O
BC	O
##AA	O
cat	O
##ab	O
##olis	O
##m	O
.	O
37	O

Third	O
##ly	O
,	O
for	O
serum	O
differential	O
meta	O
##bol	O
##ites	O
,	O
it	O
indicated	O
d	B
-	I
g	I
##ly	I
##cer	I
##ic	I
acid	I
was	O
related	O
with	O
IL	O
-	O
13	O
(	O
r	O
=	O
−	O
##0	O
.	O
48	O
;	O
P	O
=	O
0	O
.	O
02	O
##6	O
)	O
,	O
N	B
-	I
Met	I
##hyl	I
-	I
DL	I
-	I
al	I
##ani	I
##ne	I
with	O
IL	O
-	O
1	O
##β	O
(	O
r	O
=	O
0	O
.	O
52	O
;	O
P	O
=	O
0	O
.	O
01	O
##4	O
)	O
,	O
u	B
##ric	I
acid	I
with	O
IL	O
-	O
6	O
(	O
r	O
=	O
0	O
.	O
47	O
;	O
P	O
=	O
0	O
.	O
02	O
##6	O
)	O
and	O
IL	O
-	O
8	O
(	O
r	O
=	O
0	O
.	O
48	O
;	O
P	O
=	O
0	O
.	O
02	O
##4	O
)	O
.	O

)	O
of	O
the	O
O	O
##PL	O
##S	O
-	O
D	O
##A	O
model	O
from	O
the	O
pair	O
##wise	O
comparison	O
between	O
the	O
H	O
##BC	O
patients	O
and	O
healthy	O
controls	O
included	O
increasing	O
levels	O
of	O
glucose	S
,	O
g	B
##lu	I
##cona	I
##te	I
,	O
g	B
##ly	I
##cer	I
##ol	I
,	O
p	B
##yr	I
##u	I
##vate	I
,	O
3	B
-	I
h	I
##ydro	I
##xy	I
##is	I
##ova	I
##ler	I
##ate	I
,	O
2	B
-	I
o	I
##x	I
##ois	I
##ole	I
##uc	I
##ine	I
,	O
3	B
-	I
h	I
##ydro	I
##xy	I
##is	I
##ob	I
##ut	I
##yra	I
##te	I
,	O
al	B
##ani	I
##ne	I
,	O
2	B
-	I
p	I
##hos	I
##ph	I
##og	I
##ly	I
##cer	I
##ate	I
,	O
hip	B
##pura	I
##te	I
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
t	B
##ig	I
##ly	I
##l	I
##gly	I
##cine	I
,	O
u	B
##ro	I
##can	I
##ate	I
,	O
ho	B
##mo	I
##ci	I
##tr	I
##ull	I
##ine	I
,	O
thy	B
##mi	I
##dine	I
,	O
in	B
##os	I
##ine	I
,	O
c	B
##it	I
##rac	I
##ona	I
##te	I
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
car	B
##ni	I
##tine	I
,	O
2	B
-	I
amino	I
##adi	I
##pate	I
,	O
th	B
##re	I
##ona	I
##te	I
,	O
p	B
##hen	I
##yla	I
##ce	I
##ty	I
##l	I
##gly	I
##cine	I
,	O
g	B
##lut	I
##ama	I
##te	I
,	O
and	O
4	B
-	I
h	I
##ydro	I
##xy	I
##p	I
##rol	I
##ine	I
and	O
decreasing	O
levels	O
of	O
ta	B
##uri	I
##ne	I
,	O
c	B
##it	I
##ru	I
##llin	I
##e	I
,	O
4	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
,	O
5	B
-	I
h	I
##ydro	I
##xy	I
##ind	I
##ole	I
##ace	I
##tate	I
,	O
v	B
##ali	I
##ne	I
,	O
g	B
##ly	I
##cine	I
,	O
trim	B
##eth	I
##yla	I
##mine	I
n	I
-	I
oxide	I
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
c	B
##ys	I
##tein	I
##e	I
,	O
his	B
##ti	I
##dine	I
,	O
or	B
##ni	I
##thin	I
##e	I
,	O
c	B
##it	I
##rate	I
,	O
g	B
##ly	I
##co	I
##cho	I
##late	I
,	O
met	B
##hi	I

The	O
c	B
##rea	I
##tin	I
##ine	I
is	O
a	O
standard	O
manner	O
to	O
normal	O
##ize	O
the	O
concentrations	O
of	O
urine	O
sample	O
since	O
the	O
ex	O
##cre	O
##tion	O
of	O
c	B
##rea	I
##tin	I
##ine	I
is	O
rather	O
constant	O
over	O
a	O
longer	O
time	O
interval	O
.	O

A	B
##zel	I
##aic	I
acid	I
is	O
a	O
di	B
##car	I
##box	I
##yl	I
##ic	I
acid	I
known	O
to	O
have	O
T	O
##2	O
##DM	O
therapeutic	O
properties	O
and	O
was	O
inverse	O
##ly	O
correlated	O
to	O
diabetes	O
risk	O
in	O
our	O
study	O
;	O
the	O
reduction	O
of	O
a	B
##zel	I
##aic	I
acid	I
may	O
possibly	O
be	O
due	O
to	O
si	O
##m	O
##vas	O
##tat	O
##in	O
-	O
induced	O
de	O
##car	O
##box	O
##yla	O
##tion	O
.	O

D	O
##H	O
:	O
de	B
##hy	I
##dr	I
##o	I
;	O
T	O
##H	O
:	O
te	B
##tra	I
##hy	I
##dr	I
##o	I
;	O
H	O
##SD	O
:	O
h	O
##ydro	O
##xy	O
##ster	O
##oid	O
de	O
##hy	O
##dr	O
##ogen	O
##ase	O
;	O
P	O
##OR	O
:	O
P	O
##45	O
##0	O
o	O
##xi	O
##dor	O
##ed	O
##uc	O
##tase	O
;	O

It	O
is	O
intriguing	O
to	O
note	O
that	O
7	B
##α	I
-	I
h	I
##ydro	I
##xy	I
-	I
3	I
,	I
24	I
-	I
bi	I
##so	I
##x	I
##och	I
##ole	I
##st	I
-	I
4	I
-	I
en	I
-	I
26	I
-	I
o	I
##ic	I
acid	I
(	B
CA	B
_	I
4	I
-	I
7	I
##α	I
-	I
o	I
##l	I
-	I
3	I
,	I
24	I
-	I
di	I
##one	I
)	O
and	O
7	B
##α	I
,	I
24	I
-	I
di	I
##hy	I
##dr	I
##ox	I
##y	I
-	I
3	I
-	I
o	I
##x	I
##och	I
##ole	I
##st	I
-	I
4	I
-	I
en	I
-	I
26	I
-	I
o	I
##ic	I
acid	I
(	B
CA	B
_	I
4	I
-	I
7	I
##α	I
,	I
24	I
-	I
di	I
##ol	I
-	I
3	I
-	I
one	I
)	O
are	O
precursor	O
##s	O
of	O
C	O
_	O
24	O
bi	O
##le	O
acids	O
in	O
the	O
bio	O
##sy	O
##nt	O
##hetic	O
pathway	O
from	O
24	O
(	O
S	O
)	O

Cho	B
##line	I
contributes	O
to	O
tumor	O
cell	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
synthesis	O
,	O
and	O
is	O
integrated	O
into	O
le	B
##ci	I
##thin	I
,	O
a	O
major	O
cell	O
membrane	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
component	O
.	O

After	O
having	O
been	O
v	O
##ortex	O
##ed	O
for	O
10	O
s	O
,	O
samples	O
were	O
applied	O
to	O
St	O
##rata	O
-	O
X	O
##C	O
solid	O
phase	O
extraction	O
(	O
SP	O
##E	O
)	O
columns	O
(	O
60	O
mg	O
/	O
3	O
m	O
##L	O
)	O
(	O
Ph	O
##eno	O
##men	O
##ex	O
,	O
Tor	O
##rance	O
,	O
CA	O
,	O
USA	O
)	O
pre	O
##con	O
##dition	O
##ed	O
with	O
1	O
m	O
##L	O
met	B
##han	I
##ol	I
followed	O
by	O
1	O
m	O
##L	O
0	O
.	O
1	O
%	O
perch	B
##lor	I
##ic	I
acid	I
.	O

Thus	O
,	O
the	O
changes	O
observed	O
could	O
be	O
due	O
to	O
different	O
degrees	O
of	O
ace	B
##tate	I
up	O
##take	O
imp	O
##air	O
##ment	O
by	O
as	O
##tro	O
##cy	O
##tes	O
.	O

al	O
.	O
in	O
##cu	O
##bate	O
##d	O
4	O
-	O
AB	O
##P	O
,	O
A	O
##α	O
##C	O
,	O
2	B
-	I
amino	I
-	I
3	I
-	I
met	I
##hyl	I
##im	I
##ida	I
##zo	I
[	I
4	I
,	I
5	I
-	I
f	I
]	I
q	I
##uin	I
##olin	I
##e	I
(	O
I	O
##Q	O
)	O
,	O
Me	O
##I	O
##Q	O
##x	O
or	O
Ph	O
##IP	O
in	O
freshly	O
culture	O
##d	O
rode	O
##nt	O
he	O
##pa	O
##to	O
##cy	O
##tes	O
or	O
human	O
he	O
##pa	O
##to	O
##cy	O
##tes	O
from	O
eight	O
different	O
donors	O
and	O
q	O
##uant	O
##ified	O
the	O
major	O
d	O
##G	O
-	O
C	O
##8	O
add	O
##uc	O
##ts	O
of	O
these	O
car	O
##cin	O
##ogen	O
##s	O
by	O
HP	O
##LC	O
-	O
L	O
##IT	O
-	O
MS	O
_	O
3	O
.	O

Co	O
##rrel	O
##ation	O
of	O
Δ	O
glucose	S
or	O
fatty	O
acids	O
(	O
FA	O
)	O
vs	O
.	O
Δ	O
body	O
weight	O
.	O

Such	O
changes	O
were	O
parallel	O
##ed	O
by	O
increases	O
in	O
free	O
a	B
##rac	I
##hi	I
##don	I
##ic	I
acid	I
,	O
the	O
precursor	O
to	O
e	B
##ico	I
##san	I
##oids	I
such	O
as	O
pro	B
##sta	I
##g	I
##land	I
##ins	I
.	O

In	O
particular	O
,	O
a	O
genetic	O
defect	O
of	O
the	O
O	O
##CT	O
##N	O
##1	O
and	O
O	O
##CT	O
##N	O
##2	O
of	O
the	O
co	O
##lon	O
has	O
been	O
identified	O
in	O
patients	O
with	O
CD	O
,	O
resulting	O
in	O
altered	O
transportation	O
of	O
mon	B
##oam	I
##ines	I
of	O
the	O
se	B
##rot	I
##oni	I
##n	I
-	I
do	I
##pa	I
##mine	I
system	O
and	O
their	O
precursor	O
##s	O
[	O
]	O
.	O

Met	O
##ab	O
##olo	O
##mic	O
analysis	O
demonstrated	O
an	O
altered	O
metabolic	O
profile	O
in	O
the	O
AC	O
##M	O
from	O
o	O
##bes	O
##e	O
EA	O
##C	O
patients	O
,	O
with	O
significantly	O
increased	O
levels	O
of	O
the	O
g	B
##ly	I
##co	I
##ly	I
##tic	I
product	O
la	B
##ct	I
##ate	I
,	O
suggesting	O
a	O
shift	O
in	O
the	O
flux	O
of	O
g	O
##ly	O
##co	O
##lysis	O
towards	O
la	B
##ct	I
##ate	I
production	O
in	O
v	O
##is	O
##cer	O
##al	O
fat	O
from	O
o	O
##bes	O
##e	O
EA	O
##C	O
patients	O
.	O

Inc	O
##rem	O
##ental	O
value	O
of	O
u	O
##rina	O
##ry	O
my	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
over	O
traditional	O
risk	O
factors	O
for	O
predict	O
##ing	O
non	O
##res	O
##po	O
##nders	O
among	O
the	O
F	O
##S	O
##GS	O
patients	O
.	O

Not	O
##ably	O
,	O
4	O
-	O
h	O
##ydro	O
##xy	O
##phe	O
##ny	O
##lace	O
##tate	O
-	O
3	O
-	O
h	O
##ydro	O
##xy	O
##lase	O
(	O
HP	O
##A	O
##H	O
)	O
,	O
as	O
one	O
of	O
the	O
mon	O
##oo	O
##xy	O
##gen	O
##ases	O
that	O
has	O
been	O
found	O
in	O
various	O
bacteria	O
,	O
can	O
cat	O
##aly	O
##ze	O
the	O
h	O
##ydro	O
##xy	O
##lation	O
of	O
4	O
-	O
HP	O
##A	O
to	O
3	B
,	I
4	I
-	I
di	I
##hy	I
##dr	I
##ox	I
##y	I
##phe	I
##ny	I
##lace	I
##tic	I
acid	I
,	O
which	O
is	O
the	O
initial	O
step	O
in	O
the	O
a	O
##ero	O
##bic	O
degradation	O
pathway	O
of	O
4	O
-	O
HP	O
##A	O
[	O
,	O
]	O
.	O

Inc	O
##reased	O
levels	O
of	O
ta	B
##uri	I
##ne	I
have	O
been	O
reported	O
in	O
the	O
rat	O
brain	O
cortex	O
following	O
para	O
##dox	O
##ical	O
sleep	O
de	O
##p	O
##ri	O
##vation	O
and	O
have	O
been	O
shown	O
to	O
be	O
a	O
act	O
##iva	O
##tor	O
of	O
extra	O
##sy	O
##nap	O
##tic	O
GA	O
##BA	O
(	O
A	O
)	O
receptors	O
in	O
the	O
mouse	O
vent	O
##ro	O
##bas	O
##al	O
th	O
##ala	O
##mus	O
,	O
an	O
area	O
involved	O
in	O
regulating	O
the	O
transitions	O
between	O
sleep	O
and	O
wake	O
##fulness	O
.	O

Also	O
,	O
hip	B
##pura	I
##te	I
(	I
ben	I
##zo	I
##yl	I
##gly	I
##cine	I
)	I
production	O
is	O
mediated	O
via	O
co	O
##en	O
##zy	O
##me	O
A	O
add	O
##uc	O
##t	O
formation	O
,	O
which	O
is	O
mitochondrial	O
(	O
as	O
is	O
the	O
case	O
for	O
all	O
co	O
##en	O
##zy	O
##me	O
A	O
-	O
mediated	O
amino	O
acid	O
con	O
##ju	O
##gation	O
##s	O
)	O
,	O
and	O
therefore	O
is	O
linked	O
indirectly	O
to	O
mitochondrial	O
energy	O
metabolism	O
that	O
powers	O
the	O
reaction	O
.	O

There	O
was	O
no	O
statistical	O
##ly	O
significant	O
association	O
between	O
base	O
##line	O
plasma	O
lip	O
##ido	O
##me	O
and	O
current	O
CD	O
##4	O
+	O
T	O
cell	O
count	O
or	O
duration	S
of	O
known	O
HIV	O
infection	O
(	O
data	O
not	O
shown	O
)	O
.	O

Instead	O
of	O
plasma	O
la	O
##ctic	O
acid	O
##osis	O
,	O
this	O
may	O
be	O
due	O
to	O
la	B
##ctic	I
acid	I
producing	O
bacteria	O
in	O
the	O
oral	O
cavity	O
of	O
HIV	O
/	O
AIDS	O
patients	O
.	O

Fast	O
##ing	O
ve	O
##nous	O
blood	O
was	O
collected	O
in	O
6	O
-	O
m	O
##l	O
lit	B
##hium	I
he	I
##par	I
##in	I
tubes	O
and	O
stored	O
at	O
4	O
°C	O
within	O
10	O
min	O
.	O

Previous	O
investigations	O
on	O
the	O
metabolism	O
of	O
alpha	B
-	I
P	I
##EP	I
were	O
performed	O
by	O
Man	O
##ier	O
et	O
al	O
.	O
using	O
pH	O
##LM	O
and	O
p	O
##S	O
##9	O
as	O
well	O
as	O
S	O
##wo	O
##rt	O
##wood	O
et	O
al	O
.	O
using	O
primary	O
human	O
he	O
##pa	O
##to	O
##cy	O
##tes	O
(	O
P	O
##H	O
##H	O
)	O
and	O
human	O
urine	O
.	O

Since	O
the	O
meta	O
##bol	O
##ite	O
standard	O
was	O
not	O
available	O
to	O
us	O
,	O
q	O
##uant	O
##ification	O
of	O
this	O
meta	O
##bol	O
##ite	O
was	O
made	O
using	O
standard	O
curves	O
generated	O
with	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
.	O

Except	O
for	O
the	O
un	O
##sat	O
##ura	O
##ted	O
derivative	O
of	O
C	O
##24	O
##C	O
##er	O
,	O
C	B
##24	I
:	I
1	I
##C	I
##er	I
(	O
2	O
##E	O
)	O
,	O
all	O
serum	O
Ce	O
##r	O
'	O
s	O
assessed	O
were	O
up	O
##re	O
##gu	O
##lated	O
in	O
the	O
serum	O
of	O
HC	O
##C	O
patients	O
as	O
compared	O
to	O
patients	O
with	O
liver	O
c	O
##ir	O
##r	O
##hos	O
##is	O
(	O
P	O
<	O
0	O
.	O
00	O
##1	O
)	O
.	O

Re	O
##lative	O
g	B
##lut	I
##ama	I
##te	I
levels	O
do	O
not	O
significantly	O
differ	O
between	O
lung	O
cancer	O
stages	O
(	O
p	O
value	O
=	O
0	O
.	O
3	O
)	O
:	O
stage	O
I	O
0	O
.	O
161	O
(	O
SD	O
0	O
.	O
159	O
)	O
,	O
stage	O
II	O
0	O
.	O
115	O

The	O
discrimination	O
between	O
the	O
successive	O
in	O
##tra	O
##cellular	O
meta	O
##bol	O
##ites	O
resulting	O
from	O
the	O
conversion	O
of	O
N	O
##RT	O
##I	O
to	O
N	B
##RT	I
##I	I
-	I
mon	I
##op	I
##hos	I
##phate	I
(	O
MP	O
)	O
,	O
N	B
##RT	I
##I	I
-	I
dip	I
##hos	I
##phate	I
(	O
D	O
##P	O
)	O
,	O
and	O
N	O
##RT	O
##I	O
-	O
T	O
##P	O
was	O
required	O
,	O
since	O
the	O
N	O
##RT	O
##I	O
-	O
T	O
##P	O
are	O
responsible	O
for	O
anti	O
##vir	O
##al	O
efficacy	O
,	O
while	O
the	O
N	O
##RT	O
##I	O
-	O
MP	O
such	O
as	O
Z	O
##D	O
##V	O
may	O
be	O
associated	O
with	O
toxicity	O
.	O

Sc	O
##att	O
##er	O
plots	O
of	O
PC	O
##A	O
of	O
overall	O
meta	O
##bol	O
##omi	O
##cs	O
profiles	O
indicated	O
that	O
the	O
high	O
glucose	S
group	O
does	O
not	O
overlap	O
with	O
any	O
other	O
group	O
,	O
indicating	O
that	O
HK	O
-	O
2	O
cells	O
have	O
a	O
distinct	O
meta	O
##bol	O
##omi	O
##c	O
profile	O
in	O
response	O
to	O
high	O
glucose	S
exposure	O
.	O

Moreover	O
,	O
we	O
firstly	O
found	O
other	O
two	O
K	O
##B	O
,	O
A	O
##c	O
##A	O
##c	O
and	O
ace	B
##tone	I
,	O
were	O
also	O
up	O
-	O
regulated	O
in	O
re	O
##ct	O
##al	O
cancer	O
tissues	O
,	O
with	O
increases	O
of	O
1	O
.	O
2	O
and	O
1	O
.	O
1	O
folds	O
,	O
respectively	O
.	O

The	O
smart	O
is	O
##oto	O
##pe	O
tag	O
,	O
_	O
15	O
N	B
-	I
ch	I
##ola	I
##mine	I
,	O
designed	O
,	O
developed	O
and	O
used	O
in	O
this	O
s	O
##tu	O
`	O
d	O
##y	O
retains	O
all	O
the	O
characteristics	O
of	O
the	O
_	O
15	O
N	B
-	I
ethanol	I
##amine	I
tag	O
including	O
the	O
so	O
##lub	O
##ility	O
of	O
the	O
tag	O
##ged	O
meta	O
##bol	O
##ites	O
in	O
a	O
##que	O
##ous	O
media	O
,	O
large	O
one	O
-	O
bond	O
J	O
-	O
coupling	O
between	O
_	O
1	O
H	O
and	O
_	O
15	O
N	O
of	O
[UNK]	O
Hz	O
for	O
efficient	O
polar	O
##ization	O
transfer	O
between	O
_	O
1	O
H	O
and	O
_	O
15	O
N	O
nuclei	O
,	O
and	O
wide	O
chemical	O
shift	O
di	O
##sper	O
##sion	O
for	O
different	O
meta	O
##bol	O
##ites	O
in	O
the	O
resulting	O
2D	O
N	O
##MR	O
s	O
##pect	O
##ra	O
.	O

Con	O
##cent	O
##rations	O
of	O
E	O
_	O
2	O
and	O
test	B
##osterone	I
were	O
within	O
clinical	O
##ly	O
normal	O
ranges	O
.	O

The	O
six	O
est	O
##rogen	O
##s	O
analyzed	O
in	O
this	O
study	O
,	O
E	B
##2	I
,	I
16	I
##α	I
-	I
OH	I
-	I
E	I
##2	I
,	I
4	I
-	I
met	I
##ho	I
##xy	I
(	I
Me	I
##O	I
)	I
-	I
E	I
##2	I
,	I
2	I
-	I
Me	I
##O	I
-	I
E	I
##2	I
,	I
4	I
-	I
h	I
##ydro	I
##xy	I
(	O
OH	O
)	O
-	O
E	O
##2	O
and	O
2	B
-	I
OH	I
-	I
E	I
##2	I
were	O
purchased	O
from	O
St	O
##eral	O
##oids	O
Inc	O
.	O
(	O
Newport	O
,	O
R	O
##I	O
)	O
.	O

Next	O
,	O
mixture	O
##s	O
of	O
200	O
μ	O
##L	O
of	O
serum	O
and	O
400	O
μ	O
##L	O
of	O
sa	B
##line	I
solution	O
(	O
prepared	O
from	O
0	O
.	O
9	O
%	O
Na	O
##C	O
##l	O
,	O
15	O
%	O
D	O
_	O
2	O
O	O
and	O
3	O
m	O
##M	O
T	O
##SP	O
)	O
were	O
mixed	O
again	O
.	O

The	O
mixture	O
was	O
cent	O
##ri	O
##fu	O
##ged	O
,	O
filtered	O
and	O
the	O
resulting	O
yellow	O
est	B
##rone	I
met	O
##hi	O
##de	O
solution	O
was	O
used	O
for	O
recording	O
UV	O
and	O
mass	O
s	O
##pect	O
##ra	O
and	O
stability	O
studies	O
.	O

In	O
addition	O
,	O
when	O
these	O
t	O
##rig	O
##ly	O
##cer	O
##ide	O
‐	O
rich	O
V	O
##LD	O
##L	O
particles	O
undergo	O
further	O
lip	O
##oly	O
##sis	O
,	O
they	O
give	O
rise	O
to	O
L	B
##D	I
##L	I
ch	I
##ole	I
##ster	I
##ol	I
.	O

It	O
is	O
,	O
thus	O
,	O
possible	O
that	O
the	O
meta	O
##bol	O
##ite	O
changes	O
noted	O
from	O
intermediate	O
to	O
late	O
AM	O
##D	O
in	O
Co	O
##im	O
##bra	O
may	O
be	O
at	O
least	O
partially	O
due	O
to	O
heart	O
disease	O
,	O
particularly	O
regarding	O
ace	B
##to	I
##ace	I
##tate	I
and	O
β	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
levels	O
,	O
since	O
his	B
##ti	I
##dine	I
variations	O
(	O
common	O
to	O
both	O
co	O
##hor	O
##ts	O
)	O
seem	O
to	O
constitute	O
an	O
AM	O
##D	O
-	O
related	O
feature	O
.	O

A	O
representative	O
ion	O
ch	O
##roma	O
##to	O
##gram	O
of	O
the	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
meta	O
##bol	O
##ite	O
is	O
shown	O
in	O
.	O

The	O
distributions	O
of	O
S	O
##G	O
-	O
corrected	O
u	O
##rina	O
##ry	O
p	B
##ht	I
##hala	I
##te	I
meta	O
##bol	O
##ite	O
and	O
is	B
##op	I
##ros	I
##tan	I
##e	I
concentrations	O
(	O
ng	O
/	O
m	O
##L	O
)	O
as	O
well	O
as	O
sperm	O
m	O
##t	O
##D	O
##NA	O
##c	O
##n	O
(	O
ratio	O
of	O
m	O
##t	O
##D	O
##NA	O
copies	O
per	O
nuclear	O
DNA	O
copies	O
)	O
and	O
m	O
##t	O
##D	O
##NA	O
##del	O
(	O
percent	O
of	O
m	O
##t	O
##D	O
##NA	O
del	O
##eti	O
##ons	O
per	O
total	O
m	O
##t	O
##D	O
##NA	O
copies	O
)	O
for	O
male	O
partners	O
are	O
shown	O
in	O
.	O

Initial	O
experiments	O
were	O
carried	O
out	O
with	O
un	O
##la	O
##bel	O
##ed	O
glucose	S
,	O
followed	O
by	O
full	O
meta	O
##bol	O
##ite	O
profile	O
experiments	O
using	O
[	B
U	I
-	I
_	I
13	I
C	I
]	I
-	I
glucose	I
.	O

In	O
addition	O
to	O
u	O
##rina	O
##ry	O
p	O
-	O
c	O
##res	O
##ol	O
,	O
found	O
elevated	O
in	O
these	O
same	O
urine	O
samples	O
both	O
here	O
(	O
Fi	O
##g	O
.	O
)	O
and	O
previously	O
using	O
a	O
different	O
technology	O
,	O
we	O
also	O
detect	O
a	O
significant	O
increase	O
in	O
in	B
##do	I
##le	I
derivatives	O
of	O
bacterial	O
try	B
##pt	I
##op	I
##han	I
including	O
in	O
##do	O
##ly	O
##l	O
3	O
-	O
ace	O
##tic	O
acid	O
,	O
in	B
##dox	I
##yl	I
su	I
##lf	I
##ate	I
,	O
and	O
most	O
prominently	O
,	O
in	B
##do	I
##ly	I
##l	I
la	I
##ct	I
##ate	I
(	O
Fi	O
##g	O
.	O

Sur	O
##p	O
##rising	O
##ly	O
,	O
neither	O
fast	O
##ing	O
glucose	S
concentration	O
,	O
H	O
##OM	O
##A	O
-	O
I	O
##R	O
,	O
insulin	O
,	O
L	O
##n	O
##S	O
_	O
I	O
,	O
nor	O
H	O
##b	O
##A	O
##1	O
##c	O
were	O
related	O
to	O
the	O
fast	O
##ing	O
C	O
##2	O
concentrations	O
,	O
potentially	O
due	O
to	O
the	O
smaller	O
sample	O
size	O
in	O
the	O
present	O
study	O
compared	O
to	O
previous	O
investigations	O
.	O

Experimental	O
conditions	O
for	O
measuring	O
in	O
##hibition	O
of	O
micro	O
##so	O
##mal	O
C	O
##YP	O
##45	O
##0	O
activity	O
by	O
4	B
-	I
amino	I
##py	I
##rid	I
##ine	I
.	O

Extra	O
##cted	O
meta	O
##bol	O
##ites	O
were	O
e	O
##va	O
##porated	O
under	O
a	O
stream	O
of	O
N	O
_	O
2	O
at	O
60	O
°C	O
and	O
re	O
##con	O
##stituted	O
in	O
100	O
μ	O
##L	O
of	O
D	B
##MS	I
##O	I
prior	O
to	O
analysis	O
.	O

B	O
##rief	O
##ly	O
,	O
the	O
M1	O
##5	O
E	O
.	O
co	O
##li	O
cells	O
harbor	O
##ing	O
expression	O
vector	O
were	O
grown	O
at	O
37	O
##°	O
##C	O
in	O
Lu	O
##ria	O
br	O
##oth	O
(	O
L	O
##B	O
)	O
containing	O
am	O
##pic	O
##ill	O
##in	O
and	O
ka	B
##nam	I
##y	I
##cin	I
until	O
O	O
##D	O
_	O
600	O
reached	O
0	O
.	O
6	O
.	O

G	B
##uan	I
##id	I
##ino	I
##su	I
##cci	I
##nate	I
,	O
trim	B
##eth	I
##yla	I
##mine	I
N	I
-	I
oxide	I
,	O
3	B
-	I
met	I
##hyl	I
##his	I
##ti	I
##dine	I
,	O
c	B
##yt	I
##id	I
##ine	I
,	O
and	O
u	B
##rid	I
##ine	I
are	O
ones	O
of	O
the	O
earliest	O
u	O
##rem	O
##ic	O
to	B
##xin	I
##s	I
whose	O
toxicity	O
are	O
identified	O
_	O
,	O
.	O

(	O
a	O
)	O
Per	O
##cent	O
blood	O
glucose	S
reduction	O
of	O
di	B
##ch	I
##lor	I
##ome	I
##than	I
##e	I
extract	O
at	O
25	O
,	O
50	O
,	O
100	O
,	O
and	O
200	O
mg	O
/	O
kg	O
body	O
weight	O
taken	O
at	O
0	O
.	O
5	O
h	O
(	O
b	O
)	O
Per	O
##cent	O
blood	O
glucose	S
reduction	O
of	O
di	B
##ch	I
##lor	I
##ome	I
##than	I
##e	I
extract	O
at	O
25	O
,	O
50	O
,	O
100	O
,	O
and	O
200	O
mg	O
/	O
kg	O
body	O
weight	O
taken	O
at	O
1	O
h	O
(	O
c	O
)	O
Per	O
##cent	O
blood	O
glucose	S
reduction	O
of	O
di	B
##ch	I
##lor	I
##ome	I
##than	I
##e	I
extract	O
at	O
25	O
,	O
50	O
,	O
100	O
,	O
and	O
200	O
mg	O
/	O
kg	O
body	O
weight	O
taken	O
at	O
1	O
.	O
5	O
h	O
(	O
d	O
)	O
Per	O
##cent	O
blood	O
glucose	S
reduction	O
of	O
di	B
##ch	I
##lor	I
##ome	I
##than	I
##e	I
extract	O
at	O
25	O
,	O
50	O
,	O
100	O
,	O
and	O
200	O
mg	O
/	O
kg	O
body	O
weight	O
taken	O
at	O
2	O
h	O
(	O
e	O
)	O
Per	O
##cent	O
blood	O
glucose	S
reduction	O
of	O
di	B
##ch	I
##lor	I
##ome	I
##than	I
##e	I
extract	O
at	O
25	O
,	O
50	O
,	O
100	O
,	O
and	O
200	O
mg	O
/	O
kg	O
body	O
weight	O
taken	O
at	O
2	O
.	O
5	O
h	O

Also	O
in	O
urine	O
3	O
-	O
O	O
-	O
g	O
##lu	O
##cu	O
##ron	O
##ide	O
di	B
##os	I
##met	I
##in	I
is	O
the	O
main	O
meta	O
##bol	O
##ite	O
,	O
while	O
the	O
7	O
-	O
O	O
-	O
is	O
##omer	O
is	O
absent	O
;	O
interesting	O
##ly	O
,	O
the	O
levels	O
of	O
dig	O
##lu	O
##cu	O
##ron	O
##ide	O
were	O
more	O
relevant	O
in	O
urine	O
than	O
in	O
plasma	O
.	O

(	O
2018	O
)	O
reported	O
the	O
free	O
radical	O
s	O
##ca	O
##ven	O
##ging	O
potential	O
of	O
met	B
##han	I
##ol	I
-	I
extract	I
of	O
F	O
.	O
later	O
##iti	O
##um	O
end	O
##op	O
##hy	O
##te	O
of	O
R	O
##hi	O
##zo	O
##ph	O
##ora	O
m	O
##uc	O
##rona	O
##ta	O
.	O

B	O
##rief	O
##ly	O
,	O
PC	O
##R	O
samples	O
were	O
applied	O
to	O
p	B
##oly	I
##ac	I
##ryl	I
##ami	I
##de	I
gel	O
##s	O
in	O
1	O
##×	O
T	O
##A	O
##E	O
with	O
a	O
u	B
##rea	I
and	O
form	B
##ami	I
##de	I
den	O
##at	O
##uring	O
gradient	O
[	O
7	O
M	O
u	B
##rea	I
and	O
40	O
%	O
(	O
v	O
/	O
v	O
)	O
form	B
##ami	I
##de	I
correspond	O
##ed	O
to	O
the	O
100	O
%	O
gradient	O
]	O
as	O
described	O
by	O
.	O

There	O
were	O
1	O
,	O
278	O
(	O
over	O
70	O
%	O
)	O
common	O
features	O
,	O
with	O
39	O
##1	O
features	O
unique	O
to	O
the	O
met	B
##han	I
##ol	I
method	O
and	O
55	O
##3	O
features	O
unique	O
to	O
met	B
##han	I
##ol	I
-	I
ethanol	I
method	O
.	O

The	O
precursor	O
##s	O
of	O
o	O
##ct	O
##ened	O
##io	O
##ic	O
acid	O
are	O
de	B
##cene	I
##dio	I
##ic	I
acid	I
and	O
do	O
##de	O
##cene	O
##dio	O
##ic	O
acid	O
.	O

Primary	O
bi	O
##le	O
acids	O
(	O
blue	O
oval	O
##s	O
;	O
ch	B
##olic	I
acid	I
(	O
CA	O
)	O
and	O
ch	B
##eno	I
##de	I
##ox	I
##ych	I
##olic	I
acid	I
(	O
CD	O
##CA	O
)	O
)	O
are	O
produced	O
by	O
end	O
##ogen	O
##ous	O
enzymes	O
in	O
the	O
liver	O
and	O
are	O
modified	O
by	O
bacteria	O
of	O
the	O
genus	O
C	O
##los	O
##tri	O
##dia	O
co	O
##lon	O
##izing	O
the	O
gut	O
to	O
form	O
secondary	O
bi	O
##le	O
acids	O
(	O
yellow	O
oval	O
##s	O
;	O
lit	B
##ho	I
##cho	I
##lic	I
acid	I
(	O
L	O
##CA	O
)	O
and	O
de	B
##ox	I
##ych	I
##olic	I
acid	I
)	O
.	O

The	O
increased	O
level	O
of	O
gal	B
##act	I
##ose	I
may	O
be	O
related	O
to	O
its	O
participation	O
in	O
g	O
##ly	O
##co	O
##lysis	O
.	O

Ana	O
##log	O
##ous	O
to	O
previous	O
work	O
,	O
the	O
first	O
and	O
second	O
is	O
##omer	O
##s	O
probably	O
resulted	O
from	O
c	O
##is	O
and	O
trans	O
addition	O
of	O
N	O
##AC	O
to	O
the	O
di	B
##ol	I
e	I
##pox	I
##ides	I
,	O
but	O
further	O
characterization	O
was	O
not	O
pursued	O
.	O

Extreme	O
values	O
were	O
defined	O
as	O
those	O
for	O
which	O
the	O
sum	O
of	O
all	O
est	O
##rogen	O
##s	O
and	O
est	B
##rogen	I
meta	O
##bol	O
##ites	O
was	O
either	O
lower	O
than	O
the	O
25th	O
percent	O
##ile	O
of	O
the	O
distribution	O
minus	O
three	O
times	O
the	O
inter	O
##qua	O
##rt	O
##ile	O
range	O
,	O
or	O
higher	O
than	O
the	O
75	O
##th	O
percent	O
##ile	O
of	O
the	O
distribution	O
plus	O
three	O
times	O
the	O
inter	O
##qua	O
##rt	O
##ile	O
range	O
.	O

Thus	O
,	O
alter	O
##ation	O
in	O
g	O
##ly	O
##co	O
##lysis	O
and	O
the	O
synthesis	O
and	O
degradation	O
of	O
k	B
##eton	I
##e	I
bodies	O
is	O
consistent	O
with	O
an	O
alter	O
##ation	O
in	O
energy	O
generation	O
.	O

After	O
a	O
follow	O
-	O
up	O
of	O
2	O
years	O
,	O
a	O
subgroup	O
of	O
16	O
participants	O
underwent	O
a	O
second	O
O	O
##G	O
##TT	O
to	O
assess	O
longitudinal	O
changes	O
in	O
glucose	S
control	O
and	O
index	O
##es	O
of	O
insulin	O
sensitivity	O
and	O
secret	O
##ion	O
.	O

S	B
##phi	I
##ngo	I
##lip	I
##ids	I
were	O
an	O
##not	O
##ated	O
as	O
<	O
lip	O
##id	O
abbreviation	O
>	O
<	B
s	I
##phi	I
##ngo	I
##id	I
base	O
residue	O
>	O
/	O
<	O
fatty	O
a	O
##cy	O
##l	O
residue	O
>	O
.	O

For	O
instance	O
,	O
a	O
stable	O
is	O
##oto	O
##pic	O
plateau	O
was	O
not	O
attained	O
in	O
all	O
P	O
##H	O
patients	O
,	O
and	O
the	O
rate	O
of	O
appearance	O
of	O
o	B
##xa	I
##late	I
was	O
higher	O
than	O
expected	O
and	O
did	O
not	O
match	O
24	O
-	O
h	O
o	B
##xa	I
##late	I
ex	O
##cre	O
##tion	O
rates	O
in	O
the	O
healthy	O
volunteers	O
.	O

v	O
##ii	O
,	O
Na	O
##H	O
,	O
t	B
##rie	I
##thy	I
##l	I
##ph	I
##os	I
##phon	I
##oa	I
##ce	I
##tate	I
,	O
T	O
##HF	O
,	O
0	O

Internal	O
standards	O
(	O
he	O
##pta	O
##de	O
##con	O
##oi	O
##c	O
acid	O
and	O
met	B
##hyl	I
he	I
##pta	I
##de	I
##cano	I
##ate	I
)	O
as	O
well	O
as	O
saturated	O
and	O
un	O
##sat	O
##ura	O
##ted	O
fatty	O
acids	O
used	O
in	O
the	O
study	O
were	O
purchased	O
from	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
(	O
St	O
.	O
Louis	O
,	O
M	O
##O	O
,	O
U	O
.	O
S	O
.	O
A	O
)	O
.	O

In	O
our	O
series	O
,	O
the	O
most	O
significant	O
metabolic	O
alterations	O
of	O
G	O
##C	O
involve	O
the	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
,	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
##s	I
and	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
pathway	O
.	O

Sam	O
##ples	O
for	O
U	O
##HP	O
##LC	O
/	O
H	O
##R	O
##MS	O
analysis	O
were	O
cent	O
##ri	O
##fu	O
##ged	O
(	O
3	O
,	O
000	O
rpm	O
for	O
5	O
min	O
)	O
and	O
then	O
di	O
##lut	O
##ed	O
in	O
dei	O
##onized	O
water	O
(	O
di	O
##lution	O
1	B
/	I
5	I
:	I
20	I
μ	I
##l	I
of	O
urine	O
in	O
80	O
μ	O
##l	O
of	O
water	O
)	O
prior	O
to	O
analysis	O
.	O

3	O
-	O
HP	O
##MA	O
and	O
N	B
-	I
ace	I
##ty	I
##l	I
-	I
[	I
_	I
2	I
H	I
_	I
3	I
]	I
-	I
S	I
-	I
(	I
4	I
-	I
h	I
##ydro	I
##xy	I
##but	I
-	I
2	I
-	I
y	I
##l	I
)	I
-	I
l	I
-	I
c	I
##ys	I
##tein	I
##e	I
were	O
purchased	O
from	O
Toronto	O
Research	O
Chemical	O
##s	O
,	O
Toronto	O
,	O
Ontario	O
,	O
Canada	O
.	O

After	O
30	O
,	O
60	O
and	O
120	O
min	O
,	O
the	O
concentration	O
of	O
glucose	S
in	O
the	O
cell	O
culture	O
medium	O
of	O
r	O
##H	O
##la	O
-	O
treated	O
S	O
##9	O
cells	O
decreased	O
by	O
1	O
.	O
4	O
mm	O
##ol	O
/	O
l	O
,	O
1	O
.	O
8	O
mm	O
##ol	O
/	O
l	O
and	O
2	O
.	O
8	O
mm	O
##ol	O
/	O
l	O
,	O
respectively	O
.	O

×	O
25	O
cm	O
C	O
_	O
18	O
reverse	O
-	O
phase	O
)	O
was	O
e	O
##qui	O
##li	O
##bra	O
##ted	O
in	O
10	O
m	O
##M	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
in	O
30	O
%	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
.	O

Ser	O
##um	O
sample	O
spike	O
##d	O
with	O
4	O
μ	O
##M	O
of	O
l	B
##ino	I
##len	I
##ic	I
acid	I
and	O
a	B
##rac	I
##hi	I
##don	I
##ic	I
acid	I
(	O
black	O
line	O
)	O
and	O
serum	O
samples	O
analyzed	O
without	O
s	O
##pi	O
##king	O
fatty	O
acids	O
(	O
blue	O
line	O
)	O
.	O

HD	O
##L	O
-	O
c	O
was	O
negatively	O
correlated	O
with	O
the	O
changes	O
in	O
dim	B
##eth	I
##yl	I
##gly	I
##cine	I
and	O
l	B
##ys	I
##ine	I
(	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
while	O
L	O
##D	O
##L	O
-	O
c	O
was	O
positively	O
associated	O
with	O
the	O
post	O
##pra	O
##ndi	O
##al	O
changes	O
in	O
se	B
##rine	I
and	O
c	B
##rea	I
##tin	I
##ine	I
(	O
r	O
:	O
0	O
.	O
35	O
and	O
0	O
.	O
37	O
##9	O
,	O
respectively	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Furthermore	O
,	O
we	O
adjusted	O
for	O
c	B
##ys	I
##tat	I
##in	I
C	O
concentrations	O
and	O
found	O
that	O
ID	O
##O	O
-	O
T	O
##M	O
,	O
but	O
not	O
other	O
T	O
##Ms	O
such	O
as	O
in	B
##dox	I
##ys	I
##ulf	I
##ate	I
,	O
remained	O
strongly	O
predict	O
##ive	O
of	O
pulmonary	O
hem	O
##ody	O
##nam	O
##ic	O
measurements	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
create	O
a	O
model	O
using	O
amino	O
acids	O
and	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
for	O
lung	O
cancer	O
screening	O
.	O

Met	O
##hyl	O
##ated	O
2	O
-	O
h	O
##ydro	O
##xy	O
##lated	O
E	O
##M	O
may	O
actually	O
in	O
##hibit	O
met	O
##hyl	O
##ation	O
of	O
4	B
-	I
h	I
##ydro	I
##xy	I
##lated	I
cat	I
##ech	I
##ols	I
.	O

The	O
results	O
showed	O
that	O
the	O
differential	O
##ly	O
expressed	O
meta	O
##bol	O
##ites	O
mainly	O
participated	O
in	O
the	O
biological	O
metabolic	O
processes	O
of	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##let	I
##han	I
##ola	I
##mine	I
bio	O
##sy	O
##nt	O
##hesis	O
,	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
bio	O
##sy	O
##nt	O
##hesis	O
,	O
pan	B
##to	I
##the	I
##nate	I
and	O
Co	O
##A	O
bio	O
##sy	O
##nt	O
##hesis	O
,	O
mitochondrial	O
beta	O
-	O
oxidation	O
of	O
short	O
-	O
chain	O
saturated	O
fatty	O
acids	O
,	O
mitochondrial	O
beta	O
-	O
oxidation	O
of	O
long	O
-	O
chain	O
saturated	O
fatty	O
acids	O
and	O
s	B
##phi	I
##ngo	I
##lip	I
##id	I
metabolism	O
.	O

In	O
detail	O
for	O
S	O
##9	O
cells	O
,	O
the	O
glucose	S
concentration	O
decreased	O
from	O
11	O
.	O
8	O
mm	O
##ol	O
/	O
l	O
to	O
10	O
.	O
5	O
,	O
10	O
.	O
4	O
and	O
9	O
.	O
6	O
mm	O
##ol	O
/	O
l	O
at	O
30	O
,	O
60	O
and	O
120	O
min	O
,	O
respectively	O
.	O

Sol	O
##vent	O
##s	O
di	B
##ch	I
##lor	I
##ome	I
##than	I
##e	I
(	O
CH	O
_	O
2	O
C	O
##l	O
_	O
2	O
)	O
,	O
met	B
##han	I
##ol	I
(	O
Me	O
##OH	O
)	O
,	O
te	B
##tra	I
##hy	I
##dr	I
##of	I
##ura	I
##n	I
(	O
T	O
##HF	O
)	O
,	O
p	B
##yr	I
##id	I
##ine	I
(	O
P	O
##Y	O
)	O
,	O
et	B
##hyl	I
ace	I
##tate	I
(	O
E	O
##t	O
##OA	O
##c	O
)	O
,	O
he	B
##xa	I
##ne	I
(	O
H	O
##EX	O
)	O
and	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
(	O
AC	O
##N	O
)	O
were	O
obtained	O
from	O
S	O
##IN	O
##TO	O
##R	O
##GA	O
##N	O
S	O
.	O
A	O
.	O
(	O
Buenos	O
Aires	O
,	O
Argentina	O
)	O
.	O

shows	O
that	O
log	O
co	B
##tin	I
##ine	I
un	O
-	O
normal	O
##ised	O
has	O
a	O
significant	O
correlation	O
with	O
log	O
3	O
-	O
EP	O

Micro	O
##so	O
##mal	O
in	O
##cu	O
##bation	O
##s	O
were	O
conducted	O
in	O
du	O
##plicate	O
at	O
37	O
±	O
1	O
##°	O
##C	O
in	O
200	O
μ	O
##L	O
volumes	O
of	O
in	O
##cu	O
##bation	O
buffer	O
(	O
pH	O
7	O
.	O
4	O
)	O
consisting	O
of	O
high	O
purity	O
water	O
,	O
potassium	B
phosphate	I
(	O
50	O
m	O
##M	O
)	O
,	O
M	O
##g	O
##C	O
##l	O
_	O
2	O
(	O
3	O
m	O
##M	O
)	O
,	O
E	O
##D	O
##TA	O
(	O
1	O
m	O
##M	O
)	O
and	O
the	O
marker	O
substrates	O
,	O
as	O
shown	O
in	O
.	O

We	O
observed	O
significantly	O
lower	O
mac	O
##rop	O
##hage	O
inflammatory	O
protein	B
-	I
1	I
##α	I
in	O
moderate	O
cannabis	S
users	O
compared	O
to	O
levels	O
in	O
non	O
##can	O
##na	O
##bis	O
users	O
(	O
P	O
=	O
.	O
02	O
##2	O
;	O
)	O
,	O
but	O
no	O
evidence	O
of	O
a	O
dose	B
-	I
response	I
effect	O
.	O

Para	B
##ce	I
##tam	I
##ol	I
–	I
g	I
##lu	I
##cu	I
##ron	I
##ide	I
was	O
q	O
##uant	O
##ified	O
based	O
on	O
the	O
resonance	O
at	O
5	O
.	O
10	O
pp	O
##m	O
(	O
d	O
,	O
7	O
.	O
1	O
Hz	O
)	O
;	O
for	O
other	O
compounds	O
the	O
signal	O
with	O
high	O
intensity	O
and	O
low	O
degree	O
of	O
overlapping	O
was	O
chosen	O
for	O
q	O
##uant	O
##ification	O
.	O

The	O
correlation	O
coefficients	O
for	O
the	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
concentrations	O
in	O
sperm	O
with	O
those	O
in	O
seminal	O
plasma	O
are	O
presented	O
in	O
.	O

It	O
should	O
also	O
be	O
mentioned	O
that	O
in	O
the	O
present	O
study	O
we	O
also	O
observed	O
a	O
positive	O
correlation	O
between	O
ma	B
##lt	I
##ose	I
intake	O
and	O
total	O
grain	O
and	O
whole	O
grain	O
intake	O
(	O
data	O
not	O
shown	O
)	O
which	O
suggests	O
that	O
the	O
main	O
source	O
of	O
ma	B
##lt	I
##ose	I
in	O
our	O
patients	O
could	O
have	O
been	O
grain	O
or	O
grain	O
products	O
.	O

The	O
extracted	O
ion	O
ch	O
##roma	O
##to	O
##gram	O
##s	O
for	O
a	O
few	O
typical	O
car	B
##box	I
##yl	I
##ic	I
acids	I
detected	O
in	O
serum	O
with	O
_	O
15	O
N	B
-	I
ch	I
##ola	I
##mine	I
tag	O
are	O
shown	O
in	O
the	O
.	O

The	O
mean	O
P	O
##K	O
plasma	O
curves	O
of	O
di	B
##os	I
##met	I
##in	I
obtained	O
from	O
subjects	O
treated	O
oral	O
##ly	O
with	O
di	O
##os	O
##min	O
(	O
450	O
mg	O
)	O
are	O
presented	O
in	O
Fi	O
##g	O
.	O

However	O
,	O
se	B
##rine	I
and	O
g	B
##ly	I
##cine	I
concentrations	O
were	O
higher	O
with	O
increasing	O
activity	O
measures	O
.	O

Lower	O
base	O
##line	O
levels	O
of	O
x	B
##ant	I
##hine	I
(	O
p	O
<	O
0	O
.	O
000	O
##1	O
,	O
q	O
<	O
0	O
.	O
000	O
##6	O
##8	O
)	O
,	O
2	B
-	I
h	I
##ydro	I
##xy	I
##vale	I
##ric	I
acid	I
(	O
p	O
<	O
0	O
.	O
000	O
##1	O
,	O
q	O
<	O
0	O
.	O
00	O
##13	O
)	O
,	O
su	B
##cci	I
##nic	I
acid	I
(	O
p	O
<	O
0	O
.	O
000	O
##9	O
,	O
q	O
<	O
0	O
.	O
01	O
##7	O
)	O
and	O
s	B
##te	I
##ari	I
##c	I
acid	I
(	O
p	O
<	O
0	O
.	O
00	O
##39	O
,	O
q	O
<	O
0	O
.	O
03	O
##7	O
)	O
were	O
all	O
significantly	O
correlated	O
with	O
greater	O
L	O
##D	O
##L	O
-	O
C	O
response	O
.	O

The	O
residual	O
water	O
signal	O
in	O
the	O
regions	O
of	O
δ	O
4	O
.	O
20	O
–	O
5	O
.	O
20	O
was	O
discarded	O
prior	O
to	O
data	O
analyses	O
together	O
with	O
ethanol	S
resonance	O
##s	O
(	O
δ	O
1	O
.	O
14	O
–	O
1	O
.	O
18	O
,	O
δ	O
3	O
.	O
62	O
–	O
3	O
.	O
70	O
)	O
,	O
which	O
were	O
probably	O
introduced	O
during	O
sample	O
collections	O
.	O

Am	O
##ino	O
acid	O
derived	O
compounds	O
significantly	O
associated	O
with	O
em	O
##phy	O
##se	O
##ma	O
included	O
le	B
##uc	I
##ine	I
and	O
l	B
##ys	I
##ine	I
.	O

Similarly	O
,	O
pro	B
##line	I
,	O
p	B
##yr	I
##og	I
##lut	I
##ama	I
##te	I
,	O
la	B
##ct	I
##ate	I
,	O
and	O
g	B
##lut	I
##ama	I
##te	I
at	O
the	O
elevated	O
level	O
also	O
demonstrated	O
increased	O
risk	O
for	O
developing	O
c	O
##er	O
##vic	O
##al	O
cancer	O
from	O
normal	O
(	O
OR	O
range	O
24	O
.	O
52	O
–	O
34	O
.	O
22	O
;	O
p	O
for	O
trend	O
<	O
0	O
.	O
000	O
##9	O
)	O
.	O

The	O
sensitivity	O
and	O
specific	O
##ity	O
of	O
the	O
plasma	O
ne	B
##r	I
##von	I
##ic	I
acid	I
levels	O
that	O
disc	O
##rim	O
##inated	O
between	O
patients	O
with	O
MD	O
##D	O
and	O
controls	O
were	O
67	O
.	O
1	O
%	O
and	O
62	O
.	O
2	O
%	O
,	O
respectively	O
.	O

Mon	O
##o	O
and	O
o	B
##li	I
##gos	I
##ac	I
##cha	I
##ride	I
##s	I
were	O
detected	O
as	O
am	O
##monia	O
add	O
##uc	O
##ts	O
in	O
positive	O
mode	O
and	O
as	O
[	O
M	O
-	O
H	O
]	O
_	O
−	O
ions	O
in	O
negative	O
mode	O
.	O

Of	O
five	O
identified	O
meta	O
##bol	O
##ites	O
that	O
differed	O
significantly	O
among	O
groups	O
by	O
K	O
##rus	O
##kal	O
-	O
Wallis	O
test	O
,	O
four	O
remained	O
significant	O
after	O
evaluation	O
by	O
Wilcox	O
##on	O
rank	O
-	O
sum	O
tests	O
with	O
Bon	O
##fer	O
##ron	O
##i	O
correction	O
(	O
ace	O
##tone	O
,	O
ad	B
##eno	I
##sin	I
##e	I
,	O
c	B
##it	I
##rate	I
,	O
rib	O
##ose	O
)	O
.	O

Sur	O
##fa	O
##ct	O
##ant	O
protein	O
C	O
is	O
one	O
of	O
the	O
widely	O
studied	O
marker	O
which	O
is	O
mainly	O
composed	O
of	O
v	B
##ali	I
##ne	I
,	O
le	B
##uc	I
##ine	I
and	O
is	B
##ole	I
##uc	I
##ine	I
forming	O
the	O
bulk	O
of	O
its	O
h	O
##ydro	O
##phobic	O
residues	O
.	O

CH	O
##C	O
##l	O
_	O
3	O
:	O
water	O
ex	O
##t	O
+	O
U	O
##F	O
and	O
Me	B
##OH	I
:	O
CH	O
##C	O
##l	O
_	O
3	O
precipitation	O
##s	O
,	O
and	O
26	O
compounds	O
were	O
different	O
between	O
Me	B
##OH	I
:	O

Some	O
of	O
its	O
meta	O
##bol	O
##ites	O
were	O
better	O
disc	O
##rim	O
##ina	O
##nts	O
,	O
although	O
ca	B
##ffe	I
##ine	I
is	O
found	O
in	O
tea	O
,	O
co	O
##la	O
,	O
energy	O
drinks	O
and	O
supplement	O
##s	O
,	O
com	O
##p	O
##rom	O
##ising	O
specific	O
##ity	O
for	O
coffee	O
intake	O
.	O

H	B
##ydro	I
##phi	I
##lic	I
meta	O
##bol	O
##ites	O
are	O
less	O
soluble	O
in	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
,	O
and	O
therefore	O
,	O
at	O
the	O
higher	O
proportions	O
of	O
this	O
organic	O
solvent	O
,	O
the	O
meta	O
##bol	O
##ite	O
recovery	O
decreases	O
substantially	O
.	O

Our	O
study	O
,	O
for	O
the	O
first	O
time	O
,	O
demonstrated	O
that	O
lower	O
levels	O
of	O
Le	O
##uc	O
##ine	O
/	O
is	O
##ole	O
##uc	O
##ine	O
and	O
higher	O
levels	O
of	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##cho	I
##line	I
were	O
closely	O
associated	O
with	O
F	B
##D	I
symptoms	O
in	O
young	O
females	O
,	O
indicating	O
that	O
Le	O
##u	O
/	O
Il	O
##e	O
and	O
P	O
##t	O
##d	O
##cho	O
are	O
potential	O
bio	O
##mark	O
##ers	O
of	O
F	B
##D	I
.	O

In	O
addition	O
to	O
the	O
seven	O
lip	O
##id	O
clusters	O
(	O
L	O
##Cs	O
;	O
Figure	O
)	O
,	O
other	O
variables	O
included	O
in	O
the	O
analysis	O
were	O
age	O
,	O
B	O
##MI	O
,	O
fast	O
##ing	O
plasma	O
glucose	S
and	O
insulin	O
as	O
well	O
as	O
H	O
##OM	O
##A	O
-	O
I	O
##R	O
.	O

Po	O
##sitive	O
signals	O
,	O
corresponding	O
to	O
the	O
up	O
-	O
regulated	O
meta	O
##bol	O
##ites	O
in	O
gas	O
##tric	O
cancer	O
tissues	O
in	O
comparison	O
to	O
normal	O
controls	O
,	O
were	O
found	O
for	O
is	B
##ole	I
##uc	I
##ine	I
,	O
le	B
##uc	I
##ine	I
,	O
v	B
##ali	I
##ne	I
,	O
la	B
##ct	I
##ate	I
,	O
N	B
-	I
ace	I
##ty	I
##l	I
g	I
##ly	I
##co	I
##p	I
##rote	I
##in	I
,	O
O	B
-	I
ace	I
##ty	I
##l	I
g	I
##ly	I
##co	I
##p	I
##rote	I
##in	I
,	O
su	B
##cci	I
##nate	I
,	O
g	B
##lut	I
##amine	I
,	O
g	B
##lut	I
##ath	I
##ione	I
,	O
T	B
##MA	I
##O	I
,	O
l	B
##ys	I
##ine	I
and	O
se	B
##rine	I
.	O

_	O
,	O
In	O
addition	O
,	O
g	O
##ly	O
##cated	O
species	O
or	O
t	O
##runcated	O
Al	O
##b	O
products	O
have	O
been	O
identified	O
,	O
where	O
the	O
first	O
two	O
amino	O
acids	O
(	O
As	O
##p	O
-	O
Al	O
##a	O
)	O
are	O
lost	O
from	O
the	O
N	O
-	O
terminus	O
,	O
and	O
le	B
##uc	I
##ine	I
is	O
lost	O
from	O
the	O
C	O
-	O
terminus	O
of	O
Al	O
##b	O
.	O
_	O
,	O
These	O
chemical	O
modifications	O
of	O
Al	O
##b	O
have	O
been	O
detected	O
by	O
direct	O
in	O
##fusion	O
of	O
the	O
pu	O
##rified	O
Al	O
##b	O
solution	O
employing	O
E	O
##SI	O
with	O
T	O
##Q	O
MS	O
or	O
Q	O
##TO	O
##F	O
MS	O
instruments	O
.	O
_	O
−	O
However	O
,	O
pro	O
##te	O
##oly	O
##tic	O
dig	O
##est	O
##ion	O
of	O
the	O
Al	O
##b	O
followed	O
by	O
bottom	O
-	O
up	O
pro	O
##te	O
##omi	O
##cs	O
was	O
required	O
to	O
locate	O
the	O
specific	O
sites	O
of	O
add	O
##uction	O
.	O

The	O
recovery	O
,	O
covering	O
sample	O
preparation	O
,	O
and	O
stability	O
,	O
were	O
determined	O
at	O
three	O
concentration	O
levels	O
(	O
1000	O
,	O
1500	O
##0	O
,	O
and	O
4000	O
##0	O
ng	O
/	O
m	O
##L	O
)	O
in	O
du	O
##plicate	O
,	O
for	O
en	B
##zal	I
##uta	I
##mi	I
##de	I
and	O
N	B
-	I
des	I
##met	I
##hyl	I
##en	I
##zal	I
##uta	I
##mi	I
##de	I
and	O
for	O
the	O
internal	O
standard	O
D	B
_	I
6	I
-	I
en	I
##zal	I
##uta	I
##mi	I
##de	I
.	O

Met	O
##ab	O
##olic	O
pathway	O
analysis	O
also	O
suggests	O
that	O
g	O
##ly	O
##cine	O
/	O
se	O
##rine	O
/	O
th	O
##re	O
##oni	O
##ne	O
/	O
met	O
##hi	O
##oni	O
##ne	O
metabolism	O
(	O
Supporting	O
Information	O
Figure	O
S	O
##2	O
)	O
,	O
g	B
##lut	I
##ama	I
##te	I
pathway	O
(	O
Supporting	O
Information	O
Figure	O
S	O
##3	O
)	O
,	O
t	B
##yr	I
##os	I
##ine	I
metabolism	O
(	O
Supporting	O
Information	O
Figure	O
S	O
##4	O
)	O
,	O
T	O
##CA	O
cycle	O
(	O
Supporting	O
Information	O
Figure	O
S	O
##5	O
)	O
,	O
ch	B
##olin	I
##e	I
metabolism	O
(	O
Supporting	O
Information	O
Figure	O
##s	O
S	O
##2	O
and	O
S	O
##6	O
)	O
,	O
and	O
bi	O
##le	O
acid	O
metabolism	O
(	O
Supporting	O
Information	O
Figure	O
S	O
##7	O
)	O
are	O
marked	O
##ly	O
altered	O
.	O

Lu	O
##mina	O
##l	O
BC	O
##a	O
cell	O
lines	O
showed	O
elevated	O
levels	O
of	O
amino	O
acids	O
,	O
like	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
try	B
##pt	I
##op	I
##han	I
,	O
and	O
t	B
##yr	I
##os	I
##ine	I
,	O
and	O
branched	O
chain	O
amino	O
acids	O
like	O
le	B
##uc	I
##ine	I
,	O
l	B
##ys	I
##ine	I
,	O
and	O
v	B
##ali	I
##ne	I
,	O
as	O
well	O
as	O
higher	O
levels	O
of	O
la	B
##uri	I
##c	I
acid	I
and	O
o	B
##le	I
##ic	I
acid	I
.	O

Me	O
##as	O
##ure	O
##ments	O
included	O
all	B
##ant	I
##oi	I
##n	I
and	O
the	O
is	B
##op	I
##ros	I
##tan	I
##es	I
,	O
i	O
##P	O
##F	O
(	O
2	O
alpha	O
)	O
-	O
III	O
,	O
i	O
##P	O
##F	O
(	O
2	O
alpha	O
)	O
-	O
VI	O
,	O
8	B
,	I
12	I
-	I
is	I
##o	I
-	I
i	I
##P	I
##F	I
(	I
2	I
alpha	I
)	I
-	O
VI	O
along	O
with	O
the	O
pro	B
##sta	I
##g	I
##land	I
##in	I
2	I
,	I
3	I
-	I
din	I
##or	I
-	I
i	I
##P	I
##F	I
(	I
2	I
alpha	I
)	I
-	O
III	O
,	O
a	O
meta	O
##bol	O
##ite	O
of	O
i	O
##P	O
##F	O
(	O
2	O
alpha	O
)	O
-	O
III	O
.	O

m	B
-	I
Ty	I
##ros	I
##ine	I
converts	O
to	O
m	B
-	I
t	I
##yra	I
##mine	I
and	O
3	B
-	I
h	I
##ydro	I
##xy	I
##phe	I
##ny	I
##l	I
##p	I
##rop	I
##ion	I
##ic	I
acid	I
by	O
de	O
##car	O
##box	O
##yla	O
##tion	O
and	O
de	O
##ami	O
##nation	O
,	O
respectively	O
.	O

Once	O
in	O
the	O
l	O
##ume	O
##n	O
(	O
or	O
mouth	O
)	O
,	O
the	O
con	O
##ju	O
##gate	O
##s	O
are	O
subject	O
to	O
h	O
##ydro	O
##lysis	O
by	O
sa	O
##liva	O
##ry	O
and	O
/	O
or	O
bacterial	O
β	O
-	O
g	O
##lu	O
##cu	O
##ron	O
##idas	O
##e	O
or	O
a	O
##ryl	O
##sul	O
##fa	O
##tase	O
to	O
re	O
##generate	O
the	O
a	B
##gly	I
##con	I
##es	I
or	O
their	O
corresponding	O
p	O
##hen	O
##olic	O
acids	O
and	O
sustain	O
the	O
enter	O
##ic	O
cycling	O
(	O
,	O
)	O
.	O

The	O
detection	O
limit	O
for	O
met	B
##form	I
##in	I
based	O
on	O
the	O
lowest	O
standard	O
is	O
0	O
.	O
38	O
ng	O
/	O
m	O
##L	O
,	O
and	O
the	O
linear	O
range	O
was	O
determined	O
to	O
be	O
between	O
1	O
.	O
5	O
and	O
1600	O
ng	O
/	O
m	O
##L	O
,	O
determined	O
by	O
linear	O
re	O
##gression	O
with	O
an	O
r	O
_	O
2	O
fit	O
of	O
0	O
.	O
99	O
##86	O
.	O

P	O
##las	O
##ma	O
glucose	S
was	O
measured	O
using	O
a	O
S	O
##ync	O
##hr	O
##on	O
L	O
##X	O
20	O
analyze	O
##r	O
(	O
Beck	O
##man	O
-	O
Co	O
##ulter	O
,	O
High	O
W	O
##y	O
##combe	O
,	O
UK	O
)	O
.	O

4	B
-	I
H	I
##ydro	I
##xy	I
##phe	I
##ny	I
##lace	I
##tate	I
is	O
a	O
product	O
of	O
t	B
##yr	I
##os	I
##ine	I
metabolism	O
and	O
has	O
also	O
been	O
reported	O
as	O
significantly	O
decreased	O
in	O
the	O
urine	O
of	O
breast	O
cancer	O
patients	O
and	O
elevated	O
in	O
the	O
plasma	O
of	O
dial	O
##ys	O
##is	O
patients	O
.	O

However	O
,	O
a	O
16	O
-	O
year	O
-	O
old	O
boy	O
(	O
Case	O
5	O
in	O
T	O
##S	O
##G	O
,	O
)	O
with	O
a	O
simultaneous	O
detection	O
of	O
D	O
##MA	O
##P	O
and	O
th	B
##iam	I
##eth	I
##ox	I
##am	I
in	O
the	O
urine	O
and	O
a	O
62	O
-	O
year	O
-	O
old	O
woman	O
(	O
Case	O
9	O
in	O
T	O
##S	O
##G	O
,	O
)	O
did	O
not	O
experience	O
the	O
improvement	O
of	O
post	O
##ural	O
finger	O
t	O
##rem	O
##or	O
or	O
other	O
neo	O
-	O
ni	O
##cot	O
##ini	O
##c	O
symptoms	O
in	O
spite	O
of	O
the	O
diet	O
##ary	O
prohibition	O
##s	O
.	O
_	O
a	O
Report	O
##ed	O
by	O
patients	O
or	O
family	O
.	O

Several	O
reports	O
asserted	O
that	O
elevated	O
u	B
##ric	I
acid	I
levels	O
(	O
as	O
well	O
as	O
those	O
of	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
)	O
are	O
closely	O
related	O
to	O
an	O
increase	O
in	O
body	O
weight	O
and	O
body	O
fat	O
as	O
well	O
as	O
o	O
##besity	O
-	O
related	O
diseases	O
such	O
as	O
diabetes	O
,	O
abdominal	O
o	O
##besity	O
,	O
end	O
##oth	O
##eli	O
##al	O
d	O
##ys	O
##function	O
,	O
inflammation	O
,	O
and	O
sub	O
##c	O
##lini	O
##cal	O
at	O
##her	O
##os	O
##cle	O
##rosis	O
.	O

Pro	O
##tein	O
##s	O
and	O
p	O
##eptide	O
##s	O
in	O
the	O
samples	O
were	O
pre	O
##ci	O
##pit	O
##ated	O
by	O
addition	O
of	O
5	O
%	O
(	O
v	O
/	O
v	O
)	O
cold	O
solid	O
su	B
##lf	I
##osa	I
##lic	I
##yl	I
##ic	I
acid	I
,	O
holding	O
the	O
samples	O
at	O
4	O
##°	O
##C	O
for	O
1	O
h	O
,	O
and	O
cent	O
##ri	O
##fu	O
##ged	O
them	O
at	O
15	O
,	O
000	O
##×	O
##g	O
for	O
15	O
min	O
.	O

Some	O
of	O
the	O
small	O
molecules	O
could	O
be	O
efficiently	O
der	O
##iva	O
##tized	O
,	O
such	O
as	O
ATP	S
,	O
n	O
##uc	O
##leo	O
##tide	O
sugar	O
,	O
free	O
fatty	O
acids	O
,	O
and	O
meta	O
##bol	O
##ites	O
associated	O
with	O
g	O
##ly	O
##co	O
##lysis	O
.	O

Ce	B
##ram	I
##ides	I
and	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
##s	I
accounted	O
for	O
38	O
%	O
and	O
13	O
%	O
of	O
the	O
impact	O
,	O
respectively	O
.	O

Super	O
##im	O
##posed	O
in	O
color	O
are	O
the	O
fold	O
change	O
for	O
fatty	O
acids	O
and	O
o	B
##xy	I
##lip	I
##ins	I
identified	O
as	O
significantly	O
en	O
##rich	O
##ed	O
(	O
red	O
)	O
or	O
depleted	O
(	O
blue	O
)	O
post	O
##pra	O
##ndi	O
##ally	O
over	O
all	O
subjects	O
.	O

Ho	B
##mo	I
##cy	I
##stein	I
##e	I
,	O
4	B
-	I
h	I
##ydro	I
##xy	I
##hip	I
##pur	I
##ic	I
acid	I
,	O
and	O
t	B
##yr	I
##os	I
##ine	I
showed	O
relatively	O
high	O
se	O
##ns	O
##iti	O
##vi	O
##ties	O
and	O
specific	O
##ities	O
and	O
were	O
combined	O
with	O
log	O
##istic	O
re	O
##gression	O
in	O
SP	O
##SS	O
software	O
.	O

–	O
Our	O
results	O
are	O
consistent	O
with	O
a	O
previous	O
study	O
,	O
which	O
compared	O
PD	O
##R	O
patients	O
with	O
non	O
##dia	O
##bet	O
##ic	O
controls	O
and	O
found	O
elevated	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
levels	O
in	O
v	O
##it	O
##re	O
##ous	O
samples	O
.	O

Long	O
-	O
chain	O
FA	O
##s	O
act	O
as	O
an	O
important	O
source	O
of	O
fuel	O
for	O
many	O
tissues	O
(	O
e	O
.	O
g	O
.	O
,	O
skeletal	O
and	O
cardiac	O
muscle	O
)	O
,	O
where	O
a	B
##cy	I
##l	I
-	I
Co	I
##As	I
are	O
converted	O
to	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
.	O

Experiment	O
##s	O
with	O
β	O
-	O
g	O
##lu	O
##cu	O
##ron	O
##idas	O
##e	O
are	O
also	O
consistent	O
with	O
previous	O
reports	O
showing	O
that	O
the	O
detected	O
o	O
##xi	O
##dized	O
meta	O
##bol	O
##ites	O
are	O
ex	O
##cre	O
##ted	O
primarily	O
as	O
g	B
##lu	I
##cu	I
##ronic	I
acid	I
con	O
##ju	O
##gate	O
##s	O
(	O
and	O
and	O
)	O
.	O

This	O
confirmed	O
the	O
importance	O
in	O
relation	O
to	O
B	O
##MI	O
of	O
muscle	O
metabolism	O
,	O
u	O
##rina	O
##ry	O
amino	O
acids	O
,	O
gut	O
micro	O
##bial	O
co	O
-	O
metabolism	O
,	O
and	O
diet	O
##ary	O
meat	O
-	O
related	O
markers	O
;	O
u	O
##rina	O
##ry	O
g	B
##ly	I
##co	I
##p	I
##rote	I
##ins	I
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
and	O
3	B
-	I
met	I
##hyl	I
##his	I
##ti	I
##dine	I
pre	O
##dom	O
##inated	O
in	O
the	O
smaller	O
UK	O
sample	O
data	O
.	O

For	O
instance	O
,	O
al	B
##ani	I
##ne	I
levels	O
declined	O
in	O
the	O
L	O
group	O
after	O
surgery	O
but	O
increased	O
in	O
the	O
T	O
group	O
.	O

C	B
##it	I
##ric	I
acid	I
and	O
glucose	S
were	O
also	O
present	O
at	O
higher	O
levels	O
in	O
patients	O
belonging	O
to	O
group	O
G	O
##4	O
.	O

After	O
being	O
dried	O
in	O
a	O
vacuum	O
con	O
##cent	O
##rator	O
,	O
the	O
collected	O
super	O
##nat	O
##ant	O
was	O
suspended	O
in	O
40	O
μ	O
##L	O
of	O
met	B
##ho	I
##xy	I
p	I
##yr	I
##id	I
##ine	I
h	I
##ydro	I
##ch	I
##lor	I
##ide	I
(	O
20	O
mg	O
/	O
m	O
##L	O
in	O
p	B
##yr	I
##id	I
##ine	I
)	O
and	O
in	O
##cu	O
##bate	O
##d	O
for	O
30	O
min	O
at	O
80	O
°C	O
.	O

Taking	O
extreme	O
examples	O
,	O
le	B
##uc	I
##ine	I
and	O
g	B
##lut	I
##amine	I
were	O
not	O
correlated	O
(	O
r	O
=	O
0	O
.	O
03	O
,	O
p	O
=	O
0	O
.	O
23	O
)	O
but	O
BC	O
##AA	O
##s	O
le	B
##uc	I
##ine	I
,	O
is	B
##ole	I
##uc	I
##ine	I
and	O
v	B
##ali	I
##ne	I
were	O
highly	O
inter	O
##cor	O
##rel	O
##ated	O
(	O
r	O
≥	O
0	O
.	O
67	O
,	O
p	O
<	O
0	O
.	O
00	O
##1	O
)	O

Furthermore	O
,	O
decreased	O
expression	O
and	O
activity	O
of	O
E	O
##L	O
##O	O
##V	O
##L	O
##6	O
contributed	O
also	O
to	O
the	O
marked	O
increase	O
of	O
L	O
##CF	O
##A	O
culminating	O
in	O
NAS	O
##H	O
with	O
the	O
accumulation	O
of	O
my	B
##rist	I
##ic	I
acid	I
(	B
C	B
##14	I
:	I
0	I
)	O
.	O

P	O
##las	O
##ma	O
levels	O
of	O
th	B
##re	I
##oni	I
##ne	I
(	O
p	O
<	O
0	O
.	O
00	O
##60	O
,	O
q	O
<	O
0	O
.	O
05	O
##5	O
)	O
,	O
al	B
##ani	I
##ne	I
(	O
p	O
<	O
0	O
.	O
01	O
##0	O
,	O
q	O
<	O
0	O
.	O
06	O
##9	O
)	O
,	O
and	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
(	O
p	O
<	O
0	O
.	O
01	O
##1	O
,	O
q	O
<	O
0	O
.	O
06	O
##9	O
)	O
,	O
were	O
increased	O
following	O
si	B
##m	I
##vas	I
##tat	I
##in	I
treatment	O
.	O

Po	O
##si	O
##tron	O
emission	O
to	O
##mo	O
##graphy	O
(	O
P	O
##ET	O
)	O
in	O
combination	O
with	O
_	O
18	O
F	B
-	I
flu	I
##ori	I
##ne	I
-	I
labeled	I
de	I
##ox	I
##y	I
##g	I
##lu	I
##cos	I
##e	I
(	O
[	O
_	O
18	O
F	O
]	O
F	O
##D	O
##G	O
)	O
and	O
e	B
##ug	I
##ly	I
##ce	I
##mic	I
-	I
h	I
##yper	I
##ins	I
##ulin	I
##em	I
##ic	I
c	O
##lamp	O
allows	O
direct	O
measurement	O
of	O
skeletal	O
muscle	O
insulin	O
sensitivity	O
independently	O
of	O
end	O
##ogen	O
##ous	O
glucose	S
production	O
.	O

The	O
observed	O
similarities	O
in	O
the	O
variations	O
of	O
his	B
##ti	I
##dine	I
,	O
un	O
##sat	O
##ura	O
##ted	O
fatty	O
acids	O
and	O
protein	O
levels	O
suggest	O
that	O
such	O
variations	O
may	O
be	O
a	O
global	O
reflection	O
of	O
the	O
disease	O
,	O
possibly	O
trans	O
##vers	O
##al	O
to	O
different	O
co	O
##hor	O
##ts	O
and	O
,	O
therefore	O
,	O
with	O
potential	O
value	O
in	O
contributing	O
to	O
the	O
current	O
knowledge	O
of	O
the	O
biology	O
of	O
AM	O
##D	O
.	O

Re	B
##tina	I
##l	I
micro	O
##vas	O
##cular	O
d	O
##ys	O
##function	O
—	O
resulting	O
in	O
re	B
##tina	I
##l	I
is	O
##che	O
##mia	O
and	O
h	O
##y	O
##pox	O
##ia	O
—	O
could	O
also	O
a	O
##gg	O
##ra	O
##vate	O
o	O
##xi	O
##da	O
##tive	O
stress	O
,	O
which	O
is	O
thought	O
to	O
be	O
one	O
of	O
the	O
crucial	O
factors	O
in	O
the	O
path	O
##ogen	O
##esis	O
of	O
DR	O
.	O

As	O
expected	O
,	O
cats	O
in	O
the	O
me	O
##lo	O
##xi	O
##cam	O
group	O
had	O
increased	O
serum	O
B	O
##UN	O
and	O
c	B
##rea	I
##tin	I
##ine	I
concentrations	O
(	O
Su	O
##pp	O
##lement	O
##ary	O
Fi	O
##gs	O
_	O
S	O
##1	O
and	O
_	O
S	O
##2	O
)	O
.	O

By	O
comparing	O
changes	O
in	O
the	O
SL	S
meta	O
##bol	O
##ites	O
following	O
the	O
AS	O
##A	O
-	O
BP	O
##T	O
,	O
we	O
found	O
a	O
distorted	O
pattern	O
of	O
c	B
##era	I
##mi	I
##des	I
and	O
SM	O
##s	O
after	O
the	O
AS	O
##A	O
-	O
BP	O
##T	O
,	O
with	O
a	O
decreased	O
pattern	O
in	O
the	O
A	O
##ER	O
##D	O
group	O
(	O
Fi	O
##g	O
.	O
E	O
##1	O
)	O
.	O

Inc	O
##reased	O
levels	O
of	O
p	B
##hos	I
##ph	I
##och	I
##olin	I
##es	I
are	O
associated	O
with	O
proliferation	O
,	O
and	O
there	O
are	O
re	O
##ci	O
##p	O
##ro	O
##cal	O
interactions	O
between	O
on	O
##co	O
##genic	O
signalling	O
and	O
p	B
##hos	I
##ph	I
##och	I
##olin	I
##e	I
metabolism	O
.	O

The	O
current	O
data	O
for	O
base	O
##line	O
plasma	O
in	B
##os	I
##ine	I
reveal	O
that	O
this	O
compound	O
has	O
a	O
moderate	O
inverse	O
correlation	O
with	O
Δ	O
##UP	O
##DR	O
##S	O
##2	O
+	O
3	O
(	O
−	O
##3	O
.	O
53	O
,	O
p	O
=	O
0	O
.	O
01	O
##3	O
)	O
.	O

The	O
steady	O
concentration	O
of	O
x	B
##ant	I
##hine	I
and	O
slight	O
increase	O
of	O
u	B
##ric	I
acid	I
after	O
heating	O
might	O
be	O
from	O
other	O
conversion	O
processes	O
such	O
as	O
oxidation	O
of	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
.	O

no	O
.	O
86	O
##0	O
##64	O
##0	O
)	O
,	O
C	O
##17	O
c	B
##era	I
##mi	I
##de	I
(	I
d	I
##18	I
:	I
1	I
/	I
17	I
:	I
0	I
)	I
(	O
cat	O
.	O

Therefore	O
,	O
the	O
results	O
of	O
this	O
study	O
co	O
##rro	O
##bor	O
##ate	O
that	O
the	O
a	O
##ber	O
##rant	O
k	B
##yn	I
##uren	I
##ine	I
pathway	O
activation	O
by	O
ID	O
##O	O
may	O
serve	O
as	O
a	O
potential	O
cellular	O
mechanism	O
,	O
which	O
is	O
present	O
in	O
N	O
##DM	O
##M	O
patients	O
to	O
induce	O
a	O
systemic	O
der	O
##eg	O
##ulation	O
of	O
immune	O
responses	O
[	O
,	O
]	O
.	O

Mid	O
-	O
trim	O
##ester	O
maternal	O
plasma	O
was	O
analyzed	O
for	O
in	O
##te	O
##gra	O
##tive	O
profiles	O
of	O
primary	O
meta	O
##bol	O
##ite	O
and	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
using	O
gas	O
ch	O
##roma	O
##tography	O
time	O
-	O
of	O
-	O
flight	O
mass	O
s	O
##pect	O
##rome	O
##try	O
(	O
G	O
##C	O
-	O
TO	O
##F	O
MS	O
)	O
and	O
liquid	O
ch	O
##roma	O
##tography	O
Or	O
##bit	O
##rap	O
mass	O
s	O
##pect	O
##rome	O
##try	O
(	O
L	O
##C	O
-	O
Or	O
##bit	O
##rap	O
MS	O
)	O
.	O

Al	B
##kal	I
##ine	I
and	O
acid	O
h	O
##ydro	O
##ly	O
##ses	O
of	O
the	O
_	O
15	O
N	O
substituted	O
p	O
##ht	O
##hali	O
##mi	O
##de	O
to	O
yield	O
_	O
15	O
N	B
-	I
ch	I
##ola	I
##mine	I
.	O

The	O
m	O
/	O
z	O
for	O
is	O
##onia	O
##zi	O
##d	O
and	O
p	B
##yra	I
##zin	I
##ami	I
##de	I
were	O
detected	O
at	O
low	O
intensity	O
in	O
some	O
,	O
but	O
not	O
all	O
,	O
individuals	O
with	O
T	O
##B	O
disease	O
.	O

c	B
##rea	I
##tin	I
##ine	I
,	O
est	O
##imating	O
equations	O
,	O
G	O
##F	O
##R	O
,	O
kidney	O
function	O
,	O
meta	O
##bol	O
##omi	O
##cs	O

The	O
secret	O
##ion	O
site	O
might	O
be	O
of	O
particular	O
importance	O
,	O
as	O
co	B
##rt	I
##is	I
##ol	I
released	O
from	O
VA	O
##T	O
is	O
suspected	O
to	O
contribute	O
to	O
he	O
##pa	O
##tic	O
insulin	O
resistance	O
whereas	O
co	B
##rt	I
##is	I
##ol	I
released	O
from	O
SAT	O
might	O
be	O
counter	O
##act	O
##ed	O
by	O
the	O
HP	O
##A	O
-	O
axis	O
.	O

Met	O
##ab	O
##oli	O
##te	O
,	O
H	B
##y	I
##pox	I
##ant	I
##hine	I
,	O
Ph	B
##os	I
##ph	I
##oe	I
##no	I
##l	I
##py	I
##ru	I
##vate	I
,	O
Re	O
##ct	O
##al	O
neo	O
##p	O
##las	O
##ms	O
,	O
Ch	O
##em	O
##ora	O
##dio	O
##ther	O
##ap	O
##y	O
,	O
Low	O
-	O
mass	O
ions	O

In	O
addition	O
,	O
we	O
observed	O
egg	O
p	B
##hos	I
##hp	I
##hat	I
##idy	I
##let	I
##han	I
##ola	I
##mine	I
(	O
e	O
##P	O
##E	O
)	O
as	O
a	O
major	O
lip	O
##id	O
group	O
present	O
in	O
plasma	O
,	O
and	O
e	B
##P	I
##E	I
(	I
40	I
:	I
4	I
)	I
varied	O
between	O
cancer	O
patients	O
and	O
healthy	O
controls	O
in	O
this	O
study	O
.	O

(	O
C	O
)	O
L	B
-	I
As	I
##par	I
##tic	I
acid	I
is	O
up	O
-	O
regulated	O
in	O
D	O
##OC	O
##K	O
##8	O
-	O
def	O
##icient	O
patients	O
compared	O
with	O
AD	O
patients	O
.	O

All	O
models	O
are	O
adjusted	O
for	O
age	O
,	O
sex	O
,	O
B	O
##MI	O
,	O
L	B
##D	I
##L	I
ch	I
##ole	I
##ster	I
##ol	I
,	O
and	O
fast	O
##ing	O
glucose	S
.	O

Our	O
##s	O
is	O
the	O
first	O
study	O
to	O
relate	O
circulating	O
levels	O
of	O
su	B
##cci	I
##nate	I
and	O
other	O
T	O
##CA	O
cycle	O
intermediate	O
##s	O
to	O
P	O
##H	O
,	O
which	O
raises	O
the	O
possibility	O
that	O
su	B
##cci	I
##nate	I
or	O
potentially	O
other	O
T	O
##CA	O
-	O
related	O
meta	O
##bol	O
##ites	O
could	O
m	O
##od	O
##ulate	O
vascular	O
tone	O
in	O
humans	O
.	O

The	O
u	O
##rina	O
##ry	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
level	O
may	O
be	O
a	O
marker	O
of	O
gas	O
##tro	O
##int	O
##est	O
##inal	O
tumors	O
[	O
,	O
]	O
.	O

In	O
immune	O
cells	O
AD	B
##MA	I
is	O
c	O
##lea	O
##ved	O
by	O
dim	B
##eth	I
##yla	I
##rg	I
##ini	I
##ne	I
-	I
dim	I
##eth	I
##yla	I
##min	I
##oh	I
##ydro	I
##lase	I
-	I
2	I
(	O
DD	O
##A	O
##H	O
##2	O
)	O
.	O

Inc	O
##reased	O
levels	O
of	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
,	O
a	O
substrate	O
for	O
x	B
##ant	I
##hine	I
o	O
##xi	O
##das	O
##e	O
,	O
may	O
result	O
in	O
generating	O
reactive	O
oxygen	O
species	O
(	O
R	O
##OS	O
)	O
.	O

In	O
contrast	O
,	O
the	O
negative	O
correlation	O
##s	O
of	O
la	B
##ct	I
##ate	I
with	O
t	O
##C	O
##ho	O
and	O
t	O
##G	O
##lut	O
observed	O
in	O
E	O
##1	O
##A	O
-	O
Ra	O
##s	O
transformed	O
cells	O
were	O
found	O
to	O
be	O
positive	O
when	O
they	O
were	O
present	O
in	O
the	O
brain	O
t	O
##umour	O
##s	O
.	O

St	O
##ero	O
##ls	O
and	O
g	B
##ly	I
##cer	I
##oli	I
##pid	I
##s	I
were	O
separated	O
with	O
reverse	O
-	O
phase	O
HP	O
##LC	O
using	O
an	O
is	O
##oc	O
##ratic	O
mobile	O
phase	O
as	O
before	O
except	O
with	O
an	O
A	O
##gi	O
##lent	O
Z	O
##or	O
##ba	O
##x	O
Eclipse	O
X	O
##D	O
##B	O
-	O
C	O
##18	O
column	O
(	O
4	O
.	O
6	O
x	O
100	O
mm	O
)	O
.	O

F	O
##BS	O
(	O
H	O
##y	O
##c	O
##lone	O
Laboratories	O
/	O
The	O
##rm	O
##o	O
Scientific	O
,	O
Rock	O
##ford	O
,	O
IL	O
)	O
and	O
1	O
%	O
pen	B
##ici	I
##llin	I
-	I
s	I
##tre	I
##pt	I
##omy	I
##cin	I
(	O
H	O
##y	O
##c	O
##lone	O
Laboratories	O
)	O
.	O

and	O
BC	O
##AA	O
levels	O
in	O
response	O
to	O
an	O
oral	O
glucose	S
challenge	O
in	O
insulin	O
-	O
resistant	O
adolescent	O
##s	O
.	O

In	O
addition	O
to	O
tissue	O
specific	O
##ities	O
in	O
the	O
G	O
##G	O
class	O
pattern	O
,	O
our	O
thorough	O
analysis	O
of	O
G	O
##G	O
##s	O
using	O
L	O
##C	O
/	O
MS	O
also	O
revealed	O
specific	O
##ities	O
in	O
the	O
molecular	O
species	O
,	O
i	O
.	O
e	O
.	O
c	B
##era	I
##mi	I
##de	I
type	O
,	O
pattern	O
of	O
tissues	O
and	O
G	O
##G	O
classes	O
.	O

Spectrum	O
of	O
serum	O
from	O
patients	O
and	O
healthy	O
subjects	O
shows	O
the	O
presence	O
of	O
meta	O
##bol	O
##ites	O
including	O
amino	O
acids	O
like	O
al	B
##ani	I
##ne	I
,	O
l	B
##ys	I
##ine	I
,	O
g	B
##lut	I
##amine	I
,	O
g	B
##lut	I
##ama	I
##te	I
,	O
other	O
branched	O
chain	O
amino	O
acids	O
,	O
meta	O
##bol	O
##ites	O
like	O
la	B
##ct	I
##ate	I
,	O
N	B
-	I
ace	I
##ty	I
##l	I
g	I
##ly	I
##co	I
##p	I
##rote	I
##ins	I
(	O
N	O
##AG	O
)	O
,	O
glucose	S
,	O
lip	O
##ids	O
,	O
c	B
##rea	I
##tin	I
##ine	I
,	O
ace	B
##tate	I
,	O
p	B
##yr	I
##u	I
##vate	I
,	O
c	B
##it	I
##rate	I
and	O
lip	O
##op	O
##rote	O
##ins	O
(	O
HD	O
##L	O
,	O
L	O
##D	O
##L	O
and	O
V	O
##LD	O
##L	O
)	O
.	O

H	O
-	O
He	O
##p	O
##G	O
##2	O
cells	O
were	O
seeded	O
in	O
96	O
-	O
well	O
plates	O
at	O
the	O
density	O
of	O
5	O
×	O
10	O
_	O
3	O
cells	O
/	O
well	O
in	O
complete	O
media	O
in	O
presence	O
of	O
high	O
glucose	S
concentration	O
.	O

Similarly	O
,	O
the	O
increased	O
levels	O
of	O
S	O
##1	O
##P	O
and	O
s	B
##phi	I
##ngo	I
##sin	I
##e	I
in	O
the	O
A	O
##ER	O
##D	O
patients	O
showed	O
positive	O
correlation	O
##s	O
with	O
the	O
serum	O
15	B
-	I
H	I
##ET	I
##E	I
level	O
,	O
while	O
the	O
levels	O
of	O
serum	O
SM	O
##s	O
were	O
negatively	O
correlated	O
with	O
the	O
serum	O
15	B
-	I
H	I
##ET	I
##E	I
level	O
.	O

The	O
levels	O
of	O
glucose	S
(	O
p	O
<	O
0	O
.	O
05	O
)	O
and	O
1	O
-	O
M	O
##H	O
##ist	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
were	O
significantly	O
higher	O
in	O
children	O
with	O
liver	O
involvement	O
.	O

The	O
k	O
##eto	O
##genic	O
le	B
##uc	I
##ine	I
product	O
,	O
is	B
##ova	I
##ler	I
##yl	I
-	I
Co	I
##A	I
,	O
is	O
finally	O
cat	O
##ab	O
##oli	O
##zed	O
to	O
ace	B
##ty	I
##l	I
-	I
Co	I
##A	I
and	O
ace	B
##to	I
##ace	I
##tate	I
.	O

In	O
order	O
to	O
der	O
##iva	O
##ti	O
##ze	O
the	O
sample	O
,	O
100	O
μ	O
##L	O
of	O
carbon	B
##ate	I
-	I
bi	I
##car	I
##bon	I
##ate	I
buffer	O
(	O
pH	O
9	O
)	O
and	O
50	O
μ	O
##L	O
of	O
dans	B
##yl	I
chloride	I
(	O
10	O
mg	O
/	O
m	O
##L	O
in	O
ace	O
##tone	O
)	O
were	O
added	O
.	O

Since	O
practically	O
all	O
the	O
est	O
##rogen	O
##s	O
and	O
est	B
##rogen	I
meta	O
##bol	O
##ites	O
in	O
urine	O
are	O
con	O
##ju	O
##gated	O
,	O
the	O
u	O
##rina	O
##ry	O
E	O
##IA	O
for	O
both	O
meta	O
##bol	O
##ites	O
en	O
##zy	O
##matical	O
##ly	O
h	O
##ydro	O
##ly	O
##zed	O
g	O
##lu	O
##cu	O
##ron	O
##ide	O
and	O
su	B
##lf	I
##ate	I
residues	O
with	O
He	O
##lix	O
p	O
##oma	O
##tia	O
extract	O
;	O
the	O
serum	O
/	O
plasma	O
E	O
##IA	O
for	O
2	B
-	I
h	I
##ydro	I
##xy	I
##est	I
##rone	I
,	O
but	O
not	O
16	B
##α	I
-	I
h	I
##ydro	I
##xy	I
##est	I
##rone	I
,	O
also	O
included	O
an	O
en	O
##zy	O
##matic	O
h	O
##ydro	O
##lysis	O
[	O
,	O
]	O
.	O

To	O
anal	O
##ys	O
##e	O
the	O
metabolic	O
alterations	O
mainly	O
related	O
to	O
decreased	O
test	B
##osterone	I
,	O
we	O
performed	O
meta	O
##bol	O
##omi	O
##cs	O
investigations	O
on	O
the	O
plasma	O
of	O
males	O
with	O
h	O
##y	O
##po	O
##gon	O
##adi	O
##sm	O
who	O
showed	O
normal	O
insulin	O
levels	O
.	O

A	O
##ryl	O
##sul	O
##fa	O
##tase	O
is	O
another	O
ant	B
##ho	I
##cy	I
##ani	I
##n	I
and	O
local	O
enter	O
##ic	O
recycling	O
-	O
relevant	O
metabolic	O
enzyme	O
that	O
removes	O
sulfur	O
##s	O
attached	O
via	O
S	O
##U	O
##LT	O
##s	O
.	O

in	O
v	O
##it	O
##ro	O
in	O
v	O
##ivo	O
Con	O
##sist	O
##ent	O
with	O
previous	O
data	O
[	O
–	O
]	O
,	O
g	B
##ly	I
##bur	I
##ide	I
was	O
not	O
ex	O
##cre	O
##ted	O
unchanged	O
in	O
the	O
urine	O
.	O

A	O
##O	O
=	O
an	O
##ov	O
##ulation	O
;	O
FA	S
=	O
fatty	O
acid	O
;	O
H	B
##A	I
=	O
h	O
##yper	O
##and	O
##rogen	O
##ism	O
;	O
HD	O
##L	O
=	O
high	O
-	O
density	O
lip	O
##id	O
;	O
L	O
##D	O
##L	O
=	O
low	O
-	O
density	O
lip	O
##id	O
;	O
N	O
##A	O
##c	O
=	O
N	O
-	O
ace	O
##ty	O
##l	O
groups	O
of	O
g	B
##ly	I
##co	I
##p	I
##rote	I
##ins	I
;	O
PC	O
##O	O
=	O
p	O
##oly	O
##cy	O
##stic	O
o	O
##var	O
##ies	O
;	O
P	O
##t	O
##d	O
##C	O
##ho	O
=	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
;	O
U	O
=	O
unidentified	O
sugar	O
;	O
U	O
##FA	O
=	O
un	O
##sat	O
##ura	O
##ted	O
fatty	O
acid	O
;	O
V	O
##LD	O
##L	O
=	O
very	O
low	O
-	O
density	O
lip	O
##id	O
.	O

Important	O
##ly	O
,	O
thy	B
##ro	I
##xin	I
##e	I
was	O
not	O
associated	O
to	O
age	O
in	O
the	O
control	O
group	O
(	O
r	O
=	O
0	O
.	O
03	O
,	O
p	O
-	O
value	O
=	O
0	O
.	O
84	O
)	O
,	O
thus	O
eliminating	O
age	O
as	O
a	O
potential	O
con	O
##found	O
##er	O
.	O

T	O
##iss	O
##ue	O
sections	O
were	O
stained	O
with	O
conventional	O
Mayer	O
##s	O
ha	B
##ema	I
##to	I
##xy	I
##lin	I
and	O
e	B
##os	I
##in	I
stain	O
##ing	O
.	O

As	O
displayed	O
in	O
and	O
,	O
we	O
got	O
S	B
-	I
ad	I
##eno	I
##sy	I
##l	I
-	I
l	I
-	I
met	I
##hi	I
##oni	I
##ne	I
(	O
x	O
_	O
1	O
)	O
and	O

5	O
%	O
v	O
/	O
v	O
water	O
in	O
met	B
##han	I
##ol	I
,	O
20	O
m	O
##M	O
am	B
##mon	I
##ium	I
format	I
##e	I
in	O
met	B
##han	I
##ol	I
,	O
0	O
.	O
2	O
%	O
v	O
/	O
v	O
form	B
##ic	I
acid	I
in	O
met	B
##han	I
##ol	I
and	O
7	O
%	O
v	O
/	O
v	O
water	O
in	O
is	B
##op	I
##rop	I
##ano	I
##l	I
.	O

The	O
urine	O
samples	O
were	O
prepared	O
with	O
chemical	O
product	O
from	O
Sigma	O
(	O
Sigma	O
Al	O
##dric	O
##h	O
,	O
Saint	O
Quentin	O
Fall	O
##avi	O
##er	O
,	O
France	O
)	O
to	O
obtain	O
a	O
final	O
volume	O
of	O
600	O
μ	O
L	O
(	O
400	O
μ	O
L	O
of	O
urine	O
;	O
160	O
μ	O
L	O
of	O
200	O
m	O
##M	O
phosphate	S
buffer	O
at	O
pH	O
7	O
.	O
4	O
,	O
1	O
m	O
##M	O
of	O
T	B
##SP	I
-	I
Tri	I
##met	I
##hyl	I
si	I
##ly	I
##l	I
prop	I
##ion	I
##ate	I
of	O
sodium	O
salt	O
as	O
the	O
N	O
##MR	O
chemical	O
shift	O
reference	O
-	O
,	O
6	O
m	O
##M	O
of	O
Na	O
##N	O
_	O
3	O
;	O
40	O
μ	O
L	O
D	O
_	O
2	O
O	O
)	O
.	O

Finally	O
,	O
water	O
losses	O
in	O
the	O
positive	O
ion	O
mode	O
(	O
[	O
M	O
+	O
H	O
−	O
H	O
_	O
2	O
O	O
]	O
_	O
+	O
)	O
were	O
observed	O
for	O
Ce	B
##r	I
,	O
He	O
##x	O
##C	O
##er	O
and	O
D	O
##G	O
lip	O
##id	O
standards	O
,	O
as	O
already	O
described	O
(	O
Christie	O
and	O
Han	O
,	O
)	O
.	O

R	B
##V	I
is	O
the	O
power	O
of	O
the	O
meta	O
##bol	O
##ite	O
to	O
reflect	O
the	O
abnormal	O
state	O
in	O
the	O
disease	O
.	O

These	O
results	O
are	O
also	O
generally	O
consistent	O
with	O
previous	O
studies	O
in	O
animal	O
models	O
,	O
in	O
which	O
exposure	O
to	O
P	O
##F	O
##OA	O
induced	O
alter	O
##ation	O
of	O
lip	O
##ids	O
(	O
e	O
.	O
g	O
.	O
,	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
)	O
and	O
amino	O
acids	O
(	O
e	O
.	O
g	O
.	O
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
as	B
##par	I
##tate	I
and	O
as	B
##par	I
##agi	I
##ne	I
,	O
g	B
##ly	I
##cine	I
,	O
se	B
##rine	I
,	O
al	B
##ani	I
##ne	I
and	O
th	B
##re	I
##oni	I
##ne	I
)	O
metabolism	O
in	O
liver	O
tissues	O
.	O

Mon	B
##oh	I
##ex	I
##osy	I
##l	I
##cer	I
##ami	I
##des	I
major	O
species	O
in	O
healthy	O
corn	O
##eas	O
and	O
di	O
##abe	O
##tics	O
(	O
n	O
>	O
=	O
3	O
per	O
group	O
)	O
.	O

We	O
next	O
investigated	O
whether	O
the	O
high	O
fat	O
test	O
meal	O
el	O
##icit	O
##ed	O
an	O
effect	O
on	O
specific	O
classes	O
of	O
fatty	O
acids	O
or	O
o	B
##xy	I
##lip	I
##ins	I
across	O
all	O
subjects	O
.	O

The	O
plate	O
was	O
then	O
dried	O
,	O
the	O
samples	O
were	O
der	O
##iva	O
##tized	O
with	O
p	B
##hen	I
##yl	I
is	I
##oth	I
##io	I
##cy	I
##ana	I
##te	I
for	O
the	O
amino	O
acids	O
and	O
bio	O
##genic	O
am	O
##ines	O
.	O

Thus	O
,	O
the	O
level	O
of	O
try	B
##pt	I
##op	I
##han	I
and	O
its	O
cat	O
##ab	O
##olic	O
product	O
in	O
the	O
t	O
##umour	O
micro	O
##en	O
##vir	O
##on	O
##ment	O
may	O
contribute	O
to	O
m	O
##od	O
##ulate	O
the	O
im	O
##mu	O
##no	O
##cy	O
##to	O
##xi	O
##c	O
side	O
activity	O
induced	O
by	O
T	O
##ras	O
##tu	O
##zu	O
##ma	O
##b	O
.	O

Other	O
tests	O
of	O
these	O
h	O
##y	O
##pot	O
##heses	O
have	O
been	O
based	O
on	O
measurements	O
of	O
common	O
genetic	O
p	O
##oly	O
##mor	O
##phism	O
##s	O
in	O
est	B
##rogen	I
metabolism	O
pathways	O
,	O
which	O
are	O
likely	O
to	O
have	O
small	O
individual	O
effects	O
on	O
the	O
est	B
##rogen	I
and	O
est	B
##rogen	I
meta	O
##bol	O
##ite	O
p	O
##hen	O
##otype	O
(	O
,	O
)	O
.	O

s	O
##PA	O
##P	O
,	O
s	O
##ys	O
##to	O
##lic	O
pulmonary	O
artery	O
pressure	O
;	O
PC	O
##W	O
##P	O
,	O
pulmonary	O
cap	O
##illa	O
##ry	O
wedge	O
pressure	O
;	O
C	O
##VP	O
,	O
central	O
ve	O
##nous	O
pressure	O
;	O
C	O
##I	O
,	O
cardiac	O
index	O
;	O
e	O
##G	O
##F	O
##R	O
,	O
estimated	O
g	O
##lo	O
##mer	O
##ular	O
fi	O
##ltration	O
rate	O
;	O
B	O
##NP	O
,	O
B	O
-	O
type	O
na	O
##tri	O
##ure	O
##tic	O
p	O
##eptide	O
;	O
AD	B
##MA	I
,	O
as	B
##ym	I
##metric	I
dim	I
##eth	I
##yla	I
##rg	I
##ini	I
##ne	I
;	O
SD	O
##MA	O
,	O
symmetric	B
dim	I
##eth	I
##yla	I
##rg	I
##ini	I
##ne	I
;	O
MMA	O
,	O
N	B
-	I
mon	I
##o	I
-	I
met	I
##hyl	I
##ar	I
##gin	I
##ine	I
;	O
GA	O
##BR	O
,	O
global	O
a	B
##rg	I
##ini	I
##ne	I
bio	O
##ava	O
##ila	O
##bility	O
ratio	O
.	O

All	O
solutions	O
were	O
properly	O
identified	O
and	O
stored	O
at	O
8	O
##º	O
##C	O
in	O
p	B
##oly	I
##p	I
##rop	I
##yle	I
##ne	I
tubes	O
.	O

Short	O
-	O
chain	O
fatty	O
acids	O
such	O
as	O
but	B
##yra	I
##te	I
,	O
prop	B
##ion	I
##ate	I
,	O
and	O
v	B
##ale	I
##rate	I
have	O
been	O
shown	O
to	O
cause	O
growth	O
arrest	O
and	O
differentiation	O
in	O
human	O
color	O
##ec	O
##tal	O
cancer	O
cells	O
.	O

By	O
comparison	O
,	O
only	O
two	O
papers	O
have	O
documented	O
base	O
##line	O
separation	O
of	O
the	O
is	B
##ole	I
##uc	I
##ine	I
and	O
le	B
##uc	I
##ine	I
is	I
##omer	I
pair	O
[	O
,	O
]	O
.	O

In	O
addition	O
to	O
N	O
##MR	O
analysis	O
,	O
a	O
targeted	O
ultra	O
-	O
performance	O
liquid	O
ch	O
##roma	O
##tography	O
-	O
tandem	O
mass	O
s	O
##pect	O
##rome	O
##try	O
(	O
UP	O
##LC	O
-	O
MS	O
/	O
MS	O
)	O
analysis	O
of	O
met	B
##hyl	I
##ated	I
amino	I
compounds	O
was	O
conducted	O
using	O
an	O
A	O
##c	O
##qui	O
##ty	O
H	O
-	O
Class	O
UP	O
##LC	O
coupled	O
to	O
a	O
X	O
##evo	O
T	O
##Q	O
##D	O
triple	O
q	O
##uad	O
##rup	O
##ole	O
MS	O
(	O
both	O
from	O
Waters	O
,	O
E	O
##sch	O
##born	O
,	O
Germany	O
)	O
.	O

The	O
Pro	O
##tein	O
expression	O
levels	O
of	O
AR	O
##ID	O
##1	O
##A	O
and	O
SM	O
##AR	O
##CA	O
##2	O
increased	O
;	O
however	O
,	O
those	O
of	O
HD	O
##AC	O
##4	O
,	O
PD	O
##K	O
,	O
β	B
-	I
CA	I
##TE	I
##N	I
##NI	I
##N	I
,	O
and	O
P	O
##BR	O
##M	O
##1	O
did	O
not	O
(	O
Fi	O
##g	O
.	O
)	O
.	O

Ph	B
##en	I
##yla	I
##ce	I
##ty	I
##l	I
##gly	I
##cine	I
(	O
PA	O
##G	O
)	O
and	O
but	B
##yra	I
##te	I
are	O
also	O
decreased	O
in	O
AS	O
urine	O
.	O

Ho	B
##mo	I
##cy	I
##stein	I
##e	I
is	O
found	O
primarily	O
in	O
plasma	O
in	O
the	O
form	O
of	O
free	O
ho	B
##mo	I
##cy	I
##stein	I
##e	I
(	O
HC	O
##y	O
)	O
,	O
dim	O
##ers	O
,	O
and	O
analogue	O
molecular	O
forms	O
bound	O
by	O
di	B
##sul	I
##fi	I
##de	I
bridges	O
to	O
proteins	O
or	O
other	O
th	O
##iol	O
-	O
containing	O
compounds	O
.	O

P	O
##las	O
##ma	O
total	O
T	O
##4	O
levels	O
showed	O
a	O
simultaneous	O
increase	O
with	O
the	B
##op	I
##hyl	I
##line	I
levels	O
over	O
the	O
whole	O
experiment	O
time	O
and	O
were	O
accompanied	O
by	O
an	O
increase	O
in	O
plasma	O
as	O
well	O
as	O
u	O
##rina	O
##ry	O
c	O
##yclic	O
ad	O
##eno	O
##sin	O
##e	O
3	O
'	O
,	O
5	O
'	O
-	O
mon	O
##op	O
##hos	O
##phate	O
(	O
c	O
##AM	O
##P	O
)	O
levels	O
.	O

The	O
significantly	O
increased	O
levels	O
of	O
serum	O
co	B
##rt	I
##is	I
##ol	I
were	O
found	O
in	O
patients	O
with	O
advanced	O
PD	O
.	O

In	O
fact	O
,	O
2	B
-	I
amino	I
##adi	I
##pic	I
and	O
2	B
-	I
amino	I
##he	I
##pta	I
##ned	I
##io	I
##ic	I
acids	I
are	O
α	B
-	I
amino	I
bi	I
##car	I
##box	I
##yl	I
##ic	I
acids	I
differing	O
by	O
only	O
one	O
carbon	O
(	O
i	O
.	O
e	O
.	O
,	O
they	O
are	O
ho	O
##mo	O
##log	O
##ous	O
)	O
,	O
and	O
both	O
were	O
less	O
abundant	O
in	O
DL	O
##BC	O
##L	O
and	O
C	O
##LL	O
patients	O
compared	O
to	O
the	O
controls	O
.	O

The	O
strongest	O
signals	O
were	O
for	O
N	B
-	I
ace	I
##ty	I
##ltry	I
##pt	I
##op	I
##han	I
(	O
β	O
=	O
0	O
.	O
27	O
;	O
SE	O
=	O
0	O
.	O
03	O
##2	O
;	O
p	O
=	O
9	O
.	O
8	O
×	O
10	O
_	O
−	O
##17	O
)	O
,	O
my	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
(	O
β	O
=	O
0	O
.	O
23	O
;	O
SE	O
=	O
0	O
.	O
03	O
##2	O
;	O
p	O
=	O
9	O
.	O
8	O
×	O
10	O
_	O
−	O
##13	O
)	O
,	O
and	O
1	B
-	I
palm	I
##ito	I
##yl	I
##gly	I
##cer	I
##op	I
##hos	I
##ph	I
##oe	I
##than	I
##ola	I
##mine	I
(	O
β	O
=	O
0	O
.	O
22	O
;	O
SE	O
=	O
0	O
.	O
03	O
##2	O
;	O
p	O
=	O
3	O
.	O
2	O
×	O
10	O
_	O
−	O
##12	O
)	O
.	O

In	O
the	O
900	O
MHz	O
s	O
##pect	O
##ra	O
,	O
beta	B
##ine	I
and	O
ch	B
##olin	I
##e	I
were	O
added	O
to	O
the	O
above	O
list	O
of	O
meta	O
##bol	O
##ites	O
.	O

Although	O
not	O
directly	O
detected	O
by	O
the	O
N	O
##MR	O
approach	O
used	O
in	O
this	O
study	O
,	O
our	O
results	O
strongly	O
suggest	O
that	O
g	B
##ly	I
##cine	I
could	O
be	O
a	O
highly	O
inform	O
##ative	O
bio	O
##mark	O
##er	O
to	O
the	O
inflammatory	O
processes	O
that	O
character	O
##ize	O
I	O
##MI	O
##Ds	O
.	O

The	O
4	O
.	O
5	O
-	O
to	O
6	O
.	O
0	O
-	O
pp	O
##m	O
chemical	O
-	O
shift	O
region	O
was	O
left	O
out	O
of	O
the	O
analysis	O
to	O
remove	O
the	O
effects	O
of	O
variations	O
in	O
the	O
suppression	O
of	O
the	O
water	O
resonance	O
and	O
variations	O
in	O
the	O
u	B
##rea	I
signal	O
caused	O
by	O
partial	O
cross	O
-	O
solvent	O
sat	O
##uration	O
through	O
solvent	O
-	O
ex	O
##changing	O
pro	O
##tons	O
.	O

The	O
most	O
disc	O
##rim	O
##inating	O
meta	O
##bol	O
##ites	O
with	O
P	O
<	O
.	O
000	O
##0	O
##5	O
were	O
la	B
##ct	I
##ate	I
which	O
increased	O
and	O
format	B
##e	I
which	O
decreased	O
post	O
##che	O
##mother	O
##ap	O
##y	O
.	O

Further	O
research	O
is	O
needed	O
to	O
understand	O
the	O
meaning	O
of	O
these	O
findings	O
,	O
including	O
the	O
inter	O
##play	O
between	O
variation	O
in	O
end	O
##ogen	O
##ous	O
er	B
##yt	I
##hr	I
##ito	I
##l	I
synthesis	O
and	O
ex	O
##ogen	O
##ous	O
exposure	O
to	O
er	O
##yt	O
##hr	O
##ito	O
##l	O
-	O
containing	O
foods	O
.	O

High	O
##light	O
##ed	O
candidate	O
markers	O
are	O
:	O
1	O
)	O
Ace	B
##tate	I
,	O
2	O
)	O

Met	O
##ab	O
##olo	O
##mic	O
##s	O
is	O
the	O
high	O
-	O
through	O
##put	O
study	O
of	O
small	O
molecules	O
such	O
as	O
amino	O
acids	O
,	O
ni	B
##trate	I
##s	I
,	O
sugar	O
##s	O
,	O
and	O
lip	O
##ids	O
.	O

Gen	O
##omi	O
##c	O
de	B
##ox	I
##yr	I
##ib	I
##on	I
##uc	I
##le	I
##ic	I
acid	I
(	O
DNA	O
)	O
was	O
removed	O
by	O
D	O
##N	O
##ase	O
treatment	O
(	O
Pure	O
##L	O
##ink	O
[UNK]	O
D	O
##N	O
##ase	O
Set	O
)	O
.	O

In	O
the	O
case	O
when	O
su	O
##lf	O
##ata	O
##se	O
was	O
used	O
,	O
0	O
.	O
05	O
m	O
##L	O
of	O
the	O
in	O
##cu	O
##bate	O
##d	O
mixture	O
were	O
transferred	O
in	O
a	O
mi	O
##ct	O
##rot	O
##iter	O
plate	O
,	O
treated	O
with	O
0	O
.	O
05	O
m	O
##L	O
Na	O
##OH	O
1	O
M	O
and	O
the	O
obtained	O
p	B
-	I
ni	I
##tro	I
##cate	I
##cho	I
##l	I
was	O
measured	O
at	O
490	O
nm	O
to	O
appreciate	O
the	O
des	O
##ulf	O
##ata	O
##tion	O
process	O
efficiency	O
against	O
a	O
standard	O
of	O
p	B
-	I
ni	I
##tro	I
##cate	I
##cho	I
##l	I
in	O
water	O
(	O
concentration	O
of	O
0	O
.	O
32	O
m	O
##M	O
##ol	O
/	O
L	O
,	O
corresponding	O
to	O
the	O
expected	O
levels	O
of	O
p	B
-	I
ni	I
##tro	I
##cate	I
##cho	I
##l	I
a	O
##chi	O
##eva	O
##ble	O
in	O
the	O
samples	O
with	O
a	O
complete	O
en	O
##zy	O
##matic	O
degradation	O
)	O
.	O

In	O
contrast	O
,	O
the	O
CR	O
##C	O
group	O
showed	O
a	O
higher	O
abundance	O
of	O
p	B
##oly	I
##amine	I
##s	I
(	O
ca	O
##da	O
##ver	O
##ine	O
,	O
1	B
,	I
4	I
-	I
But	I
##ane	I
##dia	I
##mine	I
)	O
,	O
amino	O
acids	O
(	O
Pro	O
,	O
G	O
##lu	O
)	O
and	O
u	B
##rea	I
,	O
suggesting	O
that	O
the	O
H	O
group	O
is	O
better	O
able	O
to	O
maintain	O
car	O
##bo	O
##hy	O
##dra	O
##te	O
metabolism	O
and	O
a	O
more	O
red	O
##uctive	O
environment	O
in	O
the	O
gut	O
than	O
in	O
the	O
CR	O
##C	O
group	O
(	O
Su	O
##pp	O
##lement	O
##ary	O
Table	O
,	O
Figure	O
A	O
)	O
.	O

Ph	B
##os	I
##pha	I
##ti	I
##dy	I
##loc	I
##hol	I
##ines	I
are	O
the	O
main	O
building	O
blocks	O
of	O
membrane	O
bi	O
##layer	O
##s	O
and	O
in	O
plasma	O
they	O
are	O
mostly	O
located	O
in	O
high	O
density	O
lip	O
##op	O
##rote	O
##ins	O
(	O
HD	O
##L	O
)	O
.	O

In	O
the	O
present	O
study	O
,	O
8	O
major	O
s	B
##phi	I
##ngo	I
##lip	I
##id	I
meta	O
##bol	O
##ites	O
,	O
namely	O
SM	O
,	O
So	O
,	O
Sa	O
,	O
So	O
##1	O
##P	O
,	O
Sa	O
##1	O
##P	O
,	O
Ce	B
##r	I
,	O
G	O
##lu	O
##C	O
##er	O
and	O
Lac	B
##C	I
##er	I
,	O
which	O
occur	O
in	O
the	O
metabolic	O
pathway	O
of	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
,	O
were	O
measured	O
.	O

Between	O
analyses	O
,	O
columns	O
were	O
washed	O
with	O
1	O
:	O
1	O
CO	O
_	O
2	O
:	B
met	I
##han	I
##ol	I
at	O
1	O
m	O
##L	O
/	O
min	O
for	O
50	O
min	O
,	O
then	O
stored	O
in	O
100	O
%	O
CO	O
_	O
2	O
.	O

Reports	O
indicate	O
that	O
car	B
##ni	I
##tine	I
can	O
dim	O
##ini	O
##sh	O
the	O
risk	O
of	O
o	O
##besity	O
caused	O
by	O
a	O
high	O
-	O
fat	O
diet	O
in	O
mice	O
or	O
in	O
o	O
##bes	O
##e	O
humans	O
.	O

H	B
##y	I
##pox	I
##ant	I
##hine	I
is	O
also	O
high	O
in	O
f	O
##eca	O
##l	O
samples	O
in	O
a	O
chronic	O
variable	O
stress	O
rat	O
model	O
of	O
depression	O
.	O

Li	O
##pid	O
,	O
-	O
CH	O
=	O
CH	O
-	O
;	O
Lac	O
:	O
Lac	B
##tate	I
;	O
Le	O
##u	O
:	O
Le	B
##uc	I
##ine	I
;	O
L	O
##ys	O
:	O
L	B
##ys	I
##ine	I
;	O
MA	O
:	O
Met	B
##hyl	I
##amine	I
;	O
N	O
##AG	O
:	O
N	B
-	I
ace	I
##ty	I
##l	I
g	I
##ly	I
##co	I
##p	I
##rote	I
##in	I
signals	O
;	O
PC	O
:	O
Ph	B
##os	I
##ph	I
##och	I
##olin	I
##e	I
:	O
Ph	O
##e	O
:	O
Ph	B
##en	I
##yla	I
##lani	I
##ne	I
;	O
P	O
##y	O
:	O

Oro	O
##pha	O
##ryn	O
##ge	O
##al	O
can	O
##di	O
##dia	O
##sis	O
caused	O
by	O
C	O
.	O
al	O
##bic	O
##ans	O
,	O
which	O
produces	O
Ethan	B
##ol	I
via	O
an	O
##ae	O
##ro	O
##bic	O
f	O
##er	O
##mentation	O
,	O
is	O
the	O
most	O
prevalent	O
op	O
##port	O
##uni	O
##stic	O
infection	O
in	O
HIV	O
/	O
AIDS	O
.	O

The	O
activity	O
of	O
x	B
##ant	I
##hine	I
o	O
##xi	O
##das	O
##e	O
was	O
observed	O
to	O
decrease	O
in	O
individual	O
cancer	O
.	O

Similar	O
findings	O
were	O
found	O
for	O
un	O
##met	O
##ab	O
##oli	O
##zed	O
e	B
##pi	I
##gall	I
##oc	I
##ate	I
##chin	I
after	O
green	O
-	O
tea	O
consumption	O
.	O

It	O
is	O
apparent	O
that	O
changes	O
in	O
album	O
##in	O
,	O
total	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
L	O
##D	O
##L	O
,	O
grip	O
strength	O
,	O
l	O
##ys	O
##o	O
##PC	O
##s	O
(	O
16	O
:	O
0	O
,	O
17	O
:	O
0	O
,	O
18	O
:	O
0	O
,	O
18	O
:	O
1	O
(	O
11	O
##Z	O
)	O
,	O
18	O
:	O
3	O
(	O
9	O
##Z	O
,	O
12	O
##Z	O
,	O
15	O
##Z	O
)	O
,	O
P	B
-	I
18	I
:	I
1	I
(	I
9	I
##Z	I
)	I
,	O
20	O
:	O
1	O
(	O
11	O
##Z	O
)	O
,	O
(	O
20	O
:	O
3	O
(	B
8	B
##Z	I
,	I
11	I
##Z	I
,	I
14	I
##Z	I
)	O
)	O
,	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##och	I
##olin	I
##e	I
,	O
or	B
##ni	I
##thin	I
##e	I
,	O
g	B
##lu	I
##cu	I
##ronic	I
acid	I
,	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##ose	I
##rine	I
and	O
ta	B
##uro	I
##cho	I
##lic	I
acid	I
were	O
correlated	O
with	O
Child	O
-	O
P	O
##ugh	O
score	O
,	O
suggesting	O
that	O
these	O
index	O
##es	O
could	O
be	O
used	O
as	O
an	O
indicator	O
of	O
the	O
he	O
##pa	O
##tic	O
com	O
##pen	O
##sat	O
##ory	O
capacity	O
.	O

El	O
##eva	O
##ted	O
AD	B
##MA	I
and	O
diminished	O
GA	O
##BR	O
were	O
associated	O
with	O
higher	O
s	O
##ys	O
##to	O
##lic	O
pulmonary	O
artery	O
pressure	O
(	O
s	O
##PA	O
##P	O
)	O
and	O
higher	O
central	O
ve	O
##nous	O
pressure	O
,	O
but	O
not	O
with	O
other	O
clinical	O
or	O
hem	O
##ody	O
##nam	O
##ic	O
in	O
##dices	O
.	O

For	O
instance	O
,	O
treatment	O
with	O
ex	O
##ogen	O
##ous	O
sperm	B
##ine	I
has	O
been	O
shown	O
to	O
be	O
effective	O
in	O
decreasing	O
body	O
weight	O
and	O
fast	O
##ing	O
glucose	S
and	O
improve	O
##s	O
glucose	S
tolerance	O
in	O
diet	O
-	O
induced	O
o	O
##bes	O
##e	O
mice	O
.	O

To	O
determine	O
the	O
inhibitor	O
##y	O
effect	O
on	O
human	O
B	O
##u	O
##C	O
##h	O
##E	O
,	O
the	O
serum	O
samples	O
were	O
previously	O
in	O
##cu	O
##bate	O
##d	O
with	O
Te	O
##m	O
-	O
do	O
##x	O
-	O
S	O
##O	O
_	O
2	O
(	O
0	O
.	O
02	O
to	O
2	O
μ	O
##M	O
)	O
or	O
et	B
##hyl	I
-	I
para	I
##ox	I
##on	I
(	O
0	O
.	O
01	O
to	O
1	O
μ	O
##M	O
)	O
during	O
10	O
min	O
at	O
37	O
°C	O
,	O
and	O
the	O
en	O
##zy	O
##matic	O
activity	O
was	O
evaluated	O
as	O
previously	O
described	O
,	O
in	O
three	O
independent	O
experiments	O
conducted	O
in	O
du	O
##plicate	O
.	O

Eight	O
meta	O
##bol	O
##ites	O
(	O
AD	O
##MA	O
,	O
o	B
##ct	I
##ade	I
##cano	I
##yl	I
##car	I
##ni	I
##tine	I
and	O
6	O
PC	O
##s	O
)	O
were	O
significantly	O
altered	O
between	O
R	O
##R	O
##MM	O
-	O
and	O
MG	O
##US	O
patients	O
(	O
and	O
Part	O
E	O
in	O
)	O
.	O

(	B
CDP	I
-	I
ch	I
##olin	I
##e	I
)	I
→	I
PC	I
→	I
L	I
##ys	I
##o	I
##PC	I
→	I
l	I
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dic	I
acid	I
(	O
LP	O
##A	O
)	O
.	O

We	O
also	O
observed	O
a	O
consistent	O
down	O
##re	O
##gu	O
##lation	O
of	O
dip	O
##eptide	O
##s	O
p	B
##yr	I
##og	I
##lut	I
##am	I
##yl	I
##gly	I
##cine	I
,	O
g	B
##ly	I
##cy	I
##l	I
##val	I
##ine	I
,	O
al	B
##any	I
##lal	I
##ani	I
##ne	I
and	O
as	B
##par	I
##ty	I
##le	I
##uc	I
##ine	I
in	O
DC	O
vs	O
.	O
NH	O
##C	O
.	O

Although	O
age	O
did	O
not	O
show	O
any	O
correlation	O
with	O
se	B
##rot	I
##oni	I
##n	I
,	O
it	O
was	O
inverse	O
##ly	O
related	O
to	O
the	O
se	B
##rot	I
##oni	I
##n	I
turnover	O
meta	O
##bol	O
##ite	O
5	B
-	I
h	I
##ydro	I
##xy	I
-	I
3	I
-	I
in	I
##do	I
##le	I
ace	I
##tic	I
acid	I
(	O
5	O
-	O
OH	O
I	O
##AA	O
,	O
R	O
=	O
−	O
##0	O
.	O
55	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

In	O
generally	O
,	O
v	B
##ali	I
##ne	I
and	O
is	B
##ole	I
##uc	I
##ine	I
are	O
called	O
branched	O
-	O
chain	O
amino	O
acids	O
(	O
BC	O
##AA	O
##s	O
)	O
because	O
of	O
their	O
al	O
##ip	O
##hat	O
##ic	O
side	O
-	O
chains	O
.	O

Di	O
##abe	O
##tes	O
was	O
defined	O
as	O
the	O
use	O
of	O
glucose	O
-	O
lowering	O
medications	O
,	O
fast	O
##ing	O
glucose	S
≥	O
126	O
mg	O
/	O
d	O
##L	O
,	O
or	O
(	O
in	O
SK	O
##S	O
only	O
)	O
random	O
glucose	S
≥	O
200	O
mg	O
/	O
d	O
##L	O
.	O
H	O
##yper	O
##tens	O
##ion	O
was	O
defined	O
as	O
the	O
use	O
of	O
anti	O
##hy	O
##pert	O
##ens	O
##ive	O
medications	O
,	O
s	O
##ys	O
##to	O
##lic	O
blood	O
pressure	O

Moreover	O
,	O
serum	O
levels	O
of	O
l	B
##ys	I
##o	I
##PC	I
(	I
18	I
:	I
2	I
)	I
,	O
Ph	O
##e	O
##P	O
##he	O
,	O
u	B
##rid	I
##ine	I
,	O
ta	B
##uri	I
##ne	I
,	O
L	B
-	I
th	I
##re	I
##oni	I
##ne	I
,	O
and	O
(	B
R	I
)	I
-	I
3	I
-	I
H	I
##ydro	I
##xy	I
-	I
he	I
##xa	I
##de	I
##cano	I
##ic	I
acid	I
were	O
significantly	O
correlated	O
with	O
clinical	O
activity	O
scores	O
(	O
all	O
p	O
<	O
0	O
.	O
05	O
)	O
in	O
A	O
##OS	O
##D	O
patients	O
.	O

In	O
the	O
product	O
label	O
of	O
the	O
drug	O
,	O
h	B
##ydro	I
##xy	I
##ana	I
##stro	I
##zo	I
##le	I
g	I
##lu	I
##cu	I
##ron	I
##ide	I
has	O
been	O
stated	O
to	O
be	O
one	O
of	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
meta	O
##bol	O
##ites	O
in	O
human	O
.	O

≥	O
7	O
.	O
0	O
mm	O
##ol	O
/	O
L	O
,	O
2	O
-	O
hour	O
glucose	B

In	O
conclusion	O
,	O
we	O
have	O
identified	O
distinct	O
patterns	O
of	O
C	O
##YP	O
##2	O
##A	O
##6	O
genetic	O
variation	O
and	O
rates	O
of	O
ni	B
##cot	I
##ine	I
metabolism	O
between	O
two	O
AI	O
/	O
AN	O
tribal	O
populations	O
with	O
different	O
smoking	O
patterns	O
and	O
risk	O
for	O
lung	O
cancer	O
.	O

Evidence	O
suggests	O
that	O
disturbed	O
ch	B
##ole	I
##ster	I
##ol	I
metabolism	O
and	O
h	O
##yper	O
##cho	O
##les	O
##tero	O
##lem	O
##ia	O
are	O
important	O
factors	O
in	O
am	O
##yl	O
##oid	O
plaque	O
formation	O
and	O
ta	O
##u	O
h	O
##yper	O
##ph	O
##os	O
##ph	O
##ory	O
##lation	O
.	O

Total	O
SM	O
was	O
positively	O
correlated	O
with	O
W	O
##H	O
##R	O
and	O
3	O
lip	O
##id	O
molecular	O
species	O
,	O
such	O
as	O
CE	O
,	O
c	B
##era	I
##mi	I
##de	I
and	O
plasma	B
##ny	I
##l	I
PC	I
.	O

Our	O
findings	O
appear	O
to	O
differ	O
from	O
previous	O
investigations	O
,	O
which	O
showed	O
increased	O
plasma	O
concentrations	O
of	O
the	O
branched	O
chain	O
amino	O
acids	O
and	O
al	B
##ani	I
##ne	I
in	O
insulin	O
-	O
resistant	O
states	O
such	O
as	O
o	O
##besity	O
[	O
,	O
]	O
.	O

S	B
##phi	I
##ngo	I
##my	I
##elin	I
##s	I
(	O
SM	O
##s	O
)	O
are	O
lip	O
##ids	O
that	O
regulate	O
many	O
cellular	O
functions	O
,	O
since	O
they	O
transmit	O
the	O
trans	O
##me	O
##mb	O
##rane	O
signals	O
through	O
micro	O
##dom	O
##ain	O
##s	O
and	O
the	O
in	O
##tra	O
##cellular	O
ve	O
##si	O
##cular	O
trafficking	O
.	O

V	O
##eno	O
##us	O
specimens	O
were	O
collected	O
before	O
glucose	S
loading	O
,	O
at	O
loading	O
,	O
and	O
30	O
,	O
60	O
,	O
and	O
120	O
min	O
after	O
loading	O
to	O
determine	O
the	O
serum	O
glucose	S
levels	O
and	O
responses	O
.	O

Alt	O
##ered	O
pathways	O
include	O
changes	O
in	O
amino	O
acid	O
metabolism	O
,	O
bio	O
##sy	O
##nt	O
##hesis	O
and	O
degradation	O
(	B
g	B
##lut	I
##amine	I
,	O
l	B
##ys	I
##ine	I
,	O
car	B
##ni	I
##tine	I
,	O
v	B
##ali	I
##ne	I
,	O
le	O
##uc	O
##ine	O
/	O
is	O
##ole	O
##uc	O
##ine	O
,	O
met	B
##hi	I
##oni	I
##ne	I
,	O
try	B
##pt	I
##op	I
##han	I
,	O
5	B
-	I
h	I
##ydro	I
##xy	I
##try	I
##top	I
##han	I
,	O
and	O
t	B
##yr	I
##os	I
##ine	I
)	O
,	O
g	O
##ly	O
##co	O
##lysis	O
(	O
la	O
##ct	O
##ate	O
and	O
glucose	B
)	I
,	O
k	B
##eton	I
##e	I
bodies	O
synthesis	O
and	O
degradation	O
(	B
β	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##ya	I
##te	I
)	O
,	O
t	B
##rica	I
##rb	I
##ox	I
##yl	I
##ic	I
acid	I
(	O
T	O
##CA	O
)	O
cycle	O
(	O
c	O
##it	O
##rate	O
)	O
and	O
fatty	O
acid	O
metabolism	O
(	O
l	O
##ino	O
##le	O
##ic	O
acid	O
,	O
l	B
##ino	I
##len	I
##ic	I
acid	I
and	O
my	B
##rist	I
##ic	I
acid	O
)	O
.	O

Vita	O
##min	O
-	O
D	O
##3	O
derivatives	O
,	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
,	O
PC	O
,	O
and	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##let	I
##han	I
##ola	I
##mine	I
##s	I
(	O
P	O
##E	O
)	O
were	O
only	O
found	O
in	O
met	B
##han	I
##ol	I
-	I
ethanol	I
extracted	O
samples	O
,	O
while	O
h	B
##ydro	I
##xy	I
##l	I
-	I
or	O
br	O
##omo	O
-	O
modified	O
fatty	O
acid	O
and	O
car	B
##ni	I
##tine	I
analog	O
##s	O
were	O
found	O
only	O
when	O
the	O
met	B
##han	I
##ol	I
-	I
only	I
method	O
was	O
used	O
.	O

Met	O
##ab	O
##olic	O
changes	O
in	O
many	O
amino	O
acids	O
consist	O
of	O
se	B
##rine	I
and	O
g	B
##ly	I
##cine	I
affect	O
the	O
biological	O
behavior	O
of	O
them	O
.	O

All	O
analyses	O
were	O
done	O
using	O
ST	O
##AT	O
##A	O
(	O
St	O
##ata	O
##C	O
##or	O
##p	O
LP	S
,	O
College	O
Station	O
,	O
TX	O
)	O
and	O
P	O
values	O
less	O
than	O
0	O
.	O
05	O
considered	O
as	O
statistical	O
##ly	O
significant	O
.	O

Next	O
,	O
the	O
22	O
o	B
##xy	I
##lip	I
##ins	I
identified	O
as	O
the	O
significant	O
contributors	O
to	O
the	O
P	O
##LS	O
-	O
D	O
##A	O
model	O
were	O
cluster	O
##ed	O
by	O
expression	O
pattern	O
using	O
the	O
J	O
##MP	O
13	O
Pro	O
cluster	O
variable	O
algorithm	O
.	O

In	O
addition	O
,	O
L	O
##F	O
/	O
L	O
##C	O
-	O
MS	O
(	O
±	O
)	O
determined	O
significant	O
differences	O
in	O
non	O
-	O
polar	O
lip	O
##ids	O
such	O
as	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
(	O
PC	O
)	O
,	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
(	O
SM	O
)	O
and	O
mon	O
##o	O
,	O
di	O
-	O
and	O
t	B
##ria	I
##cy	I
##l	I
##gly	I
##cer	I
##ides	I
(	O
MG	O
,	O
D	O
##G	O
and	O
T	O
##G	O
)	O
.	O

Cell	O
p	O
##elle	O
##ts	O
were	O
suspended	O
in	O
8	O
M	O
u	B
##rea	I
(	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
)	O
,	O
50	O
m	O
##M	O
am	B
##mon	I
##ium	I
bi	O
##car	O
##bon	O
##ate	O
and	O
10	O
%	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
(	O
AC	O
##N	O
)	O
resulting	O
in	O
protein	O
yields	O
51	O
##6	O
-	O
52	O
##8	O
μ	O
##g	O
.	O

The	O
sperm	O
ch	B
##roma	I
##tin	I
structural	O
ass	O
##ay	O
(	O
SC	O
##SA	O
)	O
was	O
performed	O
as	O
described	O
with	O
slight	O
modifications	O
.	O

For	O
U	O
##HP	O
##LC	O
/	O
MS	O
analysis	O
,	O
extract	O
al	O
##iq	O
##uo	O
##ts	O
were	O
re	O
##con	O
##stituted	O
in	O
either	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
for	O
positive	O
ion	O
U	O
##HP	O
##LC	O
/	O
MS	O
,	O
or	O
6	O
.	O
5	O
m	O
##M	O
am	B
##mon	I
##ium	I
bi	O
##car	O
##bon	O
##ate	O
pH	O
8	O
.	O
0	O
for	O
negative	O
ion	O
U	O
##HP	O
##LC	O
/	O
MS	O
.	O

This	O
process	O
is	O
less	O
efficient	O
,	O
so	O
cancer	O
cells	O
must	O
enhance	O
glucose	S
up	O
##take	O
to	O
meet	O
the	O
energy	O
requirement	O
maintaining	O
their	O
quickly	O
growth	O
and	O
proliferation	O
.	O

P	O
##las	O
##ma	O
samples	O
were	O
cent	O
##ri	O
##fu	O
##ged	O
at	O
21	O
,	O
000	O
##×	O
##g	O
,	O
for	O
5	O
min	O
after	O
de	O
##p	O
##rote	O
##ination	O
with	O
an	O
equal	O
volume	O
of	O
perch	B
##lor	I
##ic	I
acid	I
(	O
0	O
.	O
4	O
M	O
,	O
containing	O
0	O
.	O
1	O
%	O
sodium	B
meta	I
##bis	I
##ulf	I
##ite	I
and	O
0	O
.	O
05	O
%	O
E	O
##D	O
##TA	O
)	O
.	O

These	O
18	O
meta	O
##bol	O
##ites	O
were	O
:	O
ace	B
##ty	I
##l	I
##phe	I
##ny	I
##lal	I
##ani	I
##ne	I
,	O
h	B
##ydro	I
##xy	I
##try	I
##pt	I
##op	I
##han	I
,	O
k	B
##yn	I
##uren	I
##ine	I
,	O
fur	B
##oy	I
##l	I
##gly	I
##cine	I
,	O
co	B
##rt	I
##is	I
##ol	I
,	O
h	B
##ydro	I
##xy	I
##phe	I
##ny	I
##lace	I
##tic	I
acid	I
,	O
g	B
##ly	I
##cine	I
,	O
t	B
##ig	I
##ly	I
##l	I
##gly	I
##cine	I
,	O
amino	B
##but	I
##yric	I
acid	I
,	O
h	B
##ydro	I
##xy	I
##ben	I
##zoic	I
acid	I
,	O
x	B
##ant	I
##hur	I
##eni	I
##c	I
acid	I
,	O
h	B
##ydro	I
##xy	I
##p	I
##rog	I
##ester	I
##one	I
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
al	B
##ani	I
##ne	I
,	O
le	B
##uc	I
##ine	I
,	O
p	B
##hen	I
##yla	I
##ce	I
##ty	I
##l	I
##g	I
##lut	I
##amine	I
,	O
di	B
##hy	I
##dr	I
##oc	I
##ort	I
##is	I
##ol	I
and	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
.	O

D	O
##MA	O
##P	O
and	O
th	B
##iam	I
##eth	I
##ox	I
##am	I
can	O
be	O
good	O
bio	O
##mark	O
##ers	O
of	O
environmental	O
N	O
##N	O
##s	O
exposure	O
related	O
to	O
neo	O
-	O
ni	O
##cot	O
##ini	O
##c	O
symptoms	O
.	O

0	O
.	O
90	O
##1	O
mg	O
T	O
##RP	O
,	O
1	O
.	O
248	O
mg	O
K	O
##Y	O
##N	O
,	O
1	O
.	O
28	O
##2	O
mg	O
Q	O
##UI	O
##N	O
were	O
weighed	O
accurately	O
and	O
then	O
dissolved	O
and	O
mixed	O
in	O
50	O
%	O
met	B
##han	I
##ol	I
solution	O
,	O
respectively	O
,	O
to	O
make	O
1	O
mg	O
/	O
m	O
##l	O
standard	O
stock	O
solution	O
;	O
0	O
.	O
67	O
##1	O
mg	O
K	O
##Y	O
##NA	O
was	O
weighed	O
accurately	O
and	O
then	O
dissolved	O
and	O
mixed	O
in	O
ultra	O
-	O
pure	O
water	O
to	O
make	O
0	O
.	O
167	O
mg	O
/	O
m	O
##l	O
standard	O
stock	O
solution	O
,	O
which	O
was	O
split	O
storing	O
in	O
−	O
##20	O
##°	O
##C	O
.	O

Most	O
u	O
##rina	O
##ry	O
s	O
##tero	O
##id	O
meta	O
##bol	O
##ites	O
showed	O
an	O
age	O
-	O
dependence	O
with	O
the	O
exception	O
of	O
6	B
##β	I
-	I
OH	I
-	I
co	I
##rt	I
##is	I
##ol	I
,	O
18	B
-	I
OH	I
-	I
co	I
##rt	I
##is	I
##ol	I
,	O
and	O
β	B
-	I
co	I
##rt	I
##ol	I
.	O

Analysis	O
of	O
the	O
P	O
##LS	O
-	O
D	O
##A	O
loading	O
plots	O
indicated	O
that	O
only	O
a	O
few	O
meta	O
##bol	O
##ites	O
,	O
such	O
as	O
v	B
##ali	I
##ne	I
,	O
ch	B
##olin	I
##e	I
,	O
al	B
##ani	I
##ne	I
,	O
c	B
##rea	I
##tine	I
and	O
as	B
##par	I
##agi	I
##ne	I
,	O
contributed	O
to	O
the	O
separation	O
.	O

The	O
O	O
-	O
P	O
##LS	O
-	O
D	O
##A	O
scores	O
plot	O
showing	O
discrimination	O
between	O
two	O
classes	O
(	O
blue	O
,	O
control	O
;	O
red	O
,	O
participants	O
who	O
had	O
taken	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
)	O
.	O

By	O
processing	O
the	O
features	O
of	O
interest	O
using	O
their	O
put	O
##ative	O
meta	O
##bol	O
##ite	O
identity	O
utilizing	O
the	O
IPA	O
_	O
®	O
platform	O
(	O
In	O
##gen	O
##uity	O
Systems	O
,	O
Inc	O
)	O
,	O
a	O
number	O
of	O
canonical	O
pathways	O
in	O
serum	O
and	O
tissue	O
were	O
identified	O
,	O
with	O
amino	S
and	O
fatty	O
acid	O
metabolism	O
ending	O
up	O
among	O
the	O
top	O
ranked	O
pathways	O
.	O

Note	O
,	O
that	O
for	O
this	O
data	O
##set	O
no	O
prior	O
c	B
##rea	I
##tin	I
##ine	I
normal	O
##ization	O
was	O
performed	O
and	O
,	O
therefore	O
,	O
in	O
the	O
top	O
left	O
part	O
of	O
the	O
Figure	O
results	O
obtained	O
from	O
non	O
-	O
normal	O
##ized	O
data	O
are	O
displayed	O
.	O

Finally	O
,	O
the	O
most	O
abundant	O
amino	O
acid	O
in	O
plasma	O
,	O
g	B
##lut	I
##amine	I
,	O
can	O
be	O
transported	O
across	O
the	O
blood	O
-	O
brain	O
-	O
barrier	O
and	O
undergo	O
conversion	O
into	O
g	B
##lut	I
##ama	I
##te	I
-	I
a	O
ne	O
##uro	O
##tra	O
##ns	O
##mit	O
##ter	O
which	O
is	O
increased	O
in	O
the	O
posterior	O
h	O
##y	O
##pot	O
##hala	O
##mic	O
region	O
of	O
sleep	O
-	O
deprived	O
rode	O
##nts	O
.	O

He	O
##tero	O
##nu	O
##cle	O
##ar	O
multiple	O
bond	O
correlation	O
experiments	O
were	O
also	O
performed	O
,	O
but	O
produced	O
inferior	O
results	O
to	O
H	O
##S	O
##Q	O
##C	O
.	O
_	O
13	O
C	O
N	O
##MR	O
spectrum	O
of	O
normal	O
human	O
urine	O
(	O
a	O
)	O
,	O
normal	O
human	O
urine	O
after	O
der	O
##iva	O
##ti	O
##zation	O
with	O
1	B
,	I
1	I
′	I
-	I
_	I
13	I
C	I
_	I
2	I
ace	I
##tic	I
an	I
##hy	I
##dr	I
##ide	I
(	O
b	O
)	O
,	O
and	O
2D	O
H	O
##S	O
##Q	O
##C	O
spectrum	O
of	O
der	O
##iva	O
##tized	O
normal	O
urine	O
showing	O
distinct	O
amino	O
acid	O
signals	O
with	O
increased	O
sensitivity	O
(	O
c	O
)	O
.	O

After	O
sample	S
loading	S
,	S
the	S
cartridges	S
were	S
washed	S
with	S
3	S
m	S
##L	S
of	S
water	S
,	S
3	S
m	S
##L	S
of	S
water	S
/	S
ace	S
##ton	O
##it	O
##ril	O
##e	O
(	O
95	O
:	O
5	O
,	O
v	O
/	O
v	O
)	O
and	O
el	O
##uted	O
with	O
3	O
m	O
##L	O
met	B
##han	I
##ol	I
.	O

17	O
[	O
Google	O
Scholar	O
]	O
Smith	O
PC	O
,	O
M	O
##c	O
##D	O
##ona	O
##gh	O
A	B
##F	I
,	O
Ben	O
##et	O
L	O
##Z	O
.	O

St	O
##ead	O
##y	O
state	O
was	O
achieved	O
from	O
4	O
to	O
6	O
h	O
after	O
start	O
of	O
the	O
prime	O
##d	O
continuous	O
in	O
##fusion	O
for	O
1	O
-	O
_	O
13	O
C	B
-	I
g	I
##ly	I
##cola	I
##te	I
.	O

Tri	B
##met	I
##hyl	I
##amine	I
N	I
-	I
oxide	I
is	O
also	O
associated	O
with	O
onset	O
of	O
C	O
##K	O
##D	O
.	O

L	O
##C	O
/	O
MS	O
grade	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
,	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
in	O
water	O
,	O
met	B
##han	I
##ol	I
,	O
and	O
ace	B
##tone	I
were	O
purchased	O
from	O
Fischer	O
Scientific	O
Co	O
.	O
(	O
Pittsburgh	O
,	O
PA	O
,	O
USA	O
)	O
.	O

I	O
##mp	O
##aire	O
##d	O
brain	B
-	I
glucose	I
regulation	O
has	O
been	O
tentatively	O
attributed	O
to	O
a	O
functional	O
defect	O
of	O
glucose	S
transport	O
##er	O
(	O
G	O
##L	O
##UT	O
)	O
-	O
mediated	O
glucose	S
up	O
##take	O
,	O
but	O
ne	O
##uron	O
##al	O
loss	O
may	O
be	O
responsible	O
for	O
some	O
of	O
this	O
effect	O
,	O
and	O
there	O
is	O
ongoing	O
argument	O
concerning	O
the	O
contribution	O
of	O
this	O
mechanism	O
to	O
defect	O
##ive	O
brain	B
-	I
glucose	I
up	O
##take	O
and	O
ne	O
##uro	O
##de	O
##gene	O
##ration	O
.	O

Those	O
enrolled	O
met	O
the	O
following	O
criteria	O
:	O
1	O
)	O
>	O
18	O
y	O
##r	O
of	O
age	O
,	O
2	O
)	O
scheduled	O
for	O
co	O
##rona	O
##ry	O
an	O
##gio	O
##graphy	O
within	O
48	O
h	O
,	O
and	O
3	O
)	O
reported	O
ing	O
##est	O
##ing	O
an	O
adequate	O
as	B
##pi	I
##rin	I
dose	O
(	O
>	O
160	O
mg	O
on	O
the	O
prior	O
calendar	O
day	O
but	O
within	O
the	O
last	O
24	O
h	O
of	O
presentation	O
,	O
or	O
>	O
75	O
mg	O
/	O
d	O
for	O
the	O
last	O
7	O
days	O
)	O
.	O

Alan	B
##ine	I
is	O
a	O
g	O
##ly	O
##co	O
##genic	O
(	O
g	O
##ly	O
##co	O
##gen	O
-	O
producing	O
)	O
amino	O
acid	O
that	O
can	O
be	O
converted	O
to	O
p	B
##yr	I
##u	I
##vate	I
and	O
t	B
##rica	I
##rb	I
##ox	I
##yl	I
##ic	I
acid	I
cycle	O
intermediate	O
##s	O
,	O
and	O
then	O
to	O
glucose	S
by	O
g	O
##lu	O
##con	O
##eo	O
##genesis	O
,	O
functioning	O
as	O
an	O
energy	O
source	O
to	O
meet	O
the	O
huge	O
demand	O
of	O
energy	O
consumed	O
in	O
various	O
metabolic	O
activities	O
in	O
tumor	O
cells	O
.	O

Other	O
clusters	O
of	O
interest	O
included	O
the	O
3rd	O
-	O
largest	O
cluster	O
(	O
33	O
members	O
)	O
,	O
which	O
was	O
consistently	O
elevated	O
among	O
non	O
-	O
I	O
##B	O
##D	O
controls	O
,	O
and	O
contained	O
a	O
variety	O
of	O
t	B
##ria	I
##cy	I
##l	I
##gly	I
##cer	I
##ol	I
meta	O
##bol	O
##ites	O
.	O

The	O
di	O
##ap	O
##ede	O
##sis	O
of	O
le	O
##uc	O
##ocytes	O
is	O
mediated	O
by	O
cellular	O
ad	O
##hesion	O
molecules	O
with	O
select	O
##ins	O
and	O
si	B
##ali	I
##c	I
acid	I
representing	O
important	O
components	O
of	O
l	O
##igan	O
##ds	O
,	O
which	O
can	O
bind	O
to	O
the	O
select	O
##in	O
family	O
of	O
the	O
cell	O
ad	O
##hesion	O
molecules	O
.	O

Another	O
possible	O
explanation	O
for	O
elevated	O
palm	B
##ito	I
##yl	I
s	I
##phi	I
##ngo	I
##my	I
##elin	I
levels	O
may	O
be	O
increased	O
shed	O
##ding	O
of	O
micro	O
##ves	O
##icles	O
by	O
bladder	O
tumors	O
.	O

The	O
meta	O
##bol	O
##ites	O
of	O
importance	O
included	O
in	O
this	O
case	O
up	O
-	O
regulated	O
ace	B
##to	I
##ace	I
##tate	I
and	O
down	O
-	O
regulated	O
c	B
##it	I
##rate	I
,	O
hip	B
##pura	I
##te	I
,	O
ta	B
##uri	I
##ne	I
,	O
su	B
##cci	I
##nate	I
,	O
g	B
##ly	I
##cine	I
,	O
al	B
##ani	I
##ne	I
and	O
format	B
##e	I
.	O

As	O
the	O
quantity	O
of	O
c	B
##rea	I
##tine	I
per	O
unit	O
of	O
skeletal	O
muscle	O
and	O
the	O
reaction	O
to	O
c	B
##rea	I
##tin	I
##ine	I
is	O
constant	O
,	O
the	O
produced	O
amount	O
of	O
c	B
##rea	I
##tin	I
##ine	I
is	O
dependent	O
on	O
the	O
muscle	O
mass	O
.	O

It	O
is	O
anticipated	O
that	O
annually	O
70	O
,	O
000	O
children	O
are	O
born	O
with	O
various	O
types	O
of	O
th	O
##ala	O
##sse	O
##mia	O
,	O
and	O
majority	O
of	O
these	O
births	O
are	O
affected	O
by	O
severe	O
forms	O
of	O
β	B
-	I
th	I
##ala	I
##sse	I
##mia	I
_	I
,	O
.	O

Within	O
the	O
central	O
nervous	O
system	O
C	O
##NS	O
,	O
ta	B
##uri	I
##ne	I
exhibits	O
an	O
age	O
-	O
dependent	O
gradient	O
expression	O
and	O
has	O
its	O
own	O
s	O
##ynth	O
##esi	O
##zing	O
enzymes	O
,	O
receptors	O
,	O
and	O
transport	O
##ers	O
.	O

Tau	B
##rine	I
was	O
decreased	O
13	O
%	O

His	B
##ti	I
##dine	I
,	O
g	B
##lut	I
##amine	I
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
c	B
##rea	I
##tine	I
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
la	B
##ctic	I
acid	I
,	O
and	O
ad	B
##oni	I
##to	I
##l	I
showed	O
an	O
elevated	O
concentration	O
and	O
3	B
,	I
7	I
-	I
ch	I
##ole	I
##st	I
-	I
5	I
-	I
en	I
##e	I
showed	O
reduced	O
concentration	O
from	O
control	O
to	O
ben	O
##ign	O
to	O
ID	O
##C	O
.	O

The	O
increased	O
level	O
of	O
f	O
##ae	O
##cal	O
d	B
-	I
al	I
##ani	I
##ne	I
produced	O
by	O
la	B
##ctic	I
acid	I
bacteria	O
m	O
##od	O
##ulates	O
the	O
immune	O
system	O
in	O
a	O
co	O
##lit	O
##is	O
animal	O
model	O
.	O

Moreover	O
,	O
March	O
##esi	O
et	O
al	O
has	O
observed	O
reduced	O
but	B
##yra	I
##te	I
,	O
ace	B
##tate	I
,	O
met	B
##hyl	I
##amine	I
and	O
trim	B
##eth	I
##yla	I
##mine	I
,	O
accompanied	O
by	O
elevated	O
quantities	O
of	O
amino	O
acids	O
in	O
the	O
f	O
##ec	O
##es	O
of	O
inflammatory	O
bow	O
##el	O
disease	O
(	O
I	O
##B	O
##D	O
)	O
patients	O
.	O

A	O
recent	O
meta	O
##bol	O
##omi	O
##cs	O
study	O
of	O
plasma	O
collected	O
from	O
healthy	O
volunteers	O
that	O
received	O
end	B
##oto	I
##xin	I
likewise	O
showed	O
a	O
shift	O
in	O
amino	O
acid	O
(	O
including	O
BC	O
##AA	O
)	O
metabolism	O
and	O
elevated	O
2	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
,	O
the	O
levels	O
of	O
which	O
are	O
all	O
influenced	O
by	O
free	O
H	O
##g	O
##b	O
as	O
shown	O
here	O
.	O

The	O
re	O
##tina	O
and	O
the	O
brain	O
also	O
contained	O
low	O
proportions	O
of	O
c	B
##era	I
##mi	I
##des	I
with	O
42	O
carbon	O
-	O
chain	O
length	O
or	O
more	O
.	O

a	O
,	O
Sc	O
##hem	O
##atic	O
of	O
the	O
sa	B
##rc	I
##os	I
##ine	I
pathway	O
and	O
its	O
potential	O
link	O
to	O
pro	O
##state	O
cancer	O
.	O

The	O
concentrations	O
of	O
ca	B
##ffe	I
##ine	I
meta	O
##bol	O
##ites	O
were	O
lower	O
in	O
the	O
PD	O
group	O
.	O

Di	B
##met	I
##hyl	I
##form	I
##ami	I
##de	I
-	I
ace	I
##ton	I
##it	I
##ril	I
##e	I
(	I
1	I
:	I
1	I
v	I
/	I
v	I
)	I
was	O
used	O
for	O
DE	O
##SI	O
-	O
MS	O
##I	O
to	O
preserve	O
tissue	O
morphology	O
for	O
subsequent	O
path	O
##ology	O
.	O

For	O
example	O
,	O
activation	O
of	O
the	O
end	B
##oc	I
##anna	I
##bino	I
##id	I
system	O
has	O
been	O
shown	O
to	O
increase	O
food	O
intake	O
,	O
promote	O
weight	O
gain	O
,	O
,	O
and	O
can	O
also	O
contribute	O
to	O
the	O
worse	O
##ning	O
of	O
a	O
card	O
##iovascular	O
profile	O
(	O
i	O
.	O
e	O
.	O
,	O
body	O
weight	O
,	O
body	O
mass	O
index	O
(	O
B	O
##MI	O
)	O
,	O
waist	O
c	O
##ir	O
##cum	O
##ference	O
,	O
insulin	O
and	O
ad	O
##ip	O
##one	O
##ct	O
##in	O
levels	O
)	O
.	O

A	O
5	O
μ	O
##l	O
al	O
##iq	O
##uo	O
##t	O
of	O
the	O
pre	O
-	O
treated	O
sample	O
was	O
injected	O
a	O
column	O
of	O
Ki	O
##net	O
##ex	O
Core	O
-	O
shell	O
Si	B
##lica	I
C	O
##18	O
2	O
.	O
1	O
mm	O
##×	O
50	O
mm	O
,	O
1	O
.	O
3	O
μ	O
##l	O
(	O
Ph	O
##eno	O
##men	O
##ex	O
,	O
Tor	O
##rance	O
,	O
CA	O
,	O
USA	O
)	O
on	O
UP	O
##LC	O
system	O
(	O
Waters	O
,	O
Milford	O
,	O
USA	O
)	O
.	O

One	O
of	O
the	O
control	O
animals	O
,	O
p	O
##rima	O
##te	O
C	O
##2	O
,	O
displayed	O
clinical	O
characteristics	O
of	O
as	O
##phy	O
##xia	O
,	O
including	O
per	O
##ina	O
##tal	O
depression	O
,	O
initial	O
blood	O
gas	O
with	O
pH	O
6	O
.	O
85	O
,	O
base	O
excess	O
−	O
##22	O
,	O
peak	O
la	B
##ct	I
##ate	I
16	O
mm	O
##ol	O
/	O

We	O
found	O
that	O
serum	O
T	B
##MA	I
##O	I
,	O
a	O
gut	O
flora	O
meta	O
##bol	O
##ite	O
of	O
ch	B
##olin	I
##e	I
,	O
was	O
positively	O
associated	O
with	O
the	O
development	O
of	O
P	O
##LC	O
,	O
whereas	O
its	O
precursor	O
ch	B
##olin	I
##e	I
was	O
inverse	O
##ly	O
associated	O
with	O
P	O
##LC	O
risk	O
.	O

All	O
30	O
meta	O
##bol	O
##ites	O
that	O
are	O
significantly	O
correlated	O
with	O
Δ	B
##g	I
##lu	I
##cos	I
##e	I
are	O
shown	O
in	O
Table	O
.	O

-	O
12	O
,	O
c	O
##is	O
)	O
)	O
,	O
1	B
,	I
2	I
-	I
di	I
##ole	I
##oy	I
##l	I
-	I
s	I
##n	I
-	I
g	I
##ly	I
##cer	I
##o	I
-	I
3	I
-	I
p	I
##hos	I
##ph	I
##oe	I
##than	I
##ola	I
##mine	I
(	O
P	O
##E	O
18	O
:	O
1	O
(	O
n	O
-	O
9	O
,	O
c	O
##is	O
)	O
/	O
18	O
:	O
1	O
(	O
n	O

Commercial	O
##ly	O
available	O
and	O
##rogen	O
standards	O
were	O
spike	O
##d	O
with	O
the	O
stable	O
is	O
##oto	O
##pe	O
internal	O
standards	O
[	O
_	O
13	O
C	O
_	O
3	O
]	O
-	O
T	O
(	O
for	O
T	O
,	O
E	O
##pi	O
-	O
T	O
,	O
Δ	O
_	O
4	O
-	O
AD	O
and	O
D	O
##H	O
##EA	O
,	O
since	O
they	O
all	O
contain	O
either	O
a	O
Δ	O
_	O
4	O
-	O
or	O
Δ	O
_	O
5	O
-	O
en	O
##e	O
)	O
or	O
with	O
[	O
_	O
13	O
C	O
_	O
3	O
]	O
-	O
D	O
##HT	O
(	O
for	O
D	O
##HT	O
,	O
Ad	B
##ione	I
and	O
A	O
,	O
since	O
they	O
are	O
5	O
##α	O
-	O
reduced	O
and	O
##rogen	O
##s	O
)	O
.	O

1	B
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
suppress	O
##es	O
gene	O
transcription	O
by	O
binding	O
to	O
vitamin	B
D	I
receptor	O
(	O
V	O
##DR	O
)	O
,	O
with	O
C	O
##YP	O
##3	O
##A	O
##4	O
being	O
the	O
most	O
important	O
c	O
##yt	O
##och	O
##rome	O
P	O
##45	O
##0	O
species	O
su	O
##pressed	O
by	O
1	B
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
.	O

These	O
12	O
meta	O
##bol	O
##ites	O
,	O
which	O
are	O
involved	O
in	O
energy	O
,	O
fatty	O
acids	O
and	O
ch	B
##olin	I
##e	I
metabolism	O
,	O
may	O
be	O
associated	O
with	O
the	O
progression	O
of	O
human	O
es	O
##op	O
##hage	O
##al	O
cancer	O
.	O

This	O
finding	O
may	O
be	O
related	O
to	O
an	O
earlier	O
finding	O
of	O
increased	O
levels	O
of	O
q	B
##uin	I
##olin	I
##ic	I
acid	I
in	O
CS	O
##F	O
but	O
,	O
to	O
our	O
knowledge	O
,	O
it	O
has	O
not	O
previously	O
been	O
reported	O
in	O
plasma	O
from	O
patients	O
with	O
SL	O
##E	O
.	O

The	O
largest	O
portion	O
of	O
the	O
CR	O
##C	O
stool	O
meta	O
##bol	O
##ome	O
were	O
meta	O
##bol	O
##ites	O
involved	O
in	O
lip	O
##id	O
metabolism	O
representing	O
car	B
##ni	I
##tine	I
,	O
end	B
##oc	I
##anna	I
##bino	I
##id	I
,	O
fatty	O
acid	O
,	O
fatty	B
alcohol	I
,	O
long	O
chain	O
,	O
g	B
##ly	I
##cer	I
##oli	I
##pid	I
,	O
in	B
##os	I
##ito	I
##l	I
,	O
k	B
##eton	I
##e	I
bodies	O
,	O
l	O
##ys	O
##oli	O
##pid	O
,	O
mon	B
##oa	I
##cy	I
##l	I
##gly	I
##cer	I
##ol	I
,	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
,	O
primary	O
and	O
secondary	O
bi	O
##le	O
acid	O
,	O
s	B
##phi	I
##ngo	I
##lip	I
##id	I
,	O
s	O
##tero	O
##id	O
,	O
and	O
s	O
##tero	O
##l	O
metabolic	O
pathways	O
.	O

Conversely	O
,	O
the	O
mean	O
diameter	O
of	O
L	O
##D	O
##L	O
particles	O
showed	O
a	O
negative	O
association	O
with	O
test	B
##osterone	I
levels	O
in	O
PC	O
##OS	O
women	O
but	O
not	O
in	O
controls	O
(	O
β	O
=	O
−	O
##3	O
.	O
4	O
,	O
P	O
=	O
3	O
.	O
9	O
×	O
10	O
_	O
−	O
##4	O
)	O
.	O

In	O
##tra	O
##my	O
##oc	O
##ell	O
##ular	O
fatty	O
a	B
##cy	I
##l	I
-	I
Co	I
##A	I
concentrations	O
track	O
plasma	O
FF	O
##A	O
availability	O
.	O

These	O
meta	O
##bol	O
##ites	O
are	O
d	O
##UM	O
##P	O
,	O
L	B
-	I
o	I
##ct	I
##ano	I
##yl	I
##car	I
##ni	I
##tine	I
,	O
L	B
-	I
pro	I
##line	I
,	O
l	O
##ys	O
##o	O
##PC	O
(	O
22	O
:	O
1	O
)	O
,	O
PS	B
(	I
22	I
:	I
0	I
/	I
0	I
:	I
0	I
)	I
,	O
and	O
u	B
##ric	I
acid	I
(	O
Table	O
)	O
.	O

Moreover	O
,	O
the	O
internal	O
standard	O
that	O
was	O
used	O
(	O
_	O
13	O
CD	B
_	I
3	I
-	I
en	I
##zal	I
##uta	I
##mi	I
##de	I
)	O
was	O
labeled	O
in	O
the	O
N	O
-	O
met	O
##hyl	O
function	O
group	O
.	O

Evidence	O
that	O
elite	O
controllers	O
harbor	O
an	O
in	O
##born	O
error	O
of	O
metabolism	O
(	O
late	O
-	O
onset	O
multiple	O
a	B
##cy	I
##l	I
-	I
co	I
##en	I
##zy	I
##me	I
A	O
de	O
##hy	O
##dr	O
##ogen	O
##ase	O
deficiency	O
[	O
MA	O
##D	O
##D	O
]	O
)	O
was	O
detected	O
.	O

AC	O
##AC	O
##A	O
,	O
ace	O
##ty	O
##l	O
-	O
Co	O
##A	O
car	O
##box	O
##yla	O
##se	O
alpha	O
;	O
AC	O
##L	O
##Y	O
,	O
ATP	B
c	I
##it	I
##rate	I
l	O
##yas	O
##e	O
;	O
AC	O
##S	O
,	O
ace	B
##ty	I
##l	I
-	I
Co	I
##A	I
s	O
##ynth	O
##eta	O
##se	O
;	O
CP	O
##T	O
,	O
car	O
##ni	O
##tine	O
palm	O
##ito	O
##yl	O
##tra	O
##ns	O
##fer	O
##ase	O
;	O
DE	O
##GS	O
,	O
delta	O
4	O
-	O
des	O
##at	O
##ura	O
##se	O
;	O
E	O
##L	O
##O	O
##V	O
##L	O
,	O
el	O
##ong	O
##ation	O
of	O
very	O
long	O
chain	O
fatty	O
acids	O
;	O
FA	O
##SN	O
,	O
fatty	O
acid	O
s	O
##ynth	O
##ase	O
;	O
FA	O
##DS	O
,	O
fatty	O
acid	O
des	O
##at	O
##ura	O
##se	O
;	O
SC	O
##D	O
,	O
s	B
##te	I
##aro	I
##yl	I
-	I
Co	I
##A	I
des	O
##at	O
##ura	O
##se	O
;	O
SL	O
##D	O
##B	O
T	O
##AG	O
,	O
short	O
-	O
low	O
-	O
double	O
-	O
bond	O
t	B
##ria	I
##cy	I
##l	I
##gly	I
##cer	I
##ol	I
.	O

H	B
##F	I
H	I
##F	I
H	I
##F	I
E	O
##F	O
H	O
##F	O
E	O
##F	O
H	O
##F	O
E	O
##F	O
H	B
##F	I
H	I
##F	I
E	O
##F	O

We	O
previously	O
determined	O
that	O
natural	O
Ah	O
##R	O
ago	O
##nist	O
##s	O
,	O
such	O
as	O
6	O
-	O
pre	O
##ny	O
##ln	O
##aring	O
##eni	O
##n	O
,	O
increase	O
est	B
##rogen	I
metabolism	O
through	O
Ah	O
##R	O
activation	O
.	O
_	O
,	O
In	O
the	O
literature	O
,	O
BA	O
and	O
F	O
##N	O
are	O
reported	O
as	O
being	O
Ah	O
##R	O
ago	O
##nist	O
##s	O
,	O
_	O
,	O
but	O
whether	O
G	O
##N	O
and	O
D	O
##Z	O
activate	O
Ah	O
##R	O
is	O
controversial	O
.	O

In	O
the	O
a	O
##que	O
##ous	O
mixture	O
of	O
serum	O
,	O
met	B
##han	I
##ol	I
is	O
quite	O
h	B
##ydro	I
##phi	I
##lic	I
and	O
recover	O
##s	O
all	O
water	O
-	O
soluble	O
meta	O
##bol	O
##ites	O
,	O
although	O
at	O
higher	O
met	B
##han	I
##ol	I
concentrations	O
one	O
can	O
see	O
some	O
reduced	O
recovery	O
.	O

For	O
example	O
,	O
t	O
##ri	O
-	O
and	O
di	B
##or	I
##gano	I
##ph	I
##os	I
##phate	I
##s	I
(	O
e	O
.	O
g	O
.	O
,	O
ad	B
##eno	I
##sin	I
##e	I
trip	I
##hos	I
##phate	I
and	O
ad	B
##eno	I
##sin	I
##e	I
dip	I
##hos	I
##phate	I
)	O
were	O
readily	O
de	O
##graded	O
into	O
a	O
mon	B
##o	I
-	I
organ	I
##op	I
##hos	I
##phate	I
(	O
e	O
.	O
g	O
.	O
,	O
ad	B
##eno	I
##sin	I
##e	I
mon	I
##op	I
##hos	I
##phate	I
)	O
during	O
heating	O
.	O

R	O
##R	O
##MS	O
subjects	O
with	O
>	O
=	O
13	O
years	O
disease	O
duration	S
exhibited	O
metabolic	O
profiles	O
intermediate	O
between	O
short	O
-	O
duration	O
R	O
##R	O
##MS	O
and	O
SP	O
##MS	O
,	O
based	O
on	O
statistical	O
significance	O
.	O

Vita	O
##min	O
B	O
-	O
12	O
deficiency	O
is	O
associated	O
with	O
the	O
red	O
##ist	O
##ri	O
##but	O
##ion	O
of	O
car	B
##ni	I
##tine	I
and	O
a	O
con	O
##se	O
##quent	O
higher	O
loss	O
due	O
to	O
the	O
formation	O
of	O
prop	O
##ion	O
##yl	O
and	O
other	O
car	B
##ni	I
##tine	I
derivatives	O
.	O

Among	O
HIV	O
-	O
infected	O
individuals	O
,	O
greater	O
activity	O
of	O
the	O
k	B
##yn	I
##uren	I
##ine	I
pathway	O
of	O
try	B
##pt	I
##op	I
##han	I
cat	O
##ab	O
##olis	O
##m	O
,	O
as	O
evidenced	O
by	O
higher	O
levels	O
of	O
plasma	O
K	O
##T	O
ratio	O
,	O
was	O
associated	O
with	O
lower	O
occurrence	O
of	O
K	O
##S	O
.	O

)	O
,	O
for	O
the	O
synthesis	O
of	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
.	O

(	O
D	O
)	O
Is	B
##ole	I
##uc	I
##ine	I
present	O
in	O
both	O
groups	O
of	O
Pan	O
##c	O
-	O
1	O
cell	O
extract	O
##s	O
but	O
at	O
a	O
higher	O
abundance	O
in	O
the	O
l	O
##yo	O
##phi	O
##li	O
##zed	O
samples	O
.	O

T	O
##rp	O
,	O
se	B
##rot	I
##oni	I
##n	I
,	O
and	O
in	B
##do	I
##le	I
-	I
3	I
-	I
la	I
##ctic	I
acid	I
show	O
similar	O
positive	O
associations	O
with	O
abdominal	O
pain	O
after	O
eating	O
.	O

The	O
majority	O
of	O
amino	O
acid	O
(	B
al	B
##ani	I
##ne	I
,	O
v	B
##ali	I
##ne	I
,	O
le	B
##uc	I
##ine	I
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
g	B
##lut	I
##ama	I
##te	I
,	O
g	B
##lut	I
##amine	I
,	O
as	B
##par	I
##tate	I
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
try	B
##pt	I
##op	I
##han	I
,	O
t	B
##yr	I
##os	I
##ine	I
and	O
gamma	B
-	I
amino	I
but	I
##yric	I
acid	I
(	O
GA	O
##BA	O
,	O
a	O
non	O
-	O
protein	O
amino	S
acid	O
)	O
were	O
present	O
in	O
higher	O
concentrations	O
in	O
the	O
sour	O
##do	O
##ugh	O
samples	O
and	O
in	O
some	O
cases	O
also	O
the	O
bread	O
made	O
using	O
this	O
process	O
.	O

Studies	O
have	O
shown	O
that	O
multiple	O
path	O
##ological	O
processes	O
are	O
involved	O
in	O
the	O
development	O
of	O
F	B
##D	I
,	O
including	O
biological	O
,	O
physiological	O
and	O
psychological	O
factors	O
.	O

The	O
levels	O
of	O
8	B
-	I
is	I
##o	I
-	I
P	I
##G	I
##F	I
_	I
2	I
##α	I
and	O
P	O
##GE	O
-	O
M	O
observed	O
here	O
would	O
reflect	O
the	O
balance	O
between	O
the	O
formation	O
of	O
these	O
end	O
##ogen	O
##ous	O
compounds	O
due	O
to	O
o	O
##xi	O
##da	O
##tive	O
damage	O
and	O
inflammation	O
and	O
their	O
metabolism	O
and	O
p	O
##har	O
##ma	O
##co	O
##kin	O
##etics	O
.	O

However	O
,	O
using	O
the	O
G	O
##C	O
-	O
MS	O
approach	O
we	O
observed	O
lower	O
levels	O
of	O
try	B
##pt	I
##op	I
##han	I
in	O
patients	O
for	O
the	O
combined	O
metabolic	O
profile	O
but	O
did	O
not	O
reach	O
significance	O
for	O
all	O
individual	O
sample	O
batch	O
##es	O
.	O

However	O
,	O
nearly	O
half	O
of	O
the	O
q	O
##uant	O
##ified	O
meta	O
##bol	O
##ites	O
in	O
ultra	O
##fi	O
##lter	O
##ed	O
serum	O
exhibited	O
10	O
–	O
74	O
%	O
lower	O
concentrations	O
;	O
specifically	O
,	O
try	B
##pt	I
##op	I
##han	I
,	O
ben	B
##zo	I
##ate	I
,	O
and	O
2	B
-	I
o	I
##x	I
##ois	I
##oc	I
##ap	I
##roa	I
##te	I
showed	O
much	O
lower	O
concentrations	O
compared	O
to	O
protein	O
pre	O
##ci	O
##pit	O
##ated	O
serum	O
.	O

High	O
c	B
##era	I
##mi	I
##de	I
kinase	O
expression	O
has	O
been	O
reported	O
to	O
be	O
associated	O
with	O
poor	O
re	O
##cu	O
##rrence	O
-	O
free	O
survival	O
in	O
women	O
with	O
ER	O
-	O
negative	O
breast	O
cancer	O
.	O

S	O
##ynth	O
##etic	O
op	O
##io	O
##ids	O
are	O
derivatives	O
of	O
either	O
of	O
three	O
di	O
##ssi	O
##mi	O
##lar	O
chemical	O
structures	O
,	O
consisting	O
of	O
the	O
ben	B
##zo	I
##mor	I
##pha	I
##ns	I
(	I
pen	I
##ta	I
##zo	I
##cine	I
and	O
lo	B
##per	I
##ami	I
##de	I
)	I
,	O
p	B
##hen	I
##yl	I
##pipe	I
##rid	I
##ines	I
(	I
me	I
##per	I
##id	I
##ine	I
,	I
f	I
##ent	I
##any	I
##l	I
,	I
su	I
##fen	I
##tani	I
##l	I
)	I
,	O
and	O
dip	B
##hen	I
##yl	I
##he	I
##pta	I
##nes	I
(	I
met	I
##had	I
##one	I
and	O
prop	B
##ox	I
##y	I
##phe	I
##ne	I
)	I
.	O

In	O
this	O
article	O
,	O
a	O
short	O
overview	O
and	O
comparison	O
of	O
published	O
multi	O
##bio	O
##mark	O
##er	O
methods	O
focusing	O
on	O
the	O
determination	O
of	O
my	B
##cot	I
##ox	I
##ins	I
and	O
relevant	O
ex	O
##cre	O
##tion	O
products	O
in	O
human	O
urine	O
is	O
presented	O
.	O

The	O
genus	O
Ba	O
##cter	O
##oid	O
##es	O
was	O
inverse	O
##ly	O
associated	O
with	O
the	O
ratio	O
of	O
est	B
##rogen	I
meta	O
##bol	O
##ites	O
to	O
parent	O
est	O
##rogen	O
##s	O
(	O
r	O
=	O
−	O
##0	O
.	O
30	O
,	O
P	O
=	O
.	O
03	O
)	O
.	O

A	O
##pp	O
##rov	O
##al	O
for	O
this	O
study	O
of	O
the	O
analyses	O
of	O
de	O
##ter	O
##mina	O
##nts	O
of	O
si	B
##m	I
##vas	I
##tat	I
##in	I
response	O
in	O
the	O
CA	O
##P	O
study	O
was	O
granted	O
by	O
the	O
Children	O
'	O
s	O
Hospital	O
and	O
Research	O
Center	O
Institution	O
##al	O
Review	O
Board	O
,	O
University	O
of	O
California	O
San	O
Francisco	O
Committee	O
on	O
Human	O
Research	O
,	O
and	O
University	O
of	O
California	O
Los	O
Angeles	O
Office	O
of	O
the	O
Human	O
Research	O
Protection	O
Program	O
and	O
written	O
informed	O
consent	O
was	O
obtained	O
from	O
all	O
participants	O
.	O

Note	O
that	O
ace	B
##ty	I
##l	I
##car	I
##ni	I
##tine	I
could	O
not	O
be	O
measured	O
by	O
UP	O
##LC	O
–	O
H	O
##R	O
##MS	O
because	O
it	O
is	O
highly	O
polar	O
and	O
el	O
##utes	O
early	O
under	O
the	O
reversed	O
-	O
phase	O
conditions	O
,	O
whereas	O
using	O
D	O
##I	O
–	O
n	O
##ES	O
##I	O
–	O
H	O
##R	O
##MS	O
,	O
it	O
can	O
be	O
measured	O
with	O
a	O
high	O
degree	O
of	O
precision	O
(	O
C	O
##V	O
%	O
<	O
20	O
%	O
)	O
.	O

Met	B
##hyl	I
##gly	I
##ox	I
##al	I
(	O
40	O
%	O
)	O
was	O
purchased	O
from	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
.	O

Of	O
the	O
evaluated	O
meta	O
##bol	O
##ites	O
,	O
the	O
concentrations	O
of	O
a	B
##rg	I
##ini	I
##ne	I
(	O
r	O
=	O
−	O
##0	O
.	O
39	O
,	O
p	O
=	O
0	O
.	O
00	O
##6	O
)	O
,	O
SD	O
##MA	O
(	O
r	O
=	O
−	O
##0	O
.	O
32	O
,	O
p	O
=	O
0	O
.	O
02	O
##1	O
)	O
,	O
and	O
c	B
##it	I
##ru	I
##llin	I
##e	I
(	O
r	O
=	O
−	O
##0	O
.	O
27	O
,	O
p	O
=	O
0	O
.	O
04	O
##8	O
)	O
in	O
CD	O
patients	O
inverse	O
##ly	O
correlated	O
with	O
CD	O
##A	O
##I	O
while	O
those	O
of	O
AD	B
##MA	I
(	O
p	O
=	O
0	O
.	O
52	O
##3	O
)	O
and	O
D	B
##MA	I
(	O
p	O
=	O
0	O
.	O
153	O
)	O
showed	O
no	O
significant	O
correlation	O
.	O

shows	O
the	O
relative	O
concentrations	O
of	O
met	B
##hi	I
##oni	I
##ne	I
,	O
an	O
is	O
##omer	O
of	O
met	B
##hi	I
##oni	I
##ne	I
and	O
c	B
##it	I
##ru	I
##llin	I
##e	I
.	O

The	O
su	O
##lf	O
##ation	O
pathway	O
of	O
most	O
drugs	O
has	O
not	O
been	O
thoroughly	O
studied	O
and	O
for	O
most	O
drugs	O
data	O
of	O
possible	O
su	B
##lf	I
##ate	I
meta	O
##bol	O
##ites	O
are	O
lacking	O
.	O

B	O
##rief	O
##ly	O
,	O
20	O
µ	O
##L	O
of	O
Con	O
A	O
(	O
0	O
.	O
25	O
mg	O
/	O
m	O
##L	O
,	O
Na	O
##cal	O
##ai	O
Te	O
##sque	O
,	O
Inc	O
.	O
)	O
dissolved	O
in	O
physiological	O
sa	B
##line	I
was	O
injected	O
into	O
the	O
v	O
##it	O
##re	O
##ous	O
body	O
of	O
the	O
right	O
eye	O
in	O
31	O
rabbits	O
(	O
Groups	O
2	O
to	O
6	O
)	O
.	O

The	O
C	O
##2	O
and	O
C	O
##3	O
levels	O
in	O
sperm	O
correlated	O
positively	O
with	O
the	O
levels	O
of	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
in	O
seminal	O
plasma	O
but	O
were	O
significantly	O
negatively	O
correlated	O
with	O
de	B
##ce	I
##noy	I
##l	I
-	I
L	I
-	I
car	I
##ni	I
##tine	I
(	I
C	I
##10	I
:	I
1	I
)	I
and	O
do	B
##de	I
##ce	I
##noy	I
##l	I
-	I
L	I
-	I
car	I
##ni	I
##tine	I
(	I
C	I
##12	I
:	I
1	I
)	I
levels	O
.	O

In	O
a	O
recent	O
model	O
proposed	O
by	O
C	O
.	O
Lo	O
##got	O
##he	O
##tis	O
et	O
al	O
,	O
the	O
progression	O
of	O
pro	O
##state	O
cancer	O
from	O
an	O
end	O
##oc	O
##rine	O
driven	O
and	O
##rogen	O
-	O
dependent	O
early	O
stage	O
cancer	O
to	O
one	O
that	O
is	O
para	B
##c	I
##rine	I
-	I
driven	I
and	O
micro	O
##en	O
##vir	O
##on	O
##ment	O
dependent	O
is	O
a	O
pivotal	O
point	O
at	O
which	O
the	O
disease	O
has	O
manifest	O
##ed	O
a	O
more	O
lethal	O
p	O
##hen	O
##otype	O
.	O

Not	O
##ably	O
,	O
the	O
in	O
##tra	O
##cellular	O
glucose	S
concentration	O
was	O
found	O
to	O
continuously	O
drop	O
in	O
r	O
##H	O
##la	O
-	O
treated	O
S	O
##9	O
cells	O
compared	O
to	O
controls	O
,	O
i	O
.	O
e	O
.	O
by	O
almost	O
70	O
%	O
within	O
120	O
min	O
.	O

Con	O
##sist	O
##ent	O
with	O
previous	O
findings	O
,	O
all	O
GP	O
##s	O
containing	O
C	B
##18	I
:	I
1	I
chain	O
were	O
found	O
to	O
be	O
a	O
mixture	O
of	O
Δ	O
##9	O
and	O
Δ	O
##11	O
C	O
=	O
C	O
location	O
is	O
##omer	O
##s	O
(	O
Su	O
##pp	O
##lement	O
##ary	O
Data	O
_	O
3	O
)	O
.	O

This	O
is	O
an	O
expected	O
consequence	O
of	O
the	O
in	B
##os	I
##ito	I
##l	I
phosphate	O
/	O
di	O
##acy	O
##l	O
##gly	O
##cer	O
##ol	O
signaling	O
pathway	O
that	O
has	O
been	O
described	O
in	O
T	O
.	O
c	O
##ru	O
##zi	O
.	O

Only	O
one	O
meta	O
##bol	O
##ite	O
(	O
format	O
##e	O
)	O
in	O
un	O
##iva	O
##ria	O
##te	O
statistical	O
analysis	O
was	O
significantly	O
lower	O
in	O
patients	O
with	O
active	O
CD	O
,	O
and	O
two	O
meta	O
##bol	O
##ites	O
(	B
al	B
##ani	I
##ne	I
and	O
N	O
-	O
ace	O
##ty	O
##lated	O
compounds	O
)	O
were	O
significantly	O
higher	O
in	O
patients	O
with	O
CD	O
when	O
comparing	O
jointly	O
patients	O
in	O
the	O
re	O
##mission	O
and	O
active	O
phase	O
of	O
the	O
diseases	O
.	O

Similar	O
knock	O
##down	O
experiments	O
performed	O
in	O
ben	O
##ign	O
R	O
##W	O
##P	O
##E	O
cells	O
significantly	O
hampered	O
the	O
ability	O
of	O
ex	O
##ogen	O
##ous	O
g	B
##ly	I
##cine	I
(	O
t	O
-	O
test	O
P	O
=	O
0	O
.	O
00	O
##8	O
##2	O
,	O
n	O
=	O
3	O
)	O
,	O
but	O
not	O
sa	B
##rc	I
##os	I
##ine	I
,	O
to	O
induce	O
invasion	O
.	O

Using	O
differential	O
is	O
##oto	O
##pe	O
label	O
##ing	O
,	O
peaks	O
belonging	O
to	O
the	O
labeled	O
am	B
##ine	I
-	I
or	O
p	O
##hen	O
##ol	O
-	O
containing	O
meta	O
##bol	O
##ites	O
can	O
be	O
picked	O
up	O
according	O
to	O
the	O
accurate	O
mass	O
difference	O
of	O
the	O
ion	O
pair	O
.	O

Some	O
o	B
##xy	I
##ster	I
##ols	I
are	O
considered	O
to	O
be	O
tumor	O
promoter	O
##s	O
(	O
,	O
)	O
and	O
est	B
##rogen	I
receptor	O
ago	O
##nist	O
##s	O
(	O
see	O
re	O
##f	O
.	O

Three	O
of	O
these	O
were	O
inter	O
##cor	O
##rel	O
##ated	O
lip	O
##ids	O
(	B
1	B
-	I
o	I
##leo	I
##yl	I
##gly	I
##cer	I
##op	I
##hos	I
##ph	I
##och	I
##olin	I
##e	I
,	O
1	B
-	I
e	I
##ico	I
##sad	I
##ien	I
##oy	I
##l	I
##gly	I
##cer	I
##op	I
##hos	I
##ph	I
##och	I
##olin	I
##e	I
,	O
2	B
-	I
l	I
##ino	I
##leo	I
##yl	I
##gly	I
##cer	I
##op	I
##hos	I
##ph	I
##och	I
##olin	I
##e	I
)	O
.	O

In	O
another	O
recent	O
study	O
,	O
higher	O
intake	O
of	O
la	B
##ct	I
##ose	I
,	O
alpha	O
l	O
##ino	O
##len	O
##ic	O
fatty	O
acid	O
,	O
and	O
my	B
##rist	I
##ic	I
fatty	O
acid	O
were	O
related	O
to	O
increased	O
risk	O
of	O
re	O
##lap	O
##se	O
in	O
UC	O
patients	O
[	O
]	O
.	O

A	O
sodium	B
format	I
##e	I
peak	O
appears	O
at	O
the	O
very	O
beginning	O
of	O
the	O
ch	O
##roma	O
##to	O
##gram	O
.	O

Am	B
##mon	I
##ium	I
ace	I
##tate	I
,	O
am	B
##mon	I
##ium	I
h	I
##ydro	I
##xi	I
##de	I
,	O
and	O
ace	B
##tic	I
acid	I
were	O
the	O
highest	O
purity	O
grade	O
available	O
from	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
.	O

20	B
-	I
H	I
##ET	I
##E	I
induced	O
cell	O
proliferation	O
and	O
DNA	O
synthesis	O
in	O
vascular	O
smooth	O
muscle	O
and	O
pro	O
##ximal	O
tub	O
##ule	O
cell	O
cultures	O
as	O
well	O
as	O
an	O
##gio	O
##genic	O
effects	O
by	O
s	O
##ti	O
##mulating	O
end	O
##oth	O
##eli	O
##al	O
cell	O
proliferation	O
,	O
which	O
was	O
accompanied	O
by	O
increased	O
vascular	O
end	O
##oth	O
##eli	O
##al	O
growth	O
factor	O
(	O
V	O
##EG	O
##F	O
)	O
expression	O
and	O
release	O
(	O
,	O
,	O
)	O
.	O

Ser	O
##um	O
samples	O
were	O
prepared	O
by	O
mixing	O
400	O
μ	O
##l	O
of	O
serum	O
and	O
200	O
μ	O
##l	O
of	O
D	O
_	O
2	O
O	O
,	O
using	O
the	O
signal	O
attribute	O
to	O
la	B
##ct	I
##ate	I
(	O
δ	O
1	O
.	O
33	O
pp	O
##m	O
)	O
as	O
a	O
chemical	O
shift	O
reference	O
.	O

Inc	O
##reased	O
levels	O
of	O
4	B
-	I
met	I
##hyl	I
##cate	I
##cho	I
##l	I
su	I
##lf	I
##ate	I
in	O
post	O
-	O
BR	O
##B	O
urine	O
and	O
plasma	O
were	O
correlated	O
with	O
a	O
higher	O
level	O
of	O
a	O
##pop	O
##to	O
##tic	O
marker	O
(	O
T	O
##UN	O
##EL	O
)	O
in	O
post	O
-	O
BR	O
##B	O
tumors	O
.	O

PC	O
##A	O
-	O
CA	O
of	O
_	O
1	O
H	O
N	O
##MR	O
CP	O
##MG	O
s	O
##pect	O
##ra	O
of	O
base	O
##line	O
plasma	O
samples	O
from	O
H	O
##ER	O
##2	O
-	O
positive	O
ER	B
(	I
+	I
)	I
(	O
c	O
##yan	O
)	O
and	O
ER	O
(	O
−	O
)	O

For	O
example	O
,	O
in	B
##dom	I
##eth	I
##ac	I
##in	I
has	O
been	O
used	O
for	O
the	O
treatment	O
and	O
prevention	O
of	O
c	O
##ys	O
##to	O
##id	O
mac	O
##ular	O
ed	O
##ema	O
related	O
to	O
cat	O
##ara	O
##ct	O
surgery	O
successfully	O
.	O

TD	O
##F	O
/	O
F	O
##TC	O
,	O
ten	O
##of	O
##ov	O
##ir	O
di	O
##so	O
##p	O
##ro	O
##xi	O
##l	O
f	O
##uma	O
##rate	O
/	O
em	O
##tric	O
##ita	O
##bine	O
;	O
Mon	O
##o	O
/	O
dual	O
,	O
mon	O
##otherapy	O
or	O
dual	O
therapy	O
(	O
plus	O
la	O
##mi	O
##vu	O
##dine	O
)	O
;	O
T	O
##AF	O
/	O
F	O
##TC	O
,	O
ten	O
##of	O
##ov	O
##ir	O
al	B
##af	I
##ena	I
##mi	I
##de	I
f	O
##uma	O
##rate	O
/	O
em	O
##tric	O
##ita	O
##bine	O
;	O
Ce	B
##r	I
,	O
c	B
##era	I
##mi	I
##de	I
.	O

The	O
2	O
-	O
pathway	O
:	O
parent	O
est	O
##rogen	O
##s	O
ratio	O
(	O
R	O
##R	O
=	O
0	O
.	O
66	O
;	O
95	O
%	O
C	O
##I	O
=	O
0	O
.	O
51	O
to	O
0	O
.	O
87	O
;	O
p	O
-	O
trend	O
=	O
.	O
00	O
##3	O
)	O
and	O
2	O
-	O
pathway	O
:	O
16	O
-	O
pathway	O
ratio	O
(	O
R	O
##R	O
=	O
0	O
.	O
62	O
;	O
95	O
%	O
C	O
##I	O
=	O
0	O
.	O
45	O
to	O
0	O
.	O
86	O
;	O
p	O
-	O
trend	O
=	O
.	O
00	O
##5	O
)	O
were	O
each	O
associated	O
with	O
decreased	O
risk	O
,	O
and	O
the	O
4	O
-	O
pathway	O
cat	B
##ech	I
##ols	I
:	I
4	I
-	I
pathway	I
met	I
##hyl	I
##ated	I
cat	I
##ech	I
##ols	I
ratio	O
(	O
R	O
##R	O
=	O
1	O
.	O
34	O
;	O
95	O
%	O
C	O
##I	O
=	O
1	O
.	O
04	O
to	O
1	O
.	O
72	O
;	O
p	O
-	O
trend	O
=	O
.	O
02	O
)	O
was	O
associated	O
with	O
increased	O
risk	O
.	O

However	O
,	O
1	B
##α	I
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
tends	O
to	O
be	O
higher	O
in	O
the	O
HIV	O
-	O
positive	O
group	O
(	O
p	O
<	O
0	O
.	O
08	O
;	O
t	O
-	O
test	O
)	O
.	O

Take	O
##n	O
together	O
,	O
try	B
##pt	I
##op	I
##han	I
held	O
comparable	O
and	O
complementary	O
value	O
to	O
the	O
established	O
AA	O
predict	O
##ors	O
.	O

The	O
lower	O
der	O
##iva	O
##ti	O
##zation	O
yield	O
in	O
SP	O
##E	O
is	O
probably	O
due	O
to	O
traces	O
of	O
pro	O
##tic	O
solvent	O
##s	O
(	O
water	O
and	O
met	B
##han	I
##ol	I
)	O
that	O
de	O
##act	O
##ivate	O
PT	O
##AD	O
while	O
the	O
low	O
so	O
##lub	O
##ility	O
of	O
water	O
in	O
M	B
##T	I
##BE	I
makes	O
the	O
LL	O
##E	O
extract	O
##s	O
the	O
preferred	O
matrix	O
for	O
the	O
der	O
##iva	O
##ti	O
##zation	O
re	O
##age	O
##nt	O
.	O

For	O
sample	O
preparation	O
,	O
proteins	O
were	O
pre	O
##ci	O
##pit	O
##ated	O
from	O
the	O
plasma	O
with	O
met	B
##han	I
##ol	I
that	O
contained	O
standards	O
in	O
order	O
to	O
report	O
extraction	O
efficiency	O
.	O

_	O
,	O
B	O
##rief	O
##ly	O
,	O
th	S
##awed	S
samples	S
were	S
treated	S
with	S
ace	S
##ton	O
##it	O
##ril	O
##e	O
(	O
2	O
:	O
1	O
,	O
v	O
/	O
v	O
)	O
,	O
with	O
an	O
internal	O
standard	O
mixture	O
,	O
and	O
cent	O
##ri	O
##fu	O
##ged	O
at	O
4	O
##°	O
##C	O
,	O
using	O
established	O
procedures	O
.	O

β	B
-	I
k	I
##eto	I
##oc	I
##tano	I
##ic	I
acid	I
is	O
another	O
fatty	O
acid	O
that	O
is	O
formed	O
from	O
the	O
precursor	O
molecule	O
,	O
ma	B
##lon	I
##yl	I
-	I
Co	I
##A	I
,	O
and	O
may	O
be	O
another	O
meta	O
##bol	O
##ite	O
related	O
to	O
identified	O
κ	O
##eto	O
acid	O
.	O

While	O
some	O
studies	O
found	O
suppressed	O
levels	O
of	O
1	B
##α	I
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
,	O
presumably	O
caused	O
by	O
anti	O
##ret	O
##rov	O
##ira	O
##l	O
treatment	O
[	O
,	O
]	O
,	O
there	O
are	O
many	O
cases	O
of	O
reported	O
increases	O
in	O
1	B
##α	I
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
[	O
–	O
]	O
.	O

Another	O
notable	O
finding	O
in	O
our	O
study	O
was	O
that	O
heavy	O
cannabis	S
use	O
,	O
compared	O
to	O
non	O
##can	O
##na	O
##bis	O
use	O
,	O
was	O
associated	O
with	O
increased	O
frequencies	O
of	O
classical	O
mon	O
##ocytes	O
and	O
decreased	O
frequencies	O
of	O
intermediate	O
and	O
non	O
##classical	O
mon	O
##ocytes	O
.	O

Although	O
the	O
inflammation	O
marker	O
CR	O
##P	O
concentration	O
was	O
not	O
significantly	O
different	O
,	O
the	O
higher	O
PA	O
##r	O
in	O
subjects	O
with	O
high	O
c	B
##ys	I
##tat	I
##hi	I
##oni	I
##ne	I
concentrations	O
(	O
P	O
<	O
0	O
.	O
00	O
##1	O
)	O
reflects	O
increased	O
vitamin	O
B	O
-	O
6	O
cat	O
##ab	O
##olis	O
##m	O
due	O
to	O
inflammation	O
.	O

For	O
the	O
longitudinal	O
analyses	O
,	O
single	O
marker	O
associations	O
were	O
evaluated	O
using	O
general	O
linear	O
models	O
(	O
SAS	O
procedure	O
:	O
G	O
##LM	O
)	O
with	O
each	O
lip	O
##id	O
marker	O
as	O
the	O
predict	O
##or	O
and	O
longitudinal	O
changes	O
in	O
each	O
metabolic	O
trait	O
(	O
B	O
##MI	O
,	O
glucose	S
,	O
T	O
##AG	O
,	O
and	O
HD	O
##L	O
-	O
C	O
)	O
as	O
the	O
outcome	O
.	O

Dec	O
##reased	O
plasma	O
levels	O
of	O
g	B
##ly	I
##cine	I
in	O
patients	O
with	O
go	O
##ut	O
might	O
be	O
caused	O
by	O
the	O
increased	O
production	O
of	O
u	B
##ric	I
acid	I
in	O
these	O
patients	O
.	O

A	O
likely	O
precursor	O
to	O
these	O
meta	O
##bol	O
##ites	O
is	O
a	O
c	B
##ys	I
##tein	I
##e	I
-	I
B	I
##DA	I
-	I
l	I
##ys	I
##ine	I
cross	O
##link	O
6	O
.	O

Ex	O
##c	O
##lu	O
##ding	O
criteria	O
included	O
une	O
##x	O
##plain	O
##ed	O
weight	O
change	O
during	O
the	O
past	O
3	O
months	O
,	O
the	O
existence	O
of	O
a	O
previous	O
di	O
##ag	O
##nose	O
of	O
chronic	O
respiratory	O
disease	O
and	O
severe	O
systemic	O
disease	O
such	O
as	O
lung	O
cancer	O
,	O
br	O
##on	O
##chi	O
##ec	O
##tas	O
##is	O
,	O
heart	O
disease	O
,	O
h	O
##yper	O
##tens	O
##ion	O
,	O
diabetes	O
or	O
psychiatric	O
disorders	O
;	O
medication	O
use	O
that	O
may	O
alter	O
systemic	O
inflammation	O
and	O
metabolism	O
(	O
e	O
.	O
g	O
.	O
,	O
ho	O
##rmon	O
##al	O
con	O
##tra	O
##ceptive	O
##s	O
or	O
s	O
##tat	O
##ins	O
)	O
;	O
pregnant	O
women	O
;	O
con	O
##tra	O
##ind	O
##ica	O
##tion	O
to	O
s	B
##pi	I
##rome	I
##try	I
or	O
inability	O
to	O
complete	O
study	O
procedures	O
.	O

N	O
##MR	O
s	O
##pect	O
##ra	O
(	O
_	O
1	O
H	O
and	O
_	O
13	O
C	O
)	O
were	O
recorded	O
in	O
dim	B
##eth	I
##yl	I
su	I
##lf	I
##oxide	I
(	O
D	O
##MS	O
##O	O
)	O
-	O
d	O
_	O
6	O
solvent	O
using	O
te	B
##tra	I
##met	I
##hyl	I
##si	I
##lane	I
as	O
an	O
internal	O
standard	O
with	O
a	O
400	O
-	O
MHz	O
B	O
##ruk	O
##er	O
s	O
##pect	O
##rome	O
##ter	O
.	O

But	O
##t	O
et	O
al	O
.	O
have	O
reported	O
a	O
correlation	O
of	O
tumor	O
growth	O
and	O
the	O
apparent	O
p	B
##yr	I
##u	I
##vate	I
–	I
la	I
##ct	I
##ate	I
rate	O
constant	O
with	O
disease	O
progression	O
with	O
and	O
without	O
ta	B
##mo	I
##xi	I
##fen	I
treatment	O
in	O
a	O
mouse	O
ma	O
##mma	O
##ry	O
tumor	O
virus	O
(	O
M	O
##MT	O
##V	O
)	O
-	O
P	O
##ym	O
##T	O
mouse	O
model	O
of	O
breast	O
cancer	O
.	O

The	O
identified	O
pathways	O
were	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
metabolism	O
,	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
metabolism	O
and	O
the	O
g	B
##ly	I
##cos	I
##yl	I
##ph	I
##os	I
##pha	I
##ti	I
##dy	I
##lino	I
##si	I
##to	I
##l	I
(	O
GP	O
##I	O
)	O
-	O
anchor	O
bio	O
##sy	O
##nt	O
##hesis	O
pathway	O
suggesting	O
that	O
these	O
pathways	O
could	O
be	O
altered	O
in	O
color	O
##ec	O
##tal	O
cancer	O
(	O
Su	O
##pp	O
##lement	O
##ary	O
Figure	O
S	O
##4	O
)	O
.	O

To	O
determine	O
the	O
groups	O
that	O
showed	O
significantly	O
different	O
levels	O
of	O
ne	B
##r	I
##von	I
##ic	I
acid	I
,	O
we	O
re	O
##ana	O
##ly	O
##zed	O
the	O
samples	O
for	O
ne	B
##r	I
##von	I
##ic	I
acid	I
using	O
G	O
##C	O
-	O
TO	O
##FM	O
##S	O
,	O
which	O
is	O
more	O
sensitive	O
than	O
L	O
##C	O
-	O
TO	O
##FM	O
##S	O
,	O
to	O
obtain	O
more	O
precise	O
data	O
.	O

T	O
/	O
T	O
g	O
##eno	O
##type	O
and	O
lower	O
plasma	O
end	B
##ox	I
##ife	I
##n	I
concentrations	O
as	O
compared	O
to	O
the	O
C	O
/	O
C	O
and	O
C	O
/	O
T	O
g	O
##eno	O
##type	O
##s	O
.	O

The	O
results	O
are	O
expressed	O
as	O
ratios	O
to	O
the	O
u	O
##rina	O
##ry	O
c	B
##rea	I
##tin	I
##ine	I
concentration	O
.	O

Ace	B
##tic	I
acid	I
(	O
100	O
μ	O
L	O
)	O
was	O
added	O
drop	O
##wise	O
to	O
reduce	O
the	O
abundance	O
of	O
Na	O
##B	O
##H	O
_	O
4	O
after	O
the	O
reduction	O
reaction	O
(	O
120	O
min	O
at	O
40	O
##°	O
##C	O
)	O
.	O

It	O
has	O
been	O
shown	O
that	O
the	O
is	O
##oe	O
##nz	O
##yme	O
S	O
##U	O
##LT	O
##1	O
##A	O
##3	O
,	O
which	O
is	O
also	O
found	O
in	O
the	O
human	O
brain	O
,	O
is	O
re	O
##gio	O
##sel	O
##ec	O
##tive	O
and	O
strongly	O
favors	O
the	O
formation	O
of	O
D	B
##A	I
-	I
3	I
-	I
O	I
-	I
S	I
over	O
D	B
##A	I
-	I
4	I
-	I
O	I
-	I
S	I
.	O

However	O
,	O
for	O
consistency	O
between	O
the	O
400	O
MHz	O
and	O
900	O
MHz	O
analysis	O
,	O
Beta	B
##ine	I
and	O
Cho	B
##line	I
were	O
not	O
used	O
as	O
classification	O
features	O
.	O

One	O
of	O
the	O
most	O
intriguing	O
bio	O
##mark	O
##ers	O
among	O
these	O
meta	O
##bol	O
##ites	O
is	O
hydrogen	B
su	I
##lf	I
##ide	I
(	O
H	O
_	O
2	O
S	O
)	O
,	O
an	O
end	O
##ogen	O
##ous	O
gas	O
##ot	O
##ran	O
##sm	O
##itte	O
##r	O
with	O
profound	O
effect	O
on	O
the	O
heart	O
.	O

A	O
working	O
hypothesis	O
is	O
that	O
x	B
##ant	I
##hine	I
and	O
in	B
##os	I
##ine	I
play	O
a	O
com	O
##pen	O
##sat	O
##ory	O
role	O
,	O
competing	O
or	O
co	O
##oper	O
##ating	O
;	O
since	O
in	O
both	O
,	O
when	O
their	O
levels	O
were	O
low	O
,	O
no	O
significant	O
association	O
was	O
found	O
between	O
T	O
##T	O
and	O
T	O
##2	O
##D	O
,	O
as	O
compared	O
to	O
their	O
high	O
levels	O
(	O
see	O
joint	O
analysis	O
)	O
.	O

Go	O
to	O
:	O
Milk	O
and	O
dairy	O
products	O
are	O
an	O
important	O
source	O
of	O
ch	B
##olin	I
##e	I
,	O
a	O
nut	O
##rient	O
essential	O
for	O
human	O
health	O
.	O

We	O
accomplished	O
this	O
with	O
the	O
addition	O
of	O
0	O
.	O
2	O
M	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
buffer	O
.	O

Lev	B
##of	I
##lo	I
##xa	I
##cin	I
,	O
he	B
##sper	I
##id	I
##in	I
,	O
and	O
r	O
##hein	O
were	O
selected	O
as	O
the	O
internal	O
standards	O
to	O
monitor	O
the	O
stability	O
of	O
analysis	O
.	O

Such	O
an	O
early	O
assessment	O
might	O
spare	O
potential	O
toxicity	O
in	O
patients	O
with	O
no	O
signal	O
of	O
efficacy	O
and	O
allow	O
a	O
pro	B
##mpt	I
switch	O
to	O
other	O
potentially	O
e	O
##ff	O
##ica	O
##cious	O
treatment	O
.	O

Finally	O
,	O
there	O
had	O
to	O
be	O
a	O
significant	O
difference	O
in	O
the	O
content	O
of	O
the	O
three	O
types	O
of	O
substances	O
,	O
such	O
as	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
,	O
long	O
chain	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
and	O
ad	B
##eno	I
##sin	I
##e	I
.	O

Di	B
##met	I
##hyl	I
su	I
##lf	I
##oxide	I
(	O
D	O
##MS	O
##O	O
)	O
,	O
cu	B
##rc	I
##umi	I
##n	I
(	O
C	O
##ur	O
)	O
,	O
hydrogen	B
per	I
##oxide	I
solution	O
(	O
H	O
_	O
2	O
O	O
_	O
2	O
)	O
,	O
(	O
3	O
w	O
##t	O
%	O
in	O
H	O
_	O
2	O
O	O
)	O
,	O
and	O
3	B
-	I
(	I
4	I
,	I
5	I
-	I
dim	I
##eth	I
##yl	I
-	I
2	I
-	I
th	I
##ia	I
##zo	I
##ly	I
##l	I
)	I
-	I
2	I
,	I
5	I
-	I
dip	I
##hen	I
##yl	I
-	I
2	I
##H	I
-	I
te	I
##tra	I
##zo	I
##lium	I
br	I
##omi	I
##de	I
(	O
M	O
##TT	O
)	O
,	O
were	O
purchased	O
from	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
(	O
St	O
.	O
Louis	O
,	O
M	O
##O	O
,	O
USA	O
)	O
.	O

A	O
total	O
of	O
six	O
meta	O
##bol	O
##ites	O
with	O
significantly	O
altered	O
serum	O
features	O
were	O
selected	O
:	O
p	B
##yr	I
##og	I
##lut	I
##ami	I
##c	I
acid	I
,	O
2	B
,	I
3	I
,	I
4	I
-	I
t	I
##ri	I
##hy	I
##dr	I
##ox	I
##y	I
##but	I
##yra	I
##te	I
,	O
c	B
##it	I
##ric	I
acid	I
,	O
gal	B
##act	I
##ose	I
,	O
palm	B
##itic	I
acid	I
,	O
and	O
l	B
##ino	I
##le	I
##ic	I
acid	I
.	O

These	O
findings	O
imply	O
that	O
the	O
k	B
##yn	I
##uren	I
##ine	I
pathway	O
is	O
path	O
##ological	O
##ly	O
relevant	O
in	O
patients	O
with	O
C	O
##MM	O
.	O

Collective	O
##ly	O
,	O
the	O
s	B
##phi	I
##ngo	I
##lip	I
##id	I
content	O
was	O
highest	O
in	O
the	O
L	O
##D	O
##L	O
/	O
V	O
##LD	O
##L	O
,	O
followed	O
by	O
the	O
E	O
##Vs	O
,	O
and	O
then	O
the	O
HD	O
##L	O
.	O

A	O
total	O
of	O
34	O
patients	O
matched	O
by	O
age	O
,	O
sex	O
,	O
and	O
body	O
mass	O
index	O
(	O
B	O
##MI	O
)	O
were	O
analyzed	O
to	O
compare	O
the	O
meta	O
##bol	O
##omi	O
##c	O
profiles	O
between	O
the	O
A	B
##F	I
and	O
control	O
groups	O
.	O

In	O
total	O
,	O
24	O
different	O
meta	O
##bol	O
##ites	O
were	O
identified	O
out	O
of	O
approximately	O
400	O
statistical	O
##ly	O
confirmed	O
candidates	O
,	O
among	O
which	O
c	B
##era	I
##mi	I
##des	I
[	I
Ce	I
##r	I
(	I
d	I
##18	I
:	I
0	I
/	I
16	I
:	I
0	I
)	I
,	I
Ce	I
##r	I
(	I
t	I
##18	I
:	I
0	I
/	I
12	I
:	I
0	I
)	I
]	I
and	O
s	B
##phi	I
##nga	I
##nine	I
achieved	O
75	O
–	O
100	O
%	O
sensitivity	O
and	O
42	O
.	O
11	O
–	O
78	O
.	O
95	O
%	O
specific	O
##ity	O
in	O
predict	O
##ing	O
major	O
adverse	O
card	O
##iovascular	O
events	O
in	O
young	O
patients	O
that	O
had	O
been	O
discharged	O
.	O

The	O
following	O
approaches	O
were	O
used	O
to	O
identify	O
possible	O
meta	O
##bol	O
##ites	O
in	O
micro	O
##so	O
##mal	O
in	O
##cu	O
##bate	O
##s	O
of	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
.	O

The	O
HC	O
##V	O
core	O
protein	O
is	O
also	O
known	O
to	O
activate	O
the	O
liver	O
X	O
receptor	O
alpha	O
(	B
L	B
##X	I
##R	I
##α	I
)	O
protein	O
which	O
activate	O
##s	O
inflammatory	O
genes	O
resulting	O
in	O
lip	O
##ogen	O
##esis	O
.	O

Lac	B
##tate	I
correlated	O
positively	O
with	O
al	B
##ani	I
##ne	I
,	O
t	O
##C	O
##r	O
,	O
t	O
##C	O
##ho	O
and	O
t	O
##G	O
##lut	O
.	O

We	O
conducted	O
a	O
D	B
##H	I
##EA	I
-	I
S	I
dig	O
##est	O
with	O
the	O
A	O
##bal	O
##one	O
en	O
##tra	O
##ils	O
su	O
##lf	O
##ata	O
##se	O
,	O
which	O
yielded	O
quantitative	O
recovery	O
of	O
1000	O
p	B
##g	I
D	I
##H	I
##EA	I
-	I
S	I
and	O
no	O
conversion	O
to	O
Δ	O
_	O
4	O
-	O
AD	O
.	O

Co	O
##s	O
-	O
1	O
cells	O
were	O
trans	O
##fected	O
with	O
p	O
##las	O
##mi	O
##ds	O
in	O
serum	O
-	O
free	O
medium	O
using	O
Li	B
##po	I
##fect	I
##amine	I
2000	O
re	O
##age	O
##nt	O
(	O
In	O
##vi	O
##tro	O
##gen	O
)	O
.	O

The	O
u	O
##rina	O
##ry	O
meta	O
##bol	O
##ite	O
with	O
the	O
highest	O
importance	O
value	O
for	O
the	O
prediction	O
of	O
age	O
in	O
men	O
was	O
4	B
-	I
h	I
##ydro	I
##xy	I
##mand	I
##eli	I
##c	I
acid	I
with	O
higher	O
concentrations	O
in	O
younger	O
men	O
.	O

CP	O
##MG	O
-	O
model	O
2	O
regional	O
association	O
plots	O
with	O
log	O
_	O
10	O
(	B
glucose	S
)	O
for	O
the	O
g	B
##lut	I
##amine	I
.	O

Association	O
between	O
beta	B
##ine	I
and	O
development	O
of	O
diabetes	O
in	O
43	O
##36	O
(	O
224	O
cases	O
)	O
subjects	O
of	O
the	O
Prevention	O
of	O
Ren	O
##al	O
and	O
V	O
##as	O
##cular	O
End	O
-	O
Stage	O
Disease	O
(	O
PR	O
##E	O
##VE	O
##ND	O
)	O
study	O
as	O
a	O
continuous	O
variable	O
(	O
_	O
2	O
log	O
-	O
transformed	O
)	O
and	O
according	O
to	O
te	O
##rt	O
##iles	O
(	O
T	O
##1	O
-	O
T	O
##3	O
)	O
.	O

In	O
##spect	O
##ion	O
of	O
the	O
complete	O
Is	O
##o	O
##P	O
,	O
P	B
##G	I
and	O
NO	O
_	O
2	O
-	O
FA	O
target	O
panel	O
found	O
that	O
H	O
.	O
p	O
##oma	O
##tia	O
G	O
##US	O
contained	O
the	O
highest	O
blank	O
effect	O
compared	O
with	O
E	O
.	O
co	O
##li	O
and	O
b	O
##ov	O
##ine	O
liver	O
(	O
see	O
E	O
##SM	O
Table	O
S	O
##7	O
)	O
.	O

In	O
addition	O
to	O
the	O
results	O
obtained	O
in	O
serum	O
,	O
pin	B
##ito	I
##l	I
,	O
ma	B
##lt	I
##ol	I
,	O
su	B
##c	I
##rose	I
,	O
g	B
##ua	I
##iac	I
##ol	I
,	O
and	O
cat	B
##ech	I
##ol	I
were	O
also	O
in	O
##dicative	O
of	O
the	O
so	O
##y	O
drink	O
intake	O
in	O
urine	O
.	O

Ser	O
##um	O
p	B
##io	I
##gli	I
##ta	I
##zone	I
levels	O
were	O
estimated	O
using	O
mass	O
s	O
##pect	O
##rome	O
##try	O
(	O
see	O
above	O
)	O
.	O

Our	O
findings	O
confirmed	O
earlier	O
reports	O
and	O
showed	O
a	O
reversal	O
of	O
Neo	B
##pt	I
##eri	I
##n	I
increase	O
following	O
AR	O
##T	O
.	O

Di	O
##abe	O
##tic	O
-	O
rat	O
brain	O
displayed	O
marked	O
elevations	O
in	O
glucose	S
,	O
so	B
##rb	I
##ito	I
##l	I
,	O
and	O
f	B
##ru	I
##ct	I
##ose	I
,	O
similar	O
to	O
those	O
in	O
human	O
AD	O
brain	O
(	O
;	O
;	O
all	O
P	O
<	O
0	O
.	O
000	O
##1	O
)	O
.	O

The	O
most	O
interesting	O
of	O
these	O
,	O
l	B
##ino	I
##len	I
##ic	I
acid	I
,	O
was	O
valid	O
##ated	O
using	O
a	O
pure	O
,	O
commercially	O
obtained	O
compound	O
.	O

The	O
following	O
were	O
purchased	O
from	O
C	O
##ayman	O
(	O
Ann	O
Arbor	O
,	O
MI	O
)	O
:	O
2	O
-	O
AG	O
;	O
the	O
end	B
##oc	I
##anna	I
##bino	I
##id	I
receptor	O
inhibitor	O
##s	O
,	O
SR	O
##14	O
##17	O
##16	O
##A	O
(	O
R	O
##imo	O
##na	O
##ban	O
##t	O
,	O
CB	O
##1	O
inverse	O
ago	O
##nist	O
)	O
,	O
AM	O
##25	O
##1	O
(	O
CB	O
##1	O
antagonist	O
)	O
and	O
SR	O
##14	O
##45	O
##28	O
(	O
CB	O
##2	O
inverse	O
ago	O
##nist	O
)	O
;	O
the	O
end	B
##oc	I
##anna	I
##bino	I
##id	I
receptor	O
act	O
##iva	O
##tors	O
,	O
CP	O
##47	O
##4	O
##9	O
##7	O
(	O
CB	O
##1	O
ago	O
##nist	O
)	O
,	O
AM	O
##12	O
##41	O
(	O
CB	O
##2	O
ago	O
##nist	O
)	O
,	O

Step	O
##wise	O
improvement	O
combined	O
with	O
leave	O
-	O
one	O
-	O
sheep	O
-	O
out	O
cross	O
-	O
valid	O
##ation	O
resulted	O
in	O
a	O
final	O
model	O
(	O
model	O
8	O
)	O
based	O
on	O
eight	O
markers	O
(	O
c	O
##it	O
##ru	O
##llin	O
##e	O
,	O
v	B
##ali	I
##ne	I
,	O
PC	B
a	I
##a	I
C	I
##40	I
:	I
4	I
,	O
PC	B
a	I
##a	I
C	I
##36	I
:	I
5	I
,	O
l	O
##ys	O
##o	O
##PC	O
a	O
C	B
##17	I
:	I
0	I
,	O
SM	O
(	O
OH	O
)	O
C	B
##24	I
:	I
1	I
,	O
th	B
##re	I
##oni	I
##ne	I
,	O
te	B
##tra	I
##de	I
##ce	I
##noy	I
##l	I
##car	I
##ni	I
##tine	I
(	I
C	I
##14	I
:	I
1	I
)	I
)	O
with	O
an	O
AU	O
##C	O
of	O
0	O
.	O
93	O
##8	O
.	O

P	O
##las	O
##ma	O
concentrations	O
of	O
l	B
-	I
a	I
##rg	I
##ini	I
##ne	I
,	O
its	O
meta	O
##bol	O
##ites	O
(	O
l	O
-	O
or	O
##ni	O
##thin	O
##e	O
and	O
l	O
-	O
c	O
##it	O
##ru	O
##llin	O
##e	O
)	O
,	O
and	O
met	B
##hyl	I
##ated	I
a	I
##rg	I
##ini	I
##ne	I
by	O
##p	O
##rod	O
##uc	O
##ts	O
(	O
MMA	O
,	O
AD	B
##MA	I
,	O
and	O
SD	O
##MA	O
)	O
were	O
q	O
##uant	O
##ified	O
as	O
described	O
in	O
an	O
earlier	O
publication	O
.	O

All	O
included	O
n	O
##uc	O
##leo	O
##side	O
##s	O
/	O
rib	O
##osy	O
##lated	O
meta	O
##bol	O
##ites	O
were	O
isolated	O
by	O
c	B
##is	I
-	I
di	I
##ol	I
specific	O
affinity	O
ch	O
##roma	O
##tography	O
and	O
measured	O
with	O
liquid	O
ch	O
##roma	O
##tography	O
ion	O
trap	O
mass	O
s	O
##pect	O
##rome	O
##try	O
(	O
L	O
##C	O
-	O
IT	O
##MS	O
)	O
.	O

Of	O
these	O
52	O
patients	O
,	O
40	O
were	O
taking	O
la	B
##ct	I
##ulos	I
##e	I
,	O
32	O
r	O
##if	O
##ax	O
##im	O
##in	O
and	O
14	O
branch	O
-	O
chain	O
amino	O
acids	O
.	O

Invasion	O
potential	O
of	O
Col	O
##o	O
##35	O
##7	O
-	O
s	O
##h	O
##S	O
##c	O
##r	O
and	O
Col	O
##o	O
##35	O
##7	O
-	O
s	O
##h	O
##MU	O
##C	O
##16	O
cells	O
E	O
.	O
and	O
Cap	O
##an	O
##1	O
-	O
s	O
##h	O
##S	O
##c	O
##r	O
and	O
Cap	O
##an	O
##1	O
-	O
s	O
##h	O
##MU	O
##C	O
##16	O
cells	O
F	O
.	O
was	O
evaluated	O
by	O
mat	O
##rig	O
##el	O
invasion	O
ass	O
##ays	O
for	O
24	O
h	O
in	O
the	O
presence	O
or	O
absence	O
of	O
la	B
##ct	I
##ate	I
supplement	O
##ation	O
.	O

Cy	B
##c	I
##lo	I
##he	I
##xy	I
##lam	I
##ine	I
is	O
a	O
toxic	O
meta	O
##bol	O
##ite	O
formed	O
by	O
des	O
##ulf	O
##ona	O
##tion	O
of	O
c	O
##y	O
##c	O
##lam	O
##ate	O
by	O
in	O
##test	O
##inal	O
bacteria	O
and	O
enhance	O
##s	O
oxidation	O
of	O
proteins	O
.	O

T	B
##hr	I
##eon	I
##ine	I
was	O
positively	O
linked	O
(	O
blue	O
edges	O
)	O
with	O
E	O
##scher	O
##ichi	O
##a	O
f	O
##er	O
##gus	O
##oni	O
##i	O
(	O
O	O
##tu	O
##4	O
)	O
and	O
En	O
##tero	O
##ba	O
##cter	O
c	O
##lo	O
##aca	O
##e	O
(	O
O	O
##tu	O
##13	O
)	O
but	O
negatively	O
related	O
(	O
red	O
edges	O
)	O
to	O
Ba	O
##cter	O
##oid	O
##es	O
v	O
##ul	O
##gat	O
##us	O
(	O
O	O
##tu	O
##1	O
)	O
and	O
Ba	O
##cter	O
##oid	O
##es	O
uniform	O
##is	O
(	O
O	O
##tu	O
##8	O
)	O
.	O

BC	O
##AA	O
(	O
0	O
.	O
93	O
–	O
1	O
.	O
07	O
pp	O
##m	O
)	O
,	O
Al	O
##a	O
(	O
1	O
.	O
45	O
–	O
1	O
.	O
51	O
pp	O
##m	O
)	O
,	O
A	O
##c	O
(	O
1	O
.	O
91	O
–	O
1	O
.	O
93	O
pp	O
##m	O
)	O
,	O
G	O
##lu	O
(	O
2	O
.	O
31	O
–	O
2	O
.	O
40	O
pp	O
##m	O
)	O
,	O
G	O
##ln	O
(	O
2	O
.	O
42	O
–	O
2	O
.	O
49	O
pp	O
##m	O
)	O
,	O
G	B
##S	I
##H	I
(	O
2	O
.	O
51	O
–	O
2	O
.	O
61	O
pp	O
##m	O
)	O
,	O
As	O
##p	O
(	O
2	O
.	O
62	O
–	O
2	O
.	O
72	O
pp	O
##m	O
)	O
,	O
C	O
##re	O
(	O
3	O
.	O
02	O
–	O
3	O
.	O
07	O
pp	O
##m	O
)	O
,	O
Tau	O
(	O
3	O
.	O
39	O
–	O
3	O
.	O
47	O
pp	O
##m	O
)	O
,	O
G	O
##ly	O
(	O
3	O
.	O
55	O
–	O
3	O
.	O
57	O
pp	O
##m	O
)	O
,	O
Ph	O
##e	O
(	O
7	O
.	O
30	O
–	O
7	O
.	O
46	O
pp	O
##m	O
)	O
,	O
and	O
Ty	O
##r	O
(	O
6	O
.	O
85	O
–	O
6	O
.	O
92	O
pp	O
##m	O
)	O
were	O
used	O
.	O

Consequently	O
,	O
we	O
pool	O
##ed	O
the	O
data	O
for	O
these	O
two	O
groups	O
to	O
give	O
t	O
##C	O
##r	O
=	O
p	B
##hos	I
##ph	I
##oc	I
##rea	I
##tine	I
+	O
c	B
##rea	I
##tine	I
,	O
and	O
t	O
##C	O
##ho	O
=	O
ch	B
##olin	I
##e	I
+	O
p	B
##hos	I
##ph	I
##och	I
##olin	I
##e	I
+	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##och	I
##olin	I
##e	I
.	O

First	O
,	O
the	O
blood	O
samples	O
were	O
collected	O
at	O
the	O
time	O
point	O
when	O
the	O
participants	O
were	O
diagnosed	O
,	O
a	O
single	O
measurement	O
may	O
not	O
fully	O
reflect	O
the	O
body	O
’	O
s	O
long	O
-	O
term	O
concentrations	O
of	O
ch	B
##olin	I
##e	I
or	O
its	O
meta	O
##bol	O
##ite	O
T	B
##MA	I
##O	I
.	O

S	B
##pi	I
##ron	I
##ola	I
##cton	I
##e	I
lost	O
its	O
th	B
##io	I
##ace	I
##ty	I
##l	I
-	I
and	O
7	B
-	I
alpha	I
-	I
met	I
##hyl	I
##thi	I
##os	I
##pi	I
##ron	I
##ola	I
##cton	I
##e	I
its	O
th	O
##io	O
##met	O
##hyl	O
group	O
,	O
rendering	O
them	O
in	O
##dis	O
##ting	O
##ui	O
##sha	O
##ble	O
by	O
m	O
/	O
z	O
from	O
can	B
##ren	I
##one	I
with	O
molecular	O
ions	O
being	O
hardly	O
detect	O
##able	O
.	O

Overall	O
,	O
based	O
on	O
the	O
drug	O
treatment	O
comparison	O
analysis	O
,	O
we	O
chose	O
12	O
.	O
5	O
##μ	O
##M	O
C	O
##75	O
and	O
25	B
##μ	I
##M	I
c	I
##ele	I
##co	I
##xi	I
##b	I
as	O
the	O
drug	O
concentration	O
for	O
treating	O
S	O
##UM	O
##14	O
##9	O
##P	O
##T	O
and	O
10	O
##μ	O
##M	O
C	O
##75	O
and	O
15	B
##μ	I
##M	I
c	I
##ele	I
##co	I
##xi	I
##b	I
as	O
the	O
drug	O
concentration	O
for	O
treating	O
S	O
##UM	O
##13	O
##15	O
##MO	O
##2	O
throughout	O
our	O
study	O
.	O

An	O
O	O
##CT	O
compound	O
medium	O
(	O
Sakura	O
Fine	O
##te	O
##k	O
USA	O
,	O
Inc	O
.	O
)	O
containing	O
10	O
.	O
24	O
%	O
w	O
/	O
w	O
p	B
##oly	I
##vin	I
##yl	I
alcohol	I
,	O
4	O
.	O
26	O
%	O
w	O
/	O
w	O
p	B
##oly	I
##eth	I
##yle	I
##ne	I
g	I
##ly	I
##co	I
##l	I
and	O
85	O
.	O
50	O
%	O
w	O
/	O
w	O
of	O
a	O
non	O
##rea	O
##ctive	O
ingredient	O
was	O
used	O
to	O
create	O
the	O
blocks	O
.	O

The	O
pro	O
##tons	O
adjacent	O
to	O
the	O
car	B
##box	I
##yl	I
##ic	I
acid	I
functional	O
group	O
(	O
2	O
,	O
27	O
)	O
appeared	O
as	O
multiple	O
##ts	O
between	O
2	O
.	O
10	O
–	O
2	O
.	O
20	O
pp	O
##m	O
.	O

Peak	O
integration	O
was	O
then	O
compared	O
to	O
the	O
one	O
obtained	O
with	O
the	O
la	B
##ct	I
##ate	I
reference	O
and	O
was	O
corrected	O
according	O
to	O
the	O
number	O
of	O
pro	O
##tons	O
.	O

We	O
also	O
found	O
elevated	O
plasma	O
levels	O
of	O
Sa	B
##rc	I
##os	I
##ine	I
in	O
HIV	O
/	O
AIDS	O
patients	O
,	O
which	O
reduced	O
on	O
AR	O
##T	O
,	O
but	O
was	O
still	O
higher	O
compared	O
to	O
healthy	O
controls	O
Inc	O
##reased	O
levels	O
of	O
Sa	B
##rc	I
##os	I
##ine	I
were	O
reported	O
earlier	O
in	O
the	O
oral	O
meta	O
##bol	O
##ites	O
of	O
HIV	O
/	O
AIDS	O
patients	O
.	O

The	O
flow	O
rate	O
was	O
150	O
μ	O
##L	O
/	O
min	O
of	O
mobile	O
phase	O
consisting	O
of	O
is	O
##op	O
##rop	O
##ano	O
##l	O
/	O
water	O
(	O
60	O
:	O
40	O
,	O
v	O
/	O
v	O
)	O
buffer	O
##ed	O
with	O
5	O
m	O
##M	O
am	B
##mon	I
##ium	I
at	O
pH	O
9	O
for	O
negative	O
mode	O
and	O
met	O
##han	O
##ol	O
/	O
water	O
(	O
60	O
:	O
40	O
,	O
v	O
/	O
v	O
)	O
with	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
at	O
pH	O
3	O
for	O
positive	O
mode	O
.	O

(	O
D	O
##MF	O
)	O
,	O
3	B
-	I
(	I
trim	I
##eth	I
##yl	I
##si	I
##ly	I
##l	I
)	I
prop	I
##ion	I
##ic	I
acid	I
-	I
2	I
,	I
2	I
,	I
3	I
,	I
3	I
-	I
d	I
_	O
4	O
sodium	O
salt	O
(	O
T	O
##SP	O
)	O
were	O
all	O
obtained	O
from	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
(	O
St	O
.	O
Louis	O
,	O
M	O
##O	O
)	O
.	O

The	O
concentration	O
of	O
each	O
meta	O
##bol	O
##ite	O
was	O
normal	O
##ized	O
to	O
each	O
urine	O
sample	O
’	O
s	O
corresponding	O
c	B
##rea	I
##tin	I
##ine	I
value	O
to	O
compensate	O
for	O
variations	O
in	O
urine	O
volume	O
(	O
the	O
concentration	O
of	O
meta	O
##bol	O
##ites	O
is	O
expressed	O
as	O
µ	O
##M	O
/	O
m	O
##M	O
c	O
##rea	O
##tin	O
##ine	O
)	O
.	O

Despite	O
the	O
high	O
success	O
rate	O
of	O
DC	O
##C	O
##V	O
,	O
A	B
##F	I
typically	O
re	O
##cu	O
##rs	O
within	O
the	O
first	O
2	O
weeks	O
.	O

The	O
he	B
##xa	I
##no	I
##ate	I
[	O
D	O
_	O
4	O
]	O
6	O
was	O
then	O
el	O
##uted	O
with	O
10	O
m	O
##L	O
of	O
H	O
_	O
2	O
O	O
/	O
Me	O
##OH	O
/	O
NH	O
_	O
4	O
OH	B
(	I
30	I
:	I
65	I
:	I
5	I
)	I
and	O
dried	O
overnight	O
(	O
Speed	O
##V	O
##ac	O
)	O
.	O

For	O
a	O
##que	O
##ous	O
mobile	O
phase	O
,	O
a	O
number	O
of	O
buffer	O
##s	O
were	O
evaluated	O
,	O
particularly	O
such	O
volatile	O
buffer	O
##s	O
as	O
t	B
##ri	I
##f	I
##lu	I
##oro	I
##ace	I
##tate	I
(	O
T	O
##FA	O
,	O
p	O
##K	O
_	O
a	O
=	O
0	O
.	O
5	O
)	O
,	O
format	B
##e	I
(	O
p	O
##K	O
_	O
a	O
=	O
3	O
.	O
8	O
)	O
,	O
and	O
ace	B
##tate	I
(	O
p	O
##K	O
_	O
a	O
=	O
4	O
.	O
8	O
)	O
.	O

To	O
determine	O
whether	O
pre	O
-	O
activation	O
of	O
the	O
recipient	O
cells	O
influences	O
ex	O
##oso	O
##me	O
up	O
##take	O
,	O
we	O
co	O
-	O
in	O
##cu	O
##bate	O
##d	O
resting	O
or	O
activated	S
T	O
cells	O
with	O
P	O
##K	O
##H	O
##26	O
-	O
labeled	O
T	O
##EX	O
or	O
DE	O
##X	O
.	O

Effect	O
of	O
al	B
##ky	I
##lam	I
##ine	I
add	O
##itive	O
##s	O
on	O
ch	O
##roma	O
##to	O
##graphic	O
performance	O
in	O
SF	O
##C	O
(	O
UV	O
-	O
v	O
##is	O
data	O
only	O
)	O
.	O

Ph	B
##en	I
##yle	I
##thy	I
##lam	I
##ine	I
was	O
the	O
highest	O
and	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
was	O
the	O
third	O
strongest	O
disc	O
##rim	O
##inating	O
meta	O
##bol	O
##ite	O
between	O
c	B
##ys	I
##tat	I
##hi	I
##oni	I
##ne	I
classes	O
in	O
these	O
L	O
##C	O
-	O
MS	O
analyses	O
.	O

Thus	O
,	O
gal	B
##act	I
##ose	I
metabolism	O
was	O
very	O
important	O
for	O
health	O
.	O

In	O
brief	O
,	O
serum	O
samples	O
,	O
which	O
had	O
been	O
stored	O
at	O
−	O
##70	O
##°	O
##C	O
and	O
not	O
previously	O
th	O
##awed	O
,	O
were	O
subjected	O
to	O
an	O
un	O
##tar	O
##get	O
##ed	O
single	O
met	B
##han	I
##ol	I
extraction	O
followed	O
by	O
protein	O
precipitation	O
.	O

D	O
##ME	O
##M	O
,	O
R	O
##PM	O
##I	O
-	O
1640	O
,	O
anti	O
##biotics	O
(	B
pen	B
##ici	I
##llin	I
and	O
s	B
##tre	I
##pt	I
##omy	I
##cin	I
)	O
,	O
and	O
f	O
##etal	O
b	O
##ov	O
##ine	O
serum	O
(	O
F	O
##BS	O
)	O
were	O
purchased	O
from	O
Atlanta	O
Biological	O
##s	O
(	O
Lawrence	O
##ville	O
,	O
GA	O
)	O
.	O

To	O
evaluate	O
the	O
benefit	O
of	O
the	O
applied	O
correction	O
,	O
we	O
compared	O
MI	O
##Ds	O
obtained	O
for	O
different	O
concentrations	O
(	O
40	O
µ	O
##M	O
and	O
200	O
µ	O
##M	O
)	O
,	O
and	O
_	O
13	O
C	O
en	O
##rich	O
##ments	O
(	O
0	O
.	O
10	O
%	O
and	O
0	O
.	O
01	O
%	O
)	O
of	O
g	B
##lut	I
##ama	I
##te	I
using	O
defined	O
mixture	O
##s	O
of	O
non	O
-	O
labeled	O
and	O
fully	O
labeled	O
g	B
##lut	I
##ama	I
##te	I
(	O
U	O
_	O
13	O
C	B
-	I
g	I
##lut	I
##ama	I
##te	I
)	O
in	O
a	O
##que	O
##ous	O
solution	O
.	O

[	O
Google	O
Scholar	O
]	O
O	O
##gle	O
##tree	O
M	O
##L	O
,	O
Harris	O
D	O
##N	O
,	O
Greenberg	O
R	O
,	O
Has	O
##lang	O
##er	O
M	O
##F	O
,	O
Na	O
##kan	O
##e	O
M	O
.	O
Ph	O
##arma	O
##cological	O
actions	O
of	O
S	O
##Q	O
29	O
,	O
54	O
##8	O
,	O
a	O
novel	O
selective	O
th	B
##rom	I
##box	I
##ane	I
antagonist	O
.	O

Pi	O
##o	O
and	O
Pi	O
##o	O
&	O
Omega	B
-	I
3	I
increased	O
body	O
weight	O
and	O
ad	O
##ip	O
##one	O
##ct	O
##in	O
levels	O
.	O

Ph	B
##en	I
##yla	I
##lani	I
##ne	I
has	O
a	O
short	O
half	O
-	O
life	O
in	O
plasma	O
of	O
approximately	O
1	O
.	O
7	O
##h	O
[	O
]	O
as	O
such	O
it	O
was	O
not	O
expected	O
that	O
there	O
would	O
be	O
any	O
o	O
##bs	O
##er	O
##vable	O
effects	O
on	O
blood	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
levels	O
under	O
normal	O
conditions	O
,	O
but	O
the	O
measure	O
was	O
undertaken	O
so	O
that	O
any	O
unusual	O
metabolic	O
effect	O
should	O
not	O
go	O
und	O
##ete	O
##cted	O
.	O

The	O
micro	O
##al	O
##bu	O
##min	O
##uri	O
##c	O
pattern	O
,	O
mainly	O
in	O
h	O
##yper	O
##tens	O
##ion	O
and	O
/	O
or	O
diabetes	O
,	O
was	O
also	O
associated	O
to	O
alterations	O
in	O
glucose	S
metabolism	O
,	O
lip	O
##id	O
β	O
-	O
oxidation	O
and	O
the	O
t	O
##rica	O
##rb	O
##ox	O
##ili	O
##c	O
acid	O
(	O
T	O
##CA	O
)	O
cycle	O
,	O
.	O

Second	O
,	O
we	O
identified	O
meta	O
##bol	O
##ites	O
that	O
might	O
be	O
lost	O
in	O
F	O
##PP	O
##E	O
due	O
to	O
their	O
reaction	O
with	O
formal	B
##de	I
##hy	I
##de	I
when	O
tissues	O
are	O
im	O
##mers	O
##ed	O
in	O
a	O
formal	B
##in	I
solution	O
.	O

Moreover	O
,	O
men	O
had	O
higher	O
B	O
##MI	O
,	O
waist	O
c	O
##ir	O
##cum	O
##ference	O
,	O
waist	O
-	O
to	O
-	O
hip	O
ratio	O
and	O
body	O
fat	O
percentage	O
compared	O
to	O
women	O
(	O
Su	O
##pp	O
##lement	O
##ary	O
Table	O
_	O
S	O
##1	O
)	O
and	O
presented	O
with	O
higher	O
serum	O
concentrations	O
of	O
BC	O
##AA	O
and	O
lower	O
serum	O
concentrations	O
of	O
se	B
##rine	I
and	O
g	B
##ly	I
##cine	I
,	O
among	O
other	O
meta	O
##bol	O
##ites	O
.	O

Line	O
##arity	O
of	O
the	O
ca	O
##li	O
##bra	O
##tion	O
curve	O
was	O
proven	O
for	O
C	B
##16	I
:	I
0	I
##C	I
##er	I
,	O
C	B
##24	I
:	I
0	I
##C	I
##er	I
,	O
C	B
##16	I
:	I
0	I
##dh	I
##C	I
##er	I
,	O
C	B
##24	I
:	I
1	I
##dh	I
##C	I
##er	I
,	O
C	B
##24	I
:	I
0	I
##dh	I
##C	I
##er	I
from	O
0	O
.	O
6	O
to	O
1	O
.	O
000	O
ng	O
/	O
m	O
##l	O
,	O
for	O
C	B
##18	I
:	I
0	I
##C	I
##er	I
from	O
0	O
.	O
18	O
to	O
300	O
ng	O
/	O
m	O
##l	O
,	O
for	O
C	B
##20	I
:	I
0	I
##C	I
##er	I
,	O
C	B
##24	I
:	I
1	I
##C	I
##er	I
from	O
0	O
.	O
24	O
to	O
400	O
ng	O
/	O
m	O
##l	O
and	O
for	O
C	B
##18	I
:	I
0	I
##dh	I
##C	I
##er	I
from	O
0	O
.	O
3	O
to	O
500	O
ng	O
/	O
m	O
##l	O
.	O

Mobile	O
phase	O
A	O
is	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
in	O
water	O
,	O
mobile	O
phase	O
B	O
is	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
in	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
.	O

The	O
resulting	O
MS	O
and	O
MS	O
/	O
MS	O
s	O
##pect	O
##ra	O
were	O
compared	O
with	O
compound	O
details	O
,	O
and	O
_	B
D	I
,	I
L	I
-	I
g	I
##lut	I
##amine	I
and	O
LP	O
##C	O
16	O
:	O
0	O
were	O
identified	O
(	O
Fi	O
##gs	O
.	O

Other	O
research	O
has	O
used	O
meta	O
##bol	O
##omi	O
##c	O
pro	O
##fi	O
##ling	O
of	O
blood	O
samples	O
to	O
identify	O
re	B
##tina	I
##l	I
diseases	O
.	O

Go	O
to	O
:	O
3	B
-	I
H	I
##ydro	I
##xy	I
##p	I
##rop	I
##yl	I
##mer	I
##cap	I
##tur	I
##ic	I
acid	I
(	O
3	O
-	O
HP	O
##MA	O
)	O
and	O
3	B
-	I
h	I
##ydro	I
##xy	I
-	I
1	I
-	I
met	I
##hyl	I
##p	I
##rop	I
##yl	I
##mer	I
##cap	I
##tur	I
##ic	I
acid	I
(	O
HM	O
##PM	O
##A	O
)	O
are	O
u	O
##rina	O
##ry	O
meta	O
##bol	O
##ites	O
of	O
the	O
toxic	O
##ants	O
a	B
##c	I
##rol	I
##ein	I
and	O
c	B
##rot	I
##onal	I
##de	I
##hy	I
##de	I
,	O
respectively	O
.	O

Within	O
systems	O
that	O
trigger	O
co	O
##agu	O
##lation	O
,	O
such	O
as	O
virus	O
infection	O
,	O
se	O
##psis	O
,	O
and	O
inflammation	O
,	O
cellular	O
precursor	O
##s	O
of	O
MV	O
##s	O
(	O
e	O
.	O
g	O
.	O
,	O
mon	O
##ocytes	O
,	O
plate	O
##lets	O
,	O
and	O
end	O
##oth	O
##eli	O
##al	O
cells	O
)	O
become	O
activated	S
,	O
moving	O
PS	O
lip	O
##ids	O
from	O
the	O
inner	O
to	O
the	O
outer	O
plasma	O
membrane	O
through	O
the	O
action	O
of	O
s	O
##c	O
##ram	O
##bla	O
##ses	O
(	O
,	O
,	O
)	O
.	O

Un	O
##su	O
##per	O
##vise	O
##d	O
(	O
PC	O
##A	O
)	O
and	O
supervised	O
(	O
P	O
##LS	O
)	O
multi	O
##var	O
##iate	O
analyses	O
of	O
the	O
whole	O
data	O
##sets	O
were	O
performed	O
,	O
respectively	O
,	O
in	O
order	O
to	O
have	O
an	O
overview	O
of	O
the	O
overall	O
var	O
##iability	O
,	O
and	O
to	O
look	O
for	O
specific	O
trends	O
according	O
to	O
collection	O
condition	O
and	O
storage	O
duration	S
.	O

In	O
our	O
study	O
,	O
we	O
also	O
found	O
association	O
of	O
the	O
same	O
S	O
##NP	O
with	O
c	B
##rea	I
##tine	I
level	O
and	O
also	O
observed	O
a	O
significant	O
correlation	O
between	O
c	B
##rea	I
##tine	I
and	O
g	B
##ly	I
##cine	I
(	O
r	O
=	O
0	O
.	O
08	O
,	O
P	O
-	O
value	O
=	O
1	O
.	O
46	O
##×	O
##10	O
_	O
−	O
##4	O
)	O
,	O
g	O
##lo	O
##mer	O
##ular	O
fi	O
##ltration	O
rate	O
(	O
r	O
=	O
−	O
##0	O
.	O
09	O
,	O
P	O
-	O
value	O
=	O
7	O
.	O
07	O
##×	O
##10	O
_	O
−	O
##5	O
)	O
and	O
T	B
##G	I
(	O
r	O
=	O
−	O
##0	O
.	O
08	O
,	O
P	O
-	O
value	O
=	O
1	O
.	O
15	O
##×	O
##10	O
_	O
−	O
##4	O
)	O
.	O

No	O
patient	O
had	O
a	O
ch	B
##ole	I
##ster	I
##ol	I
level	O
>	O
240	O
mg	O
/	O
d	O
##L	O
that	O
was	O
not	O
treated	O
with	O
a	O
s	B
##tat	I
##in	I
or	O
e	O
##ze	O
##ti	O
##mi	O
##be	O
.	O

P	O
##las	O
##ma	O
ma	B
##lon	I
##dial	I
##de	I
##hy	I
##de	I
(	O
MD	O
##A	O
)	O
was	O
measured	O
from	O
th	B
##io	I
##bar	I
##bit	I
##uri	I
##c	I
acid	O
-	O
reactive	O
substances	O
(	O
T	O
##BA	O
##RS	O
)	O
using	O
the	O
T	O
##BA	O
##RS	O
As	O
##say	O
Kit	O
(	O
Z	O
##ept	O
##o	O
##M	O
##et	O
##rix	O
Co	O
.	O
,	O
Buffalo	O
,	O
NY	O
,	O
USA	O
)	O
.	O

l	O
‐	O
As	O
##par	O
##agi	O
##nas	O
##e	O
cat	O
##aly	O
##zes	O
the	O
extra	O
##cellular	O
conversion	O
of	O
as	B
##par	I
##agi	I
##ne	I
into	O
as	B
##par	I
##tic	I
acid	I
and	O
am	O
##monia	O
.	O
_	O
29	O
It	O
is	O
important	O
for	O
solid	O
tumor	O
progression	O
to	O
maintain	O
as	B
##par	I
##agi	I
##ne	I
production	O
,	O
because	O
solid	O
tumor	O
is	O
nutrition	O
##ally	O
dependent	O
on	O
an	O
external	O
supply	O
of	O
as	B
##par	I
##agi	I
##ne	I
.	O
_	O
30	O

A	O
likely	O
cause	O
for	O
the	O
association	O
between	O
V	O
##LD	O
##L	O
lip	O
##ids	O
and	O
insulin	O
resistance	O
is	O
over	O
##p	O
##rod	O
##uction	O
of	O
V	O
##LD	O
##L	O
particles	O
and	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
from	O
the	O
liver	O
and	O
decreased	O
h	O
##ydro	O
##lysis	O
of	O
FA	O
##s	O
from	O
V	O
##LD	O
##L	O
and	O
ch	O
##yl	O
##omi	O
##c	O
##ron	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
by	O
lip	O
##op	O
##rote	O
##in	O
lip	O
##ase	O
in	O
other	O
tissues	O
in	O
an	O
insulin	O
resistant	O
state	O
[	O
,	O
]	O
.	O

O	O
##EP	O
also	O
led	O
to	O
a	O
significant	O
increase	O
in	O
ho	B
##mo	I
##vani	I
##lli	I
##c	I
acid	I
and	O
D	O
##OP	O
##AC	O
in	O
fast	O
##ed	O
plasma	O
samples	O
,	O
indicating	O
related	O
clearance	O
of	O
these	O
compounds	O
from	O
the	O
blood	O
or	O
extended	O
release	O
and	O
up	O
##take	O
from	O
the	O
in	O
##test	O
##ine	O
.	O

This	O
result	O
reflected	O
the	O
increased	O
conversion	O
of	O
c	B
##it	I
##rate	I
into	O
fatty	O
acids	O
necessary	O
for	O
β	O
-	O
oxidation	O
to	O
support	O
the	O
rapid	O
proliferation	O
of	O
cancer	O
cells	O
.	O

d	O
R	O
##OC	O
curve	O
of	O
g	B
##lut	I
##amine	I
to	O
g	B
##lut	I
##ami	I
##c	I
acid	I
ratio	O
.	O

Lac	B
##tate	I
was	O
disc	O
##erne	O
##d	O
similarly	O
and	O
based	O
on	O
the	O
peak	O
splitting	O
pattern	O
(	O
double	O
##t	O
for	O
3	O
-	O
met	O
##hyl	O
@	O
1	O
.	O
32	O
pp	O
##m	O
and	O
quartet	O
for	O
2	O
-	O
met	O
##hine	O
pro	O
##tons	O
@	O
4	O
.	O
11	O
pp	O
##m	O
)	O
.	O

Fi	O
##bri	O
##no	O
##gen	O
,	O
trans	B
##thy	I
##ret	I
##in	I
and	O
P	O
##EP	O
alone	O
cannot	O
clearly	O
separate	O
CR	O
##C	O
from	O
control	O
samples	O
,	O
but	O
they	O
showed	O
substantial	O
power	O
as	O
part	O
of	O
a	O
set	O
of	O
104	O
disc	O
##rim	O
##inator	O
##s	O
(	O
Supporting	O
Information	O
Table	O
)	O
.	O

Without	O
using	O
demographic	O
characteristics	O
,	O
a	O
number	O
of	O
meta	O
##bol	O
##ites	O
performed	O
as	O
well	O
or	O
better	O
in	O
R	O
##MS	O
##E	O
than	O
c	B
##rea	I
##tin	I
##ine	I
alone	O
(	B
N	B
-	I
ace	I
##ty	I
##lt	I
##hr	I
##eon	I
##ine	I
,	O
pseudo	B
##uri	I
##dine	I
and	O
N	B
-	I
ace	I
##ty	I
##ls	I
##eri	I
##ne	I
in	O
both	O
studies	O
and	O
me	B
##so	I
-	I
er	I
##yt	I
##hr	I
##ito	I
##l	I
,	O
a	B
##rab	I
##ito	I
##l	I
,	O
my	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
and	O
N	B
-	I
ace	I
##ty	I
##lal	I
##ani	I
##ne	I
in	O
the	O
ME	O
##SA	O
only	O
)	O
.	O

Over	O
85	O
%	O
(	O
44	O
##8	O
)	O
features	O
were	O
found	O
in	O
common	O
between	O
the	O
methods	O
and	O
there	O
were	O
64	O
features	O
unique	O
to	O
the	O
met	B
##han	I
##ol	I
method	O
and	O
78	O
features	O
unique	O
to	O
the	O
met	B
##han	I
##ol	I
-	I
ethanol	I
method	O
.	O

T	B
##hr	I
##eon	I
##ine	I
,	O
c	B
##it	I
##ru	I
##llin	I
##e	I
,	O
and	O
or	B
##ni	I
##thin	I
##e	I
displayed	O
the	O
highest	O
positive	O
correlation	O
with	O
PA	O
##SI	O
scores	O
(	O
Table	O
3	O
)	O
,	O
whereas	O
th	B
##re	I
##oni	I
##ne	I
,	O
g	B
##lut	I
##amine	I
,	O
and	O
or	B
##ni	I
##thin	I
##e	I
were	O
the	O
most	O
highly	O
ranked	O
multi	O
##var	O
##iate	O
predict	O
##ors	O
of	O
ps	O
##oria	O
##sis	O
severity	O
(	O
Figure	O
B	O
)	O
.	O

Therefore	O
,	O
k	B
##yn	I
##uren	I
##ine	I
would	O
be	O
a	O
predict	O
##ive	O
bio	O
##mark	O
##er	O
in	O
predict	O
##ing	O
the	O
OS	O
in	O
pre	O
##tre	O
##at	O
##ment	O
o	O
##var	O
##ian	O
cancer	O
.	O

B	O
##rief	O
##ly	O
,	O
the	O
a	O
##que	O
##ous	O
humor	O
(	O
25	O
µ	O
##L	O
)	O
was	O
mixed	O
with	O
an	O
internal	O
reference	O
standard	O
(	O
20	O
µ	O
##L	O
)	O
,	O
di	O
##c	O
##lo	O
##fen	O
##ac	O
-	O
d	O
##4	O
,	O
dissolved	O
in	O
met	B
##han	I
##ol	I
,	O
and	O
di	O
##lut	O
##ed	O
in	O
255	O
µ	O
##L	O
of	O
ultra	O
-	O
pure	O
water	O
.	O

P	O
##ls	O
##E	O
##t	O
##ns	O
are	O
membrane	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
,	O
primarily	O
located	O
in	O
cells	O
of	O
the	O
nervous	O
system	O
and	O
heart	O
[	O
,	O
]	O
,	O
but	O
which	O
are	O
produced	O
exclusively	O
by	O
per	O
##ox	O
##is	O
##ome	O
##s	O
in	O
the	O
liver	O
.	O

We	O
thus	O
compared	O
meta	O
##bol	O
##ites	O
extracted	O
from	O
the	O
samples	O
before	O
and	O
after	O
the	O
para	B
##ffin	I
em	O
##bed	O
##ding	O
and	O
we	O
observed	O
a	O
global	O
de	O
##ple	O
##tion	O
of	O
meta	O
##bol	O
##ites	O
in	O
all	O
classes	O
.	O

Previous	O
reports	O
have	O
suggested	O
that	O
cannabis	S
use	O
has	O
no	O
impact	O
on	O
enrollment	O
in	O
AR	O
##T	O
care	O
,	O
AR	O
##T	O
ad	O
##herence	O
,	O
or	O
successful	O
viral	O
load	O
suppression	O
,	O
while	O
others	O
have	O
demonstrated	O
that	O
cannabis	S
use	O
was	O
associated	O
with	O
missed	O
clinic	O
appointments	O
and	O
is	O
a	O
risk	O
factor	O
for	O
card	O
##iovascular	O
disease	O
in	O
middle	O
-	O
aged	O
HIV	O
-	O
infected	O
men	O
.	O

To	O
evaluate	O
the	O
loading	O
step	O
,	O
50	O
μ	O
##L	O
of	O
serum	O
was	O
di	O
##lut	O
##ed	O
with	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
,	O
with	O
additional	O
dei	O
##onized	O
water	O
as	O
needed	O
,	O
to	O
yield	O
an	O
a	O
##que	O
##ous	O
solution	O
of	O
7	O
,	O
12	O
and	O
17	O
%	O
.	O

11	O
,	O
previous	O
peripheral	O
artery	O
disease	O
;	O
CR	O
##P	O
,	O
C	O
-	O
reactive	O
protein	O
;	O
diabetes	O
_	O
m	O
,	O
diabetes	O
me	O
##lli	O
##tus	O
;	O
D	B
##MG	I
,	O
dim	B
##eth	I
##yl	I
##gly	I
##cine	I
;	O
F	B
##olate	I
,	O
serum	O
f	B
##olate	I
;	O
G	O
##F	O
##R	O
,	O
g	O
##lo	O
##mer	O
##ular	O
fi	O
##ltration	O
rate	O
;	O
G	B
##S	I
##H	I
,	O
total	O
g	B
##lut	I
##ath	I
##ione	I
;	O
H	O
##AA	O
,	O
h	B
##ydro	I
##xy	I
##ant	I
##hra	I
##ny	I
##lic	I
acid	I
;	O
H	O
##BA	O
##1	O
##C	O
,	O
g	O
##ly	O
##cated	O
hem	O
##og	O
##lo	O
##bin	O
;	O
HK	O
,	O
h	B
##ydro	I
##xy	I
##ky	I
##nu	I
##ren	I
##ine	I
;	O
HK	O
/	O
X	O
##A	O
,	O
h	B
##ydro	I
##xy	I
##ky	I
##nu	I
##ren	I
##ine	I
:	I
x	I
##ant	I
##hur	I
##eni	I
##c	I
acid	I
ratio	O
;	O
H	O
##lan	O
,	O
ho	B
##mo	I
##lant	I
##hi	I
##oni	I
##ne	I
;	O
h	O
##r	O
_	O
since	O
,	O
hours	O
since	O
last	O
meal	O
;	O
K	O
##A	O
,	O
k	B
##yn	I
##uren	I
##ic	I
acid	I
;	O
K	O
##TR	O
,	O
k	B
##yn	I
##uren	I
##ine	I
:	O
try	O
##pt	O
##op	O
##han	O
ratio	O
;	O
K	O
##yn	O
,	O
k	B
##yn	I
##uren	I
##ine	I
;	O
La	O
##n	O
,	O
la	B
##nt	I
##hi	I
##oni	I
##ne	I
;	O
ME	O
##DF	O
##SD	O
##O	O
,	O
relative	O
s	B
##tat	I
##in	I
dose	O
;	O
ME	O
##DF	O
##ST	O
##A	O
,	O
s	B
##tat	I
##in	I
use	O
;	O
MMA	O
,	O
met	B
##hyl	I
##mal	I
##onic	I
acid	I
;	O
PA	O
,	O
p	B
##yr	I
##ido	I
##xi	I
##c	I
acid	I
;	O
Pa	O
##C	O
##ar	O
##n	O
,	O
palm	B
##ito	I
##yl	I
-	I
car	I
##ni	I
##tine	I
;	O
PA	O
##r	O
,	O
p	B
##yr	I
##ido	I
##xi	I
##c	I
acid	I
:	I
p	I
##yr	I
##ido	I
##xa	I
##l	I
plus	O
p	B
##yr	I
##ido	I
##xa	I
##l	I
phosphate	I
ratio	O
;	O
P	O

P	O
##las	O
##ma	O
glucose	S
was	O
measured	O
by	O
the	O
glucose	S
o	O
##xi	O
##das	O
##e	O
method	O
using	O
a	O
S	O
##ync	O
##hr	O
##on	O
L	O
##X	O
##20	O
analyze	O
##r	O
(	O
Beck	O
##man	O
Co	O
##ulter	O
,	O
B	O
##rea	O
,	O
CA	O
,	O
USA	O
)	O
and	O
H	O
##b	O
##A	O
##1	O
##c	O
was	O
measured	O
using	O
ion	O
exchange	O
ch	O
##roma	O
##tography	O
(	O
Men	O
##ari	O
##ni	O
H	O
##A	O
-	O
81	O
##60	O
H	O
##b	O
##A	O
##1	O
##c	O
auto	O
-	O
analyze	O
##r	O
,	O
Men	O
##ari	O
##ni	O
Di	O
##ag	O
##nos	O
##tics	O
,	O
Belgium	O
)	O
.	O

The	O
lip	O
##id	O
C	B
##18	I
:	I
2	I
CE	O
was	O
detected	O
at	O
a	O
mean	O
concentration	O
of	O
12	O
.	O
71	O
nm	O
##ol	O
/	O
µ	O
##l	O
in	O
22	O
S	O
##q	O
##CC	O
patients	O
,	O
with	O
a	O
31	O
.	O
02	O
%	O
down	O
##re	O
##gu	O
##lation	O
(	O
P	O
=	O
0	O
.	O
000	O
##1	O
)	O
when	O
compared	O
with	O
the	O
demographic	O
##ally	O
matched	O
high	O
-	O
risk	O
controls	O
(	O
18	O
.	O
42	O
nm	O
##ol	O
/	O
µ	O
##l	O
;	O
)	O
.	O

Using	O
a	O
stronger	O
solvent	O
such	O
as	O
et	B
##hyl	I
ace	I
##tate	I
would	O
decrease	O
the	O
purity	O
of	O
the	O
sample	O
and	O
the	O
yield	O
of	O
the	O
der	O
##iva	O
##ti	O
##zation	O
reaction	O
.	O

We	O
show	O
a	O
significant	O
inverse	O
correlation	O
between	O
la	B
##ct	I
##ate	I
levels	O
and	O
tumor	O
size	O
(	O
Figure	O
;	O
Pearson	O
correlation	O
r	O
=	O
−	O
##0	O
.	O
30	O
##9	O
;	O
p	O
=	O
0	O
.	O
04	O
##4	O
)	O
.	O

The	O
met	B
##han	I
##ogenic	I
arch	O
##ae	O
##a	O
Met	B
##han	I
##ob	I
##re	I
##vi	I
##ba	I
##cter	I
was	O
found	O
to	O
be	O
present	O
in	O
50	O
%	O
(	O
10	O
/	O
20	O
)	O
of	O
the	O
CR	O
##C	O
micro	O
##bio	O
##ta	O
,	O
compared	O
to	O
10	O
%	O
(	O
2	O
/	O
20	O
)	O
of	O
the	O
healthy	O
controls	O
.	O

Value	O
was	O
considered	O
as	O
an	O
out	O
##lier	O
when	O
its	O
absolute	O
residual	O
was	O
4	O
.	O
5	O
times	O
larger	O
than	O
r	B
##m	I
.	O

For	O
processing	O
into	O
para	B
##ffin	I
,	O
tissues	O
are	O
fixed	O
in	O
formal	B
##in	I
(	O
an	O
a	O
##que	O
##ous	O
solution	O
)	O
for	O
variable	O
times	O
of	O
up	O
to	O
more	O
than	O
24	O
h	O
##rs	O
,	O
de	O
##hy	O
##dra	O
##ted	O
in	O
graded	O
alcohol	O
##s	O
,	O
im	O
##mers	O
##ed	O
in	O
x	B
##yle	I
##ne	I
,	O
imp	O
##re	O
##gnate	O
##d	O
with	O
para	B
##ffin	I
,	O
de	O
##par	O
##af	O
##fin	O
##ized	O
in	O
x	B
##yle	I
##ne	I
and	O
meta	O
##bol	O
##ites	O
then	O
extracted	O
.	O

In	O
a	O
similar	O
way	O
,	O
the	O
PC	B
37	I
:	I
5	I
(	O
MS	O
/	O
MS	O
of	O
m	O
/	O
z	O
85	O
##2	O
.	O
57	O
##45	O
)	O
can	O
be	O
confirmed	O
,	O
proposing	O
the	O
presence	O
of	O
the	O
molecular	O
species	O
;	O
PC	B
17	I
:	I
0	I
/	I
20	I
:	I
5	I
,	O
PC	B
P	I
-	I
18	I
:	I
0	I
/	I
20	I
:	I
4	I
,	O
PC	B
O	I
-	I
18	I
:	I
0	I
/	I
20	I
:	I
5	I
and	O
PC	B
O	I
-	I
16	I
:	I
0	I
/	I
22	I
:	I
5	I
(	O
C	O
and	O
)	O
.	O

Finally	O
,	O
an	O
in	O
v	O
##it	O
##ro	O
study	O
of	O
cell	O
via	O
##bility	O
under	O
o	O
##xi	O
##da	O
##tive	O
stress	O
showed	O
that	O
cell	O
survival	O
was	O
higher	O
in	O
the	O
presence	O
of	O
reactive	O
su	B
##lf	I
##ide	I
species	O
than	O
in	O
their	O
absence	O
.	O

To	O
re	O
##fine	O
the	O
mass	O
ca	O
##li	O
##bra	O
##tion	O
,	O
ion	O
peaks	O
of	O
ch	B
##ole	I
##ster	I
##ol	I
and	O
vitamin	B
E	I
were	O
used	O
in	O
positive	O
ion	O
mode	O
,	O
and	O
fatty	O
acid	O
car	O
##box	O
##yla	O
##te	O
ions	O
in	O
negative	O
ion	O
mode	O
based	O
on	O
previous	O
studies	O
reported	O
on	O
biological	O
samples	O
_	O
,	O
_	O
,	O
_	O
,	O
.	O

In	O
order	O
to	O
calculate	O
the	O
L	O
##OD	O
and	O
L	O
##O	O
##Q	O
,	O
a	O
solution	O
of	O
standards	O
in	O
Me	B
##OH	I
was	O
used	O
.	O

A	O
##romatic	O
region	O
(	O
5	O
.	O
0	O
–	O
9	O
.	O
5	O
pp	O
##m	O
)	O
ma	O
##gni	O
##fied	O
×	O
##4	O
compared	O
with	O
the	O
al	B
##ip	I
##hat	I
##ic	I
region	O
(	O
0	O
.	O
7	O
–	O
4	O
.	O
3	O
p	O
.	O
p	O
.	O
m	O
)	O
.	O

Indeed	O
,	O
during	O
the	O
multi	O
##ste	O
##p	O
procedure	O
of	O
fix	O
##ation	O
and	O
em	O
##bed	O
##ding	O
in	O
para	B
##ffin	I
,	O
there	O
are	O
factors	O
,	O
such	O
as	O
solvent	O
##s	O
used	O
in	O
the	O
procedure	O
or	O
reactive	O
groups	O
of	O
certain	O
molecules	O
,	O
which	O
can	O
affect	O
the	O
preservation	O
of	O
meta	O
##bol	O
##ites	O
that	O
survive	O
tissue	O
processing	O
.	O

The	O
two	O
data	O
##sets	O
differed	O
in	O
subjects	O
’	O
age	O
,	O
body	O
weight	O
,	O
glucose	S
levels	O
,	O
insulin	O
levels	O
and	O
H	O
##OM	O
##A	O
-	O
I	O
##R	O
,	O
whereas	O
no	O
significant	O
differences	O
according	O
to	O
sex	O
distribution	O
,	O
B	O
##MI	O
,	O
WC	O
and	O
the	O
lip	O
##id	O
profile	O
were	O
shown	O
(	O
Table	O
)	O
.	O

B	O
##rief	O
##ly	O
,	O
the	O
two	O
fat	O
##s	O
differed	O
in	O
the	O
content	O
of	O
T	B
##FA	I
(	I
18	I
:	I
1	I
trans	I
-	I
9	I
,	I
18	I
:	I
1	I
trans	I
-	I
8	I
,	I
18	I
:	I
1	I
trans	I
-	I
7	I
)	I
,	O
palm	B
##itic	I
(	I
16	I
:	I
0	I
)	I
,	O
o	O
##le	O
##ic	O
(	O
18	O
:	O
1	O
c	O
##is	O
-	O
9	O
)	O
and	O
l	B
##ino	I
##le	I
##ic	I
acids	I
(	O
18	O
:	O
2	O
c	O
##is	O
-	O
6	O
)	O
.	O

At	O
##rac	O
##ty	O
##li	O
##gen	O
##in	O
g	B
##lu	I
##cu	I
##ron	I
##ide	I
has	O
been	O
identified	O
in	O
the	O
urine	O
of	O
habit	O
##ual	O
coffee	O
consumers	O
at	O
3	O
µ	O
##g	O
/	O
m	O
##L	O
,	O
but	O
is	O
proposed	O
for	O
the	O
first	O
time	O
here	O
as	O
a	O
bio	O
##mark	O
##er	O
of	O
coffee	O
intake	O
.	O

The	O
fragment	O
##ation	O
spectrum	O
was	O
very	O
similar	O
to	O
that	O
of	O
the	O
c	B
##y	I
##c	I
##lo	I
(	I
le	I
##uc	I
##yl	I
-	I
pro	I
##ly	I
##l	I
)	I
standard	O
spike	O
##d	O
in	O
blank	O
urine	O
but	O
with	O
a	O
slightly	O
shorter	O
retention	O
time	O
.	O

When	O
the	O
delivery	O
of	O
β	B
-	I
pine	I
##ne	I
was	O
stopped	O
,	O
the	O
signal	O
intensity	O
dropped	O
abruptly	O
to	O
base	O
##line	O
level	O
,	O
indicating	O
no	O
carry	O
##over	O
effects	O
,	O
at	O
least	O
for	O
this	O
particular	O
compound	O
(	O
ins	O
##et	O
Fi	O
##g	O
.	O

(	O
I	O
)	O
V	O
##en	O
##n	O
diagram	O
##s	O
reflecting	O
meta	O
##bol	O
##ites	O
significantly	O
correlated	O
in	O
oral	O
fat	O
intake	O
(	O
n	O
=	O
42	O
)	O
,	O
oral	O
ca	O
##lor	O
##ic	O
intake	O
(	O
n	O
=	O
23	O
)	O
,	O
and	O
N	O
##RI	O
scores	O
(	O
n	O
=	O
4	O
)	O
among	O
195	O
meta	O
##bol	O
##ites	O
;	O
(	O
K	O
–	O
N	O
)	O
,	O
L	B
##ys	I
##o	I
##PC	I
(	I
16	I
:	I
0	I
)	I
and	O
SM	B
(	I
d	I
##18	I
:	I
1	I
/	I
24	I
:	I
1	I
)	I
significantly	O
correlated	O
with	O
oral	O
fat	O
intake	O
and	O
N	O
##RI	O
score	O
(	O
Pearson	O
’	O
s	O
r	O
correlation	O
analysis	O
)	O
.	O

Internal	O
standards	O
solution	O
for	O
plasma	O
processing	O
(	O
plasma	O
protein	O
precipitation	O
)	O
was	O
prepared	O
in	O
PP	O
tube	O
by	O
di	O
##lut	O
##ing	O
50	O
-	O
fold	O
in	O
Me	B
##OH	I
the	O
internal	O
standards	O
W	O
##S	O
to	O
obtain	O
a	O
final	O
concentration	O
for	O
all	O
internal	O
standards	O
of	O
40	O
ng	O
/	O
m	O
##L	O
.	O

Forty	O
micro	O
##lite	O
##rs	O
of	O
a	O
phosphate	S
buffer	O
solution	O
(	O
0	O
.	O
06	O
##M	O
Na	O
_	O
2	O
HP	O
##O	O
_	O
4	O
/	O
0	O
.	O
04	O

Key	O
meta	O
##bol	O
##ites	O
of	O
the	O
me	B
##val	I
##ona	I
##te	I
pathway	O
accumulated	O
in	O
SC	O
##C	O
t	O
##umour	O
##s	O
,	O
as	O
well	O
-	O
established	O
in	O
cancer	O
tissues	O
,	O
to	O
feed	O
into	O
,	O
amongst	O
other	O
things	O
,	O
ch	B
##ole	I
##ster	I
##ol	I
.	O

The	O
HP	O
##LC	O
column	O
was	O
el	O
##uted	O
at	O
15	O
μ	O
##L	O
/	O
min	O
with	O
2	O
%	O
met	B
##han	I
##ol	I
for	O
10	O
min	O
,	O
followed	O
by	O
a	O
linear	O
gradient	O
to	O
15	O
%	O
met	B
##han	I
##ol	I
over	O
30	O
min	O
.	O

T	O
##iss	O
##ue	O
samples	O
(	O
~	O
40	O
mg	O
)	O
were	O
ho	O
##mo	O
##gen	O
##ized	O
using	O
Fast	O
##p	O
##re	O
##p	O
24	O
Ho	O
##mo	O
##gen	O
##izer	O
(	O
MP	O
B	O
##io	O
##medical	O
,	O
OH	O
,	O
USA	O
)	O
in	O
Pure	O
##L	O
##ink	O
[UNK]	O
RNA	O
Mini	O
Kit	O
l	O
##ys	O
##is	O
buffer	O
(	O
The	O
##rm	O
##o	O
Fisher	O
Scientific	O
,	O
Walt	O
##ham	O
,	O
MA	O
,	O
USA	O
)	O
with	O
added	O
β	B
-	I
me	I
##rca	I
##pt	I
##oe	I
##than	I
##ol	I
(	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
,	O
St	O
.	O
Louis	O
,	O
M	O
##O	O
,	O
USA	O
)	O
.	O

Ka	O
et	O
al	O
demonstrated	O
positive	O
correlation	O
##s	O
between	O
plasma	O
u	B
##rid	I
##ine	I
concentrations	O
and	O
the	O
u	O
##rina	O
##ry	O
ex	O
##cre	O
##tions	O
of	O
u	B
##rea	I
,	O
u	B
##ric	I
acid	I
,	O
u	B
##rid	I
##ine	I
,	O
u	B
##ric	I
acid	I
clearance	O
and	O
pu	B
##rine	I
intake	O
in	O
healthy	O
males	O
.	O

Except	O
for	O
o	B
##lan	I
##za	I
##pine	I
,	O
no	O
statistical	O
differences	O
were	O
found	O
between	O
the	O
cap	O
##illa	O
##ry	O
and	O
ve	O
##nous	O
drug	O
concentrations	O
.	O

Cal	O
##ci	O
##um	O
,	O
chloride	S
,	O
potassium	O
,	O
sodium	O
,	O
phosphate	S
,	O
and	O
also	O
iron	O
concentrations	O
,	O
as	O
well	O
as	O
bi	B
##li	I
##ru	I
##bin	I
,	O
L	O
##D	O
##L	O
-	O
,	O
HD	O
##L	O
-	O
,	O
and	O
total	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
,	O
glucose	S
,	O
u	B
##ric	I
acid	I
,	O
u	B
##rea	I
,	O
free	O
T	O
##3	O
,	O
and	O
free	O
T	B
##4	I
thy	I
##roid	I
hormone	I
concentrations	O
were	O
determined	O
in	O
blood	O
serum	O
.	O

Two	O
pathways	O
are	O
used	O
in	O
ma	O
##mmal	O
##ian	O
cells	O
to	O
s	O
##ynth	O
##esi	O
##ze	O
ch	B
##ole	I
##ster	I
##ol	I
.	O

Then	O
BS	O
##TF	O
##A	O
was	O
added	O
with	O
1	O
%	O
trim	B
##eth	I
##yl	I
##ch	I
##lor	I
##os	I
##ila	I
##ne	I
(	O
T	O
##CM	O
##S	O
)	O
and	O
placed	O
at	O
70	O
##°	O
##C	O
##fo	O
##r	O
60	O
min	O
to	O
form	O
trim	O
##eth	O
##yl	O
##si	O
##ly	O
##l	O
(	O
T	O
##MS	O
)	O
derivatives	O
.	O

In	O
pool	O
##ed	O
samples	O
from	O
patients	O
with	O
se	O
##psis	O
we	O
found	O
that	O
Me	B
##OH	I
pp	O
##t	O
+	O
U	O
##F	O
offered	O
similar	O
recovery	O
and	O
variance	O
to	O
Me	B
##OH	I
:	O

Wang	O
et	O
al	O
.	O
reported	O
finding	O
remarkable	O
imp	O
##air	O
##ment	O
of	O
BC	O
##AA	O
cat	O
##ab	O
##olis	O
##m	O
in	O
the	O
my	O
##oc	O
##ard	O
##ium	O
in	O
response	O
to	O
in	O
##far	O
##ction	O
in	O
a	O
m	B
##uri	I
##ne	I
MI	O
model	O
;	O
oral	O
administration	O
of	O
BC	O
##AA	O
further	O
increased	O
BC	O
##AA	O
concentrations	O
,	O
activated	S
m	O
##TO	O
##R	O
signalling	O
,	O
and	O
ex	O
##ace	O
##rb	O
##ated	O
cardiac	O
d	O
##ys	O
##function	O
and	O
re	O
##mo	O
##dell	O
##ing	O
.	O

Additionally	O
,	O
the	O
analysis	O
is	O
consistent	O
with	O
g	O
##ly	O
##co	O
##lysis	O
and	O
PP	O
##P	O
being	O
down	O
##re	O
##gu	O
##lated	O
in	O
the	O
HC	O
##V	O
+	O
liver	O
,	O
with	O
a	O
con	O
##se	O
##quent	O
decrease	O
in	O
plasma	O
la	B
##ctic	I
acid	I
,	O
and	O
is	O
also	O
consistent	O
with	O
in	O
##tra	O
##cellular	O
glucose	S
leaking	O
from	O
the	O
cell	O
and	O
contributing	O
to	O
the	O
h	O
##yper	O
##gly	O
##ce	O
##mia	O
frequently	O
observed	O
with	O
chronic	O
HC	O
##V	O
infection	O
.	O

In	O
good	O
respond	O
##ers	O
,	O
we	O
found	O
an	O
increase	O
in	O
is	B
##ole	I
##uc	I
##ine	I
,	O
le	B
##uc	I
##ine	I
,	O
v	B
##ali	I
##ne	I
,	O
al	B
##ani	I
##ne	I
,	O
g	B
##lut	I
##amine	I
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
and	O
glucose	S
levels	O
and	O
a	O
decrease	O
in	O
3	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
levels	O
after	O
six	O
months	O
of	O
treatment	O
with	O
et	O
##ane	O
##rc	O
##ept	O
with	O
respect	O
to	O
base	O
##line	O
.	O

L	O
##D	O
##L	O
‐	O
Ce	O
##r	O
were	O
not	O
measured	O
here	O
,	O
but	O
uniquely	O
and	O
unlike	O
other	O
c	B
##era	I
##mi	I
##des	I
,	O
C	B
##18	I
:	I
0	I
c	I
##era	I
##mi	I
##de	I
concentration	O
in	O
plasma	O
and	O
muscle	O
correlated	O
positively	O
,	O
possibly	O
placing	O
C	B
##18	I
:	I
0	I
c	I
##era	I
##mi	I
##de	I
at	O
that	O
circulation	O
‐	O
muscle	O
cross	O
##link	O
.	O

The	O
number	O
of	O
samples	O
selected	O
was	O
200	O
and	O
the	O
sample	O
selection	O
was	O
made	O
based	O
on	O
the	O
presence	O
of	O
the	O
heroin	O
meta	O
##bol	O
##ite	O
6	B
-	I
ace	I
##ty	I
##lm	I
##or	I
##phine	I
measured	O
by	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
(	O
Anders	O
##son	O
et	O
al	O
.	O
)	O
.	O

G	O
##ly	O
##co	O
##lysis	O
,	O
whilst	O
less	O
efficient	O
that	O
o	O
##xi	O
##da	O
##tive	O
p	O
##hos	O
##ph	O
##ory	O
##lation	O
,	O
makes	O
ATP	S
at	O
a	O
much	O
faster	O
rate	O
.	O

Because	O
the	O
CD	O
##C	O
method	O
is	O
used	O
in	O
analysis	O
of	O
samples	O
for	O
a	O
national	O
nutrition	O
survey	O
,	O
the	O
occurrence	O
of	O
measurement	O
bias	O
arising	O
from	O
the	O
3	O
-	O
e	O
##pi	O
##mer	O
could	O
affect	O
est	O
##imation	O
##s	O
of	O
the	O
prevalence	O
of	O
vitamin	B
D	I
su	O
##ff	O
##iciency	O
in	O
the	O
U	O
.	O
S	O
.	O
population	O
.	O

For	O
example	O
,	O
the	O
decrease	O
in	O
the	O
fatty	O
acids	O
18	O
:	O
3	O
and	O
20	O
:	O
3	O
with	O
fish	O
oil	O
supplement	O
##ation	O
as	O
determined	O
by	O
G	O
##C	O
-	O
MS	O
is	O
consistent	O
with	O
the	O
decrease	O
of	O
PC	B
(	I
36	I
:	I
3	I
)	I
and	O
PC	B
(	I
38	I
:	I
3	I
)	I
if	O
one	O
assumes	O
that	O
one	O
of	O
the	O
fatty	O
acids	O
in	O
these	O
species	O
is	O
the	O
highly	O
abundant	O
palm	B
##itate	I
(	I
16	I
:	I
0	I
—	I
Fi	I
##g	I
.	O

For	O
the	O
whole	O
population	O
,	O
3	O
-	O
H	O
##IB	O
correlated	O
with	O
ace	B
##to	I
##ace	I
##tate	I
(	O
P	O
<	O
0	O
.	O
00	O
##1	O
,	O
R	O
=	O
0	O
.	O
38	O
##6	O
,	O
n	O
=	O
232	O
)	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
the	O
levels	O
of	O
serum	O
album	O
##in	O
,	O
total	O
bi	B
##li	I
##ru	I
##bin	I
,	O
as	O
##par	O
##tate	O
amino	O
##tra	O
##ns	O
##fer	O
##ase	O
,	O
al	O
##ani	O
##ne	O
amino	O
##tra	O
##ns	O
##fer	O
##ase	O
,	O
fast	O
##ing	O
blood	O
glucose	S
,	O
γ	O
-	O
g	O
##lut	O
##am	O
##yl	O
transfer	O
##ase	O
,	O
c	B
##rea	I
##tin	I
##ine	I
,	O
plate	O
##let	O
count	O
,	O
Fi	O
##b	O
-	O
4	O
index	O
,	O
elevated	O
A	O
##FP	O
or	O
DC	O
##P	O
,	O
between	O
the	O
two	O
groups	O
.	O

A	O
##bb	O
##re	O
##viation	O
##s	O
:	O
Ce	B
##r	I
=	I
c	I
##era	I
##mi	I
##de	I
;	O
LP	B
##C	I
=	I
l	I
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
;	O
SM	B
=	I
s	I
##phi	I
##ngo	I
##my	I
##elin	I
.	O

These	O
changes	O
stayed	O
significant	O
even	O
after	O
adjustment	O
for	O
known	O
relationships	O
(	O
B	O
##MI	O
,	O
fast	O
##ing	O
glucose	S
)	O
.	O

A	O
,	O
O	O
##T	O
##α	O
o	B
##ch	I
##rato	I
##xin	I
α	O
,	O
Q	O
##q	O
##Q	O
triple	O
q	O
##uad	O
##rup	O
##ole	O
,	O
SA	O
##X	O
strong	O
an	O
##ion	O
exchange	O
,	O
S	O
##ID	O
##A	O
stable	O
-	O
is	O
##oto	O
##pe	O
standard	O
-	O
di	O
##lution	O
ass	O
##ay	O
,	O
SP	O
##E	O
solid	O
-	O
phase	O
extraction	O
,	O
Z	O
##EN	O
z	B
##ear	I
##ale	I
##non	I
##e	I
,	O
Z	O
##EL	O
z	O
##ear	O
##ale	O
##no	O
##l	O
_	O
a	O
Value	O
##s	O
in	O
parent	O
##heses	O
represent	O
the	O
amount	O
of	O
urine	O
injected	O
taking	O
the	O
sample	O
en	O
##rich	O
##ment	O
/	O
di	O
##lution	O
into	O
account	O
.	O

The	O
elevation	O
of	O
FA	O
##SN	O
expression	O
in	O
cancer	O
is	O
consistent	O
with	O
evidence	O
##s	O
that	O
metabolism	O
of	O
a	B
##rac	I
##hi	I
##don	I
##ic	I
acid	I
(	O
AA	O
)	O
by	O
the	O
CO	O
##X	O
pathway	O
is	O
up	O
##re	O
##gu	O
##lated	O
,	O
which	O
plays	O
important	O
roles	O
in	O
inflammation	O
and	O
cancer	O
progression	O
.	O

N	B
-	I
Ace	I
##ty	I
##l	I
##cy	I
##stein	I
##e	I
(	O
N	O
##AC	O
)	O
was	O
purchased	O
from	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
(	O
St	O
.	O
Louis	O
,	O
M	O
##O	O
)	O
.	O

Cho	B
##line	I
was	O
excluded	O
based	O
on	O
diet	O
##ary	O
bias	O
and	O
g	B
##ly	I
##cola	I
##lde	I
##hy	I
##de	I
is	O
to	O
be	O
excluded	O
based	O
on	O
robust	O
practical	O
E	O
##SI	O
considerations	O
required	O
for	O
a	O
regulated	O
clinical	O
environment	O
.	O

The	O
resulting	O
L	B
-	I
al	I
##ani	I
##ne	I
is	O
shuttle	O
##d	O
to	O
the	O
liver	O
where	O
the	O
nitrogen	O
enters	O
the	O
u	B
##rea	I
cycle	O
and	O
the	O
p	B
##yr	I
##u	I
##vate	I
is	O
used	O
to	O
make	O
glucose	S
.	O

B	O
##io	O
##chemical	O
analyses	O
indicated	O
that	O
patients	O
who	O
underwent	O
CE	O
had	O
significantly	O
higher	O
levels	O
of	O
fast	O
##ing	O
glucose	S
and	O
H	O
##b	O
##A	O
##1	O
##c	O
(	O
p	O
=	O
0	O
.	O
01	O
##8	O
and	O
p	O
=	O
0	O
.	O
00	O
##3	O
;	O
respectively	O
)	O
and	O
lower	O
levels	O
of	O
HD	O
##L	O
-	O
C	O
(	O
p	O
=	O
0	O
.	O
00	O
##3	O
)	O
than	O
healthy	O
subjects	O
.	O

LL	O
##E	O
and	O
SP	O
##E	O
give	O
statistical	O
##ly	O
the	O
same	O
results	O
for	O
vitamin	B
D	I
meta	O
##bol	O
##ites	O
except	O
for	O
24	O
##R	O
,	O
25	O
(	O
OH	O
)	O
_	O
2	O
D	O
_	O
3	O
.	O

Part	O
##icular	O
##ly	O
,	O
serum	O
levels	O
of	O
selected	O
long	O
-	O
chain	O
l	O
##ys	O
##o	O
##PC	O
##s	O
(	O
l	O
##ys	O
##o	O
##PC	O
a	O
C	B
##18	I
:	I
2	I
,	O
l	O
##ys	O
##o	O
##PC	O
a	O
C	B
##20	I
:	I
3	I
,	O
l	O
##ys	O
##o	O
##PC	O
a	O
C	B
##20	I
:	I
4	I
)	O
decreased	O
from	O
CH	O
##B	O
to	O
c	O
##ir	O
##r	O
##hos	O
##is	O
to	O
car	O
##cin	O
##oma	O
,	O
and	O
concentrations	O
of	O
l	O
##ys	O
##o	O
##PC	O
a	O
C	B
##20	I
:	I
4	I
and	O
l	O
##ys	O
##o	O
##PC	O
a	O
C	B
##20	I
:	I
3	I
also	O
reflected	O
different	O
levels	O
of	O
disease	O
severity	O
within	O
the	O
group	O
of	O
patients	O
.	O

ul	O
##cer	O
##ative	O
co	O
##lit	O
##is	O
,	O
try	B
##pt	I
##op	I
##han	I
,	O
m	O
##uc	O
##osa	O
##l	O
healing	O

We	O
found	O
a	O
model	O
including	O
CE	O
##A	O
,	O
g	B
##ly	I
##cine	I
,	O
and	O
t	B
##yr	I
##os	I
##ine	I
as	O
best	O
disc	O
##rim	O
##inating	O
and	O
superior	O
to	O
CE	O
##A	O
alone	O
with	O
an	O
AU	O
##RO	O
##C	O
of	O
0	O
.	O
87	O
##8	O
(	O
95	O
%	O
C	O
##I	O
0	O
.	O
81	O
##5	O
–	O
0	O
.	O
94	O
##1	O
)	O
.	O

The	O
second	O
component	O
partially	O
accounts	O
for	O
the	O
sub	O
##c	O
##luster	O
##ing	O
with	O
the	O
two	O
major	O
clusters	O
with	O
larger	O
contributions	O
from	O
g	B
##lut	I
##amine	I
,	O
le	B
##uc	I
##ine	I
,	O
met	B
##hi	I
##oni	I
##ne	I
,	O
g	B
##ly	I
##cine	I
,	O
al	B
##ani	I
##ne	I
,	O
which	O
are	O
g	O
##lu	O
##co	O
##genic	O
amino	O
acids	O
,	O
and	O
c	B
##it	I
##rate	I
.	O

The	O
α	B
-	I
k	I
##eto	I
##is	I
##oc	I
##ap	I
##roa	I
##te	I
is	O
captured	O
again	O
by	O
neurons	O
through	O
a	O
reverse	O
trans	O
##ami	O
##nas	O
##e	O
reaction	O
,	O
re	O
##gene	O
##rating	O
Le	O
##u	O
in	O
a	O
process	O
using	O
g	B
##lut	I
##ama	I
##te	I
.	O

Accordingly	O
,	O
p	O
##hos	O
##ph	O
##oli	O
##pas	O
##es	O
,	O
pu	B
##rine	I
n	O
##uc	O
##leo	O
##tide	O
degradation	O
and	O
L	O
##X	O
##R	O
/	O
R	O
##X	O
##R	O
activation	O
were	O
their	O
common	O
biological	O
pathways	O
.	O

The	O
novel	O
application	O
of	O
a	O
statistical	O
total	O
correlation	O
s	O
##pect	O
##ros	O
##copy	O
(	O
ST	O
##OC	O
##S	O
##Y	O
)	O
approach	O
enabled	O
rapid	O
identification	O
of	O
the	O
major	O
and	O
certain	O
minor	O
drug	O
meta	O
##bol	O
##ites	O
in	O
common	O
use	O
in	O
the	O
population	O
,	O
in	O
particular	O
,	O
from	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
and	O
i	B
##bu	I
##p	I
##ro	I
##fen	I
meta	O
##bol	O
##ites	O
.	O

Note	O
that	O
u	B
##ric	I
acid	I
has	O
also	O
been	O
positively	O
associated	O
with	O
go	O
##ut	O
in	O
our	O
study	O
.	O

Focus	O
##ing	O
on	O
women	O
results	O
,	O
more	O
data	O
used	O
to	O
be	O
available	O
on	O
u	O
##rina	O
##ry	O
para	B
##ben	I
levels	O
and	O
more	O
specifically	O
for	O
pregnant	O
women	O
.	O

With	O
our	O
method	O
,	O
peak	O
areas	O
obtained	O
in	O
spike	O
##d	O
and	O
clinical	O
samples	O
for	O
IS	O
##T	O
##D	O
115	O
##26	O
##10	O
##2	O
and	O
Met	O
amino	B
-	I
d	I
##11	I
perfectly	O
matched	O
,	O
with	O
an	O
overall	O
RS	O
##D	O
below	O
2	O
%	O
,	O
confirming	O
the	O
reliability	O
of	O
the	O
method	O
for	O
measuring	O
not	O
only	O
P	O
##B	O
##T	O
##Z	O
##16	O
##9	O
but	O
also	O
six	O
known	O
meta	O
##bol	O
##ites	O
in	O
real	O
human	O
plasma	O
samples	O
collected	O
from	O
healthy	O
volunteers	O
.	O

The	O
development	O
of	O
co	O
##gnition	O
-	O
enhance	O
##ment	O
medication	O
is	O
an	O
ongoing	O
effort	O
to	O
address	O
brain	O
diseases	O
,	O
and	O
these	O
include	O
pharmaceutical	O
##s	O
that	O
reduce	O
the	O
formation	O
of	O
k	B
##yn	I
##uren	I
##ic	I
acid	I
in	O
the	O
brain	O
.	O

In	O
##tra	O
##day	O
and	O
inter	O
##day	O
precision	O
(	O
coefficient	O
of	O
variation	O
,	O
in	O
%	O
)	O
for	O
co	B
##tin	I
##ine	I
in	O
smoke	O
##rs	O
’	O
urine	O
were	O
1	O
.	O
2	O
%	O
and	O
1	O
.	O
1	O
%	O
,	O
respectively	O
,	O
while	O
the	O
corresponding	O
figures	O
in	O
smoke	O
##less	O
tobacco	O
users	O
’	O
urine	O
were	O
0	O
.	O
7	O
%	O
and	O
0	O
.	O
6	O
%	O
.	O

The	O
data	O
dependent	O
collision	O
-	O
induced	O
di	O
##sso	O
##ciation	O
spectrum	O
of	O
the	O
ion	O
of	O
m	O
/	O
z	O
32	O
##9	O
.	O
1	O
(	O
ii	O
)	O
showed	O
the	O
most	O
abundant	O
peak	O
with	O
m	O
/	O
z	O
153	O
,	O
corresponding	O
to	O
the	O
de	O
##p	O
##rot	O
##ona	O
##ted	O
pro	B
##to	I
##cate	I
##chu	I
##ic	I
acid	I
formed	O
via	O
the	O
lab	O
##ile	O
c	O
##lea	O
##vage	O
of	O
g	B
##ly	I
##cos	I
##id	I
##ic	I
bond	O
,	O
and	O
two	O
minor	O
peaks	O
with	O
m	O
/	O
z	O
175	O
.	O
0	O
and	O
113	O
.	O
2	O
.	O

However	O
,	O
as	O
in	O
the	O
study	O
from	O
Lin	B
##ix	I
##an	I
,	O
in	O
Xi	O
##ame	O
##n	O
the	O
highest	O
risk	O
of	O
HC	O
##C	O
was	O
seen	O
among	O
persons	O
with	O
high	O
levels	O
of	O
p	O
,	O
p	O
’	O
-	O
DD	O
##T	O
and	O
low	O
levels	O
of	O
p	O
,	O
p	O
’	O
-	O
DD	O
##E	O
.	O

A	O
##45	O
##2	O
##S	O
##K	O
##1	O
)	O
was	O
added	O
to	O
make	O
a	O
final	O
80	O
%	O
(	O
vol	O
/	O
vol	O
)	O
met	B
##han	I
##ol	I
solution	O
.	O

The	O
concentration	O
of	O
individual	O
families	O
of	O
lip	O
##id	O
species	O
before	O
(	O
pre	O
)	O
and	O
after	O
(	O
post	O
)	O
both	O
in	O
##fusion	O
##s	O
for	O
each	O
group	O
,	O
including	O
D	O
##AG	O
,	O
c	B
##era	I
##mi	I
##de	I
(	O
Ce	O
##r	O
)	O
,	O
free	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
CE	O
,	O
PC	O
,	O
LP	O
##C	O
,	O
and	O
NE	O
##FA	O
,	O
are	O
shown	O
in	O
.	O

The	O
extraction	O
method	O
for	O
25	B
(	I
OH	I
)	I
D	I
_	I
3	I
/	I
2	I
,	I
3	I
-	I
e	I
##pi	I
-	I
25	I
(	I
OH	I
)	I
D	I
_	I
3	I
,	I
1	I
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
/	O
2	O
and	O
24	B
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
was	O
adapted	O
from	O
our	O
previously	O
reported	O
technique	O
for	O
25	O
(	O
OH	O
)	O
D	O
_	O
3	O
.	O

The	O
elevated	O
bio	O
##mark	O
##ers	O
included	O
α	O
‐	O
f	O
##eto	O
##p	O
##rote	O
##in	O
,	O
car	O
##cin	O
##oe	O
##mb	O
##ryo	O
##nic	O
anti	O
##gen	O
,	O
car	O
##bo	O
##hy	O
##dra	O
##te	O
anti	O
##gen	O
19	O
–	O
9	O
,	O
car	O
##bo	O
##hy	O
##dra	O
##te	O
anti	O
##gen	O
72	O
–	O
4	O
,	O
car	O
##bo	O
##hy	O
##dra	O
##te	O
anti	O
##gen	O
12	O
–	O
5	O
,	O
car	O
##bo	O
##hy	O
##dra	O
##te	O
anti	O
##gen	O
15	O
–	O
3	O
,	O
car	O
##bo	O
##hy	O
##dra	O
##te	O
anti	O
##gen	O
242	O
,	O
car	O
##bo	O
##hy	O
##dra	O
##te	O
anti	O
##gen	O
50	O
,	O
c	B
##yt	I
##oker	I
##ati	I
##n	I
19	O
fragments	O
,	O
pro	O
##cal	O
##ci	O
##ton	O
##in	O
,	O
and	O
inter	O
##le	O
##uki	O
##n	O
‐	O
6	O
.	O

During	O
positive	O
ion	O
##ization	O
mode	O
,	O
the	O
dried	O
meta	O
##bol	O
##ite	O
extract	O
was	O
dissolved	O
with	O
50	O
μ	O
##l	O
solvent	O
(	B
6	B
.	I
5	I
:	I
2	I
.	I
5	I
:	I
1	I
ace	I
##ton	I
##it	I
##ril	I
##e	I
:	O
met	B
##han	I
##ol	I
:	O
water	O
)	O
and	O
injected	O
on	O
X	O
##B	O
##ridge	O
H	O
##IL	O
##IC	O
column	O
(	O
Waters	O
,	O
Milford	O
,	O
MA	O
)	O
.	O

Peak	O
assignments	O
:	O
0	O
,	O
unidentified	O
;	O
1	O
,	O
ch	B
##ole	I
##ster	I
##ol	I
;	O
2	O
,	O
lip	O
##ids	O
(	O
–	O
CH	O
_	O
3	O
)	O
(	O
mainly	O
L	O
##D	O
##L	O
/	O
V	O
##LD	O
##L	O
)	O
;	O
3	O
,	O
is	B
##ole	I
##uc	I
##ine	I
;	O
4	O
,	O
le	B
##uc	I
##ine	I
;	O
5	O
,	O
v	B
##ali	I
##ne	I
;	O
6	O
,	O
is	B
##ob	I
##ut	I
##yra	I
##te	I
;	O
7	O
,	O
lip	O
##ids	O
(	O
CH	O
_	O
2	O
)	O
n	O
(	O
mainly	O
L	O
##D	O
##L	O
/	O
V	O
##LD	O
##L	O
)	O
;	O
8	O
,	O
f	B
##uc	I
##ose	I
;	O
9	O
,	O
la	B
##ct	I
##ate	I
;	O
10	O
,	O
al	B
##ani	I
##ne	I
;	O
11	O
,	O
ad	O
##ip	O
##ica	O
##cid	O
;	O
12	O
,	O
a	B
##rg	I
##ini	I
##ne	I
;	O
13	O
,	O
l	B
##ys	I
##ine	I
;	O
14	O
,	O
ace	B
##tate	I
;	O
15	O
,	O
lip	O
##ids	O
(	O
CH	O
_	O
2	O
–	O
C	O
=	O
C	O
)	O
;	O
16	O
,	O
ace	O
##ty	O
##l	O
signals	O
from	O
g	B
##ly	I
##co	I
##p	I
##rote	I
##ins	I
;	O
17	O
,	O
pro	B
##line	I
;	O
18	O
,	O
g	B
##lut	I
##amine	I
;	O
19	O
,	O
lip	O
##ids	O
(	O
CH	O
_	O
2	O
–	O
CO	O
)	O
;	O
20	O
,	O
c	B
##it	I
##rate	I
;	O
21	O
,	O
lip	O
##ids	O
(	O
CH	O
=	O
CH	O
–	O
CH	O
_	O
2	O
–	O
CH	O
=	O
CH	O
–	O
)	O
;	O
22	O
,	O
Album	O
##in	O
l	O
##ys	O
##yl	O
;	O
23	O
,	O
c	B
##rea	I
##tine	I
;	O
24	O
,	O
ch	B
##olin	I
##e	I
;	O
25	O
,	O
ta	B
##uri	I
##ne	I
;	O
26	B
,	I
trim	I
##eth	I
##yl	I
N	I
-	I
oxide	I
;	O
27	O
,	O
glucose	S
and	O
α	O
-	O
pro	O
##tons	O
of	O
amino	O
acids	O
;	O
28	O
,	O
My	B
##o	I
-	I

L	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
stimulate	O
##s	O
p	O
##ha	O
##go	O
##cy	O
##te	O
recruitment	O
and	O
p	O
##ha	O
##go	O
##cy	O
##tosis	O
of	O
the	O
my	B
##elin	I
sheath	O
causing	O
dem	O
##ye	O
##lina	O
##tion	O
and	O
mimic	O
##king	O
the	O
effects	O
of	O
multiple	O
s	O
##cle	O
##rosis	O
[	O
,	O
]	O
.	O

For	O
example	O
,	O
se	B
##rine	I
(	O
2	O
.	O
07	O
nm	O
##ol	O
/	O
10	O
_	O
6	O
cells	O
)	O
,	O
th	B
##re	I
##oni	I
##ne	I
(	O
1	O
.	O
34	O
nm	O
##ol	O
/	O
10	O
_	O
6	O
cells	O
)	O
and	O
as	B
##par	I
##agi	I
##ne	I
(	O
3	O
.	O
93	O
nm	O
##ol	O
/	O
10	O
_	O
6	O
cells	O
)	O
were	O
found	O
to	O
be	O
higher	O
concentrated	O
in	O
S	O
##9	O
cells	O
when	O
compared	O
to	O
16	O
##H	O
##BE	O
##14	O
##o	O
_	O
−	O
cells	O
(	O
0	O
.	O
63	O
;	O
0	O
.	O
66	O
;	O
1	O
.	O
91	O
nm	O
##ol	O
/	O
10	O
_	O
6	O
cells	O
)	O
.	O

Ph	O
##os	O
##ph	O
##oli	O
##pas	O
##e	O
D	O
that	O
cat	O
##aly	O
##zes	O
the	O
h	O
##ydro	O
##lysis	O
of	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
ch	I
##olin	I
##e	I
(	O
LP	O
##C	O
)	O
to	O
generate	O
the	O
bio	O
##active	O
lip	O
##id	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dic	I
acid	I
(	O
LP	O
##A	O
)	O
.	O

One	O
previous	O
meta	O
##bol	O
##omi	O
##cs	O
study	O
suggested	O
γ	B
-	I
g	I
##lut	I
##am	I
##yl	I
-	I
dip	I
##eptide	I
##s	I
as	O
sensitive	O
markers	O
for	O
liver	O
function	O
,	O
ranging	O
from	O
simple	O
s	O
##te	O
##ato	O
##sis	O
to	O
he	O
##pa	O
##to	O
##cellular	O
car	O
##cin	O
##oma	O
.	O

From	O
the	O
pathway	O
analysis	O
,	O
it	O
was	O
concluding	O
that	O
g	O
##ly	O
##co	O
##lysis	O
results	O
in	O
the	O
breakdown	O
of	O
glucose	S
,	O
but	O
several	O
reactions	O
may	O
be	O
responsible	O
for	O
the	O
increased	O
levels	O
of	O
glucose	S
in	O
lung	O
cancer	O
like	O
g	O
##lu	O
##con	O
##eo	O
##genesis	O
,	O
car	O
##bo	O
##hy	O
##dra	O
##te	O
metabolism	O
and	O
lip	O
##ogen	O
##esis	O
to	O
provide	O
the	O
energy	O
in	O
the	O
form	O
of	O
glucose	S
.	O

As	O
a	O
meta	O
##bol	O
##ite	O
in	O
ho	B
##mo	I
##cy	I
##stein	I
##e	I
metabolism	O
,	O
the	O
c	B
##ys	I
##tein	I
##e	I
and	O
ho	B
##mo	I
##cy	I
##stein	I
##e	I
play	O
vital	O
roles	O
in	O
living	O
organism	O
.	O

Although	O
it	O
was	O
not	O
statistical	O
##ly	O
significant	O
,	O
le	B
##uc	I
##ine	I
too	O
showed	O
increased	O
level	O
in	O
HC	O
##C	O
versus	O
c	O
##ir	O
##r	O
##hos	O
##is	O
,	O
consistent	O
with	O
our	O
previous	O
findings	O
.	O

Among	O
the	O
remaining	O
four	O
,	O
two	O
meta	O
##bol	O
##ites	O
,	O
in	B
##dox	I
##yl	I
su	I
##lf	I
##ate	I
and	O
hip	B
##pura	I
##te	I
were	O
u	O
##rem	O
##ic	O
so	O
##lut	O
##es	O
reported	O
in	O
the	O
literature	O
,	O
but	O
not	O
significantly	O
associated	O
with	O
progression	O
in	O
the	O
global	O
pro	O
##fi	O
##ling	O
study	O
.	O

Combined	O
with	O
absolute	O
q	O
##uant	O
##itation	O
and	O
tracing	O
approaches	O
,	O
this	O
method	O
can	O
be	O
applied	O
to	O
both	O
q	O
##uant	O
##ify	O
the	O
f	B
##olate	I
intermediate	O
pool	O
and	O
estimate	O
f	B
##olate	I
intermediate	O
flux	O
,	O
which	O
will	O
contribute	O
to	O
our	O
understanding	O
of	O
the	O
precise	O
role	O
of	O
one	O
carbon	O
metabolism	O
in	O
cancer	O
.	O

Ace	B
##ton	I
##it	I
##ril	I
##e	I
(	O
L	O
##C	O
-	O
MS	O
grade	O
)	O
was	O
purchased	O
from	O
Me	O
##rc	O
##k	O
(	O
Dar	O
##ms	O
##tadt	O
,	O
Germany	O
)	O
,	O
and	O
met	B
##han	I
##ol	I
and	O
form	B
##ic	I
acid	I
(	O
both	O
L	O
##C	O
-	O
MS	O
grade	O
)	O
were	O
purchased	O
from	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
(	O
St	O
.	O
Louis	O
,	O
M	O
##O	O
,	O
USA	O
)	O
.	O

20	B
-	I
OH	I
-	I
le	I
##uk	I
##ot	I
##rien	I
##e	I
B	I
##4	I
(	O
molecular	O
weight	O
:	O
35	O
##2	O
.	O
225	O
Da	O
)	O
was	O
a	O
top	O
predicted	O
meta	O
##bol	O
##ite	O
and	O
,	O
on	O
average	O
,	O
decreased	O
in	O
intensity	O
in	O
the	O
population	O
over	O
time	O
.	O

In	O
the	O
third	O
trim	O
##ester	O
of	O
the	O
G	O
##DM	O
group	O
,	O
only	O
levels	O
of	O
4	B
-	I
p	I
##yr	I
##ido	I
##xa	I
##te	I
(	O
vitamin	O
B	O
-	O
6	O
)	O
were	O
lowered	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

In	O
the	O
present	O
case	O
-	O
co	O
##hor	O
##t	O
design	O
study	O
within	O
the	O
PR	O
##ED	O
##IM	O
##ED	O
trial	O
,	O
after	O
adjusting	O
for	O
recognized	O
T	O
##2	O
##D	O
risk	O
-	O
factors	O
and	O
multiple	O
testing	O
,	O
we	O
found	O
inverse	O
and	O
positive	O
associations	O
between	O
high	O
base	O
##line	O
levels	O
of	O
all	B
##ant	I
##oi	I
##n	I
,	O
including	O
all	O
##ant	O
##oi	O
##n	O
-	O
to	O
-	O
u	O
##ric	O
acid	O
ratio	O
and	O
high	O
x	O
##ant	O
##hine	O
-	O
to	O
-	O
h	O
##y	O
##pox	O
##ant	O
##hine	O
ratio	O
with	O
T	O
##2	O
##D	O
risk	O
,	O
respectively	O
.	O

Additionally	O
,	O
HD	O
patients	O
had	O
lower	O
concentrations	O
in	O
al	B
##ani	I
##ne	I
(	O
P	O
<	O
0	O
.	O
00	O
##1	O
)	O
,	O
a	B
##rg	I
##ini	I
##ne	I
(	O
P	O
<	O
0	O
.	O
00	O
##1	O
)	O
,	O
se	B
##rine	I
(	O
P	O
=	O
0	O
.	O
00	O
##3	O
)	O
,	O
and	O
g	B
##lut	I
##amine	I
(	O
P	O
=	O
0	O
.	O
04	O
)	O
.	O

The	O
fragment	O
##or	O
voltage	O
was	O
set	O
at	O
120	O
V	O
and	O
ski	O
##mmer	O
voltage	O
was	O
set	O
at	O
60	O
V	O
.	O
All	O
analyses	O
were	O
acquired	O
using	O
a	O
mixture	O
of	O
10	O
m	O
##M	O
pu	B
##rine	I
(	O
m	O
/	O
z	O
121	O
.	O
05	O
##0	O
##8	O
)	O
and	O
2	O
m	O
##M	O
he	O
##xa	O
##kis	O
p	B
##hos	I
##pha	I
##zine	I
(	O
m	O
/	O
z	O
92	O
##2	O
.	O
00	O
##9	O
##7	O
)	O
as	O
internal	O
standards	O
to	O
ensure	O
mass	O
accuracy	O
and	O
re	O
##p	O
##rod	O
##uc	O
##ibility	O
.	O

As	O
presented	O
in	O
,	O
clear	O
separation	O
was	O
observed	O
among	O
four	O
groups	O
(	O
E	O
##SC	O
##C	O
,	O
E	O
##SC	O
##C	O
-	O
M	O
,	O
E	O
##SC	O
##C	O
-	O
P	O
,	O
and	O
NC	O
groups	O
)	O
for	O
R	B
##RL	I
##C	I
-	I
(	I
+	I
)	I
E	I
##SI	I
-	I
MS	I
analysis	O
,	O
suggesting	O
that	O
metabolic	O
per	O
##tur	O
##bation	O
##s	O
were	O
evident	O
in	O
the	O
patients	O
,	O
dependent	O
on	O
path	O
##ological	O
condition	O
and	O
treatment	O
intervention	O
.	O

This	O
could	O
be	O
due	O
to	O
the	O
increase	O
of	O
plasma	O
co	B
##rt	I
##is	I
##ol	I
levels	O
and	O
impaired	O
se	B
##rot	I
##oni	I
##n	I
up	O
##take	O
.	O

An	O
AC	O
##Q	O
##UI	O
##TY	O
UP	O
##LC	O
®	O
system	O
(	O
Waters	O
Corporation	O
,	O
Milford	O
,	O
MA	O
)	O
including	O
binary	O
solvent	O
manager	O
,	O
sample	O
##r	O
manager	O
,	O
and	O
photo	O
di	O
##ode	O
array	O
(	O
PD	O
##A	O
)	O
detector	O
,	O
and	O
a	O
Waters	O
AC	O
##Q	O
##UI	O
##TY	O
UP	O
##LC	O
[UNK]	O
B	O
##E	O
##H	O
(	B
E	B
##thy	I
##lene	I
Bridge	O
##d	O
Hybrid	O
)	O
C	O
_	O
18	O
column	O
(	O
2	O
.	O
1	O
mm	O
×	O
50	O
mm	O
,	O
1	O
.	O
7	O
μ	O
##m	O
particle	O
size	O
)	O
were	O
used	O
for	O
online	O
L	O
##C	O
-	O
UV	O
.	O

The	O
molecule	O
observed	O
at	O
m	O
/	O
z	O
241	O
.	O
01	O
##18	O
was	O
assigned	O
as	O
in	B
##os	I
##ito	I
##l	I
c	I
##yclic	I
phosphate	I
using	O
the	O
Human	O
Met	O
##ab	O
##olo	O
##me	O
Database	O
with	O
an	O
error	O
of	O
0	O
.	O
32	O
pp	O
##m	O
and	O
matching	O
the	O
is	O
##oto	O
##pe	O
pattern	O
(	O
Su	O
##pp	O
##lement	O
##ary	O
Figure	O
3	O
)	O
.	O

As	O
expected	O
,	O
fast	O
##ing	O
glucose	S
and	O
insulin	O
concentrations	O
,	O
H	O
##OM	O
##A	O
##2	O
-	O
S	O
,	O
H	O
##OM	O
##A	O
##2	O
-	O
BS	O
and	O
us	O
##CR	O
##P	O
concentrations	O
were	O
significantly	O
improved	O
twelve	O
months	O
after	O
bar	O
##ia	O
##tric	O
surgery	O
in	O
both	O
groups	O
.	O

Once	O
charge	O
-	O
tag	O
##ged	O
by	O
the	O
GP	S
re	O
##age	O
##nt	O
,	O
o	B
##xy	I
##ster	I
##ols	I
can	O
be	O
analyzed	O
by	O
L	O
##C	O
-	O
electro	O
##sp	O
##ray	O
ion	O
##ization	O
-	O
MS	O
_	O
n	O
with	O
high	O
sensitivity	O
(	O
<	O
p	B
##g	I
injected	O
)	O
,	O
and	O
the	O
o	B
##xy	I
##ster	I
##ol	I
content	O
of	O
CS	O
##F	O
was	O
initially	O
probe	O
##d	O
by	O
generation	O
of	O
exact	O
mass	O
(	O
5	O
pp	O
##m	O
)	O
R	O
##IC	O
##s	O
for	O
all	O
potential	O
o	B
##xy	I
##ster	I
##ols	I
with	O
one	O
to	O
five	O
additional	O
oxygen	O
functions	O
on	O
the	O
ch	B
##ole	I
##ster	I
##ol	I
skeleton	O
(	O
see	O
supplement	O
##al	O
Table	O
S	O
##2	O
)	O
.	O

A	O
##cid	O
##ification	O
is	O
essential	O
for	O
the	O
h	B
##ydro	I
##ly	I
##tic	I
function	O
of	O
l	O
##ys	O
##oso	O
##mes	O
and	O
regulation	O
of	O
l	O
##ys	O
##oso	O
##mal	O
pH	O
is	O
one	O
mechanism	O
for	O
controlling	O
l	O
##ys	O
##oso	O
##mal	O
activity	O
(	O
-	O
)	O
.	O

Σ	O
##FA	O
Σ	O
##FA	O
Σ	O
Σ	O
Σ	O
FA	B
FA	I
FA	I
(	I
e	I
##pox	I
##ides	I
)	I
(	O
e	B
##pox	I
##ides	I
e	I
##pox	I
##ides	I
)	O
/	O
parent	O
fatty	O
acid	O
s	B
##E	I
##HF	I
##A	I
##ind	I
##ex	I
=	I
Σ	I
##FA	I
(	I
di	I
##ols	I
)	I
/	I
Σ	I
##FA	I
(	I
e	I
##pox	I
##ides	I
)	I
s	I
##E	I
##HF	I
##A	I
##ind	I
##ex	I
=	I
Σ	I
##FA	I
(	I
di	I
##ols	I
)	I
/	I
Σ	I
##FA	I
(	I
e	I
##pox	I
##ides	I
)	I
s	I
##E	I
##HF	I
##A	I
##ind	I
##ex	I
=	I
Σ	I
##FA	I
(	I
di	I
##ols	I
)	I
/	I
Σ	I
##FA	I
(	I
e	I
##pox	I
##ides	I
)	I
s	I
##E	I
##HF	I
##A	I
##ind	I
##ex	I
=	I
Σ	I
##FA	I
(	I
di	I
##ols	I
)	I
/	I
Σ	I
##FA	I
(	I
e	I
##pox	I
##ides	I
)	I
s	I
##E	I
##HF	I
##A	I
##ind	I
##ex	I
=	I
Σ	I
##FA	I
(	I
di	I
##ols	I
)	I
/	I
Σ	I
##FA	I
(	I
e	I
##pox	I
##ides	I
)	I
s	O
##E	O
##HF	O
##A	O
s	O
##E	O
##HF	O
##A	O
s	O
##E	O
##H	O
s	O
##E	O
##H	O
s	O
##E	O
##H	O
s	O
##E	O
##H	O
s	O
E	O
H	O
FA	B
FA	I
FA	I
FA	I
F	O
A	O
index	O
index	O

It	O
serves	O
as	O
a	O
precursor	O
of	O
signalling	O
molecules	O
and	O
plays	O
a	O
role	O
in	O
export	O
##ing	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
to	O
the	O
organs	O
.	O

However	O
,	O
the	O
strong	O
correlation	O
of	O
X	O
-	O
1892	O
##7	O
with	O
P	O
##HP	O
and	O
g	B
##ly	I
##cy	I
##l	I
##p	I
##rol	I
##ine	I
suggests	O
a	O
functional	O
link	O
between	O
these	O
three	O
meta	O
##bol	O
##ites	O
.	O

Association	O
##s	O
of	O
circulating	O
vitamin	B
D	I
meta	O
##bol	O
##ites	O
measured	O
at	O
the	O
end	O
of	O
the	O
DC	O
##CT	O
with	O
CA	O
##C	O
measured	O
during	O
the	O
E	O
##DI	O
##C	O
study	O
among	O
1	O
,	O
08	O
##1	O
DC	O
##CT	O
/	O
E	O
##DI	O
##C	O
participants	O
Distribution	O
##s	O
of	O
CA	O
##C	O
by	O
categories	O
of	O
circulating	O
vitamin	B
D	I
meta	O
##bol	O
##ites	O
among	O
1	O
,	O
08	O
##1	O
DC	O
##CT	O
/	O
E	O
##DI	O
##C	O
participants	O
.	O

_	O
1	O
H	O
N	O
##MR	O
(	O
[	O
_	O
2	O
H	O
_	O
6	O
]	O
D	O
##MS	O
##O	O
)	O
showed	O
absence	O
of	O
met	B
##hyl	I
##ene	I
pro	O
##tons	O
,	O
is	O
##oto	O
##pic	O
purity	O
>	O
99	O
%	O
)	O
.	O

P	O
##las	O
##ma	O
free	O
-	O
ch	O
##olin	O
##e	O
and	O
beta	B
##ine	I
levels	O
had	O
significantly	O
positive	O
correlation	O
(	O
r	O
=	O
0	O
.	O
49	O
##5	O
,	O
P	O

This	O
result	O
is	O
consistent	O
with	O
a	O
previous	O
report	O
of	O
a	O
correlation	O
between	O
increased	O
L	O
##p	O
-	O
P	O
##LA	O
_	O
2	O
activity	O
and	O
increased	O
levels	O
of	O
l	O
##ys	O
##o	O
##PC	O
,	O
o	O
##x	O
-	O
L	O
##D	O
##L	O
,	O
and	O
c	O
##yt	O
##oki	O
##ne	O
in	O
h	B
##yper	I
##cho	I
##les	I
##tero	I
##lem	I
##ic	I
mini	O
##pi	O
##gs	O
.	O

Inc	O
##reased	O
try	B
##pt	I
##op	I
##han	I
and	O
ta	B
##uri	I
##ne	I
could	O
explain	O
the	O
increased	O
me	B
##lat	I
##oni	I
##n	I
levels	O
,	O
as	O
ta	B
##uri	I
##ne	I
has	O
been	O
shown	O
to	O
increase	O
pine	O
##al	O
me	B
##lat	I
##oni	I
##n	I
by	O
s	O
##ti	O
##mulating	O
the	O
activity	O
of	O
its	O
rate	O
limiting	O
bio	O
##sy	O
##nt	O
##hetic	O
enzyme	O
,	O
N	O
-	O
ace	O
##ty	O
##lt	O
##ran	O
##s	O
##fer	O
##ase	O
.	O

To	O
this	O
,	O
750	O
µ	O
##l	O
met	B
##hyl	I
te	I
##rt	I
-	I
but	I
##yl	I
et	I
##her	I
(	O
M	O
##T	O
##BE	O
)	O
was	O
added	O
,	O
along	O
with	O
150	O
µ	O
##l	O
of	O
internal	O
standard	O
mix	O
,	O
containing	O
the	O
following	O
six	O
internal	O
standards	O
:	O
1	B
,	I
2	I
-	I
di	I
-	I
o	I
-	I
o	I
##ct	I
##ade	I
##cy	I
##l	I
-	I
s	I
##n	I
-	I
g	I
##ly	I
##cer	I
##o	I
-	I
3	I
-	I
p	I
##hos	I
##ph	I
##och	I
##olin	I
##e	I
(	O
0	O
.	O
6	O
µ	O
##M	O
)	O
,	O
1	B
,	I
2	I
-	I
di	I
-	I
O	I
-	I
p	I
##hy	I
##tany	I
##l	I
-	I
s	I
##n	I
-	I
g	I
##ly	I
##cer	I
##o	I
-	I
3	I
-	I
p	I
##hos	I
##ph	I
##oe	I
##than	I
##ola	I
##mine	I
(	O
1	O
.	O
2	O
µ	O
##M	O
)	O
,	O
C	B
##8	I
-	I
c	I
##era	I
##mi	I
##de	I
(	O
0	O
.	O
6	O
µ	O
##M	O
)	O
,	O
N	B
-	I
he	I
##pta	I
##de	I
##cano	I
##yl	I
-	I
D	I
-	I
er	I
##yt	I
##hr	I
##o	I
-	I
s	I
##phi	I
##ngo	I
##sy	I
##l	I
##ph	I
##os	I
##por	I
##yl	I
##cho	I
##line	I
(	O
0	O
.	O
6	O
µ	O
##M	O
)	O
,	O
und	B
##eca	I
##no	I
##ic	I
acid	I
(	O
0	O
.	O
6	O
µ	O
##M	O
)	O
,	O
and	O
t	B
##ril	I
##au	I
##rin	I
(	O
0	O
.	O
6	O
µ	O
##M	O
)	O
.	O

H	O
_	O
5	O
]	O
-	O
Ph	O
##IP	O
)	O
su	B
##lf	I
##ona	I
##mi	I
##de	I
add	O
##uc	O
##t	O
(	O
[	O
M	O
+	O
H	O
]	O
_	O
+	O
at	O
m	O
/	O
z	O
625	O
.	O
2	O
)	O
recovered	O
from	O
H	O
##ON	O
##H	O
-	O
[	O
_	O
2	O
H	O
_	O
5	O
]	O
-	O
Ph	O
##IP	O
modified	O
SA	O
dig	O
##ested	O
with	O
Pro	O
##nas	O
##e	O
E	O
,	O
le	O
##uc	O
##ine	O
amino	O
##pe	O
##pt	O
##idas	O
##e	O
,	O
and	O
pro	O
##lid	O
##ase	O
.	O

Moreover	O
,	O
p	O
-	O
c	O
##res	O
##ol	O
and	O
its	O
g	B
##lu	I
##cu	I
##ron	I
##ide	I
were	O
of	O
value	O
for	O
disc	O
##ern	O
##ing	O
the	O
different	O
stages	O
of	O
the	O
disease	O
.	O

It	O
is	O
known	O
that	O
α	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
is	O
derived	O
from	O
the	O
conversion	O
of	O
α	B
-	I
k	I
##eto	I
##but	I
##yra	I
##te	I
cat	O
##aly	O
##zed	O
by	O
la	O
##ct	O
##ate	O
de	O
##hy	O
##dr	O
##ogen	O
##ase	O
.	O

Car	B
##nos	I
##ine	I
;	O
126	O
.	O

Prior	O
to	O
G	O
##C	O
-	O
MS	O
analysis	O
,	O
the	O
following	O
steps	O
were	O
completed	O
:	O
1	O
)	O
mixed	O
and	O
v	O
##ortex	O
##ed	O
15	O
##μ	O
##l	O
urine	O
and	O
10	O
##°	O
##C	O
L	O
-	O
le	O
##uc	O
##ine	O
-	O
13	O
##C	O
##6	O
(	O
0	O
.	O
02	O
mg	O
/	O
m	O
##l	O
,	O
internal	O
standard	O
solution	O
)	O
;	O
2	O
)	O
added	O
15	O
##μ	O
##l	O
u	O
##rease	O
into	O
the	O
mixed	O
solution	O
to	O
de	O
##grade	O
the	O
u	B
##rea	I
at	I
37	O
°C	O
for	O
60	O
minutes	O
;	O
3	O
)	O
extracted	O
the	O
mixture	O
successively	O
using	O
240	O
##I	O
##1	O
/	O
4	O
##l	O
and	O
80	O
##I	O
##1	O
/	O
4	O
##l	O
of	O
ice	O
-	O
cold	O
met	B
##han	I
##ol	I
;	O
4	O
)	O
v	O
##ortex	O
##ed	O
the	O
obtained	O
mixture	O
for	O
30	O
seconds	O
and	O
then	O
conducted	O
cent	O
##ri	O
##fu	O
##gation	O
(	O
at	O
4	O
°C	O
,	O
1400	O
##0	O
rpm	O
x	O
##5	O
minutes	O
)	O
;	O
5	O
)	O
at	O
room	O
temperature	O
,	O
transferred	O
224	O
##ul	O
super	O
##nat	O
##ant	O
into	O
a	O
glass	O
via	O
##l	O
for	O
vacuum	O
drying	O
;	O
6	O
)	O
der	O
##iva	O
##tized	O
the	O
obtained	O
dried	O
metabolic	O
extract	O
using	O
30	O
##μ	O
##l	O
met	O
##ho	O
##xy	O
##amine	O
(	O
20	O
mg	O
/	O
m	O
##l	O
)	O
at	O
37	O
°C	O
for	O
90	O
minutes	O
;	O
7	O
)	O
added	O
30	O
##μ	O
##l	O
of	O
N	B
,	I
O	I
-	I
bi	I
##s	I
(	I
trim	I
##eth	I
##yl	I
##si	I
##ly	I
##l	I
)	I
t	I
##ri	I
##f	I
##lu	I
##oro	I
##ace	I
##tam	I
##ide	I
with	O
1	O
%	O
trim	B
##eth	I
##yl	I
##ch	I
##lor	I
##os	I
##ila	I
##ne	I
into	O
the	O
obtained	O
dried	O
metabolic	O
extract	O
;	O
8	O
)	O
heated	O
the	O
mixture	O
at	O
70	O
°C	O
for	O
60	O
minutes	O
to	O
obtain	O
trim	O
##eth	O
##yl	O
##si	O
##ly	O

On	O
the	O
other	O
hand	O
,	O
h	B
##ydro	I
##phi	I
##lic	I
compounds	O
have	O
improved	O
resolution	O
when	O
H	O
##IL	O
##IC	O
is	O
used	O
.	O

The	O
use	O
of	O
met	B
##han	I
##ol	I
was	O
ultimately	O
selected	O
as	O
it	O
successfully	O
extracted	O
the	O
meta	O
##bol	O
##ites	O
with	O
the	O
least	O
concentration	O
time	O
needed	O
.	O

It	O
is	O
possible	O
that	O
the	O
increase	O
in	O
or	B
##ota	I
##te	I
may	O
be	O
explained	O
by	O
the	O
variants	O
we	O
identified	O
in	O
p	B
##yr	I
##im	I
##id	I
##ine	I
bio	O
##sy	O
##nt	O
##hesis	O
genes	O
,	O
although	O
further	O
functional	O
investigation	O
would	O
be	O
required	O
to	O
confirm	O
this	O
conjecture	O
.	O

CE	O
,	O
ch	B
##ole	I
##ster	I
##ol	I
est	I
##ers	I
;	O
SM	O
,	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
;	O
PP	O
##V	O
,	O
positive	O
predict	O
##ive	O
value	O
;	O
N	O
##P	O
##V	O
,	O
negative	O
predict	O
##ive	O
value	O
;	O
OR	O
,	O
odds	O
ratio	O
;	O
AU	O
##C	O
,	O
area	O
under	O
the	O
curve	O
.	O

In	O
the	O
next	O
1	O
h	O
and	O
1	O
.	O
5	O
h	O
,	O
the	O
blood	O
glucose	S
reduction	O
may	O
be	O
due	O
to	O
insulin	O
since	O
the	O
%	O
reduction	O
for	O
the	O
a	O
##que	O
##ous	O
leaf	O
extract	O
and	O
the	O
negative	O
control	O
(	O
water	O
)	O
are	O
similar	O

Ser	O
##um	O
la	B
##ct	I
##ate	I
and	O
s	B
##phi	I
##nga	I
##nine	I
levels	O
were	O
positively	O
correlated	O
with	O
confusion	O
,	O
u	B
##rea	I
level	O
,	O
respiratory	O
rate	O
,	O
blood	O
pressure	O
,	O
and	O
age	O
>	O
65	O
years	O
(	O
C	O
##UR	O
##B	O
-	O
65	O
)	O
,	O
pneumonia	O
severity	O
index	O
(	O
PS	O
##I	O
)	O
and	O
A	O
##cute	O
Ph	O
##ys	O
##iology	O
and	O
Ch	O
##ronic	O
Health	O
Evaluation	O
II	O
(	O
AP	O
##AC	O
##H	O
##E	O
II	O
)	O
scores	O
,	O
while	O
D	B
##H	I
##EA	I
-	I
S	I
inverse	O
##ly	O
correlated	O
with	O
the	O
three	O
scoring	O
systems	O
.	O

Specifically	O
,	O
the	O
sample	O
mean	O
values	O
(	O
μ	O
##mo	O
##l	O
/	O
L	O
)	O
were	O
:	O
249	O
.	O
84	O
for	O
Val	B
##ine	I
(	O
Val	O
)	O
,	O
23	O
.	O
93	O
for	O
S	B
##phi	I
##ngo	I
##my	I
##elin	I
##e	I
C	I
##24	I
:	I
1	I
(	O
SM	O
##C	O
##24	O
)	O
,	O
200	O
.	O
53	O
for	O
L	B
##ys	I
##ine	I
(	O
L	O
##ys	O
)	O
,	O
8	O
.	O
46	O
for	O
Trip	B
##ent	I
##ade	I
##cano	I
##ate	I
T	O
##G	O
##15	O
(	O
T	O
##G	O
##15	O
)	O
,	O
0	O
.	O
76	O
for	O
S	B
##ym	I
##metric	I
dim	I
##eth	I
##yla	I
##rg	I
##ini	I
##ne	I
(	O
SD	O
##MA	O
)	O
.	O

N	O
##MP	O
##S	O
der	O
##iva	O
##ti	O
##zation	O
requires	O
the	O
initial	O
formation	O
of	O
a	O
p	B
##yr	I
##id	I
##ini	I
##um	I
su	I
##lf	I
##ona	I
##te	I
derivative	O
that	O
is	O
then	O
q	O
##uate	O
##rn	O
##ized	O
by	O
met	O
##hyl	O
##ation	O
with	O
met	B
##hyl	I
i	I
##od	I
##ide	I
.	O

[	O
]	O
showed	O
that	O
ch	B
##ole	I
##ster	I
##ols	I
can	O
be	O
detected	O
as	O
a	O
π	O
complex	O
with	O
A	O
##g	O
_	O
+	O
using	O
silver	B
ion	I
coordination	O
ions	O
##pra	O
##y	O
.	O

Extra	O
##cted	O
ion	O
ch	O
##roma	O
##to	O
##gram	O
##s	O
from	O
L	O
##C	O
-	O
N	O
##SI	O
-	O
H	O
##R	O
##MS	O
/	O
MS	O
analyses	O
of	O
su	B
##lf	I
##oxide	I
##s	I
and	O
MS	O
/	O
MS	O
fragment	O
##ation	O
s	O
##pect	O
##ra	O
.	O

The	O
3	O
meta	O
##bol	O
##ites	O
G	B
##CD	I
##CA	I
,	O
G	O
##DC	O
##A	O
and	O
G	O
##LC	O
##A	O
were	O
slightly	O
altered	O
,	O
demonstrating	O
the	O
effects	O
on	O
g	O
##ly	O
##cine	O
-	O
con	O
##ju	O
##gated	O
bi	O
##le	O
acids	O
in	O
AD	O
.	O

A	O
comparison	O
of	O
steady	O
state	O
levels	O
of	O
metabolic	O
intermediate	O
##s	O
demonstrates	O
that	O
un	O
##in	O
##fected	O
red	O
blood	O
cells	O
prefer	O
##ential	O
##ly	O
generate	O
N	O
##AD	O
_	O
+	O
via	O
ni	B
##cot	I
##ina	I
##mi	I
##de	I
mon	I
##on	I
##uc	I
##leo	I
##tide	I
(	O
N	O
##M	O
##N	O
)	O
,	O
while	O
the	O
parasite	O
produces	O
N	O
##AD	O
_	O
+	O
via	O
the	O
canonical	O
Pre	O
##iss	O
-	O
Hand	O
##ler	O
two	O
-	O
step	O
process	O
,	O
yielding	O
both	O
the	O
labeled	O
intermediate	O
##s	O
Na	O
##M	O
##N	O
and	O
ni	B
##cot	I
##inate	I
ad	I
##eni	I
##ne	I
din	O
##uc	O
##leo	O
##tide	O
(	O
Na	O
##AD	O
)	O
.	O

As	O
##ter	O
##isk	O
##s	O
indicate	O
FA	S
that	O
were	O
significantly	O
different	O
(	O
Tu	O
##key	O
Kramer	O
post	O
ho	O
##c	O
P	O
<	O
0	O
.	O
05	O
)	O
between	O
q	O
##ua	O
##rt	O
##iles	O
.	O

In	O
addition	O
,	O
the	O
H	O
##R	O
for	O
a	O
5	O
##k	O
##g	O
/	O
m	O
_	O
2	O
increase	O
in	O
B	O
##MI	O
was	O
greater	O
for	O
ER	O
+	O
breast	O
cancer	O
(	O
H	O
##R	O
=	O
1	O
.	O
28	O
(	O
95	O
%	O
C	O
##I	O
1	O
.	O
10	O
,	O
1	O
.	O
49	O
)	O
(	O
,	O
)	O
than	O
for	O
total	O
breast	O
cancer	O
(	O
1	O
.	O
15	O
(	O
95	O
%	O
C	O
##I	O
1	O
.	O
01	O
,	O
1	O
.	O
32	O
)	O
)	O
,	O
without	O
adjustment	O
for	O
un	O
##con	O
##ju	O
##gated	O
est	B
##rad	I
##iol	I
.	O

Not	O
##ably	O
,	O
the	O
rate	O
of	O
ni	B
##cot	I
##ine	I
metabolism	O
was	O
higher	O
in	O
N	O
##P	O
compared	O
to	O
S	O
##W	O
smoke	O
##rs	O
(	O
P	O
=	O
0	O
.	O
03	O
)	O
,	O
and	O
in	O
comparison	O
to	O
other	O
ethnic	O
groups	O
in	O
the	O
United	O
States	O
.	O

C	B
##rea	I
##tine	I
kinase	O
then	O
transfers	O
the	O
high	O
energy	O
phosphate	S
of	O
p	B
##hos	I
##ph	I
##oc	I
##rea	I
##tine	I
to	O
AD	B
##P	I
,	O
forming	O
ATP	S
and	O
allowing	O
the	O
energy	O
-	O
requiring	O
reaction	O
to	O
continue	O
.	O

Met	B
##form	I
##in	I
and	O
long	O
-	O
acting	O
insulin	O
were	O
discontinued	O
48	O
h	O
before	O
metabolic	O
studies	O
as	O
detailed	O
before	O
.	O

Lim	O
##its	O
of	O
q	O
##uant	O
##ification	O
for	O
specific	O
anal	O
##yte	O
##s	O
ranged	O
from	O
1	O
–	O
50	O
p	B
##g	I
with	O
a	O
signal	O
to	O
noise	O
ratio	O
of	O
>	O
10	O
.	O

Because	O
chain	O
length	O
and	O
sat	O
##uration	O
can	O
affect	O
the	O
per	O
##me	O
##ability	O
,	O
rigid	O
##ity	O
,	O
and	O
fluid	O
##ity	O
of	O
the	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
membrane	O
,	O
changes	O
in	O
the	O
degree	O
of	O
un	O
##sat	O
##uration	O
or	O
chain	O
length	O
may	O
cause	O
different	O
responses	O
for	O
o	O
##xi	O
##da	O
##tive	O
damage	O
by	O
reactive	O
oxygen	O
species	O
.	O

Note	O
that	O
D	O
also	O
demonstrates	O
the	O
beneficial	O
effect	O
of	O
using	O
am	B
##mon	I
##ium	I
format	I
##e	I
as	O
an	O
add	O
##itive	O
for	O
this	O
set	O
of	O
anal	O
##yte	O
##s	O
,	O
with	O
narrower	O
peak	O
width	O
##s	O
observed	O
across	O
all	O
column	O
types	O
in	O
the	O
presence	O
of	O
this	O
add	O
##itive	O
.	O

G	B
##lu	I
##cos	I
##e	I
and	O
x	B
##yl	I
##ito	I
##l	I
feed	O
the	O
PP	O
##P	O
through	O
glucose	B
-	I
6	I
-	I
phosphate	I
and	O
x	O
##yl	O
##ulos	O
##e	O
/	O
x	O
##yl	O
##ulos	O
##e	O
-	O
5	O
-	O
phosphate	O
,	O
respectively	O
.	O

FF	O
##M	O
=	O
fat	O
-	O
free	O
mass	O
;	O
FM	O
=	O
fat	O
mass	O
;	O
SAT	O
=	O
sub	O
##cut	O
##aneous	O
ad	O
##ip	O
##ose	O
tissue	O
;	O
VA	O
##T	O
=	O
v	O
##is	O
##cer	O
##al	O
ad	O
##ip	O
##ose	O
tissue	O
;	O
I	O
##MC	O
##L	O
=	O
in	O
##tra	O
-	O
my	O
##oc	O
##ell	O
##ular	O
lip	O
##ids	O
;	O
E	O
##MC	O
##L	O
=	O
extra	O
-	O
my	O
##oc	O
##ell	O
##ular	O
lip	O
##ids	O
;	O
H	O
##OM	O
##A	O
-	O
I	O
##R	O
=	O
home	O
##ost	O
##atic	O
model	O
assessment	O
of	O
insulin	O
resistance	O
;	O
O	O
##G	O
##TT	O
=	O
oral	O
glucose	S
tolerance	O
test	O
;	O
Mat	O
##su	O
##da	O
index	O
=	O
insulin	O
sensitivity	O
index	O
;	O
FF	O
##A	O
=	O
free	O
fatty	O
acids	O
;	O
E	O
%	O
=	O
percentage	O
of	O
total	O
energy	O
intake	O
;	O
L	O
##TP	O
##A	O
=	O
leisure	O
-	O
time	O
physical	O
activity	O
;	O
V	O
##O	O
_	O
2	O
##max	O
=	O
maximum	O
oxygen	O
up	O
##take	O
.	O

Conversely	O
,	O
there	O
was	O
a	O
significant	O
decrease	O
in	O
ta	O
##uro	O
##cho	O
##lena	O
##te	O
su	B
##lf	I
##ate	I
.	O

As	B
##par	I
##tic	I
acid	I
is	O
involved	O
in	O
protein	O
synthesis	O
and	O
degradation	O
and	O
also	O
acts	O
in	O
trans	O
##ami	O
##nation	O
reactions	O
.	O

The	O
key	O
differences	O
were	O
the	O
change	O
in	O
the	O
chemical	O
shift	O
of	O
H	O
##2	O
and	O
H	O
##6	O
(	O
δ	O
_	O
H	O
7	O
.	O
61	O
)	O
,	O
C	O
##2	O
and	O
C	O
##6	O
(	O
δ	O
_	O
C	O
126	O
.	O
6	O
)	O
,	O
and	O
C	O
##1	O
(	O
δ	O
_	O
C	O
141	O
.	O
7	O
)	O
due	O
to	O
the	O
presence	O
of	O
a	O
su	B
##lf	I
##one	I
(	O
O	O
=	O
S	O
=	O
O	O
)	O
group	O
.	O

Similarly	O
,	O
as	O
shown	O
in	O
,	O
the	O
br	O
##occo	O
##li	O
s	O
##p	O
##rout	O
beverage	O
group	O
had	O
a	O
+	O
22	O
.	O
7	O
%	O
higher	O
u	O
##rina	O
##ry	O
ex	O
##cre	O
##tion	O
of	O
3	O
-	O
HP	O
##MA	O
(	O
95	O
%	O
C	O
##I	O
:	O
+	O
5	O
.	O
0	O
%	O
,	O
+	O
43	O
.	O
4	O
%	O
:	O
p	O
=	O
0	O
.	O
01	O
##0	O
)	O
at	O
day	O
1	O
than	O
the	O
place	O
##bo	O
group	O
,	O
whose	O
average	O
level	O
was	O
35	O
##48	O
pm	O
##ol	O
/	O
mg	O
c	B
##rea	I
##tin	I
##ine	I
(	O
95	O
%	O
C	O
##I	O
:	O
31	O
##7	O
##3	O
,	O
39	O
##6	O
##8	O
)	O
.	O

,	O
P	O
##BM	O
##C	O
samples	O
contained	O
predominantly	O
trip	B
##hos	I
##phate	I
##s	I
,	O
suggesting	O
a	O
relative	O
lack	O
of	O
de	O
##ph	O
##os	O
##ph	O
##ory	O
##lation	O
during	O
the	O
handling	O
of	O
samples	O
of	O
this	O
cell	O
type	O
.	O

None	O
of	O
the	O
p	O
##har	O
##ma	O
##co	O
##kin	O
##etic	O
parameters	O
for	O
E	O
##D	O
##DP	O
,	O
especially	O
the	O
AU	O
##C	O
E	O
##D	O
##DP	O
/	O
AU	O
##C	O
met	B
##had	I
##one	I
ratios	O
,	O
differed	O
between	O
routes	O
of	O
administration	O
(	O
Table	O
3	O
)	O
,	O
although	O
concentrations	O
after	O
oral	O
met	B
##had	I
##one	I
appeared	O
somewhat	O
higher	O
.	O

Note	O
##worthy	O
,	O
however	O
,	O
in	O
our	O
current	O
study	O
,	O
the	O
color	O
##ime	O
##tric	O
analysis	O
of	O
3	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
did	O
not	O
reveal	O
any	O
statistical	O
##ly	O
significant	O
changes	O
related	O
to	O
the	O
treatment	O
(	O
data	O
not	O
showed	O
)	O
.	O

The	O
effectiveness	O
of	O
current	O
HC	O
##C	O
surveillance	O
markers	O
or	O
methods	O
such	O
as	O
alpha	B
-	I
f	I
##eto	I
##p	I
##rote	I
##in	I
(	O
A	O
##FP	O
)	O
and	O
abdominal	O
ultra	O
##sound	O
(	O
US	O
)	O
are	O
limited	O
by	O
low	O
sensitivity	O
and	O
specific	O
##ity	O
.	O

The	O
SL	O
##C	O
##22	O
family	O
of	O
transport	O
##ers	O
comprises	O
O	O
##AT	O
##s	O
,	O
u	B
##rate	I
transport	O
##ers	O
and	O
organic	O
car	B
##ni	I
##tine	I
transport	O
##ers	O
.	O

(	O
F	O
)	O
Biological	O
effects	O
of	O
2	B
-	I
o	I
##x	I
##og	I
##lut	I
##arate	I
on	O
bladder	O
cells	O
.	O

Try	B
##pt	I
##op	I
##han	I
can	O
be	O
de	O
##graded	O
by	O
try	O
##pt	O
##op	O
##han	O
2	O
,	O
3	O
-	O
di	O
##ox	O
##y	O
##gen	O
##ase	O
(	O
TD	O
##O	O
)	O
or	O
in	O
##do	O
##leam	O
##ine	O
2	O
,	O
3	O
-	O
di	O
##ox	O
##y	O
##gen	O
##ase	O
(	O
ID	O
##O	O
)	O
,	O
which	O
is	O
triggered	O
by	O
inter	O
##fer	O
##on	O
-	O
γ	O
(	B
IF	B
##N	I
-	I
γ	I
)	O
and	O
tumor	O
ne	O
##c	O
##rosis	O
factor	O
-	O
α	O
(	O
T	O
##NF	O
-	O
α	O
)	O
.	O

However	O
,	O
our	O
experiments	O
indicate	O
that	O
p	B
##yr	I
##og	I
##lut	I
##ami	I
##c	I
acid	I
levels	O
are	O
likely	O
to	O
be	O
low	O
in	O
intact	O
serum	O
.	O

[	O
,	O
]	O
The	O
amino	O
acid	O
after	O
met	B
##hi	I
##oni	I
##ne	I
in	O
fi	O
##bri	O
##no	O
##gen	O
is	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
raising	O
the	O
p	O
##oss	O
##ib	O
##lity	O
that	O
the	O
N	B
-	I
ace	I
##ty	I
##l	I
##phe	I
##ny	I
##lal	I
##ani	I
##ne	I
in	O
the	O
plasma	O
of	O
type	O
1	O
MI	O
patients	O
is	O
derived	O
from	O
a	O
breakdown	O
of	O
fi	O
##bri	O
##no	O
##gen	O
.	O

Con	O
##sist	O
##ent	O
with	O
palm	B
##itate	I
trace	O
##r	O
data	O
,	O
the	O
increases	O
in	O
plasma	O
g	B
##ly	I
##cer	I
##ol	I
concentration	O
observed	O
during	O
the	O
place	O
##bo	O
trial	O
were	O
abolished	O
during	O
the	O
r	O
##HD	O
##L	O
in	O
##fusion	O
.	O

VIP	O
:	O
V	O
##aria	O
##ble	O
I	O
##mpo	O
##rta	O
##nce	O
of	O
Project	O
##ion	O
;	O
Sa	O
:	O
S	B
##phi	I
##nga	I
##nine	I
;	O
Sa	O
##1	O
##P	O
:	O
S	B
##phi	I
##nga	I
##nine	I
-	I
1	I
-	I
Ph	I
##os	I
##phate	I
;	O
C	O
##16	O
##C	O
##er	O
:	O
Ce	B
##ram	I
##ide	I
(	I
d	I
##18	I
:	I
1	I
/	I
16	I
:	I
0	I
)	I
;	O
C	O
##24	O
##d	O
##HC	O
##er	O
:	O
Di	B
##hy	I
##dr	I
##oc	I
##era	I
##mi	I
##de	I
(	I
d	I
##18	I
:	I
1	I
/	I
24	I
:	I
1	I
)	I
:	O
C	O
##0	O
:	O
Free	O
Car	B
##ni	I
##tine	I
;	O
So	O
##1	O
##P	O
:	O
S	B
##phi	I
##ngo	I
##sin	I
##e	I
-	I
1	I
-	I
Ph	I
##os	I
##phate	I
;	O
C	O
##16	O
##G	O
##l	O
##c	O
##C	O
##er	O
:	O
G	B
##lu	I
##cos	I
##yl	I
##cer	I
##ami	I
##de	I
(	I
d	I
##18	I
:	I
1	I
/	I
16	I
:	I
0	I
)	I
;	O
C	O
##24	O
:	O
Te	B
##tra	I
##cos	I
##ano	I
##yl	I
##car	I
##ni	I
##tine	I
;	O
C	O
##2	O
:	O
Ace	B
##ty	I
##l	I
##car	I
##ni	I
##tine	I
;	O
C	O
##18	O
##C	O
##er	O
:	O
Ce	B
##ram	I
##ide	I
(	I
d	I
##18	I
:	I
1	I
/	I
18	I
:	I
0	I
)	I
;	O
C	B
##18	I
:	I
1	I
:	O
Oct	B
##ade	I
##ce	I
##noy	I
##l	I
##car	I
##ni	I
##tine	I
.	O

Among	O
them	O
,	O
serum	O
levels	O
of	O
l	B
##ys	I
##o	I
##PC	I
(	I
18	I
:	I
2	I
)	I
,	O
u	B
##ro	I
##can	I
##ic	I
acid	I
and	O
in	B
##do	I
##le	I
were	O
significantly	O
lower	O
,	O
and	O
L	B
-	I
p	I
##hen	I
##yla	I
##lani	I
##ne	I
levels	O
were	O
significantly	O
higher	O
in	O
A	O
##OS	O
##D	O
patients	O
compared	O
with	O
HC	O
.	O

The	O
de	O
##uter	O
##ated	O
buffer	O
contained	O
0	O
.	O
5	O
m	O
##M	O
sodium	B
trim	I
##eth	I
##yl	I
##si	I
##ly	I
##l	I
##ph	I
##os	I
##phate	I
(	O
T	O
##SP	O
)	O
to	O
provide	O
a	O
reference	O
substance	O
for	O
the	O
an	O
##not	O
##ation	O
of	O
the	O
N	O
##MR	O
s	O
##pect	O
##ra	O
.	O

A	O
consisted	O
of	O
33	O
.	O
3	O
%	O
met	B
##han	I
##ol	I
,	O
16	O
.	O
7	O
%	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
containing	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
,	O
and	O
mobile	O
phase	O
B	O
consisted	O
of	O
63	O
.	O
3	O
%	O
met	B
##han	I
##ol	I
31	O
.	O
7	O
%	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
containing	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
.	O

The	O
most	O
relevant	O
meta	O
##bol	O
##ites	O
that	O
differentiate	O
the	O
two	O
groups	O
of	O
patients	O
were	O
sperm	B
##id	I
##ine	I
and	O
try	B
##pt	I
##op	I
##han	I
.	O

Second	O
,	O
the	O
prediction	O
potential	O
of	O
try	B
##pt	I
##op	I
##han	I
is	O
non	O
-	O
inferior	O
to	O
the	O
5	O
existing	O
amino	O
acids	O
.	O

These	O
meta	O
##bol	O
##ites	O
included	O
c	B
##rea	I
##tine	I
,	O
c	B
##rea	I
##tin	I
##ine	I
,	O
and	O
test	O
##osterone	O
-	O
related	O
s	O
##tero	O
##ids	O
,	O
which	O
were	O
confirmed	O
by	O
MS	O
/	O
MS	O
analysis	O
.	O

At	O
present	O
,	O
major	O
u	O
##rina	O
##ry	O
meta	O
##bol	O
##ites	O
of	O
ch	B
##lor	I
##ot	I
##yr	I
##os	I
##ine	I
and	O
ni	B
##tro	I
##ty	I
##ros	I
##ine	I
have	O
been	O
identified	O
[	O
–	O
]	O
,	O
and	O
their	O
measurement	O
has	O
been	O
employed	O
for	O
the	O
assessment	O
of	O
systemic	O
inflammation	O
in	O
v	O
##ivo	O
[	O
,	O
]	O
.	O

Stock	O
solutions	O
of	O
B	O
##EN	O
,	O
B	O
##EN	O
-	O
C	O
##l	O
_	O
2	O
BA	O
,	O
BA	O
-	O
C	O
##l	O
_	O
2	O
B	O
##EN	O
-	O
(	O
OH	O
)	O
_	O
2	O
and	O
BA	O
-	O
(	O
OH	O
)	O
_	O
2	O
were	O
prepared	O
separately	O
at	O
1	O
.	O
0	O
mg	O
/	O
m	O
##L	O
in	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
containing	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
.	O

As	O
shown	O
in	O
,	O
significant	O
correlation	O
##s	O
were	O
observed	O
between	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
g	I
##lu	I
##cu	I
##ron	I
##ide	I
formation	O
and	O
U	O
##G	O
##T	O
##1	O
##A	O
##4	O
activity	O
,	O
as	O
measured	O
by	O
im	B
##ip	I
##ram	I
##ine	I
-	I

Cho	O
##line	O
-	O
containing	O
nutrients	O
that	O
reach	O
the	O
c	O
##ec	O
##um	O
and	O
large	O
bow	O
##el	O
may	O
serve	O
as	O
fuel	O
for	O
in	O
##test	O
##inal	O
micro	O
##bio	O
##ta	O
(	O
gut	O
flora	O
)	O
,	O
producing	O
trim	B
##eth	I
##yla	I
##mine	I
(	O
T	O
##MA	O
)	O
.	O

More	O
extensive	O
studies	O
are	O
needed	O
in	O
future	O
to	O
confirm	O
the	O
f	O
##eas	O
##ibility	O
of	O
testing	O
su	B
##cci	I
##nic	I
acid	I
in	O
the	O
blood	O
as	O
a	O
target	O
for	O
assessing	O
the	O
degree	O
of	O
mitochondrial	O
d	O
##ys	O
##function	O
in	O
se	O
##psis	O
,	O
while	O
monitoring	O
se	O
##psis	O
-	O
associated	O
micro	O
##bial	O
meta	O
##bol	O
##ites	O
to	O
control	O
targeted	O
therapy	O
.	O

B	O
##rief	O
##ly	O
,	O
200	O
μ	O
##L	O
serum	O
was	O
added	O
into	O
800	O
μ	O
##L	O
met	B
##han	I
##ol	I
-	I
ace	I
##ton	I
##it	I
##ril	I
##e	I
mixture	O
(	O
4	O
:	O
1	O
,	O
v	O
/	O
v	O
)	O
,	O
v	O
##ortex	O
-	O
mixing	O
undertaken	O
for	O
1	O
minute	O
.	O

Interest	O
##ingly	O
,	O
adding	O
both	O
water	O
and	O
am	B
##mon	I
##ium	I
format	I
##e	I
to	O
the	O
co	O
-	O
solvent	O
resulted	O
in	O
a	O
lower	O
hit	O
-	O
rate	O
of	O
63	O
%	O
,	O
all	O
other	O
conditions	O
(	O
column	O
,	O
temperature	O
etc	O
.	O
)	O
remaining	O
the	O
same	O
;	O
this	O
suggests	O
that	O
simply	O
combining	O
m	O
##od	O
##ifier	O
add	O
##itive	O
##s	O
is	O
not	O
sufficient	O
to	O
improve	O
performance	O
,	O
but	O
must	O
be	O
accompanied	O
by	O
an	O
op	O
##ti	O
##mis	O
##ation	O
procedure	O
for	O
each	O
set	O
of	O
anal	O
##yte	O
##s	O
.	O

Ana	O
##ly	O
##tes	O
were	O
separated	O
with	O
the	O
gradient	O
shown	O
in	O
using	O
20	O
m	O
##M	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
in	O
dei	O
##onized	O
water	O
as	O
mobile	O
phase	O
A	O
and	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
as	O
mobile	O
phase	O
B	O
.	O
All	O
anal	O
##yte	O
##s	O
el	O
##uted	O
within	O
8	O
min	O
.	O

The	O
β	O
coefficient	O
for	O
the	O
association	O
between	O
LP	O
##C	O
levels	O
and	O
components	O
of	O
the	O
Met	O
##S	O
was	O
higher	O
in	O
females	O
than	O
in	O
males	O
;	O
i	O
##rre	O
##spective	O
of	O
whether	O
it	O
was	O
a	O
positive	O
(	O
s	O
##ys	O
##B	O
##P	O
,	O
T	B
##G	I
,	O
HD	O
##L	O
)	O
or	O
negative	O
(	O
T	O
##G	O
,	O
WC	O
,	O
HD	O
##L	O
)	O
association	O
.	O

However	O
,	O
a	O
recent	O
study	O
by	O
also	O
supports	O
our	O
findings	O
regarding	O
the	O
lack	O
of	O
correlation	O
between	O
p	O
##yre	O
##ne	O
(	O
gas	O
+	O
part	O
##iculate	O
phase	O
)	O
with	O
the	O
1	B
-	I
h	I
##ydro	I
##xy	I
##py	I
##rene	I
meta	O
##bol	O
##ite	O
in	O
urine	O
.	O

Sam	O
##ples	O
of	O
the	O
a	O
##que	O
##ous	O
and	O
v	O
##it	O
##re	O
##ous	O
humor	O
##s	O
were	O
collected	O
and	O
underwent	O
mass	O
s	O
##pect	O
##rome	O
##try	O
-	O
based	O
meta	O
##bol	O
##omi	O
##c	O
pro	O
##fi	O
##ling	O
of	O
reactive	O
per	B
##sul	I
##fi	I
##des	I
and	O
p	B
##oly	I
##sul	I
##fi	I
##des	I
(	I
p	I
##oly	I
##sul	I
##fi	I
##dom	I
##ics	I
)	I
.	O

The	O
production	O
of	O
s	O
##tero	O
##ids	O
from	O
the	O
classic	O
and	O
##rogen	O
pathway	O
was	O
measured	O
by	O
the	O
q	O
##uant	O
##ification	O
of	O
the	O
major	O
and	O
##rogen	O
meta	O
##bol	O
##ites	O
and	B
##ros	I
##tero	I
##ne	I
(	O
An	O
)	O
and	O
et	B
##io	I
##cho	I
##lan	I
##olo	I
##ne	I

Another	O
example	O
,	O
2	B
-	I
met	I
##hyl	I
##ery	I
##th	I
##rito	I
##l	I
,	O
was	O
previously	O
detected	O
in	O
human	O
urine	O
but	O
no	O
concentration	O
was	O
reported	O
.	O

We	O
also	O
did	O
a	O
comparison	O
experiment	O
of	O
the	O
one	O
-	O
step	O
extraction	O
with	O
sodium	B
h	I
##ydro	I
##xi	I
##de	I
solution	O
and	O
the	O
two	O
-	O
step	O
extraction	O
using	O
sodium	B
h	I
##ydro	I
##xi	I
##de	I
solution	O
followed	O
by	O
met	B
##han	I
##ol	I
(	O
based	O
on	O
op	O
##ti	O
##mized	O
ratio	O
for	O
MC	O
##F	O
der	O
##iva	O
##ti	O
##zation	O
)	O
,	O
with	O
the	O
aim	O
of	O
increasing	O
the	O
extraction	O
efficiency	O
.	O

In	O
the	O
p	O
##ediatric	O
study	O
of	O
Mick	O
##ie	O
##wicz	O
et	O
al	O
.	O
,	O
c	B
##it	I
##rate	I
was	O
also	O
found	O
to	O
be	O
decreased	O
.	O

In	O
addition	O
to	O
the	O
c	O
##y	O
##c	O
##lo	O
##arte	O
##no	O
##l	O
##→	O
##er	O
##gos	O
##tero	O
##l	O
bio	O
##sy	O
##nt	O
##hetic	O
route	O
,	O
a	O
route	O
leading	O
to	O
de	O
no	O
##vo	O
ch	B
##ole	I
##ster	I
##ol	I
bio	O
##sy	O
##nt	O
##hesis	O
emerged	O
.	O

[	O
,	O
]	O
HC	O
##C	O
patients	O
have	O
elevated	O
levels	O
of	O
both	O
di	B
##ole	I
##oy	I
##l	I
##ph	I
##os	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
and	O
a	O
##rac	O
##hi	O
##don	O
##yl	O
l	O
##ys	O
##ole	O
##ci	O
##thin	O
compared	O
to	O
individuals	O
with	O
HC	O
##V	O
.	O

The	O
experiments	O
showed	O
that	O
c	B
##ys	I
##tein	I
##e	I
per	I
##sul	I
##fi	I
##des	I
(	O
Cy	O
##s	O
##SS	O
##H	O
)	O
,	O
o	O
##xi	O
##dized	O
g	O
##lut	O
##ath	O
##ione	O
t	O
##ris	O
##ulf	O
##ide	O
(	O
G	O
##SS	O
##S	O
##G	O
)	O
and	O
c	B
##ys	I
##tine	I
were	O
elevated	O
in	O
the	O
a	O
##que	O
##ous	O
humor	O
,	O
and	O
Cy	O
##s	O
##SS	O
##H	O
,	O
Cy	O
##s	O
,	O
and	O
c	B
##ys	I
##tine	I
were	O
elevated	O
in	O
the	O
v	O
##it	O
##re	O
##ous	O
.	O

A	O
broad	O
spectrum	O
of	O
short	O
-	O
,	O
medium	O
-	O
,	O
long	O
-	O
and	O
very	O
long	O
-	O
chain	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
species	O
is	O
generated	O
from	O
multiple	O
metabolic	O
routes	O
.	O

Eleven	O
of	O
the	O
β	B
-	I
a	I
##po	I
##car	I
##ote	I
##no	I
##ids	I
were	O
synthesized	O
by	O
standard	O
organic	O
chemical	O
transformations	O
,	O
including	O
oxidation	O
of	O
al	O
##de	O
##hy	O
##des	O
to	O
acids	O
,	O
W	O
##ads	O
##worth	O
-	O
Em	O
##mons	O
and	O
W	O
##itt	O
##ig	O
ho	O
##mo	O
##log	O
##ation	O
,	O
and	O
reduction	O
of	O
est	O
##ers	O
to	O
acids	O
followed	O
by	O
oxidation	O
to	O
al	O
##de	O
##hy	O
##des	O
.	O

In	O
a	O
prior	O
taste	O
trial	O
,	O
40	O
healthy	O
controls	O
could	O
not	O
distinguish	O
between	O
as	B
##par	I
##tam	I
##e	I
or	O
control	O
bars	O
.	O

The	O
lower	O
levels	O
of	O
LP	O
##C	O
##a	O
C	B
##16	I
:	I
0	I
,	O
LP	O
##C	O
##a	O
C	B
##18	I
:	I
0	I
and	O
LP	O
##C	O
##a	O
C	B
##18	I
:	I
1	I
in	O
HC	O
females	O
compared	O
to	O
non	O
-	O
HC	O
females	O
could	O
be	O
a	O
reflection	O
of	O
that	O
,	O
since	O
they	O
potentially	O
occur	O
after	O
c	O
##lea	O
##ving	O
a	O
fatty	O
acid	O
from	O
PC	O
##s	O
by	O
L	O
##CA	O
##T	O
activity	O
.	O

Furthermore	O
,	O
lower	O
level	O
of	O
g	B
##lut	I
##ama	I
##te	I
in	O
CR	O
##C	O
patients	O
was	O
observed	O
in	O
CR	O
##C	O
patients	O
in	O
the	O
current	O
study	O
and	O
our	O
previous	O
study	O
.	O

In	O
our	O
pilot	O
study	O
of	O
three	O
control	O
and	O
three	O
infected	O
cattle	O
,	O
we	O
found	O
small	O
to	O
no	O
changes	O
in	O
the	O
serum	O
levels	O
of	O
P	B
##G	I
,	O
PS	O
,	O
P	O
##I	O
,	O
P	O
##t	O
##d	O
##E	O
,	O
and	O
P	O
##ls	O
##E	O
(	O
data	O
not	O
shown	O
)	O
.	O

CH	O
##C	O
##l	O
_	O
3	O
:	O
water	O
ex	O
##t	O
+	O
U	O
##F	O
samples	O
,	O
PC	O
##A	O
shows	O
less	O
overall	O
variance	O
in	O
Me	B
##OH	I
:	O
CH	O
##C	O
##l	O
_	O
3	O
pp	O
##t	O
than	O
in	O
either	O
Me	B
##OH	I
:	O

Ho	B
##mo	I
##ci	I
##tr	I
##ull	I
##ine	I
(	I
ε	I
-	I
car	I
##ba	I
##mo	I
##yl	I
l	I
##ys	I
##ine	I
)	I
may	O
be	O
generated	O
in	O
v	O
##ivo	O
through	O
a	O
pathway	O
involving	O
decomposition	O
of	O
u	B
##rea	I
to	O
am	B
##monia	I
##c	I
and	O
c	B
##yana	I
##te	I
.	O

To	O
a	O
100	O
μ	O
##L	O
al	O
##iq	O
##uo	O
##t	O
of	O
urine	O
sample	O
,	O
1	O
m	O
##L	O
of	O
100	O
m	O
##M	O
sodium	B
ace	I
##tate	I
buffer	O
(	O
pH	O
5	O
,	O
adjusted	O
with	O
glacial	O
ace	O
##tic	O
acid	O
)	O
containing	O
β	O
-	O
g	O
##lu	O
##cu	O
##ron	O
##idas	O
##e	O
1000	O
U	O
/	O
m	O
##L	O
were	O
added	O
.	O

The	O
observed	O
differences	O
between	O
day	O
and	O
night	O
time	O
s	O
##tero	O
##id	O
ex	O
##cre	O
##tion	O
values	O
in	O
our	O
study	O
clearly	O
support	O
the	O
presence	O
of	O
a	O
robust	O
circa	O
##dian	O
rhythm	O
of	O
g	B
##lu	I
##co	I
##cor	I
##tic	I
##oid	I
synthesis	O
in	O
the	O
ad	O
##rena	O
##l	O
glands	O
.	O

These	O
results	O
indicate	O
that	O
the	O
effect	O
on	O
the	O
overall	O
appearance	O
induced	O
by	O
the	O
fiber	O
addition	O
was	O
strongest	O
for	O
glucose	S
and	O
was	O
at	O
##ten	O
##uated	O
downstream	O
of	O
glucose	S
.	O

In	O
conclusion	O
,	O
the	O
results	O
for	O
ta	B
##mo	I
##xi	I
##fen	I
and	O
its	O
meta	O
##bol	O
##ites	O
,	O
obtained	O
by	O
our	O
HP	O
##LC	O
fluorescent	O
method	O
,	O
has	O
shown	O
con	O
##cor	O
##dance	O
with	O
results	O
obtained	O
in	O
2	O
independent	O
laboratories	O
using	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
techniques	O
.	O

PC	B
-	I
14	I
:	I
0	I
/	I
14	I
:	I
0	I
,	O
P	B
##E	I
-	I
14	I
:	I
0	I
-	I
14	I
:	I
0	I
,	O
PS	B
-	I
14	I
:	I
0	I
/	I
14	I
:	I
0	I
,	O
PA	B
-	I
17	I
:	I
0	I
/	I
17	I
:	I
0	I
,	O
P	B
##G	I
-	I
14	I
:	I
0	I
/	I
14	I
:	I
0	I
,	O
d	B
##31	I
-	I
P	I
##I	I
-	I
18	I
:	I
1	I
/	I
16	I
:	I
0	I
,	O
C	O
##17	O
-	O
Ce	O
##r	O
,	O
C	O
##8	O
-	O
G	O
##uc	O
##C	O
##er	O
and	O
C	O
##12	O
-	O
SM	O
were	O
obtained	O
from	O
Ava	O
##nti	O
Polar	O
Li	O
##pid	O
##s	O
(	O
Al	O
##aba	O
##ster	O
,	O
AL	O
,	O
USA	O
)	O
.	O

A	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
,	O
Pro	O
##state	O
cancer	O
,	O
Met	O
##ab	O
##olo	O
##mic	O
##s	O
,	O
Disease	O
progression	O
,	O
Fat	O
##ty	O
acid	O
metabolism	O

*	O
One	O
G	O
##WI	O
pathway	O
(	B
end	B
##oc	I
##anna	I
##bino	I
##ids	I
)	O
was	O
similarly	O
decreased	O
in	O
females	O
with	O
CF	O
##S	O
,	O
but	O
not	O
in	O
males	O
with	O
CF	O
##S	O
.	O

In	O
this	O
example	O
,	O
high	O
levels	O
of	O
anti	O
-	O
X	O
##a	O
activity	O
and	O
r	B
##iva	I
##ro	I
##xa	I
##ban	I
concentration	O
were	O
found	O
despite	O
the	O
withdrawal	O
of	O
the	O
drug	O
;	O
t	O
_	O
1	O
/	O
2	O
was	O
2	O
–	O
3	O
times	O
higher	O
than	O
that	O
indicated	O
in	O
the	O
manual	O
.	O

To	O
q	O
##uant	O
##ify	O
the	O
lip	O
##ids	O
in	O
the	O
met	B
##hyl	I
format	I
##e	I
fraction	O
,	O
the	O
triple	O
q	O
##uad	O
##rup	O
##ole	O
L	O
##C	O
/	O
MS	O
system	O
was	O
operated	O
under	O
the	O
multiple	O
reaction	O
monitoring	O
(	O
MR	O
##M	O
)	O
mode	O
using	O
electro	O
##sp	O
##ray	O
ion	O
##ization	O
in	O
the	O
negative	O
ion	O
mode	O
.	O

In	O
female	O
B	O
##D	O
subjects	O
,	O
we	O
observed	O
increased	O
levels	O
of	O
α	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
as	O
well	O
as	O
decreased	O
levels	O
of	O
N	B
-	I
met	I
##hyl	I
##nic	I
##ot	I
##ina	I
##mi	I
##de	I
,	O
ace	B
##tone	I
,	O
and	O
o	B
##xa	I
##lace	I
##tate	I
.	O

The	O
enzymes	O
driving	O
relevant	O
reactions	O
are	O
:	O
1	O
,	O
la	O
##ct	O
##ate	O
de	O
##hy	O
##dr	O
##ogen	O
##ase	O
;	O
2	O
,	O
al	O
##ani	O
##ne	O
amino	O
##tra	O
##ns	O
##fer	O
##ase	O
;	O
3	O
,	O
g	B
##lut	I
##amine	I
s	O
##ynth	O
##eta	O
##se	O
;	O
4	O
,	O
g	O
##lut	O
##ami	O
##nas	O
##e	O
.	O

A	O
##bb	O
##re	O
##viation	O
##s	O
:	O
3	O
β	B
-	I
H	I
##SD	I
,	O
3	O
β	O
-	O
h	O
##ydro	O
##xy	O
##ster	O
##oid	O
de	O
##hy	O
##dr	O
##ogen	O
##ase	O
;	O
17	O
-	O
K	O
##SR	O
,	O
17	O
-	O
k	O
##eto	O
##ster	O
##oid	O
red	O
##uc	O
##tase	O
;	O
AR	O
##NT	O
,	O
Ah	O
##R	O
nuclear	O
trans	O
##loc	O
##ator	O
;	O
CO	O
##MT	O
,	O
cat	O
##ech	O
##ol	O
-	O
O	O
-	O
met	O
##hyl	O
transfer	O
##ase	O
;	O
C	O
##YP	O
##s	O
,	O
c	O
##yt	O
##och	O
##rome	O
P	O
##45	O
##0	O
enzymes	O
;	O
DR	O
##E	O
,	O
di	B
##ox	I
##in	I
re	O
##sp	O
##ons	O
##ive	O
element	O
;	O
X	O
##AP	O
##2	O
,	O
he	O
##pa	O
##titis	O
B	O
virus	O
X	O
-	O
associated	O
protein	O
2	O
;	O
H	O
##sp	O
##90	O
,	O
90	O
-	O
k	O
##D	O
##a	O
heat	O
-	O
shock	O
protein	O
.	O

Pro	B
##line	I
for	O
example	O
was	O
detected	O
in	O
15	O
/	O
24	O
samples	O
of	O
which	O
only	O
three	O
samples	O
were	O
in	O
the	O
second	O
batch	O
and	O
none	O
of	O
these	O
were	O
above	O
L	O
##OD	O
in	O
the	O
immediate	O
re	O
##in	O
##jection	O
##s	O
or	O
delayed	O
injection	O
##s	O
.	O

On	O
the	O
contrary	O
,	O
the	O
mean	O
concentrations	O
of	O
x	B
##yl	I
##ito	I
##l	I
,	O
4	B
-	I
p	I
##hen	I
##yl	I
ace	I
##tic	I
acid	I
,	O
o	B
##le	I
##ic	I
acid	I
,	O
4	B
-	I
de	I
##ox	I
##yer	I
##yt	I
##hr	I
##ona	I
##te	I
and	O
N	B
-	I
met	I
##hyl	I
ni	I
##cot	I
##inate	I
were	O
lower	O
in	O
o	O
##bes	O
##e	O
children	O
.	O

B	O
##io	O
##in	O
##formatics	O
analysis	O
showed	O
that	O
amino	O
acids	O
of	O
285	O
Alan	B
##ine	I
and	O
28	O
##4	O
Cy	B
##stein	I
##e	I
were	O
highly	O
conserved	O
between	O
species	O
.	O

Six	O
weeks	O
of	O
si	B
##m	I
##vas	I
##tat	I
##in	I
treatment	O
resulted	O
in	O
6	O
.	O
9	O
%	O
of	O
patients	O
developing	O
h	O
##yper	O
##gly	O
##ce	O
##mia	O
and	O
25	O
%	O
developing	O
changes	O
consistent	O
with	O
development	O
of	O
pre	O
-	O
diabetes	O
.	O

In	O
the	O
urine	O
##s	O
of	O
young	O
au	O
##tist	O
##ic	O
children	O
,	O
we	O
have	O
indeed	O
observed	O
a	O
substantial	O
increase	O
of	O
x	B
##ant	I
##hur	I
##eni	I
##c	I
acid	I
and	O
especially	O
of	O
q	B
##uin	I
##olin	I
##ic	I
acid	I
,	O
parallel	O
##ed	O
by	O
a	O
decrease	O
in	O
k	B
##yn	I
##uren	I
##ine	I
and	O
k	B
##yn	I
##uren	I
##ic	I
acid	I
(	O
Fi	O
##g	O
.	O

The	O
effect	O
of	O
3	O
h	O
##rs	O
of	O
in	O
##cu	O
##bation	O
in	O
glucose	B
-	I
and	O
g	O
##lut	O
##amine	O
-	O
free	O
medium	O
on	O
the	O
percent	O
of	O
L	O
##C	O
##3	O
##II	O
measured	O
by	O
Western	O
b	O
##lot	O
##ting	O
.	O

When	O
the	O
association	O
of	O
beta	B
##ine	I
with	O
T	O
##2	O
##DM	O
development	O
was	O
assessed	O
as	O
a	O
continuous	O
variable	O
,	O
the	O
same	O
trend	O
was	O
observed	O
albeit	O
the	O
association	O
of	O
beta	B
##ine	I
with	O
incident	O
T	O
##2	O
##DM	O
did	O
not	O
reach	O
statistical	O
significance	O
in	O
the	O
fully	O
adjusted	O
model	O
.	O

Only	O
m	B
##or	I
##phine	I
will	O
be	O
detect	O
##able	O
in	O
urine	O
after	O
30	O
hours	O
following	O
a	O
single	O
dose	O
of	O
code	B
##ine	I
.	O

Among	O
the	O
pro	O
##in	O
##f	O
##lam	O
##mat	O
##ory	O
end	O
##oth	O
##eli	O
##al	O
cell	O
changes	O
that	O
occur	O
in	O
response	O
to	O
20	B
-	I
H	I
##ET	I
##E	I
are	O
increased	O
ad	O
##hesion	O
molecule	O
expression	O
and	O
c	O
##yt	O
##oki	O
##ne	O
release	O
.	O

After	O
cent	O
##ri	O
##fu	O
##gation	O
at	O
200	O
g	O
and	O
4	O
°C	O
for	O
10	O
min	O
(	O
All	O
##eg	O
##ra	O
X	O
##15	O
##R	O
,	O
Beck	O
##man	O
Co	O
##ulter	O
,	O
B	O
##rea	O
,	O
CA	O
)	O
,	O
the	O
culture	O
media	O
was	O
carefully	O
removed	O
and	O
the	O
cells	O
were	O
washed	O
twice	O
with	O
50	O
m	O
##L	O
freshly	O
-	O
prepared	O
phosphate	S
buffer	O
##ed	O
sa	B
##line	I
(	O
PBS	O
)	O
.	O

This	O
includes	O
102	O
amino	O
acid	O
meta	O
##bol	O
##ites	O
representing	O
al	B
##ani	I
##ne	I
and	O
as	B
##par	I
##tate	I
,	O
g	B
##lut	I
##ama	I
##te	I
,	O
g	B
##lut	I
##ath	I
##ione	I
,	O
g	B
##ly	I
##cine	I
,	O
se	B
##rine	I
,	O
and	O
th	B
##re	I
##oni	I
##ne	I
,	O
his	B
##ti	I
##dine	I
,	O
le	B
##uc	I
##ine	I
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
and	O
v	B
##ali	I
##ne	I
,	O
l	B
##ys	I
##ine	I
,	O
met	B
##hi	I
##oni	I
##ne	I
,	O
c	B
##ys	I
##tein	I
##e	I
,	O
SA	O
##M	O
,	O
and	O
ta	B
##uri	I
##ne	I
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
and	O
t	B
##yr	I
##os	I
##ine	I
,	O
p	B
##oly	I
##amine	I
,	O
try	B
##pt	I
##op	I
##han	I
,	O
and	O
u	B
##rea	I
cycle	O
;	O
a	B
##rg	I
##ini	I
##ne	I
and	O
pro	B
##line	I
metabolic	O
pathways	O
.	O

R	B
##ib	I
##of	I
##lav	I
##in	I
concentrations	O
were	O
not	O
significantly	O
different	O
between	O
groups	O
.	O

O	O
##xy	O
##gen	O
consumption	O
and	O
carbon	B
dioxide	I
production	O
were	O
measured	O
every	O
5	O
s	O
for	O
at	O
least	O
20	O
min	O
and	O
R	O
##EE	O
was	O
defined	O
as	O
the	O
mean	O
energy	O
expenditure	O
over	O
the	O
measured	O
period	O
.	O

In	O
addition	O
,	O
N	B
##6	I
-	I
car	I
##ba	I
##mo	I
##yl	I
##th	I
##re	I
##ony	I
##lade	I
##nos	I
##ine	I
,	O
er	B
##yt	I
##hr	I
##ona	I
##te	I
,	O
er	B
##yt	I
##hr	I
##ito	I
##l	I
,	O
ads	O
##ge	O
##g	O
##d	O
##f	O
##xa	O
##eg	O
##gg	O
##v	O
##r	O
,	O
and	O
su	B
##cci	I
##ny	I
##l	I
##car	I
##ni	I
##tine	I
were	O
represented	O
as	O
the	O
top	O
meta	O
##bol	O
##ites	O
within	O
the	O
n	O
##uc	O
##leo	O
##tide	O
,	O
car	O
##bo	O
##hy	O
##dra	O
##te	O
,	O
x	O
##eno	O
##biotic	O
,	O
p	O
##eptide	O
,	O
and	O
energy	O
meta	O
##bol	O
##ite	O
classes	O
.	O

These	O
p	O
##oly	O
##sty	O
##rene	O
tubes	O
containing	O
the	O
ta	B
##mo	I
##xi	I
##fen	I
and	O
meta	O
##bol	O
##ites	O
of	O
ta	B
##mo	I
##xi	I
##fen	I
were	O
dried	O
under	O
a	O
stream	O
of	O
nitrogen	B
gas	I
using	O
low	O
heat	O
setting	O
.	O

In	O
our	O
analysis	O
,	O
both	O
ch	B
##ole	I
##ster	I
##ol	I
and	O
T	O
##G	O
##s	O
levels	O
were	O
positively	O
associated	O
with	O
H	O
##OM	O
##A	O
-	O
I	O
##R	O
.	O

The	O
met	B
##han	I
##ol	I
used	O
for	O
extraction	O
was	O
spike	O
##d	O
with	O
the	O
following	O
compounds	O
,	O
chosen	O
to	O
en	O
##com	O
##pass	O
most	O
of	O
the	O
retention	O
time	O
-	O
m	O
/	O
z	O
space	O
covered	O
by	O
the	O
method	O
,	O
while	O
being	O
und	O
##ete	O
##cted	O
in	O
non	O
##sp	O
##ike	O
##d	O
human	O
serum	O
extract	O
##s	O
:	O
try	O
##pt	O
##op	O
##han	O
-	O
d	O
_	O
5	O
(	O
in	O
##do	O
##le	O
-	O
d	O
_	O
5	O
)	O
,	O
PC	B
(	I
13	I
:	I
0	I
/	I
0	I
:	I
0	I
)	I
,	O
NE	B
##FA	I
(	I
19	I
:	I
0	I
)	I
,	O
and	O
de	B
##hy	I
##dr	I
##och	I
##olic	I
acid	I
.	O

The	O
multi	O
-	O
element	O
ca	O
##li	O
##bra	O
##tion	O
standards	O
were	O
provided	O
at	O
the	O
concentration	O
of	O
10	O
mg	O
/	O
l	O
in	O
5	O
%	O
ni	B
##tric	I
acid	I
.	O

H	O
##ydro	O
##xy	O
##lation	O
seems	O
to	O
occur	O
at	O
the	O
met	O
##hyl	O
site	O
(	O
http	O
:	O
/	O
/	O
me	O
##d	O
.	O
as	O
##tra	O
##zen	O
##eca	O
.	O
co	O
.	O
j	O
##p	O
/	O
product	O
/	O
IF	O
/	O
AR	O
##I	O
_	O
IF	O
.	O
p	O
##d	O
##f	O
)	O
,	O
but	O
the	O
possibility	O
of	O
h	O
##ydro	O
##xy	O
##lation	O
at	O
the	O
a	O
##romatic	O
or	O
met	B
##hyl	I
##ene	I
sites	O
cannot	O
be	O
ruled	O
out	O
.	O

In	O
preparation	O
for	O
the	O
recording	O
of	O
N	O
##MR	O
s	O
##pect	O
##ra	O
,	O
75	O
##μ	O
##l	O
of	O
phosphate	S
buffer	O
were	O
added	O
to	O
67	O
##5	O
##μ	O
##l	O
of	O
urine	O
to	O
set	O
the	O
pH	O
to	O
7	O
.	O
0	O
(	O
+	O
/	O
-	O
0	O
.	O
35	O
)	O
.	O

Other	O
base	O
##line	O
variables	O
included	O
age	O
,	O
sex	O
,	O
diabetes	O
defined	O
according	O
to	O
the	O
International	O
Classification	O
of	O
Disease	O
##s	O
,	O
Ten	O
##th	O
Rev	O
##ision	O
(	O
I	O
##CD	O
-	O
10	O
)	O
codes	O
E	O
##10	O
-	O
E	O
##14	O
,	O
s	O
##ys	O
##to	O
##lic	O
blood	O
pressure	O
,	O
di	O
##ast	O
##olic	O
blood	O
pressure	O
,	O
hem	O
##og	O
##lo	O
##bin	O
,	O
album	O
##in	O
,	O
calcium	O
,	O
phosphate	S
,	O
and	O
use	O
of	O
re	O
##nin	O
-	O
an	O
##gio	O
##tens	O
##in	O
system	O
inhibitor	O
,	O
beta	O
-	O
block	O
##er	O
,	O
and	O
calcium	O
block	O
##er	O
.	O

Original	O
observations	O
in	O
this	O
co	O
##hor	O
##t	O
of	O
people	O
indicate	O
that	O
insulin	O
de	O
##p	O
##ri	O
##vation	O
decreases	O
mitochondrial	O
ATP	S
production	O
.	O

Ex	O
##ample	O
shown	O
for	O
1	B
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
.	O

Ser	B
##ine	I
was	O
significantly	O
higher	O
in	O
females	O
.	O

A	B
##rg	I
##ini	I
##ne	I
is	O
a	O
semi	O
-	O
essential	O
amino	O
acid	O
and	O
can	O
be	O
synthesized	O
from	O
g	B
##lut	I
##amine	I
.	O

In	O
earlier	O
reports	O
where	O
SP	S
meta	O
##bol	O
##ites	O
significantly	O
improved	O
C	O
##a	O
##P	O
detection	O
,	O
C	O
##a	O
##P	O
-	O
positive	O
samples	O
were	O
compared	O
with	O
healthy	O
controls	O
or	O
men	O
unlikely	O
to	O
have	O
C	O
##a	O
##P	O
,	O
suggested	O
by	O
marked	O
disc	O
##re	O
##pan	O
##cies	O
in	O
serum	O
PS	O
##A	O
between	O
groups	O
.	O

El	O
##eva	O
##ted	O
level	O
of	O
al	B
##ani	I
##ne	I
,	O
which	O
is	O
also	O
another	O
important	O
end	O
product	O
of	O
g	O
##ly	O
##co	O
##lysis	O
/	O
g	O
##lut	O
##ami	O
##no	O
##lysis	O
,	O
was	O
found	O
in	O
H	O
##NS	O
##CC	O
and	O
meta	O
##static	O
tissues	O
and	O
it	O
has	O
been	O
found	O
to	O
be	O
a	O
major	O
source	O
of	O
energy	O
in	O
tumor	O
proliferation	O
and	O
growth	O
.	O

In	O
particular	O
,	O
urine	O
s	O
##pect	O
##ra	O
are	O
dominated	O
by	O
u	B
##rea	I
,	O
c	B
##rea	I
##tin	I
##ine	I
,	O
trim	B
##eth	I
##yla	I
##mine	I
-	I
N	I
-	I
oxide	I
,	O
dim	B
##eth	I
##yla	I
##mine	I
,	O
hip	B
##pur	I
##ic	I
acid	I
,	O
and	O
c	B
##it	I
##ric	I
acid	I
resonance	O
##s	O
,	O
among	O
others	O
(	O
Fi	O
##g	O
.	O

Sa	O
##tura	O
##ted	O
serum	O
FA	O
##s	O
(	O
cap	O
##ryl	O
##ic	O
,	O
a	O
##rac	O
##hi	O
##dic	O
,	O
la	O
##uri	O
##c	O
,	O
s	O
##te	O
##ari	O
##c	O
etc	O
.	O
)	O
were	O
associated	O
with	O
lower	O
while	O
FA	O
##s	O
belonging	O
to	O
the	O
e	B
##ico	I
##san	I
##oid	I
pathway	O
(	O
is	O
##o	O
-	O
l	O
##ino	O
##le	O
##ic	O
and	O
i	O
##cos	O
##eno	O
##ic	O
acids	O
)	O
were	O
associated	O
with	O
greater	O
H	O
##E	O
.	O

It	O
is	O
well	O
known	O
that	O
VA	O
##T	O
is	O
associated	O
with	O
an	O
at	O
##her	O
##ogenic	O
,	O
d	O
##ys	O
##lip	O
##ide	O
##mic	O
lip	O
##id	O
/	O
lip	O
##op	O
##rote	O
##in	O
profile	O
,	O
including	O
high	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
,	O
low	O
HD	O
##L	O
‐	O
C	O
,	O
50	O
,	O
51	O
smaller	O
L	O
##D	O
##L	O
and	O
HD	O
##L	O
particle	O
size	O
,	O
larger	O
V	O
##LD	O
##L	O
size	O
,	O
and	O
increased	O
L	O
##D	O
##L	O
and	O
V	O
##LD	O
##L	O
particle	O
number	O
.	O
3	O
Indeed	O
,	O
in	O
our	O
study	O
,	O
HD	O
##L	O
‐	O
C	O
,	O
larger	O
HD	O
##L	O
‐	O
related	O
particles	O
,	O
and	O
plasma	O
a	O
##poli	O
##pop	O
##rote	O
##in	O
‐	O
A1	O
(	O
a	O
major	O
protein	O
component	O
of	O
HD	O
##L	O
particles	O
in	O
plasma	O
)	O
were	O
inverse	O
##ly	O
associated	O
with	O
VA	O
##T	O
,	O
whereas	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
and	O
V	O
##LD	O
##L	O
‐	O
related	O
particles	O
were	O
consistently	O
positively	O
associated	O
with	O
VA	O
##T	O
(	O
in	O
both	O
der	O
##ivation	O
and	O
replication	O
co	O
##hor	O
##ts	O
)	O
.	O

Hence	O
,	O
2	B
-	I
pen	I
##tano	I
##ne	I
could	O
stem	O
from	O
2	B
-	I
pen	I
##tano	I
##l	I
,	O
and	O
2	B
-	I
non	I
##ano	I
##ne	I
could	O
be	O
derived	O
from	O
2	B
-	I
non	I
##ano	I
##l	I
.	O

These	O
alterations	O
in	O
u	O
##rina	O
##ry	O
amino	O
acid	O
ex	O
##cre	O
##tion	O
occurred	O
several	O
days	O
before	O
changes	O
in	O
u	O
##rina	O
##ry	O
protein	O
ex	O
##cre	O
##tion	O
or	O
the	O
serum	O
concentrations	O
of	O
u	B
##rea	I
and	O
c	B
##rea	I
##tin	I
##ine	I
.	O

The	O
inter	O
-	O
run	O
precision	O
was	O
in	O
the	O
range	O
of	O
3	O
.	O
2	O
%	O
C	O
##V	O
and	O
3	O
.	O
6	O
%	O
C	O
##V	O
for	O
Ce	B
##r	I
(	I
22	I
:	I
0	I
)	I
and	O
Ce	B
##r	I
(	I
24	I
:	I
0	I
)	I
,	O
respectively	O
.	O

L	O
##C	O
-	O
MS	O
grade	O
water	O
,	O
met	B
##han	I
##ol	I
,	O
ace	B
##tone	I
and	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
were	O
purchased	O
from	O
F	O
##luk	O
##a	O
via	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
(	O
St	O
.	O
Louis	O
,	O
M	O
##O	O
)	O
.	O

The	O
clinical	O
in	O
##dices	O
for	O
the	O
diagnosis	O
of	O
se	O
##psis	O
were	O
consistent	O
with	O
consensus	O
definitions	O
for	O
severe	O
se	O
##psis	O
or	O
se	O
##ptic	O
shock	O
:	O
confirmed	O
or	O
suspected	O
infection	O
,	O
two	O
or	O
more	O
systemic	O
inflammatory	O
response	O
criteria	O
,	O
and	O
h	O
##y	O
##pop	O
##er	O
##fusion	O
evidenced	O
by	O
either	O
a	O
s	O
##ys	O
##to	O
##lic	O
blood	O
pressure	O
of	O
<	O
90	O
mm	O
##H	O
##g	O
after	O
20	O
min	O
of	O
fluid	O
re	O
##sus	O
##citation	O
or	O
a	O
blood	O
la	B
##ct	I
##ate	I
level	O
of	O
at	O
least	O
36	O
mg	O
/	O
d	O
##L	O
.	O
Blood	O
was	O
drawn	O
into	O
a	O
SS	O
##T	O
,	O
was	O
allowed	O
to	O
c	O
##lot	O
at	O
least	O
30	O
minutes	O
,	O
and	O
was	O
subsequently	O
cent	O
##ri	O
##fu	O
##ged	O
(	O
10	O
min	O
at	O
1	O
,	O
800	O
×	O
g	O
at	O
15	O
##°	O
##C	O
)	O
at	O
which	O
time	O
serum	O
was	O
al	O
##iq	O
##uo	O
##ted	O
in	O
0	O
.	O
5	O
m	O
##L	O
in	O
##cre	O
##ments	O
and	O
stored	O
(	O
-	O
80	O
##°	O
##C	O
)	O
until	O
they	O
were	O
ass	O
##ay	O
##ed	O
for	O
free	O
hem	O
##og	O
##lo	O
##bin	O
.	O

Q	O
##PC	O
##R	O
for	O
enzymes	O
regulating	O
sa	B
##rc	I
##os	I
##ine	I
levels	O
,	O
E	O
##Z	O
##H	O
##2	O
and	O
ET	O
##S	O
were	O
performed	O
as	O
described	O
using	O
indicated	O
o	O
##li	O
##gon	O
##uc	O
##leo	O
##tide	O
prime	O
##rs	O
.	O

Although	O
there	O
was	O
no	O
significant	O
difference	O
in	O
L	B
##D	I
##L	I
-	I
ch	I
##ole	I
##ster	I
##ol	I
between	O
the	O
H	O
##T	O
##G	O
and	O
N	O
##T	O
##G	O
groups	O
,	O
higher	O
o	O
##x	O
-	O
L	O
##D	O
##L	O
levels	O
were	O
observed	O
in	O
the	O
H	O
##T	O
##G	O
group	O
and	O
were	O
positively	O
correlated	O
with	O
the	O
fast	O
##ing	O
T	B
##G	I
levels	O
,	O
l	O
##ys	O
##o	O
##PC	O
##s	O
containing	O
C	B
##14	I
:	I
0	I
,	O
C	B
##16	I
:	I
0	I
,	O
and	O
C	B
##18	I
:	I
0	I
,	O
and	O
primary	O
fatty	O
acid	O
amid	O
##es	O
such	O
as	O
palm	B
##ito	I
##leam	I
##ide	I
,	O
palm	B
##itic	I
amid	I
##e	I
,	O
and	O
o	B
##leam	I
##ide	I
.	O

Some	O
NSA	O
##ID	O
##S	O
containing	O
the	O
car	B
##box	I
##yl	I
##ic	I
acid	I
m	O
##oi	O
##ety	O
undergo	O
bio	O
##act	O
##ivation	O
to	O
form	O
electro	O
##phi	O
##lic	O
a	B
##cy	I
##l	I
-	I
co	I
##en	I
##zy	I
##me	I
A	O
th	B
##io	I
##ester	I
derivatives	O
(	B
a	B
##cy	I
##l	I
-	I
Co	I
##As	I
)	O
;	O
some	O
of	O
these	O
con	O
##ju	O
##gate	O
##s	O
exhibit	O
greater	O
react	O
##ivity	O
with	O
Al	O
##b	O
than	O
AG	O
##s	O
to	O
produce	O
the	O
same	O
trans	O
##acy	O
##lated	O
add	O
##uc	O
##ts	O
.	O

The	O
LP	O
##CA	O
##T	O
##1	O
,	O
which	O
converts	O
LP	O
##C	O
into	O
PC	O
##s	O
,	O
is	O
over	O
##ex	O
##pressed	O
in	O
several	O
cancer	O
##s	O
and	O
is	O
associated	O
with	O
co	O
##lon	O
cancer	O
growth	O
(	O
,	O
)	O
showed	O
that	O
LP	O
##CA	O
##T	O
##4	O
was	O
over	O
##ex	O
##pressed	O
in	O
CR	O
##C	O
and	O
contributes	O
to	O
PC	B
(	I
16	I
:	I
0	I
/	I
16	I
:	I
1	I
)	I
accumulation	O
via	O
the	O
enhanced	O
re	O
-	O
a	O
##cy	O
##lation	O
of	O
LP	O
##C	O
.	O

The	O
AL	B
##DE	I
##FL	I
##U	I
##OR	I
ass	O
##ay	O
kit	O
(	O
01	O
##70	O
##0	O
,	O
St	O
##em	O
##C	O
##ell	O
,	O
Vancouver	O
,	O
British	O
Columbia	O
,	O
Canada	O
)	O
was	O
used	O
to	O
is	O
##olate	O
the	O
AL	O
##D	O
##H	O
_	O
hi	O
CD	O
##44	O
_	O
hi	O
and	O
AL	O
##D	O
##H	O
_	O
lo	O
CD	O
##44	O
_	O
lo	O
H	O
##NS	O
##CC	O
cells	O
according	O
to	O
the	O
manufacturer	O
’	O
s	O
instructions	O
.	O

Based	O
on	O
the	O
criteria	O
formulated	O
by	O
the	O
World	O
Health	O
Organization	O
in	O
1999	O
,	O
D	O
##M	O
is	O
characterized	O
by	O
a	O
fast	O
##ing	O
plasma	O
glucose	S
(	O
F	O
##P	O
##G	O
)	O
of	O
≥	O
7	O
.	O
0	O
mm	O
##ol	O
/	O

Alt	O
##eration	O
##s	O
in	O
his	B
##ti	I
##dine	I
metabolism	O
,	O
as	O
well	O
as	O
in	O
BC	O
##AA	O
(	B
v	B
##ali	I
##ne	I
,	O
le	B
##uc	I
##ine	I
and	O
is	B
##ole	I
##uc	I
##ine	I
)	O
metabolism	O
,	O
have	O
also	O
been	O
observed	O
in	O
other	O
cancer	O
##s	O
(	O
e	O
.	O
g	O
.	O
,	O
o	O
##var	O
##ian	O
cancer	O
,	O
breast	O
cancer	O
)	O

And	B
##ros	I
##ten	I
##ed	I
##ione	I
(	O
1	O
)	O
,	O
,	O
test	B
##osterone	I
(	O
2	O
)	O
,	O
est	B
##rone	I
(	O
E	O
_	O
1	O
)	O
su	B
##lf	I
##ate	I
(	O
3	O
)	O
,	O
E	O
_	O
2	O
(	O
4	O
)	O
,	O
E	O
_	O
1	O
(	O
5	O
)	O
,	O
2	O
-	O
OH	O
##E	O
_	O
2	O
(	O
6	O
)	O
,	O
2	O
-	O
OH	O
##E	O
_	O
1	O
(	O
7	O
)	O
,	O
16	B
##α	I
-	I
OH	I
##E	I
_	I
2	I
(	O
10	O
)	O
,	O
16	B
##α	I
-	I
OH	I
##E	I
_	I
1	I
(	O
11	O
)	O
,	O
2	O
-	O
O	O
##CH	O
_	O
3	O
E	O
_	O
2	O
(	O
12	O
)	O
,	O
2	O
-	O
O	O
##CH	O
_	O
3	O
E	O
_	O
1	O
(	O
13	O
)	O
,	O
4	O
-	O
O	O
##CH	O
_	O
3	O
E	O
_	O
2	O
(	O
14	O
)	O
,	O
4	O
-	O
O	O
##CH	O
_	O
3	O
E	O
_	O
1	O
(	O
15	O
)	O
,	O
2	B
-	I
OH	I
-	I
3	I
-	I
O	I
##CH	I
_	I
3	I
E	O
_	O
2	O
(	O
16	O
)	O
and	O
2	B
-	I
OH	I
-	I
3	I
-	I
O	I
##CH	I
_	I
3	I
E	O
_	O
1	O
(	O
17	O
)	O
were	O
purchased	O
from	O
St	O
##eral	O
##oids	O
(	O
Newport	O
,	O
R	O
##I	O
)	O
.	O

Path	O
##way	O
analysis	O
through	O
MP	O
##P	O
shows	O
the	O
alter	O
##ation	O
in	O
p	B
##hos	I
##ph	I
##ori	I
##c	I
acid	I
,	O
palm	B
##itate	I
,	O
carbon	B
dioxide	I
,	O
g	B
##ly	I
##cer	I
##ol	I
and	O
arch	O
##ido	O
##nic	O
acid	O
involved	O
in	O
fatty	O
acid	O
t	O
##ria	O
##cy	O
##l	O
##gly	O
##cer	O
##ol	O
and	O
k	B
##eton	I
##e	I
body	O
metabolism	O
between	O
controls	O
and	O
lung	O
cancer	O
as	O
shown	O
in	O
.	O

It	O
can	O
be	O
assumed	O
that	O
an	O
in	O
##hibition	O
of	O
SD	O
##H	O
by	O
Ph	O
##CA	O
##s	O
can	O
occur	O
in	O
v	O
##ivo	O
,	O
since	O
these	O
compounds	O
,	O
being	O
mon	B
##oc	I
##ar	I
##box	I
##yla	I
##tes	I
,	O
easily	O
penetrate	O
into	O
cells	O
through	O
the	O
mon	B
##oc	I
##ar	I
##box	I
##yl	I
##ic	I
acid	I
transport	O
##er	O
of	O
an	O
MC	O
##T	O
-	O
mediated	O
transport	O
system	O
,	O
which	O
also	O
transports	O
p	B
##yr	I
##u	I
##vate	I
and	O
amino	O
acids	O
[	O
,	O
]	O
.	O

End	O
##ogen	O
##ous	O
est	O
##rogen	O
##s	O
and	O
est	B
##rogen	I
meta	O
##bol	O
##ites	O
were	O
found	O
in	O
all	O
NC	O
##I	O
-	O
60	O
human	O
tumor	O
cell	O
lines	O
and	O
some	O
were	O
substantially	O
elevated	O
and	O
exceeded	O
the	O
levels	O
found	O
in	O
well	O
known	O
est	O
##rogen	O
-	O
dependent	O
and	O
est	B
##rogen	I
receptor	O
-	O
positive	O
tumor	O
cells	O
such	O
as	O
MC	O
##F	O
-	O
7	O
and	O
T	O
-	O
47	O
##D	O
.	O
While	O
est	O
##rogen	O
##s	O
were	O
expected	O
to	O
be	O
present	O
at	O
high	O
levels	O
in	O
cell	O
lines	O
representing	O
the	O
female	O
reproductive	O
system	O
(	O
that	O
is	O
,	O
breast	O
and	O
o	O
##var	O
##ian	O
)	O
,	O
other	O
cell	O
lines	O
,	O
such	O
as	O
le	O
##uke	O
##mia	O
and	O
co	O
##lon	O
,	O
also	O
contained	O
very	O
high	O
levels	O
of	O
these	O
s	O
##tero	O
##id	O
hormones	O
.	O

Thus	O
the	O
Tor	O
##us	O
columns	O
,	O
and	O
in	O
particular	O
the	O
Di	B
##ol	I
column	O
,	O
offer	O
improved	O
resolution	O
due	O
to	O
narrower	O
peak	O
base	O
width	O
##s	O
for	O
all	O
classes	O
of	O
polar	O
anal	O
##yte	O
,	O
and	O
a	O
relatively	O
even	O
distribution	O
of	O
peaks	O
across	O
the	O
retention	O
time	O
range	O
.	O

The	O
analytical	O
measurement	O
range	O
of	O
the	O
c	B
##rea	I
##tin	I
##ine	I
in	O
urine	O
was	O
250	O
–	O
35	O
,	O
400	O
μ	O
##M	O
.	O

(	O
)	O
High	O
plasma	O
levels	O
of	O
two	O
other	O
p	B
##yr	I
##im	I
##id	I
##ine	I
derivatives	O
that	O
are	O
closely	O
correlated	O
with	O
plasma	O
levels	O
of	O
pseudo	B
##uri	I
##dine	I
also	O
increased	O
the	O
risk	O
of	O
E	O
##SR	O
##D	O
progression	O
(	O
N	O
##2	O
,	O
N	B
##2	I
-	I
dim	I
##eth	I
##yl	I
##gua	I
##nos	I
##ine	I
,	O
and	O
N	B
##4	I
-	I
ace	I
##ty	I
##l	I
##cy	I
##ti	I
##dine	I
)	O
.	O

The	O
significant	O
elevation	O
of	O
la	B
##ct	I
##ate	I
and	O
g	O
##lu	O
##co	O
##genic	O
amino	O
acids	O
and	O
the	O
reduction	O
of	O
glucose	S
in	O
PC	O
##OS	O
plasma	O
implied	O
elevated	O
g	O
##ly	O
##co	O
##lysis	O
in	O
muscle	O
and	O
decreased	O
g	O
##lu	O
##con	O
##eo	O
##genesis	O
in	O
liver	O
during	O
PC	O
##OS	O
path	O
##ogen	O
##esis	O
.	O

The	O
clinical	O
value	O
of	O
these	O
met	B
##hi	I
##oni	I
##ne	I
meta	O
##bol	O
##ites	O
as	O
bio	O
##mark	O
##ers	O
would	O
be	O
to	O
significantly	O
increase	O
the	O
ability	O
to	O
predict	O
aggressive	O
pro	O
##state	O
cancer	O
features	O
and	O
early	O
bio	O
##chemical	O
re	O
##cu	O
##rrence	O
over	O
and	O
above	O
exist	O
##ent	O
clinical	O
variables	O
including	O
serum	O
PS	O
##A	O
,	O
bio	O
##psy	O
G	O
##lea	O
##son	O
score	O
,	O
and	O
clinical	O
stage	O
.	O

HC	O
##V	O
plasma	O
,	O
similarly	O
,	O
differed	O
from	O
the	O
control	O
plasma	O
with	O
increased	O
lip	O
##ids	O
(	B
o	B
##leam	I
##ide	I
,	O
palm	B
##ito	I
##le	I
##ic	I
acid	I
,	O
and	O
o	O
##le	O
##ic	O
acid	O
)	O
;	O
increased	O
sugar	O
##s	O
,	O
namely	O
,	O
glucose	S
and	O
man	B
##nose	I
;	O
decreased	O
la	B
##ctic	I
acid	I
;	O
and	O
decreased	O
amino	O
acids	O
,	O
namely	O
,	O
pro	B
##line	I
and	O
the	O
essential	O
branched	O
-	O
chain	O
amino	O
acids	O
(	O
BC	O
##AA	O
##s	O
)	O
,	O
v	B
##ali	I
##ne	I
,	O
le	B
##uc	I
##ine	I
,	O
and	O
is	B
##ole	I
##uc	I
##ine	I
.	O

Since	O
previous	O
studies	O
have	O
shown	O
that	O
fewer	O
individuals	O
are	O
required	O
for	O
measuring	O
changes	O
in	O
f	O
##ae	O
##cal	O
bi	O
##fi	O
##do	O
##ba	O
##cter	O
##ia	O
and	O
because	O
of	O
its	O
clinical	O
significance	O
,	O
the	O
sample	O
size	O
calculation	O
was	O
performed	O
only	O
for	O
changes	O
in	O
L	B
##D	I
##L	I
ch	I
##ole	I
##ster	I
##ol	I
levels	O
.	O

We	O
presented	O
group	O
differences	O
in	O
sleep	O
in	O
##dices	O
and	O
co	B
##rt	I
##is	I
##ol	I
levels	O
in	O
a	O
previous	O
publication	O
.	O

[	O
Google	O
Scholar	O
]	O
Fish	O
##man	O
J	O
,	O
Boy	O
##ar	O
R	B
##M	I
,	O
Hell	O
##man	O
L	O
.	O
In	O
##f	O
##lue	O
##nce	O
of	O
body	O
weight	O
on	O
est	B
##rad	I
##iol	I
metabolism	O
in	O
young	O
women	O
.	O

Although	O
the	O
mechanisms	O
responsible	O
for	O
the	O
formation	O
of	O
the	O
eccentric	O
c	O
##lea	O
##vage	O
products	O
of	O
β	B
-	I
car	I
##ote	I
##ne	I
in	O
mammals	O
are	O
not	O
fully	O
known	O
,	O
it	O
is	O
clear	O
that	O
some	O
of	O
the	O
long	O
chain	O
β	B
-	I
a	I
##po	I
##car	I
##ote	I
##nal	I
##s	I
(	O
e	O
.	O
g	O
.	O
8	O
′	O
,	O
10	O
′	O
,	O
12	O
′	O
,	O
14	O
′	O
)	O
are	O
found	O
in	O
the	O
plasma	O
of	O
humans	O
and	O
experimental	O
animals	O
and	O
that	O
these	O
are	O
increased	O
under	O
conditions	O
of	O
o	O
##xi	O
##da	O
##tive	O
stress	O
and	O
high	O
diet	O
##ary	O
doses	O
of	O
β	B
-	I
car	I
##ote	I
##ne	I
.	O

Fr	O
##ag	O
##mentation	O
of	O
9	B
-	I
H	I
##SA	I
-	I
T	I
##MS	I
yielded	O
the	O
m	O
/	O
z	O
73	O
fragment	O
that	O
is	O
common	O
to	O
all	O
T	O
##MS	O
derivatives	O
,	O
plus	O
two	O
diagnostic	O
fragments	O
of	O
m	O
/	O
z	O
229	O
and	O
25	O
##9	O
,	O
which	O
represent	O
the	O
fragment	O
##ation	O
of	O
the	O
molecule	O
at	O
both	O
sides	O
of	O
the	O
carbon	O
carrying	O
the	O
h	O
##ydro	O
##xy	O
##l	O
group	O
(	O
B	O
,	O
noted	O
in	O
orange	O
)	O
.	O

Various	O
meta	O
##bol	O
##ites	O
related	O
to	O
vitamin	B
E	I
metabolism	O
displayed	O
changes	O
with	O
le	O
##pt	O
##in	O
therapy	O
.	O

Although	O
only	O
slightly	O
,	O
Cho	B
##E	I
(	I
18	I
:	I
2	I
)	I
correlated	O
directly	O
with	O
the	O
F	O
##O	O
##B	O
parameter	O
(	O
Su	O
##pp	O
##lement	O
##ary	O
Table	O
S	O
##3	O
)	O
.	O

In	O
sampling	O
methods	O
1	O
and	O
2	O
,	O
cold	O
ethanol	S
was	O
added	O
to	O
the	O
CS	O
##F	O
during	O
the	O
sample	O
handling	O
to	O
den	O
##ature	O
proteins	O
and	O
to	O
be	O
able	O
to	O
th	O
##aw	O
the	O
samples	O
before	O
measurements	O
at	O
lower	O
temperatures	O
.	O

These	O
include	O
negative	O
correlation	O
##s	O
to	O
CD	O
##CA	O
and	O
positive	O
correlation	O
##s	O
to	O
L	O
##CA	O
in	O
good	O
respond	O
##ers	O
;	O
and	O
,	O
in	O
poor	O
respond	O
##ers	O
,	O
negative	O
correlation	O
##s	O
to	O
both	O
secondary	O
bi	O
##le	O
acids	O
(	O
DC	O
##A	O
and	O
L	O
##CA	O
)	O
that	O
were	O
positively	O
correlated	O
to	O
si	B
##m	I
##vas	I
##tat	I
##in	I
acid	I
levels	O
in	O
good	O
and	O
normal	O
range	O
respond	O
##ers	O
.	O

Moreover	O
,	O
in	O
the	O
pan	O
##cre	O
##as	O
,	O
GA	B
##BA	I
is	O
produced	O
primarily	O
by	O
insulin	O
-	O
secret	O
##ing	O
beta	O
cells	O
,	O
and	O
the	O
release	O
of	O
GA	B
##BA	I
from	O
these	O
cells	O
appears	O
to	O
be	O
regulated	O
by	O
glucose	S
.	O

At	O
##rac	O
##ty	O
##li	O
##gen	O
##in	O
g	B
##lu	I
##cu	I
##ron	I
##ide	I
was	O
the	O
strongest	O
disc	O
##rim	O
##ina	O
##nt	O
in	O
the	O
study	O
(	O
p	O
-	O
value	O
=	O
7	O
.	O
47	O
##×	O
##10	O
_	O
−	O
##9	O
,	O
VIP	O
=	O
2	O
.	O
98	O
)	O
,	O
and	O
also	O
demonstrated	O
the	O
greatest	O
mean	O
difference	O
in	O
intensity	O
between	O
high	O
and	O
low	O
-	O
consumers	O
(	O
17	O
-	O
fold	O
)	O
.	O

Although	O
abnormal	O
a	B
##rg	I
##ini	I
##ne	I
levels	O
in	O
breast	O
cancer	O
without	O
meta	O
##sta	O
##sis	O
were	O
observed	O
,	O
the	O
same	O
metabolic	O
changes	O
were	O
shown	O
in	O
a	O
pool	O
##ed	O
group	O
of	O
patients	O
with	O
co	O
##lon	O
##ic	O
and	O
pan	O
##cre	O
##atic	O
cancer	O
with	O
/	O
without	O
meta	O
##sta	O
##sis	O
(	O
V	O
##isse	O
##rs	O
et	O
al	O
.	O
)	O
.	O

nuclei	O
have	O
documented	O
increased	O
levels	O
of	O
total	O
ch	B
##olin	I
##e	I
containing	O
compounds	O
,	O
p	B
##hos	I
##ph	I
##omo	I
##no	I
##ester	I
##s	I
and	O
p	B
##hos	I
##ph	I
##odies	I
##ters	I
in	O
human	O
breast	O
cancer	O
tissues	O
,	O
which	O
is	O
in	O
##dicative	O
of	O
altered	O
ch	B
##olin	I
##e	I
and	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
metabolism	O
.	O

Alto	O
##get	O
##her	O
,	O
our	O
data	O
suggest	O
that	O
pathways	O
related	O
to	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
and	O
ne	O
##uro	O
##de	O
##gene	O
##ration	O
are	O
altered	O
in	O
the	O
plasma	O
of	O
patients	O
of	O
AM	O
##D	O
and	O
may	O
be	O
important	O
in	O
the	O
path	O
##ogen	O
##esis	O
of	O
this	O
ne	O
##uro	O
##de	O
##gene	O
##rative	O
disease	O
.	O

However	O
,	O
T	O
##N	O
##M	O
staging	O
(	O
p	O
<	O
0	O
.	O
00	O
##5	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
95	O
%	O
C	O
##I	O
)	O
1	O
.	O
00	O
##2	O
-	O
1	O
.	O
03	O
##4	O
)	O
,	O
2	B
,	I
4	I
-	I
he	I
##xa	I
##die	I
##no	I
##ic	I
acid	I
(	O
p	O
<	O
0	O
.	O
00	O
##5	O
,	O
95	O
%	O
C	O
##I	O
1	O
.	O
00	O
##2	O
-	O
1	O
.	O
02	O
##7	O
)	O
,	O
4	B
-	I
met	I
##hyl	I
##phe	I
##ny	I
##l	I
do	I
##de	I
##cano	I
##ate	I
(	O
p	O
<	O
0	O
.	O
00	O
##5	O
,	O
95	O
%	O
C	O
##I	O
1	O
.	O
00	O
##2	O
-	O
1	O
.	O
00	O
##1	O
)	O
and	O
g	B
##ly	I
##cer	I
##ol	I
t	I
##ri	I
##but	I
##ano	I
##ate	I
(	O
p	O
<	O
0	O
.	O
00	O
##5	O
,	O
95	O
%	O
C	O
##I	O
1	O
.	O
00	O
##2	O
-	O
1	O
.	O
03	O
##2	O
)	O
were	O
subsequently	O
confirmed	O
to	O
be	O
independent	O
pro	O
##gno	O
##stic	O
factors	O
of	O
G	O
##C	O
,	O
by	O
using	O
multi	O
##var	O
##iate	O
CO	O
##X	O
re	O
##gression	O
analysis	O
(	O
Table	O
)	O
.	O

This	O
was	O
performed	O
for	O
_	O
13	O
C	B
-	I
2	I
,	I
3	I
-	I
su	I
##cci	I
##nate	I
of	O
patients	O
#	O
6	O
–	O
10	O
by	O
integrating	O
the	O
volume	O
of	O
its	O
H	O
##S	O
##Q	O
##C	O
cross	O
-	O
peak	O
(	O
c	O
##f	O
.	O

The	O
up	O
-	O
regulation	O
of	O
u	O
##rina	O
##ry	O
u	B
##ro	I
##can	I
##ic	I
acid	I
could	O
result	O
from	O
a	O
his	B
##ti	I
##dine	I
metabolism	O
disorder	O
in	O
tumor	O
tissue	O
and	O
/	O
or	O
a	O
g	B
##lut	I
##ami	I
##c	I
acid	I
metabolism	O
disorder	O
.	O

[	O
M	O
+	O
H	O
]	O
_	O
+	O
of	O
PC	B
##34	I
:	I
1	I
.	O

One	O
of	O
them	O
,	O
para	B
-	I
amino	I
##hip	I
##pur	I
##ic	I
acid	I
,	O
is	O
a	O
well	O
-	O
established	O
diagnostic	O
marker	O
for	O
re	O
##nal	O
plasma	O
flow	O
and	O
g	O
##lo	O
##mer	O
##ular	O
fi	O
##ltration	O
(	O
Re	O
##ubi	O
)	O
.	O

Total	O
experiment	O
time	O
was	O
6	O
h	O
.	O
a	O
,	O
b	O
al	B
##ip	I
##hat	I
##ic	I
region	O
.	O

Effect	O
of	O
freezing	O
on	O
pH	O
of	O
urine	O
samples	O
.	O
pH	O
values	O
were	O
determined	O
in	O
buffer	O
##ed	O
urine	O
samples	O
with	O
a	O
final	O
concentration	O
of	O
150	O
m	O
##M	O
phosphate	S
buffer	O
after	O
N	O
##MR	O
experiments	O
.	O

226	O
.	O
9	O
→	O
m	O
/	O
z	O
185	O
.	O
9	O
for	O
BP	O
##A	O
,	O
m	O
/	O
z	O
286	O
.	O
2	O
→	O
m	O
/	O
z	O
245	O
for	O
re	B
##tino	I
##l	I
and	O
m	O
/	O
z	O
116	O
→	O
m	O
/	O
z	O
69	O
.	O
9	O
for	O
L	B
-	I
pro	I
##line	I
.	O

Tam	B
##ox	I
##ife	I
##n	I
and	O
its	O
meta	O
##bol	O
##ites	O
were	O
measured	O
by	O
liquid	O
ch	O
##roma	O
##tography	O
-	O
tandem	O
mass	O
s	O
##pect	O
##rome	O
##try	O
.	O

For	O
C	O
##V	O
##2	O
,	O
Xi	O
matrices	O
were	O
randomly	O
split	O
into	O
2	O
sub	O
##mat	O
##rice	O
##s	O
Xi	O
##cal	O
(	O
A	O
,	O
J	O
)	O
and	O
Xi	O
##test	O
(	O
B	O
,	O
J	O
)	O
,	O
with	O
A	O
=	O
17	O
,	O
12	O
,	O
or	O
9	O
,	O
and	O
B	O
=	O
5	O
,	O
4	O
,	O
or	O
2	O
,	O
for	O
either	O
r	B
##is	I
##per	I
##ido	I
##ne	I
,	O
o	B
##lan	I
##za	I
##pine	I
,	O
and	O
que	B
##tia	I
##pine	I
,	O
respectively	O
.	O

Ex	O
##act	O
mass	O
measurement	O
using	O
electro	O
##sp	O
##ray	O
ion	O
##ization	O
mass	O
s	O
##pect	O
##rome	O
##try	O
(	O
E	O
##SI	O
-	O
TO	O
##FM	O
##S	O
)	O
in	O
the	O
simultaneous	O
negative	O
and	O
positive	O
mode	O
resulted	O
in	O
the	O
identification	O
of	O
different	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
in	O
the	O
met	B
##han	I
##ol	I
fraction	O
##s	O
from	O
human	O
urine	O
.	O

Li	O
##pid	O
##omi	O
##cs	O
studies	O
of	O
ex	O
##oso	O
##mes	O
generated	O
from	O
pro	O
##state	O
cancer	O
3	O
(	O
PC	O
-	O
3	O
)	O
cells	O
specifically	O
identified	O
two	O
PS	O
lip	O
##ids	O
,	O
PS	B
(	I
18	I
:	I
0	I
_	I
18	I
:	I
1	I
)	I
and	O
PS	B
(	I
18	I
:	I
0	I
_	I
22	I
:	I
6	I
)	I
,	O
that	O
were	O
elevated	O
and	O
exclusively	O
identified	O
in	O
ex	O
##oso	O
##mes	O
vs	O
.	O
the	O
parent	O
cells	O
,	O
respectively	O
.	O

(	O
a	O
)	O
Per	O
##cent	O
anal	O
##ges	O
##ic	O
effect	O
of	O
1	O
at	O
50	O
,	O
100	O
and	O
200	O
mg	O
/	O
kg	O
body	O
weight	O
(	O
b	O
)	O
Per	O
##cent	O
anal	O
##ges	O
##ic	O
effect	O
of	O
the	O
di	B
##ch	I
##lor	I
##ome	I
##than	I
##e	I
extract	O
at	O
50	O
,	O
100	O
,	O
and	O
200	O
mg	O
/	O
kg	O
body	O
weight	O
(	O
c	O
)	O
Per	O
##cent	O
anal	O
##ges	O
##ic	O
effect	O
of	O
the	O
a	O
##que	O
##ous	O
extract	O
at	O
50	O
,	O
100	O
,	O
and	O

The	O
production	O
of	O
BC	O
##FA	O
and	O
p	B
##hen	I
##yla	I
##ce	I
##tate	I
in	O
co	O
##lon	O
##ic	O
car	O
##cin	O
##ogen	O
##esis	O
warrant	O
##s	O
further	O
investigations	O
.	O

Association	O
of	O
urine	O
s	B
##phi	I
##ngo	I
##sin	I
##e	I
level	O
(	O
a	O
)	O
at	O
the	O
basal	O
status	O
with	O
H	O
##LA	O
-	O
DB	O
##P	O
##1	O
*	O
03	O
##01	O
and	O
(	O
b	O
)	O
at	O
onset	O
of	O
reaction	O
symptoms	O
after	O
the	O
AS	O
##A	O
-	O
BP	O
##T	O
test	O
with	O
C	O
##Y	O
##SL	O
##TR	O
##1	O
-	O
63	O
##4	O
##C	O
>	O
T	O
p	O
##oly	O
##mor	O
##phism	O
.	O

Moreover	O
,	O
the	O
E	O
##Vs	O
had	O
higher	O
l	B
##ys	I
##og	I
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
levels	O
than	O
HD	O
##L	O
or	O
L	O
##D	O
##L	O
/	O
V	O
##LD	O
##L	O
.	O

Lo	O
##g	O
-	O
transformed	O
u	O
##rina	O
##ry	O
my	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
significantly	O
increased	O
as	O
e	O
##G	O
##F	O
##R	O
decreased	O

These	O
alterations	O
are	O
inform	O
##ative	O
both	O
to	O
indicate	O
the	O
presence	O
of	O
HC	O
##V	O
/	O
path	O
##ological	O
state	O
bio	O
##mark	O
##ers	O
in	O
infected	O
serum	O
samples	O
(	O
e	O
.	O
g	O
.	O
2	B
-	I
o	I
##x	I
##og	I
##lut	I
##arate	I
,	O
3	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
,	O
ace	B
##tate	I
,	O
and	O
format	O
##e	O
)	O
,	O
and	O
for	O
the	O
effect	O
of	O
the	O
therapy	O
on	O
patients	O
’	O
metabolism	O
.	O

Mi	O
##to	O
##cho	O
##nd	O
##ria	O
(	O
0	O
.	O
5	O
mg	O
protein	O
/	O
m	O
##L	O
)	O
were	O
in	O
##cu	O
##bate	O
##d	O
in	O
2	O
m	O
##L	O
of	O
medium	O
containing	O
125	O
m	O
##M	O
KC	O
##l	O
,	O
15	O
m	O
##M	O
H	O
##EP	O
##ES	O
,	O
pH	O
7	O
.	O
4	O
in	O
the	O
presence	O
of	O
1	O
m	O
##M	O
c	B
##yan	I
##ide	I
,	O
20	O
μ	O
##L	O
of	O
10	O
%	O
Tri	O
##ton	O
X	O
-	O
100	O
,	O
100	O
μ	O
##M	O
DC	O
##PI	O
##P	O
.	O

For	O
G	O
##C	O
-	O
MS	O
analysis	O
,	O
50	O
mg	O
tissue	O
and	O
50	O
μ	O
##l	O
serum	O
with	O
internal	O
standard	O
2	B
-	I
is	I
##op	I
##rop	I
##yl	I
-	I
ma	I
##lic	I
acid	I
(	O
15	O
μ	O
##l	O
from	O
1	O
.	O
0	O
mg	O
/	O
m	O
##L	O
)	O
was	O
taken	O
and	O
meta	O
##bol	O
##ites	O
were	O
extracted	O
similar	O
to	O
L	O
##C	O
-	O
MS	O
.	O

Then	O
,	O
0	O
.	O
2	O
m	O
##L	O
of	O
the	O
clear	O
super	O
##nat	O
##ant	O
were	O
transferred	O
in	O
a	O
clean	O
2	O
-	O
m	O
##L	O
96	O
-	O
well	O
plate	O
,	O
di	O
##lut	O
##ed	O
with	O
other	O
0	O
.	O
2	O
m	O
##L	O
water	O
containing	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
and	O
injected	O
in	O
the	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
system	O
.	O

Basel	O
##ine	O
characteristics	O
of	O
the	O
co	O
##hor	O
##t	O
classified	O
by	O
outcome	O
status	O
Value	O
##s	O
are	O
mean	O
±	O
##SD	O
,	O
median	O
(	O
inter	O
##qua	O
##rt	O
##ile	O
range	O
)	O
or	O
n	O
(	O
%	O
)	O
AN	O
##Z	O
,	O
Australia	O
and	O
New	O
Zealand	O
;	O
SE	O
##A	O
,	O
south	O
-	O
east	O
Asia	O
Among	O
the	O
amino	O
acids	O
,	O
after	O
adjustment	O
for	O
age	O
,	O
sex	O
,	O
region	O
and	O
random	O
##ised	O
treatment	O
(	O
model	O
1	O
)	O
,	O
higher	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
and	O
lower	O
g	B
##lut	I
##amine	I
and	O
his	B
##ti	I
##dine	I
concentrations	O
were	O
associated	O
with	O
increased	O
mac	O
##rov	O
##as	O
##cular	O
risk	O
(	O
H	O
##R	O
per	O
1	O
SD	O
increase	O
was	O
1	O
.	O
22	O
[	O
95	O
%	O
C	O
##I	O
1	O
.	O
12	O
,	O
1	O
.	O
32	O
]	O
,	O
0	O
.	O
88	O
[	O
95	O
%	O
C	O
##I	O
0	O
.	O
79	O
,	O
0	O
.	O
98	O
]	O
and	O
0	O
.	O
86	O
[	O
95	O
%	O
C	O
##I	O
0	O
.	O
79	O
,	O
0	O
.	O
94	O
]	O
,	O
respectively	O
)	O
but	O
these	O
associations	O
were	O
at	O
##ten	O
##uated	O
to	O
the	O
null	O
on	O
further	O
adjustment	O
for	O
classical	O
risk	O
factors	O
(	O
model	O
2	O
)	O
(	O

Thus	O
,	O
it	O
is	O
worth	O
assessing	O
the	O
relationship	O
between	O
im	B
##ati	I
##ni	I
##b	I
dos	O
##age	O
(	O
and	O
its	O
levels	O
in	O
the	O
blood	O
)	O
and	O
the	O
efficacy	O
of	O
treatment	O
(	O
measured	O
by	O
CC	O
##R	O
and	O
M	O
##MR	O
)	O
as	O
a	O
means	O
of	O
t	O
##it	O
##rating	O
the	O
dose	O
to	O
reduce	O
adverse	O
side	O
effects	O
while	O
maintaining	O
the	O
benefits	O
of	O
treatment	O
.	O

Unlike	O
P	O
##K	O
##M	O
##1	O
,	O
the	O
normal	O
is	O
##of	O
##orm	O
,	O
P	O
##K	O
##M	O
##2	O
can	O
be	O
in	O
##hibit	O
##ed	O
,	O
which	O
blocks	O
p	B
##yr	I
##u	I
##vate	I
formation	O
at	O
the	O
end	O
of	O
the	O
g	B
##ly	I
##co	I
##ly	I
##tic	I
pathway	O
and	O
con	O
##serve	O
##s	O
g	B
##ly	I
##co	I
##ly	I
##tic	I
intermediate	O
##s	O
for	O
an	O
##ab	O
##olis	O
##m	O
(	O
see	O
)	O
.	O

After	O
del	O
##eting	O
out	O
##liers	O
,	O
there	O
were	O
55	O
at	O
##rial	O
app	O
##end	O
##age	O
samples	O
(	O
25	O
from	O
A	B
##F	I
patients	O
and	O
30	O
from	O
non	O
-	O
A	O
##F	O
patients	O
)	O
and	O
120	O
plasma	O
samples	O
(	O
36	O
from	O
A	B
##F	I
patients	O
and	O
84	O
from	O
non	O
-	O
A	O
##F	O
patients	O
)	O
in	O
our	O
meta	O
##bol	O
##omi	O
##cs	O
analysis	O
study	O
.	O

The	O
eight	O
meta	O
##bol	O
##ites	O
selected	O
were	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
ch	I
##olin	I
##e	I
PC	I
(	I
16	I
:	I
0	I
/	I
16	I
:	I
0	I
)	I
,	O
g	B
##lu	I
##cos	I
##yl	I
##cer	I
##ami	I
##de	I
G	I
##C	I
(	I
18	I
:	I
1	I
/	I
16	I
:	I
0	I
)	I
,	O
1	O
-	O
P	O
##5	O
##C	O
,	O
FA	O
##D	O
,	O
p	B
##yr	I
##og	I
##lut	I
##ami	I
##c	I
acid	I
(	O
also	O
known	O
as	O
5	B
-	I
o	I
##x	I
##op	I
##rol	I
##ine	I
)	O
,	O
2	B
-	I
h	I
##ydro	I
##xy	I
##is	I
##oc	I
##ap	I
##roi	I
##c	I
acid	I
(	O
H	O
##IC	O
##A	O
)	O
,	O
l	B
-	I
se	I
##rine	I
,	O
and	O
la	B
##th	I
##ost	I
##ero	I
##l	I
.	O

Peak	O
##s	O
due	O
to	O
the	O
ma	B
##lon	I
##yl	I
-	I
and	O
ace	B
##ty	I
##l	I
β	I
-	I
g	I
##lu	I
##cos	I
##ides	I
were	O
expressed	O
in	O
a	B
##gly	I
##con	I
##e	I
units	O
.	O

We	O
have	O
also	O
collected	O
data	O
on	O
bio	O
##chemical	O
and	O
cardiac	O
markers	O
including	O
c	B
##rea	I
##tine	I
kinase	O
(	O
C	O
##K	O
)	O
and	O
high	O
sensitivity	O
t	O
##rop	O
##oni	O
##n	O
(	O
T	O
##n	O
##T	O
)	O
for	O
these	O
patients	O
.	O

Met	B
##had	I
##one	I
has	O
favourable	O
characteristics	O
,	O
both	O
with	O
respect	O
to	O
p	O
##har	O
##ma	O
##co	O
##dynamic	O
##s	O
(	O
faster	O
onset	O
of	O
effect	O
,	O
long	O
duration	S
of	O
action	O
,	O
incomplete	O
cross	O
tolerance	O
towards	O
m	B
##or	I
##phine	I
,	O
and	O
possible	O
effects	O
on	O
N	O
##MD	O
##A	O
receptors	O
)	O
and	O
p	O
##har	O
##ma	O
##co	O
##kin	O
##etics	O
(	O
faster	O
absorption	O
,	O
long	O
half	O
-	O
life	O
,	O
no	O
active	O
or	O
toxic	O
meta	O
##bol	O
##ites	O
and	O
little	O
dependence	O
on	O
meta	O
##bol	O
##ite	O
re	O
##nal	O
ex	O
##cre	O
##tion	O
)	O
compared	O
to	O
m	B
##or	I
##phine	I
.	O

−	O
0	O
.	O
35	O
##3	O
)	O
and	B
##ros	I
##ten	I
##ed	I
##ione	I
(	O
r	O
_	O
s	O
=	O

(	O
D	O
)	O
C	B
##af	I
##fe	I
##ine	I
metabolism	O
.	O

In	O
our	O
study	O
,	O
decreased	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
and	O
x	B
##ant	I
##hine	I
levels	O
,	O
and	O
increased	O
u	B
##ric	I
acid	I
levels	O
were	O
observed	O
in	O
T	O
##2	O
##DM	O
and	O
D	O
##AC	O
##D	O
patients	O
as	O
shown	O
in	O
,	O
although	O
,	O
eliminating	O
u	B
##ric	I
acid	I
in	O
D	O
##AC	O
##D	O
and	O
x	B
##ant	I
##hine	I
in	O
T	O
##2	O
##DM	O
after	O
F	O
##DR	O
correction	O
##s	O
,	O
which	O
was	O
consistent	O
with	O
that	O
in	O
T	O
##2	O
##DM	O
and	O
vascular	O
dem	O
##ent	O
##ia	O
patients	O
,	O
as	O
reported	O
previously	O
[	O
,	O
]	O
.	O

We	O
also	O
compared	O
the	O
panel	O
derived	O
in	O
this	O
work	O
(	B
β	B
-	I
al	I
##ani	I
##ne	I
,	O
2	B
,	I
4	I
-	I
di	I
##hy	I
##dr	I
##ox	I
##y	I
##py	I
##rim	I
##id	I
##ine	I
,	O
a	B
##zel	I
##aic	I
acid	I
,	O
pseudo	B
##uri	I
##dine	I
,	O
and	O
α	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
)	O
with	O
a	O
composite	O
panel	O
directly	O
generated	O
by	O
the	O
five	O
bio	O
##mark	O
##ers	O
identified	O
in	O
our	O
previous	O
studies	O
_	O
,	O
.	O

In	O
this	O
study	O
,	O
in	O
addition	O
to	O
a	B
##rg	I
##ini	I
##ne	I
,	O
serum	O
g	B
##lut	I
##ama	I
##te	I
levels	O
in	O
patients	O
with	O
PR	O
were	O
also	O
significantly	O
higher	O
than	O
those	O
in	O
patients	O
with	O
G	O
##R	O
.	O

The	O
decreased	O
u	O
##rina	O
##ry	O
c	B
##it	I
##rate	I
in	O
the	O
pan	O
##cre	O
##ati	O
##tis	O
co	O
##hor	O
##ts	O
compared	O
to	O
healthy	O
subjects	O
may	O
be	O
associated	O
with	O
decreased	O
c	B
##it	I
##rate	I
in	O
pan	O
##cre	O
##atic	O
secret	O
##ions	O
due	O
to	O
alcohol	O
metabolism	O
.	O

However	O
,	O
su	O
##l	O
##phate	O
-	O
reducing	O
bacteria	O
can	O
convert	O
ethanol	S
to	O
ace	B
##tate	I
,	O
and	O
this	O
could	O
therefore	O
have	O
occurred	O
con	O
##com	O
##ita	O
##nt	O
with	O
the	O
production	O
of	O
higher	O
organic	O
acids	O
.	O

So	B
##dium	I
h	I
##ydro	I
##xi	I
##de	I
,	O
sodium	O
bi	O
##car	O
##bon	O
##ate	O
and	O
an	B
##hy	I
##dr	I
##ous	I
sodium	I
su	I
##lf	I
##ate	I
were	O
of	O
analytical	O
grade	O
and	O
obtained	O
from	O
J	O
##T	O
Baker	O
Co	O
.	O
(	O
Phillips	O
##burg	O
,	O
NJ	O
)	O
.	O

The	O
select	O
##ivity	O
of	O
the	O
method	O
was	O
established	O
by	O
the	O
analysis	O
of	O
blank	O
human	O
plasma	O
from	O
five	O
different	O
donors	O
(	O
including	O
two	O
lip	O
##em	O
##ic	O
plasma	O
samples	O
)	O
and	O
two	O
pool	O
##ed	O
regular	O
plasma	O
samples	O
(	O
n	O
=	O
7	O
)	O
,	O
all	O
processed	O
with	O
pure	O
Me	B
##OH	I
.	O

Since	O
2006	O
,	O
the	O
US	O
Food	O
and	O
Drug	O
Administration	O
and	O
the	O
European	O
Medicine	O
##s	O
Agency	O
have	O
approved	O
the	O
use	O
of	O
seven	O
targeted	O
the	O
##rap	O
##ies	O
for	O
m	O
##RC	O
##C	O
,	O
five	O
of	O
them	O
being	O
directed	O
to	O
V	O
##EG	O
##F	O
or	O
its	O
receptors	O
(	B
sun	B
##iti	I
##ni	I
##b	I
,	O
so	O
##ra	O
##fen	O
##ib	O
,	O
p	B
##az	I
##op	I
##ani	I
##b	I
,	O
a	B
##xi	I
##tin	I
##ib	I
,	O
be	O
##va	O
##ci	O
##zu	O
##ma	O
##b	O
)	O
and	O
two	O
corresponding	O
to	O
inhibitor	O
##s	O
of	O
the	O
m	O
##TO	O
##R	O
complex	O
(	O
te	O
##ms	O
##iro	O
##lim	O
##us	O
and	O
ever	O
##oli	O
##mus	O
)	O
.	O

For	O
this	O
purpose	O
,	O
car	B
##ni	I
##tine	I
##s	I
are	O
used	O
as	O
shuttle	O
system	O
to	O
transport	O
long	O
chain	O
FA	S
inside	O
the	O
mit	O
##och	O
##ond	O
##ria	O
.	O

Sign	O
##ificant	O
differences	O
in	O
relative	O
abundance	O
of	O
Lac	B
##to	I
##ba	I
##ci	I
##llus	I
,	O
R	O
##umi	O
##no	O
##co	O
##cc	O
##us	O
,	O
G	O
##em	O
##ella	O
##ceae	O
and	O
Ana	O
##ero	O
##fu	O
##st	O
##is	O
were	O
observed	O
between	O
treatments	O
using	O
community	O
level	O
16	O
##S	O
r	O
##RNA	O
pro	O
##fi	O
##ling	O
.	O

The	O
meta	O
##bol	O
##omi	O
##c	O
data	O
set	O
contained	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
,	O
amino	O
acids	O
,	O
car	O
##bo	O
##hy	O
##dra	O
##tes	O
,	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
,	O
lip	O
##ids	O
,	O
n	O
##uc	O
##leo	O
##tide	O
##s	O
,	O
p	O
##eptide	O
##s	O
,	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
##s	I
,	O
s	O
##tero	O
##ids	O
,	O
vitamin	O
##s	O
,	O
and	O
x	O
##eno	O
##biotics	O
.	O

We	O
sought	O
to	O
establish	O
a	O
method	O
for	O
screening	O
plasma	O
levels	O
of	O
o	B
##xy	I
##ster	I
##ols	I
in	O
breast	O
cancer	O
patients	O
,	O
estimate	O
their	O
individual	O
var	O
##iability	O
and	O
detection	O
limits	O
,	O
and	O
provide	O
basic	O
information	O
about	O
their	O
roles	O
in	O
tumor	O
biology	O
.	O

The	O
B	O
##MI	O
was	O
not	O
associated	O
with	O
the	O
serum	O
concentration	O
of	O
the	O
8	O
anal	O
##yte	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
.	O

The	O
influence	O
of	O
low	O
ad	O
##herence	O
to	O
not	O
achieving	O
relevant	O
(	B
Z	I
)	I
‐	I
end	I
##ox	I
##ife	I
##n	I
levels	O
was	O
highest	O
in	O
patients	O
with	O
non	O
##com	O
##p	O
##rom	O
##ised	O
C	O
##YP	O
##2	O
##D	O
##6	O
function	O
(	O
relative	O
risk	O
3	O
.	O
65	O
;	O
95	O
%	O
confidence	O
interval	O
1	O
.	O
48	O
–	O
8	O
.	O
99	O
)	O
.	O

However	O
,	O
the	O
common	O
name	O
is	O
27	B
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
on	O
account	O
of	O
its	O
formation	O
via	O
the	O
mitochondrial	O
C	O
##YP	O
##27	O
##A	O
##1	O
-	O
cat	O
##aly	O
##zed	O
h	O
##ydro	O
##xy	O
##lation	O
of	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
and	O
this	O
will	O
be	O
the	O
name	O
used	O
here	O
,	O
although	O
we	O
will	O
use	O
the	O
abbreviation	O
C	B
_	I
5	I
-	I
3	I
##β	I
,	I
26	I
-	I
di	I
##ol	I
in	O
accord	O
with	O
the	O
systematic	O
name	O
ch	B
##ole	I
##st	I
-	I
5	I
-	I
en	I
##e	I
-	I
3	I
##β	I
,	I
26	I
-	I
di	I
##ol	I
recommended	O
by	O
F	O
##ah	O
##y	O
et	O
al	O
.	O
.	O

[	O
C	O
##x	O
:	O
y	O
-	O
DC	O
]	O
;	O
14	O
amino	O
acids	O
;	O
1	O
sugar	O
;	O
15	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
##s	I
[	O
SM	O
##x	O
:	O

un	O
##tar	O
##get	O
##ed	O
meta	O
##bol	O
##omi	O
##cs	O
,	O
pathway	O
analysis	O
,	O
H	O
##IL	O
##IC	O
,	O
R	B
##P	I
,	O
TO	O
##F	O
,	O
F	O
##T	O
-	O
I	O
##CR	O
,	O
Or	O
##bit	O
##rap	O
,	O
Q	O
##T	O
##rap	O
,	O
mass	O
s	O
##pect	O
##rome	O
##ter	O
,	O
cancer	O
,	O
human	O
,	O
plasma	O
,	O
urine	O

The	O
surgical	O
laser	O
##s	O
were	O
connected	O
to	O
a	O
mass	O
s	O
##pect	O
##rome	O
##ter	O
though	O
p	B
##oly	I
##te	I
##tra	I
##f	I
##lu	I
##oro	I
##eth	I
##yle	I
##ne	I
tub	O
##ing	O
and	O
a	O
V	O
##ent	O
##uri	O
gas	O
jet	O
pump	O
,	O
similarly	O
to	O
the	O
i	O
##K	O
##nife	O
setup	O
.	O

[	O
]	O
reported	O
an	O
association	O
between	O
ch	B
##ole	I
##ster	I
##ol	I
serum	O
level	O
and	O
o	O
##ste	O
##op	O
##oro	O
##sis	O
diagnosis	O
.	O

Try	B
##pt	I
##op	I
##han	I
was	O
used	O
as	O
a	O
control	O
amino	O
acid	O
(	O
100	O
μ	O
##M	O
,	O
1	O
m	O
##M	O
,	O
10	O
m	O
##M	O
)	O
.	O

One	O
possible	O
explanation	O
for	O
these	O
findings	O
is	O
that	O
men	O
who	O
received	O
the	O
β	B
-	I
car	I
##ote	I
##ne	I
supplement	O
began	O
taking	O
more	O
the	B
##op	I
##hyl	I
##line	I
or	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
or	O
increased	O
their	O
ca	B
##ffe	I
##ine	I
intake	O
during	O
follow	O
-	O
up	O
relative	O
to	O
the	O
men	O
who	O
did	O
not	O
receive	O
β	B
-	I
car	I
##ote	I
##ne	I
.	O

The	O
recovery	O
of	O
the	O
anal	O
##yte	O
##s	O
from	O
plasma	O
samples	O
with	O
low	O
t	B
##rig	I
##ly	I
##cer	I
##ide	I
levels	O
was	O
between	O
98	O
–	O
100	O
%	O
for	O
SM	O
##V	O
,	O
88	O
–	O
96	O
%	O
for	O
SM	O
##V	O
-	O
A	O
,	O
97	O
–	O
100	O
%	O
for	O
AT	O
##V	O
,	O
92	O
–	O
98	O
for	O
2	B
-	I
OH	I
-	I
AT	I
##V	I
,	O
97	O
–	O
99	O
%	O
for	O
4	B
-	I
OH	I
-	I
AT	I
##V	I
,	O
and	O
88	O
–	O
95	O
for	O
RS	O
##V	O
.	O

We	O
found	O
in	O
our	O
population	O
sample	O
a	O
positive	O
correlation	O
between	O
circulating	O
v	B
##ali	I
##ne	I
and	O
β	B
-	I
glucose	I
levels	O
(	O
P	O
<	O
0	O
.	O
000	O
##1	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
comparison	O
of	O
the	O
non	O
-	O
est	O
##eri	O
##fied	O
or	O
free	O
fatty	O
acids	O
quantitative	O
results	O
between	O
the	O
T	O
##LC	O
/	O
G	O
##C	O
-	O
F	O
##ID	O
and	O
the	O
G	B
##C	I
-	I
(	I
+	I
)	I
E	I
##I	I
MS	O
platforms	O
shows	O
that	O
the	O
G	B
##C	I
-	I
(	I
+	I
)	I
E	I
##I	I
MS	O
concentrations	O
of	O
palm	B
##itic	I
acid	I
,	O
v	O
##ac	O
##cini	O
##c	O
acid	O
,	O
o	B
##le	I
##ic	I
acid	I
,	O
l	B
##ino	I
##le	I
##ic	I
acid	I
,	O
di	B
##hom	I
##o	I
-	I
γ	I
-	I
l	I
##ino	I
##len	I
##ic	I
acid	I
and	O
do	B
##cos	I
##ap	I
##ent	I
##a	I
-	I
(	I
4	I
,	I
7	I
,	I
10	I
,	I
13	I
,	I
16	I
)	I
-	I
en	I
##oi	I
##c	I
acid	I
are	O
generally	O
higher	O
than	O
those	O
measured	O
by	O
T	O
##LC	O
/	O
G	O
##C	O
-	O
F	O
##ID	O
(	O
and	O
)	O
.	O

Also	O
,	O
x	B
##ant	I
##hine	I
and	O
u	B
##rate	I
,	O
meta	O
##bol	O
##ites	O
associated	O
with	O
pu	B
##rine	I
metabolism	O
,	O
were	O
decreased	O
in	O
the	O
re	O
##current	O
patients	O
.	O

We	O
are	O
now	O
able	O
to	O
assess	O
p	B
##yr	I
##ido	I
##xin	I
##e	I
(	O
Vita	O
##min	O
B	O
##6	O
)	O
re	O
##sp	O
##ons	O
##ive	O
##ness	O
in	O
a	O
non	O
##in	O
##vasive	O
manner	O
(	O
in	O
contrast	O
to	O
performing	O
a	O
liver	O
bio	O
##psy	O
)	O
as	O
these	O
patients	O
do	O
have	O
residual	O
AG	O
##T	O
enzyme	O
activity	O
.	O

1	O
.	O
80	O
##60	O
–	O
1	O
.	O
68	O
##60	O
1	O
.	O
00	O
##20	O
–	O
0	O
.	O
98	O
##60	O
Ph	B
##os	I
##ph	I
##oli	I
##pid	I
##s	I
*	I
*	I
-	I
CH	I
_	I
2	I
-	I
C	I
=	I
O	I
or	O
-	O
CH	O
_	O
2	O
-	O
CH	O
=	O
CH	O
-	O
2	O
.	O
304	O
##0	O
–	O
2	O
.	O
29	O
##15	O
2	O
.	O
29	O
##15	O
–	O
2	O
.	O
26	O
##90	O
2	O
.	O
26	O
##90	O
–	O
2	O
.	O
230	O
##0	O
0	O
.	O
00	O
##5	O

Met	O
##ab	O
##olo	O
##mic	O
pro	O
##fi	O
##ling	O
(	O
lip	O
##ids	O
and	O
amino	S
acids	O
)	O
was	O
performed	O
by	O
ultra	O
-	O
high	O
-	O
performance	O
liquid	O
ch	O
##roma	O
##tography	O
coupled	O
to	O
mass	O
s	O
##pect	O
##rome	O
##try	O
in	O
serum	O
samples	O
.	O

AK	O
##P	O
organ	B
##oids	I
were	O
maintained	O
at	O
37	O
##°	O
##C	O
as	O
3D	O
s	O
##pher	O
##oid	O
culture	O
in	O
Mat	O
##rig	O
##el	O
.	O

[	O
Google	O
Scholar	O
]	O
Co	O
##mper	O
##no	O
##lle	O
F	O
,	O
Van	O
He	O
##es	O
GP	S
,	O
Blanc	O
##ka	O
##ert	O
N	O
,	O
He	O
##ir	O
##we	O
##gh	O
K	B
##P	I
.	O

It	O
has	O
been	O
suggested	O
that	O
plasma	O
##log	O
##ens	O
act	O
as	O
molecular	O
s	O
##ca	O
##venge	O
##rs	O
,	O
protecting	O
cells	O
and	O
lip	O
##ids	O
against	O
o	O
##xi	O
##da	O
##tive	O
stress	O
(	O
,	O
)	O
,	O
as	O
their	O
vinyl	B
-	I
et	I
##her	I
bond	O
is	O
highly	O
sensitive	O
to	O
o	O
##xi	O
##da	O
##tive	O
attack	O
compared	O
to	O
its	O
est	O
##er	O
counterparts	O
.	O

Four	O
traditional	O
bio	O
##mark	O
##ers	O
were	O
G	O
##SS	O
##G	O
(	O
q	O
=	O
0	O
.	O
02	O
##7	O
)	O
and	O
G	O
##S	O
##H	O
:	O
G	O
##SS	O
##G	O
ratio	O
(	O
q	O
=	O
0	O
.	O
03	O
##9	O
)	O
in	O
er	O
##yt	O
##hr	O
##ocytes	O
and	O
MD	O
##A	O
(	O
q	O
=	O
0	O
.	O
00	O
##6	O
)	O
and	O
IL	O
-	O
6	O
(	O
q	O
=	O
0	O
.	O
00	O
##6	O
)	O
in	O
plasma	O
;	O
and	O
sixteen	O
meta	O
##bol	O
##ites	O
were	O
amino	O
acids	O
(	B
al	B
##ani	I
##ne	I
,	O
as	B
##par	I
##agi	I
##ne	I
,	O
g	B
##lut	I
##amine	I
,	O
g	B
##ly	I
##cine	I
,	O
his	B
##ti	I
##dine	I
,	O
l	B
##ys	I
##ine	I
,	O
se	B
##rine	I
,	O
and	O
car	B
##ni	I
##tine	I
)	O
,	O
organic	O
acids	O
(	O
c	O
##it	O
##rate	O
and	O
format	O
##e	O
)	O
,	O
pu	B
##rine	I
n	O
##uc	O
##leo	O
##tide	O
(	O
ad	O
##eni	O
##ne	O
)	O
,	O
and	O
other	O
meta	O
##bol	O
##ites	O
(	B
N	B
##6	I
-	I
ace	I
##ty	I
##lly	I
##sin	I
##e	I
,	O
beta	B
##ine	I
,	O
3	B
-	I
in	I
##dox	I
##yl	I
##sul	I
##fa	I
##te	I
,	O
N	B
-	I
p	I
##hen	I
##yla	I
##ce	I
##ty	I
##l	I
##gly	I
##cine	I
(	O
PA	O
##G	O
)	O
,	O
and	O
p	B
##hen	I
##yla	I
##ce	I
##tate	I
)	O
.	O

However	O
,	O
g	B
##lut	I
##amine	I
can	O
also	O
be	O
exported	O
out	O
of	O
the	O
cell	O
by	O
anti	O
##port	O
##ers	O
in	O
exchange	O
for	O
other	O
non	O
-	O
essential	O
amino	O
acids	O
through	O
the	O
L	O
-	O
type	O
amino	B
-	I
acid	I
transport	O
##er	O
.	O

AD	B
##MA	I
=	O
as	B
##ym	I
##metric	I
dim	I
##eth	I
##yla	I
##rg	I
##ini	I
##ne	I
;	O
A	O
##rg	O
/	O
NO	O
=	O
a	O
##rg	O
##ini	O
##ne	O
/	O
ni	O
##tric	O
oxide	O
;	O
ID	O
##O	O
-	O
T	O
##M	O
=	O
in	B
##do	I
##leam	I
##ine	I
2	I
,	I
3	I
-	I
di	I
##ox	I
##y	I
##gen	I
##ase	I
try	I
##pt	I
##op	I
##han	I
meta	O
##bol	O
##ite	O
;	O
Or	O
##n	O
+	O
C	O
##it	O
##r	O
=	O
or	B
##ni	I
##thin	I
##e	I
plus	O
c	B
##it	I
##ru	I
##llin	I
##e	I
;	O
R	O
##V	O
-	O
P	O
##V	O
=	O
right	O
vent	O
##ric	O
##ular	O
-	O
pulmonary	O
vascular	O
;	O
SD	O
##MA	O
=	O
symmetric	B
dim	I
##eth	I
##yla	I
##rg	I
##ini	I
##ne	I
;	O
T	O
##CA	O
=	O
t	B
##rica	I
##rb	I
##ox	I
##yl	I
##ic	I
acid	I
;	O
other	O
abbreviation	O
##s	O
as	O
in	O
.	O

Furthermore	O
,	O
despite	O
u	O
##rina	O
##ry	O
hip	B
##pura	I
##te	I
being	O
significantly	O
different	O
from	O
healthy	O
subjects	O
,	O
our	O
analysis	O
did	O
not	O
show	O
any	O
differences	O
amongst	O
the	O
I	O
##B	O
##D	O
sub	O
-	O
p	O
##hen	O
##otype	O
##s	O
.	O

Twenty	O
-	O
four	O
hours	O
after	O
admission	O
in	O
the	O
I	O
##CU	O
,	O
the	O
u	O
##rina	O
##ry	O
cat	O
##he	O
##ter	O
was	O
blocked	O
to	O
collect	O
the	O
second	O
urine	O
sample	O
(	B
U	B
##rine	I
-	I
24	I
##h	I
)	O
.	O

We	O
found	O
that	O
a	O
single	O
parameter	O
,	O
in	B
##os	I
##ine	I
,	O
was	O
significantly	O
associated	O
(	O
p	O
=	O
0	O
.	O
01	O
##1	O
)	O
with	O
children	O
and	O
adolescent	O
##s	O
with	O
D	O
##N	O
-	O
MD	O
##D	O
(	O
Table	O
S	O
##2	O
)	O
.	O

We	O
also	O
found	O
that	O
1	B
-	I
met	I
##hyl	I
##ade	I
##nos	I
##ine	I
was	O
significantly	O
decreased	O
by	O
~	O
4	O
-	O
fold	O
among	O
H	O
##T	O
##K	O
users	O
(	O
Su	O
##pp	O
##lement	O
##ary	O
Fi	O
##g	O
.	O

Go	O
to	O
:	O
Although	O
s	B
##tat	I
##ins	I
are	O
widely	O
prescribed	O
medications	O
,	O
there	O
remains	O
considerable	O
var	O
##iability	O
in	O
therapeutic	O
response	O
.	O

The	O
mass	O
difference	O
of	O
30	O
Da	O
observed	O
between	O
the	O
fragment	O
ion	O
at	O
m	O
/	O
z	O
39	O
##6	O
.	O
2	O
and	O
the	O
pro	O
##ton	O
##ated	O
CP	O
##F	O
(	O
[	O
M	O
+	O
H	O
]	O
_	O
+	O
at	O
m	O
/	O
z	O
36	O
##6	O
.	O
1	O
)	O
is	O
consistent	O
with	O
the	O
presence	O
two	O
sulfur	B
-	I
oxygen	I
double	O
bonds	O
on	O
Cy	O
##s	O
_	O
34	O
.	O

NE	O
##FA	O
co	O
##loc	O
##ali	O
##zed	O
with	O
lip	O
##op	O
##rote	O
##in	O
lip	O
##ase	O
(	O
LP	O
##L	O
)	O
and	O
mon	O
##oc	O
##yte	O
ch	O
##em	O
##oat	O
##tract	O
##ant	O
protein	O
(	O
MC	O
##P	O
)	O
-	O
1	O
expression	O
in	O
plaque	O
##s	O
and	O
,	O
in	O
culture	O
##d	O
vascular	O
smooth	O
muscle	O
cells	O
(	O
V	O
##SM	O
##Cs	O
)	O
,	O
l	B
##ino	I
##le	I
##ic	I
acid	I
promoted	O
nuclear	O
factor	O
-	O
κ	O
##B	O
(	O
N	O
##F	O
-	O
κ	O
##B	O
)	O
activation	O
and	O
LP	O
##L	O
and	O
MC	O
##P	O
-	O
1	O
expression	O
.	O

The	O
nitrogen	B
gas	I
in	O
the	O
D	O
##AR	O
##T	O
ion	O
source	O
was	O
heated	O
to	O
350	O
°C	O
.	O

The	O
g	B
##ly	I
##co	I
##ly	I
##tic	I
ratio	O
was	O
significantly	O
higher	O
in	O
veterans	O
with	O
PT	O
##SD	O
than	O
in	O
veterans	O
without	O
PT	O
##SD	O
in	O
both	O
the	O
Discovery	O
(	O
p	O
<	O
1	O
##x	O
##10	O
-	O
4	O
q	O
=	O
0	O
.	O
00	O
)	O
and	O
Test	O
(	O
p	O
=	O
0	O
.	O
00	O
##5	O
;	O
q	O
=	O
0	O
.	O
07	O
)	O
groups	O
,	O
suggesting	O
increased	O
an	O
##ae	O
##ro	O
##bic	O
and	O
decreased	O
a	O
##ero	O
##bic	O
re	O
##spiration	O
in	O
these	O
subjects	O
,	O
which	O
may	O
indicate	O
mitochondrial	O
(	O
T	O
##CA	O
cycle	O
)	O
alterations	O
or	O
d	O
##ys	O
##function	O
.	O

It	O
has	O
been	O
reported	O
that	O
N	B
-	I
o	I
##leo	I
##yl	I
ethanol	I
##amine	I
could	O
activate	O
PP	O
##AR	O
-	O
alpha	O
receptor	O
and	O
promote	O
the	O
release	O
of	O
g	B
##ly	I
##cer	I
##ol	I
and	O
fatty	O
acids	O
from	O
rat	O
ad	O
##ip	O
##ocytes	O
.	O

The	O
AU	O
##C	O
of	O
α	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
,	O
in	O
particular	O
,	O
was	O
correlated	O
with	O
W	O
##BI	O
##SI	O
(	O
r	O
=	O
−	O
##0	O
.	O
33	O
;	O
P	O
=	O
0	O
.	O
01	O
##3	O
)	O
as	O
well	O
as	O
D	O
##I	O
(	O
r	O
=	O
−	O
##0	O
.	O
36	O
;	O
P	O
=	O
0	O
.	O
01	O
##0	O
)	O
,	O
B	O
##MI	O

Higher	O
levels	O
of	O
several	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
##s	I
(	O
SM	O
##s	O
)	O
,	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
(	O
l	O
##ys	O
##o	O
##PC	O
##s	O
)	O
and	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
(	O
PC	O
##s	O
)	O
were	O
observed	O
in	O
r	O
##s	O
##7	O
##90	O
##31	O
##46	O
risk	O
all	O
##ele	O
carriers	O
.	O

The	O
long	O
-	O
term	O
patient	O
sample	O
stability	O
was	O
demonstrated	O
for	O
en	B
##zal	I
##uta	I
##mi	I
##de	I
and	O
N	B
-	I
des	I
##met	I
##hyl	I
##en	I
##zal	I
##uta	I
##mi	I
##de	I
for	O
14	O
months	O
at	O
−	O
##40	O
°C	O
.	O
.	O

Therefore	O
,	O
in	O
C	O
##K	O
##D	O
,	O
low	O
circulating	O
24	B
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
concentration	O
could	O
reflect	O
in	O
part	O
systemic	O
tissue	O
-	O
level	O
1	B
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
deficiency	O
.	O

d	O
Co	O
##rrel	O
##ation	O
among	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
in	O
meta	O
##static	O
cases	O
.	O

PC	B
a	I
##e	I
C	I
##36	I
:	I
2	I
;	O
94	O
.	O

ACC	O
patients	O
had	O
a	O
significantly	O
higher	O
ex	O
##cre	O
##tion	O
of	O
and	O
##rogen	O
precursor	O
meta	O
##bol	O
##ites	O
[	O
pre	O
##gne	O
##ned	O
##iol	O
(	O
5	O
-	O
PD	O
)	O
,	O
pre	O
##gne	O
##net	O
##rio	O
##l	O
(	O
5	O
-	O
PT	O
)	O
,	O
D	O
##H	O
##EA	O
,	O
16	B
##α	I
-	I
OH	I
-	I
D	I
##H	I
##EA	I
;	O
see	O
Su	O
##pp	O
##lement	O
##al	O
Table	O
1	O
]	O
and	O
also	O
of	O
meta	O
##bol	O
##ites	O
of	O
active	O
and	O
##rogen	O
##s	O
(	B
and	B
##ros	I
##tero	I
##ne	I
and	O
et	B
##io	I
##cho	I
##lan	I
##olo	I
##ne	I
;	O
A	O
and	O
Su	O
##pp	O
##lement	O
##al	O
Table	O
2	O
)	O
.	O

In	O
line	O
with	O
the	O
dynamics	O
of	O
glucose	S
M	O
##6	O
,	O
the	O
formation	O
of	O
la	B
##ct	I
##ate	I
M	O
##3	O
and	O
al	B
##ani	I
##ne	I
M	O
##3	O
was	O
delayed	O
by	O
60	O
min	O
following	O
ing	O
##est	O
##ion	O
of	O
G	O
##G	O
##4	O
,	O
but	O
not	O
G	O
##G	O
##2	O
.	O

The	O
water	O
-	O
suppressed	O
Carr	O
-	O
P	O
##ur	O
##cell	O
-	O
Mei	O
##boo	O
##m	O
-	O
Gill	O
(	O
CP	O
##MG	O
)	O
pulse	O
sequence	O
[	B
R	B
##D	I
-	I
90	I
##°	I
-	I
(	I
τ	I
-	I
180	I
##°	I
-	I
τ	I
)	I
_	I
n	I
-	I
AC	I
##Q	I
]	O
was	O
used	O
here	O
.	O

The	O
column	O
was	O
el	O
##uted	O
at	O
a	O
flow	O
rate	O
of	O
450	O
μ	O
##L	O
/	O
min	O
is	O
##oc	O
##ratic	O
##ally	O
for	O
1	O
minute	O
at	O
80	O
%	O
mobile	O
phase	O
A	O
(	O
95	O
:	O
5	O
:	O
0	O
.	O
1	O
vol	O
/	O
vol	O
/	O
vol	O
10	O
m	O
##M	O
am	B
##mon	I
##ium	I
ace	O
##tate	O
/	O
met	O
##han	O
##ol	O
/	O
ace	O
##tic	O
acid	O
)	O
,	O
followed	O
by	O
a	O
linear	O
gradient	O
to	O
80	O
%	O
mobile	O
##pha	O
##se	O
B	O
(	O
99	O
.	O
9	O
:	O
0	O
.	O
1	O
vol	O
/	O
vol	O
met	O
##han	O
##ol	O
/	O
ace	O
##tic	O
acid	O
)	O
over	O
2	O
minutes	O
,	O
a	O
linear	O
gradient	O
to	O
100	O
%	O
mobile	O
phase	O
B	O
over	O
7	O
minutes	O
,	O
and	O
then	O
3	O
minutes	O
at	O
100	O
%	O
mobile	O
##pha	O
##se	O
B	O
.	O
MS	O
analyses	O
were	O
carried	O
out	O
using	O
electro	O
##sp	O
##ray	O
ion	O
##ization	O
in	O
the	O
positive	O
ion	O
mode	O
using	O
full	O
scan	O
analysis	O
over	O
m	O
/	O
z	O
2001	O
##100	O
at	O
70	O
,	O
000	O
resolution	O
and	O
3	O
Hz	O
data	O
acquisition	O
rate	O
.	O

,	O
0	O
.	O
25	O
μ	O
##m	O
ﬁ	O
##lm	O
thickness	O
;	O
(	B
5	I
%	I
-	I
p	I
##hen	I
##yl	I
)	I
-	I
met	I
##hyl	I
##pol	I
##ys	I
##ilo	I
##xa	I
##ne	I
bonded	O
and	O
cross	O
-	O
linked	O
;	O
A	O
##gi	O
##lent	O
J	O
##W	O
Sc	O
##ient	O
##i	O
##ﬁ	O
##c	O
,	O
F	O
##ols	O
##om	O
,	O
CA	O
)	O
,	O
with	O
he	O
##lium	O
as	O
the	O
carrier	O
gas	O
at	O
a	O
constant	O
ﬂ	O
##ow	O
rate	O
of	O
1	O
.	O
0	O
m	O
##L	O
/	O
min	O
.	O

As	O
expected	O
,	O
the	O
addition	O
of	O
am	B
##mon	I
##ium	I
format	I
##e	I
in	O
the	O
positive	O
ion	O
mode	O
mobile	O
phases	O
enhanced	O
the	O
signal	O
of	O
neutral	O
lip	O
##id	O
species	O
(	O
s	O
##tero	O
##ls	O
,	O
ch	B
##ole	I
##ster	I
##yl	I
est	I
##ers	I
,	O
MG	O
,	O
D	O
##G	O
and	O
T	B
##G	I
internal	O
standards	O
)	O
and	O
p	B
##hos	I
##pha	I
##ti	I
##dic	I
acids	I
(	O
PA	O
and	O
LP	O
##A	O
)	O
,	O
which	O
were	O
detected	O
as	O
[	O
M	O
+	O
NH	O
_	O
4	O
]	O
_	O
+	O
add	O
##uc	O
##ts	O
(	O
Murphy	O
et	O
al	O
.	O
)	O
.	O

The	O
one	O
year	O
delta	O
of	O
q	B
##uin	I
##olin	I
##ic	I
acid	I
concentrations	O
was	O
negatively	O
associated	O
with	O
the	O
delta	O
of	O
fast	O
##ing	O
glucose	S
(	O
p	O
=	O
0	O
.	O
01	O
##9	O
)	O
and	O
H	O
##b	O
##A	O
##1	O
##c	O
(	O
p	O
=	O
0	O
.	O
01	O
##4	O
)	O
,	O
whereas	O
the	O
delta	O
of	O
x	B
##ant	I
##hur	I
##eni	I
##c	I
acid	I
was	O
positively	O
associated	O
with	O
the	O
delta	O
of	O
insulin	O
sensitivity	O
index	O
(	O
p	O
=	O
0	O
.	O
00	O
##18	O
)	O
.	O

Moreover	O
,	O
while	O
C	O
##ID	O
produces	O
multiple	O
fragments	O
of	O
native	O
vitamin	B
D	I
meta	O
##bol	O
##ites	O
,	O
it	O
produces	O
a	O
single	O
major	O
fragment	O
for	O
the	O
der	O
##iva	O
##tized	O
products	O
.	O

The	O
serum	O
extract	O
##s	O
that	O
remained	O
on	O
the	O
bench	O
-	O
top	O
for	O
24	O
h	O
at	O
room	O
temperature	O
displayed	O
an	O
average	O
of	O
101	O
.	O
5	O
%	O
of	O
pro	B
##line	I
compare	O
to	O
the	O
freshly	O
prepared	O
ones	O
,	O
which	O
indicated	O
that	O
the	O
processed	O
pro	B
##line	I
serum	O
extract	O
##s	O
were	O
stable	O
at	O
room	O
temperature	O
at	O
least	O
for	O
24	O
h	O
.	O

These	O
include	O
5	B
-	I
met	I
##ho	I
##xy	I
##try	I
##pta	I
##mine	I
,	O
f	B
##olic	I
acid	I
,	O
thy	O
##roth	O
##rop	O
##in	O
releasing	O
hormone	O
and	O
co	B
##rt	I
##is	I
##ol	I
for	O
+	O
E	O
##SI	O
R	B
##P	I
;	O
and	O
pan	B
##to	I
##the	I
##nic	I
and	O
ch	O
##olic	O
acids	O
for	O
−	O
##ES	O
##I	O
R	B
##P	I
all	O
of	O
which	O
showed	O
no	O
matrix	O
effects	O
across	O
all	O
seven	O
extraction	O
methods	O
tested	O
as	O
shown	O
in	O
.	O

To	O
perform	O
a	O
direct	O
comparison	O
of	O
the	O
same	O
volume	O
we	O
used	O
5	O
m	O
##L	O
of	O
50	O
%	O
Me	B
##OH	I
for	O
cell	O
que	O
##nch	O
##ing	O
followed	O
by	O
increased	O
extraction	O
volumes	O
(	O
4	O
m	O
##L	O
CH	O
##C	O
##l	O
_	O
3	O
,	O
additional	O
1	O
.	O
5	O
m	O
##L	O
Me	B
##OH	I
and	O
1	O
.	O
5	O
m	O
##L	O
H	O
_	O
2	O
O	O
)	O
leading	O
to	O
a	O
1	O
:	O
1	O
:	O
1	O
,	O
v	O
/	O
v	O
/	O
v	O
ratio	O
of	O
Me	B
##OH	I
:	O

Moreover	O
,	O
c	B
##rea	I
##tine	I
shows	O
significant	O
anti	O
##can	O
##cer	O
effect	O
against	O
brain	O
tumor	O
,	O
oral	O
sq	O
##ua	O
##mous	O
cell	O
car	O
##cin	O
##oma	O
and	O
childhood	O
c	O
##ere	O
##bella	O
##r	O
t	O
##umour	O

In	O
addition	O
,	O
investigations	O
of	O
breast	O
cancer	O
cells	O
showed	O
increased	O
levels	O
of	O
th	B
##re	I
##oni	I
##ne	I
,	O
under	O
h	O
##y	O
##pox	O
##ic	O
conditions	O
,	O
and	O
such	O
an	O
increase	O
is	O
attributed	O
to	O
impaired	O
protein	O
synthesis	O
due	O
to	O
h	O
##y	O
##pox	O
##ia	O
(	O
We	O
##l	O
##ji	O
##e	O
et	O
al	O
.	O
,	O
2011	O
)	O
.	O

5	B
-	I
h	I
##ydro	I
##xy	I
##try	I
##pt	I
##op	I
##han	I
is	O
an	O
intermediate	O
in	O
se	B
##rot	I
##oni	I
##n	I
bio	O
##sy	O
##nt	O
##hesis	O
;	O
decreased	O
levels	O
in	O
P	O
##L	O
and	O
PD	O
##AC	O
could	O
reflect	O
increased	O
conversion	O
to	O
se	B
##rot	I
##oni	I
##n	I
which	O
has	O
been	O
implicated	O
in	O
tumor	O
growth	O
and	O
progression	O
[	O
,	O
]	O
.	O

(	O
d	O
##17	O
##S	O
##a	O
##1	O
##P	O
)	O
,	O
s	B
##phi	I
##ngo	I
##sin	I
##e	I
d	O
17	O
:	O
1	O
(	O
d	O
##17	O
##S	O
##o	O
)	O
,	O
s	B
##phi	I
##ngo	I
##sin	I
##e	I
-	I
1	I
-	I
phosphate	I
d	I
##17	I
:	I
1	I

In	O
short	O
,	O
first	O
proteins	O
were	O
pre	O
##ci	O
##pit	O
##ated	O
by	O
adding	O
800	O
μ	O
##L	O
of	O
chilled	O
met	B
##han	I
##ol	I
in	O
100	O
μ	O
##L	O
serum	O
containing	O
20	O
μ	O
##L	O
of	O
my	B
##rist	I
##ic	I
acid	I
(	O
2	O
mg	O
/	O
m	O
##L	O
)	O
as	O
internal	O
standard	O
.	O

A	O
measure	O
of	O
50	O
µ	O
##L	O
of	O
plasma	O
was	O
v	O
##ortex	O
##ed	O
after	O
being	O
spike	O
##d	O
with	O
internal	O
standard	O
solution	O
(	O
5	O
µ	O
##L	O
L	B
-	I
2	I
-	I
ch	I
##lor	I
##op	I
##hen	I
##yla	I
##lani	I
##ne	I
in	O
water	O
,	O
1	O
mm	O
##ol	O
L	O
_	O
−	O
##1	O
)	O
.	O

r	O
=	O
0	O
.	O
45	O
)	O
and	O
skeletal	O
muscle	O
long	O
-	O
chain	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
and	O
p	B
##yr	I
##u	I
##vate	I
(	O
;	O
r	O
=	O
0	O
.	O
08	O
)	O
,	O

That	O
fast	O
##ed	O
g	O
##ly	O
##ce	O
##mia	O
is	O
selective	O
##ly	O
increased	O
by	O
Omega	B
-	I
3	I
(	O
Table	O
)	O
could	O
also	O
reflect	O
increased	O
he	O
##pa	O
##tic	O
g	O
##lu	O
##con	O
##eo	O
##genesis	O
stimulate	O
##d	O
in	O
face	O
of	O
enhanced	O
fatty	O
acid	O
oxidation	O
.	O

Here	O
we	O
report	O
that	O
the	O
s	B
##phi	I
##ngo	I
##lip	I
##id	I
metabolism	O
pathway	O
was	O
up	O
##re	O
##gu	O
##lated	O
in	O
muscle	O
in	O
insulin	O
resistance	O
independent	O
of	O
o	O
##besity	O
.	O

Four	O
meta	O
##bol	O
##ites	O
(	O
namely	O
,	O
PC	O
di	O
##acy	O
##l	O
(	O
a	O
##a	O
)	O
C	B
##36	I
:	I
3	I
,	O
PC	O
a	O
##cy	O
##l	O
-	O
al	O
##ky	O
##l	O
(	O
a	O
##e	O
)	O
C	B
##36	I
:	I
3	I
,	O
PC	B
a	I
##e	I
C	I
##38	I
:	I
4	I
,	O
and	O
PC	B
a	I
##e	I
C	I
##38	I
:	I
5	I
)	O
were	O
significantly	O
decreased	O
between	O
points	O
A	O
and	O
B	O
then	O
remained	O
not	O
affected	O
—	O
pattern	O
A	O
>	O
B	O
=	O
C	O
;	O
a	O
similar	O
pattern	O
was	O
observed	O
in	O
the	O
case	O
of	O
24	O
and	O
3	O
meta	O
##bol	O
##ites	O
specific	O
to	O
CC	O
##RT	O
and	O
R	O
##T	O
groups	O
,	O
respectively	O
.	O

In	O
this	O
sense	O
,	O
the	O
common	O
product	O
ion	O
for	O
all	O
anal	O
##yte	O
##s	O
was	O
170	O
m	O
/	O
z	O
,	O
a	O
characteristic	O
fragment	O
of	O
dans	B
##yl	I
chloride	I
.	O

To	O
date	O
,	O
only	O
one	O
case	O
-	O
control	O
study	O
,	O
including	O
29	O
##7	O
male	O
HC	O
##C	O
patients	O
and	O
63	O
##1	O
male	O
matched	O
controls	O
,	O
has	O
reported	O
on	O
the	O
relationship	O
between	O
serum	O
ch	B
##olin	I
##e	I
and	O
HC	O
##C	O
risk	O
,	O
in	O
which	O
the	O
favorable	O
role	O
of	O
ch	B
##olin	I
##e	I
was	O
also	O
found	O
.	O

Anti	O
-	O
inflammatory	O
long	O
-	O
chain	O
fatty	O
acids	O
(	O
GT	O
##As	O
)	O
were	O
significantly	O
elevated	O
in	O
short	O
duration	S
R	O
##R	O
##MS	O
(	O
disease	O
duration	S
<	O
13	O
years	O
)	O
compared	O
to	O
SP	O
##MS	O
(	O
Fi	O
##g	O
.	O

The	O
only	O
statistical	O
##ly	O
significantly	O
altered	O
meta	O
##bol	O
##ites	O
between	O
cancer	O
-	O
associated	O
and	O
cancer	O
-	O
free	O
Barrett	O
'	O
s	O
samples	O
were	O
p	B
##hos	I
##ph	I
##och	I
##olin	I
##e	I
,	O
which	O
was	O
elevated	O
,	O
and	O
le	B
##uc	I
##ine	I
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
and	O
v	B
##ali	I
##ne	I
,	O
which	O
were	O
reduced	O
in	O
the	O
EA	O
##C	O
-	O
associated	O
Barrett	O
'	O
s	O
.	O

However	O
,	O
my	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
treatment	O
increased	O
the	O
expression	O
of	O
these	O
markers	O
again	O
.	O

The	O
cell	O
-	O
surface	O
g	B
##ly	I
##co	I
##p	I
##rote	I
##in	I
inter	O
##cellular	O
ad	O
##hesion	O
molecule	O
1	O
(	O
I	O
##CA	O
##M	O
-	O
1	O
)	O
,	O
the	O
expression	O
of	O
which	O
is	O
marked	O
##ly	O
reduced	O
by	O
def	O
##icient	O
g	O
##ly	O
##cos	O
##yla	O
##tion	O
,	O
was	O
ass	O
##ay	O
##ed	O
in	O
fi	O
##bro	O
##blast	O
cultures	O
from	O
patients	O
by	O
means	O
of	O
Western	O
b	O
##lot	O
##ting	O
and	O
im	O
##mu	O
##no	O
##f	O
##lu	O
##ores	O
##cence	O
analysis	O
with	O
the	O
use	O
of	O
a	O
mon	O
##oc	O
##lon	O
##al	O
anti	O
–	O
I	O
##CA	O
##M	O
-	O
1	O
anti	O
##body	O
(	O
see	O
the	O
)	O
.	O

Missing	O
from	O
these	O
studies	O
has	O
been	O
an	O
exploration	O
of	O
the	O
formation	O
of	O
the	O
appropriate	O
g	B
##lut	I
##ath	I
##ione	I
con	O
##ju	O
##gate	O
##s	O
in	O
humans	O
.	O

The	O
relative	O
decrease	O
of	O
try	B
##pt	I
##op	I
##han	I
and	O
increase	O
of	O
p	B
##hen	I
##yla	I
##ce	I
##ty	I
##l	I
##g	I
##lut	I
##amine	I
in	O
G	O
##C	O
patients	O
(	O
see	O
Fi	O
##gs	O
and	O
)	O
were	O
in	O
agreement	O
with	O
results	O
found	O
in	O
a	O
previous	O
un	O
##tar	O
##get	O
##ed	O
meta	O
##bol	O
##omi	O
##c	O
study	O
and	O
with	O
the	O
above	O
##ment	O
##ioned	O
alter	O
##ation	O
of	O
the	O
try	B
##pt	I
##op	I
##han	I
pathway	O
,	O
supporting	O
the	O
robust	O
##ness	O
of	O
the	O
analysis	O
.	O

The	O
individual	O
ratios	O
of	O
de	O
##pur	O
##inating	O
4	O
-	O
OH	O
##E	O
_	O
1	O
(	O
E	O
_	O
2	O
)	O
-	O
1	O
-	O
N	O
##3	O
##A	O
##de	O
and	O
4	O
-	O
OH	O
##E	O
_	O
1	O
(	O
E	O
_	O
2	O
)	O
-	O
1	O
-	O
N	O
##7	O
##G	O
##ua	O
add	O
##uc	O
##ts	O
to	O
the	O
sum	O
of	O
their	O
respective	O
est	B
##rogen	I
meta	O
##bol	O
##ites	O
and	O
con	O
##ju	O
##gate	O
##s	O
in	O
urine	O
samples	O
from	O
men	O
with	O
NHL	O
and	O
healthy	O
controls	O
are	O
presented	O
in	O
.	O

For	O
the	O
29	O
identified	O
meta	O
##bol	O
##ites	O
significantly	O
associated	O
with	O
B	O
##MI	O
from	O
_	O
1	O
H	O
N	O
##MR	O
data	O
,	O
the	O
ICC	O
coefficients	O
ranged	O
from	O
0	O
.	O
34	O
(	B
pseudo	B
##uri	I
##dine	I
)	O
to	O
0	O
.	O
72	O
(	O
N	O
##M	O
##NA	O
)	O
in	O
the	O
U	O
.	O
S	O
.	O
co	O
##hor	O
##t	O
and	O
up	O
to	O
0	O
.	O
78	O
(	B
t	B
##yr	I
##os	I
##ine	I
+	O
4	B
-	I
h	I
##ydro	I
##xy	I
##mand	I
##ela	I
##te	I
)	O
in	O
the	O
UK	O
co	O
##hor	O
##t	O
(	O
median	O
ICC	O
coefficient	O
of	O
identified	O
meta	O
##bol	O
##ites	O
is	O
0	O
.	O
53	O
)	O
.	O

Mean	O
(	O
±	O
##9	O
##5	O
%	O
C	O
##I	O
)	O
elevations	O
in	O
glucose	S
varied	O
from	O
5	O
.	O
2	O
-	O
fold	O
(	O
1	O
.	O
4	O
–	O
18	O
.	O
6	O
)	O
in	O
c	O
##ere	O
##bell	O
##um	O
to	O
16	O
.	O
4	O
-	O
fold	O
(	O
5	O
.	O
2	O
–	O
51	O
.	O
2	O
)	O
in	O
middle	O
temporal	O
g	O
##yr	O
##us	O
(	O
and	O
a	O
)	O
.	O

However	O
,	O
retention	O
was	O
significantly	O
improved	O
on	O
H	O
##IL	O
##IC	O
columns	O
compared	O
to	O
method	O
A	O
.	O
The	O
most	O
promising	O
candidates	O
for	O
mobile	O
phase	O
optimization	O
that	O
could	O
facilitate	O
base	O
##line	O
resolution	O
of	O
sugar	O
phosphate	B
##s	I
are	O
C	O
and	O
E	O
.	O

In	O
order	O
to	O
find	O
more	O
cancer	O
-	O
specific	O
low	O
abundant	O
potential	O
bio	O
##mark	O
##ers	O
,	O
Light	O
##S	O
##ight	O
_	O
T	O
##M	O
was	O
used	O
to	O
generate	O
a	O
positive	O
mode	O
method	O
with	O
neutral	O
loss	O
scan	O
of	O
132	O
(	O
loss	O
of	O
the	O
rib	B
##ose	I
m	O
##oi	O
##ety	O
)	O
to	O
screen	O
for	O
unknown	O
RNA	O
add	O
##uc	O
##ts	O
.	O

Pat	O
##ients	O
were	O
administered	O
with	O
ta	B
##mo	I
##xi	I
##fen	I
(	O
156	O
)	O
,	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
(	O
21	O
)	O
,	O
or	O
let	B
##ro	I
##zo	I
##le	I
(	O
2	O
)	O
or	O
not	O
treated	O
(	O
5	O
)	O
.	O

Among	O
all	O
potential	O
bio	O
##mark	O
##ers	O
,	O
2	B
-	I
amino	I
-	I
3	I
-	I
met	I
##hyl	I
-	I
1	I
-	I
but	I
##ano	I
##l	I
,	O
L	B
-	I
car	I
##ni	I
##tine	I
,	O
As	O
##n	O
As	O
##n	O
G	O
##ln	O
A	O
##rg	O
,	O
Al	O
##a	O
Cy	O
##s	O
Ser	O
T	O
##rp	O
,	O
Sol	B
##ad	I
##ul	I
##cid	I
##ine	I
,	O
Al	O
##a	O
Il	O
##e	O
G	O
##ln	O
A	O
##rg	O
,	O
2	B
-	I
amino	I
-	I
3	I
-	I
Met	I
##hyl	I
-	I
1	I
-	I
but	I
##ano	I
##l	I
,	O
L	B
-	I
car	I
##ni	I
##tine	I
,	O
As	O
##n	O
As	O
##n	O
G	O
##ln	O
A	O
##rg	O
,	O
Al	O
##a	O
Cy	O
##s	O
Ser	O
T	O
##rp	O
,	O
Sol	B
##ad	I
##ul	I
##cid	I
##ine	I
,	O
Al	O
##a	O
Il	O
##e	O
G	O
##ln	O
A	O
##rg	O
can	O
be	O
used	O
as	O
predict	O
##ors	O
of	O
pre	O
##can	O
##cer	O
##ous	O
lesions	O
at	O
different	O
stages	O
of	O
CC	O
.	O

[	O
Google	O
Scholar	O
]	O
Pa	O
##s	O
##qua	O
##lini	O
JR	O
,	O
G	O
##elly	O
C	O
,	O
Ng	O
##uy	O
##en	O
B	O
##L	O
,	O
V	O
##ella	O
C	O
.	O
I	O
##mpo	O
##rta	O
##nce	O
of	O
est	B
##rogen	I
su	I
##lf	I
##ates	I
in	O
breast	O
cancer	O
.	O

Di	B
##ch	I
##lor	I
##ome	I
##than	I
##e	I
,	O
met	B
##han	I
##ol	I
and	O
form	B
##ic	I
acid	I
were	O
obtained	O
from	O
E	O
##M	O
Science	O
(	O
Gibbs	O
##town	O
,	O
NJ	O
,	O
USA	O
)	O
.	O

The	O
L	O
##V	O
##1	O
weights	O
indicate	O
that	O
glucose	S
,	O
c	B
##rea	I
##tin	I
##ine	I
and	O
2	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
are	O
present	O
in	O
higher	O
concentration	O
in	O
the	O
blood	O
serum	O
of	O
patients	O
at	O
diagnosis	O
(	O
group	O
A	O
)	O
while	O
p	B
##yr	I
##u	I
##vate	I
,	O
2	B
-	I
h	I
##ydro	I
##xy	I
##is	I
##ob	I
##ut	I
##yra	I
##te	I
,	O
ch	B
##olin	I
##e	I
,	O
al	B
##ani	I
##ne	I
,	O
and	O
la	B
##ct	I
##ate	I
are	O
decreased	O
.	O

(	O
C	O
)	O
Sc	O
##hem	O
##atic	O
illustration	O
of	O
the	O
a	B
##rg	I
##ini	I
##ne	I
and	O
pro	B
##line	I
metabolism	O
.	O

In	O
a	O
single	O
sample	O
J	O
##ager	O
et	O
al	O
.	O
found	O
concentrations	O
of	O
8	O
.	O
7	O
ng	O
/	O
m	O
##L	O
J	O
##W	O
##H	O
-	O
01	O
##8	O
5	O
-	O
h	O
##ydro	O
##xy	O
##pent	O
##yl	O
,	O
0	O
.	O
89	O
ng	O
/	O
m	O
##L	O
J	O
##W	O
##H	O
-	O
01	O
##8	O
pen	B
##tano	I
##ic	I
acid	I
,	O
0	O
.	O
55	O
ng	O
/	O
m	O
##L	O
J	O
##W	O
##H	O
-	O
07	O
##3	O
but	B
##ano	I
##ic	I
acid	I
,	O
0	O
.	O
67	O
ng	O
/	O
m	O
##L	O
J	O
##W	O
##H	O
-	O
07	O
##3	O
h	O
##ydro	O
##xy	O
##but	O
##yl	O
,	O
and	O
0	O
.	O
25	O
ng	O
/	O
m	O
##L	O
J	O
##W	O
##H	O
-	O
250	O
pen	B
##tano	I
##ic	I
acid	I
.	O

Un	O
##con	O
##ju	O
##gated	O
est	B
##rad	I
##iol	I
was	O
strongly	O
associated	O
with	O
risk	O
[	O
R	O
##R	O
=	O
2	O
.	O
07	O
;	O
95	O
%	O
C	O
##I	O
=	O
1	O
.	O
19	O
to	O
3	O
.	O
62	O
;	O
p	O
-	O
trend	O
=	O
.	O
01	O
)	O
,	O
a	O
finding	O
consistent	O
with	O
the	O
pool	O
##ed	O
analysis	O
of	O
prospective	O
data	O
available	O
worldwide	O
(	O
1	O
)	O
.	O

Since	O
PGA	O
is	O
linked	O
to	O
g	B
##lut	I
##ath	I
##ione	I
turnover	O
,	O
the	O
u	O
##rina	O
##ry	O
pattern	O
may	O
reflect	O
the	O
higher	O
requirement	O
of	O
the	O
metabolism	O
in	O
g	B
##lut	I
##ath	I
##ione	I
to	O
cope	O
with	O
o	O
##xi	O
##da	O
##tive	O
stress	O
and	O
immune	O
status	O
[	O
,	O
]	O
.	O

Based	O
on	O
this	O
gene	O
an	O
##not	O
##ation	O
,	O
there	O
was	O
no	O
obvious	O
relation	O
to	O
the	O
associated	O
meta	O
##bol	O
##ite	O
ethanol	B
##amine	I
.	O

In	O
the	O
15	O
differential	O
meta	O
##bol	O
##ites	O
,	O
3	O
long	O
-	O
chain	O
fatty	O
acid	O
(	O
l	O
##ino	O
##le	O
##ic	O
acid	O
,	O
o	B
##le	I
##ic	I
acid	I
,	O
he	O
##pta	O
##de	O
##cy	O
##lic	O
acid	O
)	O
were	O
found	O
decreased	O
in	O
MD	O
##D	O
patients	O
;	O
as	O
for	O
car	O
##bo	O
##hy	O
##dra	O
##te	O
,	O
the	O
gal	B
##act	I
##ose	I
and	O
so	B
##rb	I
##ito	I
##l	I
were	O
elevated	O
while	O
the	O
my	B
##oi	I
##nos	I
##ito	I
##l	I
and	O
man	B
##nose	I
were	O
decreased	O
in	O
MD	O
##D	O
compared	O
with	O
healthy	O
control	O
;	O
4	O
amino	O
acids	O
(	B
g	B
##ly	I
##cine	I
,	O
al	B
##ani	I
##ne	I
,	O
pro	B
##line	I
,	O
se	B
##rine	I
)	O
were	O
found	O
elevated	O
while	O
only	O
le	B
##uc	I
##ine	I
was	O
decreased	O
in	O
MD	O
##D	O
compared	O
with	O
healthy	O
control	O
.	O

The	O
selection	O
of	O
the	O
C	O
/	O
a	O
##c	O
_	O
4	O
C	O
combination	O
in	O
our	O
classification	O
approach	O
appears	O
in	O
analogy	O
to	O
the	O
results	O
of	O
our	O
previous	O
work	O
with	O
cell	O
culture	O
super	O
##nat	O
##ants	O
,	O
which	O
showed	O
distinctive	O
alterations	O
in	O
the	O
ex	O
##cre	O
##tion	O
of	O
c	B
##yt	I
##id	I
##ine	I
in	O
breast	O
cancer	O
cells	O
.	O

U	O
##rina	O
##ry	O
my	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
levels	O
were	O
significantly	O
related	O
to	O
the	O
clinical	O
parameters	O
of	O
F	O
##S	O
##GS	O
patients	O
measured	O
at	O
diagnosis	O
and	O
increased	O
the	O
ability	O
to	O
distinguish	O
F	O
##S	O
##GS	O
patients	O
from	O
MC	O
##D	O
patients	O
compared	O
to	O
traditional	O
clinical	O
parameters	O
.	O

For	O
example	O
,	O
the	O
AA	O
##S	O
##K	O
model	O
containing	O
four	O
meta	O
##bol	O
##ites	O
without	O
c	B
##rea	I
##tin	I
##ine	I
or	O
demographic	O
##s	O
has	O
a	O
median	O
coefficient	O
of	O
−	O
##0	O
.	O
23	O
for	O
the	O
meta	O
##bol	O
##ites	O
compared	O
with	O
−	O
##1	O
.	O
2	O
for	O
c	B
##rea	I
##tin	I
##ine	I
alone	O
in	O
the	O
C	O
##K	O
##D	O
-	O
EP	O
##I	O
equation	O
(	O
in	O
the	O
high	O
c	B
##rea	I
##tin	I
##ine	I
part	O
of	O
the	O
s	O
##p	O
##line	O
)	O
.	O

Col	O
##onic	O
tissue	O
had	O
und	O
##ete	O
##ct	O
##able	O
levels	O
of	O
me	B
##lat	I
##oni	I
##n	I
and	O
3	B
-	I
h	I
##ydro	I
##xy	I
##xa	I
##nt	I
##hara	I
##ni	I
##lic	I
acid	I
(	O
data	O
not	O
shown	O
)	O
,	O
while	O
k	B
##yn	I
##uren	I
##ic	I
acid	I
levels	O
were	O
100	O
times	O
lower	O
than	O
K	O
##yn	O
(	O
C	O
)	O
,	O
and	O
c	O
##inn	O
##abar	O
##ini	O
##c	O
acid	O
was	O
>	O
1000	O
times	O
lower	O
than	O
K	O
##yn	O
(	O
D	O
)	O
.	O

For	O
example	O
,	O
studies	O
have	O
identified	O
P	O
##53	O
,	O
CD	O
##45	O
,	O
human	O
e	O
##pid	O
##er	O
##mal	O
growth	O
factor	O
receptor	O
2	O
and	O
β	B
-	I
act	I
##in	I
as	O
bio	O
##mark	O
##ers	O
using	O
tons	O
##il	O
and	O
breast	O
tissue	O
sections	O
from	O
FF	O
##P	O
##E	O
samples	O
in	O
retrospective	O
studies	O
.	O

Mat	B
##ric	I
##in	I
was	O
positively	O
correlated	O
with	O
Ba	O
##cter	O
##oid	O
##es	O
and	O
negatively	O
correlated	O
with	O
Act	O
##ino	O
##ba	O
##cter	O
##ia	O
;	O
pro	B
##tor	I
##if	I
##am	I
##y	I
##cin	I
I	O
was	O
negatively	O
correlated	O
with	O
Act	O
##ino	O
##ba	O
##cter	O
##ia	O
;	O
e	B
##pot	I
##hil	I
##one	I
A	O
was	O
negatively	O
correlated	O
with	O
Act	O
##ino	O
##ba	O
##cter	O
##ia	O
and	O
positively	O
correlated	O
with	O
Fi	O
##rm	O
##ic	O
##utes	O
;	O
PA	O
was	O
positively	O
correlated	O
with	O
Ba	O
##cter	O
##oid	O
##es	O
and	O
negatively	O
correlated	O
with	O
Fi	O
##rm	O
##ic	O
##utes	O
;	O
and	O
c	O
##rist	O
##aca	O
##rp	O
##in	O
was	O
positively	O
correlated	O
with	O
Act	O
##ino	O
##ba	O
##cter	O
##ia	O
;	O
however	O
,	O
this	O
correlation	O
relationship	O
does	O
not	O
imply	O
ca	O
##usal	O
##ity	O
.	O

The	O
flow	O
rate	O
was	O
15	O
m	O
##L	O
min	O
_	O
−	O
##1	O
,	O
the	O
back	O
##press	O
##ure	O
was	O
set	O
to	O
120	O
bar	O
,	O
and	O
after	O
the	O
column	O
,	O
the	O
el	O
##uen	O
##ts	O
were	O
combined	O
with	O
a	O
met	B
##han	I
##ol	I
make	O
-	O
up	O
flow	O
of	O
3	O
m	O
##L	O
min	O
_	O
−	O
##1	O
to	O
facilitate	O
the	O
detection	O
and	O
the	O
fraction	O
collection	O
.	O

Administration	O
of	O
L	B
-	I
a	I
##rg	I
##ini	I
##ne	I
stimulate	O
##d	O
the	O
th	O
##rom	O
##bus	O
l	O
##ys	O
##is	O
and	O
in	O
##hibit	O
##ed	O
plate	O
##let	O
a	O
##gg	O
##regation	O
##s	O
in	O
the	O
co	O
##rona	O
##ry	O
art	O
##eries	O
.	O

As	O
standard	O
method	O
to	O
evaluate	O
fatty	O
acid	O
-	O
s	O
##ynth	O
##eti	O
##zing	O
enzyme	O
activities	O
,	O
ass	O
##ay	O
measurement	O
of	O
the	O
rate	O
of	O
radio	O
##la	O
##bel	O
##ed	O
precursor	O
FA	S
to	O
their	O
respective	O
products	O
is	O
used	O
in	O
v	O
##it	O
##ro	O
and	O
in	O
v	O
##ivo	O
,	O
but	O
for	O
practical	O
and	O
ethical	O
reasons	O
is	O
not	O
possible	O
in	O
human	O
studies	O
.	O

The	O
ch	O
##em	O
##otype	O
##s	O
can	O
be	O
extended	O
to	O
include	O
other	O
vitamin	B
D	I
compounds	O
without	O
compromise	O
as	O
the	O
implemented	O
procedure	O
provides	O
similar	O
performance	O
for	O
all	O
meta	O
##bol	O
##ites	O
.	O

G	B
##lu	I
##cos	I
##yl	I
c	I
##era	I
##mi	I
##de	I
,	O
_	O
#	O
P	O
<	O
0	O
.	O
01	O
,	O
T	O
##2	O
##DM	O
vs	O
.	O
Pre	O
-	O
D	O
##M	O
and	O
*	O
P	O
<	O
0	O
.	O
05	O
,	O
T	O
##2	O
##DM	O
vs	O
.	O
Control	O
##s	O
;	O
s	B
##phi	I
##ngo	I
##sin	I
##e	I
-	I
1	I
phosphate	I
,	O
_	O
$	O
P	O
<	O
0	O
.	O
00	O
##1	O
,	O
Control	O
##s	O
vs	O
.	O
T	O
##2	O
##DM	O
and	O
_	O
#	O
P	O
<	O
0	O
.	O
01	O
,	O
Control	O
##s	O
vs	O
.	O
Pre	O
-	O
D	O
##M	O
;	O
s	B
##phi	I
##nga	I
##nine	I
,	O
_	O
#	O
P	O
<	O
0	O
.	O
01	O
,	O
Control	O
##s	O
vs	O
.	O
T	O
##2	O
##DM	O
,	O
and	O
_	O
$	O
P	O
<	O
0	O
.	O
00	O
##1	O
,	O
Control	O
##s	O
vs	O
.	O
Pre	O
-	O
D	O
##M	O
;	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
,	O
_	O
#	O
P	O
<	O
0	O
.	O
01	O
,	O
Control	O
##s	O
vs	O
.	O
T	O
##2	O
##DM	O
;	O
and	O
S	B
##phi	I
##ngo	I
##sin	I
##e	I
,	O
*	O
P	O
<	O
0	O
.	O
05	O
,	O
Control	O
##s	O
vs	O
.	O
T	O
##2	O
##DM	O
.	O

For	O
example	O
,	O
the	O
18	O
:	O
2	O
(	O
n	O
-	O
6	O
,	O
n	O
-	O
9	O
)	O
identified	O
here	O
is	O
most	O
likely	O
originating	O
from	O
plant	O
-	O
based	O
foods	O
in	O
the	O
patient	O
’	O
s	O
diet	O
as	O
humans	O
lack	O
the	O
bio	O
##sy	O
##nt	O
##hetic	O
machinery	O
for	O
the	O
de	O
no	O
##vo	O
synthesis	O
of	O
l	B
##ino	I
##le	I
##ic	I
acid	I
.	O

They	O
are	O
5	B
-	I
o	I
##x	I
##op	I
##rol	I
##ine	I
,	O
te	B
##tra	I
##de	I
##cane	I
##dio	I
##ate	I
,	O
he	B
##xa	I
##de	I
##cane	I
##dio	I
##ate	I
,	O
1	B
-	I
my	I
##risto	I
##yl	I
##gly	I
##cer	I
##op	I
##hos	I
##ph	I
##och	I
##olin	I
##e	I
,	O
2	B
-	I
my	I
##risto	I
##yl	I
##gly	I
##cer	I
##op	I
##hos	I
##ph	I
##or	I
##cho	I
##line	I
,	O
and	O
α	B
-	I
to	I
##co	I
##pher	I
##ol	I
.	O

Ten	O
of	O
the	O
13	O
meta	O
##bol	O
##ites	O
show	O
a	O
highly	O
significant	O
decrease	O
over	O
the	O
night	O
as	O
seen	O
in	O
the	O
example	O
of	O
me	B
##lat	I
##oni	I
##n	I
in	O
.	O

The	O
ass	O
##ay	O
exhibited	O
a	O
linear	O
dynamic	O
range	O
of	O
0	O
.	O
02	O
–	O
4	O
and	O
0	O
.	O
08	O
–	O
16	O
μ	O
##g	O
/	O
m	O
##l	O
for	O
Ce	B
##r	I
(	I
22	I
:	I
0	I
)	I
and	O
Ce	B
##r	I
(	I
24	I
:	I
0	I
)	I
,	O
respectively	O
,	O
in	O
human	O
plasma	O
with	O
corresponding	O
absolute	O
recover	O
##ies	O
from	O
plasma	O
at	O
109	O
and	O
114	O
%	O
,	O
respectively	O
.	O

Tam	B
##ox	I
##ife	I
##n	I
(	O
parent	O
drug	O
)	O
.	O

15	B
.	I
2	I
-	I
O	I
##x	I
##oa	I
##di	I
##pate	I
.	O

HP	O
##LC	O
-	O
grade	O
met	B
##han	I
##ol	I
and	O
ace	B
##tic	I
acid	I
were	O
purchased	O
from	O
Fisher	O
Scientific	O
(	O
Pittsburgh	O
,	O
PA	O
)	O
.	O

Key	O
nodes	O
linked	O
to	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
(	O
n	O
##uc	O
##leo	O
##tide	O
bio	O
##sy	O
##nt	O
##hesis	O
)	O
,	O
ch	B
##olin	I
##e	I
(	O
lip	O
##id	O
processing	O
)	O
,	O
amino	O
acids	O
,	O
ta	B
##uri	I
##ne	I
(	I
th	I
##iol	I
metabolism	I
)	I
,	O
and	O
more	O
indirectly	O
to	O
p	B
##yr	I
##u	I
##vate	I
,	O
la	B
##ct	I
##ate	I
and	O
ch	B
##ole	I
##ster	I
##ol	I
.	O

Ace	B
##ton	I
##it	I
##ril	I
##e	I
,	O
HP	O
##LC	O
grade	O
,	O
was	O
obtained	O
from	O
Me	O
##rc	O
##k	O
(	O
Dar	O
##ms	O
##tadt	O
,	O
Germany	O
)	O
;	O
met	B
##han	I
##ol	I
(	O
HP	O
##LC	O
grade	O
)	O
was	O
purchased	O
from	O
Fisher	O
Scientific	O
Corporation	O
(	O
Lou	O
##gh	O
##borough	O
,	O
UK	O
)	O
;	O
water	O
was	O
produced	O
by	O
a	O
Mill	O
##i	O
-	O
Q	O
Ultra	O
-	O
pure	O
water	O
system	O
(	O
Mill	O
##ip	O
##ore	O
,	O
Bill	O
##eric	O
##a	O
,	O
USA	O
)	O
;	O
form	B
##ic	I
acid	I
was	O
of	O
HP	O
##LC	O
grade	O
,	O
and	O
obtained	O
from	O
Honey	O
##well	O
Company	O
(	O
Morris	O
##town	O
,	O
New	O
Jersey	O
,	O
USA	O
)	O
;	O
le	B
##uc	I
##ine	I
en	I
##ke	I
##pha	I
##lin	I
was	O
purchased	O
from	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
(	O
St	O
.	O
Louis	O
,	O
M	O
##O	O
,	O
USA	O
)	O
.	O

Of	O
note	O
,	O
all	O
molecules	O
showed	O
a	O
post	O
##pra	O
##ndi	O
##al	O
increase	O
except	O
l	B
##ino	I
##le	I
##ic	I
acid	I
,	O
which	O
showed	O
a	O
post	O
##pra	O
##ndi	O
##al	O
decrease	O
.	O

He	B
##xa	I
##ne	I
(	O
as	O
blank	O
)	O
was	O
run	O
between	O
samples	O
to	O
remove	O
contamination	O
.	O

The	O
ch	O
##em	O
##otherapy	O
regime	O
##ns	O
used	O
were	O
either	O
flu	B
##oro	I
##ura	I
##ci	I
##l	I
,	O
e	B
##pi	I
##ru	I
##bic	I
##ine	I
and	O
c	O
##y	O
##c	O
##lop	O
##hos	O
##pha	O
##mi	O
##de	O
(	O
F	O
##EC	O
)	O
every	O
third	O
week	O
for	O
6	O
cycles	O
,	O
or	O
4	O
cycles	O
of	O
either	O
F	O
##EC	O
followed	O
by	O
12	O
weeks	O
of	O
either	O
do	O
##ce	O
##ta	O
##xe	O
##l	O
every	O
third	O
week	O
or	O
p	O
##ac	O
##lit	O
##ax	O
##el	O
every	O
week	O
.	O

It	O
has	O
been	O
reported	O
that	O
a	B
##rg	I
##ini	I
##ne	I
can	O
in	O
##hibit	O
chemical	O
-	O
induced	O
color	O
##ec	O
##tal	O
cancer	O
and	O
reduce	O
cell	O
proliferation	O
in	O
color	O
##ec	O
##tal	O
ad	O
##eno	O
##ma	O
patients	O
[	O
,	O
]	O
.	O

I	O
##dent	O
##ified	O
meta	O
##bol	O
##ites	O
:	O
3	O
,	O
al	B
##ani	I
##ne	I
;	O
6	O
,	O
as	B
##par	I
##agi	I
##ne	I
;	O
7	O
,	O
as	B
##par	I
##tic	I
acid	I
;	O
8	O
,	O
beta	B
##ine	I
;	O
9	O
,	O
c	B
##it	I
##ric	I
acid	I
;	O
12	O
,	O
form	B
##ic	I
acid	I
;	O
15	O
,	O
g	B
##lut	I
##ami	I
##c	I
acid	I
;	O
17	O
,	O
g	B
##ly	I
##cine	I
;	O
20	O
,	O
his	B
##ti	I
##dine	I
;	O
21	B
,	I
3	I
-	I
h	I
##ydro	I
##xy	I
##but	I
##yric	I
acid	I
;	O
22	B
,	I
4	I
-	I
h	I
##ydro	I
##xy	I
##p	I
##rol	I
##ine	I
;	O
23	B
,	I
2	I
-	I
h	I
##ydro	I
##xy	I
##is	I
##ob	I
##ut	I
##yric	I
acid	I
;	O
25	O
,	O
is	B
##ole	I
##uc	I
##ine	I
;	O
28	O
,	O
la	B
##ctic	I
acid	I
;	O
31	O
,	O
male	B
##ic	I
acid	I
;	O
33	O
,	O
ma	B
##lon	I
##ic	I
acid	I
;	O
39	O
,	O
prop	B
##ion	I
##ic	I
acid	I
;	O
48	O
,	O
v	B
##ali	I
##ne	I
.	O

The	O
analysis	O
error	O
due	O
to	O
drift	O
of	O
instrument	O
detector	O
responses	O
over	O
long	O
time	O
periods	O
were	O
corrected	O
using	O
internal	O
R	B
##I	I
standards	O
.	O

For	O
further	O
statistical	O
analysis	O
the	O
feature	O
representing	O
glucose	S
(	O
in	O
##dicative	O
for	O
diabetes	O
)	O
was	O
removed	O
from	O
the	O
data	O
.	O

The	O
levels	O
of	O
Met	B
##hi	I
##oni	I
##ne	I
,	O
2	B
-	I
Met	I
##hyl	I
##g	I
##lut	I
##ari	I
##c	I
acid	I
,	O
L	B
-	I
Alan	I
##ine	I
and	O
G	B
##ly	I
##co	I
##lic	I
acid	I
were	O
lower	O
in	O
the	O
urine	O
of	O
HIV	O
-	O
infected	O
persons	O
;	O
these	O
were	O
reduced	O
further	O
following	O
AR	O
##T	O
.	O

Value	O
##s	O
recorded	O
for	O
D	B
##MS	I
##O	I
controls	O
and	O
meta	O
##bol	O
##ite	O
-	O
treated	O
trip	O
##lica	O
##tes	O
were	O
averaged	O
.	O

A	O
h	O
##y	O
##pot	O
##hetical	O
diagram	O
suggesting	O
e	O
##pi	O
##gene	O
##tic	O
m	O
##od	O
##ulation	O
on	O
AR	O
##ID	O
##1	O
##A	O
by	O
α	B
-	I
O	I
##G	I
is	O
shown	O
in	O
Fi	O
##g	O
.	O

A	B
##rg	I
##ini	I
##ne	I
as	O
an	O
acid	O
##ifying	O
agent	O
might	O
alter	O
the	O
acid	O
-	O
base	O
equilibrium	O
in	O
C	O
##K	O
##D	O
,	O
and	O
increased	O
a	B
##rg	I
##ini	I
##ne	I
may	O
promote	O
kidney	O
injury	O
.	O

[	O
]	O
K	B
##yn	I
##uren	I
##ine	I
is	O
the	O
down	O
-	O
stream	O
meta	O
##bol	O
##ite	O
of	O
try	B
##pt	I
##op	I
##han	I
that	O
can	O
be	O
further	O
converted	O
to	O
3	B
-	I
h	I
##ydro	I
##xy	I
##ky	I
##nu	I
##ren	I
##ine	I
or	O
k	B
##yn	I
##uren	I
##ic	I
acid	I
.	O

Continuing	O
with	O
this	O
notation	O
,	O
the	O
95	O
%	O
confidence	O
limits	O
for	O
α	O
′	O
can	O
be	O
de	O
##ter	O
##mini	O
##stic	O
##ally	O
approximate	O
##d	O
by	O
q	B
##n	I
##α	I
##±	I
##n	I
##α	I
(	I
1	I
##−	I
##α	I
)	I
√	I
.	O
q	B
##n	I
##α	I
##±	I
##n	I
##α	I
(	I
1	I
##−	I
##α	I
)	I
√	I
q	I
##n	I
##α	I
##±	I
##n	I
##α	I
(	I
1	I
##−	I
##α	I
)	I
√	I
q	I
##n	I
##α	I
##±	I
##n	I
##α	I
(	I
1	I
##−	I
##α	I
)	I
√	I
q	I
##n	I
##α	I
##±	I
##n	I
##α	I
(	I
1	I
##−	I
##α	I
)	I
√	I
q	I
##n	I
##α	I
##±	I
##n	I
##α	I
(	I
1	I
##−	I
##α	I
)	I
√	I
q	I
##n	I
##α	I
##±	I
##n	I
##α	I
(	I
1	I
##−	I
##α	I
)	I
√	I
q	I
##n	I
##α	I
##±	I
##n	I
##α	I
(	I
1	I
##−	I
##α	I
)	I
√	I
q	I
##n	I
##α	I
##±	I
##n	I
##α	I
(	I
1	I
##−	I
##α	I
)	I
√	I
q	O
q	O
q	O
n	B
##α	I
##±	I
##n	I
##α	I
(	I
1	I
##−	I
##α	I
)	I
√	I
n	I
##α	I
##±	I
##n	I
##α	I
(	I
1	I
##−	I
##α	I
)	I
√	I
n	O
α	O
±	O
n	B
##α	I
(	I
1	I
##−	I
##α	I
)	I
√	I
n	I
##α	I
(	I
1	I
##−	I
##α	I
)	I
√	I
n	I
##α	I
(	I
1	I
##−	I
##α	I
)	I
n	I
##α	I
(	I
1	I
##−	I
##α	I
)	I
n	I
##α	I
(	I
1	I
##−	I
##α	I
)	I

The	O
pathways	O
significantly	O
en	O
##rich	O
##ed	O
by	O
these	O
related	O
compounds	O
were	O
(	O
F	O
##DR	O
<	O
=	O
1	O
)	O
were	O
(	O
1	O
)	O
l	B
##ino	I
##le	I
##ic	I
acid	I
and	O
alpha	B
l	I
##ino	I
##len	I
##ic	I
acid	I
metabolism	O
,	O
(	O
2	O
)	O
as	B
##par	I
##tate	I
metabolism	O
,	O
(	O
3	O
)	O
insulin	O
signaling	O
,	O
(	O
4	O
)	O
u	B
##rea	I
cycle	O
,	O
(	O
5	O
)	O
al	B
##ani	I
##ne	I
metabolism	O
and	O
(	O
6	O
)	O
c	B
##it	I
##ric	I
acid	I
cycle	O
.	O

In	O
addition	O
to	O
percentage	O
of	O
body	O
fat	O
,	O
B	O
##MI	O
co	O
##rrel	O
##ates	O
with	O
total	O
muscle	O
mass	O
,	O
so	O
it	O
was	O
important	O
to	O
adjust	O
in	O
our	O
analyses	O
for	O
u	O
##rina	O
##ry	O
c	B
##rea	I
##tin	I
##ine	I
(	O
model	O
3	O
)	O
,	O
as	O
a	O
marker	O
of	O
muscle	O
turnover	O
.	O

The	O
fi	O
##lt	O
##rate	O
was	O
dried	O
by	O
pure	O
nitrogen	B
gas	I
(	O
50	O
##°	O
##C	O
)	O
.	O

Based	O
on	O
the	O
is	O
##che	O
##mic	O
insult	O
severity	O
,	O
elevation	O
of	O
cat	B
##ech	I
##ola	I
##mine	I
levels	O
can	O
be	O
observed	O
for	O
prolonged	O
periods	O
of	O
up	O
to	O
24	O
h	O
.	O

Interest	O
##ingly	O
,	O
the	O
27	B
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
level	O
was	O
significantly	O
higher	O
in	O
the	O
first	O
sampling	O
of	O
patients	O
with	O
positive	O
personal	O
history	O
of	O
h	O
##yper	O
##cho	O
##les	O
##tero	O
##lem	O
##ia	O
,	O
h	O
##y	O
##pot	O
##hy	O
##roid	O
##ism	O
,	O
h	O
##yster	O
##ec	O
##tom	O
##y	O
,	O
or	O
ho	O
##rmon	O
##al	O
replacement	O
therapy	O
compared	O
to	O
patients	O
without	O
such	O
conditions	O
.	O

Analysis	O
of	O
N	O
##MR	O
s	O
##pect	O
##ra	O
by	O
partial	O
least	O
squares	O
disc	O
##rim	O
##ina	O
##nt	O
analysis	O
of	O
high	O
compared	O
with	O
low	O
c	B
##ys	I
##tat	I
##hi	I
##oni	I
##ne	I
classes	O
.	O

Act	O
##ual	O
and	O
E	O
##st	O
##imated	O
Value	O
##s	O
for	O
Whole	O
-	O
Body	O
In	O
##sul	O
##in	O
Sen	O
##si	O
##ti	O
##vity	O
(	O
M	O
-	O
value	O
)	O
and	O
S	O
##kel	O
##etal	O
Mu	O
##s	O
##cle	O
G	B
##lu	I
##cos	I
##e	I
Up	O
##take	O
(	O
G	O
##U	O
)	O
in	O
the	O
Test	O
Group	O
Data	O
represented	O
as	O
median	O
(	O
inter	O
##qua	O
##rt	O
##ile	O
range	O
)	O
.	O

Several	O
buffer	O
##s	O
were	O
assessed	O
,	O
such	O
as	O
am	B
##mon	I
##ium	I
format	I
##e	I
and	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
,	O
with	O
concentrations	O
ranging	O
from	O
5	O
to	O
50	O
m	O
##M	O
adjusted	O
to	O
a	O
pH	O
range	O
from	O
4	O
to	O
8	O
.	O

Free	O
o	B
##xy	I
##ster	I
##ol	I
concentrations	O
adjusted	O
to	O
free	O
ch	B
##ole	I
##ster	I
##ol	I
in	O
plasma	O
from	O
h	B
##yper	I
##cho	I
##les	I
##tero	I
##la	I
##em	I
##ic	I
patients	O
before	O
and	O
after	O
Si	B
##m	I
##vas	I
##tat	I
##in	I
intervention	O
(	O
n	O
=	O
10	O
in	O
each	O
group	O
)	O
.	O

Among	O
the	O
32	O
disc	O
##rim	O
##ina	O
##nt	O
lip	O
##ids	O
,	O
9	O
lip	O
##ids	O
were	O
significantly	O
decreased	O
in	O
NAS	O
##H	O
,	O
mainly	O
c	B
##era	I
##mi	I
##des	I
and	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
.	O

While	O
the	O
levels	O
for	O
la	B
##ctic	I
acid	I
,	O
3	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
,	O
l	B
##ys	I
##ine	I
,	O
g	B
##lut	I
##amine	I
and	O
c	B
##it	I
##rate	I
increased	O
,	O
the	O
levels	O
for	O
v	B
##ali	I
##ne	I
,	O
le	O
##uc	O
##ine	O
/	O
is	O
##ole	O
##uc	O
##ine	O
,	O
met	B
##hi	I
##oni	I
##ne	I
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
try	B
##pt	I
##op	I
##han	I
,	O
my	B
##rist	I
##ic	I
acid	I
and	O
l	B
##ino	I
##le	I
##ic	I
acid	I
decreased	O
progressively	O
.	O

Ex	O
##c	O
##lusion	O
criteria	O
,	O
based	O
on	O
surveys	O
and	O
other	O
tools	O
applied	O
by	O
trained	O
personnel	O
in	O
primary	O
health	O
centers	O
and	O
by	O
laboratory	O
analyses	O
conducted	O
at	O
the	O
Institute	O
of	O
N	O
##utrition	O
and	O
Food	O
Technology	O
,	O
University	O
of	O
Chile	O
,	O
were	O
severe	O
cognitive	O
imp	O
##air	O
##ment	O
(	O
Mini	O
Mental	O
State	O
Examination	O
score	O
<	O
19	O
)	O
,	O
diabetes	O
me	O
##lli	O
##tus	O
(	O
fast	O
##ing	O
glucose	S
≥	O
126	O
mg	O
/	O
d	O
##L	O
or	O
receiving	O
insulin	O
or	O
other	O
anti	O
##dia	O
##bet	O
##ic	O
medications	O
)	O
,	O
advanced	O
re	O
##nal	O
imp	O
##air	O
##ment	O
(	O
c	O
##rea	O
##tin	O
##ine	O
clearance	O
≥	O
30	O
g	O
/	O
L	O
)	O
,	O
h	O
##y	O
##pot	O
##hy	O
##roid	O
##ism	O
(	O
plasma	O
thy	O
##roid	O
-	O
s	O
##ti	O
##mulating	O
hormone	O
>	O
6	O
m	O
##l	O
##U	O
/	O
L	O
)	O
,	O
gas	O
##tro	O
##int	O
##est	O
##inal	O
surgery	O
,	O
alcohol	O
abuse	O
based	O
on	O
reported	O
daily	O
alcohol	O
consumption	O
in	O
the	O
past	O
3	O
m	O
##o	O
,	O
and	O
clinical	O
history	O
of	O
stroke	O
.	O

Several	O
key	O
enzymes	O
of	O
the	O
car	B
##ni	I
##tine	I
-	I
a	I
##cy	I
##l	I
##car	I
##ni	I
##tine	I
metabolic	O
pathway	O
or	O
try	B
##pt	I
##op	I
##han	I
pathway	O
were	O
selected	O
for	O
further	O
valid	O
##ation	O
.	O

A	O
large	O
number	O
of	O
ma	O
##li	O
##gnant	O
tumor	O
cells	O
need	O
a	O
large	O
and	O
rapid	O
supply	O
of	O
oxygen	O
,	O
but	O
even	O
when	O
the	O
supply	O
of	O
oxygen	O
is	O
sufficient	O
,	O
the	O
cancer	O
cells	O
still	O
rely	O
on	O
obtaining	O
a	O
large	O
number	O
to	O
consume	O
the	O
glucose	S
,	O
for	O
an	O
##ae	O
##ro	O
##bic	O
f	O
##er	O
##mentation	O
,	O
and	O
convert	O
it	O
to	O
la	B
##ctic	I
acid	I
so	O
that	O
it	O
can	O
obtain	O
the	O
energy	O
rapidly	O
under	O
the	O
function	O
of	O
la	O
##ct	O
##ate	O
de	O
##hy	O
##dr	O
##ogen	O
##ase	O
,	O
known	O
as	O
the	O
War	O
##burg	O
effect	O
.	O

Fen	O
##tany	O
##l	O
,	O
nor	O
##fen	O
##tany	O
##l	O
,	O
mid	B
##az	I
##ola	I
##m	I
,	O
and	O
1	B
′	I
-	I
OH	I
-	I
mid	I
##az	I
##ola	I
##m	I
were	O
q	O
##uant	O
##ified	O
by	O
liquid	O
ch	O
##roma	O
##tography	O
/	O
tandem	O
mass	O
s	O
##pect	O
##rome	O
##try	O
.	O

R	B
##V	I
is	O
calculated	O
as	O
follows	O
:	O
R	O
##V	O
##m	O
=	O
[UNK]	S
=	O
[UNK]	S
=	O
1	O
(	O
[UNK]	S
=	O
1	O
##EP	O
##i	O
)	O
R	O
##V	O
##m	O
=	O
[UNK]	S
=	O
[UNK]	S
=	O
1	O
(	O
[UNK]	S
=	O
1	O
##EP	O
##i	O
)	O
R	O
##V	O
##m	O
=	O
[UNK]	S
=	O
[UNK]	S
=	O
1	O
(	O
[UNK]	S
=	O
1	O
##EP	O
##i	O
)	O
R	O
##V	O
##m	O
=	O
[UNK]	S
=	O
[UNK]	S
=	O
1	O
(	O
[UNK]	S
=	O
1	O
##EP	O
##i	O
)	O
R	O
##V	O
##m	O
=	O
[UNK]	S
=	O
[UNK]	S
=	O
1	O
(	O
[UNK]	S
=	O
1	O
##EP	O
##i	O
)	O
R	O
##V	O
##m	O
=	O
[UNK]	S
=	O
[UNK]	S
=	O
1	O
(	O
[UNK]	S
=	O
1	O
##EP	O
##i	O
)	O

Collective	O
##ly	O
the	O
obtained	O
results	O
propose	O
the	O
presence	O
of	O
PC	B
17	I
:	I
0	I
/	I
20	I
:	I
5	I
,	O
PC	B
P	I
-	I
18	I
:	I
0	I
/	I
20	I
:	I
4	I
,	O
PC	B
O	I
-	I
18	I
:	I
0	I
/	I
20	I
:	I
5	I
and	O
PC	B
O	I
-	I
16	I
:	I
0	I
/	I
22	I
:	I
5	I
.	O

Z	O
##D	O
##V	O
-	O
MP	O
was	O
el	O
##uted	O
1	O
min	O
after	O
an	O
interfering	O
peak	O
,	O
which	O
could	O
be	O
d	O
##GM	O
##P	O
,	O
AM	B
##P	I
,	O
or	O
a	O
co	O
##el	O
##ution	O
of	O
both	O
.	O

In	O
the	O
present	O
study	O
,	O
MA	O
##S	O
N	O
##MR	O
results	O
clearly	O
showed	O
decreased	O
levels	O
of	O
T	B
##G	I
in	O
tumor	O
and	O
L	O
##N	O
-	O
Met	O
tissues	O
compared	O
to	O
N	O
##AT	O
.	O

Inc	O
##reased	O
my	O
##oc	O
##ard	O
##ial	O
work	O
induced	O
significant	O
changes	O
in	O
the	O
peripheral	O
concentration	O
of	O
43	O
of	O
125	O
meta	O
##bol	O
##ites	O
ass	O
##ay	O
##ed	O
,	O
including	O
large	O
changes	O
in	O
pu	B
##rine	I
[	O
ad	O
##eno	O
##sin	O
##e	O
(	O
+	O
99	O
%	O
,	O
p	O
=	O
0	O
.	O
00	O
##6	O
)	O
,	O
AD	B
##P	I
(	O
+	O
42	O
%	O
,	O
p	O
=	O
0	O
.	O
01	O
)	O
,	O
AM	B
##P	I
(	O
+	O
79	O
%	O
,	O
p	O
=	O
0	O
.	O
00	O
##4	O
)	O
,	O
GDP	O
(	O
+	O
69	O
%	O
,	O
p	O
=	O
0	O
.	O
00	O
##3	O
)	O
,	O
GM	O
##P	O
(	O
+	O
58	O
%	O
,	O
p	O
=	O
0	O
.	O
01	O
)	O
,	O
I	B
##MP	I
(	O
+	O
50	O
%	O
,	O
p	O
=	O
0	O
.	O
03	O
)	O
,	O
x	B
##ant	I
##hine	I
(	O
+	O
61	O
%	O
,	O
p	O
=	O
0	O
.	O
000	O
##6	O
)	O
]	O
,	O
and	O
several	O
bi	O
##le	O
acid	O
meta	O
##bol	O
##ites	O
.	O

As	O
a	O
preliminary	O
study	O
,	O
we	O
determined	O
su	B
##lf	I
##ate	I
and	O
ta	B
##uri	I
##ne	I
concentration	O
in	O
64	O
urine	O
samples	O
collected	O
from	O
eight	O
volunteers	O
over	O
8	O
weeks	O
.	O

Complex	O
lip	O
##ids	O
,	O
fatty	O
acids	O
,	O
and	O
related	O
meta	O
##bol	O
##ites	O
were	O
more	O
robust	O
towards	O
the	O
applied	O
con	O
##found	O
##ers	O
(	O
Table	O
S	O
##2	O
)	O
,	O
except	O
for	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
,	O
which	O
were	O
increased	O
upon	O
extended	O
serum	O
storage	O
at	O
R	O
##T	O
(	O
Table	O
S	O
##1	O
)	O
,	O
likely	O
because	O
of	O
p	O
##hos	O
##ph	O
##oli	O
##pas	O
##e	O
A	O
activity	O
.	O

In	O
all	O
,	O
61	O
##9	O
features	O
were	O
found	O
in	O
the	O
M	B
##T	I
##BE	I
lip	O
##id	O
fraction	O
and	O
512	O
were	O
found	O
in	O
the	O
met	B
##han	I
##ol	I
super	O
##nat	O
##ant	O
,	O
with	O
325	O
features	O
in	O
common	O
.	O

Finally	O
,	O
in	O
order	O
to	O
extract	O
the	O
maximum	O
amount	O
of	O
information	O
from	O
our	O
data	O
,	O
PC	O
##A	O
and	O
P	O
##LS	O
-	O
D	O
##A	O
were	O
also	O
performed	O
using	O
the	O
peak	O
areas	O
of	O
all	O
42	O
am	O
##ines	O
,	O
including	O
1	B
-	I
met	I
##hyl	I
##his	I
##ti	I
##dine	I
,	O
3	B
-	I
met	I
##hyl	I
##his	I
##ti	I
##dine	I
and	O
g	B
##lut	I
##ath	I
##ione	I
(	O
Su	O
##pp	O
##lement	O
##ary	O
Fi	O
##g	O
.	O

In	O
the	O
present	O
study	O
,	O
as	O
association	O
analysis	O
indicated	O
,	O
patients	O
with	O
higher	O
try	B
##pt	I
##op	I
##han	I
level	O
tended	O
to	O
present	O
higher	O
degree	O
of	O
insulin	O
resistance	O
(	O
H	O
##OM	O
##A	O
-	O
I	O
##R	O
and	O
Mat	O
##su	O
##da	O
index	O
)	O
,	O
and	O
more	O
active	O
insulin	O
secret	O
##ion	O
(	O
1	O
_	O
s	O
##t	O
-	O
and	O
2	O
_	O
n	O
##d	O
-	O
phase	O
secret	O
##ion	O
)	O
.	O

A	O
clean	O
-	O
up	O
step	O
with	O
ace	O
##ton	O
##it	O
##ril	O
##e	O
/	O
water	O
(	O
1	O
:	O
1	O
)	O
removed	O
membrane	O
lip	O
##ids	O
and	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
,	O
and	O
the	O
super	O
##nat	O
##ant	O
was	O
again	O
dried	O
down	O
.	O

A	O
##pp	O
##re	O
##cia	O
##ble	O
la	B
##ct	I
##ose	I
concentrations	O
in	O
urine	O
are	O
usually	O
first	O
observed	O
at	O
the	O
end	O
of	O
the	O
second	O
trim	O
##ester	O
,	O
between	O
g	O
##esta	O
##tional	O
week	O
20	O
and	O
28	O
,	O
followed	O
by	O
a	O
steady	O
increase	O
over	O
the	O
remainder	O
of	O
the	O
pregnancy	O
and	O
another	O
sharp	O
rise	O
in	O
the	O
days	O
after	O
delivery	O
.	O
,	O

It	O
should	O
be	O
noted	O
that	O
IS	O
for	O
q	O
##uant	O
##ification	O
of	O
all	O
other	O
o	B
##xy	I
##lip	I
##ins	I
covered	O
by	O
our	O
method	O
show	O
good	O
recover	O
##ies	O
from	O
matrix	O
between	O
72	O
±	O
3	O
%	O
(	O
_	O
2	O
H	O
_	O
8	O
-	O
5	O
-	O
H	O
##ET	O
##E	O
)	O
and	O
105	O
±	O
6	O
%	O
(	O
_	O
2	O
H	O
_	O
11	O
-	O
5	O
(	O
R	O
,	O
S	O
)	O
-	O
5	O
-	O
F	O
_	O
2	O
##t	O
-	O
Is	O
##o	O
##P	O
)	O
.	O

Regarding	O
p	B
##hen	I
##yla	I
##ce	I
##ty	I
##gly	I
##cine	I
,	O
increased	O
ex	O
##cre	O
##tion	O
has	O
also	O
been	O
reported	O
in	O
lung	O
cancer	O
as	O
well	O
as	O
model	O
rats	O
of	O
color	O
##ec	O
##tal	O
cancer	O
,	O
possibly	O
relating	O
to	O
gut	O
micro	O
##f	O
##lora	O
metabolism	O
,	O
.	O

Ser	O
##um	O
S	O
##1	O
##P	O
and	O
urine	O
s	B
##phi	I
##ngo	I
##sin	I
##e	I
may	O
be	O
potential	O
bio	O
##mark	O
##ers	O
for	O
the	O
A	O
##ER	O
##D	O
p	O
##hen	O
##otype	O
.	O

To	O
confirm	O
further	O
the	O
assignment	O
for	O
G	O
##6	O
##P	O
(	O
as	O
opposed	O
to	O
glucose	S
)	O
,	O
2	O
-	O
D	O
high	O
-	O
resolution	O
_	O
1	O
H	O
-	O
_	O
13	O
C	O
H	O
##S	O
##Q	O
##C	O
-	O
TO	O
##CS	O
##Y	O
s	O
##pect	O
##ra	O
were	O
analyzed	O
and	O
that	O
for	O
the	O
my	O
##ocytes	O
is	O
illustrated	O
in	O
Figure	O
.	O

Ser	O
##um	O
c	B
##rea	I
##tin	I
##ine	I
concentration	O
was	O
assessed	O
with	O
a	O
modified	O
J	O
##af	O
##fe	O
test	O
(	O
K	O
##rea	O
F	O
##lex	O
;	O
Dad	O
##e	O
Be	O
##hr	O
##ing	O
)	O
,	O
and	O
the	O
estimated	O
g	O
##lo	O
##mer	O
##ular	O
fi	O
##ltration	O
rate	O
was	O
calculated	O
using	O
the	O
C	O
##K	O
##D	O
-	O
EP	O
##I	O
equation	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
study	O
two	O
su	B
##lf	I
##ate	I
meta	O
##bol	O
##ites	O
of	O
m	B
##or	I
##phine	I
in	O
humans	O
.	O

(	O
F	O
)	O
R	O
##OC	O
of	O
the	O
combined	O
model	O
(	O
1	O
,	O
p	B
##hos	I
##ph	I
##ory	I
##l	I
##cho	I
##line	I
;	O
2	O
,	O
L	B
-	I
ace	I
##ty	I
##l	I
##car	I
##ni	I
##tine	I
;	O
3	O
,	O
a	B
##rac	I
##hi	I
##don	I
##ic	I
acid	I
;	O
4	O
,	O
g	B
##ly	I
##co	I
##cho	I
##lic	I
acid	O
)	O
.	O

Following	O
the	O
addition	O
of	O
N	O
##I	O
##HS	O
##S	O
to	O
the	O
model	O
,	O
su	B
##cci	I
##nate	I
remained	O
an	O
independent	O
predict	O
##or	O
of	O
CE	O
stroke	O
(	O
a	O
##OR	O
1	O
.	O
36	O
,	O
95	O
%	O
C	O
##I	O
1	O
.	O
01	O
–	O
1	O
.	O
83	O
,	O
p	O
=	O
0	O
.	O
04	O
##5	O
)	O
.	O

The	O
corresponding	O
loading	O
plot	O
of	O
PC	O
##1	O
indicated	O
increased	O
levels	O
of	O
car	B
##ni	I
##tine	I
,	O
beta	B
##ine	I
,	O
ch	B
##olin	I
##e	I
,	O
g	B
##ly	I
##cer	I
##ol	I
,	O
g	B
##ly	I
##cine	I
and	O
glucose	S
in	O
the	O
serum	O
of	O
ST	O
##EM	O
##I	O
patients	O
.	O
_	O
1	O
H	O
-	O
N	O
##MR	O
based	O
PC	O
##A	O
of	O
ST	O
##EM	O
##I	O
patients	O
(	O
[UNK]	O
)	O
,	O
before	O
s	O
##ten	O
##t	O
samples	O
of	O
U	O
##A	O
patients	O
and	O
healthy	O
controls	O
(	O
●	O
)	O
(	O
A	O
)	O
Score	O
plot	O
of	O
PC	O
##1	O
and	O
PC	O
##2	O
scores	O
(	O
B	O
)	O
Lo	O
##ading	O
plot	O
for	O
PC	O
##1	O
components	O
contributing	O
bin	O
numbers	O
.	O

All	O
standards	O
were	O
purchased	O
from	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
,	O
except	O
for	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
-	I
d	I
##5	I
,	O
which	O
was	O
from	O

The	O
retention	O
time	O
(	O
R	O
##T	O
)	O
C	O
##V	O
%	O
values	O
of	O
all	O
lip	O
##id	O
IS	O
##T	O
##Ds	O
on	O
reverse	O
phase	O
ch	O
##roma	O
##tography	O
in	O
both	O
met	B
##han	I
##ol	I
and	O
met	B
##han	I
##ol	I
-	I
ethanol	I
precipitation	O
methods	O
are	O
below	O
1	O
%	O
(	O
Show	O
##n	O
in	O
)	O
.	O

Selected	O
lip	O
##id	O
meta	O
##bol	O
##ites	O
,	O
including	O
fatty	O
acids	O
and	O
ch	B
##ole	I
##ster	I
##ol	I
were	O
increased	O
in	O
concentration	O
in	O
subjects	O
aged	O
between	O
51	O
–	O
65	O
years	O
of	O
age	O
compared	O
to	O
younger	O
subjects	O
.	O

Principal	O
component	O
analysis	O
(	O
PC	O
##A	O
)	O
separated	O
the	O
three	O
conditions	O
,	O
and	O
co	O
##rro	O
##bor	O
##ates	O
lower	O
variance	O
in	O
Me	B
##OH	I
pp	O
##t	O
+	O
U	O
##F	O
samples	O
(	O
Figure	O
S	O
##3	O
)	O
.	O

For	O
co	B
##tin	I
##ine	I
,	O
the	O
y	O
-	O
intercept	O
was	O
20	O
.	O
9	O
nm	O
##ol	O
/	O
m	O
##L	O
in	O
urine	O
samples	O
from	O
smoke	O
##rs	O
(	O
Figure	O
A	O
)	O
,	O
consistent	O
with	O
the	O
20	O
.	O
8	O
nm	O
##ol	O
/	O
m	O
##L	O
amount	O
determined	O
in	O
these	O
samples	O
when	O
no	O
co	B
##tin	I
##ine	I
was	O
added	O
.	O

Thus	O
,	O
we	O
suggest	O
that	O
OH	O
-	O
E	O
_	O
2	O
rather	O
than	O
Me	O
##O	O
-	O
E	O
_	O
2	O
should	O
be	O
measured	O
directly	O
when	O
studying	O
the	O
health	O
effects	O
of	O
di	B
##ox	I
##in	I
and	O
di	O
##ox	O
##in	O
-	O
like	O
compound	O
exposure	O
.	O

For	O
example	O
,	O
the	O
ratio	O
between	O
inter	O
##cellular	O
ATP	S
and	O
AM	B
##P	I
has	O
been	O
used	O
to	O
estimate	O
the	O
ma	O
##lf	O
##un	O
##ction	O
of	O
the	O
mit	O
##och	O
##ond	O
##ria	O
d	O
##ys	O
##function	O
during	O
aging	O
and	O
path	O
##ology	O
.	O

Ra	O
##s	O
remained	O
activated	S
for	O
at	O
least	O
20	O
min	O
after	O
W	O
##IT	O
##00	O
##3	O
stimulation	O
.	O

IS	O
##T	O
##Ds	O
-	O
spike	O
##d	O
BR	O
human	O
plasma	O
samples	O
were	O
processed	O
with	O
SP	O
##E	O
columns	O
before	O
el	O
##uti	O
##ng	O
with	O
1200	O
μ	O
##L	O
Me	B
##OH	I
and	O
dried	O
at	O
room	O
temperature	O
and	O
re	O
##con	O
##stituted	O
for	O
L	O
##C	O
-	O
MR	O
##M	O
-	O
MS	O
analysis	O
.	O

The	O
level	O
of	O
ace	B
##ty	I
##l	I
-	I
Co	I
##A	I
was	O
slightly	O
reduced	O
(	O
Fi	O
##g	O
.	O

concentrations	O
and	O
to	O
changes	O
in	O
ch	B
##olin	I
##e	I
metabolism	O
,	O
with	O
T	B
##MA	I
##O	I
being	O
the	O
only	O
u	O
##rina	O
##ry	O
meta	O
##bol	O
##ite	O
to	O
be	O
different	O
in	O
those	O
with	O
H	O
##E	O
re	O
##cu	O
##rrence	O
(	O
Baja	O
##j	O
et	O
al	O
.	O
)	O
.	O

In	O
total	O
,	O
2	O
,	O
08	O
##9	O
molecular	O
features	O
were	O
detected	O
when	O
met	B
##han	I
##ol	I
super	O
##nat	O
##ants	O
were	O
analyzed	O
using	O
H	O
##IL	O
##IC	O
,	O
and	O
2	O
,	O
233	O
features	O
in	O
met	B
##han	I
##ol	I
-	I
ethanol	I
super	O
##nat	O
##ants	O
.	O

Multiple	O
variants	O
in	O
C	O
##YP	O
##39	O
##A	O
##1	O
,	O
which	O
en	O
##codes	O
an	O
o	O
##xy	O
##ster	O
##ol	O
7	O
##α	O
-	O
h	O
##ydro	O
##xy	O
##lase	O
,	O
were	O
strongly	O
associated	O
with	O
increased	O
levels	O
of	O
the	O
o	B
##xy	I
##ster	I
##ol	I
24	I
##S	I
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
.	O

Is	B
##ole	I
##uc	I
##ine	I
is	O
one	O
of	O
branched	O
-	O
chain	O
amino	O
acids	O
(	O
BC	O
##AA	O
##s	O
)	O
,	O
and	O
this	O
amino	O
acid	O
is	O
transported	O
across	O
the	O
blood	O
-	O
brain	O
barrier	O
as	O
nut	O
##rient	O
signals	O
and	O
nitrogen	O
donors	O
in	O
ne	O
##uro	O
##tra	O
##ns	O
##mit	O
##ter	O
synthesis	O
and	O
G	O
##lu	O
-	O
G	O
##ln	O
cycle	O
.	O

However	O
,	O
the	O
common	O
name	O
is	O
27	B
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
on	O
account	O
of	O
its	O
formation	O
via	O
the	O
mitochondrial	O
C	O
##YP	O
##27	O
##A	O
##1	O
-	O
cat	O
##aly	O
##zed	O
h	O
##ydro	O
##xy	O
##lation	O
of	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
and	O
this	O
will	O
be	O
the	O
name	O
used	O
here	O
,	O
although	O
we	O
will	O
use	O
the	O
abbreviation	O
C	B
_	I
5	I
-	I
3	I
##β	I
,	I
26	I
-	I
di	I
##ol	I
in	O
accord	O
with	O
the	O
systematic	O
name	O
ch	B
##ole	I
##st	I
-	I
5	I
-	I
en	I
##e	I
-	I
3	I
##β	I
,	I
26	I
-	I
di	I
##ol	I
recommended	O
by	O
F	O
##ah	O
##y	O
et	O
al	O
.	O
.	O

Ace	B
##to	I
##ace	I
##tate	I
increased	O
significantly	O
at	O
post	O
-	O
event	O
(	O
6	O
.	O
1	O
±	O
1	O
.	O
5	O
mg	O
/	O
m	O
##l	O
)	O
.	O

Low	O
density	O
lip	O
##op	O
##rote	O
##in	O
(	O
L	O
##D	O
##L	O
)	O
ch	B
##ole	I
##ster	I
##ol	I
was	O
calculated	O
by	O
the	O
Fr	O
##ied	O
##ew	O
##ald	O
formula	O
if	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
were	O
<	O
4	O
.	O
5	O
mm	O
##ol	O
/	O

We	O
found	O
that	O
RC	O
##C	O
patients	O
had	O
higher	O
levels	O
of	O
la	B
##ct	I
##ate	I
and	O
al	B
##ani	I
##ne	I
in	O
serum	O
compared	O
to	O
healthy	O
subjects	O
.	O

C	B
##it	I
##ru	I
##llin	I
##e	I
and	O
or	B
##ni	I
##thin	I
##e	I
are	O
non	O
-	O
protein	O
##ogenic	O
amino	O
acids	O
that	O
are	O
involved	O
in	O
the	O
u	B
##rea	I
cycle	O
.	O

We	O
observed	O
significantly	O
increased	O
levels	O
of	O
FA	O
##s	O
(	B
FA	B
(	I
14	I
:	I
0	I
)	I
,	O
FA	B
(	I
14	I
:	I
1	I
)	I
-	I
1	I
,	O
FA	B
(	I
14	I
:	I
1	I
)	I
-	I
2	I
,	O
and	O
FA	B
(	I
18	I
:	I
0	I
)	I
)	O
in	O
MS	O
##A	O
.	O

(	O
A	O
)	O
lip	O
##id	O
metabolism	O
##s	O
;	O
(	O
B	O
)	O
g	B
##lut	I
##ath	I
##ione	I
metabolism	O
.	O

The	O
parameters	O
for	O
L	O
##T	O
##Q	O
-	O
F	O
##T	O
Ultra	O
MS	O
were	O
:	O
ion	O
source	O
voltage	O
,	O
3	O
k	B
##V	I
;	O
nitrogen	O
sheath	O
and	O
aux	O
gas	O
flow	O
,	O
0	O
and	O
0	O
units	O
,	O
respectively	O
(	O
because	O
na	O
##no	O
-	O
E	O
##SI	O
uses	O
low	O
volume	O
of	O
solvent	O
and	O
does	O
not	O
require	O
gas	O
-	O
assisted	O
de	O
-	O
so	O
##l	O
##vation	O
and	O
ion	O
##ization	O
process	O
)	O
;	O
ion	O
transfer	O
cap	O
##illa	O
##ry	O
temperature	O
,	O
250	O
°C	O
;	O
cap	O
##illa	O
##ry	O
voltage	O
,	O
35	O
V	O
;	O
tube	O
lens	O
,	O
130	O
V	O
;	O
typical	O
ion	O
gauge	O
pressure	O
,	O
0	O
.	O
60	O
×	O
10	O
-	O
5	O
Tor	O
##r	O
.	O

Overall	O
differences	O
between	O
the	O
c	B
##ys	I
##tat	I
##hi	I
##oni	I
##ne	I
groups	O
were	O
assessed	O
by	O
un	O
##tar	O
##get	O
##ed	O
N	O
##MR	O
and	O
L	O
##C	O
-	O
MS	O
meta	O
##bol	O
##omi	O
##c	O
methods	O
and	O
evaluated	O
by	O
partial	O
least	O
squares	O
disc	O
##rim	O
##ina	O
##nt	O
analysis	O
(	O
P	O
##LS	O
-	O
D	O
##A	O
)	O
with	O
significant	O
disc	O
##rim	O
##inating	O
meta	O
##bol	O
##ites	O
identified	O
with	O
99	O
%	O
confidence	O
.	O

Among	O
the	O
recognized	O
ma	O
##mmal	O
##ian	O
o	B
##xy	I
##lip	I
##ins	I
are	O
the	O
a	O
##rac	O
##hi	O
##don	O
##ic	O
acid	O
-	O
derived	O
pro	B
##sta	I
##g	I
##land	I
##ins	I
,	O
le	O
##uk	O
##ot	O
##rien	O
##es	O
,	O
lip	B
##ox	I
##ins	I
,	O
he	O
##pox	O
##ili	O
##ns	O
,	O
h	B
##ydro	I
##xy	I
,	O
e	B
##pox	I
##y	I
and	O
di	B
##hy	I
##dr	I
##ox	I
##y	I
meta	O
##bol	O
##ites	O
as	O
well	O
as	O
analog	O
##s	O
formed	O
from	O
other	O
highly	O
un	O
##sat	O
##ura	O
##ted	O
lip	O
##ids	O
(	O
e	O
.	O
g	O
.	O
re	O
##sol	O
##vin	O
##s	O
,	O
protect	O
##ins	O
)	O
,	O
and	O
an	O
array	O
of	O
oxygen	O
##ated	O
eighteen	O
carbon	O
lip	O
##ids	O
.	O

f	O
##ow	O
##ler	O
##i	O
with	O
another	O
ER	O
##G	O
##2	O
inhibitor	O
,	O
ta	B
##mo	I
##xi	I
##fen	I
,	O
a	O
non	O
-	O
s	O
##tero	O
##idal	O
est	B
##rogen	I
receptor	O
m	O
##od	O
##ulator	O
,	O
also	O
resulted	O
in	O
an	O
increase	O
of	O
the	O
er	B
##gos	I
##ta	I
-	I
5	I
,	I
7	I
-	I
die	I
##no	I
##l	I
(	O
10	O
)	O
content	O
from	O
21	O
.	O
3	O
%	O
to	O
43	O
.	O
5	O
%	O
(	O
,	O
)	O
,	O
suggesting	O
an	O
in	O
##hibition	O
of	O
22	O
-	O
des	O
##at	O
##uration	O
performed	O
by	O
a	O
yet	O
unknown	O
Na	O
##eg	O
##ler	O
##ia	O
enzyme	O
.	O

Both	O
c	B
##yt	I
##id	I
##ine	I
and	O
u	B
##rid	I
##ine	I
are	O
p	O
##yr	O
##im	O
##id	O
##ine	O
-	O
derived	O
n	O
##uc	O
##leo	O
##side	O
##s	O
,	O
and	O
the	O
level	O
of	O
c	B
##yt	I
##id	I
##ine	I
is	O
known	O
to	O
decrease	O
in	O
kidney	O
from	O
drug	O
-	O
induced	O
kidney	O
injury	O
model	O
rats	O
.	O

A	O
##cc	O
##ura	O
##cy	O
(	O
87	O
–	O
114	O
%	O
)	O
,	O
precision	O
(	O
3	O
–	O
13	O
%	O
)	O
,	O
matrix	O
effect	O
(	O
92	O
–	O
110	O
%	O
)	O
,	O
and	O
extraction	O
recovery	O
(	O
88	O
–	O
100	O
%	O
)	O
of	O
the	O
ass	O
##ay	O
were	O
within	O
the	O
15	O
%	O
acceptable	O
limit	O
of	O
FDA	O
Guide	O
##lines	O
in	O
variations	O
for	O
plasma	O
with	O
both	O
low	O
and	O
high	O
t	B
##rig	I
##ly	I
##cer	I
##ide	I
levels	O
.	O

G	B
##S	I
##H	I
is	O
supposed	O
to	O
play	O
many	O
roles	O
in	O
regulating	O
cancer	O
development	O
and	O
growth	O
,	O
such	O
as	O
cell	O
proliferation	O
,	O
a	O
##pop	O
##tosis	O
,	O
and	O
resistance	O
to	O
anti	O
##ne	O
##op	O
##lastic	O
drugs	O
.	O

Our	O
data	O
suggest	O
that	O
women	O
with	O
a	O
more	O
diverse	O
gut	O
micro	O
##bio	O
##me	O
exhibit	O
an	O
elevated	O
u	O
##rina	O
##ry	O
ratio	O
of	O
h	B
##ydro	I
##xy	I
##lated	I
est	I
##rogen	I
meta	O
##bol	O
##ites	O
to	O
parent	O
est	B
##rogen	I
.	O

Recent	O
evidence	O
suggests	O
that	O
the	O
initial	O
steps	O
of	O
the	O
acidic	O
pathway	O
of	O
bi	O
##le	O
acid	O
bio	O
##sy	O
##nt	O
##hesis	O
operate	O
in	O
brain	O
(	O
,	O
)	O
,	O
with	O
the	O
conversion	O
of	O
27	B
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
to	O
7	B
##α	I
-	I
h	I
##ydro	I
##xy	I
-	I
3	I
-	I
o	I
##x	I
##och	I
##ole	I
##st	I
-	I
4	I
-	I
en	I
-	I
26	I
-	I
o	I
##ic	I
acid	I
via	O
either	O
3	B
##β	I
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##t	I
-	I
5	I
-	I
en	I
-	I
26	I
-	I
o	I
##ic	I
acid	I
and	O
3	B
##β	I
,	I
7	I
##α	I
-	I
di	I
##hy	I
##dr	I
##ox	I
##ych	I
##ole	I
##st	I
-	I
5	I
-	I
en	I
-	I
26	I
-	I
o	I
##ic	I
acid	I
or	O
via	O
ch	B
##ole	I
##st	I
-	I
5	I
-	I
en	I
##e	I
-	I
3	I
##β	I
,	I
7	I
##α	I
,	I
26	I
-	I
trio	I
##l	I
(	I
C	I
_	I
5	I
-	I
3	I
##β	I
,	I
7	I
##α	I
,	I
26	I
-	I
trio	I
##l	I
)	I
and	O
its	O
7	B
##α	I
-	I
h	I
##ydro	I
##xy	I
-	I
3	I
-	I
o	I
##x	I
##o	I
-	I
4	I
-	I
en	I
##e	I
analogue	O
(	B
7	B
##α	I
,	I
26	I
-	I
di	I
##hy	I
##dr	I
##ox	I
##ych	I
##ole	I
##st	I
-	I
4	I
-	I
en	I
-	I
3	I
-	I
one	I
,	O
C	B
_	I
4	I
-	I
7	I
##α	I
,	I
26	I
-	I
di	I
##ol	I
-	I
3	I
-	I
one	I
)	O
(	O
,	O
)	O
(	O
Scheme	O
4	O
)	O
.	O

The	O
var	O
##iability	O
in	O
c	B
##rea	I
##tin	I
##ine	I
levels	O
agrees	O
well	O
with	O
the	O
inter	O
##play	O
between	O
liver	O
and	O
re	O
##nal	O
(	O
di	O
##s	O
)	O
function	O
in	O
liver	O
disease	O
.	O

(	O
CH	O
_	O
3	O
OH	O
)	O
;	O
per	O
##de	O
##uter	O
##ated	O
water	O
,	O
99	O
%	O
D	O
(	O
D	O
_	O
2	O
O	O
)	O
;	O
phosphate	S
buffer	O
sa	B
##line	I
(	O
PBS	O
)	O
was	O
prepared	O
at	O
10	O
m	O
##M	O
total	O
phosphate	S
concentration	O
(	O
K	O
##H	O
_	O
2	O
P	O
##O	O
_	O
4	O
+	O
K	O
_	O
2	O
HP	O
##O	O
_	O
4	O
)	O
and	O
150	O
m	O
##M	O
Na	O
##C	O
##l	O
,	O
pH	O
7	O
.	O
4	O
.	O

From	O
the	O
spectral	O
regions	O
corresponding	O
to	O
these	O
meta	O
##bol	O
##ites	O
,	O
specific	O
spectral	O
peaks	O
undergoing	O
the	O
largest	O
degree	O
of	O
change	O
were	O
identified	O
as	O
:	O
1	O
.	O
31	O
##pp	O
##m	O
for	O
la	B
##ct	I
##ate	I
(	O
27	O
.	O
4	O
%	O
increase	O
)	O
,	O
3	O
.	O
35	O
##pp	O
##m	O
for	O
glucose	S
(	O
52	O
.	O
4	O
%	O
decrease	O
)	O
and	O
0	O
.	O
92	O
pp	O
##m	O
for	O
is	B
##ole	I
##uc	I
##ine	I
(	O
60	O
.	O
5	O
%	O
decrease	O
)	O
.	O

We	O
did	O
not	O
observe	O
significant	O
differences	O
in	O
N	B
##AD	I
##P	I
##H	I
level	O
,	O
however	O
M	O
##UC	O
##16	O
knock	O
##down	O
cells	O
did	O
exhibit	O
higher	O
R	O
##OS	O
levels	O
.	O

In	O
1975	O
,	O
Lin	O
and	O
Wagner	O
pu	O
##rified	O
the	O
enzyme	O
N	O
-	O
met	O
##hyl	O
##alan	O
##ine	O
de	O
##hy	O
##dr	O
##ogen	O
##ase	O
in	O
pseudo	O
##mona	O
##s	O
MS	O
and	O
characterized	O
its	O
function	O
as	O
responsible	O
for	O
the	O
inter	O
##con	O
##version	O
of	O
N	B
-	I
met	I
##hyl	I
##alan	I
##ine	I
+	O
H	O
_	O
2	O
O	O
+	O
N	O
##AD	O
##P	O
_	O
+	O
to	O
p	B
##yr	I
##u	I
##vate	I
+	O
met	B
##hyl	I
##amine	I
+	O
N	B
##AD	I
##P	I
##H	I
+	O
H	O
_	O
+	O
.	O

Sep	O
##ara	O
##tion	O
of	O
Ce	B
##r	I
(	I
22	I
:	I
0	I
)	I
and	O
Ce	B
##r	I
(	I
24	I
:	I
0	I
)	I
was	O
carried	O
out	O
at	O
50	O
°C	O
using	O
a	O
Ph	O
##eno	O
##men	O
##ex	O
(	O
Tor	O
##rance	O
,	O
CA	O
)	O

The	O
use	O
of	O
silver	B
ion	I
coordination	O
for	O
the	O
analysis	O
of	O
OH	O
##C	O
in	O
serum	O
provided	O
an	O
excellent	O
ch	O
##roma	O
##to	O
##graphic	O
peak	O
shape	O
and	O
sufficient	O
intensity	O
for	O
quantitative	O
analysis	O
.	O

It	O
provides	O
protection	O
against	O
cellular	O
stress	O
and	O
converts	O
ha	B
##em	I
into	O
carbon	B
mon	I
##oxide	I
,	O
free	O
iron	O
and	O
bi	B
##li	I
##ver	I
##din	I
,	O
the	O
latter	O
of	O
which	O
that	O
is	O
later	O
converted	O
to	O
potent	O
anti	O
##ox	O
##ida	O
##nt	O
bi	B
##li	I
##ru	I
##bin	I
.	O

Ana	B
##stro	I
##zo	I
##le	I
(	O
10	O
µ	O
##m	O
)	O
was	O
in	O
##cu	O
##bate	O
##d	O
for	O
30	O
min	O
at	O
37	O
##°	O
##C	O
with	O
H	O
##LM	O
##s	O
(	O
0	O
.	O
5	O
mg	O
m	O
##l	O
_	O
−	O
##1	O
)	O
and	O
co	O
##fa	O
##ctor	O
in	O
the	O
absence	O
(	O
control	O
)	O
and	O
presence	O
of	O
the	O
following	O
known	O
is	O
##of	O
##orm	O
-	O
specific	O
inhibitor	O
##s	O
:	O
fur	B
##af	I
##yl	I
##line	I
(	O
20	O
µ	O
##m	O
)	O
for	O
C	O
##YP	O
##1	O
##A	O
##2	O
,	O
p	B
##ilo	I
##car	I
##pine	I
(	O
50	O
µ	O
##m	O
)	O
for	O
C	O
##YP	O
##2	O
##A	O
##6	O
,	O
th	B
##io	I
##TE	I
##PA	I
(	O
50	O
µ	O
##m	O
)	O
for	O
C	O
##YP	O
##2	O
##B	O
##6	O
,	O
que	B
##rc	I
##eti	I
##n	I
(	O
20	O
µ	O
##m	O
)	O
and	O
trim	O
##eth	O
##op	O
##rim	O
(	O
50	O
and	O
100	O
µ	O
##m	O
)	O
for	O
C	O
##YP	O
##2	O
##C	O
##8	O
,	O
su	B
##lf	I
##aph	I
##ena	I
##zo	I
##le	I
(	O
25	O
µ	O
##m	O
)	O
for	O
C	O
##YP	O
##2	O
##C	O
##9	O
,	O
t	B
##ic	I
##lop	I
##id	I
##ine	I
(	O
5	O
µ	O
##m	O
)	O
for	O
2	O
##C	O
##19	O
and	O
C	O
##YP	O
##2	O
##B	O
##6	O
,	O
q	B
##uin	I
##id	I
##ine	I
(	O
1	O
µ	O
##m	O
)	O
for	O
C	O
##YP	O
##2	O
##D	O
##6	O
,	O
diet	B
##hyl	I
##dit	I
##hi	I
##oc	I
##ar	I
##ba	I
##mate	I
(	O
50	O
µ	O
##m	O
)	O
for	O
C	O
##YP	O
##2	O
##E	O
##1	O
,	O
t	B
##rol	I
##ean	I
##dom	I
##y	I
##cin	I
(	O
50	O
µ	O
##M	O
)	O
and	O
k	B
##eto	I
##cona	I
##zo	I
##le	I
(	O
1	O
µ	O
##m	O
)	O
for	O
C	O
##YP	O
##3	O
##A	O
.	O
In	O
##hibition	O
by	O
fur	B
##af	I
##yl	I
##line	I
,	O
th	B
##io	I
##TE	I
##PA	I
,	O
diet	B
##hyl	I

The	O
is	O
##olate	O
##s	O
comprised	O
of	O
the	O
following	O
:	O
Extended	O
spectrum	O
β	O
-	O
la	O
##ct	O
##ams	O
##e	O
-	O
producing	O
species	O
of	O
the	O
family	O
En	O
##tero	O
##ba	O
##cter	O
##iac	O
##eae	O
from	O
no	O
##so	O
##com	O
##ial	O
cases	O
of	O
the	O
Philippine	S
General	O
Hospital	O
Manila	O
isolated	O
in	O
2005	O
;	O
[	O
]	O
Metal	O
##lo	O
-	O
β	O
-	O
la	O
##ct	O
##ama	O
##se	O
-	O
producing	O
P	O
##se	O
##udo	O
##mona	O
##s	O
a	O
##er	O
##ug	O
##ino	O
##sa	O
from	O
no	O
##so	O
##com	O
##ial	O
cases	O
of	O
the	O
same	O
hospital	O
isolated	O
in	O
2010	O
;	O
[	O
]	O
Met	O
##hic	O
##ill	O
##in	O
-	O
resistant	O
St	O
##aph	O
##yl	O
##oc	O
##oc	O
##cus	O
au	O
##reus	O
from	O
prison	O
inmates	O
with	O
fur	O
##un	O
##cles	O
and	O
car	O
##bu	O
##nc	O
##les	O
isolated	O
in	O
2007	O
.	O

However	O
,	O
these	O
sa	O
##mp	O
##I	O
##es	O
remained	O
metabolic	O
##ally	O
active	O
as	O
evidenced	O
by	O
changes	O
in	O
individual	O
meta	O
##bol	O
##ite	O
levels	O
(	O
e	O
.	O
g	O
.	O
,	O
c	B
##rea	I
##tine	I
,	O
ta	B
##uri	I
##ne	I
)	O
over	O
time	O
as	O
reported	O
here	O
and	O
by	O
others	O
.	O

We	O
note	O
that	O
our	O
study	O
did	O
not	O
include	O
reliable	O
recording	O
of	O
g	B
##lu	I
##co	I
##cor	I
##tic	I
##oid	I
use	O
,	O
because	O
this	O
is	O
a	O
natural	O
history	O
study	O
and	O
it	O
has	O
been	O
shown	O
that	O
D	O
##MD	O
patients	O
may	O
take	O
either	O
def	O
##la	O
##zac	O
##ort	O
or	O
pre	O
##dn	O
##ison	O
##e	O
/	O
pre	O
##dn	O
##is	O
##olo	O
##ne	O
and	O
that	O
many	O
different	O
dos	O
##ing	O
regime	O
##ns	O
exist	O
.	O

The	O
magnitude	O
of	O
c	O
##y	O
##c	O
##li	O
##zation	O
varies	O
drastically	O
for	O
different	O
samples	O
from	O
the	O
same	O
pool	O
of	O
human	O
serum	O
;	O
however	O
,	O
the	O
sum	O
of	O
the	O
apparent	O
g	B
##lut	I
##amine	I
and	O
p	B
##yr	I
##og	I
##lut	I
##ami	I
##c	I
acid	I
concentrations	O
in	O
each	O
sample	O
remains	O
the	O
same	O
suggesting	O
that	O
virtually	O
all	O
p	B
##yr	I
##og	I
##lut	I
##ami	I
##c	I
acid	I
is	O
derived	O
from	O
g	O
##lut	O
##amine	O
c	O
##y	O
##c	O
##li	O
##zation	O
.	O

The	O
treatment	O
was	O
a	O
single	O
injection	O
of	O
10	O
mg	O
vitamin	O
B	O
-	O
12	O
with	O
100	O
mg	O
p	B
##yr	I
##ido	I
##xin	I
##e	I
and	O
100	O
mg	O
th	B
##iam	I
##in	I
.	O

We	O
found	O
no	O
effect	O
of	O
A	O
##X	O
##OS	O
on	O
serum	O
levels	O
of	O
PC	O
##S	O
,	O
PC	O
##G	O
,	O
IS	O
and	O
PA	B
##G	I
,	O
and	O
only	O
a	O
border	O
##line	O
significant	O
effect	O
(	O
not	O
adjusted	O
for	O
multi	O
-	O
comparison	O
)	O
on	O
serum	O
levels	O
of	O
T	B
##MA	I
##O	I
.	O

Rather	O
,	O
our	O
findings	O
indicate	O
that	O
defect	O
##ive	O
glucose	S
metabolism	O
in	O
AD	O
may	O
occur	O
only	O
in	O
a	O
restricted	O
location	O
,	O
the	O
brain	O
.	O

HP	O
##LC	O
was	O
conducted	O
on	O
a	O
C	O
##30	O
column	O
(	O
4	O
.	O
6	O
×	O
150	O
mm	O
,	O
s	O
##5	O
,	O
Y	O
##MC	O
)	O
in	O
reversed	O
phase	O
with	O
(	O
A	O
)	O
met	O
##han	O
##ol	O
/	O
0	O
.	O
1	O
%	O
form	O
##ic	O
acid	O
(	O
80	O
/	O
20	O
v	O
/	O
v	O
)	O
and	O
(	O
B	O
)	O
met	O
##han	O
##ol	O
/	O
0	O
.	O
1	O
%	O
form	O
##ic	O
acid	O
/	O
met	O
##hyl	O
t	B
-	I
but	I
##yl	I
et	I
##her	I
(	O
20	O
/	O
2	O
/	O
78	O
v	O
/	O
v	O
/	O
v	O
)	O
as	O
mobile	O
phase	O
solvent	O
##s	O
at	O
1	O
.	O
8	O
m	O
##l	O
/	O
min	O
and	O
35	O
°C	O
(	O
A	O
##gi	O
##lent	O
1200	O
SL	S
,	O
A	O
##gi	O
##lent	O
Technologies	O
,	O
Santa	O
Clara	O
,	O
CA	O
)	O
.	O

In	O
brief	O
,	O
at	O
time	O
zero	O
,	O
plasma	O
glucose	S
was	O
increased	O
rapidly	O
to	O
225	O
mg	O
/	O
d	O
##l	O
with	O
a	O
b	O
##ol	O
##us	O
in	O
##fusion	O
of	O
de	B
##x	I
##tro	I
##se	I
over	O
2	O
min	O
and	O
maintained	O
by	O
a	O
variable	O
-	O
rate	O
in	O
##fusion	O
of	O
20	O
%	O
de	B
##x	I
##tro	I
##se	I
solution	O
for	O
120	O
min	O
.	O

Am	B
##ino	I
##acy	I
##l	I
-	I
t	I
##RNA	I
bio	O
##sy	O
##nt	O
##hesis	O
,	O
an	O
essential	O
process	O
for	O
protein	O
synthesis	O
and	O
cell	O
via	O
##bility	O
,	O
con	O
##ju	O
##gate	O
##s	O
amino	O
acids	O
to	O
t	O
##RNA	O
and	O
delivers	O
amino	O
acids	O
for	O
incorporation	O
into	O
p	O
##oly	O
##pe	O
##pt	O
##ide	O
chains	O
.	O

Sign	O
##ificant	O
##ly	O
increased	O
a	B
##rg	I
##ini	I
##ne	I
,	O
u	B
##rea	I
and	O
c	B
##it	I
##ru	I
##llin	I
##e	I
concentrations	O
were	O
observed	O
in	O
the	O
HD	O
sheep	O
compared	O
to	O
the	O
controls	O
(	O
F	O
##DR	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
standard	O
mix	O
was	O
prepared	O
at	O
5	O
μ	O
##g	O
/	O
m	O
##L	O
of	O
each	O
compound	O
in	O
25	O
m	O
##M	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
,	O
pH	O
6	O
.	O
5	O
buffer	O
.	O

Select	O
##ivity	O
ranges	O
and	O
complement	O
##arity	O
(	O
“	O
or	O
##th	O
##ogo	O
##nal	O
##ity	O
”	O
)	O
of	O
H	O
##IL	O
##IC	O
and	O
R	B
##P	I
separation	O
##s	O
as	O
well	O
as	O
the	O
performance	O
of	O
tested	O
columns	O
towards	O
specific	O
meta	O
##bol	O
##ite	O
groups	O
is	O
discussed	O
.	O

To	O
produce	O
the	O
blue	O
##berry	O
p	B
##oly	I
##phe	I
##no	I
##l	I
-	I
so	I
##y	I
protein	O
complex	O
,	O
44	O
L	O
of	O
blue	O
##berry	O
p	O
##oma	O
##ce	O
extract	O
was	O
mixed	O
with	O
176	O
L	O
of	O
water	O
(	O
5	O
##×	O
di	O
##lution	O
)	O
until	O
uniform	O
then	O
SP	O
##I	O
(	O
100	O
g	O
/	O
L	O
;	O
22	O
kg	O
)	O
was	O
added	O
to	O
the	O
di	O
##lut	O
##ed	O
blue	O
##berry	O
p	O
##oma	O
##ce	O
extract	O
and	O
mixed	O
.	O

Using	O
pathway	O
en	O
##rich	O
##ment	O
analysis	O
,	O
the	O
nitrogen	O
metabolism	O
pathway	O
,	O
which	O
includes	O
three	O
prior	O
##itis	O
##ed	O
meta	O
##bol	O
##ites	O
(	B
g	B
##ly	I
##cine	I
,	O
ta	B
##uri	I
##ne	I
and	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
)	O
,	O
was	O
significantly	O
en	O
##rich	O
##ed	O
for	O
association	O
with	O
type	O
2	O
diabetes	O
risk	O
at	O
the	O
false	O
discovery	O
rate	O
of	O
5	O
%	O
(	O
p	O
=	O
0	O
.	O
04	O
##7	O
)	O
.	O

Poole	O
##d	O
human	O
serum	O
technical	O
replica	O
##te	O
samples	O
from	O
healthy	O
individuals	O
subjected	O
to	O
either	O
met	B
##han	I
##ol	I
(	O
Me	O
##OH	O
)	O
pp	O
##t	O
+	O
U	O
##F	O
,	O
or	O
Me	B
##OH	I
:	O

Blood	O
glucose	S
and	O
insulin	O
levels	O
were	O
central	O
##ly	O
assessed	O
at	O
base	O
##line	O
and	O
at	O
the	O
end	O
of	O
1	O
-	O
year	O
of	O
follow	O
-	O
up	O
.	O

Third	O
,	O
the	O
expected	O
appearance	O
of	O
one	O
##fold	O
-	O
labeled	O
(	O
M1	O
)	O
er	B
##yt	I
##hr	I
##ito	I
##l	I
is	O
##oto	O
##pol	O
##og	O
##s	O
was	O
observed	O
after	O
the	O
[	B
6	I
-	I
_	I
13	I
C	I
_	I
1	I
]	I
glucose	I
trace	O
##r	O
was	O
applied	O
.	O

(	O
D	O
)	O
T	O
##LC	O
of	O
T	B
##G	I
and	O
P	O
##E	O
in	O
F	O
##T	O
##D	O
brain	O
(	O
N	O
=	O
10	O
)	O
compared	O
to	O
control	O
brain	O
(	O
N	O
=	O
11	O
)	O
and	O
optical	O
density	O
measurements	O
of	O
the	O
bands	O
.	O

The	O
database	O
used	O
in	O
this	O
study	O
includes	O
data	O
about	O
215	O
peaks	O
from	O
153	O
meta	O
##bol	O
##ites	O
,	O
22	O
corresponding	O
stable	O
is	O
##oto	O
##pes	O
,	O
and	O
2	B
-	I
is	I
##op	I
##rop	I
##yl	I
##mal	I
##ic	I
acid	I
.	O

They	O
also	O
noticed	O
low	O
hip	B
##pura	I
##te	I
levels	O
in	O
urine	O
of	O
I	O
##B	O
##D	O
patients	O
suggesting	O
that	O
hip	B
##pura	I
##te	I
may	O
be	O
a	O
bio	O
##mark	O
##er	O
candidate	O
.	O

In	O
this	O
study	O
,	O
a	O
total	O
of	O
165	O
card	O
##iovascular	O
disease	O
patients	O
were	O
enrolled	O
,	O
including	O
49	O
A	B
##F	I
patients	O
(	O
A	O
##F	O
group	O
)	O
and	O
116	O
non	O
-	O
A	O
##F	O
patients	O
(	O
non	O
-	O
A	O
##F	O
group	O
)	O
.	O

The	O
weak	O
wash	S
solvent	S
was	S
ace	S
##ton	S
##it	S
##ril	S
##e	S
-	S
is	S
##op	S
##rop	S
##ano	S
##l	S
(	S
3	S
:	S
1	S
,	S
v	S
/	S
v	S
)	S
and	S
the	S
strong	S
wash	S
solvent	S
is	S
H	S
_	S
2	S
O	S
-	O
met	O
##han	O
##ol	O
(	O
1	O
:	O
1	O
,	O
v	O
/	O
v	O
)	O
.	O

Interest	O
##ingly	O
,	O
in	O
normal	O
subjects	O
and	O
T	O
##2	O
##D	O
patients	O
,	O
it	O
has	O
been	O
shown	O
that	O
restoration	O
of	O
the	O
N	O
##AD	O
##H	O
/	O
N	O
##AD	O
_	O
+	O
red	O
##ox	O
balance	O
by	O
g	B
##lut	I
##ath	I
##ione	I
in	O
##fusion	O
therapy	O
resulted	O
in	O
improvement	O
of	O
insulin	O
sensitivity	O
and	O
β	O
-	O
cell	O
function	O
in	O
normal	O
subjects	O
and	O
in	O
T	O
##2	O
##D	O
patients	O
.	O

In	O
urine	O
,	O
the	O
most	O
important	O
th	B
##iol	I
##s	I
are	O
L	B
-	I
c	I
##ys	I
##tein	I
##e	I
and	O
L	B
-	I
c	I
##ys	I
##tein	I
##yl	I
##gly	I
##cine	I
,	O
,	O
,	O
.	O

A	O
UP	O
##LC	O
-	O
single	O
q	O
##uad	O
##rup	O
##ole	O
-	O
MS	O
amino	O
acid	O
analysis	O
system	O
was	O
combined	O
with	O
two	O
separate	O
UP	O
##LC	O
-	O
time	O
-	O
of	O
-	O
flight	O
(	O
TO	O
##F	O
)	O
-	O
MS	O
based	O
platforms	O
analyzing	O
met	B
##han	I
##ol	I
and	O
ch	O
##lor	O
##of	O
##orm	O
/	B
met	B
##han	I
##ol	I
serum	O
extract	O
##s	O
.	O

The	O
mobile	O
phase	O
consists	O
of	O
a	O
mixture	O
of	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
in	O
water	O
and	O
AC	O
##N	O
(	O
[UNK]	O
v	O
/	O
v	O
)	O
.	O

This	O
research	O
showed	O
,	O
for	O
the	O
first	O
time	O
,	O
N	B
-	I
des	I
##met	I
##hyl	I
-	I
ace	I
##tam	I
##ip	I
##rid	I
(	O
AM	O
-	O
2	O
)	O
was	O
q	O
##ual	O
##itative	O
##ly	O
detected	O
and	O
q	O
##uant	O
##ified	O
in	O
the	O
human	O
urine	O
.	O

We	O
observed	O
that	O
pro	O
##fi	O
##ling	O
of	O
the	O
2	B
,	I
5	I
-	I
di	I
##hy	I
##dr	I
##ox	I
##y	I
##ben	I
##zoic	I
acid	I
(	O
D	O
##H	O
##B	O
)	O
add	O
##uc	O
##t	O
ions	O
acquired	O
in	O
positive	O
ion	O
mode	O
was	O
re	O
##p	O
##rod	O
##uc	O
##ible	O
in	O
all	O
extraction	O
protocols	O
(	O
with	O
total	O
of	O
18	O
mass	O
s	O
##pect	O
##ra	O
from	O
trip	O
##lica	O
##te	O
set	O
of	O
six	O
protocols	O
analyzed	O
)	O
.	O

f	O
##ow	O
##ler	O
##i	O
to	O
the	O
SM	O
##T	O
inhibitor	O
##s	O
24	B
,	I
25	I
-	I
e	I
##pi	I
##min	I
##ola	I
##nos	I
##tero	I
##l	I
(	I
e	I
##pi	I
##min	I
##ola	I
##nos	I
##tero	I
##l	I
)	I
,	O
a	O
##ba	O
##fu	O
##ng	O
##in	O
and	O
25	O
-	O
a	O
##zac	O
##y	O
##c	O
##lo	O
##arte	O
##no	O
##l	O
(	O
25	O
-	O
A	O
##za	O
)	O
,	O
led	O
to	O
high	O
accumulation	O
of	O
ch	B
##ole	I
##sta	I
-	I
5	I
,	I
7	I
,	I
24	I
-	I
t	I
##rien	I
##ol	I
(	O
6	O
)	O
(	O
≥	O
30	O
%	O
of	O
total	O
s	O
##tero	O
##ls	O
)	O
,	O
an	O
intermediate	O
und	O
##ete	O
##ct	O
##able	O
in	O
the	O
wild	O
-	O
type	O
or	O
p	O
##osa	O
##cona	O
##zo	O
##le	O
-	O
in	O
##hibit	O
##ed	O
N	O
.	O

Lac	B
##tate	I
was	O
marked	O
##ly	O
elevated	O
in	O
PA	O
##H	O
patients	O
,	O
suggesting	O
a	O
shift	O
in	O
glucose	S
metabolism	O
towards	O
g	O
##ly	O
##co	O
##lysis	O
for	O
ATP	S
production	O
at	O
the	O
expense	O
of	O
o	O
##xi	O
##da	O
##tive	O
p	O
##hos	O
##ph	O
##ory	O
##lation	O
,	O
the	O
“	O
so	O
-	O
called	O
”	O
War	O
##burg	O
effect	O
.	O

However	O
,	O
ER	O
-	O
breast	O
cancer	O
patients	O
had	O
significantly	O
reduced	O
plasma	O
try	B
##pt	I
##op	I
##han	I
compared	O
to	O
normal	O
controls	O
,	O
while	O
ER	O
+	O
breast	O
cancer	O
patients	O
did	O
not	O
.	O

The	O
decrease	O
of	O
s	B
##pi	I
##ron	I
##ola	I
##cton	I
##e	I
content	O
at	O
room	O
temperature	O
indicates	O
the	O
need	O
for	O
controlled	O
sampling	O
conditions	O
and	O
quick	O
sample	O
processing	O
methods	O
to	O
minimize	O
the	O
time	O
samples	O
spend	O
in	O
ambient	O
conditions	O
.	O

Despite	O
the	O
potential	O
collection	O
and	O
storage	O
limitations	O
,	O
we	O
thus	O
believe	O
that	O
similar	O
p	B
##ht	I
##hala	I
##te	I
levels	O
measured	O
in	O
this	O
and	O
other	O
studies	O
are	O
likely	O
to	O
accurately	O
reflect	O
concentrations	O
at	O
the	O
time	O
of	O
collection	O
and	O
true	O
exposure	O
.	O

Form	O
##ate	O
-	O
induced	O
c	O
##yt	O
##oto	O
##xi	O
##city	O
has	O
been	O
demonstrated	O
in	O
rat	O
hip	O
##po	O
##cam	O
##pal	O
cultures	O
and	O
in	O
re	B
##tina	I
##l	I
(	O
human	O
and	O
rat	O
)	O
cell	O
cultures	O
.	O
_	O
,	O
Of	O
interest	O
,	O
met	B
##han	I
##ol	I
poisoning	O
is	O
mediated	O
by	O
format	B
##e	I
,	O
producing	O
op	O
##tic	O
nerve	O
dem	O
##ye	O
##lina	O
##tion	O
and	O
subsequent	O
progressive	O
re	B
##tina	I
##l	I
a	O
##xon	O
##al	O
loss	O
in	O
humans	O
.	O

By	O
design	O
,	O
there	O
was	O
no	O
significant	O
difference	O
in	O
gender	O
,	O
age	O
or	O
s	B
##tat	I
##in	I
use	O
between	O
PD	O
and	O
control	O
participants	O
.	O

Compared	O
with	O
G	B
##S	I
##H	I
and	O
H	O
_	O
2	O
S	O
,	O
Cy	O
##s	O
##SS	O
##H	O
derivatives	O
are	O
superior	O
n	O
##uc	O
##leo	O
##phi	O
##les	O
and	O
red	O
##uc	O
##tant	O
##s	O
,	O
capable	O
of	O
regulating	O
electro	O
##phi	O
##lic	O
cell	O
signaling	O
mediated	O
by	O
8	B
-	I
ni	I
##tro	I
-	I
c	I
##GM	I
##P	I
.	O

Therefore	O
a	O
50	O
μ	O
##L	O
al	O
##iq	O
##uo	O
##t	O
was	O
taken	O
from	O
the	O
solution	O
after	O
precipitation	O
and	O
100	O
μ	O
##L	O
of	O
lit	B
##hium	I
c	I
##it	I
##rate	I
buffer	O
were	O
added	O
.	O

De	O
##uter	O
##ated	O
1	B
##α	I
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
was	O
used	O
as	O
an	O
internal	O
reference	O
for	O
the	O
q	O
##uant	O
##ification	O
of	O
24	O
##R	O
,	O
25	O
(	O
OH	O
)	O
_	O
2	O
D	B
_	I
3	I
,	I
1	I
##α	I
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
2	O
and	O
1	B
##α	I
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
,	O
while	O
de	O
##uter	O
##ated	O
25	O
(	O
OH	O
)	O
D	O
_	O
3	O
was	O
the	O
internal	O
reference	O
for	O
the	O
q	O
##uant	O
##ification	O
of	O
25	O
(	O
OH	O
)	O
D	O
_	O
2	O
and	O
25	O
(	O
OH	O
)	O
D	O
_	O
3	O
.	O

In	O
that	O
study	O
,	O
reactions	O
of	O
meta	O
##bol	O
##ites	O
with	O
ch	B
##ola	I
##mine	I
were	O
made	O
in	O
organic	O
solution	O
in	O
contrast	O
to	O
the	O
a	O
##que	O
##ous	O
media	O
used	O
here	O
.	O

We	O
measured	O
the	O
potential	O
of	O
an	O
olive	O
p	O
##oma	O
##ce	O
-	O
en	O
##rich	O
##ed	O
bi	O
##s	O
##cu	O
##it	O
formulation	O
delivering	O
17	O
.	O
1	O
±	O
4	O
.	O
01	O
mg	O
/	O
100	O
g	O
of	O
h	B
##ydro	I
##xy	I
##ty	I
##ros	I
##ol	I
and	O
its	O
derivatives	O
,	O
to	O
m	O
##od	O
##ulate	O
the	O
composition	O
and	O
metabolic	O
activity	O
of	O
the	O
human	O
gut	O
micro	O
##bio	O
##ta	O
.	O

Mo	O
##di	O
##fia	O
##ble	O
factors	O
may	O
impact	O
the	O
E	O
##DA	O
ratio	O
,	O
with	O
studies	O
demonstrating	O
that	O
re	B
##s	I
##ver	I
##at	I
##rol	I
reduces	O
E	O
##DA	O
ratio	O
in	O
v	O
##it	O
##ro	O
.	O

These	O
results	O
are	O
consistent	O
with	O
our	O
findings	O
that	O
u	O
##rina	O
##ry	O
my	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
is	O
increased	O
in	O
F	O
##S	O
##GS	O
patients	O
with	O
reduced	O
re	O
##nal	O
function	O
(	O
increased	O
su	O
##PA	O
##R	O
level	O
)	O
or	O
reduced	O
MI	O
##OX	O
expression	O
and	O
that	O
treatment	O
with	O
my	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
in	O
the	O
in	O
v	O
##it	O
##ro	O
F	O
##S	O
##GS	O
model	O
resulted	O
in	O
an	O
increase	O
in	O
the	O
expression	O
of	O
various	O
markers	O
,	O
which	O
was	O
similar	O
to	O
the	O
at	O
##ten	O
##uation	O
of	O
the	O
disease	O
.	O

The	O
highest	O
select	O
##ivity	O
in	O
buffer	O
was	O
demonstrated	O
by	O
I	O
##EX	O
,	O
followed	O
by	O
C	O
##18	O
and	O
M	B
##T	I
##BE	I
.	O

Conversely	O
in	O
se	O
##psis	O
,	O
α	B
-	I
k	I
##eto	I
##g	I
##lut	I
##ari	I
##c	I
acid	I
was	O
revealed	O
in	O
more	O
than	O
half	O
of	O
patients	O
:	O
in	O
37	O
from	O
48	O
(	O
77	O
%	O
)	O
samples	O
in	O
early	O
se	O
##psis	O
and	O
in	O
16	O
from	O
35	O
(	O
45	O
%	O
)	O
samples	O
in	O
late	O
se	O
##psis	O
.	O

Based	O
on	O
database	O
search	O
results	O
,	O
the	O
detected	O
peaks	O
in	O
the	O
s	O
##pect	O
##ra	O
were	O
found	O
to	O
be	O
the	O
[	O
M	O
-	O
H	O
]	O
-	O
ions	O
of	O
fatty	O
acids	O
(	O
FA	O
##s	O
)	O
,	O
D	O
##G	O
##s	O
and	O
Ph	B
##os	I
##pha	I
##ti	I
##dic	I
acid	I
(	O
PA	O
)	O
.	O

Additionally	O
,	O
P	O
##UT	O
’	O
s	O
behavior	O
is	O
very	O
similar	O
to	O
the	O
behavior	O
of	O
CA	O
##D	O
and	O
1	B
,	I
3	I
-	I
D	I
##AP	I
,	O
and	O
GA	B
##BA	I
and	O
N	B
##1	I
,	I
N	I
##8	I
-	I
Di	I
##A	I
##c	I
##SP	I
##D	I
show	O
similar	O
signal	O
suppression	O
.	O

S	O
##pect	O
##ral	O
occurrence	O
##s	O
were	O
obtained	O
from	O
the	O
molecular	O
network	O
,	O
b	O
presents	O
the	O
total	O
number	O
of	O
AM	O
##L	O
-	O
related	O
s	O
##pect	O
##ra	O
in	O
each	O
urine	O
extract	O
that	O
was	O
included	O
in	O
the	O
cluster	O
,	O
c	O
presents	O
the	O
total	O
number	O
of	O
acquired	O
MS	O
##2	O
s	O
##pect	O
##ra	O
for	O
each	O
AM	O
##L	O
related	O
meta	O
##bol	O
##ite	O
,	O
d	O
total	O
over	O
1	O
×	O
10	O
_	O
6	O
occurrence	O
##s	O
for	O
each	O
AM	O
##L	O
meta	O
##bol	O
##ite	O
,	O
and	O
e	O
shows	O
the	O
in	O
##tens	O
##ities	O
(	O
c	O
##ts	O
)	O
for	O
each	O
AM	O
##L	O
related	O
meta	O
##bol	O
##ite	O
extracted	O
from	O
the	O
L	O
##C	O
–	O
MS	O
full	O
scan	O
##s	O
using	O
accurate	O
mass	O
and	O
retention	O
time	O
information	O
obtained	O
during	O
the	O
node	O
valid	O
##ation	O
process	O
,	O
including	O
the	O
accurate	O
mass	O
for	O
the	O
parent	O
drug	O
am	B
##lo	I
##di	I
##pine	I
.	O

LP	O
##Cs	O
not	O
only	O
have	O
inflammatory	O
activities	O
,	O
but	O
also	O
activate	O
signaling	O
molecules	O
including	O
t	B
##yr	I
##os	I
##ine	I
kinase	O
##s	O
[	O
–	O
]	O
.	O

The	O
dried	O
metabolic	O
extract	O
was	O
der	O
##iva	O
##tized	O
with	O
30	O
μ	O
##l	O
of	O
met	B
##ho	I
##xy	I
##amine	I
(	O
20	O
mg	O
/	O
m	O
##l	O
)	O
for	O
1	O
.	O
5	O
h	O
at	O
37	O
##°	O
##C	O
.	O

However	O
,	O
to	O
date	O
,	O
the	O
s	B
##phi	I
##ngo	I
##lip	I
##id	I
profile	O
of	O
di	O
##abe	O
##tic	O
patients	O
with	O
C	O
##VD	O
has	O
remained	O
to	O
be	O
investigated	O
.	O

In	O
particular	O
,	O
a	B
##rg	I
##ini	I
##ne	I
was	O
present	O
in	O
the	O
top	O
10	O
combinations	O
of	O
the	O
average	O
area	O
under	O
the	O
receiver	O
operating	O
characteristic	O
curve	O
(	O
AU	O
##C	O
)	O
test	O
set	O
.	O

L	O
##ys	O
##o	O
##PC	O
(	O
16	O
:	O
0	O
)	O
was	O
positively	O
and	O
independently	O
associated	O
with	O
DB	B
##P	I
and	O
S	O
##B	O
##P	O
.	O

,	O
Lac	B
##to	I
##ba	I
##ci	I
##llus	I
s	O
##pp	O
.	O
and	O
R	O
##umi	O
##no	O
##co	O
##cc	O
##us	O
s	O
##pp	O
.	O

However	O
,	O
N	B
##AA	I
##G	I
appears	O
to	O
play	O
important	O
roles	O
in	O
the	O
neural	O
system	O
related	O
to	O
regulation	O
of	O
energy	O
supply	O
[	O
,	O
]	O
,	O
and	O
it	O
cannot	O
be	O
excluded	O
that	O
its	O
absence	O
is	O
essential	O
for	O
tumor	O
growth	O
.	O

B	O
##rief	O
##ly	O
,	O
1	O
.	O
13	O
mg	O
(	O
6	O
.	O
10	O
μ	O
##mo	O
##l	O
)	O
of	O
[	O
D	O
_	O
4	O
]	O
4	O
,	O
synthesized	O
as	O
described	O
above	O
,	O
was	O
in	O
##cu	O
##bate	O
##d	O
in	O
1	O
m	O
##L	O
of	O
3	O
%	O
(	O
v	O
/	O
v	O
)	O
concentrated	O
H	O
_	O
2	O
S	O
##O	O
_	O
4	O
in	O
Me	B
##OH	I
at	O
room	O
temperature	O
overnight	O
.	O

Analysis	O
was	O
performed	O
at	O
base	O
##line	O
(	O
white	O
bars	O
)	O
and	O
at	O
week	O
24	O
(	O
black	O
bars	O
)	O
in	O
Place	O
##bo	O
(	O
a	O
)	O
Pi	O
##o	O
(	O
b	O
)	O
Omega	B
-	I
3	I
(	O
c	O
)	O
and	O
Pi	O
##o	O
&	O
Omega	B
-	I
3	I
(	O
d	O
)	O
subgroup	O
##s	O
.	O

Furthermore	O
,	O
u	O
##rina	O
##ry	O
concentrations	O
of	O
c	B
##it	I
##ru	I
##llin	I
##e	I
(	O
p	O
=	O
0	O
.	O
02	O
##0	O
##5	O
)	O
,	O
N	B
-	I
met	I
##hyl	I
##ar	I
##gin	I
##ine	I
(	O
p	O
=	O
0	O
.	O
01	O
##34	O
)	O
,	O
met	B
##hyl	I
##su	I
##cci	I
##nate	I
(	O
p	O
=	O
0	O
.	O
03	O
##5	O
##7	O
)	O
and	O
u	B
##rea	I
(	O
p	O
=	O
0	O
.	O
01	O
##5	O
##9	O
)	O
showed	O
a	O
significant	O
difference	O
with	O
increasing	O
means	O
between	O
V	O
##1	O
and	O
V	O
##3	O
while	O
no	O
significant	O
changes	O
in	O
u	O
##rina	O
##ry	O
meta	O
##bol	O
##ites	O
were	O
demonstrated	O
between	O
V	O
##1	O
and	O
V	O
##2	O
.	O

After	O
addition	O
of	O
water	O
(	O
1	O
m	O
##l	O
)	O
to	O
the	O
crude	O
,	O
FA	O
##ME	O
##s	O
were	O
extracted	O
with	O
he	B
##xa	I
##ne	I
(	O
3	O
m	O
##l	O
)	O
,	O
e	O
##va	O
##porated	O
to	O
dry	O
##ness	O
and	O
dissolved	O
in	O
et	B
##hyl	I
ace	I
##tate	I
(	O
20	O
μ	O
##l	O
)	O
.	O

The	O
decrease	O
in	O
u	B
##rea	I
and	O
or	B
##ni	I
##thin	I
##e	I
in	O
CD	O
patients	O
as	O
compared	O
to	O
the	O
control	O
co	O
##hor	O
##t	O
may	O
indicate	O
disturbance	O
##s	O
in	O
the	O
u	B
##rea	I
cycle	O
.	O

Brain	O
MR	O
##I	O
demonstrated	O
developmental	O
delay	O
of	O
my	B
##elin	I
sheath	O
,	O
in	O
addition	O
to	O
thick	O
##ened	O
m	O
##uc	O
##osa	O
of	O
bilateral	O
ma	O
##xi	O
##llar	O
##y	O
sin	O
##us	O
and	O
et	O
##hm	O
##oid	O
sin	O
##us	O
.	O

In	O
addition	O
,	O
x	O
##eno	O
##gra	O
##fts	O
generated	O
using	O
MC	O
##F	O
parental	O
cells	O
(	O
MC	O
##F	O
-	O
7	O
L	O
)	O
that	O
were	O
either	O
un	O
##tre	O
##ated	O
(	O
termed	O
parental	O
)	O
or	O
treated	O
with	O
ta	B
##mo	I
##xi	I
##fen	I
for	O
~	O
2	O
weeks	O
(	O
short	O
-	O
term	O
treatment	O
and	O
T	O
##AM	O
-	O
S	O
)	O
or	O
~	O
3	O
months	O
(	O
long	O
-	O
term	O
treatment	O
and	O
T	O
##AM	O
-	O
R	O
)	O
,	O
as	O
described	O
by	O
Mass	O
##ar	O
##we	O
##h	O
et	O
al	O
.	O
were	O
used	O
.	O

Li	B
##th	I
##och	I
##oly	I
##lta	I
##uri	I
##ne	I
and	O
7	B
-	I
alpha	I
-	I
h	I
##ydro	I
##xy	I
-	I
3	I
-	I
o	I
##x	I
##och	I
##ol	I
-	I
4	I
-	I
en	I
-	I
24	I
-	I
o	I
##ic	I
acid	I
are	O
bi	O
##le	O
acid	O
con	O
##ju	O
##gation	O
molecules	O
.	O

This	O
supports	O
the	O
observed	O
physiological	O
roles	O
of	O
mit	O
##och	O
##ond	O
##ria	O
in	O
coordinating	O
lip	O
##id	O
metabolism	O
and	O
in	O
controlling	O
reactive	O
oxygen	O
species	O
(	O
R	O
##OS	O
)	O
,	O
ATP	S
and	O
calcium	O
levels	O
,	O
several	O
factors	O
that	O
influence	O
the	O
aggressive	O
##ness	O
of	O
the	O
disease	O
.	O

(	O
A	O
)	O
Ex	O
##pan	O
##sion	O
of	O
the	O
spectrum	O
where	O
the	O
beta	B
##ine	I
region	O
is	O
extracted	O
for	O
lines	O
##ha	O
##pe	O
de	O
##con	O
##vo	O
##lution	O
.	O

Regarding	O
x	B
##yl	I
##ito	I
##l	I
in	O
the	O
urine	O
of	O
H	O
##B	O
##V	O
patients	O
,	O
this	O
p	O
##oly	O
##ol	O
was	O
found	O
to	O
exhibit	O
the	O
largest	O
decline	O
of	O
any	O
u	O
##rina	O
##ry	O
meta	O
##bol	O
##ite	O
detected	O
between	O
control	O
samples	O
and	O
liver	O
c	O
##ir	O
##r	O
##hos	O
##is	O
/	O
he	O
##pa	O
##to	O
##cellular	O
car	O
##cin	O
##oma	O
patients	O
in	O
Egypt	O
.	O

DNA	O
from	O
the	O
positive	O
control	O
strains	O
Lac	B
##to	I
##ba	I
##ci	I
##llus	I
s	I
##p	I
.	O

The	O
top	O
5	O
meta	O
##bol	O
##ites	O
were	O
ho	B
##mo	I
##cy	I
##stein	I
##e	I
(	O
generally	O
known	O
as	O
an	O
independent	O
card	O
##iovascular	O
risk	O
factor	O
)	O
,	O
g	B
##lut	I
##ami	I
##c	I
acid	I
(	O
playing	O
a	O
central	O
role	O
in	O
overall	O
nitrogen	O
home	O
##ost	O
##asis	O
)	O
,	O
his	B
##ti	I
##dine	I
(	O
having	O
anti	O
##ox	O
##ida	O
##nt	O
,	O
anti	O
-	O
inflammatory	O
,	O
and	O
anti	O
##se	O
##cre	O
##tory	O
properties	O
)	O
,	O
t	B
##yr	I
##os	I
##ine	I
(	O
important	O
for	O
protein	O
and	O
cat	B
##ech	I
##ola	I
##mine	I
bio	O
##sy	O
##nt	O
##hesis	O
)	O
,	O
and	O
k	B
##yn	I
##uren	I
##ine	I
(	O
major	O
meta	O
##bol	O
##ite	O
in	O
try	B
##pt	I
##op	I
##han	I
metabolism	O
with	O
influence	O
on	O
production	O
of	O
ne	O
##uro	O
##tra	O
##ns	O
##mit	O
##ters	O
,	O
inflammation	O
,	O
and	O
aging	O
)	O
.	O

The	O
lip	O
##id	O
C	B
##18	I
:	I
2	I
CE	O
was	O
detected	O
at	O
a	O
mean	O
concentration	O
of	O
12	O
.	O
71	O
nm	O
##ol	O
/	O
µ	O
##l	O
in	O
22	O
S	O
##q	O
##CC	O
patients	O
,	O
with	O
a	O
31	O
.	O
02	O
%	O
down	O
##re	O
##gu	O
##lation	O
(	O
P	O
=	O
0	O
.	O
000	O
##1	O
)	O
when	O
compared	O
with	O
the	O
demographic	O
##ally	O
matched	O
high	O
-	O
risk	O
controls	O
(	O
18	O
.	O
42	O
nm	O
##ol	O
/	O
µ	O
##l	O
;	O
)	O
.	O

C	B
##it	I
##rate	I
(	O
the	O
second	O
two	O
plots	O
)	O
is	O
represented	O
by	O
a	O
double	O
double	O
##t	O
at	O
2	O
.	O
56	O
pp	O
##m	O
and	O
2	O
.	O
68	O
pp	O
##m	O
.	O

I	O
##mm	O
##uno	O
##his	O
##to	O
##chemistry	O
and	O
hem	B
##ato	I
##xy	I
##lin	I
and	O
e	B
##os	I
##in	I
stain	O
##ing	O
of	O
Nell	O
-	O
1	O
protein	O
expression	O
(	O
a	O
,	O
b	O
)	O
normal	O
tissues	O
;	O
(	O
c	O
,	O
d	O
)	O
m	O
##uc	O
##osa	O
##l	O
layer	O
of	O
t	O
##umour	O
tissues	O
;	O
(	O
c	O
'	O
,	O
d	O
'	O
)	O
muscular	O
layer	O
of	O
t	O
##umour	O
tissues	O
.	O

The	O
der	O
##iva	O
##tized	O
samples	O
were	O
obtained	O
after	O
the	O
residue	O
was	O
in	O
##cu	O
##bate	O
##d	O
with	O
met	B
##ho	I
##xy	I
##amine	I
h	I
##ydro	I
##ch	I
##lor	I
##ide	I
(	O
20	O
mg	O
/	O
m	O
##L	O
in	O
p	B
##yr	I
##id	I
##ine	I
)	O
for	O
30	O
minutes	O
at	O
80	O
##°	O
##C	O
,	O
were	O
bi	O
##s	O

For	O
the	O
purpose	O
of	O
class	O
##ifying	O
these	O
medications	O
into	O
groups	O
,	O
the	O
following	O
structure	O
was	O
used	O
:	O
topic	O
##al	O
re	O
##ct	O
##al	O
medications	O
(	B
pre	B
##dn	I
##is	I
##olo	I
##ne	I
or	O
5	B
-	I
amino	I
##sal	I
##ic	I
##yl	I
##ic	I
acid	I

Sen	O
##si	O
##ti	O
##vity	O
and	O
specific	O
##ity	O
of	O
A	O
##FP	O
versus	O
plasma	O
meta	O
##bol	O
##ites	O
in	O
predict	O
##ing	O
HC	O
##C	O
cases	O
among	O
c	O
##ir	O
##r	O
##hot	O
##ic	O
patients	O
AU	O
##C	O
–	O
area	O
under	O
curve	O
,	O
p	O
–	O
value	O
:	O
probability	O
value	O
,	O
C	O
##I	O
–	O
confidence	O
interval	O
,	O
N	O
##P	O
##V	O
–	O
negative	O
predict	O
##ive	O
value	O
,	O
PP	O
##V	O
–	O
positive	O
predict	O
##ive	O
value	O
,	O
A	O
##FP	O
–	O
alpha	B
-	I
f	I
##eto	I
##p	I
##rote	I
##in	I
R	O
##OC	O
curves	O
of	O
A	O
##FP	O
and	O
plasma	O
meta	O
##bol	O
##ites	O
demonstrating	O
their	O
different	O
abilities	O
to	O
predict	O
HC	O
##C	O
cases	O
among	O
c	O
##ir	O
##r	O
##hot	O
##ic	O
patients	O

Of	O
all	O
molecules	O
anal	O
##ys	O
##ed	O
,	O
20	B
-	I
H	I
##ET	I
##E	I
was	O
the	O
only	O
meta	O
##bol	O
##ite	O
that	O
was	O
differently	O
expressed	O
in	O
plasma	O
samples	O
.	O

Combined	O
mineral	O
##oc	O
##ort	O
##ico	O
##id	O
and	O
g	B
##lu	I
##co	I
##cor	I
##tic	I
##oid	I
precursor	O
excess	O
was	O
found	O
in	O
4	O
%	O
of	O
AC	O
##A	O
and	O
2	O
%	O
of	O
ACC	O
.	O

The	O
feature	O
with	O
the	O
strongest	O
association	O
with	O
AD	O
,	O
m	O
/	O
z	O
251	O
.	O
1753	O
,	O
matched	O
the	O
mass	O
of	O
the	O
[	O
M	O
+	O
H	O
]	O
_	O
+	O
add	O
##uc	O
##t	O
of	O
r	B
##iva	I
##st	I
##ig	I
##mine	I
,	O
an	O
AD	O
medication	O
.	O

For	O
example	O
,	O
the	O
group	O
of	O
al	O
##de	O
##hy	O
##des	O
around	O
he	B
##xa	I
##nal	I
,	O
he	B
##pta	I
##nal	I
and	O
o	B
##ct	I
##ana	I
##l	I
forms	O
their	O
own	O
cluster	O
.	O

(	O
D	O
)	O
Colony	O
formation	O
ass	O
##ay	O
showing	O
survival	O
fraction	O
##s	O
of	O
the	O
indicated	O
cells	O
following	O
treatment	O
with	O
0	O
or	O
4	O
G	O
##y	O
I	O
##R	O
and	O
E	O
##tom	O
##ox	O
##ir	O
(	O
80	O
μ	O
##M	O
)	O
or	O
c	B
##is	I
##p	I
##lat	I
##in	I
(	O
0	O
.	O
8	O
μ	O
##M	O
)	O
.	O

Ser	B
##oto	I
##nin	I
levels	O
were	O
[UNK]	B
times	O
lower	O
than	O
K	O
##yn	O
(	O
E	O
)	O
.	O

A	O
##bb	O
##re	O
##viation	O
##s	O
:	O
AL	O
##T	O
,	O
al	O
##ani	O
##ne	O
amino	O
##tra	O
##ns	O
##fer	O
##ase	O
;	O
a	O
##P	O
##TT	O
,	O
activated	S
partial	O
th	B
##rom	I
##bo	I
##p	I
##last	I
##in	I
time	O
;	O
AS	O
##T	O
,	O
as	O
##par	O
##tate	O
amino	O
##tra	O
##ns	O
##fer	O
##ase	O
;	O
G	O
##F	O
##R	O
,	O
g	O
##lo	O
##mer	O
##ular	O
fi	O
##ltration	O
rate	O
;	O
IN	O
##R	O
,	O
international	O
normal	O
##ized	O
ratio	O
;	O
N	O
##I	O
##HS	O
##S	O
,	O
National	O
Institutes	O
of	O
Health	O
St	O
##roke	O
Scale	O
;	O
PT	O
,	O
pro	O
##th	O
##rom	O
##bin	O
time	O
;	O
T	O
##T	O
,	O
th	O
##rom	O
##bin	O
time	O
.	O

SD	O
##MA	O
is	O
a	O
stereo	O
##is	O
##omer	O
of	O
AD	B
##MA	I
which	O
does	O
not	O
directly	O
in	O
##hibit	O
ni	B
##tric	I
oxide	I
s	O
##ynth	O
##ase	O
(	O
,	O
)	O
.	O

Among	O
the	O
LA	O
##SS	O
##O	O
-	O
selected	O
11	O
meta	O
##bol	O
##ites	O
,	O
four	O
(	B
v	B
##ali	I
##ne	I
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
g	B
##lut	I
##ami	I
##c	I
acid	I
,	O
and	O
the	O
fur	O
##ano	O
##se	O
sugar	O
)	O
were	O
also	O
found	O
statistical	O
##ly	O
significant	O
in	O
a	O
G	O
##C	O
-	O
MS	O
–	O
based	O
meta	O
##bol	O
##omi	O
##c	O
analysis	O
we	O
conducted	O
previously	O
using	O
plasma	O
samples	O
from	O
HC	O
##C	O
cases	O
and	O
patients	O
with	O
liver	O
c	O
##ir	O
##r	O
##hos	O
##is	O
recruited	O
in	O
Tan	O
##ta	O
,	O
Egypt	O
.	O

Beta	B
##ine	I
ex	O
##cre	O
##tion	O
has	O
been	O
previously	O
reported	O
to	O
be	O
correlated	O
with	O
fast	O
##ing	O
glucose	S
levels	O
and	O
from	O
our	O
results	O
appears	O
to	O
be	O
partly	O
driven	O
by	O
g	O
##ly	O
##cos	O
##uria	O
(	O
which	O
is	O
itself	O
correlated	O
with	O
fast	O
##ing	O
glucose	S
and	O
H	O
##b	O
##A	O
##1	O
##c	O
)	O
.	O

Met	B
##han	I
##ol	I
,	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
,	O
perch	B
##lor	I
##ic	I
acid	I
(	O
PC	O
##A	O
)	O
,	O
t	O
##rich	O
##lor	O
##oa	O
##ce	O
##tic	O
acid	O
(	O
T	O
##CA	O
)	O
,	O
h	B
##ydro	I
##ch	I
##lor	I
##ic	I
acid	I
(	O
HC	O
##l	O
)	O
,	O
sodium	B
h	I
##ydro	I
##xi	I
##de	I
(	O
Na	O
##OH	O
)	O
,	O
(	B
2	I
-	I
br	I
##omo	I
##eth	I
##yl	I
)	I
trim	I
##eth	I
##yla	I
##mm	I
##onium	I
br	I
##omi	I
##de	I
,	O
dim	B
##eth	I
##yl	I
##form	I
##ami	I
##de	I

ID	O
##O	O
and	O
ID	O
##O	O
##2	O
control	O
the	O
T	O
##rp	O
cat	O
##ab	O
##olis	O
##m	O
signaling	O
pathway	O
generating	O
k	B
##yn	I
##uren	I
##ine	I
and	O
other	O
downstream	O
cat	O
##ab	O
##oli	O
##tes	O
that	O
can	O
m	O
##od	O
##ulate	O
T	O
-	O
cell	O
immunity	O
.	O

T	O
##rea	O
##ting	O
SK	O
-	O
Mel	O
23	O
me	O
##lan	O
##oma	O
cells	O
with	O
E	O
_	O
2	O
has	O
been	O
shown	O
to	O
in	O
##hibit	O
their	O
growth	O
,	O
while	O
pre	O
-	O
treating	O
the	O
cells	O
with	O
ta	B
##mo	I
##xi	I
##fen	I
(	O
an	O
anti	O
-	O
est	O
##rogen	O
)	O
blocks	O
the	O
effects	O
of	O
E	O
_	O
2	O
.	O

For	O
example	O
,	O
G	O
##ama	O
##ged	O
##ara	O
et	O
al	O
.	O
analyzed	O
urine	O
samples	O
of	O
12	O
healthy	O
subjects	O
by	O
HP	O
##LC	O
-	O
E	O
##SI	O
##Q	O
##Q	O
##Q	O
##MS	O
and	O
the	O
concentration	O
of	O
ta	B
##uri	I
##ne	I
had	O
a	O
range	O
,	O
mean	O
,	O
and	O
SD	O
,	O
respectively	O
,	O
of	O
0	O
.	O
04	O
##7	O
–	O
8	O
.	O
9	O
,	O
1	O
.	O
8	O
,	O
and	O
2	O
.	O
35	O
m	O
##M	O
(	O
1	O
.	O
5	O
–	O
258	O
,	O
58	O
.	O
6	O
,	O
and	O
75	O
.	O
2	O
μ	O
##g	O
m	O
##L	O
_	O
−	O
##1	O
)	O
,	O
while	O
T	O
##cher	O
##kas	O
et	O
al	O
.	O
found	O
a	O
mean	O
±	O
SE	O
##M	O
(	O
standard	O
error	O
of	O
the	O
mean	O
)	O
ta	B
##uri	I
##ne	I
concentration	O
in	O
serum	O
samples	O
from	O
16	O
healthy	O
volunteers	O
102	O
.	O
5	O
±	O
17	O
.	O
3	O
nm	O
##ol	O
m	O
##L	O
_	O
−	O
##1	O
(	O
3	O
.	O
3	O
±	O
0	O
.	O
55	O
μ	O
##g	O
m	O
##L	O
_	O
−	O
##1	O
,	O
analyzed	O
by	O
means	O
of	O
HP	O
##LC	O
with	O
an	O
electro	O
##chemical	O
detection	O
.	O

Water	O
and	O
ch	B
##lor	I
##of	I
##orm	I
were	O
added	O
(	O
200	O
μ	O
##l	O
of	O
each	O
)	O
and	O
the	O
samples	O
cent	O
##ri	O
##fu	O
##ged	O
for	O
20	O
min	O
.	O

Both	O
A	O
and	O
B	O
contained	O
10	O
m	O
##M	O
.	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
and	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
.	O

Car	B
##nos	I
##ine	I
;	O
C	O
##it	O
:	O
C	B
##it	I
##rate	I
;	O
Cho	O
:	O
Cho	B
##line	I
;	O
C	O
##n	O
:	O
C	B
##rea	I
##tin	I
##ine	I
;	O
D	B
##MA	I
:	O
Di	B
##met	I
##hyl	I
##amine	I
;	O
D	B
##MG	I
:	O
Di	B
##met	I
##hyl	I
##gly	I
##cine	I
;	O
For	O
:	O
Form	B
##ate	I
;	O
G	O
##ly	O
:	O
G	B
##ly	I
##cine	I
;	O
Hip	O
:	O
Hip	B
##pura	I
##te	I
;	O
I	O
##B	O
:	O
Is	B
##ob	I
##ut	I
##yra	I
##te	I
;	O
K	O
##g	O
:	O
α	B
-	I
Ke	I
##to	I
##g	I
##lut	I
##arate	I
;	O
Lac	O
:	O
Lac	B
##tate	I
;	O
M	O
##M	O
:	O
Met	B
##hyl	I
##mal	I
##ona	I
##te	I
;	O
N	O
-	O
M	O
##N	O
:	O
N	B
-	I
Met	I
##hyl	I
##nic	I
##ot	I
##ina	I
##mi	I
##de	I
;	O
N	O
##AG	O
:	O
N	B
-	I
Ace	I
##ty	I
##l	I
##g	I
##lut	I
##ama	I
##te	I
;	O
PA	B
##G	I
:	O
Ph	B
##en	I
##yla	I
##ce	I
##ty	I
##gly	I
##cine	I
;	O
p	O
-	O
HP	O
##A	O
:	O
p	B
-	I
H	I
##ydro	I
##xy	I
##phe	I
##ny	I
##lace	I
##tate	I
;	O
P	O
##y	O
:	O
P	B
##yr	I
##u	I
##vate	I
;	O
P	O
##yr	O
:	O
P	B
##yr	I
##ido	I
##xin	I
##e	I
;	O
Su	O
##c	O
:	O
Su	B
##cci	I
##nate	I
;	O
Tau	O
:	O
Tau	B
##rine	I
;	O
T	O
##MA	O
:	O

Inc	O
##reased	O
concentrations	O
of	O
le	O
##uc	O
##ine	O
/	O
is	O
##ole	O
##uc	O
##ine	O
,	O
N	B
-	I
ace	I
##ty	I
##l	I
-	I
c	I
##ys	I
##tein	I
##e	I
and	O
g	B
##lut	I
##ama	I
##te	I
and	O
decreased	O
concentrations	O
of	O
g	B
##lut	I
##amine	I
are	O
also	O
observed	O
when	O
the	O
serum	O
metabolic	O
profiles	O
of	O
N	O
##SC	O
##LC	O
patients	O
at	O
early	O
and	O
advanced	O
stages	O
of	O
the	O
disease	O
are	O
compared	O
.	O

All	O
samples	O
were	O
immediately	O
flushed	O
with	O
nitrogen	B
gas	I
upon	O
collection	O
to	O
prevent	O
auto	O
-	O
oxidation	O
.	O

Within	O
-	O
day	O
analytical	O
precision	O
was	O
measured	O
by	O
monitoring	O
the	O
retention	O
time	O
and	O
peak	O
area	O
variation	O
of	O
ca	B
##ffe	I
##ine	I
(	O
present	O
in	O
each	O
test	O
mixture	O
as	O
an	O
internal	O
standard	O
)	O
.	O

The	O
urine	O
samples	O
(	O
2	O
m	O
##L	O
each	O
)	O
with	O
internal	O
standards	O
added	O
were	O
first	O
in	O
##cu	O
##bate	O
##d	O
with	O
0	O
.	O
2	O
mg	O
of	O
β	O
-	O
g	O
##lu	O
##cu	O
##ron	O
##idas	O
##e	O
from	O
E	O
##scher	O
##ichi	O
##a	O
co	O
##li	O
(	O
in	O
0	O
.	O
07	O
##5	O
m	O
##ol	O
/	O
L	O
of	O
potassium	B
phosphate	I
buffer	O
[	O
pH	O
6	O
.	O
8	O
]	O
containing	O
1	O
g	O
/	O
L	O
of	O
BS	O
##A	O
)	O
for	O
2	O
hours	O
at	O
37	O
##°	O
##C	O
,	O
and	O
the	O
samples	O
were	O
then	O
acid	O
##ified	O
to	O
pH	O
6	O
with	O
10	O
%	O
ace	B
##tic	I
acid	I
.	O

Ph	O
##os	O
##ph	O
##og	O
##lu	O
##com	O
##uta	O
##se	O
1	O
cat	O
##aly	O
##zes	O
the	O
inter	O
##con	O
##version	O
of	O
glucose	B
-	I
6	I
-	I
phosphate	I
and	O
glucose	B
-	I
1	I
-	I
phosphate	I
.	O

Ad	O
##ju	O
##sted	O
associations	O
of	O
e	O
##G	O
##F	O
##R	O
and	O
other	O
clinical	O
characteristics	O
with	O
serum	O
24	B
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
concentration	O
in	O
ME	O
##SA	O
,	O
CH	O
##S	O
,	O
and	O
SK	O
##S	O
.	O

Pol	B
##y	I
##p	I
##rop	I
##yle	I
##ne	I
screw	O
via	O
##ls	O
and	O
safe	O
lock	O
tubes	O
were	O
purchased	O
from	O
A	O
##gi	O
##lent	O
(	O
Am	O
##ste	O
##lve	O
##en	O
,	O
The	O
Netherlands	O
)	O
and	O
E	O
##ppe	O
##ndo	O
##rf	O
(	O
Ni	O
##j	O
##me	O
##gen	O
,	O
The	O
Netherlands	O
)	O
,	O
respectively	O
.	O

Lower	O
concentrations	O
of	O
CS	O
##F	O
h	B
##ydro	I
##phi	I
##lic	I
and	O
h	O
##ydro	O
##phobic	O
compounds	O
were	O
observed	O
in	O
MS	O
patients	O
as	O
compared	O
to	O
control	O
group	O
.	O

The	O
lower	O
serum	O
concentrations	O
of	O
other	O
specific	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
belonging	O
to	O
the	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
##s	I
class	O
observed	O
in	O
this	O
study	O
further	O
reinforce	O
such	O
suggestions	O
.	O

For	O
all	O
compounds	O
including	O
the	O
additional	O
compounds	O
,	O
i	O
.	O
e	O
.	O
,	O
D	B
##MG	I
,	O
beta	B
##ine	I
,	O
ch	B
##olin	I
##e	I
,	O
and	O
5	O
-	O
M	O
##TH	O
##F	O
,	O
a	O
linear	O
re	O
##gression	O
model	O
was	O
used	O
.	O

Using	O
Kyoto	O
Encyclopedia	O
of	O
Gene	O
##s	O
and	O
Gen	O
##ome	O
##s	O
(	O
K	O
##EG	O
##G	O
)	O
database	O
,	O
several	O
key	O
metabolic	O
pathways	O
that	O
were	O
altered	O
in	O
CR	O
##C	O
patients	O
were	O
identified	O
,	O
which	O
involve	O
T	O
##CA	O
cycle	O
,	O
u	B
##rea	I
cycle	O
,	O
try	B
##pt	I
##op	I
##han	I
metabolism	O
,	O
fatty	O
acid	O
metabolism	O
,	O
and	O
gut	O
flora	O
metabolism	O
(	O
and	O
)	O
.	O

The	O
e	O
##pile	O
##psy	O
group	O
was	O
characterized	O
by	O
increased	O
levels	O
of	O
serum	O
N	B
-	I
ace	I
##ty	I
##l	I
-	I
g	I
##ly	I
##co	I
##p	I
##rote	I
##ins	I
,	O
la	B
##ct	I
##ate	I
,	O
c	B
##rea	I
##tine	I
,	O
g	B
##ly	I
##cine	I
and	O
lip	O
##ids	O
,	O
whereas	O
the	O
levels	O
of	O
c	B
##it	I
##rate	I
were	O
decreased	O
as	O
compared	O
to	O
the	O
reference	O
group	O
.	O

Using	O
mass	O
s	O
##pect	O
##rome	O
##try	O
,	O
non	O
-	O
targeted	O
bio	O
##chemical	O
pro	O
##fi	O
##ling	O
was	O
conducted	O
in	O
a	O
co	O
##hor	O
##t	O
of	O
39	O
##9	O
non	O
##dia	O
##bet	O
##ic	O
subjects	O
representing	O
a	O
broad	O
spectrum	O
of	O
insulin	O
sensitivity	O
and	O
glucose	S
tolerance	O
(	O
based	O
on	O
the	O
h	O
##yper	O
##ins	O
##ulin	O
##em	O
##ic	O
e	B
##ug	I
##ly	I
##ce	I
##mic	I
c	O
##lamp	O
and	O
oral	O
glucose	S
tolerance	O
testing	O
,	O
respectively	O
)	O
.	O

R	O
##OC	O
C	O
##ur	O
##ves	O
Analysis	O
was	O
used	O
to	O
determine	O
a	O
cut	O
-	O
off	O
value	O
of	O
different	O
##iating	O
factors	O
(	O
serum	O
concentrations	O
of	O
amino	S
acids	O
)	O
for	O
two	O
analyzed	O
groups	O
of	O
bee	O
##keepers	O
.	O

Age	O
was	O
a	O
weaker	O
but	O
significant	O
de	O
##ter	O
##mina	O
##nt	O
of	O
var	O
##iability	O
,	O
with	O
increasing	O
age	O
correlated	O
with	O
elevated	O
levels	O
of	O
some	O
s	O
##tero	O
##ls	O
such	O
as	O
7	B
-	I
de	I
##hy	I
##dr	I
##och	I
##ole	I
##ster	I
##ol	I
and	O
decreased	O
levels	O
of	O
others	O
such	O
as	O
24	B
##S	I
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
and	O
la	B
##th	I
##ost	I
##ero	I
##l	I
(	O
and	O
)	O
.	O

The	O
upper	O
a	O
##que	O
##ous	O
phase	O
was	O
transferred	O
into	O
a	O
clean	O
p	B
##oly	I
##p	I
##rop	I
##yle	I
##ne	I
tube	O
and	O
re	O
-	O
extracted	O
by	O
addition	O
of	O
200	O
μ	O
##l	O
M	B
##T	I
##BE	I
as	O
described	O
above	O
.	O

In	O
total	O
,	O
1	O
,	O
85	O
##1	O
molecular	O
features	O
were	O
extracted	O
and	O
detected	O
in	O
negative	O
and	O
positive	O
mode	O
when	O
the	O
met	B
##han	I
##ol	I
precipitation	O
method	O
was	O
used	O
versus	O
2	O
,	O
07	O
##3	O
features	O
when	O
met	B
##han	I
##ol	I
-	I
ethanol	I
(	I
1	I
:	I
1	I
)	I
precipitation	O
was	O
used	O
.	O

Not	O
##ably	O
,	O
in	O
all	O
13	O
patients	O
with	O
drug	O
-	O
susceptible	O
T	O
##B	O
with	O
the	O
detect	O
##able	O
t	B
##re	I
##hal	I
##ose	I
-	I
6	I
-	I
my	I
##cola	I
##te	I
meta	O
##bol	O
##ite	O
in	O
plasma	O
,	O
the	O
P	O
##I	O
meta	O
##bol	O
##ite	O
was	O
also	O
con	O
##com	O
##ita	O
##ntly	O
detected	O
.	O

Because	O
of	O
this	O
,	O
the	O
global	O
increase	O
in	O
k	B
##eton	I
##es	I
is	O
unlikely	O
to	O
be	O
due	O
solely	O
to	O
fast	O
##ing	O
status	O
.	O

Ser	O
##um	O
concentrations	O
of	O
est	O
##rogen	O
##s	O
and	O
est	B
##rogen	I
meta	O
##bol	O
##ite	O
pathway	O
groups	O
were	O
positively	O
and	O
statistical	O
##ly	O
significantly	O
correlated	O
with	O
base	O
##line	O
B	O
##MI	O
;	O
the	O
strongest	O
correlation	O
was	O
with	O
un	O
##con	O
##ju	O
##gated	O
est	B
##rad	I
##iol	I
(	O
r	O
=	O
0	O
.	O
45	O
)	O
.	O

Ace	B
##tam	I
##ip	I
##rid	I
and	O
ni	O
##ten	O
##py	O
##ram	O
were	O
purchased	O
from	O
W	O
##ak	O
##o	O
Chemical	O
##s	O
(	O
Osaka	O
,	O
Japan	O
)	O
and	O
im	O
##ida	O
##c	O
##lop	O
##rid	O
,	O
from	O
Ka	O
##nto	O
Chemical	O
##s	O
(	O
Tokyo	O
,	O
Japan	O
)	O
.	O

Go	O
to	O
:	O
B	B
##is	I
##phe	I
##no	I
##l	I
A	O
(	O
BP	O
##A	O
)	O
and	O
si	O
##ly	O
##bin	O
are	O
considered	O
x	O
##eno	O
##est	O
##rogen	O
##s	O
and	O
could	O
interfere	O
with	O
the	O
action	O
of	O
end	O
##ogen	O
##ous	O
hormones	O
.	O

Peak	O
##s	O
1	O
–	O
8	O
correspond	O
to	O
As	O
_	O
III	O
,	O
mon	B
##ome	I
##thy	I
##lars	I
##ono	I
##us	I
acid	I
(	O
MMA	O
_	O
III	O
)	O
,	O
dim	B
##eth	I
##yla	I
##rs	I
##ini	I
##c	I
acid	I
(	O
D	O
##MA	O
_	O
V	O
)	O
,	O
mon	B
##ome	I
##thy	I
##lars	I
##onic	I
acid	I
(	O
MMA	O
_	O
V	O
)	O
,	O
dim	B
##eth	I
##yl	I
##mon	I
##oth	I
##io	I
##ars	I
##onic	I
acid	I
,	O
dim	B
##eth	I
##yla	I
##rs	I
##ino	I
##us	I
acid	I
(	O
D	O
##MA	O
_	O
III	O
)	O
,	O
As	O
_	O
V	O
,	O
and	O
mon	B
##ome	I
##thy	I
##lm	I
##ono	I
##thi	I
##oar	I
##sonic	I
acid	I
(	O
M	O
##MM	O
##TA	O
_	O
V	O
)	O
,	O
respectively	O
To	O
confirm	O
the	O
presence	O
of	O
MMA	O
_	O
III	O
and	O
M	O
##MM	O
##TA	O
_	O
V	O
in	O
the	O
sa	O
##liva	O
of	O
AP	O
##L	O
patients	O
,	O
we	O
analyzed	O
the	O
sa	O
##liva	O
samples	O
spike	O
##d	O
with	O
authentic	O
standards	O
of	O
MMA	O
_	O
III	O
or	O
M	O
##MM	O
##TA	O
_	O
V	O
.	O

Furthermore	O
,	O
the	O
K	O
##EG	O
##G	O
database	O
indicated	O
that	O
these	O
meta	O
##bol	O
##ites	O
are	O
mainly	O
associated	O
with	O
metabolic	O
pathways	O
,	O
including	O
those	O
of	O
l	B
##ino	I
##le	I
##ic	I
acid	I
metabolism	O
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
metabolism	O
,	O
g	O
##ly	O
##cine	O
/	O
se	O
##rine	O
/	O
th	O
##re	O
##oni	O
##ne	O
metabolism	O
,	O
a	B
##rac	I
##hi	I
##don	I
##ic	I
acid	I
metabolism	O
,	O
gal	B
##act	I
##ose	I
metabolism	O
,	O
as	O
##cor	O
##bate	O
/	O
al	O
##dar	O
##ate	O
metabolism	O
,	O
the	O
c	B
##it	I
##ric	I
acid	I
cycle	O
(	O
T	O
##CA	O
cycle	O
)	O
,	O
and	O
g	B
##lut	I
##ath	I
##ione	I
metabolism	O
;	O
these	O
processes	O
were	O
further	O
associated	O
with	O
the	O
metabolism	O
of	O
amino	O
acids	O
,	O
lip	O
##ids	O
and	O
car	O
##bo	O
##hy	O
##dra	O
##tes	O
.	O

By	O
contrast	O
,	O
the	O
mean	O
PC	O
##1	O
score	O
was	O
at	O
its	O
lowest	O
during	O
the	O
evening	O
(	O
19	O
:	O
00	O
–	O
23	O
:	O
00	O
h	O
)	O
with	O
high	O
levels	O
of	O
al	B
##ani	I
##ne	I
,	O
all	B
##ant	I
##oi	I
##n	I
,	O
t	B
##rig	I
##one	I
##llin	I
##e	I
,	O
th	O
##r	O
+	O
la	O
##c	O
,	O
format	B
##e	I
,	O
x	B
##yl	I
##ose	I
,	O
v	B
##ali	I
##ne	I
,	O
and	O
t	B
##yr	I
##os	I
##ine	I
,	O
among	O
others	O
.	O

G	B
##lut	I
##ami	I
##c	I
acid	I
and	O
9	B
##H	I
-	I
pu	I
##rine	I
were	O
not	O
eligible	O
for	O
the	O
t	O
-	O
test	O
because	O
the	O
level	O
was	O
below	O
detection	O
in	O
4	O
control	O
animals	O
.	O

T	O
##HC	O
##V	O
and	O
its	O
meta	O
##bol	O
##ite	O
T	O
##HC	O
##VC	O
##O	O
##OH	O
also	O
were	O
targeted	O
for	O
distinguishing	O
intake	O
of	O
ill	O
##icit	O
cannabis	S
and	O
Marino	O
##l	O
,	O
synthetic	O
T	O
##HC	O
indicated	O
for	O
treatment	O
of	O
weight	O
loss	O
and	O
nausea	O
.	O

Furthermore	O
,	O
we	O
confirmed	O
our	O
findings	O
with	O
DB	B
##P	I
and	O
insulin	O
levels	O
in	O
which	O
we	O
observed	O
similar	O
associations	O
with	O
meta	O
##bol	O
##ite	O
levels	O
in	O
fast	O
##ed	O
status	O
and	O
after	O
the	O
SL	O
##M	O
.	O

Milk	O
and	O
blood	O
samples	O
from	O
twelve	O
Holstein	O
cows	O
were	O
collected	O
in	O
early	O
,	O
mid	O
and	O
late	O
la	O
##ct	O
##ation	O
and	O
analyzed	O
for	O
ace	B
##ty	I
##l	I
##cho	I
##line	I
,	O
free	O
ch	B
##olin	I
##e	I
,	O
beta	B
##ine	I
,	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##och	I
##olin	I
##e	I
,	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
,	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
,	O
p	B
##hos	I
##ph	I
##och	I
##olin	I
##e	I
and	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
using	O
h	B
##ydro	I
##phi	I
##lic	I
interaction	O
liquid	O
ch	O
##roma	O
##tography	O
-	O
tandem	O
mass	O
s	O
##pect	O
##rome	O
##try	O
,	O
and	O
q	O
##uant	O
##ified	O
using	O
stable	O
is	O
##oto	O
##pe	O
-	O
labeled	O
internal	O
standards	O
.	O

Furthermore	O
,	O
Ce	B
##r	I
was	O
associated	O
with	O
central	O
o	O
##besity	O
(	O
P	O
<	O
0	O
.	O
01	O
;	O
)	O
and	O
L	O
##MI	O
was	O
positively	O
associated	O
with	O
So	O
##1	O
##P	O
(	O
te	O
##rt	O
##ile	O
1	O
,	O
1	O
.	O
67	O
##±	O
##1	O
.	O
44	O
##×	O
##10	O
_	O
−	O
##2	O
ng	O
/	O
m	O
##l	O
;	O
te	O
##rt	O
##ile	O
2	O
,	O
4	O
.	O
27	O
##±	O
##3	O
.	O
94	O
##×	O
##10	O
_	O
−	O
##2	O
ng	O
/	O
m	O
##l	O
;	O
te	O
##rt	O
##ile	O
3	O
,	O
4	O
.	O
82	O
##±	O
##3	O
.	O
26	O
##×	O
##10	O
_	O
−	O
##2	O
ng	O
/	O
m	O
##l	O
;	O
P	O
<	O
0	O
.	O
01	O
,	O
te	O
##rt	O
##ile	O
1	O
vs	O
.	O
3	O
;	O
)	O
.	O

The	O
pattern	O
of	O
fatty	O
acid	O
increase	O
after	O
r	O
##if	O
##ax	O
##im	O
##in	O
were	O
a	O
higher	O
level	O
of	O
saturated	O
fatty	O
acids	O
[	O
cap	O
##ryl	O
##ic	O
(	O
[UNK]	O
)	O
,	O
my	B
##rist	I
##ic	I
(	I
[UNK]	O
)	O
and	O
p	O
##ali	O
##mit	O
##ic	O
acid	O
(	O
[UNK]	O
)	O
]	O
which	O
after	O
the	O
action	O
of	O
s	B
##te	I
##aro	I
##yl	I
-	I
Co	I
##A	I
des	O
##at	O
##ura	O
##se	O
can	O
be	O
turned	O
into	O
palm	B
##ito	I
##le	I
##ic	I
acid	I
(	O
[UNK]	O
)	O
,	O
o	O
##le	O
##ic	O
(	O
[UNK]	O
)	O
and	O
e	B
##ico	I
##san	I
##oi	I
##c	I
acid	I
(	O
[UNK]	O
)	O
.	O

Co	O
##rrel	O
##ations	O
between	O
individual	O
treatment	O
-	O
related	O
changes	O
of	O
total	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
concentration	O
(	O
PC	O
,	O
l	O
##ys	O
##o	O
##PC	O
,	O
and	O
SM	O
)	O
,	O
serum	O
album	O
##in	O
concentration	O
,	O
and	O
body	O
mass	O
during	O
the	O
first	O
stage	O
of	O
a	O
treatment	O
(	O
the	O
B	O
-	O
A	O
difference	O
)	O
in	O
CC	O
##RT	O
and	O
R	O
##T	O
samples	O
marked	O
in	O
blue	O
and	O
orange	O
,	O
respectively	O
.	O

Models	O
shown	O
on	O
the	O
right	O
-	O
hand	O
side	O
were	O
adjusted	O
for	O
log	O
-	O
transformed	O
(	O
to	O
the	O
base	O
1	O
.	O
2	O
)	O
continuous	O
un	O
##con	O
##ju	O
##gated	O
est	B
##rad	I
##iol	I
.	O

Thus	O
the	O
addition	O
of	O
am	B
##mon	I
##ium	I
h	I
##ydro	I
##xi	I
##de	I
to	O
the	O
m	O
##od	O
##ifier	O
resulted	O
in	O
a	O
median	O
peak	O
base	O
width	O
of	O
17	O
.	O
3	O
s	O
,	O
as	O
opposed	O
to	O
form	B
##ic	I
acid	I
with	O
a	O
median	O
width	O
of	O
33	O
.	O
9	O
s	O
(	O
mean	O
values	O
are	O
26	O
.	O
5	O
and	O
46	O
.	O
6	O

The	O
mobile	O
phase	O
consisted	O
of	O
a	O
gradient	O
of	O
solvent	O
A	O
(	O
he	O
##xa	O
##nes	O
/	O
2	O
-	O
prop	O
##ano	O
##l	O
,	O
30	O
:	O
40	O
,	O
v	O
/	O
v	O
)	O
and	O
solvent	O
B	O
(	O
he	O
##xa	O
##nes	O
/	O
2	O
-	O
prop	O
##ano	O
##l	O
/	O
20	O
m	O
##M	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
in	O
water	O
,	O
30	O
:	O
40	O
:	O
7	O
,	O
v	O
/	O
v	O
/	O
v	O
)	O
.	O

Method	O
specific	O
results	O
for	O
vitamin	B
D	I
meta	O
##bol	O
##ites	O
in	O
SR	O
##M	O
97	O
##2	O
##a	O
(	O
ng	O
/	O
g	O
)	O
.	O

Lowe	O
##st	O
level	O
of	O
detection	O
,	O
_	O
c	O
N	B
-	I
des	I
##met	I
##hyl	I
-	I
ace	I
##tam	I
##ip	I
##rid	I
_	O

The	O
network	O
analysis	O
showed	O
higher	O
levels	O
of	O
glucose	S
,	O
as	B
##cor	I
##bate	I
,	O
and	O
ta	B
##uri	I
##ne	I
;	O
this	O
was	O
predicted	O
in	O
long	O
-	O
term	O
survivors	O
.	O

Us	O
##ual	O
so	O
##y	O
is	B
##of	I
##lav	I
##one	I
intake	O
assessments	O
using	O
the	O
Block	O
So	O
##y	O
Screen	O
Question	O
##naire	O
by	O
S	O
-	O
(	O
−	O
)	O
e	O
##q	O
##uo	O
##l	O
producing	O
status	O
_	O
a	O

HC	O
##A	O
analysis	O
revealed	O
that	O
the	O
2	O
apparent	O
lip	O
##id	O
species	O
C	B
##18	I
:	I
2	I
CE	O
and	O
SM	O
22	O
:	O
0	O
had	O
a	O
tendency	O
to	O
gradually	O
decrease	O
in	O
mean	O
plasma	O
lip	O
##id	O
concentration	O
,	O
from	O
right	O
(	O
higher	O
concentration	O
,	O
shown	O
in	O
red	O
)	O
to	O
left	O
(	O
lower	O
concentration	O
,	O
shown	O
in	O
blue	O
;	O
)	O
.	O

Because	O
of	O
the	O
improved	O
E	O
##SI	O
response	O
and	O
ch	O
##roma	O
##to	O
##graphic	O
separation	O
,	O
we	O
were	O
able	O
to	O
achieve	O
a	O
more	O
comprehensive	O
analysis	O
of	O
the	O
am	B
##ine	I
-	I
and	O
p	O
##hen	O
##ol	O
-	O
containing	O
sub	O
##met	O
##ab	O
##olo	O
##me	O
.	O

Since	O
we	O
were	O
interested	O
in	O
covering	O
the	O
entirety	O
of	O
the	O
p	B
##oly	I
##amine	I
metabolism	O
,	O
we	O
tried	O
acid	O
##ifying	O
the	O
sample	O
with	O
T	O
##FA	O
before	O
the	O
LL	O
##E	O
to	O
achieve	O
better	O
recover	O
##ies	O
of	O
the	O
more	O
polar	O
anal	O
##yte	O
##s	O
.	O

There	O
was	O
evidence	O
for	O
differences	O
in	O
glucose	S
elevations	O
between	O
different	O
brain	O
regions	O
in	O
AD	O
where	O
levels	O
tended	O
to	O
be	O
higher	O
in	O
more	O
severely	O
affected	O
regions	O
such	O
as	O
the	O
middle	O
temporal	O
g	O
##yr	O
##us	O
(	O
;	O
and	O
a	O
)	O
.	O

The	O
un	O
##iva	O
##ria	O
##te	O
tests	O
demonstrated	O
that	O
ten	O
of	O
these	O
were	O
independently	O
altered	O
,	O
of	O
which	O
l	O
##umi	O
##ch	O
##rome	O
,	O
x	B
##ant	I
##hine	I
,	O
N	B
-	I
ace	I
##ty	I
##l	I
##p	I
##rol	I
##ine	I
,	O
is	B
##ole	I
##uc	I
##ine	I
and	O
L	B
-	I
D	I
##OP	I
##A	I
remained	O
significant	O
after	O
correct	O
##ing	O
for	O
multiple	O
comparisons	O
.	O

These	O
450	O
selected	O
s	O
##pect	O
##ra	O
were	O
chosen	O
as	O
representative	O
of	O
groups	O
A	O
and	O
B	O
(	O
see	O
)	O
,	O
and	O
were	O
subsequently	O
examined	O
visually	O
to	O
confirm	O
presence	O
or	O
absence	O
of	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
meta	O
##bol	O
##ite	O
signals	O
.	O

Two	O
solid	O
core	O
C	O
##18	O
columns	O
(	O
Ph	O
##eno	O
##men	O
##ex	O
Ki	O
##net	O
##ex	O
C	O
##18	O
,	O
150	O
×	O
4	O
.	O
6	O
mm	O
)	O
in	O
series	O
were	O
used	O
to	O
achieve	O
ch	O
##roma	O
##to	O
##graphic	O
separation	O
of	O
the	O
F	B
##2	I
-	I
is	I
##op	I
##ros	I
##tan	I
##e	I
is	I
##omer	I
##s	I
.	O

While	O
P	O
##BM	O
##C	O
were	O
not	O
collected	O
in	O
the	O
current	O
study	O
,	O
comparison	O
of	O
the	O
so	B
##fo	I
##s	I
##bu	I
##vir	I
meta	O
##bol	O
##ite	O
levels	O
in	O
P	O
##BM	O
##C	O
determined	O
in	O
the	O
prior	O
study	O
to	O
the	O
levels	O
in	O
liver	O
determined	O
here	O
suggests	O
>	O
10	O
-	O
fold	O
-	O
higher	O
levels	O
in	O
liver	O
.	O

A	O
similar	O
trend	O
was	O
also	O
observed	O
with	O
the	O
EC	O
-	O
array	O
detection	O
except	O
that	O
,	O
in	O
addition	O
to	O
try	B
##pt	I
##op	I
##han	I
,	O
a	O
significant	O
signal	O
increase	O
was	O
observed	O
for	O
D	O
##A	O
(	O
R	O
##T	O
3	O
.	O
22	O
min	O
)	O
when	O
spike	O
##d	O
into	O
serum	O
.	O

The	O
dried	O
samples	O
were	O
mixed	O
with	O
100	O
μ	O
##L	O
of	O
phosphate	S
buffer	O
in	O
D	O
_	O
2	O
O	O
containing	O
66	O
.	O
17	O
μ	O
##M	O
T	O
##SP	O
,	O
made	O
up	O
to	O
600	O
μ	O
##L	O
with	O
phosphate	S
buffer	O
in	O
D	O
_	O
2	O
O	O
,	O
and	O
transferred	O
to	O
5	O
mm	O
N	O
##MR	O
tubes	O
.	O

In	O
the	O
AD	O
##VA	O
##NC	O
##E	O
study	O
,	O
the	O
BC	O
##AA	O
##s	O
le	B
##uc	I
##ine	I
,	O
v	B
##ali	I
##ne	I
and	O
is	B
##ole	I
##uc	I
##ine	I
showed	O
no	O
association	O
with	O
mac	O
##rov	O
##as	O
##cular	O
events	O
,	O
but	O
low	O
levels	O
of	O
le	B
##uc	I
##ine	I
and	O
v	B
##ali	I
##ne	I
were	O
associated	O
with	O
increased	O
all	O
-	O
cause	O
mortality	O
.	O

Older	O
studies	O
indicated	O
that	O
D	O
##MS	O
##O	O
_	O
2	O
in	O
##hibit	O
##ed	O
o	O
##xi	O
##dant	O
production	O
in	O
activated	S
ne	O
##ut	O
##rop	O
##hil	O
##s	O
and	O
diminished	O
the	O
proliferation	O
of	O
vascular	O
smooth	O
muscle	O
cells	O
and	O
end	O
##oth	O
##eli	O
##al	O
cells	O
,	O
.	O

The	O
upper	O
phase	O
(	O
a	O
##que	O
##ous	O
phase	O
)	O
,	O
containing	O
gang	B
##lio	I
##side	I
species	O
and	O
several	O
l	B
##ys	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
,	O
was	O
transferred	O
into	O
a	O
glass	O
tube	O
and	O
then	O
dried	O
under	O
a	O
stream	O
of	O
nitrogen	O
.	O

The	O
variables	O
in	O
the	O
equation	O
of	O
logic	O
re	O
##gression	O
analysis	O
for	O
liver	O
cancer	O
plasma	O
(	O
assigned	O
as	O
1	O
as	O
dependent	O
)	O
and	O
lung	O
cancer	O
plasma	O
(	O
assigned	O
for	O
2	O
as	O
dependent	O
)	O
using	O
the	O
Con	O
##ditional	O
Method	O
as	O
analytical	O
method	O
.	O
_	O
a	O
V	O
##aria	O
##ble	O
(	O
s	O
)	O
entered	O
in	O
step	O
1	O
:	O
put	B
##res	I
##cine	I
;	O
_	O
b	O
V	O
##aria	O
##ble	O
(	O
s	O
)	O
entered	O
in	O
step	O
2	O
:	O
sperm	B
##id	I
##ine	I
;	O
_	O
c	O
V	O
##aria	O
##ble	O
(	O
s	O
)	O
entered	O
in	O
step	O
3	O
:	O
N	B
-	I
ace	I
##ty	I
##ls	I
##per	I
##mine	I
;	O
_	O
d	O
V	O
##aria	O
##ble	O
(	O
s	O
)	O
entered	O
in	O
step	O
4	O
:	O
γ	B
-	I
amino	I
##but	I
##yric	I
acid	I
.	O

The	O
G	B
##S	I
##H	I
con	O
##ju	O
##gate	O
##s	O
of	O
est	B
##rogen	I
q	I
##uin	I
##ones	I
are	O
further	O
converted	O
to	O
c	B
##ys	I
##tein	I
##e	I
and	O
N	B
-	I
ace	I
##ty	I
##l	I
-	I
c	I
##ys	I
##tein	I
##e	I
via	O
the	O
me	B
##rca	I
##pt	I
##uri	I
##c	I
acid	I
bio	O
##sy	O
##nt	O
##hesis	O
pathway	O
.	O

B	O
##rief	O
##ly	O
,	O
100	O
μ	O
##L	O
of	O
the	O
subject	O
’	O
s	O
plasma	O
,	O
ca	O
##li	O
##bra	O
##tors	O
,	O
and	O
quality	O
control	O
samples	O
were	O
pre	O
##ci	O
##pit	O
##ated	O
with	O
200	O
μ	O
##L	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
.	O

Using	O
B	O
[	O
a	O
]	O
P	O
as	O
a	O
pro	O
##to	O
##ty	O
##pical	O
PA	O
##H	O
,	O
an	O
HP	O
##LC	O
-	O
L	O
##IT	O
-	O
MS	O
_	O
3	O
method	O
was	O
developed	O
to	O
identify	O
stable	O
DNA	O
add	O
##uc	O
##ts	O
of	O
ben	B
##zo	I
[	I
a	I
]	I
p	I
##yre	I
##ne	I
-	I
7	I
,	I
8	I
-	I
di	I
##one	I
,	O
the	O
bio	O
##activated	O
form	O
of	O
B	O
[	O
a	O
]	O
P	O
cat	O
##aly	O
##zed	O
by	O
AK	O
##R	O
##s	O
,	O
in	O
human	O
lung	O
cell	O
lines	O
.	O

A	O
##bb	O
##re	O
##viation	O
##s	O
:	O
AM	B
##P	I
,	O
ad	B
##eno	I
##sin	I
##e	I
5	I
′	I
-	I
mon	I
##op	I
##hos	I
##phate	I
;	O
C	B
##MP	I
,	O
c	B
##yt	I
##id	I
##ine	I
5	I
′	I
-	I
mon	I
##op	I
##hos	I
##phate	I
;	O
I	B
##MP	I
,	O
in	B
##os	I
##ine	I
5	I
′	I
-	I
mon	I
##op	I
##hos	I
##phate	I
;	O
PR	B
##PP	I
,	O
p	B
##hos	I
##ph	I
##ori	I
##bos	I
##yl	I
p	I
##yr	I
##op	I
##hos	I
##phate	I
;	O
T	O
##MP	O
,	O
thy	B
##mi	I
##dine	I
5	I
′	I
-	I
mon	I
##op	I
##hos	I
##phate	I
;	O
U	O
##MP	O
,	O
u	B
##rid	I
##ine	I
5	I
′	I
-	I
mon	I
##op	I
##hos	I
##phate	I
;	O
X	O
##MP	O
,	O
x	B
##ant	I
##hine	I
5	I
′	I
-	I
mon	I
##op	I
##hos	I
##phate	I
.	O

To	O
the	O
dried	O
meta	O
##bol	O
##ite	O
sample	O
,	O
50	O
μ	O
##L	O
of	O
fresh	O
met	B
##ho	I
##xy	I
##lam	I
##ine	I
(	O
M	O
##OX	O
)	O
re	O
##age	O
##nt	O
(	O
20	O
mg	O
/	O
m	O
##L	O
)	O
was	O
added	O
and	O
the	O
samples	O
in	O
##cu	O
##bate	O
##d	O
in	O
the	O
oven	O
at	O
60	O
°C	O
for	O
2	O
h	O
.	O

Then	O
,	O
200	O
μ	O
##L	O
of	O
phosphate	S
buffer	O
solution	O
(	O
90	O
m	O
##M	O
Na	O
##H	O
_	O
2	O
P	O
##O	O
_	O
4	O
/	O
Na	O
_	O
2	O

The	O
p	O
##K	O
_	O
a	O
values	O
used	O
:	O
D	O
##MA	O
##N	O
,	O
p	O
##K	O
_	B
a	I
(	I
con	I
##ju	I
##gate	I
-	I
acid	I
)	I
=	O
12	O
.	O
5	O
;	O
s	B
##te	I
##ari	I
##c	I
acid	I
,	O
p	O
##K	O
_	O
a	O
=	O
10	O
.	O
15	O
;	O
t	B
##ri	I
##f	I
##lu	I
##oro	I
##ace	I
##tic	I
acid	I
,	O
p	O
##K	O
_	O
a	O
=	O
0	O
.	O
52	O
;	O
t	O
##rich	O
##lor	O
##oa	O
##ce	O
##tic	O
acid	O
,	O
p	O
##K	O
_	O
a	O
=	O
0	O
.	O
81	O
;	O
p	O
##ival	O
##ic	O
acid	O
,	O
p	O
##K	O
_	O
a	O
=	O
4	O
.	O
98	O
(	O
all	O
,	O
re	O
##fs	O
.	O
and	O
)	O
.	O

,	O
al	B
##ani	I
##ne	I
(	O
1	O
.	O
46	O
p	O
.	O
p	O
.	O
m	O
.	O
)	O
,	O
g	O
##lut	O
##amine	O
/	O
g	O
##lut	O
##ama	O
##te	O
(	O
2	O
.	O
15	O
and	O
2	O
.	O
46	O
p	O
.	O
p	O
.	O
m	O
.	O
)	O
and	O
c	B
##it	I
##rate	I
(	O
2	O
.	O
55	O
and	O
2	O
.	O
67	O
p	O
.	O
p	O
.	O
m	O
.	O
)	O
,	O
whereas	O
la	B
##ct	I
##ate	I
(	O
1	O
.	O
33	O
and	O
4	O
.	O
11	O
p	O
.	O
p	O
.	O
m	O
.	O
)	O
,	O
ace	B
##tate	I
(	O
1	O
.	O
91	O
p	O
.	O
p	O
.	O
m	O
.	O
)	O
,	O
t	B
##yr	I
##os	I
##ine	I
(	O
6	O
.	O
91	O
and	O
7	O
.	O
18	O
p	O
.	O
p	O
.	O
m	O
.	O
)	O
and	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
(	O
7	O
.	O
36	O
and	O
7	O
.	O
45	O
p	O
.	O
p	O
.	O
m	O
.	O
)	O
all	O
appeared	O
to	O
decrease	O
compared	O
with	O
place	O
##bo	O
.	O

Indeed	O
,	O
it	O
is	O
tempting	O
to	O
s	O
##pec	O
##ulate	O
that	O
such	O
congestion	O
and	O
attendant	O
in	O
##test	O
##inal	O
ed	O
##ema	O
could	O
lead	O
to	O
alterations	O
in	O
in	O
##test	O
##inal	O
micro	O
##bio	O
##ta	O
composition	O
that	O
adverse	O
##ly	O
impacts	O
(	O
enhance	O
##s	O
)	O
T	B
##MA	I
##O	I
production	O
[	O
]	O
.	O

Volume	O
of	O
ethanol	S
consumed	O
in	O
the	O
past	O
week	O
was	O
calculated	O
from	O
beverage	O
-	O
specific	O
questions	O
on	O
consumption	O
of	O
beer	O
,	O
c	O
##ider	O
and	O
long	O
drinks	O
,	O
wine	O
and	O
spirits	O
.	O

No	O
significant	O
differences	O
in	O
add	O
##uc	O
##t	O
formation	O
were	O
found	O
for	O
any	O
anal	O
##yte	O
##s	O
except	O
for	O
me	B
##lat	I
##oni	I
##n	I
where	O
so	O
##dia	O
##ted	O
add	O
##uc	O
##t	O
with	O
the	O
intensity	O
similar	O
to	O
pro	O
##ton	O
##ated	O
ions	O
was	O
formed	O
in	O
buffer	O
ca	O
##li	O
##bra	O
##tion	O
points	O
.	O

However	O
,	O
both	O
H	O
##IL	O
##IC	O
methods	O
are	O
more	O
successful	O
in	O
detect	O
##ing	O
non	O
-	O
protected	O
AA	O
##s	O
in	O
a	O
biological	O
sample	O
than	O
the	O
standard	O
R	B
##P	I
method	O
.	O

One	O
of	O
the	O
artifacts	O
that	O
were	O
found	O
in	O
the	O
analysis	O
of	O
alpha	B
-	I
P	I
##EP	I
was	O
also	O
an	O
in	O
-	O
source	O
artifact	O
of	O
the	O
parent	O
compound	O
and	O
followed	O
the	O
same	O
formation	O
principle	O
as	O
that	O
of	O
alpha	B
-	I
P	I
##B	I
##P	I
(	O
M	O
##25	O
##8	O
##T	O
##31	O
##2	O
in	O
Table	O
,	O
M	O
##25	O
##8	O
##T	O
##24	O
##9	O
in	O
Table	O
)	O
.	O

Sam	O
##ple	O
is	O
then	O
di	O
##lut	O
##ed	O
with	O
1	O
m	O
##L	O
of	O
1	O
M	O
am	B
##mon	I
##ium	I
h	I
##ydro	I
##xi	I
##de	I
solution	O
,	O
v	O
##ortex	O
##ed	O
,	O
then	O
loaded	O
onto	O
a	O
2	O
m	O
##L	O
12	O
##cc	O
St	O
##at	O
##ra	O
##DE	O

The	O
two	O
major	O
mon	O
##ois	O
##oto	O
##pic	O
L	O
##MI	O
##s	O
in	O
the	O
disc	O
##rim	O
##ina	O
##tive	O
bio	O
##mark	O
##er	O
group	O
were	O
identified	O
as	O
fi	O
##bri	O
##no	O
##gen	O
α	O
chain	O
and	O
trans	B
##thy	I
##ret	I
##in	I
(	O
Fi	O
##gs	O
.	O
,	O
,	O
and	O
,	O
and	O
Supporting	O
Information	O
Table	O
)	O
.	O

For	O
example	O
,	O
p	B
##yr	I
##u	I
##vate	I
s	O
##ynth	O
##ase	O
(	O
EC	O
1	O
.	O
2	O
.	O
7	O
.	O
1	O
)	O
,	O
an	O
an	O
##ae	O
##ro	O
##bic	O
enzyme	O
that	O
cat	O
##aly	O
##zes	O
p	B
##yr	I
##u	I
##vate	I
/	O
ace	O
##ty	O
##l	O
-	O
Co	O
##A	O
inter	O
##con	O
##version	O
,	O
was	O
en	O
##rich	O
##ed	O
in	O
controls	O
and	O
completely	O
und	O
##ete	O
##cted	O
in	O
a	O
sub	O
##pop	O
##ulation	O
of	O
CD	O
patients	O
.	O

Therefore	O
,	O
the	O
level	O
of	O
f	B
##uc	I
##ose	I
returned	O
to	O
normal	O
post	O
-	O
treatment	O
.	O

List	O
of	O
statistical	O
##ly	O
significant	O
compounds	O
identified	O
by	O
a	O
gas	O
ch	O
##roma	O
##tography	O
–	O
mass	O
s	O
##pect	O
##rome	O
##try	O
(	O
G	O
##C	O
–	O
MS	O
)	O
,	O
cap	O
##illa	O
##ry	O
electro	O
##ph	O
##ores	O
##is	O
–	O
mass	O
s	O
##pect	O
##rome	O
##try	O
(	O
CE	O
–	O
MS	O
)	O
,	O
and	O
liquid	O
ch	O
##roma	O
##tography	O
–	O
mass	O
s	O
##pect	O
##rome	O
##try	O
(	O
L	O
##C	O
–	O
MS	O
)	O
with	O
regulation	O
in	O
the	O
cache	O
##xia	O
group	O
VIP	O
,	O
variable	O
importance	O
in	O
the	O
projection	O
;	O
FC	O
,	O
fold	O
change	O
;	O
LP	O
##C	O
,	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
;	O
LP	O
##E	O
,	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##let	I
##han	I
##ola	I
##mine	I
;	O
P	O
##E	O
:	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##let	I
##han	I
##ola	I
##mine	I
;	O
LP	O
##C	O
:	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
;	O
SM	O
:	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
.	O

In	O
,	O
plasma	O
concentrations	O
and	O
pro	B
##state	I
-	I
specific	I
-	I
anti	I
##gen	I
(	O
PS	O
##A	O
)	O
levels	O
are	O
shown	O
.	O

Statistical	O
“	O
loading	O
##s	O
plot	O
”	O
of	O
information	O
obtained	O
from	O
an	O
u	O
##rina	O
##ry	O
nuclear	O
magnetic	O
resonance	O
s	O
##pect	O
##ros	O
##copy	O
data	O
set	O
showing	O
meta	O
##bol	O
##ites	O
up	O
##re	O
##gu	O
##lated	O
in	O
he	O
##pa	O
##to	O
##cellular	O
car	O
##cin	O
##oma	O
(	O
upward	O
peaks	O
:	O
Car	B
##ni	I
##tine	I
,	O
an	B
##ser	I
##ine	I
,	O
c	B
##rea	I
##tine	I
,	O
ace	B
##ty	I
##l	I
##car	I
##ni	I
##tine	I
,	O
alpha	B
-	I
k	I
##eto	I
##g	I
##lut	I
##arate	I
)	O
and	O
down	O
##re	O
##gu	O
##lated	O
in	O
he	O
##pa	O
##to	O
##cellular	O
car	O
##cin	O
##oma	O
(	O
downward	O
pointing	O
peaks	O
:	O
Hip	B
##pura	I
##te	I
,	O
g	B
##ly	I
##cine	I
,	O
trim	B
##eth	I
##yla	I
##mine	I
##oxide	I
,	O
c	B
##rea	I
##tin	I
##ine	I
,	O
c	O
##it	O
##rate	O
)	O
,	O
compared	O
to	O
u	O
##rina	O
##ry	O
nuclear	O
magnetic	O
resonance	O
s	O
##pect	O
##ros	O
##copy	O
data	O
from	O
patients	O
with	O
c	O
##ir	O
##r	O
##hos	O
##is	O
.	O

The	O
geometric	O
means	O
for	O
ben	B
##zen	I
##e	I
appropriately	O
accounted	O
for	O
left	O
-	O
c	O
##ens	O
##oring	O
using	O
the	O
flexible	O
PR	O
##OC	O
NL	O
##MI	O
##X	O
##ED	O
command	O
in	O
SAS	O
9	O
.	O
2	O
.	O

As	O
a	O
result	O
,	O
E	O
_	O
2	O
was	O
pre	O
##dom	O
##inate	O
##ly	O
meta	O
##bol	O
##ized	O
by	O
P	O
##45	O
##0	O
1	O
##B	O
##1	O
to	O
potentially	O
g	O
##eno	O
##to	O
##xi	O
##c	O
cat	B
##ech	I
##ols	I
in	O
MC	O
##F	O
-	O
7	O
cells	O
under	O
these	O
conditions	O
.	O

The	O
results	O
demonstrated	O
that	O
there	O
were	O
significant	O
differences	O
in	O
le	B
##uc	I
##ine	I
-	I
is	I
##ole	I
##uc	I
##ine	I
,	O
pro	B
##line	I
,	O
th	B
##re	I
##oni	I
##ne	I
,	O
g	B
##lut	I
##ami	I
##c	I
acid	I
,	O
and	O
a	B
##rg	I
##ini	I
##ne	I
levels	O
between	O
good	O
and	O
poor	O
recovery	O
groups	O
.	O

Studies	O
in	O
he	O
##pa	O
##to	O
##cy	O
##tes	O
indicate	O
that	O
a	O
G	B
##S	I
##H	I
-	I
B	I
##DA	I
-	I
l	I
##ys	I
##ine	I
cross	O
-	O
link	O
is	O
a	O
meta	O
##bol	O
##ite	O
of	O
fur	B
##an	I
.	O

The	O
adjusted	O
OR	O
of	O
G	O
##DM	O
comparing	O
the	O
highest	O
with	O
the	O
lowest	O
q	O
##ua	O
##rt	O
##ile	O
of	O
plasma	O
T	B
##MA	I
##O	I
was	O
1	O
.	O
94	O
(	O
95	O
%	O
C	O
##I	O
:	O
1	O
.	O
28	O
,	O
2	O
.	O
93	O
)	O
after	O
adjustment	O
for	O
age	O
,	O
pre	O
##p	O
##re	O
##gna	O
##ncy	O
B	O
##MI	O
,	O
g	O
##esta	O
##tional	O
age	O
at	O
blood	O
sample	O
collection	O
,	O
par	O
##ity	O
,	O
family	O
history	O
of	O
diabetes	O
,	O
drinking	O
habits	O
,	O
and	O
smoking	O
.	O

Using	O
the	O
program	O
AM	O
##IX	O
3	O
.	O
9	O
.	O
14	O
(	O
B	O
##ruk	O
##er	O
B	O
##io	O
##S	O
##pin	O
GmbH	O
,	O
R	O
##hein	O
##ste	O
##tten	O
,	O
Germany	O
)	O
plasma	O
s	O
##pect	O
##ra	O
were	O
then	O
referenced	O
to	O
the	O
et	B
##hyl	I
##ened	I
##iam	I
##inet	I
##et	I
##ra	I
##ace	I
##tic	I
acid	I
(	O
E	O
##D	O
##TA	O
)	O
signal	O
at	O
2	O
.	O
580	O
##9	O
pp	O
##m	O
and	O
bucket	O
##ed	O
graphical	O
##ly	O
,	O
such	O
that	O
bucket	O
##s	O
wherever	O
possible	O
contained	O
only	O
one	O
signal	O
or	O
group	O
of	O
signals	O
and	O
no	O
peaks	O
were	O
split	O
between	O
bucket	O
##s	O
.	O

Although	O
su	B
##lf	I
##ado	I
##xin	I
##e	I
–	I
p	I
##yr	I
##ime	I
##tham	I
##ine	I
is	O
only	O
recommended	O
for	O
intermittent	O
prevent	O
##ive	O
treatment	O
in	O
pregnancy	O
(	O
IP	O
##T	O
##p	O
)	O
,	O
it	O
was	O
still	O
widely	O
used	O
in	O
public	O
and	O
private	O
health	O
facilities	O
and	O
sold	O
in	O
drug	O
shops	O
.	O

A	O
similar	O
prediction	O
power	O
between	O
C	B
##18	I
:	I
2	I
CE	O
and	O
SM	O
22	O
:	O
0	O
was	O
observed	O
in	O
the	O
valid	O
##ation	O
samples	O
.	O

(	O
B	O
)	O
1	O
##D	O
NO	O
##ES	O
##Y	O
spectrum	O
of	O
SP	S
collected	O
in	O
PBS	O
.	O

In	O
addition	O
,	O
anti	O
##biotic	O
compounds	O
such	O
as	O
later	O
##opy	O
##rone	O
,	O
en	B
##nia	I
##tin	I
##s	I
B	O
,	O
B	O
##1	O
and	O
A1	O
,	O
and	O
f	B
##usa	I
##rist	I
##ati	I
##n	I
A	O
,	O
were	O
also	O
up	O
##re	O
##gu	O
##lated	O
(	O
Mo	O
##uss	O
##a	O
et	O
al	O
.	O
2019	O
)	O
.	O

The	O
library	O
subgroup	O
of	O
organic	O
acids	O
included	O
194	O
small	O
car	B
##box	I
##yl	I
##ic	I
acids	I
such	O
as	O
la	B
##ct	I
##ate	I
and	O
ta	B
##rt	I
##rate	I
,	O
short	O
-	O
chain	O
fatty	O
acids	O
,	O
N	O
-	O
protected	O
AA	O
##s	O
and	O
pharmaceutical	O
##ly	O
relevant	O
compounds	O
such	O
as	O
non	O
-	O
s	O
##tero	O
##idal	O
anti	O
-	O
inflammatory	O
drugs	O
(	O
NSA	O
##ID	O
##s	O
)	O
.	O

After	O
60	O
min	O
the	O
reaction	O
was	O
stopped	O
by	O
adding	O
50	O
µ	O
##L	O
of	O
ice	O
-	O
cold	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
and	O
the	O
mixture	O
was	O
subsequently	O
cent	O
##ri	O
##fu	O
##ged	O
for	O
2	O
min	O
at	O
14	O
,	O
000	O
×	O
g	O
.	O

The	O
method	O
of	O
Martins	O
et	O
al	O
.	O
uses	O
solid	O
phase	O
extraction	O
without	O
incorporating	O
an	O
internal	O
standard	O
which	O
demands	O
very	O
re	O
##p	O
##rod	O
##uc	O
##ible	O
recovery	O
of	O
a	B
##bir	I
##ater	I
##one	I
on	O
solid	O
phase	O
extraction	O
which	O
might	O
be	O
challenging	O
due	O
to	O
stability	O
issues	O
of	O
a	B
##bir	I
##ater	I
##one	I
(	I
)	I
.	O

After	O
der	O
##iva	O
##ti	O
##zation	O
,	O
350	O
μ	O
##L	O
of	O
water	O
and	O
25	O
μ	O
##L	O
of	O
B	O
##HT	O
solution	O
(	O
2	O
mg	O
/	O
m	O
##L	O
of	O
but	B
##yla	I
##ted	I
h	I
##ydro	I
##xy	I
##to	I
##lue	I
##ne	I
,	O
in	O
met	B
##han	I
##ol	I
)	O
were	O
added	O
to	O
each	O
plate	O
well	O
to	O
di	O
##lut	O
##e	O
and	O
stab	O
##ilize	O
the	O
final	O
solutions	O
.	O

Missing	O
data	O
:	O
AS	O
##T	O
levels	O
were	O
missing	O
in	O
2	O
patients	O
,	O
AL	O
##T	O
levels	O
were	O
missing	O
in	O
2	O
patients	O
,	O
γ	O
##G	O
##T	O
levels	O
were	O
missing	O
in	O
2	O
patients	O
,	O
A	O
##FP	O
levels	O
were	O
missing	O
in	O
14	O
patients	O
,	O
SA	O
##1	O
##P	O
levels	O
were	O
missing	O
in	O
3	O
patients	O
,	O
S	O
##1	O
##P	O
levels	O
were	O
missing	O
in	O
3	O
patients	O
,	O
S	B
##phi	I
##ngo	I
##sin	I
##e	I
levels	O
were	O
missing	O
in	O
3	O
patients	O
,	O
C	B
##24	I
:	I
1	I
##D	I
##HC	I
levels	O
were	O
missing	O
in	O
2	O
patients	O
,	O
C	O
##24	O
##D	O
##HC	O
levels	O
were	O
missing	O
in	O
2	O
patients	O
,	O
C	O
##18	O
##D	O
##HC	O
levels	O
were	O
missing	O
in	O
2	O
patients	O
,	O
C	O
##16	O
##D	O
##HC	O
levels	O
were	O
missing	O
in	O
2	O
patients	O
,	O
C	B
##24	I
:	I
1	I
##C	I
##er	I
levels	O
were	O
missing	O
in	O
2	O
patients	O
,	O
C	O
##20	O
##C	O
##er	O
levels	O
were	O
missing	O
in	O
2	O
patients	O
,	O
C	O
##18	O
##C	O
##er	O
levels	O
were	O
missing	O
in	O
2	O
patients	O
,	O
C	O
##16	O
##C	O
##er	O
levels	O
were	O
missing	O
in	O
2	O
patients	O
,	O
C	O
##24	O
##C	O
##er	O
levels	O
were	O
missing	O
in	O
2	O
patients	O
.	O

Feature	O
in	O
##tens	O
##ities	O
were	O
normal	O
##ized	O
according	O
to	O
the	O
intensity	O
of	O
met	B
##hyl	I
s	I
##te	I
##arate	I
(	O
internal	O
standard	O
)	O
prior	O
to	O
multi	O
##var	O
##iate	O
statistical	O
analyses	O
.	O

Standard	O
performance	O
tests	O
use	O
non	O
##aque	O
##ous	O
solvent	O
##s	O
(	O
1	O
%	O
ch	B
##lor	I
##of	I
##orm	I
in	O
ace	B
##tone	I
-	I
d	I
_	O
6	O
for	O
line	O
shape	O
;	O
0	O
.	O
1	O
%	O
et	B
##hyl	I
##ben	I
##zen	I
##e	I
in	O
c	O
##lor	O
##of	O
##orm	O
-	O
d	O
_	O
1	O
for	O
sensitivity	O
)	O
that	O
are	O
imp	O
##ractical	O
when	O
used	O
in	O
F	B
##I	I
systems	O
:	O
the	O
solutions	O
would	O
have	O
to	O
be	O
freshly	O
prepared	O
before	O
each	O
analysis	O
,	O
making	O
it	O
difficult	O
to	O
standard	O
##ize	O
the	O
concentration	O
over	O
time	O
,	O
and	O
it	O
would	O
have	O
to	O
be	O
injected	O
directly	O
into	O
the	O
probe	O
,	O
given	O
the	O
in	O
##com	O
##pa	O
##ti	O
##bility	O
of	O
the	O
solvent	O
##s	O
with	O
the	O
F	B
##I	I
system	O
.	O

Numerous	O
rare	O
diseases	O
involving	O
the	O
different	O
steps	O
of	O
s	B
##phi	I
##ngo	I
##lip	I
##id	I
bio	O
##sy	O
##nt	O
##hesis	O
pathway	O
,	O
from	O
de	O
-	O
no	O
##vo	O
synthesis	O
of	O
c	B
##era	I
##mi	I
##des	I
to	O
the	O
bio	O
##sy	O
##nt	O
##hesis	O
of	O
complex	O
lip	O
##ids	O
such	O
as	O
gang	B
##lio	I
##side	I
##s	I
and	O
su	B
##lf	I
##ati	I
##des	I
,	O
have	O
already	O
been	O
described	O
(	O
Han	O
et	O
al	O
.	O
;	O

H	B
##y	I
##pox	I
##ant	I
##hine	I
has	O
been	O
previously	O
reported	O
to	O
be	O
increased	O
in	O
tumor	O
tissue	O
of	O
color	O
##ec	O
##tal	O
cancer	O
patients	O
compared	O
to	O
normal	O
tissue	O
of	O
healthy	O
individuals	O
.	O
15	O

No	O
studies	O
have	O
investigated	O
F	B
_	I
2	I
-	I
is	I
##op	I
##ros	I
##tan	I
##es	I
(	O
F	O
_	O
2	O
-	O
Is	O
##o	O
##Ps	O
)	O
,	O
valid	O
bio	O
##mark	O
##ers	O
of	O
systemic	O
o	O
##xi	O
##da	O
##tive	O
stress	O
,	O
in	O
association	O
with	O
breast	O
cancer	O
pro	O
##gno	O
##sis	O
.	O

Similar	O
trends	O
in	O
the	O
increase	O
of	O
relative	O
abundance	O
of	O
PS	B
(	I
40	I
:	I
4	I
)	I
,	O
m	O
/	O
z	O
83	O
##8	O
.	O
3	O
with	O
increase	O
of	O
the	O
o	O
##li	O
##go	O
##den	O
##dr	O
##og	O
##lio	O
##ma	O
grade	O
are	O
observed	O
in	O
the	O
mixed	O
o	O
##li	O
##go	O
##ast	O
##ro	O
##cy	O
##tom	O
##as	O
,	O
likely	O
representing	O
the	O
o	O
##li	O
##go	O
##den	O
##dr	O
##io	O
##glia	O
##l	O
character	O
of	O
this	O
mixed	O
g	O
##lio	O
##ma	O
.	O

Although	O
some	O
se	B
##rine	I
is	O
produced	O
by	O
regeneration	O
from	O
g	B
##ly	I
##cine	I
(	O
15	O
%	O
)	O
,	O
most	O
(	O
>	O
50	O
%	O
)	O
comes	O
from	O
T	O
##CA	O
-	O
cycle	O
intermediate	O
##s	O
that	O
are	O
converted	O
into	O
p	B
##hos	I
##ph	I
##oe	I
##no	I
##l	I
##py	I
##ru	I
##vate	I
by	O
p	O
##hos	O
##ph	O
##oe	O
##no	O
##l	O
##py	O
##ru	O
##vate	O
car	O
##box	O
##yk	O
##inas	O
##e	O
.	O

As	O
can	O
be	O
easily	O
observed	O
,	O
the	O
u	O
##rina	O
##ry	O
profiles	O
of	O
both	O
groups	O
are	O
dominated	O
by	O
su	O
##l	O
##ph	O
##ur	O
compounds	O
and	O
k	B
##eton	I
##es	I
(	O
each	O
class	O
representing	O
nearly	O
30	O
%	O
of	O
the	O
total	O
area	O
)	O
,	O
with	O
the	O
remaining	O
classes	O
representing	O
less	O
than	O
10	O
%	O
of	O
the	O
total	O
area	O
obtained	O
in	O
each	O
group	O
.	O

This	O
study	O
compared	O
taxa	B
##ne	I
ch	O
##em	O
##otherapy	O
,	O
p	O
##ac	O
##lit	O
##ax	O
##el	O
175	O
mg	O
/	O
m	O
_	O
2	O
,	O
every	O
three	O
weeks	O
plus	O
lap	B
##ati	I
##ni	I
##b	I
1500	O
mg	O
/	O
day	O
or	O
place	O
##bo	O
in	O
57	O
##9	O
women	O
with	O
advanced	O
breast	O
cancer	O
.	O

H	B
##ydro	I
##phi	I
##lic	I
IS	O
##T	O
##Ds	O
were	O
dissolved	O
in	O
50	O
%	O
met	O
##han	O
##ol	O
-	O
water	O
to	O
form	O
a	O
solution	O
at	O
40	O
µ	O
##g	O
/	O
m	O
##L	O
;	O
h	O
##ydro	O
##phobic	O
and	O
lip	O
##id	O
IS	O
##T	O
##Ds	O
were	O
dissolved	O
in	O
ch	B
##lor	I
##of	I
##orm	I
-	I
met	I
##han	I
##ol	I
(	I
1	I
:	I
1	I
)	I
at	O
40	O
µ	O
##g	O
/	O
m	O
##L	O
.	O
Fr	O
##oz	O
##en	O
plasma	O
al	O
##iq	O
##uo	O
##ts	O
(	O
100	O
µ	O
##L	O
)	O
were	O
th	O
##awed	O
on	O
ice	O
,	O
and	O
10	O
µ	O
##L	O
of	O
each	O
IS	O
##T	O
##D	O
solution	O
was	O
added	O
.	O

This	O
vitamin	O
comes	O
from	O
car	B
##ote	I
##no	I
##id	I
and	O
re	B
##tino	I
##id	I
.	O

In	O
summary	O
,	O
50	O
μ	O
##l	O
of	O
serum	O
,	O
sa	O
##liva	O
extract	O
or	O
G	O
##CF	O
and	O
150	O
μ	O
##l	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
were	O
shaken	O
for	O
3	O
min	O
,	O
the	O
pre	O
##ci	O
##pit	O
##ated	O
protein	O
was	O
cent	O
##ri	O
##fu	O
##ged	O
at	O
13	O
.	O
000	O
rpm	O
,	O
4	O
##°	O
##C	O
for	O
6	O
min	O
,	O
130	O
μ	O
##L	O
of	O
the	O
resulting	O
super	O
##nat	O
##ant	O
was	O
spike	O
##d	O
with	O
10	O
μ	O
##l	O
is	O
##oto	O
##pe	O
super	O
##nat	O
##ant	O
mix	O
,	O
e	O
##va	O
##porated	O
in	O
E	O
##ppe	O
##ndo	O
##rf	O
reaction	O
via	O
##ls	O
with	O
an	O
E	O
##ppe	O
##ndo	O
##rf	O
con	O
##cent	O
##rator	O
at	O
30	O
##°	O
##C	O
for	O
[UNK]	O
min	O
until	O
the	O
sample	O
volume	O
was	O
[UNK]	O
µ	O
##l	O
.	O

In	O
this	O
experiment	O
,	O
g	B
##ly	I
##cine	I
content	O
in	O
p	O
##ap	O
##illa	O
##ry	O
thy	O
##roid	O
car	O
##cin	O
##oma	O
was	O
increased	O
,	O
which	O
is	O
related	O
to	O
high	O
met	O
##hyl	O
##ation	O
of	O
the	O
promoter	O
region	O
.	O

Those	O
papers	O
would	O
lead	O
one	O
to	O
expect	O
a	O
positive	O
correlation	O
between	O
lip	O
##id	O
and	O
la	B
##ct	I
##ate	I
signals	O
,	O
whereas	O
we	O
observed	O
a	O
negative	O
correlation	O
.	O

For	O
analytical	O
and	O
physiological	O
normal	O
##ization	O
,	O
the	O
integrated	O
peak	O
areas	O
were	O
related	O
to	O
the	O
internal	O
standard	O
and	O
the	O
u	O
##rina	O
##ry	O
c	B
##rea	I
##tin	I
##ine	I
level	O
(	O
in	O
mg	O
/	O
d	O
##l	O
)	O
:	O

The	O
survival	O
curve	O
of	O
4	B
-	I
h	I
##ydro	I
##xy	I
##ben	I
##zoic	I
acid	I
.	O

In	O
addition	O
,	O
the	O
differences	O
of	O
L	O
##D	O
##L	O
,	O
V	O
##LD	O
##L	O
,	O
la	B
##ct	I
##ate	I
,	O
N	B
-	I
ace	I
##ty	I
##l	I
g	I
##ly	I
##co	I
##p	I
##rote	I
##in	I
,	O
ch	B
##olin	I
##e	I
,	O
p	B
##hos	I
##ph	I
##och	I
##olin	I
##e	I
,	O
α	B
-	I
glucose	I
,	O
β	B
-	I
glucose	I
,	O
trim	B
##eth	I
##yla	I
##mine	I
-	I
N	I
-	I
oxide	I
and	O
g	B
##ly	I
##cine	I
were	O
not	O
significant	O
among	O
the	O
three	O
groups	O
.	O

Based	O
on	O
the	O
sum	O
of	O
la	B
##nt	I
##hi	I
##oni	I
##ne	I
and	O
ho	B
##mo	I
##lant	I
##hi	I
##oni	I
##ne	I
,	O
we	O
estimate	O
that	O
H	O
_	O
2	O
S	O
production	O
by	O
these	O
reactions	O
may	O
be	O
modest	O
##ly	O
higher	O
in	O
the	O
high	B
–	I
c	I
##ys	I
##tat	I
##hi	I
##oni	I
##ne	I
concentration	O
subjects	O
.	O

According	O
to	O
a	O
well	O
-	O
established	O
protocol	O
[	O
]	O
,	O
al	O
##iq	O
##uo	O
##ts	O
of	O
200	O
μ	O
##L	O
of	O
serum	O
were	O
transferred	O
into	O
a	O
p	B
##oly	I
##p	I
##rop	I
##yle	I
##ne	I
E	O
##ppe	O
##ndo	O
##rf	O
tube	O
and	O
400	O
μ	O
##L	O
of	O
0	O
.	O
9	O
%	O
sa	B
##line	I
solution	O
in	O
15	O
%	O
D	O
_	O
2	O
O	O
,	O
containing	O
3	O
mm	O
##ol	O
/	O
L	O
3	B
-	I
(	I
trim	I
##eth	I
##yl	I
##si	I
##ly	I
##l	I
)	I
-	I
2	I
,	I
2	I
’	I
,	I
3	I
,	I
3	I
’	I
-	I
te	I
##tra	I
##de	I
##uter	I
##op	I
##rop	I
##ion	I
##ate	I
sodium	I
salt	O
T	O
##SP	O
-	O
d	O
##4	O
(	O
T	O
##SP	O
)	O
were	O
added	O
.	O

The	O
_	O
1	O
H	O
-	O
N	O
##MR	O
s	O
##pect	O
##ra	O
were	O
dominated	O
by	O
high	O
-	O
intensity	O
signals	O
as	O
##c	O
##ri	O
##ba	O
##ble	O
to	O
the	O
sugar	O
m	O
##oi	O
##eti	O
##es	O
of	O
α	O
and	O
β	B
-	I
glucose	I
,	O
la	B
##ct	I
##ate	I
and	O
some	O
high	O
molecular	O
weight	O
meta	O
##bol	O
##ites	O
,	O
such	O
as	O
lip	O
##op	O
##rote	O
##ins	O
(	O
V	O
##LD	O
##L	O
/	O
L	O
##D	O
##L	O
)	O
.	O

In	O
the	O
multi	O
##fa	O
##ctor	O
log	O
##istic	O
re	O
##gression	O
model	O
containing	O
the	O
nine	O
established	O
meta	O
##bol	O
##ites	O
,	O
high	O
C	O
##16	O
and	O
low	O
SM	B
(	I
OH	I
)	I
22	I
:	I
1	I
meta	O
##bol	O
##ites	O
were	O
found	O
to	O
be	O
independent	O
risk	O
factors	O
for	O
G	O
##C	O
patients	O
;	O
in	O
the	O
training	O
set	O
the	O
odds	O
ratio	O
(	O
95	O
%	O
C	O
##I	O
)	O
were	O
2	O
.	O
83	O
(	O
1	O
.	O
66	O
–	O
4	O
.	O
82	O
)	O
and	O
1	O
.	O
39	O
(	O
1	O
.	O
19	O
–	O
1	O
.	O
62	O
)	O
for	O
C	O
##16	O
and	O
SM	B
(	I
OH	I
)	I
22	I
:	I
1	I
,	O
respectively	O
.	O

In	O
our	O
study	O
,	O
however	O
,	O
the	O
correlation	O
between	O
log	O
##ged	O
co	B
##tin	I
##ine	I
and	O
log	O
##ged	O
trans	B
-	I
3	I
′	I
-	I
h	I
##ydro	I
##xy	I
##cot	I
##ini	I
##ne	I
with	O
log	O
##ged	O
c	B
##rea	I
##tin	I
##ine	I
is	O
very	O
low	O
(	O
N	O
=	O
86	O
;	O
R	O
_	O
Co	O
##t	O
=	O
0	O
.	O
06	O
;	O
R	O
_	O
T	O
##3	O
##HC	O
##ot	O
=	O
0	O
.	O
26	O
;	O
p	O
>	O
0	O
.	O
10	O
)	O
suggesting	O
that	O
Thompson	O
’	O
s	O
method	O
is	O
not	O
valid	O
in	O
the	O
case	O
of	O
non	O
-	O
smoke	O
##r	O
subjects	O
.	O

G	B
##lu	I
##come	I
##ter	I
and	O
strips	O
will	O
be	O
given	O
to	O
both	O
groups	O
to	O
record	O
three	O
values	O
daily	O
(	O
after	O
fast	O
##ing	O
,	O
before	O
a	O
meal	O
and	O
two	O
hours	O
after	O
a	O
meal	O
)	O
.	O

Lower	O
level	O
of	O
le	B
##uc	I
##ine	I
and	O
is	B
##ole	I
##uc	I
##ine	I
reflect	O
ma	O
##la	O
##bs	O
##or	O
##ption	O
of	O
necessary	O
amino	O
acid	O
in	O
F	B
##D	I
female	O
patients	O
.	O

He	B
##xa	I
##de	I
##cano	I
##ic	I
acid	I
.	O

(	O
G	O
)	O
Ace	B
##tate	I
was	O
present	O
in	O
both	O
groups	O
but	O
at	O
a	O
higher	O
concentration	O
in	O
Speed	O
##V	O
##ac	O
samples	O
.	O

Since	O
another	O
intermediate	O
of	O
the	O
c	B
##it	I
##ric	I
acid	I
cycle	O
,	O
α	B
-	I
k	I
##eto	I
##g	I
##lut	I
##ari	I
##c	I
acid	I
,	O
is	O
also	O
higher	O
in	O
women	O
,	O
this	O
may	O
hint	O
at	O
a	O
general	O
difference	O
in	O
c	B
##it	I
##ric	I
acid	I
cycle	O
turnover	O
between	O
men	O
and	O
women	O
.	O

Ad	O
##ip	O
##one	O
##ct	O
##in	O
levels	O
in	O
the	O
Omega	B
-	I
3	I
subgroup	O
were	O
higher	O
,	O
reflecting	O
1	O
.	O
2	O
-	O
fold	O
increase	O
in	O
the	O
median	O
in	O
this	O
subgroup	O
(	O
p	O
<	O
0	O
.	O
00	O
##1	O
)	O
but	O
were	O
unchanged	O
in	O
the	O
Place	O
##bo	O
subgroup	O
(	O
Table	O
)	O
.	O

The	O
most	O
pronounced	O
increase	O
in	O
lip	O
##op	O
##rote	O
##in	O
particles	O
was	O
seen	O
in	O
the	O
total	O
ch	B
##ole	I
##ster	I
##ol	I
in	O
large	O
HD	O
##L	O
.	O

Inter	O
##ind	O
##iv	O
##id	O
##ual	O
variation	O
in	O
est	B
##rogen	I
metabolism	O
may	O
also	O
influence	O
the	O
risk	O
of	O
breast	O
cancer	O
and	O
could	O
provide	O
clues	O
to	O
mechanisms	O
of	O
breast	O
car	O
##cin	O
##ogen	O
##esis	O
.	O

We	O
generated	O
Se	O
##quential	O
Organ	O
F	O
##ail	O
##ure	O
Assessment	O
(	O
S	O
##O	O
##FA	O
)	O
scores	O
for	O
each	O
patient	O
and	O
defined	O
three	O
groups	O
:	O
patients	O
admitted	O
to	O
the	O
I	O
##CU	O
post	O
-	O
surgery	O
were	O
categorized	O
as	O
“	O
surgical	O
trauma	O
”	O
,	O
patients	O
admitted	O
to	O
the	O
I	O
##CU	O
with	O
suspected	O
or	O
diagnosed	O
infections	O
were	O
categorized	O
as	O
“	O
se	O
##psis	O
”	O
,	O
and	O
patients	O
with	O
h	O
##y	O
##pot	O
##ens	O
##ion	O
requiring	O
v	O
##as	O
##op	O
##ress	O
##or	O
therapy	O
to	O
maintain	O
mean	O
BP	O
65	O
mm	O
##H	O
##g	O
or	O
greater	O
and	O
with	O
a	O
plasma	O
la	B
##ct	I
##ate	I
concentration	O
>	O
2	O
mm	O
##ol	O
/	O

We	O
also	O
assessed	O
breast	O
bio	O
##psy	O
composition	O
in	O
samples	O
from	O
the	O
previous	O
CE	B
##R	I
study	O
for	O
comparison	O
.	O

H	B
##ydro	I
##xy	I
##ind	I
##ole	I
##s	I
were	O
rarely	O
noted	O
at	O
all	O
,	O
and	O
only	O
when	O
high	O
signals	O
for	O
the	O
other	O
main	O
meta	O
##bol	O
##ites	O
were	O
seen	O
.	O

The	O
met	B
##han	I
##ol	I
,	O
2	B
-	I
ch	I
##lor	I
##o	I
-	I
p	I
##hen	I
##yla	I
##lani	I
##ne	I
,	O
met	B
##ho	I
##xy	I
##amine	I
and	O
p	B
##yr	I
##id	I
##ine	I
were	O
bought	O
from	O
Al	O
##ad	O
##din	O
(	O
Shanghai	O
,	O
China	O
)	O
.	O

The	O
serum	O
and	O
urine	O
samples	O
from	O
A	O
##ER	O
##D	O
and	O
AT	O
##A	O
patients	O
were	O
analyzed	O
for	O
SL	S
meta	O
##bol	O
##ites	O
using	O
lip	O
##id	O
ch	O
##roma	O
##to	O
##gra	O
##py	O
-	O
mass	O
s	O
##pect	O
##rome	O
##try	O
.	O

T	O
##rop	O
##oni	O
##n	O
I	O
(	O
T	O
##n	O
##I	O
)	O
and	O
N	O
-	O
terminal	O
B	O
-	O
type	O
na	O
##tri	O
##ure	O
##tic	O
p	O
##eptide	O
(	O
N	O
##T	O
-	O
pro	O
B	O
##NP	O
)	O
concentrations	O
were	O
significantly	O
higher	O
in	O
the	O
A	B
##E	I
than	O
the	O
No	O
-	O
A	O
##E	O
group	O
(	O
7	O
.	O
7	O
±	O
19	O
µ	O
##g	O
/	O
m	O
##L	O
vs	O
.	O
8	O
.	O
8	O
±	O
6	O
.	O
9	O
µ	O
##g	O
/	O
m	O
##L	O
,	O
p	O
=	O
0	O
.	O
00	O
##1	O
and	O
29	O
##8	O
.	O
5	O
±	O
119	O
.	O
4	O
ng	O
/	O
L	O
vs	O
.	O
214	O
.	O
3	O
±	O
80	O
.	O
8	O
ng	O
/	O
L	O
,	O

A	O
positive	O
relation	O
between	O
si	B
##ali	I
##c	I
acid	I
and	O
h	O
##s	O
##CR	O
##P	O
was	O
reported	O
among	O
48	O
patients	O
with	O
chronic	O
cardiac	O
ins	O
##uff	O
##iciency	O
,	O
and	O
the	O
authors	O
post	O
##ulated	O
both	O
as	O
reliable	O
markers	O
of	O
systemic	O
inflammation	O
in	O
chronic	O
heart	O
failure	O
patients	O
.	O

Unfortunately	O
,	O
it	O
is	O
difficult	O
to	O
directly	O
compare	O
the	O
est	B
##rogen	I
and	O
E	O
##M	O
levels	O
as	O
the	O
cell	O
line	O
concentrations	O
are	O
recorded	O
in	O
p	O
##g	O
/	O
10	O
_	O
6	O
cells	O
,	O
while	O
those	O
in	O
serum	O
are	O
measured	O
as	O
p	O
##g	O
/	O
m	O
##l	O
.	O

For	O
all	O
three	O
methods	O
,	O
the	O
top	O
100	O
variables	O
are	O
distributed	O
across	O
all	O
four	O
regions	O
at	O
sample	O
sizes	O
of	O
n	O
=	O
50	O
and	O
n	O
=	O
100	O
,	O
but	O
at	O
n	O
=	O
200	O
none	O
are	O
found	O
in	O
the	O
al	B
##ip	I
##hat	I
##ic	I
double	O
##t	O
region	O
[	O
3	O
.	O
96	O
##6	O
–	O
3	O
.	O
98	O
##4	O
]	O
for	O
either	O
O	O
##2	O
##PL	O
##S	O
approach	O
.	O

Additionally	O
,	O
increased	O
fatty	O
acid	O
synthesis	O
characterized	O
by	O
increased	O
expression	O
of	O
fatty	O
acid	O
s	O
##ynth	O
##ase	O
(	O
FA	O
##S	O
)	O
and	O
s	B
##te	I
##aro	I
##yl	I
-	I
Co	I
##A	I
des	O
##at	O
##ura	O
##se	O
-	O
1	O
(	O
SC	O
##D	O
1	O
)	O
was	O
also	O
reported	O
to	O
be	O
an	O
important	O
metabolic	O
characteristic	O
for	O
cancer	O
cells	O
.	O

Of	O
the	O
twelve	O
subjects	O
undergoing	O
_	O
13	O
C	O
glucose	S
in	O
##fusion	O
,	O
the	O
median	O
age	O
was	O
63	O
(	O
range	O
52	O
–	O
76	O
)	O
,	O
67	O
%	O
were	O
male	O
,	O
67	O
%	O
had	O
sq	O
##ua	O
##mous	O
cell	O
car	O
##cin	O
##oma	O
,	O
and	O
33	O
%	O
ad	O
##eno	O
-	O
or	O
ad	O
##eno	O
##s	O
##qua	O
##mous	O
car	O
##cin	O
##oma	O
,	O
all	O
of	O
grade	O
II	O
or	O
III	O
.	O

Sex	O
specific	O
differences	O
were	O
found	O
for	O
est	B
##rogen	I
meta	O
##bol	O
##ites	O
,	O
which	O
were	O
much	O
higher	O
positively	O
correlated	O
in	O
women	O
than	O
in	O
men	O
.	O

Level	O
##s	O
of	O
L	O
##D	O
##L	O
and	O
HD	B
##L	I
ch	I
##ole	I
##ster	I
##ol	I
in	O
plasma	O
from	O
patients	O
with	O
favorable	O
outcome	O
were	O
significantly	O
higher	O
,	O
1	O
.	O
08	O
±	O
0	O
.	O
43	O
vs	O
0	O
.	O
84	O
±	O
0	O
.	O
36	O

The	O
O	O
##v	O
/	O
O	O
##b	O
subjects	O
with	O
the	O
Met	O
##S	O
had	O
a	O
more	O
deteriorated	O
plasma	O
lip	O
##id	O
profile	O
including	O
increased	O
plasma	O
T	B
##G	I
levels	O
and	O
decreased	O
plasma	O
HD	O
##L	O
-	O
C	O
levels	O
compared	O
to	O
O	O
##v	O
/	O
O	O
##b	O
without	O
Met	O
##S	O
or	O
NW	O
individuals	O
.	O

depicts	O
the	O
synthesis	O
of	O
2	B
,	I
4	I
,	I
5	I
-	I
t	I
##ris	I
##ub	I
##stituted	I
p	I
##yr	I
##im	I
##id	I
##ine	I
analogue	O
##s	O
D	O
##HP	O
##M	O
##1	O
–	O
D	O
##HP	O
##M	O
##8	O
.	O

As	O
shown	O
in	O
,	O
a	B
##rg	I
##ini	I
##ne	I
is	O
also	O
the	O
precursor	O
to	O
g	B
##lut	I
##ama	I
##te	I
.	O

The	O
cap	O
##illa	O
##ry	O
voltage	O
was	O
set	O
to	O
3	O
.	O
2	O
k	B
##V	I
and	O
3	O
k	B
##V	I
,	O
and	O
the	O
cone	O
voltage	O
of	O
30	O
##V	O
and	O
20	O
V	O
,	O
respectively	O
.	O

It	O
was	O
reported	O
that	O
p	B
##ime	I
##lic	I
acid	I
originating	O
from	O
the	O
fatty	O
acid	O
synthesis	O
pathway	O
is	O
a	O
b	O
##ona	O
fi	O
##de	O
precursor	O
of	O
bio	B
##tin	I
in	O
Ba	O
##ci	O
##llus	O
sub	O
##til	O
##is	O
.	O

We	O
confirmed	O
that	O
hip	B
##pura	I
##te	I
and	O
in	B
##dox	I
##yl	I
su	I
##lf	I
##ate	I
were	O
not	O
significantly	O
associated	O
with	O
E	O
##SR	O
##D	O
in	O
our	O
study	O
.	O

Not	O
##ably	O
,	O
N	O
##P	O
smoke	O
##rs	O
exhibited	O
a	O
faster	O
overall	O
rate	O
of	O
ni	B
##cot	I
##ine	I
metabolism	O
compared	O
to	O
smoke	O
##rs	O
in	O
the	O
S	O
##W	O
tribal	O
population	O
and	O
other	O
ethnic	O
groups	O
,	O
even	O
among	O
the	O
C	O
##YP	O
##2	O
##A	O
##6	O
wild	O
-	O
type	O
subgroup	O
.	O

The	O
ratio	O
of	O
k	B
##yn	I
##uren	I
##ic	I
acid	I
(	O
K	O
##yn	O
##A	O
)	O
to	O
q	B
##uin	I
##olin	I
##ic	I
acid	I
(	O
Q	O
##A	O
)	O
was	O
reduced	O
in	O
B	O
##D	O
The	O
ratio	O
of	O
K	O
##yn	O
##A	O
/	O
3	O
-	O
h	O
##ydro	O
##xy	O
##ky	O
##nu	O
##ren	O
##ine	O
was	O
correlated	O
with	O
hip	O
##po	O
##cam	O
##pal	O
volume	O
in	O
B	O
##D	O
A	O
##b	O
##nor	O
##mal	O
##ities	O
in	O
k	B
##yn	I
##uren	I
##ine	I
metabolism	O
may	O
impact	O
the	O
structure	O
of	O
the	O
hip	O
##po	O
##cam	O
##pus	O

The	O
nitrogen	O
metabolism	O
pathway	O
is	O
composed	O
of	O
39	O
meta	O
##bol	O
##ite	O
species	O
(	O
detailed	O
in	O
)	O
and	O
three	O
(	B
g	B
##ly	I
##cine	I
,	O
ta	B
##uri	I
##ne	I
and	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
)	O
were	O
prior	O
##itis	O
##ed	O
ten	O
or	O
more	O
times	O
in	O
the	O
training	O
set	O
for	O
type	O
2	O
diabetes	O
incidence	O
differentiation	O
.	O

Our	O
laboratory	O
routinely	O
employs	O
D	O
##N	O
##ase	O
I	O
(	O
Type	O
IV	O
,	O
b	O
##ov	O
##ine	O
pan	O
##cre	O
##as	O
)	O
,	O
al	O
##kal	O
##ine	O
p	O
##hos	O
##pha	O
##tase	O
(	O
E	O
##scher	O
##ichi	O
##a	O
co	O
##li	O
)	O
,	O
n	O
##uc	O
##lea	O
##se	O
P	O
##1	O
(	O
from	O
Pen	O
##ici	O
##lli	O
##um	O
c	B
##it	I
##rin	I
##um	I
)	O
,	O
and	O
Ph	O
##os	O
##ph	O
##odies	O
##tera	O
##se	O
I	O
(	O
from	O
C	O
##rot	O
##al	O
##us	O
ad	O
##aman	O
##te	O
##us	O
venom	O
)	O
.	O

By	O
using	O
the	O
same	O
database	O
and	O
CA	O
##RT	O
method	O
,	O
blood	O
u	B
##rea	I
nitrogen	I
was	O
found	O
as	O
the	O
most	O
significant	O
predict	O
##or	O
of	O
in	O
-	O
hospital	O
mortality	O
.	O

G	B
##ly	I
##cine	I
was	O
also	O
found	O
at	O
lower	O
concentrations	O
with	O
a	O
higher	O
number	O
of	O
Met	O
##S	O
risk	O
factors	O
in	O
both	O
gender	O
##s	O
and	O
with	O
higher	O
ad	O
##ip	O
##os	O
##ity	O
in	O
men	O
.	O

For	O
L	O
##C	O
-	O
based	O
meta	O
##bol	O
##ite	O
separation	O
,	O
both	O
h	B
##ydro	I
##phi	I
##lic	I
interaction	O
liquid	O
ch	O
##roma	O
##tography	O
(	O
H	O
##IL	O
##IC	O
)	O
and	O
ion	O
-	O
par	O
##ing	O
re	O
##age	O
##nt	O
-	O
based	O
reverse	O
phase	O
(	O
R	O
##P	O
)	O
ch	O
##roma	O
##tography	O
enable	O
the	O
separation	O
of	O
multiple	O
h	B
##ydro	I
##phi	I
##lic	I
meta	O
##bol	O
##ites	O
,	O
permitting	O
q	O
##ual	O
##itative	O
and	O
quantitative	O
meta	O
##bol	O
##ite	O
detection	O
by	O
MS	O
_	O
,	O
.	O

Phase	O
and	O
base	O
-	O
line	O
correction	O
##s	O
of	O
s	O
##pect	O
##ra	O
were	O
performed	O
by	O
operator	O
and	O
referenced	O
with	O
AM	O
##IX	O
software	O
to	O
met	O
##hyl	O
resonance	O
of	O
T	O
##MP	O
##S	O
,	O
la	B
##ct	I
##ate	I
or	O
T	O
##C	O
##B	O
for	O
di	O
##lut	O
##ed	O
plasma	O
,	O
a	O
##que	O
##ous	O
fraction	O
and	O
organic	O
fraction	O
respectively	O
.	O

An	O
over	O
-	O
expression	O
of	O
metabolic	O
genes	O
regulating	O
g	O
##ly	O
##co	O
##lysis	O
,	O
amino	B
##acy	I
##l	I
-	I
t	I
##RNA	I
bio	O
##sy	O
##nt	O
##hesis	O
,	O
p	B
##yr	I
##im	I
##id	I
##ine	I
bio	O
##sy	O
##nt	O
##hesis	O
,	O
pu	B
##rine	I
bio	O
##sy	O
##nt	O
##hesis	O
and	O
pen	B
##tos	I
##e	I
phosphate	I
pathway	O
character	O
##ize	O
tumor	O
tissues	O
compared	O
to	O
normal	O
samples	O
,	O
thus	O
highlighting	O
the	O
hypothesis	O
of	O
a	O
specific	O
metabolic	O
signature	O
at	O
the	O
tumor	O
level	O
.	O

The	O
is	O
##oto	O
##pe	O
in	O
##fusion	O
protocol	O
was	O
revised	O
and	O
upgraded	O
by	O
the	O
concurrent	O
administration	O
of	O
1	O
-	O
_	O
13	O
C	B
-	I
g	I
##ly	I
##cola	I
##te	I
with	O
_	O
13	O
C	B
_	I
2	I
-	I
o	I
##xa	I
##late	I
.	O

In	O
a	O
previous	O
study	O
,	O
the	O
increased	O
level	O
of	O
2	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yric	I
acid	I
in	O
se	O
##ra	O
of	O
color	O
##ec	O
##tal	O
cancer	O
patients	O
was	O
observed	O
,	O
being	O
consistent	O
with	O
our	O
results	O
.	O

M	O
##FS	O
and	O
L	O
##MS	O
cases	O
were	O
his	O
##to	O
##logical	O
##ly	O
graded	O
according	O
to	O
the	O
French	O
F	O
##é	O
##d	O
##ération	O
Nationale	O
des	S
Centre	O
##s	O
de	O
Lu	O
##tte	O
Con	O
##tre	O
le	O
Cancer	O
.	O

Together	O
,	O
these	O
data	O
suggested	O
that	O
this	O
meta	O
##bol	O
##ite	O
peak	O
was	O
consistent	O
with	O
the	O
mon	O
##oh	O
##ydro	O
##xy	O
##lated	O
meta	O
##bol	O
##ite	O
of	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
.	O

Of	O
note	O
,	O
several	O
diet	O
##ary	O
intervention	O
studies	O
have	O
demonstrated	O
that	O
improved	O
diet	O
quality	O
blunt	O
##s	O
the	O
association	O
between	O
Ce	B
##r	I
and	O
C	O
##VD	O
,	O
perhaps	O
due	O
to	O
the	O
dependence	O
of	O
Ce	B
##r	I
synthesis	O
on	O
diet	O
##ary	O
intake	O
of	O
saturated	O
fat	O
##s	O
.	O

Len	O
##ti	O
##virus	O
particles	O
were	O
produced	O
by	O
calcium	B
phosphate	I
trans	O
##fect	O
##ion	O
of	O
29	O
##3	O
T	O
cells	O
and	O
harvested	O
after	O
24	O
h	O
–	O
48	O
h	O
using	O
standard	O
procedures	O
.	O

Among	O
those	O
signals	O
that	O
were	O
higher	O
in	O
the	O
I	O
##C	O
group	O
,	O
three	O
peaks	O
were	O
an	O
##not	O
##ated	O
as	O
t	B
##yra	I
##mine	I
,	O
the	O
pain	O
-	O
related	O
ne	O
##uro	O
##mo	O
##du	O
##lator	O
.	O

In	O
the	O
MS	O
group	O
,	O
all	O
compounds	O
had	O
a	O
lower	O
concentration	O
as	O
compared	O
to	O
control	O
group	O
except	O
un	O
##ass	O
##ign	O
##ed	O
functional	O
group	O
signal	O
(	O
single	O
##t	O
)	O
at	O
3	O
.	O
68	O
pp	O
##m	O
and	O
=	O
HC	O
–	O
CH	O
_	O
2	O
–	O
CH	O
=	O
di	O
##uns	O
##at	O
##ura	O
##ted	O
ω	O
-	O
6	O
a	O
##cy	O
##l	O
groups	O
and	O
FA	S
that	O
had	O
a	O
higher	O
concentration	O
as	O
compared	O
to	O
control	O
group	O
(	O
Fi	O
##gs	O
.	O

Not	O
##ably	O
,	O
only	O
p	B
##yr	I
##im	I
##id	I
##ine	I
metabolism	O
had	O
a	O
P	O
value	O
<	O
.	O
1	O
for	O
the	O
CR	O
Score	O
,	O
in	O
##dicative	O
of	O
its	O
bio	O
##log	O
##ic	O
and	O
clinical	O
relevance	O
in	O
BC	O
##a	O
.	O

No	O
RS	O
##G	O
treatment	O
effects	O
were	O
noted	O
in	O
the	O
H	B
##V	I
group	O
.	O

(	O
2014	O
)	O
reveals	O
that	O
as	O
compared	O
to	O
1	B
,	I
5	I
-	I
pen	I
##tan	I
##ed	I
##iol	I
,	O
2	B
,	I
3	I
-	I
pen	I
##tan	I
##ed	I
##iol	I
(	O
105	O
)	O
isolated	O
from	O
F	O
.	O
o	B
##xy	I
##sp	I
##orum	I
end	O
##op	O
##hy	O
##te	O
of	O
C	B
##ur	I
##cum	I
##a	I
am	O
##ada	O
was	O
found	O
to	O
improve	O
anti	O
##aging	O
properties	O
against	O
C	O
##aen	O
##or	O
##hab	O
##dit	O
##is	O
el	O
##egan	O
##s	O
.	O

In	O
contrast	O
to	O
R	O
##v	O
##D	O
##1	O
,	O
the	O
AA	O
-	O
derived	O
L	O
##X	O
##A	O
_	O
4	O
was	O
not	O
significantly	O
up	O
##re	O
##gu	O
##lated	O
in	O
the	O
CS	O
##F	O
of	O
‘	O
highly	O
active	O
’	O
MS	O
patients	O
,	O
suggesting	O
a	O
differential	O
##ly	O
regulated	O
resolution	O
program	O
defining	O
a	O
ω	B
-	I
3	I
P	I
##U	I
##FA	I
versus	O
a	O
ω	B
-	I
6	I
P	I
##U	I
##FA	I
hierarchy	O
in	O
response	O
to	O
an	O
inflammatory	O
stimulus	O
within	O
a	O
spat	O
##io	O
-	O
temporal	O
re	O
##sol	O
##utive	O
context	O
.	O

The	O
positive	O
association	O
of	O
T	B
##G	I
in	O
small	O
and	O
medium	O
HD	O
##L	O
lip	O
##op	O
##rote	O
##ins	O
differed	O
from	O
the	O
inverse	O
association	O
of	O
ch	B
##ole	I
##ster	I
##ol	I
in	O
large	O
and	O
medium	O
HD	O
##L	O
lip	O
##op	O
##rote	O
##ins	O
with	O
MI	O
(	O
and	O
IS	O
)	O
,	O
which	O
raises	O
the	O
hypothesis	O
that	O
T	B
##G	I
and	O
ch	B
##ole	I
##ster	I
##ol	I
in	O
HD	O
##L	O
particles	O
have	O
opposing	O
relationships	O
with	O
risk	O
of	O
MI	O
or	O
IS	O
.	O

This	O
finding	O
may	O
indicate	O
an	O
association	O
among	O
higher	O
γ	B
-	I
to	I
##co	I
##pher	I
##ol	I
levels	O
,	O
lower	O
α	B
-	I
to	I
##co	I
##pher	I
##ol	I
levels	O
,	O
and	O
triple	O
-	O
negative	O
breast	O
cancer	O
and	O
may	O
provide	O
a	O
hint	O
for	O
why	O
AA	O
##s	O
have	O
a	O
higher	O
incidence	O
of	O
triple	O
-	O
negative	O
breast	O
cancer	O
.	O

However	O
,	O
a	O
more	O
pro	O
##sai	O
##c	O
reason	O
for	O
the	O
higher	O
g	B
##ly	I
##cine	I
levels	O
than	O
for	O
the	O
reference	O
group	O
seems	O
to	O
be	O
also	O
of	O
importance	O
–	O
it	O
may	O
be	O
due	O
to	O
the	O
fact	O
that	O
almost	O
all	O
patients	O
receive	O
the	O
anti	O
##ep	O
##ile	O
##ptic	O
drug	O
v	B
##al	I
##p	I
##roi	I
##c	I
acid	I
.	O

In	O
our	O
study	O
,	O
260	O
µ	O
##L	O
of	O
serum	O
and	O
260	O
µ	O
##L	O
of	O
sodium	B
phosphate	I
buffer	O
(	O
75	O
mm	O
##ol	O
/	O
L	O
Na	O
_	O
2	O
HP	O
##O	O
_	O
4	O
in	O
80	O
%	O
/	O
20	O
%	O
H	O
_	O
2	O
O	O
/	O
D	O
_	O
2	O
O	O
,	O
pH	O
7	O
.	O
4	O
)	O
were	O
carefully	O
mixed	O
and	O
transferred	O
to	O
the	O
N	O
##MR	O
tubes	O
.	O

Initially	O
,	O
these	O
results	O
were	O
unexpected	O
,	O
since	O
previous	O
studies	O
reported	O
an	O
increase	O
of	O
these	O
meta	O
##bol	O
##ites	O
in	O
some	O
types	O
of	O
cancer	O
(	O
W	O
##heat	O
##ley	O
and	O
Campbell	O
,	O
2002	O
)	O
,	O
and	O
or	O
##ni	O
##thin	O
##e	O
de	O
##car	O
##box	O
##yla	O
##se	O
,	O
the	O
enzyme	O
responsible	O
for	O
put	B
##res	I
##cine	I
bio	O
##genesis	O
,	O
is	O
significantly	O
elevated	O
in	O
multiple	O
L	O
##Cs	O
(	O
Grimm	O
##inger	O
et	O
al	O
.	O
,	O
2010	O
;	O
T	O
##ian	O
et	O
al	O
.	O
,	O
2006	O
)	O
.	O

As	O
indicated	O
in	O
,	O
individuals	O
with	O
one	O
or	O
more	O
variant	O
C	O
##YP	O
##39	O
##A	O
##1	O
all	O
##ele	O
##s	O
had	O
progressively	O
higher	O
serum	O
24	B
##S	I
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
levels	O
compared	O
with	O
those	O
with	O
no	O
variant	O
all	O
##ele	O
##s	O
(	O
P	O
for	O
trend	O
,	O
1	O
.	O
5	O
×	O
10	O
_	O
−	O
##34	O
)	O
.	O

Cell	O
##s	O
were	O
in	O
##cu	O
##bate	O
##d	O
with	O
dual	O
labeled	O
flu	B
##ores	I
##ce	I
##in	I
-	I
r	I
##ho	I
##dam	I
##ine	I
de	O
##x	O
##tra	O
##n	O
for	O
18	O
h	O
##rs	O
and	O
the	O
end	O
##oc	O
##yt	O
##ose	O
##d	O
de	O
##x	O
##tra	O
##n	O
was	O
chased	O
into	O
l	O
##ys	O
##oso	O
##mes	O
with	O
a	O
3	O
-	O
h	O
##r	O
in	O
##cu	O
##bation	O
in	O
medium	O
without	O
de	O
##x	O
##tra	O
##n	O
.	O

When	O
compared	O
with	O
c	B
##era	I
##mi	I
##de	I
,	O
S	O
##1	O
##P	O
and	O
C	O
##1	O
##P	O
produce	O
the	O
opposite	O
effect	O
;	O
in	O
the	O
regulation	O
of	O
cell	O
growth	O
and	O
survival	O
they	O
serve	O
as	O
pro	O
-	O
survival	O
or	O
mit	O
##ogenic	O
signals	O
in	O
the	O
majority	O
of	O
cell	O
types	O
,	O
and	O
they	O
also	O
induce	O
different	O
effects	O
in	O
controlling	O
tumor	O
progression	O
and	O
meta	O
##sta	O
##sis	O
.	O

h	O
mean	O
daytime	O
DB	B
##P	I
were	O
higher	O
in	O
non	O
-	O
ad	O
##here	O
##nt	O
(	O
either	O
partially	O
or	O
completely	O
)	O
than	O
fully	O
ad	O
##here	O
##nt	O
patients	O
.	O

AS	O
An	O
##ky	O
##los	O
##ing	O
s	O
##po	O
##ndy	O
##lit	O
##is	O
,	O
HC	O
Health	O
##y	O
control	O
subjects	O
,	O
F	O
##NF	O
Fe	O
##mor	O
##al	O
neck	O
fracture	O
,	O
2	O
-	O
P	O
##Y	O
2	B
-	I
P	I
##yr	I
##ido	I
##ne	I
-	I
3	I
-	I
car	I
##box	I
##ami	I
##de	I
,	O
L	O
##2	O
CH	O
_	O
3	O
CH	O
_	O
2	O
CH	O
_	O
2	O
C	O
=	O
,	O
L	O
##3	O
-	O
(	O
CH	O
_	O
2	O
)	O
_	O
n	O
-	O
,	O
L	O
##5	O
-	O
CH	O
_	O
2	O
C	O
=	O
C	O
-	O
,	O
L	O
##6	O
CH	O
_	O
2	O
CO	O
,	O
L	O
##7	O
C	O
=	O
CC	O
##H	O
_	O
2	O
C	O
=	O
C	O
,	O
L	O
##8	O
-	O
CH	O
=	O
CH	O
-	O
Alt	O
##ered	O
metabolic	O
pathways	O
for	O
the	O
most	O
relevant	O
distinguishing	O
meta	O
##bol	O
##ites	O
(	O
potential	O
bio	O
##mark	O
##ers	O
)	O
between	O
the	O
patients	O
with	O
AS	O
and	O
the	O
healthy	O
control	O
subjects	O
and	O
patients	O
with	O
f	O
##em	O
##oral	O
neck	O
fracture	O
.	O

The	O
results	O
of	O
the	O
current	O
study	O
showed	O
that	O
patients	O
with	O
S	O
##Z	O
exhibited	O
increased	O
levels	O
of	O
co	B
##rt	I
##ison	I
##e	I
.	O

Alto	O
##get	O
##her	O
,	O
these	O
opinions	O
pin	O
##point	O
the	O
evidence	O
that	O
c	B
##era	I
##mi	I
##de	I
plays	O
a	O
role	O
in	O
cancer	O
,	O
as	O
well	O
as	O
identify	O
a	O
potential	O
target	O
for	O
the	O
treatment	O
and	O
prevention	O
of	O
o	O
##var	O
##ian	O
cancer	O
re	O
##cu	O
##rrence	O
.	O

Although	O
the	O
shorter	O
products	O
of	O
the	O
eccentric	O
c	O
##lea	O
##vage	O
of	O
β	B
-	I
car	I
##ote	I
##ne	I
had	O
little	O
or	O
no	O
effect	O
on	O
AT	O
##RA	O
-	O
induced	O
trans	O
##act	O
##ivation	O
,	O
β	B
-	I
a	I
##po	I
-	I
10	I
′	I
-	I
car	I
##ote	I
##no	I
##ic	I
acid	I
and	O
β	B
-	I
a	I
##po	I
-	I
12	I
′	I
-	I
car	I
##ote	I
##no	I
##ic	I
acid	I
both	O
led	O
to	O
40	O
–	O
50	O
%	O
in	O
##hibition	O
of	O
AT	O
##RA	O
-	O
induced	O
activation	O
of	O
all	O
three	O
RA	O
##R	O
is	O
##of	O
##orms	O
.	O

These	O
relationships	O
were	O
observed	O
when	O
class	O
##ifier	O
##s	O
based	O
on	O
all	O
low	O
/	O
intermediate	O
-	O
risk	O
patients	O
,	O
determined	O
by	O
bio	O
##psy	O
or	O
R	B
##P	I
,	O
were	O
performed	O
(	O
D	O
,	O
5	O
##E	O
;	O
Table	O
S	O
##1	O
M	O
##6	O
)	O
.	O

For	O
comparison	O
,	O
three	O
al	O
##iq	O
##uo	O
##ts	O
of	O
10	O
μ	O
##L	O
sa	O
##liva	O
were	O
individually	O
subjected	O
to	O
ace	B
##tone	I
precipitation	O
,	O
and	O
50	O
μ	O
##L	O
of	O
super	O
##nat	O
##ant	O
from	O
each	O
al	O
##iq	O
##uo	O
##t	O
was	O
taken	O
out	O
for	O
_	O
12	O
C	B
-	I
dans	I
##yl	I
chloride	I
label	O
##ing	O
.	O

All	O
identified	O
meta	O
##bol	O
##ites	O
were	O
up	O
-	O
regulated	O
in	O
the	O
BC	O
##P	O
group	O
,	O
except	O
for	O
one	O
meta	O
##bol	O
##ite	O
;	O
p	B
##yr	I
##u	I
##vic	I
acid	I
.	O

The	O
increased	O
levels	O
of	O
try	B
##pt	I
##op	I
##han	I
measured	O
during	O
sleep	O
de	O
##p	O
##ri	O
##vation	O
may	O
contribute	O
to	O
the	O
anti	O
##de	O
##pressive	O
effect	O
of	O
sleep	O
de	O
##p	O
##ri	O
##vation	O
,	O
directly	O
or	O
indirectly	O
via	O
se	B
##rot	I
##oni	I
##n	I
synthesis	O
.	O

For	O
R	O
##RL	O
##C	O
-	O
MS	O
/	O
MS	O
based	O
valid	O
##ation	O
test	O
,	O
plasma	O
samples	O
containing	O
internal	O
standards	O
(	B
le	B
##vo	I
##f	I
##lo	I
##xa	I
##cin	I
,	O
he	B
##sper	I
##id	I
##in	I
,	O
and	O
r	O
##hein	O
,	O
5	O
μ	O
##g	O
/	O
m	O
##l	O
)	O
were	O
prepared	O
as	O
described	O
here	O
.	O

Cy	B
##stein	I
##e	I
is	O
generally	O
assumed	O
to	O
be	O
a	O
rate	O
-	O
limiting	O
substrate	O
for	O
the	O
synthesis	O
of	O
anti	O
##ox	O
##ida	O
##nt	O
g	B
##lut	I
##ath	I
##ione	I
(	O
G	O
##S	O
##H	O
)	O
.	O

Their	O
experiment	O
indicated	O
the	O
probable	O
formation	O
of	O
the	O
p	B
##hen	I
##yl	I
##but	I
##yr	I
##yl	I
-	I
β	I
-	I
g	I
##lu	I
##cu	I
##rona	I
##te	I
meta	O
##bol	O
##ite	O
of	O
P	O
##B	O
,	O
through	O
an	O
indirect	O
assessment	O
,	O
along	O
with	O
several	O
other	O
secondary	O
P	O
##B	O
meta	O
##bol	O
##ites	O
in	O
both	O
humans	O
and	O
rats	O
.	O

Met	B
##han	I
##ol	I
was	O
added	O
to	O
achieve	O
an	O
approximate	O
1	O
:	O
2	O
sample	O
:	O
Me	O
##OH	O
ratio	O
.	O

Ph	B
##os	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
,	O
representing	O
the	O
most	O
abundant	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
in	O
human	O
plasma	O
,	O
are	O
the	O
main	O
component	O
of	O
cell	O
membrane	O
##s	O
as	O
well	O
as	O
an	O
important	O
source	O
of	O
signaling	O
molecules	O
[	O
,	O
]	O
.	O

Not	O
##ably	O
,	O
all	O
meta	O
##bol	O
##ites	O
from	O
the	O
t	B
##yr	I
##os	I
##ine	I
metabolism	O
depicted	O
associations	O
to	O
disease	O
severity	O
and	O
HD	O
symptoms	O
,	O
where	O
thy	B
##ro	I
##xin	I
##e	I
in	O
particular	O
showed	O
significant	O
correlation	O
##s	O
to	O
all	O
measures	O
of	O
disease	O
severity	O
,	O
DB	O
##S	O
and	O
the	O
five	O
year	O
risk	O
of	O
onset	O
.	O

Moreover	O
,	O
the	O
decreased	O
levels	O
of	O
f	B
##uma	I
##rate	I
in	O
the	O
urine	O
of	O
PC	O
##a	O
patients	O
,	O
compared	O
with	O
individuals	O
diagnosed	O
with	O
BP	O
##H	O
,	O
positively	O
co	O
##rrel	O
##ates	O
with	O
previous	O
studies	O
showing	O
an	O
accumulation	O
of	O
this	O
meta	O
##bol	O
##ite	O
in	O
PC	O
##a	O
bone	O
meta	O
##sta	O
##ses	O
(	O
T	O
##ha	O
##par	O
and	O
Titus	O
)	O
and	O
pro	O
##state	O
tissue	O
(	O
M	O
##c	O
##D	O
##un	O
##n	O
et	O
al	O
.	O
)	O
,	O
a	O
process	O
that	O
would	O
lead	O
to	O
a	O
reduction	O
in	O
the	O
levels	O
of	O
circulating	O
f	B
##uma	I
##rate	I
.	O

Previous	O
studies	O
have	O
shown	O
that	O
elevations	O
in	O
t	O
##rop	O
##oni	O
##n	O
(	O
T	O
##rop	O
##oni	O
##n	O
T	O
)	O
and	O
c	B
##rea	I
##tine	I
kinase	O
(	O
C	O
##K	O
)	O
or	O
its	O
specific	O
MB	O
(	O
C	O
##K	O
##MB	O
)	O
is	O
##of	O
##orm	O
after	O
primary	O
PC	O
##I	O
represent	O
larger	O
in	O
##far	O
##ct	O
size	O
and	O
are	O
clearly	O
associated	O
with	O
increased	O
early	O
and	O
late	O
mortality	O
.	O

H	B
##ydro	I
##xy	I
##car	I
##box	I
##yl	I
##ic	I
acid	I
receptor	O
2	O
(	O
HC	O
##AR	O
##2	O
)	O
binds	O
and	O
is	O
activated	S
by	O
β	O
##OH	O
##B	O

Cy	B
##stein	I
##e	I
can	O
be	O
directly	O
taken	O
off	O
su	O
##lf	O
##yd	O
##ryl	O
and	O
amino	S
to	O
generate	O
p	B
##yr	I
##u	I
##vate	I
,	O
which	O
can	O
form	O
ace	B
##ty	I
##l	I
-	I
Co	I
##A	I
through	O
o	O
##xi	O
##da	O
##tive	O
de	O
##car	O
##box	O
##yla	O
##tion	O
,	O
and	O
then	O
be	O
further	O
converted	O
to	O
g	B
##lut	I
##ama	I
##te	I
.	O

Z	B
##in	I
##c	I
-	I
alpha	I
-	I
2	I
-	I
g	I
##ly	I
##co	I
##p	I
##rote	I
##in	I
(	O
Z	O
##A	O
##2	O
##G	O
)	O
,	O
a	O
secret	O
##ed	O
protein	O
that	O
stimulate	O
##s	O
lip	O
##id	O
degradation	O
in	O
ad	O
##ip	O
##ocytes	O
and	O
is	O
associated	O
with	O
excessive	O
weight	O
loss	O
and	O
cancer	O
cache	O
##xia	O
,	O
was	O
elevated	O
in	O
survivors	O
compared	O
with	O
both	O
fatalities	O
and	O
healthy	O
controls	O
.	O

We	O
therefore	O
chose	O
to	O
s	O
##ynth	O
##esi	O
##ze	O
the	O
g	B
##lu	I
##cu	I
##ron	I
##ide	I
en	O
##zy	O
##matical	O
##ly	O
to	O
une	O
##qui	O
##voc	O
##ally	O
identify	O
this	O
phase	O
II	O
meta	O
##bol	O
##ite	O
of	O
p	O
-	O
c	O
##res	O
##ol	O
as	O
the	O
β	O
-	O
O	O
-	O
g	O
##lu	O
##cu	O
##ron	O
##ide	O
.	O

In	O
(	O
B	O
)	O
,	O
T	O
##EX	O
co	O
-	O
in	O
##cu	O
##bate	O
##d	O
with	O
CD	O
##4	O
_	O
+	O
T	O
cells	O
also	O
induced	O
the	O
up	O
##re	O
##gu	O
##lation	O
of	O
in	B
##os	I
##ine	I
production	O
,	O
although	O
there	O
were	O
large	O
differences	O
among	O
cells	O
of	O
different	O
donors	O
.	O

In	O
contrast	O
to	O
the	O
dynamics	O
of	O
extra	O
##cellular	O
p	B
##yr	I
##u	I
##vate	I
in	O
control	O
cells	O
,	O
p	B
##yr	I
##u	I
##vate	I
did	O
not	O
a	O
##cc	O
##um	O
##ulate	O
in	O
the	O
extra	O
##cellular	O
medium	O
of	O
r	O
##H	O
##la	O
-	O
treated	O
S	O
##9	O
and	O
16	O
##H	O
##BE	O
##14	O
##o	O
_	O
−	O
cells	O
.	O

C	O
##ir	O
##cula	O
##ting	O
un	O
##con	O
##ju	O
##gated	O
est	B
##rad	I
##iol	I
accounted	O
for	O
10	O
%	O
(	O
1	O
.	O
8	O
cases	O
per	O
100	O
,	O
000	O
)	O
and	O
15	O
%	O
(	O
3	O
.	O
0	O
cases	O
per	O
100	O
,	O
000	O
)	O
of	O
the	O
cases	O
associated	O
with	O
over	O
##weight	O
and	O
o	O
##besity	O
,	O
respectively	O
,	O
and	O
20	O
%	O
(	O
1	O
.	O
4	O
cases	O
per	O
100	O
,	O
000	O
)	O
of	O
the	O
effect	O
of	O
a	O
5	O
kg	O
/	O
m	O
_	O
2	O
increase	O
in	O
B	O
##MI	O
.	O

M	O
##3	O
##S	O
was	O
present	O
in	O
urine	O
and	O
plasma	O
from	O
all	O
study	O
groups	O
although	O
at	O
lower	O
concentrations	O
than	O
m	B
##or	I
##phine	I
-	I
3	I
-	I
g	I
##lu	I
##cu	I
##ron	I
##ide	I
(	O
M	O
##3	O
##G	O
)	O
.	O

E	O
##ry	O
##th	O
##ro	O
##cy	O
##tes	O
do	O
not	O
possess	O
SM	O
##ase	O
activity	O
of	O
their	O
own	O
,	O
but	O
they	O
can	O
be	O
exposed	O
to	O
secret	O
##ed	O
SM	O
##ases	O
,	O
_	O
,	O
here	O
##in	O
we	O
observed	O
an	O
SM	O
concentration	O
decrease	O
in	O
se	O
##ptic	O
patients	O
(	O
,	O
)	O
,	O
but	O
the	O
corresponding	O
formation	O
of	O
Ce	B
##r	I
was	O
not	O
observed	O
in	O
the	O
lip	O
##id	O
extract	O
##s	O
of	O
both	O
plasma	O
and	O
er	O
##yt	O
##hr	O
##ocytes	O
.	O

The	O
N	O
##MR	O
sample	O
was	O
prepared	O
combining	O
300	O
µ	O
##L	O
of	O
urine	O
fi	O
##lt	O
##rate	O
with	O
300	O
µ	O
##L	O
of	O
N	O
##MR	O
buffer	O
containing	O
100	O
m	O
##M	O
phosphate	S
buffer	O
in	O
D	O
##2	O
##O	O
,	O
pH	O
7	O
.	O
3	O
,	O
and	O
1	O
.	O
0	O
m	O
##M	O
T	O
##MS	O
##P	O
(	B
3	B
-	I
Tri	I
##met	I
##hyl	I
##si	I
##ly	I
##l	I
2	I
,	I
2	I
,	I
3	I
,	I
3	I
-	I
d	I
##4	I
prop	I
##ion	I
##ate	I
)	O
.	O

C	O
##YP	O
##1	O
##A	O
##1	O
and	O
C	O
##YP	O
##1	O
##B	O
##1	O
expression	O
analyzed	O
by	O
R	O
##T	O
-	O
q	O
##PC	O
##R	O
in	O
MC	O
##F	O
-	O
7	O
cells	O
after	O
treatment	O
with	O
is	B
##of	I
##lav	I
##ones	I
.	O

This	O
information	O
is	O
crucial	O
to	O
interpret	O
##ing	O
the	O
corresponding	O
F	O
##T	O
-	O
I	O
##CR	O
-	O
MS	O
data	O
,	O
in	O
terms	O
of	O
assign	O
##ing	O
the	O
g	B
##ly	I
##cer	I
##oli	I
##pid	I
is	O
##oto	O
##pol	O
##ogue	O
##s	O
of	O
m	O
+	O
3	O
(	O
mon	O
##ois	O
##oto	O
##pic	O
mass	O
plus	O
3	O
neutron	O
##s	O
)	O
and	O
m	O
+	O
odd	O
number	O
of	O
neutron	O
##s	O
to	O
_	O
13	O
C	O
label	O
##ing	O
in	O
the	O
g	B
##ly	I
##cer	I
##ol	I
backbone	O
.	O

The	O
column	O
was	O
re	O
##con	O
##dition	O
##ed	O
with	O
25	O
m	O
##L	O
met	O
##han	O
##ol	O
/	O
water	O
(	O
2	O
:	O
8	O
,	O
v	O
/	O
v	O
)	O
and	O
45	O
m	O
##L	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
solution	O
(	O
0	O
.	O
25	O
m	O
##M	O
,	O
pH	O
8	O
.	O
8	O
)	O
for	O
the	O
next	O
sample	O
.	O

Co	O
-	O
treatment	O
of	O
the	O
cells	O
with	O
AT	O
##RA	O
and	O
the	O
parent	O
compound	O
(	B
β	B
-	I
car	I
##ote	I
##ne	I
)	O
or	O
with	O
a	O
β	B
-	I
a	I
##po	I
##car	I
##ote	I
##no	I
##id	I
that	O
does	O
not	O
ant	O
##agon	O
##ize	O
AT	O
##RA	O
-	O
induced	O
trans	O
##act	O
##ivation	O
(	O
v	O
##iz	O
.	O

V	O
##eno	O
##us	O
blood	O
samples	O
were	O
obtained	O
at	O
0	O
,	O
30	O
,	O
60	O
,	O
90	O
and	O
120	O
minutes	O
of	O
the	O
o	O
##G	O
##TT	O
for	O
determination	O
of	O
plasma	O
glucose	S
and	O
insulin	O
.	O

Go	O
to	O
:	O
The	O
amino	B
##alk	I
##yl	I
##ind	I
##ole	I
ago	O
##nist	O
##s	O
J	O
##W	O
##H	O
-	O
01	O
##8	O
and	O
J	O
##W	O
##H	O
-	O
07	O
##3	O
are	O
contained	O
in	O
“	O
K	O
##2	O
/	O
SP	O
##IC	O
##E	O
”	O
products	O
sold	O
as	O
“	O
legal	O
marijuana	O
”	O
.	O

Its	O
immediate	O
precursor	O
##s	O
in	O
the	O
acidic	O
pathway	O
,	O
3	B
##β	I
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##t	I
-	I
5	I
-	I
en	I
-	I
26	I
-	I
o	I
##ic	I
acid	I
and	O
3	B
##β	I
,	I
7	I
##α	I
-	I
di	I
##hy	I
##dr	I
##ox	I
##ych	I
##ole	I
##st	I
-	I
5	I
-	I
en	I
-	I
26	I
-	I
o	I
##ic	I
acid	I
,	O
were	O
each	O
shown	O
to	O
activate	O
the	O
L	O
##X	O
##R	O
##α	O
in	O
a	O
l	O
##uc	O
##ifer	O
##ase	O
ass	O
##ay	O
(	O
Scheme	O
4	O
and	O
)	O
,	O
whereas	O
7	B
##α	I
-	I
h	I
##ydro	I
##xy	I
-	I
3	I
-	I
o	I
##x	I
##och	I
##ole	I
##st	I
-	I
4	I
-	I
en	I
-	I
26	I
-	I
o	I
##ic	I
acid	I
was	O
inactive	O
.	O

Con	O
##cer	O
##ning	O
11	O
##β	O
-	O
h	O
##ydro	O
##xy	O
##ster	O
##oid	O
de	O
##hy	O
##dr	O
##ogen	O
##ase	O
activities	O
,	O
we	O
found	O
an	O
increased	O
type	O
2	O
and	O
decreased	O
type	O
1	O
activity	O
,	O
but	O
no	O
change	O
in	O
absolute	O
co	B
##rt	I
##is	I
##ol	I
ex	O
##cre	O
##tion	O
.	O

In	O
terms	O
of	O
platform	O
overlap	O
and	O
compound	O
complement	O
##arity	O
,	O
N	O
##MR	O
and	O
G	O
##C	O
-	O
MS	O
were	O
able	O
to	O
identify	O
a	O
common	O
set	O
of	O
88	O
meta	O
##bol	O
##ites	O
;	O
N	O
##MR	O
and	O
D	O
##FI	O
/	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
were	O
able	O
to	O
identify	O
and	O
q	O
##uant	O
##ify	O
a	O
common	O
set	O
of	O
28	O
meta	O
##bol	O
##ites	O
,	O
while	O
N	O
##MR	O
,	O
G	O
##C	O
-	O
MS	O
and	O
D	O
##FI	O
/	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
were	O
able	O
to	O
identify	O
a	O
common	O
set	O
of	O
17	O
meta	O
##bol	O
##ites	O
(	O
15	O
amino	O
acids	O
,	O
c	B
##rea	I
##tin	I
##ine	I
and	O
he	O
##x	O
##ose	O
/	O
glucose	O
)	O
.	O

(	O
EA	O
##R	O
:	O
2	O
.	O
0	O
μ	O
##g	O
;	O
R	O
##DA	O
:	O
2	O
.	O
4	O
μ	O
##g	O
)	O
,	O
and	O
f	B
##olate	I
(	O
EA	O
##R	O
:	O
320	O
μ	O
##g	O
;	O
R	O
##DA	O
:	O
400	O
μ	O
##g	O
)	O
intake	O
,	O
expressed	O
as	O
diet	O
##ary	O
f	B
##olate	I
equivalent	O
##s	O
.	O

At	O
the	O
opposite	O
pole	O
,	O
the	O
up	O
-	O
regulation	O
of	O
p	B
##hos	I
##ph	I
##oe	I
##than	I
##ola	I
##mine	I
in	O
un	O
##classified	O
PA	O
may	O
suggest	O
an	O
activation	O
of	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##let	I
##han	I
##ola	I
##mine	I
metabolism	O
,	O
which	O
is	O
involved	O
in	O
membrane	O
shape	O
changes	O
in	O
tumor	O
cells	O
.	O

Natural	O
and	O
semi	O
-	O
synthetic	O
op	O
##iate	O
##s	O
share	O
the	O
p	B
##hen	I
##ant	I
##rene	I
main	O
chemical	O
structure	O
and	O
are	O
further	O
divided	O
into	O
natural	O
op	O
##iate	O
##s	O
that	O
are	O
al	O
##kal	O
##oids	O
of	O
the	O
pop	O
##py	O
plant	O
(	O
Papa	O
##ver	O
so	O
##m	O
##nife	O
##rum	O
)	O
,	O
and	O
into	O
semi	O
-	O
synthetic	O
op	O
##iate	O
##s	O
that	O
are	O
chemical	O
##ly	O
modified	O
derivatives	O
of	O
the	O
natural	O
op	O
##iate	O
##s	O
.	O

De	B
##ox	I
##yi	I
##nos	I
##ine	I
levels	O
in	O
our	O
study	O
are	O
seen	O
to	O
increase	O
in	O
the	O
stages	O
of	O
II	O
,	O
III	O
and	O
IV	O
cancer	O
as	O
pu	B
##rine	I
metabolism	O
is	O
reported	O
to	O
be	O
high	O
in	O
tumors	O
turnover	O
##s	O
.	O

A	O
line	O
-	O
broad	O
##ening	O
factor	O
of	O
1	O
Hz	O
was	O
applied	O
to	O
F	O
##ID	O
##s	O
before	O
F	B
##T	I
.	O

For	O
healthy	O
subjects	O
the	O
response	O
of	O
urine	O
samples	O
is	O
often	O
normal	O
##ized	O
by	O
its	O
c	B
##rea	I
##tin	I
##ine	I
level	O
.	O

In	O
1999	O
,	O
the	O
proposed	O
Sa	O
##pp	O
##oro	O
classification	O
criteria	O
for	O
AP	O
##S	O
were	O
first	O
published	O
,	O
and	O
then	O
,	O
it	O
was	O
updated	O
in	O
the	O
11th	O
International	O
Congress	O
on	O
Anti	B
##ph	I
##os	I
##ph	I
##oli	I
##pid	I
Anti	O
##bo	O
##dies	O
,	O
2006	O
in	O
Sydney	O
.	O

The	O
mean	O
concentration	O
(	O
±	O
SE	O
##M	O
)	O
of	O
total	O
E	O
##2	O
and	O
16	B
##α	I
-	I
OH	I
-	I
E	I
##2	I
,	O
in	O
the	O
male	O
samples	O
were	O
17	O
.	O
4	O
p	O
##g	O
/	O
m	O
##L	O
(	O
±	O
1	O
.	O
1	O
p	O
##g	O
/	O
m	O
##L	O
)	O
and	O
36	O
.	O
5	O
p	O
##g	O
/	O
m	O
##L	O
(	O
±	O
12	O
.	O
9	O
p	O
##g	O
/	O
m	O
##L	O
)	O
,	O
respectively	O
.	O

In	O
a	O
previous	O
study	O
,	O
an	O
N	O
##MR	O
s	O
##pect	O
##ros	O
##copy	O
-	O
based	O
approach	O
was	O
used	O
to	O
identify	O
a	O
meta	O
##bot	O
##ype	O
re	O
##sp	O
##ons	O
##ive	O
to	O
vitamin	B
D	I
supplement	O
##ation	O
with	O
regard	O
to	O
markers	O
of	O
the	O
metabolic	O
syndrome	O
.	O

a	O
,	O
‘	B
G	I
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
metabolism	O
’	O
;	O
b	O
,	O
‘	O
l	O
##ino	O
##le	O
##ic	O
acid	O
metabolism	O
’	O
;	O
c	O
,	O
‘	O
primary	O
bi	O
##le	O
acid	O
bio	O
##sy	O
##nt	O
##hesis	O
’	O
;	O
d	O
,	O
‘	O
fatty	O
acid	O
bio	O
##sy	O
##nt	O
##hesis	O
’	O
;	O
e	O
,	O
‘	O
a	O
##rac	O
##hi	O
##don	O
##ic	O
acid	O
metabolism	O
’	O
;	O
f	O
,	O
‘	B
amino	I
##acy	I
##l	I
-	I
t	I
##RNA	I
bio	O
##sy	O
##nt	O
##hesis	O
’	O
;	O
g	O
,	O
‘	O
se	O
##len	O
##o	O
amino	O
acid	O
metabolism	O
’	O
.	O

However	O
,	O
patients	O
who	O
went	O
on	O
to	O
develop	O
AP	S
had	O
a	O
higher	O
incidence	O
of	O
multiple	O
di	O
##ag	O
##nose	O
##s	O
indicated	O
than	O
those	O
who	O
did	O
not	O
develop	O
AP	S
.	O

Several	O
studies	O
in	O
breast	O
cancer	O
,	O
particularly	O
assessing	O
breast	O
cancer	O
cells	O
and	O
tumor	O
tissue	O
,	O
have	O
reported	O
correlation	O
##s	O
between	O
ma	O
##li	O
##gna	O
##ncy	O
and	O
numerous	O
meta	O
##bol	O
##ites	O
,	O
including	O
ch	B
##olin	I
##e	I
and	O
ch	B
##olin	I
##e	I
derivatives	O
,	O
amino	O
acids	O
and	O
glucose	S
(	O
A	O
##boa	O
##gy	O
##e	O
and	O
B	O
##hu	O
##j	O
##wall	O
##a	O
,	O
1999	O
;	O
Katz	O
‐	O
B	O
##ru	O
##ll	O
et	O
al	O
.	O
,	O
2002	O
)	O
.	O

(	O
C	O
)	O
Ce	B
##ram	I
##ides	I
are	O
g	O
##ly	O
##cos	O
##yla	O
##ted	O
into	O
complex	O
c	B
##era	I
##mi	I
##des	I
(	O
including	O
He	O
##x	O
##C	O
##er	O
and	O
He	O
##x	O
##2	O
##C	O
##er	O
)	O
and	O
can	O
be	O
recycled	O
back	O
to	O
c	B
##era	I
##mi	I
##des	I
through	O
the	O
s	O
##ca	O
##venge	O
/	O
salvage	O
pathway	O
.	O

Thus	O
the	O
achieved	O
sample	O
may	O
not	O
be	O
representative	O
of	O
the	O
population	O
of	O
people	O
who	O
believe	O
they	O
are	O
as	B
##par	I
##tam	I
##e	I
sensitive	O
,	O
but	O
it	O
was	O
impossible	O
to	O
recruit	O
those	O
most	O
fearful	O
.	O

The	O
reduced	O
risk	O
associated	O
with	O
enhanced	O
2	O
-	O
h	O
##ydro	O
##xy	O
##lation	O
is	O
also	O
consistent	O
with	O
several	O
experiments	O
suggesting	O
that	O
2	O
-	O
pathway	O
cat	B
##ech	I
##ols	I
are	O
prefer	O
##ential	O
##ly	O
ex	O
##cre	O
##ted	O
,	O
relative	O
to	O
parent	O
est	O
##rogen	O
##s	O
[	O
,	O
]	O
.	O

Key	O
:	O
1	O
,	O
is	B
##ob	I
##ut	I
##yl	I
alcohol	I
(	O
δ	O
0	O
.	O
88	O
−	O
##CH	O
_	O
3	O
)	O
;	O
2	O
,	O
prop	B
##yle	I
##ne	I
g	I
##ly	I
##co	I
##l	I
(	O
δ	O
1	O
.	O
14	O
−	O
##CH	O
_	O
3	O
,	O
3	O
.	O
43	O
−	O
##CH	O
_	O
2	O
,	O
3	O
.	O
53	O
−	O
##CH	O
_	O
2	O
,	O
3	O
.	O
87	O
−	O
##CH	O
)	O
;	O
3	O
,	O
te	O
##r	O
t	B
-	I
but	I
##ano	I
##l	I
(	O
δ	O
1	O
.	O
25	O
−	O
##CH	O
_	O
3	O
)	O
;	O
4	O
,	O
ace	B
##tate	I
(	O
δ	O
1	O
.	O
92	O
−	O
##CH	O
_	O
3	O
)	O
;	O
5	O
,	O
N	B
,	I
N	I
-	I
dim	I
##eth	I
##yla	I
##ce	I
##tam	I
##ide	I
(	O
δ	O
2	O
.	O
1	O
−	O
##CH	O
_	O
3	O
,	O
δ	O
2	O
.	O
9	O
−	O
##CH	O
_	O
3	O
,	O
δ	O
3	O
.	O
1	O
−	O
##CH	O
_	O
3	O
)	O
;	O
6	O
,	O
ace	B
##tone	I
(	O
δ	O
2	O
.	O
23	O
−	O
##CH	O
_	O
3	O
)	O
;	O
7	O
.	O

T	O
##rp	O
meta	O
##bol	O
##ites	O
not	O
identified	O
by	O
this	O
procedure	O
included	O
3	B
-	I
h	I
##ydro	I
##xy	I
##ant	I
##hra	I
##ni	I
##lic	I
acid	I
,	O
q	B
##uin	I
##olin	I
##ic	I
acid	I
,	O
5	B
-	I
h	I
##ydro	I
##xy	I
##l	I
-	I
in	I
##do	I
##le	I
-	I
3	I
-	I
ace	I
##tic	I
acid	I
,	O
3	B
-	I
in	I
##do	I
##le	I
-	I
su	I
##lf	I
##ate	I
,	O
5	B
-	I
h	I
##ydro	I
##xy	I
-	I
try	I
##pt	I
##op	I
##han	I
,	O
x	B
##ant	I
##hur	I
##eni	I
##c	I
acid	I
,	O
and	O
3	B
-	I
h	I
##ydro	I
##xy	I
##ky	I
##nu	I
##ren	I
##ine	I
.	O

However	O
,	O
this	O
analysis	O
provided	O
increased	O
support	O
for	O
the	O
significance	O
of	O
the	O
non	O
##cano	O
##nical	O
s	B
##phi	I
##ngo	I
##id	I
backbone	O
.	O

We	O
found	O
no	O
meaningful	O
effects	O
on	O
the	O
change	O
in	O
tumor	O
size	O
for	O
urine	O
co	B
##tin	I
##ine	I
or	O
total	O
a	O
##rsen	O
##ic	O
,	O
or	O
for	O
five	O
mon	O
##oes	O
##ter	O
meta	O
##bol	O
##ites	O
of	O
three	O
widely	O
distributed	O
p	B
##ht	I
##hala	I
##te	I
dies	O
##ters	O
.	O

Therefore	O
,	O
0	O
.	O
1	O
%	O
FA	S
was	O
chosen	O
as	O
our	O
mobile	O
phase	O
add	O
##itive	O
.	O

The	O
modified	O
metabolic	O
schemes	O
depend	O
on	O
g	B
##ly	I
##co	I
##ly	I
##tic	I
activity	O
,	O
the	O
War	O
##burg	O
effect	O
,	O
and	O
on	O
elevated	O
g	B
##lut	I
##amine	I
metabolism	O
.	O

Si	O
##ly	O
##lation	O
was	O
subsequently	O
done	O
using	O
30	O
µ	O
##L	O
of	O
N	B
-	I
met	I
##hyl	I
-	I
N	I
-	I
trim	I
##eth	I
##yl	I
##si	I
##ly	I
##lt	I
##ri	I
##f	I
##lu	I
##oro	I
##ace	I
##tam	I
##ide	I
with	O
1	B
%	I
trim	I
##eth	I
##yl	I
##ch	I
##lor	I
##os	I
##ila	I
##ne	I
(	O
MS	O
##TF	O
##A	O
+	O
1	O
%	O
T	O
##MC	O
##S	O
,	O
Sigma	O
)	O
for	O
1	O
hour	O
at	O
room	O
temperature	O
.	O

This	O
suggests	O
ace	B
##tate	I
has	O
a	O
critical	O
role	O
in	O
my	B
##elin	I
lip	O
##id	O
bio	O
##sy	O
##nt	O
##hesis	O
in	O
MS	O
and	O
N	O
##MO	O
##SD	O
.	O

The	O
valid	O
##ation	O
set	O
confirmed	O
that	O
my	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
concentrations	O
were	O
significantly	O
higher	O
in	O
patients	O
with	O
F	O
##S	O
##GS	O
than	O
in	O
healthy	O
controls	O
(	O
2	O
.	O
35	O
-	O
fold	O
;	O
P	O
=	O
0	O
.	O
00	O
##8	O
)	O
and	O
MC	O
##D	O
patients	O
(	O
1	O
.	O
69	O
-	O
fold	O
;	O
P	O
=	O
0	O
.	O
04	O
##2	O
)	O

Other	O
interesting	O
findings	O
of	O
our	O
study	O
are	O
the	O
changes	O
on	O
NE	O
##FA	O
levels	O
upon	O
T	B
##NF	I
##α	I
-	I
blockade	I
.	O

Oct	B
##ade	I
##ce	I
##noy	I
##l	I
##car	I
##ni	I
##tine	I
;	O
12	O
.	O

A	O
fused	O
-	O
si	O
##lica	O
cap	O
##illa	O
##ry	O
G	O
##C	O
column	O
,	O
HP	O
-	O
5	O
##MS	O
30	O
m	O
x	O
0	O
.	O
25	O
mm	O
ID	O
(	O
A	O
##gi	O
##lent	O
J	O
&	O
W	O
Scientific	O
,	O
F	O
##ols	O
##om	O
,	O
CA	O
,	O
USA	O
)	O
,	O
chemical	O
##ly	O
bonded	O
with	O
a	O
95	O
%	O
dim	B
##eth	I
##yl	I
##pol	I
##ys	I
##ilo	I
##xa	I
##ne	I
5	O
%	O
dip	O
##hen	O
##yl	O
cross	O
-	O
linked	O
stationary	O
phase	O
(	O
0	O
.	O
25	O
mm	O
film	O
thickness	O
)	O
was	O
used	O
.	O

His	B
##ti	I
##dine	I
is	O
known	O
to	O
be	O
inverse	O
##ly	O
associated	O
with	O
inflammation	O
and	O
o	O
##xi	O
##da	O
##tive	O
stress	O
in	O
patients	O
with	O
metabolic	O
syndrome	O
and	O
chronic	O
kidney	O
disease	O
;	O
in	O
fact	O
,	O
his	B
##ti	I
##dine	I
supplement	O
##ation	O
has	O
been	O
shown	O
to	O
suppress	O
inflammatory	O
processes	O
.	O
,	O

Co	O
##mpo	O
##unds	O
included	O
energy	O
related	O
meta	O
##bol	O
##ites	O
such	O
as	O
fatty	O
,	O
organic	O
,	O
and	O
amino	O
acids	O
,	O
sugar	O
##s	O
,	O
o	O
##smo	O
##ly	O
##tes	O
,	O
am	O
##ines	O
,	O
alcohol	O
##s	O
,	O
p	O
##hen	O
##olic	O
compounds	O
,	O
n	O
##uc	O
##leo	O
##base	O
##s	O
,	O
n	O
##uc	O
##leo	O
##side	O
##s	O
,	O
n	O
##uc	O
##leo	O
##tide	O
##s	O
,	O
vitamin	B
B	I
##3	I
and	O
bacterial	O
degradation	O
products	O
.	O

The	O
absolute	O
concentration	O
levels	O
for	O
3	B
-	I
e	I
##pi	I
-	I
25	I
(	I
OH	I
)	I
D	I
_	I
3	I
mentioned	O
in	O
the	O
previous	O
section	O
hide	O
the	O
fact	O
that	O
these	O
levels	O
correspond	O
##ed	O
to	O
strongly	O
varying	O
amounts	O
of	O
the	O
3	O
-	O
e	O
##pi	O
##mer	O
relative	O
to	O
25	O
(	O
OH	O
)	O
D	O
_	O
3	O
.	O

PA	B
(	I
38	I
:	I
4	I
)	I
was	O
the	O
only	O
species	O
identified	O
in	O
v	O
##iri	O
##ons	O
,	O
and	O
it	O
was	O
also	O
elevated	O
in	O
infected	O
relative	O
to	O
mock	O
-	O
infected	O
cells	O
.	O

In	O
conclusion	O
,	O
we	O
have	O
developed	O
a	O
smart	O
is	O
##oto	O
##pe	O
tag	O
,	O
_	O
15	O
N	B
-	I
ch	I
##ola	I
##mine	I
,	O
which	O
possesses	O
dual	O
characteristics	O
for	O
meta	O
##bol	O
##ite	O
pro	O
##fi	O
##ling	O
in	O
complex	O
biological	O
mixture	O
##s	O
using	O
the	O
powerful	O
analytical	O
techniques	O
of	O
N	O
##MR	O
and	O
MS	O
.	O

By	O
contrast	O
,	O
N	O
##AC	O
treatment	O
did	O
not	O
reduce	O
elevated	O
levels	O
of	O
unique	O
PP	O
##P	O
sugar	O
##s	O
,	O
S	O
##7	O
##P	O
and	O
R	O
##5	O
##P	O
,	O
suggesting	O
that	O
altered	O
PP	O
##P	O
activity	O
lies	O
upstream	O
of	O
G	B
##S	I
##H	I
de	O
##ple	O
##tion	O
in	O
the	O
order	O
of	O
metabolic	O
signaling	O
defects	O
in	O
SL	O
##E	O
.	O

The	O
u	B
##rac	I
##il	I
rings	O
of	O
u	B
##rid	I
##ined	I
##ip	I
##hos	I
##ph	I
##og	I
##lu	I
##cos	I
##e	I
(	O
U	O
##DP	O
##G	O
)	O
also	O
exhibited	O
similar	O
cross	O
-	O
peak	O
patterns	O
as	O
those	O
of	O
G	O
##lu	O
(	O
see	O
above	O
)	O
,	O
indicating	O
_	O
13	O
C	O
at	O
either	O
C	O
##5	O
(	O
U	O
##DP	O
##G	O
-	O
H	O
##5	O
_	O
sat	O
)	O
or	O
C	O
##6	O
(	O
U	O
##DP	O
##G	O
-	O
H	O
##6	O
_	O
sat	O
)	O
and	O
at	O
both	O
C	O
##5	O
and	O
C	O
##6	O
(	O
U	O
##DP	O
##G	O
-	O
H	O
##5	O
/	O
6	O
_	O
sat	O
,	O
)	O
.	O

Peak	O
refer	O
##encing	O
was	O
done	O
on	O
the	O
signal	O
of	O
c	B
##rea	I
##tine	I
at	O
3	O
.	O
03	O
##5	O
pp	O
##m	O
for	O
a	O
##que	O
##ous	O
extract	O
##s	O
and	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
(	O
P	O
##tch	O
##o	O
)	O
at	O
3	O
.	O
26	O
pp	O
##m	O
for	O
lip	O
##id	O
extract	O
##s	O
.	O

In	O
addition	O
,	O
2	B
-	I
Benz	I
##of	I
##ura	I
##nc	I
##ar	I
##box	I
##yl	I
##ic	I
acid	I
,	O
7	B
-	I
met	I
##ho	I
##xy	I
-	I
,	I
(	I
3	I
,	I
4	I
,	I
4	I
-	I
trim	I
##eth	I
##yl	I
-	I
1	I
,	I
2	I
-	I
di	I
##ox	I
##eta	I
##n	I
-	I
3	I
-	I
y	I
##l	I
)	I
met	I
##hyl	I
est	I
##er	I
exhibited	O
significantly	O
reduced	O
levels	O
in	O
the	O
group	O
of	O
I	O
##g	O
##AN	O
patients	O
compared	O
with	O
the	O
normal	O
control	O
group	O
(	O
P	O
<	O
0	O
.	O
05	O
,	O
,	O
)	O
.	O

In	O
this	O
study	O
,	O
only	O
a	O
selected	O
group	O
of	O
V	O
##OC	O
compounds	O
mainly	O
related	O
to	O
ET	O
##S	O
is	O
presented	O
jointly	O
with	O
the	O
u	O
##rina	O
##ry	O
bio	O
##mark	O
##er	O
data	O
,	O
which	O
included	O
3	B
-	I
et	I
##hen	I
##yl	I
##py	I
##rid	I
##ine	I
(	O
3	O
-	O
EP	O
)	O
,	O
1	B
,	I
3	I
-	I
but	I
##adi	I
##ene	I
(	O
B	O
##UT	O
)	O
and	O
nap	B
##ht	I
##hale	I
##ne	I
(	O
Na	O
##ph	O
)	O
in	O
the	O
gas	O
phase	O
.	O

Association	O
##s	O
between	O
B	O
##MI	O
and	O
SP	O
##s	O
were	O
evaluated	O
using	O
linear	O
models	O
(	O
l	O
##m	O
function	O
)	O
fitted	O
to	O
before	O
and	O
after	O
adjusting	O
for	O
age	O
,	O
sex	O
,	O
L	O
##D	O
##L	O
,	O
HD	O
##L	O
,	O
and	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
.	O

Interest	O
##ingly	O
,	O
we	O
measured	O
two	O
a	B
##rac	I
##hi	I
##don	I
##ic	I
acid	I
containing	O
PC	O
##s	O
.	O

For	O
storage	O
,	O
160	O
μ	O
##L	O
of	O
ice	O
-	O
cold	O
met	B
##han	I
##ol	I
were	O
added	O
per	O
10	O
million	O
cells	O
and	O
the	O
samples	O
frozen	O
directly	O
at	O
-	O
80	O
°C	O
.	O

ID	O
##O	O
activity	O
may	O
be	O
indirectly	O
induced	O
by	O
in	B
##dox	I
##yl	I
su	I
##lf	I
##ate	I
,	O
which	O
promotes	O
inflammation	O
and	O
o	O
##xi	O
##da	O
##tive	O
stress	O
.	O

Di	O
##fference	O
##s	O
in	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
metabolism	O
can	O
reflect	O
the	O
growth	O
and	O
turnover	O
of	O
tissue	O
as	O
well	O
as	O
the	O
increase	O
after	O
degradation	O
of	O
membrane	O
##s	O
during	O
a	O
##pop	O
##tosis	O
(	O
Bel	O
##ori	O
##bi	O
‐	O
D	O
##je	O
##fa	O
##f	O
##lia	O
et	O
al	O
.	O
,	O
2016	O
;	O
Santos	O
and	O
Sc	O
##hul	O
##ze	O
,	O
2012	O
)	O
.	O

If	O
a	O
genetic	O
defect	O
imp	O
##air	O
##s	O
synthesis	O
of	O
the	O
precursor	O
g	B
##ly	I
##can	I
in	O
the	O
end	O
##op	O
##las	O
##mic	O
re	O
##tic	O
##ulum	O
,	O
one	O
or	O
both	O
g	O
##ly	O
##cos	O
##yla	O
##tion	O
sites	O
of	O
transfer	O
##rin	O
may	O
remain	O
un	O
##oc	O
##cup	O
##ied	O
(	O
white	O
arrow	O
)	O
.	O

To	O
investigate	O
the	O
efficiency	O
and	O
re	O
##p	O
##rod	O
##uc	O
##ibility	O
of	O
in	O
##tra	O
##cellular	O
meta	O
##bol	O
##ite	O
extraction	O
,	O
different	O
volumes	O
and	O
ratios	O
of	O
ch	B
##lor	I
##of	I
##orm	I
were	O
tested	O
.	O

G	B
##ly	I
##cine	I
,	O
L	B
-	I
g	I
##lut	I
##ath	I
##ione	I
reduced	O
,	O
and	O
t	B
##ri	I
##f	I
##lu	I
##oro	I
##ace	I
##tic	I
acid	I
(	O
T	O
##FA	O
)	O
were	O
purchased	O
from	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
,	O
USA	O
.	O

The	O
V	O
##US	O
of	O
the	O
amino	O
acid	O
concentrations	O
spanned	O
from	O
0	O
.	O
180	O
(	B
a	B
##rg	I
##ini	I
##ne	I
,	O
95	O
%	O
C	O
##I	O
0	O
.	O
106	O
–	O
0	O
.	O
270	O
)	O
to	O
0	O
.	O
850	O
(	B
g	B
##lut	I
##amine	I
,	O
95	O
%	O
C	O
##I	O
0	O
.	O
76	O
##1	O
–	O
0	O
.	O
92	O
##9	O
)	O
.	O

Pat	O
##ient	O
characteristics	O
(	O
shown	O
as	O
the	O
median	O
and	O
range	O
)	O
were	O
:	O
age	O
(	O
53	O
years	O
;	O
31	O
–	O
72	O
years	O
)	O
,	O
weight	O
(	O
71	O
kg	O
;	O
51	O
–	O
107	O
kg	O
)	O
,	O
height	O
(	O
168	O
cm	O
;	O
154	O
–	O
184	O
cm	O
)	O
,	O
body	O
surface	O
area	O
(	O
1	O
.	O
79	O
m	O
_	O
2	O
;	O
1	O
.	O
51	O
–	O
2	O
.	O
30	O
m	O
_	O
2	O
)	O
,	O
total	O
bi	B
##li	I
##ru	I
##bin	I
(	O
0	O
.	O
2	O
mg	O
/	O
d	O
##L	O
;	O
0	O
.	O
1	O
–	O
0	O
.	O
8	O
mg	O
/	O
d	O
##L	O
)	O
,	O
as	O
##par	O
##tate	O
amino	O
##tra	O
##ns	O
##fer	O
##ase	O
(	O
22	O
I	O
##U	O
/	O
L	O
,	O
12	O
–	O
76	O
I	O
##U	O
/	O
L	O
)	O
,	O
and	O
al	O
##ani	O
##ne	O
amino	O
##tra	O
##ns	O
##fer	O
##ase	O
(	O
30	O
I	O
##U	O
/	O
L	O
,	O
7	O
–	O
49	O
I	O
##U	O
/	O
L	O
)	O
,	O
and	O
serum	O
c	B
##rea	I
##tine	I
(	O
0	O
.	O
8	O
mg	O
/	O
d	O
##L	O
;	O
0	O
.	O
4	O
–	O
1	O
.	O
2	O
mg	O
/	O
d	O
##L	O
)	O
.	O

First	O
,	O
1	O
equivalent	O
of	O
D	O
##H	O
##EA	O
and	O
4	O
equivalent	O
##s	O
of	O
ace	B
##tic	I
an	I
##hy	I
##dr	I
##ide	I
were	O
dissolved	O
in	O
p	B
##yr	I
##id	I
##ine	I
during	O
20	O
hours	O
at	O
room	O
temperature	O
to	O
obtain	O
3	B
-	I
A	I
##c	I
##O	I
-	I
D	I
##H	I
##EA	I
.	O

The	O
good	O
repeat	O
##ability	O
of	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
measurements	O
in	O
plasma	O
samples	O
observed	O
by	O
Ma	O
et	O
al	O
.	O
was	O
in	O
line	O
with	O
our	O
observations	O
.	O

Interest	O
##ingly	O
,	O
systemic	O
ta	B
##uri	I
##ne	I
supplement	O
##ation	O
has	O
been	O
shown	O
to	O
stab	O
##ilize	O
plate	O
##lets	O
against	O
a	O
##gg	O
##regation	O
-	O
in	O
##ducing	O
stimuli	O
.	O

After	O
phase	O
separation	O
,	O
the	O
lip	O
##id	O
-	O
containing	O
M	B
##T	I
##BE	I
phase	O
forms	O
the	O
top	O
layer	O
,	O
whereas	O
the	O
H	O
##FI	O
##P	O
and	O
water	O
from	O
the	O
lower	O
phase	O
.	O

The	O
ca	O
##li	O
##bra	O
##tion	O
curves	O
were	O
linear	O
over	O
the	O
concentration	O
range	O
of	O
0	O
.	O
25	O
–	O
100	O
ng	O
/	O
m	O
##l	O
for	O
all	O
the	O
anal	O
##yte	O
##s	O
in	O
plasma	O
with	O
both	O
low	O
and	O
high	O
t	B
##rig	I
##ly	I
##cer	I
##ide	I
levels	O
.	O

In	O
these	O
women	O
,	O
test	B
##osterone	I
levels	O
were	O
positively	O
associated	O
with	O
serum	O
T	B
##G	I
as	O
well	O
as	O
with	O
P	O
##L	O
,	O
T	B
##G	I
and	O
T	O
##C	O
in	O
larger	O
V	O
##LD	O
##L	O
sub	O
##c	O
##lass	O
##es	O
,	O
which	O
is	O
consistent	O
with	O
other	O
reported	O
studies	O
in	O
women	O
with	O
PC	O
##OS	O
.	O

-	B
Δ	I
_	I
9	I
-	I
te	I
##tra	I
##hy	I
##dr	I
##oc	I
##anna	I
##bino	I
##l	I
,	O
m	B
##or	I
##phine	I
,	O
norm	B
##or	I
##phine	I
,	O
m	B
##or	I
##phine	I
3	I
##β	I
-	I
g	I
##lu	I
##cu	I
##ron	I
##ide	I
,	O
m	B
##or	I
##phine	I
6	I
##β	I
-	I
g	I
##lu	I
##cu	I
##ron	I
##ide	I
,	O
code	B
##ine	I
,	O
nor	O
##code	O
##ine	O
,	O
6	B
-	I
ace	I
##ty	I
##lm	I
##or	I
##phine	I
,	O
6	B
-	I
ace	I
##ty	I
##l	I
##code	I
##ine	I
,	O
h	B
##ydro	I
##co	I
##don	I
##e	I
,	O
h	B
##ydro	I
##mor	I
##phone	I
,	O
o	B
##xy	I
##co	I
##don	I
##e	I
,	O
nor	B
##ox	I
##y	I
##co	I
##don	I
##e	I
,	O
o	B
##xy	I
##mor	I
##phone	I
,	O
nor	B
##hy	I
##dr	I
##omo	I
##rp	I
##hone	I
,	O
nor	B
##ox	I
##ym	I
##or	I
##phone	I
,	O
(	B
R	I
)	I
-	I
(	I
+	I
)	I
-	I
cat	I
##hino	I
##ne	I
,	O
(	B
±	I
)	I
-	I
N	I
-	I
et	I
##hyl	I
##amp	I
##he	I
##tamine	I
,	O
4	B
-	I
br	I
##omo	I
-	I
2	I
,	I
5	I
-	I
dim	I
##eth	I
##ox	I
##y	I
##phe	I
##net	I
##hyl	I
##amine	I
,	O
di	B
##az	I
##ep	I
##am	I
,	O
lo	B
##raze	I
##pa	I
##m	I
,	O
o	B
##xa	I
##ze	I
##pa	I
##m	I
,	O
al	B
##pra	I
##zo	I
##lam	I
,	O
im	B
##ip	I
##ram	I
##ine	I
,	O
c	B
##lo	I
##mi	I
##pra	I
##mine	I
,	O
flu	B
##ox	I
##eti	I
##ne	I
,	O
nor	B
##f	I
##lu	I
##ox	I
##eti	I
##ne	I
o	I
##xa	I
##late	I
,	O
par	B
##ox	I
##eti	I
##ne	I
male	I
##ate	I
,	O
7	B
-	I
amino	I
##c	I
##lon	I
##az	I
##ep	I
##am	I
,	O
7	B
-	I
amino	I
##f	I
##lu	I
##ni	I
##tra	I
##ze	I
##pa	I
##m	I
,	O
7	B
-	I
amino	I
##ni	I
##tra	I
##ze	I
##pa	I
##m	I
,	O
c	B
##lon	I
##id	I
##ine	I
,	O
i	B
##bu	I
##p	I
##ro	I
##fen	I
,	O
pen	B
##ta	I
##zo	I
##cine	I
,	O
ca	B
##ffe	I

Lac	B
##tate	I
,	O
u	B
##rea	I
and	O
am	O
##monia	O
are	O
released	O
from	O
strained	O
tissues	O
and	O
,	O
at	O
the	O
same	O
time	O
,	O
c	B
##rea	I
##tine	I
kinase	O
and	O
my	O
##og	O
##lo	O
##bin	O
leak	O
into	O
blood	O
##stream	O
from	O
ex	O
##asperated	O
skeletal	O
muscles	O
.	O

p	B
##G	I
represents	O
the	O
combined	O
p	O
-	O
value	O
from	O
gene	O
en	O
##rich	O
##ment	O
and	O
probability	O
of	O
per	O
##tur	O
##bation	O
accumulation	O
in	O
the	O
pathway	O
and	O
N	O
##DE	O
represents	O
differential	O
##ly	O
expressed	O
genes	O
per	O
pathways	O
.	O

Sam	O
##ples	O
underwent	O
liquid	O
-	O
liquid	O
extraction	O
(	O
LL	O
##E	O
)	O
with	O
1	O
.	O
3	O
m	O
##L	O
of	O
M	B
##T	I
##BE	I
by	O
v	O
##ortex	O
-	O
mixing	O
for	O
10	O
min	O
,	O
followed	O
by	O
cent	O
##ri	O
##fu	O
##gation	O
at	O
340	O
##0	O
##g	O
at	O
4	O
°C	O
for	O
15	O
min	O
(	O
D	O
##37	O
##5	O
##20	O
O	O
##ster	O
##ode	O
Ben	O
##cht	O
##op	O
Ce	O
##nt	O
##ri	O
##fu	O
##ge	O
,	O
The	O
##rm	O
##o	O
El	O
##ec	O
##tron	O
)	O
.	O

Only	O
a	O
few	O
meta	O
##bol	O
##ites	O
that	O
were	O
decreased	O
in	O
UC	O
were	O
also	O
decreased	O
in	O
CD	O
patients	O
(	O
i	O
.	O
e	O
.	O
,	O
c	B
##it	I
##rate	I
,	O
su	B
##cci	I
##nate	I
,	O
beta	B
##ine	I
,	O
hip	B
##pura	I
##te	I
,	O
and	O
met	B
##han	I
##ol	I
)	O
as	O
compared	O
to	O
controls	O
.	O

1	B
,	I
2	I
-	I
N	I
##P	I
##Q	I
-	I
Al	I
##b	I
was	O
present	O
in	O
larger	O
amounts	O
than	O
1	B
,	I
4	I
-	I
N	I
##P	I
##Q	I
-	I
Al	I
##b	I
.	O

Red	O
##uce	O
##d	O
abundance	O
of	O
o	B
##me	I
##ga	I
-	I
3	I
fatty	O
acids	O
in	O
the	O
C	O
##NS	O
may	O
reduce	O
ne	O
##uro	O
##tra	O
##ns	O
##mission	O
,	O
especially	O
by	O
the	O
do	O
##pa	O
##mine	O
##rg	O
##ic	O
and	O
se	O
##rot	O
##one	O
##rg	O
##ic	O
systems	O
,	O
by	O
affecting	O
membrane	O
fluid	O
##ity	O
and	O
related	O
receptor	O
functions	O
,	O
thereby	O
ultimately	O
affecting	O
brain	O
structure	O
and	O
function	O
[	O
,	O
]	O
.	O

We	O
also	O
found	O
that	O
levels	O
of	O
GA	B
##BA	I
in	O
tumor	O
were	O
lower	O
in	O
GB	O
##M	O
compared	O
to	O
o	O
##li	O
##go	O
##den	O
##dr	O
##og	O
##lio	O
##ma	O
.	O

Try	B
##pt	I
##op	I
##han	I
also	O
plays	O
fundamental	O
roles	O
in	O
the	O
synthesis	O
of	O
ne	O
##uro	O
##tra	O
##ns	O
##mit	O
##ters	O
like	O
se	B
##rot	I
##oni	I
##n	I
,	O
me	B
##lat	I
##oni	I
##n	I
,	O
and	O
try	B
##pta	I
##mine	I
.	O

After	O
each	O
second	O
extraction	O
,	O
a	O
blank	O
sample	O
(	O
10	O
m	O
##L	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
solution	O
(	O
0	O
.	O
25	O
m	O
##M	O
,	O
pH	O
8	O
.	O
8	O
)	O
)	O
was	O
analogous	O
##ly	O
proceeded	O
to	O
remove	O
imp	O
##uri	O
##ties	O
from	O
the	O
column	O
and	O
to	O
avoid	O
possible	O
carry	O
-	O
over	O
effects	O
.	O

Using	O
co	B
##tin	I
##ine	I
as	O
a	O
co	O
##var	O
##iate	O
had	O
little	O
effect	O
on	O
meta	O
##bol	O
##ite	O
differences	O
between	O
PT	O
##SD	O
-	O
positive	O
and	O
–	O
negative	O
groups	O
:	O
17	O
of	O
21	O
meta	O
##bol	O
##ites	O
that	O
were	O
significantly	O
different	O
between	O
PT	O
##SD	O
-	O
positive	O
and	O
–	O
negative	O
subjects	O
remained	O
significant	O
,	O
while	O
the	O
other	O
4	O
meta	O
##bol	O
##ites	O
were	O
now	O
trends	O
(	O
p	O
<	O
0	O
.	O
09	O
)	O
.	O

Meanwhile	O
,	O
ID	O
##O	O
activity	O
(	O
index	O
##ed	O
by	O
the	O
K	O
##Y	O
##N	O
/	O
T	O
##RP	O
ratio	O
)	O
,	O
previously	O
linked	O
to	O
a	O
worse	O
##ning	O
of	O
de	O
##pressive	O
symptoms	O
by	O
way	O
of	O
the	O
ne	O
##uro	O
##to	O
##xi	O
##c	O
branch	O
of	O
the	O
K	B
##P	I
(	O
;	O
;	O
)	O
was	O
associated	O
with	O
decreased	O
connectivity	O
between	O
the	O
right	O
d	O
##AC	O
##C	O
and	O
the	O
right	O
pre	O
##cu	O
##ne	O
##us	O
.	O

For	O
meta	O
##bol	O
##ites	O
der	O
##iva	O
##ti	O
##zation	O
,	O
70	O
μ	O
##L	O
of	O
MS	O
##TF	O
##A	O
with	O
1	O
%	O
T	O
##MC	O
##S	O
and	O
70	O
μ	O
##L	O
p	B
##yr	I
##id	I
##ine	I
were	O
added	O
to	O
the	O
dried	O
al	O
##iq	O
##uo	O
##t	O
followed	O
by	O
in	O
##cu	O
##bation	O
at	O
60	O
°C	O
for	O
45	O
min	O
.	O

In	O
young	O
females	O
,	O
levels	O
of	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
and	O
ch	B
##ole	I
##ster	I
##ol	I
are	O
increased	O
from	O
young	O
age	O
to	O
middle	O
age	O
,	O
and	O
this	O
effect	O
is	O
elevated	O
when	O
con	O
##tra	O
##ceptive	O
##s	O
are	O
used	O
,	O
suggesting	O
a	O
strong	O
inter	O
##play	O
between	O
sex	O
hormones	O
and	O
lip	O
##id	O
levels	O
.	O

The	O
5	O
meta	O
##bol	O
##ites	O
that	O
showed	O
higher	O
abundance	O
in	O
CR	O
##C	O
includes	O
is	O
##ob	O
##ar	O
:	O
beta	B
##ine	I
al	I
##de	I
##hy	I
##de	I
,	O
N	B
-	I
met	I
##hyl	I
##die	I
##than	I
##ola	I
##mine	I
(	O
2	O
.	O
68	O
-	O
fold	O
)	O
representing	O
g	B
##ly	I
##cine	I
,	O
se	B
##rine	I
,	O
and	O
th	B
##re	I
##oni	I
##ne	I
metabolic	O
pathways	O
,	O
ad	B
##en	I
##yl	I
##os	I
##ucci	I
##nate	I
(	O
1	O
.	O
88	O
-	O
fold	O
)	O
representing	O
the	O
pu	B
##rine	I
(	O
ad	O
##eni	O
##ne	O
containing	O
)	O
metabolic	O
pathway	O
,	O
is	B
##ova	I
##ler	I
##ate	I
(	O
1	O
.	O
45	O
-	O
fold	O
)	O
representing	O
le	B
##uc	I
##ine	I
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
and	O
v	B
##ali	I
##ne	I
metabolic	O
pathways	O
,	O
v	B
##ale	I
##rate	I
(	O
1	O
.	O
37	O
-	O
fold	O
)	O
representing	O
the	O
short	O
-	O
chain	O
fatty	O
acid	O
metabolic	O
pathway	O
,	O
and	O
N	B
##1	I
-	I
met	I
##hyl	I
-	I
2	I
-	I
p	I
##yr	I
##ido	I
##ne	I
-	I
car	I
##box	I
##ami	I
##de	I
(	O
1	O
.	O
29	O
-	O
fold	O
)	O
representing	O
ni	B
##cot	I
##inate	I
and	O
ni	B
##cot	I
##ina	I
##mi	I
##de	I
metabolic	O
pathways	O
.	O

In	O
addition	O
,	O
a	O
longitudinal	O
study	O
would	O
likely	O
be	O
a	O
better	O
design	O
to	O
improve	O
the	O
assessment	O
of	O
the	O
potential	O
long	O
term	O
effects	O
of	O
est	B
##rogen	I
meta	O
##bol	O
##ites	O
on	O
pro	O
##static	O
car	O
##cin	O
##ogen	O
##esis	O
.	O

Many	O
other	O
compounds	O
an	O
##not	O
##ated	O
in	O
these	O
three	O
patients	O
,	O
representing	O
major	O
chemical	O
classes	O
of	O
meta	O
##bol	O
##ites	O
such	O
as	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
,	O
amino	O
acids	O
,	O
and	O
organic	O
acids	O
,	O
were	O
found	O
to	O
have	O
satisfactory	O
RS	O
##Ds	O
(	O
all	O
data	O
is	O
available	O
on	O
request	O
)	O
.	O

T	B
##MA	I
##O	I
was	O
q	O
##uant	O
##ified	O
as	O
described	O
in	O
the	O
method	O
section	O
.	O

The	O
diet	O
##ary	O
s	O
##tero	O
##ls	O
,	O
β	B
-	I
sit	I
##ost	I
##ero	I
##l	I
(	I
β	I
-	I
S	I
##IT	I
##O	I
)	I
,	O
s	B
##ti	I
##gma	I
##ster	I
##ol	I
(	O
ST	O
##IG	O
)	O
,	O
and	O
camp	B
##ester	I
##ol	I
(	O
CA	O
##MP	O
)	O
were	O
highly	O
positively	O
correlated	O
with	O
each	O
other	O
,	O
and	O
were	O
negatively	O
correlated	O
with	O
most	O
ch	B
##ole	I
##ster	I
##ol	I
bio	O
##sy	O
##nt	O
##hesis	O
meta	O
##bol	O
##ites	O
,	O
and	O
bi	O
##le	O
acids	O
.	O

Sam	O
##ples	O
were	O
re	O
##con	O
##stituted	O
with	O
ace	O
##ton	O
##it	O
##ril	O
##e	O
/	O
water	O
(	O
20	O
:	O
80	O
)	O
,	O
with	O
and	O
without	O
either	O
5	O
%	O
2	O
M	O
H	O
_	O
2	O
S	O
##O	O
_	O
4	O
or	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
.	O

P	O
##las	O
##ma	O
and	O
u	O
##rina	O
##ry	O
levels	O
of	O
20	B
-	I
H	I
##ET	I
##E	I
were	O
significantly	O
different	O
among	O
the	O
3	O
groups	O
;	O
subjects	O
with	O
R	O
##VD	O
demonstrated	O
the	O
highest	O
plasma	O
and	O
the	O
lowest	O
u	O
##rina	O
##ry	O
values	O
of	O
20	B
-	I
H	I
##ET	I
##E	I
.	O

Although	O
c	B
##ys	I
##tine	I
was	O
significantly	O
reduced	O
by	O
10	O
%	O
following	O
treatment	O
,	O
this	O
amino	O
acid	O
remained	O
60	O
%	O
elevated	O
in	O
the	O
treated	O
group	O
relative	O
to	O
that	O
in	O
controls	O
(	O
Table	O
2	O
)	O
.	O

This	O
test	O
system	O
de	O
##con	O
##vo	O
##lut	O
##es	O
the	O
broad	O
met	O
##hyl	O
lip	O
##op	O
##rote	O
##in	O
resonance	O
into	O
its	O
constituent	O
parts	O
allowing	O
the	O
direct	O
measurement	O
of	O
the	O
ch	B
##ole	I
##ster	I
##ol	I
content	O
,	O
number	O
of	O
particles	O
,	O
and	O
mean	O
particle	O
diameter	O
of	O
each	O
lip	O
##op	O
##rote	O
##in	O
sub	O
##pop	O
##ulation	O
.	O

In	O
v	O
##ivo	O
s	O
##pect	O
##ros	O
##copy	O
of	O
tumors	O
provides	O
a	O
sum	O
of	O
total	O
ch	O
##olin	O
##e	O
-	O
containing	O
compounds	O
and	O
cannot	O
determine	O
individual	O
signals	O
,	O
such	O
as	O
GP	B
##C	I
and	O
PC	O
,	O
due	O
to	O
resolution	O
limitations	O
.	O

For	O
example	O
,	O
neo	B
##pt	I
##eri	I
##n	I
had	O
a	O
significant	O
positive	O
association	O
with	O
the	O
K	O
##TR	O
and	O
a	O
negative	O
association	O
with	O
P	O
##LP	O
.	O

16	O
ng	O
;	O
SM	B
(	I
d	I
##18	I
:	I
1	I
/	I
12	I
:	I
0	I
)	I

Four	O
compounds	O
including	O
,	O
rigid	B
##ius	I
##cula	I
##mi	I
##de	I
E	O
(	O
111	O
)	O
,	O

The	O
structures	O
of	O
all	O
the	O
identified	O
th	B
##iol	I
##s	I
were	O
further	O
el	O
##uc	O
##idated	O
by	O
product	O
-	O
ion	O
scan	O
(	O
MS	O
/	O
MS	O
)	O
and	O
high	O
resolution	O
mass	O
s	O
##pect	O
##rome	O
##try	O
(	O
Q	O
##TO	O
##F	O
-	O
MS	O
)	O
analysis	O
.	O

The	O
levels	O
of	O
GM	B
##3	I
and	O
G	O
##lu	O
##C	O
##er	O
in	O
human	O
plasma	O
were	O
nearly	O
four	O
##fold	O
of	O
that	O
in	O
monkey	O
plasma	O
;	O
while	O
the	O
level	O
of	O
Ce	B
##r	I
in	O
monkey	O
plasma	O
was	O
approximately	O
double	O
of	O
that	O
in	O
human	O
plasma	O
.	O

Previous	O
studies	O
showed	O
an	O
increase	O
in	O
abundance	O
of	O
the	O
c	O
##yclic	O
est	O
##er	O
2	O
(	O
3	O
##H	O
)	O
-	O
fur	O
##ano	O
##ne	O
and	O
slightly	O
reduced	O
levels	O
of	O
do	O
##de	O
##cano	O
##ic	O
,	O
a	O
##zel	O
##aic	O
,	O
and	O
ad	O
##ip	O
##ic	O
acids	O
in	O
the	O
m	O
##uc	O
##osa	O
of	O
I	O
##BS	O
patients	O
,	O
while	O
the	O
f	O
##eca	O
##l	O
metabolic	O
profile	O
of	O
patients	O
with	O
I	O
##BS	O
revealed	O
increased	O
but	B
##yra	I
##te	I
and	O
reduced	O
ace	B
##tate	I
and	O
prop	B
##ion	I
##ate	I
,	O
or	O
increased	O
ace	B
##tate	I
and	O
prop	B
##ion	I
##ate	I
,	O
with	O
unchanged	O
but	B
##yra	I
##te	I
.	O

I	O
##mm	O
##uno	O
##rea	O
##ctions	O
were	O
visual	O
##ized	O
using	O
the	O
D	O
##AB	O
substrate	O
,	O
followed	O
by	O
hem	B
##ato	I
##xy	I
##lin	I
counters	O
##taining	O
.	O

An	O
increase	O
in	O
u	O
##rina	O
##ry	O
1	B
-	I
met	I
##hyl	I
##ade	I
##nos	I
##ine	I
was	O
also	O
reported	O
to	O
be	O
a	O
sensitive	O
bio	O
##mark	O
##er	O
of	O
cellular	O
h	O
##y	O
##pox	O
##ia	O
.	O

GA	B
##BA	I
can	O
m	O
##od	O
##ulate	O
the	O
immune	O
response	O
via	O
secret	O
##ion	O
of	O
c	O
##yt	O
##oki	O
##nes	O
,	O
activation	O
,	O
proliferation	O
and	O
migration	O
of	O
immune	O
cells	O
.	O

It	O
should	O
also	O
be	O
noted	O
that	O
ch	B
##olin	I
##e	I
is	O
a	O
semi	O
##ess	O
##ential	O
nut	O
##rient	O
and	O
should	O
not	O
be	O
completely	O
eliminated	O
from	O
the	O
diet	O
,	O
since	O
this	O
can	O
result	O
in	O
a	O
deficiency	O
state	O
.	O

Several	O
human	O
bio	O
##mon	O
##itor	O
##ing	O
studies	O
from	O
nearby	O
European	O
areas	O
reported	O
u	O
##rina	O
##ry	O
levels	O
of	O
co	B
##tin	I
##ine	I
,	O
a	O
##rsen	O
##ic	O
,	O
and	O
p	O
##ht	O
##hala	O
##tes	O
measured	O
in	O
general	O
population	O
samples	O
.	O

An	O
independent	O
analysis	O
using	O
mass	O
s	O
##pect	O
##rome	O
##try	O
also	O
showed	O
significantly	O
increased	O
levels	O
of	O
t	B
##yra	I
##mine	I
and	O
2	B
-	I
o	I
##x	I
##og	I
##lut	I
##arate	I
in	O
I	O
##C	O
patients	O
compared	O
to	O
controls	O
.	O

Blood	O
samples	O
were	O
taken	O
at	O
–	O
10	O
,	O
0	O
,	O
30	O
,	O
60	O
,	O
90	O
,	O
120	O
,	O
and	O
180	O
minutes	O
for	O
measurement	O
of	O
plasma	O
glucose	S
,	O
insulin	O
,	O
and	O
c	O
-	O
p	O
##eptide	O
.	O

To	O
valid	O
##ate	O
the	O
proposed	O
di	B
##car	I
##box	I
##yl	I
##ic	I
structure	O
of	O
V	B
##LC	I
##DC	I
##A	I
28	I
:	I
4	I
,	O
we	O
used	O
p	B
##ico	I
##ly	I
##lam	I
##ine	I
,	O
which	O
der	O
##iva	O
##ti	O
##zes	O
car	B
##box	I
##yl	I
##ic	I
functions	O
.	O

Two	O
factors	O
were	O
associated	O
with	O
Δ	O
##H	O
##OM	O
##A	O
-	O
I	O
##R	O
in	O
un	O
##iva	O
##ria	O
##te	O
analyses	O
(	O
factor	O
3	O
[	O
branched	O
-	O
chain	O
amino	O
acids	O
(	O
BC	O
##AA	O
##s	O
)	O
and	O
related	O
cat	O
##ab	O
##oli	O
##tes	O
]	O
and	O
factor	O
10	O
[	B
amino	S
acids	O
]	O
,	O
)	O
.	O

Finally	O
,	O
the	O
MS	O
/	O
MS	O
spectrum	O
of	O
the	O
commercial	O
standard	O
palm	B
##ito	I
##yl	I
##car	I
##ni	I
##tine	I
was	O
used	O
to	O
confirm	O
the	O
identified	O
compound	O
.	O

The	O
o	B
##xa	I
##lo	I
##ace	I
##tate	I
is	O
then	O
reduced	O
to	O
ma	B
##late	I
cat	O
##aly	O
##zed	O
by	O
c	O
##yt	O
##oso	O
##lic	O
ma	O
##late	O
de	O
##hy	O
##dr	O
##ogen	O
##ase	O
.	O

The	O
spray	O
voltage	O
for	O
positive	O
ion	O
injection	O
was	O
4	O
.	O
0	O
k	B
##V	I
.	O

On	O
q	O
##uant	O
##ifying	O
the	O
extended	O
data	O
##set	O
,	O
however	O
,	O
the	O
opposite	O
finding	O
was	O
noted	O
with	O
marked	O
##ly	O
higher	O
beta	B
##ine	I
noted	O
in	O
the	O
T	O
##2	O
##D	O
group	O
.	O

The	O
super	O
##nat	O
##ant	O
was	O
extracted	O
with	O
et	B
##hyl	I
ace	I
##tate	I
under	O
al	B
##kal	I
##ine	I
pH	O
(	O
0	O
.	O
5	O
m	O
##l	O
of	O
0	O
.	O
5	O
m	O
Na	O
##OH	O
/	O
g	O
##ly	O
##cine	O
buffer	O
,	O
adjusted	O
to	O
pH	O
10	O
)	O
.	O

Ara	B
##chi	I
##don	I
##ic	I
acid	I
and	O
precursor	O
##s	O
were	O
elevated	O
in	O
AM	O
##L	O
,	O
particularly	O
in	O
patients	O
with	O
high	O
bone	O
ma	O
##rrow	O
(	O
B	O
##M	O
)	O
or	O
peripheral	O
blast	O
##s	O
and	O
un	O
##fa	O
##vor	O
##able	O
pro	O
##gno	O
##stic	O
risk	O
.	O

We	O
further	O
examined	O
whether	O
o	O
##var	O
##ian	O
cancer	O
ho	O
##mo	O
##gen	O
##ates	O
produce	O
higher	O
levels	O
of	O
20	B
-	I
H	I
##ET	I
##E	I
when	O
in	O
##cu	O
##bate	O
##d	O
with	O
AA	O
as	O
compared	O
to	O
normal	O
tissue	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
the	O
present	O
study	O
is	O
the	O
first	O
to	O
report	O
on	O
associations	O
between	O
serum	O
T	B
##MA	I
##O	I
and	O
P	O
##LC	O
risk	O
in	O
humans	O
.	O

Ph	B
##thal	I
##ic	I
acid	I
is	O
a	O
to	B
##xin	I
or	O
poll	O
##uta	O
##nt	O
found	O
in	O
blood	O
and	O
when	O
found	O
in	O
tissues	O
or	O
bio	O
##f	O
##lu	O
##ids	O
,	O
it	O
arises	O
from	O
exposure	O
to	O
p	B
##ht	I
##hala	I
##te	I
products	O
.	O

T	B
##hy	I
##mine	I
,	O
u	B
##rid	I
##ine	I
,	O
and	O
de	B
##ox	I
##yu	I
##rid	I
##ine	I
are	O
p	B
##yr	I
##im	I
##id	I
##ines	I
that	O
would	O
be	O
affected	O
by	O
p	B
##yr	I
##im	I
##id	I
##ine	I
synthesis	O
inhibitor	O
##s	O
;	O
however	O
,	O
none	O
of	O
the	O
patients	O
here	O
##in	O
were	O
being	O
treated	O
with	O
such	O
drugs	O
.	O

By	O
using	O
a	O
boots	O
##tra	O
##p	O
cross	O
-	O
valid	O
##ation	O
method	O
on	O
in	O
v	O
##ivo	O
_	O
1	O
H	O
MR	O
##S	O
data	O
of	O
brain	O
t	O
##umour	O
##s	O
from	O
35	O
children	O
,	O
me	O
##du	O
##llo	O
##blast	O
##oma	O
##s	O
were	O
characterized	O
by	O
high	O
ta	B
##uri	I
##ne	I
,	O
p	B
##hos	I
##ph	I
##och	I
##olin	I
##e	I
and	O
g	B
##lut	I
##ama	I
##te	I
and	O
low	O
g	B
##lut	I
##amine	I
;	O
as	O
##tro	O
##cy	O
##tom	O
##as	O
by	O
low	O
c	B
##rea	I
##tine	I
and	O
high	O
N	B
-	I
ace	I
##ty	I
##lasp	I
##art	I
##ate	I
;	O
and	O
e	O
##pen	O
##dy	O
##mo	O
##mas	O
by	O
high	O
my	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
and	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##och	I
##olin	I
##e	I
.	O

Our	O
data	O
identified	O
a	O
potential	O
association	O
between	O
DE	O
##HP	O
and	O
Di	O
##NP	O
and	O
TV	O
as	O
well	O
as	O
total	O
serum	O
test	B
##osterone	I
.	O

Ce	B
##r	I
containing	O
16	O
:	O
0	O
,	O
18	O
:	O
0	O
,	O
and	O
24	O
:	O
1	O
fatty	O
acids	O
increased	O
the	O
most	O
of	O
all	O
identified	O
c	B
##era	I
##mi	I
##des	I
in	O
E	O
##VD	O
fatalities	O
compared	O
with	O
E	O
##VD	O
survivors	O
(	O
and	O
S	O
##I	O
A	O
##ppe	O
##ndi	O
##x	O
,	O
Table	O
S	O
##3	O
)	O
.	O

S	B
##per	I
##mine	I
has	O
been	O
described	O
as	O
a	O
de	O
##cap	O
##ac	O
##itation	O
factor	O
for	O
sperm	O
that	O
ensures	O
the	O
proper	O
timing	O
of	O
the	O
a	O
##c	O
##ros	O
##ome	O
reaction	O
and	O
cap	O
##ac	O
##itation	O
.	O

A	O
targeted	O
search	O
for	O
C	B
##15	I
:	I
0	I
and	O
C	B
##17	I
:	I
0	I
revealed	O
the	O
presence	O
of	O
these	O
two	O
free	O
fatty	O
acids	O
in	O
the	O
serum	O
samples	O
of	O
our	O
study	O
.	O

Over	O
the	O
past	O
two	O
decades	O
G	O
##C	O
-	O
MS	O
,	O
L	O
##C	O
-	O
MS	O
and	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
methods	O
have	O
all	O
been	O
used	O
to	O
detect	O
,	O
identify	O
and	O
q	O
##uant	O
##ify	O
o	B
##xy	I
##lip	I
##ins	I
and	O
other	O
polar	O
meta	O
##bol	O
##ites	O
,	O
however	O
the	O
latter	O
approach	O
is	O
associated	O
with	O
simpler	O
sample	O
work	O
##up	O
strategies	O
and	O
can	O
simultaneously	O
assess	O
a	O
broader	O
range	O
of	O
targets	O
.	O

Indeed	O
,	O
a	O
significantly	O
higher	O
intensity	O
of	O
a	O
characteristic	O
signal	O
of	O
la	B
##ct	I
##ate	I
relative	O
to	O
the	O
total	O
spectral	O
intensity	O
was	O
observed	O
in	O
the	O
a	O
##que	O
##ous	O
fraction	O
of	O
plasma	O
from	O
the	O
30	O
-	O
day	O
mortality	O
group	O
.	O

In	O
v	O
##ivo	O
IS	O
was	O
evaluated	O
during	O
a	O
3	O
-	O
h	O
h	B
##yper	I
##ins	I
##ulin	I
##em	I
##ic	I
-	I
e	I
##ug	I
##ly	I
##ce	I
##mic	I
c	O
##lamp	O
as	O
previously	O
reported	O
(	O
,	O
)	O
.	O

The	O
blue	O
plots	O
represent	O
the	O
significantly	O
decreased	O
and	O
the	O
red	O
plots	O
represent	O
the	O
significantly	O
increased	O
th	B
##iol	I
##s	I
compared	O
to	O
healthy	O
controls	O
.	O

MR	O
##M	O
scan	O
##s	O
of	O
a	O
extracted	O
blank	O
me	O
##con	O
##ium	O
,	O
b	O
limit	O
of	O
q	O
##uant	O
##ification	O
,	O
and	O
c	O
me	O
##con	O
##ium	O
specimens	O
from	O
five	O
drug	O
-	O
exposed	O
neon	O
##ates	O
(	O
specimens	O
1	O
–	O
5	O
)	O
demonstrating	O
method	O
app	O
##lica	O
##bility	O
:	O
specimen	O
1	O
—	O
215	O
ng	O
/	O
g	O
met	B
##ham	I
##phe	I
##tamine	I
(	O
MA	O
##MP	O
)	O
,	O
44	O
.	O
9	O
ng	O
/	O
g	O
am	B
##phe	I
##tamine	I
(	O
AM	O
##P	O
″	O
)	O
,	O
11	O
.	O
2	O
ng	O
/	O
g	O
p	B
-	I
h	I
##ydro	I
##xy	I
##met	I
##ham	I
##phe	I
##tamine	I
(	O
p	O
##OH	O
##MA	O
##MP	O
)	O
;	O

To	O
get	O
absolute	O
meta	O
##bol	O
##ite	O
concentrations	O
,	O
these	O
L	O
##CM	O
##ode	O
##l	O
output	O
values	O
would	O
have	O
to	O
be	O
corrected	O
for	O
receiver	O
gain	O
and	O
number	O
of	O
scan	O
##s	O
and	O
then	O
normal	O
##ised	O
either	O
to	O
trim	B
##eth	I
##yl	I
##si	I
##ly	I
##l	I
##p	I
##rop	I
##ano	I
##ic	I
acid	I
(	O
T	O
##SP	O
)	O
or	O
un	O
##su	O
##pp	O
##ressed	O
water	O
.	O

Until	O
recently	O
it	O
was	O
assumed	O
that	O
the	O
existence	O
of	O
straight	O
chain	O
odd	O
number	O
fatty	O
acids	O
such	O
as	O
pen	B
##tad	I
##eca	I
##no	I
##ic	I
acid	I
(	O
15	O
:	O
0	O
)	O
in	O
normal	O
physiological	O
conditions	O
were	O
rare	O
.	O

Although	O
these	O
dairy	O
cattle	O
studies	O
may	O
give	O
an	O
indication	O
of	O
the	O
ch	B
##olin	I
##e	I
requirement	O
for	O
la	O
##ct	O
##ation	O
,	O
research	O
is	O
needed	O
to	O
better	O
understand	O
what	O
levels	O
of	O
ch	B
##olin	I
##e	I
are	O
needed	O
for	O
non	O
-	O
la	O
##ct	O
##ating	O
functions	O
.	O

We	O
have	O
further	O
demonstrated	O
that	O
decreased	O
4	B
-	I
OH	I
-	I
E	I
_	I
2	I
:	I
2	I
-	I
OH	I
-	I
E	I
_	I
2	I
ratios	O
and	O
decreased	O
4	B
-	I
OH	I
-	I
E	I
_	I
2	I
levels	O
are	O
correlated	O
with	O
increasing	O
T	O
##CD	O
##D	O
level	O
,	O
after	O
the	O
adjustment	O
of	O
other	O
con	O
##gene	O
##r	O
exposure	O
and	O
maternal	O
age	O
.	O

A	O
##bb	O
##re	O
##viation	O
##s	O
:	O
PP	O
##D	O
,	O
post	O
##par	O
##tum	O
depression	O
;	O
T	O
##CA	O
,	O
t	B
##rica	I
##rb	I
##ox	I
##yl	I
##ic	I
acid	I
.	O

To	O
our	O
knowledge	O
,	O
our	O
work	O
is	O
the	O
first	O
to	O
directly	O
q	O
##uant	O
##ify	O
and	O
associate	O
high	O
plasma	O
levels	O
of	O
a	O
cannabis	S
meta	O
##bol	O
##ite	O
,	O
namely	O
T	O
##HC	O
-	O
CO	O
##OH	O
,	O
with	O
decreased	O
markers	O
of	O
immune	O
activation	O
in	O
HIV	O
-	O
infected	O
,	O
AR	O
##T	O
-	O
treated	O
individuals	O
.	O

Compared	O
to	O
the	O
N	O
##G	O
##T	O
group	O
,	O
the	O
T	O
##2	O
##D	O
group	O
had	O
higher	O
levels	O
of	O
try	B
##pt	I
##op	I
##han	I
.	O

Low	O
rates	O
of	O
post	O
##par	O
##tum	O
glucose	S
testing	O
after	O
G	O
##DM	O
have	O
been	O
reported	O
for	O
several	O
co	O
##hor	O
##ts	O
of	O
women	O
,	O
despite	O
national	O
guidelines	O
requiring	O
glucose	S
monitoring	O
,	O
and	O
transition	O
to	O
primary	O
care	O
;	O
fewer	O
than	O
half	O
of	O
women	O
with	O
G	O
##DM	O
receive	O
post	O
##par	O
##tum	O
glucose	S
testing	O
.	O

D	B
-	I
Mann	I
##ose	I
.	O

There	O
were	O
also	O
previous	O
studies	O
showed	O
t	B
##yr	I
##os	I
##ine	I
and	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
levels	O
in	O
c	O
##ere	O
##bro	O
##sp	O
##inal	O
fluid	O
of	O
patients	O
with	O
PD	O
were	O
unchanged	O
.	O

Those	O
significant	O
meta	O
##bol	O
##ites	O
are	O
the	O
compounds	O
whose	O
change	O
is	O
associated	O
with	O
s	B
##tat	I
##in	I
response	O
of	O
L	O
##D	O
##L	O
-	O
C	O
.	O
For	O
predict	O
##ing	O
response	O
of	O
L	O
##D	O
##L	O
-	O
C	O
to	O
si	B
##m	I
##vas	I
##tat	I
##in	I
,	O
base	O
##line	O
meta	O
##bol	O
##ite	O
levels	O
were	O
correlated	O
with	O
s	B
##tat	I
##in	I
response	O
of	O
L	O
##D	O
##L	O
-	O
C	O
by	O
calculating	O
their	O
S	O
##pear	O
##man	O
’	O
s	O
correlation	O
coefficients	O
with	O
post	O
-	O
treatment	O
level	O
of	O
L	O
##D	O
##L	O
-	O
C	O
,	O
adjusting	O
for	O
pre	O
-	O
treatment	O
level	O
of	O
L	O
##D	O
##L	O
-	O
C	O
using	O
the	O
same	O
aforementioned	O
method	O
.	O

Single	O
he	B
##tero	I
##cy	I
##c	I
##lic	I
pro	O
##ton	O
is	O
noticed	O
in	O
the	O
range	O
of	O
δ	O
=	O
5	O
.	O
34	O
–	O
5	O
.	O
43	O
pp	O
##m	O
.	O

Furthermore	O
,	O
among	O
critically	O
ill	O
patients	O
,	O
low	O
plasma	O
c	B
##it	I
##ru	I
##llin	I
##e	I
levels	O
were	O
related	O
to	O
low	O
levels	O
of	O
a	B
##rg	I
##ini	I
##ne	I
and	O
g	B
##lut	I
##amine	I
as	O
well	O
as	O
elevated	O
h	O
##s	O
##CR	O
##P	O
levels	O
.	O

Other	O
than	O
the	O
pathways	O
discussed	O
previously	O
,	O
it	O
is	O
worth	O
note	O
that	O
the	O
g	B
##ly	I
##ox	I
##yla	I
##te	I
and	O
di	B
##car	I
##box	I
##yla	I
##te	I
metabolism	O
has	O
also	O
been	O
reported	O
in	O
the	O
previous	O
study	O
as	O
one	O
of	O
the	O
most	O
probable	O
pathways	O
involved	O
in	O
class	O
separation	O
between	O
lean	O
and	O
o	O
##bes	O
##e	O
as	O
##th	O
##matic	O
patients	O
.	O

This	O
meta	O
##bol	O
##ite	O
is	O
also	O
closely	O
related	O
to	O
pu	B
##rine	I
degradation	O
:	O
Although	O
it	O
is	O
not	O
en	O
##zy	O
##matical	O
##ly	O
produced	O
in	O
human	O
body	O
(	O
due	O
to	O
knock	O
-	O
out	O
mutation	O
in	O
u	B
##rate	I
o	O
##xi	O
##das	O
##e	O
gene	O
)	O
,	O
it	O
was	O
referenced	O
before	O
in	O
human	O
blood	O
,	O
c	O
##ere	O
##bro	O
##sp	O
##inal	O
fluid	O
and	O
urine	O
.	O

However	O
,	O
a	O
##rg	O
##inas	O
##e	O
also	O
appears	O
to	O
ex	O
##ert	O
its	O
effects	O
downstream	O
through	O
the	O
production	O
of	O
various	O
p	B
##oly	I
##amine	I
molecules	O
(	O
i	O
.	O
e	O
.	O
put	B
##res	I
##cine	I
,	O
sperm	B
##id	I
##ine	I
,	O
sperm	B
##ine	I
and	O
their	O
ace	O
##ty	O
##lated	O
derivatives	O
)	O
which	O
influences	O
the	O
growth	O
and	O
death	O
of	O
neural	O
cells	O
.	O

When	O
column	O
performance	O
was	O
compared	O
in	O
individual	O
co	O
-	O
solvent	O
##s	O
(	O
D	O
)	O
it	O
became	O
apparent	O
that	O
the	O
overall	O
trends	O
observed	O
in	O
A	O
and	O
B	O
were	O
also	O
applicable	O
in	O
specific	O
cases	O
:	O
the	O
Di	B
##ol	I
column	O
had	O
the	O
lowest	O
median	O
peak	O
width	O
##s	O
in	O
the	O
presence	O
of	O
water	O
and	O
am	B
##mon	I
##ium	I
format	I
##e	I
(	O
12	O
.	O
6	O
and	O
11	O
.	O
3	O
s	O
respectively	O
)	O
,	O
while	O
the	O
2	O
-	O
P	O
##IC	O
column	O
had	O
the	O
lowest	O
median	O
width	O
in	O
form	B
##ic	I
acid	I
(	O
13	O
.	O
7	O
s	O
)	O
.	O

Structure	O
characteristics	O
of	O
the	O
album	O
##in	O
-	O
like	O
protein	O
of	O
Atlantic	S
co	O
##d	O
(	O
G	O
##ad	O
##us	O
m	O
##or	O
##hua	O
)	O
.	O

Next	O
,	O
800	O
μ	O
##L	O
of	O
the	O
super	O
##nat	O
##ant	O
was	O
collected	O
separately	O
from	O
each	O
sample	O
into	O
an	O
am	O
##po	O
##ule	O
bottle	O
and	O
e	O
##va	O
##porated	O
to	O
dry	O
##ness	O
under	O
a	O
stream	O
of	O
nitrogen	B
gas	I
at	O
50	O
##°	O
##C	O
for	O
approximately	O
30	O
minutes	O
.	O

Te	O
##me	O
##ph	O
##os	O
,	O
TD	O
##P	O
,	O
S	O
##OD	O
##P	O
,	O
potassium	O
period	O
##ate	O
,	O
ace	B
##ty	I
##lt	I
##hi	I
##och	I
##olin	I
##e	I
i	I
##od	I
##ide	I
(	O
AT	O
##C	O
##h	O
)	O
,	O
5	B
,	I
5	I
-	I
di	I
##thi	I
##o	I
-	I
2	I
-	I
bi	I
##s	I
-	I
ni	I
##tro	I
##ben	I
##zoic	I
acid	I
(	O
D	O
##T	O
##N	O
##B	O
)	O
,	O
Tri	O
##ton	O
X	O
-	O
100	O
,	O
but	B
##yr	I
##yl	I
##thi	I
##och	I
##olin	I
##e	I
,	O
and	O
et	B
##hop	I
##rop	I
##azi	I
##ne	I
h	I
##ydro	I
##ch	I
##lor	I
##ide	I
were	O
purchased	O
from	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
(	O
St	O
.	O
Louis	O
,	O
M	O
##O	O
,	O
USA	O
)	O
.	O

The	O
reduction	O
in	O
peak	O
base	O
width	O
followed	O
a	O
clear	O
trend	O
based	O
on	O
the	O
size	O
of	O
the	O
al	O
##ky	O
##l	O
side	O
-	O
chain	O
,	O
with	O
is	B
##op	I
##rop	I
##yla	I
##mine	I
showing	O
the	O
lowest	O
median	O
width	O
(	O
4	O
.	O
5	O
s	O
)	O
and	O
is	B
##ope	I
##nt	I
##yla	I
##mine	I
showing	O
the	O
highest	O
(	O
5	O
.	O
0	O
s	O
)	O
.	O

The	O
HP	S
f	O
##rac	O
##to	O
##gram	O
shown	O
in	O
exhibits	O
a	O
large	O
peak	O
with	O
several	O
smaller	O
peaks	O
(	O
at	O
~	O
10	O
and	O
19	O
minutes	O
)	O
on	O
the	O
tail	O
##ing	O
edge	O
.	O

The	O
mean	O
values	O
of	O
the	O
sign	O
##ific	O
##ative	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
##s	I
and	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
meta	O
##bol	O
##ites	O
according	O
to	O
H	O
.	O
p	O
##yl	O
##ori	O
infection	O
status	O
are	O
shown	O
in	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
represents	O
the	O
first	O
report	O
of	O
their	O
simultaneous	O
measurement	O
in	O
HIV	O
-	O
T	O
##B	O
individuals	O
and	O
the	O
comparison	O
with	O
healthy	O
donors	O
,	O
obtaining	O
statistical	O
##ly	O
higher	O
plasma	O
levels	O
of	O
D	O
##H	O
##EA	O
,	O
A	O
##ET	O
and	O
7	B
-	I
o	I
##x	I
##o	I
-	I
D	I
##H	I
##EA	I
in	O
patients	O
.	O

Likewise	O
,	O
we	O
previously	O
reported	O
decreased	O
long	O
-	O
chain	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
and	O
increased	O
FA	S
in	O
PD	O
,	O
suggesting	O
β	O
-	O
oxidation	O
suppression	O
.	O

R	O
_	O
2	O
(	O
squared	O
correlation	O
coefficient	O
)	O
represents	O
the	O
proportion	O
of	O
variation	O
in	O
total	O
di	B
##os	I
##met	I
##in	I
that	O
is	O
accounted	O
by	O
the	O
di	B
##os	I
##met	I
##in	I
after	O
dig	O
##est	O
##ion	O
,	O
and	O
it	O
is	O
presented	O
here	O
as	O
a	O
ratio	O
.	O

Three	O
meta	O
##bol	O
##ites	O
were	O
found	O
to	O
be	O
significantly	O
negatively	O
correlated	O
(	O
format	O
##e	O
,	O
la	B
##ct	I
##ate	I
and	O
ch	B
##olin	I
##e	I
)	O
and	O
one	O
meta	O
##bol	O
##ite	O
was	O
positively	O
correlated	O
(	B
dim	B
##eth	I
##yl	I
##sul	I
##fo	I
##ne	I
)	O
with	O
age	O
(	O
Table	O
)	O
.	O

This	O
compound	O
could	O
be	O
an	O
inter	O
##media	O
##ry	O
meta	O
##bol	O
##ite	O
produced	O
from	O
the	O
p	B
##hos	I
##ph	I
##ori	I
##c	I
dies	O
##ter	O
h	O
##ydro	O
##lysis	O
of	O
Te	O
##m	O
-	O
do	O
##x	O
-	O
S	O
##O	O
and	O
could	O
act	O
as	O
a	O
precursor	O
to	O
form	O
S	O
##OD	O
##P	O
or	O
BP	O
##S	O
.	O

There	O
was	O
a	O
positive	O
correlation	O
between	O
ma	B
##lt	I
##ose	I
intake	O
and	O
total	O
grain	O
(	O
r	O
=	O
0	O
.	O
50	O
,	O
P	O
=	O
0	O
.	O
03	O
)	O
and	O
whole	O
grain	O
intake	O
(	O
r	O
=	O
0	O
.	O
47	O
,	O
P	O
=	O
0	O
.	O
04	O
)	O
suggesting	O
that	O
the	O
main	O
source	O
of	O
ma	B
##lt	I
##ose	I
in	O
our	O
patients	O
was	O
grain	O
or	O
grain	O
products	O
.	O

The	O
en	O
##zy	O
##matic	O
ass	O
##ay	O
media	O
consisted	O
of	O
500	O
µ	O
##L	O
di	O
##lut	O
##ed	O
blood	O
,	O
1	O
m	O
##L	O
of	O
phosphate	S
buffer	O
0	O
.	O
1	O
M	O
,	O
pH	O
7	O
.	O
4	O
,	O
0	O
.	O
05	O
m	O
##L	O
of	O
D	O
##T	O
##N	O
##B	O
(	O
10	O
m	O
##M	O
)	O
,	O
and	O
5	O
µ	O
##L	O
of	O
et	B
##hop	I
##rop	I
##azi	I
##ne	I
(	O
6	O
m	O
##M	O
)	O
,	O
which	O
were	O
mixed	O
and	O
in	O
##cu	O
##bate	O
##d	O
at	O
37	O
°C	O
for	O
10	O
min	O
.	O

Whether	O
su	B
##cci	I
##nate	I
could	O
help	O
risk	O
s	O
##tra	O
##ti	O
##fy	O
em	O
##bolic	O
stroke	O
of	O
uncertain	O
source	O
would	O
also	O
require	O
further	O
study	O
in	O
future	O
prospective	O
co	O
##hor	O
##ts	O
.	O

El	O
##eva	O
##ted	O
plasma	O
protein	O
-	O
bound	O
ho	B
##mo	I
##ci	I
##tr	I
##ull	I
##ine	I
concentrations	O
predict	O
increased	O
risk	O
of	O
co	O
##rona	O
##ry	O
artery	O
disease	O
,	O
future	O
my	O
##oc	O
##ard	O
##ial	O
in	O
##far	O
##ction	O
,	O
stroke	O
and	O
death	O
,	O
and	O
elevated	O
free	O
serum	O
ho	B
##mo	I
##ci	I
##tr	I
##ull	I
##ine	I
concentration	O
is	O
associated	O
with	O
poor	O
co	O
##rona	O
##ry	O
co	O
##lla	O
##teral	O
growth	O
in	O
co	O
##rona	O
##ry	O
heart	O
disease	O
patients	O
.	O

T	B
##G	I
was	O
positively	O
correlated	O
with	O
its	O
two	O
precursor	O
##s	O
D	O
##G	O
(	O
r	O
=	O
0	O
.	O
84	O
##4	O
,	O
p	O
=	O
3	O
.	O
8	O
×	O
10	O
_	O
−	O
##15	O
)	O
and	O
MG	O
(	O
r	O
=	O
0	O
.	O
61	O
##1	O
,	O
p	O
=	O
1	O
×	O
10	O
_	O
−	O
##6	O
)	O
as	O
expected	O
,	O
positively	O
valid	O
##ating	O
our	O
lip	O
##ido	O
##mic	O
##s	O
data	O
.	O

Fast	O
##ing	O
blood	O
samples	O
were	O
obtained	O
for	O
measurements	O
of	O
le	O
##pt	O
##in	O
,	O
glucose	S
,	O
insulin	O
,	O
c	O
-	O
p	O
##eptide	O
,	O
hem	O
##og	O
##lo	O
##bin	O
A1	O
##C	O
(	O
A1	O
##C	O
)	O
,	O
lip	O
##id	O
panel	O
,	O
liver	O
and	O
re	O
##nal	O
function	O
tests	O
.	O

Previous	O
reports	O
have	O
suggested	O
the	O
levels	O
of	O
l	B
##ino	I
##le	I
##ic	I
acid	I
in	O
the	O
f	O
##oll	O
##icular	O
fluid	O
significantly	O
decreased	O
during	O
f	O
##oll	O
##icle	O
size	O
increase	O
in	O
cattle	O
,	O
and	O
l	B
##ino	I
##le	I
##ic	I
acid	I
supplement	O
##ation	O
could	O
in	O
##hibit	O
b	O
##ov	O
##ine	O
cum	O
##ulus	O
expansion	O
,	O
leading	O
to	O
reduce	O
o	O
##oc	O
##yte	O
mat	O
##uration	O
and	O
developmental	O
potential	O
.	O

Ser	O
##um	O
/	O
plasma	O
specimens	O
were	O
di	O
##lut	O
##ed	O
with	O
c	O
##it	O
##rate	O
/	O
phosphate	O
buffer	O
(	O
3	O
:	O
1	O
v	O
/	O
v	O
)	O
to	O
lower	O
the	O
pH	O
to	O
5	O
.	O
3	O
in	O
order	O
to	O
separate	O
the	O
beta	B
##ine	I
and	O
T	B
##MA	I
##O	I
signals	O
which	O
overlap	O
at	O
physiological	O
pH	O
.	O
One	O
-	O
dimensional	O
(	O
1	O
##D	O
)	O
1	O
##H	O
-	O
N	O
##MR	O
s	O
##pect	O
##ra	O
were	O
recorded	O
as	O
previously	O
described	O
[	O
,	O
]	O
.	O

For	O
processing	O
the	O
sa	O
##liva	O
sample	O
to	O
remove	O
proteins	O
,	O
ace	B
##tone	I
was	O
cooled	O
to	O
-	O
20	O
##°	O
##C	O
in	O
advance	O
.	O

Three	O
other	O
minor	O
g	B
##lu	I
##cu	I
##ron	I
##ide	I
con	O
##ju	O
##gate	O
##s	O
of	O
h	O
##ydro	O
##xy	O
##lated	O
Ph	O
##IP	O
meta	O
##bol	O
##ites	O
were	O
detected	O
;	O
their	O
structures	O
are	O
unknown	O
.	O

In	O
addition	O
,	O
sleep	O
restriction	O
was	O
accompanied	O
by	O
alterations	O
in	O
try	B
##pt	I
##op	I
##han	I
metabolism	O
including	O
elevations	O
in	O
g	B
##ly	I
##cos	I
##yla	I
##ted	I
try	I
##pt	I
##op	I
##han	I
and	O
the	O
ne	O
##uro	O
##tra	O
##ns	O
##mit	O
##ter	O
se	B
##rot	I
##oni	I
##n	I
which	O
is	O
derived	O
from	O
try	B
##pt	I
##op	I
##han	I
.	O

Finally	O
,	O
the	O
slides	O
were	O
removed	O
from	O
the	O
auto	O
##sta	O
##iner	O
,	O
counters	O
##tain	O
##ed	O
with	O
hem	B
##ato	I
##xy	I
##lin	I
,	O
de	O
##hy	O
##dra	O
##ted	O
,	O
cleared	O
,	O
and	O
covers	O
##lip	O
##ped	O
.	O

Twenty	O
-	O
eight	O
of	O
the	O
meta	O
##bol	O
##ites	O
showed	O
good	O
disc	O
##rim	O
##inator	O
##y	O
power	O
for	O
non	O
-	O
di	O
##abe	O
##tic	O
versus	O
di	O
##abe	O
##tic	O
subjects	O
,	O
with	O
an	O
area	O
under	O
the	O
curve	O
(	O
AU	O
##C	O
)	O
>	O
0	O
.	O
7	O
,	O
except	O
for	O
u	B
##rea	I
(	O
9	O
)	O
and	O
two	O
l	O
##ys	O
##o	O
##PC	O
##s	O
of	O
C	B
##14	I
:	I
0	I
(	O
21	O
)	O
and	O
C	B
##20	I
:	I
3	I
(	O
29	O
)	O
(	O
Table	O
##s	O
S	O
##2	O
,	O
S	O
##3	O
and	O
Fi	O
##gs	O
.	O

In	O
##hibit	O
##ory	O
effects	O
of	O
4	B
-	I
amino	I
##py	I
##rid	I
##ine	I
on	O
c	O
##yt	O
##och	O
##rome	O
P	O
##45	O
##0	O
enzymes	O
with	O
and	O
without	O
a	O
30	O
-	O
min	O
pre	O
-	O
in	O
##cu	O
##bation	O
with	O
N	O
##AD	O
##P	O
##H	O
-	O
fortified	O
human	O
liver	O
micro	O
##some	O
##s	O
.	O

The	O
standard	O
addition	O
was	O
performed	O
for	O
serum	O
by	O
co	O
-	O
in	O
##ject	O
##ing	O
standard	O
solutions	O
of	O
ta	B
##uri	I
##ne	I
and	O
su	B
##lf	I
##ate	I
with	O
concentrations	O
within	O
the	O
range	O
of	O
0	O
.	O
5	O
-	O
5	O
.	O
0	O
,	O
and	O
5	O
.	O
0	O
-	O
20	O
μ	O
##g	O
S	O
m	O
##l	O
-	O
1	O
,	O
respectively	O
6	O
)	O

Then	O
the	O
target	O
components	O
were	O
el	O
##uted	O
in	O
1	O
.	O
0	O
m	O
##l	O
of	O
5	O
%	O
a	O
##que	O
##ous	O
met	B
##han	I
##ol	I
.	O

For	O
instance	O
,	O
e	B
##c	I
##dy	I
##son	I
##e	I
,	O
a	O
s	O
##tero	O
##id	O
produced	O
by	O
pro	O
##th	O
##ora	O
##ci	O
##c	O
glands	O
,	O
was	O
shown	O
to	O
be	O
involved	O
in	O
the	O
e	O
##pit	O
##hel	O
##ial	O
cell	O
organization	O
of	O
the	O
R	O
.	O
pro	O
##lix	O
##us	O
mid	O
##gu	O
##t	O
and	O
the	O
d	O
##ys	O
##re	O
##gu	O
##lation	O
of	O
the	O
ne	O
##uro	O
##end	O
##oc	O
##rine	O
system	O
induced	O
by	O
a	O
##zad	O
##ira	O
##cht	O
##in	O
(	O
an	O
insect	O
growth	O
inhibitor	O
that	O
blocks	O
e	O
##c	O
##dy	O
##sis	O
)	O
.	O

We	O
next	O
examined	O
the	O
effect	O
of	O
blocking	O
FA	O
##SN	O
and	O
CO	O
##X	O
-	O
2	O
on	O
major	O
cell	O
survival	O
proteins	O
such	O
as	O
p	O
-	O
E	O
##rk	O
and	O
p	B
-	I
G	I
##S	I
##K	I
##3	I
##β	I
.	O

We	O
found	O
that	O
inclusion	O
of	O
any	O
of	O
these	O
three	O
measures	O
of	O
est	B
##rogen	I
metabolism	O
in	O
a	O
model	O
app	O
##re	O
##cia	O
##bly	O
changed	O
the	O
estimated	O
absolute	O
risk	O
of	O
breast	O
cancer	O
for	O
many	O
women	O
compared	O
with	O
risk	O
predicted	O
on	O
the	O
basis	O
of	O
un	O
##con	O
##ju	O
##gated	O
est	B
##rad	I
##iol	I
alone	O
.	O

In	O
agreement	O
with	O
our	O
results	O
,	O
ch	B
##olin	I
##e	I
was	O
increased	O
in	O
a	O
meta	O
##bol	O
##omi	O
##cs	O
study	O
of	O
CS	O
##F	O
obtained	O
from	O
patients	O
with	O
MS	O
.	O

1	O
-	O
But	O
##ano	O
##l	O
/	O
met	O
##han	O
##ol	O
(	O
100	O
m	O
##L	O
,	O
1	O
:	O
1	O
v	O
/	O
v	O
)	O
containing	O
5	O
m	O
##M	O
am	B
##mon	I
##ium	I
format	I
##e	I
was	O
then	O
added	O
to	O
the	O
sample	O
,	O
v	O
##ortex	O
##ed	O
(	O
10	O
s	O
)	O
,	O
then	O
son	O
##ica	O
##ted	O
(	O
1	O
h	O
)	O
.	O

Therefore	O
,	O
the	O
elevated	O
levels	O
of	O
la	B
##ct	I
##ate	I
found	O
in	O
the	O
serum	O
of	O
N	O
##SC	O
##LC	O
patients	O
could	O
be	O
attributed	O
to	O
the	O
enormous	O
domestic	O
for	O
cell	O
proliferation	O
.	O

The	O
levels	O
of	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
(	O
H	O
##X	O
)	O
(	O
A	O
)	O
and	O
its	O
o	O
##xi	O
##da	O
##tive	O
product	O
,	O
x	B
##ant	I
##hine	I
(	O
X	O
)	O
(	O
B	O
)	O
were	O
significantly	O
lower	O
in	O
NHL	O
urine	O
##s	O
(	O
both	O
P	O
<	O
0	O
.	O
00	O
##1	O
)	O
.	O

The	O
three	O
exceptions	O
among	O
all	O
these	O
meta	O
##bol	O
##ites	O
are	O
the	O
so	O
##y	O
candidate	O
markers	O
pin	B
##ito	I
##l	I
,	O
g	B
##ua	I
##iac	I
##ol	I
,	O
and	O
cat	B
##ech	I
##ol	I
which	O
can	O
be	O
detected	O
at	O
24	O
h	O
.	O

Over	O
a	O
9	B
-	I
week	I
-	I
period	I
,	O
diet	O
##ary	O
EPA	O
+	O
D	O
##HA	O
ex	O
##ert	O
##ed	O
a	O
trans	O
##ient	O
improvement	O
of	O
glucose	S
u	O
##til	O
##ization	O
followed	O
by	O
a	O
shift	O
from	O
glucose	S
to	O
lip	O
##id	O
cat	O
##ab	O
##olis	O
##m	O
,	O
but	O
the	O
effect	O
on	O
metabolic	O
flexibility	O
is	O
difficult	O
to	O
assess	O
from	O
these	O
data	O
since	O
a	O
relatively	O
large	O
volume	O
(	O
20	O
m	O
##l	O
)	O
of	O
crude	O
fish	O
oil	O
containing	O
different	O
lip	O
##id	O
fraction	O
##s	O
besides	O
EPA	O
+	O
D	O
##HA	O
was	O
used	O
.	O

Re	B
##tina	I
##l	I
(	I
re	I
##tina	I
##lde	I
##hy	I
##de	I
;	I
Ra	I
##ld	I
)	I
is	O
derived	O
from	O
re	B
##tino	I
##l	I
(	O
vitamin	O
A	O
)	O
o	O
##xi	O
##dized	O
by	O
alcohol	O
de	O
##hy	O
##dr	O
##ogen	O
##ases	O
.	O

HC	O
##M	O
##V	O
v	O
##iri	O
##ons	O
and	O
s	O
##yna	O
##ptic	O
ve	O
##si	O
##cles	O
contain	O
similar	O
ratios	O
of	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
head	O
group	O
classes	O
(	O
i	O
.	O
e	O
.	O
,	O
both	O
have	O
higher	O
P	O
##E	O
content	O
and	O
lower	O
PS	O
)	O
.	O

Another	O
prominent	O
change	O
in	O
lung	O
SC	O
##C	O
cells	O
was	O
the	O
increases	O
in	O
the	O
accumulation	O
of	O
most	O
amino	O
acids	O
,	O
represented	O
by	O
al	B
##ani	I
##ne	I
and	O
v	B
##ali	I
##ne	I
in	O
our	O
network	O
analysis	O
.	O

De	O
##uter	O
##ated	O
ch	B
##ole	I
##ster	I
##ol	I
was	O
purchased	O
from	O
Cambridge	O
Is	O
##oto	O
##pe	O
Laboratories	O
,	O
Inc	O
.	O
(	O
Cambridge	O
,	O
MA	O
,	O
USA	O
)	O
.	O

(	O
b	O
##3	O
)	O
Pro	B
##line	I
and	O
l	B
##ys	I
##ine	I
:	O
amino	O
acids	O
that	O
participate	O
to	O
form	O
co	O
##lla	O
##gen	O
fibre	O
##s	O

G	B
##ly	I
##bur	I
##ide	I
was	O
purchased	O
from	O
Cal	O
##bio	O
##che	O
##m	O
,	O
(	O
San	O
Diego	O
,	O
CA	O
,	O
USA	O
)	O
.	O

PC	O
##s	O
and	O
SM	O
classes	O
were	O
recognized	O
in	O
MS	O
/	O
MS	O
based	O
on	O
characteristic	O
184	O
.	O
1	O
Da	O
p	B
##hos	I
##ph	I
##och	I
##olin	I
##e	I
fragment	O
##ation	O
ion	O
,	O
while	O
LP	O
##Cs	O
based	O
on	O
both	O
184	O
.	O
1	O
Da	O
p	B
##hos	I
##ph	I
##och	I
##olin	I
##e	I
and	O
104	O
.	O
1	O
ch	B
##olin	I
##e	I
fragment	O
##ation	O
ions	O
Additionally	O
,	O
other	O
spectral	O
components	O
were	O
an	O
##not	O
##ated	O
at	O
the	O
Li	O
##pid	O
##M	O
##ap	O
##s	O
database	O
based	O
on	O
their	O
registered	O
m	O
/	O
z	O
values	O
;	O
mass	O
tolerance	O
0	O
.	O
1	O

C	O
,	O
Try	B
##pt	I
##op	I
##han	I
metabolism	O
intermediate	O
##s	O
associated	O
with	O
re	O
##current	O
disease	O
(	O
p	O
value	O
<	O
0	O
.	O
05	O
)	O
.	O

We	O
substituted	O
glucose	B
-	I
1	I
-	I
phosphate	I
for	O
the	O
substrate	O
in	O
the	O
ass	O
##ay	O
.	O

This	O
imp	O
##lica	O
##tes	O
a	O
higher	O
turnover	O
of	O
the	O
K	O
##re	O
##bs	O
cycle	O
and	O
specifically	O
a	O
higher	O
capacity	O
for	O
an	O
##ap	O
##ler	O
##otic	O
p	O
##yr	O
##u	O
##vate	O
car	O
##box	O
##yla	O
##tion	O
,	O
as	O
evident	O
by	O
the	O
enhanced	O
build	O
##up	O
of	O
_	O
13	O
C	B
-	I
4	I
,	I
5	I
-	I
G	I
##lu	I
and	O
_	O
13	O
C	B
-	I
2	I
,	I
3	I
-	I
G	I
##lu	I
,	O
respectively	O
.	O

Inc	O
##reased	O
AD	B
##MA	I
and	O
SD	O
##MA	O
concentrations	O
in	O
the	O
circulation	O
of	O
I	O
##B	O
##D	O
patients	O
have	O
been	O
reported	O
in	O
an	O
isolated	O
and	O
un	O
##chal	O
##len	O
##ged	O
study	O
of	O
O	O
##w	O
##cz	O
##are	O
##k	O
et	O
al	O
.	O
,	O
in	O
which	O
both	O
meta	O
##bol	O
##ites	O
positively	O
correlated	O
with	O
clinical	O
activity	O
of	O
CD	O
and	O
systemic	O
a	B
##rg	I
##ini	I
##ne	I
show	O
no	O
significant	O
differences	O
between	O
I	O
##B	O
##D	O
patients	O
and	O
controls	O
.	O

The	O
X	O
-	O
axis	O
shows	O
the	O
groups	O
and	O
the	O
Y	O
-	O
axis	O
shows	O
α	B
-	I
H	I
##B	I
concentration	O
in	O
µ	O
##g	O
/	O
m	O
##l	O
.	O

For	O
non	O
-	O
targeted	O
pro	O
##fi	O
##ling	O
of	O
th	B
##iol	I
##s	I
,	O
we	O
recently	O
developed	O
a	O
method	O
based	O
on	O
is	O
##oto	O
##pe	O
label	O
##ing	O
-	O
high	O
performance	O
liquid	O
ch	O
##roma	O
##tography	O
-	O
double	O
precursor	O
ion	O
scan	O
-	O
mass	O
s	O
##pect	O
##rome	O
##try	O
(	O
IL	O
-	O
L	O
##C	O
-	O
D	O
##PI	O
-	O
MS	O
)	O
analysis	O
.	O

Additionally	O
,	O
we	O
found	O
an	O
association	O
of	O
B	O
##MI	O
with	O
N	B
-	I
ace	I
##ty	I
##l	I
ne	I
##ura	I
##minate	I
(	O
P	O
=	O
2	O
.	O
02	O
×	O
10	O
_	O
−	O
##16	O
)	O
,	O
a	O
h	B
##ydro	I
##ly	I
##tic	I
breakdown	O
product	O
of	O
u	O
##rina	O
##ry	O
g	B
##ly	I
##co	I
##p	I
##rote	I
##ins	I
with	O
si	B
##ali	I
##c	I
acid	I
subunit	O
##s	O
;	O
the	O
assignment	O
was	O
confirmed	O
by	O
N	O
-	O
ace	O
##ty	O
##l	O
ne	O
##ura	O
##mini	O
##das	O
##e	O
in	O
##cu	O
##bation	O
experiments	O
.	O

For	O
cellular	O
energy	O
,	O
ATP	S
synthesis	O
is	O
a	O
major	O
function	O
of	O
the	O
mit	O
##och	O
##ond	O
##ria	O
.	O

Ad	O
##v	O
Pro	B
##sta	I
##g	I
##land	I
##in	I
T	I
##hr	I
##omb	I
##ox	I
##ane	I
Le	O
##uk	O
##ot	O
Re	O
##s	O
.	O

In	O
nervous	O
tissues	O
,	O
18	O
:	O
0	O
was	O
the	O
most	O
abundant	O
FA	S
,	O
followed	O
by	O
20	O
:	O
0	O
.	O

Next	O
,	O
the	O
column	O
was	O
el	O
##uted	O
with	O
800	O
µ	O
##L	O
2	O
%	O
ace	B
##tic	I
acid	I
in	O
diet	B
##hyl	I
et	I
##her	I
to	O
a	O
new	O
tube	O
,	O
dried	O
by	O
N	O
_	O
2	O
,	O
and	O
dissolved	O
in	O
200	O
µ	O
##L	O
met	B
##han	I
##ol	I
,	O
resulting	O
in	O
a	O
fatty	O
acids	O
fraction	O
.	O

Sub	O
##jects	O
exhibited	O
a	O
broad	O
range	O
in	O
B	O
##MI	O
(	O
19	O
.	O
81	O
–	O
30	O
.	O
25	O
kg	O
/	O
m	O
_	O
2	O
)	O
and	O
waist	O
c	O
##ir	O
##cum	O
##ference	O
(	O
24	O
.	O
5	O
–	O
43	O
.	O
0	O
in	O
)	O
,	O
and	O
ranged	O
from	O
normal	O
to	O
h	B
##yper	I
##tri	I
##gly	I
##cer	I
##ide	I
##mic	I
(	O
fast	O
##ing	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
30	O
–	O
27	O
##9	O
mg	O
/	O
d	O
##l	O
)	O
.	O

We	O
performed	O
global	O
lip	O
##id	O
pro	O
##fi	O
##ling	O
to	O
understand	O
the	O
lip	O
##id	O
changes	O
in	O
A	B
##F	I
patients	O
.	O

Dec	O
##reased	O
o	O
##xi	O
##da	O
##tive	O
p	O
##hos	O
##ph	O
##ory	O
##lation	O
may	O
also	O
explain	O
the	O
reduction	O
of	O
ATP	S
levels	O
in	O
EA	O
##C	O
cells	O
in	O
##cu	O
##bate	O
##d	O
with	O
AC	O
##M	O
,	O
as	O
mitochondrial	O
re	O
##spiration	O
is	O
the	O
most	O
efficient	O
process	O
of	O
ATP	S
generation	O
.	O

Nonetheless	O
,	O
while	O
statistical	O
power	O
has	O
become	O
less	O
of	O
a	O
problem	O
,	O
achieving	O
adequate	O
accuracy	O
and	O
specific	O
##ity	O
for	O
the	O
est	B
##rad	I
##iol	I
ass	O
##ays	O
remains	O
a	O
challenge	O
.	O

Previous	O
studies	O
showed	O
that	O
met	B
##ha	I
##c	I
##ryl	I
##yl	I
-	I
co	I
##en	I
##zy	I
##me	I
A	O
(	O
MC	O
-	O
Co	O
##A	O
)	O
,	O
a	O
toxic	O
compound	O
generated	O
in	O
v	B
##ali	I
##ne	I
cat	O
##ab	O
##olis	O
##m	O
,	O
is	O
less	O
de	O
##to	O
##xi	O
##fied	O
in	O
HC	O
##C	O
or	O
c	O
##ir	O
##r	O
##hos	O
##is	O
patients	O
.	O

Independent	O
variables	O
:	O
gender	O
(	O
reference	O
category	O
:	O
men	O
(	O
0	O
)	O
vs	O
.	O
women	O
(	O
1	O
)	O
)	O
;	O
age	O
(	O
years	O
)	O
;	O
and	O
serum	O
sperm	B
##ine	I
(	O
ng	O
/	O
m	O
##L	O
)	O
.	O

Moreover	O
,	O
a	O
decrease	O
of	O
these	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
was	O
associated	O
to	O
the	O
event	O
at	O
28	O
-	O
days	O
and	O
90	O
-	O
days	O
in	O
combination	O
with	O
clinical	O
variables	O
such	O
as	O
card	O
##iovascular	O
S	O
##O	O
##FA	O
score	O
(	O
28	O
-	O
day	O
mortality	O
model	O
)	O
or	O
re	O
##nal	O
replacement	O
therapy	O
(	O
90	O
-	O
day	O
mortality	O
model	O
)	O
.	O

Beta	B
##ine	I
and	O
a	O
number	O
of	O
close	O
meta	O
##bol	O
##ites	O
in	O
the	O
one	O
-	O
carbon	O
pathway	O
were	O
selected	O
for	O
analysis	O
:	O
total	O
ho	B
##mo	I
##cy	I
##stein	I
##e	I
,	O
met	B
##hyl	I
##mal	I
##onic	I
acid	I
,	O
c	B
##ys	I
##tein	I
##e	I
,	O
met	B
##hi	I
##oni	I
##ne	I
,	O
se	B
##rine	I
,	O
g	B
##ly	I
##cine	I
,	O
c	B
##ys	I
##tat	I
##hi	I
##oni	I
##ne	I
,	O
k	B
##yn	I
##uren	I
##ine	I
(	O
anal	O
##ys	O
##ed	O
by	O
gas	O
ch	O
##roma	O
##tography	O
/	O
mass	O
s	O
##pect	O
##rome	O
##try	O
)	O
;	O
sa	B
##rc	I
##os	I
##ine	I
and	O
try	B
##pt	I
##op	I
##han	I
(	O
gas	O
ch	O
##roma	O
##tography	O
/	O
tandem	O
mass	O
s	O
##pect	O
##rome	O
##try	O
)	O
and	O
ch	B
##olin	I
##e	I
,	O
beta	B
##ine	I
,	O
dim	B
##eth	I
##yl	I
##gly	I
##cine	I
,	O
a	B
##rg	I
##ini	I
##ne	I
and	O
as	O
##ym	O
##metric	O
/	O
symmetric	O
dim	B
##eth	I
##yla	I
##rg	I
##ini	I
##ne	I
(	O
by	O
liquid	O
ch	O
##roma	O
##tography	O
/	O
tandem	O
mass	O
s	O
##pect	O
##rome	O
##try	O
)	O
.	O

We	O
found	O
no	O
statistical	O
##ly	O
significant	O
association	O
between	O
these	O
genetic	O
variants	O
and	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
g	I
##lu	I
##cu	I
##ron	I
##ide	I
formation	O
rates	O
in	O
the	O
50	O
human	O
liver	O
micro	O
##some	O
##s	O
(	O
supporting	O
)	O
.	O

F	O
.	O
p	O
##ra	O
##us	O
##nitz	O
##ii	O
might	O
be	O
important	O
not	O
only	O
for	O
its	O
provision	O
of	O
but	B
##yra	I
##te	I
to	O
the	O
host	O
but	O
also	O
due	O
to	O
the	O
release	O
of	O
high	O
inter	O
##le	O
##uki	O
##n	O
(	O
IL	O
-	O
10	O
/	O
IL	O
-	O
12	O
)	O
c	O
##yt	O
##oki	O
##ne	O
levels	O
.	O

San	B
##sal	I
##va	I
##mi	I
##de	I
(	O
72	O
)	O
,	O
isolated	O
from	O
Fu	O
##sar	O
##ium	O
s	B
##p	I
.	O
collected	O
from	O
Hal	O
##od	O
##ule	O
w	O
##right	O
##ii	O
was	O
also	O
found	O
to	O
have	O
significant	O
anti	O
##can	O
##cer	O
activity	O
against	O
the	O
National	O
Cancer	O
Institute	O
’	O
s	O
60	B
-	I
cell	I
-	I
line	I
panel	O
(	O
Bel	O
##of	O
##sky	O
et	O
al	O
.	O
1999	O
)	O
and	O
was	O
later	O
identified	O
as	O
an	O
inhibitor	O
of	O
the	O
top	O
##ois	O
##omer	O
##ase	O
I	O
by	O
H	O
##wang	O
et	O
al	O
.	O

2	B
-	I
Na	I
##ph	I
##thal	I
##ene	I
##sul	I
##fo	I
##nic	I
acid	I
was	O
successfully	O
applied	O
for	O
MA	O
##IL	O
##D	O
analysis	O
of	O
simple	O
am	O
##ines	O
.	O

The	O
pH	O
was	O
adjusted	O
to	O
7	O
with	O
am	B
##mon	I
##ium	I
bi	O
##car	O
##bon	O
##ate	O
and	O
100	O
mg	O
of	O
Na	O
##B	O
##H	O
_	O
3	O
C	O
##N	O
was	O
added	O
.	O

From	O
the	O
FA	B
vs	I
N	O
##N	O
comparison	O
–	O
the	O
v	B
##ali	I
##ne	I
relative	O
integral	O
was	O
decreased	O
for	O
the	O
FA	S
group	O
in	O
both	O
studies	O
,	O
in	O
T	O
##C	O
vs	O
N	O
##N	O
v	B
##ali	I
##ne	I
and	O
la	B
##ct	I
##ate	I
decreased	O
in	O
serum	O
for	O
the	O
T	O
##C	O
group	O
,	O
with	O
the	O
opposite	O
trend	O
in	O
the	O
tissue	O
extract	O
study	O
.	O

In	O
this	O
context	O
,	O
the	O
h	O
##ydro	O
##lysis	O
of	O
g	B
##lut	I
##amine	I
for	O
the	O
production	O
of	O
am	O
##monia	O
and	O
g	B
##lut	I
##ama	I
##te	I
to	O
balance	O
the	O
pH	O
in	O
tumor	O
cells	O
could	O
explain	O
the	O
high	O
serum	O
levels	O
of	O
g	B
##lut	I
##ama	I
##te	I
observed	O
in	O
the	O
group	O
of	O
N	O
##SC	O
##LC	O
patients	O
.	O

The	O
mass	O
s	O
##pect	O
##rome	O
##ter	O
was	O
operated	O
in	O
heated	O
electro	O
##sp	O
##ray	O
ion	O
##ization	O
(	O
H	O
##ES	O
##I	O
)	O
mode	O
with	O
a	O
spray	O
voltage	O
of	O
3	O
.	O
5	O
k	B
##V	I
,	O
a	O
cap	O
##illa	O
##ry	O
temperature	O
of	O
300	O
##°	O
##C	O
,	O
a	O
sheath	O
gas	O
flow	O
of	O
50	O
,	O
an	O
assist	O
gas	O
of	O
10	O
.	O
S	O
lens	O
RF	O
level	O
set	O
at	O
40	O
and	O
an	O
S	O
lens	O
voltage	O
set	O
at	O
25	O
V	O
.	O

Additionally	O
,	O
in	O
##tra	O
##dial	O
##ytic	O
kinetic	O
analysis	O
of	O
g	B
##uan	I
##id	I
##ine	I
showed	O
that	O
g	B
##uan	I
##id	I
##ine	I
’	I
s	I
distribution	O
volume	O
was	O
significantly	O
higher	O
than	O
u	B
##rea	I
,	O
so	O
it	O
was	O
much	O
more	O
difficult	O
to	O
be	O
cleared	O
during	O
the	O
hem	O
##od	O
##ial	O
##ys	O
##is	O
regime	O
##n	O
.	O

As	O
a	O
result	O
of	O
enhanced	O
a	O
##ero	O
##bic	O
g	O
##ly	O
##co	O
##lysis	O
,	O
cancer	O
cells	O
exhibit	O
enhanced	O
la	B
##ct	I
##ate	I
secret	O
##ion	O
,	O
so	O
we	O
further	O
evaluated	O
the	O
effect	O
of	O
M	O
##UC	O
##16	O
knock	O
##down	O
on	O
la	B
##ct	I
##ate	I
secret	O
##ion	O
.	O

Q	O
##C	O
data	O
showed	O
no	O
evidence	O
of	O
anal	O
##yte	O
degradation	O
in	O
extracted	O
plasma	O
samples	O
except	O
possibly	O
for	O
his	B
##tamine	I
and	O
s	B
##phi	I
##ngo	I
##sin	I
##e	I
both	O
of	O
which	O
showed	O
systematic	O
20	O
–	O
30	O
%	O
decrease	O
of	O
signal	O
intensity	O
throughout	O
the	O
long	O
analytical	O
batch	O
##es	O
.	O

Hence	O
,	O
it	O
seems	O
interesting	O
to	O
publish	O
our	O
results	O
on	O
20	B
-	I
H	I
##ET	I
##E	I
as	O
a	O
possible	O
meta	O
##bol	O
##ite	O
related	O
to	O
this	O
path	O
##ology	O
.	O

A	O
prospective	O
case	O
–	O
control	O
study	O
nest	O
##ed	O
within	O
the	O
Pro	O
##state	O
,	O
Lu	O
##ng	O
,	O
Color	O
##ec	O
##tal	O
,	O
and	O
O	O
##var	O
##ian	O
Cancer	O
Screen	O
##ing	O
Trial	O
examining	O
associations	O
between	O
the	O
risk	O
of	O
breast	O
cancer	O
in	O
post	O
##men	O
##op	O
##aus	O
##al	O
women	O
not	O
currently	O
using	O
men	O
##op	O
##aus	O
##al	O
hormone	O
therapy	O
and	O
serum	O
concentrations	O
of	O
15	O
est	O
##rogen	O
##s	O
and	O
est	B
##rogen	I
meta	O
##bol	O
##ites	O
,	O
in	O
un	O
##con	O
##ju	O
##gated	O
and	O
con	O
##ju	O
##gated	O
forms	O
,	O
including	O
the	O
parent	O
est	O
##rogen	O
##s	O
and	O
est	B
##rogen	I
meta	O
##bol	O
##ites	O
in	O
pathways	O
defined	O
by	O
i	O
##rre	O
##versible	O
h	O
##ydro	O
##xy	O
##lation	O
at	O
the	O
C	O
-	O
2	O
,	O
C	O
-	O
4	O
,	O
or	O
C	O
-	O
16	O
positions	O
of	O
the	O
s	O
##tero	O
##id	O
ring	O
,	O
as	O
measured	O
by	O
liquid	O
ch	O
##roma	O
##tography	O
–	O
tandem	O
mass	O
s	O
##pect	O
##rome	O
##try	O
.	O

These	O
findings	O
implicated	O
that	O
the	O
decreased	O
plasma	O
levels	O
of	O
al	B
##ani	I
##ne	I
and	O
g	B
##ly	I
##cine	I
may	O
be	O
associated	O
with	O
the	O
E	O
##LS	O
/	O
MD	O
##D	O
mechanism	O
and	O
provide	O
an	O
E	O
##LS	O
-	O
associated	O
metabolic	O
alter	O
##ation	O
in	O
disc	O
##rim	O
##inating	O
E	O
##LS	O
/	O
MD	O
##D	O
from	O
non	O
-	O
E	O
##LS	O
/	O
MD	O
##D	O
.	O

H	B
##ydro	I
##xy	I
##he	I
##xa	I
##de	I
##ce	I
##noy	I
##l	I
##car	I
##ni	I
##tine	I
;	O
32	O
.	O

In	O
β	O
-	O
g	O
##lu	O
##cu	O
##ron	O
##idas	O
##e	O
un	O
##tre	O
##ated	O
samples	O
,	O
the	O
mean	O
(	O
±	O
##SD	O
)	O
plasma	O
concentrations	O
of	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
and	O
h	B
##ydro	I
##xy	I
##ana	I
##stro	I
##zo	I
##le	I
were	O
47	O
.	O
5	O
±	O
21	O
.	O
8	O
ng	O
m	O
##l	O
_	O
−	O
##1	O
(	O
range	O
10	O
.	O
1	O
–	O
119	O
.	O
7	O
,	O
11	O
-	O
fold	O
)	O
and	O
0	O
.	O
05	O
##6	O
±	O
0	O
.	O
02	O
##9	O
ng	O
m	O
##l	O
_	O
−	O
##1	O
(	O
range	O
0	O
.	O
00	O
##24	O
–	O
0	O
.	O
03	O
##7	O
,	O
15	O
-	O
fold	O
)	O
,	O
respectively	O
.	O

Furthermore	O
,	O
we	O
do	O
not	O
have	O
any	O
information	O
or	O
measurements	O
regarding	O
the	O
diet	O
##ary	O
habits	O
(	O
especially	O
diet	O
##ary	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
amounts	O
ing	O
##ested	O
)	O
of	O
our	O
subjects	O
,	O
nor	O
do	O
we	O
have	O
any	O
q	O
##uant	O
##ification	O
of	O
in	O
##test	O
##inal	O
micro	O
##bio	O
##ta	O
composition	O
,	O
in	O
##test	O
##inal	O
barrier	O
function	O
,	O
or	O
com	O
##men	O
##sal	O
versus	O
path	O
##ob	O
##ion	O
##t	O
bacterial	O
growth	O
.	O

In	O
this	O
study	O
,	O
we	O
found	O
the	O
levels	O
of	O
α	B
-	I
to	I
##co	I
##pher	I
##ol	I
were	O
statistical	O
##ly	O
significantly	O
higher	O
in	O
CA	O
than	O
AA	O
women	O
.	O

For	O
example	O
,	O
lip	O
##ids	O
,	O
which	O
serve	O
as	O
major	O
components	O
of	O
cellular	O
membrane	O
##s	O
and	O
function	O
as	O
signaling	O
molecules	O
,	O
have	O
chemical	O
properties	O
that	O
require	O
specialized	O
analysis	O
relative	O
to	O
other	O
h	B
##ydro	I
##phi	I
##lic	I
meta	O
##bol	O
##ites	O
.	O

(	O
b	O
)	O
Joint	O
association	O
of	O
plasma	O
in	B
##os	I
##ine	I
levels	O
and	O
T	O
##CF	O
##7	O
##L	O
##2	O
-	O
r	O
##s	O
##7	O
##90	O
##31	O
##46	O
g	O
##eno	O
##type	O
##s	O
in	O
relation	O
to	O
type	O
2	O
diabetes	O
risk	O
.	O

Our	O
study	O
does	O
not	O
reveal	O
the	O
physiological	O
role	O
of	O
my	B
##rist	I
##ic	I
acid	I
(	O
one	O
of	O
several	O
saturated	O
short	O
and	O
medium	O
chain	O
fatty	O
acids	O
present	O
in	O
the	O
human	O
meta	O
##bol	O
##ome	O
)	O
.	O

3	O
##H	O
##IB	O
was	O
shown	O
to	O
promote	O
trans	B
-	I
end	I
##oth	I
##eli	I
##al	I
fatty	O
acid	O
(	O
FA	O
)	O
transport	O
and	O
subsequent	O
accumulation	O
of	O
fat	O
in	O
muscle	O
tissue	O
favor	O
##ing	O
local	O
insulin	O
resistance	O
.	O

Whilst	O
these	O
studies	O
demonstrate	O
the	O
efficacy	O
of	O
s	B
##tat	I
##ins	I
in	O
reducing	O
CO	O
##H	O
levels	O
in	O
individuals	O
with	O
pre	O
-	O
existing	O
altered	O
lip	O
##id	O
metabolism	O
,	O
supplement	O
##ation	O
with	O
car	B
##nos	I
##ine	I
preserved	O
CO	O
##H	O
levels	O
in	O
o	O
##bes	O
##e	O
and	O
over	O
##weight	O
people	O
with	O
normal	O
lip	O
##id	O
profiles	O
.	O

Met	O
##ab	O
##oli	O
##te	O
keys	O
:	O
1	O
,	O
is	B
##ole	I
##uc	I
##ine	I
;	O
2	O
,	O
le	B
##uc	I
##ine	I
;	O
3	O
,	O
v	B
##ali	I
##ne	I
;	O
4	O
,	O
la	B
##ct	I
##ate	I
;	O
5	O
,	O
th	B
##re	I
##oni	I
##ne	I
;	O
6	O
,	O
al	B
##ani	I
##ne	I
;	O
7	O
,	O
l	B
##ys	I
##ine	I
;	O
8	O
,	O
a	B
##rg	I
##ini	I
##ne	I
;	O
9	O
,	O
pro	B
##line	I
;	O
10	O
,	O
g	B
##lut	I
##ama	I
##te	I
;	O
11	O
,	O
met	B
##hi	I
##oni	I
##ne	I
;	O
12	O
,	O
g	B
##lut	I
##amine	I
;	O
13	O
,	O
c	B
##rea	I
##tine	I
;	O
14	O
,	O
ch	B
##olin	I
##e	I
;	O
15	O
,	O
g	B
##ly	I
##cine	I
;	O
16	O
,	O
t	B
##yr	I
##os	I
##ine	I
;	O
17	O
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
;	O
18	O
,	O
s	O
##cy	O
##llo	O
-	O
in	O
##os	O
##ito	O
##l	O
;	O
19	O
,	O
lip	O
##id	O
;	O
20	O
,	O
as	B
##par	I
##tate	I
;	O
21	O
,	O
as	B
##par	I
##agi	I
##ne	I
;	O
22	O
,	O
g	B
##lut	I
##ath	I
##ione	I
;	O
23	O
,	O
c	B
##ys	I
##tein	I
##e	I
;	O
24	O
,	O
p	O
##hos	O
##ph	O
##ory	O
##l	O
##cho	O
##line	O
/	O
g	O
##ly	O
##cer	O
##op	O
##hos	O
##ph	O
##och	O
##olin	O
##e	O
;	O
25	O
,	O
ta	B
##uri	I
##ne	I
;	O
26	O
,	O
my	O
##o	O
-	O
in	O
##os	O
##ito	O
##l	O
;	O
27	O
,	O
p	B
##hos	I
##ph	I
##oe	I
##than	I
##ola	I
##mine	I
;	O
28	O
,	O
u	B
##rac	I
##il	I
;	O
29	O
,	O
c	B
##yt	I
##os	I
##ine	I
;	O
30	O
,	O
is	O
##oc	O
##yt	O
##os	O
##ine	O
;	O
31	O
,	O
ace	B
##tate	I
;	O
32	O
,	O
f	B
##uma	I
##rate	I
;	O
33	O
,	O
in	B
##os	I
##ine	I
;	O
34	O
,	O
format	B
##e	I
.	O

Effect	O
sizes	O
indicate	O
the	O
association	O
magnitude	O
##s	O
in	O
units	O
of	O
1	O
-	O
SD	O
meta	O
##bol	O
##ite	O
concentration	O
per	O
1	O
-	O
kg	O
/	O
m	O
_	O
2	O
in	O
##cre	O
##ment	O
;	O
(	O
B	O
)	O
DB	B
##P	I
:	O
1	O
-	O
SD	O
meta	O
##bol	O
##ite	O
concentration	O
per	O
1	O
-	O
mm	O
H	O
##g	O
in	O
##cre	O
##ment	O
;	O
(	O
C	O
)	O

The	O
ass	O
##ay	O
is	O
sufficiently	O
sensitive	O
and	O
re	O
##p	O
##rod	O
##uc	O
##ible	O
to	O
q	O
##uant	O
##ify	O
the	O
est	B
##rogen	I
meta	O
##bol	O
##ites	O
in	O
the	O
urine	O
of	O
men	O
;	O
the	O
range	O
of	O
est	B
##rogen	I
meta	O
##bol	O
##ite	O
concentrations	O
among	O
men	O
is	O
large	O
relative	O
to	O
ass	O
##ay	O
var	O
##iability	O
.	O

The	O
main	O
above	O
-	O
mentioned	O
ways	O
leading	O
to	O
an	O
increase	O
of	O
su	B
##cci	I
##nic	I
acid	I
and	O
micro	O
##bial	O
Ph	O
##CA	O
levels	O
in	O
the	O
blood	O
in	O
se	O
##psis	O
are	O
presented	O
in	O
.	O

Digest	O
##ed	O
β	B
-	I
case	I
##in	I
fraction	O
##s	O
were	O
collected	O
off	O
-	O
line	O
and	O
no	O
additional	O
sample	O
preparation	O
was	O
performed	O
prior	O
to	O
the	O
fraction	O
being	O
injected	O
into	O
the	O
CH	O
##IP	O
system	O
.	O

S	O
##pear	O
##man	O
correlation	O
analysis	O
revealed	O
a	O
significant	O
positive	O
correlation	O
between	O
H	O
##b	O
##A	O
##1	O
##c	O
and	O
serum	O
put	B
##res	I
##cine	I
levels	O
.	O

In	O
all	O
,	O
1	O
,	O
82	O
##8	O
molecular	O
features	O
were	O
found	O
in	O
the	O
M	B
##T	I
##BE	I
extracted	O
lip	O
##id	O
fraction	O
,	O
and	O
1	O
,	O
410	O
features	O
were	O
found	O
when	O
met	B
##han	I
##ol	I
alone	O
was	O
used	O
in	O
conjunction	O
with	O
R	O
##PC	O
.	O

In	O
case	O
of	O
su	O
##lf	O
##ata	O
##se	O
,	O
only	O
modest	O
levels	O
(	O
<	O
5	O
%	O
of	O
su	O
##lf	O
##ata	O
##se	O
+	O
g	O
##lu	O
##cor	O
##inda	O
##se	O
concentrations	O
)	O
were	O
observed	O
in	O
the	O
last	O
three	O
urine	O
fraction	O
##s	O
;	O
no	O
di	B
##os	I
##met	I
##in	I
concentrations	O
were	O
measured	O
in	O
the	O
und	O
##ige	O
##sted	O
samples	O
.	O

Time	O
of	O
day	O
and	O
di	O
##urn	O
##al	O
changes	O
in	O
N	O
##AM	O
##P	O
##T	O
activity	O
influence	O
ni	B
##cot	I
##ina	I
##mi	I
##de	I
levels	O
in	O
urine	O
and	O
blood	O
.	O

The	O
method	O
is	O
similar	O
to	O
a	O
published	O
method	O
for	O
determining	O
co	B
##tin	I
##ine	I
concentrations	O
in	O
plasma	O
of	O
non	O
-	O
smoke	O
##rs	O
(	O
contains	O
a	O
detailed	O
description	O
)	O
.	O

Meanwhile	O
,	O
plasma	O
concentrations	O
of	O
T	B
##MA	I
##O	I
before	O
20	O
g	O
##esta	O
##tional	O
weeks	O
were	O
significantly	O
higher	O
among	O
women	O
with	O
G	O
##DM	O
,	O
which	O
was	O
consistent	O
with	O
the	O
results	O
of	O
the	O
initial	O
case	O
-	O
control	O
study	O
.	O

A	O
vs	O
I	O
-	B
(	I
+	I
)	I
/	I
(	I
−	I
)	I
means	O
increased	O
/	O
decreased	O
abundance	O
in	O
C	O
##LL	O
patients	O
in	O
aggressive	O
state	O
in	O
comparison	O
to	O
C	O
##LL	O
patients	O
in	O
in	O
##do	O
##lent	O
of	O
the	O
disease	O
.	O

U	B
##ric	I
acid	I
is	O
the	O
end	O
product	O
of	O
pu	B
##rine	I
metabolism	O
and	O
an	O
important	O
anti	O
##ox	O
##ida	O
##nt	O
molecule	O
(	O
,	O
)	O
.	O

Carolyn	O
M	O
.	O
S	O
##lu	O
##ps	O
##ky	O
et	O
al	O
.	O
have	O
identified	O
67	O
different	O
meta	O
##bol	O
##ites	O
,	O
which	O
are	O
linked	O
to	O
t	B
##rica	I
##rb	I
##ox	I
##yl	I
##ic	I
acid	I
cycle	O
,	O
energy	O
and	O
amino	O
acid	O
metabolism	O
.	O

SL	O
##E	O
women	O
with	O
AP	O
##O	O
(	O
Group	O
2	O
)	O
had	O
a	O
higher	O
frequency	O
of	O
anti	B
##ph	I
##os	I
##ph	I
##oli	I
##pid	I
anti	O
##body	O
syndrome	O
and	O
h	O
##yper	O
##tens	O
##ion	O
than	O
those	O
with	O
normal	O
pregnancy	O
outcome	O
(	O
Group	O
1	O
)	O
.	O

De	B
##ox	I
##ych	I
##olic	I
acid	I
was	O
elevated	O
in	O
subjects	O
with	O
liver	O
c	O
##ir	O
##r	O
##hos	O
##is	O
and	O
he	O
##pa	O
##titis	O
by	O
a	O
factor	O
of	O
1	O
.	O
45	O
whereas	O
decreased	O
in	O
HC	O
##C	O
patients	O
without	O
c	O
##ir	O
##r	O
##hos	O
##is	O
and	O
he	O
##pa	O
##titis	O
by	O
a	O
factor	O
of	O
0	O
.	O
23	O
,	O
as	O
compared	O
with	O
the	O
healthy	O
controls	O
.	O

In	O
an	O
effort	O
to	O
eliminate	O
individuals	O
with	O
possible	O
sub	O
##c	O
##lini	O
##cal	O
inflammation	O
,	O
we	O
removed	O
47	O
subjects	O
who	O
had	O
concentrations	O
of	O
CR	O
##P	O
>	O
10	O
mg	O
/	O
L	O
or	O
neo	B
##pt	I
##eri	I
##n	I
>	O
10	O
nm	O
##ol	O
/	O
L	O
.	O

The	O
influence	O
of	O
con	O
##found	O
##ing	O
factors	O
such	O
as	O
gender	O
and	O
,	O
age	O
on	O
K	B
##P	I
meta	O
##bol	O
##ite	O
concentrations	O
was	O
compared	O
between	O
C	O
##MM	O
patients	O
and	O
healthy	O
controls	O
using	O
a	O
principal	O
component	O
analysis	O
(	O
PC	O
##A	O
)	O
.	O

In	O
the	O
Pro	O
##state	O
,	O
Lu	O
##ng	O
,	O
Color	O
##ec	O
##tal	O
,	O
and	O
O	O
##var	O
##ian	O
Cancer	O
Screen	O
##ing	O
Trial	O
(	O
P	O
##LC	O
##O	O
)	O
co	O
##hor	O
##t	O
,	O
the	O
serum	O
ratio	O
of	O
2	O
-	O
h	O
##ydro	O
##xy	O
##lation	O
pathway	O
meta	O
##bol	O
##ites	O
to	O
parent	O
est	O
##rogen	O
##s	O
was	O
associated	O
with	O
a	O
28	O
%	O
reduction	O
in	O
breast	O
cancer	O
risk	O
across	O
extreme	O
de	O
##ci	O
##les	O
(	O
p	O
-	O
trend	O
=	O
.	O
05	O
)	O
,	O
after	O
adjusting	O
for	O
un	O
##con	O
##ju	O
##gated	O
est	B
##rad	I
##iol	I
and	O
breast	O
cancer	O
risk	O
factors	O
.	O

The	O
pH	O
##b	O
##A	O
##1	O
##c	O
ratio	O
reflects	O
the	O
two	O
to	O
three	O
month	O
average	O
plasma	O
glucose	S
level	O
and	O
is	O
here	O
associated	O
with	O
elevated	O
blood	O
sugar	O
independently	O
of	O
diagnosed	O
diabetes	O
.	O

PC	O
##Y	O
##T	O
##1	O
##A	O
is	O
a	O
rate	O
-	O
limiting	O
enzyme	O
for	O
PC	O
synthesized	O
via	O
the	O
Kennedy	O
pathway	O
,	O
which	O
converts	O
p	B
##hos	I
##ph	I
##och	I
##olin	I
##e	I
to	O
CDP	B
-	I
ch	I
##olin	I
##e	I
.	O

The	O
differences	O
in	O
relative	O
levels	O
for	O
each	O
of	O
the	O
6	O
meta	O
##bol	O
##ites	O
was	O
statistical	O
##ly	O
significant	O
(	O
p	O
##≤	O
##0	O
.	O
05	O
)	O
in	O
both	O
co	O
##hor	O
##ts	O
,	O
with	O
the	O
exception	O
of	O
su	B
##cci	I
##nate	I
which	O
achieved	O
a	O
p	O
-	O
value	O
of	O
0	O
.	O
05	O
##3	O
in	O
the	O
co	O
##hor	O
##t	O
2	O
comparison	O
.	O

Tu	O
##ber	O
##cid	O
##in	O
and	O
es	B
##cule	I
##tin	I
were	O
used	O
as	O
internal	O
standard	O
of	O
positive	O
mode	O
and	O
negative	O
mode	O
,	O
respectively	O
.	O

H	B
##ydro	I
##xy	I
##ana	I
##stro	I
##zo	I
##le	I
(	O
mainly	O
as	O
a	O
g	O
##lu	O
##cu	O
##ron	O
##ide	O
)	O
and	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
were	O
q	O
##uant	O
##ified	O
in	O
plasma	O
of	O
breast	O
cancer	O
patients	O
taking	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
(	O
1	O
mg	O
day	O
_	O
−	O
##1	O
)	O
;	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
g	I
##lu	I
##cu	I
##ron	I
##ide	I
was	O
less	O
apparent	O
.	O

We	O
thus	O
selected	O
23	O
from	O
the	O
162	O
healthy	O
controls	O
with	O
comparative	O
age	O
,	O
B	O
##MI	O
,	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
t	B
##rig	I
##ly	I
##cer	I
##ide	I
,	O
glucose	S
and	O
insulin	O
levels	O
to	O
the	O
T	O
##2	O
##D	O
group	O
(	O
named	O
matched	O
N	O
##G	O
##T	O
)	O
.	O

N	B
-	I
Ace	I
##to	I
##xy	I
-	I
Ph	I
##IP	I
,	O
a	O
pen	O
##ult	O
##imate	O
meta	O
##bol	O
##ite	O
of	O
Ph	O
##IP	O
that	O
forms	O
stable	O
co	O
##valent	O
add	O
##uc	O
##ts	O
at	O
app	O
##re	O
##cia	O
##ble	O
levels	O
with	O
DNA	O
,	O
_	O
,	O
was	O
the	O
least	O
efficient	O
of	O
the	O
N	O
-	O
o	O
##xi	O
##dized	O
meta	O
##bol	O
##ites	O
of	O
Ph	O
##IP	O
to	O
react	O
with	O
human	O
SA	O
and	O
form	O
stable	O
co	O
##valent	O
add	O
##uc	O
##ts	O
.	O

A	O
lower	O
survival	O
rate	O
was	O
seen	O
to	O
be	O
associated	O
with	O
elevated	O
G	O
##ly	O
and	O
la	B
##ct	I
##ate	I
,	O
indicating	O
that	O
these	O
meta	O
##bol	O
##ites	O
may	O
be	O
useful	O
as	O
bio	O
##mark	O
##ers	O
for	O
breast	O
cancer	O
pro	O
##gno	O
##sis	O
.	O

B	O
##rief	O
##ly	O
,	O
25	O
-	O
μ	O
##L	O
al	O
##iq	O
##uo	O
##ts	O
of	O
plasma	O
were	O
spike	O
##d	O
with	O
stable	O
is	O
##oto	O
##pe	O
-	O
labeled	O
h	O
##A	O
##rg	O
,	O
l	O
##A	O
##rg	O
,	O
and	O
AD	B
##MA	I
,	O
which	O
served	O
as	O
internal	O
standards	O
.	O

An	O
inspection	O
of	O
the	O
signature	O
of	O
meta	O
##bol	O
##ites	O
that	O
del	O
##ine	O
##ates	O
patients	O
3	O
and	O
10	O
revealed	O
a	O
specific	O
en	O
##rich	O
##ment	O
in	O
meta	O
##bol	O
##ites	O
derived	O
from	O
the	O
c	B
##it	I
##ric	I
acid	I
(	O
T	O
##CA	O
)	O
cycle	O
(	O
B	O
)	O
.	O

The	O
performance	O
of	O
the	O
training	O
and	O
valid	O
##ation	O
sets	O
exhibited	O
almost	O
similar	O
tendency	O
with	O
AU	O
##C	O
(	O
≥	O
0	O
.	O
85	O
,	O
which	O
was	O
a	O
high	O
value	O
)	O
,	O
except	O
c	B
##ys	I
##tein	I
##e	I
;	O
however	O
,	O
despite	O
being	O
somewhat	O
low	O
as	O
0	O
.	O
77	O
,	O
c	B
##ys	I
##tein	I
##e	I
demonstrated	O
moderate	O
accuracy	O
as	O
a	O
bio	O
##mark	O
##er	O
candidate	O
.	O

Regarding	O
insulin	O
,	O
is	B
##ole	I
##uc	I
##ine	I
was	O
positively	O
correlated	O
with	O
the	O
fast	O
##ing	O
insulin	O
(	O
r	O
:	O
0	O
.	O
37	O
##1	O
,	O
p	O
=	O
0	O
.	O
03	O
##7	O
)	O
,	O
and	O
his	B
##ti	I
##dine	I
was	O
negatively	O
associated	O
with	O
the	O
2	O
-	O
h	O
insulin	O
(	O
r	O
:	O
−	O
##0	O
.	O
35	O
##5	O
,	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
standards	O
including	O
l	O
##ys	O
##o	O
##PC	O
(	O
16	O
:	O
0	O
)	O
,	O
l	O
##ys	O
##o	O
##PC	O
(	O
17	O
:	O
0	O
)	O
,	O
l	O
##ys	O
##o	O
##PC	O
(	O
18	O
:	O
0	O
)	O
and	O
ta	B
##uro	I
##cho	I
##late	I
were	O
purchased	O
from	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
(	O
USA	O
)	O
.	O

St	O
##ero	O
##id	O
con	O
##ju	O
##gate	O
##s	O
were	O
en	O
##zy	O
##matical	O
##ly	O
h	O
##ydro	O
##ly	O
##zed	O
,	O
re	O
##ex	O
##tracted	O
,	O
and	O
chemical	O
##ly	O
der	O
##iva	O
##tized	O
to	O
form	O
met	B
##hyl	I
##ox	I
##ime	I
trim	I
##eth	I
##yl	I
si	I
##ly	I
##l	I
et	I
##hers	I
.	O

Griffin	S
et	O
al	O
.	O
reported	O
that	O
the	O
main	O
metabolic	O
changes	O
monitored	O
using	O
N	O
##MR	O
in	O
C	O
##VD	O
patients	O
were	O
derived	O
from	O
lip	O
##ids	O
in	O
lip	O
##op	O
##rote	O
##ins	O
,	O
as	O
well	O
as	O
ch	B
##olin	I
##e	I
.	O

L	O
##C	O
check	O
solutions	O
(	O
mixture	O
of	O
do	B
##de	I
##can	I
##ami	I
##de	I
;	O
11	B
-	I
de	I
##ox	I
##y	I
##cor	I
##ico	I
##ster	I
##one	I
;	O
co	B
##rt	I
##ison	I
##e	I
;	O
thy	B
##ro	I
##xin	I
##e	I
;	O
e	B
##pit	I
##est	I
##osterone	I
and	O
N	B
-	I
ben	I
##zo	I
##yl	I
-	I
D	I
-	I
p	I
##hen	I
##yla	I
##lani	I
##ne	I
)	O
,	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
,	O
g	B
##ly	I
##cho	I
##lic	I
acid	I
(	O
G	O
##CA	O
)	O
,	O
ta	B
##uro	I
##chen	I
##ode	I
##ox	I
##ych	I
##olic	I
acid	I
(	O
T	O
##CD	O
##CA	O
)	O
,	O
g	B
##ly	I
##code	I
##ox	I
##ych	I
##olic	I
acid	I
(	O
G	O
##DC	O
##A	O
)	O
,	O
g	O
##ly	O
##code	O
##ox	O
##ych	O
##olic	O
-	O
2	O
,	O
2	O
,	O
4	O
,	O
4	O
-	O
d	O
##4	O
acid	O
(	O
D	O
##4	O
_	O
G	O
##DC	O
##A	O
)	O
,	O
g	O
##ly	O
##code	O
##ox	O
##ych	O
##olic	O
-	O
2	O
,	O
2	O
,	O
4	O
,	O
4	O
-	O
d	O
##4	O
acid	O
(	O
D	O
##4	O
_	O
G	O
##CA	O
)	O
,	O
Ph	B
##e	I
-	I
Ph	I
##e	I
,	O
2	O
##C	O
_	O
13	O
_	O
Ph	B
##e	I
-	I
Ph	I
##e	I
,	O
3	O
##bet	O
##a	O
,	O
6	B
##bet	I
##a	I
-	I
di	I
##hy	I
##dr	I
##ox	I
##y	I
-	I
5	I
##bet	I
##a	I
-	I
ch	I
##ola	I
##n	I
-	I
24	I
-	I
o	I
##ic	I
acid	I
,	O
and	O
o	B
##leo	I
##yl	I
car	I
##ni	I
##tine	I
were	O
purchased	O
from	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
(	O
St	O
.	O
Louis	O
,	O
M	O
##O	O
)	O
.	O

Besides	O
,	O
they	O
initiate	O
the	O
lip	O
##id	O
per	O
##ox	O
##ida	O
##tion	O
of	O
p	O
##oly	O
##uns	O
##at	O
##ura	O
##ted	O
o	B
##me	I
##ga	I
-	I
3	I
and	O
o	B
##me	I
##ga	I
-	I
6	I
fatty	O
acids	O
,	O
which	O
serve	O
as	O
basic	O
components	O
of	O
cell	O
membrane	O
lip	O
##ids	O
,	O
whereas	O
among	O
others	O
un	O
##sat	O
##ura	O
##ted	O
and	O
saturated	O
al	O
##de	O
##hy	O
##des	O
are	O
formed	O
as	O
secondary	O
degradation	O
products	O
[	O
,	O
]	O
.	O

In	O
normal	O
tissues	O
,	O
90	O
%	O
of	O
the	O
ATP	S
comes	O
from	O
o	O
##xi	O
##da	O
##tive	O
p	O
##hos	O
##ph	O
##ory	O
##lation	O
,	O
whereas	O
only	O
10	O
%	O
comes	O
from	O
g	O
##ly	O
##co	O
##lysis	O
.	O

Sign	O
##ificant	O
inverse	O
associations	O
were	O
limited	O
to	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##och	I
##olin	I
##e	I
,	O
co	B
##tin	I
##ine	I
and	O
cat	B
##ech	I
##ol	I
su	I
##lf	I
##ate	I
(	O
Fi	O
##g	O
.	O

The	O
polar	O
and	O
non	O
-	O
polar	O
fraction	O
##s	O
were	O
further	O
der	O
##iva	O
##tized	O
with	O
O	B
-	I
met	I
##hyl	I
-	I
h	I
##ydro	I
##xy	I
##lam	I
##ine	I
h	I
##ydro	I
##ch	I
##lor	I
##ide	I
to	O
convert	O
o	O
##x	O
##o	O
-	O
groups	O
to	O
O	B
-	I
met	I
##hyl	I
##ox	I
##imes	I
,	O
and	O
subsequently	O
with	O
a	O
si	O
##ly	O
##lating	O
agent	O
(	B
N	B
-	I
met	I
##hyl	I
-	I
N	I
-	I
(	I
trim	I
##eth	I
##yl	I
##si	I
##ly	I
##l	I
)	I
t	I
##ri	I
##f	I
##lu	I
##oro	I
##ace	I
##tam	I
##ide	I
)	O
before	O
analysis	O
.	O

The	O
membrane	O
b	O
##lot	O
##s	O
were	O
blocked	O
with	O
a	O
PBS	O
/	O
T	O
##BS	O
super	O
-	O
blocking	O
buffer	O
(	O
The	O
##rm	O
##o	O
Scientific	O
)	O
including	O
1	O
%	O
p	B
##oly	I
##vin	I
##yl	I
##py	I
##rol	I
##ido	I
##ne	I
(	O
P	O
##VP	O
)	O
and	O
2	O
m	O
##M	O
Na	O
_	O
3	O
V	O
##O	O
_	O
4	O
,	O
and	O
im	O
##mu	O
##nob	O
##lot	O
##ted	O
with	O
selected	O
p	O
##oly	O
##c	O
##lon	O
##al	O
antibodies	O
.	O

The	O
AB	O
##PR	O
pressure	O
setting	O
used	O
(	O
2000	O
ps	O
##i	O
/	O
138	O
bar	O
)	O
ensured	O
that	O
on	O
-	O
column	O
phase	O
separation	O
of	O
the	O
met	B
##han	I
##ol	I
-	I
CO	I
_	I
2	I
mixture	O
was	O
not	O
expected	O
to	O
occur	O
in	O
the	O
evaluated	O
temperature	O
range	O
,	O
and	O
the	O
relatively	O
high	O
proportion	O
of	O
m	O
##od	O
##ifier	O
meant	O
that	O
the	O
mobile	O
phase	O
density	O
remained	O
predominantly	O
liquid	O
-	O
like	O
during	O
the	O
gradient	O
run	O
.	O

In	O
our	O
analysis	O
,	O
3	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##ano	I
##ic	I
acid	I
(	O
aka	O
beta	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
(	O
β	O
##OH	O
##B	O
)	O
)	O
–	O
he	O
##pa	O
##tic	O
k	B
##eton	I
##e	I
body	O
–	O
displayed	O
a	O
negative	O
association	O
with	O
H	O
##OM	O
##A	O
-	O
I	O
##R	O
.	O

G	B
##lut	I
##ama	I
##te	I
metabolism	O
does	O
not	O
include	O
results	O
from	O
the	O
Netherlands	O
Twin	O
Regis	O
##try	O
as	O
g	B
##lut	I
##amine	I
levels	O
could	O
not	O
be	O
determined	O
in	O
this	O
co	O
##hor	O
##t	O
.	O

We	O
found	O
male	O
u	O
##rina	O
##ry	O
concentrations	O
of	O
para	B
##ce	I
##tam	I
##ol	I
in	O
the	O
highest	O
q	O
##ua	O
##rt	O
##ile	O
(	O
>	O
73	O
.	O
5	O
ng	O
/	O
m	O
##l	O
)	O
to	O
be	O
consistently	O
associated	O
with	O
a	O
longer	O
T	O
##TP	O
across	O
all	O
partner	O
-	O
specific	O
and	O
couple	O
-	O
based	O
models	O
.	O

For	O
example	O
,	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##lino	I
##si	I
##to	I
##l	I
(	O
P	O
##I	O
##s	O
)	O
and	O
P	O
##I	O
derivatives	O
including	O
p	B
##hos	I
##pha	I
##ti	I
##dic	I
acid	I
(	O
PA	O
)	O
,	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dic	I
acid	I
(	O
LP	O
##A	O
)	O
,	O
and	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##lino	I
##si	I
##to	I
##l	I
phosphate	I
(	O
P	O
##IP	O
)	O
are	O
very	O
important	O
molecules	O
to	O
cellular	O
signaling	O
ca	O
##sca	O
##des	O
to	O
activate	O
proliferation	O
,	O
maintain	O
survival	O
,	O
and	O
promote	O
migration	O
.	O

The	O
absence	O
of	O
meta	O
##bol	O
##ites	O
such	O
as	O
form	B
##ic	I
acid	I
in	O
the	O
l	O
##yo	O
##phi	O
##li	O
##zed	O
samples	O
may	O
be	O
due	O
to	O
chemical	O
conversion	O
during	O
speed	O
-	O
vacuum	O
drying	O
at	O
a	O
higher	O
temperature	O
.	O

Among	O
the	O
four	O
molecules	O
targeted	O
based	O
on	O
the	O
literature	O
,	O
two	O
of	O
them	O
(	O
ma	O
##lt	O
##ol	O
,	O
su	B
##c	I
##rose	I
)	O
showed	O
significant	O
increases	O
in	O
their	O
6	O
##h	O
-	O
i	O
##A	O
##UC	O
after	O
so	O
##y	O
drink	O
intake	O
compared	O
to	O
milk	O
and	O
cheese	O
intake	O
.	O

It	O
is	O
noticeable	O
that	O
nervous	O
system	O
G	O
##G	O
##s	O
have	O
been	O
described	O
as	O
the	O
only	O
complex	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
to	O
contain	O
significant	O
amounts	O
of	O
d	O
##20	O
L	O
##C	O
##B	O
,	O
compared	O
to	O
neutral	O
g	B
##ly	I
##cos	I
##phi	I
##ngo	I
##lip	I
##ids	I
,	O
su	B
##lf	I
##ati	I
##des	I
and	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
.	O

His	B
##ti	I
##dine	I
concentrations	O
are	O
also	O
regulated	O
by	O
the	O
en	O
##zi	O
##me	O
his	O
##ti	O
##dine	O
de	O
##car	O
##box	O
##yla	O
##se	O
(	O
HD	O
##C	O
)	O
that	O
converts	O
L	B
-	I
his	I
##ti	I
##dine	I
to	O
his	B
##tamine	I
.	O

Ph	B
##os	I
##ph	I
##oli	I
##pid	I
##s	I
extraction	O
,	O
identification	O
and	O
q	O
##uant	O
##ification	O
were	O
performed	O
as	O
described	O
by	O
our	O
previous	O
publication	O
.	O

T	O
##haw	O
##ed	O
400	O
μ	O
##L	O
urine	O
samples	O
will	O
be	O
mixed	O
with	O
200	O
μ	O
##L	O
of	O
a	O
0	O
.	O
75	O
M	O
phosphate	S
buffer	O
solution	O
(	O
containing	O
0	O
.	O
5	O
%	O
sodium	B
trim	I
##eth	I
##yl	I
##si	I
##ly	I
##l	I
##p	I
##rop	I
##ion	I
##ate	I
-	I
d	I
##4	I
(	O
T	O
##SP	O
)	O
)	O
prepared	O
in	O
D	O
_	O
2	O
O	O
and	O
transferred	O
to	O
a	O
5	O
mm	O
N	O
##MR	O
tube	O
.	O

In	O
response	O
to	O
the	O
high	O
fat	O
meal	O
challenge	O
,	O
T	O
##GR	O
##L	O
characterized	O
as	O
pro	O
-	O
or	O
anti	O
-	O
at	O
##her	O
##ogenic	O
revealed	O
different	O
o	B
##xy	I
##lip	I
##in	I
signatures	O
,	O
a	O
key	O
distinguishing	O
feature	O
of	O
which	O
was	O
a	O
shift	O
in	O
the	O
relative	O
abundance	O
of	O
non	O
-	O
est	O
##eri	O
##fied	O
(	O
free	O
)	O
di	O
##ols	O
.	O

They	O
employed	O
Apollo	O
-	O
N	O
##AD	O
##P	O
_	O
+	O
to	O
show	O
an	O
increase	O
in	O
Apollo	O
-	O
N	O
##AD	O
##P	O
_	O
+	O
an	O
##imo	O
##sity	O
in	O
beta	O
cells	O
following	O
glucose	S
supplement	O
##ation	O
consistent	O
with	O
stimulation	O
of	O
the	O
o	O
##x	O
##PP	O
##P	O
and	O
N	B
##AD	I
##P	I
##H	I
production	O
.	O

Indeed	O
,	O
AD	O
patients	O
have	O
slightly	O
(	O
18	O
–	O
27	O
%	O
)	O
lowered	O
do	B
##pa	I
##mine	I
levels	O
in	O
co	O
##rt	O
##ical	O
tissues	O
and	O
the	O
hip	O
##po	O
##cam	O
##pus	O
,	O
.	O

Generally	O
,	O
inspection	O
of	O
_	O
1	O
H	O
N	O
##MR	O
s	O
##pect	O
##ra	O
of	O
A	B
##F	I
and	O
P	O
##L	O
divided	O
into	O
the	O
chemical	O
shift	O
regions	O
showed	O
the	O
greatest	O
abundance	O
of	O
the	O
following	O
meta	O
##bol	O
##ites	O
:	O
al	B
##ip	I
##hat	I
##ic	I
region	O
(	O
0	O
–	O
3	O
pp	O
##m	O
)	O
,	O
the	O
amino	O
acids	O
(	B
le	B
##uc	I
##ine	I
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
v	B
##ali	I
##ne	I
,	O
al	B
##ani	I
##ne	I
,	O
th	B
##re	I
##oni	I
##ne	I
(	O
A	O
##F	O
)	O
,	O
l	B
##ys	I
##ine	I
,	O
g	B
##lut	I
##ama	I
##te	I
(	O
A	O
##F	O
)	O
,	O
pro	B
##line	I
,	O
g	B
##lut	I
##amine	I
and	O
met	B
##hi	I
##oni	I
##ne	I
(	O
A	O
##F	O
)	O
)	O
and	O
the	O
organic	O
acids	O
(	B
2	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
(	O
A	O
##F	O
)	O
)	O
,	O
la	B
##ct	I
##ate	I
,	O
ace	B
##tate	I
,	O
p	B
##yr	I
##u	I
##vate	I
,	O
su	B
##cci	I
##nate	I
(	O
A	O
##F	O
)	O
ace	B
##to	I
##ace	I
##tate	I
(	O
P	O
##L	O
)	O
and	O
c	B
##it	I
##rate	I
(	O
A	O
##F	O
)	O
)	O
.	O

Similarly	O
,	O
tag	O
##ging	O
of	O
meta	O
##bol	O
##ites	O
in	O
human	O
urine	O
with	O
_	O
15	O
N	B
-	I
ch	I
##ola	I
##mine	I
also	O
enabled	O
the	O
detection	O
of	O
peaks	O
corresponding	O
to	O
well	O
over	O
a	O
hundred	O
car	B
##box	I
##yl	I
##ic	I
acid	I
group	O
containing	O
meta	O
##bol	O
##ites	O
.	O

Higher	O
u	O
##rina	O
##ry	O
P	O
##GE	O
-	O
M	O
levels	O
were	O
observed	O
in	O
participants	O
with	O
greater	O
tobacco	O
exposure	O
:	O
median	O
u	O
##rina	O
##ry	O
P	O
##GE	O
-	O
M	O
concentrations	O
were	O
higher	O
among	O
smoke	O
##rs	O
reporting	O
>	O
40	O
pack	O
-	O
year	O
exposure	O
(	O
20	O
.	O
3	O
ng	O
/	O
mg	O
c	O
##rea	O
##tin	O
##ine	O
)	O
versus	O
21	O
to	O
40	O
pack	O
-	O
year	O
exposure	O
(	O
15	O
.	O
4	O
ng	O
/	O
mg	O
c	O
##rea	O
##tin	O
##ine	O
)	O
and	O
<	O
20	O
pack	O
-	O
year	O
exposure	O
(	O
14	O
.	O
2	O
ng	O
/	O
mg	O
c	O
##rea	O
##tin	O
##ine	O
)	O
versus	O
the	O
u	O
##rina	O
##ry	O
P	O
##GE	O
-	O
M	O
concentration	O
of	O
never	O
smoke	O
##rs	O
(	O
9	O
.	O
9	O
ng	O
/	O
mg	O
c	B
##rea	I
##tin	I
##ine	I
;	O
)	O
.	O

End	O
##ogen	O
##ous	O
P	O
##GE	O
##M	O
was	O
q	O
##uant	O
##ified	O
by	O
using	O
the	O
[	B
_	I
2	I
H	I
_	I
6	I
]	I
-	I
O	I
-	I
met	I
##hyl	I
##ox	I
##ime	I
P	O
##GE	O
##M	O
internal	O
standard	O
,	O
and	O
P	O
##GE	O
##M	O
results	O
were	O
reported	O
as	O
na	O
##no	O
##gram	O
##s	O
per	O
mill	O
##ig	O
##ram	O
of	O
u	O
##rina	O
##ry	O
c	B
##rea	I
##tin	I
##ine	I
.	O

He	O
##ber	O
suggested	O
that	O
decreased	O
Al	O
##a	O
in	O
plasma	O
of	O
patients	O
with	O
cancer	O
is	O
due	O
to	O
the	O
increased	O
al	B
##ani	I
##ne	I
flux	O
for	O
g	O
##lu	O
##con	O
##eo	O
##genesis	O
.	O

B	O
##rief	O
##ly	O
,	O
each	O
lip	O
##id	S
extract	S
sample	S
was	S
prepared	S
from	S
100	S
##μ	S
##l	S
of	S
plasma	S
that	S
was	S
mixed	S
with	S
900	S
##μ	S
##l	S
of	S
ch	S
##lor	O
##of	O
##orm	O
-	O
met	O
##han	O
##ol	O
(	O
5	O
:	O
4	O
v	O
/	O
v	O
)	O
,	O
followed	O
by	O
200	O
##μ	O
##l	O
of	O
1	O
##M	O
KC	O
##l	O
.	O

The	O
normal	O
range	O
of	O
serum	O
c	B
##rea	I
##tin	I
##ine	I
is	O
0	O
.	O
5	O
–	O
1	O
.	O
6	O
mg	O
/	O
d	O
##l	O

In	O
our	O
study	O
,	O
car	B
##ni	I
##tine	I
(	I
18	I
:	I
1	I
)	I
and	O
ace	B
##ty	I
##l	I
car	I
##ni	I
##tine	I
were	O
both	O
significantly	O
increased	O
,	O
while	O
de	B
##cano	I
##yl	I
car	I
##ni	I
##tine	I
was	O
found	O
decreased	O
in	O
CR	O
##C	O
patients	O
.	O

The	O
expression	O
level	O
if	O
H	O
##IF	O
-	O
1	O
can	O
be	O
induced	O
in	O
response	O
to	O
reduced	O
oxygen	O
availability	O
and	O
other	O
s	O
##ti	O
##mu	O
##lants	O
(	O
such	O
as	O
ni	B
##tric	I
oxide	I
(	O
NO	O
)	O
or	O
various	O
growth	O
factors	O
)	O
in	O
metabolic	O
processes	O
.	O

A	O
very	O
prominent	O
molecular	O
signature	O
associated	O
with	O
h	O
##s	O
##CR	O
##P	O
consisted	O
of	O
l	B
##ys	I
##og	I
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##p	I
##ds	I
with	O
ch	B
##olin	I
##e	I
(	O
l	O
##ys	O
##o	O
##PC	O
)	O
,	O
in	B
##os	I
##ito	I
##l	I
,	O
or	O
ethanol	B
##amine	I
as	O
the	O
head	O
-	O
group	O
and	O
un	O
##sat	O
##ura	O
##ted	O
fatty	O
acids	O
as	O
residues	O
merely	O
in	O
an	O
inverse	O
manner	O
.	O

The	O
prediction	O
models	O
indicated	O
that	O
64	O
##4	O
(	O
7	O
.	O
0	O
%	O
)	O
of	O
9	O
,	O
260	O
urine	O
s	O
##pect	O
##ra	O
contained	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
meta	O
##bol	O
##ites	O
and	O
38	O
##2	O
(	O
4	O
.	O
1	O
%	O
)	O
contained	O
i	B
##bu	I
##p	I
##ro	I
##fen	I
meta	O
##bol	O
##ites	O
.	O

In	O
another	O
example	O
,	O
median	O
concentrations	O
of	O
donor	O
A	O
##O	O
with	O
respect	O
to	O
c	B
##rea	I
##tin	I
##ine	I
,	O
3	B
-	I
h	I
##ydro	I
##xy	I
##is	I
##ova	I
##ler	I
##ate	I
,	O
al	B
##ani	I
##ne	I
,	O
c	B
##it	I
##rate	I
,	O
dim	B
##eth	I
##yla	I
##mine	I
,	O
g	B
##ly	I
##cine	I
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
la	O
##ct	O
##ate	O
/	O
th	O
##re	O
##oni	O
##ne	O
,	O
le	B
##uc	I
##ine	I
,	O
and	O
v	B
##ali	I
##ne	I
are	O
consistently	O
at	O
the	O
lower	O
end	O
within	O
the	O
panel	O
.	O

This	O
is	O
consistent	O
with	O
reports	O
in	O
o	O
##li	O
##gos	O
##per	O
##mic	O
men	O
showing	O
that	O
treatment	O
with	O
S	B
-	I
ad	I
##eno	I
##sy	I
##lm	I
##eth	I
##ion	I
##ine	I
,	O
a	O
p	B
##oly	I
##amine	I
precursor	O
,	O
leads	O
to	O
an	O
increase	O
in	O
p	B
##oly	I
##amine	I
content	O
and	O
improved	O
sperm	O
m	O
##ot	O
##ility	O
.	O

The	O
super	O
##nat	O
##ant	O
was	O
dried	O
under	O
a	O
gentle	O
nitrogen	O
flow	O
using	O
M	O
##U	O
##LT	O
##I	O
##VA	O
##P	O
nitrogen	O
e	O
##va	O
##por	O
##ator	O
(	O
Organ	O
##oma	O
##tion	O
Associates	O
,	O
Inc	O
.	O
,	O
Berlin	O
,	O
MA	O
,	O
USA	O
)	O
and	O
then	O
re	O
##con	O
##stituted	O
by	O
adding	O
100	O
μ	O
##L	O
of	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
in	O
water	O
followed	O
by	O
in	O
##cu	O
##bation	O
on	O
an	O
ice	O
bath	O
for	O
15	O
min	O
.	O

A	B
##rg	I
##ini	I
##ne	I
,	O
ni	B
##tric	I
oxide	I
,	O
co	O
##rona	O
##ry	O
artery	O
disease	O
,	O
pro	O
##gno	O
##sis	O

In	O
addition	O
,	O
subjects	O
who	O
use	O
chronic	O
medication	O
,	O
such	O
as	O
the	B
##op	I
##hyl	I
##line	I
,	O
ant	O
##ac	O
##ids	O
,	O
iron	O
,	O
or	O
vitamin	O
##s	O
were	O
excluded	O
.	O

In	O
accordance	O
with	O
this	O
finding	O
,	O
Bus	O
##etto	O
and	O
colleagues	O
reported	O
that	O
L	B
-	I
car	I
##ni	I
##tine	I
,	O
ace	B
##ty	I
##l	I
-	I
L	I
-	I
car	I
##ni	I
##tine	I
,	O
vitamin	O
##s	O
and	O
zinc	O
diet	O
supplement	O
##ation	O
has	O
a	O
beneficial	O
effect	O
on	O
sperm	O
concentration	O
and	O
sperm	O
m	O
##ot	O
##ility	O
in	O
men	O
with	O
abnormal	O
sperm	O
##io	O
##gram	O
##s	O
that	O
show	O
o	O
##li	O
##go	O
-	O
,	O
as	O
##the	O
##no	O
-	O
,	O
or	O
te	O
##rato	O
##zo	O
##os	O
##per	O
##mia	O
.	O

The	O
la	B
##ct	I
##ose	I
values	O
in	O
urine	O
in	O
the	O
middle	O
right	O
panel	O
were	O
consequently	O
calculated	O
by	O
excluding	O
subjects	O
11	O
and	O
20	O
.	O

To	O
identify	O
factors	O
that	O
affect	O
est	B
##rogen	I
meta	O
##bol	O
##ite	O
concentrations	O
we	O
performed	O
correlation	O
analyses	O
in	O
the	O
healthy	O
control	O
group	O
.	O

Both	O
β	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yric	I
acid	I
and	O
ace	B
##to	I
##ace	I
##tate	I
levels	O
were	O
increased	O
in	O
the	O
blood	O
of	O
the	O
patients	O
with	O
MS	O
;	O
it	O
is	O
noteworthy	O
that	O
a	O
k	O
##eto	O
##genic	O
diet	O
has	O
been	O
proposed	O
in	O
many	O
ne	O
##uro	O
##de	O
##gene	O
##rative	O
diseases	O
.	O

Box	O
and	O
w	O
##his	O
##ker	O
plots	O
of	O
compounds	O
different	O
between	O
ch	O
##ola	O
##ng	O
##io	O
##car	O
##cin	O
##oma	O
(	O
CC	O
##A	O
)	O
cases	O
and	O
ben	O
##ign	O
controls	B
–	I
car	I
##ni	I
##tine	I
species	O
.	O

These	O
results	O
show	O
the	O
capability	O
of	O
A	B
##F	I
##4	I
-	I
MA	I
##LS	I
-	I
DL	I
##S	I
to	O
character	O
##ize	O
the	O
size	O
distribution	O
of	O
L	O
##D	O
##L	O
from	O
human	O
plasma	O
before	O
or	O
after	O
isolation	O
by	O
UC	O
.	O

DS	O
##S	O
-	O
d	O
##6	O
,	O
sodium	B
2	I
,	I
2	I
-	I
dim	I
##eth	I
##yl	I
-	I
2	I
-	I
si	I
##lap	I
##ent	I
##ane	I
-	I
5	I
-	I
su	I
##lf	I
##ona	I
##te	I
-	I
d	I
##6	I
.	O

In	O
our	O
series	O
,	O
C	B
##18	I
:	I
1	I
,	O
C	B
##18	I
:	I
1	I
(	I
OH	I
)	I
and	O
C	O
##16	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
levels	O
increased	O
in	O
G	O
##C	O
patients	O
according	O
to	O
H	O
.	O
p	O
##yl	O
##ori	O
infection	O
(	O
a	O
)	O
,	O
suggesting	O
a	O
positive	O
correlation	O
between	O
these	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
and	O
the	O
bacterium	O
presence	O
.	O

More	O
recently	O
,	O
T	B
##ili	I
##n	I
et	O
al	O
.	O
reported	O
ethnic	O
##al	O
differences	O
in	O
the	O
blood	O
levels	O
of	O
these	O
amino	O
acids	O
and	O
suggested	O
that	O
these	O
differences	O
may	O
add	O
ex	O
##p	O
##lana	O
##tory	O
insights	O
into	O
the	O
increased	O
risk	O
of	O
diabetes	O
in	O
South	O
Asian	O
populations	O
compared	O
with	O
Europeans	O
.	O

Consequently	O
,	O
throughout	O
the	O
method	O
p	B
##oly	I
##p	I
##rop	I
##yle	I
##ne	I
via	O
##ls	O
and	O
utilities	O
were	O
used	O
.	O

The	O
methods	O
for	O
8	B
-	I
is	I
##o	I
-	I
P	I
##G	I
##F	I
_	I
2	I
##α	I
and	O
P	O
##GE	O
-	O
M	O
were	O
valid	O
##ated	O
in	O
our	O
laboratory	O
.	O

Ph	B
##os	I
##pha	I
##ti	I
##dy	I
##let	I
##han	I
##ola	I
##mine	I
##s	I
(	O
P	O
##Es	O
)	O
are	O
the	O
primary	O
lip	O
##id	O
components	O
of	O
the	O
inner	O
bacterial	O
membrane	O
,	O
and	O
an	O
increase	O
in	O
P	O
##E	O
levels	O
is	O
in	O
##dicative	O
of	O
significant	O
cell	O
injury	O
.	O

In	O
addition	O
to	O
_	O
13	O
C	O
-	O
labeled	O
p	B
##yr	I
##u	I
##vate	I
,	O
other	O
molecules	O
have	O
been	O
successfully	O
h	O
##yper	O
##pol	O
##ari	O
##zed	O
and	O
their	O
metabolic	O
images	O
have	O
been	O
obtained	O
.	O

Kid	O
##ney	O
needle	O
bio	O
##ps	O
##ies	O
were	O
obtained	O
from	O
re	O
##nal	O
tumor	O
tissue	O
and	O
ben	O
##ign	O
kidney	O
tissue	O
post	O
-	O
ne	O
##ph	O
##re	O
##ct	O
##omy	O
using	O
an	O
18	O
gauge	O
needle	O
and	O
placed	O
directly	O
into	O
met	B
##han	I
##ol	I
.	O

These	O
pathways	O
included	O
al	B
##ani	I
##ne	I
,	O
as	B
##par	I
##tate	I
and	O
g	B
##lut	I
##ama	I
##te	I
metabolism	O
,	O
D	B
-	I
g	I
##lut	I
##amine	I
and	O
D	B
-	I
g	I
##lut	I
##ama	I
##te	I
metabolism	O
,	O
l	B
##ys	I
##ine	I
degradation	O
,	O
amino	B
##acy	I
##l	I
-	I
t	I
##RNA	I
bio	O
##sy	O
##nt	O
##hesis	O
,	O
and	O
car	O
##bo	O
##hy	O
##dra	O
##te	O
metabolism	O
(	O
star	O
##ch	O
and	O
su	B
##c	I
##rose	I
metabolism	O
,	O
g	O
##ly	O
##co	O
##lysis	O
,	O
or	O
g	O
##lu	O
##con	O
##eo	O
##genesis	O
)	O
.	O

_	O
b	O
Low	O
Back	O
Pain	O
(	O
n	O
=	O
2	O
)	O
,	O
Sa	O
##c	O
##roi	O
##le	O
##itis	O
(	O
n	O
=	O
1	O
)	O
,	O
Pol	O
##yar	O
##th	O
##rit	O
##is	O
(	O
n	O
=	O
6	O
)	O
,	O
P	O
##sor	O
##ias	O
##ic	O
Art	O
##hr	O
##itis	O
(	O
n	O
=	O
1	O
)	O
,	O
Go	O
##nal	O
##gie	O
(	O
n	O
=	O
1	O
)	O
,	O
Cox	B
##art	I
##hr	I
##itis	I
(	O
n	O
=	O
1	O
)	O
.	O

Many	O
studies	O
have	O
shown	O
that	O
la	B
##ct	I
##ate	I
is	O
also	O
an	O
important	O
o	O
##besity	O
-	O
associated	O
meta	O
##bol	O
##ite	O
.	O

For	O
example	O
,	O
glucose	S
traits	O
and	O
the	O
inflammation	O
marker	O
g	O
##ly	O
##co	O
##p	O
##rote	O
##in	O
ace	O
##ty	O
##ls	O
were	O
similarly	O
associated	O
with	O
risk	O
of	O
I	O
##CH	O
as	O
to	O
risk	O
of	O
MI	O
and	O
IS	O
.	O

Given	O
recent	O
developments	O
in	O
treatment	O
practice	O
,	O
da	O
##bra	O
##fen	O
##ib	O
is	O
frequently	O
administered	O
together	O
with	O
tram	B
##eti	I
##ni	I
##b	I
.	O

O	O
##PL	O
##S	O
-	O
D	O
##A	O
,	O
or	O
##th	O
##ogo	O
##nal	O
partial	O
squares	O
disc	O
##rim	O
##ina	O
##nt	O
analysis	O
;	O
non	O
-	O
H	O
##FS	O
,	O
non	O
-	O
supplemented	O
group	O
;	O
H	O
##FS	O
,	O
high	O
fat	O
supplement	O
group	O
;	O
pre	O
##DC	O
,	O
day	O
before	O
discharge	O
;	O
post	O
##DC	O
,	O
first	O
out	O
##patient	O
visit	O
day	O
after	O
discharge	O
;	O
L	O
##ys	O
##o	O
##PC	O
,	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
;	O
SM	O
,	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
;	O
P	O
##E	O
,	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##let	I
##han	I
##ola	I
##mine	I
;	O
N	O
##RI	O
,	O
nutrition	O
##al	O
risk	O
index	O
.	O

The	O
cells	O
were	O
culture	O
##d	O
in	O
p	B
##hen	I
##ol	I
red	O
free	O
D	O
##ME	O
##M	O
/	O
F1	O
##2	O
medium	O
(	O
G	O
##ib	O
##co	O
/	O
In	O
##vi	O
##tro	O
##gen	O
,	O
B	O
##red	O
##a	O
,	O
the	O
Netherlands	O
)	O
containing	O
10	O
%	O
(	O
v	O
/	O
v	O
)	O
f	O
##etal	O
calf	O
serum	O
(	O
MP	O
B	O
##io	O
##medical	O
##s	O
,	O
U	O
##den	O
,	O
the	O
Netherlands	O
)	O
,	O
insulin	O
(	O
5	O
µ	O
##g	O
/	O
m	O
##l	O
)	O
,	O
transfer	O
##rin	O
(	O
5	O
µ	O
##g	O
/	O
m	O
##l	O
)	O
,	O
se	O
##len	O
##ium	O
(	O
5	O
ng	O
/	O
m	O
##l	O
)	O
,	O
h	B
##ydro	I
##cor	I
##tis	I
##one	I
(	O
36	O
ng	O
/	O
m	O
##l	O
)	O
,	O
e	O
##pit	O
##hel	O
##ial	O
growth	O
factor	O
(	O
10	O
ng	O
/	O
m	O
##l	O
)	O
,	O
and	O
t	O
##ri	O
-	O
i	O
##od	O
##oth	O
##yr	O
##oni	O
##ne	O
(	O
40	O
p	O
##g	O
/	O
m	O
##l	O
)	O
at	O
33	O
##°	O
##C	O
in	O
a	O
5	O
%	O
(	O
v	O
/	O
v	O
)	O
CO	O
_	O
2	O
atmosphere	O
.	O

In	O
order	O
to	O
separate	O
this	O
interfering	O
anal	O
##yte	O
(	O
s	O
)	O
from	O
24	B
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
,	O
met	B
##hyl	I
##amine	I
was	O
added	O
to	O
the	O
mobile	O
phase	O
in	O
the	O
liquid	O
ch	O
##roma	O
##tography	O
method	O
.	O

The	O
lip	O
##id	O
-	O
rich	O
met	B
##han	I
##ol	I
-	I
ch	I
##lor	I
##of	I
##orm	I
fraction	O
(	O
bottom	O
phase	O
after	O
low	O
temperature	O
exposure	O
)	O
was	O
e	O
##va	O
##porated	O
using	O
a	O
high	O
-	O
speed	O
vacuum	O
cent	O
##ri	O
##fu	O
##ge	O
;	O
dried	O
lip	O
##id	O
extract	O
##s	O
were	O
dissolved	O
in	O
0	O
.	O
6	O
m	O
##l	O
of	O
de	O
##uter	O
##ated	O
met	O
##han	O
##ol	O
:	O
ch	O
##lor	O
##of	O
##orm	O
(	O
1	O
:	O
2	O
vol	O
/	O
vol	O
)	O
and	O
cent	O
##ri	O
##fu	O
##ged	O
and	O
transferred	O
into	O
5	O
-	O
mm	O
N	O
##MR	O
tubes	O
.	O

All	O
dough	O
##s	O
had	O
lower	O
levels	O
of	O
r	B
##af	I
##fin	I
##ose	I
and	O
ma	B
##lt	I
##ose	I
than	O
their	O
corresponding	O
bread	O
products	O
,	O
which	O
is	O
consistent	O
with	O
their	O
use	O
as	O
substrates	O
during	O
proof	O
##ing	O
.	O

These	O
modified	O
meta	O
##bol	O
##ites	O
revealed	O
disturbance	O
of	O
g	O
##ly	O
##co	O
##lysis	O
,	O
g	O
##lut	O
##ami	O
##no	O
##lysis	O
,	O
T	O
##CA	O
,	O
amino	O
acids	O
and	O
ch	B
##olin	I
##e	I
metabolism	O
,	O
which	O
were	O
correlated	O
with	O
the	O
occurrence	O
and	O
development	O
of	O
human	O
gas	O
##tric	O
cancer	O
.	O

In	O
the	O
liver	O
,	O
g	B
##ly	I
##co	I
##lic	I
acid	I
is	O
generated	O
from	O
et	B
##hyl	I
##ene	I
g	I
##ly	I
##co	I
##l	I
by	O
enzymes	O
,	O
alcohol	O
de	O
##hy	O
##dr	O
##ogen	O
##ase	O
and	O
al	O
##de	O
##hy	O
##de	O
de	O
##hy	O
##dr	O
##ogen	O
##ase	O
;	O
and	O
then	O
is	O
meta	O
##bol	O
##ized	O
to	O
o	B
##xa	I
##lic	I
acid	I
by	O
enzymes	O
,	O
g	B
##ly	I
##cola	I
##te	I
o	O
##xi	O
##das	O
##e	O
and	O
g	O
##ly	O
##cola	O
##te	O
de	O
##hy	O
##dr	O
##ogen	O
##ase	O
.	O

In	O
the	O
lower	O
m	O
/	O
z	O
region	O
,	O
fatty	O
a	O
##cy	O
##l	O
an	O
##ions	O
,	O
i	O
.	O
e	O
.	O
C	B
##16	I
:	I
0	I
(	O
m	O
/	O
z	O
255	O
)	O
and	O
C	B
##18	I
:	I
1	I
(	O
m	O
/	O
z	O
281	O
)	O
,	O
were	O
detected	O
at	O
lower	O
relative	O
abundance	O
##s	O
.	O

This	O
assumption	O
is	O
further	O
supported	O
by	O
high	O
partial	O
correlation	O
between	O
X	O
-	O
105	O
##10	O
and	O
other	O
Met	O
##ab	O
##olo	O
##n	O
s	B
##phi	I
##ngo	I
##lip	I
##id	I
molecules	O
and	O
genetic	O
associations	O
to	O
a	O
second	O
s	B
##phi	I
##ngo	I
##lip	I
##id	I
related	O
gene	O
in	O
Shin	O
et	O
al	O
.	O
.	O

Because	O
the	O
_	O
15	O
N	B
-	I
ch	I
##ola	I
##mine	I
and	O
the	O
previously	O
used	O
_	O
15	O
N	B
-	I
ethanol	I
##amine	I
differ	O
only	O
in	O
their	O
terminal	O
group	O
,	O
the	O
tag	O
##ging	O
efficiency	O
,	O
re	O
##p	O
##rod	O
##uc	O
##ibility	O
and	O
chemical	O
shift	O
values	O
for	O
meta	O
##bol	O
##ites	O
with	O
_	O
15	O
N	B
-	I
ch	I
##ola	I
##mine	I
tag	O
were	O
similar	O
to	O
those	O
obtained	O
using	O
the	O
_	O
15	O
N	B
-	I
ethanol	I
##amine	I
tag	O
.	O

(	O
17	O
)	O
,	O
ne	B
##ct	I
##ria	I
##fu	I
##rone	I
-	I
8	I
-	I
met	I
##hyl	I
et	I
##her	I
(	O
18	O
)	O
,	O
9	O
-	O
O	O
-	O
met	O
##hyl	O
f	O
##usa	O
##ru	O
##bin	O
(	O
19	O
)	O
,	O
b	O
##ost	O
##ry	O
##co	O
##id	O
##in	O
(	O
12	O
)	O
,	O
and	O
b	B
##ost	I
##ry	I
##co	I
##id	I
##in	I
-	I
9	I
-	I
met	I
##hyl	I
et	I
##her	I
(	O
20	O
)	O
were	O
isolated	O
from	O
potent	O
extract	O
of	O
F	O
.	O
pro	O
##life	O
##rat	O
##um	O
,	O
end	O
##op	O
##hy	O
##te	O
of	O
S	O
##y	O
##zy	O
##gi	O
##um	O
cord	O
##at	O
##um	O
(	O
Dame	O
et	O
al	O
.	O
2016	O
)	O
.	O

However	O
,	O
in	O
the	O
present	O
investigation	O
there	O
was	O
no	O
difference	O
in	O
f	B
##olate	I
or	O
met	B
##hyl	I
##mal	I
##onic	I
acid	I
levels	O
between	O
re	O
##current	O
and	O
non	O
-	O
re	O
##current	O
groups	O
.	O

In	O
our	O
population	O
based	O
Young	O
Finn	O
##s	O
Study	O
(	O
Y	O
##FS	O
)	O
sample	O
,	O
we	O
have	O
recently	O
observed	O
that	O
alcohol	O
consumption	O
was	O
significantly	O
associated	O
with	O
the	O
prevalence	O
of	O
FL	O
only	O
in	O
normal	O
-	O
weight	O
individuals	O
,	O
whereas	O
in	O
over	O
##weight	O
or	O
o	O
##bes	O
##e	O
subjects	O
the	O
most	O
significant	O
co	O
##rrel	O
##ates	O
of	O
FL	O
were	O
body	O
mass	O
index	O
(	O
B	O
##MI	O
)	O
and	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
.	O

P	B
##uri	I
##ne	I
and	O
p	B
##yr	I
##im	I
##id	I
##ine	I
metabolism	O
were	O
also	O
abnormal	O
in	O
E	O
##SC	O
##C	O
patients	O
relative	O
to	O
controls	O
.	O

SP	O
##Ms	O
and	O
other	O
o	B
##xy	I
##lip	I
##ins	I
were	O
q	O
##uant	O
##ified	O
in	O
per	B
##ito	I
##nea	I
##l	I
dial	O
##ys	O
##ate	O
and	O
serum	O
samples	O
,	O
which	O
were	O
obtained	O
from	O
patients	O
with	O
end	O
stage	O
re	O
##nal	O
disease	O
treated	O
by	O
per	B
##ito	I
##nea	I
##l	I
dial	O
##ys	O
##is	O
(	O
PD	O
)	O
as	O
re	O
##nal	O
replacement	O
therapy	O
(	O
Ella	O
##m	O
and	O
W	O
##il	O
##kie	O
,	O
)	O
with	O
(	O
per	O
##ito	O
##ni	O
##tis	O
,	O
n	O
=	O
4	O
–	O
5	O
)	O
and	O
without	O
(	O
control	O
,	O
n	O
=	O
4	O
–	O
5	O
)	O
acute	O
inflammation	O
.	O

[	O
,	O
,	O
]	O
Di	O
##st	O
##ur	O
##ban	O
##ce	O
in	O
the	O
metabolic	O
pathways	O
of	O
bi	O
##le	O
acid	O
derivatives	O
such	O
as	O
su	B
##lf	I
##oli	I
##th	I
##och	I
##oly	I
##l	I
##gly	I
##cine	I
could	O
contribute	O
to	O
the	O
changes	O
in	O
ch	B
##oly	I
##l	I
##gly	I
##cine	I
,	O
while	O
variation	O
in	O
3	O
-	O
h	O
##ydro	O
##xy	O
##acy	O
##l	O
-	O
Co	O
##A	O
de	O
##hy	O
##dr	O
##ogen	O
##ase	O
activity	O
might	O
be	O
responsible	O
for	O
relative	O
differences	O
of	O
3	B
-	I
h	I
##ydro	I
##xy	I
##cap	I
##ric	I
acid	I
we	O
observe	O
in	O
HC	O
##C	O
/	O
HC	O
##V	O
patients	O
.	O

We	O
observed	O
increased	O
amounts	O
of	O
s	B
##cy	I
##llo	I
-	I
in	I
##os	I
##ito	I
##l	I
,	O
my	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
,	O
and	O
h	B
##y	I
##pot	I
##au	I
##rine	I
,	O
which	O
are	O
related	O
to	O
o	O
##smo	O
##re	O
##gu	O
##lation	O
and	O
tumor	O
volume	O
alterations	O
.	O

However	O
,	O
its	O
elevation	O
in	O
urine	O
evidence	O
##s	O
a	O
deficiency	O
of	O
the	O
activity	O
of	O
Trans	O
##aldo	O
##lase	O
—	O
a	O
key	O
enzyme	O
in	O
the	O
pen	B
##tos	I
##e	I
phosphate	I
pathway	O
.	O

Several	O
early	O
studies	O
have	O
showed	O
that	O
PD	O
patients	O
have	O
slightly	O
decreased	O
concentrations	O
of	O
le	B
##uc	I
##ine	I
and	O
is	B
##ole	I
##uc	I
##ine	I
in	O
their	O
CS	O
##F	O
and	O
plasma	O
.	O

For	O
in	O
##tra	O
##ven	O
##ous	O
administration	O
,	O
v	O
##ino	O
##rel	O
##bine	O
supplied	O
as	O
10	O
mg	O
/	O
m	O
##l	O
via	O
##ls	O
(	O
Na	O
##vel	O
##bine	O
_	O
®	O
i	O
.	O
v	O
.	O
)	O
was	O
re	O
##con	O
##stituted	O
in	O
normal	O
sa	B
##line	I
a	O
##que	O
##ous	O
solution	O
and	O
in	O
##fused	O
in	O
##tra	O
##ven	O
##ously	O
over	O
6	O
–	O
10	O
min	O
after	O
thorough	O
di	O
##lution	O
and	O
under	O
close	O
supervision	O
.	O

Therefore	O
,	O
plasma	O
ne	B
##r	I
##von	I
##ic	I
acid	I
is	O
a	O
good	O
candidate	O
diagnostic	O
bio	O
##mark	O
##er	O
for	O
MD	O
##D	O
.	O

Medical	O
treatment	O
for	O
the	O
H	O
##F	O
patients	O
consisted	O
of	O
di	O
##ure	O
##tics	O
(	O
71	O
.	O
7	O
%	O
)	O
,	O
β	O
-	O
block	O
##ers	O
(	O
73	O
.	O
9	O
%	O
)	O
,	O
an	B
##gio	I
##tens	I
##in	I
converting	O
enzyme	O
inhibitor	O
##s	O
or	O
an	B
##gio	I
##tens	I
##in	I
II	I
receptor	O
block	O
##er	O
(	O
69	O
.	O
6	O
%	O
)	O
,	O
and	O
s	B
##tat	I
##ins	I
(	O
28	O
.	O
3	O
%	O
)	O
.	O

The	O
relationship	O
between	O
he	B
##xa	I
##de	I
##cane	I
##dio	I
##ate	I
levels	O
and	O
H	O
##F	O
in	O
both	O
an	O
##ces	O
##tries	O
remained	O
significant	O
even	O
in	O
those	O
without	O
a	O
history	O
of	O
previous	O
my	O
##oc	O
##ard	O
##ial	O
in	O
##far	O
##ction	O
.	O

This	O
means	O
that	O
the	O
β	B
-	I
g	I
##lu	I
##cu	I
##ron	I
##ide	I
and	O
su	B
##lf	I
##ate	I
con	O
##ju	O
##gate	O
##s	O
(	O
7	O
.	O
9	O
p	O
##g	O
/	O
m	O
##L	O
,	O
)	O
were	O
lower	O
than	O
the	O
corresponding	O
un	O
##con	O
##ju	O
##gated	O
serum	O
E	O
##2	O
concentration	O
in	O
the	O
male	O
subjects	O
.	O

The	O
ratio	O
between	O
the	O
area	O
of	O
the	O
target	O
compound	O
and	O
area	O
of	O
the	O
IS	O
was	O
multi	O
##plied	O
by	O
the	O
known	O
IS	O
concentration	O
to	O
q	O
##uant	O
##ify	O
the	O
various	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
.	O

The	O
only	O
non	O
-	O
Tor	O
##us	O
columns	O
to	O
show	O
comparable	O
median	O
peak	O
width	O
reduction	O
and	O
peak	O
width	O
range	O
were	O
the	O
H	O
##SS	O
C	O
##18	O
S	O
##B	O
and	O
B	O
##E	O
##H	O
2	O
##EP	O
columns	O
(	O
median	O
width	O
##s	O
of	O
17	O
.	O
4	O
for	O
both	O
)	O
;	O
however	O
,	O
as	O
is	O
evident	O
in	O
C	O
,	O
peak	O
resolution	O
on	O
the	O
Di	B
##ol	I
column	O
was	O
marked	O
##ly	O
better	O
than	O
on	O
the	O
B	O
##E	O
##H	O
2	O
-	O
EP	O
column	O
.	O

B	O
##rief	O
##ly	O
,	O
we	O
a	O
##cc	O
##rue	O
##d	O
forty	O
-	O
three	O
women	O
with	O
newly	O
diagnosed	O
opera	O
##ble	O
breast	O
cancer	O
to	O
take	O
2	O
grams	O
of	O
limo	B
##nen	I
##e	I
daily	O
for	O
two	O
to	O
six	O
weeks	O
before	O
voluntary	O
surgical	O
ex	O
##cision	O
of	O
their	O
tumor	O
.	O

ID	O
##H1	O
and	O
ID	O
##H	O
##2	O
cat	O
##aly	O
##ze	O
the	O
o	O
##xi	O
##da	O
##tive	O
de	O
##car	O
##box	O
##yla	O
##tion	O
of	O
is	B
##oc	I
##it	I
##rate	I
to	O
α	B
-	I
k	I
##eto	I
##g	I
##lut	I
##arate	I
(	I
α	I
-	I
K	I
##G	I
)	I
.	O

For	O
example	O
,	O
it	O
has	O
been	O
estimated	O
that	O
ethanol	S
,	O
which	O
has	O
a	O
high	O
blood	O
so	O
##lub	O
##ility	O
(	O
λ	O
_	O
b	O
:	O
a	O
=	O
1	O
,	O
80	O
##3	O
)	O
,	O
can	O
show	O
a	O
20	O
%	O
lower	O
concentration	O
than	O
al	O
##ve	O
##olar	O
air	O
after	O
a	O
complete	O
prolonged	O
ex	O
##hala	O
##tion	O
.	O

The	O
levels	O
of	O
T	O
##C	O
,	O
HD	O
##L	O
,	O
L	O
##D	O
##L	O
,	O
and	O
T	B
##G	I
were	O
not	O
statistical	O
##ly	O
different	O
between	O
these	O
HIV	O
+	O
and	O
HIV	O
–	O
populations	O
.	O

The	O
existence	O
of	O
an	O
al	B
##ky	I
##l	I
et	I
##her	I
bond	O
at	O
the	O
s	O
##n	O
-	O
1	O
position	O
,	O
which	O
is	O
not	O
subjected	O
to	O
collision	O
-	O
induced	O
di	O
##sso	O
##ciation	O
at	O
regular	O
collision	O
energies	O
,	O
confirms	O
that	O
9	O
-	O
H	O
##SA	O
is	O
est	O
##eri	O
##fying	O
the	O
s	O
##n	O
-	O
2	O
position	O
of	O
the	O
g	B
##ly	I
##cer	I
##ol	I
backbone	O
of	O
the	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
.	O

The	O
highest	O
levels	O
of	O
is	O
##oa	O
##cid	O
##s	O
,	O
p	B
##hen	I
##yla	I
##ce	I
##tate	I
and	O
p	B
##hen	I
##yl	I
##p	I
##rop	I
##ion	I
##ate	I
were	O
all	O
associated	O
with	O
the	O
same	O
five	O
cancer	O
patients	O
.	O

In	O
this	O
work	O
,	O
we	O
have	O
demonstrated	O
s	O
##yne	O
##rgy	O
between	O
the	O
C	O
##YP	O
##51	O
(	B
is	B
##av	I
##uc	I
##ona	I
##zo	I
##le	I
)	O
,	O
SM	O
##T	O
(	B
e	B
##pi	I
##min	I
##ola	I
##nos	I
##tero	I
##l	I
)	O
and	O
s	O
##tero	O
##l	O
ER	O
##G	O
##2	O
(	B
ta	B
##mo	I
##xi	I
##fen	I
)	O
inhibitor	O
##s	O
paired	O
in	O
three	O
different	O
combinations	O
as	O
specified	O
in	O
.	O

This	O
line	O
of	O
thought	O
is	O
supported	O
by	O
a	O
P	O
##K	O
study	O
showing	O
that	O
do	B
##x	I
##or	I
##ubi	I
##cin	I
##ol	I
plasma	O
clearance	O
was	O
decreased	O
in	O
children	O
with	O
>	O
30	O
%	O
body	O
fat	O
.	O

In	O
addition	O
to	O
G	O
##N	O
##MT	O
,	O
sa	B
##rc	I
##os	I
##ine	I
levels	O
are	O
regulated	O
by	O
sa	O
##rc	O
##os	O
##ine	O
de	O
##hy	O
##dr	O
##ogen	O
##ase	O
(	O
SA	O
##RD	O
##H	O
)	O
,	O
the	O
enzyme	O
that	O
converts	O
sa	B
##rc	I
##os	I
##ine	I
back	O
to	O
g	B
##ly	I
##cine	I
and	O
dim	O
##eth	O
##yl	O
##gly	O
##cine	O
de	O
##hy	O
##dr	O
##ogen	O
##ase	O
(	O
D	O
##MG	O
##D	O
##H	O
)	O
which	O
generates	O
sa	B
##rc	I
##os	I
##ine	I
from	O
dim	B
##eth	I
##yl	I
##gly	I
##cine	I
.	O

B	O
##rief	O
##ly	O
,	O
prior	O
to	O
sample	O
introduction	O
,	O
the	O
extracted	O
plasma	O
samples	O
were	O
di	O
##lut	O
##ed	O
5	O
-	O
fold	O
in	O
5	O
m	O
##M	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
in	O
ch	O
##lor	O
##of	O
##orm	O
:	O
met	O
##han	O
##ol	O
(	O
1	O
:	O
2	O
,	O
v	O
/	O
v	O
)	O
.	O

Disc	O
##rim	O
##ina	O
##nt	O
variables	O
were	O
identified	O
as	O
signals	O
from	O
the	O
met	B
##hyl	I
##ene	I
and	O
met	O
##hyl	O
m	O
##oi	O
##eti	O
##es	O
of	O
plasma	O
lip	O
##id	O
al	B
##ip	I
##hat	I
##ic	I
chains	O
.	O

A	O
series	O
of	O
di	O
##lution	O
##s	O
of	O
re	B
##ser	I
##pine	I
stock	O
solution	O
in	O
met	B
##han	I
##ol	I
was	O
prepared	O
starting	O
from	O
0	O
.	O
1	O
mg	O
/	O
m	O
##L	O
.	O
Five	O
or	O
more	O
points	O
were	O
acceptable	O
for	O
creating	O
a	O
ca	O
##li	O
##bra	O
##tion	O
curve	O
of	O
re	B
##ser	I
##pine	I
.	O

A	O
Con	O
##over	O
-	O
In	O
##man	O
test	O
for	O
multiple	O
comparison	O
between	O
milk	O
and	O
so	O
##y	O
drink	O
intake	O
further	O
revealed	O
significant	O
differences	O
for	O
C	B
##15	I
:	I
0	I
,	O
which	O
were	O
suggest	O
##ive	O
of	O
a	O
disc	O
##rim	O
##inating	O
potential	O
of	O
this	O
molecule	O
.	O

Therefore	O
,	O
we	O
h	O
##y	O
##pot	O
##hes	O
##ized	O
that	O
sperm	O
m	O
##t	O
##D	O
##NA	O
##c	O
##n	O
and	O
m	O
##t	O
##D	O
##NA	O
##del	O
would	O
be	O
positively	O
associated	O
with	O
u	O
##rina	O
##ry	O
p	B
##ht	I
##hala	I
##te	I
meta	O
##bol	O
##ite	O
and	O
is	B
##op	I
##ros	I
##tan	I
##e	I
concentrations	O
.	O

Reference	O
values	O
for	O
the	O
13	O
detected	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
and	O
the	O
72	O
detected	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
are	O
shown	O
in	O
and	O
Table	O
##s	O
,	O
respectively	O
.	O

Women	O
who	O
were	O
accidentally	O
and	O
heavily	O
exposed	O
to	O
a	O
high	O
dose	O
of	O
di	B
##ox	I
##ins	I
in	O
an	O
industrial	O
accident	O
(	O
factory	O
explosion	O
)	O
in	O
Se	O
##ves	O
##o	O
,	O
Italy	O
,	O
developed	O
pre	O
##men	O
##op	O
##aus	O
##al	O
breast	O
cancer	O
at	O
a	O
rate	O
2	O
-	O
fold	O
higher	O
than	O
controls	O
.	O

For	O
most	O
compounds	O
investigated	O
,	O
expected	O
concentrations	O
in	O
me	O
##con	O
##ium	O
were	O
unavailable	O
;	O
therefore	O
,	O
a	O
1	O
,	O
000	O
ng	O
/	O
g	O
concentration	O
was	O
chosen	O
for	O
Δ	B
_	I
9	I
-	I
te	I
##tra	I
##hy	I
##dr	I
##oc	I
##anna	I
##bino	I
##l	I
,	O
11	B
-	I
h	I
##ydro	I
##xy	I
-	I
Δ	I
_	I
9	I
te	I
##tra	I
##hy	I
##dr	I
##oc	I
##anna	I
##bino	I
##l	I
,	O
11	B
-	I
nor	I
-	I
9	I
-	I
car	I
##box	I
##y	I
-	I
Δ	I
_	I
9	I
-	I
te	I
##tra	I
##hy	I
##dr	I
##oc	I
##anna	I
##bino	I
##l	I
,	O
di	B
##az	I
##ep	I
##am	I
,	O
lo	B
##raze	I
##pa	I
##m	I
,	O
o	B
##xa	I
##ze	I
##pa	I
##m	I
,	O
al	B
##pra	I
##zo	I
##lam	I
,	O
ni	B
##tra	I
##ze	I
##pa	I
##m	I
,	O
flu	B
##ni	I
##tra	I
##ze	I
##pa	I
##m	I
,	O
te	B
##ma	I
##ze	I
##pa	I
##m	I
,	O
nor	B
##dia	I
##ze	I
##pa	I
##m	I
,	O
br	B
##oma	I
##ze	I
##pa	I
##m	I
,	O
c	B
##lon	I
##az	I
##ep	I
##am	I
,	O
flu	B
##raze	I
##pa	I
##m	I
,	O
7	B
-	I
amino	I
##c	I
##lon	I
##az	I
##ep	I
##am	I
,	O
7	B
-	I
amino	I
##f	I
##lu	I
##ni	I
##tra	I
##ze	I
##pa	I
##m	I
,	O
im	B
##ip	I
##ram	I
##ine	I
,	O
dip	B
##hen	I
##yd	I
##ram	I
##ine	I
,	O
ch	B
##lor	I
##phe	I
##nir	I
##amine	I
,	O
br	B
##om	I
##phe	I
##nir	I
##amine	I
,	O
c	B
##lo	I
##mi	I
##pra	I
##mine	I
,	O
para	B
##xe	I
##tine	I
,	O
flu	B
##ox	I
##eti	I
##ne	I
,	O
nor	B
##f	I
##lu	I
##ox	I
##eti	I
##ne	I
,	O
c	B
##lon	I
##id	I
##ine	I
,	O
pen	B
##ta	I
##zo	I
##cine	I
,	O
i	B
##bu	I
##p	I
##ro	I
##fen	I
,	O
ca	B
##ffe	I
##ine	I
,	O
ace	B
##ty	I
##ls	I
##ali	I
##cy	I
##lic	I
acid	I
,	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
,	O
p	B
##hen	I
##cy	I
##c	I
##lid	I
##ine	I
,	O
norm	B
##or	I
##phine	I
,	O

AM	O
##P	O
##K	O
is	O
activated	S
when	O
cellular	O
energy	O
is	O
decreasing	O
.	O

The	O
final	O
model	O
(	O
P	O
<	O
0	O
.	O
00	O
##1	O
)	O
included	O
five	O
parameters	O
,	O
As	O
##n	O
,	O
C	B
##5	I
:	I
1	I
,	O
A	O
##rg	O
/	O
Or	O
##n	O
,	O
Val	O
/	O
Ph	O
##e	O
,	O
and	O
(	B
C	I
##0	I
+	I
C	I
##2	I
+	I
C	I
##3	I
+	I
C	I
##16	I
+	I
C	I
##18	I
:	I
1	I
)	I
/	I
C	I
##it	I
.	O

Cell	O
via	O
##bility	O
was	O
measured	O
by	O
A	O
Cell	O
-	O
T	O
##iter	O
-	O
G	O
##lo	O
_	O
®	O
l	O
##umi	O
##nes	O
##cent	O
cell	O
via	O
##bility	O
ass	O
##ay	O
kit	O
(	O
Pro	O
##me	O
##ga	O
,	O
Madison	O
,	O
W	O
##I	O
,	O
USA	O
)	O
which	O
based	O
on	O
the	O
production	O
of	O
ATP	S
in	O
viable	O
cells	O
.	O

F	O
##ail	O
##ure	O
of	O
co	O
##lon	O
##ocytes	O
to	O
differentiate	O
appropriately	O
may	O
mean	O
that	O
they	O
are	O
more	O
exposed	O
to	O
hydrogen	B
su	I
##l	I
##phi	I
##de	I
in	O
the	O
l	O
##ume	O
##n	O
.	O

With	O
the	O
screening	O
for	O
meta	O
##bol	O
##ites	O
in	O
precursor	O
ion	O
mode	O
,	O
precursor	O
##s	O
in	O
##dicative	O
for	O
meta	O
##bol	O
##ites	O
co	O
el	O
##uti	O
##ng	O
with	O
a	B
##bir	I
##ater	I
##one	I
were	O
not	O
found	O
.	O

The	O
most	O
up	O
##re	O
##gu	O
##lated	O
genes	O
were	O
genes	O
encoding	O
the	O
de	O
no	O
##vo	O
c	B
##era	I
##mi	I
##de	I
bio	O
##sy	O
##nt	O
##hetic	O
enzymes	O
CE	O
##RS	O
##3	O
and	O
CE	O
##RS	O
##6	O
.	O

Additionally	O
,	O
a	O
careful	O
literature	O
analysis	O
also	O
indicated	O
the	O
s	B
##cy	I
##lli	I
##to	I
##l	I
is	O
a	O
normal	O
constituent	O
of	O
human	O
urine	O
and	O
has	O
previously	O
been	O
detected	O
in	O
human	O
urine	O
via	O
other	O
methods	O
.	O

A	O
##FM	O
_	O
1	O
a	B
##f	I
##lat	I
##ox	I
##in	I
M	O
_	O
1	O
,	O
F	O
##B	O
_	O
1	O
f	O
##um	O
##oni	O
##sin	O
B	O
_	O
1	O
,	O
F	O
##B	O
_	O
2	O
f	O
##um	O
##oni	O
##sin	O
B	O
_	O
2	O
,	O
D	O
##ON	O
de	B
##ox	I
##yn	I
##ival	I
##eno	I
##l	I
,	O
D	O
##OM	O
de	B
-	I
e	I
##pox	I
##y	I
de	I
##ox	I
##yn	I
##ival	I
##eno	I
##l	I
,	O
G	O
##l	O
##c	O
##A	O
g	B
##lu	I
##cu	I
##ron	I
##ide	I
,	O
N	O
##I	O
##V	O
ni	O
##vale	O
##no	O
##l	O
,	O
O	O
##TA	O
o	B
##ch	I
##rato	I
##xin	I

S	O
##1	O
##P	O
,	O
HC	O
##C	O
,	O
bio	O
##mark	O
##er	O
,	O
s	B
##phi	I
##ngo	I
##lip	I
##id	I
,	O

In	O
both	O
cases	O
,	O
the	O
dried	O
extract	O
was	O
re	O
##con	O
##stituted	O
with	O
50	O
µ	O
##L	O
of	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
0	O
.	O
2	O
M	O
:	B
AC	B
##N	I
(	I
30	I
:	I
70	I
)	I
,	O
and	O
2	O
.	O
5	O
µ	O
##L	O
of	O
the	O
super	O
##nat	O
##ant	O
were	O
injected	O
for	O
analysis	O
.	O

After	O
e	O
##va	O
##por	O
##ation	O
,	O
lip	O
##id	O
extract	O
##s	O
were	O
resolved	O
in	O
met	B
##han	I
##ol	I
and	O
were	O
analyzed	O
using	O
HP	O
##LC	O
-	O
E	O
##SI	O
/	O
MS	O
##MS	O
.	O

The	O
reverse	O
trend	O
in	O
amino	O
acid	O
expression	O
was	O
true	O
for	O
the	O
comparison	O
between	O
DC	O
##s	O
and	O
NH	O
##Cs	O
,	O
with	O
HC	O
##V	O
-	O
c	O
##ir	O
##r	O
##hos	O
##is	O
patients	O
exhibiting	O
strongly	O
significant	O
down	O
##re	O
##gu	O
##lation	O
of	O
se	B
##rine	I
,	O
g	B
##ly	I
##cine	I
,	O
as	B
##par	I
##tate	I
,	O
g	B
##lut	I
##ama	I
##te	I
and	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
.	O

Vita	O
##min	O
D	O
_	O
3	O
cat	O
##ab	O
##olis	O
##m	O
is	O
accomplished	O
predominantly	O
by	O
C	O
##YP	O
##24	O
##A	O
##1	O
,	O
which	O
meta	O
##bol	O
##izes	O
25	O
(	O
OH	O
)	O
D	O
_	O
3	O
to	O
24	B
,	I
25	I
-	I
di	I
##hy	I
##dr	I
##ox	I
##y	I
##vi	I
##tam	I
##in	I
D	O
_	O
3	O
(	B
24	B
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
)	O
and	O
1	B
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
to	O
1	B
,	I
24	I
,	I
25	I
-	I
t	I
##ri	I
##hy	I
##dr	I
##ox	I
##y	I
##vi	I
##tam	I
##in	I
D	O
_	O
3	O
(	B
1	B
,	I
24	I
,	I
25	I
(	I
OH	I
)	I
_	I
3	I
D	O
_	O
3	O
)	O
.	O

Most	O
patients	O
are	O
diagnosed	O
F	B
##D	I
by	O
question	O
##naire	O
##s	O
,	O
which	O
largely	O
depends	O
on	O
patients	O
’	O
personal	O
perception	O
##s	O
and	O
so	O
##matic	O
symptoms	O
.	O

Moreover	O
,	O
in	O
the	O
un	O
##mat	O
##ched	O
disease	O
model	O
,	O
from	O
the	O
21	O
variables	O
that	O
showed	O
to	O
be	O
significant	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
after	O
the	O
B	O
##H	O
‐	O
F	O
##DR	O
correction	O
,	O
only	O
two	O
(	O
V	O
##OC	O
_	O
2	O
and	O
1	B
,	I
1	I
,	I
6	I
‐	I
trim	I
##eth	I
##yl	I
‐	I
1	I
,	I
2	I
‐	I
di	I
##hy	I
##dron	I
##aph	I
##thal	I
##ene	I
)	O
with	O
possible	O
bias	O
from	O
the	O
age	O
model	O
were	O
present	O
.	O

Additionally	O
,	O
the	O
utilities	O
of	O
k	B
##yn	I
##uren	I
##ine	I
(	O
K	O
##yn	O
)	O
,	O
try	B
##pt	I
##op	I
##han	I
(	O
T	O
##rp	O
)	O
,	O
and	O
their	O
ratio	O
,	O
K	O
##yn	O
/	O
T	O
##rp	O
,	O
were	O
evaluated	O
because	O
the	O
activation	O
of	O
in	O
##do	O
##leam	O
##ine	O
2	O
,	O
3	O
-	O
di	O
##ox	O
##y	O
##gen	O
##ase	O
(	O
ID	O
##O	O
-	O
1	O
)	O
,	O
which	O
converts	O
T	O
##rp	O
to	O
K	O
##yn	O
,	O
has	O
been	O
widely	O
reported	O
in	O
mac	O
##rop	O
##hage	O
##s	O
exposed	O
to	O
Mt	O
##b	O
.	O

No	O
significant	O
differences	O
were	O
observed	O
in	O
6	O
-	O
T	O
##G	O
##N	O
and	O
6	O
-	O
M	O
##MP	O
##N	O
levels	O
between	O
patients	O
who	O
were	O
wild	O
-	O
type	O
and	O
he	O
##tero	O
##zy	O
##go	O
##us	O
for	O
N	O
##U	O
##D	O
##T	O
##15	O
c	O
.	O
415	O
##C	O
>	O
T	O
(	O
r	O
##s	O
##11	O
##6	O
##8	O
##55	O
##23	O
##2	O
)	O
after	O
adjustments	O
for	O
th	B
##io	I
##pur	I
##ine	I
doses	O
.	O

-	B
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
.	O

However	O
,	O
the	O
second	O
-	O
best	O
,	O
still	O
genome	O
-	O
wide	O
significant	O
association	O
of	O
the	O
tested	O
S	O
##NP	O
with	O
v	B
##ali	I
##ne	I
replica	O
##tes	O
.	O

One	O
possible	O
explanation	O
for	O
the	O
low	O
levels	O
of	O
these	O
p	B
##hen	I
##ant	I
##hren	I
##e	I
meta	O
##bol	O
##ites	O
in	O
human	O
urine	O
is	O
that	O
they	O
are	O
ex	O
##cre	O
##ted	O
mainly	O
in	O
f	O
##ec	O
##es	O
,	O
which	O
were	O
not	O
collected	O
or	O
analyzed	O
in	O
this	O
study	O
.	O

Fast	O
meta	O
##bol	O
##izer	O
##s	O
may	O
not	O
have	O
any	O
parent	O
drug	O
in	O
their	O
blood	O
or	O
urine	O
within	O
just	O
a	O
day	O
or	O
so	O
after	O
the	O
last	O
dose	O
,	O
therefore	O
it	O
is	O
imp	O
##erative	O
that	O
the	O
met	B
##had	I
##one	I
meta	O
##bol	O
##ites	O
of	O
E	O
##D	O
##DP	O
and	O
E	O
##MD	O
##P	O
be	O
measured	O
with	O
the	O
parent	O
drug	O
before	O
non	O
-	O
compliance	O
is	O
concluded	O
on	O
the	O
basis	O
of	O
und	O
##ete	O
##ct	O
##able	O
met	B
##had	I
##one	I
concentrations	O
.	O

As	O
described	O
above	O
,	O
the	O
association	O
of	O
T	B
##MA	I
##O	I
with	O
cardiac	O
disorders	O
has	O
gained	O
much	O
attention	O
in	O
the	O
recent	O
literature	O
.	O

Is	O
##oto	O
##pic	O
label	O
##ing	O
was	O
initiated	O
by	O
re	O
##sus	O
##pen	O
##ding	O
cultures	O
in	O
R	O
##PM	O
##I	O
containing	O
_	O
13	O
C	B
-	I
U	I
-	I
glucose	I
.	O

Lewis	O
and	O
co	O
-	O
authors	O
investigated	O
ch	B
##ole	I
##ster	I
##ol	I
profile	O
in	O
people	O
with	O
newly	O
diagnosed	O
CD	O
.	O

ii	O
##i	O
,	O
M	O
##n	O
##O	O
_	O
2	O
,	O
Ce	O
##lite	O
,	O
CH	O
_	O
2	O
C	O
##l	O
_	O
2	O
,	O
room	O
temperature	O
,	O
4	O
h	O
(	O
73	O
%	O
,	O
β	B
-	I
ion	I
##yl	I
##iden	I
##ea	I
##ce	I
##tal	I
##de	I
##hy	I
##de	I
;	O
36	O
%	O
,	O
β	B
-	I
a	I
##po	I
-	I
10	I
′	I
-	I
car	I
##ote	I
##nal	I
;	O
6	O
%	O
,	O
β	B
-	I
a	I
##po	I
-	I
14	I
′	I
-	I
car	I
##ote	I
##nal	I
)	O
.	O

Thus	O
,	O
based	O
on	O
our	O
data	O
,	O
the	O
use	O
of	O
serum	O
gel	O
-	O
barrier	O
tubes	O
should	O
be	O
avoided	O
if	O
the	O
measurement	O
of	O
met	B
##hi	I
##oni	I
##ne	I
su	I
##lf	I
##oxide	I
is	O
of	O
interest	O
.	O

T	O
##B	O
-	O
D	O
##M	O
patients	O
were	O
further	O
characterized	O
by	O
lower	O
levels	O
of	O
g	B
##ly	I
##cine	I
,	O
se	B
##rine	I
,	O
th	B
##re	I
##oni	I
##ne	I
and	O
ho	B
##mos	I
##eri	I
##ne	I
compared	O
to	O
T	O
##B	O
patients	O
,	O
which	O
were	O
similarly	O
un	O
##af	O
##fected	O
by	O
T	O
##B	O
treatment	O
.	O

The	O
altered	O
metabolic	O
pathways	O
included	O
g	O
##ly	O
##co	O
##lysis	O
,	O
fatty	O
acids	O
metabolism	O
,	O
ch	B
##olin	I
##e	I
metabolism	O
,	O
g	O
##lut	O
##ami	O
##no	O
##lysis	O
,	O
pu	B
##rine	I
and	O
p	B
##yr	I
##im	I
##id	I
##ine	I
bio	O
##sy	O
##nt	O
##hesis	O
,	O
u	B
##rea	I
cycle	O
and	O
T	O
##CA	O
.	O

Moreover	O
,	O
in	O
accordance	O
with	O
previous	O
studies	O
,	O
both	O
ω	B
-	I
3	I
P	I
##U	I
##FA	I
##s	I
(	O
EPA	O
,	O
AL	O
##A	O
)	O
and	B
##ω	I
-	I
6	I
P	O
##U	O
##FA	O
##s	O
(	O
AA	O
,	O
LA	O
)	O
were	O
also	O
reduced	O
in	O
MD	O
##D	O
subjects	O
.	O

This	O
is	O
of	O
interest	O
,	O
as	O
several	O
P	O
##E	O
species	O
,	O
such	O
as	O
P	B
##E	I
(	I
38	I
:	I
6	I
)	I
or	O
P	B
##E	I
(	I
40	I
:	I
4	I
)	I
,	O
have	O
been	O
reported	O
to	O
be	O
up	O
-	O
regulated	O
in	O
CR	O
##C	O
tissues	O
as	O
compared	O
to	O
normal	O
tissues	O
.	O

From	O
this	O
analysis	O
,	O
several	O
species	O
exhibited	O
no	O
change	O
between	O
any	O
of	O
the	O
extraction	O
methods	O
,	O
such	O
as	O
the	O
Ce	B
##r	I
and	O
dig	B
##ly	I
##cer	I
##ides	I
(	O
D	O
##G	O
##s	O
)	O
.	O

We	O
can	O
notice	O
that	O
the	O
set	O
of	O
features	O
selected	O
includes	O
again	O
l	O
##ys	O
##o	O
##PC	O
##s	O
,	O
PC	O
##s	O
and	O
al	B
##ani	I
##ne	I
.	O

K	O
##R	O
##as	O
_	O
G	O
##12	O
##D	O
(	O
activated	O
from	O
L	O
##SL	O
-	O
K	O
##R	O
##as	O
_	O
G	O
##12	O
##D	O
)	O
,	O
and	O
T	O
##d	O
##T	O
##oma	O
##to	O
red	O
mouse	O
organ	B
##oids	I
(	O
AK	O
##P	O
)	O
grown	O
in	O
Mat	O
##rig	O
##el	O
were	O
in	O
##cu	O
##bate	O
##d	O
with	O
D	B
##MS	I
##O	I
,	O
25	O
µ	O
##M	O
680	O
##C	O
##9	O
##1	O
,	O
or	O
10	O
µ	O
##M	O
CH	O
##22	O
##31	O
##9	O
##1	O
.	O

These	O
samples	O
were	O
analyzed	O
under	O
the	O
conditions	O
as	O
described	O
in	O
the	O
previous	O
section	O
Det	O
##ec	O
##tion	O
of	O
residual	O
g	O
##lu	O
##cu	O
##ron	O
##idated	O
Phase	O
II	O
ant	B
##ho	I
##cy	I
##ani	I
##n	I
con	O
##ju	O
##gate	O
##s	O
in	O
post	O
-	O
r	O
##ins	O
##e	O
human	O
sa	O
##liva	O
samples	O
by	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
.	O

A	O
total	O
of	O
250	O
plasma	O
samples	O
of	O
infants	O
aged	O
4	O
months	O
(	O
IF	O
:	O
80	O
,	O
CF	O
:	O
79	O
,	O
B	O
##F	O
:	O
91	O
)	O
were	O
analyzed	O
to	O
investigate	O
59	O
different	O
car	B
##ni	I
##tine	I
est	I
##ers	I
and	O
425	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
.	O

A	O
possibility	O
of	O
the	O
pathway	O
bi	O
##fu	O
##rca	O
##tion	O
downstream	O
of	O
8	O
suggests	O
a	O
“	O
switch	O
”	O
between	O
the	O
C	O
##24	O
-	O
met	O
##hyl	O
##ation	O
and	O
Δ	O
_	O
24	O
-	O
reduction	O
steps	O
committing	O
Na	O
##eg	O
##ler	O
##ia	O
to	O
either	O
er	B
##gos	I
##tero	I
##l	I
or	O
ch	B
##ole	I
##ster	I
##ol	I
bio	O
##sy	O
##nt	O
##hesis	O
,	O
respectively	O
.	O

In	O
the	O
cases	O
where	O
V	B
##LC	I
##DC	I
##A	I
28	I
:	I
4	I
was	O
not	O
detected	O
in	O
100	O
μ	O
##L	O
bio	O
##f	O
##lu	O
##id	O
,	O
the	O
negative	O
observations	O
were	O
further	O
valid	O
##ated	O
by	O
extract	O
##ing	O
500	O
μ	O
##L	O
bio	O
##f	O
##lu	O
##id	O
.	O

1	O
Is	B
##ole	I
##uc	I
##ine	I
,	O
2	O
Le	B
##uc	I
##ine	I
,	O
3	O
Val	B
##ine	I
,	O
4	O
G	B
##lut	I
##ath	I
##ione	I
,	O
5	O
G	B
##ly	I
##cine	I
,	O
6	O
Beta	B
##ine	I
,	O
7	O
Ty	B
##ros	I
##ine	I
,	O
8	O
H	B
##y	I
##pox	I
##ant	I
##hine	I
.	O

Laboratory	O
C	O
##Vs	O
were	O
2	O
%	O
for	O
c	B
##rea	I
##tin	I
##ine	I
concentrations	O
of	O
70	O
mg	O
/	O
d	O
##L	O
and	O
155	O
mg	O
/	O
d	O
##L	O
.	O

A	O
##bb	O
##re	O
##viation	O
##s	O
:	O
PS	O
##P	O
:	O
progressive	O
su	O
##pra	O
##nu	O
##cle	O
##ar	O
p	O
##als	O
##y	O
;	O
SD	O
##MA	O
:	O
symmetric	B
dim	I
##eth	I
##yla	I
##rg	I
##ini	I
##ne	I
fatty	O
acid	O
;	O
AC	O
:	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
;	O
SE	O
##M	O
:	O
standard	O
error	O
of	O
the	O
mean	O
.	O

The	O
residues	O
were	O
re	O
##con	O
##stituted	O
in	O
50	O
µ	O
##L	O
of	O
internal	O
standards	O
solution	O
of	O
h	B
##ydro	I
##xy	I
##try	I
##pt	I
##op	I
##han	I
-	I
D	I
_	I
4	I
,	O
L	B
-	I
k	I
##yn	I
##uren	I
##ine	I
-	I
D	I
_	I
4	I
,	O
in	B
##do	I
##le	I
-	I
D	I
_	I
5	I
-	I
3	I
-	I
ace	I
##tam	I
##ide	I
,	O
4	B
-	I
ch	I
##lor	I
##o	I
-	I
k	I
##yn	I
##uren	I
##ine	I
-	I
_	I
13	I
C	O
_	O
2	O
,	O
_	O
15	O
N	O
,	O
6	B
-	I
h	I
##ydro	I
##xy	I
##mel	I
##aton	I
##in	I
-	I
D	I
_	I
4	I
,	O
k	O
##yn	O
##uren	O
##ic	O
acid	O
-	O
D	O
_	O
5	O
,	O
PA	O
##G	O
##N	O
-	O
D	O
_	O
5	O
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
-	I
D	I
_	I
5	I
,	O
se	O
##rot	O
##oni	O
##n	O
-	O
D	O
_	O
4	O
,	O
try	B
##pta	I
##mine	I
-	I
D	I
_	I
4	I
,	O
try	O
##pt	O
##op	O
##han	O
-	O
D	O
_	O
5	O
,	O
x	B
##ant	I
##hur	I
##eni	I
##c	I
acid	O
-	O
D	O
_	O
4	O
and	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
-	I
D	I
_	I
5	I
(	O
900	O
n	O
##M	O
each	O
)	O
.	O

These	O
altered	O
meta	O
##bol	O
##ites	O
clearly	O
revealed	O
d	O
##ys	O
##re	O
##gu	O
##lation	O
of	O
multiple	O
metabolic	O
events	O
,	O
including	O
a	O
##ero	O
##bic	O
g	O
##ly	O
##co	O
##lysis	O
(	O
War	O
##burg	O
effect	O
)	O
,	O
o	O
##xi	O
##da	O
##tive	O
p	O
##hos	O
##ph	O
##ory	O
##lation	O
(	O
Past	O
##eur	O
’	O
s	O
effect	O
)	O
,	O
energy	O
metabolism	O
,	O
T	O
##CA	O
cycle	O
an	O
##ap	O
##ler	O
##otic	O
flux	O
,	O
he	B
##x	I
##osa	I
##mine	I
pathway	O
,	O
o	O
##smo	O
##re	O
##gu	O
##lator	O
##y	O
,	O
and	O
anti	O
##ox	O
##ida	O
##nt	O
mechanisms	O
.	O

Our	O
analyses	O
of	O
both	O
β	O
-	O
car	O
##ote	O
##ne	O
-	O
containing	O
animal	O
diet	O
##s	O
and	O
fruits	O
containing	O
β	B
-	I
car	I
##ote	I
##ne	I
suggest	O
that	O
any	O
diet	O
##ary	O
source	O
of	O
β	B
-	I
car	I
##ote	I
##ne	I
also	O
contains	O
β	B
-	I
a	I
##po	I
##car	I
##ote	I
##no	I
##ids	I
.	O

Moreover	O
,	O
C	O
##MM	O
has	O
the	O
highest	O
rate	O
of	O
K	B
##P	I
mutations	O
(	O
>	O
20	O
%	O
)	O
,	O
specifically	O
in	O
K	O
##AT	O
##s	O
.	O

After	O
thorough	O
mixing	O
of	O
samples	O
,	O
300	O
μ	O
l	O
plasma	O
from	O
each	O
ca	O
##li	O
##bra	O
##tion	O
standard	O
,	O
Q	O
##C	O
,	O
and	O
volunteers	O
samples	O
was	O
pipe	O
##tted	O
in	O
1	O
m	O
##l	O
cent	O
##ri	O
##fu	O
##ge	O
tube	O
and	O
then	O
900	O
μ	O
l	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
containing	O
500	O
ng	O
/	O
m	O
##l	O
sit	B
##ag	I
##lip	I
##tin	I
(	O
IS	O
)	O
was	O
added	O
and	O
followed	O
by	O
mixing	O
for	O
2	O
min	O
by	O
v	O
##ortex	O
and	O
cent	O
##ri	O
##fu	O
##gation	O
at	O
3	O
,	O
000	O
rpm	O
for	O
10	O
min	O
.	O

Children	O
with	O
conventional	O
diet	O
##s	O
reportedly	O
had	O
significantly	O
higher	O
levels	O
of	O
u	O
##rina	O
##ry	O
organ	B
##op	I
##hos	I
##phorus	I
meta	O
##bol	O
##ites	O
,	O
dim	B
##eth	I
##yl	I
al	I
##ky	I
##l	I
##ph	I
##os	I
##phate	I
##s	I
,	O
than	O
did	O
children	O
with	O
organic	O
diet	O
##s	O
.	O

Another	O
meta	O
##bol	O
##ite	O
associated	O
with	O
both	O
oral	O
fat	O
intake	O
and	O
N	O
##RI	O
score	O
was	O
SM	B
(	I
d	I
##18	I
:	I
0	I
/	I
24	I
:	I
1	I
)	I
.	O

SP	O
##E	O
-	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
(	O
solid	O
phase	O
extraction	O
-	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
)	O
was	O
applied	O
for	O
the	O
determination	O
of	O
cat	B
##ech	I
##ola	I
##mine	I
and	O
s	O
##tero	O
##id	O
levels	O
.	O

R	B
##V	I
H	O
##U	O
+	O
N	O
##AF	O
##LD	O
H	O
##U	O
+	O
N	O
##AF	O
##LD	O
H	O

Our	O
study	O
supports	O
a	O
d	O
##ys	O
##re	O
##gu	O
##lation	O
of	O
pathways	O
,	O
including	O
a	B
##rg	I
##ini	I
##ne	I
and	O
pro	B
##line	I
metabolism	O
.	O

We	O
found	O
that	O
the	O
lower	O
limit	O
of	O
q	O
##uant	O
##ification	O
by	O
D	O
##FI	O
MS	O
/	O
MS	O
based	O
on	O
the	O
A	O
##bs	O
##ol	O
##ute	O
##ID	O
##Q	O
kit	O
was	O
0	O
.	O
1	O
n	O
##M	O
/	O
m	O
##M	O
c	B
##rea	I
##tin	I
##ine	I
for	O
certain	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
species	O
(	O
i	O
.	O
e	O
.	O
PC	O
a	O
##a	O
[UNK]	O
)	O
and	O
0	O
.	O
1	O
n	O
##M	O
/	O
m	O
##M	O
c	B
##rea	I
##tin	I
##ine	I
for	O
certain	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
species	O
(	O
i	O
.	O
e	O
.	O
SM	O
[UNK]	O
)	O
.	O

To	O
further	O
explore	O
the	O
u	O
##til	O
##ization	O
of	O
fatty	O
acids	O
through	O
the	O
car	B
##ni	I
##tine	I
shuttle	O
system	O
,	O
a	O
_	O
13	O
C	O
is	O
##oto	O
##po	O
##mer	O
tracing	O
experiment	O
was	O
undertaken	O
.	O

The	O
activities	O
of	O
20	B
##α	I
-	I
and	O
20	B
##β	I
-	I
h	I
##ydro	I
##xy	I
##ster	I
##oid	I
de	I
##hy	I
##dr	I
##ogen	I
##ases	I
(	I
20	I
##α	I
/	I
β	I
-	I
H	I
##SD	I
)	I
were	O
both	O
lower	O
in	O
PC	O
##OS	O
,	O
while	O
3	B
##α	I
-	I
h	I
##ydro	I
##xy	I
##ster	I
##oid	I
de	I
##hy	I
##dr	I
##ogen	I
##ase	I
(	I
3	I
##α	I
-	I
H	I
##SD	I
)	I
activity	O
was	O
higher	O
in	O
PC	O
##OS	O
.	O

where	O
R	B
##I	I
=	O
2	O
.	O
246	O

However	O
,	O
sa	B
##rc	I
##os	I
##ine	I
levels	O
were	O
elevated	O
only	O
in	O
tissue	O
bio	O
##ps	O
##ies	O
with	O
a	O
G	O
##lea	O
##son	O
pattern	O
of	O
8	O
or	O
worse	O
in	O
the	O
M	O
##c	O
##D	O
##un	O
##n	O
et	O
al	O
report	O
.	O

H	B
##ydro	I
##phi	I
##lic	I
extract	O
##s	O
were	O
dried	O
and	O
used	O
for	O
N	O
##MR	O
s	O
##pect	O
##ros	O
##copic	O
analysis	O
.	O

Di	B
##met	I
##hyl	I
su	I
##lf	I
##one	I
was	O
only	O
seen	O
in	O
the	O
Co	O
##im	O
##bra	O
co	O
##hor	O
##t	O
,	O
and	O
its	O
variation	O
differentiated	O
groups	O
with	O
similar	O
age	O
(	O
controls	O
and	O
early	O
AM	O
##D	O
)	O
.	O

The	O
method	O
was	O
successfully	O
used	O
in	O
another	O
ongoing	O
clinical	O
study	O
of	O
the	O
three	O
s	B
##tat	I
##ins	I
and	O
their	O
active	O
meta	O
##bol	O
##ites	O
before	O
and	O
after	O
gas	O
##tric	O
bypass	O
surgery	O
.	O

μ	O
##g	O
/	O
24	O
hours	O
,	O
p	O
=	O
0	O
.	O
08	O
##4	O
)	O
,	O
and	O
of	O
18	B
-	I
OH	I
-	I
co	I
##rt	I
##is	I
##ol	I
(	O
180	O
vs	O
.	O
173	O

In	O
addition	O
to	O
the	O
determination	O
of	O
mid	B
##az	I
##ola	I
##m	I
plasma	O
concentration	O
to	O
reveal	O
a	O
four	O
-	O
hour	O
p	O
##har	O
##ma	O
##co	O
##kin	O
##etic	O
profile	O
after	O
oral	O
intake	O
of	O
a	O
10	O
µ	O
##g	O
micro	O
##dos	O
##e	O
as	O
part	O
of	O
the	O
procedure	O
of	O
the	O
main	O
trial	O
,	O
plasma	O
concentrations	O
of	O
f	O
##ent	O
##any	O
##l	O
and	O
its	O
meta	O
##bol	O
##ite	O
nor	O
##fen	O
##tany	O
##l	O
were	O
measured	O
in	O
identical	O
blood	O
samples	O
.	O

Molecular	O
modeling	O
studies	O
confirmed	O
that	O
β	B
-	I
a	I
##po	I
-	I
13	I
-	I
car	I
##ote	I
##non	I
##e	I
can	O
interact	O
directly	O
with	O
the	O
l	O
##igan	O
##d	O
binding	O
site	O
of	O
the	O
re	B
##tino	I
##id	I
receptors	O
.	O

Is	B
##op	I
##rop	I
##ano	I
##l	I
was	O
present	O
at	O
higher	O
concentration	O
in	O
U	O
##F	O
samples	O
than	O
in	O
Me	B
##OH	I
pp	O
##t	O
+	O
U	O
##F	O
or	O
Me	B
##OH	I
:	O
CH	O
##C	O
##l	O
_	O
3	O
:	O
water	O
ex	O
##t	O
+	O
U	O
##F	O
serum	O
because	O
it	O
was	O
partially	O
removed	O
during	O
l	O
##yo	O
##phi	O
##li	O
##zation	O
in	O
pre	O
##ci	O
##pit	O
##ated	O
and	O
extracted	O
samples	O
,	O
while	O
U	O
##F	O
samples	O
were	O
not	O
l	O
##yo	O
##phi	O
##li	O
##zed	O
.	O

The	O
following	O
15	O
molecules	O
were	O
identified	O
:	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##ls	I
##eri	I
##ne	I
,	O
12	B
-	I
o	I
##x	I
##o	I
-	I
20	I
-	I
di	I
##hy	I
##dr	I
##ox	I
##y	I
-	I
le	I
##uk	I
##ot	I
##rien	I
##e	I
B	I
##4	I
,	I
5	I
-	I
β	I
-	I
c	I
##y	I
##p	I
##rino	I
##l	I
su	I
##lf	I
##ate	I
,	O
L	B
-	I
U	I
##ro	I
##bil	I
##ino	I
##gen	I
,	O
Li	B
##th	I
##och	I
##olic	I
acid	I
ta	I
##uri	I
##ne	I
con	I
##ju	I
##gate	I
,	O
p	B
##hos	I
##pha	I
##ti	I
##dic	I
acid	I
,	O
des	B
##mos	I
##ine	I
(	O
DE	O
##S	O
)	O
/	O
is	O
##odes	O
##mos	O
##ine	O
(	O
ID	O
##S	O
)	O
,	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
ch	I
##olin	I
##e	I
,	O
9	B
′	I
-	I
car	I
##box	I
##y	I
-	I
g	I
##ama	I
-	I
to	I
##cot	I
##rien	I
##ol	I
,	O
Li	B
##th	I
##och	I
##olate	I
3	O
-	O
O	O
-	O
g	O
##lu	O
##cu	O
##ron	O
##ide	O
,	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##lino	I
##si	I
##to	I
##l	I
,	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
ethanol	I
##amine	I
,	O
L	B
##ys	I
##o	I
##PC	I
(	I
22	I
:	I
2	I
(	I
13	I
##Z	I
,	I
16	I
##Z	I
)	I
)	I
,	O
Gang	B
##lio	I
##side	I
GM	I
##2	I
(	I
d	I
##18	I
:	I
1	I
/	I
24	I
:	I
1	I
(	I
15	I
##Z	I
)	I
)	I
,	O
and	O
S	B
##phi	I
##nga	I
##nine	I
1	I
-	I
phosphate	I
.	O

El	O
##eva	O
##ted	O
his	B
##tamine	I
can	O
a	O
##gg	O
##ra	O
##vate	O
br	O
##on	O
##cho	O
##con	O
##st	O
##ric	O
##tion	O
and	O
shrink	O
air	O
##way	O
smooth	O
muscle	O
.	O

Likewise	O
,	O
PA	O
were	O
characterized	O
by	O
an	O
increased	O
level	O
of	O
met	B
##hi	I
##oni	I
##ne	I
,	O
while	O
g	O
##lio	O
##mas	O
exhibited	O
low	O
levels	O
of	O
this	O
amino	O
acid	O
(	O
Table	O
)	O
.	O

N	O
##MR	O
meta	O
##bol	O
##omi	O
##c	O
pro	O
##fi	O
##ling	O
of	O
fast	O
##ing	O
CS	O
##F	O
samples	O
revealed	O
significantly	O
higher	O
al	B
##ani	I
##ne	I
,	O
le	B
##uc	I
##ine	I
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
v	B
##ali	I
##ne	I
,	O
la	B
##ct	I
##ate	I
,	O
p	B
##yr	I
##u	I
##vate	I
,	O
and	O
lower	O
his	B
##ti	I
##dine	I
levels	O
.	O

After	O
controlling	O
for	O
age	O
,	O
sex	O
and	O
diabetes	O
status	O
,	O
beta	B
##ine	I
was	O
correlated	O
inverse	O
##ly	O
with	O
g	O
##ly	O
##ce	O
##mia	O
,	O
non	O
-	O
HD	O
##L	O
ch	B
##ole	I
##ster	I
##ol	I
and	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
,	O
and	O
positively	O
with	O
HD	B
##L	I
ch	I
##ole	I
##ster	I
##ol	I
(	O
Table	O
)	O
.	O

SM	O
is	O
comprised	O
of	O
a	O
p	B
##hos	I
##ph	I
##ory	I
##l	I
##cho	I
##line	I
head	O
group	O
,	O
a	O
s	B
##phi	I
##ngo	I
##sin	I
##e	I
and	O
a	O
fatty	O
acid	O
tail	O
;	O
the	O
s	B
##phi	I
##ngo	I
##sin	I
##e	I
and	O
fatty	O
acid	O
together	O
are	O
known	O
as	O
a	O
c	B
##era	I
##mi	I
##de	I
.	O

Development	O
of	O
PC	O
##a	O
is	O
associated	O
with	O
the	O
metabolic	O
switch	O
from	O
a	O
high	O
level	O
of	O
c	B
##it	I
##rate	I
secret	O
##ion	O
to	O
c	B
##it	I
##rate	I
oxidation	O
.	O

This	O
may	O
indicate	O
a	O
change	O
in	O
gut	O
flora	O
,	O
and	O
it	O
is	O
possible	O
that	O
su	B
##lf	I
##ate	I
reducing	O
bacteria	O
are	O
processing	O
increased	O
available	O
hydrogen	O
,	O
or	O
in	O
fact	O
that	O
the	O
su	B
##lf	I
##ate	I
reducing	O
bacteria	O
are	O
present	O
in	O
a	O
greater	O
amount	O
in	O
the	O
bow	O
##el	O
of	O
the	O
high	O
risk	O
group	O
.	O

Second	O
##ly	O
,	O
elevated	O
levels	O
of	O
A	O
##β	O
p	O
##eptide	O
##s	O
up	O
-	O
regulate	O
p	B
##oly	I
##amine	I
metabolism	O
,	O
increasing	O
p	B
##oly	I
##amine	I
up	O
-	O
take	O
and	O
or	O
##ni	O
##thin	O
##e	O
de	O
##car	O
##box	O
##yla	O
##se	O
(	O
O	O
##DC	O
)	O
activity	O
,	O
and	O
this	O
appears	O
to	O
be	O
due	O
to	O
elevated	O
ne	O
##uro	O
##to	O
##xi	O
##city	O
.	O

Blood	O
samples	O
were	O
collected	O
into	O
E	O
##D	O
##TA	O
tubes	O
and	O
placed	O
in	O
an	O
ice	O
##d	O
sa	B
##line	I
bath	O
until	O
processing	O
occurred	O
(	O
<	O
1	O
h	O
##r	O
after	O
collection	O
)	O
.	O

MR	O
##M	O
conditions	O
for	O
the	O
est	B
##rogen	I
s	O
##tero	O
##ids	O
and	O
de	O
##uter	O
##ium	O
-	O
labeled	O
internal	O
standard	O
in	O
negative	O
ion	O
mode	O
Note	O
:	O
for	O
est	B
##rio	I
##l	I
,	O
16	B
-	I
h	I
##ydro	I
##xy	I
##est	I
##rone	I
,	O
est	B
##rone	I
,	O
and	O
est	B
##rad	I
##iol	I
,	O
the	O
first	O
MR	O
##M	O
transitions	O
were	O
listed	O
for	O
q	O
##uant	O
##itation	O
,	O
and	O
the	O
second	O
transitions	O
were	O
added	O
for	O
confirmation	O
.	O

Fast	O
##ing	O
ve	O
##nous	O
blood	O
was	O
collected	O
into	O
serum	O
gel	O
,	O
E	O
##D	O
##TA	O
plasma	O
and	O
flu	B
##ori	I
##de	I
o	I
##xa	I
##late	I
tubes	O
.	O

The	O
other	O
major	O
u	O
##rina	O
##ry	O
meta	O
##bol	O
##ite	O
detected	O
by	O
AM	O
##S	O
was	O
the	O
4	B
′	I
-	I
su	I
##lf	I
##ate	I
con	O
##ju	O
##gate	O
of	O
4	O
′	O
-	O
H	O
##O	O
-	O
Ph	O
##IP	O
,	O
which	O
accounted	O
for	O
as	O
much	O
as	O
10	O
%	O
of	O
the	O
ing	O
##ested	O
dose	O
that	O
was	O
ex	O
##cre	O
##ted	O
in	O
urine	O
.	O

It	O
was	O
identified	O
as	O
a	O
p	B
##hos	I
##ph	I
##oe	I
##no	I
##l	I
##py	I
##ru	I
##vate	I
(	O
P	O
##EP	O
)	O
by	O
comparing	O
the	O
pattern	O
of	O
MS	O
/	O
MS	O
(	O
Fi	O
##g	O
.	O
,	O
right	O
panel	O
)	O
,	O
and	O
P	O
##EP	O
level	O
in	O
se	O
##ra	O
from	O
CR	O
##C	O
patients	O
(	O
n	O
=	O
30	O
,	O
37	O
.	O
71	O
±	O
13	O
.	O
03	O
μ	O
##M	O
)	O
was	O
significantly	O
higher	O
than	O
that	O
of	O
controls	O
(	O
n	O
=	O
30	O
,	O
25	O
.	O
39	O
±	O
9	O
.	O
88	O
μ	O
##M	O
)	O
(	O
p	O
<	O
0	O
.	O
00	O
##1	O
)	O

The	O
amino	O
acids	O
of	O
285	O
Alan	B
##ine	I
and	O
28	O
##4	O
Cy	B
##stein	I
##e	I
were	O
highly	O
conserved	O
among	O
various	O
species	O
and	O
may	O
be	O
involved	O
in	O
important	O
biological	O
reactions	O
(	O
Fi	O
##g	O
.	O
)	O
.	O

In	O
comparison	O
between	O
treated	O
and	O
un	O
##tre	O
##ated	O
cases	O
,	O
is	B
##ole	I
##uc	I
##ine	I
and	O
un	O
##sat	O
##ura	O
##ted	O
lip	O
##ids	O
gave	O
the	O
highest	O
AU	O
##C	O
values	O
while	O
l	B
##ys	I
##ine	I
and	O
a	B
##rg	I
##ini	I
##ne	I
gave	O
high	O
AU	O
##C	O
when	O
disease	O
##d	O
samples	O
were	O
compared	O
with	O
healthy	O
one	O
.	O

AD	B
##MA	I
levels	O
are	O
elevated	O
in	O
various	O
conditions	O
associated	O
with	O
vascular	O
d	O
##ys	O
##function	O
,	O
such	O
as	O
diabetes	O
,	O
heart	O
failure	O
,	O
pre	O
##ec	O
##lamp	O
##sia	O
,	O
and	O
in	O
inflammation	O
,	O
and	O
has	O
therefore	O
been	O
considered	O
a	O
potential	O
bio	O
##mark	O
##er	O
for	O
card	O
##iovascular	O
disease	O
.	O

(	O
A	O
)	O
In	O
##sul	O
##in	O
;	O
(	O
B	O
)	O
G	B
##lu	I
##cos	I
##e	I
;	O
(	O
C	O
)	O
Alan	O
##ine	O
trans	O
##ami	O
##nas	O
##e	O
(	O
AL	O
##T	O
)	O
;	O
(	O
D	O
)	O
As	O
##par	O
##tate	O
trans	O
##ami	O
##nas	O
##e	O
(	O
AS	O
##T	O
)	O
;	O
(	O
E	O
)	O
Tri	B
##acy	I
##l	I
##gly	I
##cer	I
##ides	I
(	O
T	O
##AG	O
)	O
;	O
(	O
F	O
)	O
Cho	B
##les	I
##tero	I
##l	I
;	O
(	O
D	O
)	O
Low	O
-	O
density	O
lip	O
##op	O
##rote	O
##in	O
ch	B
##ole	I
##ster	I
##ol	I
(	O
L	O
##D	O
##L	O
-	O
C	O
)	O
;	O
(	O
H	O
)	O
High	O
-	O
density	O
lip	O
##op	O
##rote	O
##in	O
ch	B
##ole	I
##ster	I
##ol	I
(	O
HD	O
##L	O
-	O
C	O
)	O
.	O

In	O
order	O
to	O
concentrate	O
and	O
partially	O
pu	O
##ri	O
##fy	O
the	O
est	B
##rogen	I
meta	O
##bol	O
##ites	O
and	O
DNA	O
add	O
##uc	O
##ts	O
,	O
2	O
m	O
##L	O
of	O
urine	O
(	O
pH	O
adjusted	O
to	O
7	O
)	O
was	O
placed	O
on	O
a	O
1	O
m	O
##L	O
solid	O
phase	O
extraction	O
cartridge	O
(	O
SP	O
##E	O
;	O
Ph	O
##en	O
##yl	O
Bond	O
El	O
##ut	O
,	O
100	O
mg	O
,	O
V	O
##arian	O
,	O
Pa	O
##lo	O
Alto	O
,	O
CA	O
)	O
pre	O
##con	O
##dition	O
##ed	O
with	O
met	B
##han	I
##ol	I
,	O
water	O
,	O
and	O
10	O
m	O
##M	O
am	B
##mon	I
##ium	I
format	I
##e	I
(	O
pH	O
7	O
)	O
.	O

However	O
,	O
existing	O
literature	O
on	O
associations	O
between	O
circulating	O
T	B
##MA	I
##O	I
and	O
cancer	O
is	O
limited	O
,	O
and	O
results	O
have	O
been	O
in	O
##con	O
##clusive	O
.	O

Two	O
previous	O
studies	O
concerning	O
v	O
##it	O
##re	O
##ous	O
samples	O
from	O
patients	O
with	O
PD	O
##R	O
and	O
control	O
patients	O
without	O
diabetes	O
have	O
suggested	O
a	O
d	O
##ys	O
##re	O
##gu	O
##lation	O
in	O
several	O
bio	O
##chemical	O
pathways	O
,	O
including	O
the	O
a	B
##rg	I
##ini	I
##ne	I
to	O
pro	B
##line	I
pathway	O
,	O
p	O
##oly	O
##ol	O
pathway	O
,	O
and	O
as	O
##cor	O
##bic	O
acidic	O
pathways	O
.	O

Very	O
low	O
concentrations	O
of	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
##s	I
and	O
do	B
##pa	I
##mine	I
in	O
parallel	O
with	O
high	O
levels	O
of	O
di	B
##car	I
##box	I
##yl	I
##ica	I
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
,	O
L	B
-	I
as	I
##par	I
##tate	I
and	O
many	O
plasma	O
##log	O
##en	O
/	O
p	O
##las	O
##min	O
##ogen	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
,	O
such	O
as	O
PC	B
a	I
##e	I
C	I
##38	I
:	I
1	I
and	O
PC	B
a	I
##e	I
C	I
##40	I
:	I
3	I
,	O
were	O
detected	O
in	O
the	O
blood	O
of	O
HIV	O
-	O
1	O
-	O
infected	O
individuals	O
compared	O
with	O
controls	O
.	O

The	O
product	O
ion	O
spectrum	O
of	O
lit	O
##hat	O
##ed	O
[	O
M	O
+	O
Li	O
]	O
+	O
ions	O
for	O
PC	B
(	I
18	I
:	I
0	I
/	I
22	I
:	I
6	I
)	I
and	O
PC	B
(	I
18	I
:	I
0	I
/	I
20	I
:	I
4	I
)	I
standards	O
were	O
comparable	O
with	O
the	O
product	O
ion	O
spectrum	O
of	O
lit	O
##hat	O
##ed	O
[	O
M	O
+	O
Li	O
]	O
+	O
ions	O
in	O
samples	O
.	O

Following	O
N	O
##MR	O
analysis	O
,	O
an	O
al	O
##iq	O
##uo	O
##t	O
(	O
50	O
–	O
100	O
μ	O
##l	O
)	O
of	O
the	O
N	O
##MR	O
sample	O
was	O
re	O
-	O
e	O
##qui	O
##li	O
##bra	O
##ted	O
with	O
H	O
_	O
2	O
O	O
and	O
l	O
##yo	O
##phi	O
##li	O
##zed	O
to	O
remove	O
any	O
de	O
##uter	O
##ation	O
,	O
then	O
si	O
##ly	O
##lated	O
with	O
25	O
–	O
50	O
μ	O
##l	O
1	O
:	O
1	O
(	O
v	O
/	O
v	O
)	O
ace	O
##ton	O
##it	O
##ril	O
##e	O
:	O
M	O
##T	O
##BS	O
##TF	O
##A	O
(	B
N	B
-	I
met	I
##hyl	I
-	I
N	I
-	I
[	I
te	I
##rt	I
-	I
but	I
##yl	I
##di	I
##met	I
##hyl	I
##si	I
##ly	I
##l	I
]	I
t	I
##ri	I
##f	I
##lu	I
##oro	I
##ace	I
##tam	I
##ide	I
,	O
(	O
Regis	O
Chemical	O
,	O
Morton	O
Grove	O
,	O
IL	O
)	O
by	O
3	O
h	O
of	O
son	O
##ica	O
##tion	O
followed	O
by	O
standing	O
overnight	O
[	O
,	O
]	O
.	O

Then	O
,	O
400	O
μ	O
##L	O
of	O
di	O
##st	O
##ille	O
##d	O
water	O
and	O
400	O
μ	O
##L	O
of	O
ch	B
##lor	I
##of	I
##orm	I
were	O
added	O
to	O
each	O
sample	O
which	O
then	O
was	O
v	O
##ortex	O
##ed	O
.	O

Am	B
##mon	I
##ium	I
h	I
##ydro	I
##xi	I
##de	I
had	O
the	O
highest	O
median	O
ca	B
##ffe	I
##ine	I
peak	O
area	O
variation	O
of	O
all	O
the	O
MS	O
-	O
compatible	O
add	O
##itive	O
##s	O
(	O
16	O
.	O
3	O
%	O
vs	O
.	O
10	O
.	O
0	O
%	O
for	O
am	B
##mon	I
##ium	I
format	O
##e	O
)	O
,	O
meaning	O
that	O
the	O
improvements	O
in	O
resolution	O
obtained	O
with	O
this	O
add	O
##itive	O
were	O
accompanied	O
by	O
increased	O
analytical	O
variation	O
.	O

We	O
tested	O
the	O
influence	O
of	O
therapy	O
duration	S
(	O
12	O
or	O
24	O
weeks	O
)	O
,	O
administration	O
of	O
rib	B
##avi	I
##rin	I
(	O
RB	O
##V	O
)	O
,	O
HC	O
##V	O
g	O
##eno	O
##type	O
##s	O
and	O
ME	O
##TA	O
##VI	O
##R	O
score	O
on	O
the	O
metabolic	O
finger	O
##print	O
.	O

De	O
##F	O
##ili	O
##pp	O
##is	O
et	O
al	O
.	O
demonstrated	O
19	O
meta	O
##bol	O
##ites	O
with	O
an	O
in	O
##tra	O
-	O
subject	O
fold	O
change	O
from	O
time	O
of	O
acute	O
th	O
##rom	O
##bot	O
##ic	O
MI	O
presentation	O
to	O
the	O
q	O
##ui	O
##es	O
##cent	O
state	O
,	O
including	O
lip	O
##ids	O
2	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
,	O
and	O
amino	O
acids	O
.	O

Interest	O
##ingly	O
,	O
the	O
P	O
##I	O
,	O
P	B
##G	I
,	O
and	O
PS	O
species	O
identified	O
in	O
our	O
present	O
study	O
had	O
not	O
been	O
previously	O
identified	O
in	O
human	O
urine	O
by	O
mass	O
s	O
##pect	O
##rome	O
##try	O
.	O

Inc	O
##reased	O
blood	O
levels	O
of	O
AD	B
##MA	I
have	O
been	O
linked	O
to	O
card	O
##iovascular	O
diseases	O
,	O
re	O
##nal	O
failure	O
and	O
h	O
##yper	O
##tens	O
##ion	O
,	O
in	O
which	O
AD	B
##MA	I
was	O
described	O
as	O
an	O
independent	O
risk	O
factor	O
[	O
,	O
]	O
.	O

Rev	O
##erse	O
##ly	O
,	O
the	O
A	O
-	O
series	O
P	B
##G	I
IS	O
##T	O
##D	O
PGA	O
_	O
2	O
-	O
d	O
##4	O
showed	O
increasing	O
concentrations	O
,	O
possibly	O
due	O
to	O
P	O
##G	O
##D	O
_	O
2	O
-	O
d	O
##4	O
spontaneous	O
de	O
##hy	O
##dra	O
##tion	O
forming	O
PGA	O
_	O
2	O
-	O
d	O
##4	O
.	O

A	O
few	O
lip	O
##ids	O
were	O
also	O
confirmed	O
from	O
G	O
##C	O
-	O
MS	O
data	O
by	O
comparing	O
either	O
the	O
retention	O
times	O
of	O
standards	O
or	O
the	O
E	B
##I	I
mass	O
s	O
##pect	O
##ra	O
available	O
in	O
A	O
##OC	O
##S	O
lip	O
##id	O
library	O
.	O

The	O
second	O
reason	O
for	O
more	O
la	B
##ctic	I
acid	I
levels	O
,	O
that	O
it	O
may	O
be	O
due	O
to	O
poor	O
he	O
##pa	O
##tic	O
function	O
a	O
consequence	O
of	O
iron	O
over	O
##load	O
in	O
these	O
patients	O
as	O
abnormal	O
concentrations	O
of	O
la	B
##ctic	I
acid	I
are	O
found	O
in	O
he	O
##pa	O
##tic	O
bi	O
##lia	O
##ry	O
ma	O
##li	O
##gna	O
##ncies	O
in	O
addition	O
to	O
other	O
cancer	O
##s	O
.	O

In	O
addition	O
,	O
we	O
also	O
found	O
that	O
the	O
serum	O
L	B
-	I
c	I
##it	I
##ru	I
##llin	I
##e	I
level	O
is	O
correlated	O
with	O
B	O
##D	O
##TT	O
patient	O
survival	O
,	O
suggesting	O
its	O
potential	O
role	O
for	O
diagnosis	O
.	O

Inc	O
##reased	O
u	O
##rina	O
##ry	O
ex	O
##cre	O
##tion	O
of	O
Vita	B
##min	I
E	I
was	O
suggested	O
to	O
be	O
responsible	O
for	O
its	O
reduced	O
plasma	O
levels	O
in	O
HIV	O
patients	O
.	O

After	O
5	O
min	O
,	O
one	O
sa	B
##line	I
cry	O
##ot	O
##ube	O
was	O
removed	O
and	O
capped	O
firmly	O
until	O
_	O
1	O
H	O
-	O
N	O
##MR	O
analysis	O
.	O

Standard	O
solutions	O
(	O
1	O
μ	O
##M	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
)	O
were	O
in	O
##fused	O
directly	O
into	O
the	O
ion	O
##ization	O
source	O
of	O
the	O
mass	O
s	O
##pect	O
##rome	O
##ter	O
using	O
a	O
s	O
##yr	O
##inge	O
pump	O
(	O
1	O
.	O
0	O
μ	O
##L	O
/	O
min	O
)	O
without	O
ch	O
##roma	O
##to	O
##graphic	O
separation	O
.	O

We	O
prepared	O
the	O
initial	O
stock	O
solutions	O
of	O
analytical	O
standards	O
by	O
di	O
##sso	O
##lving	O
measured	O
amounts	O
of	O
the	O
target	O
anal	O
##yte	O
##s	O
in	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
.	O

In	O
this	O
study	O
,	O
we	O
used	O
a	O
newly	O
developed	O
N	O
##MR	O
s	O
##pect	O
##ro	O
##copy	O
-	O
based	O
ass	O
##ay	O
to	O
determine	O
plasma	O
beta	B
##ine	I
.	O

Clinical	O
measurements	O
of	O
glucose	S
and	O
insulin	O
were	O
taken	O
pre	O
and	O
post	O
treatment	O
and	O
used	O
in	O
the	O
Home	O
##ost	O
##asis	O
Model	O
Assessment	O
(	O
H	O
##OM	O
##A	O
)	O
to	O
estimate	O
beta	O
cell	O
function	O
,	O
insulin	O
sensitivity	O
and	O
insulin	O
resistance	O
;	O
c	O
-	O
p	O
##eptide	O
and	O
ch	B
##ole	I
##ster	I
##ol	I
meta	O
##bol	O
##ites	O
were	O
also	O
measured	O
pre	O
and	O
post	O
si	B
##m	I
##vas	I
##tat	I
##in	I
treatment	O
,	O
along	O
with	O
several	O
other	O
clinical	O
tests	O
.	O

L	O
of	O
l	B
##ys	I
##ine	I
-	I
lab	I
(	O
_	O
13	O
C	O
_	O
6	O
,	O
_	O
15	O
N	O
_	O
2	O
)	O
and	O
a	B
##rg	I
##ini	I
##ne	I
-	I
lab	I
(	O
_	O
13	O
C	O
_	O
6	O
,	O
_	O
15	O
N	O
_	O
4	O
)	O
prepared	O
in	O
water	O
.	O

The	O
E	O
##DC	O
##s	O
could	O
influence	O
the	O
ER	O
signaling	O
through	O
stimulation	O
of	O
a	B
##ryl	I
h	I
##ydro	I
##car	I
##bon	I
receptor	O
(	O
Ah	O
##r	O
)	O
.	O

Not	O
##ably	O
,	O
the	O
base	O
##line	O
levels	O
of	O
the	O
saturated	O
fatty	O
acids	O
my	O
##rist	O
##ic	O
acid	O
,	O
cap	B
##ric	I
acid	I
,	O
la	B
##uri	I
##c	I
acid	I
and	O
p	B
##ela	I
##rgon	I
##ic	I
acid	I
positively	O
correlated	O
to	O
the	O
change	O
in	O
glucose	S
to	O
c	O
-	O
p	O
##eptide	O
ratio	O
,	O
whereas	O
the	O
base	O
##line	O
levels	O
of	O
the	O
mon	O
##ou	O
##ns	O
##at	O
##ura	O
##ted	O
o	B
##le	I
##ic	I
acid	I
and	O
the	O
p	O
##oly	O
##uns	O
##at	O
##ura	O
##ted	O
l	B
##ino	I
##le	I
##ic	I
acid	I
negatively	O
correlated	O
with	O
this	O
ratio	O
.	O

However	O
,	O
the	O
amino	O
acid	O
and	O
car	B
##ni	I
##tine	I
est	I
##er	I
concentrations	O
found	O
in	O
the	O
Be	O
##MI	O
##M	O
infants	O
did	O
not	O
show	O
indication	O
##s	O
of	O
sat	O
##uration	O
kinetic	O
##s	O
.	O

3	B
'	I
-	I
si	I
##aly	I
##lla	I
##ct	I
##ose	I
belongs	O
to	O
the	O
group	O
of	O
o	B
##li	I
##gos	I
##ac	I
##cha	I
##ride	I
##s	I
,	O
which	O
are	O
generally	O
components	O
of	O
milk	O
and	O
have	O
a	O
protective	O
,	O
immune	O
-	O
m	O
##od	O
##ulating	O
influence	O
on	O
the	O
development	O
of	O
neon	O
##ates	O
[	O
,	O
]	O
;	O
3	B
'	I
-	I
si	I
##aly	I
##lla	I
##ct	I
##ose	I
is	O
composed	O
of	O
si	B
##ali	I
##c	I
acid	I
(	B
N	B
-	I
ace	I
##ty	I
##ln	I
##eur	I
##ami	I
##nic	I
acid	O
)	O
and	O
la	B
##ct	I
##ose	I
.	O

Sign	O
##ificant	O
decreases	O
in	O
mean	O
levels	O
of	O
P	O
##GE	O
-	O
M	O
and	O
8	B
-	I
is	I
##o	I
-	I
P	I
##G	I
##F	I
_	I
2	I
##α	I
per	O
mill	O
##ig	O
##ram	O
c	B
##rea	I
##tin	I
##ine	I
were	O
observed	O
in	O
these	O
subjects	O
,	O
by	O
44	O
%	O
(	O
p	O
=	O
0	O
.	O
00	O
##14	O
)	O
and	O
27	O
%	O
(	O
p	O
<	O
0	O
.	O
00	O
##1	O
)	O
,	O
respectively	O
.	O

The	O
ions	O
observed	O
at	O
m	O
/	O
z	O
227	O
.	O
2	O
and	O
m	O
/	O
z	O
226	O
.	O
2	O
in	O
the	O
product	O
ion	O
spectrum	O
of	O
5	B
-	I
H	I
##O	I
-	I
[	I
_	I
2	I
H	I
_	I
5	I
]	I
-	O
Ph	O
##IP	O
are	O
attributed	O
to	O
losses	O
of	O
HD	O
##O	O
and	O

Using	O
a	O
VIP	O
threshold	O
of	O
1	O
.	O
5	O
,	O
k	B
##eto	I
##g	I
##lut	I
##ari	I
##c	I
acid	I
,	O
su	B
##c	I
##rose	I
,	O
cello	B
##bio	I
##se	I
,	O
and	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
were	O
selected	O
as	O
important	O
features	O
in	O
different	O
##iating	O
the	O
follow	O
-	O
up	O
plasma	O
of	O
the	O
AT	O
##G	O
from	O
the	O
IT	O
##G	O
.	O

The	O
cat	B
##ech	I
##ol	I
est	O
##rogen	O
##s	O
,	O
4	B
-	I
OH	I
-	I
E	I
##2	I
and	O
2	B
-	I
OH	I
-	I
E	I
##2	I
,	O
which	O
each	O
contains	O
two	O
p	O
##hen	O
##olic	O
h	O
##ydro	O
##xy	O
##l	O
groups	O
,	O
reacted	O
with	O
two	O
m	O
##olar	O
equivalent	O
##s	O
of	O
the	O
p	B
##yr	I
##id	I
##ine	I
-	I
3	I
-	I
su	I
##lf	I
##ony	I
##l	I
chloride	I
generating	O
bi	O
##s	O
-	O
PS	O
derivatives	O
.	O

A	O
second	O
exception	O
is	O
car	B
##ni	I
##tine	I
C	O
##0	O
(	O
B	O
##io	O
##crates	O
)	O
,	O
which	O
clusters	O
near	O
pro	B
##line	I
,	O
v	B
##ali	I
##ne	I
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
and	O
prop	B
##ion	I
##yl	I
##car	I
##ni	I
##tine	I
in	O
the	O
Met	O
##ab	O
##olo	O
##n	O
cluster	O
.	O

Furthermore	O
,	O
R	O
##R	O
##M	O
##1	O
was	O
not	O
altered	O
between	O
ta	B
##mo	I
##xi	I
##fen	I
respond	O
##ers	O
and	O
non	O
##res	O
##po	O
##nders	O
in	O
this	O
data	O
set	O
,	O
whereas	O
R	O
##R	O
##M	O
##2	O
##b	O
was	O
not	O
measured	O
.	O

The	O
level	O
of	O
format	B
##e	I
and	O
dim	B
##eth	I
##yla	I
##mine	I
in	O
met	B
##hane	I
metabolism	O
was	O
found	O
to	O
be	O
significantly	O
changed	O
in	O
B	O
##D	O
subjects	O
.	O

A	O
possible	O
explanation	O
could	O
be	O
that	O
the	O
“	O
s	O
##chi	O
##zophrenia	O
brain	O
”	O
prefer	O
##ential	O
##ly	O
utilizes	O
la	B
##ct	I
##ate	I
over	O
glucose	S
as	O
an	O
energy	O
substrate	O
.	O

Co	O
##mpo	O
##und	O
dependent	O
parameters	O
for	O
Pro	B
##line	I
and	O
IS	O
in	O
MR	O
##M	O
mode	O
for	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
analysis	O
.	O

Con	O
##cent	O
##rations	O
as	O
geometric	O
mean	O
,	O
GM	O
,	O
and	O
standard	O
de	O
##viation	O
(	O
G	O
##SD	O
)	O
of	O
personal	O
exposure	O
##s	O
were	O
0	O
.	O
16	O
(	O
5	O
.	O
50	O
)	O
μ	O
##g	O
/	O
m	O
_	O
3	O
for	O
3	O
-	O
EP	O
,	O
0	O
.	O
22	O
(	O
4	O
.	O
28	O
)	O
μ	O
##g	O
/	O
m	O
_	O
3	O
for	O
B	O
##UT	O
and	O
0	O
.	O
09	O
(	O
3	O
.	O
03	O
)	O
ng	O
/	O
m	O
_	O
3	O
for	O
ben	B
##zo	I
(	I
a	I
)	I
p	I
##yre	I
##ne	I
.	O

As	O
d	O
##A	O
is	O
always	O
present	O
in	O
processed	O
DNA	O
samples	O
,	O
the	O
absence	O
of	O
d	O
##T	O
##G	O
in	O
negative	O
-	O
control	O
M	O
##OL	O
##T	O
##4	O
cells	O
and	O
in	O
patients	O
not	O
on	O
th	B
##io	I
##pur	I
##ine	I
therapy	O
indicates	O
select	O
##ivity	O
.	O

In	O
addition	O
,	O
the	O
alterations	O
in	O
energy	O
metabolism	O
induced	O
by	O
high	O
-	O
altitude	O
exposure	O
were	O
associated	O
with	O
ATP	S
de	O
##ple	O
##tion	O
and	O
accumulation	O
of	O
phosphate	S
.	O

Ad	O
##dition	O
of	O
Na	O
##OH	O
before	O
protein	O
precipitation	O
was	O
reported	O
to	O
release	O
anal	O
##yte	O
##s	O
from	O
vitamin	B
D	I
binding	O
proteins	O
.	O

As	O
a	O
result	O
,	O
at	O
a	O
25	O
(	O
OH	O
)	O
D	O
_	O
3	O
concentration	O
of	O
20	O
ng	O
/	O
m	O
##L	O
,	O
mean	O
24	B
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
concentration	O
was	O
2	O
.	O
92	O
(	O
95	O
%	O
C	O
##I	O
,	O
2	O
.	O
87	O
–	O
2	O
.	O
96	O
)	O
,	O
2	O
.	O
68	O
(	O
95	O
%	O
C	O
##I	O
,	O
2	O
.	O
64	O
–	O
2	O
.	O
72	O
)	O
,	O
2	O
.	O
35	O
(	O
95	O
%	O
C	O
##I	O
,	O
2	O
.	O
26	O
–	O
2	O
.	O
45	O
)	O
,	O
1	O
.	O
92	O
(	O
95	O
%	O
C	O
##I	O
,	O
1	O
.	O
74	O
–	O
2	O
.	O
10	O
)	O
,	O
1	O
.	O
69	O
(	O
95	O
%	O
C	O
##I	O
,	O
1	O
.	O
43	O
–	O
1	O
.	O
95	O
)	O
,	O
1	O
.	O
14	O
(	O
95	O
%	O
C	O
##I	O
,	O
0	O
.	O
62	O
–	O
1	O
.	O
66	O
)	O
,	O
and	O
1	O
.	O
04	O
(	O
95	O
%	O
C	O
##I	O
,	O
1	O
.	O
02	O
–	O
1	O
.	O
07	O
)	O
ng	O
/	O
m	O
##L	O
for	O
each	O
category	O
,	O
respectively	O
.	O

In	O
brief	O
,	O
the	O
a	O
##que	O
##ous	O
and	O
v	O
##it	O
##re	O
##ous	O
humor	O
##s	O
,	O
as	O
well	O
as	O
the	O
plasma	O
,	O
were	O
treated	O
with	O
the	O
addition	O
of	O
a	O
5	O
vol	O
excess	O
of	O
a	O
met	B
##han	I
##ol	I
solution	O
containing	O
5	O
m	O
##M	O
mon	B
##ob	I
##rom	I
##ob	I
##iman	I
##e	I
(	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
,	O
St	O
.	O
Luis	O
,	O
M	O
##O	O
)	O
and	O
were	O
in	O
##cu	O
##bate	O
##d	O
at	O
37	O
°C	O
for	O
15	O
min	O
.	O

Co	O
##mpo	O
##unds	O
6	O
,	O
9	O
,	O
13	O
,	O
and	O
16	O
(	O
each	O
as	O
a	O
mixture	O
of	O
un	O
##se	O
##par	O
##able	O
di	O
##aster	O
##eo	O
##mers	O
)	O
were	O
synthesized	O
by	O
reaction	O
of	O
the	O
e	B
##pox	I
##ides	I
2	O
and	O
12	O
with	O
N	B
-	I
ace	I
##ty	I
##l	I
-	I
L	I
-	I
c	I
##ys	I
##tein	I
##e	I
(	O
N	O
##AC	O
)	O
.	O

The	O
medium	O
thus	O
contained	O
0	O
.	O
17	O
m	O
##M	O
_	O
12	O
C	O
al	B
##ani	I
##ne	I
and	O
0	O
.	O
5	O
m	O
##M	O
un	O
##la	O
##bel	O
##ed	O
la	B
##ct	I
##ate	I
and	O
0	O
.	O
56	O
m	O
##M	O
un	O
##la	O
##bel	O
##ed	O
glucose	S
from	O
the	O
FC	O
##S	O
.	O

X	B
##ant	I
##hine	I
o	O
##xi	O
##das	O
##e	O
cat	O
##aly	O
##ses	O
the	O
oxidation	O
of	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
to	O
x	B
##ant	I
##hine	I
and	O
can	O
further	O
cat	O
##aly	O
##se	O
oxidation	O
of	O
x	B
##ant	I
##hine	I
to	O
u	B
##ric	I
acid	I
.	O

Biological	O
parameters	O
,	O
hem	O
##ody	O
##nam	O
##ic	O
parameters	O
,	O
and	O
the	O
use	O
of	O
cat	B
##ech	I
##ola	I
##mine	I
and	O
mechanical	O
ventilation	O
were	O
recorded	O
at	O
inclusion	O
.	O

Vita	O
##min	O
B	O
-	O
12	O
treatment	O
increased	O
metabolic	O
markers	O
of	O
my	B
##elin	I
integrity	O
and	O
m	O
##od	O
##ulator	O
##s	O
of	O
membrane	O
dynamics	O
,	O
such	O
as	O
plasma	O
##log	O
##ens	O
(	O
a	O
specific	O
type	O
of	O
et	B
##her	I
p	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
)	O
and	O
other	O
long	O
-	O
chain	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
(	O
C	O
##38	O
–	O
40	O
)	O
.	O

C	O
,	O
The	O
levels	O
of	O
ace	B
##ty	I
##l	I
-	I
Co	I
##A	I
in	O
cells	O
before	O
labeled	O
glucose	S
or	O
g	B
##lut	I
##amine	I
was	O
added	O
to	O
the	O
culture	O
media	O
.	O

Re	O
##lative	O
##ly	O
strong	O
correlation	O
##s	O
were	O
seen	O
between	O
amino	O
acids	O
(	O
i	O
##e	O
,	O
his	B
##ti	I
##dine	I
,	O
th	B
##re	I
##oni	I
##ne	I
,	O
met	B
##hi	I
##oni	I
##ne	I
,	O
as	B
##par	I
##agi	I
##ne	I
,	O
g	B
##lut	I
##amine	I
,	O
l	B
##ys	I
##ine	I
and	O
t	B
##yr	I
##os	I
##ine	I
)	O
.	O

Do	O
##ses	O
of	O
drugs	O
were	O
as	O
follows	O
:	O
(	O
1	O
)	O
Men	O
in	O
arm	O
1	O
received	O
10	O
.	O
8	O
mg	O
go	O
##ser	O
##elin	O
once	O
and	O
bi	B
##cal	I
##uta	I
##mi	I
##de	I
(	O
50	O
mg	O
daily	O
)	O
.	O

Tam	B
##ox	I
##ife	I
##n	I
and	O
the	O
meta	O
##bol	O
##ites	O
of	O
ta	B
##mo	I
##xi	I
##fen	I
,	O
(	B
end	B
##ox	I
##ife	I
##n	I
,	O
4	O
h	B
##ydro	I
##xy	I
##tam	I
##ox	I
##ife	I
##n	I
,	O
N	B
##D	I
-	I
ta	I
##mo	I
##xi	I
##fen	I
)	O
,	O
were	O
separated	O
and	O
q	O
##uant	O
##ified	O
by	O
is	O
##oc	O
##ratic	O
HP	O
##LC	O
method	O
,	O
with	O
post	O
-	O
column	O
i	O
##rra	O
##diation	O
by	O
exposure	O
to	O
UV	O
light	O
in	O
a	O
P	O
##H	O
##RE	O
##D	O
unit	O
.	O

Eleven	O
weeks	O
after	O
induction	O
,	O
we	O
e	O
##uth	O
##ani	O
##zed	O
rats	O
by	O
terminal	O
is	B
##of	I
##lu	I
##rane	I
an	O
##est	O
##hesia	O
,	O
ex	O
##cise	O
##d	O
brains	O
,	O
and	O
stored	O
them	O
at	O
−	O
##80	O
°C	O
until	O
analysis	O
.	O

However	O
,	O
an	O
analysis	O
of	O
meta	O
##bol	O
##ite	O
partial	O
correlation	O
##s	O
(	O
Figure	O
)	O
reveals	O
that	O
as	B
##par	I
##tate	I
levels	O
are	O
not	O
directly	O
linked	O
to	O
u	B
##rea	I
cycle	O
intermediate	O
##s	O
but	O
instead	O
to	O
g	B
##lut	I
##ama	I
##te	I
.	O

B	O
##rief	O
##ly	O
,	O
five	O
de	O
##uter	O
##ium	O
-	O
labeled	O
internal	O
standards	O
(	O
0	O
.	O
5	O
ng	O
)	O
were	O
added	O
to	O
plasma	O
al	O
##iq	O
##uo	O
##ts	O
[	O
d	O
_	O
5	O
-	O
R	O
##v	O
##D	O
##2	O
,	O
d	B
_	I
8	I
-	I
5	I
-	I
h	I
##ydro	I
##xy	I
##ei	I
##cos	I
##ate	I
##tra	I
##eno	I
##ic	I
acid	I
(	O
d	O
_	O
8	O
-	O
5	O
-	O
H	O
##ET	O
##E	O
)	O
,	O
d	O
_	O
4	O
-	O
le	O
##uk	O
##ot	O
##rien	O
##e	O

The	O
mobile	O
phase	O
was	O
run	O
at	O
a	O
flow	O
rate	O
of	O
300	O
μ	O
##L	O
/	O
min	O
and	O
consisted	O
of	O
2	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
in	O
Mill	O
##i	O
##Q	O
water	O
(	O
A	O
phase	O
)	O
and	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
(	O
B	O
phase	O
)	O
starting	O
with	O
5	O
%	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
for	O
2	O
min	O
following	O
gradient	O
el	O
##ution	O
,	O
total	O
run	O
time	O
of	O
10	O
min	O
.	O

Ho	B
##mos	I
##eri	I
##ne	I
acts	O
as	O
an	O
intermediate	O
for	O
the	O
bio	O
##sy	O
##nt	O
##hesis	O
of	O
met	B
##hi	I
##oni	I
##ne	I
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
and	O
th	B
##re	I
##oni	I
##ne	I
.	O

The	O
relationship	O
between	O
MS	O
and	O
the	O
se	O
##rot	O
##one	O
##rg	O
##ic	O
system	O
(	O
SS	O
)	O
,	O
of	O
which	O
se	O
##rot	O
##oni	O
##n	O
’	O
s	O
main	O
meta	O
##bol	O
##ite	O
5	B
-	I
H	I
##IA	I
##A	I
is	O
a	O
part	O
,	O
is	O
currently	O
not	O
well	O
understood	O
.	O

For	O
each	O
individual	O
sample	O
,	O
four	O
volumes	O
of	O
ice	O
-	O
cold	O
met	B
##han	I
##ol	I
were	O
added	O
to	O
one	O
volume	O
of	O
plasma	O
or	O
CS	O
##F	O
,	O
immediately	O
v	O
##ortex	O
##ed	O
for	O
45	O
seconds	O
,	O
and	O
left	O
to	O
pre	O
##ci	O
##pit	O
##ate	O
at	O
−	O
##20	O
°C	O
for	O
one	O
hour	O
.	O

At	O
4	O
##h	O
,	O
C	O
##16	O
,	O
C	B
##18	I
:	I
1	I
and	O
C	B
##18	I
:	I
2	I
finally	O
reached	O
a	O
na	O
##dir	O
and	O
then	O
began	O
to	O
rise	O
in	O
the	O
late	O
post	O
##pra	O
##ndi	O
##al	O
phase	O
when	O
diet	O
##ary	O
fatty	O
acids	O
were	O
being	O
liberated	O
in	O
the	O
plasma	O
compartment	O
,	O
and	O
at	O
the	O
same	O
time	O
ad	O
##ip	O
##ose	O
fatty	O
acid	O
release	O
resumed	O
.	O

Two	O
de	O
##uter	O
##ated	O
internal	O
standards	O
,	O
est	B
##rio	I
##l	I
-	I
,	O
est	B
##rone	I
-	I
were	O
purchased	O
from	O
C	O
/	O
D	O
/	O
N	O
Is	O
##oto	O
##pes	O
,	O
Inc	O
.	O
(	O
Point	O
##e	O
-	O
Claire	O
,	O
Quebec	O
,	O
Canada	O
)	O
,	O
est	B
##rad	I
##iol	I
-	I
was	O
supplied	O
by	O
Cambridge	O
Is	O
##oto	O
##pe	O
Laboratories	O
,	O
Inc	O
.	O
(	O
And	O
##over	O
,	O
MA	O
,	O
USA	O
)	O
and	O
al	B
##dos	I
##tero	I
##ne	I
-	I
(	I
used	I
as	I
internal	I
standard	I
for	I
16	I
-	I
OH	I
##E	I
##1	I
)	I
was	O
custom	O
synthesized	O
by	O
Is	O
##o	O
##S	O
##cie	O
##nces	O
,	O
LLC	O
(	O
King	O
of	O
Prussia	O
,	O
PA	O
,	O
USA	O
)	O
.	O

Our	O
results	O
also	O
showed	O
an	O
increasing	O
trend	O
in	O
g	B
##ly	I
##cine	I
levels	O
which	O
has	O
previously	O
been	O
described	O
as	O
a	O
short	O
-	O
term	O
effect	O
of	O
bar	O
##ia	O
##tric	O
surgery	O
and	O
inverse	O
##ly	O
related	O
to	O
type	O
2	O
diabetes	O
[	O
,	O
]	O
.	O

We	O
describe	O
the	O
development	O
and	O
valid	O
##ation	O
of	O
a	O
new	O
analysis	O
method	O
for	O
the	O
measurement	O
of	O
plasma	O
is	O
##oto	O
##pic	O
en	O
##rich	O
##ments	O
following	O
the	O
administration	O
of	O
multiple	O
trace	O
##rs	O
to	O
study	O
g	B
##ly	I
##ox	I
##yla	I
##te	I
metabolism	O
.	O

A	O
global	O
G	O
##C	O
–	O
MS	O
-	O
based	O
metabolic	O
pro	O
##fi	O
##ling	O
study	O
has	O
identified	O
elevated	O
levels	O
of	O
ch	B
##ole	I
##ster	I
##ol	I
(	O
a	O
precursor	O
of	O
and	O
##rogen	O
bio	O
##sy	O
##nt	O
##hesis	O
)	O
to	O
be	O
a	O
signature	O
of	O
PC	O
##a	O
that	O
has	O
meta	O
##sta	O
##si	O
##zed	O
to	O
bone	O
.	O

Previous	O
studies	O
have	O
confirmed	O
increased	O
levels	O
of	O
ch	B
##ole	I
##ster	I
##ol	I
in	O
color	O
##ec	O
##tal	O
cancer	O
tissue	O
and	O
serum	O
ch	B
##ole	I
##ster	I
##ol	I
levels	O
were	O
significantly	O
lower	O
in	O
co	O
##lon	O
cancer	O
,	O
stomach	O
cancer	O
,	O
and	O
oral	O
cancer	O
patients	O
.	O

An	O
additional	O
plate	O
was	O
set	O
up	O
concurrently	O
and	O
a	O
crystal	O
violet	O
ass	O
##ay	O
was	O
performed	O
to	O
normal	O
##ise	O
ATP	S
measurements	O
to	O
cell	O
number	O
.	O

Ser	O
##um	O
samples	O
from	O
the	O
same	O
patients	O
were	O
collected	O
in	O
10	O
m	O
##L	O
plain	O
glass	O
blood	O
-	O
tubes	O
(	O
B	O
##D	O
V	O
##ac	O
##uta	O
##iner	O
_	O
®	O
)	O
spun	O
down	O
,	O
fraction	O
##ated	O
and	O
frozen	O
in	O
2	O
m	O
##L	O
p	B
##oly	I
##p	I
##rop	I
##yle	I
##ne	I
via	O
##ls	O
(	O
Sa	O
##rst	O
##ed	O
##t	O
AG	O
&	O
Co	O
.	O
)	O
at	O
−	O
##20	O
°C	O
within	O
45	O
min	O
.	O

2	O
.	O
a	B
##rg	I
##ini	I
##ne	I
and	O
pro	B
##line	I
metabolism	O
.	O

Interest	O
##ingly	O
,	O
AM	B
##P	I
was	O
significantly	O
elevated	O
in	O
the	O
c	O
##er	O
##vic	O
##al	O
cancer	O
group	O
as	O
compared	O
to	O
C	O
##IN	O
and	O
normal	O
,	O
whereas	O
no	O
significant	O
difference	O
was	O
observed	O
for	O
pro	B
##line	I
between	O
C	O
##IN	O
and	O
c	O
##er	O
##vic	O
##al	O
cancer	O
as	O
compared	O
to	O
normal	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

c	O
.	O
Co	O
##rrel	O
##ation	O
analysis	O
between	O
H	O
##b	O
##A	O
##1	O
##c	O
level	O
and	O
[	B
3	I
-	I
H	I
##B	I
]	I
/	I
[	I
glucose	I
]	I
ratio	O
with	O
all	O
the	O
samples	O
.	O

G	B
##lut	I
##ama	I
##te	I
is	O
derives	O
from	O
2	B
-	I
o	I
##x	I
##og	I
##lut	I
##arate	I
by	O
trans	O
##ami	O
##nation	O
or	O
red	O
##uctive	O
am	O
##ination	O
(	O
G	O
##lu	O
de	O
##hy	O
##dr	O
##ogen	O
##ase	O
)	O
in	O
ma	O
##mmal	O
##ian	O
cells	O
.	O

This	O
pattern	O
is	O
consistent	O
with	O
the	O
en	O
##rich	O
##ment	O
of	O
multi	O
##p	O
##ly	O
labeled	O
la	B
##ct	I
##ate	I
and	O
al	B
##ani	I
##ne	I
of	O
200	O
–	O
300	O
fold	O
over	O
the	O
natural	O
abundance	O
levels	O
.	O

(	O
I	O
)	O
R	O
##T	O
-	O
q	O
##PC	O
##R	O
for	O
C	O
##YP	O
##1	O
##A	O
##1	O
in	O
DL	O
##D	O
##1	O
cells	O
in	O
##cu	O
##bate	O
##d	O
with	O
D	B
##MS	I
##O	I
,	O
20	O
µ	O
##M	O
K	O
##yn	O
,	O
or	O
10	O
µ	O
##M	O
CH	O
##22	O
##31	O
##9	O
##1	O
.	O

Similar	O
to	O
these	O
results	O
,	O
the	O
levels	O
of	O
c	O
##lea	O
##ved	O
ca	O
##sp	O
##ase	O
9	O
,	O
c	O
##lea	O
##ved	O
ca	O
##sp	O
##ase	O
3	O
,	O
molecular	O
markers	O
of	O
mitochondrial	O
a	O
##pop	O
##tosis	O
,	O
and	O
c	O
##lea	O
##ved	O
p	O
##oly	O
AD	B
##P	I
rib	I
##ose	I
polymer	O
##ase	O
(	O
PA	O
##RP	O
)	O
were	O
marked	O
##ly	O
enhanced	O
by	O
ET	O
##O	O
treatment	O
,	O
which	O
could	O
be	O
alleviate	O
##d	O
by	O
z	O
##VA	O
##D	O
in	O
response	O
to	O
radiation	O
(	O
Figure	O
C	O
)	O
.	O

In	O
the	O
urine	O
,	O
clusters	O
related	O
to	O
pen	O
##tos	O
##es	O
,	O
pu	B
##rine	I
##s	I
,	O
di	B
##sa	I
##cc	I
##hari	I
##des	I
,	O
p	B
##hen	I
##yla	I
##ce	I
##tate	I
##s	I
,	O
sugar	O
alcohol	O
##s	O
,	O
amino	O
acids	O
(	O
c	O
##yclic	O
,	O
basic	O
,	O
acidic	O
,	O
sulfur	O
and	O
a	O
##romatic	O
)	O
,	O
g	B
##lut	I
##arate	I
##s	I
,	O
he	O
##x	O
##uron	O
##ates	O
,	O
ma	B
##lates	I
,	O
he	O
##x	O
##ose	O
##s	O
,	O
sugar	O
acids	O
,	O
c	O
##it	O
##rates	O
,	O
in	O
##do	O
##les	O
,	O
saturated	O
FA	S
,	O
di	B
##car	I
##box	I
##yla	I
##tes	I
,	O
pu	B
##rino	I
##nes	I
were	O
associated	O
with	O
hospital	O
##izations	O
.	O

150	O
μ	O
##L	O
of	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
was	O
added	O
subsequently	O
and	O
the	O
PP	O
tube	O
was	O
v	O
##ortex	O
##ed	O
for	O
another	O
30	O
s	O
.	O
The	O
PP	O
tube	O
was	O
cent	O
##ri	O
##fu	O
##ged	O
at	O
35	O
,	O
000	O
×	O
g	O
for	O
10	O
min	O
at	O
4	O
##°	O
##C	O
.	O

Anti	O
-	O
h	O
##yper	O
##tensive	O
medication	O
,	O
particularly	O
an	O
##gio	O
##tens	O
##in	O
-	O
converting	O
enzyme	O
inhibitor	O
##s	O
,	O
an	B
##gio	I
##tens	I
##in	I
II	I
receptor	O
antagonist	O
##s	O
and	O
di	O
##ure	O
##tics	O
,	O
alone	O
or	O
in	O
combination	O
)	O
were	O
used	O
by	O
27	O
T	O
##2	O
##DM	O
subjects	O
.	O

In	O
both	O
cell	O
types	O
,	O
the	O
decline	O
observed	O
over	O
time	O
under	O
control	O
conditions	O
,	O
e	O
.	O
g	O
.	O
for	O
th	B
##re	I
##oni	I
##ne	I
and	O
se	B
##rine	I
,	O
is	O
at	O
##ten	O
##uated	O
during	O
the	O
presence	O
of	O
r	O
##H	O
##la	O
in	O
the	O
culture	O
medium	O
.	O

Po	O
##sitive	O
correlation	O
##s	O
were	O
observed	O
between	O
various	O
ben	B
##zo	I
##ate	I
meta	O
##bol	O
##ites	O
and	O
amino	O
acid	O
meta	O
##bol	O
##ites	O
.	O

The	O
most	O
intense	O
signals	O
in	O
urine	O
arose	O
from	O
g	B
##ly	I
##cine	I
,	O
c	B
##rea	I
##tin	I
##ine	I
,	O
c	B
##it	I
##rate	I
,	O
α	B
-	I
k	I
##eto	I
##g	I
##lut	I
##arate	I
,	O
trim	B
##eth	I
##yla	I
##mine	I
-	I
N	I
-	I
oxide	I
and	O
p	B
-	I
h	I
##ydro	I
##xy	I
##phe	I
##ny	I
##lace	I
##tate	I
.	O

A	O
.	O
S	O
##UM	O
##14	O
##9	O
##P	O
##T	O
and	O
B	O
.	O
S	O
##UM	O
##13	O
##15	O
##MO	O
##2	O
breast	O
cancer	O
cells	O
were	O
treated	O
with	O
D	B
##MS	I
##O	I
solvent	O
,	O
C	O
##75	O
or	O
c	B
##ele	I
##co	I
##xi	I
##b	I
,	O
alone	O
or	O
C	O
##75	O
and	O
c	B
##ele	I
##co	I
##xi	I
##b	I
combined	O
.	O

Gene	O
expression	O
level	O
in	O
in	O
##f	O
##lam	O
##ed	O
tissue	O
from	O
UC	O
patients	O
correlated	O
with	O
clinical	O
disease	O
activity	O
index	O
R	B
##I	I
in	O
case	O
of	O
AR	O
##G	O
##1	O
(	O
ρ	O
=	O
0	O
.	O
66	O
,	O
p	O
=	O
0	O
.	O
01	O
##9	O
,	O
n	O
=	O
12	O
)	O
,	O
AR	O
##G	O
##2	O
(	O
ρ	O
=	O
0	O
.	O
86	O
,	O
p	O
<	O
0	O
.	O
00	O
##1	O
,	O
n	O
=	O
12	O
)	O
,	O
DD	O
##A	O
##H1	O
(	O
ρ	O
=	O
0	O
.	O
75	O
,	O
p	O
=	O
0	O
.	O
00	O
##5	O
,	O
n	O
=	O
12	O
)	O
,	O
PR	O
##MT	O
##1	O
(	O
ρ	O
=	O
0	O
.	O
59	O
,	O
p	O
=	O
0	O
.	O
04	O
##3	O
,	O
n	O
=	O
12	O
)	O
,	O
and	O
PR	O
##MT	O
##2	O
(	O
ρ	O
=	O
0	O
.	O
64	O
,	O
p	O
=	O
0	O
.	O
02	O
##4	O
,	O
n	O
=	O
12	O
)	O
.	O

The	O
bi	O
##le	O
acids	O
were	O
el	O
##uted	O
with	O
met	B
##han	I
##ol	I
through	O
a	O
SP	O
##E	O
column	O
(	O
Bond	O
El	O
##ute	O
C	O
##18	O
)	O
,	O
followed	O
by	O
two	O
different	O
der	O
##iva	O
##ti	O
##zation	O
steps	O
.	O

In	O
1	O
.	O
5	O
-	O
m	O
##L	O
e	O
##ppe	O
##ndo	O
##rf	O
tubes	O
that	O
were	O
placed	O
on	O
ice	O
,	O
225	O
μ	O
##L	O
of	O
CS	O
##F	O
,	O
0	O
.	O
9	O
%	O
Na	O
##C	O
##l	O
,	O
or	O
CS	O
##F	O
/	O
ethanol	O
was	O
added	O
to	O
25	O
μ	O
##L	O
of	O
pH	O
7	O
.	O
0	O
phosphate	S
buffer	O
(	O
50	O
m	O
##M	O
)	O
in	O
D	O
##2	O
##O	O
containing	O
4	O
m	O
##M	O
of	O
sodium	B
3	I
-	I
trim	I
##eth	I
##yl	I
##si	I
##ly	I
##lt	I
##et	I
##rade	I
##uter	I
##io	I
##p	I
##rop	I
##ion	I
##ate	I
(	O
T	O
##SP	O
)	O
and	O
2	O
.	O
0	O
m	O
##M	O
Na	O
##N	O
_	O
3	O
.	O

Still	O
,	O
we	O
found	O
no	O
strong	O
correlation	O
between	O
co	B
##tin	I
##ine	I
and	O
try	B
##pt	I
##op	I
##han	I
,	O
K	O
##TR	O
,	O
k	O
##yn	O
##uren	O
##ines	O
or	O
vitamin	O
##s	O
in	O
our	O
material	O
when	O
using	O
S	O
##pear	O
##man	O
’	O
s	O
correlation	O
analyses	O
(	O
Table	O
)	O
.	O

CS	O
##F	O
samples	O
were	O
collected	O
from	O
drug	O
-	O
na	O
##ï	O
##ve	O
patients	O
diagnosed	O
with	O
first	O
episode	O
paranoid	O
s	O
##chi	O
##zophrenia	O
(	O
here	O
##aft	O
##er	O
referred	O
to	O
as	O
s	O
##chi	O
##zophrenia	O
)	O
or	O
brief	O
ps	O
##ych	O
##otic	O
disorder	O
(	O
n	O
=	O
4	O
)	O
due	O
to	O
duration	S
of	O
illness	O
(	O
DS	O
##M	O
-	O
IV	O
295	O
.	O
30	O
or	O
29	O
##8	O
.	O
8	O
;	O
n	O
=	O
54	O
)	O
and	O
from	O
demographic	O
##ally	O
matched	O
healthy	O
volunteers	O
(	O
n	O
=	O
70	O
)	O
.	O

On	O
the	O
contrary	O
,	O
C	B
##5	I
:	I
1	I
,	O
Ph	O
##e	O
/	O
Ty	O
##r	O
,	O
(	B
C	I
##0	I
+	I
C	I
##2	I
+	I
C	I
##3	I
+	I
C	I
##16	I
+	I
C	I
##18	I
:	I
1	I
)	I
/	I
C	I
##it	I
,	O
and	O
Met	O
/	O
Le	O
##u	O
were	O
of	O
lower	O
levels	O
in	O
the	O
C	O
##I	O
group	O
(	O
Fi	O
##g	O
.	O
)	O
.	O

The	O
poor	O
correlation	O
of	O
glucose	S
may	O
be	O
because	O
it	O
exhibits	O
multiple	O
MR	O
##M	O
peaks	O
,	O
and	O
sugar	O
##s	O
such	O
as	O
man	B
##nose	I
with	O
identical	O
molecular	O
weights	O
and	O
similar	O
retention	O
times	O
overlap	O
.	O

A	O
large	O
portion	O
of	O
the	O
d	O
##ys	O
##re	O
##gu	O
##lated	O
meta	O
##bol	O
##ites	O
(	O
45	O
out	O
of	O
the	O
total	O
77	O
)	O
were	O
in	O
the	O
class	O
of	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
.	O

Furthermore	O
,	O
it	O
has	O
been	O
also	O
reported	O
that	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
a	O
##gg	O
##ra	O
##vated	O
my	O
##oc	O
##ard	O
##ial	O
and	O
re	O
##nal	O
g	O
##raft	O
is	O
##che	O
##mia	O
/	O
re	O
##per	O
##fusion	O
injury	O
by	O
R	O
##OS	O
.	O

Although	O
pro	O
##sta	O
##titis	O
is	O
known	O
to	O
reduce	O
pro	O
##static	O
c	B
##it	I
##rate	I
and	O
zinc	O
content	O
and	O
potentially	O
affect	O
MV	O
##SA	O
,	O
this	O
influence	O
in	O
the	O
current	O
study	O
would	O
be	O
minimal	O
due	O
to	O
the	O
focus	O
on	O
R	O
##P	O
-	O
based	O
and	O
ma	O
##li	O
##gnant	O
path	O
##ology	O
,	O
as	O
well	O
as	O
only	O
being	O
confirmed	O
his	O
##to	O
##logical	O
##ly	O
for	O
two	O
patients	O
.	O

The	O
goal	O
of	O
this	O
study	O
was	O
to	O
monitor	O
im	B
##ati	I
##ni	I
##b	I
me	I
##sy	I
##late	I
therapeutic	O
##ally	O
in	O
the	O
Tu	O
##mor	O
Biology	O
Laboratory	O
,	O
Department	O
of	O
He	O
##mat	O
##ology	O
and	O
He	O
##mother	O
##ap	O
##y	O
,	O
Hospital	O
das	O
C	O
##l	O
##ín	O
##ica	O
##s	O
,	O
F	O
##ac	O
##uld	O
##ade	O
de	O
Medici	O
##na	O
,	O
Universidad	O
##e	O
de	O
São	O
Paulo	O
(	O
US	O
##P	O
)	O
.	O

Men	O
who	O
agreed	O
to	O
participate	O
provided	O
a	O
spot	O
urine	O
sample	O
in	O
a	O
s	O
##ter	O
##ile	O
p	B
##oly	I
##p	I
##rop	I
##yle	I
##ne	I
collection	O
cup	O
on	O
the	O
same	O
day	O
of	O
se	O
##men	O
sample	O
pro	O
##curement	O
.	O

P	O
##uri	O
##fied	O
and	O
dried	O
urine	O
samples	O
were	O
dissolved	O
in	O
200	O
μ	O
##L	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
in	O
met	B
##han	I
##ol	I
,	O
cent	O
##ri	O
##fu	O
##ged	O
at	O
21	O
,	O
000	O
g	O
and	O
super	O
##nat	O
##ant	O
were	O
transferred	O
to	O
glass	O
via	O
##ls	O
with	O
micro	O
-	O
insert	O
##s	O
which	O
were	O
c	O
##rim	O
##ped	O
with	O
pre	O
-	O
per	O
##fo	O
##rated	O
lid	O
##s	O
.	O

Important	O
features	O
of	O
the	O
new	O
vitamin	B
D	I
ch	O
##em	O
##ot	O
##y	O
##ping	O
ass	O
##ay	O
were	O
:	O
(	O
1	O
)	O
it	O
required	O
only	O
50	O
μ	O
##L	O
of	O
human	O
serum	O
and	O
was	O
conducted	O
in	O
parallel	O
96	O
-	O
well	O
plate	O
format	O
;	O
(	O
2	O
)	O
meta	O
##bol	O
##ites	O
were	O
der	O
##iva	O
##tised	O
for	O
enhanced	O
response	O
.	O

Co	B
##tin	I
##ine	I
values	O
demonstrated	O
that	O
15	O
of	O
38	O
subjects	O
quit	O
smoking	O
for	O
the	O
entire	O
84	O
day	O
period	O
.	O

The	O
ass	O
##ay	O
mixture	O
were	O
in	O
##cu	O
##bate	O
##d	O
for	O
0	O
.	O
5	O
,	O
1	O
,	O
5	O
and	O
10	O
min	O
then	O
extracted	O
with	O
100	O
µ	O
##l	O
di	B
##ch	I
##lor	I
##ome	I
##than	I
##e	I
,	O
finally	O
7	O
.	O
5	O
µ	O
##M	O
ad	B
##eni	I
##ne	I
was	O
added	O
to	O
extract	O
.	O

B	O
##rief	O
##ly	O
,	O
urine	O
samples	O
were	O
th	O
##awed	O
and	O
a	O
5	O
-	O
m	O
##l	O
al	O
##iq	O
##uo	O
##t	O
was	O
spike	O
##d	O
with	O
mass	O
-	O
labeled	O
internal	O
standards	O
(	O
d	O
_	O
10	O
-	O
B	O
##DC	O
##IP	O
##P	O
and	O
d	O
_	O
10	O
-	O
D	O
##P	O
##HP	O
)	O
and	O
acid	O
##ified	O
to	O
pH	O
<	O
6	O
.	O
5	O
with	O
form	B
##ic	I
acid	I
.	O

LP	O
##L	O
is	O
considered	O
the	O
rate	O
-	O
limiting	O
enzyme	O
for	O
h	O
##ydro	O
##lysis	O
of	O
lip	O
##op	O
##rote	O
##in	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
,	O
and	O
it	O
is	O
likely	O
to	O
be	O
secret	O
##ed	O
by	O
mac	O
##rop	O
##hage	O
##s	O
within	O
at	O
##her	O
##os	O
##cle	O
##rot	O
##ic	O
lesions	O
(	O
,	O
)	O
.	O

Similarly	O
,	O
met	B
##han	I
##ol	I
,	O
which	O
also	O
contributed	O
to	O
the	O
detection	O
of	O
ad	O
##eno	O
##ma	O
,	O
is	O
mainly	O
a	O
product	O
of	O
micro	O
##bial	O
metabolism	O
.	O

[	O
,	O
]	O
have	O
also	O
identified	O
a	O
correlation	O
between	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
and	O
PC	O
##a	O
disease	O
by	O
measuring	O
pre	O
-	O
diagnostic	O
plasma	O
meta	O
##bol	O
##ites	O
and	O
searching	O
for	O
those	O
that	O
appeared	O
to	O
be	O
associated	O
with	O
a	O
certain	O
PC	O
##a	O
grade	O
or	O
stage	O
.	O

A	O
high	O
a	B
##rg	I
##ini	I
##ne	I
concentration	O
can	O
increase	O
a	O
##rg	O
##inas	O
##e	O
activity	O
,	O
which	O
leads	O
to	O
an	O
un	O
##co	O
##up	O
##ling	O
of	O
e	O
##N	O
##OS	O
and	O
induce	O
##s	O
more	O
ne	O
##uro	O
##to	O
##xi	O
##c	O
substance	O
(	O
imaginary	O
line	O
)	O
.	O

Blood	O
level	O
of	O
1	B
,	I
5	I
‐	I
AG	I
is	O
constant	O
as	O
a	O
result	O
of	O
equilibrium	O
between	O
1	B
,	I
5	I
‐	I
AG	I
absorption	O
,	O
u	O
##rina	O
##ry	O
re	O
##ab	O
##sor	O
##ption	O
,	O
and	O
secret	O
##ion	O
by	O
the	O
in	O
##test	O
##inal	O
tract	O
.	O

Water	O
,	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
,	O
and	O
met	B
##han	I
##ol	I
(	O
L	O
##C	O
-	O
MS	O
grade	O
)	O
were	O
obtained	O
from	O
Me	O
##rc	O
##k	O
Mill	O
##ip	O
##ore	O
(	O
Warsaw	O
,	O
Poland	O
)	O
.	O

SM	B
C	I
##16	I
:	I
1	I
;	O
10	O
.	O

Regarding	O
amino	O
acids	O
,	O
in	O
addition	O
to	O
being	O
part	O
of	O
protein	O
sequences	O
and	O
the	O
main	O
ex	O
##ci	O
##tat	O
##ory	O
ne	O
##uro	O
##tra	O
##ns	O
##mit	O
##ter	O
,	O
g	B
##lut	I
##ami	I
##c	I
acid	I
and	O
g	B
##lut	I
##ama	I
##te	I
activate	O
pu	B
##rine	I
##rg	I
##ic	I
receptors	O
P	O
##2	O
##X	O
##7	O
in	O
mac	O
##rop	O
##hage	O
##s	O
and	O
also	O
contribute	O
to	O
o	O
##li	O
##go	O
##den	O
##dr	O
##oc	O
##yte	O
death	O
in	O
the	O
white	O
matter	O
.	O
_	O
,	O
Try	O
##pt	O
##op	O
##han	O
'	O
s	O
key	O
role	O
is	O
serving	O
as	O
a	O
check	O
##point	O
in	O
the	O
activation	O
of	O
the	O
immune	O
system	O
by	O
the	O
enzyme	O
in	O
##do	O
##leam	O
##ine	O
2	O
,	O
3	O
-	O
di	O
##ox	O
##y	O
##gen	O
##ase	O
.	O

Col	O
##lis	O
##ion	O
energy	O
was	O
25	O
V	O
,	O
dwell	O
time	O
was	O
0	O
.	O
05	O
s	O
,	O
and	O
typical	O
retention	O
time	O
for	O
en	B
##zal	I
##uta	I
##mi	I
##de	I
and	O
D	B
_	I
6	I
-	I
en	I
##zal	I
##uta	I
##mi	I
##de	I
was	O
2	O
.	O
5	O
min	O
and	O
for	O
N	B
-	I
des	I
##met	I
##hyl	I
##en	I
##zal	I
##uta	I
##mi	I
##de	I
2	O
.	O
4	O
min	O
.	O

For	O
example	O
,	O
the	O
drug	O
clusters	O
of	O
the	O
para	B
##ce	I
##tam	I
##ol	I
me	O
##rca	O
##pt	O
##ura	O
##tes	O
,	O
en	O
##ala	O
##p	O
##ril	O
and	O
per	O
##ind	O
##op	O
##ril	O
,	O
am	B
##lo	I
##di	I
##pine	I
,	O
the	O
su	B
##lf	I
##ony	I
##lu	I
##rea	I
class	O
drug	O
,	O
and	O
q	B
##uin	I
##id	I
##ine	I
were	O
an	O
##not	O
##ated	O
using	O
amalgamated	O
information	O
from	O
published	O
literature	O
values	O
for	O
drug	O
product	O
ions	O
,	O
Ma	O
##g	O
##M	O
##a	O
(	O
Fi	O
##g	O
.	O

l	O
##ys	O
##o	O
##PC	O
a	O
C	B
##20	I
:	I
4	I
;	O
80	O
.	O

Extra	O
##cts	O
of	O
the	O
pool	O
##ed	O
urine	O
as	O
well	O
as	O
4	O
:	O
1	O
water	O
:	O
Me	O
##OH	O
were	O
spike	O
##d	O
at	O
three	O
levels	O
of	O
B	O
##DC	O
##PP	O
(	O
52	O
##2	O
,	O
98	O
##8	O
and	O
99	O
##31	O
p	B
##g	I
per	O
extract	O
)	O
and	O
D	O
##PP	O
(	O
113	O
##9	O
,	O
242	O
##3	O
,	O
and	O
21	O
,	O
245	O
p	O
##g	O
per	O
extract	O
)	O
.	O

Two	O
thousand	O
units	O
of	O
E	O
.	O
co	O
##li	O
β	O
-	O
g	O
##lu	O
##cu	O
##ron	O
##idas	O
##e	O
in	O
0	O
.	O
1	O
m	O
##L	O
of	O
phosphate	S
buffer	O
##ed	O
sa	B
##line	I
(	O
0	O
.	O
26	O
%	O
,	O
w	O
/	O
v	O
)	O
and	O
10	O
pm	O
##ol	O
[	O
_	O
2	O
H	O
_	O
2	O
]	O
D	O
##IM	O
internal	O
standard	O
were	O
added	O
to	O
1	O
m	O
##L	O
of	O
urine	O
.	O

H	B
##ydro	I
##xy	I
##p	I
##rol	I
##ine	I
,	O
a	O
marker	O
for	O
tissue	O
co	O
##lla	O
##gen	O
degradation	O
,	O
was	O
up	O
##re	O
##gu	O
##lated	O
in	O
severe	O
ps	O
##oria	O
##sis	O
patients	O
and	O
normal	O
##ized	O
by	O
E	O
##tan	O
##er	O
##ce	O
##pt	O
treatment	O
.	O

Bar	O
graphs	O
represent	O
the	O
concentration	O
of	O
individual	O
metabolic	O
bio	O
##mark	O
##ers	O
,	O
namely	O
met	B
##hi	I
##oni	I
##ne	I
,	O
or	B
##ni	I
##thin	I
##e	I
,	O
pro	B
##line	I
,	O
p	B
##ime	I
##ly	I
##l	I
##car	I
##ni	I
##tine	I
,	O
and	O
o	B
##ct	I
##ano	I
##yl	I
##car	I
##ni	I
##tine	I
.	O

Met	O
##ab	O
##oli	O
##tes	O
significantly	O
changed	O
in	O
PA	O
##H	O
patients	O
as	O
compared	O
to	O
control	O
were	O
associated	O
with	O
g	B
##ly	I
##co	I
##ly	I
##tic	I
shift	O
,	O
lip	O
##id	O
-	O
related	O
energy	O
im	O
##bal	O
##ance	O
as	O
well	O
as	O
cellular	O
signal	O
trans	O
##duction	O
.	O

As	O
shown	O
in	O
,	O
when	O
bio	B
##tin	I
su	I
##lf	I
##one	I
,	O
5	B
-	I
o	I
##x	I
##o	I
-	I
he	I
##ne	I
##ico	I
##san	I
##oi	I
##c	I
acid	I
,	O
d	B
-	I
G	I
##lu	I
##cos	I
##ami	I
##ni	I
##de	I
and	O
2	B
-	I
met	I
##hyl	I
##hip	I
##pur	I
##ic	I
acid	I
,	O
were	O
used	O
as	O
bio	O
##mark	O
##ers	O
,	O
the	O
H	O
##B	O
##V	O
-	O
positive	O
group	O
could	O
be	O
clearly	O
separated	O
from	O
the	O
control	O
group	O
in	O
H	O
##B	O
##V	O
prediction	O
.	O

Pa	O
##ir	O
##wise	O
comparisons	O
of	O
base	O
##line	O
8	B
-	I
is	I
##o	I
-	I
P	I
##G	I
##F	I
_	I
2	I
##α	I
vs	I
.	O
each	O
time	O
point	O
are	O
provided	O
in	O
.	O

Ethan	B
##ol	I
(	O
≥	O
99	O
.	O
5	O
%	O
)	O
was	O
purchased	O
from	O
CC	O
##S	O
Healthcare	O
(	O
Malmö	O
,	O
Sweden	O
)	O
,	O
met	B
##han	I
##ol	I
(	O
≥	O
99	O
.	O
9	O
%	O
,	O
MS	O
grade	O
)	O
and	O
p	B
##yr	I
##id	I
##ine	I
(	O
p	O
.	O
a	O
.	O
grade	O
)	O
from	O
Honey	O
##well	O
(	O
See	O
##l	O
##ze	O
,	O
Germany	O
)	O
,	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
(	O
≥	O
99	O
.	O
9	O
%	O
,	O
MS	O
grade	O
)	O
and	O
is	B
##op	I
##rop	I
##ano	I
##l	I
(	O
≥	O
99	O
.	O
9	O
%	O
,	O
MS	O
grade	O
)	O
from	O
V	O
##WR	O
Chemical	O
##s	O
(	O
Le	O
##uve	O
##n	O
,	O
Belgium	O
)	O
,	O
form	B
##ic	I
acid	I
(	O
AC	O
##S	O
re	O
##age	O
##nt	O
grade	O
)	O
from	O
Me	O
##rc	O
##k	O
(	O
Dar	O
##ms	O
##tadt	O
,	O
Germany	O
)	O
,	O
and	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
(	O
≥	O
98	O
%	O
)	O
,	O
p	B
##hen	I
##yl	I
##is	I
##oth	I
##io	I
##cy	I
##ana	I
##te	I
(	O
P	O
##IT	O
##C	O
;	O
99	O
%	O
,	O
se	O
##quencing	O
grade	O
)	O
and	O
phosphate	S
buffer	O
##ed	O
sa	B
##line	I
(	O
p	O
.	O
a	O
.	O
grade	O
)	O
from	O
Sigma	O
(	O
Stein	O
##heim	O
,	O
Germany	O
)	O
.	O

In	O
our	O
study	O
,	O
the	O
changes	O
in	O
v	B
##ali	I
##ne	I
and	O
is	B
##ole	I
##uc	I
##ine	I
levels	O
were	O
different	O
from	O
those	O
in	O
le	B
##uc	I
##ine	I
levels	O
.	O

Pan	O
##cre	O
##atic	O
cancer	O
tissue	O
had	O
a	O
unique	O
profile	O
showing	O
decreased	O
levels	O
of	O
p	B
##hos	I
##ph	I
##och	I
##olin	I
##e	I
and	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##och	I
##olin	I
##e	I
,	O
but	O
not	O
ch	B
##olin	I
##e	I
(	O
Fang	O
et	O
al	O
.	O
)	O
.	O

After	O
stirring	O
overnight	O
,	O
all	O
the	O
starting	O
material	O
was	O
converted	O
to	O
the	O
corresponding	O
su	B
##lf	I
##oxide	I
.	O

Alone	O
,	O
fatty	O
a	B
##cy	I
##l	I
-	I
Co	I
##As	I
(	O
fatty	O
acids	O
)	O
cannot	O
enter	O
the	O
mit	O
##och	O
##ond	O
##ria	O
for	O
β	O
-	O
oxidation	O
and	O
must	O
first	O
be	O
converted	O
to	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
by	O
enzymes	O
of	O
the	O
car	B
##ba	I
##mo	I
##yl	I
phosphate	I
transport	O
shuttle	O
system	O
.	O

A	B
##bir	I
##ater	I
##one	I
was	O
extracted	O
by	O
protein	O
precipitation	O
,	O
separated	O
on	O
a	O
C	O
##18	O
-	O
column	O
with	O
gradient	O
el	O
##ution	O
and	O
analyzed	O
with	O
tandem	O
q	O
##uad	O
##rup	O
##ole	O
mass	O
s	O
##pect	O
##rome	O
##try	O
in	O
positive	O
ion	O
mode	O
.	O

h	O
mean	O
daytime	O
DB	B
##P	I
.	O

In	O
addition	O
,	O
relationships	O
between	O
ch	B
##olin	I
##e	I
meta	O
##bol	O
##ites	O
in	O
milk	O
and	O
blood	O
were	O
examined	O
.	O

Although	O
the	O
patient	O
did	O
not	O
complain	O
of	O
tired	O
##ness	O
during	O
the	O
first	O
evaluation	O
,	O
his	O
level	O
of	O
fatigue	O
was	O
much	O
lower	O
after	O
1	O
month	O
of	O
h	B
##ydro	I
##cor	I
##tis	I
##one	I
.	O

Re	B
##s	I
##ver	I
##at	I
##rol	I
,	O
th	B
##una	I
##l	I
##ben	I
##e	I
,	O
p	O
##ice	O
##ata	O
##nn	O
##ol	O
and	O
pin	B
##ost	I
##il	I
##ben	I
##e	I
were	O
used	O
in	O
five	O
biological	O
repetition	O
##s	O
.	O

E	O
##pid	O
##em	O
##iol	O
##ogical	O
,	O
clinical	O
,	O
and	O
nutrition	O
##al	O
studies	O
from	O
recent	O
years	O
have	O
confirmed	O
the	O
significant	O
biological	O
effects	O
of	O
s	B
##til	I
##ben	I
##oids	I
,	O
such	O
as	O
o	O
##xi	O
##da	O
##tive	O
stress	O
protection	O
and	O
the	O
prevention	O
of	O
de	O
##gene	O
##rative	O
diseases	O
,	O
including	O
cancer	O
,	O
card	O
##iovascular	O
diseases	O
,	O
and	O
ne	O
##uro	O
##de	O
##gene	O
##rative	O
diseases	O
.	O

Not	O
unexpectedly	O
,	O
th	B
##ia	I
##zi	I
##de	I
therapy	O
caused	O
a	O
13	O
%	O
increase	O
of	O
plasma	O
u	B
##ric	I
acid	I
level	O
(	O
P	O
=	O
5	O
x	O
10	O
_	O
−	O
##4	O
)	O
,	O
without	O
marked	O
##ly	O
affecting	O
the	O
levels	O
of	O
u	B
##ric	I
acid	I
precursor	O
compounds	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
and	O
x	B
##ant	I
##hine	I
.	O

Using	O
re	B
##ser	I
##pine	I
as	O
an	O
example	O
,	O
the	O
parameters	O
for	O
Mass	O
##Works	O
s	O
##CL	O
##IP	O
##S	O
algorithms	O
were	O
:	O
mass	O
tolerance	O
,	O
5	O
pp	O
##m	O
;	O
electron	O
state	O
,	O
even	O
;	O
double	O
bond	O
equivalent	O
range	O
,	O
−	O
##3	O
to	O
50	O
;	O
profile	O
mass	O
range	O
,	O
−	O
##1	O
to	O
3	O
.	O
5	O
Da	O
;	O
ca	O
##li	O
##bra	O
##tion	O
range	O
,	O
−	O
##0	O
.	O
1	O
to	O
0	O
.	O
1	O

In	O
mouse	O
models	O
,	O
Ye	O
##a	O
,	O
K	O
et	O
al	O
.	O
have	O
reported	O
that	O
the	O
blood	O
glucose	S
lowering	O
effect	O
of	O
LP	O
##C	O
were	O
found	O
to	O
be	O
sensitive	O
to	O
variations	O
in	O
LP	O
##C	O
a	O
##cy	O
##l	O
chain	O
length	O
,	O
which	O
may	O
el	O
##uc	O
##ida	O
##te	O
the	O
di	O
##vis	O
##ive	O
findings	O
mentioned	O
above	O
.	O

Typically	O
employed	O
reversed	O
-	O
phase	O
(	O
R	O
##P	O
)	O
methods	O
fail	O
to	O
target	O
polar	O
meta	O
##bol	O
##ites	O
but	O
the	O
introduction	O
of	O
h	B
##ydro	I
##phi	I
##lic	I
interaction	O
liquid	O
ch	O
##roma	O
##tography	O
(	O
H	O
##IL	O
##IC	O
)	O
is	O
slow	O
due	O
to	O
perceived	O
issues	O
of	O
re	O
##p	O
##rod	O
##uc	O
##ibility	O
and	O
rugged	O
##ness	O
and	O
a	O
limited	O
understanding	O
of	O
the	O
complex	O
retention	O
mechanisms	O
.	O

We	O
have	O
previously	O
shown	O
that	O
g	B
##lut	I
##ama	I
##te	I
can	O
dose	O
dependent	O
##ly	O
in	O
##hibit	O
β	O
-	O
oxidation	O
of	O
palm	B
##itate	I
.	O

Eleven	O
patients	O
(	O
55	O
%	O
)	O
were	O
diagnosed	O
to	O
have	O
pan	O
##co	O
##lit	O
##is	O
and	O
13	O
(	O
65	O
%	O
)	O
subjects	O
were	O
on	O
either	O
oral	O
or	O
re	O
##ct	O
##al	O
5	B
-	I
amino	I
##sal	I
##ic	I
##yl	I
##ic	I
acid	I
(	O
5	O
-	O
AS	O
##A	O
)	O
medications	O
.	O

The	O
100	O
genes	O
with	O
the	O
highest	O
variance	O
in	O
changed	O
gene	O
expression	O
in	O
breast	O
tissue	O
following	O
I	O
##ER	O
are	O
shown	O
in	O
a	O
.	O
The	O
same	O
genes	O
in	O
the	O
l	O
##ymph	O
##ocytes	O
from	O
I	O
##ER	O
participants	O
(	O
b	O
)	O
,	O
the	O
breast	O
in	O
women	O
undertaking	O
CE	B
##R	I
(	O
c	O
)	O
and	O
sub	O
##cut	O
##aneous	O
abdominal	O
fat	O
(	O
d	O
)	O
in	O
women	O
undertaking	O
CE	B
##R	I
are	O
shown	O
for	O
comparison	O
.	O

The	O
laser	O
energy	O
for	O
positive	O
-	O
mode	O
measurements	O
of	O
the	O
low	O
-	O
molecular	O
-	O
weight	O
bases	O
as	O
anal	O
##yte	O
##s	O
and	O
2	B
-	I
nap	I
##ht	I
##hyl	I
##sul	I
##fo	I
##nic	I
acid	I
as	O
matrix	O
was	O
op	O
##ti	O
##mized	O
to	O
96	O
μ	O
##J	O
per	O
pulse	O
with	O
remaining	O
parameters	O
identical	O
to	O
those	O
used	O
in	O
negative	O
mode	O
.	O

Cell	O
##s	O
were	O
maintained	O
in	O
D	O
##ME	O
##M	O
high	O
glucose	S
supplemented	O
with	O
1	O
##×	O
pen	O
##ici	O
##llin	O
/	O
s	O
##tre	O
##pt	O
##omy	O
##cin	O
and	O
1	O
%	O
F	O
##BS	O
.	O

Cancer	O
cells	O
,	O
being	O
highly	O
pro	O
##life	O
##rative	O
,	O
show	O
significant	O
alterations	O
in	O
metabolic	O
pathways	O
such	O
as	O
g	O
##ly	O
##co	O
##lysis	O
,	O
re	O
##spiration	O
,	O
the	O
t	B
##rica	I
##rb	I
##ox	I
##yl	I
##ic	I
acid	I
(	O
T	O
##CA	O
)	O
cycle	O
,	O
o	O
##xi	O
##da	O
##tive	O
p	O
##hos	O
##ph	O
##ory	O
##lation	O
,	O
lip	O
##id	O
metabolism	O
,	O
and	O
amino	O
acid	O
metabolism	O
.	O

1640	O
medium	O
,	O
supplemented	O
with	O
10	O
%	O
(	O
v	O
/	O
v	O
)	O
heat	O
-	O
inactivated	O
foe	O
##tal	O
b	O
##ov	O
##ine	O
serum	O
and	O
1	O
%	O
(	O
v	O
/	O
v	O
)	O
pen	B
##ici	I
##llin	I
-	I
s	I
##tre	I
##pt	I
##omy	I
##cin	I
(	O
50	O
U	O
/	O
m	O
##L	O
pen	B
##ici	I
##llin	I
,	O
50	O
U	O
/	O
m	O
##L	O
s	B
##tre	I
##pt	I
##omy	I
##cin	I
)	O
.	O

Interest	O
##ingly	O
,	O
[	O
_	O
68	O
G	O
##a	O
]	O
c	B
##it	I
##rate	I
was	O
recently	O
successfully	O
used	O
as	O
a	O
radio	O
##tra	O
##cer	O
in	O
p	O
##os	O
##it	O
##ron	O
emission	O
to	O
##mo	O
##graphy	O
for	O
imaging	O
of	O
PC	O
##a	O
in	O
a	O
small	O
study	O
group	O
of	O
cast	O
##ration	O
-	O
resistant	O
pro	O
##state	O
cancer	O
(	O
CR	O
##PC	O
)	O
(	O
n	O
=	O
8	O
)	O
,	O
demonstrating	O
the	O
diagnostic	O
potential	O
of	O
newly	O
detected	O
meta	O
##bol	O
##ites	O
(	O
Be	O
##hr	O
et	O
al	O
.	O
,	O
)	O
.	O

Fr	O
##act	O
##ogram	O
##s	O
of	O
UC	O
-	O
prepared	O
L	O
##D	O
##L	O
standard	O
and	O
HP	O
-	O
D	O
samples	O
are	O
super	O
##im	O
##posed	O
with	O
root	O
-	O
mean	O
-	O
square	O
radius	O
r	O
_	O
r	O
##ms	O
values	O
measured	O
by	O
MA	O
##LS	O
and	O
h	B
##ydro	I
##dynamic	I
radius	O
r	O
_	O
h	O
reported	O
by	O
DL	O
##S	O
detector	O
##s	O
.	O

N	O
##MR	O
s	O
##pect	O
##ros	O
##copy	O
was	O
able	O
to	O
identify	O
and	O
q	O
##uant	O
##ify	O
209	O
compounds	O
;	O
G	O
##C	O
-	O
MS	O
was	O
able	O
to	O
identify	O
179	O
and	O
q	O
##uant	O
##ify	O
85	O
compounds	O
;	O
D	O
##FI	O
/	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
identified	O
and	O
q	O
##uant	O
##ified	O
127	O
compounds	O
;	O
I	O
##CP	O
-	O
MS	O
identified	O
and	O
q	O
##uant	O
##ified	O
40	O
compounds	O
;	O
while	O
custom	O
##ized	O
HP	O
##LC	O
ass	O
##ays	O
(	O
with	O
UV	O
or	O
F	B
##D	I
detection	O
)	O
identified	O
and	O
q	O
##uant	O
##ified	O
10	O
compounds	O
.	O

met	B
##han	I
##ol	I
:	I
10	I
%	I
et	I
##hyl	I
ace	I
##tate	I
,	O
with	O
a	O
flow	O
rate	O
of	O
360	O
μ	O
##L	O
/	O
min	O
into	O
the	O
AP	O
##CI	O
source	O
.	O

After	O
obtaining	O
written	O
,	O
informed	O
consent	O
,	O
blood	O
was	O
drawn	O
from	O
each	O
participant	O
using	O
a	O
21	O
-	O
or	O
23	O
-	O
G	O
butterfly	O
needle	O
into	O
3	O
-	O
m	O
##L	O
blood	O
collection	O
tubes	O
containing	O
56	O
US	O
##P	O
units	O
of	O
lit	B
##hium	I
he	I
##par	I
##in	I
.	O

Another	O
group	O
compared	O
CR	O
##C	O
patients	O
at	O
different	O
stages	O
and	O
observed	O
that	O
in	B
##os	I
##ito	I
##l	I
was	O
less	O
abundant	O
in	O
tissues	O
of	O
CR	O
##C	O
liver	O
meta	O
##sta	O
##sis	O
.	O

The	O
platform	O
was	O
designed	O
to	O
include	O
as	O
many	O
polar	O
meta	O
##bol	O
##ites	O
that	O
we	O
could	O
that	O
cover	O
major	O
metabolic	O
pathways	O
including	O
g	O
##ly	O
##co	O
##lysis	O
,	O
T	O
##CA	O
cycle	O
,	O
the	O
pen	B
##tos	I
##e	I
phosphate	I
pathway	O
,	O
amino	O
acid	O
metabolism	O
,	O
n	O
##uc	O
##leo	O
##tide	O
metabolism	O
,	O
etc	O
.	O
to	O
study	O
cancer	O
cell	O
metabolism	O
.	O

All	O
meta	O
##bol	O
##ites	O
detected	O
in	O
serum	O
were	O
at	O
higher	O
concentrations	O
in	O
W	O
##B	O
with	O
the	O
exception	O
of	O
ace	B
##to	I
##ace	I
##tate	I
and	O
prop	B
##yle	I
##ne	I
g	I
##ly	I
##co	I
##l	I
.	O

Most	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
(	O
Ce	O
##r	O
,	O
G	O
##lu	O
##C	O
##er	O
and	O
SM	O
)	O
can	O
be	O
detected	O
in	O
both	O
positive	O
and	O
negative	O
E	O
##SI	O
modes	O
.	O

However	O
,	O
even	O
though	O
the	O
overall	O
decrease	O
of	O
body	O
mass	O
and	O
decrease	O
of	O
serum	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
was	O
noted	O
during	O
the	O
first	O
stage	O
of	O
a	O
treatment	O
,	O
no	O
correlation	O
between	O
both	O
parameters	O
was	O
observed	O
for	O
individual	O
patients	O
and	O
,	O
in	O
contrast	O
to	O
the	O
progress	O
##ing	O
loss	O
of	O
body	O
mass	O
,	O
the	O
level	O
of	O
serum	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
slightly	O
increased	O
in	O
the	O
second	O
stage	O
of	O
a	O
treatment	O
.	O

The	O
co	O
##lon	O
##ic	O
cell	O
lines	O
DL	O
##D	O
##1	O
,	O
H	O
##T	O
##29	O
,	O
HC	O
##T	O
##11	O
##6	O
,	O
HC	O
##T	O
##15	O
,	O
R	O
##KO	O
,	O
Lo	O
##V	O
##o	O
(	O
American	O
Type	O
Culture	O
Collection	O
)	O
,	O
and	O
HC	O
##EC	O
##1	O
CT	O
and	O
the	O
e	O
##pit	O
##hel	O
##ial	O
cell	O
line	O
AR	O
##P	O
##E	O
-	O
19	O
were	O
grown	O
in	O
D	O
##ME	O
##M	O
(	O
450	O
##0	O
mg	O
/	O
L	O
glucose	S
)	O
and	O
sodium	O
bi	O
##car	O
##bon	O
##ate	O
without	O
L	B
-	I
g	I
##lut	I
##amine	I
and	O
sodium	B
p	I
##yr	I
##u	I
##vate	I
and	O
supplemented	O
with	O
5	O
%	O
f	O
##etal	O
b	O
##ov	O
##ine	O
serum	O
.	O

P	O
##las	O
##ma	O
levels	O
of	O
l	B
-	I
a	I
##rg	I
##ini	I
##ne	I
and	O
l	B
-	I
a	I
##rg	I
##ini	I
##ne	I
cat	O
##ab	O
##olic	O
products	O
and	O
met	B
##hyl	I
##ated	I
a	I
##rg	I
##ini	I
##ne	I
derivatives	O
in	O
patients	O
with	O
r	O
##he	O
##uma	O
##to	O
##id	O
art	O
##hr	O
##itis	O
(	O
n	O
=	O
119	O
)	O
vs	O
.	O
control	O
subjects	O
(	O
n	O
=	O
238	O
)	O
were	O
measured	O
using	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
:	O
l	B
-	I
a	I
##rg	I
##ini	I
##ne	I
(	O
a	O
)	O
,	O
l	B
-	I
or	I
##ni	I
##thin	I
##e	I
(	O
b	O
)	O
,	O
l	B
-	I
c	I
##it	I
##ru	I
##llin	I
##e	I
(	O
c	O
)	O
,	O
GA	O
##BR	O
(	O
d	O
)	O
,	O
AD	B
##MA	I
(	O
e	O
)	O
,	O
SD	O
##MA	O
(	O
f	O
)	O
,	O
MMA	O
(	O
g	O
)	O
,	O
and	O
A	O
##rg	O
##MI	O
(	O
h	O
)	O
.	O

The	O
vinyl	B
-	I
et	I
##her	I
bond	O
at	O
the	O
S	O
##N	O
##1	O
position	O
is	O
required	O
for	O
the	O
lip	O
##id	O
’	O
s	O
anti	O
-	O
o	O
##xi	O
##dant	O
role	O
and	O
its	O
effect	O
on	O
membrane	O
fluid	O
##ity	O
,	O
which	O
is	O
relevant	O
to	O
ne	O
##uron	O
##al	O
imp	O
##air	O
##ment	O
because	O
it	O
affects	O
ve	O
##si	O
##cular	O
fusion	O
(	O
for	O
review	O
see	O
[	O
,	O
]	O
)	O
.	O

C	B
##4	I
=	I
but	I
##yr	I
##yl	I
##car	I
##ni	I
##tine	I
,	O
C	B
##4	I
_	I
M	I
=	I
met	I
##hyl	I
##mal	I
##ony	I
##l	I
##car	I
##ni	I
##tine	I
.	O

Only	O
2	B
-	I
amino	I
##but	I
##yra	I
##te	I
(	O
M	O
)	O
showed	O
inconsistent	O
effect	O
directions	O
,	O
being	O
positively	O
associated	O
with	O
25	O
(	O
OH	O
)	O
D	O
in	O
K	O
##OR	O
##A	O
F	O
##4	O
,	O
and	O
negatively	O
in	O
F	O
##IN	O
##RI	O
##S	O
##K	O
1997	O
.	O

This	O
was	O
true	O
for	O
all	O
lip	O
##id	O
classes	O
with	O
statistical	O
##ly	O
significant	O
differences	O
in	O
concentration	O
at	O
week	O
48	O
specifically	O
the	O
;	O
ch	B
##ole	I
##ster	I
##ol	I
est	I
##er	I
,	O
free	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
,	O
G	O
_	O
M	O
##3	O
gang	B
##lio	I
##side	I
,	O
t	B
##ri	I
##he	I
##x	I
##osy	I
##l	I
##cer	I
##ami	I
##de	I
,	O
mon	B
##oh	I
##ex	I
##osy	I
##l	I
##cer	I
##ami	I
##de	I
,	O
and	O
c	B
##era	I
##mi	I
##de	I
classes	O
.	O

The	O
data	O
showed	O
that	O
after	O
16	O
h	O
of	O
co	O
-	O
in	O
##cu	O
##bation	O
,	O
ad	B
##eno	I
##sin	I
##e	I
is	O
consumed	O
and	O
in	B
##os	I
##ine	I
is	O
the	O
main	O
product	O
of	O
en	O
##zy	O
##matic	O
ATP	O
h	O
##ydro	O
##lysis	O
.	O

Recovery	O
of	O
D	O
##G	O
and	O
T	B
##G	I
species	O
was	O
determined	O
at	O
two	O
spike	O
levels	O
(	O
E	O
##SM	O
Table	O
S	O
##1	O
)	O
.	O

Moreover	O
,	O
the	O
study	O
shows	O
that	O
the	O
CO	O
##OH	O
-	O
meta	O
##bol	O
##ite	O
of	O
o	O
##xi	O
##dized	O
am	B
##lo	I
##di	I
##pine	I
could	O
be	O
a	O
better	O
marker	O
for	O
am	B
##lo	I
##di	I
##pine	I
intake	O
than	O
the	O
currently	O
used	O
am	B
##lo	I
##di	I
##pine	I
parent	O
drug	O
(	O
Lawson	O
et	O
al	O
.	O
)	O
.	O

Overall	O
,	O
47	O
women	O
were	O
di	O
##abe	O
##tic	O
and	O
44	O
were	O
norm	B
##og	I
##ly	I
##ce	I
##mic	I
at	O
inclusion	O
and	O
no	O
significant	O
difference	O
for	O
age	O
and	O
B	O
##MI	O
between	O
the	O
two	O
groups	O
of	O
remaining	O
patients	O
was	O
observed	O
.	O

PC	O
##A	O
,	O
which	O
has	O
a	O
higher	O
chemical	O
and	O
micro	O
##bial	O
stability	O
relative	O
to	O
c	B
##yan	I
##id	I
##in	I
,	O
is	O
also	O
an	O
anti	O
##ox	O
##ida	O
##nt	O
and	O
may	O
represent	O
the	O
chemical	O
constituent	O
responsible	O
for	O
sustained	O
ch	O
##em	O
##op	O
##re	O
##vent	O
##ive	O
effects	O
.	O

The	O
average	O
daily	O
intake	O
of	O
ca	B
##ffe	I
##ine	I
at	O
home	O
was	O
76	O
mg	O
and	O
subjects	O
a	O
##bs	O
##tain	O
##ed	O
from	O
ca	B
##ffe	I
##ine	I
use	O
during	O
the	O
30	O
h	O
of	O
admission	O
#	O
2	O
.	O

Our	O
results	O
show	O
a	O
higher	O
in	O
##tra	O
-	O
individual	O
and	O
inter	O
-	O
individual	O
var	O
##iability	O
in	O
ta	B
##uri	I
##ne	I
u	O
##rina	O
##ry	O
ex	O
##cre	O
##tion	O
relative	O
to	O
the	O
ex	O
##cre	O
##tion	O
of	O
su	B
##lf	I
##ate	I
,	O
the	O
other	O
oxidation	O
product	O
of	O
c	B
##ys	I
##tein	I
##e	I
(	O
Fi	O
##g	O
.	O
)	O
.	O

A	O
linear	O
bi	O
##pha	O
##si	O
##c	O
L	O
##C	O
gradient	O
was	O
conducted	O
from	O
80	O
%	O
B	O
to	O
20	O
%	O
B	O
over	O
15	O
min	O
,	O
followed	O
by	O
a	O
2	O
min	O
wash	O
with	O
5	O
%	O
B	O
,	O
and	O
7	O
min	O
re	O
-	O
e	O
##qui	O
##li	O
##bra	O
##tion	O
with	O
80	O
%	O
B	O
,	O
where	O
solvent	O
B	O
is	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
and	O
solvent	O
A	O
is	O
20	O
m	O
##M	O
am	B
##mon	I
##ium	I
carbon	I
##ate	I
in	O
water	O
.	O

We	O
also	O
found	O
the	O
concentration	O
of	O
er	B
##yt	I
##hr	I
##ito	I
##l	I
was	O
higher	O
in	O
the	O
group	O
with	O
higher	O
g	O
##ly	O
##ce	O
##mia	O
compared	O
with	O
the	O
group	O
with	O
lower	O
g	O
##ly	O
##ce	O
##mia	O
at	O
study	O
base	O
##line	O
.	O

Also	O
levels	O
of	O
the	O
BC	O
##AA	O
##s	O
containing	O
v	B
##ali	I
##ne	I
and	O
is	B
##ole	I
##uc	I
##ine	I
declined	O
sharply	O
,	O
suggesting	O
their	O
consumption	O
in	O
large	O
quantities	O
for	O
energy	O
supply	O
,	O
meanwhile	O
is	B
##ole	I
##uc	I
##ine	I
deficiency	O
is	O
marked	O
by	O
muscle	O
t	O
##rem	O
##ors	O
.	O

Association	O
##s	O
between	O
base	O
##line	O
metabolic	O
alterations	O
and	O
longitudinal	O
changes	O
in	O
glucose	S
control	O
were	O
tested	O
in	O
16	O
subjects	O
after	O
a	O
mean	O
follow	O
-	O
up	O
of	O
2	O
.	O
3	O
years	O
.	O

Inc	O
##reased	O
c	B
##rea	I
##tine	I
levels	O
were	O
reported	O
in	O
my	O
##oto	O
##nic	O
d	O
##ys	O
##tro	O
##phy	O
.	O

Further	O
,	O
a	O
volume	O
of	O
1	O
%	O
di	B
##thi	I
##oth	I
##re	I
##ito	I
##l	I
(	O
SP	O
##UT	O
##OL	O
##Y	O
##SI	O
##N	O
Re	O
##age	O
##nt	O
;	O
Cal	O
##bio	O
##che	O
##m	O
_	O
®	O
,	O
San	O
Diego	O
,	O
CA	O
,	O
USA	O
)	O
was	O
added	O
equal	O
to	O
4	O
times	O
the	O
remaining	O
s	O
##put	O
##um	O
w	O
at	O
1	O
,	O
500	O
rpm	O
for	O
10	O
minutes	O
,	O
and	O
the	O
s	O
##put	O
##um	O
super	O
##nat	O
##ant	O
was	O
as	O
##pi	O
##rated	O
and	O
stored	O
immediately	O
at	O
−	O
##80	O
##°	O
##C	O
for	O
subsequent	O
detection	O
.	O

St	O
##ero	O
##ls	O
are	O
spontaneous	O
##ly	O
transferred	O
from	O
donor	O
membrane	O
##s	O
to	O
red	O
blood	O
cells	O
,	O
and	O
in	O
the	O
mouse	O
this	O
movement	O
may	O
account	O
for	O
a	O
substantial	O
portion	O
of	O
reverse	O
ch	B
##ole	I
##ster	I
##ol	I
transport	O
(	O
,	O
)	O
,	O
the	O
movement	O
of	O
ch	B
##ole	I
##ster	I
##ol	I
and	O
presumably	O
other	O
s	O
##tero	O
##ls	O
from	O
peripheral	O
tissues	O
to	O
the	O
liver	O
.	O

However	O
,	O
in	O
the	O
se	O
##ra	O
,	O
we	O
observed	O
high	O
levels	O
of	O
SM	B
(	I
16	I
:	I
0	I
)	I
in	O
M	O
##F	O
patients	O
.	O

Anti	B
-	I
br	I
##omo	I
##de	I
##ox	I
##yu	I
##rine	I
(	O
B	O
##rd	O
##U	O
)	O
anti	O
##body	O
was	O
purchased	O
from	O
Roche	O
Applied	O
Science	O
(	O
Indianapolis	O
,	O
IN	O
)	O
.	O

The	O
correlation	O
##s	O
with	O
A	O
##H	O
##NA	O
##K	O
n	O
##uc	O
##leo	O
##p	O
##rote	O
##in	O
(	O
A	O
##H	O
##NA	O
##K	O
)	O
,	O
t	O
##rop	O
##hin	O
##in	O
(	O
T	O
##RO	O
)	O
and	O
o	B
##xy	I
##ster	I
##ol	I
binding	O
protein	O
like	O
2	O
(	O
OS	O
##B	O
##PL	O
##2	O
)	O
were	O
significant	O
after	O
multiple	O
testing	O
correction	O
(	O
p	O
_	O
c	O
<	O
0	O
.	O
05	O
i	O
.	O
e	O
.	O
p	O
<	O
0	O
.	O
000	O
##21	O
)	O
.	O

No	O
B	O
##DC	O
##PP	O
was	O
observed	O
in	O
blank	O
extraction	O
##s	O
,	O
however	O
they	O
did	O
contain	O
traces	O
of	O
D	O
##PP	O
at	O
levels	O
of	O
79	O
±	O
41	O
p	B
##g	I
m	O
##L	O
_	O
−	O
##1	O
.	O

A	O
60	O
cm	O
long	O
fused	O
si	B
##lica	I
cap	O
##illa	O
##ry	O
,	O
used	O
in	O
the	O
experiment	O
,	O
(	O
375	O
µ	O
##m	O
O	O
.	O
D	O
.	O
,	O
with	O
50	O
µ	O
##m	O
I	O
.	O
D	O
)	O
was	O
obtained	O
from	O
Pol	O
##ym	O
##ic	O
##ro	O
Technologies	O
(	O
Phoenix	O
,	O
A	O
##Z	O
,	O
USA	O
)	O
.	O

The	O
region	O
between	O
0	O
.	O
91	O
-	O
1	O
.	O
05	O
containing	O
signals	O
from	O
is	B
##ole	I
##uc	I
##ine	I
,	O
le	B
##uc	I
##ine	I
and	O
v	B
##ali	I
##ne	I
is	O
characterized	O
as	O
the	O
branched	O
amino	O
acid	O
region	O
.	O

Waste	O
am	O
##monia	O
,	O
a	O
by	O
##p	O
##rod	O
##uc	O
##t	O
of	O
amino	O
acid	O
cat	O
##ab	O
##olis	O
##m	O
,	O
must	O
be	O
ex	O
##cre	O
##ted	O
via	O
the	O
u	B
##rea	I
cycle	O
.	O

1	O
BC	O
##AA	O
,	O
2	O
Lac	B
##tate	I
,	O
3	O
Met	B
##hyl	I
##amine	I
,	O
4	O
/	O
5	O
Cho	O
##line	O
/	O
PC	O
,	O
6	O
Tau	B
##rine	I
,	O
7	O
my	B
##o	I
-	I
In	I
##os	I
##ito	I
##l	I
,	O
8	O
G	B
##lu	I
##cos	I
##e	I
,	O
9	O
Ty	B
##ros	I
##ine	I
,	O
10	O
H	B
##y	I
##pox	I
##ant	I
##hine	I

The	O
peak	O
at	O
3	O
.	O
27	O
min	O
el	O
##utes	O
at	O
the	O
same	O
time	O
as	O
do	B
##pa	I
##mine	I
,	O
although	O
with	O
a	O
different	O
oxidation	O
profile	O
.	O

The	O
product	O
ion	O
spectrum	O
of	O
N	B
-	I
ace	I
##to	I
##xy	I
-	I
Ph	I
##IP	I
contains	O
major	O
fragment	O
ions	O
at	O
m	O
/	O
z	O
223	O
.	O
0	O
and	O
224	O
.	O
0	O
,	O
corresponding	O
,	O
respectively	O
,	O
to	O
losses	O
of	O
CH	O
_	O
3	O
CO	O
_	O
2	O

G	B
##lut	I
##ama	I
##te	I
has	O
been	O
recognized	O
in	O
a	O
few	O
studies	O
as	O
a	O
potential	O
bio	O
##mark	O
##er	O
related	O
to	O
various	O
types	O
of	O
cancer	O
##s	O
and	O
more	O
recently	O
in	O
breast	O
tissues	O
as	O
a	O
tumor	O
bio	O
##mark	O
##er	O
[	O
–	O
]	O
.	O

The	O
in	O
##tra	O
##cellular	O
amounts	O
of	O
f	B
##uma	I
##rate	I
and	O
c	B
##it	I
##rate	I
were	O
significantly	O
lower	O
in	O
r	O
##H	O
##la	O
-	O
treated	O
S	O
##9	O
or	O
16	O
##H	O
##BE	O
##14	O
##o	O
-	O
cells	O
than	O
in	O
the	O
respective	O
control	O
cells	O
over	O
time	O
during	O
r	O
##H	O
##la	O
-	O
treatment	O
.	O

Mel	B
##aton	I
##in	I
,	O
N	B
-	I
ace	I
##ty	I
##ls	I
##ero	I
##ton	I
##in	I
,	O
Au	O
##tism	O
Spectrum	O
Di	O
##sor	O
##der	O
,	O
Nan	O
##of	O
##low	O
L	O
##C	O
-	O
MS	O
/	O
MS	O

Li	O
##pid	O
##s	O
with	O
different	O
head	O
groups	O
are	O
shown	O
by	O
different	O
symbols	O
:	O
PA	O
(	O
[UNK]	O
)	O
;	O
P	O
##E	O
(	O
■	O
)	O
;	O
P	B
##G	I
(	O
[UNK]	O
)	O
;	O
P	O
##I	O
(	O
×	O
)	O
;	O
PS	O
(	O
[UNK]	O
)	O
;	O
and	O
PC	B
(	I
+	I
)	I
.	O

Put	O
##ative	O
##ly	O
identified	O
disc	O
##rim	O
##ina	O
##nt	O
meta	O
##bol	O
##ites	O
showing	O
a	O
VIP	O
>	O
1	O
in	O
the	O
BC	O
vs	O
CT	O
##RL	O
model	O
summarized	O
in	O
Table	O
_	O
S	O
##1	O
reflected	O
alterations	O
in	O
the	O
metabolic	O
pathways	O
of	O
a	B
##rg	I
##ini	I
##ne	I
,	O
pro	B
##line	I
,	O
fatty	O
acids	O
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
pu	B
##rine	I
,	O
p	B
##yr	I
##im	I
##id	I
##ine	I
,	O
and	O
try	B
##pt	I
##op	I
##han	I
,	O
among	O
others	O
(	O
see	O
Table	O
)	O
.	O

P	O
##las	O
##ma	O
meta	O
##bol	O
##ites	O
were	O
extracted	O
using	O
a	O
solvent	O
mixture	O
of	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
and	O
met	B
##han	I
##ol	I
.	O

The	O
largest	O
%	O
lip	O
##id	O
increase	O
was	O
identified	O
as	O
t	B
##rig	I
##ly	I
##cer	I
##ide	I
(	O
T	O
##G	O
)	O
with	O
carbon	O
chain	O
:	O
double	O
bond	O
ratios	O
of	O
52	O
:	O
3	O
,	O
with	O
a	O
median	O
increase	O
from	O
L	O
##D	O
##N	O
to	O
E	O
##BC	O
of	O
53	O
.	O
9	O
%	O
.	O

In	O
general	O
,	O
the	O
AD	O
related	O
metabolic	O
changes	O
are	O
light	O
to	O
moderate	O
,	O
e	O
.	O
g	O
.	O
increase	O
by	O
up	O
to	O
[UNK]	O
%	O
in	O
the	O
case	O
of	O
co	B
##rt	I
##is	I
##ol	I
or	O
increase	O
by	O
20	O
–	O
25	O
%	O
primarily	O
in	O
light	O
AD	O
patients	O
for	O
c	B
##ys	I
##tein	I
##e	I
.	O

Within	O
the	O
lip	O
##op	O
##rote	O
##in	O
sub	O
##c	O
##lass	O
##es	O
,	O
the	O
following	O
components	O
were	O
q	O
##uant	O
##ified	O
:	O
total	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
total	O
lip	O
##ids	O
,	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
,	O
free	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
ch	B
##ole	I
##ster	I
##yl	I
est	I
##ers	I
,	O
and	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
.	O

Sam	O
##ple	O
preparation	O
was	O
carried	O
out	O
by	O
precipitation	O
of	O
plasma	O
proteins	O
with	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
.	O

5	O
-	O
and	O
12	O
-	O
H	O
##ET	O
##E	O
were	O
mainly	O
found	O
in	O
higher	O
levels	O
in	O
G	O
##CF	O
and	O
serum	O
,	O
while	O
15	B
-	I
H	I
##ET	I
##E	I
was	O
found	O
in	O
significantly	O
higher	O
levels	O
in	O
all	O
samples	O
of	O
the	O
A	O
##g	O
##P	O
patients	O
.	O

For	O
all	O
the	O
studies	O
,	O
a	O
met	O
##han	O
##ol	O
:	O
-	O
water	O
(	O
1	O
:	O
1	O
)	O
mixture	O
with	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
was	O
used	O
as	O
the	O
carrier	O
solution	O
.	O

First	O
of	O
all	O
,	O
ω	B
-	I
3	I
P	I
##U	I
##FA	I
##s	I
are	O
essential	O
fatty	O
acids	O
which	O
cannot	O
be	O
synthesized	O
in	O
the	O
body	O
and	O
therefore	O
have	O
to	O
be	O
consumed	O
from	O
diet	O
;	O
thus	O
,	O
a	O
lack	O
of	O
ing	O
##est	O
##ion	O
of	O
ω	B
-	I
3	I
P	I
##U	I
##FA	I
##s	I
may	O
be	O
a	O
potential	O
reason	O
.	O

The	O
rate	O
-	O
limiting	O
precursor	O
for	O
G	B
##S	I
##H	I
synthesis	O
,	O
c	B
##ys	I
##tein	I
##e	I
,	O
was	O
present	O
in	O
higher	O
levels	O
concurrently	O
with	O
G	B
##S	I
##H	I
in	O
CR	O
##C	O
tissues	O
than	O
in	O
AN	O
##IT	O
indicating	O
a	O
red	O
##ox	O
status	O
shift	O
in	O
the	O
CR	O
##C	O
tumor	O
tissues	O
.	O

The	O
appearance	O
of	O
ch	B
##oly	I
##l	I
##gly	I
##cine	I
and	O
3	B
-	I
h	I
##ydro	I
##xy	I
##cap	I
##ric	I
acid	I
as	O
potential	O
bio	O
##mark	O
##ers	O
is	O
not	O
that	O
unexpected	O
as	O
both	O
meta	O
##bol	O
##ites	O
have	O
previously	O
been	O
used	O
to	O
gauge	O
liver	O
d	O
##ys	O
##function	O
from	O
serum	O
levels	O
employing	O
non	O
-	O
L	O
##C	O
-	O
MS	O
techniques	O
.	O

These	O
included	O
the	O
same	O
types	O
of	O
molecules	O
listed	O
above	O
for	O
the	O
met	B
##han	I
##ol	I
method	O
.	O

One	O
important	O
advantage	O
of	O
our	O
findings	O
,	O
is	O
that	O
circulating	O
B	O
##K	O
and	O
D	O
##AB	O
##K	O
levels	O
represent	O
the	O
host	O
'	O
s	O
response	O
to	O
path	O
##ogen	O
–	O
associated	O
molecular	O
patterns	O
and	O
may	O
offer	O
a	O
rational	O
route	O
forward	O
in	O
the	O
prediction	O
of	O
real	O
-	O
time	O
treatment	O
outcomes	O
at	O
both	O
early	O
and	O
late	O
treatment	O
stages	O
and	O
allow	O
individual	O
##ization	O
of	O
treatment	O
regime	O
##ns	O
,	O
dos	O
##ing	O
,	O
and	O
treatment	O
duration	S
.	O

Inc	O
##reased	O
micro	O
##bial	O
co	O
-	O
metabolism	O
of	O
ch	B
##olin	I
##e	I
has	O
also	O
been	O
associated	O
with	O
s	O
##te	O
##ato	O
##sis	O
,	O
fatty	O
liver	O
,	O
and	O
insulin	O
resistance	O
in	O
animals	O
fed	O
high	O
-	O
fat	O
diet	O
##s	O
.	O

The	O
three	O
meta	O
##bol	O
##ites	O
(	B
l	B
##ys	I
##o	I
##PC	I
(	I
16	I
:	I
1	I
)	I
,	O
o	B
##ct	I
##ano	I
##yl	I
##car	I
##ni	I
##tine	I
and	O
de	B
##cano	I
##yl	I
##car	I
##ni	I
##tine	I
)	O
that	O
significantly	O
changed	O
only	O
in	O
OR	O
##s	O
were	O
chosen	O
as	O
bio	O
##mark	O
##ers	O
related	O
to	O
therapeutic	O
effect	O
and	O
the	O
variations	O
of	O
these	O
were	O
subjected	O
to	O
in	O
-	O
depth	O
investigation	O
over	O
the	O
treatment	O
course	O
.	O

In	O
N	O
##S	O
,	O
amino	B
##ac	I
##ids	I
doubled	O
their	O
plasma	O
concentration	O
together	O
with	O
put	B
##res	I
##cine	I
and	O
sperm	B
##id	I
##ine	I
,	O
the	O
last	O
one	O
significant	O
only	O
in	O
N	O
##S	O
at	O
day	O
90	O
.	O

For	O
example	O
,	O
it	O
has	O
been	O
shown	O
that	O
the	O
relative	O
so	O
##lub	O
##ility	O
of	O
amino	O
acids	O
such	O
as	O
g	B
##ly	I
##cine	I
,	O
al	B
##ani	I
##ne	I
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
and	O
as	B
##par	I
##agi	I
##ne	I
decreases	O
as	O
much	O
as	O
3	O
orders	O
of	O
magnitude	O
from	O
water	O
to	O
pure	O
met	B
##han	I
##ol	I
.	O

Each	O
of	O
the	O
rabbits	O
in	O
Groups	O
1	O
through	O
5	O
had	O
50	O
µ	O
##L	O
of	O
a	O
topic	O
##al	O
application	O
of	O
the	O
NSA	O
##ID	O
or	O
sa	B
##line	I
3	O
times	O
/	O
day	O
for	O
4	O
days	O
.	O

Other	O
researchers	O
found	O
that	O
the	O
level	O
of	O
a	B
##zel	I
##aic	I
acid	I
was	O
significantly	O
increased	O
in	O
patients	O
with	O
ne	O
##uro	O
##psy	O
##chia	O
##tric	O
disorders	O
.	O

B	O
##rief	O
##ly	O
,	O
900	O
μ	O
##l	O
of	O
ice	O
-	O
cold	O
ch	B
##lor	I
##of	I
##orm	I
-	I
met	I
##han	I
##ol	I
(	I
1	I
:	I
2	I
;	I
volume	I
/	I
volume	I
(	I
v	I
/	I
v	I
)	I
)	I
was	O
added	O
to	O
the	O
plasma	O
samples	O
and	O
vigorously	O
v	O
##ortex	O
##ed	O
for	O
1	O
min	O
followed	O
by	O
shaking	O
at	O
4	O
°C	O
at	O
1200	O
R	O
##PM	O
for	O
30	O
min	O
using	O
a	O
the	O
##rm	O
##omi	O
##xe	O
##r	O
(	O
E	O
##ppe	O
##ndo	O
##rf	O
,	O
Hamburg	O
,	O
Germany	O
)	O
.	O

A	O
24	O
-	O
h	O
diet	O
##ary	O
history	O
was	O
also	O
recorded	O
,	O
paying	O
attention	O
to	O
foods	O
##tu	O
##ffs	O
known	O
to	O
produce	O
prominent	O
nuclear	O
magnetic	O
resonance	O
(	O
N	O
##MR	O
)	O
signals	O
,	O
such	O
as	O
van	B
##illa	I
(	O
van	O
##ill	O
##in	O
)	O
and	O
vine	B
##gar	I
(	O
ace	O
##tic	O
acid	O
)	O
.	O

In	O
the	O
E	O
##SI	O
_	O
−	O
,	O
a	O
decrease	O
in	O
the	O
levels	O
of	O
u	O
##rina	O
##ry	O
p	B
-	I
c	I
##res	I
##ol	I
su	I
##lf	I
##ate	I
,	O
in	B
##dox	I
##yl	I
##sul	I
##fa	I
##te	I
,	O
is	B
##oc	I
##it	I
##rate	I
and	O
hip	B
##pura	I
##te	I
and	O
a	O
higher	O
level	O
of	O
su	B
##lf	I
##ated	I
g	I
##ly	I
##co	I
##l	I
-	I
u	I
##rs	I
##ode	I
##ox	I
##ych	I
##olic	I
acid	I
was	O
characteristic	O
of	O
the	O
u	O
##rina	O
##ry	O
meta	O
##bot	O
##ype	O
of	O
patients	O
with	O
bi	O
##le	O
duct	O
strict	O
##ures	O
,	O
compared	O
to	O
healthy	O
controls	O
.	O

M	O
ace	B
##tic	I
acid	I
was	O
necessary	O
to	O
ensure	O
pH	O
of	O
the	O
sample	O
loaded	O
onto	O
the	O
SP	O
##E	O
was	O
well	O
below	O
the	O
so	O
##rb	O
##ent	O
p	O
##K	O
_	O
a	O
(	O
9	O
.	O
0	O
)	O
.	O

The	O
highest	O
her	O
##ita	O
##bility	O
is	O
observed	O
for	O
c	B
##it	I
##rate	I
(	O
52	O
%	O
)	O
,	O
followed	O
by	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
(	O
51	O
%	O
)	O
,	O
or	B
##ni	I
##thin	I
##e	I
(	O
47	O
%	O
)	O
and	O
met	B
##han	I
##ol	I
(	O
45	O
%	O
)	O
whereas	O
the	O
lowest	O
her	O
##ita	O
##bility	O
estimate	O
was	O
10	O
%	O
for	O
3	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
.	O

This	O
leads	O
to	O
the	O
production	O
of	O
N	B
##AD	I
##H	I
,	O
in	O
minor	O
amounts	O
with	O
respect	O
to	O
the	O
control	O
.	O

Mean	O
age	O
of	O
the	O
subjects	O
was	O
66	O
.	O
4	O
years	O
and	O
mean	O
T	O
##2	O
##D	O
duration	S
was	O
22	O
.	O
2	O
years	O
.	O

Another	O
report	O
showed	O
that	O
the	O
median	O
u	O
##rina	O
##ry	O
concentrations	O
of	O
meta	O
##bol	O
##ites	O
of	O
organ	B
##op	I
##hos	I
##phorus	I
p	O
##est	O
##icides	O
,	O
i	O
.	O
e	O
.	O
ma	B
##lat	I
##hi	I
##on	I
di	I
##car	I
##box	I
##yl	I
##ic	I
acid	I
for	O
ma	B
##lat	I
##hi	I
##on	I
and	O
3	O
,	O
5	O
,	O
6	O
-	O
t	O
##rich	O
##lor	O
##o	O
-	O
2	O
-	O
p	O
##yr	O
##id	O
##ino	O
##l	O
for	O
ch	B
##lor	I
##py	I
##ri	I
##fo	I
##s	I
,	O
are	O
significantly	O
correlated	O
with	O
the	O
median	O
consumption	O
of	O
fresh	O
product	O
(	O
fruits	O
,	O
juice	O
##s	O
,	O
and	O
vegetables	O
)	O
in	O
children	O
.	O

MG	O
can	O
be	O
used	O
as	O
a	O
source	O
of	O
FA	S
in	O
cancer	O
cells	O
in	O
order	O
to	O
maintain	O
an	O
FA	S
pool	O
always	O
available	O
,	O
given	O
the	O
over	O
##ex	O
##press	O
##ion	O
of	O
mon	B
##oa	I
##cy	I
##l	I
##gly	I
##cer	I
##ol	I
lip	O
##ase	O
(	O
MA	O
##G	O
##L	O
)	O
as	O
reported	O
by	O
No	O
##mura	O
et	O
al	O
.	O

El	O
##eva	O
##tions	O
in	O
these	O
lip	O
##id	O
levels	O
,	O
which	O
are	O
normally	O
tightly	O
regulated	O
,	O
,	O
is	O
of	O
significant	O
clinical	O
interest	O
considering	O
the	O
diverse	O
roles	O
of	O
D	O
##AG	O
##s	O
as	O
precursor	O
##s	O
of	O
structural	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
and	O
neutral	O
lip	O
##ids	O
,	O
as	O
structural	O
components	O
of	O
nuclear	O
and	O
end	O
##op	O
##las	O
##mic	O
re	O
##tic	O
##ular	O
membrane	O
##s	O
,	O
as	O
media	O
##tors	O
of	O
signal	O
trans	O
##duction	O
,	O
as	O
media	O
##tors	O
of	O
nuclear	O
signal	O
trans	O
##duction	O
,	O
and	O
in	O
Go	O
##l	O
##gi	O
transport	O
carrier	O
bio	O
##genesis	O
,	O
.	O

These	O
data	O
are	O
consistent	O
with	O
findings	O
by	O
Woodward	O
et	O
al	O
.	O
,	O
which	O
imply	O
that	O
PC	O
##A	O
g	O
##lu	O
##cu	O
##ron	O
##ides	O
represent	O
a	O
predominant	O
ant	B
##ho	I
##cy	I
##ani	I
##n	I
species	O
following	O
simulated	O
gas	O
##tro	O
##int	O
##est	O
##inal	O
dig	O
##est	O
##ion	O
.	O

Specifically	O
,	O
treatment	O
resulted	O
in	O
significant	O
reduction	O
##s	O
in	O
amino	O
acids	O
,	O
highlighted	O
by	O
230	O
,	O
233	O
,	O
and	O
150	O
%	O
decreases	O
in	O
th	B
##re	I
##oni	I
##ne	I
,	O
or	B
##ni	I
##thin	I
##e	I
,	O
and	O
met	B
##hi	I
##oni	I
##ne	I
,	O
respectively	O
(	O
Table	O
2	O
)	O
.	O

The	O
tentative	O
reference	O
range	O
of	O
the	O
sum	O
of	O
co	B
##rt	I
##is	I
##ol	I
meta	O
##bol	O
##ites	O
is	O
shown	O
in	O
.	O

S	B
-	I
ad	I
##eno	I
##sy	I
##lm	I
##eth	I
##ion	I
##ine	I
(	O
SA	O
##M	O
)	O
-	O
dependent	O
met	O
##hyl	O
##ation	O
was	O
active	O
,	O
indicated	O
by	O
_	O
13	O
C	O
_	O
14	O
SA	O
##M	O
and	O
_	O
13	O
C	O
_	O
13	O
SA	O
##H	O
,	O
while	O
c	B
##ys	I
##tat	I
##hi	I
##oni	I
##ne	I
was	O
_	O
13	O
C	O
_	O
0	O
,	O
indicating	O
that	O
the	O
“	B
trans	I
##sul	I
##fu	I
##ration	I
”	I
pathway	O
that	O
converts	O
met	B
##hi	I
##oni	I
##ne	I
into	O
c	B
##ys	I
##tein	I
##e	I
and	O
ta	B
##uri	I
##ne	I
was	O
inactive	O
.	O

Con	O
##cent	O
##rations	O
of	O
23	O
of	O
27	O
meta	O
##bol	O
##ites	O
,	O
including	O
beta	B
##ine	I
,	O
ch	B
##olin	I
##e	I
,	O
and	O
se	B
##rine	I
,	O
changed	O
from	O
pre	O
##con	O
##ception	O
across	O
g	O
##esta	O
##tion	O
after	O
application	O
of	O
a	O
Bon	O
##fer	O
##ron	O
##i	O
multiple	O
testing	O
correction	O
(	O
P	O
<	O
0	O
.	O
00	O
##18	O
##5	O
)	O
.	O

With	O
the	O
application	O
of	O
the	O
Ko	O
##lm	O
##ogo	O
##rov	O
test	O
,	O
we	O
found	O
that	O
the	O
levels	O
of	O
ad	B
##eni	I
##ne	I
,	O
N	B
##6	I
-	I
met	I
##hyl	I
##ade	I
##nos	I
##ine	I
and	O
1	B
-	I
met	I
##hyl	I
##gua	I
##nine	I
detected	O
in	O
the	O
plasma	O
samples	O
of	O
patients	O
who	O
were	O
carriers	O
of	O
BR	O
##CA	O
##1	O
mutations	O
were	O
significantly	O
lower	O
than	O
those	O
in	O
patients	O
who	O
were	O
not	O
carriers	O
of	O
BR	O
##CA	O
##1	O
mutations	O
(	O
Fi	O
##g	O
.	O
)	O
.	O

They	O
also	O
showed	O
that	O
the	O
disease	O
progression	O
is	O
characterized	O
by	O
a	O
further	O
increase	O
in	O
the	O
concentration	O
of	O
ma	B
##lic	I
acid	I
.	O

G	B
##ly	I
##co	I
##chen	I
##ode	I
##ox	I
##ych	I
##olate	I
was	O
not	O
associated	O
with	O
cancer	O
risk	O
among	O
men	O
(	O
OR	O
=	O
1	O
.	O
16	O
;	O
95	O
%	O
C	O
##I	O
=	O
0	O
.	O
58	O
-	O
2	O
.	O
33	O
;	O
P	O
-	O
value	O
=	O
0	O
.	O
67	O
)	O
.	O

P	B
##yr	I
##u	I
##vate	I
,	O
a	O
terminal	O
product	O
of	O
g	O
##ly	O
##co	O
##lysis	O
,	O
was	O
significantly	O
elevated	O
in	O
plasma	O
following	O
limo	B
##nen	I
##e	I
intervention	O
,	O
as	O
was	O
f	B
##ru	I
##ct	I
##ose	I
of	O
the	O
so	B
##rb	I
##ito	I
##l	I
pathway	O
,	O
suggesting	O
restricted	O
entry	O
or	O
usage	O
of	O
glucose	O
-	O
derived	O
carbon	O
##s	O
by	O
the	O
T	O
##CA	O
cycle	O
in	O
the	O
mit	O
##och	O
##ond	O
##ria	O
.	O

In	O
addition	O
,	O
g	O
##lu	O
##con	O
##eo	O
##genesis	O
from	O
lip	O
##ids	O
and	O
proteins	O
also	O
plays	O
a	O
key	O
role	O
,	O
which	O
consequently	O
increases	O
the	O
turnover	O
of	O
g	O
##lu	O
##co	O
##genic	O
amino	O
acids	O
(	O
e	O
.	O
g	O
.	O
g	B
##ly	I
##cine	I
,	O
al	B
##ani	I
##ne	I
)	O
and	O
free	O
FA	S
[	O
,	O
]	O
.	O

U	B
##ric	I
acid	I
is	O
generally	O
considered	O
to	O
be	O
a	O
feature	O
of	O
h	O
##yper	O
##ins	O
##ulin	O
##emia	O
or	O
/	O
and	O
insulin	O
resistance	O
;	O
however	O
,	O
in	O
patients	O
with	O
diabetes	O
,	O
its	O
level	O
may	O
be	O
low	O
,	O
due	O
to	O
increased	O
u	B
##rate	I
clearance	O
that	O
can	O
be	O
associated	O
with	O
g	O
##ly	O
##cos	O
##uria	O
,	O
increased	O
sodium	O
(	O
Na	O
)	O
secret	O
##ion	O
,	O
and	O
overall	O
decreased	O
metabolic	O
control	O
.	O

e	O
Hi	O
##era	O
##rch	O
##ical	O
cluster	O
analysis	O
based	O
on	O
C	B
##18	I
:	I
1	I
Δ	O
##9	O
/	O
Δ	O
##11	O
ratios	O
of	O
29	O
pairs	O
of	O
PC	O
and	O
P	B
##E	I
is	I
##omer	I
##s	I
in	O
normal	O
(	O
N	O
##1	O
–	O
N	O
##6	O
)	O
and	O
cancer	O
##ous	O
breast	O
tissue	O
samples	O
(	O
CA	O
##1	O
–	O
CA	O
##6	O
)	O
.	O

The	O
column	O
was	O
el	O
##uted	O
at	O
a	O
flow	O
rate	O
of	O
400	O
μ	O
##L	O
/	O
min	O
with	O
initial	O
conditions	O
of	O
10	O
%	O
mobile	O
phase	O
A	O
(	O
20	O
m	O
##M	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
and	O
20	O
m	O
##M	O
am	B
##mon	I
##ium	I
h	I
##ydro	I
##xi	I
##de	I
in	O
water	O
)	O
and	O
90	O
%	O
mobile	O
phase	O
B	O
(	O
10	O
m	O
##M	O
am	B
##mon	I
##ium	I
h	I
##ydro	I
##xi	I
##de	I
in	O
75	O
:	O
25	O
v	O
/	O
v	O
ace	O
##ton	O
##it	O
##ril	O
##e	O
/	O
met	O
##han	O
##ol	O
)	O
followed	O
by	O
a	O
10	O
min	O
linear	O
gradient	O
to	O
100	O
%	O
mobile	O
phase	O
A	O
.	O
MS	O
analyses	O
were	O
carried	O
out	O
using	O
electro	O
##sp	O
##ray	O
ion	O
##ization	O
in	O
the	O
negative	O
ion	O
mode	O
using	O
full	O
scan	O
analysis	O
over	O
m	O
/	O
z	O
60	O
##75	O
##0	O
at	O
70	O
,	O
000	O
resolution	O
and	O
3	O
Hz	O
data	O
acquisition	O
rate	O
.	O

We	O
observed	O
direct	O
associations	O
of	O
B	O
##MI	O
with	O
u	O
##rina	O
##ry	O
ex	O
##cre	O
##tion	O
of	O
the	O
BC	O
##AA	O
##s	O
le	B
##uc	I
##ine	I
,	O
v	B
##ali	I
##ne	I
,	O
and	O
is	B
##ole	I
##uc	I
##ine	I
,	O
consistent	O
with	O
previous	O
reports	O
of	O
the	O
importance	O
of	O
the	O
BC	O
##AA	O
##s	O
in	O
ad	O
##ip	O
##os	O
##ity	O
based	O
on	O
measurements	O
in	O
plasma	O
(	O
–	O
)	O
.	O

Regarding	O
p	O
##oly	O
##uns	O
##at	O
##ura	O
##ted	O
fatty	O
acids	O
(	O
P	O
##U	O
##FA	O
##s	O
)	O
h	B
##ydro	I
##xy	I
-	I
e	I
##ico	I
##sat	I
##et	I
##rae	I
##no	I
##ic	I
,	O
E	B
##ico	I
##sa	I
##pent	I
##aen	I
##oi	I
##c	I
,	O
and	O
E	B
##ico	I
##sat	I
##et	I
##rae	I
##no	I
##ic	I
were	O
significantly	O
lower	O
in	O
C	O
##LL	O
relative	O
to	O
controls	O
and	O
more	O
##over	O
lower	O
in	O
aggressive	O
relative	O
to	O
in	O
##do	O
##lent	O
patient	O
samples	O
.	O

The	O
origin	O
of	O
d	B
##18	I
:	I
2	I
SP	O
##s	O
(	O
with	O
a	O
second	O
double	O
bond	O
in	O
the	O
14	O
##Z	O
position	O
)	O
is	O
less	O
clear	O
because	O
there	O
are	O
no	O
known	O
metabolic	O
pathways	O
that	O
are	O
responsible	O
for	O
their	O
generation	O
.	O

Although	O
we	O
saw	O
no	O
differences	O
in	O
the	O
frequency	O
of	O
IL	O
-	O
6	O
_	O
+	O
B	O
cells	O
in	O
heavy	O
cannabis	S
users	O
compared	O
to	O
non	O
##user	O
##s	O
,	O
the	O
decreased	O
frequency	O
of	O
T	O
##NF	O
-	O
α	O
_	O
+	O
B	O
cells	O
in	O
heavy	O
cannabis	S
users	O
could	O
indicate	O
a	O
generalized	O
lowering	O
of	O
systemic	O
inflammation	O
.	O

The	O
correlation	O
##s	O
of	O
co	B
##tin	I
##ine	I
and	O
trans	B
-	I
3	I
′	I
-	I
h	I
##ydro	I
##xy	I
##cot	I
##ini	I
##ne	I
with	O
3	O
-	O
EP	O
,	O
B	O
##UT	O
and	O
some	O
non	O
-	O
parent	O
PA	O
##H	O
were	O
higher	O
when	O
considering	O
the	O
non	O
-	O
c	O
##rea	O
##tin	O
##ine	O
-	O
normal	O
##ised	O
ET	O
##S	O
meta	O
##bol	O
##ite	O
data	O
(	O
and	O
for	O
c	O
##rea	O
##tin	O
##ine	O
-	O
normal	O
##ised	O
data	O
)	O
.	O

One	O
of	O
the	O
17	O
household	O
contacts	O
demonstrated	O
the	O
t	B
##re	I
##hal	I
##ose	I
-	I
6	I
-	I
my	I
##cola	I
##te	I
meta	O
##bol	O
##ite	O
and	O
P	O
##I	O
con	O
##com	O
##ita	O
##ntly	O
.	O

Ser	B
##ine	I
has	O
ne	O
##uro	O
##chemical	O
properties	O
that	O
may	O
be	O
per	O
##tinent	O
to	O
PD	O
,	O
including	O
interactions	O
with	O
N	O
##MD	O
##A	O
-	O
induced	O
ne	O
##uro	O
##de	O
##gene	O
##ration	O
.	O

Autonomous	O
g	B
##lu	I
##co	I
##cor	I
##tic	I
##oid	I
excess	O
was	O
defined	O
as	O
increased	O
u	O
##rina	O
##ry	O
free	O
co	B
##rt	I
##is	I
##ol	I
ex	O
##cre	O
##tion	O
.	O

The	O
major	O
add	O
##uc	O
##t	O
was	O
d	B
##G	I
-	I
C	I
##8	I
-	I
4	I
-	I
AB	I
##P	I
,	O
followed	O
by	O
d	B
##A	I
-	I
C	I
##8	I
-	I
4	I
-	I
AB	I
##P	I
,	O
and	O
the	O
proposed	O
add	O
##uc	O
##ts	O
d	O
##G	O
-	O
N	O
_	O
2	O
,	O
N	O
_	O
4	O
-	O
4	O
-	O
AB	O
##P	O
,	O
d	O
##G	O
-	O
N	O
_	O
2	O
-	O
4	O
-	O
AB	O
##P	O
.	O

Red	O
peak	O
corresponds	O
to	O
the	O
signal	O
obtained	O
with	O
D	O
##MA	O
##N	O
as	O
the	O
matrix	O
,	O
green	O
peak	O
with	O
N	B
,	I
N	I
-	I
dim	I
##eth	I
##yla	I
##ni	I
##line	I
as	O
the	O
matrix	O
,	O
pink	O
peak	O
with	O
1	B
,	I
8	I
-	I
di	I
##ami	I
##non	I
##aph	I
##thal	I
##ene	I
as	O
the	O
matrix	O
,	O
and	O
blue	O
peak	O
with	O
an	B
##ili	I
##ne	I
as	O
the	O
matrix	O
.	O

We	O
next	O
determined	O
the	O
levels	O
of	O
each	O
species	O
of	O
SM	O
(	B
C	B
##14	I
:	I
0	I
,	O
C	B
##16	I
:	I
0	I
,	O
C	B
##18	I
:	I
1	I
,	O
C	B
##18	I
:	I
0	I
,	O
C	B
##20	I
:	I
0	I
,	O
C	B
##22	I
:	I
0	I
,	O
C	B
##24	I
:	I
1	I
,	O
C	B
##24	I
:	I
0	I
,	O
C	B
##26	I
:	I
1	I
and	O
C	B
##26	I
:	I
0	I
)	O
in	O
the	O
breast	O
cancer	O
and	O
normal	O
breast	O
tissue	O
.	O

The	O
one	O
-	O
dimensional	O
(	O
1	O
##D	O
)	O
N	O
##MR	O
spectrum	O
of	O
a	O
buffer	O
##ed	O
stock	O
solution	O
of	O
2	O
##H	O
##G	O
features	O
four	O
signature	O
multiple	O
##ts	O
arising	O
from	O
five	O
al	B
##ky	I
##l	I
hydrogen	I
##s	I
:	O
one	O
α	O
,	O
two	O
β	O
,	O
and	O
two	O
γ	O
.	O

In	O
this	O
study	O
,	O
we	O
included	O
the	O
71	O
##2	O
participants	O
for	O
whom	O
both	O
24	B
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
and	O
its	O
interfering	O
anal	O
##yte	O
(	O
s	O
)	O
were	O
measured	O
at	O
base	O
##line	O
,	O
as	O
described	O
below	O
.	O

One	O
of	O
the	O
most	O
convincing	O
in	O
v	O
##ivo	O
studies	O
to	O
date	O
functional	O
##ly	O
imp	O
##lica	O
##ting	O
ch	B
##olin	I
##e	I
metabolism	O
to	O
PC	O
was	O
by	O
Long	O
##neck	O
##er	O
et	O
al	O
.	O
,	O
who	O
showed	O
that	O
rats	O
fed	O
a	O
ch	O
##olin	O
##e	O
-	O
supplemented	O
diet	O
exhibited	O
significantly	O
reduced	O
PC	O
les	O
##ion	O
areas	O
,	O
les	O
##ion	O
diameter	O
##s	O
and	O
numbers	O
of	O
lesions	O
compared	O
to	O
rats	O
fed	O
a	O
ch	B
##olin	I
##e	I
-	I
devoid	I
diet	O
.	O

Our	O
results	O
revealed	O
that	O
the	O
urine	O
ni	B
##cot	I
##in	I
##uri	I
##c	I
acid	I
value	O
of	O
subjects	O
with	O
diabetes	O
(	O
H	O
##b	O
##A	O
_	O
1	O
##c	O
≥	O
6	O
.	O
5	O
%	O
or	O
those	O
receiving	O
diabetes	O
medications	O
)	O
(	O
n	O
=	O
25	O
)	O
was	O
higher	O
than	O
subjects	O
without	O
diabetes	O
(	O
n	O
=	O
37	O
)	O
(	O
221	O
±	O
31	O
vs	O
.	O
152	O
±	O
13	O
×	O
10	O
_	O
3	O
m	O
##A	O
##U	O
,	O
P	O
=	O
0	O
.	O
02	O
##6	O
##8	O
)	O
.	O

_	O
,	O
Inc	O
##reased	O
C	O
##YP	O
##1	O
##B	O
##1	O
expression	O
by	O
E	O
_	O
2	O
may	O
occur	O
through	O
an	O
est	B
##rogen	I
response	O
element	O
(	O
ER	O
##E	O
)	O
located	O
in	O
the	O
promoter	O
region	O
of	O
the	O
C	O
##YP	O
##1	O
##B	O
##1	O
gene	O
.	O

There	O
is	O
a	O
pre	O
##dom	O
##ina	O
##nce	O
of	O
associated	O
S	O
##NP	O
##s	O
in	O
the	O
chromosome	O
11	O
,	O
12	O
and	O
16	O
,	O
mainly	O
in	O
genes	O
related	O
with	O
metabolic	O
factors	O
,	O
o	O
##xi	O
##da	O
##tive	O
stress	O
,	O
G	O
-	O
protein	O
,	O
o	O
##besity	O
and	O
an	B
##gio	I
##tens	I
##in	I
converting	O
enzyme	O
inhibitor	O
.	O

The	O
flow	O
from	O
the	O
PD	O
##A	O
detector	O
was	O
mixed	O
with	O
0	O
.	O
2	O
m	O
##L	O
/	O
min	O
makeup	O
solvent	O
(	O
0	O
.	O
1	O
%	O
v	O
/	O
v	O
form	B
##ic	I
acid	I
in	O
met	B
##han	I
##ol	I
)	O
,	O
supplied	O
by	O
a	O
Waters	O
51	O
##5	O
HP	O
##LC	O
pump	O
,	O
and	O
the	O
AB	O
##PR	O
was	O
used	O
to	O
maintain	O
the	O
result	O
##ant	O
solvent	O
stream	O
at	O
a	O
pressure	O
of	O
2000	O
ps	O
##i	O
(	O
138	O
bar	O
)	O
throughout	O
the	O
run	O
.	O

Analysis	O
of	O
l	O
##uc	O
##ifer	O
##ase	O
activity	O
in	O
S	O
##N	O
##47	O
##41	O
cells	O
trans	O
##fected	O
with	O
an	O
L	O
##X	O
##R	O
-	O
re	O
##sp	O
##ons	O
##ive	O
l	O
##uc	O
##ifer	O
##ase	O
reporter	O
construct	O
(	O
L	O
##X	O
##RE	O
)	O
and	O
L	O
##X	O
##R	O
##α	O
,	O
as	O
indicated	O
,	O
and	O
stimulate	O
##d	O
for	O
24	O
h	O
with	O
22	B
(	B
R	I
)	I
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I

The	O
ass	O
##ay	O
provided	O
ch	O
##em	O
##otype	O
##s	O
of	O
the	O
vitamin	B
D	I
metabolic	O
process	O
rather	O
than	O
the	O
usually	O
determined	O
25	O
(	O
OH	O
)	O
D	O
_	O
3	O
concentration	O
;	O
the	O
latter	O
gives	O
an	O
incomplete	O
picture	O
that	O
may	O
or	O
may	O
not	O
co	O
##rrel	O
##ate	O
with	O
function	O
or	O
disease	O
.	O

For	O
comparison	O
between	O
the	O
serum	O
and	O
CS	O
##F	O
meta	O
##bol	O
##ome	O
,	O
equal	O
al	O
##iq	O
##uo	O
##ts	O
of	O
pool	O
##ed	O
CS	O
##F	O
and	O
serum	O
were	O
combined	O
and	O
labeled	O
with	O
_	O
13	O
C	B
-	I
dans	I
##yl	I
chloride	I
,	O
while	O
the	O
pool	O
##ed	O
CS	O
##F	O
and	O
pool	O
##ed	O
serum	O
samples	O
were	O
labeled	O
with	O
_	O
12	O
C	B
-	I
dans	I
##yl	I
chloride	I
.	O

In	O
order	O
to	O
sum	O
up	O
the	O
meta	O
##bol	O
##ites	O
in	O
na	O
##no	O
##gram	O
##s	O
/	O
mill	O
##ili	O
##ter	O
the	O
m	O
##olar	O
concentrations	O
of	O
specific	O
meta	O
##bol	O
##ites	O
were	O
calculated	O
,	O
sum	O
##med	O
,	O
and	O
multi	O
##plied	O
by	O
their	O
respective	O
p	B
##ht	I
##hala	I
##te	I
dies	O
##ter	O
(	O
Table	O
)	O
.	O

Next	O
,	O
300	O
μ	O
##L	O
of	O
met	B
##han	I
##ol	I
was	O
added	O
remove	O
the	O
remaining	O
u	O
##rease	O
.	O

Interest	O
##ingly	O
,	O
in	O
the	O
present	O
study	O
a	O
history	O
of	O
high	O
diet	O
##ary	O
intake	O
of	O
non	O
-	O
whole	O
grain	O
products	O
,	O
and	O
thus	O
less	O
fibre	O
,	O
was	O
inverse	O
##ly	O
correlated	O
with	O
u	O
##rina	O
##ry	O
ace	B
##tam	I
##ide	I
levels	O
(	O
data	O
not	O
shown	O
)	O
.	O

The	O
amount	O
of	O
et	O
##her	O
lip	O
##ids	O
as	O
measured	O
by	O
the	O
total	O
a	O
##cy	O
##l	O
-	O
al	O
##ky	O
##l	O
-	O
containing	O
p	O
##hos	O
##pha	O
##ti	O
##dy	O
##l	O
##cho	O
##lines	O
to	O
total	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
(	O
AG	O
##PS	O
)	O
ratio	O
was	O
down	O
-	O
regulated	O
after	O
1	O
year	O
of	O
follow	O
-	O
up	O
in	O
all	O
groups	O
but	O
IN	O
##R	O
(	O
p	O
=	O
1	O
.	O
140	O
##5	O
##E	O
-	O
5	O
,	O
-	O
log	O
##10	O
(	O
p	O
)	O
=	O
4	O
.	O
94	O
##29	O
,	O
F	O
##DR	O
=	O
9	O
.	O
65	O
##86	O
##E	O
-	O
5	O
,	O
)	O
.	O

(	O
D	O
)	O
Re	O
##lative	O
intensity	O
of	O
N	B
-	I
form	I
##yl	I
##ky	I
##nu	I
##ren	I
##ine	I
in	O
RC	O
##C	O
,	O
ben	O
##ign	O
and	O
control	O
groups	O
in	O
the	O
training	O
set	O
.	O

The	O
short	O
-	O
term	O
(	O
bench	O
-	O
top	O
)	O
stability	O
of	O
the	O
anal	O
##yte	O
##s	O
(	O
AB	O
##T	O
-	O
88	O
##8	O
and	O
M	O
##8	O
)	O
in	O
met	B
##han	I
##ol	I
(	O
working	O
solution	O
)	O
at	O
the	O
concentration	O
of	O
100	O
and	O
1	O
μ	O
##g	O
/	O
m	O
##l	O
as	O
well	O
as	O
in	O
plasma	O
at	O
the	O
concentrations	O
of	O
15	O
and	O
1600	O
ng	O
/	O
m	O
##l	O
were	O
tested	O
at	O
ambient	O
temperature	O
(	O
25	O
##°	O
##C	O
)	O
for	O
4	O
h	O
.	O

The	O
q	O
##uant	O
##ification	O
of	O
PA	O
##H	O
meta	O
##bol	O
##ites	O
v	O
##iz	O
.	O
,	O
1	O
-	O
nap	O
##th	O
##ol	O
(	O
1	O
-	O
N	O
##AP	O
)	O
,	O
9	B
-	I
h	I
##ydro	I
##xy	I
##f	I
##lu	I
##ore	I
##ne	I
(	O
9	O
-	O
H	O
##F	O
)	O
,	O
3	B
-	I
h	I
##ydro	I
##xy	I
##f	I
##lu	I
##ore	I
##ne	I
(	O
3	O
-	O
H	O
##F	O
)	O
,	O
2	B
-	I
h	I
##ydro	I
##xy	I
##f	I
##lu	I
##ore	I
##ne	I
(	I
2	I
-	I
H	I
##F	I
)	I
,	I
9	I
-	I
p	I
##hen	I
##ant	I
##hr	I
##ol	I
(	I
9	I
-	I
P	I
##H	I
##N	I
)	I
,	O
1	B
-	I
h	I
##ydro	I
##xy	I
##py	I
##rene	I
(	O
1	O
-	O
OH	O
##P	O
)	O
were	O
performed	O
using	O
ca	O
##li	O
##bra	O
##tion	O
graphs	O
plot	O
##ted	O
between	O
concentration	O
and	O
peak	O
area	O
of	O
spike	O
##d	O
PA	O
##H	O
meta	O
##bol	O
##ites	O
in	O
controlled	O
urine	O
sample	O
in	O
the	O
range	O
of	O
0	O
.	O
2	O
–	O
200	O
ng	O
/	O

S	O
##pect	O
##ral	O
regions	O
of	O
water	O
and	O
u	B
##rea	I
resonance	O
##s	O
were	O
excluded	O
before	O
analysis	O
to	O
eliminate	O
base	O
##line	O
effects	O
of	O
imp	O
##er	O
##fect	O
water	O
sat	O
##uration	O
.	O

A	O
comparison	O
,	O
in	O
D	O
##M	O
and	O
control	O
subjects	O
,	O
of	O
plasma	O
levels	O
of	O
reactive	O
per	B
##sul	I
##fi	I
##des	I
and	O
p	B
##oly	I
##sul	I
##fi	I
##des	I
showed	O
that	O
they	O
did	O
not	O
differ	O
.	O

Between	O
the	O
base	O
##line	O
and	O
final	O
specimen	O
collections	O
,	O
the	O
mean	O
plasma	O
concentration	O
of	O
one	O
of	O
them	O
,	O
the	B
##ob	I
##rom	I
##ine	I
,	O
decreased	O
by	O
≈	O
##8	O
%	O
.	O

_	O
,	O
It	O
has	O
also	O
been	O
shown	O
that	O
the	O
elevation	O
of	O
2	B
-	I
amino	I
##adi	I
##pic	I
acid	I
after	O
long	O
-	O
term	O
h	O
##yper	O
##gly	O
##ce	O
##mia	O
of	O
end	O
##oth	O
##eli	O
##al	O
cells	O
is	O
a	O
sign	O
of	O
l	B
##ys	I
##ine	I
breakdown	O
through	O
o	O
##xi	O
##da	O
##tive	O
stress	O
and	O
reactive	O
oxygen	O
species	O
.	O

As	O
the	O
position	O
and	O
stereo	O
##chemistry	O
of	O
the	O
double	O
bond	O
in	O
an	O
FA	S
com	O
##plicate	O
##s	O
the	O
structural	O
el	O
##uc	O
##ida	O
##tion	O
,	O
they	O
are	O
often	O
tentatively	O
assigned	O
in	O
FA	O
##s	O
and	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
.	O

and	O
Fred	O
##eri	O
##ks	O
##en	O
et	O
al	O
.	O
also	O
reported	O
roughly	O
comparable	O
correlation	O
##s	O
between	O
p	B
##ht	I
##hala	I
##te	I
meta	O
##bol	O
##ites	O
,	O
but	O
some	O
correlation	O
rates	O
could	O
slightly	O
differ	O
ill	O
##ust	O
##rating	O
the	O
var	O
##iability	O
of	O
the	O
exposure	O
pattern	O
of	O
p	O
##ht	O
##hala	O
##tes	O
through	O
the	O
European	O
countries	O
.	O

In	O
this	O
study	O
,	O
five	O
amino	O
acids	O
decreased	O
in	O
V	O
.	O
SC	O
compared	O
with	O
N	O
##V	O
.	O
SC	O
,	O
involving	O
in	O
nine	O
amino	O
acid	O
metabolism	O
pathways	O
;	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
t	B
##yr	I
##os	I
##ine	I
and	O
try	B
##pt	I
##op	I
##han	I
bio	O
##sy	O
##nt	O
##hesis	O
was	O
a	O
differential	O
metabolic	O
pathway	O
between	O
the	O
two	O
groups	O
.	O

The	O
ins	O
##et	O
is	O
its	O
data	O
-	O
dependent	O
MS	O
/	O
MS	O
scan	O
giving	O
fragments	O
of	O
135	O
,	O
119	O
,	O
and	O
59	O
m	O
/	O
z	O
indicating	O
fragments	O
of	O
the	O
proposed	O
h	B
##ydro	I
##xy	I
##phe	I
##ny	I
##l	I
##but	I
##yric	I
acid	I
meta	O
##bol	O
##ite	O
shown	O
.	O

L	O
##C	O
–	O
MS	O
-	O
MS	O
ch	O
##roma	O
##to	O
##gram	O
##s	O
for	O
so	B
##fo	I
##s	I
##bu	I
##vir	I
meta	O
##bol	O
##ites	O
.	O

Arrow	O
##s	O
indicate	O
the	O
time	O
when	O
palm	B
##itate	I
-	I
BS	I
##A	I
(	O
175	O
μ	O
##M	O
)	O
,	O
E	O
##tom	O
##ox	O
##ir	O
(	O
80	O
μ	O
##M	O
)	O
,	O
and	O
anti	B
##my	I
##cin	I
(	I
0	I
.	I
2	I
μ	I
##M	I
)	I
/	I
rot	I
##eno	I
##ne	I
(	O
0	O
.	O
2	O
μ	O
##M	O
)	O
was	O
added	O
to	O
cells	O
(	O
n	O
=	O
3	O
)	O
.	O

For	O
extraction	O
,	O
0	O
.	O
05	O
##00	O
m	O
##L	O
of	O
human	O
E	O
##D	O
##TA	O
plasma	O
was	O
spike	O
##d	O
with	O
0	O
.	O
02	O
##00	O
m	O
##L	O
α	B
-	I
H	I
##B	I
-	I
D	I
_	I
3	I
internal	O
standard	O
solution	O
(	O
30	O
.	O
0	O
µ	O
##g	O
/	O
m	O
##L	O
)	O
and	O
subjected	O
to	O
protein	O
precipitation	O
by	O
vigorously	O
mixing	O
with	O
0	O
.	O
250	O
m	O
##L	O
of	O
met	B
##han	I
##ol	I
.	O

Total	B
-	I
ch	I
##ole	I
##ster	I
##ol	I
—	I
[	I
HD	I
##L	I
-	I
ch	I
##ole	I
##ster	I
##ol	I
+	I
(	I
T	I
##G	I
/	I
5	I
)	I
]	I
.	O

Go	O
to	O
:	O
Vita	B
##min	I
D	I
is	O
an	O
important	O
de	O
##ter	O
##mina	O
##nt	O
of	O
bone	O
health	O
at	O
all	O
ages	O
.	O

Up	O
-	O
regulation	O
of	O
2	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
and	O
p	B
##yr	I
##og	I
##lut	I
##ama	I
##te	I
in	O
patients	O
indicates	O
that	O
an	O
elevated	O
o	O
##xi	O
##da	O
##tive	O
stress	O
may	O
be	O
caused	O
by	O
impaired	O
G	B
##S	I
##H	I
metabolism	O
in	O
ne	O
##uro	O
##logical	O
diseases	O
such	O
as	O
MS	O
and	O
N	O
##MO	O
##SD	O
.	O

Among	O
four	O
predicted	O
positive	O
associations	O
,	O
ta	B
##uri	I
##ne	I
and	O
do	B
##cos	I
##ap	I
##ent	I
##aen	I
##oi	I
##c	I
acid	I
were	O
confirmed	O
to	O
enhance	O
growth	O
,	O
while	O
p	B
##hy	I
##tos	I
##phi	I
##ngo	I
##sin	I
##e	I
exhibited	O
a	O
para	O
##dox	O
##ical	O
inhibitor	O
##y	O
effect	O
.	O

;	O
Walsh	O
et	O
al	O
.	O
)	O
,	O
which	O
presents	O
a	O
problem	O
when	O
trying	O
to	O
use	O
c	B
##rea	I
##tin	I
##ine	I
as	O
a	O
normal	O
##ization	O
factor	O
for	O
post	O
##pra	O
##ndi	O
##al	O
spot	O
urine	O
samples	O
.	O

Is	B
##oc	I
##it	I
##rate	I
can	O
be	O
converted	O
to	O
c	B
##it	I
##rate	I
and	O
α	B
-	I
k	I
##eto	I
##g	I
##lut	I
##arate	I
,	O
and	O
this	O
process	O
is	O
balanced	O
to	O
allow	O
generation	O
of	O
both	O
ATP	S
and	O
cellular	O
mac	O
##rom	O
##ole	O
##cule	O
##s	O
to	O
sustain	O
cell	O
growth	O
.	O

U	B
##rea	I
showed	O
strong	O
decreases	O
in	O
UC	O
as	O
well	O
as	O
in	O
CD	O
patients	O
,	O
which	O
is	O
in	O
contrast	O
with	O
previous	O
findings	O
of	O
u	B
##rea	I
production	O
in	O
I	O
##B	O
##D	O
patients	O
.	O

We	O
found	O
that	O
Val	B
##ine	I
,	O
S	B
##phi	I
##ngo	I
##my	I
##elin	I
##e	I
C	I
##24	I
:	I
1	I
,	O
L	B
##ys	I
##ine	I
,	O
His	B
##ti	I
##dine	I
,	O
Try	B
##pt	I
##op	I
##han	I
,	O
Oct	B
##ade	I
##ce	I
##noy	I
##l	I
##car	I
##ni	I
##tine	I
,	O
Trip	B
##ent	I
##ade	I
##cano	I
##ate	I
T	O
##G	O
##15	O
,	O
L	B
##ys	I
##o	I
##P	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
a	I
##cy	I
##l	I
C	I
##20	I
:	I
3	I
,	O
Doc	B
##osa	I
##he	I
##xa	I
##eno	I
##ic	I
A	I
##cid	I
,	O
S	B
##phi	I
##ngo	I
##my	I
##elin	I
##e	I
C	I
##18	I
:	I
1	I
,	O
L	B
##ys	I
##o	I
##P	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
a	I
##cy	I
##l	I
C	I
##20	I
:	I
4	I
,	O
Ph	B
##os	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lined	I
##iac	I
##yl	I
C	I
##32	I
:	I
0	I
,	O
S	B
##ym	I
##metric	I
dim	I
##eth	I
##yla	I
##rg	I
##ini	I
##ne	I
,	O
G	B
##ly	I
##co	I
##urs	I
##ode	I
##ox	I
##ych	I
##olic	I
A	I
##cid	I
,	O
1	B
##mon	I
##op	I
##al	I
##mit	I
##ole	I
##oy	I
##l	I
-	I
r	I
##ac	I
-	I
G	I
##L	I
##1	I
,	O
G	O
-	O
L	O
##CA	O
,	O
L	B
##ys	I
##o	I
##P	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
a	I
##cy	I
##l	I
C	I
##18	I
:	I
0	I
were	O
the	O
most	O
important	O
predict	O
##ors	O
of	O
one	O
year	O
mortality	O
risk	O
(	O
as	O
shown	O
in	O
Figure	O
reporting	O
from	O
the	O
most	O
to	O
the	O
less	O
important	O
)	O
.	O

In	O
addition	O
,	O
we	O
detected	O
a	O
significant	O
accumulation	O
of	O
multiple	O
products	O
from	O
pu	B
##rine	I
cat	O
##ab	O
##olis	O
##m	O
such	O
as	O
in	B
##os	I
##ine	I
,	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
,	O
x	B
##ant	I
##hine	I
and	O
x	B
##ant	I
##hos	I
##ine	I
,	O
as	O
well	O
as	O
ad	B
##eno	I
##sin	I
##e	I
,	O
ad	B
##eni	I
##ne	I
and	O
g	B
##uan	I
##os	I
##ine	I
.	O

P	O
##las	O
##ma	O
SA	O
##H	O
levels	O
are	O
often	O
more	O
strongly	O
increased	O
with	O
reduced	O
kidney	O
function	O
than	O
ho	B
##mo	I
##cy	I
##stein	I
##e	I
levels	O
,	O
,	O
and	O
SA	O
##H	O
acts	O
as	O
a	O
strong	O
inhibitor	O
of	O
most	O
met	O
##hyl	O
##ation	O
reactions	O
.	O

l	O
on	O
two	O
consecutive	O
measurements	O
;	O
non	O
-	O
di	O
##abe	O
##tic	O
control	O
animals	O
(	O
n	O
=	O
7	O
)	O
were	O
age	O
-	O
matched	O
litter	O
##mates	O
who	O
received	O
a	O
single	O
in	B
##tra	I
##per	I
##ito	I
##nea	I
##l	I
injection	O
of	O
sodium	B
-	I
c	I
##it	I
##rate	I
buffer	O
(	O
vehicle	O
)	O
only	O
.	O

Met	B
##hi	I
##oni	I
##ne	I
also	O
can	O
be	O
used	O
as	O
a	O
precursor	O
of	O
ho	B
##mo	I
##cy	I
##stein	I
##e	I
.	O

Ph	O
##arma	O
##come	O
##ta	O
##bol	O
##omi	O
##cs	O
provides	O
powerful	O
tools	O
for	O
identifying	O
global	O
bio	O
##chemical	O
changes	O
induced	O
by	O
s	B
##tat	I
##in	I
treatment	O
,	O
providing	O
insights	O
about	O
drug	O
mechanism	O
of	O
action	O
,	O
development	O
of	O
side	O
effects	O
and	O
basis	O
of	O
variation	O
of	O
response	O
.	O

The	O
effect	O
of	O
the	O
T	O
##CE	O
##P	O
and	O
B	O
##Q	O
##B	O
contents	O
on	O
reduction	O
e	O
##ff	O
##ici	O
##encies	O
of	O
di	B
##sul	I
##fi	I
##de	I
bonds	O
and	O
chemical	O
label	O
##ing	O
were	O
investigated	O
.	O

Early	O
studies	O
showed	O
that	O
id	O
##io	O
##pathic	O
portal	O
h	O
##yper	O
##tens	O
##ion	O
co	O
##rrel	O
##ates	O
to	O
decreased	O
levels	O
of	O
le	B
##uc	I
##ine	I
,	O
is	B
##ole	I
##uc	I
##ine	I
and	O
v	B
##ali	I
##ne	I
.	O

Al	O
##a	O
,	O
A	O
##rg	O
,	O
C	O
##12	O
-	O
OH	O
/	O
C	O
##10	O
-	O
DC	O
,	O
C	B
##14	I
:	I
1	I
-	I
OH	I
,	O
C	B
##16	I
:	I
1	I
,	O
C	B
##18	I
:	I
2	I
,	O
C	B
##18	I
:	I
1	I
,	O
C	B
##20	I
:	I
4	I
and	O
C	B
##18	I
:	I
1	I
-	I
DC	I
.	O

In	O
another	O
plasma	O
meta	O
##bol	O
##omi	O
##cs	O
study	O
conducted	O
on	O
patients	O
with	O
liver	O
diseases	O
,	O
the	O
level	O
of	O
g	B
##lut	I
##ami	I
##c	I
acid	I
was	O
found	O
decreased	O
in	O
all	O
three	O
types	O
of	O
liver	O
disease	O
(	O
he	O
##pa	O
##titis	O
,	O
c	O
##ir	O
##r	O
##hos	O
##is	O
,	O
HC	O
##C	O
)	O
when	O
compared	O
to	O
healthy	O
controls	O
.	O

Moreover	O
,	O
p	B
##hos	I
##pha	I
##ti	I
##dic	I
acid	I
is	O
the	O
best	O
meta	O
##bol	O
##ite	O
to	O
indicate	O
the	O
progression	O
.	O

As	O
a	O
result	O
,	O
2	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
,	O
ace	B
##tone	I
,	O
and	O
format	B
##e	I
were	O
higher	O
and	O
ace	B
##tate	I
and	O
glucose	S
were	O
lower	O
in	O
both	O
re	O
##lap	O
##se	O
and	O
re	O
##mission	O
of	O
MS	O
and	O
N	O
##MO	O
##SD	O
.	O

Inc	O
##reased	O
g	B
##lut	I
##ath	I
##ione	I
di	I
##sul	I
##phi	I
##de	I
as	O
a	O
marker	O
of	O
o	O
##xi	O
##da	O
##tive	O
stress	O
(	O
c	O
)	O
.	O

St	O
##ability	O
of	O
B	O
##EN	O
(	O
a	O
)	O
and	O
BA	O
(	O
b	O
)	O
in	O
plasma	O
at	O
room	O
temperature	O
(	O
open	O
circle	O
)	O
,	O
4	O
°C	O
(	O
filled	O
square	O
)	O
and	O
at	O
room	O
temperature	O
with	O
5	O
%	O
(	O
v	O
/	O
v	O
)	O
2	O
M	O
sulfur	B
##ic	I
acid	I
(	O
open	O
triangle	O
)	O

Tri	B
##car	I
##box	I
##yl	I
##ic	I
acid	I
(	O
T	O
##CA	O
)	O
cycle	O
meta	O
##bol	O
##ites	O
were	O
found	O
to	O
be	O
elevated	O
in	O
the	O
CS	O
##F	O
of	O
patients	O
with	O
C	O
##NS	O
tumors	O
including	O
ma	B
##lic	I
acid	I
and	O
su	B
##cci	I
##nate	I
.	O

In	O
our	O
models	O
,	O
the	O
comparison	O
of	O
his	O
##to	O
##logical	O
##ly	O
normal	O
tissue	O
in	O
EA	O
##C	O
patients	O
versus	O
controls	O
benefit	O
##ted	O
from	O
good	O
sample	O
numbers	O
pre	O
##che	O
##mother	O
##ap	O
##y	O
and	O
gave	O
a	O
strong	O
signature	O
(	O
AU	O
##RO	O
##C	O
=	O
1	O
)	O
with	O
highly	O
elevated	O
3	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
,	O
su	B
##cci	I
##nate	I
,	O
and	O
format	B
##e	I
and	O
somewhat	O
increased	O
ace	B
##tate	I
,	O
la	B
##ct	I
##ate	I
,	O
AD	B
##P	I
,	O
and	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##och	I
##olin	I
##e	I
.	O

Ace	B
##ton	I
##it	I
##ril	I
##e	I
,	O
di	O
##st	O
##ille	O
##d	O
water	O
,	O
form	B
##ic	I
acid	I
,	O
sodium	B
h	I
##ydro	I
##xi	I
##de	I
,	O
di	B
##so	I
##dium	I
hydrogen	I
phosphate	I
and	O
sodium	O
di	O
##hy	O
##dr	O
##ogen	O
phosphate	O
an	O
##hy	O
##dr	O
##ous	O
were	O
of	O
analytical	O
grade	O
purchased	O
from	O
Ka	O
##nto	O
Chemical	O
##s	O
(	O
Tokyo	O
,	O
Japan	O
)	O
.	O

E	O
##ster	O
##ified	O
fatty	O
acids	O
and	O
o	B
##xy	I
##lip	I
##ins	I
in	O
lip	O
##op	O
##rote	O
##ins	O
are	O
released	O
into	O
tissues	O
after	O
their	O
up	O
##take	O
and	O
lip	O
##oly	O
##sis	O
.	O

Moreover	O
g	O
##lut	O
##ami	O
##nas	O
##e	O
(	O
G	O
##LS	O
)	O
is	O
over	O
##ex	O
##pressed	O
in	O
many	O
tumor	O
cells	O
and	O
converts	O
g	B
##lut	I
##amine	I
to	O
g	B
##lut	I
##ami	I
##c	I
acid	I
,	O
which	O
is	O
then	O
converted	O
to	O
[UNK]	O
-	O
K	O
##G	O
and	O
introduced	O
into	O
T	O
##CA	O
cycle	O
.	O

Further	O
,	O
the	O
concentration	O
of	O
the	O
car	B
##box	I
##yl	I
##ic	I
acid	I
and	O
amino	S
meta	O
##bol	O
##ites	O
were	O
also	O
determined	O
by	O
directly	O
comparing	O
the	O
2D	O
peak	O
integral	O
##s	O
with	O
those	O
for	O
the	O
corresponding	O
standard	O
compound	O
.	O

After	O
step	O
##wise	O
adjustment	O
for	O
the	O
combination	O
of	O
age	O
,	O
sex	O
,	O
N	O
##T	O
-	O
pro	O
##B	O
##NP	O
,	O
c	B
##ys	I
##tat	I
##in	I
C	O
,	O
and	O
IL	O
-	O
6	O
,	O
ID	O
##O	O
-	O
T	O
##M	O
scores	O
remained	O
significantly	O
associated	O
with	O
RA	O
##P	O
,	O
m	O
##PA	O
##P	O
,	O
P	O
##VR	O
,	O
exercise	O
P	O
##VR	O
,	O
and	O
Δ	O
##P	O
##Q	O
(	O
p	O
≤	O
0	O
.	O
01	O
for	O
all	O
)	O
.	O

The	O
subsequent	O
accumulation	O
of	O
α	B
-	I
k	I
##eto	I
acids	I
,	O
like	O
3	B
-	I
met	I
##hyl	I
-	I
2	I
-	I
o	I
##x	I
##ob	I
##ut	I
##yra	I
##te	I
,	O
may	O
trigger	O
the	O
path	O
##op	O
##hy	O
##sio	O
##logy	O
of	O
insulin	O
resistance	O
and	O
subsequently	O
T	O
##2	O
##DM	O
with	O
support	O
from	O
animal	O
models	O
and	O
ca	O
##usal	O
assessment	O
using	O
Men	O
##del	O
##ian	O
random	O
##ization	O
.	O

Long	O
-	O
standing	O
h	O
##y	O
##pot	O
##heses	O
about	O
how	O
est	B
##rogen	I
metabolism	O
might	O
influence	O
breast	O
cancer	O
have	O
not	O
been	O
adequately	O
evaluated	O
in	O
e	O
##pid	O
##em	O
##iol	O
##ogical	O
studies	O
because	O
of	O
the	O
lack	O
of	O
accurate	O
,	O
re	O
##p	O
##rod	O
##uc	O
##ible	O
,	O
and	O
high	O
-	O
through	O
##put	O
ass	O
##ays	O
for	O
est	B
##rogen	I
meta	O
##bol	O
##ites	O
.	O

C	B
##rea	I
##tin	I
##ine	I
has	O
been	O
reported	O
to	O
be	O
significantly	O
decreased	O
in	O
the	O
blood	O
samples	O
of	O
patients	O
with	O
A	B
##F	I
with	O
h	O
##yper	O
##tens	O
##ion	O
,	O
and	O
our	O
results	O
also	O
showed	O
that	O
c	B
##rea	I
##tin	I
##ine	I
was	O
decreased	O
in	O
the	O
plasma	O
samples	O
.	O

T	O
##RP	O
is	O
an	O
essential	O
amino	O
acid	O
,	O
and	O
it	O
is	O
the	O
key	O
meta	O
##bol	O
##ite	O
of	O
2	O
pathways	O
,	O
including	O
the	O
synthesis	O
of	O
the	O
ne	O
##uro	O
##tra	O
##ns	O
##mit	O
##ter	O
5	B
-	I
h	I
##ydro	I
##xy	I
##try	I
##pta	I
##mine	I
(	O
se	O
##rot	O
##oni	O
##n	O
)	O
and	O
the	O
k	B
##yn	I
##uren	I
##ine	I
pathway	O
(	O
K	O
##P	O
)	O
,	O
which	O
ultimately	O
lead	O
to	O
the	O
production	O
of	O
ni	O
##cot	O
##ina	O
##mm	O
##ide	O
ad	O
##eni	O
##na	O
din	O
##uc	O
##leo	O
##tide	O
.	O

Either	O
def	O
##icient	O
or	O
excessive	O
re	O
##nal	O
production	O
of	O
20	B
-	I
H	I
##ET	I
##E	I
was	O
reported	O
to	O
el	O
##eva	O
##te	O
blood	O
pressure	O
.	O

U	B
##rate	I
also	O
showed	O
non	O
-	O
significant	O
elevation	O
in	O
B	O
##E	O
versus	O
GE	O
##RD	O
(	O
P	O
=	O
0	O
.	O
12	O
)	O
,	O
while	O
ho	B
##mo	I
##cy	I
##stein	I
##e	I
was	O
similarly	O
non	O
-	O
significantly	O
elevated	O
in	O
H	O
##G	O
##D	O
/	O
EA	O
versus	O
B	O
##E	O
(	O
P	O
=	O
0	O
.	O
17	O
)	O
.	O

Whereas	O
as	O
##ym	O
##metric	O
##ally	O
dim	B
##eth	I
##yla	I
##ted	I
a	I
##rg	I
##ini	I
##ne	I
(	O
AD	O
##MA	O
)	O
,	O
C	O
##it	O
,	O
k	B
##yn	I
##uren	I
##ine	I
,	O
Or	O
##n	O
,	O
put	B
##res	I
##cine	I
,	O
sa	B
##rc	I
##os	I
##ine	I
,	O
se	B
##rot	I
##oni	I
##n	I
,	O
sperm	B
##id	I
##ine	I
,	O
sperm	B
##ine	I
,	O
ta	B
##uri	I
##ne	I
and	O
total	O
dim	B
##eth	I
##yla	I
##mine	I
(	O
total	O
D	O
##MA	O
)	O
were	O
present	O
in	O
both	O
types	O
of	O
specimens	O
,	O
A	O
##c	O
-	O
Or	O
##n	O
,	O
α	B
-	I
amino	I
##adi	I
##pic	I
acid	I
(	B
alpha	B
-	I
AAA	I
)	O
,	O
car	B
##nos	I
##ine	I
,	O
c	B
##rea	I
##tin	I
##ine	I
,	O
L	B
-	I
4	I
-	I
h	I
##ydro	I
##xy	I
##p	I
##rol	I
##ine	I
(	O
OH	O
-	O
Pro	O
)	O
and	O
P	O
##EA	O
were	O
detected	O
only	O
in	O
seminal	O
plasma	O
.	O

B	O
##W	O
taken	O
within	O
a	O
3	O
h	O
blood	O
glucose	S
measurement	O
period	O
at	O
0	O
.	O
5	O
h	O
intervals	O
are	O
presented	O
in	O
Figure	O
-	O
.	O

This	O
suggests	O
that	O
the	O
ET	O
##S	O
u	O
##rina	O
##ry	O
bio	O
##mark	O
##ers	O
studied	O
are	O
good	O
biological	O
indicators	O
of	O
personal	O
exposure	O
to	O
high	O
molecular	O
weight	O
p	B
##oly	I
##cy	I
##c	I
##lic	I
a	O
##romatic	O
h	B
##ydro	I
##car	I
##bon	I
##s	I
,	O
including	O
car	O
##cin	O
##ogenic	O
PA	O
##H	O
##s	O
such	O
as	O
ben	B
##zo	I
(	I
a	I
)	I
p	I
##yre	I
##ne	I
,	O
in	O
our	O
study	O
population	O
.	O

For	O
ch	O
##roma	O
##tography	O
using	O
the	O
Shi	O
##mad	O
##zu	O
L	O
##C	O
system	O
,	O
the	O
mobile	O
phase	O
was	O
composed	O
of	O
solvent	O
A	O
,	O
10	O
m	O
##M	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
in	O
95	O
%	O
H	O
_	O
2	O
O	O
/	O
3	O
%	O
ace	O
##ton	O
##it	O
##ril	O
##e	O
/	O
2	O
%	O
met	O
##han	O
##ol	O
/	O
0	O
.	O
2	O
%	O
ace	O
##tic	O
acid	O
,	O
and	O
solvent	O
B	O
,	O
10	O
m	O
##M	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
in	O
93	O
%	O
ace	O
##ton	O
##it	O
##ril	O
##e	O
/	O
2	O
%	O
met	O
##han	O
##ol	O
/	O
5	O
%	O
H	O
_	O
2	O
O	O
/	O
0	O
.	O
2	O
%	O
ace	B
##tic	I
acid	I
.	O

The	O
dried	O
residue	O
was	O
re	O
##con	O
##stituted	O
with	O
50	O
μ	O
##L	O
of	O
ace	O
##ton	O
##it	O
##ril	O
##e	O
—	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
mixture	O
(	O
25	O
:	O
75	O
,	O
v	O
/	O
v	O
)	O
and	O
v	O
##ortex	O
##ed	O
for	O
30	O
s	O
.	O
After	O
that	O
,	O
the	O
tubes	O
were	O
cent	O
##ri	O
##fu	O
##ged	O
at	O
35	O
,	O
000	O
×	O
g	O
for	O
10	O
min	O
at	O
4	O
##°	O
##C	O
.	O

The	O
median	O
survival	O
time	O
was	O
over	O
60	O
months	O
when	O
patients	O
revealed	O
lower	O
levels	O
of	O
pro	B
##line	I
,	O
p	B
-	I
c	I
##res	I
##ol	I
and	O
4	B
-	I
h	I
##ydro	I
##xy	I
##ben	I
##zoic	I
acid	I
in	O
urine	O
.	O

Thus	O
,	O
it	O
has	O
been	O
suggested	O
that	O
q	B
##uin	I
##ones	I
could	O
be	O
formed	O
and	O
N	B
-	I
ni	I
##tro	I
##sa	I
##mine	I
##s	I
are	O
present	O
in	O
u	O
##rogen	O
##ital	O
s	O
##chi	O
##sto	O
##so	O
##mia	O
##sis	O
infection	O
.	O

For	O
instance	O
,	O
2	B
-	I
fur	I
##oy	I
##l	I
##gly	I
##cine	I
,	O
another	O
marker	O
of	O
coffee	O
consumption	O
,	O
can	O
be	O
used	O
to	O
cross	O
-	O
check	O
for	O
coffee	O
consumption	O
and	O
as	O
secondary	O
marker	O
to	O
adjust	O
the	O
concentration	O
of	O
N	O
##M	O
##NA	O
.	O

With	O
our	O
method	O
,	O
peak	O
areas	O
obtained	O
in	O
spike	O
##d	O
and	O
clinical	O
samples	O
for	O
IS	O
##T	O
##D	O
115	O
##26	O
##10	O
##2	O
and	O
Met	O
amino	B
-	I
d	I
##11	I
perfectly	O
matched	O
,	O
with	O
an	O
overall	O
RS	O
##D	O
below	O
2	O
%	O
,	O
confirming	O
the	O
reliability	O
of	O
the	O
method	O
for	O
measuring	O
not	O
only	O
P	O
##B	O
##T	O
##Z	O
##16	O
##9	O
but	O
also	O
six	O
known	O
meta	O
##bol	O
##ites	O
in	O
real	O
human	O
plasma	O
samples	O
collected	O
from	O
healthy	O
volunteers	O
.	O

In	O
domestic	O
kitchen	O
##s	O
,	O
except	O
for	O
cooking	O
practice	O
and	O
oil	O
-	O
f	O
##umes	O
,	O
there	O
were	O
other	O
PA	O
##H	O
##s	O
sources	O
,	O
such	O
as	O
smoking	O
and	O
other	O
human	O
activities	O
in	O
the	O
domestic	O
houses	O
,	O
where	O
3	O
–	O
4	O
ring	O
PA	O
##H	O
##s	O
mainly	O
came	O
from	O
cooking	O
practice	O
(	O
4	O
ring	O
PA	O
##H	O
##s	O
(	O
P	O
##Y	O
##R	O
,	O
CH	O
##R	O
##Y	O
)	O
and	O
six	O
rings	O
(	B
In	B
##den	I
##o	I
[	I
1	I
,	I
2	I
,	I
3	I
-	I
c	I
##d	I
]	I
p	O
##yre	O
##ne	O
)	O
”	O
.	O

Known	O
to	O
be	O
low	O
in	O
normal	O
physiological	O
conditions	O
,	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
levels	O
increase	O
upon	O
tissue	O
damage	O
.	O

For	O
LL	O
##E	O
,	O
separate	O
experiments	O
for	O
1	B
##α	I
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
and	O
25	O
(	O
OH	O
)	O
D	O
_	O
3	O
standard	O
spikes	O
were	O
performed	O
,	O
while	O
for	O
SP	O
##E	O
,	O
serum	O
was	O
spike	O
##d	O
with	O
a	O
mixture	O
of	O
24	O
##R	O
,	O
25	O
(	O
OH	O
)	O
_	O
2	O
D	B
_	I
3	I
,	I
1	I
##α	I
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
,	O
25	O
(	O
OH	O
)	O
D	O
_	O
2	O
and	O
25	O
(	O
OH	O
)	O
D	O
_	O
3	O
.	O

In	O
our	O
study	O
with	O
the	O
four	O
study	O
groups	O
as	O
the	O
outcome	O
(	O
i	O
.	O
e	O
.	O
,	O
controls	O
,	O
early	O
,	O
intermediate	O
and	O
late	O
AM	O
##D	O
)	O
,	O
a	O
d	O
##ys	O
##re	O
##gu	O
##lation	O
of	O
a	B
##rg	I
##ini	I
##ne	I
meta	O
##bol	O
##ites	O
(	O
such	O
as	O
N	B
-	I
ace	I
##ty	I
##lar	I
##gin	I
##ine	I
and	O
2	B
-	I
o	I
##x	I
##oar	I
##gin	I
##ine	I
)	O
has	O
also	O
been	O
observed	O
.	O

The	O
SP	O
##E	O
version	O
of	O
the	O
method	O
was	O
used	O
for	O
high	O
-	O
through	O
##put	O
p	O
##hen	O
##ot	O
##y	O
##ping	O
of	O
vitamin	B
D	I
metabolism	O
in	O
subjects	O
with	O
different	O
levels	O
of	O
sun	O
exposure	O
and	O
different	O
levels	O
of	O
skin	O
pig	O
##mentation	O
.	O

Finally	O
,	O
all	O
sections	O
were	O
counters	O
##tain	O
##ed	O
with	O
Mayer	O
’	O
s	O
hem	B
##ato	I
##xy	I
##lin	I
(	O
Sc	O
##y	O
##T	O
##ek	O
Laboratories	O
,	O
West	O
Logan	O
,	O
U	O
##T	O
,	O
USA	O
)	O
and	O
evaluated	O
under	O
light	O
micro	O
##sco	O
##py	O
.	O

Most	O
lip	O
##id	O
molecules	O
are	O
am	O
##phi	O
##phi	O
##lic	O
or	O
am	O
##phi	O
##pathic	O
molecules	O
,	O
with	O
a	O
h	B
##ydro	I
##phi	I
##lic	I
or	O
polar	O
ion	O
##ic	O
group	O
,	O
and	O
non	O
##pol	O
##ar	O
h	O
##ydro	O
##phobic	O
fatty	O
a	O
##cy	O
##l	O
chain	O
(	O
s	O
)	O
.	O

Table	O
sum	O
##mar	O
##izes	O
11	O
identified	O
metabolic	O
pathways	O
,	O
from	O
which	O
the	O
first	O
5	O
were	O
found	O
to	O
be	O
significantly	O
altered	O
in	O
terms	O
of	O
pathway	O
en	O
##rich	O
##ment	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
and	O
/	O
or	O
topology	O
(	O
Impact	O
>	O
0	O
.	O
1	O
)	O
:	O
g	B
##ly	I
##ox	I
##yla	I
##te	I
and	O
di	B
##car	I
##box	I
##yla	I
##te	I
metabolism	O
,	O
g	B
##ly	I
##cine	I
se	I
##rine	I
and	O
th	B
##re	I
##oni	I
##ne	I
metabolism	O
,	O
c	O
##yan	O
##oam	O
##ino	O
acid	O
metabolism	O
,	O
c	B
##it	I
##rate	I
cycle	O
(	O
T	O
##CA	O
cycle	O
)	O
as	O
well	O
as	O
g	B
##lut	I
##ath	I
##ione	I
metabolism	O
.	O

G	O
##ly	O
##co	O
##lysis	O
is	O
the	O
major	O
metabolic	O
pathway	O
in	O
RB	O
##Cs	O
to	O
meet	O
the	O
energy	O
demand	O
and	O
to	O
protect	O
cells	O
from	O
reactive	O
oxygen	O
species	O
using	O
G	B
##S	I
##H	I
as	O
the	O
anti	O
##ox	O
##ida	O
##nt	O
.	O

The	O
dependent	O
variable	O
of	O
each	O
linear	O
model	O
was	O
the	O
log	O
_	O
10	O
-	O
transformed	O
value	O
of	O
a	O
me	B
##rca	I
##pt	I
##uri	I
##c	I
acid	I
(	O
µ	O
##g	O
/	O
L	O
)	O
.	O

H	B
##y	I
##pot	I
##au	I
##rine	I
is	O
considered	O
to	O
play	O
a	O
protective	O
role	O
for	O
s	O
##ca	O
##ven	O
##ging	O
free	O
radical	O
##s	O
caused	O
by	O
oxygen	O
and	O
biological	O
anti	O
##ox	O
##ida	O
##nts	O
.	O

Examples	O
of	O
the	O
natural	O
op	O
##iate	O
##s	O
include	O
m	B
##or	I
##phine	I
,	O
code	B
##ine	I
and	O
the	O
##ba	O
##ine	O
.	O

H	B
##y	I
##pox	I
##ant	I
##hine	I
and	O
g	B
##lut	I
##ami	I
##c	I
acid	I
levels	O
in	O
Panel	O
##s	O
B	O
and	O
C	O
are	O
significantly	O
up	O
##re	O
##gu	O
##lated	O
in	O
pneumonia	O
samples	O
.	O

The	O
flow	O
rate	O
was	O
350	O
μ	O
##L	O
/	O
min	O
and	O
the	O
injection	O
volume	O
was	O
4	O
μ	O
##L	O
.	O
The	O
Q	O
-	O
TO	O
##F	O
mass	O
s	O
##pect	O
##rome	O
##ter	O
was	O
operated	O
in	O
electro	O
##sp	O
##ray	O
ion	O
##ization	O
source	O
(	O
E	O
##SI	O
)	O
positive	O
ion	O
mode	O
with	O
a	O
cap	O
##illa	O
##ry	O
voltage	O
of	O
3	O
.	O
5	O
k	B
##V	I
,	O
drying	O
gas	O
flow	O
of	O
11	O
L	O
/	O
min	O
,	O
and	O
a	O
gas	O
temperature	O
of	O
350	O
°C	O
.	O

As	O
a	O
hem	O
##e	O
-	O
containing	O
enzyme	O
,	O
ID	O
##O	O
may	O
be	O
in	O
##hibit	O
##ed	O
by	O
NO	O
,	O
and	O
it	O
is	O
plausible	O
that	O
production	O
of	O
ID	O
##O	O
-	O
T	O
##Ms	O
represents	O
a	O
com	O
##pen	O
##sat	O
##ory	O
pathway	O
activated	S
in	O
states	O
of	O
NO	O
deficiency	O
,	O
such	O
as	O
R	O
##V	O
-	O
P	O
##V	O
d	O
##ys	O
##function	O
.	O

Le	B
##uc	I
##ine	I
en	I
##ke	I
##pha	I
##lin	I
was	O
used	O
as	O
the	O
lock	O
mass	O
(	O
m	O
/	O
z	O
55	O
##6	O
.	O
27	O
##7	O
##1	O
in	O
E	O
##S	O
+	O
and	O
55	O
##4	O
.	O
261	O
##5	O
in	O
E	O
##S	O
-	O
)	O
at	O
a	O
concentration	O
of	O
100	O
ng	O
/	O
m	O
##l	O
and	O
flow	O
rate	O
of	O
0	O
.	O
2	O
m	O
##l	O
/	O
min	O
for	O
all	O
analyses	O
.	O

In	O
an	O
animal	O
model	O
,	O
C	O
##K	O
##D	O
induced	O
a	O
reduction	O
in	O
the	O
re	O
##nal	O
up	O
##take	O
of	O
c	B
##it	I
##ru	I
##llin	I
##e	I
in	O
the	O
abundance	O
of	O
these	O
enzymes	O
.	O

In	O
conclusion	O
,	O
our	O
results	O
raise	O
the	O
possibility	O
that	O
B	O
##D	O
-	O
associated	O
abnormal	O
##ities	O
in	O
k	B
##yn	I
##uren	I
##ine	I
metabolism	O
may	O
negatively	O
impact	O
the	O
hip	O
##po	O
##cam	O
##pus	O
and	O
possibly	O
the	O
am	O
##y	O
##g	O
##dal	O
##a	O
,	O
structures	O
that	O
have	O
been	O
shown	O
to	O
be	O
both	O
functional	O
##ly	O
impaired	O
and	O
reduced	O
in	O
volume	O
in	O
un	O
##med	O
##ica	O
##ted	O
patients	O
with	O
B	O
##D	O
.	O

T	B
##hy	I
##ro	I
##xin	I
##e	I
demonstrated	O
reduced	O
levels	O
in	O
manifest	O
compared	O
with	O
pre	O
##mani	O
##fest	O
HD	O
subjects	O
,	O
moderate	O
to	O
strong	O
associations	O
to	O
all	O
measures	O
of	O
disease	O
severity	O
and	O
lower	O
thy	B
##ro	I
##xin	I
##e	I
levels	O
were	O
associated	O
to	O
an	O
increased	O
five	O
year	O
risk	O
of	O
onset	O
in	O
pre	O
##mani	O
##fest	O
HD	O
subject	O
.	O

All	O
were	O
unchanged	O
after	O
the	O
place	O
##bo	O
in	O
##fusion	O
,	O
and	O
there	O
was	O
no	O
effect	O
of	O
r	O
##HD	O
##L	O
on	O
total	O
D	O
##AG	O
or	O
Ce	B
##r	I
.	O

We	O
sought	O
to	O
determine	O
the	O
serum	O
levels	O
of	O
5	O
-	O
H	O
##T	O
,	O
try	B
##pt	I
##op	I
##han	I
(	O
T	O
##rp	O
)	O
meta	O
##bol	O
##ites	O
and	O
L	B
-	I
D	I
##OP	I
##A	I
in	O
37	O
Finnish	O
AP	O
##EC	O
##ED	O
patients	O
and	O
to	O
co	O
##rrel	O
##ate	O
their	O
abundance	O
with	O
the	O
presence	O
of	O
T	O
##P	O
##H	O
and	O
AA	O
##DC	O
A	O
##ab	O
##s	O
,	O
G	O
##I	O
d	O
##ys	O
##function	O
and	O
de	O
##pressive	O
symptoms	O
.	O

There	O
are	O
no	O
data	O
on	O
activation	O
of	O
E	O
##ET	O
synthesis	O
by	O
est	B
##rogen	I
;	O
however	O
,	O
di	B
##hy	I
##dr	I
##otes	I
##tos	I
##tero	I
##ne	I
was	O
previously	O
shown	O
to	O
decrease	O
E	O
##ET	O
levels	O
,	O
providing	O
a	O
possible	O
reason	O
why	O
young	O
women	O
had	O
higher	O
u	O
##rina	O
##ry	O
concentrations	O
of	O
E	O
##ET	O
##s	O
.	O

Xu	O
et	O
al	O
.	O
described	O
a	O
method	O
for	O
s	O
##tero	O
##id	O
hormones	O
q	O
##uant	O
##ification	O
in	O
human	O
urine	O
by	O
chemical	O
label	O
##ing	O
with	O
4	B
-	I
(	I
dim	I
##eth	I
##yla	I
##min	I
##o	I
)	I
-	I
ben	I
##zoic	I
acid	I
(	O
D	O
##MB	O
##A	O
)	O
and	O
d	O
_	O
4	O
-	O
D	O
##MB	O
##A	O
.	O

Inc	O
##reased	O
g	B
##lut	I
##amine	I
levels	O
were	O
also	O
observed	O
in	O
early	O
stage	O
CR	O
##C	O
urine	O
samples	O
,	O
suggesting	O
augmented	O
g	O
##lut	O
##ami	O
##nal	O
##ys	O
##is	O
.	O

In	O
the	O
DC	O
##CT	O
,	O
ME	O
##SA	O
,	O
CH	O
##S	O
,	O
and	O
SK	O
##S	O
,	O
serum	O
c	B
##rea	I
##tin	I
##ine	I
concentrations	O
were	O
measured	O
using	O
methods	O
trace	O
##able	O
to	O
is	O
##oto	O
##pe	O
di	O
##lution	O
mass	O
s	O
##pect	O
##rome	O
##try	O
.	O

Using	O
corrected	O
B	O
##MI	O
,	O
the	O
percentage	O
of	O
the	O
B	O
##MI	O
effect	O
mediated	O
by	O
un	O
##con	O
##ju	O
##gated	O
est	B
##rad	I
##iol	I
was	O
19	O
for	O
the	O
A	O
##ale	O
##n	O
model	O
and	O
17	O
for	O
the	O
Cox	O
model	O
.	O

a	B
##P	I
<	O
0	O
.	O
05	O
vs	O
control	O
,	O
b	O
##P	O
<	O
0	O
.	O
01	O
vs	O
control	O
;	O
c	O
##P	O
<	O
0	O
.	O
05	O
vs	O
stage	O
I	O
,	O
d	O
##P	O
<	O
0	O
.	O
01	O
vs	O
stage	O
I	O
;	O
e	O
##P	O
<	O
0	O
.	O
01	O
vs	O
stage	O
II	O
;	O
f	O
##P	O
<	O
0	O
.	O
05	O
vs	O
stage	O
III	O
;	O
g	B
##P	I
<	O
0	O
.	O
01	O
vs	O
stage	O
III	O
.	O

With	O
regard	O
to	O
this	O
and	O
the	O
fact	O
that	O
we	O
could	O
observe	O
a	O
slight	O
,	O
but	O
not	O
significant	O
increase	O
of	O
u	O
##rina	O
##ry	O
beta	B
##ine	I
levels	O
in	O
the	O
C	O
##G	O
(	O
see	O
a	O
)	O
,	O
it	O
can	O
be	O
speculated	O
that	O
the	O
C	O
##G	O
,	O
which	O
had	O
to	O
refrain	O
from	O
their	O
usual	O
daily	O
training	O
during	O
the	O
study	O
period	O
,	O
demonstrated	O
a	O
minor	O
use	O
of	O
beta	B
##ine	I
for	O
exercise	O
-	O
related	O
physiological	O
processes	O
,	O
thus	O
leading	O
to	O
a	O
higher	O
u	O
##rina	O
##ry	O
beta	B
##ine	I
ex	O
##cre	O
##tion	O
in	O
the	O
inactive	O
state	O
.	O

Depression	O
,	O
other	O
cognitive	O
issues	O
or	O
index	O
##es	O
for	O
disease	O
activity	O
did	O
not	O
show	O
any	O
correlation	O
to	O
q	B
##uin	I
##olin	I
##ic	I
acid	I
,	O
k	B
##yn	I
##uren	I
##ine	I
,	O
try	B
##pt	I
##op	I
##han	I
or	O
k	B
##yn	I
##uren	I
##ine	I
/	I
try	I
##pt	I
##op	I
##han	I
ratio	O
;	O
however	O
,	O
a	O
weak	O
correlation	O
to	O
fatigue	O
was	O
observed	O
.	O

As	O
shown	O
in	O
,	O
53	O
meta	O
##bol	O
##ites	O
,	O
including	O
amino	O
acids	O
,	O
car	O
##bo	O
##hy	O
##dra	O
##tes	O
,	O
lip	O
##ids	O
,	O
organic	O
acids	O
and	O
u	B
##rea	I
,	O
were	O
identified	O
by	O
a	O
N	O
##IS	O
##T	O
search	O
.	O

(	O
A	O
)	O
Q	O
##uant	O
##ification	O
result	O
from	O
R	O
##T	O
-	O
PC	O
##R	O
analysis	O
to	O
measure	O
the	O
gene	O
expression	O
levels	O
of	O
six	O
candidate	O
genes	O
(	O
AR	O
##ID	O
##1	O
##A	O
,	O
HD	O
##AC	O
##4	O
,	O
P	O
##K	O
##D	O
##1	O
,	O
β	B
-	I
CA	I
##TE	I
##NI	I
##N	I
,	O
SM	O
##AR	O
##CA	O
##2	O
,	O
and	O
P	O
##BR	O
##M	O
##1	O
)	O
in	O
the	O
presence	O
or	O
absence	O
of	O
α	B
-	I
O	I
##G	I
.	O

Re	O
##ceive	O
##r	O
-	O
operator	O
characteristic	O
(	O
R	O
##OC	O
)	O
curve	O
analysis	O
was	O
applied	O
for	O
certain	O
s	B
##phi	I
##ngo	I
##lip	I
##id	I
meta	O
##bol	O
##ites	O
in	O
order	O
to	O
determine	O
the	O
predict	O
##ive	O
ability	O
for	O
patients	O
at	O
higher	O
risk	O
of	O
C	O
##VD	O
.	O

In	O
the	O
case	O
of	O
GA	B
##BA	I
,	O
a	O
decrease	O
in	O
the	O
gradient	O
slope	O
was	O
necessary	O
to	O
separate	O
it	O
from	O
the	O
is	O
##omer	O
##ic	O
amino	O
acids	O
,	O
such	O
as	O
α	B
-	I
amino	I
##but	I
##yric	I
acid	I
,	O
α	B
-	I
amino	I
##is	I
##ob	I
##ut	I
##yric	I
acid	I
,	O
and	O
β	B
-	I
amino	I
##but	I
##yric	I
acid	I
,	O
which	O
are	O
present	O
in	O
biological	O
fluids	O
.	O

As	O
anticipated	O
,	O
the	O
presence	O
of	O
double	O
bond	O
(	O
s	O
)	O
disrupt	O
##s	O
the	O
continuity	O
of	O
ions	O
corresponding	O
to	O
the	O
successive	O
c	O
##lea	O
##vage	O
##s	O
of	O
met	B
##hyl	I
##ene	I
groups	O
.	O

The	O
reaction	O
products	O
were	O
extracted	O
with	O
et	B
##hyl	I
ace	I
##tate	I
,	O
which	O
was	O
dried	O
using	O
an	B
##hy	I
##dr	I
##ous	I
sodium	I
su	I
##lf	I
##ate	I
and	O
then	O
e	O
##va	O
##porated	O
with	O
a	O
stream	O
of	O
N	O
_	O
2	O
.	O

With	O
an	O
exception	O
of	O
p	B
##yr	I
##u	I
##vate	I
,	O
k	O
##IB	O
##S	O
samples	O
contained	O
higher	O
levels	O
of	O
these	O
meta	O
##bol	O
##ites	O
.	O

The	O
results	O
from	O
the	O
meta	O
-	O
analysis	O
co	O
##rro	O
##bor	O
##ated	O
our	O
findings	O
on	O
the	O
pool	O
##ed	O
data	O
,	O
with	O
lower	O
g	B
##lut	I
##amine	I
levels	O
seen	O
for	O
all	O
co	O
##hor	O
##ts	O
(	O
un	O
##ad	O
##ju	O
##sted	O
P	O
value	O
of	O
0	O
.	O
00	O
##40	O
)	O
,	O
but	O
most	O
prominently	O
in	O
H	O
##UN	O
##T	O
##3	O
,	O
and	O
lower	O
his	B
##ti	I
##dine	I
levels	O
mostly	O
in	O
H	O
##UN	O
##T	O
##3	O
and	O
E	O
##GC	O
##UT	O
(	O
un	O
##ad	O
##ju	O
##sted	O
P	O
value	O
of	O
0	O
.	O
00	O
##22	O
)	O
(	O
,	O
with	O
similar	O
trends	O
in	O
other	O
co	O
##hor	O
##ts	O
and	O
evidence	O
for	O
significant	O
he	O
##tero	O
##gene	O
##ity	O
between	O
co	O
##hor	O
##ts	O
)	O
.	O

The	O
loading	O
##s	O
plot	O
displays	O
the	O
22	O
o	B
##xy	I
##lip	I
##ins	I
that	O
contributed	O
significantly	O
to	O
discrimination	O
between	O
the	O
groups	O
(	O
VIP	O
>	O
1	O
)	O
.	O

Eleven	O
p	B
##ht	I
##hala	I
##te	I
meta	O
##bol	O
##ites	O
were	O
detected	O
.	O

Analysis	O
of	O
only	O
the	O
samples	O
collected	O
in	O
PBS	O
,	O
un	O
##af	O
##fected	O
by	O
any	O
external	O
glucose	S
(	O
Fi	O
##g	O
.	O

Am	B
##mon	I
##ium	I
ace	I
##tate	I
(	O
NH	O
_	O
4	O
O	O
##A	O
##c	O
)	O
and	O
am	B
##mon	I
##ium	I
h	I
##ydro	I
##xi	I
##de	I
(	O
NH	O
_	O
4	O
OH	O
)	O
solution	O
were	O
purchased	O
from	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
(	O
St	O
.	O
Louis	O
,	O
M	O
##O	O
,	O
USA	O
)	O
.	O

Following	O
application	O
of	O
the	O
samples	O
,	O
the	O
plate	O
was	O
washed	O
with	O
additional	O
volumes	O
of	O
phosphate	S
buffer	O
and	O
he	B
##xa	I
##nes	I
,	O
3	O
m	O
##L	O
each	O
,	O
before	O
el	O
##ution	O
with	O
1	O
m	O
##L	O
et	B
##hyl	I
ace	I
##tate	I
into	O
a	O
T	O
##ru	O
-	O
Ta	O
##per	O
96	O
-	O
well	O
plate	O
(	O
Ana	O
##ly	O
##tical	O
Sales	O
and	O
Services	O
,	O
Cat	O
.	O

Co	O
##mp	O
##aring	O
the	O
LP	O
##IR	O
T	O
##2	O
##D	O
risk	O
with	O
other	O
traditional	O
predict	O
##ors	O
in	O
a	O
mutually	O
adjusted	O
model	O
(	O
model	O
4	O
)	O
,	O
LP	O
##IR	O
out	O
##rank	O
##ed	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
,	O
B	O
##MI	O
,	O
h	O
##s	O
-	O
CR	O
##P	O
,	O
and	O
had	O
at	O
least	O
similar	O
magnitude	O
to	O
lower	O
HD	B
##L	I
ch	I
##ole	I
##ster	I
##ol	I
,	O
1	O
.	O
35	O
per	O
SD	O
(	O
95	O
%	O
C	O
##I	O
:	O
(	O
1	O
.	O
26	O
,	O
1	O
.	O
45	O
)	O
)	O
.	O

Even	O
though	O
there	O
are	O
lip	O
##id	O
-	O
based	O
bio	O
##mark	O
##ers	O
used	O
clinical	O
##ly	O
that	O
are	O
affected	O
by	O
diet	O
##ary	O
intake	O
(	O
e	O
.	O
g	O
.	O
,	O
ch	B
##ole	I
##ster	I
##ol	I
and	O
T	B
##G	I
for	O
card	O
##iovascular	O
disease	O
)	O
,	O
the	O
effect	O
of	O
diet	O
##ary	O
intake	O
on	O
the	O
plasma	O
and	O
urine	O
lip	O
##ido	O
##me	O
need	O
to	O
be	O
considered	O
as	O
a	O
critical	O
factor	O
for	O
discovering	O
novel	O
lip	O
##id	O
-	O
based	O
bio	O
##mark	O
##ers	O
.	O

A	O
similar	O
pattern	O
was	O
expected	O
for	O
the	O
re	O
##nal	O
g	O
##ly	O
##cine	O
h	O
##ydro	O
##xy	O
##met	O
##hyl	O
##tra	O
##ns	O
##fer	O
##ase	O
(	O
EC	O
##2	O
.	O
1	O
.	O
2	O
.	O
1	O
)	O
,	O
which	O
converts	O
g	B
##ly	I
##cine	I
to	O
se	B
##rine	I
;	O
however	O
,	O
variations	O
in	O
Ser	O
/	O
G	O
##ly	O
were	O
less	O
clear	O
cut	O
,	O
and	O
changes	O
in	O
plasma	O
se	B
##rine	I
were	O
only	O
o	O
##bs	O
##er	O
##vable	O
in	O
HD	O
patients	O
.	O

On	O
##going	O
plate	O
##let	O
metabolism	O
during	O
sample	O
processing	O
may	O
explain	O
lower	O
levels	O
of	O
c	B
##it	I
##rate	I
and	O
p	B
##yr	I
##u	I
##vate	I
,	O
whereas	O
positive	O
correlation	O
##s	O
with	O
g	B
##lut	I
##ama	I
##te	I
and	O
other	O
amino	O
acids	O
may	O
be	O
explained	O
by	O
plate	O
##let	O
transport	O
of	O
these	O
molecules	O
.	O

In	O
those	O
meta	O
##bol	O
##ites	O
,	O
only	O
s	B
##te	I
##ari	I
##c	I
acid	I
is	O
significantly	O
increased	O
in	O
B	O
##D	O
##TT	O
group	O
compared	O
with	O
other	O
groups	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
AD	B
##MA	I
between	O
groups	O
.	O

The	O
concentration	O
of	O
al	B
##ani	I
##ne	I
in	O
post	O
##par	O
##tum	O
depressed	O
patients	O
was	O
significantly	O
higher	O
than	O
that	O
in	O
controls	O
in	O
this	O
study	O
,	O
which	O
was	O
consistent	O
with	O
that	O
found	O
in	O
other	O
depressed	O
patients	O
.	O

Low	O
-	O
polar	O
##ity	O
solvent	O
##s	O
,	O
i	O
.	O
e	O
.	O
diet	B
##hyl	I
et	I
##her	I
and	O
he	B
##xa	I
##ne	I
in	O
protocols	O
(	O
v	O
)	O
and	O
(	O
v	O
##i	O
)	O
,	O
respectively	O
,	O
could	O
not	O
extract	O
PC	O
and	O
SM	O
,	O
which	O
contain	O
a	O
h	B
##ydro	I
##phi	I
##lic	I
ch	I
##olin	I
##e	I
head	O
group	O
.	O

The	O
most	O
commonly	O
identified	O
bucket	O
##s	O
(	O
present	O
in	O
at	O
least	O
50	O
%	O
of	O
the	O
models	O
)	O
were	O
1	O
.	O
28	O
(	B
3	B
-	I
h	I
##ydro	I
##xy	I
##is	I
##ova	I
##ler	I
##ate	I
)	O
;	O
2	O
.	O
48	O
(	B
car	B
##ni	I
##tine	I
)	O
;	O
2	O
.	O
56	O
,	O
2	O
.	O
68	O
and	O
2	O
.	O
72	O
(	O
c	O
##it	O
##rate	O
)	O
;	O
3	O
.	O
16	O
(	B
dim	B
##eth	I
##yl	I
##sul	I
##fo	I
##ne	I
)	O
;	O
3	O
.	O
56	O
(	B
g	B
##ly	I
##cine	I
)	O
;	O
3	O
.	O
96	O
(	O
c	O
##rea	O
##tin	O
##ine	O
)	O
;	O
4	O
.	O
44	O
(	B
t	B
##rig	I
##one	I
##llin	I
##e	I
)	O
,	O
and	O
4	O
.	O
48	O
(	B
N	B
-	I
met	I
##hyl	I
ni	I
##cot	I
##ina	I
##mi	I
##de	I
)	O
.	O

De	O
##uter	O
##ium	O
oxide	O
(	O
D	O
_	O
2	O
O	O
)	O
,	O
p	B
##yr	I
##id	I
##ine	I
,	O
met	B
##ho	I
##xy	I
##amine	I
.	O

However	O
,	O
there	O
was	O
no	O
significant	O
difference	O
in	O
k	O
##yn	O
##uren	O
##ine	O
/	O
try	O
##pt	O
##op	O
##han	O
ratio	O
comparing	O
patients	O
with	O
g	B
##lu	I
##co	I
##cor	I
##tic	I
##oid	I
treatment	O
and	O
un	O
##tre	O
##ated	O
patients	O
.	O

As	O
a	O
result	O
,	O
im	O
##bal	O
##ance	O
of	O
g	B
##ly	I
##cine	I
related	O
to	O
DNA	O
damage	O
and	O
repairs	O
was	O
found	O
.	O

AFB	B
-	I
di	I
##bro	I
##mo	I
(	O
in	O
v	O
##it	O
##ro	O
)	O
or	O
AFB	B
-	I
e	I
##pox	I
##ide	I
(	O
in	O
v	O
##ivo	O
)	O
react	O
first	O
with	O
water	O
to	O
yield	O
the	O
same	O
intermediate	O
,	O
the	O
AFB	O
-	O
di	O
##ol	O
.	O

The	O
relative	O
m	O
##RNA	O
level	O
of	O
major	O
genes	O
in	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
synthesis	O
and	O
metabolism	O
in	O
He	O
##p	O
##G	O
##2	O
and	O
He	O
##p	O
##G	O
##2	O
.	O
2	O
.	O
15	O
cells	O
,	O
n	O
=	O
3	O
,	O
detailed	O
data	O
are	O
shown	O
in	O
Table	O
_	O
S	O
##4	O
.	O

We	O
observed	O
no	O
overall	O
associations	O
between	O
serum	O
meta	O
##bol	O
##ites	O
and	O
color	O
##ec	O
##tal	O
cancer	O
,	O
but	O
serum	O
g	B
##ly	I
##co	I
##chen	I
##ode	I
##ox	I
##ych	I
##olate	I
,	O
a	O
bi	O
##le	O
acid	O
meta	O
##bol	O
##ite	O
,	O
was	O
positively	O
associated	O
with	O
color	O
##ec	O
##tal	O
cancer	O
among	O
women	O
.	O

Moreover	O
,	O
c	B
##rea	I
##tine	I
is	O
a	O
bio	O
##mark	O
##er	O
of	O
cache	O
##xia	O
and	O
sa	O
##rc	O
##ope	O
##nia	O
related	O
to	O
the	O
ma	O
##li	O
##gna	O
##ncy	O
condition	O
.	O

Another	O
meta	O
##bol	O
##ite	O
that	O
plays	O
an	O
important	O
,	O
multi	O
##di	O
##men	O
##sional	O
metabolic	O
role	O
is	O
c	B
##it	I
##rate	I
and	O
the	O
flu	O
##ct	O
##uations	O
in	O
the	O
c	B
##it	I
##rate	I
levels	O
are	O
often	O
considered	O
as	O
a	O
useful	O
diagnostic	O
tool	O
or	O
bio	O
##mark	O
##er	O
.	O

Op	O
##iate	O
##s	O
,	O
op	O
##io	O
##ids	O
,	O
pain	O
medication	O
monitoring	O
,	O
im	O
##mu	O
##no	O
##ass	O
##ay	O
,	O
m	B
##or	I
##phine	I
,	O
code	B
##ine	I
,	O
semi	O
-	O
synthetic	O
op	O
##iate	O
##s	O
,	O
L	O
##CM	O
##SM	O
##S	O
,	O
urine	O
drug	O
screen	O

Males	O
had	O
higher	O
ICC	O
values	O
than	O
females	O
for	O
both	O
8	B
-	I
is	I
##o	I
-	I
P	I
##G	I
##F	I
_	I
2	I
##α	I
(	I
0	I
.	I
56	I
,	I
95	I
%	I
C	I
##I	I
[	I
0	I
.	I
48	I
,	I
0	I
.	I
64	I
]	I
for	I
males	I
vs	I
.	I
0	I
.	I
46	I
[	I
0	I
.	I
37	I
,	I
0	I
.	I
56	I
]	I
for	I
females	I
)	I
and	O
P	O
##GE	O
-	O
M	O
(	O
0	O
.	O
43	O
[	O
0	O
.	O
34	O
,	O
0	O
.	O
51	O
]	O
for	O
males	O
vs	O
0	O
.	O
26	O
[	O
0	O
.	O
18	O
,	O
0	O
.	O
37	O
]	O
for	O
females	O
)	O
.	O

The	O
body	O
produces	O
la	B
##ct	I
##ate	I
in	O
throughout	O
the	O
day	O
.	O

Depending	O
on	O
the	O
availability	O
of	O
oxygen	O
,	O
p	B
##yr	I
##u	I
##vate	I
can	O
be	O
further	O
de	O
##graded	O
to	O
ace	B
##ty	I
##l	I
-	I
Co	I
##A	I
which	O
enters	O
the	O
T	O
##CA	O
cycle	O
or	O
to	O
la	B
##ct	I
##ate	I
in	O
animals	O
and	O
ethanol	S
in	O
plants	O
and	O
micro	O
##or	O
##gan	O
##isms	O
.	O

B	O
##ile	O
acids	O
are	O
bio	O
##sy	O
##nt	O
##hes	O
##ized	O
extra	O
##he	O
##pa	O
##tically	O
via	O
the	O
acidic	O
pathway	O
starting	O
with	O
27	B
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
and	O
also	O
via	O
the	O
24	O
(	O
S	O
)	O

However	O
,	O
complete	O
structural	O
characterization	O
of	O
complex	O
lip	O
##ids	O
,	O
such	O
as	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
,	O
by	O
tandem	O
mass	O
s	O
##pect	O
##rome	O
##try	O
(	O
MS	O
/	O
MS	O
)	O
is	O
still	O
a	O
major	O
challenge	O
.	O

Between	O
analyses	O
,	O
columns	O
were	O
washed	O
with	O
1	O
:	O
1	O
CO	O
_	O
2	O
:	B
met	I
##han	I
##ol	I
at	O
1	O
m	O
##L	O
/	O
min	O
for	O
50	O
min	O
,	O
then	O
stored	O
in	O
100	O
%	O
CO	O
_	O
2	O
.	O

S	B
##phi	I
##ngo	I
##lip	I
##id	I
and	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
metabolism	O
##s	O
,	O
and	O
GP	O
##I	O
-	O
anchor	O
bio	O
##sy	O
##nt	O
##hesis	O
(	O
A	O
)	O
.	O

In	O
our	O
study	O
,	O
decreased	O
levels	O
of	O
try	B
##pt	I
##op	I
##han	I
were	O
found	O
only	O
in	O
adult	O
MD	O
##D	O
but	O
not	O
in	O
children	O
and	O
adolescent	O
##s	O
MD	O
##D	O
.	O

Lu	O
##ng	O
cancer	O
,	O
Lu	O
##ng	O
inflammation	O
,	O
_	O
1	O
H	O
-	O
N	O
##MR	O
,	O
Met	O
##ab	O
##olic	O
p	O
##hen	O
##otype	O
,	O
G	B
##lut	I
##ama	I
##te	I
,	O
R	O
##OC	O

In	O
the	O
context	O
of	O
I	O
##B	O
##D	O
,	O
CA	O
##D	O
,	O
an	O
enzyme	O
required	O
for	O
de	O
no	O
##vo	O
p	B
##yr	I
##im	I
##id	I
##ine	I
n	O
##uc	O
##leo	O
##tide	O
synthesis	O
;	O
was	O
identified	O
as	O
a	O
NO	O
##D	O
##2	O
-	O
interacting	O
protein	O
expressed	O
at	O
increased	O
levels	O
in	O
the	O
co	O
##lon	O
e	O
##pit	O
##hel	O
##ium	O
of	O
patients	O
with	O
CD	O
compared	O
with	O
controls	O
.	O

The	O
sample	O
(	O
1	O
m	O
##L	O
)	O
was	O
neutral	O
##ized	O
to	O
pH	O
7	O
with	O
NH	O
_	O
4	O
OH	O
and	O
loaded	O
onto	O
an	O
O	O
##asis	O
MA	O
##X	O
cartridge	O
(	O
1	O
m	O
##L	O
,	O
30	O
mg	O
,	O
Waters	O
)	O
previously	O
e	O
##qui	O
##li	O
##bra	O
##ted	O
using	O
1	O
m	O
##L	O
Me	B
##OH	I
,	O
and	O
1	O
m	O
##L	O
2	O
%	O
a	O
##que	O
##ous	O
NH	O
_	O
4	O
OH	O
.	O

Of	O
these	O
FA	S
,	O
l	B
##ino	I
##le	I
##ic	I
acid	I
(	O
18	O
:	O
2	O
)	O
is	O
an	O
essential	O
FA	S
and	O
reflects	O
variable	O
diet	O
.	O

Several	O
bi	O
##le	O
acids	O
were	O
correlated	O
with	O
si	B
##m	I
##vas	I
##tat	I
##in	I
acid	I
concentrations	O
in	O
the	O
good	O
and	O
the	O
poor	O
respond	O
##ers	O
,	O
with	O
border	O
##line	O
significant	O
q	O
-	O
values	O
.	O

Nevertheless	O
,	O
we	O
investigated	O
the	O
scale	O
of	O
restriction	O
due	O
to	O
using	O
only	O
meta	O
##bol	O
##ites	O
that	O
co	O
##rrel	O
##ate	O
with	O
Δ	B
##g	I
##lu	I
##cos	I
##e	I
.	O

Subsequently	O
,	O
180	O
µ	O
##L	O
of	O
trim	O
##eth	O
##yl	O
##si	O
##ly	O
##lating	O
agent	O
,	O
N	B
-	I
met	I
##hyl	I
-	I
N	I
-	I
trim	I
##eth	I
##yl	I
##si	I
##ly	I
##lt	I
##ri	I
##f	I
##lu	I
##oro	I
##ace	I
##tam	I
##ide	I
(	O
MS	O
##TF	O
##A	O
)	O
,	O
was	O
added	O
,	O
and	O
samples	O
were	O
agitated	O
at	O
37	O
°C	O
for	O
30	O
min	O
.	O

Although	O
the	O
quantitative	O
level	O
of	O
p	B
##oly	I
##amine	I
##s	I
is	O
associated	O
with	O
regulation	O
of	O
tumor	O
growth	O
and	O
with	O
period	O
##ont	O
##itis	O
,	O
our	O
results	O
indicate	O
that	O
sa	O
##liva	O
##ry	O
p	B
##oly	I
##amine	I
##s	I
are	O
affected	O
by	O
the	O
cancer	O
type	O
and	O
by	O
period	O
##ont	O
##itis	O
,	O
and	O
that	O
their	O
levels	O
were	O
marked	O
##ly	O
higher	O
in	O
patients	O
with	O
oral	O
cancer	O
.	O

Level	O
##s	O
of	O
2	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
,	O
ace	B
##tone	I
,	O
format	B
##e	I
,	O
and	O
p	B
##yr	I
##og	I
##lut	I
##ama	I
##te	I
were	O
higher	O
and	O
levels	O
of	O
ace	B
##tate	I
and	O
glucose	S
were	O
lower	O
in	O
both	O
MS	O
and	O
N	O
##MO	O
##SD	O
.	O

They	O
could	O
separate	O
PC	O
##a	O
from	O
BP	O
##H	O
patients	O
with	O
good	O
sensitivity	O
(	O
81	O
.	O
5	O
%	O
)	O
and	O
specific	O
##ity	O
(	O
75	O
.	O
2	O
%	O
)	O
,	O
demonstrating	O
that	O
fatty	O
acids	O
(	B
a	B
##cy	I
##l	I
car	I
##ni	I
##tine	I
##s	I
)	O
,	O
ch	B
##olin	I
##e	I
(	I
g	I
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
)	I
,	O
and	O
amino	O
acids	O
(	B
a	B
##rg	I
##ini	I
##ne	I
)	O
can	O
be	O
used	O
as	O
metabolic	O
markers	O
for	O
the	O
diagnostic	O
differentiation	O
between	O
PC	O
##a	O
and	O
BP	O
##H	O
.	O

In	O
particular	O
,	O
C	O
##16	O
##C	O
##er	O
levels	O
,	O
which	O
is	O
located	O
at	O
the	O
junction	O
of	O
the	O
metabolic	O
pathways	O
involved	O
in	O
s	B
##phi	I
##ngo	I
##lip	I
##id	I
metabolism	O
,	O
significantly	O
increased	O
in	O
the	O
second	O
and	O
in	O
the	O
third	O
trim	O
##ester	O
##s	O
of	O
pregnancy	O
,	O
compared	O
with	O
the	O
first	O
trim	O
##ester	O
.	O

_	O
13	O
C	O
en	O
##rich	O
##ment	O
in	O
la	B
##ct	I
##ate	I
and	O
Al	O
##a	O
was	O
determined	O
from	O
1	O
##D	O
_	O
1	O
H	O
N	O
##MR	O
experiments	O
,	O
as	O
the	O
met	O
##hyl	O
resonance	O
##s	O
of	O
these	O
meta	O
##bol	O
##ites	O
were	O
well	O
resolved	O
.	O

In	O
this	O
study	O
,	O
detection	O
of	O
re	B
##tino	I
##l	I
was	O
significantly	O
less	O
in	O
current	O
-	O
smoke	O
##r	O
patients	O
as	O
compared	O
to	O
non	O
-	O
smoke	O
##r	O
control	O
(	O
as	O
shown	O
in	O
Additional	O
file	O
9	O
)	O
.	O

For	O
R	B
##RL	I
##C	I
-	I
(	I
+	I
)	I
E	I
##SI	I
-	I
MS	I
data	O
,	O
the	O
classification	O
of	O
E	O
##SC	O
##C	O
and	O
NC	O
groups	O
resulted	O
in	O
one	O
predict	O
##ive	O
(	O
t	O
_	O
p	O
)	O
and	O
two	O
or	O
##th	O
##ogo	O
##nal	O
(	O
t	O
_	O
o	O
)	O
(	O
1	O
+	O
2	O
)	O
components	O
with	O
a	O
cross	O
-	O
valid	O
##ated	O
predict	O
##ive	O
ability	O
,	O
(	O
cum	O
)	O
,	O
of	O
54	O
.	O
7	O
%	O
.	O

an	B
##ast	I
##ro	I
##zo	I
##le	I
,	O
breast	O
cancer	O
,	O
g	O
##lu	O
##cu	O
##ron	O
##ida	O
##tion	O
,	O
h	O
##ydro	O
##xy	O
##lation	O
,	O
in	O
v	O
##it	O
##ro	O
,	O
in	O
v	O
##ivo	O

The	O
reaction	O
of	O
cat	B
##ech	I
##ol	I
est	I
##rogen	I
q	I
##uin	I
##ones	I
with	O
DNA	O
to	O
form	O
de	O
##pur	O
##inating	O
est	O
##rogen	O
-	O
DNA	O
add	O
##uc	O
##ts	O
is	O
h	O
##y	O
##pot	O
##hes	O
##ized	O
to	O
initiate	O
this	O
process	O
.	O

≥	O
90	O
mm	O
H	O
##g	O
or	O
re	O
##ceipt	O
of	O
anti	O
##hy	O
##pert	O
##ens	O
##ive	O
drugs	O
]	O
,	O
type	O
2	O
diabetes	O
[	O
American	O
Di	O
##abe	O
##tes	O
Association	O
criteria	O
_	O
,	O
]	O
and	O
metabolic	O
syndrome	O
defined	O
as	O
:	O
presence	O
of	O
central	O
o	O
##besity	O
combined	O
with	O
any	O
two	O
of	O
the	O
following	O
:	O
raised	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
,	O
low	O
HD	O
##L	O
-	O
C	O
,	O
high	O
blood	O
pressure	O
and	O
raised	O
fast	O
##ing	O
plasma	O
glucose	S
(	O
≥	O
5	O
.	O
6	O
mm	O
##ol	O
/	O
l	O
)	O
,	O
previously	O
diagnosed	O
type	O
2	O
diabetes	O
or	O
receiving	O
anti	O
-	O
di	O
##abe	O
##tic	O
medication	O
[	O
International	O
Di	O
##abe	O
##tes	O
Federation	O
definition	O
]	O
.	O

Early	O
stage	O
samples	O
have	O
significantly	O
higher	O
concentrations	O
of	O
3	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
,	O
ace	B
##to	I
##ace	I
##tate	I
and	O
ace	B
##tone	I
.	O

C	B
##rea	I
##tine	I
is	O
normally	O
involved	O
in	O
the	O
energy	O
supply	O
of	O
ma	O
##mmal	O
##ian	O
cells	O
.	O

Points	O
shown	O
are	O
the	O
means	O
of	O
six	O
determination	O
##s	O
for	O
AT	O
##RA	O
alone	O
or	O
three	O
determination	O
##s	O
for	O
each	O
of	O
the	O
curves	O
with	O
C	O
##13	O
k	B
##eton	I
##e	I
.	O

The	O
following	O
standards	O
were	O
used	O
:	O
Cho	O
chloride	B
-	I
trim	I
##eth	I
##yl	I
-	I
d	I
##9	I
(	O
Cho	O
-	O
d	O
##9	O
,	O
Cambridge	O
Is	O
##oto	O
##pe	O
Laboratories	O
DL	O
##M	O
54	O
##9	O
-	O
1	O
,	O
Te	O
##w	O
##ks	O
##bury	O
,	O
MA	O
)	O
,	O
Bet	O
(	O
Bet	O
-	O
d	O
##11	O
Cambridge	O
Is	O
##oto	O
##pe	O
Laboratories	O
DL	O
##M	O
40	O
##7	O
,	O
Te	O
##w	O
##ks	O
##bury	O
,	O
MA	O
)	O
,	O
PC	O
##ho	O
chloride	S
(	O
PC	O
##ho	O
-	O
d	O
##9	O
,	O
Cambridge	O
Is	O
##oto	O
##pe	O
Laboratories	O
,	O
DL	O
##M	O
-	O
29	O
##8	O
,	O
Te	O
##w	O
##ks	O
##bury	O
,	O
MA	O
)	O
PC	O
-	O
d	O
##9	O
(	O
Ava	O
##nti	O
polar	O
lip	O
##ids	O
,	O
86	O
##0	O
##36	O
##2	O
,	O
Al	O
##aba	O
##ster	O
,	O
AL	O
)	O
,	O
SM	O
-	O
d	O
##13	O
-	O
c	O
##13	O
(	O
Rice	O
##rca	O
-	O
custom	O
made	O
,	O
Pain	O
##es	O
##ville	O
,	O
OH	O
)	O
AC	O
##ho	O
-	O
d	O
##13	O
(	O
C	O
/	O
D	O
/	O
N	O
Is	O
##oto	O
##pes	O
I	O
##C	O
##N	O
D	O
-	O
1780	O
,	O
Quebec	O
,	O
C	O
##a	O
)	O
,	O
LP	O
##C	O
-	O
D	O
##3	O
(	O
La	O
##rod	O
##an	O
71	O
-	O
28	O
##26	O
,	O
Mal	O
##mo	O
,	O
Sweden	O
)	O
.	O

After	O
p	B
##io	I
##gli	I
##ta	I
##zone	I
therapy	O
,	O
F	O
##P	O
##G	O
,	O
FF	O
##A	O
and	O
insulin	O
concentration	O
,	O
H	O
##b	O
##A	O
_	O
1	O
##c	O
,	O
and	O
fast	O
##ing	O
plasma	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
decreased	O
significantly	O
,	O
whereas	O
HD	B
##L	I
ch	I
##ole	I
##ster	I
##ol	I
,	O
total	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
and	O
L	B
##D	I
##L	I
ch	I
##ole	I
##ster	I
##ol	I
did	O
not	O
change	O
significantly	O
after	O
p	B
##io	I
##gli	I
##ta	I
##zone	I
therapy	O
(	O
Table	O
1	O
)	O
.	O

However	O
,	O
long	O
term	O
exposure	O
to	O
ta	B
##mo	I
##xi	I
##fen	I
has	O
been	O
shown	O
to	O
induce	O
a	O
state	O
of	O
adaptive	O
h	O
##yper	O
##sen	O
##si	O
##ti	O
##vity	O
in	O
breast	O
tumors	O
to	O
E	O
##2	O
.	O

Bar	O
graphs	O
of	O
u	O
##rina	O
##ry	O
meta	O
##bol	O
##ite	O
levels	O
of	O
A	O
)	O
c	B
##rea	I
##tine	I
rib	I
##os	I
##ide	I
(	O
CR	O
)	O
,	O
B	O
)	O
N	B
-	I
ace	I
##ty	I
##ln	I
##eur	I
##ami	I
##nic	I
acid	I
(	O
N	O
##AN	O
##A	O
)	O
,	O
C	O
)	O
co	B
##rt	I
##is	I
##ol	I
su	I
##lf	I
##ate	I
(	O
CS	O
)	O
and	O
D	O
)	O
meta	O
##bol	O
##ite	O
56	O
##1	O
+	O
quantitative	O
##ly	O
measured	O
by	O
UP	O
##LC	O
-	O
MS	O
/	O
MS	O
in	O
In	O
##tra	O
##he	O
##pa	O
##tic	O
Cho	O
##lang	O
##io	O
##car	O
##cin	O
##oma	O
(	O
ICC	O
)	O
cases	O
in	O
comparison	O
to	O
un	O
##af	O
##fected	O
population	O
controls	O
and	O
high	O
-	O
risk	O
subjects	O
in	O
the	O
T	O
##IG	O
##ER	O
-	O
L	O
##C	O
co	O
##hor	O
##t	O
.	O

No	O
significant	O
interfering	O
peaks	O
were	O
found	O
for	O
any	O
of	O
the	O
anal	O
##yte	O
##s	O
except	O
1	B
##α	I
,	I
25	I
(	I
OH	I
)	I
D	I
_	I
3	I
.	O

Among	O
the	O
c	B
##era	I
##mi	I
##des	I
,	O
those	O
with	O
the	O
non	O
##cano	O
##nical	O
d	B
##16	I
:	I
1	I
backbone	O
had	O
more	O
strongly	O
positive	O
correlation	O
##s	O
relative	O
to	O
the	O
canonical	O
d	B
##18	I
:	I
1	I
c	I
##era	I
##mi	I
##des	I
,	O
while	O
the	O
d	B
##18	I
:	I
2	I
c	I
##era	I
##mi	I
##des	I
correlated	O
less	O
positively	O
or	O
,	O
in	O
some	O
cases	O
,	O
correlated	O
negatively	O
(	O
;	O
;	O
;	O
and	O
)	O
.	O

All	O
anal	O
##yte	O
standards	O
including	O
met	B
##hyl	I
##ar	I
##gin	I
##ines	I
(	O
listed	O
in	O
Su	O
##pp	O
##lement	O
##ary	O
Table	O
_	O
1	O
)	O
were	O
obtained	O
from	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
(	O
Gill	O
##ingham	O
,	O
U	O
.	O
K	O
.	O
)	O
.	O

Interest	O
##ingly	O
,	O
there	O
is	O
no	O
significant	O
difference	O
between	O
mean	O
co	B
##rt	I
##is	I
##ol	I
levels	O
in	O
the	O
light	O
dem	O
##ent	O
##ia	O
group	O
compared	O
to	O
the	O
more	O
severe	O
dem	O
##ented	O
patients	O
.	O

F	O
##G	O
##F	O
,	O
fi	O
##bro	O
##blast	O
growth	O
factor	O
;	O
PT	O
##H	O
,	O
para	O
##thy	O
##roid	O
hormone	O
;	O
24	B
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	I
_	I
3	I
,	I
24	I
,	I
25	I
-	I
di	I
##hy	I
##dr	I
##ox	I
##y	I
##vi	I
##tam	I
##in	I
D	I
_	I
3	I
;	I
25	I
(	I
OH	I
)	I
D	I
_	I
3	I
,	I
25	I
-	I
h	I
##ydro	I
##xy	I
##vi	I
##tam	I
##in	I
D	O
_	O
3	O

A	O
30	O
μ	O
##l	O
al	O
##iq	O
##uo	O
##t	O
of	O
serum	O
was	O
spike	O
##d	O
with	O
##an	O
internal	O
standard	O
(	O
1	O
.	O
5	O
μ	O
##l	O
of	O
50	O
μ	O
##M	O
met	B
##hyl	I
he	I
##pta	I
##de	I
##cano	I
##ate	I
for	O
positive	O
ion	O
E	O
##SI	O
-	O
MS	O
analysis	O
or	O
he	O
##pta	O
##de	O
##con	O
##oi	O
##c	O
acid	O
for	O
negative	O
ion	O
E	O
##SI	O
-	O
MS	O
analysis	O
)	O
,	O
and	O
added	O
with	O
190	O
μ	O
##l	O
of	O
Me	B
##OH	I
.	O

_	O
,	O
The	O
cat	O
##ab	O
##olis	O
##m	O
of	O
amino	O
acids	O
is	O
associated	O
with	O
conversion	O
of	O
their	O
amino	S
groups	O
to	O
am	O
##monia	O
,	O
which	O
is	O
used	O
for	O
the	O
synthesis	O
of	O
u	B
##rea	I
.	O

Growth	O
in	O
##hibition	O
was	O
assessed	O
after	O
48	O
h	O
using	O
an	O
ATP	S
bio	O
##lum	O
##ines	O
##cence	O
-	O
based	O
ass	O
##ay	O
.	O

Additionally	O
,	O
integrating	O
g	O
##eno	O
##mic	O
##s	O
and	O
meta	O
##bol	O
##omi	O
##cs	O
data	O
revealed	O
three	O
p	O
##oly	O
##mor	O
##phism	O
##s	O
(	O
r	O
##s	O
##27	O
##27	O
##5	O
##6	O
##3	O
PR	O
##KA	O
##G	O
##2	O
,	O
r	O
##s	O
##12	O
##60	O
##4	O
##9	O
##40	O
DC	O
##C	O
,	O
and	O
r	O
##s	O
##13	O
##26	O
##29	O
##30	O
EP	O
##H	O
##X	O
##2	O
)	O
along	O
with	O
a	B
##rac	I
##hi	I
##don	I
##ic	I
acid	I
,	O
con	O
##ver	O
##ging	O
in	O
the	O
net	O
##rin	O
signaling	O
pathway	O
(	O
p	O
=	O
1	O
##×	O
##10	O
_	O
−	O
##5	O
)	O
,	O
as	O
potential	O
markers	O
significantly	O
in	O
##f	O
##lue	O
##ncing	O
HC	O
##T	O
##Z	O
BP	O
response	O
.	O

Initial	O
sample	O
cluster	O
##ing	O
is	O
observed	O
due	O
to	O
the	O
difference	O
in	O
buffer	O
solutions	O
and	O
resulting	O
sample	O
glucose	S
content	O
(	O
principal	O
component	O
1	O
)	O
and	O
inter	O
##sa	O
##mple	O
differences	O
in	O
meta	O
##bol	O
##ite	O
(	O
c	O
##it	O
##rate	O
,	O
ch	B
##olin	I
##e	I
,	O
lip	O
##ids	O
/	O
lip	O
##op	O
##rote	O
##ins	O
and	O
p	B
##hos	I
##ph	I
##och	I
##olin	I
##e	I
)	O
variation	O
(	O
principal	O
component	O
2	O
)	O
.	O

In	O
subsequent	O
analyses	O
,	O
self	O
-	O
reported	O
anal	O
##ges	O
##ic	O
use	O
(	O
yes	O
/	O
no	O
)	O
from	O
the	O
IN	O
##TE	O
##R	O
##MA	O
##P	O
database	O
was	O
compared	O
with	O
the	O
presence	O
/	O
absence	O
of	O
u	O
##rina	O
##ry	O
_	O
1	O
H	O
N	O
##MR	O
-	O
detected	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
and	O
i	B
##bu	I
##p	I
##ro	I
##fen	I
for	O
participants	O
from	O
all	O
17	O
population	O
samples	O
.	O

We	O
believe	O
the	O
simplest	O
explanation	O
for	O
this	O
finding	O
is	O
that	O
an	O
increased	O
secret	O
##ion	O
of	O
his	B
##tamine	I
and	O
his	B
##ti	I
##dine	I
(	O
precursor	O
of	O
his	B
##tamine	I
)	O
may	O
be	O
associated	O
with	O
I	O
##C	O
symptoms	O
mediated	O
by	O
mast	O
cells	O
in	O
##fi	O
##lt	O
##rated	O
in	O
bladder	O
.	O

Ph	B
##os	I
##ph	I
##oli	I
##pid	I
classes	O
were	O
separated	O
by	O
normal	O
-	O
phase	O
HP	O
##LC	O
using	O
met	O
##han	O
##ol	O
-	O
ace	O
##ton	O
##it	O
##ril	O
-	O
water	O
gradient	O
mobile	O
phases	O
and	O
detected	O
by	O
tandem	O
mass	O
s	O
##pect	O
##rome	O
##try	O
with	O
E	O
##SI	O
.	O

For	O
instance	O
,	O
the	O
higher	O
sensitivity	O
of	O
the	O
CH	O
##C	O
##l	O
_	O
3	O
:	O
Me	O
##OH	O
extraction	O
is	O
noteworthy	O
in	O
anal	O
##yte	O
##s	O
,	O
such	O
as	O
N	O
##1	O
-	O
A	O
##c	O
##SP	O
##M	O
,	O
CA	O
##D	O
,	O
or	O
N	B
##1	I
,	I
N	I
##8	I
-	I
Di	I
##A	I
##c	I
##SP	I
##D	I
,	O
because	O
of	O
its	O
low	O
concentration	O
in	O
serum	O
samples	O
.	O

As	O
previously	O
discussed	O
,	O
some	O
authors	O
identified	O
higher	O
blood	O
levels	O
of	O
ace	B
##tate	I
in	O
both	O
patients	O
with	O
MS	O
and	O
patients	O
with	O
N	O
##MO	O
compared	O
with	O
HC	O
;	O
however	O
,	O
the	O
primary	O
meta	O
##bol	O
##ite	O
able	O
to	O
disc	O
##rim	O
##inate	O
patients	O
with	O
MS	O
vs	O
both	O
patients	O
with	O
N	O
##MO	O
and	O
HC	O
was	O
a	O
marker	O
of	O
g	O
##lial	O
proliferation	O
,	O
s	O
##cy	O
##llo	O
-	O
in	O
##os	O
##ito	O
##l	O
(	O
increased	O
2	O
.	O
4	O
-	O
and	O
2	O
.	O
6	O
-	O
fold	O
compared	O
with	O
patients	O
with	O
N	O
##MO	O
and	O
HC	O
,	O
respectively	O
)	O
.	O

This	O
simply	O
reinforce	O
##s	O
the	O
fact	O
that	O
urine	O
is	O
a	O
key	O
carrier	O
of	O
h	B
##ydro	I
##phi	I
##lic	I
waste	O
products	O
.	O

Cal	O
##ib	O
##rators	O
were	O
prepared	O
at	O
0	O
.	O
5	O
,	O
1	O
,	O
2	O
.	O
5	O
,	O
5	O
,	O
10	O
,	O
25	O
,	O
50	O
and	O
100	O
μ	O
##g	O
/	O
L	O
for	O
T	O
##HC	O
and	O
T	O
##HC	O
##CO	O
##OH	O
,	O
at	O
0	O
.	O
5	O
,	O
1	O
,	O
2	O
.	O
5	O
,	O
5	O
,	O
10	O
,	O
25	O
and	O
50	O
μ	O
##g	O
/	O
L	O
for	O
11	B
-	I
OH	I
-	I
T	I
##HC	I
,	O
CB	O
##D	O
,	O
CBN	O
,	O
T	O
##HC	O
##AA	O
and	O
T	O
##HC	O
-	O
g	O
##lu	O
##c	O
,	O
at	O
1	O
,	O
2	O
,	O
5	O
,	O
10	O
,	O
20	O
,	O
50	O
and	O
100	O
μ	O
##g	O
/	O
L	O
for	O
CB	O
##G	O
,	O
T	O
##HC	O
##V	O
and	O
T	O
##HC	O
##VC	O
##CO	O
##OH	O
and	O
at	O
5	O
,	O
10	O
,	O
25	O
,	O
50	O
,	O
100	O
,	O
250	O
and	O
500	O
μ	O
##g	O
/	O
L	O
for	O
T	O
##HC	O
##CO	O
##OH	O
-	O
g	O
##lu	O
##c	O
after	O
fort	O
##ifying	O
20	O
μ	O
##L	O
working	O
stock	O
solution	O
into	O
200	O
μ	O
##L	O
blank	O
human	O
urine	O
.	O

No	O
individual	O
est	B
##rogen	I
,	O
est	B
##rogen	I
meta	O
##bol	O
##ite	O
,	O
or	O
metabolic	O
pathway	O
group	O
remained	O
statistical	O
##ly	O
significantly	O
associated	O
with	O
the	O
risk	O
of	O
breast	O
cancer	O
after	O
adjusting	O
for	O
un	O
##con	O
##ju	O
##gated	O
est	B
##rad	I
##iol	I
;	O
the	O
hazard	O
ratio	O
associated	O
with	O
un	O
##con	O
##ju	O
##gated	O
est	B
##rad	I
##iol	I
was	O
also	O
at	O
##ten	O
##uated	O
in	O
many	O
of	O
these	O
same	O
models	O
.	O

Similarly	O
,	O
we	O
integrated	O
gene	O
expression	O
profiles	O
and	O
se	B
##rine	I
label	O
##ing	O
patterns	O
from	O
_	O
13	O
C	B
-	I
glucose	I
in	O
a	O
panel	O
of	O
human	O
N	O
##SC	O
##LC	O
cell	O
lines	O
to	O
identify	O
the	O
transcription	O
factor	O
N	O
##R	O
##F	O
##2	O
as	O
a	O
driver	O
of	O
se	B
##rine	I
bio	O
##sy	O
##nt	O
##hesis	O
in	O
N	O
##SC	O
##LC	O
.	O

Cal	O
##ib	O
##ration	O
standards	O
(	B
ca	B
##ffe	I
##ine	I
,	O
Ultra	O
##mark	O
162	O
##1	O
and	O
MR	O
##FA	O
)	O
were	O
provided	O
by	O
The	O
##rm	O
##o	O
Fisher	O
Scientific	O
.	O

Tau	B
##ro	I
##chen	I
##ode	I
##ox	I
##ych	I
##olate	I
(	O
T	O
##CD	O
##CA	O
)	O
,	O
ta	B
##uro	I
##cho	I
##late	I
(	O
T	O
##CA	O
)	O
,	O
g	B
##ly	I
##co	I
##hy	I
##och	I
##olate	I
(	O
G	O
##HC	O
##A	O
)	O
and	O
g	B
##ly	I
##co	I
##cho	I
##late	I
(	O
G	O
##CA	O
)	O
were	O
17	O
.	O
8	O
-	O
,	O
15	O
-	O
,	O
6	O
.	O
6	O
-	O
and	O
4	O
-	O
fold	O
up	O
##re	O
##gu	O
##lated	O
in	O
DC	O
vs	O
.	O
NH	O
##C	O
respectively	O
.	O

C	O
##I	O
,	O
confidence	O
interval	O
;	O
1	B
,	I
5	I
‐	I
AG	I
,	O
1	B
,	I
5	I
‐	I
an	I
##hy	I
##dr	I
##o	I
‐	I
d	I
‐	I
g	I
##lu	I
##ci	I
##to	I
##l	I
.	O

[UNK]	O
=	O
1	O
[UNK]	O
=	O
1	O
[UNK]	O
[UNK]	O
nm	O
nm	O
nm	O
nm	O
n	O
n	O
m	O
m	O
i	O
=	O
1	O
i	O
=	O
1	O
i	O
=	O
1	O
(	O
R	O
##V	O
##H	O
##U	O
+	O
N	O
##AF	O
##LD	O
##mi	O
R	O
##V	O
##H	O
##U	O
+	O
N	O
##AF	O
##LD	O
##mi	O
R	B
##V	I
R	I
##V	I

This	O
analysis	O
indicated	O
that	O
the	O
set	O
of	O
meta	O
##bol	O
##ites	O
,	O
including	O
c	B
##rea	I
##tin	I
##ine	I
(	O
p	O
-	O
value	O
=	O
1	O
.	O
5	O
×	O
10	O
_	O
−	O
##0	O
##2	O
)	O
,	O
3	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
(	O
p	O
-	O
value	O
=	O
8	O
.	O
0	O
×	O
10	O
_	O
−	O
##3	O
)	O
,	O
3	B
-	I
h	I
##ydro	I
##xy	I
##is	I
##ova	I
##ler	I
##ate	I
(	O
p	O
-	O
value	O
=	O
8	O
.	O
4	O
×	O
10	O
_	O
−	O
##0	O
##5	O
)	O
,	O
and	O
met	B
##hyl	I
##mal	I
##ona	I
##te	I
(	O
p	O
-	O
value	O
=	O
1	O
.	O
1	O
×	O
10	O
_	O
−	O
##4	O
)	O
,	O
disc	O
##rim	O
##inate	O
between	O
MS	O
and	O
N	O
##MO	O
-	O
SD	O
patients	O
.	O

Another	O
novel	O
finding	O
is	O
a	O
reduction	O
of	O
serum	O
but	B
##yra	I
##te	I
at	O
6	O
months	O
post	O
R	O
##Y	O
##GB	O
compared	O
with	O
pre	O
‐	O
surgery	O
values	O
.	O

With	O
the	O
comb	O
##inator	O
##y	O
help	O
of	O
Mass	O
##Works	O
_	O
T	O
##M	O
and	O
online	O
databases	O
such	O
as	O
HM	O
##D	O
,	O
the	O
component	O
was	O
put	O
##ative	O
##ly	O
identified	O
as	O
p	B
##hos	I
##ph	I
##ot	I
##idy	I
##l	I
##cho	I
##line	I
PC	I
##34	I
:	I
2	I
.	O

The	O
parameters	O
used	O
for	O
1	O
##D	O
CP	O
##MG	O
pulse	O
sequence	O
were	O
as	O
follows	O
:	O
spectral	O
sweep	O
width	O
:	O
12	O
pp	O
##m	O
;	O
data	O
points	O
:	O
32	O
K	O
;	O
flip	O
angle	O
of	O
radio	O
##f	O
##re	O
##q	O
##une	O
##cy	O
pulse	O
:	O
90	O
##°	O
;	O
total	O
relaxation	O
delay	O
(	O
R	O
##D	O
)	O
:	O
5	O
se	O
##c	O
;	O
T	O
_	O
2	O
filtering	O
was	O
obtained	O
with	O
an	O
echo	O
time	O
of	O
200	O
μ	O
##s	O
repeated	O
300	O
times	O
,	O
resulting	O
in	O
a	O
total	O
duration	S
of	O
effective	O
echo	O
time	O
of	O
60	O
m	O
##s	O
;	O
number	O
of	O
scan	O
##s	O
:	O
128	O
;	O
window	O
function	O
:	O
ex	O
##po	O
##nent	O
##ial	O
and	O
line	O
broad	O
##ening	O
:	O
0	O
.	O
3	O
Hz	O
.	O

Pat	O
##ient	O
2	O
,	O
who	O
had	O
elevated	O
or	B
##ota	I
##te	I
and	O
or	B
##ot	I
##id	I
##ine	I
,	O
had	O
several	O
variants	O
that	O
,	O
when	O
combined	O
,	O
may	O
explain	O
the	O
accumulation	O
of	O
these	O
meta	O
##bol	O
##ites	O
.	O

We	O
identified	O
several	O
per	O
##tur	O
##bed	O
pathways	O
,	O
including	O
fatty	O
acid	O
metabolism	O
—	O
particularly	O
the	O
p	O
##oly	O
##uns	O
##at	O
##ura	O
##ted	O
fatty	O
acids	O
metabolism	O
,	O
and	O
pu	B
##rine	I
metabolism	O
—	O
that	O
were	O
associated	O
with	O
MD	O
##D	O
in	O
these	O
young	O
patients	O
.	O

H	B
##ydro	I
##xy	I
##vale	I
##ryl	I
##car	I
##ni	I
##tine	I
;	O
34	O
.	O

The	O
most	O
disc	O
##rim	O
##inating	O
PC	O
species	O
(	O
eight	O
)	O
included	O
both	O
lower	O
MW	O
species	O
(	O
MW	O
70	O
##5	O
.	O
8	O
–	O
74	O
##1	O
.	O
8	O
)	O
,	O
containing	O
short	O
saturated	O
and	O
/	O
or	O
mon	O
##o	O
-	O
un	O
##sat	O
##ura	O
##ted	O
FA	S
chains	O
(	O
C	O
30	O
–	O
34	O
,	O
0	O
–	O
2	O
DB	O
)	O
,	O
and	O
higher	O
MW	O
species	O
(	O
80	O
##9	O
.	O
8	O
–	O
83	O
##5	O
.	O
8	O
)	O
containing	O
longer	O
and	O
more	O
un	O
##sat	O
##ura	O
##ted	O
FA	S
chains	O
(	O
C	O
38	O
–	O
40	O
,	O
3	O
–	O
6	O
DB	O
)	O
.	O

Cho	O
,	O
free	O
ch	B
##olin	I
##e	I
;	O
GP	B
##C	I
,	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##och	I
##olin	I
##e	I
;	O
PC	O
,	O
p	B
##hos	I
##ph	I
##och	I
##olin	I
##e	I
.	O

On	O
arrival	O
samples	O
were	O
cent	O
##ri	O
##fu	O
##ged	O
,	O
serum	O
and	O
urine	O
al	O
##iq	O
##uo	O
##ted	O
and	O
re	O
##f	O
##rig	O
##erated	O
at	O
4	O
##°	O
##C	O
for	O
2	O
–	O
3	O
weeks	O
before	O
storage	O
frozen	O
at	O
−	O
##20	O
##°	O
##C	O
in	O
screw	O
topped	O
,	O
o	O
-	O
ring	O
##ed	O
,	O
p	B
##oly	I
##p	I
##rop	I
##yle	I
##ne	I
tubes	O
.	O

Besides	O
,	O
it	O
is	O
of	O
great	O
interest	O
to	O
note	O
that	O
m	B
-	I
h	I
##ydro	I
##xy	I
##phe	I
##ny	I
##lace	I
##tate	I
is	O
higher	O
in	O
CO	O
##PD	O
patients	O
compared	O
to	O
healthy	O
subjects	O
.	O

Note	O
that	O
the	O
p	B
##yr	I
##og	I
##lut	I
##ami	I
##c	I
acid	I
peak	O
is	O
missing	O
in	O
intact	O
serum	O
,	O
whereas	O
it	O
is	O
present	O
in	O
both	O
ultra	O
##fi	O
##lter	O
##ed	O
and	O
protein	O
pre	O
##ci	O
##pit	O
##ated	O
serum	O
s	O
##pect	O
##ra	O
.	O

Twenty	O
mid	O
##life	O
,	O
card	O
##iovascular	O
s	O
##ym	O
##pt	O
##om	O
-	O
free	O
male	O
adults	O
(	O
40	O
–	O
60	O
years	O
old	O
,	O
mean	O
age	O
46	O
.	O
9	O
years	O
)	O
were	O
recruited	O
from	O
general	O
medical	O
practices	O
in	O
the	O
Birmingham	O
area	O
with	O
(	O
total	O
ch	B
##ole	I
##ster	I
##ol	I
>	O
6	O
.	O
5	O
m	O
##M	O
measured	O
;	O
n	O
=	O
10	O
)	O
and	O
without	O
(	O
n	O

In	O
contrast	O
,	O
car	B
##ni	I
##tine	I
,	O
which	O
is	O
required	O
for	O
activation	O
of	O
fatty	O
acids	O
and	O
re	O
##leg	O
##ating	O
them	O
towards	O
beta	O
oxidation	O
in	O
mit	O
##och	O
##ond	O
##ria	O
was	O
found	O
to	O
be	O
consequently	O
decreasing	O
throughout	O
the	O
course	O
of	O
pregnancy	O
.	O

Alex	O
##a	O
flu	B
##or	I
secondary	O
anti	O
##body	O
(	O
1	O
:	O
500	O
)	O
was	O
used	O
.	O

Working	O
standards	O
of	O
E	O
##Ms	O
and	O
S	O
##I	O
-	O
E	O
##Ms	O
at	O
8	O
ng	O
/	O
m	O
##l	O
were	O
prepared	O
by	O
di	O
##lution	O
##s	O
of	O
the	O
stock	O
solutions	O
using	O
met	B
##han	I
##ol	I
with	O
0	O
.	O
1	O
%	O
L	B
-	I
as	I
##cor	I
##bic	I
acid	I
.	O

The	O
pH	O
was	O
read	O
##ju	O
##sted	O
to	O
6	O
.	O
5	O
with	O
0	O
.	O
1	O
M	O
of	O
ace	B
##tic	I
acid	I
.	O

Direct	O
significant	O
correlation	O
##s	O
(	O
P	O
<	O
0	O
.	O
05	O
after	O
the	O
false	O
discovery	O
rate	O
procedure	O
)	O
were	O
identified	O
between	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
,	O
plasma	O
##log	O
##ens	O
,	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
,	O
l	B
##ys	I
##o	I
-	I
p	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
,	O
and	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
##s	I
compared	O
with	O
vitamin	O
B	O
-	O
12	O
status	O
and	O
nerve	O
function	O
.	O

d	O
Clinical	O
samples	O
,	O
particularly	O
those	O
acquired	O
from	O
highly	O
he	O
##tero	O
##gene	O
##ous	O
populations	O
,	O
such	O
as	O
critically	O
ill	O
patients	O
(	O
e	O
.	O
g	O
.	O
,	O
se	O
##psis	O
)	O
,	O
can	O
introduce	O
un	O
##anti	O
##ci	O
##pate	O
##d	O
variance	O
due	O
to	O
differences	O
in	O
sample	O
collection	O
and	O
handling	O
,	O
red	O
blood	O
cell	O
contamination	O
and	O
storage	O
conditions	O
and	O
duration	S
.	O

Interest	O
##ingly	O
,	O
the	O
expression	O
of	O
17	B
-	I
di	I
##hy	I
##dr	I
##ox	I
##y	I
##p	I
##re	I
##gn	I
-	I
4	I
-	I
en	I
##e	I
-	I
3	I
,	I
20	I
-	I
di	I
##one	I
in	O
c	O
##er	O
##vic	O
##al	O
cancer	O
and	O
pre	O
##can	O
##cer	O
##ous	O
lesions	O
was	O
higher	O
than	O
that	O
in	O
CO	O
##N	O
group	O
6	B
##al	I
##pha	I
-	I
F	I
##lu	I
##oro	I
-	I
11	I
##bet	I
##a	I
,	O
and	O
it	O
was	O
significantly	O
reduced	O
in	O
the	O
T	O
##RE	O
##AT	O
group	O
,	O
indicating	O
that	O
it	O
could	O
serve	O
as	O
a	O
potential	O
bio	O
##mark	O
##er	O
for	O
assessing	O
the	O
pro	O
##gno	O
##sis	O
of	O
c	O
##er	O
##vic	O
##al	O
cancer	O
(	O
H	O
)	O
.	O

For	O
SP	O
##MA	O
,	O
in	O
particular	O
,	O
median	O
levels	O
were	O
0	O
.	O
02	O
and	O
0	O
.	O
31	O
µ	O
##g	O
/	O
g	O
c	B
##rea	I
##tin	I
##ine	I
in	O
workers	O
and	O
controls	O
,	O
respectively	O
.	O

Association	O
of	O
lower	O
levels	O
of	O
P	O
##U	O
##FA	O
##s	O
in	O
CR	O
##C	O
tumor	O
could	O
be	O
attributed	O
to	O
the	O
pro	O
-	O
tumor	O
genes	O
##is	O
of	O
c	O
##y	O
##c	O
##lo	O
##ox	O
##y	O
##gen	O
##ase	O
2	O
(	O
CO	O
##X	O
-	O
2	O
)	O
,	O
an	O
enzyme	O
converting	O
P	O
##U	O
##FA	O
##s	O
to	O
pro	B
##sta	I
##g	I
##land	I
##ins	I
during	O
inflammatory	O
and	O
tumor	O
##ige	O
##nic	O
reactions	O
.	O

The	O
dried	O
samples	O
were	O
re	O
##con	O
##stituted	O
in	O
200	O
μ	O
##l	O
of	O
5	O
%	O
Met	B
##han	I
##ol	I
,	O
1	O
%	O
Ace	B
##ton	I
##it	I
##ril	I
##e	I
and	O
94	O
%	O
water	O
solution	O
.	O

No	O
o	O
##bs	O
##er	O
##vable	O
loss	O
of	O
ta	B
##uri	I
##ne	I
was	O
found	O
,	O
indicating	O
that	O
ta	B
##uri	I
##ne	I
is	O
stable	O
for	O
at	O
least	O
2	O
weeks	O
when	O
stored	O
at	O
(	O
4	O
–	O
8	O
°C	O
)	O
(	O
see	O
inter	O
-	O
day	O
precision	O
data	O
in	O
Table	O
)	O
.	O

At	O
the	O
time	O
meta	O
##bol	O
##ites	O
were	O
measured	O
,	O
mean	O
age	O
was	O
32	O
.	O
4	O
years	O
and	O
mean	O
duration	S
of	O
diabetes	O
was	O
7	O
.	O
5	O
years	O
.	O

For	O
3	O
-	O
M	O
##T	O
at	O
the	O
same	O
concentration	O
,	O
285	O
n	O
##C	O
of	O
charge	O
was	O
transferred	O
in	O
the	O
one	O
-	O
electron	O
oxidation	O
process	O
,	O
e	O
##qua	O
##ting	O
to	O
49	O
##6	O
p	B
##g	I
.	O

This	O
finding	O
is	O
in	O
con	O
##cor	O
##dance	O
with	O
the	O
inverse	O
association	O
between	O
h	O
##s	O
##CR	O
##P	O
and	O
g	B
##lut	I
##amine	I
in	O
the	O
present	O
study	O
.	O

Up	O
##re	O
##gu	O
##lation	O
of	O
ACC	O
,	O
mediated	O
by	O
insulin	O
resistance	O
,	O
enhance	O
##s	O
de	O
no	O
##vo	O
lip	O
##ogen	O
##esis	O
characterized	O
by	O
increased	O
abundance	O
of	O
palm	B
##itate	I
,	O
a	O
C	B
##16	I
fatty	I
acid	I
.	O

Col	O
##um	O
##n	O
flow	O
was	O
set	O
to	O
400	O
µ	O
##l	O
/	O
min	O
with	O
a	O
gradient	O
from	O
99	O
.	O
9	O
%	O
A	O
to	O
98	O
%	O
B	O
where	O
buffer	O
A	O
is	O
1	O
%	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
in	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
and	O
buffer	O
B	O
is	O
100	O
%	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
.	O

H	B
-	I
x	I
##an	I
:	O
h	B
##y	I
##pox	I
##anti	I
##ne	I
;	O
G	O
##lu	O
:	O
g	B
##lut	I
##ama	I
##te	I
;	O
G	O
##ln	O
:	O
g	B
##lut	I
##amine	I
;	O
Ace	O
:	O
ace	B
##tate	I
.	O

Am	O
##ino	O
acid	O
differences	O
have	O
been	O
reported	O
in	O
N	O
##SC	O
##LC	O
and	O
other	O
cancer	O
##s	O
in	O
plasma	O
[	O
,	O
,	O
,	O
,	O
]	O
with	O
Mae	O
##da	O
et	O
al	O
.	O
reporting	O
that	O
concentrations	O
of	O
Ser	O
,	O
Pro	O
,	O
G	O
##ly	O
,	O
Al	O
##a	O
,	O
Met	O
,	O
Il	O
##e	O
,	O
Le	O
##u	O
,	O
Ty	O
##r	O
,	O
Ph	O
##e	O
,	O
Or	O
##n	O
and	O
L	O
##ys	O
were	O
higher	O
and	O
his	B
##ti	I
##dine	I
was	O
lower	O
in	O
N	O
##SC	O
##LC	O
compared	O
with	O
controls	O
,	O
while	O
C	O
##as	O
##cin	O
##o	O
et	O
al	O
.	O
reported	O
increases	O
in	O
T	O
##rp	O
,	O
G	O
##lu	O
and	O
Or	O
##n	O
(	O
A	O
##rg	O
)	O
in	O
lung	O
and	O
breast	O
cancer	O
##s	O
in	O
blood	O
.	O

U	O
##rine	O
was	O
collected	O
in	O
a	O
half	O
-	O
gal	O
##lon	O
container	O
with	O
a	O
tea	O
##sp	O
##oon	O
of	O
L	B
-	I
as	I
##cor	I
##bic	I
acid	I
as	O
a	O
pre	O
##ser	O
##vat	O
##ive	O
and	O
kept	O
in	O
ice	O
or	O
re	O
##f	O
##rig	O
##erated	O
until	O
the	O
following	O
day	O
when	O
urine	O
##s	O
were	O
de	O
##can	O
##ted	O
,	O
al	O
##iq	O
##uo	O
##ted	O
and	O
stored	O
at	O
−	O
##70	O
##°	O
##C	O
.	O

The	O
higher	O
heart	O
rate	O
and	O
blood	O
glucose	S
levels	O
at	O
the	O
time	O
of	O
presentation	O
in	O
the	O
acute	O
th	O
##rom	O
##bot	O
##ic	O
MI	O
group	O
may	O
suggest	O
that	O
the	O
acute	O
th	O
##rom	O
##bot	O
##ic	O
MI	O
subjects	O
were	O
more	O
acute	O
##ly	O
ill	O
at	O
time	O
of	O
T	O
##0	O
sampling	O
than	O
the	O
non	O
-	O
th	O
##rom	O
##bot	O
##ic	O
MI	O
group	O
.	O

FA	O
##SN	O
can	O
be	O
regulated	O
by	O
other	O
lip	O
##id	O
metabolism	O
associated	O
genes	O
such	O
as	O
SR	O
##E	O
##B	O
##P	O
-	O
2	O
,	O
SR	O
##E	O
##B	O
##P	O
##1	O
##c	O
,	O
A	B
##cy	I
##l	I
-	I
Co	I
##A	I
,	O
CP	O
##T	O
##1	O
##a	O
and	O
HM	O
##G	O
-	O
Co	O
##A	O
s	O
##ynth	O
##ase	O
.	O

AD	B
##MA	I
is	O
the	O
most	O
studied	O
met	B
##hyl	I
##ar	I
##gin	I
##ine	I
and	O
elevated	O
plasma	O
levels	O
have	O
been	O
associated	O
with	O
card	O
##iovascular	O
disease	O
,	O
se	O
##psis	O
and	O
in	O
##hibition	O
of	O
c	O
##y	O
##c	O
##lo	O
##ox	O
##y	O
##gen	O
##ase	O
-	O
2	O
by	O
pain	O
medications	O
.	O

The	O
product	O
ion	O
s	O
##pect	O
##ra	O
at	O
the	O
MS	O
_	O
3	O
scan	O
stage	O
supported	O
the	O
proposed	O
structures	O
of	O
the	O
4	B
-	I
AB	I
##P	I
-	I
DNA	I
add	O
##uc	O
##ts	O
.	O

(	O
B	O
)	O
9	O
-	O
H	O
##SA	O
content	O
in	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
as	O
shown	O
by	O
class	O
.	O

(	O
A	O
)	O
The	O
initial	O
transitions	O
thought	O
to	O
differentiate	O
AD	B
##MA	I
(	O
green	O
)	O
and	O
SD	O
##MA	O
(	O
red	O
)	O
including	O
the	O
generic	O
transition	O
37	O
##3	O
→	O
202	O
.	O
99	O
m	O
/	O
z	O
,	O
and	O
the	O
most	O
abundant	O
transitions	O
seen	O
for	O
AD	B
##MA	I
(	O
37	O
##3	O
→	O
158	O
m	O
/	O
z	O
)	O
and	O
SD	O
##MA	O
(	O
37	O
##3	O
→	O
116	O
m	O
/	O
z	O
)	O
,	O
from	O
which	O
a	O
double	O
peak	O
was	O
produced	O
.	O

We	O
have	O
shown	O
an	O
association	O
between	O
ta	B
##mo	I
##xi	I
##fen	I
and	O
its	O
meta	O
##bol	O
##ites	O
and	O
est	B
##rogen	I
serum	O
levels	O
.	O

The	O
b	O
##lot	O
##s	O
were	O
stripped	O
and	O
probe	O
##d	O
for	O
housekeeper	O
proteins	O
transfer	O
##rin	O
(	O
serum	O
)	O
or	O
β	B
-	I
act	I
##in	I
(	O
tissue	O
l	O
##ys	O
##ate	O
)	O
.	O

The	O
super	O
##nat	O
##ant	O
after	O
cent	O
##ri	O
##fu	O
##gation	O
was	O
analyzed	O
by	O
injection	O
onto	O
a	O
si	B
##lica	I
column	O
interface	O
##d	O
with	O
an	O
API	O
4000	O
Q	O
-	O
T	O
##RA	O
##P	O
mass	O
s	O
##pect	O
##rome	O
##ter	O
(	O
AB	O
SC	O
##IE	O
##X	O
,	O
Fr	O
##ami	O
##ng	O
##ham	O
,	O
MA	O
,	O
USA	O
)	O
.	O

S	B
##phi	I
##ngo	I
##lip	I
##ids	I
,	O
comprised	O
of	O
Ce	O
##rs	O
,	O
SM	O
##s	O
,	O
and	O
their	O
reduced	O
forms	O
(	O
d	O
##h	O
##C	O
##ers	O
and	O
d	O
##h	O
##SM	O
##s	O
)	O
,	O
were	O
positively	O
associated	O
with	O
o	O
##besity	O
and	O
d	O
##ys	O
##gly	O
##ce	O
##mia	O
.	O

Most	O
lip	O
##id	O
media	O
##tor	O
-	O
related	O
studies	O
employ	O
C	O
##18	O
-	O
based	O
columns	O
to	O
perform	O
the	O
separation	O
;	O
however	O
,	O
C	O
##30	O
column	O
also	O
showed	O
great	O
potential	O
in	O
separation	O
of	O
lip	O
##id	O
molecular	O
species	O
[	O
,	O
]	O
and	O
could	O
be	O
used	O
as	O
an	O
alternative	O
for	O
analyzing	O
o	B
##xy	I
##lip	I
##ins	I
.	O

The	O
_	O
1	O
H	O
N	O
##MR	O
s	O
##pect	O
##ra	O
primarily	O
contained	O
resonance	O
##s	O
from	O
lip	O
##ids	O
,	O
glucose	S
,	O
amino	O
acids	O
,	O
and	O
other	O
organic	O
acids	O
.	O

Box	O
plot	O
showing	O
the	O
levels	O
of	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
(	O
H	O
##X	O
)	O
and	O
x	B
##ant	I
##hine	I
(	O
X	O
)	O
according	O
to	O
path	O
##ological	O
ch	O
##em	O
##ora	O
##dio	O
##ther	O
##ap	O
##y	O
responses	O
(	O
A	O
-	O
E	O
)	O
.	O

Ser	O
##um	O
c	B
##rea	I
##tin	I
##ine	I
levels	O
were	O
significantly	O
lower	O
in	O
the	O
HC	O
##C	O
group	O
than	O
in	O
the	O
C	O
##IR	O
group	O
(	O
P	O
=	O
0	O
.	O
00	O
##4	O
)	O
.	O

Fat	O
##ty	O
acid	O
and	O
o	B
##xy	I
##lip	I
##in	I
abundance	O
data	O
were	O
Johnson	O
transformed	O
and	O
checked	O
for	O
normal	O
##ity	O
using	O
the	O
Shapiro	O
-	O
W	O
##il	O
##k	O
test	O
.	O

Character	O
##istic	O
##ally	O
,	O
the	O
native	O
vitamin	B
D	I
compounds	O
show	O
very	O
rich	O
product	O
ion	O
s	O
##pect	O
##ra	O
,	O
due	O
to	O
the	O
availability	O
of	O
a	O
large	O
number	O
of	O
low	O
-	O
energy	O
fragment	O
##ation	O
pathways	O
.	O

In	O
this	O
study	O
,	O
c	B
##ys	I
##tein	I
##e	I
+	O
c	B
##ys	I
##tine	I
levels	O
were	O
high	O
in	O
the	O
OS	O
##CC	O
group	O
compared	O
to	O
the	O
O	O
##D	O
group	O
,	O
and	O
pre	O
-	O
and	O
post	O
##oper	O
##ative	O
comparisons	O
of	O
OS	O
##CC	O
revealed	O
a	O
high	O
value	O
of	O
c	B
##ys	I
##tein	I
##e	I
+	O
c	B
##ys	I
##tine	I
.	O

Since	O
g	B
##lut	I
##ama	I
##te	I
and	O
p	B
##yr	I
##og	I
##lut	I
##ama	I
##te	I
are	O
inter	O
##con	O
##vert	O
##ible	O
during	O
G	O
##C	O
–	O
MS	O
der	O
##iva	O
##ti	O
##zation	O
,	O
these	O
meta	O
##bol	O
##ites	O
were	O
combined	O
.	O

All	O
m	O
##od	O
##ifier	O
solutions	O
were	O
prepared	O
volume	O
##tric	O
##ally	O
or	O
,	O
in	O
the	O
case	O
of	O
the	O
am	B
##mon	I
##ium	I
salts	O
,	O
by	O
addition	O
of	O
the	O
solid	O
salt	O
to	O
the	O
met	B
##han	I
##ol	I
,	O
followed	O
by	O
son	O
##ica	O
##tion	O
at	O
room	O
temperature	O
for	O
10	O
min	O
.	O

It	O
should	O
be	O
noted	O
that	O
while	O
L	B
-	I
ace	I
##ty	I
##l	I
##car	I
##ni	I
##tine	I
was	O
not	O
significant	O
in	O
the	O
overall	O
sample	O
,	O
it	O
became	O
significant	O
in	O
the	O
male	O
-	O
only	O
sample	O
,	O
even	O
when	O
the	O
sample	O
size	O
was	O
reduced	O
,	O
suggesting	O
that	O
the	O
difference	O
in	O
L	B
-	I
ace	I
##ty	I
##l	I
##car	I
##ni	I
##tine	I
between	O
patients	O
with	O
autism	O
and	O
controls	O
may	O
be	O
sex	O
-	O
sensitive	O
,	O
possibly	O
owing	O
to	O
sex	O
bias	O
.	O

It	O
is	O
interesting	O
to	O
note	O
that	O
(	B
ω	I
)	I
-	I
and	O
(	O
ω	O
-	O
1	O
)	O
-	O
h	O
##ydro	O
##xy	O
##l	O
derivatives	O
(	O
anal	O
##yte	O
##s	O
4	O
and	O
6	O
)	O
were	O
only	O
detected	O
in	O
the	O
specimen	O
known	O
to	O
have	O
administered	O
J	O
##W	O
##H	O
-	O
07	O
##3	O
(	O
S	O
##pec	O
##ime	O
##n	O
4	O
)	O
and	O
that	O
anal	O
##yte	O
5	O
was	O
present	O
in	O
specimens	O
that	O
presumably	O
administered	O
only	O
J	O
##W	O
##H	O
-	O
01	O
##8	O
.	O

After	O
ing	O
##est	O
##ion	O
of	O
the	O
flat	O
##bre	O
##ad	O
prepared	O
from	O
2	O
%	O
_	O
13	O
C	O
en	O
##rich	O
##ed	O
flour	O
,	O
we	O
observed	O
a	O
maximum	O
of	O
0	O
.	O
98	O
%	O
is	O
##oto	O
##pic	O
en	O
##rich	O
##ment	O
in	O
plasma	O
glucose	S
(	O
b	O
,	O
left	O
panel	O
)	O
.	O

Ad	O
##ip	O
##ose	O
and	O
muscle	O
regional	O
G	O
##U	O
were	O
calculated	O
by	O
multi	O
##p	O
##lying	O
tissue	O
K	O
_	O
i	O
by	O
corresponding	O
plasma	O
glucose	S
concentration	O
and	O
divided	O
by	O
lump	O
##ed	O
constant	O
.	O

Multiple	O
studies	O
show	O
that	O
AD	B
##MA	I
levels	O
were	O
significantly	O
elevated	O
in	O
patients	O
with	O
RA	O
compared	O
with	O
control	O
subjects	O
[	O
–	O
]	O
.	O

Finally	O
,	O
CD	O
patients	O
exhibited	O
an	O
increase	O
in	O
sugar	O
##s	O
,	O
such	O
as	O
x	B
##yl	I
##ose	I
,	O
ma	B
##lt	I
##ose	I
,	O
gal	B
##act	I
##ose	I
,	O
and	O
la	B
##ct	I
##ose	I
compared	O
to	O
the	O
control	O
co	O
##hor	O
##t	O
.	O

However	O
,	O
using	O
AD	O
##HD	O
-	O
status	O
as	O
outcome	O
when	O
including	O
only	O
controls	O
and	O
patients	O
in	O
the	O
age	O
19	O
–	O
33	O
subgroup	O
,	O
there	O
were	O
still	O
significantly	O
lower	O
levels	O
of	O
try	B
##pt	I
##op	I
##han	I
[	O
OR	O
:	O
0	O
.	O
71	O
(	O
95	O
%	O
C	O
##I	O
0	O
.	O
51	O
–	O
0	O
.	O
99	O
,	O
p	O
:	O
0	O
.	O
05	O
)	O
]	O
and	O
H	O
##AA	O
[	O
0	O
.	O
66	O
(	O
0	O
.	O
47	O
–	O
0	O
.	O
91	O
,	O
0	O
.	O
01	O
)	O
]	O
in	O
patients	O
.	O

I	O
##dent	O
##ified	O
meta	O
##bol	O
##ites	O
with	O
VIP	O
values	O
>	O
1	O
were	O
:	O
glucose	S
,	O
la	B
##ct	I
##ate	I
,	O
al	B
##ani	I
##ne	I
,	O
le	B
##uc	I
##ine	I
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
g	B
##lut	I
##ama	I
##te	I
,	O
g	B
##lut	I
##amine	I
,	O
v	B
##ali	I
##ne	I
,	O
l	B
##ys	I
##ine	I
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
th	B
##re	I
##oni	I
##ne	I
,	O
β	B
-	I
h	I
##ydro	I
##xy	I
-	I
but	I
##yra	I
##te	I
,	O
ace	B
##tate	I
,	O
ace	B
##to	I
##ace	I
##tate	I
,	O
u	B
##rea	I
,	O
c	B
##rea	I
##tine	I
and	O
c	B
##rea	I
##tin	I
##ine	I
.	O

Consequently	O
,	O
c	B
##it	I
##ric	I
acid	I
was	O
also	O
inverse	O
##ly	O
related	O
to	O
vitamin	O
B	O
-	O
12	O
status	O
.	O

A	O
targeted	O
search	O
for	O
C	B
##15	I
:	I
0	I
and	O
C	B
##17	I
:	I
0	I
revealed	O
the	O
presence	O
of	O
these	O
two	O
free	O
fatty	O
acids	O
in	O
the	O
serum	O
samples	O
of	O
our	O
study	O
.	O

Of	O
note	O
,	O
HC	O
##T	O
##Z	O
produced	O
greater	O
BP	O
lowering	O
when	O
used	O
as	O
mon	O
##otherapy	O
in	O
P	O
##EA	O
##R	O
HC	O
##T	O
##Z	O
and	O
GE	O
##RA	O
HC	O
##T	O
##Z	O
compared	O
to	O
its	O
use	O
when	O
added	O
to	O
ate	B
##no	I
##lo	I
##l	I
as	O
HC	O
##T	O
##Z	O
add	O
-	O
on	O
therapy	O
.	O

Thus	O
,	O
the	O
decrease	O
in	O
g	B
##lut	I
##amine	I
concentration	O
in	O
the	O
serum	O
of	O
the	O
bee	O
##keepers	O
directly	O
after	O
a	O
bee	O
sting	O
may	O
suggest	O
its	O
participation	O
in	O
the	O
de	O
##to	O
##xi	O
##fication	O
of	O
the	O
bee	O
venom	O
spreading	O
throughout	O
the	O
body	O
.	O

In	O
any	O
case	O
,	O
our	O
data	O
suggest	O
that	O
while	O
lip	O
##id	O
-	O
lowering	O
medication	O
can	O
alter	O
lip	O
##id	O
profiles	O
,	O
namely	O
L	O
##D	O
##L	O
-	O
C	O
,	O
HD	O
##L	O
-	O
C	O
and	O
total	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
an	O
age	O
-	O
related	O
reduction	O
in	O
plasma	O
lip	O
##ids	O
may	O
be	O
independent	O
of	O
these	O
effects	O
,	O
though	O
only	O
a	O
small	O
number	O
of	O
subjects	O
were	O
on	O
lip	O
##id	O
-	O
lowering	O
medication	O
in	O
our	O
study	O
.	O

I	O
##dent	O
##ification	O
of	O
trans	B
##thy	I
##ret	I
##in	I
.	O

A	O
multiple	O
linear	O
re	O
##gression	O
model	O
was	O
generated	O
it	O
##erative	O
##ly	O
using	O
19	O
clusters	O
that	O
were	O
comprised	O
of	O
all	O
the	O
o	B
##xy	I
##lip	I
##ins	I
and	O
fatty	O
acids	O
and	O
exhibited	O
similar	O
pattern	O
of	O
expression	O
in	O
post	O
##pra	O
##ndi	O
##al	O
T	O
##GR	O
##L	O
across	O
all	O
subjects	O
.	O

However	O
,	O
PC	B
(	I
32	I
:	I
0	I
)	I
,	O
and	O
PC	B
(	I
38	I
:	I
4	I
)	I
decreased	O
in	O
M	O
##F	O
tissue	O
compared	O
to	O
adjacent	O
non	O
-	O
tumor	O
tissue	O
.	O

Once	O
again	O
,	O
as	O
illustrated	O
,	O
try	B
##pt	I
##op	I
##han	I
(	O
the	O
red	O
line	O
)	O
was	O
non	O
-	O
inferior	O
to	O
the	O
5	O
AA	O
##s	O
in	O
disc	O
##rim	O
##inating	O
future	O
T	O
##2	O
##D	O
and	O
future	O
N	O
##G	O
##T	O
(	O
with	O
comparable	O
AU	O
##Cs	O
)	O
.	O

Not	O
##ably	O
,	O
two	O
previous	O
meta	O
##bol	O
##omi	O
##cs	O
studies	O
have	O
demonstrated	O
higher	O
serum	O
c	B
##rea	I
##tine	I
levels	O
in	O
H	O
##F	O
patients	O
[	O
,	O
]	O
.	O

B	O
##rief	O
##ly	O
,	O
the	O
sample	O
preparation	O
procedure	O
consisted	O
of	O
four	O
simple	O
steps	O
(	O
i	O
)	O
urine	O
samples	O
were	O
withdrawn	O
from	O
−	O
##80	O
°C	O
and	O
left	O
at	O
room	O
temperature	O
to	O
th	O
##aw	O
,	O
(	O
ii	O
)	O
the	O
samples	O
were	O
then	O
treated	O
with	O
met	B
##han	I
##ol	I
(	I
1	I
:	I
1	I
,	I
v	I
/	I
v	I
)	I
and	O
cent	O
##ri	O
##fu	O
##ged	O
,	O
(	O
ii	O
##i	O
)	O
the	O
super	O
##nat	O
##ant	O
was	O
collected	O
and	O
subjected	O
to	O
e	O
##va	O
##por	O
##ation	O
in	O
a	O
nitrogen	O
current	O
to	O
remove	O
met	B
##han	I
##ol	I
,	O
and	O
(	O
i	O
##v	O
)	O
re	O
##con	O
##stituted	O
with	O
200	O
µ	O
##L	O
of	O
1	O
%	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
and	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
previously	O
spike	O
##d	O
with	O
a	O
labeled	O
compound	O
.	O

Among	O
the	O
met	O
##hyl	O
##ated	O
derivatives	O
,	O
AD	B
##MA	I
,	O
a	O
potent	O
end	O
##ogen	O
##ous	O
inhibitor	O
of	O
NO	O
##S	O
and	O
a	O
marker	O
of	O
end	O
##oth	O
##eli	O
##al	O
d	O
##ys	O
##function	O
,	O
has	O
been	O
shown	O
by	O
our	O
group	O
and	O
others	O
to	O
serve	O
as	O
an	O
independent	O
risk	O
factor	O
for	O
card	O
##iovascular	O
events	O
in	O
the	O
general	O
population	O
[	O
,	O
]	O
.	O

Finally	O
,	O
to	O
as	O
##cer	O
##tain	O
that	O
the	O
two	O
major	O
markers	O
identified	O
,	O
SM	B
(	I
36	I
:	I
3	I
)	I
and	O
PC	B
(	I
40	I
:	I
7	I
)	I
,	O
were	O
genuine	O
T	O
##FA	O
markers	O
in	O
plasma	O
we	O
q	O
##uant	O
##ified	O
them	O
by	O
a	O
targeted	O
lip	O
##ido	O
##mic	O
##s	O
analysis	O
of	O
a	O
subset	O
of	O
12	O
samples	O
from	O
each	O
group	O
using	O
appropriate	O
internal	O
standards	O
.	O

This	O
co	O
-	O
compartment	O
##ali	O
##zation	O
of	O
the	O
metabolic	O
processes	O
rather	O
than	O
simple	O
en	O
##zy	O
##matic	O
activity	O
explains	O
why	O
the	O
close	O
relationship	O
between	O
hip	B
##pura	I
##te	I
and	O
T	O
##CA	O
cycle	O
intermediate	O
ex	O
##cre	O
##tion	O
is	O
not	O
directly	O
apparent	O
from	O
,	O
which	O
maps	O
shortest	O
path	O
connect	O
##iv	O
##ities	O
between	O
meta	O
##bol	O
##ites	O
based	O
on	O
the	O
K	O
##EG	O
##G	O
pathways	O
.	O

Equal	O
amounts	O
of	O
protein	O
were	O
separated	O
by	O
electro	O
##ph	O
##ores	O
##is	O
in	O
SD	O
##S	O
-	O
containing	O
12	O
%	O
p	B
##oly	I
##ac	I
##ryl	I
##ami	I
##de	I
gel	O
##s	O
and	O
transferred	O
to	O
ni	O
##tro	O
##cell	O
##ulos	O
##e	O
membrane	O
##s	O
,	O
which	O
were	O
then	O
probe	O
##d	O
with	O
antibodies	O
.	O

The	O
MS	O
/	O
MS	O
s	O
##pect	O
##ra	O
of	O
the	O
[	O
M	O
+	O
H	O
]	O
_	O
+	O
ions	O
of	O
PC	O
and	O
P	O
##E	O
and	O
[	O
M	O
-	O
H	O
]	O
-	O
ion	O
of	O
FA	S
are	O
presented	O
in	O
.	O

Form	B
##ic	I
acid	I
was	O
obtained	O
from	O
F	O
##luk	O
##a	O
(	O
B	O
##uch	O
##s	O
,	O
Switzerland	O
)	O
.	O

The	O
decrease	O
of	O
g	B
##lut	I
##amine	I
observed	O
in	O
es	O
##op	O
##hage	O
##al	O
cancer	O
could	O
satisfy	O
the	O
production	O
of	O
energy	O
.	O

To	O
further	O
valid	O
##ate	O
these	O
changes	O
,	O
we	O
conducted	O
thermal	O
sensitivity	O
experiments	O
on	O
individual	O
compounds	O
of	O
ATP	S
,	O
in	B
##os	I
##ine	I
,	O
and	O
I	B
##MP	I
at	O
150	O
and	O
250	O
°C	O
with	O
higher	O
temporal	O
resolution	O
(	O
30	O
s	O
,	O
60	O
s	O
,	O
120	O
s	O
,	O
and	O
300	O
s	O
)	O
.	O

Whilst	O
su	B
##cci	I
##nate	I
does	O
not	O
show	O
a	O
significantly	O
increased	O
u	O
##rina	O
##ry	O
ex	O
##cre	O
##tion	O
(	O
in	O
agreement	O
with	O
our	O
previous	O
N	O
##MR	O
observations	O
[	O
]	O
)	O
,	O
closely	O
related	O
meta	O
##bol	O
##ites	O
,	O
namely	O
met	B
##hyl	I
##su	I
##cci	I
##nate	I
and	O
f	B
##uma	I
##rate	I
,	O
had	O
higher	O
u	O
##rina	O
##ry	O
levels	O
which	O
may	O
describe	O
a	O
selective	O
oxidation	O
of	O
as	B
##par	I
##tate	I
,	O
t	B
##yr	I
##os	I
##ine	I
and	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
.	O

As	O
a	O
result	O
,	O
I	O
##MS	O
is	O
well	O
suited	O
to	O
separate	O
such	O
is	O
##omer	O
##ic	O
lip	O
##ids	O
and	O
has	O
previously	O
been	O
used	O
to	O
resolve	O
c	O
##is	O
and	O
trans	O
is	O
##omer	O
##s	O
in	O
standard	O
materials	O
.	O
_	O
,	O
To	O
investigate	O
this	O
possibility	O
in	O
the	O
present	O
study	O
,	O
the	O
arrival	O
time	O
distributions	O
for	O
the	O
same	O
pair	O
of	O
P	B
##E	I
18	I
:	I
1	I
(	I
n	I
-	I
9	I
)	I
/	I
18	I
:	I
1	I
(	I
n	I
-	I
9	I
)	I
stereo	O
##is	O
##omer	O
##s	O
were	O
extracted	O
in	O
both	O
positive	O
and	O
negative	O
ion	O
modes	O
and	O
are	O
shown	O
in	O
.	O

Moreover	O
,	O
due	O
to	O
the	O
reduced	O
complexity	O
,	O
the	O
number	O
of	O
P	O
##L	O
##s	O
,	O
both	O
in	O
the	O
isolated	O
classes	O
,	O
e	O
.	O
g	O
.	O
,	O
PC	O
and	O
P	B
##G	I
,	O
as	O
well	O
as	O
in	O
the	O
mixed	O
fraction	O
##s	O
,	O
e	O
.	O
g	O
.	O
,	O
P	O
##E	O
/	O
PA	O
/	O
C	O
##L	O
,	O
was	O
increased	O
.	O

These	O
studies	O
indicate	O
that	O
MG	O
##H1	O
levels	O
and	O
impaired	O
glucose	S
metabolism	O
are	O
indeed	O
related	O
,	O
but	O
it	O
is	O
currently	O
unclear	O
to	O
what	O
extent	O
this	O
link	O
is	O
mediated	O
by	O
fast	O
##ing	O
or	O
post	O
##pra	O
##ndi	O
##al	O
h	O
##yper	O
##gly	O
##ca	O
##emia	O
and	O
which	O
role	O
the	O
duration	S
of	O
impaired	O
glucose	S
metabolism	O
plays	O
in	O
this	O
context	O
.	O

The	O
ca	O
##li	O
##bra	O
##tion	O
ranges	O
were	O
0	O
.	O
4	O
–	O
12	O
.	O
5	O
μ	O
##g	O
/	O
m	O
##l	O
for	O
EPA	O
and	O
γ	B
-	I
l	I
##ino	I
##len	I
##ic	I
;	O
1	O
.	O
2	O
–	O
37	O
.	O
5	O
μ	O
##g	O
/	O
m	O
##l	O
for	O
D	O
##HA	O
and	O
l	O
##ino	O
##len	O
##ic	O
;	O
2	O
.	O
3	O
–	O
75	O
μ	O
##g	O
/	O
m	O
##l	O
for	O
AA	O
and	O
palm	B
##ito	I
##le	I
##ic	I
;	O
7	O
.	O
8	O
–	O
250	O
μ	O
##g	O
/	O
m	O
##l	O
for	O
o	O
##le	O
##ic	O
and	O
l	B
##ino	I
##le	I
##ic	I
and	O
15	O
.	O
6	O
–	O
500	O
μ	O
##g	O
/	O
m	O
##l	O
for	O
palm	B
##itic	I
and	O
s	O
##te	O
##ari	O
##c	O
.	O

The	O
three	O
major	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
groups	O
(	O
SM	O
##s	O
,	O
PC	O
##s	O
,	O
l	O
##ys	O
##o	O
##PC	O
##s	O
)	O
are	O
important	O
structural	O
components	O
of	O
plasma	O
lip	O
##op	O
##rote	O
##ins	O
and	O
cell	O
membrane	O
##s	O
and	O
are	O
involved	O
in	O
regulation	O
of	O
cell	O
function	O
,	O
membrane	O
protein	O
trafficking	O
and	O
inflammation	O
.	O

I	O
##AA	O
can	O
be	O
generated	O
in	O
the	O
in	O
##test	O
##ines	O
from	O
in	B
##do	I
##le	I
produced	O
by	O
gut	O
micro	O
##f	O
##lora	O
,	O
or	O
meta	O
##bol	O
##ized	O
in	O
tissue	O
from	O
try	B
##pta	I
##mine	I
and	O
other	O
try	B
##pt	I
##op	I
##han	I
derivatives	O
.	O

They	O
reported	O
an	O
increase	O
in	O
is	B
##ob	I
##ut	I
##yra	I
##te	I
and	O
is	B
##ova	I
##ler	I
##ate	I
levels	O
with	O
age	O
and	O
attributed	O
the	O
differences	O
to	O
a	O
change	O
in	O
bacterial	O
m	B
##uc	I
##in	I
degradation	O
.	O

We	O
chose	O
hip	B
##pura	I
##te	I
as	O
the	O
associated	O
meta	O
##bol	O
##ite	O
,	O
in	O
particular	O
the	O
peak	O
at	O
7	O
.	O
84	O
##6	O
pp	O
##m	O
.	O

Compared	O
with	O
un	O
##ila	O
##teral	O
thy	O
##roid	O
##ec	O
##tom	O
##y	O
,	O
total	O
thy	O
##roid	O
##ec	O
##tom	O
##y	O
reversed	O
some	O
highly	O
increased	O
meta	O
##bol	O
##ite	O
levels	O
(	O
e	O
.	O
g	O
.	O
,	O
ta	B
##uri	I
##ne	I
and	O
beta	O
##ine	O
)	O
.	O

Total	O
co	B
##tin	I
##ine	I
and	O
total	O
N	O
##NA	O
##L	O
,	O
which	O
are	O
virtually	O
unique	O
to	O
users	O
of	O
tobacco	O
products	O
and	O
related	O
materials	O
,	O
or	O
people	O
exposed	O
to	O
second	O
##hand	O
tobacco	O
smoke	O
,	O
are	O
excellent	O
indicators	O
of	O
tobacco	O
dose	O
and	O
are	O
directly	O
associated	O
with	O
lung	O
cancer	O
risk	O
in	O
smoke	O
##rs	O
.	O

The	O
p	O
-	O
values	O
for	O
these	O
significant	O
differences	O
were	O
maintained	O
after	O
adjustment	O
for	O
age	O
,	O
sex	O
,	O
B	O
##MI	O
,	O
L	B
##D	I
##L	I
ch	I
##ole	I
##ster	I
##ol	I
,	O
and	O
fast	O
##ing	O
glucose	S
(	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
but	O
the	O
q	O
-	O
values	O
were	O
not	O
(	O
q	O
>	O
0	O
.	O
05	O
)	O
.	O

We	O
finally	O
determined	O
a	O
panel	O
of	O
four	O
lip	O
##id	O
species	O
,	O
including	O
LP	B
##E	I
(	I
18	I
:	I
1	I
)	I
,	O
e	B
##P	I
##E	I
(	I
40	I
:	I
4	I
)	I
,	O
C	B
(	I
18	I
:	I
2	I
)	I
CE	I
and	O
SM	B
(	I
22	I
:	I
0	I
)	I
,	O
as	O
candidate	O
bio	O
##mark	O
##ers	O
for	O
early	O
detection	O
of	O
N	O
##SC	O
##LC	O
disease	O
at	O
the	O
training	O
stage	O
(	O
Table	O
)	O
.	O

We	O
did	O
not	O
observe	O
statistical	O
##ly	O
significant	O
differences	O
in	O
the	O
levels	O
of	O
meta	O
##bol	O
##ites	O
in	O
samples	O
obtained	O
via	O
LP	S
versus	O
O	O
##M	O
(	O
Table	O
)	O
.	O

PC	B
a	I
##a	I
C	I
##34	I
:	I
1	I
;	O
28	O
.	O

_	O
,	O
In	O
our	O
study	O
,	O
we	O
describe	O
the	O
generation	O
of	O
the	O
pro	O
##ather	O
##ogenic	O
meta	O
##bol	O
##ite	O
T	B
##MA	I
##O	I
from	O
diet	O
##ary	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
through	O
the	O
use	O
of	O
stable	O
-	O
is	O
##oto	O
##pe	O
-	O
trace	O
##r	O
feeding	O
studies	O
.	O

Thus	O
,	O
although	O
there	O
seems	O
to	O
be	O
an	O
association	O
between	O
higher	O
age	O
,	O
lower	O
try	B
##pt	I
##op	I
##han	I
and	O
increased	O
K	O
##TR	O
,	O
low	O
level	O
of	O
try	B
##pt	I
##op	I
##han	I
in	O
the	O
AD	O
##HD	O
group	O
cannot	O
be	O
fully	O
explained	O
by	O
higher	O
ID	O
##O	O
or	O
TD	O
##O	O
activity	O
.	O

SM	O
has	O
a	O
higher	O
concentration	O
than	O
c	B
##era	I
##mi	I
##de	I
,	O
which	O
means	O
that	O
SM	O
may	O
act	O
as	O
a	O
pool	O
for	O
the	O
rapid	O
generation	O
of	O
c	B
##era	I
##mi	I
##de	I
due	O
to	O
SM	O
h	O
##ydro	O
##lysis	O
by	O
s	O
##phi	O
##ngo	O
##my	O
##elin	O
##ases	O
.	O

The	O
l	B
##ys	I
##o	I
-	I
PC	I
concentration	O
on	O
day	O
7	O
was	O
significantly	O
lower	O
in	O
non	O
##su	O
##r	O
##vi	O
##vor	O
##s	O
and	O
l	B
##ys	I
##o	I
-	I
PC	I
concentrations	O
increased	O
over	O
time	O
in	O
patients	O
treated	O
with	O
appropriate	O
anti	O
##biotics	O
but	O
not	O
in	O
those	O
treated	O
with	O
inappropriate	O
anti	O
##biotics	O
.	O

Products	O
of	O
try	B
##pt	I
##op	I
##han	I
degradation	O
(	O
B	O
)	O
k	B
##yn	I
##uren	I
##ine	I
,	O
(	O
C	O
)	O
in	B
##do	I
##le	I
##la	I
##ct	I
##ate	I
,	O
(	O
D	O
)	O
in	B
##do	I
##le	I
##p	I
##rop	I
##ion	I
##ate	I
,	O
and	O
(	O
E	O
)	O
se	B
##rot	I
##oni	I
##n	I
are	O
increased	O
following	O
le	O
##pt	O
##in	O
therapy	O
.	O

Thus	O
,	O
although	O
,	O
three	O
of	O
the	O
four	O
distinguishing	O
meta	O
##bol	O
##ites	O
,	O
th	B
##re	I
##oni	I
##ne	I
,	O
g	B
##lut	I
##amine	I
and	O
l	B
##ino	I
##len	I
##ic	I
acid	I
,	O
have	O
previously	O
been	O
shown	O
to	O
have	O
links	O
with	O
breast	O
cancer	O
,	O
the	O
mechanism	O
of	O
their	O
down	O
‐	O
regulation	O
in	O
patients	O
that	O
responded	O
to	O
ch	O
##em	O
##otherapy	O
(	O
p	O
##CR	O
group	O
)	O
compared	O
to	O
those	O
that	O
do	O
not	O
(	O
SD	O
group	O
)	O
is	O
not	O
well	O
understood	O
.	O

Product	O
ion	O
mass	O
s	O
##pect	O
##ra	O
of	O
A	O
)	O
Fr	O
##action	O
1	O
,	O
AS	O
##SA	O
##K	O
*	O
Q	O
##R	O
(	B
des	B
##ami	I
##no	I
-	I
Ph	I
##IP	I
-	I
K	I
)	O
add	O
##uc	O
##t	O
(	O
[	O
M	O
+	O
2	O
##H	O
]	O
_	O
2	O
+	O
at	O
m	O
/	O
z	O
47	O
##7	O
.	O
8	O
)	O
recovered	O
from	O
NO	O
_	O
2	O
-	O
Ph	O
##IP	O
-	O
modified	O
SA	O
;	O
B	O
)	O
AS	O
##SA	O
##K	O
*	O
Q	O
##R	O
(	B
des	B
##ami	I
##no	I
-	I
[	I
_	I
2	I
H	I
_	I
5	I
]	I
-	O
Ph	O
##IP	O
-	O
K	O
)	O
add	O
##uc	O
##t	O
(	O
[	O
M	O
+	O
2	O
##H	O
]	O
_	O
2	O
+	O
at	O
m	O
/	O
z	O
480	O
.	O
3	O
)	O
recovered	O
from	O
NO	O
_	O
2	O
-	O
[	O
_	O
2	O
H	O
_	O
5	O
]	O
-	O
Ph	O
##IP	O
modified	O
SA	O
;	O

Form	B
##ate	I
is	O
produced	O
from	O
the	O
f	B
##olate	I
cycle	O
in	O
he	O
##pa	O
##tic	O
em	O
##b	O
##ryo	O
##nic	O
cells	O
.	O

Origin	O
of	O
ma	O
##mmal	O
##ian	O
bi	O
##lip	O
##rote	O
##in	O
and	O
rear	O
##rang	O
##ement	O
of	O
bi	B
##li	I
##ru	I
##bin	I
g	O
##lu	O
##cu	O
##ron	O
##ides	O
in	O
v	O
##ivo	O
in	O
the	O
rat	O
.	O

Early	O
h	O
##yper	O
##tensive	O
ne	O
##ph	O
##ros	O
##cle	O
##rosis	O
showed	O
per	O
##tur	O
##bation	O
##s	O
of	O
in	O
##trar	O
##ena	O
##l	O
bio	O
##sy	O
##nt	O
##hesis	O
of	O
do	B
##pa	I
##mine	I
,	O
which	O
regulate	O
##s	O
na	O
##tri	O
##ures	O
##is	O
and	O
blood	O
pressure	O
.	O

IS	O
,	O
the	O
final	O
other	O
in	B
##do	I
##le	I
meta	O
##bol	O
##ite	O
in	O
this	O
study	O
,	O
is	O
produced	O
by	O
he	O
##pa	O
##tic	O
su	O
##lf	O
##ona	O
##tion	O
of	O
in	B
##do	I
##le	I
.	O

trim	B
##eth	I
##yla	I
##mine	I
-	I
N	I
-	I
oxide	I
,	O
g	O
##esta	O
##tional	O
diabetes	O
me	O
##lli	O
##tus	O
,	O
nest	O
##ed	O
case	O
-	O
control	O
study	O
,	O
nutrition	O
,	O
meta	O
##bol	O
##ite	O

In	O
this	O
group	O
of	O
patients	O
,	O
sensitivity	O
and	O
specific	O
##ity	O
above	O
80	O
%	O
were	O
obtained	O
for	O
several	O
combinations	O
of	O
three	O
to	O
five	O
meta	O
##bol	O
##ites	O
,	O
including	O
co	B
##rt	I
##is	I
##ol	I
and	O
various	O
amino	O
acids	O
,	O
in	O
addition	O
to	O
c	B
##ys	I
##tein	I
##e	I
and	O
u	B
##rid	I
##ine	I
.	O

U	O
##rine	O
analysis	O
in	O
a	O
pre	O
-	O
surgical	O
patient	O
population	O
suggested	O
products	O
of	O
met	B
##hi	I
##oni	I
##ne	I
cat	O
##ab	O
##olis	O
##m	O
might	O
co	O
##rrel	O
##ate	O
with	O
pro	O
##state	O
cancer	O
progression	O
status	O
.	O

In	O
summary	O
,	O
our	O
results	O
show	O
that	O
g	B
##lut	I
##ami	I
##c	I
acid	I
,	O
v	B
##ali	I
##ne	I
,	O
le	B
##uc	I
##ine	I
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
alpha	B
to	I
##co	I
##pher	I
##ol	I
,	O
and	O
ch	B
##ole	I
##ster	I
##ol	I
are	O
up	O
-	O
regulated	O
in	O
HC	O
##C	O
vs	O
.	O
c	O
##ir	O
##r	O
##hos	O
##is	O
,	O
while	O
c	B
##it	I
##ric	I
acid	I
,	O
la	B
##ctic	I
acid	I
,	O
and	O
so	B
##rb	I
##ose	I
are	O
down	O
-	O
regulated	O
.	O

A	O
##Z	O
##A	O
is	O
converted	O
to	O
6	O
-	O
MP	O
by	O
g	B
##lut	I
##ath	I
##ione	I
S	O
-	O
transfer	O
##ase	O
,	O
which	O
then	O
undergo	O
##es	O
complex	O
metabolism	O
involving	O
three	O
competing	O
pathways	O
that	O
are	O
cat	O
##aly	O
##zed	O
by	O
T	O
##PM	O
##T	O
,	O
X	O
##O	O
and	O
H	O
##GP	O
##RT	O

The	O
main	O
,	O
highly	O
significant	O
finding	O
of	O
our	O
study	O
was	O
that	O
la	B
##ct	I
##ate	I
(	O
Discovery	O
group	O
:	O
p	O
<	O
1	O
.	O
6	O
##x	O
##10	O
-	O
6	O
,	O
q	O
=	O
0	O
.	O
00	O
;	O
Test	O
group	O
:	O
p	O
=	O
0	O
.	O
00	O
##3	O
;	O
q	O
=	O
0	O
.	O
04	O
##7	O
)	O
and	O
p	B
##yr	I
##u	I
##vate	I
(	O
Discovery	O
group	O
:	O
p	O
=	O
0	O
.	O
01	O
##7	O
,	O
q	O
=	O
0	O
.	O
27	O
;	O
Test	O
group	O
:	O
p	O
=	O
0	O
.	O
01	O
##0	O
,	O
q	O
=	O
0	O
.	O
10	O
)	O
,	O
two	O
products	O
of	O
an	O
##ae	O
##ro	O
##bic	O
re	O
##spiration	O
in	O
g	O
##ly	O
##co	O
##lysis	O
,	O
were	O
significantly	O
elevated	O
in	O
the	O
PT	O
##SD	O
-	O
positive	O
subjects	O
compared	O
to	O
the	O
PT	O
##SD	O
negative	O
subjects	O
.	O

We	O
could	O
not	O
identify	O
significant	O
treatment	O
-	O
related	O
changes	O
in	O
meta	O
##bol	O
##ite	O
profiles	O
of	O
the	O
urine	O
samples	O
in	O
the	O
H	B
##V	I
group	O
.	O

Arab	B
##ino	I
##se	I
is	O
a	O
mon	B
##osa	I
##cc	I
##hari	I
##de	I
containing	O
five	O
carbon	O
atoms	O
and	O
is	O
de	O
##com	O
##posed	O
into	O
glucose	S
and	O
f	B
##ru	I
##ct	I
##ose	I
by	O
in	O
##test	O
##inal	O
su	B
##c	I
##rose	I
.	O

The	O
lower	O
levels	O
of	O
hip	B
##pur	I
##ic	I
acid	I
found	O
in	O
our	O
BC	O
urine	O
##s	O
compared	O
to	O
control	O
samples	O
are	O
in	O
agreement	O
with	O
previous	O
works	O
[	O
,	O
]	O
.	O

The	O
function	O
of	O
my	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
as	O
an	O
o	O
##smo	O
##re	O
##gu	O
##lator	O
in	O
different	O
stages	O
of	O
ma	O
##li	O
##gnant	O
transformation	O
could	O
be	O
a	O
further	O
explanation	O
for	O
our	O
results	O
.	O

In	O
experimental	O
models	O
,	O
plate	O
##let	O
-	O
act	O
##ivating	O
factor	O
(	O
PA	O
##F	O
)	O
has	O
been	O
shown	O
to	O
increase	O
ad	B
##rena	I
##l	I
co	I
##rt	I
##is	I
##ol	I
secret	O
##ion	O
.	O

A	O
paper	O
disc	O
of	O
3	O
mm	O
in	O
diameter	O
was	O
punched	O
from	O
the	O
DB	O
##S	O
filter	O
paper	O
(	O
equivalent	O
to	O
3	O
.	O
2	O
μ	O
##l	O
whole	O
blood	O
)	O
,	O
placed	O
into	O
a	O
well	O
in	O
Mill	O
##ip	O
##ore	O
Multi	O
##S	O
##cre	O
##en	O
H	B
##V	I
96	O
‐	O
well	O
plate	O
(	O
Tu	O
##lla	O
##green	O
,	O
Ireland	O
)	O
,	O
and	O
subjected	O
to	O
meta	O
##bol	O
##ite	O
extraction	O
.	O

Furthermore	O
,	O
there	O
were	O
significant	O
inverse	O
correlation	O
##s	O
between	O
AD	O
##HD	O
s	O
##ym	O
##pt	O
##om	O
scores	O
and	O
try	B
##pt	I
##op	I
##han	I
and	O
k	B
##yn	I
##uren	I
##ine	I
even	O
when	O
adjusting	O
for	O
smoking	O
and	O
age	O
(	O
Table	O
)	O
.	O

We	O
investigated	O
the	O
presence	O
of	O
g	O
##er	O
##m	O
##line	O
and	O
so	O
##matic	O
variants	O
in	O
four	O
genes	O
involved	O
in	O
p	B
##yr	I
##im	I
##id	I
##ine	I
metabolism	O
:	O
CA	O
##D	O
,	O
D	O
##H	O
##OD	O
##H	O
,	O
U	O
##MP	O
##S	O
,	O
T	O
##Y	O
##MS	O
.	O

The	O
limits	O
of	O
detection	O
(	O
L	O
##OD	O
)	O
were	O
IL	B
-	I
1	I
##β	I
(	I
0	I
.	I
36	I
p	I
##g	I
/	I
m	I
##L	I
)	I
,	O
IL	O
-	O
2	O
(	O
0	O
.	O
35	O
p	O
##g	O
/	O
m	O
##L	O
)	O
,	O
IL	O
-	O
6	O
(	O
0	O
.	O
27	O
p	O
##g	O
/	O
m	O
##L	O
)	O
,	O
IL	O
-	O
8	O
(	O
0	O
.	O
09	O
p	O
##g	O
/	O
m	O
##L	O
)	O
,	O
IL	O
-	O
10	O
(	O
0	O
.	O
21	O
p	O
##g	O
/	O
m	O
##L	O
)	O
,	O
IL	O
-	O
12	O
##p	O
##70	O
(	O
1	O
.	O
4	O
p	O
##g	O
/	O
m	O
##L	O
)	O
,	O
T	O
##NF	O
-	O
α	O
,	O
(	O
0	O
.	O
5	O
p	O
##g	O
/	O
m	O
##L	O
)	O
,	O
IF	O
##N	O
-	O
γ	O
(	O
0	O
.	O
74	O
p	O
##g	O
/	O
m	O
##L	O
)	O
,	O
and	O
GM	O
-	O
CS	O
##F	O
(	O
0	O
.	O
20	O
p	O
##g	O
/	O
m	O
##L	O
)	O
.	O

In	O
our	O
study	O
,	O
elevated	O
level	O
of	O
car	B
##ni	I
##tine	I
and	O
reduced	O
levels	O
of	O
v	B
##ale	I
##ryl	I
##car	I
##ni	I
##tine	I
and	O
prop	B
##ion	I
##yl	I
##car	I
##ni	I
##tine	I
were	O
indicated	O
as	O
blood	O
metabolic	O
signatures	O
of	O
N	O
##SC	O
##LC	O
.	O

Other	O
clinical	O
CS	O
##F	O
parameters	O
,	O
such	O
as	O
white	O
blood	O
cell	O
(	O
W	O
##BC	O
)	O
count	O
,	O
total	O
protein	O
level	O
,	O
glucose	S
level	O
,	O
L	O
##D	O
##H	O
level	O
,	O
and	O
c	O
##yt	O
##ology	O
were	O
also	O
ta	O
##bula	O
##ted	O
.	O

In	O
the	O
Con	O
A	O
-	O
treated	O
eyes	O
,	O
the	O
comparison	O
between	O
eyes	O
with	O
sa	B
##line	I
administration	O
(	B
sa	B
##line	I
group	O
)	O
and	O
those	O
with	O
drug	O
administration	O
was	O
analyzed	O
by	O
Dunn	O
##ett	O
'	O
s	O
test	O
(	O
1	O
-	O
sided	O
)	O
.	O

The	O
timing	O
and	O
total	O
volume	O
were	O
recorded	O
,	O
and	O
the	O
samples	O
(	O
2	O
m	O
##L	O
)	O
of	O
urine	O
were	O
stored	O
at	O
−	O
##80	O
##°	O
##C	O
for	O
the	O
ass	O
##ay	O
of	O
der	O
##ivate	O
##s	O
of	O
AA	O
by	O
C	O
##YP	O
metabolism	O
after	O
the	O
addition	O
of	O
de	O
##uter	O
##ated	O
20	B
-	I
H	I
##ET	I
##E	I
(	O
C	O
##ayman	O
Chemical	O
Co	O
)	O
,	O
D	O
##H	O
##ET	O
,	O
8	B
,	I
9	I
-	I
E	I
##ET	I
,	O
11	B
,	I
12	I
-	I
E	I
##ET	I
,	O
and	O
14	B
,	I
15	I
-	I
E	I
##ET	I
(	O
B	O
##io	O
##mo	O
##l	O
)	O
as	O
internal	O
standards	O
.	O

Although	O
there	O
were	O
expected	O
differences	O
in	O
medication	O
use	O
between	O
G	O
##WI	O
and	O
controls	O
,	O
the	O
meta	O
##bol	O
##omi	O
##c	O
profile	O
described	O
below	O
was	O
not	O
significantly	O
correlated	O
with	O
any	O
of	O
the	O
observed	O
medication	O
uses	O
and	O
none	O
is	O
known	O
to	O
produce	O
a	O
pattern	O
of	O
increased	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
and	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
found	O
.	O

Other	O
reports	O
have	O
shown	O
that	O
the	O
plasma	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
are	O
decreased	O
in	O
o	O
##var	O
##ian	O
cancer	O
whereas	O
increased	O
in	O
breast	O
cancer	O
patients	O
[	O
,	O
]	O
.	O

We	O
have	O
also	O
demonstrated	O
that	O
f	B
##oll	I
##ista	I
##tin	I
increases	O
initially	O
and	O
then	O
returns	O
to	O
base	O
##line	O
.	O

There	O
was	O
a	O
trend	O
towards	O
reduced	O
o	O
##xi	O
##dized	O
L	B
##D	I
##L	I
ch	I
##ole	I
##ster	I
##ol	I
in	O
the	O
O	O
##EP	O
-	O
treated	O
group	O
,	O
but	O
this	O
was	O
not	O
significant	O
either	O
with	O
respect	O
to	O
time	O
or	O
compared	O
to	O
the	O
control	O
treatment	O
.	O

Research	O
has	O
shown	O
that	O
a	B
##rg	I
##ini	I
##ne	I
was	O
required	O
for	O
sperm	O
production	O
,	O
and	O
a	B
##rg	I
##ini	I
##ne	I
supplement	O
##ation	O
can	O
help	O
to	O
boost	O
healthy	O
sperm	O
count	O
and	O
improve	O
fertility	O
.	O

There	O
were	O
nine	O
specimens	O
in	O
the	O
training	O
set	O
,	O
and	O
two	O
specimens	O
in	O
the	O
valid	O
##ation	O
set	O
with	O
a	O
ratio	O
between	O
0	O
.	O
5	O
and	O
1	O
;	O
the	O
significance	O
of	O
this	O
ratio	O
is	O
unknown	O
,	O
although	O
some	O
of	O
those	O
were	O
classified	O
as	O
normal	O
and	O
some	O
as	O
cancer	O
by	O
H	O
&	O
E	O
.	O
N	O
##eg	O
##ative	O
ion	O
mode	O
DE	O
##SI	O
-	O
MS	O
ion	O
signal	O
intensity	O
ratios	O
for	O
glucose	B
/	I
c	I
##it	I
##rate	I
are	O
plot	O
##ted	O
for	O
(	O
A	O
)	O
the	O
training	O
set	O
(	O
18	O
ben	O
##ign	O
and	O
18	O
cancer	O
specimens	O
)	O
,	O
and	O
(	O
B	O
)	O
the	O
valid	O
##ation	O
set	O
(	O
10	O
ben	O
##ign	O
and	O
8	O
cancer	O
specimens	O
)	O
by	O
averaging	O
the	O
ion	O
signals	O
of	O
glucose	S
and	O
c	B
##it	I
##rate	I
from	O
all	O
p	O
##ixel	O
##s	O
acquired	O
from	O
the	O
individual	O
tissue	O
sample	O
.	O

Al	O
##b	O
is	O
critical	O
for	O
maintaining	O
co	O
##llo	O
##idal	O
o	O
##smo	O
##tic	O
pressure	O
and	O
re	O
##vers	O
##ibly	O
binds	O
hormones	O
,	O
none	O
##ster	O
##ified	O
long	O
chain	O
fatty	O
acids	O
,	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
bill	O
##ir	O
##ubi	O
##n	O
,	O
hem	O
##in	O
,	O
and	O
many	O
x	O
##eno	O
##biotic	O
compounds	O
,	O
including	O
therapeutic	O
drugs	O
.	O
_	O
,	O
Many	O
commonly	O
used	O
drugs	O
contain	O
acidic	O
or	O
basic	O
functional	O
groups	O
,	O
such	O
as	O
war	O
##fari	O
##n	O
,	O
di	B
##az	I
##ep	I
##am	I
,	O
and	O
i	B
##bu	I
##p	I
##ro	I
##fen	I
.	O

In	O
this	O
paper	O
we	O
described	O
the	O
development	O
,	O
valid	O
##ation	O
and	O
application	O
of	O
a	O
UP	O
##LC	O
–	O
MS	O
/	O
MS	O
method	O
for	O
the	O
q	O
##uant	O
##ification	O
of	O
ve	O
##mura	O
##fen	O
##ib	O
,	O
co	B
##bi	I
##met	I
##ini	I
##b	I
,	O
da	O
##bra	O
##fen	O
##ib	O
,	O
cab	B
##oz	I
##anti	I
##ni	I
##b	I
,	O
re	O
##gor	O
##af	O
##eni	O
##b	O
plus	O
meta	O
##bol	O
##ite	O
re	O
##gor	O
##af	O
##eni	O
##b	O
M	O
##2	O
,	O
ni	O
##rap	O
##ari	O
##b	O
and	O
o	O
##lap	O
##ari	O
##b	O
.	O

For	O
the	O
analysis	O
of	O
the	O
dependence	O
of	O
the	O
response	O
(	O
[UNK]	O
value	O
)	O
of	O
selected	O
variables	O
on	O
the	O
corresponding	O
change	O
in	O
Omega	B
-	I
3	I
Ph	O
##L	O
Index	O
(	O
[UNK]	O
Omega	B
-	I
3	I
Ph	O
##L	O
Index	O
)	O
,	O
a	O
linear	O
re	O
##gression	O
model	O
with	O
du	O
##mmy	O
variables	O
that	O
indicate	O
a	O
subgroup	O
Place	O
##bo	O
,	O
Pi	O
##o	O
,	O
Omega	B
-	I
3	I
,	O
and	O
Pi	O
##o	O
&	O
Omega	B
-	I
3	I
,	O
respectively	O
,	O
was	O
used	O
.	O

Over	O
##p	O
##rod	O
##uction	O
of	O
ad	O
##rena	O
##l	O
and	O
##rogen	O
precursor	O
##s	O
,	O
de	B
##hy	I
##dr	I
##oe	I
##pian	I
##dr	I
##osterone	I
(	O
D	O
##H	O
##EA	O
)	O
and	O
and	B
##ros	I
##ten	I
##ed	I
##ione	I
,	O
is	O
rare	O
##r	O
but	O
may	O
pose	O
diagnostic	O
problems	O
,	O
in	O
particular	O
in	O
women	O
with	O
a	O
relatively	O
small	O
ad	O
##rena	O
##l	O
mass	O
and	O
a	O
p	O
##hen	O
##otype	O
resembling	O
p	O
##oly	O
##cy	O
##stic	O
o	O
##vary	O
syndrome	O
.	O

Pilot	O
experiments	O
that	O
were	O
performed	O
using	O
HP	O
##LC	O
methods	O
with	O
UV	O
and	O
fluorescent	O
detection	O
to	O
identify	O
any	O
potential	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
o	O
##xi	O
##da	O
##tive	O
meta	O
##bol	O
##ites	O
or	O
to	O
determine	O
the	O
disappearance	O
of	O
the	O
parent	O
drug	O
from	O
the	O
micro	O
##so	O
##mal	O
in	O
##cu	O
##bate	O
##s	O
consisting	O
of	O
H	O
##LM	O
##s	O
and	O
co	O
##fa	O
##ctors	O
were	O
non	O
##in	O
##form	O
##ative	O
.	O

In	O
another	O
review	O
,	O
Bern	O
##ini	O
et	O
.	O
al	O
stated	O
that	O
g	O
##ly	O
##co	O
##lysis	O
is	O
somehow	O
impaired	O
in	O
CD	O
explaining	O
both	O
a	O
lowering	O
of	O
la	B
##ct	I
##ate	I
levels	O
and	O
an	O
increase	O
of	O
glucose	S
levels	O
in	O
blood	O
.	O

Further	O
,	O
g	B
##lut	I
##ami	I
##c	I
acid	I
(	O
5	O
)	O
and	O
g	B
##lut	I
##amine	I
(	O
7	O
)	O
were	O
significantly	O
decreased	O
(	O
0	O
.	O
72	O
-	O
fold	O
)	O
and	O
increased	O
(	O
1	O
.	O
19	O
-	O
fold	O
)	O
in	O
DR	O
subjects	O
,	O
respectively	O
(	O
Table	O
S	O
##2	O
)	O
.	O

Countries	O
of	O
origin	O
included	O
Colombia	O
,	O
Dominican	O
Republic	O
,	O
E	O
##quatorial	O
Guinea	O
,	O
Ireland	O
(	O
ex	O
-	O
South	O
Africa	O
)	O
,	O
Peru	O
,	O
and	O
cases	O
imported	O
into	O
the	O
United	O
States	O
from	O
India	O
and	O
the	O
Philippines	S
.	O

Here	O
,	O
we	O
used	O
mass	O
s	O
##pect	O
##rome	O
##try	O
to	O
measure	O
the	O
abundance	O
of	O
>	O
60	O
s	O
##tero	O
##l	O
and	O
vitamin	B
D	I
derivatives	O
in	O
3	O
,	O
230	O
serum	O
samples	O
from	O
a	O
well	O
-	O
p	O
##hen	O
##otype	O
##d	O
patient	O
population	O
.	O

Inter	O
##ind	O
##iv	O
##id	O
##ual	O
variation	O
in	O
the	O
levels	O
of	O
these	O
anal	O
##yte	O
##s	O
ranged	O
from	O
as	O
little	O
as	O
31	O
-	O
fold	O
(	B
24	B
##S	I
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
)	O
to	O
as	O
large	O
as	O
7	O
,	O
760	O
-	O
fold	O
(	O
24	O
-	O
di	O
##hy	O
##dr	O
##ola	O
##nos	O
##tero	O
##l	O
)	O
.	O

All	O
of	O
the	O
candidate	O
F	O
##IB	O
##s	O
for	O
milk	O
intake	O
identified	O
by	O
G	O
##C	O
-	O
MS	O
in	O
the	O
serum	O
samples	O
(	B
la	B
##ct	I
##ose	I
,	O
gal	B
##act	I
##ose	I
,	O
gal	B
##act	I
##ito	I
##l	I
,	O
gal	B
##act	I
##ona	I
##te	I
,	O
and	O
gal	B
##act	I
##ono	I
-	I
1	I
,	I
5	I
-	I
la	I
##cton	I
##e	I
)	O
have	O
already	O
been	O
identified	O
and	O
discussed	O
in	O
details	O
in	O
the	O
urine	O
samples	O
of	O
the	O
same	O
study	O
.	O

It	O
has	O
been	O
shown	O
that	O
di	B
##hy	I
##dr	I
##ores	I
##ver	I
##at	I
##rol	I
could	O
be	O
produced	O
as	O
an	O
end	O
-	O
product	O
or	O
trans	O
##ient	O
intermediate	O
,	O
depending	O
on	O
the	O
donor	O
,	O
so	O
the	O
high	O
per	O
##sistence	O
of	O
di	B
##hy	I
##dr	I
##ores	I
##ver	I
##at	I
##rol	I
in	O
the	O
present	O
study	O
might	O
only	O
be	O
an	O
observed	O
effect	O
particular	O
to	O
our	O
donors	O
.	O

500	O
µ	O
##l	O
of	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
was	O
added	O
to	O
500	O
µ	O
##l	O
of	O
obtained	O
plasma	O
,	O
and	O
then	O
the	O
solution	O
was	O
placed	O
into	O
the	O
ice	O
for	O
10	O
min	O
,	O
then	O
it	O
was	O
mixed	O
using	O
a	O
v	O
##ortex	O
-	O
shake	O
##r	O
during	O
30	O
s	O
with	O
the	O
further	O
cent	O
##ri	O
##fu	O
##gation	O
at	O
10	O
,	O
000	O
rpm	O
/	O
min	O
during	O
10	O
min	O
.	O

Low	O
my	B
##oi	I
##nos	I
##ito	I
##l	I
levels	O
have	O
been	O
observed	O
in	O
A	O
##Q	O
##P	O
##4	O
-	O
A	O
##b	O
N	O
##MO	O
##SD	O
compared	O
with	O
MS	O
after	O
transverse	O
my	O
##eli	O
##tis	O
using	O
_	O
1	O
H	O
magnetic	O
resonance	O
s	O
##pect	O
##ros	O
##copy	O
(	O
MR	O
##S	O
)	O
of	O
the	O
spinal	O
cord	O
,	O
reflecting	O
as	O
##tro	O
##cy	O
##tic	O
ne	O
##c	O
##rosis	O
.	O

These	O
data	O
and	O
the	O
findings	O
obtained	O
in	O
previous	O
studies	O
suggest	O
that	O
enhanced	O
g	B
##ly	I
##co	I
##ly	I
##tic	I
activity	O
in	O
tumor	O
tissues	O
may	O
be	O
accompanied	O
by	O
a	O
der	O
##eg	O
##ulation	O
of	O
lip	O
##id	O
and	O
amino	O
acid	O
metabolism	O
during	O
c	O
##er	O
##vic	O
##al	O
car	O
##cin	O
##ogen	O
##esis	O
.	O

Although	O
previous	O
studies	O
have	O
employed	O
liquid	O
ch	O
##roma	O
##tography	O
to	O
q	O
##uant	O
##ify	O
im	B
##ati	I
##ni	I
##b	I
and	O
its	O
meta	O
##bol	O
##ite	O
(	O
C	O
##GP	O
##7	O
##45	O
##8	O
##8	O
)	O
,	O
the	O
objective	O
of	O
the	O
present	O
study	O
was	O
to	O
develop	O
and	O
fully	O
valid	O
##ate	O
a	O
method	O
that	O
q	O
##uant	O
##ifies	O
im	B
##ati	I
##ni	I
##b	I
and	O
its	O
meta	O
##bol	O
##ite	O
in	O
human	O
serum	O
using	O
U	O
##FL	O
##C	O
-	O
MS	O
with	O
a	O
single	O
q	O
##uad	O
##rup	O
##ole	O
mass	O
detector	O
adapted	O
for	O
routine	O
laboratory	O
application	O
.	O

A	O
number	O
of	O
meta	O
##bol	O
##ites	O
,	O
including	O
a	O
range	O
of	O
amino	O
acids	O
,	O
sa	B
##cc	I
##hari	I
##des	I
(	I
glucose	I
,	I
ma	I
##lt	I
##ose	I
,	I
gal	I
##act	I
##ose	I
)	I
,	O
energy	O
metabolism	O
related	O
molecules	O
(	O
p	O
##yr	O
##u	O
##vate	O
,	O
su	B
##cci	I
##nate	I
,	O
c	B
##it	I
##rate	I
,	O
la	B
##ct	I
##ate	I
,	O
c	B
##rea	I
##tine	I
,	O
c	O
##rea	O
##tin	O
##ine	O
)	O
,	O
and	O
others	O
(	B
ch	B
##olin	I
##es	I
,	O
am	O
##ines	O
and	O
amid	B
##es	I
)	O
were	O
identified	O
based	O
on	O
comparison	O
with	O
the	O
Chen	O
##om	O
##x	O
meta	O
##bol	O
##ite	O
database	O
,	O
as	O
well	O
as	O
2D	O
_	O
1	O
H	O
–	O
_	O
13	O
C	O
H	O
##S	O
##Q	O
##C	O
and	O
_	O
1	O
H	O
–	O
_	O
1	O
H	O
TO	O
##CS	O
##Y	O
N	O
##MR	O
experiments	O
(	O
see	O
a	O
complete	O
list	O
of	O
meta	O
##bol	O
##ites	O
in	O
the	O
Supporting	O
Information	O
,	O
Table	O
2	O
##S	O
)	O
.	O

El	O
##eva	O
##ted	O
levels	O
of	O
c	O
##y	O
##c	O
##lo	O
##ox	O
##y	O
##gen	O
##ase	O
(	O
CO	O
##X	O
)	O
-	O
derived	O
pro	B
##sta	I
##g	I
##land	I
##in	I
E	O
_	O
2	O
(	O
P	O
##GE	O
_	O
2	O
)	O
occur	O
in	O
in	O
##f	O
##lam	O
##ed	O
tissues	O
.	O

All	O
these	O
meta	O
##bol	O
##ites	O
are	O
car	B
##box	I
##yl	I
##ic	I
acids	I
;	O
four	O
are	O
fatty	O
acids	O
,	O
two	O
saturated	O
and	O
two	O
un	O
##sat	O
##ura	O
##ted	O
.	O

Ace	B
##tone	I
,	O
ch	B
##olin	I
##e	I
,	O
u	B
##rea	I
,	O
1	B
,	I
3	I
-	I
dim	I
##eth	I
##yl	I
##ura	I
##te	I
,	O
c	B
##rea	I
##tin	I
##ine	I
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
my	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
,	O
le	B
##uc	I
##ine	I
,	O
and	O
3	O
-	O
OH	O
but	B
##yra	I
##te	I
;	O
saturated	O
and	O
mon	O
##ou	O
##ns	O
##at	O
##ura	O
##ted	O
a	O
##cy	O
##l	O
groups	O
of	O
ω	O
–	O
9	O
,	O
ω	O
–	O
7	O
,	O
ω	O
–	O
6	O
,	O
ω	O
–	O
3	O
,	O
and	O
fatty	O
acid	O
,	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
,	O
1	B
,	I
3	I
-	I
D	I
##G	I
,	O
1	O
-	O
MG	O
,	O
and	O
un	O
##ass	O
##ign	O
##ed	O
component	O
signal	O
at	O
3	O
.	O
33	O
pp	O
##m	O
were	O
the	O
most	O
important	O
signal	O
compounds	O
in	O
group	O
separation	O
.	O

This	O
study	O
also	O
did	O
not	O
identify	O
strong	O
pro	O
##gno	O
##stic	O
markers	O
of	O
AP	S
,	O
though	O
pre	O
-	O
ER	O
##CP	O
lip	O
##ase	O
levels	O
were	O
somewhat	O
elevated	O
in	O
those	O
who	O
went	O
on	O
to	O
develop	O
AP	S
.	O

A	B
##bir	I
##ater	I
##one	I
is	O
meta	O
##bol	O
##ized	O
in	O
patients	O
to	O
a	O
more	O
potent	O
analogue	O
,	O
D	O
##4	O
##A	O
.	O

Multi	O
##var	O
##iate	O
analysis	O
preserved	O
the	O
relationship	O
observed	O
between	O
H	O
##OM	O
##A	O
and	O
g	B
##ly	I
##cine	I
(	O
negative	O
correlation	O
)	O
.	O

The	O
only	O
meta	O
##bol	O
##ite	O
of	O
re	B
##s	I
##ver	I
##at	I
##rol	I
detected	O
in	O
our	O
model	O
was	O
di	B
##hy	I
##dr	I
##ores	I
##ver	I
##at	I
##rol	I
,	O
which	O
was	O
not	O
further	O
meta	O
##bol	O
##ized	O
and	O
remained	O
stable	O
in	O
the	O
co	O
##lon	O
environment	O
.	O

Si	O
##ly	O
##bin	O
am	O
##eli	O
##ora	O
##tes	O
the	O
harmful	O
BP	O
##A	O
-	O
induced	O
effect	O
decreasing	O
glucose	S
up	O
##take	O
and	O
lip	O
##id	O
per	O
##ox	O
##ida	O
##tion	O
.	O

Mean	O
daily	O
alcohol	O
consumption	O
was	O
calculated	O
using	O
beverage	O
-	O
specific	O
pure	O
ethanol	S
volume	O
proportions	O
.	O

24	B
##S	I
-	I
H	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
[	I
ch	I
##ole	I
##st	I
-	I
5	I
-	I
en	I
##e	I
-	I
3	I
-	I
beta	I
,	I
24	I
##S	I
-	I
di	I
##ol	I
]	I
,	O
25	B
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
[	I
ch	I
##ole	I
##st	I
-	I
5	I
-	I
en	I
##e	I
-	I
3	I
-	I
beta	I
,	I
25	I
-	I
di	I
##ol	I
]	I
,	O
27	B
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
[	I
ch	I
##ole	I
##st	I
-	I
5	I
-	I
en	I
##e	I
-	I
3	I
##bet	I
##a	I
,	I
27	I
-	I
di	I
##ol	I
]	I
,	O
24	O
(	O
R	O
/	O
S	O
)	O
-	O
h	O
##ydro	O
##xy	O
##cho	O
##les	O
##tero	O
##l	O
-	O
d	O
##6	O
[	B
26	B
,	I
26	I
,	I
26	I
,	I
27	I
,	I
27	I
,	I
27	I
-	I
he	I
##xa	I
##de	I
##uter	I
##och	I
##ole	I
##st	I
-	I
5	I
-	I
en	I
##e	I
-	I
3	I
beta	O
,	O
24	O
-	O
di	O
##ol	O
]	O
,	O
25	B
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
-	I
d	I
##6	I
[	I
26	I
,	I
26	I
,	I
26	I
,	I
27	I
,	I
27	I
,	I
27	I
-	I
he	I
##xa	I
##de	I
##uter	I
##och	I
##ole	I
##st	I
-	I
5	I
-	I
en	I
##e	I
-	I
3	I
beta	I
,	I
25	I
-	I
di	I
##ol	I
]	I
and	O
27	B
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
-	I
d	I
##6	I
[	I
25	I
,	I
26	I
,	I
26	I
,	I
26	I
,	I
27	I
,	I
27	I
-	I
he	I
##xa	I
##de	I
##uter	I
##och	I
##ole	I
##st	I
-	I
5	I
-	I
en	I
##e	I
-	I
3	I
beta	I
,	I
27	I
-	I
di	I
##ol	I
]	I
were	O
obtained	O
from	O
Ava	O
##nti	O
Polar	O
Li	O
##pid	O
##s	O
(	O
Alabama	O
,	O
USA	O
)	O
.	O

It	O
is	O
involved	O
in	O
various	O
metabolic	O
pathways	O
in	O
body	O
and	O
its	O
altered	O
levels	O
are	O
also	O
reported	O
in	O
color	O
##ec	O
##tal	O
cancer	O
,	O
breast	O
cancer	O
,	O
e	B
##os	I
##ino	I
##phi	I
##lic	I
es	O
##op	O
##ha	O
##git	O
##is	O
and	O
gas	O
##tro	O
##es	O
##op	O
##hage	O
##al	O
re	O
##f	O
##lux	O
disease	O
.	O

For	O
data	O
acquisition	O
,	O
scheduled	O
MR	O
##M	O
experiments	O
without	O
EP	O
##I	O
s	O
##pect	O
##ra	O
acquisition	O
were	O
performed	O
to	O
obtain	O
reliable	O
peak	O
areas	O
for	O
all	O
meta	O
##bol	O
##ite	O
a	B
##gly	I
##con	I
##es	I
,	O
as	O
well	O
as	O
J	O
##W	O
##H	O
-	O
01	O
##8	O
h	B
##ydro	I
##xy	I
##pent	I
##yl	I
g	I
##lu	I
##cu	I
##ron	I
##ide	I
.	O

One	O
of	O
them	O
is	O
fatty	O
acid	O
bio	O
##sy	O
##nt	O
##hesis	O
so	O
it	O
can	O
be	O
assumed	O
that	O
increase	O
in	O
palm	B
##itic	I
acid	I
is	O
compensate	O
##d	O
by	O
body	O
with	O
decrease	O
in	O
s	B
##te	I
##ari	I
##c	I
acid	I
to	O
sustain	O
the	O
regulation	O
of	O
fatty	O
acid	O
bio	O
##sy	O
##nt	O
##hesis	O
pathways	O
.	O

Within	O
15	O
min	O
of	O
urine	O
collection	O
,	O
samples	O
were	O
frozen	O
at	O
–	O
20	O
##°	O
##C	O
and	O
then	O
transferred	O
to	O
the	O
Environmental	O
Health	O
Center	O
(	O
C	O
##lu	O
##j	O
-	O
Na	O
##po	O
##ca	O
,	O
Romania	O
)	O
,	O
where	O
they	O
were	O
stored	O
until	O
analysis	O
for	O
co	B
##tin	I
##ine	I
,	O
a	O
##rsen	O
##ic	O
,	O
and	O
five	O
p	B
##ht	I
##hala	I
##te	I
mon	O
##oes	O
##ters	O
.	O

Lowe	O
##st	O
limit	O
of	O
q	O
##uant	O
##ification	O
(	O
LL	O
##O	O
##Q	O
)	O
were	O
set	O
to	O
11	O
nm	O
##ol	O
/	O
L	O
for	O
M	O
##3	O
##G	O
and	O
M	O
##6	O
##G	O
,	O
14	O
nm	O
##ol	O
/	O
L	O
for	O
M	O
##3	O
##S	O
and	O
M	O
##6	O
##S	O
,	O
and	O
18	O
nm	O
##ol	O
/	O
L	O
for	O
m	B
##or	I
##phine	I
##M	I
with	O
a	O
total	O
C	O
##V	O
of	O
7	O
.	O
3	O
–	O
19	O
%	O
(	O
n	O
=	O
25	O
)	O
.	O

There	O
were	O
no	O
significant	O
changes	O
in	O
my	B
##ost	I
##ati	I
##n	I
(	O
pre	O
-	O
event	O
:	O
13	O
,	O
67	O
##6	O
±	O
12	O
,	O
61	O
##7	O
p	O
##g	O
/	O
m	O
##l	O
,	O
C	O
##1	O
:	O
20	O
,	O
52	O
##8	O
±	O
15	O
,	O
59	O
##5	O
p	O
##g	O
/	O
m	O
##l	O
,	O
C	O
##2	O
:	O
10	O
,	O
65	O
##6	O
±	O
8	O
,	O
91	O
##5	O
p	O
##g	O
/	O
m	O
##l	O
,	O
post	O
-	O
event	O
:	O
15	O
,	O
172	O
±	O
5	O
,	O
66	O
##9	O
p	O
##g	O
/	O
m	O
##l	O
)	O
,	O
but	O
the	O
values	O
at	O
C	O
##1	O
and	O
C	O
##2	O
were	O
below	O
detect	O
##able	O
limits	O
for	O
one	O
participant	O
(	O
p	O
=	O
0	O
.	O
35	O
)	O
(	O
Figure	O
)	O
.	O

Second	O
##ly	O
,	O
g	B
##lut	I
##ama	I
##te	I
receptors	O
expressed	O
on	O
brain	O
end	O
##oth	O
##eli	O
##al	O
cells	O
play	O
an	O
important	O
role	O
in	O
regulating	O
the	O
function	O
of	O
the	O
B	O
##BB	O
.	O

In	O
plasma	O
,	O
an	O
app	O
##re	O
##cia	O
##ble	O
amount	O
of	O
LP	O
##C	O
is	O
in	O
the	O
lip	O
##op	O
##rote	O
##in	O
-	O
free	O
fraction	O
and	O
is	O
formed	O
from	O
le	B
##ci	I
##thin	I
:	O

By	O
analyzing	O
the	O
decline	O
of	O
plasma	O
BC	O
##AA	O
concentrations	O
in	O
response	O
to	O
glucose	S
ing	O
##est	O
##ion	O
in	O
our	O
study	O
,	O
we	O
could	O
show	O
that	O
BC	O
##AA	O
levels	O
were	O
persistent	O
##ly	O
higher	O
during	O
the	O
O	O
##G	O
##TT	O
in	O
adolescent	O
##s	O
with	O
I	O
##R	O
(	O
;	O
)	O
.	O

We	O
previously	O
reported	O
that	O
TD	O
##O	O
activity	O
increased	O
in	O
T	O
##NBC	O
cell	O
lines	O
under	O
anchor	O
##age	O
-	O
independent	O
conditions	O
,	O
resulting	O
in	O
increased	O
in	O
##tra	O
##cellular	O
and	O
secret	O
##ed	O
k	B
##yn	I
##uren	I
##ine	I
.	O

We	O
tested	O
if	O
the	O
ratio	O
between	O
3	O
-	O
H	O
##B	O
and	O
glucose	S
can	O
be	O
a	O
useful	O
clinical	O
criterion	O
for	O
pro	O
##gno	O
##sis	O
prediction	O
of	O
metabolic	O
surgery	O
.	O

A	O
further	O
subset	O
of	O
s	O
##pect	O
##ra	O
was	O
selected	O
from	O
the	O
remaining	O
38	O
##7	O
##7	O
urine	O
s	O
##pect	O
##ra	O
that	O
did	O
not	O
contain	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
meta	O
##bol	O
##ites	O
.	O

These	O
analyses	O
were	O
adjusted	O
for	O
age	O
,	O
race	O
,	O
sex	O
,	O
and	O
ch	B
##ole	I
##ster	I
##ol	I
levels	O
.	O

O	O
##DC	O
##1	O
in	O
##hibition	O
and	O
subsequent	O
p	B
##oly	I
##amine	I
de	O
##ple	O
##tion	O
prevented	O
T	O
##NF	O
##α	O
-	O
induced	O
a	O
##pop	O
##tosis	O
in	O
normal	O
in	O
##test	O
##inal	O
e	O
##pit	O
##hel	O
##ial	O
cells	O
.	O

Go	O
to	O
:	O
Li	O
##quid	O
ch	O
##roma	O
##to	O
##graphic	O
methods	O
with	O
atmospheric	O
pressure	O
chemical	O
ion	O
##ization	O
mass	O
s	O
##pect	O
##rome	O
##try	O
were	O
developed	O
for	O
the	O
determination	O
of	O
the	O
vitamin	B
D	I
meta	O
##bol	O
##ites	O
25	B
-	I
h	I
##ydro	I
##xy	I
##vi	I
##tam	I
##in	I
D	O
_	O
2	O
(	O
25	O
(	O
OH	O
)	O
D	O
_	O
2	O
)	O
,	O
25	B
-	I
h	I
##ydro	I
##xy	I
##vi	I
##tam	I
##in	I
D	O
_	O
3	O
(	O
25	O
(	O
OH	O
)	O
D	O
_	O
3	O
)	O
,	O
and	O
3	B
-	I
e	I
##pi	I
-	I
25	I
-	I
h	I
##ydro	I
##xy	I
##vi	I
##tam	I
##in	I
-	I
D	I
_	I
3	I
(	I
3	I
-	I
e	I
##pi	I
-	I
25	I
(	I
OH	I
)	I
D	I
_	I
3	I
)	I
in	O
the	O
four	O
Level	O
##s	O
of	O
SR	O
##M	O
97	O
##2	O
,	O
Vita	B
##min	I
D	I
in	O
Human	O
Ser	O
##um	O
.	O

E	O
##2	O
-	O
3	O
##G	O
-	O
17	O
##S	O
(	O
0	O
.	O
03	O
##7	O
pm	O
##ol	O
/	O
m	O
##L	O
,	O
equal	O
to	O
10	O
p	O
##g	O
/	O
m	O
##L	O
of	O
un	O
##con	O
##ju	O
##gated	O
E	O
##2	O
;	O
and	O
0	O
.	O
37	O
p	O
##g	O
/	O
m	O
##L	O
,	O
equal	O
to	O
100	O
p	O
##g	O
/	O
m	O
##L	O
of	O
un	O
##con	O
##ju	O
##gated	O
E	O
##2	O
)	O
as	O
well	O
as	O
the	O
internal	O
standards	O
were	O
spike	O
##d	O
to	O
0	O
.	O
1	O
m	O
##L	O
of	O
water	O
,	O
then	O
in	O
##cu	O
##bate	O
##d	O
with	O
0	O
.	O
1	O
m	O
##L	O
of	O
0	O
.	O
5	O
%	O
(	O
w	O
/	O
v	O
)	O
L	B
-	I
as	I
##cor	I
##bic	I
acid	I
,	O
0	O
.	O
2	O
m	O
##L	O
of	O
sodium	B
ace	I
##tate	I
buffer	O
(	O
200	O
m	O
##M	O
,	O
pH	O
5	O
.	O
0	O
)	O
,	O
and	O
10	O
µ	O
##L	O
of	O
β	O
-	O
g	O
##lu	O
##cu	O
##ron	O
##idas	O
##e	O
/	O
a	O
##ryl	O
##sul	O
##fa	O
##tase	O
at	O
37	O
°C	O
for	O
19	O
h	O
.	O

P	O
##las	O
##ma	O
contains	O
all	O
of	O
the	O
low	O
molecular	O
weight	O
meta	O
##bol	O
##ites	O
including	O
glucose	S
,	O
amino	O
acids	O
,	O
organic	O
acids	O
,	O
and	O
metabolic	O
intermediate	O
##s	O
and	O
end	O
-	O
products	O
.	O

Table	O
displays	O
the	O
distributions	O
of	O
age	O
,	O
B	O
##MI	O
,	O
U	O
##IC	O
##C	O
cancer	O
staging	O
of	O
the	O
patients	O
,	O
the	O
CA	O
19	O
-	O
9	O
,	O
bi	B
##li	I
##ru	I
##bin	I
,	O
and	O
H	O
##b	O
##A	O
##1	O
##c	O
concentrations	O
in	O
the	O
three	O
different	O
sample	O
sets	O
.	O

K	B
##yn	I
##uren	I
##ine	I
pathway	O
,	O
resting	O
-	O
state	O
functional	O
connectivity	O
,	O
ad	O
##ole	O
##scence	O
,	O
major	O
de	O
##pressive	O
disorder	O
,	O
an	O
##hed	O
##onia	O

Both	O
g	O
##ly	O
##cos	O
##yla	O
##tion	O
residues	O
may	O
carry	O
a	O
g	B
##ly	I
##can	I
,	O
but	O
those	O
g	B
##ly	I
##cans	I
may	O
be	O
missing	O
terminal	O
si	B
##ali	I
##c	I
acid	I
residues	O
and	O
end	O
with	O
gal	B
##act	I
##ose	I
,	O
man	B
##nose	I
,	O
or	O
N	B
-	I
ace	I
##ty	I
##l	I
##g	I
##lu	I
-	I
co	I
##sa	I
##mine	I
.	O

The	O
SP	O
##M	O
pathway	O
markers	O
such	O
as	O
17	B
-	I
HD	I
##HA	I
were	O
elevated	O
in	O
the	O
per	O
##ito	O
##ni	O
##tis	O
group	O
compared	O
to	O
control	O
group	O
and	O
could	O
serve	O
as	O
indicator	O
for	O
potential	O
SP	O
##M	O
formation	O
during	O
per	O
##ito	O
##ni	O
##tis	O
.	O

With	O
the	O
intention	O
of	O
studying	O
matrix	O
effect	O
(	O
ME	O
)	O
,	O
the	O
recovery	O
(	O
R	O
)	O
and	O
the	O
efficiency	O
of	O
the	O
process	O
(	O
P	O
##E	O
)	O
,	O
three	O
different	O
solutions	O
fortified	O
with	O
standards	O
at	O
30	O
ng	O
/	O
m	O
##l	O
and	O
IS	O
at	O
40	O
ng	O
/	O
m	O
##l	O
were	O
prepared	O
:	O
(	O
A	O
)	O
Me	B
##OH	I
solution	O
;	O
(	O
B	O
)	O
Extra	O
##cted	O
pool	O
##ed	O
plasma	O
,	O
spike	O
##d	O
prior	O
to	O
HP	O
##LC	O
injection	O
;	O
(	O
C	O
)	O
Su	O
##pp	O
##lement	O
##ed	O
pool	O
##ed	O
plasma	O
,	O
subsequently	O
submitted	O
to	O
the	O
extraction	O
procedure	O
.	O

Interest	O
##ingly	O
,	O
the	O
S	O
##1	O
##P	O
pathway	O
was	O
significantly	O
en	O
##rich	O
##ed	O
in	O
the	O
pro	B
##sta	I
##g	I
##land	I
##in	I
E	I
##2	I
expression	O
signature	O
;	O
thirteen	O
up	O
-	O
regulated	O
and	O
eight	O
down	O
-	O
regulated	O
genes	O
in	O
response	O
to	O
P	O
##GE	O
##2	O
treatment	O
were	O
determined	O
to	O
be	O
part	O
of	O
the	O
S	O
##1	O
##P	O
pathway	O
.	O

In	O
addition	O
,	O
the	O
met	O
##hyl	O
##ated	O
meta	O
##bol	O
##ites	O
4	B
-	I
Me	I
##O	I
-	I
E	I
##2	I
and	O
2	B
-	I
Me	I
##O	I
-	I
E	I
##2	I
could	O
potentially	O
serve	O
as	O
bio	O
##mark	O
##ers	O
of	O
cat	B
##ech	I
##ol	I
formation	O
.	O

We	O
focused	O
on	O
12	O
meta	O
##bol	O
##ites	O
that	O
have	O
previously	O
been	O
reported	O
to	O
be	O
bio	O
##mark	O
##er	O
candidates	O
;	O
_	O
13	O
,	O
_	O
14	O
i	O
##e	O
,	O
th	B
##re	I
##oni	I
##ne	I
,	O
met	B
##hi	I
##oni	I
##ne	I
,	O
a	B
##rab	I
##ino	I
##se	I
,	O
as	B
##par	I
##agi	I
##ne	I
,	O
x	B
##yl	I
##ito	I
##l	I
,	O
g	B
##lut	I
##amine	I
,	O
1	B
,	I
5	I
‐	I
AG	I
,	O
l	B
##ys	I
##ine	I
,	O
his	B
##ti	I
##dine	I
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
in	B
##os	I
##ito	I
##l	I
and	O
u	B
##ric	I
acid	I
.	O

In	O
patients	O
with	O
Alzheimer	O
’	O
s	O
disease	O
(	O
AD	O
)	O
,	O
decreased	O
plasma	O
levels	O
of	O
L	O
##yo	O
##PC	O
have	O
been	O
reported	O
,	O
suggesting	O
that	O
two	O
ta	O
##uo	O
##path	O
##ies	O
,	O
PS	O
##P	O
and	O
AD	O
,	O
might	O
share	O
a	O
disturbance	O
in	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
metabolism	O
,	O
leading	O
to	O
suppression	O
of	O
L	O
##ys	O
##o	O
##PC	O
synthesis	O
.	O

AL	O
##T	O
,	O
al	O
##ani	O
##ne	O
amino	O
##tra	O
##ns	O
##fer	O
##ase	O
;	O
AS	O
##T	O
,	O
as	O
##par	O
##tate	O
amino	O
##tra	O
##ns	O
##fer	O
##ase	O
;	O
B	O
##MI	O
,	O
body	O
mass	O
index	O
;	O
G	O
##F	O
##R	O
,	O
g	O
##lo	O
##mer	O
##ular	O
fi	O
##ltration	O
rate	O
;	O
HD	O
##L	O
,	O
high	O
-	O
density	O
lip	O
##op	O
##rote	O
##in	O
;	O
2	O
-	O
H	O
##B	O
,	O
2	B
-	I
H	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
;	O
3	O
-	O
H	O
##B	O
,	O
3	B
-	I
H	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
;	O
IL	O
-	O
6	O
,	O
inter	O
##le	O
##uki	O
##n	O
6	O
;	O
L	O
##D	O
##L	O
,	O
low	O
-	O
density	O
lip	O
##op	O
##rote	O
##in	O
;	O
MA	O
##P	O
,	O
mean	O
art	O
##erial	O
pressure	O
;	O

e	O
##G	O
##F	O
##R	O
,	O
estimated	O
g	O
##lo	O
##mer	O
##ular	O
fi	O
##ltration	O
ratio	O
;	O
AC	O
##E	O
##i	O
,	O
an	B
##gio	I
##tens	I
##in	I
converting	O
enzyme	O
inhibitor	O
;	O
AR	O
##B	O
,	O
an	B
##gio	I
##tens	I
##in	I
receptor	O
block	O
##er	O
.	O

Ce	B
##ram	I
##ides	I
are	O
thought	O
to	O
play	O
a	O
major	O
role	O
in	O
lip	O
##oto	O
##xi	O
##c	O
cellular	O
injury	O
,	O
while	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
species	O
have	O
been	O
previously	O
associated	O
with	O
stress	O
-	O
and	O
l	O
##igan	O
##d	O
-	O
induced	O
he	O
##pa	O
##to	O
##cellular	O
death	O
,	O
which	O
contributes	O
to	O
the	O
progression	O
of	O
several	O
liver	O
diseases	O
including	O
NAS	O
##H	O
.	O

The	O
so	O
##matic	O
surface	O
mutation	O
A	O
##37	O
##5	O
##S	O
in	O
Pat	O
##ient	O
4	O
lies	O
between	O
some	O
of	O
the	O
previously	O
reported	O
variants	O
;	O
therefore	O
,	O
whether	O
this	O
variant	O
per	O
se	O
results	O
in	O
raised	O
or	B
##ota	I
##te	I
merits	O
further	O
investigation	O
.	O

The	O
elevated	O
la	B
##ct	I
##ate	I
and	O
al	B
##ani	I
##ne	I
levels	O
observed	O
in	O
t	O
##umour	O
samples	O
compared	O
to	O
ben	O
##ign	O
samples	O
indicate	O
enhanced	O
g	O
##ly	O
##co	O
##lysis	O
(	O
Fi	O
##g	O
.	O

This	O
solution	O
was	O
di	O
##lut	O
##ed	O
to	O
70	O
%	O
ethanol	S
by	O
the	O
addition	O
of	O
0	O
.	O
4	O
m	O
##l	O
of	O
water	O
,	O
ultra	O
##sonic	O
##ated	O
for	O
2	O
min	O
,	O
and	O
cent	O
##ri	O
##fu	O
##ged	O
at	O
14	O
,	O
000	O
×	O
g	O
at	O
4	O
°C	O
for	O
30	O
min	O
.	O

A	O
##pop	O
##to	O
##tic	O
b	O
##le	O
##bs	O
,	O
another	O
form	O
of	O
E	O
##Vs	O
,	O
could	O
also	O
be	O
the	O
source	O
of	O
this	O
chain	O
-	O
specific	O
Ce	B
##r	I
signature	O
.	O

Ser	O
##um	O
est	B
##rogen	I
concentration	O
is	O
an	O
established	O
predict	O
##or	O
of	O
breast	O
cancer	O
risk	O
in	O
post	O
##men	O
##op	O
##aus	O
##al	O
women	O
,	O
but	O
whether	O
bio	O
##mark	O
##ers	O
of	O
est	B
##rogen	I
metabolism	O
also	O
predict	O
the	O
risk	O
of	O
breast	O
cancer	O
is	O
unclear	O
because	O
of	O
the	O
lack	O
of	O
accurate	O
,	O
re	O
##p	O
##rod	O
##uc	O
##ible	O
,	O
sensitive	O
,	O
and	O
high	O
-	O
through	O
##put	O
ass	O
##ays	O
for	O
est	B
##rogen	I
meta	O
##bol	O
##ites	O
.	O

0	O
.	O
7	O
mg	O
/	O
kg	O
·	O
min	O
;	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
and	O
insulin	O
-	O
mediated	O
suppression	O
of	O
end	O
##ogen	O
##ous	O
glucose	S
production	O
,	O
determined	O
during	O
the	O
210	O
-	O
to	O
240	O
-	O
min	O
period	O
of	O
the	O
e	B
##ug	I
##ly	I
##ce	I
##mic	I
insulin	O
c	O
##lamp	O
(	O
0	O
.	O
15	O
±	O
0	O
.	O
05	O
vs	O
.	O
0	O
.	O
05	O
±	O
0	O
.	O
00	O
mg	O
/	O
kg	O
·	O
min	O
;	O
P	O
<	O
0	O
.	O
05	O
)	O
were	O
enhanced	O
after	O
p	B
##io	I
##gli	I
##ta	I
##zone	I
treatment	O
.	O

The	O
method	O
also	O
provided	O
wide	O
dynamic	O
ranges	O
,	O
with	O
upper	O
linear	O
##ity	O
of	O
the	O
method	O
at	O
200	O
ng	O
/	O
m	O
##L	O
(	B
2	B
-	I
OH	I
-	I
N	I
##AP	I
,	O
1	B
-	I
OH	I
-	I
N	I
##AP	I
)	O
;	O
25	O
ng	O
/	O
m	O
##L	O
(	B
2	B
-	I
OH	I
-	I
FL	I
##U	I
)	O
;	O
20	O
ng	O
/	O
m	O
##L	O
(	B
Σ	B
##2	I
,	I
3	I
-	I
OH	I
-	I
P	I
##H	I
##E	I
)	O
;	O
and	O
10	O
ng	O
/	O
m	O
##L	O
(	B
3	B
-	I
OH	I
-	I
FL	I
##U	I
,	O
1	B
-	I
OH	I
-	I
P	I
##H	I
##E	I
,	O
4	B
-	I
OH	I
-	I
P	I
##H	I
##E	I
,	O
1	B
-	I
OH	I
-	I
P	I
##Y	I
##R	I
)	O
.	O

A	O
significant	O
difference	O
between	O
the	O
6	O
##h	O
-	O
i	O
##A	O
##UC	O
was	O
found	O
for	O
C	B
##15	I
:	I
0	I
,	O
but	O
not	O
for	O
C	B
##17	I
:	I
0	I
,	O
based	O
on	O
a	O
K	O
##rus	O
##kal	O
-	O
Wallis	O
test	O
of	O
the	O
three	O
food	O
groups	O
.	O

L	O
##C	O
–	O
P	O
##B	O
–	O
MS	O
/	O
MS	O
was	O
successful	O
in	O
analyzing	O
un	O
##sat	O
##ura	O
##ted	O
free	O
FA	O
##s	O
,	O
P	B
##G	I
,	O
and	O
P	O
##I	O
in	O
negative	O
ion	O
mode	O
.	O

It	O
was	O
shown	O
that	O
as	B
##par	I
##tic	I
acid	I
,	O
g	B
##lut	I
##amine	I
,	O
l	B
##ys	I
##ine	I
,	O
met	B
##hi	I
##oni	I
##ne	I
,	O
his	B
##ti	I
##dine	I
,	O
hip	B
##pur	I
##ic	I
acid	I
,	O
alpha	B
-	I
k	I
##eto	I
##g	I
##lut	I
##arate	I
,	O
g	B
##ly	I
##cer	I
##ald	I
##eh	I
##yd	I
##e	I
,	O
h	O
##ydro	O
##xy	O
##p	O
##rol	O
##ine	O
/	O
amino	O
##lev	O
##ulin	O
##ate	O
,	O
l	B
##ino	I
##le	I
##ic	I
acid	I
,	O
l	B
##ino	I
##len	I
##ic	I
acid	I
and	O
2	B
′	I
-	I
de	I
##ox	I
##yu	I
##rid	I
##ine	I
distinguish	O
CR	O
##C	O
and	O
healthy	O
controls	O
as	O
well	O
as	O
CR	O
##C	O
and	O
p	O
##oly	O
##ps	O
.	O

A	O
decreased	O
u	O
##rina	O
##ry	O
concentration	O
of	O
dim	B
##eth	I
##yl	I
##sul	I
##fo	I
##ne	I
in	O
individuals	O
with	O
an	O
altered	O
re	O
##nal	O
function	O
might	O
be	O
a	O
consequence	O
of	O
a	O
reduced	O
clearance	O
without	O
com	O
##pen	O
##sat	O
##ory	O
tub	O
##ular	O
secret	O
##ion	O
.	O

D	B
-	I
Mann	I
##ose	I
.	O

Mi	O
##to	O
##cho	O
##nd	O
##rial	O
a	O
##con	O
##itas	O
##e	O
(	O
AC	O
##O	O
##2	O
)	O
contains	O
an	O
4	O
##F	O
##e	O
-	O
4	O
##S	O
cluster	O
that	O
is	O
particularly	O
sensitive	O
to	O
mitochondrial	O
reactive	O
oxygen	O
species	O
such	O
as	O
super	B
##oxide	I
radical	O
O	O
_	O
2	O
-	O
.	O

Met	O
##ab	O
##oli	O
##tes	O
from	O
the	O
p	B
##yr	I
##im	I
##id	I
##ine	I
metabolism	O
were	O
significantly	O
associated	O
with	O
disability	O
,	O
disease	O
activity	O
and	O
brain	O
at	O
##rop	O
##hy	O
,	O
making	O
them	O
of	O
particular	O
interest	O
for	O
understanding	O
the	O
disease	O
mechanisms	O
and	O
as	O
markers	O
of	O
disease	O
progression	O
.	O

In	O
fact	O
,	O
this	O
cluster	O
is	O
composed	O
of	O
two	O
further	O
clusters	O
,	O
whereby	O
the	O
variables	O
ace	B
##tone	I
,	O
et	B
##han	I
##oi	I
##c	I
acid	I
,	O
1	B
-	I
prop	I
##ano	I
##l	I
,	O
he	B
##xa	I
##nal	I
,	O
he	B
##pta	I
##nal	I
,	O
o	B
##ct	I
##ana	I
##l	I
,	O
non	B
##ana	I
##l	I
,	O
4	B
-	I
to	I
##lu	I
##ald	I
##eh	I
##yd	I
##e	I
are	O
contained	O
on	O
the	O
right	O
side	O
.	O

In	O
EA	O
##E	O
model	O
of	O
SM	O
,	O
the	O
block	O
##age	O
of	O
P	O
##LA	O
##2	O
is	O
highly	O
e	O
##ff	O
##ica	O
##cious	O
in	O
the	O
am	O
##eli	O
##oration	O
of	O
the	O
disease	O
courses	O
probably	O
by	O
reducing	O
T	O
cell	O
proliferation	O
,	O
pro	O
-	O
inflammatory	O
c	O
##yt	O
##oki	O
##ne	O
production	O
preventing	O
activation	O
of	O
C	O
##NS	O
micro	O
##glia	O
,	O
and	O
increasing	O
my	B
##elin	I
protein	O
levels	O
(	O
Sir	O
##ith	O
##o	O
and	O
Free	O
##dman	O
)	O
.	O

In	O
addition	O
to	O
p	O
-	O
c	O
##res	O
##ol	O
,	O
we	O
observed	O
3	B
-	I
(	I
3	I
-	I
h	I
##ydro	I
##xy	I
##phe	I
##ny	I
##l	I
)	I
-	I
3	I
-	I
h	I
##ydro	I
##xy	I
##p	I
##rop	I
##ion	I
##ate	I
,	O
a	O
meta	O
##bol	O
##ite	O
that	O
has	O
been	O
associated	O
with	O
members	O
of	O
C	O
##los	O
##tri	O
##dia	O
##e	O
,	O
to	O
be	O
elevated	O
in	O
co	O
##lon	O
cancer	O
patients	O
’	O
urine	O
compared	O
to	O
re	O
##ct	O
##al	O
cancer	O
patients	O
’	O
urine	O
.	O

A	O
.	O
AK	O
##R	O
activity	O
measured	O
by	O
P	O
##Q	O
reduction	O
by	O
color	O
##ime	O
##tric	O
ass	O
##ay	O
demonstrates	O
activity	O
in	O
human	O
ad	O
##ip	O
##ose	O
tissue	O
(	O
n	O
=	O
5	O
subjects	O
,	O
each	O
measured	O
on	O
three	O
separate	O
occasions	O
)	O
,	O
m	B
##uri	I
##ne	I
3	O
##T	O
##3	O
-	O
L	O
##1	O
cells	O
(	O
n	O
=	O
7	O
)	O
,	O
and	O
re	O
##comb	O
##ina	O
##nt	O
enzymes	O
(	O
n	O
=	O
3	O
–	O
4	O
)	O
.	O

We	O
observed	O
that	O
meta	O
##bol	O
##ites	O
with	O
significant	O
and	O
consistent	O
changes	O
between	O
HC	O
##C	O
cases	O
and	O
c	O
##ir	O
##r	O
##hos	O
##is	O
are	O
primarily	O
involved	O
in	O
bi	O
##le	O
acid	O
bio	O
##sy	O
##nt	O
##hesis	O
,	O
long	O
chain	O
car	B
##ni	I
##tine	I
and	O
small	O
p	O
##eptide	O
metabolism	O
.	O

El	O
##eva	O
##tion	O
of	O
al	B
##ani	I
##ne	I
may	O
have	O
protective	O
effects	O
since	O
al	B
##ani	I
##ne	I
has	O
anti	O
‐	O
at	O
##her	O
##ogenic	O
action	O
in	O
end	O
##oth	O
##eli	O
##al	O
cells	O
##43	O
and	O
prevents	O
he	O
##pa	O
##to	O
##cellular	O
injury	O
.	O
44	O

recently	O
discovered	O
that	O
G	O
protein	O
-	O
coupled	O
est	B
##rogen	I
receptor	O
(	O
GP	O
##ER	O
)	O
can	O
activate	O
Y	O
##AP	O
through	O
P	O
##LC	O
##β	O
signaling	O
pathway	O
and	O
is	O
related	O
to	O
cell	O
invasion	O
and	O
meta	O
##sta	O
##sis	O
in	O
breast	O
cancer	O
.	O

The	O
finding	O
of	O
sustained	O
plasma	O
and	O
u	O
##rina	O
##ry	O
o	O
##est	O
##rogen	O
##s	O
at	O
20	O
-	O
40	O
%	O
compared	O
to	O
their	O
control	O
levels	O
indirectly	O
support	O
a	O
hypothesis	O
of	O
alternative	O
o	O
##est	O
##rogen	O
sources	O
in	O
post	O
##men	O
##op	O
##aus	O
##al	O
breast	O
cancer	O
patients	O
on	O
treatment	O
with	O
4	B
-	I
h	I
##ydro	I
##xy	I
##and	I
##ros	I
##ten	I
##ed	I
##ione	I
.	O

Note	O
that	O
u	B
##ric	I
acid	I
has	O
also	O
been	O
positively	O
associated	O
with	O
go	O
##ut	O
in	O
our	O
study	O
.	O

The	O
in	O
##hibition	O
of	O
but	O
##yr	O
##yl	O
##cho	O
##lines	O
##tera	O
##se	O
(	O
BC	O
##h	O
##E	O
)	O
activity	O
by	O
para	O
##ox	O
##on	O
is	O
due	O
to	O
the	O
formation	O
of	O
p	O
##hos	O
##ph	O
##ory	O
##lated	O
BC	O
##h	O
##E	O
add	O
##uc	O
##t	O
,	O
and	O
the	O
detection	O
of	O
the	O
p	O
##hos	O
##ph	O
##ory	O
##lated	O
BC	O
##h	O
##E	O
add	O
##uc	O
##t	O
in	O
human	O
plasma	O
can	O
serve	O
as	O
an	O
exposure	O
bio	O
##mark	O
##er	O
of	O
organ	B
##op	I
##hos	I
##phate	I
p	O
##est	O
##icides	O
and	O
nerve	O
agents	O
.	O

To	O
account	O
for	O
urine	O
di	O
##lution	O
,	O
bucket	O
##s	O
were	O
normal	O
##ized	O
by	O
urine	O
c	B
##rea	I
##tin	I
##ine	I
levels	O
.	O

SP	S
meta	O
##bol	O
##ite	O
q	O
##uant	O
##ification	O
with	O
subsequent	O
log	O
##istic	O
re	O
##gression	O
showed	O
that	O
c	B
##it	I
##rate	I
or	O
my	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
were	O
not	O
significant	O
predict	O
##ors	O
of	O
C	O
##a	O
##P	O
status	O
.	O

However	O
,	O
long	O
-	O
and	O
medium	O
-	O
chain	O
a	O
##cy	O
##l	O
##car	O
##ni	O
##tine	O
##s	O
were	O
found	O
to	O
be	O
lower	O
in	O
most	O
drug	O
-	O
treatment	O
groups	O
relative	O
to	O
place	O
##bo	O
periods	O
,	O
except	O
for	O
h	B
##ydro	I
##ch	I
##lor	I
##oth	I
##ia	I
##zi	I
##de	I
,	O
which	O
resulted	O
in	O
marginal	O
decreases	O
only	O
.	O

My	B
##cot	I
##ox	I
##in	I
exposure	O
assessment	O
:	O
traditional	O
food	O
analysis	O
compared	O
to	O
the	O
innovative	O
,	O
complementary	O
bio	O
##mark	O
##er	O
approach	O

The	O
program	O
coded	O
for	O
L	B
##C	I
-	I
(	I
±	I
)	I
E	I
##SI	I
-	I
MS	I
analysis	O
is	O
available	O
in	O
the	O
.	O

Poole	O
##d	O
plasma	O
from	O
healthy	O
volunteers	O
(	O
male	O
and	O
female	O
)	O
were	O
used	O
for	O
the	O
est	O
##imation	O
of	O
o	B
##xy	I
##ster	I
##ol	I
recovery	O
and	O
stability	O
.	O

These	O
are	O
palm	B
##itic	I
acid	I
,	O
s	B
##te	I
##ari	I
##c	I
acid	I
,	O
o	B
##le	I
##ic	I
acid	I
,	O
ben	B
##zoic	I
acid	I
,	O
but	B
##ano	I
##ic	I
acid	I
,	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
g	B
##ly	I
##cine	I
,	O
3	B
-	I
he	I
##pta	I
##non	I
##e	I
,	O
4	B
-	I
he	I
##pta	I
##non	I
##e	I
,	O
he	B
##xa	I
##nal	I
,	O
1	B
-	I
te	I
##tra	I
##de	I
##cano	I
##l	I
and	O
nap	B
##ht	I
##hale	I
##ne	I
.	O

A	O
negative	O
P	O
##ET	O
-	O
CT	O
and	O
a	O
high	O
relative	O
g	B
##lut	I
##ama	I
##te	I
concentration	O
(	O
suggest	O
##ive	O
for	O
inflammation	O
)	O
exclude	O
##s	O
lung	O
cancer	O
with	O
a	O
N	O
##P	O
##V	O
of	O
100	O
%	O
.	O

Five	O
of	O
the	O
19	O
patients	O
had	O
no	O
significant	O
CA	O
##D	O
and	O
no	O
net	O
la	B
##ct	I
##ate	I
el	O
##ution	O
after	O
pacing	O
,	O
strongly	O
suggesting	O
the	O
absence	O
of	O
cardiac	O
is	O
##che	O
##mia	O
.	O

A	O
WA	O
##X	O
solid	O
-	O
phase	O
extraction	O
(	O
SP	O
##E	O
)	O
column	O
(	O
absorb	O
##ent	O
225	O
mg	O
,	O
60	O
μ	O
##m	O
,	O
volume	O
2	O
m	O
##L	O
,	O
Waters	O
,	O
Milford	O
,	O
MA	O
)	O
was	O
attached	O
with	O
a	O
manifold	O
and	O
successively	O
pre	O
-	O
conditioned	O
with	O
a	O
column	O
volume	O
of	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
and	O
water	O
.	O

The	O
independence	O
of	O
the	O
association	O
between	O
elevated	O
T	B
##MA	I
##O	I
levels	O
and	O
poor	O
outcomes	O
following	O
adjustments	O
for	O
card	O
##io	O
-	O
re	O
##nal	O
in	O
##dices	O
like	O
e	O
##G	O
##F	O
##R	O
and	O
N	O
##T	O
-	O
B	O
##NP	O
argues	O
for	O
additional	O
underlying	O
me	O
##chan	O
##istic	O
links	O
.	O

The	O
positive	O
correlation	O
##s	O
in	O
the	O
meta	O
##sta	O
##ses	O
showed	O
a	O
generally	O
similar	O
pattern	O
to	O
those	O
in	O
the	O
g	O
##lio	O
##blast	O
##oma	O
##s	O
,	O
as	O
##tro	O
##cy	O
##tom	O
##as	O
and	O
men	O
##ing	O
##io	O
##mas	O
:	O
la	B
##ct	I
##ate	I
correlated	O
positively	O
with	O
al	B
##ani	I
##ne	I
and	O
t	O
##G	O
##lut	O
,	O
the	O
t	O
##C	O
##ho	O
pool	O
correlated	O
positively	O
with	O
t	O
##C	O
##r	O
and	O
t	O
##G	O
##lut	O
,	O
and	O
g	B
##lut	I
##ama	I
##te	I
correlated	O
with	O
g	B
##lut	I
##amine	I
.	O

U	O
##rina	O
##ry	O
fur	B
##oy	I
##l	I
##gly	I
##cine	I
and	O
t	B
##ig	I
##ly	I
##l	I
##gly	I
##cine	I
were	O
significantly	O
increased	O
in	O
patients	O
with	O
early	O
-	O
stage	O
PD	O
.	O

Further	O
improvement	O
of	O
the	O
protocol	O
from	O
the	O
pilot	O
study	O
was	O
achieved	O
by	O
concurrent	O
administration	O
of	O
both	O
1	O
-	O
_	O
13	O
C	B
-	I
g	I
##ly	I
##cola	I
##te	I
and	O
_	O
13	O
C	B
_	I
2	I
-	I
o	I
##xa	I
##late	I
,	O
which	O
gives	O
additional	O
insights	O
into	O
the	O
flux	O
##es	O
involved	O
in	O
the	O
g	B
##ly	I
##ox	I
##yla	I
##te	I
metabolism	O
.	O

As	O
the	O
direct	O
method	O
provides	O
analysis	O
of	O
re	O
##gio	O
##is	O
##omer	O
##s	O
of	O
con	O
##ju	O
##gate	O
##s	O
,	O
we	O
were	O
able	O
to	O
show	O
that	O
D	B
##A	I
-	I
3	I
-	I
O	I
-	I
S	I
pre	O
##dom	O
##inate	O
##s	O
over	O
D	B
##A	I
-	I
4	I
-	I
O	I
-	I
S	I
in	O
the	O
human	O
brain	O
.	O

Ser	O
##um	O
samples	O
were	O
analyzed	O
for	O
est	B
##rone	I
(	O
E	O
_	O
1	O
)	O
and	O
est	B
##rad	I
##iol	I
(	O
E	O
_	O
2	O
)	O
using	O
radio	O
##im	O
##mu	O
##no	O
##ass	O
##ays	O
.	O

This	O
AM	O
##PP	O
-	O
der	O
##iva	O
##tized	O
FA	S
pro	O
##fi	O
##ling	O
approach	O
displayed	O
some	O
very	O
low	O
abundance	O
FA	S
species	O
in	O
human	O
serum	O
(	O
top	O
panels	O
,	O
ins	O
##ets	O
)	O
that	O
are	O
typically	O
non	O
-	O
detect	O
##able	O
by	O
direct	O
analysis	O
in	O
the	O
negative	O
-	O
ion	O
mode	O
.	O

(	O
1982	O
)	O
demonstrated	O
the	O
rapid	O
up	O
##take	O
of	O
h	B
##y	I
##pot	I
##au	I
##rine	I
into	O
ne	O
##uro	O
##blast	O
##oma	O
cells	O
,	O
suggesting	O
that	O
h	B
##y	I
##pot	I
##au	I
##rine	I
may	O
have	O
a	O
function	O
in	O
the	O
regulation	O
of	O
ne	O
##uron	O
##al	O
activity	O
.	O

A	O
maternal	O
metabolic	O
adaptation	O
during	O
pregnancy	O
is	O
essential	O
to	O
increase	O
availability	O
of	O
ch	B
##ole	I
##ster	I
##ol	I
and	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
for	O
f	O
##etal	O
development	O
and	O
the	O
synthesis	O
of	O
s	O
##tero	O
##id	O
hormones	O
by	O
the	O
place	O
##nta	O
.	O

S	B
##phi	I
##ngo	I
##lip	I
##ids	I
(	O
SL	O
##s	O
)	O
have	O
significant	O
roles	O
in	O
signal	O
trans	O
##duction	O
,	O
and	O
are	O
involved	O
in	O
the	O
progression	O
of	O
liver	O
disorders	O
,	O
including	O
viral	O
he	O
##pa	O
##titis	O
,	O
fi	O
##bro	O
##sis	O
,	O
non	O
##al	O
##co	O
##hol	O
##ic	O
s	O
##te	O
##ato	O
##sis	O
he	O
##pa	O
##titis	O
and	O
HC	O
##C	O
_	O
,	O
_	O
,	O
_	O
,	O
_	O
,	O
_	O
,	O
_	O
,	O
.	O

A	O
similar	O
_	O
13	O
C	O
en	O
##rich	O
##ment	O
pattern	O
of	O
Al	O
##a	O
,	O
la	B
##ct	I
##ate	I
,	O
su	B
##cci	I
##nate	I
and	O
c	B
##it	I
##rate	I
in	O
lung	O
tumor	O
tissues	O
was	O
observed	O
in	O
all	O
five	O
patients	O
where	O
_	O
13	O
C	O
label	O
##ing	O
in	O
these	O
meta	O
##bol	O
##ites	O
was	O
sufficient	O
to	O
be	O
q	O
##uant	O
##ified	O
by	O
G	O
##C	O
-	O
MS	O
.	O

The	O
study	O
was	O
approved	O
by	O
the	O
Co	O
##mit	O
##é	O
de	O
Protection	O
des	S
Person	O
##nes	O
of	O
Mont	O
##pel	O
##lier	O
and	O
declared	O
to	O
the	O
French	O
Ministry	O
(	O
reference	O
number	O
DC	O
-	O
2008	O
–	O
41	O
##7	O
)	O
.	O

Also	O
shown	O
are	O
the	O
structures	O
and	O
numbering	O
of	O
c	B
##it	I
##ric	I
acid	I
and	O
U	O
##DP	O
##G	O
To	O
address	O
the	O
label	O
##ing	O
of	O
the	O
carbon	O
##yl	O
groups	O
in	O
the	O
amino	O
acids	O
,	O
we	O
recorded	O
H	O
##AC	O
##AC	O
##O	O
experiments	O
that	O
co	O
##rrel	O
##ate	O
the	O
carbon	O
##yl	O
carbon	O
with	O
either	O
the	O
H	O
_	O
A	O
,	O
or	O
the	O
side	O
chain	O
carbon	O
##yl	O
with	O
H	O
_	O
G	O
;	O
these	O
two	O
carbon	O
##yl	O
##s	O
have	O
significantly	O
different	O
_	O
13	O
C	O
chemical	O
shifts	O
,	O
as	O
shown	O
in	O
.	O

Between	O
se	O
##psis	O
patients	O
and	O
controls	O
,	O
we	O
found	O
significant	O
differences	O
in	O
the	O
serum	O
concentrations	O
of	O
the	O
following	O
eight	O
meta	O
##bol	O
##ites	O
:	O
glucose	S
(	O
median	O
concentration	O
5	O
.	O
63	O
mm	O
##ol	O
/	O
l	O
vs	O
4	O
.	O
13	O
mm	O
##ol	O
/	O
l	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
,	O
c	B
##it	I
##rate	I
(	O
0	O
.	O
08	O
mm	O
##ol	O
/	O

The	O
multi	O
##var	O
##iable	O
-	O
adjusted	O
OR	O
for	O
G	O
##DM	O
per	O
SD	O
in	O
##cre	O
##ment	O
of	O
l	O
##n	O
-	O
transformed	O
plasma	O
T	B
##MA	I
##O	I
was	O
1	O
.	O
22	O
(	O
95	O
%	O
C	O
##I	O
:	O
1	O
.	O
05	O
,	O
1	O
.	O
41	O
)	O
.	O

A	O
##bb	O
##re	O
##viation	O
##s	O
:	O
PS	O
##P	O
:	O
progressive	O
su	O
##pra	O
##nu	O
##cle	O
##ar	O
p	O
##als	O
##y	O
;	O
SD	O
##MA	O
:	O
symmetric	B
dim	I
##eth	I
##yla	I
##rg	I
##ini	I
##ne	I
fatty	O
acid	O
;	O
L	B
##ys	I
##o	I
##PC	I
(	I
16	I
:	I
0	I
)	I
:	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
(	I
16	I
:	I
0	I
)	I
;	O
AC	O
:	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
.	O

Compared	O
with	O
the	O
healthy	O
controls	O
,	O
eighteen	O
amino	O
acids	O
and	O
bio	O
##genic	O
am	O
##ines	O
were	O
significantly	O
increased	O
(	B
al	B
##ani	I
##ne	I
,	O
a	B
##rg	I
##ini	I
##ne	I
,	O
g	B
##lut	I
##ami	I
##c	I
acid	I
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
le	B
##uc	I
##ine	I
,	O
l	B
##ys	I
##ine	I
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
pro	B
##line	I
,	O
se	B
##rine	I
,	O
try	B
##pt	I
##op	I
##han	I
,	O
th	B
##re	I
##oni	I
##ne	I
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
v	B
##ali	I
##ne	I
,	O
c	B
##rea	I
##tin	I
##ine	I
,	O
co	B
##tin	I
##ine	I
,	O
ni	B
##ac	I
##ina	I
##mi	I
##de	I
,	O
thy	B
##ro	I
##xin	I
##e	I
,	O
and	O
l	B
-	I
α	I
-	I
g	I
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##ory	I
##l	I
##cho	I
##line	I
,	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
and	O
three	O
meta	O
##bol	O
##ites	O
,	O
i	O
.	O
e	O
.	O
,	O
g	B
##lut	I
##amine	I
,	O
γ	B
-	I
amino	I
##but	I
##yric	I
acid	I
and	O
ta	B
##uri	I
##ne	I
,	O
were	O
decreased	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

High	O
##ly	O
over	O
##ex	O
##pressed	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
in	O
both	O
HC	O
##C	O
vs	O
.	O
DC	O
and	O
DC	O
vs	O
.	O
NH	O
##C	O
were	O
also	O
observed	O
and	O
these	O
trends	O
are	O
consistent	O
with	O
recent	O
HC	O
##C	O
meta	O
##bol	O
##omi	O
##cs	O
studies	O
showing	O
an	O
elevation	O
of	O
these	O
meta	O
##bol	O
##ites	O
in	O
chronic	O
liver	O
disease	O
patients	O
.	O

It	O
was	O
revealed	O
that	O
under	O
certain	O
conditions	O
,	O
B	O
-	O
C	O
##LL	O
cells	O
have	O
equal	O
capacity	O
to	O
my	O
##elo	O
##id	O
cells	O
to	O
bio	O
##sy	O
##nt	O
##hesis	O
##e	O
and	O
release	O
L	B
##T	I
##B	I
##4	I
.	O

Met	B
##hi	I
##oni	I
##ne	I
was	O
among	O
the	O
most	O
released	O
amino	O
acids	O
during	O
the	O
ripe	O
##ning	O
of	O
A	O
##ppe	O
##nz	O
##eller	O
cheese	O
.	O

HD	O
##L	O
-	O
c	O
:	O
High	O
-	O
density	O
lip	O
##op	O
##rote	O
##in	O
ch	B
##ole	I
##ster	I
##ol	I
;	O
L	O
##D	O
##L	O
-	O
c	O
:	O
Low	O
-	O
density	O
lip	O
##op	O
##rote	O
##in	O
ch	B
##ole	I
##ster	I
##ol	I
;	O
F	O
##B	O
##G	O
:	O
fast	O
##ing	O
plasma	O
glucose	S
;	O
2	O
h	O
-	O
P	O
##G	O
:	O
2	O
h	O
Post	O
##pra	O
##ndi	O
##al	O
plasma	O
glucose	S
;	O
H	O
##OM	O
##A	O
-	O
I	O
##R	O
:	O
Home	O
##ost	O
##asis	O
model	O
assessment	O
of	O
insulin	O
resistance	O
.	O

P	O
##las	O
##ma	O
concentrations	O
of	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
(	O
A	O
)	O
and	O
h	B
##ydro	I
##xy	I
##ana	I
##stro	I
##zo	I
##le	I
(	O
B	O
)	O
in	O
post	O
##men	O
##op	O
##aus	O
##al	O
women	O
with	O
breast	O
cancer	O
taking	O
1	O
mg	O
day	O
_	O
−	O
##1	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
oral	O
##ly	O
.	O

The	O
G	O
##U	O
rates	O
were	O
calculated	O
by	O
multi	O
##p	O
##lying	O
K	O
_	O
i	O
by	O
the	O
plasma	O
glucose	S
concentration	O
and	O
dividing	O
by	O
the	O
tissue	O
density	O
and	O
a	O
lump	O
##ed	O
constant	O
.	O

A	O
##po	O
##B	O
-	O
containing	O
lip	O
##op	O
##rote	O
##ins	O
were	O
pre	O
##ci	O
##pit	O
##ated	O
with	O
de	B
##x	I
##tra	I
##n	I
-	I
su	I
##lf	I
##ate	I
ma	I
##gnesium	I
,	O
and	O
HD	B
##L	I
-	I
ch	I
##ole	I
##ster	I
##ol	I
concentrations	O
in	O
the	O
super	O
##nat	O
##ants	O
were	O
measured	O
en	O
##zy	O
##matical	O
##ly	O
.	O

The	O
requirement	O
for	O
g	B
##lut	I
##amine	I
depends	O
on	O
the	O
energy	O
demands	O
of	O
the	O
cancer	O
cells	O
.	O

We	O
did	O
not	O
detect	O
k	B
##yn	I
##uren	I
##ine	I
in	O
our	O
u	O
##rina	O
##ry	O
samples	O
but	O
noted	O
a	O
cat	O
##ab	O
##oli	O
##te	O
,	O
x	B
##ant	I
##hur	I
##ena	I
##te	I
,	O
to	O
be	O
lowered	O
in	O
CR	O
##C	O
patients	O
prior	O
to	O
surgery	O
compared	O
to	O
post	O
-	O
surgery	O
patients	O
.	O

The	O
samples	O
in	O
the	O
valid	O
##ation	O
set	O
were	O
similarly	O
prepared	O
except	O
that	O
10	O
μ	O
##L	O
of	O
L	B
-	I
nor	I
##val	I
##ine	I
was	O
added	O
as	O
an	O
internal	O
standard	O
.	O

We	O
found	O
no	O
statistical	O
##ly	O
significant	O
association	O
between	O
these	O
genetic	O
variants	O
and	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
g	I
##lu	I
##cu	I
##ron	I
##ide	I
formation	O
rates	O
in	O
the	O
50	O
human	O
liver	O
micro	O
##some	O
##s	O
(	O
supporting	O
)	O
.	O

Human	O
hem	O
##og	O
##lo	O
##bin	O
treated	O
in	O
v	O
##it	O
##ro	O
with	O
s	B
##ty	I
##rene	I
7	I
,	I
8	I
-	I
oxide	I
.	O

In	O
contrast	O
,	O
in	O
S	O
##UM	O
##13	O
##15	O
##MO	O
##2	O
,	O
treatment	O
with	O
C	O
##75	O
and	O
c	B
##ele	I
##co	I
##xi	I
##b	I
reduced	O
the	O
lip	O
##id	O
body	O
positive	O
cells	O
to	O
23	O
.	O
4	O
%	O
and	O
37	O
.	O
2	O
%	O
in	O
comparison	O
to	O
53	O
%	O
of	O
D	B
##MS	I
##O	I
treated	O
cells	O
(	O
Figure	O
)	O
.	O

Form	B
##ic	I
acid	I
(	O
for	O
mass	O
s	O
##pect	O
##rome	O
##try	O
)	O
and	O
am	B
##mon	I
##ium	I
carbon	I
##ate	I
were	O
acquired	O
from	O
F	O
##luk	O
##a	O
Ana	O
##ly	O
##tical	O
(	O
Sigma	O
Al	O
##dric	O
##h	O
)	O
,	O
Stein	O
##heim	O
,	O
Germany	O
.	O

Figure	O
shows	O
an	O
overview	O
of	O
the	O
analysis	O
work	O
##flow	O
for	O
structural	O
identification	O
of	O
GP	S
at	O
C	O
=	O
C	O
location	O
level	O
on	O
a	O
450	O
##0	O
Q	O
##TR	O
##AP	O
mass	O
s	O
##pect	O
##rome	O
##ter	O
.	O

All	O
patients	O
with	O
e	O
##pile	O
##psy	O
were	O
treated	O
with	O
1	O
to	O
5	O
anti	O
##ep	O
##ile	O
##ptic	O
drugs	O
(	O
A	O
##ED	O
##s	O
)	O
:	O
VP	O
##A	O
=	O
23	O
(	O
47	O
,	O
9	O
%	O
)	O
,	O
L	O
##V	O
##T	O
=	O
11	O
(	O
22	O
,	O
9	O
%	O
)	O
,	O
V	O
##GB	O
=	O
9	O
(	O
18	O
,	O
8	O
%	O
)	O
,	O
ACT	O
##H	O
=	O
7	O
(	O
14	O
,	O
6	O
%	O
)	O
,	O
P	B
##B	I
=	I
4	I
(	I
8	I
,	I
3	I
%	I
)	I
,	O
CB	O
##L	O
=	O
3	O
(	O
6	O
,	O
3	O
%	O
)	O
,	O
T	O
##PM	O
=	O
2	O
(	O
4	O
,	O
55	O
%	O
)	O
,	O
L	O
##T	O
##G	O
=	O
1	O
(	O
2	O
,	O
1	O
%	O
)	O
,	O
C	B
##L	I
##Z	I
=	I
1	I
(	I
2	I
,	I
1	I
%	I
)	I
,	O
O	O
##X	O
##C	O
=	O
1	O
(	O
2	O
,	O
1	O
%	O
)	O
.	O

Mali	O
##c	O
enzyme	O
can	O
then	O
convert	O
ma	B
##late	I
to	O
p	B
##yr	I
##u	I
##vate	I
the	O
same	O
as	O
in	O
the	O
p	B
##yr	I
##u	I
##vate	I
-	I
ma	I
##late	I
cycle	O
.	O

Box	O
-	O
and	O
-	O
w	O
##his	O
##ker	O
plots	O
of	O
(	O
A	O
)	O
u	B
##ric	I
acid	I
,	O
(	O
B	O
)	O
ch	B
##oly	I
##l	I
##gly	I
##cine	I
,	O
(	O
C	O
)	O
3	B
-	I
h	I
##ydro	I
##xy	I
##cap	I
##ric	I
acid	I
,	O
(	O
D	O
)	O
D	O
-	O
le	O
##uc	O
##ic	O
acid	O
,	O
(	O
E	O
)	O
x	B
##ant	I
##hine	I
,	O
(	O
F	O
)	O
a	O
##rac	O
##hi	O
##don	O
##yl	O
l	O
##ys	O
##ole	O
##ci	O
##thin	O
,	O
(	O
G	O
)	O
di	B
##ole	I
##oy	I
##l	I
##ph	I
##os	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
.	O

This	O
was	O
expected	O
since	O
C	O
##YP	O
##3	O
##A	O
##5	O
h	B
##ydro	I
##xy	I
##lates	I
and	O
dem	B
##eth	I
##yla	I
##tes	I
ta	I
##mo	I
##xi	I
##fen	I
(	O
figure	O
)	O
.	O

1	B
…	I
2	I
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
,	O
2	B
…	I
v	I
##ali	I
##ne	I
,	O
3	B
…	I
3	I
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
,	O
4	B
…	I
la	I
##ct	I
##ate	I
,	O
5	B
…	I
al	I
##ani	I
##ne	I
,	O
6	O
…	O
c	O
##it	O
##rate	O
,	O
7	B
…	I
glucose	I
,	O
8	B
…	I
t	I
##yr	I
##os	I
##ine	I
.	O

In	O
the	O
u	B
##rea	I
cycle	O
,	O
a	B
##rg	I
##ini	I
##ne	I
is	O
c	O
##lea	O
##ved	O
by	O
a	O
##rg	O
##inas	O
##e	O
to	O
form	O
or	B
##ni	I
##thin	I
##e	I
and	O
u	B
##rea	I
.	O

In	O
both	O
situations	O
,	O
additional	O
pu	O
##rification	O
step	O
(	O
s	O
)	O
beyond	O
the	O
di	B
##ch	I
##lor	I
##ome	I
##than	I
##e	I
extraction	O
currently	O
practiced	O
will	O
be	O
necessary	O
to	O
ensure	O
accurate	O
,	O
re	O
##p	O
##rod	O
##uc	O
##ible	O
,	O
sensitive	O
measurement	O
.	O

However	O
,	O
in	O
fresh	O
patient	O
E	O
##D	O
##TA	O
plasma	O
,	O
only	O
87	O
%	O
a	B
##bir	I
##ater	I
##one	I
was	O
recovered	O
after	O
2	O
hours	O
at	O
ambient	O
temperature	O
and	O
further	O
decreasing	O
to	O
31	O
%	O
after	O
24	O
h	O
.	O
E	O
##D	O
##TA	O
whole	O
blood	O
kept	O
at	O
ambient	O
temperature	O
also	O
showed	O
equal	O
decrease	O
below	O
85	O
%	O
of	O
the	O
initial	O
concentration	O
within	O
three	O
hours	O
and	O
further	O
decreasing	O
to	O
36	O
%	O
after	O
24	O
h	O
(	O
and	O
)	O
.	O

In	O
this	O
sense	O
,	O
c	B
##ys	I
##tein	I
##e	I
has	O
been	O
shown	O
to	O
be	O
elevated	O
in	O
various	O
types	O
of	O
cancer	O
including	O
L	O
##C	O
(	O
G	O
##am	O
##cs	O
##ik	O
et	O
al	O
.	O
,	O
2012	O
;	O
K	O
##re	O
##pel	O
##a	O
et	O
al	O
.	O
,	O
1997	O
)	O
,	O
and	O
the	O
g	O
##ly	O
##cine	O
de	O
##car	O
##box	O
##yla	O
##se	O
,	O
the	O
enzyme	O
responsible	O
for	O
g	B
##ly	I
##cine	I
degradation	O
,	O
has	O
been	O
related	O
to	O
tumor	O
‐	O
in	O
##iti	O
##ating	O
cells	O
in	O
N	O
##SC	O
##LC	O
(	O
Be	O
##rez	O
##ows	O
##ka	O
et	O
al	O
.	O
,	O
2017	O
;	O
Lin	O
et	O
al	O
.	O
,	O
2017	O
)	O
.	O

This	O
may	O
be	O
a	O
consequence	O
of	O
increased	O
activation	O
of	O
x	B
##ant	I
##hine	I
o	O
##xi	O
##das	O
##e	O
and	O
ad	O
##eno	O
##sin	O
##e	O
de	O
##ami	O
##nas	O
##e	O
.	O

positive	O
ion	O
##ization	O
mode	O
Overall	O
,	O
512	O
features	O
were	O
detected	O
in	O
negative	O
mode	O
when	O
the	O
met	B
##han	I
##ol	I
super	O
##nat	O
##ant	O
was	O
analyzed	O
versus	O
52	O
##6	O
features	O
detected	O
in	O
the	O
met	B
##han	I
##ol	I
-	I
ethanol	I
(	I
1	I
:	I
1	I
)	I
super	O
##nat	O
##ant	O
.	O

GP	O
-	O
tag	O
##ged	O
o	B
##xy	I
##ster	I
##ols	I
offer	O
three	O
advantages	O
for	O
this	O
type	O
of	O
analysis	O
as	O
follows	O
:	O
(	O
i	O
)	O
charge	O
tag	O
##ging	O
improve	O
##s	O
parent	O
molecule	O
ion	O
##ization	O
by	O
2	O
–	O
3	O
orders	O
of	O
magnitude	O
;	O
(	O
ii	O
)	O
GP	O
-	O
tag	O
##ged	O
o	B
##xy	I
##ster	I
##ols	I
give	O
an	O
abundant	O
[	O
M	O
−	O
79	O
]	O
_	O
+	O
ion	O
upon	O
MS	O
_	O
2	O

Red	O
##uce	O
##d	O
met	B
##hi	I
##oni	I
##ne	I
availability	O
limits	O
SA	O
##M	O
bio	O
##sy	O
##nt	O
##hesis	O
.	O

Ser	O
##um	O
est	B
##rogen	I
concentration	O
is	O
an	O
established	O
predict	O
##or	O
of	O
breast	O
cancer	O
risk	O
in	O
post	O
##men	O
##op	O
##aus	O
##al	O
women	O
,	O
but	O
whether	O
bio	O
##mark	O
##ers	O
of	O
est	B
##rogen	I
metabolism	O
also	O
predict	O
the	O
risk	O
of	O
breast	O
cancer	O
is	O
unclear	O
because	O
of	O
the	O
lack	O
of	O
accurate	O
,	O
re	O
##p	O
##rod	O
##uc	O
##ible	O
,	O
sensitive	O
,	O
and	O
high	O
-	O
through	O
##put	O
ass	O
##ays	O
for	O
est	B
##rogen	I
meta	O
##bol	O
##ites	O
.	O

The	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
FA	I
profile	O
is	O
also	O
less	O
affected	O
by	O
fat	O
intake	O
than	O
other	O
plasma	O
lip	O
##ids	O
,	O
i	O
##e	O
,	O
t	B
##ria	I
##cy	I
##l	I
##gly	I
##cer	I
##ols	I
or	O
none	O
##ster	O
##ified	O
FA	O
##s	O
.	O

In	O
the	O
currently	O
study	O
,	O
more	O
subjects	O
in	O
the	O
high	B
–	I
c	I
##ys	I
##tat	I
##hi	I
##oni	I
##ne	I
concentration	O
group	O
had	O
type	O
2	O
diabetes	O
.	O

All	O
patients	O
received	O
at	B
##rop	I
##ine	I
before	O
an	O
##est	O
##hesia	O
was	O
induced	O
with	O
th	B
##io	I
##pent	I
##al	I
.	O

;	O
Rest	O
##ek	O
)	O
at	O
a	O
temperature	O
of	O
50	O
##°	O
##C	O
,	O
with	O
a	O
mobile	O
phase	O
consisted	O
of	O
Me	O
##OH	O
/	O
CH	O
_	O
3	O
C	O
##N	O
/	O
H	O
_	O
2	O
O	O
45	O
/	O
45	O
/	O
10	O
+	O
0	O
.	O
1	O
%	O
ace	B
##tic	I
acid	I
(	O
phase	O
A	O
)	O
and	O
CH	O
_	O
2	O
C	O
##l	O
/	O
Me	O
##OH	O
(	O
80	O
/	O
20	O
v	O
/	O
v	O
)	O
(	O
phase	O
B	O
)	O
.	O

The	O
up	O
-	O
regulation	O
of	O
serum	O
N	O
-	O
ace	O
##ty	O
##lated	O
compounds	O
that	O
was	O
demonstrated	O
in	O
the	O
active	O
phase	O
of	O
the	O
disease	O
could	O
be	O
mainly	O
associated	O
with	O
α	O
##1	O
-	O
acid	O
g	B
##ly	I
##co	I
##p	I
##rote	I
##in	I
that	O
is	O
an	O
acute	O
-	O
phase	O
protein	O
[	O
,	O
,	O
]	O
,	O
while	O
the	O
increase	O
in	O
the	O
concentration	O
of	O
serum	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
is	O
most	O
likely	O
caused	O
by	O
the	O
imp	O
##air	O
##ment	O
of	O
p	O
##hen	O
##yla	O
##lani	O
##ne	O
-	O
4	O
-	O
h	O
##ydro	O
##xy	O
##lase	O
activity	O
(	O
a	O
he	O
##pa	O
##tic	O
enzyme	O
that	O
converts	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
into	O
t	B
##yr	I
##os	I
##ine	I
)	O
associated	O
with	O
immune	O
activation	O
and	O
inflammation	O
[	O
]	O
.	O

As	O
expected	O
,	O
o	O
##bes	O
##e	O
norm	B
##og	I
##ly	I
##ce	I
##mic	I
and	O
d	B
##ys	I
##gly	I
##ce	I
##mic	I
youth	O
had	O
significantly	O
higher	O
ad	O
##ip	O
##os	O
##ity	O
parameters	O
than	O
NW	O
youth	O
.	O

As	O
we	O
have	O
previously	O
shown	O
that	O
AL	O
##L	O
cells	O
migrate	O
into	O
ad	O
##ip	O
##ose	O
tissue	O
under	O
the	O
influence	O
of	O
the	O
ch	O
##em	O
##oki	O
##ne	O
C	O
##X	O
##CL	O
-	O
12	O
,	O
ad	O
##ip	O
##ose	O
tissue	O
itself	O
could	O
be	O
an	O
un	O
##re	O
##co	O
##gni	O
##zed	O
sanctuary	O
site	O
for	O
le	O
##uke	O
##mia	O
cells	O
,	O
where	O
ant	B
##hra	I
##cy	I
##cline	I
##s	I
are	O
unable	O
to	O
reach	O
therapeutic	O
levels	O
.	O

All	O
the	O
patients	O
were	O
prescribed	O
a	O
supplement	O
containing	O
vitamin	O
##s	O
B	O
##6	O
(	B
p	B
##yr	I
##ido	I
##xa	I
##l	I
-	I
5	I
-	I
phosphate	I
,	O
as	O
p	B
##yr	I
##ido	I
##xin	I
##e	I
)	O
,	O
B	O
##5	O
(	B
pan	B
##to	I
##the	I
##nic	I
acid	O
)	O
,	O
and	O
B	O
##2	O
(	O
rib	O
##of	O
##lav	O
##in	O
)	O
.	O

However	O
,	O
it	O
is	O
still	O
unclear	O
if	O
the	O
o	O
##xi	O
##di	O
##zation	O
of	O
C	B
(	I
18	I
:	I
2	I
)	I
CE	I
is	O
involved	O
in	O
tumor	O
##ogen	O
##esis	O
of	O
lung	O
cancer	O
.	O

As	O
shown	O
in	O
,	O
2	O
/	O
3	O
of	O
the	O
reference	O
compounds	O
are	O
polar	B
-	I
h	I
##ydro	I
##phi	I
##lic	I
with	O
o	O
##ct	O
##ano	O
##l	O
-	O
water	O
distribution	O
coefficients	O
log	O
##D	O
<	O
1	O
.	O

B	B
##ili	I
##ver	I
##din	I
.	O

The	O
10	O
m	O
##L	O
fl	O
##ask	O
contained	O
80	O
mg	O
N	B
-	I
ace	I
##ty	I
##l	I
##cy	I
##stein	I
##e	I
in	O
2	O
m	O
##L	O
H	O
_	O
2	O
O	O
at	O
room	O
temperature	O
and	O
was	O
stirred	O
for	O
2	O
##h	O
.	O

For	O
am	B
##lo	I
##di	I
##pine	I
,	O
selected	O
product	O
ions	O
could	O
be	O
matched	O
to	O
those	O
reported	O
from	O
rat	O
urine	O
meta	O
##bol	O
##ites	O
(	O
Such	O
##ano	O
##va	O
et	O
al	O
.	O
,	O
)	O
alongside	O
fragment	O
##ation	O
data	O
for	O
two	O
chemical	O
##ly	O
synthesis	O
##ed	O
o	O
##xi	O
##dized	O
am	B
##lo	I
##di	I
##pine	I
meta	O
##bol	O
##ites	O
that	O
we	O
also	O
observed	O
in	O
the	O
human	O
urine	O
extract	O
##s	O
(	O
Such	O
##ano	O
##va	O
et	O
al	O
.	O
)	O
.	O

In	O
line	O
with	O
the	O
cross	O
-	O
section	O
##al	O
positive	O
association	O
of	O
F	O
##T	O
##4	O
(	O
p	O
=	O
0	O
.	O
03	O
)	O
as	O
well	O
as	O
inverse	O
association	O
of	O
log	O
(	O
T	O
##S	O
##H	O
)	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
with	O
u	O
##rina	O
##ry	O
glucose	S
in	O
Inter	O
##9	O
##9	O
,	O
former	O
studies	O
already	O
showed	O
a	O
major	O
role	O
of	O
T	O
##H	O
##s	O
in	O
the	O
regulation	O
of	O
glucose	S
home	O
##ost	O
##asis	O
by	O
e	O
.	O
g	O
.	O
increasing	O
g	O
##lu	O
##con	O
##eo	O
##genesis	O
in	O
the	O
kidney	O
and	O
liver	O
but	O
also	O
glucose	S
absorption	O
and	O
u	O
##til	O
##ization	O
in	O
target	O
cells	O
[	O
,	O
]	O
.	O

De	O
##uter	O
##ated	O
sur	O
##rogate	O
##s	O
of	O
vitamin	B
D	I
meta	O
##bol	O
##ites	O
were	O
purchased	O
from	O
S	O
##ynth	O
##etic	O
##a	O
(	O
Oslo	O
,	O
Norway	O
)	O
and	O
Medical	O
Is	O
##oto	O
##pes	O
(	O
P	O
##el	O
##ham	O
,	O
NH	O
,	O
USA	O
)	O
.	O

El	O
##eva	O
##ted	O
plasma	O
T	B
##MA	I
##O	I
,	O
ch	B
##olin	I
##e	I
and	O
beta	B
##ine	I
levels	O
are	O
each	O
associated	O
with	O
more	O
advanced	O
left	O
vent	O
##ric	O
##ular	O
di	O
##ast	O
##olic	O
d	O
##ys	O
##function	O
and	O
port	O
##end	O
poor	O
##er	O
long	O
-	O
term	O
adverse	O
clinical	O
outcomes	O
in	O
chronic	O
s	O
##ys	O
##to	O
##lic	O
H	O
##F	O
.	O

To	O
ensure	O
stab	O
##ilization	O
of	O
u	O
##rina	O
##ry	O
pH	O
,	O
500	O
µ	O
##l	O
of	O
urine	O
was	O
mixed	O
with	O
100	O
µ	O
##l	O
of	O
phosphate	S
buffer	O
(	O
90	O
%	O
D	O
##2	O
##O	O
,	O
1	O
m	O
##M	O
3	B
-	I
trim	I
##eth	I
##yl	I
##si	I
##ly	I
##l	I
-	I
1	I
-	I
[	I
2	I
,	I
2	I
,	I
3	I
,	I
3	I
-	I
_	I
2	I
H	I
##4	I
]	I
prop	I
##ion	I
##ate	I
(	O
T	O
##SP	O
)	O
,	O
and	O
3	O
m	O
##M	O
sodium	O
a	O
##zi	O
##de	O
;	O
pH	O
7	O
.	O
4	O
)	O
.	O

Standard	O
ca	O
##li	O
##bra	O
##tion	O
curves	O
were	O
prepared	O
using	O
the	O
following	O
concentration	O
ranges	O
:	O
5	O
–	O
250	O
µ	O
##M	O
for	O
a	B
##rg	I
##ini	I
##ne	I
,	O
0	O
.	O
05	O
–	O
2	O
.	O
5	O
µ	O
##M	O
for	O
AD	B
##MA	I
and	O
SD	O
##MA	O
,	O
1	O
–	O
50	O
µ	O
##M	O
for	O
c	B
##it	I
##ru	I
##llin	I
##e	I
,	O
and	O
0	O
.	O
14	O
–	O
7	O
.	O
0	O
µ	O
##M	O
for	O
D	B
##MA	I
.	O

For	O
other	O
PC	O
##s	O
such	O
as	O
PC	B
##36	I
:	I
5	I
we	O
found	O
a	O
V	O
-	O
pattern	O
or	O
a	O
steady	O
increase	O
(	B
PC	B
##40	I
:	I
7	I
)	O
,	O
both	O
meta	O
##bol	O
##ites	O
have	O
been	O
shown	O
to	O
be	O
inverse	O
##ly	O
associated	O
with	O
co	O
##rona	O
##ry	O
artery	O
disease	O
and	O
mortality	O
.	O

The	O
peaks	O
at	O
higher	O
mass	O
and	O
later	O
retention	O
time	O
are	O
from	O
the	O
t	B
##ria	I
##cy	I
##l	I
##gly	I
##cer	I
##ides	I
(	O
T	O
##AG	O
##s	O
)	O
while	O
the	O
cluster	O
of	O
peaks	O
at	O
earlier	O
retention	O
time	O
and	O
lower	O
mass	O
are	O
from	O
the	O
polar	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
(	O
a	O
)	O
.	O

The	O
p	O
##eptide	O
was	O
identified	O
as	O
A	O
##Q	O
##Y	O
##L	O
##Q	O
##Q	O
##C	O
*	O
P	O
##F	O
##ED	O
##H	O
##V	O
##K	O
(	O
170	O
##4	O
.	O
8	O
Da	O
)	O
modified	O
by	O
des	B
##ami	I
##no	I
-	I
Ph	I
##IP	I
(	O
207	O
Da	O
)	O
or	O
des	B
##ami	I
##no	I
-	I
[	I
_	I
2	I
H	I
_	I
5	I
]	I
-	O
Ph	O
##IP	O
(	O
212	O
Da	O
)	O
;	O
this	O
pair	O
of	O
p	O
##eptide	O
add	O
##uc	O
##ts	O
occurred	O
at	O
amino	O
acid	O
residues	O
28	O
–	O
41	O
of	O
SA	O
.	O

neutral	O
di	B
##ol	I
-	I
H	I
##IL	I
##IC	I
D	O
with	O
amid	B
##e	I
F	O
(	O
top	O
right	O
)	O
,	O
B	O
and	O
E	O
with	O
neutral	O
F	O
(	O
top	O
center	O
,	O
bottom	O
left	O
)	O
,	O
z	O
##wi	O
##tter	O
##ion	O
##ic	O
E	O
with	O
WA	O
##X	O
-	O
type	O
G	O
(	O
bottom	O
center	O
)	O
and	O
mixed	O
-	O
mode	O
methods	O
C	O
and	O
D	O
.	O

We	O
thereafter	O
combined	O
the	O
meta	O
##bol	O
##ites	O
into	O
various	O
sets	O
and	O
subjected	O
them	O
to	O
AU	O
##C	O
analysis	O
to	O
evaluate	O
their	O
diagnostic	O
performances	O
as	O
combined	O
bio	O
##mark	O
##ers	O
for	O
C	B
##IN	I
##s	I
and	O
c	O
##er	O
##vic	O
##al	O
cancer	O
##s	O
.	O

In	O
the	O
present	O
study	O
,	O
u	O
##rina	O
##ry	O
D	B
##MA	I
was	O
inverse	O
##ly	O
associated	O
with	O
log	O
(	O
T	O
##S	O
##H	O
)	O
in	O
cross	O
-	O
section	O
##al	O
analyses	O
.	O

Of	O
note	O
,	O
the	O
association	O
of	O
L	O
##CA	O
##T	O
activity	O
with	O
beta	B
##ine	I
was	O
no	O
longer	O
significant	O
after	O
adjustment	O
for	O
age	O
,	O
sex	O
,	O
diabetes	O
status	O
,	O
B	O
##MI	O
and	O
lip	O
##op	O
##rote	O
##in	O
variables	O
or	O
a	O
##poli	O
##pop	O
##rote	O
##ins	O
(	O
Table	O
,	O
models	O
1	O
and	O
2	O
)	O
.	O

The	O
effect	O
of	O
percent	O
met	B
##han	I
##ol	I
on	O
simultaneous	O
en	O
##anti	O
##ose	O
##par	O
##ation	O
of	O
O	O
-	O
D	O
##V	O
##X	O
and	O
V	O
##X	O
is	O
summarized	O
in	O
a	O
series	O
of	O
electro	O
##pher	O
##ogram	O
##s	O
shown	O
in	O
.	O

Compared	O
with	O
est	O
##rogen	O
##s	O
and	O
other	O
est	B
##rogen	I
meta	O
##bol	O
##ites	O
,	O
2	O
-	O
h	O
##ydro	O
##xy	O
##lation	O
pathway	O
cat	B
##ech	I
##ols	I
have	O
relatively	O
low	O
a	O
##ffin	O
##ities	O
for	O
est	B
##rogen	I
receptors	O
and	O
are	O
rapidly	O
cleared	O
from	O
circulation	O
.	O

However	O
,	O
add	O
##uc	O
##ts	O
formed	O
with	O
ben	B
##zen	I
##e	I
and	O
4	O
##AB	O
##P	O
(	B
su	B
##lf	I
##ona	I
##mi	I
##de	I
-	I
add	I
##uc	I
##t	I
with	O
sulfur	O
of	O
Cy	O
##s	O
)	O
yield	O
log	O
##D	O
values	O
of	O
−	O
##0	O
.	O
17	O
and	O
−	O
##0	O
.	O
12	O
,	O
respectively	O
,	O
at	O
pH	O
5	O
.	O
5	O
.	O

(	O
a	O
met	B
##hi	I
##oni	I
##ne	I
su	I
##lf	I
##oxide	I
red	O
##uc	O
##tase	O
)	O
within	O
the	O
peripheral	O
blood	O
was	O
uniquely	O
related	O
to	O
a	O
higher	O
risk	O
of	O
H	O
##E	O
(	O
+	O
37	O
%	O
)	O
,	O
while	O
within	O
the	O
f	O
##ae	O
##ces	O
,	O
the	O
genes	O
p	O
##dh	O
##D	O
/	O
K	O
##00	O
##38	O
##2	O

Besides	O
,	O
previous	O
study	O
employed	O
fragment	O
ion	O
m	O
/	O
z	O
281	O
(	O
[	O
M	O
-	O
H	O
-	O
H	O
_	O
2	O
O	O
-	O
CO	O
_	O
2	O
]	O
-	O
)	O
to	O
represent	O
17	B
-	I
HD	I
##o	I
##H	I
##E	I
,	O
yet	O
,	O
this	O
water	O
and	O
CO	O
_	O
2	O
loss	O
is	O
common	O
for	O
all	O
HD	O
##o	O
##H	O
##Es	O
.	O

Data	O
acquisition	O
was	O
performed	O
using	O
Ana	O
##ly	O
##st	O
software	O
1	O
.	O
6	O
(	O
Sc	O
##ie	O
##x	O
)	O
and	O
Multi	O
##Q	O
##uant	O
2	O
.	O
1	O
.	O
1	O
(	O
Sc	O
##ie	O
##x	O
)	O
for	O
q	O
##uant	O
##ification	O
of	O
all	O
vitamin	B
D	I
meta	O
##bol	O
##ites	O
.	O

Models	O
were	O
developed	O
by	O
adjustment	O
for	O
e	O
##G	O
##F	O
##R	O
,	O
the	O
level	O
of	O
u	O
##rina	O
##ry	O
protein	O
,	O
the	O
presence	O
of	O
diabetes	O
,	O
age	O
,	O
sex	O
,	O
calcium	B
*	I
phosphate	I
,	O
mean	O
blood	O
pressure	O
,	O
the	O
presence	O
of	O
past	O
card	O
##iovascular	O
events	O
,	O
and	O
the	O
level	O
of	O
hem	O
##og	O
##lo	O
##bin	O
.	O

Our	O
findings	O
revealed	O
that	O
individual	O
try	B
##pt	I
##op	I
##han	I
and	O
the	O
ratio	O
of	O
T	O
##rp	O
/	O
K	O
##yn	O
were	O
much	O
lower	O
in	O
pre	O
-	O
HD	O
and	O
pre	O
-	O
H	O
##F	O
##D	O
than	O
in	O
the	O
controls	O
,	O
whereas	O
the	O
individual	O
k	B
##yn	I
##uren	I
##ine	I
was	O
prominently	O
higher	O
in	O
patients	O
(	O
Fi	O
##g	O
.	O
)	O
.	O

All	O
women	O
we	O
examined	O
showed	O
detect	O
##able	O
levels	O
of	O
2	O
-	O
and	O
4	B
-	I
OH	I
-	I
E	I
_	I
2	I
.	O

It	O
is	O
worth	O
noting	O
that	O
by	O
using	O
a	O
much	O
larger	O
sampling	O
size	O
,	O
i	O
.	O
e	O
.	O
,	O
70	O
plasma	O
samples	O
,	O
previously	O
Wang	O
et	O
al	O
.	O
discovered	O
significant	O
changes	O
at	O
sub	O
##c	O
##lass	O
level	O
for	O
P	B
##E	I
38	I
:	I
4	I
and	O
P	B
##E	I
38	I
:	I
6	I
in	O
T	O
##2	O
##D	O
plasma	O
samples	O
.	O

Sam	O
##ple	O
loading	O
onto	O
the	O
en	O
##rich	O
##ment	O
column	O
was	O
set	O
at	O
a	O
flow	O
rate	O
of	O
4	O
µ	O
##L	O
/	O
min	O
with	O
a	O
97	O
:	O
3	O
ratio	O
of	O
solvent	O
A	O
and	O
B	O
(	O
A	O
:	O
100	O
%	O
H	O
_	O
2	O
O	O
,	O
0	O
.	O
1	O
%	O
FA	S
;	O
B	O
:	O
90	O
%	O
AC	O
##N	O
,	O
10	O
%	O
H	O
_	O
2	O
O	O
,	O
0	O
.	O
1	O
%	O
FA	O
)	O
.	O

If	O
during	O
high	O
-	O
intensive	O
exercise	O
the	O
ATP	S
degradation	O
rate	O
in	O
muscle	O
is	O
higher	O
than	O
the	O
ATP	S
re	O
##sy	O
##nt	O
##hesis	O
rate	O
,	O
accumulated	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
can	O
be	O
partly	O
re	O
##con	O
##verted	O
to	O
in	B
##os	I
##ine	I
mon	I
##op	I
##hos	I
##phate	I
(	O
I	O
##MP	O
)	O
by	O
the	O
pu	B
##rine	I
salvage	O
enzyme	O
h	O
##y	O
##pox	O
##ant	O
##hine	O
g	O
##uan	O
##ine	O
p	O
##hos	O
##ph	O
##ori	O
##bos	O
##yl	O
##tra	O
##ns	O
##fer	O
##ase	O
(	O
H	O
##GP	O
##RT	O
)	O
,	O
thus	O
contributing	O
to	O
ATP	S
restoration	O
,	O
or	O
it	O
leak	O
##s	O
out	O
to	O
the	O
blood	O
stream	O
where	O
a	O
further	O
degradation	O
to	O
u	B
##ric	I
acid	I
or	O
a	O
direct	O
elimination	O
from	O
body	O
via	O
urine	O
occurs	O
[	O
,	O
,	O
,	O
]	O
.	O

The	O
decrease	O
of	O
l	B
##ys	I
##ine	I
content	O
might	O
be	O
the	O
result	O
of	O
the	O
overs	O
##ynth	O
##esis	O
of	O
car	B
##ni	I
##tine	I
.	O

This	O
procedure	O
provided	O
patient	O
specific	O
ch	O
##em	O
##otype	O
##s	O
of	O
vitamin	B
D	I
meta	O
##bol	O
##ites	O
at	O
each	O
of	O
the	O
investigated	O
time	O
points	O
and	O
allowed	O
both	O
in	O
##tra	O
-	O
individual	O
as	O
well	O
as	O
inter	O
-	O
individual	O
comparisons	O
.	O

Similar	O
to	O
SM	B
##16	I
:	I
0	I
and	O
SM	B
##22	I
:	I
0	I
,	O
PC	B
##34	I
:	I
2	I
,	O
PC	B
##34	I
:	I
1	I
,	O
PC	B
##36	I
:	I
4	I
,	O
and	O
PC	B
##36	I
:	I
2	I
were	O
identified	O
in	O
the	O
extract	O
##s	O
of	O
protocols	O
(	O
i	O
)	O
–	O
(	O
i	O
##v	O
)	O
,	O
not	O
in	O
the	O
extract	O
##s	O
derived	O
from	O
protocols	O
(	O
v	O
)	O
and	O
(	O
v	O
##i	O
)	O
.	O

Regarding	O
patients	O
with	O
di	O
##abe	O
##tic	O
k	O
##eto	O
##ac	O
##ido	O
##sis	O
and	O
la	O
##ctic	O
acid	O
##osis	O
,	O
the	O
concentration	O
of	O
su	B
##cci	I
##nic	I
,	O
α	B
-	I
k	I
##eto	I
##g	I
##lut	I
##ari	I
##c	I
,	O
and	O
ma	O
##lic	O
acids	O
in	O
the	O
blood	O
increased	O
from	O
2	O
to	O
6	O
times	O
.	O

Ser	O
##ine	O
palm	O
##ito	O
##yl	O
##tra	O
##ns	O
##fer	O
##ase	O
(	O
SP	O
##T	O
)	O
is	O
the	O
enzyme	O
responsible	O
for	O
the	O
synthesis	O
of	O
L	O
##C	O
##B	O
by	O
con	O
##den	O
##sation	O
of	O
se	B
##rine	I
and	O
palm	B
##ito	I
##yl	I
-	I
Co	I
##A	I
,	O
its	O
preferred	O
substrate	O
.	O

Among	O
those	O
compounds	O
were	O
car	O
##bo	O
##hy	O
##dra	O
##te	O
-	O
related	O
meta	O
##bol	O
##ites	O
(	B
glucose	S
,	O
f	B
##ru	I
##ct	I
##ose	I
,	O
g	B
##lu	I
##con	I
##ic	I
acid	O
)	O
and	O
amino	O
acids	O
(	O
such	O
as	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
th	B
##re	I
##oni	I
##ne	I
,	O
se	B
##rine	I
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
g	B
##lut	I
##amine	I
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
v	B
##ali	I
##ne	I
,	O
g	B
##lut	I
##ama	I
##te	I
,	O
l	B
##ys	I
##ine	I
,	O
pro	B
##line	I
and	O
g	B
##ly	I
##cine	I
)	O
resulting	O
from	O
the	O
h	O
##ydro	O
##lysis	O
of	O
star	O
##ch	O
and	O
proteins	O
present	O
in	O
the	O
flat	O
##bre	O
##ad	O
.	O

Compared	O
with	O
the	O
control	O
population	O
,	O
six	O
meta	O
##bol	O
##ites	O
,	O
namely	O
le	B
##uc	I
##ine	I
,	O
prop	B
##yle	I
##ne	I
g	I
##ly	I
##co	I
##l	I
,	O
c	B
##it	I
##rate	I
,	O
β	B
-	I
glucose	I
,	O
ace	B
##tate	I
and	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
were	O
significantly	O
elevated	O
in	O
patients	O
with	O
BC	O
.	O

Val	B
##ine	I
;	O
5	O
.	O

At	O
base	O
##line	O
,	O
no	O
significant	O
differences	O
between	O
the	O
subgroup	O
##s	O
were	O
observed	O
;	O
at	O
week	O
24	O
,	O
Pi	O
##o	O
&	O
Omega	B
-	I
3	I
subgroup	O
showed	O
faster	O
metabolism	O
of	O
t	B
##ria	I
##cy	I
##l	I
##gly	I
##cer	I
##ol	I
(	O
lower	O
AU	O
##C	O
)	O
compared	O
with	O
both	O
Place	O
##bo	O
and	O
Omega	B
-	I
3	I
(	O
p	O
=	O
0	O
.	O
04	O
;	O
not	O
shown	O
)	O
.	O

However	O
,	O
Sa	O
##ros	O
##iek	O
et	O
al	O
observed	O
reduction	O
of	O
p	B
##yr	I
##u	I
##vate	I
at	O
1	O
month	O
after	O
bar	O
##ia	O
##tric	O
surgery	O
,	O
30	O
and	O
Tu	O
##lip	O
##ani	O
et	O
al	O
reported	O
reduction	O
of	O
c	O
##ir	O
##cula	O
##tory	O
p	B
##yr	I
##u	I
##vate	I
levels	O
following	O
bar	O
##ia	O
##tric	O
surgery	O
in	O
their	O
systematic	O
review	O
and	O
meta	O
‐	O
analysis	O
.	O
7	O
Furthermore	O
,	O
2	B
‐	I
met	I
##hyl	I
##g	I
##lut	I
##arate	I
,	O
which	O
is	O
a	O
meta	O
##bol	O
##ite	O
of	O
c	B
##it	I
##ric	I
acid	I
cycle	O
'	O
s	O
su	B
##cci	I
##nic	I
acid	I
,	O
52	O
was	O
also	O
significantly	O
reduced	O
following	O
R	O
##Y	O
##GB	O
at	O
6	O
months	O
in	O
the	O
present	O
pilot	O
study	O
,	O
and	O
this	O
has	O
not	O
been	O
previously	O
reported	O
.	O

Similar	O
investigations	O
here	O
on	O
whole	O
blood	O
meta	O
##bol	O
##ites	O
showed	O
that	O
the	O
reduced	O
forms	O
N	B
##AD	I
##H	I
and	O
N	B
##AD	I
##P	I
##H	I
become	O
o	O
##xi	O
##dized	O
to	O
N	O
##AD	O
_	O
+	O
and	O
N	O
##AD	O
##P	O
_	O
+	O
,	O
respectively	O
,	O
relatively	O
quickly	O
.	O

Legend	O
:	O
p	B
-	I
c	I
##res	I
##ol	I
su	I
##lf	I
##ate	I
(	O
the	O
top	O
two	O
plots	O
)	O
is	O
represented	O
by	O
a	O
met	O
##hyl	O
resonance	O
at	O
2	O
.	O
35	O
pp	O
##m	O
and	O
a	O
pseudo	O
-	O
double	O
##t	O
a	O
##romatic	O
resonance	O
at	O
7	O
.	O
21	O
pp	O
##m	O
.	O

In	O
the	O
volcano	O
plot	O
,	O
which	O
is	O
a	O
combination	O
of	O
fold	O
change	O
and	O
t	O
tests	O
,	O
the	O
following	O
7	O
variables	O
met	O
the	O
set	O
criteria	O
(	O
fold	O
change	O
threshold	O
1	O
.	O
5	O
and	O
the	O
F	O
##DR	O
-	O
corrected	O
p	O
value	O
threshold	O
0	O
.	O
05	O
)	O
:	O
l	O
##ys	O
##o	O
##PC	O
a	O
C	B
##26	I
:	I
0	I
;	O
l	O
##ys	O
##o	O
##PC	O
a	O
C	B
##26	I
:	I
1	I
;	O
PC	B
a	I
##a	I
C	I
##42	I
:	I
4	I
;	O
PC	B
a	I
##a	I
C	I
##34	I
:	I
4	I
;	O
PC	B
a	I
##e	I
C	I
##42	I
:	I
1	I
;	O
PC	B
a	I
##e	I
C	I
##44	I
:	I
3	I
;	O
PC	B
a	I
##a	I
C	I
##40	I
:	I
2	I
.	O

In	O
contrast	O
,	O
plasma	O
levels	O
of	O
u	B
##ric	I
acid	I
were	O
elevated	O
in	O
pneumonia	O
cases	O
.	O

E	O
##ster	O
##ified	O
o	B
##xy	I
##ster	I
##ols	I
have	O
been	O
anal	O
##ys	O
##ed	O
in	O
people	O
with	O
dem	O
##ent	O
##ia	O
and	O
card	O
##iovascular	O
diseases	O
although	O
there	O
is	O
no	O
consistent	O
relationship	O
between	O
o	B
##xy	I
##ster	I
##ol	I
est	I
##ers	I
and	O
disease	O
.	O

Solid	O
lines	O
indicate	O
significant	O
positive	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
correlation	O
##s	O
between	O
ben	B
##zo	I
##ates	I
and	O
amino	O
acid	O
meta	O
##bol	O
##ites	O
.	O

We	O
performed	O
MS	O
_	O
3	O
C	O
##ID	O
of	O
all	O
major	O
fragments	O
within	O
the	O
m	O
/	O
z	O
range	O
600	O
–	O
800	O
formed	O
from	O
MS	O
_	O
2	O
C	O
##ID	O
of	O
the	O
bi	O
##car	O
##bon	O
##ate	O
add	O
##uc	O
##t	O
of	O
PC	B
16	I
:	I
0	I
/	I
18	I
:	I
1	I
.	O

Using	O
these	O
selection	O
strategies	O
,	O
2	O
lip	O
##id	O
species	O
,	O
C	B
##18	I
:	I
2	I
CE	O
and	O
SM	O
22	O
:	O
0	O
,	O
were	O
identified	O
as	O
candidate	O
bio	O
##mark	O
##ers	O
for	O
the	O
early	O
detection	O
of	O
S	O
##q	O
##CC	O
disease	O
during	O
the	O
training	O
stage	O
.	O

Finally	O
,	O
the	O
high	O
levels	O
of	O
powerful	O
anti	O
##ox	O
##ida	O
##nts	O
detected	O
,	O
such	O
as	O
as	B
##cor	I
##bate	I
and	O
alpha	O
/	O
gamma	O
‐	O
to	O
##co	O
##pher	O
##ol	O
,	O
support	O
the	O
idea	O
that	O
an	O
accumulation	O
of	O
o	O
##xi	O
##da	O
##tive	O
stress	O
markers	O
and	O
anti	O
##ox	O
##ida	O
##nts	O
takes	O
place	O
in	O
lung	O
tumors	O
.	O

The	O
resulting	O
crude	O
residue	O
was	O
washed	O
th	O
##rice	O
using	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
(	O
5	O
m	O
##L	O
each	O
time	O
)	O
,	O
twice	O
with	O
ace	B
##tone	I
(	O
2	O
m	O
##L	O
each	O
time	O
)	O
followed	O
by	O
washing	O
again	O
once	O
with	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
(	O
3	O
m	O
##L	O
)	O
to	O
obtain	O
the	O
pure	O
_	O
15	O
N	O
-	O
substituted	O
p	O
##ht	O
##hali	O
##mi	O
##de	O
.	O
_	O
1	O
H	O
N	O
##MR	O
s	O
##pect	O
##ra	O
in	O
D	O
_	O
2	O
O	O
at	O
each	O
step	O
were	O
monitored	O
to	O
assess	O
the	O
purity	O
of	O
the	O
intermediate	O
product	O
.	O

p	O
=	O
0	O
.	O
02	O
and	O
GP	S
(	O
m	O
/	O
z	O
=	O
103	O
##1	O
.	O
54	O
##7	O
##7	O
##3	O
)	O

To	O
pre	O
##ci	O
##pit	O
##ate	O
protein	O
and	O
di	O
##sso	O
##cia	O
##te	O
vitamin	B
D	I
meta	O
##bol	O
##ites	O
from	O
vitamin	B
D	I
binding	O
proteins	O
,	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
(	O
500	O
μ	O
##L	O
for	O
SP	O
##E	O
and	O
LL	O
##E	O
,	O
150	O
μ	O
##L	O
for	O
μ	O
##el	O
##ution	O
SP	O
##E	O
)	O
was	O
added	O
and	O
v	O
##ortex	O
##ed	O
for	O
1	O
min	O
,	O
and	O
proteins	O
were	O
spun	O
down	O
by	O
cent	O
##ri	O
##fu	O
##gation	O
for	O
15	O
min	O
at	O
10	O
,	O
000	O
##×	O
##g	O
.	O

J	O
##W	O
##H	O
-	O
07	O
##3	O
h	B
##ydro	I
##xy	I
##ind	I
##ole	I
,	O
J	B
##W	I
##H	I
-	I
200	I
5	I
-	I
h	I
##ydro	I
##xy	I
##ind	I
##ole	I
,	O
and	O
J	O
##W	O
##H	O
-	O
210	O
pen	B
##tano	I
##ic	I
acid	I
were	O
not	O
detected	O
,	O
even	O
when	O
samples	O
contained	O
other	O
meta	O
##bol	O
##ites	O
originating	O
from	O
the	O
same	O
parent	O
compound	O
.	O

p	O
##hos	O
##p	O
hat	O
##id	O
##ic	O
acid	O
,	O
D	O
##AG	O
:	O
dig	B
##ly	I
##cer	I
##ide	I
,	O
PC	O
:	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
.	O

Furthermore	O
,	O
the	O
c	B
##it	I
##rate	I
signals	O
(	O
δ	O
2	O
.	O
55	O
−	O
##CH	O
_	O
2	O
;	O
δ	O
2	O
.	O
66	O
−	O
##CH	O
_	O
2	O
)	O
became	O
broader	O
after	O
treatment	O
with	O
cotton	O
wool	O
,	O
which	O
also	O
suggests	O
that	O
there	O
was	O
binding	O
of	O
this	O
meta	O
##bol	O
##ite	O
.	O

Only	O
ch	B
##olin	I
##e	I
,	O
2	B
-	I
o	I
##x	I
##ois	I
##oc	I
##ap	I
##roa	I
##te	I
,	O
3	B
-	I
met	I
##hyl	I
-	I
2	I
-	I
o	I
##x	I
##ova	I
##ler	I
##ate	I
,	O
I	B
##MP	I
,	O
and	O
p	B
##yr	I
##u	I
##vate	I
concentrations	O
were	O
not	O
different	O
between	O
any	O
of	O
the	O
three	O
conditions	O
.	O

Previous	O
meta	O
##bol	O
##omi	O
##cs	O
studies	O
already	O
linked	O
u	O
##rina	O
##ry	O
ex	O
##cre	O
##tion	O
of	O
g	B
##ly	I
##cine	I
,	O
al	B
##ani	I
##ne	I
and	O
la	B
##ctic	I
acid	I
with	O
thy	O
##roid	O
function	O
by	O
reporting	O
inverse	O
associations	O
with	O
F	O
##T	O
##4	O
in	O
cross	O
-	O
section	O
##al	O
analyses	O
.	O

Nonetheless	O
,	O
ad	O
##ip	O
##ocytes	O
accumulated	O
D	O
##NR	O
,	O
D	O
##OX	O
,	O
and	O
mit	B
##ox	I
##ant	I
##rone	I
,	O
suggesting	O
that	O
ad	O
##ip	O
##ocytes	O
can	O
se	O
##quest	O
##er	O
all	O
of	O
these	O
ch	O
##em	O
##oth	O
##era	O
##pies	O
from	O
their	O
micro	O
##en	O
##vir	O
##on	O
##ment	O
,	O
with	O
differences	O
only	O
in	O
subsequent	O
in	O
##tra	O
##cellular	O
metabolism	O
.	O

IS	O
##1	O
(	B
le	B
##vo	I
##f	I
##lo	I
##xa	I
##cin	I
)	O
:	O
36	O
##2	O
##→	O
##26	O
##1	O
;	O
IS	O
##2	O
(	O
he	O
##sper	O
##id	O
##in	O
)	O
:	O
61	O
##1	O
##→	O
##30	O
##3	O
;	O
negative	O
ion	O
mode	O
including	O
89	O
##→	O
##41	O
,	O
128	O
##→	O
##8	O
##2	O
,	O
129	O
##→	O
##8	O
##5	O
,	O
167	O
##→	O
##12	O
##4	O
,	O
178	O
##→	O
##13	O
##2	O
,	O
179	O
##→	O
##7	O
##1	O
,	O
187	O
##→	O
##80	O
,	O
187	O
##→	O
##5	O
##9	O
,	O
191	O
##→	O
##8	O
##5	O
,	O
204	O
##→	O
##14	O
##2	O
,	O
213	O
##→	O
##5	O
##9	O
,	O
215	O
##→	O
##5	O
##9	O
,	O
239	O
##→	O
##15	O
##1	O
,	O
241	O
##→	O
##5	O
##9	O
,	O
243	O
##→	O
##18	O
##3	O
,	O
26	O
##3	O
##→	O
##14	O
##5	O
,	O
26	O
##7	O
##→	O
##5	O
##9	O
,	O
26	O
##7	O
##→	O
##22	O
##3	O
,	O
27	O
##7	O
##→	O
##23	O
##3	O
,	O
27	O
##9	O
##→	O
##26	O
##1	O
,	O
281	O
##→	O
##21	O
##0	O
,	O
303	O
##→	O
##25	O
##9	O
,	O
307	O
##→	O
##5	O
##9	O
,	O
335	O
##→	O
##12	O
##4	O
,	O
36	O
##7	O
##→	O
##9	O
##7	O
,	O
36	O
##9	O
##→	O
##9	O
##7	O
,	O
38	O
##3	O
##→	O
##9	O
##7	O
,	O
39	O
##7	O
##→	O
##9	O
##7	O
,	O
40	O
##7	O
##→	O
##32	O
##5	O
,	O
44	O
##8	O
##→	O
##7	O
##4	O
,	O
46	O
##4	O
##→	O
##7	O
##4	O
,	O
47	O
##1	O
##→	O
##9	O
##7	O
,	O
47	O
##6	O
##→	O
##27	O
##9	O
,	O
480	O
##→	O
##22	O
##5	O
,	O
48	O
##5	O
##→	O
##46	O
##9	O
,	O
500	O
##→	O
##30	O
##3	O
,	O
50	O
##7	O
##→	O
##12	O
##3	O
,	O
512	O
##→	O
##43	O
##2	O
,	O
52	O
##4	O
##→	O
##19	O
##6	O
,	O
55	O
##6	O
##→	O
##27	O
##1	O
.	O

Although	O
these	O
two	O
molecules	O
were	O
not	O
identified	O
by	O
multi	O
##var	O
##iate	O
analysis	O
as	O
markers	O
in	O
serum	O
,	O
they	O
were	O
disc	O
##rim	O
##inating	O
for	O
milk	O
intake	O
in	O
serum	O
when	O
analyzed	O
in	O
a	O
targeted	O
manner	O
based	O
on	O
known	O
q	O
##uant	O
##ifier	O
and	O
qualifier	O
ion	O
as	O
well	O
as	O
R	B
##I	I
and	O
subsequent	O
un	O
##iva	O
##ria	O
##te	O
analysis	O
of	O
their	O
6	O
##h	O
-	O
i	O
##A	O
##UC	O
.	O

U	O
##rina	O
##ry	O
meta	O
##bol	O
##omi	O
##cs	O
combined	O
with	O
gene	O
expression	O
in	O
kidney	O
bio	O
##ps	O
##ies	O
displayed	O
per	O
##tur	O
##bation	O
##s	O
in	O
several	O
relevant	O
path	O
##op	O
##hy	O
##sio	O
##logy	O
pathways	O
in	O
early	O
h	O
##yper	O
##tensive	O
ne	O
##ph	O
##ros	O
##cle	O
##rosis	O
,	O
such	O
as	O
se	B
##rine	I
metabolism	O
(	O
end	O
##oth	O
##eli	O
##al	O
d	O
##ys	O
##function	O
and	O
o	O
##xi	O
##da	O
##tive	O
stress	O
)	O
,	O
met	B
##hi	I
##oni	I
##ne	I
metabolism	O
(	O
card	O
##iovascular	O
risk	O
and	O
fi	O
##bro	O
##sis	O
)	O
,	O
and	O
t	B
##yr	I
##os	I
##ine	I
metabolism	O
(	B
cat	B
##ech	I
##ola	I
##mine	I
bio	O
##sy	O
##nt	O
##hesis	O
and	O
na	O
##tri	O
##ures	O
##is	O
)	O
.	O

Inc	O
##rea	O
##sing	O
a	B
##rg	I
##ini	I
##ne	I
as	O
substrate	O
for	O
NO	O
s	O
##ynth	O
##ases	O
has	O
been	O
post	O
##ulated	O
to	O
increase	O
in	O
end	O
##oth	O
##eli	O
##al	O
NO	O
production	O
(	O
)	O
.	O

For	O
instance	O
,	O
our	O
study	O
employed	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
,	O
whereas	O
both	O
Mi	O
##cho	O
##po	O
##ulos	O
et	O
al	O
.	O

We	O
also	O
observed	O
down	O
##re	O
##gu	O
##lation	O
of	O
genes	O
that	O
encoded	O
enzymes	O
that	O
cat	O
##aly	O
##se	O
the	O
degradation	O
of	O
p	B
##hos	I
##ph	I
##och	I
##olin	I
##e	I
into	O
ch	B
##olin	I
##e	I
meta	O
##bol	O
##ite	O
,	O
mainly	O
from	O
the	O
p	O
##hos	O
##ph	O
##oli	O
##pas	O
##e	O
D	O
(	O
P	O
##LD	O
)	O
family	O
:	O
P	O
##L	O
##B	O
##1	O
,	O
P	O
##LD	O
##1	O
,	O
P	O
##NP	O
##LA	O
##7	O
,	O
P	O
##LA	O
##2	O
##G	O
##12	O
##B	O
,	O
P	O
##LA	O
##2	O
##G	O
##4	O
##C	O
(	O
B	O
)	O
.	O

The	O
resulting	O
MS	O
/	O
MS	O
data	O
for	O
vitamin	O
##s	O
A	O
,	O
D	O
,	O
E	O
,	O
K	O
as	O
well	O
as	O
the	O
s	O
##tero	O
##idal	O
molecules	O
(	O
4	O
-	O
15	O
)	O
showed	O
no	O
similarity	O
to	O
any	O
of	O
the	O
meta	O
##bol	O
##omi	O
##c	O
bio	O
##mark	O
##ers	O
;	O
for	O
vitamin	B
E	I
type	O
molecules	O
,	O
all	O
had	O
diagnostic	O
fragments	O
characteristic	O
of	O
their	O
ch	O
##roma	O
##n	O
rings	O
(	O
m	O
/	O
z	O
163	O
,	O
149	O
,	O
149	O
,	O
149	O
,	O
163	O
and	O
179	O
for	O
4	O
,	O
5	O
,	O
6	O
,	O
7	O
,	O
8	O
and	O
9	O
respectively	O
)	O
,	O
for	O
vitamin	B
D	I
and	O
analogue	O
##s	O
,	O
diagnostic	O
fragments	O
formed	O
as	O
a	O
result	O
of	O
the	O
loss	O
of	O
the	O
side	O
chain	O
(	O
m	O
/	O
z	O
27	O
##1	O
,	O
27	O
##3	O
and	O
253	O
,	O
for	O
10	O
,	O
11	O
and	O
13	O
,	O
respectively	O
)	O
,	O
for	O
p	B
##hyl	I
##lo	I
##quin	I
##one	I
(	O
13	O
)	O
,	O
the	O
diagnostic	O
fragment	O
m	O
/	O
z	O
187	O
for	O
the	O
q	B
##uin	I
##one	I
ring	O
system	O
was	O
prominent	O
,	O
for	O
vitamin	O
A	O
(	O
14	O
)	O
,	O
the	O
fragment	O
m	O
/	O
z	O
26	O
##9	O
(	O
M	O
+	O
H	O
-	O
H	O
_	O
2	O
O	O
)	O
loses	O
the	O
c	O
##y	O
##c	O
##lo	O
##he	O
##xy	O
##l	O
ring	O
m	O
##oi	O
##ety	O
to	O
form	O
a	O
diagnostic	O
m	O
/	O
z	O
145	O
for	O
re	B
##tino	I
##l	I
and	O
for	O
3	B
##β	I
,	I
7	I
##α	I
-	I
di	I
##hy	I
##dr	I
##ox	I
##y	I
-	I
5	I
-	I
ch	I
##ole	I
##sten	I
##oi	I
##c	I
acid	I
(	O
15	O
)	O
the	O
diagnostic	O
re	O
##tro	O
die	O
##ls	O
al	O
##der	O
fragment	O
at	O
m	O
/	O
z	O
27	O
##7	O
was	O
observed	O
.	O

Ni	B
##tro	I
##gen	I
gas	I
was	O
used	O
to	O
dry	O
the	O
super	O
##nat	O
##ant	O
for	O
MS	O
analysis	O
.	O

Since	O
our	O
results	O
also	O
reveal	O
that	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
are	O
significantly	O
elevated	O
in	O
H	O
##NS	O
##CC	O
,	O
this	O
class	O
of	O
meta	O
##bol	O
##ites	O
may	O
have	O
potential	O
as	O
a	O
bio	O
##mark	O
##er	O
for	O
e	O
##pit	O
##hel	O
##ial	O
-	O
derived	O
cancer	O
##s	O
.	O

Met	B
##hi	I
##oni	I
##ne	I
is	O
an	O
essential	O
amino	O
acid	O
and	O
a	O
precursor	O
of	O
ho	B
##mo	I
##cy	I
##stein	I
##e	I
,	O
a	O
meta	O
##bol	O
##ite	O
also	O
shown	O
highly	O
elevated	O
in	O
plasma	O
and	O
co	O
##lon	O
##ic	O
m	O
##uc	O
##osa	O
from	O
UC	O
and	O
CD	O
patients	O
.	O

For	O
DC	O
##C	O
r	O
##s	O
##12	O
##60	O
##4	O
##9	O
##40	O
S	O
##NP	O
,	O
we	O
didn	O
’	O
t	O
find	O
any	O
effect	O
on	O
DC	O
##C	O
gene	O
expression	O
or	O
on	O
a	B
##rac	I
##hi	I
##don	I
##ic	I
acid	I
levels	O
.	O

The	O
same	O
authors	O
observed	O
poor	O
precision	O
of	O
M	B
##T	I
##BE	I
LL	O
##E	O
with	O
e	O
##va	O
##por	O
##ation	O
/	O
re	O
##con	O
##st	O
##itution	O
step	O
whereby	O
only	O
56	O
%	O
of	O
detected	O
features	O
exhibited	O
RS	O
##D	O
≤	O
30	O
%	O
.	O

For	O
example	O
,	O
some	O
te	B
##rp	I
##ene	I
##s	I
,	O
such	O
as	O
α	B
-	I
te	I
##rp	I
##ine	I
##ol	I
and	O
l	B
##inal	I
##ool	I
occurring	O
as	O
mon	B
##oc	I
##yclic	I
respectively	O
a	B
##cy	I
##c	I
##lic	I
mon	I
##oter	I
##pen	I
##e	I
alcohol	I
##s	I
,	O
belong	O
by	O
their	O
functional	O
group	O
also	O
to	O
the	O
substance	O
class	O
of	O
alcohol	O
##s	O
.	O

Personal	O
data	O
of	O
patients	O
N	O
/	O
A	O
:	O
not	O
available	O
Clinical	O
data	O
of	O
patients	O
ER	O
=	O
est	O
##rogen	O
receptor	O
,	O
PR	B
=	I
pro	I
##ges	I
##tero	I
##ne	I
receptor	O
,	O
ER	O
##BB	O
##2	O
=	O
er	O
##b	O
-	O
b	O
##2	O
receptor	O
t	B
##yr	I
##os	I
##ine	I
kinase	O
2	O
,	O
Ki	O
##6	O
##7	O
=	O
proliferation	O
-	O
related	O
Ki	O
-	O
67	O
anti	O
##gen	O
All	O
patients	O
were	O
informed	O
about	O
the	O
study	O
and	O
those	O
who	O
agreed	O
and	O
signed	O
an	O
informed	O
consent	O
participated	O
in	O
the	O
study	O
.	O

Li	O
##pid	O
##s	O
and	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
were	O
statistical	O
##ly	O
important	O
metabolic	O
des	O
##cript	O
##ors	O
(	O
Fi	O
##g	O
.	O

A	B
##rg	I
##ini	I
##ne	I
is	O
involved	O
in	O
the	O
metabolism	O
of	O
ni	B
##tric	I
oxide	I
(	O
NO	O
)	O
,	O
a	O
type	O
of	O
v	O
##as	O
##od	O
##ila	O
##tor	O
and	O
free	O
radical	O
that	O
participates	O
in	O
the	O
inflammatory	O
process	O
and	O
car	O
##cin	O
##ogen	O
##esis	O
through	O
ni	O
##tro	O
-	O
o	O
##xi	O
##da	O
##tive	O
stress	O
,	O
a	O
##pop	O
##tosis	O
,	O
cell	O
cycle	O
,	O
an	O
##gio	O
##genesis	O
,	O
invasion	O
and	O
meta	O
##sta	O
##sis	O
.	O

The	O
samples	O
with	O
high	O
glucose	S
resonance	O
signals	O
in	O
representative	O
_	O
1	O
H	O
N	O
##MR	O
s	O
##pect	O
##ra	O
(	O
Figure	O
S	O
-	O
3	O
##A	O
)	O
were	O
identified	O
as	O
the	O
same	O
samples	O
from	O
the	O
H	O
##R	O
##MS	O
s	O
##pect	O
##ra	O
obtained	O
by	O
D	O
##I	O
–	O
n	O
##ES	O
##I	O
–	O
H	O
##R	O
##MS	O
in	O
E	O
##SI	O
+	O
(	O
Figure	O
S	O
-	O
3	O
##B	O
)	O
,	O
which	O
show	O
an	O
intense	O
signal	O
at	O
m	O
/	O
z	O
=	O

P	B
##uri	I
##fied	I
water	I
was	O
prepared	O
in	O
the	O
laboratory	O
using	O
a	O
Mill	O
##i	O
-	O
Q	O
G	O
##rad	O
##ient	O
purchased	O
from	O
Mill	O
##ip	O
##ore	O
AB	O
(	O
Sol	O
##na	O
,	O
Sweden	O
)	O
.	O

The	O
following	O
were	O
decreased	O
in	O
those	O
who	O
were	O
hospital	O
##ized	O
;	O
basic	O
amino	O
acids	O
,	O
saturated	O
fatty	O
acids	O
,	O
di	B
##car	I
##box	I
##yl	I
##ic	I
acids	I
,	O
pu	B
##rino	I
##nes	I
and	O
ad	O
##ip	O
##ates	O
.	O

Is	B
##op	I
##rop	I
##ano	I
##l	I
was	O
of	O
L	O
##C	O
-	O
MS	O
grade	O
(	O
Honey	O
##well	O
,	O
Michigan	O
,	O
USA	O
)	O
.	O

Twenty	O
-	O
four	O
meta	O
##bol	O
##ites	O
from	O
plasma	O
samples	O
and	O
24	O
meta	O
##bol	O
##ites	O
from	O
at	O
##rial	O
app	O
##end	O
##age	O
samples	O
were	O
screened	O
for	O
their	O
ability	O
to	O
distinguish	O
A	B
##F	I
from	O
non	O
-	O
A	O
##F	O
patients	O
(	O
Su	O
##pp	O
##lement	O
##ary	O
Table	O
##s	O
_	O
S	O
##1	O
and	O
_	O
S	O
##2	O
)	O
.	O

P	O
##las	O
##ma	O
ad	B
##eno	I
##sin	I
##e	I
was	O
decreased	O
in	O
females	O
(	O
,	O
Females	O
)	O
.	O

When	O
am	B
##lo	I
##di	I
##pine	I
effects	O
were	O
studied	O
and	O
both	O
s	O
##ys	O
##to	O
##lic	O
and	O
di	O
##ast	O
##olic	O
blood	O
pressure	O
responses	O
were	O
noted	O
,	O
the	O
most	O
consistent	O
effects	O
were	O
noted	O
for	O
two	O
meta	O
##bol	O
##ites	O
:	O
decreases	O
of	O
s	O
##ys	O
##to	O
##lic	O
and	O
di	O
##ast	O
##olic	O
blood	O
pressure	O
were	O
associated	O
with	O
a	O
decrease	O
of	O
plasma	O
c	B
##ys	I
##tein	I
##yl	I
##gly	I
##cine	I
(	O
P	O
=	O
0	O
.	O
000	O
##4	O
and	O
0	O
.	O
00	O
##1	O
,	O
respectively	O
)	O
and	O
,	O
to	O
somewhat	O
lesser	O
extent	O
,	O
of	O
he	B
##xa	I
##de	I
##cane	I
##dio	I
##ate	I
(	O
P	O
=	O
0	O
.	O
06	O
and	O
0	O
.	O
04	O
,	O
respectively	O
)	O
levels	O
.	O

The	O
mean	O
fast	O
##ing	O
T	B
##G	I
levels	O
in	O
the	O
H	O
##T	O
##G	O
group	O
were	O
significantly	O
higher	O
than	O
those	O
in	O
the	O
N	O
##T	O
##G	O
group	O
.	O

A	O
significant	O
difference	O
between	O
the	O
6	O
##h	O
-	O
i	O
##A	O
##UC	O
was	O
found	O
for	O
C	B
##15	I
:	I
0	I
,	O
but	O
not	O
for	O
C	B
##17	I
:	I
0	I
,	O
based	O
on	O
a	O
K	O
##rus	O
##kal	O
-	O
Wallis	O
test	O
of	O
the	O
three	O
food	O
groups	O
.	O

The	O
results	O
of	O
the	O
study	O
suggested	O
that	O
a	O
predominant	O
majority	O
of	O
the	O
identified	O
meta	O
##bol	O
##ites	O
showing	O
statistical	O
##ly	O
significant	O
concentration	O
differences	O
between	O
the	O
patient	O
group	O
and	O
the	O
control	O
group	O
were	O
mainly	O
cluster	O
##ed	O
in	O
several	O
key	O
pathways	O
,	O
including	O
those	O
associated	O
with	O
fatty	O
acid	O
metabolism	O
,	O
ad	B
##eno	I
##sin	I
##e	I
trip	I
##hos	I
##phate	I
(	O
ATP	O
)	O
degradation	O
,	O
pu	B
##rine	I
metabolism	O
and	O
end	B
##oc	I
##anna	I
##bino	I
##id	I
bio	O
##sy	O
##nt	O
##hesis	O
.	O

This	O
observation	O
##al	O
study	O
was	O
conducted	O
at	O
the	O
Am	B
##bro	I
##ise	I
Pa	O
##ré	O
Hospital	O
(	O
Mon	O
##s	O
,	O
Belgium	O
)	O
.	O

Total	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
HD	O
##L	O
,	O
and	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
were	O
measured	O
using	O
diagnostic	O
kits	O
from	O
Roche	O
(	O
Germany	O
)	O
.	O

A	O
close	O
correlation	O
of	O
the	O
level	O
of	O
su	B
##cci	I
##nic	I
acid	I
in	O
serum	O
and	O
se	O
##psis	O
-	O
induced	O
organ	O
d	O
##ys	O
##function	O
is	O
revealed	O
,	O
more	O
##over	O
the	O
most	O
significant	O
correlation	O
is	O
observed	O
at	O
high	O
concentrations	O
of	O
p	O
##hen	O
##olic	O
micro	O
##bial	O
meta	O
##bol	O
##ites	O
(	O
Ph	O
##CA	O
##s	O
)	O
in	O
late	O
-	O
stage	O
se	O
##psis	O
.	O

Additionally	O
,	O
high	O
levels	O
of	O
put	B
##res	I
##cine	I
were	O
similarly	O
shown	O
to	O
be	O
associated	O
with	O
he	O
##pa	O
##to	O
##to	O
##xi	O
##city	O
and	O
anti	O
##biotic	O
treatment	O
in	O
animal	O
models	O
.	O

Met	O
##ab	O
##oli	O
##tes	O
of	O
the	O
g	O
##ly	O
##cine	O
/	O
se	O
##rine	O
/	O
th	O
##re	O
##oni	O
##ne	O
subgroup	O
include	O
these	O
amino	O
acids	O
as	O
well	O
as	O
n	B
-	I
ace	I
##tly	I
##ls	I
##eri	I
##ne	I
and	O
beta	B
##ine	I
.	O

A	O
characterization	O
of	O
the	O
metabolic	O
profile	O
associated	O
with	O
serum	O
25	B
-	I
h	I
##ydro	I
##xy	I
##vi	I
##tam	I
##in	I
D	I

One	O
CS	O
##F	O
study	O
reported	O
higher	O
c	B
##era	I
##mi	I
##de	I
levels	O
in	O
moderate	O
versus	O
mild	O
or	O
severe	O
AD	O
,	O
while	O
another	O
examining	O
brain	O
tissue	O
reported	O
that	O
the	O
gene	O
expression	O
patterns	O
of	O
enzymes	O
participating	O
in	O
the	O
s	B
##phi	I
##ngo	I
##lip	I
##id	I
metabolism	O
pathway	O
varied	O
by	O
AD	O
severity	O
.	O

We	O
examined	O
the	O
proportion	O
of	O
est	O
##eri	O
##fied	O
to	O
free	O
car	B
##ni	I
##tine	I
##s	I
,	O
β	O
-	O
and	O
Ω	O
-	O
oxidation	O
,	O
and	O
the	O
rate	O
-	O
limiting	O
step	O
in	O
the	O
up	O
##take	O
of	O
fatty	O
acids	O
into	O
the	O
mit	O
##och	O
##ond	O
##ria	O
related	O
to	O
car	O
##ni	O
##tine	O
palm	O
##ito	O
##yl	O
transfer	O
##ase	O
I	O
(	O
CP	O
##T	O
##1	O
)	O
activity	O
.	O

These	O
essential	O
amino	O
acids	O
,	O
v	B
##ali	I
##ne	I
,	O
le	B
##uc	I
##ine	I
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
and	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
and	O
a	O
conditional	O
##ly	O
essential	O
amino	O
acid	O
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
play	O
important	O
roles	O
in	O
the	O
synthesis	O
of	O
specific	O
ne	O
##uro	O
##tra	O
##ns	O
##mit	O
##ters	O
,	O
protein	O
degradation	O
and	O
turnover	O
,	O
l	O
##ymph	O
##oc	O
##yte	O
growth	O
and	O
proliferation	O
,	O
den	O
##dr	O
##itic	O
cell	O
mat	O
##uration	O
,	O
g	B
##ly	I
##co	I
##gen	I
synthesis	O
,	O
energy	O
metabolism	O
,	O
and	O
so	O
on	O
_	O
,	O
_	O
,	O
_	O
,	O
_	O
,	O
_	O
,	O
.	O

Although	O
3	B
-	I
o	I
##x	I
##o	I
-	I
5	I
##β	I
-	I
ch	I
##ola	I
##n	I
-	I
24	I
-	I
o	I
##ic	I
acid	I
could	O
not	O
activate	O
L	O
##X	O
##R	O
##α	O
,	O
7	B
##α	I
,	I
12	I
##α	I
-	I
di	I
##hy	I
##dr	I
##ox	I
##y	I
-	I
3	I
-	I
o	I
##x	I
##o	I
-	I
5	I
##β	I
-	I
ch	I
##ola	I
##n	I
-	I
24	I
-	I
o	I
##ic	I
acid	I
was	O
found	O
to	O
be	O
an	O
L	O
##X	O
##R	O
l	O
##igan	O
##d	O
.	O

This	O
potentially	O
reveals	O
link	O
##ages	O
to	O
disturbance	O
##s	O
of	O
fatty	O
acid	O
metabolism	O
,	O
glucose	S
and	O
g	B
##ly	I
##co	I
##ly	I
##tic	I
activity	O
,	O
T	O
##CA	O
cycle	O
and	O
g	O
##lut	O
##ami	O
##no	O
##lysis	O
associated	O
with	O
tumor	O
proliferation	O
.	O

Our	O
finding	O
of	O
high	O
u	O
##rina	O
##ry	O
levels	O
of	O
glucose	S
in	O
o	O
##bes	O
##e	O
children	O
is	O
in	O
line	O
with	O
the	O
data	O
previously	O
reported	O
in	O
o	O
##bes	O
##e	O
children	O
[	O
,	O
,	O
,	O
]	O
and	O
adults	O
.	O

The	O
4	O
-	O
year	O
F	O
##U	O
of	O
the	O
Be	O
##MI	O
##M	O
study	O
showed	O
that	O
the	O
administration	O
of	O
a	O
new	O
formula	O
with	O
a	O
lower	O
protein	O
content	O
,	O
a	O
higher	O
content	O
of	O
alpha	B
-	I
la	I
##ct	I
##al	I
##bu	I
##min	I
en	O
##rich	O
##ed	O
w	B
##hey	I
and	O
containing	O
L	O
##C	O
-	O
P	O
##U	O
##FA	O
does	O
not	O
produce	O
me	O
##as	O
##urable	O
growth	O
differences	O
in	O
children	O
compared	O
with	O
children	O
receiving	O
a	O
standard	O
protein	O
content	O
formula	O
during	O
the	O
first	O
4	O
months	O
of	O
life	O
.	O

For	O
MS	O
analysis	O
,	O
1	O
m	O
##M	O
model	O
mixture	O
was	O
dissolved	O
in	O
200	O
μ	O
##L	O
H	O
_	O
2	O
O	O
of	O
which	O
10	O
μ	O
##L	O
was	O
di	O
##lut	O
##ed	O
10	O
-	O
fold	O
by	O
50	O
%	O
/	O
50	O
%	O
(	O
v	O
/	O
v	O
)	O
AC	O
##N	O
/	O
H	O
_	O
2	O
O	O
solution	O
with	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
.	O

We	O
examined	O
the	O
serum	O
meta	O
##bol	O
##ite	O
profile	O
associated	O
with	O
serum	O
25	B
-	I
h	I
##ydro	I
##xy	I
##vi	I
##tam	I
##in	I
D	I
levels	O
in	O
meta	O
##bol	O
##ites	O
obtained	O
from	O
both	O
a	O
nuclear	O
magnetic	O
resonance	O
s	O
##pect	O
##ros	O
##copy	O
(	O
N	O
##MR	O
)	O
-	O
and	O
a	O
mass	O
s	O
##pect	O
##rome	O
##try	O
(	O
MS	O
)	O
-	O
based	O
platform	O
.	O

Although	O
BR	O
##B	O
ant	B
##ho	I
##cy	I
##ani	I
##ns	I
are	O
structural	O
##ly	O
distinct	O
from	O
ch	B
##lor	I
##he	I
##xi	I
##dine	I
g	I
##lu	I
##cona	I
##te	I
,	O
the	O
post	O
-	O
r	O
##ins	O
##e	O
data	O
,	O
which	O
show	O
sustained	O
sa	O
##liva	O
##ry	O
levels	O
of	O
ant	B
##ho	I
##cy	I
##ani	I
##ns	I
,	O
suggest	O
that	O
BR	O
##B	O
ant	B
##ho	I
##cy	I
##ani	I
##ns	I
may	O
also	O
be	O
ads	O
##or	O
##bed	O
to	O
oral	O
tissues	O
and	O
/	O
or	O
oral	O
micro	O
##f	O
##lora	O
present	O
in	O
plaque	O
.	O

Hospital	O
-	O
based	O
measures	O
of	O
plasma	O
glucose	S
and	O
MS	O
-	O
based	O
measures	O
of	O
glucose	S
demonstrated	O
good	O
correlation	O
(	O
r	O
=	O
0	O
.	O
84	O
;	O
)	O
.	O

Ad	O
##ding	O
α	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
levels	O
to	O
a	O
model	O
including	O
most	O
known	O
metabolic	O
risk	O
factors	O
(	O
i	O
.	O
e	O
.	O
,	O
fast	O
##ing	O
and	O
2	O
-	O
hour	O
glucose	S
levels	O
,	O
fast	O
##ing	O
insulin	O
level	O
,	O
H	O
##b	O
##A	O
##1	O
##C	O
,	O
and	O
B	O
##MI	O
z	O
-	O
score	O
)	O
significantly	O
increased	O
the	O
ability	O
to	O
predict	O
de	O
##ter	O
##ior	O
##ations	O
in	O
D	O
##I	O
and	O
glucose	S
tolerance	O
over	O
time	O
.	O

After	O
successive	O
washing	O
with	O
solution	O
A	O
and	O
solution	O
B	O
(	O
0	O
.	O
1	O
%	O
T	O
##FA	O
and	O
80	O
%	O
ace	O
##ton	O
##it	O
##ril	O
##e	O
)	O
,	O
0	O
.	O
5	O
%	O
pipe	B
##rid	I
##ine	I
was	O
used	O
for	O
el	O
##ution	O
.	O

Moreover	O
,	O
a	O
decrease	O
in	O
g	B
##lut	I
##amine	I
level	O
can	O
be	O
explained	O
by	O
impaired	O
buffer	O
##ing	O
capacity	O
of	O
the	O
body	O
due	O
to	O
the	O
activity	O
of	O
the	O
honey	O
##bee	O
venom	O
.	O

Only	O
one	O
compound	O
,	O
u	O
##rina	O
##ry	O
g	B
##ly	I
##co	I
##lic	I
acid	I
,	O
was	O
found	O
to	O
be	O
statistical	O
##ly	O
significantly	O
different	O
between	O
H	O
##B	O
##V	O
and	O
HC	O
##V	O
patients	O
,	O
with	O
an	O
adjusted	O
p	O
value	O
of	O
0	O
.	O
02	O
##2	O
.	O

The	O
parallel	O
analysis	O
of	O
the	O
samples	O
with	O
S	O
##IM	O
##CA	O
-	O
P	O
_	O
+	O
and	O
Random	O
Forest	O
##s	O
allows	O
for	O
the	O
ability	O
to	O
verify	O
that	O
ions	O
,	O
which	O
are	O
identified	O
through	O
both	O
ways	O
(	O
i	O
.	O
e	O
.	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
)	O
,	O
are	O
highly	O
significant	O
,	O
as	O
depicted	O
through	O
two	O
completely	O
different	O
algorithms	O
.	O

Met	O
##ab	O
##oli	O
##tes	O
included	O
in	O
this	O
signature	O
comprised	O
amino	O
acids	O
,	O
saturated	O
,	O
mon	O
##ou	O
##ns	O
##at	O
##ura	O
##ted	O
,	O
and	O
p	O
##oly	O
##uns	O
##at	O
##ura	O
##ted	O
fatty	O
acids	O
,	O
dig	B
##ly	I
##cer	I
##ols	I
,	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
,	O
ch	B
##ole	I
##ster	I
##yl	I
est	I
##ers	I
,	O
bi	O
##le	O
acids	O
,	O
s	O
##tero	O
##ids	O
,	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##let	I
##han	I
##ola	I
##mine	I
,	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
,	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
-	I
in	I
##os	I
##ito	I
##l	I
,	O
c	B
##era	I
##mi	I
##de	I
,	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
,	O
and	O
mon	B
##oh	I
##ex	I
##osy	I
##l	I
##cer	I
##ami	I
##des	I
.	O

very	O
long	O
chain	O
c	B
##era	I
##mi	I
##des	I
,	O
mass	O
s	O
##pect	O
##rome	O
##try	O
,	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
,	O
valid	O
##ated	O
ass	O
##ay	O
,	O
diabetes	O

Again	O
co	B
##rt	I
##is	I
##ol	I
was	O
found	O
to	O
be	O
the	O
most	O
prominent	O
anal	O
##yte	O
contributing	O
to	O
separation	O
in	O
addition	O
to	O
do	B
##pa	I
##mine	I
,	O
so	B
##rb	I
##ito	I
##l	I
and	O
several	O
unknown	O
##s	O
.	O

Ham	O
'	O
s	O
F	O
-	O
12	O
supplemented	O
with	O
1	O
##×	O
pen	O
##ici	O
##llin	O
/	O
s	O
##tre	O
##pt	O
##omy	O
##cin	O
and	O
1	O
##×	O
/	O
2	O
m	O
##M	O
g	B
##lut	I
##ama	I
##x	I
.	O

Met	O
##ab	O
##oli	O
##tes	O
were	O
extracted	O
by	O
adding	O
four	O
volumes	O
of	O
cold	O
met	B
##han	I
##ol	I
to	O
the	O
plasma	O
sample	O
(	O
10	O
μ	O
##L	O
)	O
;	O
samples	O
were	O
v	O
##ortex	O
##ed	O
and	O
in	O
##cu	O
##bate	O
##d	O
at	O
−	O
##20	O
°C	O
for	O
1	O
h	O
.	O

Co	O
##mp	O
##aris	O
##on	O
of	O
Self	O
-	O
Report	O
##ed	O
Ana	O
##lge	O
##si	O
##c	O
Use	O
With	O
Det	O
##ec	O
##tion	O
of	O
U	O
##rina	O
##ry	O
Ace	B
##tam	I
##ino	I
##phe	I
##n	I
and	O
/	O
or	O
I	B
##bu	I
##p	I
##ro	I
##fen	I
Met	O
##ab	O
##oli	O
##tes	O
for	O
Part	O
##ici	O
##pants	O
at	O
Western	O
Location	O
##s	O
,	O
International	O
Study	O
of	O
Mac	O
##ro	O
-	O
/	O
Micro	O
-	O
N	O
##ut	O
##rient	O
##s	O
and	O
Blood	O
Press	O
##ure	O
,	O
1996	O
–	O
1999	O
A	O
##bb	O
##re	O
##viation	O
:	O
C	O
##I	O
,	O
confidence	O
interval	O
.	O

[	O
m	O
/	O
z	O
278	O
.	O
06	O
##50	O
]	O
is	O
a	O
product	O
of	O
the	O
oxidation	O
of	O
Te	B
##tra	I
##hy	I
##dr	I
##ob	I
##io	I
##pt	I
##eri	I
##n	I
(	O
B	O
##H	O
_	O
4	O
)	O
,	O
an	O
important	O
co	O
##fa	O
##ctor	O
for	O
NO	O
s	O
##ynth	O
##ase	O
(	O
NO	O
##S	O
)	O
.	O

Additionally	O
,	O
from	O
the	O
three	O
group	O
analysis	O
,	O
we	O
have	O
observed	O
try	B
##pt	I
##op	I
##han	I
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
and	O
c	B
##rea	I
##tine	I
as	O
common	O
meta	O
##bol	O
##ites	O
present	O
in	O
both	O
tissue	O
and	O
serum	O
.	O

Under	O
conditions	O
of	O
increased	O
o	O
##xi	O
##da	O
##tive	O
stress	O
,	O
a	O
higher	O
flux	O
of	O
c	B
##ys	I
##tein	I
##e	I
into	O
production	O
of	O
g	B
##lut	I
##ath	I
##ione	I
,	O
the	O
primary	O
anti	O
##ox	O
##ida	O
##nt	O
in	O
cells	O
,	O
occurs	O
from	O
a	O
shift	O
in	O
ho	B
##mo	I
##cy	I
##stein	I
##e	I
production	O
from	O
trans	O
##met	O
##hyl	O
##ation	O
of	O
met	B
##hi	I
##oni	I
##ne	I
to	O
trans	O
##sul	O
##fu	O
##ration	O
of	O
ho	B
##mo	I
##cy	I
##stein	I
##e	I
to	O
produce	O
c	B
##ys	I
##tat	I
##hi	I
##oni	I
##ne	I
.	O

Recent	O
publication	O
by	O
Zhou	O
et	O
al	O
discussed	O
the	O
differential	O
metabolism	O
of	O
car	B
##ni	I
##tine	I
##s	I
in	O
serum	O
and	O
urine	O
of	O
patients	O
with	O
HC	O
##C	O
and	O
c	O
##ir	O
##r	O
##hos	O
##is	O
,	O
and	O
concluded	O
that	O
depending	O
on	O
the	O
cause	O
and	O
the	O
progression	O
of	O
liver	O
damage	O
,	O
the	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
with	O
short	O
chain	O
and	O
long	O
chain	O
could	O
show	O
reverse	O
accumulation	O
in	O
c	O
##ir	O
##r	O
##hos	O
##is	O
and	O
HC	O
##C	O
.	O

Names	O
of	O
the	O
features	O
were	O
adopted	O
from	O
X	O
##CM	O
##S	O
using	O
“	O
M	O
”	O
followed	O
by	O
the	O
rounded	O
mass	O
and	O
“	O
T	O
”	O
followed	O
by	O
the	O
retention	O
time	O
in	O
seconds	O
(	O
e	O
.	O
g	O
.	O
“	O
M	O
##21	O
##8	O
##T	O
##21	O
##6	O
”	O
as	O
given	O
in	O
Table	O
for	O
pro	O
##ton	O
##ated	O
alpha	B
-	I
P	I
##B	I
##P	I
at	O
m	O
/	O
z	O
218	O
.	O
154	O
##0	O
and	O
a	O
retention	O
time	O
of	O
216	O
s	O
using	O
a	O
Ph	O
##en	O
##yl	O
##H	O
##ex	O
##yl	O
column	O
)	O
.	O

However	O
,	O
the	O
serum	O
concentration	O
of	O
AA	O
,	O
a	O
major	O
ω	B
-	I
6	I
P	I
##U	I
##FA	I
,	O
was	O
higher	O
in	O
urgent	O
##s	O
vs	O
.	O
as	O
##ym	O
##pt	O
##oma	O
##tic	O
(	O
0	O
.	O
42	O
##9	O
±	O
0	O
.	O
04	O
##6	O
μ	O
##M	O
versus	O
0	O
.	O
257	O
±	O
0	O
.	O
03	O
##5	O
μ	O
##M	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
.	O

The	O
quantities	O
of	O
identified	O
s	O
##tero	O
##ls	O
and	O
bi	O
##le	O
acids	O
in	O
CS	O
##F	O
were	O
determined	O
by	O
is	O
##oto	O
##pe	O
di	O
##lution	O
mass	O
s	O
##pect	O
##rome	O
##try	O
against	O
a	O
known	O
amount	O
of	O
added	O
24	O
(	O
SR	O
)	O
-	B
[	B
_	I
2	I
H	I
_	I
6	I
]	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
(	O
100	O
%	O
[	O
_	O
2	O
H	O
_	O
6	O
]	O
)	O
internal	O
standard	O
(	O
IS	O
)	O
.	O

C	O
##it	O
c	B
##it	I
##rate	I
,	O
all	O
other	O
abbreviation	O
##s	O
and	O
numbering	O
are	O
as	O
in	O
.	O

In	O
the	O
current	O
study	O
,	O
c	B
##yt	I
##id	I
##ine	I
,	O
the	O
most	O
strongly	O
retained	O
of	O
the	O
n	O
##uc	O
##leo	O
##base	O
##s	O
tested	O
,	O
only	O
el	O
##uted	O
from	O
the	O
amid	B
##e	I
column	O
when	O
5	O
%	O
water	O
was	O
used	O
as	O
an	O
add	O
##itive	O
:	O
this	O
supports	O
the	O
findings	O
of	O
Taylor	O
and	O
other	O
groups	O
,	O
and	O
suggests	O
that	O
water	O
could	O
be	O
used	O
in	O
combination	O
with	O
other	O
add	O
##itive	O
##s	O
to	O
improve	O
separation	O
of	O
the	O
most	O
polar	O
anal	O
##yte	O
##s	O
,	O
.	O

The	O
internal	O
standard	O
(	B
7	B
-	I
dim	I
##eth	I
##yla	I
##min	I
##o	I
-	I
5	I
,	I
5	I
-	I
dip	I
##hen	I
##yl	I
-	I
4	I
-	I
o	I
##ct	I
##ano	I
##ne	I
,	O
2	O
.	O
5	O
ng	O
)	O
was	O
added	O
to	O
plasma	O
(	O
0	O
.	O
5	O
m	O
##l	O
)	O
,	O
which	O
was	O
acid	O
##ified	O
and	O
processed	O
by	O
solid	O
phase	O
extraction	O
(	O
O	O
##asis	O
MC	O
##X	O
cartridges	O
,	O
Waters	O
Corp	O
,	O
Massachusetts	O
USA	O
)	O
according	O
to	O
the	O
manufacturers	O
instructions	O
.	O

Thus	O
,	O
u	O
##rina	O
##ry	O
is	B
##op	I
##ros	I
##tan	I
##e	I
concentrations	O
in	O
our	O
study	O
may	O
not	O
accurately	O
reflect	O
the	O
state	O
of	O
o	O
##xi	O
##da	O
##tive	O
stress	O
during	O
the	O
critical	O
window	O
(	O
e	O
.	O
g	O
.	O
,	O
transition	O
from	O
round	O
to	O
elongated	O
sperm	O
##ati	O
##ds	O
)	O
when	O
mit	O
##och	O
##ond	O
##ria	O
and	O
m	O
##t	O
##D	O
##NA	O
##c	O
##n	O
are	O
depleted	O
.	O

While	O
the	O
exact	O
role	O
of	O
SM	B
C	I
##24	I
:	I
1	I
in	O
the	O
progression	O
of	O
H	O
##B	O
##V	O
-	O
induced	O
liver	O
disease	O
is	O
yet	O
to	O
be	O
fully	O
determined	O
,	O
the	O
significant	O
decrease	O
seen	O
in	O
the	O
H	O
##B	O
##V	O
-	O
associated	O
c	O
##ir	O
##r	O
##hos	O
##is	O
stage	O
motivated	O
us	O
to	O
seek	O
a	O
connection	O
with	O
fi	O
##bro	O
##sis	O
.	O

Of	O
the	O
est	O
##rogen	O
##s	O
and	O
est	B
##rogen	I
meta	O
##bol	O
##ites	O
,	O
un	O
##con	O
##ju	O
##gated	O
est	B
##rad	I
##iol	I
was	O
most	O
strongly	O
associated	O
with	O
increased	O
risk	O
of	O
ER	O
+	O
breast	O
cancer	O
.	O

HP	O
##LC	O
-	O
MS	O
grade	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
,	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
,	O
and	O
ace	B
##tic	I
acid	I
were	O
all	O
purchased	O
from	O
Fisher	O
Scientific	O
(	O
Pittsburgh	O
,	O
PA	O
,	O
USA	O
)	O
.	O

He	O
##pa	O
##to	O
##cy	O
##tes	O
(	O
approximately	O
0	O
.	O
12	O
mg	O
of	O
protein	O
per	O
well	O
)	O
were	O
in	O
##cu	O
##bate	O
##d	O
with	O
BP	O
##DE	O
or	O
re	O
##v	O
-	O
BP	O
##DE	O
,	O
dissolved	O
in	O
20	O
μ	O
##l	O
of	O
dim	B
##eth	I
##yl	I
su	I
##lf	I
##oxide	I
,	O
for	O
a	O
final	O
substrate	O
concentration	O
of	O
10	O
μ	O
##M	O
,	O
except	O
as	O
noted	O
in	O
.	O

As	B
##pi	I
##rin	I
and	O
c	B
##lop	I
##ido	I
##g	I
##rel	I
(	O
both	O
300	O
mg	O
)	O
or	O
t	O
##ica	O
##g	O
##rel	O
##or	O
(	O
180	O
mg	O
)	O
were	O
administered	O
before	O
cat	O
##he	O
##ter	O
##ization	O
.	O

The	O
multi	O
##var	O
##iable	O
linear	O
association	O
between	O
lip	O
##op	O
##rote	O
##ins	O
and	O
pro	B
##ges	I
##tero	I
##ne	I
receptor	O
status	O
(	O
%	O
)	O
,	O
adjusted	O
for	O
age	O
,	O
B	O
##MI	O
and	O
men	O
##op	O
##aus	O
##al	O
status	O
with	O
95	O
%	O
confidence	O
interval	O
.	O

Interest	O
##ingly	O
,	O
only	O
one	O
species	O
each	O
of	O
PA	O
and	O
P	B
##G	I
was	O
detected	O
in	O
v	O
##iri	O
##ons	O
:	O
PA	B
(	I
38	I
:	I
4	I
)	I
and	O
P	B
##G	I
(	I
36	I
:	I
2	I
)	I
.	O

Try	O
##pt	O
##op	O
##han	O
2	O
,	O
3	O
-	O
di	O
##ox	O
##y	O
##gen	O
##ase	O
,	O
K	O
##AT	O
=	O
K	O
##yn	O
##uren	O
##ine	O
amino	O
##tra	O
##ns	O
##fer	O
##ase	O
,	O
K	O
##Y	O
##NU	O
=	O
K	O
##yn	O
##uri	O
##nas	O
##e	O
,	O
3	O
-	O
H	O
##AA	O
##O	O
=	O
3	O
-	O
H	O
##ydro	O
##xy	O
##ant	O
##hra	O
##ni	O
##late	O
3	O
,	O
4	O
-	O
di	O
##ox	O
##y	O
##gen	O
##ase	O
,	O
K	O
##MO	O
=	O
K	O
##yn	O
##uren	O
##ine	O
mon	O
##oo	O
##xy	O
##gen	O
##ase	O
,	O
3	O
-	O
HK	O
=	O
3	B
-	I
H	I
##ydro	I
##xy	I
##ky	I
##nu	I
##ren	I
##ine	I
,	O
3	O
-	O
H	O
##AA	O
=	O
3	B
-	I
H	I
##ydro	I
##xy	I
##ant	I
##hra	I
##ni	I
##lli	I
##c	I
acid	I

Many	O
tumors	O
are	O
metabolic	O
##ally	O
distinct	O
from	O
non	O
-	O
neo	O
##p	O
##lastic	O
tissue	O
(	O
e	O
.	O
g	O
.	O
,	O
_	O
18	O
F	B
-	I
de	I
##ox	I
##y	I
##g	I
##lu	I
##cos	I
##e	I
P	O
##ET	O
activity	O
)	O
,	O
reflecting	O
the	O
pronounced	O
g	B
##ly	I
##co	I
##ly	I
##tic	I
metabolism	O
of	O
cancer	O
cells	O
.	O

Then	O
,	O
50	O
µ	O
##L	O
of	O
internal	O
standard	O
solution	O
and	O
50	O
µ	O
##L	O
of	O
enzyme	O
solution	O
(	O
E	O
##scher	O
##ichi	O
##a	O
co	O
##li	O
,	O
type	O
IX	O
-	O
A	O
,	O
20	O
units	O
/	O
µ	O
##L	O
,	O
0	O
.	O
5	O
M	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
,	O
pH	O
6	O
.	O
8	O
)	O
were	O
added	O
into	O
all	O
samples	O
.	O

S	B
##per	I
##mi	I
##dine	I
,	O
one	O
member	O
of	O
the	O
p	B
##oly	I
##amine	I
meta	O
##bol	O
##ites	O
,	O
is	O
required	O
for	O
ma	O
##mmal	O
##ian	O
cell	O
growth	O
and	O
has	O
long	O
been	O
associated	O
with	O
cancer	O
progression	O
.	O

Following	O
confirmation	O
of	O
the	O
efficiency	O
of	O
the	O
na	O
##no	O
##ele	O
##ct	O
##ros	O
##pra	O
##y	O
L	O
##C	O
-	O
EC	O
-	O
array	O
-	O
MS	O
platform	O
,	O
we	O
examined	O
next	O
its	O
practical	O
utility	O
toward	O
the	O
identification	O
of	O
unknown	O
meta	O
##bol	O
##ites	O
of	O
the	O
pro	O
-	O
drug	O
sodium	B
p	I
##hen	I
##yl	I
##but	I
##yra	I
##te	I
(	O
P	O
##B	O
)	O
in	O
patient	O
serum	O
.	O

Conversely	O
to	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
,	O
some	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
derivatives	O
such	O
as	O
PC	B
a	I
##e	I
40	O
.	O
1	O
,	O
PC	B
a	I
##e	I
42	I
:	I
2	I
and	O
PC	B
a	I
##e	I
42	I
:	I
3	I
were	O
significantly	O
lower	O
in	O
the	O
serum	O
of	O
G	O
##C	O
patients	O
.	O

The	O
lowest	O
variations	O
were	O
obtained	O
for	O
the	O
s	B
##phi	I
##ngo	I
##lip	I
##id	I
and	O
fatty	O
a	O
##cy	O
##ls	O
families	O
with	O
an	O
average	O
RS	O
##D	O
of	O
3	O
.	O
9	O
and	O
5	O
.	O
8	O
%	O
,	O
respectively	O
,	O
whereas	O
the	O
highest	O
variations	O
were	O
found	O
for	O
neutral	O
lip	O
##id	O
families	O
with	O
20	O
.	O
1	O
and	O
16	O
.	O
9	O
%	O
for	O
D	O
##G	O
and	O
T	B
##G	I
species	O
,	O
respectively	O
.	O

In	O
our	O
study	O
,	O
variations	O
of	O
k	B
##eton	I
##e	I
bodies	O
and	O
related	O
compounds	O
including	O
ace	B
##tone	I
,	O
ace	B
##tate	I
,	O
and	O
ace	B
##tam	I
##ide	I
were	O
observed	O
that	O
are	O
related	O
to	O
lip	O
##id	O
metabolism	O
.	O

It	O
has	O
recently	O
been	O
shown	O
that	O
mitochondrial	O
M	O
##TH	O
##F	O
##D	O
##2	O
##L	O
is	O
responsible	O
for	O
producing	O
20	O
–	O
40	O
%	O
of	O
cellular	O
N	B
##AD	I
##P	I
##H	I
by	O
the	O
oxidation	O
of	O
met	B
##hyl	I
##ene	I
te	I
##tra	I
##hy	I
##dr	I
##of	I
##olic	I
acid	I
to	O
10	B
-	I
form	I
##yl	I
te	I
##tra	I
##hy	I
##dr	I
##of	I
##olate	I
.	O

We	O
have	O
also	O
published	O
data	O
from	O
the	O
CA	O
##P	O
study	O
co	O
##rrel	O
##ating	O
enter	O
##ic	O
micro	O
##bio	O
##me	O
meta	O
##bol	O
##ites	O
to	O
si	B
##m	I
##vas	I
##tat	I
##in	I
response	O
,	O
identifying	O
three	O
secondary	O
bacterial	O
-	O
derived	O
bi	O
##le	O
acids	O
that	O
contributed	O
to	O
prediction	O
of	O
beneficial	O
si	B
##m	I
##vas	I
##tat	I
##in	I
response	O
.	O

Except	O
for	O
ben	B
##zen	I
##e	I
1	I
,	I
4	I
-	I
bi	I
##s	I
(	I
1	I
,	I
1	I
-	I
dim	I
##eth	I
##yle	I
##thy	I
##l	I
)	I
,	O
h	B
##ydro	I
##car	I
##bon	I
##s	I
showed	O
higher	O
levels	O
in	O
the	O
f	O
##eca	O
##l	O
samples	O
of	O
N	O
##P	O
patients	O
with	O
respect	O
to	O
HC	O
.	O

In	O
our	O
study	O
,	O
we	O
used	O
sur	O
##rogate	O
standards	O
to	O
reference	O
GM	B
##3	I
levels	O
because	O
no	O
suitable	O
synthetic	O
GM	B
##3	I
standards	O
exist	O
.	O

Pre	O
##tre	O
##at	O
##ment	O
of	O
SA	O
with	O
the	O
selective	O
th	B
##iol	I
re	O
##age	O
##nts	O
4	O
-	O
C	O
##MB	O
or	O
NE	O
##M	O
prior	O
to	O
reaction	O
with	O
N	B
-	I
ace	I
##to	I
##xy	I
-	I
Ph	I
##IP	I
,	O
decreased	O
the	O
amounts	O
of	O
Ph	O
##IP	O
and	O
5	B
-	I
H	I
##O	I
-	I
Ph	I
##IP	I
recovered	O
from	O
the	O
pro	O
##te	O
##oly	O
##tic	O
dig	O
##est	O
by	O
3	O
-	O
fold	O
.	O

H	B
##ydro	I
##phi	I
##lic	I
and	O
h	O
##ydro	O
##phobic	O
compounds	O
were	O
analyzed	O
using	O
un	O
##iva	O
##ria	O
##te	O
and	O
multi	O
##var	O
##iate	O
supervised	O
analysis	O
or	O
##th	O
##ogo	O
##nal	O
partial	O
least	O
square	O
disc	O
##rim	O
##ina	O
##nt	O
analysis	O
(	O
O	O
##PL	O
##S	O
-	O
D	O
##A	O
)	O
.	O

Basel	O
##ine	O
log	O
10	B
8	I
-	I
is	I
##o	I
-	I
P	I
##G	I
##F	I
_	I
2	I
##α	I
and	O
race	O
were	O
also	O
significant	O
in	O
this	O
multi	O
##var	O
##iable	O
model	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
but	O
sex	O
was	O
not	O
(	O
p	O
>	O
0	O
.	O
05	O
)	O
.	O

d	O
U	O
##rine	O
analyses	O
of	O
di	B
##os	I
##met	I
##in	I
g	O
##lu	O
##cu	O
##ron	O
##ides	O
were	O
also	O
performed	O
using	O
a	O
high	O
-	O
through	O
##put	O
high	O
-	O
performance	O
liquid	O
ch	O
##roma	O
##tography	O
(	O
HP	O
##LC	O
)	O
system	O
model	O
Aria	O
L	O
##X	O
-	O
2	O
similar	O
to	O
the	O
one	O
described	O
above	O
.	O

Figure	O
shows	O
there	O
is	O
no	O
signal	O
for	O
P	B
##G	I
##F	I
_	I
2	I
##α	I
in	O
the	O
procedure	O
blank	O
sample	O
while	O
a	O
high	O
level	O
of	O
P	B
##G	I
##F	I
_	I
2	I
##α	I
were	O
found	O
especially	O
in	O
the	O
H	O
.	O
p	O
##oma	O
##tia	O
G	O
##US	O
blank	O
sample	O
.	O

With	O
regard	O
to	O
potential	O
sur	O
##rogate	O
markers	O
of	O
disease	O
,	O
the	O
robust	O
increase	O
in	O
nearly	O
a	O
dozen	O
plasma	O
c	B
##era	I
##mi	I
##des	I
in	O
G	O
##WI	O
veterans	O
suggests	O
that	O
a	O
reduction	O
in	O
c	B
##era	I
##mi	I
##des	I
might	O
merit	O
assessment	O
as	O
a	O
bio	O
##chemical	O
marker	O
of	O
treatment	O
benefit	O
in	O
new	O
clinical	O
trials	O
.	O

Li	O
##pop	O
##rote	O
##in	O
profiles	O
,	O
inflammatory	O
markers	O
,	O
album	O
##in	O
and	O
c	B
##rea	I
##tin	I
##ine	I
levels	O
were	O
determined	O
at	O
the	O
Clinical	O
Chemistry	O
Laboratory	O
,	O
Lund	O
University	O
.	O

In	O
h	O
##y	O
##po	O
##gon	O
##adi	O
##sm	O
,	O
car	B
##nos	I
##ine	I
,	O
as	O
well	O
as	O
its	O
component	O
β	B
-	I
al	I
##ani	I
##ne	I
and	O
u	B
##rac	I
##il	I
,	O
from	O
which	O
the	O
latter	O
is	O
derived	O
are	O
strongly	O
decreased	O
(	O
Fi	O
##g	O
.	O

For	O
im	O
##mu	O
##no	O
##his	O
##to	O
##chemistry	O
,	O
P	O
##IN	O
-	O
4	O
pre	O
-	O
di	O
##lut	O
##ed	O
cocktail	O
(	O
P	O
##50	O
##4	O
##S	O
,	O
HM	O
##W	O
Cy	B
##tok	I
##era	I
##tin	I
##s	I
,	O
and	O
p	O
##6	O
##3	O
;	O
Cat	O
#	O
PP	O
##M	O
225	O
##DS	O
)	O
was	O
purchased	O
from	O
B	O
##io	O
##care	O
Medical	O
(	O
Concord	O
,	O
CA	O
,	O
USA	O
)	O
.	O

Co	O
##mp	O
##aring	O
within	O
each	O
B	O
##MI	O
co	O
##hor	O
##t	O
,	O
there	O
were	O
no	O
significant	O
differences	O
between	O
the	O
his	O
##tology	O
groups	O
in	O
fast	O
##ing	O
serum	O
total	O
ch	B
##ole	I
##ster	I
##ol	I
(	O
lean	O
,	O
K	O
-	O
W	O
=	O
1	O
.	O
38	O
,	O
p	O
-	O
value	O
=	O
0	O
.	O
50	O
;	O
o	O
##bes	O
##e	O
,	O
K	O
-	O
W	O
=	O
4	O
.	O
14	O
,	O
p	O
-	O
value	O
=	O
0	O
.	O
13	O
;	O
m	O
##or	O
##bid	O
##ly	O
o	O
##bes	O
##e	O
,	O
K	O
-	O
W	O
=	O
3	O
.	O
84	O
,	O
p	O
-	O
value	O
=	O
0	O
.	O
15	O
)	O
.	O

All	O
re	O
##age	O
##nts	O
for	O
sample	O
preparation	O
for	O
N	O
##MR	O
and	O
liquid	O
ch	O
##roma	O
##tography	O
–	O
mass	O
s	O
##pect	O
##rome	O
##try	O
(	O
L	O
##C	O
–	O
MS	O
)	O
analysis	O
as	O
well	O
as	O
t	B
##yra	I
##mine	I
and	O
2	B
-	I
o	I
##x	I
##og	I
##lut	I
##arate	I
were	O
obtained	O
from	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
.	O

These	O
findings	O
might	O
explain	O
why	O
beta	B
##ine	I
levels	O
were	O
increased	O
in	O
subjects	O
who	O
had	O
undergone	O
diet	O
##ary	O
intervention	O
with	O
BS	O
##P	O
.	O

Clinical	O
evaluation	O
of	O
tumor	O
metabolism	O
is	O
an	O
established	O
practice	O
,	O
as	O
the	O
fundamental	O
diagnostic	O
technique	O
,	O
18	B
##F	I
-	I
flu	I
##oro	I
##de	I
##ox	I
##y	I
##g	I
##lu	I
##cos	I
##e	I
p	O
##os	O
##it	O
##ron	O
emission	O
to	O
##mo	O
##graphy	O
(	O
F	O
##D	O
##G	O
-	O
P	O
##ET	O
)	O
is	O
dependent	O
on	O
War	O
##burg	O
metabolism	O
and	O
the	O
prop	O
##ens	O
##ity	O
for	O
tumors	O
to	O
take	O
up	O
glucose	S
at	O
a	O
higher	O
rate	O
than	O
adjacent	O
normal	O
tissue	O
.	O

N	O
##eg	O
##ative	O
controls	O
were	O
treated	O
with	O
the	O
same	O
amount	O
of	O
D	B
##MS	I
##O	I
.	O

Models	O
were	O
adjusted	O
for	O
age	O
,	O
sex	O
,	O
race	O
/	O
ethnicity	O
,	O
socio	O
##economic	O
status	O
,	O
smoking	O
,	O
physical	O
activity	O
,	O
glucose	S
and	O
lip	O
##id	O
‐	O
lowering	O
medication	O
use	O
,	O
and	O
B	O
##MI	O
to	O
investigate	O
to	O
what	O
extent	O
the	O
associations	O
were	O
specific	O
for	O
VA	O
##T	O
and	O
not	O
merely	O
overall	O
body	O
mass	O
.	O

These	O
C	O
_	O
27	O
bi	O
##le	O
acids	O
could	O
originate	O
in	O
plasma	O
and	O
be	O
transferred	O
to	O
CS	O
##F	O
or	O
alternatively	O
be	O
formed	O
in	O
brain	O
from	O
27	B
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
(	O
,	O
)	O
,	O
which	O
is	O
itself	O
suggested	O
to	O
be	O
imported	O
into	O
brain	O
from	O
plasma	O
.	O

We	O
detected	O
the	O
per	O
##tur	O
##bed	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
pathway	O
in	O
AI	O
##S	O
patients	O
,	O
which	O
might	O
be	O
caused	O
by	O
abnormal	O
biological	O
functions	O
of	O
est	O
##rogen	O
##s	O
of	O
AI	O
##S	O
.	O

5	B
-	I
h	I
##ydro	I
##xy	I
##met	I
##hyl	I
-	I
2	I
′	I
-	I
de	I
##ox	I
##yu	I
##rid	I
##ine	I
,	O
is	O
reported	O
to	O
be	O
associated	O
with	O
DNA	O
repair	O
and	O
is	O
thought	O
to	O
be	O
involved	O
in	O
the	O
path	O
##ogen	O
##esis	O
of	O
many	O
diseases	O
including	O
cancer	O
.	O

Additionally	O
,	O
commercially	O
available	O
enzyme	O
-	O
linked	O
im	O
##mu	O
##nos	O
##or	O
##bent	O
ass	O
##ays	O
were	O
used	O
to	O
measure	O
N	O
-	O
terminal	O
pro	O
–	O
B	O
-	O
type	O
na	O
##tri	O
##ure	O
##tic	O
p	O
##eptide	O
(	O
N	O
##T	O
-	O
pro	O
##B	O
##NP	O
)	O
,	O
c	B
##ys	I
##tat	I
##in	I
C	O
,	O
and	O
inter	O
##le	O
##uki	O
##n	O
(	O
IL	O
)	O
-	O
6	O
levels	O
from	O
separate	O
al	O
##iq	O
##uo	O
##ts	O
of	O
the	O
same	O
samples	O
used	O
for	O
L	O
##C	O
-	O
MS	O
analysis	O
of	O
meta	O
##bol	O
##ites	O
.	O

Try	B
##pt	I
##op	I
##han	I
,	O
k	B
##yn	I
##uren	I
##ine	I
,	O
and	O
k	B
##yn	I
##uren	I
##ic	I
acid	I
were	O
all	O
decreased	O
in	O
CS	O
##F	O
of	O
pre	O
##c	O
##lini	O
##cal	O
AD	O
patients	O
,	O
which	O
was	O
in	O
agreement	O
with	O
another	O
study	O
suggested	O
the	O
correlation	O
between	O
cognitive	O
function	O
and	O
k	B
##yn	I
##uren	I
##ine	I
pathway	O
meta	O
##bol	O
##ites	O
.	O

Ad	O
##dition	O
of	O
the	O
2	O
-	O
pathway	O
:	O
parent	O
est	O
##rogen	O
##s	O
ratio	O
to	O
a	O
model	O
containing	O
un	O
##con	O
##ju	O
##gated	O
est	B
##rad	I
##iol	I
increased	O
or	O
decreased	O
,	O
by	O
at	O
least	O
14	O
%	O
,	O
the	O
absolute	O
breast	O
cancer	O
risk	O
estimate	O
for	O
36	O
%	O
of	O
the	O
women	O
.	O

S	O
##ys	O
##to	O
##lic	O
blood	O
pressure	O
also	O
positively	O
correlated	O
with	O
try	B
##pt	I
##op	I
##han	I
(	O
P	O
=	O
0	O
.	O
01	O
##5	O
)	O
.	O

The	O
disorders	O
of	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
metabolism	O
,	O
bi	O
##le	O
acids	O
metabolism	O
,	O
and	O
u	B
##ric	I
acid	I
metabolism	O
pathway	O
were	O
found	O
in	O
T	O
##2	O
##DM	O
and	O
D	O
##AC	O
##D	O
.	O

SA	O
##M	O
participates	O
in	O
the	O
bio	O
##sy	O
##nt	O
##hesis	O
of	O
PC	O
##s	O
and	O
plasma	O
##log	O
##en	O
-	O
PC	O
##s	O
via	O
the	O
addition	O
of	O
3	O
SA	O
##M	O
-	O
derived	O
met	O
##hyl	O
groups	O
to	O
the	O
p	B
##hos	I
##ph	I
##oe	I
##than	I
##ola	I
##mine	I
head	O
##group	O
of	O
P	O
##Es	O
and	O
plasma	O
##log	O
##en	O
-	O
P	O
##Es	O
(	O
3	O
and	O
4	O
)	O
.	O

Ser	O
##um	O
f	B
##olate	I
concentrations	O
were	O
significantly	O
lower	O
in	O
the	O
high	B
–	I
c	I
##ys	I
##tat	I
##hi	I
##oni	I
##ne	I
concentration	O
group	O
,	O
but	O
the	O
subjects	O
were	O
not	O
considered	O
def	O
##icient	O
.	O

The	O
LL	O
##O	O
##Q	O
of	O
most	O
of	O
these	O
methods	O
for	O
the	O
determination	O
of	O
either	O
SM	O
##V	O
(	O
ranged	O
0	O
.	O
05	O
–	O
2	O
.	O
5	O
ng	O
/	O
m	O
##l	O
)	O
and	O
its	O
meta	O
##bol	O
##ite	O
(	O
ranged	O
0	O
.	O
05	O
–	O
5	O
ng	O
/	O
m	O
##l	O
)	O
or	O
AT	O
##V	O
(	O
ranged	O
0	O
.	O
05	O
–	O
0	O
.	O
2	O
ng	O
/	O
m	O
##l	O
)	O
and	O
its	O
two	O
meta	O
##bol	O
##ites	O
(	O
ranged	O
0	O
.	O
05	O
–	O
0	O
.	O
5	O
and	O
0	O
.	O
05	O
–	O
0	O
.	O
2	O
ng	O
/	O
m	O
##l	O
for	O
2	B
-	I
OH	I
-	I
AT	I
##V	I
and	O
4	B
-	I
OH	I
-	I
AT	I
##V	I
,	O
respectively	O
)	O
was	O
lower	O
than	O
the	O
LL	O
##O	O
##Q	O
of	O
our	O
developed	O
method	O
(	O
0	O
.	O
25	O
ng	O
/	O
m	O
##l	O
)	O
.	O

As	O
the	O
u	O
##til	O
##ization	O
of	O
amino	O
acids	O
,	O
predominantly	O
g	B
##lut	I
##ama	I
##te	I
and	O
the	O
BC	O
##AA	O
##s	O
,	O
increases	O
in	O
muscle	O
during	O
prolonged	O
exercise	O
to	O
support	O
the	O
muscle	O
ATP	O
-	O
synthesis	O
,	O
a	O
release	O
of	O
g	O
##lu	O
##co	O
##genic	O
amino	O
acids	O
from	O
working	O
muscles	O
may	O
be	O
less	O
than	O
the	O
he	O
##pa	O
##tic	O
up	O
##take	O
[	O
,	O
]	O
.	O

Low	O
plasma	O
levels	O
of	O
L	B
##ys	I
##o	I
##PC	I
(	I
16	I
:	I
0	I
)	I
arose	O
as	O
a	O
potential	O
predict	O
##or	O
of	O
re	O
##cu	O
##rrence	O
,	O
especially	O
in	O
patients	O
with	O
early	O
SR	O
.	O

Re	O
##sul	O
##ting	O
data	O
were	O
processed	O
by	O
using	O
Q	O
##uan	O
##L	O
##ynx	O
software	O
(	O
Waters	O
)	O
to	O
q	O
##uant	O
##ify	O
the	O
est	B
##rogen	I
meta	O
##bol	O
##ites	O
.	O

Ice	O
-	O
cold	O
precipitation	O
solution	O
(	O
350	O
μ	O
##L	O
)	O
made	O
up	O
of	O
20	O
%	O
0	O
.	O
2	O
##M	O
Z	O
##n	O
##SO	O
_	O
4	O
in	O
met	B
##han	I
##ol	I
was	O
added	O
,	O
v	O
##ortex	O
##ed	O
for	O
30	O
seconds	O
and	O
stored	O
at	O
−	O
##20	O
##°	O
##C	O
for	O
30	O
minutes	O
.	O

Recently	O
Klein	O
et	O
al	O
.	O
used	O
N	O
##MR	O
to	O
provide	O
relative	O
q	O
##uant	O
##ification	O
to	O
estimate	O
the	O
range	O
in	O
concentration	O
of	O
four	O
water	O
-	O
soluble	O
ch	B
##olin	I
##e	I
meta	O
##bol	O
##ites	O
in	O
milk	O
during	O
la	O
##ct	O
##ation	O
of	O
dairy	O
cows	O
.	O

With	O
all	O
three	O
groups	O
included	O
,	O
2	B
-	I
p	I
##yr	I
##rol	I
##id	I
##ino	I
##ne	I
,	O
a	O
GA	B
##BA	I
meta	O
##bol	O
##ite	O
,	O
possessed	O
a	O
MD	O
##A	O
of	O
8	O
%	O
,	O
making	O
it	O
the	O
most	O
important	O
meta	O
##bol	O
##ite	O
for	O
RF	O
accuracy	O
.	O

These	O
electro	O
##phi	O
##les	O
depleted	O
the	O
Al	O
##b	O
Cy	O
##s	O
##34	O
free	O
th	B
##iol	I
and	O
marked	O
##ly	O
decreased	O
the	O
levels	O
of	O
free	O
L	O
##ys	O
residues	O
by	O
formation	O
of	O
co	O
##valent	O
carbon	O
##yl	O
add	O
##uc	O
##ts	O
.	O

Other	O
lip	O
##ids	O
that	O
significantly	O
differentiated	O
patient	O
groups	O
in	O
this	O
study	O
were	O
(	B
l	I
##ys	I
##o	I
)	I
p	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
.	O

In	O
all	O
cases	O
a	O
SV	O
##M	O
with	O
nest	O
##ed	O
cross	O
-	O
valid	O
##ation	O
was	O
employed	O
We	O
also	O
investigated	O
the	O
impact	O
of	O
the	O
use	O
of	O
c	B
##rea	I
##tin	I
##ine	I
as	O
a	O
scale	O
basis	O
for	O
re	O
##nal	O
ex	O
##cre	O
##tion	O
by	O
subject	O
##ing	O
the	O
classification	O
data	O
to	O
direct	O
normal	O
##ization	O
by	O
Q	O
##uant	O
##ile	O
and	O
C	O
##ubi	O
##c	O
-	O
S	O
##p	O
##line	O
Normal	O
##ization	O
without	O
prior	O
c	B
##rea	I
##tin	I
##ine	I
normal	O
##ization	O
.	O

It	O
has	O
been	O
shown	O
,	O
that	O
after	O
injection	O
of	O
un	O
##con	O
##ju	O
##gated	O
radio	O
##la	O
##bel	O
##ded	O
[	B
4	I
-	I
_	I
14	I
C	I
]	I
-	I
and	I
##ros	I
##tero	I
##ne	I
and	O
[	B
4	I
-	I
_	I
14	I
C	I
]	I
-	I
et	I
##io	I
##cho	I
##lan	I
##olo	I
##ne	I
both	O
are	O
cleared	O
to	O
urine	O
very	O
rapidly	O
and	O
at	O
nearly	O
identical	O
rates	O
with	O
a	O
half	O
life	O
of	O
about	O
20	O
minutes	O
,	O
whereas	O
the	O
corresponding	O
con	O
##ju	O
##gated	O
s	O
##tero	O
##id	O
g	O
##lu	O
##cu	O
##ron	O
##ides	O
are	O
ex	O
##cre	O
##ted	O
much	O
less	O
rapidly	O
and	O
at	O
different	O
rates	O
.	O

Assessment	O
of	O
c	B
##it	I
##ric	I
acid	I
was	O
performed	O
on	O
the	O
G	O
##C	O
-	O
MS	O
in	O
the	O
full	O
scan	O
mode	O
.	O

For	O
ni	B
##ac	I
##in	I
de	O
##p	O
##ri	O
##vation	O
experiments	O
standard	O
R	O
##PM	O
##I	O
media	O
was	O
re	O
##con	O
##stituted	O
using	O
50	O
##×	O
R	O
##PM	O
##I	O
Am	O
##ino	O
A	O
##cid	O
Sol	O
##ution	O
(	O
Sigma	O
Al	O
##dric	O
##h	O
)	O
and	O
individual	O
vitamin	O
##s	O
and	O
salts	O
purchased	O
from	O
Sigma	O
Al	O
##dric	O
##h	O
and	O
Fisher	O
Chemical	O
.	O

Although	O
this	O
study	O
is	O
the	O
first	O
to	O
our	O
knowledge	O
to	O
evaluate	O
the	O
entire	O
2	O
-	O
and	O
16	O
-	O
h	O
##ydro	O
##xy	O
##lation	O
pathways	O
in	O
post	O
##men	O
##op	O
##aus	O
##al	O
women	O
,	O
a	O
number	O
of	O
e	O
##pid	O
##em	O
##iol	O
##ogical	O
studies	O
have	O
assessed	O
the	O
risk	O
of	O
post	O
##men	O
##op	O
##aus	O
##al	O
breast	O
cancer	O
in	O
association	O
with	O
concentrations	O
of	O
2	B
-	I
h	I
##ydro	I
##xy	I
##est	I
##rone	I
,	O
16	B
##α	I
-	I
h	I
##ydro	I
##xy	I
##est	I
##rone	I
,	O
or	O
their	O
ratio	O
,	O
as	O
measured	O
in	O
urine	O
or	O
blood	O
.	O

Mobile	O
phases	O
were	O
water	O
(	O
A	O
)	O
and	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
(	O
B	O
)	O
containing	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
with	O
a	O
linear	O
gradient	O
from	O
3	O
%	O
B	O
to	O
100	O
%	O
B	O
in	O
8	O
min	O
.	O

P	B
##uri	I
##ne	I
metabolism	O
and	O
expression	O
of	O
AT	O
##IC	O
and	O
AD	O
##SL	O
.	O

Several	O
previous	O
clinical	O
studies	O
have	O
indicated	O
that	O
depressed	O
patients	O
display	O
a	O
disturbance	O
of	O
gut	O
micro	O
##f	O
##lora	O
,	O
including	O
concentration	O
changes	O
of	O
meta	O
##bol	O
##ites	O
such	O
as	O
T	B
##MA	I
##O	I
,	O
D	B
##MA	I
and	O
dim	B
##eth	I
##yl	I
##gly	I
##cine	I
.	O

Since	O
increased	O
ch	B
##ole	I
##ster	I
##ol	I
levels	O
have	O
previously	O
been	O
associated	O
with	O
PC	O
##a	O
,	O
and	O
ch	B
##ole	I
##ster	I
##ol	I
up	O
##take	O
and	O
its	O
bio	O
##sy	O
##nt	O
##hesis	O
are	O
regulated	O
by	O
and	O
##rogen	O
levels	O
and	O
the	O
and	O
##rogen	O
receptor	O
_	O
,	O
,	O
the	O
results	O
from	O
the	O
metabolic	O
study	O
are	O
noteworthy	O
.	O

Met	O
##hyl	O
##ation	O
profiles	O
were	O
obtained	O
using	O
the	O
Il	O
##lum	O
##ina	O
In	O
##fin	O
##ium	O
Human	B
##M	I
##eth	I
##yla	I
##tion	I
##EP	I
##IC	I
Be	O
##ad	O
##C	O
##hip	O
kit	O
,	O
which	O
ass	O
##ay	O
##ed	O
approximately	O
850	O
,	O
000	O
met	O
##hyl	O
##ation	O
sites	O
per	O
sample	O
at	O
a	O
single	O
n	O
##uc	O
##leo	O
##tide	O
resolution	O
.	O

Every	O
1	O
m	O
##l	O
pure	O
met	B
##han	I
##ol	I
was	O
added	O
to	O
N	O
##S	O
##K	O
‐	O
A	O
and	O
N	O
##S	O
##K	O
‐	O
B	O
individually	O
.	O

Further	O
com	O
##p	O
##lica	O
##ting	O
the	O
assignment	O
of	O
the	O
_	O
31	O
P	O
signals	O
,	O
the	O
resolution	O
in	O
the	O
_	O
31	O
P	O
dimension	O
for	O
common	O
p	B
##hos	I
##ph	I
##omo	I
##no	I
##ester	I
##s	I
is	O
relatively	O
poor	O
.	O

Cho	B
##line	I
,	O
se	B
##rine	I
and	O
put	B
##res	I
##cine	I
showed	O
the	O
highest	O
potential	O
for	O
disc	O
##rim	O
##inating	O
T	O
##B	O
-	O
D	O
##M	O
from	O
T	O
##B	O
patients	O
.	O

The	O
top	O
panels	O
are	O
P	O
##IS	O
of	O
m	O
/	O
z	O
183	O
s	O
##pect	O
##ra	O
for	O
non	O
-	O
est	O
##eri	O
##fied	O
FA	O
##s	O
(	O
A	O
)	O
and	O
T	O
##G	O
-	O
FA	O
##s	O
(	O
B	O
)	O
,	O
where	O
I	O
.	O
S	O
.	O
stands	O
for	O
the	O
internal	O
standards	O
of	O
non	O
-	O
est	O
##eri	O
##fied	O
FA	S
(	O
i	O
.	O
e	O
.	O
,	O
d	B
_	I
4	I
-	I
16	I
:	I
0	I
FA	O
)	O
in	O
(	O
A	O
)	O
or	O
est	O
##eri	O
##fied	O
FA	S
released	O
from	O
the	O
T	B
##G	I
internal	O
standard	O
(	O
i	O
.	O
e	O
.	O
,	O
17	O
:	O
1	O
T	O
##G	O
)	O
in	O
(	O
B	O
)	O
.	O

However	O
,	O
when	O
controlling	O
for	O
the	O
family	O
-	O
wise	O
error	O
rate	O
using	O
the	O
Bon	O
##fer	O
##ron	O
##i	O
method	O
to	O
adjust	O
for	O
multiple	O
testing	O
,	O
adjusted	O
p	O
values	O
for	O
each	O
of	O
the	O
meta	O
##bol	O
##ites	O
were	O
as	O
follows	O
:	O
p	B
##ico	I
##lini	I
##c	I
acid	I
(	O
adjusted	O
p	O
=	O
0	O
.	O
130	O
)	O
,	O
x	B
##ant	I
##hur	I
##eni	I
##c	I
acid	I
(	O
adjusted	O
p	O
=	O
0	O
.	O
250	O
)	O
,	O
and	O
k	B
##yn	I
##uren	I
##ine	I
(	O
adjusted	O
p	O
=	O
0	O
.	O
64	O
##3	O
)	O
.	O

One	O
of	O
the	O
effects	O
of	O
R	O
##OS	O
on	O
cells	O
is	O
the	O
modification	O
of	O
fatty	O
acids	O
from	O
the	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
membrane	O
,	O
a	O
process	O
that	O
alter	O
##s	O
membrane	O
fluid	O
##ity	O
and	O
cell	O
signaling	O
.	O

The	O
combined	O
e	O
##ff	O
##lue	O
##nt	O
(	O
5	O
m	O
##l	O
)	O
was	O
di	O
##lut	O
##ed	O
with	O
water	O
(	O
4	O
m	O
##l	O
)	O
to	O
give	O
9	O
m	O
##l	O
of	O
[UNK]	O
%	O
met	B
##han	I
##ol	I
.	O

We	O
acknowledge	O
some	O
limitations	O
in	O
this	O
preliminary	O
study	O
,	O
including	O
its	O
small	O
sample	O
size	O
,	O
and	O
its	O
comparison	O
of	O
two	O
different	O
populations	O
,	O
one	O
with	O
o	O
##bes	O
##e	O
norm	B
##og	I
##ly	I
##ce	I
##mic	I
individuals	O
and	O
the	O
other	O
with	O
di	O
##abe	O
##tic	O
o	O
##bes	O
##e	O
subjects	O
that	O
underwent	O
R	O
##Y	O
##GB	O
.	O

In	O
addition	O
,	O
diet	O
##ary	O
mon	B
##oso	I
##dium	I
g	I
##lut	I
##ama	I
##te	I
increases	O
weight	O
gain	O
,	O
ad	O
##ip	O
##os	O
##ity	O
and	O
reduces	O
insulin	O
sensitivity	O
in	O
an	O
animal	O
model	O
.	O

Our	O
results	O
also	O
suggest	O
the	O
possible	O
physiological	O
role	O
of	O
AR	O
##ID	O
##1	O
##A	O
in	O
maintaining	O
normal	O
home	O
##ost	O
##asis	O
in	O
the	O
bladder	O
e	O
##pit	O
##hel	O
##ium	O
through	O
controlling	O
ch	B
##roma	I
##tin	I
re	O
##mo	O
##del	O
##ing	O
.	O

The	O
ca	O
##usal	O
association	O
between	O
serum	O
u	B
##ric	I
acid	I
levels	O
and	O
T	O
##2	O
##D	O
remains	O
controversial	O
.	O

The	O
exception	O
was	O
p	B
##ico	I
##lini	I
##c	I
acid	I
,	O
where	O
stability	O
was	O
90	O
.	O
74	O
%	O
after	O
1	O
week	O
and	O
83	O
.	O
33	O
%	O
after	O
2	O
weeks	O
.	O

However	O
,	O
when	O
we	O
compared	O
plasma	O
glucose	S
concentration	O
in	O
pre	O
##pra	O
##ndi	O
##al	O
conditions	O
for	O
low	B
–	I
c	I
##ys	I
##tat	I
##hi	I
##oni	I
##ne	I
compared	O
with	O
high	B
–	I
c	I
##ys	I
##tat	I
##hi	I
##oni	I
##ne	I
concentration	O
subjects	O
,	O
we	O
observed	O
a	O
mean	O
concentration	O
of	O
5	O
.	O
83	O
±	O
1	O
.	O
76	O
mm	O
##ol	O
/	O
L	O
compared	O
with	O
6	O
.	O
45	O
±	O
2	O
.	O
89	O
mm	O
##ol	O
/	O
L	O
(	O
P	O
=	O
0	O
.	O
52	O
##9	O
)	O
.	O

Therefore	O
,	O
we	O
focused	O
on	O
the	O
q	O
##uant	O
##ification	O
of	O
T	B
##G	I
and	O
D	O
##G	O
.	O

Hip	B
##pur	I
##ic	I
acid	I
is	O
a	O
meta	O
##bol	O
##ite	O
of	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
.	O

Con	O
##cer	O
##ning	O
s	O
##tero	O
##ido	O
##genesis	O
,	O
3	B
##α	I
##HS	I
##D	I
activity	O
is	O
highly	O
promoted	O
by	O
AK	O
##R	O
##1	O
##C	O
##4	O
and	O
AK	O
##R	O
##1	O
##C	O
##2	O
.	O

Ana	O
##ly	O
##te	O
peak	O
areas	O
were	O
normal	O
##ized	O
for	O
the	O
internal	O
standard	O
peak	O
area	O
,	O
a	O
2	O
-	O
fold	O
sample	O
concentration	O
,	O
and	O
for	O
the	O
c	B
##rea	I
##tin	I
##ine	I
concentration	O
in	O
mg	O
/	O
m	O
##l	O
.	O

A	O
##bb	O
##re	O
##viation	O
##s	O
:	O
ACC	O
##1	O
,	O
ace	B
##ty	I
##l	I
-	I
Co	I
##A	I
car	I
##box	I
##yla	I
##se	I
##1	I
;	O
α	B
-	I
K	I
##G	I
,	O
α	B
-	I
k	I
##eto	I
##g	I
##lut	I
##arate	I
;	O
AC	O
##L	O
##Y	O
,	O
ATP	O
-	O
c	O
##it	O
##rate	O
l	O
##yas	O
##e	O
;	O
PC	O
,	O
p	O
##yr	O
##u	O
##vate	O
car	O
##box	O
##yla	O
##se	O
;	O
PD	O
##H	O
,	O
p	O
##yr	O
##u	O
##vate	O
de	O
##hy	O
##dr	O
##ogen	O
##ase	O
.	O

For	O
example	O
,	O
met	B
##form	I
##in	I
,	O
a	O
well	O
-	O
known	O
oral	O
anti	O
##dia	O
##bet	O
##ic	O
drug	O
has	O
recently	O
received	O
great	O
attention	O
as	O
a	O
potential	O
BC	O
therapy	O
.	O

It	O
is	O
also	O
thought	O
that	O
the	O
α	B
-	I
k	I
##eto	I
##g	I
##lut	I
##arate	I
formed	O
in	O
this	O
pathway	O
can	O
pass	O
backwards	O
(	O
i	O
.	O
e	O
.	O
anti	O
##c	O
##lock	O
##wise	O
)	O
through	O
the	O
T	O
##CA	O
to	O
c	B
##it	I
##rate	I
which	O
can	O
be	O
b	O
##led	O
off	O
to	O
form	O
fatty	O
acids	O
.	O

Val	B
##ine	I
ex	O
##cre	O
##tion	O
was	O
associated	O
with	O
both	O
protein	O
##uria	O
and	O
decreasing	O
sodium	O
levels	O
.	O

Prior	O
to	O
F	B
##T	I
,	O
each	O
F	O
##ID	O
was	O
zero	O
-	O
filled	O
to	O
40	O
##9	O
##6	O
data	O
points	O
and	O
a	O
sin	O
##e	O
–	O
bell	O
a	O
##po	O
##dis	O
##ation	O
function	O
was	O
applied	O
.	O

The	O
25	O
candidate	O
bio	O
##mark	O
##ers	O
were	O
tested	O
against	O
an	O
independent	O
urine	O
sample	O
set	O
(	O
co	O
##hor	O
##t	O
2	O
)	O
using	O
random	O
forest	O
analysis	O
,	O
with	O
palm	B
##ito	I
##yl	I
s	I
##phi	I
##ngo	I
##my	I
##elin	I
,	O
la	B
##ct	I
##ate	I
,	O
ad	B
##eno	I
##sin	I
##e	I
and	O
su	B
##cci	I
##nate	I
providing	O
the	O
strongest	O
predict	O
##ive	O
power	O
for	O
different	O
##iating	O
co	O
##hor	O
##t	O
2	O
cancer	O
from	O
non	O
-	O
cancer	O
urine	O
##s	O
.	O

AD	B
##MA	I
,	O
A	O
##rg	O
##MI	O
,	O
and	O
GA	O
##BR	O
,	O
which	O
have	O
recently	O
emerged	O
as	O
candidate	O
bio	O
##mark	O
##ers	O
of	O
C	O
##V	O
risk	O
[	O
,	O
,	O
,	O
,	O
]	O
,	O
failed	O
to	O
show	O
significant	O
changes	O
in	O
any	O
of	O
the	O
traditional	O
C	O
##VD	O
risk	O
factors	O
analyzed	O
.	O

Therefore	O
,	O
u	B
##rid	I
##ine	I
can	O
act	O
as	O
an	O
alternative	O
energy	O
source	O
when	O
glucose	S
supply	O
is	O
not	O
sufficient	O
,	O
or	O
under	O
h	O
##y	O
##pox	O
##ic	O
and	O
/	O
or	O
is	O
##che	O
##mic	O
conditions	O
.	O

For	O
example	O
,	O
strong	O
correlation	O
values	O
describing	O
the	O
relationship	O
between	O
the	O
2	O
-	O
h	O
##ydro	O
##xy	O
i	O
##bu	O
##p	O
##ro	O
##fen	O
met	O
##hyl	O
at	O
δ	O
1	O
.	O
21	O
and	O
resonance	O
##s	O
of	O
the	O
car	B
##box	I
##y	I
i	I
##bu	I
##p	I
##ro	I
##fen	I
were	O
found	O
;	O
CH	O
_	O
3	O
(	O
δ	O
1	O
.	O
40	O
,	O
r	O
=	O
0	O
.	O
97	O
;	O

A	O
targeted	O
meta	O
##bol	O
##omi	O
##c	O
investigation	O
of	O
the	O
plasma	O
pattern	O
of	O
families	O
burden	O
##ed	O
with	O
early	O
-	O
onset	O
card	O
##iovascular	O
disease	O
revealed	O
l	B
##ino	I
##le	I
##ic	I
acid	I
(	O
LA	O
)	O
and	O
a	B
##rac	I
##hi	I
##don	I
##ic	I
acid	I
(	O
AA	O
)	O
as	O
bio	O
##mark	O
##ers	O
.	O

1	O
:	O
Li	O
##pid	O
##s	O
L	O
##D	O
##L	O
CH	O
_	O
3	O
-	O
(	O
CH	O
_	O
2	O
)	O
_	O
n	O
-	O
;	O
2	O
:	O
Li	O
##pid	O
##s	O
V	O
##LD	O
##L	O
CH	O
_	O
3	O
-	O
(	O
CH	O
_	O
2	O
)	O
_	O
n	O
-	O
;	O
3	O
:	O
Le	B
##uc	I
##ine	I
;	O
4	O
:	O
Is	B
##ole	I
##uc	I
##ine	I
;	O
5	O
:	O
Val	B
##ine	I
;	O
6	O
:	O
3	O
-	O
Met	O
##hyl	O
-	O
2	O
-	O
o	O
##x	O
##ova	O
##ler	O
##ate	O
;	O
7	O
:	O
Is	B
##ob	I
##ut	I
##yra	I
##te	I
;	O
8	O
:	O
3	O
-	O
H	O
##ydro	O
##xy	O
##but	O
##yra	O
##te	O
;	O
9	O
:	O
Li	O
##pid	O
##s	O
L	O
##D	O
##L	O
CH	O
_	O
3	O
-	O
(	O
CH	O
_	O
2	O
)	O
_	O
n	O
-	O
;	O
10	O
:	O
Li	O
##pid	O
##s	O
V	O
##LD	O
##L	O
CH	O
_	O
3	O
-	O
(	O
CH	O
_	O
2	O
)	O
_	O
n	O
-	O
;	O
11	O
:	O
Lac	B
##tate	I
;	O
12	O
:	O
T	B
##hr	I
##eon	I
##ine	I
;	O
13	O
:	O
Alan	B
##ine	I
;	O
14	O
:	O
Li	O
##pid	O
##s	O
V	O
##LD	O
##L	O
CH	O
_	O
2	O
-	O
CH	O
_	O
2	O
-	O
C	O
=	O
O	O
;	O
15	O
:	O
L	B
##ys	I
##ine	I
;	O
16	O
:	O
Ace	B
##tate	I
;	O
17	O
:	O
Li	O
##pid	O
##s	O
-	O
CH	O
_	O
2	O
-	O
CH	O
=	O
CH	O
-	O
;	O
18	O
:	O
N	O
-	O
ace	O
##ty	O
##lated	O
compounds	O
;	O
19	O
:	O
G	B
##lut	I
##amine	I
;	O
20	O
:	O
Li	O
##pid	O
##s	O
-	O
CH	O
_	O
2	O
-	O
C	O
=	O
O	O
;	O
21	O
:	O
Ace	B
##tone	I
;	O
22	O
:	O
Ace	B
##to	I
##ace	I
##tate	I
;	O
23	O
:	O
P	B
##yr	I
##u	I
##vate	I
;	O
24	O
:	O
C	B
##it	I
##rate	I
;	O
25	O

Ph	B
##en	I
##yla	I
##lani	I
##ne	I
;	O
41	O
.	O

The	O
four	O
meta	O
##bol	O
##ites	O
(	B
v	B
##ali	I
##ne	I
,	O
met	B
##hi	I
##oni	I
##ne	I
,	O
c	B
##it	I
##ru	I
##llin	I
##e	I
and	O
a	B
##rg	I
##ini	I
##ne	I
)	O
were	O
altered	O
significantly	O
in	O
the	O
patients	O
with	O
lung	O
cancer	O
in	O
the	O
two	O
data	O
sets	O
,	O
and	O
these	O
results	O
suggested	O
their	O
potential	O
to	O
distinguish	O
the	O
meta	O
##bol	O
##ites	O
in	O
patients	O
with	O
lung	O
cancer	O
.	O

It	O
has	O
been	O
suggested	O
that	O
the	O
processing	O
of	O
g	B
##ly	I
##co	I
##con	I
##ju	I
##gate	I
##s	I
composed	O
of	O
glucose	O
-	O
derived	O
man	O
##nose	O
and	O
its	O
e	O
##ff	O
##lux	O
from	O
the	O
cells	O
account	O
for	O
most	O
of	O
the	O
man	B
##nose	I
present	O
in	O
blood	O
and	O
it	O
is	O
responsible	O
for	O
the	O
maintenance	O
of	O
its	O
steady	O
state	O
.	O

In	O
the	O
previous	O
study	O
,	O
the	O
levels	O
of	O
plasma	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
were	O
slightly	O
increased	O
without	O
statistical	O
significance	O
.	O

Re	O
##lative	O
concentrations	O
of	O
B	B
##is	I
##phe	I
##no	I
##l	I
A	O
(	O
a	O
)	O
,	O
Re	B
##tino	I
##l	I
(	O
b	O
)	O
,	O
and	O
L	B
-	I
pro	I
##line	I
(	O
c	O
)	O
.	O

Stock	O
solutions	O
(	O
1	O
m	O
##L	O
,	O
5	O
m	O
##M	O
)	O
of	O
g	B
##lut	I
##amine	I
and	O
p	B
##yr	I
##og	I
##lut	I
##ami	I
##c	I
acid	I
were	O
prepared	O
,	O
separately	O
,	O
in	O
D	O
_	O
2	O
O	O
by	O
di	O
##lut	O
##ing	O
their	O
50	O
m	O
##M	O
stock	O
solutions	O
,	O
which	O
were	O
first	O
prepared	O
by	O
weighing	O
the	O
standard	O
compounds	O
.	O

Twenty	O
µ	O
##L	O
was	O
injected	O
using	O
water	O
(	O
solvent	O
A	O
)	O
and	O
Met	O
##han	O
##ol	O
:	O
Is	O
##op	O
##rop	O
##ano	O
##l	O
:	O
Ace	O
##ton	O
##it	O
##ril	O
##e	O
4	O
:	O
1	O
:	O
1	O
v	O
/	O
v	O
(	O
solvent	O
B	O
)	O
,	O
both	O
with	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
as	O
the	O
mobile	O
phase	O
.	O

(	O
2	O
)	O
T	O
##iss	O
##ue	O
samples	O
were	O
cry	O
##ose	O
##ction	O
##ed	O
and	O
the	O
matrix	O
9	B
-	I
arm	I
##ino	I
##ar	I
##c	I
##rid	I
##ine	I
applied	O
.	O

Ch	O
##roma	O
##to	O
##graphic	O
separation	O
of	O
o	B
##xy	I
##ster	I
##ols	I
and	O
ch	B
##ole	I
##ster	I
##ol	I
mixture	O
(	O
5	O
ng	O
)	O
in	O
a	O
48	O
min	O
run	O
time	O
.	O

R	O
##t	O
##x	O
##5	O
##S	O
##il	O
-	O
MS	O
column	O
with	O
0	O
.	O
25	O
μ	O
##m	O
5	O
%	O
dip	B
##hen	I
##yl	I
##di	I
##met	I
##hyl	I
##si	I
##lo	I
##xa	I
##ne	I
film	O
.	O

Ser	O
##um	O
re	B
##tino	I
##l	I
concentration	O
is	O
associated	O
with	O
circulating	O
meta	O
##bol	O
##ites	O
in	O
various	O
metabolic	O
pathways	O
,	O
particularly	O
lip	O
##ids	O
,	O
amino	O
acids	O
,	O
and	O
co	O
##fa	O
##ctors	O
/	O
vitamin	O
##s	O
.	O

This	O
further	O
confirms	O
that	O
fatty	O
acid	O
oxidation	O
,	O
as	O
evidenced	O
by	O
elevated	O
levels	O
of	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
,	O
is	O
d	O
##ys	O
##function	O
##al	O
in	O
the	O
is	O
##che	O
##mic	O
my	O
##oc	O
##ard	O
##ial	O
cell	O
.	O

Red	O
##uce	O
##d	O
est	B
##rio	I
##l	I
ex	O
##cre	O
##tion	O
in	O
patients	O
with	O
breast	O
cancer	O
prior	O
to	O
end	O
##oc	O
##rine	O
therapy	O
.	O

In	O
conclusion	O
,	O
for	O
serum	O
samples	O
,	O
we	O
found	O
that	O
use	O
of	O
Me	B
##OH	I
pp	O
##t	O
+	O
U	O
##F	O
for	O
mac	O
##rom	O
##ole	O
##cule	O
precipitation	O
routinely	O
resulted	O
in	O
high	O
quality	O
N	O
##MR	O
s	O
##pect	O
##ra	O
for	O
q	O
##uant	O
##itation	O
,	O
while	O
a	O
Me	B
##OH	I
:	O
CH	O
##C	O
##l	O
_	O
3	O
pp	O
##t	O
of	O
W	O
##B	O
produced	O
highly	O
consistent	O
N	O
##MR	O
s	O
##pect	O
##ra	O
with	O
no	O
evident	O
mac	O
##rom	O
##ole	O
##cule	O
peaks	O
.	O

We	O
are	O
also	O
able	O
to	O
detect	O
4	B
-	I
h	I
##ydro	I
##xy	I
-	I
2	I
-	I
none	I
##no	I
##ic	I
acid	I
(	O
H	O
##NA	O
)	O
-	O
MA	O
,	O
4	B
-	I
h	I
##ydro	I
##xy	I
-	I
2	I
-	I
none	I
##no	I
##ic	I
acid	I
la	I
##cton	I
##e	I
(	O
H	O
##NA	O
##L	O
)	O
-	O
MA	O
,	O
and	O
4	B
-	I
o	I
##x	I
##o	I
-	I
2	I
-	I
none	I
##no	I
##ic	I
acid	I
(	O
ON	O
##A	O
)	O
-	O
MA	O
with	O
this	O
method	O
.	O

Both	O
HD	O
##C	O
and	O
his	B
##tamine	I
content	O
were	O
found	O
significantly	O
higher	O
in	O
the	O
color	O
##ec	O
##tal	O
cancer	O
specimens	O
when	O
compared	O
to	O
normal	O
m	O
##uc	O
##osa	O
(	O
Ma	O
##sin	O
##i	O
et	O
al	O
.	O
)	O
.	O

Pre	O
##tre	O
##at	O
##ment	O
of	O
SA	O
with	O
the	O
selective	O
th	B
##iol	I
re	O
##age	O
##nts	O
4	O
-	O
C	O
##MB	O
or	O
NE	O
##M	O
prior	O
to	O
reaction	O
with	O
N	B
-	I
ace	I
##to	I
##xy	I
-	I
Ph	I
##IP	I
,	O
decreased	O
the	O
amounts	O
of	O
Ph	O
##IP	O
and	O
5	B
-	I
H	I
##O	I
-	I
Ph	I
##IP	I
recovered	O
from	O
the	O
pro	O
##te	O
##oly	O
##tic	O
dig	O
##est	O
by	O
3	O
-	O
fold	O
.	O

Co	O
##mp	O
##aris	O
##on	O
of	O
levels	O
of	O
met	B
##hyl	I
##thi	I
##og	I
##uan	I
##os	I
##ine	I
and	O
th	B
##io	I
##gua	I
##nos	I
##ine	I
n	O
##uc	O
##leo	O
##tide	O
##s	O
(	O
diagram	O
##s	O
in	O
upper	O
half	O
)	O
and	O
met	B
##hyl	I
##thi	I
##oi	I
##nos	I
##ine	I
n	O
##uc	O
##leo	O
##tide	O
##s	O
and	O
th	B
##io	I
##ino	I
##sin	I
##e	I
n	O
##uc	O
##leo	O
##tide	O
##s	O
(	O
diagram	O
##s	O
in	O
lower	O
half	O
)	O
in	O
the	O
RB	O
##C	O
samples	O
washed	O
and	O
di	O
##lut	O
##ed	O
with	O
the	O
sa	B
##line	I
or	O
PBS	O
and	O
hold	O
for	O
4	O
h	O
to	O
the	O
samples	O
processed	O
immediately	O
(	O
expressed	O
as	O
%	O
)	O
.	O

–	O
Less	O
is	O
known	O
regarding	O
vitamin	B
D	I
cat	O
##ab	O
##olis	O
##m	O
.	O

The	O
un	O
##bal	O
##ance	O
##d	O
f	O
##eca	O
##l	O
organic	O
acid	O
levels	O
in	O
I	O
##BS	O
correlated	O
with	O
the	O
altered	O
profile	O
of	O
in	O
##test	O
##inal	O
micro	O
##bio	O
##ta	O
,	O
especially	O
Lac	B
##to	I
##ba	I
##ci	I
##lli	I
and	O
V	O
##eil	O
##lone	O
##lla	O
.	O
_	O
1	O
H	O
-	O
N	O
##MR	O
s	O
##pect	O
##ros	O
##copy	O
represents	O
a	O
powerful	O
technique	O
for	O
investigating	O
gut	O
meta	O
##bol	O
##omi	O
##c	O
pro	O
##fi	O
##ling	O
,	O
with	O
the	O
simplicity	O
of	O
sample	O
preparation	O
and	O
the	O
high	O
through	O
##put	O
being	O
its	O
major	O
benefits	O
.	O

Until	O
we	O
conducted	O
the	O
analysis	O
,	O
we	O
did	O
not	O
know	O
that	O
the	O
u	B
##rea	I
cycle	O
or	O
NO	O
system	O
might	O
be	O
per	O
##tur	O
##bed	O
in	O
the	O
HD	O
sheep	O
,	O
and	O
we	O
could	O
not	O
measure	O
NO	O
levels	O
in	O
the	O
plasma	O
retrospective	O
##ly	O
.	O

AU	O
##C	O
log	O
##istic	O
re	O
##gression	O
analysis	O
indicated	O
that	O
K	O
##yn	O
(	O
AU	O
##C	O
=	O
0	O
.	O
85	O
##1	O
)	O
,	O
N	B
##AD	I
##P	I
##H	I
(	O
AU	O
##C	O
=	O
0	O
.	O
75	O
##2	O
)	O
,	O
and	O
c	O
##AM	O
##P	O
had	O
the	O
greatest	O
specific	O
##ity	O
and	O
sensitivity	O
to	O
detect	O
the	O
meta	O
##bol	O
##omi	O
##c	O
effects	O
of	O
N	O
##AC	O
in	O
SL	O
##E	O
(	O
AU	O
##C	O
=	O
0	O
.	O
72	O
##3	O
)	O

RA	O
subjects	O
(	O
n	O
=	O
48	O
)	O
met	O
American	O
College	O
of	O
R	O
##he	O
##uma	O
##tology	O
1987	O
criteria	O
;	O
were	O
se	O
##rop	O
##os	O
##itive	O
(	O
positive	O
r	O
##he	O
##uma	O
##to	O
##id	O
factor	O
and	O
/	O
or	O
anti	B
-	I
c	I
##yclic	I
c	O
##it	O
##ru	O
##llin	O
##ated	O
p	O
##eptide	O
anti	O
##body	O
)	O
or	O
had	O
evidence	O
of	O
erosion	O
##s	O
on	O
hand	O
or	O
foot	O
imaging	O
;	O
had	O
no	O
medication	O
changes	O
within	O
3	O
months	O
of	O
enrollment	O
;	O
and	O
were	O
using	O
≤	O
5	O
mg	O
pre	B
##dn	I
##ison	I
##e	I
daily	O
.	O

Am	B
##mon	I
##ium	I
format	I
##e	I
(	O
A	O
.	O
R	O
)	O
was	O
provided	O
by	O
Beijing	O
Chemical	O
Factory	O
.	O

Cat	O
##ab	O
##olis	O
##m	O
of	O
P	O
##GE	O
_	O
2	O
is	O
initiated	O
by	O
15	O
-	O
pro	O
##sta	O
##g	O
##land	O
##in	O
de	O
##hy	O
##dr	O
##ogen	O
##ase	O
(	O
15	O
-	O
P	O
##G	O
##D	O
##H	O
)	O
and	O
results	O
in	O
a	O
stable	O
end	O
meta	O
##bol	O
##ite	O
,	O
11	B
-	I
α	I
-	I
h	I
##ydro	I
##xy	I
-	I
9	I
,	I
15	I
-	I
di	I
##ox	I
##o	I
-	I
2	I
,	I
3	I
,	I
4	I
,	I
5	I
-	I
te	I
##tra	I
##nor	I
-	I
pro	I
##stan	I
##e	I
-	I
1	I
,	I
20	I
-	I
di	I
##oi	I
##c	I
acid	I
(	O
P	O
##GE	O
-	O
M	O
)	O
that	O
is	O
ex	O
##cre	O
##ted	O
in	O
the	O
urine	O
(	O
;	O
re	O
##fs	O
.	O

H	O
##R	O
##s	O
(	O
without	O
adjustment	O
for	O
B	O
##MI	O
)	O
for	O
total	O
and	O
ER	O
+	O
breast	O
cancer	O
associated	O
with	O
the	O
change	O
in	O
risk	O
across	O
inter	O
##de	O
##ci	O
##le	O
ranges	O
of	O
un	O
##con	O
##ju	O
##gated	O
est	B
##rad	I
##iol	I
and	O
the	O
three	O
measures	O
that	O
showed	O
evidence	O
of	O
est	O
##rad	O
##iol	O
-	O
independent	O
associations	O
with	O
the	O
risk	O
of	O
breast	O
cancer	O
(	O
i	O
.	O
e	O
.	O
the	O
ratio	O
of	O
2	O
-	O
h	O
##ydro	O
##xy	O
##lation	O
pathway	O
:	O
parent	O
est	O
##rogen	O
##s	O
,	O
the	O
ratio	O
of	O
2	O
-	O
h	O
##ydro	O
##xy	O
##lation	O
pathway	O
:	O
16	O
-	O
h	O
##ydro	O
##xy	O
##lation	O
pathway	O
,	O
and	O
the	O
ratio	O
of	O
4	O
-	O
h	O
##ydro	O
##xy	O
##lation	O
pathway	O
cat	O
##ech	O
##ols	O
:	O
met	O
##hyl	O
##ated	O
cat	B
##ech	I
##ols	I
)	O
are	O
shown	O
in	O
.	O

In	O
whole	O
blood	O
,	O
but	O
not	O
in	O
plasma	O
,	O
B	O
##EN	O
was	O
rapidly	O
converted	O
to	O
its	O
car	B
##box	I
##yl	I
##ic	I
acid	I
analog	O
BA	O
,	O
suggesting	O
conversion	O
by	O
an	O
enzyme	O
present	O
in	O
red	O
blood	O
cells	O
.	O

Our	O
data	O
,	O
using	O
a	O
different	O
meta	O
##bol	O
##omi	O
##c	O
approach	O
based	O
on	O
_	O
1	O
H	O
-	O
N	O
##MR	O
and	O
G	O
##C	O
-	O
MS	O
techniques	O
,	O
showed	O
that	O
the	O
non	O
-	O
di	O
##abe	O
##tic	O
group	O
presented	O
an	O
increase	O
in	O
serum	O
la	B
##ct	I
##ate	I
and	O
p	B
##yr	I
##u	I
##vate	I
concentration	O
after	O
exercise	O
,	O
indicating	O
that	O
g	O
##ly	O
##co	O
##lysis	O
was	O
activated	S
,	O
as	O
previously	O
reported	O
by	O
other	O
groups	O
,	O
.	O

We	O
tested	O
the	O
Cox	O
proportional	O
hazards	O
assumption	O
for	O
est	B
##rad	I
##iol	I
and	O
B	O
##MI	O
using	O
the	O
co	O
##x	O
.	O
z	O
##ph	O
module	O
in	O
R	O
.	O
The	O
slopes	O
for	O
the	O
β	O
##s	O
across	O
attained	O
age	O
were	O
not	O
statistical	O
##ly	O
significantly	O
different	O
from	O
0	O
.	O

Ser	O
##um	O
from	O
post	O
##men	O
##op	O
##aus	O
##al	O
women	O
contains	O
15	O
est	O
##rogen	O
##s	O
and	O
est	B
##rogen	I
meta	O
##bol	O
##ites	O
.	O

3	O
.	O
c	B
##ys	I
##tein	I
##e	I
and	O
met	B
##hi	I
##oni	I
##ne	I
metabolism	O
.	O

Ser	O
##um	O
glucose	S
,	O
total	O
ch	B
##ole	I
##ster	I
##ol	I
(	O
T	O
##C	O
)	O
,	O
L	B
##D	I
##L	I
ch	I
##ole	I
##ster	I
##ol	I
(	O
L	O
##D	O
##L	O
-	O
c	O
)	O
,	O
HD	B
##L	I
ch	I
##ole	I
##ster	I
##ol	I
(	O
HD	O
##L	O
-	O
c	O
)	O
and	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
(	O
T	O
##G	O
)	O
were	O
determined	O
with	O
kits	O
purchased	O
from	O
B	O
##ios	O
##ino	O
B	O
##iot	O
##ech	O
##nology	O
(	O
Beijing	O
,	O
China	O
)	O
,	O
standard	O
en	O
##zy	O
##matic	O
color	O
##ime	O
##tric	O
techniques	O
and	O
with	O
an	O
auto	O
-	O
analyze	O
##r	O
(	O
M	O
##OL	O
-	O
300	O
,	O
Beijing	O
,	O
China	O
)	O
.	O

The	O
act	O
of	O
c	O
##lot	O
##ting	O
is	O
triggered	O
by	O
plate	O
##let	O
de	O
##gra	O
##nu	O
##lation	O
,	O
which	O
releases	O
th	B
##rom	I
##box	I
##ane	I
A2	I
(	O
TX	O
##A	O
##2	O
)	O
into	O
the	O
blood	O
,	O
in	O
##iti	O
##ating	O
the	O
c	O
##lot	O
##ting	O
response	O
.	O

For	O
lip	O
##id	O
extraction	O
from	O
plasma	O
samples	O
,	O
50	O
μ	O
##L	O
plasma	O
was	O
di	O
##lut	O
##ed	O
by	O
1	O
m	O
##L	O
dei	O
##onized	O
water	O
in	O
a	O
10	O
m	O
##L	O
-	O
cent	O
##ri	O
##fu	O
##ge	O
tube	O
and	O
followed	O
by	O
an	O
addition	O
of	O
1	O
m	O
##L	O
met	B
##han	I
##ol	I
and	O
2	O
m	O
##L	O
ch	B
##lor	I
##of	I
##orm	I
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
determine	O
the	O
levels	O
of	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
including	O
S	O
##1	O
##P	O
,	O
c	B
##era	I
##mi	I
##des	I
,	O
and	O
other	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
,	O
in	O
breast	O
cancer	O
and	O
normal	O
breast	O
tissue	O
and	O
to	O
compare	O
the	O
difference	O
in	O
levels	O
of	O
each	O
s	B
##phi	I
##ngo	I
##lip	I
##id	I
between	O
the	O
two	O
tissues	O
.	O

The	O
limit	O
of	O
detection	O
and	O
limit	O
of	O
q	O
##uant	O
##ification	O
for	O
ta	B
##uri	I
##ne	I
determination	O
was	O
found	O
to	O
be	O
0	O
.	O
2	O
and	O
0	O
.	O
7	O
pm	O
##ol	O
,	O
respectively	O
.	O

The	O
low	O
,	O
medium	O
,	O
and	O
high	O
working	O
standard	O
solutions	O
containing	O
0	O
.	O
15	O
,	O
16	O
,	O
and	O
32	O
μ	O
##g	O
/	O
m	O
##l	O
of	O
AB	O
##T	O
-	O
88	O
##8	O
and	O
M	O
##8	O
were	O
prepared	O
in	O
met	B
##han	I
##ol	I
.	O

DD	O
##A	O
##H	O
##2	O
knockout	O
in	O
mac	O
##rop	O
##hage	O
##s	O
was	O
associated	O
with	O
a	O
significantly	O
higher	O
bacterial	O
load	O
in	O
plasma	O
and	O
the	O
per	B
##ito	I
##ne	I
##um	I
.	O

Ana	O
##ly	O
##tes	O
:	O
5	O
μ	O
##M	O
concentration	O
for	O
Q	O
##A	O
and	O
t	B
##yr	I
##os	I
##ine	I
,	O
1	O
μ	O
##M	O
concentration	O
for	O
PA	O
,	O
3	B
-	I
h	I
##ydro	I
##xy	I
##pic	I
##olin	I
##ic	I
acid	I
,	O
2	B
-	I
h	I
##ydro	I
##xy	I
##nic	I
##olin	I
##ic	I
acid	I
,	O
t	B
##yra	I
##mine	I
,	O
try	B
##pta	I
##mine	I
and	O
b	O
##ac	O
##lo	O
##fen	O
spike	O
##d	O
in	O
artificial	O
CS	O
##F	O
with	O
50	O
%	O
(	O
v	O
/	O
v	O
)	O
AC	O
##N	O
.	O

Other	O
un	O
##con	O
##ju	O
##gated	O
bi	O
##le	O
acids	O
such	O
as	O
ch	B
##olic	I
acid	I
and	O
ch	B
##eno	I
##de	I
##ox	I
##ych	I
##olic	I
acid	I
were	O
also	O
shown	O
at	O
lower	O
levels	O
in	O
HC	O
##C	O
patients	O
.	O

The	O
pro	O
##gno	O
##stic	O
meta	O
##bol	O
##ite	O
bio	O
##mark	O
##er	O
in	B
##os	I
##ito	I
##l	I
c	I
##yclic	I
phosphate	I
was	O
found	O
to	O
be	O
statistical	O
##ly	O
significant	O
only	O
when	O
the	O
analysis	O
was	O
focused	O
on	O
the	O
und	O
##iff	O
##ere	O
##nti	O
##ated	O
regions	O
of	O
soft	O
tissue	O
sa	O
##rc	O
##oma	O
samples	O
.	O

For	O
some	O
con	O
##ju	O
##gated	O
alcohol	O
##s	O
,	O
the	O
h	O
##ydro	O
##xy	O
##l	O
group	O
behave	O
##s	O
like	O
a	O
p	B
##hen	I
##ol	I
group	O
and	O
thus	O
can	O
be	O
labeled	O
by	O
dans	O
##yla	O
##tion	O
.	O

U	B
##rea	I
nitrogen	I
and	O
c	B
##rea	I
##tin	I
##ine	I
in	O
plasma	O
were	O
measured	O
by	O
the	O
clinical	O
laboratory	O
and	O
hip	B
##pura	I
##te	I
,	O
p	B
##hen	I
##yla	I
##ce	I
##ty	I
##l	I
##g	I
##lut	I
##amine	I
,	O
in	B
##dox	I
##yl	I
su	I
##lf	I
##ate	I
,	O
and	O
p	B
-	I
c	I
##res	I
##ol	I
su	I
##lf	I
##ate	I
in	O
plasma	O
and	O
plasma	O
ultra	O
##fi	O
##lt	O
##rate	O
were	O
measured	O
by	O
stable	O
is	O
##oto	O
##pe	O
di	O
##lution	O
L	O
##C	O
/	O
MS	O
/	O
MS	O
as	O
previously	O
described	O
[	O
]	O
.	O

LP	B
##C	I
18	I
:	I
1	I
and	O
PC	B
36	I
:	I
2	I
were	O
inverse	O
##ly	O
associated	O
with	O
change	O
in	O
glucose	S
,	O
and	O
SM	O
36	O
:	O
0	O
and	O
SM	B
(	I
d	I
##18	I
:	I
0	I
/	I
24	I
:	I
0	I
)	I
were	O
directly	O
associated	O
with	O
change	O
in	O
glucose	S
.	O

trim	B
##eth	I
##yla	I
##mine	I
-	I
N	I
-	I
oxide	I
,	O
gut	O
micro	O
##bio	O
##ta	O
,	O
central	O
nervous	O
system	O

In	O
all	O
subjects	O
(	O
n	O
=	O
106	O
)	O
,	O
S	O
##B	O
##P	O
and	O
DB	B
##P	I
positively	O
correlated	O
with	O
B	O
##MI	O
,	O
W	O
##H	O
##R	O
,	O
total	O
-	O
and	O
L	B
##D	I
##L	I
-	I
ch	I
##ole	I
##ster	I
##ol	I
,	O
t	B
##rig	I
##ly	I
##cer	I
##ide	I
,	O
H	O
##OM	O
##A	O
-	O
I	O
##R	O
index	O
,	O
L	O
##p	O
-	O
P	O
##LA	O
_	O
2	O
activity	O
,	O
o	O
##x	O
-	O
L	O
##D	O
##L	O
,	O
MD	O
##A	O
,	O
8	B
-	I
e	I
##pi	I
-	I
P	I
##G	I
##F	I
_	I
2	I
##α	I
,	O
b	O
##a	O
-	O
P	O
##W	O
##V	O
,	O
IL	O
-	O
6	O
,	O
l	O
##ys	O
##o	O
##PC	O
##s	O
(	O
14	O
:	O
0	O
,	O
16	O
:	O
1	O
,	O
16	O
:	O
0	O
,	O
18	O
:	O
2	O
,	O
18	O
:	O
1	O
,	O
18	O
:	O
0	O
,	O
20	O
:	O
5	O
,	O
20	O
:	O
4	O
,	O
20	O
:	O
3	O
,	O
and	O
22	O
:	O
6	O
)	O
(	O
all	O
P	O
values	O
<	O
0	O
.	O
01	O
)	O
,	O
and	O
IL	O
-	O
1	O
##β	O
(	O
S	O
##B	O
##P	O
,	O
P	O
=	O
0	O
.	O
04	O
##0	O
;	O
DB	O
##P	O
,	O
P	O
=	O
0	O
.	O
02	O
##0	O
)	O
,	O
and	O
negatively	O
correlated	O
with	O
L	O
##D	O
##L	O
particle	O
size	O
(	O
all	O
P	O
values	O
<	O
0	O
.	O
01	O
)	O
.	O

1	O
m	O
##l	O
n	B
-	I
he	I
##xa	I
##ne	I
was	O
added	O
to	O
the	O
tube	O
to	O
extract	O
the	O
der	O
##iva	O
##tized	O
fatty	O
acids	O
(	O
Morrison	O
and	O
Smith	O
)	O
.	O

Therefore	O
,	O
we	O
h	O
##y	O
##pot	O
##hes	O
##ize	O
that	O
main	O
effect	O
of	O
r	O
##if	O
##ax	O
##im	O
##in	O
may	O
be	O
to	O
in	O
##hibit	O
bacterial	O
growth	O
and	O
reduce	O
end	B
##oto	I
##xin	I
absorption	O
in	O
the	O
small	O
bow	O
##el	O
.	O

Most	O
u	O
##E	O
##Vs	O
detected	O
with	O
the	O
E	O
##M	O
were	O
s	O
##pher	O
##oids	O
with	O
a	O
single	O
membrane	O
,	O
but	O
also	O
some	O
multi	B
-	I
membrane	I
-	I
layer	I
E	O
##Vs	O
were	O
found	O
(	O
Fi	O
##g	O
.	O

To	O
assess	O
the	O
his	O
##top	O
##ath	O
##ology	O
of	O
post	O
-	O
extraction	O
bio	O
##psy	O
tissue	O
,	O
we	O
transferred	O
pro	O
##state	O
bio	O
##psy	O
tissue	O
from	O
the	O
extraction	O
solvent	O
(	B
met	B
##han	I
##ol	I
or	O
ethanol	O
)	O
directly	O
into	O
Molecular	O
Fi	O
##xa	O
##tive	O
and	O
followed	O
a	O
formal	B
##in	I
fix	O
##ation	O
work	O
##flow	O
.	O

When	O
the	O
cells	O
were	O
around	O
80	O
%	O
con	O
##f	O
##lue	O
##nt	O
,	O
they	O
were	O
stimulate	O
##d	O
by	O
glucose	S
at	O
5	O
m	O
##M	O
(	O
low	O
glucose	S
)	O
or	O
25	O
m	O
##M	O
(	O
high	O
glucose	S
)	O
in	O
complete	O
medium	O
for	O
24	O
hours	O
,	O
or	O
man	B
##ni	I
##to	I
##l	I
at	O
5	O
m	O
##M	O
and	O
25	O
m	O
##M	O
as	O
o	O
##smo	O
##tic	O
control	O
.	O

In	O
our	O
study	O
,	O
end	O
##ogen	O
##ous	O
la	B
##ct	I
##ate	I
(	O
δ	O
1	O
.	O
33	O
pp	O
##m	O
)	O
in	O
serum	O
samples	O
was	O
used	O
as	O
an	O
internal	O
standard	O
reference	O
,	O
and	O
the	O
relative	O
concentrations	O
of	O
the	O
meta	O
##bol	O
##ites	O
were	O
calculated	O
and	O
statistical	O
##ly	O
disc	O
##rim	O
##inated	O
by	O
integrating	O
their	O
signals	O
in	O
the	O
N	O
##MR	O
s	O
##pect	O
##ra	O
.	O

a	O
)	O
F	O
##old	O
-	O
change	O
plot	O
comparing	B
pre	I
-	I
vs	I
.	O
post	O
-	O
surgery	O
CR	O
##C	O
patients	O
;	O
fold	O
changes	O
>	O
1	O
indicate	O
higher	O
u	O
##rina	O
##ry	O
concentrations	O
pre	O
-	O
surgery	O
,	O
fold	O
changes	O
<	O
1	O
indicate	O
lower	O
u	O
##rina	O
##ry	O
concentrations	O
pre	O
-	O
surgery	O
.	O

These	O
claims	O
were	O
further	O
supported	O
by	O
O	O
##PL	O
##S	O
-	O
D	O
##A	O
analysis	O
,	O
where	O
several	O
specific	O
meta	O
##bol	O
##ites	O
such	O
as	O
ca	B
##da	I
##ver	I
##ine	I
,	O
Pro	O
,	O
Al	O
##a	O
,	O
1	B
,	I
4	I
-	I
but	I
##ane	I
##dio	I
##ic	I
acid	I
,	O
u	B
##rea	I
,	O
Val	O
,	O
L	O
##ys	O
,	O
Le	O
##u	O
,	O
g	B
##ly	I
##cer	I
##ol	I
,	O
Il	O
##e	O
,	O
5	B
-	I
o	I
##x	I
##o	I
-	I
Pro	I
,	O
ben	B
##zen	I
##ep	I
##rop	I
##ano	I
##ic	I
acid	I
(	O
i	O
.	O
e	O
.	O
,	O
h	B
##ydro	I
##cin	I
##nam	I
##ic	I
acid	O
)	O
,	O
Ph	O
##e	O
,	O
se	B
##do	I
##he	I
##pt	I
##ulos	I
##e	I
and	O
Ty	O
##r	O
,	O
were	O
able	O
to	O
differentiate	O
CR	O
##C	O
patients	O
from	O
H	O
volunteers	O
(	O
Figure	O
C	O
)	O
.	O

The	O
second	O
step	O
is	O
to	O
identify	O
the	O
structure	O
of	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
through	O
MS	O
/	O
MS	O
s	O
##pect	O
##ra	O
performed	O
on	O
only	O
the	O
selected	O
ions	O
that	O
presented	O
in	O
samples	O
by	O
step	O
1	O
.	O

Region	O
##s	O
of	O
800	O
MHz	O
_	O
1	O
H	O
N	O
##MR	O
s	O
##pect	O
##ra	O
of	O
the	O
same	O
pool	O
##ed	O
intact	O
human	O
serum	O
:	O
(	O
a	O
)	O
serum	O
before	O
s	O
##pi	O
##king	O
with	O
p	B
##yr	I
##og	I
##lut	I
##ami	I
##c	I
acid	I
(	O
p	O
##G	O
##lu	O
)	O
;	O
(	O
b	O
–	O
d	O
)	O
serum	O
spike	O
##d	O
with	O
standard	O
solution	O
of	O
p	B
##yr	I
##og	I
##lut	I
##ami	I
##c	I
acid	I
so	O
that	O
the	O
added	O
concentration	O
is	O
86	O
,	O
172	O
and	O
103	O
##2	O
μ	O
M	O
,	O
respectively	O
.	O

In	O
##g	O
Lo	O
##ren	O
##zin	O
##i	O
et	O
al	O
described	O
the	O
case	O
of	O
gas	O
##tro	O
##int	O
##est	O
##inal	O
bleeding	O
associated	O
with	O
r	B
##iva	I
##ro	I
##xa	I
##ban	I
in	O
the	O
patient	O
–	O
carrier	O
of	O
all	O
##eli	O
##c	O
variants	O
of	O
both	O
studied	O
ABC	O
##B	O
##1	O
p	O
##oly	O
##mor	O
##phism	O
##s	O
(	O
r	O
##s	O
##20	O
##32	O
##5	O
##8	O
##2	O
and	O
r	O
##s	O
##10	O
##45	O
##64	O
##2	O
)	O
.	O

Nico	B
##tine	I
administration	O
induced	O
increases	O
in	O
protein	O
##uria	O
and	O
g	O
##lo	O
##mer	O
##ular	O
injury	O
score	O
in	O
rats	O
with	O
5	O
/	O
6	O
ne	O
##ph	O
##re	O
##ct	O
##omi	O
##es	O
,	O
which	O
were	O
prevented	O
by	O
co	O
-	O
administration	O
of	O
an	O
α	O
##7	O
-	O
n	O
##AC	O
##h	O
##R	O
selective	O
antagonist	O
,	O
met	B
##hyl	I
##lica	I
##con	I
##iti	I
##ne	I
.	O

In	O
fact	O
,	O
β	B
-	I
a	I
##po	I
-	I
13	I
-	I
car	I
##ote	I
##non	I
##e	I
displayed	O
the	O
same	O
affinity	O
for	O
the	O
RA	O
##R	O
##s	O
as	O
AT	O
##RA	O
itself	O
(	O
i	O
.	O
e	O
.	O
2	O
–	O
6	O
nm	O
)	O
(	O
B	O
)	O
.	O

Ara	B
##chi	I
##don	I
##ic	I
acid	I
and	O
its	O
meta	O
##bol	O
##ites	O
have	O
been	O
well	O
-	O
known	O
for	O
their	O
role	O
in	O
the	O
regulation	O
of	O
re	O
##nal	O
vascular	O
tone	O
,	O
BP	O
and	O
sodium	O
transport	O
.	O
_	O
,	O
Testing	O
genetic	O
variants	O
within	O
genes	O
,	O
directly	O
involved	O
in	O
the	O
synthesis	O
and	O
degradation	O
of	O
a	B
##rac	I
##hi	I
##don	I
##ic	I
acid	I
,	O
revealed	O
EP	O
##H	O
##X	O
##2	O
r	O
##s	O
##13	O
##26	O
##29	O
##30	O
S	O
##NP	O
significantly	O
associated	O
with	O
HC	O
##T	O
##Z	O
BP	O
response	O
.	O

Among	O
them	O
,	O
as	B
##par	I
##tic	I
acid	I
and	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
were	O
increased	O
,	O
but	O
se	B
##rine	I
was	O
decreased	O
.	O

Con	O
##trar	O
##y	O
to	O
the	O
P	O
##LC	O
##O	O
findings	O
,	O
the	O
ratios	O
of	O
cat	B
##ech	I
##ols	I
to	O
met	B
##hyl	I
##ated	I
cat	I
##ech	I
##ols	I
in	O
the	O
2	O
-	O
pathway	O
and	O
4	O
-	O
pathway	O
were	O
each	O
associated	O
with	O
reduced	O
risk	O
(	O
R	O
##R	O
=	O
0	O
.	O
68	O
,	O
95	O
%	O
C	O
##I	O
=	O
0	O
.	O
45	O
to	O
1	O
.	O
02	O
;	O
p	O
-	O
trend	O
=	O
.	O
05	O
and	O
R	O
##R	O
=	O
0	O
.	O
89	O
;	O
95	O
%	O
C	O
##I	O
=	O
0	O
.	O
57	O
to	O
##1	O
.	O
38	O
;	O
p	O
-	O
trend	O
=	O
.	O
28	O
,	O
respectively	O
)	O
.	O

Lac	B
##tate	I
concentration	O
was	O
higher	O
in	O
patients	O
with	O
low	O
tissue	O
expression	O
of	O
IP	O
_	O
3	O
R	O
as	O
compared	O
to	O
healthy	O
controls	O
.	O

At	O
en	O
##rol	O
##ment	O
,	O
high	O
density	O
lip	O
##op	O
##rote	O
##in	O
(	O
HD	O
##L	O
-	O
C	O
)	O
was	O
measured	O
in	O
E	O
##D	O
##TA	O
plasma	O
on	O
the	O
Roche	O
/	O
Hit	O
##achi	O
911	O
Automatic	O
Ana	O
##ly	O
##zer	O
(	O
Roche	O
Di	O
##ag	O
##nos	O
##tics	O
Corporation	O
,	O
Indianapolis	O
,	O
IN	O
)	O
,	O
and	O
low	O
density	O
lip	O
##op	O
##rote	O
##in	O
(	O
L	O
##D	O
##L	O
-	O
C	O
)	O
was	O
calculated	O
using	O
the	O
Fr	O
##ied	O
##ew	O
##ald	O
equation	O
,	O
together	O
with	O
fast	O
##ing	O
serum	O
glucose	S
using	O
the	O
glucose	S
o	O
##xi	O
##das	O
##e	O
method	O
on	O
the	O
V	O
##it	O
##ros	O
analyze	O
##r	O
(	O
Johnson	O
and	O
Johnson	O
Clinical	O
Di	O
##ag	O
##nos	O
##tics	O
)	O
.	O

B	O
##io	O
##chemical	O
h	O
##yper	O
##and	O
##rogen	O
##ism	O
was	O
defined	O
as	O
serum	O
test	B
##osterone	I
concentration	O
>	O
2	O
.	O
4	O
nm	O
##ol	O
l	O
_	O
−	O
##1	O
.	O

While	O
glucose	S
is	O
used	O
in	O
rib	B
##ose	I
production	O
of	O
pro	O
##life	O
##rating	O
cells	O
through	O
pen	B
##tos	I
##e	I
phosphate	I
pathway	O
,	O
it	O
can	O
be	O
converted	O
to	O
c	B
##it	I
##rate	I
via	O
g	O
##ly	O
##co	O
##lysis	O
and	O
K	O
##re	O
##bs	O
cycle	O
.	O

Alternatively	O
in	O
the	O
p	B
##yr	I
##u	I
##vate	I
-	I
c	I
##it	I
##rate	I
shuttle	O
,	O
c	B
##it	I
##rate	I
can	O
exit	O
mit	O
##och	O
##ond	O
##ria	O
and	O
be	O
converted	O
to	O
o	B
##xa	I
##lo	I
##ace	I
##tate	I
and	O
ace	B
##ty	I
##l	I
-	I
Co	I
##A	I
by	O
ATP	O
-	O
c	O
##it	O
##rate	O
l	O
##yas	O
##e	O
[	O
,	O
]	O
.	O

The	O
P	O
##H	O
##RE	O
##E	O
plate	O
was	O
then	O
washed	O
with	O
a	O
further	O
250	O
μ	O
##L	O
of	O
met	B
##han	I
##ol	I
containing	O
10	O
m	O
##M	O
am	B
##mon	I
##ium	I
format	I
##e	I
and	O
el	O
##uted	O
into	O
the	O
same	O
high	O
-	O
recovery	O
collection	O
plate	O
by	O
cent	O
##ri	O
##fu	O
##gation	O
at	O
500	O
##g	O
for	O
5	O
min	O
.	O

MS	O
##2	O
does	O
not	O
distinguish	O
the	O
s	O
##n	O
##1	O
and	O
s	O
##n	O
##2	O
a	O
##cy	O
##l	O
positions	O
of	O
g	B
##ly	I
##cer	I
##oli	I
##pid	I
##s	I
,	O
nor	O
the	O
position	O
of	O
un	O
##sat	O
##uration	O
##s	O
in	O
a	O
##cy	O
##l	O
chains	O
and	O
a	O
##cy	O
##l	O
branching	O
.	O

The	O
method	O
is	O
robust	O
down	O
to	O
0	O
.	O
2	O
–	O
4	O
p	B
##g	I
on	O
column	O
,	O
depending	O
on	O
the	O
and	O
##rogen	O
meta	O
##bol	O
##ite	O
q	O
##uant	O
##ified	O
,	O
and	O
can	O
also	O
q	O
##uant	O
##ify	O
de	B
##hy	I
##dr	I
##oe	I
##pian	I
##dr	I
##osterone	I
su	I
##lf	I
##ate	I
(	O
D	O
##H	O
##EA	O
-	O
S	O
)	O
in	O
only	O
1	O
μ	O
##L	O
of	O
serum	O
.	O

β	B
-	I
act	I
##in	I
were	O
used	O
as	O
internal	O
controls	O
.	O

Our	O
data	O
,	O
showing	O
increased	O
plasma	O
levels	O
of	O
IL	O
-	O
6	O
,	O
decreased	O
K	O
##Y	O
##NA	O
levels	O
,	O
and	O
an	O
increased	O
Q	O
##UI	O
##N	O
/	O
K	O
##Y	O
##NA	O
ratio	O
in	O
these	O
patients	O
,	O
supports	O
the	O
view	O
of	O
an	O
ongoing	O
low	O
-	O
grade	O
inflammation	O
and	O
an	O
im	O
##bal	O
##ance	O
##d	O
k	B
##yn	I
##uren	I
##ine	I
pathway	O
[	O
–	O
]	O
in	O
MD	O
##D	O
.	O

Among	O
the	O
24	O
meta	O
##bol	O
##ites	O
of	O
the	O
plasma	O
samples	O
,	O
9	O
meta	O
##bol	O
##ites	O
(	B
ch	B
##olin	I
##e	I
,	O
ni	B
##ac	I
##ina	I
##mi	I
##de	I
,	O
beta	B
##ine	I
,	O
L	B
-	I
v	I
##ali	I
##ne	I
,	O
L	O
-	O
la	O
##ctic	O
acid	O
/	O
T	O
##F	O
-	O
met	O
##ho	O
##xy	O
##ace	O
##tic	O
acid	O
/	O
g	O
##ly	O
##cer	O
##ald	O
##eh	O
##yd	O
##e	O
,	O
c	B
##rea	I
##tine	I
,	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##och	I
##olin	I
##e	I
,	O
c	B
##rea	I
##tin	I
##ine	I
,	O
and	O
3	B
-	I
met	I
##hyl	I
-	I
2	I
-	I
o	I
##x	I
##ova	I
##ler	I
##ic	I
acid	I
/	I
2	I
-	I
k	I
##eto	I
##he	I
##xa	I
##no	I
##ic	I
acid	O
)	O
had	O
VIP	O
values	O
above	O
3	O
.	O
0	O
,	O
which	O
indicated	O
a	O
strong	O
difference	O
between	O
the	O
A	B
##F	I
and	O
non	O
-	O
A	O
##F	O
groups	O
.	O

The	O
initial	O
focus	O
of	O
this	O
work	O
was	O
on	O
the	O
identification	O
and	O
relative	O
q	O
##uant	O
##ification	O
of	O
o	B
##xy	I
##ster	I
##ols	I
in	O
CS	O
##F	O
.	O

A	O
strong	O
and	O
meta	O
##bol	O
##ome	O
-	O
wide	O
significant	O
association	O
with	O
DE	O
##D	O
was	O
found	O
with	O
decreased	O
levels	O
of	O
the	O
meta	O
##bol	O
##ites	O
and	B
##ros	I
##tero	I
##ne	I
su	I
##lf	I
##ate	I
(	O
P	O
=	O
0	O
.	O
000	O
##30	O
)	O
and	O
e	B
##pian	I
##dr	I
##osterone	I
su	I
##lf	I
##ate	I
(	O
P	O
=	O
0	O
.	O
000	O
##36	O
)	O
.	O

Co	O
-	O
cult	O
##uring	O
F	O
.	O
t	O
##ric	O
##in	O
##ct	O
##um	O
with	O
S	O
.	O
l	O
##iv	O
##ida	O
##ns	O
also	O
led	O
to	O
the	O
production	O
of	O
new	O
compounds	O
including	O
f	B
##usa	I
##tric	I
##ino	I
##nes	I
A	O
–	O
D	O
,	O
and	O
di	B
##hy	I
##dr	I
##olate	I
##rop	I
##yr	I
##one	I
.	O

However	O
,	O
ER	B
(	I
+	I
)	I
patients	O
apparently	O
exhibited	O
also	O
enhanced	O
level	O
of	O
c	O
##yt	O
##oki	O
##nes	O
potentially	O
responsible	O
for	O
the	O
suppression	O
of	O
T	O
-	O
cells	O
as	O
IL	O
-	O
10	O
,	O
IL	O
-	O
8	O
,	O
and	O
transforming	O
growth	O
factor	O
(	O
T	O
##G	O
##F	O
)	O
-	O
β	O
##1	O
,	O
and	O
lower	O
concentrations	O
of	O
both	O
T	O
-	O
cells	O
act	O
##ivating	O
factors	O
(	B
IL	B
-	I
1	I
##α	I
and	O
IL	O
-	O
2	O
)	O
,	O
and	O
media	O
##tors	O
of	O
the	O
inflammatory	O
response	O
as	O
IL	B
-	I
1	I
##β	I
,	O
IL	O
-	O
6	O
and	O
GM	O
-	O
CS	O
##F	O
.	O

This	O
might	O
be	O
due	O
in	O
part	O
to	O
the	O
fact	O
that	O
the	O
re	O
##tina	O
,	O
despite	O
being	O
a	O
nervous	O
tissue	O
,	O
is	O
largely	O
i	O
##rri	O
##gated	O
by	O
a	O
re	B
##tina	I
##l	I
vascular	O
network	O
,	O
in	O
which	O
GM	B
##3	I
is	O
the	O
major	O
G	O
##G	O
.	O

observed	O
decreased	O
vitamin	B
D	I
cat	O
##ab	O
##olis	O
##m	O
and	O
1	B
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
production	O
in	O
chronic	O
kidney	O
disease	O
(	O
C	O
##K	O
##D	O
)	O
.	O

All	O
samples	O
,	O
ca	O
##li	O
##bra	O
##tors	O
and	O
quality	O
control	O
standards	O
were	O
re	O
##sus	O
##pen	O
##ded	O
in	O
100	O
μ	O
##L	O
of	O
9	O
:	O
1	O
(	O
v	O
/	O
v	O
)	O
10	O
##m	O
##M	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
in	O
0	O
.	O
01	O
%	O
T	O
##FA	O
in	O
water	O
:	O
0	O
.	O
01	O
%	O
T	O
##FA	O
in	O
met	B
##han	I
##ol	I
and	O
placed	O
into	O
glass	O
via	O
##ls	O
with	O
de	O
##activated	O
glass	O
insert	O
##s	O
(	O
Waters	O
Corp	O
.	O
)	O
.	O

Louis	O
et	O
al	O
.	O
assigned	O
the	O
higher	O
glucose	S
concentration	O
to	O
a	O
com	O
##pen	O
##sat	O
##ory	O
g	O
##ly	O
##co	O
##gen	O
##oly	O
##sis	O
and	O
g	O
##lu	O
##con	O
##eo	O
##genesis	O
.	O

The	O
p	O
##yr	O
##u	O
##vate	O
de	O
##hy	O
##dr	O
##ogen	O
##ase	O
complex	O
(	O
PD	O
##H	O
)	O
o	O
##xi	O
##di	O
##zes	O
and	O
de	B
##car	I
##box	I
##yla	I
##tes	I
p	I
##yr	I
##u	I
##vate	I
to	O
ace	B
##ty	I
##l	I
-	I
Co	I
##A	I
,	O
which	O
enters	O
the	O
T	O
##CA	O
cycle	O
.	O

However	O
,	O
we	O
discovered	O
that	O
LP	O
##E	O
might	O
serve	O
as	O
a	O
novel	O
bio	O
##mark	O
##er	O
for	O
N	O
##AF	O
##L	O
and	O
NAS	O
##H	O
,	O
as	O
this	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
subgroup	O
was	O
significantly	O
reduced	O
in	O
the	O
N	O
##AF	O
##LD	O
co	O
##hor	O
##t	O
.	O

A	O
previous	O
meta	O
##bol	O
##omi	O
##cs	O
investigation	O
,	O
performed	O
by	O
a	O
mass	O
s	O
##pect	O
##rome	O
##try	O
imaging	O
technique	O
,	O
revealed	O
that	O
G	O
##C	O
tissue	O
as	O
compared	O
with	O
normal	O
gas	O
##tic	O
m	O
##uc	O
##osa	O
may	O
present	O
specific	O
shortages	O
of	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
lip	O
##ids	O
derivatives	O
i	O
.	O
e	O
.	O
,	O
PC	B
36	I
:	I
4	I
and	O
PC	B
34	I
:	I
2	I
[	O
,	O
]	O
.	O

We	O
suggest	O
that	O
these	O
results	O
indicate	O
that	O
the	O
k	B
##yn	I
##uren	I
##ine	I
pathway	O
is	O
mainly	O
important	O
in	O
SL	O
##E	O
-	O
related	O
fatigue	O
.	O

D	O
.	O
The	O
survival	O
curve	O
of	O
p	B
-	I
c	I
##res	I
##ol	I
.	O

The	O
fact	O
that	O
DE	O
##HP	O
meta	O
##bol	O
##ites	O
are	O
associated	O
with	O
o	O
##besity	O
in	O
males	O
may	O
be	O
the	O
consequence	O
of	O
their	O
anti	O
-	O
and	O
##rogen	O
##ic	O
effect	O
that	O
reduce	O
levels	O
of	O
free	O
test	B
##osterone	I
(	O
;	O
;	O
)	O
and	O
an	O
alter	O
##ation	O
in	O
ad	O
##ip	O
##ose	O
tissue	O
.	O

O	O
##PL	O
##S	O
-	O
D	O
##A	O
score	O
plots	O
disc	O
##rim	O
##inating	O
between	O
control	O
and	O
w	B
##hey	I
(	O
a	O
)	O
and	O
calcium	B
case	I
##inate	I
(	O
b	O
)	O
at	O
70	O
min	O
(	O
base	O
##line	O
sub	O
##tracted	O
)	O
after	O
a	O
bout	O
of	O
heavy	O
resistance	O
.	O

El	O
##uen	O
##ts	O
were	O
checked	O
before	O
analysis	O
to	O
ensure	O
that	O
the	O
ch	B
##ole	I
##ster	I
##ol	I
had	O
been	O
completely	O
removed	O
.	O

According	O
to	O
our	O
present	O
study	O
and	O
those	O
of	O
others	O
(	O
Liu	O
et	O
al	O
.	O
,	O
;	O
Wang	O
et	O
al	O
.	O
,	O
)	O
,	O
we	O
propose	O
that	O
altered	O
u	O
##rina	O
##ry	O
a	B
##rg	I
##ini	I
##ne	I
levels	O
might	O
reflect	O
systematic	O
d	O
##ys	O
##re	O
##gu	O
##lated	O
a	B
##rg	I
##ini	I
##ne	I
metabolism	O
.	O

The	O
final	O
4	O
-	O
min	O
period	O
was	O
maintained	O
at	O
5	O
%	O
solution	O
A	O
,	O
95	O
%	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
.	O

To	O
each	O
400	O
-	O
μ	O
##l	O
specimen	O
of	O
human	O
urine	O
200	O
μ	O
##l	O
of	O
0	O
.	O
1	O
m	O
##ol	O
/	O
l	O
phosphate	S
buffer	O
,	O
pH	O
7	O
.	O
4	O
,	O
and	O
50	O
μ	O
##l	O
of	O
de	O
##uter	O
##ium	O
oxide	O
containing	O
0	O
.	O
75	O
%	O
(	O
w	O
/	O
v	O
)	O
trim	B
##eth	I
##yl	I
##si	I
##ly	I
##l	I
-	I
2	I
,	I
2	I
,	I
3	I
,	I
3	I
-	I
te	I
##tra	I
##de	I
##uter	I
##op	I
##rop	I
##ion	I
##ic	I
acid	I
(	O
T	O
##SP	O
)	O
as	O
a	O
reference	O
[	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
,	O
Stein	O
##heim	O
,	O
Germany	O
]	O
were	O
added	O
.	O

Cho	B
##les	I
##tero	I
##l	I
was	O
measured	O
by	O
the	O
CH	O
##OD	O
-	O
PA	O
##P	O
method	O
with	O
kit	O
A1	O
##1	O
##A	O
##01	O
##6	O
##34	O
and	O
la	B
##ct	I
##ate	I
was	O
measured	O
by	O
the	O
en	O
##zy	O
##matic	O
color	O
##ime	O
##tric	O
Tri	O
##nder	O
method	O
with	O
kit	O

Seven	O
of	O
17	O
meta	O
##bol	O
##ites	O
-	O
—	O
p	B
##hy	I
##tos	I
##phi	I
##ngo	I
##sin	I
##e	I
,	O
AR	O
##A	O
,	O
D	O
##PA	O
,	O
S	O
##1	O
##P	O
,	O
U	O
##A	O
,	O
ad	B
##ren	I
##ic	I
acid	I
and	O
D	O
##HA	O
—	O
were	O
identified	O
using	O
reference	O
compounds	O
;	O
chemical	O
structures	O
and	O
mass	O
fragment	O
information	O
on	O
principal	O
meta	O
##bol	O
##ites	O
are	O
shown	O
in	O
A	O
##ppe	O
##ndi	O
##x	O
1	O
,	O
Figure	O
S	O
##2	O
.	O

Rep	O
##rod	O
##uc	O
##ible	O
results	O
were	O
obtained	O
not	O
only	O
for	O
C	B
##ML	I
,	O
but	O
also	O
for	O
levels	O
of	O
p	B
##yr	I
##ral	I
##ine	I
and	O
met	O
##hyl	O
##g	O
##loy	O
##xa	O
##l	O
-	O
modified	O
proteins	O
[	O
–	O
]	O
by	O
highly	O
specified	O
im	O
##mu	O
##no	O
##chemical	O
methods	O
.	O

N	O
##MR	O
indicated	O
up	O
-	O
regulated	O
L	B
##D	I
##L	I
ch	I
##ole	I
##ster	I
##ol	I
levels	O
and	O
un	O
##sat	O
##uration	O
.	O

B	O
##rief	O
##ly	O
,	O
after	O
en	O
##zy	O
##matic	O
(	O
β	O
-	O
g	O
##lu	O
##cu	O
##ron	O
##idas	O
##e	O
)	O
h	O
##ydro	O
##lysis	O
of	O
urine	O
samples	O
,	O
p	B
##ht	I
##hala	I
##te	I
meta	O
##bol	O
##ites	O
were	O
extracted	O
with	O
a	O
solvent	O
mixture	O
(	B
he	B
##xa	I
##ne	I
,	O
ace	O
##tone	O
)	O
by	O
son	O
##ica	O
##tion	O
.	O

Incident	O
type	O
2	O
diabetes	O
was	O
determined	O
by	O
75	O
-	O
g	O
oral	O
glucose	S
tolerance	O
test	O
using	O
World	O
Health	O
Organization	O
criteria	O
.	O

Hundred	O
micro	O
##lite	O
##r	O
of	O
the	O
super	O
##nat	O
##ant	O
was	O
di	O
##lut	O
##ed	O
in	O
400	O
μ	O
##L	O
of	O
met	B
##han	I
##ol	I
.	O

After	O
phase	O
separation	O
,	O
the	O
lip	O
##id	O
-	O
containing	O
M	B
##T	I
##BE	I
phase	O
forms	O
the	O
top	O
layer	O
,	O
whereas	O
the	O
H	O
##FI	O
##P	O
and	O
water	O
from	O
the	O
lower	O
phase	O
.	O

Given	O
the	O
known	O
limitations	O
of	O
serum	O
c	B
##rea	I
##tin	I
##ine	I
and	O
widespread	O
use	O
of	O
G	O
##F	O
##R	O
est	O
##imation	O
,	O
the	O
clinical	O
implications	O
that	O
a	O
panel	O
of	O
meta	O
##bol	O
##ites	O
can	O
provide	O
an	O
accurate	O
estimate	O
of	O
G	O
##F	O
##R	O
with	O
or	O
without	O
serum	O
c	B
##rea	I
##tin	I
##ine	I
or	O
demographic	O
##s	O
could	O
be	O
substantial	O
if	O
these	O
initial	O
results	O
can	O
be	O
taken	O
through	O
the	O
full	O
diagnostic	O
test	O
development	O
process	O
.	O

Fourteen	O
out	O
of	O
15	O
tissues	O
contained	O
sodium	O
dependent	O
glucose	S
co	O
-	O
transport	O
##er	O
(	O
S	O
##G	O
##LT	O
##1	O
)	O
Inter	O
-	O
donor	O
differences	O
in	O
levels	O
of	O
protein	O
expression	O
ranged	O
from	O
3	O
.	O
5	O
fold	O
(	O
U	O
##G	O
##T	O
##s	O
)	O
to	O
14	O
.	O
2	O
fold	O
(	O
S	O
##G	O
##LT	O
##1	O
)	O
.	O

This	O
trend	O
becomes	O
less	O
clear	O
with	O
lower	O
VIP	O
scores	O
as	O
shown	O
by	O
the	O
last	O
3	O
meta	O
##bol	O
##ite	O
bin	O
##s	O
in	O
the	O
panel	O
;	O
(	O
J	O
)	O
c	B
##it	I
##rate	I
(	O
2	O
.	O
68	O
–	O
2	O
.	O
70	O
pp	O
##m	O
,	O
VIP	O
score	O
1	O
.	O
87	O
)	O
,	O
(	O
K	O
)	O
mobile	O
–	O
N	O
(	O
CH	O
_	O
3	O
)	O
_	O
3	O
/	O
free	O
ch	B
##olin	I
##e	I
(	O
3	O
.	O
20	O
–	O
3	O
.	O
22	O
pp	O
##m	O
,	O
VIP	O
score	O
1	O
.	O
85	O
)	O
,	O
and	O
(	O
L	O
)	O
a	O
##rg	O
##ini	O
##ne	O
/	O
l	O
##ys	O
##ine	O
/	O
le	O
##uc	O
##ine	O
(	O
1	O
.	O
68	O
–	O
1	O
.	O
70	O
pp	O
##m	O
,	O
VIP	O
score	O
1	O
.	O
75	O
)	O
.	O

_	O
1	O
H	O
–	O
_	O
1	O
H	O
total	O
correlation	O
s	O
##pect	O
##ros	O
##copy	O
(	O
TO	O
##CS	O
##Y	O
)	O
,	O
_	O
1	O
H	O
–	O
_	O
13	O
C	O
he	O
##tero	O
##nu	O
##cle	O
##ar	O
multiple	O
bond	O
correlation	O
(	O
HM	O
##BC	O
)	O
,	O
and	O
_	O
1	O
H	O
–	O
_	O
13	O
C	O
he	O
##tero	O
##nu	O
##cle	O
##ar	O
single	O
-	O
quantum	O
correlation	O
(	O
H	O
##S	O
##Q	O
##C	O
)	O
2D	O
N	O
##MR	O
s	O
##pect	O
##ra	O
were	O
acquired	O
on	O
two	O
urine	O
samples	O
containing	O
typical	O
levels	O
of	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
meta	O
##bol	O
##ites	O
and	O
another	O
urine	O
sample	O
containing	O
i	B
##bu	I
##p	I
##ro	I
##fen	I
meta	O
##bol	O
##ites	O
.	O

Eight	O
meta	O
##bol	O
##ites	O
revealed	O
altered	O
concentrations	O
in	O
se	O
##ptic	O
shock	O
patients	O
(	B
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
my	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
,	O
is	B
##ob	I
##ut	I
##yra	I
##te	I
,	O
3	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
,	O
u	B
##rea	I
,	O
O	B
-	I
ace	I
##ty	I
##l	I
##car	I
##ni	I
##tine	I
,	O
2	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
and	O
pro	B
##line	I
)	O
while	O
the	O
concentrations	O
of	O
prop	B
##yle	I
##ne	I
g	I
##ly	I
##co	I
##l	I
,	O
th	B
##re	I
##oni	I
##ne	I
,	O
v	B
##ali	I
##ne	I
,	O
a	B
##rg	I
##ini	I
##ne	I
,	O
g	B
##lut	I
##ama	I
##te	I
,	O
met	B
##han	I
##ol	I
and	O
glucose	S
were	O
decreased	O
.	O

Co	B
##rt	I
##is	I
##ol	I
has	O
been	O
shown	O
to	O
up	O
##re	O
##gu	O
##late	O
the	O
activity	O
of	O
T	O
##RP	O
2	O
,	O
3	O
-	O
di	O
##ox	O
##y	O
##gen	O
##ase	O
activity	O
in	O
rode	O
##nt	O
models	O
.	O

At	O
the	O
second	O
visit	O
,	O
patients	O
were	O
random	O
##ized	O
to	O
(	O
i	O
)	O
5	O
g	O
/	O
day	O
corn	O
oil	O
(	O
Place	O
##bo	O
)	O
,	O
(	O
ii	O
)	O
15	O
mg	O
/	O
day	O
p	B
##io	I
##gli	I
##ta	I
##zone	I
(	O
Pi	O
##o	O
;	O
Act	O
##os	O
,	O
Take	O
##da	O
)	O
,	O
(	O
ii	O
##i	O
)	O
5	O
g	O
/	O
day	O
EPA	O
+	O
D	O
##HA	O
concentrate	O
(	B
Omega	B
-	I
3	I
;	O

His	B
##tamine	I
,	O
met	B
##hi	I
##oni	I
##ne	I
su	I
##lf	I
##oxide	I
(	O
Met	O
-	O
S	O
##O	O
)	O
and	O
3	B
-	I
ni	I
##tro	I
##ty	I
##ros	I
##ine	I
(	O
Ni	O
##tro	O
-	O
Ty	O
##r	O
)	O
were	O
found	O
neither	O
in	O
sperm	O
nor	O
in	O
seminal	O
plasma	O
.	O

The	O
compound	O
8	B
-	I
e	I
##pi	I
-	I
P	I
##G	I
##F	I
_	I
2	I
##α	I
was	O
measured	O
using	O
an	O
enzyme	O
im	O
##mu	O
##no	O
##ass	O
##ay	O
(	B
B	B
##io	I
##xy	I
##tech	I
u	O
##rina	O
##ry	O
8	B
-	I
e	I
##pi	I
-	I
P	I
##G	I
##F	I
_	I
2	I
##α	I
As	I
##say	I
kit	O
,	O
O	O
##X	O
##IS	O
International	O
Inc	O
.	O
,	O
Portland	O
,	O
OR	O
)	O
.	O

Box	O
##p	O
##lot	O
##s	O
of	O
modeled	O
appearance	O
rates	O
for	O
glucose	S
M	O
##6	O
,	O
la	B
##ct	I
##ate	I
M	O
##3	O
,	O
al	B
##ani	I
##ne	I
M	O
##3	O
,	O
c	B
##it	I
##rate	I
M	O
##2	O
and	O
g	B
##lut	I
##ama	I
##te	I
M	O
##2	O
with	O
single	O
data	O
points	O
in	O
blue	O
;	O
*	O
indicates	O
significant	O
differences	O
in	O
relation	O
to	O
C	O
##tr	O
##l	O
,	O
p	O
<	O
0	O
.	O
05	O
.	O

The	O
primary	O
solutions	O
of	O
im	B
##ati	I
##ni	I
##b	I
,	O
its	O
meta	O
##bol	O
##ites	O
and	O
the	O
internal	O
standard	O
were	O
prepared	O
in	O
1	O
m	O
##L	O
of	O
100	O
%	O
met	B
##han	I
##ol	I
(	O
HP	O
##LC	O
grade	O
)	O
to	O
obtain	O
concentrations	O
of	O
0	O
.	O
50	O
mg	O
/	O
m	O
##L	O
,	O
0	O
.	O
50	O
mg	O
/	O
m	O
##L	O
and	O
0	O
.	O
25	O
mg	O
/	O
m	O
##L	O
,	O
respectively	O
.	O

Then	O
,	O
we	O
used	O
the	O
ratio	O
of	O
de	O
##pur	O
##inating	O
N	O
##3	O
##A	O
##de	O
and	O
N	O
##7	O
##G	O
##ua	O
add	O
##uc	O
##ts	O
to	O
the	O
sum	O
of	O
their	O
respective	O
est	B
##rogen	I
meta	O
##bol	O
##ites	O
and	O
con	O
##ju	O
##gate	O
##s	O
in	O
urine	O
samples	O
because	O
the	O
ratio	O
reflects	O
the	O
degree	O
of	O
im	O
##bal	O
##ance	O
in	O
est	B
##rogen	I
metabolism	O
that	O
can	O
lead	O
to	O
cancer	O
initiation	O
.	O

Sul	O
##fo	O
##ny	O
##lu	O
##rea	O
-	O
treated	O
di	O
##abe	O
##tic	O
patients	O
were	O
included	O
because	O
long	O
-	O
term	O
su	B
##lf	I
##ony	I
##lu	I
##rea	I
therapy	O
is	O
not	O
known	O
to	O
have	O
any	O
direct	O
effect	O
on	O
insulin	O
sensitivity	O
.	O

Dec	O
##reased	O
levels	O
of	O
c	B
##it	I
##rate	I
and	O
increased	O
levels	O
of	O
c	B
##is	I
-	I
a	I
##con	I
##itate	I
during	O
RS	O
##V	O
AR	O
##I	O
compared	O
to	O
healthy	O
controls	O
may	O
indicate	O
that	O
c	B
##it	I
##rate	I
is	O
depleted	O
to	O
supply	O
pro	O
-	O
inflammatory	O
and	O
anti	O
-	O
inflammatory	O
molecule	O
needs	O
of	O
immune	O
cells	O
to	O
counter	O
viral	O
replication	O
.	O

Two	O
of	O
the	O
six	O
markers	O
were	O
identified	O
as	O
im	B
##ida	I
##zo	I
##lea	I
##ce	I
##tic	I
acid	I
whose	O
relation	O
to	O
bladder	O
cancer	O
has	O
certain	O
degree	O
of	O
supporting	O
evidence	O
.	O

Path	O
##way	O
analysis	O
(	O
A	O
)	O
identified	O
nitrogen	O
(	O
global	O
)	O
amino	O
acid	O
metabolism	O
pathways	O
to	O
be	O
the	O
most	O
per	O
##tur	O
##bed	O
,	O
followed	O
by	O
an	O
amino	B
a	I
##cy	I
##l	I
-	I
t	I
##RNA	I
bio	O
##sy	O
##nt	O
##hesis	O
when	O
D	O
##OC	O
##K	O
##8	O
deficiency	O
was	O
compared	O
with	O
AD	O
and	O
C	O
##tr	O
##l	O
.	O

The	O
Good	O
respond	O
##ers	O
showed	O
higher	O
levels	O
of	O
sperm	B
##id	I
##ine	I
and	O
lower	O
amounts	O
of	O
try	B
##pt	I
##op	I
##han	I
compared	O
with	O
the	O
poor	O
respond	O
##ers	O
(	O
p	O
<	O
0	O
.	O
00	O
##1	O
,	O
q	O
<	O
0	O
.	O
05	O
)	O
.	O

,	O
we	O
found	O
a	O
moderate	O
age	O
-	O
related	O
increase	O
for	O
the	O
24	O
-	O
hour	O
ex	O
##cre	O
##tion	O
of	O
the	O
11	B
-	I
de	I
##ox	I
##y	I
##cor	I
##tis	I
##ol	I
meta	O
##bol	O
##ite	O
T	B
##H	I
-	I
11	I
-	I
de	I
##ox	I
##y	I
##cor	I
##tis	I
##ol	I
in	O
men	O
whereas	O
the	O
results	O
in	O
women	O
were	O
more	O
similar	O
in	O
all	O
three	O
studies	O
with	O
regard	O
to	O
age	O
-	O
related	O
changes	O
.	O

The	O
best	O
amino	O
acid	O
concentration	O
-	O
based	O
m	O
##log	O
##it	O
##BM	O
##A	O
-	O
model	O
contained	O
CA	O
19	O
-	O
9	O
and	O
as	B
##par	I
##tic	I
acid	I
,	O
which	O
both	O
were	O
also	O
contained	O
in	O
the	O
t	O
##runcated	O
amino	O
acid	O
concentration	O
-	O
based	O
CA	O
##R	O
score	O
-	O
model	O
.	O

X	B
##ant	I
##hine	I
is	O
the	O
final	O
breakdown	O
product	O
of	O
pu	B
##rine	I
n	O
##uc	O
##leo	O
##tide	O
##s	O
and	O
the	O
immediate	O
precursor	O
of	O
u	B
##ric	I
acid	I
.	O

In	O
addition	O
there	O
are	O
a	O
few	O
models	O
that	O
add	O
u	B
##rea	I
,	O
glucose	S
and	O
/	O
or	O
g	B
##lu	I
##cu	I
##rona	I
##te	I
to	O
that	O
core	O
feature	O
set	O

Compared	O
with	O
controls	O
,	O
P	O
##LC	O
patients	O
had	O
significantly	O
higher	O
serum	O
levels	O
of	O
T	B
##MA	I
##O	I
(	O
2	O
.	O
07	O
(	O
1	O
.	O
32	O
,	O
3	O
.	O
49	O
)	O

This	O
is	O
supported	O
by	O
the	O
fact	O
that	O
H	O
##AA	O
was	O
still	O
significantly	O
associated	O
with	O
AD	O
##HD	O
status	O
when	O
adjusting	O
for	O
try	B
##pt	I
##op	I
##han	I
levels	O
in	O
log	O
##istic	O
re	O
##gression	O
analyses	O
(	O
Table	O
)	O
.	O

As	O
a	O
result	O
,	O
2	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
,	O
ace	B
##tone	I
,	O
format	B
##e	I
and	O
p	B
##yr	I
##og	I
##lut	I
##ama	I
##te	I
were	O
up	O
-	O
regulated	O
in	O
MS	O
and	O
N	O
##MO	O
##SD	O
groups	O
while	O
glucose	S
and	O
ace	B
##tate	I
were	O
down	O
-	O
regulated	O
in	O
MS	O
and	O
N	O
##MO	O
##SD	O
compared	O
with	O
HC	O
##s	O
.	O

To	O
demonstrate	O
this	O
,	O
they	O
show	O
that	O
during	O
di	B
##ami	I
##de	I
treatment	O
,	O
N	B
##AD	I
##P	I
##H	I
de	O
##ple	O
##tion	O
and	O
H	O
_	O
2	O
O	O
_	O
2	O
accumulation	O
,	O
detected	O
via	O
H	O
##y	O
##P	O
##er	O
,	O
do	O
not	O
occur	O
simultaneously	O
.	O

Cal	O
##ib	O
##ration	O
curves	O
for	O
q	O
##uant	O
##ifying	O
each	O
and	O
##rogen	O
meta	O
##bol	O
##ite	O
using	O
ca	O
##li	O
##bra	O
##tors	O
in	O
the	O
range	O
from	O
2	O
to	O
1000	O
p	B
##g	I
using	O
CD	O
##S	O
-	O
F	O
##BS	O
as	O
a	O
matrix	O
.	O

We	O
recruited	O
45	O
A	O
##ER	O
##D	O
and	O
45	O
AT	O
##A	O
patients	O
from	O
the	O
A	O
##jou	O
University	O
Medical	O
Center	O
(	O
Su	O
##won	O
,	O
Korea	O
)	O
to	O
investigate	O
their	O
SL	S
meta	O
##bol	O
##ite	O
profiles	O
.	O

Since	O
S	O
-	O
1	O
-	O
P	O
is	O
both	O
a	O
precursor	O
and	O
meta	O
##bol	O
##ite	O
of	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
##s	I
,	O
it	O
remains	O
to	O
be	O
defined	O
if	O
augmented	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
metabolism	O
and	O
/	O
or	O
decreased	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
synthesis	O
occurs	O
with	O
PT	O
##B	O
infection	O
.	O

Meanwhile	O
,	O
we	O
found	O
that	O
the	O
gal	B
##act	I
##ose	I
metabolism	O
was	O
significantly	O
affected	O
in	O
T	O
##2	O
##DM	O
patients	O
with	O
PS	O
##D	O
.	O

3	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yric	I
acid	I
is	O
a	O
k	B
##eton	I
##e	I
body	O
that	O
is	O
raised	O
in	O
k	O
##eto	O
##sis	O
and	O
can	O
be	O
used	O
as	O
an	O
energy	O
source	O
when	O
usage	O
of	O
glucose	S
is	O
impaired	O
.	O

Our	O
findings	O
support	O
the	O
suggestion	O
that	O
high	O
serum	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
levels	O
may	O
be	O
in	O
##dicative	O
of	O
O	O
##VC	O
(	O
and	O
)	O
.	O

Moreover	O
,	O
t	O
##it	O
##ration	O
of	O
ni	B
##cot	I
##ine	I
intake	O
by	O
CP	O
##D	O
according	O
to	O
rate	O
of	O
ni	B
##cot	I
##ine	I
metabolism	O
may	O
not	O
be	O
observed	O
in	O
these	O
AI	O
/	O
AN	O
populations	O
,	O
similarly	O
to	O
African	O
American	O
smoke	O
##rs	O
[	O
,	O
]	O
,	O
but	O
t	O
##it	O
##ration	O
may	O
be	O
detected	O
with	O
T	O
##NE	O
as	O
measure	O
of	O
consumption	O
,	O
as	O
seen	O
among	O
Alaska	O
Native	O
smoke	O
##rs	O
.	O

p	B
##ht	I
##hala	I
##te	I
(	O
MC	O
##PP	O
)	O
;	O
Mon	B
##oc	I
##ar	I
##box	I
##y	I
-	I
is	I
##ono	I
##ny	I
##l	I
p	I
##ht	I
##hala	I
##te	I
(	O
MC	O
##NP	O
)	O
;	O
Mon	B
##o	I
-	I
n	I
-	I
but	I
##yl	I
p	I
##ht	I
##hala	I
##te	I
(	O
MB	O
##P	O
)	O
;	O
Mon	B
##o	I
-	I
3	I
-	I
h	I
##ydro	I
##xy	I
##but	I
##yl	I
p	I
##ht	I
##hala	I
##te	I
(	O
M	O
##H	O
##B	O
##P	O
)	O
;	O
Mon	B
##o	I
-	I
is	I
##ob	I
##ut	I
##yl	I
p	I
##ht	I
##hala	I
##te	I
(	O
Mi	O
##B	O
##P	O
)	O
;	O
Mon	B
##o	I
-	I
h	I
##ydro	I
##xy	I
##is	I
##ob	I
##ut	I
##yl	I
p	I
##ht	I
##hala	I
##te	I
(	O
M	O
##H	O
##i	O
##B	O
##P	O
)	O
;	O
Mon	B
##o	I
-	I
et	I
##hyl	I
p	I
##ht	I
##hala	I
##te	I
(	O
ME	O
##P	O
)	O
;	O
Mon	O
##o	O
-	O
met	O
##hyl	O
p	O
##ht	O
##ha	O
-	O
late	O
(	O
M	O
##MP	O
)	O
;	O
c	O
##y	O
##c	O
##lo	O
##he	O
##xa	O
##ne	O
-	O
1	O
,	O
2	O
-	O
di	O
##car	O
##box	O
##yl	O
##ic	O
acid	O
-	O
mon	O
##oc	O
##ar	O
##box	O
##y	O
is	O
##oo	O
##ct	O
##yl	O
est	O
##er	O
(	O
MC	O
##OC	O
##H	O
)	O
;	O
and	O
c	O
##y	O
##c	O
##lo	O
##he	O
##xa	O
##ne	O
-	O
1	O
,	O
2	O
-	O
di	O
##car	O
##box	O
##yl	O
##ic	O
acid	O
-	O
mon	O
##o	O
(	O
h	O
##ydro	O
##xy	O
##ison	O
##ony	O
##l	O
)	O
est	O
##er	O
(	O
M	O
##H	O
##i	O
##NC	O
##H	O
)	O
.	O

In	O
the	O
disc	O
##rim	O
##ina	O
##nt	O
analysis	O
applied	O
to	O
generate	O
meta	O
##bol	O
##ite	O
patterns	O
as	O
a	O
method	O
of	O
disease	O
id	O
##ent	O
##i	O
##ﬁ	O
##cation	O
,	O
u	B
##ric	I
acid	I
,	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
and	O
7	B
-	I
met	I
##hyl	I
##gua	I
##nine	I
were	O
all	O
key	O
meta	O
##bol	O
##ites	O
responsible	O
for	O
the	O
differences	O
in	O
metabolic	O
signatures	O
in	O
CC	O
##A	O
cases	O
compared	O
to	O
the	O
ma	O
##li	O
##gnant	O
controls	O
.	O

G	B
##lut	I
##amine	I
is	O
another	O
abundant	O
free	O
amino	O
acid	O
with	O
roles	O
in	O
protein	O
synthesis	O
.	O

The	O
cap	O
##illa	O
##ry	O
temperature	O
was	O
set	O
to	O
190	O
°C	O
,	O
and	O
the	O
voltage	O
was	O
held	O
at	O
2	O
.	O
0	O
k	B
##V	I
.	O

There	O
were	O
about	O
an	O
equal	O
number	O
of	O
results	O
reported	O
for	O
p	B
##hos	I
##ph	I
##ope	I
##pt	I
##ides	I
without	O
p	O
##hos	O
##ph	O
##ory	O
##lation	O
modifications	O
(	O
these	O
account	O
for	O
missing	O
line	O
numbers	O
in	O
the	O
tables	O
)	O
.	O

X	B
##ant	I
##hine	I
.	O

The	O
met	B
##hi	I
##oni	I
##ne	I
meta	O
##bol	O
##ites	O
further	O
supplemented	O
known	O
clinical	O
variables	O
to	O
provide	O
superior	O
sensitivity	O
and	O
specific	O
##ity	O
in	O
multi	O
##var	O
##iable	O
prediction	O
models	O
for	O
rapid	O
bio	O
##chemical	O
re	O
##cu	O
##rrence	O
following	O
pro	O
##state	O
##ct	O
##omy	O
.	O

Considering	O
the	O
relevance	O
of	O
this	O
finding	O
,	O
we	O
decided	O
to	O
examine	O
the	O
inhibitor	O
##y	O
potential	O
of	O
Te	O
##m	O
-	O
do	O
##x	O
-	O
S	O
##O	O
_	O
2	O
on	O
B	O
##u	O
##C	O
##h	O
##E	O
activity	O
,	O
also	O
using	O
et	B
##hyl	I
-	I
para	I
##ox	I
##on	I
as	O
positive	O
control	O
.	O

Our	O
study	O
suggests	O
for	O
evaluating	O
R	O
##R	O
##M	O
##2	O
-	O
associated	O
meta	O
##bol	O
##ites	O
as	O
non	O
##in	O
##vasive	O
markers	O
for	O
ta	B
##mo	I
##xi	I
##fen	I
resistance	O
and	O
its	O
p	O
##har	O
##ma	O
##cological	O
in	O
##hibition	O
as	O
a	O
novel	O
approach	O
to	O
overcome	O
ta	B
##mo	I
##xi	I
##fen	I
resistance	O
in	O
BC	O
##a	O
.	O

The	O
Ph	O
##IP	O
su	B
##lf	I
##ina	I
##mi	I
##de	I
link	O
##age	O
at	O
Cy	O
##s	O
_	O
34	O
of	O
SA	O
undergo	O
##es	O
h	O
##ydro	O
##lysis	O
to	O
produce	O
Ph	O
##IP	O
,	O
by	O
heat	O
and	O
treatment	O
with	O
D	O
##TT	O
during	O
the	O
den	O
##at	O
##uration	O
of	O
SA	O
(	O
Pen	O
##g	O
,	O
L	O
.	O
,	O
unpublished	O
observations	O
)	O
.	O

The	O
reactions	O
of	O
NO	O
_	O
2	O
-	O
Ph	O
##IP	O
and	O
H	O
##ON	O
##H	O
-	O
Ph	O
##IP	O
with	O
SA	O
were	O
performed	O
at	O
37	O
##°	O
##C	O
for	O
18	O
h	O
,	O
whereas	O
the	O
reaction	O
of	O
N	B
-	I
ace	I
##to	I
##xy	I
-	I
Ph	I
##IP	I
with	O
SA	O
was	O
performed	O
at	O
37	O
°C	O
for	O
2	O
h	O
.	O
Un	O
##bound	O
Ph	O
##IP	O
derivatives	O
were	O
removed	O
from	O
SA	O
by	O
solvent	O
extraction	O
with	O
et	B
##hyl	I
ace	I
##tate	I
(	O
3	O
m	O
##L	O
,	O
3	O
times	O
)	O
,	O
followed	O
by	O
gel	O
-	O
fi	O
##ltration	O
ch	O
##roma	O
##tography	O
of	O
the	O
SA	O
with	O
the	O
PD	O
-	O
10	O
column	O
containing	O
10	O
m	O
##M	O
potassium	B
phosphate	I
buffer	O
(	O
pH	O
7	O
.	O
4	O
)	O
.	O

Certain	O
se	B
##rine	I
pro	O
##te	O
##ases	O
act	O
as	O
tumor	O
suppress	O
##ors	O
and	O
promote	O
an	O
##gio	O
##genesis	O
,	O
induce	O
tumor	O
cell	O
migration	O
,	O
and	O
enhance	O
the	O
invasive	O
potential	O
of	O
pan	O
##cre	O
##atic	O
,	O
breast	O
,	O
and	O
lung	O
cancer	O
cells	O
.	O

−	O
0	O
.	O
34	O
##4	O
)	O
,	O
co	B
##rt	I
##ico	I
##ster	I
##one	I
(	O
r	O
_	O
s	O
=	O

We	O
did	O
not	O
observe	O
significant	O
associations	O
among	O
FF	O
##A	O
levels	O
and	O
s	B
##tat	I
##in	I
use	O
,	O
however	O
levels	O
of	O
LP	B
##C	I
(	I
14	I
:	I
0	I
)	I
were	O
significantly	O
reduced	O
in	O
s	B
##tat	I
##in	I
users	O
(	O
0	O
.	O
39	O
μ	O
##M	O
)	O
compared	O
to	O
non	O
-	O
users	O
(	O
0	O
.	O
56	O
μ	O
##M	O
)	O
(	O
p	O
=	O
0	O
.	O
04	O
)	O
.	O

Ser	O
##um	O
total	O
ch	B
##ole	I
##ster	I
##ol	I
(	O
T	O
##C	O
)	O
and	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
(	O
T	O
##G	O
)	O
were	O
analyzed	O
using	O
en	O
##zy	O
##matic	O
color	O
##ime	O
##tric	O
tests	O
;	O
the	O
elect	O
##ive	O
in	O
##hibition	O
method	O
was	O
used	O
to	O
measure	O
serum	O
high	O
-	O
density	O
lip	O
##op	O
##rote	O
##in	O
ch	B
##ole	I
##ster	I
##ol	I
(	O
HD	O
##L	O
-	O
C	O
)	O
.	O

L	O
##C	O
-	O
MS	O
analysis	O
was	O
performed	O
using	O
an	O
A	O
##gi	O
##lent	O
L	O
##C	O
-	O
Q	O
##TO	O
##F	O
system	O
(	O
A	O
##gi	O
##lent	O
Technologies	O
,	O
Santa	O
Clara	O
,	O
CA	O
)	O
consisting	O
of	O
an	O
A	O
##gi	O
##lent	O
1200	O
SL	S
liquid	O
ch	O
##roma	O
##tography	O
system	O
coupled	O
online	O
with	O
an	O
A	O
##gi	O
##lent	O
65	O
##20	O
time	O
-	O
of	O
-	O
flight	O
mass	O
s	O
##pect	O
##rome	O
##ter	O
.	O

Inc	O
##reased	O
per	O
##ox	O
##is	O
##oma	O
##l	O
activity	O
along	O
with	O
increased	O
availability	O
of	O
substrate	O
(	B
ace	B
##ty	I
##l	I
-	I
Co	I
##A	I
produced	O
during	O
per	O
##ox	O
##is	O
##oma	O
##l	O
β	O
-	O
oxidation	O
)	O
will	O
drive	O
P	O
##ls	O
##E	O
##t	O
##n	O
synthesis	O
,	O
el	O
##eva	O
##ting	O
their	O
levels	O
.	O

The	O
mechanisms	O
behind	O
the	O
effect	O
of	O
the	O
combined	O
intervention	O
on	O
metabolism	O
of	O
NE	O
##FA	O
and	O
t	B
##ria	I
##cy	I
##l	I
##gly	I
##cer	I
##ols	I
require	O
c	O
##lar	O
##ification	O
.	O

Effect	O
of	O
G	O
##ST	O
##M	O
##1	O
and	O
G	O
##ST	O
##T	O
##1	O
g	O
##eno	O
##type	O
##s	O
on	O
u	O
##rina	O
##ry	O
ex	O
##cre	O
##tion	O
of	O
ben	B
##zen	I
##e	I
-	I
me	I
##rca	I
##pt	I
##uri	I
##c	I
acid	I
.	O

In	O
our	O
anal	O
##ytic	O
sample	O
,	O
serum	O
ca	B
##ffe	I
##ine	I
was	O
highly	O
correlated	O
with	O
coffee	O
but	O
not	O
with	O
tea	O
,	O
soda	O
,	O
or	O
chocolate	O
;	O
partial	O
Pearson	O
correlation	O
##s	O
adjusted	O
for	O
age	O
,	O
sex	O
,	O
tobacco	O
-	O
smoking	O
status	O
,	O
and	O
B	O
##MI	O
were	O
0	O
.	O
33	O
(	O
P	O
=	O
1	O
.	O
02	O
×	O
10	O
_	O
−	O
##13	O
)	O
,	O
0	O
.	O
04	O
(	O
P	O
=	O
0	O
.	O
39	O
)	O
,	O
−	O
##0	O
.	O
01	O
(	O
P	O
=	O
0	O
.	O
74	O
)	O
,	O
and	O
−	O
##0	O
.	O
03	O
(	O
P	O
=	O
0	O
.	O
49	O
)	O
,	O
respectively	O
.	O

Each	O
sample	O
was	O
spike	O
##d	O
with	O
200	O
μ	O
##l	O
of	O
2	B
-	I
ch	I
##lor	I
##o	I
-	I
p	I
##hen	I
##yla	I
##lani	I
##ne	I
(	O
0	O
.	O
3	O
g	O
/	O
L	O
)	O
as	O
an	O
internal	O
standard	O
and	O
600	O
μ	O
##l	O
of	O
met	B
##han	I
##ol	I
.	O

4	O
:	O
Ph	B
##os	I
##ph	I
##oli	I
##pid	I
synthesis	O
occurs	O
in	O
the	O
end	O
##op	O
##las	O
##mic	O
re	O
##tic	O
##ulum	O
.	O

Interest	O
##ingly	O
,	O
we	O
observed	O
that	O
the	O
levels	O
of	O
some	O
amino	O
acids	O
,	O
such	O
as	O
al	B
##ani	I
##ne	I
(	O
P	O
_	O
frozen	O
=	O
7	O
.	O
94	O
×	O
10	O
_	O
−	O
##3	O
;	O
P	O
_	O
FF	O
##P	O
##E	O
=	O
7	O
.	O
94	O
×	O
10	O
_	O
−	O
##3	O
)	O
,	O
as	B
##par	I
##agi	I
##ne	I
(	O
P	O
_	O
frozen	O
=	O
7	O
.	O
94	O
×	O
10	O
_	O
−	O
##3	O
;	O
P	O
_	O
FF	O
##P	O
##E	O
=	O
7	O
.	O
94	O
×	O
10	O
_	O
−	O
##3	O
)	O
,	O
and	O
g	B
##lut	I
##ama	I
##te	I
(	O
P	O
_	O
frozen	O
=	O
7	O
.	O
94	O
×	O
10	O
_	O
−	O
##3	O
;	O
P	O
_	O
FF	O
##P	O
##E	O
=	O
7	O
.	O
94	O
×	O
10	O
_	O
−	O
##3	O
)	O
,	O
were	O
significantly	O
decreased	O
in	O
and	O
##rogen	O
-	O
independent	O
L	O
##NC	O
##a	O
##P	O
-	O
A	O
##b	O
##l	O
cells	O
.	O

The	O
positive	O
mode	O
analysis	O
UP	O
##LC	O
-	O
(	O
+	O
)	O
E	O
##SI	O
/	O
MS	O
/	O
MS	O
analysis	O
resulted	O
in	O
the	O
identification	O
and	O
q	O
##uant	O
##ification	O
of	O
20	O
a	B
##cy	I
##l	I
-	I
ethanol	I
##ami	I
##des	I
,	O
a	B
##cy	I
##l	I
-	I
g	I
##ly	I
##cer	I
##ols	I
,	O
and	O
a	B
##cy	I
##l	I
-	I
g	I
##ly	I
##cine	I
##s	I
.	O

For	O
the	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
analysis	O
experiment	O
,	O
the	O
cell	O
lines	O
were	O
maintained	O
for	O
1	O
h	O
in	O
D	O
##ME	O
##M	O
medium	O
modified	O
to	O
contain	O
either	O
10	O
m	O
##M	O
U	O
-	O
_	O
13	O
C	O
_	O
6	O
glucose	S
plus	O
2	O
m	O
##M	O
un	O
##la	O
##bel	O
##ed	O
g	B
##lut	I
##amine	I
or	O
2	O
m	O
##M	O
U	O
-	O
_	O
13	O
C	O
_	O
5	O
g	B
##lut	I
##amine	I
plus	O
10	O
m	O
##M	O
un	O
##la	O
##bel	O
##ed	O
glucose	S
.	O

G	B
##lut	I
##ama	I
##te	I
is	O
subsequently	O
transformed	O
into	O
α	B
-	I
k	I
##eto	I
##g	I
##lut	I
##arate	I
through	O
a	O
series	O
of	O
bio	O
##chemical	O
reactions	O
termed	O
g	O
##lut	O
##ami	O
##no	O
##lysis	O
that	O
contribute	O
to	O
re	O
##ple	O
##nish	O
depleted	O
intermediate	O
##s	O
of	O
the	O
T	O
##CA	O
cycle	O
(	O
De	O
##B	O
##era	O
##rdi	O
##nis	O
et	O
al	O
.	O
)	O
.	O

In	O
conclusion	O
,	O
we	O
have	O
shown	O
here	O
that	O
free	O
glucose	S
is	O
marked	O
##ly	O
elevated	O
in	O
AD	O
brain	O
,	O
particularly	O
in	O
vulnerable	O
regions	O
where	O
elevated	O
glucose	S
may	O
well	O
be	O
linked	O
to	O
copper	O
deficiency	O
and	O
tissue	O
-	O
damage	O
.	O

The	O
mass	O
s	O
##pect	O
##rome	O
##try	O
measurements	O
showed	O
that	O
p	B
##yr	I
##u	I
##vate	I
was	O
mostly	O
labeled	O
from	O
glucose	S
rather	O
than	O
from	O
g	B
##lut	I
##amine	I
.	O

L	B
##T	I
##B	I
##4	I
,	O
the	O
precursor	O
of	O
the	O
other	O
bio	O
##mark	O
##er	O
involved	O
with	O
AA	O
pathways	O
in	O
this	O
study	O
,	O
is	O
a	O
potent	O
lip	O
##id	O
media	O
##tor	O
capable	O
of	O
promoting	O
ch	O
##em	O
##ota	O
##xi	O
##s	O
,	O
ne	O
##ut	O
##rop	O
##hil	O
de	O
##gra	O
##nu	O
##lation	O
,	O
and	O
release	O
of	O
enzymes	O
and	O
R	O
##OS	O
.	O

Previous	O
attempts	O
to	O
predict	O
the	O
var	O
##iability	O
of	O
(	B
Z	I
)	I
‐	I
end	I
##ox	I
##ife	I
##n	I
levels	O
relied	O
on	O
p	O
##har	O
##ma	O
##co	O
##kin	O
##etic	O
and	O
p	O
##har	O
##ma	O
##co	O
##gen	O
##omi	O
##c	O
knowledge	O
,	O
_	O
17	O
,	O
_	O
38	O
,	O
_	O
39	O
which	O
has	O
been	O
implemented	O
into	O
therapeutic	O
recommendations	O
based	O
on	O
C	O
##YP	O
##2	O
##D	O
##6	O
g	O
##eno	O
##ty	O
##ping	O
.	O
_	O
14	O
Although	O
a	O
recent	O
drug	O
monitoring	O
study	O
showed	O
that	O
ta	B
##mo	I
##xi	I
##fen	I
meta	O
##bol	O
##ites	O
may	O
be	O
predict	O
##ive	O
of	O
side	O
effects	O
,	O
such	O
as	O
nausea	O
and	O
v	O
##agi	O
##nal	O
dry	O
##ness	O
,	O
_	O
40	O
clinical	O
ta	B
##mo	I
##xi	I
##fen	I
outcome	O
studies	O
as	O
of	O
yet	O
provided	O
controversial	O
results	O
possibly	O
due	O
to	O
the	O
influence	O
of	O
unidentified	O
con	O
##found	O
##ers	O
.	O
_	O
22	O
,	O
_	O
23	O
,	O
_	O
24	O
,	O
_	O
26	O
,	O
_	O
27	O
,	O
_	O
28	O
Because	O
it	O
is	O
well	O
known	O
that	O
women	O
stop	O
taking	O
their	O
medication	O
before	O
completing	O
the	O
standard	O
5	O
‐	O
year	O
regime	O
##n	O
,	O
we	O
investigated	O
patients	O
'	O
ad	O
##herence	O
behavior	O
during	O
the	O
first	O
year	O
of	O
ta	B
##mo	I
##xi	I
##fen	I
treatment	O
in	O
relation	O
to	O
their	O
metabolic	O
capacity	O
for	O
achieving	O
relevant	O
(	B
Z	I
)	I
‐	I
end	I
##ox	I
##ife	I
##n	I
concentrations	O
.	O

B	O
##rief	O
##ly	O
,	O
5	O
m	O
##l	O
al	O
##iq	O
##uo	O
##ts	O
of	O
urine	O
were	O
freeze	O
-	O
dried	O
,	O
5	O
m	O
##l	O
98	O
%	O
ni	B
##tric	I
acid	I
(	O
San	O
##ye	O
Chemical	O
Corporation	O
)	O
was	O
added	O
,	O
then	O
the	O
mixture	O
was	O
transferred	O
into	O
120	O
m	O
##l	O
Te	O
##f	O
##lon	O
dig	O
##est	O
##ion	O
vessels	O
.	O

SE	O
##T	O
##D	O
##1	O
##B	O
is	O
a	O
component	O
of	O
the	O
met	O
##hyl	O
##tra	O
##ns	O
##fer	O
##ase	O
complex	O
that	O
specifically	O
met	B
##hyl	I
##ates	I
the	O
l	B
##ys	I
##ine	I
-	I
4	I
residue	O
of	O
his	O
##tone	O
H	O
##3	O
.	O

In	O
conclusion	O
,	O
our	O
u	O
##rina	O
##ry	O
s	O
##tero	O
##id	O
pro	O
##fi	O
##ling	O
study	O
reveals	O
and	B
##ros	I
##tan	I
##ed	I
##iol	I
,	O
est	B
##rio	I
##l	I
,	O
20	B
##β	I
##D	I
##H	I
##cor	I
##tis	I
##one	I
,	O
and	O
co	B
##rt	I
##is	I
##ol	I
as	O
promising	O
diagnostic	O
markers	O
for	O
PC	O
##OS	O
.	O

The	O
pool	O
##ed	O
mixture	O
##s	O
were	O
son	O
##ica	O
##ted	O
at	O
40	O
kHz	O
for	O
60	O
s	O
.	O
Subsequently	O
,	O
extraction	O
was	O
performed	O
using	O
300	O
μ	O
##l	O
of	O
ch	B
##lor	I
##of	I
##orm	I
,	O
with	O
the	O
a	O
##que	O
##ous	O
layer	O
pH	O
carefully	O
adjusted	O
to	O
9	O
–	O
10	O
using	O
100	O
μ	O
##l	O
of	O
Na	O
##OH	O
(	O
7	O
m	O
)	O
.	O

The	O
levels	O
of	O
two	O
substances	O
were	O
increased	O
with	O
the	O
reduction	O
in	O
liver	O
com	O
##pen	O
##sat	O
##ory	O
ability	O
,	O
which	O
were	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##ose	I
##rine	I
and	O
ta	B
##uro	I
##cho	I
##lic	I
acid	I
(	O
P	O
<	O
0	O
.	O
00	O
##1	O
)	O
.	O

The	O
bio	O
##sy	O
##nt	O
##hesis	O
of	O
the	O
modified	O
u	B
##rid	I
##ine	I
derivative	O
proceeds	O
via	O
selective	O
transfer	O
of	O
the	O
car	O
##box	O
##yam	O
##ino	O
##p	O
##rop	O
##yl	O
m	O
##oi	O
##ety	O
on	O
u	B
##rid	I
##ine	I
positions	O
in	O
the	O
RNA	O
molecule	O
.	O

The	O
present	O
results	O
found	O
one	O
common	O
differential	O
meta	O
##bol	O
##ite	O
,	O
N	B
'	I
-	I
form	I
##yl	I
##ky	I
##nu	I
##ren	I
##ine	I
,	O
which	O
could	O
disc	O
##rim	O
##inate	O
RC	O
##C	O
not	O
only	O
from	O
healthy	O
controls	O
but	O
also	O
from	O
ben	O
##ign	O
controls	O
.	O

AT	O
##CC	O
®	O
CR	O
##L	O
-	O
1831	O
_	O
[UNK]	O
;	O
Rock	O
##ville	O
,	O
MD	O
,	O
USA	O
)	O
,	O
were	O
culture	O
##d	O
in	O
a	O
1	O
:	O
1	O
mixture	O
of	O
Ham	O
'	O
s	O
F1	O
##2	O
and	O
D	O
##ME	O
##M	O
(	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
;	O
Prague	O
,	O
Czech	O
Republic	O
)	O
,	O
supplemented	O
with	O
H	O
##EP	O
##ES	O
(	O
25	O
m	O
##M	O
,	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
)	O
,	O
10	O
%	O
F	O
##BS	O
,	O
ch	O
##ole	O
##ra	O
to	B
##xin	I
(	O
10	O
ng	O
/	O
m	O
##l	O
;	O
Cal	O
##bio	O
##che	O
##m	O
-	O
Nova	O
##bio	O
##che	O
##m	O
Corporation	O
;	O
La	O
Jo	O
##lla	O
,	O
CA	O
,	O
USA	O
)	O
,	O
insulin	O
(	O
0	O
.	O
00	O
##5	O
mg	O
/	O
m	O
##l	O
,	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
,	O
Prague	O
,	O
Czech	O
Republic	O
)	O
,	O
transfer	O
##rin	O
(	O
0	O
.	O
00	O
##5	O
mg	O
/	O
m	O
##l	O
,	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
)	O
and	O
h	B
##ydro	I
##cor	I
##tis	I
##one	I
(	O
1	O
mg	O
/	O
m	O
##l	O
;	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
)	O
.	O

A	O
p	O
##har	O
##ma	O
##co	O
-	O
meta	O
##bol	O
##omi	O
##cs	O
study	O
was	O
conducted	O
using	O
plasma	O
samples	O
from	O
the	O
T	O
##RO	O
##19	O
##6	O
##22	O
(	B
o	B
##les	I
##ox	I
##ime	I
)	O
trial	O
to	O
assess	O
the	O
link	O
between	O
early	O
meta	O
##bol	O
##omi	O
##c	O
profiles	O
and	O
clinical	O
outcomes	O
.	O

The	O
AU	O
##C	O
for	O
NC	O
vs	B
PC	I
for	O
th	B
##re	I
##oni	I
##ne	I
was	O
0	O
.	O
84	O
thus	O
emphasizing	O
the	O
need	O
for	O
continued	O
efforts	O
to	O
del	O
##ine	O
##ate	O
a	O
bio	O
##mark	O
##er	O
panel	O
with	O
high	O
specific	O
##ity	O
for	O
PC	O
(	O
Figure	O
)	O
.	O

The	O
co	O
##hor	O
##t	O
in	O
which	O
we	O
initially	O
discovered	O
ethanol	S
contamination	O
consisted	O
of	O
human	O
CS	O
##F	O
samples	O
that	O
were	O
collected	O
for	O
research	O
purposes	O
,	O
namely	O
to	O
investigate	O
the	O
path	O
##op	O
##hy	O
##sio	O
##logy	O
of	O
mi	O
##gra	O
##ine	O
.	O

Sc	O
##hem	O
##a	O
showing	O
the	O
partition	O
##ing	O
of	O
the	O
39	O
##9	O
subjects	O
into	O
groups	O
according	O
to	O
the	O
results	O
of	O
the	O
oral	O
glucose	S
tolerance	O
test	O
(	O
O	O
##G	O
##TT	O
)	O
,	O
fast	O
##ing	O
plasma	O
glucose	S
levels	O
(	O
F	O
##P	O
##G	O
)	O
and	O
M	O
values	O
derived	O
from	O
the	O
c	O
##lamp	O
.	O

Re	O
##lative	O
g	B
##lut	I
##ama	I
##te	I
concentrations	O
are	O
significantly	O
higher	O
in	O
patients	O
with	O
inflammation	O
than	O
in	O
controls	O
(	O
p	O
value	O
<	O
0	O
.	O
000	O
##1	O
)	O
:	O
0	O
.	O
48	O
##5	O
(	O
SD	O
0	O
.	O
237	O
)	O
versus	O
0	O
.	O
152	O
(	O
SD	O
0	O
.	O
113	O
)	O
.	O

(	O
B	O
)	O
Star	O
##ch	O
and	O
su	B
##c	I
##rose	I
metabolism	O
.	O

Seven	O
active	O
meta	O
##bol	O
##ites	O
,	O
including	O
8	B
-	I
h	I
##ydro	I
##xy	I
-	I
5	I
,	I
6	I
-	I
dim	I
##eth	I
##ox	I
##y	I
-	I
2	I
-	I
met	I
##hyl	I
-	I
3	I
-	I
(	I
2	I
-	I
o	I
##x	I
##o	I
-	I
prop	I
##yl	I
)	I
-	I
1	I
,	I
4	I
-	I
nap	I
##ht	I
##ho	I
##quin	I
##one	I
(	O
16	O
)	O
,	O
er	B
##gos	I
##ta	I
-	I
5	I
,	I
7	I
,	I
22	I
-	I
t	I
##rien	I
-	I
3	I
##β	I
-	I
o	I
##l	I

Mobile	O
phase	O
A	O
was	O
water	O
containing	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
plus	O
10	O
m	O
##M	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
.	O

This	O
allowed	O
for	O
q	O
##uant	O
##ification	O
of	O
the	O
con	O
##ju	O
##gated	O
and	O
un	O
##con	O
##ju	O
##gated	O
k	B
##eto	I
-	I
and	I
##rogen	I
##s	I
using	O
a	O
single	O
MS	O
protocol	O
.	O

This	O
level	O
of	O
detail	O
is	O
important	O
,	O
given	O
the	O
large	O
number	O
of	O
these	O
enzymes	O
and	O
is	O
##of	O
##orms	O
,	O
and	O
their	O
roles	O
in	O
meta	O
##bol	O
##izing	O
hormones	O
,	O
medications	O
,	O
and	O
to	B
##xin	I
##s	I
.	O

One	O
potential	O
issue	O
is	O
the	O
effect	O
on	O
ch	O
##roma	O
##to	O
##graphic	O
retention	O
time	O
caused	O
by	O
the	O
addition	O
of	O
the	O
ch	B
##ola	I
##mine	I
tag	O
.	O

N	B
-	I
met	I
##hyl	I
##alan	I
##ine	I
was	O
inverse	O
##ly	O
related	O
to	O
insulin	O
post	B
-	I
si	I
##m	I
##vas	I
##tat	I
##in	I
treatment	O
.	O

The	O
essential	O
amino	O
acid	O
try	O
##pt	O
##op	O
##han	O
is	O
cat	O
##ab	O
##olis	O
##ed	O
mainly	O
through	O
the	O
k	B
##yn	I
##uren	I
##ine	I
pathway	O
.	O

The	O
extent	O
of	O
_	O
13	O
C	O
en	O
##rich	O
##ment	O
in	O
glucose	S
(	O
as	O
[	O
U	O
-	O
_	O
13	O
C	O
]	O
-	O
G	O
##l	O
##c	O
)	O
for	O
non	O
-	O
cancer	O
##ous	O
tissues	O
was	O
determined	O
from	O
the	O
1	O
-	O
D	O
_	O
1	O
H	O
s	O
##pect	O
##ra	O
(	O
c	O
##f	O
.	O

These	O
amounts	O
represent	O
8	O
.	O
4	O
,	O
8	O
.	O
8	O
and	O
9	O
.	O
7	O
%	O
of	O
the	O
administered	O
daily	O
dose	O
of	O
SF	S
(	O
600	O
μ	O
##mo	O
##l	O
G	O
##R	O
+	O
40	O
μ	O
##mo	O
##l	O
SF	O
)	O
.	O

Effect	O
of	O
the	O
concentration	O
of	O
p	O
##oly	O
-	O
L	O
,	O
L	O
-	O
S	O
##U	O
##LA	O
on	O
the	O
simultaneous	O
en	O
##anti	O
##ose	O
##par	O
##ation	O
of	O
1	B
,	I
1	I
’	I
=	I
O	I
-	I
D	I
##V	I
##X	I
and	O
2	B
,	I
2	I
’	I
=	I
V	I
##X	I
.	O

Regarding	O
P	O
##t	O
##d	O
##C	O
##ho	O
,	O
relevant	O
enzymes	O
include	O
p	B
##hos	I
##ph	I
##och	I
##olin	I
##e	I
transfer	O
##ase	O
,	O
p	O
##hos	O
##ph	O
##ory	O
##l	O
##cho	O
##line	O
-	O
c	O
##yt	O
##idy	O
##l	O
-	O
transfer	O
##ase	O
(	O
CT	O
##P	O
)	O
,	O
le	B
##ci	I
##thin	I
-	I
ch	I
##ole	I
##ster	I
##ol	I
a	O
##cy	O
##lt	O
##ran	O
##s	O
##fer	O
##ase	O
(	O
L	O
##CA	O
##T	O
)	O
,	O
etc	O
.	O

A	O
recent	O
meta	O
-	O
analysis	O
also	O
demonstrated	O
that	O
the	O
food	O
intake	O
with	O
ch	B
##olin	I
##e	I
plus	O
beta	B
##ine	I
(	O
100	O
mg	O
/	O
day	O
)	O
could	O
lower	O
the	O
cancer	O
incidence	O
by	O
11	O
%	O
(	O
Sun	O
et	O
al	O
.	O
)	O
.	O

In	O
this	O
study	O
,	O
however	O
,	O
we	O
found	O
that	O
meta	O
##bol	O
##ite	O
ratios	O
such	O
as	O
t	O
-	O
ch	O
##olin	O
##e	O
/	O
t	O
-	O
c	O
##rea	O
##tine	O
,	O
t	O
-	O
ch	O
##olin	O
##e	O
/	O
c	O
##it	O
##rate	O
,	O
(	B
t	I
-	I
ch	I
##olin	I
##e	I
+	I
t	I
-	I
c	I
##rea	I
##tine	I
)	I
/	I
c	I
##it	I
##rate	I
and	O
(	B
t	I
-	I
ch	I
##olin	I
##e	I
+	I
t	I
-	I
c	I
##rea	I
##tine	I
+	I
p	I
##oly	I
##amine	I
##s	I
)	I
/	I
c	I
##it	I
##rate	I
were	O
not	O
different	O
between	O
the	O
De	O
##gar	O
##eli	O
##x	O
-	O
treated	O
and	O
un	O
##tre	O
##ated	O
pro	O
##state	O
cancer	O
samples	O
(	O
supplement	O
##ary	O
figure	O
S	O
##2	O
)	O
.	O

The	O
P	O
##E	O
derivatives	O
generated	O
[	O
M	O
+	O
2	O
p	B
##ico	I
##lini	I
##c	I
acid	I
+	O
Na	O
]	O
_	O
+	O
ions	O
as	O
the	O
base	O
peaks	O
under	O
E	O
##SI	O
positive	O
conditions	O
.	O

The	O
di	O
##s	O
##join	O
##t	O
rules	O
indicate	O
that	O
a	O
##A	O
##IP	O
patients	O
were	O
specifically	O
characterized	O
by	O
higher	O
concentrations	O
of	O
ace	B
##tate	I
,	O
c	B
##it	I
##rate	I
and	O
p	B
##yr	I
##u	I
##vate	I
,	O
the	O
inverse	O
being	O
observed	O
for	O
PC	O
##T	O
patients	O
.	O

This	O
estimate	O
is	O
possibly	O
an	O
under	O
##est	O
##imation	O
,	O
given	O
our	O
data	O
shows	O
that	O
one	O
chemical	O
is	O
able	O
to	O
affect	O
multiple	O
C	O
##p	O
##G	O
sites	O
and	O
genes	O
and	O
the	O
multi	O
##p	O
##licity	O
of	O
to	B
##xin	I
##s	I
in	O
our	O
environment	O
may	O
result	O
in	O
larger	O
responses	O
.	O

The	O
delivery	O
of	O
these	O
drugs	O
to	O
the	O
liver	O
reflects	O
trapping	O
of	O
polar	O
p	O
##hos	O
##ph	O
##ory	O
##lated	O
meta	O
##bol	O
##ites	O
for	O
both	O
drugs	O
,	O
pro	O
##dr	O
##ug	O
activation	O
for	O
so	B
##fo	I
##s	I
##bu	I
##vir	I
,	O
and	O
n	O
##uc	O
##leo	O
##side	O
transport	O
for	O
rib	B
##avi	I
##rin	I
.	O

To	O
investigate	O
the	O
metabolic	O
differences	O
based	O
on	O
the	O
re	O
##cu	O
##rrence	O
of	O
A	B
##F	I
,	O
the	O
analyses	O
described	O
above	O
were	O
repeated	O
on	O
age	O
-	O
,	O
sex	O
-	O
,	O
and	O
B	O
##MI	O
-	O
matched	O
A	B
##F	I
patients	O
who	O
experienced	O
A	B
##F	I
re	O
##cu	O
##rrence	O
within	O
1	O
month	O
after	O
DC	O
##C	O
##V	O
(	O
re	O
##current	O
A	B
##F	I
group	O
,	O
n	O
=	O
57	O
)	O
versus	O
those	O
who	O
maintained	O
sin	O
##us	O
rhythm	O
(	O
non	O
-	O
re	O
##current	O
A	B
##F	I
group	O
,	O
n	O
=	O
57	O
)	O
.	O

The	O
upper	O
a	O
##que	O
##ous	O
phase	O
was	O
transferred	O
into	O
a	O
clean	O
p	B
##oly	I
##p	I
##rop	I
##yle	I
##ne	I
tube	O
and	O
re	O
-	O
extracted	O
by	O
addition	O
of	O
200	O
μ	O
##l	O
M	B
##T	I
##BE	I
as	O
described	O
above	O
.	O

The	O
ME	O
##K	O
##C	O
-	O
MS	O
/	O
MS	O
conditions	O
are	O
the	O
same	O
as	O
in	O
except	O
that	O
15	O
m	O
##M	O
p	O
##oly	O
-	O
L	O
,	O
L	O
-	O
S	O
##U	O
##LA	O
and	O
25	O
k	B
##V	I
was	O
used	O
.	O

Moreover	O
,	O
the	O
levels	O
of	O
sulfur	O
amino	O
acids	O
(	O
i	O
.	O
e	O
.	O
,	O
ta	B
##uri	I
##ne	I
and	O
c	O
##ys	O
##tein	O
##e	O
)	O
in	O
the	O
post	O
##pra	O
##ndi	O
##al	O
state	O
were	O
significantly	O
increased	O
in	O
the	O
H	O
##LP	O
group	O
compared	O
with	O
the	O
fast	O
##ing	O
state	O
.	O

Our	O
results	O
demonstrate	O
an	O
association	O
between	O
tobacco	O
smoking	O
and	O
higher	O
th	B
##rom	I
##box	I
##ane	I
levels	O
in	O
patients	O
with	O
a	B
##rac	I
##hi	I
##don	I
##ic	I
acid	I
a	O
##gg	O
##re	O
##go	O
##metry	O
proven	O
as	B
##pi	I
##rin	I
induced	O
plate	O
##let	O
CO	O
##X	O
-	O
1	O
in	O
##hibition	O
.	O

The	O
N	B
-	I
ace	I
##to	I
##xy	I
-	I
Ph	I
##IP	I
derivatives	O
were	O
prepared	O
immediately	O
prior	O
to	O
their	O
reaction	O
with	O
p	O
##eptide	O
##s	O
or	O
SA	O
.	O

For	O
the	O
100	O
randomly	O
selected	O
full	O
range	O
participants	O
,	O
meta	O
##bol	O
##ite	O
changes	O
were	O
correlated	O
with	O
s	B
##tat	I
##in	I
response	O
of	O
L	O
##D	O
##L	O
-	O
C	O
by	O
calculating	O
their	O
S	O
##pear	O
##man	O
’	O
s	O
correlation	O
coefficients	O
with	O
post	O
-	O
treatment	O
level	O
L	O
##D	O
##L	O
-	O
C	O
,	O
adjusting	O
for	O
pre	O
-	O
treatment	O
level	O
of	O
L	O
##D	O
##L	O
-	O
C	O
.	O
The	O
adjusted	O
S	O
##pear	O
##man	O
’	O
s	O
correlation	O
is	O
equivalent	O
to	O
the	O
Pearson	O
’	O
s	O
correlation	O
between	O
the	O
residual	O
##s	O
of	O
the	O
linear	O
re	O
##gression	O
of	O
the	O
ranks	O
of	O
post	O
-	O
treatment	O
level	O
of	O
L	O
##D	O
##L	O
-	O
C	O
and	O
the	O
meta	O
##bol	O
##ite	O
change	O
on	O
the	O
ranks	O
of	O
pre	O
-	O
treatment	O
level	O
of	O
L	O
##D	O
##L	O
-	O
C	O
.	O
To	O
associate	O
meta	O
##bol	O
##ite	O
changes	O
with	O
s	B
##tat	I
##in	I
response	O
of	O
L	O
##D	O
##L	O
-	O
C	O
using	O
good	O
and	O
poor	O
respond	O
##er	O
data	O
,	O
the	O
difference	O
of	O
meta	O
##bol	O
##ite	O
changes	O
between	O
good	O
respond	O
##ers	O
and	O
poor	O
respond	O
##ers	O
using	O
the	O
Wilcox	O
##on	O
rank	O
sum	O
test	O
was	O
tested	O
.	O

Although	O
the	O
s	O
##ynth	O
##ese	O
##s	O
of	O
the	O
starting	O
materials	O
Ph	B
##e	I
-	I
e	I
##pox	I
##ides	I
2	O
and	O
12	O
have	O
been	O
previously	O
reported	O
,	O
we	O
note	O
that	O
these	O
are	O
multi	O
-	O
step	O
methods	O
resulting	O
in	O
relatively	O
low	O
overall	O
yields	O
.	O

For	O
ch	O
##roma	O
##tography	O
using	O
the	O
A	O
##gi	O
##lent	O
L	O
##C	O
system	O
,	O
the	O
mobile	O
phase	O
was	O
composed	O
of	O
solvent	O
A	O
,	O
5	O
m	O
##M	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
in	O
90	O
%	O
H	O
_	O
2	O
O	O
/	O
10	O
%	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
with	O
0	O
.	O
2	O
%	O
ace	B
##tic	I
acid	I
,	O
and	O
solvent	O
B	O
,	O
5	O
m	O
##M	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
in	O
90	O
%	O
ace	O
##ton	O
##it	O
##ril	O
##e	O
/	O
10	O
%	O
H	O
_	O
2	O
O	O
with	O
0	O
.	O
2	O
%	O
ace	B
##tic	I
acid	I
.	O

De	O
##gly	O
##cos	O
##yla	O
##tion	O
of	O
the	O
parent	O
BR	O
##B	O
ant	B
##ho	I
##cy	I
##ani	I
##n	I
to	O
its	O
respective	O
a	B
##gly	I
##con	I
##e	I
enhance	O
##s	O
ch	O
##em	O
##op	O
##re	O
##vent	O
##ive	O
impact	O
by	O
removing	O
the	O
bulk	O
##y	O
sugar	O
groups	O
which	O
could	O
cause	O
s	O
##ter	O
##ic	O
hind	O
##rance	O
,	O
replacing	O
the	O
g	B
##lu	I
##cos	I
##id	I
##ic	I
link	O
##age	O
by	O
another	O
anti	O
##ox	O
##ida	O
##nt	O
-	O
s	O
##ca	O
##ven	O
##ging	O
h	O
##ydro	O
##xy	O
##l	O
group	O
and	O
f	O
##ac	O
##ilitating	O
transport	O
independent	O
cell	O
up	O
##take	O
.	O

These	O
measures	O
showed	O
a	O
significant	O
difference	O
across	O
the	O
three	O
groups	O
,	O
with	O
the	O
least	O
u	O
##rina	O
##ry	O
glucose	S
found	O
in	O
those	O
with	O
G	O
##C	O
##K	O
-	O
M	O
##OD	O
##Y	O
and	O
the	O
most	O
in	O
those	O
with	O
H	O
##NF	O
##1	O
##A	O
-	O
M	O
##OD	O
##Y	O
.	O

Co	O
##mpo	O
##und	O
parameters	O
were	O
op	O
##ti	O
##mized	O
by	O
first	O
preparing	O
the	O
standards	O
(	O
met	O
##form	O
##in	O
and	O
synthesized	O
met	O
##form	O
##in	O
—	O
MG	O
meta	O
##bol	O
##ite	O
)	O
at	O
500	O
μ	O
g	O
/	O
m	O
##L	O
in	O
met	B
##han	I
##ol	I
and	O
di	O
##lut	O
##ing	O
to	O
approximately	O
1	O
μ	O
g	O
/	O
m	O
##L	O
in	O
water	O
.	O

It	O
is	O
evident	O
that	O
select	O
##ivity	O
varies	O
significantly	O
between	O
R	B
##P	I
and	O
H	O
##IL	O
##IC	O
but	O
,	O
more	O
importantly	O
,	O
also	O
between	O
the	O
H	O
##IL	O
##IC	O
methods	O
.	O

Ace	B
##to	I
##ace	I
##tate	I
,	O
3	O
)	O
Ace	B
##tone	I
,	O
4	O
)	O
Alan	B
##ine	I
,	O
5	O
)	O
Album	O
##in	O
L	O
##ys	O
##yl	O
,	O
6	O
)	O
Beta	B
##ine	I
,	O
7	O
)	O
Cho	B
##line	I
,	O
8	O
)	O
C	B
##it	I
##rate	I
,	O
9	O
)	O
C	B
##rea	I
##tine	I
,	O
10	O
)	O
C	B
##rea	I
##tin	I
##ine	I
,	O
11	O
)	O

Ra	B
##c	I
-	I
met	I
##had	I
##one	I
-	I
HC	I
##l	I
(	O
d	O
_	O
0	O
)	O
was	O
obtained	O
from	O
R	B
##ox	I
##ane	I
Laboratories	O
,	O
IN	O
##C	O
(	O
Columbus	O
,	O
Ohio	O
)	O
.	O

Table	O
shows	O
the	O
data	O
for	O
glucose	S
consumption	O
and	O
secret	O
##ion	O
of	O
la	B
##ct	I
##ate	I
and	O
Al	O
##a	O
into	O
the	O
medium	O
from	O
the	O
two	O
cell	O
types	O
.	O

For	O
the	O
H	O
##B	O
##V	O
,	O
HC	O
##V	O
,	O
and	O
control	O
co	O
##hor	O
##ts	O
,	O
both	O
plasma	O
and	O
urine	O
were	O
profile	O
##d	O
on	O
the	O
same	O
G	O
##CM	O
##S	O
instrument	O
by	O
the	O
same	O
operator	O
after	O
double	O
der	O
##iva	O
##ti	O
##zation	O
and	O
using	O
4	B
-	I
ch	I
##lor	I
##op	I
##hen	I
##yla	I
##ce	I
##tic	I
acid	I
as	O
internal	O
standard	O
,	O
as	O
described	O
[	O
,	O
,	O
,	O
]	O
.	O

To	O
maintain	O
home	O
##ost	O
##asis	O
,	O
more	O
h	B
##y	I
##pot	I
##au	I
##rine	I
was	O
needed	O
to	O
form	O
ta	B
##uri	I
##ne	I
.	O

The	O
ass	O
##ay	O
values	O
for	O
in	O
##tra	O
-	O
day	O
and	O
inter	O
-	O
day	O
accuracy	O
and	O
precision	O
for	O
plasma	O
with	O
either	O
low	O
or	O
high	O
t	B
##rig	I
##ly	I
##cer	I
##ide	I
levels	O
were	O
within	O
the	O
acceptable	O
15	O
%	O
limit	O
.	O

G	O
##DM	O
,	O
g	O
##esta	O
##tional	O
diabetes	O
me	O
##lli	O
##tus	O
;	O
T	B
##MA	I
##O	I
,	O
trim	B
##eth	I
##yla	I
##mine	I
-	I
N	I
-	I
oxide	I
.	O
_	O
2	O
Tests	O
for	O
linear	O
trend	O
were	O
conducted	O
by	O
using	O
the	O
medium	O
value	O
for	O
each	O
q	O
##ua	O
##rt	O
##ile	O
and	O
treating	O
it	O
as	O
a	O
continuous	O
variable	O
in	O
the	O
conditional	O
log	O
##istic	O
re	O
##gression	O
.	O

Ana	O
##ly	O
##ses	O
were	O
carried	O
out	O
in	O
negative	O
electro	O
##sp	O
##ray	O
ion	O
##ization	O
(	B
E	B
##SI	I
(	I
-	I
)	I
)	O
mode	O
.	O

The	O
concentration	O
of	O
LP	O
##Cs	O
containing	O
the	O
P	O
##U	O
##FA	O
##s	O
l	B
##ino	I
##le	I
##ic	I
acid	I
(	O
18	O
:	O
2	O
)	O
and	O
α	B
-	I
l	I
##ino	I
##len	I
##ic	I
acid	I
(	O
18	O
:	O
3	O
)	O
was	O
significantly	O
decreased	O
in	O
the	O
HIV	O
+	O
group	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Color	O
##ec	O
##tal	O
cancer	O
##s	O
(	O
CR	O
##C	O
)	O
are	O
associated	O
with	O
per	O
##tur	O
##bation	O
##s	O
in	O
cellular	O
amino	O
acids	O
,	O
n	O
##uc	O
##leo	O
##tide	O
##s	O
,	O
pen	B
##tos	I
##e	I
-	I
phosphate	I
pathway	O
car	O
##bo	O
##hy	O
##dra	O
##tes	O
,	O
and	O
g	B
##ly	I
##co	I
##ly	I
##tic	I
,	O
g	B
##lu	I
##con	I
##eo	I
##genic	I
,	O
and	O
t	B
##rica	I
##rb	I
##ox	I
##yl	I
##ic	I
acid	I
intermediate	O
##s	O
.	O

Representative	O
T	O
##IC	O
and	O
MR	O
##M	O
electro	O
##pher	O
##ogram	O
for	O
simultaneous	O
en	O
##anti	O
##ose	O
##par	O
##ation	O
of	O
1	B
,	I
1	I
’	I
=	I
O	I
-	I
D	I
##V	I
##X	I
and	O
2	B
,	I
2	I
’	I
=	I
V	I
##X	I
and	O
3	B
,	I
3	I
’	I
=	I
N	I
-	I
D	I
##V	I
##X	I
(	B
N	B
-	I
des	I
##met	I
##hyl	I
-	I
ve	I
##n	I
##la	I
##fa	I
##xin	I
##e	I
)	O
.	O

In	O
addition	O
,	O
cat	B
##ech	I
##ol	I
est	O
##rogen	O
##s	O
,	O
which	O
are	O
formed	O
by	O
2	O
-	O
and	O
4	O
-	O
h	O
##ydro	O
##xy	O
##lation	O
,	O
can	O
be	O
o	O
##xi	O
##dized	O
to	O
form	O
m	O
##uta	O
##genic	O
q	B
##uin	I
##ones	I
(	O
–	O
)	O
;	O
this	O
process	O
is	O
prevented	O
by	O
met	O
##hyl	O
##ation	O
of	O
one	O
of	O
the	O
adjacent	O
h	O
##ydro	O
##xy	O
##l	O
groups	O
.	O

The	O
daily	O
dose	O
of	O
K	O
##BR	O
represented	O
0	O
.	O
9	O
g	O
of	O
total	O
p	B
##hen	I
##ol	I
,	O
including	O
17	O
.	O
5	O
mg	O
of	O
my	B
##rice	I
##tin	I
,	O
9	O
.	O
6	O
mg	O
of	O
g	O
##eni	O
##st	O
##in	O
,	O
7	O
.	O
2	O
mg	O
of	O
que	B
##rc	I
##eti	I
##n	I
,	O
1	O
.	O
2	O
mg	O
of	O
da	B
##id	I
##ze	I
##in	I
,	O
and	O
1	O
.	O
2	O
mg	O
of	O
er	B
##io	I
##dict	I
##yo	I
##l	I
,	O
as	O
well	O
as	O
126	O
k	O
##cal	O
(	O
65	O
.	O
5	O
%	O
as	O
car	O
##bo	O
##hy	O
##dra	O
##te	O
,	O
10	O
.	O
1	O
%	O
as	O
protein	O
,	O
and	O
5	O
.	O
4	O
%	O
as	O
fat	O
)	O
.	O

A	O
step	O
gradient	O
with	O
up	O
to	O
100	O
m	O
##M	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
was	O
included	O
in	O
order	O
to	O
el	O
##ute	O
the	O
high	O
amounts	O
of	O
su	B
##lf	I
##ate	I
in	O
urine	O
.	O

To	O
evaluate	O
the	O
label	O
##ing	O
capability	O
of	O
the	O
three	O
BC	O
##AA	O
and	O
effects	O
of	O
the	O
BC	O
##KA	O
,	O
cells	O
were	O
culture	O
##d	O
in	O
6	O
-	O
well	O
plates	O
with	O
custom	O
made	O
R	O
##PM	O
##I	O
1640	O
medium	O
with	O
the	O
trace	O
##rs	O
;	O
_	O
13	O
C	B
_	I
6	I
-	I
is	I
##ole	I
##uc	I
##ine	I
,	O
_	O
13	O
C	B
_	I
6	I
-	I
le	I
##uc	I
##ine	I
and	O
_	O
13	O
C	B
_	I
5	I
-	I
v	I
##ali	I
##ne	I
,	O
individually	O
or	O
simultaneously	O
w	O
/	O
w	O
##o	O
co	O
-	O
culture	O
of	O
0	O
.	O
3	O
m	O
##M	O
per	O
BC	O
##KA	O
for	O
48	O
h	O
.	O

Additional	O
research	O
would	O
be	O
needed	O
to	O
determine	O
whether	O
su	B
##cci	I
##nate	I
or	O
other	O
T	O
##CA	O
meta	O
##bol	O
##ites	O
are	O
predict	O
##ors	O
of	O
incident	O
CE	O
stroke	O
or	O
of	O
re	O
##current	O
stroke	O
events	O
in	O
a	O
population	O
-	O
based	O
study	O
.	O

In	O
this	O
study	O
,	O
the	O
plasma	O
levels	O
of	O
al	B
##ani	I
##ne	I
and	O
g	B
##ly	I
##cine	I
were	O
decreased	O
in	O
the	O
E	O
##LS	O
/	O
MD	O
##D	O
when	O
they	O
were	O
compared	O
to	O
non	O
-	O
E	O
##LS	O
/	O
MD	O
##D	O
.	O

Two	O
PP	O
##P	O
-	O
involved	O
meta	O
##bol	O
##ites	O
,	O
a	B
##rab	I
##ito	I
##l	I
and	O
rib	B
##ito	I
##l	I
,	O
were	O
found	O
significantly	O
increased	O
in	O
the	O
comparison	O
of	O
R	O
_	O
BT	O
to	O
N	O
##R	O
_	O
BT	O
.	O

Inc	O
##reased	O
levels	O
of	O
these	O
meta	O
##bol	O
##ites	O
as	O
well	O
as	O
la	B
##ct	I
##ate	I
in	O
A	O
##HF	O
patients	O
who	O
did	O
not	O
survive	O
the	O
first	O
three	O
months	O
after	O
onset	O
of	O
A	O
##HF	O
strongly	O
indicate	O
a	O
more	O
severe	O
state	O
of	O
the	O
disease	O
and	O
more	O
severe	O
systemic	O
metabolic	O
per	O
##tur	O
##bation	O
##s	O
in	O
this	O
group	O
of	O
A	O
##HF	O
patients	O
,	O
compared	O
to	O
A	O
##HF	O
patients	O
who	O
survived	O
3	O
months	O
after	O
onset	O
of	O
A	O
##HF	O
.	O

C	O
##luster	O
##s	O
two	O
,	O
three	O
and	O
four	O
,	O
with	O
lower	O
in	O
##tens	O
##ities	O
in	O
PC	O
patients	O
relative	O
to	O
controls	O
,	O
were	O
represented	O
by	O
several	O
classes	O
of	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
and	O
ultra	O
long	O
-	O
chain	O
fatty	O
acids	O
.	O

β	B
-	I
act	I
##in	I
was	O
used	O
as	O
a	O
loading	O
control	O
.	O

In	O
plasma	O
,	O
the	O
mean	O
recovery	O
of	O
en	B
##zal	I
##uta	I
##mi	I
##de	I
was	O
100	O
%	O
with	O
a	O
C	O
##V	O
of	O
2	O
%	O
;	O
for	O
N	B
-	I
des	I
##met	I
##hyl	I
##en	I
##zal	I
##uta	I
##mi	I
##de	I
,	O
it	O
was	O
141	O
%	O
with	O
a	O
C	O
##V	O
of	O
2	O
%	O
;	O
and	O
for	O
the	O
internal	O
standard	O
,	O
the	O
mean	O
recovery	O
was	O
102	O
%	O
with	O
a	O
C	O
##V	O
of	O
2	O
%	O
.	O

In	O
our	O
measurements	O
p	B
##yr	I
##og	I
##lut	I
##ami	I
##c	I
acid	I
might	O
also	O
be	O
derived	O
from	O
g	B
##lut	I
##ami	I
##c	I
acid	I
or	O
g	B
##lut	I
##amine	I
during	O
the	O
der	O
##iva	O
##tis	O
##ation	O
process	O
.	O

Studies	O
by	O
Long	O
et	O
al	O
.	O
showed	O
that	O
the	O
activity	O
of	O
LP	O
##P	O
##1	O
is	O
closely	O
related	O
to	O
signaling	O
lip	O
##id	O
molecules	O
,	O
such	O
as	O
D	O
##AG	O
,	O
s	B
##phi	I
##ngo	I
##sin	I
##e	I
-	I
1	I
-	I
phosphate	I
(	O
S	O
##1	O
##P	O
)	O
,	O
LP	O
##A	O
,	O
etc	O
.	O

Only	O
the	O
upper	O
a	O
##que	O
##ous	O
met	B
##han	I
##olic	I
layers	O
were	O
carefully	O
collected	O
and	O
the	O
solvent	O
##s	O
were	O
dried	O
in	O
a	O
Ce	O
##nt	O
##ri	O
##V	O
##ap	O
_	O
®	O
vacuum	O
con	O
##cent	O
##rator	O
(	O
Lab	O
##con	O
##co	O
Corporation	O
,	O
Kansas	O
City	O
,	O
M	O
##O	O
)	O
.	O

In	O
this	O
prospective	O
study	O
,	O
we	O
used	O
a	O
sensitive	O
multi	O
##mo	O
##dal	O
##ity	O
platform	O
to	O
identify	O
and	O
character	O
##ize	O
an	O
essentially	O
uniform	O
but	O
opposite	O
pattern	O
of	O
disruption	O
in	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
and	O
c	B
##era	I
##mi	I
##de	I
mass	O
levels	O
in	O
AD	O
plasma	O
.	O

For	O
N	O
##MR	O
data	O
assembly	O
,	O
one	O
dimensional	O
_	O
1	O
H	O
##N	O
##MR	O
s	O
##pect	O
##ra	O
were	O
obtained	O
on	O
a	O
B	O
##ruk	O
##er	O
DR	O
##X	O
-	O
500	O
N	O
##MR	O
s	O
##pect	O
##rome	O
##ter	O
operating	O
a	O
500	O
.	O
13	O
M	O
##H	O
##Z	O
and	O
Carl	O
P	O
##ur	O
##cell	O
Mei	O
##boo	O
##m	O
Gill	O
(	O
CP	O
##MG	O
)	O
90	B
-	I
(	I
t	I
-	I
180	I
-	I
t	I
##n	I
-	I
a	I
##c	I
##quis	I
##ito	I
##n	I
)	I
.	O

Only	O
v	B
##ali	I
##ne	I
and	O
try	B
##pt	I
##op	I
##hane	I
stability	O
is	O
in	O
accordance	O
with	O
our	O
results	O
in	O
human	O
plasma	O
samples	O
.	O

In	O
##tensive	O
analysis	O
indicated	O
that	O
the	O
concentration	O
of	O
meta	O
##bol	O
##ite	O
p	B
-	I
c	I
##res	I
##ol	I
closely	O
co	O
##rrel	O
##ates	O
with	O
cancer	O
stage	O
.	O

This	O
C	O
=	O
C	O
location	O
is	O
##omer	O
composition	O
was	O
consistently	O
observed	O
for	O
all	O
GP	O
##s	O
containing	O
C	B
##18	I
:	I
1	I
from	O
b	O
##ov	O
##ine	O
liver	O
extract	O
(	O
complete	O
list	O
shown	O
in	O
Su	O
##pp	O
##lement	O
##ary	O
Data	O
_	O
1	O
)	O
.	O

In	O
ex	O
##p	O
##lora	O
##tory	O
analyses	O
,	O
there	O
was	O
no	O
significant	O
relationship	O
between	O
AP	O
##OE	O
g	O
##eno	O
##type	O
##s	O
and	O
the	O
altered	O
SM	O
and	O
c	B
##era	I
##mi	I
##de	I
profiles	O
.	O

Up	O
##re	O
##gu	O
##lated	O
lip	O
##id	O
sub	O
##c	O
##lass	O
##es	O
have	O
been	O
described	O
between	O
normal	O
,	O
localized	O
,	O
and	O
meta	O
##static	O
pro	O
##static	O
cells	O
,	O
with	O
ch	B
##olin	I
##e	I
kinase	O
α	O
implicated	O
in	O
de	O
no	O
##vo	O
lip	O
##ogen	O
##esis	O
in	O
aggressive	O
meta	O
##static	O
cells	O
.	O

In	O
an	O
independent	O
set	O
of	O
89	O
tissue	O
samples	O
,	O
sa	B
##rc	I
##os	I
##ine	I
levels	O
were	O
significantly	O
elevated	O
in	O
PC	O
##A	O
specimens	O
(	O
n	O
=	O
36	O
)	O
compared	O
to	O
ben	O
##ign	O
adjacent	O
pro	O
##state	O
(	O
n	O
=	O
25	O
,	O
Wilcox	O
##on	O
P	O
=	O
4	O
.	O
34	O
×	O
##10	O
_	O
−	O
##11	O
,	O
)	O
.	O

U	B
##ric	I
acid	I
is	O
a	O
product	O
of	O
pu	B
##rine	I
metabolism	O
that	O
c	O
##ir	O
##culate	O
##s	O
in	O
the	O
blood	O
,	O
and	O
plays	O
a	O
role	O
in	O
in	O
##iti	O
##ating	O
the	O
development	O
of	O
h	O
##yper	O
##tens	O
##ion	O
.	O

After	O
further	O
adjustment	O
for	O
plasma	O
t	B
##rig	I
##ly	I
##cer	I
##ide	I
concentrations	O
(	O
accounting	O
for	O
h	B
##yper	I
##tri	I
##gly	I
##cer	I
##ide	I
##mic	I
waist	O
)	O
,	O
ace	B
##ty	I
##l	I
##gly	I
##co	I
##p	I
##rote	I
##ins	I
,	O
branched	O
‐	O
chain	O
amino	O
acids	O
(	B
is	B
##ole	I
##uc	I
##ine	I
,	O
le	B
##uc	I
##ine	I
,	O
and	O
v	B
##ali	I
##ne	I
)	O
,	O
g	B
##lut	I
##amine	I
(	O
inverse	O
##ly	O
)	O
,	O
and	O
serum	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
remained	O
significantly	O
associated	O
with	O
VA	O
##T	O
(	O
nominal	O
P	O
<	O
0	O
.	O
05	O
for	O
all	O
,	O
Figure	O
)	O
.	O

We	O
discuss	O
our	O
results	O
with	O
respect	O
to	O
previous	O
h	O
##y	O
##pot	O
##heses	O
about	O
mechanisms	O
of	O
est	O
##rogen	O
-	O
mediated	O
car	O
##cin	O
##ogen	O
##esis	O
,	O
and	O
we	O
consider	O
the	O
use	O
of	O
est	B
##rogen	I
and	O
est	B
##rogen	I
meta	O
##bol	O
##ite	O
profiles	O
for	O
projecting	O
breast	O
cancer	O
risk	O
.	O

*	O
Part	O
##ici	O
##pants	O
who	O
had	O
major	O
adverse	O
card	O
##iovascular	O
events	O
also	O
had	O
higher	O
base	O
##line	O
levels	O
of	O
T	B
##MA	I
##O	I
,	O
as	O
compared	O
with	O
those	O
who	O
did	O
not	O
have	O
card	O
##iovascular	O
events	O
(	O
median	O
,	O
5	O
.	O
0	O
µ	O
##M	O
[	O
inter	O
##qua	O
##rt	O
##ile	O
range	O
,	O
3	O
.	O
0	O
to	O
8	O
.	O
8	O
]	O
vs	O
.	O
3	O
.	O
5	O
µ	O
##M	O
[	O
inter	O
##qua	O
##rt	O
##ile	O
range	O
,	O
2	O
.	O
4	O
to	O
5	O
.	O
9	O
]	O
;	O
P	O
<	O
0	O
.	O
00	O
##1	O
)	O
.	O

It	O
has	O
been	O
demonstrated	O
that	O
cat	B
##ech	I
##ol	I
-	I
q	I
##uin	I
##ones	I
,	O
especially	O
4	O
-	O
OH	O
##E	O
_	O
1	O
(	O
E	O
_	O
2	O
)	O
-	O
Q	O
,	O
form	O
predominantly	O
de	O
##pur	O
##inating	O
DNA	O
add	O
##uc	O
##ts	O
,	O
release	O
of	O
these	O
add	O
##uc	O
##ts	O
generates	O
a	O
##bas	O
##ic	O
sites	O
,	O
which	O
,	O
in	O
turn	O
,	O
induce	O
mutations	O
.	O

Tai	O
##l	O
defects	O
were	O
significantly	O
negatively	O
correlated	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
with	O
seminal	O
plasma	O
levels	O
of	O
AD	B
##MA	I
(	O
r	O
_	O
s	O
=	O
-	O
0	O
.	O
48	O
##8	O
)	O
,	O
car	B
##nos	I
##ine	I
(	O
-	O
0	O
.	O
44	O
##6	O
)	O
and	O
se	B
##rot	I
##oni	I
##n	I
(	O
-	O
0	O
.	O
59	O
##0	O
)	O
.	O

All	O
methods	O
identified	O
c	B
##rea	I
##tine	I
and	O
c	B
##it	I
##rate	I
as	O
being	O
present	O
at	O
higher	O
concentration	O
in	O
female	O
urine	O
samples	O
,	O
which	O
is	O
in	O
agreement	O
with	O
previously	O
reported	O
data	O
.	O
_	O
,	O
Men	O
were	O
characterized	O
by	O
higher	O
u	O
##rina	O
##ry	O
concentrations	O
of	O
c	B
##rea	I
##tin	I
##ine	I
and	O
ethanol	S
,	O
as	O
determined	O
by	O
_	O
1	O
H	O
N	O
##MR	O
profiles	O
,	O
which	O
could	O
be	O
related	O
to	O
diet	O
##ary	O
factors	O
such	O
as	O
meat	O
and	O
alcohol	O
consumption	O
;	O
the	O
levels	O
of	O
c	B
##rea	I
##tin	I
##ine	I
also	O
reflect	O
greater	O
muscle	O
turnover	O
.	O

Cy	O
##s	O
_	O
34	O
is	O
the	O
only	O
un	O
##pair	O
##ed	O
c	B
##ys	I
##tein	I
##e	I
residue	O
in	O
SA	O
that	O
is	O
available	O
for	O
reaction	O
with	O
car	O
##cin	O
##ogenic	O
meta	O
##bol	O
##ites	O
and	O
toxic	O
electro	O
##phi	O
##les	O
.	O
_	O
,	O
However	O
,	O
human	O
SA	O
contains	O
59	O
l	B
##ys	I
##ine	I
and	O
18	O
t	B
##yr	I
##os	I
##ine	I
residues	O
that	O
can	O
potentially	O
react	O
with	O
NO	O
_	O
2	O
-	O
Ph	O
##IP	O
to	O
form	O
add	O
##uc	O
##ts	O
.	O

R	B
##I	I
denotes	O
retention	O
index	O
.	O

My	B
##rist	I
##ic	I
acid	I
was	O
the	O
single	O
most	O
predict	O
##ive	O
meta	O
##bol	O
##ite	O
,	O
with	O
a	O
sensitivity	O
of	O
1	O
.	O
00	O
(	O
95	O
%	O
C	O
##I	O
0	O
.	O
85	O
–	O
1	O
.	O
00	O
)	O
and	O
specific	O
##ity	O
of	O
0	O
.	O
95	O
(	O
95	O
%	O
C	O
##I	O
0	O
.	O
74	O
–	O
0	O
.	O
99	O
)	O
,	O
and	O
performed	O
better	O
than	O
various	O
combinations	O
of	O
conventional	O
laboratory	O
and	O
clinical	O
parameters	O
.	O

Thus	O
the	O
quantitative	O
value	O
in	O
D	O
##I	O
–	O
n	O
##ES	O
##I	O
–	O
H	O
##R	O
##MS	O
is	O
likely	O
to	O
be	O
calculated	O
from	O
the	O
combined	O
sum	O
of	O
p	B
##hen	I
##yl	I
##py	I
##ru	I
##vate	I
,	O
3	B
-	I
h	I
##ydro	I
##xy	I
##cin	I
##nam	I
##ate	I
,	O
and	O
its	O
is	O
##omer	O
##s	O
.	O

In	O
terms	O
of	O
toxicity	O
,	O
AL	O
is	O
particularly	O
toxic	O
as	O
it	O
react	O
##s	O
with	O
g	B
##lut	I
##ath	I
##ione	I
>	O
100	O
times	O
faster	O
than	O
H	O
##NE	O
.	O

Inside	O
the	O
mit	O
##och	O
##ond	O
##ria	O
the	O
fatty	O
acids	O
are	O
cat	O
##ab	O
##olis	O
##ed	O
to	O
generate	O
ace	B
##ty	I
##l	I
-	I
Co	I
##A	I
,	O
N	B
##AD	I
##H	I
and	O
FA	O
##D	O
##H	O
_	O
2	O
.	O

Alt	O
##eration	O
in	O
the	O
activity	O
of	O
alcohol	O
de	O
##hy	O
##dr	O
##ogen	O
##ase	O
and	O
c	O
##yt	O
##och	O
##rome	O
P	O
##45	O
##0	O
(	O
C	O
##YP	O
450	O
)	O
activities	O
can	O
also	O
be	O
related	O
to	O
alter	O
##ation	O
in	O
k	B
##eton	I
##e	I
and	O
al	O
##de	O
##hy	O
##des	O
levels	O
,	O
since	O
h	B
##ydro	I
##car	I
##bon	I
##s	I
can	O
be	O
meta	O
##bol	O
##ized	O
to	O
al	O
##de	O
##hy	O
##des	O
or	O
k	B
##eton	I
##es	I
in	O
the	O
human	O
body	O
via	O
these	O
enzymes	O
.	O

Val	B
##ine	I
is	O
a	O
branched	O
-	O
chain	O
amino	O
acid	O
,	O
which	O
are	O
essential	O
amino	O
acids	O
that	O
serve	O
as	O
nitrogen	O
donors	O
for	O
none	O
##ssent	O
##ial	O
amino	O
acids	O
and	O
are	O
important	O
for	O
energy	O
consumption	O
.	O

In	O
addition	O
,	O
the	O
dough	O
and	O
bread	O
samples	O
produced	O
using	O
the	O
sour	O
##do	O
##ugh	O
process	O
contained	O
higher	O
levels	O
of	O
g	B
##ly	I
##cer	I
##ol	I
and	O
man	B
##ni	I
##to	I
##l	I
,	O
the	O
latter	O
not	O
being	O
present	O
in	O
bread	O
B	O
or	O
that	O
produced	O
using	O
the	O
CB	O
##P	O
.	O

While	O
R	O
##EG	O
itself	O
was	O
the	O
dominating	O
meta	O
##bol	O
##ite	O
in	O
the	O
CS	O
##F	O
of	O
patient	O
5	O
in	O
5	O
of	O
7	O
samples	O
,	O
dem	B
##eth	I
##yla	I
##ted	I
N	I
-	I
oxide	I
was	O
the	O
most	O
prevalent	O
meta	O
##bol	O
##ite	O
in	O
the	O
other	O
2	O
patients	O
.	O

By	O
employing	O
L	O
##IT	O
,	O
the	O
a	B
##gly	I
##con	I
##e	I
ion	O
[	O
B	O
##H	O
_	O
2	O
]	O
_	O
+	O
can	O
undergo	O
further	O
fragment	O
##ation	O
at	O
the	O
MS	O
_	O
3	O
scan	O
stage	O
to	O
confirm	O
the	O
add	O
##uc	O
##t	O
’	O
s	O
structure	O
and	O
by	O
comparing	O
the	O
product	O
ion	O
spectrum	O
to	O
that	O
of	O
the	O
stable	O
is	O
##oto	O
##pe	O
labeled	O
internal	O
standard	O
.	O

L	B
##ys	I
##ine	I
ex	O
##cre	O
##tion	O
was	O
consistently	O
increased	O
in	O
patients	O
with	O
lower	O
serum	O
album	O
##in	O
levels	O
(	O
Su	O
##pp	O
##lement	O
##al	O
Figure	O
1	O
##B	O
,	O
)	O
.	O

However	O
,	O
there	O
is	O
new	O
evidence	O
indicated	O
that	O
elevation	O
of	O
u	B
##ric	I
acid	I
is	O
caused	O
by	O
the	O
place	O
##nta	O
.	O

_	O
,	O
Interest	O
##ingly	O
,	O
we	O
found	O
e	B
##uri	I
##co	I
##yl	I
-	I
s	I
##phi	I
##ngo	I
##my	I
##elin	I
associated	O
with	O
25	O
(	O
OH	O
)	O
D	O
.	O
Given	O
its	O
role	O
in	O
s	B
##phi	I
##ngo	I
##lip	I
##id	I
metabolism	O
,	O
an	O
increase	O
in	O
this	O
meta	O
##bol	O
##ite	O
could	O
lead	O
to	O
production	O
of	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
necessary	O
to	O
reduce	O
β	O
-	O
cell	O
d	O
##ys	O
##function	O
in	O
T	O
##2	O
##D	O
.	O
A	O
recent	O
Men	O
##del	O
##ian	O
random	O
##ization	O
study	O
demonstrated	O
an	O
association	O
between	O
genetic	O
variants	O
of	O
low	O
plasma	O
25	O
(	O
OH	O
)	O
D	O

In	O
addition	O
,	O
Le	O
##u	O
/	O
Il	O
##e	O
also	O
works	O
jointly	O
with	O
v	B
##ali	I
##ne	I
in	O
various	O
biological	O
reactions	O
and	O
is	O
necessary	O
in	O
the	O
bio	O
##sy	O
##nt	O
##hesis	O
of	O
reduced	B
g	I
##lut	I
##ath	I
##ione	I
hormone	O
(	O
G	O
##S	O
##H	O
)	O
.	O

Polar	O
meta	O
##bol	O
##ites	O
were	O
extracted	O
using	O
60	O
%	O
cold	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
,	O
freeze	O
dried	O
and	O
then	O
red	O
##iss	O
##ol	O
##ved	O
in	O
99	O
.	O
9	O
%	O
D	O
_	O
2	O
O	O
for	O
N	O
##MR	O
analysis	O
.	O

The	O
impact	O
of	O
add	O
##itive	O
selection	O
upon	O
peak	O
base	O
width	O
##s	O
and	O
resolution	O
in	O
SF	O
##C	O
-	O
MS	O
mode	O
is	O
shown	O
in	O
:	O
the	O
three	O
am	B
##mon	I
##ium	I
salts	O
reduce	O
the	O
median	O
peak	O
base	O
width	O
considerably	O
when	O
compared	O
to	O
the	O
acidic	O
add	O
##itive	O
##s	O
.	O

The	O
significance	O
of	O
differences	O
in	O
the	O
concentration	O
of	O
reactive	O
p	B
##oly	I
##sul	I
##fi	I
##de	I
species	O
in	O
the	O
a	O
##que	O
##ous	O
and	O
v	O
##it	O
##re	O
##ous	O
humor	O
of	O
the	O
D	O
##M	O
and	O
control	O
eyes	O
was	O
assessed	O
with	O
the	O
Student	O
’	O
s	O
t	O
-	O
test	O
.	O

(	O
B	O
)	O
Form	B
##ic	I
acid	I
present	O
in	O
both	O
groups	O
of	O
Mia	O
##P	O
##a	O
##C	O
##a	O
-	O
2	O
cell	O
extract	O
##s	O
but	O
at	O
higher	O
concentration	O
in	O
Speed	O
##V	O
##ac	O
samples	O
.	O

Character	O
##izing	O
I	O
##3	O
##C	O
up	O
##take	O
using	O
u	O
##rina	O
##ry	O
D	O
##IM	O
is	O
advantage	O
##ous	O
,	O
as	O
the	O
g	B
##lu	I
##cos	I
##ino	I
##late	I
concentration	O
in	O
vegetables	O
can	O
vary	O
widely	O
based	O
on	O
factors	O
such	O
as	O
vegetable	O
type	O
,	O
growth	O
conditions	O
and	O
preparation	O
technique	O
.	O

After	O
the	O
significant	O
Wilcox	O
##on	O
rank	O
-	O
sum	O
test	O
results	O
are	O
valid	O
##ated	O
by	O
random	O
per	O
##mu	O
##tation	O
,	O
only	O
c	B
##it	I
##rate	I
and	O
ad	B
##eno	I
##sin	I
##e	I
results	O
are	O
significant	O
(	O
P	O
=	O
0	O
.	O
01	O
##9	O
and	O
P	O
=	O
0	O
.	O
02	O
##6	O
,	O
respectively	O
)	O
.	O

Previous	O
research	O
also	O
demonstrated	O
that	O
plasma	O
ch	B
##olin	I
##e	I
is	O
derived	O
from	O
p	B
##hos	I
##ph	I
##ory	I
##l	I
##cho	I
##line	I
by	O
p	O
##hos	O
##ph	O
##ot	O
##ran	O
##s	O
##fer	O
##ase	O
.	O

B	O
##rief	O
##ly	O
,	O
0	O
.	O
2	O
m	O
##l	O
al	O
##iq	O
##uo	O
##ts	O
of	O
plasma	O
were	O
transferred	O
to	O
120	O
-	O
m	O
##l	O
Te	O
##f	O
##lon	O
dig	O
##est	O
##ion	O
vessels	O
,	O
followed	O
by	O
the	O
addition	O
of	O
5	O
m	O
##l	O
of	O
ni	B
##tric	I
acid	I
.	O

Furthermore	O
,	O
samples	O
A	O
through	O
G	O
are	O
from	O
populations	O
not	O
exposed	O
to	O
ni	B
##cot	I
##ine	I
,	O
while	O
samples	O
H	O
and	O
I	O
are	O
from	O
populations	O
exposed	O
to	O
ni	B
##cot	I
##ine	I
from	O
various	O
sources	O
.	O

Our	O
data	O
strongly	O
suggest	O
that	O
S	O
##9	O
cells	O
(	O
in	O
contrast	O
to	O
16	O
##H	O
##BE	O
##14	O
##o	O
-	O
cells	O
)	O
are	O
able	O
to	O
increase	O
their	O
g	B
##ly	I
##co	I
##ly	I
##tic	I
activity	O
in	O
response	O
to	O
r	O
##H	O
##la	O
,	O
thus	O
enhancing	O
the	O
efficiency	O
of	O
their	O
energy	O
metabolism	O
.	O

There	O
is	O
mounting	O
evidence	O
that	O
enzymes	O
involved	O
in	O
the	O
u	B
##rea	I
cycle	O
,	O
including	O
two	O
mitochondrial	O
(	B
car	B
##ba	I
##mo	I
##yl	I
phosphate	I
s	O
##ynth	O
##ase	O
1	O
and	O
or	O
##ni	O
##thin	O
##e	O
trans	O
##car	O
##ba	O
##my	O
##lase	O
)	O
and	O
three	O
c	O
##yt	O
##oso	O
##lic	O
(	B
a	B
##rg	I
##ini	I
##nos	I
##ucci	I
##nate	I
s	O
##ynth	O
##ase	O
,	O
a	B
##rg	I
##ini	I
##nos	I
##ucci	I
##nate	I
l	O
##yas	O
##e	O
,	O
and	O
a	O
##rg	O
##inas	O
##e	O
)	O
enzymes	O
,	O
are	O
differential	O
##ly	O
expressed	O
in	O
the	O
liver	O
.	O

(	O
15	O
p	B
##g	I
m	O
##L	O
_	O
−	O
##1	O
)	O
.	O

Inc	O
##reased	O
meta	O
##bol	O
##ites	O
included	O
a	B
##rg	I
##ini	I
##ne	I
,	O
c	B
##rea	I
##tine	I
and	O
unknown	O
compounds	O
at	O
m	O
/	O
z	O
of	O
35	O
##7	O
and	O
312	O
while	O
decreased	O
meta	O
##bol	O
##ites	O
included	O
c	B
##rea	I
##tin	I
##ine	I
,	O
and	O
##rogen	O
derivatives	O
and	O
other	O
unknown	O
yet	O
to	O
be	O
identified	O
compounds	O
.	O

2	O
-	O
H	O
##BA	O
:	O
2	B
-	I
h	I
##ydro	I
##xy	I
-	I
but	I
##yra	I
##te	I
acid	O
;	O
2	O
-	O
K	O
##G	O
:	O
2	B
-	I
k	I
##eto	I
##g	I
##lut	I
##arate	I
;	O
2	O
-	O
P	O
##y	O
:	O
N	B
-	I
met	I
##hyl	I
-	I
2	I
-	I
p	I
##yr	I
##ido	I
##ne	I
-	I
5	I
-	I
car	I
##box	I
##ami	I
##de	I
;	O
AM	O
##P	O
:	O
ad	O
##eno	O
##sin	O
##e	O
mon	B
##op	I
##hos	I
##phate	I
;	O
GAA	O
:	O
g	B
##uan	I
##id	I
##ino	I
##ace	I
##tate	I
;	O
GM	O
##P	O
:	O
de	B
##ox	I
##y	I
-	I
g	I
##uan	I
##os	I
##ine	I
;	O
G	B
##S	I
##H	I
:	O
g	B
##lut	I
##hat	I
##ione	I
;	O
PA	O
##G	O
:	O
p	O
##hen	O
##yla	O
##ce	O
##ty	O
##l	O
##g	O
##lut	O
##amine	O
.	O

Also	O
,	O
the	O
fatty	O
acid	O
composition	O
of	O
these	O
two	O
species	O
is	O
different	O
(	O
primary	O
constituent	O
of	O
PC	B
38	I
:	I
6	I
##a	I
is	O
PC	B
16	I
:	I
0	I
/	I
22	I
:	I
6	I
while	O
that	O
for	O
PC	B
38	I
:	I
6	I
##b	I
is	O
PC	B
18	I
:	I
2	I
/	I
20	I
:	I
4	I
)	O
.	O

The	O
ch	B
##olin	I
##e	I
meta	O
##bol	O
##ite	O
,	O
beta	B
##ine	I
,	O
plays	O
a	O
role	O
in	O
lip	O
##id	O
metabolism	O
,	O
and	O
may	O
predict	O
the	O
development	O
of	O
card	O
##iovascular	O
disease	O
and	O
type	O
2	O
diabetes	O
me	O
##lli	O
##tus	O
(	O
T	O
##2	O
##DM	O
)	O
.	O

The	O
authors	O
concluded	O
that	O
o	O
##xi	O
##da	O
##tive	O
stress	O
led	O
to	O
increased	O
eccentric	O
c	O
##lea	O
##vage	O
of	O
β	B
-	I
car	I
##ote	I
##ne	I
and	O
that	O
the	O
mixture	O
of	O
c	O
##lea	O
##vage	O
products	O
led	O
to	O
disruption	O
of	O
re	B
##tino	I
##id	I
signaling	O
via	O
indirect	O
mechanisms	O
.	O

Various	O
species	O
of	O
B	O
##if	O
##ido	O
##ba	O
##cter	O
##ium	O
s	O
##ynth	O
##esi	O
##ze	O
ex	B
##o	I
-	I
p	I
##oly	I
##sa	I
##cc	I
##hari	I
##des	I
,	O
which	O
act	O
as	O
f	O
##er	O
##ment	O
##able	O
substrates	O
for	O
human	O
in	O
##test	O
##inal	O
bacteria	O
.	O

Accordingly	O
,	O
this	O
study	O
investigated	O
the	O
effects	O
of	O
these	O
oral	O
components	O
on	O
parameters	O
likely	O
to	O
m	O
##od	O
##ulate	O
BR	O
##B	O
ant	B
##ho	I
##cy	I
##ani	I
##ns	I
'	I
ch	O
##em	O
##op	O
##re	O
##vent	O
##ive	O
efficacy	O
.	O

Therefore	O
,	O
assuming	O
that	O
circulating	O
24	B
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
concentration	O
is	O
proportional	O
to	O
24	B
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
production	O
,	O
our	O
results	O
suggest	O
that	O
lower	O
G	O
##F	O
##R	O
,	O
across	O
its	O
full	O
range	O
,	O
is	O
associated	O
with	O
reduced	O
vitamin	B
D	I
cat	O
##ab	O
##olis	O
##m	O
.	O

Our	O
data	O
indicated	O
up	O
##re	O
##gu	O
##lated	O
his	B
##ti	I
##dine	I
metabolism	O
with	O
subsequently	O
increased	O
g	O
##lut	O
##amine	O
/	O
g	O
##lut	O
##ama	O
##te	O
metabolism	O
,	O
altered	O
pu	B
##rine	I
and	O
p	B
##yr	I
##im	I
##id	I
##ine	I
metabolism	O
,	O
and	O
enhanced	O
vitamin	O
B	O
_	O
6	O
metabolism	O
in	O
patients	O
receiving	O
H	O
##T	O
##K	O
.	O

Likewise	O
,	O
the	O
levels	O
of	O
S	B
-	I
ad	I
##eno	I
##sy	I
##l	I
-	I
l	I
-	I
met	I
##hi	I
##oni	I
##ne	I
in	O
liver	O
cancer	O
patient	O
urine	O
were	O
considerably	O
higher	O
than	O
in	O
lung	O
cancer	O
patients	O
,	O
while	O
the	O
levels	O
of	O
N	B
-	I
ace	I
##ty	I
##ls	I
##per	I
##mi	I
##dine	I
in	O
liver	O
cancer	O
patient	O
urine	O
were	O
considerably	O
lower	O
than	O
in	O
lung	O
cancer	O
patients	O
.	O

The	O
DC	O
##PI	O
##P	O
reduction	O
reaction	O
was	O
induced	O
by	O
the	O
addition	O
of	O
5	O
m	O
##M	O
su	B
##cci	I
##nic	I
acid	I
,	O
further	O
activated	S
with	O
250	O
μ	O
##M	O
PM	O
##S	O
,	O
and	O
the	O
accept	O
##or	O
reduction	O
rate	O
was	O
measured	O
at	O
a	O
wavelength	O
of	O
600	O
nm	O
using	O
an	O
Ocean	O
Op	O
##tics	O
USB	O
##40	O
##00	O
s	O
##pect	O
##rop	O
##hot	O
##ometer	O
.	O

As	O
the	O
hospital	O
##ized	O
individuals	O
of	O
our	O
studied	O
co	O
##hor	O
##t	O
have	O
been	O
on	O
a	O
strict	O
diet	O
excluding	O
for	O
instance	O
soda	O
##s	O
,	O
it	O
is	O
unlikely	O
that	O
variations	O
of	O
c	B
##it	I
##rate	I
concentration	O
result	O
from	O
feed	O
intake	O
.	O

Do	O
##ub	O
##ly	O
charged	O
ions	O
and	O
corresponding	O
product	O
ions	O
(	O
precursor	O
minus	O
phosphate	S
group	O
)	O
were	O
chosen	O
as	O
a	O
transition	O
pair	O
for	O
multiple	O
reactions	O
monitoring	O
for	O
q	O
##uant	O
##itation	O
.	O

O	O
##sm	O
##ium	O
te	B
##tro	I
##xi	I
##de	I
0	O
.	O
2	O
%	O
in	O
##cu	O
##bation	O
for	O
30	O
s	O
and	O
met	O
##hyl	O
green	O
counter	O
stain	O
were	O
used	O
as	O
a	O
signal	O
enhance	O
##r	O
.	O

Pearson	O
’	O
s	O
product	O
moment	O
coefficient	O
was	O
used	O
to	O
calculate	O
the	O
correlation	O
##s	O
between	O
normal	O
##ised	O
abundance	O
##s	O
of	O
lip	O
##id	O
classes	O
and	O
L	O
##D	O
##L	O
-	O
C	O
,	O
HD	O
##L	O
-	O
C	O
and	O
total	O
ch	B
##ole	I
##ster	I
##ol	I
.	O

Studies	O
led	O
by	O
Bone	O
et	O
al	O
.	O
showed	O
that	O
p	O
-	O
c	O
##res	O
##ol	O
species	O
arise	O
primarily	O
from	O
t	B
##yr	I
##os	I
##ine	I
conversion	O
of	O
an	O
##ae	O
##ro	O
##bic	O
bacteria	O
in	O
the	O
left	O
co	O
##lon	O
.	O

Furthermore	O
,	O
it	O
is	O
worth	O
to	O
note	O
that	O
un	O
##iva	O
##ria	O
##te	O
analysis	O
but	O
not	O
multi	O
##var	O
##iate	O
analysis	O
shows	O
a	O
significant	O
correlation	O
of	O
L	B
-	I
c	I
##it	I
##ru	I
##llin	I
##e	I
level	O
and	O
patient	O
survival	O
,	O
suggesting	O
L	B
-	I
c	I
##it	I
##ru	I
##llin	I
##e	I
is	O
only	O
suitable	O
for	O
diagnosis	O
(	O
Table	O
)	O
.	O

Inc	O
##rease	O
##s	O
in	O
ch	B
##olin	I
##e	I
compounds	O
,	O
probably	O
due	O
to	O
increased	O
turnover	O
of	O
cell	O
membrane	O
##s	O
,	O
are	O
well	O
known	O
markers	O
of	O
cancer	O
,	O
_	O
,	O
_	O
,	O
particularly	O
cancer	O
##s	O
with	O
high	O
G	O
##lea	O
##son	O
scores	O
.	O

We	O
also	O
detected	O
light	O
changes	O
in	O
u	B
##rate	I
expression	O
,	O
especially	O
in	O
AC	O
,	O
as	O
a	O
result	O
of	O
the	O
degradation	O
of	O
pu	B
##rine	I
metabolism	O
.	O

8	B
-	I
Ni	I
##tro	I
-	I
c	I
##GM	I
##P	I
seems	O
to	O
regulate	O
the	O
red	O
##ox	O
-	O
sensor	O
signaling	O
protein	O
Ke	O
##ap	O
##1	O
,	O
a	O
potent	O
re	O
##press	O
##or	O
of	O
Nr	O
##f	O
##2	O
-	O
dependent	O
transcription	O
,	O
via	O
S	O
-	O
g	O
##uan	O
##yla	O
##tion	O
of	O
the	O
highly	O
n	O
##uc	O
##leo	O
##phi	O
##lic	O
c	O
##ys	O
##tein	O
##e	O
su	O
##lf	O
##hy	O
##dr	O
##yl	O
##s	O
of	O
Ke	O
##ap	O
##1	O
,	O
and	O
the	O
metabolism	O
of	O
8	B
-	I
ni	I
##tro	I
-	I
c	I
##GM	I
##P	I
may	O
thus	O
also	O
be	O
valuable	O
in	O
the	O
development	O
of	O
new	O
approaches	O
to	O
the	O
diagnosis	O
and	O
treatment	O
of	O
diseases	O
related	O
to	O
o	O
##xi	O
##da	O
##tive	O
stress	O
and	O
red	O
##ox	O
metabolism	O
.	O

Blood	O
plasma	O
of	O
patients	O
with	O
MA	O
##TV	O
_	O
W	O
##T	O
##B	O
≥	O
48	O
.	O
1	O
cm	O
##³	O
and	O
T	O
##L	O
##G	O
_	O
W	O
##T	O
##B	O
≥	O
27	O
##6	O
.	O
2	O
cm	O
##³	O
is	O
characterized	O
by	O
higher	O
concentrations	O
of	O
glucose	S
,	O
g	B
##ly	I
##cer	I
##ol	I
,	O
N	O
##AG	O
,	O
th	B
##re	I
##oni	I
##ne	I
,	O
as	B
##par	I
##tate	I
and	O
v	B
##ali	I
##ne	I
,	O
but	O
lower	O
levels	O
of	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
(	O
SM	O
)	O
and	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
(	O
PC	O
)	O
.	O

In	O
mice	O
,	O
disruption	O
of	O
Nr	O
##f	O
##2	O
signaling	O
o	O
##b	O
##via	O
##tes	O
the	O
cancer	O
ch	O
##em	O
##op	O
##re	O
##vent	O
##ive	O
actions	O
of	O
SF	S
.	O

V	O
##ir	O
##us	O
stocks	O
were	O
produced	O
in	O
fi	O
##bro	O
##blast	O
##s	O
by	O
pool	O
##ing	O
cell	O
-	O
free	O
and	O
cell	O
-	O
associated	O
virus	O
,	O
concentrated	O
by	O
cent	O
##ri	O
##fu	O
##gation	O
through	O
so	B
##rb	I
##ito	I
##l	I
cushion	O
##s	O
,	O
re	O
##sus	O
##pen	O
##ded	O
in	O
serum	O
-	O
free	O
medium	O
,	O
and	O
t	O
##iter	O
##ed	O
by	O
tissue	O
culture	O
in	O
##fect	O
##ive	O
dose	O
(	O
T	O
##CI	O
##D	O
_	O
50	O
)	O
or	O
fluorescent	O
focus	O
ass	O
##ay	O
.	O

We	O
also	O
found	O
that	O
the	O
g	B
##ly	I
##co	I
##ly	I
##tic	I
intermediate	O
p	B
##yr	I
##u	I
##vic	I
acid	I
was	O
increased	O
.	O

SM	B
##24	I
:	I
0	I
was	O
detect	O
##able	O
only	O
in	O
the	O
extract	O
##s	O
of	O
protocols	O
(	O
i	O
)	O
–	O
(	O
ii	O
##i	O
)	O
.	O

SL	O
##CO	O
##1	O
##B	O
##1	O
en	O
##codes	O
a	O
protein	O
that	O
media	O
##tes	O
the	O
cellular	O
up	O
##take	O
of	O
numerous	O
end	O
##ogen	O
##ous	O
compounds	O
and	O
is	O
involved	O
in	O
the	O
metabolism	O
and	O
clearance	O
of	O
multiple	O
drug	O
compounds	O
,	O
including	O
(	O
the	O
popular	O
ch	O
##ole	O
##ster	O
##ol	O
-	O
lowering	O
drug	O
)	O
s	B
##tat	I
##ins	I
.	O

Another	O
recent	O
meta	O
##bol	O
##omi	O
##c	O
analysis	O
of	O
successful	O
cognitive	O
aging	O
found	O
lower	O
levels	O
of	O
serum	O
a	B
##rg	I
##ini	I
##ne	I
in	O
participants	O
with	O
superior	O
memory	O
(	O
Map	O
##stone	O
et	O
al	O
.	O
,	O
)	O
;	O
(	O
3	O
)	O
in	O
CS	O
##F	O
,	O
there	O
are	O
also	O
controversial	O
findings	O
.	O

Re	O
##lative	O
to	O
control	O
values	O
,	O
ta	B
##uri	I
##ne	I
and	O
its	O
con	O
##gene	O
##rs	O
had	O
e	O
##qui	O
##p	O
##ro	O
##ct	O
##ec	O
##tive	O
roles	O
in	O
reducing	O
membrane	O
damage	O
,	O
the	O
formation	O
of	O
in	O
##tra	O
##cellular	O
ma	B
##lon	I
##dial	I
##de	I
##hy	I
##de	I
and	O
o	B
##xi	I
##dized	I
g	I
##lut	I
##ath	I
##ione	I
,	O
and	O
the	O
decreases	O
in	O
reduced	B
g	I
##lut	I
##ath	I
##ione	I
and	O
anti	O
##ox	O
##ida	O
##tive	O
enzyme	O
activities	O
in	O
di	O
##abe	O
##tic	O
er	O
##yt	O
##hr	O
##ocytes	O
.	O

In	O
these	O
same	O
girls	O
,	O
who	O
were	O
15	O
and	O
17	O
years	O
of	O
age	O
,	O
respectively	O
,	O
h	O
##y	O
##po	O
##gon	O
##ado	O
##tro	O
##pic	O
h	O
##y	O
##po	O
##gon	O
##adi	O
##sm	O
resolved	O
within	O
a	O
few	O
weeks	O
after	O
the	O
initiation	O
of	O
gal	B
##act	I
##ose	I
supplement	O
##ation	O
.	O

This	O
result	O
is	O
consistent	O
with	O
the	O
hypothesis	O
that	O
m	O
##uta	O
##genic	O
q	B
##uin	I
##ones	I
derived	O
from	O
4	O
-	O
h	O
##ydro	O
##xy	O
##lation	O
pathway	O
cat	B
##ech	I
##ols	I
contribute	O
to	O
path	O
##ogen	O
##esis	O
of	O
post	O
##men	O
##op	O
##aus	O
##al	O
breast	O
cancer	O
.	O

Another	O
important	O
result	O
of	O
this	O
work	O
is	O
that	O
ta	B
##uri	I
##ne	I
and	O
O	B
-	I
p	I
##hos	I
##ph	I
##oe	I
##than	I
##ola	I
##mine	I
were	O
more	O
stable	O
during	O
prolonged	O
blood	O
in	O
##cu	O
##bation	O
when	O
E	O
##D	O
##TA	O
was	O
added	O
to	O
the	O
blood	O
samples	O
.	O

Q	O
##uant	O
##ification	O
of	O
25	B
(	I
OH	I
)	I
D	I
_	I
3	I
/	I
2	I
,	I
3	I
-	I
e	I
##pi	I
-	I
25	I
(	I
OH	I
)	I
D	I
_	I
3	I
,	I
1	I
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
/	O
2	O
and	O
24	B
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
was	O
performed	O
by	O
multiple	O
reaction	O
monitoring	O
(	O
MR	O
##M	O
)	O
using	O
the	O
[	O
M	O
+	O
H	O
]	O
_	O
+	O
→	O
[	O
(	O
M	O
+	O
H	O
)	O
−	O
(	O
N	O
(	O
CH	O
_	O
3	O
)	O
_	O
3	O
)	O
]	O
_	O
+	O
transitions	O
for	O
all	O
measured	O
vitamin	B
D	I
meta	O
##bol	O
##ites	O
with	O
200	O
m	O
##s	O
dwell	O
time	O
per	O
transition	O
(	O
,	O
)	O
.	O

Co	B
##tin	I
##ine	I
concentrations	O
were	O
q	O
##uant	O
##ified	O
with	O
a	O
previously	O
published	O
method	O
via	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
.	O

As	O
shown	O
in	O
,	O
the	O
differential	O
end	O
##ogen	O
##ous	O
compounds	O
detected	O
included	O
mitochondrial	O
metabolism	O
(	O
c	O
##it	O
##rate	O
)	O
,	O
extra	O
mitochondrial	O
metabolism	O
(	B
glucose	S
,	O
p	B
##yr	I
##u	I
##vate	I
,	O
la	B
##ct	I
##ate	I
,	O
c	B
##rea	I
##tin	I
##ine	I
,	O
c	B
##rea	I
##tine	I
,	O
c	B
##rea	I
##tine	I
phosphate	I
)	O
and	O
several	O
amino	O
acids	O
and	O
their	O
derivative	O
signals	O
(	O
such	O
as	O
pro	B
##line	I
,	O
g	B
##lut	I
##amine	I
,	O
N	B
-	I
ace	I
##ty	I
##l	I
##g	I
##lut	I
##amine	I
,	O
al	B
##ani	I
##ne	I
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
try	O
##pt	O
##op	O
##han	O
)	O
.	O

Furthermore	O
,	O
reactive	O
per	B
##sul	I
##fi	I
##des	I
/	O
p	O
##oly	O
##sul	O
##fi	O
##des	O
,	O
including	O
c	B
##ys	I
##tein	I
##e	I
per	I
##sul	I
##fi	I
##des	I
(	O
Cy	O
##s	O
##SS	O
##H	O
)	O
,	O
have	O
been	O
reported	O
to	O
form	O
end	O
##ogen	O
##ously	O
,	O
from	O
both	O
small	O
molecule	O
species	O
and	O
from	O
proteins	O
,	O
in	O
high	O
amounts	O
in	O
ma	O
##mmal	O
##ian	O
cells	O
and	O
tissues	O
,	O
including	O
human	O
plasma	O
.	O

P	O
##E	O
was	O
the	O
second	O
most	O
abundant	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
in	O
ma	O
##mmal	O
##ian	O
cells	O
.	O

G	B
##lu	I
##cos	I
##e	I
-	I
6	I
-	I
phosphate	I
and	O
f	B
##ru	I
##ct	I
##ose	I
-	I
6	I
-	I
phosphate	I
demonstrated	O
0	O
.	O
64	O
-	O
fold	O
and	O
0	O
.	O
75	O
-	O
fold	O
lower	O
expression	O
in	O
CR	O
##C	O
compared	O
to	O
m	O
##uc	O
##osa	O
,	O
respectively	O
,	O
whereas	O
is	O
##ob	O
##ar	O
:	O
beta	B
##ine	I
al	I
##de	I
##hy	I
##de	I
,	O
N	B
-	I
met	I
##hyl	I
##die	I
##than	I
##ola	I
##mine	I
,	O
and	O
ad	B
##en	I
##yl	I
##os	I
##ucci	I
##nate	I
had	O
2	O
.	O
68	O
-	O
fold	O
and	O
1	O
.	O
88	O
-	O
fold	O
higher	O
relative	O
abundance	O
in	O
CR	O
##C	O
.	O

Ser	O
##um	O
11	B
##β	I
-	I
h	I
##ydro	I
##xy	I
##and	I
##ros	I
##ten	I
##ed	I
##ione	I
and	O
11	B
-	I
k	I
##eto	I
##and	I
##ros	I
##ten	I
##ed	I
##ione	I
correlated	O
significantly	O
with	O
markers	O
of	O
insulin	O
resistance	O
.	O

Su	B
##cci	I
##nate	I
is	O
not	O
only	O
an	O
important	O
intermediate	O
meta	O
##bol	O
##ite	O
in	O
the	O
t	B
##rica	I
##rb	I
##ox	I
##yl	I
##ic	I
acid	I
cycle	O
but	O
also	O
an	O
important	O
component	O
of	O
the	O
electron	O
respiratory	O
chain	O
complex	O
II	O
.	O

Free	O
##ze	O
-	O
dried	O
powder	O
of	O
K	O
##BR	O
and	O
N	O
##AB	O
and	O
a	O
color	O
/	O
flavor	O
-	O
matched	O
place	O
##bo	O
containing	O
la	B
##ct	I
##ose	I
were	O
provided	O
by	O
the	O
Korean	O
Rural	O
Development	O
Administration	O
(	O
Su	O
##won	O
,	O
G	O
##yung	O
##gi	O
-	O
do	O
,	O
Korea	O
)	O
.	O

To	O
examine	O
the	O
sensitivity	O
and	O
specific	O
##ity	O
of	O
FA	S
pro	O
##fi	O
##ling	O
through	O
P	O
##IS	O
of	O
m	O
/	O
z	O
183	O
,	O
the	O
full	O
MS	O
scan	O
and	O
P	O
##IS	O
of	O
m	O
/	O
z	O
183	O
of	O
AM	O
##PP	O
-	O
der	O
##iva	O
##tized	O
d	B
_	I
4	I
-	I
16	I
:	I
0	I
FA	I
in	O
the	O
positive	O
-	O
ion	O
mode	O
were	O
compared	O
to	O
the	O
full	O
MS	O
scan	O
of	O
d	B
_	I
4	I
-	I
16	I
:	I
0	I
FA	I
an	O
##ion	O
in	O
the	O
negative	O
ion	O
mode	O
.	O

We	O
also	O
conducted	O
a	O
random	O
forest	O
analysis	O
and	O
found	O
that	O
20	B
-	I
H	I
##ET	I
##E	I
was	O
the	O
main	O
different	O
##iator	O
in	O
the	O
list	O
of	O
selected	O
meta	O
##bol	O
##ites	O
.	O

Many	O
O	O
##P	O
p	O
##est	O
##icides	O
possess	O
structural	O
features	O
in	O
common	O
to	O
the	O
nerve	O
agents	O
sa	O
##rin	O
and	O
so	O
##man	O
,	O
which	O
p	B
##hos	I
##phy	I
##late	I
a	O
se	B
##rine	I
residue	O
in	O
the	O
active	O
site	O
Ace	O
##ty	O
##l	O
##cho	O
##lines	O
##tera	O
##se	O
(	O
AC	O
##h	O
##E	O
)	O
,	O
resulting	O
in	O
in	O
##act	O
##ivation	O
of	O
the	O
enzyme	O
as	O
the	O
mode	O
of	O
toxicity	O
.	O

The	O
first	O
add	O
##uc	O
##t	O
was	O
characterized	O
as	O
des	B
##ami	I
##no	I
-	I
Ph	I
##IP	I
-	I
K	I
.	O
The	O
product	O
ion	O
s	O
##pect	O
##ra	O
of	O
the	O
add	O
##uc	O
##t	O
(	O
[	O
M	O
+	O
H	O
]	O
_	O
+	O
at	O
m	O
/	O
z	O
35	O
##4	O
.	O
2	O
)	O
and	O
its	O
is	O
##oto	O
##pic	O
labeled	O
species	O
(	O
[	O
M	O
+	O
H	O
]	O
_	O
+	O
at	O
m	O
/	O
z	O
35	O
##9	O
.	O
2	O
)	O
are	O
shown	O
in	O
.	O

Finally	O
,	O
significant	O
reduction	O
##s	O
in	O
GA	B
##BA	I
in	O
AD	O
patients	O
have	O
been	O
reported	O
in	O
the	O
temporal	O
cortex	O
and	O
AD	O
trans	O
##genic	O
mice	O
have	O
lower	O
GA	B
##BA	I
levels	O
in	O
the	O
hip	O
##po	O
##cam	O
##pus	O
and	O
cortex	O
[	O
,	O
]	O
.	O

For	O
the	O
L	O
##C	O
-	O
MS	O
work	O
,	O
L	O
##C	O
solvent	O
A	O
was	O
0	O
.	O
1	O
%	O
(	O
v	O
/	O
v	O
)	O
form	B
##ic	I
acid	I
in	O
5	O
%	O
(	O
v	O
/	O
v	O
)	O
AC	O
##N	O
,	O
and	O
solvent	O
B	O
was	O
0	O
.	O
1	O
%	O
(	O
v	O
/	O
v	O
)	O
form	B
##ic	I
acid	I
in	O
AC	O
##N	O
.	O

Results	O
for	O
the	O
17	O
meta	O
##bol	O
##ites	O
that	O
changed	O
in	O
response	O
to	O
β	B
-	I
car	I
##ote	I
##ne	I
supplement	O
##ation	O
at	O
the	O
nominal	O
statistical	O
level	O
of	O
P	O
<	O
0	O
.	O
05	O
are	O
shown	O
in	O
;	O
findings	O
for	O
all	O
48	O
##9	O
meta	O
##bol	O
##ites	O
appear	O
elsewhere	O
(	O
see	O
Su	O
##pp	O
##lement	O
##al	O
Table	O
1	O
under	O
“	O
Su	O
##pp	O
##lement	O
##al	O
data	O
”	O
in	O
the	O
online	O
issue	O
)	O
.	O

G	B
##lu	I
##cos	I
##e	I
(	O
_	O
13	O
C	O
)	O
and	O
g	B
##lut	I
##amine	I
(	O
_	O
13	O
C	O
,	O
_	O
15	O
N	O
)	O
trace	O
##rs	O
have	O
been	O
used	O
extensively	O
to	O
demonstrate	O
the	O
importance	O
of	O
central	O
carbon	O
metabolism	O
in	O
meeting	O
the	O
bio	O
##ener	O
##get	O
##ic	O
demands	O
of	O
tumors	O
_	O
,	O
.	O

(	O
A	O
)	O
Box	O
plots	O
from	O
U	B
##rine	I
-	I
0	I
##h	I
(	O
B	O
)	O
Box	O
plots	O
from	O
U	B
##rine	I
-	I
24	I
##h	I
samples	O
.	O

Si	B
##but	I
##ram	I
##ine	I
h	I
##ydro	I
##ch	I
##lor	I
##ide	I
(	O
S	O
##B	O
)	O
was	O
purchased	O
from	O
S	O
##yme	O
##d	O
labs	O
.	O

The	O
effects	O
of	O
CP	O
##D	O
on	O
8	B
-	I
is	I
##o	I
-	I
P	I
##G	I
##F	I
_	I
2	I
##α	I
(	I
p	I
=	I
0	I
.	I
02	I
)	I
,	O
and	O
gender	O
(	O
p	O
<	O
0	O
.	O
000	O
##1	O
)	O
and	O
age	O
(	O
p	O
<	O
0	O
.	O
01	O
)	O
on	O
P	O
##GE	O
-	O
M	O
were	O
significant	O
.	O

U	O
##rina	O
##ry	O
is	B
##of	I
##lav	I
##ones	I
and	O
S	O
-	O
(	O
−	O
)	O
e	O
##q	O
##uo	O
##l	O
concentrations	O
were	O
expressed	O
in	O
nm	O
##ol	O
/	O
L	O
.	O

Twelve	O
ACC	O
patients	O
had	O
combined	O
g	B
##lu	I
##co	I
##cor	I
##tic	I
##oid	I
and	O
ad	O
##rena	O
##l	O
and	O
##rogen	O
excess	O
,	O
with	O
additional	O
al	B
##dos	I
##tero	I
##ne	I
excess	O
in	O
two	O
of	O
them	O
.	O

Interest	O
##ingly	O
,	O
u	O
##rina	O
##ry	O
concentrations	O
of	O
meta	O
##bol	O
##ite	O
downstream	O
of	O
this	O
compound	O
(	O
q	O
##uin	O
##olin	O
##ic	O
acid	O
and	O
x	B
##ant	I
##hur	I
##eni	I
##c	I
acid	O
)	O
are	O
elevated	O
in	O
au	O
##tist	O
##ic	O
children	O
,	O
whereas	O
meta	O
##bol	O
##ite	O
upstream	O
of	O
3	B
-	I
h	I
##ydro	I
##xy	I
##kin	I
##uren	I
##ine	I
(	O
k	O
##yn	O
##uren	O
##ine	O
and	O
k	O
##yn	O
##uren	O
##ic	O
acid	O
)	O
are	O
higher	O
among	O
controls	O
(	O
Fi	O
##g	O
.	O

Thus	O
,	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
play	O
a	O
decisive	O
role	O
in	O
free	O
fatty	O
acid	O
(	O
FF	O
##A	O
)	O
oxidation	O
,	O
responsible	O
for	O
the	O
transportation	O
of	O
a	B
##cy	I
##l	I
-	I
co	I
##en	I
##zy	I
##me	I
A	O
into	O
mit	O
##och	O
##ond	O
##ria	O
,	O
especially	O
in	O
liver	O
and	O
muscle	O
cells	O
.	O

1	O
:	O
a	B
##con	I
##itic	I
acid	I
;	O
2	O
:	O
ad	B
##ip	I
##ic	I
acid	I
;	O
3	O
:	O
al	B
##ani	I
##ne	I
;	O
5	O
:	O
a	B
##rg	I
##ini	I
##ne	I
;	O
6	O
:	O
as	B
##par	I
##agi	I
##ne	I
;	O
7	O
:	O
as	B
##par	I
##tic	I
acid	I
;	O
9	O
:	O
c	B
##it	I
##ric	I
acid	I
;	O
12	O
:	O
form	B
##ic	I
acid	I
;	O
15	O
:	O
g	B
##lut	I
##ami	I
##c	I
acid	I
;	O
18	O
:	O
g	B
##ly	I
##co	I
##lic	I
acid	I
;	O
19	O
:	O
hip	B
##pur	I
##ic	I
acid	I
;	O
24	O
:	O
is	B
##oc	I
##it	I
##ric	I
acid	I
;	O
28	O
:	O
la	B
##ctic	I
acid	I
;	O
33	O
:	O
ma	B
##lon	I
##ic	I
acid	I
;	O
39	O
:	O
prop	B
##ion	I
##ic	I
acid	I
;	O
40	O
:	O
p	B
##yr	I
##og	I
##lut	I
##ami	I
##c	I
acid	I
;	O
43	O
:	O
su	B
##cci	I
##nic	I
acid	I
;	O
45	O
:	O
th	B
##re	I
##oni	I
##ne	I
;	O
46	O
:	O
try	B
##pt	I
##op	I
##han	I
.	O

A	O
##bb	O
##re	O
##viation	O
##s	O
:	O
AD	O
##HF	O
,	O
advanced	O
de	O
##com	O
##pen	O
##sat	O
##ed	O
heart	O
failure	O
;	O
CH	O
##F	O
,	O
chronic	O
s	O
##ys	O
##to	O
##lic	O
heart	O
failure	O
;	O
B	O
##MI	O
,	O
Body	O
mass	O
index	O
;	O
NY	O
##HA	O
,	O
New	O
York	O
Heart	O
Association	O
;	O
AC	O
##EI	O
,	O
an	O
##gio	O
##tens	O
##in	O
-	O
converting	O
enzyme	O
inhibitor	O
;	O
AR	O
##B	O
,	O
an	B
##gio	I
##tens	I
##in	I
receptor	O
block	O
##er	O
;	O
L	O
##VE	O
##F	O
,	O
left	O
vent	O
##ric	O
##ular	O
e	O
##jection	O
fraction	O
;	O
L	O
##VE	O
##D	O
##V	O
##i	O
,	O
left	O
vent	O
##ric	O
##ular	O
end	O
-	O
di	O
##ast	O
##olic	O
volume	O
index	O
;	O
LA	O
##V	O
##i	O
,	O
left	O
at	O
##rial	O
volume	O
index	O
;	O

Sign	O
##ificant	O
alterations	O
in	O
So	O
##1	O
##P	O
were	O
identified	O
among	O
di	O
##abe	O
##tic	O
patients	O
with	O
different	O
glucose	S
management	O
##s	O
as	O
s	O
##tra	O
##ti	O
##fied	O
by	O
H	O
##b	O
##A	O
##1	O
##c	O
levels	O
(	O
P	O
=	O
0	O
.	O
05	O
,	O
H	O
##b	O
##A	O
##1	O
##c	O
>	O
9	O
%	O
vs	O
.	O
H	O
##b	O
##A	O
##1	O
##c	O
<	O
7	O
%	O
;	O
)	O
.	O

A	O
study	O
has	O
shown	O
that	O
my	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
could	O
increase	O
sperm	O
m	O
##ot	O
##ility	O
and	O
the	O
number	O
of	O
sperm	O
##ato	O
##zo	O
##a	O
retrieved	O
after	O
swim	O
-	O
up	O
.	O

Met	B
##had	I
##one	I
,	O
meta	O
##bol	O
##ites	O
,	O
bio	O
##ava	O
##ila	O
##bility	O
,	O
re	O
##ct	O
##al	O
,	O
oral	O
,	O
in	O
##tra	O
##ven	O
##ous	O
,	O
human	O
,	O
volunteers	O
,	O
p	O
##har	O
##ma	O
##co	O
##kin	O
##etics	O
,	O
pupil	O
##lo	O
##metry	O

There	O
is	O
a	O
positive	O
correlation	O
between	O
the	O
concentration	O
of	O
la	B
##ctic	I
acid	I
in	O
ma	O
##li	O
##gnant	O
tumor	O
tissues	O
and	O
l	O
##ymph	O
node	O
or	O
distant	O
meta	O
##sta	O
##sis	O
in	O
patients	O
with	O
head	O
and	O
neck	O
cancer	O
.	O

When	O
we	O
compared	O
HC	O
##C	O
to	O
ICC	O
cases	O
in	O
T	O
##IG	O
##ER	O
-	O
L	O
##C	O
,	O
we	O
found	O
that	O
three	O
of	O
the	O
four	O
meta	O
##bol	O
##ites	O
,	O
CR	O
,	O
N	B
##AN	I
##A	I
and	O
meta	O
##bol	O
##ite	O
56	O
##1	O
+	O
,	O
are	O
significantly	O
increased	O
in	O
ICC	O
.	O

Per	O
##ip	O
##her	O
##al	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
have	O
been	O
reported	O
to	O
be	O
predict	O
##ors	O
of	O
cognitive	O
decline	O
,	O
low	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
levels	O
being	O
associated	O
with	O
a	O
faster	O
rate	O
of	O
cognitive	O
decline	O
_	O
,	O
.	O

The	O
significantly	O
increased	O
mother	O
’	O
s	O
plasma	O
g	B
##ly	I
##cer	I
##ol	I
in	O
T	O
##3	O
vs	O
T	O
##2	O
comparison	O
is	O
most	O
likely	O
a	O
result	O
of	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
breakdown	O
caused	O
by	O
high	O
lip	O
##oli	O
##tic	O
activity	O
of	O
ad	O
##ip	O
##ose	O
tissue	O
.	O

Except	O
for	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##och	I
##olin	I
##e	I
,	O
found	O
by	O
Wish	O
##art	O
,	O
all	O
meta	O
##bol	O
##ites	O
have	O
been	O
found	O
in	O
urine	O
according	O
to	O
HM	O
##D	O
##B	O
.	O

Additionally	O
,	O
environmental	O
factors	O
can	O
also	O
m	O
##od	O
##ulate	O
C	O
##YP	O
##2	O
##A	O
##6	O
activity	O
and	O
the	O
rate	O
of	O
ni	B
##cot	I
##ine	I
metabolism	O
.	O

The	O
decrease	O
in	O
u	B
##rea	I
and	O
or	B
##ni	I
##thin	I
##e	I
in	O
CD	O
patients	O
as	O
compared	O
to	O
the	O
control	O
co	O
##hor	O
##t	O
may	O
indicate	O
disturbance	O
##s	O
in	O
the	O
u	B
##rea	I
cycle	O
.	O

Data	O
comparing	B
M	I
##T	I
##BE	I
and	O
DC	O
##M	O
differ	O
q	O
##ual	O
##itative	O
##ly	O
.	O

(	O
C	O
)	O
D	O
##N	O
##MT	O
and	O
(	O
D	O
)	O
T	O
##ET	O
activity	O
were	O
measured	O
in	O
response	O
to	O
α	B
-	I
O	I
##G	I
treatment	O
.	O

cannabis	S
,	O
HIV	O
,	O
immune	O
activation	O
,	O
inn	O
##ate	O
immunity	O
,	O

The	O
p	O
##har	O
##ma	O
##co	O
##kin	O
##etic	O
application	O
of	O
this	O
method	O
enables	O
the	O
q	O
##uant	O
##ification	O
of	O
SM	O
##V	O
,	O
SM	O
##V	O
-	O
A	O
,	O
AT	O
##V	O
,	O
2	B
-	I
OH	I
-	I
AT	I
##V	I
,	O
4	B
-	I
OH	I
-	I
AT	I
##V	I
,	O
and	O
RS	O
##V	O
concentrations	O
in	O
clinical	O
plasma	O
samples	O
,	O
even	O
if	O
they	O
have	O
high	O
levels	O
of	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
.	O

Second	O
,	O
although	O
F	O
##RS	O
,	O
H	O
##b	O
##A	O
##1	O
##c	O
,	O
and	O
diabetes	O
duration	S
was	O
matched	O
between	O
subjects	O
having	O
experienced	O
CA	O
##D	O
and	O
control	O
subjects	O
,	O
the	O
small	O
sample	O
size	O
in	O
our	O
pilot	O
study	O
does	O
not	O
allow	O
adjustment	O
for	O
other	O
clinical	O
variables	O
.	O

So	O
##y	O
foods	O
contain	O
high	O
concentrations	O
of	O
is	B
##of	I
##lav	I
##ones	I
,	O
a	O
type	O
of	O
p	O
##hy	O
##to	O
##est	O
##rogen	O
,	O
which	O
possess	O
anti	O
##est	O
##rogen	O
##ic	O
and	O
anti	O
##ox	O
##ida	O
##tive	O
effects	O
.	O

The	O
h	O
##ydro	O
##xy	O
##lated	O
meta	O
##bol	O
##ite	O
el	O
##uted	O
at	O
0	O
.	O
99	O
min	O
,	O
before	O
the	O
Met	O
3	O
-	O
OH	O
,	O
was	O
finally	O
identified	O
as	O
the	O
trans	B
-	I
4	I
-	I
OH	I
P	O
##B	O
##T	O
##Z	O
##16	O
##9	O
(	O
E	O
/	O
E	O
,	O
both	O
sub	O
##st	O
##it	O
##uen	O
##ts	O
of	O
the	O
c	O
##y	O
##c	O
##lo	O
##he	O
##xy	O
##l	O
ring	O
in	O
e	O
##quatorial	O
(	O
E	O
)	O
positions	O
)	O
by	O
co	O
-	O
injection	O
with	O
the	O
synthetic	O
di	O
##aster	O
##eo	O
##is	O
##omer	O
##ic	O
mixture	O
65	O
:	O
35	O
of	O
trans	O
-	O
E	O
/	O
E	O
-	O
and	O
c	O
##is	O
-	O
E	O
/	O
A	O
-	O
4	O
##OH	O
P	O
##B	O
##T	O
##Z	O
##16	O
##9	O
.	O

Also	O
,	O
g	B
##ly	I
##cine	I
is	O
a	O
precursor	O
of	O
sa	O
##rc	O
##os	O
##ine	O
(	O
N	O
-	O
met	O
##hyl	O
g	O
##ly	O
##cine	O
)	O
,	O
which	O
was	O
shown	O
to	O
be	O
a	O
potential	O
metabolic	O
bio	O
##mark	O
##er	O
for	O
aggressive	O
pro	O
##state	O
cancer	O
.	O

However	O
,	O
after	O
normal	O
##izing	O
the	O
concentration	O
of	O
8	B
-	I
o	I
##x	I
##o	I
-	I
d	I
##G	I
in	O
urine	O
with	O
the	O
c	B
##rea	I
##tin	I
##ine	I
content	O
,	O
there	O
was	O
no	O
statistical	O
##ly	O
significant	O
difference	O
in	O
8	B
-	I
o	I
##x	I
##o	I
-	I
d	I
##G	I
levels	O
among	O
the	O
healthy	O
male	O
and	O
female	O
volunteers	O
.	O

It	O
is	O
possible	O
that	O
the	O
decreased	O
he	O
##pa	O
##tic	O
function	O
,	O
as	O
evidenced	O
by	O
higher	O
Child	O
–	O
P	O
##ugh	O
scores	O
in	O
patients	O
with	O
HC	O
##C	O
translates	O
into	O
less	O
efficient	O
ben	B
##zo	I
##ate	I
con	O
##ju	O
##gation	O
and	O
subsequently	O
lower	O
u	O
##rina	O
##ry	O
hip	B
##pura	I
##te	I
ex	O
##cre	O
##tion	O
levels	O
.	O

The	O
current	O
study	O
differs	O
from	O
the	O
a	O
##fo	O
##re	O
mentioned	O
studies	O
because	O
the	O
current	O
study	O
is	O
the	O
only	O
study	O
to	O
establish	O
appropriate	O
as	B
##pi	I
##rin	I
action	O
with	O
an	O
objective	O
bio	O
##chemical	O
test	O
–	O
eliminating	O
con	O
##found	O
##ing	O
from	O
reduced	O
as	B
##pi	I
##rin	I
compliance	O
.	O

Sol	O
##ub	O
##le	O
f	O
##ms	O
-	O
like	O
t	B
##yr	I
##os	I
##ine	I
kinase	O
-	O
1	O
(	O
s	O
##F	O
##lt	O
-	O
1	O
)	O
/	O
Place	O
##ntal	O
growth	O
factor	O
(	O
P	O
##l	O
##G	O
##F	O
)	O
were	O
measured	O
with	O
high	O
-	O
sensitive	O
multiple	O
##x	O
array	O
(	B
Me	B
##so	I
Scale	O
Discovery	O
(	O
MS	O
##D	O
)	O
V	O
-	O
P	O
##LE	O
##X	O
Ang	O
##io	O
##genesis	O
Panel	O
1	O
Human	O
kit	O
,	O
MS	O
##D	O
,	O
USA	O
)	O
,	O
according	O
to	O
the	O
manufacturer	O
’	O
instruction	O
.	O

Equal	O
amounts	O
of	O
cell	O
proteins	O
were	O
resolved	O
on	O
(	B
SD	I
##S	I
)	I
-	I
p	I
##oly	I
##ac	I
##ryl	I
##ami	I
##de	I
gel	O
##s	O
and	O
transferred	O
to	O
ni	O
##tro	O
##cell	O
##ulos	O
##e	O
membrane	O
by	O
Trans	B
-	I
b	I
##lot	I
t	O
##ur	O
##bo	O
transfer	O
system	O
(	O
B	O
##io	O
-	O
Ra	O
##d	O
,	O
Hercules	O
,	O
CA	O
USA	O
)	O
.	O

The	O
fragment	O
##ation	O
patterns	O
were	O
matched	O
with	O
the	O
fragment	O
##ation	O
patterns	O
of	O
standard	O
E	B
_	I
1	I
-	I
9	I
-	I
N	I
-	I
Ad	I
##e	I
and	O
E	B
_	I
2	I
-	I
9	I
-	I
N	I
-	I
Ad	I
##e	I
(	O
&	O
,	O
ins	O
##ets	O
)	O
.	O

Although	O
g	B
##lut	I
##amine	I
massive	O
##ly	O
c	O
##y	O
##c	O
##li	O
##zes	O
to	O
p	B
##yr	I
##og	I
##lut	I
##ami	I
##c	I
acid	I
,	O
the	O
sum	O
of	O
g	B
##lut	I
##amine	I
and	O
p	B
##yr	I
##og	I
##lut	I
##ami	I
##c	I
acid	I
is	O
the	O
same	O
in	O
all	O
the	O
portions	O
of	O
serum	O
samples	O
(	O
C	O
##V	O
<	O
3	O
%	O
)	O
.	O

To	O
test	O
this	O
hypothesis	O
we	O
applied	O
a	O
method	O
for	O
the	O
analysis	O
of	O
se	B
##rot	I
##oni	I
##n	I
,	O
metabolic	O
intermediate	O
##s	O
and	O
do	B
##pa	I
##mine	I
in	O
urine	O
by	O
stable	O
is	O
##oto	O
##pe	O
di	O
##lution	O
direct	O
in	O
##fusion	O
electro	O
##sp	O
##ray	O
ion	O
##ization	O
mass	O
s	O
##pect	O
##rome	O
##try	O
(	O
S	O
##ID	O
-	O
MS	O
)	O
.	O

L	O
##ys	O
##o	O
##P	O
##E	O
which	O
is	O
a	O
l	O
##ys	O
##o	O
-	O
type	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
,	O
is	O
a	O
metabolic	O
product	O
of	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##let	I
##han	I
##ola	I
##mine	I
(	O
P	O
##E	O
,	O
a	O
minor	O
constituent	O
of	O
cell	O
membrane	O
##s	O
)	O
generated	O
by	O
p	O
##hos	O
##ph	O
##oli	O
##pas	O
##e	O
A2	O
.	O

This	O
is	O
illustrated	O
in	O
which	O
shows	O
that	O
those	O
who	O
report	O
feeling	O
more	O
rested	O
when	O
they	O
awake	O
in	O
the	O
morning	O
have	O
higher	O
me	B
##lat	I
##oni	I
##n	I
at	O
Time	O
T	O
##1	O
,	O
followed	O
by	O
a	O
steep	O
##er	O
decline	O
over	O
the	O
night	O
.	O

Am	B
##phe	I
##tamine	I
##s	I
,	O
cocaine	O
,	O
ni	B
##cot	I
##ine	I
,	O
op	O
##iate	O
##s	O
,	O
and	O
meta	O
##bol	O
##ites	O
in	O
me	O
##con	O
##ium	O
by	O
L	O
##CM	O
##SM	O
##S	O
:	O
imp	O
##re	O
##cision	O
,	O
recovery	O
,	O
extraction	O
efficiency	O
,	O
and	O
matrix	O
effects	O
6	O
##AM	O
6	B
-	I
ace	I
##ty	I
##lm	I
##or	I
##phine	I
,	O
AM	B
##P	I
am	I
##phe	I
##tamine	I
,	O
B	O
##E	O
ben	B
##zo	I
##yle	I
##c	I
##gon	I
##ine	I
,	O
B	O
##UP	O
b	B
##up	I
##ren	I
##or	I
##phine	I
,	O
CE	O
co	B
##ca	I
##eth	I
##yle	I
##ne	I
,	O
CO	O
##C	O
cocaine	O
,	O
CO	O
##T	O
co	B
##tin	I
##ine	I
,	O
CO	O
##D	O
code	B
##ine	I
,	O
C	O
##V	O
coefficient	O
of	O
variation	O
,	O
E	O
##D	O
##DP	O
2	B
-	I
et	I
##hyl	I
##iden	I
##e	I
-	I
1	I
,	I
5	I
-	I
dim	I
##eth	I
##yl	I
-	I
3	I
,	I
3	I
-	I
dip	I
##hen	I
##yl	I
##py	I
##rro	I
##lid	I
##ine	I
,	O
H	O
##Y	O
##C	O
h	B
##ydro	I
##co	I
##don	I
##e	I
,	O
H	O
##Y	O
##M	O
h	B
##ydro	I
##mor	I
##phone	I
,	O
MA	O
##MP	O
met	B
##ham	I
##phe	I
##tamine	I
,	O
m	O
##OH	O
##BE	O
m	B
-	I
h	I
##ydro	I
##xy	I
##ben	I
##oy	I
##le	I
##c	I
##gon	I
##ine	I
,	O
M	O
##OR	O
m	B
##or	I
##phine	I
,	O
M	O
##T	O
##D	O
met	B
##had	I
##one	I
,	O
N	O
##B	O
##UP	O
nor	B
##bu	I
##p	I
##ren	I
##or	I
##phine	I
,	O
N	O
##IC	O
ni	B
##cot	I
##ine	I
,	O
OH	O
##CO	O
##T	O
trans	B
-	I
3	I
′	I
-	I
h	I
##ydro	I
##xy	I
##cot	I
##ini	I
##ne	I
,	O
O	B
##X	I
##Y	I
o	I
##xy	I
##co	I
##don	I
##e	I
,	O

In	O
the	O
R	O
##OC	O
analysis	O
,	O
the	O
addition	O
of	O
u	O
##rina	O
##ry	O
my	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
did	O
not	O
increase	O
the	O
AU	O
##C	O
for	O
the	O
prediction	O
of	O
non	O
##res	O
##po	O
##nders	O
.	O

The	O
identity	O
of	O
the	O
peak	O
was	O
supported	O
by	O
a	O
standard	O
addition	O
experiment	O
(	O
see	O
)	O
and	O
the	O
use	O
of	O
the	O
de	O
##uter	O
##ated	O
internal	O
standard	O
d	B
_	I
6	I
1	I
##α	I
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
.	O

Sam	O
##ples	O
of	O
SR	O
##M	O
90	O
##9	O
##c	O
were	O
prepared	O
with	O
and	O
without	O
fi	O
##ltration	O
,	O
with	O
different	O
ratios	O
of	O
the	O
precipitation	O
solvent	O
to	O
serum	O
,	O
and	O
with	O
different	O
protein	O
precipitation	O
solvent	O
##s	O
including	O
20	O
%	O
is	B
##op	I
##rop	I
##ano	I
##l	I
in	O
met	B
##han	I
##ol	I
(	O
the	O
original	O
method	O
solvent	O
)	O
,	O
ethanol	S
,	O
met	B
##han	I
##ol	I
,	O
and	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
.	O

We	O
found	O
a	O
clear	O
separation	O
between	O
day	O
and	O
night	O
time	O
urine	O
s	O
##tero	O
##id	O
ex	O
##cre	O
##tion	O
,	O
not	O
only	O
for	O
g	B
##lu	I
##co	I
##cor	I
##tic	I
##oids	I
,	O
but	O
also	O
for	O
most	O
other	O
s	O
##tero	O
##id	O
hormone	O
meta	O
##bol	O
##ites	O
that	O
are	O
assumed	O
to	O
be	O
predominantly	O
synthesized	O
in	O
the	O
ad	O
##rena	O
##l	O
glands	O
.	O

The	O
dried	O
extract	O
was	O
then	O
re	O
##con	O
##stituted	O
in	O
50	O
μ	O
##L	O
of	O
met	B
##han	I
##ol	I
.	O

Rat	O
##ios	O
of	O
2	O
-	O
pathway	O
E	O
##M	O
and	O
4	O
-	O
pathway	O
E	O
##M	O
to	O
16	B
##α	I
-	I
pathway	I
meta	O
##bol	O
##ites	O
significantly	O
increased	O
across	O
the	O
range	O
of	O
so	O
##y	O
intake	O
(	O
p	O
_	O
trend	O
=	O
0	O
.	O
01	O
for	O
each	O
)	O
.	O

Furthermore	O
,	O
Burton	O
and	O
Ma	O
analyzed	O
the	O
literature	O
investigating	O
the	O
use	O
of	O
u	O
##rina	O
##ry	O
meta	O
##bol	O
##omi	O
##cs	O
to	O
develop	O
cancer	O
bio	O
##mark	O
##ers	O
,	O
and	O
reported	O
a	O
significant	O
number	O
of	O
altered	O
metabolic	O
pathways	O
and	O
put	O
##ative	O
bio	O
##mark	O
##ers	O
,	O
including	O
p	B
##ter	I
##id	I
##ines	I
,	O
modified	O
n	O
##uc	O
##leo	O
##side	O
##s	O
,	O
and	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
,	O
which	O
are	O
all	O
involved	O
in	O
cancer	O
development	O
and	O
progression	O
.	O

When	O
the	O
ass	O
##ay	O
was	O
first	O
used	O
to	O
q	O
##uant	O
##ify	O
a	B
##bir	I
##ater	I
##one	I
in	O
patients	O
treated	O
which	O
this	O
drug	O
,	O
co	O
-	O
el	O
##ution	O
with	O
phase	O
I	O
meta	O
##bol	O
##ites	O
was	O
observed	O
.	O

Similarly	O
,	O
stab	O
##ly	O
suppress	O
##ing	O
g	O
##lut	O
##ami	O
##nas	O
##e	O
expression	O
in	O
these	O
cells	O
with	O
lent	O
##iv	O
##ira	O
##l	O
s	O
##h	O
##RNA	O
also	O
a	O
##bro	O
##gated	O
H	O
##NS	O
##CC	O
tumors	O
##phere	O
formation	O
and	O
g	B
##lut	I
##ama	I
##te	I
levels	O
in	O
H	O
##NS	O
##CC	O
cells	O
in	O
v	O
##it	O
##ro	O
.	O

Proto	O
##n	O
N	O
##MR	O
s	O
##pect	O
##ra	O
were	O
acquired	O
at	O
300	O
.	O
0	O
K	O
on	O
a	O
B	O
##ruk	O
##er	O
A	B
##V	I
600	O
s	O
##pect	O
##rome	O
##ter	O
equipped	O
with	O
a	O
T	O
##CI	O
cry	O
##op	O
##robe	O
and	O
an	O
automatic	O
sample	O
change	O
##r	O
.	O

We	O
found	O
a	O
strong	O
inverse	O
association	O
of	O
u	O
##rina	O
##ry	O
hip	B
##pura	I
##te	I
across	O
the	O
range	O
of	O
B	O
##MI	O
(	O
P	O
=	O
1	O
.	O
52	O
×	O
10	O
_	O
−	O
##14	O
,	O
)	O
;	O
a	O
weak	O
inverse	O
association	O
with	O
ad	O
##ip	O
##os	O
##ity	O
has	O
been	O
reported	O
previously	O
only	O
in	O
m	O
##or	O
##bid	O
##ly	O
o	O
##bes	O
##e	O
humans	O
as	O
well	O
as	O
in	O
dogs	O
and	O
mice	O
(	O
,	O
)	O
.	O

The	O
meta	O
##bol	O
##ites	O
that	O
allowed	O
to	O
distinguish	O
these	O
groups	O
were	O
:	O
N	O
-	O
ace	O
##ty	O
##lated	O
compounds	O
and	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
(	O
up	O
-	O
regulated	O
in	O
serum	O
)	O
,	O
low	O
-	O
density	O
lip	O
##op	O
##rote	O
##ins	O
and	O
very	O
low	O
-	O
density	O
lip	O
##op	O
##rote	O
##ins	O
(	O
decreased	O
in	O
serum	O
)	O
as	O
well	O
as	O
g	B
##ly	I
##cine	I
(	O
increased	O
in	O
urine	O
)	O
and	O
ace	B
##to	I
##ace	I
##tate	I
(	O
decreased	O
in	O
urine	O
)	O
.	O

U	O
##rina	O
##ry	O
meta	O
##bol	O
##ites	O
were	O
expressed	O
as	O
nm	O
##ol	O
/	O
mg	O
c	B
##rea	I
##tin	I
##ine	I
to	O
correct	O
for	O
differences	O
in	O
urine	O
volume	O
.	O

who	O
identified	O
decreases	O
in	O
his	B
##ti	I
##dine	I
,	O
g	B
##lut	I
##amine	I
and	O
th	B
##re	I
##oni	I
##ne	I
in	O
early	O
and	O
late	O
lung	O
cancer	O
in	O
plasma	O
samples	O
from	O
five	O
cancer	O
##s	O
(	O
lung	O
,	O
gas	O
##tric	O
,	O
color	O
##ec	O
##tal	O
,	O
breast	O
and	O
pro	O
##state	O
)	O
.	O

Lower	O
95	O
%	O
C	O
##I	O
limits	O
greater	O
than	O
0	O
.	O
8	O
were	O
observed	O
for	O
six	O
disc	O
##rim	O
##ina	O
##nts	O
only	O
:	O
at	O
##rac	O
##ty	O
##li	O
##gen	O
##in	O
g	B
##lu	I
##cu	I
##ron	I
##ide	I
,	O
c	O
##y	O
##c	O
##lo	O
(	O
is	O
##ole	O
##uc	O
##yl	O
-	O
pro	O
##ly	O
##l	O
)	O
,	O
1	B
-	I
met	I
##hyl	I
##xa	I
##nt	I
##hine	I
,	O
1	B
,	I
7	I
-	I
dim	I
##eth	I
##yl	I
##uri	I
##c	I
acid	I
,	O
ka	O
##w	O
##he	O
##ol	O
oxide	B
g	I
##lu	I
##cu	I
##ron	I
##ide	I
and	O
an	O
unidentified	O
disc	O
##rim	O
##ina	O
##nt	O
(	O
unknown	O
##1	O
;	O
p	O
##20	O
##0	O
.	O
108	O
)	O
.	O

Early	O
work	O
suggested	O
high	O
11	B
##β	I
-	I
H	I
##SD	I
expression	O
in	O
o	O
##mental	O
(	O
i	O
.	O
e	O
.	O
v	O
##is	O
##cer	O
##al	O
)	O
but	O
not	O
sub	O
##cut	O
##aneous	O
ad	O
##ip	O
##ose	O
tissue	O
,	O
bypass	O
##ing	O
the	O
HP	O
##A	O
-	O
axis	O
due	O
to	O
local	O
co	B
##rt	I
##is	I
##ol	I
production	O
from	O
inactive	O
co	B
##rt	I
##ison	I
##e	I
.	O

Four	O
other	O
meta	O
##bol	O
##ites	O
(	B
g	B
##lut	I
##amine	I
,	O
his	B
##ti	I
##dine	I
,	O
l	B
##ys	I
##ine	I
,	O
and	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
)	O
had	O
overall	O
time	O
-	O
related	O
patterns	O
that	O
did	O
not	O
replica	O
##te	O
.	O

Moreover	O
,	O
levels	O
of	O
h	B
##ydro	I
##cor	I
##tis	I
##one	I
,	O
g	B
##lut	I
##ami	I
##c	I
acid	I
,	O
try	B
##pt	I
##op	I
##han	I
,	O
e	B
##ico	I
##sa	I
##pent	I
##aen	I
##oi	I
##c	I
acid	I
,	O
13	B
##S	I
-	I
h	I
##ydro	I
##xy	I
##oc	I
##tad	I
##eca	I
##die	I
##no	I
##ic	I
acid	I
,	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
,	O
and	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##let	I
##han	I
##ola	I
##mine	I
##s	I
were	O
associated	O
with	O
more	O
severe	O
disease	O
(	O
non	O
-	O
re	O
##lap	O
##se	O
-	O
free	O
or	O
increase	O
in	O
E	O
##DS	O
##S	O
)	O
.	O

Whenever	O
a	O
molecule	O
of	O
al	B
##ani	I
##ne	I
is	O
formed	O
from	O
p	B
##yr	I
##u	I
##vate	I
via	O
al	O
##ani	O
##ne	O
trans	O
##ami	O
##nas	O
##e	O
a	O
molecule	O
of	O
g	B
##lut	I
##ama	I
##te	I
will	O
be	O
formed	O
from	O
α	B
-	I
k	I
##eto	I
##g	I
##lut	I
##arate	I
(	O
E	O
##q	O
2	O
)	O
,	O
and	O
that	O
in	O
turn	O
can	O
be	O
converted	O
(	O
via	O
g	O
##lut	O
##ami	O
##nas	O
##e	O
,	O
E	O
##q	O
4	O
)	O
into	O
g	B
##lut	I
##amine	I
(	O
see	O
)	O
.	O

Both	O
re	O
##p	O
##rod	O
##uc	O
##ibility	O
and	O
the	O
reaction	O
efficiency	O
were	O
assessed	O
based	O
on	O
the	O
integral	O
##s	O
of	O
the	O
carbon	O
##yl	O
carbon	O
of	O
the	O
der	O
##iva	O
##tized	O
amino	O
acids	O
with	O
reference	O
to	O
an	O
internal	O
standard	O
[	B
sodium	B
3	I
-	I
trim	I
##eth	I
##yl	I
##si	I
##ly	I
##l	I
(	I
2	I
,	I
2	I
,	I
3	I
,	I
3	I
-	I
_	I
2	I
H	I
_	I
4	I
)	I
-	I
1	I
-	I
prop	I
##ion	I
##ate	I
]	O
.	O

D	O
_	O
35	O
_	B
L	I
##ys	I
##o	I
##PC	I
##18	I
:	I
0	I
was	O
purchased	O
from	O
Ava	O
##nti	O
Polar	O
Li	O
##pid	O
##s	O
(	O
Al	O
##aba	O
##ster	O
,	O
AL	O
)	O
.	O

A	O
.	O
Co	O
##mp	O
##aris	O
##on	O
of	O
sa	O
##liva	O
##ry	O
levels	O
of	O
total	O
ant	B
##ho	I
##cy	I
##ani	I
##ns	I
detected	O
over	O
time	O
following	O
r	O
##ins	O
##ing	O
with	O
R	O
##ins	O
##es	O
I	O
,	O
II	O
or	O
III	O
or	O
topic	O
##al	O
in	O
##tra	O
##oral	O
placement	O
of	O
a	O
10	O
%	O
bio	O
##ad	O
##hesive	O
BR	O
##B	O
gel	O
.	O

P	O
##las	O
##ma	O
amino	B
##gram	I
##s	I
were	O
significantly	O
altered	O
in	O
patients	O
with	O
AD	O
comparing	O
with	O
CH	O
##D	O
,	O
especially	O
in	O
acute	O
AD	O
,	O
suggesting	O
amino	O
acid	O
profile	O
is	O
expected	O
to	O
exploit	O
a	O
novel	O
,	O
non	O
-	O
invasive	O
,	O
objective	O
diagnosis	O
for	O
AD	O
.	O

Co	O
##mp	O
##aring	O
the	O
G	O
##CS	O
=	O
15	O
points	O
patients	O
,	O
23	O
metabolic	O
pathways	O
were	O
found	O
and	O
2	O
amino	S
acid	O
-	O
connected	O
pathways	O
(	B
p	B
##hen	I
##yla	I
##lani	I
##ne	I
metabolism	O
and	O
p	B
##hos	I
##phon	I
##ate	I
and	O
p	B
##hos	I
##phi	I
##nate	I
metabolism	O
)	O
were	O
decreased	O
in	O
the	O
G	O
##CS	O
=	O
15	O
points	O
group	O
.	O

A	O
more	O
challenging	O
example	O
is	O
given	O
by	O
PC	B
33	I
:	I
1	I
.	O

The	O
influence	O
of	O
smoking	O
on	O
8	B
-	I
is	I
##o	I
-	I
P	I
##G	I
##F	I
_	I
2	I
##α	I
and	O
P	O
##GE	O
-	O
M	O
levels	O
has	O
been	O
assessed	O
in	O
smoking	O
c	O
##ess	O
##ation	O
studies	O
.	O

Omega	B
-	I
3	I
fatty	O
acids	O
,	O
T	B
##hr	I
##omb	I
##ox	I
##ane	I
,	O
As	B
##pi	I
##rin	I
resistance	O
,	O
Plate	O
##let	O
activation	O
,	O

One	O
feature	O
(	O
M	O
##32	O
##7	O
##T	O
##8	O
##2	O
in	O
Table	O
)	O
was	O
identified	O
as	O
Doc	B
##osa	I
##he	I
##xa	I
##eno	I
##ic	I
acid	I
(	O
Met	O
##lin	O
ID	O
:	O
345	O
##7	O
,	O
HM	O
##D	O
##B	O
##00	O
##0	O
##21	O
##8	O
##3	O
)	O
with	O
a	O
ME	O
##TL	O
##IN	O
score	O
of	O
58	O
and	O
a	O
HM	O
##D	O
##B	O
fit	O
of	O
85	O
%	O
.	O

We	O
observed	O
some	O
evidence	O
that	O
the	O
association	O
with	O
downstream	O
cat	O
##ab	O
##oli	O
##tes	O
of	O
BC	O
##AA	O
##s	O
,	O
such	O
as	O
3	B
-	I
met	I
##hyl	I
-	I
2	I
-	I
o	I
##x	I
##ova	I
##ler	I
##ate	I
or	O
4	B
-	I
met	I
##hyl	I
-	I
2	I
-	I
o	I
##x	I
##ope	I
##nto	I
##ate	I
and	O
VA	O
##T	O
were	O
stronger	O
in	O
men	O
compared	O
to	O
women	O
but	O
was	O
at	O
##ten	O
##uated	O
upon	O
adjustment	O
for	O
H	O
##OM	O
##A	O
-	O
I	O
##R	O
.	O

The	O
objective	O
of	O
the	O
present	O
work	O
was	O
to	O
investigate	O
the	O
possible	O
differences	O
in	O
the	O
metabolic	O
_	O
1	O
H	O
N	O
##MR	O
profile	O
associated	O
to	O
sex	O
beyond	O
lip	O
##op	O
##rote	O
##ins	O
.	O
_	O
1	O
H	O
N	O
##MR	O
s	O
##pect	O
##ra	O
from	O
whole	O
serum	O
and	O
met	B
##han	I
##ol	I
de	O
##p	O
##rote	O
##ini	O
##zed	O
samples	O
from	O
39	O
patients	O
(	O
22	O
males	O
,	O
17	O
females	O
)	O
between	O
55	O
–	O
70	O
years	O
old	O
with	O
suspected	O
co	O
##rona	O
##ry	O
artery	O
disease	O
that	O
underwent	O
a	O
stress	O
test	O
that	O
was	O
considered	O
negative	O
where	O
included	O
.	O

Free	O
fatty	O
acids	O
are	O
used	O
as	O
respiratory	O
fuel	O
by	O
the	O
tissues	O
and	O
g	B
##ly	I
##cer	I
##ol	I
is	O
taken	O
into	O
he	O
##pa	O
##to	O
##cy	O
##tes	O
for	O
g	O
##lu	O
##con	O
##eo	O
##genesis	O
.	O

Met	B
##han	I
##ol	I
was	O
removed	O
by	O
drying	O
in	O
a	O
speed	O
vacuum	O
before	O
re	O
##con	O
##stituting	O
the	O
residue	O
with	O
phosphate	S
buffer	O
and	O
addition	O
of	O
other	O
in	O
##cu	O
##bation	O
components	O
.	O

b	O
Follow	O
-	O
up	O
time	O
between	O
blood	O
collection	O
and	O
HC	O
##C	O
diagnosis	O
_	O
c	O
Ser	O
##um	O
-	O
c	O
##lot	O
contact	O
time	O
refers	O
to	O
the	O
time	O
between	O
blood	O
collection	O
and	O
blood	O
cent	O
##ri	O
##fu	O
##gation	O
for	O
serum	O
isolation	O
_	O
d	O
A	O
cat	O
##ego	O
##rical	O
liver	O
function	O
score	O
describing	O
liver	O
damage	O
was	O
constructed	O
based	O
on	O
values	O
of	O
album	O
##in	O
(	O
<	O
35	O
g	O
/	O
L	O
)	O
,	O
total	O
bi	B
##li	I
##ru	I
##bin	I
(	O
>	O
20	O
.	O
5	O
μ	O
##mo	O
##l	O
/	O
L	O
)	O
,	O
AS	O
##T	O
(	O
>	O
34	O
U	O
/	O
L	O
)	O
,	O
AL	O
##T	O
(	O
>	O
55	O
U	O
/	O
L	O
)	O
,	O
G	O
##G	O
##T	O
(	O
men	O
>	O
64	O
U	O
/	O
L	O
,	O
women	O
>	O
36	O
U	O
/	O
L	O
)	O
,	O
and	O
AP	S
(	O
>	O
150	O
U	O
/	O
L	O
)	O
,	O
each	O
contributing	O
1	O
point	O
when	O
outside	O
of	O
the	O
normal	O
range	O
The	O
O	O
-	O
P	O
##LS	O
analysis	O
presented	O
in	O
Fi	O
##g	O
.	O

These	O
included	O
a	O
master	O
regulator	O
of	O
mitochondrial	O
bio	O
##genesis	O
and	O
function	O
,	O
per	O
##ox	O
##is	O
##ome	O
pro	O
##life	O
##rator	O
-	O
activated	O
receptor	O
-	O
gamma	O
co	O
##act	O
##iva	O
##tor	O
-	O
1	O
##α	O
(	O
PP	O
##AR	O
##GC	O
##1	O
##A	O
)	O
and	O
mitochondrial	O
ace	B
##ty	I
##l	I
-	I
co	I
##en	I
##zy	I
##me	I
A	O
car	O
##box	O
##yla	O
##se	O
beta	O
(	O
AC	O
##AC	O
##B	O
)	O
,	O
which	O
is	O
an	O
important	O
regulator	O
of	O
fatty	O
acid	O
oxidation	O
and	O
synthesis	O
.	O

Our	O
results	O
suggest	O
that	O
u	O
##rina	O
##ry	O
Neo	B
##pt	I
##eri	I
##n	I
,	O
and	O
plasma	O
Cho	B
##line	I
and	O
Sa	B
##rc	I
##os	I
##ine	I
could	O
be	O
used	O
as	O
metabolic	O
bio	O
##mark	O
##ers	O
of	O
HIV	O
/	O
AIDS	O
infection	O
.	O

Non	O
-	O
est	O
##eri	O
##fied	O
o	B
##xy	I
##lip	I
##ins	I
were	O
isolated	O
directly	O
from	O
T	O
##GR	O
##L	O
solution	O
in	O
PBS	O
using	O
solid	O
phase	O
extraction	O
.	O

Our	O
H	O
##R	O
-	O
MA	O
##S	O
results	O
show	O
increased	O
levels	O
of	O
la	B
##ct	I
##ate	I
,	O
al	B
##ani	I
##ne	I
and	O
g	B
##ly	I
##cine	I
in	O
tumor	O
and	O
L	O
##N	O
-	O
Met	O
as	O
compared	O
to	O
N	O
##AT	O
.	O

L	B
-	I
al	I
##ani	I
##ne	I
is	O
formed	O
and	O
then	O
transferred	O
from	O
muscle	O
to	O
the	O
liver	O
through	O
the	O
blood	O
.	O

Models	O
analyzed	O
using	O
the	O
0	O
.	O
01	O
##pp	O
##m	O
width	O
were	O
marginal	O
##ly	O
better	O
with	O
respect	O
to	O
predict	O
##ive	O
ability	O
for	O
the	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
models	O
,	O
thus	O
,	O
the	O
0	O
.	O
01	O
pp	O
##m	O
bin	O
width	O
was	O
used	O
for	O
the	O
data	O
normal	O
##ized	O
to	O
total	O
spectral	O
area	O
.	O

Ph	O
##os	O
##ph	O
##ory	O
##lation	O
of	O
the	O
in	B
##os	I
##ito	I
##l	I
ring	O
3	O
′	O
-	O
OH	O
group	O
in	O
in	B
##os	I
##ito	I
##l	I
p	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
is	O
carried	O
out	O
by	O
the	O
enzyme	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##lino	I
##si	I
##to	I
##l	I
3	O
-	O
kinase	O
(	O
P	O
##I	O
##3	O
##K	O
)	O
.	O

In	O
addition	O
to	O
their	O
main	O
function	O
as	O
a	O
membrane	O
constituent	O
,	O
PC	O
##s	O
have	O
a	O
role	O
in	O
signaling	O
through	O
the	O
generation	O
of	O
LP	O
##Cs	O
(	O
by	O
p	O
##hos	O
##ph	O
##oli	O
##pas	O
##e	O
A	O
_	O
2	O
enzymes	O
)	O
,	O
SM	O
##s	O
(	O
by	O
SM	O
s	O
##ynth	O
##ase	O
)	O
,	O
p	B
##hos	I
##pha	I
##ti	I
##dic	I
acid	I
(	O
PA	O
;	O
by	O
p	O
##hos	O
##ph	O
##oli	O
##pas	O
##e	O
D	O
enzymes	O
)	O
and	O
/	O
or	O
di	B
##acy	I
##l	I
##gly	I
##cer	I
##ols	I
(	O
D	O
##AG	O
;	O
by	O
p	O
##hos	O
##ph	O
##oli	O
##pas	O
##e	O
C	O
enzymes	O
)	O
.	O

Ser	O
##um	O
insulin	O
concentration	O
was	O
measured	O
by	O
a	O
double	O
anti	O
##body	O
radio	O
##im	O
##mu	O
##no	O
##ass	O
##ay	O
(	O
Ph	O
##ades	O
##ep	O
##h	O
In	O
##sul	O
##in	O
R	O
##IA	O
kit	O
,	O
Ph	O
##arma	O
##cia	O
&	O
Up	O
##jo	O
##hn	O
,	O
Up	O
##ps	O
##ala	O
,	O
Sweden	O
)	O
,	O
flu	B
##oro	I
##im	I
##mu	I
##no	I
##metric	I
ass	O
##ay	O
(	O
Auto	O
##DE	O
##LF	O
##IA	O
,	O
Per	O
##kin	O
##E	O
##lmer	O
Inc	O
,	O
Tu	O
##rk	O
##u	O
,	O
Finland	O
)	O
or	O
auto	O
##mat	O
##ized	O
electro	O
-	O
ch	O
##em	O
##il	O
##umi	O
##nes	O
##cence	O
im	O
##mu	O
##no	O
##ass	O
##ay	O
(	O
Co	O
##bas	O
800	O
##0	O
,	O
Roche	O
Di	O
##ag	O
##nos	O
##tics	O
GmbH	O
,	O
Mann	O
##heim	O
,	O
Germany	O
)	O
.	O

The	O
samples	O
obtained	O
from	O
the	O
stock	O
solution	O
stored	O
at	O
4	O
°C	O
for	O
over	O
2	O
month	O
displayed	O
an	O
average	O
of	O
97	O
.	O
5	O
%	O
of	O
pro	B
##line	I
compare	O
to	O
the	O
samples	O
obtained	O
from	O
the	O
freshly	O
prepared	O
stock	O
solution	O
,	O
which	O
suggested	O
that	O
the	O
pro	B
##line	I
stock	O
solution	O
was	O
stable	O
at	O
4	O
°C	O
at	O
least	O
for	O
2	O
month	O
.	O

Additionally	O
,	O
as	O
observed	O
earlier	O
we	O
found	O
increased	O
levels	O
of	O
sa	O
##liva	O
##ry	O
E	B
##stra	I
##dio	I
##l	I
in	O
HIV	O
/	O
AIDS	O
patients	O
,	O
which	O
increased	O
further	O
on	O
AR	O
##T	O
administration	O
.	O

Despite	O
this	O
cave	O
##at	O
,	O
considerable	O
progress	O
has	O
been	O
achieved	O
in	O
the	O
direct	O
q	O
##uant	O
##ification	O
of	O
my	B
##cot	I
##ox	I
##in	I
con	O
##ju	O
##gate	O
##s	O
without	O
the	O
need	O
for	O
en	O
##zy	O
##matic	O
h	O
##ydro	O
##lysis	O
.	O

The	O
sample	O
was	O
then	O
cent	O
##ri	O
##fu	O
##ged	O
at	O
9	O
,	O
000	O
g	O
for	O
15	O
min	O
at	O
4	O
##°	O
##C	O
,	O
after	O
which	O
400	O
##μ	O
##L	O
of	O
the	O
super	O
##nat	O
##ant	O
solution	O
was	O
transferred	O
into	O
a	O
new	O
micro	O
cent	O
##ri	O
##fu	O
##ge	O
tube	O
and	O
e	O
##va	O
##porated	O
to	O
dry	O
##ness	O
using	O
a	O
steady	O
stream	O
of	O
dried	O
and	O
filtered	O
nitrogen	B
gas	I
at	O
room	O
temperature	O
.	O

In	O
the	O
Discovery	O
group	O
,	O
do	B
##cos	I
##ah	I
##ex	I
##aen	I
##oat	I
##e	I
(	I
D	I
##HA	I
##22	I
:	I
6	I
##n	I
##3	I
)	I
lost	O
significance	O
(	O
p	O
=	O
0	O
.	O
16	O
)	O
,	O
dim	O
##hom	O
##olin	O
##ole	O
##ate	O
20	O
:	O
2	O
##n	O
##6	O
,	O
10	O
##non	O
##ade	O
##ce	O
##no	O
##ate	O
19	O
:	O
1	O
##n	O
##9	O
,	O
and	O
e	B
##ico	I
##sen	I
##oat	I
##e	I
20	I
:	I
1	I
became	O
trends	O
(	O
p	O
<	O
0	O
.	O
05	O
##5	O
)	O
,	O
and	O
the	O
other	O
meta	O
##bol	O
##ites	O
remained	O
significant	O
.	O

A	O
##bs	O
##or	O
##ban	O
##ce	O
was	O
ass	O
##ay	O
##ed	O
at	O
550	O
nm	O
and	O
compared	O
with	O
a	O
standard	O
curve	O
obtained	O
using	O
sodium	B
ni	I
##tri	I
##te	I
.	O

Lac	O
la	B
##ct	I
##ate	I
,	O
Mal	O
ma	B
##late	I
,	O
G	B
##S	I
##H	I
reduced	I
g	I
##lut	I
##ath	I
##ione	I
,	O
G	O
##SS	O
##G	O
o	B
##xi	I
##dized	I
g	I
##lut	I
##ath	I
##ione	I
,	O
GA	O
##B	O
γ	B
-	I
amino	I
##but	I
##yra	I
##te	I
.	O

Overall	O
,	O
we	O
observed	O
that	O
p	O
##eptide	O
##s	O
(	O
78	O
%	O
,	O
P	O
=	O
2	O
.	O
29	O
×	O
10	O
_	O
−	O
##19	O
;	O
F	O
##DR	O
=	O
1	O
.	O
84	O
×	O
10	O
_	O
−	O
##18	O
)	O
and	O
car	O
##bo	O
##hy	O
##dra	O
##tes	O
(	O
47	O
%	O
,	O
P	O
=	O
4	O
.	O
09	O
×	O
10	O
_	O
−	O
##3	O
;	O
F	O
##DR	O
=	O
1	O
.	O
09	O
×	O
10	O
_	O
−	O
##2	O
)	O
probably	O
reacted	O
with	O
formal	B
##de	I
##hy	I
##de	I
.	O

Mini	O
##mal	O
differences	O
in	O
response	O
and	O
re	O
##p	O
##rod	O
##uc	O
##ibility	O
were	O
noted	O
between	O
1000	O
μ	O
##L	O
,	O
500	O
μ	O
##L	O
,	O
and	O
250	O
μ	O
##L	O
of	O
extraction	O
solvent	O
;	O
therefore	O
,	O
a	O
volume	O
of	O
250	O
μ	O
##L	O
of	O
met	B
##han	I
##ol	I
was	O
selected	O
.	O

N	O
##PD	O
##R	O
is	O
characterized	O
by	O
re	B
##tina	I
##l	I
micro	O
##ane	O
##ury	O
##sm	O
##s	O
and	O
hem	O
##or	O
##r	O
##hage	O
##s	O
and	O
may	O
progress	O
to	O
PD	O
##R	O
,	O
which	O
is	O
defined	O
by	O
re	B
##tina	I
##l	I
neo	O
##vas	O
##cular	O
##ization	O
with	O
the	O
potential	O
for	O
severe	O
vision	O
loss	O
.	O

Lin	B
##ole	I
##ic	I
acid	I
increased	O
LP	O
##L	O
and	O
MC	O
##P	O
-	O
1	O
m	O
##RNA	O
and	O
protein	O
,	O
and	O
this	O
effect	O
was	O
prevented	O
by	O
pre	O
##tre	O
##at	O
##ment	O
with	O
2	O
.	O
5	O
μ	O
##g	O
/	O
m	O
##l	O
part	O
##hen	O
##oli	O
##de	O
,	O
an	O
N	O
##F	O
-	O
κ	O
##B	O
inhibitor	O
(	O
,	O
)	O
(	O
A	O
–	O
D	O
)	O
(	O
,	O
)	O
.	O

Whereas	O
the	O
un	O
##fa	O
##vor	O
##able	O
factors	O
for	O
c	O
##ir	O
##r	O
##hos	O
##is	O
are	O
largely	O
long	O
-	O
chain	O
car	B
##ni	I
##tine	I
##s	I
.	O

In	O
contrast	O
to	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
T	B
##G	I
in	O
all	O
HD	O
##L	O
particles	O
other	O
than	O
large	O
HD	O
##L	O
were	O
positively	O
associated	O
with	O
risk	O
of	O
MI	O
.	O

G	O
##ly	O
##cine	O
de	O
##car	O
##box	O
##yla	O
##se	O
(	O
G	O
##LD	O
##C	O
)	O
is	O
crucial	O
for	O
t	O
##umour	O
in	O
##iti	O
##ating	O
cells	O
in	O
N	O
##SC	O
##LC	O
,	O
and	O
was	O
associated	O
with	O
p	B
##yr	I
##im	I
##id	I
##ine	I
metabolism	O
to	O
support	O
cancer	O
cell	O
proliferation	O
.	O

In	O
the	O
fully	O
adjusted	O
model	O
,	O
the	O
long	O
‐	O
chain	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
(	O
L	O
##CA	O
##C	O
)	O
factor	O
remained	O
statistical	O
##ly	O
significant	O
(	O
P	O
<	O
0	O
.	O
000	O
##1	O
)	O
at	O
the	O
Bon	O
##fer	O
##ron	O
##i	O
‐	O
corrected	O
significance	O
threshold	O
.	O

While	O
plot	O
between	O
healthy	O
and	O
BT	O
##T	O
showed	O
different	O
set	O
of	O
meta	O
##bol	O
##ites	O
that	O
include	O
amino	O
acid	O
,	O
glucose	S
and	O
g	B
##ly	I
##cer	I
##ol	I
only	O
.	O

Among	O
the	O
34	O
meta	O
##bol	O
##ites	O
associated	O
with	O
BC	O
##a	O
,	O
the	O
levels	O
of	O
bi	B
##li	I
##ru	I
##bin	I
and	O
re	B
##tina	I
##l	I
recovered	O
in	O
BC	O
##a	O
tissues	O
treated	O
with	O
g	O
##em	O
##ci	O
##ta	O
##bine	O
.	O

The	O
total	O
ion	O
ch	O
##roma	O
##to	O
##gram	O
##s	O
(	O
ii	O
##i	O
)	O
of	O
the	O
ion	O
##ic	O
transition	O
32	O
##9	O
>	O
153	O
of	O
PC	O
##A	O
##O	O
##G	O
(	O
100	O
ng	O
/	O
m	O
##L	O
)	O
in	O
1	O
%	O
form	B
##ic	I
acid	I
a	O
##que	O
##ous	O
solution	O
,	O
the	O
5	O
-	O
min	O
sa	O
##liva	O
sample	O
(	O
i	O
##v	O
)	O
,	O
and	O
the	O
30	O
min	O
sa	O
##liva	O
sample	O
(	O
v	O
)	O
from	O
a	O
healthy	O
volunteer	O
after	O
r	O
##ins	O
##e	O
with	O
r	O
##ins	O
##e	O
formulation	O
III	O
.	O

To	O
investigate	O
whether	O
RC	O
##E	O
and	O
/	O
or	O
its	O
is	B
##of	I
##lav	I
##ones	I
m	O
##od	O
##ulate	O
est	B
##rogen	I
metabolism	O
in	O
ER	O
+	O
breast	O
cancer	O
cells	O
,	O
the	O
same	O
experiments	O
performed	O
in	O
MC	O
##F	O
-	O
10	O
##A	O
cells	O
were	O
carried	O
out	O
in	O
MC	O
##F	O
-	O
7	O
cells	O
.	O

In	O
v	O
##it	O
##ro	O
studies	O
suggest	O
that	O
ta	B
##mo	I
##xi	I
##fen	I
activate	O
##s	O
nuclear	O
receptors	O
such	O
as	O
the	O
human	O
pre	O
##gna	O
##ne	O
X	O
receptor	O
(	O
P	O
##X	O
##R	O
)	O
and	O
induce	O
##s	O
C	O
##YP	O
##3	O
##A	O
##4	O
in	O
primary	O
human	O
he	O
##pa	O
##to	O
##cy	O
##tes	O
[	O
,	O
]	O
.	O

The	O
impact	O
of	O
pre	O
-	O
analytical	O
variations	O
on	O
(	O
a	O
)	O
ta	B
##uri	I
##ne	I
and	O
(	O
b	O
)	O
O	B
-	I
p	I
##hos	I
##ph	I
##oe	I
##than	I
##ola	I
##mine	I
concentrations	O
in	O
E	O
##D	O
##TA	O
blood	O
and	O
plasma	O
,	O
represented	O
by	O
box	O
##p	O
##lot	O
##s	O
;	O
In	O
(	O
a	O
,	O
b	O
)	O
,	O
stars	O
indicate	O
significant	O
differences	O
compared	O
with	O
the	O
control	O
group	O
,	O
calculated	O
by	O
using	O
AN	O
##O	O
##VA	O
with	O
a	O
significance	O
level	O
of	O
p	O
<	O
0	O
.	O
05	O
;	O
(	O
c	O
)	O
Legend	O
for	O
the	O
box	O
##p	O
##lot	O
##s	O
in	O
(	O
a	O
,	O
b	O
)	O
.	O

The	O
variations	O
of	O
three	O
meta	O
##bol	O
##ites	O
(	B
l	B
##ys	I
##o	I
##PC	I
(	I
16	I
:	I
1	I
)	I
,	O
o	B
##ct	I
##ano	I
##yl	I
##car	I
##ni	I
##tine	I
and	O
de	B
##cano	I
##yl	I
##car	I
##ni	I
##tine	I
)	O
before	O
,	O
during	O
,	O
and	O
after	O
CR	O
##T	O
treatment	O
are	O
suggest	O
##ive	O
of	O
partial	O
normal	O
##ization	O
in	O
β	O
-	O
oxidation	O
,	O
g	O
##ly	O
##co	O
##lysis	O
and	O
energy	O
metabolism	O
in	O
E	O
##SC	O
##C	O
patients	O
as	O
a	O
result	O
of	O
treatment	O
.	O

Ex	O
##pan	O
##ding	O
on	O
the	O
differences	O
observed	O
for	O
the	O
graded	O
classes	O
,	O
illustrate	O
##s	O
the	O
development	O
of	O
urine	O
c	B
##it	I
##rate	I
concentration	O
in	O
the	O
three	O
classes	O
during	O
and	O
after	O
pregnancy	O
,	O
presenting	O
the	O
class	O
-	O
wise	O
mean	O
concentration	O
relative	O
to	O
c	B
##rea	I
##tin	I
##ine	I
concentration	O
.	O

Ad	O
##v	O
Pro	B
##sta	I
##g	I
##land	I
##in	I
T	I
##hr	I
##omb	I
##ox	I
##ane	I
Le	O
##uk	O
##ot	O
Re	O
##s	O
.	O

In	O
con	O
##cor	O
##dance	O
with	O
serum	O
ch	B
##olin	I
##e	I
levels	O
,	O
the	O
present	O
study	O
also	O
shows	O
marked	O
reduction	O
in	O
serum	O
ace	B
##tate	I
levels	O
in	O
L	O
##N	O
compared	O
to	O
SL	O
##E	O
patients	O
and	O
HC	O
suggesting	O
acute	O
##ly	O
per	O
##tur	O
##bed	O
bio	O
##sy	O
##nt	O
##hesis	O
of	O
ace	B
##ty	I
##l	I
-	I
ch	I
##olin	I
##e	I
in	O
L	O
##N	O
.	O

Extra	O
##cted	O
ion	O
ch	O
##ron	O
##ogram	O
of	O
glucose	S
and	O
c	B
##it	I
##rate	I
over	O
a	O
line	O
scan	O
of	O
a	O
typical	O
pro	O
##state	O
tissue	O
specimen	O
that	O
contains	O
both	O
ben	O
##ign	O
(	O
black	O
outline	O
)	O
and	O
cancer	O
(	O
red	O
outline	O
)	O
areas	O
.	O

(	O
B	O
)	O
Representative	O
western	O
b	O
##lot	O
show	O
the	O
levels	O
of	O
candidates	O
(	O
AR	O
##ID	O
##1	O
##A	O
,	O
HD	O
##AC	O
##4	O
,	O
P	O
##K	O
##D	O
##1	O
,	O
β	B
-	I
CA	I
##TE	I
##NI	I
##N	I
,	O
SM	O
##AR	O
##CA	O
##2	O
,	O
and	O
P	O
##BR	O
##M	O
##1	O
)	O
and	O
β	B
-	I
act	I
##in	I
.	O

Some	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##och	I
##olin	I
##es	I
and	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
were	O
identified	O
in	O
the	O
absence	O
of	O
available	O
standards	O
.	O

Co	B
##rt	I
##is	I
##ol	I
,	O
the	O
HP	O
##A	O
axis	O
activity	O
marker	O
,	O
was	O
within	O
the	O
wide	O
normal	O
range	O
in	O
all	O
patients	O
and	O
did	O
not	O
show	O
significant	O
associations	O
with	O
any	O
of	O
the	O
q	O
##uant	O
##ified	O
meta	O
##bol	O
##ites	O
.	O

Per	O
##tur	O
##bation	O
##s	O
of	O
p	O
##hos	O
##ph	O
##oli	O
##pas	O
##es	O
,	O
pu	B
##rine	I
n	O
##uc	O
##leo	O
##tide	O
degradation	O
and	O
L	O
##X	O
##R	O
/	O
R	O
##X	O
##R	O
activation	O
are	O
found	O
to	O
be	O
partially	O
responsible	O
for	O
this	O
development	O
.	O

Ethan	O
##ol	O
—	O
et	O
##hyl	O
ace	O
##tate	O
mixture	O
(	O
4	O
:	O
1	O
,	O
v	O
/	O
v	O
)	O
and	O
met	B
##hyl	I
-	I
te	I
##rt	I
-	I
but	I
##yl	I
-	I
et	I
##her	I
were	O
investigated	O
as	O
organic	O
solvent	O
##s	O
for	O
liquid	O
-	O
liquid	O
extraction	O
.	O

Only	O
o	B
##le	I
##ic	I
acid	I
was	O
common	O
on	O
all	O
platforms	O
.	O

There	O
were	O
no	O
differences	O
in	O
the	O
median	O
levels	O
of	O
E	B
_	I
1	I
-	I
su	I
##lf	I
##ate	I
,	O
2	O
-	O
OH	O
##E	O
_	O
1	O
(	O
E	O
_	O
2	O
)	O
and	O
4	O
-	O
OH	O
##E	O
_	O
1	O
(	O
E	O
_	O
2	O
)	O
between	O
cases	O
and	O
controls	O
,	O
whereas	O
16	B
##α	I
-	I
OH	I
##E	I
_	I
1	I
(	O
E	O
_	O
2	O
)	O
and	O
the	O
2	O
-	O
OH	O
##E	O
_	O
1	O
(	O
E	O
_	O
2	O
)	O
-	O
con	O
##ju	O
##gate	O
##s	O
were	O
found	O
to	O
be	O
higher	O
in	O
the	O
controls	O
.	O

The	O
level	O
of	O
chemical	O
modification	O
of	O
SA	O
by	O
N	B
-	I
ace	I
##to	I
##xy	I
-	I
Ph	I
##IP	I
was	O
estimated	O
at	O
~	O
170	O
pm	O
##ol	O

Dec	O
##reased	O
meta	O
##bol	O
##ite	O
levels	O
of	O
glucose	S
,	O
g	B
##ly	I
##cine	I
,	O
c	B
##rea	I
##tin	I
##ine	I
and	O
ta	B
##uri	I
##ne	I
,	O
as	O
well	O
as	O
increased	O
c	B
##it	I
##rate	I
and	O
g	B
##lut	I
##ama	I
##te	I
in	O
EC	O
tissues	O
,	O
were	O
also	O
detect	O
##able	O
in	O
the	O
urine	O
of	O
EC	O
patients	O
.	O

In	O
the	O
de	O
##act	O
##ivation	O
pathway	O
,	O
which	O
operates	O
in	O
parallel	O
,	O
the	O
cat	B
##ech	I
##ol	I
derivatives	O
are	O
met	O
##hyl	O
##ated	O
to	O
form	O
met	B
##ho	I
##xy	I
cat	I
##ech	I
##ol	I
est	O
##rogen	O
##s	O
;	O
in	O
addition	O
,	O
the	O
q	B
##uin	I
##ones	I
are	O
reduced	O
by	O
q	B
##uin	I
##one	I
red	O
##uc	O
##tase	O
,	O
as	O
well	O
as	O
are	O
con	O
##ju	O
##gated	O
with	O
G	B
##S	I
##H	I
,	O
and	O
,	O
thus	O
,	O
are	O
rendered	O
harmless	O
.	O

In	O
contrast	O
,	O
they	O
had	O
increased	O
plasma	O
concentrations	O
in	O
as	B
##par	I
##tate	I
(	O
P	O
=	O
0	O
.	O
01	O
)	O
,	O
c	B
##it	I
##ru	I
##llin	I
##e	I
(	O
P	O
=	O
0	O
.	O
01	O
)	O
,	O
and	O
pro	B
##line	I
(	O
P	O
=	O
0	O
.	O
04	O
)	O
.	O

4	B
-	I
[	I
bi	I
##s	I
[	I
2	I
–	I
[	I
(	I
met	I
##hyl	I
##sul	I
##fo	I
##ny	I
##l	I
)	I
-	I
o	I
##xy	I
]	I
et	I
##hyl	I
]	I
amino	I
]	I
-	I
2	I
-	I
met	I
##hyl	I
-	I
ben	I
##zal	I
##de	I
##hy	I
##de	I
(	O
B	O
##EN	O
,	O
N	O
##SC	O
281	O
##6	O
##12	O
)	O
,	O
4	B
-	I
[	I
bi	I
##s	I
[	I
2	I
–	I
[	I
(	I
met	I
##hyl	I
##sul	I
##fo	I
##ny	I
##l	I
)	I
-	I
o	I
##xy	I
]	I
et	I
##hyl	I
]	I
amino	I
]	I
-	I
2	I
-	I
met	I
##hyl	I
-	I
ben	I
##zoic	I
acid	I
(	O
BA	O
,	O
N	O
##SC	O
73	O
##3	O
60	O
##9	O
)	O
,	O
4	B
-	I
[	I
bi	I
##s	I
[	I
2	I
–	I
ch	I
##lor	I
##o	I
-	I
et	I
##hyl	I
]	I
amino	I
]	I
-	I
2	I
-	I
met	I
##hyl	I
-	I
ben	I
##zal	I
##de	I
##hy	I
##de	I
(	O
B	O
##EN	O
-	O
C	O
##l	O
_	O
2	O
)	O
,	O
4	B
-	I
[	I
bi	I
##s	I
[	I
2	I
–	I
ch	I
##lor	I
##o	I
-	I
et	I
##hyl	I
]	I
amino	I
]	I
-	I
2	I
-	I
met	I
##hyl	I
-	I
ben	I
##zoic	I
acid	I
(	O
BA	O
-	O
C	O
##l	O
_	O
2	O
)	O
,	O
4	B
-	I
[	I
bi	I
##s	I
[	I
2	I
–	I
[	I
(	I
met	I
##hyl	I
##sul	I
##fo	I
##ny	I
##l	I
)	I
-	I
o	I
##xy	I
]	I
et	I
##hyl	I
]	I
amino	I
]	I
-	I
ben	I
##zal	I
##de	I
##hy	I
##de	I
(	I
des	I
##met	I
##hyl	I
-	I
B	I
##EN	I
)	I
,	O
and	O
4	B
-	I
[	I
bi	I
##s	I
[	I
2	I
–	I
ch	I
##lor	I
##o	I
-	I
et	I
##hyl	I
]	I
amino	I
]	I
-	I
ben	I
##zal	I
##de	I
##hy	I
##de	I
(	I
des	I
##met	I
##hyl	I
-	I
B	I
##EN	I
-	I
C	I
##l	I
_	I
2	I
)	I
were	O
obtained	O
from	O
the	O
Development	O
##al	O
The	O
##rap	O
##eu	O

After	O
that	O
period	O
,	O
sample	O
was	O
washed	O
with	O
cent	O
##ri	O
##fu	O
##gation	O
and	O
re	O
##sus	O
##pen	O
##ded	O
in	O
50	O
μ	O
##l	O
of	O
hybrid	O
##ization	O
buffer	O
[	O
0	O
.	O
9	O
M	O
Na	O
##C	O
##l	O
,	O
20	O
m	O
##M	O
Tri	O
##s	O
–	O
HC	O
##l	O
(	O
pH	O
7	O
.	O
5	O
)	O
,	O
0	O
.	O
1	O
%	O
[	O
w	O
##t	O
/	O
vol	O
]	O
sodium	B
do	I
##de	I
##cy	I
##l	I
su	I
##l	I
##phate	I
(	O
SD	O
##S	O
)	O
]	O
with	O
5	O
μ	O
##l	O
of	O
50	O
ng	O
/	O
μ	O
##l	O
fluorescent	O
##ly	O
Cy	O
##5	O
-	O
labelled	O
o	O
##li	O
##gon	O
##uc	O
##leo	O
##tide	O
probe	O
and	O
in	O
##cu	O
##bate	O
##d	O
at	O
the	O
appropriate	O
hybrid	O
##ization	O
temperature	O
(	O
Table	O
)	O
.	O

In	O
contrast	O
,	O
we	O
found	O
that	O
plasma	O
al	B
##ani	I
##ne	I
was	O
similar	O
in	O
insulin	O
deprived	O
compared	O
to	O
treated	O
T	O
##1	O
##D	O
.	O
We	O
also	O
found	O
modest	O
,	O
non	O
-	O
significant	O
increases	O
in	O
plasma	O
la	B
##ct	I
##ate	I
with	O
insulin	O
de	O
##p	O
##ri	O
##vation	O
.	O

The	O
MS	O
/	O
MS	O
(	O
m	O
/	O
z	O
79	O
##2	O
.	O
540	O
##8	O
)	O
confirmed	O
that	O
P	B
##E	I
40	I
:	I
5	I
is	O
present	O
and	O
predominantly	O
in	O
the	O
form	O
of	O
the	O
molecular	O
species	O
P	B
##E	I
18	I
:	I
0	I
/	I
22	I
:	I
5	I
,	O
confirmed	O
by	O
the	O
detected	O
a	O
##cy	O
##l	O
an	O
##ions	O
(	O
data	O
not	O
shown	O
)	O
.	O

R	B
=	I
Z	I
##−	I
##C	I
(	I
C	I
##−	I
##1	I
##Z	I
)	I
where	I
##R	I
=	I
[	I
[UNK]	B
]	I
,	I
Z	I
=	I
[	I
X	I
##j	I
##Y	I
]	I
,	I
and	I
##C	I
##i	I
=	I
[	I
1	I
##M	I
##i	I
]	I

The	O
reactive	O
meta	O
##bol	O
##ites	O
of	O
nap	B
##ht	I
##hale	I
##ne	I
are	O
similar	O
to	O
the	O
meta	O
##bol	O
##ites	O
of	O
ben	B
##zen	I
##e	I
.	O

As	O
mentioned	O
above	O
,	O
l	B
##ino	I
##len	I
##ic	I
acid	I
distinctly	O
separated	O
p	O
##CR	O
from	O
SD	O
with	O
an	O
AU	O
##RO	O
##C	O
=	O
1	O
.	O

This	O
was	O
in	O
agreement	O
with	O
the	O
fact	O
that	O
ace	O
##tate	O
—	O
a	O
short	O
chain	O
fatty	O
acid	O
—	O
which	O
is	O
the	O
precursor	O
molecule	O
for	O
end	O
##ogen	O
##ous	O
ch	B
##ole	I
##ster	I
##ol	I
production	O
,	O
has	O
been	O
reported	O
to	O
be	O
elevated	O
in	O
CR	O
##C	O
.	O

The	O
results	O
for	O
individual	O
u	O
##rina	O
##ry	O
est	O
##rogen	O
##s	O
,	O
metabolic	O
pathways	O
,	O
and	O
the	O
2	B
/	I
16	I
##α	I
-	I
OH	I
ratio	O
remained	O
non	O
-	O
significant	O
in	O
these	O
sensitivity	O
analyses	O
.	O

In	O
total	O
,	O
six	O
meta	O
##bol	O
##ites	O
(	B
se	B
##rine	I
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
gal	B
##act	I
##ose	I
,	O
palm	B
##itic	I
acid	I
,	O
l	B
##ino	I
##le	I
##ic	I
acid	I
,	O
and	O
a	O
##rac	O
##hi	O
##don	O
##ic	O
acid	O
)	O
were	O
identified	O
.	O

O	B
##xy	I
##ster	I
##ols	I
play	O
a	O
role	O
in	O
maintaining	O
ch	B
##ole	I
##ster	I
##ol	I
home	O
##ost	O
##asis	O
acting	O
as	O
l	O
##igan	O
##ds	O
for	O
SR	O
##E	O
##B	O
##P	O
##2	O
and	O
down	O
##re	O
##gu	O
##lating	O
end	O
##ogen	O
##ous	O
ch	B
##ole	I
##ster	I
##ol	I
synthesis	O
via	O
decreased	O
expression	O
of	O
HM	B
##G	I
Co	O
##A	O
red	O
##uc	O
##tase	O
in	O
a	O
similar	O
way	O
to	O
the	O
mechanism	O
of	O
s	B
##tat	I
##in	I
actions	O
.	O

Red	O
##uce	O
##d	O
his	B
##ti	I
##dine	I
can	O
cause	O
recession	O
of	O
anti	O
-	O
o	O
##xi	O
##dant	O
and	O
anti	O
-	O
inflammatory	O
processes	O
,	O
both	O
of	O
which	O
contribute	O
to	O
the	O
path	O
##ogen	O
##esis	O
and	O
development	O
of	O
CO	O
##PD	O
or	O
em	O
##phy	O
##se	O
##ma	O
.	O

man	O
##son	O
##i	O
–	O
mouse	O
model	O
based	O
on	O
_	O
1	O
H	O
N	O
##MR	O
s	O
##pect	O
##ros	O
##copy	O
,	O
reported	O
that	O
the	O
la	B
##ct	I
##ate	I
concentration	O
varied	O
between	O
animals	O
but	O
was	O
not	O
found	O
to	O
be	O
significant	O
in	O
disc	O
##rim	O
##inating	O
between	O
infected	O
and	O
control	O
mice	O
.	O

In	O
our	O
E	O
##G	O
group	O
serum	O
g	B
##ly	I
##cine	I
is	O
increased	O
and	O
the	O
p	O
value	O
(	O
p	O
=	O
0	O
.	O
03	O
##9	O
)	O
is	O
significant	O
in	O
the	O
Mann	O
-	O
Whitney	O
U	O
test	O
.	O

With	O
the	O
lower	O
level	O
in	O
L	O
##N	O
##M	O
-	O
positive	O
patients	O
,	O
beta	B
##ine	I
may	O
be	O
a	O
potential	O
diagnostic	O
bio	O
##mark	O
##er	O
distinguishing	O
L	O
##N	O
##M	O
-	O
positive	O
G	O
##C	O
patients	O
from	O
L	O
##N	O
##M	O
-	O
negative	O
ones	O
.	O

Re	O
##age	O
##nts	O
were	O
as	O
follows	O
:	O
De	O
##ion	O
##ized	O
Water	O
,	O
Nan	O
##op	O
##ure	O
(	O
Fisher	O
Scientific	O
)	O
;	O
met	B
##han	I
##ol	I
advanced	O
gradient	O
grade	O
(	O
Fisher	O
Scientific	O
)	O
;	O
form	B
##ic	I
acid	I
(	O
GP	O
##R	O
,	O
Re	O
##ct	O
##ap	O
##ur	O
)	O
;	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
(	O
AC	O
##N	O
)	O
(	O
Fisher	O
Scientific	O
)	O
;	O
en	O
##ala	O
##p	O
##ril	O
and	O
sit	B
##ag	I
##lip	I
##tin	I
raw	O
material	O
(	O
were	O
a	O
kind	O
gift	O
from	O
Dar	O
al	O
Da	O
##wa	O
Ph	O
##arma	O
,	O
Jordan	O
)	O
.	O

A	O
trend	O
towards	O
reduced	O
o	O
##xi	O
##dized	O
L	B
##D	I
##L	I
ch	I
##ole	I
##ster	I
##ol	I
following	O
O	O
##EP	O
ing	O
##est	O
##ion	O
was	O
observed	O
.	O

The	O
proteins	O
from	O
either	O
125	O
μ	O
##L	O
(	O
standard	O
pro	O
##fi	O
##ling	O
preparation	O
)	O
or	O
2	O
.	O
5	O
m	O
##L	O
(	O
concentrated	O
method	O
)	O
of	O
P	O
##O	O
##OL	O
were	O
pre	O
##ci	O
##pit	O
##ated	O
with	O
500	O
μ	O
##L	O
and	O
10	O
m	O
##L	O
,	O
respectively	O
,	O
of	O
cold	O
(	O
−	O
##20	O
##°	O
C	O
)	O
ace	O
##ton	O
##it	O
##ril	O
##e	O
/	O
0	O
.	O
4	O
%	O
glacial	B
ace	I
##tic	I
acid	I
,	O
while	O
on	O
ice	O
.	O

Additionally	O
,	O
PC	O
species	O
containing	O
palm	B
##itic	I
acid	I
,	O
di	B
##acy	I
##l	I
##gly	I
##cer	I
##ol	I
,	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
,	O
and	O
c	B
##era	I
##mi	I
##de	I
were	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
MI	O
,	O
whereas	O
P	O
##E	O
-	O
plasma	O
##log	O
##en	O
and	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##lino	I
##si	I
##to	I
##l	I
species	O
were	O
associated	O
with	O
a	O
decreased	O
risk	O
.	O

The	O
re	O
##nal	O
clearance	O
of	O
c	B
##it	I
##rate	I
is	O
essential	O
for	O
the	O
removal	O
of	O
c	B
##it	I
##rate	I
from	O
plasma	O
and	O
the	O
body	O
and	O
thus	O
might	O
decline	O
in	O
u	O
##rol	O
##ogical	O
patients	O
.	O

Fat	O
##ty	O
acids	O
con	O
##ju	O
##gated	O
with	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
are	O
subjected	O
to	O
beta	O
-	O
oxidation	O
in	O
the	O
he	O
##pa	O
##tic	O
mit	O
##och	O
##ond	O
##ria	O
[	O
,	O
]	O
.	O

Additional	O
plasma	O
samples	O
were	O
collected	O
from	O
6	O
healthy	O
controls	O
and	O
6	O
patients	O
with	O
A	B
##F	I
to	O
measure	O
the	O
m	O
##RNA	O
c	O
##yt	O
##oki	O
##ne	O
.	O

Ser	O
##um	O
p	B
##yr	I
##u	I
##vate	I
,	O
which	O
is	O
formed	O
following	O
g	O
##ly	O
##co	O
##lysis	O
,	O
was	O
significantly	O
elevated	O
at	O
6	O
months	O
post	O
‐	O
R	O
##Y	O
##GB	O
compared	O
with	O
pre	O
‐	O
surgery	O
in	O
the	O
present	O
study	O
,	O
and	O
similar	O
findings	O
were	O
observed	O
in	O
a	O
rat	O
model	O
of	O
R	O
##Y	O
##GB	O
.	O
42	O
,	O
51	O
El	O
##eva	O
##tion	O
of	O
p	B
##yr	I
##u	I
##vate	I
suggests	O
increased	O
glucose	S
u	O
##til	O
##ization	O
and	O
g	O
##ly	O
##co	O
##lysis	O
post	O
‐	O
R	O
##Y	O
##GB	O
.	O
42	O

Nine	O
samples	O
from	O
one	O
patient	O
included	O
extreme	O
concentrations	O
of	O
et	B
##hyl	I
##ene	I
g	I
##ly	I
##co	I
##l	I
suggesting	O
into	O
##xi	O
##cation	O
from	O
local	O
re	O
##med	O
##ies	O
or	O
counter	O
##feit	O
medications	O
.	O

Ethan	B
##ol	I
diffusion	O
through	O
air	O
during	O
sampling	O
and	O
preparation	O
stages	O
appeared	O
the	O
only	O
logical	O
explanation	O
.	O

Once	O
corrected	O
for	O
surgery	O
(	O
and	O
T	O
##NF	O
-	O
α	O
inhibitor	O
treatment	O
)	O
the	O
higher	O
abundance	O
of	O
BC	O
##AA	O
,	O
l	B
##ys	I
##ine	I
,	O
al	B
##ani	I
##ne	I
,	O
and	O
ta	B
##uri	I
##ne	I
remained	O
evident	O
only	O
for	O
active	O
UC	O
compare	O
to	O
inactive	O
UC	O
and	O
control	O
subjects	O
,	O
respectively	O
(	O
Table	O
B	O
)	O
.	O

By	O
high	O
-	O
speed	O
liquid	O
ch	O
##roma	O
##tography	O
/	O
tandem	O
mass	O
s	O
##pect	O
##rome	O
##try	O
we	O
evaluated	O
the	O
plasma	O
levels	O
of	O
24	B
##S	I
-	I
OH	I
-	I
Cho	I
##l	I
in	O
a	O
sample	O
of	O
160	O
older	O
individuals	O
:	O
60	O
patients	O
with	O
L	O
##OA	O
##D	O
,	O
35	O
patients	O
with	O
V	O
##D	O
,	O
25	O
subjects	O
affected	O
by	O
cognitive	O
imp	O
##air	O
##ment	O
no	O
-	O
dem	O
##ent	O
##ia	O
(	O
C	O
##IN	O
##D	O
)	O
,	O
and	O
40	O
(	O
144	O
for	O
genetics	O
study	O
)	O
cognitive	O
##ly	O
normal	O
Control	O
##s	O
.	O

P	B
##se	I
##udo	I
##uri	I
##dine	I
belongs	O
to	O
the	O
group	O
of	O
modified	O
n	O
##uc	O
##leo	O
##side	O
##s	O
that	O
are	O
regarded	O
as	O
indicators	O
of	O
whole	O
-	O
body	O
RNA	O
turnover	O
.	O

In	O
recent	O
years	O
it	O
has	O
become	O
widely	O
recognized	O
that	O
many	O
radio	O
##im	O
##mu	O
##no	O
##ass	O
##ays	O
for	O
un	O
##con	O
##ju	O
##gated	O
est	B
##rad	I
##iol	I
,	O
particularly	O
direct	O
radio	O
##im	O
##mona	O
##ssa	O
##ys	O
(	O
-	O
)	O
,	O
are	O
not	O
sufficiently	O
specific	O
,	O
especially	O
at	O
the	O
low	O
concentrations	O
characteristic	O
of	O
post	O
##men	O
##op	O
##aus	O
##al	O
women	O
.	O

My	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
(	O
in	O
##os	O
##ito	O
##l	O
)	O
is	O
an	O
essential	O
nut	O
##rient	O
that	O
is	O
used	O
for	O
building	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##lino	I
##si	I
##to	I
##l	I
and	O
its	O
derivatives	O
in	O
e	O
##uka	O
##ryo	O
##tes	O
.	O

This	O
enzyme	O
is	O
or	O
##th	O
##olo	O
##go	O
##us	O
to	O
the	O
L	O
-	O
la	O
##ct	O
##ate	O
de	O
##hy	O
##dr	O
##ogen	O
##ase	O
enzyme	O
which	O
converts	O
p	B
##yr	I
##u	I
##vate	I
to	O
la	B
##ct	I
##ate	I
and	O
back	O
.	O

Sep	O
##arate	O
studies	O
have	O
also	O
suggested	O
the	O
association	O
of	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
with	O
bladder	O
cancer	O
,	O
,	O
as	O
well	O
as	O
with	O
es	O
##op	O
##hage	O
##al	O
sq	O
##ua	O
##mous	O
cell	O
car	O
##cin	O
##oma	O
.	O

So	B
##rb	I
##ito	I
##l	I
,	O
formed	O
from	O
glucose	S
,	O
is	O
the	O
first	O
meta	O
##bol	O
##ite	O
in	O
the	O
p	O
##oly	O
##ol	O
pathway	O
,	O
which	O
usually	O
accounts	O
for	O
a	O
few	O
percent	O
at	O
most	O
of	O
glucose	S
u	O
##til	O
##ization	O
under	O
normal	O
conditions	O
.	O

A	O
significant	O
inter	O
-	O
patient	O
var	O
##iability	O
in	O
meta	O
##bol	O
##ite	O
plasma	O
levels	O
was	O
observed	O
,	O
especially	O
for	O
h	B
##ydro	I
##xy	I
-	I
da	I
##bra	I
##fen	I
##ib	I
as	O
seen	O
in	O
Table	O
.	O

Re	O
##mark	O
##ably	O
,	O
both	O
ER	O
##G	O
-	O
and	O
ET	O
##V	O
##1	O
-	O
induced	O
invasion	O
were	O
associated	O
with	O
a	O
3	O
-	O
fold	O
sa	B
##rc	I
##os	I
##ine	I
elevation	O
in	O
ben	O
##ign	O
R	O
##W	O
##P	O
##E	O
cells	O
.	O

Also	O
,	O
increases	O
in	O
various	O
amino	O
acids	O
and	O
k	B
##eton	I
##e	I
bodies	O
at	O
H	O
##24	O
in	O
the	O
non	O
-	O
survivors	O
are	O
known	O
as	O
effects	O
of	O
protein	O
breakdown	O
and	O
enhanced	O
lip	O
##id	O
oxidation	O
.	O

G	B
##lu	I
##cos	I
##e	I
consumption	O
was	O
hence	O
24	O
%	O
higher	O
after	O
120	O
min	O
in	O
the	O
presence	O
of	O
r	O
##H	O
##la	O
when	O
compared	O
to	O
S	O
##9	O
cells	O
under	O
control	O
conditions	O
.	O

Basic	O
##ally	O
,	O
car	B
##ote	I
##no	I
##ids	I
are	O
known	O
for	O
their	O
anti	O
##ox	O
##ida	O
##nt	O
effects	O
and	O
are	O
derived	O
from	O
plants	O
.	O

Four	O
amino	O
acids	O
were	O
significantly	O
affected	O
by	O
age	O
(	B
l	B
##ys	I
##ine	I
,	O
p	B
##hen	I
##yla	I
##lani	I
##e	I
,	O
v	B
##ali	I
##ne	I
and	O
x	B
##le	I
##uc	I
##ine	I
)	O
,	O
14	O
meta	O
##bol	O
##ites	O
by	O
batch	O
assignments	O
(	O
AC	O
(	O
2	O
:	O
0	O
)	O
,	O
AC	B
(	I
4	I
:	I
0	I
-	I
DC	I
)	I
,	O
AC	B
(	I
14	I
:	I
1	I
)	I
,	O
c	B
##it	I
##ru	I
##llin	I
##e	I
,	O
g	B
##ly	I
##cine	I
,	O
met	B
##hi	I
##oni	I
##ne	I
,	O
AD	B
##MA	I
,	O
k	B
##yn	I
##uren	I
##ine	I
,	O
PC	O
-	O
O	O
(	O
31	O
:	O
1	O
)	O
,	O
PC	O
-	O
O	O
(	O
34	O
:	O
0	O
)	O
,	O
PC	O
-	O
O	O
(	O
36	O
:	O
2	O
)	O
,	O
SM	B
(	I
34	I
:	I
1	I
)	I
,	O
CE	B
(	I
18	I
:	I
1	I
)	I
and	O
CE	B
(	I
18	I
:	I
2	I
)	I
)	O
,	O
and	O
four	O
meta	O
##bol	O
##ites	O
(	B
g	B
##ly	I
##cine	I
,	O
AD	B
##MA	I
,	O
PC	O
-	O
O	O
(	O
34	O
:	O
0	O
)	O
and	O
he	O
##x	O
##ose	O
)	O
were	O
elevated	O
in	O
SP	O
##MS	O
patients	O
compared	O
to	O
controls	O
(	O
Fi	O
##g	O
.	O

In	O
the	O
case	O
of	O
H	O
##B	O
##V	O
infection	O
,	O
it	O
could	O
be	O
interpreted	O
that	O
glucose	S
was	O
actively	O
imported	O
and	O
used	O
to	O
fuel	O
g	O
##ly	O
##co	O
##lysis	O
and	O
the	O
PP	O
##P	O
.	O

In	O
line	O
with	O
this	O
,	O
a	O
study	O
that	O
involved	O
older	O
patients	O
with	O
established	O
C	O
##VD	O
showed	O
an	O
increased	O
plasma	O
PC	O
levels	O
after	O
treatment	O
with	O
r	B
##os	I
##u	I
##vas	I
##tat	I
##in	I
.	O

Previous	O
studies	O
based	O
on	O
serum	O
samples	O
indicated	O
that	O
ta	B
##uri	I
##ne	I
is	O
a	O
potential	O
bio	O
##mark	O
##er	O
for	O
pre	O
##ec	O
##lamp	O
##sia	O
.	O

The	O
super	O
##nat	O
##ant	O
was	O
dried	O
under	O
vacuum	O
and	O
then	O
re	O
##con	O
##stituted	O
with	O
200	O
μ	O
##l	O
of	O
2	O
%	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
.	O

Here	O
,	O
marked	O
elevations	O
in	O
levels	O
of	O
so	B
##rb	I
##ito	I
##l	I
and	O
f	B
##ru	I
##ct	I
##ose	I
were	O
also	O
present	O
in	O
all	O
AD	O
brain	O
regions	O
.	O

Figure	O
1	O
##a	O
includes	O
est	B
##rone	I
(	O
E	O
_	O
1	O
)	O
and	O
est	B
##rad	I
##iol	I
(	O
E	O
_	O
2	O
)	O
;	O

Ph	B
##yt	I
##os	I
##phi	I
##ngo	I
##sin	I
##e	I
,	O
s	B
##phi	I
##nga	I
##nine	I
and	O
palm	B
##ito	I
##yl	I
##car	I
##ni	I
##tine	I
were	O
purchased	O
from	O
A	O
##c	O
##ros	O
Organic	O
##s	O
(	O
New	O
##J	O
##erse	O
##y	O
,	O
USA	O
)	O
.	O

Ana	O
##ly	O
##tes	O
were	O
el	O
##uted	O
with	O
3	O
m	O
##L	O
di	O
##ch	O
##lor	O
##ome	O
##than	O
##e	O
/	O
2	O
-	O
prop	O
##ano	O
##l	O
/	O
am	O
##mon	O
##ium	O
h	B
##ydro	I
##xi	I
##de	I
(	I
78	I
:	I
20	I
:	I
2	I
,	I
v	I
/	I
v	I
)	I
.	O

As	O
se	B
##rine	I
,	O
g	B
##ly	I
##cine	I
sustain	O
##s	O
the	O
one	O
-	O
carbon	O
metabolism	O
(	O
f	O
##olate	O
and	O
met	B
##hi	I
##oni	I
##ne	I
cycles	O
)	O
that	O
provides	O
precursor	O
##s	O
for	O
the	O
bio	O
##sy	O
##nt	O
##hesis	O
of	O
several	O
bio	O
##mo	O
##le	O
##cule	O
##s	O
and	O
the	O
increased	O
up	O
##take	O
of	O
g	B
##ly	I
##cine	I
has	O
been	O
suggested	O
to	O
relate	O
to	O
on	O
##co	O
##genesis	O
and	O
ma	O
##li	O
##gna	O
##ncy	O
in	O
several	O
cancer	O
cell	O
lines	O
.	O

#	O
59	O
##6	O
##23	O
–	O
23	O
)	O
and	O
was	O
spike	O
##d	O
with	O
120	O
pm	O
##ol	O
P	O
##GE	O
##M	O
-	O
d	O
_	O
6	O
(	O
C	O
##ayman	O
Chemical	O
,	O
Ann	O
Harbor	O
,	O
MI	O
)	O
dissolved	O
in	O
10	O
%	O
a	O
##que	O
##ous	O
form	B
##ic	I
acid	I
and	O
40	O
μ	O
##L	O
of	O
form	B
##ic	I
acid	I
(	O
AC	O
##S	O
grade	O
≥	O
98	O
%	O
)	O
.	O

Earlier	O
studies	O
reported	O
that	O
enhanced	O
try	B
##pt	I
##op	I
##han	I
degradation	O
in	O
SL	O
##E	O
patients	O
is	O
associated	O
with	O
functional	O
imp	O
##air	O
##ment	O
of	O
T	O
cell	O
,	O
and	O
a	O
more	O
recent	O
study	O
proposed	O
that	O
k	B
##yn	I
##uren	I
##ine	I
(	O
a	O
meta	O
##bol	O
##ite	O
of	O
try	O
##pt	O
##op	O
##han	O
)	O
is	O
altered	O
in	O
patients	O
with	O
SL	O
##E	O
who	O
have	O
severe	O
fatigue	O
.	O

Conversely	O
,	O
all	O
grade	O
IV	O
as	O
##tro	O
##cy	O
##tom	O
##as	O
analyzed	O
consistently	O
showed	O
absence	O
of	O
su	B
##lf	I
##ati	I
##de	I
species	O
,	O
with	O
high	O
abundance	O
of	O
PS	O
and	O
P	O
##I	O
species	O
.	O

O	O
##G	O
##TT	O
glucose	S
and	O
insulin	O
,	O
H	O
##OM	O
##A	O
-	O
I	O
##R	O
,	O
and	O
H	O
##b	O
##A	O
##1	O
##c	O
that	O
we	O
found	O
.	O

Cy	O
##to	O
##gene	O
##tic	O
sub	O
##type	O
##s	O
:	O
favorable	O
:	O
t	O
(	O
15	O
;	O
17	O
)	O
/	O
PM	O
##L	O
-	O
RA	O
##RA	O
,	O
t	O
(	O
8	O
;	O
21	O
)	O
/	O
AM	O
##L	O
##1	O
-	O
ET	O
##O	O
,	O
and	O
in	B
##v	I
##16	I
/	I
CB	I
##F	I
##β	I
-	I
M	I
##Y	I
##H1	I
##1	I
;	O
un	O
##fa	O
##vor	O
##able	O
:	O
t	O
(	O
9	O
;	O
22	O
)	O
,	O
in	O
##v	O
(	O
3	O
)	O
/	O
t	O
(	O
3	O
;	O
3	O
)	O
,	O
−	O
##5	O
,	O
−	O
##7	O
,	O
del	O
(	O
5	O
##q	O
)	O
,	O
del	O
(	O
7	O
##p	O
)	O
,	O
11	O
##q	O
##23	O
,	O
and	O
complex	O
trans	O
##location	O
##s	O
.	O

The	O
e	O
##G	O
##F	O
##R	O
is	O
based	O
on	O
c	B
##rea	I
##tin	I
##ine	I
–	I
c	I
##ys	I
##tat	I
##in	I
C	O
equation	O
;	O
Model	O
1	O
:	O
Ad	O
##ju	O
##st	O
##ment	O
for	O
age	O
and	O
sex	O
;	O
Model	O
2	O
:	O
Model	O
1	O
+	O
adjustment	O
for	O
e	O
##G	O
##F	O
##R	O
;	O
Model	O
3	O
:	O
Model	O
2	O
+	O
adjustment	O
for	O
body	O
mass	O
index	O
and	O
smoking	O
;	O
Model	O
4	O
:	O
Model	O
3	O
+	O
adjustment	O
for	O
ethnicity	O
,	O
fast	O
##ing	O
glucose	S
,	O
total	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
high	O
-	O
density	O
lip	O
##op	O
##rote	O
##in	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
,	O
C	O
-	O
reactive	O
protein	O
,	O
and	O
use	O
of	O
lip	O
##id	O
-	O
lowering	O
drugs	O
.	O

The	O
HIV	O
–	O
and	O
HIV	O
+	O
study	O
groups	O
had	O
similar	O
levels	O
of	O
T	O
##C	O
,	O
HD	O
##L	O
,	O
L	O
##D	O
##L	O
,	O
and	O
T	B
##G	I
,	O
and	O
yet	O
,	O
were	O
distinguish	O
##able	O
by	O
examining	O
specific	O
lip	O
##id	O
m	O
##oi	O
##eti	O
##es	O
.	O

We	O
prospective	O
##ly	O
determined	O
plasma	O
levels	O
of	O
as	B
##ym	I
##metric	I
dim	I
##eth	I
##yla	I
##rg	I
##ini	I
##ne	I
(	O
AD	O
##MA	O
)	O
,	O
an	O
end	O
##ogen	O
##ous	O
ni	B
##tric	I
oxide	I
s	O
##ynth	O
##ase	O
inhibitor	O
,	O
and	O
global	O
a	B
##rg	I
##ini	I
##ne	I
bio	O
##ava	O
##ila	O
##bility	O
ratio	O
[	B
GA	B
##BR	I
=	I
a	I
##rg	I
##ini	I
##ne	I
/	I
(	I
or	I
##ni	I
##thin	I
##e	I
+	I
c	I
##it	I
##ru	I
##llin	I
##e	I
)	I
]	O
by	O
tandem	O
mass	O
s	O
##pect	O
##rome	O
##try	O
in	O
subjects	O
with	O
advanced	O
de	O
##com	O
##pen	O
##sat	O
##ed	O
heart	O
failure	O
in	O
the	O
intensive	O
care	O
unit	O
(	O
“	O
AD	O
##HF	O
”	O
,	O
n	O
=	O
68	O
)	O
and	O
with	O
stable	O
chronic	O
heart	O
failure	O
(	O
“	O
CH	O
##F	O
”	O
,	O
n	O
=	O
57	O
)	O
.	O

The	O
HC	O
##ys	O
and	O
γ	B
-	I
G	I
##lu	I
##C	I
##ys	I
were	O
firstly	O
reported	O
more	O
than	O
2	O
.	O
0	O
folds	O
increase	O
in	O
the	O
urine	O
of	O
na	O
##so	O
##pha	O
##ryn	O
##ge	O
##al	O
cancer	O
and	O
gas	O
##tric	O
cancer	O
,	O
respectively	O
,	O
then	O
,	O
the	O
two	O
th	B
##iol	I
##s	I
could	O
be	O
considered	O
as	O
potential	O
bio	O
##mark	O
##er	O
for	O
the	O
na	O
##so	O
##pha	O
##ryn	O
##ge	O
##al	O
and	O
gas	O
##tric	O
cancer	O
##s	O
.	O

In	O
non	O
-	O
o	O
##bes	O
##e	O
participants	O
,	O
10	O
meta	O
##bol	O
##ites	O
were	O
inverse	O
##ly	O
associated	O
with	O
25	O
(	O
OH	O
)	O
D	O
at	O
P	O
<	O
6	O
.	O
02	O
x	O
10	O
_	O
−	O
##0	O
##5	O
in	O
K	O
##OR	O
##A	O
F	O
##4	O
,	O
eight	O
of	O
which	O
were	O
replica	O
##ted	O
in	O
F	O
##IN	O
##RI	O
##S	O
##K	O
1997	O
:	O
small	O
L	O
##D	O
##L	O
particles	O
,	O
total	O
lip	O
##ids	O
in	O
small	O
L	O
##D	O
##L	O
(	O
S	O
_	O
L	O
##D	O
##L	O
_	O
L	O
)	O
(	O
N	O
)	O
)	O
summary	O
measures	O
of	O
fatty	O
acids	O
(	O
To	O
##t	O
_	O
FA	O
)	O
(	O
N	O
)	O
,	O
M	O
##U	O
##FA	O
(	O
N	O
)	O
,	O
FA	O
##w	O
##7	O
##9	O
##S	O
(	O
N	O
)	O
,	O
CH	O
_	O
3	O
groups	O
of	O
mobile	O
lip	O
##ids	O
(	O
Mo	O
##b	O
##CH	O
_	O
3	O
)	O
(	O
N	O
)	O
and	O
total	O
p	B
##hos	I
##ph	I
##og	I
##ly	I
##cer	I
##ides	I
,	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
.	O

The	O
sensitivity	O
was	O
sufficient	O
to	O
analyze	O
accurate	O
en	O
##rich	O
##ments	O
of	O
the	O
selected	O
compounds	O
,	O
allowing	O
for	O
the	O
calculation	O
of	O
end	O
##ogen	O
##ous	O
production	O
rates	O
of	O
o	B
##xa	I
##late	I
and	O
g	B
##ly	I
##cola	I
##te	I
and	O
the	O
relative	O
contribution	O
of	O
g	B
##ly	I
##cola	I
##te	I
to	O
g	B
##ly	I
##cine	I
,	O
g	B
##ly	I
##ox	I
##yla	I
##te	I
,	O
and	O
o	B
##xa	I
##late	I
production	O
rates	O
.	O

T	O
##iss	O
##ue	O
analyses	O
included	O
a	O
comprehensive	O
pro	O
##fi	O
##ling	O
of	O
enzymes	O
of	O
interest	O
that	O
could	O
affect	O
ant	B
##ho	I
##cy	I
##ani	I
##n	I
bio	O
##act	O
##ivation	O
and	O
local	O
in	O
##tra	O
##oral	O
levels	O
.	O

Ph	B
##os	I
##ph	I
##oli	I
##pid	I
##s	I
,	O
one	O
of	O
the	O
major	O
components	O
of	O
cell	O
membrane	O
##s	O
,	O
participates	O
in	O
various	O
biological	O
functions	O
,	O
and	O
their	O
levels	O
are	O
altered	O
in	O
various	O
human	O
cancer	O
##s	O
.	O

Recent	O
investigations	O
reveal	O
that	O
the	O
NSA	O
##ID	O
in	B
##dom	I
##eth	I
##ac	I
##in	I
and	O
di	O
##c	O
##lo	O
##fen	O
##ac	O
can	O
cause	O
end	O
##op	O
##las	O
##mic	O
re	O
##tic	O
##ulum	O
stress	O
,	O
which	O
could	O
alter	O
the	O
lip	O
##id	O
machinery	O
.	O

Most	O
notably	O
,	O
these	O
included	O
end	O
##ogen	O
##ously	O
produced	O
lip	O
##id	O
media	O
##tors	O
involved	O
in	O
the	O
resolution	O
of	O
inflammation	O
in	O
a	O
large	O
number	O
of	O
conditions	O
(	O
specific	O
D	O
-	O
series	O
re	O
##sol	O
##vin	O
##s	O
)	O
,	O
,	O
and	O
meta	O
##bol	O
##ites	O
derived	O
from	O
the	O
Mt	O
##b	O
cell	O
wall	O
,	O
including	O
the	O
my	O
##co	O
##ba	O
##cter	O
##ium	O
specific	O
cell	O
wall	O
g	B
##ly	I
##co	I
##lip	I
##id	I
t	I
##re	I
##hal	I
##ose	I
-	I
6	I
-	I
my	I
##cola	I
##te	I
and	O
the	O
non	O
-	O
specific	O
cell	O
wall	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
P	O
##I	O
,	O
,	O
,	O
.	O

The	O
super	O
##nat	O
##ant	O
was	O
dried	O
completely	O
in	O
a	O
con	O
##cent	O
##rator	O
for	O
1	O
h	O
and	O
resolved	O
in	O
30	O
μ	O
##L	O
of	O
50	O
%	O
ace	O
##ton	O
##it	O
##ril	O
##e	O
/	O
0	O
.	O
1	O
%	O
t	B
##ri	I
##f	I
##lu	I
##oro	I
##ace	I
##tic	I
acid	I
(	O
T	O
##FA	O
)	O
on	O
a	O
v	O
##ortex	O
mix	O
##er	O
for	O
30	O
min	O
.	O

The	O
strong	O
VIP	O
loading	O
##s	O
of	O
try	B
##pt	I
##op	I
##han	I
pointed	O
us	O
to	O
se	B
##rot	I
##oni	I
##n	I
metabolism	O
.	O

The	O
level	O
of	O
v	B
##ali	I
##ne	I
is	O
especially	O
associated	O
with	O
a	O
decreased	O
BC	O
##AA	O
cat	O
##ab	O
##olis	O
##m	O
rate	O
which	O
is	O
attributed	O
to	O
the	O
development	O
of	O
o	O
##besity	O
-	O
associated	O
insulin	O
resistance	O
.	O

Sal	O
##adores	O
P	O
et	O
al	O
.	O
showed	O
that	O
high	O
steady	O
-	O
level	O
of	O
end	B
##ox	I
##ife	I
##n	I
and	O
normal	O
C	O
##YP	O
##2	O
##D	O
##6	O
g	O
##eno	O
##type	O
were	O
related	O
to	O
lower	O
risk	O
of	O
breast	O
cancer	O
re	O
##cu	O
##rrence	O
regardless	O
of	O
ethnicity	O
in	O
pre	O
##men	O
##op	O
##aus	O
##al	O
patients	O
.	O

Class	O
##es	O
of	O
con	O
##tam	O
##ina	O
##nts	O
:	O
process	O
imp	O
##uri	O
##ties	O
(	O
e	O
.	O
g	O
.	O
,	O
silicon	O
##e	O
oils	O
and	O
al	O
##kan	O
##e	O
h	B
##ydro	I
##car	I
##bon	I
##s	I
)	O
present	O
in	O
blank	O
##s	O
or	O
discovered	O
after	O
manual	O
cu	O
##ration	O
(	O
25	O
)	O
,	O
meta	O
##bol	O
##ites	O
present	O
in	O
blank	O
##s	O
(	O
43	O
)	O
,	O
and	O
unknown	O
##s	O
present	O
in	O
blank	O
##s	O
(	O
88	O
)	O
.	O

However	O
,	O
its	O
utility	O
in	O
personal	O
##izing	O
th	B
##io	I
##pur	I
##ine	I
treatment	O
has	O
remained	O
controversial	O
,	O
particularly	O
in	O
multi	O
##eth	O
##nic	O
Asian	O
population	O
in	O
Singapore	O
where	O
T	O
##PM	O
##T	O
variant	O
all	O
##ele	O
##s	O
have	O
only	O
been	O
shown	O
to	O
occur	O
at	O
a	O
low	O
overall	O
frequency	O
of	O
2	O
.	O
5	O
%	O
.	O

This	O
result	O
indicates	O
that	O
rib	B
##ose	I
or	O
rib	B
##ose	I
-	I
5	I
-	I
phosphate	I
(	O
R	O
##5	O
##P	O
)	O
may	O
undergo	O
in	O
v	O
##ivo	O
Mail	O
##lard	O
reaction	O
as	O
well	O
or	O
that	O
in	O
v	O
##ivo	O
g	B
##lu	I
##cos	I
##one	I
decomposition	O
results	O
in	O
3	O
-	O
D	O
##Ps	O
.	O

A	O
study	O
also	O
proposed	O
the	O
PA	O
:	O
(	O
P	O
##L	O
+	O
P	O
##LP	O
)	O
ratio	O
(	O
PA	O
##r	O
)	O
as	O
an	O
indicator	O
of	O
vitamin	B
B	I
##6	I
cat	O
##ab	O
##olis	O
##m	O
and	O
confirmed	O
that	O
the	O
PA	O
##r	O
is	O
a	O
predict	O
##or	O
for	O
all	O
-	O
cause	O
mortality	O
.	O

Ph	O
##arma	O
##co	O
##kin	O
##etic	O
studies	O
indicate	O
that	O
8	B
-	I
is	I
##o	I
-	I
P	I
##G	I
##F	I
_	I
2	I
##α	I
is	O
rapidly	O
meta	O
##bol	O
##ized	O
,	O
as	O
demonstrated	O
by	O
Roberts	O
et	O
al	O
who	O
showed	O
that	O
75	O
%	O
of	O
radioactive	O
8	O
-	O
is	O
##o	O
-	O
P	O
##G	O
##F	O
_	O
2	O
##α	O
in	O
##fused	O
into	O
a	O
human	O
was	O
ex	O
##cre	O
##ted	O
in	O
the	O
urine	O
in	O
4	O
.	O
5	O
##h	O
,	O
consistent	O
with	O
the	O
rapid	O
metabolism	O
of	O
this	O
compound	O
observed	O
in	O
rabbits	O
(	O
plasma	O
half	O
-	O
life	O
,	O
1	O
min	O
)	O
.	O

For	O
positive	O
controls	O
,	O
rabbits	O
were	O
sub	O
##cut	O
##aneous	O
##ly	O
injected	O
with	O
in	B
##dom	I
##eth	I
##ac	I
##in	I
(	O
I	O
##M	O
,	O
20	O
mg	O
/	O
kg	O
)	O
once	O
a	O
day	O
during	O
the	O
same	O
treatment	O
period	O
.	O

The	O
quantities	O
of	O
most	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
in	O
sperm	O
as	O
well	O
as	O
in	O
seminal	O
plasma	O
correlated	O
with	O
each	O
other	O
in	O
a	O
significant	O
positive	O
manner	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Ch	O
##E	O
is	O
composed	O
of	O
a	O
ch	B
##ole	I
##ster	I
##ol	I
molecule	O
with	O
a	O
single	O
fatty	O
acid	O
chain	O
.	O

The	O
corresponding	O
figure	O
for	O
urine	O
samples	O
from	O
smoke	O
##less	O
tobacco	O
users	O
(	O
Figure	O
B	O
)	O
shows	O
a	O
y	O
-	O
intercept	O
of	O
21	O
.	O
5	O
nm	O
##ol	O
/	O
m	O
##L	O
versus	O
a	O
level	O
of	O
21	O
.	O
4	O
nm	O
##ol	O
/	O
m	O
##L	O
when	O
no	O
co	B
##tin	I
##ine	I
was	O
added	O
and	O
an	O
average	O
accuracy	O
of	O
98	O
.	O
7	O
%	O
.	O

In	O
normal	O
re	O
##nal	O
tub	O
##ules	O
,	O
c	B
##rea	I
##tin	I
##ine	I
is	O
not	O
re	O
##sor	O
##bed	O
but	O
c	B
##ys	I
##tat	I
##in	I
C	O
is	O
more	O
than	O
99	O
%	O
.	O

We	O
identified	O
significant	O
associations	O
between	O
SP	O
##s	O
and	O
o	O
##besity	O
/	O
T	O
##2	O
##DM	O
characteristics	O
,	O
specifically	O
,	O
those	O
of	O
he	B
##x	I
##osy	I
##l	I
##cer	I
##ami	I
##des	I
,	O
d	B
##16	I
:	I
1	I
SP	O
##s	O
,	O
and	O
d	B
##18	I
:	I
2	I
SP	O
##s	O
.	O

As	O
our	O
findings	O
indicated	O
that	O
9	O
-	O
H	O
##SA	O
is	O
present	O
only	O
in	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
,	O
in	O
the	O
next	O
series	O
of	O
experiments	O
we	O
investigated	O
the	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
fatty	O
acid	O
composition	O
of	O
normal	O
tissue	O
and	O
tumor	O
samples	O
by	O
G	O
##C	O
/	O
MS	O
.	O

While	O
most	O
of	O
these	O
meta	O
##bol	O
##ites	O
were	O
decreased	O
in	O
urine	O
of	O
infants	O
with	O
RS	O
##V	O
AR	O
##I	O
compared	O
to	O
healthy	O
control	O
infants	O
,	O
2	B
-	I
amino	I
##but	I
##yra	I
##te	I
,	O
ace	B
##tone	I
,	O
c	B
##is	I
-	I
a	I
##con	I
##itate	I
,	O
and	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
were	O
increased	O
.	O

A	B
##c	I
##rol	I
##ein	I
react	O
##s	O
with	O
de	B
##ox	I
##y	I
##gua	I
##nos	I
##ine	I
(	O
d	O
##G	O
)	O
to	O
form	O
the	O
c	O
##yclic	O
1	O
,	O
N	O
_	B
2	I
-	I
prop	I
##ano	I
##de	I
##ox	I
##y	I
##gua	I
##nos	I
##ine	I
add	O
##uc	O
##ts	O
(	O
A	O
##c	O
##ro	O
-	O
d	O
##G	O
)	O
,	O

These	O
metabolic	O
pathways	O
consisted	O
of	O
g	O
##ly	O
##co	O
##lysis	O
,	O
se	B
##rine	I
synthesis	O
pathway	O
,	O
T	O
##CA	O
cycle	O
,	O
amino	O
acid	O
metabolism	O
,	O
p	B
##yr	I
##im	I
##id	I
##ine	I
metabolism	O
and	O
gut	O
flora	O
metabolism	O
.	O

Ser	O
##um	O
glucose	S
levels	O
were	O
also	O
significantly	O
increased	O
after	O
ER	O
##CP	O
(	O
0	O
.	O
50	O
vs	O
.	O
0	O
.	O
61	O
m	O
##M	O
,	O
P	O
=	O
0	O
.	O
000	O
##47	O
,	O
)	O
.	O

The	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
model	O
was	O
subsequently	O
applied	O
to	O
8	O
,	O
43	O
##6	O
urine	O
s	O
##pect	O
##ra	O
and	O
the	O
i	B
##bu	I
##p	I
##ro	I
##fen	I
model	O
to	O
8	O
,	O
60	O
##4	O
urine	O
s	O
##pect	O
##ra	O
,	O
after	O
excluding	O
persons	O
whose	O
urine	O
specimens	O
were	O
used	O
to	O
valid	O
##ate	O
the	O
prediction	O
models	O
.	O

The	O
employment	O
of	O
a	O
met	B
##han	I
##ol	I
/	I
ace	I
##ton	I
##it	I
##ril	I
##e	I
mixture	O
was	O
critical	O
to	O
achieve	O
this	O
separation	O
,	O
as	O
met	B
##han	I
##ol	I
or	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
as	O
sole	O
organic	O
m	O
##od	O
##ifier	O
##s	O
in	O
the	O
mobile	O
phase	O
did	O
not	O
resolve	O
the	O
ch	O
##ira	O
##l	O
compounds	O
.	O

Branch	O
##ed	O
chain	O
amino	O
acids	O
,	O
al	B
##ani	I
##ne	I
,	O
g	B
##lut	I
##ami	I
##c	I
acid	I
,	O
pro	B
##line	I
,	O
t	B
##yr	I
##os	I
##ine	I
LP	O
##C	O
##a	O
C	B
##16	I
:	I
1	I
,	O
PC	O
##aa	O
C	B
##32	I
:	I
1	I
,	O
PC	O
##aa	O
C	B
##32	I
:	I
2	I
and	O
PC	O
##aa	O
C	B
##38	I
:	I
3	I
were	O
positively	O
,	O
while	O
se	B
##rine	I
,	O
as	B
##par	I
##agi	I
##ne	I
,	O
LP	O
##C	O
##a	O
C	B
##18	I
:	I
1	I
,	O
LP	O
##C	O
##a	O
C	B
##18	I
:	I
2	I
,	O
LP	O
##C	O
##e	O
C	B
##18	I
:	I
0	I
,	O
PC	O
##ae	O
C	B
##34	I
:	I
3	I
,	O
PC	O
##ae	O
C	B
##38	I
:	I
4	I
and	O
PC	O
##ae	O
C	B
##40	I
:	I
6	I
were	O
negatively	O
associated	O
with	O
o	O
##besity	O
(	O
all	O
p	O
<	O
0	O
.	O
000	O
##48	O
)	O
.	O

L	B
-	I
Cy	I
##stein	I
##es	I
##ulf	I
##onic	I
acid	I
C	I
##rea	I
##tin	I
##ine	I
Unknown	O
1	O
Unknown	O
2	O
Unknown	O
5	O
Unknown	O
6	O
Unknown	O
7	O
Unknown	O
8	O
Unknown	O
9	O
Fu	B
##mara	I
##te	I
3	I
-	I
h	I
##ydro	I
##xy	I
##vale	I
##rate	I
Unknown	O
10	O
Unknown	O
11	O
Unknown	O
12	O
Unknown	O
13	O
Unknown	O
14	O
Unknown	O
15	O
Unknown	O
16	B
2	I
-	I
Met	I
##hyl	I
##hip	I
##pur	I
##ic	I
acid	I
5	I
-	I
Ace	I
##ty	I
##lam	I
##ino	I
-	I
6	I
-	I
amino	I
-	I
3	I
-	I
met	I
##hyl	I
##ura	I
##ci	I
##l	I
_	O
1	O
Under	O
##lined	O
meta	O
##bol	O
##ites	O
were	O
used	O
for	O
generating	O
prediction	O
model	O
.	O

Ad	O
##ding	O
further	O
evidence	O
,	O
beta	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
,	O
which	O
is	O
synthesized	O
via	O
ace	B
##ty	I
##l	I
-	I
Co	I
##A	I
during	O
beta	O
-	O
oxidation	O
of	O
fatty	O
acids	O
,	O
was	O
the	O
most	O
profound	O
##ly	O
reduced	O
meta	O
##bol	O
##ite	O
in	O
CD	O
compared	O
with	O
controls	O
.	O

The	O
ad	B
##eno	I
##sin	I
##e	I
network	O
showed	O
the	O
key	O
enzymes	O
that	O
regulate	O
ad	B
##eno	I
##sin	I
##e	I
production	O
and	O
metabolism	O
,	O
ad	O
##eno	O
##sin	O
##e	O
de	O
##ami	O
##nas	O
##e	O
(	O
AD	O
##A	O
;	O
EC	O
.	O
3	O
.	O
5	O
.	O
4	O
.	O
4	O
)	O
,	O
which	O
converts	O
ad	B
##eno	I
##sin	I
##e	I
to	O
in	B
##os	I
##ine	I
,	O
and	O
e	O
##ct	O
##o	O
-	O
5	O
′	O
-	O
n	O
##uc	O
##leo	O
##ti	O
##das	O
##e	O
(	O
EC	O
##3	O
.	O
1	O
.	O
3	O
.	O
5	O
)	O
,	O
which	O
regulate	O
##s	O
ad	B
##eno	I
##sin	I
##e	I
production	O
.	O

It	O
seems	O
that	O
the	O
reduction	O
in	O
ATP	S
production	O
due	O
to	O
the	O
in	O
##hibition	O
of	O
the	O
T	O
##CA	O
cycle	O
induced	O
by	O
h	O
##y	O
##po	O
##bari	O
##c	O
h	O
##y	O
##pox	O
##ia	O
as	O
discussed	O
above	O
could	O
lead	O
to	O
the	O
u	O
##til	O
##ization	O
of	O
BC	O
##AA	O
##s	O
as	O
alternative	O
sources	O
of	O
energy	O
.	O

The	O
auto	O
##sa	O
##mple	O
##r	O
stability	O
(	O
2	O
–	O
8	O
##°	O
C	O
)	O
for	O
a	B
##bir	I
##ater	I
##one	I
was	O
demonstrated	O
to	O
de	O
##via	O
##te	O
no	O
more	O
than	O
±	O
##2	O
.	O
2	O
%	O
after	O
192	O
hours	O
,	O
and	O
was	O
therefore	O
considered	O
stable	O
for	O
at	O
least	O
8	O
days	O
.	O

Ana	O
##ly	O
##tes	O
and	O
the	O
internal	O
standard	O
(	B
a	B
##bir	I
##ater	I
##one	I
-	I
d	I
##4	I
)	O
were	O
extracted	O
from	O
human	O
serum	O
using	O
the	O
liquid	O
–	O
liquid	O
extraction	O
procedure	O
.	O

Thus	O
,	O
IL	B
-	I
1	I
##β	I
,	O
IF	O
##N	O
-	O
γ	O
,	O
GM	O
-	O
CS	O
##F	O
,	O
and	O
IL	O
-	O
12	O
##p	O
##70	O
were	O
only	O
detected	O
in	O
a	O
limited	O
number	O
of	O
samples	O
and	O
therefore	O
not	O
further	O
analyzed	O
.	O

De	B
##hy	I
##dr	I
##oe	I
##pian	I
##dr	I
##osterone	I
(	O
D	O
##H	O
##EA	O
)	O
is	O
the	O
most	O
abundant	O
ad	O
##rena	O
##l	O
s	O
##tero	O
##id	O
hormone	O
in	O
humans	O
,	O
and	O
D	B
##H	I
##EA	I
-	I
S	I
,	O
the	O
su	O
##l	O
##phate	O
##d	O
est	O
##er	O
of	O
D	O
##H	O
##EA	O
,	O
is	O
the	O
h	B
##ydro	I
##phi	I
##lic	I
storage	O
form	O
bound	O
to	O
album	O
##in	O
in	O
the	O
blood	O
##stream	O
.	O

El	O
##uate	O
##s	O
were	O
dried	O
under	O
nitrogen	O
at	O
40	O
°C	O
;	O
a	O
drop	O
of	O
1	O
%	O
h	B
##ydro	I
##ch	I
##lor	I
##ic	I
acid	I
in	O
met	B
##han	I
##ol	I
(	O
v	O
/	O
v	O
)	O
was	O
added	O
near	O
the	O
end	O
of	O
drying	O
to	O
prevent	O
vol	O
##ati	O
##li	O
##zation	O
of	O
sensitive	O
compounds	O
.	O

For	O
serum	O
samples	O
,	O
the	O
ch	O
##roma	O
##to	O
##gram	O
##s	O
and	O
typical	O
C	B
##IS	I
-	I
MS	I
s	O
##pect	O
##ra	O
of	O
the	O
three	O
OH	O
##Cs	O
are	O
shown	O
in	O
.	O

The	O
biological	O
Q	O
##Cs	O
are	O
used	O
to	O
demonstrate	O
the	O
precision	O
of	O
q	O
##uant	O
##ification	O
for	O
individual	O
anal	O
##yte	O
##s	O
over	O
the	O
duration	S
of	O
a	O
study	O
.	O

Six	O
subjects	O
of	O
vitamin	B
D	I
##2	I
group	O
were	O
subsequently	O
excluded	O
from	O
the	O
study	O
,	O
five	O
subjects	O
were	O
newly	O
diagnosed	O
with	O
diabetes	O
within	O
three	O
months	O
of	O
the	O
study	O
period	O
and	O
one	O
subjects	O
had	O
he	O
##pa	O
##titis	O
C	O
viral	O
.	O

In	O
contrast	O
with	O
the	O
positive	O
relationship	O
between	O
most	O
c	B
##era	I
##mi	I
##des	I
and	O
diabetes	O
-	O
related	O
characteristics	O
,	O
our	O
study	O
found	O
a	O
significant	O
negative	O
correlation	O
between	O
he	B
##x	I
##osy	I
##l	I
##cer	I
##ami	I
##des	I
and	O
diabetes	O
-	O
related	O
characteristics	O
.	O

CO	O
##H	O
##b	O
:	O
car	B
##box	I
##yl	I
##hem	I
##og	I
##lo	I
##bin	I
.	O

However	O
,	O
the	O
most	O
notable	O
difference	O
was	O
the	O
exceptionally	O
low	O
average	O
concentration	O
of	O
ch	B
##olin	I
##e	I
compared	O
to	O
HC	O
(	O
q	O
=	O
6	O
.	O
45	O
##E	O
_	O
−	O
##19	O
)	O
,	O
an	O
effect	O
which	O
was	O
magnitude	O
##s	O
stronger	O
than	O
observed	O
in	O
T	O
##B	O
patients	O
without	O
D	O
##M	O
(	O
Fi	O
##g	O
.	O
)	O
.	O

Transit	O
##ions	O
were	O
determined	O
for	O
all	O
individual	O
P	O
##U	O
##FA	O
##s	O
and	O
o	B
##xy	I
##lip	I
##ins	I
using	O
MR	O
##M	O
mode	O
(	O
further	O
information	O
in	O
)	O
.	O

The	O
charge	O
numbers	O
of	O
th	B
##iol	I
were	O
further	O
examined	O
by	O
Q	O
##TO	O
##F	O
-	O
MS	O
analysis	O
and	O
total	O
103	O
ion	O
pairs	O
were	O
detected	O
in	O
all	O
the	O
5	O
types	O
of	O
cancer	O
urine	O
samples	O
.	O

The	O
abundance	O
of	O
five	O
bacterial	O
genera	O
(	O
Ba	O
##cter	O
##oid	O
##es	O
pre	O
##vo	O
##tel	O
##la	O
(	O
B	O
##p	O
)	O
,	O
C	O
##los	O
##tri	O
##dium	O
XIV	O
(	O
C	O
##X	O
##I	O
##V	O
)	O
,	O
B	O
##if	O
##ido	O
##ba	O
##cter	O
##ium	O
long	O
##um	O
(	O
B	O
##l	O
)	O
,	O
Lac	B
##to	I
##ba	I
##ci	I
##llus	I
(	O
L	O
)	O
,	O
En	O
##tero	O
##ba	O
##cter	O
##iac	O
##eae	O
(	O
E	O
)	O
)	O
,	O
representative	O
of	O
the	O
4	O
main	O
bacterial	O
p	O
##hyl	O
##a	O
present	O
in	O
the	O
gas	O
##tro	O
##int	O
##est	O
##inal	O
tract	O
,	O
were	O
q	O
##uant	O
##ified	O
from	O
bio	O
##ps	O
##ies	O
using	O
real	O
-	O
time	O
PC	O
##R	O
.	O

Met	O
##ab	O
##oli	O
##tes	O
associated	O
with	O
re	O
##current	O
stroke	O
risk	O
scores	O
(	O
A	O
)	O
Su	B
##cci	I
##nate	I
and	O
k	B
##yn	I
##uren	I
##ine	I
demonstrated	O
a	O
dose	O
–	O
response	O
relationship	O
with	O
CH	O
##AD	O
##S	O
_	O
2	O
score	O
and	O
(	O
B	O
)	O
with	O
CH	O
##A	O
_	O
2	O
DS	O
_	O
2	O
-	O
VA	O
##S	O
##c	O
scores	O
.	O

B	O
##rief	O
##ly	O
,	O
after	O
th	O
##aw	O
##ing	O
,	O
5	O
m	O
##L	O
urine	O
was	O
buffer	O
##ed	O
to	O
pH	O
=	O
6	O
.	O
5	O
with	O
1	O
M	O
ace	B
##tic	I
acid	I
if	O
the	O
samples	O
were	O
above	O
pH	O
6	O
.	O
5	O
.	O

R	B
##iba	I
##vir	I
##in	I
was	O
rapidly	O
activated	S
through	O
se	O
##quential	O
p	O
##hos	O
##ph	O
##ory	O
##lation	O
,	O
resulting	O
in	O
the	O
presence	O
of	O
in	O
##tra	O
##cellular	O
rib	B
##avi	I
##rin	I
mon	I
##op	I
##hos	I
##phate	I
,	O
dip	B
##hos	I
##phate	I
,	O
and	O
trip	B
##hos	I
##phate	I
.	O

A	O
##bb	O
##re	O
##viation	O
##s	O
:	O
SC	O
##R	O
,	O
serum	O
c	B
##rea	I
##tin	I
##ine	I
;	O
AL	O
##B	O
,	O
plasma	O
album	O
##in	O
.	O

No	O
significant	O
differences	O
were	O
seen	O
in	O
the	O
median	O
P	O
##GE	O
-	O
M	O
between	O
the	O
68	O
women	O
with	O
inflammatory	O
lung	O
conditions	O
(	O
median	O
5	O
.	O
04	O
ng	O
/	O
mg	O
c	B
##rea	I
##tin	I
##ine	I
,	O
range	O
0	O
.	O
81	O
–	O
28	O
.	O
07	O
)	O
and	O
the	O
33	O
##1	O
women	O
without	O
these	O
conditions	O
(	O
median	O
4	O
.	O
74	O
ng	O
/	O
mg	O
c	B
##rea	I
##tin	I
##ine	I
,	O
range	O
0	O
.	O
68	O
–	O
62	O
.	O
6	O
,	O
p	O
=	O
0	O
.	O
26	O
)	O
.	O

P	O
##las	O
##ma	O
beta	B
##ine	I
(	O
nuclear	O
magnetic	O
resonance	O
s	O
##pect	O
##ros	O
##copy	O
)	O
,	O
P	O
##LT	O
##P	O
activity	O
(	O
lip	O
##oso	O
##me	O
-	O
ve	O
##si	O
##cle	O
HD	O
##L	O
system	O
)	O
,	O
L	O
##CA	O
##T	O
activity	O
(	O
ex	O
##ogen	O
##ous	O
substrate	O
ass	O
##ay	O
)	O
and	O
(	O
a	O
##po	O
)	O
lip	O
##op	O
##rote	O
##ins	O
were	O
measured	O
in	O
65	O
type	O
2	O
di	O
##abe	O
##tic	O
(	O
T	O
##2	O
##DM	O
)	O
and	O
in	O
55	O
non	O
-	O
di	O
##abe	O
##tic	O
subjects	O
.	O

In	O
conclusion	O
,	O
we	O
developed	O
a	O
highly	O
sensitive	O
,	O
precise	O
and	O
accurate	O
ass	O
##ay	O
for	O
simultaneous	O
determination	O
of	O
six	O
relevant	O
vitamin	B
D	I
meta	O
##bol	O
##ites	O
in	O
human	O
serum	O
over	O
a	O
wide	O
dynamic	O
range	O
.	O

The	O
identification	O
of	O
r	O
##ham	O
##ni	O
##to	O
##l	O
as	O
u	O
##rina	O
##ry	O
bio	O
##mark	O
##er	O
of	O
apple	O
consumption	O
has	O
shown	O
how	O
overlap	O
in	O
1	O
##D	O
s	O
##pect	O
##ra	O
cannot	O
be	O
resolved	O
using	O
ST	O
##OR	O
##M	O
as	O
the	O
signals	O
overlap	O
with	O
those	O
of	O
3	B
-	I
h	I
##ydro	I
##xy	I
##is	I
##ova	I
##ler	I
##ate	I
,	O
commonly	O
found	O
in	O
urine	O
samples	O
,	O
which	O
reduces	O
the	O
power	O
of	O
the	O
statistical	O
correlation	O
method	O
.	O

The	O
mixture	O
was	O
extracted	O
with	O
240	O
μ	O
##l	O
of	O
ice	O
-	O
cold	O
met	B
##han	I
##ol	I
and	O
then	O
80	O
μ	O
##l	O
of	O
ice	O
-	O
cold	O
met	B
##han	I
##ol	I
.	O

Analysis	O
of	O
the	O
meta	O
##bol	O
##ites	O
present	O
in	O
all	O
11	O
urine	O
extract	O
##s	O
containing	O
s	O
##pect	O
##ra	O
of	O
this	O
cluster	O
(	O
the	O
nodes	O
with	O
m	O
/	O
z	O
313	O
.	O
08	O
##6	O
and	O
27	O
##1	O
.	O
07	O
##9	O
(	O
[	O
M	O
+	O
H	O
]	O
_	O
+	O
)	O
)	O
resulted	O
in	O
the	O
top	O
-	O
ranked	O
candidate	O
structure	O
of	O
para	B
##ce	I
##tam	I
##ol	I
-	I
me	I
##rca	I
##pt	I
##ura	I
##te	I
(	O
con	O
##ju	O
##gate	O
of	O
para	B
##ce	I
##tam	I
##ol	I
and	O
N	B
-	I
ace	I
##ty	I
##l	I
##cy	I
##stein	I
##e	I
)	O

However	O
,	O
as	O
beta	B
##ine	I
functions	O
as	O
an	O
organic	O
o	O
##smo	O
##ly	O
##te	O
and	O
met	O
##hyl	O
donor	O
,	O
its	O
importance	O
for	O
exercise	O
performance	O
has	O
recently	O
been	O
discussed	O
.	O

Neither	O
of	O
the	O
two	O
NHL	O
-	O
disc	O
##rim	O
##inating	O
low	O
-	O
mass	O
ions	O
,	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
and	O
x	B
##ant	I
##hine	I
,	O
was	O
significantly	O
correlated	O
with	O
individual	O
his	O
##to	O
##log	O
##ic	O
types	O
,	O
cancer	O
stage	O
,	O
extra	O
-	O
nod	O
##al	O
involvement	O
,	O
Eastern	O
Cooperative	O
On	O
##cology	O
Group	O
score	O
(	O
EC	O
##O	O
##G	O
performance	O
)	O
,	O
international	O
pro	O
##gno	O
##stic	O
index	O
(	O
low	O
,	O
low	O
/	O
intermediate	O
vs	O
.	O
high	O
/	O
intermediate	O
,	O
high	O
)	O
,	O
bone	O
ma	O
##rrow	O
involvement	O
(	O
absent	O
vs	O
.	O
present	O
)	O
,	O
first	O
response	O
to	O
ch	O
##em	O
##otherapy	O
(	O
complete	O
response	O
,	O
partial	O
response	O
vs	O
.	O
stable	O
disease	O
,	O
progressive	O
disease	O
)	O
or	O
survival	O
(	O
data	O
not	O
shown	O
)	O
.	O

An	O
example	O
of	O
a	O
ca	O
##li	O
##bra	O
##tion	O
curve	O
for	O
the	O
en	O
##rich	O
##ment	O
of	O
_	O
13	O
C	B
_	I
2	I
-	I
o	I
##xa	I
##late	I
is	O
shown	O
in	O
.	O

Fr	O
##oz	O
##en	O
plasma	O
samples	O
were	O
th	O
##awed	O
,	O
spike	O
##d	O
with	O
internal	O
standard	O
then	O
de	O
##p	O
##rote	O
##ini	O
##zed	O
with	O
cold	O
Me	B
##OH	I
followed	O
by	O
cent	O
##ri	O
##fu	O
##gation	O
at	O
10	O
,	O
000	O
g	O
for	O
5	O
minutes	O
prior	O
to	O
der	O
##iva	O
##ti	O
##zation	O
according	O
to	O
Mass	O
##T	O
##rak	O
instructions	O
.	O

Li	O
##pid	O
##s	O
,	O
1	B
,	I
2	I
-	I
di	I
##he	I
##pta	I
##de	I
##cano	I
##yl	I
-	I
s	I
##n	I
-	I
g	I
##ly	I
##cer	I
##o	I
-	I
3	I
-	I
p	I
##hos	I
##ph	I
##oe	I
##than	I
##ola	I
##mine	I
(	I
17	I
:	I
0	I
P	I
##E	I
)	I
,	O
1	B
,	I
2	I
-	I
dip	I
##ent	I
##ade	I
##cano	I
##yl	I
-	I
s	I
##n	I
-	I
g	I
##ly	I
##cer	I
##o	I
-	I
3	I
-	I
p	I
##hos	I
##ph	I
##och	I
##olin	I
##e	I
(	I
15	I
:	I
0	I
PC	I
)	I
,	O
and	O
N	B
-	I
he	I
##pta	I
##de	I
##cano	I
##yl	I
-	I
D	I
-	I
er	I
##yt	I
##hr	I
##o	I
-	I
s	I
##phi	I
##ngo	I
##sin	I
##e	I
(	O
C	O
##17	O
Ce	B
##r	I
(	I
d	I
##18	I
:	I
1	I
/	I
17	I
:	I
0	I
)	I
)	O
,	O
were	O
purchased	O
from	O
Ava	O
##nti	O
Polar	O
Li	O
##pid	O
Inc	O
.	O
(	O
Al	O
##aba	O
##ster	O
,	O
Alabama	O
)	O
.	O

In	O
contrast	O
,	O
other	O
meta	O
##bol	O
##ites	O
including	O
pseudo	B
##uri	I
##dine	I
and	O
k	B
##yn	I
##uren	I
##ine	I
demonstrated	O
a	O
graded	O
,	O
step	O
##wise	O
increase	O
across	O
the	O
spectrum	O
of	O
at	O
##rial	O
d	O
##ys	O
##function	O
and	O
A	B
##F	I
(	O
and	O
)	O
.	O

After	O
the	O
extraction	O
of	O
the	O
meta	O
##bol	O
##ites	O
and	O
internal	O
standards	O
with	O
300	O
μ	O
##l	O
5	O
m	O
##M	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
in	O
met	B
##han	I
##ol	I
and	O
shaking	O
at	O
450	O
rpm	O
(	O
The	O
##rm	O
##omi	O
##xe	O
##r	O
comfort	O
,	O
E	O
##ppe	O
##ndo	O
##rf	O
,	O
Hamburg	O
,	O
Germany	O
)	O
for	O
30	O
min	O
at	O
room	O
temperature	O
,	O
the	O
solution	O
was	O
cent	O
##ri	O
##fu	O
##ged	O
through	O
a	O
solid	O
-	O
phase	O
filter	O
membrane	O
and	O
di	O
##lut	O
##ed	O
for	O
further	O
analysis	O
.	O

Hip	B
##pur	I
##ic	I
acid	I
and	O
3	B
-	I
h	I
##ydro	I
##xy	I
##hip	I
##pur	I
##ic	I
acid	I
are	O
end	O
-	O
products	O
of	O
the	O
micro	O
##bial	O
cat	O
##ab	O
##olis	O
##m	O
of	O
numerous	O
p	O
##oly	O
##phe	O
##no	O
##ls	O
and	O
a	O
##romatic	O
amino	O
acids	O
.	O

In	O
particular	O
,	O
the	O
over	O
-	O
accumulation	O
of	O
sperm	B
##id	I
##ine	I
can	O
further	O
induce	O
the	O
up	O
-	O
regulation	O
of	O
sperm	B
##id	I
##ine	I
/	O
sperm	O
##ine	O
N	O
-	O
1	O
-	O
ace	O
##ty	O
##l	O
transfer	O
##ase	O
(	O
SS	O
##AT	O
)	O
,	O
an	O
enzyme	O
that	O
present	O
significantly	O
higher	O
levels	O
in	O
human	O
pro	O
##state	O
cancer	O
tissue	O
samples	O
.	O

S	O
##pect	O
##ral	O
regions	O
from	O
1	O
.	O
47	O
to	O
3	O
.	O
60	O
pp	O
##m	O
[	B
al	B
##ani	I
##ne	I
(	O
Al	O
##a	O
)	O
,	O
C	O
##r	O
,	O
free	O
ch	B
##olin	I
##e	I
(	O
Cho	O
)	O
,	O
p	B
##hos	I
##ph	I
##och	I
##olin	I
##e	I
(	O
PC	O
)	O
,	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##och	I
##olin	I
##e	I
(	O
GP	O
##C	O
)	O
,	O
my	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
(	O
m	O
-	O
In	O
##s	O
)	O
,	O
ta	B
##uri	I
##ne	I
(	O
Tau	O
)	O
,	O
g	B
##ly	I
##cine	I
(	O
G	O
##ly	O
)	O
,	O
and	O
su	B
##cci	I
##nate	I
(	O
Su	O
##c	O
)	O
]	O
were	O
selected	O
for	O
q	O
##uant	O
##ification	O
.	O

Pat	O
##ients	O
with	O
MC	O
##I	O
due	O
to	O
known	O
causes	O
(	O
e	O
.	O
g	O
.	O
depression	O
,	O
extensive	O
white	O
matter	O
path	O
##ology	O
,	O
vitamin	B
B	I
##12	I
deficiency	O
)	O
were	O
excluded	O
.	O

We	O
evaluated	O
multiple	O
factors	O
,	O
including	O
acute	O
MI	O
and	O
history	O
of	O
C	O
##VD	O
and	O
s	B
##tat	I
##in	I
use	O
at	O
the	O
time	O
of	O
sample	O
collection	O
in	O
a	O
un	O
##iva	O
##ria	O
##te	O
analysis	O
–	O
only	O
smoking	O
was	O
related	O
to	O
as	B
##pi	I
##rin	I
independent	O
T	O
##x	O
##A	O
_	O
2	O
generation	O
.	O

The	O
average	O
extraction	O
recovery	O
rate	O
determined	O
by	O
measuring	O
Q	O
##C	O
samples	O
at	O
three	O
different	O
concentration	O
levels	O
of	O
pro	B
##line	I
were	O
99	O
.	O
20	O
%	O
,	O
98	O
.	O
06	O
%	O
,	O
and	O
100	O
.	O
25	O
%	O
,	O
respectively	O
.	O

Te	O
##ms	O
##iro	O
##lim	O
##us	O
,	O
an	O
est	O
##er	O
analogue	O
of	O
rap	B
##am	I
##y	I
##cin	I
,	O
is	O
an	O
inhibitor	O
of	O
m	O
##TO	O
##R	O
(	O
ma	O
##mmal	O
##ian	O
target	O
of	O
rap	B
##am	I
##y	I
##cin	I
)	O
that	O
binds	O
to	O
in	O
##tra	O
##cellular	O
FK	O
##B	O
##P	O
protein	O
,	O
and	O
the	O
protein	O
–	O
drug	O
complex	O
in	O
##hibit	O
the	O
activity	O
of	O
m	O
##TO	O
##R	O
.	O

In	O
both	O
CD	O
and	O
in	O
UC	O
,	O
we	O
noticed	O
,	O
relative	O
to	O
control	O
subjects	O
,	O
a	O
decrease	O
in	O
ch	B
##olin	I
##e	I
and	O
its	O
o	O
##xi	O
##dized	O
product	O
beta	B
##ine	I
.	O

At	B
##raz	I
##ine	I
undergo	O
##es	O
metabolism	O
primarily	O
by	O
P	O
##45	O
##01	O
##A	O
##2	O
to	O
form	O
di	B
##ami	I
##no	I
##ch	I
##lor	I
##ot	I
##ria	I
##zen	I
##e	I
,	O
which	O
forms	O
add	O
##uc	O
##ts	O
with	O
the	O
Cy	O
##s	O
##34	O
residue	O
of	O
rat	O
and	O
human	O
Al	O
##b	O
in	O
v	O
##it	O
##ro	O
.	O

These	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
signals	O
were	O
then	O
subjected	O
to	O
non	O
-	O
para	O
##metric	O
un	O
##iva	O
##ria	O
##te	O
statistical	O
analysis	O
with	O
the	O
aim	O
to	O
highlight	O
specific	O
alterations	O
of	O
lip	O
##id	O
patterns	O
in	O
Mu	O
##S	O
.	O
Panel	O
B	O
shows	O
the	O
volcano	O
plot	O
,	O
reporting	O
the	O
main	O
disc	O
##rim	O
##ina	O
##nt	O
PC	O
##s	O
and	O
SM	O
##s	O
between	O
Mu	O
##S	O
and	O
HC	O
tear	O
samples	O
.	O

Other	O
try	B
##pt	I
##op	I
##han	I
degradation	O
products	O
,	O
in	B
##do	I
##le	I
##la	I
##ct	I
##ate	I
(	O
1	O
.	O
2	O
-	O
fold	O
)	O
and	O
in	B
##do	I
##le	I
##p	I
##rop	I
##ion	I
##ate	I
(	O
2	O
.	O
2	O
-	O
fold	O
)	O
,	O
related	O
to	O
micro	O
##bio	O
##me	O
metabolic	O
origin	O
tended	O
to	O
increase	O
(	O
and	O
)	O
.	O

Inc	O
##reased	O
levels	O
of	O
3	B
-	I
in	I
##dox	I
##yl	I
su	I
##lf	I
##ate	I
observed	O
in	O
urine	O
during	O
and	O
after	O
sleep	O
de	O
##p	O
##ri	O
##vation	O
may	O
thus	O
reflect	O
our	O
observation	O
of	O
increased	O
try	B
##pt	I
##op	I
##han	I
and	O
se	B
##rot	I
##oni	I
##n	I
levels	O
in	O
plasma	O
from	O
the	O
same	O
study	O
participants	O
.	O

Six	O
meta	O
##bol	O
##ites	O
were	O
detected	O
in	O
both	O
H	O
##IL	O
##IC	O
-	O
MS	O
and	O
_	O
1	O
H	O
-	O
N	O
##MR	O
to	O
be	O
significantly	O
different	O
between	O
civilian	O
and	O
veteran	O
sa	O
##rc	O
##oid	O
##osis	O
subjects	O
:	O
a	B
##rg	I
##ini	I
##ne	I
,	O
g	B
##lut	I
##amine	I
,	O
c	B
##rea	I
##tin	I
##ine	I
,	O
g	B
##ly	I
##cine	I
,	O
ta	B
##uri	I
##ne	I
,	O
and	O
met	B
##hi	I
##oni	I
##ne	I
.	O

When	O
we	O
only	O
used	O
the	O
G	O
##C	O
/	O
MS	O
meta	O
##bol	O
##ites	O
to	O
identify	O
potential	O
meta	O
##bol	O
##ite	O
bio	O
##mark	O
##er	O
panel	O
,	O
seven	O
meta	O
##bol	O
##ites	O
(	B
24	B
##di	I
##hy	I
##dr	I
##ox	I
##y	I
##py	I
##rim	I
##id	I
##ine	I
,	O
amino	B
##eth	I
##ano	I
##l	I
,	O
a	B
##rab	I
##ito	I
##l	I
,	O
RS	B
##23	I
##di	I
##hy	I
##dr	I
##ox	I
##y	I
##but	I
##ano	I
##ica	I
##cid	I
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
a	I
##zel	I
##aic	I
acid	I
,	O
β	B
-	I
al	I
##ani	I
##ne	I
)	O
were	O
included	O
into	O
the	O
potential	O
diagnostic	O
model	O
.	O

E	B
##ico	I
##san	I
##oids	I
consist	O
of	O
le	O
##uk	O
##ot	O
##rien	O
##es	O
,	O
pro	B
##sta	I
##g	I
##land	I
##ins	I
and	O
th	B
##rom	I
##box	I
##ane	I
##s	I
and	O
are	O
derived	O
from	O
a	B
##rac	I
##hi	I
##don	I
##ic	I
acid	I
or	O
l	B
##ino	I
##lea	I
##te	I
.	O

(	O
,	O
-	O
)	O
P	B
##se	I
##udo	I
##uri	I
##dine	I
is	O
synthesized	O
from	O
u	O
##rac	O
##il	O
(	O
,	O
)	O
and	O
constitutes	O
an	O
end	O
product	O
,	O
as	O
it	O
is	O
not	O
cat	O
##ab	O
##oli	O
##zed	O
in	O
humans	O
.	O

The	O
L	O
##C	O
-	O
MS	O
grade	O
re	O
##age	O
##nts	O
,	O
including	O
water	O
,	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
(	O
AC	O
##N	O
)	O
,	O
met	B
##han	I
##ol	I
,	O
and	O
form	B
##ic	I
acid	I
,	O
were	O
purchased	O
from	O
Fisher	O
Scientific	O
(	O
Ottawa	O
,	O
Canada	O
)	O
and	O
13	O
##C	O
dans	B
##yl	I
-	I
chloride	I
was	O
available	O
from	O
the	O
University	O
of	O
Alberta	O
(	O
http	O
:	O
/	O
/	O
m	O
##cid	O
.	O
ch	O
##em	O
.	O
u	O
##al	O
##bert	O
##a	O
.	O
ca	O
)	O
.	O

(	O
b	O
)	O
HIV	O
-	O
T	O
##B	O
patients	O
with	O
pu	O
##lm	O
##ona	O
##r	O
T	O
##B	O
exhibited	O
higher	O
7	B
-	I
o	I
##x	I
##o	I
-	I
D	I
##H	I
##EA	I
concentrations	O
compared	O
to	O
those	O
with	O
extra	O
##pu	O
##lm	O
##ona	O
##r	O
T	O
##B	O
.	O

Interest	O
##ingly	O
,	O
lower	O
levels	O
of	O
LP	O
##C	O
a	O
C	B
##24	I
:	I
0	I
collected	O
at	O
D	O
##7	O
were	O
the	O
strongest	O
predict	O
##ors	O
of	O
90	O
-	O
day	O
mortality	O
,	O
whereas	O
use	O
of	O
re	O
##nal	O
replacement	O
therapy	O
was	O
positively	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
death	O
.	O

Ph	B
##en	I
##yla	I
##lani	I
##ne	I
,	O
a	B
##rg	I
##ini	I
##ne	I
,	O
pro	B
##line	I
and	O
try	B
##pt	I
##op	I
##han	I
pathways	O
were	O
found	O
significantly	O
altered	O
(	O
p	O
-	O
value	O
<	O
0	O
.	O
05	O
)	O
.	O

Met	B
##hi	I
##oni	I
##ne	I
su	I
##lf	I
##oxide	I
is	O
an	O
oxidation	O
product	O
of	O
met	B
##hi	I
##oni	I
##ne	I
with	O
reactive	O
oxygen	O
species	O
so	O
it	O
is	O
considered	O
as	O
a	O
bio	O
##mark	O
##er	O
of	O
o	O
##xi	O
##da	O
##tive	O
stress	O
.	O

We	O
addressed	O
this	O
issue	O
by	O
determining	O
the	O
amount	O
of	O
β	O
-	O
g	O
##lu	O
##cu	O
##ron	O
##idas	O
##e	O
and	O
duration	S
of	O
in	O
##cu	O
##bation	O
necessary	O
to	O
ensure	O
complete	O
h	O
##ydro	O
##lysis	O
of	O
the	O
g	O
##lu	O
##cu	O
##ron	O
##ides	O
.	O

P	O
##eptide	O
add	O
##uc	O
##ts	O
observed	O
at	O
11	O
.	O
4	O
min	O
displayed	O
trip	O
##ly	O
charged	O
ions	O
[	O
M	O
+	O
3	O
##H	O
]	O
_	O
3	O
+	O
at	O
m	O
/	O
z	O
51	O
##7	O
.	O
8	O
and	O
51	O
##9	O
.	O
7	O
,	O
which	O
are	O
an	O
addition	O
mass	O
of	O
207	O
and	O
212	O
Da	O
to	O
the	O
pro	O
##ton	O
##ated	O
p	O
##eptide	O
L	O
##Q	O
##Q	O
##CP	O
##F	O
##ED	O
##H	O
##V	O
##K	O
(	O
m	O
/	O
z	O
134	O
##3	O
.	O
6	O
,	O
residues	O
31	O
–	O
41	O
of	O
SA	O
)	O
with	O
a	O
missed	O
c	O
##lea	O
##vage	O
at	O
C	O
-	O
terminal	O
of	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
.	O

Indeed	O
,	O
in	O
v	O
##it	O
##ro	O
studies	O
have	O
shown	O
that	O
both	O
glucose	B
-	I
and	O
a	O
##rg	O
##ini	O
##ne	O
-	O
mediated	O
insulin	O
release	O
in	O
β	O
cells	O
are	O
in	O
##hibit	O
##ed	O
by	O
α	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

*	O
p	O
<	O
0	O
.	O
05	O
,	O
versus	O
mon	B
##oc	I
##yclic	I
systemic	O
pattern	O
or	O
p	B
##oly	I
##cy	I
##c	I
##lic	I
systemic	O
pattern	O
.	O

This	O
method	O
is	O
being	O
used	O
in	O
a	O
controlled	O
cannabis	S
administration	O
study	O
,	O
investigating	O
urine	O
can	B
##na	I
##bino	I
##id	I
markers	O
documenting	O
recent	O
cannabis	S
use	O
,	O
chronic	O
frequent	O
smoking	O
or	O
route	O
of	O
drug	O
administration	O
and	O
potentially	O
improving	O
urine	O
can	B
##na	I
##bino	I
##id	I
result	I
interpretation	O
.	O

While	O
this	O
change	O
could	O
be	O
attributed	O
to	O
diminished	O
diet	O
##ary	O
intake	O
of	O
ca	B
##ffe	I
##ine	I
at	O
the	O
time	O
when	O
final	O
specimens	O
were	O
collected	O
,	O
another	O
explanation	O
might	O
be	O
a	O
progressive	O
change	O
for	O
overall	O
pu	B
##rine	I
metabolism	O
(	O
as	O
reflected	O
in	O
the	O
metabolism	O
of	O
both	O
end	O
##ogen	O
##ous	O
and	O
diet	O
##ary	O
x	B
##ant	I
##hine	I
compounds	O
)	O
.	O

Furthermore	O
,	O
as	O
the	O
car	B
##ni	I
##tine	I
of	O
the	O
carrier	O
of	O
the	O
internal	O
and	O
external	O
material	O
exchange	O
of	O
the	O
mitochondrial	O
membrane	O
was	O
synthesized	O
to	O
raw	O
l	B
##ys	I
##ine	I
,	O
and	O
participated	O
in	O
the	O
folded	O
le	B
##uc	I
##ine	I
of	O
protein	O
space	O
,	O
so	O
that	O
p	O
##ap	O
##illa	O
##ry	O
thy	O
##roid	O
car	O
##cin	O
##oma	O
was	O
increased	O
.	O

Additionally	O
,	O
a	O
small	O
al	O
##iq	O
##uo	O
##t	O
of	O
each	O
experimental	O
sample	O
was	O
pool	O
##ed	O
together	O
to	O
serve	O
as	O
a	O
technical	O
replica	O
##te	O
for	O
duration	S
of	O
the	O
run	O
.	O

Keys	O
:	O
1	O
-	O
M	O
##H	O
:	O
1	B
-	I
Met	I
##hyl	I
##his	I
##tide	I
##ne	I
;	O
AA	O
:	O
Ace	B
##to	I
##ace	I
##tate	I
;	O
Ace	O
:	O
Ace	B
##tate	I
;	O
Act	O
:	O
Ace	B
##tone	I
;	O
Al	O
##a	O
:	O
Alan	B
##ine	I
;	O
C	O
##r	O
:	O
C	B
##rea	I
##tine	I
;	O
E	O
##th	O
:	O
Ethan	B
##ol	I
;	O
For	O
:	O
Form	B
##ate	I
;	O
G	O
##ln	O
:	O
G	B
##lut	I
##amine	I
;	O
G	O
##lu	O
:	O
G	B
##lut	I
##ama	I
##te	I
;	O
G	O
##ly	O
:	O
G	B
##ly	I
##cine	I
;	O
GP	B
##C	I
:	O
G	B
##ly	I
##cer	I
##ol	I
##ph	I
##os	I
##ph	I
##och	I
##olin	I
##e	I
;	O
Il	O
##eu	O
:	O
Is	B
##ole	I
##uc	I
##ine	I
;	O
L	O
##1	O
:	O
L	O
##D	O
##L	O
,	O
CH	O
_	O
3	O
-	O
(	O
CH	O
_	O
2	O
)	O
_	O
n	O
-	O
;	O
L	O
##2	O
:	O
V	O
##LD	O
##L	O
,	O
CH	O
_	O
3	O
-	O
(	O
CH	O
_	O
2	O
)	O
_	O
n	O
-	O
;	O
L	O
##3	O
:	O
L	O
##D	O
##L	O
,	O
CH	O
_	O
3	O
-	O
(	O
CH	O
_	O
2	O
)	O
_	O
n	O
-	O
;	O
L	O
##4	O
:	O
V	O
##LD	O
##L	O
,	O
CH	O
_	O
3	O
-	O
(	O
CH	O
_	O
2	O
)	O
_	O
n	O
-	O
;	O
L	O
##5	O
:	O
V	O
##LD	O
##L	O
,	O
-	O
CH	O
_	O
2	O
-	O
CH	O
_	O
2	O
-	O
C	O
=	O
O	O
;	O
L	O
##6	O
:	O

F	O
##SI	O
##V	O
##G	O
##TT	O
values	O
of	O
glucose	S
were	O
analyzed	O
immediately	O
with	O
a	O
bedside	O
analyze	O
##r	O
from	O
Yellow	O
Springs	O
Instruments	O
and	O
insulin	O
was	O
analyzed	O
within	O
4	O
##d	O
by	O
E	O
##L	O
##IS	O
##A	O
(	O
Mill	O
##ip	O
##ore	O
,	O
#	O
E	O
##Z	O
##H	O
##I	O
-	O
14	O
##L	O
)	O
.	O

In	O
addition	O
,	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
in	O
matrix	O
were	O
deprived	O
by	O
the	O
so	O
##rb	O
##ent	O
of	O
O	O
##stro	O
,	O
which	O
also	O
decreased	O
the	O
matrix	O
interference	O
.	O

Also	O
,	O
it	O
has	O
been	O
shown	O
using	O
N	O
##MR	O
experiments	O
that	O
g	B
##lut	I
##amine	I
is	O
a	O
major	O
an	O
##ap	O
##ler	O
##otic	O
precursor	O
in	O
pro	O
##life	O
##rating	O
g	O
##lio	O
##ma	O
cells	O
in	O
both	O
rats	O
and	O
humans	O
.	O

In	O
our	O
study	O
,	O
we	O
observed	O
increased	O
levels	O
of	O
saturated	O
fatty	O
acids	O
,	O
such	O
as	O
palm	B
##itic	I
acid	I
(	O
16	O
:	O
0	O
)	O
,	O
s	B
##te	I
##ari	I
##c	I
acid	I
(	O
18	O
:	O
0	O
)	O
,	O
o	B
##le	I
##ic	I
acid	I
(	O
18	O
:	O
1	O
)	O
and	O
ch	B
##ole	I
##ster	I
##ol	I
in	O
CH	O
##B	O
patients	O
,	O
which	O
suggests	O
that	O
chronic	O
H	O
##B	O
##V	O
infection	O
may	O
interfere	O
with	O
fatty	O
acid	O
metabolism	O
.	O

Both	O
runs	O
were	O
performed	O
on	O
the	O
S	O
##yne	O
##rg	O
##i	O
H	B
##ydro	I
R	I
##P	I
column	O
(	O
150	O
##×	O
##2	O
.	O
0	O
mm	O
,	O
4	O
μ	O
##m	O
,	O
Ph	O
##eno	O
##men	O
##ex	O
,	O
Tor	O
##rance	O
,	O
CA	O
,	O
USA	O
)	O
maintained	O
at	O
ambient	O
temperature	O
and	O
attached	O
to	O
a	O
guard	O
column	O
of	O
the	O
same	O
packing	O
material	O
.	O

This	O
could	O
also	O
explain	O
the	O
decreased	O
lip	O
##id	O
levels	O
and	O
increased	O
β	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
and	O
ace	B
##to	I
##ace	I
##tate	I
levels	O
in	O
the	O
serum	O
of	O
lung	O
cancer	O
patients	O
.	O

Target	O
##ed	O
analysis	O
of	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
(	O
l	O
##ys	O
##o	O
##PC	O
)	O
showed	O
that	O
irregular	O
levels	O
of	O
l	O
##ys	O
##o	O
##PC	O
is	O
##omer	O
##s	O
with	O
different	O
fatty	O
a	O
##cy	O
##l	O
positions	O
were	O
found	O
in	O
the	O
plasma	O
of	O
lung	O
cancer	O
patients	O
as	O
compared	O
to	O
controls	O
.	O

U	O
##rina	O
##ry	O
levels	O
of	O
is	B
##of	I
##lav	I
##ones	I
and	O
S	O
-	O
(	O
−	O
)	O
e	O
##q	O
##uo	O
##l	O
following	O
a	O
three	O
-	O
day	O
so	O
##y	O
challenge	O
were	O
detected	O
and	O
q	O
##uant	O
##ified	O
using	O
liquid	O
ch	O
##roma	O
##tography	O
-	O
multiple	O
reaction	O
ion	O
monitoring	O
mass	O
s	O
##pect	O
##rome	O
##try	O
analysis	O
.	O

The	O
concentrations	O
of	O
ta	B
##uri	I
##ne	I
,	O
glucose	S
,	O
and	O
beta	B
##ine	I
were	O
remarkably	O
higher	O
in	O
patients	O
who	O
underwent	O
total	O
thy	O
##roid	O
##ec	O
##tom	O
##y	O
than	O
in	O
those	O
who	O
underwent	O
un	O
##ila	O
##teral	O
thy	O
##roid	O
##ec	O
##tom	O
##y	O
.	O

One	O
approach	O
under	O
development	O
by	O
Rap	O
##pa	O
##port	O
and	O
colleagues	O
is	O
the	O
selective	O
en	O
##rich	O
##ment	O
of	O
p	O
##eptide	O
add	O
##uc	O
##ts	O
formed	O
at	O
Cy	O
##s	O
##34	O
of	O
Al	O
##b	O
by	O
means	O
of	O
a	O
th	B
##iol	I
affinity	O
re	O
##sin	O
.	O

Ni	B
##tric	I
oxide	I
s	O
##ynth	O
##ase	O
,	O
as	B
##ym	I
##metric	I
dim	I
##eth	I
##yla	I
##rg	I
##ini	I
##ne	I
,	O
heart	O
failure	O
,	O
pulmonary	O
h	O
##yper	O
##tens	O
##ion	O

When	O
the	O
severe	O
group	O
only	O
was	O
considered	O
,	O
two	O
lip	O
##id	O
meta	O
##bol	O
##ites	O
(	B
T	B
##AG	I
(	I
42	I
:	I
2	I
)	I
and	O
T	B
##AG	I
(	I
42	I
:	I
1	I
)	I
)	O
,	O
were	O
positively	O
correlated	O
with	O
para	O
##si	O
##ta	O
##emia	O
and	O
16	O
exhibited	O
a	O
negative	O
correlation	O
.	O

Thus	O
,	O
purpose	O
of	O
the	O
current	O
study	O
was	O
to	O
evaluate	O
the	O
serum	O
SL	S
profile	O
of	O
patients	O
with	O
HC	O
##C	O
and	O
verify	O
possible	O
variations	O
of	O
SL	S
parameters	O
with	O
potential	O
diagnostic	O
and	O
experimental	O
value	O
both	O
for	O
the	O
clinical	O
setting	O
as	O
well	O
as	O
for	O
novel	O
research	O
approaches	O
.	O

Individual	O
meta	O
##bol	O
##ite	O
levels	O
were	O
tested	O
with	O
L	O
##MM	O
,	O
and	O
only	O
g	B
##lut	I
##ama	I
##te	I
remained	O
significantly	O
increased	O
after	O
6	O
months	O
after	O
correct	O
##ing	O
for	O
multiple	O
tests	O
(	O
Su	O
##pp	O
##lement	O
##ary	O
Table	O
2	O
)	O
.	O

Oral	O
wash	O
super	O
##nat	O
##ants	O
were	O
extracted	O
with	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
,	O
and	O
then	O
analyzed	O
for	O
the	O
presence	O
of	O
meta	O
##bol	O
##ites	O
.	O

Also	O
,	O
in	O
con	O
##cor	O
##dance	O
with	O
the	O
previous	O
analysis	O
,	O
T	B
##G	I
altered	O
meta	O
##bol	O
##ites	O
showed	O
a	O
specific	O
pattern	O
,	O
being	O
decreased	O
in	O
the	O
AD	O
group	O
.	O

Con	O
##cer	O
##ning	O
the	O
L	O
-	O
a	O
##rg	O
##ini	O
##ne	O
/	O
NO	O
pathway	O
,	O
PR	O
##MT	O
##s	O
act	O
as	O
negative	O
effect	O
##ors	O
of	O
NO	O
synthesis	O
by	O
increasing	O
the	O
pool	O
of	O
AD	B
##MA	I
and	O
SD	O
##MA	O
,	O
inhibitor	O
##s	O
of	O
NO	O
##S	O
##s	O
,	O
and	O
competitors	O
for	O
a	B
##rg	I
##ini	I
##ne	I
transport	O
##ers	O
.	O

Cap	O
##illa	O
##ry	O
glucose	S
was	O
measured	O
at	O
0	O
and	O
120	O
minutes	O
as	O
a	O
backup	O
in	O
case	O
ve	O
##nous	O
sampling	O
was	O
unsuccessful	O
.	O

Val	B
##ine	I
was	O
increased	O
14	O
%	O
in	O
G	O
##WI	O
(	O
Z	O
=	O
+	O
0	O
.	O
64	O
,	O
)	O
and	O
contributed	O
3	O
%	O
of	O
the	O
metabolic	O
impact	O
(	O
,	O
VIP	O
=	O
1	O
.	O
96	O
)	O
.	O

Given	O
previous	O
reports	O
that	O
TD	O
##O	O
##2	O
is	O
significantly	O
higher	O
in	O
ER	O
-	O
versus	O
ER	O
+	O
disease	O
,	O
the	O
plasma	O
try	B
##pt	I
##op	I
##han	I
and	O
k	B
##yn	I
##uren	I
##ine	I
concentrations	O
in	O
women	O
with	O
ER	O
-	O
and	O
ER	O
+	O
breast	O
cancer	O
were	O
next	O
compared	O
.	O

We	O
did	O
not	O
adjust	O
for	O
A	B
##F	I
since	O
this	O
was	O
one	O
of	O
our	O
major	O
outcomes	O
of	O
interest	O
and	O
A	B
##F	I
is	O
known	O
to	O
have	O
a	O
strong	O
association	O
with	O
CE	O
stroke	O
.	O

U	O
##rina	O
##ry	O
level	O
of	O
al	B
##ani	I
##ne	I
,	O
D	B
##MA	I
,	O
g	B
##ly	I
##cine	I
,	O
la	B
##ctic	I
acid	I
and	O
N	B
,	I
N	I
-	I
dim	I
##eth	I
##yl	I
##gly	I
##cine	I
were	O
significantly	O
(	O
F	O
##DR	O
<	O
0	O
.	O
05	O
)	O
associated	O
to	O
changes	O
in	O
F	O
##T	O
##4	O
levels	O
(	O
,	O
)	O
.	O

The	O
same	O
protocol	O
,	O
but	O
without	O
su	O
##lf	O
##ata	O
##se	O
and	O
p	B
-	I
ni	I
##tro	I
##cate	I
##cho	I
##l	I
,	O
was	O
applied	O
to	O
evaluate	O
only	O
the	O
di	B
##os	I
##met	I
##in	I
originating	O
from	O
g	B
##lu	I
##cu	I
##ron	I
##ide	I
meta	O
##bol	O
##ites	O
;	O
in	O
other	O
tests	O
the	O
in	O
##cu	O
##bation	O
was	O
repeated	O
also	O
without	O
g	O
##lu	O
##cu	O
##ron	O
##idas	O
##e	O
and	O
para	B
##ce	I
##tam	I
##ol	I
-	I
β	I
-	I
d	I
-	I
g	I
##lu	I
##cu	I
##ron	I
##ide	I
in	O
order	O
to	O
measure	O
only	O
di	B
##os	I
##met	I
##in	I
originating	O
from	O
su	B
##lf	I
##ate	I
con	O
##ju	O
##gate	O
##s	O
(	O
in	O
such	O
cases	O
d	B
-	I
sa	I
##cc	I
##hari	I
##c	I
acid	I
1	I
,	I
4	I
-	I
la	I
##cton	I
##e	I
mon	O
##oh	O
##yd	O
##rate	O
was	O
added	O
;	O
0	O
.	O
02	O
m	O
##L	O
at	O
a	O
concentration	O
of	O
35	O
mg	O
/	O
m	O
##L	O
,	O
during	O
in	O
##cu	O
##bation	O
,	O
to	O
in	O
##hibit	O
any	O
possible	O
residual	O
g	O
##lu	O
##cu	O
##ron	O
##idas	O
##e	O
activity	O
)	O
.	O

More	O
recently	O
,	O
Frank	O
##e	O
et	O
al	O
[	O
,	O
]	O
reported	O
different	O
in	O
##tra	O
-	O
individual	O
variations	O
during	O
high	B
-	I
vs	I
.	O
low	O
-	O
so	O
##y	O
diet	O
,	O
and	O
using	O
different	O
cut	O
-	O
off	O
methods	O
and	O
threshold	O
##s	O
for	O
S	O
-	O
(	O
−	O
)	O
e	O
##q	O
##uo	O
##l	O
producers	O
,	O
non	O
-	O
producers	O
and	O
those	O
who	O
crossed	O
-	O
over	O
to	O
either	O
from	O
being	O
a	O
producer	O
to	O
non	O
-	O
producer	O
or	O
vice	O
-	O
versa	O
.	O

In	O
inflammation	O
,	O
c	B
##it	I
##rate	I
is	O
reduced	O
to	O
its	O
derivatives	O
in	O
the	O
c	O
##yt	O
##oso	O
##l	O
to	O
supply	O
components	O
to	O
altered	O
energy	O
and	O
intermediate	O
production	O
.	O

[	O
Google	O
Scholar	O
]	O
M	O
##c	O
##D	O
##ona	O
##gh	O
A	B
##F	I
,	O
Palma	O
LA	O
,	O
Lau	O
##ff	O
J	O
##J	O
,	O
Wu	O
T	O
##W	O
.	O

Thus	O
,	O
both	O
up	O
##take	O
into	O
the	O
cells	O
and	O
up	O
##re	O
##gu	O
##lated	O
extraction	O
might	O
explain	O
the	O
decreased	O
c	B
##it	I
##rate	I
levels	O
in	O
se	O
##psis	O
serum	O
in	O
our	O
study	O
.	O

UP	O
##LC	O
-	O
E	O
##SI	O
/	O
MS	O
_	O
2	O
mass	O
ch	O
##roma	O
##to	O
##gram	O
##s	O
of	O
add	O
##uc	O
##ts	O
of	O
NO	O
_	O
2	O
-	O
Ph	O
##IP	O
-	O
modified	O
SA	O
formed	O
by	O
reaction	O
of	O
the	O
car	O
##cin	O
##ogen	O
with	O
human	O
SA	O
at	O
a	O
m	O
##olar	O
ratio	O
of	O
3	O
:	O
1	O
(	O
left	O
panel	O
)	O
and	O
0	B
.	I
3	I
:	I
1	I
(	I
right	I
panel	I
)	I
;	O
the	O
SA	O
was	O
dig	O
##ested	O
with	O
try	O
##ps	O
##in	O
.	O

El	O
##eva	O
##ted	O
la	B
##ct	I
##ate	I
and	O
p	B
##yr	I
##u	I
##vate	I
decrease	O
the	O
cellular	O
N	O
##AD	O
##H	O
/	O
N	O
##AD	O
ratio	O
,	O
which	O
in	O
turn	O
regulate	O
##s	O
various	O
clock	O
genes	O
,	O
which	O
may	O
contribute	O
to	O
the	O
disorder	O
##ed	O
sleep	O
and	O
g	B
##lu	I
##co	I
##cor	I
##tic	I
##oid	I
sensitivity	O
associated	O
with	O
PT	O
##SD	O
.	O

The	O
results	O
demonstrated	O
that	O
the	O
p	B
##hos	I
##pha	I
##ti	I
##dic	I
acid	I
and	O
CE	B
(	I
18	I
:	I
0	I
)	I
levels	O
in	O
H	O
##U	O
were	O
lower	O
than	O
those	O
in	O
H	O
##U	O
+	O
N	O
##AF	O
##LD	O
;	O
by	O
contrast	O
,	O
the	O
in	B
##os	I
##ine	I
levels	O
in	O
H	O
##U	O
were	O
higher	O
than	O
those	O
in	O
H	O
##U	O
+	O
N	O
##AF	O
##LD	O
.	O

At	O
the	O
time	O
of	O
extraction	O
,	O
spent	O
medium	O
was	O
collected	O
and	O
cells	O
were	O
rapidly	O
washed	O
twice	O
with	O
cold	O
phosphate	S
buffer	O
##ed	O
sa	B
##line	I
to	O
remove	O
con	O
##tam	O
##inating	O
medium	O
.	O

However	O
,	O
this	O
association	O
was	O
not	O
found	O
in	O
norm	O
##ote	O
##ns	O
##ive	O
subjects	O
,	O
possibly	O
due	O
to	O
low	O
levels	O
of	O
L	B
##D	I
##L	I
ch	I
##ole	I
##ster	I
##ol	I
,	O
o	O
##x	O
-	O
L	O
##D	O
##L	O
,	O
and	O
L	O
##p	O
-	O
P	O
##LA	O
_	O
2	O
activity	O
.	O

Ana	O
##ly	O
##tical	O
standards	O
were	O
prepared	O
using	O
a	O
D	B
##MS	I
##O	I
ca	O
##li	O
##bra	O
##tion	O
stock	O
solution	O
containing	O
anal	O
##yte	O
##s	O
1	O
–	O
6	O
(	O
100	O
μ	O
##g	O
/	O
m	O
##L	O
)	O
that	O
was	O
stored	O
at	O
−	O
##40	O
##°	O
##C	O
until	O
use	O
.	O

Mobile	O
phase	O
A	O
(	O
50	O
%	O
met	B
##han	I
##ol	I
containing	O
0	O
.	O
5	O
m	O
##M	O
am	B
##mon	I
##ium	I
format	I
##e	I
at	O
pH	O
4	O
at	O
a	O
flow	O
rate	O
of	O
200	O
μ	O
##L	O
/	O
min	O
)	O
was	O
used	O
from	O
0	O
to	O
15	O
min	O
,	O
followed	O
by	O
a	O
fast	O
-	O
gradient	O
100	O
%	O
mobile	O
phase	O
B	O
(	O
95	O
%	O
met	B
##han	I
##ol	I
containing	O
0	O
.	O
1	O
%	O
form	O
##ic	O
acid	O
)	O
within	O
5	O
min	O
.	O

Following	O
this	O
procedure	O
,	O
0	O
.	O
75	O
m	O
##l	O
of	O
ch	B
##lor	I
##of	I
##orm	I
and	O
0	O
.	O
3	O
m	O
##l	O
of	O
water	O
were	O
added	O
into	O
tube	O
;	O
its	O
content	O
was	O
dispersed	O
using	O
a	O
probe	O
son	O
##ica	O
##tor	O
and	O
extraction	O
process	O
continued	O
at	O
R	O
##T	O
overnight	O
.	O

56	O
##2	O
.	O
36	O
##39	O
(	O
580	O
.	O
37	O
##45	O
−	O
H	O
_	O
2	O
O	O
)	O
and	O
54	O
##6	O
.	O
36	O
##90	O
(	O
56	O
##4	O
.	O
37	O
##9	O
##6	O
−	O
H	O
_	O
2	O
O	O
)	O
assigned	O
to	O
h	B
##ydro	I
##xy	I
-	I
3	I
-	I
o	I
##x	I
##och	I
##ole	I
##sta	I
-	I
4	I
,	I
6	I
-	I
die	I
##n	I
-	I
26	I
-	I
o	I
##ic	I
acid	I
(	B
CA	B
_	I
4	I
,	I
6	I
-	I
x	I
-	I
o	I
##l	I
-	I
3	I
-	I
one	I
,	O
0	O
.	O
45	O
##3	O
±	O
0	O
.	O
204	O
ng	O
/	O
m	O
##l	O
)	O
and	O
3	B
-	I
o	I
##x	I
##och	I
##ole	I
##sta	I
-	I
4	I
,	I
6	I
-	I
die	I
##n	I
-	I
26	I
-	I
o	I
##ic	I
acid	I

The	O
flow	O
rates	O
used	O
were	O
40	O
m	O
##L	O
min	O
_	O
−	O
##1	O
for	O
V	O
##OC	O
,	O
30	O
m	O
##L	O
min	O
_	O
−	O
##1	O
for	O
1	B
,	I
3	I
-	I
but	I
##adi	I
##ene	I
and	O
3	O
L	O
##min	O
_	O
−	O
##1	O
for	O
PA	O
##H	O
.	O

It	O
has	O
been	O
proven	O
that	O
applying	O
a	O
##TR	O
##A	O
##Q	O
re	O
##age	O
##nts	O
for	O
the	O
quantitative	O
analysis	O
of	O
amino	O
acids	O
in	O
the	O
biological	O
fluids	O
increases	O
the	O
specific	O
##ity	O
of	O
the	O
method	O
and	O
significantly	O
reduces	O
the	O
duration	S
of	O
the	O
analysis	O
(	O
one	O
analytical	O
run	O
takes	O
18	O
minutes	O
)	O
.	O

Met	B
##han	I
##ol	I
super	O
##nat	O
##ants	O
and	O
the	O
M	B
##T	I
##BE	I
lip	O
##id	O
fraction	O
were	O
resolved	O
using	O
R	O
##PC	O
and	O
analyzed	O
in	O
both	O
ion	O
##ization	O
modes	O
.	O

Pre	O
##dia	O
##bet	O
##es	O
are	O
associated	O
with	O
low	O
vitamin	B
D	I
levels	O
,	O
and	O
the	O
risk	O
of	O
developing	O
diabetes	O
is	O
much	O
greater	O
for	O
pre	O
##dia	O
##bet	O
##es	O
who	O
are	O
vitamin	B
D	I
def	O
##icient	O
,	O
.	O

Overall	O
,	O
however	O
,	O
the	O
Tor	O
##us	O
Di	B
##ol	I
column	O
used	O
with	O
a	O
met	O
##han	O
##ol	O
/	O
am	O
##mon	O
##ium	O
format	B
##e	I
m	O
##od	O
##ifier	O
is	O
a	O
promising	O
starting	O
point	O
for	O
un	O
##tar	O
##get	O
##ed	O
SF	O
##C	O
analysis	O
of	O
medium	O
polar	O
##ity	O
meta	O
##bol	O
##ites	O
in	O
urine	O
.	O

Form	B
##ic	I
acid	I
and	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
(	O
AC	O
##N	O
)	O
were	O
obtained	O
from	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
;	O
Me	O
##rc	O
##k	O
K	O
##G	O
##a	O
##A	O
(	O
Dar	O
##ms	O
##tadt	O
,	O
Germany	O
)	O
.	O

Lac	B
##tate	I
concentration	O
was	O
significantly	O
higher	O
in	O
patients	O
dead	O
at	O
30	O
days	O
that	O
in	O
patients	O
alive	O
at	O
30	O
days	O
with	O
1	O
.	O
78	O
±	O
1	O
.	O
32	O
(	O
n	O
=	O
28	O
)	O
vs	O
1	O
.	O
14	O
±	O
0	O
.	O
40	O
m	O
##M	O
(	O
n	O
=	O
98	O
)	O
,	O
(	O
p	O
<	O
0	O
.	O
00	O
##1	O
)	O
,	O
respectively	O
.	O

From	O
a	O
study	O
on	O
ta	B
##mo	I
##xi	I
##fen	I
metabolism	O
in	O
pre	O
-	O
and	O
post	O
##men	O
##op	O
##aus	O
##al	O
women	O
ad	O
##ju	O
##vant	O
##ly	O
treated	O
with	O
ta	B
##mo	I
##xi	I
##fen	I
20	O
mg	O
daily	O
,	O
we	O
included	O
exclusively	O
post	O
##men	O
##op	O
##aus	O
##al	O
women	O
in	O
order	O
to	O
examine	O
patients	O
with	O
stable	O
est	B
##rogen	I
and	O
F	O
##S	O
##H	O
levels	O
.	O

Panel	O
a	O
:	O
P	B
##E	I
(	I
16	I
:	I
0	I
/	I
16	I
:	I
1	I
)	I
,	O
P	B
##E	I
(	I
16	I
:	I
0	I
/	I
18	I
:	I
3	I
)	I
,	O
P	B
##E	I
(	I
16	I
:	I
0	I
/	I
18	I
:	I
2	I
)	I
,	O
P	B
##E	I
(	I
18	I
:	I
0	I
/	I
16	I
:	I
0	I
)	I
,	O
P	B
##E	I
(	I
17	I
:	I
0	I
/	I
18	I
:	I
2	I
)	I
,	O
P	B
##E	I
(	I
18	I
:	I
0	I
/	I
17	I
:	I
1	I
)	I
,	O
P	B
##E	I
(	I
17	I
:	I
0	I
/	I
18	I
:	I
1	I
)	I
,	O
P	B
##E	I
(	I
20	I
:	I
5	I
/	I
16	I
:	I
0	I
)	I
,	O
P	B
##E	I
(	I
18	I
:	I
0	I
/	I
18	I
:	I
1	I
)	I
,	O
P	B
##E	I
(	I
18	I
:	I
1	I
/	I
20	I
:	I
4	I
)	I
,	O
P	B
##E	I
(	I
18	I
:	I
0	I
/	I
20	I
:	I
3	I
)	I
,	O
PC	B
(	I
15	I
:	I
0	I
/	I
18	I
:	I
1	I
,	I
PC	I
(	I
16	I
:	I
1	I
/	I
20	I
:	I
5	I
)	I
,	O
and	O
PC	B
(	I
18	I
:	I
0	I
/	I
20	I
:	I
1	I
)	I
;	I
Panel	I
b	I
:	I
P	I
##E	I
(	I
16	I
:	I
0	I
/	I
18	I
:	I
3	I
)	I
,	I
P	I
##E	I
(	I
18	I
:	I
0	I
/	I
16	I
:	I
0	I
)	I
,	O
P	B
##E	I
(	I
17	I
:	I
0	I
/	I
18	I
:	I
2	I
)	I
,	O
P	B
##E	I
(	I
17	I
:	I
0	I
/	I
18	I
:	I
1	I
)	I
,	O
P	B
##E	I
(	I
18	I
:	I
2	I
/	I
18	I
:	I
2	I
)	I
,	O
P	B
##E	I
(	I
18	I
:	I
1	I
/	I
18	I
:	I
2	I
)	I
,	O
P	B
##E	I
(	I
18	I
:	I
0	I
/	I
18	I
:	I
1	I
)	I

A	O
very	O
consistent	O
finding	O
in	O
the	O
M	O
##MCA	O
plots	O
was	O
the	O
negative	O
correlation	O
##s	O
of	O
the	O
1	O
.	O
3	O
##pp	O
##m	O
fatty	O
acid	O
signals	O
with	O
la	B
##ct	I
##ate	I
,	O
t	O
##G	O
##lut	O
,	O
t	O
##C	O
##r	O
and	O
t	O
##C	O
##ho	O
(	O
see	O
and	O
)	O
;	O
this	O
was	O
observed	O
in	O
four	O
of	O
the	O
five	O
t	O
##umour	O
types	O
,	O
while	O
o	O
##li	O
##go	O
##den	O
##dr	O
##og	O
##lio	O
##mas	O
had	O
significant	O
negative	O
correlation	O
##s	O
of	O
the	O
fatty	O
acids	O
with	O
la	B
##ct	I
##ate	I
and	O
t	O
##C	O
##r	O
but	O
not	O
with	O
t	O
##G	O
##lut	O
or	O
t	O
##C	O
##ho	O
.	O

In	O
addition	O
,	O
two	O
branched	O
-	O
chain	O
amino	O
acids	O
(	B
le	B
##uc	I
##ine	I
and	O
v	B
##ali	I
##ne	I
)	O
were	O
decreased	O
in	O
AS	O
plasma	O
.	O

In	O
solid	O
t	O
##umour	O
##s	O
,	O
plate	O
##let	O
a	O
##gg	O
##regation	O
can	O
release	O
se	B
##rot	I
##oni	I
##n	I
,	O
which	O
may	O
constitute	O
one	O
of	O
the	O
mechanisms	O
of	O
t	O
##umour	O
progression	O
and	O
an	O
##gio	O
##genesis	O
,	O
and	O
could	O
result	O
in	O
higher	O
se	B
##rot	I
##oni	I
##n	I
levels	O
in	O
the	O
blood	O
.	O

We	O
observed	O
a	O
negative	O
correlation	O
between	O
al	B
##ani	I
##ne	I
and	O
ace	B
##tone	I
levels	O
in	O
survivor	O
patients	O
with	O
low	O
AC	O
##S	O
and	O
RF	O
risk	O
scores	O
,	O
while	O
this	O
correlation	O
disappears	O
in	O
high	O
-	O
risk	O
patients	O
,	O
either	O
survived	O
or	O
deceased	O
at	O
2	O
years	O
after	O
AM	O
##I	O
.	O

To	O
further	O
evaluate	O
the	O
involvement	O
of	O
these	O
22	O
o	B
##xy	I
##lip	I
##ins	I
in	O
media	O
##ting	O
a	O
differential	O
response	O
to	O
the	O
meal	O
,	O
they	O
were	O
grouped	O
into	O
4	O
clusters	O
based	O
on	O
similar	O
patterns	O
of	O
expression	O
.	O

These	O
had	O
different	O
properties	O
:	O
isolated	O
peaks	O
(	B
la	B
##ct	I
##ate	I
H	O
##10	O
format	B
##e	I
H	O
##4	O
)	O
,	O
peaks	O
with	O
some	O
overlap	O
with	O
mac	O
##rom	O
##ole	O
##cule	O
signals	O
(	B
v	B
##ali	I
##ne	I
H	O
##9	O
-	O
11	O
and	O
H	O
##12	O
-	O
14	O
,	O
α	B
-	I
glucose	I
H	O
##19	O
)	O
and	O
peaks	O
with	O
major	O
overlap	O
with	O
mac	O
##rom	O
##ole	O
##cule	O
##s	O
(	B
la	B
##ct	I
##ate	I
H	O
##7	O
-	O
9	O
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
H	O
##13	O
,	O
H	O
##14	O
-	O
15	O
,	O
and	O
H	O
##16	O
-	O
17	O
)	O
.	O

A	O
60	O
-	O
person	O
panel	O
of	O
adults	O
participated	O
in	O
a	O
crossover	O
study	O
,	O
where	O
each	O
participant	O
conducted	O
a	O
highway	O
com	O
##mu	O
##te	O
and	O
random	O
##ized	O
to	O
either	O
a	O
side	B
-	I
street	I
com	O
##mu	O
##te	O
or	O
clinic	O
exposure	O
session	O
.	O

The	O
mobile	O
phase	O
was	O
composed	O
of	O
0	O
.	O
1	O
%	O
a	O
##que	O
##ous	O
form	B
##ic	I
acid	I
(	O
Phase	O
A	O
)	O
and	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
(	O
Phase	O
B	O
)	O
.	O

Pro	O
##state	O
cells	O
have	O
a	O
unique	O
metabolic	O
profile	O
and	O
show	O
increased	O
production	O
of	O
p	B
##oly	I
##amine	I
##s	I
such	O
as	O
sperm	B
##ine	I
and	O
my	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
,	O
and	O
secret	O
##e	O
very	O
high	O
levels	O
of	O
c	B
##it	I
##rate	I
,	O
resulting	O
partly	O
from	O
the	O
in	O
##hibition	O
of	O
K	O
##re	O
##bs	O
cycle	O
metabolism	O
of	O
c	B
##it	I
##rate	I
.	O

For	O
experiment	O
operations	O
,	O
briefly	O
,	O
meta	O
##bol	O
##ites	O
from	O
a	O
dried	O
blood	O
spots	O
were	O
extracted	O
with	O
met	B
##han	I
##ol	I
.	O

However	O
,	O
beta	B
##ine	I
,	O
v	B
##ali	I
##ne	I
,	O
g	B
##ly	I
##cine	I
and	O
glucose	S
were	O
elevated	O
in	O
the	O
urine	O
of	O
H	O
##NF	O
##1	O
##A	O
-	O
M	O
##OD	O
##Y	O
subjects	O
compared	O
to	O
the	O
other	O
subgroup	O
##s	O
.	O

These	O
methods	O
were	O
subsequently	O
used	O
to	O
evaluate	O
SR	O
##M	O
90	O
##9	O
##c	O
Human	O
Ser	O
##um	O
,	O
and	O
25	O
(	O
OH	O
)	O
D	O
_	O
3	O
was	O
the	O
only	O
vitamin	B
D	I
meta	O
##bol	O
##ite	O
detected	O
in	O
this	O
material	O
.	O

T	B
##hia	I
##c	I
##lop	I
##rid	I
was	O
detected	O
only	O
in	O
AS	O
##G	O
,	O
and	O
cloth	B
##ian	I
##id	I
##in	I
was	O
detected	O
in	O
N	O
##S	O
##G	O
.	O

Inc	O
##reased	O
level	O
of	O
D	B
##MA	I
and	O
T	O
##MA	O
indicated	O
the	O
up	O
-	O
regulation	O
of	O
the	O
met	B
##hyl	I
##amine	I
met	I
##hyl	I
##amine	I
.	O

Interest	O
##ingly	O
,	O
the	O
bio	O
##ava	O
##ila	O
##bility	O
of	O
the	O
G	O
##R	O
contribution	O
to	O
systemic	O
SF	S
appeared	O
to	O
increase	O
over	O
the	O
84	O
-	O
day	O
period	O
,	O
perhaps	O
due	O
to	O
changes	O
in	O
the	O
composition	O
of	O
the	O
micro	O
##f	O
##lora	O
.	O

This	O
results	O
in	O
the	O
inability	O
to	O
form	O
g	B
##ly	I
##cine	I
from	O
g	B
##ly	I
##ox	I
##yla	I
##te	I
,	O
which	O
causes	O
the	O
body	O
to	O
produce	O
increased	O
levels	O
of	O
the	O
metabolic	O
end	O
product	O
,	O
o	B
##xa	I
##late	I
.	O

However	O
,	O
the	O
fact	O
that	O
the	O
serum	O
levels	O
of	O
other	O
amino	O
acids	O
were	O
similar	O
in	O
the	O
two	O
patient	O
groups	O
presents	O
an	O
argument	O
against	O
the	O
breakdown	O
of	O
proteins	O
in	O
the	O
skeletal	O
muscle	O
being	O
responsible	O
for	O
increased	O
t	B
##yr	I
##os	I
##ine	I
serum	O
levels	O
in	O
A	O
##HF	O
patients	O
that	O
did	O
not	O
survive	O
for	O
three	O
months	O
.	O

In	O
T	O
##2	O
stage	O
disease	O
,	O
when	O
comparing	O
pre	O
-	O
g	O
##em	O
##ci	O
##ta	O
##bine	O
normal	O
vs	O
.	O
pre	O
-	O
g	O
##em	O
##ci	O
##ta	O
##bine	O
BC	O
##a	O
tissues	O
,	O
re	B
##tina	I
##l	I
was	O
decreased	O
significantly	O
in	O
the	O
BC	O
##a	O
tissues	O
(	O
P	O
=	O
4	O
.	O
98	O
##E	O
-	O
2	O
)	O
(	O
Table	O
S	O
##I	O
and	O
)	O
,	O
while	O
its	O
change	O
became	O
statistical	O
##ly	O
ins	O
##ign	O
##ificant	O
following	O
sub	O
##mu	O
##cos	O
##al	O
injection	O
of	O
g	O
##em	O
##ci	O
##ta	O
##bine	O
(	O
P	O
=	O
3	O
.	O
22	O
##E	O
-	O
1	O
)	O
(	O
Table	O
S	O
##I	O
and	O
)	O
;	O
however	O
,	O
at	O
this	O
stage	O
,	O
the	O
decrease	O
of	O
re	B
##tina	I
##l	I
in	O
tumor	O
was	O
not	O
statistical	O
##ly	O
significant	O
(	O
P	O
=	O
1	O
.	O
68	O
##E	O
-	O
1	O
)	O
(	O
Table	O
S	O
##I	O
)	O
.	O

No	O
differences	O
in	O
the	O
actual	O
concentrations	O
of	O
T	B
##MA	I
##O	I
were	O
observed	O
among	O
the	O
three	O
groups	O
(	O
one	O
-	O
way	O
AN	O
##O	O
##VA	O
p	O
=	O
0	O
.	O
32	O
##6	O
)	O
.	O

As	O
such	O
,	O
the	O
increased	O
levels	O
of	O
4	B
-	I
h	I
##ydro	I
##xy	I
##p	I
##rol	I
##ine	I
seen	O
in	O
patient	O
samples	O
is	O
consistent	O
with	O
the	O
nature	O
of	O
inflammatory	O
events	O
occurring	O
in	O
this	O
type	O
of	O
major	O
surgery	O
,	O
whilst	O
c	B
##ys	I
##tat	I
##hi	I
##oni	I
##ne	I
is	O
a	O
substrate	O
for	O
the	O
gas	O
##eous	O
media	O
##tor	O
hydrogen	B
su	I
##l	I
##phi	I
##de	I
and	O
also	O
a	O
precursor	O
for	O
g	B
##lut	I
##ath	I
##ione	I
production	O
.	O

shows	O
the	O
typical	O
low	O
frequency	O
CP	O
##MG	O
s	O
##pect	O
##ra	O
of	O
plasma	O
samples	O
obtained	O
from	O
F	B
##D	I
patients	O
and	O
healthy	O
subjects	O
.	O

Cy	O
##t	O
b	O
##5	O
:	O
Cy	O
##to	O
##ch	O
##rome	O
b	B
##5	I
;	I
5	I
##α	I
-	I
R	I
:	O
5	O
##α	O
-	O
red	O
##uc	O
##tase	O
;	O
5	B
##β	I
-	I
R	I
:	O
5	O
##β	O
-	O
red	O
##uc	O
##tase	O
.	O

Ch	O
##roma	O
##tography	O
parameters	O
of	O
N	O
##RT	O
##I	O
-	O
T	O
##P	O
represented	O
by	O
the	O
symbols	O
:	O
+	O
,	O
3	O
##TC	O
-	O
T	O
##P	O
;	O
×	O
,	O
D	O
##X	O
##G	O
-	O
T	O
##P	O
;	O
[UNK]	O
,	O
T	O
##F	O
##V	O
-	O
D	O
##P	O
;	O
[UNK]	O
,	O
CB	O
##V	O
-	O
T	O
##P	O
;	O
[UNK]	O
,	O
(	O
−	O
)	O
-	O
F	O
##TC	O
-	O
T	O
##P	O
;	O
and	O
[UNK]	O
,	O
Z	O
##D	O
##V	O
-	O
T	O
##P	O
:	O
(	O
a	O
)	O
tail	O
##ing	O
factor	O
(	O
T	O
##f	O
)	O
at	O
five	O
different	O
HM	O
##A	O
concentrations	O
;	O
0	O
,	O
3	O
,	O
6	O
,	O
9	O
,	O
and	O
12	O
m	O
##M	O
.	O
(	O
b	O
)	O
Effect	O
##ive	O
plate	O
number	O
(	O
N	O
##e	O
)	O
at	O
four	O
different	O
buffer	O
compositions	O
;	O
1	O
and	O
2	O
m	O
##M	O
am	B
##mon	I
##ium	I
phosphate	I
;	O
10	O
and	O
20	O
m	O
##M	O
am	B
##mon	I
##ium	I
hydrogen	I
carbon	I
##ate	I
.	O

We	O
also	O
measured	O
significantly	O
reduced	O
proportional	O
amounts	O
of	O
LP	B
##C	I
(	I
18	I
:	I
2	I
)	I
in	O
HIV	O
+	O
participants	O
.	O

In	O
the	O
current	O
study	O
3	O
##SP	O
was	O
found	O
in	O
abundance	O
in	O
infection	O
-	O
only	O
cases	O
;	O
it	O
is	O
known	O
to	O
be	O
a	O
ni	B
##cot	I
##ine	I
meta	O
##bol	O
##ite	O
expected	O
in	O
the	O
urine	O
of	O
tobacco	O
smoke	O
##rs	O
.	O

Det	O
##ec	O
##tion	O
of	O
a	O
g	O
##lu	O
##cu	O
##ron	O
##idated	O
con	O
##ju	O
##gate	O
is	O
therefore	O
consistent	O
with	O
ant	B
##ho	I
##cy	I
##ani	I
##n	I
e	O
##pit	O
##hel	O
##ial	O
up	O
##take	O
,	O
metabolism	O
,	O
and	O
release	O
of	O
a	O
meta	O
##bol	O
##ite	O
capable	O
of	O
undergoing	O
recycling	O
via	O
de	O
##g	O
##lu	O
##cu	O
##ron	O
##ida	O
##tion	O
and	O
cellular	O
re	O
-	O
entry	O
.	O

b	O
)	O
and	O
the	O
al	O
##ken	O
##yl	O
-	O
a	O
##cy	O
##l	O
form	O
PC	O
##32	O
##p	O
:	O
0	O
by	O
the	O
presence	O
of	O
the	O
FA	B
16	I
:	I
0	I
(	O
m	O
/	O
z	O
255	O
.	O
232	O
##7	O
)	O
at	O
9	O
.	O
3	O
min	O
(	O
Fi	O
##g	O
.	O

The	O
sample	O
size	O
calculations	O
were	O
based	O
on	O
a	O
separate	O
candidate	B
-	I
gene	I
study	O
,	O
conducted	O
as	O
part	O
of	O
the	O
broader	O
“	O
Top	O
##ography	O
and	O
Gene	O
##tics	O
of	O
S	O
##mo	O
##king	O
and	O
Nico	B
##tine	I
De	O
##pen	O
##dence	O
in	O
American	O
Indians	O
”	O
study	O
.	O

Transport	O
##ers	O
for	O
glucose	S
and	O
K	O
##re	O
##bs	O
cycle	O
intermediate	O
##s	O
have	O
been	O
identified	O
in	O
the	O
brush	O
border	O
membrane	O
of	O
the	O
tub	O
##uli	O
,	O
.	O

However	O
,	O
these	O
studies	O
were	O
limited	O
in	O
the	O
characterization	O
of	O
meta	O
##bol	O
##ites	O
lost	O
during	O
formal	B
##in	I
fix	O
##ation	O
and	O
para	B
##ffin	I
em	O
##bed	O
##ding	O
and	O
following	O
extraction	O
.	O

Se	O
##vere	O
C	O
##K	O
##D	O
patients	O
were	O
recommended	O
to	O
avoid	O
potassium	B
-	I
and	O
phosphate	O
-	O
rich	O
foods	O
.	O

Met	O
##ab	O
##oli	O
##te	O
q	O
##uant	O
##ification	O
was	O
performed	O
using	O
an	O
external	O
reference	O
standard	O
of	O
la	B
##ct	I
##ate	I
(	O
3	O
μ	O
##mo	O
##l	O
)	O
,	O
scanned	O
under	O
the	O
same	O
analytical	O
conditions	O
as	O
the	O
tissue	O
samples	O
.	O

Seven	O
meta	O
##bol	O
##ites	O
exhibited	O
changes	O
in	O
concentrations	O
both	O
at	O
room	O
temperature	O
(	O
without	O
pre	O
##ser	O
##vat	O
##ive	O
)	O
and	O
with	O
pre	O
##ser	O
##vat	O
##ive	O
or	O
at	O
4	O
°C	O
:	O
u	B
##ro	I
##bil	I
##ino	I
##gen	I
,	O
u	B
##ro	I
##bil	I
##in	I
,	O
as	B
##cor	I
##bic	I
acid	I
,	O
or	B
##otic	I
acid	I
,	O
in	O
addition	O
to	O
is	O
##omer	O
##s	O
of	O
k	O
##eto	O
##ret	O
##ino	O
##ic	O
acid	O
and	O
h	B
##ydro	I
##xy	I
##ret	I
##ino	I
##ic	I
acid	I
g	O
##lu	O
##cu	O
##ron	O
##ides	O
,	O
and	O
th	B
##re	I
##ono	I
##la	I
##cton	I
##e	I
(	O
Table	O
;	O
Figure	O
,	O
and	O
graphs	O
provided	O
as	O
supplement	O
##ary	O
material	O
6	O
)	O
.	O

High	O
MA	O
##TV	O
_	O
W	O
##T	O
##B	O
and	O
T	O
##L	O
##G	O
_	O
W	O
##T	O
##B	O
values	O
are	O
associated	O
with	O
higher	O
concentrations	O
of	O
glucose	S
,	O
g	B
##ly	I
##cer	I
##ol	I
,	O
N	B
-	I
ace	I
##ty	I
##lated	I
g	I
##ly	I
##co	I
##p	I
##rote	I
##ins	I
,	O
th	B
##re	I
##oni	I
##ne	I
,	O
as	B
##par	I
##tate	I
and	O
v	B
##ali	I
##ne	I
and	O
lower	O
levels	O
of	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
##s	I
and	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
appearing	O
at	O
the	O
surface	O
of	O
lip	O
##op	O
##rote	O
##ins	O
.	O

It	O
is	O
of	O
note	O
that	O
,	O
despite	O
ch	B
##ole	I
##ster	I
##ol	I
and	O
fatty	O
acids	O
being	O
abundant	O
classes	O
observed	O
in	O
the	O
mixed	O
-	O
mode	O
L	O
##C	O
,	O
we	O
did	O
not	O
perform	O
identification	O
of	O
these	O
two	O
classes	O
at	O
the	O
molecular	O
level	O
.	O

(	O
)	O
Hence	O
,	O
LP	O
##IR	O
un	O
##ve	O
##ils	O
an	O
early	O
under	O
##ap	O
##p	O
##re	O
##cia	O
##ted	O
dimension	O
of	O
insulin	O
resistance	O
und	O
##ete	O
##cted	O
by	O
standard	O
glucose	S
metabolism	O
parameters	O
.	O

Based	O
on	O
the	O
area	O
under	O
the	O
R	O
##OC	O
curve	O
(	O
AU	O
##RO	O
##C	O
)	O
,	O
and	O
the	O
bio	O
##mark	O
##er	O
panel	O
with	O
AU	O
##RO	O
##C	O
of	O
0	O
.	O
96	O
##9	O
,	O
six	O
serum	O
meta	O
##bol	O
##ites	O
(	B
α	B
-	I
glucose	I
,	O
ch	B
##olin	I
##e	I
,	O
g	B
##lut	I
##amine	I
,	O
g	B
##lut	I
##ama	I
##te	I
,	O
v	B
##ali	I
##ne	I
,	O
and	O
di	B
##hy	I
##dr	I
##oth	I
##ym	I
##ine	I
)	O
were	O
selected	O
as	O
potential	O
bio	O
##mark	O
##ers	O
for	O
early	O
stage	O
E	O
##SC	O
##C	O
.	O

Since	O
HIV	O
infection	O
of	O
primary	O
oral	O
e	O
##pit	O
##hel	O
##ial	O
cells	O
in	O
culture	O
is	O
increased	O
significantly	O
by	O
alcohol	O
,	O
we	O
suggest	O
that	O
increased	O
levels	O
of	O
Ethan	B
##ol	I
in	O
the	O
oral	O
cavity	O
may	O
also	O
increase	O
the	O
risk	O
of	O
continuous	O
oral	O
re	O
##in	O
##fect	O
##ion	O
.	O

Basel	O
##ine	O
Character	O
##istic	O
##s	O
and	O
B	O
##io	O
##chemical	O
Data	O
in	O
the	O
Health	O
##y	O
Control	O
Sub	O
##jects	O
and	O
the	O
PC	O
##OS	O
Co	O
##hor	O
##t	O
,	O
with	O
Additional	O
Co	O
##mp	O
##aris	O
##on	O
of	O
Non	O
##obe	O
##se	O
and	O
O	O
##bes	O
##e	O
Pat	O
##ients	O
with	O
PC	O
##OS	O
A	O
##bb	O
##re	O
##viation	O
##s	O
:	O
FA	O
##I	O
,	O
free	O
and	O
##rogen	O
index	O
;	O
SH	O
##B	O
##G	O
,	O
sex	O
hormone	O
-	O
binding	O
g	O
##lo	O
##bul	O
##in	O
;	O
U	B
-	I
11	I
##β	I
-	I
OH	I
-	I
An	I
,	O
u	O
##rina	O
##ry	O
11	B
##β	I
-	I
h	I
##ydro	I
##xy	I
##and	I
##ros	I
##tero	I
##ne	I
;	O
U	O
-	O
An	O
,	O
u	O
##rina	O
##ry	O
and	B
##ros	I
##tero	I
##ne	I
;	O
U	O
-	O
D	O
##H	O
##EA	O
,	O
u	O
##rina	O
##ry	O
de	B
##hy	I
##dr	I
##oe	I
##pian	I
##dr	I
##osterone	I
;	O
U	O
-	O
E	O
##t	O
,	O
u	O
##rina	O
##ry	O
et	B
##io	I
##cho	I
##lan	I
##olo	I
##ne	I
.	O

T	O
##CA	O
can	O
provide	O
ad	B
##eno	I
##sin	I
##e	I
trip	I
##hos	I
##phate	I
(	O
ATP	O
)	O
and	O
æ	B
-	I
k	I
##eto	I
##g	I
##lut	I
##arate	I
to	O
the	O
brain	O
,	O
while	O
reducing	O
le	B
##uc	I
##ine	I
-	I
is	I
##ole	I
##uc	I
##ine	I
and	O
th	B
##re	I
##oni	I
##ne	I
leads	O
to	O
a	O
reduction	O
in	O
ATP	S
and	O
æ	B
-	I
k	I
##eto	I
##g	I
##lut	I
##arate	I
.	O

To	O
op	O
##ti	O
##mize	O
the	O
bio	O
##sen	O
##sor	O
for	O
physiological	O
glucose	S
concentrations	O
,	O
they	O
reduced	O
the	O
space	O
between	O
the	O
flu	O
##oro	O
##ph	O
##ores	O
and	O
the	O
overall	O
flexibility	O
of	O
the	O
sensor	O
.	O

The	O
limit	O
of	O
detection	O
for	O
the	O
plasma	O
me	B
##lat	I
##oni	I
##n	I
ass	O
##ay	O
was	O
3	O
.	O
9	O
±	O
0	O
.	O
8	O
p	O
##g	O
/	O

The	O
lack	O
associations	O
observed	O
between	O
u	O
##rina	O
##ry	O
is	B
##op	I
##ros	I
##tan	I
##e	I
and	O
sperm	O
mitochondrial	O
bio	O
##mark	O
##ers	O
in	O
our	O
study	O
is	O
unknown	O
but	O
may	O
be	O
re	O
-	O
fl	O
##ec	O
##tive	O
of	O
our	O
bio	O
##mark	O
##er	O
used	O
to	O
assess	O
lip	O
##id	O
per	O
##ox	O
##ida	O
##tion	O
.	O

The	O
only	O
re	B
##s	I
##ver	I
##at	I
##rol	I
meta	O
##bol	O
##ite	O
detected	O
in	O
this	O
study	O
was	O
di	B
##hy	I
##dr	I
##ores	I
##ver	I
##at	I
##rol	I
,	O
which	O
is	O
in	O
agreement	O
with	O
other	O
in	O
v	O
##it	O
##ro	O
and	O
in	O
v	O
##ivo	O
studies	O
[	O
,	O
,	O
]	O
.	O

In	O
K	O
##S	O
et	O
##iology	O
,	O
we	O
h	O
##y	O
##pot	O
##hes	O
##ized	O
that	O
the	O
k	B
##yn	I
##uren	I
##ine	I
pathway	O
might	O
promote	O
K	O
##S	O
by	O
decreasing	O
immune	O
surveillance	O
.	O

These	O
studies	O
revealed	O
that	O
under	O
conditions	O
of	O
high	O
diet	O
##ary	O
β	B
-	I
car	I
##ote	I
##ne	I
and	O
the	O
o	O
##xi	O
##da	O
##tive	O
stress	O
of	O
smoking	O
,	O
there	O
was	O
a	O
clear	O
increase	O
in	O
pre	O
##ne	O
##op	O
##lastic	O
lung	O
cancer	O
lesions	O
in	O
the	O
animals	O
.	O

The	O
first	O
experiments	O
were	O
performed	O
with	O
a	O
“	O
pro	O
##ton	O
s	O
##po	O
##nge	O
”	O
(	O
,	O
)	O
,	O
which	O
is	O
a	O
strong	O
base	O
[	O
p	O
##K	O
_	O
a	O
of	O
its	O
con	O
##ju	O
##gate	O
acids	O
12	O
.	O
5	O
]	O
,	O
1	B
,	I
8	I
-	I
bi	I
##s	I
(	I
dim	I
##eth	I
##yla	I
##min	I
##o	I
)	I
nap	I
##ht	I
##hale	I
##ne	I
(	O
D	O
##MA	O
##N	O
)	O
,	O
never	O
previously	O
used	O
as	O
a	O
matrix	O
.	O

400	O
µ	O
##l	O
of	O
the	O
sample	O
was	O
mixed	O
with	O
200	O
µ	O
##l	O
of	O
a	O
sodium	B
hydrogen	I
phosphate	I
buffer	O
(	O
0	O
.	O
2	O
m	O
##ol	O
/	O
l	O
,	O
pH	O
7	O
.	O
0	O
)	O
including	O
1	O
mm	O
##ol	O
/	O
l	O
trim	B
##eth	I
##yl	I
##si	I
##ly	I
##l	I
prop	I
##ano	I
##ic	I
acid	I
made	O
up	O
with	O
50	O
%	O
D	O
_	O
2	O
O	O
for	O
_	O
1	O
H	O
-	O
N	O
##MR	O
analysis	O
as	O
described	O
.	O

Pro	O
##tein	O
##s	O
were	O
pre	O
##ci	O
##pit	O
##ated	O
using	O
40	O
µ	O
##L	O
met	B
##han	I
##ol	I
with	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
(	O
v	O
/	O
v	O
)	O
and	O
cent	O
##ri	O
##fu	O
##ged	O
(	O
13	O
,	O
000	O
##×	O
g	O
,	O
10	O
min	O
)	O
.	O

A	O
20	O
m	O
##M	O
su	B
##c	I
##rose	I
solution	O
,	O
0	O
.	O
5	O
m	O
##M	O
T	O
##SP	O
,	O
2	O
m	O
##M	O
Na	O
##N	O
_	O
3	O
in	O
90	O
%	O
H	O
_	O
2	O
O	O
/	O
10	O
%	O
D	O
_	O
2	O
O	O
(	O
v	O
/	O
v	O
)	O
was	O
used	O
for	O
line	O
-	O
shape	O
assessment	O
,	O
system	O
e	O
##qui	O
##li	O
##bra	O
##tion	O
,	O
and	O
quality	O
control	O
.	O

All	O
the	O
meta	O
##bol	O
##ites	O
were	O
q	O
##uant	O
##ified	O
by	O
using	O
an	O
A	O
##gi	O
##lent	O
1200	O
HP	O
##LC	O
system	O
(	O
A	O
##gi	O
##lent	O
Technologies	O
,	O
Santa	O
Clara	O
,	O
CA	O
)	O
coupled	O
to	O
a	O
64	O
##10	O
Triple	O
Q	O
##uad	O
##rup	O
##ole	O
(	O
Q	O
##Q	O
##Q	O
)	O
mass	O
s	O
##pect	O
##rome	O
##ter	O
(	O
A	O
##gi	O
##lent	O
Technologies	O
)	O
except	O
my	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
,	O
which	O
was	O
measured	O
using	O
an	O
A	O
##gi	O
##lent	O
78	O
##90	O
G	O
##C	O
system	O
(	O
A	O
##gi	O
##lent	O
Technologies	O
)	O
coupled	O
to	O
a	O
700	O
##0	O
##B	O
Q	O
##Q	O
##Q	O
mass	O
s	O
##pect	O
##rome	O
##ter	O
(	O
A	O
##gi	O
##lent	O
Technologies	O
)	O
.	O

Using	O
the	O
program	O
AM	O
##IX	O
3	O
.	O
9	O
.	O
14	O
(	O
B	O
##ruk	O
##er	O
B	O
##io	O
##S	O
##pin	O
GmbH	O
,	O
R	O
##hein	O
##ste	O
##tten	O
,	O
Germany	O
)	O
plasma	O
s	O
##pect	O
##ra	O
were	O
then	O
referenced	O
to	O
the	O
et	B
##hyl	I
##ened	I
##iam	I
##inet	I
##et	I
##ra	I
##ace	I
##tic	I
acid	I
(	O
E	O
##D	O
##TA	O
)	O
signal	O
at	O
2	O
.	O
580	O
##9	O
pp	O
##m	O
and	O
bucket	O
##ed	O
graphical	O
##ly	O
,	O
such	O
that	O
bucket	O
##s	O
wherever	O
possible	O
contained	O
only	O
one	O
signal	O
or	O
group	O
of	O
signals	O
and	O
no	O
peaks	O
were	O
split	O
between	O
bucket	O
##s	O
.	O

The	O
sealed	O
cap	O
##illa	O
##ry	O
was	O
reacted	O
at	O
60	O
°C	O
for	O
24	O
h	O
and	O
then	O
flushed	O
with	O
Me	B
##OH	I
to	O
remove	O
the	O
un	O
##rea	O
##cted	O
materials	O
.	O

Additionally	O
,	O
neo	B
##pt	I
##eri	I
##n	I
is	O
an	O
inflammatory	O
media	O
##tor	O
with	O
circulating	O
concentrations	O
elevated	O
in	O
many	O
conditions	O
when	O
the	O
cellular	O
immune	O
system	O
is	O
activated	O
.	O
_	O
,	O
A	O
comprehensive	O
review	O
of	O
the	O
metabolism	O
and	O
role	O
of	O
k	O
##yn	O
##uren	O
##ines	O
in	O
health	O
and	O
disease	O
has	O
been	O
published	O
by	O
Ce	O
##rve	O
##nka	O
et	O
al	O
.	O

Furthermore	O
,	O
the	O
bio	O
##sy	O
##nt	O
##hesis	O
may	O
be	O
decreased	O
by	O
other	O
diet	O
##ary	O
compounds	O
leading	O
to	O
constant	O
levels	O
of	O
C	B
##17	I
:	I
0	I
in	O
blood	O
even	O
though	O
dairy	O
fat	O
is	O
ing	O
##ested	O
.	O

The	O
reverse	O
di	B
##ol	I
e	I
##pox	I
##ide	I
,	O
Ph	B
##e	I
-	I
3	I
,	I
4	I
-	I
D	I
-	I
1	I
,	I
2	I
-	I
E	I
,	O
was	O
a	O
far	O
better	O
substrate	O
for	O
G	B
##S	I
##H	I
con	O
##ju	O
##gation	O
,	O
as	O
determined	O
by	O
analysis	O
of	O
Ph	B
##e	I
-	I
3	I
,	I
4	I
-	I
D	I
-	I
1	I
-	I
N	I
##AC	I
in	O
the	O
medium	O
,	O
than	O
was	O
the	O
bay	O
region	O
di	B
##ol	I
e	I
##pox	I
##ide	I
Ph	I
##e	I
-	I
1	I
,	I
2	I
-	I
D	I
-	I
3	I
,	I
4	I
-	I
E	I
,	O
for	O
which	O
only	O
minimal	O
con	O
##ju	O
##gation	O
to	O
Ph	B
##e	I
-	I
1	I
,	I
2	I
-	I
D	I
-	I
4	I
-	I
N	I
##AC	I
was	O
observed	O
.	O

Further	O
adjusting	O
for	O
H	O
##b	O
##A	O
##1	O
##c	O
,	O
C	O
-	O
reactive	O
protein	O
,	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
,	O
HD	O
##L	O
and	O
L	B
##D	I
##L	I
ch	I
##ole	I
##ster	I
##ol	I
,	O
LP	O
##IR	O
H	O
##R	O
was	O
at	O
##ten	O
##uated	O
to	O
1	O
.	O
41	O
(	O
1	O
.	O
31	O
,	O
1	O
.	O
53	O
)	O
and	O
had	O
the	O
strongest	O
association	O
with	O
T	O
##2	O
##D	O
after	O
H	O
##b	O
##A	O
##1	O
##C	O
in	O
mutually	O
adjusted	O
models	O
.	O

The	O
positive	O
association	O
between	O
these	O
two	O
meta	O
##bol	O
##ites	O
is	O
not	O
surprising	O
since	O
they	O
are	O
two	O
alternative	O
end	O
-	O
products	O
from	O
the	O
g	B
##ly	I
##co	I
##ly	I
##tic	I
pathway	O
.	O

§	O
Low	O
disease	O
activity	O
(	O
LL	O
##DA	O
##S	O
)	O
dose	O
of	O
pre	B
##dn	I
##is	I
##olo	I
##ne	I
set	O
to	O
>	O
7	O
.	O
5	O
mg	O
as	O
suggested	O
by	O
Frank	O
##lyn	O
et	O
al	O
.	O

Alt	O
##eration	O
##s	O
in	O
c	B
##era	I
##mi	I
##des	I
and	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
##s	I
have	O
been	O
post	O
##ulated	O
to	O
play	O
a	O
role	O
in	O
am	O
##yl	O
##oid	O
##ogen	O
##sis	O
and	O
inflammatory	O
stress	O
related	O
ne	O
##uron	O
##al	O
a	O
##pop	O
##tosis	O
;	O
however	O
few	O
studies	O
have	O
conducted	O
a	O
comprehensive	O
analysis	O
of	O
the	O
s	B
##phi	I
##ngo	I
##lip	I
##ido	I
##me	I
in	O
AD	O
plasma	O
using	O
analytical	O
platforms	O
with	O
accuracy	O
,	O
sensitivity	O
and	O
re	O
##p	O
##rod	O
##uc	O
##ibility	O
.	O

This	O
makes	O
it	O
unlikely	O
that	O
the	O
identification	O
of	O
g	B
##lut	I
##amine	I
and	O
his	B
##ti	I
##dine	I
in	O
our	O
study	O
is	O
due	O
to	O
pan	O
##cre	O
##ati	O
##tis	O
,	O
often	O
associated	O
with	O
pan	O
##cre	O
##atic	O
cancer	O
,	O
but	O
we	O
can	O
only	O
formally	O
exclude	O
this	O
possibility	O
by	O
including	O
a	O
co	O
##hor	O
##t	O
of	O
patients	O
with	O
chronic	O
inflammation	O
of	O
the	O
pan	O
##cre	O
##as	O
.	O

The	O
sample	O
was	O
loaded	O
onto	O
a	O
5	O
m	O
##L	O
Ch	O
##em	O
##E	O
##lut	O
cartridge	O
(	O
A	O
##gi	O
##lent	O
Tech	O
.	O
)	O
,	O
and	O
the	O
[	O
D	O
_	O
4	O
]	O
4	O
met	B
##hyl	I
est	I
##er	I
was	O
el	O
##uted	O
with	O
2	O
×	O
8	O
m	O
##L	O
of	O
CH	O
_	O
2	O
C	O
##l	O
_	O
2	O
.	O

For	O
example	O
,	O
few	O
h	B
##ydro	I
##xy	I
##l	I
acids	I
were	O
differential	O
##ly	O
regulated	O
,	O
which	O
means	O
that	O
t	O
##rich	O
##lor	O
##oa	O
##ce	O
##tic	O
(	O
T	O
##CA	O
)	O
cycle	O
meta	O
##bol	O
##ites	O
in	O
blood	O
plasma	O
did	O
not	O
reflect	O
the	O
disease	O
status	O
,	O
whereas	O
plasma	O
la	B
##ctic	I
acid	I
was	O
significantly	O
increased	O
in	O
AC	O
##D	O
N	O
##SL	O
##C	O
patients	O
.	O

Relations	O
##hip	O
between	O
the	O
decrease	O
in	O
total	O
skeletal	O
muscle	O
L	O
##C	O
-	O
FA	O
##C	O
##o	O
##A	O
(	O
Δ	O
L	O
##C	O
-	O
FA	O
##C	O
##o	O
##A	O
)	O
and	O
increase	O
in	O
insulin	O
-	O
stimulate	O
##d	O
glucose	S
disposal	O
(	O
Δ	O
Rd	O
)	O
in	O
patients	O
with	O
type	O
2	O
diabetes	O
after	O
p	B
##io	I
##gli	I
##ta	I
##zone	I
treatment	O
for	O
4	O
months	O
.	O

Compared	O
with	O
HC	O
,	O
the	O
se	O
##ra	O
of	O
SL	O
##E	O
patients	O
had	O
lower	O
levels	O
of	O
lip	O
##op	O
##rote	O
##ins	O
(	O
L	O
##D	O
##L	O
and	O
V	O
##LD	O
##L	O
)	O
,	O
lip	O
##ids	O
,	O
c	B
##it	I
##rate	I
,	O
amino	O
acids	O
,	O
la	B
##ct	I
##ate	I
and	O
ch	B
##olin	I
##e	I
,	O
whereas	O
levels	O
of	O
glucose	S
and	O
ace	B
##tate	I
were	O
significantly	O
elevated	O
(	O
and	O
)	O
.	O

presents	O
clinical	O
and	O
hem	O
##ody	O
##nam	O
##ic	O
in	O
##dices	O
s	O
##tra	O
##ti	O
##fied	O
by	O
median	O
plasma	O
AD	B
##MA	I
and	O
GA	O
##BR	O
levels	O
in	O
our	O
AD	O
##HF	O
co	O
##hor	O
##t	O
.	O

The	O
p	O
##ediatric	O
study	O
was	O
the	O
only	O
one	O
to	O
find	O
altered	O
la	B
##ct	I
##ate	I
levels	O
in	O
se	O
##psis	O
compared	O
to	O
healthy	O
controls	O
.	O

Ph	B
##os	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
promotes	O
a	O
##pop	O
##tosis	O
in	O
the	O
human	O
gas	O
##tric	O
cancer	O
cell	O
line	O
B	O
##GC	O
##8	O
##23	O
,	O
down	O
##re	O
##gu	O
##lates	O
the	O
expression	O
of	O
ATP	S
binding	O
cassette	O
subfamily	O
F	O
member	O
2	O
and	O
reduces	O
the	O
number	O
of	O
cancer	O
stem	O
cells	O
(	O
,	O
)	O
.	O

The	O
dried	O
samples	O
were	O
mixed	O
with	O
100	O
μ	O
##L	O
of	O
a	O
solution	O
of	O
phosphate	S
buffer	O
in	O
D	O
_	O
2	O
O	O
containing	O
66	O
.	O
17	O
μ	O
##M	O
T	O
##SP	O
,	O
made	O
up	O
to	O
600	O
μ	O
##L	O
with	O
phosphate	S
buffer	O
in	O
D	O
_	O
2	O
O	O
,	O
and	O
transferred	O
to	O
5	O
mm	O
N	O
##MR	O
tubes	O
.	O

V	O
##aria	O
##tion	O
of	O
expression	O
of	O
his	B
##tamine	I
,	O
g	B
##lut	I
##amine	I
,	O
x	B
##ant	I
##hur	I
##eni	I
##c	I
acid	I
and	O
ethanol	B
##amine	I
were	O
particularly	O
significant	O
and	O
predict	O
##ive	O
.	O

Ser	O
##um	O
levels	O
of	O
25	O
(	O
OH	O
)	O
D	O
_	O
3	O
of	O
the	O
C	O
##LD	O
patients	O
samples	O
were	O
determined	O
in	O
Sa	O
##arland	O
University	O
Medical	O
Center	O
##´s	O
central	O
laboratory	O
(	O
Department	O
of	O
Clinical	O
Chemistry	O
and	O
Laboratory	O
Medicine	O
)	O
using	O
the	O
Lia	O
##ison	O
25	O
-	O
OH	O
Vita	B
##min	I
D	I
ch	O
##em	O
##il	O
##umi	O
##nes	O
##cence	O
im	O
##mu	O
##no	O
##ass	O
##ay	O
(	O
Di	O
##a	O
##S	O
##ori	O
##n	O
,	O
Diet	O
##zen	O
##bach	O
,	O
Germany	O
)	O
.	O

By	O
testing	O
the	O
method	O
with	O
a	O
solution	O
of	O
ch	B
##ole	I
##ster	I
##ol	I
and	O
25	B
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
(	I
ch	I
##ole	I
##st	I
-	I
5	I
-	I
en	I
##e	I
-	I
3	I
##β	I
,	I
25	I
-	I
di	I
##ol	I
,	I
C	I
_	I
5	I
-	I
3	I
##β	I
,	I
25	I
-	I
di	I
##ol	I
)	I
in	O
70	O
%	O
ethanol	S
,	O
ch	B
##ole	I
##ster	I
##ol	I
was	O
found	O
to	O
be	O
retained	O
on	O
the	O
column	O
even	O
after	O
a	O
4	O
-	O
m	O
##l	O
column	O
wash	O
,	O
whereas	O
25	B
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
el	O
##utes	O
in	O
the	O
flow	O
-	O
through	O
and	O
column	O
wash	O
.	O

Our	O
data	O
in	O
brain	O
tissue	O
from	O
AD	O
patients	O
and	O
rats	O
with	O
severe	O
diabetes	O
were	O
similar	O
with	O
respect	O
to	O
their	O
glucose	S
,	O
so	B
##rb	I
##ito	I
##l	I
and	O
f	B
##ru	I
##ct	I
##ose	I
content	O
.	O

As	O
for	O
the	O
IT	O
##G	O
,	O
k	B
##eto	I
##g	I
##lut	I
##ari	I
##c	I
acid	I
and	O
beta	B
##ine	I
were	O
selected	O
by	O
employing	O
the	O
same	O
threshold	O
.	O

PC	B
a	I
##e	I
C	I
##38	I
:	I
0	I
;	O
100	O
.	O

In	O
##ser	O
##ts	O
were	O
introduced	O
into	O
z	B
##ir	I
##con	I
##ium	I
oxide	I
rotor	O
##s	O
for	O
analysis	O
.	O

Moreover	O
,	O
there	O
is	O
growing	O
evidence	O
of	O
h	O
##y	O
##pot	O
##hala	O
##mo	O
-	O
pit	O
##uit	O
##ary	O
-	O
ad	O
##rena	O
##l	O
axis	O
d	O
##ys	O
##function	O
and	O
blunt	O
##ed	O
co	B
##rt	I
##is	I
##ol	I
response	O
in	O
children	O
born	O
pre	O
##ter	O
##m	O
or	O
small	O
for	O
g	O
##esta	O
##tional	O
age	O
–	O
.	O

All	O
the	O
samples	O
involved	O
in	O
the	O
experiment	O
,	O
including	O
human	O
PC	O
##a	O
and	O
BP	O
##H	O
specimens	O
,	O
nude	O
mice	O
x	O
##eno	O
##gra	O
##ft	O
tissues	O
were	O
cut	O
into	O
para	B
##ffin	I
sections	O
.	O

Arte	B
##sun	I
##ate	I
,	O
di	B
##hy	I
##dr	I
##oar	I
##tem	I
##isi	I
##nin	I
,	O
and	O
ha	B
##lo	I
##fant	I
##rine	I
could	O
also	O
be	O
found	O
s	O
##poradic	O
##ally	O
in	O
a	O
few	O
drug	O
shops	O
(	O
Alba	O
S	O
et	O
al	O
.	O
,	O
in	O
preparation	O
)	O
.	O

However	O
,	O
unlike	O
the	O
ST	O
##OC	O
##S	O
##Y	O
spectrum	O
,	O
no	O
cross	O
-	O
peak	O
or	O
correlation	O
between	O
the	O
N	O
-	O
ace	O
##ty	O
##l	O
(	O
H	O
_	O
a	O
)	O
and	O
a	O
##romatic	O
pro	O
##tons	O
(	O
H	O
_	O
2	O
/	O
H	O
_	O
3	O
and	O
H	O
/	O
H	O
/	O
H	O
/	O
H	O
/	O
H	O
)	O
on	O
the	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
g	I
##lu	I
##cu	I
##ron	I
##ide	I
molecule	O
pro	O
##ton	O
groups	O
could	O
be	O
observed	O
as	O
these	O
are	O
separated	O
by	O
5	O
and	O
8	O
bond	O
(	O
lengths	O
)	O
,	O
respectively	O
,	O
for	O
H	O
_	O
3	O
and	O
H	O
.	O

Furthermore	O
,	O
try	B
##pt	I
##op	I
##han	I
and	O
in	B
##do	I
##le	I
-	I
3	I
-	I
prop	I
##ion	I
##ic	I
acid	I
(	O
S	O
##pear	O
##man	O
coefficients	O
0	O
.	O
63	O
and	O
0	O
.	O
56	O
,	O
respectively	O
,	O
P	O
<	O
.	O
00	O
##1	O
)	O
correlated	O
with	O
the	O
ankle	O
-	O
bra	O
##chia	O
##l	O
index	O
,	O
a	O
sur	O
##rogate	O
for	O
overall	O
at	O
##her	O
##os	O
##cle	O
##rot	O
##ic	O
disease	O
burden	O
.	O

B	O
##rief	O
##ly	O
,	O
meta	O
##bol	O
##ites	O
from	O
90	O
μ	O
##l	O
of	O
extracted	O
serum	O
samples	O
were	O
resolved	O
by	O
h	B
##ydro	I
##phi	I
##lic	I
interaction	O
liquid	O
ch	O
##roma	O
##tography	O
(	O
H	O
##IL	O
##IC	O
)	O
on	O
a	O
S	O
##ho	O
##de	O
##x	O
polymer	O
based	O
NH	O
_	O
2	O
HP	O
##LC	O
column	O
(	O
250	O
mm	O
×	O
2	O
.	O
0	O
mm	O
,	O
4	O
μ	O
##m	O
,	O
Show	O
##a	O
Den	O
##ko	O
,	O
USA	O
)	O
and	O
Shi	O
##mad	O
##zu	O
L	O
##C	O
-	O
20	O
##AD	O
U	O
##HP	O
##LC	O
system	O
.	O

Our	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
data	O
confirmed	O
the	O
presence	O
of	O
the	O
fl	O
##avan	O
-	O
3	O
-	O
o	O
##ls	O
in	O
the	O
green	O
tea	O
SP	O
##I	O
complex	O
as	O
well	O
as	O
several	O
h	B
##ydro	I
##xy	I
##cin	I
##nam	I
##ic	I
acids	I
,	O
g	B
##ly	I
##cos	I
##ides	I
of	O
the	O
fl	O
##av	O
##ono	O
##ls	O
que	B
##rc	I
##eti	I
##n	I
and	O
ka	B
##em	I
##pf	I
##ero	I
##l	I
and	O
a	O
single	O
my	B
##rice	I
##tin	I
g	I
##ly	I
##cos	I
##ide	I
(	O
See	O
)	O
.	O

These	O
data	O
pre	O
##c	O
##lude	O
any	O
definitive	O
conclusions	O
concerning	O
the	O
involvement	O
of	O
the	O
Co	O
##ri	O
cycle	O
or	O
glucose	B
-	I
al	I
##ani	I
##ne	I
cycle	O
.	O

However	O
,	O
it	O
is	O
still	O
noticeable	O
that	O
PC	B
(	I
40	I
:	I
7	I
)	I
is	O
so	O
abundant	O
.	O

As	B
##cor	I
##bic	I
acid	I
,	O
try	B
##pt	I
##op	I
##han	I
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
u	B
##ric	I
acid	I
,	O
U	B
##DP	I
,	O
c	B
##rea	I
##tine	I
,	O
and	O
p	B
##yr	I
##u	I
##vate	I
showed	O
reduced	O
concentration	O
in	O
ID	O
##C	O
against	O
ben	O
##ign	O
and	O
control	O
.	O

In	O
addition	O
,	O
to	O
analyze	O
whether	O
er	B
##yt	I
##hr	I
##ito	I
##l	I
is	O
o	O
##xi	O
##dized	O
to	O
er	B
##yt	I
##hr	I
##ona	I
##te	I
in	O
v	O
##ivo	O
,	O
er	B
##yt	I
##hr	I
##ito	I
##l	I
and	O
er	B
##yt	I
##hr	I
##ona	I
##te	I
levels	O
were	O
q	O
##uant	O
##ified	O
by	O
standard	O
addition	O
.	O

On	O
the	O
other	O
hand	O
,	O
h	B
##ydro	I
##phi	I
##lic	I
compounds	O
have	O
improved	O
resolution	O
when	O
H	O
##IL	O
##IC	O
is	O
used	O
.	O

The	O
product	O
ion	O
spectrum	O
of	O
the	O
des	B
##ami	I
##no	I
-	I
[	I
_	I
2	I
H	I
_	I
5	I
]	I
-	O
Ph	O
##IP	O
-	O
Y	O
(	O
[	O
M	O
+	O
H	O
]	O
_	O
+	O
at	O
m	O
/	O
z	O
39	O
##4	O
.	O
1	O
)	O
displays	O
the	O
corresponding	O
fragment	O
ions	O
at	O
m	O
/	O
z	O
34	O
##9	O
.	O
2	O
,	O
34	O
##8	O
.	O
2	O
,	O
333	O
.	O
2	O
,	O
320	O
.	O
2	O
,	O
and	O
214	O
.	O
2	O
.	O

Our	O
data	O
show	O
a	O
characteristic	O
ho	O
##rmon	O
##al	O
flu	O
##ct	O
##uation	O
for	O
est	O
##rogen	O
##s	O
and	O
pro	B
##ges	I
##tero	I
##ne	I
,	O
as	O
expected	O
.	O

S	B
##phi	I
##ngo	I
##lip	I
##id	I
related	O
trans	O
##cripts	O
in	O
the	O
P	O
##BM	O
##Cs	O
,	O
c	B
##era	I
##mi	I
##de	I
lip	O
##ids	O
in	O
the	O
plasma	O
as	O
well	O
as	O
l	B
-	I
se	I
##rine	I
from	O
the	O
plasma	O
are	O
displayed	O
on	O
the	O
s	B
##phi	I
##ngo	I
##lip	I
##id	I
metabolic	O
pathway	O
.	O

Ke	O
##to	O
##genesis	O
activation	O
by	O
m	O
##TO	O
##RC	O
##1	O
in	O
##hibition	O
induce	O
##s	O
the	O
release	O
of	O
k	B
##eton	I
##es	I
bodies	O
,	O
here	O
ace	B
##tone	I
and	O
ace	B
##to	I
##ace	I
##tate	I
,	O
in	O
the	O
serum	O
metabolic	O
profiles	O
for	O
patients	O
treated	O
with	O
T	O
+	O
E	O
(	O
Figure	O
)	O
.	O

Ph	B
##enan	I
##th	I
##rene	I
(	O
Ph	O
##e	O
)	O
is	O
the	O
simplest	O
PA	O
##H	O
with	O
a	O
bay	O
region	O
and	O
an	O
excellent	O
model	O
for	O
the	O
study	O
of	O
PA	O
##H	O
metabolism	O
.	O

For	O
all	O
the	O
studies	O
,	O
a	O
met	O
##han	O
##ol	O
:	O
water	O
(	O
1	O
:	O
1	O
)	O
mixture	O
with	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
was	O
used	O
as	O
the	O
carrier	O
solution	O
.	O

In	O
addition	O
three	O
g	O
##ly	O
##cine	O
-	O
con	O
##ju	O
##gated	O
bi	O
##le	O
acids	O
i	O
.	O
e	O
.	O
G	B
##CD	I
##CA	I
(	O
con	O
##ju	O
##gated	O
primary	O
bi	O
##le	O
acid	O
)	O
and	O
G	O
##LC	O
##A	O
and	O
G	O
##DC	O
##A	O
(	O
two	O
con	O
##ju	O
##gated	O
primary	O
bi	O
##le	O
acids	O
)	O
are	O
significantly	O
differentiated	O
AD	O
patients	O
with	O
p	O
values	O
<	O
0	O
.	O
05	O
.	O

Collective	O
##ly	O
,	O
our	O
data	O
indicated	O
that	O
1	B
-	I
met	I
##hyl	I
##ade	I
##nos	I
##ine	I
could	O
be	O
a	O
potential	O
serum	O
bio	O
##mark	O
##er	O
for	O
HC	O
##C	O
.	O

However	O
,	O
if	O
different	O
##iating	O
meta	O
##bol	O
##ites	O
between	O
the	O
o	O
##bes	O
##e	O
and	O
non	O
##obe	O
##se	O
controls	O
were	O
also	O
represented	O
as	O
a	O
different	O
##iating	O
meta	O
##bol	O
##ite	O
in	O
the	O
s	O
##chi	O
##zophrenia	O
analysis	O
,	O
but	O
their	O
concentrations	O
trend	O
##ed	O
in	O
the	O
opposite	O
direction	O
as	O
weight	O
(	O
e	O
.	O
g	O
.	O
,	O
g	B
##ly	I
##cine	I
)	O
,	O
they	O
were	O
not	O
removed	O
from	O
the	O
Mets	O
##cape	O
analysis	O
.	O

In	O
their	O
recent	O
meta	O
-	O
analysis	O
P	O
##fi	O
##ster	O
et	O
al	O
.	O
did	O
not	O
observe	O
a	O
direct	O
effect	O
of	O
serum	O
u	B
##ric	I
acid	I
or	O
associated	O
genetic	O
variants	O
on	O
development	O
of	O
type	O
2	O
diabetes	O
.	O

Apart	O
from	O
13	O
(	O
N	O
##AA	O
##G	O
)	O
,	O
this	O
was	O
the	O
case	O
also	O
for	O
9	O
,	O
which	O
has	O
the	O
put	O
##ative	O
identification	O
of	O
rib	B
##of	I
##lav	I
##in	I
.	O

Six	O
patients	O
were	O
excluded	O
because	O
of	O
met	B
##han	I
##ol	I
contamination	O
from	O
the	O
operating	O
room	O
,	O
one	O
patient	O
was	O
excluded	O
because	O
of	O
a	O
lack	O
of	O
tumor	O
cells	O
present	O
in	O
their	O
tissue	O
samples	O
,	O
and	O
one	O
patient	O
was	O
excluded	O
because	O
of	O
insufficient	O
tissue	O
size	O
(	O
<	O
0	O
.	O
5	O
mg	O
)	O
and	O
de	O
##graded	O
cellular	O
integrity	O
.	O

Four	O
s	B
##til	I
##ben	I
##oids	I
(	O
re	O
##s	O
##ver	O
##at	O
##rol	O
,	O
o	B
##xy	I
##res	I
##ver	I
##at	I
##rol	I
,	O
p	O
##ice	O
##ata	O
##nn	O
##ol	O
and	O
th	O
##una	O
##l	O
##ben	O
##e	O
)	O
were	O
metabolic	O
##ally	O
transformed	O
by	O
double	O
bond	O
reduction	O
,	O
di	O
##hy	O
##dr	O
##ox	O
##yla	O
##tion	O
,	O
and	O
dem	O
##eth	O
##yla	O
##tion	O
,	O
while	O
bat	O
##ata	O
##sin	O
III	O
and	O
pin	B
##ost	I
##il	I
##ben	I
##e	I
were	O
stable	O
under	O
conditions	O
si	O
##mulating	O
the	O
co	O
##lon	O
environment	O
.	O

In	O
the	O
research	O
samples	O
,	O
the	O
ethanol	S
levels	O
varied	O
between	O
0	O
.	O
08	O
and	O
10	O
.	O
0	O
m	O
##M	O
and	O
,	O
in	O
the	O
three	O
clinical	O
samples	O
,	O
the	O
ethanol	S
levels	O
were	O
9	O
.	O
2	O
×	O
10	O
_	O
−	O
##3	O
,	O
0	O
.	O
02	O
##3	O
and	O

Moreover	O
,	O
the	O
total	O
laboratory	O
coefficients	O
of	O
variation	O
for	O
the	O
two	O
least	O
abundant	O
est	B
##rogen	I
meta	I
##bol	I
##ites	I
—	I
4	I
-	I
met	I
##ho	I
##xy	I
##est	I
##rad	I
##iol	I
(	O
mean	O
serum	O
concentration	O
=	O
2	O
.	O
9	O
pm	O
##ol	O
/	O
L	O
)	O
and	O
17	O
-	O
e	O
##pies	O
##tri	O
##ol	O
(	O
mean	O
serum	O
concentration	O
=	O
1	O
.	O
4	O
pm	O
##ol	O
/	O
L	O
)	O
—	O
were	O
4	O
%	O
and	O
3	O
%	O
,	O
respectively	O
.	O

In	O
current	O
study	O
,	O
the	O
decreased	O
p	B
##las	I
##men	I
##yl	I
##cho	I
##line	I
(	O
p	O
##PC	O
##s	O
)	O
and	O
p	B
##las	I
##men	I
##yle	I
##than	I
##ola	I
##mine	I
(	O
p	O
##P	O
##Es	O
)	O
levels	O
in	O
E	O
##OC	O
re	O
##current	O
patients	O
suggested	O
that	O
most	O
cancer	O
cells	O
might	O
exhibit	O
elevated	O
o	O
##xi	O
##da	O
##tive	O
stress	O
,	O
which	O
is	O
consistent	O
with	O
previous	O
findings	O
that	O
o	O
##xi	O
##da	O
##tive	O
stress	O
is	O
associated	O
with	O
cancer	O
progression	O
.	O

Con	O
##tam	O
##ina	O
##nts	O
present	O
in	O
FF	O
##P	O
##E	O
samples	O
(	O
i	O
.	O
e	O
.	O
,	O
D	B
##MS	I
##O	I
,	O
la	B
##ury	I
##l	I
su	I
##lf	I
##ate	I
,	O
and	O
me	O
##lani	O
##ne	O
)	O
and	O
O	O
##CT	O
-	O
embedded	O
samples	O
(	O
i	O
.	O
e	O
.	O
,	O
he	B
##pta	I
##eth	I
##yle	I
##ne	I
g	I
##ly	I
##co	I
##l	I
,	O
he	B
##xa	I
##eth	I
##yle	I
##ne	I
g	I
##ly	I
##co	I
##l	I
,	O
o	B
##ct	I
##ae	I
##thy	I
##lene	I
g	I
##ly	I
##co	I
##l	I
,	O
pen	B
##ta	I
##eth	I
##yle	I
##ne	I
g	I
##ly	I
##co	I
##l	I
,	O
and	O
te	B
##tra	I
##eth	I
##yle	I
##ne	I
g	I
##ly	I
##co	I
##l	I
)	O
were	O
not	O
considered	O
in	O
the	O
analysis	O
.	O

U	O
##rina	O
##ry	O
album	O
##in	O
ex	O
##cre	O
##tion	O
was	O
log	O
transformed	O
(	O
log	O
##U	O
##A	O
##E	O
)	O
and	O
associations	O
were	O
tested	O
by	O
linear	O
re	O
##gression	O
models	O
,	O
adjusted	O
by	O
age	O
,	O
sex	O
,	O
B	O
##MI	O
,	O
S	O
##ys	O
##to	O
##lic	O
BP	O
and	O
fast	O
##ing	O
glucose	S
.	O

Among	O
several	O
meta	O
##bol	O
##ites	O
,	O
u	B
##ric	I
acid	I
levels	O
were	O
increased	O
in	O
the	O
blood	O
of	O
study	O
participants	O
,	O
while	O
those	O
of	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
were	O
significantly	O
decreased	O
.	O

However	O
,	O
while	O
di	B
##hy	I
##dr	I
##oc	I
##era	I
##mi	I
##de	I
was	O
most	O
highly	O
correlated	O
with	O
E	O
##uba	O
##cter	O
##ia	O
in	O
both	O
cases	O
and	O
controls	O
,	O
the	O
correlation	O
was	O
inverse	O
for	O
cases	O
and	O
direct	O
for	O
controls	O
(	O
Su	O
##pp	O
##lement	O
##al	O
Table	O
3	O
in	O
the	O
Supporting	O
Information	O
)	O
.	O

Solid	O
sodium	B
chloride	I
(	O
0	O
.	O
3	O
–	O
0	O
.	O
5	O
g	O
)	O
and	O
concentrated	O
sulfur	B
##ic	I
acid	I
(	O
15	O
µ	O
##L	O
)	O
were	O
added	O
.	O

Recent	O
developments	O
suggest	O
one	O
of	O
the	O
possible	O
drivers	O
of	O
on	O
##co	O
##genesis	O
is	O
h	O
##yper	O
##act	O
##ivation	O
of	O
the	O
one	O
-	O
carbon	O
metabolism	O
which	O
engage	O
the	O
f	B
##olate	I
and	O
met	B
##hi	I
##oni	I
##ne	I
cycles	O
and	O
hence	O
incorporate	O
carbon	O
units	O
from	O
amino	O
acids	O
including	O
se	B
##rine	I
and	O
g	B
##ly	I
##cine	I
which	O
make	O
varied	O
products	O
such	O
as	O
lip	O
##ids	O
,	O
n	O
##uc	O
##leo	O
##tide	O
##s	O
,	O
and	O
proteins	O
.	O

The	O
only	O
lip	O
##id	O
class	O
that	O
was	O
separated	O
well	O
from	O
others	O
on	O
R	O
##PL	O
##C	O
is	O
the	O
highly	O
non	O
-	O
polar	O
T	B
##G	I
.	O

(	B
CA	B
_	I
4	I
,	I
6	I
-	I
3	I
-	I
one	I
,	O
1	O
.	O
79	O
##9	O
±	O
0	O
.	O
66	O
##6	O
ng	O
/	O
m	O
##l	O
)	O
,	O
respectively	O
,	O
on	O
the	O
basis	O
of	O
their	O
retention	O
time	O
and	O
MS	O
_	O
3	O
s	O
##pect	O
##ra	O
(	O
and	O
supplement	O
##al	O
Fi	O
##g	O
.	O

Interest	O
##ingly	O
,	O
while	O
SD	O
##MA	O
remained	O
a	O
significant	O
predict	O
##or	O
of	O
significantly	O
o	O
##bs	O
##truct	O
##ive	O
CA	O
##D	O
status	O
following	O
adjustments	O
[	O
adjusted	O
OR	O
(	O
95	O
%	O
C	O
##I	O
)	O
:	O
1	O
.	O
64	O
(	O
1	O
.	O
06	O
-	O
2	O
.	O
56	O
)	O
,	O
AD	B
##MA	I
no	O
longer	O
remained	O
significantly	O
associated	O
with	O
CA	O
##D	O
status	O
[	O
adjusted	O
OR	O
(	O
95	O
%	O
C	O
##I	O
)	O
:	O
1	O
.	O
33	O
(	O
0	O
.	O
88	O
-	O
2	O
.	O
03	O
)	O
]	O
.	O

Post	O
-	O
treatment	O
meta	O
##bol	O
##ites	O
significantly	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
associated	O
with	O
post	O
-	O
treatment	O
clinical	O
measures	O
Met	O
##ab	O
##oli	O
##te	O
levels	O
post	O
-	O
treatment	O
correlated	O
with	O
clinical	O
measurements	O
post	B
-	I
s	I
##tat	I
##in	I
treatment	O
using	O
(	O
a	O
)	O
un	O
##iva	O
##ria	O
##te	O
re	O
##gression	O
analysis	O
and	O
(	O
b	O
)	O
multiple	O
re	O
##gression	O
analysis	O
.	O

Random	O
forest	O
statistical	O
analysis	O
selected	O
α	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
(	O
α	O
–	O
H	O
##B	O
)	O
as	O
the	O
top	O
-	O
ranked	O
bio	O
##chemical	O
for	O
separating	O
insulin	O
resistant	O
(	O
lower	O
third	O
of	O
the	O
c	O
##lamp	O
-	O
derived	O
M	O
_	O
FF	O
##M	O
=	O
33	O
µ	O
##mo	O
##l	O
·	O
min	O
_	O
−	O
##1	O
·	O
kg	O
_	O
FF	O
##M	O
_	O
−	O
##1	O
,	O
median	O
[	O
inter	O
##qua	O
##rt	O
##ile	O
range	O
]	O
,	O
n	O
=	O
140	O
)	O
from	O
insulin	O
sensitive	O
subjects	O
(	O
M	O
_	O
FF	O
##M	O
=	O
66	O
µ	O
##mo	O
##l	O
·	O
min	O
_	O
−	O
##1	O
·	O
kg	O
_	O
FF	O
##M	O
_	O
−	O
##1	O
)	O
with	O
a	O
76	O
%	O
accuracy	O
.	O

Thus	O
GM	B
##3	I
levels	O
cannot	O
be	O
used	O
alone	O
for	O
diagnostic	O
purposes	O
and	O
need	O
to	O
be	O
combined	O
with	O
other	O
measurements	O
to	O
have	O
diagnostic	O
value	O
.	O

The	O
double	O
##t	O
pattern	O
of	O
the	O
γ	B
-	I
(	I
C	I
-	I
4	I
)	I
and	O
α	B
-	I
(	I
C	I
-	I
2	I
)	I
carbon	O
##s	O
of	O
G	O
##lu	O
suggests	O
the	O
presence	O
of	O
_	O
13	O
C	B
-	I
4	I
,	I
5	I
-	I
G	I
##lu	I
and	O
/	O
or	O
_	O
13	O
C	B
-	I
3	I
,	I
4	I
-	I
G	I
##lu	I
as	O
well	O
as	O
_	O
13	O
C	B
-	I
1	I
,	I
2	I
-	I
G	I
##lu	I
and	O
/	O
or	O
_	O
13	O
C	B
-	I
2	I
,	I
3	I
-	I
G	I
##lu	I
is	O
##oto	O
##po	O
##mers	O
,	O
respectively	O
.	O

La	B
##nt	I
##hi	I
##oni	I
##ne	I
and	O
ho	B
##mo	I
##lant	I
##hi	I
##oni	I
##ne	I
plasma	O
concentrations	O
were	O
determined	O
by	O
G	O
##C	O
-	O
MS	O
(	O
The	O
##rm	O
##o	O
DS	O
##Q	O
##II	O
)	O
in	O
the	O
Food	O
Science	O
and	O
Human	O
N	O
##utrition	O
Department	O
at	O
the	O
University	O
of	O
Florida	O
.	O

Growing	O
evidence	O
suggests	O
that	O
the	O
mon	B
##oh	I
##ydro	I
##xy	I
fatty	O
acid	O
9	O
-	O
H	O
##SA	O
may	O
in	O
##hibit	O
cell	O
proliferation	O
by	O
acting	O
at	O
different	O
levels	O
[	O
,	O
,	O
,	O
,	O
,	O
]	O
.	O

Al	O
##co	O
##hol	O
,	O
alcohol	O
intake	O
gram	O
/	O
week	O
;	O
A	O
##po	O
##A	O
,	O
a	O
##poli	O
##pop	O
##rote	O
##in	O
A1	O
;	O
A	O
##po	O
##B	O
,	O
a	O
##poli	O
##pop	O
##rote	O
##in	O
B	O
;	O
CR	O
##P	O
,	O
c	O
-	O
reactive	O
protein	O
;	O
DB	B
##P	I
,	O
di	O
##ast	O
##olic	O
blood	O
pressure	O
;	O
e	O
##G	O
##F	O
##R	O
,	O
estimated	O
g	O
##lo	O
##mer	O
##ular	O
fi	O
##ltration	O
rate	O
;	O
G	O
##lu	O
##c	O
##0	O
,	O
fast	O
##ing	O
glucose	S
;	O
G	O
##lu	O
##c	O
##12	O
##0	O
,	O
120	O
min	O
oral	O
glucose	S
tolerance	O
test	O
(	O
O	O
##G	O
##TT	O
)	O
glucose	S
level	O
;	O
H	O
##OM	O
##A	O
-	O
B	O
,	O
home	O
##ost	O
##asis	O
model	O
assessment	O
of	O
beta	O
-	O
cell	O
function	O
;	O
H	O
##OM	O
##A	O
-	O
I	O
##R	O
,	O
home	O
##ost	O
##asis	O
model	O
assessment	O
of	O
insulin	O
resistance	O
;	O
LA	O
##EI	O
,	O
large	O
artery	O
elastic	O
##ity	O
index	O
;	O
SA	O
##EI	O
,	O
small	O
artery	O
elastic	O
##ity	O
index	O
;	O
S	O
##B	O
##P	O
,	O
s	O
##ys	O
##to	O
##lic	O
blood	O
pressure	O
;	O
SH	O
##B	O
##G	O
,	O
sex	O
hormone	O
binding	O
g	O
##lo	O
##bul	O
##in	O
;	O
T	O
##AG	O
,	O
t	B
##ria	I
##cy	I
##l	I
##gly	I
##cer	I
##ides	I
;	O
W	O
##H	O
##R	O
,	O
waist	O
/	O
hip	O
-	O
ratio	O
.	O

The	O
median	O
levels	O
of	O
meta	O
##bol	O
##ites	O
of	O
DE	O
##HP	O
,	O
including	O
mon	B
##o	I
-	I
et	I
##hyl	I
##he	I
##xy	I
##l	I
p	I
##ht	I
##hala	I
##te	I
(	O
ME	O
##HP	O
)	O
,	O
mon	B
##o	I
-	I
(	I
2	I
-	I
et	I
##hyl	I
-	I
5	I
-	I
o	I
##x	I
##oh	I
##ex	I
##yl	I
)	I
p	I
##ht	I
##hala	I
##te	I
(	O
ME	O
##OH	O
##P	O
)	O
,	O
mon	B
##o	I
-	I
(	I
2	I
-	I
et	I
##hyl	I
-	I
5	I
-	I
h	I
##ydro	I
##xy	I
##he	I
##xy	I
##l	I
)	I
p	I
##ht	I
##hala	I
##te	I
(	O
ME	O
##H	O
##HP	O
)	O
,	O
mon	B
##o	I
-	I
(	I
2	I
-	I
et	I
##hyl	I
-	I
5	I
-	I
car	I
##box	I
##ype	I
##nt	I
##yl	I
)	I
p	I
##ht	I
##hala	I
##te	I
(	O
ME	O
##CP	O
##P	O
)	O
,	O
DB	B
##P	I
(	O
D	O
##n	O
##B	O
##P	O
and	O
Di	O
##B	O
##P	O
)	O
,	O
including	O
mon	B
##o	I
-	I
n	I
-	I
but	I
##yl	I
p	I
##ht	I
##hala	I
##te	I
(	O
M	O
##n	O
##B	O
##P	O
)	O
and	O
mon	B
##o	I
-	I
is	I
##o	I
-	I
but	I
##yl	I
p	I
##ht	I
##hala	I
##te	I
(	O
Mi	O
##B	O
##P	O
)	O
,	O
and	O
mon	B
##o	I
-	I
et	I
##hyl	I
p	I
##ht	I
##hala	I
##te	I
(	O
ME	O
##P	O
)	O
in	O
urine	O
samples	O
of	O
290	O
adults	O
/	O
97	O
minors	O
(	O
<	O
18	O
years	O
)	O
were	O
7	O
.	O
9	O
/	O
6	O
.	O
1	O
,	O
12	O
.	O
6	O
/	O
17	O
.	O
8	O
,	O
22	O
.	O
0	O
/	O
25	O
.	O
8	O
,	O
25	O
.	O
4	O
/	O
30	O
.	O
8	O
,	O
18	O
.	O
1	O
/	O
23	O
.	O
6	O
,	O
9	O
.	O
4	O
/	O
13	O
.	O
6	O
and	O
14	O
.	O
5	O
/	O
12	O
.	O
4	O
μ	O
##g	O
/	O
g	O
c	B
##rea	I
##tin	I
##ine	I
,	O

d	O
Many	O
significant	O
meta	O
##bol	O
##ites	O
,	O
not	O
present	O
in	O
human	O
bio	O
##chemical	O
pathways	O
,	O
were	O
presumably	O
of	O
micro	O
##bial	O
origin	O
,	O
for	O
example	O
2	B
,	I
3	I
-	I
but	I
##ane	I
##dio	I
##l	I
,	O
male	O
##ama	O
##te	O
,	O
h	B
##ydro	I
##quin	I
##one	I
,	O
g	O
##ua	O
##ja	O
##co	O
##l	O
,	O
p	B
##yr	I
##oga	I
##llo	I
##l	I
and	O
the	O
hip	B
##pur	I
##ic	I
acid	I
derivatives	O

There	O
is	O
also	O
evidence	O
that	O
h	O
##yper	O
##tri	O
##gly	O
##cer	O
##ide	O
##mia	O
with	O
low	O
HD	B
##L	I
-	I
ch	I
##ole	I
##ster	I
##ol	I
is	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
developing	O
mild	O
cognitive	O
imp	O
##air	O
##ment	O
(	O
,	O
)	O
.	O

O	B
##xon	I
##e	I
,	O
2	B
-	I
i	I
##od	I
##obe	I
##nz	I
##oi	I
##c	I
acid	I
(	O
I	O
##BA	O
)	O
,	O
dim	B
##eth	I
##yl	I
form	I
##ami	I
##de	I
(	O
D	O
##MF	O
)	O
,	O
ch	B
##lor	I
##of	I
##orm	I
(	O
CH	O
##C	O
##l	O
_	O
3	O
)	O
,	O
met	B
##han	I
##ol	I
(	O
Me	O
##OH	O
,	O
O	O
##m	O
##nis	O
##ol	O
##v	O
grade	O
)	O
,	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
(	O
AC	O
##N	O
,	O
O	O
##m	O
##nis	O
##ol	O
##v	O
grade	O
)	O
,	O
form	B
##ic	I
acid	I
(	O
FA	O
,	O
L	O
##C	O
/	O
MS	O
grade	O
)	O
double	O
-	O
di	O
##st	O
##ille	O
##d	O
ace	B
##tic	I
acid	I
(	O
A	O
##c	O
##OH	O
,	O
Te	O
##f	O
##lon	O
grade	O
,	O
99	O
.	O
5	O
%	O
)	O
and	O
NH	O
_	O
3	O
·	O
H	O
_	O
2	O
O	O
,	O
L	O
##C	O
/	O
MS	O
grade	O
,	O
25	O
%	O
in	O
H	O
_	O
2	O
O	O
)	O
were	O
from	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
(	O
St	O
.	O
Louis	O
,	O
M	O
##O	O
)	O
.	O

It	O
is	O
generated	O
by	O
spontaneous	O
reaction	O
of	O
u	B
##ric	I
acid	I
with	O
radical	O
oxygen	O
species	O
(	O
R	O
##OS	O
)	O
.	O

This	O
hypothesis	O
is	O
consistent	O
with	O
the	O
decreased	O
amounts	O
of	O
both	O
ace	B
##to	I
##ace	I
##tate	I
and	O
3	B
-	I
h	I
##ydro	I
##xy	I
-	I
but	I
##yra	I
##te	I
(	O
3	O
-	O
H	O
##BA	O
)	O
,	O
also	O
components	O
of	O
k	B
##eton	I
##e	I
bodies	O
,	O
found	O
in	O
cancer	O
patients	O
compared	O
to	O
controls	O
(	O
meta	O
##bol	O
##ites	O
not	O
disc	O
##rim	O
##ina	O
##nt	O
according	O
to	O
their	O
VIP	O
value	O
)	O
.	O

We	O
examined	O
the	O
association	O
between	O
our	O
top	O
meta	O
##bol	O
##ites	O
and	O
β	B
-	I
car	I
##ote	I
##ne	I
supplement	O
##ation	O
s	O
##tra	O
##ti	O
##fied	O
by	O
these	O
factors	O
.	O

The	O
anal	O
##yte	O
retention	O
times	O
at	O
1	O
m	O
##L	O
min	O
_	O
−	O
##1	O
flow	O
rate	O
were	O
recorded	O
and	O
plot	O
##ted	O
against	O
the	O
met	B
##han	I
##ol	I
concentration	O
.	O

The	O
L	O
##O	O
##Q	O
for	O
3	B
-	I
e	I
##pi	I
-	I
25	I
(	I
OH	I
)	I
D	I
_	I
3	I
was	O
not	O
determined	O
.	O

AAA	O
##s	O
and	O
BC	O
##AA	O
##s	O
were	O
increased	O
and	O
g	B
##ly	I
##cine	I
was	O
decreased	O
.	O

The	O
bio	O
##chemical	O
pathway	O
for	O
the	O
conversion	O
of	O
glucose	S
into	O
er	B
##yt	I
##hr	I
##ito	I
##l	I
was	O
investigated	O
.	O

Level	O
##s	O
of	O
G	O
##S	O
-	O
33	O
##100	O
##7	O
trip	B
##hos	I
##phate	I
within	O
P	O
##BM	O
##C	O
were	O
approximately	O
4	O
μ	O
##M	O
(	O
85	O
##9	O
f	O
##mo	O
##l	O
/	O
10	O
_	O
6	O
cells	O
,	O
assuming	O
an	O
in	O
##tra	O
##cellular	O
volume	O
of	O
0	O
.	O
2	O
p	O
##l	O
)	O
.	O

The	O
total	O
concentrations	O
of	O
g	B
##lut	I
##ama	I
##te	I
+	O
g	B
##lut	I
##amine	I
or	O
as	B
##par	I
##tate	I
+	O
as	B
##par	I
##agi	I
##ne	I
were	O
calculated	O
as	O
one	O
variable	O
.	O

Out	O
of	O
48	O
analyzed	O
ICC	O
tissue	O
samples	O
,	O
one	O
sample	O
for	O
CR	O
and	O
one	O
sample	O
for	O
N	B
##AN	I
##A	I
ass	O
##ays	O
were	O
below	O
the	O
lower	O
limit	O
of	O
detection	O
.	O

c	O
SP	O
##E	O
cartridges	O
were	O
loaded	O
with	O
di	O
##lut	O
##ed	O
super	O
##nat	O
##ant	O
,	O
washed	O
with	O
70	O
%	O
met	B
##han	I
##ol	I
and	O
el	O
##uted	O
from	O
O	O
##asis	O
H	O
##L	O
##B	O
cartridges	O
with	O
3	O
##×	O
##1	O
m	O
##L	O
of	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
(	O
Me	O
##C	O
##N	O
)	O
,	O
et	B
##hyl	I
ace	I
##tate	I
(	O
E	O
##t	O
##A	O
##c	O
)	O
or	O
met	B
##han	I
##ol	I
(	O
Me	O
##OH	O
)	O
.	O

P	O
##las	O
##ma	O
glucose	S
levels	O
at	O
0	O
,	O
30	O
,	O
60	O
,	O
90	O
,	O
and	O
120	O
minutes	O
during	O
the	O
O	O
##G	O
##TT	O
were	O
determined	O
immediately	O
using	O
the	O
Y	O
##SI	O
270	O
##0	O
ST	O
##AT	O
glucose	S
analyze	O
##r	O
(	O
Yellow	O
Springs	O
Instruments	O
,	O
Yellow	O
Springs	O
,	O
OH	O
)	O
.	O

Co	O
##mpo	O
##unds	O
were	O
anal	O
##ys	O
##ed	O
on	O
a	O
fully	O
-	O
p	O
##orous	O
3	O
.	O
00	O
×	O
100	O
mm	O
,	O
1	O
.	O
7	O
μ	O
##m	O
AC	O
##Q	O
##UI	O
##TY	O
UP	O
##C	O
_	O
2	O
B	O
##E	O
##H	O
2	B
-	I
et	I
##hyl	I
##py	I
##rid	I
##ine	I
(	O
B	O
##E	O
##H	O
2	O
-	O
EP	O
)	O
column	O
maintained	O
at	O
35	O
°C	O
,	O
using	O
a	O
mobile	O
phase	O
composed	O
of	O
CO	O
_	O
2	O
(	O
solvent	O
A	O
)	O
and	O
the	O
selected	O
organic	O
m	O
##od	O
##ifier	O
(	O
solvent	O
B	O
)	O
with	O
the	O
following	O
14	O
.	O
65	O
min	O
gradient	O
el	O
##ution	O
method	O
:	O
the	O
mobile	O
phase	O
composition	O
changed	O
from	O
98	O
%	O

m	O
m	O
m	O
m	O
m	O
m	O
d	O
m	O
Ki	O
##net	O
##ic	O
studies	O
for	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
g	O
##lu	O
##cu	O
##ron	O
##ida	O
##tion	O
were	O
carried	O
out	O
in	O
pool	O
##ed	O
H	O
##LM	O
##s	O
and	O
re	O
##comb	O
##ina	O
##nt	O
U	O
##G	O
##T	O
##1	O
##A	O
##4	O
.	O

L	O
##M	O
-	O
1000	O
)	O
,	O
d	O
_	B
7	I
-	I
ch	I
##ole	I
##ster	I
##ol	I
(	O
cat	O
.	O

After	O
adjustment	O
for	O
extended	O
classical	O
risk	O
factors	O
,	O
higher	O
t	B
##yr	I
##os	I
##ine	I
and	O
al	B
##ani	I
##ne	I
levels	O
were	O
associated	O
with	O
decreased	O
risk	O
of	O
micro	O
##vas	O
##cular	O
disease	O
(	O
H	O
##R	O
0	O
.	O
78	O
;	O

A	O
signal	O
was	O
again	O
observed	O
for	O
a	O
s	B
##phi	I
##ngo	I
##lip	I
##id	I
.	O

On	O
the	O
log	O
scale	O
,	O
G	O
##F	O
##R	O
was	O
estimated	O
from	O
single	O
-	O
and	O
multiple	O
-	O
meta	O
##bol	O
##ite	O
panels	O
and	O
compared	O
with	O
e	O
##G	O
##F	O
##R	O
using	O
the	O
Ch	O
##ronic	O
Kid	O
##ney	O
Disease	O
E	O
##pid	O
##em	O
##iology	O
equations	O
with	O
c	B
##rea	I
##tin	I
##ine	I
and	O
/	O
or	O
c	B
##ys	I
##tat	I
##in	I
C	O
using	O
established	O
metric	O
##s	O
,	O
including	O
the	O
proportion	O
of	O
errors	O
>	O
30	O
%	O
of	O
m	O
##G	O
##F	O
##R	O
(	O
1	O
-	O
P	O
_	O
30	O
)	O
,	O
before	O
and	O
after	O
bias	O
correction	O
.	O

;	O
Table	O
)	O
,	O
using	O
two	O
models	O
:	O
one	O
adjusted	O
for	O
sex	O
,	O
and	O
one	O
adjusted	O
for	O
sex	O
and	O
try	B
##pt	I
##op	I
##han	I
.	O

To	O
sum	O
up	O
,	O
BC	O
##AA	O
##s	O
,	O
GP	B
##C	I
,	O
O	O
##AG	O
,	O
SC	O
##FA	O
##s	O
,	O
and	O
other	O
meta	O
##bol	O
##ites	O
were	O
tightly	O
related	O
to	O
the	O
proliferation	O
and	O
migration	O
of	O
tumor	O
cells	O
.	O

Because	O
the	O
public	O
speaking	O
stress	O
##or	O
produced	O
elevations	O
in	O
co	B
##rt	I
##is	I
##ol	I
early	O
in	O
the	O
night	O
,	O
it	O
may	O
be	O
that	O
HP	O
##A	O
axis	O
activation	O
and	O
arousal	O
prior	O
to	O
sleep	O
blunt	O
##ed	O
the	O
expected	O
rise	O
in	O
me	B
##lat	I
##oni	I
##n	I
at	O
Time	O
T	O
##3	O
.	O

In	O
agreement	O
with	O
this	O
speculation	O
,	O
many	O
previous	O
meta	O
##bon	O
##omi	O
##c	O
analyses	O
of	O
post	O
-	O
m	O
##ort	O
##em	O
brain	O
tissue	O
and	O
plasma	O
obtained	O
from	O
B	O
##D	O
patients	O
have	O
also	O
observed	O
significant	O
alterations	O
in	O
g	B
##lut	I
##amine	I
levels	O
_	O
,	O
.	O

Previous	O
reports	O
show	O
female	O
free	O
Car	O
##n	O
and	O
a	B
##cy	I
##l	I
-	I
Car	I
##n	I
levels	O
decrease	O
significantly	O
upon	O
reaching	O
fertile	O
age	O
.	O

Barr	O
##os	O
et	O
al	O
observed	O
altered	O
FA	S
profiles	O
in	O
plasma	O
PC	O
in	O
critically	O
ill	O
patients	O
,	O
mostly	O
diagnosed	O
with	O
se	O
##psis	O
and	O
se	O
##ptic	O
shock	O
,	O
compared	O
with	O
healthy	O
elderly	O
subjects	O
.	O

Additionally	O
,	O
88	O
.	O
6	O
%	O
(	O
39	O
of	O
44	O
)	O
of	O
subjects	O
in	O
this	O
study	O
had	O
T	O
##x	O
##B	O
_	O
2	O
<	O
500	O
p	O
##g	O
/	O
mg	O
c	B
##rea	I
##tin	I
##ine	I
,	O
consistent	O
with	O
a	O
normal	O
response	O
to	O
as	B
##pi	I
##rin	I
.	O

Higher	O
grade	O
tumors	O
over	O
##ex	O
##press	O
the	O
on	O
##co	O
##gene	O
M	O
##Y	O
##C	O
,	O
which	O
is	O
associated	O
with	O
d	O
##ys	O
##re	O
##gu	O
##lated	O
lip	O
##id	O
metabolism	O
and	O
display	O
altered	O
ch	B
##ole	I
##ster	I
##ol	I
metabolism	O
to	O
increase	O
energy	O
storage	O
.	O

Sam	O
##ple	O
tissues	O
were	O
disrupted	O
by	O
multi	O
-	O
beads	O
shock	O
##er	O
and	O
suspended	O
in	O
100	O
m	O
##M	O
Tri	O
##s	O
–	O
HC	O
##l	O
(	O
pH	O
9	O
.	O
0	O
)	O
containing	O
8	O
M	O
u	B
##rea	I
,	O
protein	O
p	O
##hos	O
##pha	O
##tase	O
inhibitor	O
##s	O
and	O
protein	O
p	O
##hos	O
##pha	O
##tase	O
inhibitor	O
##s	O
cocktail	O
##s	O
(	O
Sigma	O
,	O
St	O
.	O
Louis	O
,	O
M	O
##O	O
,	O
USA	O
)	O
.	O

Current	O
guidelines	O
recommend	O
the	O
use	O
of	O
an	O
SSR	O
##I	O
(	O
selective	O
se	B
##rot	I
##oni	I
##n	I
re	O
##up	O
##take	O
inhibitor	O
)	O
as	O
a	O
first	O
-	O
line	O
agent	O
where	O
treatment	O
with	O
anti	O
##de	O
##press	O
##ants	O
is	O
considered	O
in	O
C	O
##K	O
##D	O
patients	O
.	O

We	O
found	O
a	O
significant	O
difference	O
in	O
p	B
##ht	I
##hala	I
##te	I
exposure	O
according	O
to	O
age	O
and	O
gender	O
.	O

The	O
major	O
is	O
##omer	O
:	O
_	O
1	O
H	O
N	O
##MR	O
(	O
700	O
MHz	O
,	O
D	O
_	O
2	O
O	O
)	O
:	O
δ	O
7	O
.	O
26	O
(	O
s	O
,	O
1	O
##H	O
,	O
H	O
##2	O
′	O
)	O
,	O
6	O
.	O
88	O
(	O
s	O
,	O
1	O
##H	O
,	O
H	O
##5	O
′	O
)	O
,	O
6	O
.	O
46	O
(	O
s	O
,	O
1	O
##H	O
,	O
H	O
##4	O
′	O
)	O
,	O
4	O
.	O
06	O
-	O
4	O
.	O
02	O
(	O
m	O
,	O
1	O
##H	O
,	O
Cy	O
##s	O
α	B
-	I
CH	I
)	O
,	O
3	O
.	O
88	O
-	O
3	O
.	O
84	O
(	O
m	O
,	O
2	O
##H	O
,	O
H	O
##1	O
)	O
,	O
3	O
.	O
74	O
(	O
s	O
,	O
3	O
##H	O
,	O
O	O
##M	O
##e	O
)	O
,	O
3	O
.	O
58	O
-	O
3	O
.	O
54	O
(	O
m	O
,	O
1	O
##H	O
,	O
Cy	O
##s	O
β	B
-	I
CH	I
_	I
a	I
)	O
,	O
3	O
.	O
43	O
-	O
3	O
.	O
39	O
(	O
m	O
,	O
1	O
##H	O
,	O
Cy	O
##s	O
β	B
-	I
CH	I
_	I
b	I
)	O
,	O
2	O
.	O
41	O
-	O
2	O
.	O
38	O
(	O
m	O
,	O
2	O
##H	O
,	O
H	O
##4	O
)	O
,	O
1	O
.	O
79	O
(	O
s	O
,	O
3	O
##H	O
,	O
Me	O
)	O
,	O
1	O
.	O
69	O
-	O
1	O
.	O
65	O
(	O
m	O
,	O
2	O
##H	O
,	O
H	O
##2	O
)	O
,	O
1	O
.	O
33	O
-	O
1	O
.	O
30	O
(	O
m	O
,	O
2	O
##H	O
,	O
H	O
##3	O
)	O
.	O

They	O
concluded	O
that	O
an	O
altered	O
ethanol	B
##amine	I
##ph	I
##os	I
##phate	I
home	O
##ost	O
##asis	O
might	O
contribute	O
to	O
mental	O
disorders	O
such	O
as	O
s	O
##chi	O
##zophrenia	O
.	O

The	O
p	O
##eptide	O
was	O
identified	O
as	O
A	O
##Q	O
##Y	O
##L	O
##Q	O
##Q	O
##C	O
*	O
P	O
##F	O
##ED	O
##H	O
##V	O
##K	O
(	O
170	O
##4	O
.	O
8	O
Da	O
)	O
modified	O
by	O
des	B
##ami	I
##no	I
-	I
Ph	I
##IP	I
(	O
207	O
Da	O
)	O
or	O
des	B
##ami	I
##no	I
-	I
[	I
_	I
2	I
H	I
_	I
5	I
]	I
-	O
Ph	O
##IP	O
(	O
212	O
Da	O
)	O
;	O
this	O
pair	O
of	O
p	O
##eptide	O
add	O
##uc	O
##ts	O
occurred	O
at	O
amino	O
acid	O
residues	O
28	O
–	O
41	O
of	O
SA	O
.	O

Q	O
##uant	O
##ified	O
levels	O
of	O
g	B
##ly	I
##co	I
##ly	I
##tic	I
and	O
T	O
##CA	O
cycle	O
intermediate	O
##s	O
(	O
a	O
)	O
and	O
p	O
##hos	O
##ph	O
##ory	O
##lation	O
levels	O
of	O
each	O
p	O
##hos	O
##ph	O
##ory	O
##lation	O
site	O
in	O
associated	O
enzymes	O
(	O
b	O
)	O
in	O
normal	O
(	O
left	O
,	O
open	O
dots	O
)	O
and	O
tumor	O
(	O
right	O
,	O
filled	O
dots	O
)	O
tissues	O
obtained	O
from	O
lung	O
and	O
pro	O
##state	O
cancer	O
patients	O
.	O

In	O
this	O
last	O
case	O
,	O
se	B
##rine	I
is	O
de	O
##car	O
##box	O
##yla	O
##ted	O
to	O
ethanol	B
##amine	I
,	O
leading	O
in	O
two	O
further	O
steps	O
to	O
g	B
##ly	I
##co	I
##lic	I
acid	I
,	O
whereas	O
g	B
##ly	I
##cine	I
is	O
trans	O
##ami	O
##nated	O
to	O
g	B
##ly	I
##ox	I
##yl	I
##ic	I
acid	I
,	O
which	O
is	O
reduced	O
to	O
g	B
##ly	I
##co	I
##lic	I
acid	I
.	O

The	O
4	O
is	O
##of	O
##orms	O
/	O
is	O
##oz	O
##yme	O
##s	O
of	O
ω	O
-	O
h	O
##ydro	O
##xy	O
##lase	O
that	O
s	O
##ynth	O
##esi	O
##ze	O
20	B
-	I
H	I
##ET	I
##E	I
are	O
differential	O
##ly	O
localized	O
in	O
the	O
kidney	O
and	O
individually	O
regulated	O
,	O
e	O
##g	O
,	O
the	O
4	O
##A	O
##8	O
is	O
##of	O
##orm	O
is	O
regulated	O
by	O
test	B
##osterone	I
.	O

The	O
internal	O
stand	O
was	O
des	B
##met	I
##hyl	I
##dia	I
##ze	I
##pa	I
##m	I
m	O

Mon	B
##ome	I
##thy	I
##lars	I
##ono	I
##us	I
acid	I
and	O
mon	B
##ome	I
##thy	I
##lm	I
##ono	I
##thi	I
##oar	I
##sonic	I
acid	I
were	O
identified	O
along	O
with	O
a	B
##rsen	I
##ite	I
,	O
dim	B
##eth	I
##yla	I
##rs	I
##ini	I
##c	I
acid	I
,	O
mon	B
##ome	I
##thy	I
##lars	I
##onic	I
acid	I
,	O
and	O
a	O
##rsen	O
##ate	O
.	O

Lac	B
##tate	I
is	O
considered	O
a	O
key	O
player	O
in	O
development	O
and	O
meta	O
##sta	O
##sis	O
of	O
cancer	O
.	O

ace	B
##tic	I
acid	I
from	O
Fisher	O
Scientific	O
(	O
Austria	O
)	O
and	O
water	O
was	O
double	O
-	O
di	O
##st	O
##ille	O
##d	O
Mill	O
##i	O
-	O
Q	O
water	O
as	O
stated	O
above	O
.	O

P	O
##las	O
##ma	O
total	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
L	O
##D	O
##L	O
-	O
C	O
,	O
HD	O
##L	O
-	O
C	O
and	O
T	B
##G	I
were	O
measured	O
by	O
en	O
##zy	O
##matic	O
ass	O
##ay	O
at	O
SE	O
##AL	O
##S	O
path	O
##ology	O
(	O
Prince	O
of	O
Wales	O
Hospital	O
)	O
as	O
previously	O
described	O
,	O
using	O
a	O
Beck	O
##man	O
L	O
##X	O
##20	O
Ana	O
##ly	O
##zer	O
with	O
a	O
timed	O
-	O
end	O
##point	O
method	O
(	O
Fuller	O
##ton	O
,	O
CA	O
)	O
.	O

For	O
both	O
studies	O
,	O
each	O
al	O
##iq	O
##uo	O
##t	O
of	O
met	B
##han	I
##olic	I
extract	O
ball	O
##ast	O
##ed	O
with	O
Me	O
##OH	O
/	O
H	O
_	O
2	O
O	O
was	O
dried	O
with	O
a	O
Speed	O
##V	O
##ac	O
SPD	O
##11	O
##1	O
##V	O
sample	O
con	O
##cent	O
##rator	O
(	O
The	O
##rm	O
##o	O
Fisher	O
Scientific	O
,	O
Ashe	O
##ville	O
,	O
NC	O
,	O
USA	O
)	O
for	O
5	O
h	O
,	O
followed	O
by	O
the	O
addition	O
of	O
100	O
µ	O
##L	O
et	B
##hyl	I
ace	I
##tate	I
as	O
an	O
a	O
##ze	O
##ot	O
##ropic	O
drying	O
agent	O
,	O
and	O
another	O
45	O
min	O
of	O
Speed	O
##V	O
##ac	O
drying	O
.	O

The	O
significant	O
increase	O
of	O
ace	B
##tone	I
may	O
imply	O
that	O
the	O
elevated	O
flux	O
from	O
ace	B
##ty	I
##l	I
-	I
Co	I
##A	I
into	O
ace	B
##to	I
##ace	I
##ty	I
##l	I
-	I
Co	I
##A	I
,	O
resulted	O
in	O
production	O
of	O
ace	B
##tone	I
.	O

The	O
gradient	O
program	O
was	O
:	O
8	O
%	O
met	B
##han	I
##ol	I
,	O
4	O
%	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
and	O
88	O
%	O
water	O
phase	O
for	O
3	O
min	O
,	O
increased	O
to	O
12	O
%	O
met	B
##han	I
##ol	I
,	O
6	O
%	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
and	O
82	O
%	O
water	O
phase	O
over	O
1	O
min	O
and	O
hold	O
for	O
4	O
min	O
.	O

shows	O
the	O
raw	O
data	O
generated	O
for	O
one	O
anal	O
##yte	O
,	O
24	B
##S	I
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
.	O

HP	O
##LC	O
-	O
grade	O
met	B
##han	I
##ol	I
and	O
ace	B
##tic	I
acid	I
were	O
purchased	O
from	O
Fisher	O
Scientific	O
(	O
Pittsburgh	O
,	O
PA	O
)	O
.	O

In	O
MD	O
##D	O
,	O
the	O
level	O
of	O
gal	B
##act	I
##ose	I
in	O
E	O
##LS	O
/	O
MD	O
##D	O
was	O
lower	O
than	O
non	O
-	O
E	O
##LS	O
/	O
MD	O
##D	O
.	O

Am	B
##ino	I
##acy	I
##l	I
-	I
t	I
##RNA	I
##s	I
are	O
substrates	O
for	O
translation	O
and	O
are	O
pivotal	O
in	O
determining	O
how	O
the	O
genetic	O
code	O
is	O
interpreted	O
as	O
amino	O
acids	O
.	O

In	O
addition	O
,	O
vitamin	B
D	I
intake	O
among	O
Thai	O
##s	O
is	O
generally	O
low	O
because	O
few	O
natural	O
vitamin	O
D	O
-	O
rich	O
food	O
sources	O
are	O
found	O
in	O
Thailand	O
,	O
and	O
foods	O
are	O
not	O
fortified	O
with	O
vitamin	B
D	I
.	O

The	O
c	B
##it	I
##ric	I
acid	I
cycle	O
meta	O
##bol	O
##ites	O
‘	O
downstream	O
’	O
from	O
α	B
-	I
k	I
##eto	I
##g	I
##lut	I
##arate	I
i	O
.	O
e	O
.	O
su	B
##cci	I
##nate	I
,	O
ma	B
##late	I
and	O
f	B
##uma	I
##rate	I
were	O
not	O
dramatically	O
altered	O
.	O

Using	O
models	O
that	O
corrected	O
for	O
age	O
and	O
gender	O
,	O
body	O
mass	O
index	O
showed	O
weak	O
negative	O
relationships	O
with	O
co	B
##rt	I
##ico	I
##ster	I
##one	I
,	O
21	B
-	I
de	I
##ox	I
##y	I
##cor	I
##tis	I
##ol	I
,	O
co	B
##rt	I
##is	I
##ol	I
,	O
co	B
##rt	I
##ison	I
##e	I
,	O
test	B
##osterone	I
,	O
pro	B
##ges	I
##tero	I
##ne	I
,	O
17	B
-	I
h	I
##ydro	I
##xy	I
##p	I
##rog	I
##ester	I
##one	I
and	O
11	B
-	I
de	I
##ox	I
##y	I
##cor	I
##tic	I
##osterone	I
,	O
but	O
a	O
positive	O
relationship	O
with	O
18	B
-	I
h	I
##ydro	I
##xy	I
##cor	I
##tis	I
##ol	I
.	O

Two	O
independent	O
en	B
##zal	I
##uta	I
##mi	I
##de	I
and	O
N	B
-	I
des	I
##met	I
##hyl	I
##en	I
##zal	I
##uta	I
##mi	I
##de	I
stocks	O
were	O
used	O
:	O
one	O
for	O
the	O
preparation	O
of	O
ca	O
##li	O
##bra	O
##tion	O
standards	O
and	O
one	O
for	O
the	O
quality	O
control	O
samples	O
(	O
Q	O
##C	O
)	O
.	O

High	O
levels	O
of	O
circulating	O
u	B
##ric	I
acid	I
have	O
been	O
associated	O
with	O
a	O
number	O
of	O
medical	O
conditions	O
,	O
including	O
go	O
##ut	O
,	O
kidney	O
stones	O
,	O
tumor	O
l	O
##ys	O
##is	O
syndrome	O
,	O
metabolic	O
syndrome	O
,	O
and	O
diabetes	O
,	O
as	O
well	O
as	O
with	O
increased	O
risk	O
of	O
several	O
cancer	O
##s	O
(	O
,	O
)	O
.	O

These	O
include	O
(	O
i	O
)	O
pro	B
##sta	I
##g	I
##land	I
##in	I
D	I
##2	I
which	O
is	O
produced	O
from	O
a	B
##rac	I
##hi	I
##don	I
##ic	I
acid	I
(	O
AA	O
)	O
via	O
the	O
c	O
##yl	O
##co	O
##ox	O
##y	O
##gen	O
##ase	O
action	O
,	O
(	O
ii	O
)	O
8	B
-	I
h	I
##ydro	I
##xy	I
fatty	O
acids	O
including	O
5	B
-	I
H	I
##ET	I
##E	I
and	O
15	B
-	I
H	I
##ET	I
##E	I
,	O
well	O
known	O
media	O
##tors	O
of	O
inflammation	O
derived	O
from	O
AA	O
via	O
the	O
lip	O
##oo	O
##xy	O
##gen	O
##ase	O
pathway	O
,	O
and	O
(	O
ii	O
##i	O
)	O
two	O
o	B
##xy	I
##lip	I
##ins	I
of	O
the	O
c	O
##yt	O
##och	O
##rome	O
P	O
##45	O
##0	O
pathways	O
,	O
namely	O
14	B
,	I
15	I
-	I
E	I
##ET	I
and	O
5	B
,	I
6	I
-	I
Di	I
##H	I
##ET	I
##E	I
.	O

To	O
pu	O
##ri	O
##fy	O
the	O
der	O
##iva	O
##tized	O
anal	O
##yte	O
##s	O
,	O
two	O
methods	O
were	O
tested	O
:	O
LL	O
##E	O
with	O
et	B
##hyl	I
ace	I
##tate	I
and	O
SP	O
##E	O
.	O

B	O
##rief	O
##ly	O
,	O
U	O
##HP	O
##LC	O
-	O
MS	O
/	O
MS	O
analysis	O
with	O
an	O
integrated	O
X	O
##evo	O
T	O
##Q	O
-	O
S	O
tandem	O
q	O
##uad	O
##rup	O
##ole	O
mass	O
s	O
##pect	O
##rome	O
##ter	O
(	O
Waters	O
Corporation	O
,	O
UK	O
)	O
and	O
a	O
reversed	O
-	O
phase	O
U	O
##HP	O
##LC	O
separation	O
was	O
performed	O
using	O
a	O
H	O
##SS	O
T	O
##3	O
(	O
2	O
.	O
1	O
×	O
150	O
mm	O
,	O
1	O
.	O
8	O
µ	O
##m	O
)	O
column	O
(	O
Waters	O
Corporation	O
,	O
UK	O
)	O
and	O
mobile	O
phases	O
of	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
in	O
water	O
(	O
Fisher	O
Chemical	O
,	O
USA	O
)	O
and	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
in	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
(	O
R	O
##ied	O
##el	O
-	O
de	O
Ha	O
##ë	O
##n	O
,	O
USA	O
)	O
.	O

Sub	O
##jects	O
with	O
higher	O
beta	B
##ine	I
levels	O
were	O
older	O
,	O
more	O
likely	O
to	O
be	O
men	O
and	O
less	O
likely	O
to	O
be	O
Caucasian	O
.	O

The	O
finding	O
of	O
sustained	O
plasma	O
and	O
u	O
##rina	O
##ry	O
o	O
##est	O
##rogen	O
##s	O
at	O
20	O
-	O
40	O
%	O
compared	O
to	O
their	O
control	O
levels	O
indirectly	O
support	O
a	O
hypothesis	O
of	O
alternative	O
o	O
##est	O
##rogen	O
sources	O
in	O
post	O
##men	O
##op	O
##aus	O
##al	O
breast	O
cancer	O
patients	O
on	O
treatment	O
with	O
4	B
-	I
h	I
##ydro	I
##xy	I
##and	I
##ros	I
##ten	I
##ed	I
##ione	I
.	O

With	O
the	O
death	O
of	O
neurons	O
and	O
mit	O
##och	O
##ond	O
##ria	O
,	O
the	O
o	O
##xi	O
##da	O
##tive	O
stress	O
levels	O
in	O
the	O
brain	O
may	O
increase	O
and	O
lead	O
to	O
the	O
production	O
of	O
more	O
ne	O
##uro	O
##to	O
##xi	O
##c	O
substances	O
,	O
such	O
as	O
ni	B
##tro	I
##ty	I
##ros	I
##ine	I
.	O

We	O
identified	O
a	O
broad	O
disruption	O
in	O
energy	O
-	O
related	O
and	O
anti	O
-	O
inflammatory	O
metabolism	O
especially	O
in	O
c	B
##rea	I
##tine	I
,	O
g	B
##ly	I
##cine	I
,	O
th	B
##re	I
##oni	I
##ne	I
and	O
his	B
##ti	I
##dine	I
serum	O
concentrations	O
.	O

1	O
.	O
420	O
##0	O
–	O
1	O
.	O
37	O
##40	O
1	O
.	O
37	O
##40	O
–	O
1	O
.	O
345	O
##0	O
0	O
.	O
03	O
0	O
.	O
02	O
MA	O
##TV	O
_	O
W	O
##T	O
##B	O
:	O
total	O
metabolic	O
active	O
tumor	O
volume	O
;	O
N	O
##AG	O
:	O
N	B
-	I
ace	I
##ty	I
##lated	I
g	I
##ly	I
##co	I
##p	I
##rote	I
##ins	I
;	O
PC	O
,	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
;	O
SM	O
:	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
##s	I
;	O
SUV	O
:	O
standardized	O
up	O
##take	O
value	O
;	O
T	O
##L	O
##G	O
_	O
W	O
##T	O
##B	O
:	O
total	O
tumor	O
les	O
##ion	O
g	O
##ly	O
##co	O
##lysis	O
.	O

that	O
inflammation	O
-	O
induced	O
en	O
##rich	O
##ed	O
extra	O
##cellular	O
g	B
##ly	I
##co	I
##p	I
##rote	I
##ins	I
are	O
associated	O
with	O
an	O
optimal	O
response	O
during	O
se	O
##ptic	O
shock	O
.	O

They	O
must	O
come	O
from	O
the	O
dissolution	O
of	O
CO	O
_	O
2	O
and	O
subsequent	O
di	O
##sso	O
##ciation	O
of	O
the	O
carbon	B
##ic	I
acid	I
.	O

In	O
a	O
log	O
##istic	O
re	O
##gression	O
model	O
including	O
the	O
leading	O
meta	O
##bol	O
##ites	O
from	O
each	O
cluster	O
,	O
er	B
##yt	I
##hr	I
##ito	I
##l	I
,	O
g	B
##lut	I
##ary	I
##l	I
car	I
##ni	I
##tine	I
and	O
alpha	B
##hy	I
##dr	I
##ox	I
##yi	I
##so	I
##vale	I
##rate	I
(	O
from	O
clusters	O
2	O
,	O
3	O
and	O
6	O
)	O
remained	O
significant	O
.	O

The	O
in	O
v	O
##it	O
##ro	O
studies	O
we	O
have	O
completed	O
in	O
primary	O
human	O
cells	O
suggest	O
that	O
a	O
majority	O
of	O
the	O
in	O
##tra	O
##cellular	O
meta	O
##bol	O
##ites	O
were	O
in	O
trip	B
##hos	I
##phate	I
form	O
.	O

Interest	O
##ingly	O
,	O
these	O
meta	O
##bol	O
##ites	O
included	O
glucose	S
,	O
format	B
##e	I
,	O
AM	B
##P	I
,	O
N	B
##AD	I
,	O
c	B
##rea	I
##tine	I
,	O
c	B
##rea	I
##tin	I
##ine	I
,	O
D	B
##MG	I
,	O
D	B
##MA	I
,	O
trim	B
##eth	I
##yla	I
##mine	I
(	O
T	O
##MA	O
)	O
,	O
short	O
-	O
chain	O
fatty	O
acids	O
,	O
ace	B
##tate	I
and	O
GA	B
##BA	I
,	O
which	O
are	O
mainly	O
involved	O
in	O
energy	O
,	O
fatty	O
acids	O
and	O
ch	B
##olin	I
##e	I
metabolic	O
pathways	O
.	O

B	O
##rief	O
##ly	O
,	O
sample	O
extraction	O
was	O
conducted	O
by	O
using	O
a	O
##que	O
##ous	O
met	B
##han	I
##ol	I
,	O
delivered	O
by	O
an	O
automated	O
liquid	O
handle	O
##r	O
to	O
remove	O
the	O
protein	O
fraction	O
while	O
allowing	O
maximum	O
recovery	O
of	O
small	O
molecules	O
.	O

These	O
results	O
indicate	O
that	O
O	O
##PL	O
##S	O
-	O
D	O
##A	O
models	O
derived	O
from	O
the	O
R	B
##RL	I
##C	I
-	I
(	I
±	I
)	I
E	I
##SI	I
-	I
MS	I
data	O
had	O
good	O
predict	O
##ive	O
ability	O
and	O
were	O
reliable	O
.	O

Cell	O
##s	O
grown	O
in	O
25	O
and	O
5	O
m	O
##M	O
glucose	S
are	O
shown	O
.	O

The	O
daily	O
dose	O
of	O
m	B
##or	I
##phine	I
required	O
to	O
achieve	O
sufficient	O
pain	O
control	O
have	O
been	O
reported	O
between	O
60	O
and	O
1800	O
mg	O
/	O
day	O
and	O
blood	O
concentrations	O
of	O
m	B
##or	I
##phine	I
in	O
the	O
same	O
group	O
of	O
chronic	O
pain	O
patients	O
have	O
been	O
reported	O
between	O
16	O
and	O
28	O
##37	O
ng	O
/	O
m	O
##L	O
,	O
.	O

The	O
recovery	O
rates	O
of	O
the	O
vitamin	B
D	I
compounds	O
were	O
examined	O
by	O
utilizing	O
the	O
stable	O
is	O
##oto	O
##pe	O
derivatives	O
as	O
outlined	O
in	O
the	O
“	O
Experimental	O
”	O
section	O
.	O

On	O
the	O
contrary	O
,	O
high	O
L	B
##ys	I
##o	I
##PC	I
(	I
16	I
:	I
0	I
)	I
levels	O
were	O
reported	O
to	O
be	O
an	O
o	O
##var	O
##ian	O
cancer	O
bio	O
##mark	O
##er	O
.	O

U	O
##rine	O
samples	O
from	O
clinical	O
##ly	O
diagnosed	O
cases	O
with	O
well	O
-	O
preserved	O
e	O
##G	O
##F	O
##R	O
showed	O
significantly	O
reduced	O
ex	O
##cre	O
##tion	O
of	O
11	O
amino	O
acids	O
,	O
among	O
them	O
t	B
##yr	I
##os	I
##ine	I
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
do	B
##pa	I
##mine	I
,	O
ho	B
##mo	I
##cy	I
##stein	I
##e	I
,	O
and	O
se	B
##rine	I
.	O

For	O
some	O
s	O
##tero	O
##ids	O
,	O
in	O
particular	O
21	B
-	I
de	I
##ox	I
##y	I
##cor	I
##tis	I
##ol	I
,	O
11	B
-	I
de	I
##ox	I
##y	I
##cor	I
##tic	I
##osterone	I
and	O
18	B
-	I
o	I
##x	I
##oc	I
##ort	I
##is	I
##ol	I
,	O
plasma	O
concentrations	O
were	O
below	O
detect	O
##able	O
limits	O
in	O
15	O
%	O
,	O
11	O
%	O
and	O
2	O
%	O
of	O
patients	O
respectively	O
so	O
that	O
only	O
upper	O
cut	O
-	O
offs	O
of	O
reference	O
intervals	O
could	O
be	O
established	O
.	O

On	O
the	O
other	O
hand	O
,	O
2	B
-	I
O	I
-	I
met	I
##hyl	I
##asco	I
##rb	I
##ic	I
acid	I
,	O
form	B
##ic	I
acid	I
,	O
2	B
,	I
5	I
-	I
fur	I
##and	I
##ica	I
##rb	I
##ox	I
##yl	I
##ic	I
acid	I
,	O
4	B
-	I
h	I
##ydro	I
##xy	I
##phe	I
##ny	I
##lla	I
##ctic	I
acid	I
,	O
and	O
ta	B
##rta	I
##ric	I
acid	I
tend	O
to	O
be	O
higher	O
in	O
older	O
women	O
.	O

One	O
common	O
approach	O
consists	O
in	O
the	O
chemical	O
reduction	O
of	O
all	O
di	B
##sul	I
##fi	I
##de	I
bonds	O
to	O
provide	O
a	O
total	O
ho	B
##mo	I
##cy	I
##stein	I
##e	I
measurement	O
.	O

Finding	O
markers	O
like	O
2	O
-	O
H	O
##BA	O
that	O
are	O
associated	O
with	O
g	B
##ly	I
##ce	I
##mic	I
status	O
are	O
important	O
for	O
revealing	O
pathways	O
in	O
d	B
##ys	I
##gly	I
##ce	I
##mic	I
conditions	O
such	O
as	O
diabetes	O
,	O
and	O
can	O
offer	O
unique	O
perspectives	O
for	O
tracking	O
efficacy	O
of	O
therapeutic	O
interventions	O
.	O

However	O
,	O
the	O
observation	O
that	O
the	O
decrease	O
in	O
N	B
##AA	I
##G	I
in	O
the	O
urine	O
of	O
cancer	O
patients	O
is	O
substantial	O
,	O
suggests	O
that	O
the	O
concentration	O
of	O
N	B
##AA	I
##G	I
is	O
urine	O
may	O
be	O
used	O
as	O
an	O
indicator	O
of	O
RC	O
##C	O
size	O
or	O
activity	O
.	O

However	O
,	O
the	O
he	O
##xa	O
##pe	O
##pt	O
##ide	O
N	O
_	B
2	I
-	I
c	I
##ys	I
##tein	I
##es	I
##ulf	I
##in	I
##yl	I
-	I
Ph	I
##IP	I
L	O
##Q	O
##Q	O
##C	O
*	O
P	O
##F	O
(	O
C	O
-	O
[	O
S	O
=	O
O	O
]	O
-	O
Ph	O
##IP	O
,	O
t	O
_	O
R	O
=	O
16	O
.	O
8	O
min	O
,	O
[	O
M	O
+	O
2	O
##H	O
]	O
_	O
2	O
+	O
m	O
/	O
z	O
48	O
##7	O
.	O
4	O
and	O
48	O
##9	O
.	O
7	O
for	O
Ph	O
##IP	O
and	O
[	O
_	O
2	O
H	O
_	O
5	O
]	O
-	O
Ph	O
##IP	O
-	O
modified	O
p	O
##eptide	O
##s	O
)	O
was	O
recovered	O
from	O
H	O
##ON	O
##H	O
-	O
Ph	O
##IP	O
-	O
modified	O
SA	O
,	O
following	O
dig	O
##est	O
##ion	O
with	O
try	O
##ps	O
##in	O
/	O
ch	O
##ym	O
##ot	O
##ry	O
##ps	O
##in	O
without	O
heat	O
den	O
##at	O
##uration	O
and	O
D	O
##TT	O
treatment	O
.	O

Palm	B
##ito	I
##le	I
##ic	I
acid	I
enhance	O
##s	O
insulin	O
sensitivity	O
by	O
suppress	O
##ing	O
inflammation	O
and	O
in	O
##hibit	O
##ing	O
the	O
destruction	O
of	O
insulin	O
-	O
secret	O
##ing	O
pan	O
##cre	O
##atic	O
β	O
cells	O
,	O
and	O
it	O
also	O
reduces	O
o	O
##besity	O
-	O
related	O
inflammation	O
.	O

Ana	O
##ly	O
##tical	O
thin	O
layer	O
ch	O
##roma	O
##tography	O
(	O
T	O
##LC	O
)	O
was	O
carried	O
out	O
on	O
pre	B
-	I
coated	I
si	I
##lica	I
gel	O
T	O
##LC	O
aluminum	O
sheets	O
(	O
E	O
##M	O
Science	O
,	O
NJ	O
,	O
USA	O
;	O
Ki	O
##ese	O
##lge	O
##l	O
60	O
F	O
_	O
254	O
,	O
5	O
×	O
2	O
cm	O
×	O
0	O
.	O
2	O
mm	O
)	O
.	O

l	O
.	O
We	O
used	O
conventional	O
type	O
2	O
diabetes	O
risk	O
factors	O
to	O
estimate	O
risk	O
of	O
new	O
onset	O
of	O
type	O
2	O
diabetes	O
for	O
each	O
participant	O
,	O
including	O
sex	O
and	O
parental	O
history	O
of	O
diabetes	O
as	O
cat	O
##ego	O
##rical	O
variables	O
and	O
age	O
,	O
fast	O
##ing	O
glucose	S
,	O
B	O
##MI	O
,	O
HD	O
##L	O
##c	O
,	O
T	O
##AG	O
and	O
blood	O
pressure	O
as	O
continuous	O
variables	O
.	O

Sam	O
##ples	O
of	O
patients	O
treated	O
with	O
cab	B
##oz	I
##anti	I
##ni	I
##b	I
(	O
n	O
=	O
2	O
)	O
,	O
da	O
##bra	O
##fen	O
##ib	O
(	O
n	O
=	O
6	O
)	O
,	O
o	O
##lap	O
##ari	O
##b	O
(	O
n	O
=	O
2	O
)	O
,	O
ni	O
##rap	O
##ari	O
##b	O
(	O
n	O
=	O
2	O
)	O
or	O
ve	O
##mura	O
##fen	O
##ib	O
(	O
n	O
=	O
1	O
)	O
were	O
stable	O
at	O
−	O
##40	O
##°	O
##C	O
for	O
at	O
least	O
111	O
,	O
132	O
,	O
120	O
,	O
183	O
and	O
132	O
days	O
,	O
respectively	O
.	O

Dock	O
##ing	O
results	O
of	O
the	O
synthesized	O
compounds	O
D	O
##HP	O
##M	O
##1	O
–	O
D	O
##HP	O
##M	O
##8	O
against	O
human	O
lip	O
##ox	O
##y	O
##gen	O
##ase	O
in	O
complex	O
with	O
a	B
##rac	I
##hi	I
##don	I
##ic	I
acid	I
A	O
##bb	O
##re	O
##viation	O
##s	O
:	O
M	O
##OE	O
,	O
Molecular	O
Operating	O
Environment	O
;	O
D	O
##HP	O
##M	O
,	O
di	B
##hy	I
##dr	I
##opy	I
##rim	I
##id	I
##ine	I
.	O

Human	O
ma	O
##li	O
##gnant	O
me	O
##lan	O
##oma	O
t	O
##umour	O
##s	O
were	O
sliced	O
into	O
10	O
µ	O
##m	O
thick	O
sections	O
on	O
a	O
cry	O
##oto	O
##me	O
,	O
dried	O
for	O
15	O
min	O
at	O
37	O
°C	O
and	O
fixed	O
with	O
100	O
%	O
Me	B
##OH	I
.	O

PC	O
##A	O
,	O
Me	B
##OH	I
,	O
and	O
AC	O
##N	O
have	O
been	O
applied	O
in	O
previous	O
studies	O
to	O
extract	O
p	B
##oly	I
##amine	I
and	O
related	O
compounds	O
.	O

Cy	B
##ste	I
##amine	I
is	O
the	O
simplest	O
stable	O
amino	B
##thi	I
##ol	I
found	O
in	O
the	O
body	O
and	O
is	O
a	O
product	O
of	O
the	O
con	O
##st	O
##it	O
##utive	O
degradation	O
of	O
co	O
##en	O
##zy	O
##me	O
A	O
.	O
Cy	B
##ste	I
##amine	I
is	O
a	O
precursor	O
for	O
the	O
formation	O
of	O
h	B
##y	I
##pot	I
##au	I
##rine	I
(	O
which	O
is	O
subsequently	O
o	O
##xi	O
##dized	O
to	O
ta	B
##uri	I
##ne	I
)	O
by	O
c	O
##ys	O
##te	O
##amine	O
di	O
##ox	O
##y	O
##gen	O
##ase	O
.	O

C	B
##it	I
##ru	I
##llin	I
##e	I
is	O
an	O
amino	O
acid	O
having	O
a	O
role	O
in	O
the	O
u	B
##rea	I
cycle	O
and	O
can	O
act	O
as	O
a	O
source	O
for	O
the	O
feeding	O
of	O
the	O
K	O
##re	O
##bs	O
cycle	O
.	O

In	O
addition	O
,	O
higher	O
ace	B
##to	I
##ace	I
##tate	I
was	O
correlated	O
with	O
lower	O
insulin	O
sensitivity	O
in	O
our	O
study	O
.	O

4	B
-	I
(	I
4	I
,	I
6	I
-	I
Di	I
##met	I
##ho	I
##xy	I
[	I
1	I
,	I
3	I
,	I
5	I
]	I
t	I
##ria	I
##zin	I
-	I
2	I
-	I
y	I
##l	I
)	I
-	I
4	I
-	I
met	I
##hyl	I
##mor	I
##ph	I
##olin	I
##ium	I
chloride	I
(	O
D	O
##MT	O
##MM	O
)	O
was	O
obtained	O
from	O
A	O
##c	O
##ros	O
Organic	O
(	O
Pittsburgh	O
,	O
PA	O
)	O
,	O
while	O
_	O
15	O
N	O
-	O
p	O
##ht	O
##hali	O
##mi	O
##de	O
potassium	O
and	O
de	O
##uter	O
##ium	O
oxide	O
were	O
obtained	O
from	O
Cambridge	O
Is	O
##oto	O
##pe	O
Laboratories	O
(	O
And	O
##over	O
,	O
MA	O
)	O
.	O

Reg	O
##ression	O
analysis	O
demonstrated	O
that	O
six	O
of	O
them	O
–	O
A	O
##rg	O
,	O
Pro	O
,	O
C	B
##10	I
:	I
1	I
,	O
A	O
##rg	O
/	O
Or	O
##n	O
,	O
C	O
##it	O
/	O
A	O
##rg	O
,	O
and	O
C	O
##5	O
-	O
OH	O
/	O
C	O
##0	O
–	O
could	O
be	O
used	O
to	O
di	O
##ag	O
##nose	O
L	O
##C	O
with	O
a	O
sensitivity	O
of	O
91	O
.	O
3	O
%	O
and	O
a	O
specific	O
##ity	O
of	O
92	O
.	O
7	O
%	O
.	O

On	O
the	O
contrary	O
other	O
compounds	O
such	O
as	O
vitamin	B
E	I
are	O
associated	O
to	O
relative	O
in	O
##ef	O
##ficiency	O
in	O
the	O
control	O
of	O
liver	O
diseases	O
,	O
in	O
particular	O
N	O
##AF	O
##LD	O
of	O
adult	O
patients	O
.	O

It	O
has	O
been	O
demonstrated	O
that	O
peripheral	O
K	O
##Y	O
##N	O
and	O
3	O
-	O
HK	O
cross	O
the	O
blood	O
–	O
brain	O
barrier	O
and	O
fuel	O
the	O
K	B
##P	I
in	O
the	O
C	O
##NS	O
,	O
where	O
ID	O
##O	O
and	O
TD	O
##O	O
activities	O
are	O
con	O
##st	O
##it	O
##utive	O
##ly	O
low	O
.	O

In	O
pre	O
##hy	O
##pert	O
##ens	O
##ive	O
subjects	O
,	O
the	O
levels	O
of	O
l	O
##ys	O
##o	O
##PC	O
(	O
16	O
:	O
0	O
)	O
positively	O
and	O
significantly	O
correlated	O
with	O
o	O
##x	O
-	O
L	O
##D	O
##L	O
,	O
L	O
##p	O
-	O
P	O
##LA	O
_	O
2	O
activity	O
,	O
8	B
-	I
e	I
##pi	I
-	I
P	I
##G	I
##F	I
_	I
2	I
##α	I
,	O
and	O
IL	O
-	O
6	O
before	O
and	O
after	O
adjusting	O
for	O
B	O
##MI	O
,	O
W	O
##H	O
##R	O
,	O
smoking	O
,	O
alcohol	O
consumption	O
,	O
and	O
L	B
##D	I
##L	I
ch	I
##ole	I
##ster	I
##ol	I
.	O

3	B
-	I
p	I
##hen	I
##yl	I
##la	I
##ctic	I
acid	I
showed	O
significant	O
differences	O
to	O
milk	O
and	O
so	O
##y	O
drink	O
intake	O
at	O
time	O
-	O
points	O
1	O
,	O
2	O
,	O
and	O
4	O
h	O
(	O
see	O
Table	O
##s	O
S	O
##3	O
and	O
S	O
##4	O
)	O
.	O

Inc	O
##reased	O
synthesis	O
of	O
20	B
-	I
H	I
##ET	I
##E	I
by	O
pre	O
##g	O
##lo	O
##mer	O
##ular	O
micro	O
##ves	O
##sel	O
##s	O
el	O
##eva	O
##tes	O
re	O
##nova	O
##s	O
##cular	O
resistance	O
,	O
reducing	O
in	O
##tra	O
##vas	O
##cular	O
pressures	O
in	O
the	O
me	O
##du	O
##llar	O
##y	O
circulation	O
,	O
promoting	O
movement	O
of	O
fluid	O
into	O
the	O
v	O
##asa	O
re	O
##ct	O
##ae	O
with	O
expansion	O
of	O
extra	O
##cellular	O
fluid	O
volume	O
and	O
elevation	O
of	O
blood	O
pressure	O
.	O

As	O
shown	O
in	O
Fi	O
##gs	O
and	O
metabolic	O
pathways	O
with	O
pathway	O
impact	O
higher	O
than	O
0	O
.	O
1	O
are	O
screened	O
out	O
,	O
including	O
a	B
##rg	I
##ini	I
##ne	I
and	O
pro	B
##line	I
metabolism	O
(	O
AP	O
##M	O
)	O
,	O
g	B
##ly	I
##cer	I
##oli	I
##pid	I
metabolism	O
(	O
G	O
##LM	O
)	O
,	O
in	B
##os	I
##ito	I
##l	I
phosphate	I
metabolism	O
(	O
IP	O
##M	O
)	O
,	O
p	B
##yr	I
##u	I
##vate	I
metabolism	O
(	O
PM	O
)	O
,	O
g	B
##ly	I
##ox	I
##yla	I
##te	I
and	O
di	B
##car	I
##box	I
##yla	I
##te	I
metabolism	O
(	O
G	O
##DM	O
)	O
,	O
and	O
g	B
##ly	I
##cine	I
,	O
se	B
##rine	I
and	O
th	B
##re	I
##oni	I
##ne	I
metabolism	O
(	O
G	O
##ST	O
##M	O
)	O
.	O

CO	O
##H	O
levels	O
appear	O
to	O
be	O
a	O
physiological	O
constant	O
that	O
may	O
be	O
of	O
considerable	O
value	O
in	O
ch	B
##ole	I
##ster	I
##ol	I
metabolism	O
.	O

The	O
semi	O
##pur	O
##ified	O
fraction	O
(	O
el	O
##uted	O
from	O
a	O
Sep	O
##P	O
##ak	O
C	O
_	O
18	O
cartridge	O
with	O
90	O
%	O
met	B
##han	I
##ol	I
)	O
of	O
T	O
.	O
ha	O
##rz	O
##ian	O
##um	O
strain	O
E	O
##S	O
##39	O
was	O
shown	O
to	O
contain	O
five	O
major	O
p	O
##ept	O
##ai	O
##bol	O
ho	O
##mo	O
##logue	O
##s	O
.	O

Vita	B
##min	I
E	I
serves	O
as	O
a	O
diet	O
##ary	O
-	O
derived	O
anti	O
##ox	O
##ida	O
##nt	O
,	O
and	O
alterations	O
in	O
vitamin	B
E	I
meta	O
##bol	O
##ites	O
could	O
be	O
in	O
##dicative	O
of	O
changes	O
in	O
o	O
##xi	O
##da	O
##tive	O
stress	O
brought	O
about	O
by	O
le	O
##pt	O
##in	O
replacement	O
.	O

Most	O
of	O
the	O
intermediate	O
##s	O
of	O
important	O
plant	O
metabolic	O
pathways	O
(	O
K	O
##re	O
##bs	O
'	O
cycle	O
,	O
fatty	O
acid	O
bio	O
##sy	O
##nt	O
##hesis	O
and	O
g	B
##lu	I
##cos	I
##ino	I
##late	I
bio	O
##sy	O
##nt	O
##hesis	O
)	O
were	O
detected	O
(	O
A	O
In	O
##set	O
and	O
)	O
.	O

In	O
one	O
study	O
,	O
16	O
%	O
of	O
university	O
students	O
surveyed	O
admitted	O
that	O
they	O
had	O
knowing	O
##ly	O
exceeded	O
the	O
maximum	O
daily	O
dose	O
of	O
anal	O
##ges	O
##ics	O
;	O
the	O
authors	O
of	O
another	O
survey	O
concluded	O
that	O
patient	O
knowledge	O
is	O
insufficient	O
to	O
ensure	O
safe	O
usage	O
of	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
.	O

Although	O
knowledge	O
of	O
t	O
##ria	O
##tom	O
##ine	O
physiology	O
is	O
fragment	O
##ed	O
among	O
insect	O
vector	O
species	O
,	O
R	O
.	O
pro	O
##lix	O
##us	O
dig	O
##est	O
##ion	O
has	O
been	O
studied	O
for	O
many	O
years	O
,	O
and	O
the	O
activities	O
of	O
several	O
c	B
##ys	I
##tein	I
##e	I
and	O
/	O
or	O
as	B
##par	I
##tic	I
protein	O
##ases	O
have	O
been	O
identified	O
in	O
the	O
posterior	O
mid	O
##gu	O
##t	O
,	O
,	O
.	O

Total	O
ex	O
##cre	O
##tion	O
by	O
individual	O
s	O
##tero	O
##id	O
and	O
s	O
##tero	O
##id	O
subgroup	O
(	O
and	O
##rogen	O
##s	O
,	O
mineral	O
##oc	O
##ort	O
##ico	O
##ids	O
,	O
g	B
##lu	I
##co	I
##cor	I
##tic	I
##oids	I
,	O
and	O
respective	O
precursor	O
s	O
##tero	O
##ids	O
)	O
were	O
compared	O
between	O
control	O
,	O
AC	O
##A	O
,	O
and	O
ACC	O
groups	O
using	O
the	O
K	O
##rus	O
##kal	O
-	O
Wallis	O
non	O
##par	O
##ame	O
##tric	O
test	O
;	O
for	O
significance	O
values	O
of	O
P	O
<	O
0	O
.	O
05	O
,	O
pair	O
-	O
wise	O
comparisons	O
were	O
carried	O
out	O
using	O
Dunn	O
'	O
s	O
post	O
ho	O
##c	O
test	O
.	O

In	O
the	O
current	O
study	O
,	O
higher	O
P	O
##t	O
##d	O
##cho	O
was	O
found	O
in	O
F	B
##D	I
patients	O
’	O
plasma	O
,	O
compared	O
to	O
controls	O
,	O
which	O
conflicts	O
with	O
the	O
results	O
from	O
ul	O
##cer	O
##ative	O
co	O
##lit	O
##is	O
(	O
UC	O
)	O
studies	O
.	O

All	O
o	B
##xy	I
##ster	I
##ols	I
were	O
successfully	O
detected	O
in	O
patient	O
plasma	O
samples	O
.	O

In	O
addition	O
,	O
the	O
_	O
13	O
C	O
satellite	O
cross	O
-	O
peaks	O
of	O
3	O
-	O
met	O
##hyl	O
and	O
2	O
-	O
met	O
##hine	O
pro	O
##tons	O
of	O
la	B
##ct	I
##ate	I
(	O
patterns	O
1	O
and	O
2	O
)	O
and	O
Al	O
##a	O
(	O
patterns	O
3	O
and	O
4	O
)	O
were	O
evident	O
(	O
traced	O
by	O
dashed	O
green	O
re	O
##ct	O
##ang	O
##les	O
)	O
,	O
and	O
the	O
peak	O
pattern	O
indicates	O
that	O
la	B
##ct	I
##ate	I
and	O
Al	O
##a	O
were	O
uniform	O
##ly	O
_	O
13	O
C	O
labeled	O
.	O

C	O
##YP	O
##2	O
##A	O
##6	O
is	O
also	O
responsible	O
for	O
the	O
metabolism	O
of	O
ni	B
##cot	I
##ine	I
:	O
It	O
media	O
##tes	O
the	O
conversion	O
of	O
ni	B
##cot	I
##ine	I
to	O
co	B
##tin	I
##ine	I
and	O
the	O
subsequent	O
conversion	O
of	O
co	B
##tin	I
##ine	I
to	O
3	B
′	I
-	I
h	I
##ydro	I
##xy	I
##cot	I
##ini	I
##ne	I
.	O

In	O
conclusion	O
,	O
we	O
have	O
identified	O
plasma	O
meta	O
##bol	O
##ites	O
that	O
were	O
significantly	O
altered	O
during	O
acute	O
sleep	O
de	O
##p	O
##ri	O
##vation	O
(	O
mainly	O
lip	O
##ids	O
and	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
,	O
se	B
##rot	I
##oni	I
##n	I
,	O
try	B
##pt	I
##op	I
##han	I
,	O
and	O
ta	B
##uri	I
##ne	I
)	O
,	O
all	O
increasing	O
during	O
sleep	O
de	O
##p	O
##ri	O
##vation	O
.	O

As	O
a	O
test	O
example	O
of	O
potential	O
bio	O
##mark	O
##er	O
performance	O
in	O
a	O
multi	O
-	O
anal	O
##yte	O
algorithm	O
,	O
palm	B
##ito	I
##yl	I
s	I
##phi	I
##ngo	I
##my	I
##elin	I
,	O
la	B
##ct	I
##ate	I
,	O
g	B
##lu	I
##cona	I
##te	I
,	O
ad	B
##eno	I
##sin	I
##e	I
,	O
2	B
-	I
met	I
##hyl	I
##but	I
##yr	I
##yl	I
##gly	I
##cine	I
and	O
g	B
##uan	I
##din	I
##oa	I
##ce	I
##tate	I
were	O
chosen	O
for	O
algorithm	O
training	O
using	O
the	O
co	O
##hor	O
##t	O
-	O
1	O
data	O
set	O
.	O

The	O
same	O
analyses	O
were	O
undertaken	O
with	O
patients	O
divided	O
by	O
treatment	O
arm	O
(	O
p	O
##ac	O
##lit	O
##ax	O
##el	O
plus	O
lap	B
##ati	I
##ni	I
##b	I
;	O
p	O
##ac	O
##lit	O
##ax	O
##el	O
plus	O
place	O
##bo	O
)	O
.	O

The	O
five	O
remaining	O
meta	O
##bol	O
##ites	O
,	O
which	O
are	O
derivatives	O
related	O
to	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
and	O
the	O
u	B
##rea	I
cycle	O
,	O
were	O
positively	O
associated	O
with	O
progression	O
to	O
E	O
##SR	O
##D	O
with	O
smaller	O
odds	O
ratios	O
.	O

Recently	O
two	O
signaling	O
pathways	O
through	O
(	O
1	O
)	O
neutral	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
##ase	I
##2	I
(	O
n	O
##SM	O
##ase	O
##2	O
,	O
an	O
enzyme	O
that	O
h	O
##ydro	O
##ly	O
##zes	O
s	O
##phi	O
##ngo	O
##my	O
##elin	O
to	O
c	B
##era	I
##mi	I
##de	I
)	O
or	O
(	O
2	O
)	O
E	O
##G	O
##F	O
receptor	O
(	O
E	O
##G	O
##F	O
##R	O
)	O
,	O
which	O
may	O
actually	O
con	O
##ver	O
##ge	O
and	O
integrate	O
,	O
have	O
been	O
demonstrated	O
for	O
the	O
biological	O
process	O
during	O
the	O
exposure	O
of	O
cigarette	O
smoke	O
in	O
the	O
lung	O
air	O
##way	O
,	O
with	O
the	O
observation	O
that	O
E	O
##G	O
##F	O
##R	O
is	O
favor	O
##ably	O
co	O
-	O
localized	O
in	O
c	O
##era	O
##mi	O
##de	O
-	O
en	O
##rich	O
##ed	O
regions	O
of	O
the	O
plasma	O
membrane	O
[	O
,	O
]	O
.	O

Analysis	O
of	O
transfer	O
##rin	O
g	O
##ly	O
##cos	O
##yla	O
##tion	O
was	O
performed	O
on	O
serum	O
samples	O
with	O
the	O
use	O
of	O
is	O
##oe	O
##lect	O
##ric	O
focusing	O
,	O
_	O
,	O
sodium	B
do	I
##de	I
##cy	I
##l	I
su	I
##lf	I
##ate	I
–	I
p	I
##oly	I
##ac	I
##ryl	I
##ami	I
##de	I
-	I
gel	I
electro	O
##ph	O
##ores	O
##is	O
(	O
SD	O
##S	O
-	O
PA	O
##GE	O
)	O
,	O
or	O
liquid	O
ch	O
##roma	O
##tography	O
–	O
mass	O
s	O
##pect	O
##rome	O
##try	O
(	O
,	O
and	O
the	O
)	O
.	O

Then	O
,	O
the	O
tissue	O
sample	O
was	O
im	O
##mers	O
##ed	O
in	O
200	O
##μ	O
##L	O
of	O
2	B
,	I
5	I
-	I
di	I
##hy	I
##dr	I
##ox	I
##y	I
##ben	I
##zoic	I
acid	I
(	B
2	B
,	I
5	I
-	I
D	I
##H	I
##B	I
;	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
)	O
solution	O

Our	O
study	O
found	O
that	O
most	O
pu	B
##rine	I
cat	O
##ab	O
##oli	O
##tes	O
,	O
including	O
1	B
-	I
met	I
##hyl	I
##ade	I
##nos	I
##ine	I
,	O
decreased	O
in	O
the	O
H	O
##T	O
##K	O
group	O
,	O
although	O
de	O
no	O
##vo	O
pu	B
##rine	I
bio	O
##sy	O
##nt	O
##hesis	O
was	O
up	O
##re	O
##gu	O
##lated	O
.	O

The	O
re	O
##gression	O
model	O
evaluate	O
##s	O
24	B
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
as	O
dependent	O
variable	O
and	O
25	O
(	O
OH	O
)	O
D	O
_	O
3	O
,	O
co	O
##hor	O
##t	O
or	O
e	O
##G	O
##F	O
##R	O
,	O
and	O
the	O
interaction	O
of	O
25	O
(	O
OH	O
)	O
D	O
_	O
3	O
with	O
co	O
##hor	O
##t	O
or	O
e	O
##G	O
##F	O
##R	O
as	O
independent	O
variables	O
.	O

For	O
example	O
,	O
ch	B
##lor	I
##he	I
##xi	I
##dine	I
g	I
##lu	I
##cona	I
##te	I
interact	O
##s	O
with	O
sa	O
##liva	O
##ry	O
films	O
,	O
and	O
ads	O
##or	O
##bs	O
to	O
teeth	O
and	O
oral	O
m	O
##uc	O
##osa	O
##l	O
surfaces	O
(	O
,	O
)	O
.	O

_	O
,	O
It	O
acts	O
as	O
a	O
pro	O
##dr	O
##ug	O
that	O
is	O
activated	S
to	O
7	B
-	I
et	I
##hyl	I
-	I
10	I
-	I
h	I
##ydro	I
##xy	I
##cam	I
##pt	I
##oth	I
##ec	I
##in	I
(	O
S	O
##N	O
-	O
38	O
)	O
by	O
car	O
##box	O
##yle	O
##ster	O
##ase	O
2	O
in	O
the	O
blood	O
and	O
liver	O
,	O
and	O
S	O
##N	O
-	O
38	O
is	O
subsequently	O
de	O
##to	O
##xi	O
##fied	O
in	O
the	O
liver	O
by	O
u	O
##rid	O
##ine	O
dip	O
##hos	O
##phate	O
-	O
g	O
##lu	O
##cu	O
##ron	O
##osy	O
##lt	O
##ran	O
##s	O
##fer	O
##ase	O
1A	O
##1	O
to	O
form	O
a	O
β	O
-	O
g	O
##lu	O
##cu	O
##ron	O
##ide	O
con	O
##ju	O
##gate	O
,	O
S	O
##N	O
-	O
38	O
##G	O
.	O
S	O
##N	O
-	O
38	O
is	O
a	O
potent	O
inhibitor	O
of	O
DNA	O
top	O
##ois	O
##omer	O
##ase	O
I	O
,	O
an	O
essential	O
enzyme	O
that	O
controls	O
DNA	O
structural	O
changes	O
by	O
relaxing	O
DNA	O
super	O
##coil	O
and	O
re	O
##liga	O
##ting	O
c	O
##lea	O
##ved	O
DNA	O
strands	O
during	O
DNA	O
replication	O
and	O
transcription	O
.	O

The	O
double	O
##t	O
of	O
C	O
##3	O
or	O
β	B
-	I
ma	I
##late	I
and	O
the	O
triple	O
##t	O
of	O
C	O
##2	O
or	O
α	B
-	I
ma	I
##late	I
indicate	O
the	O
prevalence	O
of	O
[	B
_	I
13	I
C	I
-	I
1	I
,	I
2	I
,	I
3	I
]	I
-	I
ma	I
##late	I
.	O

Sam	O
##ples	O
were	O
then	O
re	O
##con	O
##stituted	O
in	O
100	O
μ	O
##l	O
of	O
2	O
:	O
8	O
ace	O
##ton	O
##it	O
##ril	O
##e	O
:	O
water	O
containing	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
and	O
analyzed	O
by	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
.	O

No	O
differences	O
between	O
Place	O
##bo	O
,	O
Pi	O
##o	O
and	O
Pi	O
##o	O
&	O
Omega	B
-	I
3	I
subgroup	O
##s	O
were	O
observed	O
in	O
the	O
markers	O
of	O
acute	O
and	O
long	O
-	O
term	O
g	B
##ly	I
##ce	I
##mic	I
control	O
,	O
i	O
.	O
e	O
.	O
,	O
fast	O
##ing	O
blood	O
glucose	S
and	O
serum	O
H	O
##b	O
##A	O
_	O
1	O
##c	O
level	O
,	O
respectively	O
,	O
either	O
at	O
base	O
##line	O
,	O
or	O
at	O
week	O
24	O
(	O
Table	O
)	O
.	O

When	O
N	B
##AD	I
##P	I
##H	I
levels	O
are	O
higher	O
,	O
metabolism	O
is	O
shifted	O
from	O
per	O
##sistence	O
to	O
normal	O
cell	O
function	O
and	O
growth	O
,	O
an	O
##ab	O
##olic	O
pathways	O
are	O
stimulate	O
##d	O
,	O
bio	O
##mass	O
is	O
created	O
,	O
and	O
carbon	O
##s	O
and	O
electrons	O
are	O
stored	O
as	O
bio	O
##pol	O
##yme	O
##rs	O
for	O
cell	O
growth	O
and	O
repair	O
in	O
the	O
form	O
of	O
lip	O
##ids	O
,	O
protein	O
,	O
g	B
##ly	I
##co	I
##gen	I
,	O
g	B
##ly	I
##cans	I
,	O
and	O
nuclei	O
##c	O
acids	O
.	O

Inc	O
##reased	O
free	O
fatty	O
acid	O
levels	O
and	O
the	O
secret	O
##ion	O
of	O
very	O
low	O
density	O
lip	O
##op	O
##rote	O
##in	O
and	O
L	O
##D	O
##L	O
promote	O
the	O
bio	O
##sy	O
##nt	O
##hesis	O
of	O
PC	O
,	O
which	O
is	O
regulated	O
by	O
activation	O
of	O
the	O
CDP	B
-	I
ch	I
##olin	I
##e	I
pathway	O
[	O
,	O
]	O
.	O

B	O
##K	O
indicates	O
a	O
blank	O
sample	O
(	O
50	O
%	O
met	B
##han	I
##ol	I
containing	O
0	O
.	O
1	O
%	O
form	O
##ic	O
acid	O
)	O
introduced	O
into	O
H	O
##12	O
.	O

Indeed	O
,	O
the	O
PC	B
(	I
38	I
:	I
4	I
)	I
designation	O
still	O
means	O
that	O
the	O
lip	O
##id	O
could	O
be	O
one	O
of	O
nearly	O
a	O
dozen	O
possible	O
PC	O
structures	O
.	O

In	O
##sul	O
##in	O
resistance	O
,	O
Di	O
##abe	O
##tes	O
,	O
Weight	O
loss	O
,	O
R	O
##oux	O
-	O
en	O
-	O
Y	O
gas	O
##tric	O
bypass	O
,	O
Gas	O
##tric	O
bypass	O
surgery	O
,	O
Bari	O
##at	O
##ric	O
surgery	O
,	O
Met	O
##ab	O
##olo	O
##mic	O
##s	O
,	O
2	B
-	I
H	I
##ydro	I
##xy	I
##but	I
##yric	I
acid	I

They	O
are	O
also	O
anti	O
-	O
o	O
##xi	O
##dant	O
##s	O
preventing	O
lip	O
##op	O
##rote	O
##in	O
per	O
##ox	O
##ida	O
##tion	O
;	O
the	O
hydrogen	O
atoms	O
adjacent	O
to	O
the	O
vinyl	B
-	I
et	I
##her	I
bond	O
have	O
relatively	O
low	O
di	O
##sa	O
##sso	O
##ciation	O
energies	O
and	O
are	O
prefer	O
##ential	O
##ly	O
o	O
##xi	O
##dized	O
over	O
di	B
##acy	I
##l	I
GP	I
when	O
exposed	O
to	O
various	O
free	O
radical	O
##s	O
and	O
single	B
##t	I
oxygen	I
.	O

The	O
potential	O
for	O
auto	O
##sa	O
##mple	O
##r	O
carry	O
##over	O
was	O
assessed	O
by	O
in	O
##ject	O
##ing	O
blank	O
urine	O
specimens	O
that	O
did	O
not	O
contain	O
any	O
standard	O
material	O
and	O
ethanol	S
blank	O
##s	O
.	O

S	O
##pect	O
##ra	O
in	O
(	O
d	O
,	O
red	O
box	O
)	O
regions	O
of	O
cancer	O
demonstrate	O
dramatically	O
elevated	O
ch	B
##olin	I
##e	I
,	O
and	O
a	O
reduction	O
or	O
absence	O
of	O
c	B
##it	I
##rate	I
and	O
p	B
##oly	I
##amine	I
##s	I
relative	O
to	O
(	O
c	O
,	O
green	O
box	O
)	O
regions	O
of	O
healthy	O
peripheral	O
zone	O
tissue	O
.	O

For	O
lip	O
##id	O
meta	O
##bol	O
##ites	O
and	O
ad	O
##ip	O
##oki	O
##nes	O
,	O
3	O
-	O
H	O
##IB	O
correlated	O
only	O
with	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
and	O
its	O
breakdown	O
/	O
precursor	O
meta	O
##bol	O
##ites	O
g	B
##ly	I
##cer	I
##ol	I
and	O
FF	O
##A	O
.	O

Ad	O
##ju	O
##st	O
##ments	O
were	O
made	O
for	O
Fr	O
##ami	O
##ng	O
##ham	O
Global	O
Risk	O
Score	O
,	O
c	B
##rea	I
##tin	I
##ine	I
clearance	O
,	O
and	O
plasma	O
h	O
##s	O
##CR	O
##P	O
levels	O
.	O

N	B
-	I
Ace	I
##to	I
##xy	I
-	I
Ph	I
##IP	I
is	O
a	O
pen	O
##ult	O
##imate	O
meta	O
##bol	O
##ite	O
of	O
Ph	O
##IP	O
that	O
react	O
##s	O
with	O
DNA	O
to	O
form	O
stable	O
co	O
##valent	O
add	O
##uc	O
##ts	O
.	O

A	O
consisted	O
of	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
in	O
water	O
(	O
Mill	O
##i	O
-	O
Q	O
)	O
,	O
mobile	O
phase	O
B	O
consisted	O
of	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
in	O
AC	O
##N	O
and	O
mobile	O
phase	O
C	O
consisted	O
of	O
1	O
%	O
of	O
form	B
##ic	I
acid	I
in	O
AC	O
##N	O
.	O

Consequently	O
,	O
the	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
breakdown	O
product	O
g	B
##ly	I
##cer	I
##ol	I
is	O
expected	O
to	O
a	O
##cc	O
##um	O
##ulate	O
.	O

These	O
studies	O
demonstrated	O
that	O
bay	O
region	O
and	O
f	O
##jord	O
region	O
di	B
##ol	I
e	I
##pox	I
##ides	I
can	O
be	O
converted	O
to	O
G	B
##S	I
##H	I
con	O
##ju	O
##gate	O
##s	O
by	O
G	O
##ST	O
M1	O
,	O
G	O
##ST	O
P	O
##1	O
,	O
and	O
G	O
##ST	O
A1	O
,	O
and	O
that	O
such	O
con	O
##ju	O
##gation	O
was	O
in	O
most	O
cases	O
protective	O
against	O
DNA	O
damage	O
and	O
m	O
##uta	O
##genic	O
##ity	O
.	O

B	O
##rief	O
##ly	O
whole	O
blood	O
was	O
mixed	O
with	O
3	O
vols	O
of	O
ice	O
-	O
cold	O
buffer	O
A	O
(	O
10	O
m	O
##M	O
Tri	O
##s	O
,	O
320	O
m	O
##M	O
su	B
##c	I
##rose	I
,	O

E	B
##stra	I
##dio	I
##l	I
,	O
est	B
##rone	I
,	O
and	O
est	B
##rogen	I
meta	O
##bol	O
##ites	O
can	O
exist	O
in	O
con	O
##ju	O
##gated	O
forms	O
,	O
which	O
are	O
co	O
##valent	O
##ly	O
linked	O
to	O
g	B
##lu	I
##cu	I
##ron	I
##ide	I
,	O
su	B
##lf	I
##ate	I
,	O
or	O
g	B
##lut	I
##ath	I
##ione	I
residues	O
,	O
or	O
un	O
##con	O
##ju	O
##gated	O
forms	O
.	O

The	O
BP	O
##DE	O
-	O
Al	O
##b	O
add	O
##uc	O
##ts	O
were	O
detected	O
in	O
28	O
%	O
of	O
the	O
potentially	O
exposed	O
subjects	O
.	O
_	O
,	O
In	O
a	O
limited	O
number	O
of	O
studies	O
,	O
add	O
##uc	O
##ts	O
from	O
BP	O
##DE	O
bound	O
as	O
est	O
##ers	O
to	O
Al	O
##b	O
(	O
assumed	O
to	O
be	O
(	B
+	I
)	I
-	I
anti	I
-	I
BP	I
##DE	I
add	O
##uc	O
##ts	O
)	O
have	O
been	O
measured	O
by	O
MS	O
methods	O
as	O
te	O
##tro	O
##ls	O
,	O
after	O
their	O
release	O
from	O
Al	O
##b	O
by	O
mild	O
h	O
##ydro	O
##lysis	O
.	O

However	O
,	O
it	O
has	O
also	O
been	O
post	O
##ulated	O
that	O
2	O
-	O
pathway	O
cat	B
##ech	I
##ol	I
est	O
##rogen	O
##s	O
may	O
actually	O
be	O
protective	O
since	O
their	O
formation	O
pre	O
##c	O
##lude	O
##s	O
16	O
-	O
h	O
##ydro	O
##xy	O
##lation	O
.	O

G	B
##lut	I
##amine	I
and	O
g	B
##lut	I
##ama	I
##te	I
have	O
been	O
described	O
as	O
two	O
important	O
meta	O
##bol	O
##ites	O
in	O
BC	O
.	O

This	O
suggests	O
some	O
changes	O
in	O
the	O
β	O
-	O
oxidation	O
of	O
long	O
-	O
chain	O
FA	O
##s	O
and	O
in	O
the	O
t	B
##rica	I
##rb	I
##ox	I
##yl	I
##ic	I
acid	I
cycle	O
.	O

Among	O
the	O
meta	O
##bol	O
##ites	O
identified	O
,	O
six	O
meta	O
##bol	O
##ites	O
were	O
discovered	O
to	O
have	O
the	O
strongest	O
correlation	O
with	O
CH	O
##D	O
after	O
adjusting	O
for	O
multiple	O
testing	O
:	O
palm	B
##itic	I
acid	I
(	O
β	O
=	O
0	O
.	O
205	O
;	O

Cell	O
debris	O
was	O
removed	O
by	O
cent	O
##ri	O
##fu	O
##gation	O
,	O
b	B
##ac	I
##it	I
##rac	I
##in	I
was	O
added	O
to	O
prevent	O
c	O
##lump	O
##ing	O
,	O
and	O
virus	O
particles	O
were	O
p	O
##elle	O
##tted	O
by	O
cent	O
##ri	O
##fu	O
##gation	O
through	O
the	O
20	O
%	O
so	B
##rb	I
##ito	I
##l	I
cushion	O
at	O
room	O
temperature	O
.	O

Both	O
c	B
##era	I
##mi	I
##des	I
and	O
their	O
salvage	O
precursor	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
##s	I
(	O
SM	O
##s	O
)	O
were	O
increased	O
.	O

CS	O
##F	O
AD	O
bio	O
##mark	O
##er	O
analysis	O
was	O
performed	O
as	O
previously	O
described	O
in	O
a	O
Lu	O
##mine	O
##x	O
200	O
platform	O
,	O
including	O
levels	O
of	O
beta	O
‐	O
am	O
##yl	O
##oid	O
1	O
‐	O
42	O
(	O
A	O
##β	O
42	O
)	O
,	O
total	O
ta	O
##u	O
(	O
t	O
‐	O
Tau	O
)	O
,	O
and	O
ta	O
##u	O
p	O
##hos	O
##ph	O
##ory	O
##lated	O
at	O
th	B
##re	I
##oni	I
##ne	I
181	O
(	O
p	O
‐	O
Tau	O
_	O
181	O
)	O

Many	O
of	O
the	O
meta	O
##bol	O
##ites	O
that	O
contributed	O
to	O
significant	O
differences	O
in	O
the	O
N	O
##MR	O
model	O
were	O
amino	O
acids	O
and	O
the	O
cluster	O
of	O
signals	O
from	O
glucose	S
.	O

The	O
T	O
##BC	O
-	O
related	O
and	O
age	O
-	O
related	O
metabolic	O
profiles	O
exhibited	O
some	O
similarities	O
,	O
with	O
most	O
of	O
the	O
q	O
##uant	O
##ified	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
##s	I
and	O
many	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
being	O
related	O
to	O
both	O
age	O
and	O
T	O
##BC	O
.	O

depicts	O
the	O
fragment	O
##ation	O
patterns	O
for	O
bi	O
##le	O
acid	O
meta	O
##bol	O
##ite	O
G	O
##DC	O
##A	O
,	O
Ph	B
##e	I
-	I
Ph	I
##e	I
,	O
o	O
##ley	O
##ol	O
car	B
##ni	I
##tine	I
,	O
and	O
3	O
##bet	O
##a	O
,	O
6	B
##bet	I
##a	I
-	I
di	I
##hy	I
##dr	I
##ox	I
##y	I
-	I
5	I
##bet	I
##a	I
-	I
ch	I
##ola	I
##n	I
-	I
24	I
-	I
o	I
##ic	I
acid	I
.	O

To	O
avoid	O
this	O
problem	O
,	O
in	O
all	O
subsequent	O
experiments	O
,	O
super	O
##nat	O
##ants	O
were	O
used	O
directly	O
for	O
label	O
##ing	O
after	O
ace	B
##tone	I
precipitation	O
.	O

P	B
##uri	I
##ne	I
n	O
##uc	O
##leo	O
##tide	O
degradation	O
involves	O
de	O
##ph	O
##os	O
##ph	O
##ory	O
##lation	O
,	O
de	O
##ami	O
##nation	O
,	O
and	O
c	O
##lea	O
##vage	O
of	O
g	B
##ly	I
##cos	I
##id	I
##ic	I
bonds	O
to	O
l	O
##iber	O
##ate	O
pu	B
##rine	I
n	O
##uc	O
##leo	O
##base	O
##s	O
that	O
are	O
further	O
converted	O
to	O
x	B
##ant	I
##hine	I
and	O
then	O
u	B
##ric	I
acid	I
.	O

Therefore	O
,	O
by	O
employing	O
a	O
hypothesis	O
-	O
free	O
tissue	O
-	O
based	O
meta	O
##bol	O
##omi	O
##cs	O
study	O
,	O
the	O
present	O
study	O
investigated	O
the	O
metabolic	O
signatures	O
of	O
BC	O
##a	O
and	O
found	O
that	O
bi	B
##li	I
##ru	I
##bin	I
and	O
re	B
##tina	I
##l	I
may	O
be	O
involved	O
in	O
the	O
mechanism	O
underlying	O
the	O
bio	O
##mo	O
##le	O
##cular	O
action	O
of	O
sub	O
##mu	O
##cos	O
##al	O
injection	O
of	O
g	O
##em	O
##ci	O
##ta	O
##bine	O
in	O
u	O
##roth	O
##eli	O
##al	O
BC	O
##a	O
.	O

IF	O
##N	O
-	O
γ	O
,	O
inter	O
##fer	O
##on	O
gamma	O
;	O
IL	O
,	O
inter	O
##le	O
##uki	O
##n	O
;	O
IP	O
-	O
10	O
,	O
inter	O
##fer	O
##on	O
gamma	O
-	O
induced	O
protein	O
10	O
;	O
MI	B
##P	I
-	I
1	I
##β	I
,	O
mac	O
##rop	O
##hage	O
inflammatory	O
proteins	O
1	O
beta	O
;	O
T	O
##NF	O
-	O
α	O
,	O
t	O
##umour	O
ne	O
##c	O
##rosis	O
factor	O
alpha	O
.	O

However	O
from	O
it	O
can	O
be	O
seen	O
that	O
Pearson	O
correlation	O
##s	O
of	O
0	O
.	O
75	O
and	O
0	O
.	O
64	O
respectively	O
are	O
obtained	O
when	O
co	O
##rrel	O
##ating	O
co	B
##tin	I
##ine	I
and	O
trans	B
-	I
3	I
′	I
-	I
h	I
##ydro	I
##xy	I
##cot	I
##ini	I
##ne	I
with	O
3	O
-	O
EP	O
respectively	O
.	O

The	O
separation	O
was	O
achieved	O
under	O
the	O
column	O
temperature	O
of	O
40	O
°C	O
using	O
a	O
controlled	O
gradient	O
of	O
mobile	O
phase	O
A	O
consisting	O
of	O
0	O
.	O
1	O
%	O
(	O
v	O
/	O
v	O
)	O
form	B
##ic	I
acid	I
in	O
water	O
and	O
mobile	O
phase	O
B	O
,	O
consisting	O
of	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
in	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
at	O
a	O
flow	O
rate	O
of	O
0	O
.	O
4	O
m	O
##L	O
/	O
min	O
.	O

For	O
L	O
##C	O
-	O
H	O
##R	O
##MS	O
analysis	O
,	O
150	O
µ	O
##L	O
of	O
the	O
samples	O
were	O
transferred	O
and	O
di	O
##lut	O
##ed	O
with	O
150	O
µ	O
##L	O
H	O
_	O
2	O
O	O
on	O
an	O
empty	O
plate	O
,	O
and	O
for	O
FIA	O
-	O
H	O
##R	O
##MS	O
analysis	O
,	O
250	O
µ	O
##L	O
of	O
the	O
FIA	O
mobile	O
phase	O
(	O
made	O
by	O
mixing	O
290	O
m	O
##L	O
Me	B
##OH	I
and	O
a	O
10	O
m	O
##L	O
am	O
##pu	O
##le	O
B	O
##io	O
##crates	O
FIA	O
mobile	O
phase	O
add	O
##itive	O
,	O
provided	O
with	O
the	O
kit	O
)	O
were	O
added	O
directly	O
to	O
the	O
samples	O
on	O
the	O
collection	O
plate	O
.	O

The	O
selection	O
of	O
individuals	O
into	O
the	O
healthy	O
lean	O
group	O
and	O
healthy	O
over	O
##weight	O
or	O
o	O
##bes	O
##e	O
group	O
was	O
based	O
on	O
the	O
following	O
4	O
criteria	O
:	O
(	O
1	O
)	O
lean	O
means	O
18	O
.	O
5	O
kg	O
/	O
m	O
_	O
2	O
≤	O
B	O
##MI	O
<	O
24	O
.	O
0	O
kg	O
/	O
m	O
_	O
2	O
,	O
over	O
##weight	O
means	O
24	O
.	O
0	O
kg	O
/	O
m	O
_	O
2	O
≤	O
B	O
##MI	O
<	O
28	O
.	O
0	O
kg	O
/	O
m	O
_	O
2	O
,	O
and	O
o	O
##bes	O
##e	O
means	O
B	O
##MI	O
≥	O
28	O
kg	O
/	O
m	O
_	O
2	O
;	O
(	O
2	O
)	O
fast	O
##ing	O
glucose	S
concentration	O
≤	O
6	O
.	O
1	O
mm	O
##ol	O
/	O
L	O
and	O
no	O
previous	O
history	O
of	O
diabetes	O
;	O
(	O
3	O
)	O
s	O
##ys	O
##to	O
##lic	O
/	O
di	O
##ast	O
##olic	O
blood	O
pressure	O
<	O
140	O
/	O
90	O
mm	O
##H	O
##g	O
and	O
no	O
previous	O
high	O
blood	O
pressure	O
history	O
;	O
and	O
(	O
4	O
)	O
fast	O
##ing	O
plasma	O
T	O
##G	O
<	O
1	O
.	O
7	O
mm	O
##ol	O
/	O

In	O
women	O
,	O
but	O
not	O
in	O
men	O
,	O
diet	O
##ary	O
intake	O
of	O
marine	O
-	O
derived	O
n	O
##−	O
##3	O
P	O
##U	O
##FA	O
##s	O
was	O
negatively	O
correlated	O
with	O
u	O
##rina	O
##ry	O
pro	B
##sta	I
##g	I
##land	I
##in	I
E	O
_	O
2	O
production	O
(	O
r	O
=	O
−	O
##0	O
.	O
18	O
;	O
P	O
=	O
0	O
.	O
00	O
##2	O
)	O
.	O

Upon	O
incorporation	O
into	O
the	O
u	B
##rac	I
##il	I
ring	O
,	O
these	O
As	O
##p	O
is	O
##oto	O
##po	O
##mers	O
should	O
yield	O
the	O
following	O
_	O
13	O
C	O
is	O
##oto	O
##po	O
##mers	O
respectively	O
(	O
see	O
for	O
u	B
##rac	I
##il	I
ring	O
numbering	O
)	O
:	O
_	O
12	O
C	O
##5	O
,	O
_	O
13	O
C	O
##6	O
-	O
u	O
##rac	O
##il	O
,	O
_	O
13	O
C	O
##5	O
,	O
_	O
12	O
C	O
##6	O
-	O
u	O
##rac	O
##il	O
,	O
and	O
_	O
13	O
C	O
##5	O
,	O
_	O
13	O
C	O
##6	O
-	O
u	O
##rac	O
##il	O
.	O

This	O
non	O
-	O
est	O
##eri	O
##fied	O
AA	O
is	O
then	O
rapidly	O
est	O
##eri	O
##fied	O
to	O
available	O
l	B
##ys	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
,	O
or	O
is	O
converted	O
into	O
bio	O
##active	O
a	B
##rac	I
##hi	I
##don	I
##ic	I
acid	I
meta	O
##bol	O
##ites	O
,	O
i	O
.	O
e	O
.	O
,	O
e	B
##ico	I
##san	I
##oids	I
via	O
c	O
##y	O
##c	O
##lo	O
##ox	O
##y	O
##gen	O
##ase	O
(	O
CO	O
##X	O
)	O
,	O
lip	O
##ox	O
##y	O
##gen	O
##ase	O
(	O
L	O
##OX	O
)	O
,	O
or	O
c	O
##yt	O
##och	O
##rome	O
P	O
##45	O
##0	O
(	O
C	O
##YP	O
)	O
e	O
##pox	O
##y	O
##gen	O
##ase	O
enzymes	O
.	O

These	O
include	O
amino	O
acid	O
metabolism	O
,	O
bi	O
##le	O
acid	O
bio	O
##sy	O
##nt	O
##hesis	O
and	O
the	O
u	B
##rea	I
cycle	O
.	O

(	O
b	O
)	O
Pro	O
##ba	O
##bility	O
of	O
oral	O
cancer	O
using	O
an	O
M	O
##LR	O
model	O
and	O
concentrations	O
of	O
S	B
-	I
ad	I
##eno	I
##sy	I
##lm	I
##eth	I
##ion	I
##ine	I
(	O
SA	O
##M	O
)	O
and	O
pipe	B
##cola	I
##te	I
.	O

However	O
,	O
discovery	O
of	O
meta	O
##bol	O
##ite	O
bio	O
##mark	O
##ers	O
of	O
diseases	O
from	O
a	O
##que	O
##ous	O
met	B
##han	I
##ol	I
extract	O
##s	O
,	O
such	O
as	O
those	O
from	O
pro	O
##state	O
needle	O
bio	O
##ps	O
##ies	O
,	O
poses	O
several	O
pre	O
-	O
analytical	O
and	O
analytical	O
challenges	O
.	O

The	O
C	O
##V	O
##i	O
values	O
ranged	O
from	O
0	O
.	O
6	O
%	O
(	B
g	B
##lut	I
##ama	I
##te	I
,	O
p	O
##yr	O
##u	O
##vate	O
)	O
to	O
31	O
.	O
5	O
%	O
(	O
l	O
##ino	O
##le	O
##ic	O
acid	O
)	O
and	O
C	O
##V	O
##g	O
values	O
ranged	O
from	O
1	O
.	O
2	O
%	O
(	O
c	O
##it	O
##rate	O
)	O
to	O
59	O
.	O
1	O
%	O
(	O
l	O
##ino	O
##le	O
##ic	O
acid	O
)	O
.	O

Pro	O
##te	O
##omi	O
##c	O
studies	O
have	O
shown	O
up	O
##re	O
##gu	O
##lation	O
##s	O
of	O
g	O
##ly	O
##cer	O
##ald	O
##eh	O
##yd	O
##e	O
-	O
3	O
-	O
phosphate	O
de	O
##hy	O
##dr	O
##ogen	O
##ase	O
(	O
GA	O
##PD	O
##H	O
)	O
and	O
ma	O
##late	O
de	O
##hy	O
##dr	O
##ogen	O
##ase	O
(	O
MD	O
##H	O
)	O
but	O
down	O
-	O
regulations	O
of	O
p	O
##hos	O
##ph	O
##oe	O
##no	O
##l	O
##py	O
##ru	O
##vate	O
car	O
##box	O
##yk	O
##inas	O
##e	O
(	O
P	O
##EP	O
##C	O
##K	O
)	O
,	O
U	O
##DP	O
-	O
glucose	O
p	O
##yr	O
##op	O
##hos	O
##ph	O
##ory	O
##lase	O
2	O
(	O
U	O
##GP	O
##2	O
)	O
and	O
a	B
##con	I
##itate	I
h	O
##yd	O
##rata	O
##se	O
in	O
CR	O
##C	O
tissues	O
compared	O
to	O
these	O
in	O
adjacent	O
normal	O
m	O
##uc	O
##osa	O
indicating	O
the	O
CR	O
##C	O
-	O
associated	O
alterations	O
in	O
multiple	O
metabolic	O
pathways	O
such	O
as	O
g	O
##ly	O
##co	O
##lysis	O
/	O
g	O
##lu	O
##con	O
##eo	O
##genesis	O
,	O
g	B
##lu	I
##cu	I
##rona	I
##te	I
pathway	O
and	O
t	B
##rica	I
##rb	I
##ox	I
##yl	I
##ic	I
acid	I
cycle	O
_	O
,	O
_	O
,	O
.	O

We	O
found	O
significantly	O
decreased	O
c	B
##is	I
-	I
a	I
##con	I
##itate	I
,	O
is	B
##oc	I
##it	I
##rate	I
and	O
α	B
-	I
k	I
##eto	I
##g	I
##lut	I
##arate	I
,	O
meta	O
##bol	O
##ites	O
that	O
are	O
found	O
downstream	O
of	O
the	O
metabolic	O
block	O
,	O
while	O
other	O
T	O
##CA	O
intermediate	O
##s	O
including	O
su	B
##cci	I
##nate	I
,	O
ma	B
##late	I
and	O
f	B
##uma	I
##rate	I
were	O
not	O
dramatically	O
altered	O
.	O

The	O
lone	O
distinguishing	O
meta	O
##bol	O
##ite	O
detected	O
by	O
L	O
##C	O
-	O
MS	O
,	O
p	B
##yr	I
##og	I
##lut	I
##ami	I
##c	I
acid	I
,	O
had	O
a	O
sensitivity	O
and	O
specific	O
##ity	O
of	O
74	O
%	O
and	O
75	O
%	O
,	O
respectively	O
,	O
with	O
an	O
AU	O
##RO	O
##C	O
of	O
0	O
.	O
76	O
.	O

In	O
the	O
salvage	O
pathway	O
for	O
pu	B
##rine	I
bio	O
##sy	O
##nt	O
##hesis	O
,	O
h	O
##y	O
##pox	O
##ant	O
##hine	O
-	O
g	O
##uan	O
##ine	O
p	O
##hos	O
##ph	O
##ori	O
##bos	O
##yl	O
transfer	O
##ase	O
cat	O
##aly	O
##zes	O
the	O
addition	O
of	O
5	B
-	I
p	I
##hos	I
##ph	I
##ori	I
##bos	I
##e	I
-	I
1	I
-	I
p	I
##yr	I
##op	I
##hos	I
##phate	I
to	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
to	O
produce	O
in	B
##os	I
##ine	I
mon	I
##op	I
##hos	I
##phate	I
.	O

While	O
try	B
##pt	I
##op	I
##han	I
cat	O
##ab	O
##olis	O
##m	O
is	O
known	O
to	O
media	O
##te	O
tumor	O
immune	O
e	O
##vas	O
##ion	O
,	O
the	O
impact	O
of	O
ID	O
##O	O
or	O
TD	O
##O	O
activity	O
on	O
CD	O
##8	O
T	O
cells	O
was	O
thought	O
to	O
occur	O
through	O
indirect	O
suppression	O
via	O
regulatory	O
T	O
cell	O
activation	O
.	O

There	O
are	O
few	O
published	O
quantitative	O
data	O
for	O
meta	O
##bol	O
##ites	O
of	O
synthetic	O
can	B
##na	I
##bino	I
##ids	I
in	O
human	O
urine	O
.	O

The	O
cluster	O
peaks	O
of	O
sodium	B
format	I
##e	I
were	O
used	O
for	O
mass	O
ca	O
##li	O
##bra	O
##tion	O
in	O
each	O
L	O
##C	O
run	O
.	O

Response	O
##su	O
##rro	O
##gate	O
##sp	O
##ike	O
Response	O
##su	O
##rro	O
##gate	O
##sp	O
##ike	O
Response	O
##su	O
##rro	O
##gate	O
##sp	O
##ike	O
Response	O
Response	O
sur	O
##rogate	O
##sp	O
##ike	O
sur	O
##rogate	O
##sp	O
##ike	O
sur	O
##rogate	O
spike	O
×	O
100	O
%	O
where	O
Response	O
_	O
serum	O
spike	O
is	O
the	O
peak	O
area	O
count	O
for	O
pro	B
##line	I
spike	O
##d	O
high	O
Q	O
##C	O
sample	O
in	O
human	O
serum	O
,	O
Response	O
##ser	O
##um	O
is	O
the	O
peak	O
area	O
count	O
for	O
pro	B
##line	I
in	O
“	O
blank	O
”	O
human	O
serum	O
,	O
and	O
Response	O
_	O
sur	O
##rogate	O
spike	O
is	O
the	O
peak	O
area	O
count	O
for	O
pro	B
##line	I
spike	O
##d	O
high	O
Q	O
##C	O
sample	O
in	O
sur	O
##rogate	O
serum	O
.	O

A	B
##rg	I
##ini	I
##ne	I
meta	O
##bol	O
##ites	O
(	O
as	O
##ym	O
##metric	O
dim	B
##eth	I
##yla	I
##rg	I
##ini	I
##ne	I
[	O
AD	O
##MA	O
]	O
,	O
symmetric	B
dim	I
##eth	I
##yla	I
##rg	I
##ini	I
##ne	I
[	O
SD	O
##MA	O
]	O
,	O
L	B
-	I
a	I
##rg	I
##ini	I
##ne	I
,	O
L	B
-	I
or	I
##ni	I
##thin	I
##e	I
,	O
L	O
-	O
c	O
##it	O
##ru	O
##llin	O
##e	O
)	O
were	O
q	O
##uant	O
##ified	O
using	O
stable	O
is	O
##oto	O
##pe	O
di	O
##lution	O
L	O
##C	O
/	O
electro	O
##sp	O
##ray	O
ion	O
##ization	O
(	O
E	O
##SI	O
)	O
/	O
MS	O
/	O
MS	O
ass	O
##ays	O
using	O
an	O
upgraded	O
AB	O
##I	O
365	O
triple	O
q	O
##uad	O
##rup	O
##ole	O
mass	O
s	O
##pect	O
##rome	O
##ter	O
(	O
Applied	O
B	O
##ios	O
##ys	O
##tem	O
##s	O
Inc	O
.	O
,	O
Foster	O
City	O
,	O
California	O
)	O
with	O
Ion	O
##ics	O
EP	O
10	O
+	O
redesigned	O
source	O
(	O
Concord	O
,	O
Ontario	O
,	O
Canada	O
)	O
and	O
E	O
##SI	O
needle	O
connected	O
to	O
an	O
Aria	O
L	O
##X	O
##4	O
series	O
multiple	O
##xed	O
high	O
-	O
performance	O
L	O
##C	O
system	O
with	O
F	O
##lux	O
pumps	O
(	O
Co	O
##hesive	O
Technologies	O
,	O
Franklin	O
,	O
Massachusetts	O
)	O
,	O
as	O
previously	O
described	O
[	O
]	O
.	O

This	O
study	O
is	O
the	O
first	O
to	O
evaluate	O
serum	O
S	O
##1	O
##P	O
and	O
urine	O
s	B
##phi	I
##ngo	I
##sin	I
##e	I
as	O
potential	O
bio	O
##mark	O
##ers	O
of	O
A	O
##ER	O
##D	O
as	O
well	O
as	O
to	O
examine	O
the	O
metabolic	O
disturbance	O
of	O
SL	S
in	O
A	O
##ER	O
##D	O
patients	O
.	O

Since	O
at	O
##rac	O
##ty	O
##li	O
##gen	O
##in	O
g	B
##lu	I
##cu	I
##ron	I
##ide	I
is	O
not	O
commercially	O
available	O
,	O
we	O
tested	O
the	O
performance	O
of	O
a	O
combination	O
of	O
c	O
##y	O
##c	O
##lo	O
(	O
is	O
##ole	O
##uc	O
##yl	O
-	O
pro	O
##ly	O
##l	O
)	O
,	O
1	B
-	I
met	I
##hyl	I
##xa	I
##nt	I
##hine	I
and	O
t	B
##rig	I
##one	I
##llin	I
##e	I
,	O
the	O
three	O
best	O
candidate	O
bio	O
##mark	O
##ers	O
commercially	O
available	O
.	O

The	O
levels	O
of	O
P	B
##G	I
##F	I
_	I
2	I
##α	I
in	O
E	O
.	O
co	O
##li	O
and	O
b	O
##ov	O
##ine	O
liver	O
G	O
##US	O
samples	O
were	O
lower	O
compared	O
with	O
the	O
high	O
P	O
##G	O
##F	O
_	O
2	O
##α	O
background	O
present	O
in	O
H	O
.	O
p	O
##oma	O
##tia	O
.	O

7	B
-	I
Ke	I
##to	I
##cho	I
##les	I
##tero	I
##l	I
was	O
recently	O
suggested	O
as	O
a	O
potential	O
diagnostic	O
and	O
predict	O
##ive	O
bio	O
##mark	O
##er	O
of	O
Ni	O
##emann	O
-	O
Pick	O
disease	O
.	O

Of	O
the	O
urine	O
meta	O
##bol	O
##ites	O
identified	O
in	O
this	O
study	O
format	B
##e	I
had	O
the	O
largest	O
mean	O
increase	O
(	O
45	O
.	O
6	O
%	O
)	O
during	O
sleep	O
de	O
##p	O
##ri	O
##vation	O
.	O

A	O
##bb	O
##re	O
##viation	O
##s	O
:	O
T	O
##PR	O
,	O
true	O
positive	O
rate	O
;	O
F	O
##PR	O
,	O
false	O
positive	O
rate	O
;	O
G	O
##lu	O
,	O
g	B
##lut	I
##ama	I
##te	I
;	O
G	O
##ln	O
,	O
g	B
##lut	I
##amine	I
;	O
Met	O
,	O
met	B
##hi	I
##oni	I
##ne	I
;	O
Met	O
##SO	O
,	O
su	B
##lf	I
##ox	I
##y	I
met	I
##hi	I
##oni	I
##ne	I
;	O
As	O
##p	O
,	O
as	B
##par	I
##tate	I
;	O
As	O
##n	O
,	O
as	B
##par	I
##agi	I
##ne	I
;	O
K	O
##yn	O
,	O
k	B
##yn	I
##uren	I
##ine	I
;	O
T	O
##rp	O
,	O
try	B
##pt	I
##op	I
##han	I
;	O
R	O
##OC	O
,	O
receiver	O
operating	O
characteristic	O
;	O
C	O
##I	O
,	O
confidence	O
interval	O
;	O
AU	O
##C	O
,	O
area	O
under	O
the	O
curve	O
.	O

The	O
key	O
clinical	O
disc	O
##rim	O
##inator	O
of	O
these	O
two	O
groups	O
was	O
disease	O
duration	S
.	O

The	O
concentrated	O
super	O
##nat	O
##ant	O
was	O
re	O
##con	O
##stituted	O
in	O
2	O
m	O
##L	O
0	O
.	O
1	O
M	O
phosphate	S
buffer	O
,	O
pH	O
6	O
.	O
0	O
.	O

As	O
a	O
quality	O
control	O
,	O
we	O
compared	O
the	O
meta	O
##bol	O
##ite	O
concentrations	O
of	O
fresh	O
clinical	O
samples	O
with	O
the	O
study	O
samples	O
of	O
these	O
patients	O
,	O
and	O
we	O
detected	O
that	O
glucose	S
,	O
la	B
##ct	I
##ate	I
,	O
and	O
c	B
##rea	I
##tin	I
##ine	I
values	O
were	O
within	O
range	O
.	O

Structure	O
##s	O
of	O
synthetic	O
can	B
##na	I
##bino	I
##id	I
parent	O
compounds	O
included	O
in	O
the	O
method	O
.	O

In	O
conclusion	O
,	O
su	O
##lf	O
##ation	O
of	O
m	B
##or	I
##phine	I
is	O
present	O
in	O
human	O
liver	O
but	O
this	O
metabolic	O
pathway	O
seems	O
to	O
be	O
of	O
minor	O
importance	O
in	O
v	O
##ivo	O
and	O
probably	O
lacks	O
clinical	O
significance	O
.	O

The	O
distribution	O
pattern	O
of	O
the	O
three	O
main	O
fatty	O
acids	O
was	O
similar	O
but	O
did	O
not	O
fully	O
overlap	O
with	O
t	B
##rig	I
##ly	I
##cer	I
##ide	I
distribution	O
or	O
V	O
##LD	O
##L	O
deposition	O
(	O
S	O
.	O
Ma	O
##s	O
,	O
unpublished	O
observation	O
)	O
.	O

Ser	O
##um	O
al	B
##ani	I
##ne	I
levels	O
increased	O
post	O
‐	O
surgery	O
in	O
a	O
rat	O
model	O
of	O
R	O
##Y	O
##GB	O
##42	O
similar	O
to	O
the	O
present	O
study	O
.	O

Both	O
g	B
##lut	I
##amine	I
and	O
g	B
##lut	I
##ama	I
##te	I
are	O
g	O
##lu	O
##co	O
##genic	O
amino	O
acids	O
and	O
are	O
considered	O
to	O
be	O
vital	O
for	O
maintenance	O
of	O
cell	O
function	O
.	O

Several	O
long	O
-	O
chain	O
essential	O
fatty	O
acids	O
that	O
must	O
be	O
absorbed	O
from	O
the	O
diet	O
,	O
including	O
l	B
##ino	I
##lena	I
##te	I
(	I
18	I
:	I
3	I
##n	I
##3	I
or	I
6	I
)	I
(	O
Discovery	O
group	O
:	O
p	O
=	O
0	O
.	O
03	O
##9	O
,	O
q	O
=	O
0	O
.	O
38	O
;	O
Test	O
group	O
:	O
p	O
=	O
0	O
.	O
02	O
##6	O
,	O
q	O
=	O
0	O
.	O
15	O
)	O
,	O
di	B
##hom	I
##o	I
-	I
l	I
##ino	I
##lea	I
##te	I
(	I
20	I
:	I
2	I
##n	I
##6	I
)	I
(	O
Discovery	O
group	O
:	O
p	O
=	O
0	O
.	O
04	O
##2	O
,	O
q	O
=	O
0	O
.	O
38	O
;	O
Test	O
group	O
:	O
p	O
=	O
0	O
.	O
06	O
##6	O
,	O
q	O
=	O
0	O
.	O
24	O
)	O
,	O
and	O
di	B
##hom	I
##o	I
-	I
l	I
##ino	I
##lena	I
##te	I
(	I
20	I
:	I
3	I
##n	I
##3	I
or	I
n	I
##6	I
)	I
(	O
Discovery	O
group	O
:	O
p	O
=	O
0	O
.	O
03	O
##9	O
,	O
q	O
=	O
0	O
.	O
38	O
;	O
Test	O
group	O
:	O
p	O
=	O
0	O
.	O
00	O
##1	O
,	O
q	O
=	O
0	O
.	O
02	O
)	O
,	O
and	O
do	B
##cos	I
##ah	I
##ex	I
##aen	I
##oat	I
##e	I
(	O
D	O
##HA	O
,	O
22	O
:	O
6	O
##n	O
##3	O
)	O
(	O
Discovery	O
group	O
:	O
p	O
=	O
0	O
.	O
04	O
##7	O
,	O
q	O
=	O
0	O
.	O
38	O
;	O
Test	O
group	O
:	O
p	O
<	O
0	O
.	O
00	O
##1	O
,	O
q	O
=	O
0	O
.	O
00	O
)	O
were	O
also	O
decreased	O
in	O
PT	O
##SD	O
versus	O
controls	O
.	O

The	O
ho	O
##mo	O
##gen	O
##ates	O
were	O
mixed	O
with	O
0	O
.	O
5	O
m	O
##l	O
ch	B
##lor	I
##of	I
##orm	I
and	O
0	O
.	O
2	O
m	O
##l	O
ice	O
-	O
cold	O
Mill	O
##i	O
-	O
Q	O
water	O
.	O

The	O
FF	O
##A	O
composition	O
(	O
%	O
of	O
total	O
FF	O
##As	O
)	O
indicated	O
a	O
higher	O
percentage	O
of	O
SF	O
##As	O
(	O
43	O
.	O
7	O
%	O
±	O
6	O
.	O
2	O
%	O
vs	O
.	O
32	O
.	O
9	O
%	O
±	O
3	O
.	O
1	O
%	O
,	O
p	O
<	O
0	O
.	O
00	O
##1	O
)	O
and	O
a	O
lower	O
percentage	O
of	O
M	O
##U	O
##FA	O
##s	O
(	O
33	O
.	O
7	O
%	O
±	O
4	O
.	O
4	O
%	O
vs	O
.	O
36	O
.	O
7	O
%	O
±	O
2	O
.	O
6	O
%	O
,	O
p	O
=	O
0	O
.	O
00	O
##3	O
)	O
and	O
P	O
##U	O
##FA	O
##s	O
(	O
22	O
.	O
6	O
%	O
±	O
3	O
.	O
9	O
%	O
vs	O
.	O
30	O
.	O
5	O
%	O
±	O
3	O
.	O
3	O
%	O
,	O
p	O
<	O
0	O
.	O
00	O
##1	O
)	O
in	O
A	B
##F	I
patients	O
than	O
in	O
controls	O
.	O

In	O
68	O
##5	O
participants	O
without	O
diabetes	O
of	O
the	O
In	O
##sul	O
##in	O
Resistance	O
At	O
##her	O
##os	O
##cle	O
##rosis	O
Study	O
(	O
IRA	O
##S	O
)	O
(	O
290	O
Caucasian	O
##s	O
,	O
165	O
African	O
Americans	O
,	O
and	O
230	O
Hispanic	O
##s	O
)	O
,	O
we	O
measured	O
plasma	O
BC	O
##AA	O
##s	O
(	O
sum	O
of	O
v	B
##ali	I
##ne	I
,	O
le	B
##uc	I
##ine	I
,	O
and	O
is	B
##ole	I
##uc	I
##ine	I
)	O
by	O
mass	O
s	O
##pect	O
##rome	O
##try	O
and	O
S	O
_	O
I	O
,	O
AI	O
##R	O
,	O
and	O
MC	O
##RI	O
by	O
frequently	O
sampled	O
in	O
##tra	O
##ven	O
##ous	O
glucose	S
tolerance	O
tests	O
.	O

Because	O
the	O
AS	O
##A	O
-	O
BP	O
##T	O
has	O
been	O
valid	O
##ated	O
and	O
widely	O
used	O
in	O
A	O
##ER	O
##D	O
diagnosis	O
,	O
these	O
results	O
indicate	O
that	O
the	O
serum	O
S	O
##1	O
##P	O
and	O
urine	O
s	B
##phi	I
##ngo	I
##sin	I
##e	I
levels	O
are	O
reliable	O
,	O
and	O
safer	O
markers	O
to	O
di	O
##ag	O
##nose	O
the	O
A	O
##ER	O
##D	O
p	O
##hen	O
##otype	O
,	O
without	O
the	O
fear	O
of	O
adverse	O
reactions	O
.	O

The	O
levels	O
of	O
v	B
##ali	I
##ne	I
,	O
g	B
##lut	I
##amine	I
,	O
T	B
##MA	I
##O	I
and	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
changed	O
significantly	O
and	O
reversed	O
to	O
normal	O
levels	O
after	O
B	O
##D	O
##T	O
treatment	O
(	O
P	O
<	O
0	O
.	O
01	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

AM	O
##PP	O
-	O
der	O
##iva	O
##tized	O
FA	S
internal	O
standard	O
(	O
I	O
.	O
S	O
.	O
)	O
,	O
d	B
_	I
4	I
-	I
16	I
:	I
0	I
FA	I
,	O
was	O
analyzed	O
by	O
full	O
MS	O
scan	O
(	O
A	O
)	O
and	O
precursor	O
ion	O
scan	O
(	O
P	O
##IS	O
)	O
of	O
m	O
/	O
z	O
183	O
(	O
B	O
)	O
in	O
the	O
positive	O
-	O
ion	O
mode	O
.	O

Pat	O
##ients	O
taking	O
im	O
##mu	O
##no	O
##mo	O
##du	O
##lating	O
drugs	O
,	O
anti	O
##biotics	O
,	O
mist	O
##let	O
##oe	O
preparations	O
,	O
virus	O
##tat	O
##ics	O
,	O
all	B
##op	I
##uri	I
##no	I
##l	I
and	O
dip	B
##yr	I
##ida	I
##mo	I
##l	I
were	O
not	O
included	O
in	O
this	O
study	O
.	O

Thus	O
,	O
both	O
is	B
##ob	I
##ut	I
##yl	I
-	I
and	O
is	B
##op	I
##rop	I
##yla	I
##mine	I
were	O
included	O
in	O
our	O
m	O
##od	O
##ifier	O
screen	O
,	O
along	O
with	O
is	B
##ope	I
##nt	I
##yla	I
##mine	I
to	O
determine	O
if	O
the	O
size	O
of	O
the	O
al	O
##ky	O
##l	O
side	O
-	O
chain	O
contributes	O
to	O
ch	O
##roma	O
##to	O
##graphic	O
performance	O
in	O
SF	O
##C	O
.	O

The	O
spectral	O
regions	O
of	O
water	O
and	O
u	B
##rea	I
have	O
been	O
removed	O
from	O
the	O
figure	O
.	O

Focus	O
##ing	O
on	O
the	O
u	O
##rina	O
##ry	O
para	B
##ben	I
levels	O
according	O
to	O
the	O
age	O
group	O
,	O
EP	O
levels	O
were	O
significantly	O
lower	O
in	O
the	O
age	O
group	O
of	O
7	O
–	O
11	O
years	O
,	O
while	O
con	O
##verse	O
##ly	O
BP	O
concentrations	O
were	O
statistical	O
##ly	O
higher	O
in	O
young	O
children	O
(	O
1	O
–	O
6	O
years	O
)	O
compared	O
to	O
teenagers	O
and	O
young	O
adults	O
(	O
12	O
–	O
39	O
years	O
)	O
and	O
to	O
the	O
older	O
group	O
(	O
≥	O
60	O
years	O
)	O
.	O

However	O
,	O
we	O
also	O
identified	O
differences	O
in	O
the	O
levels	O
of	O
hip	B
##pur	I
##ic	I
acid	I
among	O
urine	O
##s	O
collected	O
from	O
controls	O
and	O
patients	O
with	O
primary	O
and	O
re	O
##current	O
tumors	O
,	O
suggesting	O
differences	O
in	O
the	O
metabolism	O
of	O
these	O
types	O
of	O
tumors	O
.	O

Numerous	O
meta	O
##bol	O
##ites	O
,	O
covering	O
important	O
metabolic	O
pathways	O
(	O
K	O
##re	O
##bs	O
'	O
cycle	O
,	O
fatty	O
acid	O
and	O
g	B
##lu	I
##cos	I
##ino	I
##late	I
bio	O
##sy	O
##nt	O
##hesis	O
)	O
,	O
were	O
detected	O
in	O
extract	O
##s	O
,	O
bio	O
##f	O
##lu	O
##ids	O
,	O
and	O
/	O
or	O
in	O
biological	O
tissues	O
(	O
Arab	O
##ido	O
##psis	O
th	O
##alia	O
##na	O
,	O
Dr	O
##oso	O
##phi	O
##la	O
me	O
##lan	O
##oga	O
##ster	O
,	O
A	O
##cy	O
##rth	O
##os	O
##ip	O
##hon	O
p	O
##is	O
##um	O
,	O
and	O
human	O
blood	O
)	O
.	O

Re	O
##lative	O
retention	O
time	O
(	O
R	O
##RT	O
,	O
mean	O
)	O
was	O
to	O
7	B
##α	I
-	I
h	I
##ydro	I
##xy	I
-	I
3	I
-	I
o	I
##x	I
##och	I
##ole	I
##st	I
-	I
4	I
-	I
en	I
-	I
26	I
-	I
o	I
##ic	I
acid	I
.	O

G	B
##lut	I
##ama	I
##te	I
can	O
then	O
be	O
converted	O
to	O
α	B
-	I
k	I
##eto	I
##g	I
##lut	I
##arate	I
,	O
a	O
precursor	O
of	O
the	O
c	B
##it	I
##ric	I
acid	I
cycle	O
,	O
which	O
co	O
##rrel	O
##ates	O
with	O
the	O
occurrence	O
of	O
his	B
##ti	I
##dine	I
as	O
the	O
predominant	O
free	O
amino	O
acid	O
in	O
R	O
.	O
pro	O
##lix	O
##us	O
f	O
##ec	O
##es	O
.	O

S	O
##ynth	O
##etic	O
op	O
##io	O
##ids	O
anal	O
##ges	O
##ics	O
,	O
such	O
as	O
met	B
##had	I
##one	I
,	O
na	B
##lo	I
##xon	I
##e	I
or	O
f	O
##ent	O
##any	O
##l	O
,	O
are	O
not	O
detected	O
at	O
all	O
by	O
the	O
regular	O
urine	O
op	O
##iate	O
im	O
##mu	O
##no	O
##ass	O
##ays	O
.	O

Go	O
to	O
:	O
B	O
##ro	O
##cco	O
##li	O
s	O
##p	O
##rout	O
##s	O
are	O
a	O
convenient	O
and	O
rich	O
source	O
of	O
the	O
g	B
##lu	I
##cos	I
##ino	I
##late	I
,	O
g	B
##lu	I
##cor	I
##aph	I
##ani	I
##n	I
,	O
which	O
can	O
generate	O
the	O
ch	O
##em	O
##op	O
##re	O
##vent	O
##ive	O
agent	O
,	O
su	B
##lf	I
##ora	I
##pha	I
##ne	I
,	O
an	O
induce	O
##r	O
of	O
g	B
##lut	I
##ath	I
##ione	I
S	O
-	O
transfer	O
##ases	O
(	O
G	O
##ST	O
##s	O
)	O
and	O
other	O
c	O
##yt	O
##op	O
##rote	O
##ctive	O
enzymes	O
.	O

In	O
this	O
concern	O
,	O
it	O
may	O
be	O
that	O
se	B
##rine	I
and	O
g	B
##ly	I
##cine	I
were	O
significantly	O
increased	O
in	O
our	O
N	O
##DM	O
##M	O
-	O
and	O
R	O
##R	O
##MM	O
patients	O
.	O

Interest	O
##ingly	O
,	O
a	O
significant	O
down	O
-	O
regulation	O
of	O
meta	O
##bol	O
##ites	O
belonging	O
to	O
the	O
T	B
##G	I
family	O
was	O
observed	O
mainly	O
in	O
the	O
AD	O
group	O
(	O
B	O
)	O
.	O

Further	O
activation	O
(	O
MS	O
_	O
4	O
C	O
##ID	O
)	O
of	O
this	O
ion	O
produced	O
CC	O
diagnostic	O
ions	O
at	O
m	O
/	O
z	O
171	O
and	O
197	O
,	O
providing	O
definitive	O
evidence	O
that	O
CC	O
is	O
located	O
at	O
Δ	O
##9	O
of	O
the	O
s	O
##n	O
-	O
1	O
chain	O
(	B
C	B
##18	I
:	I
1	I
)	O
.	O

The	O
presence	O
of	O
am	B
##mon	I
##ium	I
salt	O
in	O
mobile	O
phases	O
decrease	O
drastically	O
the	O
detection	O
of	O
sodium	O
add	O
##uc	O
##ts	O
which	O
now	O
constitute	O
minor	O
lip	O
##id	O
species	O
in	O
the	O
positive	O
ion	O
mode	O
(	O
data	O
not	O
shown	O
)	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
locate	O
functional	O
PA	O
and	O
to	O
identify	O
the	O
del	O
##ine	O
##ation	O
between	O
them	O
and	O
healthy	O
pit	O
##uit	O
##ary	O
tissue	O
,	O
an	O
aspect	O
of	O
potentially	O
key	O
relevance	O
,	O
especially	O
during	O
surgery	O
,	O
on	O
one	O
hand	O
f	O
##ac	O
##ilitating	O
total	O
ad	O
##eno	O
##ma	O
re	O
##section	O
and	O
on	O
the	O
other	O
hand	O
preserving	O
v	B
##as	I
##op	I
##ress	I
##in	I
secret	O
##ory	O
cells	O
within	O
the	O
ne	O
##uro	O
##hy	O
##pop	O
##hy	O
##sis	O
and	O
pit	O
##uit	O
##ary	O
stalk	O
,	O
thus	O
avoiding	O
central	O
diabetes	O
ins	O
##ip	O
##id	O
##us	O
,	O
the	O
most	O
common	O
post	O
##oper	O
##ative	O
com	O
##plication	O
.	O

H	B
##y	I
##pox	I
##ant	I
##hine	I
(	I
x	I
##ant	I
##hine	I
)	I
associated	O
with	O
path	O
##ological	O
CR	O
##T	O
response	O
CR	O
##T	O
,	O
ch	O
##em	O
##ora	O
##dio	O
##ther	O
##ap	O
##y	O
;	O
T	O
##R	O
##G	O
,	O
tumor	O
re	O
##gression	O
grade	O
;	O
CE	O
##A	O
,	O
car	O
##cin	O
##oe	O
##mb	O
##ryo	O
##nic	O
anti	O
##gen	O
.	O

Sign	O
##ific	O
##ance	O
:	O
<	O
0	O
.	O
05	O
‘	O
*	O
’	O
T	O
##rp	O
try	B
##pt	I
##op	I
##han	I
,	O
K	O
##yn	O
k	B
##yn	I
##uren	I
##ine	I
,	O
K	O
##TR	O
k	B
##yn	I
##uren	I
##ine	I
/	I
try	I
##pt	I
##op	I
##han	I
ratio	O
,	O
HK	O
3	B
-	I
h	I
##ydro	I
##xy	I
##ky	I
##nu	I
##ren	I
##ine	I
,	O
K	O
##A	O
k	B
##yn	I
##uren	I
##ic	I
acid	I
,	O
X	O
##A	O
x	B
##ant	I
##hur	I
##eni	I
##c	I
acid	I
,	O
AA	O
ant	B
##hra	I
##ni	I
##lic	I
acid	I
,	O
H	O
##AA	O
3	B
-	I
h	I
##ydro	I
##xy	I
##ant	I
##hra	I
##ni	I
##lic	I
acid	I
,	O
Q	O
##A	O
q	B
##uin	I
##olin	I
##ic	I
acid	I
,	O

The	O
predict	O
##ive	O
power	O
of	O
C	B
##18	I
:	I
2	I
CE	O
in	O
the	O
diagnosis	O
of	O
early	O
-	O
stage	O
S	O
##q	O
##CC	O
ex	O
##ert	O
##ed	O
a	O
sensitivity	O
of	O
86	O
.	O
4	O
%	O
,	O
a	O
specific	O
##ity	O
of	O
54	O
.	O
5	O
%	O
and	O
an	O
area	O
under	O
the	O
curve	O
(	O
AU	O
##C	O
)	O
value	O
of	O
72	O
.	O
5	O
%	O
.	O

One	O
possibility	O
is	O
that	O
the	O
reverse	O
activity	O
of	O
c	O
##yt	O
##oso	O
##lic	O
or	O
mitochondrial	O
10	B
-	I
form	I
##yl	I
-	I
te	I
##tra	I
##hy	I
##dr	I
##of	I
##olate	I
s	O
##ynth	O
##eta	O
##se	O
producing	O
ATP	S
and	O
the	O
by	O
-	O
product	O
,	O
format	B
##e	I
from	O
10	B
-	I
CH	I
##O	I
-	I
T	I
##HF	I
,	O
could	O
be	O
used	O
to	O
produce	O
ATP	S
and	O
N	O
##AD	O
(	O
P	O
)	O
H	O
from	O
se	B
##rine	I
and	O
/	O
or	O
g	B
##ly	I
##cine	I
.	O

Furthermore	O
,	O
changes	O
in	O
diet	O
and	O
physical	O
activity	O
altered	O
amino	O
acid	O
and	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
metabolism	O
##s	O
[	O
–	O
]	O
.	O

S	O
##pecific	O
lip	O
##ids	O
and	O
the	O
protein	O
AD	O
##AM	O
##10	O
were	O
determined	O
as	O
membrane	O
receptors	O
for	O
H	O
##la	O
,	O
with	O
a	O
probable	O
co	O
##oper	O
##ati	O
##vity	O
in	O
the	O
m	O
##od	O
##ulation	O
of	O
cellular	O
responses	O
towards	O
the	O
to	B
##xin	I
.	O

The	O
resulting	O
white	O
residue	O
was	O
characterized	O
by	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
analysis	O
and	O
found	O
to	O
be	O
free	O
of	O
c	B
##ys	I
##tine	I
,	O
c	B
##ys	I
##tein	I
##e	I
,	O
and	O
un	O
##la	O
##bel	O
##ed	O
me	B
##rca	I
##pt	I
##uri	I
##c	I
acid	I
.	O

If	O
H	O
##AA	O
##s	O
induce	O
this	O
pathway	O
,	O
these	O
enzymes	O
may	O
also	O
act	O
upon	O
est	O
##rogen	O
##s	O
,	O
which	O
then	O
are	O
s	O
##hun	O
##ted	O
into	O
the	O
cat	B
##ech	I
##ol	I
pathway	O
leading	O
to	O
E	O
##DA	O
formation	O
.	O

Given	O
that	O
u	O
##rina	O
##ry	O
g	B
##lut	I
##ama	I
##te	I
,	O
c	B
##it	I
##rate	I
and	O
glucose	S
in	O
EC	O
patients	O
did	O
not	O
show	O
correlation	O
with	O
es	O
##op	O
##hage	O
##al	O
tissue	O
bio	O
##mark	O
##ers	O
,	O
a	O
panel	O
of	O
u	O
##rina	O
##ry	O
meta	O
##bol	O
##ite	O
markers	O
composed	O
of	O
ace	B
##to	I
##ace	I
##tate	I
,	O
c	B
##is	I
-	I
a	I
##con	I
##itate	I
,	O
hip	B
##pura	I
##te	I
,	O
ethanol	B
##amine	I
,	O
g	B
##ly	I
##cine	I
,	O
c	B
##rea	I
##tin	I
##ine	I
and	O
ta	B
##uri	I
##ne	I
was	O
selected	O
to	O
compare	O
their	O
diagnostic	O
performance	O
for	O
distinguishing	O
EC	O
patients	O
from	O
HC	O
##s	O
.	O

His	O
##to	O
##gram	O
##s	O
presented	O
in	O
Figure	O
indicated	O
that	O
Ace	B
##ty	I
##l	I
##car	I
##ni	I
##tine	I
had	O
significant	O
alterations	O
in	O
any	O
two	O
groups	O
,	O
while	O
PC	B
(	I
42	I
:	I
11	I
)	I
and	O
LP	B
##E	I
(	I
22	I
:	I
0	I
/	I
0	I
:	I
0	I
)	I
were	O
significantly	O
altered	O
in	O
short	O
-	O
term	O
mortality	O
and	O
medium	O
survival	O
.	O

Because	O
of	O
s	O
##ke	O
##wed	O
distribution	O
,	O
log	O
##ari	O
##th	O
##mic	O
##ally	O
transformed	O
values	O
of	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
were	O
used	O
.	O

Met	B
##hi	I
##oni	I
##ne	I
is	O
also	O
found	O
increased	O
in	O
lean	O
NAS	O
##H	O
as	O
compared	O
to	O
s	O
##te	O
##ato	O
##sis	O
patients	O
,	O
mirror	O
##ing	O
the	O
trend	O
observed	O
in	O
lean	O
rode	O
##nt	O
N	O
##AF	O
##LD	O
models	O
with	O
disrupted	O
one	O
-	O
carbon	O
metabolism	O
genes	O
,	O
met	B
##hi	I
##oni	I
##ne	I
ad	O
##eno	O
##sy	O
##lt	O
##ran	O
##s	O
##fer	O
##ase	O
1A	O
(	O
MA	O
##T	O
##1	O
##A	O
-	O
K	O
##O	O
)	O
and	O
g	O
##ly	O
##cine	O
N	O
-	O
met	O
##hyl	O
##tra	O
##ns	O
##fer	O
##ase	O
knock	O
-	O
out	O
(	O
G	O
##N	O
##MT	O
-	O
K	O
##O	O
)	O
.	O

In	O
addition	O
to	O
their	O
broad	O
in	O
##tra	O
##cellular	O
roles	O
as	O
intermediate	O
##s	O
and	O
energy	O
carriers	O
for	O
metabolism	O
,	O
extra	O
##cellular	O
pu	B
##rine	I
##s	I
and	O
p	B
##yr	I
##im	I
##id	I
##ines	I
play	O
a	O
critical	O
role	O
in	O
pu	B
##rine	I
##rg	I
##ic	I
signaling	O
for	O
regulation	O
of	O
energy	O
home	O
##ost	O
##asis	O
,	O
the	O
control	O
of	O
chronic	O
pain	O
and	O
inflammation	O
,	O
and	O
regulate	O
healing	O
.	O

Try	O
##ps	O
##in	O
dig	O
##est	O
##ion	O
yields	O
an	O
optimal	O
average	O
p	O
##eptide	O
length	O
of	O
[UNK]	O
amino	O
acids	O
,	O
with	O
a	O
well	O
-	O
defined	O
positive	O
charge	O
at	O
the	O
N	O
-	O
terminus	O
,	O
and	O
the	O
p	O
##eptide	O
##s	O
often	O
exist	O
as	O
do	O
##ub	O
##ly	O
[	O
M	O
+	O
2	O
##H	O
]	O
_	O
2	O
+	O
or	O
trip	O
##ly	O
charged	O
species	O
[	O
M	O
+	O
3	O
##H	O
]	O
_	O
3	O
+	O
which	O
favors	O
the	O
formation	O
of	O
y	O
-	O
ions	O
by	O
E	O
##SI	O
/	O
MS	O
.	O
_	O
,	O
Other	O
se	B
##rine	I
pro	O
##te	O
##ases	O
including	O
L	O
##ys	O
-	O
C	O
,	O
which	O
retains	O
activity	O
in	O
strong	O
den	O
##at	O
##ura	O
##nts	O
,	O
(	O
c	O
##lea	O
##ves	O
L	O
##ys	O
following	O
Pro	O
to	O
decrease	O
missed	O
c	O
##lea	O
##vage	O
##s	O
)	O
;	O
ch	O
##ym	O
##ot	O
##ry	O
##ps	O
##in	O
(	O
c	O
##lea	O
##ves	O
C	O
-	O
terminal	O
of	O
Ph	O
##e	O
,	O
Ty	O
##r	O
,	O
Le	O
##u	O
,	O
T	O
##rp	O
,	O
and	O
Met	O
)	O
;	O
G	O
##lu	O
-	O
C	O
(	O
c	O
##lea	O
##ves	O
C	O
-	O
terminal	O
of	O
G	O
##lu	O
and	O
As	O
##p	O
)	O
;	O
and	O
p	O
##ep	O
##sin	O
,	O
an	O
as	B
##par	I
##tate	I
pro	O
##te	O
##ase	O
(	O
c	O
##lea	O
##ves	O
C	O
-	O
terminal	O
of	O
Ty	O
##r	O
,	O
Ph	O
##e	O
,	O
and	O
T	O
##rp	O
)	O
have	O
also	O
been	O
employed	O
.	O

We	O
found	O
that	O
a	O
detailed	O
evaluation	O
of	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##lino	I
##si	I
##to	I
##l	I
(	O
P	O
##I	O
)	O
and	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##ls	I
##eri	I
##ne	I
(	O
PS	O
)	O
classes	O
allowed	O
us	O
to	O
cluster	O
the	O
studied	O
e	O
##pit	O
##hel	O
##ial	O
cell	O
lines	O
according	O
to	O
their	O
origin	O
:	O
i	O
)	O
cells	O
originally	O
derived	O
from	O
normal	O
co	O
##lon	O
tissue	O
(	O
NC	O
##M	O
##46	O
##0	O
,	O
F	O
##HC	O
)	O
;	O
ii	O
)	O
cell	O
lines	O
derived	O
from	O
co	O
##lon	O
ad	O
##eno	O
##ma	O
or	O
less	O
advanced	O
different	O
##iating	O
ad	O
##eno	O
##car	O
##cin	O
##oma	O
cells	O
(	O
AA	O
/	O
C	O
##1	O
,	O
H	O
##T	O
-	O
29	O
)	O
;	O
or	O
,	O
ii	O
##i	O
)	O
cells	O
obtained	O
by	O
in	O
v	O
##it	O
##ro	O
transformation	O
of	O
ad	O
##eno	O
##ma	O
cells	O
and	O
advanced	O
co	O
##lon	O
ad	O
##eno	O
##car	O
##cin	O
##oma	O
cells	O
(	O
HC	O
##T	O
-	O
116	O
,	O
AA	O
/	O
C	O
##1	O
/	O
S	O
##B	O
##10	O
,	O
S	O
##W	O
##48	O
##0	O
,	O
S	O
##W	O
##6	O
##20	O
)	O
.	O

Among	O
infants	O
with	O
RS	O
##V	O
AR	O
##I	O
,	O
al	B
##ani	I
##ne	I
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
and	O
4	B
-	I
de	I
##ox	I
##yt	I
##hr	I
##eon	I
##ic	I
acid	I
were	O
associated	O
with	O
1st	O
-	O
year	O
re	O
##current	O
w	O
##hee	O
##zing	O
;	O
ace	B
##tate	I
was	O
associated	O
with	O
2nd	O
-	O
year	O
re	O
##current	O
w	O
##hee	O
##zing	O
,	O
and	O
2	B
-	I
h	I
##ydro	I
##xy	I
##is	I
##ob	I
##ut	I
##yra	I
##te	I
was	O
associated	O
with	O
3rd	O
-	O
year	O
re	O
##current	O
w	O
##hee	O
##zing	O
.	O

One	O
-	O
dimensional	O
1	O
##H	O
N	O
##MR	O
s	O
##pect	O
##ra	O
of	O
samples	O
were	O
ca	O
##li	O
##bra	O
##ted	O
(	O
1	O
.	O
33	O
pp	O
##m	O
)	O
with	O
la	B
##ct	I
##ate	I
in	O
the	O
high	O
-	O
field	O
after	O
phase	O
and	O
base	O
##line	O
correction	O
with	O
Top	O
##sp	O
##in	O
software	O
.	O

None	O
of	O
the	O
subjects	O
had	O
metabolic	O
or	O
end	O
##oc	O
##rine	O
disorders	O
or	O
received	O
D	O
##H	O
##EA	O
or	O
g	B
##lu	I
##co	I
##cor	I
##tic	I
##oids	I
.	O

The	O
lip	O
##id	O
changes	O
were	O
verified	O
by	O
measurement	O
of	O
the	O
common	O
disease	O
markers	O
(	O
e	O
.	O
g	O
.	O
ATP	S
,	O
c	O
##yt	O
##oki	O
##ne	O
,	O
calcium	O
)	O
using	O
conventional	O
ass	O
##ays	O
.	O

All	O
m	O
##od	O
##ifier	O
solutions	O
were	O
prepared	O
volume	O
##tric	O
##ally	O
or	O
,	O
in	O
the	O
case	O
of	O
the	O
am	B
##mon	I
##ium	I
salts	O
,	O
by	O
addition	O
of	O
the	O
solid	O
salt	O
to	O
the	O
met	B
##han	I
##ol	I
,	O
followed	O
by	O
son	O
##ica	O
##tion	O
at	O
room	O
temperature	O
for	O
10	O
min	O
.	O

_	O
,	O
Tau	B
##rine	I
was	O
suggested	O
as	O
a	O
bio	O
##mark	O
##er	O
of	O
a	O
##pop	O
##tosis	O
in	O
g	O
##lial	O
tumors	O
and	O
also	O
for	O
cancer	O
therapy	O
due	O
to	O
its	O
anti	O
##ox	O
##ida	O
##nt	O
and	O
anti	O
##ang	O
##io	O
##genic	O
properties	O
.	O

To	O
further	O
explore	O
this	O
hypothesis	O
,	O
we	O
next	O
assessed	O
for	O
meta	O
##bol	O
##ites	O
significantly	O
associated	O
with	O
at	O
##rial	O
d	O
##ys	O
##function	O
,	O
where	O
at	O
##rial	O
function	O
was	O
categorized	O
into	O
normal	O
at	O
##rial	O
function	O
,	O
abnormal	O
at	O
##rial	O
function	O
,	O
and	O
f	O
##rank	O
A	B
##F	I
.	O

Furthermore	O
,	O
the	O
behaviour	O
of	O
specific	O
V	O
##OM	O
##s	O
anal	O
##ys	O
##ed	O
individually	O
is	O
not	O
uniform	O
,	O
with	O
better	O
responses	O
observed	O
with	O
60	O
min	O
of	O
e	O
##qui	O
##li	O
##bra	O
##tion	O
for	O
(	B
+	I
)	I
-	I
4	I
-	I
care	I
##ne	I
and	O
dim	B
##eth	I
##yl	I
##sul	I
##fi	I
##de	I
,	O
the	O
opposite	O
for	O
ace	B
##tone	I
and	O
2	B
-	I
but	I
##ano	I
##ne	I
and	O
irregular	O
variations	O
for	O
to	B
##lue	I
##ne	I
,	O
p	B
##hen	I
##ol	I
,	O
is	O
##op	O
##rene	O
and	O
2	B
-	I
pen	I
##tano	I
##ne	I
(	O
Su	O
##pp	O
##lement	O
##ary	O
Fi	O
##g	O
.	O

Inc	O
##rea	O
##sing	O
plasma	O
f	B
##olate	I
level	O
was	O
positive	O
correlated	O
with	O
late	O
tumor	O
stage	O
(	O
r	O
=	O
0	O
.	O
108	O
)	O
.	O

The	O
high	O
PA	O
##L	O
_	O
DL	O
##W	O
group	O
had	O
higher	O
concentrations	O
of	O
ace	B
##to	I
##ace	I
##tate	I
,	O
c	B
##rea	I
##tin	I
##ine	I
and	O
se	B
##rine	I
compared	O
to	O
the	O
low	O
PA	O
##L	O
_	O
DL	O
##W	O
group	O
.	O

Several	O
additional	O
car	B
##ni	I
##tine	I
##s	I
were	O
put	O
##ative	O
##ly	O
identified	O
in	O
this	O
work	O
(	O
14	O
–	O
28	O
)	O
.	O

H	B
=	I
[UNK]	B
=	I
1	I
##β	I
##i	I
⋅	I
##V	I
##i	I

When	O
analyses	O
were	O
restricted	O
to	O
wild	O
-	O
type	O
smoke	O
##rs	O
only	O
(	O
those	O
who	O
do	O
not	O
possess	O
any	O
known	O
C	O
##YP	O
##2	O
##A	O
##6	O
decrease	O
-	O
or	O
loss	O
-	O
of	O
-	O
function	O
all	O
##ele	O
##s	O
)	O
to	O
avoid	O
the	O
con	O
##found	O
of	O
higher	O
or	O
lower	O
frequencies	O
of	O
C	O
##YP	O
##2	O
##A	O
##6	O
g	O
##eno	O
##type	O
reduced	O
ni	B
##cot	I
##ine	I
meta	O
##bol	O
##izer	O
##s	O
between	O
populations	O
,	O
the	O
rate	O
of	O
ni	B
##cot	I
##ine	I
metabolism	O
remained	O
higher	O
among	O
N	O
##P	O
smoke	O
##rs	O
compared	O
to	O
S	O
##W	O
smoke	O
##rs	O
(	O
P	O
=	O
0	O
.	O
00	O
##3	O
)	O
,	O
and	O
compared	O
to	O
smoke	O
##rs	O
from	O
other	O
ethnic	O
groups	O
(	O
,	O
)	O
.	O

The	O
Q	O
##C	O
sample	O
was	O
spike	O
##d	O
in	O
a	O
pool	O
##ed	O
urine	O
sample	O
with	O
a	O
mixture	O
of	O
p	B
##ht	I
##hala	I
##te	I
meta	O
##bol	O
##ite	O
standards	O
(	O
20	O
–	O
50	O
ng	O
/	O
m	O
##l	O
)	O
in	O
each	O
sample	O
.	O

The	O
mobile	O
phase	O
of	O
water	O
and	O
met	B
##han	I
##ol	I
was	O
pumped	O
at	O
a	O
flow	O
rate	O
of	O
0	O
.	O
3	O
m	O
##L	O
/	O
min	O
.	O

g	O
of	O
sodium	B
chloride	I
,	O
capped	O
with	O
a	O
PT	O
##F	O
##E	O
se	O
##pt	O
##um	O
and	O
a	O
screw	O
cap	O
)	O
.	O

Form	B
##ic	I
acid	I
in	O
water	O
(	O
0	O
.	O
1	O
%	O
,	O
v	O
/	O
v	O
,	O
solvent	O
A	O
)	O
and	O
met	B
##han	I
##ol	I
(	O
solvent	O
B	O
)	O
were	O
employed	O
as	O
mobile	O
phase	O
.	O

We	O
tested	O
associations	O
of	O
estimated	O
G	O
##F	O
##R	O
(	O
e	O
##G	O
##F	O
##R	O
)	O
with	O
the	O
circulating	O
concentration	O
of	O
24	B
,	I
25	I
-	I
di	I
##hy	I
##dr	I
##ox	I
##y	I
##vi	I
##tam	I
##in	I
D	O
_	O
3	O
(	B
24	B
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
)	O
,	O
the	O
most	O
abundant	O
product	O
of	O
25	O
(	O
OH	O
)	O
D	O
_	O
3	O
cat	O
##ab	O
##olis	O
##m	O
,	O
across	O
populations	O
with	O
a	O
wide	O
range	O
of	O
G	O
##F	O
##R	O
.	O

The	O
c	O
##rea	O
##tine	O
/	O
c	O
##rea	O
##tine	O
kinase	O
(	B
C	I
##K	I
)	I
/	I
p	I
##hos	I
##ph	I
##oc	I
##rea	I
##tine	I
system	O
plays	O
a	O
key	O
role	O
in	O
cellular	O
energy	O
buffer	O
##ing	O
and	O
transport	O
,	O
especially	O
in	O
cells	O
with	O
high	O
and	O
disturbed	O
energy	O
metabolism	O
.	O

−	O
0	O
.	O
208	O
)	O
,	O
pro	B
##ges	I
##tero	I
##ne	I
(	O
r	O
_	O
s	O
=	O

Higher	O
levels	O
of	O
v	B
##ali	I
##ne	I
,	O
se	B
##rine	I
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
alpha	O
D	B
-	I
g	I
##lu	I
##cos	I
##amine	I
1	I
-	I
phosphate	I
and	O
l	B
##ino	I
##le	I
##ic	I
acid	I
were	O
found	O
in	O
HC	O
##C	O
cases	O
,	O
while	O
g	B
##ly	I
##cine	I
,	O
c	B
##rea	I
##tin	I
##ine	I
,	O
g	B
##lut	I
##ami	I
##c	I
acid	I
,	O
tag	B
##ato	I
##se	I
,	O
la	B
##uri	I
##c	I
acid	I
and	O
p	B
##hos	I
##ph	I
##ori	I
##c	I
acid	I
were	O
found	O
elevated	O
in	O
c	O
##ir	O
##r	O
##hot	O
##ic	O
controls	O
.	O

Since	O
l	O
##ys	O
##ine	O
met	O
##hyl	O
##ation	O
pathways	O
have	O
no	O
known	O
interactions	O
with	O
the	O
production	O
of	O
NO	O
or	O
its	O
end	O
##ogen	O
##ous	O
inhibitor	O
##s	O
,	O
we	O
expected	O
no	O
relationship	O
between	O
met	B
##hyl	I
-	I
l	I
##ys	I
##ine	I
levels	O
and	O
card	O
##iovascular	O
disease	O
,	O
and	O
sought	O
to	O
examine	O
levels	O
of	O
this	O
alternative	O
met	O
##hyl	O
##ated	O
amino	O
acid	O
as	O
a	O
“	O
control	O
”	O
for	O
generalized	O
protein	O
cat	O
##ab	O
##olic	O
activity	O
.	O

Three	O
metabolic	O
pathway	O
of	O
importance	O
including	O
metabolism	O
of	O
x	O
##eno	O
##biotics	O
by	O
c	O
##yt	O
##och	O
##rome	O
P	O
##45	O
##0	O
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
metabolism	O
,	O
amino	S
sugar	O
and	O
n	O
##uc	O
##leo	O
##tide	O
sugar	O
metabolism	O
were	O
found	O
to	O
be	O
disturbed	O
in	O
H	O
##B	O
##V	O
patients	O
.	O

Ch	O
##roma	O
##to	O
##gram	O
##s	O
are	O
shown	O
for	O
Ce	B
##r	I
(	I
22	I
:	I
0	I
)	I
/	I
Ce	I
##r	I
(	I
24	I
:	I
0	I
)	I
in	O
blank	O
(	O
a	O
/	O
h	O
)	O
,	O
blank	O
with	O
internal	O
standard	O
(	O
b	O
/	O
i	O
)	O
,	O
highest	O
ca	O
##li	O
##bra	O
##tor	O
without	O
internal	O
standard	O
(	O
c	O
/	O
j	O
)	O
,	O
human	O
plasma	O
without	O
internal	O
standard	O
(	O
d	O
/	O
k	O
)	O
,	O
human	O
plasma	O
with	O
internal	O
standard	O
(	O
e	O
/	O
l	O
)	O
,	O
human	O
plasma	O
in	O
2	O
MR	O
##M	O
transitions	O
(	O
f	O
/	O
m	O
)	O
,	O
and	O
LL	O
##O	O
##Q	O
(	O
g	O
/	O
n	O
)	O
.	O

The	O
multi	O
##var	O
##iant	O
R	O
##OC	O
curve	O
-	O
based	O
ex	O
##p	O
##lora	O
##tory	O
analysis	O
revealed	O
that	O
a	O
meta	O
##bol	O
##ite	O
panel	O
including	O
4	B
-	I
et	I
##ho	I
##xy	I
##met	I
##hyl	I
##phe	I
##no	I
##l	I
,	O
pro	B
##sta	I
##g	I
##land	I
##in	I
F	O
##2	O
##b	O
,	O
th	B
##rom	I
##box	I
##ane	I
B	I
##3	I
,	O
h	B
##ydro	I
##xy	I
##but	I
##yr	I
##yl	I
##car	I
##ni	I
##tine	I
,	O
3	B
-	I
h	I
##ydro	I
##xy	I
##ph	I
##lore	I
##tin	I
and	O
N	B
′	I
-	I
form	I
##yl	I
##ky	I
##nu	I
##ren	I
##ine	I
possessed	O
the	O
best	O
predict	O
##ive	O
ability	O
.	O

Cancer	O
##ous	O
lung	O
tissue	O
exhibited	O
a	O
significant	O
accumulation	O
of	O
multiple	O
long	O
‐	O
chain	O
fatty	O
acids	O
,	O
as	O
well	O
as	O
mon	B
##oa	I
##cy	I
##l	I
##gly	I
##cer	I
##ols	I
and	O
g	B
##ly	I
##cer	I
##ol	I
(	O
Fi	O
##g	O
.	O

[	O
Google	O
Scholar	O
]	O
Sal	O
##zman	O
PM	O
,	O
Salmon	O
J	O
##A	O
,	O
Mon	O
##ca	O
##da	O
S	O
.	O
Pro	B
##sta	I
##cy	I
##c	I
##lin	I
and	O
th	B
##rom	I
##box	I
##ane	I
A2	I
synthesis	O
by	O
rabbit	O
pulmonary	O
artery	O
.	O

An	O
API	O
2000	O
mass	O
s	O
##pect	O
##rome	O
##ter	O
controlled	O
by	O
the	O
Ana	O
##ly	O
##st	O
1	O
.	O
6	O
software	O
(	O
AB	O
/	O
SC	O
##IE	O
##X	O
,	O
Fr	O
##ami	O
##ng	O
##ham	O
,	O
MA	O
)	O
and	O
equipped	O
with	O
an	O
electro	O
##sp	O
##ray	O
ion	O
##ization	O
(	O
E	O
##SI	O
)	O
source	O
was	O
used	O
in	O
positive	O
ion	O
mode	O
for	O
detect	O
##ing	O
t	B
##yra	I
##mine	I
and	O
in	O
negative	O
ion	O
mode	O
for	O
detect	O
##ing	O
2	B
-	I
o	I
##x	I
##og	I
##lut	I
##arate	I
.	O

Given	O
that	O
p	O
##har	O
##ma	O
##cological	O
##ly	O
,	O
some	O
mon	B
##oa	I
##lk	I
##yl	I
##ph	I
##os	I
##ph	I
##oli	I
##pid	I
##s	I
have	O
shown	O
anti	O
##ne	O
##op	O
##lastic	O
potential	O
,	O
64	O
the	O
mechanisms	O
resulting	O
in	O
reduction	O
of	O
such	O
compounds	O
might	O
contribute	O
to	O
cancer	O
progression	O
.	O

Q	O
##uant	O
##ification	O
of	O
ace	B
##tam	I
##ip	I
##rid	I
was	O
also	O
performed	O
at	O
the	O
same	O
time	O
.	O

Not	O
##ably	O
,	O
increased	O
g	O
##ly	O
##co	O
##lysis	O
might	O
also	O
be	O
a	O
signature	O
of	O
C	O
##IN	O
,	O
which	O
are	O
considered	O
precursor	O
lesions	O
of	O
c	O
##er	O
##vic	O
##al	O
car	O
##cin	O
##oma	O
,	O
because	O
the	O
α	O
-	O
and	O
β	B
-	I
glucose	I
levels	O
were	O
decreased	O
in	O
C	O
##IN	O
compared	O
with	O
NC	O
group	O
.	O

H	O
##ydro	O
##lysis	O
of	O
S	B
-	I
ad	I
##eno	I
##sy	I
##l	I
##hom	I
##oc	I
##ys	I
##tein	I
##e	I
by	O
S	O
-	O
ad	O
##eno	O
##sy	O
##l	O
##hom	O
##oc	O
##ys	O
##tein	O
##e	O
h	O
##ydro	O
##lase	O
(	O
SA	O
##H	O
)	O
leads	O
to	O
the	O
formation	O
of	O
ho	B
##mo	I
##cy	I
##stein	I
##e	I
and	O
ad	B
##eno	I
##sin	I
##e	I
.	O

Met	O
##ab	O
##oli	O
##tes	O
elevated	O
in	O
the	O
urine	O
of	O
patients	O
with	O
HC	O
##C	O
were	O
car	B
##ni	I
##tine	I
(	O
3	O
.	O
24	O
pp	O
##m	O
,	O
P	O
=	O
0	O
.	O
31	O
)	O
and	O
format	B
##e	I
(	O
8	O
.	O
5	O
pp	O
##m	O
,	O
P	O
=	O
0	O
.	O
44	O
)	O
,	O
although	O
neither	O
result	O
reaching	O
significance	O
.	O

The	O
ion	O
##ization	O
source	O
parameters	O
were	O
as	O
follows	O
:	O
t	O
##ur	O
##bo	O
heat	O
##er	O
temperature	O
600	O
##°	O
##C	O
,	O
ne	O
##bul	O
##izer	O
gas	O
(	O
GA	O
##S	O
##1	O
)	O
60	O
ps	O
##i	O
,	O
t	O
##ur	O
##bo	O
heat	O
##er	O
gas	O
(	O
GA	O
##S	O
##2	O
)	O
60	O
ps	O
##i	O
,	O
curtain	O
gas	O
35	O
ps	O
##i	O
,	O
ion	O
-	O
spray	O
voltage	O
5	O
.	O
5	O
k	B
##V	I
,	O
and	O
collision	O
gas	O
for	O
collision	O
-	O
induced	O
di	O
##sso	O
##ciation	O
(	O
C	O
##ID	O
)	O
10	O
ps	O
##i	O
.	O

Fifty	O
micro	O
##lite	O
##rs	O
of	O
a	O
100	O
mg	O
/	O
m	O
##L	O
et	B
##ho	I
##xy	I
##amine	I
solution	O
in	O
water	O
and	O
an	O
additional	O
100	O
μ	O
##L	O
of	O
water	O
were	O
added	O
to	O
all	O
samples	O
,	O
including	O
standard	O
and	O
control	O
samples	O
.	O

Here	O
,	O
we	O
developed	O
a	O
b	O
##ov	O
##ine	O
liver	O
-	O
β	O
-	O
g	O
##lu	O
##cu	O
##ron	O
##idas	O
##e	O
h	O
##ydro	O
##ly	O
##sing	O
sample	O
preparation	O
method	O
,	O
using	O
liquid	O
ch	O
##roma	O
##tography	O
coupled	O
to	O
tandem	O
mass	O
s	O
##pect	O
##rome	O
##try	O
to	O
anal	O
##ys	O
##e	O
the	O
total	O
u	O
##rina	O
##ry	O
o	O
##xi	O
##dis	O
##ed	O
lip	O
##id	O
profile	O
including	O
the	O
pro	B
##sta	I
##g	I
##land	I
##ins	I
,	O
is	B
##op	I
##ros	I
##tan	I
##es	I
,	O
di	O
##hy	O
##dr	O
##ox	O
##y	O
-	O
fatty	O
acids	O
,	O
h	O
##ydro	O
##xy	O
-	O
fatty	O
acids	O
and	O
the	O
ni	O
##tro	O
-	O
fatty	O
acids	O
.	O

In	O
light	O
of	O
our	O
previous	O
global	O
meta	O
##bol	O
##omi	O
##cs	O
data	O
linking	O
α	B
-	I
O	I
##G	I
to	O
cell	O
cycle	O
arrest	O
and	O
proliferation	O
suppression	O
,	O
we	O
first	O
investigated	O
the	O
effects	O
of	O
α	B
-	I
O	I
##G	I
in	O
immortal	O
##ized	O
normal	O
bladder	O
e	O
##pit	O
##hel	O
##ial	O
cells	O
.	O

For	O
the	O
ultra	O
##LC	O
separation	O
,	O
the	O
sample	O
was	O
loaded	O
into	O
an	O
Atlantis	O
T	O
##3	O
sent	O
##ry	O
guard	O
cartridge	O
(	O
3	O
μ	O
##m	O
,	O
2	O
.	O
1	O
×	O
10	O
mm	O
;	O
Waters	O
)	O
,	O
and	O
then	O
separation	O
was	O
performed	O
in	O
an	O
Atlantis	O
T	O
##3	O
column	O
(	O
3	O
μ	O
##m	O
,	O
2	O
.	O
1	O
×	O
100	O
mm	O
;	O
Waters	O
)	O
in	O
a	O
two	O
-	O
step	O
linear	O
gradient	O
(	O
solvent	O
A	O
,	O
0	O
.	O
1	O
%	O
FA	S
in	O
water	O
;	O
solvent	O
B	O
,	O
100	O
%	O
Ace	B
##ton	I
##it	I
##ril	I
##e	I
;	O
with	O
1	O
%	O
solvent	O
B	O
for	O
2	O
min	O
,	O
1	O
to	O
30	O
%	O
B	O
for	O
6	O
min	O
,	O
30	O
to	O
90	O
%	O
B	O
for	O
8	O
min	O
,	O
90	O
%	O
B	O
for	O
4	O
min	O
,	O
90	O
to	O
1	O
%	O
B	O
for	O
1	O
min	O
and	O
9	O
min	O
in	O
1	O
%	O
B	O
)	O
.	O

During	O
inspection	O
of	O
the	O
remaining	O
models	O
,	O
we	O
observed	O
that	O
the	O
well	O
performing	O
models	O
either	O
contained	O
al	B
##ani	I
##ne	I
or	O
hip	B
##pura	I
##te	I
but	O
almost	O
never	O
both	O
which	O
is	O
not	O
very	O
surprising	O
,	O
because	O
these	O
two	O
meta	O
##bol	O
##ites	O
are	O
significantly	O
correlated	O
in	O
our	O
data	O
.	O

This	O
allowed	O
the	O
subsequent	O
measurement	O
of	O
the	O
ch	B
##ole	I
##ster	I
##ol	I
concentration	O
only	O
from	O
the	O
remaining	O
L	O
##D	O
##L	O
or	O
HD	O
##L	O
particles	O
in	O
the	O
second	O
step	O
using	O
R	O
##X	O
Series	O
CH	O
38	O
##41	O
protocol	O
to	O
measure	O
L	O
##D	O
##L	O
and	O
the	O
R	O
##X	O
Series	O
CH	O
38	O
##11	O
protocol	O
to	O
measure	O
HD	O
##L	O
.	O

H	O
##b	O
##A	O
##1	O
##c	O
,	O
g	O
##ly	O
##cated	O
ha	O
##em	O
##og	O
##lo	O
##bin	O
;	O
CO	O
,	O
cardiac	O
output	O
;	O
E	O
##F	O
,	O
e	O
##jection	O
fraction	O
;	O
2	O
##h	O
##P	O
##G	O
,	O
2	O
-	O
h	O
plasma	O
glucose	S
;	O
F	O
##P	O
##G	O
,	O
fast	O
##ing	O
plasma	O
glucose	S
;	O
Ce	B
##r	I
,	O
c	B
##era	I
##mi	I
##de	I
;	O
G	O
##lu	O
##C	O
##er	O
,	O
g	B
##lu	I
##cos	I
##yl	I
c	I
##era	I
##mi	I
##de	I
;	O
Lac	B
##C	I
##er	I
,	O
la	B
##ct	I
##osy	I
##l	I
c	I
##era	I
##mi	I
##de	I
;	O
SM	O
,	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
;	O
Sa	O
,	O
s	B
##phi	I
##nga	I
##nine	I
;	O
Sa	O
##1	O
##P	O
,	O
s	B
##phi	I
##nga	I
##nine	I
-	I
1	I
-	I
phosphate	I
;	O

Fen	O
##tany	O
##l	O
can	O
be	O
administered	O
i	O
.	O
v	O
.	O
or	O
i	O
.	O
m	O
.	O
,	O
but	O
because	O
of	O
its	O
short	O
duration	S
of	O
action	O
i	O
.	O
v	O
.	O
d	O
##rip	O
or	O
trans	O
##der	O
##mal	O
patch	O
are	O
the	O
preferred	O
means	O
of	O
administration	O
.	O

Of	O
particular	O
interest	O
were	O
associations	O
for	O
g	B
##ly	I
##cer	I
##ol	I
and	O
la	B
##th	I
##ost	I
##ero	I
##l	I
because	O
prior	O
studies	O
had	O
been	O
small	O
and	O
replication	O
was	O
needed	O
(	O
;	O
)	O
.	O

In	O
this	O
study	O
,	O
the	O
effect	O
of	O
storage	O
temperature	O
(	O
4	O
,	O
22	O
,	O
and	O
40	O
°C	O
)	O
,	O
storage	O
time	O
(	O
24	O
and	O
48	O
h	O
)	O
,	O
and	O
use	O
of	O
pre	O
##ser	O
##vat	O
##ives	O
(	O
b	O
##ori	O
##c	O
acid	O
(	O
BA	O
)	O
,	O
thy	O
##mo	O
##l	O
)	O
and	O
para	B
-	I
amino	I
##ben	I
##zoic	I
acid	I
(	O
PA	O
##BA	O
)	O
on	O
u	O
##rina	O
##ry	O
meta	O
##bol	O
##ites	O
in	O
the	O
pool	O
##ed	O
urine	O
samples	O
from	O
20	O
participants	O
was	O
systematically	O
investigated	O
using	O
large	O
-	O
scale	O
targeted	O
liquid	O
ch	O
##roma	O
##tography	O
tandem	O
mass	O
s	O
##pect	O
##rome	O
##try	O
(	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
)	O
-	O
based	O
meta	O
##bol	O
##omi	O
##cs	O
.	O

K	B
##P	I
m	O
##RNA	O
expression	O
levels	O
were	O
measured	O
by	O
R	O
##T	O
-	O
PC	O
##R	O
and	O
expressed	O
as	O
fold	O
change	O
compared	O
to	O
normal	O
control	O
.	O

For	O
all	O
three	O
receptors	O
,	O
the	O
three	O
β	B
-	I
a	I
##po	I
##car	I
##ote	I
##no	I
##ids	I
with	O
the	O
highest	O
antagonist	O
activity	O
competed	O
for	O
AT	O
##RA	O
binding	O
.	O

Fu	B
##sar	I
##ila	I
##cton	I
##e	I
A	O
(	O
70	O
)	O
and	O
f	B
##usa	I
##ril	I
##act	I
##one	I
B	O
(	O
71	O
)	O
isolated	O
from	O
an	O
extract	O
of	O
end	O
##op	O
##hy	O
##tic	O
fungus	O
Fu	O
##sar	O
##ium	O
s	B
##p	I
.	O

It	O
is	O
clear	O
from	O
that	O
the	O
total	O
analysis	O
time	O
was	O
over	O
40	O
min	O
at	O
10	O
k	B
##V	I

Nico	B
##tina	I
##mi	I
##de	I
n	O
##uc	O
##leo	O
##tide	O
is	O
an	O
important	O
intermediate	O
product	O
of	O
in	O
##tra	O
##cellular	O
ni	B
##cot	I
##ina	I
##mi	I
##de	I
ad	I
##eni	I
##ne	I
din	I
##uc	I
##leo	I
##tide	I
N	O
##AD	O
_	O
+	O
and	O
N	O
##AD	O
_	O
+	O
is	O
an	O
important	O
red	O
##ox	O
co	O
##fa	O
##ctor	O
which	O
is	O
involved	O
in	O
many	O
metabolic	O
processes	O
in	O
cells	O
.	O

This	O
is	O
ex	O
##em	O
##plified	O
in	O
and	O
based	O
on	O
absolute	O
concentrations	O
of	O
g	B
##lut	I
##amine	I
and	O
p	B
##yr	I
##og	I
##lut	I
##ami	I
##c	I
acid	I
from	O
different	O
sample	O
portions	O
from	O
the	O
same	O
pool	O
of	O
human	O
serum	O
.	O

Furthermore	O
,	O
the	O
c	B
##rea	I
##tine	I
level	O
in	O
tumor	O
and	O
L	O
##N	O
-	O
Met	O
tissues	O
was	O
elevated	O
which	O
can	O
be	O
attributed	O
to	O
the	O
alter	O
##ation	O
in	O
energy	O
metabolism	O
.	O

A	O
##cc	O
##um	O
##ulation	O
of	O
la	B
##ct	I
##ate	I
and	O
glucose	S
,	O
which	O
is	O
common	O
in	O
many	O
cancer	O
##s	O
mirrors	O
the	O
demand	O
for	O
higher	O
energy	O
in	O
tumor	O
ma	O
##li	O
##gna	O
##ncy	O
.	O

For	O
un	O
##bia	O
##sed	O
pro	O
##fi	O
##ling	O
studies	O
,	O
real	O
-	O
time	O
mass	O
correction	O
during	O
mass	O
s	O
##pect	O
##rome	O
##try	O
was	O
achieved	O
by	O
in	O
##fusion	O
of	O
a	O
standard	O
mixture	O
of	O
reference	O
ions	O
using	O
an	O
independent	O
1200	O
SL	S
Rapid	O
resolution	O
L	O
##C	O
is	O
##oc	O
##ratic	O
pump	O
equipped	O
with	O
100	O
:	O
1	O
split	O
##ter	O
to	O
output	O
a	O
flow	O
rate	O
of	O
5	O
m	O
##l	O
/	O
min	O
.	O

0	B
.	I
25	I
##μ	I
m	I
)	O
,	O
was	O
employed	O
.	O

In	O
the	O
case	O
of	O
in	O
##cu	O
##bation	O
with	O
enzyme	O
,	O
the	O
back	O
calculated	O
concentration	O
at	O
Q	O
##C	O
1	O
was	O
outside	O
the	O
range	O
(	O
accuracy	O
139	O
.	O
2	O
%	O
)	O
as	O
expected	O
,	O
because	O
the	O
end	O
##ogen	O
##ous	O
di	B
##os	I
##met	I
##in	I
g	O
##lu	O
##cu	O
##ron	O
##ides	O
from	O
plasma	O
were	O
de	O
##con	O
##ju	O
##gated	O
,	O
and	O
added	O
to	O
the	O
spike	O
##d	O
concentration	O
.	O

The	O
sample	O
was	O
acid	O
##ified	O
with	O
the	O
addition	O
of	O
2	O
.	O
5	O
µ	O
##L	O
of	O
t	B
##ri	I
##f	I
##lu	I
##oro	I
##ace	I
##tic	I
acid	I
(	O
T	O
##FA	O
)	O
,	O
and	O
the	O
extraction	O
step	O
with	O
250	O
µ	O
##L	O
of	O
et	B
##hyl	I
ace	I
##tate	I
was	O
repeated	O
.	O

Only	O
the	O
improved	O
group	O
showed	O
normal	O
##ized	O
oral	O
glucose	S
tolerance	O
test	O
results	O
at	O
3	O
months	O
after	O
surgery	O
,	O
even	O
though	O
both	O
group	O
had	O
significant	O
reduction	O
in	O
B	O
##MI	O
and	O
AC	O
.	O

Sub	O
##jects	O
a	O
##bs	O
##tain	O
##ed	O
from	O
g	B
##lu	I
##cos	I
##ino	I
##lates	I
starting	O
7	O
days	O
prior	O
to	O
consumption	O
of	O
the	O
first	O
study	O
vegetable	O
.	O

These	O
included	O
the	O
N	O
-	O
ace	O
##ty	O
##lated	O
forms	O
of	O
1	O
-	O
and	O
3	B
-	I
met	I
##hyl	I
##his	I
##ti	I
##dine	I
and	O
of	O
the	O
plant	O
amino	O
acid	O
all	O
##ii	O
##n	O
and	O
N	B
##2	I
,	I
N	I
##5	I
-	I
di	I
##ace	I
##ty	I
##lor	I
##ni	I
##thin	I
##e	I
.	O

Sur	O
##p	O
##rising	O
##ly	O
,	O
there	O
were	O
only	O
560	O
shared	O
features	O
between	O
these	O
two	O
methods	O
,	O
and	O
1	O
,	O
26	O
##8	O
unique	O
features	O
were	O
detected	O
in	O
the	O
lip	O
##id	O
M	B
##T	I
##BE	I
fraction	O
.	O

The	O
MS	O
resolution	O
was	O
set	O
at	O
100	O
,	O
000	O
full	O
width	O
half	O
maximum	O
and	O
the	O
ca	O
##li	O
##bra	O
##tion	O
standards	O
were	O
provided	O
by	O
The	O
##rm	O
##o	O
Fisher	O
Scientific	O
,	O
Inc	O
.	O
(	B
ca	B
##ffe	I
##ine	I
,	O
Ultra	O
##mark	O
162	O
##1	O
and	O
MR	O
##FA	O
)	O
.	O

The	O
observed	O
plasma	O
metabolic	O
signature	O
in	O
patients	O
was	O
well	O
replica	O
##ted	O
in	O
the	O
culture	O
medium	O
of	O
He	O
##pa	O
##to	O
##C	O
##ell	O
##s	O
,	O
whereby	O
S	O
##N	O
-	O
38	O
exposure	O
induced	O
concentration	O
-	O
and	O
time	O
-	O
dependent	O
accumulation	O
of	O
amino	O
acid	O
meta	O
##bol	O
##ites	O
,	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
,	O
as	O
well	O
as	O
p	O
##yr	O
##im	O
##id	O
##ine	O
/	O
pu	O
##rine	O
n	O
##uc	O
##leo	O
##side	O
##s	O
and	O
n	O
##uc	O
##leo	O
##base	O
##s	O
.	O

Out	O
of	O
40	O
##8	O
targeted	O
meta	O
##bol	O
##ites	O
,	O
196	O
(	O
48	O
%	O
)	O
were	O
detected	O
above	O
the	O
limit	O
of	O
detection	O
(	O
L	O
##OD	O
;	O
defined	O
for	O
each	O
meta	O
##bol	O
##ite	O
as	O
three	O
times	O
the	O
background	O
noise	O
level	O
)	O
,	O
corresponding	O
to	O
82	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
,	O
38	O
g	B
##ly	I
##cer	I
##ides	I
,	O
22	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
,	O
19	O
amino	O
acids	O
,	O
18	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
,	O
9	O
bio	O
##genic	O
am	O
##ines	O
,	O
7	O
ch	B
##ole	I
##ster	I
##ol	I
est	I
##ers	I
and	O
the	O
sum	O
of	O
he	O
##x	O
##ose	O
##s	O
(	O
Fi	O
##g	O
.	O

We	O
selected	O
4	O
amino	O
acids	O
(	B
t	B
##yr	I
##os	I
##ine	I
,	O
th	B
##re	I
##oni	I
##ne	I
,	O
try	B
##pt	I
##op	I
##han	I
and	O
g	B
##ly	I
##cine	I
)	O
,	O
10	O
meta	O
##bol	O
##ites	O
with	O
high	O
confidence	O
in	O
identification	O
(	O
level	O
1	O
or	O
2	O
)	O
and	O
6	O
unidentified	O
,	O
but	O
highly	O
significant	O
species	O
(	O
see	O
for	O
list	O
of	O
selected	O
meta	O
##bol	O
##ites	O
;	O
all	O
p	O
-	O
adjust	O
<	O
0	O
.	O
10	O
)	O
.	O

This	O
may	O
under	O
##lie	O
the	O
lack	O
of	O
newly	O
synthesized	O
g	B
##ly	I
##co	I
##gen	I
in	O
R	O
##h	O
##30	O
cells	O
versus	O
its	O
significant	O
presence	O
in	O
the	O
my	O
##ocytes	O
(	O
c	O
##f	O
.	O

MS	O
/	O
MS	O
s	O
##pect	O
##ra	O
of	O
PC	B
16	I
:	I
1	I
/	I
18	I
:	I
2	I
in	O
a	O
positive	O
ion	O
mode	O
and	O
b	O
negative	O
ion	O
mode	O
.	O

Z	O
##io	O
##uze	O
##nko	O
##va	O
et	O
al	O
reported	O
re	B
##tina	I
##l	I
as	O
a	O
distinct	O
biological	O
regulator	O
involved	O
in	O
suppress	O
##ing	O
ad	O
##ip	O
##o	O
-	O
genes	O
##is	O
,	O
diet	O
-	O
induced	O
o	O
##besity	O
and	O
insulin	O
resistance	O
.	O

spray	O
voltage	O
,	O
3	O
.	O
6	O
k	B
##V	I
;	O
Cap	O
##illa	O
##ry	O
temperature	O
,	O
320	O
°C	O
;	O
S	O
-	O
lens	O
RF	O
level	O
,	O
70	O
and	O
heat	O
##er	O
temperature	O
450	O
°C	O
.	O

In	O
summary	O
,	O
T	O
##CD	O
##CA	O
,	O
G	O
##CA	O
,	O
and	O
SM	B
(	I
d	I
##18	I
:	I
0	I
/	I
18	I
:	I
0	I
)	I
,	O
which	O
rose	O
very	O
significantly	O
along	O
with	O
the	O
severity	O
of	O
liver	O
fi	O
##bro	O
##sis	O
,	O
were	O
the	O
meta	O
##bol	O
##ites	O
that	O
better	O
disc	O
##rim	O
##inate	O
between	O
rapid	O
and	O
slow	O
fi	O
##bro	O
##ser	O
##s	O
in	O
both	O
,	O
un	O
##iva	O
##ria	O
##te	O
and	O
multi	O
##var	O
##iate	O
analyses	O
(	O
Fi	O
##g	O
.	O

The	O
h	O
##ydro	O
##ly	O
##zed	O
sample	O
was	O
subsequently	O
neutral	O
##ized	O
to	O
pH	O
7	O
with	O
75	O
μ	O
##L	O
of	O
p	B
##hos	I
##ph	I
##ori	I
##c	I
acid	I
.	O

Super	B
##oxide	I
##s	I
easily	O
react	O
with	O
cellular	O
membrane	O
components	O
(	O
i	O
.	O
e	O
.	O
lip	O
##ids	O
and	O
proteins	O
)	O
and	O
DNA	O
.	O

After	O
approval	O
by	O
an	O
ethics	O
committee	O
and	O
informed	O
written	O
consent	O
,	O
18	O
type	O
2	O
di	O
##abe	O
##tic	O
subjects	O
underwent	O
a	O
e	B
##ug	I
##ly	I
##ce	I
##mic	I
glucose	I
c	O
##lamp	O
study	O
after	O
sub	O
##cut	O
##aneous	O
injection	O
of	O
0	O
.	O
4	O
units	O
/	O
kg	O
g	O
##lar	O
##gin	O
##e	O
and	O
1	O
week	O
of	O
daily	O
g	O
##lar	O
##gin	O
##e	O
treatment	O
,	O
as	O
previously	O
reported	O
.	O

More	O
meaningful	O
was	O
the	O
mass	O
spectrum	O
results	O
displayed	O
that	O
compared	O
with	O
the	O
control	O
group	O
,	O
the	O
concentration	O
of	O
se	B
##rine	I
and	O
g	B
##ly	I
##cine	I
of	O
the	O
cells	O
decreased	O
obviously	O
in	O
the	O
s	O
##h	O
-	O
P	O
##LC	O
##ε	O
group	O
or	O
adding	O
VP	O
group	O
.	O

Then	O
a	O
bio	O
##mark	O
##er	O
panel	O
containing	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
g	B
##lut	I
##amine	I
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
c	B
##it	I
##rate	I
,	O
N	B
-	I
ace	I
##ty	I
##l	I
-	I
g	I
##ly	I
##co	I
##p	I
##rote	I
##ins	I
and	O
T	B
##MA	I
##O	I
was	O
identified	O
and	O
high	O
correlation	O
with	O
the	O
state	O
of	O
psychological	O
sub	O
##op	O
##ti	O
##mal	O
was	O
also	O
demonstrated	O
.	O

Po	O
##ssi	O
##ble	O
fragment	O
##ation	O
mechanisms	O
leading	O
to	O
formation	O
of	O
those	O
smaller	O
fragment	O
ions	O
include	O
1	B
,	I
4	I
-	I
hydrogen	I
elimination	O
followed	O
by	O
ho	O
##mo	O
##ly	O
##tic	O
s	O
##cis	O
##sion	O
and	O
subsequent	O
radical	O
elimination	O
_	O
,	O
.	O

The	O
_	O
13	O
C	O
satellite	O
cross	O
-	O
peak	O
patterns	O
for	O
the	O
pro	O
##tons	O
of	O
G	O
##lu	O
(	O
5	O
,	O
6	O
,	O
12	O
,	O
20	O
)	O
,	O
G	O
##ln	O
(	O
9	O
)	O
,	O
g	O
##lut	O
##am	O
##yl	O
residue	O
of	O
o	B
##xi	I
##dized	I
g	I
##lut	I
##ath	I
##ione	I
(	O
G	O
##SS	O
##G	O
)	O
(	O
7	O
,	O
10	O
,	O
13	O
)	O
and	O
As	O
##p	O
(	O
16	O
–	O
19	O
)	O
were	O
present	O
and	O
noted	O
by	O
vertical	O
and	O
horizontal	O
dashed	O
green	O
lines	O
.	O

However	O
,	O
although	O
such	O
an	O
approach	O
assumes	O
correctly	O
that	O
c	B
##rea	I
##tin	I
##ine	I
from	O
end	O
##ogen	O
##ous	O
sources	O
is	O
ex	O
##cre	O
##ted	O
into	O
urine	O
at	O
an	O
approximately	O
constant	O
rate	O
throughout	O
the	O
day	O
(	O
Bingham	O
and	O
Cummings	O
)	O
,	O
it	O
fails	O
to	O
take	O
into	O
account	O
the	O
contribution	O
that	O
recent	O
diet	O
##ary	O
intake	O
of	O
meat	O
-	O
based	O
foods	O
makes	O
to	O
u	O
##rina	O
##ry	O
c	B
##rea	I
##tin	I
##ine	I
output	O
(	O
Stella	O
et	O
al	O
.	O

Previous	O
studies	O
with	O
whole	O
plant	O
foods	O
or	O
o	O
##at	O
-	O
derived	O
beta	O
-	O
g	O
##lu	O
##can	O
in	O
particular	O
,	O
have	O
shown	O
significant	O
and	O
clinical	O
##ly	O
meaningful	O
reduction	O
##s	O
in	O
ch	B
##ole	I
##ster	I
##ol	I
upon	O
ing	O
##est	O
##ion	O
.	O

These	O
in	O
##tens	O
##ities	O
were	O
normal	O
##ized	O
to	O
internal	O
standard	O
su	B
##cci	I
##nic	I
acid	O
-	O
d	O
##4	O
.	O

)	O
showed	O
that	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
and	O
lip	O
##id	O
##2	O
levels	O
are	O
increased	O
after	O
treatment	O
,	O
while	O
most	O
MR	O
##S	O
-	O
measured	O
meta	O
##bol	O
##ites	O
other	O
than	O
lip	O
##id	O
##2	O
were	O
unchanged	O
or	O
decreased	O
.	O

Our	O
in	O
v	O
##it	O
##ro	O
data	O
together	O
with	O
in	O
v	O
##ivo	O
evidence	O
suggest	O
that	O
an	O
##ast	O
##ro	O
##zo	O
##le	O
h	O
##ydro	O
##xy	O
##lation	O
to	O
h	B
##ydro	I
##xy	I
##ana	I
##stro	I
##zo	I
##le	I
by	O
C	O
##YP	O
##3	O
##A	O
##4	O
,	O
which	O
then	O
undergo	O
rapid	O
and	O
extensive	O
con	O
##ju	O
##gation	O
probably	O
by	O
U	O
##G	O
##T	O
##s	O
,	O
and	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
N	O
-	O
g	O
##lu	O
##cu	O
##ron	O
##ida	O
##tion	O
to	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
g	I
##lu	I
##cu	I
##ron	I
##ide	I
predominantly	O
by	O
U	O
##G	O
##T	O
##1	O
##A	O
##4	O
are	O
the	O
principal	O
metabolic	O
pathways	O
of	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
.	O

We	O
also	O
found	O
that	O
a	O
higher	O
base	O
##line	O
concentration	O
of	O
plasma	O
f	B
##ru	I
##ct	I
##ose	I
was	O
associated	O
with	O
the	O
incident	O
central	O
ad	O
##ip	O
##os	O
##ity	O
gain	O
p	O
##hen	O
##otype	O
.	O

Fat	O
##ty	O
acid	O
(	B
palm	B
##itate	I
)	O
trace	O
##r	O
kinetic	O
##s	O
during	O
r	O
##HD	O
##L	O
and	O
place	O
##bo	O
in	O
##fusion	O
.	O

On	O
ass	O
##ay	O
days	O
,	O
this	O
solution	O
was	O
di	O
##lut	O
##ed	O
with	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
to	O
obtain	O
the	O
lower	O
ca	O
##li	O
##bra	O
##tion	O
working	O
solutions	O
of	O
0	O
.	O
01	O
and	O
0	O
.	O
00	O
##1	O
mg	O
/	O
m	O
##L	O
.	O
These	O
ca	O
##li	O
##bra	O
##tion	O
working	O
solutions	O
were	O
di	O
##lut	O
##ed	O
in	O
plasma	O
with	O
2	O
M	O
H	O
_	O
2	O
S	O
##O	O
_	O
4	O
(	O
5	O
%	O
,	O
v	O
/	O
v	O
)	O
to	O
produce	O
200	O
-	O
µ	O
##L	O
al	O
##iq	O
##uo	O
##ts	O
of	O
the	O
following	O
concentrations	O
:	O
1	O
,	O
3	O
,	O
10	O
,	O
30	O
,	O
100	O
,	O
300	O
,	O
500	O
,	O
750	O
and	O
1	O
,	O
000	O
ng	O
/	O
m	O
##L	O
.	O
Ali	O
##q	O
##uo	O
##ts	O
of	O
10	O
µ	O
##L	O
of	O
a	O
mixture	O
of	O
des	B
##met	I
##hyl	I
-	I
B	I
##EN	I
and	O
des	B
##met	I
##hyl	I
-	I
B	I
##EN	I
-	I
C	I
##l	I
_	I
2	I
(	O
1	O
µ	O
##g	O
/	O
m	O
##L	O
each	O
in	O
ace	O
##ton	O
##it	O
##ril	O
##e	O
)	O
were	O
added	O
as	O
internal	O
standards	O
.	O

Line	O
##ar	O
re	O
##gression	O
analysis	O
showed	O
that	O
the	O
relative	O
levels	O
of	O
ch	B
##ole	I
##ster	I
##yl	I
est	I
##er	I
,	O
di	B
##acy	I
##l	I
##gly	I
##cer	I
##ol	I
and	O
t	B
##ria	I
##cy	I
##l	I
##gly	I
##cer	I
##ol	I
at	O
1	O
month	O
were	O
associated	O
to	O
the	O
change	O
in	O
c	O
-	O
p	O
##eptide	O
levels	O
from	O
1	O
to	O
6	O
months	O
(	O
corrected	O
p	O
-	O
values	O
of	O
4	O
.	O
06	O
##E	O
##−	O
##0	O
##3	O
,	O
1	O
.	O
72	O
##E	O
##−	O
##0	O
##2	O
and	O
1	O
.	O
72	O
##E	O
##0	O
##2	O
,	O
respectively	O
)	O
.	O

The	O
studies	O
about	O
human	O
he	O
##pa	O
##to	O
##cellular	O
car	O
##cin	O
##oma	O
also	O
showed	O
u	B
##ric	I
acid	I
was	O
elevated	O
in	O
urine	O
sample	O
of	O
patients	O
but	O
not	O
obvious	O
variation	O
in	O
serum	O
sample	O
.	O

This	O
is	O
consistent	O
with	O
our	O
findings	O
from	O
the	O
L	O
##C	O
-	O
MS	O
meta	O
##bol	O
##omi	O
##c	O
analysis	O
,	O
in	O
which	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
and	O
its	O
meta	O
##bol	O
##ite	O
p	B
##hen	I
##yle	I
##thy	I
##lam	I
##ine	I
concentrations	O
were	O
higher	O
in	O
the	O
high	B
–	I
c	I
##ys	I
##tat	I
##hi	I
##oni	I
##ne	I
concentration	O
group	O
.	O

It	O
is	O
known	O
that	O
long	O
-	O
chain	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
play	O
an	O
important	O
role	O
in	O
free	O
fatty	O
acid	O
(	O
FF	O
##A	O
)	O
oxidation	O
responsible	O
for	O
the	O
transportation	O
of	O
a	B
##cy	I
##l	I
-	I
co	I
##en	I
##zy	I
##me	I
A	O
(	O
Co	O
##A	O
)	O
into	O
mit	O
##och	O
##ond	O
##ria	O
.	O

To	O
each	O
sample	O
316	O
µ	O
##l	O
Me	B
##OH	I
was	O
added	O
and	O
v	O
##ortex	O
##ed	O
for	O
30	O
seconds	O
before	O
the	O
addition	O
of	O
63	O
##3	O
µ	O
##l	O
DC	O
##M	O
.	O

There	O
was	O
a	O
significant	O
improvement	O
in	O
serum	O
bi	B
##li	I
##ru	I
##bin	I

P	B
##yr	I
##ido	I
##xa	I
##l	I
5	I
’	I
-	I
phosphate	I
(	O
P	O
##LP	O
)	O
,	O
the	O
active	O
form	O
of	O
vitamin	B
B	I
##6	I
,	O
works	O
as	O
co	O
##fa	O
##ctor	O
in	O
numerous	O
en	O
##zy	O
##matic	O
reactions	O
;	O
it	O
behave	O
##s	O
as	O
anti	O
##ox	O
##ida	O
##nt	O
molecule	O
.	O

The	O
mobile	O
phases	O
were	O
100	O
m	O
##M	O
am	B
##mon	I
##ium	I
format	I
##e	I
(	O
pH	O
4	O
.	O
0	O
)	O
(	O
A	O
)	O
and	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
(	O
B	O
)	O
with	O
a	O
column	O
temperature	O
of	O
40	O
°C	O
and	O
a	O
flow	O
rate	O
of	O
0	O
.	O
4	O
m	O
##L	O
/	O
min	O
.	O

Finally	O
,	O
the	O
levels	O
of	O
each	O
species	O
of	O
c	B
##era	I
##mi	I
##de	I
(	I
C	I
##14	I
:	I
0	I
,	I
C	I
##16	I
:	I
0	I
,	I
C	I
##18	I
:	I
1	I
,	I
C	I
##18	I
:	I
0	I
,	I
C	I
##20	I
:	I
0	I
,	I
C	I
##22	I
:	I
0	I
,	I
C	I
##24	I
:	I
1	I
,	I
C	I
##24	I
:	I
0	I
,	I
C	I
##26	I
:	I
1	I
and	O
C	B
##26	I
:	I
0	I
)	I
in	O
breast	O
cancer	O
and	O
normal	O
breast	O
tissue	O
were	O
determined	O
.	O

In	O
agreement	O
with	O
a	O
signaling	O
role	O
of	O
this	O
meta	O
##bol	O
##ite	O
,	O
k	B
##yn	I
##uren	I
##ine	I
was	O
not	O
used	O
for	O
downstream	O
synthesis	O
of	O
N	B
##AD	I
,	O
since	O
a	O
_	O
13	O
C	O
_	O
20	O
mass	O
is	O
##oto	O
##po	O
##mer	O
of	O
N	B
##AD	I
was	O
not	O
observed	O
;	O
instead	O
,	O
cells	O
incorporated	O
_	O
12	O
C	O
ni	B
##cot	I
##ina	I
##mi	I
##de	I
from	O
the	O
medium	O
to	O
form	O
_	O
13	O
C	O
_	O
14	O
N	B
##AD	I
.	O

A	O
linear	O
re	O
##gression	O
of	O
the	O
combined	O
I	O
##ER	O
and	O
CE	B
##R	I
data	O
##sets	O
including	O
both	O
these	O
factors	O
explained	O
38	O
%	O
of	O
the	O
variation	O
in	O
fat	O
cell	O
size	O
.	O

Data	O
acquisition	O
was	O
performed	O
through	O
a	O
parent	O
ion	O
scan	O
of	O
m	O
/	O
z	O
=	O
184	O
Da	O
,	O
which	O
corresponds	O
to	O
the	O
ch	B
##olin	I
##e	I
fragment	O
,	O
allowing	O
the	O
MS	O
/	O
MS	O
detection	O
of	O
PC	O
##s	O
,	O
SM	O
##s	O
and	O
the	O
respective	O
L	O
##ys	O
##o	O
-	O
forms	O
(	O
LP	O
##Cs	O
and	O
L	O
##SM	O
##s	O
)	O
.	O

Ph	B
##en	I
##yla	I
##lani	I
##ne	I
can	O
be	O
converted	O
into	O
f	B
##uma	I
##rate	I
.	O

Ch	B
##lor	I
##of	I
##orm	I
(	O
CH	O
##C	O
##l	O
_	O
3	O
)	O
and	O
met	B
##han	I
##ol	I
(	O
CH	O
_	O
3	O
OH	O
)	O
were	O
obtained	O
from	O
SD	O
##S	O
,	O
France	O
.	O

Therefore	O
,	O
serum	O
concentrations	O
of	O
g	B
##ly	I
##cine	I
,	O
v	B
##ali	I
##ne	I
,	O
met	B
##hi	I
##oni	I
##ne	I
,	O
c	B
##it	I
##ru	I
##llin	I
##e	I
,	O
a	B
##rg	I
##ini	I
##ne	I
and	O
C	B
##16	I
-	I
car	I
##ni	I
##tine	I
may	O
be	O
integrated	O
into	O
the	O
current	O
method	O
for	O
screening	O
for	O
lung	O
cancer	O
.	O

It	O
can	O
be	O
concluded	O
from	O
previous	O
studies	O
that	O
an	O
increased	O
level	O
of	O
hem	O
##oly	O
##sis	O
in	O
β	O
-	O
th	O
##ala	O
##sse	O
##mia	O
may	O
be	O
a	O
cause	O
of	O
disruption	O
in	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
particularly	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
ch	I
##olin	I
##e	I
,	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##let	I
##han	I
##ola	I
##mine	I
and	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##ls	I
##eri	I
##ne	I
in	O
patients	O
.	O

Furthermore	O
,	O
there	O
was	O
a	O
significant	O
decline	O
in	O
s	O
##phi	O
##ngo	O
##sin	O
##e	O
‐	O
1	O
‐	O
phosphate	O
p	O
##hos	O
##pha	O
##tase	O
1	O
activity	O
(	O
S	O
##GP	O
##P	O
##1	O
,	O
S	O
##Y	O
##NE	O
##2	O
lo	O
##cus	O
)	O
after	O
treatment	O
,	O
particularly	O
among	O
IN	O
##R	O
,	O
when	O
evaluated	O
by	O
the	O
ratio	O
PC	O
a	O
##a	O
C	B
##28	I
:	I
1	I
/	I
PC	I
a	I
##e	I
C	I
##40	I
:	I
2	I
(	O
p	O
=	O
8	O
.	O
46	O
##6	O
##7	O
##E	O
-	O
7	O
,	O
-	O
log	O
##10	O
(	O
p	O
)	O
=	O

In	O
the	O
current	O
study	O
,	O
we	O
also	O
found	O
that	O
the	O
relative	O
concentration	O
of	O
2	B
-	I
o	I
##x	I
##og	I
##lut	I
##arate	I
was	O
increased	O
in	O
the	O
urine	O
of	O
I	O
##C	O
patients	O
.	O

Visual	O
inspection	O
of	O
the	O
s	O
##pect	O
##ra	O
of	O
these	O
tissues	O
revealed	O
that	O
the	O
levels	O
of	O
some	O
meta	O
##bol	O
##ites	O
such	O
as	O
lip	O
##ids	O
,	O
amino	O
acids	O
,	O
and	O
ch	B
##olin	I
##e	I
were	O
obviously	O
different	O
between	O
tumor	O
tissues	O
and	O
AN	O
##IT	O
.	O

A	O
0	O
.	O
9	O
%	O
Na	O
##C	O
##l	O
solution	O
(	B
sa	B
##line	I
)	O
was	O
used	O
instead	O
of	O
CS	O
##F	O
in	O
an	O
exact	O
simulation	O
of	O
the	O
CS	O
##F	O
sampling	O
protocol	O
(	O
see	O
Fi	O
##g	O
.	O

In	O
the	O
subgroup	O
analysis	O
by	O
the	O
effect	O
of	O
the	O
24	O
-	O
week	O
-	O
intervention	O
(	O
see	O
[UNK]	O
-	O
values	O
in	O
Table	O
)	O
,	O
both	O
Pi	O
##o	O
and	O
Pi	O
##o	O
&	O
Omega	B
-	I
3	I
increased	O
body	O
weight	O
and	O
B	O
##MI	O
compared	O
with	O
Place	O
##bo	O
or	O
Omega	B
-	I
3	I
(	O
except	O
for	O
Place	O
##bo	O
vs	O
.	O
Pi	O
##o	O
in	O
the	O
case	O
of	O
body	O
weight	O
;	O
p	O
=	O
0	O
.	O
10	O
)	O
.	O

However	O
,	O
the	O
mechanism	O
about	O
vitamin	B
K	I
##2	I
anti	O
##tum	O
##or	O
is	O
still	O
disputed	O
,	O
it	O
may	O
act	O
by	O
involving	O
in	O
mitochondrial	O
electron	O
signal	O
transmission	O
,	O
affecting	O
the	O
B	O
##c	O
##l	O
-	O
2	O
protein	O
,	O
in	O
##ducing	O
cell	O
a	O
##pop	O
##tosis	O
of	O
ca	O
##sp	O
##ase	O
family	O
,	O
adjusting	O
the	O
G	O
##1	O
phase	O
-	O
relevant	O
molecular	O
expression	O
of	O
cell	O
cycle	O
,	O
etc	O
.	O

We	O
observed	O
no	O
significant	O
change	O
in	O
serum	O
PC	O
##S	O
(	O
P	O
0	O
.	O
42	O
)	O
,	O
PC	O
##G	O
(	O
P	O
0	O
.	O
59	O
)	O
,	O
IS	O
(	O
P	O
0	O
.	O
70	O
)	O
,	O
and	O
PA	B
##G	I
(	O
P	O
0	O
.	O
41	O
)	O
.	O

It	O
was	O
noticeable	O
that	O
c	B
##era	I
##mi	I
##de	I
42	I
:	I
3	I
,	O
the	O
only	O
species	O
with	O
3	O
un	O
##sat	O
##uration	O
##s	O
,	O
was	O
systematically	O
absent	O
from	O
the	O
re	O
##tina	O
and	O
brain	O
while	O
it	O
was	O
present	O
in	O
various	O
G	O
##G	O
classes	O
of	O
the	O
other	O
tissues	O
.	O

Our	O
measurements	O
of	O
F	O
##P	O
##G	O
and	O
H	O
##b	O
##A	O
##1	O
##c	O
in	O
this	O
group	O
of	O
patients	O
with	O
AD	O
provide	O
no	O
evidence	O
for	O
increased	O
prevalence	O
of	O
und	O
##ia	O
##gno	O
##sed	O
T	O
##2	O
##D	O
,	O
I	O
##G	O
##T	O
or	O
IF	O
##G	O
(	O
see	O
)	O
:	O
therefore	O
,	O
it	O
is	O
unlikely	O
that	O
dem	O
##ent	O
##ia	O
in	O
these	O
patients	O
occurred	O
as	O
a	O
result	O
of	O
systemic	O
disorders	O
of	O
glucose	S
metabolism	O
such	O
as	O
diabetes	O
or	O
I	O
##G	O
##T	O
.	O

B	O
##rief	O
##ly	O
,	O
samples	O
destined	O
for	O
gas	O
ch	O
##roma	O
##tography	O
(	O
G	O
##C	O
)	O
mass	O
s	O
##pect	O
##rome	O
##try	O
(	O
MS	O
)	O
analysis	O
were	O
dried	O
under	O
vacuum	O
des	O
##ic	O
##cation	O
for	O
a	O
minimum	O
of	O
24	O
h	O
and	O
then	O
der	O
##iva	O
##tized	O
under	O
nitrogen	O
using	O
bi	B
##st	I
##rim	I
##eth	I
##yl	I
-	I
si	I
##ly	I
##l	I
-	I
t	I
##ri	I
##f	I
##lour	I
##oa	I
##ce	I
##tam	I
##ide	I
(	O
BS	O
##TF	O
##A	O
)	O
.	O

Sam	O
##ples	O
were	O
processed	O
in	O
a	O
96	O
-	O
well	O
plate	O
,	O
in	O
each	O
plate	O
al	O
##iq	O
##uo	O
##ts	O
of	O
100	O
μ	O
##L	O
of	O
plasma	O
of	O
each	O
samples	O
were	O
mixed	O
with	O
800	O
μ	O
##L	O
of	O
solvent	O
met	B
##han	I
##ol	I
,	O
20	O
μ	O
##L	O
of	O
internal	O
standard	O
my	O
##rist	O
##ic	O
-	O
d	O
_	O
27	O
acid	O
(	O
1	O
mg	O
/	O
m	O
##L	O
stock	O
solution	O
)	O
was	O
added	O
and	O
left	O
on	O
ice	O
for	O
30	O
minutes	O
.	O

Micro	O
##so	O
##mal	O
mediated	O
U	O
##DP	O
-	O
g	O
##lu	O
##cu	O
##ron	O
##osy	O
##lt	O
##ran	O
##s	O
##fer	O
##ases	O
cat	O
##aly	O
##ze	O
the	O
bio	O
##act	O
##ivation	O
of	O
NSA	O
##ID	O
##S	O
by	O
the	O
formation	O
of	O
a	B
##cy	I
##l	I
g	I
##lu	I
##cu	I
##ron	I
##ide	I

The	O
n	O
##ume	O
##rator	O
L	O
##MI	O
##s	O
of	O
49	O
##6	O
.	O
50	O
##22	O
m	O
/	O
z	O
and	O
52	O
##4	O
.	O
56	O
##14	O
m	O
/	O
z	O
were	O
earlier	O
identified	O
as	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
(	O
LP	O
##C	O
)	O
16	O
:	O
0	O
and	O
LP	B
##C	I
18	I
:	I
0	I
[	I
,	I
]	I
.	O

However	O
,	O
our	O
analyses	O
revealed	O
small	O
proportions	O
of	O
original	O
L	O
##C	O
##B	O
with	O
odd	O
(	B
d	B
##17	I
:	I
0	I
and	O
d	B
##17	I
:	I
1	I
)	O
and	O
p	O
##oly	O
##uns	O
##at	O
##ura	O
##ted	O
(	B
d	B
##18	I
:	I
2	I
)	O
chain	O
length	O
.	O

Ser	O
##um	O
meta	O
##bol	O
##omi	O
##cs	O
varied	O
with	O
ME	O
##E	O
changed	O
,	O
and	O
3	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
,	O
ace	B
##tone	I
and	O
su	B
##cci	I
##nate	I
were	O
significantly	O
elevated	O
with	O
the	O
increasing	O
ME	O
##E	O
.	O

In	O
in	O
v	O
##it	O
##ro	O
studies	O
,	O
u	B
##ric	I
acid	I
reacted	O
rapidly	O
with	O
oz	O
##one	O
and	O
conferred	O
protection	O
of	O
plasma	O
lip	O
##ids	O
from	O
per	O
##ox	O
##ida	O
##tion	O
and	O
er	O
##yt	O
##hr	O
##oc	O
##yte	O
l	O
##ys	O
##is	O
.	O

_	O
–	O
My	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
is	O
synthesized	O
from	O
glucose	B
6	I
-	I
phosphate	I
by	O
my	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
-	I
3	I
-	I
phosphate	I
s	O
##ynth	O
##ase	O
(	O
IP	O
s	O
##ynth	O
##ase	O
)	O
in	O
most	O
tissues	O
,	O
however	O
,	O
there	O
are	O
several	O
IP	S
s	O
##ynth	O
##ase	O
is	O
##of	O
##orms	O
,	O
in	O
both	O
rats	O
and	O
humans	O
,	O
suggesting	O
that	O
in	B
##os	I
##ito	I
##l	I
bio	O
##sy	O
##nt	O
##hesis	O
by	O
IP	S
s	O
##ynth	O
##ase	O
is	O
a	O
highly	O
regulated	O
and	O
multi	O
##face	O
##ted	O
process	O
.	O

In	O
v	O
##ivo	O
imaging	O
of	O
meta	O
##bol	O
##ites	O
and	O
their	O
en	O
##zy	O
##matic	O
conversion	O
into	O
other	O
species	O
,	O
and	O
the	O
metabolic	O
flux	O
##es	O
in	O
central	O
metabolic	O
pathways	O
,	O
like	O
g	O
##ly	O
##co	O
##lysis	O
and	O
the	O
t	B
##rica	I
##rb	I
##ox	I
##yl	I
##ic	I
acid	I
cycle	O
,	O
has	O
been	O
reported	O
.	O

Ana	O
##ly	O
##tes	O
were	O
kept	O
at	O
10	O
°C	O
in	O
the	O
auto	O
##sa	O
##mple	O
##r	O
and	O
injected	O
h	B
##ydro	I
##dynamic	I
##ally	I
at	O
the	O
pressure	O
of	O
5	O
m	O
##bar	O
for	O
100	O
s	O
.	O
Unless	O
otherwise	O
stated	O
,	O
the	O
following	O
E	O
##SI	O
-	O
MS	O
/	O
MS	O
conditions	O
were	O
used	O
:	O
sheath	O
liquid	O
,	O
Me	O
##OH	O
/	O
H	O
_	O
2	O
O	O
(	O
80	O
/	O
20	O
,	O
v	O
/	O
v	O
)	O
containing	O
40	O
m	O
##M	O
H	O
##OA	O
##c	O
;	O
sheath	O
liquid	O
flow	O
rate	O
,	O
5	O
μ	O
##L	O
/	O
min	O
;	O
cap	O
##illa	O
##ry	O
voltage	O
,	O
+	O
350	O
##0	O
V	O
;	O
drying	O
gas	O
flow	O
rate	O
,	O
5	O
.	O
0	O
L	O
/	O
min	O
;	O
drying	O
gas	O
temperature	O
,	O
200	O
°C	O
;	O
ne	O
##bul	O
##izer	O
pressure	O
,	O
7	O
ps	O
##i	O
;	O
collision	O
cell	O
gas	O
(	O
N	O
_	O
2	O
)	O
pressure	O
was	O
~	O
30	O
ps	O
##i	O
.	O

Ana	O
##ly	O
##tes	O
,	O
neat	O
or	O
extracted	O
from	O
plasma	O
,	O
de	O
##com	O
##posed	O
in	O
the	O
auto	O
##sa	O
##mple	O
##r	O
after	O
re	O
##con	O
##st	O
##itution	O
in	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
or	O
water	O
.	O

In	O
the	O
absence	O
of	O
met	B
##ho	I
##xy	I
##amine	I
,	O
9	O
disappeared	O
and	O
a	O
new	O
meta	O
##bol	O
##ite	O
with	O
a	O
molecular	O
ion	O
at	O
m	O
/	O
z	O
345	O
increased	O
in	O
abundance	O
.	O

−	O
1	O
−	O
N	O
3	O
Ad	O
##e	O
+	O
4	O
−	O
OH	O
##E	O
##1	O
OH	O
##E	O
##1	O
OH	O
##E	O
OH	O
##E	O
1	O
1	O
(	O
E	O
##2	O
E	O
##2	O
E	O
E	O
2	O
2	O
)	O
−	O
1	O
−	O
N	O
7	O
G	O
##ua	O
4	B
##−	I
##cate	I
##cho	I
##les	I
##tro	I
##gens	I
+	I
4	I
##−	I
##cate	I
##cho	I
##les	I
##tro	I
##gen	I
##con	I
##ju	I
##gate	I
##s	I
4	I
##−	I
##cate	I
##cho	I
##les	I
##tro	I
##gens	I
+	I
4	I
##−	I
##cate	I
##cho	I
##les	I
##tro	I
##gen	I
##con	I
##ju	I
##gate	I
##s	I
4	O
−	O
cat	B
##ech	I
##ol	I
est	O
##rogen	O
##s	O
+	O
4	O
−	O
cat	B
##ech	I
##ol	I
est	I
##rogen	I
con	O
##ju	O
##gate	O
##s	O
=	O

A	O
##bb	O
##re	O
##viation	O
##s	O
:	O
5	O
##AA	O
##s	O
-	O
Combined	O
score	O
:	O
the	O
combined	O
score	O
derived	O
from	O
the	O
abundance	O
of	O
5	O
AA	O
##s	O
(	B
v	B
##ali	I
##ne	I
,	O
le	B
##uc	I
##ine	I
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
and	O
p	B
##hen	I
##ela	I
##lani	I
##ne	I
)	O
;	O
6	O
##AA	O
##s	O
-	O
Combined	O
score	O
:	O
the	O
combined	O
score	O
derived	O
from	O
the	O
abundance	O
of	O
6	O
AA	O
##s	O
(	B
v	B
##ali	I
##ne	I
,	O
le	B
##uc	I
##ine	I
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
p	B
##hen	I
##ela	I
##lani	I
##ne	I
,	O
and	O
try	O
##pt	O
##op	O
##han	O
)	O
.	O

Nan	O
##ose	O
##p	O
cent	O
##ri	O
##fu	O
##gal	O
filters	O
with	O
3	O
k	O
##D	O
##a	O
cut	O
##off	O
(	O
Pa	O
##ll	O
Life	O
Science	O
,	O
Port	O
Washington	O
,	O
NY	O
)	O
were	O
washed	O
8	O
times	O
with	O
0	O
.	O
5	O
m	O
##L	O
water	O
at	O
4000	O
g	O
and	O
36	O
##°	O
##C	O
to	O
remove	O
g	B
##ly	I
##cer	I
##ol	I
from	O
the	O
filter	O
membrane	O
.	O

One	O
proposed	O
route	O
for	O
primary	O
fatty	O
acid	B
amid	I
##e	I
bio	O
##sy	O
##nt	O
##hesis	O
is	O
the	O
am	O
##mon	O
##oly	O
##sis	O
of	O
fatty	O
a	B
##cy	I
##l	I
-	I
Co	I
##A	I
th	I
##io	I
##ester	I
##s	I
.	O

Mali	B
##c	I
acid	I
and	O
su	B
##cci	I
##nate	I
were	O
particularly	O
elevated	O
in	O
ID	O
##H	O
-	O
mutant	O
g	O
##lio	O
##mas	O
,	O
consistent	O
with	O
d	O
##ys	O
##re	O
##gu	O
##lation	O
of	O
the	O
T	O
##CA	O
cycle	O
in	O
these	O
tumors	O
.	O

Additionally	O
,	O
the	O
relative	O
increases	O
of	O
:	O
(	O
C	O
)	O
U	O
##TP	O
,	O
U	B
##DP	I
,	O
and	O
U	O
##MP	O
;	O
D	O
)	O
ATP	S
,	O
AD	B
##P	I
,	O
and	O
AM	B
##P	I
;	O
and	O
(	O
E	O
)	O
in	B
##os	I
##ine	I
,	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
(	O
HP	O
##X	O
)	O
,	O
and	O
u	B
##ric	I
acid	I
heated	O
at	O
250	O
°C	O
for	O
60	O
s	O
compared	O
with	O
25	O
°C	O
are	O
shown	O
.	O

G	B
##lu	I
##cos	I
##e	I
and	O
the	O
branched	O
-	O
chain	O
amino	O
acids	O
is	O
##ole	O
##uc	O
##ine	O
and	O
v	B
##ali	I
##ne	I
positively	O
correlated	O
with	O
change	O
in	O
the	O
glucose	S
to	O
c	O
-	O
p	O
##eptide	O
ratio	O
,	O
indicating	O
that	O
individuals	O
with	O
high	O
base	O
##line	O
levels	O
of	O
these	O
three	O
meta	O
##bol	O
##ites	O
had	O
decreased	O
beta	O
cell	O
function	O
after	O
si	B
##m	I
##vas	I
##tat	I
##in	I
treatment	O
.	O

Moreover	O
,	O
the	O
put	O
##ative	O
threshold	O
of	O
5	O
.	O
9	O
ng	O
/	O
m	O
##L	O
(	B
Z	I
)	I
‐	I
end	I
##ox	I
##ife	I
##n	I
_	I
20	I
has	O
not	O
been	O
prospective	O
##ly	O
valid	O
##ated	O
and	O
con	O
##tro	O
##vers	O
##ies	O
on	O
the	O
C	O
##YP	O
##2	O
##D	O
##6	O
—	O
end	O
##ox	O
##ife	O
##n	O
relationship	O
for	O
the	O
prediction	O
of	O
ta	B
##mo	I
##xi	I
##fen	I
efficacy	O
have	O
not	O
been	O
finally	O
resolved	O
,	O
which	O
currently	O
limits	O
the	O
clinical	O
utility	O
of	O
our	O
findings	O
.	O
_	O
29	O
,	O
_	O
47	O
,	O
_	O
48	O
,	O
_	O
49	O
,	O
_	O
50	O
,	O
_	O
51	O
,	O
_	O
52	O

Of	O
note	O
,	O
over	O
##weight	O
and	O
increasing	O
Met	O
##S	O
risk	O
factors	O
were	O
associated	O
with	O
lower	O
g	B
##ly	I
##cine	I
concentrations	O
in	O
women	O
(	O
VIP	O
>	O
1	O
,	O
Su	O
##pp	O
##lement	O
##ary	O
Table	O
_	O
S	O
##4	O
)	O
.	O

Here	O
,	O
we	O
showed	O
significant	O
down	O
-	O
regulation	O
of	O
the	O
BC	O
##AA	O
degradation	O
pathway	O
genes	O
in	O
the	O
ad	O
##ip	O
##ose	O
tissue	O
of	O
norm	B
##og	I
##ly	I
##ce	I
##mic	I
subjects	O
with	O
high	O
insulin	O
resistance	O
.	O

The	O
statistical	O
significance	O
of	O
c	B
##y	I
##c	I
##lo	I
##he	I
##xy	I
##lam	I
##ine	I
in	O
pre	O
drug	O
treated	O
plasma	O
to	O
post	O
drug	O
treated	O
glucose	S
and	O
insulin	O
levels	O
is	O
surprising	O
,	O
since	O
the	O
artificial	O
sweet	O
##ener	O
c	O
##y	O
##c	O
##lam	O
##ate	O
is	O
banned	O
in	O
the	O
United	O
States	O
.	O

P	O
values	O
comparing	O
*	O
1	O
/	O
*	O
1	O
and	O
R	B
##M	I
groups	O
are	O
based	O
on	O
Mann	O
-	O
Whitney	O
tests	O
.	O

Multi	O
##var	O
##iate	O
statistical	O
analysis	O
found	O
that	O
serum	O
metabolism	O
in	O
G	O
##DM	O
patients	O
was	O
different	O
significantly	O
from	O
healthy	O
pregnant	O
women	O
,	O
36	O
differential	O
meta	O
##bol	O
##ites	O
and	O
corresponding	O
metabolic	O
pathways	O
were	O
identified	O
in	O
serum	O
,	O
which	O
involved	O
several	O
metabolic	O
ways	O
like	O
,	O
fatty	O
acid	O
metabolism	O
,	O
but	B
##yric	I
acid	I
metabolism	O
,	O
bi	O
##le	O
secret	O
##ion	O
,	O
and	O
amino	O
acid	O
metabolism	O
.	O

The	O
dominant	O
meta	O
##bol	O
##ites	O
detected	O
in	O
serum	O
were	O
lip	O
##op	O
##rote	O
##ins	O
and	O
several	O
amino	O
acids	O
(	O
e	O
.	O
g	O
.	O
,	O
al	B
##ani	I
##ne	I
,	O
l	B
##ys	I
##ine	I
,	O
g	B
##lut	I
##amine	I
,	O
g	B
##ly	I
##cine	I
,	O
his	B
##ti	I
##dine	I
)	O
.	O

There	O
were	O
9	O
and	O
11	O
meta	O
##bol	O
##ites	O
that	O
changed	O
their	O
abundance	O
in	O
CC	O
##RT	O
and	O
R	O
##T	O
groups	O
,	O
respectively	O
,	O
including	O
2	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
##s	I
(	O
SM	O
##s	O
)	O
that	O
increased	O
abundance	O
between	O
points	O
B	O
and	O
C	O
in	O
both	O
groups	O
of	O
patients	O
.	O

FA	O
##B	O
-	O
M	O
##3	O
samples	O
were	O
not	O
included	O
in	O
this	O
study	O
because	O
most	O
of	O
those	O
patients	O
were	O
treated	O
by	O
more	O
effective	O
ch	O
##em	O
##otherapy	O
with	O
all	O
-	O
trans	O
re	B
##tino	I
##ic	I
acid	I
.	O

Since	O
the	O
original	O
study	O
by	O
Sr	O
##eek	O
##uma	O
##r	O
and	O
colleagues	O
was	O
published	O
,	O
Jen	O
##tz	O
##mi	O
##k	O
et	O
al	O
_	O
,	O
reported	O
con	O
##tra	O
##dict	O
##ory	O
findings	O
in	O
which	O
no	O
correlation	O
was	O
observed	O
between	O
sa	B
##rc	I
##os	I
##ine	I
levels	O
in	O
either	O
post	O
-	O
DR	O
##E	O
urine	O
or	O
tissues	O
,	O
with	O
pro	O
##state	O
cancer	O
aggressive	O
##ness	O
.	O

Current	O
results	O
could	O
be	O
consistent	O
with	O
in	O
##ef	O
##ficient	O
glucose	S
u	O
##til	O
##ization	O
caused	O
by	O
impaired	O
g	O
##ly	O
##co	O
##lysis	O
and	O
con	O
##se	O
##quent	O
elevation	O
in	O
p	B
##oly	I
##ol	I
-	I
pathway	I
meta	O
##bol	O
##ites	O
;	O
consistent	O
with	O
this	O
interpretation	O
,	O
for	O
example	O
,	O
hip	O
##po	O
##cam	O
##pal	O
la	B
##ct	I
##ate	I
was	O
elevated	O
by	O
2	O
.	O
6	O
-	O
fold	O
in	O
cases	O
compared	O
with	O
controls	O
;	O
fold	O
-	O
values	O
(	O
case	O
-	O
control	O
ratios	O
)	O
measured	O
in	O
other	O
brain	O
regions	O
were	O
as	O
follows	O
:	O
EC	O
,	O
0	O
.	O
5	O
;	O
M	O
##T	O
##G	O
,	O
1	O
.	O
3	O
;	O
SC	O
##x	O
,	O
3	O
.	O
4	O
;	O
MC	O
##x	O
,	O
7	O
.	O
3	O
;	O
C	O
##G	O
,	O
1	O
.	O
7	O
;	O
CB	O
,	O
0	O
.	O
6	O
;	O
thus	O
values	O
in	O
SC	O
##x	O
and	O
MC	O
##x	O
showed	O
apparent	O
upward	O
trends	O
,	O
although	O
these	O
were	O
not	O
significant	O
,	O
possibly	O
due	O
to	O
the	O
limited	O
numbers	O
in	O
each	O
group	O
.	O

The	O
meta	O
##bol	O
##ites	O
most	O
contributor	O
##y	O
to	O
the	O
overlapping	O
region	O
were	O
related	O
to	O
energy	O
metabolism	O
and	O
cellular	O
proliferation	O
(	B
1	B
-	I
met	I
##hyl	I
##his	I
##ti	I
##dine	I
,	O
o	B
-	I
ace	I
##ty	I
##l	I
##car	I
##ni	I
##tine	I
)	O
as	O
well	O
as	O
those	O
reflective	O
of	O
muscle	O
wasting	O
,	O
including	O
p	B
##i	I
-	I
met	I
##hyl	I
##his	I
##ti	I
##dine	I
,	O
c	B
##rea	I
##tin	I
##ine	I
,	O
and	O
a	O
number	O
of	O
amino	O
acids	O
and	O
amino	O
acid	O
derivatives	O
(	B
le	B
##uc	I
##ine	I
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
v	B
##ali	I
##ne	I
,	O
try	B
##pt	I
##op	I
##han	I
and	O
4	B
-	I
h	I
##ydro	I
##xy	I
##phe	I
##ny	I
##lace	I
##tate	I
)	O
.	O

We	O
plan	O
to	O
further	O
evaluate	O
how	O
this	O
profile	O
changes	O
over	O
time	O
,	O
how	O
it	O
is	O
affected	O
by	O
per	O
##ina	O
##tal	O
treatments	O
(	O
norm	O
##oth	O
##er	O
##mia	O
,	O
h	O
##y	O
##pot	O
##her	O
##mia	O
,	O
er	B
##yt	I
##hr	I
##op	I
##oi	I
##eti	I
##n	I
,	O
and	O
h	O
##y	O
##pot	O
##her	O
##mia	O
plus	O
er	O
##yt	O
##hr	O
##op	O
##oi	O
##eti	O
##n	O
)	O
,	O
and	O
whether	O
this	O
profile	O
co	O
##rrel	O
##ates	O
to	O
ne	O
##uro	O
##de	O
##vel	O
##op	O
##mental	O
outcomes	O
at	O
9	O
months	O
of	O
age	O
(	O
which	O
corresponds	O
roughly	O
to	O
36	O
months	O
of	O
human	O
development	O
)	O
.	O

The	O
f	O
##ae	O
##cal	O
_	O
1	O
H	O
N	O
##MR	O
s	O
##pect	O
##ra	O
were	O
dominated	O
by	O
signals	O
arising	O
from	O
the	O
three	O
main	O
SC	O
##FA	O
namely	O
,	O
ace	B
##tate	I
,	O
prop	B
##ion	I
##ate	I
,	O
and	O
but	B
##yra	I
##te	I
and	O
characterised	O
by	O
low	O
levels	O
of	O
many	O
other	O
meta	O
##bol	O
##ites	O
(	O
Figure	O
)	O
.	O

IP	O
##I	O
:	O
international	O
pro	O
##gno	O
##stic	O
index	O
CH	O
##OP	O
regime	O
##n	O
includes	O
c	O
##y	O
##c	O
##lop	O
##hos	O
##pha	O
##mi	O
##de	O
,	O
do	B
##x	I
##or	I
##ubi	I
##cin	I
,	O
v	B
##in	I
##c	I
##rist	I
##ine	I
,	O
and	O
pre	B
##dn	I
##is	I
##olo	I
##ne	I
.	O

In	O
some	O
cases	O
,	O
met	B
##ho	I
##xy	I
##amine	I
(	O
20	O
mm	O
##ol	O
)	O
was	O
added	O
after	O
1	O
hour	O
to	O
der	O
##iva	O
##ti	O
##ze	O
all	O
carbon	O
##yl	O
groups	O
.	O

The	O
ch	B
##olin	I
##e	I
peak	O
was	O
confirmed	O
in	O
a	O
small	O
series	O
of	O
3	O
children	O
with	O
non	O
-	O
functional	O
PA	O
(	O
Table	O
)	O
.	O

To	O
analyze	O
P	O
##L	O
,	O
an	O
al	O
##iq	O
##uo	O
##t	O
of	O
30	O
μ	O
##L	O
of	O
the	O
super	O
##nat	O
##ant	O
was	O
di	O
##lut	O
##ed	O
by	O
500	O
μ	O
##L	O
met	B
##han	I
##ol	I
including	O
1	B
,	I
2	I
-	I
dim	I
##yr	I
##ist	I
##oy	I
##l	I
-	I
s	I
##n	I
-	I
g	I
##ly	I
##cer	I
##o	I
-	I
3	I
-	I
p	I
##hos	I
##ph	I
##och	I
##olin	I
##e	I
and	O
1	B
-	I
t	I
##ride	I
##cano	I
##yl	I
-	I
2	I
-	I
h	I
##ydro	I
##xy	I
-	I
s	I
##n	I
-	I
g	I
##ly	I
##cer	I
##o	I
-	I
3	I
-	I
p	I
##hos	I
##ph	I
##och	I
##olin	I
##e	I
(	O
Ava	O
##nti	O
Polar	O
Li	O
##pid	O
##s	O
,	O
Al	O
##aba	O
##ster	O
,	O
USA	O
)	O
as	O
internal	O
standards	O
.	O

A	O
##bb	O
##re	O
##viation	O
##s	O
:	O
C	O
##L	O
,	O
card	O
##iol	O
##ip	O
##in	O
;	O
F	O
##DR	O
,	O
false	O
discovery	O
rate	O
;	O
l	B
##ys	I
##o	I
-	I
PC	I
,	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
;	O
n	O
##d	O
,	O
not	O
detected	O
;	O
PC	O
,	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
;	O
PS	O
,	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##ls	I
##eri	I
##ne	I
;	O
SM	O
,	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
.	O

p	O
<	O
0	O
.	O
000	O
##1	O
)	O
,	O
car	B
##ni	I
##tine	I
(	I
14	I
:	I
1	I
)	I
(	O
β	O
=	O
0	O
.	O
33	O
##2	O
;	O
p	O
<	O
0	O
.	O
000	O
##1	O
)	O
and	O
lit	B
##ho	I
##cho	I
##lic	I
acid	I
(	O
β	O
=	O
0	O
.	O
224	O
;	O
p	O
<	O
0	O
.	O
000	O
##1	O
)	O
;	O
of	O
these	O
,	O
4	B
-	I
p	I
##yr	I
##ido	I
##xi	I
##c	I
acid	I
,	O
lit	B
##ho	I
##cho	I
##lic	I
acid	I
and	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##gly	I
##cer	I
##ol	I
(	I
20	I
:	I
3	I
/	I
2	I
:	I
0	I
)	I
were	O
,	O
to	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
first	O
reported	O
in	O
this	O
study	O
.	O

As	O
a	O
result	O
,	O
B	O
##D	O
##T	O
treatment	O
showed	O
the	O
obvious	O
effect	O
on	O
the	O
bio	O
##mark	O
##er	O
panel	O
that	O
levels	O
of	O
g	B
##lut	I
##amine	I
,	O
T	B
##MA	I
##O	I
,	O
and	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
that	O
changed	O
significantly	O
and	O
also	O
c	B
##it	I
##rate	I
,	O
t	B
##yr	I
##os	I
##ine	I
and	O
N	B
-	I
ace	I
##ty	I
##l	I
-	I
g	I
##ly	I
##co	I
##p	I
##rote	I
##ins	I
exhibited	O
a	O
trend	O
to	O
normal	O
levels	O
.	O

To	O
avoid	O
any	O
potential	O
disturbance	O
##s	O
of	O
the	O
test	O
system	O
caused	O
by	O
coffee	O
intake	O
it	O
was	O
finally	O
decided	O
to	O
exclude	O
all	O
models	O
that	O
used	O
t	B
##rig	I
##one	I
##llin	I
##e	I
as	O
a	O
feature	O
,	O
leaving	O
a	O
total	O
of	O
33	O
and	O
60	O
candidates	O
for	O
the	O
strict	O
and	O
extended	O
setting	O
,	O
respectively	O
.	O

Our	O
evaluation	O
##s	O
of	O
synthetic	O
V	B
##LC	I
##DC	I
##A	I
28	I
:	I
4	I
have	O
shown	O
that	O
this	O
di	B
##car	I
##box	I
##yl	I
##ic	I
acid	I
has	O
anti	O
-	O
inflammatory	O
activity	O
in	O
v	O
##it	O
##ro	O
,	O
blocking	O
the	O
ability	O
of	O
lip	B
##op	I
##oly	I
##sa	I
##cc	I
##hari	I
##de	I
(	O
LP	O
##S	O
)	O
to	O
stimulate	O
ni	B
##tric	I
oxide	I
production	O
in	O
human	O
mon	O
##ocytes	O
.	O

P	O
##las	O
##ma	O
dim	B
##eth	I
##yl	I
##gly	I
##cine	I
was	O
significantly	O
higher	O
in	O
the	O
high	B
–	I
c	I
##ys	I
##tat	I
##hi	I
##oni	I
##ne	I
concentration	O
group	O
(	O
P	O
=	O
0	O
.	O
00	O
##2	O
)	O
,	O
but	O
the	O
concentrations	O
of	O
plasma	O
g	B
##ly	I
##cine	I
were	O
not	O
different	O
between	O
the	O
2	O
groups	O
.	O

In	O
a	O
study	O
comprising	O
12	O
,	O
66	O
##4	O
adolescent	O
##s	O
and	O
young	O
adults	O
(	O
16	O
–	O
39	O
years	O
old	O
,	O
51	O
%	O
women	O
)	O
,	O
W	O
##ü	O
##rt	O
##z	O
et	O
al	O
.	O
found	O
an	O
association	O
between	O
B	O
##MI	O
and	O
levels	O
of	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
lip	O
##ids	O
,	O
fatty	O
acids	O
,	O
k	B
##eton	I
##e	I
bodies	O
,	O
g	O
##ly	O
##co	O
##lysis	O
related	O
meta	O
##bol	O
##ites	O
and	O
amino	O
acids	O
.	O

Although	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
had	O
been	O
described	O
as	O
major	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
in	O
lip	O
##op	O
##rote	O
##ins	O
and	O
cellular	O
membrane	O
##s	O
for	O
a	O
long	O
time	O
,	O
several	O
recent	O
advances	O
have	O
expanded	O
on	O
the	O
notion	O
that	O
PC	O
##s	O
are	O
not	O
just	O
a	O
kind	O
of	O
cellular	O
bricks	O
.	O

G	B
##ly	I
##cer	I
##ol	I
3	I
-	I
phosphate	I
is	O
a	O
p	B
##hos	I
##ph	I
##ori	I
##c	I
est	I
##er	I
of	O
g	B
##ly	I
##cer	I
##ol	I
that	O
controls	O
the	O
flux	O
through	O
the	O
g	O
##ly	O
##cer	O
##oli	O
##pid	O
/	O
free	O
fatty	O
acid	O
cycle	O
,	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
bio	O
##sy	O
##nt	O
##hesis	O
and	O
many	O
other	O
cellular	O
functions	O
.	O

Pol	B
##yam	I
##ines	I
are	O
involved	O
in	O
the	O
regulation	O
of	O
many	O
cellular	O
functions	O
and	O
are	O
promising	O
bio	O
##mark	O
##ers	O
of	O
numerous	O
physiological	O
conditions	O
.	O

To	O
test	O
the	O
hypothesis	O
that	O
g	O
##lut	O
##ami	O
##no	O
##lysis	O
promotes	O
cancer	O
stem	O
##ness	O
,	O
g	O
##lut	O
##ami	O
##nas	O
##e	O
expression	O
and	O
g	B
##lut	I
##ama	I
##te	I
levels	O
were	O
examined	O
in	O
the	O
context	O
of	O
sphere	O
ass	O
##ays	O
.	O

Since	O
o	B
##xa	I
##lace	I
##tic	I
acid	I
was	O
converted	O
to	O
p	B
##yr	I
##u	I
##vate	I
during	O
the	O
pre	O
-	O
treatment	O
procedure	O
,	O
o	B
##xa	I
##lace	I
##tic	I
acid	I
was	O
detected	O
as	O
p	B
##yr	I
##u	I
##vate	I
in	O
our	O
system	O
.	O

The	O
organic	O
extract	O
was	O
dissolved	O
in	O
550	O
μ	O
##L	O
of	O
cold	O
de	O
##uter	O
##ated	O
ch	B
##lor	I
##of	I
##orm	I
(	O
CD	O
##C	O
##l	O
_	O
3	O
with	O
0	O
.	O
03	O
%	O
trim	B
##eth	I
##yl	I
##si	I
##ly	I
##l	I
prop	I
##ano	I
##ic	I
acid	I
,	O
T	O
##MS	O
)	O
.	O

mi	O
##R	O
-	O
23	O
##b	O
and	O
mi	O
##R	O
-	O
27	O
##a	O
were	O
predominantly	O
associated	O
with	O
ad	O
##ip	O
##os	O
##ity	O
while	O
mi	O
##R	O
-	O
223	O
was	O
predominantly	O
associated	O
with	O
increased	O
thigh	O
muscle	O
fat	O
,	O
and	O
altered	O
plasma	O
metabolic	O
and	O
lip	O
##op	O
##rote	O
##ins	O
profiles	O
,	O
namely	O
small	O
HD	O
##L	O
particles	O
,	O
plasma	O
short	O
,	O
and	O
medium	O
chain	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
and	O
non	O
-	O
branched	O
chain	O
amino	O
acids	O
.	O

After	O
treatment	O
with	O
metre	O
##le	O
##pt	O
##in	O
,	O
the	O
com	O
##or	O
##bid	O
##ities	O
were	O
treated	O
with	O
met	B
##form	I
##in	I
(	O
n	O
=	O
12	O
)	O
,	O
insulin	O
(	O
n	O
=	O
6	O
)	O
,	O
th	B
##ia	I
##zo	I
##lid	I
##ined	I
##ione	I
##s	I
(	O
n	O
=	O
3	O
)	O
,	O
su	B
##lf	I
##ony	I
##lu	I
##rea	I
##s	I
(	O
n	O
=	O
1	O
)	O
,	O
and	O
fi	O
##bra	O
##tes	O
(	O
n	O
=	O
10	O
)	O
.	O

The	O
increased	O
levels	O
of	O
SF	O
##As	O
in	O
the	O
A	B
##F	I
patients	O
may	O
have	O
been	O
influenced	O
by	O
ad	O
##ip	O
##ose	O
-	O
stimulate	O
##d	O
lip	O
##oly	O
##sis	O
and	O
thus	O
contributed	O
to	O
inflammation	O
.	O

Nico	B
##tine	I
and	O
PA	O
##H	O
u	O
##rina	O
##ry	O
meta	O
##bol	O
##ites	O
from	O
100	O
first	O
morning	O
urine	O
samples	O
of	O
non	O
-	O
occupational	O
##ly	O
exposed	O
subjects	O
have	O
been	O
anal	O
##ys	O
##ed	O
.	O

Standard	O
E	O
##rro	O
##r	O
;	O
G	B
##l	I
##c	I
–	I
glucose	I
,	O
Ser	B
–	I
se	I
##rine	I
,	O
G	B
##ly	I
–	I
g	I
##ly	I
##cine	I
,	O
P	O
##yr	O
–	O
P	O
##yr	O
##u	O
##vate	O
,	O
Al	B
##a	I
–	I
al	I
##ani	I
##ne	I
,	O
Lac	B
–	I
la	I
##ct	I
##ate	I
,	O
C	O
##it	O
–	O
c	O
##it	O
##rate	O
,	O
a	B
##K	I
##G	I
–	I
α	I
-	I
k	I
##eto	I
##g	I
##lut	I
##arate	I
,	O
Su	B
##cc	I
–	I
su	I
##cci	I
##nate	I
,	O
Fu	O
##m	O
–	O
f	O
##uma	O
##rate	O
,	O
Mal	B
–	I
ma	I
##late	I
,	O
O	B
##x	I
##A	I
##c	I
–	I
o	I
##xa	I
##lo	I
##ace	I
##tate	I
,	O
G	B
##lu	I
–	I
g	I
##lut	I
##ama	I
##te	I
,	O
G	B
##ln	I
–	I
G	I
##lut	I
##amine	I
,	O
T	B
##hr	I
–	I
T	I
##hr	I
##eon	I
##ine	I
,	O
Val	B
–	I
Val	I
##ine	I
,	O
Le	B
##u	I
–	I
Le	I
##uc	I
##ine	I
,	O
Il	B
##e	I
–	I
Is	I
##ole	I
##uc	I
##ine	I
,	O
L	B
##ys	I
–	I
L	I
##ys	I
##ine	I
,	O
Ty	B
##r	I
–	I
Ty	I
##ros	I
##ine	I
.	O

BR	O
##B	O
,	O
which	O
served	O
as	O
the	O
active	O
agents	O
in	O
the	O
gel	O
,	O
contain	O
numerous	O
compounds	O
with	O
potential	O
ch	O
##em	O
##op	O
##re	O
##vent	O
##ive	O
activities	O
,	O
including	O
ant	B
##ho	I
##cy	I
##ani	I
##ns	I
,	O
el	O
##lag	O
##ic	O
,	O
f	O
##er	O
##uli	O
##c	O
,	O
and	O
p	O
-	O
co	O
##ume	O
##ric	O
acids	O
,	O
vitamin	O
##s	O
(	O
as	O
##cor	O
##bic	O
acid	O
,	O
α	O
and	O
β	B
-	I
car	I
##ote	I
##ne	I
and	O
f	O
##olate	O
)	O
,	O
and	O
minerals	O
.	O

No	O
G	O
##R	O
or	O
SF	S
was	O
detected	O
in	O
the	O
place	O
##bo	O
beverage	O
.	O

Our	O
data	O
is	O
in	O
agreement	O
with	O
previously	O
reported	O
studies	O
,	O
where	O
significant	O
differently	O
lower	O
levels	O
of	O
pro	B
##line	I
have	O
been	O
observed	O
in	O
serum	O
samples	O
of	O
re	O
##nal	O
cell	O
car	O
##cin	O
##oma	O
,	O
oral	O
cancer	O
,	O
and	O
color	O
##ec	O
##tal	O
cancer	O
.	O

Using	O
HP	O
##LC	O
with	O
UV	O
detection	O
,	O
a	O
single	O
ch	O
##roma	O
##to	O
##graphic	O
peak	O
that	O
was	O
unique	O
to	O
in	O
##cu	O
##bation	O
##s	O
consisting	O
of	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
,	O
H	O
##LM	O
##s	O
and	O
co	O
##fa	O
##ctors	O
was	O
noted	O
.	O

Ha	O
##zard	O
ratios	O
(	O
H	O
##R	O
)	O
and	O
95	O
%	O
confidence	O
intervals	O
(	O
C	O
##I	O
)	O
for	O
est	O
##rogen	O
-	O
receptor	O
positive	O
(	O
ER	O
+	O
)	O
breast	O
cancer	O
per	O
5	O
##k	O
##g	O
/	O
m	O
_	O
2	O
increase	O
in	O
body	O
mass	O
index	O
(	O
B	O
##MI	O
)	O
adjusted	O
for	O
different	O
combinations	O
of	O
est	O
##rogen	O
##s	O
and	O
est	B
##rogen	I
meta	O
##bol	O
##ites	O
.	O

Super	O
##nat	O
##ant	O
(	O
550	O
μ	O
##L	O
)	O
was	O
transferred	O
to	O
a	O
2	O
.	O
0	O
m	O
##L	O
micro	O
##cent	O
##ri	O
##fu	O
##ge	O
tube	O
containing	O
200	O
μ	O
##L	O
5	O
%	O
a	O
##que	O
##ous	O
form	B
##ic	I
acid	I
followed	O
by	O
as	O
##piration	O
4	O
times	O
through	O
1	O
m	O
##L	O
WA	O
##X	O
-	O
S	O
tips	O
(	O
D	O
##P	O
##X	O
Labs	O
,	O
Columbia	O
,	O
SC	O
)	O
containing	O
20	O
mg	O
re	O
##sin	O
and	O
40	O
mg	O
salt	O
.	O

Character	O
##istic	O
##s	O
of	O
control	O
subjects	O
and	O
breast	O
cancer	O
case	O
subjects	O
The	O
median	O
serum	O
concentrations	O
of	O
est	O
##rogen	O
##s	O
,	O
est	B
##rogen	I
meta	O
##bol	O
##ites	O
,	O
and	O
metabolic	O
pathway	O
groups	O
,	O
with	O
inter	O
##de	O
##ci	O
##les	O
ranges	O
,	O
for	O
case	O
subjects	O
and	O
control	O
subjects	O
are	O
presented	O
in	O
.	O

Individuals	O
within	O
the	O
lowest	O
20	O
%	O
of	O
g	B
##lut	I
##amine	I
levels	O
ran	O
a	O
1	O
.	O
5	O
-	O
fold	O
elevated	O
risk	O
of	O
pan	O
##cre	O
##atic	O
cancer	O
,	O
and	O
individuals	O
within	O
the	O
lowest	O
20	O
%	O
of	O
his	B
##ti	I
##dine	I
levels	O
ran	O
a	O
2	O
.	O
2	O
-	O
fold	O
elevated	O
risk	O
of	O
pan	O
##cre	O
##atic	O
cancer	O
.	O

De	O
##p	O
##rote	O
##ini	O
##zed	O
super	O
##nat	O
##ants	O
were	O
then	O
transferred	O
to	O
clean	O
plastic	O
E	O
##ppe	O
##ndo	O
##rf	O
tubes	O
,	O
and	O
fifty	O
volumes	O
of	O
met	B
##han	I
##ol	I
containing	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
(	O
F	O
##luk	O
##a	O
)	O
was	O
added	O
to	O
each	O
tube	O
.	O

[	O
95	O
%	O
C	O
##I	O
93	O
##13	O
##8	O
–	O
295	O
##48	O
##7	O
]	O
,	O
p	O
=	O
0	O
.	O
04	O
##1	O
)	O
and	O
di	B
##acy	I
##gly	I
##cer	I
##ol	I
(	O
D	O
##G	O
)	O
16	O
:	O
0	O
/	O
22	O
:	O
6	O
(	O
β	O
coefficient	O
62	O
##37	O
##5	O
.	O

At	O
this	O
point	O
,	O
studies	O
seem	O
to	O
disagree	O
on	O
how	O
FA	S
regulation	O
is	O
involved	O
in	O
tumor	O
##ige	O
##nes	O
##is	O
.	O

Six	O
rabbits	O
(	O
Group	O
6	O
)	O
received	O
a	O
sub	O
##cut	O
##aneous	O
injection	O
of	O
in	B
##dom	I
##eth	I
##ac	I
##in	I
(	O
20	O
mg	O
/	O
kg	O
,	O
Na	O
##cal	O
##ai	O
Te	O
##sque	O
,	O
Inc	O
.	O
,	O
Kyoto	O
,	O
Japan	O
)	O
dissolved	O
in	O
4	O
%	O
Na	O
##HC	O
##O	O
_	O
3	O
once	O
a	O
day	O
.	O

As	O
a	O
precursor	O
of	O
pu	B
##rine	I
synthesis	O
,	O
reduced	O
g	B
##ly	I
##cine	I
in	O
BC	O
##a	O
indicates	O
that	O
a	O
critical	O
metabolic	O
process	O
associated	O
with	O
cell	O
proliferation	O
is	O
altered	O
in	O
BC	O
##a	O
.	O

The	O
pro	B
##line	I
pathway	O
was	O
linked	O
with	O
h	O
##y	O
##pox	O
##ia	O
in	O
pan	O
##cre	O
##atic	O
cancer	O
and	O
triggered	O
a	O
h	O
##y	O
##pox	O
##ic	O
stress	O
response	O
.	O

Indeed	O
,	O
a	O
previous	O
study	O
assessing	O
occupational	O
exposure	O
through	O
personal	O
air	O
measurements	O
showed	O
that	O
the	O
exposure	O
to	O
ben	B
##zen	I
##e	I
,	O
to	B
##lue	I
##ne	I
,	O
and	O
x	B
##yle	I
##ne	I
was	O
higher	O
in	O
co	O
##ke	O
by	O
##p	O
##rod	O
##uc	O
##t	O
workers	O
,	O
while	O
co	O
##ke	O
oven	O
workers	O
are	O
more	O
exposed	O
to	O
PA	O
##H	O
##s	O
.	O

A	O
series	O
of	O
eight	O
working	O
solutions	O
for	O
each	O
anal	O
##yte	O
,	O
except	O
CB	O
##Z	O
,	O
was	O
prepared	O
by	O
di	O
##lut	O
##ing	O
the	O
stock	O
solutions	O
in	O
D	B
##MS	I
##O	I
.	O

Spike	O
##d	O
s	O
##pect	O
##ra	O
were	O
acquired	O
on	O
the	O
400	O
MHz	O
and	O
900	O
MHz	O
s	O
##pect	O
##rome	O
##ters	O
for	O
37	O
meta	O
##bol	O
##ites	O
:	O
al	B
##ani	I
##ne	I
,	O
a	B
##rg	I
##ini	I
##ne	I
,	O
as	B
##par	I
##agi	I
##ne	I
,	O
as	B
##par	I
##tate	I
,	O
c	B
##ys	I
##tein	I
##e	I
,	O
g	B
##lut	I
##amine	I
,	O
g	B
##lut	I
##ama	I
##te	I
,	O
g	B
##ly	I
##cine	I
,	O
his	B
##ti	I
##dine	I
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
le	B
##uc	I
##ine	I
,	O
l	B
##ys	I
##ine	I
,	O
met	B
##hi	I
##oni	I
##ne	I
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
pro	B
##line	I
,	O
se	B
##rine	I
,	O
th	B
##re	I
##oni	I
##ne	I
,	O
try	B
##pt	I
##op	I
##han	I
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
v	B
##ali	I
##ne	I
,	O
glucose	S
,	O
my	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
,	O
ace	B
##tate	I
,	O
ace	B
##to	I
##ace	I
##tate	I
,	O
α	B
-	I
k	I
##eto	I
##g	I
##lut	I
##arate	I
,	O
β	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
,	O
c	B
##it	I
##rate	I
,	O
la	B
##ct	I
##ate	I
,	O
p	B
##yr	I
##u	I
##vate	I
,	O
su	B
##cci	I
##nate	I
,	O
c	B
##rea	I
##tine	I
,	O
c	B
##rea	I
##tin	I
##ine	I
,	O
ace	B
##tone	I
,	O
beta	B
##ine	I
,	O
ch	B
##olin	I
##e	I
,	O
g	B
##ly	I
##cer	I
##ol	I
,	O
and	O
met	B
##han	I
##ol	I
.	O

Across	O
all	O
time	O
points	O
,	O
severe	O
C	O
##YP	O
##2	O
##D	O
##6	O
imp	O
##air	O
##ment	O
(	O
AS	O
≤	O
0	O
.	O
5	O
;	O
PM	O
/	O
PM	O
and	O
PM	O
/	O
I	O
##M	O
)	O
was	O
the	O
strongest	O
de	O
##ter	O
##mina	O
##nt	O
of	O
(	B
Z	I
)	I
‐	I
end	I
##ox	I
##ife	I
##n	I
var	O
##iability	O
.	O

We	O
assessed	O
whether	O
cannabis	S
use	O
was	O
associated	O
with	O
alterations	O
in	O
markers	O
of	O
CD	O
##4	O
_	O
+	O
and	O
CD	O
##8	O
_	O
+	O
T	O
-	O
cell	O
activation	O
,	O
a	O
hall	O
##mark	O
of	O
HIV	O
disease	O
path	O
##ogen	O
##esis	O
[	O
,	O
]	O
.	O

Unfortunately	O
,	O
we	O
are	O
not	O
able	O
to	O
explain	O
the	O
significant	O
differences	O
with	O
increasing	O
means	O
in	O
u	O
##rina	O
##ry	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
levels	O
in	O
the	O
C	O
##G	O
between	O
V	O
##1	O
and	O
V	O
##3	O
and	O
V	O
##2	O
and	O
V	O
##3	O
,	O
respectively	O
.	O

(	O
B	O
)	O
Level	O
##s	O
of	O
g	B
##lut	I
##ama	I
##te	I
in	O
U	O
##M	O
-	O
SC	O
##C	O
-	O
14	O
##A	O
cells	O
culture	O
##d	O
in	O
the	O
presence	O
or	O
absence	O
of	O
the	O
g	O
##lut	O
##ami	O
##nas	O
##e	O
inhibitor	O
(	O
D	O
##ON	O
)	O
under	O
ad	O
##here	O
##nt	O
or	O
suspension	O
conditions	O
for	O
3	O
days	O
,	O
based	O
on	O
is	O
##oto	O
##pe	O
di	O
##lution	O
G	O
##C	O
-	O
MS	O
.	O

Inc	O
##reased	O
A	O
##rg	O
might	O
theoretical	O
##ly	O
be	O
used	O
for	O
ni	B
##tric	I
oxide	I
(	O
NO	O
)	O
synthesis	O
and	O
contribute	O
to	O
vascular	O
headache	O
##s	O
or	O
mi	O
##gra	O
##ines	O
,	O
however	O
the	O
link	O
##age	O
between	O
A	O
##rg	O
and	O
mi	O
##gra	O
##ine	O
is	O
complex	O
,	O
and	O
this	O
use	O
would	O
run	O
counter	O
to	O
the	O
nitrogen	O
spa	O
##ring	O
use	O
of	O
A	O
##rg	O
needed	O
during	O
times	O
of	O
environmental	O
stress	O
.	O

Therefore	O
,	O
met	B
##hyl	I
##amine	I
##s	I
may	O
indicate	O
the	O
disturbance	O
of	O
liver	O
home	O
##ost	O
##asis	O
in	O
development	O
of	O
re	O
##ct	O
##al	O
cancer	O
.	O

The	O
As	O
-	O
G	O
##S	O
##H	O
complexes	O
standards	O
were	O
prepared	O
by	O
mixing	O
As	O
standard	O
solutions	O
(	O
As	O
_	O
III	O
,	O
MMA	O
_	O
III	O
,	O
and	O
D	O
##MA	O
_	O
III	O
)	O
with	O
excess	O
G	B
##S	I
##H	I
,	O
and	O
thus	O
the	O
standards	O
of	O
As	O
-	O
G	O
##S	O
##H	O
complexes	O
,	O
e	O
.	O
g	O
.	O
,	O
As	O
_	O
III	O
(	O
G	O
##S	O
)	O
_	O
3	O
,	O
MMA	O
_	O
III	O
(	O
G	O
##S	O
)	O
_	O
2	O
,	O
and	O
D	O
##MA	O
_	O
III	O
(	O
G	O
##S	O
)	O
,	O
were	O
always	O
present	O
in	O
excess	O
G	B
##S	I
##H	I
.	O

Para	B
##ce	I
##tam	I
##ol	I
(	O
resulted	O
from	O
para	B
##ce	I
##tam	I
##ol	I
-	I
β	I
-	I
d	I
-	I
g	I
##lu	I
##cu	I
##ron	I
##ide	I
degradation	O
)	O
and	O
d	B
_	I
4	I
-	I
para	I
##ce	I
##tam	I
##ol	I
were	O
monitored	O
in	O
the	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
method	O
,	O
and	O
the	O
ratio	O
between	O
them	O
was	O
used	O
to	O
evaluate	O
the	O
efficiency	O
of	O
the	O
de	O
##g	O
##lu	O
##cu	O
##ron	O
##ida	O
##tion	O
process	O
,	O
keeping	O
in	O
mind	O
that	O
e	O
##qui	O
##mo	O
##lar	O
amount	O
of	O
para	B
##ce	I
##tam	I
##ol	I
and	O
de	B
##uter	I
##ated	I
-	I
para	I
##ce	I
##tam	I
##ol	I
were	O
added	O
in	O
the	O
reaction	O
and	O
the	O
ion	O
##ization	O
efficiency	O
of	O
the	O
two	O
anal	O
##yte	O
##s	O
.	O

Form	B
##ic	I
acid	I
was	O
obtained	O
from	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
(	O
Z	O
##wi	O
##jn	O
##dre	O
##cht	O
,	O
The	O
Netherlands	O
)	O
.	O

Another	O
limitation	O
of	O
this	O
study	O
is	O
the	O
treatment	O
with	O
a	O
vitamin	O
mixture	O
(	O
the	O
single	O
in	O
##tra	O
##mus	O
##cular	O
dose	O
of	O
10	O
mg	O
c	B
##yan	I
##oc	I
##ob	I
##ala	I
##min	I
contained	O
100	O
mg	O
th	B
##iam	I
##in	I
and	O
100	O
mg	O
p	B
##yr	I
##ido	I
##xin	I
##e	I
)	O
.	O

For	O
the	O
external	O
valid	O
##ation	O
,	O
du	O
##plicate	O
sets	O
of	O
blinded	O
Q	O
##Cs	O
at	O
the	O
three	O
concentration	O
levels	O
were	O
exchanged	O
with	O
the	O
University	O
of	O
Pittsburgh	O
Cancer	O
Institute	O
where	O
a	O
valid	O
##ated	O
en	B
##zal	I
##uta	I
##mi	I
##de	I
ass	O
##ay	O
is	O
in	O
use	O
.	O

The	O
differences	O
in	O
the	O
levels	O
of	O
insulin	O
and	O
glucose	S
under	O
fast	O
##ing	O
condition	O
were	O
of	O
greater	O
significance	O
than	O
those	O
acquired	O
under	O
normal	O
ch	O
##ow	O
-	O
feeding	O
condition	O
.	O

The	O
patients	O
were	O
a	O
82	O
-	O
year	O
old	O
male	O
with	O
a	O
c	O
##ere	O
##bella	O
##r	O
in	O
##far	O
##ct	O
(	O
patient	O
3	O
)	O
,	O
a	O
46	O
-	O
year	O
old	O
female	O
with	O
sub	B
##ara	I
##ch	I
##no	I
##id	I
hem	O
##or	O
##r	O
##hage	O
(	O
patient	O
4	O
)	O
,	O
a	O
35	O
-	O
year	O
old	O
male	O
with	O
a	O
c	O
##ere	O
##bella	O
##r	O
in	O
##far	O
##ct	O
(	O
patient	O
5	O
)	O
,	O
and	O
a	O
55	O
-	O
year	O
old	O
female	O
with	O
a	O
tumor	O
(	O
patient	O
6	O
)	O
.	O

Ad	O
##dition	O
of	O
all	O
E	O
##M	O
,	O
the	O
sum	O
of	O
all	O
15	O
parent	O
est	O
##rogen	O
##s	O
and	O
est	B
##rogen	I
meta	O
##bol	O
##ites	O
,	O
to	O
a	O
model	O
containing	O
un	O
##con	O
##ju	O
##gated	O
est	B
##rad	I
##iol	I
changed	O
the	O
absolute	O
risk	O
estimate	O
by	O
at	O
least	O
14	O
%	O
for	O
only	O
14	O
%	O
of	O
the	O
women	O
.	O

Important	O
meta	O
##bol	O
##ites	O
for	O
distinguishing	O
CR	O
##C	O
from	O
EC	O
patients	O
included	O
the	O
T	O
##CA	O
cycle	O
intermediate	O
##s	O
(	O
f	O
##uma	O
##rate	O
and	O
c	B
##is	I
-	I
a	I
##con	I
##itate	I
)	O
,	O
amino	O
acid	O
metabolism	O
(	O
ho	O
##mo	O
##gent	O
##isi	O
##c	O
acid	O
,	O
in	B
##do	I
##lea	I
##ce	I
##tate	I
)	O
,	O
u	B
##rea	I
metabolism	O
(	O
c	O
##rea	O
##tin	O
##ine	O
,	O
c	B
##rea	I
##tine	I
and	O
u	O
##rea	O
)	O
,	O
n	O
##uc	O
##leo	O
##tide	O
metabolism	O
(	B
thy	B
##mi	I
##dine	I
and	O
u	O
##rac	O
##il	O
)	O
,	O
gut	O
micro	O
##f	O
##lora	O
-	O
derived	O
meta	O
##bol	O
##ites	O
(	O
hip	O
##pura	O
##te	O
)	O
,	O
g	O
##lut	O
##ami	O
##no	O
##lysis	O
meta	O
##bol	O
##ites	O
(	B
g	B
##lut	I
##amine	I
)	O
,	O
and	O
others	O
(	B
p	B
##yr	I
##ido	I
##xi	I
##c	I
acid	I
,	O
c	B
##inn	I
##ami	I
##c	I
acid	I
,	O
o	B
##xy	I
##pur	I
##ino	I
##l	I
,	O
and	O
t	B
##rig	I
##one	I
##llin	I
##e	I
)	O
(	O
Table	O
)	O
.	O

l	B
##ys	I
##o	I
##PC	I
(	I
16	I
:	I
0	I
)	I
and	O
l	B
##ys	I
##o	I
##PC	I
(	I
18	I
:	I
0	I
)	I
are	O
the	O
two	O
most	O
abundant	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
measured	O
in	O
plasma	O
.	O

The	O
observed	O
association	O
between	O
IL	O
-	O
10	O
and	O
k	B
##yn	I
##uren	I
##ine	I
is	O
unexpected	O
and	O
suggests	O
that	O
k	O
##yn	O
##uren	O
##ine	O
-	O
linked	O
mechanisms	O
promoting	O
negative	O
regulation	O
of	O
inflammatory	O
responses	O
are	O
associated	O
with	O
normal	O
immune	O
home	O
##ost	O
##asis	O
.	O

HP	O
##LC	O
-	O
grade	O
form	B
##ic	I
acid	I
,	O
dim	B
##eth	I
##yl	I
su	I
##lf	I
##oxide	I
(	O
D	O
##MS	O
##O	O
)	O
,	O
and	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
were	O
purchased	O
from	O
the	O
Ted	O
##ia	O
Company	O
,	O
Inc	O
.	O
(	O
Fairfield	O
,	O
OH	O
,	O
USA	O
)	O
.	O

shows	O
the	O
box	O
plots	O
of	O
selected	O
meta	O
##bol	O
##ites	O
with	O
significant	O
changes	O
(	O
i	O
.	O
e	O
.	O
,	O
al	B
##any	I
##l	I
##his	I
##ti	I
##dine	I
,	O
6	B
-	I
dim	I
##eth	I
##yla	I
##min	I
##op	I
##uri	I
##ne	I
,	O
le	B
##uc	I
##yl	I
##p	I
##rol	I
##ine	I
,	O
and	O
met	B
##hi	I
##oni	I
##ne	I
su	I
##lf	I
##oxide	I
)	O
.	O

Den	O
##ker	O
##t	O
et	O
al	O
.	O
found	O
in	O
a	O
comprehensive	O
study	O
al	B
##ani	I
##ne	I
,	O
met	B
##hi	I
##oni	I
##ne	I
,	O
th	B
##re	I
##oni	I
##ne	I
,	O
le	B
##uc	I
##ine	I
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
v	B
##ali	I
##ne	I
,	O
and	O
less	O
significantly	O
also	O
g	B
##ly	I
##cine	I
and	O
l	B
##ys	I
##ine	I
(	O
G	O
##C	O
-	O
TO	O
##F	O
MS	O
)	O
increased	O
in	O
human	O
CR	O
##C	O
tissues	O
,	O
Chan	O
et	O
al	O
.	O

K	B
##yn	I
##uren	I
##ine	I
and	O
D	B
-	I
er	I
##yt	I
##hr	I
##o	I
-	I
s	I
##phi	I
##ngo	I
##sin	I
##e	I
(	O
further	O
mentioned	O
as	O
s	B
##phi	I
##ngo	I
##sin	I
##e	I
for	O
br	O
##evity	O
)	O
were	O
purchased	O
from	O
C	O
##ayman	O
Chemical	O
##s	O
(	O
Ann	O
Arbor	O
,	O
MI	O
,	O
USA	O
)	O
.	O

Furthermore	O
test	B
##osterone	I
has	O
also	O
a	O
s	O
##ti	O
##mu	O
##lator	O
##y	O
effect	O
on	O
G	O
##L	O
##UT	O
##2	O
expression	O
and	O
g	O
##ly	O
##co	O
##gen	O
p	O
##hos	O
##ph	O
##ory	O
##lase	O
activity	O
.	O

Two	O
meta	O
##bol	O
##ites	O
,	O
m	O
/	O
z	O
246	O
.	O
95	O
##50	O
and	O
pipe	B
##rine	I
,	O
were	O
associated	O
with	O
MC	O
##I	O
(	O
vs	O
.	O
NC	O
)	O
in	O
A	O
##FT	O
models	O
adjusted	O
for	O
sex	O
and	O
age	O
,	O
both	O
in	O
the	O
same	O
direction	O
as	O
their	O
associations	O
with	O
AD	O
dem	O
##ent	O
##ia	O
.	O

In	O
general	O
,	O
s	O
##pect	O
##ra	O
corresponding	O
to	O
this	O
bio	O
##f	O
##lu	O
##id	O
contain	O
signals	O
from	O
a	O
wide	O
range	O
of	O
low	O
-	O
molecular	O
-	O
weight	O
meta	O
##bol	O
##ites	O
of	O
diverse	O
chemical	O
classes	O
(	O
Bo	O
##ua	O
##tra	O
et	O
al	O
.	O
)	O
,	O
including	O
organic	O
acids	O
,	O
simple	O
sugar	O
##s	O
and	O
p	B
##oly	I
##sa	I
##cc	I
##hari	I
##des	I
,	O
amino	O
acids	O
,	O
and	O
low	O
-	O
molecular	O
-	O
weight	O
proteins	O
.	O

If	O
plasma	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
her	O
##ald	O
in	O
##ci	O
##pie	O
##nt	O
ne	O
##uro	O
##de	O
##gene	O
##ration	O
,	O
it	O
may	O
be	O
useful	O
as	O
a	O
predict	O
##ive	O
bio	O
##mark	O
##er	O
.	O

1	O
,	O
very	O
-	O
low	O
density	O
lip	O
##op	O
##rote	O
##in	O
(	O
V	O
##LD	O
##L	O
)	O
;	O
2	O
,	O
ace	B
##tone	I
;	O
3	O
,	O
un	O
##sat	O
##ura	O
##ted	O
lip	O
##id	O
;	O
4	O
,	O
car	B
##ni	I
##tine	I
;	O
5	O
,	O
is	B
##ole	I
##uc	I
##ine	I
;	O
6	O
,	O
le	B
##uc	I
##ine	I
;	O
7	O
,	O
v	B
##ali	I
##ne	I
;	O
8	O
,	O
la	B
##ct	I
##ate	I
;	O
9	O
,	O
al	B
##ani	I
##ne	I
;	O
10	O
,	O
g	B
##ly	I
##cine	I
;	O
11	O
,	O
ace	B
##ty	I
##l	I
##cy	I
##stein	I
##e	I
;	O
13	O
,	O
c	B
##rea	I
##tine	I
;	O
15	O
,	O
ch	O
##o	O
-	O
line	O
;	O
16	O
,	O
g	B
##ly	I
##co	I
##p	I
##rote	I
##in	I
;	O
17	O
,	O
α	B
-	I
glucose	I
;	O
18	O
,	O
β	B
-	I
glucose	I
;	O
N	O
##MR	O
,	O
nuclear	O
magnetic	O
resonance	O
;	O
CS	O
##CC	O
,	O
c	O
##er	O
##vic	O
##al	O
sq	O
##ua	O
##mous	O
cell	O
car	O
##cin	O
##oma	O
;	O
C	O
##IN	O
,	O
c	O
##er	O
##vic	O
##al	O
in	O
##tra	O
##ep	O
##ith	O
##eli	O
##al	O
neo	O
##p	O
##lasia	O
.	O

Other	O
gut	O
-	O
derived	O
meta	O
##bol	O
##ites	O
from	O
PS	O
##PC	O
p	O
##oly	O
##phe	O
##no	O
##lic	O
##s	O
that	O
were	O
elevated	O
post	O
-	O
exercise	O
compared	O
to	O
place	O
##bo	O
included	O
2	B
-	I
h	I
##ydro	I
##xy	I
##hip	I
##pura	I
##te	I
(	O
interaction	O
effect	O
,	O
P	O
=	O
0	O
.	O
02	O
##21	O
)	O
,	O
3	B
-	I
h	I
##ydro	I
##xy	I
##hip	I
##pura	I
##te	I
(	O
P	O
=	O
0	O
.	O
03	O
##5	O
##2	O
)	O
,	O
cat	B
##ech	I
##ol	I
su	I
##lf	I
##ate	I
(	O
P	O
=	O
0	O
.	O
06	O
##8	O
##7	O
)	O
,	O
and	O
O	B
-	I
met	I
##hyl	I
##cate	I
##cho	I
##ls	I
##ulf	I
##ate	I
(	O
P	O
=	O
0	O
.	O
08	O
##5	O
)	O
.	O

Model	O
1	O
was	O
adjusted	O
for	O
age	O
,	O
sex	O
,	O
smoking	O
behavior	O
,	O
alcohol	O
consumption	O
,	O
low	O
-	O
density	O
lip	O
##oro	O
##tein	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
s	O
##ys	O
##to	O
##lic	O
blood	O
pressure	O
,	O
and	O
estimated	O
g	O
##lo	O
##mer	O
##ular	O
fi	O
##ltration	O
rate	O
.	O

The	O
direct	O
comparison	O
of	O
50	O
%	O
or	O
80	O
%	O
Me	B
##OH	I
as	O
que	O
##nch	O
##ing	O
buffer	O
showed	O
a	O
higher	O
sum	O
of	O
area	O
and	O
lower	O
median	O
RS	O
##Ds	O
when	O
using	O
50	O
_	O
H	O
##IG	O
##H	O
conditions	O
for	O
the	O
analyzed	O
cells	O
and	O
FC	O
##S	O
conditions	O
.	O

As	O
for	O
the	O
ta	O
##m	O
##N	O
##ox	O
to	O
ta	B
##mo	I
##xi	I
##fen	I
ratio	O
was	O
inverse	O
##ly	O
related	O
with	O
C	O
##YP	O
##2	O
##C	O
##19	O
predicted	O
activity	O
(	O
p	O
=	O
0	O
.	O
00	O
##1	O
,	O
figure	O
)	O
.	O

Pat	O
##ients	O
with	O
any	O
of	O
the	O
following	O
criteria	O
will	O
be	O
excluded	O
:	O
1	O
)	O
pregnant	O
and	O
la	O
##ct	O
##ating	O
;	O
2	O
)	O
have	O
any	O
gas	O
##tro	O
##int	O
##est	O
##inal	O
disorder	O
that	O
interfere	O
##s	O
the	O
bow	O
##el	O
function	O
,	O
severe	O
he	O
##pa	O
##tic	O
or	O
re	O
##nal	O
disease	O
(	O
dial	O
##ys	O
##is	O
)	O
,	O
an	O
infection	O
that	O
requires	O
anti	O
##biotics	O
within	O
three	O
weeks	O
;	O
3	O
)	O
on	O
insulin	O
regime	O
##n	O
;	O
4	O
)	O
Individuals	O
on	O
the	O
anti	O
##coa	O
##gu	O
##lant	O
drugs	O
such	O
as	O
war	O
##fari	O
##n	O
and	O
as	B
##pi	I
##rin	I
.	O

Moreover	O
,	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
(	O
P	O
##L	O
##s	O
)	O
,	O
which	O
are	O
the	O
highly	O
abundant	O
component	O
of	O
re	O
##nal	O
e	O
##pit	O
##hel	O
##ial	O
cell	O
membrane	O
,	O
are	O
detect	O
##able	O
in	O
the	O
urine	O
of	O
kidney	O
stone	O
former	O
##s	O
_	O
,	O
.	O

Ace	B
##tal	I
##de	I
##hy	I
##de	I
,	O
which	O
is	O
produced	O
from	O
p	B
##hos	I
##ph	I
##ory	I
##l	I
##cho	I
##line	I
,	O
is	O
the	O
link	O
between	O
the	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
and	O
p	B
##yr	I
##u	I
##vate	I
metabolic	O
pathways	O
.	O

Met	B
##han	I
##ol	I
,	O
is	B
##op	I
##rop	I
##ano	I
##l	I
,	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
and	O
water	O
for	O
HP	O
##LC	O
were	O
of	O
L	O
##C	O
-	O
MS	O
grade	O
and	O
obtained	O
from	O
Me	O
##rc	O
##k	O
K	O
##G	O
##a	O
##A	O
(	O
Dar	O
##ms	O
##tadt	O
,	O
Germany	O
)	O
.	O

It	O
has	O
been	O
previously	O
reported	O
that	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
insulin	O
resistance	O
,	O
and	O
ad	O
##ip	O
##os	O
##ity	O
are	O
significantly	O
correlated	O
with	O
left	O
vent	O
##ric	O
##ular	O
mass	O
in	O
h	O
##yper	O
##tensive	O
patients	O
.	O

The	O
voltage	O
of	O
the	O
detector	O
was	O
set	O
at	O
1	O
.	O
1	O
k	B
##V	I
.	O

In	O
##f	O
##lam	O
##mation	O
-	O
related	O
changes	O
in	O
the	O
concentrations	O
of	O
k	B
##yn	I
##uren	I
##ine	I
-	I
pathway	I
meta	O
##bol	O
##ites	O
occur	O
in	O
depression	O
secondary	O
to	O
medical	O
conditions	O
but	O
have	O
not	O
been	O
well	O
characterized	O
in	O
primary	O
bi	O
##pol	O
##ar	O
disorder	O
(	O
B	O
##D	O
)	O
,	O
with	O
con	O
##tra	O
##dict	O
##ory	O
results	O
potentially	O
at	O
##tri	O
##but	O
##able	O
to	O
the	O
presence	O
or	O
absence	O
of	O
ps	O
##ych	O
##osis	O
and	O
/	O
or	O
medication	O
effects	O
.	O

Overall	O
,	O
these	O
studies	O
show	O
that	O
red	O
c	O
##lover	O
and	O
its	O
is	B
##of	I
##lav	I
##ones	I
have	O
differential	O
effects	O
on	O
est	B
##rogen	I
metabolism	O
in	O
“	O
normal	O
”	O
vs	O
breast	O
cancer	O
cells	O
.	O

The	O
d	O
##ys	O
##re	O
##gu	O
##lated	O
lip	O
##id	O
and	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
metabolism	O
##s	O
showed	O
great	O
significance	O
in	O
cell	O
mortality	O
,	O
cell	O
invasion	O
and	O
t	O
##umour	O
meta	O
##sta	O
##sis	O
,	O
and	O
this	O
result	O
may	O
produce	O
enormous	O
t	O
##umour	O
bio	O
##mark	O
##ers	O
.	O

A	O
possible	O
decrease	O
in	O
24	B
##S	I
-	I
OH	I
-	I
Cho	I
##l	I
plasma	O
levels	O
has	O
been	O
reported	O
late	O
onset	O
Alzheimer	O
'	O
s	O
disease	O
(	O
L	O
##OA	O
##D	O
)	O
and	O
vascular	O
dem	O
##ent	O
##ia	O
(	O
V	O
##D	O
)	O
,	O
but	O
results	O
of	O
previous	O
studies	O
are	O
partially	O
con	O
##tra	O
##dict	O
##ory	O
.	O

These	O
associations	O
remained	O
significant	O
for	O
all	O
tested	O
meta	O
##bol	O
##ites	O
except	O
la	B
##ct	I
##ate	I
,	O
upon	O
adjusting	O
for	O
the	O
established	O
pro	O
##gno	O
##stic	O
parameters	O
in	O
H	O
##F	O
,	O
namely	O
age	O
,	O
sex	O
,	O
B	O
##MI	O
,	O
T	O
##2	O
##DM	O
,	O
N	O
##T	O
-	O
pro	O
##B	O
##NP	O
,	O
G	O
##F	O
##R	O
,	O
MA	O
##P	O
,	O
and	O
L	B
##D	I
##L	I
ch	I
##ole	I
##ster	I
##ol	I
.	O

In	O
addition	O
,	O
as	O
reported	O
by	O
Lawrence	O
G	O
.	O
Miller	O
Jr	O
.	O
et	O
al	O
.	O
,	O
the	O
elevation	O
of	O
So	O
levels	O
in	O
an	O
animal	O
model	O
of	O
Experimental	O
auto	O
##im	O
##mu	O
##ne	O
en	O
##ce	O
##pha	O
##lo	O
##my	O
##eli	O
##tis	O
(	O
EA	O
##E	O
)	O
spinal	O
cord	O
,	O
caused	O
by	O
de	O
no	O
##vo	O
synthesis	O
of	O
c	B
##era	I
##mi	I
##de	I
and	O
m	O
##od	O
##ulated	O
by	O
se	O
##rine	O
-	O
palm	O
##ito	O
##yl	O
##tra	O
##ns	O
##fer	O
##ase	O
(	O
SP	O
##T	O
)	O
activation	O
,	O
evolved	O
to	O
o	O
##li	O
##go	O
##den	O
##dr	O
##oc	O
##yte	O
cell	O
death	O
that	O
contributes	O
to	O
progressive	O
dem	O
##ye	O
##lina	O
##tion	O
in	O
Mu	O
##S	O
.	O

SP	O
##C	O
was	O
found	O
also	O
in	O
humans	O
occupational	O
##ly	O
exposed	O
to	O
0	O
–	O
23	O
pp	O
##m	O
ben	B
##zen	I
##e	I
.	O

β	B
-	I
act	I
##in	I
were	O
used	O
as	O
internal	O
controls	O
.	O

Q	O
##uant	O
##itative	O
analyses	O
were	O
carried	O
out	O
using	O
internal	O
standards	O
:	O
2	B
,	I
3	I
,	I
4	I
,	I
5	I
,	I
6	I
-	I
D	I
_	I
5	I
-	I
ben	I
##zoic	I
acid	I
for	O
BA	O
and	O
Ph	O
##PA	O
;	O
3	B
,	I
4	I
-	I
di	I
##hy	I
##dr	I
##ox	I
##y	I
##ben	I
##zoic	I
acid	I
for	O
Ph	O
##LA	O
,	O
p	O
-	O
HP	O
##h	O
##AA	O
,	O
and	O
p	O
-	O
HP	O
##h	O
##LA	O
.	O

Ace	B
##ty	I
##l	I
-	I
N	I
-	I
form	I
##yl	I
-	I
5	I
-	I
met	I
##ho	I
##xy	I
##ky	I
##nu	I
##rena	I
##mine	I
(	O
A	O
##FM	O
##K	O
)	O
and	O
in	B
##do	I
##le	I
##la	I
##ctic	I
acid	I
were	O
purchased	O
from	O
Ha	O
##or	O
##ui	O
Chemical	O
##s	O
and	O
See	O
##bio	O
B	O
##iot	O
##ech	O
(	O
s	O
##hang	O
##hai	O
)	O
Co	O
.	O
,	O
Ltd	O
,	O
respectively	O
.	O

It	O
is	O
not	O
clear	O
if	O
the	O
increase	O
in	O
s	B
##phi	I
##ngo	I
##lip	I
##id	I
classes	O
observed	O
in	O
the	O
e	O
##fa	O
##vir	O
##en	O
##z	O
arm	O
(	O
10	O
–	O
35	O
%	O
increase	O
compared	O
with	O
z	O
##ido	O
##vu	O
##dine	O
/	O
a	O
##ba	O
##ca	O
##vir	O
)	O
is	O
of	O
sufficient	O
magnitude	O
to	O
be	O
clinical	O
##ly	O
relevant	O
and	O
further	O
work	O
is	O
needed	O
to	O
determine	O
this	O
.	O

Although	O
its	O
response	O
to	O
systemic	O
o	O
##xi	O
##da	O
##tive	O
stress	O
is	O
not	O
as	O
pronounced	O
as	O
those	O
observed	O
in	O
F	B
##2	I
-	I
is	I
##op	I
##ros	I
##tan	I
##es	I
,	O
this	O
bio	O
##mark	O
##er	O
can	O
serve	O
an	O
important	O
role	O
in	O
divers	O
##ifying	O
the	O
panel	O
of	O
o	O
##xi	O
##da	O
##tive	O
in	O
##dices	O
available	O
for	O
the	O
assessment	O
of	O
o	O
##xi	O
##da	O
##tive	O
status	O
in	O
humans	O
.	O

In	O
addition	O
,	O
there	O
was	O
substantial	O
improvement	O
in	O
g	O
##ly	O
##cos	O
##yla	O
##tion	O
of	O
the	O
total	O
serum	O
N	B
-	I
g	I
##ly	I
##come	I
(	O
the	O
set	O
of	O
all	O
N	O
-	O
g	O
##ly	O
##cos	O
##yla	O
##ted	O
proteins	O
)	O
with	O
gal	B
##act	I
##ose	I
supplement	O
##ation	O
.	O

Recently	O
,	O
researchers	O
have	O
paid	O
much	O
attention	O
to	O
the	O
non	O
##ap	O
##eptide	O
o	B
##xy	I
##to	I
##cin	I
for	O
its	O
potential	O
involvement	O
in	O
depression	O
.	O

The	O
key	O
limiting	O
enzyme	O
of	O
the	O
BC	O
##AA	O
cat	O
##ab	O
##olic	O
process	O
,	O
branched	O
-	O
chain	O
α	O
-	O
k	O
##eto	O
acid	O
de	O
##hy	O
##dr	O
##ogen	O
##ase	O
(	O
BC	O
##K	O
##D	O
##H	O
)	O
,	O
is	O
activated	S
by	O
de	O
##ph	O
##os	O
##ph	O
##ory	O
##lation	O
with	O
mitochondrial	O
targeted	O
2	O
##C	O
-	O
type	O
se	O
##rine	O
/	O
th	O
##re	O
##oni	O
##ne	O
protein	O
p	O
##hos	O
##pha	O
##tase	O
(	O
PP	O
##2	O
##C	O
##m	O
)	O
.	O

For	O
each	O
sample	O
,	O
5	O
μ	O
L	O
of	O
diet	B
##hyl	I
##ami	I
##nob	I
##en	I
##zal	I
##de	I
##hy	I
##de	I
(	O
DE	O
##AB	O
)	O
,	O
a	O
specific	O
AL	O
##D	O
##H	O
inhibitor	O
,	O
was	O
added	O
to	O
0	O
.	O
5	O
m	O
##L	O
of	O
Al	O
##de	O
##f	O
##lu	O
##or	O
-	O
stained	O
cells	O
as	O
a	O
negative	O
control	O
.	O

The	O
meta	O
##bol	O
##omi	O
##c	O
profile	O
was	O
explicitly	O
described	O
in	O
the	O
case	O
of	O
g	O
##lio	O
##mas	O
,	O
indicating	O
a	O
decrease	O
in	O
N	B
-	I
ace	I
##ty	I
##l	I
as	I
##par	I
##tate	I
and	O
2	B
-	I
h	I
##ydro	I
##xy	I
##g	I
##lut	I
##ari	I
##c	I
acid	I
,	O
while	O
this	O
was	O
not	O
very	O
well	O
achieved	O
in	O
PA	O
.	O

Mean	O
estimated	O
total	O
clearance	O
of	O
f	O
##ent	O
##any	O
##l	O
and	O
mean	O
metabolic	O
clearance	O
of	O
mid	B
##az	I
##ola	I
##m	I
(	O
as	O
a	O
marker	O
of	O
C	O
##YP	O
##3	O
##A	O
activity	O
)	O
were	O
75	O
.	O
5	O
and	O
36	O
.	O
3	O
L	O
/	O
h	O
.	O

Our	O
results	O
showed	O
g	B
##ly	I
##cer	I
##oli	I
##pid	I
metabolism	O
and	O
related	O
meta	O
##bol	O
##ites	O
(	O
including	O
g	B
##ly	I
##cer	I
##ol	I
,	O
g	B
##ly	I
##cer	I
##ol	I
3	I
-	I
phosphate	I
and	O
g	B
##ly	I
##cer	I
##ald	I
##eh	I
##yd	I
##e	I
)	O
differed	O
between	O
V	O
.	O
SC	O
and	O
N	O
##V	O
.	O
SC	O
.	O

The	O
standards	O
of	O
meta	O
##bol	O
##ites	O
(	B
L	B
-	I
a	I
##rg	I
##ini	I
##ne	I
,	O
L	B
-	I
his	I
##ti	I
##dine	I
,	O
L	B
-	I
as	I
##par	I
##tic	I
acid	I
,	O
la	B
##ctic	I
acid	I
,	O
and	O
c	O
##it	O
##ric	O
acid	O
)	O
were	O
added	O
into	O
the	O
blank	O
urine	O
in	O
accordance	O
with	O
low	O
(	O
20	O
μ	O
M	O
)	O
,	O
middle	O
(	O
50	O
μ	O
M	O
)	O
,	O
and	O
high	O
(	O
80	O
μ	O
M	O
)	O
concentration	O
;	O
each	O
Q	O
##C	O
sample	O
was	O
repeatedly	O
measured	O
three	O
times	O
continuously	O
.	O

The	O
cells	O
were	O
transferred	O
to	O
a	O
H	O
##EP	O
##ES	O
-	O
balanced	O
salt	O
solution	O
with	O
10	O
m	O
##M	O
glucose	S
and	O
image	O
##d	O
live	O
by	O
e	O
##pi	O
##f	O
##lu	O
##ores	O
##cence	O
in	O
both	O
flu	B
##ores	I
##ce	I
##in	I
and	O
r	B
##ho	I
##dam	I
##ine	I
channels	O
.	O

Indeed	O
,	O
the	O
high	O
respiratory	O
exchange	O
ratio	O
for	O
car	O
##bo	O
##hy	O
##dra	O
##te	O
oxidation	O
is	O
the	O
proof	O
that	O
fat	O
oxidation	O
requires	O
more	O
oxygen	O
than	O
car	O
##bo	O
##hy	O
##dra	O
##te	O
oxidation	O
to	O
produce	O
ATP	S
,	O
making	O
glucose	S
more	O
efficient	O
as	O
a	O
fuel	O
source	O
.	O

For	O
the	O
pilot	O
studies	O
,	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
(	O
10	O
µ	O
##m	O
)	O
and	O
a	O
N	O
##AD	O
##P	O
##H	O
-	O
generating	O
system	O
(	O
13	O
mm	O
N	B
##AD	I
##P	I
,	O
33	O
mm	O
glucose	B
6	I
-	I
phosphate	I
,	O
33	O
mm	O
M	O
##g	O
##C	O
##l	O
_	O
2	O
,	O
and	O
0	O
.	O
4	O
U	O
m	O
##l	O
_	O
−	O
##1	O
glucose	O
6	O
-	O
phosphate	O
de	O
##hy	O
##dr	O
##ogen	O
##ase	O
)	O
in	O
potassium	B
phosphate	I
buffer	O
(	O
pH	O
7	O
.	O
4	O
)	O
were	O
allowed	O
to	O
e	O
##qui	O
##li	O
##bra	O
##te	O
for	O
5	O
min	O
at	O
37	O
##°	O
##C	O
.	O

These	O
are	O
s	B
##te	I
##aro	I
##yl	I
s	I
##phi	I
##ngo	I
##my	I
##elin	I
(	I
s	I
##phi	I
##ngo	I
##lip	I
##id	I
metabolism	I
)	I
,	O
v	B
##ale	I
##rate	I
(	O
short	O
-	O
chain	O
fatty	O
acid	O
metabolism	O
)	O
,	O
7	B
-	I
k	I
##eto	I
##de	I
##ox	I
##ych	I
##olate	I
and	O
de	B
##ox	I
##ych	I
##olate	I
(	O
secondary	O
bi	O
##le	O
acid	O
metabolism	O
)	O
,	O
f	B
##ru	I
##ct	I
##ose	I
-	I
6	I
-	I
phosphate	I
and	O
glucose	O
-	O
6	O
-	O
phosphate	O
(	O
g	O
##ly	O
##co	O
##lysis	O
,	O
g	O
##lu	O
##con	O
##eo	O
##genesis	O
,	O
and	O
p	B
##yr	I
##u	I
##vate	I
metabolism	I
)	I
,	O
so	B
##rb	I
##ito	I
##l	I
(	O
f	O
##ru	O
##ct	O
##ose	O
,	O
man	B
##nose	I
,	O
and	O
gal	B
##act	I
##ose	I
metabolism	O
)	O
,	O
4	B
-	I
h	I
##ydro	I
##xy	I
##phe	I
##ny	I
##l	I
##p	I
##ru	I
##vate	I
(	I
p	I
##hen	I
##yla	I
##lani	I
##ne	I
and	O
t	B
##yr	I
##os	I
##ine	I
metabolism	I
)	I
,	O
is	O
##ob	O
##ar	O
:	O
beta	B
##ine	I
al	I
##de	I
##hy	I
##de	I
,	O
N	B
-	I
met	I
##hyl	I
##die	I
##than	I
##ola	I
##mine	I
(	I
g	I
##ly	I
##cine	I
,	I
se	I
##rine	I
,	O
and	O
th	B
##re	I
##oni	I
##ne	I
metabolism	I
)	I
,	O
2	B
-	I
amino	I
##adi	I
##pate	I
(	I
l	I
##ys	I
##ine	I
metabolism	I
)	I
,	O
as	B
##par	I
##agi	I
##ne	I
(	I
al	I
##ani	I
##ne	I
and	O
as	B
##par	I
##tate	I
metabolism	I
)	I
,	O
c	B
##ys	I
-	I
g	I
##ly	I
,	O
o	O
##xi	O
##dized	O
(	B
g	B
##lut	I
##ath	I
##ione	I
metabolism	O
)	O
,	O
alpha	B
-	I
h	I
##ydro	I
##xy	I
##is	I
##ova	I
##ler	I
##ate	I
and	O
v	B
##ale	I
##rate	I
(	I
le	I
##uc	I
##ine	I
,	I
is	I
##ole	I
##uc	I
##ine	I
,	O
and	O
v	B
##ali	I
##ne	I
metabolism	I
)	I
,	O
and	O
N	B
##1	I
-	I
met	I
##hyl	I
-	I
2	I
-	I
p	I
##yr	I
##ido	I
##ne	I

24	O
individuals	O
(	O
16	O
norm	B
##og	I
##ly	I
##ce	I
##mic	I
and	O
8	O
di	O
##abe	O
##tic	O
)	O
chose	O
AG	O
##B	O
and	O
67	O
individuals	O
(	O
28	O
norm	B
##og	I
##ly	I
##ce	I
##mic	I
and	O
39	O
di	O
##abe	O
##tic	O
)	O
chose	O
R	O
##Y	O
##GB	O
.	O

Compared	O
with	O
the	O
control	O
group	O
,	O
the	O
N	O
##SC	O
##LC	O
group	O
showed	O
elevated	O
levels	O
of	O
la	B
##ct	I
##ate	I
,	O
al	B
##ani	I
##ne	I
,	O
g	B
##lut	I
##ama	I
##te	I
,	O
pro	B
##line	I
,	O
g	B
##ly	I
##co	I
##p	I
##rote	I
##in	I
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
t	B
##yr	I
##os	I
##ine	I
and	O
try	B
##pt	I
##op	I
##han	I
,	O
and	O
decreased	O
levels	O
of	O
glucose	S
,	O
ta	B
##uri	I
##ne	I
,	O
g	B
##lut	I
##amine	I
,	O
g	B
##ly	I
##cine	I
,	O
p	B
##hos	I
##ph	I
##oc	I
##rea	I
##tine	I
and	O
th	B
##re	I
##oni	I
##ne	I
,	O
which	O
could	O
be	O
partially	O
or	O
completely	O
reversed	O
by	O
MW	O
##A	O
treatment	O
.	O

Con	O
##sist	O
##ent	O
with	O
such	O
hypothesis	O
,	O
our	O
results	O
indeed	O
points	O
to	O
elevated	O
levels	O
of	O
glucose	S
,	O
g	B
##ly	I
##cer	I
##ol	I
and	O
FF	O
##A	O
as	O
palm	B
##itic	I
,	O
s	O
##te	O
##ari	O
##c	O
,	O
l	B
##ino	I
##le	I
##ic	I
,	O
and	O
o	B
##le	I
##ic	I
acid	I
in	O
the	O
serum	O
of	O
ST	O
##EM	O
##I	O
patients	O
(	O
and	O
)	O
.	O

Models	O
were	O
constructed	O
using	O
either	O
the	O
complete	O
digitally	O
reduced	O
spectrum	O
(	O
excluding	O
water	O
and	O
u	B
##rea	I
resonance	O
##s	O
)	O
or	O
only	O
selected	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
meta	O
##bol	O
##ite	O
regions	O
(	O
δ	O
1	O
.	O
84	O
–	O
1	O
.	O
88	O
,	O
2	O
.	O
13	O
–	O
2	O
.	O
25	O
and	O
7	O
.	O
13	O
–	O
7	O
.	O
49	O
)	O
;	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
g	I
##lu	I
##cu	I
##ron	I
##ide	I
resonance	O
##s	O
present	O
in	O
the	O
regions	O
δ	O
3	O
.	O
62	O
and	O
3	O
.	O
88	O
were	O
not	O
included	O
due	O
to	O
significant	O
overlap	O
with	O
other	O
resonance	O
##s	O
,	O
e	O
.	O
g	O
.	O
,	O
glucose	S
signals	O
making	O
it	O
difficult	O
to	O
distinguish	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
meta	O
##bol	O
##ites	O
from	O
end	O
##ogen	O
##ous	O
and	O
other	O
ex	O
##ogen	O
##ous	O
resonance	O
##s	O
.	O

Finally	O
,	O
while	O
early	O
(	O
up	O
to	O
5	O
minute	O
post	O
r	O
##ins	O
##e	O
)	O
sa	O
##liva	O
samples	O
obtained	O
from	O
all	O
three	O
r	O
##ins	O
##e	O
groups	O
showed	O
detect	O
##able	O
levels	O
of	O
the	O
a	B
##gly	I
##con	I
##e	I
,	O
c	B
##yan	I
##id	I
##in	I
,	O
in	O
all	O
donors	O
,	O
c	B
##yan	I
##id	I
##in	I
levels	O
rapidly	O
decreased	O
and	O
were	O
und	O
##ete	O
##ct	O
##able	O
in	O
all	O
samples	O
from	O
all	O
r	O
##ins	O
##es	O
by	O
60	O
minutes	O
(	O
data	O
not	O
shown	O
)	O
.	O

In	O
order	O
to	O
analyze	O
sample	O
with	O
an	O
even	O
higher	O
concentration	O
,	O
samples	O
with	O
pro	B
##line	I
concentration	O
of	O
400	O
or	O
800	O
μ	O
##g	O
/	O
m	O
##L	O
were	O
di	O
##lut	O
##ed	O
5	O
or	O
10	O
times	O
before	O
analysis	O
,	O
and	O
evaluated	O
for	O
accuracy	O
and	O
precision	O
.	O

A	O
decrease	O
in	O
se	B
##rine	I
and	O
th	B
##re	I
##oni	I
##ne	I
content	O
of	O
the	O
cart	O
##ila	O
##ge	O
pro	B
##te	I
##og	I
##ly	I
##can	I
in	O
anti	O
##gen	O
-	O
induced	O
art	O
##hr	O
##itis	O
of	O
rabbit	O
,	O
supporting	O
our	O
findings	O
showing	O
the	O
decreased	O
levels	O
of	O
is	O
##ova	O
##ler	O
##yl	O
##sar	O
##cos	O
##ine	O
in	O
A	O
##OS	O
##D	O
patients	O
with	O
chronic	O
art	O
##icular	O
pattern	O
of	O
disease	O
outcome	O
.	O

The	O
radical	O
cat	O
##ion	O
at	O
m	O
/	O
z	O
315	O
.	O
2	O
[	O
M	O
+	O
H	O
-	O
C	O
_	O
2	O
H	O
_	O
4	O
NO	O
_	O
2	O
•	O
]	O
_	O
+	O
(	O
m	O
/	O
z	O
320	O
.	O
2	O
for	O
des	B
##ami	I
##no	I
-	I
[	I
_	I
2	I
H	I
_	I
5	I
]	I
-	O
Ph	O
##IP	O
-	O
Y	O
)	O
is	O
proposed	O
to	O
arise	O
by	O
ho	O
##mo	O
##ly	O
##tic	O
c	O
##lea	O
##vage	O
of	O
the	O
bond	O
between	O
the	O
α	O
and	O
β	B
-	I
carbon	I
atoms	O
of	O
t	B
##yr	I
##os	I
##ine	I
;	O
this	O
is	O
an	O
uncommon	O
mechanism	O
of	O
fragment	O
##ation	O
of	O
amino	O
acids	O
by	O
E	O
##SI	O
-	O
MS	O
under	O
low	O
-	O
energy	O
C	O
##ID	O
conditions	O
.	O

The	O
correlation	O
coefficients	O
between	O
the	O
formation	O
rates	O
of	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
meta	O
##bol	O
##ites	O
and	O
the	O
activity	O
of	O
each	O
C	O
##YP	O
is	O
##of	O
##orm	O
in	O
different	O
H	O
##LM	O
##s	O
were	O
calculated	O
(	O
see	O
Data	O
analysis	O
)	O
.	O

Our	O
main	O
finding	O
was	O
that	O
the	O
human	O
liver	O
tissue	O
can	O
execute	O
su	O
##lf	O
##ation	O
of	O
m	B
##or	I
##phine	I
both	O
at	O
position	O
3	O
and	O
6	O
,	O
even	O
in	O
the	O
newborn	O
period	O
.	O

The	O
elevated	O
level	O
of	O
format	B
##e	I
might	O
reflect	O
a	O
ma	O
##lf	O
##un	O
##ction	O
of	O
brain	O
mit	O
##och	O
##ond	O
##ria	O
as	O
well	O
as	O
o	O
##xi	O
##da	O
##tive	O
stress	O
.	O

E	O
##pid	O
##em	O
##iol	O
##og	O
##ic	O
research	O
has	O
also	O
highlighted	O
relationships	O
between	O
PD	O
and	O
pu	B
##rine	I
compounds	O
.	O

Thus	O
,	O
the	O
activation	O
of	O
g	O
##lut	O
##ami	O
##no	O
##lysis	O
represents	O
an	O
adaptive	O
reaction	O
of	O
cells	O
to	O
produce	O
energy	O
as	O
a	O
consequence	O
of	O
the	O
deficiency	O
of	O
test	B
##osterone	I
but	O
only	O
when	O
insulin	O
is	O
active	O
,	O
while	O
it	O
disappears	O
in	O
the	O
I	O
##R	O
stage	O
.	O

U	O
##rine	O
hip	B
##pur	I
##ic	I
acid	I
was	O
elevated	O
in	O
at	O
##her	O
##os	O
##cle	O
##rot	O
##ic	O
rats	O
in	O
a	O
single	O
study	O
.	O

The	O
two	O
out	O
##liers	O
in	O
the	O
C	O
##LF	O
group	O
exhibited	O
high	O
levels	O
of	O
ethanol	S
:	O
1	O
.	O
11	O
and	O
3	O
.	O
66	O
pp	O
##m	O
.	O

Na	O
_	O
2	O
HP	O
##O	O
_	O
4	O
·	O
7	O
##H	O
_	O
2	O
O	O
;	O
6	O
.	O
1	O
m	O
##M	O
Na	O
##N	O
_	O
3	O
;	O
4	O
.	O
6	O
m	O
##M	O
sodium	B
trim	I
##eth	I
##yl	I
##si	I
##ly	I
##l	I
[	I
2	I
,	I
2	I
,	I
3	I
,	I
3	I
-	I
_	I
2	I
H	I
_	I
4	I
]	I
prop	I
##ion	I
##ate	I
(	O
T	O
##MS	O
##P	O
)	O
,	O
20	O
%	O
(	O
v	O
/	O
v	O
)	O
_	O
2	O
H	O
_	O
2	O
O	O
in	O
H	O
_	O
2	O
O	O
;	O
pH	O
7	O
.	O
4	O
)	O
was	O
added	O
to	O
350	O
µ	O
##L	O
of	O
each	O
sample	O
,	O
and	O
the	O
mixture	O
was	O
ho	O
##mo	O
##gen	O
##ized	O
by	O
v	O
##ortex	O
##ing	O
for	O
30	O
s	O
.	O

Group	O
differences	O
in	O
a	B
##cy	I
##l	I
-	I
car	I
##ni	I
##tine	I
concentrations	O
in	O
our	O
study	O
may	O
be	O
explained	O
by	O
a	O
composition	O
##al	O
difference	O
in	O
the	O
study	O
formula	O
##e	O
.	O

The	O
strongest	O
association	O
with	O
serum	O
re	B
##tino	I
##l	I
was	O
seen	O
for	O
N	B
-	I
ace	I
##ty	I
##ltry	I
##pt	I
##op	I
##han	I
(	O
β	O
=	O
0	O
.	O
27	O
per	O
SD	O
increase	O
in	O
re	B
##tino	I
##l	I
concentration	O
;	O
p	O
=	O
9	O
.	O
9	O
×	O
10	O
_	O
−	O
##17	O
)	O
,	O
followed	O
by	O
the	O
lip	O
##ids	O
my	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
and	O
1	B
-	I
palm	I
##ito	I
##yl	I
##gly	I
##cer	I
##op	I
##hos	I
##ph	I
##oe	I
##than	I
##ola	I
##mine	I
,	O
the	O
amino	O
acid	O
4	O
-	O
ace	O
##tam	O
##ido	O
##but	O
##ano	O
##ate	O
,	O
and	O
the	O
pu	B
##rine	I
N	I
##6	I
-	I
car	I
##ba	I
##mo	I
##yl	I
##th	I
##re	I
##ony	I
##lade	I
##nos	I
##ine	I
(	O
β	O
=	O
0	O
.	O
23	O
,	O

Pro	B
##ges	I
##tero	I
##ne	I
,	O
17	B
-	I
h	I
##ydro	I
##xy	I
##p	I
##rog	I
##ester	I
##one	I
and	O
11	B
-	I
de	I
##ox	I
##y	I
##cor	I
##tic	I
##osterone	I
were	O
55	O
%	O
to	O
98	O
%	O
lower	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
in	O
post	O
##men	O
##op	O
##aus	O
##al	O
than	O
younger	O
women	O
who	O
were	O
not	O
taking	O
oral	O
con	O
##tra	O
##ceptive	O
##s	O
.	O

Mo	B
##rp	I
##hine	I
can	O
be	O
administered	O
oral	O
##ly	O
or	O
via	O
s	O
.	O
c	O
.	O
,	O
i	O
.	O
m	O
.	O
or	O
i	O
.	O
v	O
.	O

There	O
were	O
no	O
significant	O
differences	O
for	O
specific	O
heart	O
conditions	O
or	O
current	O
heart	O
medications	O
between	O
the	O
subjects	O
according	O
to	O
c	B
##ys	I
##tat	I
##hi	I
##oni	I
##ne	I
group	O
.	O

AC	O
##N	O
in	O
10	O
m	O
##M	O
am	B
##mon	I
##ium	I
format	I
##e	I
and	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
and	O
phase	O
B	O
of	O
90	O
:	O
10	O
IPA	O
:	O
AC	O
##N	O
also	O
with	O
10	O
m	O
##M	O
am	B
##mon	I
##ium	I
format	I
##e	I
and	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
.	O

We	O
examined	O
whether	O
the	O
addition	O
of	O
u	O
##rina	O
##ry	O
my	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
could	O
better	O
disc	O
##rim	O
##inate	O
F	O
##S	O
##GS	O
compared	O
to	O
traditional	O
clinical	O
parameters	O
,	O
including	O
protein	O
##uria	O
and	O
su	O
##PA	O
##R	O
(	O
Table	O
)	O
.	O

PC	O
##s	O
were	O
known	O
as	O
the	O
most	O
abundant	O
bi	O
##layer	O
-	O
forming	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
found	O
in	O
e	O
##uka	O
##ryo	O
##tic	O
membrane	O
##s	O
and	O
can	O
contribute	O
to	O
pro	O
##life	O
##rative	O
growth	O
in	O
cancer	O
cells	O
[	O
,	O
]	O
.	O

For	O
the	O
DC	O
##M	O
method	O
,	O
the	O
P	O
##U	O
##LS	O
##E	O
Tu	O
##bes	O
were	O
modified	O
with	O
(	O
DC	O
##M	O
-	O
resistant	O
)	O
ultra	O
##hi	O
##gh	O
purity	O
flu	B
##oro	I
##pol	I
##yme	I
##r	I
O	O
-	O
rings	O
.	O

The	O
accuracy	O
was	O
better	O
for	O
ch	B
##ole	I
##ster	I
##ol	I
(	O
AU	O
##C	O
:	O
0	O
.	O
76	O
,	O
P	O
<	O
0	O
.	O
000	O
##1	O
)	O
than	O
for	O
la	B
##ct	I
##ate	I
(	O
AU	O
##C	O
:	O
0	O
.	O
73	O
,	O
P	O
=	O
0	O
.	O
000	O
##3	O
)	O
.	O

For	O
the	O
cell	O
line	O
studies	O
,	O
the	O
cells	O
were	O
grown	O
in	O
trip	O
##lica	O
##te	O
in	O
10	O
-	O
cm	O
dishes	O
and	O
,	O
48	O
h	O
after	O
p	O
##lating	O
,	O
were	O
extracted	O
with	O
1	O
m	O
##L	O
of	O
80	O
%	O
met	B
##han	I
##ol	I
and	O
spun	O
.	O

We	O
also	O
found	O
that	O
elevated	O
plasma	O
x	B
##ant	I
##hine	I
and	O
in	B
##os	I
##ine	I
levels	O
were	O
associated	O
with	O
a	O
higher	O
T	O
##2	O
##D	O
risk	O
in	O
individuals	O
with	O
T	O
##T	O
all	O
##ele	O
##s	O
on	O
r	O
##s	O
##7	O
##90	O
##31	O
##46	O
.	O

Tri	B
##ter	I
##pen	I
##e	I
1	O
was	O
c	O
##yt	O
##oto	O
##xi	O
##c	O
against	O
human	O
co	O
##lon	O
car	O
##cin	O
##oma	O
116	O
with	O
an	O
I	O
##C	O
_	O
50	O
value	O
of	O
28	O
.	O
7	O
but	O
did	O
not	O
exhibit	O
c	O
##yt	O
##oto	O
##xi	O
##city	O
against	O
A	O
##5	O
##4	O
##9	O
.	O

Treatment	O
with	O
EC	O
##T	O
was	O
associated	O
with	O
a	O
significant	O
decrease	O
in	O
the	O
plasma	O
levels	O
of	O
try	B
##pt	I
##op	I
##han	I
(	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
k	B
##yn	I
##uren	I
##ine	I
(	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
and	O
Q	O
##UI	O
##N	O
(	O
P	O
<	O
0	O
.	O
00	O
##1	O
)	O
,	O
whereas	O
plasma	O
levels	O
of	O
K	O
##Y	O
##NA	O
did	O
not	O
change	O
.	O

Interest	O
##ingly	O
,	O
N	O
##MR	O
detect	O
##s	O
20	O
compounds	O
that	O
G	O
##C	O
-	O
MS	O
methods	O
cannot	O
detect	O
while	O
G	O
##C	O
-	O
MS	O
detect	O
##s	O
45	O
compounds	O
that	O
N	O
##MR	O
cannot	O
routinely	O
detect	O
,	O
including	O
3	O
very	O
high	O
abundance	O
compounds	O
(	B
p	B
##hos	I
##ph	I
##ori	I
##c	I
acid	I
/	O
phosphate	O
,	O
u	B
##ric	I
acid	I
and	O
N	B
-	I
ace	I
##ty	I
##l	I
-	I
g	I
##ly	I
##cine	I
)	O
.	O

We	O
further	O
investigated	O
the	O
content	O
changes	O
of	O
the	O
103	O
th	B
##iol	I
##s	I
in	O
5	O
types	O
of	O
cancer	O
urine	O
samples	O
(	O
na	O
##so	O
##pha	O
##ryn	O
##ge	O
##al	O
cancer	O
,	O
es	O
##op	O
##ha	O
##gus	O
cancer	O
,	O
gas	O
##tric	O
cancer	O
,	O
l	O
##ymph	O
cancer	O
,	O
and	O
lung	O
cancer	O
)	O
compared	O
to	O
the	O
healthy	O
controls	O
by	O
our	O
developed	O
IL	O
-	O
L	O
##C	O
-	O
MR	O
##M	O
-	O
MS	O
method	O
.	O

That	O
means	O
that	O
a	O
test	O
using	O
glucose	S
as	O
a	O
feature	O
is	O
prone	O
to	O
interference	O
by	O
g	O
##lu	O
##cos	O
##uria	O
and	O
thus	O
und	O
##esi	O
##rable	O
.	O

On	O
the	O
other	O
hand	O
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
in	O
N	O
##F	O
tumors	O
was	O
found	O
to	O
be	O
elevated	O
in	O
both	O
serum	O
and	O
W	O
##B	O
when	O
compared	O
with	O
pro	O
##la	O
##ct	O
##ino	O
##mas	O
but	O
it	O
met	O
the	O
statistical	O
significance	O
criteria	O
(	O
p	O
≤	O
0	O
.	O
00	O
##28	O
)	O
only	O
in	O
the	O
serum	O
.	O

O	O
##bs	O
##erve	O
##d	O
ace	B
##ty	I
##l	I
##cho	I
##line	I
concentrations	O
in	O
normal	O
patients	O
reach	O
30	O
##±	O
##10	O
n	O
##M	O
,	O
compared	O
to	O
8	O
##±	O
##4	O
n	O
##M	O
in	O
AD	O
patients	O
.	O

Met	O
##ab	O
##oli	O
##tes	O
identified	O
in	O
N	O
##MR	O
and	O
P	O
##LS	O
-	O
D	O
##A	O
as	O
significant	O
in	O
different	O
##iating	O
low	O
–	O
and	O
high	B
–	I
c	I
##ys	I
##tat	I
##hi	I
##oni	I
##ne	I
concentration	O
groups	O
with	O
the	O
use	O
of	O
the	O
VIP	O
spectral	O
plot	O
shown	O
in	O
_	O
1	O
Score	O
plot	O
from	O
partial	O
least	O
squares	O
disc	O
##rim	O
##ina	O
##nt	O
analysis	O
of	O
_	O
1	O
H	O
-	O
N	O
##MR	O
s	O
##pect	O
##ra	O
in	O
adults	O
with	O
high	O
or	O
low	O
plasma	O
c	B
##ys	I
##tat	I
##hi	I
##oni	I
##ne	I
concentrations	O
.	O

This	O
g	B
##lu	I
##co	I
##cor	I
##tic	I
##oid	I
has	O
a	O
highly	O
relevant	O
role	O
in	O
the	O
complications	O
of	O
age	O
‐	O
related	O
de	O
##gene	O
##rative	O
diseases	O
,	O
45	O
and	O
the	O
regulation	O
of	O
muscle	O
mass	O
mediated	O
by	O
co	O
##rt	O
##is	O
##ol	O
.	O
46	O

A	B
##rg	I
##ini	I
##ne	I
,	O
c	B
##it	I
##ru	I
##llin	I
##e	I
,	O
g	B
##lut	I
##ami	I
##c	I
γ	I
-	I
semi	I
##ald	I
##eh	I
##yd	I
##e	I
,	O
and	O
de	B
##hy	I
##dr	I
##ox	I
##y	I
##car	I
##ni	I
##tine	I
were	O
key	O
contributors	O
to	O
these	O
pathway	O
differences	O
.	O

Total	O
levels	O
of	O
Spin	B
##go	I
##my	I
##elin	I
##s	I
in	O
human	O
ca	O
##da	O
##ver	O
corn	O
##eas	O
from	O
Health	O
##y	O
,	O
T	O
##1	O
##DM	O
,	O
and	O
T	O
##2	O
##DM	O
donors	O
.	O

Ph	B
##os	I
##ph	I
##oli	I
##pid	I
##s	I
for	O
relative	O
q	O
##uant	O
##ification	O
were	O
extracted	O
as	O
neutral	O
lip	O
##ids	O
but	O
with	O
2	O
%	O
ace	B
##tic	I
acid	I
in	O
the	O
presence	O
of	O
the	O
internal	O
##s	O
standards	O
(	B
Ce	B
##r	I
(	I
d	I
##18	I
:	I
1	I
/	I
15	I
:	I
0	I
)	I
16	O
ng	O
;	O
P	B
##E	I
(	I
12	I
:	I
0	I
/	I
12	I
:	I
0	I
)	I
180	O
ng	O
;	O
PC	B
(	I
13	I
:	I
0	I
/	I
13	I
:	I
0	I
)	I

To	O
replica	O
##te	O
the	O
main	O
meta	O
##bol	O
##omi	O
##cs	O
findings	O
of	O
the	O
H	O
##UN	O
##T	O
study	O
,	O
we	O
also	O
analyzed	O
urine	O
and	O
blood	O
samples	O
from	O
the	O
Study	O
of	O
G	B
##lu	I
##cos	I
##e	I
and	O
In	O
##sul	O
##in	O
in	O
Ren	O
##al	O
Disease	O
(	O
S	O
##U	O
##GA	O
##R	O
)	O
.	O

For	O
a	O
key	O
to	O
the	O
identity	O
of	O
i	B
##bu	I
##p	I
##ro	I
##fen	I
meta	O
##bol	O
##ites	O
,	O
refer	O
to	O
and	O
.	O
_	O
1	O
H	O
and	O
_	O
13	O
C	O
N	O
##MR	O
Chemical	O
Shi	O
##fts	O
and	O
Co	O
##up	O
##ling	O
Con	O
##stant	O
##s	O
(	O
J	O
/	O
Hz	O
)	O
for	O
Ace	B
##tam	I
##ino	I
##phe	I
##n	I
and	O
Its	O
Met	O
##ab	O
##oli	O
##tes	O
The	O
PC	O
##A	O
model	O
which	O
based	O
on	O
all	O
the	O
42	O
##90	O
urine	O
s	O
##pect	O
##ra	O
was	O
used	O
to	O
identify	O
41	O
##3	O
samples	O
containing	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
and	O
its	O
meta	O
##bol	O
##ites	O
with	O
the	O
remaining	O
38	O
##7	O
##7	O
urine	O
s	O
##pect	O
##ra	O
not	O
showing	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
meta	O
##bol	O
##ites	O
.	O

Go	O
to	O
:	O
It	O
has	O
been	O
suggested	O
that	O
the	O
concentrations	O
of	O
ta	B
##mo	I
##xi	I
##fen	I
and	O
its	O
dem	O
##eth	O
##yla	O
##ted	O
meta	O
##bol	O
##ites	O
increase	O
with	O
age	O
.	O

Ole	B
##ami	I
##de	I
(	I
c	I
##is	I
-	I
9	I
,	I
10	I
-	I
o	I
##ct	I
##ade	I
##ce	I
##no	I
##ami	I
##de	I
)	I
was	O
at	O
a	O
consistently	O
low	O
level	O
from	O
stage	O
I	O
to	O
IV	O
.	O

However	O
,	O
longitudinal	O
studies	O
are	O
needed	O
to	O
assess	O
the	O
possible	O
anti	O
-	O
inflammatory	O
effect	O
of	O
high	O
base	O
##line	O
g	B
##lut	I
##amine	I
concentrations	O
.	O

10	B
,	I
2	I
-	I
H	I
##ydro	I
##xy	I
##is	I
##ob	I
##ut	I
##yra	I
##te	I
;	O
11	B
,	I
2	I
-	I
Ph	I
##en	I
##yl	I
##p	I
##rop	I
##ion	I
##ate	I
;	O
12	O
,	O
Un	O
##k	O
_	O
2	O
;	O
13	O
,	O
Alan	B
##ine	I
;	O
14	O
,	O
Ace	B
##tate	I
;	O
15	O
,	O
Un	O
##k	O
_	O
3	O
;	O
16	O
,	O
Un	O
##k	O
_	O
4	O
;	O
17	O
,	O
N	B
-	I
Is	I
##ova	I
##ler	I
##oy	I
##l	I
##gly	I
##cine	I
;	O
18	O
,	O
Ace	B
##tone	I
;	O
19	B
,	I
2	I
-	I
Am	I
##ino	I
##adi	I
##pate	I
;	O
20	O
,	O
Un	O
##k	O
_	O
5	O
;	O
21	O
,	O
Un	O
##k	O
_	O
6	O
;	O
22	O
,	O
C	B
##it	I
##rate	I
;	O
23	O
,	O
Di	B
##met	I
##hyl	I
##amine	I
;	O
24	O
,	O
Un	O
##k	O
_	O
7	O
;	O
25	O
,	O
C	B
##rea	I
##tine	I
;	O
26	O
,	O
C	B
##rea	I
##tin	I
##ine	I
;	O
27	O
,	O
Car	B
##ni	I
##tine	I
;	O
28	O
,	O
T	B
##MA	I
##O	I
;	O
29	O
,	O
Un	O
##k	O
_	O
8	O
;	O
30	O
,	O
Un	O
##k	O
_	O
9	O
;	O
31	O
,	O
G	B
##ly	I
##cine	I
;	O
32	O
,	O
G	B
##ly	I
##cy	I
##l	I
##p	I
##rol	I
##ine	I
;	O
33	O
,	O
Hip	B
##pura	I
##te	I
;	O
34	O
,	O
Tri	B
##gon	I
##elli	I
##ne	I
;	O
35	O
,	O
As	B
##cor	I
##bate	I
;	O
36	B
,	I
2	I
-	I
Fu	I
##roy	I
##l	I
##gly	I
##cine	I
;	O
37	B
,	I
3	I
-	I
H	I
##ydro	I
##xy	I
##phe	I
##ny	I
##lace	I
##tate	I
;	O
38	O
,	O
Ty	B
##ros	I
##ine	I
;	O
39	O
,	O
N	B
-	I
Ph	I
##en	I
##yla	I
##ce	I
##ty	I
##l	I
##gly	I
##cine	I
;	O
40	B
,	I
3	I
-	I
Indo	I
##xy	I
##ls	I
##ulf	I
##ate	I
;	O
41	O
,	O
Un	O
##k	O
_	O
10	O
;	O
42	O
,	O
Form	B
##ate	I
;	O
43	O

[UNK]	O
,	O
a	O
difference	O
between	O
week	O
24	O
and	O
base	O
##line	O
values	O
;	O
[UNK]	O
(	O
%	O
)	O
,	O
a	O
difference	O
between	O
week	O
24	O
and	O
base	O
##line	O
values	O
in	O
%	O
of	O
the	O
base	O
##line	O
value	O
;	O
B	O
##W	O
,	O
body	O
weight	O
;	O
B	O
##MI	O
,	O
body	O
mass	O
index	O
,	O
NE	O
##FA	O
,	O
non	O
-	O
est	O
##eri	O
##fied	O
fatty	O
acids	O
;	O
S	O
##OD	O
,	O
super	B
##oxide	I
di	O
##sm	O
##uta	O
##se	O
;	O
T	O
##BA	O
##RS	O
,	O
th	B
##io	I
##bar	I
##bit	I
##uri	I
##c	I
acid	I
reactive	O
substances	O
;	O
G	O
##SS	O
##H	O
,	O
o	B
##xi	I
##dized	I
g	I
##lut	I
##ath	I
##ione	I
;	O
G	B
##S	I
##H	I
,	O
reduced	B
g	I
##lut	I
##ath	I
##ione	I
.	O
_	O
a	O
,	O
b	O
,	O
c	O
Sign	O
##ificant	O
differences	O
compared	O
with	O
Place	O
##bo	O
,	O
Pi	O
##o	O
,	O
and	O
Omega	B
-	I
3	I
,	O

An	O
al	O
##iq	O
##uo	O
##t	O
of	O
200	O
μ	O
##L	O
of	O
super	O
##nat	O
##ant	O
was	O
transferred	O
to	O
a	O
p	B
##oly	I
##p	I
##rop	I
##yle	I
##ne	I
auto	O
##sa	O
##mple	O
##r	O
via	O
##l	O
.	O

It	O
is	O
not	O
clear	O
whether	O
low	O
levels	O
of	O
glucose	S
are	O
caused	O
by	O
their	O
impaired	O
delivery	O
through	O
the	O
blood	O
-	O
brain	O
barrier	O
(	O
B	O
##BB	O
)	O
and	O
/	O
or	O
by	O
rapid	O
consumption	O
due	O
to	O
increased	O
energy	O
demand	O
in	O
active	O
MS	O
and	O
N	O
##MO	O
##SD	O
lesions	O
.	O

It	O
is	O
well	O
-	O
known	O
that	O
the	O
daily	O
u	O
##rina	O
##ry	O
o	B
##xa	I
##late	I
ex	O
##cre	O
##tion	O
may	O
vary	O
up	O
to	O
36	O
%	O
within	O
P	O
##H	O
patients	O
.	O

Therefore	O
,	O
in	O
conjunction	O
with	O
recent	O
e	O
##pid	O
##em	O
##iol	O
##ogical	O
evidence	O
ass	O
##oc	O
##iating	O
dairy	O
consumption	O
with	O
changes	O
in	O
circulating	O
LP	B
##C	I
17	I
:	I
0	I
,	O
an	O
abundance	O
of	O
genetic	O
,	O
e	O
##pid	O
##em	O
##iol	O
##og	O
##ic	O
,	O
functional	O
,	O
and	O
bio	O
##chemical	O
data	O
imp	O
##lica	O
##ting	O
LP	O
##Cs	O
in	O
C	O
##VD	O
suggest	O
that	O
me	O
##chan	O
##istic	O
##ally	O
understanding	O
the	O
enzyme	O
kinetic	O
##s	O
and	O
complex	O
##ities	O
of	O
LP	O
##C	O
metabolism	O
may	O
highlight	O
promising	O
therapeutic	O
targets	O
.	O

It	O
is	O
obvious	O
that	O
subjects	O
of	O
the	O
E	O
##G	O
were	O
exposed	O
to	O
a	O
remarkable	O
metabolic	O
and	O
psychological	O
stress	O
,	O
as	O
indicated	O
by	O
an	O
increase	O
in	O
post	O
-	O
exercise	O
blood	O
la	B
##ct	I
##ate	I
and	O
a	O
decrease	O
in	O
MD	O
##BF	O
scores	O
during	O
intervention	O
,	O
which	O
reflect	O
subjective	O
well	O
-	O
being	O
.	O

Specifically	O
,	O
at	O
early	O
exposure	O
times	O
(	O
1	O
hour	O
)	O
,	O
only	O
a	O
few	O
p	O
##yr	O
##im	O
##id	O
##ine	O
/	O
pu	O
##rine	O
n	O
##uc	O
##leo	O
##side	O
##s	O
and	O
n	O
##uc	O
##leo	O
##base	O
##s	O
were	O
significantly	O
accumulated	O
(	O
i	O
##e	O
,	O
g	B
##uan	I
##ine	I
and	O
thy	B
##mine	I
in	O
MD	O
##A	O
-	O
MB	O
-	O
231	O
medium	O
;	O
g	B
##uan	I
##ine	I
,	O
c	B
##yt	I
##os	I
##ine	I
,	O
and	O
de	B
##ox	I
##ya	I
##den	I
##os	I
##ine	I
in	O
T	O
##47	O
##D	O
medium	O
)	O
.	O

Co	O
##rrel	O
##ation	O
testing	O
in	O
the	O
whole	O
population	O
showed	O
positive	O
correlation	O
##s	O
between	O
insulin	O
sensitivity	O
and	O
g	B
##ly	I
##cine	I
and	O
g	B
##lut	I
##amine	I
,	O
whereas	O
al	B
##ani	I
##ne	I
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
le	B
##uc	I
##ine	I
,	O
v	B
##ali	I
##ne	I
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
and	O
t	B
##yr	I
##os	I
##ine	I
had	O
negative	O
correlation	O
with	O
insulin	O
sensitivity	O
.	O

P	B
##yr	I
##ido	I
##xi	I
##c	I
acid	I
has	O
received	O
little	O
attention	O
in	O
card	O
##iovascular	O
research	O
.	O

Interest	O
##ingly	O
,	O
we	O
identified	O
dim	B
##eth	I
##yla	I
##mine	I
(	O
D	O
##MA	O
)	O
,	O
dim	B
##eth	I
##yl	I
##gly	I
##cine	I
(	O
D	O
##MG	O
)	O
,	O
p	O
##oly	O
##uns	O
##at	O
##ura	O
##ted	O
fatty	O
acids	O
and	O
his	B
##ti	I
##dine	I
,	O
which	O
are	O
associated	O
with	O
the	O
stage	O
of	O
es	O
##op	O
##hage	O
##al	O
cancer	O
.	O

U	O
##rina	O
##ry	O
c	B
##rea	I
##tin	I
##ine	I
was	O
measured	O
with	O
the	O
Beck	O
##man	O
L	O
##X	O
##20	O
analyze	O
##r	O
(	O
B	O
##rea	O
CA	O
)	O
,	O
using	O
a	O
technique	O
based	O
on	O
the	O
J	O
##af	O
##fe	O
reaction	O
.	O

In	O
addition	O
,	O
pu	B
##rine	I
##s	I
,	O
ca	B
##ffe	I
##ine	I
,	O
para	B
##xa	I
##nt	I
##hine	I
,	O
and	O
the	B
##op	I
##hyl	I
##line	I
(	O
component	O
4	O
,	O
5	O
.	O
0	O
%	O
)	O
,	O
branched	O
-	O
chain	O
and	O
a	O
##romatic	O
amino	O
acids	O
(	O
component	O
5	O
,	O
4	O
.	O
3	O
%	O
)	O
,	O
bi	O
##le	O
acids	O
(	O
component	O
6	O
,	O
3	O
.	O
4	O
%	O
)	O
,	O
LP	O
##E	O
,	O
p	B
##hos	I
##ph	I
##och	I
##olin	I
##e	I
,	O
and	O
amino	O
acids	O
(	O
component	O
7	O
,	O
3	O
.	O
2	O
%	O
)	O
,	O
PC	O
species	O
(	O
component	O
8	O
,	O
3	O
.	O
0	O
%	O
)	O
,	O
and	O
u	O
##rem	O
##ic	O
a	O
##romatic	O
ho	B
##mo	I
-	I
mon	I
##oc	I
##yclic	I
compounds	O
(	O
component	O
9	O
,	O
2	O
.	O
5	O
%	O
)	O
cluster	O
##ed	O
along	O
a	O
particular	O
component	O
(	O
Table	O
S	O
##1	O
in	O
Su	O
##pp	O
##lement	O
##ary	O
Materials	O
)	O
.	O

We	O
retrieved	O
10	O
μ	O
##L	O
of	O
serum	O
and	O
added	O
water	O
/	O
met	O
##han	O
##ol	O
/	O
di	O
##ch	O
##lor	O
##ome	O
##than	O
##e	O
at	O
room	O
temperature	O
with	O
2	O
:	O
2	O
:	O
2	O
volume	O
ratio	O
,	O
followed	O
by	O
s	O
##pi	O
##king	O
internal	O
standards	O
PC	B
17	I
:	I
0	I
/	I
17	I
:	I
0	I
,	O
LP	O
##C	O
17	O
:	O
0	O
,	O
P	B
##G	I
17	I
:	I
0	I
/	I
17	I
:	I
0	I
,	O
P	B
##E	I
17	I
:	I
0	I
/	I
17	I
:	I
0	I
,	O
T	B
##AG	I
17	I
:	I
0	I
/	I
17	I
:	I
0	I
/	I
17	I
:	I
0	I
,	O
SM	B
18	I
:	I
1	I
/	I
17	I
:	I
0	I
,	O
MA	O
##G	O
17	O
:	O
0	O
,	O
D	B
##AG	I
16	I
:	I
0	I
/	I
18	I
:	I
1	I
,	O
CE	O
17	O
:	O
0	O
,	O
c	B
##era	I
##mi	I
##de	I
phosphate	I
18	I
:	I
1	I
/	I
17	I
:	I
0	I
,	O
PA	O
17	O
:	O
0	O
,	O
P	B
##I	I
17	I
:	I
0	I
/	I
20	I
:	I
4	I
,	O
and	O
PS	B
17	I
:	I
0	I
/	I
17	I
:	I
0	I
.	O

G	B
##ly	I
##c	I
-	I
ER	I
-	I
G	I
##FP	I
was	O
trans	O
##fected	O
into	O
patient	O
fi	O
##bro	O
##blast	O
##s	O
in	O
culture	O
,	O
and	O
flu	O
##ores	O
##cence	O
was	O
measured	O
by	O
means	O
of	O
quantitative	O
micro	O
##sco	O
##py	O
(	O
see	O
the	O
)	O
.	O

P	B
##yr	I
##rol	I
##e	I
had	O
the	O
largest	O
AU	O
##C	O
value	O
which	O
was	O
0	O
.	O
90	O
##7	O
,	O
with	O
a	O
sensitivity	O
of	O
0	O
.	O
93	O
##3	O
and	O
a	O
specific	O
##ity	O
of	O
0	O
.	O
86	O
##7	O
at	O
the	O
best	O
cut	O
-	O
off	O
point	O
.	O

Not	O
##ably	O
,	O
three	O
patients	O
diagnosed	O
with	O
AP	S
voluntarily	O
chose	O
not	O
to	O
be	O
admitted	O
to	O
the	O
hospital	O
;	O
one	O
patient	O
without	O
AP	S
was	O
admitted	O
to	O
the	O
hospital	O
because	O
of	O
pain	O
.	O

The	O
amid	B
##o	I
nitrogen	I
of	O
G	O
##ln	O
is	O
also	O
the	O
immediate	O
donor	O
for	O
n	O
##uc	O
##leo	O
##base	O
bio	O
##sy	O
##nt	O
##hesis	O
and	O
amino	B
##su	I
##gar	I
##s	I
such	O
as	O
g	B
##lu	I
##cos	I
##amine	I
and	O
gal	B
##act	I
##osa	I
##mine	I
.	O

Only	O
met	B
##hi	I
##oni	I
##ne	I
su	I
##lf	I
##oxide	I
showed	O
significant	O
changes	O
in	O
concentration	O
in	O
gel	O
-	O
barrier	O
tubes	O
compared	O
to	O
serum	O
W	O
tubes	O
.	O

From	O
these	O
,	O
c	B
##it	I
##rate	I
showed	O
the	O
strongest	O
hub	O
properties	O
,	O
showing	O
a	O
significantly	O
lower	O
concentration	O
in	O
the	O
urine	O
of	O
most	O
I	O
##MI	O
##Ds	O
compared	O
to	O
controls	O
(	O
Fi	O
##g	O
.	O

Con	O
##cent	O
##ration	O
of	O
all	O
amino	O
acids	O
injected	O
into	O
the	O
electro	O
##ph	O
##ore	O
##tic	O
analyze	O
##r	O
was	O
100	O
μ	O
##M	O
,	O
except	O
from	O
c	B
##ys	I
##tein	I
##e	I
(	O
50	O
μ	O
##M	O
)	O
.	O

We	O
systematically	O
excluded	O
g	B
##lu	I
##co	I
##cor	I
##tic	I
##oid	I
meta	O
##bol	O
##ites	O
from	O
the	O
s	O
##tero	O
##id	O
analysis	O
,	O
as	O
these	O
would	O
be	O
compromised	O
both	O
by	O
mit	O
##ota	O
##ne	O
-	O
induced	O
changes	O
in	O
g	B
##lu	I
##co	I
##cor	I
##tic	I
##oid	I
metabolism	O
and	O
ex	O
##ogen	O
##ous	O
h	B
##ydro	I
##cor	I
##tis	I
##one	I
replacement	O
.	O

Although	O
he	O
made	O
seminal	O
discoveries	O
in	O
re	O
##spiration	O
,	O
cell	O
physiology	O
,	O
and	O
metabolism	O
,	O
he	O
is	O
known	O
mostly	O
for	O
his	O
careful	O
observation	O
that	O
cancer	O
cells	O
consume	O
more	O
glucose	S
and	O
secret	O
##e	O
more	O
la	B
##ct	I
##ate	I
compared	O
to	O
normal	O
cells	O
,	O
even	O
in	O
the	O
presence	O
of	O
excess	O
oxygen	O
that	O
should	O
in	O
fact	O
meta	O
##bol	O
##ize	O
all	O
of	O
the	O
glucose	S
to	O
CO	O
_	O
2	O
_	O
,	O
via	O
mitochondrial	O
o	O
##xi	O
##da	O
##tive	O
p	O
##hos	O
##ph	O
##ory	O
##lation	O
.	O

Ho	B
##mo	I
##cy	I
##stein	I
##e	I
as	O
well	O
as	O
c	B
##ys	I
##tein	I
##e	I
have	O
been	O
reported	O
to	O
be	O
elevated	O
in	O
plasma	O
and	O
serum	O
of	O
AD	O
patients	O
.	O

All	O
blood	O
sampling	O
was	O
carried	O
out	O
between	O
8	O
:	O
00	O
–	O
10	O
:	O
00	O
AM	O
after	O
an	O
overnight	O
fast	O
and	O
refrain	O
##ing	O
from	O
ca	O
##ffe	O
##inated	O
beverages	O
in	O
the	O
morning	O
before	O
sampling	O
,	O
which	O
was	O
carried	O
out	O
after	O
20	O
min	O
or	O
more	O
of	O
su	B
##pine	I
rest	O
.	O

First	O
,	O
ch	B
##olin	I
##e	I
is	O
an	O
important	O
met	O
##hyl	O
donor	O
in	O
one	O
-	O
carbon	O
metabolism	O
,	O
which	O
can	O
affect	O
DNA	O
met	O
##hyl	O
##ation	O
levels	O
.	O

These	O
were	O
g	B
##ly	I
##cine	I
,	O
g	B
##lut	I
##ami	I
##c	I
acid	I
and	O
2	B
-	I
H	I
##ydro	I
##xy	I
##but	I
##yric	I
acid	I
,	O
which	O
are	O
involved	O
in	O
g	B
##lut	I
##ath	I
##ione	I
formation	O
,	O
an	O
important	O
he	O
##pa	O
##to	O
-	O
protective	O
meta	O
##bol	O
##ite	O
[	O
]	O
.	O

Take	O
##n	O
together	O
,	O
the	O
rise	O
of	O
7	B
-	I
k	I
##eto	I
##cho	I
##les	I
##tero	I
##l	I
levels	O
after	O
tumor	O
removal	O
,	O
which	O
is	O
not	O
relevant	O
to	O
est	B
##rogen	I
expression	O
or	O
ta	B
##mo	I
##xi	I
##fen	I
therapy	O
,	O
suggests	O
that	O
it	O
may	O
be	O
connected	O
with	O
tumor	O
growth	O
,	O
independent	O
of	O
est	O
##rogen	O
##ic	O
activity	O
.	O

Our	O
study	O
sample	O
set	O
had	O
the	O
significant	O
differences	O
in	O
the	O
plasma	O
levels	O
of	O
total	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
t	B
##rig	I
##ly	I
##cer	I
##ide	I
,	O
glucose	S
,	O
total	O
bi	B
##li	I
##ru	I
##bin	I
and	O
AS	O
##T	O
between	O
the	O
color	O
##ec	O
##tal	O
cancer	O
patients	O
and	O
healthy	O
volunteers	O
,	O
so	O
it	O
is	O
impossible	O
to	O
completely	O
deny	O
the	O
involvement	O
of	O
these	O
factors	O
’	O
alterations	O
in	O
the	O
establishment	O
of	O
our	O
model	O
at	O
this	O
time	O
.	O

Re	B
##tino	I
##id	I
are	O
physiological	O
regulator	O
##s	O
of	O
em	O
##b	O
##ryo	O
##nic	O
development	O
,	O
vision	O
,	O
reproduction	O
,	O
bone	O
formation	O
,	O
hem	O
##ato	O
##po	O
##ies	O
##is	O
,	O
differentiation	O
,	O
proliferation	O
and	O
a	O
##pop	O
##tosis	O
.	O

Sa	B
##bat	I
##ine	I
et	O
al	O
.	O
group	O
observed	O
a	O
drop	O
in	O
the	O
level	O
of	O
c	B
##it	I
##ru	I
##llin	I
##e	I
in	O
AM	O
##I	O
patients	O
.	O

d	O
:	O
double	O
##t	O
,	O
T	O
##hr	O
+	O
la	O
##c	O
:	O
double	O
##t	O
containing	O
signal	O
from	O
both	O
th	B
##re	I
##oni	I
##ne	I
and	O
la	B
##ct	I
##ate	I
(	O
1	O
.	O
33	O
pp	O
##m	O
)	O
.	O

For	O
example	O
,	O
the	O
correlation	O
between	O
Ce	B
##r	I
and	O
SM	O
was	O
r	O
=	O
0	O
.	O
65	O
##4	O
,	O
p	O
=	O
1	O
.	O
5	O
×	O
10	O
_	O
−	O
##7	O
,	O
and	O
between	O
SM	O
and	O
So	O
was	O
r	O
=	O
0	O
.	O
68	O
##5	O
,	O
p	O
=	O
2	O
.	O
2	O
×	O
10	O
_	O
−	O
##8	O
.	O

In	O
other	O
experiments	O
,	O
cells	O
were	O
treated	O
with	O
either	O
g	B
##lut	I
##amine	I
(	O
10	O
–	O
30	O
μ	O
g	O
/	O
m	O
##L	O
)	O
(	O
49	O
##41	O
##9	O
,	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
,	O
St	O
.	O
Louis	O
,	O
M	O
##O	O
)	O
or	O
6	B
-	I
di	I
##az	I
##o	I
-	I
5	I
-	I
o	I
##x	I
##o	I
-	I
L	I
-	I
nor	I
##le	I
##uc	I
##ine	I
(	O
D	O
##ON	O
;	O
1	O
m	O
##M	O
)	O
(	O
D	O
##21	O
##41	O
,	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
,	O
St	O
.	O
Louis	O
,	O
M	O
##O	O
)	O
and	O
culture	O
##d	O
under	O
ad	O
##here	O
##nt	O
or	O
suspension	O
conditions	O
for	O
72	O
h	O
.	O

Ad	O
##ip	O
##ocytes	O
expressed	O
high	O
levels	O
of	O
AK	O
##R	O
and	O
CB	O
##R	O
is	O
##oe	O
##nz	O
##yme	O
##s	O
that	O
de	O
##act	O
##ivate	O
ant	B
##hra	I
##cy	I
##cline	I
##s	I
.	O

The	O
emergence	O
of	O
lip	O
##ido	O
##mic	O
,	O
applied	O
to	O
g	B
##ly	I
##co	I
##biology	I
,	O
has	O
helped	O
answer	O
these	O
questions	O
by	O
offering	O
a	O
direct	O
access	O
to	O
the	O
c	B
##era	I
##mi	I
##de	I
structures	O
.	O

After	O
washed	O
with	O
T	O
##BS	O
##T	O
,	O
the	O
sections	O
were	O
in	O
##cu	O
##bate	O
##d	O
with	O
liquid	O
D	O
##AB	O
-	O
ch	O
##rom	O
##ogen	O
solution	O
for	O
10	O
min	O
,	O
and	O
counters	O
##tain	O
##ed	O
in	O
hem	B
##ato	I
##xy	I
##lin	I
for	O
2	O
min	O
.	O

Inc	O
##reased	O
c	B
##rea	I
##tin	I
##ine	I
is	O
con	O
##st	O
##rue	O
##d	O
as	O
a	O
sign	O
of	O
kidney	O
failure	O
[	O
,	O
]	O
.	O

A	O
put	O
##ative	O
nap	B
##ht	I
##hale	I
##ne	I
based	O
compound	O
,	O
1	B
-	I
Ni	I
##tro	I
-	I
5	I
,	I
6	I
-	I
di	I
##hy	I
##dr	I
##ox	I
##y	I
-	I
di	I
##hy	I
##dron	I
##aph	I
##thal	I
##ene	I
(	O
DD	O
##N	O
)	O
,	O
was	O
abundant	O
in	O
,	O
and	O
a	O
put	O
##ative	O
bio	O
##mark	O
##er	O
of	O
,	O
infection	O
-	O
only	O
cases	O
.	O

level	O
,	O
the	O
ratio	O
of	O
reduced	B
g	I
##lut	I
##ath	I
##ione	I
(	O
G	O
##S	O
##H	O
)	O
to	O
G	O
##SS	O
##G	O
(	O
q	O
=	O
0	O
.	O
03	O
##9	O
)	O
in	O
er	O
##yt	O
##hr	O
##ocytes	O
,	O
ma	B
##lon	I
##dial	I
##de	I
##hy	I
##de	I
(	O
MD	O
##A	O
,	O
q	O
=	O
0	O
.	O
00	O
##6	O
)	O
and	O
inter	O
##le	O
##uki	O
##n	O
-	O
6	O
(	O
q	O
=	O
0	O
.	O
00	O
##6	O
)	O
levels	O
in	O
plasma	O
,	O
and	O
seventeen	O
N	O
##MR	O
meta	O
##bol	O
##ites	O
in	O
urine	O
compared	O
with	O
those	O
in	O
the	O
place	O
##bo	O
group	O
.	O

Similar	O
patterns	O
of	O
mutations	O
have	O
also	O
been	O
observed	O
in	O
the	O
big	O
blue	O
(	O
B	O
##B	O
)	O
rat	O
ma	O
##mma	O
##ry	O
g	O
##land	O
and	O
culture	O
##d	O
B	O
##B	O
rat	O
##2	O
em	O
##b	O
##ryo	O
##nic	O
cells	O
after	O
treatment	O
with	O
4	B
-	I
h	I
##ydro	I
##xy	I
##est	I
##rad	I
##iol	I
(	O
4	O
-	O
OH	O
##E	O
_	O
2	O
)	O
or	O
E	B
_	I
2	I
-	I
3	I
,	I
4	I
-	I
Q	I
.	I
_	I
,	O
The	O
transforming	O
activity	O
of	O
E	O
_	O
2	O
and	O
4	O
-	O
OH	O
##E	O
_	O
2	O
has	O
been	O
observed	O
in	O
human	O
breast	O
e	O
##pit	O
##hel	O
##ial	O
(	O
MC	O
##F	O
-	O
10	O
##F	O
)	O
cells	O
,	O
which	O
do	O
not	O
contain	O
est	B
##rogen	I
receptor	O
-	O
α	O
,	O
and	O
it	O
is	O
not	O
affected	O
by	O
the	O
presence	O
of	O
an	O
anti	O
-	O
est	O
##rogen	O
.	O
_	O

The	O
semi	O
##pur	O
##ified	O
p	O
##ept	O
##ai	O
##bol	O
mixture	O
(	O
el	O
##uted	O
with	O
90	O
%	O
met	B
##han	I
##ol	I
from	O
a	O
Sep	O
##P	O
##ak	O
C	O
_	O
18	O
cartridge	O
)	O
of	O
T	O
.	O
ha	O
##rz	O
##ian	O
##um	O
strain	O
E	O
##S	O
##39	O
was	O
present	O
in	O
the	O
c	O
##is	O
side	O
.	O

The	O
analysis	O
described	O
that	O
combined	O
u	O
##rina	O
##ry	O
u	B
##rea	I
and	O
p	O
##hen	O
##yla	O
##ce	O
##ty	O
##l	O
##g	O
##lut	O
##amine	O
—	O
two	O
read	O
##outs	O
of	O
nitrogen	O
metabolism	O
—	O
may	O
be	O
relevant	O
to	O
monitor	O
metabolic	O
status	O
in	O
the	O
course	O
of	O
disease	O
.	O

Multiple	O
s	O
##cle	O
##rosis	O
(	O
Mu	O
##S	O
)	O
is	O
an	O
auto	O
##im	O
##mu	O
##ne	O
disease	O
of	O
the	O
central	O
nervous	O
system	O
characterized	O
by	O
ne	O
##uro	O
##in	O
##f	O
##lam	O
##mation	O
,	O
ne	O
##uro	O
##de	O
##gene	O
##ration	O
,	O
and	O
degradation	O
of	O
the	O
my	B
##elin	I
sheath	O
.	O

B	O
##rief	O
##ly	O
,	O
540	O
µ	O
##l	O
of	O
urine	O
(	O
at	O
room	O
temperature	O
)	O
was	O
mixed	O
with	O
180	O
µ	O
##l	O
of	O
0	O
.	O
4	O
M	O
phosphate	S
buffer	O
(	O
pH	O
7	O
;	O
containing	O
0	O
.	O
75	O
%	O
w	O
/	O
v	O
sodium	O
a	O
##zi	O
##de	O
)	O
.	O

One	O
group	O
was	O
used	O
to	O
label	O
meta	O
##bol	O
##ites	O
containing	O
car	B
##box	I
##yl	I
##ic	I
acid	I
groups	O
with	O
_	O
15	O
N	B
-	I
ethanol	I
##amine	I
,	O
and	O
the	O
second	O
group	O
was	O
used	O
to	O
label	O
meta	O
##bol	O
##ites	O
containing	O
am	O
##ine	O
groups	O
with	O
_	O
13	O
C	O
-	O
form	O
##ic	O
acid	O
,	O
after	O
the	O
addition	O
of	O
internal	O
standards	O
,	O
either	O
male	B
##ic	I
acid	I
or	O
ethanol	B
##amine	I
,	O
appropriately	O
.	O

An	O
alternative	O
mechanism	O
for	O
Al	O
##b	O
add	O
##uc	O
##t	O
formation	O
was	O
proposed	O
to	O
occur	O
via	O
a	O
concert	O
##ed	O
elimination	O
–	O
addition	O
mechanism	O
,	O
where	O
the	O
His	O
##14	O
##6	O
residue	O
or	O
some	O
other	O
nearby	O
basic	O
residues	O
in	O
Al	O
##b	O
acted	O
as	O
a	O
general	O
base	O
,	O
abstract	O
##ing	O
the	O
pro	O
##ton	O
from	O
amid	B
##e	I
and	O
promoting	O
the	O
elimination	O
of	O
the	O
su	O
##lf	O
##ox	O
##yl	O
group	O
to	O
form	O
a	O
q	B
##uin	I
##one	I
met	O
##hi	O
##de	O
intermediate	O
.	O

The	O
plasma	O
f	B
##olate	I
levels	O
had	O
significantly	O
positive	O
correlation	O
with	O
energy	O
adjusted	O
f	B
##olate	I
intake	O
(	O
r	O
=	O
0	O
.	O
46	O
##4	O
,	O
P	O
=	O
0	O
.	O
03	O
##4	O
)	O
.	O

W	O
##heat	O
##ley	O
demonstrated	O
that	O
cancer	O
may	O
be	O
controlled	O
by	O
restrict	O
##ing	O
a	B
##rg	I
##ini	I
##ne	I
availability	O
through	O
in	O
##hibit	O
##ing	O
a	O
##rg	O
##ini	O
##ne	O
-	O
cat	O
##ab	O
##oli	O
##zing	O
enzymes	O
,	O
which	O
function	O
as	O
anti	O
##can	O
##cer	O
agents	O
.	O

The	O
s	O
##pect	O
##ra	O
were	O
referenced	O
using	O
the	O
double	O
##t	O
of	O
Alan	B
##ine	I
at	O
1	O
.	O
47	O
##8	O
pp	O
##m	O
.	O

_	B
7	I
3	I
-	I
O	I
##x	I
##och	I
##ole	I
##sta	I
-	I
4	I
,	I
6	I
-	I
die	I
##n	I
-	I
26	I
-	I
o	I
##ic	I
acid	I
is	O
a	O
de	O
##hy	O
##dra	O
##tion	O
product	O
of	O
7	B
##α	I
-	I
h	I
##ydro	I
##xy	I
-	I
3	I
-	I
o	I
##x	I
##och	I
##ole	I
##st	I
-	I
4	I
-	I
en	I
-	I
26	I
-	I
o	I
##ic	I
acid	I
.	O

a	O
,	O
competitive	O
displacement	O
of	O
10	O
nm	O
t	O
##rit	O
##iated	O
9	O
-	O
c	O
##is	O
-	O
RA	O
from	O
pu	O
##rified	O
R	O
##X	O
##R	O
##α	O
protein	O
by	O
un	O
##la	O
##bel	O
##ed	O
9	O
-	O
c	O
##is	O
-	O
RA	O
(	O
♦	O
)	O
as	O
a	O
positive	O
control	O
,	O
C	O
##13	O
k	B
##eton	I
##e	I
(	O
[UNK]	O
)	O
,	O
14	O
′	O
-	O
AL	O
(	O
■	O
)	O
,	O
14	O
′	O
-	O
CA	O
(	O
+	O
)	O
,	O
and	O
re	B
##tin	I
##yl	I
ace	I
##tate	I
(	O
×	O
)	O
as	O
a	O
negative	O
control	O
.	O

0	O
.	O
55	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
and	O
showed	O
moderate	O
positive	O
correlation	O
##s	O
with	O
six	O
try	B
##pt	I
##op	I
##han	I
meta	O
##bol	O
##ites	O
(	O
see	O
Table	O
)	O
.	O

Thus	O
,	O
p	O
##eptide	O
h	O
##VD	O
##AC	O
##2	O
(	O
12	O
–	O
36	O
)	O
was	O
predicted	O
to	O
fold	O
as	O
a	O
longer	O
α	B
-	I
he	I
##lix	I
,	O
seemingly	O
starting	O
from	O
the	O
fifth	O
residue	O
,	O
with	O
a	O
kin	O
##k	O
at	O
the	O
level	O
of	O
G	O
##11	O
.	O

H	O
##R	O
##MA	O
##S	O
_	O
1	O
H	O
N	O
##MR	O
data	O
from	O
the	O
pro	O
##state	O
are	O
sometimes	O
expressed	O
as	O
meta	O
##bol	O
##ite	O
ratios	O
with	O
respect	O
to	O
c	B
##it	I
##rate	I
(	O
Ko	O
##bus	O
et	O
al	O
.	O
)	O
.	O

The	O
mean	O
meta	O
##bol	O
##ite	O
-	O
level	O
percent	O
##ile	O
was	O
lowest	O
in	O
those	O
who	O
reported	O
no	O
coffee	O
consumption	O
and	O
increased	O
with	O
increasing	O
coffee	O
intake	O
;	O
e	O
.	O
g	O
.	O
,	O
non	O
-	O
,	O
low	O
,	O
and	O
high	O
coffee	O
drink	O
##ers	O
had	O
mean	O
t	B
##rig	I
##one	I
##llin	I
##e	I
(	O
N	O
′	B
-	I
met	I
##hyl	I
##nic	I
##ot	I
##inate	I
)	O
levels	O
in	O
the	O
17th	O
,	O
44	O
##th	O
,	O
and	O
65	O
##th	O
percent	O
##iles	O
of	O
the	O
distribution	O
,	O
respectively	O
.	O

Alto	O
##get	O
##her	O
,	O
our	O
studies	O
reveal	O
the	O
potential	O
role	O
of	O
α	B
-	I
O	I
##G	I
in	O
e	O
##pi	O
##gene	O
##tic	O
re	O
##mo	O
##del	O
##ing	O
through	O
its	O
effects	O
on	O
AR	O
##ID	O
##1	O
##A	O
and	O
T	O
##ET	O
expression	O
in	O
the	O
bladder	O
.	O

A	O
mixture	O
of	O
10	O
μ	O
##g	O
/	O
m	O
##l	O
each	O
(	O
SM	O
##V	O
,	O
SM	O
##V	O
-	O
A	O
,	O
AT	O
##V	O
,	O
2	B
-	I
OH	I
-	I
AT	I
##V	I
,	O
4	B
-	I
OH	I
-	I
AT	I
##V	I
,	O
RS	O
##V	O
)	O
was	O
prepared	O
from	O
the	O
stock	O
solutions	O
by	O
a	O
di	O
##lution	O
with	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
.	O

All	O
of	O
the	O
measured	O
nor	B
##le	I
##uc	I
##ine	I
and	O
nor	B
##val	I
##ine	I
concentrations	O
were	O
within	O
that	O
range	O
.	O

In	O
conclusion	O
,	O
we	O
found	O
t	B
##yr	I
##os	I
##ine	I
metabolism	O
,	O
including	O
the	O
do	O
##pa	O
##mine	O
##rg	O
##ic	O
species	O
,	O
to	O
be	O
altered	O
in	O
manifest	O
HD	O
patients	O
.	O

L	B
-	I
D	I
##OP	I
##A	I
:	O
only	O
11	O
controls	O
.	O

A	O
,	O
P	O
##las	O
##ma	O
levels	O
of	O
Δ	B
_	I
9	I
-	I
te	I
##tra	I
##hy	I
##dr	I
##oc	I
##anna	I
##bino	I
##l	I
(	O
T	O
##HC	O
)	O
,	O
11	B
-	I
h	I
##ydro	I
##xy	I
-	I
T	I
##HC	I
(	I
11	I
-	I
OH	I
-	I
T	I
##HC	I
)	I
,	O
11	B
-	I
nor	I
-	I
car	I
##box	I
##y	I
-	I
T	I
##HC	I
(	O
T	O
##HC	O
-	O
CO	O
##OH	O
)	O
,	O
and	O
11	B
-	I
nor	I
-	I
car	I
##box	I
##y	I
-	I
T	I
##HC	I
g	I
##lu	I
##cu	I
##ron	I
##ide	I
(	O
T	O
##HC	O
-	O
CO	O
##OH	O
g	O
##lu	O
##cu	O
##ron	O
##ide	O
)	O
were	O
evaluated	O
in	O
each	O
individual	O
.	O

However	O
,	O
increasing	O
the	O
L	O
##C	O
##B	O
chain	O
length	O
from	O
18	O
to	O
20	O
carbon	O
##s	O
increases	O
the	O
h	O
##ydro	O
##phobic	O
volume	O
and	O
the	O
transition	O
temperature	O
of	O
G	O
##G	O
species	O
leading	O
to	O
think	O
that	O
d	B
##20	I
:	I
1	I
L	O
##C	O
##B	O
must	O
be	O
more	O
segregated	O
and	O
more	O
efficient	O
in	O
reducing	O
membrane	O
fluid	O
##ity	O
than	O
d	B
##18	I
:	I
1	I
L	O
##C	O
##B	O
.	O

A	O
recent	O
study	O
also	O
reported	O
that	O
high	O
plasma	O
c	B
##ys	I
##tine	I
(	O
o	O
##xi	O
##dized	O
)	O
and	O
low	O
g	B
##lut	I
##ath	I
##ione	I
concentrations	O
were	O
strongly	O
associated	O
with	O
higher	O
mortality	O
.	O

O	O
##wing	O
to	O
the	O
strong	O
signals	O
we	O
identify	O
in	O
our	O
glucose	S
MW	O
##AS	O
,	O
we	O
report	O
very	O
high	O
replication	O
proportions	O
in	O
glucose	O
-	O
associated	O
regions	O
.	O

These	O
l	B
##ys	I
##ine	I
residues	O
are	O
known	O
to	O
form	O
a	O
##cy	O
##l	O
-	O
linked	O
add	O
##uc	O
##ts	O
with	O
g	B
##lu	I
##cu	I
##ron	I
##ide	I
con	O
##ju	O
##gate	O
##s	O
of	O
to	B
##lm	I
##eti	I
##n	I
and	O
per	O
##met	O
##hr	O
##in	O
.	O
_	O
,	O
L	O
##ys	O
_	O
195	O
or	O
L	O
##ys	O
_	O
199	O
was	O
also	O
reported	O
to	O
form	O
an	O
add	O
##uc	O
##t	O
with	O
2	B
,	I
4	I
-	I
din	I
##it	I
##ro	I
-	I
1	I
-	I
ch	I
##lor	I
##obe	I
##nz	I
##ene	I
,	O
and	O
both	O
l	B
##ys	I
##ine	I
residues	O
are	O
reactive	O
sites	O
in	O
SA	O
and	O
form	O
add	O
##uc	O
##ts	O
with	O
4	B
-	I
h	I
##ydro	I
##xy	I
-	I
trans	I
-	I
2	I
-	I
none	I
##nal	I
.	O

Over	O
3	O
times	O
more	O
17	O
:	O
0	O
Ce	O
##r	O
and	O
17	O
:	O
0	O
P	O
##E	O
were	O
extracted	O
using	O
the	O
met	B
##han	I
##ol	I
-	I
ethanol	I
method	O
compared	O
to	O
the	O
met	B
##han	I
##ol	I
method	O
.	O

All	O
P	O
##U	O
##LS	O
##E	O
tubes	O
were	O
washed	O
with	O
Me	B
##OH	I
and	O
dried	O
prior	O
to	O
the	O
experiment	O
.	O

Co	O
##rrel	O
##ation	O
analyses	O
of	O
2	O
-	O
H	O
##B	O
,	O
3	O
-	O
H	O
##B	O
,	O
la	B
##ct	I
##ate	I
,	O
c	B
##it	I
##rate	I
and	O
t	B
##yr	I
##os	I
##ine	I
with	O
clinical	O
and	O
laboratory	O
parameters	O
.	O

FIA	O
is	O
used	O
for	O
the	O
semi	O
-	O
quantitative	O
measurement	O
of	O
146	O
h	O
##ydro	O
##phobic	O
molecules	O
such	O
as	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
,	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
##s	I
(	O
SM	O
:	O
type	O
of	O
s	B
##phi	I
##ngo	I
##lip	I
##id	I
consisting	O
of	O
p	B
##hos	I
##ph	I
##ory	I
##l	I
##cho	I
##line	I
and	O
c	B
##era	I
##mi	I
##de	I
.	O
)	O
and	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
(	O
l	O
##ys	O
##o	O
-	O
,	O
di	B
##acy	I
##l	I
-	I
and	O
a	B
##cy	I
##l	I
-	I
al	I
##ky	I
##l	I
p	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
(	O
PC	O
)	O
)	O
.	O

It	O
is	O
converted	O
to	O
6	B
-	I
mon	I
##oa	I
##ce	I
##ty	I
##l	I
-	I
m	I
##or	I
##phine	I
in	O
the	O
central	O
nervous	O
system	O
via	O
de	O
##ace	O
##ty	O
##lation	O
with	O
a	O
half	O
life	O
of	O
<	O
60	O
minutes	O
,	O
then	O
further	O
meta	O
##bol	O
##ized	O
to	O
m	B
##or	I
##phine	I
.	O

Al	O
##a	O
and	O
la	B
##ct	I
##ate	I
show	O
only	O
fully	O
un	O
##la	O
##bel	O
##ed	O
and	O
fully	O
labeled	O
cross	O
peak	O
patterns	O
,	O
whereas	O
the	O
G	O
##lu	O
cross	O
peak	O
patterns	O
exhibit	O
both	O
sing	O
##ly	O
and	O
do	O
##ub	O
##ly	O
labeled	O
is	O
##oto	O
##po	O
##mer	O
species	O
(	O
c	O
##f	O
.	O
.	O

Cho	B
##line	I
appears	O
pro	O
##ton	O
##ated	O
and	O
has	O
a	O
positive	O
charge	O
,	O
whereas	O
c	B
##it	I
##rate	I
is	O
de	O
##p	O
##rot	O
##ona	O
##ted	O
and	O
has	O
a	O
negative	O
charge	O
.	O

Seven	O
of	O
these	O
18	O
meta	O
##bol	O
##ites	O
were	O
highly	O
correlated	O
(	O
r	O
##≥	O
##0	O
.	O
5	O
)	O
with	O
the	O
known	O
B	O
##MI	O
-	O
associated	O
meta	O
##bol	O
##ites	O
of	O
v	B
##ali	I
##ne	I
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
le	B
##uc	I
##ine	I
,	O
or	O
is	B
##ole	I
##uc	I
##ine	I
.	O

Path	O
##ways	O
are	O
labelled	O
:	O
try	B
##pt	I
##op	I
##han	I
metabolism	O
(	O
1	O
)	O
,	O
D	B
-	I
g	I
##lut	I
##amine	I
and	O
D	B
-	I
g	I
##lut	I
##ama	I
##te	I
metabolism	O
(	O
2	O
)	O
,	O
synthesis	O
and	O
degradation	O
of	O
k	B
##eton	I
##e	I
bodies	O
(	O
3	O
)	O
,	O
al	B
##ani	I
##ne	I
,	O
as	B
##par	I
##tate	I
and	O
g	B
##lut	I
##ama	I
##te	I
metabolism	O
(	O
4	O
)	O
,	O
l	B
##ys	I
##ine	I
degradation	O
(	O
5	O
)	O
,	O
g	B
##ly	I
##ox	I
##yla	I
##te	I
and	O
di	B
##car	I
##box	I
##yla	I
##te	I
metabolism	O
(	O
6	O
)	O
,	O
but	B
##ano	I
##ate	I
metabolism	O
(	O
7	O
)	O
,	O
l	B
##ys	I
##ine	I
bio	O
##sy	O
##nt	O
##hesis	O
(	O
8	O
)	O
,	O
amino	B
##acy	I
##l	I
-	I
t	I
##RNA	I
bio	O
##sy	O
##nt	O
##hesis	O
(	O
9	O
)	O
,	O
p	B
##yr	I
##u	I
##vate	I
metabolism	O
(	O
10	O
)	O
,	O
ta	B
##uri	I
##ne	I
and	O
h	B
##y	I
##pot	I
##au	I
##rine	I
metabolism	O
(	O
11	O
)	O
,	O
a	B
##rg	I
##ini	I
##ne	I
and	O
pro	B
##line	I
metabolism	O
(	O
12	O
)	O
and	O
g	B
##ly	I
##cine	I
,	O
se	B
##rine	I
and	O
th	B
##re	I
##oni	I
##ne	I
metabolism	O
(	O
13	O
)	O

The	O
ion	O
in	O
##tens	O
##ities	O
of	O
PC	B
(	I
34	I
:	I
2	I
)	I
at	O
m	O
/	O
z	O
79	O
##6	O
.	O
52	O
##53	O
,	O
PC	B
(	I
34	I
:	I
1	I
)	I
at	O
m	O
/	O
z	O
79	O
##8	O
.	O
54	O
##10	O
,	O
PC	B
(	I
36	I
:	I
3	I
)	I
at	O
m	O
/	O
z	O
82	O
##2	O
.	O
54	O
##10	O
,	O
and	O
PC	B
(	I
36	I
:	I
2	I
)	I
at	O
m	O
/	O
z	O
82	O
##4	O
.	O
55	O
##6	O
##6	O
were	O
higher	O
in	O
the	O
cancer	O
areas	O
compared	O
to	O
the	O
adjacent	O
non	O
-	O
cancer	O
areas	O
(	O
Figure	O
)	O
.	O

The	O
two	O
definitely	O
identified	O
meta	O
##bol	O
##ites	O
are	O
des	B
##ami	I
##not	I
##yr	I
##os	I
##ine	I
and	O
5	B
-	I
h	I
##ydro	I
##xy	I
##ly	I
##sin	I
##e	I
.	O

Although	O
neo	B
##pt	I
##eri	I
##n	I
was	O
not	O
directly	O
associated	O
with	O
try	B
##pt	I
##op	I
##han	I
levels	O
,	O
it	O
was	O
significantly	O
correlated	O
with	O
K	O
##Y	O
##N	O
/	O
T	O
##RP	O
(	O
R	O
=	O

Since	O
si	B
##m	I
##vas	I
##tat	I
##in	I
treatment	O
either	O
has	O
no	O
effect	O
or	O
can	O
improve	O
kidney	O
function	O
,	O
,	O
it	O
is	O
unlikely	O
that	O
the	O
changes	O
in	O
amino	O
acids	O
were	O
due	O
to	O
re	O
##nal	O
d	O
##ys	O
##function	O
.	O

Auto	O
##xi	O
##dis	O
##ed	O
ch	B
##ole	I
##ster	I
##ols	I
,	O
including	O
7	O
-	O
KC	O
and	O
7	B
##β	I
-	I
OH	I
##C	I
have	O
been	O
shown	O
to	O
affect	O
the	O
bio	O
##ava	O
##ila	O
##bility	O
of	O
other	O
reactive	O
oxygen	O
and	O
nitrogen	O
species	O
,	O
by	O
chemical	O
interaction	O
with	O
ni	B
##tric	I
oxide	I
.	O

Conversely	O
,	O
a	O
significantly	O
lower	O
intensity	O
of	O
a	O
characteristic	O
signal	O
of	O
ch	B
##ole	I
##ster	I
##ol	I
relative	O
to	O
the	O
total	O
spectral	O
intensity	O
was	O
measured	O
in	O
the	O
lip	O
##id	O
fraction	O
of	O
plasma	O
from	O
the	O
30	O
-	O
day	O
mortality	O
group	O
.	O

On	O
the	O
other	O
hand	O
,	O
excessive	O
bi	B
##li	I
##ru	I
##bin	I
can	O
enter	O
the	O
brain	O
via	O
the	O
blood	O
–	O
brain	O
barrier	O
to	O
induce	O
ne	O
##uro	O
##log	O
##ic	O
damage	O
.	O

In	O
addition	O
,	O
meta	O
##bol	O
##ites	O
such	O
as	O
la	B
##ct	I
##ate	I
,	O
which	O
possess	O
α	O
-	O
h	O
##ydro	O
##xy	O
##l	O
groups	O
,	O
show	O
more	O
than	O
one	O
peak	O
for	O
the	O
same	O
meta	O
##bol	O
##ite	O
as	O
we	O
described	O
earlier	O
using	O
the	O
_	O
15	O
N	O
-	O
ethanol	O
##ma	O
##ine	O
tag	O
.	O

Two	O
groups	O
relating	O
to	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
status	O
could	O
be	O
visual	O
##ized	O
in	O
the	O
data	O
##set	O
from	O
the	O
scores	O
plot	O
(	O
see	O
)	O
,	O
one	O
group	O
containing	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
meta	O
##bol	O
##ite	O
resonance	O
##s	O
(	O
group	O
A	O
,	O
n	O
=	O
60	O
##5	O
s	O
##pect	O
##ra	O
)	O
,	O
the	O
other	O
s	O
##pect	O
##ra	O
not	O
containing	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
meta	O
##bol	O
##ites	O
(	O
group	O
B	O
,	O
n	O
=	O
8	O
,	O
65	O
##5	O
)	O
.	O

Target	O
##ed	O
meta	O
##bol	O
##omi	O
##cs	O
studies	O
have	O
shown	O
G	O
##WI	O
is	O
a	O
unique	O
metabolic	O
syndrome	O
that	O
is	O
characterized	O
with	O
increased	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
and	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
and	O
decreased	O
pu	B
##rine	I
##s	I
and	O
end	B
##oc	I
##anna	I
##bino	I
##ids	I
,	O
a	O
specific	O
metabolic	O
finger	O
##print	O
different	O
to	O
other	O
conditions	O
with	O
similar	O
s	O
##ym	O
##pt	O
##oma	O
##tology	O
such	O
as	O
my	O
##al	O
##gic	O
en	O
##ce	O
##pha	O
##lo	O
##my	O
##eli	O
##tis	O
/	O
chronic	O
fatigue	O
syndrome	O
(	O
ME	O
/	O
CF	O
##S	O
)	O
.	O

In	O
the	O
HC	O
##T	O
##11	O
##6	O
cells	O
,	O
we	O
found	O
that	O
the	O
fatty	O
acid	O
carrier	O
car	B
##ni	I
##tine	I
was	O
_	O
13	O
C	O
_	O
0	O
and	O
hence	O
not	O
synthesized	O
,	O
although	O
the	O
initial	O
steps	O
of	O
this	O
pathway	O
leading	O
to	O
_	O
13	O
C	O
_	O
7	O
trim	B
##eth	I
##yla	I
##mm	I
##oni	I
##ob	I
##uta	I
##no	I
##ate	I
were	O
found	O
to	O
be	O
active	O
,	O
suggesting	O
that	O
the	O
car	O
##ni	O
##tine	O
-	O
s	O
##ynth	O
##esi	O
##zing	O
B	O
##BO	O
##X	O
##1	O
enzyme	O
was	O
absent	O
.	O

The	O
ions	O
observed	O
at	O
m	O
/	O
z	O
29	O
##1	O
.	O
1	O
and	O
m	O
/	O
z	O
29	O
##6	O
.	O
1	O
,	O
respectively	O
,	O
in	O
the	O
spectrum	O
of	O
NO	O
_	O
2	O
-	O
Ph	O
##IP	O
-	O
and	O
NO	O
_	O
2	O
-	O
[	O
_	O
2	O
H	O
_	O
5	O
]	O
-	O
Ph	O
##IP	O
-	O
modified	O
AS	O
##SA	O
##K	O
##Q	O
##R	O
are	O
at	O
the	O
same	O
m	O
/	O
z	O
observed	O
in	O
the	O
s	O
##pect	O
##ra	O
of	O
des	B
##ami	I
##no	I
-	I
Ph	I
##IP	I
-	I
K	I
(	O
[	O
K	O
*	O
-	O
NH	O
_	O
3	O
-	O
HC	O
##O	O
_	O
2	O
H	O
]	O
_	O
+	O
,	O
suggesting	O
that	O
NO	O
_	O
2	O
-	O
Ph	O
##IP	O
had	O
bound	O
to	O
l	B
##ys	I
##ine	I
.	O

The	O
g	B
##lu	I
##cu	I
##ron	I
##ide	I
con	O
##ju	O
##gate	O
was	O
the	O
dominant	O
u	O
##rina	O
##ry	O
ex	O
##cre	O
##tion	O
product	O
of	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
in	O
all	O
41	O
##3	O
cases	O
with	O
a	O
mean	O
ratio	O
of	O
1	O
:	O
2	O
.	O
1	O
for	O
su	O
##lf	O
##ate	O
/	B
g	B
##lu	I
##cu	I
##ron	I
##ide	I
.	O

In	O
order	O
to	O
reach	O
a	O
reliable	O
result	O
,	O
we	O
took	O
all	O
types	O
of	O
50	O
cancer	O
urine	O
##s	O
as	O
“	O
cancer	O
samples	O
”	O
,	O
also	O
collected	O
30	O
healthy	O
urine	O
##s	O
as	O
“	O
healthy	O
control	O
”	O
,	O
then	O
,	O
the	O
pool	O
##ed	O
samples	O
of	O
cancer	O
and	O
healthy	O
control	O
were	O
labeled	O
with	O
B	O
##Q	O
##B	O
and	O
B	O
##Q	O
##B	O
-	O
d	O
_	O
7	O
to	O
form	O
the	O
forward	O
and	O
reverse	O
label	O
##ing	O
samples	O
to	O
access	O
the	O
content	O
changes	O
of	O
th	B
##iol	I
in	O
mixed	O
cancer	O
##s	O
compared	O
to	O
healthy	O
control	O
.	O

In	O
addition	O
,	O
and	O
importantly	O
,	O
_	O
15	O
N	B
-	I
ch	I
##ola	I
##mine	I
possesses	O
a	O
permanent	O
positive	O
charge	O
,	O
which	O
enables	O
efficient	O
positive	O
mode	O
detection	O
of	O
the	O
same	O
car	O
##box	O
##yl	O
-	O
containing	O
meta	O
##bol	O
##ites	O
by	O
MS	O
,	O
i	O
##rre	O
##spective	O
of	O
the	O
pH	O
or	O
solvent	O
conditions	O
of	O
the	O
el	O
##uti	O
##ng	O
media	O
,	O
commonly	O
used	O
for	O
ch	O
##roma	O
##to	O
##graphic	O
separation	O
before	O
detection	O
by	O
MS	O
.	O

Similar	O
findings	O
were	O
observed	O
when	O
we	O
excluded	O
the	O
54	O
color	O
##ec	O
##tal	O
cancer	O
cases	O
:	O
C	O
##MP	O
##F	O
0	O
.	O
36	O
per	O
unit	O
SD	O
;	O
s	B
##te	I
##aro	I
##yl	I
-	I
a	I
##rac	I
##hi	I
##don	I
##oy	I
##l	I
-	I
GP	I
##P	I
##E	I
–	O
0	O
.	O
39	O
per	O
unit	O
SD	O
;	O
s	B
##te	I
##aro	I
##yl	I
-	I
l	I
##ino	I
##leo	I
##yl	I
-	I
GP	I
##P	I
##E	I
–	O
0	O
.	O
41	O
per	O
unit	O
SD	O
;	O
3	B
-	I
h	I
##ydro	I
##xy	I
##se	I
##ba	I
##cate	I
–	O
0	O
.	O
25	O
per	O
unit	O
SD	O
;	O
er	B
##uc	I
##oy	I
##l	I
s	I
##phi	I
##ngo	I
##my	I
##elin	I
0	O
.	O
35	O
per	O
unit	O
SD	O
;	O
p	B
##ali	I
##mit	I
##oy	I
##l	I
-	I
o	I
##leo	I
##yl	I
-	I
GP	I
##P	I
##G	I
0	O
.	O
20	O
per	O
unit	O
SD	O
;	O
EPA	O
0	O
.	O
20	O
per	O
unit	O
SD	O
;	O
and	O
D	O
##HA	O
0	O
.	O
11	O
per	O
unit	O
SD	O
.	O

Similarly	O
,	O
GP	O
-	O
tag	O
##ged	O
3	B
-	I
o	I
##x	I
##och	I
##ole	I
##st	I
-	I
4	I
-	I
en	I
-	I
26	I
-	I
o	I
##ic	I
acid	I
(	O
CA	O
_	O
4	O
-	O
3	O
-	O
one	O
)	O
was	O
only	O
identified	O
following	O
treatment	O
with	O
bacterial	O
ch	B
##ole	I
##ster	I
##ol	I
o	O
##xi	O
##das	O
##e	O
and	O
thus	O
must	O
originate	O
from	O
end	O
##ogen	O
##ous	O
3	B
##β	I
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##t	I
-	I
5	I
-	I
en	I
-	I
26	I
-	I
o	I
##ic	I
acid	I
.	O

Ham	O
##man	O
et	O
al	O
.	O
have	O
demonstrated	O
that	O
0	O
.	O
1	O
%	O
am	B
##mon	I
##ium	I
h	I
##ydro	I
##xi	I
##de	I
in	O
met	B
##han	I
##ol	I
as	O
a	O
m	O
##od	O
##ifier	O
improve	O
##s	O
peak	O
shape	O
and	O
decreases	O
retention	O
of	O
basic	O
drugs	O
on	O
both	O
et	B
##hyl	I
##py	I
##rid	I
##ine	I
and	O
di	B
##ol	I
columns	O
,	O
and	O
have	O
also	O
tested	O
the	O
stability	O
of	O
si	O
##lica	O
-	O
supported	O
ch	O
##ira	O
##l	O
stationary	O
phases	O
in	O
the	O
presence	O
of	O
this	O
m	O
##od	O
##ifier	O
under	O
SF	O
##C	O
conditions	O
.	O

The	O
down	O
##re	O
##gu	O
##lation	O
of	O
u	O
##ri	O
-	O
din	O
##e	O
and	O
x	B
##ant	I
##hine	I
in	O
DC	O
vs	O
.	O
NH	O
##C	O
followed	O
by	O
increased	O
levels	O
of	O
these	O
n	O
##uc	O
##leo	O
##tide	O
##s	O
in	O
HC	O
##C	O
supports	O
the	O
principle	O
of	O
metabolic	O
enhance	O
##ment	O
during	O
HC	O
##C	O
development	O
.	O

The	O
u	O
##rina	O
##ry	O
u	B
##rea	I
concentration	O
positively	O
associated	O
with	O
kidney	O
transplant	O
rejection	O
in	O
our	O
study	O
might	O
be	O
reflective	O
of	O
increases	O
in	O
the	O
respective	O
serum	O
levels	O
.	O

Tri	B
##acy	I
##l	I
##gly	I
##cer	I
##ides	I
with	O
longer	O
fatty	O
acid	O
chains	O
and	O
higher	O
degree	O
of	O
un	O
##sat	O
##uration	O
were	O
found	O
at	O
higher	O
levels	O
in	O
infected	O
individuals	O
compared	O
to	O
controls	O
.	O

The	O
flow	O
-	O
rate	O
was	O
1	O
m	O
##L	O
/	O
min	O
or	O
1	O
.	O
2	O
m	O
##L	O
/	O
min	O
,	O
depending	O
upon	O
whether	O
is	B
##op	I
##rop	I
##ano	I
##l	I
or	O
met	B
##han	I
##ol	I
(	O
respectively	O
)	O
was	O
used	O
as	O
m	O
##od	O
##ifier	O
.	O

Several	O
s	O
##tero	O
##id	O
meta	O
##bol	O
##ites	O
in	O
the	O
pre	B
##gne	I
##no	I
##lone	I
pathway	O
were	O
increased	O
after	O
le	O
##pt	O
##in	O
replacement	O
.	O

A	O
##bb	O
##re	O
##viation	O
##s	O
:	O
A	B
##F	I
,	O
at	O
##rial	O
fi	O
##bri	O
##lla	O
##tion	O
;	O
VIP	O
,	O
variable	O
importance	O
in	O
the	O
projection	O
;	O
SF	O
##A	O
,	O
saturated	O
fatty	O
acid	O
;	O

Moreover	O
,	O
ace	B
##tone	I
,	O
which	O
was	O
identified	O
as	O
a	O
potential	O
female	O
-	O
specific	O
bio	O
##mark	O
##er	O
in	O
this	O
study	O
,	O
was	O
significantly	O
increased	O
in	O
female	O
B	O
##D	O
subjects	O
but	O
non	O
-	O
statistical	O
##ly	O
significantly	O
increased	O
in	O
male	O
B	O
##D	O
subjects	O
.	O

St	O
##ero	O
##id	O
treatment	O
is	O
known	O
to	O
alter	O
the	O
lip	O
##op	O
##rote	O
##in	O
profile	O
,	O
with	O
the	O
primary	O
effect	O
of	O
pre	B
##dn	I
##is	I
##olo	I
##ne	I
being	O
an	O
increase	O
in	O
total	O
L	B
##D	I
##L	I
ch	I
##ole	I
##ster	I
##ol	I
concentration	O
.	O

In	O
human	O
plasma	O
,	O
PC	O
##s	O
comprise	O
about	O
60	O
-	O
70	O
%	O
,	O
SM	O
##s	O
10	O
-	O
20	O
%	O
and	O
l	O
##ys	O
##o	O
##PC	O
##s	O
10	O
-	O
20	O
%	O
of	O
the	O
circulating	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
.	O

Ch	O
##eese	O
samples	O
were	O
extracted	O
with	O
n	B
-	I
pen	I
##tan	I
##e	I
in	O
a	O
Sox	O
##hl	O
##et	O
apparatus	O
.	O

The	O
con	O
##com	O
##ita	O
##nt	O
elevation	O
of	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
in	O
our	O
HC	O
##C	O
vs	O
.	O
DC	O
comparison	O
suggests	O
over	O
##act	O
##ivity	O
of	O
x	B
##ant	I
##hine	I
o	O
##xi	O
##das	O
##e	O
in	O
HC	O
##C	O
.	O

Cho	B
##line	I
has	O
also	O
been	O
associated	O
with	O
the	O
dem	O
##ye	O
##lina	O
##ting	O
process	O
in	O
the	O
C	O
##NS	O
.	O

Su	O
##spect	O
##ed	O
masses	O
identified	O
through	O
the	O
precursor	O
ion	O
scan	O
were	O
targeted	O
for	O
product	O
ion	O
analysis	O
to	O
confirm	O
further	O
the	O
identity	O
of	O
these	O
anal	O
##yte	O
##s	O
as	O
true	O
meta	O
##bol	O
##ites	O
derived	O
from	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
.	O

With	O
respect	O
to	O
ad	O
##ip	O
##ose	O
tissue	O
distribution	O
,	O
a	O
study	O
in	O
mice	O
suggested	O
a	O
body	O
fat	O
lowering	O
effect	O
and	O
pipe	B
##rine	I
-	I
treatment	I
of	O
3	O
##T	O
##3	O
-	O
L	O
##1	O
cells	O
reduced	O
lip	O
##id	O
storage	O
as	O
well	O
as	O
blocked	O
their	O
differentiation	O
into	O
ad	O
##ip	O
##ocytes	O
.	O

C	O
illustrate	O
##s	O
the	O
change	O
in	O
peak	O
width	O
and	O
resolution	O
observed	O
when	O
using	O
a	O
Tor	O
##us	O
D	B
##IO	I
##L	I
column	O
at	O
55	O
°C	O
rather	O
than	O
at	O
35	O
°C	O
.	O

Con	O
##c	O
##lusion	O
##s	O
:	O
Male	O
smoke	O
##rs	O
supplemented	O
with	O
β	B
-	I
car	I
##ote	I
##ne	I
developed	O
meta	O
##bol	O
##omi	O
##c	O
profiles	O
consistent	O
with	O
the	O
induction	O
of	O
c	O
##yt	O
##och	O
##rome	O
P	O
##45	O
##0	O
enzymes	O
,	O
the	O
primary	O
meta	O
##bol	O
##izer	O
##s	O
of	O
x	O
##eno	O
##biotics	O
in	O
humans	O
.	O

After	O
addition	O
of	O
internal	O
standard	O
(	O
10	O
μ	O
L	O
of	O
L	B
-	I
2	I
-	I
ch	I
##lor	I
##op	I
##hen	I
##yla	I
##lani	I
##ne	I
in	O
water	O
,	O
0	O
.	O
3	O
mg	O
/	O
m	O
##L	O
)	O
,	O
the	O
samples	O
were	O
combined	O
with	O
400	O
μ	O
L	O
of	O
a	O
mixture	O
of	O
water	O
,	O
met	B
##han	I
##ol	I
,	O
and	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
(	I
1	I
:	I
2	I
:	I
7	I
)	I
.	O

However	O
,	O
fraction	O
of	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
to	O
total	O
lip	O
##ids	O
in	O
medium	O
and	O
small	O
L	O
##D	O
##L	O
were	O
negatively	O
correlated	O
with	O
insulin	O
sensitivity	O
similarly	O
to	O
t	B
##rig	I
##ly	I
##cer	I
##ide	I
fraction	O
and	O
fraction	O
of	O
ch	B
##ole	I
##ster	I
##ol	I
to	O
total	O
lip	O
##ids	O
had	O
a	O
positive	O
correlation	O
to	O
insulin	O
sensitivity	O
.	O

In	O
contrast	O
to	O
the	O
40	O
T	O
##h	O
series	O
of	O
fragment	O
ions	O
whose	O
m	O
/	O
z	O
values	O
are	O
larger	O
than	O
the	O
diagnostic	O
fragment	O
ion	O
at	O
m	O
/	O
z	O
30	O
##9	O
,	O
the	O
fragment	O
ions	O
of	O
m	O
/	O
z	O
values	O
smaller	O
than	O
m	O
/	O
z	O
30	O
##9	O
were	O
present	O
in	O
a	O
similar	O
pattern	O
in	O
tandem	O
mass	O
s	O
##pect	O
##ra	O
of	O
un	O
##sat	O
##ura	O
##ted	O
FA	O
##s	O
compared	O
to	O
the	O
corresponding	O
saturated	O
FA	S
.	O

For	O
this	O
reason	O
,	O
and	O
not	O
surprisingly	O
,	O
92	O
.	O
7	O
pp	O
##b	O
of	O
β	B
-	I
pine	I
##ne	I
nearly	O
saturated	O
the	O
detector	O
of	O
the	O
Or	O
##bit	O
##rap	O
mass	O
analyze	O
##r	O
.	O

However	O
,	O
since	O
the	O
absolute	O
c	B
##rea	I
##tin	I
##ine	I
concentration	O
,	O
which	O
was	O
used	O
for	O
normal	O
##ization	O
,	O
varied	O
by	O
20	O
–	O
30	O
%	O
between	O
visits	O
it	O
is	O
not	O
clear	O
which	O
of	O
the	O
smaller	O
changes	O
are	O
specific	O
to	O
pregnancy	O
and	O
which	O
are	O
due	O
to	O
di	O
##lution	O
effects	O
.	O

Similarly	O
,	O
an	O
increase	O
in	O
x	B
##ant	I
##hine	I
o	O
##xi	O
##das	O
##e	O
activity	O
has	O
also	O
been	O
observed	O
in	O
the	O
plasma	O
of	O
T	O
##2	O
##DM	O
patients	O
,	O
which	O
may	O
be	O
the	O
reason	O
of	O
the	O
up	O
##re	O
##gu	O
##lation	O
of	O
u	B
##ric	I
acid	I
and	O
down	O
##re	O
##gu	O
##lation	O
of	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
and	O
x	B
##ant	I
##hine	I
.	O

_	O
,	O
These	O
studies	O
,	O
based	O
on	O
liquid	O
ch	O
##roma	O
##tography	O
-	O
mass	O
s	O
##pect	O
##rome	O
##try	O
(	O
L	O
##C	O
-	O
MS	O
)	O
methods	O
,	O
have	O
shown	O
that	O
the	O
magnitude	O
of	O
g	O
##lut	O
##amine	O
c	O
##y	O
##c	O
##li	O
##zation	O
to	O
p	B
##yr	I
##og	I
##lut	I
##ami	I
##c	I
acid	I
is	O
significant	O
,	O
which	O
highlights	O
the	O
magnitude	O
of	O
error	O
introduced	O
in	O
the	O
analysis	O
of	O
these	O
meta	O
##bol	O
##ites	O
if	O
not	O
accounted	O
for	O
appropriately	O
.	O

The	O
established	O
risk	O
markers	O
are	O
:	O
gender	O
,	O
waist	O
c	O
##ir	O
##cum	O
##ference	O
,	O
B	O
##MI	O
,	O
age	O
and	O
base	O
##line	O
fast	O
##ing	O
glucose	S
levels	O
.	O

The	O
product	O
ion	O
s	O
##pect	O
##ra	O
of	O
these	O
meta	O
##bol	O
##ites	O
differ	O
from	O
those	O
s	O
##pect	O
##ra	O
of	O
the	O
g	B
##lu	I
##cu	I
##ron	I
##ide	I
con	O
##ju	O
##gate	O
##s	O
of	O
H	O
##ON	O
##H	O
-	O
Ph	O
##IP	O
and	O
4	O
′	O
-	O
H	O
##O	O
-	O
Ph	O
##IP	O
.	O

L	O
[	O
I	O
##Q	O
##R	O
-	O
0	O
.	O
20	O
,	O
0	O
.	O
56	O
]	O
)	O
compared	O
with	O
the	O
other	O
treatment	O
regime	O
##ns	O
which	O
had	O
stable	O
or	O
slight	O
decreases	O
in	O
L	B
##D	I
##L	I
ch	I
##ole	I
##ster	I
##ol	I
(	O
at	O
##az	O
##ana	O
##vir	O
/	O
r	O
0	O
.	O
16	O
mm	O
##ol	O
/	O
L	O

The	O
loading	O
##s	O
and	O
explained	O
variance	O
of	O
PC	O
1	O
also	O
show	O
that	O
all	O
the	O
labs	O
are	O
identifying	O
glucose	S
and	O
other	O
sugar	O
##s	O
as	O
the	O
major	O
difference	O
among	O
the	O
samples	O
.	O

In	O
this	O
regard	O
,	O
Yo	O
##o	O
found	O
low	O
amounts	O
of	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
in	O
the	O
urine	O
of	O
non	O
-	O
Ho	O
##d	O
##g	O
##kin	O
l	O
##ymph	O
##oma	O
(	O
NHL	O
)	O
patients	O
,	O
while	O
plasma	O
levels	O
were	O
elevated	O
in	O
children	O
with	O
acute	O
l	O
##ymph	O
##ob	O
##lastic	O
le	O
##uke	O
##mia	O
(	O
AL	O
##L	O
)	O
or	O
NHL	O
:	O
In	O
these	O
patients	O
,	O
treatment	O
with	O
high	O
-	O
dose	O
met	O
##hot	O
##re	O
##xa	O
##te	O
lowered	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
levels	O
.	O

Historically	O
,	O
e	O
##pid	O
##em	O
##iol	O
##og	O
##ic	O
and	O
clinical	O
studies	O
of	O
est	B
##rad	I
##iol	I
have	O
relied	O
on	O
radio	O
##im	O
##mu	O
##no	O
##ass	O
##ays	O
and	O
E	O
##IA	O
,	O
which	O
could	O
include	O
extraction	O
and	O
/	O
or	O
ch	O
##roma	O
##tography	O
(	O
indirect	O
methods	O
)	O
or	O
no	O
pu	O
##rification	O
(	O
direct	O
methods	O
)	O
.	O

Ana	O
##ly	O
##ses	O
were	O
conducted	O
in	O
148	O
participants	O
in	O
the	O
Cho	B
##les	I
##tero	I
##l	I
and	O
Ph	O
##arma	O
##co	O
##gene	O
##tics	O
study	O
who	O
were	O
profile	O
##d	O
pre	O
and	O
six	O
weeks	O
post	O
treatment	O
with	O
40	O
mg	O
/	O
day	O
si	B
##m	I
##vas	I
##tat	I
##in	I
:	O
100	O
randomly	O
selected	O
from	O
the	O
full	O
range	O
of	O
the	O
L	O
##D	O
##L	O
-	O
C	O
response	O
distribution	O
and	O
24	O
each	O
from	O
the	O
top	O
and	O
bottom	O
10	O
%	O
of	O
this	O
distribution	O
(	O
“	O
good	O
”	O
and	O
“	O
poor	O
”	O
respond	O
##ers	O
,	O
respectively	O
)	O
.	O

In	O
our	O
population	O
,	O
the	O
relative	O
presence	O
of	O
t	B
##yr	I
##os	I
##ine	I
(	O
Ty	O
##r	O
/	O
Ph	O
##e	O
ratio	O
)	O
was	O
gradually	O
lower	O
in	O
more	O
evolved	O
C	O
##K	O
##D	O
stages	O
,	O
and	O
we	O
found	O
a	O
tendency	O
to	O
declining	O
t	B
##yr	I
##os	I
##ine	I
concentrations	O
with	O
C	O
##K	O
##D	O
severity	O
.	O

The	O
molecular	O
networking	O
approach	O
thus	O
allows	O
an	O
##not	O
##ation	O
of	O
numerous	O
anti	O
##hy	O
##pert	O
##ens	O
##ive	O
drugs	O
(	O
and	O
anti	O
##dia	O
##bet	O
##ic	O
and	O
his	B
##tamine	I
antagonist	O
##s	O
,	O
see	O
Se	O
##ct	O
.	O
3	O
.	O
3	O
)	O
in	O
the	O
urine	O
extract	O
##s	O
.	O

Another	O
home	O
##ost	O
##atic	O
phenomenon	O
,	O
i	O
.	O
e	O
.	O
lip	O
##oly	O
##sis	O
of	O
ad	O
##ip	O
##ose	O
tissue	O
,	O
results	O
in	O
the	O
liberation	O
of	O
g	B
##ly	I
##cer	I
##ol	I
and	O
free	O
fatty	O
acids	O
.	O

Therefore	O
,	O
in	B
##os	I
##ine	I
and	O
ch	B
##eno	I
##de	I
##ox	I
##ych	I
##olic	I
acid	I
should	O
be	O
further	O
investigated	O
as	O
potential	O
markers	O
for	O
HC	O
##C	O
s	O
##tra	O
##ti	O
##fication	O
.	O

As	O
shown	O
in	O
Figure	O
S	O
##5	O
,	O
ATP	S
was	O
readily	O
de	O
##graded	O
to	O
AD	B
##P	I
and	O
AM	B
##P	I
at	O
both	O
150	O
and	O
250	O
°C	O
,	O
which	O
could	O
be	O
further	O
de	O
##graded	O
into	O
ad	B
##eno	I
##sin	I
##e	I
and	O
ad	B
##eni	I
##ne	I
at	O
250	O
°C	O
.	O

Fast	O
##er	O
ni	B
##cot	I
##ine	I
metabolism	O
may	O
contribute	O
to	O
an	O
elevated	O
risk	O
for	O
smoking	O
and	O
tobacco	O
-	O
related	O
disease	O
in	O
the	O
N	O
##P	O
relative	O
to	O
the	O
S	O
##W	O
,	O
as	O
well	O
as	O
in	O
comparison	O
to	O
other	O
ethnic	O
populations	O
in	O
the	O
United	O
States	O
.	O

The	O
current	O
base	O
width	O
data	O
supports	O
the	O
use	O
of	O
water	O
as	O
an	O
add	O
##itive	O
to	O
improve	O
peak	O
shapes	O
for	O
acids	O
and	O
sugar	O
##s	O
,	O
while	O
its	O
use	O
has	O
previously	O
been	O
demonstrated	O
to	O
give	O
sharp	O
##er	O
peaks	O
for	O
n	O
##uc	O
##leo	O
##base	O
##s	O
on	O
a	O
variety	O
of	O
stationary	O
phases	O
,	O
including	O
di	B
##ol	I
,	O
c	O
##yan	O
##op	O
##rop	O
##yl	O
and	O
2	O
-	O
EP	O
.	O

In	O
addition	O
,	O
ch	B
##olin	I
##e	I
is	O
found	O
in	O
various	O
water	O
-	O
and	O
lip	O
##id	O
-	O
soluble	O
forms	O
in	O
milk	O
,	O
which	O
can	O
differ	O
in	O
their	O
absorption	O
,	O
transport	O
and	O
metabolism	O
in	O
the	O
nursing	O
infant	O
.	O

3	B
-	I
H	I
##B	I
=	I
3	I
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
,	O
BC	O
##AA	O
##s	O
=	O
branched	O
-	O
chain	O
amino	O
acids	O
,	O
G	O
##CT	O
=	O
giant	O
cell	O
tumor	O
of	O
bone	O
,	O
GP	B
##C	I
=	I
g	I
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##och	I
##olin	I
##e	I
,	O
HC	O
=	O
healthy	O
controls	O
,	O
O	B
##AG	I
=	I
O	I
-	I
ace	I
##ty	I
##l	I
-	I
g	I
##ly	I
##co	I
##p	I
##rote	I
##in	I
,	O
R	O
##OS	O
=	O
reactive	O
oxygen	O
species	O
,	O
SC	O
##FA	O
##s	O
=	O
short	O
-	O
chain	O
fatty	O
acids	O
,	O
T	B
##G	I
=	I
t	I
##rig	I
##ly	I
##cer	I
##ide	I
.	O

After	O
controlling	O
for	O
sex	O
and	O
batch	O
effects	O
,	O
there	O
was	O
no	O
significant	O
effect	O
of	O
diagnosis	O
on	O
CR	O
##P	O
,	O
IL	O
##1	O
-	O
RA	O
,	O
and	O
any	O
of	O
the	O
individual	O
k	B
##yn	I
##uren	I
##ine	I
meta	O
##bol	O
##ites	O
although	O
IL	O
-	O
1	O
##RA	O
concentrations	O
trend	O
##ed	O
higher	O
in	O
the	O
d	O
##MD	O
##D	O
group	O
versus	O
the	O
HC	O
##s	O
(	O
p	O
=	O
0	O
.	O
05	O
##9	O
)	O
.	O

The	O
abnormal	O
##ities	O
in	O
the	O
group	O
of	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
were	O
also	O
observed	O
in	O
urine	O
of	O
patients	O
with	O
kidney	O
and	O
he	O
##pa	O
##to	O
##cellular	O
cancer	O
(	O
Kim	O
##hof	O
##er	O
et	O
al	O
.	O
;	O
G	O
##anti	O
et	O
al	O
.	O
)	O
.	O

The	O
film	O
was	O
digit	O
##ized	O
using	O
a	O
high	O
-	O
resolution	O
scan	O
##ner	O
and	O
the	O
image	O
density	O
of	O
appropriate	O
bands	O
(	O
130	O
k	O
##D	O
##a	O
for	O
PC	O
and	O
50	O
k	O
##D	O
##a	O
for	O
α	B
-	I
tub	I
##ulin	I
)	O
was	O
analyzed	O
using	O
Image	O
J	O
(	O
N	O
##I	O
##H	O
,	O
Beth	O
##es	O
##da	O
,	O
MD	O
)	O
.	O

Within	O
PC	O
,	O
saturated	O
and	O
mon	O
##ou	O
##ns	O
##at	O
##ura	O
##ted	O
lower	O
MW	O
species	O
,	O
as	O
well	O
as	O
higher	O
un	O
##sat	O
##ura	O
##ted	O
MW	O
species	O
were	O
significantly	O
increased	O
in	O
tumor	O
e	O
##pit	O
##hel	O
##ial	O
cells	O
(	O
for	O
their	O
expected	O
FA	S
composition	O
,	O
see	O
)	O
.	O

OR	O
##s	O
of	O
potential	O
s	B
##phi	I
##ngo	I
##lip	I
##id	I
bio	O
##mark	O
##ers	O
for	O
T	O
##2	O
##DM	O
with	O
card	O
##iovascular	O
complications	O
.	O

Data	O
from	O
the	O
SS	O
##Q	O
were	O
analyzed	O
for	O
median	O
is	B
##of	I
##lav	I
##one	I
intake	O
##s	O
and	O
were	O
reported	O
along	O
with	O
the	O
25	O
_	O
th	O
and	O
75	O
_	O
th	O
percent	O
##ile	O
.	O

It	O
is	O
well	O
known	O
that	O
12	B
,	I
13	I
-	I
Di	I
##H	I
##OM	I
##E	I
is	O
produced	O
in	O
humans	O
from	O
l	B
##ino	I
##le	I
##ic	I
acid	I
,	O
via	O
its	O
oxidation	O
(	O
by	O
P	O
##45	O
##0	O
mon	O
##ox	O
##y	O
##gen	O
##ase	O
)	O
to	O
the	O
pro	B
##to	I
##xin	I
12	I
,	I
13	I
-	I
E	I
##p	I
##OM	I
##E	I
(	O
is	O
##ole	O
##uk	O
##oto	O
##xin	O
)	O
,	O
followed	O
by	O
conversion	O
to	O
12	B
,	I
13	I
-	I
Di	I
##H	I
##OM	I
##E	I
via	O
the	O
12	B
,	I
13	I
-	I
E	I
##p	I
##OM	I
##E	I
by	O
s	O
##E	O
##H	O
.	O

Inc	O
##reased	O
levels	O
of	O
p	B
##hy	I
##tos	I
##phi	I
##ngo	I
##sin	I
##e	I
and	O
s	B
##phi	I
##nga	I
##nine	I
may	O
reflect	O
a	O
relatively	O
higher	O
tumor	O
cell	O
proliferation	O
rate	O
and	O
increased	O
lip	O
##id	O
membrane	O
re	O
##mo	O
##del	O
##ing	O
.	O

FF	O
##A	O
,	O
Free	O
Fat	O
A	O
##cid	O
##s	O
;	O
T	O
##CA	O
,	O
Tri	B
##car	I
##box	I
##yl	I
##ic	I
A	I
##cid	I
;	O
N	B
##AD	I
##P	I
##H	I
,	O
Nico	B
##tina	I
##mi	I
##de	I
ad	I
##eni	I
##ne	I
din	I
##uc	I
##leo	I
##tide	I
phosphate	I
;	O
NO	O
##S	O
,	O
Ni	B
##tric	I
O	I
##xi	I
##de	I
S	O
##ynth	O
##ase	O
;	O
AA	O
,	O
Ara	B
##chi	I
##don	I
##ic	I
acid	I
;	O
P	O
##GB	O
##2	O
,	O
Pro	B
##sta	I
##g	I
##land	I
##in	I
B	I
##2	I
;	O
Car	B
##box	I
##y	I
-	I
L	I
##T	I
##B	I
##4	I
,	O
Car	B
##box	I
##y	I
-	I
Le	I
##uk	I
##ot	I
##rien	I
##e	I
B	O
##4	O
.	O

Initial	O
stocks	O
,	O
1	O
µ	O
##g	O
/	O
µ	O
##L	O
,	O
were	O
made	O
in	O
D	B
##MS	I
##O	I
.	O

Indoor	O
air	O
PA	O
##H	O
##s	O
identified	O
are	O
Na	B
##pt	I
##hale	I
##ne	I
,	O
flu	O
##ori	O
##ne	O
,	O
ace	O
##nap	O
##ht	O
##hen	O
##e	O
,	O
p	B
##hen	I
##ant	I
##hren	I
##e	I
,	O
p	O
##yre	O
##ne	O
,	O
ch	O
##ry	O
##sen	O
##e	O
and	O
in	O
##den	O
##o	O
[	B
1	B
,	I
2	I
,	I
3	I
-	I
c	I
##d	I
)	O
p	O
##yre	O
##ne	O
.	O

In	O
summary	O
,	O
these	O
prior	O
studies	O
identified	O
similar	O
meta	O
##bol	O
##ites	O
as	O
the	O
current	O
study	O
,	O
including	O
ace	B
##tone	I
,	O
a	B
##rg	I
##ini	I
##ne	I
,	O
and	O
g	B
##ly	I
##cine	I
,	O
as	O
well	O
as	O
pathways	O
such	O
as	O
g	B
##ly	I
##cine	I
and	O
se	B
##rine	I
metabolism	O
.	O

Not	O
##ably	O
,	O
we	O
detected	O
ta	B
##mo	I
##xi	I
##fen	I
and	O
its	O
meta	O
##bol	O
##ites	O
in	O
all	O
serum	O
samples	O
[	O
range	O
31	O
-	O
247	O
ng	O
/	O
m	O
##l	O
for	O
ta	B
##mo	I
##xi	I
##fen	I
]	O
indicating	O
good	O
compliance	O
for	O
the	O
patients	O
included	O
(	O
Table	O
)	O
.	O

In	O
contrast	O
,	O
al	B
##ani	I
##ne	I
and	O
g	B
##lut	I
##ami	I
##c	I
acid	I
post	O
-	O
treatment	O
levels	O
were	O
high	O
in	O
patients	O
with	O
high	O
post	O
-	O
treatment	O
insulin	O
or	O
H	O
##OM	O
##A	O
levels	O
;	O
however	O
,	O
the	O
relationship	O
did	O
not	O
pass	O
multiple	O
hypothesis	O
testing	O
.	O

-	O
9	O
,	O
trans	O
)	O
)	O
,	O
obtained	O
from	O
Ava	O
##nti	O
Polar	O
Li	O
##pid	O
##s	O
(	O
Al	O
##aba	O
##ster	O
,	O
AL	O
)	O
,	O
and	O
the	O
PC	B
18	I
:	I
0	I
_	I
18	I
:	I
2	I
(	I
n	I
-	I
7	I
trans	I
,	I
n	I
-	I
9	I
c	I
##is	I
)	I
and	O
PC	B
18	I
:	I
0	I
_	I
18	I
:	I
2	I
(	I
n	I
-	I
6	I
trans	I
,	I
n	I
-	I
8	I
c	I
##is	I
)	I
standards	O
,	O
purchased	O
from	O
Mat	O
##rey	O
##a	O
LLC	O
(	O
State	O
College	O
,	O
PA	O
)	O
,	O
were	O
di	O
##lut	O
##ed	O
to	O
5	O
µ	O
##M	O
in	O
2	O
:	O
1	O
met	O
##han	O
##ol	O
:	O
ch	O
##lor	O
##of	O
##orm	O
and	O
in	O
##fused	O
directly	O
into	O
the	O
mass	O
s	O
##pect	O
##rome	O
##ter	O
at	O
a	O
flow	O
rate	O
of	O
50	O
µ	O
##L	O
min	O
_	O
−	O
##1	O
.	O

Tri	O
##gly	O
##cer	O
##ides	O
h	O
##ydro	O
##lysis	O
results	O
in	O
a	O
high	O
concentration	O
of	O
free	O
fatty	O
acids	O
that	O
undergo	O
beta	O
oxidation	O
which	O
is	O
supplement	O
##ing	O
T	O
##CA	O
cycle	O
and	O
k	B
##eton	I
##e	I
bodies	O
synthesis	O
by	O
providing	O
ace	B
##ty	I
##l	I
-	I
Co	I
##A	I
m	O
##oi	O
##eti	O
##es	O
.	O

We	O
previously	O
reported	O
a	O
weaker	O
vitamin	O
B	O
-	O
12	O
bio	O
##chemical	O
response	O
to	O
vitamin	O
B	O
-	O
12	O
treatment	O
in	O
participants	O
from	O
this	O
study	O
who	O
had	O
moderately	O
high	O
and	O
high	O
f	B
##olate	I
at	O
base	O
##line	O
.	O

AM	O
-	O
2	O
was	O
detected	O
in	O
the	O
urine	O
of	O
Case	O
#	O
1	O
at	O
a	O
concentration	O
of	O
3	O
.	O
2	O
ng	O
/	O
m	O
##L	O
.	O
Ace	B
##tam	I
##ip	I
##rid	I
was	O
not	O
detected	O
in	O
Case	O

Inc	O
##reased	O
long	O
-	O
chain	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
levels	O
have	O
also	O
been	O
associated	O
with	O
insulin	O
resistance	O
with	O
diabetes	O
,	O
possibly	O
via	O
interference	O
of	O
insulin	O
signaling	O
within	O
the	O
cell	O
membrane	O
,	O
while	O
this	O
relation	O
is	O
less	O
clear	O
for	O
short	O
-	O
chain	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
.	O

The	O
de	O
##uter	O
##ated	O
buffer	O
contained	O
0	O
.	O
5	O
m	O
##M	O
sodium	B
trim	I
##eth	I
##yl	I
##si	I
##ly	I
##l	I
##ph	I
##os	I
##phate	I
(	O
T	O
##SP	O
)	O
to	O
provide	O
a	O
reference	O
substance	O
for	O
the	O
an	O
##not	O
##ation	O
of	O
the	O
N	O
##MR	O
s	O
##pect	O
##ra	O
.	O

In	O
fact	O
,	O
a	O
recent	O
study	O
showed	O
that	O
a	O
low	O
fat	O
diet	O
(	O
L	O
##F	O
##D	O
)	O
led	O
to	O
an	O
increase	O
in	O
very	O
-	O
L	O
##D	O
##L	O
(	O
V	O
##LD	O
##L	O
)	O
palm	B
##itic	I
(	I
C	I
##16	I
:	I
0	I
)	I
,	O
s	O
##te	O
##ari	O
##c	O
(	B
C	B
##18	I
:	I
0	I
)	O
,	O
and	O
palm	O
##ito	O
##le	O
##ic	O
(	O
C	O
##16	O
:	O
1	O
##n	O
##7	O
##c	O
)	O
acids	O
,	O
while	O
no	O
changes	O
were	O
observed	O
on	O
the	O
H	O
##F	O
##D	O
,	O
usually	O
linked	O
to	O
induced	O
I	O
##R	O
.	O

Pre	O
##hy	O
##pert	O
##ens	O
##ion	O
-	O
associated	O
elevations	O
in	O
l	O
##ys	O
##o	O
##PC	O
##s	O
,	O
L	O
##p	O
-	O
P	O
##LA	O
_	O
2	O
activity	O
,	O
o	O
##x	O
-	O
L	O
##D	O
##L	O
,	O
u	O
##rina	O
##ry	O
8	B
-	I
e	I
##pi	I
-	I
P	I
##G	I
##F	I
_	I
2	I
##α	I
,	O
IL	O
-	O
6	O
,	O
and	O
b	O
##a	O
-	O
P	O
##W	O
##V	O
could	O
indicate	O
increased	O
o	O
##xi	O
##da	O
##tive	O
stress	O
from	O
L	O
##p	O
-	O
P	O
##LA	O
_	O
2	O
-	O
cat	O
##aly	O
##zed	O
PC	O
h	O
##ydro	O
##lysis	O
during	O
increased	O
L	O
##D	O
##L	O
oxidation	O
,	O
thereby	O
enhancing	O
pro	O
##in	O
##f	O
##lam	O
##mation	O
and	O
art	O
##erial	O
stiff	O
##ness	O
.	O

The	O
intermediate	O
##s	O
in	O
this	O
pathway	O
,	O
ch	B
##olin	I
##e	I
,	O
beta	B
##ine	I
,	O
dim	B
##eth	I
##yl	I
##gly	I
##cine	I
,	O
and	O
sa	B
##rc	I
##os	I
##ine	I
all	O
tend	O
to	O
be	O
higher	O
in	O
men	O
.	O

St	B
##yre	I
##ne	I
-	I
7	I
,	I
8	I
-	I
oxide	I
(	O
S	O
##O	O
)	O
is	O
the	O
primary	O
meta	O
##bol	O
##ite	O
of	O
s	B
##ty	I
##rene	I
that	O
forms	O
add	O
##uc	O
##ts	O
with	O
DNA	O
and	O
proteins	O
.	O

The	O
main	O
features	O
of	O
participants	O
included	O
in	O
the	O
longitudinal	O
analyses	O
were	O
similar	O
to	O
those	O
of	O
the	O
whole	O
study	O
population	O
,	O
including	O
age	O
(	O
15	O
.	O
4	O
±	O
3	O
.	O
1	O
years	O
;	O
P	O
=	O
0	O
.	O
52	O
)	O
,	O
sex	O
(	O
nine	O
males	O
and	O
seven	O
females	O
;	O
P	O
=	O
0	O
.	O
33	O
)	O
,	O
ethnicity	O
(	O
nine	O
whites	O
,	O
two	O
blacks	O
,	O
three	O
Hispanic	O
##s	O
,	O
two	O
Asian	O
##s	O
;	O
P	O
=	O
0	O
.	O
83	O
)	O
,	O
B	O
##MI	O
(	O
30	O
.	O
5	O
±	O
7	O
.	O
1	O
kg	O
/	O
m	O
_	O
2	O
;	O
P	O
=	O
0	O
.	O
50	O
)	O
,	O
B	O
##MI	O
z	O
-	O
score	O
(	O
1	O
.	O
76	O
±	O
1	O
.	O
03	O
;	O
P	O
=	O
0	O
.	O
67	O
)	O
,	O
W	O
##BI	O
##SI	O
(	O
2	O
.	O
23	O
±	O
1	O
.	O
86	O
;	O
P	O
=	O
0	O
.	O
28	O
)	O
,	O
I	O
##GI	O
(	O
3	O
.	O
15	O
±	O
1	O
.	O
6	O
;	O
P	O
=	O
0	O
.	O
75	O
)	O
;	O
D	O
##I	O
(	O
4	O
.	O
4	O
±	O
1	O
.	O
5	O
;	O
P	O
=	O
0	O
.	O
07	O
)	O
,	O
H	O
##b	O
##A	O
##1	O
##c	O
(	O
5	O
.	O
4	O
%	O
±	O
0	O
.	O
3	O
%	O
;	O
P	O
=	O
0	O
.	O
91	O
)	O
,	O
and	O
levels	O
of	O
fast	O
##ing	O
glucose	S
(	O
92	O
.	O
3	O
±	O
6	O
.	O
9	O
mg	O
/	O
d	O
##L	O
;	O
P	O
=	O
0	O
.	O
08	O
)	O
and	O
2	O
-	O
hour	O
glucose	S
(	O
122	O
.	O
3	O
±	O
27	O
.	O
5	O
mg	O
/	O
d	O
##L	O
;	O
P	O
=	O
0	O
.	O
21	O
)	O
.	O

B	B
##iot	I
##in	I
su	I
##lf	I
##one	I
is	O
a	O
natural	O
bio	B
##tin	I
meta	O
##bol	O
##ite	O
in	O
human	O
urine	O
.	O

Thus	O
,	O
our	O
study	O
presents	O
the	O
first	O
report	O
for	O
the	O
increased	O
level	O
of	O
HC	O
##ys	O
and	O
γ	B
-	I
G	I
##lu	I
##C	I
##ys	I
in	O
urine	O
of	O
na	O
##so	O
##pha	O
##ryn	O
##ge	O
##al	O
cancer	O
and	O
gas	O
##tric	O
cancer	O
,	O
respectively	O
.	O

A	O
total	O
of	O
48	O
distinguishing	O
meta	O
##bol	O
##ites	O
were	O
identified	O
and	O
13	O
of	O
them	O
were	O
changed	O
along	O
with	O
the	O
development	O
of	O
gas	O
##tric	O
cancer	O
,	O
including	O
is	B
##ole	I
##uc	I
##ine	I
,	O
la	B
##ct	I
##ate	I
,	O
g	B
##lut	I
##ama	I
##te	I
,	O
g	B
##lut	I
##ath	I
##ione	I
,	O
T	B
##MA	I
##O	I
,	O
4	B
-	I
h	I
##ydro	I
##xy	I
##phe	I
##ny	I
##la	I
##ct	I
##ate	I
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
p	B
##hen	I
##ya	I
##ce	I
##ty	I
##l	I
##g	I
##lut	I
##amine	I
,	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
,	O
c	B
##it	I
##ru	I
##llin	I
##e	I
,	O
v	B
##ali	I
##ne	I
,	O
ace	B
##to	I
##ace	I
##tate	I
and	O
met	B
##hyl	I
##amine	I
.	O

Therefore	O
,	O
3	O
##HP	O
##A	O
would	O
be	O
expected	O
to	O
be	O
formed	O
if	O
there	O
are	O
amounts	O
of	O
m	B
-	I
t	I
##yra	I
##mine	I
for	O
the	O
substrate	O
of	O
the	O
two	O
enzymes	O
.	O

g	O
##ru	O
##ber	O
##i	O
t	O
##rop	O
##ho	O
##zo	O
##ites	O
on	O
the	O
U	O
_	O
13	O
C	O
-	O
glucose	O
-	O
containing	O
growth	O
medium	O
identified	O
an	O
ex	O
##ogen	O
##ous	O
origin	O
of	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
while	O
7	B
-	I
de	I
##hy	I
##dr	I
##och	I
##ole	I
##ster	I
##ol	I
(	O
7	O
##D	O
##HC	O
)	O
had	O
en	O
##rich	O
##ed	O
_	O
13	O
C	O
-	O
content	O
,	O
suggesting	O
a	O
dual	O
origin	O
of	O
this	O
meta	O
##bol	O
##ite	O
both	O
from	O
de	O
no	O
##vo	O
bio	O
##sy	O
##nt	O
##hesis	O
and	O
metabolism	O
of	O
s	O
##ca	O
##venge	O
##d	O
ch	B
##ole	I
##ster	I
##ol	I
.	O

Sam	O
##ples	O
were	O
dried	O
under	O
vacuum	O
,	O
and	O
the	O
super	O
##nat	O
##ant	O
was	O
then	O
blended	O
with	O
200	O
μ	O
##l	O
of	O
2	O
%	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
.	O

This	O
study	O
also	O
demonstrated	O
decreased	O
levels	O
of	O
the	O
membrane	O
meta	O
##bol	O
##ite	O
GP	B
##C	I
(	O
Table	O
)	O
.	O

We	O
further	O
conclude	O
that	O
lip	O
##op	O
##rote	O
##ins	O
such	O
as	O
T	O
##GR	O
##L	O
can	O
serve	O
as	O
a	O
depot	O
for	O
fatty	O
acids	O
and	O
o	B
##xy	I
##lip	I
##ins	I
,	O
and	O
propose	O
that	O
these	O
bio	O
##active	O
fatty	O
acid	O
meta	O
##bol	O
##ites	O
transported	O
in	O
T	O
##GR	O
##L	O
could	O
act	O
remotely	O
to	O
directly	O
m	O
##od	O
##ulate	O
an	O
end	O
##oth	O
##eli	O
##al	O
inflammatory	O
response	O
.	O

Re	O
##fer	O
##ring	O
to	O
other	O
types	O
of	O
su	O
##pra	O
##sel	O
##lar	O
tumors	O
,	O
the	O
authors	O
reported	O
low	O
levels	O
of	O
N	B
-	I
ace	I
##ty	I
##l	I
as	I
##par	I
##tate	I
and	O
c	B
##rea	I
##tine	I
and	O
high	O
levels	O
of	O
ch	O
##olin	O
##e	O
-	O
containing	O
compounds	O
in	O
the	O
case	O
of	O
g	O
##lio	O
##mas	O
.	O

(	O
C	O
)	O
Total	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
##s	I
concentration	O
according	O
to	O
the	O
age	O
group	O
.	O

As	O
shown	O
in	O
,	O
the	O
responses	O
of	O
interfering	O
peaks	O
from	O
blank	O
were	O
less	O
than	O
1	O
%	O
of	O
that	O
of	O
Ce	B
##r	I
(	I
22	I
:	I
0	I
)	I
and	O
Ce	B
##r	I
(	I
24	I
:	I
0	I
)	I
in	O
LL	O
##O	O
##Q	O
and	O
less	O
than	O
1	O
%	O
of	O
that	O
of	O
internal	O
standards	O
.	O

Expo	O
##sure	O
to	O
trip	B
##hen	I
##yl	I
phosphate	I
was	O
associated	O
with	O
h	O
##yper	O
##met	O
##hyl	O
##ation	O
at	O
the	O
G	O
##RB	O
##10	O
D	O
##MR	O
;	O
and	O
t	B
##ris	I
(	I
1	I
,	I
3	I
-	I
di	I
##ch	I
##lor	I
##o	I
-	I
2	I
-	I
prop	I
##yl	I
)	I
phosphate	I
exposure	O
was	O
associated	O
with	O
altered	O
met	O
##hyl	O
##ation	O
at	O
the	O
ME	O
##G	O
##3	O
and	O
H	O
##19	O
D	O
##MR	O
##s	O
.	O

Already	O
after	O
15	O
min	O
,	O
we	O
started	O
to	O
observe	O
M	O
##6	O
glucose	S
is	O
##oto	O
##pol	O
##ogue	O
##s	O
,	O
reaching	O
a	O
maximum	O
of	O
1	O
.	O
5	O
%	O
of	O
total	O
glucose	S
after	O
150	O
–	O
200	O
min	O
.	O

,	O
we	O
detected	O
a	O
significant	O
decrease	O
in	O
the	O
levels	O
of	O
various	O
g	O
##ly	O
##co	O
##lysis	O
meta	O
##bol	O
##ites	O
involved	O
in	O
both	O
tumor	O
sub	O
##type	O
##s	O
,	O
such	O
as	O
glucose	S
,	O
3	O
‐	O
and	O
2	B
‐	I
p	I
##hos	I
##ph	I
##og	I
##ly	I
##cer	I
##ate	I
and	O
p	B
##hos	I
##ph	I
##oe	I
##no	I
##l	I
##py	I
##ru	I
##vate	I
.	O

The	O
associations	O
of	O
these	O
11	O
meta	O
##bol	O
##ites	O
with	O
prevalent	O
type	O
2	O
diabetes	O
were	O
stronger	O
than	O
those	O
with	O
incident	O
type	O
2	O
diabetes	O
,	O
except	O
LP	B
##I	I
(	I
16	I
:	I
1	I
)	I
and	O
(	O
18	O
:	O
0	O
)	O
,	O
for	O
which	O
the	O
associations	O
with	O
incident	O
type	O
2	O
diabetes	O
were	O
more	O
evident	O
.	O

Most	O
RA	O
patients	O
had	O
been	O
treated	O
with	O
met	O
##hot	O
##re	O
##xa	O
##tes	O
and	O
/	O
or	O
g	B
##lu	I
##co	I
##cor	I
##tic	I
##oids	I
,	O
and	O
none	O
had	O
been	O
treated	O
with	O
bio	O
##log	O
##ics	O
.	O

A	O
higher	O
concentration	O
of	O
my	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
and	O
g	B
##ly	I
##cer	I
##ol	I
was	O
shown	O
in	O
PP	O
tissue	O
samples	O
.	O

For	O
meta	O
##bol	O
##ites	O
that	O
showed	O
multiple	O
peaks	O
during	O
der	O
##iva	O
##ti	O
##zation	O
,	O
i	O
.	O
e	O
.	O
from	O
is	O
##omer	O
##s	O
or	O
partial	O
si	O
##ly	O
##lation	O
of	O
amino	S
groups	O
,	O
only	O
the	O
most	O
abundant	O
peak	O
was	O
used	O
for	O
analysis	O
.	O

In	O
addition	O
,	O
previous	O
studies	O
(	O
;	O
)	O
have	O
shown	O
that	O
o	B
##me	I
##ga	I
-	I
3	I
and	O
o	B
##me	I
##ga	I
-	I
6	I
p	O
##oly	O
##uns	O
##at	O
##ura	O
##ted	O
fatty	O
acids	O
are	O
altered	O
in	O
patients	O
with	O
MD	O
##D	O
compared	O
with	O
controls	O
.	O

Con	O
##tam	O
##ination	O
of	O
the	O
finger	O
or	O
finger	O
‐	O
stick	O
‐	O
derived	O
plasma	O
sample	O
by	O
drug	O
in	O
sa	O
##liva	O
may	O
be	O
a	O
possible	O
explanation	O
;	O
for	O
this	O
subject	O
a	O
high	O
level	O
of	O
flu	O
##ct	O
##uation	O
in	O
cap	O
##illa	O
##ry	O
r	B
##is	I
##per	I
##ido	I
##ne	I
concentrations	O
was	O
observed	O
,	O
whereas	O
this	O
was	O
not	O
the	O
case	O
for	O
ve	O
##nous	O
r	B
##is	I
##per	I
##ido	I
##ne	I
concentrations	O
.	O

We	O
also	O
found	O
that	O
the	O
mean	O
level	O
of	O
x	B
##ant	I
##hine	I
decreased	O
in	O
HC	O
##C	O
compared	O
to	O
HC	O
##V	O
.	O

(	O
A	O
)	O
Ph	B
##os	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
synthesis	O
and	O
metabolism	O
pathways	O
.	O

Ph	B
##en	I
##yla	I
##lani	I
##ne	I
_	O
2	O
H	O
_	O
5	O
(	O
98	O
%	O
)	O
was	O
obtained	O
through	O
(	O
Cambridge	O
Is	O
##oto	O
##pe	O
Laboratories	O
,	O
And	O
##over	O
MA	O
)	O
.	O

The	O
negative	O
-	O
ion	O
TO	O
##F	O
mass	O
spectrum	O
obtained	O
by	O
using	O
1	B
,	I
8	I
-	I
di	I
##ami	I
##non	I
##aph	I
##thal	I
##ene	I
shows	O
,	O
in	O
addition	O
to	O
the	O
expected	O
m	O
/	O
z	O
28	O
##3	O
of	O
s	B
##te	I
##arate	I
,	O
cop	O
##ious	O
matrix	O
cluster	O
ions	O
o	O
##bs	O
##cu	O
##ring	O
both	O
high	O
-	O
and	O
low	O
-	O
mass	O
regions	O
(	O
C	O
)	O
.	O

Next	O
,	O
50	O
µ	O
##L	O
of	O
N	B
-	I
met	I
##hyl	I
-	I
N	I
-	I
(	I
trim	I
##eth	I
##yl	I
##si	I
##ly	I
##l	I
)	I
t	I
##ri	I
##f	I
##lu	I
##oro	I
##ace	I
##tam	I
##ide	I
(	O
MS	O
##TF	O
##A	O
)	O
with	O
1	O
%	O
trim	B
##eth	I
##yl	I
##ch	I
##lor	I
##os	I
##ila	I
##ne	I
(	O
T	O
##MC	O
##S	O
)	O
was	O
added	O
to	O
the	O
samples	O
which	O
were	O
then	O
put	O
on	O
a	O
heated	O
block	O
shake	O
##r	O
for	O
60	O
min	O
at	O
1400	O
rpm	O
and	O
70	O
°C	O
.	O

Model	O
4	O
:	O
adjusted	O
for	O
h	O
##yper	O
##tens	O
##ion	O
at	O
sampling	O
,	O
anti	B
##ph	I
##os	I
##ph	I
##oli	I
##pid	I
anti	O
##body	O
syndrome	O
,	O
use	O
of	O
he	O
##par	O
##in	O
/	O
as	O
##pi	O
##rin	O
at	O
sampling	O
,	O
plate	O
##let	O
counts	O
,	O
and	O
the	O
level	O
of	O
C	O
##4	O
.	O

The	O
recovery	O
testing	O
was	O
performed	O
by	O
manually	O
s	O
##pi	O
##king	O
900	O
μ	O
##L	O
of	O
urine	O
with	O
100	O
μ	O
##L	O
of	O
standard	O
solutions	O
,	O
producing	O
a	O
s	O
##pi	O
##king	O
level	O
of	O
5	O
μ	O
##g	O
S	O
m	O
##l	O
-	O
1	O
(	O
L	O
##1	O
)	O
and	O
25	O
μ	O
##g	O
S	O
m	O
##l	O
-	O
1	O
(	O
L	O
##2	O
)	O
of	O
ta	B
##uri	I
##ne	I
,	O
and	O
250	O
μ	O
##g	O
S	O
m	O
##l	O
-	O
1	O
(	O
L	O
##1	O
)	O
and	O
125	O
##0	O
μ	O
##g	O
S	O
m	O
##l	O
-	O
1	O
(	O
L	O
##2	O
)	O
of	O
su	B
##lf	I
##ate	I
4	O
)	O
Pre	O
##cision	O
is	O
expressed	O
as	O
the	O
%	O
RS	O
##D	O
5	O
)	O

Pro	O
-	O
inflammatory	O
events	O
could	O
be	O
suggested	O
by	O
increases	O
of	O
the	O
amino	O
acid	O
his	O
##ti	O
##dine	O
through	O
its	O
meta	O
##bol	O
##ite	O
his	B
##tamine	I
(	O
Su	O
##pp	O
##lement	O
##ary	O
Figure	O
S	O
##9	O
)	O
.	O

The	O
obtained	O
raw	O
data	O
##sets	O
,	O
after	O
alignment	O
step	O
,	O
consisted	O
of	O
27	O
##36	O
##2	O
,	O
123	O
##60	O
and	O
139	O
features	O
for	O
L	B
##C	I
-	I
E	I
##SI	I
(	I
+	I
)	I
-	I
MS	I
,	O
L	B
##C	I
-	I
E	I
##SI	I
(	I
-	I
)	I
-	I
MS	I
and	O
G	O
##C	O
-	O
MS	O
,	O
respectively	O
.	O

Con	O
##tras	O
##ting	O
##ly	O
,	O
in	O
S	O
##UM	O
##13	O
##15	O
##MO	O
##2	O
,	O
C	O
##75	O
was	O
more	O
effective	O
in	O
decreasing	O
levels	O
of	O
p	O
-	O
E	O
##rk	O
and	O
p	B
-	I
G	I
##S	I
##K	I
##3	I
##β	I
when	O
compared	O
to	O
that	O
of	O
c	B
##ele	I
##co	I
##xi	I
##b	I
.	O

Our	O
study	O
provided	O
detailed	O
information	O
on	O
the	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
changes	O
of	O
host	O
in	O
response	O
to	O
H	O
##B	O
##V	O
infection	O
,	O
and	O
shed	O
new	O
light	O
on	O
potential	O
drug	O
targets	O
for	O
the	O
treatment	O
of	O
H	O
##B	O
##V	O
infection	O
.	O

LP	B
##C	I
(	I
16	I
:	I
1	I
)	I
,	O
T	B
##G	I
(	I
46	I
:	I
4	I
)	I
A	I
,	O
T	B
##G	I
(	I
42	I
:	I
3	I
)	I
and	O
T	B
##G	I
(	I
46	I
:	I
3	I
)	I
were	O
statistical	O
##ly	O
different	O
in	O
the	O
me	O
##lo	O
##xi	O
##cam	O
and	O
sa	O
##line	O
-	O
treated	O
cats	O
(	O
p	O
=	O
0	O
.	O
00	O
##2	O
,	O
0	O
.	O
01	O
##7	O
,	O
0	O
.	O
01	O
##2	O
and	O
0	O
.	O
02	O
##8	O
,	O
respectively	O
)	O
.	O

The	O
observed	O
high	O
inter	O
-	O
patient	O
range	O
in	O
serum	O
concentrations	O
of	O
ta	B
##mo	I
##xi	I
##fen	I
and	O
its	O
meta	O
##bol	O
##ites	O
,	O
especially	O
in	O
the	O
highest	O
age	O
group	O
,	O
suggest	O
that	O
use	O
of	O
therapeutic	O
monitoring	O
of	O
ta	B
##mo	I
##xi	I
##fen	I
and	O
its	O
meta	O
##bol	O
##ites	O
is	O
warrant	O
##ed	O
inside	O
as	O
well	O
as	O
outside	O
clinical	O
studies	O
.	O

(	O
,	O
)	O
Hip	B
##pura	I
##te	I
is	O
an	O
interesting	O
example	O
of	O
a	O
u	O
##rem	O
##ic	O
so	O
##lut	O
##e	O
that	O
is	O
not	O
a	O
u	O
##rem	O
##ic	O
to	B
##xin	I
.	O

In	O
addition	O
,	O
we	O
re	O
-	O
anal	O
##ys	O
##ed	O
data	O
from	O
that	O
study	O
in	O
which	O
f	O
##ent	O
##any	O
##l	O
was	O
given	O
in	O
##tra	O
##ven	O
##ously	O
alone	O
and	O
during	O
C	O
##YP	O
##3	O
##A	O
in	O
##hibition	O
by	O
k	B
##eto	I
##cona	I
##zo	I
##le	I
,	O
and	O
mid	B
##az	I
##ola	I
##m	I
was	O
co	O
-	O
administered	O
oral	O
##ly	O
as	O
C	O
##YP	O
##3	O
##A	O
probe	O
drug	O
.	O

We	O
report	O
a	O
valid	O
##ated	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
method	O
for	O
simultaneously	O
q	O
##uant	O
##ifying	O
eleven	O
can	B
##na	I
##bino	I
##ids	I
and	O
meta	O
##bol	O
##ites	O
in	O
urine	O
.	O

Many	O
of	O
the	O
meta	O
##bol	O
##ites	O
reported	O
in	O
the	O
above	O
studies	O
are	O
robust	O
##ly	O
extracted	O
using	O
the	O
novel	O
Al	O
##she	O
##hr	O
##y	O
method	O
,	O
such	O
as	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
,	O
PC	O
,	O
P	O
##E	O
and	O
their	O
corresponding	O
l	B
##ys	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
,	O
and	O
have	O
also	O
similarly	O
been	O
found	O
to	O
be	O
altered	O
in	O
post	O
-	O
m	O
##ort	O
##em	O
brain	O
tissue	O
or	O
CS	O
##F	O
in	O
patients	O
with	O
Alzheimer	O
'	O
s	O
disease	O
(	O
,	O
,	O
)	O
.	O

1	O
μ	O
##l	O
of	O
the	O
lip	O
##id	O
extract	O
was	O
analyzed	O
by	O
gas	O
-	O
liquid	O
ch	O
##roma	O
##tography	O
on	O
a	O
F	O
##OC	O
##US	O
The	O
##rm	O
##o	O
El	O
##ec	O
##tron	O
system	O
using	O
a	O
Z	O
##eb	O
##ron	O
-	O
1	O
Ph	O
##eno	O
##men	O
##ex	O
fused	O
si	B
##lica	I
cap	O
##illa	O
##ry	O
columns	O
coupled	O
to	O
mass	O
s	O
##pect	O
##rome	O
##try	O
according	O
to	O
previous	O
publication	O
.	O

This	O
analysis	O
revealed	O
significant	O
per	O
##tur	O
##bation	O
of	O
14	O
metabolic	O
networks	O
,	O
including	O
but	O
not	O
limited	O
to	O
short	O
-	O
chain	O
fatty	O
acid	O
(	O
23	O
.	O
32	O
)	O
,	O
f	B
##ru	I
##ct	I
##ose	I
,	O
man	B
##nose	I
,	O
and	O
gal	B
##act	I
##ose	I
(	O
5	O
.	O
83	O
)	O
,	O
and	O
g	B
##ly	I
##co	I
##ly	I
##tic	I
,	O
g	B
##lu	I
##con	I
##eo	I
##genic	I
,	O
and	O
p	B
##yr	I
##u	I
##vate	I
(	O
5	O
.	O
18	O
)	O
metabolic	O
pathways	O
(	O
Fi	O
##g	O
.	O
)	O
.	O

We	O
demonstrated	O
that	O
Si	O
##l	O
alone	O
or	O
in	O
combination	O
with	O
BP	O
##A	O
in	O
our	O
experimental	O
model	O
(	O
H	O
-	O
He	O
##p	O
##G	O
##2	O
)	O
counter	O
##acts	O
the	O
BP	O
##A	O
proliferation	O
effect	O
both	O
decreasing	O
the	O
glucose	S
up	O
##take	O
and	O
p	O
##hos	O
##ph	O
##ory	O
##lation	O
of	O
ER	O
##K	O
##1	O
/	O
2	O
.	O

The	O
samples	O
were	O
dried	O
using	O
Gene	O
##V	O
##ac	O
V	O
##ac	O
##cum	O
system	O
at	O
37	O
##°	O
##C	O
and	O
el	O
##uted	O
with	O
5	O
m	O
##M	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
in	O
met	B
##han	I
##ol	I
and	O
then	O
were	O
di	O
##lut	O
##ed	O
with	O
water	O
for	O
L	O
##C	O
-	O
MS	O
.	O

The	O
unit	O
of	O
c	B
##it	I
##ric	I
acid	I
,	O
α	B
-	I
k	I
##eto	I
##g	I
##lut	I
##ari	I
##c	I
acid	I
,	O
and	O
f	B
##uma	I
##ric	I
acid	I
are	O
pm	O
##ol	O
/	O
10	O
_	O
6	O
cells	O
;	O
The	O
unit	O
of	O
reduced	O
G	B
##S	I
##H	I
and	O
total	O
G	B
##S	I
##H	I
are	O
nm	O
##ol	O
/	O
10	O
_	O
6	O
cells	O
.	O

The	O
goal	O
of	O
this	O
work	O
was	O
to	O
identify	O
a	O
unique	O
metabolic	O
response	O
linked	O
to	O
ER	O
##CP	O
-	O
induced	O
AP	S
.	O

For	O
in	O
##tra	O
##cellular	O
stain	O
##ing	O
,	O
T	O
cells	O
were	O
stimulate	O
##d	O
for	O
4	O
hours	O
after	O
the	O
activation	O
using	O
p	B
##hor	I
##bol	I
-	I
12	I
-	I
my	I
##rist	I
##ate	I
-	I
13	I
-	I
ace	I
##tate	I
(	O
PM	O
##A	O
)	O
at	O
20	O
ng	O
/	O
m	O
##L	O
,	O
ion	B
##omy	I
##cin	I
at	O
1	O
μ	O
##g	O
/	O
m	O
##L	O
,	O
and	O
Go	O
##l	O
##gi	O
##S	O
##top	O
(	O
B	O
##D	O
B	O
##ios	O
##cie	O
##nces	O
)	O
.	O

Co	O
##mpo	O
##und	O
-	O
specific	O
optimization	O
of	O
MS	O
##MS	O
parameters	O
was	O
performed	O
via	O
direct	O
in	O
##fusion	O
of	O
individual	O
100	O
ng	O
/	O
m	O
##L	O
met	B
##han	I
##olic	I
reference	O
solutions	O
using	O
a	O
s	O
##yr	O
##inge	O
pump	O
.	O

Therefore	O
it	O
is	O
not	O
surprising	O
to	O
observe	O
the	O
decrease	O
in	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
levels	O
in	O
plasma	O
of	O
patients	O
with	O
either	O
ben	O
##ign	O
or	O
ma	O
##li	O
##gnant	O
SP	O
##N	O
##s	O
,	O
such	O
as	O
LP	O
##Cs	O
,	O
LP	O
##Es	O
,	O
PC	O
##s	O
,	O
P	O
##Es	O
,	O
PS	O
##s	O
.	O

Higher	O
concentrations	O
of	O
my	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
and	O
g	B
##ly	I
##cer	I
##ol	I
were	O
shown	O
in	O
PP	O
,	O
whereas	O
higher	O
levels	O
of	O
glucose	S
,	O
as	B
##cor	I
##bate	I
,	O
ethanol	B
##amine	I
,	O
la	B
##ct	I
##ate	I
,	O
and	O
ta	B
##uri	I
##ne	I
were	O
revealed	O
in	O
PA	O
.	O

End	O
##ogen	O
##ous	O
o	B
##xa	I
##late	I
production	O
was	O
determined	O
by	O
in	O
##fusion	O
of	O
stable	O
is	O
##oto	O
##pe	O
labeled	O
_	O
13	O
C	B
_	I
2	I
-	I
o	I
##xa	I
##late	I
.	O

Benz	B
##oi	I
##c	I
acid	I
was	O
associated	O
with	O
lower	O
H	O
##E	O
development	O
and	O
is	O
likely	O
related	O
to	O
gut	O
micro	O
##bial	O
changes	O
associated	O
with	O
c	O
##ir	O
##r	O
##hos	O
##is	O
,	O
which	O
can	O
influence	O
hip	B
##pura	I
##te	I
formation	O
[	O
]	O
.	O

Our	O
results	O
showed	O
that	O
a	B
##rg	I
##ini	I
##ne	I
levels	O
in	O
the	O
PR	O
group	O
were	O
significantly	O
higher	O
than	O
those	O
in	O
the	O
G	O
##R	O
group	O
.	O

Mal	B
##ate	I
and	O
as	B
##par	I
##tate	I
also	O
showed	O
substantial	O
_	O
13	O
C	O
en	O
##rich	O
##ment	O
(	O
Figure	O
)	O
in	O
both	O
do	O
##ub	O
##ly	O
and	O
trip	O
##ly	O
labeled	O
mass	O
is	O
##oto	O
##po	O
##mers	O
based	O
on	O
the	O
G	O
##C	O
-	O
MS	O
analysis	O
.	O

The	O
human	O
PC	O
##a	O
cell	O
lines	O
L	O
##NC	O
##a	O
##P	O
(	O
and	O
##rogen	O
dependent	O
cells	O
)	O
and	O
PC	O
##3	O
(	O
and	O
##rogen	O
independent	O
cells	O
)	O
were	O
obtained	O
from	O
AT	O
##CC	O
and	O
maintained	O
in	O
normal	O
growth	O
media	O
(	O
R	O
##PM	O
##I	O
-	O
1640	O
(	O
Sigma	O
)	O
supplemented	O
with	O
10	O
%	O
f	O
##etal	O
b	O
##ov	O
##ine	O
serum	O
(	O
F	O
##BS	O
)	O
along	O
with	O
100	O
units	O
/	O
m	O
##l	O
pen	B
##ici	I
##llin	I
and	O
s	B
##tre	I
##pt	I
##omy	I
##cin	I
)	O
.	O

GM	B
##3	I
gang	I
##lio	I
##side	I
concentration	O
had	O
the	O
most	O
significant	O
difference	O
between	O
PD	O
and	O
controls	O
(	O
1	O
.	O
53	O
##1	O
##±	O
##0	O
.	O
03	O
##7	O
pm	O
##ol	O
/	O
μ	O
##l	O
versus	O
1	O
.	O
33	O
##7	O
##±	O
##0	O
.	O
04	O
##0	O
pm	O
##ol	O
/	O
μ	O
##l	O
respectively	O
;	O
p	O
-	O
value	O
=	O
5	O
.	O
96	O
##E	O
-	O
04	O
;	O
q	O
-	O
value	O
=	O
0	O
.	O
04	O
##8	O
;	O
when	O
normal	O
##ized	O
to	O
total	O
lip	O
##id	O
:	O
p	O
-	O
value	O
=	O
2	O
.	O
89	O
##0	O
##E	O
-	O
05	O
;	O
q	O
-	O
value	O
=	O
2	O
.	O
93	O
##3	O
##E	O
-	O
03	O
)	O
.	O

Compared	O
to	O
the	O
un	O
##tre	O
##ated	O
control	O
cells	O
,	O
this	O
corresponds	O
to	O
an	O
almost	O
20	O
%	O
higher	O
g	B
##lut	I
##amine	I
up	O
##take	O
rate	O
which	O
was	O
mediated	O
by	O
r	O
##H	O
##la	O
-	O
treatment	O
of	O
the	O
cells	O
.	O

Line	O
##arity	O
of	O
the	O
Cal	O
##ib	O
##ration	O
C	O
##ur	O
##ves	O
for	O
SM	O
##V	O
,	O
SM	O
##V	O
-	O
A	O
,	O
AT	O
##V	O
,	O
2	B
-	I
OH	I
-	I
AT	I
##V	I
,	O
4	B
-	I
OH	I
-	I
AT	I
##V	I
,	O
and	O
RS	O
##V	O
in	O
P	O
##las	O
##ma	O
with	O
Low	O
and	O
High	O
Tri	B
##gly	I
##cer	I
##ide	I
Level	O
##s	O
[	O
Data	O
are	O
Present	O
##ed	O
as	O
Mean	O
±	O
SD	O
(	O
%	O
C	O
##V	O
)	O
]	O

The	O
synthesis	O
mainly	O
occurs	O
from	O
c	B
##it	I
##ru	I
##llin	I
##e	I
both	O
in	O
the	O
liver	O
and	O
in	O
kidney	O
.	O

Met	B
##hi	I
##oni	I
##ne	I
is	O
an	O
essential	O
amino	O
acid	O
that	O
has	O
a	O
critical	O
role	O
in	O
cellular	O
metabolism	O
.	O

We	O
also	O
measured	O
a	O
strong	O
decrease	O
in	O
the	O
1	B
-	I
met	I
##hyl	I
##his	I
##ti	I
##dine	I
level	O
in	O
AD	O
##V	O
vs	O
EA	O
##R	O
HC	O
##C	O
patients	O
.	O

One	O
potential	O
explanation	O
for	O
decreased	O
brain	B
-	I
glucose	I
up	O
##take	O
could	O
be	O
that	O
of	O
impaired	O
G	O
##L	O
##UT	O
activity	O
,	O
leading	O
to	O
con	O
##se	O
##quent	O
cerebral	O
‘	O
h	O
##y	O
##po	O
##met	O
##ab	O
##olis	O
##m	O
’	O
.	O

Li	O
##pid	O
samples	O
were	O
measured	O
and	O
recorded	O
in	O
PR	O
##OC	O
##N	O
##O	O
11	O
using	O
a	O
simple	O
pre	O
-	O
sat	O
##uration	O
sequence	O
(	O
re	O
##cycle	O
delay	O
(	O
R	O
##D	O
)	O
-	O
90	O
##°	O
-	O
AC	O
##Q	O
pre	O
-	O
sat	O
##uration	O
pulse	O
(	O
z	O
##g	O
##p	O
##r	O
)	O
program	O
)	O
to	O
eliminate	O
the	O
residual	O
water	O
moisture	O
of	O
de	O
##uter	O
##ated	O
met	B
##han	I
##ol	I
.	O

hi	B
hi	I
h	O

The	O
el	O
##ution	O
profile	O
was	O
improved	O
by	O
using	O
h	B
##ydro	I
##phi	I
##lic	I
interaction	O
liquid	O
ch	O
##roma	O
##tography	O
(	O
H	O
##IL	O
##IC	O
)	O
on	O
a	O
Waters	O
X	O
##B	O
##ridge	O
Am	B
##ide	I
column	O
(	O
50	O
mm	O
x	O
2	O
.	O
1	O
mm	O
,	O
3	O
.	O
5	O
μ	O
##m	O
)	O
and	O
a	O
Ph	O
##eno	O
##men	O
##ex	O
Ki	O
##net	O
##ex	O
H	O
##IL	O
##IC	O
column	O
(	O
100	O
mm	O
x	O
2	O
.	O
1	O
mm	O
,	O
2	O
.	O
6	O
μ	O
##m	O
)	O
.	O

Ser	O
##um	O
samples	O
were	O
collected	O
with	O
B	O
##D	O
V	O
##ac	O
##uta	O
##iner	O
serum	O
tubes	O
,	O
processed	O
according	O
to	O
the	O
standard	O
B	O
##D	O
V	O
##ac	O
##uta	O
##iner	O
protocol	O
,	O
and	O
stored	O
at	O
-	O
80	O
##°	O
C	O
.	O
Con	O
##cent	O
##rations	O
of	O
try	B
##pt	I
##op	I
##han	I
(	O
T	O
##RP	O
)	O
,	O
k	B
##yn	I
##uren	I
##ine	I
(	O
K	O
##Y	O
##N	O
)	O
,	O
k	B
##yn	I
##uren	I
##ic	I
acid	I
(	O
K	O
##yn	O
##A	O
)	O
,	O
3	B
-	I
h	I
##ydro	I
##xy	I
##ky	I
##nu	I
##ren	I
##ine	I
(	O
3	O
##H	O
##K	O
)	O
,	O
and	O
q	B
##uin	I
##olin	I
##ic	I
acid	I
(	O
Q	O
##A	O
)	O
were	O
measured	O
blind	O
to	O
diagnosis	O
by	O
Brain	O
##s	O
Online	O
,	O
LLC	O
in	O
2	O
separate	O
batch	O
##es	O
.	O

Il	O
##lum	O
##ina	O
Human	B
##M	I
##eth	I
##yla	I
##tion	I
##EP	I
##IC	I
data	O
(	O
ID	O
##AT	O
files	O
)	O
were	O
imported	O
into	O
the	O
B	O
##ion	O
##conductor	O
min	O
##fi	O
package	O
.	O

E	O
##pile	O
##ptic	O
seizure	O
##s	O
are	O
activated	S
by	O
the	O
ne	O
##uro	O
##end	O
##oc	O
##rine	O
system	O
secret	O
##ing	O
hormones	O
.	O

who	O
reported	O
an	O
inverse	O
correlation	O
between	O
test	B
##osterone	I
levels	O
and	O
impaired	O
mitochondrial	O
function	O
.	O

A	O
large	O
-	O
scale	O
metabolic	O
profile	O
analysis	O
of	O
60	O
cancer	O
cell	O
lines	O
using	O
L	O
##C	O
/	O
MS	O
-	O
MS	O
found	O
that	O
g	B
##ly	I
##cine	I
bio	O
##sy	O
##nt	O
##hesis	O
was	O
among	O
the	O
most	O
important	O
pathways	O
for	O
the	O
development	O
of	O
a	O
broad	O
spectrum	O
of	O
cancer	O
##s	O
.	O

The	O
relationship	O
of	O
l	B
-	I
a	I
##rg	I
##ini	I
##ne	I
meta	O
##bol	O
##ites	O
and	O
a	O
##rg	O
##inas	O
##e	O
activity	O
to	O
C	O
##VD	O
risk	O
factors	O
was	O
evaluated	O
using	O
Pearson	O
’	O
s	O
ch	O
##i	O
-	O
square	O
test	O
.	O

These	O
findings	O
,	O
combined	O
with	O
the	O
present	O
study	O
,	O
suggest	O
that	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
may	O
be	O
interesting	O
general	O
markers	O
of	O
ne	O
##uro	O
##de	O
##gene	O
##ration	O
.	O

Con	O
##ce	O
##iva	O
##bly	O
,	O
these	O
trends	O
could	O
reflect	O
an	O
out	O
##flow	O
of	O
3	B
-	I
h	I
##ydro	I
##xy	I
##ky	I
##nu	I
##ren	I
##ine	I
from	O
the	O
central	O
nervous	O
system	O
(	O
C	O
##NS	O
)	O
into	O
the	O
systemic	O
circulation	O
,	O
where	O
mac	O
##rop	O
##hage	O
activation	O
presumably	O
at	O
the	O
level	O
of	O
the	O
gut	O
or	O
in	O
other	O
peripheral	O
organs	O
,	O
can	O
transform	O
this	O
compound	O
into	O
q	B
##uin	I
##olin	I
##ic	I
acid	I
and	O
x	B
##ant	I
##hur	I
##eni	I
##c	I
acid	I
,	O
as	O
well	O
as	O
into	O
ni	B
##cot	I
##ini	I
##c	I
acid	I
(	O
N	O
##AD	O
)	O
,	O
in	O
agreement	O
with	O
previous	O
data	O
.	O

The	O
product	O
ion	O
s	O
##pect	O
##ra	O
of	O
des	B
##ami	I
##no	I
-	I
Ph	I
##IP	I
-	I
K	I
(	O
[	O
M	O
+	O
H	O
]	O
_	O
+	O
at	O
m	O
/	O
z	O
35	O
##4	O
.	O
2	O
)	O
and	O
[	B
_	I
2	I
H	I
_	I
5	I
]	I
-	I
des	I
##ami	I
##no	I
-	I
Ph	I
##IP	I
-	I
K	I
(	O
[	O
M	O
+	O
H	O
]	O
_	O
+	O
at	O
m	O
/	O
z	O
35	O
##9	O
.	O
2	O
)	O
exhibited	O
a	O
‘	O
twin	O
’	O
pattern	O
of	O
ions	O
that	O
differ	O
by	O
5	O
Da	O
.	O

This	O
disc	O
##re	O
##pan	O
##cy	O
between	O
sa	O
##liva	O
##ry	O
and	O
plasma	O
Test	B
##osterone	I
found	O
in	O
our	O
study	O
was	O
noticed	O
previously	O
as	O
well	O
.	O

Through	O
meta	O
##bol	O
##omi	O
##c	O
analysis	O
,	O
we	O
found	O
that	O
the	O
significant	O
changed	O
amino	O
acids	O
were	O
his	B
##ti	I
##dine	I
,	O
g	B
##ly	I
##cine	I
,	O
se	B
##rine	I
,	O
c	B
##it	I
##rate	I
,	O
or	B
##ni	I
##thin	I
##e	I
,	O
h	B
##ydro	I
##xy	I
##p	I
##rol	I
##ine	I
,	O
pro	B
##line	I
and	O
sa	B
##rc	I
##os	I
##ine	I
in	O
acute	O
AD	O
patients	O
;	O
and	O
c	B
##it	I
##rate	I
,	O
GA	B
##BA	I
,	O
g	B
##lut	I
##ama	I
##te	I
and	O
c	B
##ys	I
##tein	I
##e	I
in	O
chronic	O
AD	O
patients	O
.	O

Total	O
RNA	O
from	O
each	O
sample	O
was	O
normal	O
##ized	O
to	O
β	B
-	I
ACT	I
##IN	I
,	O
K	O
##IF	O
and	O
T	O
##B	O
##P	O
for	O
the	O
B	O
##J	O
and	O
H	O
##U	O
##H	O
##7	O
cell	O
line	O
or	O
K	O
##IF	O
in	O
the	O
case	O
of	O
CA	O
##K	O
##I	O
##2	O
cell	O
line	O
.	O

A	O
high	O
-	O
performance	O
liquid	O
ch	O
##roma	O
##tography	O
study	O
has	O
also	O
revealed	O
reduced	O
ethanol	B
##amine	I
levels	O
in	O
the	O
CS	O
##F	O
of	O
MD	O
##D	O
patients	O
.	O

This	O
result	O
is	O
consistent	O
with	O
two	O
prior	O
studies	O
;	O
Ma	O
and	O
colleagues	O
compared	O
serum	O
of	O
30	O
color	O
##ec	O
##tal	O
cancer	O
patients	O
to	O
30	O
color	O
##ec	O
##tal	O
cancer	O
‐	O
free	O
controls	O
,	O
12	O
and	O
Far	O
##shi	O
##d	O
##far	O
et	O
al	O
.	O
investigated	O
meta	O
##bol	O
##omi	O
##c	O
signatures	O
in	O
color	O
##ec	O
##tal	O
cancer	O
serum	O
of	O
stage	O
I	O
‐	O
IV	O
patients	O
.	O
14	O
Co	O
##mp	O
##ara	O
##ble	O
to	O
v	B
##ali	I
##ne	I
,	O
decreased	O
plasma	O
levels	O
of	O
le	B
##uc	I
##ine	I
were	O
also	O
reported	O
in	O
our	O
color	O
##ec	O
##tal	O
cancer	O
patients	O
compared	O
to	O
controls	O
.	O

Per	O
##cent	O
of	O
ma	O
##ximal	O
activation	O
of	O
cells	O
treated	O
with	O
10	O
_	O
−	O
##5	O
m	O
AT	O
##RA	O
alone	O
(	O
left	O
most	O
bar	O
in	O
each	O
his	O
##to	O
##gram	O
)	O
or	O
co	O
-	O
treated	O
with	O
10	O
_	O
−	O
##5	O
m	O
AT	O
##RA	O
and	O
10	O
_	O
−	O
##5	O
m	O
of	O
the	O
β	B
-	I
a	I
##po	I
##car	I
##ote	I
##no	I
##ids	I
resulting	O
from	O
c	O
##lea	O
##vage	O
at	O
the	O
a	O
,	O
b	O
,	O
c	O
,	O
or	O
d	O
sites	O
are	O
shown	O
in	O
a	O
,	O
b	O
,	O
c	O
,	O
and	O
d	O
,	O
respectively	O
(	O
n	O
=	O
3	O
to	O
6	O
)	O
;	O

Cancer	O
cells	O
prefer	O
to	O
meta	O
##bol	O
##ize	O
glucose	S
through	O
g	O
##ly	O
##co	O
##lysis	O
to	O
generate	O
ATP	S
instead	O
of	O
o	O
##xi	O
##da	O
##tive	O
p	O
##hos	O
##ph	O
##ory	O
##lation	O
even	O
in	O
presence	O
of	O
ample	O
oxygen	O
.	O

All	O
the	O
analytical	O
standards	O
were	O
di	O
##lut	O
##ed	O
in	O
Me	B
##OH	I
at	O
the	O
final	O
concentration	O
of	O
10	O
μ	O
##g	O
/	O
m	O
##l	O
for	O
direct	O
in	O
##fusion	O
.	O

Recently	O
2	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
has	O
been	O
observed	O
to	O
a	O
##cc	O
##um	O
##ulate	O
in	O
blood	O
plasma	O
of	O
individuals	O
at	O
the	O
early	O
stages	O
of	O
diabetes	O
and	O
in	O
a	O
non	O
-	O
di	O
##abe	O
##tic	O
population	O
affected	O
by	O
insulin	O
resistance	O
and	O
impaired	O
glucose	S
regulation	O
.	O

The	O
likely	O
an	O
##not	O
##ations	O
are	O
given	O
for	O
the	O
valid	O
##ated	O
peaks	O
and	O
the	O
m	O
/	O
z	O
value	O
of	O
the	O
add	O
##uc	O
##t	O
in	O
the	O
L	O
##C	O
-	O
MS	O
experiment	O
is	O
given	O
for	O
the	O
other	O
peaks	O
;	O
the	O
peak	O
labelled	O
test	B
##osterone	I
su	I
##lf	I
##ate	I
may	O
be	O
de	B
##hy	I
##dr	I
##oe	I
##pian	I
##dr	I
##osterone	I
su	I
##lf	I
##ate	I
or	O
e	B
##pit	I
##ester	I
##one	I
su	I
##lf	I
##ate	I
.	O

Le	B
##uc	I
##ine	I
-	I
en	I
##ke	I
##pha	I
##lin	I
was	O
used	O
as	O
the	O
lock	O
##mass	O
in	O
positive	O
ion	O
mode	O
(	O
m	O
/	O
z	O
55	O
##6	O
.	O
27	O
##7	O
##1	O
[	O
M	O
+	O
H	O
]	O
_	O
+	O
)	O
.	O

De	O
##ple	O
##ted	O
c	B
##rea	I
##tine	I
/	O
c	O
##rea	O
##tin	O
##ine	O
levels	O
in	O
tumor	O
tissues	O
have	O
been	O
related	O
to	O
altered	O
energy	O
transfer	O
processes	O
and	O
may	O
re	O
##ﬂ	O
##ec	O
##t	O
increased	O
activity	O
of	O
c	B
##rea	I
##tine	I
kinase	O
,	O
which	O
has	O
been	O
previously	O
reported	O
to	O
be	O
lower	O
in	O
lung	O
tumors	O
compared	O
to	O
normal	O
adjacent	O
tissues	O
[	O
]	O
.	O

However	O
,	O
a	O
previous	O
study	O
showed	O
that	O
G	B
##S	I
##H	I
levels	O
in	O
the	O
CS	O
##F	O
of	O
MS	O
patients	O
were	O
significantly	O
lower	O
compared	O
to	O
controls	O
.	O

El	O
##eva	O
##tion	O
of	O
circulating	O
pu	B
##rine	I
/	I
p	I
##yr	I
##im	I
##id	I
##ine	I
n	O
##uc	O
##leo	O
##base	O
##s	O
(	O
e	O
##g	O
,	O
u	B
##rac	I
##il	I
,	O
thy	B
##mine	I
,	O
and	O
x	B
##ant	I
##hine	I
)	O
in	O
cancer	O
patients	O
following	O
i	O
##rino	O
##teca	O
##n	O
administration	O
indicates	O
pu	B
##rine	I
and	O
p	B
##yr	I
##im	I
##id	I
##ine	I
n	O
##uc	O
##leo	O
##tide	O
degradation	O
following	O
i	O
##rino	O
##teca	O
##n	O
/	O
S	O
##N	O
-	O
38	O
-	O
induced	O
DNA	O
double	O
-	O
strand	O
breaks	O
.	O

H	O
.	O
p	O
##yl	O
##ori	O
infection	O
was	O
detected	O
in	O
tissue	O
sections	O
using	O
hem	B
##ato	I
##xy	I
##lin	I
and	O
e	B
##os	I
##in	I
and	O
G	O
##ie	O
##ms	O
##a	O
stain	O
##s	O
as	O
previously	O
reported	O
.	O

G	O
##ut	O
bacteria	O
can	O
interact	O
with	O
the	O
enter	B
##och	I
##roma	I
##ffin	I
cells	O
to	O
stimulate	O
synthesis	O
of	O
se	B
##rot	I
##oni	I
##n	I
.	O

Three	O
SP	O
##Ms	O
,	O
i	O
.	O
e	O
.	O
,	O
R	O
##v	O
##E	O
##1	O
,	O
R	O
##v	O
##D	O
##2	O
and	O
R	O
##v	O
##D	O
##5	O
were	O
chosen	O
representing	O
the	O
structure	O
of	O
di	O
-	O
and	O
t	B
##ri	I
##hy	I
##dr	I
##ox	I
##y	I
fatty	O
acids	O
and	O
a	O
broad	O
el	O
##ution	O
window	O
and	O
thus	O
different	O
compositions	O
of	O
the	O
mobile	O
phase	O
during	O
el	O
##ution	O
and	O
e	O
##va	O
##por	O
##ation	O
with	O
retention	O
times	O
of	O
6	O
.	O
19	O
min	O
(	O
R	O
##v	O
##E	O
##1	O
,	O
40	O
%	O
solvent	O
B	O
)	O
,	O
9	O
.	O
52	O
min	O
(	O
R	O
##v	O
##D	O
##2	O
,	O
50	O
%	O
solvent	O
B	O
)	O
and	O
13	O
.	O
80	O
min	O
(	O
R	O
##v	O
##D	O
##5	O
,	O
57	O
%	O
solvent	O
B	O
)	O
.	O

c	O
The	O
meta	O
##bol	O
##ite	O
regulatory	O
network	O
of	O
the	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
t	B
##yr	I
##os	I
##ine	I
and	O
try	B
##pt	I
##op	I
##han	I
bio	O
##sy	O
##nt	O
##hesis	O
pathway	O
.	O

The	O
separation	O
was	O
performed	O
in	O
a	O
cat	O
##ion	O
##ic	O
separation	O
regime	O
,	O
the	O
applied	O
voltage	O
was	O
set	O
at	O
+	O
30	O
k	B
##V	I
.	O
Before	O
each	O
injection	O
the	O
cap	O
##illa	O
##ry	O
was	O
re	O
-	O
e	O
##qui	O
##li	O
##bra	O
##ted	O
by	O
applying	O
of	O
negative	O
voltage	O
−	O
##20	O
k	B
##V	I
for	O
30	O
s	O
and	O
flush	O
##ing	O
with	O
B	O
##GE	O
for	O
2	O
min	O
.	O

Unfortunately	O
,	O
due	O
to	O
the	O
retrospective	O
nature	O
of	O
this	O
study	O
,	O
these	O
parameters	O
were	O
not	O
available	O
at	O
the	O
moment	O
of	O
the	O
_	O
1	O
H	O
-	O
N	O
##MR	O
analysis	O
,	O
preventing	O
to	O
look	O
for	O
possible	O
correlation	O
##s	O
between	O
the	O
g	B
##lut	I
##ama	I
##te	I
concentration	O
and	O
these	O
markers	O
.	O

For	O
human	O
blood	O
plasma	O
samples	O
,	O
H	O
##IL	O
##IC	O
-	O
L	O
##C	O
-	O
MS	O
was	O
performed	O
on	O
a	O
Luna	O
H	O
##IL	O
##IC	O
Di	B
##ol	I
HP	O
##LC	O
column	O
(	O
150	O
×	O
3	O
m	O
##M	O
,	O
3	O
µ	O
##M	O
particle	O
size	O
,	O
Ph	O
##eno	O
##men	O
##ex	O
,	O
Tor	O
##rance	O
,	O
CA	O
,	O
USA	O
)	O
.	O

Before	O
extraction	O
,	O
solid	O
phase	O
was	O
activated	S
with	O
600	O
µ	O
##L	O
met	B
##han	I
##ol	I
and	O
600	O
µ	O
##L	O
dei	O
##onized	O
water	O
(	O
Mill	O
##i	O
Q	O
)	O
.	O

Met	O
##ab	O
##olo	O
##mic	O
analysis	O
revealed	O
changes	O
in	O
pathways	O
involving	O
branched	O
-	O
chain	O
amino	O
acid	O
metabolism	O
,	O
fatty	O
acid	O
oxidation	O
,	O
protein	O
degradation	O
,	O
u	B
##rea	I
cycle	O
,	O
try	B
##pt	I
##op	I
##han	I
metabolism	O
,	O
n	O
##uc	O
##leo	O
##tide	O
cat	O
##ab	O
##olis	O
##m	O
,	O
vitamin	B
E	I
,	O
and	O
s	O
##tero	O
##id	O
metabolism	O
.	O

Su	O
##mma	O
##ry	O
of	O
potential	O
bio	O
##mark	O
##ers	O
of	O
an	O
##ky	O
##los	O
##ing	O
s	O
##po	O
##ndy	O
##lit	O
##is	O
by	O
plasma	O
,	O
urine	O
and	O
tissue	O
meta	O
##bol	O
##omi	O
##c	O
analysis	O
A	O
##bb	O
##re	O
##viation	O
##s	O
:	O
AS	O
An	O
##ky	O
##los	O
##ing	O
s	O
##po	O
##ndy	O
##lit	O
##is	O
,	O
VIP	O
V	O
##aria	O
##ble	O
importance	O
for	O
projection	O
,	O
FC	O
F	O
##old	O
change	O
,	O
3	O
-	O
H	O
##B	O
3	B
-	I
H	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
,	O
N	O
##AG	O
N	B
-	I
ace	I
##ty	I
##l	I
g	I
##ly	I
##co	I
##p	I
##rote	I
##in	I
,	O
T	B
##G	I
Tri	I
##gly	I
##cer	I
##ides	I
,	O
PA	B
##G	I
Ph	I
##en	I
##yla	I
##ce	I
##ty	I
##l	I
##gly	I
##cine	I
,	O
2	O
-	O
P	O
##Y	O
2	B
-	I
P	I
##yr	I
##ido	I
##ne	I
-	I
3	I
-	I
car	I
##box	I
##ami	I
##de	I
,	O
L	O
##1	O
CH	O
_	O
3	O

Only	O
three	O
of	O
these	O
meta	O
##bol	O
##ites	O
—	O
ch	O
##olin	O
##e	O
,	O
p	B
##hos	I
##ph	I
##och	I
##olin	I
##e	I
and	O
g	O
##ly	O
##cer	O
##op	O
##hos	O
##ph	O
##och	O
##olin	O
##e	O
—	O
could	O
be	O
q	O
##uant	O
##ified	O
in	O
the	O
brain	O
t	O
##umour	O
s	O
##pect	O
##ra	O
,	O
and	O
as	O
their	O
peaks	O
could	O
not	O
always	O
be	O
resolved	O
they	O
are	O
sum	O
##med	O
as	O
the	O
total	O
ch	B
##olin	I
##e	I
pool	O
,	O
t	O
##C	O
##ho	O
.	O

After	O
cent	O
##ri	O
##fu	O
##gation	O
at	O
4000	O
##×	O
g	O
for	O
30	O
min	O
,	O
1	O
m	O
##L	O
of	O
the	O
upper	O
organic	O
layer	O
was	O
dried	O
by	O
cent	O
##ri	O
##fu	O
##gal	O
vacuum	O
e	O
##va	O
##por	O
##ation	O
and	O
dissolved	O
in	O
150	O
μ	O
##L	O
of	O
is	O
##op	O
##rop	O
##ano	O
##l	O
:	O
met	O
##han	O
##ol	O
:	O
ch	O
##lor	O
##of	O
##orm	O
(	O
4	O
:	O
2	O
:	O
1	O
)	O
containing	O
15	O
m	O
##M	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
.	O

The	O
fact	O
that	O
ta	O
##c	O
##rine	O
represents	O
the	O
lowest	O
p	O
-	O
value	O
while	O
concentration	O
was	O
only	O
reduced	O
20	O
%	O
compared	O
to	O
pre	B
##dn	I
##ison	I
##e	I
and	O
prop	B
##af	I
##eno	I
##ne	I
which	O
were	O
completely	O
removed	O
,	O
illustrate	O
##s	O
that	O
factors	O
such	O
as	O
ch	O
##roma	O
##tography	O
and	O
S	O
/	O
N	O
will	O
be	O
reflected	O
as	O
smaller	O
standard	O
de	O
##viation	O
and	O
hence	O
lower	O

The	O
direct	O
association	O
of	O
B	O
##MI	O
with	O
u	O
##rina	O
##ry	O
pseudo	B
##uri	I
##dine	I
ex	O
##cre	O
##tion	O
(	O
P	O
=	O
2	O
.	O
10	O
×	O
10	O
_	O
−	O
##12	O
)	O
reflected	O
increased	O
whole	O
-	O
body	O
nuclei	O
##c	O
acid	O
turnover	O
with	O
higher	O
B	O
##MI	O
,	O
consistent	O
with	O
enhanced	O
ad	O
##ip	O
##ose	O
tissue	O
turnover	O
associated	O
with	O
o	O
##besity	O
.	O

In	O
patients	O
with	O
se	O
##psis	O
,	O
plasma	O
h	O
##A	O
##rg	O
concentrations	O
are	O
decreased	O
and	O
AD	B
##MA	I
concentrations	O
are	O
increased	O
.	O

G	B
##lu	I
##cos	I
##e	I
(	O
increased	O
)	O
,	O
format	B
##e	I
(	O
increased	O
)	O
and	O
se	B
##rine	I
(	O
decreased	O
)	O
in	O
r	O
##abi	O
##es	O
CS	O
##F	O
moved	O
inverse	O
##ly	O
to	O
the	O
same	O
meta	O
##bol	O
##ites	O
measured	O
in	O
media	O
from	O
my	O
##ot	O
##ube	O
##s	O
into	O
##xi	O
##cated	O
with	O
rot	B
##eno	I
##ne	I
or	O
anti	B
##my	I
##cin	I
A	O
.	O
ATP	S
deficiency	O
from	O
mitochondrial	O
d	O
##ys	O
##function	O
can	O
be	O
partially	O
offset	O
by	O
increased	O
g	O
##ly	O
##co	O
##lysis	O
.	O

In	O
individuals	O
with	O
depressed	O
25	O
(	O
OH	O
)	O
D	O
level	O
but	O
elevated	O
1	B
##α	I
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
production	O
,	O
diet	O
##ary	O
supplement	O
##ation	O
with	O
vitamin	B
D	I
or	O
sun	O
exposure	O
may	O
have	O
a	O
del	O
##eter	O
##ious	O
effect	O
because	O
of	O
possible	O
1	B
##α	I
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
der	O
##eg	O
##ulated	O
extra	O
-	O
re	O
##nal	O
production	O
and	O
the	O
resulting	O
toxicity	O
,	O
as	O
observed	O
for	O
example	O
in	O
some	O
l	O
##ymph	O
##oma	O
##s	O
,	O
sa	O
##rc	O
##oid	O
##osis	O
and	O
tuberculosis	O
.	O

The	O
q	B
##uin	I
##ones	I
react	O
with	O
DNA	O
to	O
form	O
de	O
##pur	O
##inating	O
DNA	O
add	O
##uc	O
##ts	O
.	O

In	O
that	O
regard	O
,	O
Play	O
##don	O
et	O
al	O
.	O
recently	O
proposed	O
gal	B
##act	I
##ona	I
##te	I
as	O
a	O
marker	O
for	O
dairy	O
product	O
intake	O
.	O

T	O
cells	O
are	O
known	O
to	O
express	O
the	O
A	O
_	O
2	O
##A	O
R	O
and	O
respond	O
to	O
ad	B
##eno	I
##sin	I
##e	I
by	O
c	O
##AM	O
##P	O
up	O
##re	O
##gu	O
##lation	O
,	O
which	O
results	O
in	O
alterations	O
in	O
their	O
functions	O
,	O
as	O
we	O
and	O
others	O
have	O
shown	O
.	O

First	O
,	O
this	O
is	O
the	O
first	O
study	O
to	O
report	O
on	O
associations	O
between	O
serum	O
T	B
##MA	I
##O	I
and	O
P	O
##LC	O
risk	O
in	O
humans	O
.	O

In	O
addition	O
,	O
seven	O
compounds	O
had	O
concentrations	O
somewhat	O
higher	O
than	O
previously	O
reported	O
values	O
(	O
L	O
-	O
as	O
##par	O
##agi	O
##ne	O
,	O
g	B
##ly	I
##cer	I
##ol	I
,	O
g	B
##ly	I
##cine	I
,	O
L	B
-	I
his	I
##ti	I
##dine	I
,	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
,	O
met	B
##han	I
##ol	I
and	O
prop	B
##yle	I
##ne	I
g	I
##ly	I
##co	I
##l	I
)	O
,	O
while	O
two	O
compounds	O
had	O
concentrations	O
lower	O
than	O
previously	O
reported	O
(	B
L	B
-	I
c	I
##ys	I
##tine	I
and	O
form	O
##ic	O
acid	O
)	O
.	O

Product	O
-	O
ion	O
mass	O
s	O
##pect	O
##ra	O
of	O
4	B
-	I
OH	I
-	I
E	I
_	I
1	I
-	I
1	I
-	I
N	I
##3	I
(	I
U	I
-	I
_	I
15	I
N	I
)	I
Ad	O
##e	O
recovered	O
(	O
top	O
panel	O
)	O
and	O
4	O
-	O
OH	O
-	O
E	O
_	O
1	O
-	O
1	O
-	O
N	O
##3	O
##A	O
##de	O
identified	O
from	O
breast	O
tissue	O
extract	O
(	O
bottom	O
)	O
.	O

Using	O
PC	B
34	I
:	I
1	I
as	O
an	O
example	O
,	O
MS	O
_	O
2	O
C	O
##ID	O
of	O
[	O
M	O
+	O
HC	O
##O	O
_	O
3	O
]	O
_	O
–	O
(	O
m	O
/	O
z	O
82	O
##0	O
)	O
suggested	O
that	O
it	O
contained	O
94	O
%	O
PC	B
16	I
:	I
0	I
/	I
18	I
:	I
1	I
and	O
6	O
%	O
PC	B
18	I
:	I
1	I
/	I
16	I
:	I
0	I
.	O

_	O
,	O
Furthermore	O
,	O
statistical	O
analyses	O
involving	O
c	B
##it	I
##rate	I
levels	O
,	O
particularly	O
ratios	O
between	O
c	B
##it	I
##rate	I
and	O
other	O
meta	O
##bol	O
##ites	O
,	O
are	O
complicated	O
by	O
its	O
var	O
##iability	O
,	O
especially	O
if	O
some	O
samples	O
have	O
s	O
##pect	O
##ros	O
##copic	O
##ally	O
base	O
##line	O
levels	O
so	O
ratios	O
have	O
close	O
to	O
infinite	O
values	O
.	O

As	O
##suming	O
that	O
the	O
patients	O
with	O
residual	O
SP	S
in	O
their	O
plasma	O
had	O
taken	O
a	O
single	O
dose	O
of	O
su	B
##lf	I
##ado	I
##xin	I
##e	I
according	O
to	O
body	O
weight	O
,	O
most	O
patients	O
must	O
have	O
taken	O
the	O
drug	O
[UNK]	O
.	O
5	O
months	O
(	O
median	O
108	O
days	O
)	O
prior	O
blood	O
withdrawal	O
.	O

Target	O
##ed	O
analysis	O
of	O
selected	O
plasma	O
variables	O
in	O
80	O
adults	O
from	O
the	O
Western	O
Norway	O
Co	O
##rona	O
##ry	O
Ang	O
##io	O
##graphy	O
Co	O
##hor	O
##t	O
classified	O
according	O
to	O
plasma	O
c	B
##ys	I
##tat	I
##hi	I
##oni	I
##ne	I
concentration	O
_	O
1	O
Sub	O
##jects	O
with	O
high	O
c	B
##ys	I
##tat	I
##hi	I
##oni	I
##ne	I
concentrations	O
had	O
75	O
%	O
higher	O
plasma	O
la	B
##nt	I
##hi	I
##oni	I
##ne	I
concentrations	O
(	O
0	O
.	O
12	O
±	O
0	O
.	O
04	O
##4	O
μ	O
##mo	O
##l	O
/	O
L	O
)	O
than	O
subjects	O
with	O
low	O
c	B
##ys	I
##tat	I
##hi	I
##oni	I
##ne	I
concentrations	O
(	O
0	O
.	O
03	O
##2	O
±	O
0	O
.	O
01	O
##3	O
μ	O
##mo	O
##l	O
/	O
L	O
;	O
P	O
<	O
0	O
.	O
00	O
##1	O
)	O
.	O

Using	O
the	O
standard	O
_	O
1	O
H	O
spectrum	O
we	O
were	O
able	O
to	O
identify	O
broad	O
signals	O
from	O
ch	B
##ole	I
##ster	I
##ols	I
or	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
.	O

We	O
examined	O
the	O
serum	O
meta	O
##bol	O
##ite	O
profile	O
associated	O
with	O
serum	O
25	B
-	I
h	I
##ydro	I
##xy	I
##vi	I
##tam	I
##in	I
D	I
levels	O
in	O
meta	O
##bol	O
##ites	O
obtained	O
from	O
both	O
a	O
nuclear	O
magnetic	O
resonance	O
s	O
##pect	O
##ros	O
##copy	O
(	O
N	O
##MR	O
)	O
-	O
and	O
a	O
mass	O
s	O
##pect	O
##rome	O
##try	O
(	O
MS	O
)	O
-	O
based	O
platform	O
.	O

Different	O
abundance	O
##s	O
of	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
lip	O
##ids	O
were	O
observed	O
in	O
the	O
cancer	O
##ous	O
regions	O
of	O
the	O
tissue	O
when	O
compared	O
to	O
adjacent	O
normal	O
tissue	O
by	O
positive	O
ion	O
mode	O
DE	O
##SI	O
-	O
MS	O
.	O

B	O
-	O
cell	O
frequency	O
,	O
is	O
##otype	O
,	O
and	O
c	O
##yt	O
##oki	O
##ne	O
production	O
in	O
heavy	O
users	O
of	O
cannabis	S
compared	O
to	O
non	O
##user	O
##s	O
.	O

This	O
meta	O
##bol	O
##ite	O
has	O
the	O
same	O
molecular	O
formula	O
and	O
hence	O
the	O
same	O
accurate	O
mass	O
as	O
p	B
##hen	I
##yl	I
##py	I
##ru	I
##vate	I
,	O
which	O
is	O
present	O
in	O
urine	O
,	O
according	O
to	O
the	O
reported	O
data	O
,	O
at	O
concentrations	O
that	O
are	O
an	O
order	O
of	O
magnitude	O
higher	O
than	O
the	O
concentration	O
of	O
3	B
-	I
h	I
##ydro	I
##xy	I
##cin	I
##nam	I
##ate	I
.	O

Figure	O
shows	O
the	O
collision	O
-	O
induced	O
di	O
##sso	O
##ciation	O
(	O
C	O
##ID	O
)	O
spectrum	O
of	O
PT	B
##AD	I
-	I
1	I
,	I
25	I
-	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
and	O
its	O
proposed	O
fragment	O
##ation	O
behavior	O
in	O
comparison	O
with	O
the	O
under	O
##iva	O
##tized	O
C	O
##ID	O
spectrum	O
.	O

For	O
each	O
sample	O
,	O
10	O
μ	O
##L	O
al	O
##iq	O
##uo	O
##ts	O
were	O
analyzed	O
in	O
trip	O
##lica	O
##te	O
using	O
h	B
##ydro	I
##phi	I
##lic	I
interaction	O
liquid	O
ch	O
##roma	O
##tography	O
(	O
H	O
##IL	O
##IC	O
)	O
with	O
the	O
electro	O
##sp	O
##ray	O
ion	O
##ization	O
(	O
E	O
##SI	O
)	O
source	O
operated	O
in	O
positive	O
mode	O
for	O
meta	O
##bol	O
##omi	O
##c	O
pro	O
##fi	O
##ling	O
and	O
reverse	O
phase	O
ch	O
##roma	O
##tography	O
(	O
R	O
##PC	O
)	O
with	O
E	O
##SI	O
in	O
negative	O
mode	O
for	O
q	O
##uant	O
##ification	O
of	O
P	O
##FA	O
##S	O
.	O

We	O
observed	O
a	O
significant	O
decrease	O
in	O
the	O
_	O
13	O
C	O
-	O
label	O
##ling	O
of	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
and	O
PA	O
-	O
based	O
O	O
##CR	O
in	O
CP	O
##T	O
##1	O
##A	O
knock	O
##down	O
cells	O
.	O

B	O
##rief	O
##ly	O
,	O
c	B
##ys	I
##tine	I
(	O
5	O
.	O
3	O
mm	O
##ol	O
)	O
was	O
added	O
to	O
13	O
m	O
##l	O
of	O
a	O
1	O
.	O
5	O
M	O
Na	O
##OH	O
solution	O
and	O
the	O
mixture	O
was	O
cooled	O
in	O
an	O
ice	O
bath	O
with	O
stirring	O
.	O

From	O
the	O
subsequent	O
standard	O
addition	O
experiments	O
we	O
found	O
that	O
1	B
##α	I
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
measurements	O
above	O
the	O
LL	O
##O	O
##Q	O
have	O
precision	O
##s	O
of	O
<	O
20	O
%	O
for	O
both	O
LL	O
##E	O
and	O
SP	O
##E	O
(	O
and	O
)	O
.	O

After	O
mixing	O
,	O
ho	O
##mo	O
##gen	O
##ization	O
,	O
and	O
cent	O
##ri	O
##fu	O
##gation	O
,	O
a	O
100	O
μ	O
##L	O
volume	O
of	O
the	O
super	O
##nat	O
##ant	O
was	O
transferred	O
,	O
and	O
100	O
μ	O
##L	O
of	O
water	O
containing	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
was	O
added	O
to	O
the	O
sample	O
.	O

(	O
Fi	O
##g	O
.	O
)	O
and	O
diminished	O
levels	O
of	O
the	O
NO	O
##S	O
cat	O
##ab	O
##olic	O
product	O
l	B
-	I
c	I
##it	I
##ru	I
##llin	I
##e	I
(	O
29	O
.	O
6	O
vs	O
.	O
35	O
.	O
6	O
μ	O
##mo	O
##l	O
/	O
L	O
,	O
p	O
<	O
0	O
.	O
00	O
##1	O
)	O

Most	O
of	O
them	O
have	O
been	O
described	O
before	O
in	O
the	O
context	O
of	O
age	O
[	O
,	O
,	O
,	O
]	O
,	O
although	O
u	O
##rina	O
##ry	O
hip	B
##pur	I
##ic	I
acid	I
was	O
found	O
to	O
be	O
elevated	O
in	O
younger	O
persons	O
.	O

The	O
meta	O
##bol	O
##ite	O
25	O
(	O
OH	O
)	O
D	O
_	O
2	O
was	O
not	O
detected	O
using	O
either	O
method	O
,	O
and	O
the	O
presence	O
of	O
3	B
-	I
e	I
##pi	I
-	I
25	I
(	I
OH	I
)	I
D	I
_	I
3	I
in	O
SR	O
##M	O
90	O
##9	O
##c	O
was	O
not	O
confirmed	O
with	O
the	O
C	O
##N	O
method	O
.	O

N	O
##G	O
##T	O
,	O
normal	O
glucose	S
tolerant	O
;	O
I	O
##G	O
##T	O
,	O
impaired	O
glucose	S
tolerant	O
;	O
N	O
##G	O
##T	O
-	O
IS	O
,	O
normal	O
glucose	S
tolerant	O
and	O
insulin	O
sensitive	O
(	O
M	O
_	O
FF	O
##M	O
>	O
45	O
µ	O
##mo	O
##l	O
·	O
min	O
_	O
−	O
##1	O
·	O
kg	O
_	O
FF	O
##M	O
_	O
−	O
##1	O
)	O
;	O
N	O
##G	O
##T	O
-	O
I	O
##R	O
,	O
normal	O
glucose	S
tolerant	O
and	O
insulin	O
resistant	O
(	O
M	O
_	O
FF	O
##M	O
≤	O
45	O
µ	O
##mo	O
##l	O
·	O
min	O
_	O
−	O
##1	O
·	O
kg	O
_	O
FF	O
##M	O
_	O
−	O
##1	O
)	O
;	O
IF	O
##G	O
,	O
normal	O
glucose	S
tolerant	O
and	O
impaired	O
fast	O
##ing	O
glucose	S
.	O

It	O
is	O
also	O
involved	O
in	O
energy	O
processes	O
by	O
entering	O
the	O
K	O
##re	O
##bs	O
cycle	O
and	O
in	O
GA	B
##BA	I
bio	O
##sy	O
##nt	O
##hesis	O
,	O
which	O
is	O
an	O
inhibitor	O
##y	O
media	O
##tor	O
in	O
the	O
brain	O
.	O

In	O
general	O
,	O
the	O
observed	O
trend	O
of	O
alterations	O
in	O
levels	O
of	O
glucose	S
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
la	B
##ct	I
##ate	I
,	O
c	B
##it	I
##rate	I
,	O
al	B
##ani	I
##ne	I
,	O
l	B
##ys	I
##ine	I
,	O
le	B
##uc	I
##ine	I
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
and	O
v	B
##ali	I
##ne	I
was	O
in	O
agreement	O
with	O
the	O
observations	O
in	O
oral	O
cancer	O
.	O

A	O
difficulty	O
arose	O
during	O
the	O
der	O
##iva	O
##tis	O
##ation	O
from	O
the	O
two	O
possible	O
sides	O
of	O
attack	O
of	O
the	O
c	O
##is	O
-	O
die	O
##ne	O
m	O
##oi	O
##ety	O
of	O
vitamin	B
D	I
compounds	O
_	O
,	O
.	O

We	O
found	O
a	O
significant	O
interaction	O
between	O
o	O
##besity	O
,	O
test	B
##osterone	I
and	O
d	O
##ys	O
##lip	O
##ide	O
##mia	O
in	O
women	O
with	O
PC	O
##OS	O
,	O
which	O
indicates	O
that	O
the	O
syndrome	O
itself	O
is	O
an	O
important	O
player	O
in	O
the	O
lip	O
##op	O
##rote	O
##in	O
abnormal	O
##ities	O
beyond	O
the	O
effects	O
of	O
o	O
##besity	O
per	O
se	O
.	O

Fast	O
##ing	O
spot	O
urine	O
from	O
all	O
participants	O
was	O
collected	O
into	O
p	B
##oly	I
##p	I
##rop	I
##yle	I
##ne	I
collection	O
cups	O
the	O
day	O
before	O
the	O
training	O
started	O
(	O
V	O
##isi	O
##t	O
1	O
,	O
V	O
##1	O
)	O
,	O
the	O
day	O
after	O
the	O
last	O
training	O
session	O
(	O
V	O
##isi	O
##t	O
2	O
,	O
V	O
##2	O
)	O
as	O
well	O
as	O
after	O
four	O
days	O
of	O
recovery	O
(	O
V	O
##isi	O
##t	O
3	O
,	O
V	O
##3	O
)	O
.	O

a	O
In	O
##dicate	O
##s	O
values	O
that	O
are	O
×	O
##10	O
_	O
2	O
;	O
SD	O
=	O
standard	O
de	O
##viation	O
,	O
3	O
-	O
HK	O
=	O
3	B
-	I
H	I
##ydro	I
##xy	I
##ky	I
##nu	I
##ren	I
##ine	I
,	O
3	O
-	O
H	O
##AA	O
=	O
3	B
-	I
H	I
##ydro	I
##xy	I
##ant	I
##hra	I
##ni	I
##lli	I
##c	I
acid	I
,	O
N	O
##S	O
=	O
Not	O
Sign	O
##ificant	O
Un	O
##iva	O
##ria	O
##te	O
log	O
##istic	O
re	O
##gression	O
revealed	O
significant	O
odds	O
of	O
moderate	O
to	O
severe	O
end	O
##os	O
##copic	O
inflammation	O
(	O
Mayo	O
end	O
##os	O
##copic	O
score	O
of	O
2	O
or	O
3	O
)	O
associated	O
with	O
higher	O
K	O
##Y	O
##NA	O
/	O
T	O
and	O
3	O
##HA	O
##A	O
/	O
T	O
.	O
Multi	O
##var	O
##iate	O
analysis	O
adjusting	O
for	O
age	O
at	O
diagnosis	O
,	O
smoking	O
status	O
,	O
extent	O
of	O
disease	O
,	O
and	O
medication	O
use	O
resulted	O
in	O
significant	O
odds	O
of	O
moderate	O
to	O
severe	O
end	O
##os	O
##copic	O
inflammation	O
with	O
higher	O
K	O
##Y	O
##NA	O
/	O
T	O
[	O
OR	O
1	O
.	O
00	O
##15	O
(	O
95	O
%	O
C	O
##I	O
1	O
.	O
000	O
##3	O
–	O
1	O
.	O
00	O
##29	O
)	O
,	O
P	O
=	O
0	O
.	O
01	O
##86	O
)	O
.	O

Cy	O
##c	O
##lic	O
,	O
de	B
##ox	I
##y	I
,	O
mon	O
##o	O
-	O
,	O
di	O
-	O
and	O
trip	B
##hos	I
##phate	I
##s	I
showed	O
similar	O
retention	O
regardless	O
of	O
the	O
base	O
.	O

Anti	O
##bo	O
##dies	O
were	O
as	O
following	O
:	O
anti	O
-	O
P	O
##LC	O
##ε	O
(	O
di	O
##lution	O
1	O
:	O
1000	O
;	O
Santa	O
Cruz	O
B	O
##iot	O
##ech	O
##nology	O
)	O
;	O
anti	O
-	O
Y	O
##AP	O
(	O
di	O
##lution	O
1	O
:	O
1000	O
;	O
CS	O
##T	O
)	O
;	O
anti	O
-	O
PS	O
##AT	O
##1	O
(	O
di	O
##lution	O
1	O
:	O
1000	O
;	O
A	O
##bs	O
##in	O
)	O
;	O
anti	O
-	O
PS	O
##P	O
##H	O
(	O
di	O
##lution	O
1	O
:	O
1000	O
;	O
A	O
##bs	O
##in	O
)	O
;	O
anti	O
-	O
SH	O
##MT	O
##2	O
(	O
di	O
##lution	O
1	O
:	O
500	O
;	O
Nov	O
##us	O
)	O
;	O
anti	B
-	I
Cy	I
##c	I
##lin	I
##D	I
##1	I
(	O
di	O
##lution	O
1	O
:	O
500	O
)	O
and	O
anti	O
-	O
PC	O
##NA	O
(	O
di	O
##lution	O
1	O
:	O
500	O
)	O
were	O
from	O
Wan	O
##le	O
##i	O
-	O
bio	O
(	O
Shen	O
##yang	O
,	O
China	O
)	O
,	O
anti	B
-	I
β	I
-	I
act	I
##in	I
(	O
di	O
##lution	O
1	O
:	O
3000	O
)	O
,	O
and	O
anti	O
-	O
H	O
##3	O
(	O
di	O
##lution	O
1	O
:	O
2000	O
)	O
were	O
purchased	O
from	O
A	O
##b	O
##cam	O
(	O
Cambridge	O
,	O
UK	O
)	O
.	O

This	O
set	O
of	O
Q	O
##C	O
samples	O
prepared	O
in	O
pool	O
##ed	O
human	O
serum	O
displayed	O
97	O
.	O
4	O
%	O
average	O
pro	B
##line	I
amount	O
remaining	O
,	O
which	O
suggested	O
that	O
pro	B
##line	I
in	O
human	O
serum	O
was	O
stable	O
after	O
three	O
freeze	O
-	O
th	O
##aw	O
cycles	O
.	O

It	O
can	O
be	O
provided	O
via	O
animal	O
fat	O
##s	O
or	O
converted	O
from	O
alpha	B
-	I
l	I
##ino	I
##len	I
##ic	I
acid	I
and	O
l	B
##ino	I
##le	I
##ic	I
acid	I
in	O
the	O
human	O
liver	O
.	O

7	B
-	I
(	I
N	I
-	I
Ace	I
##ty	I
##l	I
##cs	I
##yte	I
##in	I
##yl	I
)	I
-	I
8	I
,	I
9	I
,	I
10	I
-	I
t	I
##ri	I
##hy	I
##dr	I
##ox	I
##y	I
-	I
7	I
,	I
8	I
,	I
9	I
,	I
10	I
-	I
te	I
##tra	I
##hy	I
##dr	I
##obe	I
##nz	I
##o	I
[	I
a	I
]	I
p	O
##yre	O
##ne	O
(	O
re	O
##v	O
-	O
BP	O
##DE	O
-	O
7	O
-	O
N	O
##AC	O
)	O
was	O
prepared	O
essentially	O
as	O
described	O
previously	O
.	O

P	O
##las	O
##ma	O
samples	O
(	O
50	O
μ	O
##L	O
)	O
were	O
extracted	O
using	O
a	O
500	O
μ	O
##L	O
ch	O
##lor	O
##of	O
##orm	O
:	O
met	O
##han	O
##ol	O
(	O
2	O
:	O
1	O
,	O
v	O
/	O
v	O
)	O
solution	O
and	O
dried	O
under	O
nitrogen	B
gas	I
.	O

Results	O
:	O
In	O
healthy	O
human	O
serum	O
,	O
met	B
##han	I
##ol	I
:	O
ch	O
##lor	O
##of	O
##orm	O
:	O
water	O
extraction	O
with	O
ultra	O
##fi	O
##ltration	O
was	O
compared	O
to	O
met	B
##han	I
##ol	I
precipitation	O
with	O
and	O
without	O
ultra	O
##fi	O
##ltration	O
.	O

The	O
specific	O
increase	O
in	O
T	B
##G	I
containing	O
C	B
##22	I
:	I
6	I
in	O
fatalities	O
(	O
or	O
decrease	O
in	O
survivors	O
with	O
E	O
##VD	O
progression	O
)	O
,	O
is	O
unclear	O
given	O
the	O
lack	O
of	O
nutrition	O
while	O
ill	O
.	O

The	O
findings	O
in	O
(	O
ii	O
##i	O
)	O
indicate	O
that	O
impaired	O
cerebral	O
glucose	S
up	O
##take	O
pre	O
##sa	O
##ges	O
the	O
development	O
of	O
(	O
presumably	O
s	O
##poradic	O
)	O
AD	O
:	O
these	O
findings	O
are	O
consistent	O
with	O
elevated	O
brain	O
glucose	S
as	O
a	O
key	O
early	O
aspect	O
of	O
path	O
##ogen	O
##esis	O
.	O

c	O
L	O
##ymph	O
node	O
progression	O
free	O
survival	O
calculated	O
by	O
the	O
Kaplan	O
Mei	O
##er	O
method	O
for	O
is	B
##ova	I
##ler	I
##yl	I
##car	I
##ni	I
##tine	I
(	O
C	O
##5	O
)	O
.	O

Overall	O
,	O
however	O
,	O
the	O
Tor	O
##us	O
Di	B
##ol	I
column	O
used	O
with	O
a	O
met	O
##han	O
##ol	O
/	O
am	O
##mon	O
##ium	O
format	B
##e	I
m	O
##od	O
##ifier	O
is	O
a	O
promising	O
starting	O
point	O
for	O
un	O
##tar	O
##get	O
##ed	O
SF	O
##C	O
analysis	O
of	O
medium	O
polar	O
##ity	O
meta	O
##bol	O
##ites	O
in	O
urine	O
.	O

In	O
fact	O
,	O
it	O
has	O
been	O
reported	O
that	O
members	O
of	O
the	O
genus	O
E	O
##scher	O
##ichi	O
##a	O
are	O
associated	O
with	O
high	O
blood	O
ethanol	S
concentrations	O
,	O
which	O
in	O
turn	O
is	O
associated	O
with	O
an	O
increase	O
of	O
gut	O
per	O
##me	O
##ability	O
and	O
inflammation	O
.	O

A	O
separate	O
study	O
showed	O
that	O
4	O
-	O
HP	O
##A	O
reduced	O
inflammatory	O
c	O
##yt	O
##oki	O
##ne	O
levels	O
through	O
suppress	O
##ing	O
h	O
##yper	O
##ton	O
##icit	O
##y	O
-	O
and	O
h	O
##y	O
##pox	O
##ia	O
-	O
induced	O
H	B
##IF	I
-	I
1	I
##α	I
in	O
mac	O
##rop	O
##hage	O
##s	O
.	O

Ethan	B
##ola	I
##mine	I
am	O
##monia	O
-	O
l	O
##yas	O
##e	O
(	O
EC	O
4	O
.	O
3	O
.	O
1	O
.	O
7	O
)	O
was	O
similarly	O
en	O
##rich	O
##ed	O
in	O
the	O
I	O
##B	O
##D	O
gut	O
.	O

The	O
response	O
of	O
changes	O
in	O
s	B
##te	I
##aro	I
##yl	I
-	I
Co	I
##A	I
des	O
##at	O
##ura	O
##se	O
(	O
SC	O
##D	O
)	O
and	O
al	O
##do	O
##lase	O
C	O
,	O
f	B
##ru	I
##ct	I
##ose	I
-	I
bi	I
##sp	I
##hos	I
##phate	I
(	O
AL	O
##D	O
##OC	O
)	O
in	O
breast	O
tissue	O
across	O
the	O
two	O
studies	O
are	O
reported	O
in	O
Fi	O
##g	O
.	O

Regarding	O
the	O
L	O
##C	O
system	O
,	O
h	B
##ydro	I
##phi	I
##lic	I
interaction	O
ch	O
##roma	O
##tography	O
(	O
H	O
##IL	O
##IC	O
)	O
was	O
employed	O
for	O
lip	O
##id	O
class	O
separation	O
and	O
the	O
P	O
##B	O
re	O
##age	O
##nt	O
,	O
ace	B
##tone	I
,	O
was	O
directly	O
employed	O
in	O
the	O
mobile	O
phase	O
.	O

Met	O
##ab	O
##oli	O
##tes	O
CR	O
and	O
N	B
##AN	I
##A	I
were	O
significantly	O
elevated	O
in	O
ICC	O
when	O
compared	O
to	O
HC	O
##C	O
cases	O
in	O
both	O
urine	O
and	O
tissue	O
samples	O
.	O

The	O
results	O
obtained	O
with	O
the	O
valid	O
##ation	O
population	O
(	O
10	O
low	O
and	O
10	O
high	O
coffee	O
consumers	O
)	O
confirmed	O
that	O
at	O
##rac	O
##ty	O
##li	O
##gen	O
##in	O
g	B
##lu	I
##cu	I
##ron	I
##ide	I
would	O
be	O
a	O
much	O
more	O
effective	O
marker	O
of	O
coffee	O
consumption	O
than	O
ca	B
##ffe	I
##ine	I
(	O
AU	O
##C	O
0	O
.	O
95	O
vs	O
0	O
.	O
72	O
;	O
)	O
.	O

The	O
lip	O
##ids	O
were	O
separated	O
using	O
an	O
A	O
##c	O
##qui	O
##ty	O
UP	O
##LC	O
charged	O
surface	O
hybrid	O
C	O
##18	O
column	O
(	O
2	O
.	O
1	O
×	O
100	O
mm	O
,	O
1	O
.	O
7	O
μ	O
##m	O
,	O
Waters	O
)	O
with	O
a	O
gradient	O
mobile	O
phase	O
comprised	O
of	O
10	O
m	O
##M	O
am	B
##mon	I
##ium	I
format	I
##e	I
with	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
in	O
ace	O
##ton	O
##it	O
##ril	O
##e	O
/	O
water	O
(	O
A	O
,	O
60	O
:	O
40	O
,	O
v	O
/	O
v	O
)	O
and	O
10	O
m	O
##M	O
am	B
##mon	I
##ium	I
format	I
##e	I
with	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
in	O
is	O
##op	O
##rop	O
##ano	O
##l	O
/	O
ace	O
##ton	O
##it	O
##ril	O
##e	O
(	O
B	O
,	O
90	O
:	O
10	O
,	O
v	O
/	O
v	O
)	O
.	O

Compared	O
with	O
healthy	O
controls	O
,	O
N	O
##SC	O
##LC	O
patients	O
showed	O
significantly	O
elevated	O
serum	O
levels	O
of	O
la	B
##ct	I
##ate	I
,	O
al	B
##ani	I
##ne	I
,	O
g	B
##lut	I
##ama	I
##te	I
,	O
pro	B
##line	I
,	O
g	B
##ly	I
##co	I
##p	I
##rote	I
##in	I
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
t	B
##yr	I
##os	I
##ine	I
and	O
try	B
##pt	I
##op	I
##han	I
,	O
and	O
marked	O
##ly	O
decreased	O
serum	O
levels	O
of	O
glucose	S
,	O
ta	B
##uri	I
##ne	I
,	O
g	B
##lut	I
##amine	I
,	O
g	B
##ly	I
##cine	I
,	O
p	B
##hos	I
##ph	I
##oc	I
##rea	I
##tine	I
and	O
th	B
##re	I
##oni	I
##ne	I
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

The	O
meta	O
##bol	O
##ites	O
identified	O
in	O
CT	O
##RL	O
and	O
L	O
##C	O
urine	O
samples	O
span	O
diverse	O
chemical	O
families	O
,	O
being	O
the	O
most	O
representative	O
the	O
k	B
##eton	I
##es	I
,	O
in	O
addition	O
to	O
sulfur	B
##ic	I
,	O
ben	B
##zen	I
##ic	I
,	O
fur	O
##ani	O
##c	O
and	O
te	O
##rp	O
##eni	O
##c	O
compounds	O
.	O

The	O
results	O
were	O
obtained	O
by	O
in	O
##ject	O
##ing	O
10	O
μ	O
##L	O
of	O
50	O
ng	O
/	O
m	O
##L	O
standard	O
solutions	O
for	O
A	O
,	O
A	O
##bi	O
;	O
B	O
,	O
D	O
##4	O
##A	O
;	O
C	O
,	O
3	B
-	I
k	I
##eto	I
-	I
5	I
##α	I
-	I
A	I
##bi	I
;	O
D	O
,	O
3	B
##α	I
-	I
OH	I
-	I
5	I
##α	I
-	I
A	I
##bi	I
;	O
E	O
,	O
3	B
##β	I
-	I
OH	I
-	I
5	I
##α	I
-	I
A	I
##bi	I
;	O
F	O
,	O
3	B
-	I
k	I
##eto	I
-	I
5	I
##β	I
-	I
A	I
##bi	I
;	O
G	O
,	O
3	B
##α	I
-	I
OH	I
-	I
5	I
##β	I
-	I
A	I
##bi	I
;	O
and	O
H	O
,	O
3	B
##β	I
-	I
OH	I
-	I
5	I
##β	I
-	I
A	I
##bi	I
.	O

CO	O
_	O
3	O
buffer	O
(	O
250	O
m	O
##M	O
,	O
pH	O
=	O
10	O
.	O
3	O
)	O
and	O
50	O
μ	O
##L	O
_	O
12	O
C	B
-	I
dans	I
##yl	I
chloride	I
(	O
D	O
##ns	O
##C	O
##l	O
)	O
(	O
18	O
mg	O
/	O
m	O
##l	O
in	O
AC	O
##N	O
)	O
.	O

However	O
,	O
the	O
s	O
##tra	O
##ti	O
##fication	O
of	O
T	B
##MA	I
##O	I
levels	O
according	O
to	O
the	O
ne	O
##uro	O
##logical	O
di	O
##ag	O
##nose	O
##s	O
revealed	O
no	O
differences	O
among	O
the	O
three	O
groups	O
.	O

To	O
0	O
.	O
25	O
m	O
##l	O
of	O
the	O
serum	O
or	O
W	O
##B	O
,	O
0	O
.	O
5	O
m	O
##L	O
of	O
met	B
##han	I
##ol	I
and	O
0	O
.	O
5	O
m	O
##L	O
ch	B
##lor	I
##of	I
##orm	I
(	O
both	O
solvent	O
##s	O
kept	O
at	O
4	O
°C	O
)	O
were	O
added	O
in	O
the	O
ratio	O
1	O
:	O
2	O
:	O
2	O
(	O
sample	O
:	B
met	B
##han	I
##ol	I
:	I
ch	I
##lor	I
##of	I
##orm	I
,	O
v	O
/	O
v	O
/	O
v	O
)	O
.	O

The	O
low	O
-	O
risk	O
group	O
did	O
not	O
have	O
any	O
risk	O
factors	O
,	O
the	O
moderate	B
-	I
risk	I
group	O
had	O
one	O
risk	O
factor	O
,	O
and	O
the	O
high	O
-	O
risk	O
group	O
had	O
both	O
risk	O
factors	O
.	O

G	B
##lut	I
##amine	I
(	O
M	O
##5	O
)	O
,	O
g	B
##lut	I
##ama	I
##te	I
(	O
M	O
##5	O
)	O
,	O
th	B
##re	I
##oni	I
##ne	I
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
l	B
##ys	I
##ine	I
and	O
is	B
##ole	I
##uc	I
##ine	I
,	O
on	O
the	O
other	O
hand	O
,	O
originate	O
from	O
wheat	O
protein	O
.	O

Multiple	O
reaction	O
monitoring	O
(	O
MR	O
##M	O
)	O
transitions	O
from	O
the	O
CE	O
-	O
MS	O
/	O
MS	O
analysis	O
of	O
a	O
10	O
-	O
fold	O
di	O
##lut	O
##ed	O
human	O
urine	O
sample	O
obtained	O
from	O
a	O
patient	O
suffering	O
from	O
inflammatory	O
bow	O
##el	O
disease	O
undergoing	O
treatment	O
with	O
th	B
##io	I
##pur	I
##ines	I
(	I
a	I
##za	I
##thi	I
##op	I
##rine	I
)	I
.	O

The	O
higher	O
test	B
##osterone	I
levels	O
,	O
adjusted	O
for	O
WC	O
,	O
associated	O
adverse	O
##ly	O
with	O
insulin	O
levels	O
and	O
H	O
##OM	O
##A	O
I	O
##R	O
in	O
cases	O
but	O
not	O
in	O
the	O
controls	O
.	O

Although	O
needing	O
confirmation	O
in	O
larger	O
studies	O
,	O
our	O
study	O
shows	O
that	O
it	O
is	O
possible	O
to	O
detect	O
a	O
multitude	O
of	O
est	B
##rogen	I
meta	O
##bol	O
##ites	O
as	O
well	O
as	O
differences	O
in	O
est	B
##rogen	I
meta	O
##bol	O
##ites	O
in	O
urine	O
between	O
pro	O
##state	O
cancer	O
cases	O
and	O
controls	O
.	O

The	O
maximum	O
peak	O
area	O
was	O
<	O
5	O
%	O
of	O
the	O
signal	O
of	O
LL	O
##O	O
##Q	O
a	B
##bir	I
##ater	I
##one	I
and	O
the	O
IS	B
(	I
D	I
_	I
4	I
-	I
a	I
##bir	I
##ater	I
##one	I
)	I
.	O

Ph	O
##IP	O
/	O
nm	O
##ol	O
SA	O
,	O
based	O
on	O
the	O
assumption	O
that	O
N	B
-	I
ace	I
##to	I
##xy	I
-	I
Ph	I
##IP	I
-	I
SA	I
add	O
##uc	O
##ts	O
possess	O
m	O
##olar	O
absorption	O
coefficients	O
that	O
are	O
comparable	O
to	O
that	O
of	O
Ph	O
##IP	O
(	O
315	O
nm	O
;	O
ε	O
(	O
M	O
_	O
−	O
##1	O
cm	O
_	O
−	O
##1	O
)	O
at	O
22	O
,	O
220	O
)	O
.	O

No	O
carry	O
##over	O
was	O
observed	O
for	O
can	B
##na	I
##bino	I
##ids	I
after	O
in	O
##ject	O
##ing	O
negative	O
specimens	O
after	O
samples	O
containing	O
twice	O
the	O
U	O
##L	O
##O	O
##Q	O
.	O

Ser	O
##um	O
levels	O
of	O
novel	O
h	B
##ydro	I
##xy	I
p	O
##oly	O
##uns	O
##at	O
##ura	O
##ted	O
ultra	O
long	O
-	O
chain	O
fatty	O
acids	O
(	O
h	O
##P	O
##U	O
##LC	O
##FA	O
##s	O
)	O
have	O
been	O
previously	O
shown	O
to	O
be	O
reduced	O
in	O
pre	O
-	O
treatment	O
CR	O
##C	O
patients	O
compared	O
to	O
disease	O
-	O
free	O
subjects	O
,	O
independent	O
of	O
disease	O
stage	O
.	O

They	O
were	O
maintained	O
in	O
Du	O
##l	O
##be	O
##cco	O
’	O
s	O
Mo	O
##dified	O
Eagle	O
medium	O
supplemented	O
with	O
10	O
%	O
(	O
v	O
/	O
v	O
)	O
f	O
##etal	O
b	O
##ov	O
##ine	O
serum	O
,	O
2	O
m	O
##M	O
g	B
##lut	I
##amine	I
,	O
pen	B
##ici	I
##llin	I
(	O
100	O
units	O
/	O
m	O
##L	O
)	O
,	O
and	O
s	B
##tre	I
##pt	I
##omy	I
##cin	I
100	O
μ	O
##g	O
/	O
m	O
##L	O
.	O

The	O
variable	O
core	O
was	O
mainly	O
composed	O
of	O
pre	B
##no	I
##l	I
lip	O
##ids	O
,	O
amino	O
acids	O
,	O
g	B
##ly	I
##cer	I
##oli	I
##pid	I
##s	I
,	O
s	O
##tero	O
##ids	O
,	O
p	O
##hen	O
##ols	O
,	O
fatty	O
acids	O
and	O
derivatives	O
,	O
ben	B
##zoic	I
acid	I
and	O
derivatives	O
,	O
fl	B
##av	I
##ono	I
##ids	I
,	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
,	O
ben	B
##zo	I
##py	I
##ran	I
##s	I
,	O
and	O
q	B
##uin	I
##olin	I
##es	I
.	O

A	O
##bs	O
##ol	O
##ute	O
in	O
##tra	O
##cellular	O
amounts	O
of	O
monitored	O
meta	O
##bol	O
##ites	O
of	O
the	O
g	B
##ly	I
##co	I
##ly	I
##tic	I
pathway	O
are	O
presented	O
as	O
bar	O
charts	O
(	O
nm	O
##ol	O
per	O
10	O
_	O
6	O
cells	O
)	O
.	O

I	O
##dent	O
##ified	O
ion	O
features	O
in	O
the	O
met	O
##han	O
##ol	O
-	O
extraction	O
platform	O
included	O
fatty	O
acids	O
,	O
bi	O
##le	O
acids	O
,	O
mon	B
##oa	I
##cy	I
##l	I
##gly	I
##cer	I
##ol	I
p	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
,	O
mon	O
##oe	O
##ther	O
g	B
##ly	I
##cer	I
##ol	I
p	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
,	O
and	O
free	O
s	B
##phi	I
##ngo	I
##id	I
bases	O
.	O

These	O
findings	O
suggested	O
that	O
24	B
##S	I
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
was	O
synthesized	O
in	O
gray	O
matter	O
neurons	O
,	O
a	O
hypothesis	O
subsequently	O
confirmed	O
by	O
his	O
##to	O
##chemical	O
studies	O
.	O

C	B
##it	I
##rate	I
,	O
another	O
meta	O
##bol	O
##ite	O
related	O
to	O
cellular	O
energetic	O
##s	O
,	O
was	O
negatively	O
correlated	O
with	O
g	B
##lut	I
##ama	I
##te	I
during	O
insulin	O
de	O
##p	O
##ri	O
##vation	O
but	O
the	O
relationship	O
between	O
these	O
two	O
meta	O
##bol	O
##ites	O
became	O
positive	O
with	O
insulin	O
treatment	O
.	O

Further	O
study	O
of	O
est	B
##rogen	I
metabolism	O
and	O
E	O
##M	O
p	O
##hen	O
##otype	O
##s	O
in	O
relation	O
to	O
cancer	O
risk	O
will	O
provide	O
more	O
information	O
about	O
the	O
mechanisms	O
by	O
which	O
so	O
##y	O
can	O
modify	O
breast	O
cancer	O
risk	O
.	O

Upon	O
analysis	O
the	O
dried	O
samples	O
were	O
re	O
##con	O
##stituted	O
in	O
100	O
µ	O
##L	O
5	O
%	O
Me	B
##OH	I
,	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
and	O
94	O
.	O
9	O
%	O
dei	O
##onized	O
Mill	O
##i	O
##Q	O
water	O
.	O

The	O
q	O
##uant	O
##ified	O
meta	O
##bol	O
##ites	O
were	O
put	O
into	O
bio	O
##chemical	O
context	O
via	O
the	O
s	O
##che	O
##matic	O
overview	O
of	O
try	B
##pt	I
##op	I
##han	I
metabolism	O
illustrated	O
in	O
Fi	O
##g	O
.	O

Few	O
previous	O
studies	O
have	O
reported	O
concentrations	O
of	O
p	B
##ht	I
##hala	I
##te	I
meta	O
##bol	O
##ites	O
in	O
serum	O
.	O

Of	O
the	O
seven	O
L	O
##MI	O
##s	O
,	O
four	O
##with	O
a	O
137	O
.	O
04	O
##55	O
m	O
/	O
z	O
ion	O
at	O
##ret	O
##ent	O
##ion	O
times	O
of	O
2	O
.	O
04	O
-	O
3	O
.	O
14	O
minutes	O
##wer	O
##e	O
up	O
##re	O
##gu	O
##lated	O
in	O
se	O
##ra	O
from	O
O	O
##VC	O
patients	O
;	O
the	O
ion	O
was	O
identified	O
as	O
that	O
derived	O
from	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
.	O

The	O
meta	O
##bol	O
##ites	O
detected	O
also	O
had	O
some	O
very	O
minor	O
differences	O
(	O
e	O
.	O
g	O
.	O
,	O
pro	B
##line	I
was	O
only	O
detected	O
in	O
50	O
_	O
H	O
##IG	O
##H	O
and	O
t	B
##yr	I
##os	I
##ine	I
,	O
u	B
##rac	I
##il	I
,	O
and	O
rib	B
##ose	I
-	I
5	I
-	I
phosphate	I
were	O
only	O
detected	O
in	O
80	O
_	O
H	O
##IG	O
##H	O
)	O
.	O

The	O
other	O
four	O
pathways	O
included	O
p	B
##yr	I
##im	I
##id	I
##ine	I
,	O
le	O
##uk	O
##ot	O
##rien	O
##e	O
,	O
pu	B
##rine	I
,	O
and	O
l	B
##ys	I
##ine	I
metabolism	O
.	O

Under	O
the	O
op	O
##ti	O
##mized	O
ch	O
##roma	O
##to	O
##graphic	O
conditions	O
,	O
G	O
##L	O
##Y	O
,	O
GP	S
,	O
M1	O
and	O
M	O
##2	O
were	O
el	O
##uted	O
with	O
retention	O
times	O
of	O
8	O
.	O
2	O
,	O
6	O
.	O
5	O
,	O
5	O
.	O
6	O
and	O
6	O
.	O
9	O
min	O
,	O
respectively	O
.	O

These	O
matrix	O
peaks	O
could	O
possibly	O
represent	O
other	O
unidentified	O
vitamin	B
D	I
meta	O
##bol	O
##ites	O
,	O
but	O
identification	O
of	O
these	O
compounds	O
was	O
beyond	O
the	O
scope	O
of	O
the	O
present	O
investigation	O
.	O

Selected	O
ion	O
ch	O
##roma	O
##to	O
##gram	O
##s	O
of	O
der	O
##iva	O
##tized	O
amino	O
acids	O
provided	O
by	O
the	O
U	O
##HP	O
##LC	O
-	O
MS	O
analysis	O
of	O
clinical	O
human	O
urine	O
samples	O
obtained	O
from	O
an	O
I	O
##B	O
##D	O
patient	O
treated	O
with	O
th	B
##io	I
##pur	I
##ines	I
and	O
from	O
a	O
healthy	O
control	O
are	O
presented	O
in	O
Su	O
##pp	O
##lement	O
##ary	O
Material	O
,	O
Figure	O
S	O
##1	O
.	O

At	O
50	O
and	O
100	O
μ	O
##M	O
k	B
##yn	I
##uren	I
##ine	I
,	O
CD	O
##8	O
T	O
cell	O
death	O
increased	O
as	O
measured	O
by	O
a	O
fix	O
##able	O
via	O
##bility	O
dye	O
,	O
while	O
CF	O
##SE	O
analysis	O
of	O
live	O
CD	O
##8	O
T	O
cells	O
indicated	O
no	O
change	O
in	O
proliferation	O
,	O
demonstrating	O
a	O
direct	O
impact	O
of	O
k	B
##yn	I
##uren	I
##ine	I
specifically	O
on	O
human	O
CD	O
##8	O
T	O
cell	O
via	O
##bility	O
.	O

)	O
,	O
the	O
plasma	O
concentrations	O
of	O
L	O
##ys	O
##o	O
P	B
##E	I
(	I
18	I
:	I
3	I
)	I
,	O
L	O
##ys	O
##o	O
P	B
##E	I
(	I
20	I
:	I
4	I
)	I
,	O
L	O
##ys	O
##o	O
P	B
##E	I
(	I
22	I
:	I
1	I
)	I
showed	O
a	O
strong	O
positive	O
correlation	O
with	O
G	O
##lo	O
##mer	O
##ular	O
Fi	O
##ltration	O
Rate	O
(	O
e	O
##G	O
##F	O
##R	O
)	O
,	O
as	O
were	O
a	O
number	O
of	O
other	O
meta	O
##bol	O
##ites	O
.	O

In	O
contrast	O
to	O
the	O
E	O
##V	O
-	O
derived	O
factor	O
and	O
ratio	O
normal	O
##izations	O
,	O
normal	O
##ization	O
to	O
urine	O
volume	O
or	O
c	B
##rea	I
##tin	I
##ine	I
did	O
not	O
produce	O
any	O
systematic	O
differences	O
that	O
would	O
distinguish	O
the	O
pre	O
-	O
pro	O
##state	O
##ct	O
##omy	O
u	O
##E	O
##V	O
samples	O
from	O
the	O
other	O
study	O
groups	O
(	O
data	O
not	O
shown	O
)	O
.	O

V	O
##aria	O
##tion	O
in	O
PM	O
##D	O
did	O
not	O
affect	O
glucose	S
values	O
here	O
(	O
data	O
not	O
shown	O
)	O
.	O

We	O
demonstrate	O
that	O
a	O
number	O
of	O
lip	O
##id	O
-	O
,	O
amino	S
acid	O
-	O
,	O
and	O
t	B
##rica	I
##rb	I
##ox	I
##yl	I
##ic	I
acid	I
(	O
T	O
##CA	O
)	O
cycle	O
-	O
related	O
meta	O
##bol	O
##ites	O
were	O
significantly	O
altered	O
in	O
I	O
##B	O
##D	O
patients	O
,	O
more	O
specifically	O
in	O
CD	O
.	O

Prior	O
studies	O
have	O
documented	O
that	O
the	O
expression	O
and	O
activity	O
of	O
key	O
genes	O
in	O
the	O
fatty	O
acid	O
metabolism	O
pathway	O
,	O
including	O
ATP	B
c	I
##it	I
##rate	I
l	O
##yas	O
##e	O
(	O
AC	O
##L	O
##Y	O
)	O
,	O
ace	O
##ty	O
##l	O
-	O
Co	O
##A	O
car	O
##box	O
##yla	O
##se	O
(	O
ACC	O
)	O
,	O
fatty	O
acid	O
s	O
##ynth	O
##ase	O
,	O
and	O
s	B
##te	I
##aro	I
##yl	I
-	I
co	I
##en	I
##zy	I
##me	I
A	O
des	O
##at	O
##ura	O
##se	O
,	O
are	O
observed	O
in	O
various	O
tumors	O
and	O
are	O
closely	O
related	O
to	O
poor	O
pro	O
##gno	O
##sis	O
of	O
these	O
patients	O
.	O

For	O
the	O
trip	B
##hos	I
##phate	I
n	O
##uc	O
##leo	O
##tide	O
##s	O
(	O
See	O
C	O
–	O
E	O
and	O
Table	O
S	O
-	O
1	O
)	O
,	O
such	O
as	O
ATP	S
,	O
U	O
##TP	O
,	O
and	O
GT	O
##P	O
,	O
no	O
detect	O
##able	O
concentration	O
was	O
left	O
after	O
heating	O
for	O
60	O
s	O
,	O
which	O
was	O
followed	O
by	O
similar	O
degradation	O
of	O
their	O
dip	B
##hos	I
##phate	I
meta	O
##bol	O
##ites	O
.	O

G	O
##C	O
-	O
MS	O
data	O
was	O
normal	O
##ized	O
by	O
sum	O
,	O
log	O
-	O
transformed	O
and	O
auto	O
-	O
scaled	O
prior	O
to	O
analysis	O
,	O
whereas	O
u	O
##rina	O
##ry	O
concentrations	O
determined	O
by	O
_	O
1	O
H	O
-	O
N	O
##MR	O
were	O
normal	O
##ized	O
to	O
c	B
##rea	I
##tin	I
##ine	I
(	O
µ	O
##mo	O
##l	O
/	O
mm	O
##ol	O
c	O
##rea	O
##tin	O
##ine	O
)	O
,	O
log	O
transformed	O
and	O
auto	O
-	O
scaled	O
.	O

The	O
slightly	O
decreased	O
levels	O
of	O
AD	B
##P	I
and	O
ATP	S
in	O
the	O
PC	O
209	O
##6	O
4	O
##B	O
cell	O
line	O
may	O
be	O
linked	O
to	O
the	O
lowered	O
levels	O
of	O
rib	B
##ose	I
-	I
5	I
-	I
phosphate	I
(	O
see	O
and	O
)	O
,	O
which	O
supplies	O
the	O
rib	B
##ose	I
m	O
##oi	O
##ety	O
of	O
these	O
n	O
##uc	O
##leo	O
##tide	O
##s	O
and	O
/	O
or	O
decreased	O
as	B
##par	I
##tate	I
which	O
contributes	O
to	O
nitrogen	O
-	O
donation	O
in	O
pu	B
##rine	I
ring	O
synthesis	O
.	O

Full	O
-	O
scan	O
MS	O
_	O
2	O
mass	O
s	O
##pect	O
##ra	O
of	O
b	B
##up	I
##ren	I
##or	I
##phine	I
(	O
B	O
##UP	O
)	O
and	O
nor	B
##bu	I
##p	I
##ren	I
##or	I
##phine	I
(	O
N	O
##B	O
##UP	O
)	O
and	O
MS	O
_	O
3	O
mass	O
s	O
##pect	O
##ra	O
of	O
b	B
##up	I
##ren	I
##or	I
##phine	I
g	I
##lu	I
##cu	I
##ron	I
##ide	I
(	O
B	O
##UP	O
-	O
G	O
##lu	O
##c	O
)	O
and	O
nor	B
##bu	I
##p	I
##ren	I
##or	I
##phine	I
g	I
##lu	I
##cu	I
##ron	I
##ide	I
(	O
N	O
##B	O
##UP	O
-	O
G	O
##lu	O
##c	O
)	O

e	O
.	O
g	O
.	O
7	B
-	I
o	I
##x	I
##och	I
##ole	I
##ster	I
##ol	I
(	I
7	I
-	I
o	I
##x	I
##och	I
##ole	I
##st	I
-	I
5	I
-	I
en	I
-	I
3	I
##β	I
-	I
o	I
##l	I
,	I
C	I
_	I
5	I
-	I
3	I
##β	I
-	I
o	I
##l	I
-	I
7	I
-	I
one	I
)	I
.	O

SM	O
##s	O
can	O
be	O
meta	O
##bol	O
##ized	O
to	O
s	B
##phi	I
##ngo	I
##sin	I
##e	I
-	I
1	I
-	I
phosphate	I
(	O
S	O
##1	O
##P	O
)	O
which	O
has	O
been	O
shown	O
to	O
be	O
a	O
potent	O
m	O
##od	O
##ulator	O
of	O
fi	O
##bro	O
##sis	O
,	O
ex	O
##ert	O
##ing	O
pro	O
-	O
fi	O
##bro	O
##tic	O
effects	O
via	O
its	O
ability	O
to	O
increase	O
proliferation	O
and	O
migration	O
activated	S
he	O
##pa	O
##tic	O
s	O
##tel	O
##late	O
cells	O
(	O
H	O
##SC	O
)	O
.	O

Although	O
not	O
ideal	O
,	O
it	O
is	O
possible	O
to	O
draw	O
some	O
conclusions	O
related	O
to	O
the	O
h	O
##y	O
##pot	O
##heses	O
of	O
interest	O
based	O
on	O
eight	O
subjects	O
who	O
had	O
complete	O
set	O
of	O
samples	O
for	O
pre	O
‐	O
surgery	O
,	O
2	O
weeks	O
and	O
6	O
months	O
post	O
‐	O
surgery	O
,	O
with	O
the	O
following	O
cave	O
##ats	O
:	O
It	O
is	O
true	O
that	O
power	O
is	O
reduced	O
when	O
the	O
sample	O
size	O
is	O
small	O
and	O
false	O
negative	O
results	O
(	O
type	O
II	O
errors	O
)	O
may	O
be	O
observed	O
due	O
to	O
lack	O
of	O
power	O
.	O
56	O
This	O
may	O
be	O
one	O
of	O
the	O
driving	O
reasons	O
for	O
not	O
observing	O
significant	O
changes	O
for	O
meta	O
##bol	O
##ites	O
and	O
FA	S
at	O
2	O
weeks	O
post	O
‐	O
surgery	O
.	O

First	O
,	O
it	O
can	O
co	O
##valent	O
##ly	O
bind	O
with	O
CE	O
q	B
##uin	I
##one	I
to	O
form	O
an	O
inactive	O
q	B
##uin	I
##one	I
con	O
##ju	O
##gate	O
(	O
4	O
-	O
OH	O
##E	O
_	O
2	O
-	O
2	O
-	O
N	O
##A	O
##c	O
##C	O
##ys	O
)	O
.	O

In	O
this	O
case	O
,	O
p	B
##yr	I
##u	I
##vate	I
is	O
s	O
##hun	O
##ted	O
towards	O
al	B
##ani	I
##ne	I
and	O
away	O
from	O
la	B
##ct	I
##ate	I
synthesis	O
.	O

The	O
concentration	O
of	O
every	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
in	O
sperm	O
was	O
significantly	O
correlated	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
with	O
at	O
least	O
one	O
sperm	O
##io	O
##gram	O
parameter	O
.	O

Early	O
studies	O
reported	O
o	O
##xi	O
##da	O
##tive	O
damage	O
and	O
carbon	O
##yla	O
##tion	O
of	O
proteins	O
by	O
the	O
Western	O
b	O
##lot	O
##ting	O
technique	O
,	O
where	O
o	O
##xi	O
##dized	O
proteins	O
were	O
der	O
##iva	O
##tized	O
with	O
din	B
##it	I
##rophe	I
##ny	I
##l	I
##hy	I
##dra	I
##zine	I
,	O
separated	O
by	O
SD	O
##S	O
–	O
gel	O
electro	O
##ph	O
##ores	O
##is	O
,	O
and	O
screened	O
with	O
antibodies	O
against	O
the	O
din	O
##it	O
##rophe	O
##ny	O
##l	O
groups	O
.	O

Probably	O
the	O
different	O
scheme	O
in	O
nutrition	O
explains	O
the	O
missing	O
correlation	O
between	O
liver	O
function	O
and	O
plasma	O
amino	O
acids	O
and	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
.	O

The	O
changes	O
in	O
3	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
as	O
well	O
as	O
other	O
clinical	O
parameters	O
during	O
the	O
treatment	O
course	O
for	O
the	O
patient	O
denoted	O
in	O
Fi	O
##gs	O
.	O

In	O
animals	O
N	O
##D	O
##D	O
##tam	O
appears	O
to	O
decrease	O
the	O
rate	O
of	O
ta	B
##mo	I
##xi	I
##fen	I
metabolism	O
whereas	O
ta	O
##m	O
##N	O
##ox	O
may	O
represent	O
a	O
pool	O
for	O
its	O
'	O
re	O
##con	O
##version	O
back	O
to	O
ta	B
##mo	I
##xi	I
##fen	I
.	O

L	O
,	O
HD	B
##L	I
-	I
ch	I
##ole	I
##ster	I
##ol	I
of	O
1	O
.	O
78	O
mm	O
##ol	O
/	O
L	O
,	O
L	B
##D	I
##L	I
-	I
ch	I
##ole	I
##ster	I
##ol	I
of	O
3	O
.	O
45	O
mm	O
##ol	O
/	O
L	O
,	O
and	O
Tri	B
##gly	I
##cer	I
##ides	I
of	O
1	O
.	O
18	O
mm	O
##ol	O
/	O

Ali	O
##q	O
##uo	O
##ts	O
of	O
ch	B
##lor	I
##of	I
##orm	I
extract	O
##s	O
were	O
analyzed	O
directly	O
by	O
electro	O
##sp	O
##ray	O
as	O
described	O
in	O
method	O
section	O
.	O

The	O
resulting	O
300	O
-	O
μ	O
##L	O
super	O
##nat	O
##ant	O
from	O
the	O
urine	O
sample	O
was	O
mixed	O
with	O
300	O
μ	O
##L	O
of	O
0	O
.	O
2	O
M	O
sodium	B
phosphate	I
buffer	O
(	O
pH	O
7	O
.	O
0	O
)	O
and	O
1	O
m	O
##M	O
sodium	O
a	O
##zi	O
##de	O
in	O
de	O
##uter	O
##ium	O
oxide	O
(	O
D	O
_	O
2	O
O	O
)	O
.	O

The	O
is	B
##ole	I
##uc	I
##ine	I
and	O
le	B
##uc	I
##ine	I
peaks	O
have	O
similar	O
retention	O
times	O
,	O
resulting	O
in	O
some	O
overlapping	O
label	O
##ing	O
pattern	O
regarding	O
both	O
the	O
amino	O
acids	O
and	O
k	O
##eto	O
acids	O
.	O

No	O
clear	O
separation	O
in	O
P	O
##LS	O
-	O
D	O
##A	O
models	O
was	O
found	O
between	O
CD	O
and	O
UC	O
patients	O
based	O
on	O
the	O
analysis	O
of	O
serum	O
and	O
urine	O
samples	O
,	O
although	O
one	O
meta	O
##bol	O
##ite	O
(	O
format	O
##e	O
)	O
in	O
un	O
##iva	O
##ria	O
##te	O
statistical	O
analysis	O
was	O
significantly	O
lower	O
in	O
serum	O
of	O
patients	O
with	O
active	O
CD	O
,	O
and	O
two	O
meta	O
##bol	O
##ites	O
(	B
al	B
##ani	I
##ne	I
and	O
N	O
-	O
ace	O
##ty	O
##lated	O
compounds	O
)	O
were	O
significantly	O
higher	O
in	O
serum	O
of	O
patients	O
with	O
CD	O
when	O
comparing	O
jointly	O
patients	O
in	O
the	O
re	O
##mission	O
and	O
active	O
phase	O
of	O
the	O
diseases	O
.	O

Both	O
the	O
fast	O
##ing	O
est	O
##eri	O
##fied	O
and	O
non	O
-	O
est	O
##eri	O
##fied	O
E	O
##L	O
##O	O
##V	O
##L	O
-	O
6	O
in	O
##dices	O
(	O
s	O
##te	O
##ari	O
##c	O
acid	O
to	O
palm	B
##itic	I
acid	I
ratio	O
)	O
inverse	O
##ly	O
correlated	O
with	O
VC	O
##AM	O
-	O
1	O
expression	O
.	O

M	B
##T	I
##BE	I
was	O
the	O
most	O
efficient	O
solvent	O
to	O
extract	O
all	O
est	O
##rogen	O
##s	O
tested	O
;	O
further	O
##more	O
,	O
it	O
removed	O
many	O
of	O
the	O
co	O
-	O
el	O
##uti	O
##ng	O
interfering	O
peaks	O
.	O

Moreover	O
,	O
increased	O
levels	O
of	O
several	O
car	B
##ni	I
##tine	I
##s	I
in	O
BC	O
were	O
reported	O
by	O
Shen	O
et	O
al	O
.	O
,	O
including	O
he	B
##xa	I
##noy	I
##l	I
##car	I
##ni	I
##tine	I
,	O
o	B
##ct	I
##ano	I
##yl	I
##car	I
##ni	I
##tine	I
and	O
c	B
##is	I
-	I
4	I
-	I
de	I
##ce	I
##noy	I
##l	I
##car	I
##ni	I
##tine	I
.	O

Neither	O
did	O
try	B
##pt	I
##op	I
##han	I
nor	O
any	O
other	O
k	B
##yn	I
##uren	I
##ine	I
meta	O
##bol	O
##ite	O
or	O
c	O
##yt	O
##oki	O
##ne	O
co	O
##rrel	O
##ate	O
to	O
the	O
MA	O
##DR	O
##S	O
score	O
before	O
or	O
after	O
EC	O
##T	O
.	O

The	O
ions	O
monitored	O
for	O
q	O
##uant	O
##ification	O
included	O
m	O
/	O
z	O
38	O
##3	O
for	O
25	B
(	I
OH	I
)	I
D	I
##3	I
and	O
3	B
-	I
e	I
##pi	I
-	I
25	I
(	I
OH	I
)	I
D	I
##3	I
;	O
m	O
/	O
z	O
38	O
##6	O
for	O
3	B
-	I
e	I
##pi	I
-	I
25	I
(	I
OH	I
)	I
D	I
##3	I
-	I
d	I
_	O
3	O
;	O
m	O
/	O
z	O
38	O
##9	O
for	O
25	O
(	O
OH	O
)	O
D	O
##3	O
-	O
d	O
_	O
6	O
;	O
m	O
/	O
z	O
395	O
for	O
25	O
(	O
OH	O
)	O
D	O
##2	O
;	O
and	O
m	O
/	O
z	O
39	O
##8	O
for	O
25	O
(	O
OH	O
)	O
D	O
##2	O
-	O
d	O
_	O
3	O
.	O

Met	O
##ab	O
##olo	O
##mic	O
##s	O
also	O
revealed	O
an	O
influence	O
of	O
vitamin	O
B	O
-	O
12	O
on	O
primary	O
intermediate	O
##s	O
of	O
one	O
-	O
carbon	O
meta	O
##bol	O
##ites	O
and	O
the	O
K	O
##re	O
##bs	O
cycle	O
,	O
as	O
well	O
as	O
on	O
a	O
number	O
of	O
car	O
##bo	O
##hy	O
##dra	O
##tes	O
,	O
amino	O
acids	O
,	O
amid	B
##es	I
,	O
organic	O
acids	O
,	O
n	O
##uc	O
##leo	O
##tide	O
##s	O
,	O
lip	O
##ids	O
,	O
and	O
s	O
##tero	O
##ls	O
.	O

It	O
was	O
found	O
that	O
a	O
l	B
##is	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
(	O
LP	O
##C	O
)	O
plasma	O
##log	O
##en	O
containing	O
palm	B
##ito	I
##le	I
##ic	I
acid	I

Pre	O
##cu	O
##rs	O
##or	O
–	O
product	O
relationships	O
explained	O
several	O
positive	O
correlation	O
##s	O
,	O
such	O
as	O
that	O
between	O
27	B
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
and	O
7	B
##α	I
,	I
27	I
-	I
di	I
##hy	I
##dr	I
##ox	I
##ych	I
##ole	I
##ster	I
##ol	I
,	O
which	O
are	O
se	O
##quential	O
intermediate	O
##s	O
in	O
the	O
alternate	O
pathway	O
of	O
bi	O
##le	O
acid	O
synthesis	O
,	O
and	O
that	O
between	O
7	B
-	I
de	I
##hy	I
##dr	I
##och	I
##ole	I
##ster	I
##ol	I
and	O
8	B
-	I
de	I
##hy	I
##dr	I
##och	I
##ole	I
##ster	I
##ol	I
.	O

The	O
standard	O
solution	O
of	O
As	O
-	O
G	O
##S	O
##H	O
complexes	O
could	O
not	O
mixed	O
with	O
the	O
non	O
-	O
G	O
##S	O
##H	O
complex	O
##ed	O
As	O
standards	O
,	O
because	O
,	O
once	O
mixed	O
,	O
the	O
non	O
-	O
G	O
##S	O
##H	O
complex	O
##ed	O
a	O
##rsen	O
##ical	O
##s	O
(	O
free	O
As	O
_	O
III	O
,	O
MMA	O
_	O
III	O
,	O
and	O
D	O
##MA	O
_	O
III	O
)	O
would	O
be	O
complex	O
##ed	O
by	O
G	B
##S	I
##H	I
from	O
the	O
solution	O
of	O
As	O
-	O
G	O
##S	O
##H	O
complexes	O
.	O

P	O
##est	O
##icide	O
standards	O
(	B
α	B
-	I
c	I
##yper	I
##met	I
##hr	I
##in	I
,	O
α	B
-	I
end	I
##os	I
##ulf	I
##an	I
,	O
cap	O
##tan	O
,	O
ch	B
##lor	I
##py	I
##ri	I
##fo	I
##s	I
,	O
delta	O
##met	O
##hr	O
##in	O
,	O
im	O
##az	O
##ali	O
##l	O
,	O
p	O
##hos	O
##alo	O
##ne	O
and	O
to	O
##l	O
##c	O
##lo	O
##fo	O
##s	O
-	O
met	O
##hyl	O
)	O
,	O
each	O
at	O
100	O
mg	O
·	O
L	O
_	O
−	O
##1	O
in	O
met	B
##han	I
##ol	I
(	O
Me	O
##OH	O
)	O
or	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
(	O
AC	O
##N	O
)	O
,	O
were	O
purchased	O
from	O
U	O
##LT	O
##RA	O
Scientific	O
(	O
North	O
Kings	O
##town	O
,	O
R	B
##I	I
,	O
USA	O
)	O
.	O

B	O
##ile	O
acids	O
were	O
also	O
different	O
between	O
the	O
good	O
and	O
poor	O
respond	O
##ers	O
,	O
with	O
primary	O
bi	O
##le	O
acids	O
(	O
T	O
##CA	O
,	O
G	O
##CA	O
,	O
T	O
##CD	O
##CA	O
,	O
G	O
##CD	O
##CA	O
)	O
changing	O
from	O
no	O
correlation	O
with	O
ch	B
##ole	I
##ster	I
##ol	I
bio	O
##sy	O
##nt	O
##hesis	O
and	O
negative	O
correlation	O
with	O
diet	O
##ary	O
s	O
##tero	O
##l	O
meta	O
##bol	O
##ites	O
in	O
good	O
respond	O
##ers	O
to	O
a	O
slightly	O
positive	O
correlation	O
in	O
poor	O
respond	O
##ers	O
.	O

One	O
widely	O
accepted	O
pathway	O
of	O
metabolic	O
activation	O
proceeds	O
through	O
formation	O
of	O
“	O
bay	O
region	O
”	O
di	B
##ol	I
e	I
##pox	I
##ides	I
which	O
are	O
highly	O
reactive	O
with	O
DNA	O
and	O
can	O
cause	O
mutations	O
.	O

Our	O
results	O
indicate	O
that	O
CA	O
19	O
-	O
9	O
provides	O
the	O
select	O
##ivity	O
mainly	O
for	O
the	O
discrimination	O
between	O
healthy	O
controls	O
and	O
pan	O
##cre	O
##atic	O
cancer	O
patients	O
(	O
Table	O
)	O
,	O
whilst	O
as	B
##par	I
##tic	I
acid	I
predominantly	O
contributed	O
to	O
the	O
identification	O
of	O
pan	O
##cre	O
##ati	O
##tis	O
patients	O
.	O

This	O
is	O
in	O
line	O
with	O
the	O
evidence	O
suggesting	O
that	O
the	O
up	O
##re	O
##gu	O
##lation	O
of	O
ch	B
##ole	I
##ster	I
##ol	I
synthesis	O
in	O
meta	O
##static	O
cells	O
alter	O
##s	O
signaling	O
functions	O
of	O
lip	O
##id	O
r	O
##aft	O
##s	O
,	O
and	O
that	O
it	O
is	O
a	O
part	O
of	O
general	O
changes	O
in	O
lip	O
##id	O
metabolism	O
,	O
including	O
also	O
FA	S
synthesis	O
,	O
transport	O
,	O
or	O
their	O
oxidation	O
.	O

X	B
##ant	I
##hos	I
##ine	I
is	O
associated	O
with	O
pu	B
##rine	I
metabolism	O
and	O
indicates	O
altered	O
pu	B
##rine	I
metabolism	O
that	O
is	O
further	O
supported	O
by	O
the	O
observed	O
significant	O
changes	O
in	O
x	B
##ant	I
##hine	I
,	O
which	O
is	O
also	O
associated	O
with	O
pu	B
##rine	I
metabolism	O
.	O

The	O
c	O
##yt	O
##oki	O
##nes	O
,	O
vitamin	O
B	O
-	O
6	O
v	O
##ita	O
##mers	O
,	O
and	O
try	B
##pt	I
##op	I
##han	I
meta	O
##bol	O
##ites	O
had	O
non	O
-	O
normal	O
distributions	O
,	O
so	O
data	O
are	O
expressed	O
as	O
median	O
(	O
range	O
:	O
5th	O
,	O
95	O
##th	O
percent	O
##ile	O
)	O
.	O

These	O
results	O
suggest	O
a	O
link	O
between	O
the	O
molecules	O
,	O
where	O
the	O
more	O
specific	O
Met	O
##ab	O
##olo	O
##n	O
lip	O
##id	O
chain	O
length	O
can	O
hint	O
that	O
the	O
PC	O
a	O
##a	O
C	B
##28	I
:	I
1	I
association	O
is	O
possibly	O
driven	O
by	O
the	O
involvement	O
of	O
a	O
18	O
:	O
0	O
lip	O
##id	O
chain	O
.	O

Composition	O
##s	O
of	O
SF	O
##As	O
,	O
M	O
##U	O
##FA	O
##s	O
,	O
and	O
P	O
##U	O
##FA	O
##s	O
(	O
%	O
of	O
total	O
free	O
fatty	O
acids	O
)	O
in	O
plasma	O
samples	O
obtained	O
from	O
healthy	O
controls	O
and	O
A	B
##F	I
patients	O
(	O
A	O
)	O
and	O
non	O
-	O
re	O
##current	O
and	O
re	O
##current	O
A	B
##F	I
patients	O
(	O
B	O
)	O
.	O

This	O
large	O
-	O
scale	O
a	O
##gno	O
##stic	O
investigation	O
of	O
nearly	O
1	O
,	O
300	O
men	O
identified	O
63	O
meta	O
##bol	O
##ites	O
in	O
several	O
chemical	O
classes	O
associated	O
with	O
serum	O
re	B
##tino	I
##l	I
concentrations	O
after	O
string	O
##ent	O
correction	O
for	O
94	O
##7	O
re	B
##tino	I
##l	I
-	I
meta	I
##bol	I
##ite	I
comparisons	O
.	O

Pat	O
##ients	O
with	O
long	O
-	O
term	O
survival	O
showed	O
increased	O
plasma	O
relative	O
intensity	O
of	O
LP	B
##E	I
(	I
20	I
:	I
0	I
/	I
0	I
:	I
0	I
)	I
and	O
decreased	O
relative	O
intensity	O
of	O
K	B
##yn	I
##uren	I
##ine	I
,	O
Ace	B
##ty	I
##l	I
##car	I
##ni	I
##tine	I
,	O
and	O
PC	B
(	I
42	I
:	I
11	I
)	I
.	O

The	O
most	O
striking	O
differences	O
between	O
controls	O
and	O
PD	O
were	O
in	O
GM	B
##3	I
(	O
1	O
.	O
33	O
##7	O
##±	O
##0	O
.	O
04	O
##0	O
pm	O
##ol	O
/	O
μ	O
##l	O
vs	O
.	O
1	O
.	O
53	O
##1	O
##±	O
##0	O
.	O
03	O
##7	O
pm	O
##ol	O
/	O
μ	O
##l	O
for	O
controls	O
and	O
PD	O
respectively	O
;	O
p	O
-	O
value	O
=	O
5	O
.	O
96	O
##E	O
-	O
04	O
;	O
q	O
-	O
value	O
=	O
0	O
.	O
04	O
##8	O
;	O
when	O
normal	O
##ized	O
to	O
total	O
lip	O
##id	O
:	O
p	O
-	O
value	O
=	O
2	O
.	O
89	O
##0	O
##E	O
-	O
05	O
;	O
q	O
-	O
value	O
=	O
2	O
.	O
93	O
##3	O
##E	O
-	O
03	O
;	O
)	O
.	O

In	O
other	O
studies	O
,	O
vitamin	B
D	I
levels	O
were	O
shown	O
to	O
be	O
lower	O
in	O
patients	O
with	O
late	O
AM	O
##D	O
and	O
were	O
associated	O
with	O
poor	O
##er	O
visual	O
a	O
##cu	O
##ity	O
in	O
older	O
adults	O
.	O

The	O
table	O
shows	O
the	O
G	O
##lea	O
##son	O
score	O
,	O
path	O
##ological	O
stage	O
and	O
proportion	O
of	O
the	O
tumor	O
area	O
in	O
the	O
pro	O
##state	O
##ct	O
##omy	O
tissue	O
sections	O
,	O
pro	O
##state	O
specific	O
anti	O
##gen	O
(	O
PS	O
##A	O
)	O
concentration	O
in	O
the	O
serum	O
and	O
c	B
##rea	I
##tin	I
##ine	I
values	O
in	O
the	O
matched	O
urine	O
and	O
plasma	O
samples	O
derived	O
from	O
the	O
pro	O
##state	O
cancer	O
patients	O
of	O
the	O
Helsinki	O
U	O
##rol	O
##ogical	O
B	O
##io	O
##bank	O
project	O
(	O
H	O
##U	O
##B	O
.	O
1	O
-	O
3	O
)	O
.	O

However	O
,	O
the	O
C	O
##V	O
%	O
values	O
of	O
17	O
:	O
0	O
Ce	O
##r	O
and	O
17	O
:	O
0	O
P	O
##E	O
are	O
significantly	O
lower	O
when	O
the	O
met	B
##han	I
##ol	I
method	O
is	O
used	O
(	O
25	O
%	O
and	O
30	O
%	O
versus	O
47	O
%	O
and	O
49	O
%	O
)	O
.	O

AD	B
##MA	I
,	O
SD	O
##MA	O
and	O
the	O
integrated	O
q	O
##uant	O
##ification	O
of	O
a	O
##rg	O
##ini	O
##ne	O
met	O
##hyl	O
##ation	O
(	O
in	O
the	O
form	O
of	O
a	O
met	O
##hyl	O
##ation	O
index	O
)	O
provided	O
independent	O
risk	O
prediction	O
for	O
both	O
significantly	O
o	O
##bs	O
##truct	O
##ive	O
CA	O
##D	O
and	O
incident	O
MAC	O
##E	O
in	O
stable	O
patients	O
undergoing	O
cardiac	O
evaluation	O
.	O

The	O
χ	B
-	I
axis	I
represents	O
the	O
pathway	O
impact	O
,	O
and	O
the	O
y	O
-	O
axis	O
represents	O
the	O
−	O
##log	O
(	O
p	O
)	O
.	O

Given	O
previous	O
reports	O
demonstrating	O
that	O
α	B
-	I
O	I
##G	I
m	O
##od	O
##ulates	O
e	O
##pi	O
##gene	O
##tic	O
regulation	O
,	O
we	O
next	O
tested	O
our	O
hypothesis	O
that	O
the	O
global	O
DNA	O
met	B
##hyl	I
##ome	I
is	O
altered	O
in	O
response	O
to	O
α	B
-	I
O	I
##G	I
in	O
immortal	O
##ized	O
normal	O
human	O
bladder	O
e	O
##pit	O
##hel	O
##ial	O
cells	O
.	O

In	O
##test	O
##inal	O
micro	O
##bio	O
##ta	O
convert	O
the	O
ch	B
##olin	I
##e	I
m	O
##oi	O
##ety	O
of	O
diet	O
##ary	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
into	O
trim	B
##eth	I
##yla	I
##mine	I
,	O
which	O
is	O
subsequently	O
converted	O
into	O
T	B
##MA	I
##O	I
by	O
he	O
##pa	O
##tic	O
fl	O
##avi	O
##n	O
-	O
containing	O
mon	B
##oo	I
##xy	I
##gen	I
##ases	I
.	I
_	I

The	O
in	B
##do	I
##le	I
su	I
##lf	I
##ona	I
##tes	I
(	O
I	O
and	O
J	O
in	O
)	O
,	O
found	O
in	O
the	O
urine	O
of	O
only	O
the	O
HD	O
subjects	O
treated	O
with	O
SP	O
##B	O
,	O
point	O
to	O
a	O
possible	O
role	O
of	O
SP	O
##B	O
in	O
m	O
##od	O
##ulating	O
in	B
##do	I
##le	I
pathways	O
.	O

G	B
##lut	I
##amine	I
thereby	O
acts	O
as	O
an	O
an	O
##ap	O
##ler	O
##otic	O
substrate	O
and	O
supports	O
cell	O
survival	O
.	O

Average	O
recovery	O
rates	O
for	O
internal	O
standards	O
was	O
mon	B
##oh	I
##ydro	I
##xy	I
P	O
##U	O
##FA	O
(	O
15	O
-	O
H	O
##ET	O
##E	O
)	O

Likewise	O
,	O
p	B
##yr	I
##im	I
##id	I
##ine	I
n	O
##uc	O
##leo	O
##tide	O
##s	O
undergo	O
similar	O
degradation	O
reactions	O
(	O
de	O
##ph	O
##os	O
##ph	O
##ory	O
##lation	O
,	O
de	O
##ami	O
##nation	O
,	O
and	O
c	O
##lea	O
##vage	O
of	O
g	B
##ly	I
##cos	I
##id	I
##ic	I
bonds	O
)	O
to	O
l	O
##iber	O
##ate	O
p	B
##yr	I
##im	I
##id	I
##ine	I
n	O
##uc	O
##leo	O
##base	O
##s	O
including	O
c	B
##yt	I
##os	I
##ine	I
,	O
u	B
##rac	I
##il	I
,	O
and	O
thy	B
##mine	I
.	O

For	O
instance	O
,	O
in	O
this	O
study	O
we	O
did	O
not	O
replica	O
##te	O
our	O
previous	O
finding	O
of	O
lower	O
concentrations	O
of	O
v	B
##ali	I
##ne	I
and	O
le	B
##uc	I
##ine	I
in	O
late	O
-	O
onset	O
F	O
##GR	O
,	O
nor	O
we	O
could	O
demonstrate	O
differences	O
in	O
other	O
essential	O
##s	O
amino	B
##ac	I
##ids	I
in	O
S	O
##GA	O
f	O
##etus	O
##es	O
as	O
reported	O
in	O
other	O
studies	O
.	O

A	O
##b	O
##nor	O
##mal	O
##ities	O
in	O
ch	B
##olin	I
##e	I
metabolism	O
are	O
emerging	O
as	O
a	O
metabolic	O
hall	O
##mark	O
of	O
on	O
##co	O
##genesis	O
and	O
t	O
##umour	O
progression	O
.	O

Upon	O
injection	O
of	O
the	O
standard	O
,	O
the	O
mass	O
spectrum	O
was	O
dominated	O
by	O
the	O
expected	O
pro	O
##ton	O
##ated	O
β	B
-	I
pine	I
##ne	I
at	O
m	O
/	O
z	O
137	O
.	O
132	O
##6	O
(	O
C	O
_	O
10	O
H	O
_	O
17	O
)	O
,	O
along	O
with	O
some	O
o	O
##xi	O
##dized	O
species	O
(	O
C	O
_	O
10	O
H	O
_	O
15	O
O	O
and	O
C	O
_	O
10	O
H	O
_	O
17	O
O	O
_	O
2	O
;	O
E	O
##SM	O
Fi	O
##g	O
.	O
S	O
##3	O
)	O
.	O

τ	O
,	O
spin	O
echo	O
delay	O
between	O
two	O
pulses	O
;	O
τ	O
_	O
ma	O
##x	O
,	O
total	O
duration	S
of	O
the	O
spin	O
echo	O
.	O

A	O
mixed	O
-	O
mode	O
an	O
##ion	O
exchange	O
solid	O
phase	O
extraction	O
(	O
St	O
##rata	O
-	O
X	O
-	O
A	O
##W	O
,	O
60	O
mg	O
/	O
3	O
m	O
##L	O
,	O
Ph	O
##eno	O
##men	O
##ex	O
Inc	O
.	O
,	O
Tor	O
##rance	O
,	O
CA	O
,	O
USA	O
)	O
was	O
pre	O
##con	O
##dition	O
##ed	O
with	O
di	B
##ch	I
##lor	I
##ome	I
##than	I
##e	I
(	O
3	O
m	O
##L	O
)	O
and	O
met	B
##han	I
##ol	I
(	O
3	O
m	O
##L	O
)	O
se	O
##quential	O
##ly	O
.	O

The	O
increase	O
of	O
a	O
##rg	O
##inas	O
##e	O
activity	O
will	O
decrease	O
the	O
cat	O
##alytic	O
activity	O
of	O
a	B
##rg	I
##ini	I
##ne	I
for	O
NO	O
production	O
and	O
lead	O
to	O
the	O
un	O
##co	O
##up	O
##ling	O
of	O
e	O
##N	O
##OS	O
,	O
while	O
un	O
##co	O
##up	O
##led	O
e	O
##N	O
##OS	O
can	O
induce	O
the	O
transfer	O
of	O
electrons	O
from	O
N	B
##AD	I
##P	I
##H	I
to	O
oxygen	O
molecules	O
to	O
form	O
super	B
##oxide	I
an	O
##ions	O
(	O
O	O
##2	O
-	O
)	O
.	O

Ho	B
##mo	I
##cy	I
##stein	I
##e	I
,	O
g	B
##lut	I
##ami	I
##c	I
acid	I
,	O
and	O
k	B
##yn	I
##uren	I
##ine	I
also	O
had	O
similar	O
results	O
.	O

Here	O
,	O
a	O
significantly	O
decreased	O
level	O
of	O
hip	B
##pur	I
##ic	I
acid	I
was	O
observed	O
in	O
BC	O
subjects	O
compared	O
to	O
healthy	O
controls	O
,	O
suggesting	O
the	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
metabolism	O
is	O
per	O
##tur	O
##bed	O
in	O
BC	O
subjects	O
.	O

However	O
,	O
the	O
sum	O
of	O
the	O
k	O
##eto	O
and	O
h	B
##ydro	I
##xy	I
acids	I
is	O
an	O
inform	O
##ative	O
aggregate	O
bio	O
##mark	O
##er	O
for	O
the	O
q	O
##uant	O
##itation	O
of	O
the	O
total	O
efficiency	O
of	O
the	O
N	O
##N	O
##K	O
and	O
N	O
##NA	O
##L	O
α	O
-	O
h	O
##ydro	O
##xy	O
##lation	O
pathways	O
,	O
and	O
is	O
expected	O
to	O
be	O
used	O
in	O
future	O
large	O
-	O
scale	O
studies	O
.	O

The	O
SP	O
##E	O
bed	O
was	O
washed	O
with	O
0	O
.	O
6	O
m	O
##l	O
of	O
he	B
##xa	I
##ne	I
to	O
el	O
##ute	O
h	O
##ydro	O
##phobic	O
lip	O
##ids	O
.	O

Furthermore	O
,	O
2	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##ano	I
##ic	I
acid	I
(	B
α	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
;	O
A	O
##H	O
##BA	O
)	O
shows	O
the	O
lowest	O
p	O
-	O
value	O
of	O
all	O
meta	O
##bol	O
##ites	O
between	O
control	O
and	O
G	O
##DM	O
and	O
therefore	O
is	O
one	O
of	O
the	O
strongest	O
metabolic	O
alterations	O
(	O
Su	O
##pp	O
##lement	O
##ary	O
Figure	O
)	O
.	O

No	O
significant	O
differences	O
were	O
observed	O
in	O
the	O
na	O
##dir	O
W	O
##BC	O
,	O
AN	O
##C	O
and	O
plate	O
##let	O
counts	O
of	O
patients	O
with	O
compound	O
-	O
he	O
##tero	O
##zy	O
##go	O
##us	O
dip	O
##lot	O
##ype	O
##s	O
(	O
N	O
##U	O
##D	O
##T	O
##15	O
*	O
1	O
/	O
*	O
2	O
,	O
*	O
1	O
/	O
*	O
3	O
,	O
*	O
1	O
/	O
*	O
2	O
and	O
*	O
1	O
/	O
*	O
6	O
)	O
within	O
4	O
,	O
8	O
and	O
12	O
weeks	O
and	O
6	O
months	O
of	O
th	B
##io	I
##pur	I
##ine	I
initiation	O
(	O
overall	O
p	O
>	O
0	O
.	O
05	O
)	O
.	O

N	O
##AA	O
,	O
a	O
free	O
amino	O
acid	O
,	O
synthesized	O
from	O
L	O
-	O
as	O
##par	O
##ate	O
and	O
ace	B
##ty	I
##l	I
-	I
Co	I
##A	I
,	O
serves	O
as	O
a	O
source	O
of	O
ace	B
##tate	I
for	O
lip	O
##id	O
and	O
my	B
##elin	I
synthesis	O
.	O

Aside	O
from	O
those	O
listed	O
in	O
Figure	O
3	O
,	O
other	O
pathways	O
such	O
as	O
o	O
##xi	O
##da	O
##tive	O
p	O
##hos	O
##ph	O
##ory	O
##lation	O
,	O
ch	B
##olin	I
##e	I
metabolism	O
in	O
cancer	O
,	O
and	O
bi	O
##le	O
secret	O
##ion	O
pathways	O
with	O
meta	O
##bol	O
##ites	O
like	O
N	B
##AD	I
##H	I
,	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
,	O
and	O
g	B
##lut	I
##ath	I
##ione	I
were	O
observed	O
to	O
be	O
affected	O
in	O
NHL	O
patients	O
.	O

Furthermore	O
,	O
peripheral	O
administration	O
of	O
K	O
##Y	O
##N	O
has	O
been	O
shown	O
to	O
induce	O
behavioral	O
analog	O
##s	O
of	O
depression	O
in	O
rode	O
##nts	O
,	O
and	O
)	O
reported	O
that	O
mice	O
subjected	O
to	O
chronic	O
mild	O
stress	O
showed	O
a	O
peripheral	O
increase	O
in	O
k	B
##yn	I
##uren	I
##ine	I
pathway	O
activity	O
that	O
was	O
inverse	O
##ly	O
correlated	O
with	O
K	O
##A	O
concentration	O
in	O
the	O
am	O
##y	O
##g	O
##dal	O
##a	O
.	O

ant	B
##ho	I
##cy	I
##ani	I
##ns	I
,	O
enter	O
##ic	O
recycling	O
,	O
oral	O
ch	O
##em	O
##op	O
##re	O
##vention	O
,	O
bio	O
##act	O
##ivation	O
,	O
sustainability	O

For	O
OH	O
##C	O
_	O
CS	O
##F	O
,	O
ch	B
##ole	I
##ster	I
##ol	I
removed	O
CS	O
##F	O
was	O
converted	O
to	O
p	B
##ico	I
##lini	I
##c	I
acid	I
derivatives	O
and	O
was	O
evaluated	O
as	O
blank	O
for	O
ca	O
##li	O
##bra	O
##tion	O
.	O

An	O
alternative	O
explanation	O
for	O
the	O
al	O
##de	O
##hy	O
##de	O
levels	O
variation	O
can	O
be	O
related	O
to	O
alterations	O
in	O
al	O
##de	O
##hy	O
##de	O
de	O
##hy	O
##dr	O
##ogen	O
##ases	O
(	O
AL	O
##D	O
##H	O
##s	O
)	O
activity	O
,	O
responsible	O
for	O
the	O
al	O
##de	O
##hy	O
##des	O
oxidation	O
to	O
car	B
##box	I
##yl	I
##ic	I
acids	I
.	O

The	O
silver	B
ion	I
is	O
a	O
soft	O
Lewis	O
acid	O
,	O
and	O
carbon	O
–	O
carbon	O
double	O
bonds	O
in	O
un	O
##sat	O
##ura	O
##ted	O
compounds	O
are	O
soft	O
Lewis	O
bases	O
and	O
serve	O
as	O
likely	O
sites	O
for	O
π	O
complex	O
formation	O
which	O
is	O
charged	O
complex	O
.	O

According	O
to	O
rules	O
of	O
priority	O
of	O
numbering	O
the	O
correct	O
description	O
of	O
27	B
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
is	O
25	B
(	B
R	I
)	I
,	I
26	I
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
.	O

In	O
the	O
present	O
study	O
,	O
we	O
examined	O
the	O
effect	O
of	O
p	B
##io	I
##gli	I
##ta	I
##zone	I
,	O
a	O
PP	O
##AR	O
-	O
γ	O
ago	O
##nist	O
,	O
on	O
skeletal	O
muscle	O
lip	O
##id	O
metabolism	O
and	O
insulin	O
sensitivity	O
in	O
type	O
2	O
di	O
##abe	O
##tic	O
patients	O
.	O

I	O
##BS	O
subjects	O
had	O
a	O
significantly	O
higher	O
diversity	O
of	O
total	O
bacteria	O
,	O
as	O
measured	O
by	O
the	O
Shannon	O
index	O
(	O
H	O
′	O
)	O
(	O
3	O
.	O
36	O
<	O
H	O
′	O
<	O
4	O
.	O
37	O
,	O
P	O
=	O
0	O
.	O
00	O
##4	O
)	O
,	O
Ba	O
##cter	O
##oid	O
##ete	O
##s	O
and	O
la	B
##ct	I
##ob	I
##ac	I
##ill	I
##i	I
;	O
however	O
,	O
less	O
diversity	O
was	O
observed	O
for	O
B	O
##if	O
##ido	O
##ba	O
##cter	O
(	O
1	O
.	O
7	O
<	O
H	O
′	O
<	O
3	O
.	O
08	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
and	O
C	O
##los	O
##tri	O
##dium	O
co	O
##cco	O
##ides	O
(	O
0	O
.	O
9	O
<	O
H	O
′	O
<	O
2	O
.	O
98	O
,	O
P	O
=	O
0	O
.	O
00	O
##7	O
)	O
.	O

Co	O
##mpo	O
##nent	O
4	O
was	O
mainly	O
contributed	O
by	O
pu	B
##rine	I
##s	I
,	O
suggesting	O
an	O
inverse	O
association	O
between	O
kidney	O
function	O
and	O
circulating	O
levels	O
of	O
pu	B
##rine	I
##s	I
.	O

The	O
2	B
-	I
i	I
##od	I
##ox	I
##y	I
##ben	I
##zoic	I
acid	I
(	O
I	O
##B	O
##X	O
)	O
,	O
was	O
synthesized	O
from	O
I	O
##BA	O
and	O
o	B
##xon	I
##e	I
.	O

D	B
-	I
er	I
##yt	I
##hr	I
##o	I
-	I
S	I
##phi	I
##ngo	I
##sin	I
##e	I
C	O
-	O
17	O
was	O
used	O
as	O
the	O
internal	O
standard	O
for	O
s	B
##phi	I
##ngo	I
##sin	I
##e	I
and	O
S	O
##1	O
##P	O
(	O
C	O
##ayman	O
Chemical	O
.	O

Cell	O
##s	O
were	O
disrupted	O
with	O
IP	S
l	O
##ys	O
##is	O
buffer	O
containing	O
pro	O
##te	O
##ase	O
inhibitor	O
cocktail	O
##s	O
(	O
Roche	O
Di	O
##ag	O
##nos	O
##tics	O
,	O
Basel	O
,	O
Switzerland	O
)	O
.	O

The	O
reduced	O
level	O
of	O
AM	B
##P	I
in	O
tumor	O
tissue	O
may	O
reflect	O
the	O
ad	B
##eno	I
##sin	I
##e	I
,	O
AD	B
##P	I
and	O
/	O
or	O
ATP	S
metabolic	O
activity	O
changes	O
.	O

Ana	O
##ly	O
##tes	O
were	O
el	O
##uted	O
from	O
the	O
column	O
with	O
a	O
gradient	O
el	O
##ution	O
(	O
A	O
(	O
10	O
m	O
##M	O
am	B
##mon	I
##ium	I
format	I
##e	I
and	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
,	O
v	O
/	O
v	O
)	O
and	O
B	O
(	O
ace	O
##ton	O
##it	O
##ril	O
##e	O
with	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
,	O
v	O
/	O
v	O
)	O
)	O
.	O

try	B
##pt	I
##op	I
##han	I

In	O
contrast	O
,	O
BC	O
##AA	O
,	O
le	B
##uc	I
##ine	I
(	O
OR	O
=	O
0	O
.	O
60	O
;	O
95	O
%	O
C	O
##I	O
,	O
0	O
.	O
43	O
–	O
0	O
.	O
85	O
)	O
,	O
is	B
##ole	I
##uc	I
##ine	I
(	O
OR	O
=	O
0	O
.	O
72	O
;	O
95	O
%	O
C	O
##I	O
,	O
0	O
.	O
53	O
–	O
0	O
.	O
98	O
)	O
,	O
ch	B
##olin	I
##e	I
(	O
OR	O
=	O
0	O
.	O
45	O
;	O
95	O
%	O
C	O
##I	O
,	O
0	O
.	O
31	O
–	O
0	O
.	O
65	O
)	O
,	O
N	B
-	I
ace	I
##ty	I
##l	I
g	I
##ly	I
##co	I
##p	I
##rote	I
##ins	I
(	O
OR	O
=	O
0	O
.	O
46	O
;	O
95	O
%	O
C	O
##I	O
,	O
0	O
.	O
32	O
–	O
0	O
.	O
67	O
)	O
,	O
un	O
##sat	O
##ura	O
##ted	O
lip	O
##ids	O
(	O
OR	O
=	O
0	O
.	O
36	O
;	O
95	O
%	O
C	O
##I	O
,	O
0	O
.	O
21	O
–	O
0	O
.	O
63	O
)	O
,	O
and	O
V	O
##LD	O
##L	O
(	O
OR	O
=	O
0	O
.	O
52	O
;	O
95	O
%	O
C	O
##I	O
,	O
0	O
.	O
36	O
–	O
0	O
.	O
74	O
)	O
were	O
inverse	O
##ly	O
associated	O
with	O
HC	O
##C	O
risk	O
(	O
Table	O
)	O
.	O

PC	O
species	O
in	O
the	O
r	O
##HD	O
##L	O
in	O
##fu	O
##sat	O
##e	O
and	O
plasma	O
PC	O
species	O
after	O
4	O
h	O
in	O
##fusion	O
of	O
r	O
##HD	O
##L	O
or	O
sa	B
##line	I
place	O
##bo	O
r	O
##HD	O
##L	O
,	O
re	O
##con	O
##stituted	O
HD	O
##L	O
;	O
PC	O
,	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
;	O
N	O
##D	O
,	O
not	O
detect	O
##able	O
.	O

Car	B
##nos	I
##ine	I
and	O
β	B
-	I
al	I
##ani	I
##ne	I
are	O
strongly	O
reduced	O
resulting	O
in	O
increased	O
fatigue	O
and	O
mental	O
confusion	O
.	O

Cell	O
##s	O
from	O
the	O
human	O
lung	O
e	O
##pit	O
##hel	O
##ial	O
car	O
##cin	O
##oma	O
cell	O
line	O
A	O
##5	O
##4	O
##9	O
(	O
AT	O
##CC	O
CC	O
##L	O
-	O
185	O
)	O
were	O
maintained	O
in	O
Du	O
##l	O
##be	O
##cco	O
'	O
s	O
Eagle	O
'	O
s	O
medium	O
supplemented	O
with	O
pen	B
##ici	I
##llin	I
(	O
0	O
.	O
6	O
μ	O
##g	O
m	O
##l	O
_	O
−	O
##1	O
)	O
,	O
s	B
##tre	I
##pt	I
##omy	I
##cin	I
(	O
60	O
μ	O
##g	O
m	O
##l	O
_	O
−	O
##1	O
)	O
,	O

Among	O
ACC	O
patients	O
,	O
only	O
those	O
with	O
abnormal	O
routine	O
bio	O
##chemistry	O
had	O
increased	O
g	B
##lu	I
##co	I
##cor	I
##tic	I
##oid	I
meta	O
##bol	O
##ite	O
ex	O
##cre	O
##tion	O
(	O
P	O
<	O
0	O
.	O
00	O
##1	O
;	O
Su	O
##pp	O
##lement	O
##al	O
Table	O
3	O
)	O
.	O

Though	O
g	B
##lut	I
##ama	I
##te	I
is	O
found	O
in	O
lesser	O
concentration	O
in	O
plasma	O
,	O
it	O
govern	O
##s	O
signal	O
media	O
##tion	O
in	O
peripheral	O
organs	O
and	O
tissues	O
.	O

Dr	O
##ied	O
blood	O
controls	O
for	O
amino	O
acids	O
and	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
(	O
Level	O
1	O
and	O
Level	O
2	O
)	O
were	O
obtained	O
from	O
Ch	O
##rom	O
##sy	O
##ste	O
##ms	O
(	O
Munich	O
,	O
Germany	O
)	O
.	O

The	O
at	O
##ten	O
##uation	O
of	O
a	O
number	O
of	O
meta	O
##bol	O
##ites	O
such	O
as	O
la	B
##ct	I
##ate	I
,	O
his	B
##ti	I
##dine	I
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
and	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
has	O
thus	O
been	O
described	O
earlier	O
using	O
N	O
##MR	O
of	O
intact	O
blood	O
serum	O
/	O
plasma	O
.	O
_	O
−	O

Strong	O
positive	O
associations	O
between	O
this	O
p	O
##hen	O
##otype	O
and	O
the	O
N	O
##MR	O
bucket	O
at	O
8	O
.	O
115	O
pp	O
##m	O
(	O
edge	O
weight	O
=	O
0	O
.	O
27	O
)	O
,	O
corresponding	O
to	O
unidentified	O
small	O
p	O
##eptide	O
##s	O
,	O
alcohol	O
(	O
edge	O
weight	O
=	O
0	O
.	O
20	O
)	O
,	O
8	O
.	O
125	O
pp	O
##m	O
(	O
edge	O
weight	O
=	O
0	O
.	O
19	O
)	O
(	O
unidentified	O
small	O
p	O
##eptide	O
##s	O
)	O
,	O
as	O
well	O
as	O
anal	O
##get	O
##ic	O
ne	O
##ph	O
##rop	O
##athy	O
(	O
an	O
_	O
ne	O
##ph	O
)	O
(	O
edge	O
weight	O
=	O
0	O
.	O
17	O
)	O
,	O
and	O
strong	O
negative	O
associations	O
with	O
the	O
N	O
##MR	O
bucket	O
at	O
3	O
.	O
56	O
##5	O
pp	O
##m	O
(	O
edge	O
weight	O
=	O
−	O
##0	O
.	O
16	O
)	O
,	O
identified	O
as	O
g	B
##ly	I
##cine	I
,	O
can	O
be	O
observed	O
.	O

The	O
functional	O
role	O
of	O
changes	O
in	O
plasma	B
##ny	I
##l	I
-	I
lip	I
##ids	I
in	O
ma	O
##li	O
##gna	O
##ncy	O
and	O
meta	O
##sta	O
##sis	O
are	O
still	O
poorly	O
understood	O
.	O

Instead	O
,	O
a	O
common	O
metabolic	O
response	O
to	O
ER	O
##CP	O
was	O
identified	O
,	O
regardless	O
of	O
whether	O
the	O
patients	O
developed	O
AP	S
or	O
not	O
.	O

B	O
##rief	O
##ly	O
,	O
H	O
##NS	O
##CC	O
cells	O
(	O
U	O
##M	O
-	O
SC	O
##C	O
-	O
14	O
##A	O
)	O
were	O
try	O
##ps	O
##ini	O
##zed	O
and	O
washed	O
with	O
PBS	O
,	O
and	O
then	O
the	O
Al	B
##de	I
##f	I
##lu	I
##or	I
substrate	O
was	O
added	O
to	O
1	O
×	O
10	O
_	O
6	O
cells	O
/	O
m	O
##L	O
suspended	O
in	O
Al	B
##de	I
##f	I
##lu	I
##or	I
ass	O
##ay	O
buffer	O
and	O
in	O
##cu	O
##bate	O
##d	O
at	O
37	O
°C	O
for	O
45	O
min	O
.	O

(	O
C	O
)	O
Le	B
##uc	I
##ine	I
present	O
only	O
in	O
the	O
l	O
##yo	O
##phi	O
##li	O
##zed	O
Pan	O
##c	O
-	O
1	O
samples	O
.	O

Rapid	O
and	O
sustained	O
,	O
statistical	O
##ly	O
significant	O
(	O
p	O
≤	O
0	O
.	O
01	O
)	O
increases	O
in	O
the	O
levels	O
of	O
ex	O
##cre	O
##tion	O
of	O
the	O
g	O
##lut	O
##ath	O
##ione	O
-	O
derived	O
con	O
##ju	O
##gate	O
##s	O
of	O
ben	B
##zen	I
##e	I
(	O
61	O
%	O
)	O
,	O
a	B
##c	I
##rol	I
##ein	I
(	O
23	O
%	O
)	O
,	O
but	O
not	O
c	B
##rot	I
##onal	I
##de	I
##hy	I
##de	I
were	O
found	O
in	O
those	O
receiving	O
br	O
##occo	O
##li	O
s	O
##p	O
##rout	O
beverage	O
compared	O
with	O
place	O
##bo	O
.	O

Ava	O
##ila	O
##ble	O
information	O
suggests	O
that	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
is	O
predominantly	O
cleared	O
by	O
he	O
##pa	O
##tic	O
metabolism	O
via	O
oxidation	O
and	O
g	O
##lu	O
##cu	O
##ron	O
##ida	O
##tion	O
in	O
humans	O
to	O
p	O
##har	O
##ma	O
##cological	O
##ly	O
inactive	O
meta	O
##bol	O
##ites	O
that	O
include	O
t	B
##ria	I
##zo	I
##le	I
,	O
h	B
##ydro	I
##xy	I
##ana	I
##stro	I
##zo	I
##le	I
(	O
free	O
and	O
g	B
##lu	I
##cu	I
##ron	I
##ide	I
con	O
##ju	O
##gated	O
)	O
as	O
well	O
as	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
N	O
-	O
g	O
##lu	O
##cu	O
##ron	O
##ide	O
[	O
–	O
]	O
.	O

In	O
Huang	O
et	O
al	O
.	O
,	O
a	O
solved	O
structure	O
with	O
1	O
##a	O
-	O
a	O
and	O
the	O
B	O
.	O
ant	B
##hra	I
##cis	I
N	O
##M	O
##NA	O
##T	O
demonstrated	O
an	O
interaction	O
between	O
the	O
para	O
positioned	O
br	O
##omi	O
##ne	O
and	O
the	O
His	O
##18	O
residue	O
in	O
the	O
T	O
/	O
H	O
##X	O
##G	O
##H	O
motif	O
.	O

Alan	B
##ine	I
(	O
p	O
≤	O
0	O
.	O
01	O
##1	O
)	O
,	O
t	B
##yr	I
##os	I
##ine	I
(	O
p	O
≤	O
0	O
.	O
01	O
##4	O
)	O
and	O
format	B
##e	I
(	O
p	O
≤	O
0	O
.	O
01	O
##1	O
)	O
were	O
also	O
elevated	O
in	O
N	O
##F	O
tumors	O
but	O
none	O
showed	O
statistical	O
##ly	O
significance	O
when	O
compared	O
with	O
pro	O
##la	O
##ct	O
##ino	O
##mas	O
.	O

One	O
of	O
the	O
most	O
likely	O
reasons	O
is	O
that	O
ch	B
##olin	I
##e	I
is	O
not	O
the	O
only	O
precursor	O
of	O
T	B
##MA	I
##O	I
.	O

AD	B
##MA	I
may	O
contribute	O
to	O
vascular	O
d	O
##ys	O
##function	O
through	O
competitive	O
##ly	O
in	O
##hibit	O
##ing	O
the	O
oxidation	O
of	O
a	B
##rg	I
##ini	I
##ne	I
to	O
c	B
##it	I
##ru	I
##llin	I
##e	I
,	O
thereby	O
hind	O
##ering	O
ni	B
##tric	I
oxide	I
production	O
.	O

An	O
amount	O
of	O
40	O
µ	O
##L	O
as	O
injected	O
and	O
separated	O
using	O
the	O
following	O
mobile	O
phases	O
:	O
water	O
(	O
solvent	O
A	O
)	O
and	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
(	O
solvent	O
B	O
)	O
,	O
both	O
with	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
.	O

Among	O
these	O
meta	O
##bol	O
##ites	O
,	O
a	B
##rab	I
##ino	I
##se	I
,	O
me	B
##so	I
-	I
er	I
##yt	I
##hr	I
##ito	I
##l	I
,	O
and	O
la	O
##ct	O
##ito	O
##l	O
are	O
frequently	O
consumed	O
in	O
the	O
diet	O
.	O

Con	O
##sist	O
##ently	O
,	O
le	O
##uk	O
##oc	O
##yte	O
trans	B
-	I
end	I
##oth	I
##eli	I
##al	I
migration	O
,	O
F	O
##c	O
gamma	O
R	O
-	O
mediated	O
p	O
##ha	O
##go	O
##cy	O
##tosis	O
,	O
toll	O
-	O
like	O
receptor	O
signaling	O
,	O
and	O
the	O
complement	O
system	O
,	O
(	O
complement	O
C	O
##1	O
[	O
C	O
##1	O
##S	O
,	O
C	O
##1	O
##Q	O
##A	O
,	O
C	O
##1	O
##Q	O
##B	O
,	O
C	O
##1	O
##Q	O
##C	O
]	O
)	O
were	O
up	O
-	O
regulated	O
in	O
the	O
high	O
H	O
##OM	O
##A	O
-	O
I	O
##R	O
subjects	O
.	O

H	B
##ydro	I
##ch	I
##lor	I
##oth	I
##ia	I
##zi	I
##de	I
(	O
HC	O
##T	O
##Z	O
)	O
is	O
among	O
the	O
most	O
commonly	O
prescribed	O
anti	O
##hy	O
##pert	O
##ens	O
##ives	O
,	O
yet	O
<	O
50	O
%	O
of	O
HC	O
##T	O
##Z	O
treated	O
patients	O
achieve	O
blood	O
pressure	O
(	O
BP	O
)	O
control	O
.	O

PC	B
a	I
##a	I
C	I
##40	I
:	I
6	I
;	O
112	O
.	O

Many	O
resonance	O
##s	O
from	O
fatty	O
a	O
##cy	O
##l	O
chain	O
of	O
lip	O
##op	O
##rote	O
##ins	O
and	O
g	B
##ly	I
##co	I
##p	I
##rote	I
##ins	I
were	O
also	O
seen	O
in	O
the	O
CP	O
##MG	O
spectrum	O
.	O

The	O
mobile	O
phase	O
consisted	O
of	O
the	O
following	O
:	O
phase	O
A	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
(	O
volume	O
ratio	O
)	O
,	O
1	O
m	O
##l	O
of	O
form	B
##ic	I
acid	I
was	O
added	O
to	O
a	O
1	O
liter	O
bottle	O
of	O
HP	O
##LC	O
-	O
grade	O
water	O
;	O
phase	O
B	O
95	O
%	O
AC	O
##N	O
and	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
,	O
950	O
m	O
##l	O
AC	O
##N	O
,	O
50	O
m	O
##l	O
HP	O
##LC	O
-	O
grade	O
water	O
and	O
1	O
m	O
##l	O
form	B
##ic	I
acid	I
were	O
combined	O
.	O

It	O
seems	O
that	O
in	O
MS	O
there	O
is	O
an	O
increase	O
of	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
and	O
a	O
decrease	O
of	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
,	O
perhaps	O
reflecting	O
a	O
reduction	O
of	O
my	B
##elin	I
-	I
specific	I
lip	O
##id	O
content	O
or	O
production	O
in	O
the	O
C	O
##NS	O
associated	O
with	O
increased	O
cellular	O
##ity	O
due	O
to	O
g	O
##lial	O
scars	O
.	O

As	O
shown	O
in	O
,	O
only	O
the	O
level	O
of	O
a	B
##rg	I
##ini	I
##ne	I
rather	O
than	O
the	O
level	O
of	O
c	B
##ys	I
##tein	I
##e	I
in	O
the	O
urine	O
of	O
a	O
##MC	O
##I	O
subjects	O
was	O
significantly	O
lower	O
than	O
that	O
of	O
control	O
subjects	O
.	O

Interest	O
##ingly	O
,	O
each	O
cat	B
##ech	I
##ol	I
PS	O
derivative	O
only	O
formed	O
mon	O
##o	O
-	O
N	O
##MP	O
##S	O
derivatives	O
as	O
a	O
mixture	O
of	O
two	O
re	O
##gio	O
##is	O
##omer	O
##s	O
.	O

Path	O
##ways	O
of	O
met	B
##hi	I
##oni	I
##ne	I
metabolism	O
involve	O
two	O
mechanisms	O
for	O
sa	B
##rc	I
##os	I
##ine	I
formation	O
.	O

Indeed	O
,	O
we	O
identified	O
two	O
meta	O
##bol	O
##ites	O
in	O
plasma	O
,	O
his	B
##ti	I
##dine	I
and	O
g	B
##uan	I
##ido	I
##ace	I
##tic	I
acid	I
,	O
and	O
one	O
meta	O
##bol	O
##ite	O
,	O
h	B
##y	I
##pot	I
##au	I
##rine	I
,	O
in	O
urine	O
,	O
as	O
possible	O
bio	O
##mark	O
##ers	O
that	O
may	O
be	O
closely	O
associated	O
with	O
RA	O
disease	O
activity	O
.	O

After	O
v	O
##ortex	O
##ing	O
(	O
2	O
minutes	O
)	O
and	O
standing	O
(	O
1	O
hour	O
)	O
the	O
tubes	O
were	O
cent	O
##ri	O
##fu	O
##ged	O
at	O
10	O
,	O
000	O
rpm	O
for	O
3	O
minutes	O
and	O
60	O
μ	O
##l	O
of	O
the	O
lower	O
organic	O
phase	O
was	O
separated	O
and	O
spike	O
##d	O
with	O
a	O
standard	O
mixture	O
containing	O
three	O
labeled	O
lip	O
##ids	O
(	O
0	O
.	O
1	O
μ	O
##g	O
/	O
sample	O
;	O
LP	B
##C	I
(	I
16	I
:	I
1	I
/	I
0	I
:	I
0	I
-	I
D	I
_	I
3	I
)	I
,	O
PC	B
(	I
16	I
:	I
1	I
/	I
16	I
:	I
1	I
-	I
D	I
_	I
6	I
)	I
,	O
T	B
##G	I
(	I
16	I
:	I
0	I
/	I
16	I
:	I
0	I
/	I
16	I
:	I
0	I
-	I
_	I
13	I
C	I
##3	I
)	I
)	O
.	O

Blood	O
pressure	O
was	O
recorded	O
(	O
the	O
mean	O
of	O
3	O
readings	O
)	O
between	O
8	O
am	O
and	O
10	O
pm	O
using	O
an	O
o	O
##s	O
##ci	O
##llo	O
##metric	O
device	O
(	O
T	O
##M	O
-	O
255	O
##1	O
,	O
A	O
&	O
D	O
Instruments	O
)	O
with	O
the	O
subjects	O
in	O
the	O
su	B
##pine	I
position	O
for	O
30	O
minutes	O
.	O

Each	O
spectrum	O
(	O
9	O
.	O
0	O
-	O
0	O
.	O
5	O
pp	O
##m	O
)	O
was	O
divided	O
into	O
approximately	O
41	O
##9	O
segments	O
with	O
equal	O
bin	O
width	O
(	O
0	O
.	O
02	O
pp	O
##m	O
)	O
excluding	O
the	O
residual	O
water	O
(	O
5	O
.	O
18	O
-	O
4	O
.	O
67	O
pp	O
##m	O
)	O
and	O
u	B
##rea	I
(	O
6	O
.	O
40	O
-	O
5	O
.	O
40	O
pp	O
##m	O
)	O
regions	O
.	O

Therefore	O
,	O
we	O
tested	O
our	O
hypothesis	O
by	O
investigating	O
S	O
##NP	O
##s	O
within	O
eleven	O
genes	O
directly	O
involved	O
in	O
the	O
synthesis	O
and	O
degradation	O
of	O
a	B
##rac	I
##hi	I
##don	I
##ic	I
acid	I
and	O
have	O
been	O
previously	O
reported	O
to	O
be	O
associated	O
with	O
BP	O
regulation	O
.	O

After	O
ace	B
##tone	I
precipitation	O
,	O
the	O
volume	O
of	O
the	O
super	O
##nat	O
##ant	O
was	O
about	O
25	O
μ	O
##L	O
.	O
In	O
our	O
experiment	O
,	O
25	O
μ	O
##L	O
of	O
the	O
super	O
##nat	O
##ant	O
was	O
used	O
directly	O
for	O
dans	O
##yla	O
##tion	O
label	O
##ing	O
without	O
di	O
##lution	O
with	O
water	O
to	O
50	O
μ	O
##L	O
.	O
In	O
other	O
words	O
,	O
the	O
scale	O
of	O
the	O
label	O
##ing	O
reaction	O
was	O
ha	O
##lved	O
.	O

Try	B
##pt	I
##op	I
##han	I
metabolism	O
demonstrated	O
strong	O
relevance	O
as	O
it	O
achieved	O
the	O
highest	O
impact	O
in	O
the	O
comparison	O
between	O
SP	O
##MS	O
and	O
controls	O
and	O
the	O
second	O
highest	O
in	O
the	O
comparison	O
with	O
R	O
##R	O
##MS	O
patients	O
.	O

Li	O
##pid	O
##s	O
in	O
human	O
blood	O
plasma	O
are	O
associated	O
with	O
lip	O
##op	O
##rote	O
##in	O
membrane	O
##s	O
[	O
e	O
.	O
g	O
.	O
,	O
di	B
##acy	I
##l	I
##gly	I
##cer	I
##op	I
##hos	I
##ph	I
##och	I
##olin	I
##es	I
(	O
PC	O
##s	O
)	O
]	O
,	O
lip	O
##op	O
##rote	O
##in	O
cargo	O

Since	O
the	O
blood	O
samples	O
in	O
this	O
study	O
were	O
taken	O
after	O
an	O
overnight	O
fast	O
and	O
g	B
##lut	I
##ama	I
##te	I
concentrations	O
are	O
normal	O
##ized	O
within	O
105	O
min	O
after	O
ing	O
##est	O
##ion	O
,	O
the	O
influence	O
of	O
g	B
##lut	I
##ama	I
##te	I
intake	O
should	O
be	O
ne	O
##gli	O
##gible	O
.	O

We	O
measured	O
plasma	O
vitamin	B
D	I
meta	O
##bol	O
##ite	O
concentrations	O
for	O
all	O
non	O
-	O
pregnant	O
participants	O
with	O
available	O
frozen	O
samples	O
collected	O
at	O
or	O
near	O
the	O
end	O
of	O
the	O
DC	O
##CT	O
(	O
N	O
=	O
119	O
##3	O
)	O
.	O

We	O
chose	O
to	O
describe	O
AA	O
##P	O
use	O
among	O
insulin	O
q	O
##ua	O
##rt	O
##iles	O
in	O
the	O
s	O
##chi	O
##zophrenia	O
co	O
##hor	O
##t	O
with	O
two	O
different	O
approaches	O
:	O
(	O
1	O
)	O
comparing	O
the	O
proportion	O
of	O
patients	O
using	O
medications	O
at	O
three	O
different	O
levels	O
of	O
metabolic	O
risk	O
,	O
and	O
2	O
)	O
normal	O
##izing	O
average	O
daily	O
AA	O
##P	O
exposure	O
using	O
ch	B
##lor	I
##p	I
##roma	I
##zine	I
equivalent	O
##s	O
.	O

In	O
mouse	O
models	O
,	O
exposure	O
to	O
si	B
##lica	I
dust	O
leads	O
to	O
meta	O
##bol	O
##omi	O
##c	O
alterations	O
after	O
lung	O
inflammation	O
.	O

The	O
cells	O
were	O
grown	O
in	O
the	O
presence	O
of	O
10	O
.	O
75	O
m	O
##M	O
[	B
U	I
–	I
_	I
13	I
C	I
]	I
-	I
glucose	I
for	O
24	O
h	O
,	O
and	O
the	O
meta	O
##bol	O
##ites	O
were	O
extracted	O
as	O
described	O
in	O
the	O
“	O
Method	O
##s	O
”	O
.	O

Moreover	O
,	O
higher	O
concentrations	O
of	O
H	O
##F	O
##o	O
were	O
essential	O
for	O
the	O
separation	O
of	O
problematic	O
anal	O
##yte	O
##s	O
such	O
as	O
is	B
##ole	I
##uc	I
##ine	I
and	O
le	B
##uc	I
##ine	I
is	I
##omer	I
##s	I
that	O
could	O
not	O
be	O
resolved	O
by	O
Q	O
##q	O
##Q	O
MS	O
itself	O
(	O
see	O
right	O
panels	O
in	O
)	O
.	O

Instead	O
,	O
they	O
arise	O
from	O
different	O
types	O
of	O
carbon	B
-	I
hydrogen	I
bond	O
in	O
all	O
fatty	O
a	O
##cy	O
##l	O
chains	O
:	O
0	O
.	O
9	O
##pp	O
##m	O
–	O
CH	O
_	O
3	O
;	O
1	O
.	O
3	O
##pp	O
##m	O
–	O
(	O
CH	O
_	O
2	O
)	O
_	O
n	O
-	O
;	O
2	O
.	O
0	O
##pp	O
##m	O
–	O
CH	O
_	O
2	O
-	O
CH	O
=	O
CH	O
-	O
CH	O
_	O
2	O
-	O
.	O

Hence	O
,	O
therapy	O
-	O
related	O
changes	O
in	O
serum	O
levels	O
of	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
(	O
and	O
album	O
##in	O
)	O
were	O
not	O
associated	O
directly	O
with	O
a	O
treatment	O
-	O
related	O
drop	O
in	O
the	O
patient	O
’	O
s	O
body	O
mass	O
.	O

Among	O
them	O
,	O
try	B
##pt	I
##op	I
##han	I
metabolism	O
,	O
as	O
well	O
as	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
nitrogen	O
,	O
al	B
##ani	I
##ne	I
and	O
his	B
##ti	I
##dine	I
metabolism	O
##s	O
and	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
t	B
##yr	I
##os	I
##ine	I
and	O
try	B
##pt	I
##op	I
##han	I
bio	O
##sy	O
##nt	O
##hesis	O
pathways	O
were	O
also	O
significantly	O
altered	O
after	O
multiple	O
testing	O
correction	O
##s	O
(	O
F	O
##DR	O
p	O
-	O
value	O
<	O
0	O
.	O
05	O
)	O
when	O
G	O
##C	O
and	O
P	O
##L	O
##GC	O
metabolic	O
profiles	O
were	O
compared	O
.	O

In	O
pool	O
##ed	O
healthy	O
b	O
##ab	O
##oon	O
W	O
##B	O
,	O
41	O
compounds	O
were	O
detected	O
and	O
q	O
##uant	O
##ified	O
after	O
Me	B
##OH	I
:	O
CH	O
##C	O
##l	O
_	O
3	O
:	O
water	O
ex	O
##t	O
+	O
U	O
##F	O
(	O
n	O
=	O
10	O
)	O
,	O
and	O
39	O
compounds	O
after	O
blood	O
was	O
Me	B
##OH	I
:	O

Its	O
de	O
##car	O
##box	O
##yla	O
##ted	O
form	O
,	O
S	B
-	I
ad	I
##eno	I
##sy	I
##lm	I
##eth	I
##ion	I
##ine	I
,	O
is	O
increasingly	O
recognized	O
for	O
its	O
role	O
in	O
he	O
##pa	O
##to	O
##cy	O
##te	O
growth	O
,	O
death	O
,	O
and	O
ma	O
##li	O
##gnant	O
de	O
##gene	O
##ration	O
.	O

By	O
Mann	O
-	O
Whitney	O
U	O
test	O
,	O
the	O
candidate	O
meta	O
##bol	O
##ites	O
showed	O
s	O
##tat	O
##istic	O
significance	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O
The	O
meta	O
##bol	O
##ites	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
car	B
##ba	I
##mic	I
acid	I
and	O
2	B
,	I
3	I
-	I
o	I
##ct	I
##ane	I
##dio	I
##ne	I
were	O
excluded	O
because	O
of	O
low	O
match	O
percentage	O
with	O
standard	O
mass	O
spectrum	O
.	O

Long	O
chain	O
(	O
>	O
C	O
##10	O
)	O
and	O
un	O
##sat	O
##ura	O
##ted	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
showed	O
low	O
reliability	O
either	O
due	O
to	O
low	O
concentration	O
or	O
due	O
to	O
higher	O
within	O
-	O
person	O
var	O
##iability	O
compared	O
to	O
between	O
-	O
person	O
var	O
##iability	O
.	O

Car	B
##ni	I
##tine	I
and	O
several	O
car	B
##ni	I
##tine	I
meta	O
##bol	O
##ites	O
were	O
also	O
among	O
the	O
most	O
disc	O
##rim	O
##ina	O
##nt	O
meta	O
##bol	O
##ites	O
.	O

(	O
A	O
##gi	O
##lent	O
J	O
&	O
W	O
Scientific	O
,	O
F	O
##ols	O
##om	O
,	O
CA	O
,	O
USA	O
)	O
,	O
chemical	O
##ly	O
bonded	O
with	O
a	O
5	O
%	O
dip	O
##hen	O
##yl	O
95	O
%	O
dim	B
##eth	I
##yl	I
##pol	I
##ys	I
##ilo	I
##xa	I
##ne	I
cross	O
-	O
linked	O
stationary	O
phase	O
(	O
0	O
.	O
25	O
mm	O
film	O
thickness	O
)	O
according	O
to	O
our	O
previous	O
report	O
.	O

Models	O
were	O
further	O
adjusted	O
for	O
h	O
##y	O
##pot	O
##hy	O
##roid	O
##ism	O
and	O
h	O
##yper	O
##tens	O
##ion	O
as	O
an	O
attempt	O
to	O
account	O
for	O
possible	O
indication	O
##s	O
of	O
para	B
##ce	I
##tam	I
##ol	I
medication	O
use	O
.	O

To	O
begin	O
to	O
address	O
the	O
role	O
of	O
the	O
k	B
##yn	I
##uren	I
##ine	I
pathway	O
in	O
the	O
development	O
of	O
K	O
##S	O
,	O
we	O
studied	O
it	O
directly	O
in	O
HIV	O
-	O
infected	O
adults	O
newly	O
diagnosed	O
with	O
K	O
##S	O
in	O
sub	O
-	O
Saharan	O
Africa	O
.	O

Li	O
##quid	O
-	O
ch	O
##roma	O
##tography	O
coupled	O
with	O
tandem	O
mass	O
s	O
##pect	O
##rome	O
##try	O
was	O
used	O
for	O
determination	O
of	O
levels	O
of	O
25	B
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
,	O
27	B
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
,	O
7	B
##α	I
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
,	O
and	O
7	B
-	I
k	I
##eto	I
##cho	I
##les	I
##tero	I
##l	I
in	O
plasma	O
sample	O
pairs	O
from	O
patients	O
before	O
and	O
12	O
–	O
24	O
months	O
after	O
surgical	O
removal	O
of	O
tumors	O
(	O
n	O
=	O
24	O
)	O
.	O

Alt	O
##ered	O
ace	B
##ty	I
##l	I
##car	I
##ni	I
##tine	I
in	O
cancer	O
cells	O
is	O
a	O
sign	O
of	O
fatty	O
acids	O
beta	O
-	O
oxidation	O
in	O
mit	O
##och	O
##ond	O
##ria	O
for	O
providing	O
energy	O
.	O

When	O
administered	O
through	O
injection	O
,	O
all	B
##ant	I
##oi	I
##n	I
decreased	O
blood	O
glucose	S
levels	O
and	O
increased	O
blood	O
insulin	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
in	O
normal	O
rats	O
.	O

In	O
line	O
with	O
this	O
,	O
our	O
study	O
showed	O
that	O
the	O
level	O
of	O
g	B
##lut	I
##amine	I
in	O
the	O
H	O
##T	O
##K	O
group	O
was	O
significantly	O
increased	O
.	O

N	O
##AD	O
##P	O
-	O
Na	O
_	O
2	O
,	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
(	O
L	O
##C	O
-	O
MS	O
grade	O
)	O
,	O
and	O
met	B
##han	I
##ol	I
(	O
L	O
##C	O
-	O
MS	O
grade	O
)	O
were	O
obtained	O
from	O
V	O
##WR	O
(	O
Dar	O
##ms	O
##tadt	O
,	O
Germany	O
)	O
,	O
M	O
##g	O
##C	O
##l	O
_	O
2	O
,	O
K	O
_	O
2	O
HP	O
##O	O
_	O
4	O
,	O
K	O
_	O
3	O
P	O
##O	O
_	O
4	O
,	O
super	B
##oxide	I
di	O
##sm	O
##uta	O
##se	O
,	O
is	O
##oc	O
##it	O
##rate	O
de	O
##hy	O
##dr	O
##ogen	O
##ase	O
,	O
is	B
##oc	I
##it	I
##rate	I
,	O
am	B
##mon	I
##ium	I
format	I
##e	I
,	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
,	O
and	O
form	B
##ic	I
acid	I
from	O
Sigma	O
(	O
Tau	O
##f	O
##ki	O
##rchen	O
,	O
Germany	O
)	O
.	O

The	O
amino	O
acids	O
were	O
separated	O
on	O
AB	O
Sc	O
##ie	O
##x	O
C	O
##18	O
(	O
5	O
µ	O
##m	O
,	O
4	O
.	O
6	O
mm	O
##×	O
##15	O
##0	O
mm	O
)	O
column	O
by	O
binary	O
gradient	O
of	O
water	O
(	O
mobile	O
phase	O
A	O
)	O
and	O
met	B
##han	I
##ol	I
(	O
mobile	O
phase	O
B	O
)	O
,	O
both	O
containing	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
and	O
0	O
.	O
01	O
%	O
he	B
##pta	I
##f	I
##lu	I
##oro	I
##but	I
##yric	I
acid	I
.	O

Thus	O
,	O
we	O
can	O
assume	O
that	O
the	O
elevated	O
c	B
##rea	I
##tine	I
in	O
blood	O
samples	O
from	O
the	O
E	O
##G	O
patients	O
indicate	O
an	O
increased	O
energy	O
demand	O
in	O
the	O
form	O
of	O
ATP	S
and	O
fatty	O
acids	O
,	O
both	O
during	O
the	O
disease	O
and	O
due	O
to	O
impaired	O
liver	O
function	O
caused	O
by	O
VP	O
##A	O
.	O

Furthermore	O
,	O
our	O
survival	O
analysis	O
found	O
that	O
2	O
SP	O
##s	O
(	O
SM	O
d	B
##16	I
:	I
1	I
/	I
18	I
:	I
0	I
and	O
SM	B
d	I
##18	I
:	I
1	I
/	I
18	I
:	I
0	I
)	O
were	O
significantly	O
associated	O
with	O
diabetes	O
occurrence	O
,	O
independent	O
of	O
age	O
,	O
sex	O
,	O
plasma	O
lip	O
##id	O
profile	O
,	O
and	O
B	O
##MI	O
,	O
with	O
H	O
##R	O
##s	O
of	O
about	O
1	O
.	O
4	O
,	O
suggesting	O
that	O
these	O
SP	O
##s	O
may	O
be	O
used	O
as	O
potential	O
novel	O
predict	O
##ors	O
for	O
the	O
development	O
of	O
diabetes	O
.	O

together	O
with	O
main	O
P	O
##K	O
parameters	O
;	O
the	O
data	O
were	O
obtained	O
analyzing	O
non	O
##di	O
##ges	O
##ted	O
samples	O
(	O
evaluation	O
of	O
free	O
di	O
##os	O
##met	O
##in	O
)	O
,	O
following	O
g	O
##lu	O
##cu	O
##ron	O
##idas	O
##e	O
dig	O
##est	O
##ion	O
(	B
di	B
##os	I
##met	I
##in	I
g	O
##lu	O
##cu	O
##ron	O
##ides	O
levels	O
)	O
,	O
su	O
##lf	O
##ata	O
##se	O
dig	O
##est	O
##ion	O
(	B
di	B
##os	I
##met	I
##in	I
su	I
##lf	I
##ate	I
levels	O
)	O
,	O
and	O
combined	O
su	O
##lf	O
##ata	O
##se	O
with	O
g	O
##lu	O
##cu	O
##ron	O
##idas	O
##e	O
dig	O
##est	O
##ion	O
(	O
total	O
con	O
##ju	O
##gated	O
di	O
##os	O
##met	O
##in	O
)	O
.	O

The	O
concentration	O
of	O
the	O
ch	B
##olin	I
##e	I
m	O
##oi	O
##ety	O
in	O
milk	O
decreased	O
from	O
early	O
to	O
mid	O
-	O
la	O
##ct	O
##ation	O
before	O
rising	O
again	O
in	O
late	O
la	O
##ct	O
##ation	O
;	O
however	O
,	O
throughout	O
la	O
##ct	O
##ation	O
milk	O
ch	B
##olin	I
##e	I
remained	O
below	O
the	O
levels	O
reported	O
previously	O
in	O
commercial	O
milk	O
.	O

In	O
contrast	O
,	O
the	O
decreased	O
levels	O
of	O
G	B
##S	I
##H	I
and	O
these	O
anti	O
##ox	O
##ida	O
##nt	O
enzymes	O
were	O
observed	O
in	O
plasma	O
_	O
–	O
of	O
oral	O
cancer	O
patients	O
.	O

Con	O
##ducted	O
in	O
NHS	O
II	O
,	O
this	O
nest	O
##ed	O
case	O
-	O
control	O
study	O
measured	O
total	O
(	O
g	O
##lu	O
##cu	O
##ron	O
##idated	O
+	O
su	O
##lf	O
##ated	O
+	O
un	O
##con	O
##ju	O
##gated	O
)	O
concentrations	O
of	O
the	O
15	O
E	O
##M	O
,	O
adjusted	O
for	O
c	B
##rea	I
##tin	I
##ine	I
,	O
in	O
carefully	O
timed	O
mid	O
-	O
l	O
##ute	O
##al	O
phase	O
urine	O
##s	O
from	O
pre	O
##men	O
##op	O
##aus	O
##al	O
women	O
.	O

The	O
ch	B
##lor	I
##of	I
##orm	I
based	O
-	O
extraction	O
method	O
has	O
been	O
recently	O
replaced	O
with	O
modified	O
methods	O
using	O
less	O
hazardous	O
met	B
##hyl	I
-	I
te	I
##rt	I
-	I
but	I
##yl	I
et	I
##her	I
(	O
M	O
##T	O
##BE	O
)	O
and	O
but	B
##ano	I
##l	I
–	I
met	I
##han	I
##ol	I
(	O
B	O
##UM	O
##E	O
)	O
non	O
##pol	O
##ar	O
organic	O
solvent	O
##s	O
.	O

5	B
-	I
Met	I
##hyl	I
##cy	I
##ti	I
##dine	I
,	O
o	B
##ct	I
##ano	I
##yl	I
##car	I
##ni	I
##tine	I
,	O
g	B
##ly	I
##co	I
##cho	I
##lic	I
acid	I
and	O
de	B
##cano	I
##yl	I
##car	I
##ni	I
##tine	I
were	O
purchased	O
from	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
(	O
St	O
.	O
Louis	O
,	O
M	O
##O	O
)	O
.	O

To	O
determine	O
where	O
in	O
the	O
sampling	O
protocol	O
the	O
ethanol	S
contamination	O
occurs	O
,	O
we	O
performed	O
a	O
CS	O
##F	O
sampling	O
protocol	O
simulation	O
with	O
0	O
.	O
9	O
%	O
Na	O
##C	O
##l	O
(	B
sa	B
##line	I
)	O
instead	O
of	O
CS	O
##F	O
and	O
detected	O
ethanol	S
in	O
all	O
simulation	O
samples	O
.	O

Ten	O
##tative	O
identification	O
of	O
compounds	O
showed	O
that	O
species	O
such	O
as	O
ho	B
##mos	I
##eri	I
##ne	I
,	O
his	B
##ti	I
##dine	I
,	O
u	B
##ric	I
acid	I
,	O
and	O
g	B
##ly	I
##co	I
##ph	I
##os	I
##ph	I
##och	I
##olin	I
##e	I
could	O
be	O
recovered	O
in	O
M	B
##T	I
##BE	I
a	O
##que	O
##ous	O
fraction	O
but	O
were	O
not	O
detected	O
in	O
met	B
##han	I
##ol	I
super	O
##nat	O
##ants	O
(	O
Show	O
##n	O
in	O
)	O
.	O

E	B
##SI	I
(	I
+	I
)	I
-	I
MS	I
indicates	O
electro	O
##sp	O
##ray	O
ion	O
##ization	O
mass	O
s	O
##pect	O
##rome	O
##try	O
;	O
l	B
##ys	I
##o	I
-	I
PC	I
,	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
;	O
SM	O
,	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
.	O

Over	O
40	O
meta	O
##bol	O
##ites	O
were	O
identified	O
and	O
q	O
##uant	O
##ified	O
by	O
_	O
1	O
H	O
-	O
N	O
##MR	O
from	O
each	O
data	O
set	O
(	O
lip	O
##op	O
##hil	O
##ic	O
and	O
h	B
##ydro	I
##phi	I
##lic	I
fraction	O
##s	O
)	O
of	O
each	O
plasma	O
sample	O
.	O

These	O
studies	O
indicated	O
that	O
a	B
##rg	I
##ini	I
##ne	I
might	O
have	O
positive	O
effect	O
on	O
AP	O
##S	O
patients	O
.	O

While	O
some	O
of	O
these	O
meta	O
##bol	O
##ites	O
have	O
been	O
reported	O
previously	O
,	O
recent	O
work	O
by	O
Wang	O
et	O
al	O
.	O
has	O
shown	O
the	O
discovery	O
of	O
down	O
-	O
regulation	O
of	O
G	B
##CD	I
##CA	I
and	O
its	O
fragments	O
(	O
m	O
/	O
z	O
41	O
##4	O
.	O
3	O
)	O
in	O
serum	O
of	O
patients	O
with	O
HC	O
##C	O
,	O
and	O
up	O
-	O
regulations	O
of	O
LP	B
##C	I
(	I
16	I
:	I
0	I
)	I
,	O
LP	B
##C	I
(	I
18	I
:	I
0	I
)	I
and	O
other	O
PC	O
##s	O
,	O
supporting	O
our	O
previous	O
interpretation	O
.	O

The	O
der	O
##iva	O
##ti	O
##zation	O
re	O
##age	O
##nt	O
3	O
##n	O
but	B
##ano	I
##lic	I
HC	O
##l	O
was	O
made	O
in	O
-	O
house	O
by	O
mixing	O
4	O
:	O
1	O
v	O
/	O
v	O
of	O
1	B
-	I
but	I
##ano	I
##l	I
(	O
for	O
s	O
##pect	O
##ros	O
##copy	O
)	O
from	O
Me	O
##rc	O
##k	O
(	O
Dar	O
##ms	O
##tadt	O
,	O
Germany	O
)	O
and	O
ace	B
##ty	I
##l	I
chloride	I
(	O
p	O
.	O
a	O
.	O
)	O
from	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
(	O
Stein	O
##heim	O
,	O
Germany	O
)	O
.	O

An	O
interesting	O
finding	O
revealed	O
from	O
the	O
current	O
results	O
that	O
could	O
relate	O
to	O
o	O
##xi	O
##da	O
##tive	O
stress	O
,	O
is	O
u	B
##ric	I
acid	I
.	O

Considering	O
the	O
higher	O
rates	O
of	O
glucose	S
up	O
##take	O
and	O
la	B
##ct	I
##ate	I
secret	O
##ion	O
in	O
16	O
##H	O
##BE	O
##14	O
##o	O
_	O
−	O
cells	O
,	O
we	O
pre	O
##sume	O
that	O
the	O
g	B
##ly	I
##co	I
##ly	I
##tic	I
flux	O
may	O
be	O
33	O
%	O
higher	O
in	O
16	O
##H	O
##BE	O
##14	O
##o	O
_	O
−	O
than	O
in	O
S	O
##9	O
cells	O
.	O

We	O
next	O
focused	O
on	O
g	B
##lut	I
##amine	I
,	O
the	O
differential	O
meta	O
##bol	O
##ite	O
in	O
al	B
##ani	I
##ne	I
,	O
as	B
##par	I
##tate	I
and	O
g	B
##lut	I
##ama	I
##te	I
metabolism	O
pathway	O
and	O
in	O
d	B
-	I
g	I
##lut	I
##amine	I
and	O
d	B
-	I
g	I
##lut	I
##ama	I
##te	I
metabolism	O
pathway	O
,	O
because	O
many	O
studies	O
have	O
showed	O
that	O
g	B
##lut	I
##amine	I
plays	O
an	O
important	O
role	O
in	O
signal	O
trans	O
##duction	O
and	O
proliferation	O
of	O
tumor	O
cells	O
[	O
,	O
]	O
.	O

In	O
our	O
R	O
##OC	O
analysis	O
different	O
##iating	O
between	O
a	O
##MC	O
##I	O
and	O
normal	O
control	O
,	O
the	O
area	O
under	O
the	O
curve	O
of	O
a	B
##rg	I
##ini	I
##ne	I
is	O
0	O
.	O
68	O
##2	O
,	O
the	O
best	O
cut	O
-	O
off	O
point	O
is	O
288	O
.	O
5	O
ng	O
/	O
m	O
##L	O
,	O
at	O
which	O
the	O
sum	O
of	O
sensitivity	O
and	O
specific	O
##ity	O
reaches	O
the	O
ma	O
##ximal	O
value	O
,	O
with	O
a	O
sensitivity	O
of	O
80	O
.	O
8	O
%	O
and	O
specific	O
##ity	O
of	O
42	O
.	O
3	O
%	O
for	O
a	O
##MC	O
##I	O
diagnosis	O
;	O
the	O
area	O
under	O
the	O
curve	O
of	O
GA	O
##BR	O
is	O
0	O
.	O
79	O
##7	O
,	O
the	O
best	O
cut	O
-	O
off	O
point	O
is	O
0	O
.	O
52	O
##3	O
,	O
at	O
which	O
the	O
sum	O
of	O
sensitivity	O
and	O
specific	O
##ity	O
reaches	O
the	O
ma	O
##ximal	O
value	O
,	O
with	O
a	O
sensitivity	O
of	O
84	O
.	O
6	O
%	O
and	O
specific	O
##ity	O
of	O
80	O
.	O
8	O
%	O
for	O
a	O
##MC	O
##I	O
diagnosis	O
.	O

Ace	B
##tate	I
,	O
prop	B
##ion	I
##ate	I
and	O
n	B
-	I
but	I
##yra	I
##te	I
,	O
altered	O
in	O
Group	O
3	O
and	O
related	O
to	O
the	O
meta	O
##bol	O
##ites	O
mentioned	O
above	O
,	O
are	O
the	O
most	O
important	O
short	O
chain	O
fatty	O
acids	O
(	O
SC	O
##FA	O
##s	O
)	O
produced	O
during	O
f	O
##er	O
##mentation	O
by	O
gut	O
bacteria	O
.	O

D	B
##MA	I
can	O
also	O
be	O
a	O
product	O
of	O
gut	O
bacterial	O
metabolism	O
of	O
diet	O
##ary	O
ch	B
##olin	I
##e	I
,	O
although	O
it	O
can	O
originate	O
from	O
the	O
N	O
-	O
met	O
##hyl	O
##ation	O
of	O
met	B
##hyl	I
##amine	I
##s	I
from	O
the	O
breakdown	O
of	O
c	B
##rea	I
##tine	I
.	O

Post	O
##pra	O
##ndi	O
##al	O
T	O
##GR	O
##L	O
m	O
##od	O
##ulates	O
VC	O
##AM	O
-	O
1	O
surface	O
expression	O
in	O
end	O
##oth	O
##eli	O
##al	O
cells	O
in	O
proportion	O
to	O
an	O
individual	O
’	O
s	O
post	O
##pra	O
##ndi	O
##al	O
change	O
in	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
.	O

There	O
were	O
significant	O
correlation	O
##s	O
between	O
e	O
##G	O
##F	O
##R	O
and	O
u	O
##rina	O
##ry	O
ex	O
##cre	O
##tion	O
of	O
C	O
##it	O
,	O
AD	B
##MA	I
,	O
and	O
Pro	O
(	O
ρ	O
=	O
−	O
##0	O
.	O
74	O
,	O
0	O
.	O
65	O
,	O
and	O
−	O
##0	O
.	O
68	O
,	O
respectively	O
,	O
all	O
P	O
<	O
0	O
.	O
00	O
##1	O
)	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
only	O
two	O
ass	O
##ays	O
included	O
more	O
than	O
two	O
compounds	O
:	O
Hu	O
##tter	O
et	O
al	O
.	O
performed	O
a	O
study	O
of	O
seven	O
compounds	O
and	O
de	O
J	O
##ager	O
et	O
al	O
.	O
q	O
##uant	O
##ified	O
eleven	O
u	O
##rina	O
##ry	O
meta	O
##bol	O
##ites	O
from	O
eight	O
synthetic	O
can	B
##na	I
##bino	I
##ids	I
.	O

Rat	O
##s	O
treated	O
with	O
h	B
##y	I
##po	I
##gly	I
##cin	I
,	O
an	O
inhibitor	O
of	O
fatty	O
acid	O
beta	O
-	O
oxidation	O
,	O
exhibited	O
massive	O
di	B
##car	I
##box	I
##yl	I
##ic	I
acid	O
##uria	O
,	O
including	O
c	O
##is	O
-	O
4	O
-	O
o	O
##ct	O
##ened	O
##io	O
##ic	O
acid	O
,	O
as	O
a	O
consequence	O
of	O
in	O
##hibit	O
##ed	O
fatty	O
acid	O
oxidation	O
.	O

Additional	O
p	O
##hen	O
##otypic	O
de	O
##ter	O
##mina	O
##nts	O
of	O
inter	O
##ind	O
##iv	O
##id	O
##ual	O
variation	O
in	O
other	O
s	O
##tero	O
##ls	O
and	O
vitamin	B
D	I
meta	O
##bol	O
##ites	O
were	O
identified	O
by	O
co	O
##rrel	O
##ating	O
further	O
clinical	O
measurements	O
in	O
each	O
participant	O
with	O
individual	O
serum	O
lip	O
##id	O
levels	O
.	O

The	O
following	O
internal	O
standards	O
and	O
buffer	O
solutions	O
were	O
used	O
:	O
(	O
A	O
)	O
internal	O
standard	O
:	O
d	O
_	O
6	O
-	O
25	O
(	O
OH	O
)	O
D	O
_	O
3	O
/	O
2	O
(	O
50	O
ng	O
/	O
m	O
##L	O
)	O
,	O
d	B
_	I
6	I
-	I
3	I
-	I
e	I
##pi	I
-	I
25	I
(	I
OH	I
)	I
D	I
_	I
3	I
(	O
25	O
ng	O
/	O
m	O
##L	O
)	O
,	O
d	B
_	I
6	I
-	I
1	I
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
/	O
2	O
(	O
0	O
.	O
20	O
ng	O
/	O
m	O
##L	O
)	O
and	O
d	B
_	I
6	I
-	I
24	I
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
(	O
15	O
ng	O
/	O
m	O
##L	O
)	O
in	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
;	O
(	O
B	O
)	O
extraction	O
buffer	O
(	O
0	O
.	O
2	O
M	O
sodium	B
carbon	I
##ate	I
/	I
sodium	I
hydrogen	I
carbon	I
##ate	I
1	I
:	I
1	I
(	O
v	O
/	O
v	O
)	O
in	O
water	O
/	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
95	O
:	O
5	O
v	O
/	O
v	O
)	O
;	O
(	O
C	O
)	O
washing	O
buffer	O
(	O
water	O
/	B
met	B
##han	I
##ol	I
90	O
:	O
10	O
v	O
/	O
v	O
)	O
;	O
and	O
(	O
D	O
)	O
el	O
##ution	O
buffer	O
(	O
water	O
/	O
met	B
##han	I
##ol	I
10	O
:	O
90	O
v	O
/	O
v	O
)	O
.	O

Beta	B
##ine	I
may	O
influence	O
lip	O
##op	O
##rote	O
##in	O
metabolism	O
via	O
an	O
effect	O
on	O
P	O
##LT	O
##P	O
activity	O
.	O

Stock	O
solutions	O
(	O
1	O
mg	O
/	O
m	O
##L	O
)	O
for	O
5	B
-	I
h	I
##ydro	I
##xy	I
##ind	I
##ole	I
-	I
3	I
-	I
ace	I
##tic	I
acid	O
-	O
D	O
_	O
5	O
(	B
5	B
-	I
H	I
##IA	I
##A	I
-	I
D	I
_	I
5	I
)	O
,	O
c	B
##it	I
##ru	I
##llin	I
##e	I
-	I
D	I
_	I
4	I
,	O
do	B
##pa	I
##mine	I
-	I
D	I
_	I
4	I
,	O
p	B
##ico	I
##lini	I
##c	I
acid	O
-	O
D	O
_	O
3	O
,	O
q	O
##uin	O
##olin	O
##ic	O
acid	O
-	O
D	O
_	O
3	O
,	O
3	B
-	I
h	I
##ydro	I
##xy	I
##ky	I
##nu	I
##ren	I
##ine	I
-	I
_	I
13	I
C	O
_	O
2	O
-	O
_	O
15	O
N	O
(	B
3	B
-	I
HK	I
-	I
_	I
13	I
C	O
_	O
2	O
-	O
_	O
15	O
N	O
)	O
,	O
ni	O
##cot	O
##ini	O
##c	O
acid	O
-	O
D	O
_	O
4	O
,	O
k	B
##yn	I
##uren	I
##ine	I
-	I
D	I
_	I
4	I
,	O
try	O
##pt	O
##op	O
##han	O
-	O
D	O
_	O
5	O
,	O
and	O
ni	B
##cot	I
##ina	I
##mi	I
##de	I
rib	I
##os	I
##ide	I
-	I
D	I
_	I
3	I
were	O
dissolved	O
in	O
100	O
%	O
di	O
##lue	O
##nt	O
-	O
D	O
##1	O
.	O

PC	O
##A	O
has	O
detected	O
a	O
group	O
of	O
distinct	O
out	O
##liers	O
corresponding	O
to	O
k	B
##eton	I
##e	I
bodies	O
(	O
3	O
##H	O
##B	O
,	O
Ace	O
,	O
Ace	O
##A	O
##ce	O
)	O
.	O

Our	O
paper	O
describes	O
a	O
newly	O
developed	O
and	O
valid	O
##ated	O
analysis	O
method	O
for	O
the	O
measurement	O
of	O
1	O
-	O
_	O
13	O
C	B
-	I
g	I
##ly	I
##ox	I
##yla	I
##te	I
,	O
1	O
-	O
_	O
13	O
C	B
-	I
g	I
##ly	I
##cola	I
##te	I
,	O
1	O
-	O
_	O
13	O
C	B
-	I
o	I
##xa	I
##late	I
,	O
and	O
_	O
13	O
C	B
_	I
2	I
-	I
o	I
##xa	I
##late	I
is	O
##oto	O
##pic	O
en	O
##rich	O
##ment	O
.	O

Many	O
of	O
the	O
meta	O
##bol	O
##ites	O
that	O
contributed	O
to	O
significant	O
differences	O
in	O
the	O
N	O
##MR	O
model	O
were	O
amino	O
acids	O
and	O
the	O
cluster	O
of	O
signals	O
from	O
glucose	S
.	O

This	O
open	O
‐	O
label	O
,	O
parallel	O
‐	O
group	O
study	O
was	O
performed	O
to	O
compare	O
finger	O
‐	O
stick	O
‐	O
based	O
cap	O
##illa	O
##ry	O
with	O
corresponding	O
ve	O
##nous	O
plasma	O
concentrations	O
for	O
r	B
##is	I
##per	I
##ido	I
##ne	I
,	O
p	B
##ali	I
##per	I
##ido	I
##ne	I
,	O
que	B
##tia	I
##pine	I
,	O
o	B
##lan	I
##za	I
##pine	I
,	O
and	O
a	B
##rip	I
##ip	I
##raz	I
##ole	I
and	O
their	O
major	O
meta	O
##bol	O
##ites	O
after	O
repeated	O
dos	O
##ing	O
in	O
patients	O
with	O
s	O
##chi	O
##zophrenia	O
or	O
related	O
illness	O
##es	O
.	O

Ser	O
##um	O
c	B
##ys	I
##tat	I
##in	I
C	O
concentrations	O
were	O
measured	O
using	O
a	O
ne	O
##phe	O
##lo	O
##metric	O
ass	O
##ay	O
(	O
Di	O
##men	O
##sion	O
VI	O
##ST	O
##A	O
,	O
Siemens	O
Healthcare	O
Di	O
##ag	O
##nos	O
##tics	O
)	O
with	O
a	O
functional	O
sensitivity	O
of	O
0	O
.	O
05	O
mg	O
/	O
L	O
.	O
Cy	B
##sta	I
##tin	I
C	O
-	O
based	O
estimated	O
g	O
##lo	O
##mer	O
##ular	O
fi	O
##ltration	O
rate	O
(	O
e	O
##G	O
##F	O
##R	O
)	O
was	O
calculated	O
using	O
the	O
C	O
##K	O
##D	O
-	O
EP	O
##I	O
c	B
##ys	I
##tat	I
##in	I
C	O
equation	O
:	O

Our	O
team	O
previously	O
reported	O
that	O
L	B
-	I
try	I
##pt	I
##op	I
##han	I
metabolism	O
,	O
including	O
L	B
-	I
try	I
##pt	I
##op	I
##han	I
,	O
3	B
-	I
in	I
##do	I
##le	I
##p	I
##rop	I
##ion	I
##ic	I
acid	I
,	O
k	B
##yn	I
##uren	I
##ine	I
,	O
and	O
5	B
-	I
h	I
##ydro	I
##xy	I
##ind	I
##ole	I
##ace	I
##tal	I
##de	I
##hy	I
##de	I
,	O
was	O
disturbed	O
in	O
E	O
##OC	O
patients	O
.	O

In	O
particular	O
,	O
the	O
metabolism	O
of	O
C	B
##15	I
:	I
0	I
long	O
-	O
chain	O
fatty	O
acids	O
may	O
originate	O
pen	B
##tad	I
##eca	I
##n	I
-	I
2	I
-	I
one	I
in	O
PC	O
##a	O
cell	O
lines	O
.	O

In	O
a	O
comparison	O
of	O
self	O
-	O
reported	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
and	O
i	B
##bu	I
##p	I
##ro	I
##fen	I
use	O
with	O
_	O
1	O
H	O
N	O
##MR	O
-	O
detected	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
and	O
i	B
##bu	I
##p	I
##ro	I
##fen	I
meta	O
##bol	O
##ites	O
among	O
49	O
##6	O
participants	O
from	O
Chicago	O
,	O
Illinois	O
,	O
and	O
Belfast	O
,	O
Northern	O
Ireland	O
,	O
the	O
overall	O
rate	O
of	O
con	O
##cor	O
##dance	O
was	O
81	O
%	O
–	O
84	O
%	O
;	O
the	O
rate	O
of	O
under	O
##re	O
##port	O
##ing	O
was	O
15	O
%	O
–	O
17	O
%	O
;	O
and	O
the	O
rate	O
of	O
under	O
##det	O
##ec	O
##tion	O
was	O
approximately	O
1	O
%	O
.	O

St	O
##ero	O
##ids	O
,	O
cat	B
##ech	I
##ola	I
##mine	I
##s	I
and	O
their	O
meta	O
##bol	O
##ites	O
were	O
measured	O
by	O
online	O
SP	O
##E	O
-	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
.	O

The	O
relative	O
_	O
13	O
C	O
abundance	O
(	O
a	O
measure	O
of	O
selective	O
en	O
##rich	O
##ment	O
)	O
of	O
these	O
two	O
carbon	O
##s	O
was	O
calculated	O
by	O
normal	O
##izing	O
the	O
H	O
##S	O
##Q	O
##C	O
peak	O
volume	O
to	O
the	O
total	O
su	B
##cci	I
##nate	I
concentration	O
.	O

AA	O
=	O
amino	O
acids	O
;	O
AC	O
=	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
;	O
BA	O
=	O
bi	O
##le	O
acids	O
;	O
Ce	B
##r	I
=	O
c	B
##era	I
##mi	I
##des	I
;	O
Cho	O
##E	O
=	O
ch	B
##ole	I
##ster	I
##yl	I
est	I
##ers	I
;	O
C	O
##M	O
##H	O
=	O
mon	B
##oh	I
##ex	I
##osy	I
##l	I
##cer	I
##ami	I
##des	I
;	O
D	O
##G	O
=	O
dig	B
##ly	I
##cer	I
##ols	I
;	O
LP	O
##C	O
=	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
;	O
LP	O
##E	O
=	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##let	I
##han	I
##ola	I
##mine	I
##s	I
;	O
LP	O
##I	O
=	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##lino	I
##si	I
##to	I
##ls	I
;	O
M	O
##U	O
##FA	O
=	O
mon	O
##ou	O
##ns	O
##at	O
##ura	O
##ted	O
fatty	O
acids	O
;	O
PC	O
=	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
;	O
P	O
##E	O
=	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##let	I
##han	I
##ola	I
##mine	I
##s	I
;	O
P	O
##I	O
=	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##lino	I
##si	I
##to	I
##ls	I
;	O
P	O
##U	O
##FA	O
=	O
p	O
##oly	O
##uns	O
##at	O
##ura	O
##ted	O
fatty	O
acids	O
;	O
SF	O
##A	O
=	O
saturated	O
fatty	O
acids	O
;	O
SM	O
=	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
##s	I
;	O
ST	O
=	O
s	O
##tero	O
##ids	O
;	O
T	B
##G	I
=	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
.	O

In	O
subjects	O
who	O
were	O
diagnosed	O
in	O
the	O
first	O
0	O
‐	O
6	O
years	O
,	O
as	B
##par	I
##agi	I
##ne	I
,	O
u	B
##ric	I
acid	I
,	O
and	O
t	B
##yr	I
##os	I
##ine	I
showed	O
a	O
similar	O
tendency	O
(	O
Table	O
)	O
,	O
and	O
these	O
results	O
support	O
our	O
previous	O
report	O
.	O
_	O
13	O
,	O
_	O
14	O
l	O
l	O
The	O
present	O
study	O
has	O
several	O
limitations	O
.	O

Internal	O
standard	O
(	O
IS	O
##T	O
##D	O
)	O
compounds	O
:	O
c	B
##rea	I
##tin	I
##ine	I
-	I
d	I
_	I
3	I
(	I
h	I
##ydro	I
##phi	I
##lic	I
)	I
was	O
purchased	O
from	O
CD	O
##N	O
Is	O
##oto	O
##pes	O
(	O
Point	O
##e	O
-	O
Claire	O
,	O
Canada	O
)	O
;	O
l	B
##ys	I
##ine	I
-	I
d	I
_	I
4	I
(	I
h	I
##ydro	I
##phi	I
##lic	I
)	I
and	O
test	O
##osterone	O
-	O
d	O
_	O
2	O
(	O
h	O
##ydro	O
##phobic	O
)	O
were	O
purchased	O
from	O
Cambridge	O
Is	O
##oto	O
##pe	O
Laboratories	O
(	O
And	O
##over	O
,	O
Massachusetts	O
)	O
;	O
he	B
##pta	I
##de	I
##cano	I
##ic	I
acid	I
(	O
17	O
:	O
0	O
FA	O
)	O
and	O
c	O
##is	O
-	O
10	O
-	O
non	O
##ade	O
##ce	O
##no	O
##ic	O
acid	O
(	O
19	O
:	O
1	O
FA	O
)	O
were	O
purchased	O
from	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
(	O
St	O
.	O
Louis	O
,	O
Missouri	O
)	O
.	O

S	B
##pi	I
##rome	I
##try	I
(	O
Sen	O
##sor	O
##M	O
##edic	O
##s	O
,	O
Yo	O
##rb	O
##a	O
Linda	O
,	O
CA	O
,	O
USA	O
)	O
was	O
performed	O
in	O
all	O
subjects	O
according	O
to	O
American	O
Thor	O
##ac	O
##ic	O
Society	O
/	O
European	O
Re	O
##sp	O
##ira	O
##tory	O
Society	O
guidelines	O
.	O

Interest	O
##ingly	O
,	O
and	O
with	O
the	O
exception	O
of	O
6	B
-	I
h	I
##ydro	I
##xy	I
##sp	I
##hing	I
##os	I
##ine	I
,	O
the	O
identified	O
meta	O
##bol	O
##ites	O
could	O
be	O
classified	O
into	O
two	O
major	O
groups	O
attending	O
to	O
its	O
trend	O
of	O
variation	O
with	O
severity	O
of	O
the	O
disease	O
as	O
assessed	O
with	O
the	O
C	O
##MT	O
##NS	O
##v	O
##s	O
##2	O
.	O

Specifically	O
,	O
cluster	O
two	O
contained	O
several	O
P	O
##ls	O
##E	O
##t	O
##ns	O
(	O
P	O
##t	O
##d	O
##E	O
##t	O
##ns	O
containing	O
a	O
vinyl	B
-	I
et	I
##her	I
link	O
##age	O
at	O
the	O
S	O
##N	O
##1	O
position	O
)	O
,	O
while	O
cluster	O
three	O
contained	O
multiple	O
p	O
##hos	O
##ph	O
##och	O
##olin	O
##e	O
-	O
related	O
systems	O
including	O
P	O
##t	O
##d	O
##C	O
##hos	O
,	O
l	O
##ys	O
##o	O
##PC	O
##s	O
,	O
and	O
several	O
SM	O
##s	O
.	O

This	O
lo	O
##cus	O
has	O
also	O
been	O
associated	O
with	O
beta	B
##ine	I
,	O
which	O
is	O
a	O
closely	O
related	O
meta	O
##bol	O
##ite	O
.	O

According	O
to	O
bio	O
##mark	O
##er	O
analysis	O
through	O
receiver	O
-	O
operating	O
characteristic	O
curves	O
,	O
9	B
-	I
c	I
##is	I
-	I
re	I
##tino	I
##ic	I
acid	I
(	O
9	O
##c	O
##RA	O
)	O
dominated	O
the	O
first	O
page	O
of	O
bio	O
##mark	O
##ers	O
,	O
with	O
area	O
under	O
the	O
curve	O
(	O
AU	O
##C	O
)	O
value	O
0	O
.	O
88	O
##8	O
.	O

Seven	O
meta	O
##bol	O
##ites	O
(	B
L	B
-	I
le	I
##uc	I
##ine	I
,	O
g	B
##lut	I
##arate	I
semi	O
##ald	O
##eh	O
##yd	O
##e	O
/	O
alpha	O
-	O
k	O
##eto	O
##is	O
##ova	O
##ler	O
##ic	O
acid	O
,	O
L	O
-	O
la	O
##ctic	O
acid	O
/	O
T	O
##F	O
-	O
met	O
##ho	O
##xy	O
##ace	O
##tic	O
acid	O
/	O
g	O
##ly	O
##cer	O
##ald	O
##eh	O
##yd	O
##e	O
,	O
c	B
##rea	I
##tin	I
##ine	I
,	O
3	B
-	I
met	I
##hyl	I
-	I
2	I
-	I
o	I
##x	I
##ova	I
##ler	I
##ic	I
acid	I
/	I
2	I
-	I
k	I
##eto	I
##he	I
##xa	I
##no	I
##ic	I
acid	I
,	O
a	O
met	O
##ha	O
##cho	O
##line	O
-	O
like	O
meta	O
##bol	O
##ite	O
,	O
and	O
tag	O
##ato	O
##se	O
/	O
glucose	O
/	O
f	O
##ru	O
##ct	O
##ose	O
/	O
gal	O
##act	O
##ose	O
/	O
man	O
##nose	O
/	O
so	O
##rb	O
##ose	O
/	O
all	O
##ose	O
)	O
were	O
significantly	O
decreased	O
in	O
the	O
A	B
##F	I
group	O
relative	O
to	O
the	O
levels	O
in	O
the	O
non	O
-	O
A	O
##F	O
group	O
,	O
whereas	O
the	O
17	O
remaining	O
meta	O
##bol	O
##ites	O
(	B
ch	B
##olin	I
##e	I
,	O
o	B
##xi	I
##dized	I
g	I
##lut	I
##ath	I
##ione	I
,	O
ni	B
##ac	I
##ina	I
##mi	I
##de	I
,	O
beta	B
##ine	I
,	O
L	B
-	I
v	I
##ali	I
##ne	I
,	O
D	B
-	I
g	I
##lut	I
##ami	I
##c	I
acid	I
,	O
g	B
##lu	I
##con	I
##ic	I
acid	I
,	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
,	O
c	B
##rea	I
##tine	I
,	O
c	B
##it	I
##ru	I
##llin	I
##e	I
,	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##och	I
##olin	I
##e	I
,	O
ma	B
##lic	I
acid	I
,	O
(	B
S	I
)	I
-	I
2	I
-	I
met	I
##hyl	I
##mal	I
##ate	I
/	I
(	I
R	I
)	I
-	I
2	I
-	I
met	I
##hyl	I
##mal	I
##ate	I
/	I
2	I
-	I
h	I
##ydro	I
##xy	I
##g	I
##lut	I
##arate	I
,	O
ace	O
##ty	O
##l	O
##cho	O

For	O
semi	O
-	O
q	O
##uant	O
##ification	O
,	O
we	O
calculated	O
the	O
peak	O
height	O
of	O
each	O
ion	O
and	O
normal	O
##ized	O
to	O
that	O
of	O
2	B
-	I
is	I
##op	I
##rop	I
##yl	I
##mal	I
##ic	I
acid	I
as	O
an	O
internal	O
standard	O
.	O

Higher	O
g	B
##ly	I
##cer	I
##ol	I
and	O
free	O
fatty	O
acid	O
levels	O
in	O
the	O
blood	O
have	O
been	O
implicated	O
in	O
metabolic	O
disorders	O
and	O
o	O
##besity	O
.	O

The	O
vol	O
##ati	O
##lity	O
of	O
polar	O
compounds	O
was	O
increased	O
by	O
ex	O
##changing	O
acidic	O
pro	O
##tons	O
against	O
the	O
trim	O
##eth	O
##yl	O
##si	O
##ly	O
##l	O
group	O
using	O
100	O
µ	O
##l	O
N	B
-	I
met	I
##hyl	I
-	I
N	I
-	I
trim	I
##eth	I
##yl	I
##si	I
##ly	I
##lt	I
##ri	I
##f	I
##lu	I
##oro	I
##ace	I
##tam	I
##ide	I

Because	O
of	O
the	O
method	O
used	O
to	O
generate	O
s	O
##pect	O
##ra	O
,	O
N	O
##MR	O
profiles	O
could	O
not	O
be	O
used	O
to	O
measure	O
individual	O
lip	O
##id	O
concentrations	O
,	O
nor	O
meta	O
##bol	O
##ites	O
in	O
very	O
small	O
concentrations	O
,	O
such	O
as	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
.	O

In	O
connection	O
to	O
enhanced	O
g	O
##ly	O
##co	O
##lysis	O
,	O
increased	O
circulating	O
and	O
ex	O
##cre	O
##ted	O
al	B
##ani	I
##ne	I
and	O
la	B
##ct	I
##ate	I
levels	O
in	O
RC	O
##C	O
have	O
been	O
interpreted	O
as	O
evidence	O
of	O
the	O
expected	O
War	O
##burg	O
effect	O
in	O
cancer	O
cells	O
_	O
,	O
,	O
however	O
,	O
in	O
this	O
co	O
##hor	O
##t	O
we	O
have	O
only	O
observed	O
a	O
small	O
increasing	O
tendency	O
for	O
la	B
##ct	I
##ate	I
.	O

The	O
liver	O
is	O
central	O
to	O
gal	B
##act	I
##ose	I
metabolism	O
;	O
however	O
,	O
there	O
are	O
no	O
reported	O
alterations	O
in	O
gal	B
##act	I
##ose	I
metabolism	O
in	O
tumor	O
cells	O
.	O

Not	O
##ably	O
,	O
sa	O
##liva	O
and	O
/	O
or	O
oral	O
e	O
##pit	O
##hel	O
##ia	O
also	O
contributed	O
to	O
β	O
-	O
g	O
##lu	O
##cos	O
##idas	O
##e	O
activity	O
in	O
10	O
of	O
11	O
donors	O
,	O
as	O
indicated	O
by	O
retention	O
of	O
app	O
##re	O
##cia	O
##ble	O
functional	O
activity	O
following	O
r	O
##ins	O
##ing	O
with	O
ch	B
##lor	I
##he	I
##xi	I
##dine	I
g	I
##lu	I
##cona	I
##te	I
.	O

Dec	O
##reased	O
labeled	O
p	B
##yr	I
##u	I
##vate	I
,	O
la	B
##ct	I
##ate	I
and	O
ace	B
##ty	I
##l	I
-	I
Co	I
##A	I
from	O
U	O
-	O
_	O
13	O
C	B
_	I
6	I
-	I
glucose	I
or	O
U	O
-	O
_	O
13	O
C	B
_	I
5	I
-	I
g	I
##lut	I
##amine	I
in	O
p	O
##yr	O
##u	O
##vate	O
car	O
##box	O
##yla	O
##se	O
(	O
PC	O
)	O
knock	O
##down	O
cell	O
lines	O
derived	O
from	O
the	O
MD	O
##A	O
-	O
MB	O
231	O
breast	O
cancer	O
cell	O
line	O
.	O

However	O
,	O
prop	B
##yle	I
##ne	I
g	I
##ly	I
##co	I
##l	I
is	O
meta	O
##bol	O
##ized	O
by	O
he	O
##pa	O
##tic	O
alcohol	O
de	O
##hy	O
##dr	O
##ogen	O
##ase	O
to	O
form	O
la	B
##ct	I
##ate	I
.	O

Indeed	O
,	O
animal	O
model	O
studies	O
employing	O
either	O
in	O
##fusion	O
of	O
AD	B
##MA	I
or	O
over	O
-	O
expression	O
of	O
DD	O
##A	O
##H	O
-	O
1	O
(	O
major	O
cat	O
##ab	O
##olic	O
pathway	O
for	O
AD	O
##MA	O
)	O
have	O
co	O
##rro	O
##bor	O
##ated	O
a	O
potential	O
role	O
for	O
a	O
##rg	O
##ini	O
##ne	O
met	O
##hyl	O
##ation	O
derivatives	O
and	O
their	O
cat	O
##ab	O
##olic	O
pathways	O
in	O
the	O
m	O
##od	O
##ulation	O
of	O
NO	O
bio	O
##ava	O
##ila	O
##bility	O
,	O
particularly	O
under	O
conditions	O
where	O
elevated	O
AD	B
##MA	I
are	O
present	O
-	O
.	O

Di	O
##pe	O
##pt	O
##ides	O
(	B
L	B
,	I
L	I
-	I
le	I
##uc	I
##yl	I
-	I
al	I
##ani	I
##nate	I
,	O
L	O
,	O
L	O
-	O
le	O
##uc	O
##yl	O
##val	O
##inate	O
,	O
L	O
,	O
L	O
-	O
le	O
##uc	O
##yl	O
##le	O
##uc	O
##inate	O
)	O
were	O
purchased	O
from	O
Bach	O
##em	O
(	O
Tor	O
##rance	O
,	O
CA	O
,	O
USA	O
)	O
.	O

This	O
supports	O
previous	O
work	O
demonstrating	O
that	O
ad	O
##ip	O
##ose	O
tissue	O
from	O
v	O
##is	O
##cer	O
##ally	O
o	O
##bes	O
##e	O
EA	O
##C	O
patients	O
induce	O
##s	O
expression	O
of	O
key	O
g	B
##ly	I
##co	I
##ly	I
##tic	I
genes	O
in	O
EA	O
##C	O
cells	O
and	O
a	O
study	O
in	O
breast	O
cancer	O
,	O
which	O
demonstrated	O
that	O
le	O
##pt	O
##in	O
receptor	O
-	O
mediated	O
signalling	O
was	O
required	O
to	O
support	O
a	O
##ero	O
##bic	O
g	O
##ly	O
##co	O
##lysis	O
.	O

SM	O
(	O
OH	O
)	O
C	B
##22	I
:	I
1	I
;	O
22	O
.	O

A	O
##rg	O
##MI	O
showed	O
a	O
superior	O
pro	O
##gno	O
##stic	O
utility	O
in	O
secondary	O
prevention	O
subjects	O
compared	O
to	O
primary	O
prevention	O
,	O
suggesting	O
protein	O
a	O
##rg	O
##ini	O
##ne	O
met	O
##hyl	O
##ation	O
,	O
pro	O
##te	O
##oly	O
##sis	O
and	O
downstream	O
interference	O
of	O
ni	B
##tric	I
oxide	I
production	O
are	O
bio	O
##chemical	O
pathways	O
with	O
greater	O
association	O
to	O
path	O
##op	O
##hy	O
##sio	O
##logical	O
processes	O
relevant	O
to	O
later	O
stages	O
of	O
at	O
##her	O
##os	O
##cle	O
##rot	O
##ic	O
plaque	O
progression	O
and	O
/	O
or	O
vulnerable	O
plaque	O
development	O
.	O

Ho	B
##mo	I
##cy	I
##stein	I
##e	I
was	O
also	O
increased	O
in	O
patients	O
with	O
g	O
##lio	O
##blast	O
##oma	O
.	O

Individuals	O
who	O
developed	O
type	O
2	O
diabetes	O
did	O
not	O
differ	O
in	O
age	O
and	O
parental	O
history	O
of	O
type	O
2	O
diabetes	O
distribution	O
from	O
those	O
who	O
did	O
not	O
develop	O
type	O
2	O
diabetes	O
,	O
but	O
diabetes	O
incidence	O
was	O
higher	O
in	O
men	O
and	O
in	O
individuals	O
who	O
had	O
significantly	O
higher	O
B	O
##MI	O
and	O
slightly	O
higher	O
g	B
##ly	I
##ca	I
##em	I
##ic	I
trait	O
measurements	O
(	O
fast	O
##ing	O
and	O
2	O
h	O
glucose	S
)	O
at	O
meta	O
##bol	O
##omi	O
##cs	O
sampling	O
.	O

Thus	O
,	O
we	O
found	O
higher	O
abundance	O
of	O
5	B
-	I
O	I
##x	I
##op	I
##rol	I
##inate	I
(	O
VIP	O
,	O
1	O
.	O
8	O
)	O
,	O
E	B
##ry	I
##th	I
##ronic	I
acid	I
(	O
VIP	O
,	O
1	O
.	O
7	O
)	O
,	O
N	B
-	I
Ace	I
##ty	I
##lasp	I
##art	I
##ic	I
acid	I
(	O
VIP	O
,	O
1	O
.	O
6	O
)	O
,	O
4	B
-	I
H	I
##ydro	I
##xy	I
##but	I
##uri	I
##c	I
acid	I
(	O
VIP	O
,	O
1	O
.	O
6	O
)	O
,	O
A	B
##con	I
##itic	I
acid	I
(	O
VIP	O
,	O
1	O
.	O
5	O
)	O
,	O
C	B
##it	I
##ric	I
acid	I
(	O
VIP	O
,	O
1	O
.	O
3	O
)	O
,	O
5	B
-	I
O	I
##x	I
##op	I
##rol	I
##ine	I
(	O
VIP	O
,	O
1	O
.	O
2	O
)	O
,	O
G	B
##lut	I
##ari	I
##c	I
acid	I
(	O
VIP	O
,	O
1	O
.	O
2	O
)	O
,	O
U	B
##ric	I
acid	I
(	O
VIP	O
,	O
1	O
.	O
1	O
)	O
and	O
Ace	B
##tic	I
acid	I
(	O
VIP	O
,	O
1	O
.	O
1	O
)	O
(	O
,	O
)	O
.	O

In	O
contrast	O
,	O
al	B
##ani	I
##ne	I
levels	O
are	O
reduced	O
in	O
CS	O
##F	O
samples	O
from	O
patients	O
with	O
ID	O
##H	O
-	O
mutant	O
g	O
##lio	O
##mas	O
or	O
meta	O
##static	O
lung	O
or	O
breast	O
car	O
##cin	O
##oma	O
##s	O
,	O
in	O
comparison	O
to	O
control	O
CS	O
##F	O
samples	O
.	O

The	O
combinations	O
of	O
seven	O
meta	O
##bol	O
##ites	O
including	O
Cho	B
##E	I
(	I
18	I
:	I
1	I
)	I
,	O
Cho	B
##E	I
(	I
18	I
:	I
2	I
)	I
,	O
Cho	B
##E	I
(	I
20	I
:	I
4	I
)	I
,	O
P	B
##E	I
(	I
16	I
:	I
0	I
/	I
18	I
:	I
1	I
)	I
,	O
SM	B
(	I
d	I
##18	I
:	I
1	I
/	I
23	I
:	I
0	I
)	I
,	O
SM	B
(	I
42	I
:	I
3	I
)	I
and	O
T	B
##G	I
(	I
54	I
:	I
1	I
)	I
,	O
disc	O
##rim	O
##inated	O
advanced	O
neo	O
##p	O
##lasia	O
patients	O
from	O
healthy	O
controls	O
.	O

The	O
corresponding	O
loading	O
plot	O
of	O
PC	O
##1	O
indicated	O
that	O
serum	O
of	O
ST	O
##EM	O
##I	O
patients	O
exhibited	O
higher	O
levels	O
of	O
H	O
_	O
2	O
S	O
,	O
β	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yric	I
acid	I
,	O
la	B
##ctic	I
acid	I
,	O
u	B
##rea	I
,	O
g	B
##ly	I
##cer	I
##ol	I
and	O
glucose	S
as	O
compared	O
to	O
healthy	O
controls	O
.	O

The	O
significantly	O
decreased	O
level	O
of	O
his	B
##ti	I
##dine	I
observed	O
in	O
the	O
blood	O
of	O
lung	O
cancer	O
patients	O
was	O
also	O
observed	O
by	O
P	O
##uch	O
##ades	O
-	O
Carr	O
##asco	O
et	O
al	O
.	O

We	O
q	O
##uant	O
##ified	O
185	O
plasma	O
meta	O
##bol	O
##ites	O
,	O
including	O
amino	O
acids	O
,	O
bio	O
##genic	O
am	O
##ines	O
,	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
,	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
,	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
##s	I
and	O
he	B
##x	I
##ose	I
,	O
using	O
tandem	O
mass	O
s	O
##pect	O
##rome	O
##try	O
with	O
the	O
B	O
##io	O
##crates	O
A	O
##bs	O
##ol	O
##ute	O
##ID	O
##Q	O
p	O
##18	O
##0	O
kit	O
.	O

No	O
significant	O
matrix	O
effect	O
for	O
plasma	O
samples	O
from	O
o	O
##bes	O
##e	O
patients	O
was	O
observed	O
even	O
when	O
the	O
samples	O
were	O
spike	O
##d	O
with	O
extra	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
to	O
reach	O
t	B
##rig	I
##ly	I
##cer	I
##ide	I
levels	O
of	O
more	O
than	O
300	O
mg	O
/	O
d	O
##l	O
(	O
ranged	O
35	O
##2	O
–	O
40	O
##3	O
mg	O
/	O
d	O
##l	O
)	O
.	O

The	O
association	O
of	O
B	O
##MI	O
with	O
u	O
##rina	O
##ry	O
g	B
##ly	I
##co	I
##p	I
##rote	I
##ins	I
is	O
thought	O
to	O
reflect	O
the	O
known	O
higher	O
g	O
##lo	O
##mer	O
##ular	O
fi	O
##ltration	O
rate	O
associated	O
with	O
o	O
##besity	O
and	O
may	O
also	O
provide	O
a	O
useful	O
non	O
##in	O
##vasive	O
indicator	O
of	O
the	O
g	O
##lo	O
##mer	O
##ular	O
h	O
##yper	O
##fi	O
##ltration	O
process	O
that	O
is	O
known	O
to	O
pre	O
##cede	O
diabetes	O
.	O

Because	O
St	O
##rata	O
-	O
X	O
-	O
A	O
##W	O
extract	O
##s	O
el	O
##uted	O
with	O
2	O
%	O
NH	O
_	O
4	O
OH	O
in	O
met	B
##han	I
##ol	I
provided	O
satisfying	O
recover	O
##ies	O
for	O
all	O
target	O
anal	O
##yte	O
##s	O
,	O
we	O
did	O
not	O
evaluate	O
the	O
performance	O
of	O
other	O
weak	O
an	O
##ion	O
exchange	O
so	O
##rb	O
##ents	O
.	O

K	B
##yn	I
##uren	I
##ine	I
,	O
which	O
is	O
a	O
central	O
compound	O
in	O
the	O
try	B
##pt	I
##op	I
##han	I
metabolism	O
pathway	O
,	O
is	O
used	O
in	O
the	O
production	O
of	O
ni	B
##ac	I
##in	I
.	O

T	O
##1	O
##DM	O
is	O
a	O
metabolic	O
disorder	O
,	O
and	O
in	O
recent	O
decades	O
it	O
has	O
been	O
shown	O
that	O
meta	O
##bol	O
##ites	O
other	O
than	O
glucose	S
play	O
an	O
important	O
role	O
in	O
insulin	O
deficiency	O
and	O
the	O
development	O
of	O
diabetes	O
[	O
,	O
]	O
.	O

Gang	B
##lio	I
##side	I
##s	I
make	O
a	O
wide	O
family	O
of	O
g	B
##ly	I
##cos	I
##phi	I
##ngo	I
##lip	I
##ids	I
,	O
highly	O
he	O
##tero	O
##gene	O
##ous	O
in	O
both	O
the	O
c	B
##era	I
##mi	I
##de	I
m	O
##oi	O
##ety	O
and	O
the	O
o	B
##li	I
##gos	I
##ac	I
##cha	I
##ride	I
chain	O
.	O

Specifically	O
,	O
we	O
examined	O
the	O
effect	O
of	O
heating	O
on	O
the	O
stability	O
of	O
small	O
molecules	O
by	O
observing	O
the	O
global	O
meta	O
##bol	O
##omi	O
##c	O
profile	O
(	O
using	O
HP	O
##LC	O
-	O
E	O
##SI	O
-	O
Q	O
##TO	O
##F	O
/	O
MS	O
)	O
of	O
human	O
plasma	O
meta	O
##bol	O
##ite	O
extract	O
##s	O
and	O
a	O
standard	O
mixture	O
of	O
64	O
small	O
molecules	O
including	O
amino	O
acids	O
,	O
pu	B
##rine	I
##s	I
,	O
sugar	O
##s	O
,	O
sugar	O
phosphate	B
##s	I
,	O
and	O
free	O
fatty	O
acids	O
.	O

Second	O
,	O
we	O
found	O
three	O
intro	O
##nic	O
variants	O
in	O
strong	O
L	O
##D	O
with	O
each	O
other	O
(	O
R	O
_	O
2	O
>	O
0	O
.	O
89	O
)	O
in	O
CP	O
##S	O
##1	O
that	O
independently	O
associated	O
with	O
g	B
##ly	I
##cine	I
(	O
lowest	O
P	O
-	O
value	O
=	O
2	O
.	O
55	O
##×	O
##10	O
_	O
−	O
##5	O
for	O
r	O
##s	O
##18	O
##25	O
##48	O
##51	O
##3	O
,	O
)	O
when	O
conditioned	O
on	O
the	O
leading	O
G	O
##WA	O
##S	O
S	O
##NP	O
.	O

Some	O
confusion	O
may	O
arise	O
concerning	O
the	O
no	O
##menclature	O
of	O
27	B
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
and	O
related	O
compounds	O
.	O

These	O
data	O
clearly	O
valid	O
##ate	O
the	O
di	B
##car	I
##box	I
##yl	I
##ic	I
structure	O
of	O
V	B
##LC	I
##DC	I
##A	I
28	I
:	I
4	I
;	O
however	O
,	O
the	O
h	O
##y	O
##pot	O
##hes	O
##ized	O
positions	O
of	O
the	O
double	O
bonds	O
were	O
based	O
on	O
the	O
assumption	O
that	O
previously	O
reported	O
V	O
##LC	O
##FA	O
28	O
:	O
4	O
##n	O
##6	O
could	O
be	O
the	O
direct	O
precursor	O
.	O

Blood	O
co	B
##tin	I
##ine	I
can	O
also	O
be	O
derived	O
from	O
ni	B
##cot	I
##ine	I
in	O
smoke	O
##less	O
tobacco	O
/	O
s	O
##nu	O
##ff	O
tobacco	O
.	O

Results	O
presented	O
as	O
correlation	O
coefficients	O
r	O
and	O
analyzed	O
on	O
log	O
-	O
transformed	O
data	O
using	O
Pearson	O
’	O
s	O
correlation	O
test	O
;	O
_	O
a	O
p	O
<	O
0	O
.	O
05	O
;	O
_	O
b	O
p	O
<	O
0	O
.	O
01	O
;	O
_	O
c	O
p	O
<	O
0	O
.	O
00	O
##1	O
;	O
_	O
d	O
p	O
<	O
0	O
.	O
000	O
##1	O
;	O
n	O
##s	O
,	O
non	O
-	O
significant	O
;	O
AR	O
##G	O
,	O
a	O
##rg	O
##inas	O
##e	O
;	O
DD	O
##A	O
##H	O
,	O
dim	O
##eth	O
##yla	O
##rg	O
##ini	O
##ne	O
dim	O
##eth	O
##yla	O
##min	O
##oh	O
##ydro	O
##lase	O
,	O
NO	O
##S	O
,	O
ni	B
##tric	I
oxide	I
s	O
##ynth	O
##ase	O
;	O
O	O
##DC	O
,	O
or	O
##ni	O
##thin	O
##e	O
de	O
##car	O
##box	O
##yla	O
##se	O
;	O
PR	O
##MT	O
,	O
a	O
##rg	O
##ini	O
##ne	O
N	O
-	O
met	O
##hyl	O
##tra	O
##ns	O
##fer	O
##ase	O
.	O

R	O
##ogan	O
and	O
C	O
##ava	O
##lier	O
##i	O
are	O
pioneers	O
in	O
studying	O
the	O
role	O
of	O
un	O
##bal	O
##ance	O
##d	O
metabolism	O
of	O
est	B
##rogen	I
in	O
the	O
et	O
##iology	O
of	O
ho	O
##rmon	O
##al	O
associated	O
cancer	O
##s	O
,	O
such	O
as	O
breast	O
cancer	O
,	O
o	O
##var	O
##ian	O
cancer	O
and	O
thy	O
##roid	O
cancer	O
.	O

In	O
general	O
these	O
differences	O
are	O
moderate	O
,	O
the	O
increase	O
is	O
only	O
up	O
to	O
around	O
40	O
%	O
(	O
for	O
co	B
##rt	I
##is	I
##ol	I
,	O
see	O
below	O
)	O
and	O
in	O
addition	O
there	O
is	O
a	O
considerable	O
overlap	O
between	O
the	O
sample	O
groups	O
.	O

The	O
retention	O
time	O
of	O
di	B
##car	I
##box	I
##yl	I
##ic	I
acids	I
increased	O
with	O
h	B
##ydro	I
##car	I
##bon	I
chain	O
length	O
on	O
R	B
##P	I
column	O
A	O
in	O
accordance	O
with	O
a	O
retention	O
mechanism	O
driven	O
by	O
di	O
##sper	O
##sive	O
interactions	O
.	O

The	O
gradient	O
mobile	O
phase	O
consisted	O
of	O
water	O
with	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
(	O
A	O
)	O
and	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
containing	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
(	O
B	O
)	O
.	O

The	O
top	O
2	O
disc	O
##rim	O
##inator	O
##y	O
meta	O
##bol	O
##ites	O
,	O
my	B
##oi	I
##nos	I
##ito	I
##l	I
and	O
format	B
##e	I
,	O
are	O
identified	O
by	O
their	O
high	O
VIP	O
scores	O
.	O

Figure	O
B	O
shows	O
the	O
structures	O
and	O
relative	O
abundance	O
of	O
t	B
##yra	I
##mine	I
and	O
2	B
-	I
o	I
##x	I
##og	I
##lut	I
##arate	I
.	O

N	O
##uc	O
##leo	O
##base	O
##s	O
were	O
mostly	O
_	O
13	O
C	O
_	O
4	O
,	O
indicating	O
active	O
turnover	O
of	O
n	O
##uc	O
##leo	O
##tide	O
and	O
de	B
##ox	I
##yn	I
##uc	I
##leo	I
##tide	I
pools	O
,	O
but	O
little	O
salvage	O
of	O
medium	O
(	O
_	O
13	O
C	O
_	O
0	O
)	O
n	O
##uc	O
##leo	O
##tide	O
##s	O
.	O

Two	O
300	O
μ	O
##L	O
serum	O
samples	O
were	O
mixed	O
with	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
in	O
a	O
1	O
:	O
2	O
ratio	O
(	O
v	O
/	O
v	O
)	O
,	O
v	O
##ortex	O
##ed	O
,	O
and	O
in	O
##cu	O
##bate	O
##d	O
at	O
−	O
##20	O
°C	O
for	O
20	O
min	O
.	O

Progressive	O
##ly	O
lower	O
levels	O
of	O
long	O
-	O
chain	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
(	O
l	O
##ys	O
##o	O
##PC	O
a	O
C	B
##18	I
:	I
2	I
,	O
l	O
##ys	O
##o	O
##PC	O
a	O
C	B
##20	I
:	I
3	I
,	O
l	O
##ys	O
##o	O
##PC	O
a	O
C	B
##20	I
:	I
4	I
)	O
were	O
observed	O
from	O
CH	O
##B	O
to	O
c	O
##ir	O
##r	O
##hos	O
##is	O
to	O
car	O
##cin	O
##oma	O
;	O
lower	O
levels	O
of	O
l	O
##ys	O
##o	O
##PC	O
a	O
C	B
##20	I
:	I
4	I
were	O
found	O
in	O
patients	O
with	O
higher	O
model	O
for	O
end	O
-	O
stage	O
liver	O
disease	O
in	O
the	O
same	O
disease	O
group	O
;	O
and	O
l	O
##ys	O
##o	O
##PC	O
a	O
C	B
##20	I
:	I
3	I
levels	O
were	O
lower	O
in	O
Child	O
-	O
P	O
##ugh	O
Class	O
C	O
than	O
in	O
Class	O
A	O
and	O
Class	O
B	O
in	O
H	O
##B	O
##V	O
-	O
associated	O
c	O
##ir	O
##r	O
##hos	O
##is	O
and	O
H	O
##B	O
##V	O
-	O
associated	O
HC	O
##C	O
groups	O
.	O

Sul	B
##fi	I
##de	I
,	O
ally	O
##l	O
met	O
##hyl	O
had	O
the	O
largest	O
AU	O
##C	O
value	O
which	O
was	O
0	O
.	O
55	O
##2	O
,	O
with	O
a	O
sensitivity	O
of	O
0	O
.	O
93	O
##3	O
and	O
a	O
specific	O
##ity	O
of	O
0	O
.	O
81	O
##0	O
at	O
the	O
best	O
cut	O
-	O
off	O
point	O
.	O

Among	O
them	O
,	O
three	O
positively	O
identified	O
significant	O
meta	O
##bol	O
##ites	O
,	O
ad	B
##eno	I
##sin	I
##e	I
mon	I
##op	I
##hos	I
##phate	I
,	O
u	B
##rac	I
##il	I
and	O
sperm	B
##id	I
##ine	I
,	O
along	O
with	O
the	O
other	O
five	O
unidentified	O
meta	O
##bol	O
##ites	O
,	O
could	O
be	O
used	O
to	O
provide	O
classification	O
of	O
tumors	O
vs	O
.	O
normal	O
with	O
high	O
sensitivity	O
and	O
specific	O
##ity	O
.	O

In	O
B	O
##EA	O
##N	O
##1	O
,	O
timing	O
was	O
determined	O
using	O
o	O
##vu	O
##lation	O
kits	O
and	O
confirmed	O
retrospective	O
##ly	O
by	O
serum	O
pro	B
##ges	I
##tero	I
##ne	I
levels	O
,	O
while	O
in	O
B	O
##EA	O
##N	O
##2	O
the	O
cycle	O
day	O
was	O
estimated	O
based	O
on	O
the	O
last	O
men	O
##st	O
##ru	O
##ation	O
date	O
and	O
confirmed	O
by	O
the	O
onset	O
date	O
of	O
the	O
next	O
men	O
##st	O
##ru	O
##ation	O
obtained	O
via	O
telephone	O
contact	O
with	O
participants	O
.	O

Dry	O
extract	O
##s	O
were	O
re	O
##sus	O
##pen	O
##ded	O
in	O
40	O
μ	O
##L	O
of	O
water	O
containing	O
10	O
m	O
##M	O
am	B
##mon	I
##ium	I
format	I
##e	I
and	O
0	O
.	O
5	O
%	O
form	B
##ic	I
acid	I
.	O

This	O
re	O
##ple	O
##nish	O
##ment	O
of	O
T	O
##CA	O
intermediate	O
##s	O
was	O
due	O
to	O
g	O
##lut	O
##ami	O
##no	O
##lysis	O
,	O
a	O
process	O
by	O
which	O
g	B
##lut	I
##amine	I
is	O
converted	O
into	O
g	B
##lut	I
##ama	I
##te	I
,	O
which	O
is	O
in	O
turn	O
transformed	O
into	O
α	B
-	I
k	I
##eto	I
##g	I
##lut	I
##arate	I
,	O
and	O
finally	O
into	O
as	B
##par	I
##tate	I
and	O
thence	O
to	O
o	B
##xa	I
##lo	I
##ace	I
##tate	I
(	O
Fi	O
##g	O
.	O
)	O
.	O

To	O
determine	O
if	O
reduced	O
glucose	S
affects	O
dip	O
##eptide	O
production	O
,	O
the	O
abundance	O
of	O
the	O
17	O
dip	O
##eptide	O
##s	O
measured	O
in	O
the	O
meta	O
##bol	O
##omi	O
##c	O
pro	O
##fi	O
##ling	O
were	O
determined	O
for	O
7	O
CA	O
##F	O
##s	O
/	O
N	O
##F	O
##s	O
grown	O
in	O
5	O
m	O
##M	O
glucose	S
.	O

R	B
##RL	I
##C	I
-	I
(	I
-	I
)	I
E	I
##SI	I
-	I
MS	I
data	O
were	O
similarly	O
analyzed	O
(	O
supplement	O
##al	O
Fi	O
##g	O
.	O

In	O
their	O
study	O
,	O
positively	O
charged	O
meta	O
##bol	O
##ites	O
,	O
such	O
as	O
al	O
##ani	O
##ne	O
-	O
related	O
meta	O
##bol	O
##ites	O
,	O
showed	O
disc	O
##rim	O
##ina	O
##tive	O
characteristics	O
and	O
were	O
correlated	O
with	O
several	O
diet	O
##ary	O
factors	O
such	O
as	O
energy	O
intake	O
,	O
diet	O
##ary	O
ch	B
##ole	I
##ster	I
##ol	I
and	O
alcohol	O
intake	O
.	O

This	O
closely	O
el	O
##uti	O
##ng	O
peak	O
is	O
likely	O
4	B
-	I
c	I
##ish	I
##ydro	I
##xy	I
g	I
##ly	I
##bur	I
##ide	I
,	O
as	O
the	O
el	O
##ution	O
time	O
is	O
consistent	O
with	O
that	O
observed	O
in	O
the	O
recent	O
in	O
v	O
##it	O
##ro	O
study	O
with	O
human	O
liver	O
micro	O
##some	O
##s	O
.	O

Nevertheless	O
,	O
we	O
have	O
not	O
yet	O
investigated	O
c	O
##yt	O
##oki	O
##ne	O
levels	O
in	O
relation	O
to	O
stimulate	O
##d	O
C	O
-	O
p	O
##eptide	O
levels	O
in	O
this	O
particular	O
co	O
##hor	O
##t	O
and	O
cannot	O
conclude	O
on	O
their	O
effect	O
on	O
ch	B
##ole	I
##ster	I
##yl	I
est	I
##ers	I
.	O

The	O
six	O
differential	O
meta	O
##bol	O
##ites	O
were	O
pseudo	B
##uri	I
##dine	I
,	O
ma	B
##lic	I
acid	I
,	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
,	O
3	B
,	I
4	I
-	I
di	I
##hy	I
##dr	I
##ox	I
##y	I
##but	I
##yric	I
acid	I
,	O
f	B
##ru	I
##ct	I
##ose	I
and	O
in	B
##os	I
##ito	I
##l	I
.	O

Panel	O
D	O
shows	O
prediction	O
on	O
test	O
set	O
samples	O
using	O
my	B
##rist	I
##ic	I
acid	I
(	O
solid	O
line	O
)	O
,	O
white	O
blood	O
cell	O
count	O
(	O
dotted	O
line	O
)	O
and	O
C	O
-	O
reactive	O
protein	O
(	O
dashed	O
line	O
)	O
.	O

The	O
loading	O
##s	O
of	O
PC	O
2	O
are	O
likely	O
due	O
to	O
ni	B
##cot	I
##ine	I
meta	O
##bol	O
##ites	O
,	O
as	O
there	O
is	O
roughly	O
a	O
gradient	O
along	O
the	O
PC	O
2	O
direction	O
from	O
non	O
##smo	O
##kers	O
to	O
smoke	O
##rs	O
.	O

Our	O
results	O
also	O
showed	O
higher	O
levels	O
of	O
a	B
##rg	I
##ini	I
##ne	I
and	O
c	B
##it	I
##ru	I
##llin	I
##e	I
in	O
u	O
##rem	O
##ia	O
.	O

[	O
13	O
##C	O
##4	O
,	O
99	O
%	O
]	O
,	O
d	O
‐	O
x	O
##yl	O
##ito	O
##l	O
[	O
U	O
‐	O
13	O
##C	O
##5	O
,	O
99	O
%	O
]	O
,	O
l	B
‐	I
g	I
##lut	I
##amine	I
[	O
13	O
##C	O
##5	O
,	O
99	O
%	O
]	O
,	O
1	B
,	I
5	I
‐	I
AG	I
[	O
U	O
‐	O
13	O
##C	O
##6	O
,	O
98	O
%	O
+	O
]	O
,	O
l	B
‐	I
l	I
##ys	I
##ine	I
:	I
2	I
##HC	I
##l	I
[	O
13	O
##C	O
##6	O
,	O
99	O
%	O
]	O
,	O
l	O
‐	O
his	O
##ti	O
##dine	O
:	O
HC	O
##l	O
:	O
H	O
_	O
2	O
O	O

Sept	O
##ic	O
shock	O
patients	O
showed	O
also	O
high	O
levels	O
of	O
inter	O
##fer	O
##on	O
-	O
in	O
##du	O
##cible	O
protein	O
-	O
10	O
(	O
IP	O
-	O
10	O
)	O
,	O
he	O
##pa	O
##to	O
##cy	O
##te	O
growth	O
factor	O
(	O
H	O
##G	O
##F	O
)	O
,	O
inter	O
##le	O
##uki	O
##n	O
-	O
18	O
(	O
IL	O
-	O
18	O
)	O
,	O
IL	O
-	O
1	O
and	O
IL	O
-	O
2	O
receptor	O
antagonist	O
##s	O
(	O
IL	O
-	O
1	O
##R	O
##a	O
,	O
IL	O
-	O
2	O
##R	O
##a	O
)	O
and	O
decreased	O
concentrations	O
of	O
IL	B
-	I
1	I
##α	I
,	O
mon	O
##oc	O
##yte	O
-	O
specific	O
ch	O
##em	O
##oki	O
##ne	O
3	O
(	O
MC	O
##P	O
-	O
3	O
)	O
and	O
tumor	O
ne	O
##c	O
##rosis	O
factor	O
beta	O
(	B
T	B
##NF	I
-	I
β	I
)	O
.	O

Each	O
spectrum	O
was	O
aligned	O
to	O
the	O
met	O
##hyl	O
peak	O
of	O
al	B
##ani	I
##ne	I
at	O
1	O
.	O
48	O
pp	O
##m	O
,	O
and	O
normal	O
##ized	O
using	O
the	O
integrated	O
T	O
##SP	O
signal	O
.	O

Two	O
300	O
μ	O
##L	O
serum	O
samples	O
were	O
cooled	O
in	O
an	O
ice	O
bath	O
and	O
mixed	O
with	O
perch	B
##lor	I
##ic	I
acid	I
(	O
30	O
μ	O
##L	O
;	O
4	O
M	O
)	O
,	O
v	O
##ortex	O
##ed	O
,	O
and	O
kept	O
aside	O
for	O
10	O
min	O
,	O
then	O
cent	O
##ri	O
##fu	O
##ged	O
at	O
11	O
000	O
rpm	O
for	O
30	O
min	O
to	O
p	O
##elle	O
##t	O
proteins	O
.	O

The	O
ch	O
##roma	O
##to	O
##graphic	O
conditions	O
were	O
thoroughly	O
op	O
##ti	O
##mized	O
in	O
order	O
to	O
ensure	O
a	O
complete	O
and	O
robust	O
separation	O
of	O
ta	B
##uri	I
##ne	I
from	O
the	O
variable	O
and	O
complex	O
urine	O
matrix	O
.	O

The	O
influence	O
of	O
in	O
##tra	O
##mus	O
##cular	O
4	B
-	I
h	I
##ydro	I
##xy	I
##and	I
##ros	I
##ten	I
##ed	I
##ione	I
on	O
peripheral	O
a	O
##roma	O
##tis	O
##ation	O
in	O
breast	O
cancer	O
patients	O
.	O

Then	O
,	O
the	O
extracted	O
meta	O
##bol	O
##ites	O
were	O
dried	O
in	O
a	O
vacuum	O
con	O
##cent	O
##rator	O
without	O
heating	O
,	O
and	O
30	O
μ	O
##L	O
of	O
met	B
##ho	I
##xy	I
##lam	I
##ine	I
h	I
##ydro	I
##ch	I
##lor	I
##ide	I
was	O
added	O
.	O

For	O
the	O
G	O
##C	O
/	O
TO	O
##F	O
-	O
MS	O
measurement	O
,	O
plasma	O
samples	O
(	O
100	O
μ	O
##l	O
)	O
were	O
th	O
##awed	O
before	O
the	O
immediate	O
addition	O
of	O
500	O
μ	O
##l	O
of	O
met	B
##han	I
##ol	I
(	O
100	O
%	O
)	O
to	O
stop	O
en	O
##zy	O
##matic	O
activity	O
.	O

Using	O
a	O
modified	O
B	O
##li	O
##gh	O
and	O
Dyer	O
extraction	O
conventional	O
##ly	O
used	O
to	O
analyze	O
major	O
lip	O
##id	O
families	O
in	O
biological	O
matrices	O
,	O
recover	O
##ies	O
were	O
calculated	O
from	O
CS	O
##F	O
Q	O
##C	O
samples	O
(	O
n	O
=	O
5	O
)	O
spike	O
##d	O
with	O
22	O
non	O
end	O
##ogen	O
##ous	O
internal	O
standards	O
(	O
IS	O
)	O
representing	O
the	O
five	O
major	O
lip	O
##id	O
families	O
(	O
fatty	O
a	O
##cy	O
##ls	O
,	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
,	O
g	B
##ly	I
##cer	I
##oli	I
##pid	I
##s	I
,	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
and	O
s	O
##tero	O
##l	O
lip	O
##ids	O
,	O
see	O
Table	O
S	O
##1	O
provided	O
as	O
supplement	O
##ary	O
material	O
)	O
.	O

In	B
##os	I
##ito	I
##l	I
phosphate	I
and	O
my	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
are	O
components	O
of	O
my	B
##elin	I
,	O
and	O
have	O
roles	O
in	O
neural	O
function	O
and	O
home	O
##ost	O
##asis	O
in	O
the	O
C	O
##NS	O
[	O
,	O
,	O
]	O
and	O
so	O
the	O
plasma	O
my	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
and	O
s	B
##cy	I
##llo	I
-	I
in	I
##os	I
##ito	I
##l	I
concentrations	O
may	O
reflect	O
per	O
##tur	O
##bation	O
##s	O
in	O
in	B
##os	I
##ito	I
##l	I
phosphate	I
metabolism	O
as	O
a	O
result	O
of	O
dem	O
##ye	O
##lina	O
##tion	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
4	O
of	O
these	O
16	O
meta	O
##bol	O
##ites	O
(	B
N	B
-	I
car	I
##ba	I
##mo	I
##yl	I
-	I
β	I
-	I
al	I
##ani	I
##ne	I
,	O

Our	O
study	O
did	O
not	O
detect	O
any	O
sa	B
##lic	I
##yl	I
##ic	I
acid	I
or	O
any	O
active	O
or	O
inactive	O
meta	O
##bol	O
##ites	O
of	O
medications	O
in	O
the	O
f	O
##ec	O
##es	O
of	O
study	O
participants	O
;	O
however	O
,	O
it	O
remains	O
difficult	O
to	O
decide	O
if	O
medications	O
have	O
any	O
impact	O
on	O
f	O
##eca	O
##l	O
V	O
##OM	O
##s	O
profiles	O
.	O

Lac	B
##tate	I
could	O
therefore	O
be	O
considered	O
as	O
a	O
potential	O
metabolic	O
bio	O
##mark	O
##er	O
for	O
the	O
assessment	O
of	O
risk	O
of	O
severe	O
CA	O
##P	O
.	O

For	O
this	O
study	O
,	O
blood	O
plasma	O
samples	O
from	O
control	O
subjects	O
(	O
n	O
=	O
30	O
)	O
and	O
patients	O
with	O
I	O
##G	O
##T	O
(	O
n	O
=	O
20	O
)	O
were	O
treated	O
with	O
met	B
##han	I
##ol	I
and	O
low	O
molecular	O
weight	O
fraction	O
were	O
then	O
analyzed	O
by	O
direct	O
in	O
##fusion	O
mass	O
s	O
##pect	O
##rome	O
##try	O
.	O

Typical	O
ch	O
##roma	O
##to	O
##gram	O
##s	O
for	O
human	O
plasma	O
and	O
human	O
CS	O
##F	O
are	O
shown	O
in	O
;	O
plasma	O
is	O
dominated	O
by	O
peaks	O
arising	O
from	O
l	B
##ys	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
.	O

(	O
B	O
)	O
Both	O
le	B
##uc	I
##ine	I
-	I
is	I
##ole	I
##uc	I
##ine	I
and	O
th	B
##re	I
##oni	I
##ne	I
can	O
be	O
converted	O
to	O
ace	B
##ty	I
##l	I
-	I
co	I
##A	I
and	O
come	O
into	O
the	O
T	O
##CA	O
)	O
.	O

7	B
-	I
Ke	I
##to	I
##cho	I
##les	I
##tero	I
##l	I
(	O
Ch	O
##em	O
##S	O
##pid	O
##er	O
ID	O
:	O
82	O
##5	O
##9	O
##9	O
)	O
,	O
7	B
##α	I
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
(	O
96	O
##8	O
##9	O
##1	O
)	O
,	O
25	B
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
(	O
58	O
##60	O
##4	O
)	O
,	O
and	O
27	B
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
(	O
110	O
##4	O
##9	O
##5	O
)	O
and	O
their	O
de	O
##uter	O
##ated	O
standards	O
(	B
7	B
-	I
k	I
##eto	I
##cho	I
##les	I
##tero	I
##l	I
-	I
d	I
_	I
7	I
,	I
7	I
##α	I
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
-	I
d	I
_	I
7	I
,	I
25	I
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
-	I
d	I
_	O
6	O
,	O
and	O
27	B
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
-	I
d	I
_	O
6	O
)	O
were	O
purchased	O
from	O
St	O
##eral	O
##oids	O
(	O
Newport	O
,	O
R	O
##I	O
)	O
.	O

Another	O
study	O
demonstrated	O
that	O
neurons	O
exposed	O
to	O
extra	O
##cellular	O
g	B
##lut	I
##ama	I
##te	I
show	O
a	O
reduction	O
in	O
den	O
##dr	O
##itic	O
growth	O
that	O
is	O
prevented	O
by	O
administration	O
of	O
K	O
##A	O
.	O

Important	O
##ly	O
,	O
the	O
performance	O
and	O
practical	O
##ity	O
of	O
combining	O
meta	O
##bol	O
##ites	O
with	O
low	O
molecular	O
weight	O
proteins	O
such	O
as	O
c	B
##ys	I
##tat	I
##in	I
C	O
was	O
not	O
tested	O
.	O

Ch	O
##roma	O
##to	O
##graphic	O
traces	O
of	O
3	O
-	O
O	O
-	O
G	O
##lu	O
##c	O
and	O
3	B
,	I
7	I
-	I
O	I
-	I
Di	I
##g	I
##lu	I
##c	I
after	O
the	O
injection	O
of	O
blank	O
(	O
a	O
,	O
e	O
)	O
,	O
Cal	O
##ib	O
##rator	O
1	O
(	O
50	O
p	O
##g	O
/	O
m	O
##L	O
)	O
(	O
b	O
,	O
f	O
)	O
and	O
Cal	O
##ib	O
##rator	O
8	O
(	O
1500	O
##0	O
p	O
##g	O
/	O
m	O
##L	O
)	O
(	O
c	O
,	O
g	O
)	O
in	O
plasma	O
,	O
together	O
with	O
a	O
sample	O
from	O
a	O
treated	O
volunteer	O
(	O
d	O
,	O
h	O
)	O
.	O

De	O
##uter	O
##ated	O
standards	O
of	O
all	O
o	B
##xy	I
##ster	I
##ols	I
were	O
used	O
for	O
method	O
valid	O
##ation	O
.	O

This	O
reduction	O
is	O
particularly	O
pronounced	O
for	O
n	O
##uc	O
##leo	O
##base	O
##s	O
and	O
am	O
##ines	O
,	O
in	O
keeping	O
with	O
the	O
basic	O
nature	O
of	O
the	O
am	B
##mon	I
##ium	I
salt	O
add	O
##itive	O
##s	O
.	O

Two	O
more	O
add	O
##uc	O
##ted	O
p	O
##eptide	O
##s	O
containing	O
NO	O
_	O
2	O
-	O
Ph	O
##IP	O
modified	O
l	B
##ys	I
##ine	I
residues	O
were	O
detected	O
in	O
Fr	O
##action	O
3	O
(	O
t	O
_	O
R	O
=	O
5	O
.	O
9	O
min	O
)	O
and	O
Fr	O
##action	O
4	O
(	O
t	O
_	O
R	O
=	O
8	O
.	O
3	O
min	O
)	O
at	O
relatively	O
low	O
abundance	O
,	O
which	O
encompasses	O
the	O
amino	O
acid	O
sequences	O
198	O
–	O
205	O
(	O
L	O
##K	O
*	O
CA	O
##SL	O
##Q	O
##K	O
)	O
and	O
34	O
##9	O
–	O
35	O
##9	O
(	O
LA	O
##K	O
*	O
T	O
##Y	O
##ET	O
##TL	O
##E	O
##K	O
)	O
of	O
SA	O
,	O
respectively	O
.	O

The	O
non	O
##via	O
##ble	O
cells	O
were	O
excluded	O
using	O
7	B
-	I
amino	I
##act	I
##ino	I
##my	I
##cin	I
D	O
(	O
P	O
##1	O
=	O
viable	O
cells	O
)	O
.	O

d	O
The	O
low	O
level	O
of	O
al	B
##ani	I
##ne	I
and	O
p	B
##yr	I
##og	I
##lut	I
##ami	I
##c	I
acid	I
in	O
n	O
##IB	O
##S	O
indicates	O
a	O
lowered	O
level	O
of	O
bacterial	O
pro	O
##te	O
##ase	O
and	O
p	O
##eptide	O
cat	O
##ab	O
##olis	O
##m	O
,	O
whereas	O
Lac	B
##to	I
##ba	I
##ci	I
##llus	I
activity	O
is	O
increased	O
in	O
I	O
##BS	O
,	O
indicated	O
by	O
the	O
elevated	O
levels	O
of	O
f	O
##ae	O
##cal	O
al	B
##ani	I
##ne	I
released	O
by	O
protein	O
cat	O
##ab	O
##olis	O
##m	O
.	O

Level	O
##s	O
of	O
me	O
##rca	O
##pt	O
##uri	O
##c	O
acids	O
formed	O
in	O
the	O
metabolism	O
of	O
ben	B
##zen	I
##e	I
[	I
S	I
-	I
p	I
##hen	I
##yl	I
##mer	I
##cap	I
##tur	I
##ic	I
acid	I
(	I
SP	I
##MA	I
)	I
]	I
,	O
a	B
##c	I
##rol	I
##ein	I
[	I
3	I
-	I
h	I
##ydro	I
##xy	I
##p	I
##rop	I
##yl	I
##mer	I
##cap	I
##tur	I
##ic	I
acid	I
(	I
3	I
-	I
HP	I
##MA	I
)	I
,	I
]	I
and	O
c	B
##rot	I
##onal	I
##de	I
##hy	I
##de	I
[	I
3	I
-	I
h	I
##ydro	I
##xy	I
-	I
1	I
-	I
met	I
##hyl	I
##p	I
##rop	I
##yl	I
##mer	I
##cap	I
##tur	I
##ic	I
acid	I
(	I
HM	I
##PM	I
##A	I
)	I
]	I
are	O
also	O
substantially	O
higher	O
in	O
these	O
Qi	O
##dong	O
##ese	O
compared	O
to	O
non	O
-	O
smoke	O
##r	O
residents	O
of	O
Singapore	O
.	O

The	O
correlation	O
coefficients	O
between	O
the	O
formation	O
rates	O
of	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
meta	O
##bol	O
##ites	O
and	O
the	O
activity	O
of	O
each	O
C	O
##YP	O
is	O
##of	O
##orm	O
in	O
different	O
H	O
##LM	O
##s	O
were	O
calculated	O
(	O
see	O
Data	O
analysis	O
)	O
.	O

Mel	B
##aton	I
##in	I
was	O
reported	O
as	O
a	O
free	O
radical	O
s	O
##ca	O
##venge	O
##r	O
and	O
an	O
anti	O
##ox	O
##ida	O
##nt	O
for	O
protection	O
from	O
the	O
o	O
##xi	O
##da	O
##tive	O
stress	O
,	O
especially	O
reducing	O
o	O
##xi	O
##da	O
##tive	O
damage	O
to	O
lip	O
##ids	O
,	O
which	O
is	O
important	O
for	O
the	O
maintenance	O
of	O
mitochondrial	O
home	O
##ost	O
##asis	O
.	O

Vita	B
##min	I
K	I
##2	I
and	O
its	O
derivatives	O
have	O
the	O
inhibitor	O
##y	O
effect	O
on	O
the	O
liver	O
cancer	O
cells	O
,	O
influence	O
the	O
post	O
##oper	O
##ative	O
re	O
##cu	O
##rrence	O
and	O
overall	O
survival	O
of	O
liver	O
cancer	O
.	O

Ch	O
##roma	O
##to	O
##graphic	O
separation	O
was	O
achieved	O
with	O
a	O
30	O
m	O
0	O
.	O
25	O
mm	O
CP	O
-	O
Si	O
##l	O
8	O
CB	O
fused	O
si	B
##lica	I
cap	O
##illa	O
##ry	O
G	O
##C	O
column	O
with	O
1	O
.	O
00	O
µ	O
##m	O
film	O
thickness	O
from	O
A	O
##gi	O
##lent	O
(	O
A	O
##gi	O
##lent	O
,	O
J	O
&	O
W	O
Scientific	O
,	O
F	O
##ols	O
##om	O
,	O
CA	O
,	O
USA	O
)	O
,	O
with	O
he	O
##lium	O
as	O
carrier	O
gas	O
.	O

The	O
following	O
corresponding	O
stable	O
labeled	O
compounds	O
were	O
used	O
as	O
internal	O
standards	O
:	O
α	B
-	I
H	I
##B	I
-	I
D	I
_	I
3	I
,	O
β	B
-	I
H	I
##B	I
-	I
D	I
_	I
3	I
,	I
3	I
-	I
met	I
##hyl	I
-	I
2	I
-	I
o	I
##x	I
##ob	I
##ut	I
##yric	I
acid	O
-	O
D	O
_	O
7	O
,	O
palm	B
##itic	I
acid	O
-	O
_	O
13	O
C	O
_	O
16	O
,	O
ma	O
##rga	O
##ric	O
acid	O
-	O
D	O
_	O
3	O
,	O
o	O
##le	O
##ic	O
acid	O
-	O
_	O
13	O
C	O
_	O
18	O
,	O
s	O
##te	O
##ari	O
##c	O
acid	O
-	O
D	O
_	O
3	O
,	O
l	B
##ino	I
##le	I
##ic	I
acid	O
-	O
_	O
13	O
C	O
_	O
18	O
,	O
l	O
##ino	O
##len	O
##ic	O
acid	O
-	O
_	O
13	O
C	O
_	O
18	O
,	O
(	O
used	O
for	O
palm	B
##ito	I
##le	I
##ic	I
acid	O
)	O
,	O
c	B
##rea	I
##tine	I
-	I
D	I
_	I
3	I
,	O
o	B
##ct	I
##ano	I
##yl	I
car	I
##ni	I
##tine	I
-	I
D	I
_	I
3	I
,	O
de	B
##cano	I
##yl	I
car	I
##ni	I
##tine	I
-	I
D	I
_	I
3	I
,	O
g	B
##lut	I
##ami	I
##c	I
acid	O
-	O
D	O
_	O
5	O
,	O
g	B
##ly	I
##cine	I
-	I
_	I
13	I
C	O
_	O
2	O
-	O
_	O
15	O
N	O
,	O
se	B
##rine	I
-	I
D	I
##3	I
,	O
th	B
##re	I
##oni	I
##ne	I
-	I
_	I
13	I
C	O
_	O
4	O
-	O
_	O
15	O
N	O
,	O
try	O
##pt	O
##op	O
##han	O
-	O
D	O
_	O
5	O
,	O
l	B
##ino	I
##leo	I
##yl	I
-	I
l	I
##ys	I
##o	I
-	I
PC	I
-	I
D	I
_	I
9	I
(	O
also	O
used	O
for	O
palm	B
##ito	I
##yl	I
-	I
l	I
##ys	I
##o	I
-	I
PC	I
and	O
o	B
##leo	I
##yl	I
-	I
l	I
##ys	I
##o	I
-	I
PC	I
)	O
.	O

Our	O
finding	O
confirms	O
that	O
in	O
se	O
##psis	O
k	B
##eton	I
##e	I
levels	O
increase	O
.	O

Po	O
##sitive	O
correlation	O
##s	O
were	O
also	O
observed	O
between	O
the	O
N	O
-	O
ace	O
##ty	O
##l	O
of	O
the	O
g	B
##lu	I
##cu	I
##ron	I
##ide	I
con	O
##ju	O
##gate	O
and	O
the	O
a	O
##romatic	O
pro	O
##tons	O
of	O
the	O
su	B
##lf	I
##ate	I
con	O
##ju	O
##gate	O
at	O
δ	O
7	O
.	O
31	O
and	O
7	O
.	O
46	O
(	O
r	O
=	O
0	O
.	O
76	O
;	O
95	O
%	O
C	O
##I	O
of	O
0	O
.	O
66	O
##−	O
##0	O
.	O
83	O
and	O
0	O
.	O
90	O
;	O
95	O
%	O
C	O
##I	O
of	O
0	O
.	O
85	O
##−	O
##0	O
.	O
93	O
,	O
respectively	O
)	O
.	O

Investigation	O
of	O
protein	O
precipitation	O
using	O
other	O
solvent	O
##s	O
indicated	O
that	O
met	B
##han	I
##ol	I
was	O
the	O
best	O
choice	O
.	O

The	O
compound	O
D	O
##HP	O
##M	O
##8	O
has	O
the	O
met	B
##ho	I
##xy	I
group	O
at	O
the	O
second	O
and	O
fourth	O
positions	O
on	O
the	O
ben	O
##zy	O
##l	O
ring	O
and	O
exhibited	O
half	O
-	O
ma	O
##ximal	O
inhibitor	O
##y	O
concentration	O
values	O
of	O
0	O
.	O
92	O
##±	O
##0	O
.	O
09	O
μ	O
##M	O
and	O
1	O
.	O
97	O
##±	O
##0	O
.	O
08	O
μ	O
##M	O
against	O
MC	O
##F	O
-	O
7	O
and	O
U	O
##AC	O
##C	O
-	O
62	O
cell	O
lines	O
,	O
respectively	O
,	O
according	O
to	O
.	O

However	O
,	O
no	O
significant	O
differences	O
in	O
c	B
##rea	I
##tin	I
##ine	I
and	O
u	B
##rea	I
levels	O
were	O
observed	O
between	O
the	O
non	O
-	O
survivor	O
and	O
survivor	O
groups	O
.	O

For	O
instance	O
,	O
4	B
-	I
c	I
##res	I
##yl	I
su	I
##lf	I
##ate	I
,	O
hip	B
##pura	I
##te	I
,	O
p	B
##hen	I
##yl	I
-	I
ace	I
##ty	I
##l	I
##g	I
##lut	I
##amine	I
,	O
and	O
3	O
-	O
and	O
4	B
-	I
h	I
##ydro	I
##xy	I
##mand	I
##ela	I
##te	I
map	O
to	O
the	O
a	O
##romatic	O
amino	O
acid	O
pathway	O
cluster	O
,	O
and	O
dim	B
##eth	I
##yla	I
##mine	I
and	O
T	O
##MA	O
map	O
to	O
ch	B
##olin	I
##e	I
metabolism	O
,	O
as	O
does	O
format	B
##e	I
.	O

All	O
of	O
the	O
ca	O
##li	O
##bra	O
##tion	O
standards	O
and	O
three	O
levels	O
of	O
the	O
quality	O
control	O
(	O
Q	O
##C	O
)	O
samples	O
(	O
12	O
.	O
20	O
,	O
610	O
.	O
0	O
,	O
and	O
1952	O
ng	O
/	O
m	O
##L	O
for	O
P	O
;	O
13	O
.	O
25	O
,	O
66	O
##2	O
.	O
5	O
,	O
and	O
212	O
##0	O
ng	O
/	O
m	O
##L	O
for	O
P	O
-	O
1	O
;	O
5	O
.	O
05	O
,	O
252	O
.	O
5	O
,	O
and	O
80	O
##8	O
ng	O
/	O
m	O
##L	O
for	O
P	O
-	O
2	O
;	O
12	O
.	O
65	O
,	O
63	O
##2	O
.	O
5	O
,	O
and	O
202	O
##4	O
ng	O
/	O
m	O
##L	O
for	O
IP	S
;	O
11	O
.	O
15	O
,	O
55	O
##7	O
.	O
5	O
,	O
and	O
1784	O
ng	O
/	O
m	O
##L	O
for	O
IP	O
-	O
1	O
;	O
and	O
5	O
.	O
35	O
,	O
26	O
##7	O
.	O
5	O
,	O
and	O
85	O
##6	O
ng	O
/	O
m	O
##L	O
for	O
IP	O
-	O
2	O
in	O
a	O
drug	O
-	O
free	O
culture	O
medium	O
were	O
prepared	O
by	O
s	O
##pi	O
##king	O
the	O
inactivated	O
bacterial	O
suspension	O
##s	O
and	O
relative	O
mixed	O
standard	O
working	O
solutions	O
into	O
the	O
blank	O
culture	O
medium	O
.	O

G	B
##lut	I
##amine	I
increased	O
(	O
FC	O
=	O
1	O
.	O
38	O
,	O
adjusted	O
P	O
=	O
0	O
.	O
02	O
##8	O
)	O
while	O
its	O
elevation	O
was	O
less	O
than	O
g	B
##lut	I
##ami	I
##c	I
acids	I
(	O
FC	O
=	O
4	O
.	O
24	O
,	O
adjusted	O
P	O
=	O
0	O
.	O
000	O
##01	O
##3	O
)	O
,	O
which	O
was	O
confirmed	O
to	O
be	O
significantly	O
elevated	O
in	O
the	O
latter	O
half	O
of	O
the	O
T	O
##CA	O
cycle	O
,	O
and	O
also	O
included	O
su	B
##cci	I
##nate	I
,	O
f	B
##uma	I
##rate	I
,	O
and	O
ma	B
##late	I
,	O
e	O
.	O
g	O
.	O
downstream	O
of	O
g	O
##lut	O
##ami	O
##no	O
##lysis	O
via	O
α	B
-	I
k	I
##eto	I
##g	I
##lut	I
##arate	I
.	O

P	O
##las	O
##ma	O
la	B
##th	I
##ost	I
##ero	I
##l	I
was	O
decreased	O
in	O
both	O
males	O
and	O
females	O
with	O
CF	O
##S	O
(	O
and	O
)	O
.	O

It	O
contains	O
a	O
reactive	O
amino	S
group	O
and	O
a	O
reporter	O
ion	O
.	O

Sharma	O
et	O
al	O
.	O
assessed	O
mac	O
##ros	O
##copic	O
##ally	O
involved	O
and	O
un	O
##in	O
##volved	O
m	O
##uc	O
##osa	O
of	O
the	O
co	O
##lon	O
from	O
I	O
##B	O
##D	O
patients	O
by	O
_	O
1	O
H	O
N	O
##MR	O
s	O
##pect	O
##ros	O
##copy	O
and	O
detected	O
similar	O
metabolic	O
profiles	O
in	O
these	O
bio	O
##ps	O
##ies	O
while	O
another	O
study	O
reported	O
differences	O
between	O
bio	O
##ps	O
##ies	O
from	O
I	O
##B	O
##D	O
patients	O
and	O
healthy	O
subjects	O
with	O
regard	O
to	O
amino	O
acids	O
,	O
membrane	O
components	O
and	O
la	B
##ct	I
##ate	I
.	O

The	O
mobile	O
phase	O
consisted	O
of	O
90	O
%	O
(	O
v	O
/	O
v	O
)	O
met	B
##han	I
##ol	I
a	O
##que	O
##ous	O
solution	O
containing	O
0	O
.	O
1	O
%	O
(	O
v	O
/	O
v	O
)	O
FA	S
and	O
55	O
m	O
##M	O
A	B
##F	I
.	O

D	B
-	I
as	I
##par	I
##tic	I
acid	I
is	O
an	O
amino	O
acid	O
that	O
is	O
found	O
to	O
be	O
decreased	O
in	O
B	O
##D	O
##TT	O
patient	O
.	O

P	O
##las	O
##ma	O
levels	O
of	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
in	O
PT	O
##B	O
positive	O
versus	O
negative	O
cows	O
(	O
N	O
=	O
12	O
per	O
group	O
)	O
.	O

Rapid	O
##ly	O
pro	O
##life	O
##rating	O
cancer	O
cells	O
express	O
the	O
P	O
##K	O
##M	O
##2	O
is	O
##of	O
##orm	O
of	O
the	O
g	B
##ly	I
##co	I
##ly	I
##tic	I
enzyme	O
p	B
##yr	I
##u	I
##vate	I
kinase	O
.	O

Additionally	O
,	O
the	O
mean	O
coefficient	O
of	O
variation	O
(	O
Co	O
##V	O
±	O
95	O
%	O
confidence	O
interval	O
)	O
was	O
lower	O
in	O
Me	B
##OH	I
pp	O
##t	O
+	O
U	O
##F	O
(	O
11	O
.	O
1	O
±	O
1	O
.	O
8	O
%	O
)	O
than	O
in	O
Me	B
##OH	I
:	O

On	O
the	O
other	O
hand	O
,	O
serum	O
after	O
protein	O
precipitation	O
using	O
met	B
##han	I
##ol	I
provided	O
the	O
most	O
optimal	O
N	O
##MR	O
s	O
##pect	O
##ra	O
in	O
terms	O
of	O
both	O
the	O
number	O
of	O
meta	O
##bol	O
##ites	O
detected	O
as	O
well	O
as	O
their	O
peak	O
in	O
##tens	O
##ities	O
.	O

The	O
cells	O
were	O
culture	O
##d	O
in	O
Du	O
##l	O
##be	O
##cco	O
’	O
s	O
Mo	O
##dified	O
Eagle	O
’	O
s	O
Medium	O
,	O
supplemented	O
with	O
10	O
%	O
(	O
v	O
/	O
v	O
)	O
f	O
##etal	O
calf	O
serum	O
and	O
100	O
μ	O
##g	O
/	O
m	O
##L	O
s	B
##tre	I
##pt	I
##omy	I
##cin	I
and	O
100	O
units	O
/	O
m	O
##L	O
pen	B
##ici	I
##llin	I
in	O
humid	O
##ified	O
5	O
%	O
CO	O
_	O
2	O
at	O
37	O
##°	O
##C	O
.	O

illustrate	O
##s	O
the	O
separation	O
of	O
25	O
(	O
OH	O
)	O
D	O
_	O
3	O
and	O
3	B
-	I
e	I
##pi	I
-	I
25	I
(	I
OH	I
)	I
D	I
_	I
3	I
on	O
the	O
P	O
##FP	O
column	O
for	O
Level	O
1	O
of	O
SR	O
##M	O
97	O
##2	O
##a	O
.	O

There	O
were	O
28	O
V	O
##OM	O
##s	O
which	O
were	O
significantly	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
more	O
abundant	O
in	O
I	O
##BS	O
-	O
D	O
and	O
of	O
these	O
,	O
22	O
V	O
##OM	O
##s	O
belong	O
to	O
the	O
est	O
##er	O
class	O
showing	O
its	O
strong	O
association	O
with	O
I	O
##BS	O
-	O
D	O
.	O
However	O
,	O
no	O
distinctive	O
pattern	O
of	O
V	O
##OM	O
##s	O
was	O
found	O
to	O
be	O
positively	O
associated	O
with	O
healthy	O
controls	O
;	O
k	B
##eton	I
##es	I
,	O
al	O
##de	O
##hy	O
##des	O
and	O
organic	O
acids	O
were	O
each	O
found	O
to	O
have	O
a	O
weak	O
association	O
with	O
this	O
group	O
.	O

Therefore	O
,	O
the	O
lower	O
levels	O
of	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
might	O
be	O
a	O
reflection	O
of	O
deficiency	O
,	O
or	O
reduced	O
activity	O
,	O
of	O
a	O
##cy	O
##l	O
-	O
Co	O
##A	O
de	O
##hy	O
##dr	O
##ogen	O
##ase	O
in	O
E	O
##SC	O
##C	O
patients	O
,	O
and	O
also	O
reflected	O
the	O
disturbed	O
ability	O
of	O
β	O
-	O
oxidation	O
of	O
long	O
-	O
chain	O
fatty	O
acids	O
.	O

Interest	O
##ingly	O
,	O
fatigue	O
correlated	O
weakly	O
with	O
measures	O
of	O
enhanced	O
try	B
##pt	I
##op	I
##han	I
metabolism	O
,	O
while	O
depression	O
did	O
not	O
.	O

In	O
some	O
cases	O
,	O
urine	O
(	O
100	O
μ	O
##L	O
)	O
from	O
control	O
rats	O
and	O
[	O
_	O
12	O
C	O
_	O
4	O
]	O
fur	O
##an	O
-	O
or	O
[	O
_	O
13	O
C	O
_	O
4	O
]	O
fur	O
##an	O
-	O
treated	O
rats	O
was	O
reacted	O
with	O
met	B
##hy	I
##ox	I
##yam	I
##ine	I
(	O
10	O
mg	O
)	O
at	O
37	O
°C	O
for	O
2	O
hours	O
before	O
cent	O
##ri	O
##fu	O
##gation	O
at	O
5	O
,	O
000	O
rpm	O
for	O
3	O
min	O
to	O
remove	O
any	O
solid	O
##s	O
.	O

The	O
association	O
between	O
u	O
##rina	O
##ry	O
concentrations	O
of	O
p	O
##ht	O
##hala	O
##tes	O
meta	O
##bol	O
##ites	O
(	O
continuous	O
)	O
and	O
diabetes	O
was	O
assessed	O
by	O
multi	O
##var	O
##iate	O
log	O
##istic	O
re	O
##gression	O
models	O
that	O
were	O
adjusted	O
by	O
c	B
##rea	I
##tin	I
##ine	I
,	O
as	O
recommended	O
by	O
,	O
as	O
well	O
as	O
the	O
variables	O
that	O
were	O
significantly	O
correlated	O
to	O
the	O
specific	O
p	B
##ht	I
##hala	I
##te	I
meta	O
##bol	O
##ite	O
among	O
healthy	O
women	O
.	O

De	O
##ple	O
##tion	O
of	O
ω	B
-	I
3	I
P	I
##U	I
##FA	I
##s	I
have	O
previously	O
been	O
reported	O
to	O
be	O
associated	O
with	O
inflammatory	O
processes	O
and	O
lip	O
##id	O
per	O
##ox	O
##ida	O
##tion	O
in	O
the	O
path	O
##op	O
##hy	O
##sio	O
##logy	O
of	O
depression	O
.	O

Ace	B
##tam	I
##ino	I
##phe	I
##n	I
,	O
i	B
##bu	I
##p	I
##ro	I
##fen	I
,	O
and	O
their	O
related	O
meta	O
##bol	O
##ites	O
are	O
readily	O
id	O
##ent	O
##ifiable	O
in	O
_	O
1	O
H	O
N	O
##MR	O
urine	O
s	O
##pect	O
##ra	O
,	O
and	O
their	O
spectral	O
signatures	O
are	O
distinctive	O
(	O
see	O
Web	O
Figure	O
1	O
,	O
which	O
is	O
posted	O
on	O
the	O
Journal	O
’	O
s	O
Web	O
site	O
(	O
http	O
:	O
/	O
/	O
a	O
##je	O
.	O
o	O
##x	O
##ford	O
##jou	O
##rnal	O
##s	O
.	O
org	O
/	O
)	O
)	O

Re	O
##age	O
##nts	O
:	O
met	B
##han	I
##ol	I
(	O
B	O
##ur	O
##dic	O
&	O
Jackson	O
,	O
Germany	O
)	O
,	O
5	O
%	O
a	O
##que	O
##ous	O
solution	O
of	O
met	B
##han	I
##ol	I
;	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
(	O
Sigma	O
,	O
Germany	O
)	O
.	O

N	O
##1	O
,	O
N	B
##12	I
-	I
di	I
##ace	I
##ty	I
##ls	I
##per	I
##mine	I
is	O
an	O
am	O
##ine	O
metabolic	O
compound	O
known	O
to	O
be	O
a	O
urine	O
tumor	O
bio	O
##mark	O
##er	O
.	O

Laboratory	O
studies	O
included	O
glucose	S
,	O
insulin	O
,	O
g	O
##ly	O
##cated	O
ha	O
##em	O
##og	O
##lo	O
##bin	O
(	O
H	O
##b	O
##A	O
##1	O
##c	O
)	O
,	O
total	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
high	O
-	O
density	O
lip	O
##op	O
##rote	O
##in	O
ch	B
##ole	I
##ster	I
##ol	I
(	O
HD	O
##L	O
-	O
C	O
)	O
,	O
low	O
-	O
density	O
lip	O
##op	O
##rote	O
##in	O
ch	B
##ole	I
##ster	I
##ol	I
(	O
L	O
##D	O
##L	O
-	O
C	O
)	O
and	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
,	O
all	O
of	O
which	O
were	O
anal	O
##ys	O
##ed	O
using	O
a	O
conventional	O
automated	O
anal	O
##ys	O
##er	O
.	O

Results	O
of	O
a	O
limited	O
time	O
course	O
study	O
of	O
11	O
human	O
subjects	O
indicated	O
moderate	O
chemical	O
instability	O
of	O
1	B
,	I
4	I
-	I
B	I
##Q	I
-	I
Al	I
##b	I
(	O
half	O
-	O
life	O
=	O
13	O
.	O
5	O
days	O
compared	O
with	O
19	O
–	O
25	O
days	O
for	O
normal	O
Al	O
##b	O
turnover	O
)	O
,	O
whereas	O
no	O
evidence	O
of	O
instability	O
of	O
B	O
##O	O
-	O
Al	O
##b	O
was	O
observed	O
.	O

We	O
observed	O
modest	O
differences	O
in	O
est	B
##rogen	I
meta	O
##bol	O
##ite	O
concentrations	O
between	O
pro	O
##state	O
cancer	O
patients	O
and	O
subjects	O
without	O
cancer	O
.	O

While	O
the	O
vital	O
role	O
of	O
vitamin	B
D	I
in	O
bone	O
health	O
is	O
clearly	O
established	O
,	O
its	O
functional	O
involvement	O
in	O
other	O
diseases	O
such	O
diabetes	O
,	O
cancer	O
,	O
multiple	O
s	O
##cle	O
##rosis	O
,	O
depression	O
,	O
he	O
##pa	O
##tic	O
,	O
re	O
##nal	O
and	O
card	O
##iovascular	O
diseases	O
is	O
currently	O
the	O
subject	O
of	O
intense	O
research	O
_	O
,	O
,	O
particularly	O
because	O
vitamin	B
D	I
receptor	O
is	O
present	O
in	O
virtually	O
all	O
organs	O
.	O

Although	O
amino	O
acids	O
are	O
obviously	O
not	O
suitable	O
as	O
F	O
##IB	O
##s	O
because	O
they	O
are	O
u	O
##bi	O
##quito	O
##us	O
##ly	O
present	O
in	O
foods	O
and	O
released	O
during	O
dig	O
##est	O
##ion	O
,	O
their	O
increased	O
post	O
##pra	O
##ndi	O
##al	O
appearance	O
after	O
cheese	O
intake	O
,	O
compared	O
to	O
milk	O
,	O
is	O
interesting	O
as	O
it	O
might	O
reflect	O
the	O
ability	O
of	O
the	O
milk	O
f	O
##er	O
##mentation	O
process	O
to	O
further	O
increase	O
the	O
release	O
of	O
free	O
amino	O
acids	O
for	O
their	O
up	O
##take	O
into	O
the	O
circulation	O
:	O
A	O
survey	O
of	O
the	O
free	O
amino	O
acids	O
released	O
during	O
the	O
ripe	O
##ning	O
of	O
a	O
range	O
of	O
Swiss	O
cheese	O
showed	O
that	O
pro	B
##line	I
was	O
among	O
the	O
most	O
released	O
amino	O
acids	O
in	O
G	O
##ru	O
##y	O
##ère	O
.	O

In	O
##f	O
##lue	O
##nce	O
of	O
Ph	O
##LA	O
,	O
p	O
-	O
HP	O
##h	O
##LA	O
,	O
p	O
-	O
HP	O
##h	O
##AA	O
and	O
it	B
##acon	I
##ic	I
acid	I
at	O
a	O
0	O
.	O
5	O
–	O
5	O
.	O
0	O
m	O
##M	O
concentration	O
range	O
(	O
indicated	O
under	O
the	O
columns	O
)	O
on	O
SD	O
##H	O
activity	O
after	O
the	O
10	O
min	O
.	O

This	O
is	O
a	O
significant	O
advancement	O
compared	O
with	O
the	O
results	O
presented	O
in	O
the	O
only	O
reported	O
co	O
-	O
exposure	O
study	O
in	O
which	O
three	O
separate	O
methods	O
based	O
on	O
E	O
##L	O
##IS	O
##A	O
,	O
HP	O
##LC	O
with	O
flu	O
##ores	O
##cence	O
detection	O
,	O
and	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
were	O
applied	O
to	O
reveal	O
exposure	O
to	O
a	B
##f	I
##lat	I
##ox	I
##in	I
and	O
D	O
##ON	O
in	O
pregnant	O
women	O
from	O
Egypt	O
.	O

Co	O
-	O
detection	O
of	O
the	O
m	O
/	O
z	O
matched	O
to	O
t	B
##re	I
##hal	I
##ose	I
-	I
6	I
-	I
my	I
##cola	I
##te	I
,	O
P	O
##I	O
,	O
and	O
the	O
D	O
-	O
series	O
re	O
##sol	O
##vin	O
##s	O
within	O
study	O
subject	O
plasma	O
(	O
T	O
##B	O
disease	O
subjects	O
with	O
drug	O
-	O
susceptible	O
T	O
##B	O
,	O
MD	O
##R	O
-	O
T	O
##B	O
,	O
and	O
household	O
contacts	O
)	O
is	O
shown	O
in	O
.	O

Treatment	O
with	O
high	O
dose	O
rib	B
##of	I
##lav	I
##in	I
could	O
enhance	O
lung	O
car	O
##cin	O
##ogen	O
##esis	O
,	O
but	O
increases	O
have	O
not	O
been	O
linked	O
to	O
SC	O
##C	O
t	O
##umour	O
##s	O
.	O

The	O
application	O
of	O
HP	O
##LM	O
resulted	O
in	O
significant	O
metabolic	O
alterations	O
relative	O
to	O
the	O
traditional	O
media	O
including	O
an	O
in	O
##hibition	O
of	O
de	O
no	O
##vo	O
p	B
##yr	I
##im	I
##id	I
##ine	I
synthesis	O
.	O

Ph	B
##os	I
##ph	I
##oli	I
##pid	I
##s	I
,	O
total	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
free	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
ch	B
##ole	I
##ster	I
##ol	I
est	I
##ers	I
and	O
total	O
lip	O
##ids	O
in	O
the	O
larger	O
HD	O
##L	O
sub	O
##c	O
##lass	O
##es	O
were	O
lower	O
in	O
PC	O
##OS	O
.	O

Association	O
##s	O
of	O
circulating	O
vitamin	B
D	I
meta	O
##bol	O
##ites	O
measured	O
at	O
the	O
end	O
of	O
the	O
DC	O
##CT	O
with	O
internal	O
car	O
##ot	O
##id	O
I	O
##MT	O
measured	O
during	O
the	O
E	O
##DI	O
##C	O
study	O
among	O
99	O
##1	O
DC	O
##CT	O
/	O
E	O
##DI	O
##C	O
participants	O

D	B
##MA	I
is	O
one	O
of	O
the	O
most	O
abundant	O
components	O
of	O
the	O
human	O
urine	O
and	O
ex	O
##ogen	O
##ous	O
as	O
well	O
as	O
end	O
##ogen	O
##ous	O
sources	O
of	O
D	B
##MA	I
are	O
known	O
.	O

[	B
N	B
-	I
ace	I
##ty	I
##l	I
-	I
D	I
_	I
3	I
]	O
HM	O
##PM	O
##A	O
in	O
0	O
.	O
1	O
m	O
##L	O
H	O
_	O
2	O
O	O
was	O
added	O
carefully	O
to	O
each	O
well	O
.	O

Previously	O
,	O
using	O
HP	O
##LC	O
and	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
,	O
our	O
group	O
demonstrated	O
that	O
in	B
##do	I
##le	I
-	I
3	I
-	I
ace	I
##tic	I
acid	I
,	O
in	B
##dox	I
##yl	I
su	I
##lf	I
##ate	I
and	O
k	B
##yn	I
##uren	I
##ic	I
acid	I
accumulated	O
in	O
CR	O
##F	O
patients	O
with	O
mean	O
concentrations	O
of	O
4	O
.	O
4	O
µ	O
##M	O
,	O
67	O
µ	O
##M	O
and	O
0	O
.	O
6	O
µ	O
##M	O
,	O
respectively	O
.	O

Here	O
,	O
we	O
identified	O
AT	O
-	O
rich	O
interactive	O
domain	O
1	O
A	O
(	O
AR	O
##ID	O
##1	O
##A	O
)	O
,	O
a	O
key	O
ch	B
##roma	I
##tin	I
re	O
##mo	O
##del	O
##er	O
,	O
as	O
being	O
h	O
##y	O
##po	O
##met	O
##hyl	O
##ated	O
and	O
up	O
##re	O
##gu	O
##lated	O
by	O
α	B
-	I
O	I
##G	I
treatment	O
.	O

In	O
pregnancy	O
research	O
in	O
particular	O
,	O
this	O
issue	O
has	O
been	O
brought	O
up	O
in	O
relation	O
with	O
album	O
##in	O
measurements	O
,	O
where	O
the	O
use	O
of	O
c	B
##rea	I
##tin	I
##ine	I
as	O
a	O
reference	O
was	O
deemed	O
appropriate	O
.	O

Another	O
meta	O
##bol	O
##ite	O
,	O
k	B
##yn	I
##uren	I
##ine	I
,	O
which	O
is	O
an	O
intermediate	O
in	O
the	O
try	B
##pt	I
##op	I
##han	I
metabolic	O
pathway	O
producing	O
ni	B
##ac	I
##in	I
,	O
was	O
increased	O
over	O
two	O
##fold	O
in	O
the	O
patients	O
with	O
a	O
BS	O
pattern	O
.	O

Five	O
identical	O
meta	O
##bol	O
##ites	O
including	O
c	B
##rea	I
##tin	I
##ine	I
,	O
D	B
-	I
g	I
##lut	I
##ami	I
##c	I
acid	I
,	O
ch	B
##olin	I
##e	I
,	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
,	O
and	O
ni	B
##ac	I
##ina	I
##mi	I
##de	I
(	O
VIP	O
≥	O
1	O
.	O
5	O
,	O
P	O
<	O
0	O
.	O
01	O
,	O
F	O
##DR	O
<	O
0	O
.	O
05	O
)	O
in	O
at	O
##rial	O
app	O
##end	O
##age	O
and	O
plasma	O
samples	O
were	O
considered	O
prominent	O
features	O
of	O
A	B
##F	I
patients	O
,	O
and	O
the	O
D	B
-	I
g	I
##lut	I
##amine	I
and	O
D	B
-	I
g	I
##lut	I
##ama	I
##te	I
metabolic	O
pathway	O
was	O
also	O
identified	O
as	O
a	O
feature	O
of	O
A	B
##F	I
patients	O
.	O

One	O
study	O
reported	O
that	O
GM	O
levels	O
of	O
u	O
##rina	O
##ry	O
ME	O
##HP	O
,	O
ME	O
##H	O
##HP	O
,	O
ME	O
##OH	O
##P	O
,	O
ME	O
##P	O
,	O
MB	O
##P	O
were	O
around	O
9	O
.	O
87	O
,	O
50	O
.	O
9	O
,	O
24	O
.	O
1	O
,	O
19	O
.	O
8	O
and	O
55	O
.	O
9	O
μ	O
##g	O
/	O
g	O
c	B
##rea	I
##tin	I
##ine	I
,	O
respectively	O
,	O
in	O
adult	O
Taiwanese	O
during	O
2005	O
–	O
08	O
,	O
two	O
times	O
higher	O
than	O
those	O
in	O
the	O
current	O
study	O
.	O

Blood	O
and	O
urine	O
collections	O
were	O
performed	O
after	O
a	O
12	O
h	O
overnight	O
fast	O
and	O
12	O
h	O
after	O
car	B
##nos	I
##ine	I
ing	O
##est	O
##ion	O
.	O

For	O
the	O
der	O
##iva	O
##ti	O
##zation	O
of	O
individual	O
amino	O
acids	O
,	O
100	O
μ	O
##l	O
(	O
10	O
μ	O
##mo	O
##l	O
)	O
of	O
each	O
amino	O
acid	O
di	O
##lut	O
##ed	O
with	O
650	O
μ	O
##l	O
of	O
20	O
m	O
##M	O
phosphate	S
buffer	O
(	O
pH	O
8	O
.	O
0	O
)	O
was	O
reacted	O
with	O
1	B
,	I
1	I
′	I
-	I
_	I
13	I
C	I
_	I
2	I
ace	I
##tic	I
an	I
##hy	I
##dr	I
##ide	I
(	O
2	O
μ	O
##l	O
,	O
20	O
μ	O
##mo	O
##l	O
)	O
at	O
room	O
temperature	O
.	O

Using	O
media	O
##tion	O
analysis	O
,	O
we	O
found	O
that	O
25	O
%	O
of	O
the	O
association	O
between	O
so	O
##y	O
consumption	O
and	O
higher	O
lung	O
cancer	O
risk	O
was	O
significantly	O
mediated	O
via	O
5	B
-	I
met	I
##hyl	I
-	I
2	I
-	I
fur	I
##oi	I
##c	I
acid	I
.	O

Previous	O
relationships	O
between	O
u	O
##rina	O
##ry	O
u	B
##rea	I
nitrogen	I
ex	O
##cre	O
##tion	O
and	O
appearance	O
of	O
urine	O
hip	B
##pura	I
##te	I
and	O
/	O
or	O
PA	B
##G	I
nitrogen	I
were	O
reported	O
in	O
normal	O
subjects	O
given	O
sodium	B
ben	I
##zo	I
##ate	I
or	O
sodium	B
p	I
##hen	I
##yla	I
##ce	I
##tate	I
,	O
respectively	O
.	O

c	O
,	O
molecular	O
modeling	O
of	O
the	O
dock	O
##ing	O
of	O
AT	O
##RA	O
(	O
red	O
)	O
and	O
β	B
-	I
a	I
##po	I
-	I
13	I
-	I
car	I
##ote	I
##non	I
##e	I
(	O
purple	O
)	O
into	O
the	O
l	O
##igan	O
##d	O
binding	O
site	O
(	O
protein	O
backbone	O
in	O
green	O
)	O
of	O
RA	O
##R	O
##β	O
(	O
Pro	O
##tein	O
Data	O
Bank	O
code	O
1	O
##X	O
##AP	O
)	O
(	O
left	O
)	O
.	O

C	B
##rea	I
##tin	I
##ine	I
alone	O
performed	O
worse	O
than	O
e	O
##G	O
##F	O
##R	O
##c	O
##r	O
in	O
both	O
the	O
AA	O
##S	O
##K	O
and	O
ME	O
##SA	O
.	O

This	O
observation	O
fits	O
with	O
the	O
notion	O
that	O
pu	B
##rine	I
and	O
p	B
##yr	I
##im	I
##id	I
##ine	I
n	O
##uc	O
##leo	O
##tide	O
degradation	O
occurs	O
following	O
cellular	O
DNA	O
double	O
-	O
strand	O
breaks	O
induced	O
by	O
i	O
##rino	O
##teca	O
##n	O
/	O
S	O
##N	O
-	O
38	O
.	O

We	O
also	O
detected	O
bi	B
##set	I
##hane	I
,	O
but	O
it	O
appears	O
to	O
be	O
art	O
##ef	O
##act	O
of	O
chemical	O
der	O
##iva	O
##ti	O
##zation	O
and	O
is	O
not	O
a	O
urine	O
meta	O
##bol	O
##ite	O
.	O

The	O
difference	O
in	O
α	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
AU	O
##C	O
among	O
W	O
##BI	O
##SI	O
te	O
##rt	O
##iles	O
remained	O
statistical	O
##ly	O
significant	O
after	O
correction	O
for	O
age	O
,	O
sex	O
,	O
ethnicity	O
,	O
Tanner	O
stage	O
,	O
and	O
B	O
##MI	O
z	O
-	O
score	O
(	O
P	O
=	O
0	O
.	O
03	O
##4	O
)	O
.	O

C	O
##K	O
##D	O
##2	O
–	O
3	O
,	O
C	O
##K	O
##D	O
stages	O
2	O
and	O
3	O
;	O
C	O
##K	O
##D	O
##4	O
–	O
5	O
,	O
C	O
##K	O
##D	O
stages	O
4	O
and	O
5	O
;	O
AA	O
,	O
amino	O
acid	O
;	O
AD	B
##MA	I
,	O
as	B
##ym	I
##metric	I
dim	I
##eth	I
##yla	I
##rg	I
##ini	I
##ne	I
;	O
SD	O
##MA	O
,	O
symmetric	B
dim	I
##eth	I
##yla	I
##rg	I
##ini	I
##ne	I
.	O

The	O
activity	O
of	O
main	O
enzymes	O
could	O
even	O
be	O
reduced	O
due	O
to	O
reduced	O
regeneration	O
of	O
their	O
co	O
-	O
enzyme	O
te	B
##tra	I
##hy	I
##dr	I
##ob	I
##io	I
##pt	I
##eri	I
##n	I
,	O
which	O
represents	O
a	O
potential	O
connection	O
with	O
the	O
down	O
##re	O
##gu	O
##lated	O
f	B
##olate	I
cycle	O
.	O

No	O
other	O
features	O
emerged	O
with	O
similar	O
strong	O
contrasts	O
and	O
other	O
PC	O
##s	O
such	O
as	O
two	O
PC	B
(	I
36	I
:	I
2	I
)	I
is	I
##omer	I
##s	I
did	O
not	O
differ	O
between	O
the	O
two	O
treatments	O
.	O

R	B
##iba	I
##vir	I
##in	I
meta	O
##bol	O
##ite	O
levels	O
suggest	O
that	O
its	O
mon	B
##op	I
##hos	I
##phate	I
is	O
in	O
great	O
excess	O
of	O
its	O
in	O
##hibition	O
constant	O
for	O
I	O
##MP	O
de	O
##hy	O
##dr	O
##ogen	O
##ase	O
and	O
that	O
its	O
trip	B
##hos	I
##phate	I
is	O
approaching	O
the	O
binding	O
constant	O
for	O
incorporation	O
by	O
the	O
HC	O
##V	O
N	O
##S	O
##5	O
##B	O
RNA	O
-	O
dependent	O
RNA	O
polymer	O
##ase	O
.	O

1	B
-	I
met	I
##hyl	I
##his	I
##ti	I
##dine	I
was	O
detected	O
in	O
nine	O
patients	O
,	O
t	B
##rig	I
##one	I
##llin	I
##e	I
and	O
trim	B
##eth	I
##yla	I
##mine	I
N	I
-	I
oxide	I
were	O
found	O
in	O
six	O
patients	O
and	O
pseudo	B
##uri	I
##dine	I
was	O
found	O
in	O
five	O
patients	O
;	O
whereas	O
,	O
dim	B
##eth	I
##yla	I
##mine	I
was	O
only	O
detected	O
in	O
one	O
individual	O
.	O

O	B
##xy	I
##lip	I
##ins	I
yielded	O
the	O
strongest	O
discrimination	O
between	O
the	O
pro	O
-	O
and	O
anti	O
-	O
T	O
##GR	O
##L	O
samples	O
(	O
Q	O
_	O
2	O
=	O
0	O
.	O
32	O
)	O

It	O
is	O
well	O
-	O
recognized	O
now	O
that	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
and	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
are	O
well	O
-	O
ion	O
##ized	O
by	O
electro	O
##sp	O
##ray	O
.	O

Met	O
##ab	O
##oli	O
##tes	O
were	O
el	O
##uted	O
using	O
a	O
gradient	O
composed	O
of	O
A	O
,	O
water	O
with	O
0	O
.	O
1	O
%	O
(	O
v	O
/	O
v	O
)	O
form	B
##ic	I
acid	I
,	O
and	O
B	O
,	O
ace	O
##ton	O
##it	O
##ril	O
##e	O
/	O
is	O
##op	O
##rop	O
##ano	O
##l	O
(	O
75	O
/	O
25	O
,	O
v	O
/	O
v	O
)	O
with	O
0	O
.	O
1	O
%	O
(	O
v	O
/	O
v	O
)	O
form	B
##ic	I
acid	I
.	O

In	O
addition	O
to	O
the	O
Multi	O
-	O
Ethnic	O
Co	O
##hor	O
##t	O
study	O
,	O
the	O
present	O
method	O
is	O
being	O
applied	O
in	O
a	O
large	O
clinical	O
study	O
examining	O
the	O
effects	O
of	O
consumption	O
of	O
compounds	O
derived	O
from	O
br	O
##occo	O
##li	O
s	O
##p	O
##rout	O
##s	O
on	O
me	B
##rca	I
##pt	I
##uri	I
##c	I
acid	I
metabolism	O
of	O
a	B
##c	I
##rol	I
##ein	I
and	O
c	B
##rot	I
##onal	I
##de	I
##hy	I
##de	I
.	O

Further	O
work	O
addressed	O
a	O
x	O
##eno	O
##gra	O
##ft	O
mouse	O
model	O
of	O
highly	O
meta	O
##static	O
RC	O
##C	O
and	O
showed	O
that	O
urine	O
is	O
less	O
reflective	O
of	O
tumor	O
##al	O
meta	O
##bol	O
##omi	O
##c	O
changes	O
compared	O
to	O
tissue	O
or	O
serum	O
,	O
nevertheless	O
,	O
increased	O
u	O
##rina	O
##ry	O
levels	O
of	O
some	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
were	O
found	O
in	O
RC	O
##C	O
cases	O
,	O
consistent	O
with	O
previous	O
work	O
.	O

Similar	O
to	O
N	O
##ez	O
##ami	O
Ra	O
##n	O
##j	O
##bar	O
et	O
al	O
.	O
52	O
in	O
plasma	O
samples	O
from	O
he	O
##pa	O
##to	O
##cellular	O
car	O
##cin	O
##oma	O
patients	O
vs	O
.	O
patients	O
with	O
liver	O
c	O
##ir	O
##r	O
##hos	O
##is	O
,	O
we	O
show	O
decreased	O
levels	O
of	O
c	B
##it	I
##ric	I
acid	I
(	O
p	O
‐	O
value	O
=	O
0	O
.	O
01	O
##4	O
)	O
in	O
plasma	O
from	O
cache	O
##ctic	O
cancer	O
versus	O
non	O
‐	O
cache	O
##ctic	O
cancer	O
patients	O
.	O

Indo	B
##le	I
p	I
##yr	I
##u	I
##vate	I
levels	O
were	O
higher	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
in	O
those	O
who	O
experienced	O
more	O
than	O
15	O
%	O
of	O
their	O
sleep	O
time	O
in	O
R	O
##EM	O
sleep	O
.	O

But	B
##yra	I
##te	I
has	O
been	O
considered	O
to	O
regulate	O
the	O
in	O
##test	O
##inal	O
flora	O
balance	O
,	O
and	O
the	O
addition	O
of	O
low	O
doses	O
of	O
but	B
##yra	I
##te	I
to	O
the	O
diet	O
has	O
a	O
certain	O
therapeutic	O
effect	O
on	O
ul	O
##cer	O
##ative	O
co	O
##lit	O
##is	O
.	O

Most	O
of	O
them	O
were	O
involved	O
in	O
amino	O
acid	O
metabolic	O
pathways	O
,	O
such	O
as	O
al	B
##ani	I
##ne	I
and	O
as	B
##par	I
##tate	I
metabolism	O
,	O
a	B
##rg	I
##ini	I
##ne	I
and	O
pro	B
##line	I
metabolism	O
,	O
and	O
try	B
##pt	I
##op	I
##han	I
metabolism	O
(	O
,	O
)	O
.	O

The	O
presence	O
of	O
ch	B
##olin	I
##e	I
suggests	O
that	O
et	O
##ane	O
##rc	O
##ept	O
may	O
alter	O
lip	O
##id	O
metabolism	O
.	O

The	O
models	O
suggest	O
that	O
a	B
##rg	I
##ini	I
##ne	I
is	O
important	O
in	O
stroke	O
recovery	O
.	O

Although	O
generally	O
not	O
native	O
to	O
ma	O
##mmal	O
##ian	O
cell	O
lip	O
##ido	O
##me	O
,	O
g	B
##ly	I
##cer	I
##ol	I
##ph	I
##os	I
##ph	I
##oli	I
##pid	I
##s	I
containing	O
odd	O
chain	O
fatty	O
a	O
##cy	O
##ls	O
and	O
longer	O
chain	O
fatty	O
a	O
##cy	O
##ls	O
on	O
the	O
s	O
##n	O
-	O
1	O
position	O
were	O
also	O
observed	O
and	O
passed	O
our	O
valid	O
##ation	O
criteria	O
.	O

Try	B
##pt	I
##op	I
##han	I
and	O
its	O
meta	O
##bol	O
##ites	O
,	O
vitamin	O
B	O
-	O
6	O
,	O
and	O
lifestyle	O
data	O
,	O
including	O
smoking	O
status	O
,	O
reported	O
alcohol	O
intake	O
,	O
and	O
con	O
##tra	O
##ceptive	O
use	O
in	O
women	O
,	O
were	O
available	O
on	O
the	O
full	O
set	O
of	O
800	O
subjects	O
.	O

For	O
serum	O
samples	O
,	O
calcium	B
format	I
##e	I
(	O
50	O
μ	O
##L	O
)	O
of	O
known	O
concentration	O
was	O
used	O
as	O
the	O
internal	O
standard	O
;	O
for	O
W	O
##B	O
,	O
the	O
internal	O
standard	O
was	O
DS	O
##S	O
-	O
d	O
_	O
6	O
(	O
50	O
μ	O
##L	O
)	O
of	O
known	O
concentration	O
with	O
0	O
.	O
2	O
%	O
sodium	O
a	O
##zi	O
##de	O
.	O

Ace	B
##ty	I
##l	I
-	I
Co	I
##A	I
is	O
required	O
for	O
the	O
de	O
no	O
##vo	O
synthesis	O
of	O
fatty	O
acids	O
.	O

It	O
is	O
calculated	O
as	O
follows	O
:	O
T	O
##I	O
##m	O
=	O
R	O
##V	O
##H	O
##U	O
+	O
[UNK]	O
=	O
1	O
(	O
R	O
##V	O
##H	O
##U	O
+	O
N	O
##AF	O
##LD	O
##mi	O
##−	O
##R	O
##V	O
##H	O
##U	O
##mi	O
)	O
T	O
##I	O
##m	O
=	O
R	O
##V	O
##H	O
##U	O
+	O
[UNK]	O
=	O
1	O
(	O
R	O
##V	O
##H	O
##U	O
+	O
N	O
##AF	O
##LD	O
##mi	O
##−	O
##R	O
##V	O
##H	O
##U	O
##mi	O
)	O
T	O
##I	O
##m	O
=	O
R	O
##V	O
##H	O
##U	O
+	O
[UNK]	O
=	O
1	O
(	O
R	O
##V	O
##H	O
##U	O
+	O
N	O
##AF	O
##LD	O
##mi	O
##−	O
##R	O
##V	O
##H	O
##U	O
##mi	O
)	O
T	O
##I	O
##m	O
=	O
R	O
##V	O
##H	O
##U	O
+	O
[UNK]	O
=	O
1	O
(	O
R	O
##V	O
##H	O
##U	O
+	O
N	O
##AF	O
##LD	O
##mi	O
##−	O
##R	O
##V	O
##H	O
##U	O
##mi	O
)	O
T	O
##I	O
##m	O
=	O
R	O
##V	O
##H	O
##U	O
+	O
[UNK]	O
=	O
1	O
(	O
R	O
##V	O
##H	O
##U	O
+	O
N	O
##AF	O
##LD	O
##mi	O
##−	O
##R	O
##V	O
##H	O
##U	O
##mi	O
)	O
T	O
##I	O
##m	O
=	O
R	O
##V	O
##H	O
##U	O
+	O
[UNK]	O
=	O
1	O
(	O
R	O
##V	O
##H	O
##U	O
+	O
N	O
##AF	O
##LD	O
##mi	O
##−	O
##R	O
##V	O
##H	O
##U	O
##mi	O
)	O
T	O
##I	O
##m	O
T	O
##I	O
##m	O
T	O
##I	O
T	O
##I	O
T	O
##I	O
m	O
m	O
=	O
R	O
##V	O
##H	O
##U	O
+	O
[UNK]	O
=	O
1	O
(	O
R	O
##V	O
##H	O
##U	O
+	O
N	O
##AF	O
##LD	O
##mi	O
##−	O
##R	O
##V	O
##H	O
##U	O
##mi	O
)	O
R	O
##V	O
##H	O
##U	O
+	O
[UNK]	O
=	O
1	O
(	O
R	O
##V	O
##H	O
##U	O
+	O
N	O
##AF	O
##LD	O
##mi	O
##−	O
##R	O
##V	O
##H	O
##U	O
##mi	O
)	O
R	I
##V	I
##H	O
##U	O
+	O
N	O
##AF	O
##LD	O
##m	O

The	O
previously	O
saved	O
serum	O
samples	O
were	O
th	O
##awed	O
at	O
4	O
°C	O
,	O
200	O
µ	O
##L	O
of	O
it	O
was	O
taken	O
out	O
and	O
placed	O
in	O
1	O
.	O
5	O
m	O
##L	O
EP	O
tube	O
,	O
mixed	O
with	O
800	O
µ	O
##L	O
of	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
,	O
v	O
##ortex	O
##ed	O
for	O
2	O
minutes	O
,	O
and	O
then	O
cent	O
##ri	O
##fu	O
##ged	O
at	O
13	O
,	O
000	O
rpm	O
for	O
20	O
min	O
##s	O
at	O
4	O
°C	O
.	O

PR	O
##MT	O
,	O
a	O
##rg	O
##ini	O
##ne	O
N	O
-	O
met	O
##hyl	O
##tra	O
##ns	O
##fer	O
##ase	O
;	O
PM	O
,	O
plasma	O
membrane	O
;	O
CA	O
##T	O
##s	O
,	O
cat	O
##ion	O
##ic	O
amino	O
acid	O
transport	O
##ers	O
;	O
DD	O
##A	O
##H	O
,	O
dim	O
##eth	O
##yla	O
##rg	O
##ini	O
##ne	O
dim	O
##eth	O
##yla	O
##min	O
##oh	O
##ydro	O
##lase	O
;	O
D	B
##MA	I
,	O
dim	B
##eth	I
##yla	I
##mine	I
;	O
AD	B
##MA	I
,	O
as	B
##ym	I
##metric	I
dim	I
##eth	I
##yla	I
##rg	I
##ini	I
##ne	I
;	O
SD	O
##MA	O
,	O
symmetric	B
dim	I
##eth	I
##yla	I
##rg	I
##ini	I
##ne	I
;	O
NO	O
##S	O
,	O
ni	B
##tric	I
oxide	I
s	O
##ynth	O
##ase	O
;	O
NO	O
,	O
ni	B
##tric	I
oxide	I
;	O
AR	O
##G	O
,	O
a	O
##rg	O
##inas	O
##e	O
;	O
O	O
##DC	O
,	O
or	O
##ni	O
##thin	O
##e	O
de	O
##car	O
##box	O
##yla	O
##se	O
;	O
protein	O
-	O
CH	O
_	O
3	O
,	O
met	O
##hyl	O
##ated	O
proteins	O
.	O

To	O
analyze	O
15	B
-	I
H	I
##ET	I
##E	I
,	O
20	O
H	O
##ET	O
##E	O
,	O
11	O
(	O
12	O
)	O
-	O
Di	O
##H	O
##ET	O
and	O
14	O
(	O
15	O
)	O
-	O
Di	O
##H	O
##ET	O
a	O
modified	O
version	O
of	O
the	O
method	O
described	O
by	O
Man	O
##gal	O
et	O
al	O
.	O
was	O
used	O
.	O

In	O
a	O
sensitivity	O
analysis	O
including	O
H	O
##OM	O
##A	O
-	O
I	O
##R	O
and	O
2	O
h	O
glucose	S
as	O
additional	O
type	O
2	O
diabetes	O
risk	O
factors	O
,	O
meta	O
##bol	O
##ites	O
still	O
significantly	O
improved	O
type	O
2	O
diabetes	O
prediction	O
(	O
AU	O
##C	O
was	O
0	O
.	O
82	O
##8	O

Le	B
##uc	I
##ine	I
–	I
en	I
##ke	I
##pha	I
##lin	I
was	O
obtained	O
from	O
Waters	O
(	O
Warsaw	O
,	O
Poland	O
)	O
.	O

In	O
N	O
##MR	O
analyses	O
,	O
V	O
##LD	O
##L	O
/	O
L	O
##D	O
##L	O
fatty	O
a	O
##cy	O
##l	O
groups	O
,	O
la	B
##ct	I
##ate	I
,	O
g	B
##lut	I
##amine	I
,	O
and	O
37	O
lip	O
##op	O
##rote	O
##in	O
sub	O
##c	O
##lass	O
##es	O
(	O
mainly	O
from	O
the	O
HD	O
##L	O
fraction	O
##s	O
)	O
were	O
higher	O
in	O
serum	O
than	O
plasma	O
while	O
glucose	S
and	O
some	O
V	O
##LD	O
##L	O
,	O
L	O
##D	O
##L	O
,	O
and	O
ID	O
##L	O
sub	O
##c	O
##lass	O
##es	O
were	O
lower	O
.	O

This	O
sign	O
##ifies	O
the	O
need	O
and	O
magnitude	O
of	O
ATP	S
production	O
.	O

During	O
development	O
,	O
the	O
limit	O
of	O
q	O
##uant	O
##ification	O
of	O
cab	B
##oz	I
##anti	I
##ni	I
##b	I
was	O
expanded	O
from	O
300	O
to	O
100	O
μ	O
##g	O
/	O
L	O
to	O
cover	O
the	O
full	O
range	O
of	O
clinical	O
##ly	O
relevant	O
plasma	O
concentrations	O
.	O

Also	O
,	O
3	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##ira	I
##te	I
is	O
down	O
##re	O
##gu	O
##lated	O
in	O
c	O
##ir	O
##r	O
##hot	O
##ic	O
patients	O
(	O
G	O
##4	O
)	O
as	O
compared	O
to	O
G	O
##0	O
samples	O
which	O
has	O
been	O
already	O
observed	O
in	O
he	O
##pa	O
##titis	O
B	O
virus	O
-	O
infected	O
c	O
##ir	O
##r	O
##hos	O
##is	O
and	O
alcoholic	O
c	O
##ir	O
##r	O
##hos	O
##is	O
patients	O
by	O
using	O
_	O
1	O
H	O
N	O
##MR	O
-	O
based	O
meta	O
##bon	O
##omi	O
##cs	O
.	O

Ex	O
##ami	O
##ning	O
receiver	O
operating	O
characteristic	O
analysis	O
,	O
the	O
area	O
under	O
the	O
curve	O
was	O
0	O
.	O
660	O
for	O
su	B
##cci	I
##nate	I
and	O
CE	O
stroke	O
.	O

Mel	B
##aton	I
##in	I
and	O
me	B
##lat	I
##oni	I
##n	I
d	O
_	O
4	O
both	O
had	O
similar	O
high	O
recover	O
##ies	O
in	O
P	O
##EP	O
##2	O
and	O
C	O
##18	O
SP	O
##E	O
,	O
which	O
pointed	O
to	O
the	O
fact	O
this	O
result	O
may	O
be	O
due	O
to	O
co	O
-	O
suppression	O
of	O
spike	O
##d	O
meta	O
##bol	O
##ites	O
.	O

Try	B
##pt	I
##op	I
##han	I
is	O
the	O
precursor	O
of	O
several	O
ne	O
##uro	O
##tra	O
##ns	O
##mit	O
##ters	O
and	O
hormones	O
such	O
as	O
se	B
##rot	I
##oni	I
##n	I
and	O
me	B
##lat	I
##oni	I
##n	I
,	O
but	O
also	O
of	O
k	B
##yn	I
##uren	I
##ine	I
and	O
its	O
downstream	O
cat	O
##ab	O
##oli	O
##tes	O
.	O

Do	O
##se	O
-	O
reduction	O
studies	O
,	O
such	O
as	O
the	O
Phase	O
3	O
clinical	O
studies	O
designated	O
TO	O
##PS	O
(	O
acronym	O
for	O
Ty	B
##ros	I
##ine	I
Ki	O
##nas	O
##e	O
In	O
##hibit	O
##or	O
Op	O
##ti	O
##mi	O
##zation	O
and	O
Select	O
##ivity	O
)	O
,	O
which	O
compared	O
400	O
mg	O
/	O
day	O
doses	O
to	O
800	O
mg	O
/	O
day	O
doses	O
,	O
have	O
reported	O
reduction	O
##s	O
in	O
adverse	O
side	O
effects	O
.	O

In	O
brief	O
,	O
du	O
##plicate	O
in	O
##cu	O
##bation	O
##s	O
were	O
conducted	O
at	O
37	O
±	O
1	O
##°	O
##C	O
in	O
400	O
μ	O
##L	O
in	O
##cu	O
##bation	O
mixture	O
##s	O
containing	O
potassium	B
phosphate	I
buffer	O
(	O
50	O
m	O
##M	O
,	O
pH	O
7	O
.	O
4	O
)	O
,	O
M	O
##g	O
##C	O
##l	O
_	O
2	O
(	O
3	O
m	O
##M	O
)	O
,	O
E	O
##D	O
##TA	O

The	O
in	O
##tra	O
class	O
correlation	O
coefficient	O
for	O
total	O
est	B
##rad	I
##iol	I
over	O
a	O
six	O
-	O
year	O
period	O
was	O
0	O
.	O
73	O
in	O
one	O
study	O
,	O
although	O
the	O
authors	O
note	O
that	O
in	O
##tra	O
class	O
correlation	O
coefficients	O
in	O
prior	O
studies	O
ranged	O
from	O
0	O
.	O
36	O
to	O
0	O
.	O
69	O
over	O
shorter	O
time	O
periods	O
.	O

The	O
mass	O
s	O
##pect	O
##rome	O
##ter	O
was	O
operated	O
in	O
negative	O
mode	O
with	O
the	O
following	O
MR	O
##M	O
transitions	O
(	O
m	O
/	O
z	O
)	O
:	O
35	O
##3	O
/	O
193	O
[	O
i	O
##P	O
##F	O
(	O
2	O
alpha	O
)	O
-	O
III	O
]	O
,	O
35	O
##7	O
/	O
197	O
[	O
i	O
##P	O
##F	O
(	O
2	O
alpha	O
)	O
-	O
III	O
-	O
d	O
##4	O
]	O
,	O
325	O
/	O
237	O
[	B
2	B
,	I
3	I
-	I
din	I
##or	I
-	I
i	I
##P	I
##F	I
(	I
2	I
alpha	I
)	I
-	O
III	O
]	O
,	O
35	O
##3	O
/	O
115	O
[	O
i	O
##P	O
##F	O
(	O
2	O
alpha	O
)	O
-	O
VI	O
and	O
8	B
,	I
12	I
-	I
is	I
##o	I
-	I
i	I
##P	I
##F	I
(	I
2	I
alpha	I
)	I
-	O
VI	O
]	O
,	O
36	O
##4	O
/	O
115	O
[	O
i	O
##P	O
##F	O
(	O
2	O
alpha	O
)	O
-	O
VI	O
-	O
d	O
##11	O
]	O
,	O
and	O
35	O
##7	O
/	O
115	O

The	O
bulk	O
powder	O
##s	O
were	O
tested	O
for	O
micro	O
##bial	O
con	O
##tam	O
##ina	O
##nts	O
prior	O
to	O
release	O
by	O
Oregon	O
Free	O
##ze	O
Dry	O
and	O
again	O
upon	O
re	O
##ceipt	O
in	O
Baltimore	O
(	O
I	O
##E	O
##H	O
-	O
J	O
##L	O
Ana	O
##ly	O
##tical	O
Services	O
,	O
Mode	O
##sto	O
,	O
CA	O
and	O
Euro	O
##fin	O
##s	O
St	O
##ras	O
##burg	O
##er	O
&	O
Siege	O
##l	O
,	O
Hanover	O
,	O
MD	O
)	O
,	O
heavy	O
metals	O
(	O
El	O
##ement	O
##al	O
Analysis	O
,	O
Inc	O
.	O
,	O
Lexington	O
,	O
K	O
##Y	O
)	O
and	O
ben	B
##zen	I
##e	I
(	O
Test	O
##A	O
##mer	O
##ica	O
,	O
Pittsburgh	O
,	O
PA	O
)	O
.	O

As	O
shown	O
in	O
(	B
Met	B
##han	I
##ol	I
precipitation	O
)	O
and	O
1	O
##B	O
(	B
Met	B
##han	I
##ol	I
-	I
ethanol	I
precipitation	O
)	O
,	O
while	O
most	O
compounds	O
were	O
recovered	O
and	O
resolved	O
using	O
R	O
##PC	O
,	O
ch	B
##ole	I
##ster	I
##ol	I
and	O
T	B
##G	I
(	I
17	I
:	I
2	I
/	I
17	I
:	I
2	I
/	I
18	I
:	I
0	I
)	I
were	O
not	O
seen	O
when	O
either	O
precipitation	O
method	O
was	O
used	O
.	O
also	O
includes	O
data	O
resulting	O
from	O
M	B
##T	I
##BE	I
extraction	O
and	O
M	B
##T	I
##BE	I
:	O
SP	O
##E	O
extraction	O
,	O
as	O
discussed	O
in	O
detail	O
later	O
.	O

Whereas	O
put	B
##res	I
##cine	I
and	O
sperm	B
##id	I
##ine	I
appear	O
to	O
affect	O
pro	O
##ins	O
##ulin	O
bio	O
##sy	O
##nt	O
##hesis	O
,	O
sperm	B
##ine	I
may	O
have	O
a	O
s	O
##ti	O
##mu	O
##lator	O
##y	O
role	O
in	O
long	O
-	O
term	O
insulin	O
release	O
.	O

Though	O
we	O
are	O
unable	O
to	O
identify	O
studies	O
examining	O
the	O
effects	O
of	O
diet	O
##ary	O
l	B
##ino	I
##le	I
##ic	I
acid	I
intake	O
on	O
V	O
##O	O
_	O
2	O
peak	O
,	O
studies	O
do	O
not	O
support	O
supplement	O
##ation	O
with	O
con	O
##ju	O
##gated	O
l	B
##ino	I
##le	I
##ic	I
acids	I
,	O
is	O
##omer	O
##s	O
of	O
l	B
##ino	I
##le	I
##ic	I
acid	I
.	O
_	O
,	O
However	O
,	O
a	O
higher	O
diet	O
##ary	O
intake	O
of	O
l	B
##ino	I
##le	I
##ic	I
acid	I
may	O
protect	O
against	O
is	O
##che	O
##mic	O
stroke	O
.	O
_	O
,	O
Dec	O
##reased	O
blood	O
pressure	O
,	O
lip	O
##ids	O
,	O
glucose	S
,	O
as	O
well	O
as	O
reduced	O
plate	O
##let	O
a	O
##gg	O
##regation	O
,	O
and	O
enhanced	O
def	O
##orm	O
##ability	O
of	O
er	O
##yt	O
##hr	O
##oc	O
##yte	O
cells	O
,	O
are	O
proposed	O
as	O
potential	O
mechanisms	O
of	O
this	O
apparent	O
protective	O
effect	O
.	O

L	B
##ys	I
##o	I
-	I
g	I
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
(	O
LP	O
##L	O
##s	O
)	O
including	O
LP	O
##C	O
,	O
LP	O
##I	O
,	O
LP	O
##G	O
,	O
and	O
LP	O
##E	O
were	O
also	O
found	O
in	O
the	O
serum	O
sample	O
with	O
a	O
diverse	O
fatty	O
a	O
##cy	O
##l	O
chain	O
length	O
of	O
12	O
–	O
22	O
carbon	O
.	O

Eleven	O
subjects	O
(	O
55	O
%	O
)	O
displayed	O
reduction	O
##s	O
in	O
energy	O
restriction	O
-	O
associated	O
metabolic	O
gene	O
pathways	O
including	O
lip	O
##id	O
synthesis	O
,	O
g	O
##lu	O
##con	O
##eo	O
##genesis	O
and	O
g	B
##ly	I
##co	I
##gen	I
synthesis	O
.	O

This	O
change	O
,	O
coupled	O
with	O
the	O
above	O
-	O
mentioned	O
en	O
##rich	O
##ments	O
for	O
L	O
##CF	O
##As	O
and	O
ch	B
##ole	I
##ster	I
##ols	I
,	O
is	O
consistent	O
with	O
previously	O
suggested	O
per	O
##tur	O
##bation	O
##s	O
of	O
fatty	O
acid	O
metabolism	O
in	O
I	O
##B	O
##D	O
.	O

Sal	O
##iva	O
and	O
oral	O
micro	O
##f	O
##lora	O
contributions	O
to	O
ant	B
##ho	I
##cy	I
##ani	I
##n	I
metabolism	O
were	O
assessed	O
via	O
p	O
##har	O
##ma	O
##co	O
##kin	O
##etic	O
analyses	O
of	O
three	O
different	O
BR	O
##B	O
r	O
##ins	O
##e	O
formulation	O
##s	O
as	O
well	O
as	O
functional	O
activity	O
ass	O
##ays	O
.	O

When	O
met	B
##han	I
##ol	I
was	O
used	O
for	O
extraction	O
,	O
an	O
additional	O
44	O
##1	O
(	O
512	O
–	O
71	O
)	O
features	O
were	O
found	O
compared	O
to	O
positive	O
mode	O
.	O

In	O
##tra	O
##cellular	O
reactive	O
oxygen	O
species	O
(	O
R	O
##OS	O
)	O
was	O
detected	O
by	O
di	B
##hy	I
##dr	I
##oe	I
##thi	I
##dium	I
ass	O
##ay	O
.	O

Fi	O
##g	O
.	O
)	O
of	O
the	O
build	O
##up	O
of	O
various	O
_	O
13	O
C	O
position	O
##al	O
is	O
##oto	O
##po	O
##mers	O
of	O
meta	O
##bol	O
##ites	O
including	O
[	O
_	O
13	O
C	O
-	O
3	O
]	O
-	O
Al	O
##a	O
,	O
[	B
_	I
13	I
C	I
-	I
2	I
,	I
3	I
]	I
-	I
la	I
##ct	I
##ate	I
,	O
[	B
_	I
13	I
C	I
-	I
2	I
,	I
3	I
,	I
4	I
]	I
-	I
G	I
##lu	I
,	O
[	O
_	O
13	O
C	O
-	O
4	O
]	O
-	O
G	O
##ln	O
,	O
[	B
_	I
13	I
C	I
-	I
2	I
,	I
3	I
]	I
-	I
As	I
##p	I
,	O
[	B
_	I
13	I
C	I
-	I
2	I
,	I
4	I
]	I
-	I
c	I
##it	I
##rate	I
and	O
[	B
_	I
13	I
C	I
##2	I
,	I
3	I
]	I
-	I
su	I
##cci	I
##nate	I
for	O
the	O
tumor	O
,	O
compared	O
with	O
the	O
paired	O
non	O
-	O
cancer	O
##ous	O
tissues	O
of	O
#	O
6	O
.	O

Those	O
that	O
increase	O
in	O
the	O
severe	O
group	O
correspond	O
to	O
meta	O
##bol	O
##ites	O
revealing	O
an	O
enhanced	O
protein	O
cat	O
##ab	O
##olis	O
##m	O
such	O
as	O
u	B
##ro	I
##bil	I
##ino	I
##gen	I
and	O
g	B
##lut	I
##ami	I
##ny	I
##l	I
-	I
se	I
##rine	I
and	O
the	O
mob	O
##ilization	O
of	O
membrane	O
lip	O
##ids	O
involved	O
in	O
inflammation	O
,	O
immune	O
response	O
and	O
q	O
##ui	O
##mio	O
##ta	O
##xi	O
##s	O
(	B
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
and	O
s	B
##phi	I
##ngo	I
##sin	I
##e	I
-	I
1	I
-	I
phosphate	I
.	O

Our	O
observation	O
of	O
the	O
higher	O
levels	O
of	O
ta	B
##uri	I
##ne	I
and	O
s	O
##cy	O
##llo	O
-	O
in	O
##os	O
##ito	O
##l	O
in	O
CR	O
##C	O
tissues	O
than	O
in	O
AN	O
##IT	O
was	O
in	O
##dicative	O
of	O
a	O
localized	O
change	O
in	O
o	O
##smo	O
##tic	O
regulation	O
in	O
CR	O
##C	O
tumor	O
tissues	O
since	O
both	O
these	O
meta	O
##bol	O
##ites	O
may	O
function	O
as	O
o	O
##smo	O
##tic	O
re	O
##gu	O
##lative	O
meta	O
##bol	O
##ites	O
though	O
ta	B
##uri	I
##ne	I
could	O
have	O
multiple	O
functions	O
.	O

These	O
included	O
su	B
##c	I
##rose	I
,	O
1	B
,	I
6	I
-	I
an	I
##hy	I
##dr	I
##o	I
-	I
D	I
-	I
beta	I
-	I
glucose	I
,	O
ad	B
##ip	I
##ate	I
,	O
2	B
-	I
h	I
##yr	I
##ox	I
##yi	I
##so	I
##but	I
##yra	I
##te	I
,	O
as	B
##cor	I
##bate	I
,	O
ethanol	S
and	O
x	B
##yl	I
##ose	I
.	O

At	O
24	O
h	O
,	O
the	O
trip	B
##hos	I
##phate	I
meta	O
##bol	O
##ites	O
accounted	O
for	O
approximately	O
70	O
%	O
of	O
the	O
total	O
in	O
##tra	O
##cellular	O
meta	O
##bol	O
##ites	O
for	O
both	O
so	B
##fo	I
##s	I
##bu	I
##vir	I
and	O
rib	B
##avi	I
##rin	I
.	O

Another	O
metabolic	O
fate	O
of	O
h	B
##ydro	I
##xy	I
##p	I
##rol	I
##ine	I
is	O
g	B
##ly	I
##ox	I
##yla	I
##te	I
,	O
which	O
can	O
be	O
trans	O
##ami	O
##nated	O
in	O
mit	O
##och	O
##ond	O
##ria	O
to	O
produce	O
g	B
##ly	I
##cine	I
and	O
meta	O
##bol	O
##ized	O
in	O
per	O
##ox	O
##is	O
##ome	O
##s	O
to	O
o	B
##xa	I
##late	I
and	O
per	B
##oxide	I
for	O
cell	O
defense	O
and	O
inn	O
##ate	O
and	O
anti	O
##vir	O
##al	O
immunity	O
.	O

Sign	O
##ificant	O
##ly	O
altered	O
meta	O
##bol	O
##ites	O
caused	O
by	O
high	O
temperature	O
(	O
40	O
°C	O
)	O
in	O
urine	O
samples	O
with	O
no	O
pre	O
##ser	O
##vat	O
##ive	O
or	O
preserved	O
with	O
thy	B
##mo	I
##l	I
in	O
the	O
PA	O
##BA	O
group	O
.	O

Re	O
##ct	O
##al	O
administration	O
of	O
met	B
##had	I
##one	I
may	O
be	O
an	O
alternative	O
to	O
in	O
##tra	O
##ven	O
##ous	O
and	O
oral	O
dos	O
##ing	O
in	O
cancer	O
pain	O
,	O
but	O
the	O
bio	O
##ava	O
##ila	O
##bility	O
of	O
the	O
re	O
##ct	O
##al	O
route	O
is	O
not	O
known	O
.	O

The	O
samples	O
were	O
re	O
##sus	O
##pen	O
##ded	O
in	O
8	O
##μ	O
##L	O
of	O
met	B
##han	I
##ol	I
,	O
placed	O
in	O
du	O
##plicate	O
of	O
1	O
##μ	O
##L	O
per	O
spot	O
on	O
M	O
##TP	O
38	O
##4	O
plate	O
(	O
B	O
##ruk	O
##er	O
Dalton	O
##ics	O
,	O
Bremen	O
,	O
Germany	O
)	O
and	O
topped	O
with	O
1	O
##μ	O
##L	O
of	O
2	B
,	I
5	I
-	I
di	I
##hy	I
##dr	I
##ox	I
##y	I
##ben	I
##zoic	I
acid	I
(	O
D	O
##H	O
##B	O
)	O
and	O
4	B
-	I
h	I
##ydro	I
##xy	I
##cin	I
##nam	I
##ic	I
acid	I
(	O
CH	O
##CA	O
)	O
,	O
both	O
at	O
the	O
concentration	O
of	O
7	O
##m	O
##g	O
/	O
m	O
##l	O
,	O
0	O
.	O
01	O
%	O
t	B
##ri	I
##f	I
##lu	I
##oro	I
##ace	I
##tic	I
acid	I
(	O
T	O
##FA	O
)	O
,	O
dissolved	O
in	O
70	O
%	O
met	B
##han	I
##ol	I
and	O
30	O
%	O
water	O
.	O

C	B
##rea	I
##tin	I
##ine	I
levels	O
were	O
obtained	O
to	O
adjust	O
E	O
##M	O
levels	O
for	O
differences	O
in	O
urine	O
volume	O
.	O

The	O
following	O
u	O
##rina	O
##ry	O
p	B
##ht	I
##hala	I
##te	I
and	O
D	O
##IN	O
##CH	O
meta	O
##bol	O
##ites	O
and	O
were	O
analyzed	O
:	O
Mon	B
##o	I
(	I
2	I
-	I
et	I
##hyl	I
##he	I
##xy	I
##l	I
)	I
p	I
##ht	I
##hala	I
##te	I
(	O
ME	O
##HP	O
)	O
;	O
Mon	B
##o	I
(	I
2	I
-	I
et	I
##hyl	I
-	I
5	I
-	I
h	I
##ydro	I
##xy	I
##he	I
##xy	I
##l	I
)	I
p	I
##ht	I
##hala	I
##te	I
(	O
ME	O
##H	O
##HP	O
)	O
;	O
Mon	B
##o	I
(	I
2	I
-	I
et	I
##hyl	I
-	I
5	I
-	I
o	I
##x	I
##oh	I
##ex	I
##yl	I
)	I
p	I
##ht	I
##hala	I
##te	I
(	O
ME	O
##OH	O
##P	O
)	O
;	O
Mon	B
##o	I
(	I
2	I
-	I
et	I
##hyl	I
-	I
5	I
-	I
car	I
##box	I
##ype	I
##nt	I
##yl	I
)	I
p	I
##ht	I
##hala	I
##te	I
(	O
ME	O
##CP	O
##P	O
)	O
;	O
Mon	B
##oc	I
##ar	I
##b	I
##xy	I
##is	I
##oo	I
##ct	I
##yl	I
p	I
##ht	I
##hala	I
##te	I
(	O
MC	O
##OP	O
)	O
;	O
Mon	B
##o	I
-	I
is	I
##ono	I
##ny	I
##l	I
p	I
##ht	I
##hala	I
##te	I
(	O
M	O
##NP	O
)	O
;	O
Mon	B
##obe	I
##nz	I
##yl	I
p	I
##ht	I
##hala	I
##te	I
(	O
MB	O
##z	O
##P	O
)	O
;	O
Mon	O
##o	O
(	O
3	O
-	O
car	O
##box	O
##y	O
##p	O
##rop	O
##yl	O
)	O

Final	O
analyses	O
of	O
the	O
meta	O
##bol	O
##ite	O
data	O
##set	O
were	O
completed	O
after	O
removal	O
of	O
c	B
##it	I
##rate	I
levels	O
.	O

Blood	O
for	O
co	B
##rt	I
##is	I
##ol	I
determination	O
was	O
collected	O
peripheral	O
##ly	O
via	O
in	O
##tra	O
##ven	O
##ous	O
(	O
IV	O
)	O
cat	O
##he	O
##ter	O
1	O
h	O
##r	O
after	O
sleep	O
onset	O
in	O
silicon	O
##e	O
-	O
coated	O
tubes	O
,	O
cent	O
##ri	O
##fu	O
##ged	O
,	O
and	O
the	O
serum	O
layer	O
removed	O
.	O

The	O
3	O
ID	O
##O	O
-	O
T	O
##Ms	O
with	O
trans	O
##pu	O
##lm	O
##ona	O
##ry	O
release	O
in	O
the	O
high	O
-	O
P	O
##VR	O
group	O
(	B
ant	B
##hra	I
##ni	I
##late	I
,	O
q	B
##uin	I
##olin	I
##ate	I
,	O
and	O
k	O
##yn	O
##uren	O
##ine	O
)	O
demonstrated	O
significantly	O
higher	O
levels	O
in	O
PA	O
##H	O
,	O
with	O
C	O
-	O
statistics	O
of	O
0	O
.	O
79	O
to	O
0	O
.	O
86	O
;	O
k	B
##yn	I
##uren	I
##ate	I
did	O
not	O
differ	O
between	O
groups	O
.	O

Li	O
##pid	O
##s	O
are	O
the	O
major	O
species	O
of	O
cell	O
membrane	O
##s	O
and	O
removal	O
of	O
one	O
of	O
the	O
FA	S
results	O
in	O
the	O
increase	O
of	O
l	B
##ys	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
(	O
LP	O
##L	O
)	O
usually	O
through	O
the	O
en	O
##zy	O
##matic	O
action	O
of	O
a	O
p	O
##hos	O
##ph	O
##oli	O
##pas	O
##e	O
A2	O
(	O
P	O
##LA	O
##2	O
)	O
.	O

This	O
is	O
consistent	O
with	O
a	O
previous	O
report	O
that	O
mi	O
##g	O
##lus	O
##tat	O
treatment	O
reduces	O
T	B
##G	I
plasma	O
levels	O
in	O
patients	O
with	O
G	O
##au	O
##cher	O
’	O
s	O
disease	O
.	O

Also	O
,	O
New	O
##ki	O
##rk	O
et	O
al	O
.	O
reported	O
that	O
the	O
r	O
##he	O
##uma	O
##to	O
##id	O
factor	O
avid	O
##ity	O
was	O
significantly	O
correlated	O
with	O
the	O
presence	O
of	O
the	O
g	B
##ly	I
##co	I
##form	I
of	O
I	O
##g	O
##G	O
lacking	O
gal	B
##act	I
##ose	I
in	O
both	O
circulating	O
and	O
immune	O
complexes	O
-	O
derived	O
I	O
##g	O
##G	O
.	O
G	B
##ly	I
##co	I
-	I
bio	I
##mark	I
##ers	I
also	O
reflect	O
RA	O
activity	O
and	O
pro	O
##gno	O
##sis	O
as	O
they	O
are	O
correlated	O
with	O
r	O
##he	O
##uma	O
##to	O
##id	O
factor	O
,	O
tender	O
joint	O
score	O
,	O
and	O
frequency	O
of	O
sub	O
##cut	O
##aneous	O
nod	O
##ules	O
as	O
well	O
as	O
structural	O
damage	O
[	O
–	O
]	O
.	O

Previous	O
studies	O
showed	O
that	O
my	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
acts	O
as	O
a	O
cancer	O
ch	O
##em	O
##op	O
##re	O
##vention	O
agent	O
[	O
,	O
]	O
.	O

The	O
L	O
##OD	O
##s	O
for	O
D	B
##A	I
-	I
3	I
-	I
O	I
-	I
and	O
D	B
##A	I
-	I
4	I
-	I
O	I
-	I
S	I
,	O
H	O
##VA	O
,	O
D	O
##OP	O
##AC	O
,	O
5	B
-	I
H	I
##IA	I
##A	I
,	O
and	O
their	O
g	O
##lu	O
##cu	O
##ron	O
##ides	O
and	O
su	B
##lf	I
##ates	I
in	O
the	O
negative	O
ion	O
mode	O
varied	O
between	O
0	O
.	O
3	O
and	O
25	O
n	O
##M	O
(	O
4	O
.	O
5	O
–	O
375	O
f	O
##mo	O
##l	O
injected	O
on	O
the	O
column	O
)	O
.	O

For	O
correlation	O
the	O
p	O
values	O
are	O
for	O
S	O
##pear	O
##man	O
’	O
s	O
correlation	O
analysis	O
and	O
group	O
-	O
wise	O
p	O
values	O
are	O
for	O
the	O
Wilcox	O
##on	O
test	O
The	O
previous	O
CE	B
##R	I
study	O
included	O
abdominal	O
sub	O
##cut	O
##aneous	O
fat	O
and	O
breast	O
bio	O
##ps	O
##ies	O
.	O

The	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
composition	O
was	O
then	O
held	O
at	O
95	O
%	O
AC	O
##N	O
for	O
1	O
min	O
before	O
returning	O
to	O
the	O
initial	O
conditions	O
for	O
column	O
re	O
-	O
e	O
##qui	O
##li	O
##bra	O
##tion	O
prior	O
to	O
the	O
next	O
analysis	O
.	O

Sign	O
##ific	O
##ance	O
:	O
<	O
0	O
.	O
05	O
‘	O
*	O
’	O
T	O
##rp	O
try	B
##pt	I
##op	I
##han	I
,	O
K	O
##yn	O
k	B
##yn	I
##uren	I
##ine	I
,	O
K	O
##TR	O
k	B
##yn	I
##uren	I
##ine	I
/	I
try	I
##pt	I
##op	I
##han	I
ratio	O
,	O
HK	O
3	B
-	I
h	I
##ydro	I
##xy	I
##ky	I
##nu	I
##ren	I
##ine	I
,	O
K	O
##A	O
k	B
##yn	I
##uren	I
##ic	I
acid	I
,	O
X	O
##A	O
x	B
##ant	I
##hur	I
##eni	I
##c	I
acid	I
,	O
AA	O
ant	B
##hra	I
##ni	I
##lic	I
acid	I
,	O
H	O
##AA	O
3	B
-	I
h	I
##ydro	I
##xy	I
##ant	I
##hra	I
##ni	I
##lic	I
acid	I
,	O
Q	O
##A	O
q	B
##uin	I
##olin	I
##ic	I
acid	I
,	O

In	O
addition	O
,	O
T	O
##S	O
##H	O
suppression	O
therapy	O
had	O
an	O
impact	O
on	O
metabolism	O
,	O
and	O
abnormal	O
meta	O
##bol	O
##ites	O
were	O
increased	O
(	O
e	O
.	O
g	O
.	O
,	O
ta	B
##uri	I
##ne	I
and	O
glucose	S
)	O
.	O

Con	O
##sist	O
##ent	O
with	O
a	O
previous	O
report	O
,	O
as	O
ch	B
##olin	I
##e	I
demand	O
increases	O
in	O
tumor	O
tissues	O
,	O
blood	O
ch	B
##olin	I
##e	I
levels	O
drop	O
,	O
leading	O
to	O
decreased	O
u	O
##rina	O
##ry	O
ch	B
##olin	I
##e	I
in	O
CR	O
##C	O
patients	O
.	O

We	O
found	O
nominally	O
positive	O
correlation	O
##s	O
between	O
the	O
relative	O
concentrations	O
of	O
6	O
meta	O
##bol	O
##ites	O
(	B
is	B
##ole	I
##uc	I
##ine	I
,	O
le	B
##uc	I
##ine	I
,	O
2	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yric	I
acid	I
,	O
v	B
##ali	I
##ne	I
,	O
3	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yric	I
acid	I
,	O
and	O
2	B
-	I
amino	I
##adi	I
##pic	I
acid	O
)	O
and	O
HD	O
##SR	O
scores	O
(	O
r	O
=	O
0	O
.	O
59	O
##3	O
,	O
r	O
=	O
0	O
.	O
47	O
##3	O
,	O
r	O
=	O
0	O
.	O
42	O
##1	O
,	O
r	O
=	O
0	O
.	O
44	O
##8	O
,	O
r	O
=	O
0	O
.	O
42	O
##4	O
,	O
r	O
=	O
0	O
.	O
36	O
##7	O
,	O
and	O
r	O
=	O
0	O
.	O
35	O
##4	O
,	O
respectively	O
;	O
p	O
<	O
0	O
.	O
05	O
;	O
S	O
##pear	O
##man	O
rank	O
correlation	O
##s	O
)	O
.	O

In	O
addition	O
to	O
the	O
23	O
protein	O
##ogenic	O
(	O
20	O
DNA	O
-	O
encoded	O
)	O
α	O
-	O
amino	O
acids	O
(	O
AA	O
##s	O
)	O
,	O
the	O
library	O
contained	O
61	O
β	O
-	O
AA	O
##s	O
,	O
unusual	O
AA	O
##s	O
and	O
small	O
p	O
##eptide	O
##s	O
whose	O
common	O
feature	O
is	O
the	O
presence	O
of	O
charge	O
##able	O
amino	S
and	O
car	B
##box	I
##yla	I
##te	I
groups	O
.	O

A	O
lit	B
##hia	I
##ted	I
t	I
##ria	I
##cy	I
##l	I
##gly	I
##cer	I
##ol	I
species	O
at	O
m	O
/	O
z	O
83	O
##7	O
.	O
7	O
must	O
contain	O
53	O
total	O
carbon	O
atoms	O
with	O
2	O
double	O
bonds	O
or	O
54	O
total	O
carbon	O
atoms	O
with	O
9	O
double	O
bonds	O
,	O
and	O
the	O
ion	O
in	O
##tens	O
##ities	O
resulting	O
from	O
the	O
neutral	O
loss	O
of	O
the	O
three	O
a	O
##cy	O
##l	O
chains	O
from	O
a	O
given	O
T	O
##AG	O
molecule	O
are	O
nearly	O
equal	O
.	O

Our	O
data	O
show	O
that	O
N	O
##SC	O
##LC	O
patients	O
,	O
compared	O
with	O
healthy	O
individuals	O
,	O
exhibit	O
higher	O
serum	O
levels	O
of	O
le	O
##uc	O
##ine	O
/	O
is	O
##ole	O
##uc	O
##ine	O
(	O
15	O
.	O
75	O
%	O
)	O
,	O
N	B
-	I
ace	I
##ty	I
##l	I
-	I
c	I
##ys	I
##tein	I
##e	I
(	O
14	O
.	O
94	O
%	O
)	O
and	O
g	B
##lut	I
##ama	I
##te	I
(	O
37	O
.	O
65	O
%	O
)	O
,	O
and	O
lower	O
levels	O
of	O
g	B
##lut	I
##amine	I
(	O
−	O
##14	O
.	O
37	O
%	O
)	O
,	O
th	B
##re	I
##oni	I
##ne	I
(	O
−	O
##15	O
.	O
34	O
%	O
)	O
and	O
his	B
##ti	I
##dine	I
(	O
−	O
##20	O
.	O
76	O
%	O
)	O
.	O

The	O
ins	O
##et	O
is	O
its	O
data	O
-	O
dependent	O
MS	O
/	O
MS	O
scan	O
giving	O
fragments	O
of	O
135	O
,	O
119	O
,	O
and	O
59	O
m	O
/	O
z	O
indicating	O
fragments	O
of	O
the	O
proposed	O
h	B
##ydro	I
##xy	I
##phe	I
##ny	I
##l	I
##but	I
##yric	I
acid	I
meta	O
##bol	O
##ite	O
shown	O
.	O

I	O
##dent	O
##ified	O
meta	O
##bol	O
##ites	O
were	O
related	O
to	O
the	O
bra	B
##dy	I
##kini	I
##n	I
system	O
,	O
involved	O
in	O
o	O
##xi	O
##da	O
##tive	O
stress	O
(	O
e	O
.	O
g	O
.	O
,	O
g	B
##lut	I
##amine	I
or	O
pipe	B
##cola	I
##te	I
)	O
or	O
linked	O
to	O
the	O
u	B
##rea	I
cycle	O
(	O
e	O
.	O
g	O
.	O
,	O
or	B
##ni	I
##thin	I
##e	I
or	O
c	O
##it	O
##ru	O
##llin	O
##e	O
)	O
.	O

Part	O
##ici	O
##pants	O
who	O
had	O
incident	O
major	O
adverse	O
card	O
##iovascular	O
events	O
during	O
3	O
years	O
of	O
follow	O
-	O
up	O
had	O
higher	O
risk	O
profiles	O
at	O
base	O
##line	O
than	O
those	O
without	O
events	O
,	O
including	O
an	O
older	O
age	O
,	O
higher	O
fast	O
##ing	O
glucose	S
levels	O
,	O
and	O
higher	O
rates	O
of	O
diabetes	O
,	O
h	O
##yper	O
##tens	O
##ion	O
,	O
and	O
previous	O
my	O
##oc	O
##ard	O
##ial	O
in	O
##far	O
##ction	O
.	O

These	O
bio	O
##mark	O
##ers	O
can	O
be	O
identified	O
as	O
either	O
meta	O
##bol	O
##ites	O
of	O
SP	O
##B	O
itself	O
,	O
such	O
as	O
g	B
##lu	I
##cu	I
##ron	I
##ide	I
con	O
##ju	O
##gate	O
##s	O
,	O
or	O
molecules	O
from	O
other	O
metabolic	O
pathways	O
that	O
are	O
being	O
affected	O
by	O
SP	O
##B	O
treatment	O
.	O

It	O
was	O
also	O
demonstrated	O
that	O
many	O
cancer	O
cells	O
survive	O
without	O
g	B
##lut	I
##amine	I
and	O
only	O
use	O
am	O
##monia	O
as	O
a	O
nitrogen	O
source	O
.	O

In	O
a	O
parallel	O
-	O
group	O
,	O
four	O
-	O
arm	O
,	O
random	O
##ized	O
trial	O
,	O
69	O
patients	O
(	O
66	O
%	O
men	O
)	O
were	O
assigned	O
to	O
24	O
-	O
week	O
-	O
intervention	O
using	O
:	O
(	O
i	O
)	O
corn	O
oil	O
(	O
5	O
g	O
/	O
day	O
;	O
Place	O
##bo	O
)	O
,	O
(	O
ii	O
)	O
p	B
##io	I
##gli	I
##ta	I
##zone	I
(	O
15	O
mg	O
/	O
day	O
;	O
Pi	O
##o	O
)	O
,	O
(	O
ii	O
##i	O
)	O
EPA	O
+	O
D	O
##HA	O
concentrate	O
(	O
5	O
g	O
/	O
day	O
,	O
containing	O
~	O
2	O
.	O
8	O
g	O
EPA	O
+	O
D	O
##HA	O
;	O
Omega	B
-	I
3	I
)	O
,	O
or	O
(	O
i	O
##v	O
)	O
p	B
##io	I
##gli	I
##ta	I
##zone	I
and	O
EPA	O
+	O
D	O
##HA	O
concentrate	O
(	O
Pi	O
##o	O
&	O
Omega	B
-	I
3	I
)	O
.	O

P	O
##t	O
##d	O
##C	O
##ho	O
indicates	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
in	O
cell	O
membrane	O
##s	O
which	O
is	O
invisible	O
to	O
H	O
##R	O
##MA	O
##S	O
_	O
1	O
H	O
N	O
##MR	O
.	O

Car	O
##tri	O
##dges	O
were	O
subsequently	O
washed	O
with	O
1	O
m	O
##L	O
of	O
H	O
_	O
2	O
O	O
and	O
1	O
m	O
##L	O
of	O
a	O
##que	O
##ous	O
30	O
%	O
met	B
##han	I
##ol	I
,	O
followed	O
by	O
drying	O
using	O
negative	O
pressure	O
.	O

The	O
normal	O
reference	O
interval	O
for	O
beta	B
##ine	I
was	O
confirmed	O
in	O
two	O
populations	O
,	O
a	O
co	O
##hor	O
##t	O
of	O
apparently	O
healthy	O
volunteers	O
and	O
the	O
full	O
set	O
of	O
PR	O
##E	O
##VE	O
##ND	O
co	O
##hor	O
##t	O
participants	O
.	O

A	O
##β	O
1	O
-	O
42	O
,	O
ta	O
##u	O
,	O
and	O
p	B
##hos	I
##ph	I
##o	I
-	I
ta	I
##u	I
levels	O
were	O
evaluated	O
via	O
enzyme	O
-	O
linked	O
im	O
##mu	O
##nos	O
##or	O
##bent	O
ass	O
##ay	O
(	O
E	O
##L	O
##IS	O
##A	O
)	O

For	O
hybrid	O
##isation	O
with	O
the	O
probe	O
##s	O
specific	O
for	O
Lac	B
##to	I
##ba	I
##ci	I
##llus	I
/	O
En	O
##tero	O
##co	O
##cc	O
##us	O
s	O
##pp	O
.	O
,	O
B	O
##if	O
##ido	O
##ba	O
##cter	O
##ium	O
s	O
##pp	O
.	O

In	O
the	O
valid	O
##ation	O
set	O
,	O
the	O
most	O
significant	O
difference	O
in	O
mean	O
plasma	O
concentration	O
was	O
PC	B
(	I
38	I
:	I
3	I
)	I
(	O
p	O
=	O
5	O
.	O
70	O
##48	O
##1	O
##E	O
-	O
11	O
,	O
Student	O
'	O
s	O
t	O
-	O
test	O
)	O
.	O

It	O
should	O
also	O
be	O
pointed	O
out	O
that	O
the	O
el	O
##ution	O
range	O
of	O
[UNK]	O
min	O
for	O
the	O
four	O
meta	O
##bol	O
##ites	O
in	O
is	O
earlier	O
than	O
that	O
of	O
the	O
parent	O
drug	O
,	O
which	O
was	O
observed	O
at	O
20	O
.	O
74	O
min	O
when	O
translated	O
to	O
the	O
format	B
##e	I
buffer	O
system	O
(	O
data	O
not	O
shown	O
)	O
.	O

Ho	B
##mo	I
##cy	I
##stein	I
##e	I
can	O
be	O
meta	O
##bol	O
##ized	O
to	O
c	B
##ys	I
##tein	I
##e	I
and	O
the	O
observed	O
increased	O
levels	O
of	O
c	B
##ys	I
##tein	I
##e	I
could	O
reflect	O
a	O
mi	O
##s	O
##bal	O
##ance	O
in	O
the	O
ho	B
##mo	I
##cy	I
##stein	I
##e	I
metabolic	O
system	O
.	O

In	O
conclusion	O
,	O
this	O
study	O
provides	O
evidence	O
for	O
a	O
complex	O
per	O
##tur	O
##bation	O
of	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
metabolism	O
possibly	O
linked	O
to	O
early	O
β	O
-	O
cell	O
d	O
##ys	O
##function	O
in	O
T	O
##CF	O
##7	O
##L	O
##2	O
risk	O
all	O
##ele	O
carriers	O
,	O
in	O
a	O
state	O
when	O
conventional	O
parameters	O
of	O
glucose	S
home	O
##ost	O
##asis	O
are	O
not	O
yet	O
affected	O
.	O

Ser	O
##um	O
T	B
##MA	I
##O	I
and	O
ch	B
##olin	I
##e	I
were	O
assessed	O
using	O
high	O
-	O
performance	O
liquid	O
ch	O
##roma	O
##tography	O
with	O
online	O
electro	O
##sp	O
##ray	O
ion	O
##ization	O
tandem	O
mass	O
s	O
##pect	O
##rome	O
##try	O
(	O
HP	O
##LC	O
-	O
MS	O
/	O
MS	O
)	O
(	O
A	O
##gi	O
##lent	O
640	O
##0	O
Series	O
Triple	O
Q	O
##uad	O
L	O
##CM	O
##S	O
;	O
CA	O
,	O
USA	O
)	O
,	O
using	O
multi	O
-	O
reaction	O
monitoring	O
(	O
MR	O
##M	O
)	O
functions	O
.	O

The	O
double	O
##t	O
observed	O
between	O
1	O
.	O
12	O
and	O
1	O
.	O
16	O
might	O
be	O
is	B
##ob	I
##ut	I
##yric	I
acid	I
a	O
meta	O
##bol	O
##ite	O
derived	O
from	O
micro	O
##bial	O
activity	O
.	O

Afterward	O
,	O
15	O
mill	O
##ig	O
##rams	O
of	O
l	O
##yo	O
##phi	O
##li	O
##zed	O
stool	O
samples	O
were	O
mixed	O
with	O
45	O
μ	O
##L	O
sodium	B
chloride	I
(	O
50	O
m	O
##M	O
)	O
and	O
450	O
μ	O
##L	O
ch	O
##lor	O
##of	O
##orm	O
/	O
met	O
##han	O
##ol	O
(	O
30	O
:	O
1	O
)	O
in	O
1	O
.	O
5	O
m	O
##L	O
micro	O
##tub	O
##es	O
at	O
room	O
temperature	O
.	O

We	O
identified	O
and	O
replica	O
##ted	O
three	O
novel	O
genetic	O
signals	O
,	O
PR	O
##KA	O
##G	O
##2	O
r	O
##s	O
##27	O
##27	O
##5	O
##6	O
##3	O
,	O
DC	O
##C	O
r	O
##s	O
##12	O
##60	O
##4	O
##9	O
##40	O
and	O
EP	O
##H	O
##X	O
##2	O
r	O
##s	O
##13	O
##26	O
##29	O
##30	O
with	O
clinical	O
##ly	O
relevant	O
effects	O
on	O
the	O
blood	O
pressure	O
response	O
of	O
European	O
Americans	O
treated	O
with	O
h	B
##ydro	I
##ch	I
##lor	I
##oth	I
##ia	I
##zi	I
##de	I
.	O

L	O
phosphate	S
buffer	O
(	O
right	O
panels	O
)	O
.	O

It	O
is	O
known	O
that	O
g	B
##lut	I
##amine	I
,	O
as	O
a	O
precursor	O
of	O
g	B
##lut	I
##ath	I
##ione	I
,	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
prevention	O
of	O
o	O
##xi	O
##da	O
##tive	O
damage	O
in	O
the	O
human	O
body	O
and	O
thus	O
also	O
has	O
a	O
positive	O
influence	O
on	O
the	O
maintenance	O
of	O
the	O
gas	O
##tro	O
##int	O
##est	O
##inal	O
barrier	O
and	O
the	O
end	O
##oth	O
##eli	O
##al	O
function	O
of	O
the	O
blood	O
vessels	O
.	O

Whether	O
a	O
reduction	O
in	O
me	B
##lat	I
##oni	I
##n	I
early	O
in	O
the	O
night	O
as	O
well	O
as	O
a	O
lack	O
of	O
correlation	O
between	O
me	B
##lat	I
##oni	I
##n	I
and	O
sleep	O
in	O
##dices	O
are	O
associated	O
with	O
functional	O
G	O
##I	O
measures	O
such	O
as	O
increased	O
per	O
##me	O
##ability	O
and	O
/	O
or	O
increased	O
v	O
##is	O
##cer	O
##al	O
sensitivity	O
in	O
persons	O
with	O
I	O
##BS	O
-	O
D	O
remains	O
to	O
be	O
established	O
.	O

A	O
n	O
##uc	O
##leo	O
##side	O
,	O
put	O
##ative	O
##ly	O
identified	O
as	O
N	B
-	I
but	I
##eno	I
##yl	I
-	I
g	I
##uan	I
##os	I
##ine	I
(	O
m	O
/	O
z	O
33	O
##6	O
,	O
R	O
##T	O
3	O
.	O
65	O
min	O
)	O
,	O
was	O
found	O
using	O
positive	O
neutral	O
loss	O
scan	O
of	O
m	O
/	O
z	O
132	O
on	O
A	O
##c	O
##qui	O
##ty	O
UP	O
##LC	O
-	O
4000	O
Q	O
##T	O
##rap	O
MS	O
in	O
pool	O
##ed	O
urine	O
from	O
cc	O
##RC	O
##C	O
patients	O
(	O
orange	O
line	O
)	O
two	O
-	O
folds	O
higher	O
than	O
in	O
post	O
-	O
operative	O
controls	O
(	O
grey	O
line	O
)	O
.	O

Primary	O
end	O
##points	O
were	O
changes	O
from	O
base	O
##line	O
in	O
insulin	O
sensitivity	O
evaluated	O
using	O
h	B
##yper	I
##ins	I
##ulin	I
##em	I
##ic	I
-	I
e	I
##ug	I
##ly	I
##ce	I
##mic	I
c	O
##lamp	O
and	O
in	O
serum	O
t	B
##ria	I
##cy	I
##l	I
##gly	I
##cer	I
##ol	I
concentrations	O
in	O
fast	O
##ing	O
state	O
.	O

The	O
increased	O
levels	O
of	O
se	B
##rot	I
##oni	I
##n	I
,	O
try	B
##pt	I
##op	I
##han	I
,	O
and	O
ta	B
##uri	I
##ne	I
may	O
explain	O
the	O
anti	O
##de	O
##pressive	O
effect	O
of	O
acute	O
sleep	O
de	O
##p	O
##ri	O
##vation	O
and	O
deserve	O
further	O
study	O
.	O

The	O
collected	O
S	O
##IM	O
glucose	S
data	O
did	O
not	O
allow	O
for	O
accurate	O
MI	O
##D	O
determination	O
,	O
thus	O
,	O
the	O
glucose	S
M	O
##6	O
data	O
were	O
kindly	O
provided	O
by	O
the	O
Department	O
of	O
Laboratory	O
Medicine	O
,	O
University	O
Medical	O
Center	O
G	O
##ron	O
##ingen	O
,	O
University	O
of	O
G	O
##ron	O
##ingen	O
,	O
G	O
##ron	O
##ingen	O
,	O
The	O
Netherlands	O
.	O

On	O
the	O
other	O
hand	O
,	O
women	O
had	O
higher	O
heart	O
rate	O
,	O
total	O
and	O
high	O
density	O
lip	O
##op	O
##rote	O
##in	O
(	O
HD	O
##L	O
)	O
serum	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
h	O
##s	O
-	O
CR	O
##P	O
,	O
l	O
##ymph	O
##oc	O
##yte	O
and	O
plate	O
##let	O
counts	O
.	O

B	O
##rief	O
##ly	O
,	O
the	O
5	O
′	O
end	O
of	O
one	O
prime	O
##r	O
of	O
each	O
PC	O
##R	O
prime	O
##r	O
pair	O
was	O
con	O
##ju	O
##gated	O
to	O
bio	B
##tin	I
to	O
facilitate	O
post	O
-	O
PC	O
##R	O
retention	O
of	O
one	O
strand	O
with	O
s	O
##tre	O
##pta	O
##vid	O
##in	O
beads	O
.	O

They	O
also	O
had	O
higher	O
c	B
##it	I
##ru	I
##llin	I
##e	I
concentrations	O
than	O
controls	O
but	O
lower	O
than	O
I	O
##BS	O
patients	O
,	O
lower	O
concentrations	O
of	O
SD	O
##MA	O
than	O
controls	O
but	O
higher	O
than	O
I	O
##BS	O
patients	O
,	O
and	O
higher	O
D	B
##MA	I
concentrations	O
than	O
controls	O
and	O
patients	O
with	O
inactive	O
CD	O
.	O

Ser	O
##um	O
concentrations	O
of	O
g	B
##lut	I
##ami	I
##c	I
acid	I
(	O
A	O
)	O
,	O
met	B
##hi	I
##oni	I
##ne	I
(	O
B	O
)	O
and	O
γ	B
-	I
g	I
##lut	I
##am	I
##yl	I
-	I
g	I
##ly	I
##cine	I
-	I
g	I
##ly	I
##cine	I
(	O
C	O
)	O
in	O
he	O
##pa	O
##titis	O
B	O
virus	O
-	O
related	O
he	O
##pa	O
##to	O
##cellular	O
car	O
##cin	O
##oma	O
and	O
he	O
##pa	O
##titis	O
C	O
virus	O
-	O
related	O
he	O
##pa	O
##to	O
##cellular	O
car	O
##cin	O
##oma	O
.	O

This	O
result	O
suggests	O
that	O
ch	B
##olin	I
##e	I
meta	O
##bol	O
##ites	O
in	O
milk	O
,	O
in	O
addition	O
to	O
being	O
located	O
in	O
the	O
bi	O
##layer	O
membrane	O
of	O
the	O
fat	O
g	O
##lo	O
##bul	O
##e	O
,	O
may	O
also	O
be	O
related	O
to	O
the	O
protein	O
component	O
in	O
milk	O
.	O

The	O
relationship	O
between	O
my	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
and	O
decreased	O
re	O
##nal	O
function	O
or	O
MI	O
##OX	O
expression	O
suggests	O
a	O
link	O
between	O
my	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
and	O
tub	O
##ular	O
d	O
##ys	O
##function	O
.	O

As	O
with	O
the	O
above	O
results	O
,	O
the	O
mass	O
s	O
##pect	O
##rome	O
##try	O
results	O
showed	O
that	O
both	O
se	B
##rine	I
and	O
g	B
##ly	I
##cine	I
concentrations	O
of	O
cells	O
in	O
P	O
##LC	O
##ε	O
-	O
de	O
##ple	O
##tion	O
group	O
were	O
lower	O
than	O
control	O
group	O
.	O

This	O
type	O
of	O
protein	O
cat	O
##aly	O
##zes	O
the	O
p	O
##hos	O
##ph	O
##ory	O
##lation	O
of	O
se	B
##rine	I
or	O
th	B
##re	I
##oni	I
##ne	I
residues	O
on	O
target	O
proteins	O
by	O
using	O
ATP	S
as	O
a	O
phosphate	S
donor	O
.	O

For	O
testing	O
the	O
h	B
##y	I
##po	I
##gly	I
##ce	I
##mic	I
potential	O
of	O
the	O
DC	O
##M	O
leaf	O
extract	O
,	O
the	O
extract	O
was	O
dissolved	O
in	O
Pol	O
##ys	O
##or	O
##bate	O
80	O
(	O
negative	O
control	O
)	O
.	O

In	O
addition	O
to	O
the	O
four	O
meta	O
##bol	O
##ites	O
,	O
the	O
pre	O
-	O
pro	O
##state	O
##ct	O
##omy	O
u	O
##E	O
##V	O
samples	O
showed	O
2	O
.	O
3	O
-	O
22	O
.	O
8	O
-	O
fold	O
lower	O
levels	O
of	O
1	B
-	I
met	I
##hyl	I
##his	I
##tamine	I
,	O
c	B
##rea	I
##tine	I
,	O
g	B
##lut	I
##ath	I
##ione	I
,	O
prop	B
##ion	I
##yl	I
##car	I
##ni	I
##tine	I
,	O
is	B
##ova	I
##ler	I
##yl	I
##car	I
##ni	I
##tine	I
and	O
N	O
##AD	O
_	O
+	O
as	O
compared	O
to	O
controls	O
and	O
post	O
-	O
pro	O
##state	O
##ct	O
##omy	O
samples	O
when	O
normal	O
##ized	O
to	O
one	O
or	O
two	O
E	O
##V	O
-	O
derived	O
factors	O
(	O
all	O
p	O
<	O
0	O
.	O
05	O
,	O
data	O
not	O
shown	O
)	O
.	O

Using	O
0	O
.	O
02	O
##5	O
‐	O
m	O
##L	O
al	O
##iq	O
##uo	O
##ts	O
of	O
sample	O
for	O
analysis	O
,	O
the	O
lower	O
limits	O
of	O
q	O
##uant	O
##ification	O
for	O
plasma	O
ass	O
##ays	O
were	O
as	O
follows	O
:	O
0	O
.	O
100	O
ng	O
/	O
m	O
##L	O
for	O
r	B
##is	I
##per	I
##ido	I
##ne	I
,	O
p	B
##ali	I
##per	I
##ido	I
##ne	I
(	I
9	I
‐	I
h	I
##ydro	I
##xy	I
##ris	I
##per	I
##ido	I
##ne	I
)	I
,	O
and	O
o	B
##lan	I
##za	I
##pine	I
;	O
2	O
.	O
00	O
ng	O
/	O
m	O
##L	O
for	O
que	B
##tia	I
##pine	I
,	O
and	O
1	O
.	O
00	O
ng	O
/	O
m	O
##L	O
for	O
a	B
##rip	I
##ip	I
##raz	I
##ole	I
and	O
de	B
##hy	I
##dr	I
##oar	I
##ip	I
##ip	I
##raz	I
##ole	I
.	O

System	O
##ic	O
l	O
##up	O
##us	O
er	O
##yt	O
##hem	O
##ato	O
##sus	O
(	O
SL	O
##E	O
)	O
patients	O
exhibit	O
de	O
##ple	O
##tion	O
of	O
the	O
in	O
##tra	O
##cellular	O
anti	O
##ox	O
##ida	O
##nt	O
g	B
##lut	I
##ath	I
##ione	I
and	O
downstream	O
activation	O
of	O
the	O
metabolic	O
sensor	O
,	O
me	O
##chan	O
##istic	O
target	O
of	O
rap	B
##am	I
##y	I
##cin	I
(	O
m	O
##TO	O
##R	O
)	O
.	O

Fast	O
##ing	O
plasma	O
lip	O
##ids	O
[	O
total	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
t	B
##rig	I
##ly	I
##cer	I
##ide	I
,	O
high	O
-	O
density	O
lip	O
##op	O
##rote	O
##in	O
(	O
HD	O
##L	O
)	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
and	O
low	O
-	O
density	O
lip	O
##op	O
##rote	O
##in	O
(	O
L	O
##D	O
##L	O
)	O
ch	B
##ole	I
##ster	I
##ol	I
]	O
were	O
measured	O
monthly	O
.	O

Other	O
in	O
v	O
##ivo	O
studies	O
have	O
demonstrated	O
that	O
inflammation	O
can	O
drive	O
est	B
##rogen	I
production	O
in	O
the	O
breast	O
through	O
the	O
up	O
-	O
regulation	O
of	O
a	O
##roma	O
##tase	O
.	O

There	O
was	O
a	O
significant	O
mon	O
##oto	O
##nic	O
dose	B
-	I
response	I
association	O
between	O
5	B
-	I
met	I
##hyl	I
-	I
2	I
-	I
fur	I
##oi	I
##c	I
acid	I
and	O
lung	O
cancer	O
risk	O
when	O
analyzed	O
as	O
te	O
##rt	O
##iles	O
.	O

In	O
the	O
majority	O
of	O
work	O
to	O
date	O
,	O
increased	O
k	B
##yn	I
##uren	I
##ine	I
pathway	O
activity	O
has	O
been	O
positively	O
associated	O
with	O
the	O
occurrence	O
of	O
cancer	O
,	O
which	O
is	O
generally	O
attributed	O
to	O
the	O
escape	O
of	O
tumor	O
from	O
immune	O
surveillance	O
.	O

The	O
relation	O
between	O
est	B
##rogen	I
levels	O
and	O
exposure	O
to	O
PC	O
##D	O
##Ds	O
/	O
PC	O
##DF	O
##s	O
and	O
PC	O
##B	O
##s	O
has	O
been	O
historically	O
difficult	O
to	O
investigate	O
because	O
of	O
the	O
marked	O
variation	O
in	O
hormone	O
levels	O
during	O
the	O
men	O
##st	O
##ru	O
##al	O
cycle	O
.	O

One	O
sub	O
##type	O
identified	O
contained	O
meta	O
##bol	O
##ites	O
en	O
##rich	O
##ed	O
in	O
c	B
##it	I
##ric	I
acid	I
cycle	O
components	O
.	O

G	B
##lut	I
##ath	I
##ione	I
is	O
a	O
main	O
in	O
##tra	O
##cellular	O
anti	O
##ox	O
##ida	O
##nt	O
and	O
thus	O
plays	O
an	O
important	O
role	O
in	O
maintaining	O
red	O
##ox	O
home	O
##ost	O
##asis	O
and	O
eliminating	O
R	O
##OS	O
in	O
the	O
cell	O
.	O

The	O
u	B
##rea	I
cycle	O
pathway	O
and	O
the	O
effects	O
of	O
le	O
##pt	O
##in	O
replacement	O
on	O
various	O
protein	O
degradation	O
and	O
u	B
##rea	I
cycle	O
by	O
##p	O
##rod	O
##uc	O
##ts	O
is	O
illustrated	O
in	O
.	O

To	O
the	O
super	O
##nat	O
##ant	O
,	O
in	O
a	O
volume	O
of	O
500	O
µ	O
##l	O
,	O
600	O
µ	O
##l	O
of	O
5	O
%	O
a	O
##que	O
##ous	O
met	B
##han	I
##ol	I
solution	O
was	O
added	O
,	O
then	O
the	O
sample	O
in	O
a	O
volume	O
of	O
1	O
m	O
##l	O
was	O
transferred	O
to	O
a	O
pre	O
-	O
activated	O
with	O
1	O
m	O
##l	O
met	B
##han	I
##ol	I
so	O
##rp	O
##tion	O
cartridge	O
.	O

This	O
double	O
bond	O
position	O
is	O
characteristic	O
of	O
the	O
d	B
##18	I
:	I
2	I
s	I
##phi	I
##nga	I
##die	I
##ne	I
backbone	O
and	O
has	O
also	O
recently	O
be	O
observed	O
in	O
de	B
##ox	I
##y	I
##cer	I
##ami	I
##des	I
derived	O
from	O
H	O
##E	O
##K	O
cell	O
lines	O
.	O

We	O
did	O
however	O
confirm	O
the	O
expected	O
difference	O
of	O
increased	O
u	O
##rina	O
##ry	O
glucose	S
in	O
H	O
##NF	O
##1	O
##A	O
-	O
M	O
##OD	O
##Y	O
highlighting	O
that	O
the	O
numbers	O
of	O
cases	O
included	O
and	O
the	O
study	O
design	O
was	O
adequate	O
to	O
identify	O
differences	O
between	O
the	O
subgroup	O
##s	O
.	O

By	O
contrast	O
,	O
glucose	O
-	O
stimulate	O
##d	O
insulin	O
secret	O
##ion	O
during	O
an	O
O	O
##G	O
##TT	O
or	O
h	O
##yper	O
##ins	O
##ulin	O
##emia	O
during	O
a	O
e	B
##ug	I
##ly	I
##ce	I
##mic	I
c	O
##lamp	O
significantly	O
reduce	O
AC	O
concentrations	O
[	O
,	O
]	O
.	O

Character	O
##istic	O
##ally	O
,	O
the	O
1	O
.	O
3	O
-	O
pp	O
##m	O
and	O
2	O
.	O
2	O
-	O
pp	O
##m	O
peaks	O
are	O
considered	O
as	O
representative	O
of	O
t	B
##rig	I
##ly	I
##cer	I
##ide	I
and	O
un	O
##sat	O
##ura	O
##ted	O
fatty	O
acids	O
,	O
but	O
actual	O
values	O
obtained	O
by	O
bio	O
##chemical	O
measurements	O
(	O
see	O
below	O
)	O
suggest	O
the	O
combination	O
of	O
multiple	O
signals	O
from	O
other	O
compounds	O
.	O

color	O
##ec	O
##tal	O
cancer	O
,	O
h	B
##ydro	I
##xy	I
##ste	I
##ari	I
##c	I
acid	I
,	O
fatty	O
acid	O
est	O
##ers	O
of	O
h	B
##ydro	I
##xy	I
fatty	O
acids	O
,	O
a	O
##pop	O
##tosis	O

study	O
results	O
emphasize	O
that	O
EP	O
##H	O
##X	O
##2	O
might	O
be	O
involved	O
in	O
the	O
BP	O
lowering	O
mechanism	O
of	O
th	B
##ia	I
##zi	I
##de	I
di	O
##ure	O
##tics	O
and	O
suggest	O
that	O
it	O
might	O
be	O
an	O
important	O
predict	O
##or	O
of	O
th	B
##ia	I
##zi	I
##de	I
di	O
##ure	O
##tics	O
’	O
BP	O
response	O
.	O

Part	O
##ici	O
##pants	O
had	O
their	O
serum	O
c	B
##rea	I
##tin	I
##ine	I
levels	O
measured	O
as	O
part	O
of	O
the	O
study	O
protocol	O
at	O
base	O
##line	O
,	O
4	O
months	O
and	O
1	O
year	O
and	O
annually	O
thereafter	O
until	O
completion	O
of	O
the	O
study	O
,	O
with	O
further	O
tests	O
at	O
the	O
discretion	O
of	O
clinic	O
##ians	O
.	O

The	O
high	O
level	O
of	O
u	B
##ric	I
acid	I
may	O
depend	O
on	O
metabolic	O
changes	O
as	O
a	O
result	O
of	O
pan	O
##cre	O
##atic	O
cancer	O
.	O

The	O
majority	O
of	O
the	O
other	O
meta	O
##bol	O
##ites	O
in	O
tumor	O
tissues	O
showed	O
higher	O
concentrations	O
,	O
especially	O
k	B
##yn	I
##uren	I
##ine	I
,	O
a	O
meta	O
##bol	O
##ite	O
synthesized	O
from	O
try	B
##pt	I
##op	I
##han	I
,	O
which	O
showed	O
the	O
highest	O
fold	O
change	O
(	O
FC	O
=	O
38	O
.	O
1	O
,	O
adjusted	O
P	O
=	O
0	O
.	O
000	O
##27	O
;	O
)	O
,	O
indicating	O
increased	O
reactive	O
oxygen	O
species	O
stress	O
in	O
tumor	O
tissues	O
.	O

Mini	O
-	O
Mental	O
Status	O
Ex	O
##am	O
(	O
M	O
##MS	O
##E	O
)	O
bracket	O
##ed	O
scores	O
,	O
Ba	O
##b	O
##cock	O
Story	O
Re	O
##cal	O
##l	O
Test	O
(	O
BS	O
##RT	O
)	O
scores	O
for	O
memory	O
,	O
di	B
##acy	I
##l	I
##gly	I
##cer	I
##ol	I
(	O
D	O
##AG	O
)	O
levels	O
,	O
and	O
ethanol	B
##amine	I
plasma	O
##log	O
##en	O
(	O
P	O
##ls	O
##E	O
)	O
levels	O
in	O
control	O
,	O
Mi	O
##ld	O
Co	O
##gni	O
##tive	O
I	O
##mp	O
##air	O
##ment	O
(	O
MC	O
##I	O
)	O
,	O
and	O
Late	O
On	O
##set	O
Alzheimer	O
'	O
s	O
Disease	O
(	O
L	O
##OA	O
##D	O
)	O
patients	O
.	O

Association	O
##s	O
of	O
circulating	O
vitamin	B
D	I
meta	O
##bol	O
##ites	O
with	O
CA	O
##C	O
were	O
assessed	O
with	O
a	O
bin	O
##omi	O
##al	O
re	O
##gression	O
model	O
to	O
estimate	O
the	O
relative	O
risk	O
for	O
presence	O
(	O
vs	O
.	O
absence	O
)	O
of	O
CA	O
##C	O
.	O

Finally	O
,	O
in	O
plasma	O
samples	O
,	O
the	O
combination	O
of	O
D	B
-	I
g	I
##lut	I
##ami	I
##c	I
acid	I
,	O
c	B
##rea	I
##tin	I
##ine	I
,	O
and	O
ch	B
##olin	I
##e	I
had	O
an	O
AU	O
##C	O
value	O
of	O
0	O
.	O
92	O
##7	O
(	O
95	O
%	O
C	O
##I	O
:	O
0	O
.	O
87	O
##5	O
–	O
0	O
.	O
97	O
##9	O
,	O
P	O
<	O
0	O
.	O
00	O
##1	O
)	O
and	O
displayed	O
90	O
.	O
5	O
%	O
sensitivity	O
and	O
83	O
.	O
3	O
%	O
specific	O
##ity	O
;	O
this	O
group	O
of	O
meta	O
##bol	O
##ites	O
was	O
thus	O
defined	O
as	O
a	O
combination	O
##al	O
bio	O
##mark	O
##er	O
for	O
the	O
recognition	O
of	O
A	B
##F	I
and	O
non	O
-	O
A	O
##F	O
patients	O
.	O

Met	O
##ab	O
##oli	O
##te	O
inter	O
##media	O
##ries	O
of	O
one	O
-	O
carbon	O
metabolism	O
,	O
including	O
met	B
##hi	I
##oni	I
##ne	I
and	O
c	B
##ys	I
##tein	I
##e	I
,	O
were	O
reduced	O
after	O
treatment	O
with	O
vitamin	O
B	O
-	O
12	O
,	O
in	O
keeping	O
with	O
the	O
higher	O
metabolic	O
u	O
##til	O
##ization	O
of	O
these	O
compounds	O
via	O
vitamin	O
B	O
-	O
12	O
–	O
dependent	O
pathways	O
.	O

This	O
platform	O
provides	O
simultaneous	O
q	O
##uant	O
##ification	O
of	O
147	O
individual	O
meta	O
##bol	O
##ites	O
and	O
79	O
meta	O
##bol	O
##ite	O
ratios	O
,	O
for	O
example	O
,	O
routine	O
lip	O
##ids	O
,	O
lip	O
##op	O
##rote	O
##in	O
sub	O
##c	O
##lass	O
pro	O
##fi	O
##ling	O
with	O
lip	O
##id	O
concentrations	O
within	O
14	O
sub	O
##c	O
##lass	O
##es	O
,	O
est	O
##eri	O
##fied	O
fatty	O
acid	O
composition	O
,	O
and	O
various	O
low	O
‐	O
molecular	O
-	O
weight	O
meta	O
##bol	O
##ites	O
,	O
including	O
amino	O
acids	O
,	O
k	B
##eton	I
##e	I
bodies	O
,	O
and	O
g	O
##lu	O
##con	O
##eo	O
##genesis	O
‐	O
related	O
meta	O
##bol	O
##ites	O
in	O
m	O
##olar	O
concentration	O
units	O
.	O

In	O
general	O
,	O
high	O
concentrations	O
of	O
p	B
##oly	I
##amine	I
##s	I
are	O
found	O
in	O
rapidly	O
growing	O
cells	O
,	O
while	O
low	O
concentrations	O
are	O
present	O
in	O
q	O
##ui	O
##es	O
##cent	O
cells	O
[	O
,	O
]	O
.	O

Identity	O
of	O
specific	O
D	O
-	O
series	O
re	O
##sol	O
##vin	O
##s	O
[	O
re	O
##sol	O
##vin	O
D	O
##1	O
(	O
R	O
##v	O
##D	O
##1	O
)	O
,	O
7	O
##S	O
,	O
8	B
##R	I
,	I
17	I
##S	I
-	I
t	I
##ri	I
##hy	I
##dr	I
##ox	I
##y	I
-	I
4	I
##Z	I
,	O
9	O
##E	O
,	O
11	O
##E	O
,	O
13	O
##Z	O
,	O
15	O
##E	O
,	O
19	O
##Z	O
-	O
do	O
##cos	O
##ah	O
##ex	O
##aen	O
##oi	O
##c	O
acid	O
)	O
,	O
re	O
##sol	O
##vin	O
D	O
##2	O
(	O
R	O
##v	O
##D	O
##2	O
)	O
,	O
7	O
##S	O
,	O
16	O
##R	O
,	O
17	B
##S	I
-	I
t	I
##ri	I
##hy	I
##dr	I
##ox	I
##y	I
-	I
4	I
##Z	I
,	O
8	O
##E	O
,	O
10	O
##Z	O
,	O
12	O
##E	O
,	O
14	B
##E	I
,	I
19	I
##Z	I
-	I
do	I
##cos	I
##ah	I
##ex	I
##aen	I
##oi	I
##c	I
acid	O
)	O
and	O
the	O
as	O
##pi	O
##rin	O
-	O
triggered	O
R	O
##v	O
##D	O
##1	O
(	O
AT	O
-	O
R	O
##v	O
##D	O
##1	O
)	O
,	O
7	O
##S	O
,	O
8	B
##R	I
,	I
17	I
##R	I
-	I
t	I
##ri	I
##hy	I
##dr	I
##ox	I
##y	I
-	I
4	I
##Z	I
,	O
9	O
##E	O
,	O
11	O
##E	O
,	O
13	O
##Z	O
,	O
15	O
##E	O
,	O
19	O
##Z	O
-	O
do	O
##cos	O
##ah	O
##ex	O
##aen	O
##oi	O
##c	O
acid	O
]	O
was	O
confirmed	O
using	O
lip	O
##id	O
media	O
##tor	O
meta	O
##bol	O
##oli	O
##pid	O
##omi	O
##cs	O
analytical	O
methods	O
,	O
as	O
described	O
by	O
Ser	O
##han	O
and	O
colleagues	O
,	O
.	O

Non	O
##linear	O
re	O
##gression	O
analysis	O
of	O
the	O
log	O
transformed	O
f	O
##ent	O
##any	O
##l	O
C	O
##L	O
and	O
mid	B
##az	I
##ola	I
##m	I
C	O
##L	O
_	O
met	O
(	O
Fi	O
##g	O
.	O

A	O
gradient	O
el	O
##ution	O
of	O
mobile	O
phase	O
A	O
(	O
10	O
m	O
##M	O
am	B
##mon	I
##ium	I
format	I
##e	I
and	O
0	O
.	O
04	O
%	O
form	B
##ic	I
acid	I
in	O
water	O
)	O
and	O
mobile	O
phase	O
B	O
(	O
ace	O
##ton	O
##it	O
##ril	O
##e	O
)	O
was	O
used	O
with	O
a	O
flow	O
rate	O
of	O
0	O
.	O
4	O
m	O
##l	O
/	O
min	O
and	O
run	O
time	O
of	O
5	O
min	O
.	O

Ch	O
##roma	O
##to	O
##gram	O
of	O
(	O
a	O
)	O
si	B
##but	I
##ram	I
##ine	I
,	O
(	O
b	O
)	O
si	B
##but	I
##ram	I
##ine	I
d	O
##7	O
,	O
(	O
c	O
)	O
N	O
-	O
des	O
met	B
##hyl	I
si	I
##but	I
##ram	I
##ine	I
,	O
(	O
d	O
)	O
N	O
-	O
des	O
met	B
##hyl	I
si	I
##but	I
##ram	I
##ine	I
d	O
##7	O
,	O
(	O
e	O
)	O
N	O
-	O
di	O
des	B
met	I
##hyl	I
si	I
##but	I
##ram	I
##ine	I
and	O
(	O
f	O
)	O
N	O
-	O
di	O
des	B
met	I
##hyl	I
si	I
##but	I
##ram	I
##ine	I
d	O
##7	O
.	O

In	O
the	O
current	O
study	O
,	O
f	B
##olate	I
status	O
was	O
considered	O
adequate	O
in	O
both	O
groups	O
,	O
although	O
lower	O
concentrations	O
were	O
observed	O
among	O
subjects	O
in	O
the	O
high	B
–	I
c	I
##ys	I
##tat	I
##hi	I
##oni	I
##ne	I
concentration	O
group	O
.	O

Therefore	O
,	O
m	B
-	I
t	I
##yr	I
##os	I
##ine	I
might	O
play	O
a	O
direct	O
role	O
in	O
causing	O
abnormal	O
behaviors	O
in	O
AS	O
##Ds	O
.	O

F	O
##DR	O
=	O
1	O
.	O
11	O
×	O
10	O
_	O
−	O
##2	O
)	O
,	O
and	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
(	O
46	O
%	O
,	O
P	O
=	O
5	O
.	O
74	O
×	O
10	O
_	O
−	O
##1	O
;	O
F	O
##DR	O
=	O
7	O
.	O
65	O
×	O
10	O
_	O
−	O
##1	O
)	O
were	O
poorly	O
detect	O
##able	O
in	O
FF	O
##P	O
##E	O
samples	O
.	O

These	O
results	O
are	O
consistent	O
with	O
the	O
proposal	O
of	O
a	O
pu	B
##rine	I
-	I
driven	I
cell	O
danger	O
response	O
,	O
accompanied	O
by	O
over	O
##p	O
##rod	O
##uction	O
of	O
e	O
##pile	O
##pt	O
##ogenic	O
and	O
ex	O
##ci	O
##to	O
##to	O
##xi	O
##c	O
q	B
##uin	I
##olin	I
##ic	I
acid	I
,	O
large	O
reduction	O
##s	O
in	O
me	B
##lat	I
##oni	I
##n	I
synthesis	O
,	O
and	O
gut	O
d	O
##ys	O
##bio	O
##sis	O
.	O

However	O
,	O
it	O
is	O
also	O
found	O
in	O
al	O
##fa	O
##lf	O
##a	O
s	O
##p	O
##rout	O
##s	O
,	O
lent	O
##ils	O
,	O
chick	O
##pe	O
##as	O
,	O
o	O
##ats	O
and	O
f	O
##en	O
##ug	O
##ree	O
##k	O
,	O
and	O
is	O
a	O
plasma	O
and	O
u	O
##rina	O
##ry	O
meta	O
##bol	O
##ite	O
of	O
ni	B
##ac	I
##in	I
(	O
vitamin	O
B	O
##3	O
)	O
.	O

PC	B
a	I
##e	I
C	I
##38	I
:	I
5	I
;	O
90	O
.	O

Third	O
,	O
we	O
did	O
not	O
systematically	O
evaluated	O
A	O
##po	O
E	O
p	O
##oly	O
##mor	O
##phism	O
in	O
our	O
sample	O
,	O
and	O
it	O
is	O
probable	O
that	O
a	O
##po	O
E	O
p	O
##hen	O
##otype	O
might	O
influence	O
plasma	O
levels	O
of	O
24	B
##S	I
-	I
OH	I
-	I
Cho	I
##l	I
.	O

Since	O
no	O
standardized	O
normal	O
##ization	O
method	O
for	O
the	O
meta	O
##bol	O
##omi	O
##cs	O
data	O
from	O
the	O
E	O
##Vs	O
existed	O
,	O
we	O
tested	O
several	O
different	O
options	O
:	O
normal	O
##ization	O
to	O
E	O
##V	O
volume	O
,	O
E	O
##V	O
number	O
,	O
CD	O
##9	O
optical	O
density	O
,	O
other	O
meta	O
##bol	O
##ites	O
,	O
urine	O
volume	O
or	O
urine	O
c	B
##rea	I
##tin	I
##ine	I
.	O

The	O
patients	O
were	O
separated	O
into	O
two	O
groups	O
,	O
divided	O
at	O
median	O
tissue	O
level	O
for	O
(	O
A	O
)	O
PS	O
##A	O
,	O
(	O
B	O
)	O
ho	B
##mo	I
##cy	I
##stein	I
##e	I
,	O
(	O
C	O
)	O
c	B
##ys	I
##tat	I
##hi	I
##oni	I
##ne	I
,	O
and	O
(	O
D	O
)	O
c	B
##ys	I
##tein	I
##e	I
as	O
significantly	O
associated	O
with	O
time	O
to	O
re	O
##cu	O
##rrence	O
.	O

The	O
difference	O
seen	O
in	O
the	O
MR	O
s	O
##pect	O
##ra	O
of	O
intact	O
breast	O
cancer	O
tissue	O
using	O
H	O
##R	O
##MA	O
##S	O
and	O
the	O
perch	B
##lor	I
##ic	I
acid	I
extract	O
##s	O
is	O
largely	O
in	O
the	O
region	O
of	O
lip	O
##id	O
resonance	O
##s	O
(	O
due	O
to	O
ad	O
##ip	O
##ose	O
tissue	O
present	O
in	O
the	O
breast	O
tissue	O
)	O
and	O
in	O
the	O
low	O
field	O
region	O
.	O

We	O
therefore	O
re	O
-	O
examined	O
our	O
W	O
##GS	O
data	O
for	O
possible	O
S	O
##N	O
##V	O
and	O
C	O
##N	O
##V	O
mutations	O
affecting	O
four	O
genes	O
of	O
the	O
p	B
##yr	I
##im	I
##id	I
##ine	I
bio	O
##sy	O
##nt	O
##hesis	O
pathway	O
(	O
Su	O
##pp	O
##lement	O
##ary	O
Figure	O
S	O
##4	O
)	O
:	O
the	O
t	O
##ri	O
-	O
functional	O
enzyme	O
CA	O
##D	O
(	B
car	B
##ba	I
##mo	I
##yl	I
-	I
phosphate	I
s	O
##ynth	O
##eta	O
##se	O
2	O
,	O
as	O
##par	O
##tate	O
trans	O
##car	O
##ba	O
##my	O
##lase	O
,	O
and	O
di	O
##hy	O
##dr	O
##oor	O
##ota	O
##se	O
)	O
,	O
D	O
##H	O
##OD	O
##H	O
(	O

Therefore	O
,	O
we	O
developed	O
a	O
fast	O
on	O
-	O
line	O
solid	O
phase	O
extraction	O
–	O
high	O
performance	O
liquid	O
ch	O
##roma	O
##tography	O
–	O
is	O
##oto	O
##pe	O
di	O
##lution	O
tandem	O
mass	O
s	O
##pect	O
##rome	O
##try	O
(	O
HP	O
##LC	O
-	O
MS	O
/	O
MS	O
)	O
method	O
to	O
measure	O
in	O
urine	O
the	O
concentrations	O
of	O
DE	O
##ET	O
and	O
two	O
of	O
its	O
o	O
##xi	O
##da	O
##tive	O
meta	O
##bol	O
##ites	O
:	O
N	B
,	I
N	I
-	I
diet	I
##hyl	I
-	I
3	I
-	I
(	I
h	I
##ydro	I
##xy	I
##met	I
##hyl	I
)	I
ben	I
##zam	I
##ide	I
and	O
3	B
-	I
(	I
diet	I
##hyl	I
##car	I
##ba	I
##mo	I
##yl	I
)	I
ben	I
##zoic	I
acid	I
(	O
DC	O
##BA	O
)	O
.	O

For	O
each	O
of	O
the	O
listed	O
pathways	O
,	O
the	O
respective	O
meta	O
##bol	O
##ites	O
identified	O
are	O
listed	O
below	O
:	O
G	B
##ly	I
##cer	I
##ol	I
phosphate	I
shuttle	O
:	O
H	B
##ydro	I
##quin	I
##one	I
(	O
1	O
/	O
11	O
)	O
;	O
al	B
##ani	I
##ne	I
metabolism	O
:	O
G	B
##ly	I
##cine	I
(	O
1	O
/	O
17	O
)	O
;	O
rib	B
##of	I
##lav	I
##in	I
metabolism	O
:	O
H	B
##ydro	I
##quin	I
##one	I
(	O
1	O
/	O
20	O
)	O
;	O
g	B
##lut	I
##ath	I
##ione	I
metabolism	O
:	O
G	B
##ly	I
##cine	I
(	O
1	O
/	O
21	O
)	O
;	O
car	B
##ni	I
##tine	I
synthesis	O
:	O
G	B
##ly	I
##cine	I
(	O
1	O
/	O
22	O
)	O
;	O
g	B
##ly	I
##cer	I
##oli	I
##pid	I
metabolism	O
:	O
H	B
##ydro	I
##quin	I
##one	I
(	O
1	O
/	O
25	O
)	O
;	O
am	O
##monia	O
recycling	O
:	O
G	B
##ly	I
##cine	I
(	O
1	O
/	O
32	O
)	O
;	O
p	O
##or	O
##phy	O
##rin	O
metabolism	O
:	O
G	B
##ly	I
##cine	I
(	O
1	O
/	O
40	O
)	O
;	O
met	B
##hi	I
##oni	I
##ne	I
metabolism	O
:	O
G	B
##ly	I
##cine	I
(	O
1	O
/	O
43	O
)	O
;	O
g	B
##lut	I
##ama	I
##te	I
metabolism	O
:	O
G	B
##ly	I
##cine	I
(	O
1	O
/	O
49	O
)	O
;	O
a	B
##rg	I
##ini	I
##ne	I
and	O
pro	B
##line	I
metabolism	O
:	O
G	B
##ly	I
##cine	I
(	O
1	O
/	O
53	O
)	O
;	O
g	B
##ly	I
##cine	I
and	O
se	B
##rine	I
metabolism	O
:	O
G	B
##ly	I
##cine	I
(	O
1	O
/	O
59	O
)	O
;	O
bi	O
##le	O
acid	O
bio	O
##sy	O
##nt	O
##hesis	O
:	O
G	B
##ly	I
##cine	I
(	O
1	O
/	O
65	O
)	O
;	O
t	B
##yr	I
##os	I
##ine	I
metabolism	O
:	O
Am	B
##ino	I
##mal	I
##ona	I
##te	I
(	O
1	O
/	O
72	O
)	O
;	O
pu	B
##rine	I
metabolism	O
:	O
G	B
##ly	I
##cine	I
(	O
1	O
/	O
74	O
)	O
.	O

In	O
this	O
study	O
of	O
133	O
adult	O
patients	O
with	O
AD	O
##HD	O
and	O
131	O
adult	O
controls	O
,	O
we	O
found	O
significantly	O
lower	O
concentrations	O
of	O
try	B
##pt	I
##op	I
##han	I
,	O
K	O
##A	O
,	O
X	O
##A	O
and	O
H	O
##AA	O
in	O
the	O
patient	O
group	O
(	O
Table	O
)	O
.	O

In	O
the	O
whole	O
set	O
(	O
the	O
combined	O
training	O
and	O
valid	O
##ation	O
sets	O
)	O
,	O
the	O
most	O
significant	O
difference	O
in	O
mean	O
plasma	O
concentration	O
was	O
PC	B
(	I
38	I
:	I
3	I
)	I
(	O
p	O
=	O
1	O
.	O
00	O
##7	O
##4	O
##9	O
##E	O
-	O
17	O
,	O
Student	O
'	O
s	O
t	O
-	O
test	O
)	O
.	O

In	O
g	O
##ly	O
##co	O
##lysis	O
,	O
he	O
##x	O
##oki	O
##nas	O
##e	O
and	O
p	O
##hos	O
##ph	O
##of	O
##ru	O
##ct	O
##oki	O
##nas	O
##e	O
cat	O
##aly	O
##se	O
reactions	O
where	O
ATP	S
is	O
the	O
phosphate	O
-	O
group	O
donor	O
.	O

Second	O
##ly	O
,	O
the	O
IL	O
-	O
L	O
##C	O
-	O
MR	O
##M	O
-	O
MS	O
method	O
was	O
developed	O
for	O
relative	O
q	O
##uant	O
##ification	O
of	O
th	B
##iol	I
##s	I
in	O
cancer	O
##s	O
compared	O
to	O
healthy	O
controls	O
.	O

In	O
contrast	O
,	O
the	O
u	O
##rina	O
##ry	O
ad	B
##eni	I
##ne	I
level	O
was	O
negatively	O
associated	O
with	O
a	O
decrease	O
in	O
the	O
plasma	O
MD	O
##A	O
level	O
(	O
p	O
=	O
0	O
.	O
01	O
##8	O
)	O
.	O

We	O
confirmed	O
the	O
identity	O
of	O
the	O
metabolic	O
systems	O
predicted	O
above	O
,	O
including	O
side	O
-	O
chain	O
s	O
##pec	O
##iation	O
##s	O
of	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
,	O
by	O
designing	O
flow	O
-	O
injection	O
tandem	O
MS	O
(	O
F	O
##I	O
-	O
MS	O
/	O
MS	O
)	O
ass	O
##ays	O
for	O
each	O
system	O
(	O
see	O
Method	O
##s	O
)	O
.	O

In	O
addition	O
,	O
the	O
findings	O
suggested	O
that	O
compared	O
with	O
that	O
of	O
c	O
##ir	O
##r	O
##hos	O
##is	O
,	O
the	O
development	O
of	O
HC	O
##C	O
was	O
more	O
strongly	O
associated	O
with	O
the	O
d	O
##ys	O
##re	O
##gu	O
##lation	O
of	O
am	O
##monia	O
recycling	O
,	O
the	O
u	B
##rea	I
cycle	O
,	O
and	O
amino	O
acid	O
metabolism	O
.	O

For	O
cab	B
##oz	I
##anti	I
##ni	I
##b	I
total	O
extraction	O
recovery	O
was	O
additionally	O
determined	O
for	O
Q	O
##C	O
##X	O
##L	O
in	O
du	O
##plicate	O
.	O

B	O
##ios	O
##ynth	O
##etic	O
##ally	O
,	O
s	O
##tero	O
##ls	O
are	O
derived	O
from	O
is	B
##ope	I
##nte	I
##ny	I
##l	I
dip	I
##hos	I
##phate	I
(	O
IP	O
##P	O
)	O
,	O
the	O
precursor	O
of	O
sq	B
##ual	I
##ene	I
and	O
its	O
downstream	O
c	O
##y	O
##c	O
##li	O
##zed	O
products	O
.	O

Internal	O
standards	O
,	O
C	O
##8	O
–	O
C	O
##30	O
fatty	O
acid	O
met	O
##hyl	O
est	O
##ers	O
(	O
FA	O
##ME	O
##s	O
)	O
,	O
were	O
added	O
to	O
samples	O
and	O
der	O
##iva	O
##tized	O
with	O
met	B
##ho	I
##xy	I
##amine	I
h	I
##ydro	I
##ch	I
##lor	I
##ide	I
in	O
p	B
##yr	I
##id	I
##ine	I
and	O
subsequently	O
by	O
MS	O
##TF	O
##A	O
(	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
)	O
for	O
trim	O
##eth	O
##yl	O
##si	O
##ly	O
##lation	O
of	O
acidic	O
pro	O
##tons	O
and	O
anal	O
##ys	O
##ed	O
by	O
G	O
##C	O
-	O
TO	O
##F	O
mass	O
s	O
##pect	O
##rome	O
##try	O
.	O

The	O
components	O
of	O
factor	O
9	O
containing	O
amino	O
acids	O
reporting	O
on	O
the	O
u	B
##rea	I
cycle	O
(	B
a	B
##rg	I
##ini	I
##ne	I
,	O
his	B
##ti	I
##dine	I
,	O
c	B
##it	I
##ru	I
##llin	I
##e	I
,	O
and	O
C	O
##i	O
##4	O
-	O
DC	O
:	O
C	O
##4	O
-	O
DC	O
)	O
from	O
the	O
previous	O
study	O
did	O
not	O
group	O
into	O
any	O
one	O
factor	O
in	O
our	O
PC	O
##A	O
analysis	O
;	O
thus	O
,	O
we	O
analyzed	O
the	O
individual	O
meta	O
##bol	O
##ites	O
from	O
this	O
factor	O
in	O
the	O
current	O
study	O
.	O

In	O
that	O
study	O
,	O
it	O
was	O
suggested	O
that	O
o	B
##leo	I
##yle	I
##than	I
##ola	I
##mi	I
##de	I
is	O
produced	O
in	O
C	O
##LL	O
cells	O
as	O
a	O
lip	O
##oly	O
##tic	O
factor	O
that	O
later	O
plays	O
a	O
role	O
in	O
drug	O
resistance	O
as	O
well	O
as	O
cache	O
##xia	O
.	O

Ser	O
##um	O
levels	O
of	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
(	O
P	O
##t	O
##d	O
##C	O
)	O
36	O
:	O
4	O
in	O
experimental	O
##ly	O
infected	O
(	O
N	O
=	O
7	O
)	O
and	O
control	O
cows	O
(	O
N	O
=	O
6	O
)	O
from	O
time	O
zero	O
and	O
1	O
to	O
16	O
months	O
post	O
-	O
infection	O
.	O

in	B
##os	I
##ito	I
##l	I
phosphate	I
metabolism	O
,	O
g	B
##ly	I
##cos	I
##yl	I
##ph	I
##os	I
##pha	I
##ti	I
##dy	I
##lino	I
##si	I
##to	I
##l	I
-	I
anchor	I
bio	O
##sy	O
##nt	O
##hesis	O
,	O
le	O
##uk	O
##oc	O
##yte	O
trans	B
-	I
end	I
##oth	I
##eli	I
##al	I
migration	O
,	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##lino	I
##si	I
##to	I
##l	I
signaling	O
were	O
en	O
##rich	O
##ed	O
for	O
by	O
h	O
##y	O
##po	O
-	O
met	O
##hyl	O
##ated	O
genes	O
and	O
end	O
##oc	O
##yt	O
##osis	O
,	O
Alzheimer	O
’	O
s	O
disease	O
,	O
o	O
##xi	O
##da	O
##tive	O
p	O
##hos	O
##ph	O
##ory	O
##lation	O
,	O
Huntington	O
’	O
s	O
disease	O
were	O
en	O
##rich	O
##ed	O
for	O
by	O
h	O
##yper	O
-	O
met	O
##hyl	O
##ated	O
genes	O
(	O
Fi	O
##g	O
.	O
)	O
.	O

Further	O
,	O
demonstrated	O
using	O
mouse	O
models	O
of	O
AD	O
and	O
HD	O
that	O
peripheral	O
administration	O
of	O
an	O
experimental	O
drug	O
that	O
directly	O
in	O
##hibit	O
##s	O
K	O
##MO	O
,	O
elevated	O
brain	O
levels	O
of	O
K	O
##yn	O
##A	O
and	O
decreased	O
g	B
##lut	I
##ama	I
##te	I
release	O
and	O
ex	O
##ci	O
##to	O
##to	O
##xi	O
##city	O
in	O
the	O
brain	O
par	O
##en	O
##chy	O
##ma	O
despite	O
the	O
fact	O
that	O
neither	O
the	O
pro	O
##dr	O
##ug	O
nor	O
its	O
meta	O
##bol	O
##ite	O
were	O
capable	O
of	O
crossing	O
the	O
blood	O
brain	O
barrier	O
.	O

I	O
##B	O
##D	O
children	O
showed	O
a	O
significant	O
increase	O
in	O
the	O
u	O
##rina	O
##ry	O
content	O
of	O
several	O
closely	O
related	O
intermediate	O
##s	O
of	O
the	O
T	O
##CA	O
cycle	O
(	O
f	O
##uma	O
##rate	O
,	O
is	B
##oc	I
##it	I
##rate	I
,	O
2	B
-	I
h	I
##ydro	I
##xy	I
##g	I
##lut	I
##ari	I
##c	I
acid	I
,	O
met	B
##hyl	I
##su	I
##cci	I
##nic	I
acid	O
)	O
.	O

Su	O
##mma	O
##ry	O
of	O
pathway	O
analysis	O
by	O
lip	O
##ido	O
##mic	O
##s	O
(	O
A	O
:	O
N	O
##SC	O
##LC	O
versus	O
HC	O
;	O
B	O
:	O
N	O
##SC	O
##LC	O
versus	O
L	O
##B	O
##D	O
;	O
C	O
:	O
L	O
##B	O
##D	O
versus	O
HC	O
;	O
a	O
:	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
metabolism	O
;	O
b	O
:	O
g	B
##ly	I
##cos	I
##yl	I
##ph	I
##os	I
##pha	I
##ti	I
##dy	I
##lino	I
##si	I
##to	I
##l	I
-	I
(	I
GP	I
##I	I
-	I
)	I
anchor	O
bio	O
##sy	O
##nt	O
##hesis	O
;	O
c	O
:	O
l	B
##ino	I
##le	I
##ic	I
acid	I
metabolism	O
;	O
d	O
:	O
g	B
##ly	I
##cer	I
##oli	I
##pid	I
metabolism	O
;	O
)	O
.	O

P	O
##las	O
##ma	O
palm	B
##itate	I
trace	O
##r	O
concentration	O
was	O
determined	O
by	O
gas	O
ch	O
##roma	O
##tography	O
(	O
G	O
##C	O
)	O
(	O
Auto	O
##sy	O
##ste	O
##m	O
X	O
##L	O
,	O
Per	O
##kin	O
Elmer	O
)	O
and	O
plasma	O
[	O
U	O
-	O
_	O
13	O
C	O
]	O
palm	B
##itate	I
en	O
##rich	O
##ment	O
was	O
determined	O
by	O
G	O
##C	O
-	O
combustion	O
is	O
##oto	O
##pe	O
ratio	O
mass	O
s	O
##pect	O
##rome	O
##try	O
(	O
G	O
##C	O
-	O
C	O
-	O
I	O
##R	O
##MS	O
)	O
as	O
previously	O
described	O
.	O

L	O
##C	O
gradient	O
started	O
at	O
98	O
%	O
A	O
(	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
in	O
water	O
)	O
2	O
%	O
B	O
(	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
in	O
ace	O
##ton	O
##it	O
##ril	O
##e	O
)	O
and	O
ramp	O
##ed	O
to	O
85	O
%	O
A	O
-	O
15	O
%	O
B	O
at	O
8	O
.	O
00	O
min	O
,	O
held	O
for	O
2	O
.	O
60	O
min	O
and	O
e	O
##qui	O
##li	O
##bra	O
##ted	O
for	O
an	O
additional	O
4	O
.	O
00	O
min	O
to	O
the	O
starting	O
condition	O
.	O

The	O
fragment	O
##ation	O
pattern	O
was	O
examined	O
under	O
various	O
levels	O
of	O
collision	O
energy	O
,	O
as	O
a	O
result	O
,	O
a	O
[	B
M	B
+	I
p	I
##ico	I
##lini	I
##c	I
acid	O
+	O
Na	O
]	O
_	O
+	O
(	O
m	O
/	O
z	O
512	O
)	O
ion	O
was	O
observed	O
as	O
the	O
predominant	O
ion	O
,	O
but	O
a	O
[	B
p	B
##ico	I
##lini	I
##c	I
acid	O
+	O
Na	O
]	O
_	O
+	O
(	O
m	O
/	O
z	O
146	O
)	O
ion	O
was	O
also	O
present	O
.	O

Path	O
##way	O
of	O
try	B
##pt	I
##op	I
##han	I
degradation	O
.	O

-	B
car	I
##box	I
##ami	I
##de	I

In	O
W	O
##B	O
,	O
high	O
quality	O
,	O
q	O
##uant	O
##ifiable	O
s	O
##pect	O
##ra	O
were	O
obtained	O
with	O
the	O
use	O
of	O
a	O
met	B
##han	I
##ol	I
:	O
ch	B
##lor	I
##of	I
##orm	I
precipitation	O
.	O

On	O
the	O
day	O
of	O
extraction	O
of	O
ta	B
##mo	I
##xi	I
##fen	I
and	O
its	O
meta	O
##bol	O
##ites	O
,	O
the	O
serum	O
samples	O
were	O
th	O
##awed	O
at	O
room	O
temperature	O
under	O
subdued	O
lighting	O
conditions	O
(	O
subdued	O
lighting	O
conditions	O
is	O
the	O
natural	O
working	O
environment	O
of	O
choice	O
for	O
our	O
laboratory	O
)	O
.	O

l	O
A	O
total	O
of	O
18	O
meta	O
##bol	O
##ites	O
were	O
tentatively	O
identified	O
as	O
potential	O
bio	O
##mark	O
##ers	O
for	O
the	O
diagnosis	O
of	O
E	O
##SC	O
##C	O
:	O
five	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
(	O
l	O
##ys	O
##o	O
##PC	O
##s	O
)	O
,	O
car	B
##ni	I
##tine	I
and	O
four	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
,	O
three	O
organic	O
acids	O
,	O
four	O
fatty	O
acids	O
and	O
one	O
s	O
##tero	O
##l	O
meta	O
##bol	O
##ite	O
.	O

o	O
##j	O
o	O
##j	O
o	O
j	O
+	O
Xi	O
##1	O
Xi	O
##1	O
X	O
X	O
i	O
##1	O
i	O
##1	O
i	O
1	O
β	O
##1	O
##j	O
β	O
##1	O
##j	O
β	O
β	O
1	O
##j	O
1	O
##j	O
1	O
j	O
+	O
Xi	O
##2	O
Xi	O
##2	O
X	O
X	O
i	O
##2	O
i	O
##2	O
i	O
2	O
β	O
##2	O
##j	O
β	O
##2	O
##j	O
β	O
β	O
2	O
##j	O
2	O
##j	O
2	O
j	O
+	O
…	O
+	O
Xi	O
##p	O
Xi	O
##p	O
X	O
X	O
i	B
##p	I
i	I
##p	I
i	O
p	O
β	O
##p	O
##j	O
β	O
##p	O
##j	O
β	O
β	O
p	O
##j	O
p	O
##j	O
p	O
j	O
+	O
ε	O
##i	O
##j	O
ε	O
##i	O
##j	O
ε	O
ε	O
i	O
##j	O

Our	O
data	O
justify	O
further	O
investigations	O
on	O
the	O
role	O
of	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
in	O
HC	O
##C	O
.	O

Thus	O
,	O
the	O
phenomena	O
of	O
metabolic	O
in	O
##fle	O
##xi	O
##bility	O
mainly	O
described	O
in	O
T	O
##2	O
##D	O
and	O
other	O
insulin	O
-	O
resistant	O
states	O
could	O
explain	O
some	O
of	O
the	O
alterations	O
occurring	O
in	O
the	O
machinery	O
of	O
lip	O
##id	O
and	O
glucose	S
metabolism	O
,	O
.	O

Since	O
new	O
synthetic	O
can	B
##na	I
##bino	I
##ids	I
appear	O
on	O
the	O
market	O
regularly	O
,	O
adding	O
new	O
substances	O
will	O
be	O
a	O
constant	O
issue	O
.	O

Mel	B
##aton	I
##in	I
concentrations	O
were	O
measured	O
on	O
hourly	O
plasma	O
samples	O
by	O
radio	O
##im	O
##mu	O
##no	O
##ass	O
##ay	O
as	O
previously	O
described	O
.	O

The	O
central	O
node	O
in	O
the	O
HC	O
##V	O
plasma	O
network	O
(	O
b	O
)	O
is	O
se	B
##rine	I
,	O
which	O
is	O
connected	O
directly	O
to	O
the	O
three	O
BC	O
##AA	O
##s	O
,	O
le	B
##uc	I
##ine	I
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
and	O
v	B
##ali	I
##ne	I
(	O
positive	O
correlation	O
##s	O
)	O
,	O
and	O
also	O
to	O
my	O
##o	O
-	O
in	O
##os	O
##ito	O
##l	O

Using	O
the	O
Ma	O
##ven	O
software	O
,	O
103	O
variables	O
were	O
identified	O
in	O
a	O
targeted	O
approach	O
to	O
the	O
H	O
##IL	O
##IC	O
-	O
MS	O
analysis	O
and	O
consisted	O
of	O
sugar	O
##s	O
,	O
amino	O
acids	O
,	O
organic	O
acids	O
,	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
and	O
their	O
derivatives	O
.	O

Long	O
-	O
term	O
stability	O
of	O
PC	B
h	I
##ydro	I
##per	I
##oxide	I
##s	I
,	O
T	O
##AG	O
h	B
##ydro	I
##per	I
##oxide	I
##s	I
,	O
and	O
CE	O
h	B
##ydro	I
##per	I
##oxide	I
during	O
storage	O
at	O
−	O
##80	O
##°	O
##C	O
,	O
shown	O
by	O
box	O
plots	O
.	O

Therefore	O
,	O
our	O
requirement	O
to	O
concurrently	O
determine	O
g	B
##ly	I
##cola	I
##te	I
,	O
o	B
##xa	I
##late	I
,	O
and	O
g	B
##ly	I
##ox	I
##yla	I
##te	I
in	O
one	O
single	O
analysis	O
was	O
in	O
some	O
cases	O
also	O
the	O
reason	O
to	O
reject	O
a	O
potential	O
candidate	O
re	O
##age	O
##nt	O
for	O
der	O
##iva	O
##ti	O
##zation	O
.	O

The	O
C	O
##ID	O
mass	O
spectrum	O
of	O
the	O
pro	O
##ton	O
##ated	O
[	O
M	O
+	O
H	O
]	O
_	O
+	O
ion	O
confirmed	O
the	O
presence	O
of	O
the	O
p	B
##hos	I
##ph	I
##och	I
##olin	I
##e	I
polar	O
head	O
(	O
c	O
)	O
,	O
whereas	O
the	O
C	O
##ID	O
mass	O
spectrum	O
of	O
the	O
format	B
##e	I
add	O
##uc	O
##t	O
[	O
M	O
−	O
H	O
+	O
CH	O
##O	O
_	O
2	O
]	O
_	O
−	O
ion	O
enabled	O
the	O
detection	O
of	O
the	O
two	O
FA	B
C	I
##18	I
:	I
1	I
(	O
m	O
/	O
z	O
281	O
.	O
248	O
##7	O
)	O
and	O
FA	B
C	I
##16	I
:	I
0	I
(	O
m	O
/	O
z	O
255	O
.	O
232	O
##9	O
)	O
associated	O
fatty	O
acids	O
(	O
d	O
)	O
,	O
leading	O
to	O
an	O
improved	O
structural	O
characterization	O
of	O
this	O
lip	O
##id	O
species	O
The	O
characterization	O
of	O
is	O
##omer	O
##ic	O
lip	O
##id	O
species	O
constitutes	O
another	O
critical	O
issue	O
,	O
not	O
only	O
of	O
“	O
shotgun	O
lip	O
##ido	O
##mic	O
approaches	O
”	O
,	O
but	O
also	O
of	O
h	O
##y	O
##phe	O
##nated	O
liquid	O
ch	O
##roma	O
##tography	O
coupled	O
mass	O
s	O
##pect	O
##rome	O
##try	O
.	O

Two	O
f	O
##ae	O
##cal	O
Ba	O
##cter	O
##oid	O
##ete	O
##s	O
members	O
,	O
Ba	O
##cter	O
##oid	O
##es	O
f	O
##rag	O
##ilis	O
and	O
Para	O
##ba	O
##cter	O
##oid	O
##es	O
me	O
##rda	O
##e	O
,	O
showed	O
a	O
positive	O
correlation	O
with	O
portal	O
blood	O
pro	O
##in	O
##f	O
##lam	O
##mat	O
##ory	O
c	O
##yt	O
##oki	O
##nes	O
(	O
IL	O
##6	O
,	O
T	O
##NF	O
##α	O
,	O
IL	B
##1	I
##β	I
)	O

We	O
observed	O
that	O
eight	O
lip	O
##id	O
species	O
from	O
the	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##let	I
##han	I
##ola	I
##mine	I
and	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
lip	O
##id	O
classes	O
were	O
discovered	O
and	O
valid	O
##ated	O
to	O
vary	O
consistently	O
across	O
the	O
three	O
time	O
-	O
points	O
,	O
where	O
the	O
within	O
-	O
subject	O
variance	O
can	O
be	O
up	O
to	O
1	O
.	O
3	O
-	O
fold	O
higher	O
than	O
between	O
-	O
subject	O
variance	O
.	O

Finally	O
,	O
a	O
correlation	O
analysis	O
was	O
performed	O
between	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
and	O
t	B
##yr	I
##os	I
##ine	I
as	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
is	O
related	O
to	O
the	O
t	B
##yr	I
##os	I
##ine	I
metabolism	O
and	O
was	O
found	O
up	O
-	O
regulated	O
in	O
I	O
##B	O
##D	O
.	O

As	O
a	O
result	O
,	O
non	B
##ano	I
##ic	I
acid	I
(	O
C	O
##9	O
)	O
and	O
p	B
-	I
h	I
##ydro	I
##xy	I
##ben	I
##zoic	I
acid	I
displayed	O
relatively	O
high	O
sensitivity	O
,	O
with	O
values	O
of	O
86	O
.	O
7	O
%	O
and	O
90	O
%	O
,	O
respectively	O
.	O

Con	O
##cent	O
##ration	O
of	O
c	B
##rea	I
##tin	I
##ine	I
is	O
therefore	O
constant	O
and	O
within	O
-	O
person	O
var	O
##iability	O
is	O
relatively	O
low	O
in	O
healthy	O
people	O
,	O
as	O
long	O
as	O
the	O
muscle	O
mass	O
remains	O
constant	O
.	O

A	O
##bb	O
##re	O
##viation	O
:	O
D	O
##HP	O
##M	O
,	O
di	B
##hy	I
##dr	I
##opy	I
##rim	I
##id	I
##ine	I
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
disc	O
##re	O
##pan	O
##cy	O
noted	O
on	O
the	O
met	B
##hi	I
##oni	I
##ne	I
results	O
between	O
the	O
G	O
##C	O
-	O
MS	O
and	O
N	O
##MR	O
results	O
raises	O
the	O
issue	O
of	O
the	O
analytical	O
valid	O
##ation	O
of	O
meta	O
##bol	O
##ites	O
derived	O
from	O
un	O
##tar	O
##get	O
##ed	O
meta	O
##bol	O
##omi	O
##cs	O
methods	O
as	O
subsequent	O
steps	O
in	O
the	O
valid	O
##ation	O
of	O
candidate	O
F	O
##IB	O
##s	O
need	O
to	O
include	O
harm	O
##onized	O
sample	O
preparation	O
procedures	O
as	O
well	O
as	O
analytical	O
methods	O
whose	O
performance	O
(	O
sensitivity	O
,	O
precision	O
)	O
are	O
well	O
characterized	O
.	O

Considering	O
model	O
experiments	O
,	O
extra	O
##cellular	O
su	B
##cci	I
##nic	I
acid	I
increased	O
as	O
a	O
consequence	O
of	O
is	O
##che	O
##mia	O
or	O
h	O
##y	O
##pox	O
##ia	O
[	O
,	O
,	O
,	O
]	O
,	O
reaching	O
mill	O
##imo	O
##lar	O
concentrations	O
in	O
the	O
h	O
##y	O
##pox	O
##ic	O
area	O
.	O

α	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
was	O
increased	O
in	O
B	O
##D	O
patients	O
.	O

P	O
##las	O
##ma	O
from	O
patients	O
with	O
low	O
test	B
##osterone	I
(	O
<	O
8	O
nm	O
##ol	O
/	O
l	O
)	O
and	O
home	O
##ost	O
##atic	O
model	O
assessment	O
for	O
insulin	O
-	O
resistance	O
-	O
index	O
(	O
H	O
##OM	O
##A	O
##i	O
)	O
<	O
2	O
.	O
5	O
,	O
as	O
well	O
as	O
matched	O
controls	O
,	O
was	O
anal	O
##ys	O
##ed	O
by	O
U	O
##HP	O
##LC	O
and	O
mass	O
s	O
##pect	O
##rome	O
##try	O
.	O

If	O
increased	O
CO	O
##X	O
-	O
2	O
activity	O
is	O
responsible	O
for	O
elevated	O
u	O
##rina	O
##ry	O
P	O
##GE	O
-	O
M	O
levels	O
,	O
then	O
P	O
##GE	O
-	O
M	O
should	O
be	O
useful	O
as	O
a	O
bio	O
##mark	O
##er	O
to	O
determine	O
the	O
minimum	O
dose	O
of	O
a	O
selective	O
CO	O
##X	O
-	O
2	O
inhibitor	O
,	O
such	O
as	O
c	B
##ele	I
##co	I
##xi	I
##b	I
,	O
which	O
is	O
required	O
to	O
a	O
##bro	O
##gate	O
CO	O
##X	O
-	O
2	O
activity	O
in	O
smoke	O
##rs	O
.	O

The	O
mixture	O
was	O
der	O
##iva	O
##tized	O
with	O
Tri	O
-	O
Si	O
##l	O
and	O
prop	B
##yl	I
ch	I
##lor	I
##of	I
##orm	I
##ate	I
in	O
n	B
-	I
prop	I
##ano	I
##l	I
and	O
then	O
extracted	O
into	O
ch	B
##lor	I
##of	I
##orm	I
under	O
nitrogen	O
and	O
re	O
##con	O
##stituted	O
in	O
is	O
##o	O
-	O
o	O
##ct	O
##ane	O
:	B
ch	B
##lor	I
##of	I
##orm	I
.	O

Pre	O
##oper	O
##ative	O
ch	O
##em	O
##otherapy	O
was	O
administered	O
using	O
5	B
-	I
flu	I
##oro	I
##ura	I
##ci	I
##l	I
and	O
le	B
##uc	I
##ovo	I
##rin	I
:	O
two	O
cycles	O
of	O
an	O
in	O
##tra	O
##ven	O
##ous	O
b	O
##ol	O
##us	O
injection	O
of	O
5	B
-	I
flu	I
##oro	I
##ura	I
##ci	I
##l	I
(	O
400	O
mg	O
/	O
m	O
_	O
2	O
/	O
day	O
)	O
and	O
le	B
##uc	I
##ovo	I
##rin	I
(	O
20	O
mg	O
/	O
m	O
_	O
2	O
/	O
day	O
)	O
for	O
three	O
days	O
during	O
the	O
first	O
and	O
fifth	O
weeks	O
of	O
radio	O
##ther	O
##ap	O
##y	O
.	O

R	O
##umi	O
##no	O
##co	O
##cca	O
##ceae	O
_	O
UC	O
##G	O
–	O
00	O
##5	O
,	O
Lac	O
##hn	O
##os	O
##pi	O
##race	O
##ae	O
_	O
N	O
##K	O
##4	O
##A	O
##13	O
##6	O
_	O
group	O
,	O
B	O
##if	O
##ido	O
##ba	O
##cter	O
##ium	O
,	O
Para	O
##ba	O
##cter	O
##oid	O
##es	O
,	O
Ba	O
##cter	O
##oid	O
##es	O
,	O
In	B
##test	I
##ini	I
##ba	I
##cter	I
,	O
and	O
Sub	O
##do	O
##li	O
##gra	O
##nu	O
##lum	O
were	O
correlated	O
with	O
4	O
f	O
##ae	O
##cal	O
meta	O
##bol	O
##ites	O
(	O
Su	O
##pp	O
##lement	O
##ary	O
)	O
.	O

shows	O
10	O
p	O
##eptide	O
matches	O
for	O
Fr	O
##action	O
2	O
using	O
the	O
Spectrum	O
Mill	O
database	O
searching	O
tool	O
with	O
the	O
five	O
p	O
##hos	O
##ph	O
##ory	O
##lated	O
p	O
##eptide	O
##s	O
shown	O
and	O
including	O
p	B
##hos	I
##ph	I
##ory	I
##lation	I
##s	I
at	O
all	O
three	O
possible	O
sites	O
;	O
se	B
##rine	I
(	O
S	O
)	O
,	O
th	B
##re	I
##oni	I
##ne	I
(	O
T	O
)	O
,	O
and	O
t	B
##yr	I
##os	I
##ine	I
(	O
Y	O
)	O
.	O

A	O
##b	O
##nor	O
##mal	O
expression	O
of	O
car	B
##ni	I
##tine	I
##s	I
in	O
patients	O
with	O
ma	O
##li	O
##gna	O
##ncies	O
is	O
well	O
known	O
.	O

As	O
such	O
,	O
fewer	O
samples	O
had	O
a	O
result	O
for	O
g	B
##lut	I
##amine	I
.	O

Last	O
##ly	O
,	O
palm	B
##itic	I
c	O
##id	O
(	O
16	O
:	O
0	O
)	O
enhanced	O
,	O
while	O
LP	O
##Cs	O
##oy	O
significantly	O
in	O
##hibit	O
##ed	O
,	O
LP	O
##S	O
-	O
induced	O
production	O
of	O
IL	O
-	O
6	O
from	O
P	O
##BM	O
##Cs	O
.	O

A	O
##cc	O
##um	O
##ulation	O
of	O
car	B
##ni	I
##tine	I
in	O
the	O
serum	O
of	O
ST	O
##EM	O
##I	O
patients	O
may	O
be	O
in	O
##dicative	O
of	O
an	O
increased	O
β	O
-	O
oxidation	O
and	O
mitochondrial	O
d	O
##ys	O
##function	O
.	O

In	O
contrast	O
,	O
levels	O
of	O
n	O
##uc	O
##leo	O
##tide	O
##s	O
like	O
g	B
##uan	I
##ine	I
,	O
ad	B
##eni	I
##ne	I
,	O
thy	B
##mine	I
,	O
u	B
##rac	I
##il	I
,	O
x	B
##ant	I
##hine	I
,	O
and	O
g	B
##uan	I
##os	I
##ine	I
were	O
elevated	O
in	O
basal	O
BC	O
##a	O
cells	O
compared	O
to	O
the	O
l	O
##umi	O
##nal	O
counterparts	O
.	O

Di	O
##fference	O
##s	O
in	O
concentrations	O
of	O
lip	O
##id	O
species	O
in	O
plasma	O
and	O
skeletal	O
muscle	O
,	O
including	O
differences	O
that	O
al	O
##ign	O
with	O
(	O
A	O
)	O
insulin	O
resistance	O
,	O
(	O
B	O
)	O
skeletal	O
muscle	O
concentrations	O
of	O
c	B
##era	I
##mi	I
##de	I
species	O
,	O
(	O
C	O
)	O
differences	O
between	O
lip	O
##ids	O
in	O
plasma	O
and	O
skeletal	O
muscle	O
that	O
al	O
##ign	O
with	O
over	O
##weight	O
/	O
o	O
##besity	O
,	O
and	O
(	O
D	O
)	O
mixed	O
differences	O
.	O

SR	O
##M	O
-	O
based	O
q	O
##uant	O
##itation	O
confirmed	O
significant	O
differences	O
between	O
HC	O
##C	O
and	O
c	O
##ir	O
##r	O
##hot	O
##ic	O
controls	O
in	O
meta	O
##bol	O
##ite	O
levels	O
of	O
bi	O
##le	O
acid	O
meta	O
##bol	O
##ites	O
,	O
long	O
chain	O
car	B
##ni	I
##tine	I
##s	I
and	O
small	O
p	O
##eptide	O
.	O

N	B
-	I
met	I
##hyl	I
-	I
α	I
-	I
amino	I
##but	I
##yric	I
acid	I
was	O
detected	O
only	O
in	O
the	O
l	O
##yo	O
##phi	O
##li	O
##zed	O
samples	O
(	O
F	O
)	O
.	O

Yi	B
##j	I
=	I
β	I
##o	I
##j	I
+	I
Xi	I
##1	I
##β	I
##1	I
##j	I
+	I
Xi	I
##2	I
##β	I
##2	I
##j	I
+	I
…	I
+	I
Xi	I
##p	I
##β	I
##p	I
##j	I
+	I
ε	I
##i	I
##j	I

Of	O
70	O
u	O
##rina	O
##ry	O
meta	O
##bol	O
##ites	O
,	O
my	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
was	O
significantly	O
higher	O
in	O
F	O
##S	O
##GS	O
patients	O
than	O
in	O
control	O
patients	O
(	O
discovery	O
set	O
,	O
2	O
.	O
34	O
-	O
fold	O
,	O
P	O
<	O
0	O
.	O
00	O
##1	O
;	O
valid	O
##ation	O
set	O
,	O
2	O
.	O
35	O
-	O
fold	O
,	O
P	O
=	O
0	O
.	O
00	O
##8	O
)	O
and	O
MC	O
##D	O
patients	O
(	O
discovery	O
set	O
,	O
2	O
.	O
48	O
-	O
fold	O
,	O
P	O
=	O
0	O
.	O
00	O
##2	O
;	O
valid	O
##ation	O
set	O
,	O
1	O
.	O
69	O
-	O
fold	O
,	O
P	O
=	O
0	O
.	O
04	O
##2	O
)	O
.	O

Beta	O
-	O
coefficients	O
represent	O
the	O
change	O
in	O
total	O
ch	B
##ole	I
##ster	I
##ol	I
level	O
associated	O
with	O
each	O
inter	O
##qua	O
##rt	O
##ile	O
range	O
increase	O
in	O
lip	O
##id	O
class	O
concentration	O
at	O
week	O
48	O
.	O

The	O
ratio	O
of	O
the	O
2	O
-	O
h	O
##ydro	O
##xy	O
##lation	O
pathway	O
to	O
parent	O
est	O
##rogen	O
##s	O
was	O
associated	O
with	O
a	O
statistical	O
##ly	O
significantly	O
decreased	O
risk	O
of	O
breast	O
cancer	O
after	O
adjustment	O
for	O
un	O
##con	O
##ju	O
##gated	O
est	B
##rad	I
##iol	I
.	O

When	O
the	O
age	O
19	O
–	O
33	O
AD	O
##HD	O
subgroup	O
(	O
N	O
=	O
97	O
)	O
was	O
compared	O
to	O
the	O
control	O
group	O
(	O
18	O
–	O
33	O
,	O
N	O
=	O
131	O
)	O
,	O
lower	O
levels	O
of	O
try	B
##pt	I
##op	I
##han	I
[	O
0	O
.	O
71	O
(	O
0	O
.	O
51	O
–	O
0	O
.	O
99	O
,	O
0	O
.	O
05	O
)	O
]	O
,	O
H	O
##AA	O
[	O
0	O
.	O
66	O
(	O
0	O
.	O
47	O
–	O
0	O
.	O
91	O
,	O
0	O
.	O
01	O
)	O
]	O
and	O
rib	B
##of	I
##lav	I
##in	I
[	O
0	O
.	O
53	O
(	O
0	O
.	O
37	O
–	O
0	O
.	O
75	O
,	O
<	O
0	O
.	O
00	O
##1	O
)	O
]	O
,	O
and	O
higher	O
levels	O
of	O
co	B
##tin	I
##ine	I
[	O
7	O
.	O
84	O
(	O
4	O
.	O
63	O
–	O
14	O
.	O
22	O
,	O
<	O
0	O
.	O
00	O
##1	O
)	O
]	O
were	O
significantly	O
associated	O
with	O
increased	O
risk	O
of	O
having	O
AD	O
##HD	O
.	O

We	O
recognise	O
that	O
H	O
##OM	O
##A	O
I	O
##R	O
is	O
not	O
an	O
ideal	O
index	O
of	O
insulin	O
resistance	O
but	O
in	O
general	O
population	O
studies	O
it	O
is	O
often	O
imp	O
##ractical	O
to	O
perform	O
e	B
##ug	I
##ly	I
##ce	I
##mic	I
h	O
##yper	O
##ins	O
##ulin	O
##em	O
##ic	O
c	O
##lamp	O
studies	O
in	O
all	O
subjects	O
and	O
,	O
in	O
this	O
case	O
,	O
H	O
##OM	O
##A	O
I	O
##R	O
and	O
fast	O
##ing	O
insulin	O
are	O
satisfactory	O
sur	O
##rogate	O
measures	O
.	O

The	O
MS	O
_	O
3	O
s	O
##pect	O
##ra	O
correspond	O
to	O
GP	O
-	O
tag	O
##ged	O
7	B
##α	I
-	I
h	I
##ydro	I
##xy	I
-	I
3	I
,	I
x	I
-	I
bi	I
##so	I
##x	I
##och	I
##ole	I
##st	I
-	I
4	I
-	I
en	I
-	I
26	I
-	I
o	I
##ic	I
acid	I
(	O
c	O
)	O
,	O
and	O
7	B
##α	I
,	I
x	I
-	I
di	I
##hy	I
##dr	I
##ox	I
##y	I
-	I
3	I
-	I
o	I
##x	I
##och	I
##ole	I
##st	I
-	I
4	I
-	I
en	I
-	I
26	I
-	I
o	I
##ic	I
acid	I
(	O
d	O
)	O
.	O

Down	O
-	O
regulation	O
of	O
la	B
##ct	I
##ate	I
as	O
observed	O
in	O
our	O
HC	O
##C	O
samples	O
may	O
favor	O
tumor	O
growth	O
.	O

Ph	B
##os	I
##ph	I
##oli	I
##pid	I
fatty	O
acid	O
composition	O
of	O
human	O
color	O
##ec	O
##tal	O
tumors	O
.	O

Indeed	O
,	O
most	O
c	B
##era	I
##mi	I
##des	I
retained	O
significant	O
positive	O
associations	O
with	O
ad	O
##ip	O
##one	O
##ct	O
##in	O
even	O
with	O
the	O
use	O
of	O
B	O
##MI	O
as	O
a	O
co	O
##var	O
##iate	O
.	O

Of	O
notes	O
,	O
P	O
##G	O
##D	O
##2	O
as	O
well	O
as	O
5	O
-	O
and	O
15	B
-	I
H	I
##ET	I
##E	I
are	O
media	O
##tors	O
of	O
inflammation	O
.	O

_	O
a	O
N	B
-	I
des	I
##met	I
##hyl	I
-	I
ace	I
##tam	I
##ip	I
##rid	I
_	O
a	O
N	B
-	I
des	I
##met	I
##hyl	I
-	I
ace	I
##tam	I
##ip	I
##rid	I
S	O
is	O
the	O
slope	O
of	O
the	O
ca	O
##li	O
##bra	O
##tion	O
curve	O
.	O

Palm	B
##itic	I
acid	I
trend	O
##ed	O
upward	O
in	O
Q	O
##3	O
-	O
4	O
,	O
whereas	O
l	B
##ino	I
##le	I
##ic	I
and	O
l	O
##ign	O
##oc	O
##eric	O
acids	O
trend	O
##ed	O
lower	O
.	O

P	B
##yr	I
##og	I
##lut	I
##ami	I
##c	I
acid	I
,	O
a	O
c	O
##y	O
##c	O
##li	O
##zed	O
derivative	O
of	O
L	B
-	I
g	I
##lut	I
##ami	I
##c	I
acid	I
,	O
is	O
formed	O
none	O
##nz	O
##ym	O
##atic	O
##ally	O
from	O
g	B
##lut	I
##ama	I
##te	I
,	O
g	B
##lut	I
##amine	I
,	O
and	O
γ	O
-	O
g	O
##lut	O
##am	O
##yla	O
##ted	O
p	O
##eptide	O
##s	O
,	O
but	O
it	O
can	O
also	O
be	O
produced	O
through	O
the	O
action	O
of	O
γ	O
-	O
g	O
##lut	O
##am	O
##yl	O
##cy	O
##c	O
##lot	O
##ran	O
##s	O
##fer	O
##ase	O
on	O
L	O
-	O
amino	O
acid	O
.	O

As	O
reported	O
in	O
the	O
literature	O
,	O
la	B
##ct	I
##ate	I
(	O
coupled	O
with	O
p	B
##yr	I
##u	I
##vate	I
and	O
glucose	S
)	O
is	O
the	O
most	O
sensitive	O
marker	O
for	O
sample	O
degradation	O
.	O

Ch	O
##roma	O
##to	O
##graphic	O
separation	O
of	O
(	O
A	O
)	O
18	O
SP	O
##Ms	O
(	O
100	O
n	O
##M	O
each	O
)	O
and	O
(	O
B	O
)	O
5	O
de	O
##uter	O
##ated	O
internal	O
standards	O
(	O
20	O
n	O
##M	O
)	O
covered	O
by	O
the	O
method	O
including	O
(	O
C	O
)	O
D	O
##HA	O
derived	O
D	O
-	O
series	O
re	O
##sol	O
##vin	O
##s	O
,	O
(	O
D	O
)	O
EPA	O
derived	O
E	O
-	O
series	O
re	O
##sol	O
##vin	O
##s	O
,	O
(	O
E	O
)	O
EPA	O
and	O
AR	O
##A	O
derived	O
lip	B
##ox	I
##ins	I
,	O
D	O
##HA	O
derived	O
(	O
F	O
)	O
protect	O
##ins	O
,	O
and	O
(	O
G	O
)	O
mare	O
##sin	O
##s	O
.	O

These	O
are	O
the	O
same	O
people	O
who	O
exhibited	O
high	O
insulin	O
sensitivity	O
,	O
low	O
post	O
##pra	O
##ndi	O
##al	O
na	O
##dir	O
FF	O
##A	O
concentrations	O
,	O
and	O
a	O
switch	O
to	O
glucose	S
oxidation	O
in	O
the	O
fed	O
state	O
.	O

So	O
,	O
it	O
is	O
certain	O
that	O
during	O
β	O
-	O
th	O
##ala	O
##sse	O
##mia	O
because	O
of	O
metabolic	O
stress	O
g	B
##ly	I
##cer	I
##ol	I
is	O
more	O
consumed	O
for	O
energy	O
production	O
.	O

The	O
predicted	O
3D	O
model	O
of	O
the	O
album	O
##in	O
-	O
like	O
protein	O
of	O
Atlantic	S
co	O
##d	O
(	O
G	O
##ad	O
##us	O
m	O
##or	O
##hua	O
)	O
based	O
upon	O
its	O
amino	O
acid	O
sequence	O
1	O
–	O
85	O
.	O

Alt	O
##ered	O
meta	O
##bol	O
##ite	O
levels	O
could	O
reflect	O
disturbed	O
g	O
##ly	O
##come	O
##ta	O
##bol	O
##ism	O
(	O
g	O
##ly	O
##co	O
##lysis	O
and	O
the	O
T	O
##CA	O
cycle	O
)	O
,	O
fatty	O
acids	O
,	O
amino	O
acids	O
,	O
ch	B
##olin	I
##e	I
,	O
k	B
##eton	I
##e	I
bodies	O
,	O
n	O
##uc	O
##leo	O
##tide	O
##s	O
,	O
and	O
lip	O
##id	O
metabolism	O
.	O

Co	O
##rrel	O
##ations	O
between	O
the	O
k	B
##yn	I
##uren	I
##ine	I
meta	O
##bol	O
##ite	O
measurements	O
and	O
the	O
c	O
##yt	O
##oki	O
##ne	O
measurements	O
are	O
provided	O
in	O
.	O

They	O
found	O
that	O
the	O
presence	O
of	O
BA	O
(	O
200	O
m	O
##M	O
)	O
regardless	O
of	O
temperature	O
and	O
duration	S
of	O
storage	O
affected	O
the	O
metabolic	O
composition	O
of	O
urine	O
.	O

The	O
authors	O
followed	O
through	O
with	O
a	O
targeted	O
MS	O
approach	O
that	O
q	O
##uant	O
##ified	O
sa	B
##rc	I
##os	I
##ine	I
levels	O
in	O
89	O
tissue	O
samples	O
(	O
36	O
PC	O
##a	O
,	O
25	O
ben	O
##ign	O
,	O
and	O
28	O
meta	O
##static	O
)	O
.	O

The	O
observation	O
of	O
PGA	O
may	O
also	O
point	O
towards	O
g	B
##ly	I
##cine	I
deficiency	O
[	O
]	O
,	O
whilst	O
the	O
higher	O
u	O
##rina	O
##ry	O
ex	O
##cre	O
##tion	O
of	O
many	O
essential	O
and	O
non	O
-	O
essential	O
amino	O
acid	O
mainly	O
reflected	O
higher	O
protein	O
breakdown	O
related	O
to	O
higher	O
metabolic	O
requirements	O
in	O
I	O
##B	O
##D	O
children	O
.	O

Similarly	O
,	O
a	O
number	O
of	O
B	O
vitamin	O
##s	O
,	O
namely	O
ni	B
##cot	I
##ina	I
##mi	I
##de	I
,	O
th	B
##iam	I
##in	I
,	O
p	B
##yr	I
##ido	I
##xin	I
##e	I
,	O
rib	B
##of	I
##lav	I
##in	I
,	O
p	B
-	I
amino	I
##ben	I
##zoic	I
acid	I
and	O
bio	B
##tin	I
,	O
were	O
shown	O
to	O
be	O
essential	O
to	O
R	O
.	O
pro	O
##lix	O
##us	O
m	O
##olt	O
##ing	O
and	O
were	O
associated	O
with	O
s	O
##ym	O
##bio	O
##nts	O
.	O

Further	O
,	O
kitchen	O
workers	O
who	O
were	O
smoke	O
##rs	O
,	O
consuming	O
alcohol	O
,	O
ca	B
##ffe	I
##ine	I
,	O
vitamin	O
supplement	O
##s	O
or	O
medicines	O
like	O
ps	O
##ych	O
##ot	O
##ropic	O
drugs	O
,	O
anti	O
##hy	O
##pert	O
##ens	O
##ive	O
drugs	O
and	O
anti	B
##his	I
##tamine	I
##s	I
were	O
excluded	O
from	O
the	O
study	O
,	O
as	O
these	O
chemicals	O
can	O
in	O
##hibit	O
the	O
##rm	O
##ore	O
##gu	O
##lation	O
and	O
interfere	O
with	O
the	O
study	O
.	O

The	O
mobile	O
phase	O
(	O
met	O
##han	O
##ol	O
‐	O
10	O
mm	O
##ol	O
/	O
L	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
containing	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
(	O
80	O
:	O
20	O
,	O
v	O
/	O
v	O
)	O
)	O
pumped	O
at	O
a	O
flow	O
rate	O
of	O
0	O
.	O
3	O
m	O
##L	O
/	O
min	O
,	O
the	O
is	O
##oc	O
##ratic	O
el	O
##ution	O
time	O
is	O
2	O
minutes	O
.	O

Those	O
who	O
developed	O
AP	S
were	O
matched	O
1	O
:	O
2	O
by	O
age	O
and	O
gender	O
with	O
controls	O
who	O
did	O
not	O
develop	O
AP	S
for	O
comparison	O
via	O
meta	O
##bol	O
##omi	O
##cs	O
.	O

Inc	O
##reased	O
plasma	O
P	O
##FA	O
##S	O
concentrations	O
were	O
associated	O
with	O
metabolic	O
per	O
##tur	O
##bation	O
in	O
numerous	O
amino	O
acids	O
and	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
,	O
key	O
metabolic	O
pathways	O
previously	O
found	O
also	O
to	O
be	O
altered	O
in	O
N	O
##AF	O
##LD	O
/	O
NAS	O
##H	O
.	O

However	O
,	O
a	O
significant	O
effect	O
on	O
ben	B
##zen	I
##e	I
metabolism	O
and	O
ex	O
##cre	O
##tion	O
was	O
seen	O
following	O
treatment	O
with	O
the	O
br	O
##occo	O
##li	O
beverage	O
,	O
indicating	O
a	O
potential	O
,	O
partial	O
role	O
for	O
N	O
##R	O
##F	O
##2	O
in	O
the	O
actions	O
of	O
SF	S
in	O
this	O
setting	O
.	O

In	O
combination	O
with	O
the	O
conventional	O
tumor	O
marker	O
CE	O
##A	O
,	O
which	O
had	O
an	O
AU	O
##RO	O
##C	O
(	O
0	O
.	O
79	O
##4	O
)	O
comparable	O
to	O
the	O
recent	O
literature	O
(	O
Wild	O
et	O
al	O
.	O
)	O
,	O
g	B
##ly	I
##cine	I
and	O
t	B
##yr	I
##os	I
##ine	I
,	O
however	O
,	O
introduced	O
a	O
surplus	O
of	O
8	O
%	O
,	O
suggesting	O
that	O
—	O
regarding	O
their	O
AU	O
##RO	O
##Cs	O
of	O
0	O
.	O
70	O
##7	O
and	O
0	O
.	O
63	O
##6	O
as	O
single	O
markers	O
—	O
their	O
principal	O
value	O
might	O
be	O
of	O
add	O
##itive	O
nature	O
and	O
be	O
missed	O
when	O
routinely	O
available	O
CE	O
##A	O
concentrations	O
are	O
not	O
taken	O
into	O
account	O
.	O

Four	O
of	O
the	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
had	O
increased	O
levels	O
in	O
plasma	O
samples	O
from	O
PC	O
##a	O
patients	O
compared	O
with	O
BP	O
##H	O
controls	O
.	O

Although	O
patients	O
with	O
liver	O
failure	O
were	O
excluded	O
,	O
some	O
patients	O
showed	O
significant	O
variations	O
in	O
relevant	O
bio	O
##chemical	O
bio	O
##mark	O
##ers	O
,	O
such	O
as	O
direct	O
bi	B
##li	I
##ru	I
##bin	I
,	O
total	O
bi	B
##li	I
##ru	I
##bin	I
,	O
total	O
bi	O
##le	O
acid	O
,	O
al	O
##kal	O
##ine	O
p	O
##hos	O
##pha	O
##tase	O
,	O
γ	O
‐	O
g	O
##lut	O
##am	O
##yl	O
##tra	O
##ns	O
##fer	O
##ase	O
,	O
as	O
##par	O
##tate	O
amino	O
##tra	O
##ns	O
##fer	O
##ase	O
,	O
α	O
‐	O
h	O
##ydro	O
##xy	O
##but	O
##yric	O
de	O
##hy	O
##dr	O
##ogen	O
##ase	O
,	O
and	O
la	O
##ct	O
##ate	O
de	O
##hy	O
##dr	O
##ogen	O
##ase	O
.	O

Three	O
meta	O
##bol	O
##ites	O
had	O
distinct	O
patterns	O
in	O
the	O
2	O
populations	O
:	O
ta	B
##uri	I
##ne	I
,	O
an	O
AA	O
not	O
used	O
in	O
protein	O
synthesis	O
but	O
which	O
is	O
important	O
for	O
f	O
##etal	O
growth	O
and	O
place	O
##ntal	O
function	O
;	O
th	B
##re	I
##oni	I
##ne	I
,	O
an	O
essential	O
AA	O
;	O
and	O
ch	B
##olin	I
##e	I
,	O
a	O
major	O
component	O
of	O
cell	O
membrane	O
##s	O
that	O
is	O
critical	O
for	O
f	O
##etal	O
brain	O
development	O
(	O
,	O
)	O
.	O

For	O
the	O
G	O
##C	O
–	O
MS	O
analysis	O
,	O
p	B
##yr	I
##id	I
##ine	I
and	O
N	B
-	I
met	I
##hyl	I
-	I
N	I
-	I
trim	I
##eth	I
##yl	I
##si	I
##ly	I
##l	I
t	I
##ri	I
##f	I
##lu	I
##oro	I
##ace	I
##tam	I
##ide	I
were	O
obtained	O
from	O
Mall	O
##in	O
##ck	O
##rod	O
##t	O
Baker	O
B	O
##V	O
(	O
Dev	O
##enter	O
,	O
The	O
Netherlands	O
)	O
and	O
All	O
##tech	O
(	O
B	O
##red	O
##a	O
,	O
The	O
Netherlands	O
)	O
,	O
respectively	O
.	O

OS	O
##C	O
-	O
P	O
##LS	O
-	O
D	O
##A	O
of	O
blood	O
serum	O
comparing	O
patients	O
in	O
post	O
treatment	O
re	O
##mission	O
versus	O
re	O
##lap	O
##se	O
(	O
groups	O
B	O
and	O
C	O
##2	O
)	O
identified	O
car	B
##ni	I
##tine	I
and	O
ace	B
##ty	I
##l	I
##car	I
##ni	I
##tine	I
as	O
disc	O
##rim	O
##inator	O
##y	O
meta	O
##bol	O
##ites	O
that	O
increase	O
on	O
re	O
##lap	O
##se	O
.	O

[	O
D	O
_	O
10	O
]	O
Ph	O
##e	O
##O	O
-	O
N	O
##AC	O
was	O
prepared	O
the	O
same	O
way	O
from	O
[	B
D	I
_	I
10	I
]	I
Ph	I
##e	I
-	I
9	I
,	I
10	I
-	I
e	I
##pox	I
##ide	I
,	O
which	O
in	O
turn	O
was	O
synthesized	O
from	O
[	O
D	O
_	O
10	O
]	O
Ph	O
##e	O
(	O
Cambridge	O
Is	O
##oto	O
##pe	O
Laboratories	O
,	O
And	O
##over	O
,	O
MA	O
)	O
.	O

T	O
##MA	O
could	O
be	O
converted	O
by	O
ch	B
##olin	I
##e	I
via	O
gut	O
micro	O
##bio	O
##ta	O
and	O
then	O
de	O
##to	O
##xi	O
##fied	O
through	O
fl	O
##avi	O
##n	O
mon	O
##oo	O
##xy	O
##gen	O
##ase	O
in	O
the	O
liver	O
,	O
forming	O
T	B
##MA	I
##O	I
.	O

The	O
reversed	O
phase	O
ch	O
##roma	O
##to	O
##graphic	O
conditions	O
were	O
adapted	O
from	O
Hu	O
et	O
al	O
.	O
.	O
Met	B
##han	I
##ol	I
was	O
preferred	O
to	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
since	O
it	O
has	O
been	O
observed	O
that	O
it	O
decreased	O
the	O
carry	O
##over	O
of	O
most	O
a	O
##pol	O
##ar	O
lip	O
##id	O
species	O
(	O
data	O
not	O
shown	O
)	O
.	O

Statistical	O
##ly	O
significant	O
correlation	O
was	O
observed	O
between	O
plasma	O
20	B
-	I
H	I
##ET	I
##E	I
and	O
PR	O
##A	O
either	O
when	O
all	O
of	O
the	O
studied	O
subjects	O
were	O
considered	O
(	O
n	O
=	O
30	O
)	O
or	O
when	O
only	O
data	O
from	O
patients	O
with	O
R	O
##VD	O
were	O
analyzed	O
.	O

However	O
,	O
7	O
un	O
##sat	O
##ura	O
##ted	O
PC	O
species	O
decreased	O
significantly	O
stronger	O
in	O
the	O
T	O
##CF	O
##7	O
##L	O
##2	O
group	O
(	O
PC	O
a	O
##a	O
C	B
##36	I
:	I
6	I
,	O
PC	B
a	I
##a	I
C	I
##40	I
:	I
4	I
,	O
PC	B
a	I
##e	I
C	I
##40	I
:	I
2	I
,	O
PC	B
a	I
##e	I
C	I
##40	I
:	I
5	I
,	O
PC	B
a	I
##e	I
C	I
##44	I
:	I
5	I
,	O
PC	B
a	I
##e	I
C	I
##44	I
:	I
6	I
)	O
.	O

For	O
the	O
whole	O
blood	O
stimulation	O
experiments	O
,	O
blood	O
(	O
1	O
m	O
##L	O
)	O
was	O
in	O
##cu	O
##bate	O
##d	O
in	O
15	O
-	O
m	O
##L	O
con	O
##ical	O
tubes	O
(	O
B	O
##D	O
B	O
##ios	O
##cie	O
##nces	O
)	O
for	O
3	O
h	O
with	O
individual	O
fatty	O
acids	O
(	O
10	O
μ	O
##M	O
final	O
concentration	O
for	O
all	O
)	O
or	O
ethanol	S
vehicle	O
control	O
.	O

Because	O
we	O
chose	O
log	O
##ari	O
##th	O
##mic	O
bases	O
as	O
described	O
above	O
,	O
the	O
hazard	O
ratio	O
associated	O
with	O
a	O
unit	O
increase	O
in	O
the	O
log	O
-	O
transformed	O
continuous	O
est	B
##rogen	I
or	O
est	B
##rogen	I
metabolism	O
measure	O
approximately	O
represents	O
the	O
relative	O
risk	O
comparing	O
the	O
highest	O
with	O
the	O
lowest	O
de	O
##ci	O
##le	O
of	O
the	O
measure	O
.	O

Similarly	O
,	O
no	O
peak	O
interference	O
##s	O
were	O
observed	O
for	O
the	O
studied	O
hem	O
##oly	O
##zed	O
matrix	O
and	O
add	O
##itive	O
##s	O
matrix	O
containing	O
lit	B
##hium	I
he	I
##par	I
##in	I
,	O
E	O
##D	O
##TA	O
and	O
c	B
##it	I
##ric	I
acid	I
.	O

For	O
the	O
model	O
based	O
on	O
the	O
samples	O
obtained	O
before	O
treatment	O
,	O
the	O
combination	O
of	O
as	B
##par	I
##tate	I
and	O
g	B
##lut	I
##ama	I
##te	I
showed	O
an	O
accuracy	O
of	O
100	O
%	O
in	O
R	O
##OC	O
(	O
Figure	O
)	O
.	O

In	O
adjusted	O
models	O
,	O
post	O
##men	O
##op	O
##aus	O
##al	O
status	O
and	O
vitamin	B
C	I
supplement	O
use	O
were	O
significantly	O
associated	O
with	O
higher	O
F	O
_	O
2	O
-	O
Is	O
##o	O
##Ps	O
levels	O
.	O

With	O
increasing	O
evidence	O
suggesting	O
that	O
R	O
##OS	O
may	O
be	O
involved	O
in	O
end	O
##ome	O
##tri	O
##osis	O
progression	O
,	O
it	O
may	O
be	O
worth	O
##while	O
to	O
further	O
explore	O
the	O
role	O
of	O
pro	B
##line	I
in	O
the	O
path	O
##ogen	O
##esis	O
of	O
the	O
disease	O
.	O

Interest	O
##ingly	O
,	O
the	O
metabolic	O
‘	O
impact	O
’	O
of	O
PC	O
##OS	O
was	O
modest	O
in	O
women	O
with	O
a	O
small	O
waist	O
c	O
##ir	O
##cum	O
##ference	O
apart	O
from	O
a	O
tendency	O
for	O
higher	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
V	O
##LD	O
##L	O
ch	B
##ole	I
##ster	I
##ol	I
and	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
(	O
[UNK]	O
cm	O
)	O
.	O

The	O
main	O
outcome	O
measures	O
were	O
acute	O
effects	O
of	O
as	B
##par	I
##tam	I
##e	I
measured	O
using	O
repeated	O
ratings	O
of	O
14	O
symptoms	O
,	O
bio	O
##chemistry	O
and	O
meta	O
##bon	O
##omi	O
##cs	O
.	O

In	O
contrast	O
to	O
fi	O
##bri	O
##no	O
##gen	O
,	O
the	O
serum	O
trans	B
##thy	I
##ret	I
##in	I
levels	O
were	O
slightly	O
lower	O
in	O
the	O
CR	O
##C	O
samples	O
(	O
160	O
.	O
39	O
±	O
62	O
.	O
41	O
ng	O
/	O
m	O
##L	O
)	O
than	O
in	O
the	O
control	O
samples	O
(	O
171	O
.	O
19	O
±	O
30	O
.	O
86	O
ng	O
/	O
m	O
##L	O
)	O

In	O
that	O
regard	O
,	O
we	O
recently	O
demonstrated	O
that	O
T	O
##2	O
##DM	O
youth	O
have	O
lower	O
fatty	O
acid	O
-	O
derived	O
medium	O
-	O
to	O
short	O
-	O
chain	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
species	O
,	O
consistent	O
with	O
enhanced	O
,	O
rather	O
than	O
reduced	O
,	O
mitochondrial	O
use	O
of	O
these	O
intermediate	O
##s	O
,	O
despite	O
having	O
similar	O
inputs	O
into	O
β	O
-	O
oxidation	O
to	O
their	O
lean	O
counterparts	O
.	O

The	O
subjects	O
were	O
lying	O
in	O
a	O
su	B
##pine	I
position	O
throughout	O
the	O
e	B
##ug	I
##ly	I
##ce	I
##mic	I
-	I
h	I
##yper	I
##ins	I
##ulin	I
##em	I
##ic	I
c	O
##lamp	O
and	O
P	O
##ET	O
scanning	O
.	O

Important	O
##ly	O
,	O
no	O
difference	O
was	O
observed	O
in	O
serum	O
levels	O
of	O
P	O
##GE	O
_	O
2	O
and	O
15	B
-	I
H	I
##ET	I
##E	I
,	O
suggesting	O
C	O
##NS	O
-	O
specific	O
effects	O
.	O

In	O
addition	O
,	O
the	O
al	O
##de	O
##hy	O
##des	O
and	O
k	B
##eton	I
##es	I
are	O
enhanced	O
in	O
the	O
urine	O
of	O
patients	O
,	O
even	O
if	O
this	O
relationship	O
has	O
no	O
significant	O
character	O
.	O

RC	O
##E	O
(	O
A	O
)	O
and	O
its	O
major	O
is	B
##of	I
##lav	I
##ones	I
(	O
Figure	O
S	O
##1	O
)	O
,	O
G	O
##N	O
,	O
D	O
##Z	O
,	O
BA	O
,	O
and	O
F	O
##N	O
,	O
showed	O
no	O
effect	O
.	O

A	O
key	O
finding	O
is	O
the	O
inverse	O
association	O
of	O
t	B
##yr	I
##os	I
##ine	I
with	O
risk	O
of	O
micro	O
##vas	O
##cular	O
events	O
,	O
independent	O
of	O
e	O
##G	O
##F	O
##R	O
and	O
u	O
##rina	O
##ry	O
AC	O
##R	O
.	O

G	B
##ly	I
##cine	I
has	O
been	O
reported	O
to	O
negatively	O
co	O
##rrel	O
##ate	O
with	O
go	O
##ut	O
in	O
other	O
metabolic	O
studies	O
.	O

After	O
fix	O
##ation	O
,	O
the	O
tissue	O
is	O
de	O
##hy	O
##dra	O
##ted	O
via	O
a	O
series	O
of	O
graded	O
ethanol	O
##s	O
followed	O
by	O
x	B
##yle	I
##nes	I
and	O
finally	O
liquid	O
para	B
##ffin	I
.	O

One	O
of	O
the	O
principal	O
element	O
of	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
and	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
is	O
g	B
##ly	I
##cer	I
##ol	I
that	O
can	O
be	O
utilize	O
as	O
a	O
source	O
of	O
energy	O
after	O
conversion	O
in	O
to	O
glucose	S
by	O
liver	O
.	O

A	O
previous	O
report	O
also	O
indicated	O
that	O
decreased	O
medium	O
-	O
and	O
long	O
-	O
chain	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
could	O
be	O
found	O
in	O
the	O
urine	O
of	O
non	O
-	O
SC	O
##LC	O
patients	O
,	O
whereas	O
the	O
exact	O
biological	O
significance	O
is	O
still	O
el	O
##usive	O
.	O

For	O
example	O
,	O
increased	O
f	O
##uc	O
##osy	O
##lation	O
despite	O
low	O
gal	B
##act	I
##ose	I
levels	O
of	O
the	O
I	O
##g	O
##G	O
F	O
##c	O
region	O
strongly	O
m	O
##od	O
##ifies	O
anti	O
##body	O
binding	O
capacities	O
and	O
induce	O
##s	O
abnormal	O
inflammatory	O
reaction	O
[	O
,	O
]	O
.	O

Para	O
##lle	O
##ls	O
are	O
often	O
drawn	O
between	O
hydrogen	B
su	I
##l	I
##phi	I
##de	I
and	O
NO	O
,	O
both	O
of	O
which	O
have	O
dual	O
protective	O
and	O
inflammatory	O
roles	O
depending	O
upon	O
the	O
concentrations	O
generated	O
and	O
the	O
local	O
environment	O
.	O

This	O
adult	O
vs	O
.	O
p	O
##ediatric	O
contrast	O
was	O
also	O
present	O
in	O
our	O
previous	O
publication	O
of	O
positive	O
associations	O
between	O
IS	O
and	O
several	O
AA	O
##s	O
and	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
in	O
youth	O
in	O
distinction	O
to	O
adults	O
(	O
–	O
,	O
)	O
.	O

β	B
-	I
act	I
##in	I
was	O
used	O
for	O
protein	O
normal	O
##ization	O
.	O

Of	O
the	O
20	O
amino	O
acids	O
q	O
##uant	O
##ified	O
,	O
only	O
c	B
##it	I
##ru	I
##llin	I
##e	I
and	O
a	B
##rg	I
##ini	I
##ne	I
had	O
significantly	O
increased	O
levels	O
in	O
HD	O
compared	O
to	O
control	O
sheep	O
.	O

The	O
gut	O
micro	O
##bio	O
##ta	O
play	O
a	O
key	O
role	O
in	O
hip	B
##pura	I
##te	I
home	O
##ost	O
##asis	O
through	O
meta	O
##bol	O
##izing	O
a	O
##romatic	O
compounds	O
to	O
form	O
ben	B
##zo	I
##ate	I
and	O
m	O
##od	O
##ulating	O
hip	B
##pura	I
##te	I
u	O
##rina	O
##ry	O
ex	O
##cre	O
##tion	O
.	O
_	O
,	O

Furthermore	O
,	O
a	O
reduction	O
of	O
but	O
##yra	O
##te	O
‐	O
producing	O
gut	O
bacteria	O
has	O
been	O
observed	O
following	O
lap	O
##aro	O
##scopic	O
sleeve	O
gas	O
##tre	O
##ct	O
##omy	O
.	O
55	O
Hence	O
,	O
lower	O
levels	O
of	O
but	B
##yra	I
##te	I
post	O
‐	O
R	O
##Y	O
##GB	O
in	O
the	O
present	O
study	O
could	O
be	O
due	O
to	O
either	O
lower	O
consumption	O
of	O
diet	O
##ary	O
fibre	O
/	O
resistant	O
star	O
##ch	O
and	O
/	O
or	O
alterations	O
in	O
the	O
gut	O
micro	O
##bio	O
##ta	O
following	O
R	O
##Y	O
##GB	O
surgery	O
.	O

In	O
presence	O
of	O
M	O
##n	O
##O	O
_	O
2	O
est	O
##rogen	O
##s	O
were	O
o	O
##xi	O
##dized	O
to	O
q	B
##uin	I
##one	I
met	O
##hi	O
##des	O
.	O

B	O
##rief	O
##ly	O
,	O
to	O
3	O
m	O
##L	O
of	O
dried	O
plasma	O
lip	O
##id	O
extract	O
##s	O
,	O
pu	O
##rified	O
by	O
an	O
##ion	O
exchange	O
,	O
were	O
added	O
20	O
μ	O
##L	O
of	O
trip	B
##hen	I
##yl	I
##ph	I
##os	I
##phine	I
(	O
2	O
.	O
6	O
mg	O
/	O
m	O
##L	O
ace	O
##ton	O
##it	O
##ril	O
##e	O
)	O
,	O
20	O
μ	O
##L	O
di	B
##thi	I
##opy	I
##rid	I
##ine	I
(	O
2	O
.	O
2	O
mg	O
/	O
m	O
##L	O
ace	O
##ton	O
##it	O
##ril	O
##e	O
)	O
,	O
and	O
20	O
μ	O
##L	O
2	B
-	I
p	I
##ico	I
##ly	I
##lam	I
##ine	I
(	O
20	O
μ	O
##L	O
2	B
-	I
p	I
##ico	I
##ly	I
##lam	I
##ine	I
/	O
m	O
##l	O
ace	O
##ton	O
##it	O
##ril	O
##e	O
)	O
.	O

Interest	O
##ingly	O
,	O
higher	O
PA	O
##L	O
_	O
DL	O
##W	O
levels	O
in	O
Met	O
##S	O
_	O
any	O
women	O
were	O
associated	O
with	O
se	B
##rine	I
levels	O
comparable	O
to	O
the	O
less	O
active	O
Met	O
##S	O
_	O
zero	O
women	O
.	O

Also	O
supporting	O
the	O
H	O
##E	O
-	O
related	O
systemic	O
mi	O
##lie	O
##u	O
,	O
there	O
was	O
higher	O
in	B
##os	I
##ito	I
##l	I
which	O
is	O
ex	O
##tr	O
##uded	O
from	O
as	O
##tro	O
##cy	O
##tes	O
after	O
am	O
##monia	O
influx	O
,	O
and	O
a	O
##romatic	O
amino	O
acid	O
meta	O
##bol	O
##ites	O
such	O
as	O
p	B
##hen	I
##yla	I
##ce	I
##tate	I
##s	I
,	O
p	B
##hen	I
##yl	I
-	I
la	I
##ct	I
##ates	I
,	O
in	O
##do	O
##les	O
,	O
and	O
u	B
##rea	I
cycle	O
intermediate	O
##s	O
that	O
were	O
higher	O
in	O
those	O
who	O
developed	O
over	O
##t	O
H	O
##E	O
[	O
,	O
]	O
.	O

The	O
determination	O
of	O
14	O
amino	O
acids	O
(	O
AA	O
##s	O
)	O
,	O
free	O
car	B
##ni	I
##tine	I
(	O
C	O
##0	O
)	O
,	O
35	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
(	O
ACC	O
##s	O
)	O
,	O
su	B
##cci	I
##ny	I
##l	I
ace	I
##tone	I
(	O
SA	O
)	O
,	O
2	O
n	O
##uc	O
##leo	O
##side	O
##s	O
and	O
4	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
was	O
performed	O
in	O
serum	O
samples	O
(	O
7	O
µ	O
##L	O
)	O
by	O
D	O
##IM	O
##S	O
analysis	O
,	O
using	O
the	O
Neo	O
##B	O
##ase	O
2	O
Non	O
-	O
der	O
##iva	O
##tized	O
MS	O
##MS	O
Kit	O
(	O
Per	O
##kin	O
Elmer	O
Life	O
and	O
Ana	O
##ly	O
##tical	O
Sciences	O
,	O
Tu	O
##rk	O
##u	O
,	O
Finland	O
)	O
,	O
as	O
already	O
reported	O
[	O
,	O
]	O
.	O

We	O
observed	O
that	O
many	O
meta	O
##bol	O
##ites	O
(	O
e	O
.	O
g	O
.	O
,	O
ni	B
##cot	I
##in	I
##uri	I
##c	I
acid	I
,	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
,	O
t	B
##ig	I
##ly	I
##l	I
##car	I
##ni	I
##tine	I
,	O
1	B
-	I
met	I
##hyl	I
##his	I
##ti	I
##dine	I
)	O
were	O
the	O
basis	O
for	O
cluster	O
##ing	O
of	O
certain	O
index	O
##es	O
(	O
B	O
##MI	O
,	O
T	O
##C	O
,	O
T	B
##G	I
and	O
blood	O
pressure	O
before	O
eating	O
,	O
and	O
having	O
or	O
not	O
having	O
diabetes	O
)	O
,	O
but	O
only	O
ni	B
##cot	I
##in	I
##uri	I
##c	I
acid	I
cluster	O
##ed	O
all	O
index	O
##es	O
.	O

Le	B
##uc	I
##ine	I
-	I
en	I
##ke	I
##pha	I
##lin	I
was	O
used	O
as	O
the	O
lock	O
mass	O
(	O
m	O
/	O
z	O
55	O
##6	O
.	O
27	O
##7	O
##1	O
in	O
E	O
##S	O
+	O
and	O
55	O
##4	O
.	O
261	O
##5	O
in	O
E	O
##S	O
##−	O
)	O
.	O

Another	O
interesting	O
meta	O
##bol	O
##ite	O
group	O
that	O
has	O
been	O
significantly	O
impacted	O
by	O
long	O
-	O
term	O
storage	O
is	O
lip	O
##id	O
h	B
##ydro	I
##per	I
##oxide	I
##s	I
,	O
which	O
have	O
been	O
increased	O
over	O
time	O
by	O
lip	O
##id	O
oxidation	O
and	O
auto	O
-	O
oxidation	O
processes	O
.	O

Fr	O
##and	O
##sen	O
tentatively	O
identified	O
three	O
g	B
##lu	I
##cu	I
##ron	I
##ide	I
con	O
##ju	O
##gate	O
##s	O
of	O
5	B
-	I
H	I
##O	I
-	I
Ph	I
##IP	I
,	O
a	O
so	O
##l	O
##vo	O
##lysis	O
product	O
of	O
the	O
reactive	O
N	B
-	I
ace	I
##to	I
##xy	I
-	I
Ph	I
##IP	I
intermediate	O
.	O

Mean	O
percent	O
ion	O
abundance	O
de	O
##viation	O
##s	O
of	O
a	B
##cy	I
##l	I
car	I
##ni	I
##tine	I
##s	I
,	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
(	O
upper	O
plots	O
)	O
,	O
and	O
o	O
##xi	O
##dized	O
fatty	O
acids	O
(	O
lower	O
plots	O
)	O
found	O
in	O
the	O
se	O
##ra	O
of	O
patients	O
diagnosed	O
with	O
NAS	O
##H	O
as	O
compared	O
to	O
isolated	O
s	O
##te	O
##ato	O
##sis	O
.	O

These	O
precursor	O
meta	O
##bol	O
##ites	O
do	O
not	O
a	O
##cc	O
##um	O
##ulate	O
in	O
AD	O
convert	O
##ers	O
most	O
likely	O
because	O
put	B
##res	I
##cine	I
is	O
prefer	O
##ential	O
##ly	O
meta	O
##bol	O
##ised	O
to	O
other	O
p	B
##oly	I
##amine	I
##s	I
.	O

Similar	O
results	O
were	O
obtained	O
for	O
M	O
##5	O
g	B
##lut	I
##amine	I
and	O
M	O
##5	O
v	B
##ali	I
##ne	I
(	O
Su	O
##pp	O
##lement	O
##ary	O
Figure	O
S	O
##2	O
)	O
.	O

Try	B
##pt	I
##op	I
##han	I
pathway	O
was	O
significantly	O
changed	O
in	O
RC	O
##C	O
.	O

β	O
Co	O
##ef	O
##ficient	O
##s	O
represent	O
the	O
difference	O
in	O
v	O
##is	O
##cer	O
##al	O
ad	O
##ip	O
##ose	O
tissue	O
area	O
(	O
in	O
cm	O
_	O
2	O
)	O
per	O
SD	O
meta	O
##bol	O
##ite	O
intensity	O
and	O
are	O
from	O
a	O
model	O
adjusted	O
for	O
age	O
,	O
sex	O
,	O
race	O
/	O
ethnicity	O
,	O
socio	O
##economic	O
status	O
,	O
smoking	O
,	O
physical	O
activity	O
,	O
glucose	S
and	O
lip	O
##id	O
‐	O
lowering	O
medication	O
use	O
,	O
and	O
body	O
mass	O
index	O
.	O

A	O
trend	O
for	O
decreasing	O
levels	O
of	O
amino	O
acids	O
,	O
including	O
le	B
##uc	I
##ine	I
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
v	B
##ali	I
##ne	I
and	O
al	B
##ani	I
##ne	I
,	O
has	O
been	O
reported	O
in	O
pan	O
##cre	O
##atic	O
cancer	O
samples	O
(	O
Fang	O
et	O
al	O
.	O
)	O
.	O

As	O
shown	O
in	O
Figure	O
,	O
the	O
combination	O
of	O
as	B
##par	I
##tate	I
and	O
g	B
##lut	I
##ama	I
##te	I
represents	O
an	O
R	O
##OC	O
=	O
0	O
.	O
83	O
for	O
the	O
prediction	O
of	O
HC	O
##C	O
re	O
##cu	O
##rrence	O
in	O
the	O
BT	O
samples	O
.	O

E	B
##thy	I
##l	I
ace	I
##tate	I
extract	O
##s	O
of	O
commercial	O
serum	O
(	O
180	O
m	O
##L	O
serum	O
,	O
500	O
mg	O
extract	O
)	O
was	O
subjected	O
to	O
reverse	O
phase	O
flash	O
column	O
ch	O
##roma	O
##tography	O
(	O
FCC	O
)	O
with	O
a	O
step	O
gradient	O
el	O
##ution	O
;	O
ace	O
##ton	O
##it	O
##ril	O
##e	O
-	O
water	O
25	O
:	O
75	O
to	O
100	O
%	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
.	O

1	O
,	O
CH	O
_	O
3	O
bond	O
of	O
lip	O
##ids	O
mainly	O
V	O
##LD	O
##L	O
;	O
2	O
,	O
Le	B
##uc	I
##ine	I
;	O
3	O
,	O
Is	B
##ole	I
##uc	I
##ine	I
;	O
4	O
,	O
Val	B
##ine	I
;	O
5	O
,	O
Pro	B
##py	I
##lene	I
g	I
##ly	I
##co	I
##l	I
;	O
6	O
,	O
Ethan	B
##ol	I
;	O
7	O
,	O
CH	O
_	O
2	O
bond	O
of	O
lip	O
##ids	O
;	O
8	O
,	O
CH	O
_	O
2	O
-	O
CH	O
_	O
2	O
-	O
CO	O
##OC	O
bond	O
of	O
lip	O
##ids	O
;	O
9	O
,	O
Ace	B
##tate	I
;	O
10	O
,	O
CH	O
_	O
2	O
-	O
CH	O
=	O
bond	O
of	O
lip	O
##ids	O
;	O
11	O
,	O
N	B
-	I
ace	I
##ty	I
##l	I
g	I
##ly	I
##co	I
##p	I
##rote	I
##ins	I
;	O
12	O
,	O
Ace	B
##tone	I
and	O
CH	O
_	O
2	O
-	O
CH	O
_	O
2	O
-	O
CO	O
##OC	O
bond	O
of	O
lip	O
##ids	O
;	O
13	O
,	O
G	B
##lut	I
##ama	I
##te	I
;	O
14	O
,	O
G	B
##lut	I
##amine	I
;	O
15	O
,	O
C	B
##it	I
##rate	I
;	O
16	O
=	O
CH	O
-	O
CH	O
_	O
2	O
-	O
CH	O
=	O
bond	O
of	O
lip	O
##ids	O
;	O
17	O
,	O
Cho	B
##line	I
;	O
18	O
,	O
G	B
##lu	I
##cos	I
##e	I
;	O
19	O
,	O
Li	O
##pid	O
O	O
-	O
CH	O
_	O
2	O
;	O
20	O
,	O
Mann	B
##ose	I
and	O
lip	O
##ids	O
;	O
21	O
,	O
CH	O
=	O
CH	O
bond	O
of	O
lip	O
##ids	O
;	O
22	O
,	O
Ty	B
##ros	I
##ine	I
;	O
23	O
,	O
Ph	B
##en	I
##yla	I
##lani	I
##ne	I
Higher	O
R	O
##OC	O
parameters	O
(	O
Table	O
)	O
were	O
found	O
for	O
O	O
-	O
P	O
##LS	O
C	O
##V	O
status	O
compared	O
to	O
A	O
##FP	O
and	O
the	O
liver	O
score	O
(	O
O	O
-	O
P	O
##LS	O
C	O
##V	O
status	O
vs	O
.	O
A	O
##FP	O
,	O
liver	O
score	O
:	O

In	O
order	O
to	O
investigate	O
further	O
the	O
role	O
on	O
test	B
##osterone	I
on	O
the	O
g	B
##ly	I
##ca	I
##em	I
##ic	I
status	O
in	O
PC	O
##OS	O
we	O
conducted	O
a	O
re	O
##gression	O
analysis	O
of	O
fast	O
##ing	O
insulin	O
levels	O
and	O
an	O
index	O
of	O
insulin	O
resistance	O
(	O
H	O
##OM	O
##A	O
I	O
##R	O
)	O
adjusting	O
for	O
WC	O
.	O

C	O
##V	O
##1	O
and	O
C	O
##V	O
##2	O
were	O
determined	O
for	O
a	O
urine	O
volume	O
of	O
1	O
.	O
5	O
m	O
##L	O
.	O
OH	O
:	O
h	B
##ydro	I
##xy	I
,	O
D	O
##H	O
:	O
di	B
##hy	I
##dr	I
##o	I
,	O
T	O
##H	O
:	O
te	B
##tra	I
##hy	I
##dr	I
##o	I
.	O

The	O
other	O
product	O
ion	O
in	O
the	O
spectrum	O
appeared	O
at	O
m	O
/	O
z	O
27	O
##9	O
provides	O
the	O
information	O
about	O
one	O
of	O
the	O
a	O
##cy	O
##l	O
m	O
##oi	O
##ety	O
of	O
the	O
P	O
##E	O
as	O
FA	B
(	I
18	I
:	I
3	I
)	I
.	O

Author	O
##s	O
showed	O
that	O
his	B
##tamine	I
receptors	O
1	O
and	O
2	O
m	O
##od	O
##ulate	O
p	O
##el	O
##vic	O
pain	O
and	O
anti	B
##his	I
##tamine	I
##s	I
at	O
##ten	O
##uate	O
bladder	O
pain	O
in	O
their	O
animal	O
model	O
.	O

Subsequently	O
,	O
400	O
µ	O
##L	O
of	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
and	O
10	O
µ	O
##L	O
of	O
10	O
%	O
BC	O
##l	O
in	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
were	O
added	O
and	O
v	O
##ortex	O
##ed	O
again	O
(	O
5	O
min	O
,	O
1100	O
rpm	O
,	O
25	O
°C	O
)	O
.	O

An	O
increase	O
was	O
also	O
observed	O
in	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
(	O
SM	O
)	O
34	O
:	O
2	O
(	O
CH	O
##E	O
##BI	O
:	O
64	O
##5	O
##8	O
##7	O
)	O
.	O

PC	O
is	O
the	O
main	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
component	O
in	O
all	O
the	O
lip	O
##op	O
##rote	O
##in	O
classes	O
,	O
with	O
its	O
proportion	O
ranging	O
from	O
60	O
to	O
80	O
%	O
of	O
total	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
.	O

The	O
parent	O
est	O
##rogen	O
##s	O
and	O
their	O
meta	O
##bol	O
##ites	O
(	O
jointly	O
referred	O
to	O
as	O
E	O
##M	O
)	O
can	O
be	O
further	O
modified	O
via	O
con	O
##ju	O
##gation	O
with	O
su	B
##lf	I
##ate	I
or	O
g	B
##lu	I
##cu	I
##ron	I
##ide	I
m	O
##oi	O
##eti	O
##es	O
,	O
which	O
m	O
##od	O
##ifies	O
their	O
disposition	O
and	O
half	O
-	O
life	O
.	O

Card	O
##io	O
##met	O
##ab	O
##olic	O
risk	O
factors	O
were	O
identified	O
,	O
according	O
to	O
the	O
ATP	O
##II	O
##I	O
criteria	O
used	O
for	O
MS	O
,	O
and	O
MS	O
was	O
defined	O
by	O
the	O
presence	O
of	O
three	O
or	O
more	O
of	O
the	O
following	O
components	O
:	O
1	O
)	O
high	O
waist	O
c	O
##ir	O
##cum	O
##ference	O
(	O
men	O
≥	O
102	O
##c	O
##m	O
;	O
women	O
≥	O
88	O
cm	O
)	O
;	O
2	O
)	O
high	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
(	O
≥	O
150	O
##m	O
##g	O
/	O
d	O
##L	O
)	O
;	O
3	O
)	O
low	O
HD	B
##L	I
ch	I
##ole	I
##ster	I
##ol	I
(	O
men	O
≥	O
40	O
##m	O
##g	O
/	O
d	O
##L	O
;	O
women	O
≥	O
50	O
##m	O
##g	O
/	O
d	O
##L	O
)	O
;	O
4	O
)	O
high	O
blood	O
pressure	O
(	O
s	O
##ys	O
##to	O
##lic	O
blood	O
pressure	O
≥	O
130	O
mm	O
##H	O
##g	O
and	O
/	O
or	O
di	O
##ast	O
##olic	O
blood	O
pressure	O
≥	O
85	O
mm	O
##H	O
##g	O
or	O
being	O
on	O
anti	O
##hy	O
##pert	O
##ens	O
##ive	O
medications	O
)	O
and	O
5	O
)	O
high	O
fast	O
##ing	O
glucose	S
(	O
≥	O
110	O
mg	O
/	O
d	O
##L	O
or	O
being	O
on	O
drug	O
treatment	O
for	O
elevated	O
glucose	S
)	O
.	O

However	O
the	O
tissue	O
la	B
##ct	I
##ate	I
was	O
increasing	O
systematically	O
with	O
N	O
##N	O
>	O
A	O
##F	O
>	O
T	O
##C	O
,	O
which	O
was	O
found	O
to	O
be	O
reversal	O
to	O
blood	O
serum	O
level	O
.	O

Integrated	O
s	O
##che	O
##matic	O
illustration	O
of	O
metabolic	O
alterations	O
in	O
p	B
##yr	I
##im	I
##id	I
##ine	I
metabolism	O
induced	O
by	O
H	O
##T	O
##K	O
.	O

_	O
,	O
While	O
several	O
studies	O
detected	O
and	O
q	O
##uant	O
##ified	O
HP	O
##B	O
-	O
releasing	O
DNA	O
and	O
g	O
##lo	O
##bin	O
add	O
##uc	O
##ts	O
in	O
humans	O
,	O
_	O
−	O
it	O
is	O
not	O
clear	O
how	O
much	O
of	O
the	O
total	O
measured	O
level	O
of	O
these	O
add	O
##uc	O
##ts	O
is	O
derived	O
from	O
N	O
##N	O
##K	O
versus	O
the	O
related	O
tobacco	O
car	O
##cin	O
##ogen	O
N	O
′	B
-	I
ni	I
##tro	I
##son	I
##orn	I
##ico	I
##tine	I
,	O
which	O
shares	O
common	O
metabolic	O
pathways	O
with	O
N	O
##N	O
##K	O
and	O
leads	O
to	O
the	O
formation	O
of	O
the	O
same	O
add	O
##uc	O
##ts	O
.	O

Cox	O
proportional	O
hazards	O
analysis	O
were	O
used	O
to	O
assess	O
the	O
clinical	O
risks	O
associated	O
with	O
higher	O
T	B
##MA	I
##O	I
,	O
ch	B
##olin	I
##e	I
,	O
and	O
/	O
or	O
beta	B
##ine	I
levels	O
,	O
in	O
which	O
the	O
proportional	O
hazards	O
assumption	O
was	O
verified	O
with	O
log	O
(	O
time	O
)	O
vs	O
.	O
log	O
[	O
-	O
log	O
(	O
survival	O
)	O
]	O
plots	O
.	O

The	O
observed	O
inverse	O
correlation	O
of	O
the	O
se	B
##rot	I
##oni	I
##n	I
concentration	O
in	O
sperm	O
with	O
the	O
sperm	O
concentration	O
is	O
consistent	O
with	O
the	O
results	O
of	O
former	O
studies	O
in	O
which	O
it	O
was	O
shown	O
that	O
h	O
##yper	O
##ser	O
##oto	O
##ne	O
##mia	O
leads	O
to	O
a	O
##zo	O
##os	O
##per	O
##mia	O
and	O
that	O
increased	O
se	B
##rot	I
##oni	I
##n	I
concentration	O
in	O
the	O
sperm	O
##atic	O
vein	O
is	O
correlated	O
with	O
significantly	O
lower	O
sperm	O
quality	O
.	O

2	B
-	I
Indo	I
##le	I
##car	I
##box	I
##yl	I
##ic	I
acid	I
similar	O
to	O
me	B
##lat	I
##oni	I
##n	I
is	O
a	O
strong	O
inhibitor	O
of	O
lip	O
##id	O
per	O
##ox	O
##ida	O
##tion	O
.	O

Interest	O
##ingly	O
,	O
the	O
initiation	O
of	O
the	O
s	B
##phi	I
##ngo	I
##sin	I
##e	I
production	O
pathway	O
involves	O
the	O
combination	O
of	O
palm	B
##ito	I
##yl	I
-	I
Co	I
##A	I
and	O
se	B
##rine	I
via	O
se	O
##rine	O
palm	O
##ito	O
##yl	O
##tra	O
##ns	O
##fer	O
##ase	O
to	O
produce	O
the	O
bio	O
##sy	O
##nt	O
##hetic	O
intermediate	O
3	B
-	I
k	I
##eto	I
##sp	I
##hing	I
##ani	I
##ne	I
.	O

In	O
addition	O
,	O
high	O
levels	O
of	O
the	O
k	B
##eton	I
##e	I
-	I
body	I
3	I
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
were	O
also	O
found	O
to	O
be	O
associated	O
with	O
card	O
##iovascular	O
diseases	O
and	O
were	O
identified	O
as	O
part	O
of	O
a	O
panel	O
of	O
card	O
##iovascular	O
risk	O
bio	O
##mark	O
##ers	O
through	O
different	O
analyses	O
.	O

T	O
##AG	O
profiles	O
in	O
human	O
and	O
monkey	O
plasma	O
demonstrated	O
that	O
monkey	O
plasma	O
contained	O
higher	O
levels	O
of	O
T	B
##AG	I
52	I
:	I
5	I
,	O
52	O
:	O
4	O
,	O
56	O
:	O
8	O
,	O
56	O
:	O
7	O
,	O
56	O
:	O
6	O
,	O
58	O
:	O
10	O
,	O
58	O
:	O
9	O
,	O
58	O
:	O
8	O
,	O
58	O
:	O
7	O
and	O
58	O
:	O
6	O
.	O

Our	O
findings	O
described	O
that	O
among	O
all	O
meta	O
##bol	O
##ites	O
of	O
the	O
plate	O
##let	O
activation	O
/	O
a	O
##gg	O
##regation	O
pathway	O
anal	O
##ys	O
##ed	O
in	O
a	O
group	O
of	O
men	O
with	O
unstable	O
car	O
##ot	O
##id	O
plaque	O
vs	O
a	O
healthy	O
control	O
group	O
,	O
the	O
only	O
meta	O
##bol	O
##ite	O
which	O
showed	O
the	O
highest	O
and	O
most	O
significant	O
levels	O
is	O
20	B
-	I
H	I
##ET	I
##E	I
.	O

The	O
changes	O
in	O
amino	O
acids	O
were	O
then	O
examined	O
more	O
closely	O
using	O
targeted	O
pro	O
##fi	O
##ling	O
of	O
the	O
N	O
##MR	O
s	O
##pect	O
##ra	O
to	O
obtain	O
relative	O
q	O
##uant	O
##ification	O
of	O
al	B
##ani	I
##ne	I
,	O
g	B
##ly	I
##cine	I
,	O
his	B
##ti	I
##dine	I
,	O
l	B
##ys	I
##ine	I
,	O
met	B
##hi	I
##oni	I
##ne	I
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
th	B
##re	I
##oni	I
##ne	I
,	O
try	B
##pt	I
##op	I
##han	I
,	O
t	B
##yr	I
##os	I
##ine	I
and	O
v	B
##ali	I
##ne	I
.	O

Not	O
surprisingly	O
,	O
the	O
ten	O
-	O
meta	O
##bol	O
##ite	O
panel	O
proved	O
to	O
be	O
a	O
poor	O
class	O
##ifier	O
for	O
CR	O
##C	O
vs	B
PC	I
(	O
AU	O
##C	O
=	O
0	O
.	O
65	O
)	O

47	O
target	O
meta	O
##bol	O
##ites	O
(	B
L	B
-	I
Ty	I
##ros	I
##ine	I
,	O
L	B
-	I
Ph	I
##en	I
##yla	I
##lani	I
##ne	I
,	O
L	B
-	I
T	I
##hr	I
##eon	I
##ine	I
,	O
L	B
-	I
(	I
+	I
)	I
-	I
Lac	I
##tic	I
acid	I
,	O
L	B
-	I
Val	I
##ine	I
,	O
L	B
-	I
Le	I
##uc	I
##ine	I
,	O
L	B
-	I
Pro	I
##line	I
,	O
Beta	B
##ine	I
,	O
Palm	B
##itic	I
acid	I
,	O
St	B
##ear	I
##ic	I
acid	I
,	O
G	B
##ly	I
##cine	I
,	O
(	B
±	I
)	I
-	I
a	I
-	I
To	I
##co	I
##pher	I
##ol	I
,	O
β	B
-	I
Sit	I
##ose	I
##tero	I
##l	I
,	O
L	B
-	I
Try	I
##pt	I
##op	I
##han	I
,	O
DL	B
-	I
g	I
##ly	I
##cer	I
##ald	I
##eh	I
##yd	I
##e	I
,	O
G	B
##ly	I
##co	I
##cho	I
##lic	I
acid	I
,	O
o	B
##le	I
##ic	I
acid	I
,	O
e	B
##ico	I
##san	I
##oi	I
##c	I
acid	I
,	O
he	B
##xa	I
##no	I
##ic	I
acid	I
,	O
He	B
##pta	I
##no	I
##ic	I
acid	I
,	O
non	B
##ano	I
##ic	I
acid	I
,	O
Gala	B
##ct	I
##ose	I
,	O
Su	B
##c	I
##rose	I
,	O
So	B
##rb	I
##ito	I
##l	I
,	O
my	B
##oi	I
##nos	I
##ito	I
##l	I
,	O
Fr	B
##uc	I
##tos	I
##e	I
,	O
Cell	B
##ob	I
##ios	I
##e	I
,	O
U	B
##rea	I
,	O
Is	B
##ole	I
##uc	I
##ine	I
,	O
Alan	B
##ine	I
,	O
c	B
##it	I
##ric	I
acid	I
,	O
A	B
##zel	I
##aic	I
acid	I
,	O
As	B
##par	I
##tic	I
acid	I
,	O
4	B
-	I
H	I
##ydro	I
##xy	I
##ben	I
##zoic	I
acid	I
,	O
Pi	B
##mel	I
##ic	I
acid	I
,	O
L	B
-	I
Ser	I
##ine	I
,	O
H	B
##y	I
##pox	I
##ant	I
##hine	I
,	O
D	B
-	I
Ho	I
##mos	I
##eri	I
##ne	I
,	O
U	B
##ric	I
acid	I
,	O
Tri	B
##met	I
##hyl	I
##amine	I
oxide	I
,	O
Pen	B
##tan	I
##ed	I
##io	I
##ic	I
acid	I
,	O
Allan	B
##to	I
##in	I
,	O
Lin	B
##ole	I
##ic	I
acid	I
,	O
C	B

B	O
##rief	O
##ly	O
,	O
v	O
##is	O
##cer	O
##al	O
ad	O
##ip	O
##ose	O
tissue	O
was	O
finely	O
min	O
##ced	O
,	O
washed	O
in	O
PBS	O
to	O
remove	O
excess	O
blood	O
and	O
culture	O
##d	O
in	O
M1	O
##9	O
##9	O
medium	O
(	O
containing	O
0	O
.	O
05	O
mg	O
/	O
m	O
##L	O
g	B
##ent	I
##am	I
##y	I
##cin	I
)	O
at	O
a	O
ratio	O
of	O
5	O
g	O
ad	O
##ip	O
##ose	O
tissue	O
to	O
10	O
m	O
##L	O
of	O
media	O
for	O
72	O
h	O
.	O
AC	O
##M	O
was	O
then	O
removed	O
and	O
stored	O
at	O
-	O
80	O
##°	O
##C	O
until	O
required	O
.	O

The	O
Ce	B
##r	I
(	I
22	I
:	I
0	I
)	I
and	O
Ce	B
##r	I
(	I
24	I
:	I
0	I
)	I
were	O
determined	O
to	O
be	O
stable	O
for	O
38	O
days	O
at	O
−	O
##80	O
°C	O
.	O

Po	O
##ssi	O
##bly	O
,	O
the	O
ben	B
##zo	I
##ate	I
-	I
B	I
##MI	I
association	O
is	O
driven	O
by	O
behavioral	O
patterns	O
related	O
to	O
personal	O
care	O
product	O
use	O
.	O

Internal	O
standards	O
were	O
purchased	O
from	O
Ava	O
##nti	O
(	O
S	O
##p	O
##lash	O
Li	O
##pid	O
##omi	O
##x	O
,	O
Al	O
##aba	O
##ster	O
,	O
United	O
States	O
)	O
and	O
included	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
15	I
:	I
0	I
–	I
18	I
:	I
1	I
(	I
d	I
##7	I
)	I
PC	I
,	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##let	I
##han	I
##ola	I
##mine	I

that	O
in	O
the	O
analysis	O
of	O
alpha	B
-	I
P	I
##B	I
##P	I
in	O
positive	O
mode	O
using	O
the	O
Ph	O
##en	O
##yl	O
##H	O
##ex	O
##yl	O
column	O
(	O
Fi	O
##g	O
.	O

The	O
VIP	O
plot	O
(	O
Figure	O
)	O
,	O
sorted	O
by	O
importance	O
,	O
showed	O
the	O
meta	O
##bol	O
##ites	O
try	B
##pt	I
##op	I
##han	I
and	O
3	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##ano	I
##ic	I
acid	I
as	O
most	O
disc	O
##rim	O
##inator	O
##y	O
between	O
G	O
##DM	O
and	O
control	O
.	O

Di	O
##aster	O
##eo	O
##mer	O
2	O
:	O
_	O
1	O
H	O
N	O
##MR	O
(	O
600	O
MHz	O
,	O
D	O
##MS	O
##O	O
-	O
d	O
_	O
6	O
)	O
:	O
δ	O
8	O
.	O
45	O
(	O
d	O
,	O
1	O
##H	O
,	O
NH	O
)	O
,	O
7	O
.	O
23	O
(	O
s	O
,	O
1	O
##H	O
,	O
H	O
##2	O
′	O
)	O
,	O
6	O
.	O
92	O
(	O
s	O
,	O
1	O
##H	O
,	O
H	O
##5	O
′	O
)	O
,	O
6	O
.	O
34	O
(	O
s	O
,	O
1	O
##H	O
,	O
H	O
##4	O
′	O
)	O
,	O
3	O
.	O
94	O
-	O
3	O
.	O
85	O
(	O
m	O
,	O
2	O
##H	O
,	O
H	O
##5	O
,	O
Cy	O
##s	O
α	B
-	I
CH	I
)	O
,	O
3	O
.	O
28	O
-	O
3	O
.	O
12	O
(	O
m	O
,	O
4	O
##H	O
,	O
Cy	O
##s	O
β	B
-	I
CH	I
_	I
2	I
,	O
H	O
##1	O
)	O
,	O
1	O
.	O
79	O
(	O
s	O
,	O
3	O
##H	O
,	O
Me	O
)	O
,	O
1	O
.	O
65	O
-	O
1	O
.	O
57	O
(	O
m	O
,	O
4	O
##H	O
,	O
H	O
##2	O
,	O
H	O
##4	O
)	O
,	O
1	O
.	O
15	O
-	O
1	O
.	O
06	O
(	O
m	O
,	O
2	O
##H	O
,	O
H	O
##3	O
)	O
;	O
_	O
13	O
C	O
N	O
##MR	O
(	O
150	O
MHz	O
,	O
D	O
##MS	O
##O	O
-	O
d	O
_	O
6	O
)	O
:	O
δ	O
124	O
.	O
2	O
,	O
124	O
.	O
0	O
,	O
106	O
.	O
3	O
,	O
58	O
.	O
2	O
,	O
54	O
.	O
4	O
,	O
49	O
.	O
2	O
,	O
30	O
.	O
8	O
,	O
30	O
.	O
8	O
,	O
23	O
.	O
0	O
,	O
22	O
.	O
6	O
:	O
E	O
##SI	O
-	O
MS	O
/	O
MS	O
:	O
m	O
/	O
z	O
37	O
##4	O

The	O
Western	O
data	O
are	O
organized	O
to	O
depict	O
:	O
number	O
of	O
tissues	O
that	O
contain	O
the	O
specific	O
protein	O
e	O
.	O
g	O
.	O
x	O
/	O
15	O
,	O
the	O
fold	O
difference	O
between	O
the	O
highest	O
and	O
lowest	O
protein	O
levels	O
among	O
the	O
15	O
tissues	O
evaluated	O
,	O
and	O
last	O
##ly	O
the	O
percent	O
##ile	O
range	O
in	O
respective	O
protein	O
level	O
expression	O
relative	O
to	O
the	O
house	O
##keeping	O
protein	O
,	O
β	B
-	I
act	I
##in	I
.	O

Ali	O
##q	O
##uo	O
##ts	O
of	O
the	O
G	O
##G	O
extract	O
##s	O
(	O
equivalent	O
to	O
10	O
nm	O
##ol	O
G	O
##G	O
-	O
bound	O
si	B
##ali	I
##c	I
acid	I
as	O
a	O
pool	O
of	O
the	O
individual	O
samples	O
for	O
each	O
tissue	O
type	O
,	O
n	O
=	O
4	O
–	O
7	O
)	O
were	O
applied	O
to	O
a	O
HP	O
##TL	O
##C	O
plate	O
(	O
Me	O
##rc	O
##k	O
,	O
Germany	O
)	O
.	O

Most	O
importantly	O
,	O
the	O
above	O
data	O
suggest	O
that	O
7	B
-	I
k	I
##eto	I
##cho	I
##les	I
##tero	I
##l	I
levels	O
rise	O
after	O
tumor	O
removal	O
.	O

SL	O
##C	O
##7	O
##A	O
##5	O
,	O
SL	O
##C	O
##1	O
##A	O
##5	O
,	O
and	O
A	O
##FM	O
##ID	O
were	O
elevated	O
in	O
co	O
##lon	O
cancer	O
cells	O
and	O
tissues	O
,	O
and	O
k	B
##yn	I
##uren	I
##ine	I
was	O
significantly	O
greater	O
in	O
tumor	O
samples	O
than	O
in	O
the	O
respective	O
adjacent	O
normal	O
tissue	O
from	O
patients	O
with	O
co	O
##lon	O
cancer	O
.	O

Path	O
##way	O
abnormal	O
##ities	O
included	O
s	B
##phi	I
##ngo	I
##lip	I
##id	I
,	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
,	O
pu	B
##rine	I
,	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
micro	O
##bio	O
##me	O
,	O
p	B
##yr	I
##rol	I
##ine	I
-	I
5	I
-	I
car	I
##box	I
##yla	I
##te	I
,	O
rib	B
##of	I
##lav	I
##in	I
,	O
branch	O
chain	O
amino	O
acid	O
,	O
per	O
##ox	O
##is	O
##oma	O
##l	O
,	O
and	O
mitochondrial	O
metabolism	O
.	O

While	O
ace	B
##to	I
##ace	I
##tate	I
was	O
used	O
for	O
the	O
combined	O
meta	O
##bol	O
##ites	O
and	O
N	O
##T	O
-	O
pro	O
##B	O
##NP	O
panel	O
.	O

Inc	O
##reased	O
intake	O
of	O
pu	B
##rine	I
##s	I
has	O
been	O
linked	O
to	O
h	O
##yper	O
##uri	O
##ce	O
##mia	O
and	O
go	O
##ut	O
,	O
which	O
in	O
turn	O
was	O
associated	O
with	O
increased	O
re	O
##nal	O
disease	O
progression	O
in	O
animals	O
.	O

The	O
low	O
amount	O
of	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
may	O
impact	O
cellular	O
membrane	O
##s	O
in	O
which	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
are	O
important	O
components	O
.	O

N	B
-	I
ace	I
##ty	I
##lasp	I
##art	I
##ate	I
was	O
associated	O
with	O
auto	O
##pha	O
##gy	O
and	O
his	O
##tone	O
ace	O
##ty	O
##lation	O
in	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
and	O
impacted	O
cell	O
survival	O
(	O
,	O
)	O
.	O

For	O
instance	O
for	O
the	O
bin	O
at	O
3	O
.	O
20	O
pp	O
##m	O
(	O
corresponding	O
to	O
ch	B
##olin	I
##e	I
)	O
yields	O
a	O
sensitivity	O
(	O
i	O
.	O
e	O
.	O
percentage	O
of	O
G	O
##4	O
samples	O
correctly	O
classified	O
as	O
positive	O
##s	O
)	O
and	O
specific	O
##ity	O
(	O
i	O
.	O
e	O
.	O
percentage	O
of	O
control	O
samples	O
correctly	O
classified	O
as	O
negative	O
##s	O
)	O
of	O
80	O
%	O
and	O
70	O
%	O
,	O
respectively	O
,	O
with	O
a	O
classification	O
rate	O
of	O
87	O
%	O
(	O
i	O
.	O
e	O
.	O
total	O
number	O
of	O
correctly	O
classified	O
samples	O
,	O
data	O
not	O
shown	O
)	O
.	O

The	O
acidic	O
ch	B
##ole	I
##ster	I
##ol	I
meta	O
##bol	O
##ites	O
3	B
##β	I
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##t	I
-	I
5	I
-	I
en	I
-	I
26	I
-	I
o	I
##ic	I
acid	I
and	O
3	B
##β	I
,	I
7	I
##α	I
-	I
di	I
##hy	I
##dr	I
##ox	I
##ych	I
##ole	I
##st	I
-	I
5	I
-	I
en	I
-	I
26	I
-	I
o	I
##ic	I
acid	I
were	O
found	O
to	O
activate	O
L	O
##X	O
##R	O
in	O
a	O
l	O
##uc	O
##ifer	O
##ase	O
ass	O
##ay	O
,	O
but	O
the	O
major	O
meta	O
##bol	O
##ite	O
identified	O
in	O
this	O
study	O
,	O
i	O
.	O
e	O
.	O
7	B
##α	I
-	I
h	I
##ydro	I
##xy	I
-	I
3	I
-	I
o	I
##x	I
##och	I
##ole	I
##st	I
-	I
4	I
-	I
en	I
-	I
26	I
-	I
o	I
##ic	I
acid	I
,	O
was	O
not	O
an	O
L	O
##X	O
##R	O
l	O
##igan	O
##d	O
.	O

Sul	B
##fu	I
##r	I
dioxide	I
gas	O
used	O
for	O
the	O
synthesis	O
of	O
MMA	O
_	O
III	O
I	O
_	O
2	O
and	O
D	O
##MA	O
_	O
III	O
I	O
was	O
acquired	O
from	O
Special	O
##ty	O
Gas	O
##ses	O
of	O
America	O
.	O

We	O
compared	O
these	O
results	O
with	O
bio	O
##psy	O
tissue	O
that	O
was	O
fixed	O
directly	O
in	O
formal	B
##in	I
.	O

G	B
##lut	I
##ama	I
##te	I
;	O
103	O
.	O

Co	O
##rrel	O
##ation	O
between	O
plasma	O
k	B
##yn	I
##uren	I
##ine	I
and	O
total	O
scores	O
from	O
Montgomery	O
-	O
Å	O
##sberg	O
Depression	O
Rat	O
##ing	O
Scale	O
(	O
MA	O
##DR	O
##AS	O
)	O
before	O
EC	O
##T	O
treatment	O
(	O
a	O
,	O
n	O
=	O
18	O
)	O
and	O
after	O
three	O
EC	O
##T	O
treatments	O
(	O
b	O
,	O
n	O
=	O
15	O
)	O

Given	O
the	O
reaction	O
cat	O
##aly	O
##zed	O
by	O
the	O
encoded	O
P	O
##45	O
##0	O
,	O
the	O
association	O
of	O
this	O
variant	O
with	O
higher	O
serum	O
levels	O
of	O
the	O
o	B
##xy	I
##ster	I
##ol	I
implied	O
that	O
R	O
##10	O
##3	O
##H	O
was	O
a	O
h	O
##y	O
##po	O
##morphic	O
all	O
##ele	O
of	O
C	O
##YP	O
##39	O
##A	O
##1	O
.	O

The	O
purpose	O
of	O
f	B
##olate	I
metabolism	O
is	O
to	O
supply	O
reduced	O
f	O
##olate	O
##s	O
for	O
the	O
conversion	O
of	O
de	B
##ox	I
##yu	I
##rid	I
##ine	I
5	I
′	I
-	I
phosphate	I
(	O
d	O
##UM	O
##P	O
)	O
to	O
de	B
##ox	I
##yt	I
##hy	I
##mi	I
##dine	I
5	I
′	I
-	I
phosphate	I
(	O
d	O
##TM	O
##P	O
)	O
and	O
form	O
thy	B
##mi	I
##dine	I
for	O
DNA	O
replication	O
.	O

While	O
4	B
-	I
h	I
##ydro	I
##xy	I
-	I
2	I
,	I
6	I
-	I
pen	I
##tad	I
##eca	I
##die	I
##nal	I
in	O
Fi	O
##g	O
.	O

The	O
formation	O
of	O
car	B
##ni	I
##tine	I
con	O
##ju	O
##gate	O
##s	O
is	O
crucial	O
for	O
the	O
transport	O
of	O
activated	S
fatty	O
acids	O
(	B
a	B
##cy	I
##l	I
-	I
Co	I
##As	I
)	O
from	O
the	O
c	O
##yt	O
##oso	O
##l	O
across	O
the	O
inner	O
mitochondrial	O
membrane	O
into	O
the	O
matrix	O
where	O
fatty	O
acid	O
oxidation	O
takes	O
place	O
.	O

It	O
is	O
well	O
known	O
that	O
mit	O
##och	O
##ond	O
##ria	O
can	O
compensate	O
for	O
decreased	O
energy	O
production	O
by	O
increasing	O
la	B
##ct	I
##ate	I
production	O
under	O
h	O
##y	O
##pox	O
##ia	O
.	O

The	O
second	O
pathway	O
class	O
relates	O
to	O
di	O
##stal	O
co	O
##lon	O
##ic	O
micro	O
##bial	O
protein	O
put	O
##re	O
##fa	O
##ction	O
and	O
the	O
metabolism	O
of	O
t	B
##yr	I
##os	I
##ine	I
and	O
related	O
compounds	O
.	O

(	O
)	O
They	O
did	O
not	O
find	O
d	B
##G	I
-	I
C	I
##8	I
-	I
4	I
-	I
AB	I
##P	I
add	O
##uc	O
##t	O
,	O
and	O
d	O
##G	O
-	O
C	O
##8	O
-	O
Ph	O
##IP	O
was	O
only	O
detected	O
in	O
one	O
out	O
of	O
70	O
bio	O
##psy	O
samples	O
even	O
though	O
the	O
level	O
of	O
sensitivity	O
of	O
the	O
L	O
##IT	O
-	O
MS	O
based	O
method	O
was	O
100	O
-	O
fold	O
lower	O
than	O
the	O
average	O
level	O
of	O
Ph	O
##IP	O
add	O
##uc	O
##ts	O
reported	O
by	O
I	O
##HC	O
.	O

These	O
results	O
are	O
,	O
for	O
the	O
most	O
part	O
,	O
in	O
agreement	O
with	O
previous	O
studies	O
showing	O
the	O
utility	O
of	O
volatile	O
am	B
##mon	I
##ium	I
salts	O
for	O
SF	O
##C	O
-	O
MS	O
separation	O
of	O
polar	O
molecules	O
.	O

In	O
particular	O
,	O
elevated	O
levels	O
of	O
my	B
##rist	I
##ic	I
acid	I
were	O
associated	O
with	O
subsequent	O
positive	O
blood	O
culture	O
.	O

The	O
fast	O
##ing	O
blood	O
was	O
collected	O
in	O
5	O
m	O
##L	O
v	O
##ac	O
##uta	O
##iner	O
tubes	O
containing	O
he	B
##par	I
##in	I
lit	I
##hium	I
,	O
then	O
the	O
samples	O
were	O
cent	O
##ri	O
##fu	O
##ged	O
for	O
15	O
min	O
(	O
1500	O
×	O
g	O
,	O
4	O
°C	O
)	O
.	O

G	O
##C	O
-	O
MS	O
samples	O
were	O
der	O
##iva	O
##tized	O
using	O
bi	B
##s	I
(	I
trim	I
##eth	I
##yl	I
##si	I
##ly	I
##l	I
)	I
t	I
##ri	I
##f	I
##lu	I
##oro	I
##ace	I
##tia	I
##mi	I
##de	I
under	O
nitrogen	B
gas	I
.	O

_	O
13	O
C	B
_	I
5	I
-	I
met	I
##hi	I
##oni	I
##ne	I
(	O
C	O
##LM	O
-	O
89	O
##3	O
-	O
H	O
)	O
,	O
_	O
13	O
C	B
_	I
9	I
-	I
p	I
##hen	I
##yla	I
##lani	I
##ne	I
(	O
C	O
##LM	O
-	O
225	O
##0	O
-	O
H	O
)	O
,	O
_	O
13	O
C	B
_	I
5	I
-	I
pro	I
##line	I
(	O
C	O
##LM	O
-	O
226	O
##0	O
-	O
H	O
)	O
,	O
_	O
13	O
C	B
_	I
3	I
-	I
se	I
##rine	I
(	O
C	O
##LM	O
-	O
157	O
##4	O
-	O
H	O
)	O
,	O
_	O
13	O
C	B
_	I
4	I
-	I
th	I
##re	I
##oni	I
##ne	I
(	O
C	O
##LM	O
-	O
226	O
##1	O
-	O
0	O
)	O
,	O
_	O
13	O
C	O
_	O
11	O
-	O
try	O
##pt	O
##op	O
##han	O
(	O
C	O
##LM	O
-	O
42	O
##90	O
-	O
H	O
)	O
,	O
_	O
13	O
C	B
_	I
9	I
-	I
t	I
##yr	I
##os	I
##ine	I
(	O
C	O
##LM	O
-	O
226	O
##3	O
-	O
H	O
)	O
and	O
_	O
13	O
C	B
_	I
5	I
-	I
v	I
##ali	I
##ne	I

10	B
-	I
(	I
N	I
-	I
Ace	I
##ty	I
##l	I
##cy	I
##stein	I
##yl	I
)	I
-	I
9	I
-	I
h	I
##ydro	I
##xy	I
-	I
9	I
,	I
10	I
-	I
di	I
##hy	I
##dr	I
##op	I
##hen	I
##ant	I
##hren	I
##e	I
(	I
Ph	I
##e	I
-	I
9	I
-	I
h	I
##ydro	I
##xy	I
-	I
10	I
-	I
N	I
##AC	I
)	I
was	O
prepared	O
as	O
described	O
previously	O
.	O

However	O
,	O
l	B
##ino	I
##le	I
##ic	I
and	O
D	O
##HA	O
were	O
impaired	O
in	O
patients	O
without	O
previous	O
exposure	O
to	O
treatments	O
(	O
RA	O
onset	O
)	O
,	O
thereby	O
supporting	O
that	O
other	O
factors	O
than	O
disease	O
duration	S
are	O
responsible	O
for	O
the	O
NE	O
##FA	O
disturbance	O
##s	O
in	O
RA	O
.	O

The	O
formal	B
##in	I
solution	O
was	O
kept	O
in	O
the	O
culture	O
dish	O
for	O
20	O
-	O
minute	O
cross	O
-	O
links	O
at	O
room	O
temperature	O
.	O

V	O
##esi	O
##cle	O
-	O
induced	O
C	O
##a	O
_	O
2	O
+	O
influx	O
in	O
recipient	O
T	O
cells	O
was	O
monitored	O
,	O
and	O
T	O
##EX	O
-	O
induced	O
in	B
##os	I
##ine	I
production	O
in	O
T	O
##re	O
##g	O
was	O
determined	O
by	O
mass	O
s	O
##pect	O
##rome	O
##try	O
.	O

Therefore	O
,	O
the	O
Ph	O
##eno	O
##men	O
##ex	O
Lu	O
##x	O
5	O
##u	O
Cell	B
##ulos	I
##e	I
-	I
1	I
column	O
was	O
selected	O
in	O
this	O
work	O
because	O
it	O
provided	O
a	O
satisfactory	O
retention	O
time	O
to	O
separate	O
pro	B
##line	I
and	O
IS	O
from	O
the	O
serum	O
matrix	O
and	O
sharp	O
peaks	O
.	O

P	O
##elle	O
##ts	O
from	O
ch	B
##lor	I
##of	I
##orm	I
extract	O
##s	O
(	O
see	O
above	O
)	O
were	O
im	O
##mers	O
##ed	O
in	O
600	O
µ	O
##L	O
of	O
de	O
##uter	O
##ed	O
ch	B
##lor	I
##of	I
##orm	I
,	O
and	O
550	O
μ	O
##L	O
of	O
each	O
sample	O
was	O
transferred	O
to	O
a	O
5	O
mm	O
N	O
##MR	O
tube	O
.	O

We	O
found	O
significantly	O
increased	O
levels	O
of	O
met	B
##hi	I
##oni	I
##ne	I
su	I
##lf	I
##oxide	I
,	O
decreased	O
levels	O
of	O
Met	O
,	O
and	O
altered	O
Met	O
/	B
met	B
##hi	I
##oni	I
##ne	I
su	I
##lf	I
##oxide	I
ratio	O
in	O
samples	O
of	O
blood	O
plasma	O
collected	O
from	O
medication	O
-	O
free	O
MD	O
##D	O
patients	O
.	O

The	O
potential	O
importance	O
of	O
this	O
finding	O
lies	O
in	O
the	O
reported	O
over	O
##ex	O
##press	O
##ion	O
of	O
AL	O
##D	O
##H	O
in	O
stem	O
cells	O
of	O
many	O
tumor	O
types	O
,	O
making	O
these	O
stem	O
cells	O
potential	O
targets	O
for	O
B	O
##EN	O
therapy	O
,	O
existing	O
p	O
##oly	O
##mor	O
##phism	O
##s	O
in	O
AL	O
##D	O
##H	O
and	O
potential	O
drug	O
–	O
drug	O
interactions	O
with	O
inhibitor	O
##s	O
of	O
AL	O
##D	O
##H	O
such	O
as	O
di	B
##sul	I
##fi	I
##ram	I
and	O
metro	B
##ni	I
##da	I
##zo	I
##le	I
[	O
–	O
]	O
.	O

Para	O
##meter	O
##s	O
of	O
liquid	O
ch	O
##roma	O
##tography	O
-	O
tandem	O
mass	O
s	O
##pect	O
##rome	O
##try	O
method	O
for	O
measuring	O
g	B
##lut	I
##ama	I
##te	I
,	O
as	B
##par	I
##tate	I
,	O
g	B
##lut	I
##amine	I
and	O
as	B
##par	I
##agi	I
##ne	I
.	O

P	O
##las	O
##mal	O
##ogen	O
##s	O
are	O
a	O
class	O
of	O
membrane	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
with	O
a	O
vinyl	B
-	I
et	I
##her	I
bond	O
at	O
s	O
##n	O
-	O
1	O
position	O
and	O
protect	O
p	O
##oly	O
##uns	O
##at	O
##ura	O
##ted	O
fatty	O
acid	O
from	O
o	O
##xi	O
##da	O
##tive	O
damage	O
,	O
thus	O
acting	O
as	O
sa	O
##c	O
##ri	O
##fic	O
##ial	O
end	O
##ogen	O
##ous	O
o	O
##xi	O
##dant	O
##s	O
.	O

HC	O
##l	O
solution	O
(	O
20	O
mg	O
/	O
m	O
##L	O
in	O
p	B
##yr	I
##id	I
##ine	I
)	O
was	O
added	O
to	O
each	O
tube	O
,	O
followed	O
by	O
in	O
##cu	O
##bation	O
and	O
shaking	O
at	O
1200	O
rpm	O
for	O
120	O
min	O
at	O
37	O
##°	O
##C	O
.	O

The	O
d	B
##9	I
-	I
p	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
was	O
isolated	O
by	O
means	O
of	O
se	O
##quential	O
pre	O
##par	O
##ative	O
thin	O
-	O
layer	O
ch	O
##roma	O
##tography	O
and	O
high	O
-	O
performance	O
liquid	O
ch	O
##roma	O
##tography	O
and	O
was	O
crystal	O
##li	O
##zed	O
and	O
dried	O
under	O
vacuum	O
.	O

The	O
product	O
ion	O
s	O
##pect	O
##ra	O
were	O
in	O
excellent	O
agreement	O
with	O
the	O
mass	O
s	O
##pect	O
##ra	O
previously	O
reported	O
for	O
the	O
N	O
_	B
2	I
-	I
c	I
##ys	I
##tein	I
##es	I
##ulf	I
##in	I
##yl	I
-	I
Ph	I
##IP	I
trip	O
##eptide	O
C	O
*	O
P	O
##F	O
(	O
C	O
-	O
[	O
S	O
=	O
O	O
]	O
-	O
Ph	O
##IP	O
)	O
and	O
(	O
C	O
-	O
[	O
S	O
=	O
O	O
]	O
-	O
[	O
_	O
2	O
H	O
_	O
5	O
]	O
-	O
Ph	O
##IP	O
)	O
add	O
##uc	O
##ts	O
.	O

Numerous	O
stimuli	O
implicated	O
in	O
insulin	O
resistance	O
induce	O
s	B
##phi	I
##ngo	I
##lip	I
##id	I
metabolism	O
and	O
determine	O
c	B
##era	I
##mi	I
##de	I
metabolic	O
fate	O
.	O

In	O
##hibition	O
of	O
p	B
##yr	I
##im	I
##id	I
##ine	I
bio	O
##sy	O
##nt	O
##hesis	O
with	O
5	B
-	I
amino	I
##im	I
##ida	I
##zo	I
##le	I
-	I
4	I
-	I
car	I
##box	I
##ami	I
##de	I
-	I
1	I
-	I
β	I
-	I
rib	I
##os	I
##ide	I
(	O
AI	O
##CA	O
##r	O
)	O
induce	O
##s	O
a	O
##pop	O
##tosis	O
in	O
multiple	O
my	O
##elo	O
##ma	O
cells	O
,	O
with	O
in	O
##hibition	O
of	O
U	O
##MP	O
##S	O
and	O
increases	O
in	O
or	B
##ota	I
##te	I
,	O
further	O
supporting	O
p	B
##yr	I
##im	I
##id	I
##ine	I
bio	O
##sy	O
##nt	O
##hesis	O
as	O
a	O
potential	O
molecular	O
target	O
in	O
multiple	O
my	O
##elo	O
##ma	O
cells	O
.	O

The	O
majority	O
of	O
PC	O
and	O
LP	O
##C	O
species	O
showed	O
lower	O
values	O
at	O
D	O
##1	O
and	O
D	O
##7	O
in	O
N	O
##S	O
when	O
compared	O
to	O
S	O
at	O
day	O
28	O
,	O
whereas	O
increased	O
concentrations	O
of	O
ace	B
##ty	I
##l	I
##car	I
##ni	I
##tine	I
(	O
C	O
##2	O
)	O
and	O
of	O
K	O
##Y	O
##N	O
were	O
observed	O
in	O
N	O
##S	O
on	O
D	O
##1	O
and	O
D	O
##7	O
,	O
respectively	O
.	O

These	O
meta	O
##bol	O
##ites	O
are	O
associated	O
with	O
o	O
##xi	O
##dant	O
stress	O
(	O
total	O
g	B
##lut	I
##ath	I
##ione	I
)	O
,	O
loss	O
of	O
ATP	S
home	O
##ost	O
##asis	O
(	O
ad	O
##eno	O
##sin	O
##e	O
)	O
,	O
a	O
##pop	O
##tosis	O
(	O
P	O
##t	O
##d	O
##S	O
##er	O
)	O
,	O
and	O
disruption	O
of	O
end	O
##oth	O
##eli	O
##al	O
barrier	O
function	O
(	B
s	B
##phi	I
##ngo	I
##my	I
##elin	I
)	O
.	O

The	O
mass	O
s	O
##pect	O
##rome	O
##ter	O
was	O
tuned	O
for	O
each	O
anal	O
##yte	O
and	O
set	O
at	O
a	O
cap	O
##illa	O
##ry	O
voltage	O
of	O
3	O
.	O
0	O
V	O
,	O
cone	O
voltage	O
of	O
16	O
V	O
,	O
source	O
temperature	O
of	O
150	O
°C	O
,	O
des	O
##ol	O
##vation	O
temperature	O
of	O
350	O
°C	O
,	O
and	O
des	O
##ol	O
##vation	O
gas	O
flow	O
of	O
650	O
L	O
/	O
h	O
.	O
Mass	O
spectral	O
transition	O
for	O
Q	O
##UI	O
##N	O
was	O
m	O
/	O
z	O
168	O
>	O
106	O
,	O
k	B
##yn	I
##uren	I
##ine	I
209	O
>	O
146	O
,	O
and	O
try	B
##pt	I
##op	I
##han	I
205	O
>	O
118	O
using	O
collision	O
energies	O
of	O
14	O
,	O
18	O
,	O
and	O
24	O
e	O
##V	O
,	O
respectively	O
.	O

In	O
A	O
,	O
the	O
score	O
plot	O
of	O
p	O
##hos	O
##pha	O
##ti	O
##dy	O
##l	O
##cho	O
##line	O
/	O
SM	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
is	O
shown	O
,	O
whereas	O
B	O
shows	O
the	O
score	O
plot	O
of	O
the	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##let	I
##han	I
##ola	I
##mine	I
class	O
;	O
C	O
shows	O
the	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##gly	I
##cer	I
##ol	I
lip	O
##ids	O
;	O
and	O
the	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##ls	I
##eri	I
##ne	I
class	O
is	O
reported	O
in	O
.	O

Among	O
those	O
,	O
28	O
had	O
a	O
normal	O
son	O
##ographic	O
est	O
##imation	O
of	O
f	O
##etal	O
weight	O
that	O
was	O
confirmed	O
at	O
birth	O
[	B
Ad	B
##e	I
##qua	I
##te	I
-	I
for	I
-	I
g	I
##esta	I
##tional	I
age	O
f	O
##etus	O
##es	O
(	O
AG	O
##A	O
)	O
]	O
and	O
52	O
pre	O
##gna	O
##ncies	O
had	O
an	O
ant	O
##ena	O
##tal	O
diagnosis	O
of	O
f	O
##etal	O
small	O
##ness	O
[	O
estimated	O
son	O
##ographic	O
f	O
##etal	O
weight	O
(	O
E	O
##F	O
##W	O
)	O
below	O
the	O
10	O
_	O
th	O
cent	O
##ile	O
]	O
that	O
was	O
confirmed	O
at	O
birth	O
(	O
birth	O
##weight	O
<	O
10	O
_	O
th	O
cent	O
##ile	O
)	O
and	O
were	O
included	O
as	O
cases	O
.	O

O	O
##C	O
##N	O
def	O
##icient	O
mice	O
demonstrated	O
decreased	O
glucose	S
tolerance	O
and	O
accumulation	O
of	O
body	O
fat	O
,	O
which	O
can	O
also	O
be	O
provoked	O
by	O
insulin	O
resistance	O
.	O

Similarly	O
,	O
in	O
case	O
of	O
VA	O
##S	O
6	O
–	O
10	O
,	O
five	O
pathways	O
were	O
found	O
to	O
be	O
significant	O
namely	O
,	O
Ph	B
##en	I
##yla	I
##lani	I
##ne	I
metabolism	O
(	O
p	O
-	O
value	O
=	O
9	O
.	O
32	O
##E	O
-	O
05	O
)	O
,	O
Ty	B
##ros	I
##ine	I
metabolism	O
(	O
p	O
-	O
value	O
=	O
0	O
.	O
00	O
##8	O
##5	O
##7	O
)	O
,	O
Ph	B
##en	I
##yla	I
##lani	I
##ne	I
,	O
t	B
##yr	I
##os	I
##ine	I
and	O
try	B
##pt	I
##op	I
##han	I
bio	O
##sy	O
##nt	O
##hesis	O
(	O
p	O
-	O
value	O
=	O
0	O
.	O
01	O
##01	O
##5	O
)	O
,	O
U	B
##bi	I
##quin	I
##one	I
and	O
other	O
te	B
##rp	I
##eno	I
##id	I
-	I
q	I
##uin	I
##one	I
bio	O
##sy	O
##nt	O
##hesis	O
(	O
p	O
-	O
value	O
=	O
0	O
.	O
01	O
##7	O
##6	O
##8	O
##2	O
)	O
and	O
Ni	O
##tro	O
##gen	O
metabolism	O
with	O
p	O
-	O
value	O
of	O
0	O
.	O
02	O
##0	O
##5	O
##9	O
##1	O
.	O

After	O
checking	O
the	O
exact	O
masses	O
in	O
the	O
meta	O
##bol	O
##omi	O
##cs	O
databases	O
and	O
literature	O
,	O
five	O
bio	O
##mark	O
##ers	O
were	O
characterized	O
:	O
Di	B
##hy	I
##dr	I
##ob	I
##io	I
##pt	I
##eri	I
##n	I
,	O
A	B
##rg	I
##ini	I
##nos	I
##ucci	I
##nate	I
,	O
3	B
-	I
car	I
##box	I
##y	I
-	I
4	I
-	I
met	I
##hyl	I
-	I
5	I
-	I
prop	I
##yl	I
-	I
2	I
-	I
fur	I
##an	I
##p	I
##rop	I
##ano	I
##ic	I
acid	I
(	O
C	O
##MP	O
##F	O
)	O
,	O
a	O
pro	B
##sta	I
##g	I
##land	I
##in	I
(	O
P	O
##GB	O
##2	O
)	O
and	O
a	O
meta	O
##bol	O
##ite	O
of	O
le	O
##uk	O
##ot	O
##rien	O
##e	O
(	B
Car	B
##box	I
##y	I
-	I
L	I
##T	I
##B	I
##4	I
)	O
.	O

The	O
results	O
showed	O
that	O
the	O
differential	O
meta	O
##bol	O
##ites	O
were	O
mainly	O
en	O
##rich	O
##ed	O
in	O
Ph	B
##os	I
##pha	I
##ti	I
##dy	I
##let	I
##han	I
##ola	I
##mine	I
B	O
##ios	O
##ynth	O
##esis	O
,	O
Ph	B
##os	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
B	O
##ios	O
##ynth	O
##esis	O
,	O
Beta	O
O	O
##xi	O
##dation	O
of	O
Very	O
Long	O
-	O
Chain	O
Fat	O
##ty	O
A	O
##cid	O
##s	O
,	O
Beta	B
##ine	I
Met	O
##ab	O
##olis	O
##m	O
and	O
Car	B
##ni	I
##tine	I
S	O
##ynth	O
##esis	O
.	O

Some	O
examples	O
are	O
the	O
diagnosis	O
of	O
protein	O
##uria	O
,	O
through	O
detection	O
of	O
protein	O
am	O
##ine	O
groups	O
;	O
ha	O
##ema	O
##tur	O
##ia	O
,	O
thanks	O
to	O
per	O
##ox	O
##id	O
##ise	O
activity	O
of	O
l	O
##ys	O
##is	O
-	O
released	O
ha	O
##em	O
##og	O
##lo	O
##bin	O
;	O
infection	O
,	O
through	O
the	O
detection	O
of	O
le	O
##uk	O
##oc	O
##yte	O
est	O
##era	O
##se	O
and	O
ni	O
##tri	O
##tes	O
;	O
g	O
##ly	O
##cos	O
##uria	O
,	O
thanks	O
to	O
the	O
conversion	O
to	O
hydrogen	B
per	I
##oxide	I
by	O
glucose	S
o	O
##xi	O
##das	O
##e	O
and	O
pregnancy	O
,	O
with	O
a	O
strip	O
-	O
based	O
im	O
##mu	O
##no	O
##ass	O
##ay	O
for	O
rapid	O
determination	O
of	O
beta	O
human	O
ch	O
##orio	O
##nic	O
go	O
##nado	O
##tro	O
##pin	O
[	O
,	O
]	O
.	O

Two	O
-	O
tailed	O
S	O
##pear	O
##man	O
correlation	O
rank	O
tests	O
were	O
used	O
to	O
examine	O
the	O
correlation	O
##s	O
between	O
ta	B
##mo	I
##xi	I
##fen	I
and	O
meta	O
##bol	O
##ite	O
concentrations	O
in	O
serum	O
and	O
breast	O
cancer	O
tissues	O
.	O

)	O
,	O
whereas	O
levels	O
of	O
a	B
##rg	I
##ini	I
##ne	I
and	O
as	B
##par	I
##tic	I
acid	I
,	O
two	O
other	O
important	O
intermediate	O
##s	O
in	O
the	O
u	B
##rea	I
cycle	O
,	O
were	O
higher	O
in	O
T	O
##B	O
patients	O
.	O

(	O
E	O
)	O
Label	O
##ing	O
incorporation	O
from	O
_	O
13	O
C	B
_	I
16	I
-	I
palm	I
##itate	I
into	O
palm	B
##ito	I
##yl	I
-	I
car	I
##ni	I
##tine	I
(	O
C	O
##16	O
)	O
,	O
my	B
##risto	I
##yl	I
-	I
car	I
##ni	I
##tine	I
(	O
C	O
##14	O
)	O
and	O
la	B
##uro	I
##yl	I
-	I
car	I
##ni	I
##tine	I
(	O
C	O
##12	O
)	O
in	O
C	O
##NE	O
##2	O
-	O
I	O
##R	O
and	O
HK	O
##1	O
-	O
I	O
##R	O
cells	O
compared	O
with	O
parental	O
cells	O
at	O
24	O
h	O
after	O
exposure	O
to	O
4	O
G	O
##y	O
i	O
##rra	O
##diation	O
(	O
I	O
##R	O
)	O
.	O

G	O
##eo	O
##metric	O
mean	O
u	O
##rina	O
##ry	O
co	B
##tin	I
##ine	I
was	O
modest	O
##ly	O
lower	O
in	O
120	O
Romanian	O
mothers	O
25	O
–	O
45	O
years	O
of	O
age	O
(	O
9	O
.	O
10	O
μ	O
##g	O
/	O
g	O
c	O
##rea	O
##tin	O
##ine	O
)	O
than	O
for	O
women	O
in	O
our	O
study	O
.	O

In	O
addition	O
,	O
findings	O
from	O
our	O
group	O
based	O
on	O
size	O
and	O
extent	O
of	O
primary	O
pro	O
##state	O
cancer	O
cases	O
demonstrated	O
a	O
positive	O
association	O
with	O
his	B
##ti	I
##dine	I
meta	O
##bol	O
##ites	O
including	O
N	B
-	I
ace	I
##ty	I
##l	I
-	I
3	I
-	I
met	I
##hyl	I
##his	I
##ti	I
##dine	I
,	O
and	O
1	O
-	O
and	O
3	B
-	I
met	I
##hyl	I
##his	I
##ti	I
##dine	I
in	O
T	O
##2	O
pro	O
##state	O
cancer	O
##s	O
.	O

The	O
total	O
f	O
##olate	O
##s	O
,	O
as	O
well	O
as	O
the	O
proportions	O
of	O
f	B
##olate	I
meta	O
##bol	O
##ite	O
,	O
also	O
revealed	O
an	O
interesting	O
trend	O
in	O
the	O
two	O
groups	O
.	O

Independent	O
variables	O
:	O
gender	O
(	O
reference	O
category	O
:	O
men	O
(	O
0	O
)	O
vs	O
.	O
women	O
(	O
1	O
)	O
)	O
;	O
age	O
(	O
years	O
)	O
;	O
B	O
##MI	O
(	O
kg	O
/	O
m	O
##2	O
)	O
;	O
put	B
##res	I
##cine	I
(	O
ng	O
/	O
m	O
##L	O
)	O
;	O
sperm	B
##id	I
##ine	I
(	O
ng	O
/	O
m	O
##L	O
)	O
;	O
and	O
sperm	B
##ine	I
(	O
ng	O
/	O
m	O
##L	O
)	O
.	O

Finally	O
,	O
1	B
##μ	I
L	I
of	O
sample	O
was	O
removed	O
with	O
a	O
glass	O
micro	O
##sy	O
##ring	O
##e	O
(	O
Hamilton	O
,	O
Bon	O
##ad	O
##uz	O
,	O
G	O
##R	O
,	O
Switzerland	O
)	O
and	O
manually	O
injected	O
into	O
the	O
ch	O
##roma	O
##to	O
##graph	O
.	O

Tri	B
##gon	I
##elli	I
##ne	I
(	O
or	O
N	B
-	I
met	I
##hyl	I
##nic	I
##ot	I
##inate	I
)	O
may	O
relate	O
to	O
particular	O
diet	O
##ary	O
products	O
(	O
e	O
.	O
g	O
.	O
coffee	O
)	O
but	O
may	O
also	O
arise	O
from	O
end	O
##ogen	O
##ous	O
ni	O
##ac	O
##in	O
met	O
##hyl	O
##ation	O
.	O

(	O
29	O
)	O
,	O
C	O
##MF	O
IV	O
(	O
Cy	O
##c	O
##lop	O
##hos	O
##pha	O
##mi	O
##de	O
+	O
Met	O
##hot	O
##re	O
##xa	O
##te	O
+	O
F	B
##lu	I
##oro	I
##ura	I
##ci	I
##l	I
/	O
5	O
##F	O
##U	O
(	O
C	O
##MF	O
)	O

The	O
_	O
1	O
H	O
and	O
_	O
15	O
N	O
chemical	O
shift	O
data	O
derived	O
from	O
the	O
2D	O
N	O
##MR	O
experiments	O
,	O
after	O
tag	O
##ging	O
with	O
_	O
15	O
N	O
ch	B
##ola	I
##mine	I
,	O
are	O
shown	O
in	O
.	O

Ana	O
##ly	O
##ses	O
on	O
s	O
##ym	O
##pt	O
##om	O
scores	O
in	O
the	O
AD	O
##HD	O
group	O
separately	O
(	O
N	O
=	O
133	O
)	O
confirmed	O
that	O
lower	O
levels	O
of	O
try	B
##pt	I
##op	I
##han	I
and	O
total	O
vitamin	B
B	I
##6	I
were	O
correlated	O
with	O
higher	O
total	O
AS	O
##RS	O
score	O
and	O
higher	O
score	O
on	O
the	O
AS	O
##RS	O
in	O
##att	O
##ent	O
##ive	O
sub	O
##sca	O
##le	O
(	O
Table	O
)	O
.	O

Then	O
increased	O
to	O
30	O
%	O
met	B
##han	I
##ol	I
,	O
15	O
%	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
and	O
55	O
%	O
water	O
phase	O
over	O
2	O
min	O
and	O
hold	O
for	O
4	O
min	O
,	O
followed	O
by	O
increase	O
to	O
50	O
%	O
met	B
##han	I
##ol	I
,	O
25	O
%	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
and	O
25	O
%	O
water	O
phase	O
over	O
3	O
min	O
and	O
hold	O
for	O
5	O
min	O
,	O
and	O
back	O
to	O
8	O
%	O
met	B
##han	I
##ol	I
,	O
4	O
%	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
and	O
88	O
%	O
water	O
phase	O
over	O
1	O
min	O
and	O
hold	O
for	O
3	O
min	O
to	O
re	O
-	O
e	O
##qui	O
##li	O
##bra	O
##te	O
the	O
column	O
.	O

Looking	O
at	O
u	O
##rina	O
##ry	O
and	O
##rogen	O
metabolism	O
,	O
ex	O
##cre	O
##tion	O
of	O
the	O
11	O
-	O
oxygen	O
##ated	O
and	O
##rogen	O
meta	O
##bol	O
##ite	O
11	B
##β	I
-	I
OH	I
-	I
An	I
was	O
significantly	O
higher	O
in	O
the	O
non	O
##obe	O
##se	O
PC	O
##OS	O
co	O
##hor	O
##t	O
[	O
59	O
##5	O
(	O
I	O
##Q	O
##R	O
,	O
43	O
##8	O
to	O
84	O
##1	O
)	O
vs	O
35	O
##3	O
(	O
I	O
##Q	O
##R	O
,	O
171	O
to	O
48	O
##7	O
)	O
in	O
controls	O
;	O
P	O
=	O
0	O
.	O
00	O
##2	O
]	O
,	O
whereas	O
there	O
was	O
only	O
a	O
trend	O
toward	O
significantly	O
higher	O
u	O
##rina	O
##ry	O
ex	O
##cre	O
##tion	O
of	O
An	O
(	O
P	O
=	O
0	O
.	O
07	O
)	O
.	O

Act	B
##ivated	I
plate	O
##lets	O
augmented	O
PP	O
##AR	O
##α	O
m	O
##RNA	O
expression	O
in	O
human	O
um	O
##bil	O
##ical	O
end	O
##oth	O
##eli	O
##al	O
cells	O
30	O
.	O

This	O
four	O
-	O
carbon	O
h	B
##ydro	I
##xy	I
acid	I
was	O
also	O
increased	O
in	O
plasma	O
from	O
he	O
##pa	O
##to	O
##cellular	O
car	O
##cin	O
##oma	O
cases	O
,	O
and	O
it	O
was	O
suggested	O
as	O
a	O
potential	O
bio	O
##mark	O
##er	O
of	O
insulin	O
resistance	O
and	O
impaired	O
glucose	S
regulation	O
[	O
,	O
]	O
.	O

Lim	O
##its	O
of	O
q	O
##uant	O
##itation	O
(	O
L	O
##O	O
##Q	O
)	O
,	O
linear	O
dynamic	O
range	O
,	O
and	O
in	O
##tra	O
-	O
and	O
inter	O
-	O
day	O
precision	O
in	O
the	O
determination	O
of	O
vitamin	B
D	I
meta	O
##bol	O
##ites	O
from	O
plasma	O
No	O
L	O
##OD	O
was	O
given	O
because	O
of	O
the	O
lack	O
of	O
a	O
commercial	O
de	O
##uter	O
##ated	O
standard	O
.	O

Both	O
its	O
phosphate	S
derivative	O
S	O
##1	O
##P	O
as	O
well	O
as	O
the	O
phosphate	S
derivative	O
of	O
s	B
##phi	I
##nga	I
##nine	I
,	O
s	B
##phi	I
##nga	I
##nine	I
1	I
-	I
phosphate	I
(	O
SA	O
##1	O
##P	O
)	O
showed	O
a	O
significant	O
accumulation	O
in	O
HC	O
##C	O
as	O
compared	O
to	O
c	O
##ir	O
##r	O
##hos	O
##is	O
(	O
Figure	O
,	O
P	O
<	O
0	O
.	O
00	O
##1	O
,	O
respectively	O
)	O
.	O

We	O
next	O
examined	O
differences	O
in	O
auto	O
##pha	O
##gy	O
between	O
CA	O
##F	O
##s	O
and	O
N	O
##F	O
##s	O
in	O
response	O
to	O
chronic	O
reduction	O
in	O
glucose	S
availability	O
rather	O
than	O
acute	O
challenge	O
with	O
no	O
glucose	S
.	O

Our	O
study	O
aimed	O
to	O
investigated	O
the	O
metabolic	O
profile	O
of	O
P	O
and	O
IP	S
in	O
the	O
in	O
##test	O
##inal	O
condition	O
,	O
co	O
-	O
culture	O
##d	O
with	O
human	O
f	O
##eca	O
##l	O
bacteria	O
an	O
##ae	O
##ro	O
##bic	O
##ally	O
.	O

As	O
shown	O
in	O
,	O
t	B
##rol	I
##ean	I
##dom	I
##y	I
##cin	I
(	O
50	O
µ	O
##m	O
)	O
and	O
k	B
##eto	I
##cona	I
##zo	I
##le	I
(	O
1	O
µ	O
##m	O
)	O
showed	O
strong	O
inhibitor	O
##y	O
effect	O
on	O
rates	O
of	O
h	B
##ydro	I
##xy	I
##ana	I
##stro	I
##zo	I
##le	I
formation	O
(	O
by	O
80	O
%	O
and	O
95	O
%	O
,	O
respectively	O
)	O
,	O
while	O
th	B
##io	I
##TE	I
##PA	I
(	O
50	O
µ	O
##m	O
)	O
,	O
que	B
##rc	I
##eti	I
##n	I
(	O
20	O
µ	O
##m	O
)	O
and	O
p	B
##ilo	I
##car	I
##pine	I
(	O
50	O
µ	O
##m	O
)	O
were	O
moderate	O
inhibitor	O
##s	O
(	O
by	O
46	O
%	O
,	O
54	O
%	O
and	O
60	O
%	O
,	O
respectively	O
)	O
.	O

Cell	O
##s	O
were	O
then	O
maintained	O
in	O
D	O
##ME	O
##M	O
medium	O
containing	O
either	O
10	O
m	O
##M	O
[	O
U	O
-	O
_	O
13	O
C	O
_	O
6	O
]	O
glucose	S
or	O
2	O
m	O
##M	O
[	B
U	I
-	I
_	I
13	I
C	I
_	I
5	I
]	I
g	I
##lut	I
##amine	I
for	O
1	O
h	O
before	O
metabolism	O
was	O
stopped	O
and	O
cells	O
were	O
analyzed	O
by	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
as	O
described	O
under	O
Experimental	O
Pro	O
##ced	O
##ures	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
highest	O
activity	O
of	O
the	O
hydrogen	B
su	I
##lf	I
##ide	I
oxidation	O
pathways	O
leading	O
to	O
th	B
##ios	I
##ulf	I
##ate	I
is	O
found	O
in	O
the	O
co	O
##lon	O
##ic	O
m	O
##uc	O
##osa	O
,	O
rendering	O
u	O
##rina	O
##ry	O
th	B
##ios	I
##ulf	I
##ate	I
much	O
more	O
heavily	O
dependent	O
on	O
the	O
in	O
##test	O
##inal	O
hydrogen	B
su	I
##lf	I
##ide	I
exposure	O
than	O
is	O
T	O
##MS	O
.	O

Figure	O
shows	O
the	O
s	O
##cat	O
##ter	O
##p	O
##lot	O
##s	O
of	O
th	B
##re	I
##oni	I
##ne	I
versus	O
SUV	O
_	O
ma	O
##x	O
,	O
MA	O
##TV	O
_	O
W	O
##T	O
##B	O
and	O
T	O
##L	O
##G	O
_	O
W	O
##T	O
##B	O
(	O
the	O
horizontal	O
lines	O
represent	O
the	O
median	O
th	B
##re	I
##oni	I
##ne	I
values	O
in	O
the	O
two	O
groups	O
and	O
the	O
difference	O
is	O
the	O
fold	O
change	O
)	O
and	O
reveals	O
that	O
,	O
although	O
the	O
correlation	O
between	O
th	B
##re	I
##oni	I
##ne	I
and	O
the	O
P	O
##ET	O
parameters	O
is	O
rather	O
weak	O
,	O
the	O
fold	O
change	O
of	O
especially	O
MA	O
##TV	O
_	O
W	O
##T	O
##B	O
and	O
T	O
##L	O
##G	O
_	O
W	O
##T	O
##B	O
allows	O
discrimination	O
between	O
the	O
groups	O
.	O

Con	O
##cent	O
##rations	O
of	O
u	O
##rina	O
##ry	O
meta	O
##bol	O
##ites	O
of	O
ni	B
##cot	I
##ine	I
were	O
lower	O
than	O
in	O
most	O
previous	O
studies	O
,	O
suggesting	O
very	O
low	O
exposure	O
##s	O
in	O
the	O
ET	O
##S	O
-	O
exposed	O
group	O
.	O

L	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
(	I
18	I
:	I
0	I
)	I
were	O
purchased	O
from	O
La	O
##rod	O
##an	O
AB	O
(	O
Malmö	O
,	O
Sweden	O
)	O
.	O

We	O
utilized	O
dans	O
##yla	O
##tion	O
L	O
##C	O
-	O
MS	O
to	O
enable	O
relative	O
q	O
##uant	O
##ification	O
of	O
the	O
am	B
##ine	I
-	I
and	O
p	O
##hen	O
##ol	O
-	O
containing	O
sub	O
##met	O
##ab	O
##olo	O
##me	O
with	O
high	O
coverage	O
.	O

_	O
,	O
The	O
identities	O
of	O
2	B
-	I
H	I
##O	I
-	I
Ph	I
##IP	I
and	O
5	B
-	I
H	I
##O	I
-	I
Ph	I
##IP	I
were	O
confirmed	O
by	O
their	O
characteristic	O
product	O
ion	O
s	O
##pect	O
##ra	O
.	O
_	O
,	O
Am	O
##ino	O
acid	O
add	O
##uc	O
##ts	O
of	O
NO	O
_	O
2	O
-	O
Ph	O
##IP	O
were	O
synthesized	O
by	O
the	O
reaction	O
of	O
c	B
##ys	I
##tein	I
##e	I
,	O
try	B
##pt	I
##op	I
##han	I
,	O
t	B
##yr	I
##os	I
##ine	I
or	O
l	B
##ys	I
##ine	I
(	O
0	O
.	O
1	O
μ	O
m	O
##ol	O
)	O
with	O
NO	O
_	O
2	O
-	O
Ph	O
##IP	O

Re	O
##ceive	O
##r	O
operating	O
characteristic	O
curve	O
analysis	O
of	O
the	O
four	O
bio	O
##mark	O
##ers	O
(	B
p	B
##hos	I
##ph	I
##ory	I
##l	I
##cho	I
##line	I
,	O
L	B
-	I
ace	I
##ty	I
##l	I
##car	I
##ni	I
##tine	I
,	O
a	B
##rac	I
##hi	I
##don	I
##ic	I
acid	I
and	O
g	B
##ly	I
##co	I
##cho	I
##lic	I
acid	O
)	O
and	O
the	O
combined	O
model	O
.	O

In	O
HC	O
##C	O
compared	O
to	O
N	O
##TT	O
,	O
statistical	O
models	O
showed	O
high	O
levels	O
of	O
la	B
##ct	I
##ate	I
and	O
p	B
##hos	I
##ph	I
##och	I
##olin	I
##e	I
,	O
and	O
low	O
level	O
of	O
glucose	S
.	O

Higher	O
levels	O
of	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
were	O
seen	O
in	O
MB	O
##C	O
,	O
in	O
line	O
with	O
other	O
studies	O
(	O
,	O
)	O
,	O
and	O
correlated	O
with	O
re	O
##lap	O
##se	O
in	O
E	O
##BC	O
.	O

In	O
particular	O
,	O
low	O
levels	O
of	O
L	B
##ys	I
##o	I
##PC	I
(	I
16	I
:	I
0	I
)	I
in	O
cancer	O
tissues	O
were	O
suggested	O
to	O
be	O
a	O
bio	O
##mark	O
##er	O
associated	O
with	O
re	O
##cu	O
##rrence	O
in	O
pro	O
##state	O
cancer	O
patients	O
.	O

Clinical	O
bio	O
##chemical	O
analyses	O
detected	O
higher	O
values	O
of	O
C	O
‐	O
reactive	O
protein	O
(	O
CR	O
##P	O
)	O
and	O
co	B
##rt	I
##is	I
##ol	I
in	O
cache	O
##ctic	O
patients	O
,	O
as	O
well	O
as	O
a	O
significantly	O
lower	O
concentration	O
of	O
plasma	O
album	O
##in	O
and	O
a	O
non	O
‐	O
significant	O
decrease	O
in	O
circulating	O
lip	O
##ids	O
(	O
total	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
)	O
(	O
Table	O
)	O
.	O

Under	O
stress	O
conditions	O
,	O
pro	B
##line	I
from	O
co	O
##lla	O
##gen	O
breakdown	O
is	O
s	O
##hun	O
##ted	O
to	O
A	O
##rg	O
synthesis	O
to	O
spare	O
nitrogen	O
from	O
other	O
amino	O
acids	O
and	O
limit	O
wasting	O
during	O
periods	O
of	O
decreased	O
ca	O
##lor	O
##ie	O
and	O
or	O
protein	O
intake	O
.	O

Non	B
##ana	I
##l	I
,	O
ben	B
##zal	I
##de	I
##hy	I
##de	I
and	O
he	B
##pta	I
##nal	I
were	O
found	O
at	O
the	O
highest	O
levels	O
in	O
the	O
urine	O
samples	O
of	O
N	O
##P	O
patients	O
.	O

In	O
comparison	O
of	O
self	O
-	O
reported	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
and	O
/	O
or	O
i	B
##bu	I
##p	I
##ro	I
##fen	I
data	O
with	O
_	O
1	O
H	O
N	O
##MR	O
-	O
detected	O
u	O
##rina	O
##ry	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
and	O
/	O
or	O
i	B
##bu	I
##p	I
##ro	I
##fen	I
meta	O
##bol	O
##ites	O
,	O
overall	O
rates	O
of	O
con	O
##cor	O
##dance	O
were	O
high	O
for	O
both	O
populations	O
:	O
83	O
.	O
8	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
(	O
C	O
##I	O
)	O
:	O
78	O
.	O
9	O
,	O
88	O
.	O
7	O
)	O
in	O
Belfast	O
and	O
81	O
.	O
1	O
%	O
(	O
95	O
%	O
C	O
##I	O
:	O
76	O
.	O
5	O
,	O
85	O
.	O
7	O
)	O
in	O
Chicago	O
.	O

Con	O
##sist	O
##ent	O
with	O
these	O
results	O
,	O
we	O
observed	O
decreased	O
serum	O
levels	O
of	O
al	B
##ani	I
##ne	I
,	O
g	B
##lut	I
##amine	I
,	O
1	B
-	I
met	I
##hyl	I
##his	I
##ti	I
##dine	I
,	O
l	B
##ys	I
##ine	I
and	O
v	B
##ali	I
##ne	I
in	O
AD	O
##V	O
with	O
respect	O
to	O
EA	O
##R	O
HC	O
##C	O
patients	O
;	O
on	O
the	O
contrary	O
,	O
serum	O
g	B
##ly	I
##cine	I
level	O
was	O
increased	O
in	O
AD	O
##V	O
vs	O
EA	O
##R	O
patients	O
.	O

Independent	O
of	O
e	O
##G	O
##F	O
##R	O
,	O
plasma	O
c	B
##it	I
##ru	I
##llin	I
##e	I
concentrations	O
were	O
significantly	O
increased	O
in	O
di	O
##abe	O
##tic	O
patients	O
(	O
P	O
=	O
0	O
.	O
02	O
)	O
,	O
and	O
both	O
plasma	O
AD	B
##MA	I
and	O
OH	O
-	O
K	O
##yn	O
levels	O
were	O
directly	O
associated	O
with	O
serum	O
sodium	O
levels	O
(	O
P	O
=	O
0	O
.	O
03	O
and	O
P	O
=	O
0	O
.	O
01	O
,	O
respectively	O
)	O
.	O

X	B
##ant	I
##hine	I
on	O
the	O
other	O
hand	O
was	O
not	O
identified	O
as	O
a	O
marker	O
through	O
the	O
statistical	O
analysis	O
.	O

Higher	O
D	O
##HA	O
##P	O
levels	O
,	O
which	O
indicate	O
lower	O
g	B
##ly	I
##co	I
##ly	I
##tic	I
flux	O
,	O
were	O
observed	O
in	O
M	O
##UC	O
##16	O
knock	O
##down	O
cells	O
as	O
well	O
as	O
M	O
##UC	O
##16	O
-	O
low	O
tumors	O
(	O
Figure	O
)	O
.	O

Note	O
that	O
the	O
only	O
structural	O
difference	O
between	O
A	O
-	O
5	O
-	O
D	O
##P	O
(	O
blue	O
)	O
and	O
A	B
-	I
3	I
,	I
5	I
-	I
D	I
##P	I
(	O
green	O
)	O
is	O
the	O
location	O
of	O
a	O
phosphate	S
group	O
from	O
the	O
central	O
rib	B
##ose	I
unit	O
.	O

It	O
is	O
a	O
harmful	O
u	O
##rem	O
##ic	O
to	B
##xin	I
,	O
and	O
the	O
accumulation	O
in	O
blood	O
is	O
responsible	O
for	O
a	O
variety	O
of	O
path	O
##ological	O
conditions	O
.	O

Mass	O
-	O
spectral	O
data	O
were	O
acquired	O
in	O
positive	O
ion	O
mode	O
with	O
the	O
following	O
E	O
##SI	O
-	O
MS	O
parameters	O
:	O
sheath	O
gas	O
flow	O
rate	O
setting	O
,	O
50	O
;	O
auxiliary	O
gas	O
flow	O
rate	O
setting	O
,	O
10	O
;	O
spray	O
voltage	O
,	O
5	O
.	O
00	O
k	B
##V	I
;	O
and	O
transfer	O
cap	O
##illa	O
##ry	O
temperature	O
,	O
250	O
°C	O
.	O

This	O
study	O
aimed	O
to	O
explore	O
a	O
novel	O
diagnostic	O
method	O
analyzing	O
peripheral	O
blood	O
with	O
mass	O
s	O
##pect	O
##rome	O
##try	O
to	O
assess	O
meta	O
##bol	O
##ites	O
from	O
K	B
##P	I
in	O
patients	O
with	O
MD	O
##D	O
and	O
B	O
##ip	O
##olar	O
Depression	O
(	O
B	O
##D	O
)	O
.	O

The	O
met	B
##hyl	I
##ene	I
quartet	O
at	O
3	O
.	O
66	O
pp	O
##m	O
will	O
itself	O
be	O
masked	O
,	O
as	O
it	O
lies	O
in	O
the	O
heavily	O
crowded	O
glucose	S
region	O
of	O
the	O
spectrum	O
.	O

6	O
##h	O
-	O
i	O
##A	O
##UC	O
(	B
cat	B
##ech	I
##ol	I
and	O
g	B
##ua	I
##iac	I
##ol	I
:	O
24	O
##h	O
-	O
i	O
##A	O
##UC	O
)	O
;	O
Lower	O
graph	O
of	O
panels	O
:	O
time	O
-	O
points	O
analysis	O
from	O
0	O
to	O
24	O
h	O
.	O

2	O
.	O
04	O
,	O
2	O
.	O
00	O
,	O
2	O
.	O
04	O
,	O
2	O
.	O
20	O
,	O
2	O
.	O
06	O
,	O
and	O
2	O
.	O
02	O
mg	O
of	O
Cap	O
,	O
5	O
'	O
-	O
D	O
##FC	O
##R	O
,	O
5	O
'	O
-	O
D	O
##F	O
##UR	O
,	O
2	O
'	O
-	O
D	O
##F	O
##UR	O
,	O
5	O
-	O
F	O
##U	O
,	O
and	O
F	O
##U	O
##H	O
##2	O
were	O
accurately	O
weighed	O
and	O
dissolved	O
in	O
met	B
##han	I
##ol	I
.	O

When	O
all	O
three	O
precursor	O
##s	O
were	O
anal	O
##ys	O
##ed	O
combined	O
,	O
none	O
of	O
the	O
ace	B
##tal	I
##de	I
##hy	I
##de	I
m	O
/	O
z	O
values	O
were	O
found	O
to	O
be	O
significant	O
with	O
P	O
##LS	O
-	O
D	O
##A	O
and	O
ST	O
##T	O
but	O
m	O
/	O
z	O
81	O
(	O
which	O
is	O
pro	O
##ton	O
##ated	O
ace	B
##tal	I
##de	I
##hy	I
##de	I
with	O
2	O
water	O
molecules	O
)	O
was	O
significant	O
using	O
P	O
##LS	O
-	O
D	O
##A	O
and	O
W	O
##TT	O
.	O

Te	B
##tra	I
##de	I
##ce	I
##noy	I
##l	I
##car	I
##ni	I
##tine	I
;	O
6	O
.	O

(	O
A	O
)	O
,	O
(	O
B	O
)	O
,	O
(	O
C	O
)	O
,	O
and	O
(	O
D	O
)	O
refer	O
to	O
g	O
##lut	O
##ama	O
##te	O
de	O
##car	O
##box	O
##yla	O
##se	O
1	O
(	O
GA	O
##D	O
##1	O
)	O
,	O
g	B
##ly	I
##co	I
##gen	I
s	O
##ynth	O
##ase	O
kinase	O
3	O
beta	O
(	O
G	O
##S	O
##K	O
##3	O
##B	O
)	O
,	O
p	B
##yr	I
##u	I
##vate	I
kinase	O
muscle	O
is	O
##oz	O
##yme	O
2	O
(	O
P	O
##K	O
##M	O
##2	O
)	O
,	O
and	O
car	O
##ni	O
##tine	O
palm	O
##ito	O
##yl	O
##tra	O
##ns	O
##fer	O
##ase	O
1	O
(	O
CP	O
##T	O
##1	O
)	O
,	O
respectively	O
.	O

Level	O
##s	O
of	O
put	B
##res	I
##cine	I
and	O
ca	B
##da	I
##ver	I
##ine	I
,	O
which	O
co	O
##rrel	O
##ate	O
with	O
oral	O
ma	O
##lo	O
##dor	O
,	O
were	O
marked	O
##ly	O
altered	O
during	O
waking	O
time	O
,	O
even	O
in	O
healthy	O
donors	O
(	O
Cooke	O
et	O
al	O
.	O
)	O
.	O

(	O
a	O
)	O
P	B
##uri	I
##ne	I
metabolism	O
;	O
(	O
b	O
)	O
v	B
##ali	I
##ne	I
,	O
le	B
##uc	I
##ine	I
and	O
is	B
##ole	I
##uc	I
##ine	I
degradation	O
;	O
(	O
c	O
)	O
amino	B
##acy	I
##l	I
-	I
t	I
##RNA	I
bio	O
##sy	O
##nt	O
##hesis	O
;	O
(	O
d	O
)	O
try	B
##pt	I
##op	I
##han	I
metabolism	O
;	O
(	O
e	O
)	O
c	B
##ys	I
##tein	I
##e	I
and	O
met	B
##hi	I
##oni	I
##ne	I
metabolism	O
;	O
(	O
f	O
)	O
l	B
##ys	I
##ine	I
degradation	O
;	O
(	O
g	O
)	O
p	B
##yr	I
##im	I
##id	I
##ine	I
metabolism	O
;	O
(	O
h	O
)	O
a	B
##rg	I
##ini	I
##ne	I
and	O
pro	B
##line	I
metabolism	O
;	O
(	O
i	O
)	O
g	B
##ly	I
##cine	I
,	O
se	B
##rine	I
and	O
th	B
##re	I
##oni	I
##ne	I
metabolism	O
;	O
(	O
j	O
)	O
ta	B
##uri	I
##ne	I
and	O
h	B
##y	I
##pot	I
##au	I
##rine	I
metabolism	O
;	O
(	O
k	O
)	O
al	B
##ani	I
##ne	I
,	O
as	B
##par	I
##tate	I
and	O
g	B
##lut	I
##ama	I
##te	I
metabolism	O
;	O
(	O
l	O
)	O
pan	B
##to	I
##the	I
##nate	I
and	O
Co	O
##A	O
bio	O
##sy	O
##nt	O
##hesis	O
.	O

Abe	O
##rra	O
##nt	O
g	O
##lut	O
##ami	O
##no	O
##lysis	O
has	O
been	O
described	O
as	O
a	O
hall	O
##mark	O
of	O
cancer	O
,	O
as	O
many	O
cancer	O
cells	O
undergo	O
metabolic	O
re	O
##p	O
##rog	O
##ram	O
##ming	O
that	O
makes	O
them	O
highly	O
g	B
##lut	I
##amine	I
dependent	O
for	O
their	O
survival	O
and	O
proliferation	O
[	O
,	O
]	O
.	O

Quality	O
and	O
concentration	O
of	O
RNA	O
extract	O
##s	O
were	O
determined	O
using	O
1	O
%	O
a	B
##gar	I
##ose	I
-	I
0	I
.	I
5	I
##X	I
T	O
##BE	O
gel	O
##s	O
and	O
s	O
##pect	O
##rop	O
##hot	O
##ometric	O
measurements	O
at	O
260	O
,	O
280	O
and	O
230	O
nm	O
through	O
the	O
Nan	O
##o	O
##D	O
##rop	O
N	O
##D	O
-	O
1000	O
S	O
##pect	O
##rop	O
##hot	O
##ometer	O
.	O

The	O
limit	O
of	O
detection	O
of	O
the	O
ass	O
##ay	O
was	O
50	O
p	B
##g	I
m	O
##l	O
_	O
−	O
##1	O
and	O
the	O
limit	O
of	O
q	O
##uant	O
##ification	O
was	O
100	O
p	B
##g	I
m	O
##l	O
_	O
−	O
##1	O
.	O

The	O
first	O
step	O
consists	O
of	O
the	O
im	O
##mers	O
##ion	O
of	O
the	O
tissue	O
in	O
the	O
formal	B
##in	I
solution	O
.	O

f	B
-	I
g	I
Express	O
##ion	O
of	O
AL	O
##D	O
##H	O
##7	O
##A	O
##1	O
m	O
##RNA	O
levels	O
in	O
the	O
patient	O
groups	O
defined	O
as	O
normal	O
-	O
like	O
(	O
red	O
)	O
,	O
intermediate	O
(	O
black	O
)	O
and	O
low	O
PP	O
##AR	O
activity	O
(	O
blue	O
)	O
.	O

Benz	B
##o	I
[	I
a	I
]	I
p	O
##yre	O
##ne	O
(	O
B	O
[	O
a	O
]	O
P	O
)	O
is	O
a	O
pro	O
##to	O
##ty	O
##pical	O
PA	O
##H	O
and	O
classified	O
as	O
a	O
Group	O
1	O
human	O
car	O
##cin	O
##ogen	O
by	O
the	O
I	O
##AR	O
##C	O
.	O

Therefore	O
,	O
the	O
low	O
average	O
intake	O
of	O
foods	O
rich	O
in	O
ch	B
##olin	I
##e	I
and	O
l	B
-	I
car	I
##ni	I
##tine	I
among	O
our	O
participants	O
may	O
be	O
the	O
leading	O
cause	O
of	O
lower	O
plasma	O
T	B
##MA	I
##O	I
in	O
our	O
study	O
.	O

Index	O
variables	O
with	O
connection	O
to	O
depression	O
and	O
fatigue	O
were	O
investigated	O
(	O
SL	O
##AM	O
headache	O
,	O
SL	O
##AM	O
fatigue	O
,	O
SL	O
##AM	O
co	O
##rt	O
##ical	O
d	O
##ys	O
##function	O
,	O
SL	O
##IC	O
##C	O
ne	O
##uro	O
##psy	O
##chia	O
##tric	O
,	O
H	O
##AD	O
##S	O
anxiety	O
and	O
H	O
##AD	O
##S	O
depression	O
)	O
,	O
but	O
no	O
correlation	O
was	O
found	O
in	O
relation	O
to	O
the	O
meta	O
##bol	O
##ites	O
in	O
the	O
k	B
##yn	I
##uren	I
##ine	I
pathway	O
except	O
weak	O
correlation	O
##s	O
between	O
k	B
##yn	I
##uren	I
##ine	I
and	O
SL	O
##IC	O
##C	O
ne	O
##uro	O
##psy	O
##chia	O
##tric	O
damage	O
(	O
=	O
0	O
.	O
18	O
,	O
p	O
=	O
0	O
.	O
03	O
)	O
and	O
between	O
try	B
##pt	I
##op	I
##han	I
and	O
SL	O
##AM	O
co	O
##rt	O
##ical	O
d	O
##ys	O
##function	O
(	O
=	O

Such	O
sustained	O
signaling	O
resulted	O
in	O
the	O
significant	O
up	O
##re	O
##gu	O
##lation	O
of	O
the	O
conversion	O
of	O
extra	O
##cellular	O
ATP	S
to	O
in	B
##os	I
##ine	I
(	O
ad	O
##eno	O
##sin	O
##e	O
meta	O
##bol	O
##ite	O
)	O
by	O
T	O
##re	O
##g	O
,	O
suggesting	O
that	O
T	O
##EX	O
signaling	O
could	O
have	O
functional	O
consequences	O
in	O
these	O
recipient	O
cells	O
.	O

The	O
flow	O
rate	O
was	O
400	O
μ	O
##L	O
/	O
min	O
and	O
the	O
injection	O
volume	O
was	O
3	O
μ	O
##L	O
.	O
An	O
A	O
##gi	O
##lent	O
65	O
##30	O
A	B
##cc	I
##ura	I
##te	I
-	I
Mass	I
Q	O
##uad	O
##rup	O
##ole	O
Time	O
-	O
of	O
-	O
Flight	O
(	O
Q	O
-	O
TO	O
##F	O
)	O
mass	O
s	O
##pect	O
##rome	O
##ter	O
(	O
A	O
##gi	O
##lent	O
,	O
USA	O
)	O
was	O
used	O
in	O
the	O
study	O
.	O

The	O
sex	O
-	O
specific	O
effects	O
observed	O
for	O
VA	O
##T	O
and	O
the	O
plasma	O
meta	O
##bol	O
##ites	O
co	B
##rt	I
##ison	I
##e	I
,	O
X	O
-	O
121	O
##0	O
##4	O
,	O
3	O
-	O
met	O
##hyl	O
-	O
2	O
-	O
o	O
##x	O
##ova	O
##ler	O
##ate	O
,	O
and	O
u	B
##rate	I
remained	O
un	O
##af	O
##fected	O
after	O
adjusting	O
for	O
H	O
##OM	O
##A	O
-	O
I	O
##R	O
,	O
similar	O
as	O
those	O
for	O
the	O
urine	O
meta	O
##bol	O
##ites	O
te	B
##tra	I
##hy	I
##dr	I
##oc	I
##ort	I
##ison	I
##e	I
,	O
N	B
-	I
ace	I
##ty	I
##lasp	I
##art	I
##ate	I
,	O
car	B
##nos	I
##ine	I
or	O
several	O
unknown	O
compounds	O
such	O
as	O
X	O
-	O
173	O
##40	O
or	O
X	O
-	O
173	O
##5	O
##7	O
.	O

In	O
the	O
Discovery	O
group	O
,	O
do	B
##cos	I
##ah	I
##ex	I
##aen	I
##oat	I
##e	I
(	I
D	I
##HA	I
##22	I
:	I
6	I
##n	I
##3	I
)	I
lost	O
significance	O
(	O
p	O
=	O
0	O
.	O
16	O
)	O
,	O
dim	O
##hom	O
##olin	O
##ole	O
##ate	O
20	O
:	O
2	O
##n	O
##6	O
,	O
10	O
##non	O
##ade	O
##ce	O
##no	O
##ate	O
19	O
:	O
1	O
##n	O
##9	O
,	O
and	O
e	B
##ico	I
##sen	I
##oat	I
##e	I
20	I
:	I
1	I
became	O
trends	O
(	O
p	O
<	O
0	O
.	O
05	O
##5	O
)	O
,	O
and	O
the	O
other	O
meta	O
##bol	O
##ites	O
remained	O
significant	O
.	O

Rep	O
##rod	O
##uc	O
##ibility	O
is	O
improved	O
when	O
M	B
##T	I
##BE	I
is	O
used	O
with	O
C	O
##V	O
’	O
s	O
less	O
than	O
8	O
%	O
for	O
lip	O
##ids	O
and	O
5	O
%	O
for	O
h	B
##ydro	I
##phi	I
##lic	I
compounds	O
versus	O
29	O
%	O
and	O
15	O
%	O
for	O
the	O
met	B
##han	I
##ol	I
method	O
.	O

Due	O
to	O
its	O
rather	O
low	O
concentration	O
,	O
a	O
direct	O
confirmation	O
of	O
resulting	O
lowering	O
of	O
ace	B
##ty	I
##l	I
##cho	I
##line	I
in	O
CS	O
##F	O
could	O
be	O
demonstrated	O
only	O
in	O
the	O
mid	O
-	O
90s	O
.	O

S	O
##pect	O
##ral	O
bin	O
##ning	O
IS	O
##R	O
##s	O
for	O
103	O
regions	O
based	O
on	O
the	O
a	B
##p	I
900	O
MHz	O
s	O
##pect	O
##ra	O
.	O

To	O
conclude	O
,	O
our	O
female	O
-	O
specific	O
observation	O
of	O
VA	O
##T	O
-	O
associated	O
levels	O
of	O
O	B
-	I
met	I
##hyl	I
##asco	I
##rb	I
##ate	I
maybe	O
explain	O
##able	O
by	O
a	O
common	O
genetic	O
architecture	O
of	O
ant	O
##hr	O
##op	O
##ometric	O
traits	O
and	O
inter	O
##media	O
##ry	O
metabolism	O
but	O
further	O
studies	O
are	O
needed	O
to	O
di	O
##sent	O
##ang	O
##le	O
the	O
relationship	O
in	O
more	O
detail	O
.	O

To	O
determine	O
whether	O
the	O
levels	O
of	O
ne	B
##r	I
##von	I
##ic	I
acid	I
changed	O
in	O
a	O
state	O
-	O
dependent	O
manner	O
in	O
patients	O
with	O
MD	O
##D	O
,	O
we	O
divided	O
the	O
patients	O
with	O
MD	O
##D	O
into	O
the	O
following	O
2	O
groups	O
based	O
on	O
the	O
M	O
.	O
I	O
.	O
N	O
.	O
I	O
.	O
results	O
:	O
depressed	O
(	O
d	O
##MD	O
##D	O
)	O
patients	O
(	O
n	O
=	O
34	O
)	O
and	O
re	O
##mit	O
##ted	O
(	O
r	O
##MD	O
##D	O
)	O
patients	O
(	O
n	O
=	O
11	O
)	O
(	O
supplement	O
##ary	O
Table	O
2	O
)	O
.	O

Fat	O
##ty	O
acids	O
(	O
actually	O
the	O
1	O
.	O
3	O
##pp	O
##m	O
peak	O
due	O
to	O
the	O
–	O
(	O
CH	O
_	O
2	O
)	O
_	O
n	O
-	O
groups	O
in	O
fatty	O
acids	O
)	O
correlated	O
negatively	O
with	O
la	B
##ct	I
##ate	I
,	O
t	O
##C	O
##r	O
,	O
t	O
##C	O
##ho	O
and	O
t	O
##G	O
##lut	O
in	O
all	O
the	O
five	O
t	O
##umour	O
types	O
,	O
except	O
that	O
there	O
was	O
no	O
significant	O
correlation	O
between	O
fatty	O
acids	O
and	O
t	O
##G	O
##lut	O
or	O
t	O
##C	O
##ho	O
in	O
o	O
##li	O
##go	O
##den	O
##dr	O
##og	O
##lio	O
##mas	O
.	O

The	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
method	O
used	O
for	O
the	O
determination	O
of	O
su	B
##lf	I
##ado	I
##xin	I
##e	I
(	O
LLC	O
=	O
0	O
.	O
5	O
ng	O
/	O
m	O
##L	O
)	O
would	O
theoretical	O
##ly	O
make	O
it	O
possible	O
to	O
detect	O
traces	O
of	O
su	B
##lf	I
##ado	I
##xin	I
##e	I
up	O
to	O
4	O
months	O
(	O
127	O
days	O
)	O
after	O
a	O
single	O
dose	O
of	O
25	O
mg	O
/	O
kg	O
of	O
su	B
##lf	I
##ado	I
##xin	I
##e	I
.	O

There	O
is	O
substantial	O
evidence	O
,	O
particularly	O
from	O
animal	O
studies	O
,	O
that	O
h	O
##y	O
##pox	O
##ia	O
develops	O
in	O
ad	O
##ip	O
##ose	O
tissue	O
as	O
the	O
tissue	O
mass	O
expands	O
,	O
and	O
the	O
reduction	O
in	O
the	O
oxygen	O
content	O
under	O
##lies	O
an	O
inflammatory	O
response	O
.	O
36	O
In	O
h	O
##y	O
##pox	O
##ic	O
ad	O
##ip	O
##ose	O
tissue	O
,	O
secret	O
##ion	O
of	O
multiple	O
inflammation	O
‐	O
related	O
ad	O
##ip	O
##oki	O
##nes	O
is	O
up	O
##re	O
##gu	O
##lated	O
,	O
and	O
there	O
is	O
a	O
switch	O
from	O
o	O
##xi	O
##da	O
##tive	O
metabolism	O
to	O
an	O
##ae	O
##ro	O
##bic	O
g	O
##ly	O
##co	O
##lysis	O
,	O
with	O
corresponding	O
increases	O
in	O
la	B
##ct	I
##ate	I
production	O
.	O
37	O
The	O
positive	O
association	O
between	O
elevated	O
la	B
##ct	I
##ate	I
and	O
VA	O
##T	O
seen	O
in	O
our	O
study	O
may	O
reflect	O
the	O
systemic	O
effects	O
of	O
ad	O
##ip	O
##ose	O
tissue	O
h	O
##y	O
##pox	O
##ia	O
,	O
which	O
are	O
more	O
common	O
in	O
VA	O
##T	O
compared	O
with	O
other	O
depot	O
##s	O
.	O
38	O
Alternatively	O
,	O
higher	O
la	B
##ct	I
##ate	I
,	O
seen	O
in	O
our	O
study	O
,	O
may	O
reflect	O
abnormal	O
mitochondrial	O
function	O
.	O
39	O
,	O
40	O
Met	O
##ab	O
##olic	O
flux	O
studies	O
using	O
biological	O
trace	O
##rs	O
have	O
shown	O
that	O
glucose	S
feeds	O
the	O
t	B
##rica	I
##rb	I
##ox	I
##yl	I
##ic	I
acid	I
cycle	O
(	O
an	O
integral	O
component	O
of	O
o	O
##xi	O
##da	O
##tive	O
p	O
##hos	O
##ph	O
##ory	O
##lation	O
in	O
the	O
electron	O
transport	O
chain	O
in	O
mit	O
##och	O
##ond	O
##ria	O
)	O
via	O
circulating	O
la	B
##ct	I
##ate	I
and	O
that	O
c	O
##ir	O
##cula	O
##tory	O
turnover	O
flux	O
of	O
la	B
##ct	I
##ate	I
is	O
the	O
highest	O
of	O
all	O
meta	O
##bol	O
##ites	O
,	O
exceeding	O
that	O
of	O
glucose	S
in	O
mice	O
.	O
41	O
Down	O
##re	O
##gu	O
##lation	O
of	O
several	O
genes	O
in	I

All	O
four	O
of	O
these	O
cellular	O
meta	O
##bol	O
##ites	O
have	O
relationships	O
to	O
the	O
pen	B
##tos	I
##e	I
phosphate	I
pathway	O
(	O
PP	O
##P	O
)	O
.	O

AC	O
=	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
;	O
CE	O
=	O
ch	B
##ole	I
##ster	I
##yl	I
est	I
##ers	I
;	O
Ce	B
##r	I
=	O
c	B
##era	I
##mi	I
##des	I
;	O
C	O
##L	O
=	O
card	O
##iol	O
##ip	O
##ins	O
;	O
CS	O
=	O
ch	B
##ole	I
##ster	I
##ol	I
su	I
##lf	I
##ate	I
;	O
D	O
##AG	O
=	O
di	B
##acy	I
##l	I
##gly	I
##cer	I
##ols	I
;	O
FAA	O
=	O
primary	O
fatty	O
amid	B
##es	I
;	O
G	O
##3	O
##P	O
=	O
g	B
##ly	I
##cer	I
##ol	I
3	I
-	I
phosphate	I
;	O
LP	O
##C	O
=	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
;	O
LP	O
##E	O
=	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##let	I
##han	I
##ola	I
##mine	I
##s	I
;	O
LP	O
##G	O
=	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##gly	I
##cer	I
##ols	I
;	O
LP	O
##I	O
=	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##lino	I
##si	I
##to	I
##ls	I
;	O
MA	O
##G	O
=	O
mon	B
##oa	I
##cy	I
##l	I
##gly	I
##cer	I
##ols	I
;	O
N	O
##A	O
##E	O
=	O
N	B
-	I
a	I
##cy	I
##let	I
##han	I
##ola	I
##mine	I
##s	I
;	O
NE	O
##FA	O
=	O
none	O
##ster	O
##ified	O
fatty	O
acids	O
;	O
o	O
##x	O
##FA	O
=	O
o	O
##xi	O
##dized	O
fatty	O
acids	O
;	O
PA	O
=	O
p	B
##hos	I
##pha	I
##ti	I
##dic	I
acids	I
;	O
PC	O
=	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
;	O
P	O
##E	O
=	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##let	I
##han	I
##ola	I
##mine	I
##s	I
;	O
P	B
##G	I
=	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##gly	I
##cer	I
##ols	I
;	O
P	O
##I	O
=	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##lino	I
##si	I
##to	I
##ls	I
;	O
PS	O
=	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##ls	I
##eri	I
##nes	I
;	O
SA	O
##M	O
##e	O
=	O
S	O

Re	O
##lative	O
to	O
the	O
study	O
presented	O
here	O
,	O
the	O
Hu	O
##yn	O
##h	O
et	O
al	O
.	O
study	O
q	O
##uant	O
##ified	O
a	O
larger	O
number	O
of	O
meta	O
##bol	O
##ites	O
(	O
63	O
##6	O
species	O
)	O
,	O
across	O
more	O
lip	O
##id	O
classes	O
(	O
SP	O
##s	O
,	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
,	O
ch	B
##ole	I
##ster	I
##ols	I
,	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
)	O
,	O
in	O
fewer	O
individuals	O
(	O
640	O
samples	O
)	O
,	O
whereas	O
the	O
Le	O
##ma	O
##it	O
##re	O
et	O
al	O
.	O
study	O
evaluated	O
fewer	O
SP	O
##s	O
(	O
15	O
species	O
)	O
on	O
a	O
similar	O
number	O
of	O
individuals	O
(	O
208	O
##6	O
samples	O
)	O
.	O

The	O
levels	O
of	O
la	B
##ct	I
##ate	I
,	O
long	O
-	O
chain	O
fatty	O
acids	O
,	O
t	B
##rig	I
##ly	I
##cer	I
##ide	I
and	O
very	O
low	O
-	O
density	O
lip	O
##op	O
##rote	O
##in	O
were	O
elevated	O
,	O
while	O
glucose	S
,	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
and	O
high	O
-	O
density	O
lip	O
##op	O
##rote	O
##in	O
(	O
HD	O
##L	O
)	O
concentrations	O
were	O
reduced	O
in	O
PC	O
##OS	O
patients	O
as	O
compared	O
with	O
controls	O
.	O

Our	O
results	O
indicate	O
that	O
in	O
both	O
stable	O
MC	O
##I	O
and	O
in	O
AD	O
convert	O
##ers	O
there	O
is	O
a	O
significant	O
increase	O
in	O
L	B
-	I
a	I
##rg	I
##ini	I
##ne	I
which	O
is	O
coupled	O
with	O
a	O
decrease	O
in	O
L	B
-	I
or	I
##ni	I
##thin	I
##e	I
.	O

The	O
ME	O
##K	O
##C	O
-	O
MS	O
/	O
MS	O
conditions	O
are	O
the	O
same	O
as	O
in	O
except	O
that	O
15	O
m	O
##M	O
p	O
##oly	O
-	O
L	O
,	O
L	O
-	O
S	O
##U	O
##LA	O
and	O
25	O
k	B
##V	I
was	O
used	O
.	O

In	O
contrast	O
,	O
plasma	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
concentrations	O
were	O
independent	O
of	O
kidney	O
function	O
but	O
increased	O
with	O
the	O
degree	O
of	O
inflammation	O
and	O
acid	O
##osis	O
.	O

Indoor	O
air	O
PA	O
##H	O
##s	O
identified	O
was	O
Na	B
##pt	I
##hale	I
##ne	I
,	O
F	O
##lu	O
##ori	O
##ne	O
,	O
Ace	O
##nap	O
##ht	O
##hen	O
##e	O
,	O
Ph	B
##enan	I
##th	I
##rene	I
,	O
P	O
##yre	O
##ne	O
,	O
Ch	O
##ry	O
##sen	O
##e	O
and	O
In	B
##den	I
##o	I
[	I
1	I
,	I
2	I
,	I
3	I
-	I
c	I
##d	I
]	I
p	I
##yre	I
##ne	I
.	O

T	B
##hy	I
##mine	I
is	O
a	O
p	B
##yr	I
##im	I
##id	I
##ine	I
n	O
##uc	O
##leo	O
##base	O
,	O
and	O
2	B
-	I
amino	I
##is	I
##ob	I
##ut	I
##yric	I
acid	I
is	O
an	O
end	O
-	O
product	O
of	O
p	B
##yr	I
##im	I
##id	I
##ine	I
metabolism	O
.	O

The	O
method	O
presented	O
here	O
only	O
requires	O
a	O
simple	O
met	B
##han	I
##olic	I
di	O
##lution	O
step	O
,	O
and	O
depending	O
on	O
the	O
specific	O
anal	O
##yte	O
of	O
interest	O
,	O
may	O
require	O
β	O
-	O
g	O
##lu	O
##cu	O
##ron	O
##idas	O
##e	O
treatment	O
.	O

It	O
also	O
accounts	O
for	O
more	O
than	O
70	O
%	O
of	O
total	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
within	O
the	O
in	O
##test	O
##inal	O
m	O
##uc	O
##us	O
layer	O
.	O

3	O
-	O
HP	O
##MA	O
,	O
[	B
N	B
-	I
ace	I
##ty	I
##l	I
-	I
D	I
_	I
3	I
]	O
3	O
-	O
HP	O
##MA	O
di	B
##cy	I
##c	I
##lo	I
##he	I
##xy	I
##lam	I
##ine	I
salt	O
,	O
HM	O
##PM	O
##A	O
di	B
##cy	I
##c	I
##lo	I
##he	I
##xy	I
##lam	I
##ine	I
salt	O
,	O
and	O
[	B
N	B
-	I
ace	I
##ty	I
##l	I
-	I
D	I
_	I
3	I
]	O
HM	O
##PM	O
##A	O
di	B
##cy	I
##c	I
##lo	I
##he	I
##xy	I
##lam	I
##ine	I
salt	O
were	O
obtained	O
from	O
Toronto	O
Research	O
Chemical	O
##s	O
.	O

To	O
this	O
,	O
750	O
µ	O
##l	O
met	B
##hyl	I
te	I
##rt	I
-	I
but	I
##yl	I
et	I
##her	I
(	O
M	O
##T	O
##BE	O
)	O
was	O
added	O
,	O
along	O
with	O
150	O
µ	O
##l	O
of	O
internal	O
standard	O
mix	O
,	O
containing	O
the	O
following	O
six	O
internal	O
standards	O
:	O
1	B
,	I
2	I
-	I
di	I
-	I
o	I
-	I
o	I
##ct	I
##ade	I
##cy	I
##l	I
-	I
s	I
##n	I
-	I
g	I
##ly	I
##cer	I
##o	I
-	I
3	I
-	I
p	I
##hos	I
##ph	I
##och	I
##olin	I
##e	I
(	O
0	O
.	O
6	O
µ	O
##M	O
)	O
,	O
1	B
,	I
2	I
-	I
di	I
-	I
O	I
-	I
p	I
##hy	I
##tany	I
##l	I
-	I
s	I
##n	I
-	I
g	I
##ly	I
##cer	I
##o	I
-	I
3	I
-	I
p	I
##hos	I
##ph	I
##oe	I
##than	I
##ola	I
##mine	I
(	O
1	O
.	O
2	O
µ	O
##M	O
)	O
,	O
C	B
##8	I
-	I
c	I
##era	I
##mi	I
##de	I
(	O
0	O
.	O
6	O
µ	O
##M	O
)	O
,	O
N	B
-	I
he	I
##pta	I
##de	I
##cano	I
##yl	I
-	I
D	I
-	I
er	I
##yt	I
##hr	I
##o	I
-	I
s	I
##phi	I
##ngo	I
##sy	I
##l	I
##ph	I
##os	I
##por	I
##yl	I
##cho	I
##line	I
(	O
0	O
.	O
6	O
µ	O
##M	O
)	O
,	O
und	B
##eca	I
##no	I
##ic	I
acid	I
(	O
0	O
.	O
6	O
µ	O
##M	O
)	O
,	O
and	O
t	B
##ril	I
##au	I
##rin	I
(	O
0	O
.	O
6	O
µ	O
##M	O
)	O
.	O

Des	O
##cript	O
##ive	O
statistics	O
were	O
used	O
to	O
describe	O
the	O
patient	O
characteristics	O
,	O
including	O
:	O
age	O
,	O
ant	O
##hr	O
##op	O
##ometric	O
measurements	O
,	O
serum	O
lip	O
##ids	O
(	B
ch	B
##ole	I
##ster	I
##ol	I
,	O
HD	B
##L	I
-	I
ch	I
##ole	I
##ster	I
##ol	I
,	O
L	B
##D	I
##L	I
-	I
ch	I
##ole	I
##ster	I
##ol	I
,	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
,	O
a	O
##poli	O
##pop	O
##rote	O
##ins	O
)	O
and	O
tumor	O
characteristics	O
(	O
tumor	O
size	O
,	O
number	O
of	O
meta	O
##static	O
l	O
##ymph	O
nodes	O
,	O
est	B
##rogen	I
and	O
pro	B
##ges	I
##tero	I
##ne	I
receptor	O
,	O
H	O
##ER	O
-	O
2	O
,	O
and	O
Ki	O
-	O
67	O
hot	O
spot	O
index	O
)	O
.	O

At	O
the	O
concentration	O
of	O
25	O
ng	O
/	O
m	O
##L	O
,	O
625	O
p	B
##g	I
of	O
each	O
was	O
injected	O
on	O
column	O
and	O
80	O
%	O
or	O
500	O
p	B
##g	I
was	O
directed	O
to	O
the	O
EC	O
-	O
array	O
.	O

nicely	O
demonstrated	O
a	O
mathematical	O
model	O
using	O
base	O
##line	O
and	O
6	O
months	O
meta	O
##bol	O
##ite	O
levels	O
of	O
vitamin	O
D	O
_	O
3	O
,	O
25	O
(	O
OH	O
)	O
D	O
_	O
3	O
and	O
24	B
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
to	O
allow	O
efficient	O
“	O
treat	O
-	O
to	O
-	O
target	O
”	O
prediction	O
of	O
25	O
(	O
OH	O
)	O
D	O
_	O
3	O
levels	O
.	O

The	O
O	O
##W	O
/	O
O	O
##B	O
group	O
had	O
significantly	O
higher	O
levels	O
of	O
the	O
five	O
AA	O
##s	O
compared	O
to	O
the	O
H	B
##L	I
group	O
(	O
fold	O
change	O
range	O
1	O
.	O
07	O
–	O
1	O
.	O
19	O
)	O
.	O

These	O
results	O
might	O
support	O
that	O
at	O
least	O
1	B
,	I
5	I
‐	I
AG	I
,	O
as	B
##par	I
##agi	I
##ne	I
,	O
t	B
##yr	I
##os	I
##ine	I
and	O
u	B
##ric	I
acid	I
are	O
useful	O
for	O
early	O
detection	O
of	O
pan	O
##cre	O
##atic	O
cancer	O
.	O

Based	O
on	O
these	O
observations	O
,	O
the	O
lower	O
level	O
of	O
both	O
al	B
##ani	I
##ne	I
and	O
g	B
##lut	I
##amine	I
,	O
found	O
in	O
the	O
serum	O
of	O
AD	O
##V	O
in	O
comparison	O
with	O
EA	O
##R	O
HC	O
##C	O
patients	O
,	O
might	O
be	O
seen	O
as	O
a	O
consequence	O
of	O
a	O
higher	O
u	O
##til	O
##ization	O
of	O
these	O
amino	O
acids	O
in	O
the	O
AD	O
##V	O
HC	O
##C	O
stage	O
.	O

(	O
a	O
)	O
Heat	O
-	O
map	O
of	O
fold	O
change	O
of	O
66	O
differential	O
meta	O
##bol	O
##ites	O
;	O
(	O
b	O
)	O
Disc	O
##rim	O
##ination	O
of	O
D	O
##AC	O
##D	O
in	O
the	O
training	O
set	O
(	O
1	O
)	O
and	O
in	O
the	O
test	O
set	O
(	O
2	O
)	O
using	O
p	B
##hy	I
##tos	I
##phi	I
##ngo	I
##sin	I
##e	I
.	O

However	O
,	O
we	O
consistently	O
observe	O
superior	O
effects	O
on	O
weight	O
loss	O
,	O
N	O
##AF	O
##LD	O
and	O
lip	O
##id	O
and	O
glucose	S
metabolic	O
der	O
##ang	O
##ement	O
##s	O
using	O
bar	O
##ia	O
##tric	O
surgery	O
as	O
compared	O
with	O
intensive	O
but	O
conservative	O
medical	O
therapy	O
.	O

Two	O
h	O
##ydro	O
##phi	O
##lic	O
-	O
interaction	O
-	O
ch	O
##roma	O
##tography	O
(	O
H	O
##IL	O
##IC	O
)	O
columns	O
(	O
Se	O
##Q	O
##uant	O
Z	O
##IC	O
-	O
c	O
##H	O
##IL	O
##IC	O
,	O
150	O
×	O
2	O
.	O
1	O
mm	O
,	O
3	O
.	O
0	O
μ	O
m	O
particle	O
size	O
,	O
Me	O
##rc	O
##k	O
K	O
##G	O
##a	O
##A	O
,	O
Dar	O
##ms	O
##tadt	O
,	O
Germany	O
for	O
A	O
##gi	O
##lent	O
L	O
##C	O
;	O
Waters	O
X	O
##B	O
##ridge	O
Am	B
##ide	I
,	O
150	O
×	O
2	O
.	O
1	O
mm	O
,	O
2	O
.	O
5	O
μ	O
m	O
particle	O
size	O
for	O
Shi	O
##mad	O
##zu	O
L	O
##C	O
)	O
connected	O
in	O
parallel	O
were	O
run	O
under	O
identical	O
conditions	O
for	O
the	O
positive	O
-	O
and	O
negative	O
-	O
ion	O
##ization	O
modes	O
.	O

Indeed	O
,	O
we	O
found	O
serum	O
glucose	S
levels	O
increased	O
in	O
patients	O
treated	O
with	O
at	O
##y	O
##pical	O
anti	O
##psy	O
##cho	O
##tic	O
medication	O
.	O

SM	O
species	O
are	O
meta	O
##bol	O
##ized	O
into	O
c	B
##era	I
##mi	I
##des	I
,	O
an	O
important	O
second	O
messenger	O
involving	O
in	O
regulation	O
of	O
cellular	O
differentiation	O
,	O
proliferation	O
,	O
and	O
a	O
##pop	O
##tosis	O
.	O

The	O
correlation	O
##s	O
were	O
significant	O
for	O
C	B
##14	I
:	I
2	I
-	I
OH	I
,	O
C	B
##16	I
:	I
2	I
,	O
C	B
##18	I
:	I
1	I
-	I
OH	I
,	O
C	O
##2	O
,	O
C	O
##3	O
,	O
C	O
##5	O
,	O
C	O
##5	O
-	O
DC	O
,	O
C	O
##5	O
-	O
OH	O
,	O
C	B
##5	I
:	I
1	I
-	I
DC	I
,	O
C	O
##6	O
and	O
C	B
##6	I
:	I
1	I
.	O

Our	O
results	O
are	O
in	O
con	O
##cor	O
##dance	O
with	O
-	O
and	O
independently	O
valid	B
##ate	I
-	I
earlier	I
metabolic	O
bio	O
##mark	O
##er	O
studies	O
for	O
T	O
##B	O
,	O
currently	O
in	O
a	O
co	O
##hor	O
##t	O
from	O
Indonesia	O
.	O

S	B
##phi	I
##ngo	I
##sin	I
##e	I
(	I
d	I
##18	I
:	I
1	I
)	I
was	O
by	O
far	O
the	O
main	O
L	O
##C	O
##B	O
in	O
our	O
G	O
##G	O
extract	O
##s	O
but	O
d	B
##20	I
:	I
1	I
was	O
also	O
well	O
represented	O
in	O
nervous	O
tissues	O
(	O
brain	O
,	O
re	O
##tina	O
,	O
op	O
##tic	O
nerve	O
)	O
.	O

Representative	O
ch	O
##roma	O
##to	O
##gram	O
of	O
select	O
##ivity	O
studies	O
comparing	O
blank	O
samples	O
(	O
left	O
ch	O
##roma	O
##to	O
##gram	O
##s	O
)	O
matched	O
to	O
LL	O
##O	O
##Q	O
(	O
right	O
ch	O
##roma	O
##to	O
##gram	O
##s	O
)	O
for	O
A	O
,	O
A	O
##bi	O
;	O
B	O
,	O
D	O
##4	O
##A	O
;	O
C	O
,	O
3	B
-	I
k	I
##eto	I
-	I
5	I
##α	I
-	I
A	I
##bi	I
;	O
D	O
,	O
3	B
-	I
k	I
##eto	I
-	I
5	I
##β	I
-	I
A	I
##bi	I
;	O
E	O
,	O
3	B
##α	I
-	I
OH	I
-	I
5	I
##α	I
-	I
A	I
##bi	I
;	O
F	O
,	O
3	B
##α	I
-	I
OH	I
-	I
5	I
##β	I
-	I
A	I
##bi	I
;	O
G	O
,	O
3	B
##β	I
-	I
OH	I
-	I
5	I
##α	I
-	I
A	I
##bi	I
;	O
and	O
H	O
,	O
3	B
##β	I
-	I
OH	I
-	I
5	I
##β	I
-	I
A	I
##bi	I
.	O

Each	O
of	O
the	O
anal	O
##yte	O
##s	O
,	O
D	O
##NR	O
,	O
da	O
##uno	O
##ru	O
##bic	O
##ino	O
##l	O
,	O
and	O
do	B
##x	I
##or	I
##ubi	I
##cin	I
was	O
q	O
##uant	O
##ified	O
using	O
specific	O
MR	O
##M	O
:	O
52	O
##8	O
.	O
50	O
##→	O
##36	O
##3	O
.	O
3	O
,	O
530	O
.	O
60	O
##→	O
##32	O
##1	O
.	O
30	O
,	O
54	O
##4	O
.	O
50	O
##→	O
##36	O
##1	O
.	O
1	O
,	O
and	O
54	O
##6	O
.	O
5	O
##→	O
##36	O
##3	O
.	O
2	O
and	O
39	O
##9	O
.	O
4	O
,	O
for	O
D	O
##NR	O
,	O
da	O
##uno	O
##ru	O
##bic	O
##ino	O
##l	O
,	O
D	O
##OX	O
,	O
and	O
do	B
##x	I
##or	I
##ubi	I
##cin	I
##ol	I
,	O
respectively	O
.	O

Branch	O
##ed	O
‐	O
chain	O
amino	O
acids	O
are	O
act	O
##iva	O
##tors	O
of	O
the	O
ma	O
##mmal	O
##ian	O
target	O
of	O
rap	B
##am	I
##y	I
##cin	I
signaling	O
pathway	O
,	O
and	O
high	O
concentrations	O
of	O
these	O
amino	O
acids	O
induce	O
ma	O
##mmal	O
##ian	O
target	O
of	O
rap	B
##am	I
##y	I
##cin	I
h	O
##yper	O
##act	O
##ivity	O
,	O
leading	O
to	O
impaired	O
pan	O
##cre	O
##atic	O
β	O
cell	O
insulin	O
secret	O
##ion	O
and	O
insulin	O
resistance	O
.	O
46	O
New	O
##gard	O
and	O
colleagues	O
showed	O
,	O
in	O
a	O
rat	O
model	O
,	O
that	O
a	O
diet	O
##ary	O
pattern	O
of	O
high	O
‐	O
fat	O
consumption	O
with	O
branched	O
‐	O
chain	O
amino	O
acid	O
supplement	O
##ation	O
led	O
to	O
o	O
##besity	O
‐	O
associated	O
insulin	O
resistance	O
via	O
long	O
‐	O
term	O
activation	O
of	O
ma	O
##mmal	O
##ian	O
target	O
of	O
rap	B
##am	I
##y	I
##cin	I
that	O
was	O
reversed	O
by	O
the	O
ma	O
##mmal	O
##ian	O
target	O
of	O
rap	B
##am	I
##y	I
##cin	I
inhibitor	O
,	O
rap	B
##am	I
##y	I
##cin	I
.	I
47	I
They	O
also	O
used	O
principal	O
components	O
analysis	O
to	O
show	O
that	O
branched	O
‐	O
chain	O
amino	O
acid	O
concentrations	O
can	O
be	O
used	O
to	O
differentiate	O
metabolic	O
signatures	O
between	O
o	O
##bes	O
##e	O
and	O
lean	O
humans	O
.	O

C	B
##it	I
##rate	I
was	O
lower	O
only	O
in	O
MS	O
patients	O
and	O
la	B
##ct	I
##ate	I
and	O
were	O
higher	O
only	O
in	O
N	O
##MO	O
##SD	O
patients	O
.	O

A	O
##rg	O
,	O
a	B
##rg	I
##ini	I
##ne	I
;	O
C	O
##it	O
,	O
c	B
##it	I
##ru	I
##llin	I
##e	I
;	O
Or	O
##n	O
,	O
or	B
##ni	I
##thin	I
##e	I
;	O
Val	O
,	O
v	B
##ali	I
##ne	I
;	O
G	O
##ly	O
,	O
g	B
##ly	I
##cine	I
;	O
SD	O
##MA	O
,	O
symmetric	B
dim	I
##eth	I
##yla	I
##rg	I
##ini	I
##ne	I
;	O
OH	O
-	O
K	O
##yn	O
,	O
h	B
##ydro	I
##xy	I
##ky	I
##nu	I
##ren	I
##ine	I
;	O
T	O
##rp	O
,	O
try	B
##pt	I
##op	I
##han	I
.	O

Indeed	O
,	O
PC	O
,	O
as	O
well	O
as	O
ch	B
##olin	I
##e	I
meta	O
##bol	O
##ites	O
derived	O
from	O
its	O
synthesis	O
and	O
cat	O
##ab	O
##olis	O
##m	O
,	O
contribute	O
to	O
regulation	O
of	O
cell	O
proliferation	O
and	O
survival	O
.	O

This	O
finding	O
is	O
consistent	O
with	O
changes	O
in	O
A1	O
##C	O
or	O
2	O
-	O
hour	O
O	O
##G	O
##TT	O
glucose	S
in	O
this	O
study	O
and	O
previous	O
studies	O
(	O
,	O
,	O
)	O
.	O

Ser	O
##um	O
samples	O
were	O
v	O
##ortex	O
##ed	O
with	O
1	O
m	O
##L	O
of	O
met	B
##han	I
##ol	I
containing	O
stable	O
is	O
##oto	O
##pe	O
internal	O
standards	O
.	O

Furthermore	O
,	O
cold	O
met	B
##han	I
##ol	I
(	O
-	O
20	O
##°	O
##C	O
)	O
was	O
added	O
to	O
effectively	O
que	O
##nch	O
the	O
metabolism	O
of	O
cells	O
.	O

There	O
were	O
15	O
ch	B
##ole	I
##ster	I
##yl	I
est	I
##er	I
(	O
CE	O
)	O
,	O
16	O
c	B
##era	I
##mi	I
##de	I
(	O
Ce	O
##r	O
)	O
,	O
7	O
di	B
##acy	I
##l	I
##gly	I
##cer	I
##ol	I
(	O
D	O
##G	O
)	O
,	O
10	O
di	B
##he	I
##x	I
##osy	I
##l	I
##cer	I
##ami	I
##de	I
(	O
He	O
##x	O
##2	O
##C	O
##er	O
)	O
,	O
7	O
he	B
##x	I
##osy	I
##l	I
##cer	I
##ami	I
##de	I
(	O
He	O
##x	O
##C	O
##er	O
)	O
,	O
1	B
2	I
-	I
mon	I
##og	I
##ly	I
##cer	I
##ide	I
(	O
MG	O
)	O
,	O
16	O
p	B
##hos	I
##pha	I
##ti	I
##dic	I
acid	I
(	O
PA	O
)	O
,	O
214	O
PC	O
##s	O
,	O
14	O
PC	O
##s	O
with	O
al	O
##ky	O
##l	O
sub	O
##st	O
##it	O
##uen	O
##t	O
(	O
PC	O
-	O
O	O
)	O
,	O
61	O
PC	O
##s	O
with	O
al	O
##ken	O
##yl	O
sub	O
##st	O
##it	O
##uen	O
##t	O
(	O
PC	O
-	O
P	O
)	O
,	O
72	O
P	O
##Es	O
,	O
21	O
P	O
##E	O
with	O
al	O
##ken	O
##yl	O
sub	O
##st	O
##it	O
##uen	O
##t	O
(	O
P	O
##E	O
-	O
P	O
)	O
,	O
22	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##gly	I
##cer	I
##ol	I
(	O
P	O
##G	O
)	O
,	O
45	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##lino	I
##si	I
##to	I
##l	I
(	O
P	O
##I	O
)	O
,	O
43	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
(	O
SM	O
)	O
,	O
1	O
s	B
##phi	I
##ngo	I
##sin	I
##e	I
(	O
SP	O
)	O
,	O
and	O
129	O
t	B
##rig	I
##ly	I
##cer	I
##ide	I
(	O
T	O
##G	O
)	O
.	O

N	B
,	I
O	I
-	I
B	I
##is	I
(	I
trim	I
##eth	I
##yl	I
##si	I
##ly	I
##l	I
)	I
-	I
t	I
##ri	I
##f	I
##lu	I
##oro	I
##ace	I
##tam	I
##ide	I
(	O
BS	O
##TF	O
##A	O
)	O
der	O
##iva	O
##ti	O
##zation	O
has	O
previously	O
been	O
used	O
for	O
the	O
concurrent	O
analysis	O
of	O
o	B
##xa	I
##late	I
and	O
g	B
##ly	I
##cola	I
##te	I
,	I
_	I
,	O
however	O
,	O
we	O
tested	O
M	O
##T	O
##BS	O
##TF	O
##A	O
as	O
a	O
der	O
##iva	O
##ti	O
##zation	O
re	O
##age	O
##nt	O
,	O
_	O
,	O
as	O
it	O
generally	O
results	O
in	O
higher	O
analytical	O
responses	O
than	O
BS	O
##TF	O
##A	O
.	O

Likewise	O
,	O
in	O
a	O
series	O
of	O
brain	O
tumors	O
from	O
57	O
patients	O
,	O
including	O
5	O
PA	O
vs	O
.	O
7	O
healthy	O
volunteers	O
,	O
Is	O
##obe	O
et	O
al	O
.	O
identified	O
an	O
increased	O
peak	O
of	O
ch	B
##olin	I
##e	I
and	O
a	O
lack	O
of	O
N	B
-	I
ace	I
##ty	I
##l	I
as	I
##par	I
##tate	I
and	O
total	O
c	B
##rea	I
##tine	I
.	O

The	O
di	B
##sul	I
##fi	I
##de	I
bridges	O
significantly	O
contribute	O
to	O
the	O
stability	O
of	O
Al	O
##b	O
and	O
its	O
long	O
biological	O
lifetime	O
.	O

The	O
meta	O
##bol	O
##omi	O
##c	O
profile	O
of	O
tumor	O
tissues	O
showed	O
a	O
significant	O
increase	O
in	O
mon	B
##oa	I
##cy	I
##l	I
##gly	I
##cer	I
##ols	I
and	O
g	B
##ly	I
##cer	I
##ol	I
,	O
as	O
well	O
as	O
elevated	O
levels	O
of	O
medium	O
‐	O
and	O
long	O
‐	O
chain	O
fatty	O
acids	O
(	O
Fi	O
##g	O
.	O

Although	O
_	O
1	O
H	O
-	O
N	O
##MR	O
s	O
##pect	O
##ros	O
##copy	O
is	O
a	O
robust	O
method	O
for	O
analysis	O
of	O
many	O
meta	O
##bol	O
##ites	O
,	O
G	O
##C	O
/	O
TO	O
##FM	O
##S	O
has	O
the	O
advantage	O
to	O
discover	O
changes	O
in	O
meta	O
##bol	O
##ites	O
present	O
at	O
lower	O
concentrations	O
due	O
to	O
the	O
increased	O
sensitivity	O
(	O
for	O
instance	O
,	O
to	O
analyze	O
meta	O
##bol	O
##ites	O
such	O
as	O
g	B
##lut	I
##ami	I
##c	I
acid	O
)	O
hence	O
N	O
##MR	O
and	O
mass	O
s	O
##pect	O
##rome	O
##try	O
should	O
be	O
regarded	O
as	O
complementary	O
techniques	O
.	O

The	O
un	O
##con	O
##ju	O
##gated	O
est	B
##rogen	I
was	O
q	O
##uant	O
##ified	O
from	O
the	O
relevant	O
standard	O
.	O

No	O
associations	O
between	O
ant	O
##ena	O
##tal	O
serum	O
p	B
##ht	I
##hala	I
##te	I
meta	O
##bol	O
##ite	O
concentrations	O
and	O
adult	O
male	O
serum	O
in	O
##h	O
##B	O
,	O
E	O
_	O
1	O
,	O
or	O
E	O
_	O
2	O
concentrations	O
were	O
found	O
.	O

For	O
S	O
##9	O
and	O
16	O
##H	O
##BE	O
##14	O
##o	O
_	O
−	O
cells	O
,	O
g	B
##lut	I
##amine	I
consumption	O
rates	O
were	O
found	O
to	O
be	O
highest	O
of	O
all	O
measured	O
amino	O
acids	O
.	O

SP	O
##E	O
cartridges	O
were	O
conditioned	O
with	O
2	O
m	O
##L	O
met	B
##han	I
##ol	I
followed	O
by	O
2	O
m	O
##L	O
HP	O
##LC	O
-	O
grade	O
water	O
.	O

The	O
relatively	O
weak	O
signals	O
for	O
some	O
co	O
##en	O
##zy	O
##mes	O
such	O
as	O
N	B
##AD	I
##H	I
and	O
N	B
##AD	I
##P	I
##H	I
,	O
due	O
to	O
their	O
low	O
concentrations	O
of	O
a	O
few	O
μ	O
M	O
(	O
Figure	O
##s	O
and	O
)	O
,	O
added	O
to	O
the	O
challenge	O
.	O

However	O
,	O
our	O
understanding	O
of	O
the	O
path	O
##op	O
##hy	O
##sio	O
##logy	O
of	O
A	B
##F	I
re	O
##cu	O
##rrence	O
,	O
incidence	O
,	O
and	O
progression	O
are	O
highly	O
limited	O
.	O

Since	O
manipulation	O
of	O
blood	O
flow	O
alter	O
##s	O
both	O
oxygen	O
and	O
glucose	S
delivery	O
to	O
a	O
solid	O
tumor	O
,	O
these	O
studies	O
have	O
not	O
been	O
able	O
to	O
separate	O
the	O
relative	O
contribution	O
of	O
oxygen	B
vs	I
.	O
glucose	S
in	O
energy	O
metabolism	O
in	O
v	O
##ivo	O
.	O

Ph	B
##en	I
##yla	I
##lani	I
##ne	I
was	O
persistent	O
##ly	O
up	O
-	O
regulated	O
and	O
positively	O
correlated	O
with	O
t	B
##yr	I
##os	I
##ine	I
in	O
I	O
##B	O
##D	O
patients	O
even	O
during	O
induction	O
of	O
re	O
##mission	O
,	O
especially	O
in	O
patients	O
with	O
CD	O
(	O
Table	O
)	O
.	O

A	O
control	O
group	O
of	O
28	O
pre	O
##gna	O
##ncies	O
with	O
adequate	B
-	I
for	I
-	I
g	I
##esta	I
##tional	I
ages	O
(	O
AG	O
##A	O
)	O
f	O
##etus	O
##es	O
were	O
selected	O
among	O
low	O
-	O
risk	O
pre	O
##gna	O
##ncies	O
attending	O
third	O
trim	O
##ester	O
routine	O
pregnancy	O
care	O
and	O
were	O
included	O
if	O
they	O
delivered	O
term	O
neon	O
##ates	O
with	O
a	O
normal	O
birth	O
##weight	O
(	O
between	O
20	O
_	O
th	O
and	O
90	O
_	O
th	O
cent	O
##ile	O
)	O
.	O

In	O
addition	O
,	O
an	O
inverse	O
relation	O
was	O
found	O
between	O
vitamin	O
B	O
-	O
12	O
bio	O
##mark	O
##ers	O
and	O
try	B
##pt	I
##op	I
##han	I
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
p	B
##yr	I
##u	I
##vic	I
acid	I
,	O
and	O
su	B
##cci	I
##nic	I
acid	I
,	O
among	O
other	O
inter	O
##media	O
##ries	O
of	O
the	O
c	B
##it	I
##ric	I
acid	I
cycle	O
.	O

All	O
samples	O
passed	O
these	O
criteria	O
except	O
1	B
##α	I
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
measurement	O
in	O
native	O
serum	O
after	O
SP	O
##E	O
,	O
which	O
was	O
below	O
the	O
LL	O
##O	O
##Q	O
and	O
above	O
the	O
20	O
%	O
precision	O
criterion	O
.	O

As	O
such	O
,	O
3	B
-	I
p	I
##hen	I
##yl	I
##la	I
##ctic	I
acid	I
was	O
not	O
only	O
identified	O
after	O
cheese	O
intake	O
(	O
this	O
report	O
)	O
but	O
also	O
after	O
the	O
intake	O
of	O
yo	O
##gh	O
##urt	O
.	O

Then	O
,	O
metabolism	O
d	O
##ys	O
##re	O
##gu	O
##lation	O
##s	O
were	O
investigated	O
in	O
both	O
patients	O
and	O
m	B
##uri	I
##ne	I
models	O
.	O

Re	O
##lative	O
concentrations	O
obtained	O
using	O
BA	O
##TM	O
##AN	O
for	O
33	O
meta	O
##bol	O
##ites	O
and	O
10	O
lip	O
##id	O
features	O
based	O
on	O
the	O
a	B
##p	I
900	O
MHz	O
s	O
##pect	O
##ra	O
.	O

The	O
met	B
##han	I
##ol	I
,	O
2	B
‐	I
ch	I
##lor	I
##o	I
‐	I
p	I
##hen	I
##yla	I
##lani	I
##ne	I
,	O
met	B
##ho	I
##xy	I
##amine	I
and	O
p	B
##yr	I
##id	I
##ine	I
were	O
purchased	O
from	O
Al	O
##ad	O
##din	O
(	O
Shanghai	O
,	O
China	O
)	O
.	O

To	O
evaluate	O
er	B
##yt	I
##hr	I
##ito	I
##l	I
synthesis	O
from	O
glucose	S
in	O
v	O
##ivo	O
,	O
2	O
g	O
of	O
[	B
U	I
_	I
13	I
C	I
]	I
glucose	I
(	O
C	O
##LM	O
-	O
139	O
##6	O
-	O
MP	O
##T	O
;	O
Cambridge	O
Is	O
##oto	O
##pes	O
)	O
was	O
administered	O
oral	O
##ly	O
to	O
three	O
healthy	O
male	O
donors	O
and	O
dried	O
blood	O
samples	O
were	O
collected	O
via	O
finger	O
p	O
##rick	O
at	O
T	O
##0	O
and	O
at	O
5	O
,	O
15	O
,	O
30	O
,	O
45	O
,	O
60	O
,	O
90	O
,	O
120	O
,	O
and	O
180	O
min	O
after	O
ing	O
##est	O
##ion	O
on	O
dried	O
blood	O
spot	O
cards	O
(	O
What	O
##man	O
protein	O
save	O
##r	O
cards	O
,	O
Z	O
##6	O
##9	O
##9	O
##51	O
##9	O
-	O
100	O
##EA	O
;	O
Sigma	O
–	O
Al	O
##dric	O
##h	O
)	O
.	O

This	O
potential	O
difference	O
between	O
patients	O
with	O
low	O
and	O
high	O
_	O
18	O
F	O
-	O
F	O
##D	O
##G	O
up	O
##take	O
was	O
the	O
stimulus	O
to	O
explore	O
a	O
possible	O
relationship	O
between	O
the	O
up	O
##take	O
of	O
labeled	O
glucose	S
and	O
the	O
metabolic	O
profile	O
in	O
plasma	O
of	O
lung	O
cancer	O
patients	O
.	O

The	O
six	O
meta	O
##bol	O
##ite	O
panel	O
consisted	O
of	O
L	O
##ys	O
##o	O
##P	O
##E	O
(	O
0	O
:	O
0	O
/	O
18	O
:	O
2	O
)	O
,	O
PC	B
(	I
16	I
:	I
0	I
/	I
16	I
:	I
0	I
)	I
,	O
PC	B
(	I
18	I
:	I
0	I
/	I
22	I
:	I
4	I
)	I
,	O
P	B
##E	I
(	I
17	I
:	I
0	I
/	I
0	I
:	I
0	I
)	I
,	O
SM	B
(	I
d	I
##18	I
:	I
1	I
/	I
16	I
:	I
0	I
)	I
and	O
5	B
-	I
h	I
##ydro	I
##xy	I
##try	I
##pt	I
##op	I
##han	I
.	O

Tri	B
##met	I
##hyl	I
##amine	I
-	I
N	I
-	I
oxide	I
(	O
T	O
##MA	O
##O	O
)	O
is	O
a	O
q	O
##uant	O
##ifiable	O
plasma	O
meta	O
##bol	O
##ite	O
produced	O
from	O
diet	O
##ary	O
ch	B
##olin	I
##e	I
and	O
car	B
##ni	I
##tine	I
through	O
a	O
micro	O
##bial	O
-	O
ma	O
##mmal	O
##ian	O
pathway	O
.	O

At	O
low	O
pH	O
and	O
up	O
to	O
9	O
.	O
5	O
,	O
Z	O
##D	O
##V	O
-	O
T	O
##P	O
was	O
better	O
ion	O
##ized	O
in	O
the	O
negative	O
mode	O
than	O
in	O
the	O
positive	O
mode	O
,	O
due	O
to	O
the	O
inability	O
of	O
the	O
thy	B
##mine	I
base	O
to	O
accept	O
an	O
extra	O
pro	O
##ton	O
unless	O
conditions	O
are	O
extremely	O
basic	O
(	O
thy	O
##mi	O
##dine	O
n	O
##uc	O
##leo	O
##side	O
and	O
n	O
##uc	O
##leo	O
##tide	O
p	O
##K	O
_	O
a	O
>	O
9	O
.	O
5	O
)	O
.	O

Cho	B
##line	I
has	O
important	O
roles	O
in	O
the	O
development	O
of	O
P	O
##ca	O
and	O
is	O
heavily	O
incorporated	O
into	O
pro	O
##state	O
tumors	O
,	O
which	O
is	O
exploited	O
in	O
ch	B
##olin	I
##e	I
-	I
P	I
##ET	I
scan	O
##s	O
.	O

Here	O
we	O
found	O
that	O
ing	O
##est	O
##ion	O
of	O
the	O
O	O
##EP	O
bi	O
##s	O
##cu	O
##its	O
for	O
8	O
weeks	O
resulted	O
in	O
a	O
significantly	O
higher	O
level	O
of	O
t	B
##yr	I
##oso	I
##l	I
meta	O
##bol	O
##ites	O
,	O
ho	B
##mo	I
##vani	I
##lli	I
##c	I
acid	I
and	O
3	B
,	I
4	I
-	I
di	I
##hy	I
##dr	I
##ox	I
##y	I
##phe	I
##ny	I
##l	I
ace	I
##tic	I
acid	I
(	O
D	O
##OP	O
##AC	O
)	O
.	O

P	B
##ela	I
##rgon	I
##ic	I
acid	I
is	O
a	O
nine	B
-	I
carbon	I
,	O
chained	O
,	O
mon	B
##oc	I
##ar	I
##box	I
##yl	I
##ic	I
acid	I
that	O
occurs	O
in	O
e	O
##pid	O
##er	O
##mis	O
and	O
blood	O
in	O
humans	O
,	O
and	O
is	O
known	O
as	O
a	O
substance	O
associated	O
with	O
body	O
odor	O
.	O

Met	O
##ab	O
##oli	O
##tes	O
en	O
##rich	O
##ed	O
in	O
the	O
pathway	O
analyses	O
were	O
further	O
analyzed	O
with	O
a	O
Wilcox	O
##on	O
rank	O
sum	O
test	O
and	O
using	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
,	O
revealing	O
a	B
##rg	I
##ini	I
##ne	I
,	O
c	B
##it	I
##ru	I
##llin	I
##e	I
,	O
de	B
##hy	I
##dr	I
##ox	I
##y	I
##car	I
##ni	I
##tine	I
,	O
and	O
g	B
##lut	I
##ami	I
##c	I
γ	I
-	I
semi	I
##ald	I
##eh	I
##yd	I
##e	I
levels	O
are	O
significantly	O
increased	O
in	O
DR	O
patients	O
compared	O
with	O
di	O
##abe	O
##tic	O
controls	O
.	O

A	O
put	O
##ative	O
##ly	O
identified	O
meta	O
##bol	O
##ite	O
,	O
20	B
-	I
OH	I
-	I
L	I
##T	I
##B	I
##4	I
,	O
decreased	O
after	O
in	O
-	O
vehicle	O
exposure	O
to	O
part	O
##iculate	O
metals	O
,	O
suggesting	O
a	O
sub	O
##c	O
##lini	O
##cal	O
immune	O
response	O
.	O

A	O
positive	O
relationship	O
existed	O
between	O
the	O
changes	O
in	O
the	O
levels	O
of	O
l	O
##ys	O
##o	O
##PC	O
##s	O
with	O
saturated	O
fatty	O
acids	O
at	O
s	O
##n	O
-	O
2	O
position	O
of	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
,	O
while	O
the	O
levels	O
of	O
l	O
##ys	O
##o	O
##PC	O
##s	O
with	O
un	O
##sat	O
##ura	O
##ted	O
fatty	O
acid	O
est	O
##eri	O
##fied	O
at	O
s	O
##n	O
-	O
2	O
position	O
increased	O
during	O
the	O
diet	O
intervention	O
.	O

Un	O
##con	O
##ju	O
##gated	O
bi	O
##le	O
acid	O
,	O
lit	B
##ho	I
##cho	I
##lic	I
acid	I
,	O
and	O
de	B
##ox	I
##ych	I
##olic	I
acid	I
on	O
the	O
other	O
hand	O
,	O
was	O
at	O
lower	O
level	O
in	O
HC	O
##C	O
patients	O
compared	O
with	O
healthy	O
controls	O
.	O

The	O
L	O
##C	O
-	O
MS	O
data	O
in	O
positive	O
ion	O
mode	O
indicated	O
,	O
by	O
both	O
exact	O
mass	O
(	O
the	O
m	O
/	O
z	O
205	O
.	O
09	O
##5	O
##2	O
corresponding	O
to	O
the	O
[	O
M	O
+	O
H	O
]	O
+	O
species	O
)	O
and	O
HC	O
##D	O
fragment	O
##ation	O
(	O
the	O
m	O
/	O
z	O
188	O
.	O
06	O
##5	O
##6	O
fragment	O
representing	O
the	O
loss	O
of	O
–	O
NH	O
_	O
3	O
and	O
the	O
m	O
/	O
z	O
146	O
.	O
05	O
##9	O
##3	O
fragment	O
corresponding	O
to	O
beta	O
c	O
##lea	O
##vage	O
adjacent	O
to	O
the	O
in	B
##do	I
##le	I
group	O
)	O
that	O
this	O
peak	O
was	O
most	O
likely	O
the	O
meta	O
##bol	O
##ite	O
try	B
##pt	I
##op	I
##han	I
(	O
T	O
##RP	O
)	O
.	O

The	O
working	O
internal	O
standard	O
solution	O
(	B
sit	B
##ag	I
##lip	I
##tin	I
500	O
ng	O
/	O
m	O
##l	O
)	O
was	O
prepared	O
in	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
by	O
taking	O
50	O
mg	O
in	O
a	O
100	O
m	O
##l	O
volume	O
##tric	O
fl	O
##ask	O
being	O
then	O
dissolved	O
in	O
10	O
m	O
##l	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
.	O

For	O
meta	O
##bol	O
##ite	O
extraction	O
,	O
high	O
purity	O
HP	O
##LC	O
(	O
or	O
higher	O
)	O
grade	O
solvent	O
##s	O
met	B
##han	I
##ol	I
,	O
ace	B
##tone	I
,	O
is	B
##op	I
##rop	I
##ano	I
##l	I
,	O
and	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
,	O
and	O
M	O
##Q	O
water	O
(	O
18	O
.	O
2	O
M	O
·	O
cm	O
,	O
<	O
3	O
pp	O
##b	O
TO	O
##C	O
)	O
were	O
used	O
.	O

Indeed	O
,	O
in	O
positive	O
ion	O
mode	O
two	O
peaks	O
at	O
m	O
/	O
z	O
79	O
##4	O
.	O
56	O
##7	O
##4	O
and	O
m	O
/	O
z	O
79	O
##4	O
.	O
60	O
##34	O
,	O
corresponding	O
to	O
PC	B
37	I
:	I
5	I
and	O
PC	O
-	O
O	O
38	O
:	O
5	O
,	O
respectively	O
,	O
were	O
detected	O
(	O
A	O
)	O
.	O

Regardless	O
of	O
the	O
method	O
,	O
all	O
h	B
##ydro	I
##phi	I
##lic	I
compounds	O
were	O
detected	O
and	O
had	O
excellent	O
resolution	O
on	O
the	O
H	O
##IL	O
##IC	O
column	O
.	O
also	O
includes	O
data	O
resulting	O
from	O
M	B
##T	I
##BE	I
extraction	O
and	O
M	B
##T	I
##BE	I
:	O
SP	O
##E	O
extraction	O
,	O
as	O
discussed	O
in	O
detail	O
later	O
.	O

B	O
##ile	O
acids	O
were	O
present	O
in	O
greater	O
abundance	O
than	O
mon	B
##oh	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##ls	I
,	O
and	O
this	O
allowed	O
their	O
q	O
##uant	O
##ification	O
from	O
reconstructed	O
ion	O
ch	O
##roma	O
##to	O
##gram	O
##s	O
(	O
R	O
##IC	O
##s	O
)	O
recorded	O
on	O
the	O
Or	O
##bit	O
##rap	O
.	O

There	O
were	O
no	O
statistical	O
##ly	O
significant	O
differences	O
between	O
cap	O
##illa	O
##ry	O
and	O
ve	O
##nous	O
drug	O
concentrations	O
except	O
for	O
o	B
##lan	I
##za	I
##pine	I
(	O
Table	O
)	O
:	O
cap	O
##illa	O
##ry	O
o	B
##lan	I
##za	I
##pine	I
plasma	O
concentrations	O
were	O
on	O
average	O
approximately	O
20	O
%	O
higher	O
than	O
ve	O
##nous	O
concentrations	O
,	O
with	O
a	O
wide	O
range	O
of	O
individual	O
%	O
difference	O
values	O
,	O
mostly	O
within	O
50	O
%	O
(	O
Figure	O
)	O
.	O

demonstrates	O
the	O
relationship	O
between	O
T	B
##MA	I
##O	I
,	O
ch	B
##olin	I
##e	I
,	O
and	O
beta	B
##ine	I
levels	O
s	O
##tra	O
##ti	O
##fied	O
according	O
to	O
mit	O
##ral	O
se	O
##pta	O
##l	O
E	O
/	O
E	O
##a	O
cut	O
-	O
offs	O
at	O
15	O
.	O

In	O
the	O
assessment	O
of	O
changes	O
in	O
the	O
urine	O
samples	O
,	O
the	O
decreased	O
trend	O
in	O
c	B
##it	I
##rate	I
,	O
ace	B
##tone	I
and	O
3	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
level	O
for	O
the	O
FA	S
group	O
were	O
reported	O
in	O
both	O
studies	O
showed	O
metabolism	O
directed	O
towards	O
energy	O
demand	O
.	O

Therefore	O
,	O
we	O
proposed	O
a	O
structure	O
of	O
N	B
-	I
ace	I
##ty	I
##l	I
-	I
S	I
-	I
[	I
1	I
-	I
(	I
5	I
-	I
o	I
##x	I
##o	I
-	I
5	I
-	I
car	I
##box	I
##ype	I
##nt	I
##yl	I
)	I
-	I
1	I
##H	I
-	I
p	I
##yr	I
##rol	I
-	I
3	I
-	I
y	I
##l	I
]	I
-	I
L	I
-	I
c	I
##ys	I
##tein	I
##e	I
su	I
##lf	I
##oxide	I
(	O
9	O
,	O
)	O
.	O

(	O
2011	O
)	O
reported	O
the	O
pu	O
##rification	O
of	O
T	B
##2	I
‐	I
to	I
##xin	I
(	O
30	O
)	O
and	O
a	O
mixture	O
of	O
8	B
‐	I
n	I
‐	I
but	I
##yr	I
##yl	I
##ne	I
##oso	I
##lani	I
##ol	I
(	O
31	O
)	O
and	O
8	B
‐	I
is	I
##ob	I
##ut	I
##yr	I
##yl	I
##sol	I
##ani	I
##ol	I
(	O
32	O
)	O
exhibiting	O
anti	O
##fu	O
##nga	O
##l	O
activity	O
(	O
MI	O
##C	O
75	O
–	O
640	O
##μ	O
##M	O
)	O
against	O
eleven	O
clinical	O
strains	O
of	O
Para	O
##co	O
##cci	O
##dio	O
##ides	O
bra	O
##si	O
##lie	O
##nsis	O
.	O

NE	O
##FA	O
may	O
also	O
contribute	O
to	O
vascular	O
injury	O
by	O
in	O
##ducing	O
the	O
synthesis	O
of	O
pro	B
##te	I
##og	I
##ly	I
##can	I
core	O
proteins	O
that	O
promote	O
L	O
##D	O
##L	O
accumulation	O
at	O
the	O
sub	O
##end	O
##oth	O
##eli	O
##al	O
layers	O
.	O

Other	O
N	O
##MR	O
peaks	O
,	O
such	O
as	O
3	O
.	O
243	O
and	O
2	O
.	O
92	O
##4	O
pp	O
##m	O
,	O
were	O
also	O
an	O
##not	O
##ated	O
to	O
t	B
##yra	I
##mine	I
,	O
and	O
peaks	O
at	O
3	O
.	O
01	O
##5	O
##7	O
and	O
3	O
.	O
02	O
##12	O
pp	O
##m	O
were	O
an	O
##not	O
##ated	O
to	O
2	B
-	I
o	I
##x	I
##og	I
##lut	I
##arate	I
(	O
Figure	O
A	O
)	O
.	O

Try	B
##pt	I
##op	I
##han	I
and	O
k	B
##yn	I
##uren	I
##ine	I
levels	O
were	O
measured	O
on	O
cry	O
##op	O
##res	O
##erve	O
##d	O
plasma	O
samples	O
by	O
liquid	O
ch	O
##roma	O
##tography	O
tandem	O
mass	O
s	O
##pect	O
##rome	O
##try	O
as	O
previously	O
described	O
.	O

Numerous	O
studies	O
have	O
consistently	O
confirmed	O
accumulation	O
of	O
la	B
##ct	I
##ate	I
and	O
reduced	O
levels	O
of	O
T	O
##CA	O
cycle	O
intermediate	O
##s	O
in	O
many	O
cancer	O
types	O
,	O
including	O
color	O
##ec	O
##tal	O
cancer	O
(	O
–	O
,	O
,	O
–	O
,	O
,	O
)	O
.	O

Ser	O
##um	O
samples	O
were	O
th	O
##awed	O
and	O
v	O
##ortex	O
##ed	O
,	O
and	O
200	O
μ	O
##L	O
al	O
##iq	O
##uo	O
##ts	O
mixed	O
with	O
400	O
μ	O
##L	O
of	O
0	O
.	O
2	O
M	O
phosphate	S
buffer	O
to	O
minimize	O
pH	O
variations	O
.	O

The	O
most	O
comprehensive	O
report	O
identified	O
meta	O
##bol	O
##ites	O
of	O
seven	O
synthetic	O
can	B
##na	I
##bino	I
##ids	I
:	O
J	O
##W	O
##H	O
-	O
01	O
##8	O
,	O
J	O
##W	O
##H	O
-	O
07	O
##3	O
,	O
J	O
##W	O
##H	O
-	O
08	O
##1	O
,	O
J	O
##W	O
##H	O
-	O
122	O
,	O
J	O
##W	O
##H	O
-	O
210	O
,	O
J	O
##W	O
##H	O
-	O
250	O
,	O
and	O
RC	O
##S	O
-	O
4	O
.	O

Even	O
more	O
striking	O
in	O
##hibition	O
was	O
observed	O
for	O
the	O
products	O
of	O
the	O
“	O
d	O
”	O
c	O
##lea	O
##vage	O
of	O
β	B
-	I
car	I
##ote	I
##ne	I
(	O
v	O
##iz	O
.	O

Of	O
these	O
,	O
26	O
meta	O
##bol	O
##ites	O
(	B
3	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
,	O
ace	B
##tate	I
,	O
ace	B
##tone	I
,	O
al	B
##ani	I
##ne	I
,	O
a	B
##rg	I
##ini	I
##ne	I
,	O
beta	B
##ine	I
,	O
ch	B
##olin	I
##e	I
,	O
c	B
##it	I
##rate	I
,	O
c	B
##rea	I
##tine	I
,	O
format	B
##e	I
,	O
glucose	S
,	O
g	B
##lut	I
##amine	I
,	O
g	B
##ly	I
##cer	I
##ol	I
,	O
g	B
##ly	I
##cine	I
,	O
his	B
##ti	I
##dine	I
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
la	B
##ct	I
##ate	I
,	O
le	B
##uc	I
##ine	I
,	O
l	B
##ys	I
##ine	I
,	O
met	B
##han	I
##ol	I
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
p	B
##yr	I
##u	I
##vate	I
,	O
se	B
##rine	I
,	O
su	B
##cci	I
##nate	I
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
and	O
v	B
##ali	I
##ne	I
)	O
were	O
detected	O
in	O
both	O
bio	O
##f	O
##lu	O
##ids	O
.	O

Second	O
##ly	O
,	O
the	O
targeted	O
relative	O
q	O
##uant	O
##ification	O
of	O
the	O
th	B
##iol	I
##s	I
between	O
the	O
cancer	O
and	O
healthy	O
control	O
was	O
investigated	O
by	O
the	O
IL	O
-	O
L	O
##C	O
-	O
MR	O
##M	O
-	O
MS	O
method	O
.	O

Post	O
##pra	O
##ndi	O
##ally	O
,	O
plasma	O
glucose	S
,	O
insulin	O
,	O
and	O
T	B
##G	I
concentrations	O
increased	O
,	O
and	O
FF	O
##A	O
concentrations	O
decreased	O
significantly	O
.	O

The	O
three	O
T	O
##RP	O
meta	O
##bol	O
##ites	O
of	O
primary	O
interest	O
in	O
this	O
study	O
were	O
K	O
##Y	O
##N	O
,	O
K	O
##Y	O
##NA	O
,	O
and	O
me	B
##lat	I
##oni	I
##n	I
.	O

In	O
comparison	O
to	O
red	O
meat	O
,	O
p	O
##ou	O
##ltry	O
has	O
less	O
saturated	O
fat	O
and	O
hem	B
##e	I
iron	O
,	O
both	O
being	O
induce	O
##rs	O
of	O
o	O
##xi	O
##da	O
##tive	O
stress	O
and	O
DNA	O
damage	O
[	O
]	O
.	O

To	O
determine	O
the	O
effect	O
of	O
alpha	B
-	I
l	I
##ino	I
##len	I
##ic	I
acid	I
(	O
18	O
:	O
3	O
)	O
on	O
pro	O
##state	O
cancer	O
cell	O
growth	O
,	O
we	O
have	O
treated	O
the	O
L	O
##NC	O
##a	O
##P	O
and	O
PC	O
##3	O
pro	O
##state	O
cancer	O
cells	O
with	O
alpha	B
-	I
l	I
##ino	I
##len	I
##ic	I
acid	I
both	O
in	O
dose	O
and	O
time	O
dependent	O
manner	O
.	O

E	O
and	O
G	O
(	O
“	O
T	O
##S	O
##K	O
-	O
NH	O
_	O
2	O
”	O
,	O
al	B
##ky	I
##lam	I
##ine	I
)	O
have	O
weak	O
an	O
##ion	O
exchange	O
##r	O
characteristics	O
due	O
to	O
a	O
terminal	O
amino	S
group	O
.	O

It	O
has	O
been	O
reported	O
that	O
t	B
##rig	I
##ly	I
##cer	I
##ide	I
metabolism	O
in	O
bone	O
tissue	O
is	O
associated	O
with	O
o	O
##ste	O
##ob	O
##last	O
and	O
o	O
##ste	O
##oc	O
##last	O
differentiation	O
controlling	O
genes	O
like	O
lip	O
##op	O
##rote	O
##in	O
lip	O
##ase	O
(	O
LP	O
##L	O
)	O
,	O

T	O
.	O
ha	O
##rz	O
##ian	O
##um	O
strain	O
E	O
##S	O
##39	O
was	O
grown	O
on	O
2	O
%	O
ma	O
##lt	O
extract	O
a	O
##gar	O
plates	O
(	O
B	O
##io	O
##kar	O
##r	O
Di	O
##ag	O
##nos	O
##tics	O
,	O
Beau	O
##va	O
##is	O
,	O
France	O
)	O
or	O
on	O
di	B
##ch	I
##lora	I
##n	I
a	O
##gar	O
plates	O
with	O
18	O
%	O
g	B
##ly	I
##cer	I
##ol	I
(	O
D	O
##G	O
-	O
18	O
a	O
##gar	O
;	O

We	O
observed	O
higher	O
D	O
##HA	O
##P	O
levels	O
,	O
but	O
reduced	O
P	O
##EP	O
levels	O
in	O
M	O
##UC	O
##16	O
knock	O
##down	O
cells	O
,	O
suggesting	O
a	O
potential	O
metabolic	O
block	O
##age	O
in	O
the	O
en	O
##zy	O
##matic	O
activities	O
that	O
cat	O
##aly	O
##ze	O
the	O
g	B
##ly	I
##co	I
##ly	I
##tic	I
flux	O
of	O
carbon	O
downstream	O
of	O
D	O
##HA	O
##P	O
.	O

T	O
##RT	O
-	O
H	O
##U	O
##1	O
bladder	O
cell	O
proliferation	O
was	O
suppressed	O
in	O
the	O
presence	O
of	O
2	B
-	I
o	I
##x	I
##og	I
##lut	I
##arate	I
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

Interest	O
##ingly	O
,	O
the	O
edges	O
connecting	O
is	B
##ole	I
##uc	I
##ine	I
to	O
other	O
amino	O
acids	O
(	B
th	B
##re	I
##oni	I
##ne	I
,	O
se	B
##rine	I
,	O
pro	B
##line	I
)	O
all	O
consist	O
of	O
positive	O
correlation	O
##s	O
,	O
while	O
the	O
connections	O
to	O
the	O
two	O
mon	O
##ou	O
##ns	O
##at	O
##ura	O
##ted	O
fatty	O
acids	O
(	O
M	O
##U	O
##FA	O
##s	O
)	O
,	O
o	B
##le	I
##ic	I
acid	I
and	O
palm	B
##ito	I
##le	I
##ic	I
acid	I
,	O
represent	O
negative	O
correlation	O
##s	O
.	O

Inc	O
##reased	O
secret	O
##ion	O
levels	O
of	O
and	B
##ros	I
##ten	I
##ed	I
##ione	I
could	O
result	O
from	O
g	O
##lo	O
##mer	O
##ular	O
fi	O
##ltration	O
function	O
disorder	O
in	O
RC	O
##C	O
patients	O
.	O

Na	B
##ph	I
##thal	I
##ene	I
is	O
an	O
important	O
industrial	O
chemical	O
,	O
which	O
has	O
recently	O
been	O
shown	O
to	O
cause	O
tumors	O
of	O
the	O
respiratory	O
tract	O
in	O
rode	O
##nts	O
.	O

This	O
leads	O
to	O
an	O
increased	O
production	O
of	O
k	B
##eton	I
##e	I
bodies	O
(	B
3	B
-	I
OH	I
-	I
but	I
##yra	I
##te	I
,	O
ace	B
##to	I
##ace	I
##tate	I
,	O
ace	O
##tone	O
)	O
in	O
patients	O
with	O
MS	O
.	O

The	O
O	O
##stro	O
plate	O
provided	O
a	O
high	O
-	O
through	O
##put	O
re	O
##p	O
##rod	O
##uc	O
##ible	O
method	O
of	O
removing	O
proteins	O
and	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
with	O
minimal	O
sample	O
preparation	O
.	O

One	O
-	O
way	O
analysis	O
of	O
variance	O
was	O
performed	O
to	O
determine	O
the	O
significant	O
effects	O
of	O
the	O
h	B
##y	I
##po	I
##gly	I
##ce	I
##mic	I
potential	O
##s	O
of	O
1	O
and	O
the	O
a	O
##que	O
##ous	O
and	O
DC	O
##M	O
extract	O
##s	O
of	O
G	O
.	O
op	O
##po	O
##si	O
##ti	O
##fo	O
##lis	O
leaves	O
.	O

H	O
##B	O
##V	O
virus	O
is	O
known	O
to	O
integrate	O
host	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
to	O
form	O
he	O
##pa	O
##titis	O
B	O
surface	O
anti	O
##gen	O
.	O

Super	O
##nat	O
##ants	O
were	O
transferred	O
to	O
tubes	O
and	O
dried	O
by	O
cent	O
##ri	O
##fu	O
##gal	O
e	O
##va	O
##por	O
##ation	O
,	O
and	O
the	O
p	O
##elle	O
##ts	O
were	O
re	O
##sus	O
##pen	O
##ded	O
in	O
600	O
μ	O
##L	O
of	O
N	O
##MR	O
phosphate	S
buffer	O
(	O
92	O
##8	O
.	O
6	O
mg	O
an	B
##hy	I
##dr	I
##ous	I
mon	I
##oso	I
##dium	I
phosphate	I
and	O
320	O
.	O
9	O
mg	O
di	B
##so	I
##dium	I
phosphate	I
were	O
dissolved	O
in	O
80	O
m	O
##L	O
D	O
_	O
2	O
O	O
,	O
after	O
which	O
333	O
.	O
3	O
μ	O
##L	O
of	O
01	O
.	O
M	O
DS	O
##S	O
-	O
D	O
##6	O
stock	O
solution	O
was	O
added	O
,	O
pH	O
was	O
adjusted	O
to	O
7	O
.	O
0	O
,	O
and	O
the	O
final	O
volume	O
was	O
brought	O
to	O
100	O
m	O
##L	O
with	O
D	O
_	O
2	O
O	O
)	O
.	O

Public	O
##ly	O
available	O
data	O
revealed	O
that	O
high	O
TD	O
##O	O
##2	O
,	O
the	O
gene	O
encoding	O
TD	O
##O	O
,	O
co	O
##rrel	O
##ates	O
with	O
poor	O
breast	O
cancer	O
clinical	O
outcomes	O
,	O
including	O
overall	O
survival	O
and	O
distant	O
meta	O
##sta	O
##sis	O
-	O
free	O
survival	O
,	O
while	O
expression	O
of	O
the	O
gene	O
encoding	O
the	O
more	O
commonly	O
studied	O
try	B
##pt	I
##op	I
##han	I
cat	O
##ab	O
##oli	O
##zing	O
enzyme	O
ID	O
##O	O
##1	O
did	O
not	O
.	O

The	O
c	B
##era	I
##mi	I
##de	I
structures	O
(	O
combinations	O
of	O
L	O
##C	O
##B	O
and	O
FA	O
)	O
were	O
determined	O
after	O
fragment	O
##ation	O
of	O
the	O
G	O
##G	O
molecular	O
species	O
using	O
the	O
L	O
##T	O
##Q	O
-	O
Or	O
##bit	O
##rap	O
mass	O
s	O
##pect	O
##rome	O
##ter	O
,	O
as	O
detailed	O
previously	O
.	O

Try	B
##pt	I
##op	I
##han	I
metabolism	O
was	O
significantly	O
altered	O
,	O
with	O
per	O
##tur	O
##bed	O
levels	O
of	O
k	B
##yn	I
##uren	I
##ate	I
,	O
5	B
-	I
h	I
##ydro	I
##xy	I
##try	I
##pt	I
##op	I
##han	I
,	O
5	B
-	I
h	I
##ydro	I
##xy	I
##ind	I
##ole	I
##ace	I
##tate	I
,	O
and	O
N	B
-	I
ace	I
##ty	I
##ls	I
##ero	I
##ton	I
##in	I
in	O
SP	O
##MS	O
patients	O
compared	O
with	O
R	O
##R	O
##MS	O
and	O
controls	O
.	O

Total	O
ch	B
##ole	I
##ster	I
##ol	I
was	O
lower	O
in	O
T	O
##2	O
##DM	O
which	O
was	O
in	O
part	O
at	O
##tri	O
##but	O
##able	O
to	O
lower	O
HD	B
##L	I
ch	I
##ole	I
##ster	I
##ol	I
.	O

Higher	O
levels	O
of	O
p	B
##yr	I
##og	I
##lut	I
##ami	I
##c	I
acid	I
and	O
lower	O
levels	O
of	O
hip	B
##pur	I
##ic	I
acid	I
before	O
T	O
##UR	O
##B	O
##T	O
were	O
in	O
also	O
agreement	O
with	O
previous	O
studies	O
reporting	O
results	O
from	O
the	O
analysis	O
of	O
urine	O
samples	O
collected	O
from	O
BC	O
patients	O
and	O
reference	O
healthy	O
groups	O
.	O

This	O
agrees	O
with	O
evidence	O
that	O
upon	O
or	O
##chi	O
##ec	O
##tom	O
##y	O
,	O
car	B
##nos	I
##ine	I
levels	O
significantly	O
decrease	O
in	O
male	O
mice	O
,	O
which	O
can	O
be	O
restored	O
by	O
test	B
##osterone	I
replacement	O
,	O
suggesting	O
a	O
relationship	O
between	O
test	B
##osterone	I
and	O
car	B
##nos	I
##ine	I
concentration	O
.	O

This	O
assignment	O
was	O
further	O
valid	O
##ated	O
by	O
the	O
negative	O
signal	O
at	O
3	O
.	O
21	O
pp	O
##m	O
from	O
ch	B
##olin	I
##e	I
,	O
as	O
it	O
is	O
already	O
known	O
that	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
is	O
a	O
major	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
.	O

The	O
verified	O
meta	O
##bol	O
##ites	O
are	O
involved	O
in	O
primary	O
bi	O
##le	O
acid	O
bio	O
##sy	O
##nt	O
##hesis	O
and	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
metabolism	O
.	O

In	O
A	O
,	O
the	O
use	O
of	O
am	B
##mon	I
##ium	I
format	I
##e	I
rather	O
than	O
water	O
as	O
m	O
##od	O
##ifier	O
add	O
##itive	O
resulted	O
in	O
base	O
##line	O
separation	O
of	O
u	B
##rid	I
##ine	I
and	O
c	B
##yt	I
##os	I
##ine	I
on	O
the	O
B	O
##E	O
##H	O
2	O
-	O
EP	O
column	O
and	O
improved	O
resolution	O
on	O
the	O
Di	B
##ol	I
column	O
;	O
however	O
,	O
when	O
the	O
B	O
##E	O
##H	O
2	O
-	O
EP	O
column	O
was	O
replaced	O
by	O
the	O
Di	B
##ol	I
column	O
,	O
both	O
peak	O
shape	O
(	O
B	O
)	O
and	O
resolution	O
improved	O
,	O
regardless	O
of	O
which	O
add	O
##itive	O
is	O
used	O
.	O

try	B
##pt	I
##op	I
##han	I
,	O
k	B
##yn	I
##uren	I
##ine	I
,	O
in	B
##do	I
##leam	I
##ine	I
2	I
,	I
3	I
-	I
di	I
##ox	I
##y	I
##gen	I
##ase	I
-	I
1	I
,	O
HIV	O
,	O
Ka	O
##po	O
##si	O
'	O
s	O
sa	O
##rc	O
##oma	O
,	O
plasma	O
HIV	O
RNA	O
,	O
Africa	O

In	O
contrast	O
,	O
the	O
D	O
##HA	O
-	O
derived	O
re	B
##sol	I
##vin	I
D	I
##1	I
(	O
R	O
##v	O
##D	O
##1	O
)	O
was	O
increased	O
in	O
CS	O
##F	O
of	O
patients	O
with	O
highly	O
active	O
MS	O
(	O
0	O
.	O
89	O
p	O
##g	O
/	O
m	O
##l	O
±	O
##0	O
.	O
41	O
vs	O
.	O
0	O
.	O
12	O
p	O
##g	O
/	O
m	O
##l	O
±	O
##0	O
.	O
05	O
,	O
P	O
=	O
0	O
.	O
01	O
##4	O
)	O
.	O

Therefore	O
,	O
the	O
value	O
of	O
sa	B
##rc	I
##os	I
##ine	I
as	O
a	O
pro	O
##gno	O
##stic	O
marker	O
for	O
PC	O
##a	O
progression	O
is	O
controversial	O
.	O

Š	O
##t	O
##ě	O
##tino	O
##v	O
##á	O
et	O
al	O
.	O
performed	O
an	O
in	O
v	O
##it	O
##ro	O
study	O
with	O
a	O
standard	O
lip	O
##id	O
per	O
##ox	O
##ida	O
##tion	O
ass	O
##ay	O
,	O
and	O
they	O
finally	O
found	O
that	O
tested	O
drugs	O
in	O
##hibit	O
##ed	O
lip	O
##id	O
per	O
##ox	O
##ida	O
##tion	O
in	O
the	O
order	O
of	O
try	B
##pta	I
##mine	I
(	O
59	O
%	O
)	O
>	O
2	B
-	I
in	I
##do	I
##le	I
##car	I
##box	I
##yl	I
##ic	I
acid	I
(	O
38	O
%	O
)	O
>	O
in	B
##dom	I
##eth	I
##ac	I
##in	I
(	O
26	O
%	O
)	O
>	O
me	B
##lat	I
##oni	I
##n	I
and	O
in	B
##do	I
##le	I
-	I
3	I
-	I
car	I
##box	I
##yl	I
##ic	I
acid	I
(	O
13	O
%	O
)	O
.	O

A	O
S	O
##pear	O
##man	O
correlation	O
coefficient	O
was	O
calculated	O
to	O
sum	O
##mar	O
##ize	O
the	O
correlation	O
between	O
GA	O
##BR	O
and	O
AD	B
##MA	I
.	O

After	O
adjusting	O
for	O
try	B
##pt	I
##op	I
##han	I
levels	O
,	O
only	O
3	B
-	I
h	I
##ydro	I
##xy	I
##ant	I
##hra	I
##ni	I
##lic	I
acid	I
and	O
co	B
##tin	I
##ine	I
remained	O
significant	O
.	O

The	O
inclusion	O
criteria	O
were	O
:	O
B	O
##MI	O
20	O
–	O
33	O
kg	O
/	O
m	O
_	O
2	O
,	O
serum	O
total	O
ch	B
##ole	I
##ster	I
##ol	I
concentration	O
5	O
.	O
0	O
-	O
8	O
.	O
5	O
mm	O
##ol	O
/	O

The	O
mixture	O
was	O
then	O
analyzed	O
under	O
the	O
conditions	O
as	O
described	O
in	O
the	O
Section	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
Det	O
##ec	O
##tion	O
of	O
An	B
##th	I
##oc	I
##yan	I
##in	I
Con	O
##ju	O
##gate	O
##s	O
.	O

(	O
A	O
)	O
G	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
metabolism	O
.	O

The	O
components	O
were	O
el	O
##uted	O
with	O
50	O
%	O
of	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
in	O
water	O
and	O
50	O
%	O
of	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
which	O
was	O
de	O
##gas	O
##sed	O
in	O
a	O
son	O
##ica	O
##tor	O
for	O
15	O
min	O
and	O
delivered	O
at	O
a	O
flow	O
rate	O
of	O
0	O
.	O
15	O
m	O
##l	O
min	O
_	O
−	O
##1	O
.	O

Also	O
,	O
the	O
pot	O
##ency	O
(	O
I	O
##C	O
_	O
50	O
1	O
.	O
62	O
–	O
4	O
.	O
38	O
μ	O
##g	O
/	O
m	O
##L	O
)	O
of	O
extract	O
##s	O
from	O
Fu	O
##sar	O
##ium	O
s	B
##p	I
.	O

The	O
quantities	O
of	O
identified	O
s	O
##tero	O
##ls	O
and	O
bi	O
##le	O
acids	O
in	O
CS	O
##F	O
were	O
determined	O
by	O
is	O
##oto	O
##pe	O
di	O
##lution	O
mass	O
s	O
##pect	O
##rome	O
##try	O
against	O
a	O
known	O
amount	O
of	O
added	O
24	O
(	O
SR	O
)	O
-	B
[	B
_	I
2	I
H	I
_	I
6	I
]	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
(	O
100	O
%	O
[	O
_	O
2	O
H	O
_	O
6	O
]	O
)	O
internal	O
standard	O
(	O
IS	O
)	O
.	O

It	O
is	O
also	O
an	O
important	O
precursor	O
of	O
u	B
##rea	I
.	O

Moreover	O
,	O
a	O
decreased	O
amount	O
of	O
su	B
##cci	I
##nate	I
was	O
shown	O
by	O
the	O
network	O
analysis	O
in	O
long	O
-	O
term	O
survivors	O
compared	O
to	O
short	O
-	O
term	O
survivors	O
,	O
suggesting	O
a	O
decreased	O
activity	O
of	O
the	O
T	O
##CA	O
cycle	O
.	O

L	B
-	I
Palm	I
##ito	I
##yl	I
##car	I
##ni	I
##tine	I
.	O

The	O
link	O
between	O
sub	O
##c	O
##lini	O
##cal	O
pan	O
##cre	O
##atic	O
disease	O
and	O
elevated	O
serum	O
lip	O
##ase	O
could	O
be	O
exploited	O
to	O
determine	O
risk	O
of	O
ER	O
##CP	O
-	O
induced	O
AP	S
,	O
and	O
deserves	O
further	O
study	O
.	O

GP	O
##R	O
##8	O
##1	O
is	O
also	O
en	O
##rich	O
##ed	O
at	O
the	O
blood	O
-	O
brain	O
barrier	O
,	O
further	O
suggesting	O
that	O
la	B
##ct	I
##ate	I
may	O
play	O
a	O
role	O
in	O
signaling	O
in	O
the	O
brain	O
.	O

The	O
sample	O
via	O
##ls	O
containing	O
dried	O
lip	O
##id	O
extract	O
##s	O
were	O
added	O
with	O
1	O
m	O
##l	O
of	O
freshly	O
prepared	O
di	B
##az	I
##ome	I
##than	I
##e	I
in	O
et	O
##her	O
solution	O
.	O

Four	O
of	O
the	O
five	O
p	B
##hos	I
##ph	I
##og	I
##ly	I
##cer	I
##oli	I
##pid	I
##s	I
that	O
were	O
changed	O
were	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
(	O
PC	O
)	O
lip	O
##ids	O
that	O
were	O
increased	O
by	O
an	O
average	O
of	O
20	O
%	O
±	O
4	O
%	O
compared	O
to	O
controls	O
.	O

Val	B
##ine	I
,	O
la	B
##ct	I
##ate	I
,	O
g	B
##lut	I
##amine	I
,	O
al	B
##ani	I
##ne	I
,	O
trim	B
##eth	I
##yla	I
##mine	I
-	I
n	I
-	I
oxide	I
(	O
T	O
##MA	O
##O	O
)	O
,	O
l	B
##ys	I
##ine	I
and	O
PC	B
(	I
p	I
##hos	I
##ph	I
##och	I
##olin	I
##e	I
)	I
were	O
increased	O
in	O
all	O
re	O
##ct	O
##al	O
cancer	O
patients	O
except	O
stage	O
I	O
.	O
Interest	O
##ingly	O
,	O
ace	B
##tate	I
,	O
o	B
-	I
ace	I
##ty	I
##l	I
g	I
##ly	I
##co	I
##p	I
##rote	I
##in	I
,	O
dim	B
##eth	I
##yla	I
##mine	I
and	O
le	B
##uc	I
##ine	I
became	O
significantly	O
different	O
form	O
stage	O
III	O
to	O
stage	O
IV	O
.	O

Six	O
meta	O
##bol	O
##ites	O
(	B
ta	B
##uri	I
##ne	I
,	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
,	O
v	B
##ali	I
##ne	I
,	O
le	B
##uc	I
##ine	I
,	O
bi	B
##li	I
##ru	I
##bin	I
,	O
and	O
1	B
‐	I
met	I
##hyl	I
##nic	I
##ot	I
##ina	I
##mi	I
##de	I
)	O
were	O
identified	O
using	O
authentic	O
standards	O
resulting	O
in	O
a	O
level	O
1	O
identification	O
according	O
to	O
the	O
Met	O
##ab	O
##olo	O
##mic	O
##s	O
Standards	O
Initiative	O
(	O
MS	O
##I	O
)	O
,	O
nine	O
compounds	O
(	O
seven	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
(	O
L	O
##ys	O
##o	O
##PC	O
##s	O
)	O
and	O
two	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##let	I
##han	I
##ola	I
##mine	I
##s	I
(	O
L	O
##ys	O
##o	O
##P	O
##Es	O
)	O
)	O
reached	O
MS	O
##I	O
level	O
2	O
identification	O
,	O
and	O
14	O
compounds	O
could	O
not	O
be	O
identified	O
(	O
unknown	O
meta	O
##bol	O
##ites	O
,	O
MS	O
##I	O
level	O
4	O
)	O
.	O

a	O
)	O
Met	B
##han	I
##ol	I
and	O
H	O
_	O
2	O
O	B
(	I
2	I
:	I
1	I
(	I
v	I
/	I
v	I
)	I
)	I
method	O
,	O
b	O
)	O
ch	B
##lor	I
##of	I
##orm	I
,	O
met	B
##han	I
##ol	I
,	O
and	O
H	O
_	O
2	O
O	B
(	I
1	I
:	I
1	I
:	I
1	I
(	I
v	I
/	I
v	I
/	I
v	I
)	I
)	I
method	O
,	O
c	O
)	O
na	O
##no	O
##par	O
##tic	O
##le	O
addition	O
,	O
cent	O
##ri	O
##fu	O
##gation	O
,	O
and	O
super	O
##nat	O
##ant	O
extraction	O
followed	O
by	O
the	O
extraction	O
of	O
met	B
##han	I
##ol	I
and	O
H	O
_	O
2	O
O	B
(	I
2	I
:	I
1	I
(	I
v	I
/	I
v	I
)	I
)	I
,	O
d	O
)	O
na	O
##no	O
##par	O
##tic	O
##le	O
addition	O
,	O
cent	O
##ri	O
##fu	O
##gation	O
,	O
and	O
super	O
##nat	O
##ant	O
extraction	O
followed	O
by	O
the	O
extraction	O
of	O
ch	B
##lor	I
##of	I
##orm	I
,	O
met	B
##han	I
##ol	I
,	O
and	O
H	O
_	O
2	O
O	B
(	I
1	I
:	I
1	I
:	I
1	I
(	I
v	I
/	I
v	I
/	I
v	I
)	I
)	I
.	O

5	O
-	O
OH	O
I	O
##AA	O
also	O
highly	O
correlated	O
with	O
K	O
##Y	O
##N	O
/	O
T	O
##RP	O
,	O
and	O
was	O
moderately	O
correlated	O
with	O
neo	B
##pt	I
##eri	I
##n	I
and	O
in	B
##dox	I
##yl	I
su	I
##lf	I
##ate	I
(	O
see	O
Table	O
)	O
.	O

In	O
addition	O
,	O
applying	O
ultra	O
##sonic	O
##ation	O
on	O
the	O
cap	O
##illa	O
##ries	O
containing	O
single	O
cells	O
proved	O
to	O
improve	O
exhaust	O
##ive	O
##ness	O
and	O
lip	O
##id	O
coverage	O
.	O
_	O
21	O
Consequently	O
,	O
most	O
of	O
the	O
potential	O
bio	O
##mark	O
##ers	O
detected	O
in	O
this	O
study	O
were	O
mainly	O
lip	O
##ids	O
,	O
such	O
as	O
GP	O
##L	O
##s	O
,	O
FA	O
##s	O
,	O
a	B
##cy	I
##l	I
car	I
##ni	I
##tine	I
##s	I
,	O
SL	O
##s	O
,	O
and	O
pre	B
##no	I
##l	I
lip	O
##ids	O
.	O

Similar	O
variations	O
were	O
found	O
in	O
ch	B
##olin	I
##e	I
,	O
hip	B
##pur	I
##ic	I
acid	I
,	O
and	O
form	B
##ic	I
acid	I
as	O
.	O

P	O
##las	O
##ma	O
concentration	O
-	O
time	O
profile	O
of	O
g	B
##ly	I
##bur	I
##ide	I
and	O
its	O
meta	O
##bol	O
##ite	O
M1	O
over	O
a	O
dos	O
##ing	O
interval	O
in	O
a	O
g	O
##esta	O
##tional	O
diabetes	O
subject	O
who	O
received	O
1	O
.	O
25	O
mg	O
oral	O
dose	O
of	O
g	B
##ly	I
##bur	I
##ide	I
every	O
12	O
h	O
##rs	O
.	O

The	O
o	B
##li	I
##gos	I
##ac	I
##cha	I
##ride	I
compounds	O
,	O
which	O
el	O
##ute	O
immediately	O
after	O
the	O
void	O
volume	O
and	O
overwhelming	O
##ly	O
prefer	O
M	B
##T	I
##BE	I
extraction	O
,	O
also	O
ex	O
##em	O
##p	O
##lify	O
this	O
trend	O
.	O

Our	O
data	O
show	O
for	O
the	O
first	O
time	O
m	O
/	O
z	O
matches	O
for	O
two	O
Mt	O
##b	O
cell	O
wall	O
components	O
in	O
the	O
plasma	O
of	O
patients	O
with	O
T	O
##B	O
disease	O
,	O
the	O
verified	O
g	B
##ly	I
##co	I
##lip	I
##id	I
t	I
##re	I
##hal	I
##ose	I
-	I
6	I
-	I
my	I
##cola	I
##te	I
(	O
a	O
component	O
of	O
the	O
my	O
##co	O
##lic	O
acid	O
layer	O
of	O
the	O
cell	O
wall	O
)	O
and	O
P	O
##I	O
.	O

Furthermore	O
,	O
the	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
L	O
##MI	O
disc	O
##rim	O
##inated	O
O	O
##VC	O
from	O
non	O
-	O
O	O
##VC	O
patients	O
(	O
and	O
)	O
.	O

The	O
effect	O
on	O
G	B
##ly	I
##c	I
-	I
ER	I
-	I
G	I
##FP	I
was	O
further	O
enhanced	O
by	O
the	O
addition	O
of	O
u	B
##rid	I
##ine	I
to	O
the	O
culture	O
medium	O
,	O
which	O
resulted	O
in	O
essentially	O
normal	O
g	O
##ly	O
##cos	O
##yla	O
##tion	O
of	O
this	O
test	O
protein	O
.	O

The	O
cut	O
##aneous	O
me	O
##lan	O
##oma	O
data	O
##set	O
for	O
K	B
##P	I
related	O
analyses	O
in	O
me	O
##lan	O
##oma	O
patients	O
was	O
comprised	O
of	O
m	O
##RNA	O
-	O
se	O
##q	O
data	O
(	O
data	O
accessed	O
at	O
c	O
##B	O
##io	O
##P	O
##ort	O
##al	O
for	O
Cancer	O
Gen	O
##omi	O
##cs	O
in	O
December	O
2017	O
,	O
http	O
:	O
/	O
/	O
www	O
.	O
c	O
##bio	O
##port	O
##al	O
.	O
org	O
/	O
)	O
.	O

The	O
work	O
reported	O
here	O
could	O
be	O
expanded	O
in	O
several	O
different	O
directions	O
:	O
(	O
1	O
)	O
valid	O
##ate	O
the	O
results	O
in	O
a	O
larger	O
independent	O
series	O
;	O
(	O
2	O
)	O
assess	O
whether	O
in	B
##os	I
##ito	I
##l	I
(	I
1	I
,	I
2	I
-	I
)	I
c	I
##yclic	I
phosphate	I
and	O
car	B
##ni	I
##tine	I
are	O
also	O
pro	O
##gno	O
##stic	O
for	O
additional	O
sub	O
##type	O
##s	O
of	O
soft	O
-	O
tissue	O
sa	O
##rc	O
##oma	O
;	O
(	O
3	O
)	O
investigate	O
the	O
biological	O
foundations	O
of	O
their	O
pro	O
##gno	O
##stic	O
value	O
,	O
which	O
may	O
ultimately	O
lead	O
to	O
novel	O
treatment	O
strategies	O
.	O

B	O
##MI	O
,	O
body	O
mass	O
index	O
;	O
DE	O
##D	O
,	O
dry	O
eye	O
disease	O
;	O
D	O
##H	O
##EA	O
,	O
de	B
##hy	I
##dr	I
##oe	I
##pian	I
##dr	I
##osterone	I
;	O
D	B
##H	I
##EA	I
-	I
S	I
,	O
de	B
##hy	I
##dr	I
##oe	I
##pian	I
##dr	I
##osterone	I
su	I
##lf	I
##ate	I
;	O
SD	O
,	O
standard	O
de	O
##viation	O
;	O
S	O
##Q	O
##DE	O
##S	O
,	O
Short	O
Question	O
##naire	O
for	O
Dry	O
Eye	O
S	O
##yn	O
##drome	O

Both	O
am	B
##mon	I
##ium	I
format	I
##e	I
and	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
increased	O
the	O
el	O
##ution	O
of	O
highly	O
polar	O
pharmaceutical	O
##ly	O
-	O
relevant	O
anal	O
##yte	O
##s	O
from	O
a	O
c	B
##yan	I
##o	I
column	O
,	O
and	O
both	O
were	O
found	O
to	O
improve	O
ch	O
##roma	O
##to	O
##graphic	O
peak	O
shapes	O
for	O
a	O
range	O
of	O
do	O
##ping	O
agents	O
separated	O
on	O
B	O
##E	O
##H	O
and	O
B	O
##E	O
##H	O
2	O
-	O
EP	O
columns	O
.	O

A	O
diagnostic	O
model	O
was	O
constructed	O
using	O
a	O
panel	O
of	O
five	O
meta	O
##bol	O
##ites	O
including	O
g	B
##lut	I
##ama	I
##te	I
,	O
ch	B
##olin	I
##e	I
,	O
1	B
,	I
5	I
-	I
an	I
##hy	I
##dr	I
##o	I
-	I
d	I
-	I
g	I
##lu	I
##ci	I
##to	I
##l	I
,	O
beta	B
##ine	I
,	O
and	O
met	B
##hyl	I
##gua	I
##ni	I
##dine	I
,	O
which	O
robust	O
##ly	O
distinguished	O
PC	O
patients	O
in	O
CT	O
from	O
controls	O
with	O
high	O
sensitivity	O
(	O
97	O
.	O
7	O
%	O
)	O
and	O
specific	O
##ity	O
(	O
83	O
.	O
1	O
%	O
)	O
(	O
area	O
under	O
the	O
receiver	O
operating	O
characteristic	O
curve	O
[	O
AU	O
##C	O
]	O
=	O
0	O
.	O
94	O
##3	O
,	O
95	O
%	O
confidence	O
interval	O
[	O
C	O
##I	O
]	O
=	O
0	O
.	O
90	O
##8	O
–	O
0	O
.	O
97	O
##7	O
)	O
.	O

The	O
bio	O
##mark	O
##er	O
panel	O
:	O
1	B
-	I
h	I
##ydro	I
##xy	I
-	I
2	I
-	I
o	I
##x	I
##op	I
##rop	I
##yl	I
te	I
##tra	I
##hy	I
##dr	I
##op	I
##ter	I
##in	I
,	O
1	B
-	I
ace	I
##to	I
##xy	I
-	I
2	I
-	I
h	I
##ydro	I
##xy	I
-	I
16	I
-	I
he	I
##pta	I
##de	I
##cy	I
##n	I
-	I
4	I
-	I
one	I
,	O
1	B
,	I
2	I
-	I
de	I
##hy	I
##dr	I
##osa	I
##ls	I
##olin	I
##ol	I
and	O
L	B
-	I
t	I
##yr	I
##os	I
##ine	I

The	O
additional	O
small	O
peak	O
in	O
(	O
b	O
)	O
between	O
the	O
d	O
##A	O
and	O
d	O
##T	O
##G	O
peaks	O
is	O
th	B
##io	I
##gua	I
##nos	I
##ine	I
.	O

(	O
d	O
##17	O
##S	O
##a	O
)	O
,	O
S	B
##phi	I
##nga	I
##nine	I
-	I
1	I
-	I
phosphate	I
d	I
##17	I
:	I
0	I

Ice	O
-	O
cold	O
ch	B
##lor	I
##of	I
##orm	I
and	O
water	O
were	O
added	O
in	O
a	O
3	O
:	O
1	O
ratio	O
for	O
a	O
final	O
proportion	O
of	O
4	O
:	O
3	O
:	O
2	O
met	O
##han	O
##ol	O
:	O
ch	B
##lor	I
##of	I
##orm	I
:	O
water	O
.	O

The	O
internal	O
standards	O
,	O
the	O
extraction	O
solution	O
,	O
and	O
the	O
quality	O
controls	O
(	O
Q	O
##Cs	O
)	O
related	O
to	O
amino	O
acids	O
(	O
AA	O
##s	O
)	O
,	O
free	O
car	B
##ni	I
##tine	I
(	O
C	O
##0	O
)	O
,	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
(	O
ACC	O
##s	O
)	O
,	O
k	B
##eton	I
##es	I
as	O
su	B
##cci	I
##ny	I
##l	I
ace	I
##tone	I
(	O
SA	O
)	O
,	O
n	O
##uc	O
##leo	O
##side	O
##s	O
,	O
and	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
were	O
obtained	O
from	O
the	O
Neo	O
##B	O
##ase	O
2	O
Non	O
-	O
der	O
##iva	O
##tized	O
MS	O
##MS	O
Kit	O
(	O
Per	O
##kin	O
Elmer	O
Life	O
and	O
Ana	O
##ly	O
##tical	O
Sciences	O
,	O
Tu	O
##rk	O
##u	O
,	O
Finland	O
)	O
.	O

These	O
relationships	O
remained	O
essentially	O
un	O
##altered	O
after	O
additional	O
adjustment	O
for	O
the	O
use	O
of	O
glucose	S
lowering	O
drugs	O
or	O
anti	O
##hy	O
##pert	O
##ens	O
##ive	O
medication	O
(	O
β	O
=	O
−	O
##0	O
.	O
204	O
to	O
−	O
##0	O
.	O
16	O
,	O
p	O
=	O
0	O
.	O
01	O
##5	O
to	O
p	O
=	O
0	O
.	O
05	O
##2	O
;	O
data	O
not	O
shown	O
)	O
.	O

This	O
might	O
be	O
due	O
to	O
the	O
case	O
,	O
that	O
the	O
di	B
##hy	I
##dr	I
##o	I
meta	O
##bol	O
##ite	O
showed	O
a	O
similar	O
retention	O
time	O
as	O
the	O
parent	O
compound	O
when	O
using	O
a	O
Ph	O
##en	O
##yl	O
##H	O
##ex	O
##yl	O
column	O
and	O
is	O
thus	O
hard	O
to	O
distinguish	O
from	O
the	O
parent	O
compound	O
is	O
##oto	O
##pe	O
containing	O
two	O
_	O
13	O
C	O
atoms	O
.	O

Test	B
##osterone	I
was	O
also	O
significantly	O
associated	O
with	O
insulin	O
resistance	O
(	O
H	O
##OM	O
##A	O
I	O
##R	O
)	O
in	O
cases	O
(	O
β	O
=	O
0	O
.	O
09	O
##2	O
,	O
P	O
=	O
0	O
.	O
04	O
##2	O
)	O
but	O
not	O
in	O
controls	O
(	O
β	O
=	O
0	O
.	O
00	O
##1	O
,	O
P	O
=	O
0	O
.	O
97	O
)	O
.	O

On	O
the	O
basis	O
of	O
VIP	O
score	O
,	O
As	B
##cor	I
##bic	I
acid	I
,	O
try	B
##pt	I
##op	I
##han	I
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
and	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
were	O
identified	O
as	O
the	O
top	O
four	O
meta	O
##bol	O
##ites	O
showing	O
significant	O
alterations	O
in	O
serum	O
for	O
this	O
three	O
group	O
comparative	O
study	O
.	O

In	O
addition	O
,	O
the	O
extent	O
of	O
the	O
abnormal	O
##ity	O
in	O
try	B
##pt	I
##op	I
##han	I
metabolism	O
has	O
been	O
shown	O
to	O
directly	O
co	O
##rrel	O
##ate	O
with	O
the	O
aggressive	O
##ness	O
of	O
the	O
ma	O
##li	O
##gna	O
##ncy	O
[	O
,	O
]	O
.	O

The	O
le	O
##uk	O
##ot	O
##rien	O
##es	O
,	O
h	O
##ydro	O
##xy	O
##l	O
-	O
fatty	O
acids	O
,	O
e	O
##pox	O
##y	O
-	O
fatty	O
acids	O
and	O
lip	B
##ox	I
##ins	I
were	O
anal	O
##ys	O
##ed	O
by	O
high	O
-	O
performance	O
liquid	O
ch	O
##roma	O
##tography	O
(	O
A	O
##gi	O
##lent	O
126	O
##0	O
,	O
San	O
Jose	O
,	O
CA	O
,	O
USA	O
)	O
coupled	O
to	O
a	O
triple	O
-	O
q	O
##uad	O
##rup	O
##ole	O
mass	O
s	O
##pect	O
##rome	O
##ter	O
(	O
A	O
##gi	O
##lent	O
64	O
##60	O
,	O
San	O
Jose	O
,	O
CA	O
,	O
USA	O
)	O
,	O
using	O
an	O
As	O
##cent	O
##is	O
®	O
Express	O
column	O
(	O
2	O
.	O
7	O
μ	O
##m	O
,	O
2	O
.	O
1	O
×	O
150	O
mm	O
)	O
as	O
detailed	O
in	O
St	O
##rass	O
##burg	O
et	O
al	O
.	O
.	O

The	O
result	O
of	O
our	O
correlation	O
analysis	O
shows	O
that	O
v	B
##ali	I
##ne	I
has	O
a	O
moderate	O
and	O
strong	O
positive	O
correlation	O
with	O
is	B
##ole	I
##uc	I
##ine	I
in	O
both	O
HC	O
##C	O
cases	O
and	O
c	O
##ir	O
##r	O
##hot	O
##ic	O
controls	O
,	O
respectively	O
,	O
suggesting	O
its	O
connection	O
not	O
only	O
to	O
cancer	O
but	O
other	O
liver	O
diseases	O
such	O
as	O
c	O
##ir	O
##r	O
##hos	O
##is	O
as	O
previously	O
reported	O
.	O

The	O
lower	O
level	O
of	O
u	B
##bi	I
##quin	I
##one	I
in	O
CR	O
##C	O
patients	O
is	O
consistent	O
with	O
the	O
higher	O
levels	O
of	O
meta	O
##bol	O
##ites	O
associated	O
with	O
g	B
##lut	I
##ath	I
##ione	I
metabolism	O
such	O
as	O
2	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
and	O
2	B
-	I
amino	I
##but	I
##yra	I
##te	I
.	O

L	O
##C	O
-	O
MS	O
grade	O
,	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
,	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
,	O
met	B
##han	I
##ol	I
,	O
and	O
ace	B
##tic	I
acid	I
were	O
purchased	O
from	O
Fisher	O
Scientific	O
(	O
Pittsburgh	O
,	O
PA	O
,	O
USA	O
)	O
.	O

We	O
also	O
evaluated	O
the	O
contribution	O
of	O
SP	S
alone	O
,	O
AL	O
alone	O
or	O
both	O
,	O
using	O
likelihood	O
ratio	O
tests	O
.	O

The	O
increase	O
in	O
the	O
concentration	O
of	O
ta	B
##uro	I
##cho	I
##lic	I
acid	I
in	O
the	O
serum	O
of	O
patients	O
with	O
he	O
##pa	O
##titis	O
B	O
c	O
##ir	O
##r	O
##hos	O
##is	O
may	O
be	O
related	O
to	O
the	O
occurrence	O
of	O
c	O
##ir	O
##r	O
##hos	O
##is	O
of	O
the	O
liver	O
.	O

The	O
surplus	O
of	O
lip	O
##ids	O
due	O
to	O
h	O
##yper	O
##lip	O
##ide	O
##mia	O
co	O
##rrel	O
##ates	O
with	O
an	O
excess	O
of	O
k	B
##eton	I
##e	I
bodies	O
(	B
ace	B
##to	I
##ace	I
##tate	I
and	O
ace	O
##tone	O
)	O
,	O
which	O
are	O
the	O
end	O
-	O
products	O
of	O
lip	O
##id	O
metabolism	O
in	O
the	O
blood	O
.	O

In	O
addition	O
,	O
overall	O
retention	O
was	O
reduced	O
,	O
which	O
could	O
be	O
due	O
to	O
either	O
the	O
different	O
packing	O
materials	O
(	O
B	O
:	O
polymer	O
,	O
E	O
:	O
si	O
##lica	O
)	O
or	O
the	O
absence	O
of	O
a	O
terminal	O
acid	O
m	O
##oi	O
##ety	O
on	O
the	O
surface	O
of	O
E	O
.	O
On	O
amid	B
##e	I
column	O
F	O
,	O
we	O
observed	O
inconsistent	O
el	O
##ution	O
sequences	O
of	O
the	O
n	O
##uc	O
##leo	O
##base	O
##s	O
(	O
U	O
<	O
[UNK]	O
~	O
A	O
<	O
C	O
)	O
compared	O
to	O
the	O
respective	O
n	O
##uc	O
##leo	O
##side	O
##s	O
(	O
U	O
<	O
A	O
<	O
C	O
,	O
G	O
not	O
detected	O
)	O
and	O
de	O
##ox	O
##yn	O
##uc	O
##leo	O
##side	O
##s	O
(	O
T	O
<	O
d	O
##U	O
<	O
d	O
##C	O
<	O
d	O
##G	O
~	O
d	O
##A	O
)	O
.	O

E	B
##ti	I
##och	I
##ola	I
##no	I
##lone	I
,	O
T	O
##HA	O
:	O
11	B
-	I
de	I
##hy	I
##dr	I
##o	I
-	I
T	I
##H	I
-	I
co	I
##rt	I
##ico	I
##ster	I
##one	I
,	O
T	B
##H	I
##B	I
:	O

JR	O
##ES	O
s	O
##pect	O
##ra	O
were	O
tilted	O
by	O
45	O
##°	O
,	O
s	O
##ym	O
##met	O
##rise	O
##d	O
about	O
F1	O
,	O
referenced	O
to	O
la	B
##ctic	I
acid	I
at	O
δ	O
##H	O
=	O
1	O
.	O
33	O
pp	O
##m	O

As	O
expected	O
,	O
the	O
abundant	O
ni	B
##cot	I
##ine	I
meta	O
##bol	O
##ites	O
,	O
co	B
##tin	I
##ine	I
and	O
h	B
##ydro	I
##xy	I
-	I
co	I
##tin	I
##ine	I
,	O
were	O
dramatically	O
increased	O
in	O
serum	O
from	O
both	O
healthy	O
and	O
CO	O
##PD	O
smoke	O
##r	O
groups	O
.	O

My	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
was	O
previously	O
reported	O
to	O
be	O
low	O
within	O
spinal	O
cord	O
lesions	O
in	O
a	O
group	O
of	O
5	O
N	O
##MO	O
##SD	O
patients	O
(	O
2	O
A	O
##Q	O
##P	O
##4	O
-	O
A	O
##b	O
positive	O
and	O
3	O
negative	O
)	O
and	O
elevated	O
white	O
matter	O
my	O
##o	O
-	O
ins	O
##oit	O
##ol	O
has	O
been	O
linked	O
with	O
multiple	O
s	O
##cle	O
##rosis	O
.	O

Although	O
met	B
##hyl	I
##xa	I
##nt	I
##hine	I
was	O
detected	O
and	O
was	O
in	O
the	O
VIP	O
list	O
,	O
we	O
could	O
not	O
differentiate	O
its	O
three	O
is	O
##omer	O
##s	O
without	O
standards	O
.	O

Furthermore	O
,	O
we	O
added	O
established	O
risk	O
markers	O
(	O
gender	O
,	O
waist	O
c	O
##ir	O
##cum	O
##ference	O
,	O
B	O
##MI	O
,	O
age	O
,	O
base	O
##line	O
fast	O
##ing	O
glucose	S
)	O
to	O
the	O
meta	O
##bol	O
##ites	O
and	O
again	O
performed	O
feature	O
selection	O
based	O
on	O
Random	O
Forest	O
importance	O
and	O
built	O
a	O
Random	O
Forest	O
re	O
##gression	O
model	O
.	O

In	O
contrast	O
,	O
post	O
##pra	O
##ndi	O
##al	O
T	O
##GR	O
##L	O
from	O
those	O
subjects	O
in	O
whom	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
increased	O
<	O
120	O
mg	O
/	O
d	O
##l	O
reduced	O
or	O
had	O
a	O
neutral	O
effect	O
on	O
T	O
##NF	O
##α	O
-	O
stimulate	O
##d	O
VC	O
##AM	O
-	O
1	O
surface	O
expression	O
in	O
H	O
##A	O
##EC	O
(	O
Fi	O
##g	O
.	O

M	B
##T	I
##BE	I
is	O
both	O
highly	O
volatile	O
and	O
float	O
##s	O
on	O
the	O
surface	O
of	O
the	O
resulting	O
bi	O
##pha	O
##si	O
##c	O
mixture	O
.	O

In	O
any	O
case	O
,	O
even	O
though	O
age	O
was	O
a	O
potential	O
major	O
con	O
##found	O
##er	O
in	O
this	O
study	O
,	O
differences	O
in	O
this	O
parameter	O
were	O
found	O
to	O
only	O
possibly	O
affect	O
plasma	O
##tic	O
dim	B
##eth	I
##yl	I
su	I
##lf	I
##one	I
levels	O
,	O
leaving	O
the	O
remaining	O
finger	O
##print	O
un	O
##af	O
##fected	O
.	O

C	B
##rea	I
##tin	I
##ine	I
,	O
car	B
##ni	I
##tine	I
,	O
ace	B
##to	I
##ace	I
##tate	I
,	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
a	I
##cy	I
##l	I
C	I
##18	I
:	I
2	I
,	I
2	I
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
,	O
and	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
a	I
##cy	I
##l	I
C	I
##20	I
:	I
4	I
were	O
used	O
in	O
the	O
meta	O
##bol	O
##ites	O
-	O
only	O
panel	O
.	O

Several	O
experimental	O
studies	O
point	O
towards	O
a	O
direct	O
role	O
of	O
vitamin	B
D	I
in	O
m	O
##od	O
##ulating	O
liver	O
inflammation	O
and	O
fi	O
##bro	O
##genesis	O
.	O

LA	O
##SS	O
##O	O
regular	O
##ized	O
log	O
##istic	O
re	O
##gression	O
(	O
LA	O
##SS	O
##O	O
-	O
L	O
##R	O
)	O
identified	O
three	O
disc	O
##rim	O
##inator	O
##y	O
meta	O
##bol	O
##ites	O
:	O
2	B
-	I
h	I
##ydro	I
##xy	I
##is	I
##ob	I
##ut	I
##yra	I
##te	I
,	O
3	B
-	I
in	I
##dox	I
##yl	I
##sul	I
##fa	I
##te	I
,	O
and	O
al	B
##ani	I
##ne	I
,	O
which	O
clearly	O
separated	O
gas	O
##tric	O
cancer	O
from	O
healthy	O
controls	O
(	O
AU	O
##C	O
:	O
0	O
.	O
95	O
)	O
.	O

Alt	O
##eration	O
##s	O
in	O
the	O
levels	O
of	O
N	B
-	I
ace	I
##ty	I
##l	I
-	I
g	I
##ly	I
##co	I
##p	I
##rote	I
##ins	I
may	O
indicate	O
that	O
people	O
have	O
been	O
suffering	O
in	O
an	O
extreme	O
environment	O
and	O
are	O
developing	O
psychological	O
sub	O
##op	O
##ti	O
##mal	O
health	O
.	O

For	O
example	O
,	O
x	B
##ant	I
##hine	I
o	O
##xi	O
##dor	O
##ed	O
##uc	O
##tase	O
,	O
a	O
key	O
enzyme	O
in	O
the	O
degradation	O
of	O
DNA	O
and	O
RNA	O
,	O
is	O
associated	O
with	O
his	O
##to	O
##logical	O
grade	O
of	O
differentiation	O
and	O
extent	O
of	O
disease	O
in	O
color	O
##ec	O
##tal	O
cancer	O
,	O
as	O
well	O
as	O
the	O
mi	O
##gratory	O
activity	O
of	O
human	O
breast	O
cancer	O
cells	O
[	O
,	O
]	O
.	O

T	O
##CA	O
cycle	O
analog	O
##s	O
2	B
-	I
h	I
##ydro	I
##xy	I
##g	I
##lut	I
##arate	I
(	O
2	O
-	O
H	O
##G	O
)	O
and	O
3	O
-	O
GM	O
##P	O
were	O
detected	O
exclusively	O
in	O
tumor	O
tissues	O
.	O

Our	O
results	O
about	O
PP	O
’	O
s	O
meta	O
##bol	O
##ome	O
show	O
a	O
higher	O
level	O
of	O
la	B
##ct	I
##ate	I
,	O
glucose	S
,	O
p	B
##hos	I
##ph	I
##ory	I
##l	I
##cho	I
##line	I
,	O
ta	B
##uri	I
##ne	I
,	O
as	B
##par	I
##tate	I
,	O
la	B
##ct	I
##ate	I
,	O
g	B
##lut	I
##amine	I
,	O
and	O
su	B
##cci	I
##nate	I
in	O
patients	O
who	O
received	O
neo	O
##ad	O
##ju	O
##vant	O
ch	O
##em	O
##otherapy	O
(	O
g	O
##em	O
##ci	O
##ta	O
##bine	O
)	O
.	O

It	O
is	O
known	O
that	O
there	O
is	O
a	O
significant	O
diversity	O
of	O
neon	B
##ico	I
##tino	I
##id	I
metabolism	O
in	O
species	O
,	O
as	O
well	O
as	O
the	O
activity	O
of	O
enzymes	O
,	O
e	O
.	O
g	O
.	O
c	O
##yt	O
##och	O
##rome	O
P	O
##45	O
##0	O
and	O
al	O
##de	O
##hy	O
##de	O
o	O
##xi	O
##das	O
##e	O
.	O

In	O
analogy	O
to	O
a	O
similar	O
observation	O
made	O
while	O
comparing	O
the	O
post	O
##pra	O
##ndi	O
##al	O
response	O
of	O
human	O
subjects	O
to	O
milk	O
and	O
yo	O
##gh	O
##urt	O
intake	O
,	O
our	O
results	O
suggest	O
that	O
the	O
f	O
##er	O
##mentation	O
of	O
milk	O
to	O
cheese	O
increases	O
the	O
bio	O
##ava	O
##ila	O
##bility	O
of	O
dairy	O
amino	O
acids	O
,	O
as	O
shown	O
for	O
pro	B
##line	I
,	O
le	B
##uc	I
##ine	I
,	O
g	B
##lut	I
##ami	I
##c	I
acid	I
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
v	B
##ali	I
##ne	I
,	O
le	B
##uc	I
##ine	I
,	O
and	O
eventually	O
met	B
##hi	I
##oni	I
##ne	I
,	O
what	O
makes	O
milk	O
f	O
##er	O
##mentation	O
an	O
attractive	O
approach	O
for	O
the	O
management	O
of	O
muscle	O
metabolism	O
.	O

In	O
particular	O
,	O
we	O
targeted	O
(	O
identified	O
and	O
q	O
##uant	O
##ified	O
)	O
a	O
subset	O
of	O
o	B
##xy	I
##lip	I
##ins	I
(	O
n	O
=	O
76	O
)	O
,	O
a	B
##cy	I
##l	I
-	I
g	I
##ly	I
##cine	I
##s	I
(	O
n	O
=	O
2	O
)	O
,	O
a	B
##cy	I
##l	I
-	I
ethanol	I
##ami	I
##des	I
(	O
n	O
=	O
12	O
)	O
,	O
and	O
mon	B
##o	I
-	I
a	I
##cy	I
##l	I
##gly	I
##cer	I
##ols	I
(	O
n	O
=	O
6	O
)	O
.	O

The	O
stock	O
solution	O
of	O
internal	O
standard	O
was	O
prepared	O
in	O
met	B
##han	I
##ol	I
at	O
the	O
z	O
##ile	O
##uto	O
##n	O
concentration	O
of	O
0	O
.	O
1	O
μ	O
##g	O
/	O
m	O
##l	O
.	O

Among	O
the	O
9	O
meta	O
##bol	O
##ites	O
,	O
l	O
##ys	O
##o	O
##PC	O
a	O
C	B
##20	I
:	I
3	I
was	O
found	O
significantly	O
lower	O
in	O
Class	O
C	O
than	O
in	O
Class	O
A	O
and	O
Class	O
B	O
in	O
both	O
H	O
##B	O
##V	O
-	O
associated	O
c	O
##ir	O
##r	O
##hos	O
##is	O
and	O
H	O
##B	O
##V	O
-	O
associated	O
HC	O
##C	O
groups	O
.	O

P	O
##las	O
##ma	O
AD	B
##MA	I
levels	O
were	O
increased	O
in	O
patients	O
with	O
se	O
##psis	O
;	O
and	O
both	O
h	O
##A	O
##rg	O
and	O
AD	B
##MA	I
were	O
associated	O
with	O
se	O
##psis	O
severity	O
.	O

Ser	O
##um	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
were	O
determined	O
by	O
liquid	O
-	O
ch	O
##roma	O
##tography	O
mass	O
s	O
##pect	O
##rome	O
##try	O
(	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
)	O
.	O

The	O
earlier	O
el	O
##uti	O
##ng	O
peak	O
had	O
a	O
mass	O
and	O
gave	O
MS	O
_	O
2	O
and	O
MS	O
_	O
3	O
s	O
##pect	O
##ra	O
compatible	O
with	O
a	O
t	B
##ri	I
##hy	I
##dr	I
##ox	I
##ych	I
##ola	I
##no	I
##ic	I
acid	I
(	O
BA	O
-	O
trio	O
##l	O
)	O
possibly	O
with	O
a	O
3	B
##β	I
-	I
h	I
##ydro	I
##xy	I
-	I
5	I
##α	I
-	I
hydrogen	I
functionality	O
(	O
i	O
.	O
e	O
.	O
3	B
##β	I
,	I
x	I
,	I
y	I
-	I
t	I
##ri	I
##hy	I
##dr	I
##ox	I
##y	I
-	I
5	I
##α	I
-	I
ch	I
##ola	I
##n	I
-	I
24	I
-	I
o	I
##ic	I
acid	I
,	O
5	B
##α	I
-	I
BA	I
-	I
3	I
##β	I
,	I
x	I
,	O
y	O
-	O
trio	O
##l	O
)	O
.	O

Red	O
##uction	O
##s	O
in	O
breast	O
fat	O
indicated	O
by	O
reduced	O
bust	O
measurements	O
with	O
CE	B
##R	I
did	O
not	O
occur	O
alongside	O
significant	O
reduction	O
##s	O
in	O
breast	O
ad	O
##ip	O
##oc	O
##yte	O
size	O
suggesting	O
that	O
reduced	O
fat	O
in	O
the	O
breast	O
may	O
result	O
from	O
reduced	O
fat	O
cell	O
numbers	O
,	O
rather	O
than	O
reduced	O
fat	O
cell	O
size	O
.	O

Similarly	O
,	O
although	O
11	O
##KA	O
##4	O
is	O
a	O
substrate	O
for	O
AK	O
##R	O
##1	O
##C	O
##3	O
,	O
the	O
expression	O
of	O
11	O
##β	O
-	O
h	O
##ydro	O
##xy	O
##ster	O
##oid	O
de	O
##hy	O
##dr	O
##ogen	O
##ase	O
type	O
1	O
in	O
ad	O
##ip	O
##ose	O
tissue	O
may	O
minimize	O
its	O
conversion	O
to	O
11	O
##K	O
##T	O
because	O
11	B
##β	I
H	I
##SD	I
##1	I
efficiently	O
converts	O
11	O
##KA	O
##4	O
to	O
11	O
##OH	O
##A	O
##4	O
,	O
which	O
is	O
not	O
a	O
substrate	O
for	O
AK	O
##R	O
##1	O
##C	O
##3	O
.	O

3	B
-	I
h	I
##ydro	I
##xy	I
##ky	I
##nu	I
##ren	I
##ine	I
is	O
a	O
ne	O
##uro	O
##to	O
##xi	O
##c	O
meta	O
##bol	O
##ite	O
which	O
causes	O
ne	O
##uron	O
##al	O
death	O
.	O

This	O
reduced	O
fitness	O
correspond	O
##ed	O
with	O
increased	O
sensitivity	O
to	O
the	O
big	B
##uan	I
##ide	I
class	O
of	O
mitochondrial	O
inhibitor	O
##s	O
.	O

L	B
-	I
As	I
##par	I
##tate	I
.	O

Un	O
##iva	O
##ria	O
##te	O
analysis	O
revealed	O
similar	O
levels	O
of	O
N	O
##N	O
##N	O
,	O
1	O
-	O
H	O
##OP	O
,	O
and	O
co	B
##tin	I
##ine	I
between	O
groups	O
but	O
,	O
as	O
reported	O
previously	O
,	O
significantly	O
higher	O
DNA	O
add	O
##uc	O
##t	O
formation	O
in	O
the	O
cases	O
.	O

We	O
sought	O
to	O
examine	O
whether	O
changes	O
in	O
serum	O
try	B
##pt	I
##op	I
##han	I
meta	O
##bol	O
##ites	O
and	O
tissue	O
expression	O
of	O
K	B
##P	I
enzymes	O
are	O
associated	O
with	O
UC	O
end	O
##os	O
##copic	O
and	O
his	O
##to	O
##log	O
##ic	O
disease	O
severity	O
.	O

In	O
addition	O
,	O
multiple	O
peaks	O
derived	O
from	O
an	O
identical	O
peak	O
with	O
tail	O
##ing	O
,	O
e	O
.	O
g	O
.	O
42	O
peaks	O
for	O
cloth	B
##ian	I
##id	I
##in	I
,	O
were	O
inspected	O
with	O
ch	O
##roma	O
##to	O
##gram	O
##s	O
,	O
and	O
the	O
strongest	O
peak	O
with	O
the	O
earliest	O
retention	O
time	O
was	O
assigned	O
as	O
a	O
parent	O
peak	O
.	O

Lac	B
##tate	I
to	O
p	B
##yr	I
##u	I
##vate	I
ratio	O
was	O
decreased	O
in	O
A	B
##F	I
and	O
con	O
##verse	O
##ly	O
increased	O
in	O
P	O
##L	O
.	O

S	O
##ynth	O
##etic	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
including	O
1	B
,	I
2	I
-	I
dim	I
##yr	I
##ist	I
##ole	I
##oy	I
##l	I
-	I
s	I
##n	I
-	I
g	I
##ly	I
##cer	I
##o	I
-	I
3	I
-	I
p	I
##hos	I
##ph	I
##och	I
##olin	I
##e	I
(	I
14	I
:	I
1	I
-	I
14	I
:	I
1	I
PC	I
)	I
,	O
1	B
,	I
2	I
-	I
dip	I
##al	I
##mit	I
##ole	I
##oy	I
##l	I
-	I
s	I
##n	I
-	I
g	I
##ly	I
##cer	I
##o	I
-	I
3	I
-	I
p	I
##hos	I
##ph	I
##oe	I
##than	I
##ola	I
##mine	I
(	I
16	I
:	I
1	I
-	I
16	I
:	I
1	I
P	I
##E	I
)	I
,	O
1	B
,	I
2	I
-	I
dip	I
##ent	I
##ade	I
##cano	I
##yl	I
-	I
s	I
##n	I
-	I
g	I
##ly	I
##cer	I
##o	I
-	I
3	I
-	I
p	I
##hos	I
##ph	I
##og	I
##ly	I
##cer	I
##ol	I
(	I
15	I
:	I
0	I
-	I
15	I
:	I
0	I
P	I
##G	I
)	I
,	O
1	B
-	I
my	I
##risto	I
##yl	I
-	I
2	I
-	I
h	I
##ydro	I
##xy	I
##l	I
-	I
s	I
##n	I
-	I
g	I
##ly	I
##cer	I
##o	I
-	I
3	I
-	I
p	I
##hos	I
##ph	I
##och	I
##olin	I
##e	I
(	I
14	I
:	I
0	I
LP	I
##C	I
)	I
,	O
N	B
-	I
la	I
##uro	I
##yl	I
s	I
##phi	I
##ngo	I
##my	I
##elin	I
(	I
N	I
##12	I
:	I
0	I
SM	I
)	I
,	O
and	O
N	B
-	I
he	I
##pta	I
##de	I
##cano	I
##yl	I
c	I
##era	I
##mi	I
##de	I
(	I
N	I
##17	I
:	I
0	I
c	I
##era	I
##mi	I
##de	I
)	I
were	O
purchased	O
from	O
Ava	O
##nti	O
Polar	O
Li	O
##pid	O
##s	O
,	O
Inc	O
.	O
(	O
Al	O
##aba	O
##ster	O
,	O
AL	O
,	O
USA	O
)	O
.	O

4	B
-	I
OH	I
-	I
E	I
_	I
2	I
:	I
2	I
-	I
OH	I
-	I
E	I
_	I
2	I
and	O
2	B
-	I
OH	I
-	I
E	I
_	I
2	I
were	O
positively	O
associated	O
with	O
1	B
,	I
2	I
,	I
3	I
,	I
4	I
,	I
6	I
,	I
7	I
,	I
8	I
-	I
he	I
##pta	I
##CD	I
##F	I
level	O
,	O
according	O
to	O
a	O
q	O
##uad	O
##ratic	O
model	O
.	O

Additionally	O
palm	B
##ito	I
##yl	I
##car	I
##ni	I
##tine	I
increases	O
with	O
a	O
##pop	O
##tosis	O
consistent	O
with	O
our	O
observed	O
effect	O
.	O

The	O
fused	O
si	B
##lica	I
cap	O
##illa	O
##ry	O
and	O
analysis	O
re	O
##age	O
##nts	O
were	O
provided	O
by	O
HM	O
##T	O
.	O

The	O
joint	O
pathway	O
analysis	O
revealed	O
5	O
significantly	O
altered	O
metabolic	O
pathways	O
,	O
however	O
with	O
only	O
two	O
involved	O
meta	O
##bol	O
##ites	O
,	O
g	B
##ly	I
##cine	I
(	O
4	O
pathways	O
)	O
and	O
c	B
##it	I
##rate	I
(	O
2	O
pathways	O
)	O
.	O

ID	O
##O	O
-	O
T	O
##Ms	O
remained	O
significantly	O
related	O
to	O
index	O
##es	O
of	O
R	O
##V	O
-	O
P	O
##V	O
d	O
##ys	O
##function	O
after	O
further	O
adjustment	O
for	O
N	O
##T	O
-	O
pro	O
##B	O
##NP	O
,	O
a	O
marker	O
of	O
my	O
##oc	O
##ard	O
##ial	O
wall	O
stress	O
and	O
P	O
##H	O
;	O
c	B
##ys	I
##tat	I
##in	I
C	O
,	O
in	O
##dicative	O
of	O
re	O
##nal	O
function	O
;	O
and	O
IL	O
-	O
6	O
,	O
an	O
inflammatory	O
c	O
##yt	O
##oki	O
##ne	O
previously	O
associated	O
with	O
P	O
##H	O
.	O

Twelve	O
of	O
the	O
lip	O
##id	O
species	O
and	O
two	O
lip	O
##id	O
classes	O
(	B
ch	B
##ole	I
##ster	I
##ol	I
est	I
##ers	I
and	O
c	B
##era	I
##mi	I
##des	I
)	O
that	O
were	O
significantly	O
increased	O
in	O
the	O
e	O
##fa	O
##vir	O
##en	O
##z	O
arm	O
compared	O
with	O
the	O
at	O
##az	O
##ana	O
##vir	O
/	O
r	O
or	O
z	O
##ido	O
##vu	O
##dine	O
/	O
a	O
##ba	O
##ca	O
##vir	O
arms	O
have	O
previously	O
been	O
associated	O
with	O
future	O
card	O
##iovascular	O
events	O
in	O
HIV	O
positive	O
patients	O
.	O

and	O
Ce	B
##r	I
(	I
24	I
:	I
0	I
)	I
and	O
their	O
de	O
##uter	O
##ated	O
internal	O
standards	O
were	O
extracted	O
by	O
protein	O
precipitation	O
and	O
ch	O
##roma	O
##to	O
##graphical	O
##ly	O
separated	O
by	O
HP	O
##LC	O
.	O

*	O
P	O
<	O
0	O
.	O
01	O
vs	O
.	O
S	O
##ham	O
(	O
Student	O
'	O
s	O
t	O
test	O
,	O
one	O
-	O
side	O
)	O
,	O
†	O
†	O
P	O
<	O
0	O
.	O
01	O
,	O
†	O
P	O
<	O
0	O
.	O
05	O
vs	O
.	O
Sal	B
##ine	I
(	O
Dunn	O
##ett	O
'	O
s	O
test	O
,	O
one	O
-	O
side	O
)	O
.	O

AM	B
##P	I
plays	O
important	O
roles	O
in	O
the	O
regulation	O
of	O
cell	O
proliferation	O
and	O
in	O
acting	O
as	O
an	O
intermediate	O
in	O
pu	B
##rine	I
metabolism	O
.	O

It	O
should	O
also	O
be	O
noted	O
that	O
g	B
##ly	I
##cer	I
##ol	I
-	I
3	I
-	I
P	I
and	O
F	O
##6	O
##P	O
could	O
not	O
be	O
un	O
##am	O
##bi	O
##guous	O
##ly	O
assigned	O
in	O
_	O
1	O
H	O
and	O
_	O
13	O
C	O
-	O
edited	O
experiments	O
due	O
to	O
their	O
low	O
abundance	O
and	O
/	O
or	O
spectral	O
crowd	O
##ing	O
(	O
c	O
##f	O
.	O
)	O
.	O

According	O
to	O
an	O
N	O
##MR	O
-	O
based	O
meta	O
##bol	O
##omi	O
##cs	O
study	O
in	O
adults	O
,	O
lower	O
levels	O
of	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
in	O
T	O
##1	O
##DM	O
patients	O
may	O
also	O
be	O
at	O
##tri	O
##but	O
##able	O
to	O
treatment	O
with	O
insulin	O
,	O
which	O
is	O
known	O
to	O
have	O
an	O
anti	O
-	O
lip	O
##oly	O
##tic	O
action	O
.	O

E	B
##stro	I
##gen	I
Con	O
##cent	O
##rations	O
by	O
S	O
##mo	O
##king	O
Status	O
and	O
Pro	O
##tein	O
/	O
C	O
##rea	O
##tin	O
##ine	O
Rat	O
##io	O
among	O
men	O
in	O
the	O
healthy	O
control	O
group	O
E	B
##stro	I
##gen	I
meta	O
##bol	O
##ite	O
values	O
are	O
denoted	O
as	O
p	B
##g	I
est	I
##rogen	I
meta	O
##bol	O
##ite	O
/	O
mg	O
c	B
##rea	I
##tin	I
##ine	I
high	O
protein	O
/	B
c	B
##rea	I
##tin	I
##ine	I
ratio	O
when	O
>	O
0	O
.	O
2	O

(	O
A	O
)	O
The	O
O	O
##PL	O
##S	O
-	O
D	O
##A	O
loading	O
coefficient	O
plot	O
showing	O
that	O
the	O
basis	O
of	O
differentiation	O
between	O
these	O
two	O
groups	O
(	B
ace	B
##tam	I
##ino	I
##phe	I
##n	I
ing	O
##est	O
##ion	O
versus	O
controls	O
)	O
primarily	O
results	O
from	O
the	O
presence	O
of	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
(	O
A	O
)	O
,	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
g	I
##lu	I
##cu	I
##ron	I
##ide	I
(	O
AG	O
)	O
,	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
su	I
##lf	I
##ate	I
(	O
AS	O
)	O
,	O
and	O
the	O
N	B
-	I
ace	I
##ty	I
##l	I
##cy	I
##stein	I
##e	I
con	O
##ju	O
##gate	O
of	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
(	O
N	O
##AC	O
)	O
denoted	O
by	O
the	O
red	O
/	O
orange	O
color	O
of	O
the	O
resonance	O
##s	O
indicating	O
a	O
r	O
_	O
2	O
>	O
0	O
.	O
5	O
in	O
disc	O
##rim	O
##inating	O
between	O
the	O
two	O
groups	O
.	O

In	O
Boston	O
,	O
ex	O
-	O
smoke	O
##rs	O
showed	O
a	O
slight	O
increase	O
in	O
is	B
##ole	I
##uc	I
##ine	I
(	O
p	O
-	O
value	O
=	O
4	O
.	O
35	O
##x	O
##10	O
-	O
2	O
)	O
,	O
compared	O
to	O
non	O
-	O
smoke	O
##rs	O
.	O

The	O
combined	O
analysis	O
of	O
plasma	O
meta	O
##bol	O
##omi	O
##cs	O
and	O
targeted	O
meta	O
##bol	O
##omi	O
##cs	O
of	O
se	B
##rot	I
##oni	I
##n	I
metabolism	O
in	O
urine	O
revealed	O
an	O
improvement	O
in	O
prediction	O
accuracy	O
for	O
G	O
##DM	O
(	O
see	O
Figure	O
)	O
.	O

Previous	O
studies	O
have	O
also	O
shown	O
decreased	O
levels	O
of	O
other	O
T	O
##CA	O
meta	O
##bol	O
##ites	O
(	O
is	O
##oc	O
##it	O
##rate	O
,	O
a	B
##con	I
##itate	I
and	O
su	B
##cci	I
##nate	I
)	O
in	O
the	O
urine	O
of	O
PC	O
##a	O
patients	O
,	O
all	O
the	O
data	O
supporting	O
a	O
disruption	O
in	O
energy	O
metabolism	O
(	O
St	O
##ru	O
##ck	O
-	O
Le	O
##wick	O
##a	O
et	O
al	O
.	O
)	O
.	O

B	O
##O	O
and	O
1	B
,	I
4	I
-	I
B	I
##Q	I
add	O
##uc	O
##ts	O
with	O
Al	O
##b	O
both	O
decay	O
##ed	O
with	O
rates	O
consistent	O
with	O
those	O
of	O
Al	O
##b	O
turnover	O
in	O
the	O
rat	O
.	O

1	O
:	O
3	O
-	O
in	O
##do	O
##lea	O
##ce	O
##ton	O
##it	O
##ril	O
##e	O
;	O
2	O
:	O
q	B
##uin	I
##olin	I
##ic	I
acid	I
;	O
3	O
:	O
amino	B
##phe	I
##no	I
##l	I
;	O
4	O
:	O
3	O
-	O
h	O
##ydro	O
##xy	O
##ky	O
##nu	O
##ren	O
##ine	O
;	O
5	O
:	O
p	B
-	I
t	I
##yr	I
##os	I
##ine	I
;	O
6	O
:	O
m	B
-	I
t	I
##yr	I
##os	I
##ine	I
;	O
7	O
:	O
se	B
##rot	I
##oni	I
##n	I
;	O
8	O
:	O
5	O
-	O
h	O
##ydro	O
##xy	O
##try	O
##pt	O
##op	O
##han	O
;	O
9	O
:	O
o	B
-	I
t	I
##yr	I
##os	I
##ine	I
;	O
10	O
:	O
k	B
##yn	I
##uren	I
##ine	I
;	O
11	O
:	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
;	O
12	O
:	O
N	B
-	I
form	I
##yl	I
##ky	I
##nu	I
##ren	I
##ine	I
;	O
13	O
:	O
h	B
##ydro	I
##xy	I
##ant	I
##hra	I
##ni	I
##lli	I
##c	I
acid	I
;	O
14	O
:	O
try	B
##pt	I
##op	I
##han	I
;	O
15	O
:	O
x	B
##ant	I
##hur	I
##eni	I
##c	I
acid	I
;	O
16	O
:	O
try	B
##pta	I
##mine	I
;	O
17	O
:	O
k	B
##yn	I
##uren	I
##ic	I
acid	I
;	O
18	O
:	O
5	O
-	O
met	O
##ho	O
##xy	O
##try	O
##pta	O
##mine	O
;	O
19	O
:	O
4	O
-	O
ch	O
##lor	O
##ok	O
##yn	O
##uren	O
##ine	O
;	O
20	O
:	O
N	B
-	I
ace	I
##ty	I
##ls	I
##ero	I
##ton	I
##in	I
;	O
21	O
:	O
p	B
##hen	I
##yla	I
##ce	I
##ty	I
##l	I
##g	I
##lut	I
##amine	I
;	O
22	O
:	O
6	O
-	O
h	O
##ydro	O
##xy	O
##mel	O
##aton	O
##in	O
;	O
23	O
:	O
in	B
##do	I
##le	I
-	I
3	I
-	I
ace	I
##tam	I
##ide	I
;	O
24	O
:	O
ant	B
##hra	I
##ni	I
##lli	I
##c	I
acid	I
;	O
25	O
:	O
form	B
##yl	I
-	I
ace	I
##ty	I
##lm	I
##eth	I
##ox	I
##yk	I
##yn	I
##uren	I
##amine	I
;	O
26	O
:	O
in	B
##do	I
##le	I
##la	I
##ctic	I
acid	O

The	O
elevation	O
of	O
a	B
##rac	I
##hi	I
##don	I
##ate	I
may	O
be	O
of	O
associated	O
with	O
increased	O
liberation	O
of	O
free	O
fatty	O
acids	O
from	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
either	O
in	O
the	O
tumor	O
or	O
in	O
adjacent	O
tissue	O
.	O

Met	O
##ab	O
##oli	O
##te	O
predict	O
##ors	O
of	O
insulin	O
resistance	O
in	O
the	O
models	O
included	O
glucose	S
,	O
FF	O
##As	O
,	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
to	O
p	B
##hos	I
##ph	I
##og	I
##ly	I
##cer	I
##ides	I
ratio	O
,	O
fraction	O
of	O
saturated	O
fatty	O
acids	O
(	O
FA	O
##s	O
)	O
from	O
total	O
FA	O
##s	O
,	O
small	O
HD	B
##L	I
p	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
,	O
large	O
V	O
##LD	O
##L	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
,	O
total	O
serum	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
,	O
al	B
##ani	I
##ne	I
,	O
v	B
##ali	I
##ne	I
,	O
ace	B
##to	I
##ace	I
##tate	I
,	O
and	O
o	B
##me	I
##ga	I
-	I
3	I
FA	O
##s	O
(	O
and	O
)	O
.	O

Co	O
##mpo	O
##unds	O
7	O
,	O
10	O
,	O
14	O
,	O
and	O
17	O
were	O
prepared	O
by	O
de	O
##hy	O
##dra	O
##ting	O
compounds	O
6	O
,	O
9	O
,	O
13	O
,	O
and	O
16	O
,	O
respectively	O
,	O
by	O
treatment	O
with	O
form	B
##ic	I
acid	I
.	O

Fourteen	O
T	O
##2	O
##DM	O
patients	O
used	O
met	B
##form	I
##in	I
and	O
13	O
used	O
su	B
##lf	I
##ony	I
##lu	I
##rea	I
alone	O
.	O

Our	O
data	O
may	O
support	O
the	O
anti	O
-	O
at	O
##her	O
##os	O
##cle	O
##rot	O
##ic	O
effect	O
of	O
g	B
##lu	I
##cos	I
##amine	I
,	O
because	O
its	O
level	O
was	O
significantly	O
lower	O
in	O
patients	O
who	O
developed	O
CA	O
##D	O
during	O
the	O
observation	O
period	O
.	O

Effects	O
of	O
exposing	O
functional	O
##ly	O
stained	O
human	O
lung	O
e	O
##pit	O
##hel	O
##ial	O
car	O
##cin	O
##oma	O
A	O
##5	O
##4	O
##9	O
cells	O
to	O
T	O
.	O
ha	O
##rz	O
##ian	O
##um	O
strain	O
E	O
##S	O
##39	O
and	O
different	O
concentrations	O
of	O
al	B
##ame	I
##thi	I
##cin	I

Similarly	O
,	O
the	O
in	O
##te	O
##gra	O
##tive	O
analysis	O
showed	O
a	O
significant	O
correlation	O
between	O
serum	O
FF	O
##As	O
,	O
g	B
##ly	I
##cer	I
##oli	I
##pid	I
##s	I
,	O
and	O
AC	O
##s	O
and	O
genes	O
regulating	O
de	O
no	O
##vo	O
fatty	O
acid	O
synthesis	O
,	O
des	O
##at	O
##uration	O
,	O
el	O
##ong	O
##ation	O
,	O
and	O
β	O
-	O
oxidation	O
.	O

Color	O
##s	O
represent	O
different	O
ratios	O
as	O
indicated	O
by	O
the	O
color	O
bar	O
Given	O
the	O
u	O
##bi	O
##quito	O
##us	O
existence	O
of	O
Δ	O
##9	O
/	O
Δ	O
##11	O
is	O
##omer	O
pair	O
in	O
all	O
C	O
##18	O
:	O
1	O
-	O
containing	O
lip	O
##ids	O
,	O
composition	O
##al	O
analysis	O
was	O
performed	O
for	O
29	O
pairs	O
of	O
PC	O
and	O
P	B
##E	I
is	I
##omer	I
##s	I
from	O
normal	O
and	O
cancer	O
##ous	O
breast	O
tissue	O
samples	O
(	O
Su	O
##pp	O
##lement	O
##ary	O
Fi	O
##g	O
.	O

Forest	O
plots	O
from	O
random	O
effects	O
meta	O
-	O
analysis	O
across	O
different	O
co	O
##hor	O
##ts	O
for	O
(	O
A	O
)	O
g	B
##lut	I
##amine	I
and	O
(	O
B	O
)	O
his	B
##ti	I
##dine	I
.	O

The	O
identification	O
of	O
f	B
##elin	I
##e	I
-	I
specific	I
pre	O
-	O
clinical	O
bio	O
##mark	O
##ers	O
of	O
NSA	O
##ID	O
-	O
induced	O
toxicity	O
would	O
be	O
extremely	O
valuable	O
for	O
op	O
##ti	O
##mizing	O
individual	O
##ized	O
drug	O
the	O
##rap	O
##ies	O
.	O

Finally	O
,	O
in	O
L	O
##C	O
–	O
MS	O
,	O
the	O
most	O
populated	O
category	O
correspond	O
##ed	O
to	O
l	B
##ys	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
,	O
followed	O
by	O
s	O
##tero	O
##l	O
lip	O
##ids	O
.	O

Effect	O
of	O
disease	O
duration	S
was	O
further	O
illustrated	O
by	O
the	O
negative	O
correlation	O
observed	O
between	O
disease	O
duration	S
and	O
the	O
level	O
of	O
GT	O
##A	O
##46	O
##5	O
/	O
40	O
##3	O
in	O
R	O
##R	O
##MS	O
patients	O
(	O
Fi	O
##g	O
.	O
)	O
.	O

P	O
##las	O
##ma	O
bio	O
##chemical	O
analyses	O
were	O
carried	O
out	O
on	O
an	O
AM	O
##S	O
-	O
18	O
automatic	O
bio	O
##chemistry	O
analyze	O
##r	O
(	O
Beijing	O
Op	O
##tion	O
Science	O
&	O
Technology	O
Development	O
Co	O
.	O
,	O
Ltd	O
.	O
,	O
Beijing	O
,	O
China	O
)	O
including	O
U	B
##rea	I
,	O
c	B
##rea	I
##tin	I
##ine	I
(	O
C	O
##r	O
)	O
,	O
sodium	O
(	O
Na	O
)	O
and	O
potassium	O
(	O
K	O
)	O
.	O

These	O
findings	O
were	O
in	O
agreement	O
with	O
previous	O
reports	O
that	O
indicate	O
an	O
increased	O
rate	O
of	O
re	O
##lap	O
##se	O
for	O
the	O
ER	B
(	I
+	I
)	I
patients	O
in	O
spite	O
of	O
the	O
use	O
of	O
ad	O
##ju	O
##vant	O
therapy	O
with	O
ta	B
##mo	I
##xi	I
##fen	I
and	O
/	O
or	O
a	O
##roma	O
##tase	O
inhibitor	O
##s	O
.	O

NE	O
su	B
##lf	I
##ate	I
concentration	O
in	O
plasma	O
increases	O
after	O
sympathetic	O
nervous	O
system	O
activation	O
by	O
an	O
exhaust	O
##ing	O
in	O
##cre	O
##mental	O
exercise	O
test	O
and	O
remain	O
elevated	O
up	O
to	O
2	O
h	O
after	O
exercise	O
.	O

C	O
##lon	O
##ing	O
of	O
the	O
and	O
##rogen	O
receptor	O
(	O
AR	O
)	O
,	O
a	O
hormone	O
activated	S
transcription	O
factor	O
and	O
a	O
key	O
regulator	O
of	O
and	O
##rogen	O
-	O
dependent	O
growth	O
proved	O
Hu	O
##ggins	O
’	O
original	O
observations	O
,	O
revolution	O
##ized	O
our	O
understanding	O
of	O
PC	O
##a	O
,	O
and	O
led	O
to	O
the	O
development	O
of	O
novel	O
cancer	O
therapeutic	O
##s	O
.	O

Since	O
the	O
reduction	O
of	O
the	O
cat	B
##hino	I
##ne	I
o	O
##x	O
##o	O
group	O
introduces	O
an	O
additional	O
stereo	O
center	O
into	O
the	O
molecule	O
,	O
these	O
two	O
features	O
are	O
most	O
likely	O
different	O
di	O
##aster	O
##eo	O
##mers	O
of	O
the	O
same	O
compound	O
.	O

Ad	O
##ding	O
insult	O
to	O
injury	O
,	O
defects	O
in	O
but	B
##yra	I
##te	I
transport	O
across	O
the	O
e	O
##pit	O
##hel	O
##ium	O
and	O
in	O
the	O
but	B
##yra	I
##te	I
oxidation	O
pathway	O
exist	O
during	O
inflammation	O
in	O
both	O
CD	O
(	O
De	O
Pre	O
##ter	O
et	O
al	O
.	O
)	O

The	O
2	B
-	I
OH	I
##E	I
##1	I
/	I
16	I
##α	I
-	I
OH	I
##E	I
##1	I
ratio	O
has	O
been	O
used	O
as	O
an	O
index	O
of	O
the	O
relative	O
strengths	O
of	O
the	O
two	O
competing	O
o	O
##xi	O
##da	O
##tive	O
pathways	O
in	O
breast	O
cancer	O
with	O
higher	O
ratios	O
having	O
been	O
associated	O
with	O
a	O
reduced	O
risk	O
for	O
the	O
disease	O
.	O

However	O
,	O
this	O
is	O
unlikely	O
to	O
have	O
been	O
a	O
major	O
factor	O
,	O
since	O
we	O
previously	O
demonstrated	O
that	O
the	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
and	O
i	B
##bu	I
##p	I
##ro	I
##fen	I
prediction	O
models	O
each	O
had	O
a	O
sensitivity	O
greater	O
than	O
98	O
%	O
;	O
further	O
##more	O
,	O
detailed	O
data	O
on	O
anal	O
##ges	O
##ic	O
use	O
from	O
Belfast	O
and	O
Chicago	O
participants	O
indicated	O
an	O
under	O
##det	O
##ec	O
##tion	O
rate	O
of	O
approximately	O
1	O
%	O
.	O

In	O
the	O
case	O
of	O
compound	O
classes	O
(	O
i	O
.	O
e	O
.	O
level	O
3	O
an	O
##not	O
##ations	O
)	O
,	O
we	O
mapped	O
meta	O
##bol	O
##ites	O
to	O
their	O
closest	O
an	O
##not	O
##ated	O
chemical	O
entity	O
(	O
i	O
.	O
e	O
.	O
g	B
##lu	I
##con	I
##ic	I
acid	I
for	O
sugar	O
acids	O
,	O
su	B
##c	I
##rose	I
for	O
di	B
##sa	I
##cc	I
##hari	I
##des	I
)	O
.	O

Met	B
##han	I
##ol	I
and	O
is	B
##op	I
##rop	I
##ano	I
##l	I
were	O
purchased	O
from	O
Me	O
##rc	O
##k	O
(	O
Dar	O
##ms	O
##tadt	O
,	O
Germany	O
)	O
and	O
ace	B
##ty	I
##l	I
chloride	I
(	O
p	O
.	O
a	O
.	O
)	O
from	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
(	O
Stein	O
##heim	O
,	O
Germany	O
)	O
.	O

Further	O
,	O
neither	O
study	O
addressed	O
the	O
possibility	O
that	O
it	O
is	O
tissue	O
levels	O
of	O
est	B
##rad	I
##iol	I
,	O
rather	O
than	O
circulating	O
levels	O
,	O
that	O
are	O
important	O
.	O

In	O
that	O
population	O
of	O
5	O
,	O
31	O
##4	O
men	O
and	O
women	O
aged	O
45	O
to	O
84	O
years	O
followed	O
for	O
7	O
.	O
7	O
years	O
,	O
LP	O
##IR	O
H	O
##R	O
for	O
T	O
##2	O
##D	O
was	O
1	O
.	O
59	O
for	O
Q	O
##4	O
versus	O
Q	O
##1	O
in	O
a	O
model	O
adjusted	O
for	O
fast	O
##ing	O
glucose	S
,	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
to	O
HD	O
##L	O
-	O
c	O
ratio	O
and	O
other	O
traditional	O
markers	O
.	O

Ten	O
##tative	O
identification	O
of	O
the	O
meta	O
##bol	O
##ites	O
found	O
to	O
be	O
unique	O
to	O
the	O
M	B
##T	I
##BE	I
lip	O
##id	O
fraction	O
was	O
performed	O
.	O

This	O
trend	O
observed	O
in	O
di	O
##abe	O
##tic	O
monkeys	O
was	O
unexpected	O
as	O
GM	B
##3	I
has	O
been	O
reported	O
as	O
a	O
negative	O
regulator	O
of	O
insulin	O
signaling	O
,	O
,	O
.	O

P	O
##las	O
##ma	O
levels	O
of	O
car	B
##ni	I
##tine	I
are	O
elevated	O
in	O
PD	O
##R	O
patients	O
.	O

Abe	O
##rra	O
##nt	O
ch	B
##olin	I
##e	I
metabolism	O
can	O
be	O
explained	O
as	O
a	O
result	O
of	O
enhanced	O
membrane	O
synthesis	O
and	O
degradation	O
,	O
which	O
represent	O
excessive	O
proliferation	O
of	O
cancer	O
cells	O
.	O

Figure	O
S	O
##4	O
)	O
,	O
most	O
probably	O
as	O
a	O
consequence	O
of	O
a	O
reduced	O
g	B
##ly	I
##ce	I
##mic	I
effect	O
.	O

p	O
>	O
.	O
20	O
;	O
SD	O
=	O
standard	O
de	O
##viation	O
;	O
T	O
##RP	O
=	O
try	B
##pt	I
##op	I
##han	I
;	O
5	O
-	O
H	O
##TP	O
=	O
5	B
-	I
h	I
##ydro	I
##xy	I
##try	I
##pt	I
##op	I
##han	I
;	O
K	O
##Y	O
##N	O
=	O
k	B
##yn	I
##uren	I
##ine	I
;	O
K	O
##Y	O
##NA	O
=	O
k	B
##yn	I
##uren	I
##ate	I
;	O
3	O
-	O
HK	O
##Y	O
##N	O
=	O
3	B
-	I
h	I
##ydro	I
##xy	I
##ky	I
##nu	I
##ren	I
##ine	I
.	O

Ce	B
##ram	I
##ides	I
are	O
typically	O
recognized	O
as	O
[	O
M	O
+	O
H	O
]	O
_	O
+	O
and	O
[	O
M	O
+	O
H	O
##−	O
##H	O
_	O
2	O
O	O
]	O
_	O
+	O
in	O
positive	O
ion	O
mode	O
.	O

This	O
suggests	O
that	O
the	O
ET	O
##S	O
u	O
##rina	O
##ry	O
bio	O
##mark	O
##ers	O
studied	O
are	O
good	O
biological	O
indicators	O
of	O
personal	O
exposure	O
to	O
high	O
molecular	O
weight	O
p	B
##oly	I
##cy	I
##c	I
##lic	I
a	O
##romatic	O
h	B
##ydro	I
##car	I
##bon	I
##s	I
,	O
including	O
car	O
##cin	O
##ogenic	O
PA	O
##H	O
##s	O
such	O
as	O
ben	B
##zo	I
(	I
a	I
)	I
p	I
##yre	I
##ne	I
,	O
in	O
our	O
study	O
population	O
.	O

Try	B
##pt	I
##op	I
##han	I
and	O
k	B
##yn	I
##uren	I
##ine	I
meta	O
##bol	O
##ites	O
were	O
detected	O
with	O
high	O
-	O
performance	O
liquid	O
ch	O
##roma	O
##tography	O
(	O
HP	O
##LC	O
)	O
and	O
L	O
##C	O
/	O
MS	O
.	O

Rai	O
##sed	O
T	B
##G	I
production	O
has	O
been	O
suggested	O
as	O
a	O
cell	O
strategy	O
to	O
decrease	O
the	O
c	O
##yt	O
##oto	O
##xi	O
##city	O
generated	O
by	O
the	O
high	O
amount	O
of	O
free	O
FA	S
in	O
the	O
c	O
##yt	O
##op	O
##las	O
##m	O
[	O
,	O
]	O
.	O

Three	O
of	O
these	O
peaks	O
were	O
valid	O
##ated	O
as	O
being	O
c	B
##rea	I
##tin	I
##ine	I
,	O
c	B
##rea	I
##tine	I
,	O
and	O
5	B
##a	I
-	I
D	I
##HT	I
.	O

The	O
var	O
##iability	O
of	O
p	B
##ht	I
##hala	I
##te	I
exposure	O
can	O
vary	O
in	O
time	O
from	O
changes	O
in	O
use	O
of	O
personal	O
care	O
products	O
,	O
diet	O
,	O
or	O
daily	O
activities	O
(	O
;	O
)	O
.	O

The	O
detection	O
of	O
some	O
particular	O
lip	O
##id	O
species	O
such	O
as	O
LP	O
##C	O
/	O
PC	O
and	O
SM	O
in	O
both	O
positive	O
and	O
negative	O
ion	O
##ization	O
modes	O
,	O
as	O
pro	O
##ton	O
##ated	O
ion	O
(	O
[	O
M	O
+	O
H	O
]	O
_	O
+	O
)	O
and	O
format	B
##e	I
add	O
##uc	O
##t	O
(	O
[	O
M	O
−	O
H	O
+	O
CH	O
##O	O
_	O
2	O
]	O
_	O
−	O
)	O
,	O
enabled	O
to	O
confirm	O
their	O
an	O
##not	O
##ation	O
and	O
also	O
improved	O
their	O
structural	O
characterization	O
.	O

To	O
as	O
##cer	O
##tain	O
that	O
α	B
-	I
O	I
##G	I
treatment	O
m	O
##od	O
##ifies	O
the	O
DNA	O
met	B
##hyl	I
##ome	I
in	O
T	O
##RT	O
-	O
H	O
##U	O
##1	O
cells	O
,	O
we	O
next	O
q	O
##uant	O
##ified	O
the	O
levels	O
of	O
DNA	O
met	O
##hyl	O
##ation	O
and	O
gene	O
expression	O
of	O
the	O
targeted	O
candidate	O
genes	O
.	O

4	B
-	I
Am	I
##ino	I
##py	I
##rid	I
##ine	I
,	O
Dal	B
##fa	I
##mp	I
##rid	I
##ine	I
,	O
Met	O
##ab	O
##olis	O
##m	O
,	O
Cy	O
##to	O
##ch	O
##rome	O
P	O
##45	O
##0	O
,	O
Drug	O
-	O
drug	O
interactions	O

A	O
liver	O
function	O
score	O
was	O
calculated	O
from	O
concentrations	O
of	O
album	O
##in	O
,	O
total	O
bi	B
##li	I
##ru	I
##bin	I
,	O
AL	O
##T	O
,	O
AS	O
##T	O
,	O
G	O
##G	O
##T	O
,	O
and	O
AP	S
,	O
each	O
contributing	O
1	O
point	O
when	O
outside	O
of	O
the	O
normal	O
range	O
.	O

Go	O
to	O
:	O
A	O
liquid	O
ch	O
##roma	O
##tography	O
coupled	O
with	O
tandem	O
mass	O
s	O
##pect	O
##rome	O
##try	O
(	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
)	O
ass	O
##ay	O
was	O
developed	O
and	O
valid	O
##ated	O
for	O
simultaneously	O
determination	O
of	O
1	B
-	I
(	I
2	I
′	I
-	I
de	I
##ox	I
##y	I
-	I
2	I
′	I
-	I
flu	I
##oro	I
-	I
β	I
-	I
D	I
-	I
a	I
##rab	I
##ino	I
##fu	I
##rano	I
##sy	I
##l	I
)	I
u	I
##rac	I
##il	I
(	O
FA	O
##U	O
)	O
and	O
its	O
active	O
meta	O
##bol	O
##ite	O
1	B
-	I
(	I
2	I
′	I
-	I
de	I
##ox	I
##y	I
-	I
2	I
′	I
-	I
flu	I
##oro	I
-	I
β	I
-	I
D	I
-	I
a	I
##rab	I
##ino	I
##fu	I
##rano	I
##sy	I
##l	I
5	I
-	I
met	I
##hyl	I
##ura	I
##ci	I
##l	I
(	I
FM	I
##A	I
##U	I
)	I
in	O
human	O
plasma	O
.	O

In	O
I	O
##BS	O
,	O
neither	O
AD	B
##MA	I
nor	O
SD	O
##MA	O
correlated	O
with	O
c	B
##it	I
##ru	I
##llin	I
##e	I
,	O
which	O
instead	O
becomes	O
inverse	O
##ly	O
related	O
to	O
D	B
##MA	I
concentrations	O
.	O

This	O
pathway	O
is	O
composed	O
of	O
39	O
species	O
,	O
three	O
of	O
which	O
(	B
g	B
##ly	I
##cine	I
,	O
ta	B
##uri	I
##ne	I
and	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
)	O
were	O
prior	O
##itis	O
##ed	O
by	O
LA	O
##SS	O
##O	O
in	O
the	O
training	O
set	O
ten	O
or	O
more	O
times	O
.	O

The	O
Waters	O
UP	O
##C	O
_	O
2	O
was	O
coupled	O
to	O
a	O
Waters	O
Q	O
##ua	O
##tt	O
##ro	O
Premier	O
tandem	O
mass	O
s	O
##pect	O
##rome	O
##ter	O
via	O
a	O
purpose	B
-	I
built	I
,	O
two	O
-	O
part	O
stainless	O
steel	O
split	O
##ter	O
supplied	O
by	O
Waters	O
.	O

G	B
##lut	I
##amine	I
S	O
##ynth	O
##eta	O
##se	O
im	O
##mu	O
##no	O
-	O
stain	O
##ing	O
and	O
correlation	O
with	O
N	O
##MR	O
data	O
.	O

There	O
are	O
two	O
main	O
sources	O
of	O
end	O
##ogen	O
##ous	O
micro	O
##bial	O
substrate	O
:	O
in	O
##test	O
##inal	O
s	O
##lough	O
##ed	O
cells	O
and	O
host	O
g	B
##ly	I
##can	I
m	I
##uc	I
##ins	I
[	O
,	O
]	O
.	O

We	O
concluded	O
that	O
the	O
0	O
.	O
1	O
%	O
format	B
##e	I
gradient	O
utilized	O
in	O
method	O
G	O
was	O
not	O
sufficient	O
to	O
facilitate	O
the	O
displacement	O
of	O
the	O
strong	O
acids	O
from	O
the	O
amino	S
A	O
##X	O
sites	O
.	O

However	O
,	O
both	O
ca	B
##ffe	I
##ine	I
and	O
the	B
##op	I
##hyl	I
##line	I
were	O
measured	O
as	O
part	O
of	O
the	O
meta	O
##bol	O
##omi	O
##c	O
profile	O
,	O
and	O
neither	O
changed	O
with	O
β	B
-	I
car	I
##ote	I
##ne	I
supplement	O
##ation	O
(	B
ca	B
##ffe	I
##ine	I
:	O
P	O
=	O
0	O
.	O
75	O
;	O
the	B
##op	I
##hyl	I
##line	I
:	O
P	O
=	O
0	O
.	O
33	O
;	O
see	O
Su	O
##pp	O
##lement	O
##al	O
Table	O
1	O
under	O
“	O
Su	O
##pp	O
##lement	O
##al	O
data	O
”	O
in	O
the	O
online	O
issue	O
)	O
.	O

In	O
this	O
paper	O
we	O
describe	O
the	O
use	O
of	O
tandem	O
mass	O
s	O
##pect	O
##rome	O
##try	O
to	O
locate	O
binding	O
sites	O
and	O
el	O
##uc	O
##ida	O
##te	O
the	O
binding	O
mechanism	O
involved	O
in	O
the	O
formation	O
of	O
co	O
##valent	O
add	O
##uc	O
##ts	O
from	O
to	B
##lm	I
##eti	I
##n	I
g	I
##lu	I
##cu	I
##ron	I
##ide	I
and	O
album	O
##in	O
in	O
v	O
##it	O
##ro	O
.	O

The	O
network	O
of	O
u	O
##rina	O
##ry	O
molecules	O
separating	O
the	O
lean	O
and	O
o	O
##bes	O
##e	O
groups	O
was	O
characterized	O
by	O
lower	O
levels	O
of	O
x	B
##yl	I
##ito	I
##l	I
and	O
PA	O
##A	O
in	O
o	O
##bes	O
##e	O
individuals	O
.	O

We	O
evaluated	O
the	O
specific	O
##ity	O
of	O
the	O
method	O
by	O
comparing	O
the	O
ch	O
##roma	O
##to	O
##gram	O
##s	O
obtained	O
from	O
the	O
anal	O
##yte	O
##s	O
in	O
a	O
solution	O
of	O
Me	B
##OH	I
with	O
an	O
extracted	O
plasma	O
sample	O
,	O
both	O
fortified	O
with	O
standards	O
and	O
IS	O
.	O

Both	O
PM	O
##N	O
##s	O
and	O
P	O
##BM	O
##Cs	O
le	O
##uk	O
##ocytes	O
contained	O
very	O
large	O
amounts	O
of	O
g	B
##ly	I
##cer	I
##ol	I
,	O
a	O
compound	O
that	O
,	O
among	O
other	O
functions	O
,	O
is	O
a	O
vital	O
o	O
##smo	O
##p	O
##rote	O
##ctive	O
agent	O
for	O
cells	O
in	O
suspension	O
.	O

Nonetheless	O
,	O
the	O
fourth	O
q	O
##ua	O
##rt	O
##ile	O
of	O
male	O
partners	O
'	O
u	O
##rina	O
##ry	O
para	B
##ce	I
##tam	I
##ol	I
was	O
associated	O
with	O
delayed	O
T	O
##TP	O
in	O
the	O
adjusted	O
couple	O
-	O
based	O
models	O
[	O
a	O
F	O
##OR	O
=	O
0	O
.	O
65	O
;	O
95	O
%	O
C	O
##I	O
=	O
(	O
0	O
.	O
47	O
,	O
0	O
.	O
98	O
)	O
;	O
P	O
-	O
trend	O
=	O
0	O
.	O
02	O
]	O
.	O

P	O
##GE	O
-	O
M	O
and	O
8	B
-	I
is	I
##o	I
-	I
P	I
##G	I
##F	I
_	I
2	I
##α	I
data	I
were	O
normal	O
##ized	O
by	O
dividing	O
by	O
mg	O
c	B
##rea	I
##tin	I
##ine	I
to	O
account	O
for	O
differences	O
in	O
urine	O
concentration	O
and	O
log	O
transformed	O
because	O
of	O
right	O
s	O
##ke	O
##wed	O
##ness	O
.	O

Tri	B
##gly	I
##cer	I
##ides	I
in	O
the	O
larger	O
V	O
##LD	O
##L	O
sub	O
##c	O
##lass	O
##es	O
,	O
the	O
serum	O
concentration	O
of	O
V	O
##LD	O
##L	O
particles	O
,	O
the	O
V	O
##LD	O
##L	O
mean	O
diameter	O
as	O
well	O
as	O
the	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
and	O
total	O
lip	O
##ids	O
in	O
V	O
##LD	O
##L	O
sub	O
##c	O
##lass	O
##es	O
(	O
ranging	O
from	O
medium	O
to	O
extremely	O
large	O
particles	O
)	O
,	O
and	O
the	O
total	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
ch	B
##ole	I
##ster	I
##ol	I
est	I
##ers	I
and	O
free	O
ch	B
##ole	I
##ster	I
##ol	I
in	O
large	O
V	O
##LD	O
##L	O
sub	O
##c	O
##lass	O
##es	O
were	O
all	O
positively	O
associated	O
with	O
test	B
##osterone	I
levels	O
(	O
β	O
>	O
0	O
.	O
73	O
,	O
P	O
<	O
1	O
.	O
4	O
×	O
10	O
_	O
−	O
##3	O
)	O
.	O

In	O
poor	O
respond	O
##ers	O
,	O
si	B
##m	I
##vas	I
##tat	I
##in	I
induced	O
a	O
reduction	O
in	O
plasma	O
levels	O
of	O
the	O
sugar	O
##s	O
f	B
##ru	I
##ct	I
##ose	I
(	O
p	O
<	O
0	O
.	O
00	O
##12	O
,	O
q	O
<	O
0	O
.	O
03	O
##9	O
)	O
and	O
glucose	S
(	O
p	O
<	O
0	O
.	O
00	O
##20	O
,	O
q	O
<	O
0	O
.	O
03	O
##9	O
)	O
–	O
the	O
latter	O
strongly	O
correlated	O
with	O
reduction	O
##s	O
in	O
alpha	B
-	I
man	I
##nos	I
##yl	I
##gly	I
##cer	I
##ate	I
(	O
0	O
.	O
80	O
##9	O
,	O
p	O
<	O
0	O
.	O
000	O
##1	O
)	O
and	O
pseudo	B
##uri	I
##dine	I
(	O
0	O
.	O
70	O
##4	O
,	O
p	O
<	O
0	O
.	O
000	O
##1	O
)	O
(	O
data	O
not	O
shown	O
)	O
.	O

Similarly	O
,	O
another	O
small	O
meta	O
##bol	O
##omi	O
##c	O
study	O
of	O
the	O
CS	O
##F	O
found	O
differences	O
in	O
meta	O
##bol	O
##ite	O
concentration	O
based	O
on	O
disease	O
activity	O
,	O
with	O
increased	O
levels	O
of	O
h	B
##ydro	I
##xy	I
##ei	I
##cos	I
##ate	I
##tra	I
##eno	I
##ic	I
acid	I
,	O
pro	B
##sta	I
##g	I
##land	I
##in	I
E	I
##2	I
,	O
and	O
re	B
##sol	I
##vin	I
D	I
##1	I
in	O
patients	O
with	O
highly	O
active	O
MS	O
.	O

The	O
run	O
started	O
with	O
20	O
%	O
met	B
##han	I
##ol	I
for	O
2	O
minutes	O
with	O
a	O
linear	O
gradient	O
from	O
20	O
%	O
to	O
100	O
%	O
being	O
later	O
applied	O
over	O
seven	O
minutes	O
;	O
100	O
%	O
was	O
kept	O
until	O
the	O
tenth	O
minute	O
,	O
returning	O
to	O
the	O
initial	O
condition	O
(	O
20	O
%	O
met	B
##han	I
##ol	I
)	O
to	O
re	O
-	O
e	O
##qui	O
##li	O
##bra	O
##te	O
the	O
column	O
for	O
3	O
minutes	O
.	O

Super	O
##nat	O
##ants	O
were	O
discarded	O
,	O
0	O
.	O
5	O
m	O
##L	O
of	O
ice	O
-	O
cold	O
met	B
##han	I
##ol	I
was	O
added	O
to	O
the	O
p	O
##elle	O
##ts	O
,	O
that	O
were	O
stored	O
at	O
-	O
80	O
##°	O
##C	O
until	O
performing	O
the	O
extraction	O
for	O
_	O
1	O
H	O
-	O
N	O
##MR	O
analysis	O
.	O

Total	O
ch	B
##ole	I
##ster	I
##ol	I
concentrations	O
,	O
high	O
-	O
density	O
lip	O
##op	O
##rote	O
##in	O
(	O
HD	O
##L	O
)	O
and	O
low	O
-	O
density	O
lip	O
##op	O
##rote	O
##in	O
(	O
L	O
##D	O
##L	O
)	O
levels	O
were	O
measured	O
with	O
en	O
##zy	O
##matic	O
methods	O
(	O
CH	O
##OD	O
-	O
PA	O
##P	O
,	O
Dad	O
##e	O
Be	O
##hr	O
##ing	O
)	O
.	O

Nevertheless	O
,	O
only	O
42	O
%	O
of	O
our	O
women	O
visited	O
a	O
primary	O
care	O
physician	O
for	O
after	O
##care	O
during	O
the	O
study	O
period	O
,	O
confirming	O
the	O
reported	O
low	O
rates	O
of	O
follow	O
-	O
up	O
with	O
glucose	S
testing	O
and	O
primary	O
care	O
visits	O
after	O
delivery	O
.	O

Furthermore	O
,	O
researchers	O
have	O
shown	O
that	O
a	O
higher	O
level	O
of	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
would	O
induce	O
damage	O
in	O
the	O
nervous	O
system	O
,	O
resulting	O
in	O
h	O
##y	O
##po	O
##kin	O
##esi	O
##a	O
,	O
depression	O
and	O
ps	O
##ych	O
##ogen	O
##y	O
.	O

Co	O
##valent	O
binding	O
of	O
z	O
##ome	O
##pi	O
##rac	O
g	B
##lu	I
##cu	I
##ron	I
##ide	I
to	O
proteins	O
:	O
evidence	O
for	O
a	O
Sc	O
##hi	O
##ff	O
base	O
mechanism	O
.	O

HC	O
##M	O
##V	O
up	O
-	O
regulate	O
##s	O
much	O
of	O
central	O
carbon	O
metabolism	O
,	O
including	O
the	O
production	O
of	O
fatty	O
acids	O
;	O
and	O
,	O
although	O
the	O
changes	O
observed	O
for	O
total	O
cellular	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
ass	O
##ay	O
##ed	O
were	O
modest	O
(	O
and	O
Data	O
##set	O
S	O
##1	O
)	O
,	O
v	O
##iri	O
##ons	O
exhibited	O
a	O
signature	O
marked	O
##ly	O
distinct	O
from	O
the	O
whole	O
cell	O
(	O
and	O
Data	O
##set	O
S	O
##2	O
)	O
.	O

In	O
past	O
studies	O
,	O
where	O
the	O
L	O
##C	O
-	O
MS	O
and	O
L	O
##C	O
-	O
EC	O
were	O
run	O
in	O
parallel	O
from	O
a	O
single	O
injection	O
,	O
_	O
,	O
the	O
more	O
MS	O
-	O
friendly	O
salt	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
was	O
utilized	O
to	O
maintain	O
sufficient	O
EC	O
conduct	O
##ivity	O
.	O

MS	O
##EA	O
revealed	O
alterations	O
in	O
s	O
##tero	O
##ido	O
##genesis	O
,	O
and	B
##ros	I
##ten	I
##ed	I
##ione	I
metabolism	O
,	O
and	O
the	O
metabolism	O
of	O
and	O
##rogen	O
##s	O
and	O
est	O
##rogen	O
##s	O
in	O
patients	O
who	O
were	O
over	O
##weight	O
or	O
at	O
various	O
stages	O
of	O
o	O
##besity	O
.	O

Met	O
##ab	O
##oli	O
##tes	O
were	O
purchased	O
from	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
(	O
Q	O
##UI	O
##N	O
,	O
k	B
##yn	I
##uren	I
##ine	I
,	O
and	O
_	O
2	O
H	O
_	O
5	O
-	O
try	O
##pt	O
##op	O
##han	O
)	O
and	O
S	O
##yn	O
##fine	O
Research	O
Inc	O
.	O
,	O
Ontario	O
,	O
Canada	O
(	O
_	O
13	O
C	O
_	O
3	O
_	O
15	O
N	O
_	O
1	O
-	O
Q	O
##UI	O
##N	O
)	O
.	O

Lower	O
total	O
ch	B
##ole	I
##ster	I
##ol	I
levels	O
have	O
been	O
associated	O
with	O
increased	O
in	O
-	O
hospital	O
mortality	O
of	O
patients	O
with	O
various	O
diseases	O
,	O
including	O
mi	O
##s	O
##cell	O
##aneous	O
heart	O
diseases	O
,	O
and	O
was	O
proposed	O
as	O
one	O
of	O
the	O
first	O
signs	O
of	O
forthcoming	O
de	O
##ter	O
##ior	O
##ation	O
of	O
a	O
pre	O
##ex	O
##ist	O
##ing	O
disease	O
.	O

The	O
e	B
##ico	I
##san	I
##oids	I
were	O
separated	O
by	O
HP	O
##LC	O
on	O
a	O
Beta	O
##bas	O
##ic	O
C	O
_	O
18	O
column	O
(	O
150	O
##×	O
##2	O
.	O
1	O
mm	O
,	O
3	O
μ	O
##M	O
;	O
The	O
##rm	O
##o	O
H	O
##yper	O
##si	O
##l	O
-	O
Keys	O
##tone	O
,	O
Belle	O
##fo	O
##nte	O
,	O
PA	O
)	O
at	O
a	O
flow	O
rate	O
of	O
0	O
.	O
2	O
m	O
##l	O
/	O
min	O
using	O
an	O
is	O
##oc	O
##ratic	O
el	O
##ution	O
with	O
51	O
:	O
9	O
:	O
40	O
:	O
0	O
.	O
01	O
mixture	O
of	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
:	O
met	O
##han	O
##ol	O
:	O
water	O
:	O
ace	O
##tic	O
acid	O
for	O
30	O
min	O
followed	O
by	O
a	O
step	O
gradient	O
to	O
68	O
:	O
13	O
:	O
19	O
:	O
0	O
.	O
01	O
ace	O
##ton	O
##it	O
##ril	O
##e	O
:	O
met	O
##han	O
##ol	O
:	O
water	O
:	O
ace	O
##tic	O
acid	O
for	O
15	O
min	O
.	O

These	O
associations	O
have	O
long	O
been	O
thought	O
to	O
result	O
from	O
mit	O
##ogenic	O
effects	O
mediated	O
by	O
the	O
est	B
##rogen	I
receptor	O
.	O

After	O
e	O
##va	O
##por	O
##ating	O
the	O
solvent	O
,	O
0	O
.	O
5	O
m	O
##l	O
of	O
met	B
##han	I
##olic	I
HC	O
##l	O
(	O
2	O
.	O
5	O
M	O
)	O
was	O
added	O
to	O
each	O
tube	O
.	O

Specifically	O
,	O
to	O
demonstrate	O
the	O
performance	O
of	O
the	O
new	O
method	O
,	O
we	O
measured	O
cardiac	O
N	B
##AD	I
##H	I
and	O
N	O
##AD	O
_	O
+	O
ratios	O
as	O
well	O
as	O
their	O
pool	O
sizes	O
in	O
heart	O
tissue	O
from	O
mouse	O
models	O
with	O
a	O
cardiac	O
specific	O
knockout	O
of	O
the	O
mitochondrial	O
Complex	O
I	O
N	O
##du	O
##fs	O
##4	O
gene	O
(	O
c	O
##KO	O
)	O
.	O

When	O
looking	O
at	O
the	O
control	O
group	O
,	O
p	O
##rima	O
##te	O
C	O
##2	O
has	O
an	O
increase	O
in	O
the	O
more	O
sensitive	O
meta	O
##bol	O
##ites	O
(	O
specifically	O
su	B
##cci	I
##nic	I
acid	I
and	O
but	B
##ano	I
##ic	I
acid	O
)	O
.	O

Pre	O
##rand	O
##omi	O
##zation	O
characteristics	O
of	O
the	O
study	O
population	O
by	O
the	O
trial	O
β	B
-	I
car	I
##ote	I
##ne	I
assignment	O
are	O
shown	O
in	O
.	O

In	O
fact	O
,	O
β	B
-	I
a	I
##po	I
-	I
13	I
-	I
car	I
##ote	I
##non	I
##e	I
displayed	O
the	O
same	O
affinity	O
for	O
the	O
RA	O
##R	O
##s	O
as	O
AT	O
##RA	O
itself	O
(	O
i	O
.	O
e	O
.	O
2	O
–	O
6	O
nm	O
)	O
(	O
B	O
)	O
.	O

Shea	O
##th	O
liquid	O
##s	O
with	O
different	O
composition	O
of	O
organic	O
solvent	O
##s	O
(	B
met	B
##han	I
##ol	I
,	O
is	O
##op	O
##rop	O
##ano	O
##l	O
)	O
and	O
volatile	O
acid	O
(	O
0	O
.	O
1	O
–	O
0	O
.	O
5	O
%	O
H	O
##F	O
##o	O
)	O
or	O
salt	O
of	O
volatile	O
acid	O
(	O
1	O
–	O
10	O
m	O
##M	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
,	O
NH	O
_	O
4	O
A	O
##c	O
)	O
were	O
examined	O
.	O

The	O
goal	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
capacity	O
for	O
mass	O
s	O
##pect	O
##rome	O
##try	O
of	O
blood	O
plasma	O
to	O
di	O
##ag	O
##nose	O
impaired	O
glucose	S
tolerance	O
(	O
I	O
##G	O
##T	O
)	O
.	O

The	O
lower	O
values	O
obtained	O
for	O
24	O
##R	O
,	O
25	O
(	O
OH	O
)	O
_	O
2	O
D	O
_	O
3	O
in	O
the	O
SP	O
##E	O
procedure	O
compared	O
to	O
LL	O
##E	O
can	O
be	O
explained	O
by	O
the	O
relatively	O
high	O
polar	O
##ity	O
of	O
24	O
##R	O
,	O
25	O
(	O
OH	O
)	O
_	O
2	O
D	O
_	O
3	O
,	O
which	O
could	O
result	O
in	O
losses	O
during	O
the	O
SP	O
##E	O
wash	O
,	O
and	O
the	O
lack	O
of	O
a	O
de	O
##uter	O
##ated	O
internal	O
standard	O
(	B
d	B
_	I
6	I
1	I
##α	I
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
was	O
used	O
as	O
a	O
reference	O
for	O
24	O
##R	O
,	O
25	O
(	O
OH	O
)	O
_	O
2	O
D	O
_	O
3	O
q	O
##uant	O
##ification	O
)	O
.	O

We	O
plot	O
##ted	O
the	O
retention	O
time	O
versus	O
the	O
total	O
carbon	O
number	O
of	O
fatty	O
a	O
##cy	O
##ls	O
and	O
observed	O
,	O
as	O
shown	O
in	O
,	O
a	O
relationship	O
of	O
second	O
degree	O
polynomial	O
re	O
##gression	O
for	O
the	O
fully	O
saturated	O
species	O
of	O
the	O
abundant	O
serum	O
lip	O
##id	O
classes	O
:	O
T	B
##G	I
,	O
SM	O
,	O
PC	O
,	O
LP	O
##C	O
,	O
and	O
Ce	B
##r	I
,	O
with	O
each	O
class	O
having	O
a	O
different	O
slope	O
reflecting	O
the	O
actual	O
gradient	O
conditions	O
experienced	O
by	O
species	O
in	O
each	O
class	O
.	O

There	O
were	O
several	O
key	O
findings	O
that	O
emerged	O
:	O
First	O
,	O
we	O
demonstrated	O
significant	O
reduction	O
##s	O
of	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
mass	O
and	O
significant	O
increases	O
in	O
c	B
##era	I
##mi	I
##de	I
content	O
in	O
plasma	O
of	O
AD	O
patients	O
.	O

It	O
can	O
be	O
seen	O
that	O
the	O
three	O
characteristic	O
meta	O
##bol	O
##ites	O
with	O
the	O
highest	O
change	O
ratio	O
belong	O
to	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
.	O

Sam	O
##ples	O
then	O
underwent	O
slow	O
inverse	O
extraction	O
at	O
8	O
rpm	O
(	O
R	O
##K	O
##VS	O
##D	O
[UNK]	O
,	O
AT	O
##R	O
,	O
Inc	O
.	O
,	O
Laurel	O
,	O
MD	O
,	O
USA	O
)	O
with	O
5	O
m	O
##l	O
di	B
##ch	I
##lor	I
##ome	I
##than	I
##e	I
for	O
30	O
minutes	O
.	O

Interest	O
##ingly	O
,	O
we	O
noticed	O
that	O
L	B
-	I
c	I
##it	I
##ru	I
##llin	I
##e	I
and	O
D	B
-	I
as	I
##par	I
##tic	I
acid	I
are	O
not	O
only	O
can	O
be	O
used	O
to	O
distinguish	O
B	O
##D	O
##TT	O
from	O
Stone	O
,	O
they	O
are	O
also	O
effective	O
in	O
separating	O
B	O
##D	O
##TT	O
from	O
two	O
other	O
diseases	O
.	O

N	B
##1	I
-	I
met	I
##hyl	I
2	I
-	I
p	I
##yr	I
##ido	I
##ne	I
-	I
5	I
-	I
car	I
##box	I
##ami	I
##de	I
(	O
N	O
##12	O
##5	O
)	O
has	O
been	O
increased	O
in	O
high	O
fat	O
diet	O
-	O
induced	O
o	O
##besity	O
,	O
which	O
is	O
an	O
elevated	O
CR	O
##C	O
risk	O
factor	O
.	O

We	O
com	O
##puted	O
ratios	O
of	O
c	B
##era	I
##mi	I
##des	I
to	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
##s	I
,	O
and	O
then	O
used	O
Wilcox	O
##on	O
rank	O
sum	O
tests	O
to	O
compare	O
ratios	O
between	O
groups	O
.	O

OS	O
##B	O
##PL	O
##2	O
has	O
also	O
been	O
previously	O
shown	O
affect	O
the	O
metabolism	O
of	O
neutral	O
lip	O
##ids	O
,	O
possibly	O
integrating	O
the	O
cellular	O
metabolism	O
of	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
with	O
that	O
of	O
ch	B
##ole	I
##ster	I
##ol	I
.	O

To	O
determine	O
the	O
origin	O
of	O
ethanol	S
during	O
our	O
sample	O
processing	O
procedure	O
,	O
we	O
performed	O
a	O
CS	O
##F	O
sampling	O
protocol	O
simulation	O
.	O

The	O
resulting	O
sample	O
was	O
dried	O
and	O
dissolved	O
in	O
200	O
µ	O
##L	O
met	B
##han	I
##ol	I
,	O
resulting	O
in	O
a	O
neutral	O
lip	O
##id	O
fraction	O
.	O

A	O
##bb	O
##re	O
##viation	O
##s	O
:	O
AP	O
##C	O
,	O
ad	O
##eno	O
##mat	O
##ous	O
p	O
##oly	O
##po	O
##sis	O
co	O
##li	O
;	O
F	O
,	O
female	O
;	O
M	O
,	O
male	O
;	O
w	O
##t	O
,	O
wild	O
type	O
;	O
P	O
##I	O
##K	O
##3	O
##CA	O
,	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##lino	I
##si	I
##to	I
##l	I
-	I
4	I
,	I
5	I
-	I
bi	I
##sp	I
##hos	I
##phate	I
3	O
-	O
kinase	O
cat	O
##alytic	O
subunit	O
alpha	O
;	O
PT	O
##EN	O
,	O
p	O
##hos	O
##pha	O
##tase	O
and	O
tens	O
##in	O
ho	O
##mo	O
##log	O
;	O
?	O
,	O
not	O
known	O
All	O
lip	O
##id	O
analyses	O
were	O
based	O
on	O
peak	O
area	O
values	O
(	O
directly	O
derived	O
from	O
ch	O
##roma	O
##to	O
##gram	O
##s	O
)	O
reflecting	O
the	O
content	O
of	O
individual	O
lip	O
##id	O
compounds	O
(	O
represented	O
by	O
specific	O
molecular	O
weight	O
—	O
MW	O
species	O
)	O
.	O

Excellent	O
recover	O
##ies	O
of	O
Ce	B
##r	I
(	I
22	I
:	I
0	I
)	I
and	O
Ce	B
##r	I
(	I
24	I
:	I
0	I
)	I
from	O
plasma	O
and	O
from	O
BS	O
##A	O
were	O
obtained	O
(	O
see	O
)	O
.	O

G	B
##lu	I
##cos	I
##e	I
and	O
1	B
,	I
5	I
-	I
AG	I
compete	O
for	O
re	O
##ab	O
##sor	O
##ption	O
in	O
the	O
kidney	O
and	O
are	O
their	O
plasma	O
levels	O
are	O
inverse	O
##ly	O
proportional	O
to	O
each	O
other	O
,	O
with	O
serum	O
1	B
,	I
5	I
-	I
AG	I
levels	O
reducing	O
in	O
h	O
##yper	O
##gly	O
##ce	O
##mia	O
.	O

Consequently	O
,	O
since	O
there	O
is	O
a	O
correlation	O
between	O
la	B
##ct	I
##ate	I
and	O
test	B
##osterone	I
production	O
in	O
rat	O
Le	O
##yd	O
##ig	O
cells	O
,	O
in	O
these	O
patients	O
,	O
test	B
##osterone	I
production	O
can	O
be	O
further	O
reduced	O
upon	O
time	O
.	O

F	O
##IE	O
-	O
MS	O
_	O
2	O
was	O
employed	O
to	O
provide	O
further	O
confirmation	O
that	O
these	O
observed	O
signals	O
were	O
add	O
##uc	O
##ts	O
and	O
is	O
##oto	O
##pes	O
of	O
an	B
##ser	I
##ine	I
(	O
Fi	O
##g	O
.	O

Finally	O
,	O
in	O
contrast	O
to	O
the	O
AA	O
canonical	O
e	B
##ico	I
##san	I
##oid	I
ca	O
##sca	O
##de	O
,	O
leading	O
to	O
the	O
meta	O
##bol	O
##ites	O
discussed	O
above	O
,	O
data	O
from	O
the	O
parallel	O
pathway	O
starting	O
with	O
e	B
##ico	I
##sa	I
##pent	I
##aen	I
##oi	I
##c	I
acid	I
(	O
EPA	O
;	O
20	O
:	O
5	O
##n	O
-	O
3	O
)	O
was	O
also	O
collected	O
(	O
Su	O
##pp	O
##lement	O
##al	O
Fi	O
##g	O
.	O
11	O
##C	O
)	O
.	O

Thus	O
,	O
2	O
-	O
h	O
##ydro	O
##xy	O
##lation	O
could	O
reduce	O
breast	O
cancer	O
risk	O
simply	O
by	O
decreasing	O
the	O
concentration	O
of	O
bio	O
##active	O
un	O
##con	O
##ju	O
##gated	O
est	B
##rad	I
##iol	I
in	O
circulation	O
and	O
in	O
the	O
breast	O
.	O

The	O
second	O
step	O
of	O
our	O
investigation	O
was	O
to	O
perform	O
an	O
in	O
v	O
##it	O
##ro	O
study	O
of	O
re	B
##tina	I
##l	I
cell	O
via	O
##bility	O
in	O
the	O
presence	O
of	O
reactive	O
per	B
##sul	I
##fi	I
##des	I
and	O
p	B
##oly	I
##sul	I
##fi	I
##des	I
.	O

The	O
a	B
##cy	I
##l	I
-	I
ethanol	I
##ami	I
##des	I
and	O
2	B
-	I
a	I
##cy	I
##l	I
g	I
##ly	I
##cer	I
##ols	I
have	O
emerged	O
as	O
important	O
end	O
##ogen	O
##ous	O
l	O
##igan	O
##ds	O
of	O
the	O
can	B
##na	I
##bino	I
##id	I
receptors	O
,	O
van	O
##illo	O
##id	O
receptors	O
,	O
and	O
per	O
##ox	O
##is	O
##ome	O
pro	O
##life	O
##rator	O
activated	S
receptors	O
,	O
and	O
their	O
regulated	O
synthesis	O
and	O
degradation	O
impacts	O
sat	O
##iet	O
##y	O
,	O
the	O
##rm	O
##ogen	O
##esis	O
,	O
pain	O
perception	O
,	O
and	O
lip	O
##id	O
metabolism	O
,	O
,	O
In	O
addition	O
,	O
circulating	O
levels	O
of	O
a	B
##cy	I
##let	I
##han	I
##ola	I
##mi	I
##des	I
,	O
but	O
not	O
2	B
-	I
a	I
##rac	I
##hi	I
##don	I
##yl	I
g	I
##ly	I
##cer	I
##ol	I
,	O
are	O
elevated	O
in	O
c	O
##ir	O
##r	O
##hot	O
##ic	O
liver	O
disease	O
and	O
altered	O
by	O
ps	O
##ych	O
##oso	O
##cial	O
stress	O
.	O

Interest	O
##ingly	O
,	O
both	O
try	B
##pt	I
##op	I
##han	I
and	O
k	B
##yn	I
##uren	I
##ine	I
were	O
lower	O
in	O
the	O
plasma	O
from	O
breast	O
cancer	O
patients	O
compared	O
to	O
controls	O
,	O
particularly	O
in	O
women	O
with	O
est	B
##rogen	I
receptor	O
(	O
ER	O
)	O
-	O
negative	O
and	O
stage	O
-	O
3	O
and	O
−	O
##4	O
breast	O
cancer	O
.	O

The	O
acidic	O
pathway	O
starts	O
with	O
26	O
-	O
h	O
##ydro	O
##xy	O
##lation	O
of	O
ch	B
##ole	I
##ster	I
##ol	I
by	O
C	O
##YP	O
##27	O
##A	O
##1	O
,	O
and	O
the	O
24	B
(	B
S	I
)	I
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
pathway	O
by	O
24	O
(	O
S	O
)	O
-	O
h	O
##ydro	O
##xy	O
##lation	O
of	O
ch	B
##ole	I
##ster	I
##ol	I
by	O
C	O
##YP	O
##46	O
##A	O
##1	O
.	O

The	O
plate	O
was	O
washed	O
with	O
0	O
.	O
7	O
m	O
##L	O
2	O
%	O
NH	O
_	O
4	O
OH	O
and	O
0	O
.	O
7	O
m	O
##L	O
Me	B
##OH	I
,	O
then	O
dried	O
with	O
a	O
stream	O
of	O
N	O
_	O
2	O
for	O
5	O
min	O
.	O

As	O
a	O
result	O
,	O
seven	O
“	O
differential	O
meta	O
##bol	O
##ites	O
”	O
were	O
identified	O
,	O
including	O
:	O
PC	B
(	I
40	I
:	I
4	I
)	I
(	O
1	O
)	O
,	O
2	B
-	I
he	I
##xen	I
##oy	I
##l	I
##car	I
##ni	I
##tine	I
(	O
2	O
)	O
,	O
beta	B
-	I
D	I
-	I
g	I
##lu	I
##copy	I
##ran	I
##uron	I
##ic	I
acid	I
(	O
3	O
)	O
,	O
D	B
##G	I
(	I
38	I
:	I
9	I
)	I
(	O
4	O
)	O
,	O
MG	B
(	I
20	I
:	I
3	I
)	I
(	O
5	O
)	O
,	O
L	B
##ys	I
##o	I
##PC	I
(	I
18	I
:	I
2	I
)	I
(	O
6	O
)	O
and	O
L	B
##ys	I
##o	I
##PC	I
(	I
16	I
:	I
0	I
)	I
(	O
7	O
)	O
.	O

For	O
the	O
IS	O
,	O
extraction	O
recovery	O
from	O
high	O
t	B
##rig	I
##ly	I
##cer	I
##ide	I
plasma	O
was	O
performed	O
.	O

That	O
N	O
##R	O
##F	O
##2	O
signaling	O
may	O
be	O
the	O
responsible	O
target	O
for	O
SF	S
is	O
further	O
butt	O
##ressed	O
by	O
our	O
finding	O
that	O
a	O
functional	O
p	O
##oly	O
##mor	O
##phism	O
in	O
the	O
pro	O
##ximal	O
promoter	O
of	O
the	O
N	O
##R	O
##F	O
##2	O
gene	O
(	O
−	O
##6	O
##17	O
)	O
affects	O
rates	O
of	O
SP	O
##MA	O
ex	O
##cre	O
##tion	O
following	O
treatment	O
with	O
the	O
br	O
##occo	O
##li	O
beverage	O
.	O

G	B
##lut	I
##ama	I
##te	I
or	O
g	B
##lut	I
##amine	I
are	O
either	O
directly	O
derived	O
from	O
protein	O
h	O
##ydro	O
##lysis	O
or	O
from	O
star	O
##ch	O
h	O
##ydro	O
##lysis	O
and	O
subsequent	O
T	O
##CA	O
metabolism	O
of	O
g	B
##ly	I
##co	I
##ly	I
##tic	I
ace	I
##ty	I
##l	I
-	I
Co	I
##A	I
.	O

Ph	B
##os	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
with	O
the	O
elemental	O
composition	O
C	O
_	O
40	O
H	O
_	O
78	O
NO	O
_	O
8	O
P	O
was	O
present	O
at	O
higher	O
levels	O
in	O
the	O
I	O
##G	O
##T	O
patients	O
analyzed	O
in	O
this	O
study	O
.	O

Examples	O
demonstrating	O
that	O
I	O
##ER	O
induce	O
##s	O
more	O
subtle	O
and	O
variable	O
changes	O
than	O
continuous	O
energy	O
restriction	O
(	O
CE	O
##R	O
)	O
in	O
breast	O
tissue	O
,	O
both	O
in	O
terms	O
of	O
fat	O
and	O
weight	O
percentage	O
changes	O
and	O
changes	O
in	O
transcription	O
of	O
s	B
##te	I
##aro	I
##yl	I
-	I
Co	I
##A	I
des	O
##at	O
##ura	O
##se	O
(	O
SC	O
##D	O
)	O
(	O
fat	O
synthesis	O
)	O
and	O
al	O
##do	O
##lase	O
C	O
,	O
f	B
##ru	I
##ct	I
##ose	I
-	I
bi	I
##sp	I
##hos	I
##phate	I
(	O
AL	O
##D	O
##OC	O
)	O
(	O
g	O
##ly	O
##co	O
##lysis	O
)	O
.	O

E	B
##stro	I
##gen	I
meta	O
##bol	O
##ites	O
in	O
the	O
2	O
-	O
,	O
4	O
-	O
,	O
and	O
16	O
-	O
h	O
##ydro	O
##xy	O
##lation	O
pathways	O
accounted	O
for	O
approximately	O
12	O
%	O
,	O
3	O
%	O
,	O
and	O
47	O
%	O
,	O
respectively	O
,	O
of	O
total	O
est	O
##rogen	O
##s	O
and	O
est	B
##rogen	I
meta	O
##bol	O
##ites	O
.	O

I	O
##dent	O
##ification	O
of	O
a	O
met	O
##form	O
##in	O
–	O
MG	O
s	O
##ca	O
##venge	O
##d	O
product	O
reveals	O
that	O
met	B
##form	I
##in	I
possesses	O
a	O
potential	O
secondary	O
mechanism	O
of	O
lowering	O
the	O
AG	O
##Es	O
and	O
MG	O
burden	O
.	O

One	O
particularly	O
interesting	O
marker	O
revealed	O
for	O
the	O
first	O
time	O
in	O
the	O
present	O
study	O
that	O
was	O
able	O
to	O
significantly	O
disc	O
##rim	O
##inate	O
all	O
groups	O
from	O
each	O
other	O
was	O
bi	B
##li	I
##ver	I
##din	I
.	O

PC	O
##A	O
was	O
used	O
for	O
preliminary	O
data	O
mining	O
on	O
whole	O
set	O
of	O
an	O
##not	O
##ated	O
peaks	O
from	O
G	O
##C	O
-	O
MS	O
and	O
not	O
an	O
##not	O
##ated	O
peaks	O
from	O
H	O
##IL	O
##IC	O
and	O
R	B
##P	I
L	O
##C	O
-	O
MS	O
in	O
an	O
un	O
##su	O
##per	O
##vise	O
##d	O
fashion	O
.	O

The	O
major	O
cat	O
##ab	O
##olic	O
products	O
of	O
a	B
##rg	I
##ini	I
##ne	I
are	O
or	B
##ni	I
##thin	I
##e	I
and	O
c	B
##it	I
##ru	I
##llin	I
##e	I
.	O

All	O
of	O
these	O
meta	O
##bol	O
##ites	O
are	O
involved	O
in	O
glucose	S
metabolism	O
,	O
amino	O
acid	O
metabolism	O
,	O
or	O
o	O
##xi	O
##da	O
##tive	O
stress	O
.	O

Take	O
##n	O
together	O
,	O
we	O
profile	O
##d	O
the	O
meta	O
##bol	O
##omi	O
##c	O
alterations	O
of	O
pro	O
##state	O
cancer	O
progression	O
revealing	O
sa	B
##rc	I
##os	I
##ine	I
as	O
a	O
potentially	O
important	O
metabolic	O
inter	O
##media	O
##ry	O
of	O
cancer	O
cell	O
invasion	O
and	O
a	O
##gg	O
##ress	O
##ivity	O
.	O

S	B
##phi	I
##ngo	I
##my	I
##elin	I
accumulation	O
has	O
been	O
associated	O
with	O
T	O
##2	O
##DM	O
and	O
observed	O
in	O
mouse	O
models	O
of	O
insulin	O
resistance	O
[	O
,	O
]	O
as	O
well	O
as	O
in	O
the	O
skeletal	O
muscle	O
and	O
serum	O
of	O
o	O
##bes	O
##e	O
,	O
insulin	O
-	O
resistant	O
humans	O
[	O
,	O
,	O
]	O
.	O

In	O
our	O
study	O
,	O
a	O
high	O
level	O
of	O
self	O
-	O
reported	O
physical	O
activity	O
was	O
significantly	O
more	O
common	O
in	O
the	O
N	O
##G	O
##T	O
group	O
,	O
even	O
after	O
B	O
##MI	O
adjustment	O
,	O
and	O
correlated	O
negatively	O
with	O
waist	O
c	O
##ir	O
##cum	O
##ference	O
,	O
H	O
##OM	O
##A	O
-	O
I	O
##R	O
,	O
fast	O
##ing	O
insulin	O
and	O
glucose	S
,	O
and	O
H	O
##b	O
##A	O
##1	O
##c	O
,	O
suggesting	O
a	O
strong	O
prevent	O
##ive	O
or	O
delay	O
##ing	O
effect	O
of	O
I	O
##G	O
##T	O
.	O

After	O
v	O
##ortex	O
##ing	O
,	O
2	O
m	O
##l	O
Me	B
##OH	I
and	O
0	O
.	O
9	O
m	O
##l	O
di	B
##ch	I
##lor	I
##ome	I
##than	I
##e	I
were	O
added	O
.	O

C	O
##rud	O
##e	O
extract	O
##s	O
of	O
plasma	O
from	O
normal	O
and	O
di	O
##abe	O
##tic	O
monkeys	O
under	O
fast	O
##ing	O
and	O
fed	O
conditions	O
were	O
examined	O
by	O
L	O
##CM	O
##S	O
to	O
quantitative	O
##ly	O
assess	O
the	O
differences	O
in	O
the	O
levels	O
of	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
and	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
(	O
,	O
,	O
,	O
)	O
.	O

3	B
-	I
(	I
4	I
,	I
5	I
-	I
dim	I
##eth	I
##yl	I
##thi	I
##az	I
##ol	I
-	I
2	I
-	I
y	I
##l	I
)	I
-	I
2	I
,	I
5	I
-	I
dip	I
##hen	I
##yl	I
##te	I
##tra	I
##zo	I
##lium	I
br	I
##omi	I
##de	I
ass	O
##ay	O
;	O
anal	O
##ges	O
##ic	O
;	O
anti	O
##mic	O
##ro	O
##bial	O
;	O
c	O
##yt	O
##oto	O
##xi	O
##c	O
;	O
G	O
##lin	O
##us	O
op	O
##po	O
##si	O
##ti	O
##fo	O
##lius	O
Lin	O
##n	O
;	O
h	B
##y	I
##po	I
##gly	I
##ce	I
##mic	I
;	O
m	O
##oll	O
##ug	O
##ina	O
##ceae	O
;	O

Val	B
##ine	I
shows	O
a	O
common	O
moderate	O
and	O
strong	O
positive	O
correlation	O
with	O
is	B
##ole	I
##uc	I
##ine	I
in	O
both	O
HC	O
##C	O
cases	O
and	O
c	O
##ir	O
##r	O
##hot	O
##ic	O
controls	O
.	O

The	O
fragment	O
##ation	O
pathway	O
for	O
AM	O
##PP	O
-	O
der	O
##iva	O
##tized	O
Δ	B
_	I
9	I
,	I
12	I
,	I
15	I
18	I
:	I
3	I
FA	I
is	O
presented	O
.	O

Ty	B
##ros	I
##ine	I
was	O
di	O
##lut	O
##ed	O
in	O
h	B
##ydro	I
##ch	I
##lor	I
##ica	I
##cid	I
.	O

The	O
internal	O
stand	O
was	O
des	B
##met	I
##hyl	I
##dia	I
##ze	I
##pa	I
##m	I
m	O
Ki	O
##net	O
##ic	O
analysis	O
for	O
the	O
formation	O
of	O
h	B
##ydro	I
##xy	I
##ana	I
##stro	I
##zo	I
##le	I
from	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
was	O
studied	O
in	O
four	O
different	O
H	O
##LM	O
preparations	O
.	O

A	O
striking	O
observation	O
was	O
the	O
total	O
absence	O
of	O
long	O
chain	O
p	O
##oly	O
##uns	O
##at	O
##ura	O
##ted	O
fatty	O
acids	O
(	O
L	O
##CP	O
##U	O
##FA	O
##s	O
)	O
in	O
G	O
##G	O
##s	O
of	O
the	O
re	O
##tina	O
and	O
brain	O
considering	O
that	O
these	O
tissues	O
contain	O
very	O
high	O
amounts	O
of	O
L	O
##CP	O
##U	O
##FA	O
##s	O
,	O
especially	O
do	B
##cos	I
##ah	I
##ex	I
##aen	I
##oi	I
##c	I
acid	I
(	O
22	O
:	O
6	O
D	O
##HA	O
)	O
:	O
about	O
20	O
and	O
7	O
%	O
of	O
total	O
FA	O
##s	O
in	O
the	O
re	O
##tina	O
and	O
brain	O
c	O
##ere	O
##b	O
##rum	O
,	O
respectively	O
.	O

Given	O
that	O
ta	B
##uri	I
##ne	I
may	O
prevent	O
the	O
ne	O
##uro	O
##to	O
##xi	O
##city	O
of	O
β	B
-	I
am	I
##yl	I
##oid	I
and	O
the	O
ex	O
##ci	O
##to	O
##to	O
##xi	O
##city	O
of	O
g	B
##lut	I
##ama	I
##te	I
,	O
it	O
may	O
be	O
ne	O
##uro	O
##p	O
##rote	O
##ctive	O
for	O
some	O
ne	O
##uro	O
##de	O
##gene	O
##rative	O
diseases	O
.	O

AM	O
##L	O
,	O
acute	O
my	O
##elo	O
##id	O
le	O
##uke	O
##mia	O
;	O
M	O
##U	O
##FA	O
,	O
mon	O
##ou	O
##ns	O
##at	O
##ura	O
##ted	O
fatty	O
acid	O
;	O
C	B
##ML	I
,	O
chronic	O
my	O
##elo	O
##gen	O
##ous	O
le	O
##uke	O
##mia	O
;	O
AL	O
##L	O
,	O
acute	O
l	O
##ymph	O
##ob	O
##lastic	O
le	O
##uke	O
##mia	O
;	O
FA	O
##O	O
,	O
fatty	O
acid	O
oxidation	O
;	O
CP	O
##T	O
##1	O
##a	O
,	O
car	B
##ni	I
##tine	I
palm	I
##itate	I
transfer	O
##ase	O
1	O
##a	O
;	O
SC	O
##D	O
##1	O
,	O
s	O
##te	O
##aro	O
##yl	O
Co	O
##A	O
des	O
##at	O
##ura	O
##se	O
1	O
;	O
FA	O
##B	O
,	O
French	O
-	O
American	O
-	O
British	O
classification	O
;	O
G	O
##CM	O
##S	O
,	O
gas	O
ch	O
##roma	O
##tography	O
–	O
mass	O
s	O
##pect	O
##rome	O
##try	O
;	O
FA	O
##ME	O
,	O
fatty	O
acid	O
met	O
##hyl	O
est	O
##er	O
;	O
PC	O
##A	O
,	O
principal	O
components	O
analysis	O
;	O
P	O
##LS	O
-	O
D	O
##A	O
,	O
projection	O
to	O
late	O
##nt	O
structures	O
-	O
disc	O
##rim	O
##ina	O
##nt	O
analysis	O
;	O
O	O
##PL	O
##S	O
-	O
D	O
##A	O
,	O
or	O
##th	O
##ogo	O
##nal	O
P	O
##LS	O
-	O
D	O
##A	O
;	O
UP	O
##LC	O
-	O
E	O
##SI	O
-	O
Q	O
##TO	O
##FM	O
##S	O
,	O
ultra	O
##per	O
##form	O
##ance	O
liquid	O
ch	O
##roma	O
##tography	O
-	O
electro	O
##sp	O
##ray	O
ion	O
##ization	O
-	O
q	O
##uad	O
##rup	O
##ole	O
time	O
-	O
of	O
-	O
flight	O
mass	O
s	O
##pect	O
##rome	O
##try	O
;	O
E	O
##SI	O
+	O
,	O
electro	O
##sp	O
##ray	O
ion	O
##ization	O
positive	O
mode	O
;	O
E	O
##SI	O
-	O
,	O
electro	O
##sp	O
##ray	O
ion	O
##ization	O
negative	O
mode	O
;	O
P	O
##U	O
##FA	O
,	O
p	O
##oly	O
##uns	O
##at	O
##ura	O
##ted	O
fatty	O
acid	O
;	O
FL	O
##C	O
-	O
Q	O
##q	O
##L	O
##IT	O
-	O
MS	O
,	O
fast	O
liquid	O
ch	O

Sc	O
##hem	O
##atic	O
diagram	O
of	O
the	O
metabolism	O
of	O
p	B
##hos	I
##ph	I
##ory	I
##l	I
##cho	I
##line	I
,	O
L	B
-	I
ace	I
##ty	I
##l	I
##car	I
##ni	I
##tine	I
,	O
a	B
##rac	I
##hi	I
##don	I
##ic	I
acid	I
and	O
g	B
##ly	I
##co	I
##cho	I
##lic	I
acid	I
.	O

Additionally	O
,	O
some	O
abundant	O
non	O
-	O
sugar	O
compounds	O
always	O
present	O
in	O
urine	O
,	O
such	O
as	O
c	B
##rea	I
##tin	I
##ine	I
,	O
were	O
also	O
captured	O
.	O

Ch	O
##roma	O
##tography	O
was	O
carried	O
out	O
on	O
a	O
Ki	O
##net	O
##ex	O
1	O
.	O
7	O
µ	O
##m	O
F	O
##5	O
100	O
Å	O
100	O
×	O
2	O
.	O
1	O
mm	O
column	O
(	O
Ph	O
##eno	O
##men	O
##ex	O
,	O
Tor	O
##rance	O
,	O
CA	O
,	O
USA	O
)	O
using	O
a	O
mobile	O
phase	O
consisting	O
of	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
(	O
solvent	O
A	O
)	O
and	O
met	B
##han	I
##ol	I
(	O
solvent	O
B	O
)	O
.	O

H	B
##ydro	I
##ch	I
##lor	I
##ic	I
acid	I
(	O
HC	O
##l	O
)	O
,	O
sodium	B
chloride	I
(	O
Na	O
##C	O
##l	O
)	O
,	O
all	O
the	O
standards	O
used	O
for	O
V	O
##OM	O
##s	O
confirmation	O
(	O
purity	O
higher	O
than	O
98	O
.	O
5	O
%	O
)	O
and	O
the	O
n	O
-	O
al	O
##kan	O
##es	O
mixture	O
containing	O
C	O
_	O
8	O
–	O
C	O
_	O
20	O
straight	O
-	O
chain	O
al	O
##kan	O
##es	O
in	O
he	B
##xa	I
##ne	I
were	O
obtained	O
from	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
(	O
St	O
.	O
Louis	O
,	O
M	O
##O	O
,	O
USA	O
)	O
.	O

Ser	O
##um	O
insulin	O
,	O
glucose	S
,	O
lip	O
##ids	O
and	O
liver	O
function	O
tests	O
were	O
anal	O
##ys	O
##ed	O
using	O
standard	O
##ised	O
protocols	O
in	O
the	O
Path	O
##W	O
##est	O
Laboratory	O
at	O
Royal	O
Perth	O
Hospital	O
,	O
Perth	O
,	O
Western	O
Australia	O
.	O

Thus	O
,	O
up	O
##take	O
by	O
cancer	O
cells	O
of	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
and	O
g	B
##uan	I
##ine	I
,	O
produced	O
in	O
other	O
tissues	O
or	O
ing	O
##ested	O
,	O
should	O
facilitate	O
pu	B
##rine	I
bio	O
##sy	O
##nt	O
##hesis	O
.	O

(	O
)	O
Three	O
additional	O
so	O
##lut	O
##e	O
derivatives	O
of	O
amino	O
acids	O
that	O
are	O
synthesized	O
in	O
the	O
gut	O
,	O
p	B
##hen	I
##ol	I
su	I
##lf	I
##ate	I
,	O
in	B
##do	I
##lea	I
##ce	I
##tate	I
and	O
3	B
-	I
in	I
##dox	I
##yl	I
su	I
##lf	I
##ate	I
,	O
were	O
elevated	O
in	O
plasma	O
of	O
progress	O
##ors	O
compared	O
to	O
non	O
-	O
progress	O
##ors	O
,	O
however	O
,	O
the	O
differences	O
did	O
not	O
reach	O
statistical	O
significance	O
(	O
see	O
)	O
.	O

However	O
,	O
less	O
polar	O
o	B
##xy	I
##lip	I
##ins	I
were	O
not	O
sufficiently	O
dissolved	O
leading	O
to	O
unacceptable	O
low	O
recover	O
##ies	O
of	O
e	O
.	O
g	O
.	O
,	O
e	B
##pox	I
##y	I
-	I
FA	I
but	O
also	O
mon	B
##oh	I
##ydro	I
##xy	I
-	I
FA	I
.	O

S	O
##pear	O
##man	O
’	O
s	O
ranked	O
correlation	O
analyses	O
were	O
performed	O
between	O
altered	O
meta	O
##bol	O
##ite	O
levels	O
and	O
radio	O
##logical	O
data	O
as	O
well	O
as	O
the	O
E	O
##DS	O
##S	O
and	O
disease	O
duration	S
reported	O
in	O
months	O
in	O
R	O
##R	O
##MS	O
and	O
SP	O
##MS	O
patients	O
.	O

V	O
##ary	O
##ing	O
amounts	O
of	O
the	O
pool	O
##ed	O
met	B
##han	I
##olic	I
extract	O
were	O
then	O
di	O
##spense	O
##d	O
into	O
new	O
micro	O
##cent	O
##ri	O
##fu	O
##ge	O
tubes	O
,	O
and	O
ball	O
##ast	O
##ed	O
with	O
7	B
.	I
5	I
:	I
1	I
Me	I
##OH	I
/	O
H	O
_	O
2	O
O	O
(	O
v	O
/	O
v	O
)	O
for	O
a	O
total	O
volume	O
of	O
700	O
µ	O
##L	O
.	O
The	O
limiting	O
-	O
di	O
##lution	O
and	O
concentration	O
-	O
specific	O
study	O
differed	O
in	O
the	O
volumes	O
of	O
pool	O
##ed	O
met	B
##han	I
##olic	I
extract	O
used	O
,	O
corresponding	O
to	O
different	O
plasma	O
concentrations	O
.	O

Regarding	O
meta	O
##bol	O
##ite	O
sub	O
##c	O
##lass	O
##es	O
,	O
reliability	O
was	O
lowest	O
for	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
both	O
in	O
serum	O
and	O
plasma	O
,	O
as	O
h	B
##ydro	I
##xy	I
##acy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
showed	O
low	O
reliability	O
due	O
to	O
low	O
concentrations	O
.	O

Last	O
##ly	O
,	O
again	O
long	O
-	O
to	O
medium	O
-	O
chain	O
fatty	O
acids	O
and	O
branched	O
chain	O
amino	O
acids	O
,	O
v	B
##ali	I
##ne	I
,	O
le	B
##uc	I
##ine	I
and	O
is	B
##ole	I
##uc	I
##ine	I
,	O
were	O
consistently	O
represented	O
among	O
the	O
serum	O
meta	O
##bol	O
##ites	O
.	O

In	O
addition	O
,	O
associations	O
involving	O
the	O
d	B
##16	I
:	I
1	I
SP	O
##s	O
were	O
more	O
strongly	O
positive	O
across	O
SP	S
classes	O
relative	O
to	O
those	O
with	O
d	B
##18	I
:	I
1	I
or	O
d	B
##18	I
:	I
2	I
s	I
##phi	I
##ngo	I
##id	I
backbone	O
##s	O
.	O

The	O
H	O
##ER	O
##2	O
gene	O
en	O
##codes	O
for	O
a	O
185	O
‐	O
k	O
##D	O
##a	O
t	B
##yr	I
##os	I
##ine	I
kinase	O
g	B
##ly	I
##co	I
##p	I
##rote	I
##in	I
trans	O
##me	O
##mb	O
##rane	O
receptor	O
which	O
is	O
over	O
##ex	O
##pressed	O
in	O
15	O
–	O
25	O
%	O
of	O
breast	O
cancer	O
##s	O
.	O

The	O
peak	O
intensity	O
of	O
each	O
meta	O
##bol	O
##ite	O
was	O
normal	O
##ized	O
to	O
that	O
of	O
the	O
internal	O
standard	O
;	O
i	O
.	O
e	O
.	O
,	O
4	B
-	I
h	I
##ydro	I
##xy	I
##ben	I
##zoic	I
acid	O
-	O
_	O
13	O
C	O
_	O
6	O
-	O
2	O
##TM	O
##S	O
.	O

Individual	O
changes	O
in	O
levels	O
of	O
l	O
##ys	O
##o	O
##PC	O
a	O
C	B
##20	I
:	I
3	I
(	O
Panel	O
A	O
)	O
and	O
PC	B
a	I
##e	I
C	I
##40	I
:	I
3	I
(	O
Panel	O
B	O
)	O
between	O
consecutive	O
samples	O
.	O

(	O
11	O
.	O
1	O
mm	O
##mo	O
##l	O
/	O
L	O
)	O
or	O
higher	O
;	O
(	O
2	O
)	O
in	O
the	O
absence	O
of	O
symptoms	O
,	O
2	O
or	O
more	O
elevated	O
plasma	O
glucose	S
concentrations	O
(	O

The	O
PP	O
##P	O
-	O
connected	O
and	O
N	O
##AC	O
-	O
re	O
##sp	O
##ons	O
##ive	O
accumulation	O
of	O
k	B
##yn	I
##uren	I
##ine	I
and	O
its	O
stimulation	O
of	O
m	O
##TO	O
##R	O
are	O
identified	O
as	O
novel	O
metabolic	O
check	O
##points	O
in	O
l	O
##up	O
##us	O
path	O
##ogen	O
##esis	O
.	O

During	O
the	O
e	O
##T	O
##umour	O
project	O
,	O
after	O
the	O
H	O
##R	O
##MA	O
##S	O
protocol	O
had	O
been	O
completed	O
,	O
samples	O
had	O
been	O
fixed	O
in	O
formal	B
##in	I
,	O
stained	O
with	O
ha	B
##ema	I
##to	I
##xy	I
##lin	I
and	O
e	B
##os	I
##in	I
and	O
sent	O
for	O
his	O
##top	O
##ath	O
##ological	O
review	O
[	O
]	O
.	O

The	O
tentative	O
reference	O
range	O
of	O
the	O
sum	O
of	O
co	B
##rt	I
##is	I
##ol	I
meta	O
##bol	O
##ites	O
.	O

For	O
measurement	O
of	O
total	O
protein	O
amount	O
,	O
the	O
p	O
##elle	O
##t	O
was	O
re	O
##sus	O
##pen	O
##ded	O
in	O
8	O
M	O
u	B
##rea	I
buffer	O
(	O
in	O
50	O
m	O
##M	O
H	O
##EP	O
##ES	O
,	O
pH	O
8	O
.	O
5	O
)	O
.	O

Whether	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
and	O
x	B
##ant	I
##hine	I
levels	O
are	O
altered	O
in	O
urine	O
samples	O
from	O
gas	O
##tro	O
##int	O
##est	O
##inal	O
cancer	O
patients	O
is	O
still	O
a	O
matter	O
of	O
debate	O
.	O

Second	O
,	O
as	O
expected	O
,	O
two	O
##fold	O
-	O
labeled	O
(	O
M	O
##2	O
)	O
er	B
##yt	I
##hr	I
##ito	I
##l	I
is	O
##oto	O
##pol	O
##og	O
##s	O
emerged	O
after	O
addition	O
of	O
the	O
[	B
1	I
,	I
2	I
-	I
_	I
13	I
C	I
_	I
2	I
]	I
glucose	I
trace	O
##r	O
to	O
the	O
blood	O
cells	O
.	O

Typical	O
ca	O
##li	O
##bra	O
##tion	O
curve	O
of	O
a	B
##bir	I
##ater	I
##one	I
(	O
range	O
1	O
–	O
500	O
ng	O
/	O
m	O
##L	O
)	O
.	O

The	O
metabolic	O
compound	O
candidates	O
for	O
the	O
195	O
.	O
08	O
##8	O
##7	O
m	O
/	O
z	O
L	O
##MI	O
were	O
:	O
1	O
)	O
ca	B
##ffe	I
##ine	I
,	O
the	O
most	O
widely	O
consumed	O
ps	O
##ych	O
##ost	O
##im	O
##ula	O
##nt	O
drug	O
,	O
and	O
2	O
)	O
en	B
##p	I
##ro	I
##fy	I
##llin	I
##e	I
,	O
which	O
is	O
used	O
for	O
treatment	O
of	O
as	O
##th	O
##ma	O
and	O
chronic	O
o	O
##bs	O
##truct	O
##ive	O
pulmonary	O
disease	O
,	O
and	O
for	O
the	O
management	O
of	O
c	O
##ere	O
##bro	O
##vas	O
##cular	O
ins	O
##uff	O
##iciency	O
,	O
sick	O
##le	O
cell	O
disease	O
,	O
and	O
di	O
##abe	O
##tic	O
ne	O
##uro	O
##pathy	O
.	O

The	O
Mill	O
##ip	O
##ore	O
Se	O
##Q	O
##uant	O
Z	O
##ic	O
-	O
H	O
##IL	O
##IC	O
(	O
2	O
.	O
1	O
×	O
100	O
mm	O
,	O
3	O
.	O
5	O
μ	O
##m	O
)	O
column	O
was	O
used	O
with	O
mobile	O
phase	O
A	O
and	O
B	O
being	O
9	O
:	O
1	O
and	O
1	O
:	O
9	O
(	O
water	O
:	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
,	O
buffer	O
##ed	O
with	O
5	O
m	O
##M	O
am	B
##mon	I
##ium	I
format	O
##e	O
)	O
,	O
respectively	O
.	O

Ce	B
##ram	I
##ide	I
expression	O
has	O
been	O
detected	O
in	O
patients	O
with	O
em	O
##phy	O
##se	O
##ma	O
and	O
chronic	O
-	O
o	O
##bs	O
##truct	O
##ive	O
pulmonary	O
disease	O
.	O

S	O
##put	O
##um	O
and	O
peripheral	O
blood	O
meta	O
##bol	O
##ites	O
were	O
analyzed	O
according	O
to	O
the	O
procedure	O
as	O
described	O
in	O
the	O
previously	O
published	O
meta	O
##bol	O
##omi	O
##cs	O
pro	O
##fi	O
##ling	O
methods	O
.	O
_	O
,	O
B	O
##rief	O
##ly	O
,	O
the	O
th	O
##awed	O
s	O
##put	O
##um	O
and	O
serum	O
were	O
extracted	O
with	O
met	B
##han	I
##ol	I
following	O
v	O
##ortex	O
for	O
30	O
seconds	O
.	O

All	O
u	O
##rina	O
##ry	O
measurements	O
were	O
expressed	O
per	O
mg	O
c	B
##rea	I
##tin	I
##ine	I
to	O
adjust	O
for	O
urine	O
volume	O
.	O

fast	O
##ing	O
plasma	O
glucose	S
of	O
≥	O
126	O
##m	O
##d	O
/	O
d	O
##L	O
[	O
7	O
.	O
0	O
mm	O
##ol	O
/	O
L	O
]	O
,	O
random	O
plasma	O
glucose	S
≥	O
200	O
mg	O
/	O
d	O
##L	O

The	O
formation	O
of	O
this	O
artifact	O
might	O
have	O
been	O
occurred	O
within	O
the	O
ion	O
source	O
while	O
using	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
as	O
an	O
el	O
##uen	O
##t	O
or	O
after	O
terminating	O
the	O
in	O
##cu	O
##bation	O
with	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
.	O

The	O
accumulation	O
of	O
K	O
##yn	O
may	O
be	O
a	O
result	O
of	O
decreased	O
cat	O
##ab	O
##olis	O
##m	O
by	O
K	O
##yn	O
h	O
##ydro	O
##xy	O
##lase	O
owing	O
to	O
N	B
##AD	I
##P	I
##H	I
dependence	O
of	O
this	O
enzyme	O
(	O
Breton	O
et	O
al	O
.	O
)	O
.	O

Car	B
##nos	I
##ine	I
has	O
been	O
shown	O
to	O
reduce	O
oxidation	O
and	O
g	O
##ly	O
##cation	O
of	O
low	O
density	O
lip	O
##op	O
##rote	O
##in	O
hence	O
improving	O
d	O
##ys	O
##lip	O
##idae	O
##mia	O
in	O
rode	O
##nts	O
.	O

Met	B
##hyl	I
##do	I
##pa	I
is	O
known	O
to	O
be	O
an	O
a	O
##romatic	O
-	O
amino	O
-	O
acid	O
de	O
##car	O
##box	O
##yla	O
##se	O
(	O
AA	O
##DC	O
)	O
inhibitor	O
in	O
animals	O
and	O
in	O
humans	O
.	O

Taking	O
u	B
##rea	I
as	O
an	O
example	O
,	O
its	O
relative	O
intensity	O
increased	O
in	O
the	O
pre	O
-	O
dial	O
##ys	O
##is	O
groups	O
versus	O
controls	O
(	O
17	O
.	O
30	O
±	O
3	O
.	O
68	O
in	O
pre	O
-	O
H	O
##F	O
##D	O
,	O
FC	O
=	O
3	O
.	O
74	O
and	O
17	O
.	O
90	O
±	O
3	O
.	O
28	O
in	O
pre	O
-	O
HD	O
,	O
FC	O
=	O
3	O
.	O
86	O
vs	O
.	O
4	O
.	O
63	O
±	O
1	O
.	O
12	O
in	O
control	O
)	O
and	O
then	O
dramatically	O
decreased	O
to	O
7	O
.	O
87	O
±	O
2	O
.	O
36	O
in	O
post	O
-	O
H	O
##F	O
##D	O
,	O
FC	O
=	O
1	O
.	O
70	O
and	O
7	O
.	O
66	O
±	O
1	O
.	O
92	O
in	O
post	O
-	O
HD	O
,	O
FC	O
=	O
1	O
.	O
66	O
.	O

Op	O
##ti	O
##mi	O
##zation	O
of	O
sample	O
preparation	O
according	O
to	O
recovery	O
was	O
also	O
performed	O
,	O
varying	O
volumes	O
of	O
M	B
##T	I
##BE	I
,	O
as	O
well	O
as	O
evaluating	O
acidic	O
and	O
neutral	O
re	O
##con	O
##st	O
##itution	O
solutions	O
.	O

A	O
##pop	O
##tosis	O
of	O
ad	O
##ip	O
##ocytes	O
(	O
or	O
lip	O
##oly	O
##sis	O
,	O
another	O
limo	B
##nen	I
##e	I
effect	O
)	O
,	O
would	O
also	O
increase	O
circulating	O
lip	O
##ids	O
and	O
ch	B
##ole	I
##ster	I
##ol	I
.	O

Met	O
##ab	O
##olo	O
##mic	O
statistical	O
analyses	O
were	O
performed	O
on	O
all	O
continuous	O
variables	O
using	O
the	O
St	O
##ati	O
##stic	O
##a	O
Data	B
##M	I
##iner	I
software	O
version	O
7	O
.	O
1	O
.	O

The	O
17	B
##β	I
-	I
E	I
_	I
2	I
S	I
/	I
2	I
-	I
Me	I
##O	I
-	I
E	I
_	I
1	I
ratio	O
was	O
0	O
.	O
8	O
±	O
0	O
.	O
03	O
in	O
BP	O
##A	O
treated	O
cells	O
,	O
whereas	O
was	O
decreased	O
at	O
0	O
.	O
6	O
±	O
0	O
.	O
02	O
##5	O
in	O
Si	O
##l	O
and	O
BP	O
##A	O
/	O
Si	O
##l	O
treated	O
cells	O
.	O

Of	O
the	O
20	O
meta	O
##bol	O
##ites	O
identified	O
to	O
shift	O
with	O
ps	O
##oria	O
##sis	O
,	O
only	O
c	B
##ys	I
##tat	I
##hi	I
##oni	I
##ne	I
and	O
c	B
##ys	I
##tine	I
were	O
not	O
normal	O
##ized	O
to	O
healthy	O
levels	O
following	O
E	O
##tan	O
##er	O
##ce	O
##pt	O
treatment	O
(	O
Table	O
2	O
and	O
Figure	O
)	O
.	O

Meanwhile	O
,	O
the	O
levels	O
of	O
2	B
-	I
he	I
##xen	I
##oy	I
##l	I
##car	I
##ni	I
##tine	I
(	O
2	O
)	O
and	O
beta	B
-	I
D	I
-	I
g	I
##lu	I
##copy	I
##ran	I
##uron	I
##ic	I
acid	I
(	O
3	O
)	O
were	O
significantly	O
increased	O
in	O
AI	O
##S	O
group	O
.	O

Furthermore	O
,	O
the	O
second	O
strongest	O
g	O
##ly	O
##cine	O
-	O
associated	O
S	O
##NP	O
r	O
##s	O
##10	O
##47	O
##8	O
##9	O
##1	O
causes	O
a	O
non	O
-	O
synonymous	O
mutation	O
(	O
T	O
##hr	O
>	O
As	O
##n	O
)	O
in	O
the	O
C	O
-	O
terminal	O
domain	O
of	O
the	O
CP	O
##S	O
##1	O
p	O
##oly	O
##pe	O
##pt	O
##ide	O
,	O
which	O
hosts	O
the	O
binding	O
site	O
for	O
the	O
all	O
##ost	O
##eric	O
act	O
##iva	O
##tor	O
N	B
-	I
act	I
##ey	I
##l	I
-	I
L	I
-	I
g	I
##lut	I
##ama	I
##te	I
(	O
N	O
##AG	O
)	O
.	O

Indeed	O
,	O
both	O
c	O
##yt	O
##oki	O
##nes	O
contribute	O
to	O
the	O
m	O
##od	O
##ulation	O
of	O
the	O
patients	O
’	O
immune	O
system	O
,	O
involved	O
in	O
the	O
response	O
to	O
t	O
##ras	O
##tu	O
##zu	O
##ma	O
##b	O
,	O
taxa	B
##nes	I
as	O
well	O
as	O
ho	O
##rmon	O
##al	O
therapy	O
.	O

In	O
fully	O
-	O
adjusted	O
model	O
(	O
MV	O
##2	O
)	O
,	O
all	B
##ant	I
##oi	I
##n	I
when	O
modelled	O
as	O
q	O
##ua	O
##rt	O
##ile	O
,	O
was	O
significantly	O
associated	O
with	O
lower	O
T	O
##2	O
##D	O
risk	O
[	O
H	O
##R	O
in	O
the	O
highest	O
versus	O
lowest	O
q	O
##ua	O
##rt	O
##ile	O
was	O
0	O
.	O
44	O
(	O
95	O
%	O
C	O
##I	O
0	O
.	O
25	O
–	O
0	O
.	O
80	O
)	O
.	O

A	O
panel	O
consisting	O
of	O
pseudo	B
##uri	I
##dine	I
,	O
ma	B
##lic	I
acid	I
,	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
,	O
3	B
,	I
4	I
-	I
di	I
##hy	I
##dr	I
##ox	I
##y	I
##but	I
##yric	I
acid	I
,	O
f	B
##ru	I
##ct	I
##ose	I
and	O
in	B
##os	I
##ito	I
##l	I
was	O
identified	O
.	O

Similarly	O
plasma	O
concentrations	O
of	O
and	B
##ros	I
##ten	I
##ed	I
##ione	I
,	O
al	B
##dos	I
##tero	I
##ne	I
and	O
co	B
##rt	I
##ison	I
##e	I
were	O
also	O
lower	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
in	O
post	O
##men	O
##op	O
##aus	O
##al	O
women	O
than	O
in	O
all	O
other	O
groups	O
,	O
though	O
differences	O
were	O
of	O
only	O
a	O
small	O
to	O
moderate	O
magnitude	O
(	O
18	O
%	O
to	O
44	O
%	O
)	O
.	O

P	O
##las	O
##ma	O
was	O
extracted	O
in	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
and	O
applied	O
to	O
an	O
A	O
##c	O
##qui	O
##ty	O
UP	O
##LC	O
H	O
##IL	O
##IC	O
(	O
1	O
.	O
7	O
##μ	O
##m	O
x	O
2	O
.	O
1	O
x	O
100	O
mm	O
)	O
column	O
coupled	O
to	O
a	O
X	O
##evo	O
G	O
##2	O
Q	O
##T	O
##of	O
mass	O
s	O
##pect	O
##rome	O
##ter	O
using	O
a	O
previously	O
op	O
##ti	O
##mise	O
##d	O
method	O
.	O

The	O
reported	O
increase	O
of	O
la	B
##ctic	I
acid	I
in	O
long	O
-	O
term	O
stability	O
studies	O
was	O
only	O
observed	O
in	O
Ex	O
##p	O
.	O

Our	O
results	O
are	O
consistent	O
with	O
other	O
literature	O
in	O
finding	O
positive	O
correlation	O
##s	O
between	O
circulating	O
est	B
##rogen	I
levels	O
and	O
B	O
##MI	O
in	O
post	O
-	O
men	O
##op	O
##aus	O
##al	O
women	O
(	O
,	O
-	O
)	O
;	O
others	O
have	O
not	O
examined	O
correlation	O
##s	O
for	O
the	O
full	O
range	O
of	O
est	O
##rogen	O
##s	O
and	O
est	B
##rogen	I
meta	O
##bol	O
##ites	O
.	O

An	O
al	O
##iq	O
##uo	O
##t	O
of	O
100	O
μ	O
L	O
of	O
serum	O
was	O
mixed	O
with	O
400	O
μ	O
L	O
of	O
a	O
mixture	O
of	O
met	B
##han	I
##ol	I
and	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
[	O
5	O
:	O
3	O
,	O
(	O
containing	O
0	O
.	O
1	O
mg	O
/	O
m	O
##L	O

The	O
cartridge	O
was	O
then	O
washed	O
with	O
the	O
following	O
solutions	O
(	O
%	O
in	O
H	O
_	O
2	O
O	O
)	O
:	O
1	O
m	O
##L	O
of	O
2	O
%	O
NH	O
_	O
4	O
OH	O
,	O
1	O
m	O
##L	O
Me	B
##OH	I
,	O
1	O
m	O
##L	O
2	O
%	O
HC	O
##O	O
##OH	O
,	O
1	O
m	O
##L	O
30	O
%	O
Me	B
##OH	I
and	O
2	O
%	O
HC	O
##O	O
##OH	O
,	O
1	O
m	O
##L	O
50	O
%	O
Me	B
##OH	I
and	O
2	O
%	O
HC	O
##O	O
##OH	O
.	O

Therefore	O
,	O
a	O
sensitive	O
L	O
##C	O
/	O
MS	O
/	O
MS	O
analytical	O
method	O
was	O
developed	O
to	O
identify	O
and	O
q	O
##uant	O
##ify	O
human	O
metabolism	O
of	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
.	O

Inc	O
##reased	O
levels	O
of	O
pro	B
##line	I
,	O
or	B
##ni	I
##thin	I
##e	I
,	O
c	B
##it	I
##ru	I
##llin	I
##e	I
,	O
and	O
a	B
##rg	I
##ini	I
##ne	I
have	O
been	O
found	O
in	O
the	O
v	O
##it	O
##re	O
##ous	O
of	O
patients	O
with	O
PD	O
##R	O
,	O
and	O
elevations	O
in	O
serum	O
a	B
##rg	I
##ini	I
##ne	I
were	O
discovered	O
in	O
patients	O
with	O
severe	O
DR	O
.	O

ET	O
##r	O
##A	O
acid	O
=	O
5	O
,	O
8	O
,	O
11	O
-	O
E	O
##ico	O
##sat	O
##rien	O
##oi	O
##c	O
acid	O
;	O
D	O
##HA	O
=	O
do	O
##cos	O
##ah	O
##ex	O
##aen	O
##oi	O
##c	O
acid	O
;	O
N	B
##AA	I
##G	I
=	I
N	I
-	I
Ace	I
##ty	I
##lasp	I
##art	I
##yl	I
##g	I
##lut	I
##ami	I
##c	I
acid	I
;	O
L	B
##ys	I
##o	I
##PC	I
=	I
l	I
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
;	O
P	B
##I	I
=	I
p	I
##hos	I
##pha	I
##ti	I
##dy	I
##lino	I
##si	I
##to	I
##l	I
;	O
T	B
##CA	I
=	I
t	I
##rica	I
##rb	I
##ox	I
##yl	I
##ic	I
acid	I
.	O

Solid	O
lines	O
represent	O
mean	O
24	B
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
concentrations	O
estimated	O
using	O
locally	O
-	O
weighted	O
s	O
##cat	O
##ter	O
##p	O
##lot	O
smooth	O
##ing	O
(	O
L	O
##OW	O
##ES	O
##S	O
)	O
among	O
subgroup	O
##s	O
defined	O
by	O
co	O
##hor	O
##t	O
(	O
Panel	O
A	O
)	O
or	O
category	O
of	O
estimated	O
G	O
##F	O
##R	O
(	O
Panel	O
B	O
)	O
.	O

In	O
either	O
case	O
,	O
higher	O
levels	O
of	O
these	O
biological	O
##ly	O
active	O
compounds	O
mediated	O
by	O
O	O
##EP	O
ing	O
##est	O
##ion	O
warrant	O
further	O
investigation	O
in	O
acute	O
or	O
post	O
-	O
p	O
##rand	O
##ial	O
studies	O
specifically	O
targeting	O
L	B
##D	I
##L	I
ch	I
##ole	I
##ster	I
##ol	I
oxidation	O
and	O
cognitive	O
function	O
.	O

After	O
receiving	O
re	O
##ind	O
##uction	O
therapy	O
with	O
AT	O
##RA	O
,	O
second	O
CR	O
was	O
obtained	O
,	O
followed	O
by	O
two	O
7	O
-	O
day	O
course	O
of	O
consolidation	O
ch	O
##em	O
##otherapy	O
comprising	O
mit	B
##ox	I
##ant	I
##rone	I
6	O
mg	O
/	O
m	O
_	O
2	O
in	O
##tra	O
##ven	O
##ous	O
(	O
IV	O
)	O
b	O
##ol	O
##us	O
from	O
day	O
5	O
to	O
7	O
,	O
et	B
##op	I
##os	I
##ide	I
100	O
mg	O
/	O
m	O
_	O
2	O
IV	O
administration	O
for	O
1	O
h	O
from	O
day	O
1	O
to	O
day	O
5	O
,	O
and	O
c	O
##yt	O
##ara	O
##bine	O
(	O
Ara	O
-	O
C	O
)	O

P	O
##las	O
##ma	O
concentrations	O
of	O
14	O
anti	O
##mal	O
##aria	O
##l	O
drugs	O
and	O
their	O
meta	O
##bol	O
##ites	O
,	O
i	O
.	O
e	O
.	O
art	O
##em	O
##eth	O
##er	O
,	O
art	B
##es	I
##unate	I
,	O
di	B
##hy	I
##dr	I
##oar	I
##tem	I
##isi	I
##nin	I
,	O
am	O
##od	O
##ia	O
##quin	O
##e	O
,	O
N	B
-	I
des	I
##eth	I
##yl	I
-	I
am	I
##od	I
##ia	I
##quin	I
##e	I
,	O
l	O
##ume	O
##fant	O
##rine	O
,	O
des	B
##but	I
##yl	I
-	I
l	I
##ume	I
##fant	I
##rine	I
,	O
pipe	B
##ra	I
##quin	I
##e	I
,	O
p	B
##yr	I
##ona	I
##rid	I
##ine	I
,	O
me	B
##f	I
##lo	I
##quin	I
##e	I
,	O
ch	B
##lor	I
##o	I
##quin	I
##e	I
,	O
q	O
##uin	O
##ine	O
,	O
p	B
##yr	I
##ime	I
##tham	I
##ine	I
and	O
su	B
##lf	I
##ado	I
##xin	I
##e	I
,	O
were	O
determined	O
by	O
liquid	O
ch	O
##roma	O
##tography	O
coupled	O
to	O
tandem	O
triple	O
stage	O
mass	O
s	O
##pect	O
##rome	O
##try	O
(	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
)	O
.	O

We	O
included	O
adults	O
(	O
>	O
18	O
years	O
old	O
)	O
with	O
an	O
admission	O
S	O
##O	O
##FA	O
score	O
≥	O
6	O
and	O
art	O
##erial	O
la	B
##ct	I
##ate	I
≥	O
2	O
mm	O
##ol	O
/	O

We	O
aimed	O
to	O
explore	O
the	O
potential	O
A	O
##ER	O
##D	O
bio	O
##mark	O
##ers	O
by	O
conducting	O
lip	O
##ido	O
##mic	O
##s	O
targeting	O
SL	S
meta	O
##bol	O
##ites	O
.	O

Ser	O
##um	O
al	B
##dos	I
##tero	I
##ne	I
to	O
plasma	O
re	O
##nin	O
ratio	O
was	O
determined	O
to	O
screen	O
for	O
primary	O
al	O
##dos	O
##tero	O
##nis	O
##m	O
,	O
serum	O
de	B
##hy	I
##dr	I
##o	I
-	I
e	I
##pian	I
##dr	I
##osterone	I
##sul	I
##fa	I
##te	I
(	O
D	O
##H	O
##EA	O
##S	O
)	O
,	O
and	O
test	B
##osterone	I
were	O
measured	O
to	O
demonstrate	O
h	O
##yper	O
##and	O
##rogen	O
##ism	O
(	O
cut	O
-	O
off	O
values	O
based	O
on	O
individual	O
age	O
and	O
gender	O
-	O
related	O
upper	O
reference	O
limits	O
)	O
.	O

The	O
proteins	O
were	O
separated	O
by	O
sodium	B
do	I
##de	I
##cy	I
##l	I
su	I
##lf	I
##ate	I
-	I
p	I
##oly	I
##ac	I
##ryl	I
##ami	I
##de	I
gel	O
electro	O
##ph	O
##ores	O
##is	O
(	O
SD	O
##S	O
-	O
PA	O
##GE	O
)	O
using	O
N	O
##u	O
##PA	O
##GE	O
4	O
–	O
12	O
%	O

Con	O
##cent	O
##ration	O
variations	O
were	O
more	O
extreme	O
in	O
R	O
##T	O
conditions	O
than	O
at	O
4	O
°C	O
,	O
as	O
observed	O
for	O
the	O
decrease	O
of	O
as	B
##cor	I
##bic	I
acid	I
levels	O
(	O
Fi	O
##g	O
.	O
)	O
.	O

HP	O
##LC	O
-	O
grade	O
et	B
##hyl	I
ace	I
##tate	I
(	O
E	O
##t	O
##OA	O
##c	O
)	O
and	O
n	B
-	I
but	I
##ano	I
##l	I
(	O
n	O
-	O
B	O
##u	O
##OH	O
)	O
were	O
obtained	O
from	O
Beijing	O
Chemical	O
Works	O
(	O
Beijing	O
,	O
China	O
)	O
.	O

Our	O
findings	O
indicated	O
that	O
patients	O
with	O
early	O
stage	O
N	O
##SC	O
##LC	O
(	O
stage	O
I	O
##A	O
–	O
II	O
##B	O
)	O
exhibited	O
different	O
serum	O
levels	O
of	O
such	O
meta	O
##bol	O
##ite	O
classes	O
as	O
amino	O
acids	O
and	O
their	O
derivatives	O
,	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
,	O
and	O
organic	O
acids	O
as	O
compared	O
with	O
a	O
healthy	O
control	O
group	O
(	O
Table	O
)	O
.	O

Two	O
serum	O
lip	O
##id	O
classes	O
that	O
are	O
known	O
to	O
participate	O
in	O
inflammatory	O
response	O
are	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
(	O
LP	O
##C	O
)	O
and	O
plate	O
##let	O
-	O
act	O
##ivating	O
factor	O
(	O
PA	O
##F	O
)	O
.	O

Unfortunately	O
,	O
plasma	O
concentrations	O
of	O
vitamin	B
B	I
##2	I
were	O
not	O
assessed	O
in	O
the	O
present	O
study	O
and	O
hence	O
we	O
can	O
only	O
s	O
##pec	O
##ulate	O
about	O
the	O
end	O
##ogen	O
##ous	O
availability	O
of	O
vitamin	B
B	I
##2	I
.	O

m	O
m	O
m	O
β	B
-	I
A	I
##po	I
-	I
13	I
-	I
car	I
##ote	I
##non	I
##e	I
is	O
a	O
potent	O
antagonist	O
of	O
re	B
##tino	I
##ic	I
acid	I
receptor	O
-	O
mediated	O
induction	O
of	O
reporter	O
gene	O
expression	O
and	O
blocks	O
AT	O
##RA	O
induction	O
of	O
end	O
##ogen	O
##ous	O
gene	O
expression	O
.	O

Sam	O
##ples	O
were	O
re	O
##con	O
##stituted	O
with	O
50	O
μ	O
##L	O
of	O
5	O
%	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
for	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
analysis	O
.	O

As	O
a	O
major	O
class	O
of	O
ma	O
##mmal	O
##ian	O
lip	O
##ids	O
,	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
(	O
PC	O
##s	O
)	O
often	O
contain	O
mixture	O
##s	O
of	O
structural	O
is	O
##omer	O
##s	O
,	O
resulting	O
from	O
different	O
lip	O
##ogen	O
##esis	O
pathways	O
.	O

Total	O
levels	O
of	O
Ce	B
##ram	I
##ides	I
in	O
human	O
ca	O
##da	O
##ver	O
corn	O
##eas	O
from	O
Health	O
##y	O
,	O
T	O
##1	O
##DM	O
,	O
and	O
T	O
##2	O
##DM	O
donors	O
.	O

We	O
identified	O
alterations	O
in	O
l	O
##ys	O
##o	O
##PC	O
##s	O
,	O
amid	B
##es	I
,	O
and	O
c	B
##is	I
-	I
4	I
-	I
o	I
##ct	I
##ened	I
##io	I
##ic	I
acid	I
among	O
non	O
-	O
di	O
##abe	O
##tic	O
and	O
non	O
-	O
o	O
##bes	O
##e	O
individuals	O
with	O
border	O
##line	O
-	O
to	O
-	O
moderate	O
H	O
##T	O
##G	O
.	O

The	O
same	O
chain	O
also	O
re	O
##ox	O
##id	O
##izes	O
c	O
##yt	O
##oso	O
##lic	O
N	B
##AD	I
##H	I
produced	O
by	O
g	O
##ly	O
##co	O
##lysis	O
,	O
and	O
transported	O
into	O
the	O
mit	O
##och	O
##ond	O
##ria	O
via	O
the	O
ma	B
##late	I
-	I
as	I
##par	I
##tate	I
shuttle	O
(	O
c	O
##f	O
.	O

Co	O
##mb	O
##ination	O
of	O
L	B
-	I
c	I
##it	I
##ru	I
##llin	I
##e	I
and	O
D	B
-	I
as	I
##par	I
##tic	I
acid	I
for	O
B	O
##D	O
##TT	O
diagnosis	O
has	O
high	O
sensitivity	O
and	O
specific	O
##ity	O
.	O

Based	O
on	O
our	O
earlier	O
findings	O
that	O
E	O
##Z	O
##H	O
##2	O
over	O
-	O
expression	O
in	O
ben	O
##ign	O
cells	O
could	O
media	O
##te	O
cell	O
invasion	O
and	O
neo	O
##p	O
##lastic	O
progression	O
_	O
,	O
_	O
,	O
,	O
sa	B
##rc	I
##os	I
##ine	I
levels	O
were	O
assessed	O
upon	O
m	O
##od	O
##ulation	O
of	O
E	O
##Z	O
##H	O
##2	O
expression	O
.	O

G	B
##S	I
##H	I
,	O
G	O
##SS	O
##H	O
,	O
Cy	O
##s	O
,	O
Cy	O
##s	O
##SS	O
##H	O
,	O
G	O
##SS	O
##G	O
,	O
G	O
##SS	O
##S	O
##H	O
and	O
c	B
##ys	I
##tine	I
were	O
all	O
detected	O
in	O
the	O
plasma	O
of	O
both	O
D	O
##M	O
patients	O
(	O
n	O
=	O
7	O
)	O
and	O
controls	O
(	O
n	O
=	O
7	O
)	O
.	O

Since	O
these	O
were	O
not	O
brain	O
t	O
##umour	O
##s	O
,	O
N	O
##AA	O
and	O
N	B
##AA	I
##G	I
were	O
omitted	O
from	O
the	O
analysis	O
;	O
instead	O
,	O
c	B
##it	I
##rate	I
,	O
p	B
##oly	I
##amine	I
##s	I
and	O
p	B
##hos	I
##ph	I
##oc	I
##rea	I
##tine	I
(	O
PC	O
##r	O
)	O
signals	O
were	O
simulated	O
.	O

E	O
##M	O
levels	O
were	O
expressed	O
in	O
p	O
##ico	O
##mo	O
##les	O
per	O
mill	O
##ig	O
##ram	O
c	B
##rea	I
##tin	I
##ine	I
(	O
which	O
was	O
measured	O
in	O
the	O
same	O
samples	O
)	O
and	O
were	O
grouped	O
and	O
sum	O
##med	O
by	O
metabolic	O
pathways	O
.	O

Other	O
anal	O
##ges	O
##ics	O
such	O
as	O
i	B
##bu	I
##p	I
##ro	I
##fen	I
are	O
used	O
commonly	O
in	O
Western	O
countries	O
;	O
for	O
example	O
,	O
in	O
the	O
United	O
Kingdom	O
,	O
total	O
i	B
##bu	I
##p	I
##ro	I
##fen	I
sales	O
of	O
46	O
tons	O
were	O
reported	O
in	O
2000	O
.	O

These	O
data	O
support	O
the	O
notion	O
that	O
these	O
less	O
polar	O
derivatives	O
bind	O
less	O
avid	O
##ly	O
to	O
water	O
and	O
met	B
##han	I
##ol	I
,	O
f	O
##ac	O
##ilitating	O
des	O
##ol	O
##vation	O
and	O
increasing	O
transmission	O
of	O
ions	O
into	O
the	O
mass	O
s	O
##pect	O
##rome	O
##ter	O
.	O

St	O
##rik	O
##ingly	O
,	O
test	O
of	O
significance	O
for	O
CR	O
##C	O
vs	O
NC	O
(	O
based	O
on	O
p	O
-	O
value	O
and	O
fold	O
change	O
cut	O
-	O
offs	O
)	O
,	O
yielded	O
8	O
of	O
the	O
10	O
meta	O
##bol	O
##ites	O
as	O
being	O
significant	O
and	O
the	O
direction	O
of	O
regulation	O
was	O
also	O
con	O
##cor	O
##dant	O
as	O
in	O
NC	O
vs	B
PC	I
(	O
as	O
##par	O
##agi	O
##ne	O
and	O
th	B
##re	I
##oni	I
##ne	I
were	O
non	O
-	O
significant	O
)	O
.	O

T	B
##MA	I
##O	I
and	O
d	O
##9	O
-	O
T	O
##MA	O
##O	O
were	O
monitored	O
in	O
positive	O
-	O
ion	O
mode	O
with	O
multiple	O
reaction	O
monitoring	O
of	O
precursor	O
and	O
characteristic	O
product	O
-	O
ion	O
transitions	O
of	O
m	O
/	O
z	O
76	O
##→	O
##5	O
##8	O
and	O
85	O
##→	O
##6	O
##6	O
,	O
respectively	O
.	O

Lower	O
concentrations	O
of	O
CS	O
##F	O
h	B
##ydro	I
##phi	I
##lic	I
compounds	O
were	O
observed	O
in	O
MS	O
patients	O
as	O
compared	O
to	O
control	O
group	O
.	O

For	O
instance	O
,	O
there	O
is	O
conflicting	O
information	O
regarding	O
the	O
concentration	O
changes	O
of	O
c	B
##ys	I
##tein	I
##e	I
(	O
,	O
,	O
)	O
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
(	O
,	O
)	O
,	O
and	O
ta	B
##uri	I
##ne	I
(	O
,	O
,	O
)	O
toward	O
the	O
end	O
of	O
pregnancy	O
.	O

Interest	O
##ingly	O
,	O
among	O
the	O
met	B
##hyl	I
##ated	I
a	I
##rg	I
##ini	I
##ne	I
parameters	O
examined	O
(	O
i	O
##e	O
AD	B
##MA	I
,	O
SD	O
##MA	O
,	O
MMA	O
and	O
A	O
##rg	O
##MI	O
)	O
,	O
the	O
integrated	O
met	O
##hyl	O
##ation	O
index	O
,	O
A	O
##rg	O
##MI	O
,	O
remained	O
the	O
most	O
robust	O
independent	O
predict	O
##or	O
of	O
significantly	O
o	O
##bs	O
##truct	O
##ive	O
CA	O
##D	O
status	O
after	O
adjustments	O
for	O
traditional	O
risk	O
factors	O
,	O
re	O
##nal	O
function	O
,	O
and	O
h	O
##s	O
##CR	O
##P	O
,	O
demonstrating	O
odds	O
ratios	O
of	O
[	O
adjusted	O
OR	O
(	O
95	O
%	O
C	O
##I	O
)	O
:	O
1	O
.	O
63	O
(	O
1	O
.	O
09	O
-	O
2	O
.	O
46	O
)	O
,	O
p	O
=	O
0	O
.	O
01	O
##9	O
]	O
for	O
the	O
third	O
q	O
##ua	O
##rt	O
##ile	O
and	O
[	O
adjusted	O
OR	O
(	O
95	O
%	O
C	O
##I	O
)	O
:	O
2	O
.	O
64	O
(	O
1	O
.	O
71	O
-	O
4	O
.	O
08	O
)	O
,	O
p	O
<	O
0	O
.	O
00	O
##1	O
]	O
for	O
fourth	O
q	O
##ua	O
##rt	O
##ile	O
.	O

In	O
the	O
patients	O
with	O
s	O
##chi	O
##zophrenia	O
,	O
g	B
##ly	I
##cine	I
(	O
A	O
)	O
concentration	O
trend	O
##ed	O
lower	O
but	O
was	O
increased	O
in	O
o	O
##bes	O
##e	O
B	O
##MI	O
controls	O
compared	O
with	O
non	O
##obe	O
##se	O
B	O
##MI	O
controls	O
(	O
B	O
)	O
.	O

And	O
then	O
the	O
12	O
an	O
##not	O
##ated	O
differential	O
meta	O
##bol	O
##ites	O
,	O
which	O
were	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
l	B
##ino	I
##le	I
##ic	I
acid	I
,	O
g	B
##ly	I
##cine	I
,	O
al	B
##ani	I
##ne	I
,	O
but	B
##ane	I
##dio	I
##ic	I
acid	I
,	O
la	B
##ctic	I
acid	I
,	O
glucose	S
,	O
o	B
##le	I
##ic	I
acid	I
,	O
g	B
##lu	I
##copy	I
##rano	I
##se	I
,	O
so	B
##rb	I
##ito	I
##l	I
,	O
pro	B
##line	I
and	O
s	B
##te	I
##ari	I
##c	I
acid	I
,	O
were	O
explored	O
by	O
P	O
##LS	O
-	O
D	O
##A	O
model	O
class	O
##ifying	O
the	O
non	O
-	O
E	O
##LS	O
/	O
MD	O
##D	O
and	O
healthy	O
control	O
.	O

Each	O
of	O
the	O
BA	O
products	O
generated	O
had	O
a	O
corresponding	O
g	B
##lu	I
##cu	I
##ron	I
##ide	I
.	O

PC	B
(	I
34	I
:	I
2	I
)	I
,	O
PC	B
(	I
34	I
:	I
1	I
)	I
,	O
PC	B
(	I
36	I
:	I
3	I
)	I
,	O
and	O
PC	B
(	I
36	I
:	I
2	I
)	I
levels	O
were	O
increased	O
in	O
both	O
tissues	O
and	O
se	O
##ra	O
from	O
M	O
##F	O
patients	O
,	O
whereas	O
SM	B
(	I
16	I
:	I
0	I
)	I
,	O
PC	B
(	I
32	I
:	I
0	I
)	I
,	O
and	O
PC	B
(	I
38	I
:	I
4	I
)	I
levels	O
were	O
increased	O
in	O
M	O
##F	O
se	O
##ra	O
but	O
were	O
decreased	O
in	O
M	O
##F	O
tissues	O
.	O

After	O
re	O
##ceipt	O
of	O
the	O
anti	O
##biotics	O
,	O
a	O
repeat	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
challenge	O
was	O
performed	O
at	O
visit	O
2	O
.	O

St	B
##ati	I
##ns	I
are	O
associated	O
with	O
7	O
–	O
25	O
%	O
higher	O
risk	O
of	O
diabetes	O
,	O
with	O
variation	O
of	O
effect	O
based	O
on	O
the	O
particular	O
s	B
##tat	I
##in	I
and	O
dose	O
.	O

S	B
##phi	I
##ngo	I
##sin	I
##e	I
-	I
1	I
-	I
phosphate	I
,	O
Ce	B
##ram	I
##ides	I
,	O
B	O
##rea	O
##st	O
cancer	O
,	O
Tu	O
##mor	O
micro	O
##en	O
##vir	O
##on	O
##ment	O

I	O
##mm	O
##uno	O
##sta	O
##ining	O
was	O
performed	O
using	O
rabbit	O
anti	O
-	O
AL	O
##D	O
##H	O
##7	O
##A	O
##1	O
(	O
Sigma	O
:	O
HP	O
##A	O
##0	O
##23	O
##29	O
##6	O
)	O
and	O
the	O
s	B
##tre	I
##pta	I
##vid	I
##in	I
–	I
bio	I
##tin	I
per	O
##ox	O
##idas	O
##e	O
complex	O
method	O
according	O
to	O
the	O
manufacturer	O
’	O
s	O
instructions	O
(	O
Ultra	O
##V	O
##ision	O
H	O
##RP	O
D	O
##AB	O
system	O
,	O
The	O
##rm	O
##o	O
)	O
.	O

P	O
##las	O
##ma	O
meta	O
##bol	O
##ite	O
analysis	O
revealed	O
bio	O
##mark	O
##er	O
meta	O
##bol	O
##ites	O
associated	O
with	O
ICC	O
and	O
in	O
particular	O
2	B
-	I
h	I
##ydro	I
##xy	I
##g	I
##lut	I
##arate	I
(	O
2	O
-	O
H	O
##G	O
)	O
levels	O
were	O
elevated	O
in	O
both	O
samples	O
from	O
the	O
only	O
patient	O
showing	O
a	O
variant	O
all	O
##ele	O
in	O
ID	O
##H1	O
.	O

Thin	O
layer	O
ch	O
##roma	O
##tography	O
was	O
performed	O
with	O
plastic	O
-	O
backed	O
plates	O
coated	O
with	O
si	B
##lica	I
gel	O
F	O
_	O
254	O
,	O
and	O
the	O
plates	O
were	O
visual	O
##ized	O
by	O
spray	O
##ing	O
with	O
van	O
##ill	O
##in	O
/	O
H	O
_	O
2	O
S	O
##O	O
_	O
4	O
solution	O
,	O
followed	O
by	O
warming	O
.	O

Although	O
base	O
##line	O
metabolic	O
parameters	O
varied	O
modest	O
##ly	O
in	O
the	O
three	O
groups	O
of	O
study	O
subjects	O
(	O
Table	O
1	O
)	O
,	O
in	O
all	O
three	O
protocols	O
p	B
##io	I
##gli	I
##ta	I
##zone	I
similarly	O
reduced	O
(	O
all	O
P	O
<	O
0	O
.	O
05	O
)	O
the	O
H	O
##b	O
##A	O
_	O
1	O
##c	O
(	O
Δ	O
=	O
0	O
.	O
8	O
–	O
1	O
.	O
2	O
%	O
)	O
,	O
F	O
##P	O
##G	O
(	O
39	O
–	O
76	O
mg	O
/	O
d	O
##l	O
)	O
,	O
fast	O
##ing	O
plasma	O
FF	O
##A	O
(	O
132	O
–	O
236	O
μ	O
##mo	O
##l	O
/	O
liter	O
)	O
,	O
and	O
plasma	O
t	B
##rig	I
##ly	I
##cer	I
##ide	I
(	O
23	O
–	O
42	O
mg	O
/	O
d	O
##l	O
)	O
concentrations	O
.	O

As	O
a	O
first	O
example	O
,	O
we	O
identified	O
significant	O
associations	O
of	O
variants	O
upstream	O
of	O
ET	O
##NP	O
##PL	O
with	O
ethanol	B
##amine	I
.	O

Diet	O
##ary	O
implementation	O
with	O
pre	O
##biotics	O
and	O
/	O
or	O
pro	O
##biotic	O
could	O
be	O
a	O
useful	O
tool	O
to	O
restore	O
some	O
micro	O
##bial	O
gaps	O
(	O
e	O
.	O
g	O
.	O
,	O
la	B
##ct	I
##ob	I
##ac	I
##ill	I
##i	I
and	O
bi	O
##fi	O
##do	O
##ba	O
##cter	O
##ia	O
)	O
.	O

The	O
most	O
abundant	O
amino	O
acid	O
was	O
L	B
-	I
g	I
##lut	I
##amine	I
(	O
0	O
.	O
66	O
mm	O
##ol	O
/	O
L	O
)	O
,	O
and	O
the	O
least	O
abundant	O
was	O
L	B
-	I
as	I
##par	I
##tic	I
acid	I
(	O
6	O
.	O
7	O
μ	O
##mo	O
##l	O
/	O
L	O
)	O
.	O

As	O
a	O
third	O
example	O
,	O
we	O
discuss	O
the	O
association	O
of	O
variants	O
in	O
X	O
##Y	O
##L	O
##B	O
with	O
increased	O
u	O
##rina	O
##ry	O
g	B
##ly	I
##cola	I
##te	I
levels	O
.	O

The	O
lip	O
##ids	O
in	O
the	O
mixture	O
were	O
separated	O
over	O
a	O
34	O
min	O
gradient	O
(	O
mobile	O
phase	O
A	O
:	O
ace	O
##ton	O
##it	O
##ril	O
##e	O
/	O
water	O
(	O
40	O
:	O
60	O
)	O
containing	O
10	O
m	O
##M	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
;	O
mobile	O
phase	O
B	O
:	O
ace	O
##ton	O
##it	O
##ril	O
##e	O
/	O
is	O
##op	O
##rop	O
##yla	O
##l	O
##co	O
##hol	O
(	O
10	O
:	O
90	O
)	O
containing	O
10	O
m	O
##M	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
)	O
at	O
a	O
flow	O
rate	O
of	O
250	O
µ	O
##L	O
min	O
_	O
−	O
##1	O
.	O

In	O
contrast	O
,	O
they	O
had	O
increased	O
plasma	O
concentrations	O
in	O
as	B
##par	I
##tate	I
(	O
P	O
=	O
0	O
.	O
01	O
)	O
,	O
c	B
##it	I
##ru	I
##llin	I
##e	I
(	O
P	O
=	O
0	O
.	O
01	O
)	O
,	O
and	O
pro	B
##line	I
(	O
P	O
=	O
0	O
.	O
04	O
)	O
.	O

MS	O
##2	O
does	O
not	O
distinguish	O
the	O
s	O
##n	O
##1	O
and	O
s	O
##n	O
##2	O
a	O
##cy	O
##l	O
positions	O
of	O
g	B
##ly	I
##cer	I
##oli	I
##pid	I
##s	I
,	O
nor	O
the	O
position	O
of	O
un	O
##sat	O
##uration	O
##s	O
in	O
a	O
##cy	O
##l	O
chains	O
and	O
a	O
##cy	O
##l	O
branching	O
.	O

Amongst	O
both	O
cases	O
and	O
controls	O
,	O
we	O
excluded	O
any	O
woman	O
with	O
a	O
history	O
of	O
pregnancy	O
in	O
the	O
prior	O
12	O
months	O
given	O
the	O
influence	O
of	O
pregnancy	O
on	O
the	O
k	B
##yn	I
##uren	I
##ine	I
pathway	O
and	O
the	O
fact	O
that	O
pregnant	O
women	O
were	O
excluded	O
from	O
the	O
AR	O
##KS	O
trial	O
.	O

As	O
24	B
(	B
S	I
)	I
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
is	O
biological	O
##ly	O
active	O
,	O
its	O
conversion	O
to	O
bi	O
##le	O
acids	O
in	O
brain	O
could	O
represent	O
a	O
method	O
for	O
in	O
sit	O
##u	O
de	O
##act	O
##ivation	O
.	O

These	O
proteins	O
contribute	O
to	O
various	O
functions	O
of	O
HD	O
##L	O
,	O
including	O
media	O
##ting	O
the	O
reverse	O
ch	B
##ole	I
##ster	I
##ol	I
transport	O
pathway	O
and	O
anti	O
##ox	O
##ida	O
##tive	O
,	O
anti	O
-	O
inflammatory	O
,	O
and	O
anti	O
##th	O
##rom	O
##bot	O
##ic	O
effects	O
.	O

We	O
believe	O
it	O
is	O
reasonable	O
to	O
consider	O
the	O
use	O
of	O
interventions	O
targeting	O
the	O
metabolism	O
of	O
L	B
##ys	I
##o	I
##PC	I
(	I
P	I
-	I
15	I
:	I
0	I
)	I
,	O
PC	B
(	I
P	I
-	I
34	I
:	I
4	I
)	I
,	O
and	O
PC	B
(	I
38	I
:	I
6	I
)	I
as	O
a	O
p	O
##all	O
##ia	O
##tive	O
treatment	O
for	O
patients	O
with	O
as	O
##cite	O
##s	O
.	O

Six	O
participants	O
then	O
received	O
broad	O
-	O
spectrum	O
anti	O
##biotics	O
for	O
1	O
week	O
,	O
followed	O
by	O
a	O
second	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
challenge	O
(	O
visit	O
2	O
)	O
.	O

H	O
##IL	O
##IC	O
retains	O
h	B
##ydro	I
##phi	I
##lic	I
compounds	O
and	O
is	O
ideal	O
for	O
polar	O
low	O
molecular	O
weight	O
compounds	O
in	O
contrast	O
to	O
the	O
more	O
common	O
reversed	O
phase	O
ch	O
##roma	O
##tography	O
.	O

_	O
1	O
H	O
N	O
##MR	O
,	O
pro	O
##ton	O
nuclear	O
magnetic	O
resonance	O
;	O
A	O
##FP	O
,	O
alpha	B
-	I
f	I
##eto	I
##p	I
##rote	I
##in	I
;	O
AL	O
##T	O
,	O
al	O
##ani	O
##ne	O
trans	O
##ami	O
##nas	O
##e	O
;	O
BC	O
##LC	O
,	O
Barcelona	O
Clinic	O
Live	O
##r	O
Cancer	O
;	O
B	O
##MI	O
,	O
body	O
mass	O
index	O
;	O
H	O
##B	O
##V	O
,	O
he	O
##pa	O
##titis	O
B	O
virus	O
;	O
HC	O
##C	O
,	O
he	O
##pa	O
##to	O
##cellular	O
car	O
##cin	O
##oma	O
;	O
HC	O
##V	O
,	O
he	O
##pa	O
##titis	O
C	O
virus	O
;	O
HIV	O
,	O
human	O
im	O
##mu	O
##no	O
##de	O
##ficiency	O
virus	O
;	O
IN	O
##R	O
,	O
International	O
Normal	O
##ized	O
Rat	O
##io	O
;	O
NAS	O
##H	O
,	O
non	O
-	O
alcoholic	O
s	O
##te	O
##ato	O
##he	O
##pa	O
##titis	O
;	O
PC	O
##A	O
,	O
principal	O
component	O
analysis	O
;	O
P	O
##LS	O
-	O
D	O
##A	O
,	O
partial	O
least	O
squares	O
disc	O
##rim	O
##ina	O
##nt	O
analysis	O
;	O
SE	O
##ER	O
,	O
surveillance	O
E	O
##pid	O
##em	O
##iology	O
and	O
End	O
Results	O
;	O
ST	O
##OC	O
##S	O
##Y	O
,	O
statistical	O
total	O
correlation	O
s	O
##pect	O
##ros	O
##copy	O
;	O
T	O
##SP	O
,	O
trim	B
##eth	I
##yl	I
-	I
si	I
##ly	I
##l	I
phosphate	I
;	O
US	O
,	O

MC	O
##T	O
,	O
medium	O
-	O
chain	O
t	O
##rig	O
##ly	O
##cer	O
##ides	O
;	O
L	O
##CT	O
,	O
long	O
-	O
chain	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
;	O
non	O
-	O
H	O
##FS	O
,	O
non	O
-	O
supplemented	O
group	O
;	O
H	O
##FS	O
,	O
high	O
fat	O
supplement	O
group	O
;	O
P	O
##N	O
,	O
parent	O
##eral	O
nutrition	O
;	O
P	O
##OD	O
,	O
post	O
##oper	O
##ative	O
day	O
.	O

We	O
did	O
not	O
observe	O
any	O
increase	O
of	O
c	B
##rea	I
##tin	I
##ine	I
or	O
decrease	O
of	O
c	B
##it	I
##ric	I
acid	I
levels	O
using	O
either	O
L	O
##C	O
/	O
MS	O
or	O
N	O
##MR	O
,	O
contrary	O
to	O
what	O
has	O
been	O
noted	O
in	O
long	O
-	O
term	O
stability	O
studies	O
using	O
N	O
##MR	O
experiments	O
(	O
Lau	O
##rid	O
##sen	O
et	O
al	O
.	O
;	O

Finally	O
,	O
g	B
##lut	I
##ama	I
##te	I
correlated	O
with	O
g	B
##lut	I
##amine	I
.	O

The	O
sum	O
of	O
5	B
##β	I
-	I
te	I
##tra	I
##hy	I
##dr	I
##oc	I
##ort	I
##is	I
##ol	I
,	O
5	B
##α	I
-	I
te	I
##tra	I
##hy	I
##dr	I
##oc	I
##ort	I
##is	I
##ol	I
,	O
5	B
##β	I
-	I
te	I
##tra	I
##hy	I
##dr	I
##oc	I
##ort	I
##ison	I
##e	I
,	O
and	O
5	B
##α	I
-	I
te	I
##tra	I
##hy	I
##dr	I
##oc	I
##ort	I
##ison	I
##e	I
was	O
calculated	O
as	O
mg	O
/	O
g	O
c	B
##rea	I
##tin	I
##ine	I
.	O

Con	O
##sist	O
##ent	O
with	O
our	O
previous	O
report	O
,	O
p	B
##yr	I
##u	I
##vate	I
,	O
an	O
important	O
intermediate	O
in	O
g	O
##ly	O
##co	O
##lysis	O
,	O
was	O
also	O
detected	O
higher	O
in	O
the	O
CR	O
##C	O
patients	O
compared	O
with	O
healthy	O
controls	O
.	O

The	O
resulting	O
sample	O
was	O
dried	O
and	O
dissolved	O
in	O
200	O
µ	O
##L	O
met	B
##han	I
##ol	I
,	O
resulting	O
in	O
a	O
neutral	O
lip	O
##id	O
fraction	O
.	O

In	O
conclusion	O
,	O
in	O
norm	B
##og	I
##ly	I
##ce	I
##mic	I
women	O
insulin	O
resistance	O
was	O
associated	O
with	O
increased	O
serum	O
BC	O
##AA	O
concentrations	O
,	O
down	O
-	O
regulation	O
of	O
mitochondrial	O
energy	O
metabolism	O
and	O
increased	O
expression	O
of	O
inflammation	O
-	O
related	O
genes	O
in	O
the	O
ad	O
##ip	O
##ose	O
tissue	O
.	O

Blood	O
concentrations	O
of	O
v	O
##ino	O
##rel	O
##bine	O
and	O
its	O
meta	O
##bol	O
##ite	O
,	O
4	B
′	I
-	I
O	I
-	I
de	I
##ace	I
##ty	I
##lvin	I
##ore	I
##l	I
##bine	I
,	O
were	O
q	O
##uant	O
##ified	O
by	O
a	O
valid	O
##ated	O
liquid	O
ch	O
##roma	O
##tography	O
–	O
tandem	O
mass	O
s	O
##pect	O
##rome	O
##try	O
method	O
at	O
S	O
##IM	O
##M	O
B	O
##io	O
##ana	O
##ly	O
##tical	O
Laboratory	O
(	O
Shanghai	O
,	O
China	O
)	O
.	O

However	O
,	O
meta	O
##bol	O
##ites	O
including	O
g	B
##lut	I
##amine	I
,	O
p	B
##yr	I
##og	I
##lut	I
##ami	I
##c	I
acid	I
,	O
glucose	S
,	O
and	O
sa	B
##rc	I
##os	I
##ine	I
showed	O
very	O
poor	O
correlation	O
##s	O
.	O

Adults	O
with	O
chronic	O
kidney	O
disease	O
(	O
C	O
##K	O
##D	O
)	O
exhibit	O
alterations	O
in	O
try	B
##pt	I
##op	I
##han	I
metabolism	O
,	O
mainly	O
via	O
the	O
k	B
##yn	I
##uren	I
##ine	I
pathway	O
,	O
due	O
to	O
higher	O
en	O
##zy	O
##matic	O
activity	O
induced	O
mainly	O
by	O
inflammation	O
.	O

On	O
the	O
next	O
day	O
,	O
1	O
m	O
##L	O
of	O
freshly	O
prepared	O
3	O
%	O
(	O
v	O
/	O
v	O
)	O
concentrated	O
H	O
_	O
2	O
S	O
##O	O
_	O
4	O
in	O
Me	B
##OH	I
was	O
added	O
to	O
the	O
dry	O
residue	O
,	O
followed	O
by	O
son	O
##ica	O
##tion	O
and	O
v	O
##ortex	O
##ing	O
to	O
completely	O
dissolve	O
the	O
sample	O
.	O

Therefore	O
,	O
the	O
increase	O
of	O
1	B
-	I
met	I
##hyl	I
##ade	I
##nos	I
##ine	I
in	O
HC	O
##C	O
samples	O
may	O
be	O
due	O
to	O
the	O
h	O
##yper	O
##act	O
##ivation	O
of	O
met	O
##hyl	O
##tra	O
##ns	O
##fer	O
##ases	O
,	O
which	O
was	O
followed	O
by	O
the	O
n	O
##uc	O
##leo	O
##tide	O
##s	O
modification	O
in	O
response	O
to	O
inflammatory	O
stress	O
or	O
o	O
##xi	O
##da	O
##tive	O
DNA	O
damage	O
.	O

Shot	O
##gun	O
lip	O
##ido	O
##mic	O
##s	O
by	O
hybrid	O
q	O
##uad	O
##rup	O
##ole	O
time	O
-	O
of	O
-	O
flight	O
mass	O
s	O
##pect	O
##rome	O
##try	O
has	O
allowed	O
absolute	O
q	O
##uant	O
##ification	O
of	O
hundreds	O
of	O
intact	O
molecular	O
species	O
including	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
species	O
,	O
g	B
##ly	I
##cer	I
##oli	I
##pid	I
species	O
,	O
s	B
##phi	I
##ngo	I
##lip	I
##id	I
species	O
,	O
and	O
s	O
##tero	O
##l	O
lip	O
##ids	O
.	O

Mobile	O
phases	O
A	O
and	O
B	O
involved	O
10	O
m	O
##M	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
in	O
an	O
ace	O
##ton	O
##it	O
##ril	O
##e	O
:	O
water	O
(	O
4	O
:	O
6	O
,	O
v	O
/	O
v	O
)	O
solution	O
and	O
10	O
m	O
##M	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
in	O
an	O
ace	O
##ton	O
##it	O
##ril	O
##e	O
:	O
is	O
##op	O
##rop	O
##ano	O
##l	O
(	O
1	O
:	O
9	O
,	O
v	O
/	O
v	O
)	O
solution	O
,	O
respectively	O
.	O

The	O
diversity	O
and	O
quantity	O
were	O
inter	O
-	O
linked	O
only	O
in	O
the	O
Ba	O
##cter	O
##oid	O
##ete	O
##s	O
,	O
B	O
##if	O
##ido	O
##ba	O
##cter	O
##ia	O
and	O
Lac	B
##to	I
##ba	I
##ci	I
##llus	I
groups	O
.	O

Because	O
g	B
##lut	I
##ama	I
##te	I
is	O
produced	O
from	O
α	B
-	I
k	I
##eto	I
##g	I
##lut	I
##arate	I
via	O
a	O
trans	O
##ami	O
##nation	O
reaction	O
,	O
the	O
lowered	O
level	O
of	O
α	B
-	I
k	I
##eto	I
##g	I
##lut	I
##arate	I
in	O
the	O
PC	O
-	O
knock	O
##down	O
MD	O
##A	O
-	O
MB	O
-	O
231	O
cells	O
may	O
in	O
turn	O
lower	O
the	O
rate	O
of	O
g	B
##lut	I
##ama	I
##te	I
formation	O
which	O
consequently	O
affects	O
the	O
trans	O
##ami	O
##nation	O
reaction	O
cat	O
##aly	O
##zed	O
by	O
p	O
##hos	O
##ph	O
##ose	O
##rine	O
amino	O
##tra	O
##ns	O
##fer	O
##ase	O
.	O

Because	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
is	O
a	O
key	O
constituent	O
of	O
my	B
##elin	I
,	O
it	O
is	O
abundant	O
in	O
the	O
white	O
matter	O
of	O
the	O
brain	O
.	O

These	O
changes	O
impacted	O
on	O
the	O
a	B
##rg	I
##ini	I
##ne	I
:	O
or	B
##ni	I
##thin	I
##e	I
ratio	O
;	O
a	O
bio	O
##mark	O
##er	O
of	O
a	O
##rg	O
##inas	O
##e	O
activity	O
and	O
a	O
predict	O
##or	O
of	O
a	O
wide	O
range	O
of	O
clinical	O
outcomes	O
in	O
a	O
number	O
of	O
diseases	O
including	O
sick	O
##le	O
cell	O
and	O
on	O
GA	O
##BR	O
(	O
a	O
##rg	O
##ini	O
##ne	O
/	O
(	O
or	O
##ni	O
##thin	O
##e	O
+	O
c	O
##it	O
##ru	O
##llin	O
##e	O
)	O
)	O

The	O
total	O
amount	O
of	O
each	O
class	O
of	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
in	O
cells	O
.	O

Similarly	O
,	O
p	B
##hen	I
##yla	I
##lain	I
##e	I
and	O
t	B
##yr	I
##os	I
##ine	I
could	O
also	O
be	O
involved	O
in	O
an	O
##ap	O
##ler	O
##osis	O
,	O
which	O
enters	O
the	O
t	B
##rica	I
##rb	I
##ox	I
##yl	I
##ic	I
acid	I
cycle	O
by	O
converting	O
into	O
f	B
##uma	I
##rate	I
.	O

Pearson	O
correlation	O
coefficients	O
(	O
r	O
)	O
and	O
coefficients	O
of	O
determination	O
(	O
R	O
_	O
2	O
)	O
for	O
base	O
##line	O
body	O
mass	O
index	O
and	O
serum	O
concentrations	O
of	O
est	B
##rogen	I
meta	O
##bol	O
##ite	O
measures	O
among	O
study	O
controls	O
(	O
N	O
=	O
26	O
##8	O
)	O

Although	O
the	O
origin	O
of	O
this	O
meta	O
##bol	O
##ite	O
in	O
blood	O
has	O
not	O
been	O
well	O
el	O
##uc	O
##idated	O
yet	O
,	O
amino	B
##mal	I
##onic	I
acid	I
can	O
be	O
routinely	O
detected	O
in	O
the	O
serum	O
meta	O
##bol	O
##ome	O
of	O
healthy	O
individuals	O
by	O
G	O
##C	O
-	O
MS	O
.	O

Moreover	O
,	O
L	B
-	I
car	I
##ni	I
##tine	I
and	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
have	O
been	O
shown	O
to	O
contribute	O
to	O
the	O
development	O
of	O
at	O
##her	O
##os	O
##cle	O
##rosis	O
by	O
increasing	O
the	O
levels	O
of	O
the	O
independent	O
CH	O
##D	O
risk	O
factor	O
trim	B
##eth	I
##yla	I
##mine	I
N	I
-	I
oxide	I
(	O
T	O
##MA	O
##O	O
)	O
in	O
experimental	O
animals	O
.	O

Considering	O
the	O
base	O
##line	O
correlation	O
##s	O
with	O
H	O
##OM	O
##A	O
-	O
I	O
##R	O
,	O
only	O
those	O
for	O
2	O
-	O
H	O
##BA	O
,	O
2	B
-	I
h	I
##ydro	I
##xy	I
##vale	I
##ric	I
acid	I
(	O
2	O
-	O
H	O
##VA	O
)	O
,	O
and	O
c	B
##ys	I
##tein	I
##e	I
were	O
significant	O
.	O

P	B
##yr	I
##im	I
##id	I
##ine	I
metabolism	O
–	O
associated	O
R	O
##R	O
##M	O
##2	O
is	O
differently	O
expressed	O
in	O
breast	O
cancer	O
sub	O
##type	O
##s	O
and	O
is	O
a	O
predict	O
##or	O
of	O
outcome	O
.	O

A	O
ca	O
##usal	O
relationship	O
between	O
re	O
##nal	O
loss	O
and	O
altered	O
c	B
##it	I
##ru	I
##llin	I
##e	I
metabolism	O
is	O
supported	O
by	O
experimental	O
results	O
in	O
mice	O
showing	O
that	O
partial	O
ne	O
##ph	O
##re	O
##ct	O
##omy	O
induced	O
c	O
##it	O
##ru	O
##llin	O
##uria	O
,	O
possibly	O
because	O
of	O
over	O
##load	O
and	O
sat	O
##uration	O
of	O
tub	O
##ular	O
transport	O
##ers	O
.	O

After	O
p	B
##io	I
##gli	I
##ta	I
##zone	I
therapy	O
,	O
F	O
##P	O
##G	O
,	O
FF	O
##A	O
,	O
H	O
##b	O
##A	O
##1	O
##c	O
,	O
and	O
fast	O
##ing	O
plasma	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
decreased	O
significantly	O
,	O
whereas	O
HD	B
##L	I
ch	I
##ole	I
##ster	I
##ol	I
,	O
total	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
and	O
L	B
##D	I
##L	I
ch	I
##ole	I
##ster	I
##ol	I
did	O
not	O
change	O
significantly	O
after	O
p	B
##io	I
##gli	I
##ta	I
##zone	I
therapy	O
(	O
Table	O
1	O
)	O
.	O

1	O
–	O
5	O
)	O
have	O
been	O
recognized	O
as	O
Cy	O
##s	O
,	O
HC	O
##ys	O
,	O
Na	O
##c	O
,	O
γ	B
-	I
G	I
##lu	I
##C	I
##ys	I
,	O
and	O
G	B
##S	I
##H	I
by	O
the	O
standards	O
,	O
and	O
12	O
(	O
No	O
.	O
6	O
–	O
17	O
)	O
were	O
given	O
the	O
possible	O
structures	O
by	O
the	O
MS	O
/	O
MS	O
and	O
Q	O
##TO	O
##F	O
-	O
MS	O
information	O
from	O
our	O
previous	O
work	O
.	O

In	O
addition	O
,	O
we	O
show	O
that	O
the	O
serum	O
levels	O
of	O
sperm	B
##ine	I
are	O
significantly	O
correlated	O
with	O
insulin	O
levels	O
and	O
H	O
##OM	O
##A	O
-	O
I	O
##R	O
,	O
suggesting	O
the	O
possible	O
relationship	O
of	O
circulating	O
sperm	B
##ine	I
with	O
elevated	O
circulating	O
insulin	O
levels	O
.	O

In	O
our	O
study	O
,	O
all	O
except	O
N	B
-	I
ace	I
##ty	I
##l	I
##car	I
##nos	I
##ine	I
were	O
very	O
strongly	O
negatively	O
correlated	O
with	O
m	O
##G	O
##F	O
##R	O
.	O

In	O
addition	O
,	O
the	O
levels	O
of	O
o	B
##ct	I
##ade	I
##cano	I
##yl	I
##car	I
##ni	I
##tine	I
,	O
AD	B
##MA	I
and	O
six	O
PC	O
##s	O
were	O
significantly	O
different	O
between	O
R	O
##R	O
##MM	O
and	O
MG	O
##US	O
patients	O
.	O

Live	O
##r	O
enzymes	O
were	O
associated	O
with	O
the	O
6	O
##MP	O
meta	O
##bol	O
##ites	O
in	O
the	O
correlation	O
analysis	O
,	O
but	O
the	O
association	O
was	O
not	O
significant	O
in	O
the	O
multi	O
##var	O
##iate	O
analysis	O
with	O
adjustment	O
for	O
age	O
,	O
6	O
##MP	O
,	O
M	O
##T	O
##X	O
dose	O
,	O
and	O
duration	S
of	O
treatment	O
.	O

The	O
mobile	O
phase	O
was	O
composed	O
of	O
solvent	O
A	O
(	O
0	O
.	O
1	O
%	O
FA	S
in	O
H	O
_	O
2	O
O	O
)	O
and	O
solvent	O
B	O
(	O
0	O
.	O
1	O
%	O
FA	S
in	O
AC	O
##N	O
)	O
.	O

The	O
first	O
reaction	O
is	O
the	O
conversion	O
of	O
3	B
-	I
p	I
##hos	I
##ph	I
##og	I
##ly	I
##cer	I
##ate	I
to	O
3	B
-	I
p	I
##hos	I
##ph	I
##oh	I
##ydro	I
##xy	I
##py	I
##ru	I
##vate	I
by	O
p	B
##hos	I
##ph	I
##og	I
##ly	I
##cer	I
##ate	I
de	I
##hy	I
##dr	I
##o	I
g	O
##ena	O
##se	O
followed	O
by	O
further	O
conversion	O
to	O
3	B
-	I
p	I
##hos	I
##ph	I
##ose	I
##rine	I
by	O
p	O
##hos	O
##ph	O
##ose	O
##rine	O
amino	O
##tra	O
##ns	O
##fer	O
##ase	O
before	O
the	O
final	O
conversion	O
to	O
se	B
##rine	I
by	O
protein	O
se	O
##rine	O
p	O
##hos	O
##pha	O
##tase	O
.	O

The	O
dig	O
##lu	O
##cu	O
##ron	O
##ide	O
of	O
di	B
##os	I
##met	I
##in	I
was	O
detect	O
##able	O
,	O
however	O
,	O
at	O
very	O
low	O
levels	O
,	O
with	O
concentrations	O
at	O
<	O
5	O
%	O
of	O
those	O
of	O
3	O
-	O
O	O
-	O
G	O
##lu	O
##c	O
and	O
in	O
the	O
AU	O
##C	O
##0	O
-	O
t	O
calculations	O
the	O
dig	O
##lu	O
##cu	O
##ron	O
##ide	O
represents	O
only	O
2	O
.	O
1	O
%	O
of	O
the	O
total	O
di	B
##os	I
##met	I
##in	I
g	I
##lu	I
##cu	I
##ron	I
##ide	I
AU	O
##C	O
##0	O
-	O
t	O
.	O
A	O
mean	O
P	O
##K	O
curve	O
obtained	O
from	O
the	O
experiments	O
performed	O
with	O
g	O
##lu	O
##cu	O
##ron	O
##idas	O
##e	O
dig	O
##est	O
##ion	O
(	O
G	O
##L	O
##UC	O
##ase	O
di	B
##os	I
##met	I
##in	I
trace	O
)	O
is	O
also	O
reported	O
in	O
Fi	O
##g	O
.	O

The	O
K	O
_	O
m	O
and	O
V	O
_	O
ma	O
##x	O
values	O
for	O
formation	O
of	O
h	B
##ydro	I
##xy	I
##ana	I
##stro	I
##zo	I
##le	I
by	O
expressed	O
C	O
##YP	O
##2	O
##C	O
##8	O
was	O
86	O
.	O
8	O
µ	O
##m	O
and	O
0	O
.	O
000	O
##0	O
##5	O
pm	O
##ol	O
min	O
_	O
−	O
##1	O
pm	O
##ol	O
_	O
−	O
##1	O
P	O
##45	O
##0	O
,	O
respectively	O
.	O

Analysis	O
of	O
the	O
u	O
##rina	O
##ry	O
E	O
##Vs	O
from	O
the	O
patients	O
indicated	O
that	O
the	O
levels	O
of	O
g	B
##lu	I
##cu	I
##rona	I
##te	I
,	O
D	B
-	I
rib	I
##ose	I
5	I
-	I
phosphate	I
and	O
is	B
##ob	I
##ut	I
##yr	I
##yl	I
-	I
L	I
-	I
car	I
##ni	I
##tine	I
were	O
2	O
-	O
26	O
-	O
fold	O
lower	O
in	O
all	O
pre	O
-	O
pro	O
##state	O
##ct	O
##omy	O
samples	O
compared	O
to	O
the	O
healthy	O
control	O
and	O
post	O
-	O
pro	O
##state	O
##ct	O
##omy	O
samples	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Various	O
pu	B
##rine	I
and	O
p	B
##yr	I
##im	I
##id	I
##ine	I
n	O
##uc	O
##leo	O
##tide	O
modified	O
bases	O
were	O
elevated	O
following	O
therapy	O
,	O
including	O
N	B
##1	I
-	I
met	I
##hyl	I
##ade	I
##nos	I
##ine	I
,	O
7	B
-	I
met	I
##hyl	I
##gua	I
##nine	I
,	O
5	B
-	I
met	I
##hyl	I
##uri	I
##dine	I
,	O
N	B
##4	I
-	I
ace	I
##ty	I
##l	I
##cy	I
##ti	I
##dine	I
,	O
N	B
##1	I
-	I
met	I
##hyl	I
##gua	I
##nos	I
##ine	I
,	O
and	O
N	B
-	I
ace	I
##ty	I
##l	I
-	I
beta	I
-	I
al	I
##ani	I
##ne	I
,	O
among	O
others	O
.	O

For	O
example	O
,	O
targeting	O
e	B
##ico	I
##san	I
##oids	I
,	O
specifically	O
L	B
##T	I
##B	I
##4	I
,	O
in	O
a	O
future	O
it	O
##eration	O
of	O
a	O
traffic	O
exposure	O
meta	O
##bol	O
##omi	O
##cs	O
study	O
may	O
improve	O
our	O
understanding	O
of	O
the	O
inter	O
##play	O
of	O
systemic	O
inflammation	O
in	O
acute	O
response	O
.	O

A	O
higher	O
diversity	O
of	O
Ba	O
##cter	O
##oid	O
##ete	O
##s	O
and	O
Lac	B
##to	I
##ba	I
##ci	I
##llus	I
groups	O
in	O
I	O
##BS	O
f	O
##ae	O
##cal	O
samples	O
also	O
correlated	O
with	O
the	O
respective	O
total	O
quantity	O
.	O

The	O
glucose	B
-	I
al	I
##ani	I
##ne	I
cycle	O
is	O
a	O
bio	O
##chemical	O
route	O
between	O
muscle	O
and	O
liver	O
metabolism	O
.	O

Ace	B
##tate	I
is	O
a	O
final	O
product	O
of	O
lip	O
##id	O
metabolism	O
and	O
can	O
be	O
converted	O
into	O
ace	B
##ty	I
##l	I
-	I
Co	I
##en	I
##zy	I
##me	I
A	O
(	B
ace	B
##ty	I
##l	I
-	I
Co	I
##A	I
)	O
by	O
ace	B
##ty	I
##l	I
-	I
Co	I
##A	I
s	O
##ynth	O
##eta	O
##se	O
.	O

Equal	O
amounts	O
of	O
den	O
##ature	O
##d	O
proteins	O
were	O
separated	O
by	O
electro	O
##ph	O
##ores	O
##is	O
using	O
SD	O
##S	O
-	O
PA	O
##GE	O
gel	O
##s	O
and	O
transferred	O
to	O
activated	S
P	O
##VD	O
##F	O
membrane	O
##s	O
.	O

A	B
##rg	I
##ini	I
##ne	I
association	O
with	O
Mayo	O
end	O
##os	O
##copic	O
score	O
.	O

In	O
conclusion	O
,	O
we	O
have	O
shown	O
that	O
in	O
##test	O
##inal	O
micro	O
##bes	O
participate	O
in	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
metabolism	O
to	O
form	O
circulating	O
and	O
u	O
##rina	O
##ry	O
T	B
##MA	I
##O	I
.	O

The	O
rest	O
of	O
the	O
sample	O
was	O
used	O
to	O
extract	O
gang	B
##lio	I
##side	I
##s	I
.	O

Several	O
studies	O
have	O
suggested	O
a	O
relative	O
a	B
##rg	I
##ini	I
##ne	I
deficiency	O
exists	O
in	O
subjects	O
with	O
h	O
##yper	O
##tens	O
##ion	O
or	O
heart	O
failure	O
as	O
a	O
result	O
of	O
abnormal	O
transport	O
mechanisms	O
across	O
vascular	O
cellular	O
membrane	O
##s	O
(	O
,	O
,	O
)	O
.	O

Met	O
##ab	O
##oli	O
##tes	O
of	O
ch	B
##olin	I
##e	I
were	O
analyzed	O
using	O
H	O
##IL	O
##IC	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
based	O
on	O
methods	O
outlined	O
by	O
Zhao	O
et	O
al	O
.	O
.	O

Among	O
them	O
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
altered	O
in	O
different	O
directions	O
,	O
presumably	O
because	O
of	O
the	O
different	O
metabolic	O
process	O
involving	O
gut	O
micro	O
##f	O
##lora	O
in	O
urine	O
.	O

The	O
composition	O
of	O
free	O
P	O
##U	O
##FA	O
##s	O
,	O
including	O
levels	O
of	O
α	B
-	I
l	I
##ino	I
##len	I
##ic	I
acid	I
(	O
18	O
:	O
3	O
)	O
and	O
EPA	B
(	I
20	I
:	I
5	I
)	I
,	O
were	O
inverse	O
##ly	O
associated	O
with	O
tissue	O
factor	O
(	O
T	O
##F	O
)	O
expression	O
on	O
inflammatory	O
mon	O
##ocytes	O
.	O

The	O
extract	O
##s	O
were	O
e	O
##va	O
##porated	O
to	O
dry	O
##ness	O
using	O
a	O
Sa	O
##vant	O
Speed	O
##V	O
##ac	O
e	O
##va	O
##por	O
##ator	O
(	O
The	O
##rm	O
##o	O
Fisher	O
Scientific	O
,	O
Walt	O
##ham	O
,	O
MA	O
)	O
and	O
re	O
##con	O
##stituted	O
to	O
20	O
μ	O
##L	O
with	O
ace	O
##ton	O
##it	O
##ril	O
##e	O
/	O
10	O
m	O
##M	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
(	O
30	O
/	O
70	O
,	O
v	O
/	O
v	O
)	O
.	O

In	O
summary	O
,	O
our	O
study	O
comprehensive	O
##ly	O
captured	O
alterations	O
in	O
the	O
human	O
meta	O
##bol	O
##ome	O
associated	O
with	O
different	O
glucose	S
tolerance	O
outcomes	O
of	O
pre	O
-	O
D	O
##M	O
in	O
a	O
longitudinal	O
co	O
##hor	O
##t	O
study	O
.	O

However	O
,	O
the	O
metabolic	O
a	O
##ber	O
##ration	O
of	O
re	O
##nal	O
tub	O
##ular	O
cells	O
in	O
an	O
h	B
##yper	I
##gly	I
##ce	I
##mic	I
mi	O
##lie	O
##u	O
has	O
not	O
been	O
fully	O
el	O
##uc	O
##idated	O
.	O

To	O
our	O
knowledge	O
,	O
the	O
present	O
study	O
is	O
the	O
first	O
to	O
report	O
on	O
associations	O
between	O
serum	O
T	B
##MA	I
##O	I
and	O
P	O
##LC	O
risk	O
in	O
humans	O
.	O

El	O
##eva	O
##ted	O
al	B
##ani	I
##ne	I
but	O
low	O
N	B
-	I
ace	I
##ty	I
##l	I
-	I
as	I
##par	I
##tate	I
concentrations	O
were	O
reported	O
in	O
PA	O
,	O
nonetheless	O
,	O
a	O
similar	O
pattern	O
was	O
apparent	O
in	O
men	O
##ing	O
##io	O
##ma	O
and	O
g	O
##lio	O
##mas	O
(	O
,	O
)	O
.	O

Con	O
##com	O
##ita	O
##ntly	O
with	O
the	O
decline	O
of	O
this	O
intermediate	O
meta	O
##bol	O
##ite	O
,	O
n	O
##uc	O
##leo	O
##tide	O
meta	O
##bol	O
##ites	O
,	O
including	O
the	O
p	O
##har	O
##ma	O
##cological	O
##ly	O
active	O
G	O
##S	O
-	O
33	O
##100	O
##7	O
trip	B
##hos	I
##phate	I
,	O
were	O
observed	O
.	O

Final	O
Turbo	O
##I	O
##on	O
##S	O
##our	O
##ce	O
parameters	O
were	O
:	O
curtain	O
gas	O
(	O
C	O
##UR	O
)	O
,	O
20	O
ps	O
##i	O
;	O
collision	O
gas	O
(	O
CA	O
##D	O
)	O
,	O
high	O
;	O
ion	O
##S	O
##pra	O
##y	O
voltage	O
(	O
IS	O
)	O
,	O
5	O
.	O
2	O
k	B
##V	I
;	O
temperature	O
(	O
T	O
##EM	O
)	O
,	O
300	O
°C	O
;	O
ion	O
source	O
gas	O
1	O
(	O
G	O
##S	O
##1	O
)	O
,	O
50	O
ps	O
##i	O
;	O
ion	O
source	O
gas	O
2	O
(	O
G	O
##S	O
##2	O
)	O
,	O
50	O
ps	O
##i	O
;	O
and	O
interface	O
heat	O
##er	O
(	O
I	O
##H	O
##E	O
)	O
,	O
turned	O
on	O
.	O

Red	O
##uce	O
##d	O
circulating	O
24	B
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
concentration	O
may	O
therefore	O
be	O
a	O
sign	O
of	O
reduced	O
net	O
tub	O
##ular	O
C	O
##YP	O
##24	O
##A	O
##1	O
function	O
.	O

The	O
proposed	O
g	B
##lu	I
##cu	I
##ron	I
##ide	I
meta	O
##bol	O
##ite	O
structure	O
also	O
explains	O
the	O
absence	O
of	O
any	O
EC	O
-	O
array	O
signal	O
at	O
18	O
.	O
4	O
min	O
since	O
its	O
functional	O
groups	O
are	O
not	O
expected	O
to	O
undergo	O
red	O
##ox	O
reaction	O
at	O
the	O
voltage	O
##s	O
employed	O
.	O

For	O
example	O
,	O
female	O
hormone	O
replacement	O
therapy	O
has	O
been	O
seriously	O
re	O
##con	O
##side	O
##red	O
or	O
even	O
abandoned	O
by	O
many	O
women	O
following	O
data	O
indicating	O
that	O
the	O
oral	O
combination	O
of	O
est	O
##rogen	O
##s	O
and	O
a	O
pro	B
##ges	I
##tin	I
causes	O
a	O
26	O
%	O
increase	O
in	O
the	O
incidence	O
of	O
breast	O
cancer	O
with	O
a	O
negative	O
impact	O
on	O
card	O
##iovascular	O
events	O
.	O

The	O
activity	O
of	O
c	B
##it	I
##rate	I
s	O
##ynth	O
##ase	O
was	O
measured	O
as	O
described	O
in	O
reference	O
.	O

Target	O
##ed	O
meta	O
##bol	O
##ites	O
[	O
166	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
,	O
amino	O
acids	O
,	O
sugar	O
##s	O
,	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
,	O
and	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
(	O
liquid	O
ch	O
##roma	O
##tography	O
–	O
tandem	O
mass	O
s	O
##pect	O
##rome	O
##try	O
)	O
]	O
,	O
and	O
un	O
##tar	O
##get	O
##ed	O
meta	O
##bol	O
##ites	O
[	O
247	O
chemical	O
entities	O
(	O
gas	O
ch	O
##roma	O
##tography	O
time	O
-	O
of	O
-	O
flight	O
mass	O
s	O
##pect	O
##rome	O
##try	O
)	O
]	O
were	O
measured	O
at	O
base	O
##line	O
and	O
4	O
m	O
##o	O
after	O
treatment	O
.	O

The	O
disease	O
process	O
in	O
at	O
##her	O
##os	O
##cle	O
##rosis	O
prone	O
mice	O
accent	O
##uated	O
when	O
mitochondrial	O
anti	O
##ox	O
##ida	O
##nt	O
capacity	O
was	O
weakened	O
by	O
lower	O
super	B
##oxide	I
di	O
##sm	O
##uta	O
##se	O
2	O
activity	O
.	O

For	O
the	O
preparation	O
of	O
plasma	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
and	O
amino	O
acids	O
,	O
the	O
proteins	O
were	O
first	O
removed	O
by	O
precipitation	O
with	O
met	B
##han	I
##ol	I
.	O

In	O
a	O
comparison	O
between	O
C	O
##LL	O
and	O
normal	O
l	O
##ymph	O
##ocytes	O
,	O
it	O
has	O
been	O
shown	O
previously	O
that	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
levels	O
are	O
significantly	O
altered	O
with	O
the	O
disease	O
and	O
that	O
C	O
##LL	O
can	O
be	O
characterised	O
by	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
metabolism	O
activation	O
,	O
with	O
different	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
being	O
increased	O
and	O
decreased	O
with	O
the	O
disease	O
.	O

further	O
demonstrated	O
that	O
radioactive	O
##ly	O
labelled	O
g	B
##ly	I
##cine	I
was	O
incorporated	O
in	O
the	O
pu	B
##rine	I
n	O
##uc	O
##leo	O
##tide	O
##s	O
of	O
the	O
rapidly	O
pro	O
##life	O
##rating	O
cancer	O
cells	O
.	O

This	O
mechanism	O
was	O
sub	O
##stant	O
##iated	O
by	O
examination	O
of	O
tandem	O
mass	O
s	O
##pect	O
##ra	O
of	O
AM	O
##PP	O
-	O
der	O
##iva	O
##tized	O
stable	O
is	O
##oto	O
##pe	O
labeled	O
FA	S
(	O
i	O
.	O
e	O
.	O
,	O
7	B
,	I
7	I
,	I
8	I
,	I
8	I
-	I
d	I
_	I
4	I
-	I
16	I
:	I
0	I
FA	I
;	O
see	O
and	O
)	O
.	O

Full	O
kinetic	O
analyses	O
for	O
h	B
##ydro	I
##xy	I
##ana	I
##stro	I
##zo	I
##le	I
formation	O
were	O
carried	O
out	O
for	O
C	O
##YP	O
##3	O
##A	O
##4	O
,	O
C	O
##YP	O
##3	O
##A	O
##5	O
and	O
C	O
##YP	O
##2	O
##C	O
##8	O
.	O

In	O
summary	O
,	O
these	O
potential	O
bio	O
##mark	O
##ers	O
reflected	O
the	O
der	O
##eg	O
##ulation	O
of	O
glucose	S
metabolism	O
in	O
di	O
##abe	O
##tic	O
individuals	O
,	O
which	O
might	O
help	O
in	O
D	O
##M	O
diagnosis	O
and	O
T	O
##CM	O
syndrome	O
differentiation	O
.	O

Tau	B
##rine	I
is	O
a	O
highly	O
abundant	O
amino	O
acid	O
in	O
mammals	O
,	O
and	O
can	O
be	O
found	O
in	O
blood	O
plasma	O
and	O
blood	O
cells	O
.	O

Sur	O
##p	O
##rising	O
##ly	O
,	O
the	O
lip	O
##id	O
drop	O
##lets	O
were	O
abundant	O
in	O
tumor	O
cells	O
especially	O
located	O
on	O
the	O
edge	O
of	O
the	O
typical	O
cell	O
death	O
region	O
,	O
where	O
the	O
cells	O
are	O
found	O
with	O
ho	O
##mogeneous	O
c	O
##yt	O
##op	O
##las	O
##m	O
,	O
p	O
##yk	O
##not	O
##ic	O
nuclei	O
and	O
lack	O
of	O
cell	O
structures	O
under	O
hem	B
##ato	I
##xy	I
##lin	I
and	O
e	B
##os	I
##in	I
stain	O
##ing	O
.	O

The	O
major	O
findings	O
of	O
this	O
study	O
are	O
that	O
re	O
##ct	O
##al	O
absorption	O
of	O
met	B
##had	I
##one	I
is	O
rapid	O
and	O
the	O
bio	O
##ava	O
##ila	O
##bility	O
of	O
the	O
drug	O
given	O
by	O
this	O
route	O
is	O
76	O
%	O
,	O
only	O
slightly	O
lower	O
than	O
reported	O
by	O
us	O
for	O
oral	O
and	O
nasal	O
administration	O
.	O

Form	B
##ali	I
##n	I
fix	O
##ation	O
protocols	O
include	O
a	O
##que	O
##ous	O
alcohol	O
in	O
##cu	O
##bation	O
steps	O
,	O
so	O
one	O
approach	O
could	O
be	O
to	O
perform	O
meta	O
##bol	O
##omi	O
##cs	O
analysis	O
on	O
the	O
extract	O
from	O
this	O
first	O
alcohol	O
in	O
##cu	O
##bation	O
.	O

Pro	O
##mine	O
##nt	O
k	B
##era	I
##tin	I
production	O
in	O
the	O
form	O
of	O
k	B
##era	I
##tin	I
pearl	O
##s	O
was	O
observed	O
in	O
case	O
No	O
.	O
2	O
and	O
18	O
,	O
a	O
l	O
##ymph	O
##oid	O
aggregate	O
associated	O
with	O
tumor	O
cells	O
was	O
observed	O
in	O
No	O
.	O

Fr	O
##ag	O
##ments	O
produced	O
by	O
the	O
generation	O
of	O
the	O
car	B
##box	I
##yl	I
##ic	I
an	O
##ion	O
of	O
9	O
-	O
H	O
##SA	O
(	O
m	O
/	O
z	O
29	O
##9	O
.	O
3	O
)	O
and	O
its	O
neutral	O
loss	O
as	O
a	O
k	O
##ete	O
##ne	O
(	O
m	O
/	O
z	O
46	O
##6	O
.	O
3	O
)	O
are	O
observed	O
,	O
confirming	O
that	O
9	O
-	O
H	O
##SA	O
is	O
est	O
##eri	O
##fied	O
at	O
the	O
s	O
##n	O
-	O
2	O
position	O
of	O
the	O
g	B
##ly	I
##cer	I
##ol	I
backbone	O
of	O
the	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
molecule	O
.	O

The	O
buffer	O
pH	O
was	O
adjusted	O
to	O
7	O
.	O
00	O
using	O
a	O
ca	O
##li	O
##bra	O
##ted	O
electronic	O
pH	O
meter	O
through	O
the	O
drop	O
##wise	O
addition	O
of	O
0	O
.	O
1	O
M	O
potassium	B
h	I
##ydro	I
##xi	I
##de	I
or	O
0	O
.	O
1	O
M	O
p	B
##hos	I
##ph	I
##ori	I
##c	I
acid	I
.	O

To	O
evaluate	O
the	O
recover	O
##ies	O
of	O
the	O
Ce	B
##r	I
(	I
22	I
:	I
0	I
)	I
and	O
Ce	B
##r	I
(	I
24	I
:	I
0	I
)	I
from	O
human	O
plasma	O
and	O
matrix	O
(	O
5	O
%	O
BS	O
##A	O
)	O
,	O
signals	O
of	O
[	B
_	I
2	I
H	I
_	I
4	I
]	I
Ce	I
##r	I
(	I
22	I
:	I
0	I
)	I
and	O
[	B
_	I
2	I
H	I
_	I
4	I
]	I
Ce	I
##r	I
(	I
24	I
:	I
0	I
)	I
from	I
pre	O
-	O
extraction	O
spike	O
##d	O
samples	O
to	O
those	O
post	O
-	O
extraction	O
spike	O
##d	O
samples	O
were	O
compared	O
.	O

and	O
incorporating	O
ultra	O
##sonic	O
activation	O
,	O
we	O
were	O
able	O
to	O
develop	O
a	O
far	O
simpler	O
,	O
higher	O
yielding	O
,	O
two	O
-	O
step	O
procedure	O
for	O
the	O
direct	O
synthesis	O
of	O
HP	O
##HP	O
##A	O
starting	O
from	O
3	B
-	I
h	I
##ydro	I
##xy	I
##ben	I
##zal	I
##de	I
##hy	I
##de	I
1	O
without	O
the	O
need	O
to	O
protect	O
the	O
h	O
##ydro	O
##xy	O
##l	O
group	O
(	O
Scheme	O
2	O
##A	O
)	O
.	O

The	O
detection	O
of	O
g	O
##lu	O
##cu	O
##ron	O
##ides	O
of	O
BA	O
analog	O
##s	O
without	O
h	O
##ydro	O
##xy	O
##eth	O
##yl	O
m	O
##oi	O
##eti	O
##es	O
suggests	O
that	O
g	O
##lu	O
##cu	O
##ron	O
##ida	O
##tion	O
takes	O
place	O
on	O
the	O
car	B
##box	I
##yl	I
##ic	I
acid	I
functionality	O
.	O

Whether	O
poor	O
sleep	O
is	O
associated	O
with	O
try	B
##pt	I
##op	I
##han	I
(	O
T	O
##rp	O
)	O
meta	O
##bol	O
##ites	O
is	O
unknown	O
.	O

10	B
-	I
(	I
N	I
-	I
Ace	I
##ty	I
##l	I
##cy	I
##stein	I
##yl	I
)	I
-	I
7	I
,	I
8	I
,	I
9	I
-	I
t	I
##ri	I
##hy	I
##dr	I
##ox	I
##y	I
-	I
7	I
,	I
8	I
,	I
9	I
,	I
10	I
-	I
te	I
##tra	I
##hy	I
##dr	I
##obe	I
##nz	I
##o	I
[	I
a	I
]	I
p	O
##yre	O
##ne	O
(	O
BP	O
##DE	O
-	O
10	O
-	O
N	O
##AC	O
)	O
was	O
similarly	O
prepared	O
,	O
0	O
.	O
87	O
mg	O
,	O
23	O
.	O
4	O
%	O
overall	O
yield	O
.	O

PC	B
a	I
##a	I
C	I
##42	I
:	I
4	I
;	O

Because	O
the	O
liver	O
plays	O
an	O
essential	O
role	O
in	O
the	O
metabolism	O
of	O
SL	O
##s	O
,	O
liver	O
diseases	O
are	O
associated	O
with	O
major	O
changes	O
in	O
serum	O
SL	S
concentrations	O
.	O


The	O
mixture	O
was	O
cent	O
##ri	O
##fu	O
##ged	O
twice	O
(	O
16	O
,	O
000	O
×	O
g	O
at	O
4	O
°C	O
for	O
10	O
min	O
)	O
,	O
and	O
then	O
the	O
super	O
##nat	O
##ant	O
was	O
divided	O
into	O
two	O
parts	O
:	O
one	O
100	O
µ	O
##L	O
for	O
L	O
##C	O
/	O
MS	O
analysis	O
directly	O
and	O
another	O
100	O
µ	O
##L	O
for	O
G	O
##C	O
/	O
MS	O
analysis	O
,	O
which	O
was	O
first	O
transferred	O
to	O
a	O
glass	O
via	O
##l	O
and	O
e	O
##va	O
##porated	O
to	O
dry	O
##ness	O
and	O
then	O
der	O
##iva	O
##tized	O
by	O
100	O
µ	O
##L	O
met	B
##ho	I
##xy	I
##amine	I
(	O
50	O
µ	O
##g	O
/	O
m	O
##L	O
in	O
p	B
##yr	I
##id	I
##ine	I
,	O
37	O
°C	O
×	O
2	O
h	O
)	O
and	O
followed	O
by	O
100	O
µ	O
##L	O
MS	O
##TF	O
##A	O
(	O
37	O
°C	O
×	O
16	O
h	O
)	O
.	O

[	O
]	O
It	O
may	O
have	O
an	O
increased	O
concentration	O
in	O
PD	O
via	O
conversion	O
from	O
V	O
##MA	O
or	O
ho	B
##mo	I
##vani	I
##lli	I
##c	I
acid	I
.	O

Of	O
the	O
20	O
amino	O
acids	O
measured	O
,	O
10	O
had	O
significantly	O
reduced	O
concentrations	O
in	O
the	O
HD	O
sheep	O
,	O
with	O
the	O
branched	O
chain	O
amino	O
acids	O
(	B
v	B
##ali	I
##ne	I
,	O
le	B
##uc	I
##ine	I
,	O
is	B
##ole	I
##uc	I
##ine	I
)	O
showing	O
the	O
most	O
pronounced	O
effect	O
of	O
g	O
##eno	O
##type	O
followed	O
by	O
th	B
##re	I
##oni	I
##ne	I
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
met	B
##hi	I
##oni	I
##ne	I
,	O
al	B
##ani	I
##ne	I
,	O
as	B
##par	I
##agi	I
##ne	I
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
and	O
g	B
##lut	I
##amine	I
(	O
,	O
)	O
.	O

A	O
4	O
.	O
5	O
k	B
##V	I
ion	O
spray	O
voltage	O
was	O
applied	O
to	O
the	O
MS	O
system	O
.	O

_	O
13	O
C	B
_	I
5	I
-	I
met	I
##hi	I
##oni	I
##ne	I
(	O
C	O
##LM	O
-	O
89	O
##3	O
-	O
H	O
)	O
,	O
_	O
13	O
C	B
_	I
9	I
-	I
p	I
##hen	I
##yla	I
##lani	I
##ne	I
(	O
C	O
##LM	O
-	O
225	O
##0	O
-	O
H	O
)	O
,	O
_	O
13	O
C	B
_	I
5	I
-	I
pro	I
##line	I
(	O
C	O
##LM	O
-	O
226	O
##0	O
-	O
H	O
)	O
,	O
_	O
13	O
C	B
_	I
3	I
-	I
se	I
##rine	I
(	O
C	O
##LM	O
-	O
157	O
##4	O
-	O
H	O
)	O
,	O
_	O
13	O
C	B
_	I
4	I
-	I
th	I
##re	I
##oni	I
##ne	I
(	O
C	O
##LM	O
-	O
226	O
##1	O
-	O
0	O
)	O
,	O
_	O
13	O
C	O
_	O
11	O
-	O
try	O
##pt	O
##op	O
##han	O
(	O
C	O
##LM	O
-	O
42	O
##90	O
-	O
H	O
)	O
,	O
_	O
13	O
C	B
_	I
9	I
-	I
t	I
##yr	I
##os	I
##ine	I
(	O
C	O
##LM	O
-	O
226	O
##3	O
-	O
H	O
)	O
and	O
_	O
13	O
C	B
_	I
5	I
-	I
v	I
##ali	I
##ne	I

Moreover	O
,	O
most	O
of	O
these	O
fl	B
##av	I
##ono	I
##ids	I
are	O
also	O
meta	O
##bol	O
##ized	O
as	O
g	O
##lu	O
##cu	O
##ron	O
##ides	O
.	O

Additionally	O
,	O
a	O
panel	O
of	O
six	O
potential	O
u	O
##rina	O
##ry	O
meta	O
##bol	O
##ite	O
bio	O
##mark	O
##ers	O
,	O
including	O
p	B
##yr	I
##u	I
##vate	I
,	O
is	B
##ob	I
##ut	I
##yra	I
##te	I
,	O
α	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
,	O
ma	B
##lon	I
##ate	I
,	O
N	B
-	I
met	I
##hyl	I
##nic	I
##ot	I
##ina	I
##mi	I
##de	I
and	O
ace	B
##to	I
##ace	I
##tate	I
,	O
was	O
identified	O
as	O
an	O
effective	O
class	O
##ifier	O
.	O

The	O
ions	O
arising	O
from	O
loss	O
of	O
trim	B
##eth	I
##yla	I
##mine	I
[	O
M	O
-	O
59	O
]	O
,	O
et	B
##hyl	I
##ene	I
phosphate	I
[	O
M	O
-	O
183	O
]	O
and	O
lit	B
##hium	I
et	I
##hyl	I
##ene	I
phosphate	I
[	O
M	O
-	O
189	O
]	O
were	O
common	O
fragments	O
for	O
C	O
##ID	O
s	O
##pect	O
##ra	O
of	O
PC	O
##s	O
and	O
SM	O
##s	O
.	O

_	O
b	O
Ho	O
##rmon	O
##e	O
receptors	O
are	O
receptors	O
for	O
est	B
##rogen	I
and	O
pro	B
##ges	I
##tero	I
##ne	I
;	O
H	O
##R	O
-	O
:	O
at	O
least	O
one	O
of	O
the	O
two	O
receptors	O
are	O
negative	O
;	O
H	O
##R	O
+	O
:	O
both	O
receptors	O
are	O
positive	O
.	O

Met	O
##ab	O
##oli	O
##tes	O
in	O
the	O
try	B
##pt	I
##op	I
##han	I
degradation	O
pathway	O
increased	O
following	O
le	O
##pt	O
##in	O
therapy	O
.	O

However	O
,	O
our	O
study	O
did	O
not	O
have	O
sufficient	O
power	O
to	O
precisely	O
estimate	O
this	O
correlation	O
,	O
and	O
using	O
a	O
Bon	O
##fer	O
##ron	O
##i	O
corrected	O
threshold	O
of	O
0	O
.	O
05	O
/	O
53	O
##9	O
,	O
could	O
only	O
find	O
7	O
meta	O
##bol	O
##ites	O
(	B
or	B
##ot	I
##id	I
##ine	I
,	O
and	O
##ro	O
s	O
##tero	O
##id	O
mon	B
##os	I
##ulf	I
##ate	I
and	O
five	O
unidentified	O
meta	O
##bol	O
##ites	O
)	O
with	O
a	O
ρ	O
statistical	O
##ly	O
significantly	O
larger	O
than	O
0	O
.	O

There	O
is	O
abundant	O
evidence	O
that	O
f	B
##olate	I
and	O
B	O
##12	O
deficiency	O
and	O
kidney	O
disease	O
can	O
contribute	O
to	O
h	O
##yper	O
##hom	O
##oc	O
##ys	O
##tein	O
##emia	O
.	O

Of	O
these	O
,	O
six	O
meta	O
##bol	O
##ites	O
were	O
discovered	O
as	O
having	O
the	O
strongest	O
correlation	O
##s	O
with	O
CH	O
##D	O
after	O
adjusting	O
for	O
multiple	O
testing	O
(	O
the	O
adjusted	O
OR	O
##s	O
ranged	O
from	O
2	O
.	O
79	O
to	O
7	O
.	O
24	O
)	O
;	O
to	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
the	O
correlation	O
##s	O
of	O
CH	O
##D	O
with	O
4	B
-	I
p	I
##yr	I
##ido	I
##xi	I
##c	I
acid	I
,	O
lit	B
##ho	I
##cho	I
##lic	I
acid	I
and	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##gly	I
##cer	I
##ol	I
(	I
20	I
:	I
3	I
/	I
2	I
:	I
0	I
)	I
were	O
first	O
reported	O
in	O
this	O
study	O
.	O

Media	O
##n	O
levels	O
of	O
3	O
-	O
HP	O
##MA	O
were	O
significantly	O
higher	O
(	O
290	O
##0	O
pm	O
##ol	O
/	O
mg	O
c	B
##rea	I
##tin	I
##ine	I
,	O
N	O
=	O
35	O
)	O
in	O
smoke	O
##rs	O
than	O
in	O
non	O
-	O
smoke	O
##rs	O
(	O
68	O
##3	O
pm	O
##ol	O
/	O
mg	O
c	B
##rea	I
##tin	I
##ine	I
,	O
N	O
=	O
21	O
)	O
(	O
P	O
=	O
0	O
.	O
000	O
##2	O
)	O
.	O

Total	O
ch	B
##ole	I
##ster	I
##ol	I
was	O
measured	O
on	O
a	O
Beck	O
##man	O
Co	O
##ulter	O
®	O
AU	O
##6	O
##80	O
analyze	O
##r	O
,	O
and	O
high	O
-	O
density	O
lip	O
##op	O
##rote	O
##in	O
ch	B
##ole	I
##ster	I
##ol	I
(	O
HD	O
##L	O
-	O
C	O
)	O
and	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
(	O
T	O
##G	O
)	O
were	O
measured	O
on	O
an	O
O	O
##ly	O
##mpus	O
AU	O
##40	O
##0	O
analyze	O
##r	O
(	O
Beck	O
##man	O
Co	O
##ulter	O
,	O
B	O
##rea	O
,	O
CA	O
,	O
USA	O
)	O
.	O

It	O
has	O
been	O
reported	O
that	O
try	B
##pt	I
##op	I
##han	I
is	O
cat	O
##ab	O
##oli	O
##zed	O
through	O
K	B
##yn	I
##uren	I
##ine	I
Path	O
##way	O
(	O
K	O
##P	O
)	O
to	O
vital	O
energy	O
co	O
##fa	O
##ctor	O
,	O
ni	B
##cot	I
##ina	I
##mi	I
##de	I
ad	I
##eni	I
##ne	I
din	I
##uc	I
##leo	I
##tide	I
(	O
H	O
##AD	O
_	O
+	O
)	O
,	O
which	O
could	O
promote	O
cellular	O
growth	O
.	O

Heat	O
##ma	O
##p	O
cluster	O
##ing	O
lip	O
##ids	O
in	O
urine	O
from	O
me	O
##lo	O
##xi	O
##cam	O
-	O
treated	O
(	O
n	O
=	O
6	O
)	O
and	O
sa	O
##line	O
-	O
treated	O
(	O
n	O
=	O
6	O
)	O
cats	O
before	O
(	O
time	O
1	O
)	O
and	O
after	O
the	O
administration	O
of	O
sa	B
##line	I
or	O
me	O
##lo	O
##xi	O
##cam	O
at	O
0	O
.	O
3	O
mg	O
/	O
kg	O

Our	O
initial	O
attempts	O
to	O
s	O
##ynth	O
##esi	O
##ze	O
HP	O
##HP	O
##A	O
,	O
which	O
were	O
based	O
on	O
the	O
method	O
described	O
in	O
1957	O
with	O
slight	O
modification	O
,	O
started	O
with	O
the	O
initial	O
protection	O
of	O
the	O
p	O
##hen	O
##olic	O
h	O
##ydro	O
##xy	O
##l	O
of	O
the	O
starting	O
3	B
-	I
h	I
##ydro	I
##xy	I
##ben	I
##zal	I
##de	I
##hy	I
##de	I
1	O
using	O
a	O
ben	O
##zy	O
##l	O
group	O
.	O

In	O
such	O
cases	O
,	O
only	O
dedicated	O
experiments	O
(	O
similar	O
to	O
the	O
one	O
for	O
the	O
car	O
##ni	O
##tine	O
/	O
SL	O
##C	O
##16	O
##A	O
##9	O
association	O
mentioned	O
above	O
)	O
could	O
valid	O
##ate	O
the	O
connection	O
of	O
ethanol	B
##amine	I
to	O
the	O
gene	O
product	O
.	O

More	O
than	O
30	O
years	O
ago	O
,	O
Jack	O
Fish	O
##man	O
and	O
Leon	O
Brad	O
##low	O
published	O
one	O
of	O
the	O
first	O
e	O
##pid	O
##em	O
##iol	O
##og	O
##ic	O
studies	O
of	O
est	B
##rogen	I
metabolism	O
and	O
breast	O
cancer	O
.	O

Key	O
HC	O
##C	O
vs	O
.	O
DC	O
trends	O
among	O
o	O
##xi	O
##da	O
##tive	O
stress	O
-	O
associated	O
meta	O
##bol	O
##ites	O
included	O
1	O
.	O
62	O
-	O
fold	O
up	O
##re	O
##gu	O
##lation	O
of	O
x	B
##ant	I
##hine	I
(	O
P	O
=	O
9	O
.	O
35	O
9	O
10	O
_	O
−	O
##5	O
)	O
,	O
a	O
pu	B
##rine	I
degradation	O
intermediate	O
whose	O
production	O
is	O
accompanied	O
by	O
generation	O
of	O
reactive	O
oxygen	O
species	O
(	O
R	O
##OS	O
)	O
hydrogen	B
per	I
##oxide	I
(	O
H	O
_	O
2	O
O	O
_	O
2	O
)	O
and	O
1	O
.	O
56	O
-	O
fold	O
elevated	O
2	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
(	O
2	O
##H	O
##B	O
)	O
(	O
P	O
<	O
0	O
.	O
000	O
##3	O
)	O
,	O
an	O
important	O
neutral	O
##izing	O
agent	O
of	O
reactive	O
oxygen	O
species	O
that	O
complement	O
##s	O
g	B
##lut	I
##ath	I
##ione	I
during	O
periods	O
of	O
overwhelming	O
o	O
##xi	O
##da	O
##tive	O
stress	O
.	O

Apart	O
from	O
that	O
,	O
l	B
##ys	I
##ine	I
is	O
an	O
act	O
##iva	O
##tor	O
of	O
GP	O
##RC	O
##6	O
##A	O
,	O
the	O
O	O
##C	O
##N	O
receptor	O
.	O

Unlike	O
those	O
of	O
the	O
g	B
##ly	I
##cer	I
##ol	I
backbone	O
,	O
these	O
cross	O
-	O
peaks	O
showed	O
scrambled	O
label	O
patterns	O
,	O
i	O
.	O
e	O
.	O
for	O
a	O
given	O
pair	O
of	O
pro	O
##tons	O
,	O
there	O
were	O
four	O
_	O
13	O
C	O
is	O
##oto	O
##po	O
##mer	O
species	O
.	O

Our	O
data	O
indicated	O
that	O
the	O
levels	O
of	O
as	B
##par	I
##tate	I
,	O
as	B
##par	I
##agi	I
##ne	I
,	O
g	B
##lut	I
##ama	I
##te	I
,	O
g	B
##lut	I
##amine	I
,	O
c	B
##ys	I
##tein	I
##e	I
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
and	O
le	B
##uc	I
##ine	I
were	O
higher	O
,	O
while	O
the	O
levels	O
of	O
met	B
##hi	I
##oni	I
##ne	I
and	O
t	B
##yr	I
##os	I
##ine	I
were	O
lower	O
,	O
in	O
serum	O
samples	O
from	O
lung	O
cancer	O
patients	O
compared	O
to	O
controls	O
.	O

Finally	O
,	O
the	O
data	O
also	O
show	O
reduced	O
substrate	O
and	O
gene	O
expression	O
consistent	O
with	O
reduced	O
in	O
##trar	O
##ena	O
##l	O
do	B
##pa	I
##mine	I
synthesis	O
,	O
which	O
would	O
strongly	O
imp	O
##air	O
na	O
##tri	O
##ures	O
##is	O
and	O
blood	O
pressure	O
control	O
.	O

The	O
small	O
sample	O
size	O
of	O
the	O
individual	O
l	O
##ymph	O
##oma	O
sub	O
##type	O
##s	O
prevented	O
obtaining	O
P	O
##LS	O
-	O
D	O
##A	O
valid	O
##ated	O
models	O
,	O
although	O
specific	O
peculiar	O
features	O
of	O
each	O
sub	O
##type	O
were	O
observed	O
;	O
for	O
instance	O
,	O
fatty	O
acids	O
were	O
most	O
represented	O
in	O
M	O
##M	O
and	O
H	B
##L	I
patients	O
,	O
while	O
2	B
-	I
amino	I
##adi	I
##pic	I
acid	I
,	O
2	B
-	I
amino	I
##he	I
##pta	I
##ned	I
##io	I
##ic	I
acid	I
,	O
er	B
##yt	I
##hr	I
##ito	I
##l	I
,	O
and	O
th	B
##re	I
##ito	I
##l	I
characterized	O
DL	O
##BC	O
##L	O
and	O
C	O
##LL	O
.	O

For	O
non	O
-	O
para	O
##metric	O
##ally	O
distributed	O
data	O
sets	O
,	O
with	O
the	O
exception	O
of	O
is	O
##onia	O
##zi	O
##d	O
and	O
sa	B
##line	I
treatment	O
groups	O
,	O
a	O
K	O
##rus	O
##kal	O
-	O
Wallis	O
AN	O
##O	O
##VA	O
was	O
performed	O
.	O

The	O
presence	O
or	O
absence	O
of	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
or	O
i	B
##bu	I
##p	I
##ro	I
##fen	I
for	O
the	O
remaining	O
IN	O
##TE	O
##R	O
##MA	O
##P	O
data	O
,	O
which	O
were	O
not	O
visually	O
verified	O
(	O
n	O
=	O
8	O
,	O
43	O
##6	O
for	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
and	O
n	O
=	O
8	O
,	O
60	O
##4	O
for	O
i	B
##bu	I
##p	I
##ro	I
##fen	I
)	O
,	O
but	O
were	O
determined	O
here	O
using	O
the	O
op	O
##ti	O
##mized	O
parameters	O
as	O
defined	O
in	O
models	O
PC	O
##T	O
##10	O
and	O
I	O
##B	O
##U	O
##1	O
.	O

Product	O
ion	O
mass	O
s	O
##pect	O
##ra	O
of	O
des	B
##ami	I
##no	I
-	I
Ph	I
##IP	I
-	I
K	I
(	O
[	O
M	O
+	O
H	O
]	O
_	O
+	O
,	O
m	O
/	O
z	O
35	O
##4	O
.	O
2	O
)	O
recovered	O
from	O
NO	O
_	O
2	O
-	O
Ph	O
##IP	O
-	O
modified	O
SA	O
(	O
upper	O
panel	O
)	O
and	O
des	B
##ami	I
##no	I
-	I
[	I
_	I
2	I
H	I
_	I
5	I
]	I
-	O
Ph	O
##IP	O
-	O
K	O
(	O
[	O
M	O
+	O
H	O
]	O
_	O
+	O
,	O
m	O
/	O
z	O
35	O
##9	O
.	O
2	O
)	O
recovered	O
from	O
NO	O
_	O
2	O
-	O
[	O
_	O
2	O
H	O
_	O
5	O
]	O
-	O
Ph	O
##IP	O
modified	O
SA	O
(	O
bottom	O
panel	O
)	O
,	O
following	O
dig	O
##est	O
##ion	O
of	O
with	O
Pro	O
##nas	O
##e	O
E	O
,	O
le	O
##uc	O
##ine	O
amino	O
##pe	O
##pt	O
##idas	O
##e	O
,	O
and	O
pro	O
##lid	O
##ase	O
.	O

Another	O
example	O
of	O
a	O
meta	O
##bol	O
##ite	O
found	O
to	O
be	O
increased	O
in	O
the	O
pre	O
-	O
di	O
##abe	O
##tic	O
group	O
(	O
IS	O
##I	O
_	O
Mat	O
##su	O
##da	O
<	O
15	O
)	O
compared	O
to	O
the	O
group	O
with	O
normal	O
insulin	O
sensitivity	O
is	O
the	O
meta	O
##bol	O
##ite	O
ion	O
possibly	O
assigned	O
to	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
.	O

The	O
increase	O
of	O
the	O
G	O
##S	O
##H	O
/	O
G	O
##SS	O
##G	O
seems	O
to	O
be	O
specific	O
for	O
na	O
##no	O
##par	O
##tic	O
##les	O
with	O
anti	O
-	O
o	O
##xi	O
##dant	O
properties	O
,	O
such	O
as	O
gold	O
and	O
silver	B
na	I
##no	I
##par	I
##tic	I
##les	I
,	O
as	O
it	O
has	O
not	O
been	O
detected	O
for	O
copper	O
,	O
co	O
##balt	O
or	O
t	O
##ita	O
##nium	O
na	O
##no	O
##par	O
##tic	O
##les	O
.	O

[	O
more	O
commonly	O
known	O
as	O
bi	B
##s	I
(	I
mon	I
##oa	I
##cy	I
##l	I
##gly	I
##cer	I
##ol	I
)	I
phosphate	I
(	O
B	O
##MP	O
)	O
]	O
,	O
a	O
structural	O
is	O
##omer	O
of	O
P	B
##G	I
since	O
P	B
##G	I
and	O
B	O
##MP	O
lip	O
##ids	O
have	O
very	O
similar	O
tandem	O
mass	O
s	O
##pect	O
##ra	O
.	O

U	O
##rina	O
##ry	O
co	B
##tin	I
##ine	I
was	O
analyzed	O
by	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
.	O

Ba	O
##sal	O
plasma	O
concentrations	O
in	O
volunteers	O
were	O
depressed	O
by	O
pre	O
##tre	O
##at	O
##ment	O
with	O
325	O
mg	O
of	O
as	B
##pi	I
##rin	I
.	O

Sign	O
##ificant	O
differences	O
between	O
the	O
intake	O
of	O
the	O
three	O
foods	O
after	O
6	O
h	O
were	O
found	O
in	O
case	O
of	O
gal	B
##act	I
##ona	I
##te	I
,	O
gal	B
##act	I
##ito	I
##l	I
,	O
and	O
gal	B
##act	I
##ono	I
-	I
1	I
,	I
5	I
-	I
la	I
##cton	I
##e	I
(	O
see	O
Table	O
##s	O
S	O
##3	O
and	O
S	O
##4	O
)	O
.	O

The	O
column	O
was	O
maintained	O
at	O
40	O
°C	O
and	O
el	O
##uted	O
at	O
a	O
flowing	O
rate	O
of	O
0	O
.	O
45	O
m	O
##L	O
/	O
min	O
,	O
using	O
a	O
mobile	O
phase	O
of	O
(	O
A	O
)	O
5	O
%	O
(	O
by	O
volume	O
)	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
in	O
water	O
and	O
(	O
B	O
)	O
95	O
%	O
(	O
by	O
volume	O
)	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
in	O
water	O
.	O

2	B
-	I
O	I
##x	I
##og	I
##lut	I
##arate	I
(	O
also	O
called	O
α	B
-	I
k	I
##eto	I
##g	I
##lut	I
##arate	I
)	O
,	O
which	O
is	O
an	O
important	O
player	O
in	O
the	O
K	O
##re	O
##bs	O
cycle	O
,	O
is	O
known	O
to	O
be	O
involved	O
in	O
the	O
cellular	O
de	O
##to	O
##xi	O
##fication	O
of	O
o	O
##xi	O
##da	O
##tive	O
damage	O
.	O

Red	O
##uction	O
of	O
2	B
‐	I
o	I
##x	I
##ois	I
##oc	I
##ap	I
##roa	I
##te	I
is	O
comparable	O
with	O
low	O
le	B
##uc	I
##ine	I
levels	O
post	O
‐	O
surgery	O
and	O
suggests	O
increased	O
BC	O
##AA	O
degradation	O
post	O
‐	O
R	O
##Y	O
##GB	O
.	O

De	O
##ple	O
##tion	O
of	O
a	O
second	O
S	O
##NA	O
##RE	O
component	O
,	O
syntax	B
##in	I
3	O
,	O
has	O
also	O
been	O
found	O
to	O
reduce	O
the	O
yield	O
of	O
HC	O
##M	O
##V	O
.	O

A	O
number	O
of	O
meta	O
##bol	O
##ites	O
,	O
such	O
as	O
T	O
##CA	O
,	O
T	O
##CD	O
##CA	O
,	O
G	O
##CA	O
,	O
Cho	B
##E	I
(	I
18	I
:	I
1	I
)	I
,	O
PC	B
(	I
16	I
:	I
0	I
/	I
16	I
:	I
0	I
)	I
,	O
PC	B
(	I
32	I
:	I
1	I
)	I
,	O
PC	B
(	I
20	I
:	I
0	I
/	I
0	I
:	I
0	I
)	I
,	O
PC	B
(	I
O	I
-	I
20	I
:	I
0	I
/	I
0	I
:	I
0	I
)	I
,	O
SM	B
(	I
d	I
##18	I
:	I
0	I
/	I
14	I
:	I
0	I
)	I
,	O
and	O
SM	B
(	I
d	I
##18	I
:	I
0	I
/	I
18	I
:	I
0	I
)	I
were	O
found	O
also	O
significant	O
in	O
the	O
O	O
##PL	O
##S	O
-	O
D	O
##A	O
.	O

When	O
met	B
##han	I
##ol	I
-	I
ethanol	I
was	O
used	O
,	O
an	O
additional	O
45	O
##3	O
(	O
52	O
##6	O
–	O
73	O
)	O
features	O
were	O
found	O
compared	O
to	O
positive	O
mode	O
.	O

5	O
-	O
AS	O
##A	O
,	O
5	B
-	I
amino	I
##sal	I
##ic	I
##yl	I
##ic	I
acid	I
;	O
T	O
##NF	O
,	O
t	O
##umour	O
ne	O
##c	O
##rosis	O
factor	O
.	O

ace	B
##tam	I
##ino	I
##phe	I
##n	I
,	O
bio	O
##mark	O
##ers	O
,	O
f	O
##ec	O
##und	O
##ity	O
,	O
para	B
##ce	I
##tam	I
##ol	I
,	O
p	B
-	I
amino	I
##phe	I
##no	I
##l	I
,	O
T	O
##TP	O

For	O
G	O
##C	O
-	O
MS	O
analysis	O
,	O
the	O
non	O
-	O
polar	O
fraction	O
was	O
treated	O
with	O
met	B
##han	I
##ol	I
under	O
acidic	O
conditions	O
to	O
give	O
fatty	O
acid	O
met	O
##hyl	O
est	O
##ers	O
that	O
were	O
derived	O
from	O
both	O
free	O
fatty	O
acids	O
and	O
h	O
##ydro	O
##ly	O
##zed	O
complex	O
lip	O
##ids	O
.	O

The	O
data	O
show	O
that	O
glucose	S
had	O
no	O
effect	O
on	O
ATP	S
levels	O
in	O
response	O
to	O
radiation	O
,	O
but	O
supplement	O
##ation	O
with	O
g	B
##lut	I
##amine	I
dramatically	O
enhanced	O
ATP	S
production	O
in	O
control	O
cells	O
,	O
but	O
only	O
slightly	O
increased	O
the	O
ATP	S
levels	O
in	O
CP	O
##T	O
##1	O
##A	O
knock	O
##down	O
cells	O
(	O
Figure	O
C	O
)	O
.	O

There	O
is	O
also	O
evidence	O
that	O
reduced	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
levels	O
may	O
be	O
on	O
##co	O
##genic	O
as	O
demonstrated	O
by	O
in	O
##hibition	O
of	O
the	O
RA	O
##S	O
-	O
MA	O
##P	O
##K	O
,	O
Cy	O
##c	O
##lin	O
##D	O
-	O
CD	O
##K	O
##4	O
/	O
CD	O
##K	O
##6	O
and	O
P	O
##I	O
##3	O
##K	O
-	O
AK	O
##T	O
axes	O
through	O
the	O
activation	O
of	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
s	O
##ynth	O
##ase	O
by	O
a	O
synthetic	O
fatty	O
acid	O
.	O

O	O
##bt	O
##aine	O
##d	O
results	O
of	O
area	O
under	O
the	O
curve	O
(	O
AU	O
##C	O
)	O
,	O
sensitivity	O
,	O
and	O
specific	O
##ity	O
slightly	O
improved	O
when	O
these	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
were	O
grouped	O
.	O

G	B
##lu	I
##cos	I
##e	I
regions	O
were	O
also	O
removed	O
due	O
to	O
high	O
urine	O
glucose	S
levels	O
in	O
many	O
of	O
the	O
H	O
##NF	O
##1	O
##A	O
-	O
M	O
##OD	O
##Y	O
samples	O
.	O

In	O
short	O
,	O
D	O
_	O
2	O
O	O
phosphate	S
buffer	O
pH	O
7	O
.	O
4	O
(	O
0	O
.	O
07	O
##5	O
##M	O
Na	O
_	O
2	O
HP	O
##O	O
_	O
4	O
·	O
7	O
##H	O
_	O
2	O
O	O
)	O
with	O
3	B
-	I
trim	I
##eth	I
##yl	I
##si	I
##ly	I
##l	I
prop	I
##ion	I
##ic	I
acid	I
(	O
T	O
##SP	O
)	O
(	O
350	O
μ	O
##L	O
)	O
was	O
added	O
to	O
he	B
##par	I
##in	I
containing	O
plasma	O
samples	O
(	O
350	O
μ	O
##L	O
)	O
.	O

Overall	O
,	O
512	O
features	O
were	O
detected	O
in	O
negative	O
mode	O
when	O
the	O
met	B
##han	I
##ol	I
super	O
##nat	O
##ant	O
was	O
analyzed	O
versus	O
52	O
##6	O
features	O
detected	O
in	O
the	O
met	B
##han	I
##ol	I
-	I
ethanol	I
(	I
1	I
:	I
1	I
)	I
super	O
##nat	O
##ant	O
.	O

The	O
system	O
utilized	O
a	O
DB	O
-	O
5	O
##MS	O
cap	O
##illa	O
##ry	O
column	O
coated	O
with	O
5	O
%	O
dip	O
##hen	O
##yl	O
cross	O
-	O
linked	O
with	O
95	O
%	O
dim	B
##eth	I
##yl	I
##pol	I
##ys	I
##ilo	I
##xa	I
##ne	I
(	O
30	O
m	O
×	O
250	O

In	O
the	O
RA	O
##C	O
group	O
,	O
ions	O
of	O
m	O
/	O
z	O
73	O
##4	O
and	O
75	O
##6	O
identified	O
as	O
PC	O
or	O
P	O
##E	O
;	O
and	O
ions	O
of	O
m	O
/	O
z	O
79	O
##2	O
,	O
82	O
##0	O
identified	O
as	O
PC	O
plasma	O
##log	O
##en	O
(	O
PC	O
##P	O
)	O
or	O
1	B
-	I
al	I
##ky	I
##l	I
PC	I
(	O
PC	O
##O	O
)	O
were	O
up	O
-	O
regulated	O
,	O
while	O
l	B
##is	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
(	O
LP	O
##C	O
)	O
meta	O
##bol	O
##ites	O
(	O
m	O
/	O
z	O
49	O
##6	O
and	O
52	O
##4	O
)	O
and	O
three	O
LP	O
##C	O
plasma	O
##log	O
##ens	O
(	O
m	O
/	O
z	O
47	O
##8	O
,	O
50	O
##6	O
and	O
50	O
##4	O
)	O
were	O
down	O
##re	O
##gu	O
##lated	O
compared	O
with	O
healthy	O
subjects	O
.	O

Lac	B
##tate	I
was	O
significantly	O
increased	O
(	O
p	O
<	O
0	O
.	O
00	O
##2	O
)	O
,	O
whilst	O
al	B
##ani	I
##ne	I
(	O
p	O
<	O
0	O
.	O
01	O
##7	O
)	O
and	O
the	O
branched	O
-	O
chain	O
amino	O
acids	O
(	O
BC	O
##AA	O
)	O
is	B
##ole	I
##uc	I
##ine	I
(	O
p	O
<	O
0	O
.	O
02	O
##9	O
)	O
and	O
v	B
##ali	I
##ne	I
(	O
p	O
<	O
0	O
.	O
00	O
##4	O
)	O
were	O
all	O
significantly	O
decreased	O
in	O
AC	O
##M	O
from	O
o	O
##bes	O
##e	O
patients	O
,	O
when	O
compared	O
to	O
non	O
-	O
o	O
##bes	O
##e	O
patients	O
(	O
Table	O
)	O
.	O

c	O
a	O
d	O
Co	O
##py	O
number	O
and	O
single	O
n	O
##uc	O
##leo	O
##tide	O
variants	O
in	O
p	B
##yr	I
##im	I
##id	I
##ine	I
metabolism	O
pathway	O
genes	O
.	O

Ph	B
##yt	I
##os	I
##phi	I
##ngo	I
##sin	I
##e	I
and	O
s	B
##phi	I
##nga	I
##nine	I
-	I
phosphate	I
can	O
correctly	O
predict	O
100	O
%	O
patients	O
with	O
the	O
corresponding	O
AU	O
##C	O
equal	O
to	O
1	O
.	O
00	O
in	O
the	O
training	O
set	O
and	O
can	O
correctly	O
predict	O
99	O
%	O
patients	O
with	O
the	O
corresponding	O
AU	O
##C	O
equal	O
to	O
0	O
.	O
99	O
in	O
the	O
test	O
set	O
.	O

A	O
##bb	O
##re	O
##viation	O
##s	O
:	O
Al	B
##ky	I
##l	I
##ph	I
##os	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
(	O
PC	O
-	O
O	O
)	O
,	O
Ce	B
##ram	I
##ide	I
(	O
Ce	O
##r	O
)	O
,	O
GM	B
##3	I
gang	I
##lio	I
##side	I
(	I
GM	I
##3	I
)	I
,	O
L	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
(	O
LP	O
##C	O
)	O
,	O
L	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##lino	I
##si	I
##to	I
##l	I
(	O
LP	O
##I	O
)	O
,	O
L	B
##ys	I
##oa	I
##lk	I
##yl	I
##ph	I
##os	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
(	O
LP	O
##C	O
(	O
O	O
)	O
)	O
,	O
Mon	B
##oh	I
##ex	I
##osy	I
##l	I
##cer	I
##ami	I
##de	I
(	I
M	I
##HC	I
)	I
,	O
Ph	B
##os	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
(	O
PC	O
)	O
,	O
Ph	B
##os	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
plasma	O
##log	O
##en	O
(	O
PC	O
-	O
P	O
)	O
,	O
Ph	B
##os	I
##pha	I
##ti	I
##dy	I
##lino	I
##si	I
##to	I
##l	I
(	O
P	O
##I	O
)	O
,	O
S	B
##phi	I
##ngo	I
##my	I
##elin	I
(	O
SM	O
)	O
,	O
Tri	B
##acy	I
##l	I
##gly	I
##cer	I
##ol	I
(	O
T	O
##G	O
)	O
,	O
Tri	B
##he	I
##x	I
##osy	I
##l	I
##cer	I
##ami	I
##de	I
(	O
T	O
##HC	O
)	O
.	O

Furthermore	O
,	O
compared	O
to	O
that	O
of	O
normal	O
donors	O
,	O
higher	O
concentrations	O
of	O
sperm	B
##ine	I
and	O
sperm	B
##id	I
##ine	I
were	O
reported	O
in	O
the	O
seminal	O
plasma	O
of	O
o	O
##bes	O
##e	O
men	O
(	O
B	O
##MI	O
>	O
30	O
)	O
with	O
a	O
poor	O
sperm	O
##io	O
##gram	O
.	O

Since	O
we	O
studied	O
the	O
MD	O
##A	O
-	O
MB	O
-	O
231	O
cell	O
line	O
which	O
is	O
triple	O
negative	O
for	O
est	B
##rogen	I
receptor	O
(	O
ER	O
)	O
,	O
pro	B
##ges	I
##tero	I
##ne	I
receptor	O
(	O
PR	O
)	O
and	O
e	O
##pid	O
##er	O
##mal	O
growth	O
factor	O
receptor	O
2	O
(	O
H	O
##ER	O
##2	O
)	O
in	O
our	O
study	O
,	O
one	O
might	O
argue	O
whether	O
over	O
##ex	O
##press	O
##ion	O
of	O
PC	O
is	O
a	O
specific	O
characteristic	O
of	O
breast	O
cancer	O
cell	O
lines	O
.	O

Met	O
##ab	O
##olo	O
##mic	O
analysis	O
,	O
using	O
quantitative	O
mass	O
s	O
##pect	O
##rome	O
##try	O
,	O
of	O
try	B
##pt	I
##op	I
##han	I
and	O
its	O
cat	O
##ab	O
##oli	O
##tes	O
-	O
including	O
k	B
##yn	I
##uren	I
##ine	I
-	I
in	O
the	O
plasma	O
from	O
pre	O
-	O
surgical	O
breast	O
cancer	O
patients	O
(	O
n	O
=	O
77	O
)	O
and	O
40	O
cancer	O
-	O
free	O
donors	O
(	O
n	O
=	O
40	O
)	O
indicated	O
a	O
strong	O
correlation	O
between	O
substrate	O
and	O
cat	O
##ab	O
##oli	O
##te	O
in	O
both	O
groups	O
.	O

Alan	B
##ine	I
has	O
been	O
previously	O
identified	O
as	O
a	O
meta	O
##bol	O
##ite	O
disc	O
##rim	O
##inating	O
healthy	O
and	O
chronic	O
o	O
##bs	O
##truct	O
##ive	O
pulmonary	O
disease	O
in	O
older	O
adults	O
.	O

Two	O
sperm	B
##id	I
##ine	I
pathway	O
meta	O
##bol	O
##ites	O
,	O
or	B
##ni	I
##thin	I
##e	I
and	O
sperm	B
##id	I
##ine	I
,	O
were	O
en	O
##rich	O
##ed	O
over	O
800	O
-	O
fold	O
in	O
the	O
u	O
##E	O
##Vs	O
relative	O
to	O
urine	O
.	O

We	O
could	O
not	O
find	O
any	O
association	O
between	O
changes	O
in	O
the	O
concentrations	O
of	O
try	B
##pt	I
##op	I
##han	I
meta	O
##bol	O
##ites	O
and	O
the	O
anti	O
-	O
de	O
##pressive	O
response	O
(	O
data	O
not	O
shown	O
)	O
.	O

(	O
C	O
)	O
ST	O
##OR	O
##M	O
analysis	O
of	O
the	O
tentative	O
single	O
##t	O
reveals	O
potential	O
overlap	O
of	O
signal	O
with	O
3	B
-	I
h	I
##ydro	I
##xy	I
##is	I
##ova	I
##ler	I
##ate	I
(	O
δ	O
1	O
.	O
275	O
(	O
s	O
)	O
)	O
.	O

The	O
proportion	O
of	O
g	B
##lu	I
##co	I
##bra	I
##ssi	I
##cin	I
ex	O
##cre	O
##ted	O
in	O
the	O
urine	O
as	O
D	O
##IM	O
was	O
low	O
,	O
most	O
likely	O
from	O
a	O
low	O
rate	O
of	O
conversion	O
of	O
I	O
##3	O
##C	O
to	O
D	O
##IM	O
in	O
the	O
stomach	O
due	O
to	O
the	O
complex	O
he	O
##tero	O
##gene	O
##ity	O
of	O
gas	O
##tric	O
contents	O
.	O

Peak	O
##s	O
in	O
the	O
1	O
##D	O
and	O
2D	O
N	O
##MR	O
s	O
##pect	O
##ra	O
were	O
assigned	O
to	O
various	O
meta	O
##bol	O
##ites	O
based	O
on	O
literature	O
reports	O
.	O
-	O
In	O
##te	O
##gra	O
##ls	O
for	O
well	O
resolved	O
peaks	O
in	O
1	O
##D	O
and	O
2D	O
s	O
##pect	O
##ra	O
were	O
obtained	O
with	O
respect	O
to	O
the	O
peak	O
for	O
the	O
internal	O
standard	O
DS	O
##S	O
,	O
male	B
##ic	I
acid	I
or	O
ethanol	B
##amine	I
.	O

After	O
plasma	O
was	O
th	O
##awed	O
on	O
ice	O
,	O
400	O
µ	O
##L	O
of	O
ice	O
-	O
cooled	O
met	B
##han	I
##ol	I
was	O
added	O
to	O
100	O
µ	O
##L	O
of	O
plasma	O
in	O
a	O
2	O
-	O
m	O
##L	O
micro	O
##fu	O
##ge	O
tube	O
.	O

According	O
to	O
the	O
results	O
,	O
increased	O
amounts	O
of	O
try	B
##pt	I
##op	I
##han	I
,	O
h	B
##y	I
##pot	I
##au	I
##rine	I
,	O
c	B
##it	I
##rate	I
,	O
ch	B
##olin	I
##e	I
,	O
hip	B
##pura	I
##te	I
,	O
met	B
##hi	I
##oni	I
##ne	I
,	O
s	B
##cy	I
##llo	I
-	I
in	I
##os	I
##ito	I
##l	I
,	O
ace	B
##ty	I
##l	I
-	I
car	I
##ni	I
##tine	I
,	O
g	B
##lut	I
##ath	I
##ione	I
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
and	O
is	B
##ole	I
##uc	I
##ine	I
were	O
observed	O
in	O
thy	O
##roid	O
lesions	O
(	O
including	O
PT	O
##C	O
+	O
M	O
##NG	O
)	O
compared	O
to	O
healthy	O
controls	O
where	O
k	B
##yn	I
##uren	I
##ine	I
level	O
was	O
decreased	O
.	O

Thus	O
,	O
we	O
found	O
an	O
inverse	O
association	O
with	O
B	O
##MI	O
of	O
pro	B
##line	I
beta	I
##ine	I
(	O
P	O
=	O
7	O
.	O
29	O
×	O
10	O
_	O
−	O
##9	O
)	O
,	O
a	O
bio	O
##mark	O
##er	O
of	O
c	O
##itrus	O
fruit	O
consumption	O
(	O
,	O
)	O
associated	O
with	O
a	O
healthy	O
eating	O
pattern	O
,	O
and	O
a	O
direct	O
association	O
of	O
B	O
##MI	O
with	O
u	O
##rina	O
##ry	O
ex	O
##cre	O
##tion	O
of	O
O	B
-	I
ace	I
##ty	I
##l	I
car	I
##ni	I
##tine	I
(	O
r	O
=	O
0	O
.	O
10	O
,	O
P	O
=	O
1	O
.	O
46	O
×	O
10	O
_	O
−	O
##5	O
)	O
,	O
a	O
marker	O
of	O
red	O
meat	O
intake	O
(	O
,	O
)	O
,	O
which	O
in	O
turn	O
has	O
been	O
associated	O
with	O
long	O
-	O
term	O
weight	O
gain	O
.	O

Inc	O
##reased	O
palm	B
##itate	I
promotes	O
el	O
##ong	O
##ation	O
and	O
des	O
##at	O
##uration	O
,	O
as	O
evidenced	O
by	O
up	O
##re	O
##gu	O
##lation	O
of	O
s	B
##te	I
##aro	I
##yl	I
-	I
Co	I
##A	I
des	O
##at	O
##ura	O
##se	O
(	O
SC	O
##D	O
)	O
1	O
and	O
2	O
(	O
and	O
re	O
##f	O
.	O
)	O
.	O

Inc	O
##reased	O
g	B
##lut	I
##ama	I
##te	I
(	O
G	O
##lu	O
)	O
levels	O
and	O
decreased	O
g	B
##lut	I
##amine	I
(	O
G	O
##ln	O
)	O
levels	O
were	O
found	O
in	O
the	O
MD	O
##D	O
group	O
(	O
F	O
##DR	O
q	O
=	O
3	O
.	O
7	O
×	O
10	O
_	O
−	O
##7	O
and	O
4	O
.	O
8	O
×	O
10	O
_	O
−	O
##7	O
,	O
respectively	O
)	O

The	O
resulting	O
met	B
##han	I
##ol	I
solution	O
was	O
dried	O
under	O
nitrogen	O
and	O
re	O
##sus	O
##pen	O
##ded	O
in	O
50	O
μ	O
##L	O
of	O
HP	O
##LC	O
mobile	O
phase	O
before	O
liquid	O
ch	O
##roma	O
##tography	O
/	O
tandem	O
mass	O
s	O
##pect	O
##rome	O
##try	O
analysis	O
.	O

With	O
respect	O
to	O
T	O
##S	O
##H	O
,	O
four	O
urine	O
meta	O
##bol	O
##ites	O
including	O
dim	B
##eth	I
##yla	I
##mine	I
(	O
D	O
##MA	O
)	O
,	O
D	B
-	I
glucose	I
-	I
beta	I
,	O
g	B
##ly	I
##cine	I
and	O
la	B
##ctic	I
acid	I
were	O
significantly	O
(	O
F	O
##DR	O
<	O
0	O
.	O
05	O
)	O
and	O
inverse	O
##ly	O
associated	O
in	O
both	O
study	O
populations	O
(	O
,	O
)	O
.	O

AD	B
##MA	I
is	O
meta	O
##bol	O
##ized	O
to	O
c	B
##it	I
##ru	I
##llin	I
##e	I
and	O
dim	B
##eth	I
##yla	I
##mine	I
by	O
DD	O
##A	O
##H	O
and	O
enters	O
cells	O
through	O
cat	O
##ion	O
##ic	O
amino	B
-	I
acid	I
transport	O
##ers	O
(	O
CA	O
##T	O
)	O
.	O

For	O
LL	O
##E	O
,	O
200	O
μ	O
##L	O
et	B
##hyl	I
ace	I
##tate	I
and	O
100	O
μ	O
##L	O
water	O
were	O
added	O
to	O
the	O
samples	O
after	O
protein	O
precipitation	O
,	O
vigorously	O
v	O
##ortex	O
##ed	O
for	O
30	O
s	O
,	O
and	O
cent	O
##ri	O
##fu	O
##ged	O
for	O
5	O
min	O
at	O
3	O
,	O
000	O
##×	O
##g	O
,	O
and	O
the	O
upper	O
et	B
##hyl	I
ace	I
##tate	I
layer	O
was	O
transferred	O
into	O
E	O
##ppe	O
##ndo	O
##rf	O
via	O
##ls	O
.	O

A	B
##cy	I
##l	I
-	I
car	I
##n	I
analyses	O
were	O
performed	O
by	O
adding	O
internal	O
standards	O
(	B
D	B
##3	I
-	I
ace	I
##ty	I
##l	I
##car	I
##ni	I
##tine	I
,	O
D	B
##3	I
-	I
o	I
##ct	I
##ano	I
##yl	I
##car	I
##ni	I
##tine	I
and	O
D	B
##3	I
-	I
palm	I
##ito	I
##yl	I
##car	I
##ni	I
##tine	I
(	O
Cam	O
##bri	O
##g	O
##de	O
Is	O
##oto	O
##pe	O
Laboratories	O
,	O
USA	O
)	O
)	O
to	O
100	O
μ	O
##L	O
of	O
the	O
super	O
##nat	O
##ant	O
and	O
in	O
##ject	O
##ing	O
it	O
to	O
a	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
system	O
(	O
1200	O
HP	O
##LC	O
A	O
##gi	O
##lent	O
,	O
W	O
##ald	O
##bro	O
##nn	O
,	O
Germany	O
coupled	O
to	O
4000	O
##Q	O
##TR	O
##AP	O
Sc	O
##ie	O
##x	O
,	O
Dar	O
##ms	O
##tadt	O
,	O
Germany	O
)	O
.	O

Table	O
S	O
##1	O
lists	O
all	O
sixty	O
polar	O
compounds	O
tested	O
during	O
the	O
compound	O
screening	O
study	O
;	O
these	O
were	O
obtained	O
as	O
pure	O
solid	O
##s	O
of	O
≥	O
95	O
%	O
purity	O
from	O
Sigma	O
,	O
with	O
the	O
exception	O
of	O
l	B
-	I
his	I
##ti	I
##dine	I
and	O
c	B
##yt	I
##os	I
##ine	I
,	O
which	O
were	O
purchased	O
from	O
Alfa	O
A	O
##es	O
##ar	O
(	O
Hey	O
##sham	O
,	O
UK	O
)	O
.	O

The	O
four	O
conditions	O
can	O
be	O
summarized	O
here	O
as	O
:	O
(	O
1	O
)	O
50	O
_	O
L	O
##OW	O
:	O
50	O
%	O
Me	B
##OH	I
que	O
##nch	O
##ing	O
solution	O
with	O
1	O
m	O
##L	O
of	O
CH	O
##C	O
##l	O
_	O
3	O
for	O
extraction	O
with	O
a	O
final	O
ratio	O
of	O
1	O
:	O
0	O
.	O
4	O
:	O
1	O
(	O
Me	O
##OH	O
:	O
CH	O
##C	O
##l	O
_	O
3	O
:	O
H	O
_	O
2	O
O	O
)	O
and	O
collection	O
of	O
3	O
m	O
##L	O
polar	O
phase	O
for	O
analysis	O
;	O
(	O
2	O
)	O
50	O
_	O
ME	O
##DI	O
##UM	O
:	O
50	O
%	O
Me	B
##OH	I
que	O
##nch	O
##ing	O
solution	O
with	O
2	O
.	O
5	O
m	O
##L	O
of	O
CH	O
##C	O
##l	O
_	O
3	O
for	O
extraction	O
with	O
a	O
final	O
ratio	O
of	O
1	O
:	O
1	O
:	O
1	O
(	O
Me	O
##OH	O
:	O
CH	O
##C	O
##l	O
_	O
3	O
:	O
H	O
_	O
2	O
O	O
)	O
and	O
collection	O
of	O
3	O
m	O
##L	O
polar	O
phase	O
for	O
analysis	O
;	O
(	O
3	O
)	O
80	O
_	O
H	O
##IG	O
##H	O
:	O
80	O
%	O
Me	B
##OH	I
que	O
##nch	O
##ing	O
solution	O
with	O
4	O
m	O
##L	O
of	O
CH	O
##C	O
##l	O
_	O
3	O
for	O
extraction	O
with	O
a	O
final	O
ratio	O
of	O
1	O
:	O
1	O
:	O
1	O
(	O
Me	O
##OH	O
:	O
CH	O
##C	O
##l	O
_	O
3	O
:	O
H	O
_	O
2	O
O	O
)	O
and	O
collection	O
of	O
6	O
m	O
##L	O
polar	O
phase	O
for	O
analysis	O
;	O
and	O

The	O
_	O
13	O
C	O
##1	O
,	O
_	O
13	O
C	O
##2	O
-	O
c	O
##it	O
##rate	O
species	O
was	O
disc	O
##erne	O
##d	O
from	O
the	O
H	O
##AC	O
-	O
AC	O
##O	O
analysis	O
(	O
c	O
##f	O
.	O
)	O
,	O
while	O
un	O
##la	O
##bel	O
##ed	O
c	B
##it	I
##rate	I
was	O
detected	O
by	O
G	O
##C	O
–	O
MS	O
(	O
data	O
not	O
shown	O
)	O
.	O

Furthermore	O
,	O
a	O
negative	O
correlation	O
with	O
pro	B
##ges	I
##tero	I
##ne	I
levels	O
was	O
observed	O
for	O
amino	O
acids	O
and	O
for	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
,	O
while	O
an	O
im	O
##bal	O
##ance	O
of	O
different	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
pathways	O
was	O
found	O
during	O
pregnancy	O
.	O

Other	O
small	O
molecule	O
components	O
found	O
in	O
high	O
abundance	O
in	O
urine	O
include	O
h	B
##ydro	I
##xy	I
acids	I
and	O
derivatives	O
(	O
such	O
as	O
c	O
##it	O
##ric	O
acid	O
)	O
,	O
u	B
##rea	I
,	O
am	O
##monia	O
,	O
c	B
##rea	I
##tin	I
##ine	I
and	O
hip	B
##pur	I
##ic	I
acid	I
.	O

Of	O
the	O
BC	O
##AA	O
##s	O
and	O
3	O
-	O
H	O
##IB	O
,	O
only	O
le	B
##uc	I
##ine	I
correlated	O
with	O
body	O
fat	O
percentage	O
(	O
P	O
<	O
0	O
.	O
01	O
,	O
R	O
=	O
0	O
.	O
3	O
,	O
n	O
=	O
89	O
)	O
.	O

Not	O
##ably	O
,	O
c	B
##rea	I
##tine	I
,	O
a	O
non	O
-	O
pro	O
##te	O
##ogenic	O
amino	O
acid	O
,	O
is	O
an	O
important	O
intermediate	O
in	O
the	O
metabolism	O
of	O
tissues	O
with	O
high	O
energy	O
demand	O
such	O
as	O
skeletal	O
muscle	O
.	O

Ace	B
##ty	I
##l	I
##car	I
##ni	I
##tine	I
could	O
influence	O
the	O
ch	B
##olin	I
##ergic	I
system	O
as	O
a	O
ch	B
##olin	I
##ergic	I
receptor	O
ago	O
##nist	O
,	O
promoting	O
synthesis	O
and	O
release	O
of	O
ace	B
##ty	I
##l	I
##cho	I
##line	I
,	O
and	O
it	O
has	O
been	O
reported	O
that	O
Ace	B
##ty	I
##l	I
##car	I
##ni	I
##tine	I
d	O
##ys	O
##re	O
##gu	O
##lation	O
usually	O
occurs	O
in	O
ne	O
##uro	O
##logical	O
disorders	O
[	O
–	O
]	O
,	O
Zhao	O
et	O
al	O
.	O
have	O
demonstrated	O
that	O
low	O
Ace	O
##ty	O
##l	O
##cho	O
##lines	O
##tera	O
##se	O
expression	O
was	O
discovered	O
in	O
he	O
##pa	O
##to	O
##cellular	O
car	O
##cin	O
##oma	O
tissue	O
and	O
had	O
significantly	O
associated	O
with	O
high	O
risk	O
of	O
cancer	O
re	O
##cu	O
##rrence	O
and	O
poor	O
survival	O
.	O

This	O
suggests	O
that	O
the	O
higher	O
ace	B
##ty	I
##l	I
-	I
Co	I
##A	I
levels	O
in	O
BC	O
are	O
largely	O
due	O
to	O
elevated	O
beta	O
##ox	O
##ida	O
##tion	O
,	O
rather	O
than	O
the	O
result	O
of	O
conversion	O
from	O
p	B
##yr	I
##u	I
##vate	I
.	O

Given	O
the	O
evidence	O
for	O
variable	O
de	O
##ph	O
##os	O
##ph	O
##ory	O
##lation	O
in	O
the	O
clinical	O
samples	O
,	O
in	O
v	O
##it	O
##ro	O
studies	O
were	O
initiated	O
to	O
allow	O
for	O
a	O
quantitative	O
understanding	O
of	O
the	O
relative	O
distribution	O
of	O
the	O
individual	O
meta	O
##bol	O
##ites	O
and	O
levels	O
of	O
the	O
p	O
##har	O
##ma	O
##cological	O
##ly	O
active	O
trip	B
##hos	I
##phate	I
meta	O
##bol	O
##ites	O
.	O

First	O
,	O
a	O
[	B
1	I
,	I
2	I
-	I
_	I
13	I
C	I
_	I
2	I
]	I
glucose	I
trace	O
##r	O
,	O
which	O
contains	O
stable	O
is	O
##oto	O
##pes	O
at	O
the	O
first	O
two	O
positions	O
,	O
was	O
used	O
.	O

G	B
##lut	I
##ama	I
##te	I
can	O
be	O
converted	O
to	O
g	B
##lut	I
##amine	I
by	O
the	O
action	O
of	O
the	O
G	O
##S	O
enzyme	O
.	O

It	O
was	O
found	O
that	O
all	O
##eli	O
##c	O
variants	O
of	O
ABC	O
##B	O
##1	O
and	O
SL	O
##CO	O
##1	O
##B	O
##1	O
genes	O
do	O
not	O
affect	O
the	O
ed	B
##ox	I
##aba	I
##n	I
p	O
##har	O
##ma	O
##co	O
##kin	O
##etics	O
.	O

U	O
##rina	O
##ry	O
meta	O
##bol	O
##ites	O
reduced	O
in	O
patients	O
with	O
HC	O
##C	O
included	O
c	B
##it	I
##rate	I
double	O
double	O
##t	O
(	O
2	O
.	O
56	O
pp	O
##m	O
and	O
2	O
.	O
68	O
pp	O
##m	O
,	O
P	O
=	O

Beta	B
##ine	I
,	O
ch	B
##olin	I
##e	I
,	O
and	O
L	B
-	I
v	I
##ali	I
##ne	I
have	O
been	O
reported	O
in	O
the	O
literature	O
to	O
be	O
associated	O
with	O
A	B
##F	I
,	O
and	O
our	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
meta	O
##bol	O
##ites	O
added	O
to	O
this	O
consensus	O
.	O

For	O
example	O
,	O
both	O
the	O
M	O
##O	O
-	O
3	O
and	O
M	O
##O	O
-	O
6	O
g	B
##lu	I
##cu	I
##ron	I
##ide	I
con	O
##ju	O
##gate	O
##s	O
are	O
recognized	O
at	O
~	O
60	O
%	O
cross	O
react	O
##ivity	O
by	O
the	O
CE	O
##DI	O
##A	O
op	O
##iate	O
im	O
##mu	O
##no	O
##ass	O
##ay	O
but	O
the	O
S	O
##y	O
##va	O
EMI	O
##T	O
ass	O
##ay	O
package	O
insert	O
does	O
not	O
provide	O
information	O
regarding	O
g	B
##lu	I
##cu	I
##ron	I
##ide	I
con	O
##ju	O
##gate	O
cross	O
react	O
##ivity	O
.	O

Ser	O
##um	O
T	O
##NF	O
##α	O
was	O
negatively	O
associated	O
with	O
try	B
##pt	I
##op	I
##han	I
(	O
P	O
<	O
0	O
.	O
00	O
##1	O
)	O
,	O
but	O
was	O
not	O
significantly	O
associated	O
with	O
any	O
of	O
its	O
k	B
##yn	I
##uren	I
##ine	I
meta	O
##bol	O
##ites	O
.	O

In	O
the	O
assessment	O
of	O
changes	O
in	O
the	O
meta	O
##bol	O
##ite	O
statistical	O
data	O
of	O
FA	B
vs	I
HC	O
,	O
for	O
serum	O
and	O
urine	O
samples	O
,	O
four	O
meta	O
##bol	O
##ites	O
and	O
three	O
meta	O
##bol	O
##ites	O
,	O
respectively	O
,	O
were	O
matched	O
to	O
the	O
tissue	O
study	O
results	O
,	O
namely	O
,	O
v	B
##ali	I
##ne	I
,	O
c	B
##it	I
##rate	I
,	O
la	B
##ct	I
##ate	I
,	O
and	O
t	B
##yr	I
##os	I
##ine	I
for	O
serum	O
and	O
c	B
##it	I
##rate	I
,	O
ace	B
##tone	I
and	O
3	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
for	O
urine	O
samples	O
.	O

This	O
finding	O
served	O
as	O
an	O
internal	O
control	O
confirming	O
quality	O
of	O
meta	O
##bol	O
##ite	O
extraction	O
and	O
anal	O
##ytic	O
pipeline	O
given	O
that	O
our	O
tissue	O
samples	O
were	O
extracted	O
with	O
c	B
##it	I
##rate	I
buffer	O
.	O

This	O
could	O
explain	O
the	O
o	O
##ste	O
##op	O
##oro	O
##sis	O
commonly	O
observed	O
in	O
h	O
##y	O
##po	O
##gon	O
##adi	O
##sm	O
_	O
,	O
and	O
related	O
to	O
a	O
decrease	O
in	O
test	B
##osterone	I
_	I
,	O
independent	O
of	O
insulin	O
activity	O
.	O

For	O
E	O
##SI	O
(	O
–	O
)	O
the	O
composition	O
of	O
mobile	O
phases	O
was	O
identical	O
but	O
10	O
m	O
##M	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
(	O
77	O
##1	O
mg	O
per	O
1	O
L	O
)	O
was	O
used	O
instead	O
as	O
m	O
##od	O
##ifier	O
.	O

Met	B
##hi	I
##oni	I
##ne	I
(	O
Met	O
)	O
,	O
C	B
##18	I
:	I
0	I
##e	I
LP	O
##C	O
,	O
3	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##ano	I
##ic	I
acid	I
and	O
C	B
##42	I
:	I
3	I
SM	O
were	O
those	O
with	O
the	O
highest	O
negative	O
coefficients	O
,	O
whereas	O
l	B
##ino	I
##le	I
##ic	I
acid	I
,	O
C	B
##40	I
:	I
6	I
PC	I
and	O
pro	B
##line	I
(	O
Pro	O
)	O
were	O
those	O
with	O
the	O
highest	O
positive	O
coefficients	O
.	O

The	O
first	O
one	O
at	O
8	O
.	O
6	O
min	O
(	O
b	O
)	O
corresponds	O
to	O
the	O
_	O
13	O
C	O
is	O
##oto	O
##pe	O
of	O
P	O
##I	O
##38	O
##a	O
:	O
4	O
,	O
at	O
m	O
/	O
z	O
88	O
##6	O
.	O
55	O
##51	O
,	O
and	O
the	O
second	O
one	O
at	O
9	O
.	O
1	O
min	O
(	O
c	O
)	O
to	O
the	O
de	O
##p	O
##rot	O
##ona	O
##ted	O
ion	O
of	O
su	B
##lf	I
##ati	I
##de	I
d	I
##18	I
:	I
2	I
/	I
C	I
##24	I
:	I
1	I
,	O
at	O
m	O
/	O
z	O
88	O
##6	O
.	O
60	O
##9	O
##9	O

Two	O
meta	O
##bol	O
##ites	O
were	O
put	O
##ative	O
##ly	O
matched	O
through	O
matching	O
mass	O
in	O
HM	O
##D	O
##B	O
to	O
be	O
4	B
-	I
h	I
##ydro	I
##xy	I
##p	I
##rol	I
##ine	I
and	O
5	B
-	I
h	I
##ydro	I
##xy	I
##ly	I
##sin	I
##e	I
.	O

As	O
shown	O
in	O
,	O
the	O
apparent	O
formation	O
rate	O
of	O
h	B
##ydro	I
##xy	I
##ana	I
##stro	I
##zo	I
##le	I
by	O
C	O
##YP	O
##3	O
##A	O
##4	O
and	O
C	O
##YP	O
##3	O
##A	O
##5	O
was	O
170	O
-	O
and	O
4	O
.	O
6	O
-	O
fold	O
higher	O
in	O
those	O
preparations	O
with	O
b	O
##5	O
than	O
those	O
without	O
b	O
##5	O
(	O
the	O
K	O
_	O
m	O
value	O
was	O
increased	O
by	O
3	O
.	O
7	O
and	O
decreased	O
by	O
2	O
.	O
3	O
-	O
fold	O
,	O
respectively	O
)	O
.	O

In	O
the	O
present	O
study	O
,	O
receiver	O
–	O
operator	O
curves	O
were	O
calculated	O
with	O
serum	O
1	B
-	I
met	I
##hyl	I
##ade	I
##nos	I
##ine	I
and	O
/	O
or	O
A	O
##FP	O
.	O

The	O
apparent	O
decrease	O
in	O
fat	O
and	O
increase	O
in	O
weight	O
and	O
FF	O
##M	O
between	O
T	O
##P	O
##2	O
and	O
T	O
##P	O
##3	O
most	O
likely	O
reflects	O
an	O
increase	O
in	O
g	B
##ly	I
##co	I
##gen	I
stores	O
and	O
body	O
water	O
which	O
will	O
increase	O
the	O
imp	O
##eda	O
##nce	O
-	O
derived	O
FF	O
##M	O
measurement	O
.	O

Me	O
##MP	O
-	O
d	O
##3	O
was	O
used	O
as	O
an	O
internal	O
standard	O
as	O
it	O
was	O
the	O
only	O
de	O
##uter	O
##ated	O
th	B
##io	I
##pur	I
##ine	I
meta	O
##bol	O
##ite	O
available	O
commercially	O
at	O
the	O
time	O
.	O

The	O
co	O
##lon	O
##ic	O
micro	O
##bial	O
metabolism	O
is	O
a	O
key	O
contributor	O
to	O
the	O
syndrome	O
of	O
u	O
##rem	O
##ia	O
and	O
various	O
micro	O
##bial	O
meta	O
##bol	O
##ites	O
,	O
including	O
PC	O
##S	O
,	O
PC	O
##G	O
,	O
IS	O
,	O
T	B
##MA	I
##O	I
and	O
PA	B
##G	I
,	O
have	O
been	O
related	O
to	O
adverse	O
outcomes	O
in	O
patients	O
with	O
varying	O
degrees	O
of	O
re	O
##nal	O
d	O
##ys	O
##function	O
[	O
–	O
]	O
.	O

Those	O
57	O
meta	O
##bol	O
##ites	O
used	O
in	O
this	O
study	O
can	O
be	O
categorized	O
into	O
six	O
classes	O
,	O
that	O
is	O
,	O
12	O
are	O
unique	O
for	O
ace	B
##tam	I
##ip	I
##rid	I
(	O
AM	O
-	O
1	O
–	O
12	O
)	O
,	O
11	O
are	O
unique	O
for	O
im	O
##ida	O
##c	O
##lop	O
##rid	O
(	O
I	O
##M	O
-	O
1	O
–	O
11	O
)	O
,	O
13	O
are	O
unique	O
for	O
cloth	B
##ian	I
##id	I
##in	I
(	O
C	O
##M	O
-	O
1	O
–	O
13	O
)	O
,	O
10	O
are	O
common	O
for	O
ch	B
##lor	I
##opy	I
##rid	I
##in	I
##yl	I
neon	I
##ico	I
##tino	I
##id	I
(	O
CP	O
##M	O
-	O
1	O
–	O
10	O
)	O
,	O
one	O
is	O
common	O
for	O
im	O
##ida	O
##c	O
##lop	O
##rid	O
and	O
cloth	B
##ian	I
##id	I
##in	I
(	O
I	O
##CM	O
-	O
1	O
)	O
,	O
and	O
10	O
are	O
common	O
for	O
cloth	B
##ian	I
##id	I
##in	I
and	O
th	B
##iam	I
##eth	I
##ox	I
##am	I
(	O
CT	O
##M	O
-	O
1	O
–	O
10	O
)	O
(	O
,	O
)	O
.	O

Indo	B
##le	I
p	I
##yr	I
##u	I
##vate	I
levels	O
were	O
higher	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
in	O
those	O
who	O
experienced	O
more	O
than	O
15	O
%	O
of	O
their	O
sleep	O
time	O
in	O
R	O
##EM	O
sleep	O
.	O

When	O
performing	O
multi	O
##var	O
##iable	O
linear	O
re	O
##gression	O
,	O
the	O
following	O
associations	O
were	O
found	O
between	O
P	O
##g	O
##R	O
expression	O
and	O
lip	O
##ids	O
:	O
total	O
plasma	O
A	O
##po	O
-	O
A1	O
(	O
β	O
0	O
.	O
46	O
,	O
p	O
<	O
0	O
.	O
00	O
##1	O
)	O
,	O
HD	B
##L	I
-	I
ch	I
##ole	I
##ster	I
##ol	I
(	O
β	O
0	O
.	O
95	O
,	O
p	O
<	O
0	O
.	O
00	O
##1	O
)	O

The	O
correlation	O
coefficients	O
calculated	O
from	O
the	O
data	O
point	O
corresponding	O
to	O
δ	O
1	O
.	O
21	O
,	O
at	O
the	O
apex	O
of	O
the	O
met	B
##hyl	I
group	I
signal	O
from	O
the	O
is	O
##ob	O
##ut	O
##yl	O
side	O
chain	O
of	O
2	B
-	I
h	I
##ydro	I
##xy	I
i	I
##bu	I
##p	I
##ro	I
##fen	I
(	O
,	O
H	O
_	O
c	O
/	O
H	O
_	O
d	O
position	O
for	O
M1	O
)	O
and	O
its	O
g	B
##lu	I
##cu	I
##ron	I
##ide	I
con	O
##ju	O
##gate	O
(	O
M	O
##6	O
)	O
are	O
shown	O
in	O
.	O

However	O
,	O
including	O
un	O
##con	O
##ju	O
##gated	O
est	B
##rone	I
in	O
the	O
models	O
did	O
not	O
at	O
##ten	O
##uate	O
risk	O
by	O
>	O
10	O
%	O
.	O

The	O
serum	O
concentrations	O
of	O
total	O
ch	B
##ole	I
##ster	I
##ol	I
and	O
L	B
##D	I
##L	I
ch	I
##ole	I
##ster	I
##ol	I
were	O
significantly	O
different	O
between	O
the	O
patients	O
with	O
an	O
##gin	O
##a	O
and	O
the	O
controls	O
.	O

A	O
mixture	O
of	O
amino	O
acids	O
at	O
known	O
concentrations	O
(	O
Sigma	O
Chemical	O
Co	O
.	O
,	O
Milan	O
,	O
Italy	O
)	O
was	O
added	O
with	O
c	O
##ys	O
##te	O
##ic	O
acid	O
,	O
met	B
##hi	I
##oni	I
##ne	I
su	I
##lf	I
##oxide	I
,	O
met	B
##hi	I
##oni	I
##ne	I
su	I
##lf	I
##one	I
,	O
try	B
##pt	I
##op	I
##han	I
,	O
or	B
##ni	I
##thin	I
##e	I
,	O
g	B
##lut	I
##ami	I
##c	I
acid	I
,	O
and	O
γ	B
-	I
amino	I
-	I
but	I
##yric	I
acid	I
(	O
GA	O
##BA	O
)	O
and	O
used	O
as	O
standard	O
.	O

A	O
very	O
good	O
correlation	O
between	O
measured	O
di	B
##os	I
##met	I
##in	I
and	O
g	B
##lu	I
##cu	I
##ron	I
##ide	I
meta	O
##bol	O
##ites	O
concentrations	O
was	O
obtained	O
.	O

The	O
control	O
and	O
LP	B
##S	I
wells	O
also	O
received	O
an	O
equal	O
volume	O
of	O
ethanol	S
.	O

B	O
##rief	O
##ly	O
,	O
10	O
μ	O
##L	O
al	O
##iq	O
##uo	O
##ts	O
of	O
plasma	O
and	O
10	O
μ	O
##L	O
of	O
internal	O
lip	O
##id	O
standards	O
(	O
Ava	O
##nti	O
SP	O
##LA	O
##S	O
##H	O
Li	O
##pid	O
##omi	O
##x	O
)	O
that	O
had	O
been	O
first	O
di	O
##lut	O
##ed	O
1	O
:	O
10	O
in	O
1	O
-	O
but	O
##ano	O
##l	O
/	B
met	B
##han	I
##ol	I
were	O
added	O
to	O
160	O
μ	O
##l	O
of	O
ice	O
-	O
cold	O
met	B
##han	I
##ol	I
followed	O
by	O
addition	O
of	O
320	O
μ	O
##l	O
of	O
ice	O
-	O
cold	O
ch	B
##lor	I
##of	I
##orm	I
and	O
v	O
##ortex	O
##ed	O
(	O
10	O
s	O
)	O
,	O
then	O
son	O
##ica	O
##ted	O
(	O
1	O
h	O
)	O
.	O

Multi	O
##var	O
##iable	O
linear	O
re	O
##gression	O
analyses	O
were	O
carried	O
out	O
to	O
disc	O
##ern	O
the	O
independent	O
associations	O
P	O
##LT	O
##P	O
activity	O
and	O
L	O
##CA	O
##T	O
activity	O
with	O
beta	B
##ine	I
(	O
Table	O
)	O
.	O

Alan	B
##ine	I
is	O
one	O
of	O
the	O
most	O
important	O
amino	O
acids	O
released	O
by	O
muscle	O
tissue	O
,	O
acting	O
as	O
a	O
major	O
energy	O
source	O
and	O
an	O
important	O
regulator	O
in	O
glucose	S
metabolism	O
,	O
l	O
##ymph	O
##oc	O
##yte	O
production	O
,	O
and	O
immunity	O
.	O

Since	O
L	O
##CP	O
##U	O
##FA	O
##s	O
reduce	O
T	O
-	O
cell	O
activation	O
and	O
damp	O
##en	O
inflammation	O
,	O
it	O
might	O
be	O
speculated	O
that	O
a	O
decrease	O
in	O
PC	O
containing	O
L	O
##CP	O
##U	O
##FA	O
##s	O
can	O
ha	O
##mper	O
their	O
protective	O
effects	O
,	O
including	O
a	O
concert	O
##ed	O
action	O
of	O
either	O
withdrawing	O
pro	O
-	O
inflammatory	O
e	B
##ico	I
##san	I
##oids	I
or	O
in	O
##cre	O
##ment	O
##ing	O
anti	O
-	O
inflammatory	O
e	B
##ico	I
##san	I
##oids	I
.	O

The	O
sample	O
(	O
200	O
μ	O
l	O
)	O
was	O
weighed	O
into	O
screw	O
-	O
capped	O
reaction	O
tubes	O
,	O
water	O
was	O
e	O
##va	O
##porated	O
under	O
nitrogen	O
and	O
internal	O
standard	O
(	O
t	O
##ri	O
##he	O
##pta	O
##de	O
##cano	O
##in	O
)	O
in	O
is	B
##oo	I
##ct	I
##ane	I
was	O
added	O
.	O

Additionally	O
,	O
our	O
study	O
was	O
limited	O
to	O
a	O
single	O
spot	O
urine	O
sample	O
on	O
the	O
day	O
of	O
se	O
##men	O
collection	O
;	O
thus	O
,	O
we	O
recognize	O
that	O
the	O
short	O
half	O
-	O
life	O
of	O
p	O
##ht	O
##hala	O
##tes	O
may	O
pose	O
a	O
concern	O
for	O
accurate	O
exposure	O
assessment	O
;	O
however	O
,	O
several	O
reports	O
indicate	O
that	O
a	O
single	O
spot	O
urine	O
sample	O
su	O
##f	O
-	O
fi	O
##cie	O
##ntly	O
represents	O
p	B
##ht	I
##hala	I
##te	I
exposure	O
over	O
several	O
months	O
(	O
;	O
;	O
)	O
.	O

Sen	O
##si	O
##ti	O
##vity	O
and	O
specific	O
##ity	O
of	O
UP	O
##LC	O
-	O
MS	O
profiles	O
,	O
A	O
##FP	O
and	O
individual	O
peaks	O
for	O
HC	O
##C	O
diagnosis	O
R	O
##OC	O
receiver	O
operating	O
characteristic	O
,	O
AU	O
##C	O
area	O
under	O
the	O
curve	O
,	O
HC	O
##C	O
he	O
##pa	O
##to	O
##cellular	O
car	O
##cin	O
##oma	O
,	O
L	O
##C	O
liver	O
c	O
##ir	O
##r	O
##hos	O
##is	O
,	O
A	O
##FP	O
alpha	B
-	I
f	I
##eto	I
##p	I
##rote	I
##in	I
,	O
UP	O
##LC	O
ultra	O
performance	O
liquid	O
ch	O
##roma	O
##tography	O
,	O
MS	O
mass	O
s	O
##pect	O
##rome	O
##try	O
,	O
CH	O
##B	O
chronic	O
he	O
##pa	O
##titis	O
B	O
,	O
R	O
##T	O
retention	O
time	O
,	O
n	O
neutral	O
,	O
m	O
/	O
z	O
mass	O
to	O
charge	O
ratio	O
,	O
H	O
##S	O
healthy	O
subjects	O
.	O

This	O
was	O
clearly	O
evident	O
in	O
our	O
samples	O
as	O
the	O
average	O
male	O
c	B
##rea	I
##tin	I
##ine	I
level	O
was	O
20	O
m	O
##M	O
while	O
the	O
average	O
female	O
c	B
##rea	I
##tin	I
##ine	I
level	O
was	O
11	O
m	O
##M	O
.	O

A	O
##cc	O
##ele	O
##rated	O
gal	B
##act	I
##ose	I
metabolism	O
was	O
apparent	O
(	O
P	O
-	O
value	O
=	O
0	O
.	O
000	O
##6	O
on	O
un	O
##iva	O
##ria	O
##te	O
analysis	O
)	O
.	O

The	O
residue	O
was	O
re	O
##con	O
##stituted	O
using	O
50	O
μ	O
##L	O
of	O
1	O
%	O
as	B
##cor	I
##bic	I
acid	I
,	O
where	O
20	O
μ	O
##L	O
was	O
injected	O
onto	O
an	O
L	O
##C	O
-	O
MS	O
system	O
linked	O
to	O
a	O
reverse	O
-	O
phase	O
column	O
(	O
Ph	O
##eno	O
##men	O
##ex	O
Technologies	O
Inc	O
.	O
,	O
Tor	O
##rance	O
,	O
CA	O
)	O
.	O

An	O
adequate	O
separation	O
was	O
achieved	O
using	O
a	O
multi	O
##ste	O
##p	O
gradient	O
,	O
mobile	O
phase	O
composition	O
(	O
variation	O
of	O
is	B
##op	I
##rop	I
##ano	I
##l	I
percentage	O
in	O
met	B
##han	I
##ol	I
)	O
in	O
combination	O
with	O
a	O
careful	O
selection	O
of	O
Q	O
##1	O
/	O
Q	O
##3	O
transition	O
pairs	O
.	O

r	O
##HD	O
##L	O
prevented	O
this	O
fast	O
##ing	O
-	O
induced	O
increase	O
in	O
lip	O
##oly	O
##sis	O
observed	O
during	O
the	O
place	O
##bo	O
in	O
##fusion	O
,	O
as	O
demonstrated	O
by	O
stable	O
palm	B
##itate	I
R	O
_	O
a	O
,	O
R	O
_	O
d	O
,	O
and	O
oxidation	O
rate	O
.	O

The	O
final	O
concentration	O
of	O
ethanol	S
in	O
the	O
reaction	O
was	O
less	O
than	O
0	O
.	O
1	O
%	O
.	O

G	B
##lu	I
##cos	I
##e	I
metabolic	O
disorder	O
is	O
a	O
typical	O
s	O
##ym	O
##pt	O
##om	O
of	O
patients	O
with	O
OS	O
##A	O
and	O
usually	O
occurs	O
with	O
an	O
increase	O
in	O
glucose	S
and	O
insulin	O
resistance	O
.	O

Also	O
,	O
it	O
is	O
noteworthy	O
that	O
c	B
##it	I
##ru	I
##llin	I
##e	I
ex	O
##cre	O
##tion	O
increased	O
with	O
protein	O
##uria	O
but	O
was	O
not	O
a	O
con	O
##st	O
##it	O
##utive	O
element	O
of	O
proteins	O
.	O

A	O
saturated	O
fatty	O
acid	O
or	O
a	O
mon	O
##ou	O
##ns	O
##at	O
##ura	O
##ted	O
fatty	O
acid	O
pre	O
##dom	O
##inate	O
##s	O
in	O
the	O
s	O
##n	O
-	O
1	O
position	O
of	O
the	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
.	O

In	O
line	O
with	O
this	O
conclusion	O
,	O
Le	O
Mo	O
##ye	O
##c	O
et	O
al	O
.	O
demonstrated	O
that	O
c	B
##it	I
##rate	I
is	O
a	O
u	O
##rina	O
##ry	O
marker	O
that	O
can	O
identify	O
transplant	O
##ed	O
kidney	O
##s	O
with	O
a	O
favorable	O
pro	O
##gno	O
##sis	O
(	O
Le	O
Mo	O
##ye	O
##c	O
et	O
al	O
.	O
)	O
.	O

However	O
,	O
we	O
did	O
not	O
find	O
significant	O
differences	O
in	O
the	O
shape	O
of	O
BC	O
##AA	O
profiles	O
between	O
insulin	O
-	O
sensitive	O
and	O
insulin	O
-	O
resistant	O
subjects	O
(	O
i	O
.	O
e	O
.	O
,	O
a	O
blunt	O
##ed	O
suppression	O
of	O
BC	O
##AA	O
levels	O
during	O
the	O
glucose	S
challenge	O
in	O
insulin	O
-	O
resistant	O
individuals	O
)	O
.	O

Using	O
re	B
##ser	I
##pine	I
as	O
an	O
example	O
,	O
10	O
μ	O
##L	O
of	O
sample	O
mixture	O
were	O
delivered	O
from	O
the	O
well	O
on	O
the	O
plate	O
to	O
the	O
back	O
plane	O
of	O
the	O
na	O
##no	O
-	O
E	O
##SI	O
chip	O
with	O
the	O
op	O
##ti	O
##mized	O
positive	O
ion	O
##ization	O
conditions	O
of	O
1	O
.	O
65	O
k	B
##V	I
in	O
positive	O
mode	O
and	O
0	O
.	O
5	O
ps	O
##i	O
nitrogen	O
head	O
pressure	O
,	O
so	O
that	O
the	O
solution	O
in	O
the	O
pipe	O
##tte	O
tip	O
had	O
a	O
constant	O
flow	O
to	O
the	O
chip	O
at	O
a	O
rate	O
of	O
200	O
n	O
##L	O
/	O
min	O
.	O

Generally	O
,	O
ch	B
##olin	I
##e	I
is	O
an	O
essential	O
meta	O
##bol	O
##ite	O
in	O
the	O
synthesis	O
of	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
for	O
cancer	O
cell	O
membrane	O
##s	O
.	O

An	O
influence	O
of	O
gut	O
mi	O
##co	O
##f	O
##lora	O
on	O
si	B
##m	I
##vas	I
##tat	I
##in	I
response	O
was	O
also	O
suggested	O
by	O
our	O
recent	O
finding	O
that	O
several	O
secondary	O
bi	O
##le	O
acids	O
derived	O
from	O
micro	O
##bial	O
metabolism	O
are	O
predict	O
##ive	O
of	O
L	O
##D	O
##L	O
-	O
C	O
response	O
to	O
si	B
##m	I
##vas	I
##tat	I
##in	I
in	O
the	O
CA	O
##P	O
study	O
.	O

We	O
observed	O
that	O
changes	O
in	O
g	B
##lut	I
##amine	I
were	O
common	O
to	O
all	O
variables	O
.	O

Association	O
##s	O
between	O
plasma	O
levels	O
of	O
AG	O
##Es	O
and	O
fast	O
##ing	O
glucose	S
,	O
fast	O
##ing	O
insulin	O
and	O
H	O
##OM	O
##A	O
-	O
I	O
##R	O
were	O
weak	O
(	O
r	O
between	O
-	O
0	O
.	O
2	O
and	O
0	O
.	O
2	O
)	O
and	O
not	O
statistical	O
##ly	O
significant	O
(	O
all	O
p	O
>	O
0	O
.	O
05	O
)	O
.	O

Con	O
##fi	O
##dence	O
interval	O
;	O
AM	B
##P	I
:	O
Aden	B
##os	I
##ine	I
mon	I
##op	I
##hos	I
##phate	I
;	O
N	O
:	O
Normal	O
,	O
C	O
##IN	O
##1	O
:	O
Ce	O
##r	O
##vic	O
##al	O
in	O
##tra	O
##ep	O
##ith	O
##eli	O
##al	O
neo	O
##p	O
##lasia	O
1	O
,	O
C	O
##IN	O
##2	O
/	O
3	O
:	O

Of	O
note	O
,	O
low	O
do	B
##pa	I
##mine	I
levels	O
have	O
been	O
implicated	O
in	O
the	O
mechanisms	O
of	O
psychiatric	O
diseases	O
such	O
as	O
depression	O
[	O
–	O
]	O
and	O
s	O
##chi	O
##zophrenia	O
[	O
]	O
.	O

The	O
purpose	O
of	O
this	O
testing	O
was	O
to	O
ensure	O
that	O
naturally	O
produced	O
g	B
##lu	I
##cu	I
##ron	I
##ide	I
and	O
su	B
##lf	I
##ate	I
meta	O
##bol	O
##ites	O
did	O
not	O
interfere	O
in	O
the	O
method	O
.	O

When	O
chemical	O
##ly	O
s	O
##ynth	O
##eti	O
##zed	O
by	O
the	O
reduction	O
of	O
P	O
##B	O
##T	O
##Z	O
##16	O
##9	O
with	O
Na	O
##B	O
##H	O
_	O
4	O
,	O
a	O
mixture	O
of	O
two	O
position	O
o	O
-	O
and	O
p	B
-	I
is	I
##omer	I
##s	I
of	O
H	O
_	O
2	O
-	O
P	O
##B	O
##T	O
##Z	O
##16	O
##9	O
is	O
formed	O
,	O
yet	O
only	O
the	O
p	O
-	O
is	O
##omer	O
is	O
found	O
in	O
v	O
##ivo	O
.	O

All	O
IS	O
were	O
dissolved	O
in	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
to	O
yield	O
a	O
final	O
concentration	O
of	O
100	O
ng	O
/	O
m	O
##L	O
.	O
One	O
-	O
hundred	O
micro	O
##lite	O
##rs	O
of	O
urine	O
was	O
then	O
mixed	O
with	O
200	O
μ	O
##L	O
IS	O
solution	O
,	O
and	O
v	O
##ortex	O
##ed	O
for	O
1	O
min	O
.	O

Ce	B
##ram	I
##ides	I
are	O
associated	O
with	O
lip	O
##op	O
##rote	O
##in	O
a	O
##gg	O
##regation	O
,	O
inflammation	O
,	O
reactive	O
oxygen	O
species	O
production	O
and	O
a	O
##pop	O
##tosis	O
,	O
and	O
seem	O
to	O
be	O
an	O
intermediate	O
link	O
between	O
over	O
-	O
nutrition	O
and	O
some	O
abnormal	O
##ities	O
related	O
to	O
C	O
##V	O
risk	O
such	O
as	O
insulin	O
resistance	O
and	O
metabolic	O
syndrome	O
.	O

These	O
meta	O
##bol	O
##ites	O
are	O
further	O
de	O
##graded	O
by	O
the	O
t	B
##rica	I
##rb	I
##ox	I
##yl	I
##ic	I
acid	I
cycle	O
(	O
T	O
##CA	O
cycle	O
)	O
and	O
o	O
##xi	O
##da	O
##tive	O
p	O
##hos	O
##ph	O
##ory	O
##lation	O
(	O
Fi	O
##g	O
.	O

As	O
it	O
was	O
demonstrated	O
that	O
met	B
##form	I
##in	I
,	O
the	O
first	O
-	O
line	O
medication	O
for	O
the	O
treatment	O
of	O
type	O
2	O
diabetes	O
,	O
could	O
in	O
##hibit	O
TD	O
##O	O
##2	O
,	O
a	O
key	O
enzyme	O
in	O
try	B
##pt	I
##op	I
##han	I
metabolism	O
,	O
we	O
assessed	O
the	O
potential	O
impact	O
of	O
diabetes	O
therapy	O
(	O
except	O
insulin	O
,	O
as	O
patients	O
on	O
insulin	O
therapy	O
were	O
excluded	O
)	O
on	O
K	O
##P	O
##m	O
concentrations	O
.	O

Age	O
,	O
sex	O
,	O
B	O
##MI	O
,	O
W	O
##H	O
##R	O
,	O
total	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
H	O
##OM	O
##A	O
-	O
I	O
##R	O
index	O
,	O
L	O
##p	O
-	O
P	O
##LA	O
_	O
2	O
activity	O
,	O
le	B
##uc	I
##ine	I
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
try	B
##pt	I
##op	I
##han	I
,	O
and	O
l	O
##ys	O
##o	O
##PC	O
##s	O
(	O
14	O
:	O
0	O
,	O
16	O
:	O
1	O
,	O
16	O
:	O
0	O
,	O
18	O
:	O
2	O
,	O
18	O
:	O
1	O
,	O
18	O
:	O
0	O
,	O
20	O
:	O
5	O
,	O
20	O
:	O
4	O
,	O
20	O
:	O
3	O
,	O
and	O
22	O
:	O
6	O
)	O
were	O
tested	O
.	O

A	O
linear	O
range	O
covering	O
most	O
of	O
the	O
tested	O
samples	O
was	O
demonstrated	O
up	O
to	O
120	O
mg	O
d	O
##w	O
/	O
m	O
##L	O
and	O
90	O
mg	O
d	O
##w	O
/	O
m	O
##L	O
for	O
D	O
##G	O
and	O
T	B
##G	I
,	O
respectively	O
.	O

In	O
order	O
to	O
check	O
label	O
##ing	O
efficiency	O
,	O
the	O
non	O
-	O
pro	O
##te	O
##ogenic	O
amino	O
acids	O
(	B
nor	B
##le	I
##uc	I
##ine	I
and	O
nor	B
##val	I
##ine	I
)	O
were	O
used	O
.	O

The	O
alterations	O
observed	O
in	O
car	B
##ni	I
##tine	I
are	O
interesting	O
,	O
and	O
its	O
increase	O
in	O
HC	O
##C	O
is	O
consistent	O
with	O
the	O
previous	O
u	O
##rina	O
##ry	O
N	O
##MR	O
pro	O
##fi	O
##ling	O
studies	O
in	O
HC	O
##C	O
[	O
-	O
]	O
.	O

Considering	O
the	O
marked	O
changes	O
of	O
plasma	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
induced	O
by	O
am	B
##lo	I
##di	I
##pine	I
in	O
the	O
present	O
study	O
,	O
it	O
is	O
of	O
interest	O
that	O
Men	O
##ni	O
et	O
al	O
.	O
also	O
observed	O
an	O
inverse	O
correlation	O
between	O
plasma	O
he	B
##xa	I
##de	I
##cane	I
##dio	I
##ate	I
and	O
car	B
##ni	I
##tine	I
levels	O
.	O

This	O
inverse	O
##ly	O
correlated	O
with	O
increased	O
levels	O
of	O
u	B
##rea	I
and	O
via	O
or	B
##ni	I
##thin	I
##e	I
to	O
the	O
p	B
##oly	I
##amine	I
sperm	I
##id	I
##ine	I
.	O

This	O
difference	O
in	O
reaction	O
efficiency	O
has	O
been	O
observed	O
previously	O
for	O
ion	O
##ized	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
and	O
has	O
also	O
been	O
described	O
for	O
gas	O
-	O
phase	O
reactions	O
of	O
neutral	O
o	O
##le	O
##fin	O
##s	O
with	O
oz	O
##one	O
.	O

P	O
##I	O
lip	O
##ids	O
have	O
a	O
greater	O
association	O
with	O
HD	O
##L	O
(	O
,	O
)	O
,	O
with	O
roles	O
in	O
increasing	O
HD	O
##L	O
-	O
C	O
levels	O
during	O
transport	O
of	O
ch	B
##ole	I
##ster	I
##ol	I
from	O
peripheral	O
tissues	O
to	O
the	O
liver	O
.	O

The	O
detection	O
rate	O
of	O
D	O
##MA	O
##P	O
was	O
higher	O
in	O
the	O
high	O
UC	O
##CR	O
group	O
in	O
T	O
##S	O
##G	O
and	O
N	O
##S	O
##G	O
,	O
but	O
the	O
trend	O
was	O
not	O
observed	O
in	O
that	O
of	O
th	B
##iam	I
##eth	I
##ox	I
##am	I
in	O
T	O
##S	O
##G	O
.	O

Basel	O
##ine	O
meta	O
##bol	O
##ites	O
significantly	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
associated	O
with	O
base	O
##line	O
clinical	O
measures	O
Met	O
##ab	O
##oli	O
##te	O
levels	O
pre	B
-	I
s	I
##tat	I
##in	I
treatment	O
correlated	O
with	O
clinical	O
measurements	O
pre	B
-	I
s	I
##tat	I
##in	I
treatment	O
using	O
(	O
a	O
)	O
un	O
##iva	O
##ria	O
##te	O
re	O
##gression	O
analysis	O
and	O
(	O
b	O
)	O
multiple	O
re	O
##gression	O
analysis	O
.	O

Thus	O
,	O
by	O
act	O
##ivating	O
the	O
trans	O
##ami	O
##nation	O
of	O
t	B
##yr	I
##os	I
##ine	I
to	O
p	B
-	I
h	I
##ydro	I
##xy	I
##phe	I
##ny	I
##l	I
##py	I
##ru	I
##vate	I
the	O
serum	O
level	O
of	O
t	B
##yr	I
##os	I
##ine	I
was	O
reduced	O
.	O

In	O
that	O
context	O
,	O
a	O
study	O
investigating	O
the	O
inter	O
-	O
individual	O
variation	O
in	O
the	O
plasma	O
up	O
##take	O
of	O
the	O
un	O
##met	O
##ab	O
##oli	O
##zed	O
α	B
-	I
to	I
##co	I
##her	I
##ol	I
has	O
shown	O
differences	O
of	O
up	O
to	O
40	O
-	O
fold	O
.	O

The	O
possibility	O
also	O
exists	O
that	O
C	O
_	O
27	O
bi	O
##le	O
acids	O
could	O
be	O
formed	O
in	O
brain	O
from	O
ch	B
##ole	I
##ster	I
##ol	I
itself	O
.	O

In	O
human	O
color	O
##ec	O
##tal	O
ad	O
##eno	O
##car	O
##cin	O
##oma	O
##s	O
and	O
liver	O
meta	O
##sta	O
##sis	O
,	O
high	O
mass	O
resolution	O
DE	O
##SI	O
-	O
MS	O
##I	O
allowed	O
the	O
identification	O
of	O
many	O
lip	O
##ids	O
with	O
increased	O
abundance	O
in	O
color	O
##ec	O
##tal	O
ad	O
##eno	O
##car	O
##cin	O
##oma	O
tissue	O
,	O
including	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oe	I
##tano	I
##lam	I
##ines	I
,	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##og	I
##ly	I
##cer	I
##ols	I
,	O
and	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oi	I
##nos	I
##ito	I
##ls	I
.	O

D	B
##HC	I
:	O
di	B
##hy	I
##dr	I
##oc	I
##era	I
##mi	I
##de	I
.	O

It	O
was	O
also	O
challenging	O
to	O
compare	O
the	O
T	O
##LC	O
/	O
G	O
##C	O
-	O
F	O
##ID	O
lip	O
##id	O
results	O
with	O
the	O
G	O
##C	O
-	O
MS	O
results	O
as	O
the	O
two	O
methods	O
only	O
identified	O
and	O
q	O
##uant	O
##ified	O
8	O
meta	O
##bol	O
##ites	O
in	O
common	O
(	O
a	O
##rac	O
##hi	O
##don	O
##ic	O
acid	O
,	O
e	B
##ico	I
##san	I
##oi	I
##c	I
acid	I
,	O
l	B
##ino	I
##le	I
##ic	I
acid	I
,	O
o	B
##le	I
##ic	I
acid	I
,	O
palm	B
##ite	I
##laid	I
##ic	I
acid	I
,	O
palm	B
##itic	I
acid	I
,	O
s	B
##te	I
##ari	I
##c	I
acid	I
and	O
te	O
##tra	O
##de	O
##cano	O
##ic	O
acid	O
)	O
.	O

After	O
5	O
min	O
under	O
a	O
be	O
##aker	O
,	O
ethanol	S
was	O
detected	O
at	O
0	O
.	O
82	O
m	O
##M	O
compared	O
to	O
7	O
.	O
2	O
×	O
10	O
_	O
−	O
##3	O
m	O
##M	O
after	O
5	O
min	O
open	O
on	O
the	O
lab	O
bench	O
.	O

B	O
:	O
Rate	O
##s	O
of	O
palm	B
##itate	I
trace	O
##r	O
oxidation	O
(	O
μ	O
##mo	O
##l	O
/	O
min	O
)	O
during	O
4	O
h	O
##r	O
r	O
##HD	O
##L	O
(	O
solid	O
lines	O
)	O
and	O
place	O
##bo	O
(	O
dotted	O
lines	O
)	O
in	O
##fusion	O
.	O

Line	O
##ar	O
re	O
##gression	O
was	O
used	O
in	O
order	O
to	O
evaluate	O
the	O
effects	O
of	O
medication	O
status	O
(	O
yes	O
/	O
no	O
)	O
,	O
a	O
history	O
of	O
ps	O
##ych	O
##osis	O
(	O
yes	O
/	O
no	O
;	O
B	O
##D	O
P	O
+	O
/	O
B	O
##D	O
P	O
-	O
)	O
,	O
and	O
a	O
history	O
of	O
suicide	O
attempts	O
(	O
yes	O
/	O
no	O
)	O
on	O
the	O
concentration	O
of	O
k	B
##yn	I
##uren	I
##ine	I
meta	O
##bol	O
##ites	O
and	O
GM	O
volume	O
within	O
the	O
B	O
##D	O
group	O
.	O

The	O
product	O
of	O
mutant	O
ID	O
##H1	O
,	O
2	O
-	O
H	O
##G	O
,	O
is	O
a	O
small	O
organic	O
acid	O
containing	O
two	O
car	B
##box	I
##yl	I
##ic	I
acid	I
functional	O
groups	O
in	O
its	O
structure	O
.	O

A	B
##rg	I
##ini	I
##ne	I
also	O
appeared	O
to	O
be	O
feeding	O
into	O
the	O
production	O
of	O
c	B
##rea	I
##tin	I
##ine	I
,	O
which	O
apparently	O
accumulated	O
to	O
the	O
de	O
##tri	O
##ment	O
of	O
its	O
cat	O
##ab	O
##oli	O
##tes	O
,	O
particularly	O
c	B
##rea	I
##tin	I
##ine	I
(	O
Su	O
##pp	O
##lement	O
##ary	O
Figure	O
S	O
##7	O
)	O
.	O

Ultra	O
##pur	O
##e	O
HP	O
##LC	O
-	O
grade	O
water	O
,	O
L	O
##CM	O
##S	O
-	O
grade	O
met	B
##han	I
##ol	I
,	O
L	O
##CM	O
##S	O
-	O
grade	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
and	O
form	B
##ic	I
acid	I
were	O
purchased	O
from	O
Fisher	O
Scientific	O
(	O
Pitt	O
##sburg	O
,	O
PA	O
,	O
USA	O
)	O
and	O
were	O
used	O
for	O
sample	O
processing	O
and	O
mobile	O
phase	O
systems	O
.	O

However	O
,	O
these	O
data	O
do	O
not	O
exclude	O
the	O
possibility	O
that	O
direct	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
con	O
##ju	O
##gation	O
(	O
N	O
-	O
g	O
##lu	O
##cu	O
##ron	O
##ida	O
##tion	O
)	O
is	O
an	O
important	O
pathway	O
for	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
metabolism	O
in	O
v	O
##ivo	O
.	O

In	O
addition	O
,	O
plasma	O
levels	O
of	O
20	B
-	I
H	I
##ET	I
##E	I
correlated	O
positively	O
with	O
body	O
mass	O
index	O
(	O
r	O
=	O
0	O
.	O
42	O
##7	O
,	O
p	O
=	O
0	O
.	O
00	O
##7	O
)	O
and	O
di	O
##ast	O
##olic	O
blood	O
pressure	O
(	O
r	O
=	O
0	O
.	O
365	O
,	O
p	O
=	O
0	O
.	O
02	O
##8	O
)	O
.	O

Further	O
meta	O
##bol	O
##ites	O
contained	O
in	O
the	O
pattern	O
for	O
continuous	O
age	O
in	O
women	O
,	O
that	O
have	O
not	O
been	O
reported	O
in	O
this	O
context	O
,	O
include	O
pseudo	B
##uri	I
##dine	I
,	O
potassium	O
(	O
higher	O
in	O
older	O
women	O
)	O
,	O
and	O
ma	B
##lic	I
acid	I
(	O
higher	O
in	O
younger	O
women	O
)	O
.	O

Among	O
these	O
,	O
only	O
PC	B
32	I
:	I
1	I
and	O
PC	B
34	I
:	I
2	I
showed	O
significant	O
changes	O
in	O
relative	O
ion	O
abundance	O
##s	O
(	O
IS	O
:	O
PC	B
15	I
:	I
0	I
/	I
15	I
:	I
0	I
)	O
.	O

AU	O
##C	O
_	O
0	O
–	O
120	O
##min	O
of	O
the	O
meta	O
##bol	O
##ite	O
levels	O
of	O
glucose	S
,	O
la	B
##ct	I
##ate	I
,	O
al	B
##ani	I
##ne	I
,	O
c	B
##it	I
##rate	I
and	O
g	B
##lut	I
##ama	I
##te	I
were	O
calculated	O
with	O
R	O
(	O
version	O
3	O
.	O
4	O
.	O
4	O
)	O
using	O
the	O
package	O
“	O
Des	O
##c	O
##T	O
##ool	O
##s	O
”	O
with	O
the	O
trap	O
##ez	O
##oid	O
##al	O
rule	O
.	O

Det	O
##ails	O
of	O
the	O
method	O
for	O
the	O
Li	O
##po	O
##sca	O
##le	O
for	O
lip	O
##op	O
##rote	O
##in	O
characterization	O
and	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
compounds	O
and	O
g	B
##ly	I
##co	I
##p	I
##rote	I
##in	I
peak	O
de	O
##con	O
##vo	O
##lution	O
are	O
explained	O
in	O
the	O
supplement	O
##al	O
material	O
.	O

We	O
found	O
that	O
card	O
##iol	O
##ip	O
##in	O
,	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
,	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
,	O
plate	O
##let	O
-	O
act	O
##ivating	O
factor	O
,	O
o	B
-	I
a	I
##cy	I
##l	I
-	I
ω	I
-	I
h	I
##ydro	I
##xy	I
fatty	O
acid	O
and	O
a	B
##c	I
##rol	I
##ein	I
were	O
specifically	O
altered	O
in	O
F	O
##T	O
##D	O
with	O
strong	O
correlation	O
between	O
the	O
lip	O
##ids	O
,	O
sign	O
##ifying	O
path	O
##op	O
##hy	O
##sio	O
##logical	O
changes	O
in	O
F	O
##T	O
##D	O
.	O

As	O
##say	O
performance	O
for	O
beta	B
##ine	I
q	O
##uant	O
##ification	O
was	O
assessed	O
and	O
Cox	O
proportional	O
hazards	O
re	O
##gression	O
was	O
employed	O
to	O
evaluate	O
the	O
association	O
of	O
beta	B
##ine	I
with	O
incident	O
T	O
##2	O
##DM	O
in	O
43	O
##36	O
participants	O
in	O
the	O
Prevention	O
of	O
Ren	O
##al	O
and	O
V	O
##as	O
##cular	O
End	O
-	O
Stage	O
Disease	O
(	O
PR	O
##E	O
##VE	O
##ND	O
)	O
study	O
.	O

The	O
1	B
,	I
1	I
′	I
-	I
_	I
13	I
C	I
_	I
2	I
ace	I
##tic	I
an	I
##hy	I
##dr	I
##ide	I
(	O
12	O
μ	O
##l	O
,	O
120	O
μ	O
##mo	O
##l	O
)	O
was	O
then	O
added	O
manually	O
in	O
steps	O
of	O
2	O
μ	O
##l	O
to	O
the	O
well	O
stirred	O
solution	O
of	O
urine	O
at	O
room	O
temperature	O
,	O
while	O
the	O
pH	O
was	O
maintained	O
at	O
8	O
.	O
0	O
by	O
the	O
addition	O
of	O
10	O
-	O
μ	O
##l	O
al	O
##iq	O
##uo	O
##ts	O
of	O
1	O
M	O
Na	O
##OH	O
solution	O
.	O

To	O
determine	O
whether	O
2	O
-	O
H	O
##G	O
could	O
be	O
detected	O
directly	O
from	O
g	O
##lio	O
##ma	O
tissue	O
sections	O
by	O
DE	O
##SI	O
MS	O
imaging	O
,	O
we	O
analyzed	O
human	O
g	O
##lio	O
##ma	O
samples	O
by	O
DE	O
##SI	O
MS	O
in	O
the	O
negative	O
ion	O
mode	O
using	O
either	O
an	O
L	O
##T	O
##Q	O
ion	O
trap	O
(	O
The	O
##rm	O
##o	O
Fisher	O
Scientific	O
)	O
or	O
an	O
am	B
##a	I
##Z	I
##on	I
speed	O
ion	O
trap	O
(	O
B	O
##ruk	O
##er	O
Dalton	O
##ics	O
)	O
.	O

Similarly	O
,	O
5	B
-	I
h	I
##ydro	I
##xy	I
-	I
7	I
-	I
met	I
##ho	I
##xy	I
-	I
40	I
-	I
O	I
-	I
(	I
3	I
-	I
met	I
##hyl	I
##but	I
-	I
2	I
-	I
en	I
##yl	I
)	I
is	I
##of	I
##lav	I
##one	I
,	O
along	O
with	O
known	O
compounds	O
,	O
er	B
##io	I
##dict	I
##yo	I
##l	I
,	O
v	O
##itt	O
##ari	O
##n	O
-	O
B	O
,	O
3	B
,	I
6	I
,	I
7	I
-	I
t	I
##ri	I
##hy	I
##dr	I
##ox	I
##y	I
-	I
1	I
-	I
met	I
##ho	I
##xy	I
##xa	I
##nt	I
##hone	I
,	O
1	B
,	I
3	I
,	I
6	I
-	I
Tri	I
##hy	I
##dr	I
##ox	I
##y	I
-	I
8	I
-	I
met	I
##hyl	I
##xa	I
##nt	I
##hine	I
and	O
c	O
##y	O
##c	O
##lo	O
(	O
Ph	O
##e	O
–	O
Ty	O
##r	O
)	O
were	O
isolated	O
from	O
Fu	O
##sar	O
##ium	O
s	B
##p	I
.	O

Prior	O
to	O
MS	O
analysis	O
,	O
the	O
total	O
lip	O
##id	O
extract	O
was	O
dried	O
down	O
and	O
then	O
re	O
##con	O
##stituted	O
in	O
5	O
µ	O
##L	O
of	O
ch	B
##lor	I
##of	I
##orm	I
first	O
and	O
then	O
95	O
µ	O
##L	O
of	O
met	B
##han	I
##ol	I
so	O
that	O
all	O
lip	O
##ids	O
would	O
be	O
brought	O
into	O
solution	O
.	O

Blood	O
was	O
collected	O
in	O
et	B
##hyl	I
##ened	I
##iam	I
##inet	I
##et	I
##ra	I
##ace	I
##tic	I
acid	I
(	O
E	O
##D	O
##TA	O
)	O
-	O
containing	O
tubes	O
,	O
cent	O
##ri	O
##fu	O
##ged	O
and	O
isolated	O
plasma	O
immediately	O
stored	O
frozen	O
at	O
−	O
##80	O
##°	O
##C	O
.	O

The	O
increased	O
serum	O
concentration	O
of	O
1	B
-	I
met	I
##hyl	I
##ade	I
##nos	I
##ine	I
in	O
HC	O
##C	O
patients	O
may	O
reflect	O
the	O
h	O
##yper	O
##active	O
n	O
##uc	O
##leo	O
##side	O
modification	O
associated	O
with	O
h	O
##yper	O
met	O
##hyl	O
##ation	O
in	O
response	O
to	O
long	O
-	O
term	O
inflammation	O
and	O
o	O
##xi	O
##da	O
##tive	O
DNA	O
damage	O
,	O
which	O
have	O
often	O
been	O
found	O
in	O
patients	O
with	O
cancer	O
##s	O
of	O
other	O
dig	O
##estive	O
organs	O
[	O
,	O
]	O
.	O

General	O
linear	O
re	O
##gression	O
and	O
q	O
##uad	O
##ratic	O
models	O
were	O
performed	O
to	O
evaluate	O
the	O
relations	O
of	O
body	O
burden	O
##s	O
of	O
PC	O
##D	O
##Ds	O
/	O
PC	O
##DF	O
##s	O
and	O
PC	O
##B	O
##s	O
to	O
levels	O
of	O
est	B
##rogen	I
meta	O
##bol	O
##ites	O
.	O

highlights	O
two	O
key	O
metabolic	O
intermediate	O
##s	O
of	O
the	O
c	B
##it	I
##ric	I
acid	I
cycle	O
,	O
c	B
##it	I
##rate	I
and	O
is	B
##oc	I
##it	I
##rate	I
,	O
which	O
are	O
constitutional	O
rear	O
##rang	O
##ement	O
##s	O
of	O
a	O
single	O
h	O
##ydro	O
##xy	O
##l	O
group	O
along	O
the	O
central	O
carbon	O
chain	O
.	O

R	O
##p	O
/	O
P	O
##m	O
&	O
T	O
##i	O
:	O
1	O
.	O
9	O
%	O
,	O
T	O
##i	O
/	O
P	O
##m	O
&	O
R	O
##p	O
:	O
2	O
.	O
2	O
%	O
)	O
,	O
q	B
##uin	I
##olo	I
##nes	I
(	O
P	O
##m	O
/	O
R	O
##p	O
&	O
T	O
##i	O
:	O
2	O
.	O
5	O
%	O
,	O
R	O
##p	O
/	O
P	O
##m	O
&	O
T	O
##i	O
:	O
1	O
.	O
6	O
%	O
,	O
T	O
##i	O
/	O
P	O
##m	O
&	O
R	O
##p	O
:	O
2	O
.	O
2	O
%	O
)	O
,	O
s	O
##tero	O
##ids	O
(	O
P	O
##m	O
/	O
R	O
##p	O
&	O
T	O
##i	O
:	O
2	O
.	O
5	O
%	O
,	O
R	O
##p	O
/	O
P	O
##m	O
&	O
T	O
##i	O
:	O
5	O
.	O
2	O
%	O
,	O
T	O
##i	O
/	O
P	O
##m	O
&	O
R	O
##p	O
:	O
4	O
.	O
5	O
%	O
)	O
,	O
and	O
others	O
(	O
Figure	O
8	O
and	O
)	O
.	O

Treatment	O
of	O
C	O
##4	O
–	O
2	O
##B	O
##4	O
and	O
PC	O
-	O
3	O
M	O
-	O
Pro	O
##4	O
cells	O
with	O
palm	B
##itic	I
acid	I
(	O
PA	O
)	O
(	O
range	O
between	O
50	O
and	O
200	O
μ	O
##M	O
)	O
resulted	O
in	O
increased	O
proliferation	O
(	O
Fi	O
##g	O
.	O

G	O
##u	O
H	O
.	O
et	O
al	O
.	O
identified	O
la	B
##ct	I
##ate	I
,	O
glucose	S
and	O
al	B
##ani	I
##ne	I
among	O
other	O
meta	O
##bol	O
##ites	O
disc	O
##rim	O
##inating	O
serum	O
samples	O
collected	O
from	O
BC	O
patients	O
and	O
healthy	O
controls	O
.	O

Following	O
the	O
same	O
procedure	O
,	O
the	O
best	O
model	O
adds	O
five	O
se	B
##rot	I
##oni	I
##n	I
compounds	O
,	O
namely	O
,	O
se	B
##rot	I
##oni	I
##n	I
,	O
5	B
-	I
H	I
##IA	I
##A	I
,	O
L	B
-	I
try	I
##pt	I
##op	I
##han	I
,	O
me	B
##lat	I
##oni	I
##n	I
and	O
6	B
-	I
h	I
##ydro	I
##xy	I
##mel	I
##aton	I
##in	I
,	O
and	O
achieve	O
##s	O
a	O
higher	O
AU	O
##C	O
value	O
of	O
0	O
.	O
99	O
.	O

This	O
label	O
was	O
sufficient	O
to	O
q	O
##uant	O
##ify	O
the	O
spill	O
##over	O
of	O
diet	O
##ary	O
fatty	O
acids	O
into	O
the	O
plasma	O
FF	O
##A	O
pool	O
,	O
and	O
the	O
trace	O
##r	O
_	O
13	O
C	O
_	O
4	O
IV	O
palm	B
##itate	I
delivered	O
at	O
a	O
rate	O
of	O
7	O
µ	O
##g	O
/	O
kg	O
/	O
min	O
was	O
sufficient	O
to	O
measure	O
fatty	O
acid	O
turnover	O
,	O
but	O
both	O
doses	O
were	O
so	O
low	O
so	O
as	O
to	O
not	O
be	O
detect	O
##able	O
in	O
the	O
plasma	O
AC	O
pool	O
(	O
see	O
below	O
)	O
.	O

Inspired	O
by	O
the	O
successful	O
use	O
of	O
strong	O
bases	O
for	O
MA	O
##IL	O
##D	O
analysis	O
of	O
acidic	O
compounds	O
,	O
we	O
tested	O
the	O
suit	O
##ability	O
of	O
several	O
su	B
##lf	I
##onic	I
acids	I
as	O
MA	O
##IL	O
##D	O
matrices	O
for	O
the	O
positive	O
-	O
ion	O
mode	O
.	O

In	O
the	O
preliminary	O
negative	O
ion	O
analysis	O
,	O
we	O
identified	O
187	O
unique	O
lip	O
##ids	O
(	O
again	O
focused	O
on	O
mon	O
##ois	O
##oto	O
##pic	O
mass	O
)	O
from	O
4	O
L	O
##IP	O
##ID	O
MA	O
##PS	O
categories	O
,	O
including	O
FA	S
,	O
g	B
##ly	I
##cer	I
##oli	I
##pid	I
##s	I
,	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
,	O
and	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
.	O

In	O
the	O
h	O
##UC	O
##B	O
##P	O
samples	O
the	O
c	B
##it	I
##ric	I
acid	I
value	O
presented	O
high	O
values	O
in	O
terms	O
of	O
the	O
integral	O
##s	O
for	O
signal	O
intensity	O
because	O
this	O
meta	O
##bol	O
##ite	O
was	O
originated	O
from	O
the	O
anti	O
##coa	O
##gu	O
##lant	O
used	O
in	O
sample	O
collection	O
rather	O
than	O
being	O
present	O
in	O
the	O
plasma	O
.	O

The	O
F	B
##T	I
500	O
-	O
N	O
##D	O
P	O
##U	O
##LS	O
##E	O
Tu	O
##bes	O
were	O
from	O
Press	O
##ure	O
B	O
##io	O
##S	O
##cie	O
##nces	O
(	O
South	O
Easton	O
,	O
MA	O
)	O
.	O

With	O
data	O
from	O
our	O
small	O
co	O
##hor	O
##t	O
we	O
cannot	O
conclude	O
that	O
decreased	O
DD	O
##A	O
##H	O
##2	O
expression	O
is	O
mon	O
##oc	O
##yte	O
or	O
mac	O
##rop	O
##hage	O
specific	O
,	O
as	O
P	O
##BM	O
##C	O
contain	O
not	O
just	O
blood	O
mon	O
##ocytes	O
,	O
but	O
also	O
B	O
cells	O
,	O
den	O
##dr	O
##itic	O
cells	O
,	O
and	O
activated	S
T	O
cells	O
,	O
which	O
is	O
a	O
limitation	O
of	O
our	O
expression	O
findings	O
.	O

The	O
products	O
were	O
identified	O
as	O
p	B
##ter	I
##in	I
-	I
6	I
-	I
al	I
##de	I
##hy	I
##de	I
and	O
p	B
-	I
amino	I
##ben	I
##zo	I
##yl	I
##g	I
##lut	I
##ami	I
##c	I
acid	I
.	O

Second	O
##ly	O
,	O
u	O
##rina	O
##ry	O
ta	B
##uri	I
##ne	I
concentration	O
significantly	O
differed	O
with	O
decreasing	O
means	O
between	O
V	O
##1	O
and	O
V	O
##3	O
(	O
p	O
=	O
0	O
.	O
00	O
##31	O
)	O
,	O
as	O
well	O
as	O
u	O
##rina	O
##ry	O
as	B
##ym	I
##metric	I
dim	I
##eth	I
##yla	I
##rg	I
##ini	I
##ne	I
(	O
AD	O
##MA	O
)	O
concentration	O
(	O
p	O
=	O
0	O
.	O
03	O
##80	O
)	O
.	O

There	O
were	O
changes	O
in	O
parallel	O
with	O
weight	O
loss	O
,	O
especially	O
improvements	O
in	O
glucose	S
and	O
lip	O
##id	O
metabolism	O
,	O
and	O
in	O
the	O
circulating	O
levels	O
of	O
le	O
##pt	O
##in	O
and	O
ad	O
##ip	O
##one	O
##ct	O
##in	O
and	O
the	O
para	O
##ox	O
##ona	O
##se	O
activity	O
.	O

Ana	B
##stro	I
##zo	I
##le	I
(	O
1	O
µ	O
##m	O
or	O
20	O
µ	O
##m	O
)	O
was	O
in	O
##cu	O
##bate	O
##d	O
for	O
30	O
min	O
at	O
37	O
##°	O
##C	O
with	O
H	O
##LM	O
##s	O
(	O
0	O
.	O
5	O
mg	O
m	O
##l	O
_	O
−	O
##1	O
)	O
.	O

This	O
shows	O
a	O
4	O
times	O
increase	O
in	O
ethanol	S
production	O
in	O
control	O
-	O
derived	O
samples	O
while	O
almost	O
no	O
increase	O
was	O
observed	O
in	O
I	O
##BS	O
-	O
derived	O
samples	O
.	O

Sign	O
##ificant	O
associations	O
were	O
found	O
between	O
B	O
##MI	O
and	O
do	B
##pa	I
##mine	I
(	O
PC	O
##C	O
=	O
0	O
.	O
50	O
,	O
p	O
-	O
value	O
=	O
0	O
.	O
02	O
##2	O
)	O
,	O
and	O
5	B
-	I
H	I
##IA	I
##A	I
(	O
PC	O
##C	O
=	O
0	O
.	O
49	O
,	O
p	O
-	O
value	O
=	O
0	O
.	O
02	O
##3	O
)	O
,	O
respectively	O
.	O

Su	O
##pp	O
##ression	O
of	O
PC	O
decreased	O
the	O
levels	O
of	O
total	O
c	B
##it	I
##rate	I
and	O
ma	B
##late	I
and	O
_	O
13	O
C	O
incorporation	O
into	O
their	O
is	O
##oto	O
##po	O
##mers	O
from	O
_	O
13	O
C	O
_	O
6	O
-	O
labeled	O
glucose	S
and	O
_	O
13	O
C	O
_	O
5	O
-	O
labeled	O
g	B
##lut	I
##amine	I
.	O

There	O
was	O
a	O
greater	O
age	O
span	O
in	O
the	O
AD	O
##HD	O
group	O
than	O
in	O
the	O
control	O
group	O
,	O
and	O
it	O
is	O
known	O
that	O
try	B
##pt	I
##op	I
##han	I
levels	O
may	O
decrease	O
with	O
age	O
.	O

The	O
column	O
was	O
conditioned	O
by	O
the	O
se	O
##quential	O
addition	O
of	O
2	O
m	O
##L	O
of	O
met	B
##han	I
##ol	I
,	O
2	O
m	O
##L	O
of	O
water	O
,	O
and	O
2	O
m	O
##L	O
of	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
.	O

Immediately	O
after	O
washing	O
,	O
10	O
µ	O
##g	O
of	O
bio	B
##tin	I
con	O
##ju	O
##gated	O
anti	O
##body	O
in	O
120	O
µ	O
##l	O
phosphate	S
buffer	O
##ed	O
sa	B
##line	I
(	O
PBS	O
)	O
was	O
added	O
to	O
the	O
magnetic	O
beads	O
and	O
v	O
##ortex	O
##ed	O
for	O
30	O
min	O
at	O
room	O
temperature	O
.	O

Compared	O
to	O
previous	O
studies	O
,	O
our	O
study	O
systematically	O
investigated	O
the	O
influence	O
of	O
storage	O
temperature	O
(	O
4	O
,	O
22	O
,	O
and	O
40	O
°C	O
)	O
,	O
storage	O
duration	S
(	O
24	O
and	O
48	O
h	O
)	O
,	O
and	O
the	O
use	O
of	O
different	O
pre	O
##ser	O
##vat	O
##ives	O
(	O
BA	O
,	O
thy	B
##mo	I
##l	I
,	O
N	O
##P	O
)	O
on	O
meta	O
##bol	O
##ite	O
finger	O
##prints	O
in	O
urine	O
using	O
targeted	O
meta	O
##bol	O
##omi	O
##cs	O
(	O
158	O
re	O
##lia	O
##bly	O
detected	O
meta	O
##bol	O
##ites	O
)	O
.	O

The	O
meta	O
##bol	O
##ites	O
de	B
##cano	I
##yl	I
##car	I
##ni	I
##tine	I
(	O
c	O
##10	O
)	O
,	O
te	B
##tra	I
##de	I
##ce	I
##noy	I
##l	I
##car	I
##ni	I
##tine	I
(	O
c	O
##14	O
:	O
1	O
)	O
,	O
o	B
##ct	I
##ano	I
##yl	I
##car	I
##ni	I
##tine	I
(	O
c	O
##8	O
)	O
,	O
dim	B
##eth	I
##yl	I
##sul	I
##fo	I
##ne	I
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
and	O
l	B
##ys	I
##ine	I
are	O
of	O
high	O
importance	O
for	O
classification	O
,	O
with	O
increased	O
levels	O
in	O
PC	O
##a	O
patients	O
,	O
while	O
the	O
meta	O
##bol	O
##ites	O
p	O
##hos	O
##pha	O
##ti	O
##dy	O
##l	O
##cho	O
##line	O
di	O
##acy	O
##l	O
C	O
##34	O
:	O
4	O
and	O
lip	O
##id	O
##2	O
have	O
higher	O
levels	O
in	O
the	O
controls	O
.	O

Only	O
the	O
association	O
of	O
al	B
##ani	I
##ne	I
with	O
1st	O
-	O
year	O
re	O
##current	O
w	O
##hee	O
##zing	O
remained	O
significant	O
after	O
F	O
##DR	O
correction	O
at	O
0	O
.	O
05	O
.	O

While	O
la	B
##ctic	I
acid	I
and	O
c	B
##it	I
##ric	I
acid	I
show	O
decreasing	O
trend	O
with	O
the	O
progression	O
of	O
HC	O
##C	O
,	O
so	B
##rb	I
##ose	I
is	O
down	O
-	O
regulated	O
overall	O
in	O
HC	O
##C	O
vs	O
.	O
c	O
##ir	O
##r	O
##hos	O
##is	O
.	O

Ph	B
##os	I
##pha	I
##ti	I
##dic	I
acid	I
,	O
as	O
an	O
important	O
signal	O
trans	O
##du	O
##cer	O
,	O
is	O
involved	O
in	O
p	O
##hos	O
##ph	O
##oli	O
##pas	O
##e	O
metabolism	O
[	O
–	O
]	O
.	O

Cole	O
##tta	O
et	O
al	O
.	O
reported	O
that	O
the	O
deficiency	O
in	O
end	O
##oth	O
##eli	O
##al	O
ni	B
##tric	I
oxide	I
s	O
##ynth	O
##ase	O
(	O
e	O
##N	O
##OS	O
)	O
prevented	O
the	O
ability	O
of	O
H	O
_	O
2	O
S	O
to	O
induce	O
an	O
##gio	O
##genesis	O
,	O
suggesting	O
that	O
NO	O
is	O
required	O
for	O
H	O
_	O
2	O
S	O
to	O
have	O
its	O
vascular	O
effects	O
.	O

Specifically	O
,	O
valid	O
models	O
were	O
obtained	O
for	O
separation	O
between	O
low	O
-	O
and	O
intermediate	B
-	I
risk	I
samples	O
(	O
M1	O
##2	O
,	O
Fi	O
##gs	O
.	O

We	O
found	O
that	O
glucose	S
was	O
up	O
##re	O
##gu	O
##lated	O
in	O
se	O
##psis	O
patients	O
,	O
which	O
is	O
in	O
line	O
with	O
a	O
previous	O
p	O
##ediatric	O
se	O
##psis	O
study	O
.	O

It	O
is	O
of	O
note	O
that	O
plasma	O
ch	B
##ole	I
##ster	I
##ol	I
is	O
approximately	O
similar	O
to	O
the	O
levels	O
recorded	O
in	O
IS	O
h	O
##y	O
##po	O
##gon	O
##adi	O
##sm	O
(	O
ranging	O
between	O
213	O
to	O
243	O
mg	O
/	O
d	O
##L	O
)	O
indicating	O
that	O
insulin	O
does	O
not	O
significantly	O
influence	O
this	O
metabolism	O
in	O
I	O
##R	O
h	O
##y	O
##po	O
##gon	O
##adi	O
##sm	O
.	O

Ce	B
##ram	I
##ide	I
was	O
significantly	O
associated	O
with	O
central	O
o	O
##besity	O
.	O

Furthermore	O
,	O
BC	O
##AA	O
##s	O
regulate	O
glucose	S
and	O
lip	O
##id	O
metabolism	O
through	O
the	O
Ph	B
##os	I
##pha	I
##ti	I
##dy	I
##lino	I
##si	I
##to	I
##l	I
3	O
-	O
kinase	O
##s	O
(	O
P	O
##I	O
##3	O
##K	O
)	O
-	O
A	O
##kt	O
pathway	O
and	O
may	O
also	O
drive	O
the	O
m	O
##TO	O
##R	O
(	O
the	O
ma	O
##mmal	O
##ian	O
target	O
of	O
rap	B
##am	I
##y	I
##cin	I
)	O
pathway	O
to	O
regulate	O
protein	O
synthesis	O
[	O
,	O
,	O
,	O
,	O
]	O
.	O

This	O
change	O
in	O
code	B
##ine	I
:	O
m	B
##or	I
##phine	I
concentration	O
ratio	O
can	O
provide	O
a	O
rough	O
estimate	O
of	O
the	O
last	O
dose	O
of	O
code	B
##ine	I
administration	O
.	O

Although	O
electrical	O
card	O
##io	O
##version	O
is	O
usually	O
successful	O
in	O
restoring	O
sin	O
##us	O
rhythm	O
in	O
patients	O
with	O
A	B
##F	I
,	O
maintaining	O
sin	O
##us	O
rhythm	O
after	O
successful	O
card	O
##io	O
##version	O
is	O
often	O
difficult	O
.	O

Points	O
shown	O
are	O
the	O
means	O
of	O
six	O
determination	O
##s	O
for	O
AT	O
##RA	O
alone	O
or	O
three	O
determination	O
##s	O
for	O
each	O
of	O
the	O
curves	O
with	O
C	O
##13	O
k	B
##eton	I
##e	I
.	O

A	O
possible	O
explanation	O
for	O
these	O
almost	O
uniform	O
negative	O
correlation	O
##s	O
is	O
that	O
the	O
fatty	O
acids	O
that	O
give	O
rise	O
to	O
q	O
##uant	O
##ifiable	O
H	O
##R	O
-	O
MA	O
##S	O
_	O
1	O
H	O
N	O
##MR	O
signals	O
arise	O
mainly	O
from	O
the	O
lip	O
##id	O
drop	O
##lets	O
that	O
form	O
in	O
ne	O
##c	O
##rot	O
##ic	O
tissue	O
or	O
pre	O
-	O
ne	O
##c	O
##rot	O
##ic	O
brain	O
t	O
##umour	O
tissue	O
(	O
fatty	O
acid	O
components	O
of	O
biological	O
membrane	O
##s	O
are	O
held	O
rigid	O
##ly	O
and	O
thus	O
give	O
rise	O
to	O
broad	O
signals	O
)	O
and	O
that	O
t	O
##umour	O
samples	O
with	O
high	O
concentrations	O
of	O
lip	O
##id	O
drop	O
##lets	O
have	O
less	O
viable	O
tissue	O
containing	O
la	B
##ct	I
##ate	I
,	O
t	O
##G	O
##lut	O
,	O
t	O
##C	O
##r	O
and	O
t	O
##C	O
##ho	O
,	O
and	O
vice	O
versa	O
.	O

Ce	B
##r	I
(	I
22	I
:	I
0	I
)	I
and	O
Ce	B
##r	I
(	I
24	I
:	I
0	I
)	I
were	O
obtained	O
from	O
Ava	O
##nti	O
Polar	O
Li	O
##pid	O
##s	O
(	O
Al	O
##aba	O
##ster	O
,	O
AL	O
)	O
.	O

The	O
following	O
internal	O
standards	O
were	O
added	O
before	O
lip	O
##id	O
extraction	O
:	O
10	O
nm	O
##ol	O
of	O
1	B
,	I
2	I
-	I
di	I
##he	I
##pta	I
##de	I
##cano	I
##yl	I
-	I
s	I
##n	I
-	I
g	I
##ly	I
##cer	I
##o	I
-	I
3	I
-	I
p	I
##hos	I
##ph	I
##och	I
##olin	I
##e	I
,	O
10	O
nm	O
##ol	O
of	O
1	B
,	I
2	I
,	I
3	I
-	I
t	I
##ri	I
##he	I
##pta	I
##de	I
##cano	I
##yl	I
-	I
s	I
##n	I
-	I
g	I
##ly	I
##cer	I
##ol	I
and	O
30	O
nm	O
##ol	O
of	O
ch	B
##ole	I
##ster	I
##yl	I
t	I
##ride	I
##cano	I
##ate	I
.	O

Ta	O
##e	O
-	O
E	O
##um	O
type	O
showed	O
higher	O
la	B
##ct	I
##ate	I
levels	O
in	O
serum	O
than	O
So	O
-	O
Yang	O
type	O
for	O
similar	O
B	O
##MI	O
groups	O
,	O
suggesting	O
that	O
the	O
levels	O
of	O
serum	O
la	B
##ct	I
##ate	I
might	O
be	O
dependent	O
on	O
the	O
SC	O
type	O
regardless	O
of	O
B	O
##MI	O
.	O

MG	O
,	O
di	B
##acy	I
##l	I
##gly	I
##cer	I
##ol	I
15	I
:	I
0	I
–	I
18	I
:	I
1	I
(	I
d	I
##7	I
)	I
D	O
##G	O
,	O
t	B
##ria	I
##cy	I
##l	I
##gly	I
##cer	I
##ol	I
15	I
:	I
0	I
–	I
18	I
:	I
1	I
(	I
d	I
##7	I
)	I
-	I
15	I
:	I
0	I
T	I
##G	I
,	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
18	I
:	I
1	I
(	I
d	I
##9	I
)	I

In	O
addition	O
to	O
the	O
meta	O
##bol	O
##ites	O
identified	O
as	O
statistical	O
##ly	O
significant	O
after	O
one	O
week	O
of	O
treatment	O
,	O
un	O
##iva	O
##ria	O
##te	O
testing	O
highlights	O
a	O
significant	O
increase	O
in	O
the	O
levels	O
of	O
lip	O
##ids	O
(	B
g	B
##ly	I
##cer	I
##ol	I
backbone	O
of	O
p	B
##hos	I
##ph	I
##og	I
##ly	I
##cer	I
##ides	I
(	O
P	O
##G	O
##L	O
##Y	O
##s	O
)	O
and	O
t	B
##ria	I
##cy	I
##l	I
##gly	I
##cer	I
##ides	I
(	O
T	O
##AG	O
##s	O
)	O
,	O
lip	O
##op	O
##rote	O
##ins	O
mainly	O
very	O
low	O
density	O
(	O
V	O
##LD	O
##L	O
)	O
and	O
low	O
density	O
(	O
L	O
##D	O
##L	O
)	O
)	O
at	O
W	O
##4	O
,	O
whereas	O
ace	B
##to	I
##ace	I
##tate	I
,	O
c	B
##it	I
##rate	I
,	O
ch	B
##olin	I
##e	I
,	O
glucose	S
,	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##och	I
##olin	I
##e	I
,	O
my	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
and	O
met	B
##han	I
##ol	I
concentrations	O
decreased	O
with	O
respect	O
to	O
base	O
##line	O
.	O

In	O
separate	O
models	O
,	O
we	O
selected	O
each	O
of	O
the	O
try	B
##pt	I
##op	I
##han	I
meta	O
##bol	O
##ites	O
and	O
P	O
##LP	O
as	O
dependent	O
variables	O
and	O
performed	O
multiple	O
linear	O
re	O
##gression	O
analysis	O
against	O
immune	O
system	O
bio	O
##mark	O
##ers	O
as	O
independent	O
variables	O
,	O
adjusting	O
for	O
sex	O
,	O
B	O
##MI	O
,	O
smoking	O
,	O
alcohol	O
intake	O
,	O
and	O
oral	O
con	O
##tra	O
##ceptive	O
use	O
.	O

Re	B
##tino	I
##l	I
plays	O
an	O
important	O
role	O
in	O
lip	O
##id	O
metabolism	O
through	O
activation	O
of	O
RA	O
##R	O
and	O
PP	O
##AR	O
##β	O
/	O
δ	O
signaling	O
and	O
gene	O
expression	O
enhancing	O
lip	O
##id	O
accumulation	O
through	O
control	O
of	O
ad	O
##ip	O
##oc	O
##yte	O
differentiation	O
,	O
fatty	O
acid	O
oxidation	O
,	O
and	O
lip	O
##oly	O
##sis	O
.	O

B	O
##ile	O
acids	O
were	O
present	O
in	O
greater	O
abundance	O
than	O
mon	B
##oh	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##ls	I
,	O
and	O
this	O
allowed	O
their	O
q	O
##uant	O
##ification	O
from	O
reconstructed	O
ion	O
ch	O
##roma	O
##to	O
##gram	O
##s	O
(	O
R	O
##IC	O
##s	O
)	O
recorded	O
on	O
the	O
Or	O
##bit	O
##rap	O
.	O

Factor	O
1	O
is	O
composed	O
of	O
long	O
chain	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
and	O
SM	O
##s	O
.	O

Fast	O
##ing	O
glucose	S
concentrations	O
were	O
higher	O
in	O
o	O
##bes	O
##e	O
N	O
##AF	O
##LD	O
patients	O
as	O
compared	O
to	O
normal	O
liver	O
subjects	O
,	O
reaching	O
statistical	O
significance	O
in	O
the	O
o	O
##bes	O
##e	O
class	O
I	O
–	O
II	O
co	O
##hor	O
##t	O
(	O
lean	O
,	O
K	O
-	O
W	O
=	O
0	O
.	O
89	O
,	O
p	O
-	O
value	O
=	O
0	O
.	O
64	O
;	O
o	O
##bes	O
##e	O
,	O
K	O
-	O
W	O
=	O
9	O
.	O
75	O
,	O
p	O
-	O
value	O
=	O
0	O
.	O
01	O
;	O
m	O
##or	O
##bid	O
##ly	O
o	O
##bes	O
##e	O
,	O
K	O
-	O
W	O
=	O
5	O
.	O
79	O
,	O
p	O
-	O
value	O
=	O
0	O
.	O
06	O
)	O
.	O

Although	O
the	O
number	O
of	O
substances	O
detected	O
in	O
our	O
study	O
was	O
smaller	O
than	O
those	O
studies	O
,	O
two	O
substances	O
,	O
i	O
.	O
e	O
.	O
AM	O
-	O
8	O
(	B
N	B
-	I
[	I
(	I
6	I
-	I
ch	I
##lor	I
##opy	I
##rid	I
##in	I
-	I
3	I
-	I
y	I
##l	I
)	I
met	I
##hyl	I
]	I
form	I
##ami	I
##de	I
)	O
and	O
I	O
##M	O
-	O
2	O
(	B
1	B
-	I
(	I
6	I
-	I
ch	I
##lor	I
##o	I
-	I
3	I
-	I
p	I
##yr	I
##idy	I
##lm	I
##eth	I
##yl	I
)	I
-	I
2	I
-	I
ni	I
##tro	I
##gua	I
##ni	I
##dine	I
)	O
,	O
were	O
detected	O
and	O
reported	O
for	O
the	O
first	O
time	O
.	O

In	O
(	O
C	O
)	O
,	O
red	O
indicates	O
correlation	O
##s	O
significant	O
at	O
P	O
<	O
0	O
.	O
00	O
##1	O
and	O
dots	O
indicate	O
correlation	O
##s	O
stronger	O
than	O
the	O
un	O
##tar	O
##get	O
##ed	O
serum	O
c	B
##rea	I
##tin	I
##ine	I
.	O

Wells	O
were	O
then	O
in	O
##cu	O
##bate	O
##d	O
for	O
90	O
s	O
with	O
5	O
µ	O
##l	O
of	O
a	O
50	O
%	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
(	O
AC	O
##N	O
)	O
and	O
0	O
.	O
1	O
%	O
t	B
##ri	I
##f	I
##lu	I
##oro	I
##ace	I
##tic	I
acid	I
(	O
T	O
##FA	O
)	O
solution	O
,	O
and	O
el	O
##uted	O
material	O
was	O
spotted	O
onto	O
a	O
target	O
plate	O
,	O
allowed	O
to	O
completely	O
dry	O
(	O
≈	O
##10	O
min	O
)	O
,	O
after	O
which	O
0	O
.	O
5	O
µ	O
##l	O
of	O
matrix	O
solution	O
(	O
5	O
g	O
/	O
l	O
of	O
a	B
-	I
c	I
##yan	I
##o	I
-	I
4	I
-	I
h	I
##ydro	I
##xy	I
##cin	I
##nam	I
##ic	I
acid	I
(	O
CH	O
##CA	O
)	O
in	O
50	O
%	O
AC	O
##N	O
and	O
0	O
.	O
1	O
%	O
T	O
##FA	O
)	O
which	O
was	O
spotted	O
on	O
the	O
target	O
plate	O
and	O
allowed	O
to	O
completely	O
dry	O
.	O

Currently	O
,	O
it	O
is	O
not	O
known	O
how	O
this	O
gene	O
may	O
be	O
affecting	O
3	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
levels	O
.	O

In	O
the	O
E	O
##SI	O
+	O
mode	O
,	O
the	O
MS	O
spray	O
voltage	O
was	O
4	O
.	O
2	O
K	B
##V	I
while	O
it	O
was	O
3	O
.	O
6	O
K	B
##V	I
in	O
the	O
E	O
##SI	O
##−	O
mode	O
.	O

Per	O
##cent	O
difference	O
_	O
1	O
in	O
concentrations	O
of	O
u	O
##rina	O
##ry	O
est	O
##rogen	O
##s	O
and	O
est	B
##rogen	I
meta	O
##bol	O
##ites	O
(	O
E	O
##M	O
)	O
among	O
Asian	O
American	O
women	O
in	O
highest	O
vs	O
.	O
lowest	O
te	O
##rt	O
##iles	O
of	O
so	O
##y	O
intake	O
,	O
by	O
men	O
##op	O
##aus	O
##al	O
status	O
.	O

Compared	O
with	O
the	O
AU	O
##C	O
_	O
R	O
##OC	O
value	O
of	O
the	O
base	O
model	O
of	O
B	O
##MI	O
,	O
history	O
of	O
h	O
##yper	O
##tens	O
##ion	O
,	O
smoking	O
,	O
physical	O
activity	O
,	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
,	O
and	O
HD	B
##L	I
ch	I
##ole	I
##ster	I
##ol	I
,	O
no	O
meta	O
##bol	O
##ites	O
led	O
to	O
a	O
significant	O
increase	O
in	O
AU	O
##C	O
values	O
,	O
whereas	O
ID	O
##I	O
and	O
N	O
##RI	O
statistics	O
showed	O
that	O
di	O
##hom	O
##o	O
-	O
γ	O
-	O
l	O
##ino	O
##len	O
##ic	O
acid	O
and	O
LP	B
##I	I
(	I
16	I
:	I
1	I
)	I
could	O
significantly	O
improve	O
risk	O
re	O
##c	O
##lass	O
##ification	O
of	O
incident	O
type	O
2	O
diabetes	O
at	O
P	O
<	O
0	O
.	O
01	O
.	O

This	O
article	O
reports	O
evidence	O
for	O
hit	O
##her	O
##to	O
unknown	O
est	B
##rogen	I
metabolic	O
pathway	O
in	O
human	O
breast	O
,	O
cat	O
##aly	O
##zed	O
by	O
per	O
##ox	O
##idas	O
##e	O
,	O
which	O
could	O
initiate	O
cancer	O
.	O

We	O
have	O
also	O
observed	O
a	O
down	O
##re	O
##gu	O
##lation	O
of	O
CE	O
##RS	O
##4	O
,	O
SM	O
##PD	O
##1	O
and	O
SM	O
##PD	O
##3	O
(	O
B	O
)	O
,	O
which	O
are	O
responsible	O
for	O
the	O
transformation	O
of	O
s	B
##phi	I
##ngo	I
##sin	I
##es	I
and	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
##s	I
to	O
c	B
##era	I
##mi	I
##des	I
.	O

The	O
three	O
other	O
meta	O
##bol	O
##ites	O
were	O
identified	O
as	O
l	B
-	I
th	I
##re	I
##onic	I
acid	I
,	O
l	B
-	I
c	I
##ys	I
##tein	I
##e	I
,	O
and	O
c	B
##rea	I
##tine	I
from	O
both	O
the	O
G	O
##C	O
-	O
MS	O
and	O
G	O
##C	O
##×	O
##GC	O
-	O
MS	O
data	O
.	O

Det	O
##ec	O
##tion	O
limits	O
were	O
as	O
follows	O
:	O
0	O
.	O
10	O
μ	O
##g	O
/	O
m	O
##l	O
EPA	O
,	O
0	O
.	O
46	O
μ	O
##g	O
/	O
m	O
##l	O
D	O
##HA	O
,	O
0	O
.	O
01	O
μ	O
##g	O
/	O
m	O
##l	O
AA	O
,	O
0	O
.	O
01	O
μ	O
##g	O
/	O
m	O
##l	O
γ	B
-	I
l	I
##ino	I
##len	I
##ic	I
,	O
0	O
.	O
42	O
μ	O
##g	O
/	O
m	O
##l	O
l	O
##ino	O
##len	O
##ic	O
,	O
0	O
.	O
04	O
μ	O
##g	O
/	O
m	O
##l	O
palm	B
##ito	I
##le	I
##ic	I
,	O
0	O
.	O
45	O
μ	O
##g	O
/	O
m	O
##l	O
l	B
##ino	I
##le	I
##ic	I
,	O
0	O
.	O
34	O
μ	O
##g	O
/	O
m	O
##l	O
palm	B
##itic	I
,	O
1	O
.	O
01	O
μ	O
##g	O
/	O
m	O
##l	O
o	O
##le	O
##ic	O
and	O
1	O
.	O
91	O
μ	O
##g	O
/	O
m	O
##l	O
s	O
##te	O
##ari	O
##c	O
.	O

Take	O
##n	O
together	O
,	O
these	O
results	O
suggest	O
that	O
individuals	O
with	O
border	O
##line	O
-	O
to	O
-	O
moderate	O
H	O
##T	O
##G	O
may	O
have	O
an	O
increase	O
in	O
the	O
oxidation	O
of	O
l	B
##ino	I
##le	I
##ic	I
acid	I
.	O

Others	O
have	O
demonstrated	O
increased	O
urine	O
la	B
##ct	I
##ate	I
levels	O
and	O
T	O
##CA	O
cycle	O
disturbance	O
##s	O
in	O
rats	O
treated	O
with	O
s	B
##tre	I
##pt	I
##oz	I
##oto	I
##cin	I
.	O

B	B
##iot	I
##in	I
is	O
a	O
co	O
##fa	O
##ctor	O
in	O
car	O
##box	O
##yla	O
##se	O
-	O
based	O
reactions	O
for	O
pro	O
##te	O
##oly	O
##sis	O
and	O
is	O
used	O
in	O
BC	O
##AA	O
cat	O
##ab	O
##olis	O
##m	O
.	O
_	O
,	O
Although	O
bio	B
##tin	I
is	O
a	O
known	O
co	O
##fa	O
##ctor	O
in	O
a	O
my	O
##riad	O
of	O
other	O
bio	O
##log	O
##ic	O
pathways	O
,	O
interpretation	O
of	O
this	O
marker	O
in	O
the	O
context	O
of	O
other	O
changes	O
in	O
the	O
trauma	O
meta	O
##bol	O
##ome	O
supports	O
the	O
notion	O
that	O
bio	B
##tin	I
is	O
depleted	O
after	O
injury	O
due	O
,	O
in	O
part	O
,	O
to	O
increased	O
demand	O
for	O
BC	O
##AA	O
cat	O
##ab	O
##olis	O
##m	O
.	O

(	O
B	O
)	O
Ex	O
##pan	O
##sion	O
for	O
the	O
a	O
##romatic	O
region	O
showing	O
signals	O
for	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
and	O
its	O
related	O
meta	O
##bol	O
##ites	O
.	O

Con	O
##cent	O
##rations	O
of	O
ni	B
##ac	I
##ina	I
##mi	I
##de	I
,	O
another	O
oxidation	O
substrate	O
and	O
vitamin	O
derivative	O
,	O
were	O
lower	O
in	O
trauma	O
patients	O
.	O

The	O
obtained	O
solution	O
was	O
separated	O
in	O
ten	O
al	O
##iq	O
##uo	O
##ts	O
of	O
1	O
m	O
##L	O
.	O
Each	O
al	O
##iq	O
##uo	O
##t	O
was	O
mixed	O
with	O
9	O
m	O
##L	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
solution	O
(	O
0	O
.	O
25	O
m	O
##M	O
,	O
pH	O
8	O
.	O
8	O
)	O
to	O
give	O
a	O
sample	O
volume	O
of	O
10	O
m	O
##L	O
,	O
v	O
##ortex	O
##ed	O
and	O
proceeded	O
as	O
described	O
in	O
sections	O
""""	O
extraction	O
procedure	O
""""	O
and	O
""""	O
integration	O
procedure	O
""""	O
.	O

There	O
was	O
a	O
significant	O
correlation	O
between	O
detect	O
##ability	O
and	O
levels	O
of	O
this	O
me	B
##rca	I
##pt	I
##uri	I
##c	I
acid	I
and	O
G	O
##ST	O
##M	O
##1	O
g	O
##eno	O
##type	O
,	O
demonstrating	O
a	O
solid	O
p	O
##hen	O
##otype	O
-	O
g	O
##eno	O
##type	O
relationship	O
for	O
this	O
gene	O
.	O

Tri	B
##gly	I
##cer	I
##ides	I
reduced	O
within	O
all	O
sub	O
‐	O
classes	O
of	O
V	O
##LD	O
##L	O
and	O
HD	O
##L	O
,	O
except	O
large	O
HD	O
##L	O
(	O
Figure	O
L	O
)	O
.	O

However	O
,	O
in	O
most	O
samples	O
we	O
were	O
unable	O
to	O
detect	O
the	O
simple	O
me	O
##rca	O
##pt	O
##uri	O
##c	O
acids	O
h	O
##y	O
##pot	O
##hes	O
##ized	O
to	O
be	O
formed	O
from	O
Ph	B
##e	I
-	I
e	I
##pox	I
##ides	I
2	O
and	O
12	O
,	O
which	O
might	O
have	O
helped	O
to	O
explain	O
the	O
influence	O
of	O
G	O
##ST	O
##M	O
##1	O
null	O
status	O
on	O
levels	O
of	O
Ph	O
##e	O
-	O
te	O
##tra	O
##ols	O
5	O
and	O
21	O
in	O
cigarette	O
smoke	O
##rs	O
.	O

To	O
test	O
the	O
app	O
##lica	O
##bility	O
of	O
this	O
ass	O
##ay	O
,	O
en	B
##zal	I
##uta	I
##mi	I
##de	I
and	O
N	B
-	I
des	I
##met	I
##hyl	I
##en	I
##zal	I
##uta	I
##mi	I
##de	I
concentrations	O
were	O
q	O
##uant	O
##ified	O
in	O
samples	O
collected	O
from	O
a	O
patient	O
participating	O
in	O
a	O
clinical	O
trial	O
who	O
was	O
treated	O
with	O
160	O
mg	O
en	B
##zal	I
##uta	I
##mi	I
##de	I
once	O
daily	O
and	O
had	O
reached	O
steady	O
-	O
state	O
p	O
##har	O
##ma	O
##co	O
##kin	O
##etics	O
.	O

There	O
was	O
also	O
an	O
association	O
between	O
total	O
g	B
##lut	I
##ath	I
##ione	I
and	O
AP	O
##S	O
(	O
ρ	O
=	O
0	O
.	O
56	O
,	O
P	O
=	O
0	O
.	O
04	O
,	O
q	O
=	O
0	O
.	O
25	O
)	O
.	O

This	O
may	O
indicate	O
that	O
g	B
##lut	I
##ama	I
##te	I
is	O
further	O
meta	O
##bol	O
##ized	O
to	O
2	B
-	I
o	I
##x	I
##og	I
##lut	I
##arate	I
which	O
can	O
be	O
achieved	O
by	O
a	O
coupled	O
trans	O
##ami	O
##nation	O
reaction	O
in	O
which	O
o	B
##xa	I
##lo	I
##ace	I
##tate	I
is	O
converted	O
to	O
as	B
##par	I
##tate	I
.	O

Third	O
,	O
cluster	O
7	O
scores	O
were	O
associated	O
with	O
an	O
increased	O
likelihood	O
of	O
central	O
o	O
##besity	O
,	O
raised	O
serum	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
and	O
type	O
2	O
diabetes	O
.	O

In	O
our	O
study	O
,	O
the	O
measured	O
meta	O
##bol	O
##ites	O
are	O
described	O
by	O
a	O
number	O
of	O
carbon	O
atoms	O
in	O
both	O
fatty	O
a	O
##cy	O
##l	O
chains	O
together	O
and	O
number	O
of	O
double	O
bonds	O
without	O
their	O
exact	O
position	O
,	O
where	O
PC	O
a	O
##a	O
and	O
PC	B
a	I
##e	I
abbreviation	O
##s	O
denote	O
di	B
##acy	I
##l	I
p	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
and	O
a	B
##cy	I
##l	I
-	I
al	I
##ky	I
##l	I
p	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
,	O
respectively	O
.	O

Finally	O
,	O
other	O
studies	O
found	O
an	O
increase	O
in	O
20	B
##α	I
-	I
H	I
##SD	I
activity	O
(	O
lower	O
ratio	O
of	O
T	O
##HF	O
+	O
α	O
##TH	O
##F	O
+	O
THE	O
/	O
α	O
##C	O
+	O
α	O
##C	O
##l	O
)	O

Furthermore	O
,	O
in	O
the	O
setting	O
of	O
ta	B
##mo	I
##xi	I
##fen	I
treatment	O
that	O
is	O
routinely	O
administered	O
to	O
ER	O
+	O
patients	O
,	O
R	O
##R	O
##M	O
##2	O
was	O
able	O
to	O
distinguish	O
patients	O
who	O
were	O
resistant	O
to	O
treatment	O
from	O
those	O
who	O
responded	O
to	O
the	O
therapy	O
.	O

The	O
_	O
13	O
C	O
and	O
_	O
12	O
C	O
la	B
##ct	I
##ate	I
and	O
Al	O
##a	O
concentrations	O
were	O
determined	O
by	O
integration	O
of	O
the	O
met	O
##hyl	O
peak	O
and	O
its	O
satellites	O
and	O
ca	O
##li	O
##bra	O
##ted	O
against	O
the	O
concentration	O
of	O
la	B
##ct	I
##ate	I
determined	O
independently	O
by	O
G	O
##C	O
-	O
MS	O
.	O

The	O
total	O
levels	O
of	O
so	B
##fo	I
##s	I
##bu	I
##vir	I
meta	O
##bol	O
##ites	O
in	O
the	O
liver	O
##s	O
of	O
patients	O
currently	O
on	O
therapy	O
(	O
77	O
.	O
1	O
μ	O
##M	O
)	O
and	O
the	O
estimated	O
trip	B
##hos	I
##phate	I
concentrations	O
based	O
on	O
the	O
proportions	O
of	O
in	O
##tra	O
##cellular	O
meta	O
##bol	O
##ites	O
observed	O
in	O
v	O
##it	O
##ro	O
(	O
[UNK]	O
μ	O
##M	O
)	O
greatly	O
exceed	O
the	O
in	O
##hibition	O
constant	O
for	O
the	O
HC	O
##V	O
N	O
##S	O
##5	O
##B	O
RNA	O
-	O
dependent	O
RNA	O
polymer	O
##ase	O
(	O
0	O
.	O
42	O
μ	O
##M	O
)	O
.	O

The	O
features	O
in	O
C	O
##luster	O
4	O
matched	O
dip	O
##eptide	O
##s	O
(	O
His	O
,	O
A	O
##rg	O
;	O
T	O
##rp	O
,	O
Ph	O
##e	O
)	O
and	O
a	O
meta	O
##bol	O
##ite	O
of	O
a	O
natural	O
product	O
,	O
did	B
##em	I
##eth	I
##yl	I
##si	I
##mm	I
##ond	I
##sin	I
.	O

The	O
ratio	O
of	O
co	O
##rt	O
##is	O
##ol	O
/	O
ACT	O
##H	O
was	O
inverse	O
##ly	O
related	O
to	O
T	O
##rp	O
(	O
r	O
=	O
−	O
##0	O
.	O
44	O
)	O
,	O
k	B
##yn	I
##uren	I
##ine	I
(	O
r	O
=	O
−	O
##0	O
.	O
50	O
)	O
,	O
k	B
##yn	I
##uren	I
##ic	I
acid	I
(	O
r	O
=	O
−	O
##0	O
.	O
58	O
)	O
,	O
ni	B
##cot	I
##ini	I
##c	I
acid	I
(	O
r	O
=	O
−	O
##0	O
.	O
42	O
)	O
,	O
and	O
in	B
##do	I
##le	I
-	I
3	I
-	I
ace	I
##tic	I
acid	I
(	O
r	O
=	O
−	O
##0	O
.	O
41	O
)	O
.	O

This	O
UP	O
##LC	O
system	O
was	O
performed	O
using	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
containing	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
(	O
solvent	O
A	O
)	O
and	O
water	O
containing	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
(	O
solvent	O
B	O
)	O
as	O
the	O
mobile	O
phase	O
at	O
a	O
flow	O
rate	O
of	O
0	O
.	O
3	O
m	O
##l	O
/	O
min	O
at	O
40	O
##°	O
##C	O
.	O

Interest	O
##ingly	O
,	O
the	O
C	O
##18	O
B	O
##E	O
##H	O
UP	O
##LC	O
stationary	O
phase	O
does	O
not	O
separate	O
is	O
##omer	O
##s	O
of	O
der	O
##iva	O
##tized	O
1	B
##α	I
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
,	O
probably	O
due	O
to	O
the	O
anti	O
position	O
of	O
h	O
##ydro	O
##xy	O
##l	O
groups	O
on	O
its	O
A	O
ring	O
,	O
which	O
make	O
this	O
structure	O
more	O
symmetric	O
.	O

Chen	O
J	O
et	O
al	O
.	O
have	O
found	O
that	O
pro	B
##line	I
concentration	O
in	O
urine	O
of	O
patients	O
with	O
he	O
##pa	O
##to	O
##cellular	O
car	O
##cin	O
##oma	O
was	O
higher	O
than	O
that	O
of	O
normal	O
people	O
.	O

Internal	O
mass	O
ca	O
##li	O
##bra	O
##tion	O
was	O
performed	O
using	O
a	O
sodium	B
format	I
##e	I
solution	O
(	O
50	O
%	O
water	O
,	O
50	O
%	O
is	B
##op	I
##rop	I
##ano	I
##l	I
,	O
0	O
.	O
2	O
%	O
form	B
##ic	I
acid	I
and	O
10	O
mm	O
##ol	O
/	O
l	O
Na	O
##OH	O
)	O
in	O
negative	O
mode	O
for	O
automated	O
m	O
/	O
z	O
ca	O
##li	O
##bra	O
##tion	O
in	O
each	O
ch	O
##roma	O
##to	O
##graphic	O
run	O
.	O

Level	O
##s	O
of	O
several	O
identified	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
,	O
including	O
(	O
PC	O
##34	O
)	O
,	O
(	O
PC	O
##36	O
)	O
and	O
(	O
PC	O
##38	O
)	O
variants	O
,	O
and	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
,	O
including	O
(	O
LP	O
##C	O
##16	O
)	O
and	O
(	O
LP	O
##C	O
##18	O
)	O
variants	O
,	O
were	O
first	O
significantly	O
decreased	O
and	O
then	O
increased	O
in	O
post	O
-	O
treatment	O
samples	O
.	O

Thus	O
both	O
ni	B
##cot	I
##ine	I
meta	O
##bol	O
##ites	O
correlated	O
extremely	O
well	O
,	O
but	O
co	B
##tin	I
##ine	I
co	O
##rrel	O
##ates	O
most	O
highly	O
with	O
our	O
chemical	O
marker	O
of	O
v	O
##ap	O
##our	O
phase	O
ET	O
##S	O
(	O
3	O
-	O
EP	O
)	O
,	O
supporting	O
the	O
hypothesis	O
that	O
3	O
-	O
EP	O
can	O
be	O
used	O
as	O
a	O
chemical	O
trace	O
##r	O
of	O
ET	O
##S	O
.	O

The	O
human	O
body	O
controls	O
the	O
am	O
##monia	O
concentration	O
in	O
an	O
accepted	O
level	O
by	O
consumption	O
of	O
am	O
##monia	O
to	O
generate	O
g	B
##lut	I
##amine	I
and	O
u	B
##rea	I
.	O

The	O
step	O
##wise	O
re	O
##gression	O
##s	O
,	O
co	O
##rrel	O
##ating	O
central	O
ad	O
##ip	O
##os	O
##ity	O
,	O
IP	S
and	O
the	O
Kid	O
##M	O
##ed	O
score	O
with	O
u	O
##rina	O
##ry	O
meta	O
##bol	O
##ites	O
,	O
selected	O
12	O
,	O
11	O
and	O
12	O
meta	O
##bol	O
##ites	O
,	O
respectively	O
,	O
with	O
a	O
statistical	O
##ly	O
significant	O
value	O
and	O
a	O
good	O
performance	O
of	O
prediction	O
(	O
A	O
–	O
C	O
)	O
.	O

24	B
##S	I
-	I
OH	I
-	I
Cho	I
##les	I
##tero	I
##l	I
values	O
were	O
L	O
##O	O
##G	O
-	O
t	O
##ran	O
##formed	O
before	O
entering	O
AN	O
##O	O
##VA	O
.	O

B	O
.	O
–	O
F	O
.	O
Box	O
plots	O
of	O
concentrations	O
(	O
µ	O
##g	O
/	O
m	O
##l	O
)	O
of	O
representative	O
meta	O
##bol	O
##ites	O
that	O
change	O
significantly	O
with	O
insulin	O
resistance	O
and	O
/	O
or	O
d	O
##ys	O
##gly	O
##ce	O
##mia	O
as	O
measured	O
by	O
is	O
##oto	O
##pic	O
di	O
##lution	O
ass	O
##ays	O
in	O
subjects	O
with	O
normal	O
glucose	S
tolerance	O
that	O
are	O
insulin	O
sensitive	O
(	O
N	O
##G	O
##T	O
-	O
IS	O
)	O
or	O
insulin	O
resistant	O
(	O
N	O
##G	O
##T	O
-	O
IS	O
)	O
and	O
in	O
d	B
##ys	I
##gly	I
##ce	I
##mic	I
subjects	O
with	O
impaired	O
glucose	S
tolerance	O
(	O
I	O
##G	O
##T	O
)	O
or	O
impaired	O
fast	O
##ing	O
plasma	O
glucose	S
levels	O
(	O
IF	O
##G	O
)	O
.	O

The	O
fourth	O
al	O
##iq	O
##uo	O
##t	O
was	O
analyzed	O
via	O
negative	O
ion	O
##ization	O
following	O
el	O
##ution	O
from	O
a	O
H	O
##IL	O
##IC	O
column	O
(	O
Waters	O
UP	O
##LC	O
B	O
##E	O
##H	O
Am	B
##ide	I
2	O
.	O
1	O
##x	O
##15	O
##0	O
mm	O
,	O
1	O
.	O
7	O
μ	O
##m	O
)	O
using	O
a	O
gradient	O
consisting	O
of	O
water	O
and	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
with	O
10	O
##m	O
##M	O
am	B
##mon	I
##ium	I
format	I
##e	I
,	O
pH	O
10	O
.	O
8	O
.	O

It	O
is	O
possible	O
that	O
further	O
flux	O
through	O
the	O
k	B
##yn	I
##uren	I
##ine	I
pathway	O
in	O
tumor	O
cells	O
could	O
account	O
for	O
the	O
comparatively	O
low	O
k	B
##yn	I
##uren	I
##ine	I
concentration	O
in	O
plasma	O
from	O
women	O
with	O
breast	O
cancer	O
.	O

Organic	O
acids	O
,	O
comprised	O
particularly	O
of	O
amino	O
acids	O
,	O
represented	O
the	O
largest	O
individual	O
group	O
,	O
but	O
also	O
pu	B
##rine	I
meta	O
##bol	O
##ites	O
in	O
the	O
n	O
##uc	O
##leo	O
##tide	O
group	O
,	O
as	O
well	O
as	O
fatty	O
a	B
##cy	I
##l	I
car	I
##ni	I
##tine	I
##s	I
in	O
the	O
car	B
##ni	I
##tine	I
group	O
were	O
common	O
.	O

Our	O
aims	O
were	O
as	O
follows	O
:	O
1	O
)	O
to	O
identify	O
metabolic	O
signatures	O
that	O
could	O
distinguish	O
patients	O
with	O
PD	O
##R	O
from	O
those	O
with	O
long	O
duration	S
but	O
without	O
DR	O
,	O
and	O
2	O
)	O
to	O
identify	O
the	O
metabolic	O
pathways	O
that	O
respond	O
to	O
DR	O
.	O

In	O
addition	O
,	O
is	B
##ole	I
##uc	I
##ine	I
and	O
gal	B
##act	I
##osy	I
##l	I
-	I
g	I
##ly	I
##cer	I
##ate	I
(	O
negative	O
correlation	O
)	O
changes	O
correlated	O
to	O
glucose	S
;	O
N	B
-	I
met	I
##hyl	I
##alan	I
##ine	I
,	O
g	B
##ly	I
##cer	I
##ol	I
,	O
palm	B
##ito	I
##le	I
##ic	I
acid	I
(	O
negative	O
correlation	O
)	O
and	O
g	B
##lu	I
##cu	I
##ronic	I
acid	I
(	O
positive	O
correlation	O
)	O
changes	O
correlated	O
to	O
insulin	O
changes	O
;	O
se	B
##rine	I
,	O
palm	B
##ito	I
##le	I
##ic	I
acid	I
,	O
beta	B
-	I
al	I
##ani	I
##ne	I
and	O
an	O
is	O
##omer	O
of	O
a	B
##rac	I
##hi	I
##don	I
##ic	I
acid	I
(	O
negative	O
correlation	O
)	O
changes	O
correlated	O
to	O
H	O
##OM	O
##A	O
changes	O
and	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
is	B
##oc	I
##it	I
##ric	I
acid	I
,	O
f	B
##ru	I
##ct	I
##ose	I
and	O
a	B
##rab	I
##ito	I
##l	I
(	O
positive	O
correlation	O
)	O
changes	O
correlated	O
to	O
c	O
-	O
p	O
##eptide	O
changes	O
.	O

The	O
latter	O
el	O
##utes	O
at	O
2	O
.	O
55	O
min	O
and	O
the	O
transitions	O
m	O
/	O
z	O
198	O
.	O
2	O
[UNK]	O
m	O
/	O
z	O
152	O
for	O
L	B
-	I
D	I
##OP	I
##A	I
and	O
m	O
/	O
z	O
201	O
.	O
2	O
[UNK]	O
m	O
/	O
z	O
155	O
for	O
the	O
corresponding	O
de	O
##uter	O
##ated	O
internal	O
standard	O
L	O
-	O
D	O
##OP	O
##A	O
-	O
d	O
##3	O
were	O
monitored	O
.	O

Au	O
##tism	O
,	O
Au	O
##tism	O
spectrum	O
disorder	O
,	O
K	B
##yn	I
##uren	I
##ine	I
,	O
Mel	B
##aton	I
##in	I
,	O
Met	O
##ab	O
##olo	O
##mic	O
##s	O
,	O
P	O
##uri	O
##ner	O
##gic	O
signaling	O
,	O
Q	B
##uin	I
##olin	I
##ic	I
acid	I
,	O
Ser	B
##oto	I
##nin	I
,	O
Try	B
##pt	I
##op	I
##han	I

All	O
est	O
##rogen	O
##s	O
and	O
est	B
##rogen	I
meta	O
##bol	O
##ites	O
were	O
statistical	O
##ly	O
significantly	O
correlated	O
with	O
B	O
##MI	O
,	O
with	O
un	O
##con	O
##ju	O
##gated	O
est	B
##rad	I
##iol	I
most	O
strongly	O
correlated	O
(	O
Pearson	O
correlation	O
(	O
r	O
)	O
=	O
0	O
.	O
45	O
)	O
.	O

Cal	O
##cula	O
##tions	O
of	O
correlation	O
##s	O
between	O
base	O
##line	O
meta	O
##bol	O
##ite	O
levels	O
to	O
h	B
##ydro	I
##ch	I
##lor	I
##oth	I
##ia	I
##zi	I
##de	I
or	O
los	O
##art	O
##an	O
responses	O
mostly	O
yielded	O
less	O
significant	O
data	O
.	O

Similar	O
observations	O
were	O
made	O
in	O
the	O
highest	O
q	O
##ua	O
##rt	O
##ile	O
of	O
c	B
##it	I
##ru	I
##llin	I
##e	I
after	O
adjusting	O
for	O
AD	B
##MA	I
for	O
higher	O
incidence	O
of	O
MAC	O
##E	O
[	O
adjusted	O
H	O
##R	O
(	O
95	O
%	O
C	O
##I	O
)	O
:	O
2	O
.	O
03	O
(	O
1	O
.	O
44	O
-	O
2	O
.	O
87	O
)	O
,	O
p	O
<	O
0	O
.	O
00	O
##1	O
]	O
.	O

This	O
consistent	O
finding	O
does	O
not	O
support	O
the	O
laboratory	O
-	O
based	O
hypothesis	O
that	O
2	O
-	O
pathway	O
cat	B
##ech	I
##ols	I
produce	O
semi	B
##quin	I
##ones	I
and	O
q	B
##uin	I
##ones	I
which	O
through	O
red	O
##ox	O
cycling	O
generate	O
reactive	O
oxygen	O
species	O
that	O
damage	O
DNA	O
[	O
,	O
]	O
.	O

500	O
μ	O
##L	O
of	O
plasma	O
and	O
CS	O
##F	O
samples	O
were	O
separately	O
analyzed	O
for	O
bio	O
##chemical	O
and	O
clinical	O
parameters	O
including	O
plasma	O
glucose	S
,	O
plasma	O
insulin	O
,	O
plasma	O
g	O
##ly	O
##cated	O
hem	O
##og	O
##lo	O
##bin	O
A1	O
##c	O
(	O
H	O
##b	O
##A	O
##1	O
##c	O
)	O
,	O
CS	O
##F	O
glucose	S
,	O
and	O
CS	O
##F	O
insulin	O
level	O
.	O

While	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
are	O
only	O
a	O
class	O
of	O
lip	O
##ids	O
,	O
we	O
found	O
significant	O
differences	O
between	O
healthy	O
and	O
di	O
##abe	O
##tic	O
samples	O
.	O

Further	O
investigations	O
focused	O
on	O
the	O
quantitative	O
evaluation	O
of	O
c	O
##y	O
##c	O
##li	O
##zation	O
showed	O
that	O
,	O
whereas	O
the	O
magnitude	O
of	O
c	O
##y	O
##c	O
##li	O
##zation	O
of	O
g	B
##lut	I
##amine	I
to	O
p	B
##yr	I
##og	I
##lut	I
##ami	I
##c	I
acid	I
varied	O
drastically	O
in	O
different	O
portions	O
of	O
samples	O
from	O
the	O
same	O
pool	O
of	O
human	O
serum	O
,	O
the	O
sum	O
of	O
g	B
##lut	I
##amine	I
and	O
p	B
##yr	I
##og	I
##lut	I
##ami	I
##c	I
acid	I
concentrations	O
in	O
each	O
sample	O
was	O
the	O
same	O
in	O
all	O
portions	O
of	O
the	O
serum	O
(	O
C	O
##V	O
<	O
3	O
%	O
)	O
.	O

The	O
detection	O
and	O
q	O
##uant	O
##ification	O
of	O
key	O
k	B
##eto	I
-	I
and	I
##rogen	I
##s	I
that	O
comprise	O
the	O
and	O
##rogen	O
meta	O
##bol	O
##ome	O
poses	O
several	O
technical	O
challenges	O
.	O

We	O
are	O
now	O
able	O
to	O
assess	O
the	O
contribution	O
of	O
g	B
##ly	I
##cola	I
##te	I
as	O
a	O
source	O
for	O
end	O
##ogen	O
##ous	O
o	B
##xa	I
##late	I
production	O
.	O

The	O
re	O
##p	O
##rod	O
##uc	O
##ibility	O
of	O
the	O
results	O
and	O
effects	O
of	O
ps	O
##ych	O
##ot	O
##ropic	O
medication	O
on	O
ne	B
##r	I
##von	I
##ic	I
acid	I
were	O
verified	O
in	O
co	O
##hor	O
##t	O
2	O
,	O
an	O
independent	O
sample	O
set	O
of	O
me	O
##dicated	O
patients	O
[	O
major	O
de	O
##pressive	O
disorder	O
(	O
n	O
=	O
45	O
)	O
,	O
bi	O
##pol	O
##ar	O
disorder	O
(	O
n	O
=	O
71	O
)	O
,	O
s	O
##chi	O
##zophrenia	O
(	O
n	O
=	O
115	O
)	O
]	O
,	O
and	O
controls	O
(	O
n	O
=	O
90	O
)	O
using	O
gas	O
ch	O
##roma	O
##tography	O
time	O
-	O
of	O
-	O
flight	O
mass	O
s	O
##pect	O
##rome	O
##try	O
.	O

(	O
A	O
)	O
G	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
metabolism	O
.	O

The	O
present	O
work	O
demonstrates	O
that	O
specific	O
β	B
-	I
a	I
##po	I
##car	I
##ote	I
##no	I
##ids	I
ex	O
##ert	O
an	O
anti	O
-	O
vitamin	O
A	O
activity	O
by	O
directly	O
interacting	O
with	O
RA	O
##R	O
##s	O
as	O
high	O
affinity	O
antagonist	O
##s	O
.	O

Similarly	O
,	O
positive	O
correlation	O
##s	O
between	O
these	O
s	O
##tero	O
##ls	O
and	O
22	B
##R	I
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
and	O
25	B
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
suggest	O
that	O
some	O
amount	O
of	O
these	O
two	O
o	B
##xy	I
##ster	I
##ols	I
reflects	O
formation	O
by	O
spontaneous	O
as	O
opposed	O
to	O
en	O
##zy	O
##matic	O
oxidation	O
.	O

A	O
##bb	O
##re	O
##viation	O
##s	O
:	O
AC	O
##E	O
an	O
##gio	O
##tens	O
##in	O
-	O
converting	O
enzyme	O
,	O
BA	O
##I	O
,	O
Beck	O
An	O
##xi	O
##ety	O
In	O
##vent	O
##ory	O
,	O
C	O
##K	O
##D	O
chronic	O
kidney	O
disease	O
,	O
e	O
##G	O
##F	O
##R	O
estimated	O
g	O
##lo	O
##mer	O
##ular	O
fi	O
##ltration	O
rate	O
,	O
K	B
##D	I
##Q	I
##OL	I
-	I
SF	I
,	O
Kid	O
##ney	O
Disease	O
Quality	O
of	O
Life	O
short	O
-	O
form	O
,	O
P	O
##H	O
##Q	O
-	O
9	O
,	O

Un	O
##iva	O
##ria	O
##te	O
analysis	O
for	O
bio	O
##mark	O
##er	O
identification	O
using	O
receiver	O
operating	O
characteristic	O
(	O
R	O
##OC	O
)	O
curve	O
demonstrated	O
that	O
9	B
-	I
c	I
##is	I
-	I
re	I
##tino	I
##ic	I
acid	I
(	O
9	O
##c	O
##RA	O
)	O
dominated	O
the	O
first	O
page	O
of	O
bio	O
##mark	O
##ers	O
,	O
with	O
area	O
under	O
the	O
curve	O
(	O
AU	O
##C	O
)	O
value	O
0	O
.	O
88	O
##8	O
.	O

We	O
aim	O
to	O
determine	O
p	B
##ht	I
##hala	I
##te	I
exposure	O
and	O
other	O
relevant	O
factors	O
in	O
a	O
sample	O
of	O
the	O
general	O
Taiwanese	O
population	O
in	O
order	O
to	O
evaluate	O
actual	O
p	B
##ht	I
##hala	I
##te	I
exposure	O
levels	O
after	O
this	O
disclosure	O
of	O
DE	O
##HP	O
use	O
.	O

PC	B
a	I
##a	I
C	I
##40	I
:	I
2	I
;	O
93	O
.	O

Mon	O
##ocytes	O
were	O
activated	S
with	O
10	O
ng	O
/	O
m	O
##L	O
of	O
LP	B
##S	I
(	O
Sigma	O
Al	O
##dric	O
##h	O
,	O
St	O
.	O
Louis	O
)	O
.	O

For	O
example	O
it	O
was	O
recently	O
proposed	O
that	O
le	O
##uka	O
##emia	O
cells	O
o	O
##xi	O
##dis	O
##e	O
fatty	O
acids	O
and	O
that	O
they	O
un	O
##co	O
##up	O
##le	O
o	O
##xi	O
##da	O
##tive	O
p	O
##hos	O
##ph	O
##ory	O
##lation	O
in	O
order	O
to	O
shift	O
ATP	S
production	O
from	O
fatty	O
acid	O
oxidation	O
to	O
g	O
##ly	O
##co	O
##lysis	O
.	O

Ana	O
##ly	O
##ses	O
of	O
sugar	O
meta	O
##bol	O
##ites	O
in	O
fi	O
##bro	O
##blast	O
##s	O
from	O
patients	O
revealed	O
increased	O
concentrations	O
of	O
gal	B
##act	I
##ose	I
-	I
1	I
-	I
phosphate	I
and	O
glucose	B
-	I
1	I
phosphate	I
,	O
as	O
compared	O
with	O
fi	O
##bro	O
##blast	O
##s	O
from	O
controls	O
.	O

While	O
L	O
##F	O
/	O
L	O
##C	O
-	O
MS	O
(	O
±	O
)	O
analysis	O
found	O
alterations	O
in	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
(	O
PC	O
)	O
,	O
M	O
##F	O
/	O
L	O
##C	O
-	O
MS	O
(	O
±	O
)	O
analysis	O
found	O
changes	O
in	O
p	B
##hos	I
##pha	I
##ti	I
##dic	I
acid	I
(	O
PA	O
)	O
,	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
(	O
LP	O
##C	O
)	O
and	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##let	I
##han	I
##ola	I
##mine	I
##s	I
(	O
LP	O
##E	O
)	O
.	O

Line	O
##arity	O
was	O
evaluated	O
by	O
comparing	O
known	O
spike	O
##d	O
concentrations	O
of	O
beta	B
##ine	I
with	O
expected	O
concentrations	O
tested	O
in	O
q	O
##uad	O
##rup	O
##lica	O
##tes	O
across	O
the	O
biological	O
range	O
from	O
25	O
to	O
1200	O
μ	O
##M	O
(	O
n	O
=	O
13	O
)	O
.	O

Very	O
recently	O
,	O
the	O
dig	O
##est	O
##ion	O
of	O
Al	O
##b	O
with	O
try	O
##ps	O
##in	O
using	O
pressure	O
cycling	O
was	O
shown	O
to	O
efficiently	O
recover	O
the	O
T	O
##3	O
p	O
##eptide	O
A	O
_	O
21	O
L	O
##V	O
##L	O
##IA	O
##FA	O
##Q	O
##Y	O
##LL	O
##V	O
##L	O
##IA	O
##FA	O
##Q	O
##Y	O
##L	O
##Q	O
##Q	O
##CP	O
##F	O
##ED	O
##H	O
##V	O
##K	O
_	O
40	O
without	O
prior	O
den	O
##at	O
##uration	O
and	O
reduction	O
of	O
internal	O
di	B
##sul	I
##fi	I
##de	I
bonds	O
.	O

Cell	O
culture	O
experiments	O
have	O
demonstrated	O
that	O
co	O
##Q	O
##10	O
can	O
also	O
prevent	O
a	O
##pop	O
##tosis	O
by	O
decreasing	O
c	B
##era	I
##mi	I
##de	I
release	O
,	O
and	O
both	O
in	O
v	O
##ivo	O
and	O
in	O
v	O
##it	O
##ro	O
studies	O
showed	O
that	O
co	O
##Q	O
##10	O
can	O
decrease	O
a	O
##pop	O
##tosis	O
in	O
response	O
to	O
c	B
##era	I
##mi	I
##de	I
exposure	O
.	O

Moreover	O
,	O
al	B
##ani	I
##ne	I
and	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
showed	O
opposite	O
trends	O
to	O
that	O
observed	O
above	O
.	O

Mi	O
##to	O
##cho	O
##nd	O
##rial	O
function	O
in	O
EA	O
##C	O
cell	O
lines	O
was	O
assessed	O
using	O
fluorescent	O
probe	O
##s	O
,	O
mitochondrial	O
gene	O
expression	O
was	O
assessed	O
using	O
q	O
##PC	O
##R	O
-	O
based	O
gene	O
array	O
##s	O
and	O
in	O
##tra	O
##cellular	O
ATP	S
levels	O
were	O
determined	O
using	O
a	O
l	O
##umi	O
##nes	O
##cence	O
-	O
based	O
kit	O
.	O

Cho	B
##les	I
##tero	I
##l	I
el	O
##uted	O
in	O
fraction	O
3	O
from	O
the	O
first	O
SP	O
##E	O
column	O
(	B
SP	B
##E	I
##1	I
-	I
Fr	I
-	I
3	I
)	O
and	O
,	O
in	O
its	O
GP	O
-	O
tag	O
##ged	O
form	O
,	O
in	O
fraction	O
##s	O
1	O
and	O
2	O
from	O
the	O
second	O
column	O
(	B
SP	B
##E	I
##2	I
-	I
Fr	I
-	I
1	I
and	O
SP	B
##E	I
##2	I
-	I
Fr	I
-	I
2	I
)	O
.	O

Cao	O
et	O
al	O
also	O
reported	O
a	O
modest	O
correlation	O
between	O
sa	B
##rc	I
##os	I
##ine	I
levels	O
and	O
PC	O
##a	O
progression	O
,	O
and	O
the	O
pro	O
##gno	O
##stic	O
value	O
of	O
sa	B
##rc	I
##os	I
##ine	I
was	O
found	O
to	O
be	O
inferior	O
to	O
the	O
more	O
robust	O
PC	O
##A	O
##3	O
and	O
f	O
##PS	O
##A	O
bio	O
##mark	O
##ers	O
.	O

HP	O
##LC	O
mobile	O
phases	O
were	O
0	O
.	O
1	O
%	O
ace	B
##tic	I
acid	I
in	O
water	O
and	O
100	O
%	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
.	O

The	O
main	O
finding	O
was	O
that	O
P	O
##GB	O
##2	O
induced	O
Inter	O
##le	O
##uki	O
##n	O
2	O
(	O
IL	O
-	O
2	O
)	O
,	O
activation	O
of	O
t	B
##yr	I
##os	I
##ine	I
kinase	O
activities	O
,	O
and	O
Nuclear	O
factor	O
ka	O
##ppa	O
B	O
(	O
N	O
##F	O
-	O
κ	O
##B	O
)	O
.	O

L	B
-	I
la	I
##ct	I
##ate	I
-	I
_	I
13	I
C	O
_	O
3	O
and	O
142	O
µ	O
##M	O
L	B
-	I
g	I
##lut	I
##ami	I
##c	I
acid	O
-	O
_	O
13	O
C	O
_	O
5	O
,	O
which	O
was	O
used	O
to	O
monitor	O
the	O
analytical	O
variations	O
during	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
analysis	O
thus	O
ensure	O
the	O
precision	O
and	O
accuracy	O
of	O
the	O
results	O
.	O

This	O
solvent	O
extracted	O
primarily	O
polar	O
lip	O
##ids	O
and	O
ch	B
##ole	I
##ster	I
##ol	I
.	O

Cross	O
-	O
section	O
##al	O
associations	O
between	O
PC	O
##A	O
factor	O
scores	O
and	O
card	O
##io	O
##met	O
##ab	O
##olic	O
risk	O
traits	O
(	O
body	O
weight	O
,	O
B	O
##MI	O
,	O
WC	O
,	O
2	O
-	O
hour	O
glucose	S
,	O
fast	O
##ing	O
insulin	O
,	O
insulin	O
AU	O
##C	O
,	O
H	O
##OM	O
##A	O
-	O
I	O
##R	O
,	O
s	O
##ys	O
##to	O
##lic	O
blood	O
pressure	O
(	O
S	O
##B	O
##P	O
)	O
,	O
di	O
##ast	O
##olic	O
blood	O
pressure	O
(	O
DB	O
##P	O
)	O
)	O
were	O
assessed	O
with	O
multiple	O
linear	O
re	O
##gression	O
adjusted	O
for	O
age	O
and	O
sex	O
.	O

An	O
algorithm	O
,	O
utilizing	O
the	O
candidate	O
bio	O
##mark	O
##ers	O
palm	B
##ito	I
##yl	I
s	I
##phi	I
##ngo	I
##my	I
##elin	I
,	O
la	B
##ct	I
##ate	I
,	O
g	B
##lu	I
##cona	I
##te	I
,	O
ad	B
##eno	I
##sin	I
##e	I
,	O
2	B
-	I
met	I
##hyl	I
##but	I
##yr	I
##yl	I
##gly	I
##cine	I
and	O
g	B
##uan	I
##id	I
##ino	I
##ace	I
##tate	I
was	O
trained	O
using	O
the	O
co	O
##hor	O
##t	O
-	O
1	O
data	O
set	O
and	O
then	O
tested	O
on	O
the	O
co	O
##hor	O
##t	O
-	O
2	O
data	O
set	O
.	O

Mi	O
##to	O
##cho	O
##nd	O
##rial	O
d	O
##ys	O
##function	O
accompanied	O
by	O
increased	O
R	O
##OS	O
production	O
in	O
rode	O
##nts	O
was	O
also	O
observed	O
with	O
re	O
##nal	O
failure	O
and	O
resulting	O
c	B
##rea	I
##tin	I
##ine	I
accumulation	O
.	O

Si	B
##m	I
##vas	I
##tat	I
##in	I
(	O
40	O
mg	O
/	O
day	O
)	O
was	O
prescribed	O
to	O
those	O
with	O
h	O
##yper	O
##cho	O
##les	O
##tero	O
##la	O
##emia	O
.	O

Di	B
##ch	I
##lor	I
##oa	I
##ce	I
##tate	I
,	O
a	O
p	B
##yr	I
##u	I
##vate	I
mi	O
##met	O
##ic	O
that	O
in	O
##hibit	O
##s	O
p	O
##yr	O
##u	O
##vate	O
de	O
##hy	O
##dr	O
##ogen	O
##ase	O
kinase	O
,	O
has	O
been	O
shown	O
to	O
increase	O
p	O
##yr	O
##u	O
##vate	O
de	O
##hy	O
##dr	O
##ogen	O
##ase	O
activity	O
and	O
the	O
oxidation	O
of	O
glucose	S
,	O
reduce	O
the	O
proliferation	O
of	O
breast	O
cancer	O
cell	O
lines	O
,	O
in	O
##hibit	O
proliferation	O
,	O
and	O
slow	O
x	O
##eno	O
##gra	O
##ft	O
tumor	O
growth	O
.	O

We	O
focus	O
on	O
the	O
media	O
##ting	O
effect	O
of	O
un	O
##con	O
##ju	O
##gated	O
est	B
##rad	I
##iol	I
on	O
ER	O
+	O
positive	O
breast	O
cancer	O
for	O
the	O
following	O
reasons	O
:	O
although	O
several	O
metabolic	O
pathway	O
ratios	O
con	O
##founded	O
the	O
B	O
##MI	O
-	O
breast	O
cancer	O
association	O
to	O
a	O
similar	O
degree	O
as	O
un	O
##con	O
##ju	O
##gated	O
est	B
##rad	I
##iol	I
when	O
un	O
##con	O
##ju	O
##gated	O
est	B
##rad	I
##iol	I
was	O
not	O
included	O
in	O
the	O
model	O
,	O
un	O
##con	O
##ju	O
##gated	O
est	B
##rad	I
##iol	I
was	O
the	O
strongest	O
predict	O
##or	O
of	O
ER	O
+	O
breast	O
cancer	O
in	O
our	O
analysis	O
,	O
it	O
was	O
more	O
highly	O
correlated	O
with	O
B	O
##MI	O
than	O
other	O
est	O
##rogen	O
##s	O
,	O
est	B
##rogen	I
meta	O
##bol	O
##ites	O
,	O
and	O
metabolic	O
pathway	O
ratios	O
,	O
and	O
additional	O
adjustment	O
of	O
the	O
B	O
##MI	O
-	O
breast	O
cancer	O
association	O
for	O
metabolic	O
pathway	O
ratios	O
after	O
adjustment	O
for	O
un	O
##con	O
##ju	O
##gated	O
est	B
##rad	I
##iol	I
did	O
not	O
change	O
the	O
B	O
##MI	O
risk	O
estimate	O
.	O

In	O
addition	O
,	O
le	B
##uc	I
##ine	I
,	O
v	B
##ali	I
##ne	I
,	O
se	B
##rine	I
,	O
and	O
g	B
##lut	I
##amine	I
were	O
all	O
decreased	O
in	O
CD	O
compared	O
to	O
UC	O
subjects	O
(	O
all	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Ph	B
##en	I
##yla	I
##lani	I
##ne	I
,	O
g	B
##lut	I
##amine	I
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
T	B
##MA	I
##O	I
,	O
N	B
-	I
ace	I
##ty	I
##l	I
-	I
g	I
##ly	I
##co	I
##p	I
##rote	I
##ins	I
and	O
c	B
##it	I
##rate	I
have	O
been	O
demonstrated	O
a	O
positive	O
correlation	O
,	O
whereas	O
a	O
negative	O
correlation	O
of	O
is	B
##ole	I
##uc	I
##ine	I
,	O
v	B
##ali	I
##ne	I
and	O
glucose	S
was	O
observed	O
between	O
the	O
two	O
groups	O
of	O
different	O
groups	O
.	O

In	O
case	O
of	O
starvation	O
or	O
diabetes	O
me	O
##lli	O
##tus	O
,	O
the	O
levels	O
of	O
k	B
##eton	I
##e	I
bodies	O
are	O
significantly	O
increased	O
due	O
to	O
high	O
levels	O
of	O
fatty	O
acids	O
and	O
low	O
insulin	O
.	O

Mat	O
##ern	O
##al	O
thy	B
##ro	I
##xin	I
##e	I
is	O
crucial	O
in	O
f	O
##etal	O
development	O
due	O
to	O
it	O
supplies	O
thy	O
##roid	O
hormone	O
-	O
dependent	O
tissues	O
in	O
critical	O
periods	O
during	O
the	O
first	O
trim	O
##ester	O
of	O
pregnancy	O
.	O

Overall	O
,	O
the	O
selection	O
of	O
appropriate	O
transitions	O
is	O
a	O
crucial	O
step	O
for	O
the	O
detection	O
of	O
SP	O
##Ms	O
and	O
other	O
o	B
##xy	I
##lip	I
##ins	I
.	O

The	O
levels	O
of	O
c	B
##it	I
##rate	I
,	O
GA	B
##BA	I
,	O
g	B
##lut	I
##ama	I
##te	I
and	O
c	B
##ys	I
##tein	I
##e	I
were	O
significant	O
different	O
in	O
chronic	O
AD	O
patients	O
comparing	O
with	O
CH	O
##D	O
patients	O
.	O

b	O
,	O
induction	O
of	O
expression	O
of	O
m	O
##RNA	O
##s	O
for	O
RA	O
##R	O
##β	O
(	O
left	O
lower	O
panel	O
)	O
or	O
c	O
##yt	O
##och	O
##rome	O
P	O
##45	O
##0	O
,	O
26	O
##A	O
##1	O
(	O
C	O
##YP	O
##26	O
##A	O
##1	O
)	O
(	O
right	O
lower	O
panel	O
)	O
by	O
10	O
nm	O
AT	O
##RA	O
treatment	O
alone	O
or	O
by	O
co	O
-	O
treatment	O
with	O
AT	O
##RA	O
and	O
the	O
test	O
compounds	O
at	O
10	O
nm	O
,	O
including	O
β	B
-	I
car	I
##ote	I
##ne	I
(	O
BC	O
)	O
,	O
β	B
-	I
ion	I
##yl	I
##iden	I
##ea	I
##ce	I
##tic	I
acid	I
(	O
B	O
##IA	O
##A	O
)	O
,	O
β	B
-	I
a	I
##po	I
-	I
14	I
′	I
-	I
car	I
##ote	I
##nal	I
(	O
14	O
′	O
-	O
AL	O
)	O
,	O
β	B
-	I
a	I
##po	I
-	I
14	I
′	I
-	I
car	I
##ote	I
##no	I
##ic	I
acid	I
(	O
14	O
′	O
-	O
CA	O
)	O
,	O
and	O
β	B
-	I
a	I
##po	I
-	I
13	I
-	I
car	I
##ote	I
##non	I
##e	I
(	O
C	O
##13	O
k	B
##eton	I
##e	I
)	O
.	O

Met	O
##ab	O
##oli	O
##te	O
t	B
##yra	I
##mine	I
,	O
at	O
R	O
##T	O
4	O
.	O
33	O
min	O
,	O
is	O
clearly	O
detected	O
in	O
the	O
MS	O
ch	O
##roma	O
##to	O
##gram	O
;	O
however	O
,	O
its	O
signal	O
is	O
suppressed	O
in	O
the	O
EC	O
-	O
array	O
due	O
to	O
a	O
matrix	O
peak	O
at	O
4	O
.	O
5	O
min	O
.	O

The	O
within	O
-	O
ass	O
##ay	O
C	O
##V	O
for	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
using	O
4	O
standards	O
was	O
1	O
.	O
7	O
-	O
2	O
.	O
4	O
%	O
and	O
the	O
between	O
-	O
ass	O
##ay	O
C	O
##V	O
was	O
1	O
.	O
3	O
-	O
1	O
.	O
6	O
%	O
(	O
3	O
standards	O
)	O
.	O

Two	O
groups	O
of	O
card	O
##iovascular	O
disease	O
patients	O
,	O
an	O
A	B
##F	I
group	O
(	O
49	O
A	B
##F	I
patients	O
)	O
and	O
a	O
non	O
-	O
A	O
##F	O
group	O
(	O
116	O
non	O
-	O
A	O
##F	O
patients	O
)	O
,	O
were	O
included	O
in	O
the	O
present	O
study	O
.	O

The	O
primary	O
outcome	O
variables	O
were	O
changes	O
in	O
N	O
##MR	O
‐	O
based	O
meta	O
##bol	O
##ites	O
,	O
FA	O
##ME	O
‐	O
based	O
FA	S
,	O
and	O
NE	O
##FA	O
at	O
2	O
weeks	O
and	O
6	O
months	O
post	O
‐	O
R	O
##Y	O
##GB	O
.	O

Odd	O
##s	O
Rat	O
##io	O
(	O
Una	O
##d	O
##ju	O
##sted	O
and	O
Ad	O
##ju	O
##sted	O
)	O
for	O
Co	O
##rona	O
##ry	O
Arte	O
##ry	O
Disease	O
(	O
CA	O
##D	O
)	O
Pre	O
##valence	O
and	O
Major	O
Ad	O
##verse	O
Card	O
##iac	O
Events	O
(	O
MAC	O
##E	O
)	O
at	O
3	O
Years	O
with	O
Dec	O
##rea	O
##sing	O
Q	O
##ua	O
##rt	O
##iles	O
of	O
GA	O
##BR	O
and	O
A	B
##rg	I
##ini	I
##ne	I
Level	O
##s	O
Odd	O
##s	O
Rat	O
##io	O
(	O
Una	O
##d	O
##ju	O
##sted	O
and	O
Ad	O
##ju	O
##sted	O
)	O
for	O
Co	O
##rona	O
##ry	O
Arte	O
##ry	O
Disease	O
(	O
CA	O
##D	O
)	O
Pre	O
##valence	O
and	O
Major	O
Ad	O
##verse	O
Card	O
##iac	O
Events	O
(	O
MAC	O
##E	O
)	O
at	O
3	O
Years	O
with	O
Inc	O
##rea	O
##sing	O
Q	O
##ua	O
##rt	O
##iles	O
of	O
C	B
##it	I
##ru	I
##llin	I
##e	I
and	O
Or	B
##ni	I
##thin	I
##e	I
Level	O
##s	O

Likewise	O
,	O
major	O
meta	O
##bol	O
##ites	O
in	O
16	O
##H	O
##BE	O
##14	O
##o	O
_	O
−	O
cells	O
included	O
g	B
##lut	I
##ama	I
##te	I
,	O
glucose	S
,	O
g	B
##lut	I
##amine	I
and	O
ATP	S
.	O

In	O
Asian	O
women	O
,	O
so	O
##y	O
consumption	O
is	O
associated	O
with	O
reduced	O
breast	O
cancer	O
risk	O
,	O
perhaps	O
due	O
to	O
effects	O
on	O
est	B
##rogen	I
production	O
or	O
metabolism	O
.	O

L	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
such	O
as	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
(	I
18	I
:	I
0	I
)	I
,	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
(	I
18	I
:	I
1	I
)	I
,	O
and	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
(	I
18	I
:	I
2	I
)	I
were	O
all	O
negatively	O
correlated	O
with	O
H	O
##OM	O
##A	O
-	O
I	O
##R	O
.	O

We	O
therefore	O
conclude	O
that	O
a	O
significant	O
reduction	O
in	O
the	O
_	O
13	O
C	O
-	O
en	O
##rich	O
##ment	O
found	O
for	O
la	B
##ct	I
##ate	I
and	O
al	B
##ani	I
##ne	I
does	O
not	O
necessarily	O
result	O
in	O
a	O
reduced	O
appearance	O
rate	O
.	O

He	O
##mo	O
##g	O
##lo	O
##bin	O
A1	O
##c	O
(	O
H	O
##b	O
##A	O
##1	O
##c	O
)	O
reflects	O
average	O
blood	O
glucose	S
levels	O
over	O
the	O
previous	O
three	O
months	O
.	O

Dash	O
##ed	O
boxes	O
indicate	O
pools	O
of	O
meta	O
##bol	O
##ites	O
:	O
t	O
##C	O
##r	O
,	O
total	O
c	B
##rea	I
##tine	I
##s	I
(	I
c	I
##rea	I
##tine	I
+	I
p	I
##hos	I
##ph	I
##oc	I
##rea	I
##tine	I
)	I
;	O
t	O
##C	O
##ho	O
,	O
total	O
ch	B
##olin	I
##es	I
(	I
ch	I
##olin	I
##e	I
+	I
p	I
##hos	I
##ph	I
##och	I
##olin	I
##e	I
+	I
g	I
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##och	I
##olin	I
##e	I
)	I
.	O

Go	O
to	O
:	O
Background	O
:	O
Changes	O
in	O
try	B
##pt	I
##op	I
##han	I
metabolism	O
through	O
the	O
vitamin	O
B	O
-	O
6	O
–	O
dependent	O
k	B
##yn	I
##uren	I
##ine	I
pathway	O
have	O
been	O
linked	O
to	O
activation	O
of	O
the	O
immune	O
system	O
.	O

AR	O
##G	O
,	O
a	O
##rg	O
##inas	O
##e	O
;	O
DD	O
##A	O
##H	O
,	O
dim	O
##eth	O
##yla	O
##rg	O
##ini	O
##ne	O
dim	O
##eth	O
##yla	O
##min	O
##oh	O
##ydro	O
##lase	O
,	O
NO	O
##S	O
,	O
ni	B
##tric	I
oxide	I
s	O
##ynth	O
##ase	O
;	O
O	O
##DC	O
,	O
or	O
##ni	O
##thin	O
##e	O
de	O
##car	O
##box	O
##yla	O
##se	O
;	O
PR	O
##MT	O
,	O
a	O
##rg	O
##ini	O
##ne	O
N	O
-	O
met	O
##hyl	O
##tra	O
##ns	O
##fer	O
##ase	O
;	O
CD	O
_	O
i	O
,	O
in	O
##f	O
##lam	O
##ed	O
tissue	O
obtained	O
from	O
patients	O
with	O
C	O
##ro	O
##hn	O
’	O
s	O
disease	O
;	O
CD	O
_	O
q	O
,	O
q	O
##ui	O
##es	O
##cent	O
tissue	O
obtained	O
from	O
patients	O
with	O
C	O
##ro	O
##hn	O
’	O
s	O
disease	O
;	O
UC	O
_	O
n	O
,	O
normal	O
small	O
bow	O
##el	O
tissue	O
obtained	O
from	O
patients	O
with	O
ul	O
##cer	O
##ative	O
co	O
##lit	O
##is	O
;	O
_	O
a	O
significantly	O
different	O
from	O
CD	O
_	O
q	O
;	O
_	O
b	O
significantly	O
different	O
from	O
UC	O
_	O
n	O
;	O
_	O
c	O
significantly	O
different	O
from	O
CD	O
_	O
i	O
.	O

Similarly	O
,	O
we	O
found	O
a	O
significant	O
decrease	O
of	O
s	B
##phi	I
##ngo	I
##sin	I
##e	I
in	O
the	O
plasma	O
of	O
PA	O
##H	O
patients	O
.	O

Indeed	O
in	O
the	O
media	O
of	O
the	O
BP	O
##A	O
treated	O
H	O
-	O
He	O
##p	O
##G	O
##2	O
cells	O
was	O
evident	O
the	O
17	B
-	I
h	I
##ydro	I
##xy	I
##p	I
##rog	I
##ester	I
##one	I
,	O
meta	O
##bol	O
##ite	O
derived	O
from	O
pre	B
##gne	I
##no	I
##lone	I
by	O
C	O
##YP	O
##17	O
and	O
3	O
##β	O
-	O
h	O
##ydro	O
##xy	O
##ster	O
##oid	O
de	O
##hy	O
##dr	O
##ogen	O
##ase	O
enzyme	O
(	O
H	O
##SD	O
)	O
activity	O
and	O
lead	O
to	O
the	O
final	O
synthesis	O
of	O
est	B
##rone	I
or	O
est	B
##rad	I
##iol	I
by	O
C	O
##YP	O
##19	O
activity	O
(	O
a	O
##roma	O
##tase	O
)	O
.	O

At	O
time	O
zero	O
,	O
a	O
prime	O
-	O
continuous	O
in	O
##fusion	O
of	O
human	O
regular	O
insulin	O
(	B
Nov	B
##olin	I
;	O
Nov	O
##o	O
Nord	O
##isk	O
Ph	O
##arma	O
##ce	O
##utical	O
##s	O
,	O
Princeton	O
,	O
NJ	O
)	O
was	O
started	O
and	O
continued	O
for	O
180	O
min	O
.	O

The	O
absolute	O
concentrations	O
(	O
ng	O
/	O
m	O
##l	O
)	O
of	O
each	O
PC	O
and	O
P	O
##E	O
were	O
calculated	O
based	O
on	O
the	O
peak	O
areas	O
of	O
the	O
PC	O
and	O
P	O
##E	O
identified	O
in	O
the	O
sample	O
and	O
the	O
peak	O
areas	O
of	O
the	O
internal	O
standards	O
of	O
PC	B
(	I
15	I
:	I
0	I
/	I
18	I
:	I
1	I
)	I
and	O
P	B
##E	I
(	I
15	I
:	I
0	I
/	I
18	I
:	I
1	I
)	I
corresponding	O
to	O
the	O
sample	O
.	O

ME	O
##DF	O
##ST	O
##A	O
,	O
s	B
##tat	I
##in	I
use	O
coded	O
0	O
–	O
9	O
(	O
0	O
:	O
no	O
s	B
##tat	I
##in	I
;	O
1	O
:	O
r	B
##os	I
##u	I
##vas	I
##tat	I
##in	I
;	O
2	O
:	O
si	B
##m	I
##vas	I
##tat	I
##in	I
;	O
3	O
:	O
lo	B
##vas	I
##tat	I
##in	I
;	O
4	O
:	O
at	B
##or	I
##vas	I
##tat	I
##in	I
;	O
5	O
:	O
p	B
##ra	I
##vas	I
##tat	I
##in	I
;	O
6	O
:	O
flu	B
##vas	I
##tat	I
##in	I
;	O
7	O
:	O
c	B
##eri	I
##vas	I
##tat	I
##in	I
;	O
8	O
:	O
un	O
##sp	O
##ec	O
##ified	O
;	O
and	O
9	O
:	O
unknown	O
)	O
.	O

These	O
findings	O
suggest	O
that	O
defects	O
on	O
c	B
##era	I
##mi	I
##de	I
generation	O
and	O
s	B
##phi	I
##ngo	I
##lip	I
##id	I
metabolism	O
exist	O
in	O
order	O
to	O
promote	O
cancer	O
cell	O
survival	O
and	O
cancer	O
therapy	O
resistance	O
.	O

AA	O
is	O
the	O
precursor	O
of	O
many	O
biological	O
media	O
##tors	O
,	O
including	O
pro	B
##sta	I
##g	I
##land	I
##ins	I
,	O
pro	B
##sta	I
##cy	I
##c	I
##lin	I
,	O
th	B
##rom	I
##box	I
##ane	I
##s	I
,	O
le	O
##uk	O
##ot	O
##rien	O
##es	O
and	O
he	O
##pox	O
##ili	O
##ns	O
.	O

FF	O
##P	O
##E	O
samples	O
showed	O
a	O
decrease	O
of	O
meta	O
##bol	O
##ites	O
with	O
characteristic	O
functional	O
groups	O
,	O
such	O
as	O
secondary	O
car	B
##box	I
##yl	I
##ic	I
acid	I
amid	I
##e	I
(	O
28	O
%	O
,	O
P	O
=	O
7	O
.	O
43	O
×	O
10	O
_	O
−	O
##12	O
;	O
F	O
##DR	O
=	O
6	O
.	O
42	O
×	O
10	O
_	O
−	O
##10	O
)	O
,	O
present	O
in	O
p	O
##eptide	O
##s	O
and	O
q	O
##uate	O
##rna	O
##ry	O
am	B
##mon	I
##ium	I
salts	O
(	O
33	O
%	O
,	O
P	O
=	O
1	O
.	O
01	O
×	O
10	O
_	O
−	O
##3	O
;	O
F	O
##DR	O
=	O
2	O
.	O
30	O
×	O
10	O
_	O
−	O
##2	O
)	O
present	O
in	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##och	I
##olin	I
##es	I
and	O
absent	O
in	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oe	I
##than	I
##ola	I
##mine	I
##s	I
.	O

The	O
reason	O
for	O
including	O
these	O
two	O
meta	O
##bol	O
##ites	O
is	O
the	O
presence	O
of	O
other	O
related	O
meta	O
##bol	O
##ites	O
or	O
fragments	O
(	O
e	O
.	O
g	O
.	O
,	O
G	B
##CD	I
##CA	I
,	O
G	O
##DC	O
##A	O
,	O
T	O
##CA	O
,	O
and	O
fragment	O
of	O
G	O
##CA	O
)	O
that	O
were	O
statistical	O
##ly	O
significant	O
in	O
at	O
least	O
two	O
out	O
of	O
the	O
three	O
experiments	O
.	O

For	O
this	O
reason	O
,	O
a	O
deep	O
un	O
##su	O
##per	O
##vise	O
##d	O
neural	O
network	O
based	O
technique	O
,	O
para	O
##metric	O
t	O
-	O
S	O
##NE	O
,	O
is	O
adopted	O
to	O
map	O
a	O
3D	B
-	I
DE	I
##SI	I
-	I
MS	I
data	O
##set	O
from	O
a	O
human	O
color	O
##ec	O
##tal	O
ad	O
##eno	O
##car	O
##cin	O
##oma	O
bio	O
##psy	O
onto	O
a	O
2	O
-	O
dimensional	O
manifold	O
.	O

In	O
present	O
study	O
,	O
the	O
family	O
of	O
fatty	O
acid	O
materials	O
,	O
short	O
-	O
chain	O
fatty	O
acids	O
,	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
,	O
and	O
p	O
##oly	O
##uns	O
##at	O
##ura	O
##ted	O
fatty	O
acids	O
were	O
up	O
##re	O
##gu	O
##lated	O
,	O
indicating	O
the	O
activation	O
of	O
fatty	O
acids	O
metabolism	O
.	O

Car	B
##ni	I
##tine	I
is	O
required	O
for	O
energy	O
metabolism	O
,	O
enabling	O
fatty	O
acids	O
to	O
enter	O
the	O
mit	O
##och	O
##ond	O
##ria	O
for	O
β	B
-	I
oxidation	I
[	I
]	I
.	O

Less	O
strongly	O
retained	O
c	B
##rea	I
##tin	I
##ine	I
(	O
mean	O
t	O
_	O
R	O
=	O
6	O
.	O
8	O
min	O
,	O
k	O
=	O
3	O
.	O
9	O
)	O
gave	O
an	O
RS	O
##D	O
of	O
0	O
.	O
2	O
%	O
.	O

The	O
analytical	O
standards	O
for	O
I	O
##M	O
,	O
its	O
meta	O
##bol	O
##ite	O
C	O
##GP	O
##7	O
##45	O
##8	O
##8	O
and	O
internal	O
standards	O
for	O
im	B
##ati	I
##ni	I
##b	I
-	I
D	I
##8	I
were	O
provided	O
by	O
Nova	O
##rt	O
##is	O
(	O
Brazil	O
SA	O
)	O
.	O

The	O
difficulty	O
of	O
finding	O
a	O
suitable	O
der	O
##iva	O
##ti	O
##zation	O
re	O
##age	O
##nt	O
with	O
enough	O
analytical	O
response	O
for	O
our	O
compounds	O
of	O
interest	O
when	O
using	O
G	O
##C	O
–	O
MS	O
with	O
an	O
electron	O
ion	O
##ization	O
ion	O
source	O
could	O
be	O
explained	O
by	O
the	O
small	O
molecular	O
sizes	O
of	O
o	B
##xa	I
##late	I
,	O
g	B
##ly	I
##cola	I
##te	I
,	O
and	O
g	B
##ly	I
##ox	I
##yla	I
##te	I
.	O

Dr	O
##ied	O
extract	O
##s	O
were	O
re	O
-	O
dissolved	O
in	O
250	O
µ	O
##L	O
of	O
met	B
##han	I
##ol	I
for	O
ultra	O
-	O
performance	O
liquid	O
ch	O
##roma	O
##tography	O
–	O
q	O
##uad	O
##rup	O
##ole	O
/	O
time	O
-	O
of	O
-	O
flight	O
mass	O
s	O
##pect	O
##rome	O
##try	O
(	O
UP	O
##LC	O
–	O
Q	O
–	O
TO	O
##F	O
–	O
MS	O
)	O
analysis	O
,	O
and	O
100	O
µ	O
##L	O
of	O
the	O
samples	O
were	O
dried	O
under	O
a	O
vacuum	O
for	O
gas	O
ch	O
##roma	O
##tography	O
(	O
G	O
##C	O
)	O
–	O
TO	O
##F	O
–	O
MS	O
analysis	O
.	O

Further	O
,	O
four	O
meta	O
##bol	O
##ites	O
,	O
th	B
##re	I
##oni	I
##ne	I
,	O
g	B
##lut	I
##amine	I
,	O
is	B
##ole	I
##uc	I
##ine	I
and	O
l	B
##ino	I
##len	I
##ic	I
acid	I
each	O
showed	O
a	O
minimum	O
AU	O
##RO	O
##C	O
of	O
0	O
.	O
80	O
in	O
class	O
##ifying	O
p	O
##CR	O
and	O
SD	O
patients	O
,	O
while	O
only	O
l	B
##ino	I
##len	I
##ic	I
acid	I
distinguished	O
p	O
##CR	O
from	O
both	O
SD	O
and	O
PR	O
patients	O
with	O
an	O
AU	O
##RO	O
##C	O
of	O
greater	O
than	O
0	O
.	O
80	O
.	O

A	O
decreased	O
plasma	O
level	O
of	O
in	B
##os	I
##ine	I
was	O
correlated	O
with	O
an	O
increased	O
risk	O
of	O
D	O
##N	O
-	O
MD	O
##D	O
in	O
children	O
and	O
adolescent	O
##s	O
(	O
odds	O
ratio	O
0	O
.	O
01	O
,	O
95	O
%	O
confidence	O
interval	O
0	O
.	O
00	O
–	O
0	O
.	O
35	O
)	O
.	O

For	O
the	O
M	B
##T	I
##BE	I
method	O
of	O
extraction	O
,	O
we	O
used	O
he	B
##xa	I
##f	I
##lu	I
##oro	I
##is	I
##op	I
##rop	I
##ano	I
##l	I
from	O
Du	O
##P	O
##ont	O
and	O
met	B
##hyl	I
-	I
te	I
##rt	I
-	I
but	I
##yl	I
et	I
##her	I
(	O
B	O
##D	O
##H	O
brand	O
)	O
from	O
V	O
##WR	O
.	O

However	O
,	O
excessive	O
accumulation	O
of	O
extra	O
-	O
or	O
in	O
##tra	O
##cellular	O
ta	B
##uri	I
##ne	I
could	O
cause	O
di	O
##zzi	O
##ness	O
in	O
E	O
##SR	O
##D	O
patients	O
.	O

The	O
pattern	O
of	O
daily	O
responses	O
seen	O
in	O
AA	O
##s	O
contrasted	O
with	O
that	O
for	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
.	O

The	O
ass	O
##ay	O
upper	O
linear	O
##ity	O
limits	O
are	O
:	O
250	O
##ng	O
/	O
m	O
##L	O
for	O
N	B
##D	I
-	I
Tam	I
##ox	I
##ife	I
##n	I
,	O
125	O
##ng	O
/	O
m	O
##L	O
for	O
ta	B
##mo	I
##xi	I
##fen	I
,	O
end	B
##ox	I
##ife	I
##n	I
,	O
and	O
4	B
-	I
h	I
##ydro	I
##xy	I
##tam	I
##ox	I
##ife	I
##n	I
.	O

Do	O
##se	O
-	O
dependent	O
increases	O
in	O
systemic	O
levels	O
of	O
both	O
AD	B
##MA	I
and	O
SD	O
##MA	O
within	O
subjects	O
were	O
strongly	O
associated	O
with	O
increased	O
risk	O
for	O
experiencing	O
a	O
MAC	O
##E	O
over	O
the	O
3	O
year	O
monitoring	O
period	O
following	O
enrollment	O
.	O

Six	O
meta	O
##bol	O
##ites	O
were	O
directly	O
assigned	O
to	O
AD	O
classification	O
in	O
HM	O
##D	O
##B	O
based	O
on	O
literature	O
record	O
,	O
including	O
g	B
##lut	I
##ama	I
##te	I
,	O
try	B
##pt	I
##op	I
##han	I
,	O
glucose	S
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##och	I
##olin	I
##e	I
,	O
and	O
ho	O
##mo	O
##ci	O
##tric	O
acids	O
.	O

Na	B
##ph	I
##thal	I
##ene	I
-	I
1	I
,	I
2	I
-	I
oxide	I
(	O
N	O
##PO	O
)	O
,	O
1	B
,	I
2	I
-	I
nap	I
##ht	I
##ho	I
##quin	I
##one	I
(	I
1	I
,	I
2	I
-	I
N	I
##P	I
##Q	I
)	I
,	O
and	O
1	B
,	I
4	I
-	I
nap	I
##ht	I
##ho	I
##quin	I
##one	I
(	I
1	I
,	I
4	I
-	I
N	I
##P	I
##Q	I
)	I
are	O
the	O
major	O
reactive	O
meta	O
##bol	O
##ites	O
of	O
nap	B
##ht	I
##hale	I
##ne	I
(	O
Supporting	O
Information	O
,	O
Figure	O
S	O
##1	O
and	O
Table	O
1	O
)	O
.	O

Inc	O
##reased	O
secret	O
##ion	O
of	O
11	B
-	I
de	I
##ox	I
##y	I
##cor	I
##tis	I
##ol	I
by	O
ad	O
##rena	O
##l	O
tumors	O
has	O
been	O
previously	O
described	O
but	O
has	O
not	O
been	O
used	O
for	O
different	O
##iating	O
ben	O
##ign	O
from	O
ma	O
##li	O
##gnant	O
ad	O
##rena	O
##l	O
tumors	O
.	O

We	O
also	O
used	O
matching	O
IS	O
for	O
each	O
anal	O
##yte	O
class	O
,	O
except	O
GP	O
##C	O
##ho	O
,	O
for	O
absolute	O
q	O
##uant	O
##ification	O
for	O
a	O
member	O
of	O
each	O
ch	B
##olin	I
##e	I
meta	O
##bol	O
##ite	O
class	O
as	O
well	O
as	O
for	O
enhanced	O
q	O
##uant	O
##ification	O
of	O
all	O
other	O
compounds	O
.	O

We	O
excluded	O
patients	O
with	O
advanced	O
kidney	O
disease	O
,	O
and	O
average	O
c	B
##rea	I
##tin	I
##ine	I
levels	O
were	O
normal	O
in	O
both	O
our	O
der	O
##ivation	O
and	O
valid	O
##ation	O
co	O
##hor	O
##ts	O
(	O
1	O
.	O
1	O
mg	O
/	O
d	O
##l	O
in	O
each	O
)	O
.	O

We	O
thus	O
compared	O
meta	O
##bol	O
##ites	O
extracted	O
from	O
the	O
samples	O
before	O
and	O
after	O
the	O
para	B
##ffin	I
em	O
##bed	O
##ding	O
and	O
we	O
observed	O
a	O
global	O
de	O
##ple	O
##tion	O
of	O
meta	O
##bol	O
##ites	O
in	O
all	O
classes	O
.	O

A	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
facilitate	O
the	O
entry	O
of	O
long	O
-	O
chain	O
FA	O
##s	O
into	O
the	O
mit	O
##och	O
##ond	O
##ria	O
via	O
the	O
car	B
##ni	I
##tine	I
shuttle	O
.	O

_	O
,	O
The	O
IT	O
##Cs	O
formed	O
add	O
##uc	O
##ts	O
with	O
l	B
##ys	I
##ine	I
of	O
Al	O
##b	O
:	O
B	O
##IT	O
##C	O
-	O
L	O
##ys	O
,	O
P	O
##EI	O
##TC	O
-	O
L	O
##ys	O
,	O
SF	O
##N	O
-	O
L	O
##ys	O
,	O
and	O
AI	O
##TC	O
-	O
L	O
##ys	O
.	O

Whole	O
genome	O
sequence	O
data	O
were	O
examined	O
for	O
S	O
##N	O
##Vs	O
and	O
copy	O
number	O
variants	O
(	O
C	O
##N	O
##Vs	O
)	O
relating	O
to	O
four	O
genes	O
of	O
the	O
p	B
##yr	I
##im	I
##id	I
##ine	I
metabolism	O
pathway	O
:	O
CA	O
##D	O
(	O
t	O
##ri	O
-	O
functional	O
enzyme	O
,	O
car	B
##ba	I
##mo	I
##yl	I
-	I
phosphate	I
s	O
##ynth	O
##eta	O
##se	O
2	O
(	O
CP	O
##S	O
##2	O
)	O
,	O
as	O
##par	O
##tate	O
trans	O
##car	O
##ba	O
##my	O
##lase	O
(	O
AT	O
##C	O
##ase	O
)	O
,	O
and	O
di	O
##hy	O
##dr	O
##oor	O
##ota	O
##se	O
(	O
D	O
##H	O
##O	O
##ase	O
)	O
)	O
;	O
D	O
##H	O
##OD	O
##H	O
(	O
di	O
##hy	O
##dr	O
##oor	O
##ota	O
##te	O
de	O
##hy	O
##dr	O
##ogen	O
##ase	O
)	O
;	O
U	O
##MP	O
##S	O
(	O
bi	O
-	O
functional	O
enzyme	O
,	O
or	O
##ota	O
##te	O
p	O
##hos	O
##ph	O
##ori	O
##bos	O
##yl	O
##tra	O
##ns	O
##fer	O
##ase	O
and	O
O	O
##MP	O
de	O
##car	O
##box	O
##yla	O
##se	O
)	O
;	O
and	O
T	O
##Y	O
##MS	O
(	O
thy	O
##mi	O
##dy	O
##late	O
s	O
##ynth	O
##ase	O
)	O
.	O

Moreover	O
,	O
we	O
demonstrated	O
that	O
er	B
##yt	I
##hr	I
##ito	I
##l	I
is	O
con	O
##st	O
##it	O
##utive	O
##ly	O
synthesized	O
in	O
humans	O
from	O
glucose	S
,	O
most	O
probably	O
via	O
E	O
##4	O
##P	O
,	O
which	O
is	O
an	O
intermediate	O
of	O
the	O
PP	O
##P	O
.	O

The	O
certain	O
signals	O
from	O
5	O
.	O
0	O
to	O
9	O
.	O
5	O
pp	O
##m	O
were	O
few	O
,	O
including	O
glucose	S
,	O
u	B
##rac	I
##il	I
,	O
ad	B
##eni	I
##ne	I
and	O
format	B
##e	I
.	O

The	O
monitored	O
amounts	O
after	O
one	O
hour	O
of	O
culture	O
rank	O
the	O
N	O
##TP	O
##s	O
as	O
follows	O
:	O
ATP	S
(	O
5	O
.	O
96	O
nm	O
##ol	O
/	O
10	O
_	O
6	O
S	O
##9	O
cells	O
;	O
7	O
.	O
77	O
nm	O
##ol	O
/	O
10	O
_	O
6	O
16	O
##H	O
##BE	O
##14	O
##o	O
_	O
−	O
cells	O
)	O
,	O
U	O
##TP	O
(	O
1	O
.	O
66	O
;	O
2	O
.	O
27	O
)	O
,	O
GT	O
##P	O
(	O
1	O
.	O
33	O
;	O
1	O
.	O
14	O
)	O
and	O
CT	B
##P	I
(	O
0	O
.	O
65	O
;	O
0	O
.	O
92	O
)	O
.	O

The	O
levels	O
of	O
P	B
##E	I
(	I
16	I
:	I
0	I
/	I
18	I
:	I
3	I
)	I
,	O
P	B
##E	I
(	I
18	I
:	I
0	I
/	I
16	I
:	I
0	I
)	I
,	O
P	B
##E	I
(	I
17	I
:	I
0	I
/	I
18	I
:	I
2	I
)	I
,	O
P	B
##E	I
(	I
17	I
:	I
0	I
/	I
18	I
:	I
1	I
)	I
,	O
P	B
##E	I
(	I
18	I
:	I
2	I
/	I
18	I
:	I
2	I
)	I
,	O
P	B
##E	I
(	I
18	I
:	I
1	I
/	I
18	I
:	I
2	I
)	I
,	O
P	B
##E	I
(	I
18	I
:	I
0	I
/	I
18	I
:	I
1	I
)	I
,	O
P	B
##E	I
(	I
18	I
:	I
1	I
/	I
20	I
:	I
4	I
)	I
,	O
PC	B
(	I
16	I
:	I
1	I
/	I
20	I
:	I
5	I
)	I
,	O
and	O
PC	B
(	I
18	I
:	I
0	I
/	I
20	I
:	I
1	I
)	I
in	O
L	O
##B	O
##D	O
were	O
significantly	O
increased	O
compared	O
with	O
HC	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Con	O
##ju	O
##gated	O
bi	O
##le	O
acids	O
and	O
their	O
su	O
##lf	O
##ation	O
product	O
enable	O
the	O
absorption	O
of	O
lip	O
##ids	O
,	O
ch	B
##ole	I
##ster	I
##ol	I
and	O
fat	O
-	O
soluble	O
vitamin	O
and	O
are	O
reported	O
to	O
play	O
a	O
key	O
role	O
in	O
the	O
de	O
##to	O
##xi	O
##fication	O
of	O
end	O
##ogen	O
##ous	O
and	O
ex	O
##ogen	O
##ous	O
lip	O
##op	O
##hil	O
##ic	O
compounds	O
.	O

Panel	O
C	O
shows	O
log	O
##istic	O
re	O
##gression	O
modelling	O
on	O
single	O
variables	O
of	O
work	O
set	O
samples	O
for	O
my	B
##rist	I
##ic	I
acid	I
(	O
solid	O
line	O
)	O
,	O
white	O
blood	O
cell	O
count	O
(	O
dotted	O
line	O
)	O
and	O
C	O
-	O
reactive	O
protein	O
(	O
dashed	O
line	O
)	O
.	O

The	O
ions	O
##pra	O
##y	O
voltage	O
and	O
source	O
temperature	O
were	O
−	O
##3	O
.	O
0	O
k	B
##V	I
and	O
500	O
°C	O
,	O
respectively	O
.	O

Si	B
##m	I
##vas	I
##tat	I
##in	I
concentrations	O
were	O
analyzed	O
in	O
the	O
samples	O
collected	O
at	O
6	O
weeks	O
.	O

Therefore	O
,	O
the	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
p	O
##oly	O
##amine	O
-	O
related	O
meta	O
##bol	O
##ome	O
in	O
a	O
co	O
##hor	O
##t	O
of	O
metabolic	O
syndrome	O
individuals	O
with	O
and	O
without	O
T	O
##2	O
##D	O
.	O
Design	O
and	O
methods	O
:	O
This	O
was	O
a	O
nest	O
##ed	O
case	O
–	O
control	O
study	O
within	O
the	O
PR	O
##ED	O
##IM	O
##ED	O
-	O
Plus	O
trial	O
that	O
included	O
44	O
patients	O
with	O
T	O
##2	O
##D	O
and	O
70	O
patients	O
without	O
T	O
##2	O
##D	O
.	O
We	O
measured	O
serum	O
levels	O
of	O
a	B
##rg	I
##ini	I
##ne	I
,	O
or	B
##ni	I
##thin	I
##e	I
,	O
p	B
##oly	I
##amine	I
##s	I
,	O
and	O
ace	B
##ty	I
##l	I
p	I
##oly	I
##amine	I
##s	I
with	O
an	O
ultra	O
-	O
high	O
performance	O
liquid	O
ch	O
##roma	O
##tography	O
tandem	O
mass	O
s	O
##pect	O
##rome	O
##try	O
platform	O
.	O

As	O
we	O
observed	O
reduced	O
g	B
##ly	I
##co	I
##ly	I
##tic	I
flux	O
in	O
M	O
##UC	O
##16	O
knock	O
##down	O
cells	O
,	O
we	O
also	O
investigated	O
the	O
effect	O
of	O
di	B
##ch	I
##lor	I
##oa	I
##ce	I
##tate	I
(	O
DC	O
##A	O
)	O
,	O
which	O
increases	O
flux	O
of	O
the	O
g	O
##ly	O
##co	O
##lysis	O
end	O
product	O
p	B
##yr	I
##u	I
##vate	I
to	O
the	O
T	O
##CA	O
cycle	O
,	O
on	O
cell	O
survival	O
.	O

Analysis	O
of	O
the	O
individual	O
meta	O
##bol	O
##ites	O
revealed	O
that	O
c	B
##it	I
##ru	I
##llin	I
##e	I
and	O
C	O
##i	O
##4	O
-	O
DC	O
:	O
C	O
##4	O
##DC	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
were	O
significantly	O
associated	O
with	O
CA	O
##D	O
severity	O
in	O
un	O
##ad	O
##ju	O
##sted	O
analysis	O
,	O
but	O
not	O
after	O
adjusting	O
for	O
clinical	O
co	O
##var	O
##iate	O
##s	O
.	O

The	O
structure	O
of	O
the	O
acid	O
-	O
lab	O
##ile	O
su	B
##lf	I
##ina	I
##mi	I
##de	I
Al	O
##b	O
add	O
##uc	O
##t	O
of	O
I	O
##Q	O
,	O
a	O
car	O
##cin	O
##ogenic	O
H	O
##AA	O
,	O
formed	O
in	O
rat	O
was	O
characterized	O
by	O
_	O
1	O
H	O
N	O
##MR	O
and	O
MS	O
.	O

The	O
marked	O
reduction	O
of	O
se	B
##rine	I
and	O
g	B
##ly	I
##cine	I
levels	O
in	O
the	O
PC	O
knock	O
##down	O
cells	O
may	O
under	O
##lie	O
the	O
re	O
##tar	O
##ded	O
growth	O
p	O
##hen	O
##otype	O
of	O
the	O
knock	O
##down	O
cells	O
because	O
se	B
##rine	I
contributes	O
to	O
various	O
bio	O
##sy	O
##nt	O
##hetic	O
pathways	O
including	O
protein	O
synthesis	O
,	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
and	O
n	O
##uc	O
##leo	O
##tide	O
##s	O
which	O
are	O
in	O
high	O
demand	O
during	O
tumor	O
##ige	O
##nes	O
##is	O
.	O

volatile	O
organic	O
compounds	O
,	O
me	O
##rca	O
##pt	O
##uri	O
##c	O
acids	O
,	O
co	O
##ke	O
oven	O
workers	O
,	O
steel	O
industry	O
workers	O
,	O
S	B
-	I
p	I
##hen	I
##yl	I
me	I
##rca	I
##pt	I
##uri	I
##c	I
acid	I
,	O
human	O
bio	O
##mon	O
##itor	O
##ing	O

For	O
his	O
##to	O
##logical	O
analysis	O
,	O
tissue	O
specimens	O
were	O
re	O
##sect	O
##ed	O
surgical	O
##ly	O
and	O
fixed	O
in	O
10	O
%	O
neutral	O
formal	B
##in	I
,	O
embedded	O
in	O
para	B
##ffin	I
,	O
cut	O
into	O
5	O
m	O
sections	O
,	O
and	O
stained	O
with	O
hem	B
##ato	I
##xy	I
##lin	I
and	O
e	B
##os	I
##in	I
.	O

The	O
kit	O
provides	O
q	O
##uant	O
##ification	O
of	O
up	O
to	O
188	O
meta	O
##bol	O
##ites	O
including	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
,	O
amino	O
acids	O
,	O
he	O
##x	O
##ose	O
##s	O
,	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
,	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
and	O
bio	O
##genic	O
am	O
##ines	O
.	O

This	O
solution	O
was	O
di	O
##lut	O
##ed	O
to	O
70	O
%	O
ethanol	S
by	O
the	O
addition	O
of	O
0	O
.	O
4	O
m	O
##l	O
of	O
water	O
,	O
ultra	O
##sonic	O
##ated	O
for	O
2	O
min	O
,	O
and	O
cent	O
##ri	O
##fu	O
##ged	O
at	O
14	O
,	O
000	O
×	O
g	O
at	O
4	O
°C	O
for	O
30	O
min	O
.	O

Cell	O
##s	O
were	O
washed	O
with	O
PBS	O
and	O
then	O
in	O
##cu	O
##bate	O
##d	O
with	O
1	O
μ	O
##M	O
E	O
_	O
2	O
for	O
24	O
h	O
.	O
Cell	O
media	O
were	O
collected	O
and	O
spike	O
##d	O
with	O
0	O
.	O
4	O
n	O
##M	O
internal	O
standard	O
(	O
4	O
-	O
Me	O
##OE	O
_	O
1	O
-	O
d	O
_	O
4	O
)	O
and	O
2	O
m	O
##M	O
as	B
##cor	I
##bic	I
acid	I
.	O

G	O
##eo	O
##metric	O
mean	O
levels	O
[	O
I	O
##Q	O
##R	O
]	O
of	O
ben	B
##zen	I
##e	I
,	O
a	B
##c	I
##rol	I
##ein	I
and	O
c	B
##rot	I
##onal	I
##de	I
##hy	I
##de	I
me	O
##rca	O
##pt	O
##uri	O
##c	O
acids	O
at	O
day	O
0	O
by	O
treatment	O
assignment	O

Yet	O
,	O
our	O
analysis	O
of	O
%	O
ME	O
##HP	O
suggested	O
an	O
enhanced	O
response	O
to	O
c	O
##er	O
##vic	O
##al	O
cancer	O
treatment	O
,	O
indicating	O
that	O
less	O
efficient	O
conversion	O
of	O
the	O
primary	O
h	B
##ydro	I
##ly	I
##tic	I
DE	O
##HP	O
p	B
##ht	I
##hala	I
##te	I
mon	O
##oes	O
##ter	O
ME	O
##HP	O
,	O
to	O
its	O
secondary	O
-	O
o	O
##xi	O
##da	O
##tive	O
meta	O
##bol	O
##ites	O
ME	O
##OH	O
##P	O
and	O
ME	O
##H	O
##HP	O
,	O
may	O
con	O
##fer	O
benefit	O
.	O

We	O
found	O
significantly	O
lower	O
levels	O
of	O
rib	B
##of	I
##lav	I
##in	I
(	O
vitamin	O
B	O
##2	O
)	O
in	O
the	O
AD	O
##HD	O
group	O
,	O
in	O
addition	O
to	O
lower	O
H	O
##AA	O
and	O
X	O
##A	O
.	O

In	O
our	O
study	O
,	O
the	O
plasma	O
su	B
##c	I
##rose	I
level	O
was	O
significantly	O
reduced	O
,	O
suggesting	O
that	O
a	O
##cup	O
##un	O
##cture	O
may	O
in	O
##hibit	O
the	O
duo	O
##den	O
##al	O
absorption	O
of	O
su	B
##c	I
##rose	I
,	O
or	O
accelerate	O
its	O
an	O
##ab	O
##olis	O
##m	O
to	O
improve	O
metabolic	O
abnormal	O
##ity	O
.	O

Several	O
ch	O
##roma	O
##to	O
##graphic	O
,	O
chemical	O
,	O
and	O
mass	O
s	O
##pect	O
##rome	O
##try	O
(	O
MS	O
)	O
-	O
based	O
techniques	O
for	O
q	O
##uant	O
##ification	O
of	O
beta	B
##ine	I
have	O
been	O
reported	O
[	O
,	O
,	O
,	O
,	O
]	O
.	O

They	O
have	O
also	O
been	O
reported	O
as	O
disc	O
##rim	O
##ina	O
##nt	O
for	O
many	O
p	O
##hy	O
##sio	O
##path	O
##ological	O
conditions	O
or	O
for	O
exposure	O
##s	O
to	O
chemical	O
to	B
##xin	I
##s	I
in	O
meta	O
##bol	O
##omi	O
##cs	O
studies	O
.	O

U	O
##rina	O
##ry	O
PS	O
##I	O
level	O
,	O
which	O
mainly	O
originates	O
from	O
rib	O
##oso	O
##mal	O
and	O
transfer	O
RNA	O
degradation	O
,	O
may	O
reflect	O
RNA	O
turnover	O
[	O
,	O
]	O
and	O
hence	O
,	O
like	O
1	B
-	I
M	I
##H	I
##is	I
,	O
is	O
a	O
measure	O
of	O
protein	O
turnover	O
.	O

Tri	B
##ter	I
##pen	I
##e	I
1	O
(	O
in	O
95	O
%	O
E	B
##t	I
##OH	I
or	O
in	O
DC	O
##M	O
)	O
,	O
DC	O
##M	O
and	O
a	O
##que	O
##ous	O
leaf	O
extract	O
##s	O
were	O
tested	O
at	O
concentrations	O
of	O
30	O
,	O
150	O
,	O
450	O
,	O
1500	O
,	O
3000	O
,	O
4000	O
,	O
5000	O
,	O
600	O
##0	O
,	O
and	O
10	O
,	O
000	O
μ	O
##g	O
/	O
m	O
##l	O
.	O

Important	O
##ly	O
,	O
we	O
investigated	O
the	O
use	O
of	O
AD	O
treatment	O
drugs	O
(	O
ch	O
##olin	O
##ester	O
##ase	O
inhibitor	O
##s	O
and	O
me	O
##man	O
##tine	O
)	O
,	O
as	O
well	O
as	O
anti	O
##de	O
##press	O
##ants	O
,	O
anti	O
##psy	O
##cho	O
##tics	O
,	O
an	O
##xi	O
##oly	O
##tics	O
,	O
co	O
##rt	O
##ico	O
##ster	O
##oids	O
and	O
s	B
##tat	I
##ins	I
to	O
identify	O
meta	O
##bol	O
##ites	O
that	O
might	O
potentially	O
be	O
associated	O
with	O
drug	O
metabolism	O
and	O
/	O
or	O
response	O
.	O

Similarly	O
,	O
L	B
-	I
o	I
##ct	I
##ano	I
##yl	I
##car	I
##ni	I
##tine	I
,	O
an	O
important	O
meta	O
##bol	O
##ite	O
in	O
car	B
##ni	I
##tine	I
metabolism	O
,	O
has	O
been	O
shown	O
to	O
be	O
a	O
pro	O
##gno	O
##stic	O
marker	O
to	O
differentiate	O
between	O
pro	O
##state	O
cancer	O
and	O
ben	O
##ign	O
pro	O
##static	O
h	O
##yper	O
##p	O
##lasia	O
.	O

R	O
##OC	O
curves	O
analysis	O
of	O
la	B
##ct	I
##ate	I
,	O
ch	B
##ole	I
##ster	I
##ol	I
and	O
la	B
##ct	I
##ate	I
to	O
ch	B
##ole	I
##ster	I
##ol	I
ratio	O
in	O
relation	O
with	O
30	O
-	O
day	O
mortality	O
in	O
the	O
training	O
co	O
##hor	O
##t	O
.	O

While	O
ho	B
##mo	I
##vani	I
##lla	I
##te	I
is	O
the	O
predominant	O
meta	O
##bol	O
##ite	O
and	O
the	O
end	O
product	O
of	O
do	B
##pa	I
##mine	I
cat	O
##ab	O
##olis	O
##m	O
in	O
humans	O
,	O
previous	O
studies	O
of	O
CS	O
##F	O
ho	B
##mo	I
##vani	I
##lla	I
##te	I
concentration	O
have	O
yielded	O
inconsistent	O
results	O
as	O
to	O
the	O
utility	O
of	O
this	O
compound	O
for	O
cross	O
-	O
section	O
##al	O
analysis	O
of	O
PD	O
severity	O
or	O
for	O
distinguishing	O
patients	O
with	O
PD	O
from	O
healthy	O
controls	O
.	O

Another	O
possibility	O
to	O
consider	O
is	O
that	O
although	O
females	O
had	O
higher	O
measured	O
concentrations	O
of	O
u	O
##rina	O
##ry	O
para	B
##ce	I
##tam	I
##ol	I
,	O
perhaps	O
in	O
the	O
context	O
of	O
human	O
health	O
,	O
the	O
source	O
of	O
para	B
##ce	I
##tam	I
##ol	I
exposure	O
may	O
be	O
of	O
more	O
importance	O
than	O
the	O
magnitude	O
of	O
measured	O
concentrations	O
.	O

This	O
pilot	O
adds	O
evidence	O
to	O
the	O
put	O
##ative	O
role	O
of	O
the	O
K	B
##P	I
in	O
MD	O
##D	O
.	O

The	O
can	B
##na	I
##bino	I
##ids	I
were	O
detected	O
by	O
multiple	O
reaction	O
monitoring	O
(	O
MR	O
##M	O
)	O
in	O
positive	O
ion	O
polar	O
##ity	O
using	O
electro	O
##sp	O
##ray	O
ion	O
##ization	O
.	O

The	O
pathway	O
analysis	O
performed	O
in	O
Met	O
##ab	O
##o	O
##A	O
##nal	O
##ys	O
##t	O
linked	O
these	O
meta	O
##bol	O
##ites	O
with	O
alterations	O
in	O
ta	B
##uri	I
##ne	I
and	O
h	B
##y	I
##pot	I
##au	I
##rine	I
,	O
al	B
##ani	I
##ne	I
,	O
as	B
##par	I
##tate	I
,	O
g	B
##lut	I
##ama	I
##te	I
,	O
and	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
metabolic	O
pathways	O
,	O
among	O
others	O
(	O
p	O
-	O
value	O
<	O
0	O
.	O
05	O
)	O
(	O
see	O
and	O
)	O
.	O

The	O
80	O
_	O
L	O
##OW	O
condition	O
(	O
5	O
m	O
##L	O
80	O
%	O
Me	B
##OH	I
for	O
que	O
##nch	O
##ing	O
and	O
1	O
m	O
##L	O
of	O
CH	O
##C	O
##l	O
_	O
3	O
for	O
extraction	O
)	O
was	O
discarded	O
from	O
the	O
optimization	O
tests	O
since	O
no	O
phase	O
separation	O
could	O
be	O
achieved	O
,	O
as	O
seen	O
in	O
Figure	O
S	O
##1	O
.	O

(	O
A	O
)	O
Ethan	B
##ol	I
present	O
in	O
the	O
l	O
##yo	O
##phi	O
##li	O
##zed	O
Mia	O
##P	O
##a	O
##C	O
##a	O
-	O
2	O
samples	O
only	O
.	O

Ch	O
##roma	O
##to	O
##gram	O
##s	O
obtained	O
upon	O
L	O
##C	O
-	O
E	O
##SI	O
-	O
MS	O
/	O
MS	O
-	O
SR	O
##M	O
analysis	O
of	O
products	O
formed	O
in	O
the	O
reaction	O
of	O
race	O
##mic	O
re	O
##v	O
-	O
BP	O
##DE	O
with	O
N	O
##AC	O
(	O
A	O
)	O
;	O
internal	O
standard	O
Ph	B
##e	I
-	I
9	I
-	I
h	I
##ydro	I
##xy	I
-	I
10	I
-	I
N	I
##AC	I
for	O
the	O
he	O
##pa	O
##to	O
##cy	O
##te	O
analysis	O
(	O
B	O
)	O
;	O
and	O
medium	O
from	O
he	O
##pa	O
##to	O
##cy	O
##tes	O
in	O
##cu	O
##bate	O
##d	O
with	O
10	O
μ	O
##M	O
re	O
##v	O
-	O
BP	O
##DE	O
for	O
24	O
h	O
(	O
C	O
)	O
.	O

E	B
##thy	I
##l	I
-	I
para	I
##ox	I
##on	I
(	O
0	O
.	O
01	O
to	O
1	O
μ	O
##M	O
)	O
was	O
used	O
as	O
the	O
positive	O
control	O
of	O
RB	O
##C	O
AC	O
##h	O
##E	O
in	O
##hibition	O
.	O

Sam	O
##ples	O
were	O
fraction	O
##ated	O
with	O
a	O
format	B
##e	I
gradient	O
,	O
ion	O
##ized	O
with	O
electro	O
##sp	O
##ray	O
ion	O
##ization	O
in	O
the	O
positive	O
mode	O
,	O
and	O
detected	O
with	O
an	O
L	O
##T	O
##Q	O
-	O
F	O
##T	O
s	O
##pect	O
##rome	O
##ter	O
(	O
The	O
##rm	O
##o	O
,	O
San	O
Jose	O
,	O
CA	O
)	O
from	O
mass	O
/	O
charge	O
ratio	O
(	O
m	O
/	O
z	O
)	O
85	O
to	O
850	O
over	O
10	O
minutes	O
.	O

The	O
e	O
##qui	O
##valence	O
of	O
the	O
results	O
for	O
25	O
(	O
OH	O
)	O
D	O
_	O
3	O
from	O
all	O
three	O
methods	O
indicates	O
3	B
-	I
e	I
##pi	I
-	I
25	I
(	I
OH	I
)	I
D	I
_	I
3	I
is	O
not	O
a	O
significant	O
meta	O
##bol	O
##ite	O
in	O
SR	O
##M	O
90	O
##9	O
##c	O
(	O
or	O
SR	O
##M	O
97	O
##2	O
Level	O
1	O
)	O
because	O
the	O
C	O
##18	O
results	O
are	O
not	O
bias	O
##ed	O
high	O
.	O

The	O
spectrum	O
shows	O
resonance	O
##s	O
of	O
p	B
-	I
c	I
##res	I
##yl	I
su	I
##l	I
##phate	I
.	O

Canon	O
##ical	O
correlation	O
analysis	O
(	O
CC	O
##or	O
##A	O
)	O
plot	O
revealing	O
associations	O
between	O
the	O
PC	O
scores	O
vectors	O
arising	O
from	O
(	O
1	O
)	O
total	O
lip	O
##op	O
##rote	O
##in	O
t	B
##ria	I
##cy	I
##l	I
##gly	I
##cer	I
##ol	I
-	I
CH	I
_	I
3	I
function	O
-	O
normal	O
##ised	O
_	O
1	O
H	O
N	O
##MR	O
t	B
##ria	I
##cy	I
##l	I
##gly	I
##cer	I
##ol	I
resonance	O
##s	O
(	O
PC	O
##s	O
1	O
–	O
4	O
)	O
,	O
and	O
(	O
2	O
)	O
total	O
t	B
##ria	I
##cy	I
##l	I
##gly	I
##cer	I
##ol	I
concentration	O
-	O
normal	O
##ised	O
clinical	O
chemistry	O
-	O
determined	O
total	O
,	O
L	O
##D	O
##L	O
-	O
and	O
HD	O
##L	O
-	O
associated	O
ch	B
##ole	I
##ster	I
##ol	I
concentrations	O
(	O
PC	O
##s	O
1	O
*	O
and	O
2	O
*	O
)	O
.	O

The	O
highest	O
number	O
of	O
significantly	O
affected	O
meta	O
##bol	O
##ites	O
was	O
observed	O
in	O
the	O
T	O
##3	O
vs	O
.	O
T	O
##2	O
comparison	O
,	O
in	O
which	O
sixteen	O
meta	O
##bol	O
##ites	O
in	O
the	O
A	B
##F	I
(	I
le	I
##uc	I
##ine	I
,	I
v	I
##ali	I
##ne	I
,	I
is	I
##ole	I
##uc	I
##ine	I
,	I
al	I
##ani	I
##ne	I
,	I
met	I
##hi	I
##oni	I
##ne	I
,	I
t	I
##yr	I
##os	I
##ine	I
,	I
p	I
##hen	I
##yla	I
##lani	I
##ne	I
,	I
N	I
,	I
N	I
-	I
dim	I
##eth	I
##yl	I
##gly	I
##cine	I
,	I
car	I
##ni	I
##tine	I
,	I
c	I
##rea	I
##tin	I
##ine	I
,	I
su	I
##cci	I
##nate	I
,	I
p	I
##yr	I
##u	I
##vate	I
,	I
u	I
##ro	I
##can	I
##ate	I
,	I
glucose	I
,	I
ch	I
##olin	I
##e	I
and	O
AU	B
##2	I
)	I
and	O
five	O
meta	O
##bol	O
##ites	O
in	O
the	O
P	O
##L	O
(	O
p	O
##yr	O
##u	O
##vate	O
,	O
3	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
,	O
ace	B
##to	I
##ace	I
##tate	I
,	O
g	B
##ly	I
##cer	I
##ol	I
,	O
and	O
ch	B
##olin	I
##e	I
)	O
were	O
found	O
.	O

However	O
,	O
we	O
excluded	O
them	O
from	O
the	O
statistical	O
analyses	O
as	O
the	O
relative	O
SD	O
for	O
their	O
corresponding	O
internal	O
standards	O
(	O
Ch	O
##E	O
(	O
12	O
:	O
0	O
)	O
for	O
Ch	O
##E	O
,	O
D	B
##G	I
(	I
12	I
:	I
0	I
/	I
12	I
:	I
0	I
)	I
for	O
D	O
##G	O
,	O
and	O
T	B
##G	I
(	I
16	I
:	I
0	I
/	I
16	I
:	I
0	I
/	I
16	I
:	I
0	I
-	I
13	I
##C	I
##3	I
for	I
T	I
##G	I
)	I
)	O
were	O
>	O
30	O
%	O
.	O

[	O
,	O
]	O
;	O
2	O
)	O
in	O
##hibition	O
of	O
CE	O
-	O
act	O
##ivating	O
enzyme	O
,	O
C	O
##YP	O
##1	O
##B	O
##1	O
,	O
by	O
re	B
##s	I
##ver	I
##at	I
##rol	I
as	O
demonstrated	O
in	O
MC	O
##F	O
-	O
10	O
##F	O
cells	O
and	O
by	O
be	O
##rry	O
supplement	O
##ation	O
in	O
animal	O
models	O
;	O
and	O
3	O
)	O
p	O
##hy	O
##to	O
##chemical	O
##s	O
,	O
including	O
re	B
##s	I
##ver	I
##at	I
##rol	I
,	O
in	O
##ducing	O
U	O
##G	O
##T	O
activity	O
.	O

Cell	O
l	O
##ys	O
##ates	O
were	O
Western	O
b	O
##lot	O
##ted	O
using	O
p	O
-	O
E	O
##rk	O
and	O
p	B
-	I
G	I
##S	I
##K	I
##3	I
##β	I
antibodies	I
.	O

In	O
the	O
left	O
cluster	O
,	O
the	O
variables	O
2	B
-	I
he	I
##xa	I
##non	I
##e	I
,	O
3	B
-	I
he	I
##pta	I
##non	I
##e	I
,	O
4	B
-	I
met	I
##hyl	I
-	I
2	I
-	I
he	I
##pta	I
##non	I
##e	I
,	O
et	B
##hyl	I
##ben	I
##zen	I
##e	I
,	O
s	B
##ty	I
##rene	I
and	O
1	B
,	I
3	I
-	I
di	I
-	I
te	I
##rt	I
-	I
but	I
##yl	I
##ben	I
##zen	I
##e	I
are	O
combined	O
into	O
a	O
common	O
group	O
.	O

Fat	O
##ty	O
liver	O
is	O
robust	O
##ly	O
associated	O
with	O
well	O
‐	O
known	O
card	O
##io	O
##met	O
##ab	O
##olic	O
risk	O
factors	O
(	O
such	O
as	O
o	O
##besity	O
,	O
d	O
##ys	O
##lip	O
##ide	O
##mia	O
,	O
and	O
insulin	O
resistance	O
)	O
and	O
increases	O
the	O
risk	O
for	O
type	O
2	O
diabetes	O
and	O
card	O
##iovascular	O
disease	O
.	O
4	O
,	O
5	O
Fat	O
##ty	O
liver	O
,	O
i	O
.	O
e	O
.	O
,	O
mild	O
s	O
##te	O
##ato	O
##sis	O
,	O
can	O
develop	O
into	O
more	O
severe	O
liver	O
disease	O
,	O
an	O
inflammatory	O
s	O
##te	O
##ato	O
##he	O
##pa	O
##titis	O
,	O
and	O
i	O
##rre	O
##versible	O
fi	O
##bro	O
##sis	O
or	O
c	O
##ir	O
##r	O
##hos	O
##is	O
.	O
1	O
Although	O
fatty	O
liver	O
is	O
related	O
to	O
o	O
##besity	O
and	O
insulin	O
resistance	O
,	O
its	O
molecular	O
path	O
##ogen	O
##esis	O
remains	O
poorly	O
understood	O
,	O
and	O
therapeutic	O
options	O
are	O
limited	O
.	O
1	O
,	O
6	O
Fat	O
##ty	O
liver	O
is	O
caused	O
by	O
the	O
accumulation	O
of	O
t	B
##rig	I
##ly	I
##cer	I
##ide	I
deposits	O
in	O
the	O
liver	O
and	O
their	O
tendency	O
to	O
form	O
lip	O
##id	O
drop	O
##lets	O
.	O
1	O
Fat	O
accumulation	O
has	O
been	O
linked	O
to	O
increased	O
none	O
##ster	O
##ified	O
fatty	O
acid	O
in	O
##flow	O
to	O
the	O
liver	O
,	O
he	O
##pa	O
##tic	O
de	O
no	O
##vo	O
lip	O
##ogen	O
##esis	O
,	O
impaired	O
mitochondrial	O
fat	O
oxidation	O
,	O
and	O
inadequate	O
he	O
##pa	O
##tic	O
fat	O
secret	O
##ion	O
through	O
very	O
‐	O
low	O
‐	O
density	O
lip	O
##op	O
##rote	O
##ins	O
(	O
V	O
##LD	O
##L	O
##s	O
)	O
.	O
1	O
,	O
7	O
Because	O
the	O
function	O
of	O
the	O
liver	O
is	O
critical	O
in	O
multiple	O
pathways	O
regulating	O
systemic	O
metabolism	O
,	O
it	O
can	O
be	O
argued	O
that	O
character	O
##izing	O
a	O
metabolic	O
signature	O
of	O
mild	O
s	O
##te	O
##ato	O
##sis	O
may	O
shed	O
light	O
on	O
the	O
path	O

Thus	O
,	O
alterations	O
in	O
plasma	O
ethanol	B
##amine	I
levels	O
may	O
indicate	O
a	O
disruption	O
in	O
protective	O
mechanisms	O
.	O

Additionally	O
,	O
concentrations	O
of	O
some	O
try	B
##pt	I
##op	I
##han	I
cat	O
##ab	O
##oli	O
##tes	O
,	O
e	O
.	O
g	O
.	O
3	B
-	I
in	I
##dox	I
##yl	I
##sul	I
##fa	I
##te	I
,	O
x	B
##ant	I
##hur	I
##ena	I
##te	I
and	O
in	B
##do	I
##le	I
-	I
3	I
-	I
ace	I
##tate	I
,	O
were	O
found	O
to	O
be	O
altered	O
.	O

We	O
investigated	O
the	O
contribution	O
of	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
species	O
in	O
N	O
##AF	O
##LD	O
-	O
associated	O
com	O
##or	O
##bid	O
##ities	O
.	O

Despite	O
a	O
p	O
##let	O
##hora	O
of	O
risk	O
factors	O
,	O
C	O
##LL	O
therapy	O
initiation	O
is	O
still	O
based	O
on	O
clinical	O
features	O
and	O
currently	O
the	O
diagnosis	O
of	O
C	O
##LL	O
does	O
not	O
always	O
lead	O
to	O
pro	B
##mpt	I
treatment	O
due	O
to	O
potentially	O
harmful	O
consequences	O
for	O
the	O
patient	O
.	O

G	O
##C	O
-	O
MS	O
data	O
were	O
first	O
de	O
##con	O
##vo	O
##lut	O
##ed	O
with	O
AM	O
##DI	O
##S	O
(	O
build	O
140	O
.	O
24	O
,	O
version	O
2	O
.	O
72	O
,	O
National	O
Institute	O
of	O
Standards	O
and	O
Technology	O
,	O
G	O
##ait	O
##hers	O
##burg	O
,	O
MD	O
,	O
USA	O
)	O
,	O
with	O
the	O
following	O
settings	O
,	O
which	O
experience	O
has	O
shown	O
to	O
be	O
suitable	O
:	O
component	O
width	O
12	O
scan	O
##s	O
;	O
exclusion	O
##s	O
of	O
the	O
total	O
-	O
ion	O
ch	O
##roma	O
##to	O
##gram	O
and	O
m	O
/	O
z	O
73	O
,	O
74	O
,	O
75	O
,	O
147	O
,	O
148	O
,	O
and	O
149	O
;	O
adjacent	O
peak	O
sub	B
##traction	I
-	I
none	I
;	O
resolution	O
-	O
medium	O
;	O
sensitivity	O
-	O
high	O
;	O
and	O
shape	O
requirements	O
-	O
low	O
.	O

Furthermore	O
,	O
dim	O
##ini	O
##sh	O
##ment	O
of	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
suggests	O
that	O
subjects	O
at	O
risk	O
of	O
s	O
##chi	O
##zophrenia	O
may	O
be	O
more	O
susceptible	O
to	O
infections	O
.	O

As	O
shown	O
in	O
,	O
the	O
selection	O
ion	O
ch	O
##roma	O
##to	O
##gram	O
##s	O
(	O
S	O
##IM	O
)	O
of	O
g	B
##lu	I
##cos	I
##ide	I
(	O
m	O
/	O
z	O
625	O
)	O
,	O
c	B
##yan	I
##id	I
##in	I
-	I
3	I
r	I
##uti	I
##nos	I
##ide	I
(	O
m	O
/	O
z	O
77	O
##1	O
)	O
and	O
c	B
##yan	I
##id	I
##in	I
-	I
3	I
sa	I
##mb	I
##ubi	I
##os	I
##ide	I
(	O
m	O
/	O
z	O
75	O
##7	O
)	O
in	O
the	O
five	O
minute	O
R	O
##ins	O
##e	O
III	O
sa	O
##liva	O
samples	O
did	O
not	O
reveal	O
any	O
novel	O
peaks	O
that	O
demonstrated	O
the	O
appropriate	O
molecular	O
weight	O
and	O
their	O
product	O
ions	O
corresponding	O
to	O
the	O
g	O
##lu	O
##cu	O
##ron	O
##ides	O
of	O
c	B
##yan	I
##id	I
##in	I
-	I
3	I
g	I
##lu	I
##cos	I
##ide	I
and	O
c	B
##yan	I
##id	I
##in	I
-	I
3	I
r	I
##uti	I
##nos	I
##ide	I
(	O
m	O
/	O
z	O
77	O
##1	O
)	O
(	O
Data	O
not	O
shown	O
)	O
.	O

The	O
cartridge	O
was	O
conditioned	O
with	O
1	O
##m	O
##l	O
of	O
met	B
##han	I
##ol	I
followed	O
by	O
e	O
##qui	O
##li	O
##bra	O
##tion	O
with	O
1	O
##m	O
##l	O
of	O
di	O
##st	O
##ille	O
##d	O
water	O
.	O

m	O
m	O
m	O
β	B
-	I
A	I
##po	I
-	I
13	I
-	I
Car	I
##ote	I
##non	I
##e	I
is	O
a	O
high	O
affinity	O
l	O
##igan	O
##d	O
for	O
pu	O
##rified	O
re	B
##tino	I
##ic	I
acid	I
receptors	O
and	O
fits	O
into	O
the	O
l	O
##igan	O
##d	O
binding	O
site	O
.	O

All	O
meta	O
##bol	O
##ites	O
were	O
positively	O
correlated	O
except	O
for	O
c	B
##it	I
##rate	I
(	O
structure	O
coefficient	O
was	O
−	O
##0	O
.	O
56	O
)	O
.	O

We	O
h	O
##y	O
##pot	O
##hes	O
##ized	O
that	O
my	O
##oc	O
##ard	O
##ial	O
is	O
##che	O
##mia	O
from	O
cardiac	O
stress	O
testing	O
will	O
produce	O
dynamic	O
changes	O
in	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
and	O
amino	O
acid	O
levels	O
compared	O
to	O
levels	O
seen	O
in	O
matched	O
control	O
patients	O
with	O
normal	O
stress	O
tests	O
.	O

Association	O
##s	O
unique	O
to	O
women	O
in	O
plasma	O
included	O
co	B
##rt	I
##ison	I
##e	I
,	O
cap	B
##rate	I
,	O
c	B
##it	I
##rate	I
(	O
all	O
inverse	O
##ly	O
)	O
and	O
is	B
##ova	I
##ler	I
##yl	I
##car	I
##ni	I
##tine	I
(	O
positively	O
)	O
.	O

(	O
SM	O
)	O
d	B
##18	I
:	I
1	I
/	I
12	I
:	I
0	I
,	O
di	B
##hy	I
##dr	I
##os	I
##phi	I
##ngo	I
##my	I
##elin	I
d	O
##h	O
##SM	O
d	B
##18	I
:	I
0	I
/	I
12	I
:	I
0	I
,	O
gal	B
##act	I
##osy	I
##l	I
##cer	I
##ami	I
##de	I
(	O
G	O
##al	O
##C	O
##er	O
)	O
d	B
##18	I
:	I
1	I
/	I
12	I
:	I
0	I
,	O
su	B
##lf	I
##ati	I
##de	I
(	I
Sul	I
##f	I
)	I
d	I
##18	I
:	I
1	I
/	I
12	I
:	I
0	I
,	O
g	B
##lu	I
##cos	I
##yl	I
##cer	I
##ami	I
##de	I
(	O
G	O
##l	O
##c	O
##C	O
##er	O
)	O
d	B
##18	I
:	I
1	I
/	I
12	I
:	I
0	I
,	O
la	B
##ct	I
##osy	I
##l	I
##cer	I
##ami	I
##de	I
(	O
Lac	O
##C	O
##er	O
)	O
d	B
##18	I
:	I
1	I
/	I
12	I
:	I
0	I
,	O
D	B
##7	I
-	I
ch	I
##ole	I
##ster	I
##ol	I
,	O
ch	B
##ole	I
##ster	I
##ol	I
est	I
##er	I
(	O
CE	O
)	O
17	O
:	O
0	O
,	O
mon	B
##oa	I
##cy	I
##l	I
##gly	I
##cer	I
##ol	I
(	O
MG	O
)	O
17	O
:	O
0	O
,	O
4	O
##met	O
##hyl	O
16	O
:	O
0	O
diet	O
##her	O
di	B
##acy	I
##l	I
##gly	I
##cer	I
##ol	I
(	O
D	O
##G	O
)	O
,	O
D	B
##5	I
-	I
t	I
##ria	I
##cy	I
##l	I
##gly	I
##cer	I
##ol	I
(	O
T	O
##G	O
)	O
16	O
:	O
0	O
/	O
18	O
:	O
0	O
/	O
16	O
:	O
0	O
and	O
Li	O
##pid	O
##omi	O
##x	O
HP	O
(	O
25	O
)	O
(	O
Ava	O
##nti	O
Polar	O
Li	O
##pid	O
##s	O
,	O
Al	O
##aba	O
##ster	O
,	O
AL	O
)	O
.	O

Pro	O
##te	O
##omi	O
##cs	O
data	O
revealed	O
two	O
proteins	O
with	O
ad	B
##ip	I
##ose	I
-	I
lip	I
##id	I
related	O
functions	O
(	O
S	O
##I	O
A	O
##ppe	O
##ndi	O
##x	O
,	O
Table	O
S	O
##8	O
)	O
.	O

For	O
full	O
identification	O
,	O
the	O
mass	O
s	O
##pect	O
##ra	O
of	O
the	O
identified	O
compounds	O
not	O
only	O
had	O
to	O
match	O
the	O
E	O
##I	O
-	O
MS	O
s	O
##pect	O
##ra	O
in	O
the	O
N	O
##IS	O
##T	O
database	O
(	O
with	O
a	O
match	O
factor	O
of	O
>	O
60	O
%	O
and	O
a	O
probability	O
score	O
>	O
20	O
%	O
)	O
,	O
but	O
also	O
the	O
retention	O
index	O
(	O
R	O
##I	O
)	O
of	O
the	O
compounds	O
in	O
the	O
University	O
of	O
Alberta	O
R	B
##I	I
library	O
,	O
which	O
consists	O
of	O
312	O
T	O
##MS	O
-	O
der	O
##iva	O
##tized	O
human	O
meta	O
##bol	O
##ites	O
.	O

H	O
##ydro	O
##lysis	O
of	O
this	O
compound	O
yielded	O
the	O
_	O
15	O
N	B
-	I
ch	I
##ola	I
##mine	I
in	O
pure	O
form	O
as	O
can	O
be	O
as	O
##cer	O
##tain	O
##ed	O
from	O
its	O
_	O
1	O
H	O
N	O
##MR	O
spectrum	O
(	O
;	O
peaks	O
at	O
3	O
.	O
16	O
;	O
3	O
.	O
48	O
;	O
3	O
.	O
64	O
pp	O
##m	O
)	O
.	O

The	O
Waters	O
UP	O
##C	O
_	O
2	O
was	O
coupled	O
to	O
a	O
Waters	O
Q	O
##ua	O
##tt	O
##ro	O
Premier	O
tandem	O
mass	O
s	O
##pect	O
##rome	O
##ter	O
via	O
a	O
purpose	B
-	I
built	I
,	O
two	O
-	O
part	O
stainless	O
steel	O
split	O
##ter	O
supplied	O
by	O
Waters	O
.	O

Lower	O
ex	O
##cre	O
##tion	O
of	O
pre	B
##gna	I
##ned	I
##iol	I
and	O
est	B
##rio	I
##l	I
in	O
PC	O
##OS	O
persisted	O
even	O
after	O
adjust	O
##ement	O
for	O
age	O
and	O
B	O
##MI	O
.	O

As	O
such	O
,	O
the	O
end	O
##ogen	O
##ous	O
car	B
##ni	I
##tine	I
pool	O
is	O
comprised	O
of	O
l	B
-	I
car	I
##ni	I
##tine	I
and	O
various	O
short	O
-	O
,	O
medium	O
-	O
and	O
long	O
-	O
chain	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
(	O
M	O
##c	O
##C	O
##oi	O
##n	O
et	O
al	O
.	O
)	O
.	O

Van	O
Bee	O
##k	O
et	O
al	O
.	O
suggested	O
a	O
dual	O
interaction	O
between	O
h	B
##ydro	I
##xy	I
##l	I
oxygen	I
and	O
the	O
double	O
bonds	O
,	O
with	O
silver	O
ions	O
.	O

G	B
##lut	I
##ama	I
##te	I
is	O
one	O
of	O
the	O
most	O
abundant	O
free	O
amino	O
acids	O
in	O
the	O
ma	O
##mmal	O
##ian	O
central	O
nervous	O
system	O
(	O
C	O
##NS	O
)	O
and	O
is	O
at	O
the	O
intersection	O
of	O
multiple	O
metabolic	O
pathways	O
.	O

The	O
serum	O
concentration	O
of	O
s	B
##phi	I
##nga	I
##nine	I
in	O
severe	O
CA	O
##P	O
patients	O
is	O
higher	O
than	O
that	O
in	O
non	O
-	O
severe	O
CA	O
##P	O
patients	O
,	O
and	O
lower	O
than	O
controls	O
,	O
but	O
the	O
AU	O
##C	O
to	O
distinguish	O
between	O
non	O
-	O
severe	O
CA	O
##P	O
and	O
severe	O
CA	O
##P	O
was	O
0	O
.	O
82	O
##1	O
and	O
it	O
correlated	O
positively	O
with	O
C	O
##UR	O
##B	O
-	O
65	O
,	O
PS	O
##I	O
and	O
AP	O
##AC	O
##H	O
##E	O
II	O
scores	O
.	O

The	O
in	O
##tra	O
-	O
run	O
accuracy	O
levels	O
were	O
−	O
##3	O
.	O
2	O
–	O
0	O
.	O
0	O
%	O
R	O
##E	O
and	O
−	O
##1	O
.	O
0	O
–	O
4	O
.	O
1	O
%	O
R	O
##E	O
for	O
Ce	B
##r	I
(	I
22	I
:	I
0	I
)	I
and	O
Ce	B
##r	I
(	I
24	I
:	I
0	I
)	I
,	O
respectively	O
.	O

alpha	B
-	I
P	I
##B	I
##P	I
itself	O
formed	O
one	O
in	O
-	O
source	O
artifact	O
(	O
M	O
##21	O
##6	O
##T	O
##21	O
##4	O
in	O
Table	O
and	O
M	O
##21	O
##6	O
##T	O
##34	O
##7	O
in	O
Table	O
)	O
.	O

N	B
##AD	I
,	O
N	B
##AD	I
##H	I
,	O
AM	B
##P	I
and	O
ATP	S
changes	O
in	O
h	O
##y	O
##po	O
##gon	O
##adi	O
##sm	O
.	O

This	O
poses	O
the	O
question	O
of	O
the	O
appropriate	O
##ness	O
of	O
normal	O
##ising	O
the	O
ET	O
##S	O
u	O
##rina	O
##ry	O
bio	O
##mark	O
##ers	O
with	O
c	B
##rea	I
##tin	I
##ine	I
.	O

Fat	O
##ty	O
a	B
##cy	I
##l	I
-	I
Co	I
##As	I
were	O
ion	O
##ized	O
in	O
a	O
negative	O
electro	O
##sp	O
##ray	O
mode	O
,	O
and	O
the	O
transition	O
pairs	O
[	B
M	I
-	I
2	I
##H	I
]	I
2	I
-	I
/	I
[	I
M	I
-	I
H	I
-	I
80	I
]	I
were	O
monitored	O
in	O
multiple	O
reaction	O
monitoring	O
mode	O
.	O

Fourth	O
,	O
a	O
con	O
##found	O
##ing	O
effect	O
of	O
metabolic	O
syndrome	O
on	O
plasma	O
ne	B
##r	I
##von	I
##ic	I
acid	I
cannot	O
be	O
totally	O
ruled	O
out	O
,	O
because	O
a	O
relationship	O
between	O
ne	B
##r	I
##von	I
##ic	I
acid	I
and	O
metabolic	O
syndrome	O
has	O
been	O
reported	O
.	O

ex	B
##p	I
(	I
[UNK]	B
=	I
[UNK]	B
=	I
1	I
##β	I
##st	I
##x	I
##s	I
##x	I
##t	I
+	I
[UNK]	B
=	I
1	I
##α	I
##s	I
##x	I
##s	I
ex	I
##p	I
(	I
[UNK]	B
=	I
[UNK]	B
=	I
1	I
##β	I
##st	I
##x	I
##s	I
##x	I
##t	I
+	I
[UNK]	B
=	I
1	I
##α	I
##s	I
##x	I
##s	I
ex	I
##p	I
(	I
[UNK]	B
=	I
[UNK]	B
=	I
1	I
##β	I
##st	I
##x	I
##s	I
##x	I
##t	I
+	I
[UNK]	B
=	I
1	I
##α	I
##s	I
##x	I
##s	I
ex	I
##p	I
(	I
[UNK]	B
=	I
[UNK]	B
=	I
1	I
##β	I
##st	I
##x	I
##s	I
##x	I
##t	I
+	I
[UNK]	B
=	I
1	I
##α	I
##s	I
##x	I
##s	I
ex	O
##p	O
(	B
[UNK]	B
=	I
[UNK]	B
=	I
1	I
##β	I
##st	I
##x	I
##s	I
##x	I
##t	I
+	I
[UNK]	B
=	I
1	I
##α	I
##s	I
##x	I
##s	I
(	O
(	O
[UNK]	B
=	I
[UNK]	B
=	I
1	I
##β	I
##st	I
##x	I
##s	I
##x	I
##t	I
+	I
[UNK]	B
=	I
1	I
##α	I
##s	I
##x	I
##s	I
12	O
12	O
1	O
1	O
2	O
2	O
[UNK]	B
=	O
1	O
[UNK]	B
=	O
1	O
[UNK]	B
[UNK]	B
p	O
p	O
s	O
=	O
1	O
s	O
=	O
1	O
s	O
=	O
1	O
[UNK]	B
=	O
1	O
[UNK]	B
=	O
1	O
[UNK]	B
[UNK]	B
p	O
p	O
t	O
=	O
1	O
t	O
=	O
1	O
t	O
=	O
1	O
β	O
##st	O
β	O
##st	O

Ph	B
##os	I
##ph	I
##oli	I
##pid	I
species	O
were	O
detected	O
as	O
[	O
M	O
##−	O
##H	O
]	O
_	O
−	O
ions	O
except	O
for	O
ch	B
##olin	I
##e	I
p	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
,	O
which	O
were	O
detected	O
as	O
[	O
M	O
+	O
CH	O
_	O
3	O
CO	O
##O	O
_	O
−	O
]	O
_	O
−	O
add	O
##uc	O
##ts	O
,	O
and	O
were	O
identified	O
by	O
comparison	O
with	O
previously	O
published	O
data	O
[	O
,	O
,	O
,	O
,	O
,	O
,	O
]	O
.	O

K	B
##yn	I
##uren	I
##ine	I
is	O
synthesized	O
by	O
try	O
##pt	O
##op	O
##han	O
di	O
##ox	O
##y	O
##gen	O
##ase	O
and	O
in	O
##do	O
##leam	O
##ine	O
2	O
,	O
3	O
-	O
di	O
##ox	O
##y	O
##gen	O
##ase	O
ca	O
##sca	O
##des	O
and	O
correlated	O
with	O
card	O
##iovascular	O
disease	O
and	O
stroke	O
[	O
,	O
]	O
.	O

Thus	O
,	O
based	O
on	O
insulin	O
sensitivity	O
and	O
glucose	S
tolerance	O
subjects	O
were	O
classified	O
into	O
four	O
categories	O
:	O
N	O
##G	O
##T	O
insulin	O
sensitive	O
(	O
N	O
##G	O
##T	O
-	O
IS	O
)	O
;	O
N	O
##G	O
##T	O
insulin	O
resistant	O
(	O
N	O
##G	O
##T	O
-	O
I	O
##R	O
)	O
;	O
IF	O
##G	O
;	O
and	O
I	O
##G	O
##T	O
.	O

Cho	B
##les	I
##tero	I
##l	I
7	O
-	O
des	O
##at	O
##ura	O
##se	O
is	O
a	O
critical	O
enzyme	O
in	O
insects	O
and	O
ne	O
##mat	O
##odes	O
involved	O
in	O
the	O
synthesis	O
of	O
s	O
##tero	O
##id	O
hormones	O
(	O
D	O
##AF	O
-	O
36	O
)	O
.	O

Further	O
,	O
a	O
marginal	O
improvement	O
in	O
meta	O
##bol	O
##ite	O
recovery	O
(	O
average	O
concentration	O
3	O
.	O
9	O
%	O
)	O
could	O
be	O
observed	O
when	O
multiple	O
extraction	O
##s	O
were	O
performed	O
using	O
met	B
##han	I
##ol	I
solvent	O
.	O

Mi	O
##to	O
##cho	O
##nd	O
##rial	O
electron	O
transport	O
is	O
affected	O
with	O
a	O
reduction	O
in	O
ATP	S
production	O
.	O

O	O
##PL	O
##S	O
-	O
D	O
##A	O
models	O
with	O
w	B
##hey	I
and	O
calcium	B
case	I
##inate	I
as	O
classes	O
made	O
to	O
investigate	O
the	O
difference	O
between	O
w	B
##hey	I
and	O
calcium	B
case	I
##inate	I
intake	O
were	O
poor	O
,	O
and	O
they	O
were	O
un	O
##sui	O
##table	O
for	O
interpretation	O
(	O
Q	O
##2	O
<	O
0	O
.	O
5	O
;	O
data	O
not	O
shown	O
)	O
.	O

The	O
cap	O
##illa	O
##ry	O
voltage	O
was	O
set	O
to	O
4	O
k	B
##V	I
,	O
the	O
drying	O
gas	O
temperature	O
in	O
the	O
electro	O
##sp	O
##ray	O
source	O
was	O
set	O
to	O
350	O
##°	O
##C	O
,	O
the	O
ne	O
##bul	O
##izer	O
gas	O
was	O
set	O
to	O
45	O
ps	O
##i	O
and	O
the	O
drying	O
gas	O
to	O
9	O
.	O
0	O
L	O
/	O
min	O
.	O

Mobile	O
phase	O
A	O
was	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
in	O
water	O
,	O
and	O
mobile	O
phase	O
B	O
was	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
in	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
.	O

Other	O
than	O
the	O
administered	O
trace	O
##r	O
itself	O
(	O
[	O
U	O
-	O
_	O
13	O
C	O
]	O
-	O
G	O
##l	O
##c	O
)	O
,	O
the	O
major	O
_	O
13	O
C	O
-	O
labeled	O
meta	O
##bol	O
##ite	O
in	O
plasma	O
was	O
la	B
##ct	I
##ate	I
.	O

For	O
the	O
experimental	O
arm	O
A	O
,	O
lip	O
##ids	O
(	B
g	B
##ly	I
##cer	I
##ol	I
backbone	O
of	O
p	B
##hos	I
##ph	I
##og	I
##ly	I
##cer	I
##ides	I
and	O
t	B
##ria	I
##cy	I
##l	I
##gly	I
##cer	I
##ides	I
fatty	O
acids	O
)	O
,	O
lip	O
##op	O
##rote	O
##ins	O
mainly	O
very	O
low	O
-	O
density	O
lip	O
##op	O
##rote	O
##ins	O
and	O
low	O
-	O
density	O
lip	O
##op	O
##rote	O
##ins	O
(	O
L	O
##D	O
##L	O
)	O
as	O
well	O
as	O
glucose	S
and	O
N	B
-	I
ace	I
##ty	I
##l	I
##gly	I
##co	I
##p	I
##rote	I
##ins	I
(	O
N	O
##AC	O
##1	O
&	O
2	O
)	O
were	O
found	O
in	O
significantly	O
higher	O
concentrations	O
in	O
the	O
serum	O
at	O
W	O
##2	O
as	O
compared	O
with	O
base	O
##line	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

There	O
were	O
,	O
however	O
,	O
three	O
peaks	O
with	O
the	O
retention	O
time	O
of	O
19	O
.	O
22	O
,	O
21	O
.	O
28	O
and	O
25	O
.	O
65	O
min	O
labeled	O
as	O
Peak	O
I	O
,	O
II	O
and	O
III	O
in	O
the	O
S	O
##IC	O
of	O
c	B
##yan	I
##id	I
##in	I
-	I
3	I
sa	I
##mb	I
##ubi	I
##os	I
##ide	I
g	O
##lu	O
##cu	O
##ron	O
##ides	O
detected	O
in	O
6	O
of	O
the	O
6	O
five	O
minute	O
time	O
point	O
samples	O
and	O
3	O
of	O
6	O
samples	O
from	O
the	O
30	O
minute	O
samples	O
,	O
but	O
absent	O
in	O
the	O
original	O
R	O
##ins	O
##e	O
III	O
solution	O
.	O

The	O
top	O
layer	O
was	O
transferred	O
to	O
a	O
1	O
.	O
5	O
m	O
##l	O
p	B
##oly	I
##p	I
##rop	I
##yle	I
##ne	I
screw	O
top	O
tube	O
,	O
and	O
e	O
##va	O
##porated	O
to	O
dry	O
##ness	O
under	O
a	O
stream	O
of	O
nitrogen	O
in	O
a	O
water	O
bath	O
at	O
50	O
±	O
5	O
_	O
0	O

Changes	O
in	O
the	O
metabolism	O
of	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
t	O
##rig	O
##y	O
##cer	O
##ides	O
and	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
that	O
were	O
demonstrated	O
in	O
a	O
mouse	O
model	O
of	O
C	O
##ro	O
##hn	O
’	O
s	O
disease	O
,	O
highlight	O
the	O
importance	O
of	O
inflammatory	O
lip	O
##id	O
media	O
##tors	O
as	O
potential	O
bio	O
##mark	O
##ers	O
of	O
I	O
##B	O
##D	O
.	O

The	O
exceptions	O
to	O
this	O
general	O
pattern	O
were	O
the	O
o	O
##li	O
##go	O
##den	O
##dr	O
##og	O
##lio	O
##mas	O
:	O
in	O
those	O
t	O
##umour	O
##s	O
,	O
the	O
only	O
significant	O
positive	O
correlation	O
##s	O
were	O
between	O
la	B
##ct	I
##ate	I
and	O
t	O
##G	O
##lut	O
and	O
between	O
t	O
##C	O
##r	O
and	O
la	B
##ct	I
##ate	I
.	O

Very	O
few	O
studies	O
have	O
reported	O
on	O
the	O
association	O
of	O
bio	O
##mark	O
##ers	O
of	O
o	O
##xi	O
##da	O
##tive	O
stress	O
and	O
breast	O
cancer	O
outcomes	O
,	O
and	O
no	O
studies	O
have	O
investigated	O
F	B
_	I
2	I
-	I
is	I
##op	I
##ros	I
##tan	I
##es	I
.	O

Specifically	O
,	O
the	O
width	O
of	O
one	O
of	O
the	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
peaks	O
was	O
significantly	O
lower	O
in	O
F	O
##GR	O
cases	O
(	O
p	O
=	O
0	O
.	O
02	O
)	O
.	O

PC	B
a	I
##a	I
C	I
##38	I
:	I
5	I
;	O
104	O
.	O

Pat	O
##ients	O
who	O
developed	O
AP	S
(	O
n	O
=	O
9	O
)	O
were	O
matched	O
to	O
patients	O
who	O
did	O
not	O
develop	O
AP	S
(	O
n	O
=	O
18	O
)	O
by	O
age	O
and	O
gender	O
.	O

We	O
observed	O
large	O
AU	O
##C	O
values	O
(	O
AU	O
##C	O
≥	O
0	O
.	O
9	O
)	O
between	O
AI	O
##S	O
A	O
and	O
C	O
for	O
four	O
meta	O
##bol	O
##ites	O
used	O
alone	O
:	O
N	O
##1	O
,	O
N	B
##12	I
-	I
di	I
##ace	I
##ty	I
##ls	I
##per	I
##mine	I
,	O
la	B
##ctic	I
acid	I
,	O
c	B
##it	I
##ru	I
##llin	I
##e	I
and	O
g	B
##ly	I
##cer	I
##ol	I
,	O
with	O
good	O
sensitivity	O
and	O
specific	O
##ity	O
at	O
the	O
cut	O
-	O
off	O
threshold	O
.	O

However	O
,	O
the	O
mechanisms	O
by	O
which	O
these	O
foods	O
media	O
##te	O
their	O
ch	B
##ole	I
##ster	I
##ol	I
lowering	O
effects	O
are	O
still	O
very	O
much	O
unclear	O
,	O
with	O
different	O
mechanisms	O
suggesting	O
involving	O
p	B
##hy	I
##tos	I
##tero	I
##ls	I
,	O
gel	O
-	O
forming	O
and	O
ch	B
##ole	I
##ster	I
##ol	I
binding	O
activities	O
,	O
modified	O
bi	O
##le	O
acid	O
profiles	O
and	O
/	O
or	O
pre	O
##biotic	O
type	O
m	O
##od	O
##ulation	O
of	O
the	O
gut	O
micro	O
##bio	O
##ta	O
[	O
,	O
]	O
.	O

In	O
addition	O
,	O
p	B
##yr	I
##og	I
##lut	I
##ami	I
##c	I
acid	I
could	O
improve	O
the	O
learning	O
and	O
memory	O
capacities	O
in	O
old	O
rat	O
;	O
this	O
effect	O
could	O
also	O
be	O
related	O
to	O
an	O
activation	O
of	O
ch	B
##olin	I
##ergic	I
mechanisms	O
.	O

The	O
remaining	O
two	O
measured	O
were	O
all	B
##ant	I
##oi	I
##n	I
and	O
u	B
##rac	I
##il	I
,	O
linked	O
in	O
the	O
metabolic	O
pathways	O
related	O
to	O
u	B
##rate	I
and	O
pseudo	B
##uri	I
##dine	I
,	O
respectively	O
.	O

PC	B
a	I
##e	I
C	I
##38	I
:	I
2	I
;	O
66	O
.	O

Because	O
of	O
this	O
com	O
##pen	O
##sat	O
##ory	O
mechanism	O
,	O
the	O
development	O
of	O
any	O
drug	O
targeting	O
the	O
f	B
##olate	I
pathway	O
in	O
try	O
##pan	O
##oso	O
##mat	O
##ids	O
should	O
consider	O
the	O
in	O
##hibition	O
of	O
both	O
D	O
##HF	O
##R	O
and	O
PT	O
##R	O
##1	O
.	O

Ph	B
##os	I
##pha	I
##ti	I
##dy	I
##ls	I
##eri	I
##ne	I
can	O
be	O
synthesized	O
from	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
or	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##let	I
##han	I
##ola	I
##mine	I
by	O
two	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##ls	I
##eri	I
##ne	I
s	O
##ynth	O
##ases	O
(	O
PS	O
##S	O
##1	O
and	O
PS	O
##S	O
##2	O
)	O
.	O

N	O
##ume	O
##rical	O
characteristics	O
are	O
shown	O
of	O
the	O
threshold	O
-	O
average	O
R	O
##OC	O
curves	O
for	O
all	O
32	O
s	O
##tero	O
##ids	O
and	O
the	O
subset	O
##s	O
of	O
three	O
s	O
##tero	O
##ids	O
(	O
T	O
##HS	O
,	O
5	O
-	O
PT	O
,	O
and	O
5	O
-	O
PD	O
)	O
and	O
nine	O
s	O
##tero	O
##ids	O
[	O
T	O
##HS	O
,	O
5	O
-	O
PT	O
,	O
5	O
-	O
PD	O
,	O
PT	O
,	O
T	O
##HD	O
##OC	O
,	O
5	B
##α	I
##TH	I
##A	I
E	O
##ti	O
##o	O
,	O
5	B
##α	I
##TH	I
##F	I
,	O
and	O
PD	O
;	O
for	O
explanation	O
of	O
s	O
##ter	O
##io	O
##d	O
meta	O
##bol	O
##ite	O
abbreviation	O
##s	O
see	O
Su	O
##pp	O
##lement	O
##al	O
Table	O
1	O
]	O
identified	O
as	O
most	O
disc	O
##rim	O
##ina	O
##tive	O
after	O
GM	O
##L	O
##V	O
##Q	O
analysis	O
.	O

For	O
3	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
,	O
we	O
found	O
that	O
r	O
##s	O
##17	O
##31	O
##35	O
located	O
3	O
′	O
U	O
##TR	O
of	O
KC	O
##N	O
##J	O
##2	O
gene	O
is	O
most	O
likely	O
the	O
ca	O
##usal	O
S	O
##NP	O
(	O
P	O
-	O
value	O
=	O
1	O
.	O
01	O
##×	O
##10	O
_	O
−	O
##0	O
##7	O
)	O
in	O
##f	O
##lue	O
##ncing	O
the	O
circulating	O
level	O
of	O
this	O
meta	O
##bol	O
##ite	O
.	O

This	O
de	O
##p	O
##rote	O
##ini	O
##zation	O
method	O
using	O
perch	B
##lor	I
##ic	I
acid	I
showed	O
a	O
better	O
recovery	O
rate	O
while	O
being	O
a	O
less	O
labor	O
-	O
intensive	O
procedure	O
,	O
as	O
compared	O
to	O
the	O
liquid	O
–	O
liquid	O
extraction	O
methods	O
described	O
by	O
Len	O
##nard	O
and	O
Single	O
##ton	O
and	O
modified	O
by	O
C	O
##uff	O
##ari	O
et	O
al	O
.	O

Target	O
##ed	O
c	B
##rea	I
##tin	I
##ine	I
was	O
highly	O
correlated	O
with	O
the	O
J	O
##af	O
##fe	O
ass	O
##ay	O
in	O
the	O
AA	O
##S	O
##K	O
and	O
the	O
en	O
##zy	O
##matic	O
c	B
##rea	I
##tin	I
##ine	I
ass	O
##ay	O
in	O
the	O
ME	O
##SA	O
(	O
r	O
=	O
0	O
.	O
98	O
##4	O
and	O
0	O
.	O
99	O
##3	O
,	O
intercept	O
##s	O
of	O
−	O
##0	O
.	O
04	O
and	O
0	O
.	O
02	O
mg	O
/	O
d	O
##L	O
and	O
slopes	O
of	O
0	O
.	O
98	O
##9	O
and	O
0	O
.	O
99	O
##6	O
,	O
respectively	O
)	O
.	O

Forty	O
quality	O
markers	O
,	O
including	O
l	B
##ys	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
,	O
dip	O
##eptide	O
##s	O
,	O
fatty	O
acids	O
,	O
su	B
##cci	I
##nic	I
acid	I
,	O
amino	O
acids	O
,	O
glucose	S
,	O
and	O
u	B
##ric	I
acid	I
were	O
identified	O
by	O
G	O
-	O
Met	O
for	O
the	O
evaluation	O
of	O
plasma	O
sample	O
quality	O
and	O
established	O
the	O
equation	O
of	O
calculating	O
the	O
quality	O
score	O
.	O

In	O
addition	O
,	O
levels	O
of	O
g	B
##ly	I
##cine	I
,	O
se	B
##rine	I
,	O
th	B
##re	I
##oni	I
##ne	I
and	O
ho	B
##mos	I
##eri	I
##ne	I
did	O
not	O
increase	O
with	O
treatment	O
,	O
further	O
establishing	O
their	O
association	O
with	O
D	O
##M	O
in	O
these	O
patients	O
.	O

U	B
##DP	I
-	I
G	I
##l	I
##c	I
##NA	I
##c	I
,	O
a	O
n	O
##uc	O
##leo	O
##tide	O
sugar	O
,	O
is	O
the	O
end	O
-	O
product	O
of	O
the	O
he	B
##x	I
##osa	I
##mine	I
bio	O
##sy	O
##nt	O
##hetic	O
pathway	O
(	O
H	O
##B	O
##P	O
)	O
and	O
acts	O
as	O
a	O
substrate	O
for	O
the	O
O	O
-	O
linked	O
N	B
-	I
ace	I
##ty	I
##l	I
##g	I
##lu	I
##cos	I
##amine	I
transfer	O
##ase	O
enzymes	O
(	O
O	O
##G	O
##T	O
##s	O
)	O
.	O

Met	O
##ab	O
##olic	O
valid	O
##ation	O
studies	O
revealed	O
that	O
these	O
H	O
##NS	O
##CC	O
tumors	O
##phere	O
##s	O
exhibited	O
elevated	O
levels	O
of	O
g	B
##lut	I
##ama	I
##te	I
,	O
compared	O
to	O
ad	O
##here	O
##nt	O
controls	O
.	O

Ph	B
##os	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
.	O
8	O
.	O

H	B
##ydro	I
##quin	I
##one	I
(	I
1	I
,	I
4	I
-	I
ben	I
##zen	I
##ed	I
##iol	I
)	I
is	O
a	O
ben	B
##zen	I
##e	I
meta	O
##bol	O
##ite	O
.	O

The	O
p	B
##yr	I
##ido	I
##xi	I
##c	I
acid	O
:	O
p	O
##yr	O
##ido	O
##xa	O
##l	O
plus	O
p	B
##yr	I
##ido	I
##xa	I
##l	I
phosphate	I
ratio	O
(	O
PA	O
##r	O
)	O
was	O
greater	O
in	O
the	O
high	B
–	I
c	I
##ys	I
##tat	I
##hi	I
##oni	I
##ne	I
concentration	O
group	O
,	O
which	O
indicated	O
a	O
greater	O
extent	O
of	O
vitamin	O
B	O
-	O
6	O
cat	O
##ab	O
##olis	O
##m	O
(	O
P	O
=	O
0	O
.	O
00	O
##1	O
)	O
.	O

S	B
##phi	I
##ngo	I
##lip	I
##id	I
meta	O
##bol	O
##ites	O
,	O
such	O
as	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
,	O
GM	B
##3	I
,	O
c	B
##era	I
##mi	I
##des	I
and	O
the	O
precursor	O
and	O
meta	O
##bol	O
##ites	O
of	O
c	B
##era	I
##mi	I
##de	I
,	O
di	B
##hy	I
##dr	I
##oc	I
##era	I
##mi	I
##de	I
,	O
mon	B
##oh	I
##ex	I
##osy	I
##l	I
##cer	I
##ami	I
##de	I
,	O
di	B
##he	I
##x	I
##osy	I
##l	I
##cer	I
##ami	I
##de	I
and	O
t	B
##ri	I
##he	I
##x	I
##osy	I
##l	I
##cer	I
##ami	I
##de	I
,	O
were	O
overall	O
associated	O
with	O
a	O
lower	O
C	O
-	O
p	O
##eptide	O
level	O
after	O
3	O
,	O
6	O
and	O
12	O
months	O
(	O
Table	O
)	O
,	O
although	O
not	O
reaching	O
significance	O
after	O
correction	O
for	O
multiple	O
testing	O
.	O

The	O
sample	O
preparation	O
protocol	O
included	O
in	O
the	O
first	O
step	O
an	O
in	O
##cu	O
##bation	O
of	O
a	O
mixture	O
containing	O
100	O
μ	O
##L	O
plasma	O
,	O
25	O
μ	O
##L	O
g	O
##lu	O
##cu	O
##ron	O
##idas	O
##e	O
,	O
8	O
mg	O
/	O
m	O
##L	O
(	O
corresponding	O
to	O
an	O
activity	O
of	O
113	O
.	O
2	O
U	O
)	O
;	O
25	O
μ	O
##L	O
su	O
##lf	O
##ata	O
##se	O
,	O
50	O
units	O
/	O
m	O
##L	O
;	O
10	O
μ	O
##L	O
para	B
##ce	I
##tam	I
##ol	I
-	I
β	I
-	I
d	I
-	I
g	I
##lu	I
##cu	I
##ron	I
##ide	I
,	O
10	O
μ	O
##g	O
/	O
m	O
##L	O
;	O
40	O
μ	O
##L	O
p	B
-	I
ni	I
##tro	I
##cate	I
##cho	I
##l	I
su	I
##lf	I
##ate	I
,	O
1	O
mg	O
/	O
m	O
##L	O
(	O
all	O
solutions	O
prepared	O
in	O
sodium	B
ace	I
##tate	I
0	O
.	O
2	O
M	O
,	O
pH	O
4	O
.	O
5	O
)	O
;	O
and	O
200	O
μ	O
##L	O
sodium	B
ace	I
##tate	I
,	O
0	O
.	O
2	O
M	O
(	O
pH	O
4	O
.	O
5	O
)	O
,	O
for	O
12	O
h	O
at	O
37	O
°C	O
,	O
with	O
constant	O
mixing	O
(	O
Me	O
##mmer	O
##t	O
)	O
.	O

It	O
could	O
be	O
expected	O
that	O
this	O
difference	O
in	O
amino	O
acid	O
concentration	O
observed	O
about	O
15	O
-	O
45	O
min	O
after	O
exercise	O
for	O
the	O
w	B
##hey	I
and	O
calcium	B
case	I
##inate	I
groups	O
was	O
accompanied	O
by	O
other	O
metabolic	O
effects	O
.	O

After	O
oral	O
ing	O
##est	O
##ion	O
,	O
as	B
##par	I
##tam	I
##e	I
is	O
rapidly	O
h	O
##ydro	O
##ly	O
##sed	O
within	O
the	O
l	O
##ume	O
##n	O
of	O
the	O
gas	O
##tro	O
-	O
in	O
##test	O
##inal	O
(	O
G	O
##I	O
)	O
tract	O
,	O
with	O
a	O
half	O
-	O
life	O
in	O
the	O
order	O
of	O
minutes	O
[	O
]	O
resulting	O
in	O
formation	O
of	O
met	B
##han	I
##ol	I
and	O
the	O
amino	O
acids	O
,	O
as	B
##par	I
##tic	I
acid	I
and	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
.	O

Sub	O
##jects	O
were	O
classified	O
as	O
norm	B
##og	I
##ly	I
##ce	I
##mic	I
or	O
d	B
##ys	I
##gly	I
##ce	I
##mic	I
based	O
upon	O
the	O
results	O
of	O
fast	O
##ing	O
plasma	O
glucose	S
(	O
F	O
##P	O
##G	O
)	O
and	O
the	O
oral	O
glucose	S
tolerance	O
test	O
(	O
O	O
##G	O
##TT	O
)	O
as	O
illustrated	O
in	O
.	O

Previously	O
,	O
only	O
ch	B
##lor	I
##of	I
##orm	I
and	O
met	B
##han	I
##ol	I
were	O
used	O
for	O
extract	O
##ing	O
lip	O
##ids	O
from	O
the	O
urine	O
.	O

The	O
cells	O
were	O
grown	O
in	O
the	O
presence	O
of	O
10	O
.	O
75	O
m	O
##M	O
[	B
U	I
–	I
_	I
13	I
C	I
]	I
-	I
glucose	I
for	O
24	O
h	O
,	O
and	O
the	O
meta	O
##bol	O
##ites	O
were	O
extracted	O
as	O
described	O
in	O
the	O
“	O
Method	O
##s	O
”	O
.	O

Other	O
modified	O
meta	O
##bol	O
##ites	O
were	O
involved	O
in	O
ch	B
##olin	I
##e	I
metabolic	O
pathway	O
,	O
including	O
c	B
##rea	I
##tin	I
##ine	I
,	O
c	B
##rea	I
##tine	I
,	O
D	B
##MG	I
,	O
D	B
##MA	I
and	O
T	O
##MA	O
.	O

It	O
is	O
likely	O
that	O
differences	O
in	O
study	O
design	O
and	O
clinical	O
p	O
##hen	O
##ot	O
##y	O
##ping	O
,	O
as	O
well	O
as	O
small	O
sample	O
sizes	O
in	O
some	O
studies	O
,	O
contribute	O
to	O
the	O
in	O
##con	O
##sist	O
##encies	O
thus	O
far	O
in	O
the	O
literature	O
regarding	O
car	B
##ni	I
##tine	I
meta	O
##bol	O
##ites	O
and	O
DR	O
.	O

Furthermore	O
,	O
we	O
examined	O
the	O
levels	O
of	O
the	O
substrates	O
for	O
the	O
PC	O
bio	O
##sy	O
##nt	O
##hesis	O
in	O
He	O
##p	O
##G	O
##2	O
and	O
He	O
##p	O
##G	O
##2	O
.	O
2	O
.	O
15	O
cells	O
and	O
found	O
that	O
p	B
##hos	I
##ph	I
##och	I
##olin	I
##e	I
and	O
CDP	B
-	I
ch	I
##olin	I
##e	I
increased	O
in	O
He	O
##p	O
##G	O
##2	O
.	O
2	O
.	O
15	O
cells	O
(	O
Fi	O
##g	O
.	O
)	O
.	O

Micro	O
##some	O
##s	O
were	O
pre	O
-	O
in	O
##cu	O
##bate	O
##d	O
with	O
al	B
##ame	I
##thi	I
##cin	I
(	O
25	O
µ	O
##g	O
m	O
##l	O
_	O
−	O
##1	O
in	O
final	O
in	O
##cu	O
##bation	O
)	O
on	O
ice	O
for	O
15	O
min	O
.	O

We	O
measured	O
serum	O
concentrations	O
of	O
25	O
(	O
OH	O
)	O
D	O
,	O
1	B
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
,	O
and	O
24	B
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
among	O
1	O
,	O
193	O
participants	O
in	O
the	O
Di	O
##abe	O
##tes	O
Control	O
and	O
Co	O
##mp	O
##lication	O
##s	O
Trial	O
/	O
E	O
##pid	O
##em	O
##iology	O
of	O
Di	O
##abe	O
##tes	O
Inter	O
##vention	O
##s	O
and	O
Co	O
##mp	O
##lication	O
##s	O
(	O
DC	O
##CT	O
/	O
E	O
##DI	O
##C	O
)	O
study	O
.	O

L	O
##ys	O
##ates	O
of	O
both	O
sub	O
##cut	O
##aneous	O
human	O
ad	O
##ip	O
##ose	O
tissue	O
bio	O
##ps	O
##ies	O
and	O
m	B
##uri	I
##ne	I
3	O
##T	O
##3	O
-	O
L	O
##1	O
ad	O
##ip	O
##ocytes	O
showed	O
AK	O
##R	O
activity	O
.	O

In	O
t	O
##umour	O
samples	O
,	O
this	O
apparently	O
was	O
linked	O
to	O
increases	O
in	O
g	B
##lut	I
##ath	I
##ione	I
,	O
g	B
##lut	I
##ath	I
##ione	I
derivatives	O
,	O
(	B
la	B
##ct	I
##oy	I
##l	I
-	I
g	I
##lut	I
##ath	I
##ione	I
and	O
h	B
##ydro	I
##xy	I
##lm	I
##eth	I
##yt	I
##l	I
g	I
##lut	I
##ath	I
##ione	I
)	O
,	O
and	O
also	O
ta	B
##uri	I
##ne	I
.	O

By	O
virtue	O
of	O
their	O
ability	O
to	O
control	O
sa	B
##rc	I
##os	I
##ine	I
levels	O
in	O
cells	O
,	O
these	O
enzymes	O
may	O
assume	O
a	O
critical	O
role	O
in	O
m	O
##od	O
##ulating	O
pro	O
##state	O
cancer	O
invasion	O
.	O

L	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
(	I
20	I
:	I
0	I
)	I
and	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
(	I
18	I
:	I
2	I
)	I
were	O
purchased	O
from	O
La	O
##rod	O
##an	O
AB	O
(	O
Mal	O
##mo	O
,	O
Sweden	O
)	O
.	O

The	O
cell	O
membrane	O
of	O
er	O
##yt	O
##hr	O
##ocytes	O
infected	O
with	O
parasite	O
also	O
undergo	O
##es	O
re	O
##mo	O
##del	O
##ing	O
and	O
exhibits	O
a	O
decrease	O
in	O
the	O
level	O
of	O
p	O
##oly	O
##uns	O
##at	O
##ura	O
##ted	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
(	O
Via	O
##l	O
et	O
al	O
.	O
)	O
.	O

It	O
is	O
also	O
thought	O
that	O
the	O
α	B
-	I
k	I
##eto	I
##g	I
##lut	I
##arate	I
formed	O
in	O
this	O
pathway	O
can	O
pass	O
backwards	O
(	O
i	O
.	O
e	O
.	O
anti	O
##c	O
##lock	O
##wise	O
)	O
through	O
the	O
T	O
##CA	O
to	O
c	B
##it	I
##rate	I
which	O
can	O
be	O
b	O
##led	O
off	O
to	O
form	O
fatty	O
acids	O
.	O

these	O
p	O
-	O
values	O
remain	O
<	O
0	O
.	O
05	O
after	O
correction	O
by	O
F	O
##DR	O
;	O
I	O
vs	B
C	I
-	I
(	I
+	I
)	I
/	I
(	I
−	I
)	I
means	O
increased	O
/	O
decreased	O
abundance	O
in	O
C	O
##LL	O
patients	O
in	O
in	O
##do	O
##lent	O
state	O
of	O
the	O
disease	O
in	O
comparison	O
to	O
controls	O
;	O

The	O
changes	O
in	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
(	O
l	O
##ys	O
##o	O
##PC	O
)	O
16	O
:	O
0	O
levels	O
were	O
positively	O
related	O
to	O
those	O
of	O
l	O
##ys	O
##o	O
##PC	O
15	O
:	O
0	O
(	O
r	O
=	O
0	O
.	O
90	O
,	O
P	O
<	O
0	O
.	O
00	O
##1	O
)	O
and	O
l	O
##ys	O
##o	O
##PC	O
18	O
:	O
0	O
(	O
r	O
=	O
0	O
.	O
76	O
,	O
P	O
<	O
0	O
.	O
00	O
##1	O
)	O
,	O
while	O
that	O
of	O
l	O
##ys	O
##o	O
##PC	O
18	O
:	O
0	O
was	O
closely	O
related	O
to	O
that	O
of	O
l	O
##ys	O
##o	O
##PC	O
15	O
:	O
0	O
(	O
r	O
=	O
0	O
.	O
77	O
,	O
P	O
<	O
0	O
.	O
00	O
##1	O
)	O
.	O

The	O
possibility	O
also	O
exists	O
that	O
C	O
_	O
27	O
bi	O
##le	O
acids	O
could	O
be	O
formed	O
in	O
brain	O
from	O
ch	B
##ole	I
##ster	I
##ol	I
itself	O
.	O

Although	O
stress	O
is	O
also	O
linked	O
with	O
poor	O
sleep	O
,	O
we	O
failed	O
to	O
find	O
marked	O
relationships	O
among	O
sleep	O
variables	O
and	O
k	B
##yn	I
##uren	I
##ine	I
levels	O
.	O

This	O
independent	O
study	O
gives	O
re	O
##ass	O
##urance	O
to	O
both	O
regulatory	O
bodies	O
and	O
the	O
public	O
that	O
acute	O
ing	O
##est	O
##ion	O
of	O
as	B
##par	I
##tam	I
##e	I
does	O
not	O
have	O
any	O
detect	O
##able	O
psychological	O
or	O
metabolic	O
effects	O
in	O
humans	O
.	O

Two	O
300	O
μ	O
##L	O
serum	O
samples	O
were	O
mixed	O
with	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
in	O
a	O
1	O
:	O
2	O
ratio	O
(	O
v	O
/	O
v	O
)	O
,	O
v	O
##ortex	O
##ed	O
,	O
and	O
in	O
##cu	O
##bate	O
##d	O
at	O
−	O
##20	O
°C	O
for	O
20	O
min	O
.	O

A	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
meta	O
##bol	O
##ites	O
including	O
he	B
##xa	I
##noy	I
##l	I
##car	I
##ni	I
##tine	I
,	O
o	B
##ct	I
##ano	I
##yl	I
##car	I
##ni	I
##tine	I
,	O
and	O
c	B
##is	I
-	I
4	I
-	I
de	I
##ce	I
##noy	I
##l	I
car	I
##ni	I
##tine	I
remained	O
notably	O
different	O
(	O
>	O
2	O
-	O
fold	O
decrease	O
,	O
p	O
<	O
0	O
.	O
01	O
)	O
,	O
and	O
several	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
species	O
remained	O
decreased	O
.	O

This	O
p	B
##hos	I
##ph	I
##oc	I
##rea	I
##tine	I
might	O
have	O
been	O
taken	O
up	O
by	O
t	O
##umour	O
tissues	O
then	O
de	O
##ph	O
##os	O
##ph	O
##ory	O
##lated	O
back	O
to	O
c	B
##rea	I
##tine	I
to	O
f	O
##ulf	O
##il	O
the	O
energy	O
demand	O
.	O

G	B
##lut	I
##ari	I
##c	I
acid	I
is	O
mainly	O
produced	O
from	O
the	O
metabolism	O
of	O
l	B
##ys	I
##ine	I
,	O
whose	O
flu	O
##ct	O
##uation	O
in	O
post	O
##par	O
##tum	O
depressed	O
patients	O
indicates	O
the	O
change	O
of	O
l	B
##ys	I
##ine	I
metabolism	O
.	O

Also	O
,	O
high	O
tumor	O
fraction	O
tissues	O
show	O
elevated	O
la	B
##ct	I
##ate	I
,	O
c	B
##rea	I
##tine	I
,	O
G	O
##ly	O
,	O
and	O
PC	O
.	O

The	O
β	B
-	I
la	I
##ct	I
##am	I
anti	O
##biotics	O
,	O
such	O
as	O
am	O
##ox	O
##ici	O
##llin	O
(	O
A	O
##X	O
)	O
,	O
are	O
among	O
the	O
most	O
widely	O
prescribed	O
drugs	O
and	O
frequently	O
el	O
##icit	O
all	O
##ergic	O
reactions	O
.	O
_	O
,	O
The	O
co	O
##valent	O
add	O
##uction	O
of	O
A	O
##X	O
,	O
other	O
anti	O
##biotics	O
,	O
and	O
drugs	O
to	O
proteins	O
is	O
considered	O
a	O
key	O
process	O
for	O
the	O
all	O
##ergic	O
response	O
.	O
_	O
,	O

The	O
reduced	O
bacterial	O
β	O
-	O
g	O
##lu	O
##cos	O
##idas	O
##e	O
and	O
la	O
##ct	O
##ase	O
p	O
##hyl	O
##ori	O
##zin	O
h	O
##ydro	O
##lase	O
activities	O
in	O
the	O
R	O
##ins	O
##e	O
II	O
samples	O
would	O
decrease	O
de	O
##gly	O
##cos	O
##yla	O
##tion	O
,	O
enabling	O
increased	O
retention	O
of	O
parent	O
BR	O
##B	O
ant	B
##ho	I
##cy	I
##ani	I
##ns	I
in	O
sa	O
##liva	O
.	O

By	O
our	O
measurements	O
,	O
the	O
most	O
abundant	O
metals	O
/	O
salts	O
are	O
sodium	O
(	O
Na	O
)	O
(	O
12	O
.	O
5	O
±	O
10	O
.	O
6	O
m	O
##M	O
/	O
m	O
##M	O
c	O
##rea	O
##tin	O
##ine	O
)	O
and	O
potassium	O
(	O
K	O
)	O
(	O
3	O
.	O
6	O
±	O
2	O
.	O
5	O
m	O
##M	O
/	O
m	O
##M	O
c	O
##rea	O
##tin	O
##ine	O
)	O
–	O
as	O
expected	O
,	O
while	O
the	O
least	O
abundant	O
was	O
r	O
##hen	O
##ium	O
(	O
Re	O
)	O
with	O
a	O
lower	O
limit	O
of	O
q	O
##uant	O
##ification	O
by	O
I	O
##CP	O
-	O
MS	O
of	O
96	O
p	O
##M	O
/	O
m	O
##M	O
c	B
##rea	I
##tin	I
##ine	I
.	O

Advanced	O
models	O
were	O
adjusted	O
with	O
the	O
same	O
three	O
co	O
##var	O
##iant	O
##s	O
of	O
basic	O
models	O
and	O
11	O
more	O
metabolic	O
markers	O
,	O
including	O
fast	O
##ing	O
and	O
post	O
##pra	O
##ndi	O
##al	O
glucose	S
,	O
fast	O
##ing	O
and	O
post	O
##pra	O
##ndi	O
##al	O
insulin	O
,	O
T	O
##C	O
,	O
T	B
##G	I
,	O
HD	O
##L	O
,	O
L	O
##D	O
##L	O
,	O
SP	S
,	O
D	O
##P	O
,	O
and	O
H	O
##OM	O
##A	O
-	O
I	O
##R	O
.	O

Our	O
previous	O
results	O
based	O
on	O
the	O
E	O
##SC	O
##C	O
plasma	O
meta	O
##bol	O
##omi	O
##cs	O
also	O
revealed	O
that	O
the	O
levels	O
of	O
car	B
##ni	I
##tine	I
##s	I
changed	O
in	O
patients	O
.	O

Met	O
##ab	O
##oli	O
##tes	O
involved	O
in	O
the	O
u	B
##rea	I
cycle	O
were	O
also	O
increased	O
after	O
le	O
##pt	O
##in	O
replacement	O
(	O
and	O
)	O
.	O

The	O
serum	O
samples	O
were	O
de	O
##p	O
##rote	O
##ini	O
##zed	O
using	O
met	B
##han	I
##ol	I
at	O
a	O
final	O
concentration	O
of	O
20	O
%	O
prior	O
to	O
measurement	O
.	O

Among	O
s	B
##phi	I
##ngo	I
##lip	I
##id	I
species	O
measured	O
in	O
human	O
and	O
monkey	O
plasma	O
,	O
GM	B
##3	I
,	O
Ce	B
##r	I
and	O
G	O
##lu	O
##C	O
##er	O
were	O
found	O
to	O
be	O
significantly	O
different	O
in	O
quantities	O
.	O

Alternatively	O
,	O
given	O
the	O
inflammatory	O
his	O
##top	O
##ath	O
##ological	O
nature	O
of	O
K	O
##S	O
lesions	O
,	O
it	O
is	O
con	O
##ce	O
##ivable	O
that	O
the	O
induction	O
of	O
the	O
k	B
##yn	I
##uren	I
##ine	I
pathway	O
may	O
in	O
##hibit	O
emergence	O
of	O
K	O
##S	O
by	O
suppression	O
of	O
l	O
##ymph	O
##oc	O
##yte	O
proliferation	O
.	O

For	O
plasma	O
specimens	O
,	O
change	O
in	O
concentration	O
from	O
base	O
##line	O
to	O
final	O
for	O
a	O
group	O
of	O
3	O
compounds	O
(	B
1	B
,	I
3	I
-	I
dim	I
##eth	I
##yl	I
##ura	I
##te	I
,	O
as	B
##par	I
##ty	I
##l	I
##phe	I
##ny	I
##lal	I
##ani	I
##ne	I
,	O
and	O
p	B
##hen	I
##yl	I
##car	I
##ni	I
##tine	I
)	O
best	O
predicted	O
Δ	O
##UP	O
##DR	O
##S	O
##2	O
+	O
3	O
.	O

The	O
changes	O
in	O
the	O
levels	O
of	O
p	B
##yr	I
##u	I
##vate	I
,	O
la	B
##ct	I
##ate	I
,	O
ma	B
##late	I
and	O
c	B
##it	I
##rate	I
raise	O
the	O
possibility	O
of	O
certain	O
pathway	O
(	O
s	O
)	O
in	O
which	O
these	O
three	O
meta	O
##bol	O
##ites	O
are	O
connected	O
.	O

The	O
second	O
and	O
third	O
major	O
pathways	O
of	O
gut	O
micro	O
##bial	O
activity	O
concern	O
the	O
di	O
##stal	O
co	O
##lon	O
##ic	O
put	O
##re	O
##fa	O
##ction	O
of	O
proteins	O
by	O
the	O
micro	O
##bio	O
##ta	O
,	O
which	O
leads	O
to	O
the	O
production	O
of	O
4	B
-	I
c	I
##res	I
##ol	I
from	O
t	B
##yr	I
##os	I
##ine	I
and	O
p	B
##hen	I
##yla	I
##ce	I
##ty	I
##l	I
##g	I
##lut	I
##amine	I
from	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
;	O
4	B
-	I
C	I
##res	I
##ol	I
is	O
O	O
-	O
su	O
##lf	O
##ated	O
in	O
the	O
liver	O
and	O
ex	O
##cre	O
##ted	O
in	O
the	O
urine	O
.	O

In	O
the	O
Be	O
##MI	O
##M	O
study	O
,	O
a	O
total	O
of	O
12	O
meta	O
##bol	O
##ites	O
(	O
8	O
amino	O
acids	O
,	O
free	O
car	B
##ni	I
##tine	I
,	O
3	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
)	O
were	O
identified	O
to	O
show	O
significant	O
associations	O
between	O
infant	O
weight	O
or	O
B	O
##MI	O
z	O
-	O
score	O
change	O
from	O
1	O
to	O
4	O
months	O
of	O
age	O
.	O

The	O
percent	O
blood	O
glucose	S
reduction	O
##s	O
of	O
DC	O
##M	O
leaf	O
extract	O
##s	O
at	O
25	O
,	O
50	O
,	O
100	O
,	O
and	O
200	O
mg	O
/	O
kg	O

The	O
mobile	O
phase	O
consisted	O
of	O
5	O
m	O
##M	O
am	B
##mon	I
##ium	I
format	O
##e	O
:	O
ace	O
##ton	O
##it	O
##ril	O
##e	O
(	O
10	O
:	O
90	O
,	O
v	O
/	O
v	O
)	O
,	O
which	O
was	O
run	O
at	O
a	O
flow	O
-	O
rate	O
of	O
0	O
.	O
6	O
m	O
##L	O
/	O
min	O
.	O

Level	O
##s	O
of	O
3	O
-	O
HP	O
##MA	O
in	O
the	O
urine	O
of	O
35	O
smoke	O
##rs	O
were	O
(	O
mean	O
±	O
S	O
.	O
D	O
.	O
)	O
395	O
##0	O
±	O
295	O
##0	O
pm	O
##ol	O
/	O
mg	O
c	B
##rea	I
##tin	I
##ine	I
and	O
in	O
21	O
non	O
-	O
smoke	O
##rs	O
were	O
1900	O
±	O
3000	O
pm	O
##ol	O
/	O
mg	O
c	B
##rea	I
##tin	I
##ine	I
.	O

After	O
phase	O
separation	O
,	O
lip	O
##ids	O
are	O
found	O
in	O
the	O
ch	B
##lor	I
##of	I
##orm	I
phase	O
.	O

The	O
al	O
##iq	O
##uo	O
##t	O
was	O
gradient	O
el	O
##uted	O
from	O
a	O
C	O
##18	O
column	O
(	O
Waters	O
AC	O
##Q	O
##UI	O
##TY	O
UP	O
##LC	O
_	O
®	O
B	O
##E	O
##H	O
C	O
##18	O
-	O
2	O
.	O
1	O
##×	O
##50	O
mm	O
;	O
1	O
.	O
7	O
µ	O
m	O
)	O
using	O
ch	O
##orm	O
##ato	O
##graphic	O
grade	O
met	B
##han	I
##ol	I
(	O
purity	O
>	O
99	O
.	O
99	O
%	O
)	O
and	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
(	O
purity	O
>	O
99	O
.	O
99	O
%	O
)	O
as	O
well	O
as	O
water	O
phase	O
containing	O
0	O
.	O
05	O
%	O
per	B
##f	I
##lu	I
##oro	I
##pent	I
##ano	I
##ic	I
acid	I
and	O
0	O
.	O
05	O
%	O
form	B
##ic	I
acid	I
.	O

Both	O
PC	O
84	O
##7	O
2	O
##C	O
and	O
PC	O
209	O
##6	O
4	O
##B	O
knock	O
##down	O
cell	O
lines	O
showed	O
decreased	O
levels	O
of	O
se	B
##rine	I
and	O
g	B
##ly	I
##cine	I
.	O

This	O
finding	O
may	O
have	O
implications	O
for	O
sperm	O
count	O
and	O
couple	O
f	O
##ec	O
##und	O
##ity	O
,	O
but	O
there	O
remains	O
a	O
need	O
for	O
more	O
research	O
to	O
further	O
el	O
##uc	O
##ida	O
##te	O
the	O
mechanisms	O
by	O
which	O
para	B
##ce	I
##tam	I
##ol	I
affects	O
f	O
##ec	O
##und	O
##ity	O
.	O

The	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dic	I
acid	I
(	O
l	O
##ys	O
##o	O
-	O
PA	O
)	O
production	O
occurs	O
by	O
action	O
of	O
auto	B
##ta	I
##xin	I
,	O
a	O
plasma	O
l	O
##ys	O
##op	O
##hos	O
##ph	O
##oli	O
##pas	O
##e	O
D	O
which	O
acts	O
in	O
l	O
##ys	O
##o	O
-	O
PC	O
h	O
##ydro	O
##lysis	O
and	O
promotes	O
l	O
##ys	O
##o	O
-	O
PA	O
’	O
s	O
anti	O
-	O
inflammatory	O
action	O
on	O
mac	O
##rop	O
##hage	O
##s	O
.	O

These	O
were	O
grouped	O
together	O
with	O
the	O
4	O
s	O
##pect	O
##ra	O
from	O
the	O
104	O
s	O
##pect	O
##ra	O
found	O
not	O
to	O
display	O
i	B
##bu	I
##p	I
##ro	I
##fen	I
meta	O
##bol	O
##ites	O
(	O
from	O
here	O
on	O
,	O
referred	O
to	O
as	O
‘	O
C	O
##i	O
’	O
class	O
)	O
giving	O
a	O
total	O
of	O
270	O
s	O
##pect	O
##ra	O
that	O
did	O
not	O
contain	O
i	B
##bu	I
##p	I
##ro	I
##fen	I
meta	O
##bol	O
##ites	O
.	O

Additional	O
studies	O
have	O
shown	O
that	O
u	B
##ric	I
acid	I
released	O
from	O
injured	O
cells	O
constitutes	O
a	O
major	O
end	O
##ogen	O
##ous	O
danger	O
signal	O
that	O
activate	O
##s	O
the	O
N	O
##AL	O
##P	O
##3	O
in	O
##f	O
##lam	O
##mas	O
##ome	O
(	O
also	O
called	O
cry	B
##opy	I
##rin	I
or	O
NL	O
##RP	O
##3	O
)	O
,	O
leading	O
to	O
IL	O
-	O
1	O
##b	O
production	O
as	O
part	O
of	O
the	O
host	O
response	O
to	O
lung	O
inflammation	O
and	O
fi	O
##bro	O
##sis	O
.	O

Evaluation	O
of	O
breath	O
mass	O
s	O
##pect	O
##ra	O
at	O
varying	O
ex	O
##hala	O
##tion	O
flow	O
rates	O
and	O
using	O
s	B
##pi	I
##rome	I
##try	I
filters	O
.	O

Another	O
previous	O
study	O
analyzed	O
the	O
effect	O
of	O
endurance	O
exercise	O
on	O
u	O
##rina	O
##ry	O
ta	B
##uri	I
##ne	I
ex	O
##cre	O
##tion	O
.	O

Go	O
to	O
:	O
Alt	O
##ered	O
serum	O
pro	B
##line	I
levels	O
are	O
related	O
to	O
cancer	O
metabolism	O
.	O

Based	O
on	O
previous	O
reports	O
,	O
serum	O
CR	O
##P	O
>	O
10	O
mg	O
/	O
L	O
and	O
neo	B
##pt	I
##eri	I
##n	I
>	O
10	O
nm	O
##ol	O
/	O
L	O
were	O
considered	O
to	O
be	O
clinical	O
##ly	O
relevant	O
indicators	O
of	O
current	O
inflammation	O
(	O
–	O
)	O
.	O

By	O
removing	O
heavily	O
con	O
##tri	O
##but	O
##ive	O
meta	O
##bol	O
##ites	O
,	O
such	O
as	O
la	B
##ct	I
##ate	I
,	O
the	O
PC	O
became	O
a	O
second	O
bio	O
##mark	O
##er	O
of	O
HC	O
##C	O
tissue	O
(	O
data	O
not	O
shown	O
)	O
.	O

It	O
is	O
worth	O
to	O
note	O
that	O
D	B
-	I
as	I
##par	I
##tic	I
acid	I
is	O
also	O
an	O
important	O
metabolic	O
intermediate	O
in	O
u	B
##rea	I
cycle	O
,	O
and	O
it	O
is	O
produced	O
from	O
c	B
##it	I
##ru	I
##llin	I
##e	I
.	O

In	O
##sul	O
##in	O
sensitivity	O
was	O
increased	O
by	O
Pi	B
##o	I
&	I
Omega	I
-	I
3	I
,	O
and	O
tended	O
to	O
be	O
improved	O
by	O
Pi	O
##o	O
compared	O
with	O
Omega	B
-	I
3	I
(	O
Table	O
)	O
,	O
which	O
is	O
also	O
in	O
agreement	O
with	O
the	O
induction	O
of	O
ad	O
##ip	O
##one	O
##ct	O
##in	O
by	O
both	O
Pi	O
##o	O
&	O
Omega	B
-	I
3	I
and	O
Pi	O
##o	O
(	O
Table	O
)	O
.	O

Co	O
##ef	O
##ficient	O
##s	O
of	O
variance	O
of	O
the	O
fatty	O
acids	O
of	O
interest	O
(	O
a	O
##rac	O
##hi	O
##don	O
##ic	O
acid	O
,	O
total	O
o	B
##me	I
##ga	I
-	I
3	I
/	I
6	I
fatty	O
acids	O
)	O
are	O
all	O
<	O
13	O
%	O
in	O
this	O
laboratory	O
.	O

Box	O
plots	O
for	O
the	O
relative	O
metabolic	O
concentrations	O
(	O
normal	O
vs	O
.	O
tumor	O
)	O
of	O
put	O
##ative	O
bio	O
##mark	O
##ers	O
in	O
the	O
discovery	O
sample	O
set	O
:	O
(	O
A	O
)	O
ad	B
##eno	I
##sin	I
##e	I
mon	I
##op	I
##hos	I
##phate	I
(	O
AM	O
##P	O
)	O
,	O
(	O
B	O
)	O
unknown	O
ID	O
##13	O
##5	O
##7	O
,	O
(	O
C	O
)	O
unknown	O
ID	O
##20	O
##25	O
,	O
(	O
D	O
)	O
sperm	B
##id	I
##ine	I
,	O
and	O
(	O
E	O
)	O
u	B
##rac	I
##il	I
.	O

Micro	O
##bio	O
##ta	O
from	O
donor	O
D	O
##3	O
were	O
effectively	O
meta	O
##bol	O
##izing	O
re	B
##s	I
##ver	I
##at	I
##rol	I
(	O
20	O
±	O
1	O
%	O
occurred	O
after	O
48	O
h	O
)	O
,	O
and	O
dem	B
##eth	I
##yla	I
##ting	I
th	I
##una	I
##l	I
##ben	I
##e	I
to	O
is	O
##ores	O
##ver	O
##at	O
##rol	O
,	O
but	O
was	O
the	O
least	O
effective	O
in	O
meta	O
##bol	O
##izing	O
o	B
##xy	I
##res	I
##ver	I
##at	I
##rol	I
(	O
84	O
±	O
1	O
%	O
occurred	O
after	O
48	O
h	O
)	O
.	O

Several	O
el	O
##uen	O
##ts	O
were	O
tested	O
,	O
including	O
am	B
##mon	I
##ium	I
phosphate	I
,	O
am	B
##mon	I
##ium	I
c	I
##it	I
##rate	I
,	O
and	O
am	B
##mon	I
##ium	I
bi	O
##car	O
##bon	O
##ate	O
.	O

This	O
approach	O
reduced	O
the	O
multi	O
##var	O
##iate	O
data	O
for	O
projection	O
on	O
the	O
2	O
coordinate	O
axes	O
resulting	O
in	O
the	O
maximum	O
separation	O
between	O
the	O
pro	O
-	O
and	O
anti	O
-	O
T	O
##GR	O
##L	O
groups	O
based	O
on	O
fatty	O
acid	O
and	O
o	B
##xy	I
##lip	I
##in	I
abundance	O
.	O

Therefore	O
,	O
in	O
the	O
following	O
investigation	O
into	O
the	O
effect	O
of	O
the	O
meal	O
on	O
pro	O
-	O
and	O
anti	O
-	O
at	O
##her	O
##ogenic	O
T	O
##GR	O
##L	O
composition	O
,	O
o	B
##xy	I
##lip	I
##in	I
and	O
fatty	O
acid	O
abundance	O
are	O
expressed	O
as	O
a	O
ratio	O
of	O
post	O
##pra	O
##ndi	O
##al	O
/	O
fast	O
##ing	O
.	O

Because	O
ch	B
##olin	I
##e	I
is	O
a	O
precursor	O
of	O
beta	B
##ine	I
,	O
the	O
de	O
##ple	O
##tion	O
of	O
both	O
beta	B
##ine	I
and	O
ch	B
##olin	I
##e	I
in	O
PC	O
may	O
be	O
inter	O
##rel	O
##ated	O
(	O
Supporting	O
Information	O
Figure	O
##s	O
S	O
##2	O
and	O
S	O
##6	O
)	O
.	O

Therefore	O
,	O
a	O
single	O
meta	O
##bol	O
##ite	O
explains	O
up	O
to	O
16	O
.	O
2	O
%	O
of	O
the	O
observed	O
variance	O
in	O
Δ	B
##g	I
##lu	I
##cos	I
##e	I
(	O
see	O
Table	O
)	O
.	O

The	O
E	O
##D	O
##50	O
values	O
of	O
P	O
,	O
P	O
-	O
1	O
,	O
P	O
-	O
2	O
;	O
IP	S
,	O
IP	O
-	O
1	O
,	O
and	O
IP	O
-	O
2	O
were	O
18	O
.	O
08	O
±	O
4	O
.	O
32	O
,	O
8	O
.	O
54	O
±	O
3	O
.	O
14	O
,	O
7	O
.	O
78	O
±	O
0	O
.	O
11	O
;	O
17	O
.	O
09	O
±	O
1	O
.	O
55	O
,	O
5	O
.	O
63	O
±	O
0	O
.	O
55	O
,	O
and	O
3	O
.	O
49	O
±	O
0	O
.	O
11	O
μ	O
##M	O
,	O
respectively	O
.	O

Each	O
tissue	O
sample	O
(	O
about	O
15	O
mg	O
)	O
was	O
individually	O
placed	O
in	O
D	O
_	O
2	O
O	O
sa	B
##line	I
and	O
inserted	O
into	O
a	O
4	O
mm	O
diameter	O
z	B
##ir	I
##con	I
##ium	I
oxide	I
rotor	O
for	O
all	O
N	O
##MR	O
acquisitions	O
.	O

A	O
competing	O
reaction	O
to	O
NO	O
production	O
is	O
cat	O
##aly	O
##zed	O
by	O
a	O
##rg	O
##inas	O
##e	O
enzymes	O
to	O
generate	O
or	B
##ni	I
##thin	I
##e	I
and	O
u	B
##rea	I
.	O

P	O
,	O
N	O
–	O
meta	O
##bol	O
##ite	O
identified	O
in	O
positive	O
or	O
negative	O
E	O
##SI	O
mode	O
,	O
respectively	O
;	O
N	O
##S	O
–	O
non	O
-	O
significant	O
;	O
*	O
-	O
these	O
p	O
-	O
values	O
remain	O
<	O
0	O
.	O
05	O
after	O
correction	O
by	O
F	O
##DR	O
;	O
N	O
vs	B
C	I
-	I
(	I
+	I
)	I
/	I
(	I
−	I
)	I
means	O
increased	O
/	O
decreased	O
abundance	O
in	O
C	O
##LL	O
patients	O
who	O
do	O
not	O
require	O
treatment	O
in	O
comparison	O
to	O
controls	O
;	O
A	O
vs	B
C	I
-	I
(	I
+	I
)	I
/	I
(	I
−	I
)	I
means	O
increased	O
/	O
decreased	O
abundance	O
in	O
C	O
##LL	O
patients	O
in	O
aggressive	O
state	O
of	O
the	O
disease	O
in	O
comparison	O
to	O
controls	O
;	O

In	O
particular	O
,	O
levels	O
of	O
p	B
##yr	I
##og	I
##lut	I
##ami	I
##c	I
acid	I
,	O
g	B
##lut	I
##ami	I
##c	I
acid	I
,	O
g	B
##ly	I
##cine	I
and	O
c	B
##ys	I
##tein	I
##e	I
,	O
were	O
significantly	O
higher	O
in	O
I	O
##B	O
##D	O
children	O
in	O
the	O
course	O
of	O
the	O
study	O
.	O

One	O
al	O
##iq	O
##uo	O
##t	O
was	O
analyzed	O
using	O
acidic	O
positive	O
ion	O
conditions	O
,	O
ch	O
##roma	O
##to	O
##graphical	O
##ly	O
op	O
##ti	O
##mized	O
for	O
more	O
h	B
##ydro	I
##phi	I
##lic	I
compounds	O
.	O

The	O
concentration	O
of	O
la	B
##ct	I
##ate	I
,	O
an	O
end	O
product	O
of	O
g	O
##ly	O
##co	O
##lysis	O
,	O
was	O
significantly	O
elevated	O
,	O
whereas	O
other	O
intermediate	O
meta	O
##bol	O
##ites	O
,	O
e	O
.	O
g	O
.	O
g	B
##ly	I
##cer	I
##ald	I
##eh	I
##yd	I
##e	I
3	I
-	I
phosphate	I
(	O
3	O
##P	O
##G	O
)	O
and	O
p	B
##hos	I
##ph	I
##oe	I
##no	I
##l	I
##py	I
##ru	I
##vate	I
(	O
P	O
##EP	O
)	O
were	O
significantly	O
decreased	O
in	O
the	O
O	O
##C	O
group	O
.	O

The	O
application	O
of	O
this	O
approach	O
for	O
the	O
analysis	O
of	O
fatty	O
acids	O
in	O
human	O
serum	O
demonstrated	O
the	O
existence	O
of	O
two	O
double	O
bond	O
is	O
##omer	O
##s	O
of	O
l	B
##ino	I
##len	I
##ic	I
acid	I
(	O
i	O
.	O
e	O
.	O
,	O
Δ	B
_	I
6	I
,	I
9	I
,	I
12	I
18	I
:	I
3	I
,	O
γ	B
-	I
l	I
##ino	I
##len	I
##ic	I
acid	I
(	O
G	O
##LA	O
)	O
,	O
and	O
Δ	B
_	I
9	I
,	I
12	I
,	I
15	I
18	I
:	I
3	I
,	O
α	B
-	I
l	I
##ino	I
##len	I
##ic	I
acid	I
(	O
AL	O
##A	O
)	O
)	O
.	O

Among	O
those	O
samples	O
,	O
a	O
subset	O
of	O
100	O
urine	O
samples	O
were	O
chosen	O
for	O
analysis	O
balancing	O
the	O
following	O
criteria	O
:	O
(	O
a	O
)	O
prior	O
##itis	O
##e	O
the	O
analysis	O
of	O
at	O
least	O
one	O
urine	O
sample	O
from	O
each	O
subject	O
;	O
(	O
b	O
)	O
ma	O
##xi	O
##mise	O
the	O
number	O
of	O
urine	O
samples	O
related	O
to	O
the	O
day	O
where	O
V	O
##OC	O
and	O
PA	O
##H	O
were	O
sampled	O
concurrently	O
;	O
(	O
c	O
)	O
select	O
wherever	O
possible	O
urine	O
samples	O
representative	O
of	O
days	O
with	O
reported	O
ET	O
##S	O
exposure	O
,	O
which	O
was	O
verified	O
with	O
the	O
levels	O
of	O
3	B
-	I
et	I
##hen	I
##yl	I
##py	I
##rid	I
##ine	I
in	O
personal	O
exposure	O
.	O

Among	O
11	O
meta	O
##bol	O
##ites	O
associated	O
with	O
incident	O
type	O
2	O
diabetes	O
,	O
we	O
further	O
adjusted	O
for	O
random	O
glucose	S
and	O
H	O
##b	O
##A	O
##1	O
##c	O
levels	O
and	O
found	O
that	O
all	O
meta	O
##bol	O
##ites	O
remained	O
significantly	O
associated	O
with	O
type	O
2	O
diabetes	O
risk	O
.	O

The	O
activation	O
of	O
pu	B
##rine	I
receptors	O
in	O
the	O
R	O
##P	O
##E	O
may	O
also	O
contribute	O
to	O
the	O
accumulation	O
of	O
d	O
##rus	O
##en	O
,	O
and	O
to	O
drive	O
the	O
development	O
of	O
ch	O
##oro	O
##idal	O
neo	O
##vas	O
##cular	O
##ization	O
.	O

However	O
,	O
the	O
mechanism	O
for	O
g	B
##uan	I
##ido	I
##ace	I
##tic	I
acid	I
to	O
first	O
meta	O
##bol	O
##ize	O
to	O
c	B
##rea	I
##tine	I
and	O
then	O
meta	O
##bol	O
##ize	O
to	O
u	B
##rea	I
and	O
c	B
##rea	I
##tin	I
##ine	I
might	O
be	O
distinctly	O
enhanced	O
by	O
considerations	O
of	O
reduced	O
g	B
##uan	I
##ido	I
##ace	I
##tic	I
acid	I
,	O
and	O
there	O
was	O
no	O
prominently	O
changed	O
c	B
##rea	I
##tine	I
but	O
increased	O
c	B
##rea	I
##tin	I
##ine	I
and	O
u	B
##rea	I
levels	O
.	O

Part	O
##ici	O
##pants	O
received	O
the	O
research	O
cigarettes	O
(	O
either	O
men	B
##th	I
##ol	I
or	O
non	O
-	O
men	O
##th	O
##ol	O
according	O
to	O
their	O
preference	O
)	O
free	O
of	O
charge	O
over	O
a	O
period	O
of	O
20	O
weeks	O
.	O

Kaplan	O
##−	O
##M	O
##ei	O
##er	O
curve	O
est	O
##imation	O
of	O
the	O
survival	O
rate	O
of	O
the	O
patients	O
according	O
to	O
the	O
ch	B
##ole	I
##ster	I
##ol	I
to	O
la	B
##ct	I
##ate	I
ratio	O
at	O
the	O
cut	O
##off	O
value	O
.	O

I	O
##dent	O
##ified	O
meta	O
##bol	O
##ites	O
with	O
VIP	O
values	O
≥	O
1	O
were	O
:	O
la	B
##ct	I
##ate	I
,	O
glucose	S
,	O
p	B
##yr	I
##u	I
##vate	I
,	O
g	B
##lut	I
##amine	I
,	O
g	B
##lut	I
##ama	I
##te	I
,	O
al	B
##ani	I
##ne	I
,	O
v	B
##ali	I
##ne	I
,	O
le	B
##uc	I
##ine	I
,	O
g	B
##ly	I
##cine	I
,	O
c	B
##rea	I
##tine	I
,	O
c	B
##rea	I
##tin	I
##ine	I
,	O
u	B
##rea	I
,	O
ace	B
##tate	I
,	O
ace	B
##to	I
##ace	I
##tate	I
and	O
β	B
-	I
h	I
##ydro	I
##xy	I
##bury	I
##rate	I
.	O

Li	O
##pid	O
meta	O
##bol	O
##ites	O
with	O
a	O
variable	O
importance	O
in	O
the	O
projection	O
(	O
VIP	O
)	O
score	O
>	O
1	O
were	O
considered	O
to	O
be	O
the	O
meta	O
##bol	O
##ites	O
responsible	O
for	O
the	O
differences	O
between	O
healthy	O
controls	O
and	O
A	B
##F	I
patients	O
.	O

The	O
concentration	O
of	O
the	O
ground	O
extract	O
was	O
adjusted	O
by	O
adding	O
80	O
%	O
met	B
##han	I
##ol	I
to	O
be	O
equivalent	O
to	O
32	O
mg	O
of	O
initial	O
wet	O
weight	O
per	O
mill	O
##ili	O
##ter	O
of	O
met	B
##han	I
##ol	I
extract	O
.	O

Finally	O
,	O
the	O
mean	O
he	B
##x	I
##ose	I
(	O
sum	O
of	O
he	B
##x	I
##ose	I
,	O
widely	O
represented	O
by	O
glucose	S
:	O
90	O
–	O
95	O
%	O
)	O
concentration	O
was	O
510	O
##2	O
##±	O
##5	O
##9	O
##5	O
μ	O
##mo	O
##l	O
/	O
L	O
,	O
with	O
a	O
median	O
of	O
50	O
##8	O
##8	O
μ	O
##mo	O
##l	O
/	O
L	O
(	O
inter	O
##qua	O
##rt	O
##ile	O
range	O
46	O
##9	O
##8	O
–	O
54	O
##5	O
##2	O
)	O
and	O
a	O
range	O
of	O
35	O
##45	O
to	O
88	O
##9	O
##8	O
μ	O
##mo	O
##l	O
/	O
L	O
.	O

Hero	O
##in	O
,	O
or	O
di	B
##ace	I
##ty	I
##lm	I
##or	I
##phine	I
,	O
is	O
not	O
a	O
prescription	O
op	O
##iate	O
.	O

In	O
particular	O
,	O
high	O
levels	O
of	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
my	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
-	I
1	I
-	I
phosphate	I
,	O
c	B
##it	I
##ric	I
acid	I
,	O
f	B
##uma	I
##rate	I
,	O
g	B
##ly	I
##cer	I
##ol	I
-	I
3	I
-	I
phosphate	I
,	O
and	O
fatty	O
acids	O
were	O
found	O
in	O
PC	O
##a	O
bone	O
meta	O
##sta	O
##ses	O
samples	O
compared	O
to	O
normal	O
bone	O
.	O

In	O
agreement	O
with	O
these	O
findings	O
,	O
our	O
meta	O
##bol	O
##omi	O
##cs	O
results	O
revealed	O
substantially	O
higher	O
levels	O
of	O
ad	B
##eno	I
##sin	I
##e	I
,	O
in	B
##os	I
##ine	I
and	O
pu	B
##rine	I
,	O
as	O
well	O
as	O
a	O
moderately	O
lower	O
concentration	O
of	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
in	O
the	O
BA	O
##V	O
patients	O
of	O
this	O
study	O
,	O
which	O
were	O
signs	O
of	O
ATP	S
degradation	O
that	O
possibly	O
arose	O
from	O
a	O
lack	O
of	O
oxygen	O
supply	O
.	O

Therefore	O
,	O
the	O
shift	O
in	O
B	O
##H	O
##MT	O
-	O
R	O
after	O
the	O
RB	O
period	O
may	O
be	O
at	O
##tri	O
##but	O
##able	O
to	O
reduced	O
insulin	O
secret	O
##ion	O
,	O
most	O
likely	O
due	O
to	O
the	O
r	O
##ye	O
factor	O
[	O
-	O
]	O
,	O
and	O
to	O
higher	O
availability	O
of	O
beta	B
##ine	I
as	O
a	O
reaction	O
precursor	O
.	O

The	O
but	B
##ano	I
##l	I
layer	O
was	O
dried	O
by	O
Speed	O
-	O
v	O
##ac	O
e	O
##va	O
##por	O
##ation	O
and	O
re	O
##con	O
##stituted	O
by	O
v	O
##ortex	O
##ing	O
in	O
10	O
μ	O
##L	O
of	O
10	O
%	O
CH	O
_	O
3	O
C	O
##N	O
.	O

B	O
##rea	O
##st	O
cell	O
lines	O
(	O
basal	O
-	O
like	O
or	O
me	O
##sen	O
##chy	O
##mal	O
breast	O
cancer	O
—	O
BT	O
##5	O
##4	O
##9	O
,	O
H	O
##S	O
##5	O
##7	O
##8	O
,	O
MD	O
##A	O
MB	O
231	O
,	O
MD	O
##A	O
MB	O
43	O
##6	O
,	O
and	O
MD	O
##A	O
MB	O
46	O
##8	O
;	O
l	O
##umi	O
##nal	O
breast	O
cancer	O
—	O
BT	O
##47	O
##4	O
,	O
MC	O
##F	O
-	O
7	O
,	O
MD	O
##A	O
MB	O
45	O
##3	O
,	O
and	O
T	O
##47	O
##D	O
)	O
were	O
purchased	O
from	O
American	O
Type	O
Culture	O
Collection	O
(	O
Man	O
##ass	O
##as	O
,	O
VA	S
;	O
see	O
Su	O
##pp	O
##lement	O
##ary	O
Table	O
1	O
for	O
description	O
of	O
the	O
cell	O
lines	O
)	O
.	O

2	O
‐	O
O	O
##x	O
##op	O
##rop	O
##ana	O
##l	O
is	O
a	O
reactive	O
carbon	O
##yl	O
compound	O
produced	O
end	O
##ogen	O
##ously	O
by	O
the	O
metabolism	O
of	O
ace	B
##tone	I
and	O
the	O
cat	O
##ab	O
##olis	O
##m	O
of	O
di	B
##hy	I
##dr	I
##ox	I
##ya	I
##ce	I
##tone	I
phosphate	I
,	O
g	B
##ly	I
##cer	I
##ald	I
##eh	I
##yd	I
##e	I
‐	I
3	I
‐	I
phosphate	I
and	O
th	B
##re	I
##oni	I
##ne	I
45	O
,	O
46	O
.	O

However	O
,	O
two	O
L	O
##MI	O
##s	O
(	O
49	O
##6	O
.	O
3	O
m	O
/	O
z	O
at	O
an	O
R	O
##T	O
of	O
18	O
.	O
9	O
min	O
and	O
54	O
##4	O
.	O
3	O
m	O
/	O
z	O
at	O
an	O
R	O
##T	O
of	O
18	O
.	O
3	O
min	O
)	O
,	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
(	O
L	O
##ys	O
##o	O
##PC	O
)	O
(	O
16	O
:	O
0	O
)	O
and	O
L	B
##ys	I
##o	I
##PC	I
(	I
20	I
:	I
4	I
(	I
5	I
##Z	I
,	I
8	I
##Z	I
,	I
11	I
##Z	I
,	I
14	I
##Z	I
)	I
)	I
,	O
identified	O
according	O
to	O
their	O
MS	O
/	O
MS	O
patterns	O
in	O
the	O
analyses	O
of	O
the	O
se	O
##ra	O
of	O
BT	O
##C	O
patients	O
,	O
could	O
disc	O
##rim	O
##inate	O
between	O
PC	O
and	O
BT	O
##C	O
(	O
Fi	O
##gs	O
.	O
and	O
,	O
Table	O
)	O
.	O

In	O
brief	O
,	O
P	O
##EA	O
##R	O
was	O
a	O
prospective	O
,	O
multi	O
##cent	O
##er	O
study	O
that	O
recruited	O
mild	O
to	O
moderate	O
h	O
##yper	O
##tensive	O
participants	O
,	O
aged	O
17	O
–	O
65	O
years	O
,	O
with	O
a	O
primary	O
goal	O
of	O
evaluating	O
the	O
role	O
of	O
genetics	O
on	O
BP	O
response	O
of	O
HC	O
##T	O
##Z	O
and	O
ate	B
##no	I
##lo	I
##l	I
mon	O
##otherapy	O
and	O
combination	O
therapy	O
of	O
both	O
drugs	O
.	O

The	O
present	O
study	O
indicated	O
that	O
x	B
##yl	I
##ose	I
and	O
C	O
_	O
4	O
sugar	O
2	O
were	O
higher	O
in	O
the	O
excess	O
than	O
in	O
the	O
deficiency	O
group	O
.	O

Semi	O
-	O
synthetic	O
op	O
##iate	O
##s	O
are	O
produced	O
from	O
m	B
##or	I
##phine	I
or	O
the	O
##ba	O
##ine	O
by	O
chemical	O
##ly	O
modify	O
##ing	O
the	O
h	O
##ydro	O
##xy	O
##l	O
groups	O
or	O
other	O
parts	O
of	O
the	O
op	O
##io	O
##id	O
al	O
##kal	O
##oids	O
.	O

C	O
=	O
,	O
L	O
##3	O
-	O
(	O
CH	O
_	O
2	O
)	O
n	O
-	O
,	O
L	O
##4	O
CH	O
_	O
2	O
CH	O
_	O
2	O
CO	O
,	O
L	O
##5	O
-	O
CH	O
_	O
2	O
C	O
=	O
C	O
-	O
,	O
L	O
##6	O
CH	O
_	O
2	O
CO	O
,	O
L	O
##7	O
C	O
=	O
CC	O
##H	O
_	O
2	O
C	O
=	O
C	O
,	O
L	O
##8	O
-	O
CH	O
=	O
CH	O
-	O
,	O
Lac	O
Lac	B
##tate	I
,	O
Le	O
##u	O
Le	B
##uc	I
##ine	I
,	O
L	O
##ys	O
L	B
##ys	I
##ine	I
,	O
Met	O
Met	B
##hi	I
##oni	I
##ne	I
,	O
N	O
##AG	O
N	B
-	I
ace	I
##ty	I
##l	I
g	I
##ly	I
##co	I
##p	I
##rote	I
##in	I
,	O
PA	B
##G	I
Ph	I
##en	I
##yla	I
##ce	I
##ty	I
##l	I
##gly	I
##cine	I
,	O
Ph	O
##e	O
Ph	B
##en	I
##yla	I
##lani	I
##ne	I
,	O
P	O
##yr	O
P	B
##yr	I
##u	I
##vate	I
,	O
Ty	O
##r	O
Ty	B
##ros	I
##ine	I
,	O
Val	O
Val	B
##ine	I

Fat	O
##s	O
comprised	O
22	O
.	O
3	O
%	O
of	O
MC	O
##T	O
and	O
57	O
.	O
3	O
%	O
of	O
high	O
o	B
##le	I
##ic	I
acid	I
sun	O
##flower	O
oils	O
in	O
ca	O
##lor	O
##ic	O
content	O
.	O

Co	O
##mp	O
##aris	O
##on	O
of	O
concentrations	O
of	O
mitochondrial	O
and	O
micro	O
##bial	O
meta	O
##bol	O
##ites	O
in	O
relation	O
to	O
la	B
##ct	I
##ate	I
levels	O
obtained	O
in	O
the	O
serum	O
samples	O
of	O
the	O
patients	O
with	O
late	O
-	O
stage	O
se	O
##psis	O
in	O
Group	O
II	O
(	O
n	O
=	O
22	O
)	O
.	O

For	O
instance	O
,	O
co	B
##en	I
##zy	I
##me	I
Q	I
##10	I
(	O
co	O
##Q	O
##10	O
)	O
,	O
reported	O
to	O
significantly	O
improve	O
symptoms	O
and	O
function	O
in	O
veterans	O
with	O
G	O
##WI	O
,	O
is	O
known	O
to	O
support	O
electron	O
transport	O
in	O
mit	O
##och	O
##ond	O
##ria	O
,	O
in	O
##hibit	O
red	O
##ox	O
changes	O
under	O
cell	O
stress	O
,	O
and	O
protect	O
the	O
cell	O
against	O
free	O
radical	O
injury	O
.	O

Interest	O
##ingly	O
,	O
only	O
for	O
r	O
##s	O
##11	O
##6	O
##8	O
##7	O
##7	O
##65	O
(	B
v	B
##ali	I
##ne	I
-	I
Q	I
##TL	I
)	O
association	O
with	O
risk	O
factors	O
reached	O
nominally	O
significant	O
P	O
-	O
values	O
:	O
specifically	O
glucose	S
(	O
P	O
-	O
value	O
=	O
0	O
.	O
01	O
##3	O
)	O
,	O
H	O
##OM	O
##A	O
,	O
insulin	O
resistance	O
(	O
P	O
-	O
value	O
=	O
0	O
.	O
04	O
##9	O
)	O
and	O
g	B
##yn	I
##oid	I
fat	O
mass	O
(	O
P	O
-	O
value	O
=	O
0	O
.	O
00	O
##3	O
)	O
.	O

U	O
##rina	O
##ry	O
c	B
##rea	I
##tin	I
##ine	I
was	O
ass	O
##ay	O
##ed	O
by	O
the	O
Ha	O
##gers	O
##town	O
Medical	O
Laboratory	O
,	O
Ha	O
##gers	O
##town	O
,	O
MD	O
.	O

As	O
previously	O
discussed	O
by	O
our	O
group	O
,	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
participate	O
in	O
signal	O
trans	O
##duction	O
[	O
,	O
]	O
,	O
and	O
are	O
involved	O
in	O
o	O
##xi	O
##da	O
##tive	O
stress	O
processes	O
in	O
ne	O
##uro	O
##log	O
##ic	O
disorders	O
,	O
namely	O
,	O
in	O
Alzheimer	O
’	O
s	O
disease	O
,	O
which	O
may	O
share	O
important	O
path	O
##ogenic	O
mechanisms	O
with	O
AM	O
##D	O
.	O

The	O
detection	O
limit	O
was	O
1	O
ng	O
/	O
m	O
##L	O
and	O
the	O
q	O
##uant	O
##ification	O
limit	O
5	O
ng	O
/	O
m	O
##L	O
.	O
24	B
##S	I
-	I
OH	I
-	I
Cho	I
##l	I
was	O
reported	O
as	O
plasma	O
levels	O
(	O
ng	O
/	O
m	O
##l	O
)	O
.	O

λ	O
_	O
ma	O
##x	O
,	O
37	O
##8	O
nm	O
(	O
[UNK]	O
,	O
52	O
,	O
200	O
)	O
;	O
H	O
##R	O
##MS	O
calculated	O
for	O
C	O
_	O
22	O
H	O
_	O
30	O
O	O
_	O
2	O
(	O
M	O
+	O
Na	O
)	O
34	O
##9	O
.	O
214	O
##3	O
,	O
observed	O
,	O
34	O
##9	O
.	O
213	O
##6	O
.	O
_	O
1	O
H	O
N	O
##MR	O
(	O
CD	O
##C	O
##l	O
_	O
3	O
)	O
δ	O
,	O
1	O
.	O
00	O
(	O
6	O
##H	O
,	O
s	O
)	O
,	O
1	O
.	O
45	O
–	O
1	O
.	O
43	O
(	O
2	O
##H	O
,	O
m	O
)	O
,	O
1	O
.	O
65	O
–	O
1	O
.	O
57	O
(	O
4	O
##H	O
,	O
m	O
)	O
,	O
1	O
.	O
69	O
(	O
3	O
##H	O
,	O
s	O
)	O
,	O
1	O
.	O
85	O
(	O
3	O
##H	O
,	O
s	O
)	O
,	O
1	O
.	O
99	O
(	O
3	O
##H	O
,	O
s	O
)	O
,	O
2	O
.	O
02	O
(	O
3	O
##H	O
,	O
s	O
)	O
,	O
6	O
.	O
14	O
(	O
3	O
##H	O
,	O
m	O
)	O
,	O
6	O
.	O
19	O
(	O
1	O
##H	O
,	O
d	O
##d	O
,	O
J	O
=	O
13	O
.	O
8	O
,	O
14	O
.	O
2	O
Hz	O
)	O
,	O
6	O
.	O
36	O
(	O
1	O
##H	O
,	O
d	O
,	O
J	O
=	O
11	O
.	O
9	O
Hz	O
)	O
,	O
6	O
.	O
68	O
(	O
1	O
##H	O
,	O
d	O
,	O
J	O
=	O
11	O
.	O
8	O
Hz	O
)	O
,	O
6	O
.	O
77	O
(	O
1	O
##H	O
,	O
d	O
##d	O
,	O
J	O
=	O
14	O
.	O
2	O
,	O
13	O
.	O
8	O
Hz	O
)	O
,	O
6	O
.	O
92	O
(	O
1	O
##H	O
,	O
d	O
##d	O
,	O
J	O
=	O
13	O
.	O
8	O
,	O
11	O
.	O
6	O
Hz	O
)	O
,	O
7	O
.	O
00	O

The	O
is	O
##omer	O
##ic	O
g	B
##lu	I
##cu	I
##ron	I
##ide	I
con	O
##ju	O
##gate	O
##s	O
of	O
H	O
##ON	O
##H	O
-	O
Ph	O
##IP	O
and	O
their	O
is	O
##oto	O
##pical	O
##ly	O
labelled	O
internal	O
standards	O
were	O
monitored	O
by	O
use	O
of	O
the	O
transitions	O
[	O
M	O
+	O
H	O
]	O
_	O
+	O
→	O
[	O
M	O
+	O
H	O
–	O
192	O
]	O
_	O
+	O
and	O
[	O
M	O
+	O
H	O
–	O
193	O
]	O
_	O
+	O
,	O
which	O
are	O
attributed	O
to	O
the	O
loss	O
of	O
the	O
g	B
##lu	I
##cu	I
##ron	I
##ide	I
m	O
##oi	O
##ety	O
and	O
an	O
oxygen	O
atom	O
or	O
loss	O
of	O
the	O
g	B
##lu	I
##cu	I
##ron	I
##ide	I
m	O
##oi	O
##ety	O
and	O
the	O
h	O
##ydro	O
##xy	O
##l	O
group	O
.	O

These	O
features	O
included	O
matches	O
to	O
multiple	O
car	B
##ni	I
##tine	I
add	O
##uc	O
##ts	O
,	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
,	O
and	O
fatty	O
acids	O
.	O

First	O
,	O
of	O
the	O
113	O
patients	O
enrolled	O
in	O
the	O
study	O
,	O
only	O
9	O
developed	O
AP	S
.	O

A	O
group	O
of	O
213	O
healthy	O
individuals	O
(	O
20	O
–	O
75	O
year	O
-	O
old	O
)	O
with	O
normal	O
glucose	S
tolerance	O
was	O
selected	O
from	O
a	O
prospective	O
co	O
##hor	O
##t	O
study	O
called	O
Shanghai	O
Di	O
##abe	O
##tes	O
Study	O
(	O
SH	O
##DS	O
)	O

The	O
multi	O
##var	O
##iable	O
models	O
for	O
serum	O
ethanol	S
concentration	O
were	O
not	O
adjusted	O
for	O
level	O
of	O
alcohol	O
consumption	O
at	O
recruitment	O
.	O

Finally	O
,	O
the	O
presence	O
of	O
a	O
su	B
##lf	I
##oxide	I
(	O
S	O
=	O
O	O
)	O
group	O
was	O
evidenced	O
by	O
the	O
I	O
##R	O
band	O
at	O
1	O
,	O
01	O
##0	O
cm	O
_	O
−	O
##1	O
(	O
Resource	O
_	O
9	O
)	O
.	O

P	O
##las	O
##ma	O
was	O
obtained	O
by	O
cent	O
##ri	O
##fu	O
##gation	O
(	O
1970	O
##g	O
(	O
3000	O
rpm	O
)	O
for	O
10	O
min	O
,	O
+	O
4	O
##°	O
##C	O
,	O
He	O
##tti	O
##ch	O
model	O
R	O
##ota	O
##nta	O
460	O
##R	O
##F	O
cent	O
##ri	O
##fu	O
##ge	O
;	O
Tu	O
##tt	O
##li	O
##gen	O
,	O
Germany	O
)	O
after	O
collection	O
in	O
t	B
##ris	I
##od	I
##ium	I
c	I
##it	I
##rate	I
(	O
3	O
.	O
2	O
%	O
)	O

In	O
case	O
of	O
the	O
Li	B
-	I
He	I
##par	I
##in	I
tube	O
,	O
65	O
of	O
the	O
71	O
total	O
measured	O
levels	O
(	O
1	O
meta	O
##bol	O
##ite	O
in	O
one	O
sample	O
was	O
below	O
lower	O
limit	O
of	O
q	O
##uant	O
##ification	O
(	O
LL	O
##O	O
##Q	O
)	O
)	O
were	O
outside	O
of	O
the	O
acceptance	O
interval	O
(	O
i	O
.	O
e	O
.	O
,	O
91	O
.	O
5	O
%	O
out	O
##liers	O
ranged	O
in	O
the	O
interval	O
of	O
65	O
.	O
4	O
–	O
131	O
.	O
3	O
%	O
)	O
.	O

A	O
##cc	O
##um	O
##ulation	O
of	O
α	O
–	O
H	O
##B	O
is	O
post	O
##ulated	O
to	O
occur	O
in	O
v	O
##ivo	O
when	O
either	O
(	O
a	O
)	O
the	O
formation	O
of	O
α	O
–	O
K	O
##B	O
exceeds	O
the	O
rate	O
of	O
its	O
cat	O
##ab	O
##olis	O
##m	O
,	O
which	O
leads	O
to	O
substrate	O
accumulation	O
,	O
or	O
(	O
b	O
)	O
there	O
is	O
product	O
in	O
##hibition	O
of	O
the	O
de	O
##hy	O
##dr	O
##ogen	O
##ase	O
that	O
cat	O
##aly	O
##zes	O
the	O
conversion	O
of	O
α	O
–	O
K	O
##B	O
to	O
prop	B
##ion	I
##yl	I
-	I
Co	I
##A	I
,	O
.	O

Almost	O
all	O
of	O
the	O
participants	O
(	O
[UNK]	O
%	O
)	O
met	O
the	O
f	B
##olate	I
EA	O
##R	O
just	O
by	O
consuming	O
bread	O
.	O

As	O
an	O
important	O
component	O
of	O
co	O
##lla	O
##gen	O
,	O
the	O
level	O
of	O
pro	B
##line	I
was	O
down	O
-	O
regulated	O
in	O
acute	O
AD	O
patients	O
.	O

Similar	O
exposure	O
to	O
ni	B
##tro	I
##sa	I
##mine	I
##s	I
and	O
1	O
-	O
H	O
##OP	O
in	O
both	O
groups	O
suggests	O
comparable	O
car	O
##cin	O
##ogen	O
exposure	O
among	O
subjects	O
in	O
both	O
groups	O
.	O

C	O
##lea	O
##vage	O
of	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
,	O
by	O
neutral	O
s	O
##phi	O
##ngo	O
##my	O
##elin	O
##ases	O
,	O
results	O
in	O
the	O
formation	O
of	O
both	O
ch	B
##olin	I
##e	I
phosphate	I
and	O
c	B
##era	I
##mi	I
##de	I
.	O

A	O
small	O
portion	O
of	O
ace	B
##ty	I
##l	I
-	I
Co	I
##A	I
is	O
converted	O
into	O
me	B
##val	I
##onic	I
acid	I
(	O
Fi	O
##g	O
.	O

Also	O
,	O
vitamin	O
B	O
_	O
6	O
,	O
rib	B
##of	I
##lav	I
##in	I
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
-	I
t	I
##yr	I
##os	I
##ine	I
-	I
try	I
##pt	I
##op	I
##han	I
bio	O
##sy	O
##nt	O
##hesis	O
,	O
pan	B
##to	I
##the	I
##nate	I
and	O
Co	O
##A	O
,	O
and	O
p	B
##yr	I
##im	I
##id	I
##ine	I
metabolism	O
differed	O
significantly	O
.	O

And	O
the	O
discrimination	O
power	O
of	O
this	O
model	O
was	O
comparable	O
to	O
the	O
model	O
consisting	O
of	O
the	O
four	O
G	O
##C	O
/	O
MS	O
meta	O
##bol	O
##ites	O
(	B
β	B
-	I
al	I
##ani	I
##ne	I
,	O
2	B
,	I
4	I
-	I
di	I
##hy	I
##dr	I
##ox	I
##y	I
##py	I
##rim	I
##id	I
##ine	I
,	O
a	B
##zel	I
##aic	I
acid	I
,	O
and	O
pseudo	B
##uri	I
##dine	I
)	O
in	O
the	O
current	O
bio	O
##mark	O
##er	O
panel	O
.	O

Re	B
##tina	I
##l	I
GT	O
##3	O
was	O
characterized	O
by	O
the	O
abundance	O
of	O
22	O
:	O
1	O
,	O
22	O
:	O
0	O
and	O
24	O
:	O
1	O
FA	O
##s	O
compared	O
to	O
18	O
:	O
0	O
and	O
20	O
:	O
0	O
.	O

Five	O
-	O
fold	O
cross	O
valid	O
##ation	O
identified	O
the	O
c	B
##rea	I
##tine	I
and	O
c	B
##rea	I
##tin	I
##ine	I
peaks	O
as	O
the	O
only	O
peaks	O
being	O
selected	O
in	O
3	O
of	O
the	O
5	O
combinations	O
.	O

Sam	O
##ples	O
were	O
th	O
##awed	O
and	O
glucose	S
measured	O
as	O
described	O
above	O
.	O

It	O
has	O
also	O
been	O
shown	O
to	O
have	O
the	O
function	O
of	O
protection	O
against	O
g	B
##lut	I
##ama	I
##te	I
ex	O
##ci	O
##to	O
##to	O
##xi	O
##city	O
and	O
prevention	O
of	O
e	O
##pile	O
##ptic	O
seizure	O
##s	O
.	O

The	O
implementation	O
of	O
prevent	O
##ive	O
the	O
##rap	O
##ies	O
on	O
high	O
risk	O
individuals	O
is	O
possible	O
considering	O
try	B
##pt	I
##op	I
##han	I
level	O
,	O
along	O
with	O
other	O
meta	O
##bol	O
##ites	O
and	O
/	O
or	O
clinical	O
markers	O
associated	O
with	O
T	O
##2	O
##D	O
risk	O
.	O

Statistical	O
differences	O
were	O
determined	O
using	O
Tu	O
##key	O
’	O
s	O
multiple	O
comparisons	O
where	O
significant	O
interactions	O
were	O
observed	O
B	O
##MI	O
body	O
mass	O
index	O
,	O
T	B
##G	I
t	I
##rig	I
##ly	I
##cer	I
##ides	I
,	O
L	O
##D	O
##L	O
low	O
-	O
density	O
lip	O
##op	O
##rote	O
##in	O
,	O

The	O
ch	O
##roma	O
##to	O
##graphic	O
fraction	O
containing	O
MMA	O
_	O
III	O
was	O
also	O
collected	O
and	O
treated	O
with	O
hydrogen	B
per	I
##oxide	I
(	O
H	O
_	O
2	O
O	O
_	O
2	O
)	O
to	O
render	O
the	O
oxidation	O
of	O
MMA	O
_	O
III	O
to	O
MMA	O
_	O
V	O
.	O

T	O
##iss	O
##ue	O
blocks	O
were	O
section	O
##ed	O
at	O
20	O
µ	O
m	O
and	O
stained	O
with	O
hem	B
##ato	I
##xy	I
##lin	I
and	O
e	B
##os	I
##in	I
to	O
del	O
##ine	O
##ate	O
tumor	O
and	O
healthy	O
areas	O
in	O
each	O
block	O
.	O

We	O
found	O
low	O
concentrations	O
of	O
the	O
o	B
##me	I
##ga	I
-	I
3	I
un	O
##sat	O
##ura	O
##ted	O
fatty	O
acid	O
do	O
##cos	O
##ah	O
##ex	O
##aen	O
##oi	O
##c	O
acid	O
(	O
D	O
##HA	O
)	O
in	O
PT	O
##SD	O
subjects	O
,	O
raising	O
the	O
possibility	O
that	O
its	O
reduced	O
plasma	O
concentration	O
may	O
contribute	O
to	O
inflammation	O
in	O
these	O
PT	O
##SD	O
subjects	O
[	O
,	O
]	O
.	O

Con	O
##sist	O
##ent	O
with	O
this	O
observation	O
,	O
smoking	O
-	O
derived	O
to	B
##xin	I
##s	I
have	O
been	O
related	O
to	O
the	O
activation	O
of	O
P	O
##I	O
##3	O
##K	O
signaling	O
pathway	O
[	O
–	O
]	O
,	O
altering	O
cell	O
growth	O
,	O
proliferation	O
,	O
survival	O
,	O
and	O
m	O
##ot	O
##ility	O
in	O
CO	O
##PD	O
smoke	O
##rs	O
.	O

PC	O
is	O
mainly	O
synthesized	O
by	O
two	O
pathways	O
,	O
the	O
CDP	B
-	I
ch	I
##olin	I
##e	I
pathway	O
(	O
Kennedy	O
pathway	O
)	O
and	O
p	O
##hos	O
##pha	O
##ti	O
##dy	O
##let	O
##han	O
##ola	O
##mine	O
N	O
-	O
met	O
##hyl	O
##tra	O
##ns	O
##fer	O
##ase	O
(	O
P	O
##EM	O
##T	O
)	O
pathways	O
(	O
Fi	O
##g	O
.	O

The	O
he	O
##pa	O
##to	O
##cy	O
##tes	O
were	O
in	O
##cu	O
##bate	O
##d	O
with	O
so	B
##fo	I
##s	I
##bu	I
##vir	I
(	O
1	O
,	O
5	O
,	O
or	O
10	O
μ	O
##M	O
)	O
or	O
rib	B
##avi	I
##rin	I
(	O
100	O
μ	O
##M	O
)	O
for	O
2	O
h	O
and	O
were	O
then	O
in	O
##cu	O
##bate	O
##d	O
in	O
drug	O
-	O
free	O
medium	O
,	O
with	O
serial	O
sampling	O
over	O
24	O
h	O
.	O

N	O
##AG	O
##s	O
,	O
mainly	O
N	B
-	I
ace	I
##ty	I
##l	I
##g	I
##lu	I
##cos	I
##amine	I
and	O
N	B
-	I
ace	I
##ty	I
##ln	I
##eur	I
##ami	I
##c	I
acid	I
,	O
strongly	O
contribute	O
to	O
the	O
weight	O
loss	O
classes	O
separation	O
.	O

The	O
plasma	O
sample	O
was	O
added	O
to	O
a	O
mixture	O
of	O
400	O
µ	O
##L	O
met	B
##han	I
##ol	I
,	O
25	O
µ	O
##L	O
1	O
##N	O
HC	O
##l	O
,	O
and	O
1000	O
µ	O
##L	O
is	B
##oo	I
##ct	I
##ane	I
.	O

Next	O
,	O
the	O
linear	O
relationship	O
between	O
log	O
-	O
transformed	O
u	O
##rina	O
##ry	O
my	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
and	O
plasma	O
concentration	O
of	O
su	O
##PA	O
##R	O
was	O
investigated	O
in	O
F	O
##S	O
##GS	O
patients	O
.	O

To	O
25	O
μ	O
##L	O
of	O
plasma	O
,	O
100	O
μ	O
##L	O
of	O
met	B
##han	I
##ol	I
and	O
5	O
μ	O
##L	O
of	O
internal	O
standard	O
(	O
AA	O
-	O
d	O
##8	O
)	O
were	O
added	O
.	O

Except	O
for	O
g	B
##ly	I
##cine	I
(	O
q	O
=	O
0	O
.	O
15	O
)	O
,	O
these	O
findings	O
were	O
also	O
significant	O
in	O
linear	O
mixed	O
models	O
(	O
L	O
##MM	O
)	O
analyses	O
of	O
the	O
identified	O
meta	O
##bol	O
##ites	O
.	O

C	B
##it	I
##ru	I
##llin	I
##e	I
,	O
an	O
intermediate	O
of	O
u	B
##rea	I
bio	O
##sy	O
##nt	O
##hesis	O
,	O
and	O
u	B
##rea	I
were	O
elevated	O
upon	O
h	B
##ydro	I
##ch	I
##lor	I
##oth	I
##ia	I
##zi	I
##de	I
administration	O
(	O
,	O
)	O
.	O

The	O
expected	O
changes	O
included	O
decreased	O
free	O
ch	B
##ole	I
##ster	I
##ol	I
in	O
individuals	O
selected	O
from	O
both	O
the	O
full	O
range	O
of	O
L	O
##D	O
##L	O
-	O
C	O
response	O
and	O
those	O
selected	O
from	O
the	O
10	O
%	O
tail	O
of	O
good	O
respond	O
##ers	O
,	O
but	O
not	O
from	O
the	O
poor	O
response	O
tail	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
D	O
##HA	O
meta	B
##bol	I
##ite	I
##19	I
,	I
20	I
-	I
Di	I
##HD	I
##o	I
##P	I
##E	I
,	O
which	O
was	O
present	O
at	O
lower	O
abundance	O
but	O
was	O
also	O
a	O
strong	O
contributor	O
to	O
distinguishing	O
pro	O
-	O
at	O
##her	O
##ogenic	O
T	O
##GR	O
##L	O
(	O
Fi	O
##g	O
.	O
)	O
,	O
did	O
not	O
itself	O
el	O
##icit	O
a	O
detect	O
##able	O
effect	O
on	O
VC	O
##AM	O
-	O
1	O
.	O

shows	O
the	O
association	O
between	O
two	O
est	B
##rogen	I
meta	O
##bol	O
##ites	O
and	O
pro	O
##state	O
cancer	O
risk	O
.	O

*	O
C	O
##14	O
Ce	B
##ram	I
##ide	I
and	O
s	B
##phi	I
##nga	I
##nine	I
were	O
not	O
detected	O
in	O
human	O
serum	O
samples	O
.	O

The	O
scores	O
plot	O
displays	O
the	O
separation	O
between	O
the	O
pro	O
-	O
and	O
anti	O
-	O
at	O
##her	O
##ogenic	O
T	O
##GR	O
##L	O
groups	O
,	O
and	O
the	O
loading	O
##s	O
plot	O
super	O
##im	O
##pose	O
##s	O
the	O
22	O
o	B
##xy	I
##lip	I
##ins	I
that	O
contributed	O
significantly	O
to	O
the	O
separation	O
.	O

We	O
developed	O
and	O
valid	O
##ated	O
a	O
sensitive	O
and	O
low	O
sample	O
volume	O
liquid	O
ch	O
##roma	O
##to	O
##graphic	O
-	O
mass	O
s	O
##pect	O
##rome	O
##tric	O
(	O
L	O
##C	O
-	O
MS	O
)	O
method	O
for	O
simultaneous	O
determination	O
of	O
g	B
##ly	I
##bur	I
##ide	I
(	O
G	O
##L	O
##Y	O
)	O
and	O
its	O
meta	O
##bol	O
##ite	O
,	O
4	B
-	I
trans	I
##hy	I
##dr	I
##ox	I
##y	I
g	I
##ly	I
##bur	I
##ide	I
(	O
M1	O
)	O
in	O
human	O
plasma	O
(	O
0	O
.	O
5	O
m	O
##l	O
)	O
or	O
urine	O
(	O
0	O
.	O
1	O
m	O
##l	O
)	O
.	O

Of	O
note	O
,	O
both	O
beta	B
##ine	I
and	O
P	O
##LT	O
##P	O
affect	O
he	O
##pa	O
##tic	O
t	B
##rig	I
##ly	I
##cer	I
##ide	I
metabolism	O
although	O
by	O
different	O
mechanisms	O
[	O
,	O
]	O
.	O

The	O
average	O
difference	O
was	O
8	O
.	O
73	O
pm	O
##ol	O
/	O
mg	O
c	B
##rea	I
##tin	I
##ine	I
(	O
95	O
%	O
C	O
##I	O
5	O
.	O
36	O
,	O
12	O
.	O
10	O
,	O
p	O
=	O
0	O
.	O
000	O
##0	O
##2	O
)	O
.	O

Compared	O
to	O
the	O
metabolic	O
ratio	O
(	O
MR	O
)	O
of	O
nor	O
##fen	O
##tany	O
##l	O
and	O
f	O
##ent	O
##any	O
##l	O
(	O
1	O
.	O
1	O
±	O
1	O
.	O
3	O
)	O
the	O
MR	O
of	O
1	B
′	I
-	I
OH	I
-	I
mid	I
##az	I
##ola	I
##m	I
and	O
mid	B
##az	I
##ola	I
##m	I
was	O
much	O
higher	O
(	O
286	O
±	O
236	O
)	O
.	O

Normally	O
,	O
g	O
##lo	O
##mer	O
##ular	O
fi	O
##ltration	O
followed	O
by	O
re	O
##ab	O
##sor	O
##ption	O
and	O
h	O
##ydro	O
##lysis	O
in	O
the	O
pro	O
##ximal	O
tub	O
##ule	O
cells	O
allows	O
recovery	O
of	O
the	O
native	O
amino	S
acids	O
[	O
,	O
]	O
.	O

The	O
h	B
##ydro	I
##ly	I
##sat	I
##e	I
was	O
stored	O
at	O
-	O
80	O
##°	O
##C	O
prior	O
analysis	O
.	O

Most	O
visible	O
s	O
##pect	O
##ra	O
were	O
concentrated	O
on	O
the	O
region	O
between	O
0	O
.	O
5	O
and	O
5	O
pp	O
##m	O
,	O
including	O
BC	O
##AA	O
,	O
al	B
##ani	I
##ne	I
,	O
la	B
##ct	I
##ate	I
,	O
glucose	S
,	O
ch	O
##olin	O
##e	O
/	O
PC	O
,	O
ta	B
##uri	I
##ne	I
,	O
beta	B
##ine	I
,	O
and	O
so	O
on	O
.	O

It	O
is	O
of	O
particular	O
interest	O
that	O
our	O
serum	O
models	O
generated	O
a	O
positive	O
and	O
significant	O
separation	O
between	O
R	O
##R	O
and	O
SP	S
patient	O
groups	O
.	O

Representative	O
_	O
1	O
H	O
N	O
##MR	O
s	O
##pect	O
##ra	O
of	O
a	O
##que	O
##ous	O
met	B
##han	I
##ol	I
extract	O
##s	O
of	O
whole	O
blood	O
(	O
W	O
##B	O
)	O
showing	O
signals	O
arising	O
from	O
co	O
##fa	O
##ctors	O
ATP	S
,	O
AD	B
##P	I
,	O
AM	B
##P	I
,	O
N	O
##AD	O
_	O
+	O
,	O
and	O
N	O
##AD	O
##P	O
_	O
+	O
in	O
L	O
##H	O
/	O
F	O
##S	O
##H	O
-	O
secret	O
##ing	O
pit	O
##uit	O
##ary	O
tumor	O
,	O
pro	O
##la	O
##ct	O
##ino	O
##ma	O
,	O
and	O
N	O
##F	O
pit	O
##uit	O
##ary	O
tumor	O
patients	O
.	O

The	O
C	O
-	O
18	O
SP	O
##E	O
plate	O
was	O
then	O
washed	O
with	O
5	O
%	O
met	B
##han	I
##ol	I
in	O
water	O
(	O
2	O
m	O
##L	O
)	O
,	O
followed	O
by	O
el	O
##ution	O
with	O
100	O
%	O
met	B
##han	I
##ol	I
(	O
2	O
m	O
##L	O
)	O
to	O
recover	O
the	O
s	O
##tero	O
##ids	O
.	O

Each	O
15	O
mg	O
tissue	O
sample	O
was	O
ho	O
##mo	O
##gen	O
##ized	O
individually	O
in	O
cold	O
met	B
##han	I
##ol	I
using	O
a	O
T	O
##iss	O
##ue	O
##L	O
##ys	O
##er	O
(	O
20	O
Hz	O
,	O
90	O
s	O
)	O
.	O

The	O
levels	O
of	O
5	B
-	I
H	I
##O	I
-	I
Ph	I
##IP	I
and	O
its	O
g	B
##lu	I
##cu	I
##ron	I
##ide	I
con	O
##ju	O
##gate	O
##s	O
,	O
if	O
these	O
were	O
formed	O
in	O
either	O
type	O
of	O
micro	O
##so	O
##mal	O
sample	O
,	O
were	O
ne	O
##gli	O
##gible	O
.	O

Ka	O
##rk	O
##ela	O
and	O
cow	O
##or	O
##kers	O
have	O
analyzed	O
the	O
al	B
##ani	I
##ne	I
concentration	O
in	O
c	O
##ere	O
##bro	O
##sp	O
##inal	O
fluid	O
of	O
patients	O
after	O
acute	O
is	O
##che	O
##mic	O
stroke	O
and	O
found	O
that	O
al	B
##ani	I
##ne	I
levels	O
gradually	O
increased	O
within	O
the	O
first	O
four	O
hours	O
,	O
and	O
then	O
,	O
there	O
was	O
a	O
rapid	O
decline	O
.	O

Ethan	B
##ola	I
##mine	I
.	O
10	O
.	O

The	O
algorithm	O
correctly	O
identified	O
age	O
,	O
gender	O
,	O
and	O
serum	O
c	B
##rea	I
##tin	I
##ine	I
in	O
the	O
first	O
order	O
neighborhood	O
,	O
which	O
are	O
used	O
for	O
the	O
com	O
##putation	O
of	O
e	O
##G	O
##F	O
##R	O
.	O

The	O
purpose	O
for	O
ch	B
##lor	I
##he	I
##xi	I
##dine	I
inclusion	O
was	O
to	O
determine	O
whether	O
or	O
not	O
ch	B
##lor	I
##he	I
##xi	I
##dine	I
could	O
au	O
##gment	O
BR	O
##B	O
absorption	O
and	O
sustainability	O
.	O

This	O
could	O
help	O
improve	O
test	B
##osterone	I
therapy	O
,	O
which	O
does	O
not	O
completely	O
restore	O
h	O
##y	O
##po	O
##gon	O
##adi	O
##c	O
metabolism	O
##s	O
.	O

shows	O
that	O
serum	O
levels	O
of	O
five	O
l	O
##ys	O
##o	O
##PC	O
species	O
(	O
l	O
##ys	O
##o	O
##PC	O
a	O
C	B
##18	I
:	I
0	I
,	O
l	O
##ys	O
##o	O
##PC	O
a	O
C	B
##18	I
:	I
2	I
,	O
l	O
##ys	O
##o	O
##PC	O
a	O
C	B
##20	I
:	I
3	I
,	O
l	O
##ys	O
##o	O
##PC	O
a	O
C	B
##20	I
:	I
4	I
,	O
l	O
##ys	O
##o	O
##PC	O
a	O
C	B
##24	I
:	I
0	I
)	O
and	O
one	O
PC	O
(	O
PC	O
a	B
##e	I
C	I
##42	I
:	I
1	I
)	O
decreased	O
gradually	O
from	O
CH	O
##B	O
to	O
H	O
##B	O
##V	O
-	O
associated	O
c	O
##ir	O
##r	O
##hos	O
##is	O
and	O
to	O
H	O
##B	O
##V	O
-	O
associated	O
HC	O
##C	O
.	O

A	O
3	B
-	I
o	I
##x	I
##o	I
-	I
4	I
-	I
en	I
##e	I
functionality	O
was	O
generated	O
by	O
oxidation	O
of	O
the	O
native	O
3	B
##β	I
-	I
h	I
##ydro	I
##xy	I
-	I
5	I
-	I
en	I
##e	I
function	O
by	O
ch	B
##ole	I
##ster	I
##ol	I
o	O
##xi	O
##das	O
##e	O
prior	O
to	O
treatment	O
with	O
GP	S
re	O
##age	O
##nt	O
.	O

We	O
measured	O
my	B
##ost	I
##ati	I
##n	I
and	O
f	B
##oll	I
##ista	I
##tin	I
because	O
of	O
their	O
widely	O
known	O
roles	O
in	O
regulating	O
muscle	O
growth	O
and	O
metabolism	O
(	O
;	O
;	O
)	O
,	O
and	O
yet	O
limited	O
information	O
with	O
regard	O
to	O
their	O
adaptive	O
responses	O
to	O
sustained	O
ex	O
##ert	O
##ion	O
and	O
cold	O
exposure	O
in	O
a	O
“	O
real	O
-	O
world	O
”	O
field	O
setting	O
.	O

Pro	B
##sta	I
##g	I
##land	I
##in	I
T	I
##hr	I
##omb	I
##ox	I
##ane	I
Le	O
##uk	O
##ot	O
Re	O
##s	O
.	O

Average	O
meta	O
##bol	O
##ite	O
recovery	O
was	O
higher	O
in	O
Me	B
##OH	I
pp	O
##t	O
+	O
U	O
##F	O
serum	O
than	O
in	O
Me	B
##OH	I
:	O
CH	O
##C	O
##l	O
_	O
3	O
:	O
water	O
extraction	O
##s	O
or	O
Me	B
##OH	I
pp	O
##t	O
alone	O
,	O
while	O
variance	O
in	O
meta	O
##bol	O
##ite	O
concentrations	O
were	O
consistently	O
lower	O
.	O

Me	O
##as	O
##ure	O
##ments	O
of	O
individual	O
meta	O
##bol	O
##ites	O
indicated	O
that	O
the	O
in	O
##test	O
##inal	O
environment	O
in	O
I	O
##BS	O
-	O
D	O
was	O
characterized	O
by	O
increased	O
pro	O
##te	O
##oly	O
##sis	O
,	O
incomplete	O
an	O
##ae	O
##ro	O
##bic	O
f	O
##er	O
##mentation	O
and	O
possible	O
change	O
in	O
met	B
##hane	I
production	O
.	O

PC	O
##A	O
was	O
performed	O
on	O
base	O
##line	O
levels	O
of	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
,	O
amino	O
acids	O
,	O
NE	O
##FA	O
,	O
k	B
##eton	I
##es	I
and	O
β	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
.	O

A	O
##cc	O
##ele	O
##rated	O
g	B
##lut	I
##amine	I
and	O
g	B
##lut	I
##ama	I
##te	I
metabolism	O
was	O
also	O
apparent	O
(	O
P	O
-	O
value	O
=	O
0	O
.	O
04	O
on	O
un	O
##iva	O
##ria	O
##te	O
analysis	O
)	O
.	O

These	O
higher	O
concentrations	O
of	O
glucose	S
and	O
non	O
-	O
car	O
##bo	O
##hy	O
##dra	O
##te	O
glucose	O
precursor	O
##s	O
such	O
as	O
amino	O
acids	O
and	O
g	B
##ly	I
##cer	I
##ol	I
suggests	O
involvement	O
of	O
the	O
g	O
##lu	O
##con	O
##eo	O
##genesis	O
pathway	O
.	O

They	O
showed	O
that	O
C	B
##5	I
##2	I
:	I
1	I
T	I
##G	I
was	O
linked	O
with	O
an	O
increased	O
risk	O
of	O
T	O
##2	O
##D	O
,	O
whereas	O
C	B
##38	I
:	I
6	I
PC	I
was	O
linked	O
with	O
a	O
decreased	O
risk	O
.	O

After	O
5	O
min	O
,	O
the	O
reactions	O
were	O
terminated	O
by	O
addition	O
of	O
an	O
equal	O
volume	O
of	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
(	O
v	O
/	O
v	O
)	O
containing	O
an	O
appropriate	O
internal	O
standard	O
.	O

In	O
skeletal	O
muscle	O
T	B
##AG	I
(	I
48	I
:	I
2	I
)	I
and	O
T	B
##AG	I
(	I
48	I
:	I
1	I
)	I
were	O
decreased	O
in	O
the	O
P	O
##OK	O
##O	O
mouse	O
but	O
not	O
in	O
o	O
##b	O
/	O
o	O
##b	O
.	O

Ser	O
##um	O
se	B
##rine	I
and	O
a	B
##rg	I
##ini	I
##ne	I
concentrations	O
for	O
Met	O
##S	O
_	O
any	O
(	O
black	O
bars	O
)	O
and	O
Met	O
##S	O
_	O
zero	O
women	O
(	O
white	O
bars	O
)	O
with	O
high	O
(	O
H	O
)	O
or	O
low	O
(	O
L	O
)	O
levels	O
of	O
A	O
##EE	O
/	O
kg	O
_	O
DL	O
##W	O
and	O
PA	O
##L	O
_	O
DL	O
##W	O
,	O
and	O
A	O
##EE	O
_	O
DL	O
##W	O
respectively	O
.	O

[	O
,	O
]	O
Higher	O
serum	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
was	O
significantly	O
associated	O
with	O
future	O
MI	O
in	O
a	O
meta	O
##bol	O
##omi	O
##cs	O
study	O
of	O
over	O
13	O
,	O
000	O
subjects	O
and	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
in	O
##fusion	O
has	O
been	O
shown	O
to	O
limit	O
post	O
MI	O
stunning	O
via	O
h	O
##ydro	O
##xy	O
##l	O
s	O
##ca	O
##ven	O
##ging	O
in	O
an	O
animal	O
model	O
.	O

Consequently	O
,	O
functional	O
ass	O
##ays	O
,	O
im	O
##mu	O
##nob	O
##lot	O
##ting	O
and	O
im	O
##mu	O
##no	O
##his	O
##to	O
##chemical	O
analyses	O
to	O
evaluate	O
levels	O
and	O
distribution	O
of	O
BR	O
##B	O
ant	B
##ho	I
##cy	I
##ani	I
##n	I
-	I
relevant	I
metabolic	O
enzymes	O
in	O
human	O
oral	O
tissues	O
were	O
performed	O
.	O

The	O
ca	B
##ffe	I
##ine	I
content	O
of	O
the	O
green	O
tea	O
SP	O
##I	O
complex	O
was	O
determined	O
to	O
be	O
14	O
.	O
2	O
##±	O
##0	O
.	O
3	O
mg	O
/	O
g	O
.	O

The	O
positive	O
association	O
with	O
plasma	O
u	B
##rate	I
had	O
a	O
stronger	O
effect	O
size	O
in	O
women	O
compared	O
to	O
men	O
,	O
whereas	O
the	O
positive	O
associations	O
with	O
the	O
BC	O
##AA	O
meta	O
##bol	O
##ites	O
3	B
-	I
met	I
##hyl	I
-	I
2	I
-	I
o	I
##x	I
##ova	I
##ler	I
##ate	I
and	O
4	B
-	I
met	I
##hyl	I
-	I
2	I
-	I
o	I
##x	I
##ope	I
##nto	I
##ate	I
were	O
unique	O
to	O
men	O
.	O

l	O
-	O
amino	O
acids	O
,	O
sodium	B
3	I
-	I
trim	I
##eth	I
##yl	I
##si	I
##ly	I
##l	I
(	I
2	I
,	I
2	I
,	I
3	I
,	I
3	I
-	I
_	I
2	I
H	I
_	I
4	I
)	I
-	I
1	I
-	I
prop	I
##ion	I
##ate	I
,	O
and	O
human	O
serum	O
(	O
all	O
from	O
Sigma	O
–	O
Al	O
##dric	O
##h	O
,	O
St	O
.	O
Louis	O
,	O
M	O
##O	O
)	O
,	O
and	O
1	B
,	I
1	I
′	I
-	I
_	I
13	I
C	I
_	I
2	I
ace	I
##tic	I
an	I
##hy	I
##dr	I
##ide	I
(	O
Cambridge	O
Is	O
##oto	O
##pe	O
Laboratories	O
,	O
And	O
##over	O
,	O
MA	O
)	O
were	O
used	O
without	O
further	O
pu	O
##rification	O
.	O

Thus	O
,	O
car	B
##ni	I
##tine	I
and	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
are	O
considered	O
important	O
bio	O
##mark	O
##ers	O
for	O
o	O
##besity	O
(	O
[	O
]	O
,	O
see	O
http	O
:	O
/	O
/	O
en	O
.	O
w	O
##iki	O
##ped	O
##ia	O
.	O
org	O
/	O
w	O
##iki	O
/	O
Car	O
##ni	O
##tine	O
)	O
.	O

Together	O
,	O
these	O
findings	O
suggest	O
alterations	O
in	O
glucose	S
up	O
##take	O
and	O
u	O
##til	O
##ization	O
,	O
which	O
may	O
support	O
an	O
increase	O
in	O
pen	B
##tos	I
##e	I
phosphate	I
pathway	O
activity	O
and	O
the	O
generation	O
of	O
g	O
##ly	O
##cation	O
products	O
that	O
may	O
potentially	O
contribute	O
to	O
the	O
path	O
##ogen	O
##esis	O
and	O
growth	O
of	O
these	O
tumors	O
.	O

Four	O
out	O
of	O
the	O
top	O
five	O
combinations	O
ranked	O
by	O
values	O
of	O
mean	O
AU	O
##C	O
in	O
the	O
test	O
set	O
contained	O
both	O
g	B
##lut	I
##ama	I
##te	I
and	O
a	B
##rg	I
##ini	I
##ne	I
.	O

Tau	B
##rine	I
is	O
highly	O
concentrated	O
in	O
the	O
muscles	O
and	O
involved	O
in	O
cell	O
volume	O
regulation	O
,	O
calcium	O
home	O
##ost	O
##asis	O
,	O
membrane	O
stab	O
##ilization	O
and	O
anti	O
##ox	O
##ida	O
##nt	O
activities	O
,	O
all	O
important	O
with	O
respect	O
to	O
physical	O
exercise	O
.	O

2	B
-	I
h	I
##ydro	I
##xy	I
##cin	I
##nam	I
##ic	I
acid	I
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
L	B
-	I
c	I
##it	I
##ru	I
##llin	I
##e	I
,	O
sa	B
##cc	I
##hari	I
##c	I
acid	I
,	O
D	B
-	I
as	I
##par	I
##tic	I
acid	I
and	O
be	O
##hani	O
##c	O
acid	O
,	O
are	O
significantly	O
decreased	O
in	O
B	O
##D	O
##TT	O
group	O
.	O

_	O
S	O
##1	O
##a	O
)	O
,	O
and	O
the	O
Z	O
-	O
score	O
of	O
the	O
plasma	O
samples	O
in	O
the	O
A	B
##F	I
group	O
was	O
in	O
the	O
range	O
of	O
−	O
##3	O
to	O
4	O
(	O
Fi	O
##g	O
.	O

Inc	O
##reased	O
levels	O
of	O
Cho	B
##line	I
,	O
which	O
are	O
reduced	O
on	O
AR	O
##T	O
,	O
indicate	O
Cho	B
##line	I
to	O
be	O
a	O
bio	O
##mark	O
##er	O
of	O
HIV	O
/	O
AIDS	O
,	O
especially	O
in	O
the	O
AIDS	O
dem	O
##ent	O
##ia	O
complex	O
.	O

Con	O
##cent	O
##rations	O
of	O
B	O
##DC	O
##PP	O
standard	O
and	O
sample	O
were	O
97	O
##00	O
p	B
##g	I
m	O
##L	O
_	O
−	O
##1	O
and	O
71	O
##70	O
p	B
##g	I
m	O
##L	O
_	O
−	O
##1	O
,	O
respectively	O
.	O

At	O
base	O
##line	O
,	O
un	O
##iva	O
##ria	O
##te	O
analyses	O
showed	O
that	O
3	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
,	O
20	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
and	O
SM	B
C	I
##24	I
:	I
1	I
had	O
significantly	O
lower	O
levels	O
in	O
patients	O
who	O
later	O
gained	O
weight	O
before	O
but	O
not	O
after	O
correct	O
##ing	O
for	O
multiple	O
tests	O
(	O
Su	O
##pp	O
##lement	O
##ary	O
Table	O
2	O
)	O
.	O

Co	B
##tin	I
##ine	I
,	O
[	O
_	O
13	O
CD	O
_	O
3	O
]	O
co	O
##tin	O
##ine	O
,	O
N	O
##NA	O
##L	O
,	O
and	O
[	O
_	O
13	O
C	O
_	O
6	O
]	O
N	O
##NA	O
##L	O
(	O
Figure	O
)	O
were	O
pro	O
##cure	O
##d	O
from	O
Toronto	O
Research	O
Chemical	O
##s	O
(	O
Ontario	O
,	O
Canada	O
)	O
.	O

Ace	B
##tate	I
was	O
also	O
significantly	O
reduced	O
in	O
the	O
CS	O
##F	O
of	O
drug	O
-	O
na	O
##ï	O
##ve	O
patients	O
with	O
first	O
-	O
onset	O
s	O
##chi	O
##zophrenia	O
.	O

Race	O
,	O
diabetes	O
,	O
urine	O
album	O
##in	O
ex	O
##cre	O
##tion	O
,	O
and	O
the	O
circulating	O
concentrations	O
of	O
para	O
##thy	O
##roid	O
hormone	O
and	O
fi	O
##bro	O
##blast	O
growth	O
factor	O
23	O
more	O
modest	O
##ly	O
modified	O
the	O
association	O
of	O
24	B
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
with	O
25	O
(	O
OH	O
)	O
D	O
_	O
3	O
.	O

Alan	B
##ine	I
can	O
be	O
produced	O
by	O
the	O
red	O
##uctive	O
animation	O
of	O
p	B
##yr	I
##u	I
##vate	I
,	O
thus	O
this	O
reduction	O
in	O
al	B
##ani	I
##ne	I
may	O
suggest	O
a	O
shift	O
from	O
p	B
##yr	I
##u	I
##vate	I
towards	O
la	B
##ct	I
##ate	I
production	O
in	O
v	O
##is	O
##cer	O
##al	O
fat	O
from	O
o	O
##bes	O
##e	O
EA	O
##C	O
patients	O
,	O
supporting	O
the	O
demonstrated	O
increase	O
in	O
la	B
##ct	I
##ate	I
in	O
AC	O
##M	O
from	O
these	O
patients	O
.	O

After	O
that	O
,	O
the	O
residue	O
was	O
red	O
##iss	O
##ol	O
##ved	O
by	O
100	O
μ	O
##L	O
of	O
a	O
mixture	O
of	O
met	B
##han	I
##ol	I
and	O
water	O
(	O
1	O
:	O
1	O
,	O
v	O
/	O
v	O
)	O
with	O
1	O
μ	O
##g	O
/	O
m	O
##L	O
of	O
L	B
-	I
2	I
-	I
ch	I
##lor	I
##op	I
##hen	I
##yla	I
##lani	I
##ne	I
followed	O
by	O
the	O
same	O
v	O
##ortex	O
##ing	O
,	O
ultra	O
##sonic	O
##ation	O
and	O
cent	O
##ri	O
##fu	O
##gation	O
steps	O
ahead	O
.	O

Therefore	O
,	O
the	O
higher	O
levels	O
of	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
might	O
be	O
reflected	O
the	O
d	O
##ys	O
##re	O
##gu	O
##lated	O
fatty	O
acid	O
β	O
-	O
oxidation	O
pathway	O
in	O
BC	O
patients	O
.	O

A	O
total	O
of	O
103	O
S	O
##NP	O
##s	O
were	O
selected	O
,	O
from	O
P	O
##EA	O
##R	O
HC	O
##T	O
##Z	O
mon	O
##otherapy	O
S	O
##B	O
##P	O
and	O
DB	B
##P	I
G	O
##WA	O
##S	O
analyses	O
,	O
based	O
on	O
our	O
suggest	O
##ive	O
cut	O
off	O
p	O
-	O
value	O
(	O
i	O
.	O
e	O
.	O
p	O
<	O
5	O
##×	O
##10	O
_	O
−	O
##5	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
observed	O
low	O
levels	O
of	O
SM	B
(	I
16	I
:	I
0	I
)	I
in	O
M	O
##F	O
tissues	O
.	O

The	O
AU	O
##Cs	O
of	O
L	B
-	I
as	I
##par	I
##ty	I
##l	I
-	I
4	I
-	I
phosphate	I
and	O
L	O
##ys	O
##o	O
##PC	O
[	O
20	O
:	O
5	O
(	O
5	O
##Z	O
,	O
8	O
##Z	O
,	O
11	O
##Z	O
,	O
14	O
##Z	O
,	O
17	O
##Z	O
)	O
]	O
were	O
higher	O
compared	O
with	O
that	O
of	O
A	O
##FP	O
when	O
different	O
##iating	O
between	O
early	O
,	O
and	O
middle	O
stage	O
HC	O
##C	O
.	O

U	O
##rine	O
specimens	O
were	O
th	O
##awed	O
completely	O
before	O
mixing	O
500	O
µ	O
##L	O
of	O
urine	O
with	O
250	O
µ	O
##L	O
of	O
phosphate	S
buffer	O
(	O
0	O
.	O
2	O
##M	O
)	O
for	O
the	O
stab	O
##ilization	O
of	O
u	O
##rina	O
##ry	O
pH	O
7	O
.	O
4	O
(	O
±	O
0	O
.	O
5	O
)	O
,	O
and	O
75	O
µ	O
##L	O
of	O
sodium	B
3	I
-	I
trim	I
##eth	I
##yl	I
##si	I
##ly	I
##l	I
-	I
(	I
2	I
,	I
2	I
,	I
3	I
,	I
3	I
-	I
_	I
2	I
H	I
_	I
4	I
)	I
-	I
1	I
-	I
prop	I
##ion	I
##ate	I
(	O
T	O
##SP	O
)	O
in	O
D	O
_	O
2	O
O	O
(	O
final	O
concentration	O
0	O
.	O
1	O
##m	O
##g	O
/	O
m	O
##L	O
)	O
solution	O
for	O
chemical	O
shift	O
refer	O
##encing	O
of	O
T	O
##SP	O
(	O
δ	O
0	O
.	O
0	O
)	O
.	O

Two	O
h	O
##ydro	O
##phi	O
##lic	O
-	O
interaction	O
-	O
ch	O
##roma	O
##tography	O
(	O
H	O
##IL	O
##IC	O
)	O
columns	O
(	O
Se	O
##Q	O
##uant	O
Z	O
##IC	O
-	O
c	O
##H	O
##IL	O
##IC	O
,	O
150	O
×	O
2	O
.	O
1	O
mm	O
,	O
3	O
.	O
0	O
μ	O
m	O
particle	O
size	O
,	O
Me	O
##rc	O
##k	O
K	O
##G	O
##a	O
##A	O
,	O
Dar	O
##ms	O
##tadt	O
,	O
Germany	O
for	O
A	O
##gi	O
##lent	O
L	O
##C	O
;	O
Waters	O
X	O
##B	O
##ridge	O
Am	B
##ide	I
,	O
150	O
×	O
2	O
.	O
1	O
mm	O
,	O
2	O
.	O
5	O
μ	O
m	O
particle	O
size	O
for	O
Shi	O
##mad	O
##zu	O
L	O
##C	O
)	O
connected	O
in	O
parallel	O
were	O
run	O
under	O
identical	O
conditions	O
for	O
the	O
positive	O
-	O
and	O
negative	O
-	O
ion	O
##ization	O
modes	O
.	O

The	O
effects	O
of	O
hem	O
##oly	O
##zed	O
blood	O
and	O
commonly	O
used	O
add	O
##itive	O
##s	O
in	O
blood	O
tubes	O
such	O
as	O
lit	B
##hium	I
he	I
##par	I
##in	I
,	O
et	B
##hyl	I
##ened	I
##iam	I
##inet	I
##et	I
##ra	I
##ace	I
##tic	I
acid	I
(	O
E	O
##D	O
##TA	O
)	O
and	O
c	B
##it	I
##ric	I
acid	I
were	O
investigated	O
.	O

The	O
levels	O
of	O
g	B
##lut	I
##ama	I
##te	I
and	O
g	B
##lut	I
##amine	I
were	O
assessed	O
in	O
tissues	O
,	O
cell	O
lines	O
,	O
sa	O
##liva	O
,	O
and	O
plasma	O
samples	O
using	O
is	O
##otype	O
di	O
##lution	O
G	O
##C	O
-	O
MS	O
as	O
described	O
previously	O
.	O

Individuals	O
with	O
any	O
all	O
##er	O
##gies	O
other	O
than	O
possible	O
as	B
##par	I
##tam	I
##e	I
sensitivity	O
were	O
excluded	O
,	O
as	O
was	O
those	O
taking	O
any	O
over	O
-	O
the	O
-	O
counter	O
or	O
prescription	O
medications	O
during	O
the	O
previous	O
3	O
months	O
.	O

Un	O
##iva	O
##ria	O
##te	O
and	O
Multi	O
##var	O
##iate	O
Analysis	O
of	O
K	B
##P	I
Met	O
##ab	O
##oli	O
##tes	O
and	O
En	O
##zy	O
##mes	O
to	O
In	O
##f	O
##lam	O
##mation	O
as	O
As	O
##ses	O
##sed	O
by	O
End	O
##os	O
##copy	O
and	O
His	O
##tology	O
.	O

Blood	O
la	B
##ct	I
##ate	I
was	O
found	O
elevated	O
among	O
o	O
##bes	O
##e	O
,	O
I	O
##R	O
and	O
T	O
##2	O
##D	O
subjects	O
and	O
decreased	O
following	O
weight	O
loss	O
.	O

Specifically	O
,	O
N	B
##AD	I
##P	I
##H	I
cannot	O
be	O
simply	O
added	O
as	O
a	O
nutrition	O
##al	O
supplement	O
to	O
produce	O
the	O
tidal	O
change	O
in	O
metabolism	O
needed	O
to	O
shift	O
the	O
da	O
##uer	O
state	O
of	O
CF	O
##S	O
to	O
normal	O
health	O
.	O

Although	O
studies	O
have	O
tested	O
the	O
impact	O
of	O
glucose	S
u	O
##til	O
##ization	O
on	O
AC	O
concentrations	O
,	O
post	O
##pra	O
##ndi	O
##al	O
changes	O
in	O
plasma	O
AC	O
concentrations	O
in	O
adults	O
have	O
not	O
been	O
investigated	O
in	O
the	O
physiological	O
setting	O
of	O
eating	O
,	O
i	O
.	O
e	O
.	O
,	O
subjects	O
consuming	O
a	O
mixed	O
meal	O
containing	O
fat	O
and	O
car	O
##bo	O
##hy	O
##dra	O
##te	O
.	O

The	O
classes	O
of	O
lip	O
##ids	O
found	O
were	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
,	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
and	O
police	O
##ti	O
##dis	O
.	O

Biological	O
##ly	O
,	O
experimental	O
studies	O
have	O
shown	O
that	O
g	B
##ly	I
##co	I
##chen	I
##ode	I
##ox	I
##ych	I
##olate	I
generates	O
reactive	O
oxygen	O
species	O
,	O
and	O
has	O
been	O
positively	O
associated	O
with	O
he	O
##pa	O
##to	O
##cellular	O
car	O
##cin	O
##oma	O
.	O

For	O
example	O
,	O
the	O
cooked	O
meat	O
car	O
##cin	O
##ogen	O
,	O
Ph	O
##IP	O
,	O
has	O
been	O
reported	O
to	O
form	O
add	O
##uc	O
##t	O
(	O
s	O
)	O
with	O
Al	O
##b	O
in	O
humans	O
at	O
a	O
level	O
of	O
[UNK]	O
p	B
##g	I
Ph	O
##IP	O
/	O
g	O

PA	O
##s	O
from	O
long	O
-	O
term	O
survivors	O
also	O
show	O
decreased	O
levels	O
of	O
th	B
##re	I
##oni	I
##ne	I
,	O
as	B
##par	I
##tate	I
,	O
g	B
##ly	I
##cer	I
##ol	I
,	O
g	B
##lut	I
##ama	I
##te	I
,	O
and	O
g	B
##lut	I
##amine	I
compared	O
to	O
those	O
from	O
short	O
-	O
term	O
survivors	O
.	O

Not	O
##ably	O
,	O
try	B
##pt	I
##op	I
##han	I
metabolism	O
was	O
the	O
pathway	O
linked	O
to	O
the	O
most	O
unique	O
meta	O
##bol	O
##ites	O
.	O

Our	O
patients	O
were	O
in	O
lip	O
##id	O
lowering	O
treatment	O
only	O
with	O
s	B
##tat	I
##ins	I
.	O

The	O
ion	O
source	O
voltage	O
was	O
5	O
k	B
##V	I
.	O
Ni	O
##tro	O
##gen	O
sheath	O
and	O
aux	O
gas	O
flow	O
was	O
60	O
and	O
20	O
units	O
respectively	O
.	O

The	O
glucose	S
level	O
was	O
measured	O
by	O
means	O
of	O
glucose	S
o	O
##xi	O
##das	O
##e	O
method	O
.	O

B	O
##rief	O
##ly	O
,	O
samples	O
were	O
prepared	O
by	O
addition	O
of	O
500	O
µ	O
##L	O
of	O
42	O
m	O
##M	O
H	O
_	O
2	O
S	O
##O	O
_	O
4	O
and	O
125	O
µ	O
##L	O
of	O
p	B
##hos	I
##ph	I
##ot	I
##ung	I
##stic	I
acid	I
solution	O
to	O
50	O
µ	O
##L	O
of	O
serum	O
samples	O
.	O

Alternatively	O
,	O
Will	O
##enberg	O
et	O
al	O
.	O
mentioned	O
product	O
ion	O
s	O
##pect	O
##ra	O
of	O
9	B
-	I
H	I
##ET	I
##E	I
and	O
12	B
-	I
H	I
##ET	I
##E	I
were	O
similar	O
and	O
these	O
two	O
compounds	O
must	O
be	O
separated	O
ch	O
##roma	O
##to	O
##graphical	O
##ly	O
for	O
their	O
identification	O
.	O

Using	O
these	O
criteria	O
(	O
VIP	O
>	O
1	O
and	O
P	O
<	O
0	O
.	O
05	O
)	O
,	O
the	O
15	O
meta	O
##bol	O
##ites	O
listed	O
in	O
Table	O
were	O
found	O
to	O
be	O
significantly	O
changed	O
in	O
EC	O
tissues	O
compared	O
to	O
their	O
corresponding	O
non	O
##can	O
##cer	O
##ous	O
tissues	O
,	O
including	O
elevated	O
levels	O
of	O
v	B
##ali	I
##ne	I
,	O
le	B
##uc	I
##ine	I
,	O
al	B
##ani	I
##ne	I
,	O
ace	B
##tate	I
,	O
c	B
##it	I
##rate	I
,	O
su	B
##cci	I
##nate	I
,	O
ch	B
##olin	I
##e	I
and	O
g	B
##lut	I
##ama	I
##te	I
,	O
as	O
well	O
as	O
depleted	O
levels	O
of	O
c	B
##rea	I
##tin	I
##ine	I
and	O
c	B
##rea	I
##tine	I
,	O
g	B
##ly	I
##cine	I
,	O
th	B
##re	I
##oni	I
##ne	I
,	O
ta	B
##uri	I
##ne	I
,	O
glucose	S
,	O
and	O
g	B
##lut	I
##amine	I
.	O

P	B
##yr	I
##u	I
##vate	I
concentration	O
was	O
low	O
,	O
while	O
possible	O
precursor	O
##s	O
of	O
p	B
##yr	I
##u	I
##vate	I
,	O
such	O
as	O
c	B
##ys	I
##tein	I
##e	I
,	O
t	B
##yr	I
##os	I
##ine	I
and	O
al	B
##ani	I
##ne	I
,	O
increased	O
significantly	O
in	O
plasma	O
ruling	O
out	O
their	O
involvement	O
in	O
p	B
##yr	I
##u	I
##vate	I
production	O
.	O

H	B
##ydro	I
##xy	I
##p	I
##rol	I
##ine	I
(	O
H	O
##y	O
##p	O
)	O
itself	O
,	O
a	O
major	O
component	O
of	O
co	O
##lla	O
##gen	O
,	O
showed	O
no	O
difference	O
in	O
ex	O
##cre	O
##tion	O
levels	O
by	O
stage	O
.	O

Tests	O
were	O
performed	O
with	O
7	O
concentrations	O
of	O
each	O
drug	O
to	O
construct	O
a	O
dose	B
-	I
response	I
curve	O
and	O
to	O
determine	O
the	O
concentration	O
causing	O
a	O
half	O
-	O
ma	O
##ximal	O
in	O
##hibition	O
(	O
I	O
##C	O
_	O
50	O
)	O
relative	O
to	O
the	O
control	O
values	O
.	O

Lower	O
levels	O
of	O
u	O
##rina	O
##ry	O
u	B
##rea	I
in	O
late	O
-	O
stage	O
cancer	O
##s	O
might	O
indicate	O
less	O
nitrogen	O
flux	O
into	O
cat	O
##ab	O
##olic	O
reactions	O
,	O
and	O
a	O
likely	O
higher	O
amino	O
acid	O
flux	O
into	O
protein	O
bio	O
##sy	O
##nt	O
##hesis	O
.	O

Mobile	O
phase	O
A	O
was	O
1	O
m	O
##M	O
am	B
##mon	I
##ium	I
format	I
##e	I
,	O
pH	O
3	O
.	O
4	O
and	O
B	O
,	O
95	O
%	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
with	O
5	O
%	O
mobile	O
phase	O
A	O
.	O

In	O
this	O
study	O
,	O
levels	O
of	O
long	O
-	O
chain	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
were	O
at	O
the	O
lower	O
limit	O
of	O
detection	O
in	O
more	O
than	O
50	O
%	O
of	O
participants	O
.	O

To	O
prove	O
whether	O
storage	O
under	O
the	O
above	O
mentioned	O
conditions	O
leads	O
to	O
a	O
me	O
##as	O
##urable	O
amount	O
of	O
CO	O
_	O
2	O
or	O
hydrogen	B
carbon	I
##ate	I
in	O
the	O
solution	O
,	O
we	O
employed	O
infrared	O
s	O
##pect	O
##ros	O
##copy	O
.	O

Other	O
disc	O
##re	O
##pan	O
##cies	O
may	O
be	O
due	O
to	O
sample	O
collection	O
/	O
preservation	O
effects	O
(	O
the	O
ultra	O
##fi	O
##ltration	O
devices	O
we	O
used	O
contain	O
trace	O
amounts	O
of	O
g	B
##ly	I
##cer	I
##ol	I
)	O
or	O
possibly	O
sample	O
size	O
effects	O
(	O
2	O
patients	O
versus	O
35	O
patients	O
)	O
.	O

S	B
-	I
(	I
3	I
-	I
met	I
##hyl	I
##but	I
##ano	I
##yl	I
)	I
-	I
di	I
##hy	I
##dr	I
##oli	I
##po	I
##ami	I
##de	I
-	I
E	I
participates	O
in	O
the	O
degradation	O
of	O
v	B
##ali	I
##ne	I
,	O
le	B
##uc	I
##ine	I
and	O
is	B
##ole	I
##uc	I
##ine	I
and	O
in	O
the	O
synthesis	O
of	O
branched	O
chain	O
fatty	O
acids	O
.	O

Studies	O
have	O
suggested	O
that	O
in	B
##do	I
##le	I
-	I
3	I
-	I
ace	I
##tate	I
directly	O
m	O
##od	O
##ulates	O
inflammatory	O
responses	O
in	O
he	O
##pa	O
##to	O
##cy	O
##tes	O
and	O
mac	O
##rop	O
##hage	O
##s	O
by	O
at	O
##ten	O
##uation	O
of	O
the	O
release	O
of	O
pro	O
-	O
inflammatory	O
c	O
##yt	O
##oki	O
##nes	O
and	O
induction	O
of	O
the	O
liver	O
to	O
s	O
##ynth	O
##esi	O
##ze	O
free	O
fatty	O
acids	O
.	O

Global	O
Regis	O
##try	O
of	O
A	O
##cute	O
Co	O
##rona	O
##ry	O
Events	O
;	O
HD	O
##L	O
=	O
high	O
-	O
density	O
lip	O
##op	O
##rote	O
##in	O
;	O
I	O
##AB	O
##P	O
=	O
in	O
##tra	O
-	O
a	O
##ort	O
##ic	O
balloon	O
pump	O
;	O
L	O
##D	O
##L	O
=	O
low	O
-	O
density	O
lip	O
##op	O
##rote	O
##in	O
;	O
N	O
##T	O
-	O
pro	O
B	O
##NP	O
=	O
N	O
-	O
terminal	O
pro	O
-	O
B	O
-	O
type	O
na	O
##tri	O
##ure	O
##tic	O
p	O
##eptide	O
;	O
T	O
##C	O
=	O
total	O
ch	B
##ole	I
##ster	I
##ol	I
;	O
T	O
##n	O
##I	O

Ace	B
##ton	I
##it	I
##ril	I
##e	I
(	O
HP	O
##LC	O
grade	O
)	O
,	O
met	B
##han	I
##ol	I
(	O
HP	O
##LC	O
grade	O
)	O
,	O
and	O
met	B
##hyl	I
##im	I
##ida	I
##zo	I
##le	I
were	O
purchased	O
from	O
Fisher	O
/	O
Al	O
##dric	O
##h	O
(	O
NJ	O
,	O
USA	O
)	O
.	O

To	O
500	O
μ	O
##l	O
urine	O
,	O
100	O
μ	O
##l	O
of	O
a	O
solution	O
of	O
1	O
M	O
ace	B
##tic	I
acid	I
(	O
adjusted	O
to	O
pH	O
6	O
.	O
0	O
with	O
sodium	B
h	I
##ydro	I
##xi	I
##de	I
)	O
,	O
50	O
μ	O
##l	O
of	O
the	O
internal	O
standards	O
mix	O
(	B
v	B
##ali	I
##ne	I
-	I
d	I
##8	I
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
-	I
d	I
##5	I
,	O
try	O
##pt	O
##op	O
##han	O
-	O
d	O
##5	O
,	O
thy	B
##mine	I
-	I
d	I
##4	I
and	O
re	B
##ser	I
##pine	I
in	O
water	O
at	O
a	O
concentration	O
of	O
60	O
,	O
60	O
,	O
60	O
,	O
100	O
,	O
20	O
μ	O
##g	O
/	O
m	O
##l	O
,	O
respectively	O
)	O
and	O
a	O
varying	O
volume	O
of	O
the	O
ca	O
##li	O
##bra	O
##tion	O
mix	O
(	B
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
try	B
##pt	I
##op	I
##han	I
and	O
sa	B
##lic	I
##yla	I
##mi	I
##de	I
in	O
water	O
at	O
a	O
concentration	O
of	O
100	O
μ	O
##g	O
/	O
m	O
##l	O
)	O
were	O
added	O
.	O

(	O
A	O
)	O
(	O
left	O
)	O
Phase	O
contrast	O
images	O
;	O
(	O
right	O
)	O
levels	O
of	O
g	B
##lut	I
##ama	I
##te	I
in	O
H	O
##NS	O
##CC	O
cells	O
(	O
U	O
##M	O
-	O
SC	O
##C	O
-	O
14	O
##A	O
)	O
culture	O
##d	O
under	O
ad	O
##here	O
##nt	O
or	O
suspension	O
conditions	O
for	O
3	O
days	O
.	O

The	O
L	O
##O	O
##Q	O
values	O
were	O
derived	O
based	O
on	O
a	O
threshold	O
of	O
10	B
##σ	I
SD	I
units	O
above	O
the	O
background	O
signal	O
levels	O
,	O
in	O
the	O
urine	O
samples	O
from	O
three	O
volunteers	O
,	O
during	O
the	O
pre	O
-	O
exposure	O
phase	O
of	O
the	O
study	O
.	O

A	O
##bs	O
##ol	O
##ute	O
levels	O
of	O
each	O
u	O
##rina	O
##ry	O
E	O
##M	O
were	O
expressed	O
in	O
p	O
##ico	O
##mo	O
##les	O
per	O
mg	O
c	B
##rea	I
##tin	I
##ine	I
.	O

For	O
cab	B
##oz	I
##anti	I
##ni	I
##b	I
an	O
additional	O
extra	O
low	O
quality	O
control	O
sample	O
(	O
Q	O
##C	O
##X	O
##L	O
)	O
was	O
included	O
.	O

We	O
found	O
that	O
pathways	O
involved	O
in	O
the	O
transport	O
of	O
in	O
##or	O
##gan	O
##ic	O
cat	O
##ions	O
/	O
an	O
##ions	O
and	O
amino	S
acids	O
/	O
o	O
##li	O
##go	O
##pe	O
##pt	O
##ides	O
,	O
c	B
##rea	I
##tine	I
metabolism	O
,	O
amino	O
acid	O
synthesis	O
,	O
and	O
inter	O
##con	O
##version	O
(	O
trans	O
##ami	O
##nation	O
)	O
,	O
amino	O
acid	O
transport	O
across	O
the	O
plasma	O
membrane	O
,	O
transport	O
of	O
g	B
##ly	I
##cer	I
##ol	I
from	O
ad	O
##ip	O
##ocytes	O
to	O
the	O
liver	O
by	O
a	O
##qua	O
##por	O
##ins	O
,	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
cat	O
##ab	O
##olis	O
##m	O
,	O
and	O
GA	B
##BA	I
bio	O
##sy	O
##nt	O
##hesis	O
,	O
metabolism	O
,	O
and	O
cat	O
##ab	O
##olis	O
##m	O
could	O
be	O
the	O
most	O
relevant	O
biological	O
networks	O
that	O
differ	O
between	O
veterans	O
and	O
civilians	O
with	O
sa	O
##rc	O
##oid	O
##osis	O
.	O

But	O
this	O
compensation	O
is	O
not	O
sufficient	O
enough	O
by	O
body	O
because	O
decreased	O
g	B
##ly	I
##cer	I
##ol	I
has	O
no	O
such	O
significant	O
impression	O
on	O
this	O
pathway	O
as	O
compared	O
to	O
increased	O
su	B
##c	I
##rose	I
.	O

The	O
my	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
level	O
was	O
significantly	O
higher	O
in	O
the	O
OS	O
##A	O
and	O
SS	O
groups	O
and	O
could	O
be	O
part	O
of	O
a	O
com	O
##pen	O
##sat	O
##ory	O
response	O
for	O
I	O
##H	O
-	O
induced	O
skeletal	O
muscle	O
injury	O
in	O
patients	O
with	O
OS	O
##A	O
.	O

PC	O
##A	O
-	O
CA	O
of	O
_	O
1	O
H	O
N	O
##MR	O
CP	O
##MG	O
s	O
##pect	O
##ra	O
of	O
base	O
##line	O
plasma	O
samples	O
from	O
patients	O
who	O
achieved	O
complete	O
path	O
##ological	O
response	O
(	O
G	O
##R	O
,	O
green	O
)	O
and	O
partial	O
respond	O
##ers	O
(	O
PR	O
,	O
purple	O
)	O
to	O
neo	O
##ad	O
##ju	O
##vant	O
ch	O
##em	O
##otherapy	O
in	O
ER	B
(	I
+	I
)	I
(	O
A	O
)	O
and	O
ER	O
(	O
−	O
)	O
sub	O
##type	O
##s	O
(	O
B	O
)	O
.	O

To	O
determine	O
whether	O
human	O
ad	O
##ip	O
##ose	O
tissue	O
expresses	O
enzymes	O
known	O
to	O
meta	O
##bol	O
##ize	O
ant	B
##hra	I
##cy	I
##cline	I
##s	I
,	O
we	O
evaluated	O
four	O
publicly	O
available	O
gene	O
expression	O
profile	O
data	O
##sets	O
(	O
–	O
)	O
,	O
which	O
included	O
A	O
##ffy	O
##met	O
##rix	O
analyses	O
of	O
human	O
sub	O
##cut	O
##aneous	O
and	O
v	O
##is	O
##cer	O
##al	O
ad	O
##ip	O
##ose	O
tissue	O
from	O
children	O
and	O
adults	O
.	O

The	O
sample	O
residues	O
were	O
then	O
treated	O
with	O
50	O
µ	O
##L	O
met	B
##ho	I
##xy	I
##lam	I
##ine	I
for	O
a	O
2	O
h	O
in	O
##cu	O
##bation	O
at	O
60	O
°C	O
,	O
followed	O
by	O
rapid	O
addition	O
of	O
100	O
µ	O
##L	O
N	B
-	I
met	I
##hyl	I
-	I
N	I
-	I
(	I
trim	I
##eth	I
##yl	I
##si	I
##ly	I
##l	I
)	I
t	I
##ri	I
##f	I
##lu	I
##oro	I
##ace	I
##tam	I
##ide	I
(	O
MS	O
##TF	O
##A	O
)	O
with	O
1	O
%	O
t	O
##rich	O
##lor	O
##ome	O
##thy	O
##ls	O
##ilo	O
##xa	O
##ne	O
(	O
T	O
##CM	O
##S	O
)	O
,	O
for	O
a	O
1	O
h	O
in	O
##cu	O
##bation	O
at	O
60	O
°C	O
.	O

Similarly	O
,	O
we	O
prepared	O
the	O
initial	O
stock	O
solutions	O
of	O
stable	O
is	O
##oto	O
##pe	O
-	O
labeled	O
internal	O
standards	O
in	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
.	O

Ana	B
##stro	I
##zo	I
##le	I
is	O
primarily	O
cleared	O
by	O
he	O
##pa	O
##tic	O
metabolism	O
via	O
o	O
##xi	O
##da	O
##tive	O
and	O
con	O
##ju	O
##gating	O
enzymes	O
.	O

The	O
specific	O
representation	O
of	O
c	B
##era	I
##mi	I
##des	I
43	I
:	I
1	I
and	O
44	O
:	O
2	O
in	O
the	O
op	O
##tic	O
nerve	O
correspond	O
##ed	O
mainly	O
to	O
the	O
presence	O
of	O
24	O
:	O
1	O
,	O
25	O
:	O
0	O
and	O
26	O
:	O
1	O
FA	O
##s	O
.	O

(	O
a	O
)	O
Heat	O
-	O
map	O
of	O
fold	O
change	O
of	O
33	O
differential	O
meta	O
##bol	O
##ites	O
;	O
(	O
b	O
)	O
Disc	O
##rim	O
##ination	O
T	O
##2	O
##DM	O
from	O
D	O
##AC	O
##D	O
in	O
the	O
training	O
set	O
using	O
p	B
##hy	I
##tos	I
##phi	I
##ngo	I
##sin	I
##e	I
(	O
1	O
)	O
,	O
s	B
##phi	I
##nga	I
##nine	I
-	I
phosphate	I
(	O
2	O
)	O
,	O
and	O
the	O
combination	O
of	O
them	O
(	O
3	O
)	O
.	O

Therefore	O
,	O
the	O
functional	O
importance	O
of	O
higher	O
milk	O
PC	O
##ho	O
in	O
early	O
la	O
##ct	O
##ation	O
,	O
observed	O
in	O
similar	O
concentrations	O
(	O
[UNK]	O
µ	O
##mo	O
##l	O
/	O
L	O
)	O
in	O
the	O
human	O
,	O
p	B
##or	I
##cine	I
and	O
b	O
##ov	O
##ine	O
,	O
may	O
be	O
to	O
provide	O
a	O
rapidly	O
bio	O
##ava	O
##ila	O
##ble	O
supply	O
of	O
ch	B
##olin	I
##e	I
for	O
sustaining	O
growth	O
and	O
maintenance	O
of	O
new	O
born	O
animals	O
.	O

The	O
integrated	O
peak	O
area	O
for	O
_	O
13	O
C	B
_	I
2	I
-	I
o	I
##xa	I
##late	I
was	O
divided	O
by	O
the	O
peak	O
area	O
for	O
un	O
##la	O
##bel	O
##ed	O
o	B
##xa	I
##late	I
for	O
the	O
ca	O
##li	O
##bra	O
##tion	O
standards	O
to	O
obtain	O
the	O
experimental	O
trace	O
##r	O
to	O
trace	O
##e	O
ratio	O
(	O
T	O
##TR	O
)	O
.	O

The	O
diagnostic	O
utility	O
in	O
combining	O
measurement	O
of	O
the	O
up	O
-	O
regulated	O
(	B
de	B
##cano	I
##yl	I
##car	I
##ni	I
##tine	I
,	O
l	B
##ys	I
##o	I
##PC	I
(	I
16	I
:	I
0	I
)	I
,	O
l	B
##ys	I
##o	I
##PC	I
(	I
18	I
:	I
0	I
)	I
,	O
l	B
##ys	I
##o	I
##PC	I
(	I
16	I
:	I
1	I
)	I
and	O
o	B
##ct	I
##ano	I
##yl	I
##car	I
##ni	I
##tine	I
)	O
with	O
the	O
down	O
-	O
regulated	O
(	O
l	O
##ino	O
##le	O
##ic	O
acid	O
and	O
u	O
##ric	O
acid	O
)	O
was	O
relatively	O
high	O
,	O
with	O
a	O
sensitivity	O
and	O
specific	O
##ity	O
up	O
to	O
90	O
.	O
2	O
%	O
and	O
96	O
.	O
0	O
%	O
,	O
respectively	O
.	O

LP	O
##I	O
is	O
a	O
bio	O
##active	O
lip	O
##id	O
produced	O
from	O
membrane	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##lino	I
##si	I
##to	I
##l	I
(	O
P	O
##I	O
)	O
through	O
the	O
cat	O
##alytic	O
activity	O
of	O
the	O
p	O
##hos	O
##ph	O
##oli	O
##pas	O
##e	O
A	O
(	O
P	O
##LA	O
)	O
family	O
of	O
lip	O
##ases	O
,	O
including	O
P	O
##LA	O
##1	O
and	O
P	O
##LA	O
##2	O
.	O

Path	O
##way	O
analysis	O
through	O
MP	O
##P	O
shows	O
the	O
alter	O
##ation	O
or	O
disturbance	O
in	O
la	B
##ctic	I
acid	I
,	O
carbon	B
dioxide	I
and	O
p	B
##hos	I
##ph	I
##ori	I
##c	I
acid	I
involved	O
in	O
p	B
##yr	I
##u	I
##vate	I
metabolism	O
and	O
c	B
##it	I
##ric	I
acid	I
(	O
T	O
##CA	O
)	O
cycle	O
between	O
controls	O
and	O
lung	O
cancer	O
.	O

The	O
g	O
##ly	O
##co	O
##lysis	O
product	O
p	B
##yr	I
##u	I
##vic	I
acid	I
cannot	O
be	O
used	O
in	O
the	O
t	B
##rica	I
##rb	I
##ox	I
##yl	I
##ic	I
acid	I
cycle	O
and	O
is	O
meta	O
##bol	O
##ized	O
to	O
la	B
##ctic	I
acid	I
;	O
thus	O
,	O
la	B
##ctic	I
acid	I
levels	O
were	O
increased	O
after	O
surgery	O
.	O

HP	O
##LC	O
-	O
grade	O
is	B
##op	I
##rop	I
##ano	I
##l	I
and	O
et	B
##hyl	I
ace	I
##tate	I
were	O
bought	O
from	O
The	O
##rm	O
##o	O
fish	O
##er	O
(	O

[	O
Google	O
Scholar	O
]	O
L	O
##ø	O
##nning	O
P	O
##E	O
,	O
K	O
##vin	O
##ns	O
##land	O
S	O
.	O
Me	O
##chan	O
##isms	O
of	O
action	O
of	O
amino	B
##g	I
##lut	I
##eth	I
##im	I
##ide	I
as	O
end	O
##oc	O
##rine	O
therapy	O
of	O
breast	O
cancer	O
.	O

Since	O
bi	O
##le	O
acid	O
synthesis	O
is	O
a	O
primary	O
route	O
for	O
ch	B
##ole	I
##ster	I
##ol	I
ex	O
##cre	O
##tion	O
and	O
can	O
affect	O
in	O
##test	O
##inal	O
absorption	O
of	O
diet	O
##ary	O
fat	O
##s	O
,	O
these	O
observations	O
suggest	O
that	O
sleep	O
duration	S
may	O
interact	O
with	O
various	O
diet	O
##ary	O
and	O
intrinsic	O
gas	O
##tro	O
##int	O
##est	O
##inal	O
factors	O
to	O
influence	O
systemic	O
lip	O
##id	O
metabolism	O
.	O

Whether	O
this	O
con	O
##fers	O
a	O
difference	O
in	O
long	O
##evity	O
between	O
sexes	O
is	O
still	O
unclear	O
,	O
though	O
we	O
were	O
able	O
to	O
show	O
a	O
negative	O
correlation	O
between	O
some	O
of	O
these	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
with	O
t	B
##rig	I
##ly	I
##cer	I
##ide	I
and	O
L	O
##D	O
##L	O
-	O
C	O
levels	O
among	O
females	O
,	O
which	O
could	O
be	O
in	O
##dicative	O
of	O
an	O
anti	O
-	O
at	O
##her	O
##ogenic	O
profile	O
in	O
extreme	O
aged	O
females	O
.	O

To	O
explore	O
the	O
bio	O
##chemical	O
differences	O
,	O
shows	O
an	O
O	O
##PL	O
##S	O
-	O
D	O
##A	O
model	O
with	O
one	O
predicted	O
and	O
one	O
or	O
##th	O
##ogo	O
##nal	O
component	O
(	O
R	O
##2	O
##X	O
=	O
0	O
.	O
42	O
,	O
R	O
##2	O
##Y	O
=	O
0	O
.	O
82	O
and	O
Q	O
##2	O
=	O
0	O
.	O
53	O
)	O
between	O
time	O
-	O
points	O
70	O
and	O
220	O
min	O
for	O
the	O
calcium	B
case	I
##inate	I
treatment	O
.	O

Le	B
##uc	I
##ine	I
en	O
##ka	O
##pha	O
##lin	O
was	O
used	O
as	O
the	O
reference	O
compound	O
(	O
positive	O
ion	O
mode	O
(	O
[	O
M	O
+	O
H	O
]	O
_	O
+	O
=	O
55	O
##6	O
.	O
27	O
##7	O
##1	O
)	O
and	O
[	O
M	O
##−	O
##H	O
]	O
_	O
−	O
=	O
55	O
##4	O
.	O
261	O
##5	O
)	O
at	O
a	O
concentration	O
of	O
0	O
.	O
2	O
ng	O
/	O
m	O
##L	O
under	O
a	O
flow	O
rate	O
of	O
100	O
µ	O
##l	O
·	O
min	O
_	O
−	O
##1	O
,	O
to	O
ensure	O
accuracy	O
and	O
re	O
##p	O
##rod	O
##uc	O
##ibility	O
during	O
the	O
MS	O
analysis	O
.	O

Em	O
##erging	O
data	O
suggest	O
that	O
impaired	O
at	O
##rial	O
function	O
,	O
or	O
card	O
##io	O
##pathy	O
,	O
predict	O
##s	O
future	O
A	B
##F	I
and	O
incident	O
stroke	O
.	O

To	O
begin	O
to	O
address	O
this	O
question	O
,	O
the	O
l	O
##ute	O
##al	O
phase	O
u	O
##rina	O
##ry	O
E	O
##M	O
data	O
for	O
the	O
controls	O
in	O
the	O
NHS	O
II	O
study	O
were	O
combined	O
with	O
comparable	O
data	O
from	O
a	O
bio	O
##mark	O
##er	O
re	O
##p	O
##rod	O
##uc	O
##ibility	O
study	O
in	O
NHS	O
II	O
in	O
order	O
to	O
explore	O
co	O
##rrel	O
##ates	O
and	O
possible	O
de	O
##ter	O
##mina	O
##nts	O
of	O
est	B
##rogen	I
production	O
and	O
metabolism	O
in	O
60	O
##3	O
pre	O
##men	O
##op	O
##aus	O
##al	O
women	O
.	O

In	O
addition	O
,	O
ho	B
##mo	I
##cy	I
##stein	I
##e	I
(	O
HC	O
##Y	O
)	O
,	O
met	B
##hi	I
##oni	I
##ne	I
(	O
ME	O
##TH	O
)	O
,	O
S	B
-	I
ad	I
##eno	I
##sy	I
##l	I
met	I
##hi	I
##oni	I
##ne	I
(	O
SA	O
##M	O
)	O
,	O
S	B
-	I
ad	I
##eno	I
##sy	I
##l	I
ho	I
##mo	I
##cy	I
##stein	I
##e	I
(	O
SA	O
##H	O
)	O
,	O
de	O
##uter	O
##ated	O
SA	O
##H	O
,	O
c	B
##ys	I
##tat	I
##hi	I
##oni	I
##ne	I
(	O
C	O
##Y	O
##ST	O
##H	O
)	O
,	O
met	B
##hyl	I
##mal	I
##onic	I
acid	I
(	O
MMA	O
)	O
,	O
and	O
t	B
##ris	I
(	I
2	I
-	I
car	I
##bi	I
##xy	I
##eth	I
##yl	I
)	I
p	I
##hos	I
##phine	I
(	O
T	O
##CE	O
##P	O
)	O
were	O
bought	O
from	O
Sigma	O
(	O
St	O
Louis	O
,	O
M	O
##O	O
,	O
USA	O
)	O
.	O

Collective	O
##ly	O
,	O
these	O
results	O
support	O
that	O
therapeutic	O
intervention	O
by	O
MA	O
##P	O
##K	O
##I	O
##s	O
leads	O
to	O
different	O
k	B
##yn	I
##uren	I
##ine	I
pathways	O
meta	O
##bol	O
##ite	O
trajectory	O
which	O
is	O
of	O
importance	O
in	O
altered	O
T	O
##h	O
##1	O
/	O
T	O
##h	O
##2	O
differentiation	O
markers	O
in	O
PR	O
##E	O
and	O
T	O
##R	O
##M	O
C	O
##MM	O
groups	O
.	O

We	O
found	O
that	O
P	O
,	O
IP	S
,	O
and	O
I	O
.	O
S	O
.	O
presented	O
a	O
stronger	O
ion	O
##ization	O
in	O
the	O
positive	O
ion	O
mode	O
,	O
while	O
the	O
other	O
four	O
meta	O
##bol	O
##ites	O
presented	O
a	O
stronger	O
ion	O
##ization	O
in	O
the	O
negative	O
ion	O
mode	O
.	O

The	O
best	O
MS	O
/	O
MS	O
transition	O
(	O
Table	O
)	O
for	O
s	B
##pi	I
##ron	I
##ola	I
##cton	I
##e	I
and	O
can	B
##ren	I
##one	I
found	O
(	O
as	O
already	O
reported	O
by	O
others	O
[	O
,	O
]	O
)	O
was	O
m	O
/	O
z	O
34	O
##1	O

W	O
##heat	O
flour	O
is	O
composed	O
of	O
approximately	O
63	O
–	O
72	O
%	O
star	O
##ch	O
and	O
12	O
%	O
protein	O
,	O
both	O
of	O
which	O
are	O
h	O
##ydro	O
##ly	O
##zed	O
by	O
am	O
##yla	O
##ses	O
and	O
pro	O
##te	O
##ases	O
in	O
the	O
gas	O
##tro	O
##int	O
##est	O
##inal	O
tract	O
(	O
G	O
##IT	O
)	O
,	O
resulting	O
in	O
the	O
release	O
of	O
glucose	S
and	O
free	O
amino	O
acids	O
,	O
respectively	O
,	O
into	O
the	O
blood	O
.	O

Meanwhile	O
,	O
the	O
a	O
##MC	O
##I	O
group	O
also	O
demonstrated	O
an	O
increased	O
concentration	O
of	O
c	B
##ys	I
##tein	I
##e	I
,	O
with	O
a	O
mean	O
value	O
of	O
230	O
.	O
43	O
ng	O
/	O
m	O
##l	O
compared	O
with	O
177	O
.	O
42	O
ng	O
/	O
m	O
##l	O
in	O
controls	O
,	O
suggesting	O
that	O
altered	O
c	B
##ys	I
##tein	I
##e	I
metabolism	O
occurs	O
in	O
a	O
##MC	O
##I	O
patients	O
.	O

Finally	O
,	O
er	B
##yt	I
##hr	I
##onic	I
acid	I
was	O
one	O
of	O
three	O
up	O
##re	O
##gu	O
##lated	O
meta	O
##bol	O
##ites	O
in	O
both	O
plasma	O
and	O
urine	O
in	O
response	O
to	O
a	O
single	O
oral	O
dose	O
of	O
either	O
50	O
or	O
100	O
g	O
su	B
##c	I
##rose	I
.	O

We	O
in	O
##cu	O
##bate	O
##d	O
human	O
he	O
##pa	O
##to	O
##cy	O
##tes	O
from	O
10	O
donors	O
with	O
race	O
##mic	O
anti	B
-	I
Ba	I
##P	I
-	I
7	I
,	I
8	I
-	I
di	I
##ol	I
-	I
9	I
,	I
10	I
-	I
e	I
##pox	I
##ide	I
(	O
BP	O
##DE	O
)	O
,	O
believed	O
to	O
be	O
a	O
major	O
ultimate	O
car	O
##cin	O
##ogen	O
of	O
Ba	O
##P	O
,	O
or	O
with	O
the	O
non	O
##car	O
##cin	O
##ogenic	O
reverse	O
di	B
##ol	I
e	I
##pox	I
##ide	I
,	O
race	O
##mic	O
anti	B
-	I
Ba	I
##P	I
-	I
9	I
,	I
10	I
-	I
di	I
##ol	I
-	I
7	I
,	I
8	I
-	I
e	I
##pox	I
##ide	I
(	O
re	O
##v	O
-	O
BP	O
##DE	O
)	O
.	O

As	O
compared	O
to	O
controls	O
,	O
I	O
##BS	O
patients	O
had	O
higher	O
c	B
##it	I
##ru	I
##llin	I
##e	I
and	O
D	B
##MA	I
and	O
lower	O
SD	O
##MA	O
concentrations	O
.	O

As	O
expected	O
,	O
la	B
##ct	I
##ate	I
levels	O
were	O
increased	O
with	O
longer	O
f	O
##er	O
##mentation	O
and	O
were	O
very	O
high	O
in	O
both	O
the	O
sour	O
##do	O
##ugh	O
(	O
405	O
µ	O
##mo	O
##les	O
/	O
g	O
)	O
and	O
the	O
sour	O
##do	O
##ugh	O
bread	O
(	O
111	O
.	O
4	O
405	O
µ	O
##mo	O
##les	O
/	O
g	O
)	O
.	O

From	O
left	O
to	O
right	O
:	O
tissue	O
micro	O
##graph	O
(	O
A	O
)	O
;	O
palm	B
##itate	I
(	I
C	I
##16	I
:	I
0	I
)	I
(	O
B	O
)	O
;	O
palm	B
##ito	I
##lea	I
##te	I
(	I
C	I
##16	I
:	I
1	I
)	I
(	O
C	O
)	O
;	O
s	B
##te	I
##arate	I
(	I
C	I
##18	I
:	I
0	I
)	I
(	O
D	O
)	O
;	O
o	B
##lea	I
##te	I
(	I
C	I
##18	I
:	I
1	I
)	I
(	O
E	O
)	O
;	O
l	B
##ino	I
##lea	I
##te	I
(	I
C	I
##18	I
:	I
2	I
)	I
(	O
F	O
)	O
;	O
image	O
over	O
##lay	O
of	O
palm	B
##ite	I
##lea	I
##te	I
(	O
red	O
)	O
,	O
ch	B
##ole	I
##ster	I
##ol	I
(	O
green	O
)	O
,	O
and	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
(	O
blue	O
)	O
(	O
G	O
)	O
;	O
phosphate	S
(	O
H	O
)	O
,	O
p	B
##hos	I
##ph	I
##oi	I
##nos	I
##ito	I
##l	I
fragment	O
(	O
I	O
)	O
,	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
(	O
J	O
)	O
,	O
ch	B
##ole	I
##ster	I
##ol	I
(	O
K	O
)	O
,	O
and	O
total	O
ion	O
intensity	O
(	O
L	O
)	O
.	O

OR	O
##s	O
and	O
95	O
%	O
C	O
##I	O
##s	O
of	O
P	O
##LC	O
in	O
four	O
groups	O
:	O
low	O
T	O
##MA	O
##O	O
/	O
high	O
ch	B
##olin	I
##e	I
,	O
low	O
T	O
##MA	O
##O	O
/	O
low	O
ch	B
##olin	I
##e	I
,	O
high	O
T	O
##MA	O
##O	O
/	O
high	O
ch	B
##olin	I
##e	I
,	O
and	O
high	O
T	O
##MA	O
##O	O
/	O
low	O
ch	B
##olin	I
##e	I
.	O

K	O
##A	O
,	O
X	O
##A	O
,	O
H	O
##AA	O
and	O
Q	O
##A	O
showed	O
positive	O
correlation	O
with	O
both	O
vitamin	B
B	I
##2	I
(	O
r	O
:	O
0	O
.	O
15	O
–	O
0	O
.	O
27	O
)	O
and	O
total	O
vitamin	B
B	I
##6	I
(	O
r	O
:	O
0	O
.	O
18	O
–	O
0	O
.	O
24	O
)	O
.	O

Studies	O
examining	O
associations	O
between	O
pu	B
##rine	I
meta	O
##bol	O
##ites	O
and	O
type	O
2	O
diabetes	O
(	O
T	O
##2	O
##D	O
)	O
are	O
limited	O
.	O

(	O
β	O
=	O
0	O
.	O
49	O
,	O
R	O
_	O
2	O
=	O
0	O
.	O
27	O
,	O
P	O
=	O
0	O
.	O
01	O
)	O
,	O
PC	B
(	I
O	I
-	I
14	I
:	I
1	I
/	I
2	I
:	I
0	I
)	I
(	O
β	O
=	O
0	O
.	O
45	O
,	O
R	O
_	O
2	O
=	O
0	O
.	O
23	O
,	O
P	O
=	O
0	O
.	O
02	O
)	O
,	O
PC	B
(	I
O	I
-	I
17	I
:	I
3	I
/	I
2	I
:	I
0	I
)	I
(	O
β	O
=	O
0	O
.	O
48	O
,	O
R	O
_	O
2	O
=	O
0	O
.	O
29	O
,	O
P	O
=	O
0	O
.	O
02	O
)	O
,	O
and	O
PC	B
(	I
O	I
-	I
18	I
:	I
3	I
/	I
2	I
:	I
0	I
)	I
(	O
β	O
=	O
0	O
.	O
52	O
,	O
R	O
_	O
2	O
=	O
0	O
.	O
29	O
,	O
P	O
=	O
0	O
.	O
01	O
)	O
remained	O
significantly	O
associated	O
with	O
H	O
##AM	O
-	O
D	O
score	O
.	O

La	B
##nt	I
##hi	I
##oni	I
##ne	I
and	O
ho	B
##mo	I
##lant	I
##hi	I
##oni	I
##ne	I
have	O
both	O
been	O
measured	O
in	O
urine	O
in	O
ho	O
##mo	O
##cy	O
##st	O
##ine	O
##uria	O
.	O

The	O
N	O
-	O
A	O
##c	O
##CA	O
##D	O
,	O
N	O
-	O
A	O
##c	O
##DA	O
##P	O
,	O
and	O
N	O
##1	O
-	O
A	O
##c	O
##I	O
##so	O
##P	O
##UT	O
##R	O
levels	O
were	O
semi	O
##qua	O
##nti	O
##fied	O
with	O
the	O
current	O
method	O
in	O
urine	O
and	O
serum	O
samples	O
with	O
CA	O
##D	O
,	O
D	O
##AP	O
,	O
and	O
GA	B
##BA	I
ca	O
##li	O
##bra	O
##tion	O
curves	O
,	O
respectively	O
.	O

However	O
,	O
there	O
was	O
no	O
evidence	O
for	O
a	O
decreased	O
level	O
of	O
lip	O
##op	O
##rote	O
##in	O
lip	O
##ase	O
in	O
the	O
ad	O
##ip	O
##ose	O
tissue	O
of	O
cancer	O
patients	O
,	O
but	O
there	O
was	O
a	O
two	O
‐	O
fold	O
increase	O
in	O
the	O
relative	O
level	O
of	O
m	O
##RNA	O
for	O
hormone	O
‐	O
sensitive	O
lip	O
##ase	O
,	O
suggesting	O
an	O
up	O
##re	O
##gu	O
##lation	O
of	O
t	O
##ria	O
##cy	O
##l	O
##gly	O
##cer	O
##ol	O
h	O
##ydro	O
##lysis	O
.	O
6	O
,	O
61	O
Also	O
,	O
in	O
response	O
to	O
glucose	S
limitation	O
,	O
fatty	O
acid	O
can	O
also	O
be	O
consumed	O
through	O
β	O
‐	O
oxidation	O
to	O
provide	O
key	O
substitute	O
energy	O
for	O
cancer	O
cell	O
survival	O
.	O

PC	B
(	I
16	I
:	I
0	I
/	I
14	I
:	I
0	I
)	I
and	O
PC	B
(	I
18	I
:	I
0	I
/	I
18	I
:	I
2	I
)	I
showed	O
a	O
reduction	O
in	O
level	O
from	O
pre	O
-	O
D	O
##M	O
to	O
D	O
##M	O
,	O
while	O
PC	B
(	I
14	I
:	I
1	I
/	I
16	I
:	I
1	I
)	I
increased	O
and	O
PC	B
(	I
18	I
:	I
3	I
/	I
20	I
:	I
3	I
)	I
decreased	O
from	O
pre	O
-	O
D	O
##M	O
to	O
N	O
##GR	O
.	O

These	O
compounds	O
included	O
22	O
amino	O
acids	O
(	O
AA	O
)	O
,	O
45	O
non	O
-	O
est	O
##eri	O
##fied	O
fatty	O
acids	O
(	O
NE	O
##FA	O
)	O
,	O
19	O
o	O
##xi	O
##dis	O
##ed	O
fatty	O
acids	O
,	O
11	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
,	O
12	O
di	B
##acy	I
##l	I
##gly	I
##cer	I
##ols	I
,	O
69	O
t	B
##ria	I
##cy	I
##l	I
##gly	I
##cer	I
##ols	I
(	O
T	O
##AG	O
)	O
,	O
14	O
ch	B
##ole	I
##ster	I
##yl	I
est	I
##ers	I
(	O
Cho	O
##E	O
)	O
,	O
12	O
bi	O
##le	O
acids	O
(	O
BA	O
)	O
,	O
203	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
,	O
and	O
37	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
.	O

L	O
##C	O
-	O
MS	O
grade	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
(	O
AC	O
##N	O
)	O
,	O
met	B
##han	I
##ol	I
(	O
Me	O
##OH	O
)	O
,	O
and	O
is	B
##op	I
##rop	I
##yl	I
alcohol	I
(	O
IPA	O
)	O
as	O
well	O
as	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
and	O
ace	B
##tic	I
acid	I
were	O
obtained	O
from	O
Fisher	O
Scientific	O
(	O
Pittsburgh	O
,	O
PA	O
)	O
.	O

Further	O
,	O
both	O
ta	B
##uri	I
##ne	I
and	O
my	O
##o	O
-	O
in	O
##os	O
##ito	O
##l	O
showed	O
strong	O
positive	O
correlation	O
with	O
r	O
##AF	O
##S	O
scores	O
(	O
Su	O
##pp	O
##lement	O
##ary	O
figure	O
3	O
)	O
suggesting	O
their	O
role	O
in	O
disease	O
progression	O
.	O

While	O
prior	O
clinical	O
meta	O
##bol	O
##omi	O
##cs	O
studies	O
have	O
focus	O
##sed	O
on	O
a	O
mixture	O
of	O
individuals	O
with	O
norm	O
##og	O
##ly	O
##ca	O
##emia	O
and	O
prevalent	O
d	O
##ys	O
##gly	O
##ca	O
##emia	O
[	O
–	O
]	O
,	O
our	O
work	O
is	O
novel	O
in	O
its	O
study	O
of	O
participants	O
who	O
were	O
norm	B
##og	I
##ly	I
##ca	I
##em	I
##ic	I
yet	O
progressed	O
to	O
type	O
2	O
diabetes	O
.	O

_	O
,	O
_	O
,	O
The	O
var	O
##iability	O
and	O
practical	O
consequences	O
of	O
c	B
##it	I
##rate	I
were	O
observed	O
in	O
our	O
study	O
,	O
since	O
the	O
log	O
##istic	O
re	O
##gression	O
analysis	O
showed	O
the	O
C	O
##it	O
/	O
C	O
##re	O
ratio	O
to	O
be	O
significantly	O
(	O
P	O
=	O
0	O
.	O
01	O
##0	O
)	O
related	O
to	O
aggressive	O
##ness	O
(	O
tumor	O
G	O
##lea	O
##son	O
score	O
)	O
without	O
adjusting	O
for	O
cluster	O
##ing	O
,	O
but	O
non	O
-	O
significantly	O
related	O
(	O
P	O
=	O
0	O
.	O
08	O
##1	O
)	O
after	O
adjusting	O
for	O
cluster	O
##ing	O
.	O

Other	O
factors	O
such	O
as	O
sex	O
,	O
and	O
the	O
duration	S
of	O
maintenance	O
therapy	O
did	O
not	O
affect	O
concentrations	O
of	O
6	O
##MP	O
meta	O
##bol	O
##ites	O
.	O

It	O
is	O
unfortunate	O
that	O
the	O
PA	O
##H	O
meta	O
##bol	O
##ites	O
measured	O
in	O
urine	O
derive	O
from	O
the	O
low	O
molecular	O
weight	O
compounds	O
(	B
nap	B
##ht	I
##hale	I
##ne	I
,	O
flu	B
##ore	I
##ne	I
,	O
p	B
##hen	I
##ant	I
##hren	I
##e	I
and	O
p	O
##yre	O
##ne	O
)	O
,	O
for	O
which	O
our	O
data	O
do	O
not	O
reflect	O
the	O
entire	O
airborne	O
concentration	O
,	O
as	O
the	O
sampling	O
technique	O
collects	O
only	O
the	O
particle	O
phase	O
,	O
which	O
contains	O
a	O
minor	O
proportion	O
of	O
the	O
low	O
molecular	O
weight	O
PA	O
##H	O
##s	O
.	O

In	O
the	O
A	O
##con	O
-	O
knock	O
##down	O
flies	O
,	O
ATP	S
content	O
was	O
reduced	O
indicating	O
an	O
imp	O
##air	O
##ment	O
of	O
downstream	O
o	O
##xi	O
##da	O
##tive	O
p	O
##hos	O
##ph	O
##ory	O
##lation	O
.	O

Also	O
other	O
meta	O
##bol	O
##omi	O
##c	O
studies	O
of	O
I	O
##B	O
##D	O
have	O
revealed	O
a	O
down	O
##re	O
##gu	O
##lation	O
of	O
ch	B
##olin	I
##e	I
,	I
_	I
,	O
which	O
is	O
an	O
essential	O
nut	O
##rient	O
.	O

Po	O
##ssi	O
##bly	O
,	O
even	O
sub	O
##c	O
##lini	O
##cal	O
inflammation	O
could	O
be	O
able	O
to	O
increase	O
k	B
##yn	I
##uren	I
##ine	I
concentrations	O
by	O
changing	O
expression	O
of	O
ID	O
##O	O
##1	O
and	O
reduce	O
B	O
##MD	O
by	O
in	O
##ducing	O
bone	O
re	O
##sor	O
##ption	O
.	O

Certainly	O
,	O
further	O
in	O
v	O
##it	O
##ro	O
and	O
in	O
v	O
##ivo	O
studies	O
are	O
necessary	O
to	O
shed	O
light	O
into	O
the	O
path	O
##op	O
##hy	O
##sio	O
##log	O
##ic	O
links	O
between	O
SL	S
metabolism	O
and	O
HC	O
##C	O
.	O

Since	O
the	O
meta	O
##bol	O
##ite	O
standard	O
was	O
not	O
available	O
to	O
us	O
,	O
q	O
##uant	O
##ification	O
of	O
this	O
meta	O
##bol	O
##ite	O
was	O
made	O
using	O
standard	O
curves	O
generated	O
with	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
.	O

G	O
##C	O
separation	O
of	O
volatile	O
##s	O
was	O
carried	O
out	O
on	O
a	O
DB	O
-	O
5	O
m	O
##s	O
column	O
(	O
A	O
##gi	O
##lent	O
,	O
30	O
m	O
length	O
,	O
0	O
.	O
25	O
mm	O
inner	O
diameter	O
,	O
and	O
0	O
.	O
25	O
μ	O
##m	O
film	O
,	O
non	O
-	O
polar	O
phase	O
,	O
p	B
##hen	I
##yl	I
a	I
##ryl	I
##ene	I
polymer	O
)	O
.	O

P	B
##se	I
##udo	I
##uri	I
##dine	I
,	O
the	O
C	B
-	I
g	I
##ly	I
##cos	I
##ide	I
is	I
##omer	I
of	O
the	O
RNA	O
n	O
##uc	O
##leo	O
##tide	O
u	B
##rid	I
##ine	I
,	O
is	O
present	O
in	O
essentially	O
all	O
rib	O
##oso	O
##mal	O
RNA	O
##s	O
and	O
seems	O
to	O
be	O
affected	O
by	O
si	B
##m	I
##vas	I
##tat	I
##in	I
.	O

The	O
resolution	O
of	O
the	O
instrument	O
in	O
single	O
-	O
stage	O
TO	O
##F	O
mode	O
was	O
measured	O
at	O
5	O
,	O
400	O
at	O
50	O
%	O
valley	O
definition	O
with	O
le	B
##uc	I
##ine	I
en	I
##ke	I
##pha	I
##lin	I

Apart	O
from	O
p	B
##oly	I
##amine	I
and	O
L	B
-	I
a	I
##rg	I
##ini	I
##ne	I
metabolism	O
several	O
other	O
areas	O
of	O
metabolism	O
were	O
affected	O
in	O
AD	O
convert	O
##ers	O
,	O
and	O
within	O
the	O
context	O
of	O
AD	O
these	O
appear	O
to	O
be	O
both	O
plausible	O
and	O
relevant	O
.	O

Given	O
our	O
current	O
findings	O
and	O
these	O
previous	O
studies	O
,	O
it	O
is	O
possible	O
that	O
d	O
##ys	O
##re	O
##gu	O
##lated	O
a	B
##rg	I
##ini	I
##ne	I
metabolism	O
may	O
be	O
linked	O
not	O
only	O
through	O
u	B
##rea	I
cycle	O
meta	O
##bol	O
##ites	O
,	O
but	O
also	O
through	O
AD	B
##MA	I
and	O
NO	O
.	O

)	O
as	O
does	O
its	O
precursor	O
me	B
##val	I
##onic	I
acid	I
.	O

These	O
results	O
were	O
surprising	O
given	O
the	O
presumed	O
anti	O
##in	O
##f	O
##lam	O
##mat	O
##ory	O
action	O
of	O
α	B
-	I
l	I
##ino	I
##len	I
##ic	I
acid	I
.	O

MR	O
##M	O
time	O
segments	O
,	O
precursor	O
/	O
product	O
ion	O
transitions	O
,	O
and	O
collision	O
energies	O
for	O
the	O
investigated	O
vitamin	B
D	I
compounds	O
_	O
a	O
(	O
M	O
+	O
H	O
–	O
H	O
_	O
2	O
O	O
)	O
_	O
+	O
MR	O
##M	O
signal	O
in	O
##tens	O
##ities	O
obtained	O
for	O
different	O
mobile	O
phase	O
compositions	O
:	O
solvent	O
1	O
and	O
3	O
,	O
ion	O
currents	O
for	O
transition	O
der	O
##iva	O
##tized	O
precursor	O
ion	O
/	O
fragment	O
ion	O
;	O
solvent	O
2	O
and	O
4	O
,	O
ion	O
currents	O
for	O
transition	O
met	B
##hyl	I
##amine	I
add	O
##uc	O
##t	O
of	O
der	O
##iva	O
##tized	O
precursor	O
ion	O
/	O
fragment	O
ion	O
.	O

In	O
a	O
prospective	O
co	O
##hor	O
##t	O
study	O
,	O
His	O
##ama	O
##tsu	O
et	O
al	O
[	O
]	O
measured	O
plasma	O
levels	O
of	O
nineteen	O
amino	O
acids	O
and	O
found	O
that	O
decreased	O
his	B
##ti	I
##dine	I
level	O
in	O
plasma	O
free	O
amino	O
acids	O
was	O
associated	O
with	O
increased	O
risk	O
of	O
re	O
##lap	O
##se	O
in	O
UC	O
patients	O
during	O
a	O
one	O
-	O
year	O
follow	O
-	O
up	O
.	O

The	O
main	O
trend	O
in	O
meta	O
##bol	O
##ite	O
profile	O
consists	O
in	O
a	O
decrease	O
of	O
SM	B
(	I
OH	I
)	I
22	I
:	I
1	I
and	O
SM	B
(	I
OH	I
)	I
22	I
:	I
2	I
levels	O
and	O
an	O
increase	O
of	O
C	O
##16	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
in	O
both	O
infected	O
and	O
not	O
infected	O
individuals	O
.	O

The	O
other	O
one	O
,	O
PC	B
(	I
C	I
##16	I
:	I
0	I
,	I
C	I
##20	I
:	I
4	I
)	I
(	O
data	O
not	O
shown	O
)	O
,	O
displayed	O
a	O
similar	O
behavior	O
but	O
failed	O
to	O
reach	O
F	O
##DR	O
<	O
0	O
.	O
05	O
.	O

In	O
contrast	O
,	O
higher	O
levels	O
in	O
tumor	O
tissues	O
of	O
other	O
p	B
##oly	I
##amine	I
##s	I
(	I
put	I
##res	I
##cine	I
,	I
sperm	I
##ine	I
and	O
sperm	B
##id	I
##ine	I
)	I
,	O
as	O
well	O
as	O
related	O
molecules	O
(	O
N	O
‐	B
ace	I
##ty	I
##l	I
##put	I
##res	I
##cine	I
and	O
M	O
##TA	O
)	O
,	O
critical	O
regulator	O
##s	O
of	O
nuclei	O
##c	O
acid	O
stab	O
##ilization	O
and	O
cell	O
cycle	O
progression	O
,	O
were	O
detected	O
(	O
G	O
##erne	O
##r	O
and	O
Me	O
##ys	O
##ken	O
##s	O
,	O
2004	O
;	O
P	O
##eg	O
##g	O
,	O
2009	O
)	O
.	O

It	O
remains	O
intriguing	O
that	O
the	O
only	O
amino	O
acid	O
and	O
bio	O
##genic	O
am	O
##ines	O
shown	O
here	O
to	O
increase	O
during	O
acute	O
sleep	O
de	O
##p	O
##ri	O
##vation	O
(	O
se	O
##rot	O
##oni	O
##n	O
,	O
try	B
##pt	I
##op	I
##han	I
,	O
ta	B
##uri	I
##ne	I
)	O
have	O
been	O
implicated	O
in	O
the	O
et	O
##iology	O
of	O
depression	O
(	O
,	O
,	O
,	O
,	O
)	O
.	O

Based	O
on	O
their	O
chemical	O
compositions	O
,	O
2	B
-	I
he	I
##pta	I
##non	I
##e	I
and	O
4	B
-	I
He	I
##pta	I
##non	I
##e	I
are	O
k	B
##eton	I
##es	I
.	O

All	O
the	O
V	O
##OC	O
concentrations	O
,	O
including	O
1	B
,	I
3	I
-	I
but	I
##adi	I
##ene	I
,	O
PA	O
##H	O
and	O
u	O
##rina	O
##ry	O
bio	O
##mark	O
##er	O
(	O
ET	O
##S	O
and	O
PA	O
##H	O
meta	O
##bol	O
##ites	O
)	O
concentrations	O
were	O
found	O
to	O
have	O
right	O
-	O
s	O
##ke	O
##wed	O
distributions	O
.	O

Furthermore	O
,	O
higher	O
levels	O
of	O
the	O
la	O
##ctic	O
-	O
acid	O
bacterial	O
genus	O
Lac	B
##to	I
##ba	I
##ci	I
##llus	I
were	O
associated	O
with	O
increased	O
risk	O
for	O
CR	O
##C	O
.	O

When	O
the	O
T	O
##CA	O
cycle	O
cannot	O
supply	O
sufficient	O
ATP	S
due	O
to	O
h	O
##y	O
##pox	O
##ia	O
,	O
g	O
##ly	O
##co	O
##lysis	O
compensate	O
##s	O
by	O
enhancing	O
its	O
activity	O
.	O

(	O
B	O
)	O
Representative	O
western	O
b	O
##lot	O
showed	O
the	O
reduced	O
levels	O
of	O
p	O
##53	O
and	O
p	O
##21	O
expression	O
in	O
T	O
##RT	O
-	O
H	O
##U	O
##1	O
cells	O
treated	O
with	O
α	B
-	I
O	I
##G	I
.	O

The	O
column	O
was	O
el	O
##uted	O
is	O
##oc	O
##ratic	O
##ally	O
at	O
a	O
flow	O
rate	O
of	O
400	O
μ	O
##L	O
/	O
min	O
with	O
25	O
%	O
mobile	O
phase	O
A	O
(	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
in	O
water	O
)	O
for	O
1	O
minute	O
followed	O
by	O
a	O
linear	O
gradient	O
to	O
100	O
%	O
mobile	O
phase	O
B	O
(	O
ace	O
##ton	O
##it	O
##ril	O
##e	O
with	O
0	O
.	O
1	O
%	O
form	O
##ic	O
acid	O
)	O
over	O
11	O
minutes	O
.	O

Met	O
##ab	O
##oli	O
##tes	O
with	O
>	O
25	O
%	O
of	O
values	O
below	O
the	O
lower	O
limit	O
of	O
q	O
##uant	O
##ification	O
were	O
excluded	O
from	O
analysis	O
(	B
he	B
##xa	I
##noy	I
##l	I
car	I
##ni	I
##tine	I
,	O
p	B
##ime	I
##ly	I
##l	I
‐	I
l	I
‐	I
car	I
##ni	I
##tine	I
)	O
.	O

To	O
monitor	O
the	O
efficiency	O
of	O
the	O
en	O
##zy	O
##matic	O
h	O
##ydro	O
##lysis	O
and	O
confirm	O
that	O
the	O
enzyme	O
functioned	O
properly	O
,	O
we	O
used	O
the	O
area	O
ratio	O
of	O
4	B
-	I
met	I
##hyl	I
##um	I
##bell	I
##ifer	I
##one	I
/	I
_	I
13	I
C	I
_	I
4	I
-	I
4	I
-	I
met	I
##hyl	I
##um	I
##bell	I
##ifer	I
##one	I
for	O
each	O
sample	O
[	O
–	O
]	O
.	O

Met	O
##ab	O
##olic	O
Path	O
##way	O
Analysis	O
showed	O
that	O
the	O
al	B
##ani	I
##ne	I
and	O
g	B
##lut	I
##ama	I
##te	I
metabolism	O
was	O
the	O
most	O
impact	O
##ing	O
pathway	O
different	O
##iating	O
EA	O
##R	O
from	O
AD	O
##V	O
HC	O
##C	O
patients	O
.	O

F	B
_	I
2	I
-	I
is	I
##op	I
##ros	I
##tan	I
##es	I
were	O
converted	O
to	O
pen	B
##ta	I
##f	I
##lu	I
##oro	I
##ben	I
##zy	I
##l	I
est	I
##ers	I
,	O
subjected	O
to	O
thin	O
layer	O
ch	O
##roma	O
##tography	O
,	O
and	O
converted	O
to	O
trim	B
##eth	I
##yl	I
##si	I
##ly	I
##l	I
et	I
##her	I
derivatives	O
.	O

As	O
an	O
anti	O
##ox	O
##ida	O
##tive	O
,	O
it	O
is	O
known	O
to	O
at	O
##ten	O
##uate	O
h	O
##y	O
##pox	O
##ia	O
,	O
inflammation	O
,	O
vascular	O
leak	O
,	O
and	O
ed	O
##ema	O
and	O
to	O
decrease	O
H	B
##IF	I
-	I
1	I
##α	I
protein	I
levels	O
.	O

The	O
retention	O
times	O
of	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
g	I
##lu	I
##cu	I
##ron	I
##ide	I
,	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
and	O
test	B
##osterone	I
were	O
5	O
.	O
8	O
min	O
,	O
6	O
.	O
8	O
min	O
,	O
and	O
8	O
.	O
7	O
min	O
,	O
respectively	O
.	O

sum	O
##mar	O
##izes	O
the	O
most	O
relevant	O
identified	O
meta	O
##bol	O
##ites	O
including	O
amino	O
acids	O
(	B
al	B
##ani	I
##ne	I
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
g	B
##ly	I
##cine	I
,	O
l	B
##ys	I
##ine	I
)	O
,	O
ben	B
##zen	I
##oids	I
(	O
hip	O
##pur	O
##ic	O
acid	O
)	O
,	O
organic	O
nitrogen	O
compounds	O
(	B
trim	B
##eth	I
##yla	I
##mine	I
-	I
N	I
-	I
oxide	I
)	O
,	O
organic	O
acids	O
(	B
la	B
##ct	I
##ate	I
,	O
c	O
##it	O
##rate	O
)	O
,	O
c	B
##rea	I
##tin	I
##ine	I
,	O
and	O
u	B
##rea	I
.	O

P	O
##las	O
##ma	O
concentrations	O
of	O
total	O
ch	B
##ole	I
##ster	I
##ol	I
and	O
low	O
-	O
density	O
lip	O
##op	O
##rote	O
##in	O
ch	B
##ole	I
##ster	I
##ol	I
were	O
significantly	O
lower	O
after	O
le	O
##pt	O
##in	O
replacement	O
therapy	O
.	O

In	O
the	O
case	O
of	O
the	O
male	O
T	O
##2	O
##DM	O
patients	O
,	O
meta	O
##bol	O
##ites	O
such	O
as	O
the	O
branched	O
chain	O
amino	O
acids	O
,	O
al	B
##ani	I
##ne	I
,	O
g	O
##lut	O
##amine	O
/	O
g	O
##lut	O
##ama	O
##te	O
and	O
th	B
##re	I
##oni	I
##ne	I
(	O
4	O
.	O
28	O
p	O
.	O
p	O
.	O
m	O
.	O
)	O
appeared	O
to	O
increase	O
with	O
RS	O
##G	O
treatment	O
.	O

As	O
noted	O
,	O
25	B
-	I
h	I
##ydro	I
##xy	I
##vi	I
##tam	I
##in	I
D	O
_	O
3	O
levels	O
were	O
highest	O
in	O
individuals	O
of	O
European	O
-	O
American	O
descent	O
,	O
intermediate	O
in	O
Hispanic	O
##s	O
,	O
and	O
lowest	O
in	O
African	O
Americans	O
.	O

The	O
time	O
course	O
(	O
0	O
–	O
24	O
h	O
)	O
of	O
resting	O
pupil	O
diameter	O
(	O
mean	O
(	O
s	O
.	O
d	O
.	O
)	O
)	O
in	O
seven	O
healthy	O
subjects	O
after	O
IV	O
-	O
re	O
##ct	O
##al	O
,	O
and	O
oral	O
-	O
re	O
##ct	O
##al	O
administration	O
of	O
met	B
##had	I
##one	I
-	I
HC	I
##l	I
(	O
5	O
mg	O
IV	O
,	O
10	O
mg	O
re	O
##ct	O
##ally	O
and	O
oral	O
##ly	O
)	O
_	O
pp	O

[	O
_	O
2	O
H	O
_	O
6	O
]	O
Ace	O
##tic	O
an	O
##hy	O
##dr	O
##ide	O
(	O
10	O
.	O
6	O
mm	O
##ol	O
)	O
was	O
added	O
drop	O
##wise	O
over	O
20	O
min	O
,	O
the	O
ice	O
bath	O
was	O
removed	O
,	O
and	O
the	O
reaction	O
continued	O
stirring	O
at	O
room	O
temperature	O
for	O
1	O
h	O
.	O
1	B
,	I
4	I
-	I
Di	I
##thi	I
##oth	I
##re	I
##ito	I
##l	I
(	O
10	O
.	O
6	O
mm	O
##ol	O
)	O
was	O
added	O
,	O
and	O
the	O
reaction	O
mixture	O
was	O
stirred	O
continuously	O
at	O
room	O
temperature	O
for	O
1	O
h	O
,	O
concentrated	O
in	O
v	O
##ac	O
##uo	O
,	O
washed	O
with	O
et	O
##her	O
,	O
frozen	O
,	O
and	O
l	O
##yo	O
##phi	O
##li	O
##zed	O
.	O

We	O
were	O
successful	O
in	O
changing	O
daily	O
sleep	O
duration	S
from	O
[UNK]	O
to	O
[UNK]	O
(	O
which	O
approximate	O
##s	O
the	O
e	O
##pid	O
##em	O
##iol	O
##og	O
##ic	O
sleep	O
categories	O
with	O
low	O
vs	O
.	O
high	O
metabolic	O
risk	O
)	O
while	O
participants	O
maintained	O
comparable	O
levels	O
of	O
food	O
intake	O
,	O
total	O
daily	O
activity	O
,	O
and	O
body	O
weight	O
during	O
each	O
study	O
session	O
.	O

G	O
##rad	O
##ient	O
el	O
##ution	O
(	O
solvent	O
A	O
,	O
0	O
.	O
2	O
%	O
FA	S
in	O
water	O
;	O
solvent	O
B	O
,	O
AC	O
##N	O
)	O
was	O
used	O
according	O
to	O
the	O
following	O
program	O
:	O
is	O
##oc	O
##ratic	O
step	O
that	O
holds	O
25	O
%	O
solvent	O
B	O
from	O
0	O
to	O
2	O
.	O
2	O
min	O
,	O
up	O
to	O
90	O
%	O
solvent	O
B	O
in	O
1	O
.	O
5	O
min	O
,	O
held	O
90	O
%	O
solvent	O
B	O
to	O
4	O
min	O
and	O
column	O
re	O
##con	O
##dition	O
##ing	O
at	O
25	O
%	O
solvent	O
B	O
to	O
5	O
min	O
(	O
total	O
analysis	O
time	O
)	O
.	O

I	O
##maging	O
parameters	O
derived	O
from	O
post	O
##p	O
##ro	O
##cess	O
##ed	O
diffusion	O
-	O
weighted	O
imaging	O
and	O
s	O
##pect	O
##ros	O
##copic	O
data	O
helped	O
guide	O
the	O
designation	O
of	O
small	O
,	O
put	O
##ative	O
##ly	O
defined	O
tumor	O
regions	O
(	B
5	B
-	I
mm	I
-	I
diameter	I
spheres	O
)	O
on	O
surgical	O
navigation	O
software	O
.	O

In	O
the	O
spontaneous	O
##ly	O
h	O
##yper	O
##tensive	O
rat	O
,	O
increased	O
re	O
##nal	O
20	B
-	I
H	I
##ET	I
##E	I
contributes	O
to	O
elevation	O
of	O
blood	O
pressure	O
,	O
whereas	O
in	O
the	O
salt	O
-	O
sensitive	O
Da	O
##hl	O
rat	O
,	O
reduced	O
20	B
-	I
H	I
##ET	I
##E	I
synthesis	O
also	O
el	O
##eva	O
##tes	O
blood	O
pressure	O
.	O

Top	O
meta	O
##bol	O
##ites	O
that	O
co	O
##rrel	O
##ate	O
with	O
separation	O
of	O
the	O
groups	O
include	O
x	B
##ant	I
##hine	I
(	O
VIP	O
:	O
3	O
.	O
5	O
,	O
c	O
##v	O
##SE	O
:	O
0	O
.	O
69	O
)	O
,	O
2	B
-	I
h	I
##ydro	I
##xy	I
##vale	I
##ric	I
acid	I
(	O
VIP	O
:	O
3	O
.	O
0	O
,	O
c	O
##v	O
##SE	O
:	O
0	O
.	O
44	O
)	O
,	O
su	B
##cci	I
##nic	I
acid	I
(	O
VIP	O
:	O
2	O
.	O
5	O
,	O
c	O
##v	O
##SE	O
:	O
0	O
.	O
78	O
)	O
,	O
s	B
##te	I
##ari	I
##c	I
acid	I
(	O
VIP	O
:	O
2	O
.	O
3	O
,	O
c	O
##v	O
##SE	O
:	O
0	O
.	O
55	O
)	O
and	O
f	B
##ru	I
##ct	I
##ose	I
(	O
VIP	O
:	O
2	O
.	O
0	O
,	O
c	O
##v	O
##SE	O
:	O
0	O
.	O
87	O
)	O
.	O

Aside	O
from	O
the	O
combinations	O
shown	O
in	O
which	O
are	O
dominated	O
by	O
c	B
##ys	I
##tein	I
##e	I
,	O
u	B
##rid	I
##ine	I
and	O
co	B
##rt	I
##is	I
##ol	I
,	O
further	O
combinations	O
with	O
slightly	O
lower	O
AU	O
##C	O
values	O
exist	O
and	O
which	O
are	O
thus	O
less	O
dependent	O
on	O
the	O
performance	O
of	O
these	O
three	O
meta	O
##bol	O
##ites	O
,	O
e	O
.	O
g	O
.	O
the	O
quartet	O
##s	O
co	B
##rt	I
##is	I
##ol	I
,	O
se	B
##rine	I
,	O
unknown	O
U	O
##5	O
##28	O
and	O
either	O
unknown	O
U	O
##0	O
##9	O
##6	O
or	O
do	B
##pa	I
##mine	I
with	O
AU	O
##C	O
values	O
0	O
.	O
80	O
##6	O
and	O
0	O
.	O
80	O
##4	O
,	O
respectively	O
.	O

-	B
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
being	O
formed	O
from	O
ch	B
##ole	I
##ster	I
##ol	I
in	O
a	O
reaction	O
cat	O
##aly	O
##zed	O
by	O
ne	O
##uron	O
-	O
specific	O
c	O
##yt	O
##och	O
##rome	O
(	O
C	O
##YP	O
)	O
P	O
##45	O
##0	O
46	O
##A	O
##1	O
,	O
27	O
-	O
h	O
##ydro	O
##xy	O
##cho	O
##les	O
##tero	O
##l	O
being	O
formed	O
in	O
many	O
tissues	O
in	O
a	O
reaction	O
cat	O
##aly	O
##zed	O
by	O
C	O
##YP	O
##27	O
##A	O
##1	O
,	O
and	O
7	B
##α	I
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
being	O
formed	O
he	O
##pa	O
##tically	O
in	O
a	O
C	O
##YP	O
##7	O
##A	O
##1	O
-	O
cat	O
##aly	O
##zed	O
reaction	O
.	O

Higher	O
values	O
of	O
g	B
##lut	I
##ami	I
##c	I
acid	I
are	O
found	O
in	O
CS	O
##F	O
samples	O
stored	O
even	O
for	O
a	O
short	O
time	O
at	O
room	O
temperature	O
or	O
−	O
##20	O
##°	O
##C	O
.	O

He	B
##xa	I
##de	I
##cano	I
##ic	I
acid	I
.	O

Similar	O
to	O
P	O
##I	O
,	O
P	B
##G	I
##36	I
:	I
5	I
,	O
P	B
##G	I
##38	I
:	I
8	I
,	O
P	B
##G	I
##38	I
:	I
3	I
,	O
P	B
##G	I
##40	I
:	I
6	I
and	O
P	B
##G	I
##40	I
:	I
3	I
were	O
detected	O
by	O
all	O
protocols	O
,	O
but	O
with	O
a	O
gradual	O
increase	O
in	O
their	O
in	O
##tens	O
##ities	O
from	O
protocols	O
(	O
i	O
)	O
to	O
(	O
v	O
##i	O
)	O
.	O

Further	O
pu	O
##rification	O
was	O
carried	O
out	O
by	O
acid	O
##ification	O
to	O
pH	O
3	O
with	O
1	O
M	O
HC	O
##l	O
and	O
extraction	O
with	O
et	B
##hyl	I
ace	I
##tate	I
in	O
order	O
to	O
remove	O
any	O
remaining	O
c	B
##ys	I
##tine	I
or	O
c	B
##ys	I
##tein	I
##e	I
.	O

I	O
##B	O
##D	O
-	O
en	O
##rich	O
##ed	O
bi	O
##le	O
acids	O
included	O
ch	B
##olate	I
(	O
q	O
=	O
0	O
.	O
00	O
##3	O
)	O
and	O
ch	B
##eno	I
##de	I
##ox	I
##ych	I
##olate	I
(	O
q	O
=	O
0	O
.	O
000	O
##2	O
;	O
)	O
.	O

The	O
results	O
specifically	O
showed	O
that	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
metabolism	O
decreased	O
and	O
try	B
##pt	I
##op	I
##han	I
metabolism	O
increased	O
in	O
the	O
samples	O
.	O

With	O
a	O
database	O
-	O
based	O
ve	O
##rification	O
protocol	O
,	O
11	O
molecules	O
were	O
identified	O
,	O
and	O
six	O
up	O
##re	O
##gu	O
##lated	O
molecules	O
of	O
interest	O
in	O
E	O
##SC	O
##C	O
were	O
found	O
to	O
belong	O
to	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
as	O
follows	O
:	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##ls	I
##eri	I
##ne	I
,	O
p	B
##hos	I
##pha	I
##ti	I
##dic	I
acid	I
,	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
ch	I
##olin	I
##e	I
,	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##lino	I
##si	I
##to	I
##l	I
,	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
ethanol	I
##amine	I
,	O
and	O
s	B
##phi	I
##nga	I
##nine	I
1	I
-	I
phosphate	I
.	O

Then	O
,	O
each	O
via	O
##l	O
was	O
v	O
##ortex	O
##ed	O
for	O
30	O
##s	O
and	O
subjected	O
to	O
700	O
##W	O
of	O
microwave	O
i	O
##rra	O
##diation	O
(	O
Phil	O
##co	O
,	O
São	O
Paulo	O
,	O
SP	S
,	O
Brazil	O
)	O
for	O
3	O
min	O
.	O

R	B
##ib	I
##of	I
##lav	I
##in	I
has	O
,	O
as	O
a	O
majority	O
of	O
other	O
findings	O
here	O
##in	O
,	O
been	O
connected	O
to	O
the	O
energy	O
metabolism	O
where	O
a	O
rib	B
##of	I
##lav	I
##in	I
deficiency	O
has	O
resulted	O
in	O
a	O
mitochondrial	O
d	O
##ys	O
##function	O
.	O

I	O
##M	O
##Z	O
was	O
never	O
detected	O
when	O
met	B
##form	I
##in	I
was	O
not	O
found	O
to	O
be	O
present	O
.	O

C	B
##lot	I
##hian	I
##id	I
##in	I
was	O
only	O
detected	O
in	O
AS	O
##G	O
(	O
6	O
.	O
3	O
%	O
,	O
not	O
q	O
##uant	O
##ified	O
)	O
,	O
and	O
in	O
N	O
##S	O
##G	O
(	O
2	O
.	O
0	O
%	O
,	O
1	O
.	O
6	O
pp	O
##b	O
)	O
.	O

During	O
g	O
##lut	O
##ami	O
##no	O
##lysis	O
,	O
g	B
##lut	I
##amine	I
is	O
converted	O
to	O
g	B
##lut	I
##ama	I
##te	I
,	O
meta	O
##bol	O
##ized	O
to	O
2	B
-	I
o	I
##x	I
##og	I
##lut	I
##arate	I
and	O
further	O
distributed	O
to	O
diverse	O
pathways	O
via	O
reactions	O
of	O
the	O
T	O
##CA	O
cycle	O
.	O

However	O
,	O
the	O
most	O
abundant	O
and	O
stable	O
meta	O
##bol	O
##ite	O
of	O
T	B
##x	I
##B	I
_	I
2	I
,	I
11	I
-	I
de	I
##hy	I
##ro	I
-	I
TX	I
##B	I
_	I
2	I
,	O
is	O
ex	O
##cre	O
##ted	O
into	O
the	O
urine	O
linear	O
##ly	O
,	O
over	O
a	O
range	O
greater	O
than	O
calculated	O
rates	O
of	O
end	O
##ogen	O
##ous	O
T	O
##x	O
##A	O
_	O
2	O
generation	O
.	O

The	O
concentration	O
of	O
1	B
-	I
met	I
##hyl	I
##ade	I
##nos	I
##ine	I
in	O
urine	O
has	O
been	O
reported	O
to	O
be	O
increased	O
in	O
patients	O
with	O
o	O
##var	O
##ian	O
and	O
breast	O
cancer	O
[	O
,	O
]	O
.	O

In	O
##test	O
##inal	O
barrier	O
damage	O
was	O
diagnosed	O
based	O
on	O
IP	S
assessed	O
by	O
HP	O
##LC	O
analysis	O
of	O
la	B
##ct	I
##ulos	I
##e	I
and	O
man	B
##ni	I
##to	I
##l	I
u	O
##rina	O
##ry	O
values	O
5	O
h	O
after	O
sugar	O
ing	O
##est	O
##ion	O
in	O
fast	O
##ing	O
children	O
.	O

Cap	O
##illa	O
##ry	O
electro	O
##ph	O
##ores	O
##is	O
-	O
tandem	O
mass	O
,	O
s	O
##pect	O
##rome	O
##try	O
,	O
Ce	O
##re	O
##bro	O
##sp	O
##inal	O
fluid	O
,	O
Pi	B
##co	I
##lini	I
##c	I
acid	I
,	O
Q	B
##uin	I
##olin	I
##ic	I
acid	I
,	O
Q	O
##uate	O
##rna	O
##ry	O
am	O
##mon	O
##ium	O
coated	O
cap	O
##illa	O
##ry	O

The	O
duration	S
of	O
in	O
##patient	O
##s	O
ranged	O
from	O
0	O
.	O
2	O
to	O
14	O
years	O
(	O
V	O
.	O
SC	O
:	O
0	O
.	O
3	O
–	O
14	O
.	O
0	O
years	O
;	O
N	O
##V	O
.	O
SC	O
:	O
0	O
.	O
2	O
–	O
8	O
.	O
0	O
years	O
)	O
and	O
differed	O
significantly	O
between	O
groups	O
.	O

Cho	B
##les	I
##tero	I
##l	I
production	O
slightly	O
increased	O
in	O
IS	O
h	O
##y	O
##po	O
##gon	O
##adi	O
##sm	O
,	O
as	O
did	O
its	O
precursor	O
me	B
##val	I
##onic	I
acid	I
(	O
but	O
not	O
significantly	O
)	O
,	O
in	O
agreement	O
with	O
the	O
hypothesis	O
that	O
low	O
test	B
##osterone	I
promotes	O
ch	B
##ole	I
##ster	I
##ol	I
mob	O
##ilis	O
##ation	O
from	O
the	O
liver	O
.	O

The	O
meta	O
##bol	O
##ites	O
holding	O
differential	O
power	O
primarily	O
belonged	O
to	O
a	O
range	O
of	O
amino	O
acids	O
,	O
micro	O
##bio	O
##ta	O
-	O
related	O
short	O
chain	O
fatty	O
acids	O
,	O
and	O
la	B
##ct	I
##ate	I
suggest	O
##ive	O
of	O
an	O
inflammation	O
-	O
driven	O
ma	O
##la	O
##bs	O
##or	O
##ption	O
and	O
d	O
##ys	O
##bio	O
##sis	O
of	O
the	O
normal	O
bacterial	O
ecology	O
.	O

In	O
healthy	O
donors	O
,	O
C	B
##24	I
:	I
1	I
species	O
were	O
the	O
highest	O
followed	O
by	O
C	B
##24	I
:	I
0	I
,	O
C	B
##22	I
:	I
0	I
,	O
and	O
C	B
##16	I
:	I
0	I
.	O

It	O
is	O
well	O
known	O
that	O
T	O
##FA	O
incorporate	O
membrane	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
into	O
plasma	O
altering	O
the	O
packing	O
of	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
and	O
in	O
##f	O
##lue	O
##ncing	O
the	O
physical	O
properties	O
and	O
responses	O
of	O
membrane	O
receptors	O
,	O
.	O

Analysis	O
of	O
clinical	O
data	O
revealed	O
that	O
a	O
set	O
of	O
few	O
meta	O
##bol	O
##ites	O
including	O
PA	O
##I	O
-	O
1	O
,	O
a	O
##zo	O
##tem	O
##ia	O
,	O
and	O
c	B
##rea	I
##tin	I
##ine	I
were	O
increased	O
in	O
the	O
T	O
##2	O
##DM	O
-	O
C	O
group	O
and	O
potentially	O
related	O
to	O
disease	O
complications	O
.	O

FF	O
##P	O
##E	O
samples	O
showed	O
a	O
decrease	O
of	O
meta	O
##bol	O
##ites	O
with	O
characteristic	O
functional	O
groups	O
,	O
such	O
as	O
secondary	O
car	B
##box	I
##yl	I
##ic	I
acid	I
amid	I
##e	I
(	O
28	O
%	O
,	O
P	O
=	O
7	O
.	O
43	O
×	O
10	O
_	O
−	O
##12	O
;	O
F	O
##DR	O
=	O
6	O
.	O
42	O
×	O
10	O
_	O
−	O
##10	O
)	O
,	O
present	O
in	O
p	O
##eptide	O
##s	O
and	O
q	O
##uate	O
##rna	O
##ry	O
am	B
##mon	I
##ium	I
salts	O
(	O
33	O
%	O
,	O
P	O
=	O
1	O
.	O
01	O
×	O
10	O
_	O
−	O
##3	O
;	O
F	O
##DR	O
=	O
2	O
.	O
30	O
×	O
10	O
_	O
−	O
##2	O
)	O
present	O
in	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##och	I
##olin	I
##es	I
and	O
absent	O
in	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oe	I
##than	I
##ola	I
##mine	I
##s	I
.	O

E	O
.	O
co	O
##li	O
express	O
the	O
protein	O
as	O
##par	O
##tate	O
amino	O
##tra	O
##ns	O
##fer	O
##ase	O
,	O
which	O
converts	O
k	B
##yn	I
##uren	I
##ine	I
into	O
K	O
##Y	O
##NA	O
.	O
_	O
,	O

It	O
is	O
a	O
breakdown	O
product	O
of	O
c	B
##rea	I
##tine	I
phosphate	I
,	O
which	O
can	O
be	O
used	O
as	O
a	O
reserve	O
of	O
high	O
-	O
energy	O
phosphate	B
##s	I
for	O
the	O
brain	O
,	O
an	O
##ae	O
##ro	O
##bic	O
##ally	O
p	B
##hos	I
##ph	I
##ory	I
##lating	I
AD	I
##P	I
to	O
ATP	S
.	O

Next	O
we	O
considered	O
a	O
multi	O
-	O
meta	O
##bol	O
##ite	O
association	O
model	O
,	O
in	O
which	O
m	O
=	O
3	O
meta	O
##bol	O
##ites	O
(	O
hip	O
##pura	O
##te	O
,	O
al	B
##ani	I
##ne	I
and	O
format	O
##e	O
)	O
are	O
assumed	O
to	O
be	O
associated	O
with	O
the	O
disease	O
.	O

Am	O
##ino	O
acid	O
AU	O
##RO	O
##Cs	O
and	O
their	O
95	O
%	O
C	O
##I	O
##s	O
for	O
the	O
differentiation	O
of	O
co	O
##lon	O
cancer	O
patients	O
and	O
controls	O
AU	O
##RO	O
##Cs	O
and	O
95	O
%	O
C	O
##I	O
##s	O
for	O
the	O
different	O
amino	O
acids	O
with	O
respect	O
to	O
the	O
disc	O
##rim	O
##inator	O
##y	O
power	O
between	O
co	O
##lon	O
cancer	O
patients	O
and	O
healthy	O
controls	O
R	O
##OC	O
curves	O
,	O
95	O
%	O
confidence	O
bands	O
(	O
B	O
=	O
99	O
##9	O
)	O
and	O
AU	O
##RO	O
##Cs	O
for	O
CE	O
##A	O
(	O
red	O
)	O
,	O
the	O
model	O
consisting	O
of	O
CE	O
##A	O
and	O
principal	O
component	O
1	O
(	O
PC	O
##1	O
orange	O
)	O
,	O
and	O
the	O
model	O
consisting	O
of	O
CE	O
##A	O
,	O
g	B
##ly	I
##cine	I
,	O
and	O
t	B
##yr	I
##os	I
##ine	I
(	O
green	O
)	O
.	O

Pre	O
##cision	O
##s	O
for	O
lower	O
-	O
limit	O
-	O
of	O
-	O
q	O
##uant	O
##ification	O
level	O
were	O
<	O
10	O
%	O
and	O
a	O
##cc	O
##ura	O
##cies	O
within	O
116	O
%	O
for	O
en	B
##zal	I
##uta	I
##mi	I
##de	I
and	O
N	B
-	I
des	I
##met	I
##hyl	I
##en	I
##zal	I
##uta	I
##mi	I
##de	I
.	O

However	O
,	O
the	O
effect	O
of	O
exercise	O
on	O
u	O
##rina	O
##ry	O
AD	B
##MA	I
ex	O
##cre	O
##tion	O
in	O
healthy	O
individuals	O
has	O
rarely	O
been	O
examined	O
so	O
far	O
.	O

In	O
contrast	O
,	O
c	B
##it	I
##rate	I
,	O
car	B
##ni	I
##tine	I
and	O
car	B
##ni	I
##tine	I
con	O
##ju	O
##gated	O
lip	O
##ids	O
were	O
significantly	O
lower	O
.	O

and	O
I	O
_	O
x	O
is	O
the	O
c	B
##rea	I
##tin	I
##ine	I
normal	O
##ized	O
,	O
log	O
-	O
transformed	O
,	O
centered	O
and	O
scaled	O
signal	O
intensity	O
of	O
meta	O
##bol	O
##ite	O
x	O
in	O
the	O
sample	O
.	O

Therefore	O
,	O
changes	O
within	O
NE	O
##FA	O
serum	O
pool	O
may	O
be	O
connected	O
with	O
clinical	O
outcome	O
and	O
IF	B
##N	I
##γ	I
-	I
CD	I
##4	I
_	I
+	I
immune	O
response	O
in	O
RA	O
patients	O
upon	O
T	B
##NF	I
##α	I
-	I
blockade	I
.	O

B	O
##io	O
##psy	O
and	O
R	B
##P	I
specimens	O
were	O
reported	O
by	O
u	O
##rop	O
##ath	O
##ologists	O
according	O
to	O
the	O
2005	O
International	O
Society	O
of	O
U	O
##rol	O
##ogical	O
Path	O
##ology	O
classification	O
.	O

The	O
levels	O
of	O
the	O
ratios	O
of	O
de	O
##pur	O
##inating	O
DNA	O
add	O
##uc	O
##ts	O
to	O
their	O
respective	O
est	B
##rogen	I
meta	O
##bol	O
##ites	O
and	O
con	O
##ju	O
##gate	O
##s	O
were	O
significantly	O
higher	O
in	O
high	O
-	O
risk	O
women	O
(	O
p	O
<	O
0	O
.	O
00	O
##1	O
)	O
and	O
women	O
with	O
breast	O
cancer	O
(	O
p	O
<	O
0	O
.	O
00	O
##1	O
)	O
than	O
in	O
control	O
subjects	O
.	O

The	O
et	B
##hyl	I
ace	I
##tate	I
was	O
e	O
##va	O
##porated	O
to	O
dry	O
##ness	O
using	O
a	O
Speed	O
##va	O
##c	O
con	O
##cent	O
##rator	O
(	O
The	O
##rm	O
##o	O
Fisher	O
)	O
,	O
and	O
the	O
plates	O
were	O
capped	O
and	O
stored	O
at	O
-	O
20	O
##°	O
##C	O
until	O
L	O
##C	O
-	O
electro	O
##sp	O
##ray	O
ion	O
##ization	O
(	O
E	O
##SI	O
-	O
)	O
-	O
MS	O
/	O
MS	O
analysis	O
.	O

However	O
,	O
in	O
T	O
##2	O
stage	O
disease	O
,	O
when	O
comparing	O
pre	O
-	O
g	O
##em	O
##ci	O
##ta	O
##bine	O
normal	O
vs	O
.	O
pre	O
-	O
g	O
##em	O
##ci	O
##ta	O
##bine	O
BC	O
##a	O
tissues	O
,	O
the	O
decrease	O
in	O
his	B
##tamine	I
(	O
P	O
=	O
4	O
.	O
61	O
##E	O
-	O
3	O
)	O
(	O
Table	O
S	O
##I	O
and	O
)	O
and	O
th	B
##iam	I
##ine	I
(	O
P	O
=	O
4	O
.	O
13	O
##E	O
-	O
4	O
)	O
(	O
Table	O
S	O
##I	O
and	O
)	O
in	O
the	O
BC	O
##a	O
tissues	O
was	O
significant	O
.	O

Thus	O
,	O
although	O
G	O
##ST	O
##T	O
##1	O
g	O
##eno	O
##type	O
is	O
an	O
important	O
m	O
##od	O
##ifier	O
of	O
ben	B
##zen	I
##e	I
metabolism	O
,	O
the	O
br	O
##occo	O
##li	O
beverage	O
-	O
induced	O
effects	O
on	O
increased	O
ex	O
##cre	O
##tion	O
of	O
SP	O
##MA	O
appear	O
to	O
be	O
independent	O
of	O
G	O
##ST	O
##T	O
##1	O
status	O
.	O

The	O
responses	O
of	O
plasma	O
AC	O
species	O
depended	O
on	O
chain	O
length	O
and	O
sat	O
##uration	O
,	O
with	O
C	B
##14	I
:	I
0	I
,	O
C	B
##16	I
:	I
0	I
,	O
and	O
C	B
##18	I
:	I
0	I
remaining	O
unchanged	O
,	O
and	O
un	O
##sat	O
##ura	O
##ted	O
species	O
(	O
e	O
.	O
g	O
.	O
,	O
C	B
##14	I
:	I
1	I
,	O
C	B
##14	I
:	I
2	I
)	O
falling	O
significantly	O
(	O
21	O
–	O
46	O
%	O
,	O
P	O
<	O
0	O
.	O
03	O
)	O
.	O

The	O
level	O
of	O
u	O
##rina	O
##ry	O
try	B
##pt	I
##op	I
##han	I
cat	O
##ab	O
##oli	O
##tes	O
involving	O
k	B
##yn	I
##uren	I
##ine	I
,	O
h	B
##ydro	I
##xy	I
##try	I
##pt	I
##op	I
##han	I
and	O
x	B
##ant	I
##hur	I
##eni	I
##c	I
acid	I
were	O
significantly	O
elevated	O
in	O
patients	O
with	O
early	O
-	O
stage	O
PD	O
(	O
and	O
)	O
.	O

The	O
super	O
##nat	O
##ant	O
was	O
transferred	O
to	O
0	O
.	O
7	O
-	O
m	O
##L	O
p	B
##oly	I
##p	I
##rop	I
##yle	I
##ne	I
HP	O
##LC	O
via	O
##ls	O
with	O
p	B
##oly	I
##eth	I
##yle	I
##ne	I
snap	O
-	O
caps	O
and	O
injected	O
into	O
the	O
HP	O
##LC	O
-	O
I	O
##CP	O
##Q	O
##Q	O
##Q	O
##MS	O
system	O
.	O

Therefore	O
,	O
we	O
also	O
concluded	O
that	O
the	O
product	O
of	O
p	B
##yr	I
##id	I
##ini	I
##um	I
di	O
##ch	O
##roma	O
##te	O
oxidation	O
of	O
10	O
generated	O
9	O
.	O

However	O
,	O
th	B
##iam	I
##ine	I
was	O
significantly	O
decreased	O
in	O
BC	O
##a	O
,	O
and	O
its	O
level	O
was	O
significantly	O
decreased	O
in	O
normal	O
tissues	O
after	O
sub	O
##mu	O
##cos	O
##al	O
injection	O
of	O
g	O
##em	O
##ci	O
##ta	O
##bine	O
.	O

The	O
CH	O
_	O
3	O
OH	O
el	O
##uen	O
##ts	O
were	O
concentrated	O
to	O
dry	O
##ness	O
by	O
vacuum	O
cent	O
##ri	O
##fu	O
##gation	O
and	O
re	O
##sus	O
##pen	O
##ded	O
in	O
1	O
:	O
1	O
H	O
_	O
2	O
O	O
:	O
D	B
##MS	I
##O	I
for	O
UP	O
##LC	O
-	O
E	O
##SI	O
/	O
MS	O
_	O
n	O
analysis	O
.	O

P	O
##las	O
##ma	O
lip	O
##ids	O
specific	O
to	O
o	O
##besity	O
‐	O
related	O
insulin	O
resistance	O
(	O
i	O
.	O
e	O
.	O
,	O
different	O
between	O
O	O
##IS	O
and	O
O	O
##IR	O
,	O
but	O
not	O
between	O
O	O
##IR	O
and	O
Lea	O
##n	O
)	O
included	O
D	B
##G	I
(	I
14	I
:	I
1	I
_	I
16	I
:	I
0	I
)	I
,	O
CE	B
(	I
22	I
:	I
4	I
)	I
and	O
PC	B
(	I
O	I
‐	I
35	I
:	I
4	I
)	I
(	O
higher	O
)	O
and	O
He	O
##x	O
##2	O
##C	O
##er	O
(	O
d	O
##18	O
:	O
1	O
/	O
22	O
:	O
0	O
)	O
,	O
He	O
##x	O
##2	O
##C	O
##er	O
(	O
d	O
##18	O
:	O
1	O
/	O
24	O
:	O
0	O
)	O
and	O
LP	B
##C	I
(	I
22	I
:	I
0	I
)	I
(	O
lower	O
)	O
.	O

Gamma	O
-	O
g	O
##lut	O
##am	O
##yl	O
dip	O
##eptide	O
##s	O
are	O
formed	O
by	O
gamma	O
-	O
g	O
##lut	O
##am	O
##yl	O
##tra	O
##ns	O
##fer	O
##ase	O
(	O
G	O
##G	O
##T	O
)	O
as	O
by	O
##p	O
##rod	O
##uc	O
##ts	O
of	O
anti	O
-	O
o	O
##xi	O
##da	O
##tive	O
g	B
##lut	I
##ath	I
##ione	I
synthesis	O
and	O
therefore	O
reflect	O
o	O
##xi	O
##da	O
##tive	O
stress	O
.	O

U	O
##rina	O
##ry	O
levels	O
of	O
N	B
-	I
ace	I
##ty	I
##l	I
-	I
S	I
-	I
p	I
##hen	I
##yl	I
-	I
L	I
-	I
c	I
##ys	I
##tein	I
##e	I
(	O
SP	O
##MA	O
)	O
(	O
meta	O
##bol	O
##ite	O
of	O
ben	B
##zen	I
##e	I
)	O
,	O
N	B
-	I
ace	I
##ty	I
##l	I
-	I
S	I
-	I
(	I
2	I
-	I
h	I
##ydro	I
##xy	I
-	I
1	I
/	I
2	I
-	I
p	I
##hen	I
##yle	I
##thy	I
##l	I
)	I
-	I
L	I
-	I
c	I
##ys	I
##tein	I
##e	I
(	O
P	O
##H	O
##EM	O
##A	O
)	O
(	B
meta	I
##bol	I
##ite	I
of	I
s	I
##ty	I
##rene	I
)	I
,	I
N	I
-	I
ace	I
##ty	I
##l	I
-	I
S	I
-	I
(	I
2	I
-	I
c	I
##yan	I
##oe	I
##thy	I
##l	I
)	I
-	I
L	I
-	I
c	I
##ys	I
##tein	I
##e	I
(	I
CE	I
##MA	I
)	I
(	I
meta	I
##bol	I
##ite	I
of	I
a	I
##c	I
##ryl	I
##oni	I
##tri	I
##le	I
)	I
,	I
N	I
-	I
ace	I
##ty	I
##l	I
-	I
S	I
-	I
[	I
1	I
-	I
(	I
h	I
##ydro	I
##xy	I
##met	I
##hyl	I
)	I
-	I
2	I
-	I
prop	I
##en	I
-	I
1	I
-	I
y	I
##l	I
)	I
-	I
L	I
-	I
c	I
##ys	I
##tein	I
##e	I
and	O
N	B
-	I
ace	I
##ty	I
##l	I
-	I
S	I
-	I
(	I
2	I
-	I
h	I
##ydro	I
##xy	I
-	I
3	I
-	I
but	I
##en	I
-	I
1	I
-	I
y	I
##l	I
)	I
-	I
L	I
-	I
c	I
##ys	I
##tein	I
##e	I
(	O
M	O
##H	O
##BM	O
##A	O
)	O
(	O
meta	O
##bol	O
##ites	O
of	O
1	B
,	I
3	I
-	I
but	I
##adi	I
##ene	I
)	O
were	O
2	O
–	O
10	O
fold	O
higher	O
in	O
workers	O
than	O
in	O
controls	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Lower	O
e	O
##G	O
##F	O
##R	O
is	O
strongly	O
associated	O
with	O
reduced	O
vitamin	B
D	I
cat	O
##ab	O
##olis	O
##m	O
as	O
measured	O
by	O
circulating	O
24	B
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
concentration	O
.	O

A	O
##cy	O
##l	O
group	O
arising	O
from	O
the	O
metabolism	O
of	O
BC	O
##AA	O
##s	O
has	O
been	O
suggested	O
to	O
be	O
contributing	O
proportion	O
##ately	O
to	O
the	O
a	B
##cy	I
##l	I
-	I
car	I
##ni	I
##tine	I
fraction	O
in	O
c	O
##ir	O
##r	O
##hos	O
##is	O
.	O

The	O
first	O
2	O
-	O
min	O
period	O
consisted	O
of	O
5	O
%	O
solution	O
A	O
[	O
2	O
%	O
(	O
v	O
/	O
v	O
)	O
form	B
##ic	I
acid	I
in	O
water	O
]	O
,	O
60	O
%	O
water	O
,	O
35	O
%	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
,	O
followed	O
by	O
a	O
4	O
-	O
min	O
linear	O
gradient	O
to	O
5	O
%	O
solution	O
A	O
,	O
0	O
%	O
water	O
,	O
95	O
%	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
.	O

Similarly	O
,	O
linear	O
models	O
were	O
also	O
used	O
to	O
evaluate	O
the	O
associations	O
between	O
H	O
##OM	O
##A	O
-	O
I	O
##R	O
and	O
SP	O
##s	O
after	O
adjusting	O
for	O
age	O
,	O
sex	O
,	O
L	O
##D	O
##L	O
,	O
HD	O
##L	O
,	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
,	O
and	O
B	O
##MI	O
.	O

In	O
urine	O
and	O
tissue	O
extract	O
only	O
two	O
meta	O
##bol	O
##ites	O
were	O
overlapping	O
:	O
3	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
(	O
3	O
-	O
H	O
##B	O
)	O
and	O
ace	B
##tone	I
,	O
both	O
statistical	O
##ly	O
important	O
and	O
followed	O
the	O
same	O
types	O
of	O
changes	O
–	O
decreasing	O
in	O
N	O
##N	O
.	O

1	O
##D	O
_	O
1	O
H	O
spectrum	O
of	O
whole	O
plasma	O
with	O
1	O
##D	O
NO	O
##ES	O
##Y	O
pre	O
##sat	O
and	O
CP	O
##MG	O
pre	O
##sat	O
,	O
using	O
standardized	O
parameters	O
(	O
a	O
)	O
,	O
along	O
with	O
a	O
close	B
-	I
up	I
of	O
the	O
CP	O
##MG	O
pre	O
##sat	O
spectrum	O
,	O
showing	O
in	O
green	O
frame	O
regions	O
where	O
there	O
is	O
still	O
some	O
significant	O
signal	O
from	O
mac	O
##rom	O
##ole	O
##cule	O
##s	O
(	O
b	O
)	O
.	O

Equal	O
##ly	O
,	O
tumor	O
samples	O
showed	O
high	O
levels	O
of	O
anti	O
##ox	O
##ida	O
##nts	O
,	O
such	O
as	O
as	B
##cor	I
##bate	I
and	O
alpha	O
/	O
gamma	O
‐	O
to	O
##co	O
##pher	O
##ol	O
.	O

number	O
of	O
carbon	O
##s	O
for	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
,	O
for	O
extract	O
##s	O
of	O
HC	O
##T	O
##11	O
##6	O
cells	O
grown	O
in	O
the	O
_	O
13	O
C	O
medium	O
.	O

This	O
compound	O
was	O
used	O
as	O
a	O
coupling	O
partner	O
in	O
the	O
Reform	O
##ats	O
##ky	O
reaction	O
with	O
h	B
##ydro	I
##xy	I
##ben	I
##zal	I
##de	I
##hy	I
##de	I
1	O
.	O

To	O
ensure	O
that	O
we	O
were	O
observing	O
a	O
matrix	O
-	O
assisted	O
process	O
and	O
not	O
laser	O
des	O
##or	O
##ption	O
/	O
ion	O
##ization	O
(	O
L	O
##DI	O
)	O
,	O
mixture	O
##s	O
of	O
an	O
al	B
##ip	I
##hat	I
##ic	I
base	O
(	B
t	B
##rie	I
##thy	I
##lam	I
##ine	I
)	O
and	O
an	O
in	O
##or	O
##gan	O
##ic	O
base	O
(	O
K	O
##OH	O
)	O
with	O
strong	O
al	B
##ip	I
##hat	I
##ic	I
acids	I
(	O
e	O
.	O
g	O
.	O
,	O
t	B
##ri	I
##f	I
##lu	I
##oro	I
##ace	I
##tic	I
acid	O
)	O
were	O
made	O
and	O
tested	O
for	O
the	O
presence	O
of	O
an	O
##ion	O
signals	O
.	O

1	B
,	I
2	I
-	I
dip	I
##et	I
##rose	I
##len	I
##oy	I
##l	I
-	I
s	I
##n	I
-	I
g	I
##ly	I
##cer	I
##o	I
-	I
3	I
-	I
p	I
##hos	I
##ph	I
##och	I
##olin	I
##e	I
(	O
PC	O
18	O
:	O
1	O
(	O
n	O
-	O
12	O
,	O
c	O
##is	O
)	O
/	O
18	O
:	O
1	O
(	O
n	O

Some	O
of	O
the	O
significantly	O
changed	O
meta	O
##bol	O
##ites	O
are	O
found	O
in	O
the	O
glucose	B
-	I
L	I
-	I
al	I
##ani	I
##ne	I
cycle	O
,	O
which	O
plays	O
a	O
role	O
in	O
g	O
##ly	O
##co	O
##lysis	O
and	O
g	O
##lu	O
##con	O
##eo	O
##genesis	O
.	O

Gala	B
##ct	I
##ito	I
##l	I
and	O
gal	B
##act	I
##ono	I
-	I
1	I
,	I
5	I
-	I
la	I
##cton	I
##e	I
were	O
in	O
##dicative	O
of	O
milk	O
intake	O
in	O
urine	O
from	O
samples	O
collected	O
within	O
this	O
study	O
.	O

*	O
α	B
-	I
Ke	I
##to	I
##g	I
##lut	I
##ari	I
##c	I
acid	I
was	O
determined	O
q	O
##ual	O
##itative	O
##ly	O
and	O
its	O
quantitative	O
analysis	O
is	O
presumably	O
limited	O
to	O
the	O
conditions	O
of	O
sample	O
preparation	O
.	O

r	O
##HD	O
##L	O
in	O
##fusion	O
in	O
##hibit	O
##ed	O
fast	O
##ing	O
-	O
induced	O
lip	O
##oly	O
##sis	O
(	O
P	O
=	O
0	O
.	O
03	O
)	O
,	O
fatty	O
acid	O
oxidation	O
(	O
P	O
<	O
0	O
.	O
01	O
)	O
,	O
and	O
circulating	O
g	B
##ly	I
##cer	I
##ol	I
(	O
P	O
=	O
0	O
.	O
04	O
)	O
.	O

G	B
##lu	I
##cu	I
##rona	I
##te	I
does	O
not	O
have	O
that	O
problem	O
directly	O
,	O
but	O
it	O
’	O
s	O
signal	O
is	O
located	O
in	O
the	O
immediate	O
neighborhood	O
of	O
the	O
glucose	S
signal	O
requiring	O
a	O
simultaneous	O
q	O
##uant	O
##ification	O
of	O
both	O
meta	O
##bol	O
##ites	O
in	O
order	O
to	O
avoid	O
interference	O
between	O
them	O
.	O

However	O
,	O
increasing	O
vascular	O
per	O
##me	O
##ability	O
and	O
enhance	O
##ment	O
of	O
smooth	O
muscle	O
tone	O
are	O
only	O
two	O
of	O
several	O
mechanisms	O
of	O
bra	B
##dy	I
##kini	I
##n	I
action	O
.	O

As	O
an	O
example	O
,	O
the	O
mass	O
s	O
##pect	O
##ra	O
of	O
C	B
##19	I
:	I
1	I
CE	O
was	O
shown	O
in	O
Figure	O
for	O
a	O
patient	O
with	O
breast	O
cancer	O
and	O
a	O
patient	O
with	O
ben	O
##ign	O
breast	O
disease	O
.	O

In	O
agreement	O
with	O
this	O
pre	O
##sumption	O
,	O
previous	O
urine	O
meta	O
##bon	O
##omi	O
##c	O
studies	O
have	O
consistently	O
reported	O
that	O
BC	O
is	O
associated	O
with	O
significantly	O
reduced	O
levels	O
of	O
meta	O
##bol	O
##ites	O
in	O
this	O
metabolic	O
pathway	O
such	O
as	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
and	O
hip	O
##pur	O
##ic	O
acid	O
_	O
,	O
.	O

In	O
addition	O
,	O
ta	B
##uri	I
##ne	I
and	O
man	B
##ni	I
##to	I
##l	I
presented	O
superior	O
levels	O
in	O
BC	O
group	O
,	O
respectively	O
.	O

(	O
Co	O
##en	O
##zy	O
##me	O
A	O
)	O
bio	O
##sy	O
##nt	O
##hesis	O
and	O
l	B
##ys	I
##ine	I
degradation	O
.	O

In	O
UP	O
##LC	O
-	O
MS	O
analyses	O
,	O
l	B
##ys	I
##op	I
##hos	I
-	I
p	I
##hat	I
##idy	I
##let	I
##han	I
##ola	I
##mine	I
(	I
l	I
##ys	I
##o	I
##P	I
##E	I
)	I
(	I
18	I
:	I
0	I
)	I
and	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dic	I
acid	I
(	I
20	I
:	I
0	I
)	I
were	O
higher	O
in	O
serum	O
,	O
and	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
(	O
PC	O
)	O
(	O
16	O
:	O
1	O
/	O
18	O
:	O
2	O
,	O
20	O
:	O
3	O
/	O
18	O
:	O
0	O
,	O
O	B
-	I
20	I
:	I
0	I
/	I
22	I
:	I
4	I
)	O
,	O
l	B
##ys	I
##o	I
##PC	I
(	I
16	I
:	I
0	I
)	I
,	O
P	B
##E	I
(	I
O	I
-	I
18	I
:	I
2	I
/	I
20	I
:	I
4	I
)	I
,	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
(	I
18	I
:	I
0	I
/	I
22	I
:	I
0	I
)	I
,	O
and	O
l	B
##ino	I
##le	I
##ic	I
acid	I
were	O
lower	O
.	O

Another	O
notable	O
study	O
found	O
that	O
only	O
approximately	O
1	O
to	O
2	O
%	O
of	O
the	O
rate	O
expected	O
for	O
G	B
##S	I
##H	I
con	O
##ju	O
##gation	O
of	O
BP	O
##DE	O
was	O
actually	O
observed	O
in	O
cells	O
,	O
which	O
indicated	O
the	O
importance	O
of	O
competing	O
reactions	O
of	O
BP	O
##DE	O
.	O

_	O
13	O
C	O
_	O
3	O
-	O
la	O
##ctic	O
acid	O
,	O
_	O
13	O
C	B
_	I
2	I
-	I
o	I
##xa	I
##lic	I
acid	I
,	O
_	O
2	O
H	O
_	O
3	O
-	O
sa	O
##c	O
##ros	O
##ine	O
,	O
_	O
2	O
H	B
_	I
8	I
-	I
v	I
##ali	I
##ne	I
,	O
_	O
13	O
C	B
_	I
3	I
-	I
di	I
##hy	I
##dr	I
##ox	I
##ya	I
##ce	I
##tone	I
,	O
_	O
2	O
H	B
_	I
10	I
-	I
is	I
##ole	I
##uc	I
##ine	I
,	O
_	O
13	O
C	O
_	O
4	O
-	O
f	O
##uma	O
##ric	O
acid	O
,	O
_	O
13	O
C	O
_	O
4	O
-	O
ma	O
##lic	O
acid	O
,	O
_	O
2	O
H	B
_	I
3	I
-	I
as	I
##par	I
##tic	I
acid	I
,	O
_	O
13	O
C	B
_	I
5	I
-	I
g	I
##lut	I
##ami	I
##c	I
acid	I
,	O
_	O
13	O
C	B
_	I
6	I
-	I
4	I
-	I
h	I
##ydro	I
##xy	I
##ben	I
##zoic	I
acid	I
,	O
_	O
2	O
H	O
_	O
3	O
-	O
la	O
##uri	O
##c	O
acid	O
,	O
_	O
13	O
C	O
_	O
5	O
-	O
rib	O
##ose	O
,	O
_	O
13	O
C	B
_	I
2	I
-	I
ta	I
##uri	I
##ne	I
,	O
_	O
2	O
H	O
_	O
4	O
-	O
c	O
##it	O
##ric	O
acid	O
,	O
_	O
2	O
H	O
_	O
7	O
-	O
or	O
##ni	O
##thin	O
##e	O
,	O
_	O
13	O
C	B
_	I
6	I
-	I
t	I
##yr	I
##os	I
##ine	I
,	O
_	O
13	O
C	O
_	O
6	O
-	O
do	O
##pa	O
,	O
_	O
2	O
H	O
_	O
6	O
-	O
k	O
##yn	O
##uren	O
##ine	O
,	O
_	O
2	O
H	B
_	I
8	I
-	I
c	I
##ys	I
##tamine	I
,	O
and	O
_	O
13	O
C	O
_	O
11	O
-	O
try	O
##pt	O
##op	O
##han	O
were	O
purchased	O
from	O
Cambridge	O
Is	O
##oto	O
##pe	O
Laboratories	O
,	O
Inc	O
.	O
(	O
MA	O
,	O
USA	O
)	O
.	O

For	O
example	O
,	O
inter	O
##le	O
##uki	O
##n	O
-	O
6	O
has	O
been	O
also	O
demonstrated	O
to	O
initially	O
increase	O
during	O
s	O
##tre	O
##nu	O
##ous	O
exercise	O
,	O
promote	O
alterations	O
in	O
substrate	O
u	O
##til	O
##ization	O
that	O
could	O
be	O
beneficial	O
to	O
skeletal	O
muscle	O
,	O
and	O
then	O
decline	O
in	O
a	O
fashion	O
similar	O
to	O
the	O
alterations	O
in	O
f	B
##oll	I
##ista	I
##tin	I
.	O

G	B
##ly	I
##cine	I
def	O
##ici	O
##encies	O
would	O
increase	O
the	O
demands	O
on	O
the	O
u	B
##rea	I
cycle	O
and	O
the	O
g	O
##lut	O
##ama	O
##te	O
/	O
AK	O
##G	O
pathways	O
.	O

The	O
SP	O
##E	O
cartridges	O
were	O
first	O
activated	S
with	O
et	B
##hyl	I
ace	I
##tate	I
,	O
followed	O
by	O
met	B
##han	I
##ol	I
and	O
e	O
##qui	O
##li	O
##bra	O
##tion	O
with	O
water	O
(	O
for	O
SP	O
##E	O
,	O
1	O
m	O
##L	O
and	O
for	O
μ	O
##el	O
##ution	O
SP	O
##E	O
,	O
200	O
μ	O
##L	O
of	O
each	O
were	O
used	O
)	O
.	O

We	O
found	O
that	O
plasma	O
3	B
-	I
met	I
##hyl	I
##his	I
##ti	I
##dine	I
(	O
3	O
-	O
M	O
##H	O
)	O
levels	O
were	O
similar	O
in	O
insulin	O
treated	O
and	O
deprived	O
T	O
##1	O
##D	O
,	O
suggesting	O
that	O
my	O
##of	O
##ib	O
##rilla	O
##r	O
protein	O
degradation	O
is	O
not	O
likely	O
to	O
be	O
affected	O
by	O
short	O
-	O
term	O
insulin	O
de	O
##p	O
##ri	O
##vation	O
.	O

Ace	B
##to	I
##ace	I
##tate	I
up	O
##re	O
##gu	O
##lation	O
leads	O
to	O
increased	O
production	O
of	O
ace	B
##ty	I
##l	I
-	I
Co	I
##A	I
,	O
an	O
inter	O
##media	O
##ry	O
that	O
promotes	O
T	O
##CA	O
cycle	O
alternative	O
energy	O
u	O
##til	O
##ization	O
in	O
cancer	O
##s	O
when	O
glucose	S
and	O
T	O
##CA	O
intermediate	O
##s	O
(	O
such	O
as	O
is	O
##oc	O
##it	O
##rate	O
)	O
are	O
insufficient	O
.	O

Dam	O
##age	O
to	O
membrane	O
per	O
##me	O
##ability	O
barriers	O
of	O
sperm	O
##ato	O
##zo	O
##a	O
and	O
A	O
##5	O
##4	O
##9	O
cells	O
was	O
inspected	O
by	O
differential	O
stain	O
##ing	O
with	O
prop	O
##id	O
##ium	O
i	B
##od	I
##ide	I
and	O
S	O
##Y	O
##BR	O
-	O
14	O
as	O
described	O
by	O
P	O
##el	O
##to	O
##la	O
et	O
al	O
.	O

Ser	O
##um	O
T	B
##MA	I
##O	I
concentrations	O
were	O
greater	O
in	O
the	O
P	O
##LC	O
group	O
than	O
the	O
control	O
group	O
(	O
P	O
=	O
0	O
.	O
00	O
##2	O
)	O
.	O

The	O
activity	O
of	O
several	O
G	O
##l	O
##x	O
consuming	O
or	O
producing	O
enzymes	O
(	O
e	O
.	O
g	O
.	O
γ	O
-	O
g	O
##lut	O
##am	O
##yl	O
##tra	O
##ns	O
##fer	O
##ase	O
[	O
-	O
]	O
,	O
g	O
##lut	O
##amine	O
f	O
##ru	O
##ct	O
##ose	O
-	O
6	O
-	O
phosphate	O
amid	O
##ot	O
##ran	O
##s	O
##fer	O
##ase	O
,	O
g	O
##lut	O
##ama	O
##te	O
p	O
##yr	O
##u	O
##vate	O
trans	O
##ami	O
##nas	O
##e	O
)	O
were	O
reported	O
to	O
be	O
associated	O
with	O
diabetes	O
me	O
##lli	O
##tus	O
,	O
impaired	O
glucose	S
tolerance	O
and	O
insulin	O
resistance	O
and	O
are	O
used	O
as	O
bio	O
##mark	O
##ers	O
to	O
monitor	O
liver	O
functionality	O
.	O

co	B
##rt	I
##is	I
##ol	I
,	O
CC	O
##ON	O
##E	O
:	O
co	B
##rt	I
##ico	I
##ster	I
##one	I
,	O
11	O
##DE	O
##CO	O
##L	O
:	O
11	B
-	I
de	I
##ox	I
##y	I
##cor	I
##tis	I
##ol	I
,	O
AD	B
##ION	I
##E	I
:	O
17	B
-	I
di	I
##one	I
,	O
T	O
##ES	O
##TO	O
:	O
test	B
##osterone	I
,	O
17	O
-	O
OH	O
##IP	O
:	O
17	B
##α	I
-	I
h	I
##ydro	I
##xy	I
##p	I
##rog	I
##ester	I
##one	I
,	O
PR	O
##O	O
##G	O
:	O
pro	B
##ges	I
##tero	I
##ne	I
,	O
E	O
##2	O
:	O
est	B
##rad	I
##iol	I
,	O
E	O
##1	O
:	O
est	B
##rone	I
.	O

The	O
mass	O
s	O
##pect	O
##rome	O
##ter	O
was	O
operating	O
in	O
the	O
positive	O
ion	O
mode	O
and	O
con	O
##figured	O
in	O
multiple	O
reaction	O
monitoring	O
(	O
MR	O
##M	O
)	O
mode	O
for	O
q	O
##uant	O
##ification	O
of	O
a	B
##bir	I
##ater	I
##one	I
and	O
its	O
internal	O
standard	O
(	O
m	O
/	O
z	O
350	O
→	O
156	O
and	O
35	O
##4	O
→	O
160	O
)	O
.	O

Car	B
##box	I
##yl	I
##ic	I
acids	I
and	O
am	O
##ines	O
represent	O
a	O
majority	O
of	O
the	O
meta	O
##bol	O
##ites	O
in	O
body	O
fluids	O
and	O
their	O
analysis	O
by	O
is	O
##oto	O
##pe	O
tag	O
##ging	O
significantly	O
enhance	O
##s	O
the	O
detect	O
##able	O
metabolic	O
pool	O
for	O
bio	O
##mark	O
##er	O
discovery	O
applications	O
.	O

Sam	O
##ple	O
preparation	O
for	O
_	O
1	O
H	O
N	O
##MR	O
was	O
done	O
as	O
follows	O
:	O
al	O
##iq	O
##uo	O
##ts	O
of	O
urine	O
specimens	O
(	O
500	O
μ	O
##L	O
/	O
each	O
)	O
were	O
re	O
##sus	O
##pen	O
##ded	O
in	O
50	O
μ	O
##L	O
of	O
D	O
_	O
2	O
O	O
containing	O
sodium	B
-	I
3	I
-	I
trim	I
##eth	I
##yl	I
##si	I
##ly	I
-	I
[	I
2	I
,	I
2	I
,	I
3	I
,	I
3	I
-	I
2	I
##H	I
4	I
]	I
-	I
1	I
-	I
prop	I
##ion	I
##ate	I
(	O
T	O
##SP	O
,	O
0	O
.	O
02	O
##5	O
%	O
,	O
w	O
/	O
v	O
)	O
in	O
a	O
5	O
mm	O
N	O
##MR	O
tube	O
.	O

Data	O
were	O
mass	O
corrected	O
during	O
acquisition	O
using	O
a	O
le	B
##uc	I
##ine	I
en	I
##ke	I
##pha	I
##lin	I
reference	O
spray	O
(	O
Lock	O
##S	O
##pra	O
##y	O
)	O
in	O
##fused	O
at	O
3	O
μ	O
##L	O
min	O
_	O
−	O
##1	O
.	O

In	O
fact	O
,	O
several	O
studies	O
were	O
reported	O
describing	O
the	O
potential	O
of	O
end	O
##op	O
##hy	O
##tic	O
F	O
.	O
o	B
##xy	I
##sp	I
##orum	I
is	O
##olate	O
##s	O
to	O
in	O
##hibit	O
various	O
ne	O
##mat	O
##odes	O
parasite	O
##s	O
at	O
different	O
stages	O
of	O
their	O
development	O
(	O
Hall	O
##man	O
and	O
Si	O
##kor	O
##a	O
1994	O
;	O
V	O
##u	O
et	O
al	O
.	O

The	O
trend	O
of	O
over	O
##ex	O
##pressed	O
amino	O
acids	O
in	O
HC	O
##C	O
vs	O
.	O
DC	O
was	O
further	O
seen	O
among	O
amino	O
acids	O
v	O
##ali	O
##ne	O
(	O
P	O
=	O
0	O
.	O
04	O
##0	O
##9	O
)	O
,	O
t	B
##yr	I
##os	I
##ine	I
(	O
P	O
=	O
0	O
.	O
02	O
##11	O
)	O
,	O
as	B
##par	I
##agi	I
##ne	I
(	O
P	O
=	O
0	O
.	O
01	O
##0	O
##8	O
)	O
and	O
try	B
##pt	I
##op	I
##han	I
(	O
P	O
=	O
0	O
.	O
00	O
##36	O
)	O
.	O

Mi	O
##gra	O
##ine	O
,	O
Li	O
##pid	O
##omi	O
##cs	O
,	O
B	O
##io	O
##mark	O
##ers	O
,	O
L	O
##ys	O
##o	O
##PC	O
,	O
A	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
,	O
Ce	O
##r	O
_	O
N	O
##S	O
,	O
L	O
##ys	O
##o	O
##P	O
##E	O

Co	B
##rt	I
##is	I
##ol	I
(	O
CO	O
##RT	O
)	O
,	O
co	B
##rt	I
##ico	I
##ster	I
##one	I
(	O
CC	O
##ON	O
##E	O
)	O
,	O
11	B
-	I
de	I
##ox	I
##y	I
##cor	I
##tis	I
##ol	I
(	O
11	O
-	O
DE	O
##CO	O
##L	O
)	O
,	O
4	B
-	I
and	I
##ros	I
##ten	I
##e	I
-	I
3	I
,	I
17	I
-	I
di	I
##one	I
(	O
AD	O
##ION	O
##E	O
)	O
,	O
test	B
##osterone	I
(	O
T	O
##ES	O
##TO	O
)	O
,	O
17	B
##α	I
-	I
h	I
##ydro	I
##xy	I
##p	I
##rog	I
##ester	I
##one	I
(	O
17	O
-	O
OH	O
##P	O
)	O
,	O
pro	B
##ges	I
##tero	I
##ne	I
(	O
PR	O
##O	O
##G	O
)	O
,	O
est	B
##rone	I
(	O
E	O
##1	O
)	O
,	O
and	O
est	B
##rad	I
##iol	I
(	O
E	O
##2	O
)	O
were	O
purchased	O
from	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
_	O
®	O
(	O
St	O
.	O
Louis	O
,	O
M	O
##O	O
,	O
USA	O
)	O
.	O

For	O
the	O
analyses	O
of	O
AA	O
,	O
amino	O
acid	O
standards	O
set	O
A	O
,	O
L	B
-	I
as	I
##par	I
##agi	I
##ne	I
and	O
L	B
-	I
try	I
##pt	I
##op	I
##hane	I
(	O
Cam	O
##bri	O
##g	O
##de	O
Is	O
##oto	O
##pe	O
Laboratories	O
,	O
Te	O
##w	O
##ks	O
##bury	O
,	O
USA	O
)	O
were	O
added	O
to	O
50	O
μ	O
##L	O
of	O
the	O
super	O
##nat	O
##ant	O
.	O

The	O
in	O
##tra	O
-	O
and	O
inter	O
##ass	O
##ay	O
coefficients	O
of	O
variation	O
for	O
beta	B
##ine	I
are	O
6	O
.	O
2	O
and	O
7	O
.	O
2	O
%	O
,	O
respectively	O
.	O

The	O
code	O
##ine	O
-	O
derived	O
m	O
##or	O
##phine	O
then	O
follows	O
the	O
same	O
metabolic	O
pathways	O
that	O
were	O
described	O
when	O
discussing	O
m	B
##or	I
##phine	I
.	O

Most	O
serum	O
s	O
##tero	O
##ls	O
are	O
associated	O
with	O
circulating	O
lip	O
##op	O
##rote	O
##in	O
particles	O
(	O
L	O
##D	O
##L	O
,	O
very	O
low	O
-	O
density	O
lip	O
##op	O
##rote	O
##in	O
,	O
HD	O
##L	O
)	O
leading	O
to	O
strong	O
correlation	O
##s	O
between	O
these	O
lip	O
##ids	O
and	O
ch	B
##ole	I
##ster	I
##ol	I
and	O
t	B
##rig	I
##ly	I
##cer	I
##ide	I
levels	O
(	O
,	O
,	O
)	O
.	O

Ion	O
di	O
##sso	O
##ciation	O
(	O
MS	O
_	O
2	O
)	O
studies	O
were	O
completed	O
and	O
s	O
##pect	O
##ra	O
characterized	O
using	O
CF	O
##M	O
‐	O
ID	O
##40	O
and	O
Sirius	O
3	O
.	O
0	O
.	O
41	O
Piper	B
##ine	I
was	O
confirmed	O
by	O
comparing	O
m	O
/	O
z	O
values	O
,	O
retention	O
times	O
,	O
is	O
##oto	O
##pic	O
distribution	O
,	O
and	O
detected	O
add	O
##uc	O
##ts	O
to	O
a	O
pipe	B
##rine	I
reference	O
standard	O
(	O
Sigma	O
Al	O
##dric	O
##h	O
)	O
.	O

f	B
##ru	I
##ct	I
##ose	I
-	I
6	I
-	I
phosphate	I
,	O
my	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
-	I
phosphate	I
)	O
,	O
O	B
-	I
p	I
##hos	I
##ph	I
##oe	I
##than	I
##ola	I
##mine	I
,	O
and	O
the	O
amino	O
acids	O
as	O
##par	O
##tate	O
,	O
g	B
##lut	I
##ama	I
##te	I
,	O
and	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
which	O
were	O
all	O
affected	O
by	O
both	O
a	O
6	O
h	O
-	O
blood	O
in	O
##cu	O
##bation	O
and	O
a	O
24	O
h	O
-	O
serum	O
storage	O
at	O
R	O
##T	O
.	O

At	O
the	O
time	O
of	O
screening	O
for	O
trial	O
inclusion	O
,	O
potential	O
participants	O
received	O
thorough	O
written	O
and	O
oral	O
information	O
on	O
the	O
purpose	O
and	O
duration	S
of	O
the	O
study	O
,	O
as	O
well	O
as	O
possible	O
adverse	O
events	O
,	O
and	O
signed	O
the	O
informed	O
consent	O
.	O

Finally	O
,	O
decreased	O
levels	O
of	O
a	B
##rg	I
##ini	I
##ne	I
and	O
pro	B
##line	I
metabolism	O
and	O
in	B
##os	I
##ito	I
##l	I
phosphate	I
metabolism	O
were	O
observed	O
.	O

Free	O
##ze	O
-	O
th	O
##aw	O
(	O
F	O
##T	O
)	O
stability	O
.	O
_	O
a	O
Signal	O
change	O
compared	O
to	O
F	B
##T	I
cycle	O
1	O
.	O

The	O
serum	O
levels	O
of	O
c	B
##it	I
##rate	I
and	O
3	O
-	O
H	O
##B	O
were	O
negatively	O
correlated	O
with	O
G	O
##F	O
##R	O
,	O
suggesting	O
that	O
the	O
re	O
##nal	O
ex	O
##cre	O
##tion	O
might	O
be	O
factor	O
in	O
the	O
regulation	O
of	O
the	O
serum	O
levels	O
of	O
these	O
meta	O
##bol	O
##ites	O
in	O
A	O
##HF	O
.	O

(	O
a	O
)	O
R	O
##OC	O
analysis	O
was	O
performed	O
using	O
the	O
values	O
of	O
1	B
-	I
met	I
##hyl	I
##ade	I
##nos	I
##ine	I
,	O
A	O
##FP	O
,	O
H	O
##B	O
##V	O
-	O
DNA	O
,	O
or	O
1	B
-	I
met	I
##hyl	I
##ade	I
##nos	I
##ine	I
plus	O
A	O
##FP	O
.	O

N	B
-	I
Ace	I
##to	I
##xy	I
-	I
Ph	I
##IP	I
undergo	O
##es	O
so	O
##l	O
##vo	O
##lysis	O
more	O
f	O
##ac	O
##ile	O
##ly	O
than	O
H	O
##ON	O
##H	O
-	O
Ph	O
##IP	O
,	O
to	O
produce	O
the	O
ni	O
##tre	O
##nium	O
ion	O
,	O
and	O
explains	O
the	O
superior	O
react	O
##ivity	O
of	O
N	B
-	I
ace	I
##to	I
##xy	I
-	I
Ph	I
##IP	I
towards	O
DNA	O
.	O

We	O
monitored	O
for	O
V	B
##LC	I
##DC	I
##A	I
28	I
:	I
4	I
levels	O
in	O
a	O
number	O
of	O
human	O
bio	O
##f	O
##lu	O
##ids	O
and	O
in	O
plasma	O
from	O
Cy	O
##no	O
##mo	O
##log	O
##ous	O
monkeys	O
,	O
R	O
##hes	O
##us	O
mac	O
##aque	O
monkeys	O
,	O
dogs	O
,	O
rats	O
,	O
cows	O
,	O
and	O
cats	O
.	O

=	O
he	B
##xa	I
##noy	I
##l	I
##car	I
##ni	I
##tine	I
(	O
Met	O
##ab	O
##olo	O
##n	O
,	O
P	O
=	O
1	O
.	O
6	O
##×	O
##10	O
_	O
−	O
##13	O
)	O
,	O
C	O
##8	O
(	O
B	O
##io	O
##crates	O
,	O
P	O
=	O
2	O
.	O
4	O
##×	O
##10	O
_	O
−	O
##8	O
)	O
=	O
o	B
##ct	I
##ano	I
##yl	I
##car	I
##ni	I
##tine	I
(	O
Met	O
##ab	O
##olo	O
##n	O
,	O
P	O
=	O
4	O
.	O
8	O
##×	O
##10	O
_	O
−	O
##11	O
)	O
,	O
g	B
##ly	I
##cine	I
(	O
B	O
##io	O
##crates	O
,	O
P	O
=	O
5	O
.	O
3	O
##×	O
##10	O
_	O
−	O
##17	O
)	O
=	O
g	B
##ly	I
##cine	I
(	O
Met	O
##ab	O
##olo	O
##n	O
,	O
P	O
=	O
7	O
.	O
1	O
##×	O
##10	O
_	O
−	O
##27	O
)	O
,	O
C	O
##0	O
(	O
B	O
##io	O
##crates	O
,	O
P	O
=	O
4	O
.	O
6	O
##×	O
##10	O
_	O
−	O
##12	O
)	O
=	O
car	B
##ni	I
##tine	I

The	O
following	O
source	O
parameters	O
were	O
applied	O
:	O
a	O
##cc	O
##ele	O
##rating	O
voltage	O
,	O
24	O
k	B
##V	I
;	O
76	O
%	O
grid	O
voltage	O
;	O
and	O
delay	O
time	O
,	O
180	O
n	O
##s	O
.	O

P	O
##las	O
##ma	O
samples	O
(	O
20	O
μ	O
##L	O
)	O
were	O
pre	O
##ci	O
##pit	O
##ated	O
by	O
adding	O
750	O
μ	O
##L	O
of	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
(	O
AC	O
##N	O
)	O
and	O
10	O
μ	O
##L	O
internal	O
standards	O
(	O
T	O
##MA	O
##O	O
-	O
d	O
##9	O
,	O
ch	B
##olin	I
##e	I
-	I
d	I
##9	I
,	O
beta	B
##ine	I
-	I
d	I
##9	I
,	O
c	B
##rea	I
##tin	I
##ine	I
-	I
d	I
##3	I
,	O
and	O
L	B
-	I
car	I
##ni	I
##tine	I
-	I
d	I
##3	I
)	O
.	O

In	O
the	O
fully	O
saturated	O
model	O
with	O
model	O
2	O
co	O
##var	O
##iate	O
##s	O
,	O
based	O
on	O
a	O
conservative	O
Bon	O
##fer	O
##ron	O
##i	O
threshold	O
of	O
P	O
≤	O
2	O
.	O
50	O
×	O
10	O
_	O
−	O
##4	O
for	O
the	O
U	O
.	O
S	O
.	O
samples	O
,	O
u	O
##rina	O
##ry	O
g	B
##ly	I
##co	I
##p	I
##rote	I
##ins	I
,	O
c	B
##ys	I
##tine	I
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
ethanol	B
##amine	I
,	O
and	O
3	B
-	I
met	I
##hyl	I
##his	I
##ti	I
##dine	I
remained	O
significantly	O
and	O
directly	O
associated	O
with	O
B	O
##MI	O
(	O
P	O
=	O
4	O
.	O
44	O
×	O
10	O
_	O
−	O
##6	O
to	O
P	O
=	O
1	O
.	O
99	O
×	O
10	O
_	O
−	O
##35	O
)	O
,	O
whereas	O
g	B
##lut	I
##amine	I
,	O
4	B
-	I
c	I
##res	I
##yl	I
su	I
##lf	I
##ate	I
,	O
O	B
-	I
ace	I
##ty	I
##l	I
car	I
##ni	I
##tine	I
,	O
the	O
k	O
##eto	O
##le	O
##uc	O
##ine	O
/	O
le	O
##uc	O
##ine	O
ratio	O
,	O
ta	B
##uri	I
##ne	I
,	O
and	O
as	B
##par	I
##agi	I
##ne	I
were	O
inverse	O
##ly	O
associated	O
(	O
P	O
=	O
1	O
.	O
60	O
×	O
10	O
_	O
−	O
##4	O
to	O
P	O
=	O
6	O
.	O
17	O
×	O
10	O
_	O
−	O
##9	O
)	O
.	O

A	O
double	O
##t	O
at	O
2	O
.	O
63	O
–	O
2	O
.	O
68	O
pp	O
##m	O
indicated	O
that	O
met	B
##hi	I
##oni	I
##ne	I
was	O
disc	O
##rim	O
##ina	O
##tive	O
between	O
dairy	O
products	O
(	O
i	O
.	O
e	O
.	O
,	O
milk	O
and	O
cheese	O
)	O
and	O
the	O
so	O
##y	O
drink	O
.	O

K	O
##re	O
##bs	O
cycle	O
intermediate	O
##s	O
may	O
also	O
be	O
re	O
##ple	O
##nish	O
##ed	O
via	O
g	O
##lut	O
##ami	O
##no	O
##lysis	O
[	O
,	O
,	O
]	O
,	O
which	O
has	O
been	O
shown	O
to	O
be	O
activated	S
in	O
g	O
##lio	O
##blast	O
##oma	O
cells	O
,	O
based	O
on	O
the	O
production	O
of	O
labeled	O
la	B
##ct	I
##ate	I
derived	O
from	O
labeled	O
G	O
##ln	O
.	O

In	O
a	O
recent	O
N	O
##MR	O
study	O
,	O
glucose	S
,	O
la	B
##ct	I
##ate	I
,	O
and	O
p	B
##yr	I
##u	I
##vate	I
concentration	O
changes	O
were	O
most	O
pronounced	O
in	O
plasma	O
meta	O
##bol	O
##ites	O
after	O
the	O
exposure	O
of	O
E	O
##D	O
##TA	O
blood	O
to	O
25	O
##°	O
##C	O
for	O
up	O
to	O
4	O
h	O
.	O

All	O
peak	O
areas	O
were	O
then	O
normal	O
##ized	O
to	O
the	O
synthetic	O
internal	O
standard	O
(	B
PC	B
[	I
13	I
:	I
0	I
/	I
0	I
:	I
0	I
]	I
)	O
spike	O
##d	O
at	O
time	O
of	O
lip	O
##id	O
extraction	O
from	O
plasma	O
and	O
multi	O
##plied	O
by	O
10	O
_	O
6	O
before	O
log	O
_	O
2	O
transformation	O
,	O
yielding	O
the	O
abundance	O
.	O

Cy	B
##st	I
##ine	I
and	O
c	B
##ys	I
##tein	I
##e	I
are	O
limiting	O
substrates	O
in	O
the	O
bio	O
##sy	O
##nt	O
##hesis	O
of	O
trip	O
##eptide	O
g	B
##lut	I
##ath	I
##ione	I
(	O
G	O
##S	O
##H	O
)	O
,	O
which	O
is	O
known	O
to	O
be	O
the	O
most	O
important	O
in	O
##tra	O
##cellular	O
anti	O
##ox	O
##ida	O
##nt	O
.	O

The	O
pathway	O
analysis	O
showed	O
significantly	O
altered	O
al	B
##ani	I
##ne	I
,	O
as	B
##par	I
##tate	I
,	O
and	O
g	B
##lut	I
##ama	I
##te	I
metabolic	O
pathways	O
(	O
F	O
##DR	O
p	O
-	O
value	O
<	O
0	O
.	O
05	O
)	O
in	O
both	O
the	O
discovery	O
and	O
valid	O
##ation	O
phases	O
.	O

As	O
in	O
the	O
DS	O
##S	O
model	O
,	O
we	O
found	O
,	O
relative	O
to	O
the	O
control	O
co	O
##hor	O
##t	O
,	O
higher	O
levels	O
of	O
all	B
##ant	I
##oi	I
##n	I
and	O
try	B
##pt	I
##op	I
##han	I
in	O
UC	O
and	O
higher	O
levels	O
of	O
la	B
##ct	I
##ate	I
and	O
car	B
##ni	I
##tine	I
in	O
UC	O
and	O
CD	O
.	O

The	O
novel	O
I	O
##1	O
##R	O
ago	O
##nist	O
S	O
##43	O
##12	O
##6	O
(	B
2	B
-	I
[	I
4	I
′	I
-	I
met	I
##ho	I
##xy	I
##phe	I
##ny	I
##l	I
]	I
-	I
4	I
,	I
5	I
-	I
di	I
##hy	I
##dr	I
##o	I
-	I
1	I
##H	I
-	I
im	I
##ida	I
##zo	I
##le	I
)	O
and	O
the	O
known	O
anti	O
##hy	O
##pert	O
##ens	O
##ive	O
and	O
I	O
##1	O
##R	O
ago	O
##nist	O
m	B
##ox	I
##oni	I
##dine	I
are	O
both	O
capable	O
of	O
engaging	O
this	O
phenomenon	O
.	O

In	O
good	O
respond	O
##ers	O
we	O
found	O
a	O
decrease	O
in	O
ch	B
##ole	I
##ster	I
##ol	I
(	O
p	O
<	O
0	O
.	O
00	O
##22	O
,	O
q	O
<	O
0	O
.	O
18	O
)	O
and	O
an	O
increase	O
in	O
s	B
##hi	I
##kim	I
##ic	I
acid	I
(	O
p	O
<	O
0	O
.	O
00	O
##9	O
##6	O
,	O
q	O
<	O
0	O
.	O
38	O
)	O
.	O

This	O
three	O
-	O
fold	O
difference	O
in	O
is	O
##omer	O
##ic	O
composition	O
demonstrates	O
the	O
specific	O
##ity	O
of	O
FA	S
double	O
bond	O
position	O
##al	O
is	O
##omer	O
##s	O
in	O
discrete	O
lip	O
##id	O
classes	O
in	O
human	O
serum	O
.	O

The	O
internal	O
standard	O
(	B
a	B
##bir	I
##ater	I
##one	I
-	I
d	I
##4	I
)	O
was	O
purchased	O
from	O
Toronto	O
Research	O
Chemical	O
##s	O
,	O
(	O
Toronto	O
,	O
Canada	O
)	O
.	O

P	O
##las	O
##ma	O
samples	O
were	O
de	O
##p	O
##rote	O
##ini	O
##zed	O
by	O
[UNK]	O
di	O
##lution	O
in	O
66	O
%	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
containing	O
2	O
m	O
##M	O
debris	B
##o	I
##quin	I
##e	I
su	I
##lf	I
##ate	I
and	O
30	O
m	O
##M	O
4	B
-	I
ni	I
##tro	I
##ben	I
##zoic	I
acid	I
as	O
internal	O
controls	O
.	O

All	O
urine	O
ass	O
##ays	O
in	O
the	O
original	O
data	O
set	O
were	O
normal	O
##ized	O
to	O
c	B
##rea	I
##tin	I
##ine	I
.	O

For	O
LP	O
##C	O
,	O
PC	O
,	O
plasma	B
##ny	I
##l	I
PC	I
,	O
p	B
##las	I
##men	I
##yl	I
PC	I
,	O
and	O
SM	O
species	O
,	O
the	O
transition	O
from	O
the	O
pro	O
##ton	O
##ated	O
molecular	O
ion	O
(	O
[	O
M	O
+	O
H	O
]	O
_	O
+	O
)	O
to	O
the	O
polar	O
head	O
fragment	O
ion	O
(	O
m	O
/	O
z	O
184	O
,	O
p	B
##hos	I
##ph	I
##och	I
##olin	I
##e	I
)	O
was	O
recorded	O
for	O
the	O
q	O
##uant	O
##itation	O
.	O

Among	O
these	O
,	O
2	B
-	I
amino	I
##adi	I
##pic	I
acid	I
/	I
2	I
-	I
amino	I
##he	I
##pta	I
##ned	I
##io	I
##ic	I
acid	I
(	O
common	O
name	O
2	B
-	I
amino	I
##pi	I
##mel	I
##ic	I
acid	O
)	O
,	O
and	O
er	O
##yt	O
##hr	O
##ito	O
##l	O
/	O
th	O
##re	O
##ito	O
##l	O
are	O
chemical	O
##ly	O
closely	O
related	O
.	O

The	O
same	O
approach	O
was	O
also	O
used	O
to	O
extend	O
this	O
analysis	O
to	O
consider	O
the	O
complex	O
cross	O
##tal	O
##k	O
between	O
this	O
pathway	O
map	O
and	O
two	O
of	O
the	O
remaining	O
altered	O
pathways	O
identified	O
in	O
this	O
study	O
:	O
pu	B
##rine	I
metabolism	O
(	O
Fi	O
##g	O
.	O
)	O
and	O
p	B
##yr	I
##im	I
##id	I
##ine	I
metabolism	O
(	O
Fi	O
##g	O
.	O
)	O
.	O

(	O
C	O
)	O
Z	O
-	O
scores	O
of	O
control	O
samples	O
,	O
other	O
patient	O
samples	O
and	O
the	O
samples	O
of	O
this	O
patient	O
for	O
γ	B
-	I
but	I
##yr	I
##obe	I
##tain	I
##e	I
,	O
the	O
meta	O
##bol	O
##ite	O
decreased	O
in	O
all	O
patient	O
samples	O
.	O

The	O
concentration	O
of	O
total	O
p	O
##oly	O
##phe	O
##no	O
##ls	O
so	O
##rb	O
##ed	O
per	O
gram	O
for	O
each	O
of	O
the	O
SP	O
##I	O
’	O
s	O
was	O
q	O
##uant	O
##ified	O
by	O
the	O
F	O
##olin	O
-	O
C	O
##io	O
##cal	O
##te	O
##u	O
method	O
with	O
samples	O
read	O
at	O
760	O
nm	O
using	O
a	O
UV	O
/	O
V	O
##is	O
s	O
##pect	O
##rop	O
##hot	O
##ometer	O
(	O
Beck	O
##man	O
Co	O
##ulter	O
D	O
##U	O
##5	O
##20	O
)	O
against	O
a	O
gal	B
##lic	I
acid	I
standard	O
curve	O
.	O

the	O
circulating	O
levels	O
of	O
drugs	O
such	O
as	O
r	B
##is	I
##per	I
##ido	I
##ne	I
and	O
que	B
##tia	I
##pine	I
are	O
meta	O
##bol	O
##ized	O
in	O
the	O
liver	O
to	O
produce	O
the	O
active	O
meta	O
##bol	O
##ites	O
and	O
some	O
classes	O
of	O
lip	O
##ids	O
can	O
in	O
##hibit	O
the	O
activity	O
of	O
the	O
meta	O
##bol	O
##izing	O
enzymes	O
.	O

S	O
##pecific	O
inhibitor	O
##s	O
of	O
glucose	S
transport	O
##er	O
may	O
be	O
added	O
to	O
see	O
if	O
it	O
can	O
reverse	O
the	O
meta	O
##bol	O
##omi	O
##c	O
profiles	O
changes	O
.	O

As	O
shown	O
in	O
,	O
the	O
subjects	O
’	O
average	O
B	O
##MI	O
,	O
blood	O
glucose	S
level	O
,	O
blood	O
pressure	O
,	O
and	O
lip	O
##id	O
levels	O
were	O
just	O
slightly	O
above	O
the	O
standard	O
values	O
,	O
reflecting	O
the	O
typical	O
characteristics	O
of	O
patients	O
with	O
metabolic	O
syndrome	O
.	O

(	O
c	O
)	O
P	O
##LS	O
-	O
D	O
##A	O
score	O
plot	O
of	O
fever	O
duration	S
6	O
–	O
12	O
.	O

Lac	B
##tate	I
is	O
an	O
end	O
product	O
of	O
g	O
##ly	O
##co	O
##lysis	O
which	O
shows	O
elevation	O
during	O
tissue	O
h	O
##y	O
##pox	O
##ia	O
and	O
is	O
##che	O
##mia	O
.	O

These	O
were	O
mon	B
##oga	I
##la	I
##ct	I
##osy	I
##ld	I
##iac	I
##yl	I
##gly	I
##cer	I
##ol	I
(	O
MG	O
##D	O
##G	O
)	O
,	O
s	B
##ti	I
##gma	I
##ster	I
##yl	I
est	I
##er	I
(	O
St	O
##E	O
)	O
,	O
sit	B
##ost	I
##ery	I
##l	I
est	I
##er	I
(	O
Si	O
##E	O
)	O
,	O
and	O
wax	O
est	O
##er	O
(	O
W	O
##E	O
)	O
.	O

VC	O
##a	O
##P	O
and	O
L	O
##n	O
##CA	O
##P	O
were	O
grown	O
in	O
charcoal	O
stripped	O
serum	O
containing	O
media	O
for	O
24	O
##h	O
,	O
before	O
treatment	O
for	O
further	O
24	O
h	O
with	O
vehicle	O
or	O
1	O
##n	O
##M	O
met	B
##hyl	I
##tri	I
##eno	I
##lone	I
(	O
R	O
##18	O
##8	O
##1	O
,	O
NE	O
##N	O
)	O
dissolved	O
in	O
ethanol	S
.	O

G	B
##ly	I
##cine	I
is	O
a	O
precursor	O
for	O
the	O
formation	O
of	O
pu	B
##rine	I
.	O

This	O
finding	O
is	O
supported	O
by	O
recent	O
reports	O
indicating	O
that	O
o	O
##besity	O
,	O
insulin	O
resistance	O
and	O
metabolic	O
syndrome	O
are	O
associated	O
with	O
lower	O
concentrations	O
of	O
se	B
##rine	I
and	O
g	B
##ly	I
##cine	I
(	O
substrates	O
)	O
and	O
higher	O
concentrations	O
of	O
s	B
##phi	I
##ngo	I
##lip	I
##id	I
species	O
(	O
products	O
)	O
in	O
humans	O
.	O

Bo	O
##vin	O
##e	O
serum	O
album	O
##in	O
(	O
≥	O
96	O
%	O
)	O
,	O
phosphate	B
-	I
buffer	I
##ed	I
sa	I
##line	I
(	O
PBS	O
)	O
,	O
25	O
(	O
OH	O
)	O
D	O
_	O
2	O
and	O
25	O
(	O
OH	O
)	O
D	O
_	O
3	O
were	O
obtained	O
from	O
Sigma	O
(	O
St	O
.	O
Louis	O
,	O
M	O
##O	O
)	O
.	O

Both	O
genetic	O
and	O
p	O
##har	O
##ma	O
##cological	O
in	O
##hibition	O
of	O
this	O
key	O
enzyme	O
in	O
ta	O
##mo	O
##xi	O
##fen	O
-	O
resistant	O
cells	O
significantly	O
decreased	O
proliferation	O
,	O
reduced	O
expression	O
of	O
cell	O
cycle	O
genes	O
,	O
and	O
se	O
##ns	O
##iti	O
##zed	O
the	O
cells	O
to	O
ta	B
##mo	I
##xi	I
##fen	I
treatment	O
.	O

Mo	B
##rp	I
##hine	I
-	I
3	I
-	I
g	I
##lu	I
##cu	I
##ron	I
##ide	I
is	O
biological	O
##ly	O
inactive	O
but	O
m	B
##or	I
##phine	I
-	I
6	I
-	I
g	I
##lu	I
##cu	I
##ron	I
##ide	I
has	O
considerable	O
anal	O
##ges	O
##ic	O
activity	O
.	O

_	O
–	O
Given	O
the	O
expanding	O
use	O
of	O
mass	O
s	O
##pect	O
##rome	O
##try	O
-	O
based	O
methods	O
for	O
measurement	O
of	O
25	O
(	O
OH	O
)	O
D	O
,	O
3	B
-	I
e	I
##pi	I
-	I
25	I
(	I
OH	I
)	I
D	I
_	I
3	I
was	O
considered	O
to	O
be	O
an	O
important	O
aspect	O
of	O
the	O
design	O
of	O
SR	O
##M	O
97	O
##2	O
##a	O
.	O

To	O
examine	O
whether	O
try	B
##pt	I
##op	I
##han	I
cat	O
##ab	O
##olis	O
##m	O
correlated	O
with	O
outcomes	O
in	O
this	O
breast	O
cancer	O
data	O
set	O
,	O
we	O
divided	O
the	O
patient	O
data	O
into	O
try	O
##pt	O
##op	O
##han	O
-	O
low	O
and	O
try	O
##pt	O
##op	O
##han	O
-	O
high	O
groups	O
based	O
on	O
the	O
median	O
concentration	O
of	O
plasma	O
try	B
##pt	I
##op	I
##han	I
,	O
and	O
compared	O
the	O
progression	O
-	O
free	O
survival	O
of	O
these	O
groups	O
,	O
where	O
progression	O
was	O
defined	O
as	O
local	O
,	O
regional	O
,	O
or	O
distant	O
re	O
##cu	O
##rrence	O
,	O
or	O
patient	O
death	O
.	O

[	O
1	O
]	O
,	O
o	O
##ste	O
##oar	O
##th	O
##rit	O
##is	O
[	O
3	O
]	O
,	O
h	O
##yper	O
##tens	O
##ion	O
[	O
3	O
]	O
,	O
increased	O
ch	B
##ole	I
##ster	I
##ol	I
[	O
1	O
]	O
,	O
for	O
##ami	O
##nal	O
s	O
##ten	O
##osis	O
[	O
1	O
]	O
and	O
depression	O
[	O
1	O
]	O
.	O

Statistical	O
analysis	O
was	O
not	O
performed	O
to	O
compare	O
AD	B
##MA	I
concentrations	O
in	O
the	O
h	O
##yper	O
##tensive	O
compared	O
with	O
the	O
norm	O
##ote	O
##ns	O
##ive	O
subjects	O
due	O
to	O
the	O
small	O
number	O
of	O
subjects	O
involved	O
.	O

A	O
cave	O
##at	O
of	O
our	O
study	O
is	O
that	O
although	O
our	O
direct	O
measurement	O
of	O
cannabis	S
meta	O
##bol	O
##ites	O
in	O
the	O
plasma	O
of	O
the	O
study	O
participants	O
is	O
a	O
more	O
accurate	O
measure	O
of	O
cannabis	S
use	O
than	O
self	O
-	O
reported	O
status	O
,	O
we	O
were	O
not	O
able	O
to	O
assess	O
host	O
factors	O
that	O
could	O
influence	O
the	O
rate	O
of	O
cannabis	S
metabolism	O
in	O
each	O
individual	O
,	O
such	O
as	O
he	O
##pa	O
##tic	O
enzymes	O
and	O
genetics	O
.	O

Previous	O
p	O
##har	O
##ma	O
##co	O
##kin	O
##etic	O
studies	O
indicated	O
that	O
R	O
##EG	O
is	O
the	O
main	O
component	O
and	O
that	O
R	O
##EG	O
N	B
-	I
oxide	I
is	O
the	O
major	O
R	O
##EG	O
meta	O
##bol	O
##ite	O
in	O
plasma	O
,	O
whereas	O
in	O
our	O
serum	O
measurements	O
the	O
meta	O
##bol	O
##ite	O
R	O
##EG	O
N	B
-	I
oxide	I
surpassed	O
the	O
concentrations	O
of	O
R	O
##EG	O
itself	O
.	O

These	O
events	O
suggested	O
f	B
##uma	I
##ric	I
acid	I
may	O
play	O
a	O
role	O
in	O
tissue	O
o	O
##xi	O
##da	O
##tive	O
stress	O
.	O

Tri	B
##ter	I
##pen	I
##e	I
1	O
,	O
DC	O
##M	O
,	O
and	O
a	O
##que	O
##ous	O
leaf	O
extract	O
##s	O
were	O
tested	O
for	O
h	B
##y	I
##po	I
##gly	I
##ce	I
##mic	I
potential	O
using	O
the	O
oral	O
glucose	S
tolerance	O
test	O
;	O
anal	O
##ges	O
##ic	O
potential	O
using	O
the	O
tail	O
-	O
flick	O
ass	O
##ay	O
,	O
and	O
anti	O
##mic	O
##ro	O
##bial	O
potential	O
using	O
the	O
disc	O
diffusion	O
method	O
.	O

The	O
V	O
mode	O
was	O
used	O
for	O
the	O
mass	O
s	O
##pect	O
##rome	O
##ter	O
and	O
data	O
were	O
collected	O
in	O
the	O
cent	O
##roid	O
mode	O
with	O
a	O
scan	O
accumulation	O
of	O
0	O
.	O
2	O
s	O
.	O
Le	B
##uc	I
##ine	I
en	O
##ce	O
##pha	O
##lin	O
was	O
used	O
as	O
reference	O
lock	O
mass	O
(	O
m	O
/	O
z	O
55	O
##4	O
.	O
261	O
##5	O
)	O
by	O
independent	O
Lock	O
##S	O
##pra	O
##y	O
interference	O
.	O

In	O
the	O
authentic	O
urine	O
pool	O
of	O
pre	O
##su	O
##mpt	O
##ive	O
positive	O
synthetic	O
can	B
##na	I
##bino	I
##ids	I
,	O
14	O
meta	O
##bol	O
##ites	O
were	O
detected	O
after	O
h	O
##ydro	O
##lysis	O
.	O

Cho	O
:	O
ch	B
##olin	I
##e	I
;	O

The	O
impact	O
of	O
add	O
##itive	O
selection	O
upon	O
peak	O
base	O
width	O
##s	O
and	O
resolution	O
in	O
SF	O
##C	O
-	O
MS	O
mode	O
is	O
shown	O
in	O
:	O
the	O
three	O
am	B
##mon	I
##ium	I
salts	O
reduce	O
the	O
median	O
peak	O
base	O
width	O
considerably	O
when	O
compared	O
to	O
the	O
acidic	O
add	O
##itive	O
##s	O
.	O

We	O
conclude	O
that	O
the	O
serum	O
concentrations	O
of	O
4	O
##OH	O
##ND	O
##tam	O
(	B
end	B
##ox	I
##ife	I
##n	I
)	O
,	O
ta	B
##mo	I
##xi	I
##fen	I
,	O
and	O
its	O
dem	O
##eth	O
##yla	O
##ted	O
meta	O
##bol	O
##ites	O
increase	O
with	O
age	O
during	O
steady	O
-	O
state	O
ta	B
##mo	I
##xi	I
##fen	I
treatment	O
.	O

The	O
link	O
between	O
high	O
ch	B
##ole	I
##ster	I
##ol	I
and	O
later	O
development	O
of	O
dem	O
##ent	O
##ia	O
is	O
less	O
strong	O
in	O
women	O
.	O

Cross	O
-	O
section	O
##al	O
serum	O
samples	O
from	O
24	O
secondary	O
progressive	O
(	O
SP	O
##MS	O
)	O
,	O
100	O
re	O
##lap	O
##sing	O
re	O
##mit	O
##ting	O
(	O
R	O
##R	O
##MS	O
)	O
,	O
19	O
primary	O
progressive	O
MS	O
(	O
PP	O
##MS	O
)	O
,	O
and	O
55	O
age	O
-	O
matched	O
control	O
subjects	O
were	O
analyzed	O
by	O
flow	O
injection	O
tandem	O
mass	O
s	O
##pect	O
##rome	O
##try	O
for	O
very	O
long	O
chain	O
fatty	O
acid	O
(	O
V	O
##LC	O
##FA	O
)	O
containing	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
ethanol	I
##amine	I
##s	I
(	O
P	O
##t	O
##d	O
##E	O
##t	O
##n	O
)	O
,	O
plasma	O
##log	O
##en	O
ethanol	B
##amine	I
##s	I
(	O
P	O
##ls	O
##E	O
##t	O
##n	O
)	O
and	O
for	O
novel	O
anti	O
-	O
inflammatory	O
gas	O
##tro	O
##int	O
##est	O
##inal	O
tract	O
acids	O
(	O
GT	O
##As	O
)	O
.	O

In	O
general	O
,	O
the	O
results	O
in	O
suggest	O
that	O
con	O
##ju	O
##gation	O
with	O
su	B
##lf	I
##ona	I
##te	I
is	O
the	O
major	O
phase	O
II	O
metabolism	O
pathway	O
in	O
the	O
human	O
brain	O
.	O

The	O
complete	O
un	O
##am	O
##bi	O
##guous	O
assignments	O
for	O
the	O
_	O
1	O
H	O
and	O
_	O
13	O
C	O
N	O
##MR	O
signals	O
of	O
IP	O
-	O
2	O
were	O
made	O
by	O
a	O
combination	O
of	O
the	O
_	O
1	O
H	O
##−	O
_	O
1	O
H	O
CO	O
##S	O
##Y	O
,	O
H	O
##S	O
##Q	O
##C	O
,	O
HM	O
##BC	O
,	O
and	O
nuclear	O
over	O
##haus	O
##er	O
effect	O
s	O
##pect	O
##ros	O
##copy	O
(	O
NO	O
##ES	O
##Y	O
)	O
s	O
##pect	O
##ra	O
,	O
suggesting	O
the	O
presence	O
of	O
a	O
met	B
##ho	I
##xy	I
group	O
at	O
δ	O
3	O
.	O
64	O
(	O
3	O
##H	O
,	O
s	O
,	O
O	O
##M	O
##e	O
)	O
,	O
one	O
o	O
##le	O
##fin	O
##ic	O
at	O
δ	O
7	O
.	O
56	O
(	O
1	O
##H	O
,	O
d	O
,	O
J	O
=	O
2	O
.	O
2	O

Alternatively	O
,	O
it	O
can	O
undergo	O
β	O
-	O
elimination	O
followed	O
by	O
S	O
-	O
met	O
##hyl	O
##ation	O
to	O
a	O
met	B
##hyl	I
##thi	I
##ol	I
intermediate	O
that	O
is	O
further	O
o	O
##xi	O
##dized	O
to	O
a	O
su	B
##lf	I
##oxide	I
.	O

At	O
base	O
##line	O
,	O
weight	O
gain	O
##ers	O
had	O
less	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
,	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
,	O
l	B
##ys	I
##o	I
-	I
p	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
and	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
,	O
and	O
showed	O
an	O
inflammatory	O
lip	O
##id	O
profile	O
.	O

The	O
therapy	O
em	O
##pt	O
##ies	O
the	O
liver	O
and	O
muscle	O
g	B
##ly	I
##co	I
##gen	I
stores	O
resulting	O
in	O
the	O
decrease	O
of	O
g	O
##ly	O
##co	O
##gen	O
##oly	O
##sis	O
and	O
g	O
##lu	O
##con	O
##eo	O
##genesis	O
.	O

d	O
Model	O
based	O
on	O
the	O
cross	O
-	O
valid	O
##ated	O
(	O
C	O
##V	O
)	O
case	O
/	O
control	O
status	O
of	O
the	O
O	O
-	O
P	O
##LS	O
analysis	O
_	O
e	O
Co	O
##mb	O
##ination	O
between	O
the	O
C	O
##V	O
status	O
of	O
the	O
O	O
-	O
P	O
##LS	O
and	O
the	O
A	O
##FP	O
variable	O
_	O
f	O
Co	O
##mb	O
##ination	O
between	O
the	O
C	O
##V	O
status	O
of	O
the	O
O	O
-	O
P	O
##LS	O
and	O
the	O
liver	O
function	O
score	O
Odd	O
##s	O
ratios	O
[	O
OR	O
(	O
95	O
%	O
confidence	O
intervals	O
)	O
]	O
of	O
HC	O
##C	O
risk	O
by	O
serum	O
meta	O
##bol	O
##ites	O
*	O
P	O
value	O
<	O
0	O
.	O
05	O
;	O
*	O
*	O
P	O
value	O
<	O
0	O
.	O
01	O
;	O
*	O
*	O
*	O
P	O
value	O
<	O
0	O
.	O
00	O
##1	O
_	O
a	O
Model	O
1	O
,	O
C	O
##rud	O
##e	O
OR	O
based	O
on	O
log	O
##istic	O
re	O
##gression	O
conditioned	O
on	O
matching	O
factors	O
(	O
sex	O
,	O
age	O
,	O
date	O
and	O
time	O
of	O
blood	O
collection	O
,	O
fast	O
##ing	O
status	O
,	O
and	O
men	O
##op	O
##aus	O
##al	O
status	O
and	O
use	O
of	O
hormones	O
)	O
_	O
b	O
Model	O
2	O
,	O
OR	O
based	O
on	O
multi	O
##var	O
##iable	O
C	O
##LR	O
adjusted	O
for	O
smoking	O
status	O
,	O
ethanol	S
at	O
recruitment	O
,	O
lifetime	O
alcohol	O
,	O
educational	O
status	O
,	O
physical	O
activity	O
,	O
body	O
mass	O
index	O
,	O
serum	O
-	O
c	O
##lot	O
contact	O
time	O
,	O
and	O
waist	O
c	O
##ir	O
##cum	O
##ference	O
_	O
c	O
Model	O
3	O
,	O
as	O
in	O
model	O
2	O
and	O
additionally	O
adjusted	O
for	O
liver	O
function	O
score	O
_	O
d	O
Model	O
4	O
,	O
as	O
model	O
2	O
but	O
obtained	O
on	O
HC	O
##C	O
cases	O
free	O
of	O
H	O
##B	O
##V	O
/	O
HC	O
##V	O
infection	O
and	O
their	O
matched	O
controls	O
(	O
n	O
=	O

The	O
use	O
of	O
anti	O
-	O
o	O
##besity	O
drugs	O
such	O
as	O
si	B
##but	I
##ram	I
##ine	I
is	O
somewhat	O
helpful	O
.	O

These	O
M	O
##U	O
##FA	O
##s	O
are	O
the	O
key	O
components	O
of	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
and	O
membrane	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
.	O

In	O
particular	O
,	O
ion	O
number	O
3	O
with	O
[	O
M	O
##−	O
##H	O
]	O
_	O
−	O
=	O
167	O
.	O
02	O
##0	O
##2	O
m	O
/	O
z	O
,	O
retention	O
time	O
of	O
0	O
.	O
31	O
##7	O
##9	O
min	O
was	O
verified	O
as	O
u	B
##ric	I
acid	I
,	O
which	O
as	O
mentioned	O
earlier	O
is	O
involved	O
in	O
the	O
pu	B
##rine	I
metabolism	O
.	O

The	O
Ho	O
##rda	O
##land	O
Health	O
Study	O
discovered	O
a	O
relation	O
between	O
try	B
##pt	I
##op	I
##han	I
metabolism	O
and	O
bone	O
mineral	O
density	O
(	O
B	O
##MD	O
)	O
whereby	O
k	B
##yn	I
##uren	I
##ine	I
showed	O
a	O
positive	O
association	O
to	O
B	O
##MD	O
in	O
middle	O
-	O
aged	O
women	O
and	O
men	O
and	O
older	O
women	O
.	O

The	O
p	O
##oly	O
##phe	O
##no	O
##lic	O
content	O
was	O
unchanged	O
over	O
the	O
course	O
of	O
the	O
study	O
and	O
in	O
real	O
terms	O
is	O
equivalent	O
to	O
the	O
daily	O
combined	O
consumption	O
of	O
3	O
whole	O
cups	O
of	O
fresh	O
blue	O
##berries	O
(	O
148	O
g	O
/	O
cup	O
)	O
and	O
1	O
–	O
1	O
/	O
3	O
cups	O
of	O
br	O
##ew	O
##ed	O
green	O
tea	O
with	O
its	O
associated	O
ca	B
##ffe	I
##ine	I
content	O
(	O
assuming	O
8	O
fl	O
oz	O
or	O
247	O
m	O
##ls	O
per	O
cup	O
)	O
.	O

T	O
##rp	O
meta	O
##bol	O
##ites	O
not	O
identified	O
by	O
this	O
procedure	O
included	O
3	B
-	I
h	I
##ydro	I
##xy	I
##ant	I
##hra	I
##ni	I
##lic	I
acid	I
,	O
q	B
##uin	I
##olin	I
##ic	I
acid	I
,	O
5	B
-	I
h	I
##ydro	I
##xy	I
##l	I
-	I
in	I
##do	I
##le	I
-	I
3	I
-	I
ace	I
##tic	I
acid	I
,	O
3	B
-	I
in	I
##do	I
##le	I
-	I
su	I
##lf	I
##ate	I
,	O
5	B
-	I
h	I
##ydro	I
##xy	I
-	I
try	I
##pt	I
##op	I
##han	I
,	O
x	B
##ant	I
##hur	I
##eni	I
##c	I
acid	I
,	O
and	O
3	B
-	I
h	I
##ydro	I
##xy	I
##ky	I
##nu	I
##ren	I
##ine	I
.	O

U	O
##rine	O
samples	O
were	O
collected	O
in	O
s	O
##ter	O
##ile	O
p	B
##oly	I
##eth	I
##yle	I
##ne	I
specimen	O
containers	O
.	O

While	O
we	O
found	O
in	O
this	O
study	O
reduced	O
level	O
of	O
g	B
##lut	I
##ami	I
##c	I
acid	I
in	O
HC	O
##C	O
versus	O
c	O
##ir	O
##r	O
##hos	O
##is	O
,	O
we	O
observed	O
increased	O
level	O
in	O
our	O
previous	O
study	O
involving	O
the	O
Egyptian	O
co	O
##hor	O
##t	O
.	O

Form	B
##ate	I
causes	O
mitochondrial	O
damage	O
by	O
in	O
##hibit	O
##ing	O
c	O
##yt	O
##och	O
##rome	O
c	O
o	O
##xi	O
##das	O
##e	O
resulting	O
in	O
disruption	O
of	O
the	O
electron	O
transport	O
chain	O
and	O
production	O
of	O
reactive	O
oxygen	O
species	O
.	O

Changes	O
detected	O
in	O
gamma	O
‐	O
g	O
##lut	O
##am	O
##yl	O
amino	O
acid	O
levels	O
suggest	O
an	O
alter	O
##ation	O
in	O
the	O
levels	O
of	O
g	B
##lut	I
##ath	I
##ione	I
.	O

(	O
B	O
)	O
Box	O
-	O
and	O
-	O
w	O
##his	O
##ker	O
plots	O
of	O
log	O
_	O
2	O
in	O
##tens	O
##ities	O
comparing	O
individuals	O
with	O
T	O
##B	O
disease	O
and	O
household	O
contacts	O
for	O
selected	O
meta	O
##bol	O
##ites	O
,	O
with	O
m	O
/	O
z	O
and	O
put	O
##ative	O
meta	O
##bol	O
##ite	O
identification	O
from	O
Met	O
##lin	O
and	O
K	O
##EG	O
##G	O
(	O
left	O
to	O
right	O
upper	O
panel	O
:	O
g	B
##lut	I
##ama	I
##te	I
,	O
D	O
-	O
series	O
re	O
##sol	O
##vin	O
,	O
and	O
t	B
##re	I
##hal	I
##ose	I
-	I
6	I
-	I
my	I
##cola	I
##te	I
,	O
respectively	O
;	O
left	O
to	O
right	O
lower	O
panel	O
:	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##lino	I
##si	I
##to	I
##l	I
,	O
and	O
two	O
unidentified	O
meta	O
##bol	O
##ites	O
that	O
did	O
not	O
match	O
to	O
known	O
meta	O
##bol	O
##ites	O
in	O
the	O
databases	O
,	O
respectively	O
)	O
.	O

Finally	O
,	O
a	O
1	O
-	O
m	O
##M	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
a	O
##que	O
##ous	O
solution	O
(	O
A	O
)	O
and	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
(	O
AC	O
##N	O
;	O
B	O
)	O
were	O
chosen	O
as	O
the	O
mobile	O
phase	O
,	O
which	O
produced	O
the	O
best	O
response	O
and	O
sensitivity	O
.	O

Both	O
meta	O
##bol	O
##ites	O
retain	O
their	O
positive	O
beta	O
estimates	O
,	O
but	O
this	O
is	O
only	O
seen	O
in	O
men	O
with	O
high	O
serum	O
re	B
##tino	I
##l	I
(	O
greater	O
than	O
the	O
median	O
)	O
(	O
data	O
not	O
shown	O
)	O
.	O

The	O
mass	O
error	O
calculated	O
against	O
their	O
theoretical	O
masses	O
was	O
shown	O
to	O
be	O
below	O
1	O
.	O
5	O
pp	O
##m	O
,	O
thus	O
aid	O
##ing	O
in	O
un	O
##am	O
##bi	O
##guous	O
identification	O
of	O
both	O
c	B
##era	I
##mi	I
##de	I
molecular	O
species	O
.	O

P	O
##las	O
##ma	O
levels	O
of	O
meta	O
##bol	O
##ites	O
in	O
healthy	O
subjects	O
and	O
in	O
patients	O
who	O
underwent	O
car	O
##ot	O
##id	O
end	O
##arte	O
##re	O
##ct	O
##omy	O
(	O
CE	O
)	O
:	O
(	O
a	O
)	O
20	B
-	I
H	I
##ET	I
##E	I
;	O
(	O
b	O
)	O
Ara	B
##chi	I
##don	I
##ic	I
acid	I
;	O
(	O
c	O
)	O
12	B
-	I
H	I
##ET	I
##E	I
;	O
(	O
d	O
)	O
11	O
(	O
12	O
)	O
-	O
Di	O
##H	O
##ET	O
##E	O
;	O
(	O
e	O
)	O
15	B
-	I
H	I
##ET	I
##E	I
;	O
(	O
f	O
)	O
14	O
(	O
15	O
)	O
-	O
Di	O
##H	O
##ET	O
##E	O
.	O

Li	O
##pid	O
‐	O
mob	O
##ili	O
##zing	O
and	O
protein	O
‐	O
mob	O
##ili	O
##zing	O
factors	O
produced	O
by	O
the	O
t	O
##umour	O
also	O
contribute	O
to	O
activate	O
the	O
inflammatory	O
ca	O
##sca	O
##de	O
,	O
42	O
which	O
in	O
turn	O
stimulate	O
the	O
release	O
of	O
co	B
##rt	I
##is	I
##ol	I
and	O
cat	B
##ech	I
##ola	I
##mine	I
##s	I
from	O
the	O
ad	O
##rena	O
##l	O
glands	O
,	O
41	O
subsequently	O
leading	O
to	O
changes	O
in	O
the	O
metabolism	O
of	O
proteins	O
(	O
together	O
with	O
direct	O
c	O
##yt	O
##oki	O
##ne	O
activation	O
of	O
the	O
u	O
##bi	O
##qui	O
##tin	O
‐	O
mediated	O
pro	O
##te	O
##oly	O
##tic	O
system	O
)	O
,	O
car	O
##bo	O
##hy	O
##dra	O
##tes	O
,	O
and	O
lip	O
##ids	O
.	O

These	O
findings	O
show	O
that	O
whilst	O
E	O
##L	O
##IS	O
##As	O
can	O
provide	O
very	O
useful	O
indicators	O
of	O
a	B
##rg	I
##ini	I
##ne	I
and	O
AD	B
##MA	I
levels	O
,	O
their	O
accuracy	O
for	O
determining	O
absolute	O
concentrations	O
may	O
be	O
con	O
##founded	O
by	O
other	O
constituents	O
in	O
plasma	O
.	O

To	O
partially	O
assess	O
the	O
validity	O
of	O
meta	O
##bol	O
##omi	O
##c	O
techniques	O
in	O
a	O
trauma	O
population	O
,	O
Pearson	O
correlation	O
was	O
used	O
to	O
assess	O
con	O
##cor	O
##dance	O
between	O
hospital	O
-	O
based	O
plasma	O
measures	O
and	O
meta	O
##bol	O
##ome	O
-	O
based	O
plasma	O
measures	O
for	O
glucose	S
.	O

Ole	B
##ami	I
##de	I
is	O
a	O
sleep	O
regulator	O
via	O
the	O
CB	O
##1	O
receptor	O
and	O
P	B
##OE	I
##A	I
has	O
been	O
implicated	O
in	O
anxiety	O
disorders	O
seen	O
in	O
a	O
##bs	O
##tinent	O
cocaine	O
add	O
##ict	O
##s	O
.	O

This	O
trend	O
of	O
increased	O
ta	B
##uri	I
##ne	I
concentration	O
is	O
also	O
visible	O
in	O
a	O
plot	O
of	O
mean	O
ta	B
##uri	I
##ne	I
concentrations	O
over	O
time	O
.	O

K	O
##yn	O
can	O
be	O
further	O
meta	O
##bol	O
##ized	O
to	O
give	O
rise	O
to	O
k	B
##yn	I
##uren	I
##ic	I
acid	I
,	O
c	O
##inn	O
##abar	O
##ini	O
##c	O
acid	O
,	O
x	B
##ant	I
##hur	I
##eni	I
##c	I
acid	I
,	O
p	B
##ico	I
##lini	I
##c	I
acid	I
,	O
q	B
##uin	I
##olin	I
##ic	I
acid	I
,	O
and	O
N	O
##AD	O
_	O
+	O
(	O
;	O
;	O
)	O
.	O

Indeed	O
,	O
with	O
the	O
exception	O
of	O
la	B
##ct	I
##ate	I
the	O
levels	O
of	O
2	O
-	O
H	O
##B	O
,	O
3	O
-	O
H	O
##B	O
,	O
c	B
##it	I
##rate	I
,	O
and	O
t	B
##yr	I
##os	I
##ine	I
were	O
significantly	O
positively	O
correlated	O
with	O
N	O
##T	O
-	O
pro	O
##B	O
##NP	O
,	O
reflecting	O
a	O
positive	O
relationship	O
with	O
the	O
severity	O
of	O
H	O
##F	O
.	O

It	O
is	O
normally	O
ex	O
##cre	O
##ted	O
in	O
the	O
urine	O
and	O
is	O
considered	O
a	O
u	O
##rem	O
##ic	O
to	B
##xin	I
since	O
it	O
a	O
##cc	O
##um	O
##ulates	O
in	O
the	O
plasma	O
in	O
chronic	O
kidney	O
disease	O
.	O

One	O
-	O
carbon	O
metabolism	O
requires	O
f	B
##olate	I
,	O
vitamin	O
B	O
-	O
6	O
,	O
vitamin	O
B	O
-	O
12	O
,	O
and	O
rib	B
##of	I
##lav	I
##in	I
as	O
co	O
##fa	O
##ctors	O
to	O
different	O
enzymes	O
throughout	O
the	O
pathway	O
.	O

Di	O
##aster	O
##eo	O
##mer	O
1	O
:	O
_	O
1	O
H	O
N	O
##MR	O
(	O
600	O
MHz	O
,	O
D	O
##MS	O
##O	O
-	O
d	O
_	O
6	O
)	O
:	O
δ	O
8	O
.	O
32	O
(	O
s	O
,	O
1	O
##H	O
,	O
NH	O
)	O
,	O
7	O
.	O
27	O
(	O
s	O
,	O
1	O
##H	O
,	O
H	O
##2	O
′	O
)	O
,	O
6	O
.	O
90	O
(	O
s	O
,	O
1	O
##H	O
,	O
H	O
##5	O
′	O
)	O
,	O
6	O
.	O
36	O
(	O
s	O
,	O
1	O
##H	O
,	O
H	O
##4	O
′	O
)	O
,	O
4	O
.	O
23	O
-	O
4	O
.	O
22	O
(	O
m	O
,	O
1	O
##H	O
,	O
Cy	O
##s	O
α	B
-	I
CH	I
)	O
,	O
3	O
.	O
88	O
-	O
3	O
.	O
86	O
(	O
m	O
,	O
2	O
##H	O
,	O
H	O
##1	O
)	O
,	O
3	O
.	O
38	O
-	O
3	O
.	O
35	O
(	O
m	O
,	O
1	O
##H	O
,	O
Cy	O
##s	O
β	B
-	I
CH	I
_	I
a	I
)	O
,	O
3	O
.	O
35	O
-	O
3	O
.	O
10	O
(	O
m	O
,	O
1	O
##H	O
,	O
H	O
##5	O
)	O
,	O
2	O
.	O
99	O
-	O
2	O
.	O
97	O
(	O
m	O
,	O
1	O
##H	O
,	O
Cy	O
##s	O
β	B
-	I
CH	I
_	I
b	I
)	O
,	O
1	O
.	O
80	O
(	O
s	O
,	O
3	O
##H	O
,	O
Me	O
)	O
,	O
1	O
.	O
64	O
-	O
1	O
.	O
56	O
(	O
m	O
,	O
4	O
##H	O
,	O
H	O
##4	O
,	O
H	O
##2	O
)	O
,	O
1	O
.	O
22	O
-	O
1	O
.	O
16	O
(	O
m	O
,	O
2	O
##H	O
,	O
H	O
##3	O
)	O
;	O
_	O
13	O
C	O
N	O
##MR	O
(	O
150	O
MHz	O
,	O
D	O
##MS	O
##O	O
-	O
d	O
_	O
6	O
)	O
:	O
δ	O
124	O
.	O
5	O
,	O
124	O
.	O
1	O
,	O
107	O

A	O
##45	O
##6	O
-	O
4	O
)	O
,	O
to	B
##lue	I
##ne	I
(	O
Sigma	O
–	O
Al	O
##dric	O
##h	O
,	O
cat	O
.	O

Although	O
the	O
concentrations	O
of	O
some	O
amino	O
acids	O
were	O
primarily	O
affected	O
by	O
co	O
-	O
variables	O
such	O
as	O
fast	O
##ing	O
status	O
,	O
many	O
other	O
amino	O
acids	O
,	O
such	O
as	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
th	B
##re	I
##oni	I
##ne	I
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
l	B
##ys	I
##ine	I
,	O
try	B
##pt	I
##op	I
##han	I
,	O
as	B
##par	I
##agi	I
##ne	I
and	O
g	B
##ly	I
##cine	I
for	O
example	O
,	O
were	O
ex	O
##cre	O
##ted	O
at	O
lower	O
concentrations	O
in	O
pre	O
-	O
surgery	O
CR	O
##C	O
patients	O
’	O
urine	O
.	O

Val	O
##ida	O
##tion	O
parameters	O
of	O
the	O
method	O
for	O
di	B
##os	I
##met	I
##in	I
g	I
##lu	I
##cu	I
##ron	I
##ide	I
meta	O
##bol	O
##ites	O
q	O
##uant	O
##ification	O
from	O
plasma	O
Ad	O
##e	O
##qua	O
##te	O
stability	O
,	O
analytical	O
precision	O
/	O
accuracy	O
and	O
matrix	O
effect	O
were	O
obtained	O
.	O

In	O
fact	O
,	O
the	O
concentrations	O
of	O
many	O
meta	O
##bol	O
##ites	O
differed	O
significantly	O
between	O
HC	O
##C	O
-	O
B	O
and	O
HC	O
##C	O
-	O
C	O
,	O
and	O
M	O
##LR	O
analysis	O
using	O
three	O
chosen	O
meta	B
##bol	I
##ites	I
-	I
g	I
##lut	I
##ami	I
##c	I
acid	I
,	O
met	B
##hi	I
##oni	I
##ne	I
and	O
γ	B
-	I
G	I
##lu	I
-	I
G	I
##ly	I
-	I
G	I
##ly	I
-	I
was	O
able	O
to	O
disc	O
##rim	O
##inate	O
cases	O
of	O
HC	O
##C	O
-	O
C	O
from	O
those	O
of	O
HC	O
##C	O
-	O
B	O
with	O
a	O
high	O
degree	O
of	O
significance	O
(	O
P	O
<	O
0	O
.	O
000	O
##1	O
)	O
.	O

As	O
shown	O
in	O
,	O
the	O
metabolic	O
processes	O
found	O
to	O
be	O
most	O
significantly	O
altered	O
between	O
T	O
##B	O
patients	O
and	O
healthy	O
controls	O
were	O
protein	O
bio	O
##sy	O
##nt	O
##hesis	O
,	O
followed	O
by	O
al	B
##ani	I
##ne	I
metabolism	O
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
and	O
t	B
##yr	I
##os	I
##ine	I
metabolism	O
and	O
am	O
##monia	O
recycling	O
.	O

Active	O
CD	O
can	O
be	O
distinguished	O
from	O
inactive	O
disease	O
by	O
weaker	O
AD	B
##MA	I
and	O
SD	O
##MA	O
correlation	O
,	O
positive	O
association	O
between	O
SD	O
##MA	O
and	O
D	B
##MA	I
,	O
and	O
by	O
AD	B
##MA	I
correlation	O
with	O
both	O
c	B
##it	I
##ru	I
##llin	I
##e	I
and	O
a	B
##rg	I
##ini	I
##ne	I
.	O

Whilst	O
it	O
was	O
previously	O
thought	O
that	O
the	O
shift	O
to	O
g	O
##ly	O
##co	O
##lysis	O
in	O
cancer	O
cells	O
was	O
due	O
to	O
an	O
imp	O
##air	O
##ment	O
of	O
mitochondrial	O
function	O
,	O
the	O
demonstrated	O
presence	O
of	O
functional	O
mit	O
##och	O
##ond	O
##ria	O
in	O
numerous	O
tumor	O
types	O
[	O
–	O
]	O
has	O
resulted	O
in	O
an	O
emerging	O
theory	O
that	O
suggests	O
the	O
g	B
##ly	I
##co	I
##ly	I
##tic	I
metabolic	O
shift	O
characteristic	O
of	O
cancer	O
cells	O
is	O
due	O
to	O
enhanced	O
g	O
##ly	O
##co	O
##lysis	O
suppress	O
##ing	O
o	O
##xi	O
##da	O
##tive	O
p	O
##hos	O
##ph	O
##ory	O
##lation	O
,	O
rather	O
than	O
defects	O
in	O
mitochondrial	O
re	O
##spiration	O
.	O

The	O
increase	O
might	O
reflect	O
the	O
state	O
of	O
an	O
##ae	O
##ro	O
##bic	O
g	O
##ly	O
##co	O
##lysis	O
of	O
glucose	S
during	O
severe	O
pulmonary	O
infections	O
.	O

Usually	O
,	O
la	B
##ct	I
##ate	I
is	O
not	O
detected	O
as	O
a	O
major	O
f	O
##er	O
##mentation	O
product	O
,	O
which	O
is	O
assumed	O
to	O
reflect	O
the	O
presence	O
of	O
la	O
##ct	O
##ate	O
-	O
utilizing	O
bacterial	O
species	O
in	O
the	O
micro	O
##bio	O
##ta	O
of	O
a	O
healthy	O
gut	O
(	O
Duncan	O
et	O
al	O
.	O
)	O
.	O

1	B
,	I
2	I
-	I
N	I
##P	I
##Q	I
-	I
and	O
1	B
,	I
4	I
-	I
N	I
##P	I
##Q	I
-	I
Al	I
##b	I
were	O
detected	O
in	O
human	O
subjects	O
(	O
n	O
=	O
22	O
)	O
.	O

Inc	O
##reased	O
levels	O
of	O
4	B
-	I
met	I
##hyl	I
##cate	I
##cho	I
##l	I
su	I
##lf	I
##ate	I
in	O
both	O
post	O
-	O
BR	O
##B	O
urine	O
and	O
post	O
-	O
BR	O
##B	O
plasma	O
were	O
significantly	O
correlated	O
with	O
a	O
higher	O
level	O
of	O
a	O
##pop	O
##to	O
##tic	O
marker	O
(	O
T	O
##UN	O
##EL	O
)	O
in	O
post	O
-	O
BR	O
##B	O
tumors	O
.	O

Regarding	O
our	O
exposure	O
of	O
interest	O
,	O
para	B
##ce	I
##tam	I
##ol	I
has	O
a	O
short	O
bio	O
##log	O
##ic	O
half	O
-	O
life	O
,	O
such	O
that	O
24	O
h	O
post	O
-	O
ing	O
##est	O
##ion	O
,	O
85	O
–	O
95	O
%	O
of	O
the	O
chemical	O
has	O
been	O
ex	O
##cre	O
##ted	O
by	O
the	O
kidney	O
##s	O
.	O

Blood	O
samples	O
were	O
drawn	O
from	O
a	O
peripheral	O
vein	O
,	O
collected	O
in	O
et	B
##hyl	I
##ened	I
##iam	I
##inet	I
##et	I
##ra	I
##ace	I
##tic	I
acid	O
-	O
2	O
##N	O
##a	O
-	O
containing	O
vacuum	O
blood	O
collection	O
tubes	O
(	O
V	O
##EN	O
##O	O
##J	O
##EC	O
##T	O
II	O
,	O
Te	O
##rum	O
##o	O
Corporation	O
)	O
,	O
and	O
immediately	O
placed	O
on	O
ice	O
.	O

CD	O
##G	O
-	O
I	O
defects	O
are	O
easily	O
identified	O
owing	O
to	O
the	O
occurrence	O
of	O
transfer	O
##rin	O
is	O
##of	O
##orms	O
with	O
two	O
or	O
no	O
si	B
##ali	I
##c	I
acid	I
residues	O
detected	O
by	O
means	O
of	O
I	O
##EF	O
.	O

(	O
B	O
)	O
P	B
##uri	I
##ne	I
metabolism	O
.	O

(	O
A	O
)	O
metabolic	O
pathway	O
of	O
L	O
##ys	O
##o	O
##PC	O
;	O
(	O
B	O
)	O
cat	O
##ab	O
##olis	O
##m	O
pathway	O
of	O
t	B
##ria	I
##cy	I
##l	I
##gly	I
##cer	I
##ol	I
;	O
C	O
##1	O
-	O
C	O
##2	O
,	O
R	O
##T	O
-	O
PC	O
##R	O
results	O
of	O
AT	O
##G	O
##L	O
and	O
H	O
##SL	O
in	O
ad	O
##ip	O
##ose	O
tissues	O
(	O
L	O
##IP	O
##E	O
is	O
the	O
gene	O
alias	O
##e	O
of	O
H	O
##SL	O
;	O
C	O
##1	O
-	O
2	O
,	O
ad	O
##ip	O
##ose	O
tissues	O
from	O
the	O
two	O
control	O
patients	O
;	O
IS	O
##1	O
-	O
4	O
,	O
ad	O
##ip	O
##ose	O
tissues	O
from	O
the	O
four	O
AI	O
##S	O
patients	O
)	O
.	O

However	O
,	O
ET	O
##O	O
significantly	O
activated	S
a	O
##pop	O
##tosis	O
in	O
these	O
cells	O
,	O
which	O
could	O
be	O
rescued	O
by	O
the	O
ca	O
##sp	O
##ase	O
-	O
inhibitor	O
z	O
##VA	O
##D	O
following	O
radiation	O
treatment	O
(	O
Figure	O
B	O
)	O
.	O

Therefore	O
,	O
decreased	O
metabolic	O
flux	O
through	O
PD	O
##H	O
and	O
BC	O
##K	O
##D	O
##H	O
,	O
as	O
reported	O
in	O
T	O
##2	O
##DM	O
(	O
,	O
)	O
,	O
may	O
increase	O
plasma	O
α	B
-	I
k	I
##eto	I
##but	I
##yra	I
##te	I
by	O
decreasing	O
its	O
cat	O
##ab	O
##olic	O
rate	O
in	O
insulin	O
-	O
resistant	O
individuals	O
.	O

P	O
patients	O
showed	O
median	O
values	O
of	O
pre	O
##su	O
##mpt	O
##ive	O
En	O
##tero	O
##co	O
##cc	O
##us	O
,	O
Lac	B
##to	I
##ba	I
##ci	I
##llus	I
and	O
Le	O
##uc	O
##ono	O
##sto	O
##c	O
lower	O
than	O
those	O
found	O
for	O
HC	O
and	O
N	O
##P	O
.	O

A	O
working	O
internal	O
standard	O
solution	O
mixture	O
in	O
75	O
%	O
a	O
##que	O
##ous	O
met	B
##han	I
##ol	I
was	O
made	O
by	O
mixing	O
and	O
di	O
##lut	O
##ing	O
all	O
the	O
is	O
##oto	O
##pe	O
-	O
labeled	O
stock	O
solutions	O
,	O
with	O
a	O
final	O
concentration	O
of	O
160	O
µ	O
##M	O
for	O
_	O
13	O
C	O
-	O
HP	O
##HP	O
##A	O
.	O

TO	O
##CS	O
##Y	O
spectrum	O
of	O
T	O
##CA	O
extract	O
of	O
R	O
##h	O
##30	O
cells	O
grown	O
for	O
24	O
h	O
in	O
the	O
presence	O
of	O
0	O
.	O
2	O
%	O
[	B
U	I
-	I
_	I
13	I
C	I
]	I
-	I
glucose	I
and	O
10	O
%	O
FC	O
##S	O
,	O
using	O
a	O
mixing	O
time	O
of	O
50	O
m	O
##s	O
and	O
a	O
spin	O
lock	O
strength	O
of	O
8	O
kHz	O
.	O

An	O
increased	O
concentration	O
of	O
a	B
##rg	I
##ini	I
##ne	I
in	O
the	O
patients	O
with	O
se	O
##ptic	O
shock	O
might	O
be	O
related	O
to	O
c	O
##yt	O
##oki	O
##ne	O
production	O
.	O

pro	B
##line	I
,	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
,	O
serum	O
,	O
bio	O
##mark	O
##er	O
,	O
es	O
##op	O
##hage	O
##al	O
cancer	O

Ph	B
##os	I
##pha	I
##ti	I
##dy	I
##let	I
##ano	I
##lam	I
##ine	I
(	O
P	O
##E	O
)	O
:	O
The	O
first	O
component	O
is	O
strongly	O
correlated	O
with	O
species	O
with	O
MW	O
<	O
720	O
,	O
74	O
##7	O
.	O
6	O
and	O
82	O
##9	O
.	O
7	O
and	O
explains	O
almost	O
80	O
%	O
variation	O
of	O
the	O
data	O
.	O

This	O
could	O
result	O
from	O
elevation	O
of	O
trans	B
-	I
a	I
##con	I
##itate	I
,	O
which	O
is	O
then	O
converted	O
into	O
c	B
##is	I
-	I
a	I
##con	I
##itate	I
(	O
Figure	O
)	O
.	O

The	O
analysis	O
of	O
organic	O
M	B
##T	I
##BE	I
fraction	O
resulted	O
in	O
288	O
##7	O
put	O
##ative	O
meta	O
##bol	O
##ites	O
as	O
revealed	O
by	O
+	O
E	O
##SI	O
R	B
##P	I
analysis	O
.	O

BC	O
##A	O
includes	O
is	B
##ole	I
##uc	I
##ine	I
,	O
le	B
##uc	I
##ine	I
and	O
v	B
##ali	I
##ne	I
which	O
are	O
vital	O
components	O
of	O
immune	O
enhancing	O
formula	O
with	O
imp	O
##erative	O
role	O
in	O
muscle	O
re	O
##ju	O
##ven	O
##ation	O
,	O
nitrogen	O
balance	O
and	O
protein	O
synthesis	O
.	O

N	O
##1	O
,	O
N	B
##12	I
-	I
di	I
##ace	I
##ty	I
##ls	I
##per	I
##mine	I
and	O
fi	O
##bri	O
##no	O
##gen	O
alpha	O
chain	O
fragments	O
were	O
identified	O
as	O
an	O
L	O
##MI	O
in	O
the	O
L	O
##OM	O
##E	O
1	O
-	O
33	O
that	O
disc	O
##rim	O
##inated	O
cancer	O
patients	O
from	O
patients	O
without	O
cancer	O
.	O

Considering	O
that	O
u	B
##rea	I
cycle	O
is	O
primarily	O
taking	O
place	O
in	O
liver	O
,	O
our	O
analyses	O
strongly	O
suggest	O
that	O
the	O
imp	O
##air	O
##ment	O
of	O
liver	O
function	O
in	O
B	O
##D	O
##TT	O
patient	O
but	O
not	O
in	O
other	O
bi	O
##le	O
duct	O
disease	O
patient	O
results	O
in	O
the	O
decrease	O
of	O
u	B
##rea	I
cycle	O
and	O
the	O
intermediate	O
meta	O
##bol	O
##ites	O
L	B
-	I
c	I
##it	I
##ru	I
##llin	I
##e	I
and	O
D	B
-	I
as	I
##par	I
##tic	I
acid	I
,	O
which	O
lead	O
a	O
new	O
diagnosis	O
strategy	O
.	O

Only	O
higher	O
T	B
##MA	I
##O	I
levels	O
predicted	O
incident	O
adverse	O
clinical	O
events	O
independent	O
of	O
age	O
,	O
e	O
##G	O
##F	O
##R	O
,	O
mit	O
##ral	O
E	O
/	O
se	O
##pta	O
##l	O
E	O
##a	O
,	O
and	O
N	O
##T	O
-	O
pro	O
##B	O
##NP	O
levels	O
(	O
H	O
##R	O
1	O
.	O
46	O
[	O
1	O
.	O
03	O
2	O
.	O
14	O
]	O
,	O
p	O
=	O
0	O
.	O
03	O
)	O
.	O

A	O
##bb	O
##re	O
##viation	O
:	O
PC	O
##A	O
,	O
principal	O
component	O
analysis	O
;	O
e	O
##G	O
##F	O
##R	O
,	O
estimated	O
g	O
##lo	O
##mer	O
##ular	O
fi	O
##ltration	O
rate	O
;	O
CA	O
##B	O
##G	O
,	O
co	O
##rona	O
##ry	O
artery	O
bypass	O
g	O
##raft	O
##ing	O
;	O
H	O
##T	O
##K	O
,	O
B	O
##rets	O
##ch	O
##ne	O
##ider	O
’	O
s	O
his	B
##ti	I
##dine	I
-	I
try	I
##pt	I
##op	I
##han	I
-	I
k	I
##eto	I
##g	I
##lut	I
##arate	I
solution	O
.	O

A	O
total	O
of	O
five	O
significant	O
meta	O
##bol	O
##ites	O
(	O
P	O
##E	O
(	O
14	O
:	O
0	O
/	O
20	O
:	O
3	O
)	O
,	O
7	B
-	I
de	I
##hy	I
##dr	I
##o	I
-	I
des	I
##most	I
##ero	I
##l	I
,	O
c	O
##rist	O
##aca	O
##rp	O
##in	O
,	O
p	O
##ice	O
##id	O
,	O
and	O
gamma	B
-	I
g	I
##lut	I
##am	I
##yl	I
##g	I
##lut	I
##amine	I
)	O
from	O
these	O
16	O
different	O
meta	O
##bol	O
##ites	O
between	O
T	O
##2	O
##DM	O
and	O
N	O
##G	O
##T	O
could	O
be	O
an	O
##not	O
##ated	O
while	O
nineteen	O
meta	O
##bol	O
##ites	O
were	O
an	O
##not	O
##ated	O
from	O
the	O
I	O
##GR	O
and	O
N	O
##G	O
##T	O
groups	O
(	O
Su	O
##pp	O
##lement	O
##ary	O
Table	O
##s	O
and	O
)	O
.	O

We	O
observed	O
a	O
graded	O
increase	O
in	O
risk	O
with	O
increasing	O
levels	O
of	O
T	B
##MA	I
##O	I
,	O
as	O
illustrated	O
in	O
the	O
Kaplan	O
–	O
Mei	O
##er	O
analysis	O
shown	O
in	O
.	O

the	O
researchers	O
measured	O
several	O
levels	O
of	O
s	O
##tero	O
##l	O
hormones	O
in	O
the	O
blood	O
during	O
pregnancy	O
and	O
found	O
that	O
levels	O
of	O
11	B
-	I
de	I
##ox	I
##y	I
##cor	I
##tis	I
##ol	I
,	O
17	B
##a	I
-	I
h	I
##ydro	I
##xy	I
##p	I
##rog	I
##ester	I
##one	I
,	O
and	O
pro	B
##ges	I
##tero	I
##ne	I
increased	O
throughout	O
the	O
whole	O
period	O
of	O
pregnancy	O
.	O

Twenty	O
-	O
six	O
patients	O
had	O
been	O
taking	O
one	O
of	O
the	O
s	B
##tat	I
##ins	I
at	O
various	O
doses	O
,	O
10	O
,	O
20	O
,	O
40	O
,	O
or	O
80	O
mg	O
for	O
SM	O
##V	O
,	O
10	O
,	O
40	O
,	O
or	O
80	O
mg	O
for	O
AT	O
##V	O
,	O
or	O
5	O
,	O
10	O
,	O
20	O
,	O
or	O
40	O
mg	O
for	O
RS	O
##V	O
.	O

In	O
##hibition	O
,	O
by	O
V	B
##LC	I
##DC	I
##A	I
28	I
:	I
4	I
,	O
of	O
lip	B
##op	I
##oly	I
##sa	I
##cc	I
##hari	I
##de	I
(	O
LP	O
##S	O
)	O
(	O
1	O
µ	O
##g	O
/	O
m	O
##L	O
of	O
media	O
)	O
stimulation	O
of	O
ni	B
##tric	I
oxide	I
(	O
NO	O
)	O
release	O
into	O
the	O
medium	O
of	O
T	O
##HP	O
-	O
1	O
mon	O
##ocytes	O
in	O
##cu	O
##bate	O
##d	O
for	O
48	O
h	O
.	O
in	O
24	O
well	O
plates	O
.	O

Thirty	O
molecular	O
species	O
of	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
were	O
decreased	O
in	O
males	O
,	O
and	O
21	O
were	O
decreased	O
in	O
females	O
.	O

Thus	O
,	O
the	O
combined	O
G	O
##C	O
-	O
MS	O
and	O
N	O
##MR	O
determination	O
of	O
ma	B
##late	I
and	O
As	O
##p	O
is	O
##oto	O
##po	O
##mers	O
not	O
only	O
revealed	O
an	O
enhanced	O
activity	O
of	O
the	O
K	O
##re	O
##bs	O
'	O
cycle	O
but	O
also	O
activation	O
of	O
p	O
##yr	O
##u	O
##vate	O
car	O
##box	O
##yla	O
##tion	O
in	O
the	O
R	O
##h	O
##30	O
cells	O
over	O
the	O
primary	O
my	O
##ocytes	O
.	O

In	O
brief	O
,	O
the	O
Ph	O
##IP	O
-	O
modified	O
SA	O
(	O
5	O
μ	O
g	O
,	O
75	O
pm	O
##ol	O
)	O
in	O
50	O
m	O
##M	O
am	B
##mon	I
##ium	I
bi	O
##car	O
##bon	O
##ate	O
buffer	O
(	O
pH	O
8	O
.	O
5	O
)	O
containing	O
1	O
m	O
##M	O
M	O
##n	O
##C	O
##l	O
_	O
2	O
was	O
treated	O
with	O
Pro	O
##nas	O
##e	O
E	O
at	O
a	O
pro	O
##te	O
##ase	O
:	O
protein	O
ratio	O
of	O
1	O
:	O
2	O
(	O
w	O
/	O
w	O
)	O
,	O
le	O
##uc	O
##ine	O
amino	O
##pe	O
##pt	O
##idas	O
##e	O
at	O
a	O
pro	O
##te	O
##ase	O
:	O
protein	O
ratio	O
of	O
1	O
:	O
30	O
(	O
w	O
/	O
w	O
)	O
,	O
and	O
pro	O
##lid	O
##ase	O
at	O
a	O
pro	O
##te	O
##ase	O
:	O
SA	O
ratio	O
of	O
1	O
:	O
8	O
(	O
w	O
/	O
w	O
)	O
.	O

Such	O
that	O
meta	O
##bol	O
##ites	O
in	O
the	O
upper	O
half	O
of	O
the	O
g	B
##ly	I
##co	I
##ly	I
##tic	I
pathway	O
and	O
genes	O
encoding	O
glucose	S
transport	O
##ers	O
are	O
significantly	O
increased	O
,	O
while	O
intermediate	O
##s	O
in	O
the	O
lower	O
half	O
of	O
the	O
pathway	O
and	O
specific	O
T	O
##CA	O
cycle	O
meta	O
##bol	O
##ites	O
and	O
genes	O
are	O
reduced	O
in	O
response	O
to	O
RC	O
##C	O
[	O
,	O
]	O
.	O

Using	O
human	O
serum	O
_	O
1	O
H	O
N	O
##MR	O
s	O
##pect	O
##ros	O
##copic	O
profiles	O
from	O
39	O
##48	O
participants	O
from	O
the	O
Multi	O
-	O
Ethnic	O
Study	O
of	O
At	O
##her	O
##os	O
##cle	O
##rosis	O
(	O
ME	O
##SA	O
)	O
,	O
we	O
have	O
performed	O
a	O
series	O
of	O
MW	O
##AS	O
for	O
serum	O
levels	O
of	O
glucose	S
.	O

The	O
best	O
-	O
disc	O
##rim	O
##inating	O
model	O
comprised	O
CE	O
##A	O
,	O
G	B
##ly	I
##cine	I
,	O
and	O
Ty	B
##ros	I
##ine	I
(	O
AU	O
##RO	O
##C	O
0	O
.	O
87	O
##8	O
,	O
95	O
%	O
C	O
##I	O
0	O
.	O
81	O
##5	O
–	O
0	O
.	O
94	O
##1	O
)	O
,	O
followed	O
by	O
the	O
model	O
comprising	O
CE	O
##A	O
and	O
PC	O
##1	O
(	O
AU	O
##RO	O
##C	O
0	O
.	O
84	O
##4	O
,	O
95	O
%	O
C	O
##I	O
0	O
.	O
77	O
##3	O
–	O
0	O
.	O
91	O
##6	O
)	O
,	O
CE	O
##A	O
alone	O
(	O
AU	O
##RO	O
##C	O
0	O
.	O
79	O
##4	O
,	O
95	O
%	O
C	O
##I	O
0	O
.	O
71	O
##2	O
–	O
0	O
.	O
87	O
##7	O
)	O
and	O
G	B
##ly	I
##cine	I
(	O
AU	O
##RO	O
##C	O
0	O
.	O
70	O
##7	O
,	O
95	O
%	O
C	O
##I	O
0	O
.	O
61	O
##3	O
–	O
0	O
.	O
80	O
##1	O
)	O
as	O
the	O
best	O
disc	O
##rim	O
##inating	O
single	O
amino	O
acid	O
.	O

Fast	O
##ing	O
glucose	S
concentrations	O
were	O
within	O
the	O
norm	B
##og	I
##ly	I
##ce	I
##mic	I
range	O
in	O
the	O
majority	O
of	O
the	O
subjects	O
(	O
92	O
%	O
)	O
.	O

Thus	O
,	O
our	O
findings	O
support	O
the	O
hypothesis	O
that	O
interactions	O
between	O
β	B
-	I
car	I
##ote	I
##ne	I
supplement	O
##ation	O
and	O
prescription	O
(	O
and	O
non	O
##p	O
##res	O
##cription	O
)	O
medications	O
may	O
have	O
led	O
to	O
adverse	O
mortality	O
outcomes	O
in	O
the	O
AT	O
##BC	O
Study	O
.	O

μ	O
##M	O
(	O
P	O
<	O
.	O
00	O
##1	O
)	O
,	O
and	O
v	B
##ali	I
##ne	I
levels	O
increased	O
from	O
122	O
.	O
56	O
(	O
95	O
.	O
63	O
–	O
140	O
.	O
61	O
)	O
μ	O
##M	O
to	O
190	O
.	O
52	O
(	O
136	O
.	O
68	O
–	O
226	O
.	O
07	O
)	O
μ	O
##M	O

The	O
initial	O
step	O
of	O
BC	O
##AA	O
cat	O
##ab	O
##olis	O
##m	O
was	O
transferring	O
amino	S
groups	O
to	O
α	B
-	I
k	I
##eto	I
##g	I
##lut	I
##arate	I
by	O
branched	O
-	O
chain	O
amino	O
##tra	O
##ns	O
##fer	O
##ase	O
(	O
c	O
##yt	O
##oso	O
##lic	O
BC	O
##AT	O
##1	O
or	O
mitochondrial	O
BC	O
##AT	O
##2	O
)	O
,	O
generating	O
g	B
##lut	I
##ama	I
##te	I
and	O
the	O
respective	O
α	B
-	I
k	I
##eto	I
##ac	I
##ids	I
(	B
α	B
-	I
k	I
##eto	I
##is	I
##oc	I
##ap	I
##roi	I
##c	I
acid	I
(	O
K	O
##IC	O
)	O
,	O
α	B
-	I
k	I
##eto	I
-	I
β	I
-	I
met	I
##hyl	I
##vale	I
##ric	I
acid	I
(	O
K	O
##M	O
##V	O
)	O
and	O
α	B
-	I
k	I
##eto	I
##is	I
##ova	I
##ler	I
##ic	I
acid	I
(	O
K	O
##I	O
##V	O
)	O
)	O

The	O
class	O
of	O
serum	O
end	O
##otype	O
##s	O
included	O
pro	B
##line	I
,	O
g	B
##lut	I
##ama	I
##te	I
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
and	O
v	B
##ali	I
##ne	I
.	O

The	O
home	O
##ost	O
##asis	O
of	O
L	B
-	I
car	I
##ni	I
##tine	I
and	O
its	O
est	O
##ers	O
is	O
maintained	O
in	O
a	O
careful	O
and	O
narrow	O
fashion	O
in	O
the	O
human	O
body	O
(	O
for	O
review	O
,	O
see	O
)	O
.	O

Post	O
##men	O
##op	O
##aus	O
##al	O
women	O
also	O
had	O
25	O
to	O
56	O
%	O
lower	O
(	O
P	O
<	O
0	O
.	O
00	O
##5	O
)	O
plasma	O
concentrations	O
of	O
co	B
##rt	I
##is	I
##ol	I
,	O
co	B
##rt	I
##ico	I
##ster	I
##one	I
,	O
18	B
-	I
o	I
##x	I
##oc	I
##ort	I
##is	I
##ol	I
and	O
test	B
##osterone	I
,	O
but	O
for	O
co	B
##rt	I
##is	I
##ol	I
and	O
test	B
##osterone	I
these	O
differences	O
were	O
confined	O
to	O
women	O
in	O
the	O
l	O
##ute	O
##al	O
phase	O
or	O
taking	O
oral	O
con	O
##tra	O
##ceptive	O
##s	O
,	O
while	O
for	O
18	B
-	I
o	I
##x	I
##oc	I
##ort	I
##is	I
##ol	I
the	O
difference	O
was	O
confined	O
to	O
women	O
in	O
the	O
former	O
group	O
.	O

The	O
i	O
##A	O
##UC	O
of	O
this	O
amino	O
acid	O
could	O
be	O
increased	O
in	O
infants	O
fed	O
a	O
milk	O
-	O
based	O
formula	O
,	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
in	O
healthy	O
adults	O
fed	O
w	B
##hey	I
protein	O
,	O
and	O
in	O
healthy	O
older	O
people	O
by	O
supplement	O
##ing	O
a	O
w	B
##hey	I
protein	O
extract	O
with	O
le	B
##uc	I
##ine	I
.	O

N	O
##eg	O
##li	O
##gible	O
basal	O
induce	O
##r	O
activity	O
was	O
detected	O
(	O
0	O
.	O
87	O
±	O
0	O
.	O
24	O
μ	O
##mo	O
##l	O
of	O
SF	S
equivalent	O
##s	O
)	O
in	O
the	O
place	O
##bo	O
beverage	O
.	O

[	O
Google	O
Scholar	O
]	O
Con	O
##ney	O
A	B
##H	I
.	O

These	O
meta	O
##bol	O
##ites	O
are	O
positively	O
correlated	O
with	O
as	O
##par	O
##tate	O
trans	O
##ami	O
##nas	O
##e	O
(	O
AS	O
##T	O
;	O
P	O
=	O
0	O
.	O
000	O
##6	O
)	O
and	O
white	O
blood	O
cell	O
counts	O
(	O
P	O
=	O
0	O
.	O
00	O
##5	O
)	O
in	O
patients	O
who	O
develop	O
AP	S
.	O

Similar	O
to	O
the	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
described	O
above	O
,	O
most	O
of	O
the	O
species	O
of	O
c	B
##era	I
##mi	I
##de	I
had	O
levels	O
that	O
were	O
significantly	O
higher	O
in	O
cancer	O
than	O
in	O
the	O
normal	O
breast	O
tissue	O
.	O

The	O
unique	O
elemental	O
composition	O
of	O
m	O
/	O
z	O
40	O
##7	O
.	O
152	O
##7	O
was	O
assigned	O
as	O
C	O
_	O
15	O
H	O
_	O
28	O
O	O
_	O
11	O
Na	O
using	O
Mass	O
Works	O
_	O
T	O
##M	O
based	O
on	O
L	O
##C	O
-	O
MS	O
data	O
acquired	O
using	O
HP	O
##LC	O
-	O
L	O
##T	O
##Q	O
F	B
##T	I
Ultra	O
MS	O
at	O
100	O
,	O
000	O
resolution	O
.	O

In	O
cross	O
-	O
section	O
##al	O
studies	O
,	O
we	O
have	O
demonstrated	O
significant	O
imp	O
##air	O
##ment	O
in	O
D	O
##I	O
in	O
o	O
##bes	O
##e	O
youth	O
across	O
the	O
spectrum	O
of	O
glucose	S
tolerance	O
(	O
,	O
–	O
)	O
.	O

These	O
results	O
help	O
highlight	O
the	O
differential	O
lip	O
##id	O
patterns	O
between	O
R	B
##P	I
and	O
N	O
##RP	O
se	O
##ra	O
and	O
are	O
summarized	O
in	O
.	O

Nevertheless	O
,	O
19	O
LP	O
##C	O
and	O
6	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##let	I
##han	I
##ola	I
##mine	I
##s	I
were	O
found	O
lower	O
in	O
cache	O
##xia	O
group	O
.	O

In	O
addition	O
,	O
an	O
increased	O
reliance	O
on	O
the	O
an	O
##ae	O
##ro	O
##bic	O
my	O
##oc	O
##ard	O
##ial	O
metabolism	O
takes	O
place	O
,	O
which	O
increases	O
la	B
##ctic	I
acid	I
release	O
out	O
of	O
cardiac	O
my	O
##ocytes	O
for	O
maintenance	O
of	O
ATP	S
levels	O
.	O

And	O
##rogen	O
excess	O
was	O
closely	O
related	O
to	O
the	O
lip	O
##id	O
metabolic	O
disorder	O
,	O
the	O
levels	O
of	O
three	O
long	O
-	O
chain	O
fatty	O
acids	O
(	O
for	O
example	O
,	O
palm	O
##ic	O
acid	O
,	O
s	B
##te	I
##ari	I
##c	I
acid	I
,	O
l	B
##ino	I
##le	I
##ic	I
acid	O
)	O
were	O
all	O
significantly	O
reduced	O
in	O
PC	O
##OS	O
patients	O
with	O
h	O
##yper	O
##and	O
##rogen	O
##ism	O
compared	O
with	O
women	O
with	O
PC	O
##OS	O
without	O
clinical	O
or	O
bio	O
##chemical	O
h	O
##yper	O
##and	O
##rogen	O
##ism	O
(	O
Additional	O
file	O
)	O
,	O
whereas	O
no	O
significant	O
difference	O
of	O
these	O
fatty	O
acids	O
levels	O
were	O
observed	O
between	O
PC	O
##OS	O
cases	O
with	O
I	O
##R	O
and	O
without	O
I	O
##R	O
.	O

Co	O
##mp	O
##liance	O
was	O
monitored	O
by	O
breath	O
CO	O
and	O
u	O
##rina	O
##ry	O
and	O
sa	O
##liva	O
co	B
##tin	I
##ine	I
.	O

These	O
analyses	O
revealed	O
that	O
19	O
or	O
65	O
patients	O
would	O
be	O
needed	O
for	O
the	O
median	O
(	O
3	O
.	O
62	O
for	O
u	B
##rid	I
##ine	I
)	O
or	O
lowest	O
hazard	O
ratios	O
(	O
2	O
.	O
01	O
for	O
p	O
##ht	O
##hala	O
##te	O
)	O
of	O
the	O
selected	O
meta	O
##bol	O
##ites	O
in	O
the	O
prediction	O
set	O
,	O
respectively	O
.	O

The	O
score	O
s	O
##cat	O
##ter	O
plots	O
of	O
O	O
##PL	O
##S	O
-	O
D	O
##A	O
models	O
from	O
the	O
L	B
##C	I
-	I
(	I
±	I
)	I
E	I
##SI	I
-	I
MS	I
data	O
showed	O
the	O
clear	O
differentiation	O
of	O
early	O
-	O
stage	O
(	O
T	O
##1	O
–	O
2	O
)	O
E	O
##SC	O
##C	O
patients	O
,	O
advanced	O
-	O
stage	O
(	O
T	O
##3	O
–	O
4	O
)	O
E	O
##SC	O
##C	O
patients	O
,	O
and	O
NC	O
groups	O
,	O
indicating	O
that	O
changes	O
in	O
some	O
end	O
##ogen	O
##ous	O
meta	O
##bol	O
##ites	O
were	O
related	O
to	O
disease	O
stage	O
.	O

All	O
sheep	O
were	O
given	O
a	O
dose	O
of	O
anti	O
##biotic	O
(	O
10	O
m	O
##L	O
R	B
##ile	I
##xin	I
##e	I
150	O
,	O
sub	O
##cut	O
##aneous	O
##ly	O
;	O
V	O
##ir	O
##ba	O
##c	O
,	O
Australia	O
)	O
.	O

i	O
##j	O
i	O
j	O
}	O
}	O
1	B
+	I
ex	I
##p	I
{	I
β	I
##0	I
+	I
[UNK]	O
=	I
1	I
##β	I
##j	I
##X	I
##i	I
##j	I
}	I
1	I
+	I
ex	I
##p	I
{	I
β	I
##0	I
+	I
[UNK]	O
=	I
1	I
##β	I
##j	I
##X	I
##i	I
##j	I
}	I
1	O
+	O
ex	O
##p	O
{	B
β	B
##0	I
+	I
[UNK]	O
=	I
1	I
##β	I
##j	I
##X	I
##i	I
##j	I
}	O
{	O
{	O
β	B
##0	I
+	I
[UNK]	O
=	I
1	I
##β	I
##j	I
##X	I
##i	I
##j	I
β	O
##0	O
β	O
##0	O
β	O
β	O
β	O
0	O
0	O
+	O
[UNK]	O
=	O
1	O
[UNK]	O
=	O
1	O
[UNK]	O
[UNK]	O
m	O
m	O
j	O
=	O
1	O
j	O
=	O
1	O
j	O
=	O
1	O
β	O
##j	O
##X	O
##i	O
##j	O
β	O
##j	O
β	O
##j	O
β	O
β	O
β	O

Blood	O
glucose	S
was	O
measured	O
within	O
a	O
3	O
h	O
period	O
at	O
30	O
min	O
intervals	O
.	O

L	O
##C	O
–	O
MS	O
grade	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
,	O
met	B
##han	I
##ol	I
,	O
and	O
water	O
were	O
purchased	O
from	O
B	O
##ur	O
##dick	O
and	O
Jackson	O
(	O
V	O
##WR	O
International	O
,	O
West	O
Chester	O
,	O
PA	O
,	O
USA	O
)	O
.	O

In	O
patients	O
with	O
kidney	O
disease	O
,	O
car	O
##ba	O
##my	O
##lation	O
reaction	O
products	O
with	O
l	B
##ys	I
##ine	I
of	O
Al	O
##b	O
were	O
found	O
.	O

CA	O
##RT	O
was	O
applied	O
on	O
lip	O
##id	O
families	O
such	O
as	O
total	O
T	B
##G	I
,	O
total	O
D	O
##G	O
,	O
Total	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
Total	O
CE	O
,	O
Total	O
SF	O
##A	O
,	O
Total	O
US	O
##FA	O
,	O
Total	O
M	O
##U	O
##FA	O
,	O
Total	O
P	O
##U	O
##FA	O
,	O
Total	O
PC	O
,	O
Total	O
P	O
##E	O
,	O
Total	O
P	O
##I	O
,	O
Total	O
PS	O
,	O
Total	O
Ce	B
##r	I
and	O
Total	O
SM	O
.	O

T	O
##ip	O
size	O
of	O
the	O
Pi	O
##co	O
##C	O
##hip	O
_	O
T	O
##M	O
na	O
##no	O
em	O
##itte	O
##r	O
was	O
15	O
μ	O
##m	O
and	O
N	O
##SI	O
source	O
parameters	O
were	O
as	O
follows	O
:	O
source	O
voltage	O
1	O
.	O
9	O
k	B
##V	I
,	O
source	O
current	O
100	O
μ	O
##A	O
,	O
sheath	O
gas	O
0	O
,	O
aux	O
gas	O
0	O
and	O
cap	O
##illa	O
##ry	O
temperature	O
275	O
##°	O
##C	O
.	O

High	O
glucose	S
levels	O
have	O
been	O
previously	O
noted	O
in	O
the	O
f	O
##ae	O
##ces	O
,	O
co	O
##lon	O
##ic	O
m	O
##uc	O
##osa	O
and	O
serum	O
_	O
,	O
of	O
patients	O
with	O
I	O
##B	O
##D	O
relative	O
to	O
controls	O
.	O

Cho	B
##line	I
,	O
an	O
essential	O
nut	O
##rient	O
,	O
can	O
also	O
induce	O
a	O
##pop	O
##tosis	O
when	O
def	O
##icient	O
in	O
the	O
diet	O
(	O
,	O
)	O
.	O

Do	O
##ub	O
##ly	O
labeled	O
water	O
(	O
DL	O
##W	O
:	O
de	O
##uter	O
##ium	O
and	O
oxygen	B
-	I
18	I
(	O
_	O
18	O
O	O
)	O
)	O
was	O
used	O
to	O
derive	O
total	O
energy	O
expenditure	O
(	O
T	O
##EE	O
_	O
DL	O
##W	O
)	O
.	O

Un	O
##co	O
##up	O
##led	O
NO	O
##S	O
generates	O
super	B
##oxide	I
instead	O
of	O
ni	B
##tric	I
oxide	I
,	O
leading	O
to	O
an	O
o	O
##xi	O
##da	O
##tive	O
stress	O
state	O
.	O

A	O
previous	O
study	O
of	O
more	O
than	O
1000	O
participants	O
demonstrated	O
different	O
plasma	O
levels	O
of	O
several	O
s	B
##phi	I
##ngo	I
##lip	I
##id	I
sub	O
##c	O
##lass	O
##es	O
between	O
males	O
and	O
females	O
.	O

T	O
##RP	O
,	O
1	O
.	O
248	O
mg	O
K	O
##Y	O
##N	O
,	O
1	O
.	O
28	O
##2	O
mg	O
Q	O
##UI	O
##N	O
were	O
weighed	O
accurately	O
and	O
then	O
dissolved	O
and	O
mixed	O
in	O
50	O
%	O
met	B
##han	I
##ol	I
solution	O
,	O
respectively	O
,	O
to	O
make	O
1	O
mg	O
/	O
m	O
##l	O
standard	O
stock	O
solution	O
;	O
0	O
.	O
67	O
##1	O
mg	O
K	O
##Y	O
##NA	O
was	O
weighed	O
accurately	O
and	O
then	O
dissolved	O
and	O
mixed	O
in	O
ultra	O
-	O
pure	O
water	O
to	O
make	O
0	O
.	O
167	O
mg	O
/	O
m	O
##l	O
standard	O
stock	O
solution	O
,	O
which	O
was	O
split	O
storing	O
in	O
−	O
##20	O
##°	O
##C	O
.	O

There	O
was	O
a	O
significant	O
increase	O
in	O
G	O
##LP	O
-	O
1	O
and	O
a	O
reduction	O
in	O
G	O
##IP	O
,	O
t	B
##yr	I
##os	I
##ine	I
and	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
in	O
both	O
the	O
as	B
##par	I
##tam	I
##e	I
sensitive	O
and	O
non	O
-	O
sensitive	O
groups	O
after	O
as	B
##par	I
##tam	I
##e	I
and	O
control	O
preparations	O
.	O

Figure	O
)	O
,	O
which	O
is	O
also	O
consistent	O
with	O
the	O
significant	O
correlation	O
##s	O
between	O
_	O
13	O
C	O
-	O
labeled	O
c	B
##it	I
##rate	I
,	O
su	B
##cci	I
##nate	I
,	O
and	O
G	O
##lu	O
in	O
the	O
lung	O
tumor	O
tissues	O
(	O
c	O
##f	O
.	O

No	O
similar	O
p	O
##hen	O
##otype	O
has	O
been	O
reported	O
on	O
con	O
##gen	O
##ital	O
p	B
##yr	I
##im	I
##id	I
##ine	I
metabolic	O
disorders	O
.	O

Tau	O
,	O
ta	B
##uri	I
##ne	I
.	O

_	O
c	O
No	O
statistical	O
difference	O
was	O
detected	O
between	O
the	O
ages	O
(	O
P	O
=	O
.	O
42	O
)	O
,	O
CD	O
##4	O
_	O
+	O
count	O
(	O
P	O
=	O
.	O
78	O
)	O
,	O
CD	O
##8	O
_	O
+	O
count	O
(	O
P	O
=	O
.	O
72	O
)	O
,	O
CD	O
##4	O
/	O
CD	O
##8	O
ratio	O
(	O
P	O
=	O
.	O
88	O
)	O
,	O
viral	O
load	O
(	O
P	O
=	O
.	O
44	O
)	O
,	O
estimated	O
time	O
since	O
HIV	O
diagnosis	O
(	O
P	O
=	O
.	O
28	O
)	O
,	O
and	O
duration	S
of	O
viral	O
suppression	O
of	O
individuals	O
in	O
each	O
group	O
(	O
P	O
=	O
.	O
7	O
)	O

(	O
BC	O
##AA	O
;	O
is	B
##ole	I
##uc	I
##ine	I
,	O
le	B
##uc	I
##ine	I
,	O
and	O
v	B
##ali	I
##ne	I
)	O
found	O
in	O
greater	O
abundance	O
in	O
CD	O
samples	O
.	O

We	O
have	O
previously	O
identified	O
ch	B
##olin	I
##e	I
as	O
a	O
bio	O
##mark	O
##er	O
of	O
co	O
##lon	O
cancer	O
risk	O
in	O
susceptible	O
individuals	O
associated	O
with	O
altered	O
micro	O
##bio	O
##me	O
metabolism	O
.	O

As	O
shown	O
in	O
,	O
the	O
peak	O
areas	O
of	O
five	O
th	B
##iol	I
derivatives	O
increased	O
with	O
the	O
increase	O
in	O
T	O
##CE	O
##P	O
concentration	O
from	O
10	O
to	O
100	O
nm	O
##ol	O
.	O

Inc	O
##uba	O
##tion	O
of	O
12	O
in	O
the	O
presence	O
of	O
R	O
##L	O
##H	O
led	O
to	O
the	O
formation	O
of	O
9	O
which	O
was	O
converted	O
to	O
11	O
upon	O
reaction	O
with	O
met	B
##ho	I
##xy	I
##amine	I
.	O

Our	O
meta	O
##bol	O
##omi	O
##c	O
study	O
of	O
high	O
-	O
altitude	O
pulmonary	O
ed	O
##ema	O
using	O
high	O
resolution	O
_	O
1	O
H	O
N	O
##MR	O
s	O
##pect	O
##ros	O
##copy	O
identified	O
a	O
panel	O
of	O
20	O
differential	O
plasma	O
meta	O
##bol	O
##ites	O
,	O
including	O
v	B
##ali	I
##ne	I
,	O
le	B
##uc	I
##ine	I
,	O
c	B
##it	I
##rate	I
and	O
glucose	S
,	O
demonstrating	O
that	O
metabolic	O
profiles	O
can	O
be	O
used	O
in	O
the	O
discovery	O
of	O
bio	O
##mark	O
##ers	O
of	O
disease	O
.	O

We	O
identified	O
and	O
replica	O
##ted	O
three	O
novel	O
genetic	O
signals	O
,	O
PR	O
##KA	O
##G	O
##2	O
r	O
##s	O
##27	O
##27	O
##5	O
##6	O
##3	O
,	O
DC	O
##C	O
r	O
##s	O
##12	O
##60	O
##4	O
##9	O
##40	O
and	O
EP	O
##H	O
##X	O
##2	O
r	O
##s	O
##13	O
##26	O
##29	O
##30	O
with	O
clinical	O
##ly	O
relevant	O
effects	O
on	O
the	O
blood	O
pressure	O
response	O
of	O
European	O
Americans	O
treated	O
with	O
h	B
##ydro	I
##ch	I
##lor	I
##oth	I
##ia	I
##zi	I
##de	I
.	O

The	O
et	B
##hyl	I
ace	I
##tate	I
was	O
e	O
##va	O
##porated	O
to	O
dry	O
##ness	O
using	O
a	O
Speed	O
##va	O
##c	O
con	O
##cent	O
##rator	O
(	O
The	O
##rm	O
##o	O
Fisher	O
)	O
,	O
and	O
the	O
plates	O
were	O
capped	O
and	O
stored	O
at	O
-	O
20	O
##°	O
##C	O
until	O
L	O
##C	O
E	O
##SI	O
_	O
—	O
MS	O
/	O
MS	O
analysis	O
.	O

We	O
observed	O
that	O
changes	O
in	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##let	I
##han	I
##ola	I
##mine	I
over	O
time	O
were	O
associated	O
with	O
the	O
use	O
of	O
disease	O
-	O
modify	O
##ing	O
drugs	O
(	B
inter	B
##fer	I
##on	I
-	I
β	I
)	O
(	O
p	O
=	O
0	O
.	O
01	O
)	O

The	O
figures	O
show	O
that	O
the	O
broad	O
protein	O
peaks	O
have	O
been	O
largely	O
removed	O
by	O
both	O
methods	O
,	O
although	O
after	O
treatment	O
with	O
met	B
##han	I
##ol	I
alone	O
,	O
residual	O
protein	O
signals	O
cause	O
a	O
well	O
-	O
visible	O
curved	O
base	O
##line	O
under	O
the	O
crowded	O
peak	O
regions	O
as	O
well	O
as	O
a	O
broad	O
lip	O
##id	O
feature	O
around	O
1	O
.	O
2	O
pp	O
##m	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
whether	O
T	B
##MA	I
##O	I
is	O
present	O
at	O
detect	O
##able	O
levels	O
in	O
human	O
c	O
##ere	O
##bro	O
##sp	O
##inal	O
fluid	O
(	O
CS	O
##F	O
)	O
.	O

While	O
larger	O
,	O
(	O
very	O
)	O
low	O
-	O
density	O
lip	O
##op	O
##rote	O
##ins	O
(	O
(	O
V	O
)	O
L	O
##D	O
##L	O
)	O
contain	O
a	O
high	O
concentration	O
of	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
and	O
ch	B
##ole	I
##ster	I
##ol	I
est	I
##ers	I
in	O
their	O
h	O
##ydro	O
##phobic	O
core	O
,	O
the	O
concentration	O
of	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
is	O
significantly	O
higher	O
in	O
smaller	O
high	O
-	O
density	O
lip	O
##op	O
##rote	O
##ins	O
(	O
HD	O
##L	O
)	O
.	O

As	B
##par	I
##tam	I
##e	I
sensitive	O
and	O
non	O
-	O
sensitive	O
participants	O
differed	O
psychological	O
##ly	O
at	O
base	O
##line	O
in	O
handling	O
feelings	O
and	O
perceived	O
stress	O
.	O

B	O
##MI	O
:	O
body	O
mass	O
index	O
;	O
H	O
##R	O
:	O
heart	O
rate	O
;	O
E	O
##F	O
:	O
e	O
##jection	O
fraction	O
;	O
LA	O
##D	O
:	O
left	O
at	O
##rial	O
diameter	O
;	O
L	O
##VE	O
##D	O
##D	O
:	O
left	O
vent	O
##ric	O
##ular	O
end	O
di	O
##ast	O
##olic	O
diameter	O
;	O
C	O
##c	O
##r	O
:	O
c	B
##rea	I
##tin	I
##ine	I
clearance	O
rate	O
;	O
CO	O
##PD	O
:	O
chronic	O
o	O
##bs	O
##truct	O
##ive	O
pulmonary	O
disease	O
;	O
MAC	O
##CE	O
:	O
major	O
adverse	O
cardiac	O
and	O
c	O
##ere	O
##bro	O
##vas	O
##cular	O
events	O
;	O
NY	O
##HA	O
:	O
New	O
York	O
Heart	O
Association	O
.	O

Post	O
-	O
ER	O
##CP	O
serum	O
metabolic	O
networks	O
indicate	O
functional	O
differences	O
surrounding	O
as	B
##par	I
##tate	I
metabolism	O
between	O
patients	O
with	O
AP	S
and	O
those	O
without	O
.	O

So	B
##dium	I
h	I
##ydro	I
##xi	I
##de	I
was	O
purchased	O
from	O
West	O
Long	O
Chemical	O
Co	O
.	O
,	O
Ltd	O
.	O
,	O
and	O
Am	O
##monia	O
was	O
from	O
Hong	O
##du	O
B	O
##io	O
##chemistry	O
Co	O
.	O
,	O
Ltd	O
.	O
(	O
Jiang	O
##xi	O
province	O
,	O
China	O
)	O
.	O

An	O
entirely	O
novel	O
change	O
identified	O
in	O
the	O
a	O
##que	O
##ous	O
meta	O
##bol	O
##ites	O
was	O
a	O
decrease	O
in	O
the	O
essential	O
branched	O
-	O
chain	O
amino	O
acid	O
(	O
BC	O
##AA	O
)	O
is	B
##ole	I
##uc	I
##ine	I
with	O
ascent	O
.	O

In	O
##st	O
##rum	O
##ent	O
ca	O
##li	O
##bra	O
##tion	O
was	O
performed	O
external	O
##ly	O
prior	O
to	O
each	O
batch	O
run	O
with	O
1	O
m	O
##M	O
sodium	B
format	I
##e	I
solution	O
in	O
is	O
##op	O
##rop	O
##ano	O
##l	O
/	O
water	O
(	O
9	O
:	O
1	O
,	O
v	O
/	O
v	O
)	O
.	O

The	O
independent	O
variables	O
were	O
:	O
plant	O
(	O
J	O
=	O
reference	O
,	O
D	O
,	O
or	O
R	O
)	O
,	O
job	O
title	O
(	O
fore	O
##men	O
=	O
reference	O
,	O
engine	O
operators	O
,	O
or	O
co	O
##ke	O
markers	O
)	O
,	O
dirty	O
skin	O
(	O
no	O
or	O
yes	O
)	O
,	O
age	O
(	O
years	O
)	O
,	O
log	O
_	O
10	O
c	B
##rea	I
##tin	I
##ine	I
(	O
g	O
/	O
L	O
)	O
,	O
and	O
log	O
_	O
10	O
co	B
##tin	I
##ine	I
(	O
µ	O
##g	O
/	O
L	O
)	O
(	O
n	O
=	O
49	O
)	O
.	O

Furthermore	O
,	O
an	O
analysis	O
of	O
plant	O
lip	O
##ids	O
revealed	O
significant	O
decreases	O
in	O
mon	B
##oga	I
##la	I
##ct	I
##osy	I
##ld	I
##iac	I
##yl	I
##gly	I
##cer	I
##ol	I
and	O
sit	B
##ost	I
##ery	I
##l	I
est	I
##er	I
in	O
b	O
##v	O
##FT	O
##D	O
,	O
indicating	O
altered	O
eating	O
behavior	O
in	O
b	O
##v	O
##FT	O
##D	O
.	O

Our	O
data	O
suggests	O
that	O
s	B
##tat	I
##ins	I
significantly	O
lowered	O
levels	O
of	O
both	O
SM	O
and	O
c	B
##era	I
##mi	I
##des	I
in	O
both	O
AD	O
and	O
controls	O
.	O

However	O
,	O
O	O
##EP	O
did	O
not	O
induce	O
statistical	O
##ly	O
significant	O
changes	O
in	O
either	O
o	O
##x	O
-	O
L	O
##D	O
##L	O
or	O
u	O
##rina	O
##ry	O
is	B
##op	I
##ros	I
##tan	I
##e	I
in	O
this	O
study	O
.	O

Several	O
meta	O
##bol	O
##ites	O
,	O
such	O
as	O
ta	B
##uri	I
##ne	I
,	O
ace	B
##tone	I
,	O
al	B
##ani	I
##ne	I
,	O
and	O
h	B
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
,	O
are	O
observed	O
to	O
have	O
large	O
variations	O
between	O
the	O
two	O
s	O
##pect	O
##ra	O
in	O
.	O

All	O
the	O
patients	O
were	O
treated	O
with	O
the	O
a	B
##za	I
##thi	I
##op	I
##rine	I
.	O

B	O
##rief	O
##ly	O
,	O
a	O
sub	O
##sa	O
##mple	O
of	O
IN	O
##TE	O
##R	O
##MA	O
##P	O
urine	O
specimens	O
was	O
visually	O
inspected	O
for	O
the	O
presence	O
or	O
absence	O
of	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
and	O
i	B
##bu	I
##p	I
##ro	I
##fen	I
meta	O
##bol	O
##ites	O
;	O
these	O
s	O
##pect	O
##ra	O
were	O
then	O
used	O
to	O
valid	O
##ate	O
statistical	O
models	O
for	O
detection	O
of	O
each	O
anal	O
##ges	O
##ic	O
.	O

For	O
instance	O
,	O
for	O
human	O
urine	O
,	O
identification	O
of	O
c	B
##rea	I
##tine	I
solely	O
based	O
on	O
_	O
13	O
C	O
-	O
_	O
1	O
H	O
H	O
##S	O
##Q	O
##C	O
alone	O
was	O
challenging	O
.	O

Based	O
on	O
c	B
##rea	I
##tin	I
##ine	I
measurements	O
,	O
the	O
urine	O
samples	O
were	O
di	O
##lut	O
##ed	O
to	O
0	O
.	O
65	O
mg	O
/	O
m	O
##L	O
c	B
##rea	I
##tin	I
##ine	I
,	O
and	O
samples	O
with	O
c	B
##rea	I
##tin	I
##ine	I
levels	O
equal	O
to	O
or	O
below	O
this	O
value	O
were	O
analyzed	O
without	O
di	O
##lution	O
.	O

El	O
##eva	O
##ted	O
level	O
of	O
fatty	O
acids	O
,	O
glucose	S
and	O
acids	O
were	O
observed	O
in	O
lung	O
cancer	O
in	O
comparison	O
with	O
control	O
groups	O
apparently	O
due	O
to	O
enhanced	O
g	O
##ly	O
##co	O
##lysis	O
,	O
g	O
##lu	O
##con	O
##eo	O
##genesis	O
,	O
lip	O
##ogen	O
##esis	O
and	O
acid	O
##osis	O
,	O
indicating	O
the	O
metabolic	O
signature	O
for	O
lung	O
cancer	O
.	O

D	B
##MA	I
and	O
T	O
##MA	O
increased	O
in	O
F	O
##S	O
##GS	O
patients	O
compared	O
with	O
healthy	O
controls	O
.	O

For	O
R	B
##RL	I
##C	I
-	I
(	I
+	I
)	I
E	I
##SI	I
-	I
MS	I
data	O
,	O
the	O
classification	O
of	O
E	O
##SC	O
##C	O
and	O
NC	O
groups	O
resulted	O
in	O
one	O
predict	O
##ive	O
(	O
t	O
_	O
p	O
)	O
and	O
two	O
or	O
##th	O
##ogo	O
##nal	O
(	O
t	O
_	O
o	O
)	O
(	O
1	O
+	O
2	O
)	O
components	O
with	O
a	O
cross	O
-	O
valid	O
##ated	O
predict	O
##ive	O
ability	O
,	O
(	O
cum	O
)	O
,	O
of	O
54	O
.	O
7	O
%	O
.	O

100	O
##μ	O
##l	O
of	O
1	O
-	O
but	O
##ano	O
##l	O
/	O
met	O
##han	O
##ol	O
(	O
1	O
:	O
1	O
v	O
/	O
v	O
)	O
containing	O
5	O
m	O
##M	O
am	B
##mon	I
##ium	I
format	I
##e	I
was	O
then	O
added	O
to	O
the	O
sample	O
.	O

From	O
these	O
,	O
ion	O
ch	O
##roma	O
##to	O
##gram	O
##s	O
were	O
developed	O
using	O
the	O
transitions	O
,	O
ma	B
##lon	I
##yl	I
##dai	I
##d	I
##zin	I
m	O
/	O
z	O
50	O
##3	O
to	O
m	O
/	O
z	O
255	O
;	O
ace	B
##ty	I
##lda	I
##id	I
##zin	I
m	O
/	O
z	O
45	O
##9	O
to	O
m	O
/	O
z	O
255	O
;	O
da	B
##id	I
##zin	I
m	O
/	O
z	O
41	O
##7	O
to	O
m	O
/	O
z	O
255	O
;	O
ma	B
##lon	I
##yl	I
##gen	I
##ist	I
##in	I
m	O
/	O
z	O
51	O
##9	O
to	O
m	O
/	O
z	O
27	O
##1	O
;	O
ace	B
##ty	I
##lge	I
##nist	I
##in	I
m	O
/	O
z	O
47	O
##5	O
to	O
m	O
/	O
z	O
27	O
##1	O
;	O
and	O
g	O
##eni	O
##st	O
##in	O
m	O
/	O
z	O
43	O
##3	O
to	O
m	O
/	O
z	O
27	O
##1	O
.	O

A	O
study	O
protocol	O
such	O
as	O
that	O
used	O
by	O
Lab	O
##us	O
and	O
colleagues	O
in	O
which	O
participants	O
were	O
exposed	O
to	O
acute	O
try	B
##pt	I
##op	I
##han	I
de	O
##ple	O
##tion	O
and	O
brain	O
connectivity	O
patterns	O
examined	O
in	O
response	O
to	O
v	O
##is	O
##cer	O
##al	O
stimuli	O
may	O
reveal	O
insights	O
regarding	O
the	O
role	O
of	O
peripheral	O
T	O
##rp	O
on	O
central	O
networks	O
including	O
those	O
involved	O
in	O
sleep	O
.	O

Numbers	O
indicate	O
the	O
following	O
meta	O
##bol	O
##ites	O
(	O
q	O
##uant	O
##ified	O
compounds	O
)	O
:	O
1	O
:	O
p	B
##yr	I
##u	I
##vic	I
acid	I
;	O
2	O
:	O
L	B
-	I
la	I
##ctic	I
acid	I
;	O
3	O
:	O
alpha	B
-	I
h	I
##ydro	I
##xy	I
##is	I
##ob	I
##ut	I
##yric	I
acid	I
;	O
4	O
:	O
g	B
##ly	I
##co	I
##lic	I
acid	I
;	O
5	O
:	O
le	B
##vu	I
##lini	I
##c	I
acid	I
;	O
[UNK]	O
-	O
h	O
##ydro	O
##xy	O
##is	O
##ova	O
##ler	O
##ic	O
acid	O
;	O
[UNK]	O
-	O
h	O
##ydro	O
##xy	O
-	O
2	O
-	O
met	O
##hyl	O
##but	O
##yric	O
acid	O
;	O
8	O
:	O
h	B
##ydro	I
##xy	I
##p	I
##rop	I
##ion	I
##ic	I
acid	I
;	O
[UNK]	O
-	O
met	O
##hyl	O
-	O
3	O
-	O
h	O
##ydro	O
##xy	O
##but	O
##yric	O
acid	O
;	O
10	O
:	O
ma	B
##lon	I
##ic	I
acid	I
;	O
[UNK]	O
-	O
h	O
##ydro	O
##xy	O
##is	O
##ova	O
##ler	O
##ic	O
acid	O
;	O
12	O
:	O
met	B
##hyl	I
##mal	I
##onic	I
acid	I
;	O
[UNK]	O
-	O
et	O
##hyl	O
##hy	O
##dra	O
##c	O
##ryl	O
##ic	O
acid	O
;	O
14	O
:	O
ben	B
##zoic	I
acid	I
;	O
15	O
:	O
p	B
##hos	I
##ph	I
##ori	I
##c	I
acid	I
;	O
16	O
:	O
et	B
##hyl	I
##mal	I
##onic	I
acid	I
;	O
17	O
:	O
su	B
##cci	I
##nic	I
acid	I
;	O
18	O
:	O
met	B
##hyl	I
##su	I
##cci	I
##nic	I
acid	I
;	O
[UNK]	O
-	O
de	O
##ox	O
##yt	O
##hr	O
##eon	O
##ic	O
acid	O
;	O
[UNK]	O
-	O
h	O
##ydro	O
##xy	O
##he	O
##xa	O
##no	O
##ic	O
acid	O
;	O
21	O
:	O
c	B
##it	I
##rac	I
##onic	I
acid	I
;	O
22	O
:	O
g	B
##lut	I
##ari	I
##c	I
acid	I
;	O
23	O
:	O
m	B
-	I
ch	I
##lor	I
##obe	I
##nz	I
##oi	I
##c	I
acid	I
;	O
24	B
;	I
3	I
,	I
4	I
-	I
di	I
##hy	I
##dr	I
##ox	I
##y	I
##but	I
##ano	I
##ic	I
acid	I
;	O
[UNK]	O
-	O
met	O
##hyl	O

L	O
##C	O
-	O
MS	O
/	O
MS	O
analyses	O
of	O
time	O
course	O
sa	O
##liva	O
samples	O
collected	O
following	O
BR	O
##B	O
r	O
##ins	O
##es	O
were	O
conducted	O
to	O
assess	O
local	O
p	O
##har	O
##ma	O
##co	O
##kin	O
##etics	O
and	O
compare	O
the	O
capacities	O
of	O
three	O
different	O
BR	O
##B	O
r	O
##ins	O
##e	O
formulation	O
##s	O
to	O
provide	O
sustained	O
in	O
##tra	O
##oral	O
levels	O
of	O
ant	B
##ho	I
##cy	I
##ani	I
##ns	I
.	O

PA	B
##G	I
is	O
a	O
major	O
nitrogen	O
##ous	O
meta	O
##bol	O
##ite	O
for	O
which	O
synthesis	O
depends	O
on	O
the	O
availability	O
of	O
g	B
##lut	I
##amine	I
,	O
mainly	O
generated	O
in	O
the	O
K	O
##re	O
##bs	O
cycle	O
from	O
AK	O
##G	O
.	O

From	O
this	O
viewpoint	O
,	O
we	O
have	O
focused	O
on	O
the	O
meta	O
##bol	O
##ites	O
associated	O
with	O
g	B
##lut	I
##ath	I
##ione	I
metabolism	O
as	O
indicators	O
for	O
monitoring	O
of	O
liver	O
disease	O
,	O
because	O
g	B
##lut	I
##ath	I
##ione	I
metabolism	O
in	O
liver	O
cells	O
plays	O
a	O
significant	O
role	O
in	O
protecting	O
them	O
against	O
R	O
##OS	O
[	O
-	O
]	O
.	O

Aden	B
##ine	I
(	O
7	O
.	O
5	O
mm	O
##ol	O
,	O
in	O
10	O
m	O
##l	O
D	O
##MF	O
)	O
was	O
added	O
to	O
a	O
mixture	O
of	O
est	B
##rad	I
##iol	I
(	O
3	O
.	O
7	O
mm	O
##ol	O
)	O
,	O
M	O
##n	O
##O	O
_	O
2	O
(	O
2	O
g	O
##m	O
,	O
23	O
mm	O
##ol	O
)	O
and	O
D	O
##MF	O
(	O
40	O
m	O
##l	O
)	O
under	O
nitrogen	O
.	O

The	O
results	O
demonstrate	O
that	O
the	O
developed	O
method	O
can	O
be	O
used	O
to	O
analyze	O
biological	O
samples	O
for	O
the	O
study	O
of	O
p	B
##oly	I
##amine	I
metabolism	O
and	O
its	O
association	O
with	O
human	O
diseases	O
.	O

Previous	O
studies	O
reported	O
the	O
concentration	O
of	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
decreased	O
with	O
the	O
development	O
of	O
di	O
##abe	O
##tic	O
micro	O
##vas	O
##cular	O
complications	O
.	O

Ren	O
##al	O
function	O
usually	O
improve	O
##s	O
as	O
patients	O
enter	O
into	O
re	O
##mission	O
and	O
may	O
de	O
##ter	O
##ior	O
##ate	O
at	O
re	O
##lap	O
##se	O
with	O
associated	O
changes	O
in	O
beta	O
##2	O
micro	O
##g	O
##lo	O
##bul	O
##in	O
and	O
c	B
##rea	I
##tin	I
##ine	I
levels	O
.	O

Unlike	O
the	O
study	O
of	O
Lu	O
##t	O
##jo	O
##han	O
##n	O
et	O
al	O
.	O
,	O
but	O
in	O
agreement	O
with	O
other	O
following	O
clinical	O
observations	O
[	O
-	O
]	O
,	O
we	O
found	O
that	O
plasma	O
24	B
##S	I
-	I
OH	I
-	I
Cho	I
##l	I
levels	O
were	O
lower	O
in	O
V	O
##D	O
patients	O
compared	O
with	O
controls	O
.	O

S	B
##phi	I
##ngo	I
##lip	I
##ids	I
,	O
which	O
represent	O
less	O
than	O
20	O
%	O
of	O
total	O
lip	O
##id	O
species	O
in	O
CS	O
##F	O
,	O
are	O
of	O
particular	O
importance	O
in	O
the	O
context	O
of	O
bio	O
##mark	O
##er	O
discovery	O
for	O
ne	O
##uro	O
##logical	O
diseases	O
,	O
such	O
as	O
l	O
##ys	O
##oso	O
##mal	O
or	O
unknown	O
ne	O
##uro	O
##met	O
##ab	O
##olic	O
diseases	O
.	O

Specifically	O
for	O
pre	B
##gne	I
##no	I
##lone	I
,	O
D	O
##H	O
##EA	O
,	O
D	O
##H	O
##EA	O
-	O
S	O
##O	O
_	O
4	O
,	O
and	B
##ros	I
##ten	I
##ed	I
##ione	I
,	O
17	B
-	I
h	I
##ydro	I
##xy	I
##p	I
##rog	I
##ester	I
##one	I
,	O
co	B
##rt	I
##ison	I
##e	I
,	O
co	B
##rt	I
##ico	I
##ster	I
##one	I
and	O
11	B
-	I
de	I
##ox	I
##y	I
##cor	I
##tic	I
##osterone	I
age	O
-	O
specific	O
reference	O
intervals	O
are	O
provided	O
that	O
can	O
be	O
calculated	O
according	O
to	O
equations	O
established	O
from	O
curve	O
fitting	O
.	O

The	O
four	O
cell	O
lines	O
were	O
pre	O
-	O
treated	O
with	O
the	O
MA	O
##G	O
##L	O
selective	O
inhibitor	O
,	O
J	O
##Z	O
##L	O
##18	O
##4	O
(	O
1	O
μ	O
##M	O
)	O
,	O
the	O
CO	O
##X	O
-	O
1	O
selective	O
inhibitor	O
,	O
SC	O
-	O
560	O
(	O
1	O
μ	O
##M	O
)	O
;	O
and	O
the	O
CO	O
##X	O
-	O
1	O
and	O
-	O
2	O
non	O
##sel	O
##ec	O
##tive	O
inhibitor	O
,	O
I	B
##bu	I
##p	I
##ro	I
##fen	I
(	O
40	O
μ	O
##M	O
)	O
,	O
for	O
6	O
hours	O
and	O
then	O
co	O
-	O
treated	O
with	O
2	O
-	O
AG	O
for	O
3	O
days	O
.	O

For	O
h	O
##yper	O
##p	O
##lastic	O
p	O
##oly	O
##p	O
risk	O
,	O
there	O
was	O
no	O
evidence	O
of	O
a	O
significant	O
interaction	O
between	O
sex	O
and	O
l	B
##ino	I
##le	I
##ic	I
acid	I
(	O
P	O
=	O
0	O
.	O
54	O
)	O
,	O
a	B
##rac	I
##hi	I
##don	I
##ic	I
acid	I
(	O
P	O
=	O
0	O
.	O
25	O
)	O
,	O
α	B
-	I
l	I
##ino	I
##len	I
##ic	I
acid	I
(	O
P	O
=	O
0	O
.	O
69	O
)	O
,	O
marine	O
-	O
derived	O
n	O
##−	O
##3	O
P	O
##U	O
##FA	O
intake	O
(	O
P	O
=	O
0	O
.	O
38	O
)	O
,	O
or	O
the	O
ratio	O
of	O
n	O
##−	O
##6	O
P	O
##U	O
##FA	O
##s	O
to	O
marine	O
-	O
derived	O
n	O
##−	O
##3	O
P	O
##U	O
##FA	O
##s	O
(	O
P	O
=	O
0	O
.	O
17	O
)	O
.	O

BC	O
##AA	O
##s	O
such	O
as	O
v	B
##ali	I
##ne	I
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
and	O
le	B
##uc	I
##ine	I
are	O
essential	O
amino	O
acids	O
whose	O
carbon	O
structures	O
are	O
marked	O
by	O
a	O
branch	O
point	O
.	O

Another	O
2	O
meta	O
##bol	O
##ites	O
with	O
the	O
same	O
pattern	O
of	O
changes	O
in	O
CC	O
##RT	O
and	O
R	O
##T	O
groups	O
(	O
namely	O
,	O
SM	O
(	O
OH	O
)	O
C	B
##16	I
:	I
1	I
and	O
SM	B
C	I
##18	I
:	I
0	I
)	O
were	O
not	O
affected	O
between	O
points	O
A	O
and	O
B	O
then	O
increased	O
significantly	O
in	O
point	O
C	O
—	O
pattern	O
A	O
=	O
B	O
<	O
C	O
;	O
a	O
similar	O
pattern	O
was	O
observed	O
in	O
case	O
of	O
4	O
and	O
1	O
meta	O
##bol	O
##ites	O
specific	O
to	O
CC	O
##RT	O
and	O
R	O
##T	O
,	O
respectively	O
.	O

In	O
addition	O
,	O
from	O
the	O
perspective	O
of	O
energy	O
metabolism	O
of	O
cancer	O
,	O
glucose	S
de	O
##ple	O
##tion	O
is	O
reportedly	O
caused	O
by	O
active	O
g	O
##ly	O
##co	O
##lysis	O
metabolism	O
in	O
cancer	O
cells	O
,	O
resulting	O
in	O
a	O
change	O
of	O
the	O
amino	O
acid	O
level	O
in	O
cancer	O
cells	O
(	O
,	O
,	O
)	O
.	O

A	O
modest	O
inter	O
##cor	O
##rel	O
##ation	O
was	O
observed	O
between	O
these	O
17	O
meta	O
##bol	O
##ites	O
,	O
and	O
a	O
few	O
were	O
highly	O
correlated	O
:	O
3	B
-	I
(	I
3	I
-	I
h	I
##ydro	I
##xy	I
##phe	I
##ny	I
##l	I
)	I
prop	I
##ion	I
##ate	I
and	O
3	B
-	I
h	I
##ydro	I
##xy	I
##hip	I
##pura	I
##te	I
(	O
r	O
=	O
0	O
.	O
93	O
)	O
and	O
1	B
-	I
met	I
##hyl	I
##ura	I
##te	I
and	O
5	B
-	I
ace	I
##ty	I
##lam	I
##ino	I
-	I
6	I
-	I
amino	I
-	I
3	I
-	I
met	I
##hyl	I
##ura	I
##ci	I
##l	I
(	O
r	O
=	O
0	O
.	O
79	O
)	O
.	O

The	O
meta	O
##bol	O
##ite	O
profile	O
of	O
T	O
##B	O
-	O
D	O
##M	O
patients	O
(	O
Fi	O
##g	O
.	O
)	O
was	O
mostly	O
characterized	O
by	O
low	O
levels	O
of	O
am	O
##ines	O
when	O
compared	O
to	O
HC	O
,	O
while	O
only	O
two	O
meta	O
##bol	O
##ites	O
,	O
put	B
##res	I
##cine	I
and	O
g	B
##ly	I
##cy	I
##l	I
##gly	I
##cine	I
,	O
were	O
significantly	O
elevated	O
.	O

Met	O
##hyl	O
##ene	O
/	O
met	O
##hyl	O
ratio	O
in	O
al	B
##ip	I
##hat	I
##ic	I
lip	O
##id	O
chains	O
from	O
plasma	O
lip	O
##ids	O
of	O
control	O
,	O
h	O
##yper	O
##tensive	O
patients	O
with	O
normal	O
L	O
##V	O
size	O
(	O
H	O
##T	O
##N	O
normal	O
L	O
##V	O
size	O
)	O
and	O
h	O
##yper	O
##tensive	O
patients	O
with	O
L	O
##V	O
h	O
##yper	O
##tro	O
##phy	O
(	O
H	O
##T	O
##N	O
L	O
##V	O
##H	O
)	O
.	O

In	O
conclusion	O
,	O
the	O
novel	O
Al	O
##she	O
##hr	O
##y	O
method	O
was	O
at	O
least	O
as	O
good	O
as	O
,	O
if	O
not	O
better	O
than	O
the	O
established	O
bi	O
##pha	O
##si	O
##c	O
extraction	O
methods	O
in	O
detect	O
##ing	O
a	O
wide	O
range	O
of	O
lip	O
##id	O
classes	O
,	O
using	O
as	O
little	O
as	O
10	O
μ	O
##L	O
of	O
plasma	O
,	O
and	O
was	O
highly	O
re	O
##p	O
##rod	O
##uc	O
##ible	O
,	O
safer	O
and	O
more	O
environmental	O
##ly	O
-	O
friendly	O
as	O
it	O
doesn	O
'	O
t	O
require	O
ch	B
##lor	I
##of	I
##orm	I
.	O

Additional	O
analyses	O
by	O
using	O
a	O
T	O
##C	O
##GA	O
co	O
##hor	O
##t	O
was	O
processed	O
by	O
the	O
Broad	O
Institute	O
'	O
s	O
pipeline	O
(	O
Fire	O
##hos	O
##e	O
run	O
“	O
28	O
January	O
2016	O
”	O
:	O
doi	O
:	O
10	O
.	O
79	O
##0	O
##8	O
/	O
C	O
##11	O
##G	O
##0	O
##K	O
##M	O
##9	O
)	O
consisting	O
of	O
36	O
##8	O
C	O
##MM	O
samples	O
showing	O
that	O
BR	O
##AF	O
-	O
mutant	O
tumors	O
retain	O
distinct	O
K	B
##P	I
gene	O
expression	O
profiles	O
compared	O
to	O
those	O
with	O
wild	O
-	O
type	O
BR	O
##AF	O
(	O
,	O
)	O
.	O

De	O
##mo	O
##graphic	O
profiles	O
in	O
de	O
##dic	O
##ator	O
of	O
c	O
##yt	O
##oki	O
##nes	O
##is	O
8	O
(	O
D	O
##OC	O
##K	O
##8	O
)	O
-	O
def	O
##icient	O
and	O
atop	O
##ic	O
der	O
##mat	O
##itis	O
(	O
AD	O
)	O
patients	O
:	O
(	O
A	O
)	O
Only	O
blood	O
e	B
##os	I
##ino	I
##phi	I
##l	I
counts	O
were	O
statistical	O
##ly	O
different	O
between	O
D	O
##OC	O
##K	O
##8	O
-	O
def	O
##icient	O
and	O
AD	O
patients	O
.	O

To	O
accommodate	O
the	O
expected	O
large	O
number	O
of	O
associations	O
with	O
glucose	S
levels	O
,	O
efficient	O
signal	O
prior	O
##iti	O
##zation	O
strategies	O
are	O
key	O
.	O

C	B
##it	I
##rate	I
contributes	O
to	O
the	O
production	O
of	O
pro	B
##sta	I
##g	I
##land	I
##in	I
,	O
reactive	O
oxygen	O
species	O
(	O
R	O
##OS	O
)	O
,	O
and	O
ni	B
##tric	I
oxide	I
(	O
NO	O
)	O
,	O
which	O
have	O
a	O
remarkable	O
role	O
in	O
inflammation	O
and	O
cell	O
damage	O
.	O

We	O
did	O
however	O
find	O
convincing	O
evidence	O
for	O
further	O
oxidation	O
of	O
the	O
anticipated	O
me	O
##rca	O
##pt	O
##uri	O
##c	O
acids	O
7	O
,	O
10	O
,	O
14	O
,	O
and	O
17	O
in	O
analyses	O
of	O
urine	O
from	O
c	O
##re	O
##oso	O
##te	O
workers	O
exposed	O
to	O
high	O
levels	O
of	O
PA	O
##H	O
,	O
by	O
detection	O
of	O
su	B
##lf	I
##oxide	I
##s	I
t	O
##y	O
##pi	O
##fied	O
by	O
8	O
,	O
11	O
,	O
15	O
,	O
and	O
18	O
,	O
although	O
these	O
were	O
also	O
non	O
-	O
detect	O
##able	O
in	O
the	O
urine	O
of	O
smoke	O
##rs	O
.	O

Inc	O
##reased	O
man	B
##nose	I
was	O
also	O
observed	O
in	O
our	O
DS	O
##S	O
co	O
##lit	O
##is	O
mouse	O
model	O
,	O
while	O
another	O
group	O
has	O
found	O
high	O
levels	O
of	O
glucose	S
in	O
extract	O
##s	O
of	O
mac	O
##ros	O
##copic	O
##ally	O
un	O
##in	O
##volved	O
co	O
##lon	O
##ic	O
m	O
##uc	O
##osa	O
of	O
I	O
##B	O
##D	O
patients	O
.	O

Additionally	O
,	O
some	O
of	O
the	O
meta	O
##bol	O
##ites	O
and	O
the	O
FA	S
that	O
did	O
not	O
show	O
significant	O
change	O
at	O
6	O
months	O
post	O
‐	O
surgery	O
might	O
be	O
false	O
negative	O
results	O
,	O
but	O
they	O
could	O
also	O
be	O
true	O
negative	O
results	O
and	O
we	O
are	O
not	O
powered	O
to	O
re	O
##lia	O
##bly	O
make	O
such	O
a	O
distinction	O
in	O
that	O
case	O
.	O

The	O
decrease	O
in	O
p	B
##hos	I
##ph	I
##och	I
##olin	I
##e	I
derivatives	O
,	O
g	B
##ly	I
##cer	I
##ides	I
(	O
Au	O
##C	O
##hi	O
)	O
and	O
M	O
##U	O
##FA	O
,	O
P	O
##U	O
##FA	O
and	O
ch	B
##ole	I
##ster	I
##ol	I
(	O
Au	O
##C	O
##e	O
##O	O
_	O
2	O
)	O
could	O
also	O
be	O
in	O
##dicative	O
for	O
an	O
alter	O
##ation	O
in	O
the	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
metabolism	O
of	O
P	O
##BM	O
##Cs	O
(	O
Table	O
E	O
and	O
F	O
in	O
)	O
.	O

P	O
-	O
values	O
were	O
calculated	O
using	O
the	O
non	O
##tra	O
##ns	O
##formed	O
median	O
in	O
K	O
##rus	O
##kal	O
–	O
Wallis	O
tests	O
comparing	O
u	O
##rina	O
##ry	O
para	B
##ce	I
##tam	I
##ol	I
and	O
p	B
-	I
amino	I
##phe	I
##no	I
##l	I
concentrations	O
across	O
the	O
three	O
pregnancy	O
status	O
groups	O
.	O

As	O
expected	O
,	O
the	O
Δ	O
q	B
##uin	I
##olin	I
##ic	I
acid	I
over	O
x	B
##ant	I
##hur	I
##eni	I
##c	I
acid	I
ratio	O
was	O
negatively	O
correlated	O
with	O
the	O
Δ	O
fast	O
##ing	O
glucose	S
(	O
β	O
=	O
-	O
1	O
.	O
09	O
##8	O
;	O
p	O
=	O
0	O
.	O
00	O
##75	O
)	O
and	O
positively	O
correlated	O
with	O
the	O
improvement	O
of	O
the	O
H	O
##OM	O
##A	O
##2	O
-	O
S	O
(	O
β	O
=	O
91	O
.	O
12	O
;	O
p	O
=	O
0	O
.	O
000	O
##7	O
##4	O
)	O
and	O
H	O
##OM	O
##A	O
##2	O
-	O
BS	O
(	O
β	O
=	O
27	O
.	O
09	O
;	O
p	O
=	O
0	O
.	O
000	O
##8	O
##2	O
)	O
index	O
##es	O
.	O

These	O
two	O
is	O
##omer	O
##s	O
are	O
in	O
turn	O
differentiated	O
structural	O
##ly	O
from	O
2	B
’	I
-	I
de	I
##ox	I
##y	I
##gua	I
##nos	I
##ine	I
-	I
5	I
’	I
-	I
dip	I
##hos	I
##phate	I
(	O
D	O
##G	O
##DP	O
,	O
orange	O
)	O
by	O
molecular	O
substitution	O
##s	O
on	O
the	O
pu	B
##rine	I
ring	O
,	O
where	O
a	O
h	O
##ydro	O
##xy	O
##l	O
group	O
has	O
been	O
relocated	O
from	O
the	O
rib	B
##ose	I
sugar	O
to	O
the	O
g	B
##uan	I
##ine	I
ring	O
,	O
as	O
well	O
as	O
an	O
am	O
##ine	O
rear	O
##rang	O
##ement	O
in	O
the	O
same	O
region	O
.	O

Overall	O
,	O
t	B
##rig	I
##ly	I
##cer	I
##ide	I
metabolism	O
was	O
associated	O
with	O
PC	O
##OS	O
mainly	O
via	O
larger	O
V	O
##LD	O
##L	O
particles	O
and	O
total	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
levels	O
.	O

It	O
is	O
also	O
important	O
to	O
note	O
that	O
the	O
use	O
of	O
amino	O
acid	O
a	O
##cy	O
##lation	O
pathways	O
has	O
been	O
successfully	O
exploited	O
in	O
em	O
##pi	O
##ric	O
studies	O
of	O
patients	O
with	O
in	O
##born	O
errors	O
of	O
u	B
##rea	I
synthesis	O
(	O
e	O
.	O
g	O
.	O
,	O
car	B
##ba	I
##my	I
##l	I
phosphate	I
s	O
##ynth	O
##eta	O
##se	O
(	O
CA	O
##D	O
)	O
deficiency	O
)	O
.	O

A	O
##rg	O
##MI	O
was	O
predict	O
##ive	O
of	O
incident	O
MAC	O
##E	O
even	O
following	O
adjustments	O
for	O
global	O
a	B
##rg	I
##ini	I
##ne	I
bio	O
##ava	O
##ila	O
##bility	O
,	O
particularly	O
within	O
secondary	O
prevention	O
patients	O
.	O

We	O
found	O
positive	O
correlation	O
##s	O
for	O
C	B
##ML	I
and	O
CE	O
##L	O
(	O
r	O
=	O
0	O
.	O
74	O
)	O
,	O
3	O
-	O
D	O
##Ps	O
and	O
3	O
-	O
D	O
##F	O
(	O
r	O
=	O
0	O
.	O
48	O
)	O
,	O
MG	O
##H1	O
and	O
C	B
##ML	I
(	O
r	O
=	O
0	O
.	O
38	O
)	O
as	O
well	O
as	O
Met	O
##SO	O
and	O
Fr	O
##u	O
##L	O
##ys	O
(	O
r	O
=	O
0	O
.	O
29	O
)	O
,	O
whereas	O
a	O
negative	O
correlation	O
was	O
observed	O
for	O
Fr	O
##u	O
##L	O
##ys	O
and	O
MG	O
##H1	O
(	O
r	O
=	O
-	O
0	O
.	O
32	O
)	O
.	O

The	O
dried	O
samples	O
were	O
di	O
##lut	O
##ed	O
in	O
is	B
##op	I
##rop	I
##ano	I
##l	I
(	O
IPA	O
)	O
/	O
Me	O
##OH	O
/	O
CH	O
##C	O
##l	O
_	O
3	O
4	O
:	O
2	O
:	O
1	O
(	O
v	O
/	O
v	O
/	O
v	O
)	O
containing	O
7	O
.	O
5	O
m	O
##M	O
am	B
##mon	I
##ium	I
format	I
##e	I
and	O
30	O
μ	O
##L	O
was	O
placed	O
in	O
a	O
96	O
-	O
well	O
twin	O
.	O
te	O
##c	O
®	O
plate	O
(	O
E	O
##ppe	O
##ndo	O
##rf	O
,	O
Hamburg	O
,	O
Germany	O
)	O
.	O

[	O
Chemical	O
En	O
##ti	O
##ties	O
of	O
Biological	O
Interest	O
(	O
CH	O
##E	O
##BI	O
)	O
:	O
64	O
##55	O
##2	O
)	O
,	O
β	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
(	O
CH	O
##E	O
##BI	O
:	O
370	O
##5	O
##4	O
)	O
,	O
is	B
##ole	I
##uc	I
##ine	I
(	O
CH	O
##E	O
##BI	O
:	O
171	O
##9	O
##1	O
)	O
,	O
la	B
##ct	I
##ate	I
(	O
CH	O
##E	O
##BI	O
:	O
75	O
##22	O
##8	O
)	O
,	O
le	B
##uc	I
##ine	I
(	O
CH	O
##E	O
##BI	O
:	O
250	O
##17	O
)	O
,	O
and	O
v	B
##ali	I
##ne	I
(	O
CH	O
##E	O
##BI	O
:	O
272	O
##6	O
##6	O
)	O
.	O

A	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
and	O
amino	O
acids	O
were	O
then	O
analyzed	O
by	O
tandem	O
mass	O
s	O
##pect	O
##rome	O
##try	O
(	O
MS	O
/	O
MS	O
)	O
using	O
a	O
Q	O
##ua	O
##tt	O
##ro	O
Micro	O
instrument	O
(	O
Waters	O
Corporation	O
,	O
Milford	O
,	O
MA	O
)	O
.	O

S	O
##pear	O
##man	O
correlation	O
##s	O
of	O
serum	O
a	B
##rg	I
##ini	I
##ne	I
or	O
p	B
##oly	I
##amine	I
(	I
put	I
##res	I
##cine	I
and	O
sperm	B
##ine	I
)	I
levels	O
with	O
clinical	O
parameters	O
related	O
to	O
T	O
##2	O
##D	O
.	O
Line	O
##ar	O
re	O
##gression	O
analysis	O
with	O
H	O
##b	O
##A	O
##1	O
##c	O
as	O
the	O
dependent	O
variable	O
,	O
and	O
gender	O
,	O
age	O
and	O
put	B
##res	I
##cine	I
as	O
independent	O
parameters	O
.	O

f	O
##ow	O
##ler	O
##i	O
with	O
p	B
##osa	I
##cona	I
##zo	I
##le	I
,	O
the	O
cumulative	O
content	O
of	O
the	O
14	B
##α	I
-	I
met	I
##hyl	I
##ster	I
##ols	I
,	O
including	O
12	O
,	O
14	O
,	O
16	O
,	O
19	O
,	O
20	O
,	O
21	O
and	O
22	O
,	O
increased	O
from	O
6	O
.	O
5	O
%	O
to	O
49	O
.	O
1	O
%	O
,	O
with	O
the	O
major	O
intermediate	O
being	O
31	B
-	I
nor	I
##lan	I
##ost	I
##ero	I
##l	I
(	O
14	O
)	O
followed	O
by	O
its	O
C	O
##24	O
-	O
C	O
##25	O
hydrogen	O
##ated	O
product	O
,	O
4	B
,	I
14	I
-	I
dim	I
##eth	I
##yl	I
##cho	I
##les	I
##t	I
-	I
8	I
-	I
en	I
##ol	I
(	O
12	O
)	O
.	O

Hip	B
##pura	I
##te	I
and	O
3	B
-	I
(	I
3	I
-	I
h	I
##ydro	I
##xy	I
##phe	I
##ny	I
##l	I
)	I
-	I
3	I
-	I
h	I
##ydro	I
##xy	I
##p	I
##rop	I
##ion	I
##ate	I
were	O
ex	O
##cre	O
##ted	O
in	O
higher	O
concentrations	O
in	O
co	O
##lon	O
cancer	O
patients	O
,	O
whereas	O
the	O
opposite	O
was	O
true	O
for	O
c	B
##is	I
-	I
a	I
##con	I
##itic	I
acid	I
,	O
p	B
##yr	I
##og	I
##lut	I
##ama	I
##te	I
,	O
4	B
-	I
h	I
##ydro	I
##xy	I
-	I
3	I
-	I
met	I
##ho	I
##xy	I
-	I
man	I
##dela	I
##te	I
and	O
two	O
unidentified	O
meta	O
##bol	O
##ites	O
.	O

In	O
addition	O
,	O
the	O
levels	O
of	O
he	B
##xa	I
##nal	I
,	O
he	B
##pta	I
##non	I
##e	I
and	O
nap	B
##ht	I
##hale	I
##ne	I
were	O
significantly	O
increased	O
in	O
CH	O
##B	O
patients	O
comparing	O
with	O
control	O
subjects	O
.	O

Our	O
study	O
shows	O
that	O
plasma	O
AD	B
##MA	I
is	O
significantly	O
elevated	O
in	O
patients	O
with	O
RA	O
compared	O
with	O
control	O
subjects	O
;	O
in	O
future	O
larger	O
studies	O
,	O
we	O
will	O
include	O
end	O
##oth	O
##eli	O
##al	O
function	O
and	O
determine	O
the	O
relationship	O
of	O
AD	B
##MA	I
/	O
SD	O
##MA	O
and	O
end	O
##oth	O
##eli	O
##al	O
function	O
in	O
an	O
RA	O
group	O
.	O

The	O
p	O
##oly	O
##aro	O
##matic	O
m	O
##oi	O
##ety	O
present	O
as	O
the	O
R	O
_	O
2	O
group	O
in	O
1	O
##a	O
-	O
a	O
was	O
shown	O
by	O
crystal	O
##log	O
##raphy	O
to	O
exhibit	O
π	O
-	O
stack	O
##ing	O
with	O
up	O
to	O
three	O
a	O
##romatic	O
residues	O
of	O
the	O
B	O
.	O
ant	B
##hra	I
##cis	I
N	O
##M	O
##NA	O
##T	O
in	O
the	O
ni	O
##cot	O
##ino	O
##sy	O
##l	O
binding	O
pocket	O
.	O

D	O
-	O
amino	O
acids	O
of	O
primary	O
am	O
##ines	O
el	O
##uted	O
earlier	O
than	O
their	O
en	O
##anti	O
##omer	O
##s	O
,	O
whereas	O
L	O
-	O
amino	O
acids	O
of	O
a	O
secondary	O
am	O
##ine	O
,	O
such	O
as	O
pro	B
##line	I
,	O
el	O
##uted	O
earlier	O
than	O
its	O
en	O
##anti	O
##omer	O
##s	O
.	O

Changes	O
in	O
lip	O
##ids	O
,	O
glucose	S
,	O
p	B
##yr	I
##u	I
##vate	I
,	O
la	B
##ct	I
##ate	I
,	O
al	B
##ani	I
##ne	I
and	O
g	B
##lut	I
##amine	I
suggest	O
shifts	O
in	O
energy	O
metabolism	O
.	O

The	O
results	O
showed	O
that	O
the	O
development	O
process	O
of	O
lung	O
cancer	O
was	O
closely	O
related	O
to	O
potential	O
biological	O
markers	O
,	O
including	O
hip	B
##pura	I
##te	I
,	O
go	O
##ur	O
##d	O
t	B
##rig	I
##one	I
##llin	I
##e	I
,	O
β	B
-	I
h	I
##ydro	I
##xy	I
##is	I
##ova	I
##ler	I
##ic	I
acid	I
,	O
α	B
-	I
h	I
##ydro	I
##xy	I
##is	I
##ob	I
##ut	I
##yric	I
acid	I
,	O
N	B
-	I
ace	I
##g	I
##lut	I
##ami	I
##de	I
,	O
and	O
c	B
##rea	I
##tine	I
an	I
##hy	I
##dr	I
##ide	I
.	O

Given	O
the	O
disappearance	O
of	O
this	O
strong	O
association	O
in	O
the	O
longitudinal	O
analyses	O
an	O
altering	O
effect	O
of	O
t	B
##rig	I
##one	I
##llin	I
##e	I
in	O
the	O
conversion	O
or	O
clearance	O
of	O
T	O
##H	O
is	O
likely	O
.	O

Similarly	O
,	O
12	B
-	I
H	I
##SA	I
-	I
T	I
##MS	I
yielded	O
the	O
m	O
/	O
z	O
73	O
fragment	O
and	O
two	O
diagnostic	O
fragments	O
at	O
m	O
/	O
z	O
187	O
and	O
301	O
(	O
B	O
,	O
noted	O
in	O
blue	O
)	O
.	O

We	O
believe	O
that	O
the	O
meta	O
##bol	O
##ite	O
identified	O
in	O
this	O
study	O
represents	O
met	O
##hyl	O
-	O
h	O
##ydro	O
##xy	O
##lation	O
of	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
.	O

L	B
##ys	I
##o	I
##PC	I
(	I
16	I
:	I
0	I
)	I
by	O
itself	O
increases	O
on	O
brain	O
after	O
stroke	O
where	O
it	O
media	O
##tes	O
p	O
##ha	O
##go	O
##cy	O
##te	O
recruiting	O
that	O
can	O
contribute	O
to	O
is	O
##che	O
##mic	O
brain	O
injury	O
and	O
also	O
produces	O
ne	O
##uro	O
##in	O
##f	O
##lam	O
##mat	O
##ory	O
effects	O
when	O
applied	O
on	O
C	O
##NS	O
.	O

In	O
the	O
end	O
,	O
one	O
hundred	O
and	O
fifty	O
micro	O
##lit	O
##res	O
of	O
n	B
-	I
he	I
##pta	I
##ne	I
was	O
employed	O
to	O
stop	O
the	O
reaction	O
.	O

From	O
protein	O
breakdown	O
L	B
-	I
v	I
##ali	I
##ne	I
is	O
generated	O
and	O
finally	O
su	B
##cci	I
##ny	I
##l	I
-	I
Co	I
##A	I
appears	O
to	O
contribute	O
to	O
the	O
c	B
##it	I
##ric	I
acid	I
cycle	O
in	O
muscle	O
.	O

The	O
ch	B
##lor	I
##of	I
##orm	I
layer	O
was	O
then	O
dried	O
over	O
Na	O
_	O
2	O
S	O
##O	O
_	O
4	O
and	O
concentrated	O
under	O
diminished	O
pressure	O
to	O
obtain	O
the	O
crude	O
diet	B
##hyl	I
α	I
-	I
ni	I
##cot	I
##in	I
##yl	I
su	I
##cci	I
##nate	I
as	O
a	O
brown	O
oil	O
.	O

Instead	O
,	O
est	B
##rogen	I
metabolism	O
and	O
signaling	O
,	O
p	O
##oly	O
##mor	O
##phism	O
##s	O
in	O
the	O
est	B
##rogen	I
receptor	O
-	O
2	O
gene	O
and	O
the	O
time	O
of	O
men	O
##op	O
##aus	O
##e	O
are	O
known	O
to	O
be	O
related	O
to	O
the	O
occurrence	O
of	O
T	O
##AM	O
-	O
induced	O
hot	O
flashes	O
.	O

As	O
shown	O
in	O
,	O
all	O
different	O
##iating	O
PC	O
species	O
were	O
found	O
up	O
-	O
regulated	O
in	O
the	O
BC	O
##P	O
group	O
,	O
including	O
some	O
already	O
reported	O
as	O
PC	B
(	I
32	I
:	I
1	I
)	I

I	O
##dent	O
##ification	O
of	O
h	B
##ydro	I
##xy	I
##cho	I
##les	I
##ten	I
##oi	I
##c	I
and	O
h	B
##ydro	I
##xy	I
##ox	I
##och	I
##ole	I
##sten	I
##oi	I
##c	I
acids	I
in	O
CS	O
##F	O
.	O

Met	O
##S	O
_	O
any	O
women	O
had	O
higher	O
levels	O
of	O
his	B
##ti	I
##dine	I
and	O
l	B
##ys	I
##ine	I
and	O
lower	O
levels	O
of	O
se	B
##rine	I
,	O
c	B
##rea	I
##tin	I
##ine	I
,	O
my	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
,	O
a	B
##rg	I
##ini	I
##ne	I
,	O
ace	B
##to	I
##ace	I
##tate	I
and	O
beta	B
##ine	I
compared	O
with	O
Met	O
##S	O
_	O
zero	O
women	O
.	O

The	O
super	O
##nat	O
##ant	O
was	O
transferred	O
into	O
a	O
250	O
μ	O
##l	O
p	B
##oly	I
##p	I
##rop	I
##yle	I
##ne	I
auto	O
##sa	O
##mple	O
##r	O
via	O
##l	O
,	O
sealed	O
with	O
a	O
Te	O
##f	O
##lon	O
c	O
##rim	O
##p	O
cap	O
.	O

H	B
##y	I
##pot	I
##au	I
##rine	I
,	O
g	B
##uan	I
##os	I
##ine	I
,	O
and	O
2	B
-	I
amino	I
##oc	I
##tano	I
##ic	I
acid	I
were	O
not	O
found	O
to	O
be	O
significantly	O
differential	O
##ly	O
expressed	O
in	O
D	O
##OC	O
##K	O
##8	O
deficiency	O
compared	O
with	O
AD	O
after	O
using	O
one	O
-	O
way	O
analysis	O
of	O
variance	O
(	O
AN	O
##O	O
##VA	O
)	O
/	O
post	O
-	O
Tu	O
##key	O
’	O
s	O
method	O
(	O
G	O
–	O
I	O
)	O
.	O

The	O
treatment	O
was	O
a	O
single	O
injection	O
of	O
10	O
mg	O
vitamin	O
B	O
-	O
12	O
with	O
100	O
mg	O
p	B
##yr	I
##ido	I
##xin	I
##e	I
and	O
100	O
mg	O
th	B
##iam	I
##in	I
.	O

B	O
##MI	O
Body	O
mass	O
index	O
,	O
ER	O
:	O
E	O
##stro	O
##gen	O
receptors	O
,	O
P	O
##g	O
##R	O
:	O
pro	B
##ges	I
##tero	I
##ne	I
receptors	O
.	O

The	O
y	O
-	O
axis	O
shows	O
p	B
##g	I
E	O
##M	O
/	O
mg	O
c	B
##rea	I
##tin	I
##ine	I
on	O
a	O
log	O
##ari	O
##th	O
##mic	O
scale	O
.	O

V	O
##arian	O
##ce	O
(	O
Co	O
##V	O
±	O
95	O
%	O
confidence	O
interval	O
)	O
was	O
much	O
lower	O
in	O
Me	B
##OH	I
:	O

Furthermore	O
,	O
A	O
##F	O
##4	O
separation	O
##s	O
are	O
performed	O
in	O
a	O
50	O
m	O
##M	O
phosphate	S
buffer	O
which	O
is	O
preferred	O
for	O
biological	O
systems	O
(	O
rather	O
than	O
the	O
3	O
M	O
K	O
##B	O
##r	O
used	O
in	O
UC	O
lip	O
##op	O
##rote	O
##in	O
isolation	O
)	O
.	O

We	O
report	O
here	O
,	O
a	O
simple	O
,	O
specific	O
,	O
and	O
re	O
##p	O
##rod	O
##uc	O
##ible	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
method	O
for	O
the	O
q	O
##uant	O
##ification	O
of	O
pro	B
##line	I
in	O
human	O
serum	O
was	O
as	O
a	O
potential	O
screening	O
bio	O
##mark	O
##er	O
for	O
es	O
##op	O
##hage	O
##al	O
cancer	O
.	O

Also	O
,	O
in	O
certain	O
cancer	O
cells	O
with	O
mitochondrial	O
d	O
##ys	O
##function	O
,	O
α	B
-	I
k	I
##eto	I
##g	I
##lut	I
##arate	I
can	O
be	O
car	O
##box	O
##yla	O
##ted	O
to	O
produce	O
is	B
##oc	I
##it	I
##rate	I
,	O
c	B
##it	I
##rate	I
,	O
and	O
ace	B
##ty	I
##l	I
-	I
Co	I
##A	I
.	O

Using	O
PC	B
18	I
:	I
1	I
/	I
16	I
:	I
0	I
as	O
a	O
model	O
compound	O
(	O
10	O
μ	O
##M	O
,	O
50	O
/	O
50	O
,	O
v	O
/	O
v	O
,	O
ace	O
##tone	O
/	O
H	O
_	O
2	O
O	O
with	O
5	O
m	O
##M	O
NH	O
_	O
4	O
HC	O
##O	O
_	O
3	O
)	O
,	O
the	O
solution	O
was	O
subjected	O
to	O
off	O
##line	O
P	O
##B	O
reaction	O
and	O
collected	O
for	O
na	O
##no	O
##ES	O
##I	O
in	O
negative	O
ion	O
mode	O
(	O
experimental	O
details	O
are	O
provided	O
in	O
the	O
E	O
##SI	O
_	O
†	O
)	O
.	O

However	O
,	O
suggest	O
that	O
although	O
co	B
##tin	I
##ine	I
has	O
been	O
used	O
extensively	O
as	O
a	O
ni	B
##cot	I
##ine	I
marker	O
in	O
the	O
urine	O
of	O
both	O
active	O
and	O
passive	O
smoke	O
##rs	O
,	O
trans	B
-	I
3	I
′	I
-	I
h	I
##ydro	I
##xy	I
##cot	I
##ini	I
##ne	I
is	O
the	O
predominant	O
ni	B
##cot	I
##ine	I
meta	O
##bol	O
##ite	O
,	O
corresponding	O
to	O
40	O
%	O
of	O
the	O
total	O
ni	B
##cot	I
##ine	I
ex	O
##cre	O
##tion	O
and	O
is	O
better	O
used	O
alongside	O
co	B
##tin	I
##ine	I
when	O
monitoring	O
passive	O
ET	O
##S	O
exposure	O
.	O

Li	O
##pid	O
##s	O
are	O
a	O
group	O
of	O
naturally	O
occurring	O
molecules	O
such	O
as	O
types	O
of	O
vitamin	O
##s	O
,	O
mon	B
##og	I
##ly	I
##cer	I
##ides	I
,	O
and	O
others	O
.	O

Un	O
##iva	O
##ria	O
##te	O
and	O
multi	O
##var	O
##iate	O
log	O
##istic	O
re	O
##gression	O
model	O
analyses	O
were	O
performed	O
to	O
identify	O
the	O
relevant	O
s	B
##phi	I
##ngo	I
##lip	I
##id	I
meta	O
##bol	O
##ites	O
in	O
patients	O
with	O
T	O
##2	O
##DM	O
.	O

One	O
of	O
the	O
significant	O
meta	O
##bol	O
##ites	O
(	O
p	O
##os	O
_	O
2	O
.	O
61	O
_	O
127	O
.	O
03	O
##8	O
##2	O
##m	O
/	O
z	O
)	O
was	O
identified	O
as	O
5	B
-	I
met	I
##hyl	I
-	I
2	I
-	I
fur	I
##oi	I
##c	I
acid	I
based	O
on	O
its	O
fragment	O
##ation	O
pattern	O
by	O
tandem	O
mass	O
s	O
##pect	O
##rome	O
##try	O
(	O
e	O
##T	O
##able	O
4	O
in	O
the	O
)	O
.	O

_	O
13	O
C	B
,	I
d	I
_	I
3	I
-	I
di	I
##os	I
##met	I
##in	I

Mobile	O
phases	O
were	O
mill	O
##i	O
-	O
Q	O
water	O
(	O
A	O
)	O
and	O
HP	O
##LC	O
-	O
grade	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
(	O
B	O
)	O
,	O
and	O
each	O
phase	O
contained	O
0	O
.	O
2	O
%	O
form	B
##ic	I
acid	I
;	O
the	O
gradient	O
used	O
for	O
meta	O
##bol	O
##ites	O
separation	O
was	O
0	O
minutes	O
,	O
0	O
%	O
B	O
;	O
0	O
.	O
5	O
minutes	O
,	O
0	O
%	O
B	O
;	O
5	O
.	O
5	O
minutes	O
,	O
95	O
%	O
B	O
;	O
6	O
.	O
5	O
minutes	O
,	O
95	O
%	O
B	O
;	O
7	O
minutes	O
,	O
0	O
%	O
B	O
;	O
9	O
.	O
5	O
minutes	O
,	O
0	O
%	O

This	O
receptor	O
has	O
the	O
same	O
affinity	O
as	O
the	O
classical	O
receptor	O
and	O
also	O
binds	O
ta	B
##mo	I
##xi	I
##fen	I
.	O

It	O
is	O
known	O
that	O
mothers	O
can	O
become	O
h	B
##y	I
##po	I
##gly	I
##ce	I
##mic	I
even	O
though	O
their	O
g	O
##lu	O
##con	O
##eo	O
##genesis	O
rates	O
are	O
increased	O
.	O

We	O
used	O
L	O
##C	O
MR	O
##M	O
-	O
MS	O
/	O
MS	O
methodology	O
to	O
analyze	O
the	O
serum	O
extract	O
##s	O
because	O
it	O
offers	O
high	O
sensitivity	O
,	O
re	O
##p	O
##rod	O
##uc	O
##ibility	O
,	O
and	O
select	O
##ivity	O
to	O
analyze	O
small	O
molecules	O
,	O
including	O
the	O
compounds	O
targeted	O
in	O
this	O
report	O
[	O
–	O
]	O
.	O
and	O
present	O
the	O
op	O
##ti	O
##mized	O
MR	O
##M	O
parent	O
ions	O
in	O
Q	O
##1	O
sector	O
,	O
signature	O
daughter	O
ions	O
in	O
Q	O
##3	O
sector	O
,	O
cone	O
voltage	O
##s	O
,	O
collision	O
voltage	O
##s	O
,	O
and	O
L	O
##C	O
MR	O
##M	O
-	O
MS	O
/	O
MS	O
retention	O
times	O
for	O
each	O
compound	O
that	O
,	O
together	O
,	O
yielded	O
the	O
best	O
sensitivity	O
and	O
re	O
##p	O
##rod	O
##uc	O
##ibility	O
in	O
analysis	O
of	O
inflammation	O
-	O
re	O
##sol	O
##ving	O
re	O
##sol	O
##vin	O
D	O
series	O
and	O
lip	B
##ox	I
##in	I
A	O
_	O
4	O
,	O
as	O
well	O
as	O
their	O
respective	O
precursor	O
##s	O
D	O
##HA	O
and	O
AA	O
.	O

β	B
-	I
act	I
##in	I
and	O
His	O
##tone	O
(	O
H	O
)	O
3	O
were	O
used	O
as	O
an	O
internal	O
control	O
.	O

H	B
##y	I
##pox	I
##ant	I
##hine	I
is	O
involved	O
in	O
the	O
pu	B
##rine	I
metabolism	O
pathway	O
.	O

T	B
##G	I
,	O
t	B
##rig	I
##ly	I
##cer	I
##ide	I
;	O
Total	O
-	O
C	O
,	O
total	O
ch	B
##ole	I
##ster	I
##ol	I
;	O
HD	O
##L	O
-	O
C	O
,	O
high	O
-	O
density	O
lip	O
##op	O
##rote	O
##in	O
ch	B
##ole	I
##ster	I
##ol	I
;	O
L	O
##D	O
##L	O
-	O
C	O
,	O
low	O
-	O
density	O
lip	O
##op	O
##rote	O
##in	O
ch	B
##ole	I
##ster	I
##ol	I
;	O
CR	O
##P	O
,	O
C	O
-	O
reactive	O
protein	O
.	O

Further	O
a	O
##ber	O
##rations	O
in	O
lip	O
##id	O
metabolism	O
were	O
witnessed	O
through	O
strong	O
elevations	O
in	O
bi	O
##le	O
acids	O
T	O
##CD	O
##CA	O
,	O
T	O
##CA	O
,	O
G	B
##HC	I
##A	I
and	O
G	O
##CA	O
in	O
DC	O
vs	O
.	O
NH	O
##C	O
.	O

We	O
observed	O
here	O
SM	B
(	I
36	I
:	I
3	I
)	I
as	O
a	O
marker	O
of	O
T	O
##FA	O
intake	O
.	O

A	O
##bb	O
##re	O
##viation	O
##s	O
used	O
:	O
AL	O
##T	O
,	O
al	O
##ani	O
##ne	O
amino	O
##tra	O
##ns	O
##fer	O
##ase	O
;	O
AS	O
##T	O
,	O
as	O
##par	O
##tate	O
amino	O
##tra	O
##ns	O
##fer	O
##ase	O
;	O
Score	O
,	O
the	O
first	O
de	O
##com	O
##posed	O
principal	O
component	O
derived	O
from	O
the	O
abundance	O
of	O
the	O
five	O
AA	O
##s	O
;	O
D	O
##M	O
,	O
over	O
##weight	O
or	O
o	O
##besity	O
with	O
type	O
2	O
diabetes	O
;	O
D	O
##P	O
,	O
di	O
##ast	O
##olic	O
blood	O
pressure	O
;	O
γ	B
-	I
GT	I
,	O
gamma	O
-	O
g	O
##lut	O
##am	O
##yl	O
trans	O
-	O
su	O
##pe	O
##pt	O
##idas	O
##e	O
;	O
G	B
##lu	I
##cos	I
##e	I
##0	I
,	O
fast	O
##ing	O
glucose	S
;	O
G	O
##lu	O
##cos	O
##e	O
##12	O
##0	O
,	O
2	O
h	O
glucose	S
;	O
HD	O
##L	O
,	O
high	O
-	O
density	O
lip	B
##op	I
##rote	I
##in	I
-	I
ch	I
##ole	I
##ster	I
##ol	I
;	O
H	B
##L	I
,	O
healthy	O
lean	O
;	O
H	B
##OM	I
##A	I
-	I
Beta	I
=	I
20	I
*	I
IN	I
##S	I
##0	I
/	I
(	I
G	I
##lu	I
##cos	I
##e	I
##0	I
-	I
3	I
.	I
5	I
)	I
;	O
H	O
##OM	O
##A	O
-	O
I	O
##R	O
=	O
G	O
##lu	O
##cos	O
##e	O
##0	O
*	O
G	O
##lu	O
##cos	O
##e	O
##12	O
##0	O
/	O
22	O
.	O
5	O
;	O
IN	O
##S	O
##0	O
,	O
fast	O
##ing	O
insulin	O
;	O
IN	O
##S	O
##12	O
##0	O
,	O
2	O
h	O
insulin	O
;	O
Is	O
##ole	O
##u	O
,	O
is	B
##ole	I
##uc	I
##ine	I
;	O
L	O
##D	O
##L	O
,	O
low	O
-	O
density	O
lip	B
##op	I
##rote	I
##in	I
-	I
ch	I
##ole	I
##ster	I
##ol	I
;	O

We	O
already	O
observed	O
in	O
our	O
previous	O
study	O
on	O
a	O
healthy	O
population	O
that	O
3	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##ira	I
##te	I
is	O
more	O
connected	O
in	O
younger	O
people	O
;	O
thus	O
,	O
we	O
can	O
h	O
##y	O
##pot	O
##hes	O
##ize	O
that	O
the	O
pattern	O
of	O
connections	O
of	O
this	O
meta	O
##bol	O
##ite	O
is	O
directly	O
influenced	O
by	O
aging	O
.	O

The	O
specific	O
decrease	O
of	O
serum	O
th	B
##re	I
##oni	I
##ne	I
and	O
his	B
##ti	I
##dine	I
levels	O
observed	O
in	O
N	O
##SC	O
##LC	O
patients	O
,	O
compared	O
with	O
healthy	O
individuals	O
,	O
most	O
probably	O
reflects	O
the	O
up	O
-	O
regulation	O
of	O
the	O
g	O
##ly	O
##cine	O
/	O
se	O
##rine	O
/	B
th	B
##re	I
##oni	I
##ne	I
and	O
p	B
##yr	I
##im	I
##id	I
##ine	I
metabolic	O
pathways	O
,	O
respectively	O
,	O
that	O
have	O
been	O
described	O
as	O
metabolic	O
hall	O
##marks	O
of	O
N	O
##SC	O
##LC	O
tumor	O
-	O
in	O
##iti	O
##ating	O
cells	O
.	O

The	O
most	O
significant	O
decreases	O
in	O
the	O
post	O
-	O
part	O
##um	O
period	O
were	O
obviously	O
observed	O
for	O
17	B
-	I
OH	I
##P	I
,	O
PR	O
##O	O
##G	O
,	O
E	O
##2	O
,	O
E	O
##1	O
,	O
and	O
,	O
surprisingly	O
,	O
also	O
for	O
CO	O
##RT	O
,	O
as	O
highlighted	O
in	O
and	O
in	O
.	O

For	O
test	B
##osterone	I
,	O
relationships	O
with	O
body	O
mass	O
index	O
and	O
age	O
were	O
gender	O
specific	O
.	O

Am	B
##mon	I
##ium	I
format	I
##e	I
(	O
purity	O
>	O
99	O
.	O
0	O
%	O
)	O
was	O
purchased	O
from	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
(	O
Vienna	O
,	O
Austria	O
)	O
.	O

Ser	O
##um	O
branched	O
chain	O
amino	O
acids	O
,	O
2	B
‐	I
amino	I
##but	I
##yra	I
##te	I
,	O
but	B
##yra	I
##te	I
,	O
2	B
‐	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
,	O
3	B
‐	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
,	O
ace	B
##tone	I
,	O
2	B
‐	I
met	I
##hyl	I
##g	I
##lut	I
##arate	I
,	O
and	O
2	B
‐	I
o	I
##x	I
##ois	I
##oc	I
##ap	I
##roa	I
##te	I
were	O
significantly	O
reduced	O
,	O
while	O
serum	O
al	B
##ani	I
##ne	I
,	O
g	B
##ly	I
##cine	I
,	O
p	B
##yr	I
##u	I
##vate	I
,	O
and	O
ta	B
##uri	I
##ne	I
were	O
significantly	O
elevated	O
at	O
6	O
months	O
post	O
‐	O
surgery	O
compared	O
with	O
pre	O
‐	O
surgery	O
(	O
n	O

Met	O
##ab	O
##oli	O
##tes	O
have	O
a	O
wide	O
range	O
of	O
functional	O
groups	O
are	O
present	O
from	O
volatile	O
alcohol	O
##s	O
,	O
k	B
##eton	I
##es	I
,	O
am	O
##ines	O
,	O
organic	O
acids	O
to	O
complex	O
lip	O
##ids	O
,	O
car	O
##bo	O
##hy	O
##dra	O
##tes	O
and	O
other	O
secondary	O
meta	O
##bol	O
##ites	O
.	O

As	O
sur	O
##rogate	O
marker	O
of	O
insulin	O
resistance	O
,	O
the	O
home	O
##ost	O
##asis	O
model	O
assessment	O
-	O
insulin	O
resistance	O
(	O
H	O
##OM	O
##A	O
-	O
I	O
##R	O
)	O
was	O
calculated	O
as	O
fast	O
##ing	O
glucose	S
(	O
mm	O
##ol	O
/	O
L	O
)	O
*	O
fast	O
##ing	O
insulin	O
(	O
μ	O
##U	O
/	O
m	O
##l	O
)	O
/	O
22	O
.	O
5	O
.	O

They	O
observed	O
that	O
plasma	O
al	B
##ani	I
##ne	I
levels	O
were	O
lowered	O
in	O
E	O
##BC	O
patients	O
compared	O
to	O
healthy	O
controls	O
and	O
especially	O
in	O
patients	O
bearing	O
the	O
aggressive	O
T	O
##R	O
##N	O
tumors	O
.	O

Ph	B
##os	I
##ph	I
##oli	I
##pid	I
##s	I
analysis	O
of	O
He	O
##p	O
##G	O
##2	O
and	O
He	O
##p	O
##G	O
##2	O
.	O
2	O
.	O
15	O
cells	O
.	O

Form	B
##ate	I
,	O
the	O
product	O
of	O
sugar	O
u	O
##til	O
##ization	O
of	O
En	O
##tero	O
##co	O
##cc	O
##us	O
ca	O
##ssel	O
##if	O
##lav	O
##us	O
,	O
was	O
significantly	O
increased	O
along	O
with	O
the	O
progression	O
;	O
more	O
##over	O
,	O
it	O
up	O
##re	O
##gu	O
##lated	O
21	O
.	O
48	O
folds	O
in	O
stage	O
IV	O
compared	O
to	O
normal	O
m	O
##uc	O
##osa	O
##e	O
.	O

Mass	O
transitions	O
29	O
##7	O
>	O
121	O
m	O
/	O
z	O
,	O
300	O
>	O
121	O
m	O
/	O
z	O
,	O
29	O
##9	O
>	O
135	O
m	O
/	O
z	O
,	O
302	O
>	O
135	O
m	O
/	O
z	O
,	O
47	O
##5	O
>	O
281	O
m	O
/	O
z	O
,	O
and	O
47	O
##8	O
>	O
28	O
##4	O
m	O
/	O
z	O
were	O
monitored	O
for	O
ex	O
##em	O
##esta	O
##ne	O
,	O
ex	B
##em	I
##esta	I
##ne	I
-	I
d	I
##3	I
,	I
17	I
##β	I
-	I
di	I
##hy	I
##dr	I
##oe	I
##xe	I
##mes	I
##tan	I
##e	I
,	O
17	B
##β	I
-	I
di	I
##hy	I
##dr	I
##oe	I
##xe	I
##mes	I
##tan	I
##e	I
-	I
d	I
##3	I
,	I
17	I
##β	I
-	I
di	I
##hy	I
##dr	I
##oe	I
##xe	I
##mes	I
##tan	I
##e	I
-	I
17	I
-	I
O	I
-	I
β	I
-	I
D	I
-	I
g	I
##lu	I
##cu	I
##ron	I
##ide	I
,	O
and	O
17	B
##β	I
-	I
di	I
##hy	I
##dr	I
##oe	I
##xe	I
##mes	I
##tan	I
##e	I
-	I
17	I
-	I
O	I
-	I
β	I
-	I
D	I
-	I
g	I
##lu	I
##cu	I
##ron	I
##ide	I
-	I
d	I
##3	I
respectively	O
.	O

[	O
,	O
]	O
,	O
the	O
dim	O
##eric	O
p	B
##yr	I
##u	I
##vate	I
kinase	O
muscle	O
is	O
##oz	O
##yme	O
2	O
(	O
P	O
##K	O
##M	O
##2	O
)	O
,	O
car	O
##ni	O
##tine	O
palm	O
##ito	O
##yl	O
##tra	O
##ns	O
##fer	O
##ase	O
1A	O
(	O
CP	O
##T	O
##1	O
##A	O
)	O
and	O
g	O
##lut	O
##ama	O
##te	O
de	O
##car	O
##box	O
##yla	O
##se	O
1	O
(	O
GA	O
##D	O
##1	O
)	O
,	O
was	O
examined	O
in	O
the	O
tumor	O
and	O
NC	O
tissues	O
.	O

Of	O
the	O
meta	O
##bol	O
##ites	O
listed	O
in	O
the	O
top	O
20	O
mean	O
ranks	O
,	O
many	O
could	O
be	O
identified	O
,	O
some	O
of	O
which	O
have	O
also	O
been	O
described	O
by	O
others	O
:	O
in	O
plasma	O
,	O
c	B
##rea	I
##tin	I
##ine	I
[	O
,	O
]	O
,	O
v	B
##ali	I
##ne	I
[	O
,	O
,	O
]	O
,	O
le	B
##uc	I
##ine	I
[	O
,	O
,	O
]	O
,	O
g	B
##ly	I
##cine	I
,	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
C	I
##18	I
:	I
1	I
,	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
C	I
##16	I
:	I
1	I
,	O
and	O
u	B
##ric	I
acid	I
,	O
in	O
urine	O
,	O
c	B
##rea	I
##tin	I
##ine	I
[	O
,	O
]	O
,	O
c	B
##it	I
##rate	I
,	O
4	B
-	I
de	I
##ox	I
##yt	I
##hr	I
##eon	I
##ic	I
acid	I
,	O
3	B
-	I
in	I
##dox	I
##yl	I
##sul	I
##fa	I
##te	I
[	O
,	O
]	O
,	O
α	B
-	I
k	I
##eto	I
##g	I
##lut	I
##ari	I
##c	I
acid	I
,	O
and	O
g	B
##lu	I
##con	I
##ic	I
acid	I
could	O
be	O
identified	O
.	O

Only	O
the	O
use	O
of	O
ethanol	B
##amine	I
as	O
a	O
single	O
screening	O
test	O
showed	O
a	O
higher	O
accuracy	O
in	O
distinguishing	O
long	O
-	O
term	O
from	O
short	O
-	O
term	O
survivors	O
.	O

The	O
median	O
levels	O
were	O
290	O
##0	O
pm	O
##ol	O
/	O
mg	O
c	B
##rea	I
##tin	I
##ine	I
in	O
smoke	O
##rs	O
and	O
68	O
##3	O
pm	O
##ol	O
/	O
mg	O
c	B
##rea	I
##tin	I
##ine	I
in	O
non	O
-	O
smoke	O
##rs	O
(	O
P	O
=	O
0	O
.	O
000	O
##2	O
)	O
.	O

The	O
O	O
##asis	O
H	O
##L	O
##B	O
extraction	O
cartridge	O
was	O
pre	O
##con	O
##dition	O
##ed	O
with	O
5	O
m	O
##L	O
of	O
met	B
##han	I
##ol	I
and	O
4	O
m	O
##L	O
of	O
water	O
,	O
500	O
μ	O
##L	O
of	O
serum	O
or	O
CS	O
##F	O
were	O
then	O
loaded	O
,	O
and	O
the	O
el	O
##uen	O
##t	O
without	O
solvent	O
using	O
gravity	O
was	O
used	O
as	O
the	O
ch	O
##ole	O
##ster	O
##ol	O
-	O
stripped	O
sample	O
.	O

B	O
##ile	O
acids	O
serve	O
many	O
important	O
physiological	O
functions	O
,	O
including	O
ch	B
##ole	I
##ster	I
##ol	I
home	O
##ost	O
##asis	O
,	O
lip	O
##id	O
absorption	O
and	O
generation	O
of	O
bi	O
##le	O
flow	O
,	O
that	O
help	O
in	O
the	O
ex	O
##cre	O
##tion	O
and	O
re	O
##ci	O
##rc	O
##ulation	O
of	O
drugs	O
,	O
vitamin	O
##s	O
and	O
end	O
##ogen	O
##ous	O
and	O
ex	O
##ogen	O
##ous	O
to	B
##xin	I
##s	I
.	O

Tan	O
##de	O
##m	O
mass	O
s	O
##pect	O
##ra	O
of	O
an	O
AM	O
##PP	O
-	O
der	O
##iva	O
##tized	O
FA	S
internal	O
standard	O
(	O
i	O
.	O
e	O
.	O
,	O
d	B
_	I
4	I
-	I
16	I
:	I
0	I
FA	O
)	O
demonstrated	O
two	O
major	O
fragment	O
ions	O
present	O
at	O
m	O
/	O
z	O
169	O
and	O
183	O
arising	O
from	O
c	O
##lea	O
##vage	O
of	O
the	O
AM	O
##PP	O
tag	O
(	O
and	O
ins	O
##et	O
)	O
.	O

Each	O
lip	O
##id	O
extract	O
was	O
di	O
##lut	O
##ed	O
with	O
di	O
##ch	O
##lor	O
##ome	O
##than	O
##e	O
/	O
met	O
##han	O
##ol	O
/	O
is	O
##op	O
##rop	O
##ano	O
##l	O
(	O
1	O
:	O
2	O
:	O
4	O
,	O
v	O
/	O
v	O
/	O
v	O
and	O
5	O
m	O
##M	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
)	O
prior	O
to	O
in	O
##fusion	O
into	O
a	O
mass	O
s	O
##pect	O
##rome	O
##ter	O
(	O
MS	O
;	O
Q	O
##TR	O
##AP	O
550	O
##0	O
,	O
Sc	O
##ie	O
##x	O
,	O
USA	O
;	O
equipped	O
with	O
Turbo	O
V	O
E	O
##SI	O
)	O
for	O
the	O
analysis	O
of	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
.	O

Representative	O
box	O
-	O
cum	O
-	O
w	O
##his	O
##ker	O
plots	O
showing	O
quantitative	O
variations	O
of	O
relative	O
signal	O
integral	O
##s	O
for	O
(	O
A	O
)	O
Ace	B
##tate	I
,	O
(	O
B	O
)	O
L	O
##3	O
/	O
L	O
##4	O
,	O
(	O
C	O
)	O
L	O
##5	O
and	O
(	O
D	O
)	O
L	O
##9	O
in	O
L	O
##N	O
,	O
SL	O
##E	O
and	O
HC	O
se	O
##ra	O
.	O

Beta	B
-	I
al	I
##ani	I
##ne	I
is	O
a	O
direct	O
precursor	O
of	O
pan	B
##to	I
##the	I
##nic	I
acid	I
(	O
PA	O
)	O
which	O
is	O
needed	O
for	O
the	O
synthesis	O
of	O
co	O
##en	O
##zy	O
##me	O
A	O
(	O
Co	O
##A	O
)	O
.	O

Clinical	O
and	O
bio	O
##chemical	O
data	O
Sign	O
##ific	O
##ance	O
<	O
0	O
.	O
00	O
##1	O
:	O
‘	O
*	O
*	O
*	O
’	O
,	O
<	O
0	O
.	O
01	O
:	O
‘	O
*	O
*	O
’	O
,	O
<	O
0	O
.	O
05	O
:	O
‘	O
*	O
’	O
_	O
a	O
χ	O
_	O
2	O
test	O
_	O
b	O
Student	O
’	O
s	O
T	O
test	O
_	O
c	O
Mann	O
–	O
Whitney	O
U	O
test	O
_	O
d	O
Cal	O
##culate	O
##d	O
based	O
on	O
serum	O
co	B
##tin	I
##ine	I
levels	O
:	O
80	O
–	O
1000	O
nm	O
##ol	O
/	O
l	O
:	O
moderate	O
smoke	O
##r	O
,	O
>	O
1000	O
nm	O
##ol	O
/	O
l	O
:	O
heavy	O
smoke	O
##r	O
_	O
e	O
Cal	O
##culate	O
##d	O
based	O
on	O
AS	O
##RS	O
scores	O
:	O
A	O
score	O
of	O
21	O
or	O
higher	O
on	O
the	O
nine	O
questions	O
on	O
in	O
##att	O
##ent	O
##ive	O
##ness	O
is	O
in	O
##dicative	O
of	O
in	O
##att	O
##ent	O
##ive	O
type	O
,	O
while	O
a	O
score	O
of	O
21	O
or	O
higher	O
on	O
the	O
h	O
##yper	O
##act	O
##ivity	O
/	O
imp	O
##ul	O
##sive	O
questions	O
is	O
in	O
##dicative	O
for	O
h	O
##yper	O
##active	O
/	O
imp	O
##ul	O
##sive	O
type	O
.	O

The	O
corresponding	O
molecular	O
species	O
P	B
##E	I
16	I
:	I
0	I
/	I
20	I
:	I
4	I
and	O
P	B
##E	I
18	I
:	I
2	I
/	I
18	I
:	I
2	I
were	O
determined	O
by	O
MS	O
/	O
MS	O
##AL	O
##L	O
to	O
2	O
.	O
7	O
and	O
0	O
.	O
5	O
µ	O
##M	O
respectively	O
,	O
which	O
adds	O
up	O
to	O
precisely	O
the	O
same	O
amount	O
as	O
by	O
the	O
Q	O
##q	O
##Q	O
analysis	O
.	O

P	O
##las	O
##ma	O
glucose	S
levels	O
were	O
derived	O
from	O
the	O
collected	O
SC	O
##AN	O
data	O
.	O

,	O
But	B
##yr	I
##iv	I
##ib	I
##rio	I
cross	O
##ot	O
##us	O
)	O
and	O
E	O
##uba	O
##cter	O
##iac	O
##eae	O
(	O
E	O
##uba	O
##cter	O
##ium	O
s	O
##p	O
.	O
)	O
.	O

In	O
all	O
experiments	O
with	O
g	O
##lu	O
##cu	O
##ron	O
##idas	O
##e	O
or	O
g	O
##lu	O
##cu	O
##ron	O
##idas	O
##e	O
+	O
su	O
##lf	O
##ata	O
##se	O
dig	O
##est	O
##ions	O
,	O
a	O
ratio	O
para	B
##ce	I
##tam	I
##ol	I
peak	O
area	O
/	B
d	B
_	I
4	I
-	I
para	I
##ce	I
##tam	I
##ol	I
peak	O
area	O
>	O
0	O
.	O
75	O
(	O
corresponding	O
to	O
a	O
degradation	O
>	O
85	O
%	O
)	O
was	O
selected	O
as	O
threshold	O
to	O
accept	O
the	O
individual	O
samples	O
.	O

Thus	O
,	O
the	O
H	O
##S	O
##Q	O
##C	O
analysis	O
enabled	O
the	O
reconstruction	O
of	O
nitrogen	O
pathway	O
from	O
G	O
##ln	O
to	O
the	O
synthesis	O
of	O
pu	B
##rine	I
bases	O
.	O

The	O
parameters	O
used	O
to	O
accomplish	O
these	O
were	O
:	O
R	O
##T	O
range	O
2	O
.	O
8	O
–	O
34	O
.	O
0	O
min	O
;	O
m	O
/	O
z	O
range	O
50	O
–	O
250	O
;	O
MS	O
data	O
noise	O
level	O
1	O
.	O
0	O
×	O
10	O
_	O
4	O
;	O
m	O
/	O
z	O
tolerance	O
0	O
.	O
5	O
;	O
ch	O
##roma	O
##to	O
##gram	O
base	O
##line	O
level	O
1	O
.	O
0	O
×	O
10	O
_	O
3	O
;	O
peak	O
duration	S
range	O
0	O
.	O
02	O
–	O
0	O
.	O
30	O
min	O
.	O

Data	O
were	O
recorded	O
in	O
positive	O
-	O
and	O
negative	O
-	O
ion	O
modes	O
with	O
broadband	O
mode	O
detection	O
and	O
an	O
F	B
##T	I
acquisition	O
size	O
of	O
1	O
,	O
02	O
##4	O
k	O
##ilo	O
##by	O
##tes	O
per	O
second	O
within	O
a	O
range	O
of	O
m	O
/	O
z	O
150	O
to	O
1	O
,	O
000	O
.	O

I	O
##B	O
##D	O
,	O
inflammatory	O
bow	O
##el	O
disease	O
;	O
CD	O
,	O
C	O
##ro	O
##hn	O
’	O
s	O
disease	O
;	O
UC	O
,	O
ul	O
##cer	O
##ative	O
co	O
##lit	O
##is	O
;	O
I	O
##BS	O
,	O
i	O
##rri	O
##table	O
bow	O
##el	O
syndrome	O
;	O
n	O
,	O
number	O
of	O
observations	O
;	O
AD	B
##MA	I
,	O
as	B
##ym	I
##metric	I
dim	I
##eth	I
##yla	I
##rg	I
##ini	I
##ne	I
;	O
SD	O
##MA	O
,	O
symmetric	B
dim	I
##eth	I
##yla	I
##rg	I
##ini	I
##ne	I
;	O
D	B
##MA	I
,	O
dim	B
##eth	I
##yla	I
##mine	I
;	O
_	O
a	O
significantly	O
different	O
from	O
active	O
CD	O
;	O
_	O
b	O
significantly	O
different	O
from	O
controls	O
;	O
_	O
c	O
significantly	O
different	O
from	O
active	O
UC	O
;	O
_	O
d	O
significantly	O
different	O
from	O
inactive	O
CD	O
;	O
_	O
e	O
significantly	O
different	O
from	O
I	O
##BS	O
;	O
_	O
f	O
significantly	O
different	O
from	O
inactive	O
UC	O
.	O

The	O
meta	O
##bol	O
##ite	O
most	O
significantly	O
different	O
between	O
good	O
and	O
poor	O
respond	O
##ers	O
at	O
base	O
##line	O
was	O
the	O
pu	B
##rine	I
meta	O
##bol	O
##ite	O
x	B
##ant	I
##hine	I
,	O
which	O
is	O
implicated	O
in	O
o	O
##xi	O
##da	O
##tive	O
stress	O
ca	O
##sca	O
##des	O
.	O

The	O
dried	O
super	O
##nat	O
##ant	O
residue	O
was	O
re	O
##con	O
##stituted	O
in	O
80	O
µ	O
##L	O
of	O
met	B
##han	I
##ol	I
followed	O
by	O
20	O
µ	O
##L	O
of	O
water	O
,	O
then	O
cent	O
##ri	O
##fu	O
##ged	O
again	O
at	O
1800	O
##0	O
×	O
g	O
0	O
##°	O
##C	O
for	O
15	O
min	O
.	O

1	O
-	O
M	O
##N	O
,	O
a	O
met	O
##hyl	O
##ation	O
product	O
of	O
ni	B
##cot	I
##ina	I
##mi	I
##de	I
,	O
has	O
been	O
shown	O
to	O
ex	O
##ert	O
anti	O
-	O
inflammatory	O
properties	O
and	O
s	O
##ca	O
##venge	O
oxygen	O
radical	O
##s	O
,	O
.	O

Another	O
possibility	O
for	O
the	O
association	O
with	O
elevated	O
T	B
##MA	I
##O	I
levels	O
among	O
subjects	O
with	O
poor	O
##er	O
pro	O
##gno	O
##sis	O
may	O
arise	O
due	O
to	O
the	O
greater	O
degree	O
of	O
in	O
##test	O
##inal	O
congestion	O
from	O
right	O
-	O
sided	O
H	O
##F	O
.	O

A	O
##bb	O
##re	O
##viation	O
##s	O
:	O
5	B
##α	I
##3	I
##α	I
##dio	I
##l	I
:	O
and	B
##ros	I
##tan	I
##ed	I
##iol	I
,	O
F	O
:	O
co	B
##rt	I
##is	I
##ol	I
,	O
20	B
##β	I
##D	I
##H	I
##E	I
:	O
20	B
##β	I
-	I
D	I
##H	I
-	I
co	I
##rt	I
##ison	I
##e	I
,	O
PP	O
##V	O
:	O
positive	O
predict	O
##ive	O
value	O
,	O
N	O
##P	O
##V	O
:	O
negative	O
predict	O
##ive	O
value	O
,	O
log	O
:	O
natural	O
log	O
##ari	O
##th	O
##m	O
.	O

In	O
particular	O
ion	O
number	O
8	O
(	O
[	O
M	O
##−	O
##H	O
]	O
_	O
−	O
=	O
145	O
.	O
06	O
##0	O
##6	O
m	O
/	O
z	O
,	O
retention	O
time	O
of	O
2	O
.	O
76	O
##4	O
min	O
)	O
,	O
ion	O
number	O
9	O
(	O
[	O
M	O
+	O
H	O
]	O
_	O
+	O
=	O
101	O
.	O
03	O
##5	O
##6	O
m	O
/	O
z	O
,	O
retention	O
time	O
of	O
0	O
.	O
29	O
##48	O
min	O
)	O
,	O
ion	O
number	O
10	O
(	O
[	O
M	O
+	O
H	O
]	O
_	O
+	O
=	O
335	O
.	O
06	O
##7	O
##6	O
m	O
/	O
z	O
,	O
retention	O
time	O
of	O
2	O
.	O
39	O
##8	O
##3	O
min	O
)	O
,	O
ion	O
number	O
11	O
(	O
[	O
M	O
+	O
H	O
]	O
_	O
+	O
=	O
241	O
.	O
03	O
##26	O
m	O
/	O
z	O
,	O
retention	O
time	O
of	O
3	O
.	O
99	O
##9	O
##9	O
min	O
)	O
,	O
and	O
ion	O
number	O
12	O
(	O
[	O
M	O
+	O
H	O
]	O
_	O
+	O
=	O
243	O
.	O
09	O
##86	O
m	O
/	O
z	O
,	O
retention	O
time	O
of	O
0	O
.	O
316	O
##6	O
min	O
)	O
were	O
tested	O
against	O
L	B
-	I
g	I
##lut	I
##amine	I
,	O
al	B
##any	I
##l	I
-	I
g	I
##ly	I
##cine	I
(	O
Al	O
##a	O
-	O
G	O
##ly	O
)	O
,	O
ad	B
##ip	I
##ic	I
acid	I
,	O
and	O
D	B
-	I
g	I
##lut	I
##amine	I
for	O
ion	O
8	O
,	O
h	O
##yd	O
##ant	O
##oi	O
##n	O
for	O
ion	O
9	O
,	O
b	B
-	I
ni	I
##cot	I
##ina	I
##mi	I
##de	I
mon	O
##on	O
##uc	O
##leo	O
##tide	O
for	O
ion	O
10	O
,	O
L	B
-	I
c	I
##ys	I
##tine	I
for	O
ion	O
11	O
,	O
and	O
b	B
-	I
thy	I
##mi	I
##dine	I
for	O
ion	O
12	O
.	O

S	B
##phi	I
##ngo	I
##lip	I
##id	I
meta	O
##bol	O
##ites	O
in	O
healthy	O
controls	O
s	O
##tra	O
##ti	O
##fied	O
by	O
the	O
absence	O
/	O
presence	O
of	O
central	O
o	O
##besity	O
.	O

Furthermore	O
,	O
in	O
a	O
manner	O
akin	O
to	O
human	O
type	O
2	O
diabetes	O
me	O
##lli	O
##tus	O
(	O
T	O
##2	O
##DM	O
)	O
,	O
di	O
##abe	O
##tic	O
c	O
##yn	O
##omo	O
##l	O
##gus	O
monkeys	O
exhibited	O
significantly	O
higher	O
plasma	O
concentrations	O
of	O
T	O
##AG	O
and	O
marginal	O
##ly	O
significant	O
lower	O
levels	O
of	O
HD	B
##L	I
ch	I
##ole	I
##ster	I
##ol	I
.	O

U	B
##ric	I
acid	I
is	O
a	O
major	O
circulating	O
anti	O
##ox	O
##ida	O
##nt	O
and	O
is	O
regarded	O
as	O
a	O
com	O
##pen	O
##sat	O
##ory	O
mechanism	O
to	O
counter	O
##act	O
o	O
##xi	O
##da	O
##tive	O
stress	O
in	O
depression	O
.	O

Re	O
##cover	O
##ies	O
of	O
71	O
±	O
12	O
%	O
,	O
76	O
±	O
8	O
%	O
and	O
97	O
±	O
3	O
%	O
were	O
observed	O
for	O
D	O
##PP	O
added	O
at	O
the	O
low	O
(	O
238	O
p	B
##g	I
m	O
##L	O
_	O
−	O
##1	O
)	O
,	O
medium	O
(	O
44	O
##6	O
##2	O
p	B
##g	I
m	O
##L	O
_	O
−	O
##1	O
)	O
and	O
high	O
(	O
23	O
,	O
202	O
p	O
##g	O
m	O
##L	O
_	O
−	O
##1	O
)	O
spike	O
levels	O
,	O
respectively	O
.	O

In	O
other	O
studies	O
,	O
u	O
##rina	O
##ry	O
Nor	B
##ep	I
##ine	I
##ph	I
##rine	I
levels	O
correlated	O
positively	O
with	O
HIV	O
viral	O
load	O
,	O
and	O
with	O
depression	O
and	O
anxiety	O
,	O
which	O
is	O
frequently	O
observed	O
in	O
HIV	O
/	O
AIDS	O
patients	O
.	O

As	O
shown	O
in	O
,	O
amongst	O
the	O
decreased	O
th	B
##iol	I
##s	I
,	O
compound	O
32	O
decreased	O
more	O
than	O
2	O
.	O
0	O
folds	O
in	O
all	O
types	O
of	O
cancer	O
##s	O
,	O
which	O
may	O
be	O
employed	O
as	O
potential	O
indicator	O
for	O
the	O
screening	O
of	O
cancer	O
##s	O
.	O

Normal	O
##ized	O
fold	O
activation	O
relative	O
to	O
vehicle	O
-	O
treated	O
cells	O
is	O
shown	O
for	O
all	O
-	O
trans	O
-	O
re	O
##tino	O
##ic	O
acid	O
(	O
far	O
left	O
bar	O
in	O
each	O
his	O
##to	O
##gram	O
)	O
or	O
the	O
β	B
-	I
a	I
##po	I
##car	I
##ote	I
##no	I
##ids	I
resulting	O
from	O
c	O
##lea	O
##vage	O
at	O
the	O
“	O
a	O
”	O
,	O
“	O
b	O
”	O
,	O
“	O
c	O
”	O
,	O
or	O
“	O
d	O
”	O
sites	O
from	O
top	O
to	O
bottom	O
,	O
respectively	O
.	O

Most	O
studies	O
examining	O
the	O
relationships	O
between	O
vitamin	B
D	I
and	O
disease	O
or	O
health	O
focus	O
on	O
the	O
main	O
25	B
-	I
h	I
##ydro	I
##xy	I
##vi	I
##tam	I
##in	I
D	O
_	O
3	O
(	O
25	O
(	O
OH	O
)	O
D	O
_	O
3	O
)	O
meta	O
##bol	O
##ite	O
,	O
thus	O
potentially	O
overlooking	O
contributions	O
and	O
dynamic	O
effects	O
of	O
other	O
vitamin	B
D	I
meta	O
##bol	O
##ites	O
,	O
the	O
crucial	O
roles	O
of	O
several	O
of	O
which	O
have	O
been	O
previously	O
demonstrated	O
.	O

Through	O
activation	O
of	O
multiple	O
signaling	O
pathways	O
,	O
bi	O
##le	O
acids	O
are	O
critical	O
to	O
the	O
regulation	O
of	O
t	B
##rig	I
##ly	I
##cer	I
##ide	I
,	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
glucose	S
,	O
and	O
energy	O
home	O
##ost	O
##asis	O
.	O

In	O
addition	O
,	O
the	O
diagnostic	O
power	O
of	O
increased	O
levels	O
of	O
PC	O
was	O
greatest	O
among	O
the	O
altered	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
species	O
(	O
Table	O
)	O
.	O

First	O
,	O
T	B
##MA	I
##O	I
was	O
el	O
##uc	O
##idated	O
to	O
ex	O
##ace	O
##rb	O
##ate	O
impaired	O
glucose	S
tolerance	O
,	O
o	O
##bs	O
##truct	O
he	O
##pa	O
##tic	O
insulin	O
signaling	O
,	O
and	O
promote	O
ad	O
##ip	O
##ose	O
tissue	O
inflammation	O
.	O

Most	O
commonly	O
,	O
l	B
##ys	I
##ine	I
deficiency	O
is	O
seen	O
in	O
non	O
-	O
Western	O
societies	O
and	O
manifest	O
##s	O
as	O
protein	O
-	O
energy	O
ma	O
##ln	O
##utrition	O
,	O
which	O
has	O
profound	O
and	O
systemic	O
effects	O
on	O
the	O
health	O
of	O
the	O
individual	O
.	O

Sa	B
##rc	I
##os	I
##ine	I
,	O
a	O
meta	O
##bol	O
##ite	O
in	O
ch	B
##olin	I
##e	I
metabolism	O
pathway	O
,	O
is	O
generated	O
from	O
g	B
##ly	I
##cine	I
by	O
g	O
##ly	O
##cine	O
-	O
N	O
-	O
met	O
##hyl	O
transfer	O
##ase	O
.	O

Val	B
##ine	I
,	O
le	B
##uc	I
##ine	I
and	O
is	B
##ole	I
##uc	I
##ine	I
bio	O
##sy	O
##nt	O
##hesis	O
.	O

By	O
contrast	O
,	O
LP	O
##C	O
plasma	O
##log	O
##ens	O
were	O
decreasing	O
in	O
RA	O
##C	O
patients	O
;	O
this	O
may	O
occur	O
due	O
to	O
increased	O
actions	O
of	O
l	B
##ys	I
##o	I
-	I
PC	I
a	O
##cy	O
##lt	O
##ran	O
##s	O
##fer	O
##ases	O
(	O
LP	O
##CA	O
##T	O
)	O
.	O

In	O
addition	O
,	O
the	O
decrease	O
of	O
L	B
-	I
c	I
##it	I
##ru	I
##llin	I
##e	I
,	O
sa	B
##cc	I
##hari	I
##c	I
acid	I
and	O
D	B
-	I
as	I
##par	I
##tic	I
acid	I
can	O
also	O
be	O
used	O
as	O
effective	O
bio	O
##mark	O
##ers	O
for	O
B	O
##D	O
##TT	O
diagnosis	O
,	O
which	O
provides	O
an	O
AU	O
##C	O
(	O
Area	O
under	O
the	O
C	O
##ur	O
##ve	O
of	O
R	O
##OC	O
)	O
of	O
0	O
.	O
91	O
##6	O
,	O
0	O
.	O
97	O
##3	O
and	O
0	O
.	O
95	O
##2	O
,	O
respectively	O
(	O
Table	O
)	O
.	O

un	O
##am	O
##bi	O
##guous	O
##ly	O
revealed	O
the	O
presence	O
of	O
uniform	O
##ly	O
_	O
13	O
C	O
labeled	O
la	B
##ct	I
##ate	I
(	B
[	B
U	I
-	I
_	I
13	I
C	I
]	I
-	I
la	I
##ct	I
##ate	I
)	O
and	O
Al	O
##a	O
(	O
(	O
[	O
U	O
-	O
_	O
13	O
C	O
]	O
-	O
Al	O
##a	O
)	O
by	O
the	O
_	O
13	O
C	O
satellite	O
cross	O
-	O
peak	O
pattern	O
(	O
patterns	O
1	O
–	O
4	O
)	O
of	O
3	O
-	O
met	O
##hyl	O
and	O
2	O
-	O
met	O
##hine	O
pro	O
##tons	O
of	O
la	B
##ct	I
##ate	I
(	I
la	I
##ct	I
##ate	I
-	I
H	I
##3	I
and	O
H	O
##2	O
)	O
and	O
Al	O
##a	O
(	O
Al	O
##a	O
-	O
H	O
##3	O
and	O
H	O
##2	O
)	O
(	O
traced	O
by	O
dashed	O
green	O
re	O
##ct	O
##ang	O
##les	O
in	O
Figure	O
)	O
.	O

In	B
##os	I
##ito	I
##l	I
1	O
,	O
4	O
,	O
5	O
t	B
##ris	I
##ph	I
##os	I
##phate	I
(	O
IP	O
_	O
3	O
R	O
)	O
receptor	O
is	O
an	O
in	O
##tra	O
##cellular	O
calcium	O
channel	O
known	O
to	O
regulate	O
metabolism	O
and	O
cellular	O
bio	O
##ener	O
##get	O
##ics	O
.	O

In	O
one	O
report	O
,	O
α	O
–	O
H	O
##B	O
was	O
associated	O
with	O
excess	O
g	B
##lut	I
##ath	I
##ione	I
demand	O
and	O
disrupted	O
mitochondrial	O
energy	O
metabolism	O
and	O
shown	O
to	O
derive	O
from	O
he	O
##pa	O
##tic	O
g	B
##lut	I
##ath	I
##ione	I
stress	O
,	O
supporting	O
the	O
idea	O
that	O
elevated	O
α	O
–	O
H	O
##B	O
may	O
be	O
associated	O
with	O
increased	O
o	O
##xi	O
##da	O
##tive	O
stress	O
in	O
the	O
I	O
##R	O
state	O
.	O

A	O
##pp	O
##lying	O
MS	O
##EA	O
to	O
an	O
##not	O
##ated	O
compounds	O
with	O
an	O
abnormal	O
concentration	O
in	O
the	O
blood	O
revealed	O
statistical	O
##ly	O
significant	O
alterations	O
in	O
s	O
##tero	O
##ido	O
##genesis	O
,	O
and	B
##ros	I
##ten	I
##ed	I
##ione	I
metabolism	O
,	O
and	O
and	O
##rogen	O
and	O
est	B
##rogen	I
metabolism	O
in	O
o	O
##bes	O
##e	O
patients	O
.	O

P	O
##las	O
##ma	O
glucose	S
was	O
ma	O
##ximal	O
##ly	O
en	O
##rich	O
##ed	O
(	O
up	O
to	O
49	O
%	O
)	O
in	O
_	O
13	O
C	O
immediately	O
(	O
0	O
.	O
5	O
h	O
##r	O
)	O
following	O
the	O
trace	O
##r	O
in	O
##fusion	O
.	O

The	O
L	O
##NS	O
did	O
not	O
contain	O
ch	B
##olin	I
##e	I
or	O
beta	B
##ine	I
,	O
which	O
could	O
also	O
account	O
for	O
the	O
absence	O
of	O
statistical	O
differences	O
in	O
these	O
meta	O
##bol	O
##ites	O
.	O

My	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
is	O
responsible	O
for	O
cell	O
cycle	O
control	O
,	O
a	O
##pop	O
##tosis	O
,	O
in	O
##hibition	O
of	O
the	O
P	O
##I	O
##3	O
##K	O
/	O
A	O
##kt	O
pathway	O
and	O
N	O
##F	O
-	O
k	O
##B	O
activity	O
.	O

L	B
-	I
his	I
##ti	I
##dine	I
is	O
a	O
precursor	O
for	O
the	O
synthesis	O
of	O
his	B
##tamine	I
,	O
a	O
major	O
contributor	O
to	O
inflammation	O
,	O
as	O
##th	O
##ma	O
,	O
and	O
potentially	O
pneumonia	O
in	O
both	O
human	O
and	O
animal	O
studies	O
.	O

However	O
,	O
changes	O
in	O
p	B
##yr	I
##u	I
##vate	I
and	O
la	B
##ct	I
##ate	I
have	O
also	O
been	O
noted	O
upon	O
prolonged	O
blood	O
or	O
plasma	O
processing	O
and	O
attributed	O
to	O
er	O
##yt	O
##hr	O
##oc	O
##yte	O
-	O
derived	O
en	O
##zy	O
##matic	O
actions	O
[	O
,	O
]	O
.	O

Similarly	O
,	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
Ce	B
##r	I
(	I
d	I
##18	I
:	I
0	I
/	I
24	I
:	I
1	I
)	I
(	O
p	O
<	O
0	O
.	O
00	O
##1	O
)	O
,	O
T	B
##G	I
(	I
17	I
:	I
2	I
/	I
17	I
:	I
2	I
/	I
18	I
:	I
2	I
)	I
(	O
p	O
=	O
0	O
.	O
00	O
##26	O
##1	O
)	O
,	O
and	O
T	B
##G	I
(	I
17	I
:	I
2	I
/	I
17	I
:	I
2	I
/	I
18	I
:	I
0	I
)	I
(	O
p	O
=	O
0	O
.	O
00	O
##29	O
##1	O
)	O
were	O
detected	O
when	O
M	B
##T	I
##BE	I
was	O
used	O
but	O
were	O
not	O
observed	O
when	O
met	B
##han	I
##ol	I
alone	O
was	O
used	O
.	O

Using	O
Met	O
##ab	O
##o	O
##Net	O
##works	O
to	O
analyze	O
the	O
associated	O
meta	O
##bol	O
##ite	O
profiles	O
we	O
found	O
a	O
over	O
##re	O
##p	O
##res	O
##entation	O
of	O
meta	O
##bol	O
##ites	O
from	O
the	O
c	B
##it	I
##ric	I
acid	I
cycle	O
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
metabolism	O
and	O
g	B
##ly	I
##cine	I
-	I
se	I
##rine	I
metabolism	O
pathways	O
(	O
Fi	O
##g	O
.	O

In	O
pool	O
##ed	O
healthy	O
human	O
serum	O
Me	B
##OH	I
pp	O
##t	O
+	O
U	O
##F	O
was	O
a	O
superior	O
method	O
of	O
mac	O
##rom	O
##ole	O
##cule	O
removal	O
compared	O
to	O
Me	B
##OH	I
:	O

El	O
##eva	O
##ted	O
CS	O
##F	O
glucose	S
has	O
not	O
previously	O
been	O
reported	O
for	O
s	O
##chi	O
##zophrenia	O
;	O
however	O
,	O
abnormal	O
##ly	O
high	O
fast	O
##ing	O
glucose	S
tolerance	O
has	O
been	O
observed	O
in	O
serum	O
from	O
first	O
-	O
onset	O
patients	O
.	O

After	O
addition	O
of	O
0	O
.	O
14	O
µ	O
##g	O
rib	B
##ito	I
##l	I
and	O
0	O
.	O
25	O
µ	O
##g	O
[	B
U	I
-	I
_	I
13	I
C	I
]	I
-	I
glucose	I
as	O
internal	O
standards	O
,	O
each	O
sample	O
was	O
der	O
##iva	O
##tized	O
with	O
100	O
µ	O
##L	O
of	O
20	O
mg	O
/	O
m	O
##L	O
met	B
##ho	I
##xy	I
##amine	I
h	I
##ydro	I
##ch	I
##lor	I
##ide	I
in	O
p	B
##yr	I
##id	I
##ine	I
and	O
200	O
µ	O
##L	O
of	O
N	B
-	I
met	I
##hyl	I
-	I
trim	I
##eth	I
##yl	I
##sy	I
##li	I
##l	I
-	I
t	I
##ri	I
##f	I
##lu	I
##oro	I
##ace	I
##tam	I
##ide	I
(	O
MS	O
##TF	O
##A	O
)	O
,	O
following	O
the	O
protocol	O
.	O

N	O
##MR	O
pro	O
##fi	O
##ling	O
of	O
urine	O
from	O
healthy	O
controls	O
or	O
EA	O
/	O
E	O
##SC	O
##C	O
patients	O
has	O
identified	O
differences	O
in	O
su	B
##c	I
##rose	I
,	O
pan	B
##to	I
##the	I
##nate	I
,	O
u	B
##rea	I
,	O
met	B
##han	I
##ol	I
,	O
p	B
##yr	I
##og	I
##lut	I
##ama	I
##te	I
,	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
,	O
f	B
##uc	I
##ose	I
,	O
2	B
-	I
amino	I
##but	I
##yra	I
##te	I
,	O
and	O
c	B
##is	I
-	I
a	I
##con	I
##itate	I
.	O

The	O
CS	O
##F	O
of	O
our	O
co	O
##hor	O
##t	O
had	O
ch	B
##ole	I
##ster	I
##yl	I
su	I
##lf	I
##ate	I
that	O
positively	O
correlated	O
with	O
the	O
tumor	O
size	O
.	O

The	O
results	O
of	O
these	O
studies	O
are	O
perfectly	O
consistent	O
not	O
only	O
with	O
the	O
fact	O
that	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##o	I
-	I
N	I
-	I
o	I
##leo	I
##yl	I
ethanol	I
##amine	I
was	O
revealed	O
in	O
this	O
study	O
to	O
be	O
one	O
of	O
the	O
best	O
predict	O
##ing	O
markers	O
for	O
BA	O
##V	O
,	O
but	O
also	O
with	O
the	O
detection	O
of	O
elevated	O
levels	O
of	O
certain	O
types	O
of	O
free	O
fatty	O
acids	O
and	O
mon	B
##og	I
##ly	I
##cer	I
##ides	I
in	O
the	O
patients	O
.	O

In	O
addition	O
,	O
23	O
out	O
of	O
59	O
meta	O
##bol	O
##ite	O
chemical	O
sub	O
-	O
classes	O
exceeded	O
the	O
Bon	O
##fer	O
##ron	O
##i	O
threshold	O
(	O
P	O
<	O
8	O
.	O
5	O
×	O
10	O
_	O
−	O
##4	O
)	O
,	O
with	O
the	O
top	O
signals	O
being	O
for	O
in	B
##os	I
##ito	I
##l	I
,	O
c	B
##rea	I
##tine	I
,	O
v	O
##ali	O
##ne	O
/	O
le	O
##uc	O
##ine	O
/	O
is	O
##ole	O
##uc	O
##ine	O
,	O
and	O
pu	O
##rine	O
/	O
u	O
##rate	O
pathways	O
(	O
p	O
=	O
2	O
.	O
0	O
×	O
10	O
_	O
−	O
##14	O
,	O
1	O
.	O
4	O
×	O
10	O
_	O
−	O
##12	O
,	O
2	O
.	O
8	O
×	O
10	O
_	O
−	O
##11	O
,	O
and	O
2	O
.	O
4	O
×	O
10	O
_	O
−	O
##10	O
,	O
respectively	O
;	O
Table	O
,	O
Su	O
##pp	O
##lement	O
##al	O
Table	O
_	O
3	O
)	O
.	O

;	O
data	O
can	O
be	O
easily	O
compared	O
with	O
the	O
data	O
of	O
total	O
di	B
##os	I
##met	I
##in	I
g	I
##lu	I
##cu	I
##ron	I
##ide	I
(	O
sum	O
of	O
3	O
-	O
O	O
-	O
G	O
##lu	O
##c	O
and	O
Di	O
##o	O
-	O
3	O
-	O
O	O
-	O
G	O
##lu	O
##c	O
)	O
;	O
these	O
curves	O
are	O
expressed	O
in	O
p	O
##M	O
##ol	O
/	O
L	O
.	O
As	O
it	O
can	O
be	O
seen	O
,	O
they	O
are	O
very	O
close	O
as	O
further	O
confirmed	O
by	O
the	O
P	O
##K	O
data	O
;	O
the	O
AU	O
##C	O
_	O
0	O
–	O
t	O
calculated	O
on	O
di	B
##os	I
##met	I
##in	I
after	O
g	O
##lu	O
##cu	O
##ron	O
##idas	O
##e	O
dig	O
##est	O
##ion	O
is	O
just	O
3	O
.	O
4	O
%	O
higher	O
than	O
the	O
one	O
calculated	O
on	O
the	O
sum	O
of	O
the	O
di	O
##os	O
##met	O
##ine	O
g	B
##lu	I
##cu	I
##ron	I
##ide	I
meta	O
##bol	O
##ites	O
(	O
data	O
calculated	O
on	O
m	O
##olar	O
basis	O
)	O
,	O
such	O
difference	O
is	O
within	O
the	O
accepted	O
error	O
of	O
the	O
analytical	O
method	O
.	O

Random	O
urine	O
samples	O
(	O
10	O
m	O
##L	O
)	O
were	O
also	O
collected	O
at	O
base	O
##line	O
to	O
measure	O
the	O
ratio	O
of	O
u	O
##rina	O
##ry	O
protein	O
to	O
c	B
##rea	I
##tin	I
##ine	I
.	O

Con	O
##cent	O
##rations	O
of	O
E	O
##3	O
,	O
E	B
##1	I
,	I
16	I
-	I
K	I
##E	I
##2	I
,	I
2	I
-	I
OH	I
##E	I
##1	I
and	O
E	O
##2	O
were	O
the	O
highest	O
among	O
all	O
groups	O
,	O
accounting	O
for	O
approximately	O
60	O
–	O
70	O
%	O
of	O
the	O
total	O
u	O
##rina	O
##ry	O
est	B
##rogen	I
meta	O
##bol	O
##ites	O
with	O
E	O
##3	O
being	O
the	O
dominant	O
est	B
##rogen	I
in	O
all	O
study	O
groups	O
.	O

Met	O
##ab	O
##oli	O
##tes	O
identified	O
in	O
N	O
##MR	O
and	O
P	O
##LS	O
-	O
D	O
##A	O
as	O
significant	O
in	O
different	O
##iating	O
low	O
–	O
and	O
high	B
–	I
c	I
##ys	I
##tat	I
##hi	I
##oni	I
##ne	I
concentration	O
groups	O
with	O
the	O
use	O
of	O
the	O
VIP	O
spectral	O
plot	O
shown	O
in	O
_	O
1	O
Score	O
plot	O
from	O
partial	O
least	O
squares	O
disc	O
##rim	O
##ina	O
##nt	O
analysis	O
of	O
_	O
1	O
H	O
-	O
N	O
##MR	O
s	O
##pect	O
##ra	O
in	O
adults	O
with	O
high	O
or	O
low	O
plasma	O
c	B
##ys	I
##tat	I
##hi	I
##oni	I
##ne	I
concentrations	O
.	O

In	O
our	O
work	O
,	O
the	O
top	O
BA	O
##L	O
compounds	O
associated	O
with	O
F	O
##E	O
##V	O
_	O
1	O
/	O
F	O
##VC	O
ratio	O
included	O
p	B
-	I
c	I
##res	I
##ol	I
,	O
a	O
meta	O
##bol	O
##ite	O
of	O
human	O
gut	O
micro	O
##bio	O
##ta	O
and	O
ni	B
##cot	I
##ine	I
,	O
four	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##let	I
##han	I
##ola	I
##mine	I
##s	I
(	O
a	O
type	O
of	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
)	O
,	O
free	O
ho	B
##mo	I
##cy	I
##stein	I
##e	I
,	O
a	O
c	B
##ys	I
##tein	I
##e	I
containing	O
compound	O
,	O
and	O
a	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
.	O

This	O
was	O
unlike	O
decreases	O
observed	O
in	O
ta	B
##uri	I
##ne	I
in	O
the	O
lung	O
ad	O
##eno	O
##car	O
##cin	O
##oma	O
cell	O
line	O
A	O
##5	O
##4	O
##9	O
,	O
which	O
allowed	O
us	O
to	O
conclude	O
that	O
ta	B
##uri	I
##ne	I
can	O
in	O
##hibit	O
cell	O
proliferation	O
,	O
or	O
that	O
levels	O
of	O
ta	B
##uri	I
##ne	I
are	O
reduced	O
in	O
patients	O
with	O
breast	O
cancer	O
.	O

The	O
significant	O
reduction	O
in	O
4	B
-	I
OH	I
-	I
E	I
_	I
2	I
level	O
along	O
with	O
T	O
##CD	O
##D	O
exposure	O
may	O
then	O
be	O
due	O
to	O
a	O
rapid	O
subsequent	O
metabolism	O
and	O
ex	O
##cre	O
##tion	O
of	O
this	O
compound	O
.	O

Neo	B
##pt	I
##eri	I
##n	I
is	O
a	O
cat	O
##ab	O
##olic	O
product	O
of	O
g	B
##uan	I
##os	I
##ine	I
trip	I
##hos	I
##phate	I
(	O
GT	O
##P	O
)	O
synthesized	O
by	O
mon	O
##ocytes	O
/	O
mac	O
##rop	O
##hage	O
##s	O
,	O
end	O
##oth	O
##eli	O
##al	O
cells	O
,	O
B	O
cells	O
and	O
den	O
##dr	O
##itic	O
cells	O
,	O
measurement	O
of	O
which	O
in	O
body	O
fluids	O
is	O
in	O
##dicative	O
of	O
a	O
pro	O
-	O
inflammatory	O
immune	O
status	O
.	O

To	O
facilitate	O
continued	O
testing	O
in	O
population	O
-	O
based	O
studies	O
of	O
the	O
multiple	O
laboratory	O
-	O
based	O
h	O
##y	O
##pot	O
##heses	O
about	O
the	O
roles	O
of	O
est	B
##rogen	I
meta	O
##bol	O
##ites	O
,	O
a	O
novel	O
liquid	O
ch	O
##roma	O
##tography	O
-	O
tandem	O
mass	O
s	O
##pect	O
##rome	O
##try	O
(	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
)	O
ass	O
##ay	O
was	O
developed	O
to	O
measure	O
concurrently	O
all	O
15	O
est	O
##rogen	O
##s	O
and	O
est	B
##rogen	I
meta	O
##bol	O
##ites	O
in	O
human	O
serum	O
and	O
urine	O
,	O
as	O
un	O
##con	O
##ju	O
##gated	O
and	O
total	O
(	O
g	O
##lu	O
##cu	O
##ron	O
##idated	O
+	O
su	O
##lf	O
##ated	O
+	O
un	O
##con	O
##ju	O
##gated	O
)	O
concentrations	O
.	O

In	O
the	O
β	O
-	O
oxidation	O
,	O
car	B
##ni	I
##tine	I
and	O
their	O
car	B
##ni	I
##tine	I
derivatives	O
are	O
ex	O
##cre	O
##ted	O
in	O
the	O
urine	O
from	O
BC	O
##A	O
tissue	O
,	O
because	O
CP	O
##T	O
##1	O
,	O
CP	O
##T	O
##2	O
,	O
CA	O
##CT	O
m	O
##RNA	O
expression	O
associated	O
with	O
a	B
##cy	I
##l	I
-	I
car	I
##ni	I
##tine	I
and	O
car	B
##ni	I
##tine	I
metabolism	O
were	O
decreased	O
.	O

C	B
##it	I
##rate	I
was	O
mainly	O
+	O
2	O
labeled	O
with	O
_	O
13	O
C	B
_	I
6	I
-	I
glucose	I
,	O
suggesting	O
that	O
p	O
##yr	O
##u	O
##vate	O
de	O
-	O
hydrogen	O
##ase	O
supplied	O
ace	B
##ty	I
##l	I
-	I
Co	I
##A	I
that	O
was	O
incorporated	O
into	O
c	B
##it	I
##rate	I
in	O
the	O
c	B
##it	I
##rate	I
s	O
##ynth	O
##ase	O
reaction	O
.	O

In	O
patients	O
from	O
Arm	O
1	O
of	O
the	O
T	O
##AP	O
##S	O
clinical	O
trial	O
,	O
go	O
##ser	O
##elin	O
ace	B
##tate	I
and	O
bi	B
##cal	I
##uta	I
##mi	I
##de	I
significantly	O
reduced	O
the	O
mean	O
concentration	O
of	O
serum	O
T	O
,	O
but	O
there	O
were	O
no	O
significant	O
reduction	O
##s	O
in	O
the	O
other	O
anal	O
##yte	O
##s	O
,	O
but	O
there	O
is	O
a	O
modest	O
increase	O
in	O
the	O
mean	O
serum	O
concentration	O
of	O
un	O
##con	O
##ju	O
##gated	O
D	O
##H	O
##EA	O
and	O
Δ	O
_	O
4	O
-	O
AD	O
(	O
and	O
)	O
.	O

For	O
optimization	O
of	O
operating	O
conditions	O
,	O
1	O
–	O
5	O
μ	O
##M	O
M	O
##MM	O
##TA	O
_	O
V	O
in	O
a	O
solution	O
of	O
met	B
##han	I
##ol	I
and	O
water	O
(	O
1	O
:	O
1	O
,	O
v	O
/	O
v	O
)	O
was	O
in	O
##fused	O
into	O
a	O
triple	O
-	O
q	O
##uad	O
##rup	O
##ole	O
mass	O
s	O
##pect	O
##rome	O
##ter	O
(	O
5000	O
Q	O
##TR	O
##AP	O
,	O
MD	O
##S	O
SC	O
##IE	O
##X	O
,	O
Concord	O
,	O
ON	O
,	O
Canada	O
)	O
equipped	O
with	O
an	O
electro	O
##sp	O
##ray	O
ion	O
source	O
.	O

Free	O
##ze	O
/	O
th	O
##aw	O
stability	O
experiments	O
resulted	O
in	O
no	O
degradation	O
of	O
a	B
##bir	I
##ater	I
##one	I
over	O
three	O
freeze	O
/	O
th	O
##aw	O
cycles	O
.	O

Wilcox	O
##on	O
signed	O
rank	O
test	O
and	O
Chi	O
-	O
square	O
tests	O
were	O
used	O
for	O
continuous	O
and	O
cat	O
##ego	O
##rical	O
variables	O
,	O
respectively	O
A	O
##bb	O
##re	O
##viation	O
##s	O
:	O
B	O
##MI	O
body	O
mass	O
index	O
,	O
S	O
##B	O
##P	O
s	O
##ys	O
##to	O
##lic	O
blood	O
pressure	O
,	O
DB	B
##P	I
di	O
##ast	O
##olic	O
blood	O
pressure	O

HP	O
##LC	O
-	O
grade	O
met	B
##han	I
##ol	I
and	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
(	O
AC	O
##N	O
)	O
were	O
purchased	O
from	O
Me	O
##rk	O
(	O
Dar	O
##ms	O
##tadt	O
,	O
Germany	O
)	O
.	O

F	O
_	B
(	I
6	I
,	I
43	I
)	I
=	O
8	O
.	O
60	O
p	O
<	O
0	O
.	O
00	O
##1	O
*	O
Classification	O
after	O
L	O
##O	O
##OC	O
##V	O
.	O

[	B
_	I
2	I
H	I
]	I
Ch	I
##lor	I
##of	I
##orm	I
was	O
purchased	O
from	O
Cambridge	O
Is	O
##oto	O
##pe	O
Laboratories	O
(	O
And	O
##over	O
,	O
MA	O
)	O
.	O

Similar	O
to	O
the	O
metabolic	O
observations	O
in	O
other	O
cancer	O
##s	O
,	O
higher	O
levels	O
of	O
p	B
##yr	I
##u	I
##vate	I
and	O
la	B
##ct	I
##ate	I
were	O
also	O
discovered	O
in	O
the	O
serum	O
of	O
HC	O
##C	O
patients	O
as	O
compared	O
with	O
healthy	O
controls	O
,	O
presumably	O
because	O
of	O
higher	O
energy	O
consumption	O
involving	O
g	O
##ly	O
##co	O
##lysis	O
in	O
the	O
solid	O
tumor	O
tissues	O
.	O

P	O
##las	O
##ma	O
and	O
muscle	O
concentrations	O
of	O
D	B
##G	I
(	I
18	I
:	I
2	I
_	I
18	I
:	I
2	I
)	I
and	O
6	O
T	B
##G	I
species	O
also	O
correlated	O
.	O

Moreover	O
,	O
the	O
est	B
##rogen	I
could	O
have	O
significant	O
effects	O
on	O
the	O
metabolism	O
of	O
p	O
##oly	O
##uns	O
##at	O
##ura	O
##ted	O
fatty	O
acid	O
.	O

Sep	O
##ara	O
##tion	O
of	O
As	O
meta	O
##bol	O
##ites	O
demonstrated	O
by	O
(	O
A	O
)	O
injection	O
of	O
g	B
##lut	I
##ath	I
##ione	I
complexes	O
and	O
th	O
##iol	O
##ated	O
a	O
##rsen	O
##ical	O
##s	O
and	O
(	O
B	O
)	O
over	O
##lay	O
of	O
the	O
ch	O
##roma	O
##to	O
##gram	O
##s	O
for	O
injection	O
of	O
sulfur	O
-	O
containing	O
and	O
non	O
-	O
sulfur	O
-	O
containing	O
a	O
##rsen	O
##ical	O
##s	O
(	O
25	O
μ	O
##g	O
L	O
-	O
1	O
)	O
.	O

that	O
k	B
##eton	I
##e	I
bodies	O
levels	O
were	O
significantly	O
higher	O
in	O
patients	O
with	O
chronic	O
H	O
##F	O
than	O
the	O
normal	O
population	O
,	O
possibly	O
due	O
to	O
ne	O
##uro	O
##end	O
##oc	O
##rine	O
hormone	O
activation	O
.	O

In	O
##tri	O
##guin	O
##gly	O
,	O
C	B
##15	I
:	I
0	I
,	O
C	B
##17	I
:	I
0	I
,	O
and	O
the	O
unknown	O
C	O
##17	O
acid	O
showed	O
a	O
post	O
##pra	O
##ndi	O
##al	O
decrease	O
until	O
4	O
h	O
after	O
the	O
intake	O
independent	O
from	O
the	O
food	O
ing	O
##ested	O
.	O

According	O
to	O
the	O
variable	O
importance	O
in	O
the	O
projection	O
plot	O
,	O
la	B
##ct	I
##ate	I
serum	O
levels	O
were	O
higher	O
in	O
the	O
coin	O
##fected	O
group	O
,	O
while	O
the	O
signals	O
attributed	O
to	O
HD	O
##L	O
serum	O
ch	B
##ole	I
##ster	I
##ol	I
were	O
more	O
intense	O
in	O
the	O
mon	O
##oi	O
##n	O
##fected	O
group	O
.	O

However	O
,	O
the	O
C	O
##ID	O
spectrum	O
of	O
SM	B
(	I
36	I
:	I
3	I
)	I
did	O
not	O
reveal	O
any	O
abundant	O
ions	O
that	O
identify	O
the	O
fatty	O
a	O
##cy	O
##l	O
sub	O
##st	O
##it	O
##uen	O
##ts	O
.	O

Further	O
studies	O
of	O
the	O
regulation	O
of	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
might	O
also	O
be	O
helpful	O
in	O
diagnosis	O
,	O
treatment	O
and	O
prevention	O
of	O
corn	O
##ea	O
di	O
##abe	O
##tic	O
defects	O
.	O

When	O
SA	O
##M	O
##e	O
transfers	O
its	O
met	B
##hyl	I
group	I
to	O
an	O
accept	O
##or	O
,	O
S	B
-	I
ad	I
##eno	I
##sy	I
##l	I
##hom	I
##oc	I
##ys	I
##tein	I
##e	I
is	O
formed	O
.	O

AU	O
##C	O
:	O
Area	O
under	O
the	O
curve	O
;	O
CE	O
:	O
ch	B
##ole	I
##ster	I
##yl	I
est	I
##er	I
;	O
Ce	B
##r	I
:	O
Ce	B
##ram	I
##ides	I
;	O
D	O
##G	O
:	O
di	B
##acy	I
##l	I
##gly	I
##cer	I
##ols	I
;	O
N	O
##AF	O
##L	O
:	O
non	O
##al	O
##co	O
##hol	O
##ic	O
fatty	O
liver	O
;	O
NAS	O
##H	O
:	O
non	O
##al	O
##co	O
##hol	O
##ic	O
s	O
##te	O
##ato	O
##he	O
##pa	O
##titis	O
;	O
PC	O
:	O
Ph	B
##os	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
;	O
P	O
##E	O
:	O
Ph	B
##os	I
##pha	I
##ti	I
##dy	I
##let	I
##han	I
##ola	I
##mine	I
##s	I
;	O
P	O
##I	O
:	O
Ph	B
##os	I
##pha	I
##ti	I
##dy	I
##lino	I
##si	I
##to	I
##ls	I
;	O
PS	O
:	O
Ph	B
##os	I
##pha	I
##ti	I
##dy	I
##ls	I
##eri	I
##nes	I
;	O
P	O
##V	O
:	O
predict	O
##ive	O
value	O
;	O
SM	O
:	O
S	B
##phi	I
##ngo	I
##my	I
##elin	I
##s	I
,	O
T	B
##G	I
:	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
.	O

Cho	B
##line	I
and	O
ch	B
##olin	I
##e	I
meta	O
##bol	O
##ites	O
in	O
blood	O
were	O
of	O
interest	O
as	O
it	O
is	O
unknown	O
how	O
their	O
concentrations	O
may	O
change	O
during	O
la	O
##ct	O
##ation	O
in	O
the	O
dairy	O
cow	O
.	O

We	O
##ak	O
wash	O
solvent	S
was	S
H	S
_	S
2	S
O	S
-	O
met	O
##han	O
##ol	O
(	O
1	O
:	O
1	O
,	O
v	O
/	O
v	O
)	O
and	O
strong	O
wash	O
solvent	O
was	O
ace	O
##ton	O
##it	O
##ril	O
##e	O
/	O
is	O
##op	O
##rop	O
##ano	O
##l	O
(	O
3	O
:	O
1	O
,	O
v	O
/	O
v	O
)	O
.	O

Bin	O
##ding	O
of	O
oxygen	O
to	O
c	O
##yt	O
##och	O
##rome	O
c	O
o	O
##xi	O
##das	O
##e	O
is	O
in	O
##hibit	O
##ed	O
by	O
hydrogen	B
su	I
##l	I
##phi	I
##de	I
non	O
-	O
competitive	O
##ly	O
.	O

Two	O
potential	O
bio	O
##mark	O
##ers	O
,	O
re	B
##tino	I
##l	I
and	O
L	B
-	I
pro	I
##line	I
,	O
were	O
identified	O
and	O
these	O
findings	O
may	O
create	O
opportunities	O
for	O
the	O
development	O
of	O
new	O
lung	O
cancer	O
diagnostic	O
tools	O
.	O

(	O
A	O
)	O
Effect	O
of	O
the	O
addition	O
of	O
individual	O
FA	S
to	O
P	O
##BM	O
##C	O
cultures	O
.	O

MC	O
##F	O
-	O
10	O
##A	O
cells	O
were	O
culture	O
##d	O
in	O
D	O
##ME	O
##M	O
/	O
F1	O
##2	O
supplemented	O
with	O
e	O
##pid	O
##er	O
##mal	O
growth	O
factor	O
(	O
20	O
ng	O
/	O
m	O
##L	O
)	O
,	O
ch	O
##ole	O
##ra	O
to	B
##xin	I
(	O
100	O
ng	O
/	O
m	O
##L	O
)	O
,	O
h	B
##ydro	I
##cor	I
##tis	I
##one	I
(	O
0	O
.	O
5	O
μ	O
##g	O
/	O
m	O
##L	O
)	O
,	O
insulin	O
(	O
10	O
μ	O
##g	O
/	O
m	O
##L	O
)	O
,	O
5	O
%	O
horse	O
serum	O
,	O
and	O
1	O
%	O
pen	B
##ici	I
##llin	I
–	I
s	I
##tre	I
##pt	I
##omy	I
##cin	I
.	O

End	O
##ogen	O
##ous	O
est	O
##rogen	O
##s	O
and	O
est	B
##rogen	I
meta	O
##bol	O
##ites	O
play	O
an	O
important	O
role	O
in	O
the	O
path	O
##ogen	O
##esis	O
and	O
development	O
of	O
human	O
breast	O
,	O
end	O
##ome	O
##tri	O
##al	O
,	O
and	O
o	O
##var	O
##ian	O
cancer	O
##s	O
.	O

On	O
the	O
other	O
hand	O
,	O
ne	B
##r	I
##von	I
##ic	I
acid	I
levels	O
would	O
not	O
be	O
useful	O
to	O
disc	O
##rim	O
##inate	O
e	O
##uth	O
##ym	O
##ic	O
patients	O
with	O
MD	O
##D	O
from	O
controls	O
or	O
patients	O
with	O
other	O
mental	O
disorders	O
(	O
S	O
##Z	O
or	O
B	O
##D	O
)	O
.	O

Alternatively	O
,	O
by	O
applying	O
an	O
ion	O
-	O
pairing	O
re	O
##age	O
##nt	O
consisting	O
of	O
both	O
h	B
##ydro	I
##phi	I
##lic	I
and	O
h	O
##ydro	O
##phobic	O
residues	O
in	O
a	O
single	O
molecule	O
,	O
the	O
h	B
##ydro	I
##phi	I
##lic	I
meta	O
##bol	O
##ite	O
can	O
interact	O
with	O
the	O
h	O
##ydro	O
##phobic	O
stationary	O
phase	O
of	O
the	O
R	B
##P	I
column	O
(	O
Fi	O
##g	O
.	O
)	O
.	O

Su	O
##sp	O
##ens	O
##ion	O
culture	O
was	O
achieved	O
using	O
plates	O
coated	O
with	O
12	O
mg	O
/	O
m	O
##L	O
p	B
##oly	I
(	I
2	I
-	I
h	I
##ydro	I
##xy	I
##eth	I
##yl	I
met	I
##ha	I
##c	I
##ryl	I
##ate	I
)	I

(	O
D	O
)	O
PA	B
##F	I
14	I
:	I
0	I
##p	I
levels	O
were	O
increased	O
in	O
F	O
##T	O
##D	O
.	O

While	O
individual	O
amino	O
acids	O
and	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
have	O
distinct	O
characteristics	O
and	O
functions	O
,	O
they	O
also	O
participate	O
in	O
larger	O
metabolic	O
networks	O
.	O

Biological	O
##ly	O
relevant	O
meta	O
##bol	O
##ites	O
including	O
free	O
fatty	O
acid	O
,	O
mon	B
##oa	I
##cy	I
##l	I
##gly	I
##cer	I
##ol	I
(	O
MG	O
)	O
,	O
di	B
##acy	I
##l	I
##gly	I
##cer	I
##ol	I
(	O
D	O
##G	O
)	O
,	O
short	O
chain	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
(	O
PC	O
)	O
,	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
(	O
GP	O
##C	O
)	O
,	O
and	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##let	I
##han	I
##ola	I
##mine	I
(	O
GP	O
##E	O
)	O
were	O
found	O
in	O
both	O
methods	O
.	O

This	O
deficiency	O
may	O
lead	O
to	O
less	O
conversion	O
of	O
Sa	B
##rc	I
##os	I
##ine	I
to	O
G	B
##ly	I
##cine	I
causing	O
sa	O
##rc	O
##os	O
##ine	O
##mia	O
in	O
HIV	O
/	O
AIDS	O
patients	O
,	O
which	O
was	O
observed	O
in	O
our	O
study	O
.	O

The	O
DC	O
##M	O
leaf	O
extract	O
showed	O
a	O
lower	O
%	O
blood	O
glucose	S
reduction	O
of	O
18	O
.	O
52	O
%	O
±	O
##13	O
.	O
5	O
%	O
at	O
200	O
mg	O
/	O
kg	O
B	O
##W	O
within	O
1	O
.	O
5	O
h	O
after	O
introduction	O
,	O
while	O
1	O
did	O
not	O
exhibit	O
h	B
##y	I
##po	I
##gly	I
##ce	I
##mic	I
activity	O
.	O

These	O
ch	O
##roma	O
##to	O
##gram	O
##s	O
reveal	O
near	O
-	O
base	O
##line	O
resolution	O
of	O
25	O
(	O
OH	O
)	O
D	O
_	O
3	O
and	O
3	B
-	I
e	I
##pi	I
-	I
25	I
(	I
OH	I
)	I
D	I
_	I
3	I
.	O

Higher	O
expression	O
of	O
R	O
##R	O
##M	O
##2	O
was	O
significantly	O
(	O
log	O
-	O
rank	O
P	O
=	O
.	O
00	O
##2	O
)	O
associated	O
with	O
tumors	O
having	O
intrinsic	O
ta	B
##mo	I
##xi	I
##fen	I
resistance	O
and	O
poor	O
survival	O
in	O
this	O
patient	O
group	O
.	O

Variations	O
in	O
the	O
lip	O
##id	O
levels	O
in	O
on	O
##cological	O
patients	O
have	O
been	O
previously	O
associated	O
with	O
an	O
increased	O
up	O
##take	O
of	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
an	O
essential	O
component	O
of	O
cell	O
membrane	O
##s	O
,	O
by	O
tumor	O
cells	O
.	O

These	O
meta	O
##bol	O
##ites	O
are	O
associated	O
with	O
o	O
##xi	O
##dant	O
stress	O
(	O
total	O
g	B
##lut	I
##ath	I
##ione	I
)	O
,	O
loss	O
of	O
ATP	S
home	O
##ost	O
##asis	O
(	O
ad	O
##eno	O
##sin	O
##e	O
)	O
,	O
a	O
##pop	O
##tosis	O
(	O
P	O
##t	O
##d	O
##S	O
##er	O
)	O
,	O
and	O
disruption	O
of	O
end	O
##oth	O
##eli	O
##al	O
barrier	O
function	O
(	B
s	B
##phi	I
##ngo	I
##my	I
##elin	I
)	O
.	O

Our	O
results	O
revealed	O
that	O
ultra	O
##fi	O
##ltration	O
and	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
extraction	O
are	O
complementary	O
de	O
##p	O
##rote	O
##ini	O
##zation	O
techniques	O
and	O
both	O
are	O
required	O
as	O
sample	O
preparation	O
methods	O
for	O
the	O
proper	O
detection	O
of	O
u	O
##rem	O
##ic	O
retention	O
so	O
##lut	O
##es	O
using	O
_	O
1	O
H	O
-	O
N	O
##MR	O
s	O
##pect	O
##ros	O
##copy	O
.	O

In	O
addition	O
,	O
other	O
work	O
demonstrated	O
that	O
Δ	B
_	I
9	I
-	I
te	I
##tra	I
##hy	I
##dr	I
##oc	I
##anna	I
##bino	I
##l	I
(	O
T	O
##HC	O
)	O
administration	O
to	O
male	O
si	O
##mian	O
im	O
##mu	O
##no	O
##de	O
##ficiency	O
virus	O
(	O
S	O
##I	O
##V	O
)	O
–	O
infected	O
r	O
##hes	O
##us	O
mac	O
##aque	O
##s	O
resulted	O
in	O
decreased	O
early	O
mortality	O
,	O
lowered	O
plasma	O
viral	O
load	O
,	O
and	O
reduced	O
tissue	O
inflammation	O
,	O
although	O
these	O
findings	O
were	O
not	O
re	O
##p	O
##rod	O
##uc	O
##ible	O
in	O
female	O
S	O
##I	O
##V	O
-	O
infected	O
r	O
##hes	O
##us	O
mac	O
##aque	O
##s	O
,	O
suggesting	O
a	O
potential	O
sex	O
-	O
specific	O
effect	O
.	O

n	O
##s	O
non	O
-	O
significant	O
Association	O
between	O
the	O
ho	B
##mo	I
##ar	I
##gin	I
##ine	I
(	O
h	O
##A	O
##rg	O
)	O
and	O
as	B
##ym	I
##metric	I
dim	I
##eth	I
##yla	I
##rg	I
##ini	I
##ne	I
(	O
AD	O
##MA	O
)	O
ratio	O
and	O
the	O
Se	O
##quential	O
Organ	O
F	O
##ail	O
##ure	O
Assessment	O
(	O
S	O
##O	O
##FA	O
)	O
score	O
,	O
and	O
as	O
a	O
predict	O
##ive	O
marker	O
to	O
differentiate	O
se	O
##ptic	O
shock	O
from	O
surgical	O
trauma	O
.	O

Although	O
not	O
statistical	O
##ly	O
significant	O
,	O
there	O
was	O
a	O
tendency	O
for	O
lower	O
values	O
of	O
HD	O
##L	O
and	O
L	O
##D	O
##L	O
and	O
higher	O
values	O
of	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
in	O
the	O
coin	O
##fected	O
group	O
,	O
which	O
may	O
explain	O
the	O
importance	O
of	O
signals	O
attributed	O
to	O
HD	O
##L	O
in	O
the	O
discrimination	O
among	O
the	O
samples	O
.	O

After	O
24	O
h	O
the	O
chamber	O
was	O
washed	O
once	O
with	O
PBS	O
and	O
cells	O
were	O
fixed	O
with	O
4	O
%	O
formal	B
##de	I
##hy	I
##de	I
.	O

Met	O
##ab	O
##olic	O
pathways	O
involving	O
g	B
##ly	I
##cine	I
,	O
se	B
##rine	I
and	O
th	B
##re	I
##oni	I
##ne	I
metabolism	O
(	O
P	O
=	O
0	O
.	O
00	O
##5	O
##29	O
,	O
impact	O
=	O
0	O
.	O
26	O
)	O
and	O
beta	B
-	I
al	I
##ani	I
##ne	I
(	O
P	O
=	O
0	O
.	O
02	O
##8	O
##4	O
,	O
impact	O
=	O
0	O
.	O
27	O
)	O
along	O
with	O
the	O
T	O
##CA	O
cycle	O
(	O
P	O
=	O
0	O
.	O
01	O
##13	O
,	O
impact	O
=	O
0	O
.	O
19	O
)	O
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
metabolism	O
(	O
P	O
=	O
0	O
.	O
02	O
##17	O
,	O
impact	O
=	O
0	O
.	O
17	O
)	O
,	O
and	O
g	O
##ly	O
##co	O
##lysis	O
(	O
P	O
=	O
0	O
.	O
03	O
##7	O
,	O
impact	O
=	O
0	O
.	O
1	O
)	O
were	O
highlighted	O
as	O
targets	O
for	O
investigating	O
the	O
path	O
##ological	O
mechanisms	O
underlying	O
RS	O
##A	O
(	O
showed	O
in	O
)	O
.	O

2	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
,	O
o	B
##ct	I
##ade	I
##ce	I
##noy	I
##l	I
##car	I
##ni	I
##tine	I
(	I
C	I
##18	I
:	I
1	I
)	I
,	O
h	B
##ydro	I
##xy	I
##p	I
##rion	I
##yl	I
##car	I
##ni	I
##tine	I
(	O
C	O
##3	O
-	O
OH	O
)	O
,	O
and	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
C	I
##24	I
:	I
1	I
were	O
used	O
in	O
the	O
meta	O
##bol	O
##ites	O
-	O
only	O
panel	O
.	O

F	O
##DR	O
p	O
=	O
0	O
.	O
00	O
##3	O
)	O
,	O
1	B
-	I
met	I
##hyl	I
-	I
ad	I
##eno	I
##sin	I
##e	I
(	O
r	O
=	O
0	O
.	O
49	O
;	O
F	O
##DR	O
p	O
=	O
0	O
.	O
01	O
##2	O
)	O
,	O
car	B
##ba	I
##mo	I
##yl	I
phosphate	I
(	O
r	O
=	O
0	O
.	O
48	O
;	O
F	O
##DR	O
p	O
=	O
0	O
.	O
01	O
##6	O
)	O
,	O
de	B
##ox	I
##yi	I
##nos	I
##ine	I
(	O
r	O
=	O
0	O
.	O
47	O
;	O
F	O
##DR	O
p	O
=	O
0	O
.	O
01	O
##6	O
)	O
,	O
in	B
##os	I
##ito	I
##l	I
(	O
r	O
=	O
0	O
.	O
47	O
;	O
F	O
##DR	O
p	O
=	O
0	O
.	O
01	O
##6	O
)	O
,	O
di	B
##hy	I
##dr	I
##oor	I
##ota	I
##te	I
(	O
r	O
=	O
0	O
.	O
45	O
;	O

Whether	O
as	O
cause	O
and	O
/	O
or	O
consequence	O
,	O
LP	O
##I	O
is	O
clearly	O
elevated	O
in	O
type	O
2	O
diabetes	O
,	O
and	O
,	O
importantly	O
,	O
it	O
might	O
occur	O
earlier	O
than	O
glucose	S
and	O
H	O
##b	O
##A	O
##1	O
##c	O
changes	O
.	O

By	O
UP	O
##LC	O
-	O
MS	O
,	O
P	B
##E	I
(	I
18	I
:	I
0	I
/	I
18	I
:	I
2	I
)	I
and	O
PC	B
(	I
P	I
-	I
16	I
:	I
0	I
/	I
20	I
:	I
4	I
)	I
were	O
higher	O
in	O
PR	O
##P	O
compared	O
with	O
P	O
##FP	O
samples	O
.	O

B	O
##rief	O
##ly	O
,	O
proteins	O
were	O
pre	O
##ci	O
##pit	O
##ated	O
from	O
plasma	O
samples	O
using	O
three	O
volumes	O
of	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
,	O
and	O
polar	O
and	O
non	O
##pol	O
##ar	O
fraction	O
##s	O
were	O
separated	O
by	O
adding	O
water	O
and	O
a	O
mixture	O
of	O
ethanol	S
and	O
di	B
##ch	I
##lor	I
##ome	I
##than	I
##e	I
(	I
2	I
:	I
1	I
,	I
v	I
/	I
v	I
)	I
.	O

I	O
##mp	O
##re	O
##cision	O
was	O
generally	O
<	O
10	O
%	O
for	O
most	O
anal	O
##yte	O
##s	O
,	O
except	O
for	O
su	B
##cci	I
##nate	I
.	O

Eight	O
t	B
##ria	I
##cy	I
##l	I
##gly	I
##cer	I
##ols	I
were	O
also	O
associated	O
with	O
a	O
decrease	O
in	O
C	O
-	O
p	O
##eptide	O
after	O
6	O
months	O
.	O

L	B
##ys	I
##ine	I
(	O
_	O
13	O
C	O
_	O
6	O
,	O
_	O
15	O
N	O
_	O
2	O
)	O
and	O
a	B
##rg	I
##ini	I
##ne	I
(	O
_	O
13	O
C	O
_	O
6	O
,	O
_	O
15	O
N	O
_	O
4	O
)	O
were	O
supplied	O
by	O
Cambridge	O
Is	O
##oto	O
##pe	O
Laboratories	O
(	O
Te	O
##w	O
##ks	O
##bury	O
,	O
MA	O
,	O
USA	O
)	O
.	O

Mark	O
##ers	O
related	O
to	O
in	O
##ﬂ	O
##am	O
##mat	O
##ory	O
status	O
,	O
as	O
well	O
as	O
to	O
per	O
##tur	O
##bation	O
##s	O
in	O
bi	O
##le	O
acid	O
metabolism	O
(	O
elevations	O
in	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
un	O
##con	O
##ju	O
##gated	O
,	O
con	O
##ju	O
##gated	O
and	O
su	O
##lf	O
##ated	O
bi	O
##le	O
acid	O
)	O
,	O
lip	O
##id	O
metabolism	O
(	O
elevations	O
in	O
fatty	O
acids	O
,	O
k	B
##eton	I
##e	I
bodies	O
and	O
several	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
)	O
and	O
protein	O
metabolism	O
(	O
de	O
##ple	O
##tion	O
in	O
dip	O
##eptide	O
##s	O
)	O
,	O
were	O
associated	O
with	O
the	O
PS	O
##C	O
patient	O
’	O
s	O
meta	O
##bol	O
##ome	O
,	O
compared	O
to	O
healthy	O
controls	O
.	O

The	O
lower	O
layer	O
was	O
dried	O
by	O
N	O
_	O
2	O
,	O
and	O
then	O
re	O
##con	O
##stituted	O
in	O
100	O
µ	O
##L	O
water	O
followed	O
by	O
400	O
µ	O
##L	O
met	B
##han	I
##ol	I
.	O

An	O
N	O
##MR	O
pattern	O
has	O
emerged	O
to	O
separate	O
HC	O
##C	O
from	O
C	O
##IR	O
and	O
CT	O
##R	O
,	O
which	O
includes	O
a	O
reduction	O
in	O
hip	B
##pura	I
##te	I
,	O
c	B
##it	I
##rate	I
,	O
c	B
##rea	I
##tin	I
##ine	I
,	O
and	O
T	B
##MA	I
##O	I
and	O
an	O
increase	O
in	O
ace	B
##tate	I
,	O
car	B
##ni	I
##tine	I
,	O
and	O
c	B
##rea	I
##tine	I
.	O

Although	O
our	O
data	O
are	O
preliminary	O
,	O
in	O
patients	O
with	O
AN	O
in	O
childhood	O
and	O
ad	O
##ole	O
##scence	O
,	O
who	O
have	O
recovered	O
body	O
weight	O
by	O
treatment	O
,	O
the	O
circa	O
##dian	O
variation	O
of	O
co	B
##rt	I
##is	I
##ol	I
secret	O
##ion	O
may	O
be	O
conserved	O
.	O

Fast	O
##ing	O
ve	O
##nous	O
blood	O
of	O
T	O
##1	O
##DM	O
patients	O
was	O
collected	O
in	O
2	O
-	O
m	O
##l	O
flu	B
##ori	I
##de	I
-	I
o	I
##xa	I
##late	I
tubes	O
for	O
bio	O
##chemical	O
analysis	O
at	O
the	O
Clinical	O
Laboratory	O
of	O
Jess	O
##a	O
Hospital	O
.	O

5	B
-	I
O	I
##x	I
##op	I
##rol	I
##ine	I
is	O
a	O
by	O
##p	O
##rod	O
##uc	O
##t	O
of	O
g	B
##lut	I
##ath	I
##ione	I
synthesis	O
and	O
has	O
been	O
proposed	O
as	O
a	O
bio	O
##mark	O
##er	O
of	O
g	B
##lut	I
##ath	I
##ione	I
status	O
.	O

Association	O
##s	O
between	O
p	B
##ht	I
##hala	I
##te	I
meta	O
##bol	O
##ites	O
and	O
their	O
sums	O
were	O
performed	O
using	O
Pearson	O
correlation	O
coefficients	O
.	O

G	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
are	O
major	O
components	O
of	O
cellular	O
membrane	O
##s	O
.	O

(	O
E	O
)	O
I	O
##HC	O
for	O
se	B
##rot	I
##oni	I
##n	I
in	O
a	O
representative	O
human	O
co	O
##lon	O
cancer	O
patient	O
sample	O
and	O
adjacent	O
normal	O
tissue	O
.	O

Based	O
on	O
this	O
model	O
,	O
rapid	O
and	O
slow	O
fi	O
##bro	O
##ser	O
##s	O
were	O
accurately	O
classified	O
with	O
two	O
SM	O
:	O
SM	B
(	I
d	I
##18	I
:	I
2	I
/	I
16	I
:	I
0	I
)	I
,	O
and	O
SM	B
(	I
38	I
:	I
1	I
)	I
:	O
SM	B
(	I
d	I
##18	I
:	I
1	I
/	I
20	I
:	I
0	I
)	I

_	O
,	O
Me	O
##as	O
##uring	O
the	O
various	O
pathways	O
involved	O
in	O
g	B
##ly	I
##ox	I
##yla	I
##te	I
metabolism	O
and	O
o	B
##xa	I
##late	I
production	O
would	O
allow	O
for	O
the	O
reliable	O
and	O
fast	O
assessment	O
of	O
the	O
therapeutic	O
effects	O
of	O
various	O
new	O
drugs	O
.	O

The	O
solutions	O
were	O
dried	O
and	O
re	O
##con	O
##stituted	O
in	O
600	O
μ	O
##l	O
of	O
phosphate	S
buffer	O
(	O
pH	O
8	O
)	O
.	O

A	O
##bb	O
##re	O
##viation	O
##s	O
:	O
PS	O
##P	O
:	O
progressive	O
su	O
##pra	O
##nu	O
##cle	O
##ar	O
p	O
##als	O
##y	O
;	O
AU	O
##C	O
:	O
area	O
under	O
the	O
curve	O
;	O
SD	O
##MA	O
:	O
symmetric	B
dim	I
##eth	I
##yla	I
##rg	I
##ini	I
##ne	I
fatty	O
acid	O
;	O
L	B
##ys	I
##o	I
##PC	I
(	I
16	I
:	I
0	I
)	I
:	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
(	I
16	I
:	I
0	I
)	I
;	O
AC	O
:	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I

The	O
three	O
groups	O
that	O
did	O
not	O
show	O
significant	O
differences	O
were	O
prop	B
##ion	I
##ate	I
metabolism	O
consisting	O
of	O
four	O
detected	O
meta	O
##bol	O
##ites	O
,	O
bi	O
##le	O
acid	O
metabolism	O
consisting	O
of	O
four	O
meta	O
##bol	O
##ites	O
,	O
and	O
k	B
##eton	I
##e	I
bodies	O
consisting	O
of	O
two	O
meta	O
##bol	O
##ites	O
.	O

Besides	O
a	O
_	O
31	O
P	O
MR	O
##S	O
study	O
on	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
from	O
se	O
##ra	O
of	O
patients	O
with	O
M	O
##M	O
,	O
to	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
paper	O
represents	O
the	O
first	O
study	O
of	O
global	O
blood	O
serum	O
and	O
urine	O
-	O
derived	O
meta	O
##bol	O
##ites	O
in	O
the	O
context	O
of	O
M	O
##M	O
.	O

The	O
ME	O
##K	O
##C	O
-	O
MS	O
/	O
MS	O
conditions	O
are	O
the	O
same	O
as	O
in	O
except	O
that	O
25	O
m	O
##M	O
p	O
##oly	O
-	O
L	O
,	O
L	O
-	O
S	O
##U	O
##LA	O
and	O
25	O
k	B
##V	I
was	O
used	O
.	O

However	O
,	O
clinical	O
stage	O
and	O
serum	O
levels	O
of	O
sa	B
##rc	I
##os	I
##ine	I
,	O
dim	B
##eth	I
##yl	I
##gly	I
##cine	I
,	O
f	B
##olate	I
,	O
met	B
##hyl	I
##ci	I
##trate	I
,	O
and	O
met	B
##hyl	I
##mal	I
##onic	I
acid	I
were	O
not	O
significantly	O
different	O
between	O
the	O
two	O
populations	O
.	O

U	B
##ric	I
acid	I
is	O
considered	O
an	O
anti	O
##ox	O
##ida	O
##nt	O
,	O
and	O
previous	O
studies	O
have	O
indicated	O
that	O
low	O
serum	O
u	B
##ric	I
acid	I
levels	O
are	O
correlated	O
with	O
the	O
risk	O
of	O
disease	O
and	O
progression	O
in	O
PS	O
##P	O
.	O

Au	O
##the	O
##nti	O
##c	O
standard	O
substances	O
of	O
SP	O
##Ms	O
were	O
purchased	O
from	O
C	O
##ayman	O
Chemical	O
##s	O
(	O
local	O
distributor	O
:	O
B	O
##io	O
##mo	O
##l	O
,	O
Hamburg	O
,	O
Germany	O
)	O
,	O
i	O
.	O
e	O
.	O
,	O
re	O
##sol	O
##vin	O
##s	O
(	O
R	O
##v	O
)	O
R	O
##v	O
##E	O
##1	O
,	O
R	O
##v	O
##D	O
##1	O
,	O
17	O
(	O
R	O
)	O
-	O
R	O
##v	O
##D	O
##1	O
,	O
R	O
##v	O
##D	O
##2	O
,	O
R	O
##v	O
##D	O
##3	O
,	O
R	O
##v	O
##D	O
##5	O
,	O
mare	O
##sin	O
##s	O
(	O
Ma	O
##R	O
)	O
Ma	O
##R	O
##1	O
and	O
7	O
(	O
S	O
)	O
-	O
Ma	O
##R	O
##1	O
,	O
protect	O
##in	O
PD	O
##X	O
as	O
well	O
as	O
lip	B
##ox	I
##ins	I
(	O
L	O
##X	O
)	O
L	O
##X	O
##A	O
_	O
5	O
,	O
6	O
(	O
R	O
)	O
-	O
L	O
##X	O
##A	O
_	O
4	O
,	O
15	O
(	O
R	O
)	O

Finally	O
,	O
the	O
diminished	O
f	O
##eca	O
##l	O
level	O
of	O
ni	B
##cot	I
##ini	I
##c	I
acid	I
in	O
CR	O
##C	O
patients	O
was	O
in	O
agreement	O
with	O
the	O
previously	O
established	O
link	O
between	O
ni	B
##cot	I
##ini	I
##c	I
acid	I
deficiency	O
and	O
g	O
##eno	O
##mic	O
instability	O
.	O

all	O
processed	O
with	O
pure	O
Me	B
##OH	I
(	O
i	O
.	O
e	O
.	O

Other	O
neon	B
##ico	I
##tino	I
##id	I
meta	O
##bol	O
##ites	O
may	O
be	O
detect	O
##able	O
in	O
the	O
urine	O
of	O
other	O
species	O
,	O
such	O
as	O
rabbits	O
,	O
after	O
oral	O
administration	O
of	O
neon	B
##ico	I
##tino	I
##id	I
.	O

For	O
24	B
,	I
25	I
-	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
,	O
no	O
de	O
##uter	O
##ated	O
standard	O
was	O
commercially	O
available	O
;	O
therefore	O
,	O
D	B
##6	I
-	I
1	I
,	I
25	I
-	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
was	O
used	O
instead	O
because	O
of	O
its	O
similar	O
structure	O
and	O
p	O
##hy	O
##si	O
##co	O
##chemical	O
properties	O
.	O

Mat	O
##ern	O
##al	O
serum	O
collected	O
at	O
18	O
and	O
34	O
weeks	O
g	O
##esta	O
##tion	O
,	O
stored	O
at	O
−	O
##80	O
##°	O
##C	O
,	O
was	O
pool	O
##ed	O
and	O
analyzed	O
for	O
32	O
p	B
##ht	I
##hala	I
##te	I
meta	O
##bol	O
##ites	O
by	O
liquid	O
ch	O
##roma	O
##tography	O
-	O
tandem	O
mass	O
s	O
##pect	O
##rome	O
##try	O
.	O

While	O
glucose	S
should	O
not	O
be	O
present	O
in	O
app	O
##re	O
##cia	O
##ble	O
concentrations	O
in	O
the	O
urine	O
of	O
healthy	O
people	O
,	O
g	O
##lu	O
##cos	O
##uria	O
is	O
not	O
that	O
uncommon	O
in	O
the	O
co	O
##hor	O
##t	O
of	O
interest	O
.	O

Recently	O
,	O
it	O
has	O
been	O
described	O
that	O
tumor	O
cells	O
red	O
##ire	O
##ct	O
glucose	S
flow	O
to	O
generate	O
rib	B
##ose	I
‐	I
5	I
‐	I
phosphate	I
in	O
order	O
to	O
increase	O
the	O
synthesis	O
of	O
n	O
##uc	O
##leo	O
##tide	O
##s	O
and	O
thus	O
maintain	O
a	O
high	O
rate	O
of	O
growth	O
(	O
C	O
##io	O
##u	O
et	O
al	O
.	O
,	O
2015	O
)	O
.	O

We	O
note	O
that	O
the	O
ratio	O
between	O
c	B
##rea	I
##tine	I
and	O
c	B
##rea	I
##tin	I
##ine	I
may	O
also	O
serve	O
as	O
a	O
possible	O
bio	O
##mark	O
##er	O
,	O
as	O
it	O
generally	O
appears	O
to	O
increase	O
in	O
D	O
##MD	O
patients	O
and	O
decrease	O
in	O
controls	O
and	O
is	O
more	O
significantly	O
associated	O
with	O
D	O
##MD	O
status	O
than	O
either	O
c	B
##rea	I
##tine	I
or	O
c	B
##rea	I
##tin	I
##ine	I
individually	O
.	O

To	O
maintain	O
cell	O
home	O
##ost	O
##asis	O
,	O
ch	B
##ole	I
##ster	I
##ol	I
concentrations	O
are	O
tightly	O
regulated	O
.	O

Some	O
##w	O
##hat	O
surprisingly	O
,	O
the	O
metabolism	O
of	O
v	B
##ali	I
##ne	I
,	O
le	B
##uc	I
##ine	I
,	O
and	O
is	B
##ole	I
##uc	I
##ine	I
was	O
significantly	O
associated	O
with	O
mi	O
##gra	O
##ine	O
,	O
and	O
not	O
in	O
line	O
with	O
the	O
findings	O
from	O
the	O
single	O
-	O
meta	O
##bol	O
##ite	O
analyses	O
.	O

Distribution	O
##s	O
of	O
ben	B
##zen	I
##e	I
-	I
me	I
##rca	I
##pt	I
##uri	I
##c	I
acid	I
levels	O
(	O
geometric	O
means	O
and	O
95	O
%	O
confidence	O
intervals	O
)	O
in	O
participants	O
either	O
null	O
or	O
positive	O
for	O
the	O
G	O
##ST	O
##T	O
##1	O
gene	O
(	O
panel	O
A	O
)	O
or	O
the	O
G	O
##ST	O
##M	O
##1	O
gene	O
(	O
panel	O
B	O
)	O
by	O
assignment	O
group	O
(	O
place	O
##bo	O
or	O
treated	O
and	O
day	O
of	O
study	O
)	O
.	O

These	O
results	O
suggested	O
that	O
ne	B
##r	I
##von	I
##ic	I
acid	I
levels	O
can	O
be	O
used	O
as	O
a	O
bio	O
##mark	O
##er	O
to	O
disc	O
##rim	O
##inate	O
the	O
de	O
##pressive	O
state	O
of	O
patients	O
with	O
MD	O
##D	O
from	O
the	O
e	O
##uth	O
##ym	O
##ic	O
state	O
of	O
patients	O
with	O
MD	O
##D	O
or	O
the	O
de	O
##pressive	O
state	O
of	O
patients	O
with	O
B	O
##D	O
.	O

Ten	O
micro	O
##lite	O
##r	O
of	O
a	O
mixture	O
of	O
1	O
µ	O
##g	O
/	O
m	O
##L	O
des	B
##met	I
##hyl	I
-	I
B	I
##EN	I
and	O
1	O
µ	O
##g	O
/	O
m	O
##L	O
des	B
##met	I
##hyl	I
-	I
B	I
##EN	I
-	I
C	I
##l	I
_	I
2	I
in	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
(	O
internal	O
standards	O
)	O
and	O
1	O
m	O
##L	O
of	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
were	O
added	O
to	O
200	O
µ	O
##L	O
of	O
standard	O
or	O
sample	O
.	O

We	O
accomplished	O
this	O
with	O
the	O
addition	O
of	O
0	O
.	O
2	O
M	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
buffer	O
.	O

T	O
##x	O
##A	O
_	O
2	O
production	O
was	O
measured	O
via	O
liquid	O
ch	O
##roma	O
##tography	O
–	O
tandem	O
mass	O
s	O
##pect	O
##rome	O
##try	O
for	O
the	O
stable	O
T	O
##x	O
##A	O
_	O
2	O
meta	O
##bol	O
##ite	O
11	B
-	I
de	I
##hy	I
##dr	I
##o	I
-	I
th	I
##rom	I
##box	I
##ane	I
B	O
_	O
2	O
(	O
U	O
##T	O
##x	O
##B	O
_	O
2	O
)	O
in	O
urine	O
.	O

It	O
has	O
been	O
reported	O
that	O
mon	O
##oc	O
##yte	O
derived	O
mac	O
##rop	O
##hage	O
##s	O
infected	O
with	O
HIV	O
-	O
1	O
or	O
HIV	O
-	O
2	O
displayed	O
elevated	O
rib	B
##ose	I
5	I
-	I
phosphate	I
,	O
a	O
PP	O
##P	O
intermediate	O
,	O
with	O
no	O
change	O
in	O
T	O
##CA	O
cycle	O
intermediate	O
##s	O
such	O
as	O
c	B
##it	I
##rate	I
when	O
compared	O
with	O
non	O
##in	O
##fected	O
cells	O
.	O

H	B
##y	I
##pox	I
##ant	I
##hine	I
has	O
been	O
described	O
as	O
a	O
protective	O
agent	O
against	O
h	O
##y	O
##pox	O
##ic	O
injury	O
and	O
c	O
##yt	O
##oto	O
##xi	O
##c	O
compounds	O
in	O
normal	O
and	O
cancer	O
##ous	O
cells	O
.	O

Further	O
evidence	O
of	O
heightened	O
β	O
-	O
oxidation	O
is	O
shown	O
by	O
relatively	O
higher	O
ace	B
##tate	I
in	O
the	O
urine	O
of	O
HC	O
##C	O
patients	O
than	O
in	O
controls	O
[	O
]	O
.	O

Ser	O
##um	O
meta	O
##bol	O
##ite	O
associations	O
with	O
test	B
##osterone	I
levels	O
in	O
PC	O
##OS	O
cases	O
and	O
controls	O
with	O
large	O
waist	O
c	O
##ir	O
##cum	O
##ference	O
(	O
[UNK]	O
)	O
.	O

Co	O
##mp	O
##aris	O
##on	O
of	O
E	O
##SI	O
sensitivity	O
for	O
N	O
##NA	O
##L	O
,	O
N	O
##NA	O
##L	O
ace	B
##tate	I
,	O
and	O
N	O
##NA	O
##L	O
he	B
##xa	I
##no	I
##ate	I
with	O
different	O
HP	O
##LC	O
mobile	O
phase	O
compositions	O
.	O

N	O
##eg	O
##ative	O
associations	O
are	O
revealed	O
between	O
e	O
##G	O
##F	O
##R	O
and	O
serum	O
c	B
##ys	I
##tat	I
##in	I
C	O
values	O
(	O
Cy	O
##s	O
##C	O
)	O
(	O
edge	O
weight	O
=	O
−	O
##0	O
.	O
76	O
)	O
,	O
and	O
the	O
N	O
##MR	O
bucket	O
at	O
3	O
.	O
04	O
##5	O
pp	O
##m	O
(	O
edge	O
weight	O
=	O
−	O
##0	O
.	O
37	O
)	O
,	O
corresponding	O
to	O
c	B
##rea	I
##tin	I
##ine	I
,	O
respectively	O
.	O

The	O
direction	O
of	O
association	O
of	O
all	O
ant	O
##ena	O
##tal	O
serum	O
p	B
##ht	I
##hala	I
##te	I
meta	O
##bol	O
##ite	O
concentrations	O
with	O
TV	O
was	O
negative	O
for	O
all	O
other	O
meta	O
##bol	O
##ites	O
,	O
apart	O
from	O
ME	O
##P	O
,	O
although	O
not	O
significant	O
.	O

μ	O
m	O
##ol	O
/	O
L	O
;	O
range	O
:	O
71	O
.	O
6	O
to	O
163	O
.	O
5	O
μ	O
m	O
##ol	O
/	O
L	O
;	O
E	O
##H	O
:	O
80	O
.	O
8	O
μ	O
m	O
##ol	O
/	O
L	O
;	O
range	O
:	O
52	O
.	O
1	O
to	O
95	O
.	O
4	O
μ	O
m	O
##ol	O
/	O
L	O
;	O
control	O
subjects	O
:	O
67	O
.	O
6	O
μ	O
m	O
##ol	O
/	O
L	O
;	O
range	O
:	O
60	O
.	O
0	O
to	O
102	O
.	O
5	O
μ	O
m	O
##ol	O
/	O
L	O
;	O
P	O
<	O
0	O
.	O
05	O
,	O
R	O
##VD	O
versus	O
control	O
subjects	O
)	O
and	O
a	O
lower	O
c	B
##rea	I
##tin	I
##ine	I
clearance	O
(	O
R	O
##VD	O
:	O
50	O
.	O
1	O
m	O
##L	O
/	O
min	O
;	O
range	O
:	O
29	O
.	O
3	O
to	O
168	O
.	O
7	O
m	O
##L	O
/	O
min	O
;	O
E	O
##H	O
:	O
79	O
.	O
9	O
m	O
##L	O
/	O
min	O
;	O
range	O
:	O
51	O
.	O
5	O
to	O
134	O
.	O
5	O
m	O
##L	O
/	O
min	O
;	O
control	O
subjects	O
:	O
84	O
.	O
8	O
m	O
##L	O
/	O
min	O
;	O
range	O
:	O
42	O
.	O
0	O
to	O
170	O
.	O
3	O
m	O
##L	O
/	O
min	O
;	O
P	O
<	O
0	O
.	O
05	O
,	O
R	O
##VD	O
versus	O
control	O
subjects	O
;	O
)	O
.	O

For	O
the	O
direct	O
q	O
##uant	O
##ification	O
of	O
di	B
##os	I
##met	I
##in	I
g	I
##lu	I
##cu	I
##ron	I
##ide	I
meta	O
##bol	O
##ites	O
in	O
plasma	O
,	O
ca	O
##li	O
##bra	O
##tion	O
curves	O
were	O
built	O
with	O
3	O
-	O
O	O
-	O
G	O
##lu	O
##c	O
,	O
7	O
-	O
O	O
-	O
G	O
##lu	O
##c	O
,	O
and	O
3	B
,	I
7	I
-	I
O	I
-	I
Di	I
##g	I
##lu	I
##c	I
at	O
the	O
same	O
concentrations	O
,	O
0	O
–	O
50	O
–	O
100	O
–	O
300	O
–	O
900	O
–	O
2	O
,	O
500	O
–	O
5	O
,	O
000	O
–	O
10	O
,	O
000	O
–	O
15	O
,	O
000	O
p	O
##g	O
/	O
m	O
##L	O
and	O
Q	O
##C	O
at	O
150	O
–	O
3	O
,	O
000	O
–	O
6	O
,	O
000	O
–	O
12	O
,	O
000	O
p	O
##g	O
/	O
m	O
##L	O

Then	O
,	O
0	O
.	O
2	O
m	O
##L	O
of	O
the	O
clear	O
super	O
##nat	O
##ant	O
were	O
transferred	O
in	O
a	O
clean	O
2	O
-	O
m	O
##L	O
96	O
-	O
well	O
plate	O
,	O
di	O
##lut	O
##ed	O
with	O
other	O
0	O
.	O
8	O
m	O
##L	O
water	O
/	O
met	O
##han	O
##ol	O
(	O
95	O
:	O
5	O
,	O
v	O
/	O
v	O
)	O
containing	O
2	O
%	O
ace	B
##tic	I
acid	I
and	O
injected	O
in	O
the	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
system	O
.	O

We	O
combined	O
20	O
µ	O
##L	O
plasma	O
with	O
180	O
µ	O
##L	O
extraction	O
fluid	O
composed	O
of	O
4	O
parts	O
of	O
met	B
##han	I
##ol	I
and	O
1	O
part	O
of	O
water	O
which	O
contained	O
three	O
internal	O
standards	O
(	O
Pen	O
##tan	O
##ed	O
##io	O
##ic	O
acid	O
-	O
d	O
##6	O
(	O
final	O
concentration	O
:	O
20	O
µ	O
##M	O
)	O
,	O
U	O
_	O
13	O
C	B
-	I
R	I
##ibi	I
##to	I
##l	I
(	O
final	O
concentration	O
:	O
12	O
.	O
7	O
µ	O
##M	O
)	O
,	O
Nor	B
##le	I
##uc	I
##ine	I
(	O
final	O
concentration	O
:	O
10	O
µ	O
##M	O
)	O
)	O
.	O

The	O
authors	O
identified	O
a	O
1	O
.	O
9	O
-	O
fold	O
increase	O
in	O
ace	B
##tate	I
in	O
the	O
patients	O
with	O
MS	O
vs	O
the	O
HC	O
,	O
but	O
it	O
was	O
mainly	O
increased	O
in	O
patients	O
with	O
N	O
##MO	O
(	O
1	O
.	O
8	O
-	O
fold	O
and	O
3	O
.	O
4	O
-	O
fold	O
higher	O
than	O
patients	O
with	O
MS	O
and	O
HC	O
)	O
.	O

In	O
conclusion	O
,	O
the	O
most	O
appropriate	O
mobile	O
phase	O
was	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
and	O
10	O
mm	O
##ol	O
/	O
L	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
plus	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
in	O
water	O
at	O
a	O
flow	O
rate	O
of	O
0	O
.	O
25	O
m	O
##L	O
/	O
min	O
,	O
and	O
the	O
column	O
temperature	O
was	O
kept	O
at	O
30	O
##°	O
##C	O
.	O

Ser	O
##um	O
was	O
de	O
##p	O
##rote	O
##ini	O
##zed	O
using	O
met	B
##han	I
##ol	I
prior	O
to	O
meta	O
##bol	O
##ite	O
tag	O
##ging	O
and	O
urine	O
was	O
used	O
with	O
no	O
pre	O
##tre	O
##at	O
##ment	O
.	O

P	O
<	O
0	O
.	O
05	O
for	O
all	O
,	O
data	O
not	O
shown	O
)	O
,	O
while	O
fed	O
-	O
state	O
glucose	S
oxidation	O
again	O
negatively	O
correlated	O
with	O
na	O
##dir	O
AC	O
(	O
C	O
##12	O
:	O
1	O
,	O
C	O
##14	O
:	O
1	O
,	O
C	O
##14	O
:	O
2	O
,	O
C	O
##16	O
;	O
r	O
=	O
−	O
##0	O
.	O
51	O
##6	O
to	O
−	O
##0	O
.	O
64	O
##4	O
;	O
P	O
<	O
0	O
.	O
05	O
for	O
all	O
,	O
data	O
not	O
shown	O
)	O
.	O

The	O
alter	O
##ation	O
of	O
serum	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
levels	O
is	O
another	O
noticeable	O
observation	O
in	O
this	O
study	O
.	O

As	O
expected	O
,	O
it	O
was	O
by	O
far	O
the	O
most	O
abundant	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
in	O
our	O
plasma	O
samples	O
.	O

PC	B
(	I
40	I
:	I
7	I
)	I
(	O
A	O
)	O
and	O
SM	B
(	I
36	I
:	I
3	I
)	I
(	O
B	O
)	O
at	O
w	O
##0	O
,	O
w	O
##16	O
and	O
w	O
##28	O
.	O

The	O
specific	O
##ity	O
of	O
the	O
relationship	O
between	O
L	O
##OA	O
##D	O
and	O
increased	O
24	B
##S	I
-	I
OH	I
-	I
Cho	I
##l	I
plasma	O
concentrations	O
might	O
be	O
indirectly	O
supported	O
by	O
the	O
result	O
of	O
un	O
##iva	O
##ria	O
##te	O
analysis	O
(	O
Table	O
)	O
showing	O
a	O
significant	O
correlation	O
of	O
24	B
##S	I
-	I
OH	I
-	I
Cho	I
##l	I
with	O
memory	O
tests	O
imp	O
##air	O
##ment	O
and	O
brain	O
at	O
##rop	O
##hy	O
on	O
CT	O
scan	O
,	O
both	O
typical	O
characteristics	O
of	O
L	O
##OA	O
##D	O
but	O
not	O
of	O
V	O
##D	O
.	O

Mid	O
/	O
survivor	O
samples	O
were	O
characterized	O
by	O
lower	O
concentrations	O
of	O
is	B
##op	I
##rop	I
##ano	I
##l	I
and	O
p	B
##yr	I
##u	I
##vate	I
,	O
and	O
higher	O
concentrations	O
of	O
format	B
##e	I
,	O
ace	B
##tate	I
,	O
prop	B
##ion	I
##ate	I
and	O
g	B
##ly	I
##cola	I
##te	I
.	O

Our	O
findings	O
point	O
toward	O
several	O
amino	S
acid	O
–	O
based	O
d	O
##ys	O
##re	O
##gu	O
##lation	O
##s	O
in	O
central	O
metabolic	O
pathways	O
compared	O
with	O
age	O
-	O
and	O
sex	O
-	O
matched	O
controls	O
,	O
which	O
can	O
both	O
initiate	O
and	O
a	O
##gg	O
##ra	O
##vate	O
ne	O
##ph	O
##ros	O
##cle	O
##rosis	O
path	O
##ology	O
.	O

Ph	B
##os	I
##pha	I
##ti	I
##dy	I
##let	I
##han	I
##ola	I
##mine	I
##s	I
in	O
food	O
break	O
down	O
to	O
form	O
p	O
##hos	O
##pha	O
##ti	O
##dy	O
##let	O
##han	O
##ola	O
##mine	O
-	O
linked	O
Am	O
##ador	O
##i	O
products	O
as	O
a	O
part	O
of	O
the	O
Mail	O
##lard	O
reaction	O
.	O

A	O
comparison	O
of	O
the	O
end	O
##oc	O
##rine	O
effects	O
of	O
low	O
dose	O
amino	B
##g	I
##lut	I
##eth	I
##im	I
##ide	I
with	O
and	O
without	O
h	B
##ydro	I
##cor	I
##tis	I
##one	I
in	O
post	O
##men	O
##op	O
##aus	O
##al	O
breast	O
cancer	O
patients	O
.	O

PC	O
##s	O
,	O
which	O
are	O
known	O
as	O
the	O
major	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
found	O
in	O
the	O
membrane	O
##s	O
of	O
ma	O
##mmal	O
##ian	O
cells	O
,	O
were	O
mediated	O
by	O
P	O
##LA	O
##2	O
in	O
breast	O
cancer	O
cells	O
.	O

Ph	B
##en	I
##yla	I
##lani	I
##ne	I
,	O
ch	B
##olin	I
##e	I
and	O
t	B
##yr	I
##os	I
##ine	I
levels	O
decreased	O
after	O
surgery	O
,	O
an	O
effect	O
that	O
was	O
sustained	O
after	O
one	O
year	O
at	O
follow	O
-	O
up	O
,	O
similar	O
to	O
previous	O
findings	O
that	O
have	O
described	O
increased	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
and	O
t	B
##yr	I
##os	I
##ine	I
as	O
bio	O
##mark	O
##ers	O
for	O
C	O
##VR	O
[	O
,	O
]	O
.	O

In	O
case	O
of	O
disc	O
##re	O
##pan	O
##cy	O
between	O
SUV	O
_	O
ma	O
##x	O
and	O
the	O
g	B
##lut	I
##ama	I
##te	I
concentration	O
,	O
lung	O
cancer	O
is	O
missed	O
in	O
19	O
%	O
of	O
the	O
cases	O
.	O

The	O
investigation	O
of	O
anti	O
##fu	O
##nga	O
##l	O
extract	O
from	O
Fu	O
##sar	O
##ium	O
s	B
##p	I
.	O

Subsequently	O
,	O
degree	O
of	O
insulin	O
resistance	O
was	O
compared	O
with	O
the	O
home	O
##ost	O
##asis	O
model	O
assessment	O
of	O
insulin	O
resistance	O
index	O
(	O
H	O
##OM	O
##A	O
-	O
I	O
##R	O
)	O
,	O
which	O
was	O
derived	O
from	O
fast	O
##ing	O
glucose	S
(	O
mg	O
/	O
d	O
##L	O
)	O
×	O
fast	O
##ing	O
insulin	O
(	O
m	O
##U	O
/	O
L	O
)	O
divided	O
by	O
405	O
.	O

Co	O
##gni	O
##tive	O
functioning	O
was	O
assessed	O
using	O
the	O
cognitive	O
sub	O
##sca	O
##le	O
of	O
the	O
K	B
##D	I
##Q	I
##OL	I
-	I
SF	I
1	O
.	O
3	O
,	O
and	O
the	O
results	O
are	O
summarized	O
in	O
Additional	O
file	O
3	O
:	O
Table	O
S	O
##2	O
##A	O
.	O
The	O
cognitive	O
function	O
sub	O
##sca	O
##le	O
has	O
been	O
previously	O
valid	O
##ated	O
in	O
patients	O
with	O
C	O
##K	O
##D	O
with	O
a	O
median	O
score	O
of	O
87	O
.	O

Sign	O
##ificant	O
correlation	O
##s	O
were	O
also	O
observed	O
between	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
g	I
##lu	I
##cu	I
##ron	I
##ide	I
formation	O
with	O
m	B
##or	I
##phine	I
3	O
-	O
g	O
##lu	O
##cu	O
##ron	O
##ida	O
##tion	O
(	O
Pearson	O
r	O
=	O
0	O
.	O
56	O
,	O
P	O
<	O
0	O
.	O
000	O
##1	O
)	O
,	O
a	O
probe	O
reaction	O
for	O
U	O
##G	O
##T	O
##2	O
##B	O
##7	O
.	O

Some	O
of	O
the	O
main	O
pathways	O
involve	O
in	O
plate	O
##let	O
activation	O
/	O
a	O
##gg	O
##regation	O
are	O
the	O
ad	B
##eno	I
##sin	I
##e	I
dip	I
##hos	I
##phate	I
and	O
a	B
##rac	I
##hi	I
##don	I
##ic	I
acid	I
metabolism	O
.	O

The	O
a	O
##que	O
##ous	O
phase	O
was	O
re	O
-	O
extracted	O
with	O
500	O
μ	O
##l	O
of	O
ice	O
-	O
cold	O
ch	B
##lor	I
##of	I
##orm	I
,	O
v	O
##ortex	O
##ed	O
again	O
for	O
2	O
min	O
and	O
cent	O
##ri	O
##fu	O
##ged	O
at	O
12	O
,	O
000	O
R	O
##PM	O
for	O
2	O
min	O
.	O

G	B
##S	I
##H	I
,	O
reduced	B
g	I
##lut	I
##ath	I
##ione	I
;	O
G	O
##SS	O
##G	O
,	O
o	B
##xi	I
##dized	I
g	I
##lut	I
##ath	I
##ione	I
:	O
GP	O
##x	O
,	O
g	B
##lut	I
##ath	I
##ione	I
per	O
##ox	O
##idas	O
##e	O
;	O
H	O
##b	O
,	O
hem	O
##og	O
##lo	O
##bin	O
;	O
S	O
##OD	O
,	O
super	B
##oxide	I
di	O
##sm	O
##uta	O
##se	O
;	O
MD	O
##A	O
,	O
ma	B
##lon	I
##dial	I
##de	I
##hy	I
##de	I
;	O
IL	O
-	O
6	O
,	O
inter	O
##le	O
##uki	O
##n	O
-	O
6	O
,	O
T	O
##NF	O
-	O
α	O
:	O
tumor	O
ne	O
##c	O
##rosis	O
factor	O
-	O
alpha	O
;	O
K	O
##BR	O
,	O
Korean	O
black	O
r	O
##as	O
##p	O
##berry	O
.	O
_	O
1	O

The	O
cross	O
-	O
peak	O
patterns	O
are	O
characteristic	O
of	O
particular	O
meta	O
##bol	O
##ites	O
,	O
such	O
as	O
the	O
rib	B
##ose	I
m	O
##oi	O
##eti	O
##es	O
of	O
n	O
##uc	O
##leo	O
##tide	O
##s	O
,	O
la	B
##ct	I
##ate	I
,	O
Al	O
##a	O
and	O
G	O
##lu	O
,	O
as	O
an	O
##not	O
##ated	O
.	O

Similarly	O
,	O
the	O
dominance	O
of	O
_	O
13	O
C	B
-	I
3	I
,	I
4	I
-	I
G	I
##lu	I
is	O
clear	O
from	O
the	O
_	O
13	O
C	O
satellite	O
pattern	O
for	O
the	O
cross	O
peak	O
of	O
H	O
##4	O
to	O
H	O
##3	O
of	O
G	O
##lu	O
(	O
2	O
.	O
65	O
to	O
4	O
.	O
08	O
pp	O
##m	O
in	O
Fi	O
##g	O
.	O
)	O

A	O
bio	O
##mark	O
##er	O
cluster	O
of	O
7	O
meta	O
##bol	O
##ites	O
(	B
al	B
##ani	I
##ne	I
,	O
c	B
##rea	I
##tine	I
,	O
ch	B
##olin	I
##e	I
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
la	B
##ct	I
##ate	I
,	O
le	B
##uc	I
##ine	I
,	O
and	O
v	B
##ali	I
##ne	I
)	O
was	O
identified	O
for	O
the	O
early	O
diagnosis	O
of	O
RC	O
##C	O
.	O

They	O
reported	O
that	O
a	O
multitude	O
of	O
u	O
##rem	O
##ic	O
to	B
##xin	I
##s	I
were	O
retained	O
including	O
my	O
##o	O
-	O
in	O
##os	O
##ito	O
##l	O
and	O
3	B
-	I
met	I
##hyl	I
##his	I
##ti	I
##dine	I
,	O
similar	O
to	O
our	O
findings	O
in	O
non	O
-	O
dial	O
##ys	O
##is	O
C	O
##K	O
##D	O
patients	O
.	O

Con	O
##ditions	O
:	O
60	O
cm	O
long	O
(	O
375	O
µ	O
##m	O
O	O
.	O
D	O
.	O
,	O
50	O
µ	O
##m	O
I	O
.	O
D	O
.	O
)	O
fused	O
si	B
##lica	I
cap	O
##illa	O
##ry	O
.	O

Con	O
##cent	O
##rations	O
in	O
21	O
AA	O
##s	O
and	O
3	O
bio	O
##genic	O
am	O
##ines	O
(	O
as	O
##ym	O
##metric	O
dim	B
##eth	I
##yl	I
a	I
##rg	I
##ini	I
##ne	I
[	O
AD	O
##MA	O
]	O
,	O
symmetric	O
dim	B
##eth	I
##yl	I
a	I
##rg	I
##ini	I
##ne	I
[	O
SD	O
##MA	O
]	O
,	O
and	O
h	B
##ydro	I
##xy	I
##ky	I
##nu	I
##ren	I
##ine	I
[	O
OH	O
-	O
K	O
##yn	O
]	O
)	O
were	O
determined	O
by	O
liquid	O
ch	O
##roma	O
##tography	O
coupled	O
with	O
tandem	O
mass	O
s	O
##pect	O
##rome	O
##try	O
with	O
electro	O
##sp	O
##ray	O
ion	O
##ization	O
using	O
the	O
A	O
##bs	O
##ol	O
##ute	O
ID	O
##Q	O
p	O
##18	O
##0	O
Kit	O
(	O
B	O
##IO	O
##CR	O
##AT	O
##ES	O
Life	O
Sciences	O
AG	O
,	O
Inn	O
##s	O
##bruck	O
,	O
Austria	O
)	O
.	O

These	O
preparations	O
were	O
loaded	O
onto	O
a	O
Te	O
##can	O
Li	O
##quid	O
Hand	O
##ling	O
System	O
(	O
Te	O
##can	O
,	O
Research	O
Triangle	O
Park	O
,	O
NC	O
)	O
,	O
and	O
reactions	O
were	O
initiated	O
by	O
addition	O
of	O
an	O
N	O
##AD	O
##P	O
##H	O
-	O
generating	O
system	O
containing	O
N	B
##AD	I
##P	I
(	O
1	O
m	O
##M	O
)	O
,	O
glucose	B
-	I
6	I
-	I
phosphate	I
(	O
5	O
m	O
##M	O
)	O
,	O
and	O
glucose	O
-	O
6	O
-	O
phosphate	O
de	O
##hy	O
##dr	O
##ogen	O
##ase	O
(	O
1	O
Unit	O
/	O
m	O
##L	O
)	O
.	O

Thereafter	O
,	O
al	O
##iq	O
##uo	O
##ts	O
of	O
50	O
μ	O
##L	O
of	O
the	O
di	O
##lut	O
##ed	O
samples	O
were	O
transferred	O
to	O
the	O
well	O
plates	O
,	O
adding	O
25	O
μ	O
##L	O
of	O
the	O
multi	O
##ana	O
##ly	O
##te	O
mixture	O
of	O
labeled	O
internal	O
standards	O
prepared	O
in	O
met	B
##han	I
##ol	I
to	O
each	O
well	O
.	O

The	O
combined	O
e	O
##ff	O
##lue	O
##nt	O
(	O
5	O
m	O
##l	O
)	O
was	O
di	O
##lut	O
##ed	O
with	O
water	O
(	O
4	O
m	O
##l	O
)	O
to	O
give	O
9	O
m	O
##l	O
of	O
[UNK]	O
%	O
met	B
##han	I
##ol	I
.	O

BC	O
,	O
breast	O
cancer	O
;	O
A	O
##rg	O
,	O
a	B
##rg	I
##ini	I
##ne	I
;	O
G	O
##lu	O
,	O
g	B
##lut	I
##ama	I
##te	I
;	O
L	O
##ys	O
,	O
l	B
##ys	I
##ine	I
;	O
Ty	O
##r	O
,	O
t	B
##yr	I
##os	I
##ine	I
;	O
His	O
,	O
his	B
##ti	I
##dine	I
.	O

For	O
17	B
-	I
h	I
##ydro	I
##xy	I
##p	I
##rog	I
##ester	I
##one	I
,	O
age	O
specific	O
references	O
are	O
shown	O
for	O
males	O
,	O
whereas	O
for	O
females	O
reference	O
intervals	O
are	O
shown	O
according	O
pre	O
-	O
versus	O
post	O
-	O
men	O
##op	O
##aus	O
##al	O
status	O
.	O

However	O
,	O
a	O
weak	O
correlation	O
was	O
observed	O
in	O
the	O
CC	O
##RT	O
group	O
between	O
individual	O
changes	O
in	O
serum	O
levels	O
of	O
total	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
and	O
album	O
##in	O
(	O
B	O
)	O
.	O

Other	O
negative	O
correlation	O
##s	O
in	O
HC	O
##V	O
plasma	O
worthy	O
of	O
note	O
are	O
between	O
v	B
##ali	I
##ne	I
and	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
is	B
##ole	I
##uc	I
##ine	I
with	O
o	B
##le	I
##ic	I
acid	I
(	O
common	O
to	O
H	O
##B	O
##V	O
plasma	O
;	O
a	O
)	O
,	O
and	O
g	B
##ly	I
##cine	I
with	O
ethanol	B
##amine	I
.	O

According	O
to	O
insect	O
models	O
,	O
the	O
chemical	O
components	O
of	O
in	O
##fect	O
##ing	O
micro	O
##or	O
##gan	O
##isms	O
,	O
such	O
as	O
lip	B
##op	I
##oly	I
##sa	I
##cc	I
##hari	I
##de	I
,	O
stimulate	O
a	O
number	O
of	O
in	O
##tra	O
##cellular	O
trans	O
##duction	O
systems	O
,	O
including	O
those	O
responsible	O
for	O
up	O
##re	O
##gu	O
##lation	O
of	O
e	B
##ico	I
##san	I
##oid	I
bio	O
##sy	O
##nt	O
##hesis	O
by	O
p	O
##hos	O
##ph	O
##oli	O
##pas	O
##e	O
A	O
_	O
2	O
activation	O
.	O

Su	B
##cci	I
##nic	I
and	O
f	O
##uma	O
##ric	O
acids	O
were	O
found	O
in	O
all	O
103	O
studied	O
serum	O
samples	O
.	O

[	O
]	O
,	O
the	O
current	O
study	O
replica	O
##ted	O
this	O
importance	O
and	O
demonstrated	O
that	O
the	O
concentration	O
of	O
1	B
-	I
met	I
##hyl	I
##ade	I
##nos	I
##ine	I
was	O
increased	O
in	O
cluster	O
Y	O
.	O
Heat	O
map	O
of	O
q	O
##uant	O
##ified	O
meta	O
##bol	O
##ites	O
showing	O
significant	O
differences	O
(	O
P	O
<	O
0	O
.	O
05	O
;	O
Mann	O
-	O
Whitney	O
test	O
)	O
between	O
the	O
he	O
##pa	O
##titis	O
B	O
virus	O
-	O
related	O
he	O
##pa	O
##to	O
##cellular	O
car	O
##cin	O
##oma	O
and	O
he	O
##pa	O
##titis	O
C	O
virus	O
-	O
related	O
he	O
##pa	O
##to	O
##cellular	O
car	O
##cin	O
##oma	O
groups	O
.	O

It	O
was	O
found	O
that	O
the	O
identified	O
meta	O
##bol	O
##ites	O
were	O
primarily	O
involved	O
in	O
pu	B
##rine	I
,	O
p	B
##yr	I
##im	I
##id	I
##ine	I
,	O
try	B
##pt	I
##op	I
##han	I
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
fatty	O
acid	O
β	O
-	O
oxidation	O
,	O
c	B
##it	I
##rate	I
cycle	O
,	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
,	O
s	B
##phi	I
##ngo	I
##lip	I
##id	I
,	O
and	O
bi	O
##le	O
acid	O
bio	O
##sy	O
##nt	O
##hesis	O
metabolism	O
.	O

One	O
unit	O
of	O
a	O
##rg	O
##inas	O
##e	O
converts	O
1	O
μ	O
##mo	O
##l	O
of	O
l	B
-	I
a	I
##rg	I
##ini	I
##ne	I
to	O
or	B
##ni	I
##thin	I
##e	I
and	O
u	B
##rea	I
per	O
minute	O
at	O
pH	O
9	O
.	O
5	O
and	O
37	O
°C	O
.	O

Major	O
fragment	O
ions	O
are	O
observed	O
in	O
the	O
product	O
ion	O
spectrum	O
of	O
des	B
##ami	I
##no	I
-	I
Ph	I
##IP	I
-	I
modified	I
t	I
##yr	I
##os	I
##ine	I
(	O
[	O
M	O
+	O
H	O
]	O
_	O
+	O
at	O
m	O
/	O
z	O
38	O
##9	O
.	O
3	O
)	O
at	O
m	O
/	O
z	O
34	O
##4	O
.	O
2	O
[	O
M	O
+	O
H	O
-	O
NH	O
_	O
3	O
-	O
CO	O
]	O
_	O
+	O
,	O
34	O
##3	O
.	O
2	O
[	O
M	O
+	O
H	O
-	O

The	O
internal	O
standard	O
,	O
z	O
##ile	O
##uto	O
##n	O
[	B
N	B
-	I
(	I
1	I
-	I
ben	I
##zo	I
##bt	I
##hi	I
##en	I
-	I
2	I
-	I
y	I
##let	I
##hyl	I
)	I
–	I
N	I
-	I
h	I
##ydro	I
##xy	I
##ure	I
##a	I
)	O
]	O
was	O
obtained	O
from	O

Several	O
meta	O
##bol	O
##ites	O
were	O
significantly	O
associated	O
with	O
1st	O
-	O
,	O
2nd	O
-	O
,	O
and	O
3rd	O
##ye	O
##ar	O
re	O
##current	O
w	O
##hee	O
##zing	O
,	O
however	O
,	O
only	O
al	B
##ani	I
##ne	I
remained	O
significantly	O
associated	O
with	O
reduced	O
risk	O
for	O
1st	O
-	O
year	O
re	O
##current	O
w	O
##hee	O
##zing	O
after	O
F	O
##DR	O
adjustment	O
(	O
F	O
##DR	O
adjusted	O
p	O
value	O
<	O
0	O
.	O
00	O
##1	O
)	O
.	O

After	O
loading	O
of	O
sample	O
on	O
plate	O
,	O
the	O
phase	O
was	O
washed	O
with	O
2	O
×	O
200	O
μ	O
##L	O
of	O
water	O
and	O
el	O
##uted	O
with	O
600	O
μ	O
##L	O
of	O
met	B
##han	I
##ol	I
.	O

Met	O
##ab	O
##olis	O
##m	O
of	O
these	O
essential	O
FA	O
##s	O
can	O
increase	O
the	O
levels	O
of	O
the	O
inflammation	O
-	O
associated	O
free	O
FA	B
a	I
##rac	I
##hi	I
##don	I
##ate	I
(	I
20	I
:	I
4	I
##n	I
##6	I
)	I
,	O
which	O
was	O
also	O
significantly	O
higher	O
in	O
C	O
-	O
3	O
##N	O
subjects	O
and	O
had	O
a	O
non	O
##sign	O
##ificant	O
increased	O
trend	O
in	O
A	O
-	O
3	O
##N	O
subjects	O
compared	O
to	O
control	O
subjects	O
.	O

Within	O
-	O
run	O
(	O
n	O
=	O
20	O
replica	O
##tes	O
)	O
and	O
within	O
-	O
laboratory	O
(	O
n	O
=	O
80	O
replica	O
##tes	O
)	O
imp	O
##re	O
##cision	O
were	O
determined	O
using	O
serum	O
pools	O
with	O
low	O
,	O
intermediate	O
and	O
high	O
beta	B
##ine	I
values	O
.	O

High	O
levels	O
of	O
try	B
##pt	I
##op	I
##han	I
have	O
also	O
been	O
shown	O
in	O
urine	O
from	O
AD	O
##HD	O
children	O
along	O
with	O
low	O
H	O
##AA	O
/	O
HK	O
ratios	O
which	O
made	O
the	O
authors	O
suggest	O
that	O
this	O
was	O
due	O
to	O
a	O
low	O
activity	O
of	O
B	O
##6	O
-	O
dependent	O
enzymes	O
.	O

To	O
evaluate	O
carry	O
##over	O
,	O
a	O
blank	O
sample	O
was	O
immediately	O
injected	O
following	O
the	O
highest	O
standard	O
(	O
4	O
/	O
16	O
μ	O
##g	O
/	O
m	O
##L	O
of	O
Ce	B
##r	I
(	I
22	I
:	I
0	I
)	I
/	I
Ce	I
##r	I
(	I
24	I
:	I
0	I
)	I
)	O
.	O

ii	O
,	O
Li	O
##A	O
##I	O
##H	O
_	O
4	O
,	O
te	B
##tra	I
##hy	I
##dr	I
##of	I
##ura	I
##n	I
,	O
room	O
temperature	O
,	O
45	O
min	O
(	O
for	O
compound	O
2	O
,	O
9	O
)	O
;	O
D	O
##IB	O
##AL	O
-	O
H	O
,	O
CH	O
_	O
2	O
C	O
##l	O
_	O
2	O
,	O
room	O
temperature	O
,	O
30	O
min	O
(	O
for	O
compound	O
6	O
)	O
.	O

Here	O
,	O
brain	O
-	O
f	O
##ru	O
##ct	O
##ose	O
levels	O
were	O
elevated	O
in	O
all	O
cases	O
,	O
consistent	O
with	O
the	O
findings	O
for	O
glucose	S
and	O
so	B
##rb	I
##ito	I
##l	I
(	O
and	O
a	O
;	O
)	O
.	O

The	O
ass	O
##ay	O
demonstrated	O
linear	O
ranges	O
of	O
0	O
.	O
4	O
–	O
40	O
.	O
0	O
ng	O
/	O
m	O
##L	O
,	O
for	O
ex	O
##em	O
##esta	O
##ne	O
;	O
and	O
0	O
.	O
2	O
–	O
15	O
.	O
0	O
ng	O
/	O
m	O
##L	O
,	O
for	O
17	B
##β	I
-	I
di	I
##hy	I
##dr	I
##oe	I
##xe	I
##mes	I
##tan	I
##e	I
and	O
17	B
##β	I
-	I
di	I
##hy	I
##dr	I
##oe	I
##xe	I
##mes	I
##tan	I
##e	I
-	I
17	I
-	I
O	I
-	I
β	I
-	I
D	I
-	I
g	I
##lu	I
##cu	I
##ron	I
##ide	I
,	O
with	O
coefficient	O
of	O
determination	O
(	O
r	O
_	O
2	O
)	O
of	O
>	O
0	O
.	O
99	O
##8	O
.	O

This	O
is	O
to	O
be	O
expected	O
from	O
the	O
metabolic	O
point	O
of	O
view	O
,	O
as	O
al	B
##ip	I
##hat	I
##ic	I
al	I
##de	I
##hy	I
##des	I
in	O
humans	O
are	O
largely	O
produced	O
by	O
a	O
ca	O
##sca	O
##de	O
of	O
cat	O
##ab	O
##olic	O
metabolism	O
of	O
several	O
lip	O
##ids	O
.	O

After	O
transfer	O
of	O
the	O
met	B
##hyl	I
group	I
SA	O
##M	O
is	O
converted	O
to	O
S	B
-	I
ad	I
##eno	I
##sy	I
##l	I
##hom	I
##oc	I
##ys	I
##tein	I
##e	I
(	O
SA	O
##H	O
)	O
,	O
which	O
is	O
broken	O
down	O
further	O
to	O
ho	B
##mo	I
##cy	I
##stein	I
##e	I
,	O
c	B
##ys	I
##tat	I
##hi	I
##oni	I
##ne	I
and	O
c	B
##ys	I
##tein	I
##e	I
.	O

The	O
su	B
##lf	I
##oxide	I
##s	I
were	O
detected	O
in	O
the	O
urine	O
of	O
highly	O
exposed	O
c	O
##re	O
##oso	O
##te	O
workers	O
.	O

Dec	O
##reased	O
se	B
##rine	I
palm	I
##ito	I
##yl	I
-	I
Co	I
##A	I
transfer	O
##ase	O
(	O
SP	O
##T	O
)	O
activity	O
is	O
associated	O
with	O
met	O
##ha	O
##cho	O
##line	O
-	O
induced	O
air	O
##way	O
h	O
##yper	O
##rea	O
##ct	O
##ivity	O
.	O

Next	O
,	O
we	O
explored	O
the	O
potential	O
relationships	O
of	O
serum	O
co	B
##rt	I
##is	I
##ol	I
,	O
PS	O
##G	O
variables	O
(	O
sleep	O
efficiency	O
,	O
percentage	O
time	O
in	O
rapid	O
eye	O
movement	O
[	O
R	O
##EM	O
]	O
sleep	O
)	O
and	O
self	O
-	O
reported	O
sleep	O
indicators	O
to	O
T	O
##RP	O
meta	O
##bol	O
##ites	O
.	O

Pa	O
##sik	O
##anti	O
,	O
et	O
al	O
.	O
showed	O
elevated	O
concentrations	O
of	O
try	B
##pt	I
##op	I
##han	I
meta	O
##bol	O
##ites	O
in	O
the	O
urine	O
of	O
BC	O
##A	O
patients	O
.	O

Groups	O
did	O
not	O
differ	O
at	O
any	O
time	O
point	O
for	O
measures	O
included	O
in	O
the	O
chemistry	O
panel	O
(	O
all	O
interaction	O
effects	O
,	O
P	O
>	O
0	O
.	O
05	O
)	O
despite	O
strong	O
exercise	O
induced	O
increases	O
for	O
many	O
of	O
these	O
including	O
blood	O
u	B
##rea	I
nitrogen	I
(	O
B	O
##UN	O
)	O
,	O
bi	B
##li	I
##ru	I
##bin	I
,	O
c	B
##rea	I
##tin	I
##ine	I
,	O
al	O
##kal	O
##ine	O
p	O
##hos	O
##pha	O
##tase	O
(	O
AL	O
##K	O
)	O
,	O
and	O
as	O
##par	O
##tate	O
amino	O
##tra	O
##ns	O
##fer	O
##ase	O
(	O
AS	O
##T	O
)	O
(	O
time	O
effects	O
,	O
P	O
<	O
0	O
.	O
00	O
##1	O
,	O
data	O
not	O
shown	O
)	O
.	O

N	B
-	I
Ace	I
##ty	I
##l	I
##cy	I
##stein	I
##e	I
(	O
N	O
##AC	O
)	O
was	O
purchased	O
from	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
(	O
St	O
.	O
Louis	O
,	O
M	O
##O	O
)	O
.	O

Then	O
,	O
300	O
μ	O
##L	O
of	O
th	O
##awed	O
sample	O
was	O
mixed	O
with	O
300	O
μ	O
##L	O
of	O
phosphate	S
buffer	O
(	O
pH	O
7	O
.	O
4	O
)	O
containing	O
10	O
%	O
D	O
_	O
2	O
O	O
.	O
After	O
v	O
##ortex	O
mixing	O
and	O
cent	O
##ri	O
##fu	O
##gation	O
,	O
550	O
μ	O
##L	O
of	O
the	O
solution	O
was	O
transferred	O
into	O
5	O
mm	O
N	O
##MR	O
tubes	O
and	O
kept	O
at	O
4	O
°C	O
prior	O
to	O
the	O
N	O
##MR	O
analysis	O
.	O

The	O
ratio	O
represents	O
the	O
observed	O
level	O
of	O
_	O
13	O
C	O
-	O
labeled	O
intermediate	O
observed	O
in	O
i	O
##RB	O
##C	O
compared	O
to	O
that	O
in	O
u	O
##RB	O
##C	O
after	O
a	O
40	O
hour	O
in	O
##cu	O
##bation	O
with	O
_	O
13	O
C	B
-	I
U	I
-	I
glucose	I
.	O

There	O
are	O
two	O
main	O
processes	O
that	O
orchestra	O
##te	O
DNA	O
met	O
##hyl	O
##ation	O
of	O
key	O
e	O
##pi	O
##gene	O
##tic	O
regulator	O
##s	O
;	O
these	O
involve	O
5	B
-	I
met	I
##hyl	I
##cy	I
##tos	I
##ine	I
(	O
5	O
##m	O
##C	O
)	O
and	O
5	B
-	I
h	I
##ydro	I
##xy	I
##met	I
##hyl	I
##cy	I
##tos	I
##ine	I
(	O
5	O
##hm	O
##C	O
)	O
,	O
which	O
are	O
located	O
on	O
the	O
C	O
##p	O
##G	O
islands	O
of	O
gene	O
promoter	O
##s	O
and	O
enhance	O
##rs	O
.	O

After	O
adding	O
Me	B
##OH	I
and	O
CH	O
##C	O
##l	O
_	O
3	O
,	O
the	O
upper	O
-	O
layer	O
solvent	O
became	O
[UNK]	O
50	O
%	O
Me	B
##OH	I
with	O
some	O
CH	O
##C	O
##l	O
_	O
3	O
at	O
an	O
apparent	O
pH	O
[UNK]	O
3	O
.	O

However	O
our	O
study	O
showed	O
clearly	O
that	O
weight	O
loss	O
with	O
the	O
addition	O
of	O
diet	O
##ary	O
fish	O
oil	O
supplement	O
##ation	O
causes	O
a	O
large	O
rear	O
##rang	O
##ement	O
of	O
the	O
lip	O
##id	O
t	B
##rig	I
##ly	I
##cer	I
##ide	I
pool	O
.	O

Recently	O
,	O
whole	O
blood	O
ch	B
##olin	I
##e	I
(	O
W	O
##BC	O
##H	O
##O	O
)	O
is	O
used	O
as	O
an	O
early	O
marker	O
for	O
AC	O
##S	O
patients	O
,	O
in	O
addition	O
to	O
predict	O
##ing	O
cardiac	O
is	O
##che	O
##mia	O
in	O
patients	O
with	O
negative	O
t	O
##rop	O
##oni	O
##n	O
.	O

Because	O
patient	O
5	O
required	O
repeated	O
pu	O
##nc	O
##tures	O
of	O
the	O
Rick	O
##ham	O
reservoir	O
due	O
to	O
o	O
##cc	O
##lus	O
##ive	O
h	B
##ydro	I
##ce	I
##pha	I
##lus	I
(	O
Figure	O
S	O
##2	O
)	O
,	O
CF	O
##S	O
levels	O
could	O
be	O
monitored	O
over	O
time	O
.	O

When	O
the	O
metabolic	O
flux	O
of	O
conversion	O
of	O
[	O
1	O
-	O
_	O
13	O
C	O
]	O
-	O
p	O
##yr	O
##u	O
##vate	O
to	O
[	B
1	I
-	I
_	I
13	I
C	I
]	I
-	I
la	I
##ct	I
##ate	I
was	O
measured	O
,	O
the	O
ratio	O
of	O
[	B
1	I
-	I
_	I
13	I
C	I
]	I
-	I
la	I
##ct	I
##ate	I
/	I
[	I
1	I
-	I
_	I
13	I
C	I
]	I
-	O
p	O
##yr	O
##u	O
##vate	O
was	O
significantly	O
elevated	O
in	O
regions	O
of	O
meta	O
##static	O
PC	O
##a	O
compared	O
to	O
normal	O
tissue	O
.	O

However	O
,	O
PC	O
##ho	O
is	O
h	O
##ydro	O
##ly	O
##zed	O
by	O
p	O
##hos	O
##pha	O
##tase	O
to	O
free	O
ch	B
##olin	I
##e	I
,	O
which	O
is	O
absorbed	O
via	O
carrier	O
-	O
mediated	O
transport	O
at	O
the	O
in	O
##test	O
##ine	O
.	O

The	O
two	O
d	O
##h	O
##SM	O
##s	O
positively	O
associated	O
with	O
o	O
##besity	O
–	O
SM	O
36	O
:	O
0	O
and	O
SM	B
(	I
d	I
##18	I
:	I
0	I
/	I
24	I
:	I
0	I
)	I
–	O
were	O
also	O
positively	O
associated	O
with	O
d	O
##ys	O
##gly	O
##ce	O
##mia	O
,	O
along	O
with	O
Ce	B
##r	I
(	I
d	I
##18	I
:	I
0	I
/	I
24	I
:	I
0	I
)	I
.	O

Met	B
##hi	I
##oni	I
##ne	I
is	O
first	O
converted	O
to	O
SA	O
##M	O
,	O
the	O
donor	O
of	O
met	O
##hyl	O
groups	O
in	O
all	O
but	O
one	O
met	O
##hyl	O
##tra	O
##ns	O
##fer	O
##ase	O
reaction	O
.	O

Inter	O
-	O
day	O
and	O
inter	O
-	O
day	O
accuracy	O
,	O
precision	O
,	O
extraction	O
recovery	O
,	O
and	O
matrix	O
effect	O
results	O
were	O
compared	O
at	O
each	O
Q	O
##C	O
concentration	O
level	O
by	O
Student	O
’	O
s	O
t	O
-	O
test	O
between	O
plasma	O
containing	O
low	O
and	O
high	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
.	O

Previously	O
,	O
a	O
European	O
study	O
analyzing	O
g	O
##eno	O
##mic	O
alterations	O
in	O
promoter	O
variants	O
involved	O
in	O
bi	B
##li	I
##ru	I
##bin	I
home	O
##ost	O
##asis	O
,	O
and	O
another	O
study	O
investigating	O
serum	O
bi	B
##li	I
##ru	I
##bin	I
levels	O
in	O
a	O
large	O
U	O
.	O
S	O
.	O
population	O
have	O
proposed	O
a	O
protective	O
effect	O
of	O
bi	B
##li	I
##ru	I
##bin	I
against	O
color	O
##ec	O
##tal	O
car	O
##cin	O
##ogen	O
##esis	O
;	O
43	O
,	O
44	O
our	O
meta	O
##bol	O
##omi	O
##cs	O
findings	O
carefully	O
support	O
this	O
hypothesis	O
.	O

104	O
cases	O
(	O
77	O
%	O
)	O
had	O
raised	O
serum	O
test	B
##osterone	I
,	O
including	O
all	O
those	O
women	O
who	O
did	O
not	O
report	O
being	O
affected	O
by	O
hi	O
##rs	O
##uti	O
##sm	O
.	O

In	O
general	O
,	O
the	O
abundance	O
##s	O
of	O
LP	B
##C	I
(	I
16	I
:	I
1	I
)	I
and	O
PC	B
(	I
33	I
:	I
1	I
)	I
were	O
higher	O
in	O
the	O
me	O
##lo	O
##xi	O
##cam	O
group	O
than	O
those	O
in	O
the	O
control	O
group	O
.	O

Since	O
all	O
compounds	O
containing	O
the	O
N	B
-	I
ace	I
##ty	I
##l	I
##cy	I
##stein	I
##e	I
su	I
##lf	I
##oxide	I
m	O
##oi	O
##ety	O
(	O
5	O
,	O
9	O
,	O
13	O
and	O
12	O
)	O
lost	O
147	O
Da	O
(	O
C	O
_	O
5	O
H	O
_	O
9	O
N	O
##0	O
_	O
5	O
)	O
as	O
a	O
neutral	O
fragment	O
,	O
the	O
urine	O
samples	O
were	O
re	O
-	O
analyzed	O
by	O
tandem	O
mass	O
s	O
##pect	O
##rome	O
##try	O
with	O
a	O
constant	O
neutral	O
loss	O
scan	O
of	O
147	O
.	O

According	O
to	O
the	O
profile	O
,	O
the	O
levels	O
of	O
α	O
-	O
and	O
β	B
-	I
glucose	I
decreased	O
,	O
those	O
of	O
la	B
##ct	I
##ate	I
and	O
low	O
-	O
density	O
lip	O
##op	O
##rote	O
##ins	O
increased	O
,	O
and	O
the	O
expression	O
of	O
multiple	O
amino	O
acids	O
was	O
altered	O
.	O

For	O
example	O
,	O
studies	O
showed	O
that	O
ca	O
##ffe	O
##inated	O
coffee	O
stimulate	O
##s	O
co	O
##lon	O
##ic	O
motor	O
activity	O
to	O
a	O
greater	O
extent	O
than	O
does	O
de	O
##ca	O
##ffe	O
##inated	O
coffee	O
,	O
ca	B
##ffe	I
##ine	I
in	O
##hibit	O
##s	O
co	O
##lon	O
cancer	O
cell	O
growth	O
,	O
and	O
the	B
##op	I
##hyl	I
##line	I
induce	O
##s	O
a	O
##pop	O
##tosis	O
in	O
cancer	O
cell	O
lines	O
.	O

A	O
stripped	O
sample	O
that	O
had	O
undergone	O
preparation	O
procedure	O
was	O
injected	O
into	O
the	O
column	O
,	O
and	O
the	O
effect	O
of	O
matrix	O
suppression	O
on	O
the	O
response	O
of	O
the	O
in	O
##fused	O
o	B
##xy	I
##ster	I
##ols	I
was	O
monitored	O
.	O

In	O
contrast	O
,	O
F	O
.	O
p	O
##ra	O
##us	O
##nitz	O
##ii	O
(	O
lower	O
quantity	O
in	O
CD	O
)	O
is	O
not	O
using	O
la	B
##ct	I
##ate	I
in	O
its	O
production	O
of	O
but	B
##yra	I
##te	I
(	O
Duncan	O
et	O
al	O
.	O
)	O
,	O
and	O
no	O
la	B
##ct	I
##ate	I
increase	O
is	O
detected	O
in	O
the	O
samples	O
from	O
active	O
CD	O
.	O

This	O
method	O
measures	O
the	O
concentration	O
of	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
,	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
and	O
/	O
or	O
a	O
##poli	O
##pop	O
##rote	O
##ins	O
A1	O
,	O
A2	O
and	O
B	O
in	O
the	O
serum	O
sample	O
(	O
total	O
values	O
)	O
and	O
in	O
each	O
of	O
the	O
lip	O
##op	O
##rote	O
##in	O
sub	O
##fra	O
##ctions	O
(	O
total	O
very	O
low	O
-	O
density	O
lip	O
##op	O
##rote	O
##ins	O
(	O
V	O
##LD	O
##L	O
)	O
,	O
intermediate	O
density	O
lip	O
##op	O
##rote	O
##ins	O
(	O
ID	O
##L	O
)	O
,	O
L	O
##D	O
##L	O
and	O
HD	O
##L	O
,	O
in	O
addition	O
to	O
the	O
sub	O
##c	O
##lass	O
##es	O
V	O
##LD	O
##L	O
-	O
1	O
–	O
6	O
,	O
L	O
##D	O
##L	O
-	O
1	O
–	O
6	O
and	O
HD	O
##L	O
-	O
1	O
–	O
4	O
)	O
.	O

Ethan	B
##ol	I
was	O
purchased	O
from	O
Commercial	O
Al	O
##co	O
##hol	O
##s	O
,	O
Canada	O
.	O

B	O
##io	O
##mark	O
##ers	O
were	O
adjusted	O
for	O
c	B
##rea	I
##tin	I
##ine	I
concentrations	O
and	O
expressed	O
as	O
ng	O
/	O
mg	O
of	O
c	B
##rea	I
##tin	I
##ine	I
.	O

I	O
##dea	O
##lly	O
met	B
##had	I
##one	I
screening	O
ass	O
##ay	O
should	O
measure	O
the	O
parent	O
drug	O
,	O
E	O
##D	O
##DP	O
and	O
the	O
minor	O
meta	O
##bol	O
##ite	O
,	O
E	O
##MD	O
##P	O
.	O

For	O
those	O
k	B
##yn	I
##uren	I
##ine	I
meta	O
##bol	O
##ites	O
that	O
were	O
statistical	O
##ly	O
correlated	O
with	O
hip	O
##po	O
##cam	O
##pal	O
and	O
/	O
or	O
am	O
##y	O
##g	O
##dal	O
##ar	O
volume	O
and	O
/	O
or	O
the	O
clinical	O
rating	O
scales	O
,	O
we	O
subsequently	O
conducted	O
a	O
linear	O
re	O
##gression	O
analysis	O
to	O
control	O
for	O
the	O
potential	O
con	O
##found	O
##s	O
,	O
age	O
,	O
sex	O
,	O
B	O
##MI	O
,	O
and	O
I	O
##C	O
##V	O
(	O
model	O
3	O
)	O
.	O

Of	O
interest	O
would	O
be	O
studies	O
to	O
determine	O
whether	O
plasma	O
metabolic	O
profiles	O
can	O
predict	O
development	O
of	O
T	O
##B	O
disease	O
in	O
individuals	O
with	O
late	O
##nt	O
T	O
##B	O
,	O
whether	O
meta	O
##bol	O
##ite	O
pro	O
##fi	O
##ling	O
can	O
identify	O
subjects	O
with	O
drug	O
-	O
susceptible	O
versus	O
MD	O
##R	O
-	O
T	O
##B	O
,	O
and	O
the	O
utility	O
of	O
these	O
approaches	O
and	O
specific	O
meta	O
##bol	O
##omi	O
##c	O
signatures	O
to	O
predict	O
responses	O
to	O
new	O
anti	O
-	O
T	O
##B	O
the	O
##rap	O
##ies	O
including	O
vaccine	B
##s	I
and	O
newer	O
drug	O
combinations	O
.	O

Among	O
multiple	O
meta	O
##bol	O
##ites	O
detected	O
,	O
2	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yric	I
acid	I
(	O
2	O
-	O
H	O
##BA	O
)	O
declined	O
most	O
significantly	O
after	O
six	O
months	O
in	O
comparing	O
patients	O
that	O
underwent	O
R	O
##Y	O
##GB	O
versus	O
those	O
in	O
W	O
##LM	O
(	O
P	O
<	O
0	O
.	O
00	O
##1	O
)	O
,	O
corresponding	O
with	O
decline	O
##s	O
in	O
H	O
##OM	O
##A	O
-	O
I	O
##R	O
(	O
P	O
=	O
0	O
.	O
02	O
##5	O
)	O
.	O

The	O
FC	O
(	O
fold	O
change	O
)	O
of	O
c	B
##it	I
##ru	I
##llin	I
##e	I
,	O
v	B
##ali	I
##ne	I
,	O
and	O
ace	B
##to	I
##ace	I
##tate	I
were	O
increasingly	O
changed	O
from	O
stage	O
I	O
to	O
stage	O
IV	O
,	O
suggesting	O
the	O
expression	O
of	O
these	O
meta	O
##bol	O
##ites	O
were	O
growing	O
along	O
with	O
the	O
progression	O
of	O
gas	O
##tric	O
cancer	O
.	O

According	O
to	O
the	O
AU	O
##C	O
,	O
la	B
##ct	I
##ate	I
and	O
glucose	S
levels	O
were	O
significantly	O
higher	O
and	O
g	B
##lut	I
##ama	I
##te	I
,	O
v	B
##ali	I
##ne	I
,	O
l	B
##ys	I
##ine	I
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
c	B
##rea	I
##tin	I
##ine	I
,	O
ace	B
##tate	I
and	O
ace	B
##to	I
##ace	I
##tate	I
were	O
significantly	O
lower	O
in	O
cluster	O
M	O
##T	O
-	O
2	O
as	O
compared	O
to	O
cluster	O
M	O
##T	O
-	O
1	O
.	O

Lo	O
##gis	O
##tic	O
re	O
##gression	O
demonstrated	O
that	O
the	O
L	O
##C	O
emergence	O
was	O
independently	O
affected	O
by	O
serum	O
levels	O
of	O
my	B
##rist	I
##ic	I
acid	I
,	O
palm	B
##itic	I
acid	I
,	O
l	B
##ino	I
##le	I
##ic	I
acid	I
,	O
e	B
##ico	I
##sa	I
##pent	I
##aen	I
##oi	I
##c	I
acid	I
(	O
EPA	O
)	O
,	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dic	I
acid	I
(	O
LP	O
##A	O
)	O
(	O
18	O
:	O
1	O
)	O
,	O
g	B
##ly	I
##co	I
##lic	I
acid	I
,	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
(	O
l	O
##ys	O
##o	O
##PC	O
)	O
(	O
22	O
:	O
6	O
)	O
,	O
and	O
su	B
##cci	I
##ny	I
##lace	I
##tone	I
(	O
R	O
_	O
2	O
=	O
0	O
.	O
83	O
##7	O
,	O
P	O
<	O
0	O
.	O
00	O
##1	O
)	O
.	O

Method	O
##s	O
:	O
Health	O
##y	O
young	O
adults	O
(	O
n	O
=	O
737	O
)	O
aged	O
18	O
–	O
28	O
y	O
without	O
any	O
known	O
diseases	O
or	O
clinical	O
evidence	O
of	O
inflammation	O
provided	O
blood	O
samples	O
for	O
analysis	O
of	O
serum	O
try	O
##pt	O
##op	O
##han	O
/	O
k	O
##yn	O
##uren	O
##ine	O
meta	O
##bol	O
##ites	O
,	O
neo	B
##pt	I
##eri	I
##n	I
,	O
C	O
-	O
reactive	O
protein	O
(	O
CR	O
##P	O
)	O
,	O
and	O
plasma	O
p	B
##yr	I
##ido	I
##xa	I
##l	I

Although	O
the	O
final	O
pu	O
##rine	O
/	O
p	O
##yr	O
##im	O
##id	O
##ine	O
de	O
##graded	O
products	O
(	O
i	O
##e	O
,	O
u	B
##ric	I
acid	I
,	O
β	B
-	I
al	I
##ani	I
##ne	I
,	O
and	O
β	B
-	I
amino	I
##is	I
##ob	I
##ut	I
##yra	I
##te	I
)	O
were	O
not	O
measured	O
by	O
our	O
targeted	O
meta	O
##bol	O
##omi	O
##cs	O
platform	O
,	O
we	O
observed	O
significant	O
accumulation	O
##s	O
of	O
pu	O
##rine	O
/	O
p	O
##yr	O
##im	O
##id	O
##ine	O
degradation	O
intermediate	O
##s	O
including	O
n	O
##uc	O
##leo	O
##side	O
##s	O
and	O
n	O
##uc	O
##leo	O
##base	O
##s	O
in	O
the	O
culture	O
medium	O
of	O
both	O
He	O
##pa	O
##to	O
##C	O
##ell	O
##s	O
and	O
cancer	O
cells	O
on	O
S	O
##N	O
-	O
38	O
exposure	O
,	O
with	O
more	O
significant	O
accumulation	O
in	O
cancer	O
-	O
cell	O
medium	O
.	O

P	O
##las	O
##ma	O
my	O
##elo	O
##per	O
##ox	O
##idas	O
##e	O
(	O
MP	O
##O	O
)	O
and	O
high	O
-	O
sensitivity	O
C	O
-	O
reactive	O
protein	O
(	O
h	O
##s	O
##CR	O
##P	O
)	O
levels	O
were	O
measured	O
by	O
Card	O
##io	O
##MP	O
##O	O
ass	O
##ay	O
(	O
Cleveland	O
Heart	O
Labs	O
,	O
Cleveland	O
OH	O
)	O
as	O
well	O
as	O
N	O
late	O
##x	O
Cy	B
##sta	I
##tin	I
C	O
Card	O
##io	O
##P	O
##has	O
##e	O
ass	O
##ay	O
(	O
Siemens	O
/	O
Dad	O
##e	O
Be	O
##hr	O
##ing	O
,	O
Deer	O
##field	O
IL	O
)	O

Co	O
##mp	O
##elling	O
studies	O
have	O
demonstrated	O
the	O
effect	O
of	O
as	B
##pi	I
##rin	I
and	O
other	O
non	O
-	O
s	O
##tero	O
##idal	O
anti	O
-	O
inflammatory	O
drugs	O
(	O
NSA	O
##ID	O
##s	O
)	O
or	O
specific	O
CO	O
##X	O
-	O
2	O
inhibitor	O
##s	O
to	O
block	O
P	O
##GE	O
##2	O
synthesis	O
,	O
car	O
##cin	O
##ogen	O
##esis	O
,	O
proliferation	O
,	O
an	O
##gio	O
##genesis	O
,	O
and	O
inflammation	O
in	O
cancer	O
##s	O
of	O
the	O
co	O
##lon	O
,	O
es	O
##op	O
##ha	O
##gus	O
,	O
lung	O
,	O
bladder	O
,	O
breast	O
and	O
pro	O
##state	O
[	O
,	O
–	O
]	O
.	O

In	O
contrast	O
to	O
these	O
results	O
,	O
other	O
studies	O
demonstrated	O
that	O
l	O
##ys	O
##o	O
##PC	O
##s	O
stimulate	O
glucose	S
up	O
##take	O
in	O
3	O
##T	O
##3	O
-	O
L	O
##1	O
ad	O
##ip	O
##ocytes	O
by	O
el	O
##eva	O
##ting	O
glucose	S
transport	O
##er	O
type	O
4	O
levels	O
at	O
the	O
plasma	O
membrane	O
yielding	O
to	O
lower	O
blood	O
glucose	S
levels	O
in	O
normal	O
and	O
di	O
##abe	O
##tic	O
mice	O
.	O

D	O
##ys	O
##re	O
##gu	O
##lation	O
of	O
the	O
k	B
##yn	I
##uren	I
##ine	I
pathway	O
has	O
been	O
regarded	O
as	O
a	O
mechanism	O
of	O
tumor	O
immune	O
escape	O
by	O
the	O
en	O
##zy	O
##matic	O
activity	O
of	O
in	B
##do	I
##leam	I
##ine	I
2	O
,	O
3	O
di	O
##ox	O
##y	O
##gen	O
##ase	O
and	O
k	B
##yn	I
##uren	I
##ine	I
production	O
.	O

A	O
comparison	O
of	O
the	O
plasma	O
concentrations	O
of	O
try	B
##pt	I
##op	I
##han	I
and	O
k	B
##yn	I
##uren	I
##ine	I
in	O
women	O
with	O
breast	O
cancer	O
versus	O
normal	O
controls	O
demonstrated	O
that	O
women	O
with	O
breast	O
cancer	O
had	O
significantly	O
reduced	O
try	B
##pt	I
##op	I
##han	I
(	O
mean	O
=	O
141	O
.	O
39	O
μ	O
##M	O
)	O
compared	O
to	O
normal	O
(	O
mean	O
=	O
173	O
.	O
32	O
μ	O
##M	O
)	O
.	O

SP	O
##E	O
and	O
LL	O
##E	O
methods	O
demonstrated	O
lower	O
repeat	O
##ability	O
then	O
met	B
##han	I
##ol	I
blend	O
##s	O
with	O
the	O
poor	O
##est	O
performance	O
by	O
M	B
##T	I
##BE	I
and	O
C	O
##18	O
SP	O
##E	O
.	O

In	O
contrast	O
,	O
p	O
-	O
c	O
##res	O
##ol	O
and	O
its	O
g	B
##lu	I
##cu	I
##ron	I
##ide	I
tended	O
to	O
be	O
present	O
at	O
higher	O
concentrations	O
in	O
pre	O
-	O
surgical	O
patients	O
.	O

Free	O
e	B
##ico	I
##san	I
##oids	I
were	O
directly	O
extracted	O
with	O
2	O
m	O
##L	O
of	O
et	B
##hyl	I
ace	I
##tate	I
twice	O
from	O
plasma	O
samples	O
(	O
0	O
.	O
4	O
m	O
##L	O
)	O
after	O
adding	O
internal	O
standards	O
(	O
D	O
##H	O
##ET	O
##s	O
-	O
d	O
##8	O
4	O
.	O
8	O
ng	O
,	O
20	B
-	I
H	I
##ET	I
##E	I
-	I
d	I
##6	I
4	O
ng	O
,	O
and	O
E	O
##ET	O
-	O
d	O
##8	O
12	O
ng	O
)	O
and	O
acid	O
##ified	O
to	O
pH	O
4	O
with	O
ace	B
##tic	I
acid	I
.	O

Cy	O
##c	O
##lic	O
G	O
##uan	O
##os	O
##ine	O
mon	O
##op	O
##hos	O
##phate	O
(	O
c	O
##GM	O
##P	O
)	O
is	O
a	O
second	O
messenger	O
that	O
media	O
##tes	O
in	B
##cre	I
##tin	I
effects	O
;	O
potent	O
##iate	O
##s	O
glucose	O
-	O
stimulate	O
##d	O
insulin	O
secret	O
##ion	O
;	O
promotes	O
proper	O
beta	O
-	O
cells	O
differentiation	O
,	O
and	O
prevents	O
beta	O
-	O
cells	O
a	O
##pop	O
##tosis	O
,	O
co	O
##oper	O
##ating	O
with	O
bio	B
##tin	I
.	O

The	O
SP	O
##LA	O
##S	O
##H	O
mix	O
was	O
di	O
##lut	O
##ed	O
100	O
-	O
fold	O
in	O
met	B
##han	I
##ol	I
and	O
10	O
µ	O
##L	O
was	O
then	O
injected	O
onto	O
a	O
reversed	O
phase	O
Waters	O
CS	O
##H	O
column	O
(	O
3	O
.	O
0	O
mm	O
×	O
150	O
mm	O
×	O
1	O
.	O
7	O
µ	O
##m	O
particle	O
size	O
)	O
.	O

Co	O
##mp	O
##aris	O
##on	O
of	O
s	O
##pect	O
##ra	O
of	O
samples	O
stab	O
##ilized	O
in	O
water	O
or	O
is	B
##op	I
##rop	I
##ano	I
##l	I
showed	O
clear	O
differences	O
in	O
all	O
D	O
##G	O
species	O
profiles	O
and	O
in	O
the	O
T	B
##G	I
profiles	O
of	O
three	O
of	O
the	O
six	O
samples	O
(	O
E	O
##SM	O
Table	O
S	O
##5	O
)	O
.	O

However	O
,	O
there	O
is	O
also	O
co	O
-	O
el	O
##ution	O
of	O
neutral	O
and	O
lip	O
##id	O
compounds	O
;	O
test	B
##osterone	I
-	I
d	I
_	I
2	I
co	O
-	O
el	O
##uted	O
with	O
17	O
:	O
0	O
Ce	O
##r	O
,	O
and	O
PC	B
(	I
19	I
:	I
0	I
/	I
15	I
:	I
1	I
)	I
co	O
-	O
el	O
##uted	O
with	O
an	O
unknown	O
compound	O
with	O
a	O
similar	O
m	O
/	O

_	O
,	O
Ser	O
##um	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
are	O
routinely	O
measured	O
in	O
the	O
screening	O
of	O
neon	O
##ates	O
for	O
mitochondrial	O
fatty	O
acid	O
β	O
-	O
oxidation	O
deficiency	O
disorders	O
caused	O
by	O
defects	O
in	O
either	O
car	O
##ni	O
##tine	O
/	O
a	O
##cy	O
##l	O
##car	O
##ni	O
##tine	O
transport	O
##ers	O
or	O
enzymes	O
involved	O
in	O
β	O
-	O
oxidation	O
.	O

Before	O
meta	O
##bol	O
##ite	O
analysis	O
,	O
sample	O
was	O
that	O
0	O
.	O
6	O
m	O
##l	O
extract	O
(	O
V	O
met	B
##han	I
##ol	I
:	O
ch	B
##lor	I
##of	I
##orm	I
=	I
3	I
:	I
1	I
)	O
in	O
2	O
m	O
##l	O
EP	O
tube	O
and	O
10	O
μ	O
##L	O
L	B
-	I
2	I
-	I
ch	I
##ol	I
##rophe	I
##ny	I
##lal	I
##ani	I
##ne	I
(	O
1	O
mg	O
/	O
m	O
##L	O
stock	O
in	O
d	O
##H	O
_	O
2	O
O	O
)	O
as	O
internal	O
standard	O
were	O
mixed	O
.	O

Standard	O
solutions	O
were	O
added	O
to	O
urine	O
in	O
1	O
:	O
3	O
di	O
##lution	O
##s	O
(	O
n	O
=	O
8	O
)	O
:	O
hip	B
##pur	I
##ic	I
acid	I
(	O
δ	O
_	O
H	O
=	O
7	O
.	O
750	O
±	O
0	O
.	O
05	O
##0	O
pp	O
##m	O
)	O
,	O
su	B
##cci	I
##nic	I
acid	I
(	O
δ	O
_	O
H	O
=	O
2	O
.	O
335	O
±	O
0	O
.	O
03	O
##5	O
pp	O
##m	O
)	O
,	O
al	B
##ani	I
##ne	I
(	O
δ	O
_	O
H	O
=	O
1	O
.	O
400	O
±	O
0	O
.	O
05	O
##0	O
pp	O
##m	O
)	O
,	O
and	O
(	O
±	O
)	O
-	O
glucose	O
(	O
alpha	O
-	O
,	O
δ	O
_	O
H	O
=	O
5	O
.	O
150	O
±	O
0	O
.	O
05	O
##0	O
pp	O
##m	O
;	O
beta	O
-	O
,	O
δ	O
_	O
H	O
=	O
4	O
.	O
56	O
##3	O
±	O
0	O
.	O
03	O
##7	O
pp	O
##m	O
)	O
.	O

Since	O
the	O
major	O
f	O
##er	O
##ment	O
##ative	O
substrate	O
for	O
V	O
##eil	O
##lone	O
##lla	O
is	O
la	B
##ctic	I
acid	I
,	O
it	O
often	O
has	O
a	O
s	O
##ym	O
##biotic	O
relationship	O
with	O
taxa	O
such	O
as	O
St	O
##re	O
##pt	O
##oc	O
##oc	O
##ca	O
##ceae	O
whose	O
end	O
-	O
product	O
of	O
metabolism	O
is	O
la	B
##ct	I
##ate	I
.	O

Ana	B
##line	I
;	O
5	O
.	O

One	O
mill	O
##ili	O
##ter	O
of	O
et	B
##hyl	I
ace	I
##tate	I
was	O
added	O
,	O
and	O
samples	O
were	O
then	O
v	O
##ortex	O
##ed	O
and	O
cent	O
##ri	O
##fu	O
##ged	O
for	O
5	O
min	O
at	O
3000	O
##g	O
.	O

Most	O
anal	O
##yte	O
##s	O
showed	O
log	O
-	O
normal	O
distributions	O
as	O
ex	O
##em	O
##plified	O
by	O
24	B
##S	I
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##l	I
and	O
the	O
over	O
##laid	O
best	O
-	O
fit	O
curves	O
shown	O
in	O
.	O

The	O
performance	O
of	O
at	O
##rac	O
##ty	O
##li	O
##gen	O
##in	O
g	B
##lu	I
##cu	I
##ron	I
##ide	I
and	O
ca	B
##ffe	I
##ine	I
is	O
illustrated	O
in	O
.	O

The	O
potential	O
bio	O
##mark	O
##er	O
panel	O
,	O
which	O
reflects	O
metabolic	O
pathways	O
including	O
g	O
##ly	O
##co	O
##lysis	O
,	O
and	O
ch	B
##olin	I
##e	I
,	O
amino	O
acid	O
,	O
and	O
n	O
##uc	O
##leo	O
##tide	O
metabolism	O
,	O
could	O
significantly	O
differentiate	O
E	O
##SC	O
##C	O
patients	O
from	O
controls	O
.	O

We	O
fit	O
log	O
##istic	O
re	O
##gression	O
models	O
to	O
assess	O
the	O
risk	O
of	O
an	O
##gin	O
##a	O
and	O
MI	O
after	O
adjustment	O
for	O
age	O
,	O
sex	O
,	O
B	O
##MI	O
,	O
L	B
##D	I
##L	I
ch	I
##ole	I
##ster	I
##ol	I
,	O
and	O
fast	O
##ing	O
glucose	S
(	O
and	O
)	O
.	O

The	O
resulting	O
products	O
may	O
enter	O
the	O
Kennedy	O
pathway	O
for	O
the	O
de	O
no	O
##vo	O
synthesis	O
of	O
membrane	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
.	O

Cho	B
##les	I
##tero	I
##l	I
o	O
##xi	O
##das	O
##e	O
converts	O
s	O
##tero	O
##ls	O
with	O
a	O
3	B
##β	I
-	I
h	I
##ydro	I
##xy	I
-	I
5	I
-	I
en	I
##e	I
function	O
to	O
3	B
-	I
o	I
##x	I
##o	I
-	I
4	I
-	I
en	I
##e	I
analogue	O
##s	O
(	O
Scheme	O
2	O
)	O
and	O
a	O
3	B
##β	I
-	I
h	I
##ydro	I
##xy	I
-	I
5	I
##α	I
-	I
hydrogen	I
function	O
to	O
a	O
3	O
-	O
o	O
##x	O
##o	O
function	O
.	O

P	O
##las	O
##ma	O
Ce	B
##r	I
are	O
largely	O
associated	O
with	O
L	O
##D	O
##L	O
particles	O
;	O
however	O
,	O
SM	O
##s	O
are	O
also	O
largely	O
associated	O
with	O
L	O
##D	O
##L	O
##s	O
but	O
were	O
not	O
significantly	O
elevated	O
in	O
E	O
##VD	O
,	O
with	O
the	O
exception	O
of	O
SM	B
(	I
d	I
##18	I
:	I
0	I
_	I
18	I
:	I
0	I
)	I
,	O
indicating	O
the	O
Ce	B
##r	I
signature	O
is	O
not	O
solely	O
due	O
to	O
the	O
presence	O
of	O
L	O
##D	O
##L	O
##s	O
.	O

S	O
##kel	O
##etal	O
muscle	O
is	O
the	O
main	O
site	O
of	O
glucose	S
disposal	O
during	O
e	B
##ug	I
##ly	I
##ce	I
##mic	I
h	O
##yper	O
##ins	O
##ulin	O
##emia	O
and	O
the	O
key	O
organ	O
in	O
post	O
##pra	O
##ndi	O
##al	O
glucose	S
disposal	O
.	O

Given	O
the	O
low	O
var	O
##iability	O
in	O
retention	O
time	O
values	O
across	O
columns	O
,	O
the	O
large	O
variations	O
in	O
ca	B
##ffe	I
##ine	I
peak	O
area	O
were	O
investigated	O
further	O
,	O
and	O
found	O
to	O
be	O
in	O
##dicative	O
of	O
spray	O
pulsing	O
into	O
the	O
E	O
##SI	O
source	O
.	O

P	O
##las	O
##ma	O
samples	O
were	O
red	O
##iss	O
##ol	O
##ved	O
and	O
50	O
ul	O
plasma	O
was	O
placed	O
in	O
a	O
1	O
.	O
5	O
m	O
##l	O
EP	O
tube	O
,	O
then	O
200	O
ul	O
met	B
##han	I
##ol	I
solution	O
was	O
added	O
to	O
the	O
plasma	O
sample	O
.	O

Tan	O
##de	O
##m	O
use	O
of	O
mass	O
s	O
##pect	O
##rome	O
##try	O
may	O
be	O
useful	O
to	O
better	O
resolve	O
the	O
in	O
##tens	O
##ities	O
of	O
g	B
##lut	I
##amine	I
and	O
g	B
##lut	I
##ama	I
##te	I
and	O
give	O
wider	O
meta	O
##bol	O
##ite	O
coverage	O
.	O

Total	O
ch	B
##ole	I
##ster	I
##ol	I
and	O
L	B
##D	I
##L	I
ch	I
##ole	I
##ster	I
##ol	I
did	O
not	O
change	O
significantly	O
after	O
p	B
##io	I
##gli	I
##ta	I
##zone	I
mon	O
##otherapy	O
(	O
Table	O
1	O
)	O
.	O

N	B
,	I
N	I
-	I
dim	I
##eth	I
##yl	I
##gly	I
##cine	I
in	O
CD	O
(	O
P	O
_	O
CD	O
=	O
5	O
.	O
5	O
×	O
10	O
_	O
–	O
3	O
)	O
(	O
Table	O
)	O
.	O

A	O
total	O
of	O
23	O
serum	O
FA	S
were	O
identified	O
and	O
q	O
##uant	O
##ified	O
.	O

Using	O
re	B
##ser	I
##pine	I
as	O
an	O
example	O
,	O
the	O
parameters	O
for	O
Mass	O
##Works	O
s	O
##CL	O
##IP	O
##S	O
algorithms	O
were	O
:	O
mass	O
tolerance	O
,	O
5	O
pp	O
##m	O
;	O
electron	O
state	O
,	O
even	O
;	O
double	O
bond	O
equivalent	O
range	O
,	O
−	O
##3	O
to	O
50	O
;	O
profile	O
mass	O
range	O
,	O
−	O
##1	O
to	O
3	O
.	O
5	O
Da	O
;	O
ca	O
##li	O
##bra	O
##tion	O
range	O
,	O
−	O
##0	O
.	O
1	O
to	O
0	O
.	O
1	O

Present	O
##ed	O
are	O
examples	O
of	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
:	O
LP	B
##C	I
(	I
18	I
:	I
2	I
)	I

The	O
resonance	O
##s	O
ex	O
##ert	O
##ing	O
the	O
strongest	O
influence	O
on	O
the	O
class	O
discrimination	O
relate	O
to	O
the	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
parent	O
compound	O
,	O
its	O
g	B
##lu	I
##cu	I
##ron	I
##ide	I
,	O
and	O
su	B
##lf	I
##ate	I
con	O
##ju	O
##gate	O
##s	O
,	O
with	O
a	O
slightly	O
weaker	O
contribution	O
from	O
the	O
N	B
-	I
ace	I
##ty	I
##l	I
##cy	I
##stein	I
##e	I
con	O
##ju	O
##gate	O
(	O
–	O
)	O
.	O

Although	O
mechanisms	O
linking	O
glucose	S
and	O
lip	O
##id	O
metabolism	O
are	O
not	O
well	O
-	O
known	O
,	O
low	O
absorption	O
and	O
high	O
synthesis	O
of	O
ch	B
##ole	I
##ster	I
##ol	I
are	O
associated	O
with	O
high	O
circulating	O
glucose	S
levels	O
,	O
I	O
##R	O
,	O
and	O
o	O
##besity	O
.	O

The	O
levels	O
of	O
some	O
p	B
##ht	I
##hala	I
##te	I
meta	O
##bol	O
##ites	O
in	O
the	O
present	O
study	O
are	O
in	O
accordance	O
with	O
serum	O
levels	O
observed	O
in	O
others	O
.	O

The	O
mass	O
s	O
##pect	O
##rome	O
##ter	O
was	O
operated	O
in	O
the	O
positive	O
ion	O
mode	O
and	O
con	O
##figured	O
in	O
multiple	O
reaction	O
monitoring	O
(	O
MR	O
##M	O
)	O
mode	O
for	O
detection	O
of	O
en	B
##zal	I
##uta	I
##mi	I
##de	I
(	O
m	O
/	O
z	O
46	O
##5	O
→	O
209	O
)	O
,	O
N	B
-	I
des	I
##met	I
##hyl	I
##en	I
##zal	I
##uta	I
##mi	I
##de	I
(	O
m	O
/	O
z	O
45	O
##1	O
→	O
195	O
)	O
,	O
and	O
D	B
_	I
6	I
-	I
en	I
##zal	I
##uta	I
##mi	I
##de	I
(	O
m	O
/	O
z	O
47	O
##1	O
→	O
215	O
)	O
.	O

Therefore	O
one	O
important	O
step	O
in	O
developing	O
requirements	O
for	O
dairy	O
cattle	O
is	O
increasing	O
the	O
understanding	O
of	O
the	O
incorporation	O
of	O
ch	B
##olin	I
##e	I
in	O
milk	O
and	O
how	O
this	O
varies	O
through	O
la	O
##ct	O
##ation	O
.	O

Su	O
##mma	O
##ry	O
:	O
Pre	O
-	O
processing	O
parameters	O
for	O
each	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
prediction	O
model	O
.	O

All	O
six	O
p	O
##eptide	O
##s	O
contained	O
to	B
##lm	I
##eti	I
##n	I
linked	O
co	O
##valent	O
##ly	O
via	O
a	O
g	B
##lu	I
##cu	I
##ronic	I
acid	I
to	O
protein	O
l	B
##ys	I
##ine	I
groups	O
.	O

The	O
control	O
samples	O
in	O
the	O
NC	O
##NP	O
B	O
##io	O
##bank	O
were	O
collected	O
by	O
advertising	O
in	O
local	O
free	O
magazines	S
and	O
on	O
websites	O
.	O

Specifically	O
,	O
for	O
is	O
##ob	O
##ari	O
##c	O
species	O
of	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
,	O
al	B
##ky	I
##l	I
##ph	I
##os	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
and	O
al	B
##ken	I
##yl	I
##ph	I
##os	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
the	O
parent	O
and	O
product	O
ions	O
(	O
m	O
/	O
z	O
184	O
)	O
were	O
the	O
same	O
.	O

The	O
standard	O
stock	O
solutions	O
of	O
SM	O
##V	O
,	O
SM	O
##V	O
-	O
A	O
,	O
AT	O
##V	O
,	O
2	B
-	I
OH	I
-	I
AT	I
##V	I
,	O
4	B
-	I
OH	I
-	I
AT	I
##V	I
,	O
RS	O
##V	O
and	O
IS	O
were	O
prepared	O
separately	O
at	O
a	O
concentration	O
of	O
50	O
μ	O
##g	O
/	O
m	O
##l	O
each	O
in	O
met	B
##han	I
##ol	I
.	O

Given	O
that	O
o	O
##bes	O
##e	O
individuals	O
are	O
less	O
likely	O
to	O
be	O
exposed	O
to	O
sunlight	O
,	O
due	O
to	O
less	O
involvement	O
in	O
outdoor	O
activities	O
and	O
due	O
to	O
different	O
clothing	O
habits	O
,	O
their	O
major	O
source	O
of	O
vitamin	B
D	I
might	O
be	O
diet	O
rather	O
than	O
exposure	O
to	O
sunlight	O
.	O

The	O
relative	O
q	O
##uant	O
##ification	O
of	O
th	B
##iol	I
##s	I
between	O
the	O
cancer	O
and	O
healthy	O
urine	O
##s	O
was	O
performed	O
by	O
L	O
##C	O
-	O
MR	O
##M	O
-	O
MS	O
in	O
positive	O
mode	O
.	O

Re	O
##age	O
##nts	O
:	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
(	O
Sigma	O
,	O
Germany	O
)	O
.	O

L	O
of	O
trip	B
##hen	I
##yl	I
##ph	I
##os	I
##phine	I
as	O
an	O
anti	O
##ox	O
##ida	O
##nt	O
according	O
to	O
the	O
method	O
of	O
Kara	O
##ra	O
et	O
al	O
.	O

A	O
targeted	O
meta	O
##bol	O
##omi	O
##cs	O
study	O
used	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
to	O
reveal	O
that	O
lip	O
##id	O
compounds	O
(	B
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
and	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
)	O
may	O
be	O
helpful	O
for	O
different	O
##iating	O
infection	O
,	O
and	O
that	O
identified	O
lip	O
##id	O
compounds	O
may	O
become	O
promising	O
candidate	O
bio	O
##mark	O
##ers	O
.	O

G	B
##lut	I
##ama	I
##te	I
has	O
been	O
implicated	O
as	O
a	O
bio	O
##mark	O
##er	O
of	O
PC	O
##a	O
aggressive	O
##ness	O
,	O
suggesting	O
that	O
m	O
##od	O
##ulation	O
of	O
the	O
pathways	O
and	O
the	O
meta	O
##bol	O
##ome	O
could	O
m	O
##od	O
##ulate	O
tumor	O
behavior	O
(	O
,	O
)	O
.	O

Co	O
##rre	O
##ctions	O
were	O
made	O
for	O
the	O
amount	O
of	O
free	O
ch	B
##ole	I
##ster	I
##ol	I
in	O
the	O
plasma	O
samples	O
.	O

For	O
the	O
internal	O
standard	O
,	O
no	O
el	O
##uti	O
##ng	O
peaks	O
with	O
areas	O
of	O
>	O
5	O
%	O
of	O
the	O
normal	O
response	O
of	O
D	B
_	I
6	I
-	I
en	I
##zal	I
##uta	I
##mi	I
##de	I
were	O
observed	O
.	O

The	O
concentrations	O
of	O
three	O
Ph	O
##CA	O
##s	O
and	O
su	B
##cci	I
##nic	I
acid	I
are	O
shown	O
on	O
a	O
log	O
scale	O
with	O
a	O
base	O
of	O
10	O
.	O

The	O
line	O
-	O
shape	O
test	O
using	O
the	O
conventional	O
standard	O
sample	O
(	O
1	O
%	O
ch	B
##lor	I
##of	I
##orm	I
in	O
ace	B
##tone	I
-	I
d	I
_	O
6	O
)	O
gave	O
the	O
following	O
results	O
:	O
hum	O
##p	O
6	O
.	O
9	O
/	O
11	O
.	O
9	O

Lac	B
##tate	I
has	O
been	O
found	O
to	O
be	O
associated	O
with	O
the	O
progression	O
of	O
ma	O
##li	O
##gna	O
##ncy	O
through	O
the	O
formation	O
of	O
tumor	O
ne	O
##c	O
##rosis	O
.	O

Co	O
##rrel	O
##ations	O
between	O
age	O
,	O
education	O
and	O
ant	O
##hr	O
##op	O
##ometric	O
measures	O
with	O
p	B
##ht	I
##hala	I
##te	I
meta	O
##bol	O
##ites	O
are	O
shown	O
in	O
.	O

Upon	O
collection	O
,	O
the	O
CS	O
##F	O
was	O
immediately	O
frozen	O
in	O
1	O
m	O
##l	O
p	B
##oly	I
##p	I
##rop	I
##yle	I
##ne	I
tubes	O
to	O
−	O
##80	O
##°	O
##C	O
as	O
described	O
.	O

The	O
internal	O
standard	O
L	O
-	O
2	O
ch	B
##lor	I
##op	I
##hen	I
##yla	I
##lani	I
##ne	I
was	O
obtained	O
from	O
Ark	O
Ph	O
##arm	O
,	O
Inc	O
.	O
and	O
ultra	O
##pur	O
##e	O
water	O
was	O
purchased	O
from	O
E	O
##MD	O
Mill	O
##ip	O
##ore	O
.	O

Ser	O
##um	O
levels	O
of	O
AC	B
C	I
##18	I
:	I
2	I
was	O
higher	O
but	O
those	O
of	O
AC	O
C	O
##3	O
-	O
OH	O
and	O
SM	B
C	I
##24	I
:	I
1	I
were	O
lower	O
in	O
the	O
H	O
##B	O
##V	O
-	O
associated	O
c	O
##ir	O
##r	O
##hos	O
##is	O
group	O
than	O
in	O
either	O
CH	O
##B	O
or	O
H	O
##B	O
##V	O
-	O
associated	O
HC	O
##C	O
groups	O
.	O

β	B
-	I
Tu	I
##bul	I
##in	I
was	O
utilized	O
as	O
an	O
internal	O
control	O
.	O

(	O
N	O
=	O
360	O
vs	O
83	O
##7	O
##2	O
)	O
,	O
his	B
##ti	I
##dine	I
was	O
found	O
particularly	O
low	O
in	O
patients	O
with	O
re	O
##sect	O
##able	O
disease	O
stage	O
0	O
-	O
II	O
##B	O
.	O

In	O
patients	O
with	O
high	O
disease	O
activity	O
,	O
diet	O
##ary	O
factors	O
might	O
contribute	O
to	O
lower	O
levels	O
of	O
try	B
##pt	I
##op	I
##han	I
.	O

Cho	B
##line	I
containing	O
lip	O
##id	O
classes	O
(	O
SM	O
,	O
LP	O
##C	O
and	O
PC	O
)	O
were	O
also	O
detected	O
in	O
the	O
negative	O
ion	O
mode	O
as	O
format	B
##e	I
add	O
##uc	O
##ts	O
(	O
[	O
M	O
−	O

Fast	O
##ing	O
concentrations	O
of	O
bio	O
##chemical	O
efficacy	O
parameters	O
[	B
glucose	S
,	O
g	O
##ly	O
##cos	O
##yla	O
##ted	O
ha	O
##em	O
##og	O
##lo	O
##bin	O
,	O
insulin	O
,	O
C	O
-	O
p	O
##eptide	O
,	O
f	B
##ru	I
##ct	I
##osa	I
##mine	I
,	O
total	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
high	O
-	O
density	O
lip	O
##op	O
##rote	O
##in	O
-	O
and	O
low	O
-	O
density	O
lip	B
##op	I
##rote	I
##in	I
-	I
ch	I
##ole	I
##ster	I
##ol	I
,	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
,	O
free	O
fatty	O
acids	O
,	O
t	O
##umour	O
ne	O
##c	O
##rosis	O
factor	O
-	O
α	O
,	O
inter	O
##le	O
##uki	O
##n	O
(	O
IL	O
)	O
-	O
6	O
,	O
IL	B
-	I
1	I
##β	I
,	O
high	O
-	O
sensitivity	O
C	O
-	O
reactive	O
protein	O
and	O
white	O
blood	O
cell	O
count	O
]	O
were	O
determined	O
as	O
previously	O
described	O
.	O

The	O
samples	O
were	O
extracted	O
using	O
a	O
single	O
extraction	O
with	O
400	O
µ	O
##l	O
of	O
met	B
##han	I
##ol	I
,	O
containing	O
the	O
recovery	O
standards	O
:	O
t	B
##ride	I
##cano	I
##ic	I
acid	I
,	O
flu	B
##oro	I
##phe	I
##ny	I
##l	I
##gly	I
##cine	I
,	O
ch	B
##lor	I
##op	I
##hen	I
##yla	I
##lani	I
##ne	I
and	O
d	B
##6	I
-	I
ch	I
##ole	I
##ster	I
##ol	I
.	O

We	O
suggest	O
that	O
4	B
-	I
h	I
##ydro	I
##xy	I
##phe	I
##ny	I
##lace	I
##tic	I
acid	I
may	O
be	O
a	O
potential	O
bio	O
##mark	O
##er	O
for	O
SA	O
##E	O
and	O
useful	O
in	O
predict	O
##ing	O
patient	O
pro	O
##gno	O
##sis	O
.	O

Stock	O
solutions	O
(	O
1	O
mg	O
/	O
m	O
##L	O
)	O
for	O
5	B
-	I
h	I
##ydro	I
##xy	I
##ind	I
##ole	I
-	I
3	I
-	I
ace	I
##tic	I
acid	I
(	O
5	O
-	O
H	O
##IA	O
##A	O
)	O
,	O
ni	B
##cot	I
##ina	I
##mi	I
##de	I
ad	I
##eni	I
##ne	I
din	I
##uc	I
##leo	I
##tide	I
(	O
N	O
##AD	O
_	O
+	O
)	O
,	O
c	B
##it	I
##ru	I
##llin	I
##e	I
,	O
do	B
##pa	I
##mine	I
,	O
p	B
##ico	I
##lini	I
##c	I
acid	I
,	O
se	B
##rot	I
##oni	I
##n	I
,	O
q	B
##uin	I
##olin	I
##ic	I
acid	I
,	O
3	B
-	I
h	I
##ydro	I
##xy	I
##ky	I
##nu	I
##ren	I
##ine	I
(	O
3	O
-	O
HK	O
)	O
,	O
ni	B
##cot	I
##ini	I
##c	I
acid	I
,	O
k	B
##yn	I
##uren	I
##ine	I
,	O
β	B
-	I
ni	I
##cot	I
##ina	I
##mi	I
##de	I
mon	O
##on	O
##uc	O
##leo	O
##tide	O
(	O
β	O
##N	O
##M	O
)	O
,	O
try	B
##pt	I
##op	I
##han	I
,	O
and	O
ni	B
##cot	I
##ina	I
##mi	I
##de	I
rib	I
##os	I
##ide	I
were	O
dissolved	O
in	O
100	O
%	O
di	O
##lue	O
##nt	O
-	O
D	O
##1	O
.	O

In	O
ex	O
##p	O
##lora	O
##tory	O
subgroup	O
analyses	O
,	O
u	B
##rate	I
also	O
remained	O
highly	O
significant	O
(	O
P	O
=	O
0	O
.	O
00	O
##1	O
,	O
q	O
=	O
0	O
.	O
05	O
##8	O
)	O
when	O
the	O
H	O
##G	O
##D	O
/	O
EA	O
case	O
group	O
of	O
100	O
participants	O
was	O
restricted	O
to	O
the	O
22	O
included	O
EA	O
cases	O
with	O
blood	O
specimens	O
drawn	O
at	O
the	O
time	O
of	O
cancer	O
diagnosis	O
(	O
data	O
not	O
shown	O
)	O
.	O

The	O
top	O
30	O
meta	O
##bol	O
##ites	O
for	O
predict	O
##ing	O
control	O
,	O
primary	O
,	O
and	O
meta	O
##static	O
groups	O
included	O
meta	O
##bol	O
##ites	O
related	O
to	O
lip	O
##id	O
metabolism	O
(	O
cap	O
##rate	O
,	O
do	B
##cos	I
##at	I
##rien	I
##oat	I
##e	I
,	O
CDP	B
-	I
ch	I
##olin	I
##e	I
,	O
ad	O
##rena	O
##te	O
)	O
,	O
the	O
u	B
##rea	I
cycle	O
(	B
pro	B
-	I
h	I
##ydro	I
##xy	I
-	I
pro	I
,	O
put	B
##res	I
##cine	I
,	O
N	B
-	I
ace	I
##ty	I
##l	I
##g	I
##lut	I
##ama	I
##te	I
)	O
,	O
inflammation	O
or	O
ni	B
##ac	I
##in	I
bio	O
##sy	O
##nt	O
##hesis	O
(	O
k	O
##yn	O
##uren	O
##ine	O
)	O
,	O
and	O
g	O
##lut	O
##ami	O
##no	O
##lysis	O
/	O
g	O
##lut	O
##ama	O
##te	O
metabolism	O
(	B
g	B
##lut	I
##ama	I
##te	I
)	O
.	O

F	O
##E	O
_	O
i	O
is	O
a	O
vector	O
of	O
fixed	O
effect	O
observations	O
for	O
individual	O
i	O
and	O
the	O
vector	O
B	O
_	O
2	O
com	O
##pile	O
##s	O
the	O
re	O
##gression	O
coefficients	O
for	O
each	O
adjustment	O
co	O
##var	O
##iate	O
;	O
for	O
model	O
1	O
,	O
age	O
,	O
gender	O
,	O
phase	O
,	O
and	O
ethnicity	O
,	O
and	O
for	O
model	O
2	O
,	O
we	O
additionally	O
correct	O
for	O
L	O
##D	O
##L	O
and	O
HD	B
##L	I
ch	I
##ole	I
##ster	I
##ol	I
,	O
lip	O
##ids	O
and	O
blood	O
pressure	O
treatment	O
,	O
s	O
##ys	O
##to	O
##lic	O
blood	O
pressure	O
,	O
smoking	O
status	O
,	O
and	O
diabetes	O
.	O

AR	O
##ID	O
##1	O
##A	O
sustain	O
##s	O
ch	B
##roma	I
##tin	I
access	O
##ibility	O
through	O
H	O
##3	O
##K	O
##27	O
##me	O
##3	O
and	O
H	O
##3	O
##k	O
##27	O
##ac	O
in	O
the	O
enhance	O
##r	O
regions	O
.	O

While	O
a	O
significant	O
impact	O
of	O
the	O
fiber	O
supplement	O
##ation	O
on	O
the	O
post	O
##pra	O
##ndi	O
##al	O
glucose	S
response	O
could	O
be	O
confirmed	O
,	O
the	O
levels	O
of	O
the	O
downstream	O
meta	O
##bol	O
##ites	O
la	B
##ct	I
##ate	I
,	O
al	B
##ani	I
##ne	I
,	O
c	B
##it	I
##rate	I
and	O
g	B
##lut	I
##ama	I
##te	I
did	O
not	O
significantly	O
differ	O
from	O
control	O
.	O

The	O
diverse	O
profiles	O
associated	O
with	O
breast	O
cancer	O
may	O
result	O
in	O
a	O
similar	O
situation	O
because	O
breast	O
cancer	O
comprises	O
structural	O
##ly	O
differing	O
types	O
according	O
to	O
the	O
expression	O
of	O
hormone	O
receptors	O
such	O
as	O
est	B
##rogen	I
and	O
pro	B
##ges	I
##tero	I
##ne	I
,	O
and	O
is	O
affected	O
by	O
clinical	O
parameters	O
,	O
such	O
as	O
the	O
patient	O
’	O
s	O
age	O
or	O
men	O
##op	O
##aus	O
##e	O
status	O
.	O

In	O
addition	O
,	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
are	O
essential	O
components	O
of	O
lip	O
##op	O
##rote	O
##ins	O
and	O
influence	O
their	O
metabolism	O
and	O
functions	O
_	O
,	O
.	O

×	O
100	O
%	O
where	O
Response	O
_	O
post	O
-	O
extraction	O
spike	O
is	O
the	O
mean	O
peak	O
area	O
count	O
for	O
the	O
pro	B
##line	I
spike	O
##d	O
into	O
extracted	O
matrix	O
after	O
the	O
extraction	O
procedure	O
,	O
and	O
Response	O
_	O
matrix	O
-	O
free	O
spike	O
is	O
for	O
the	O
same	O
concentration	O
of	O
pro	B
##line	I
in	O
water	O
.	O

l	O
l	O
l	O
El	O
##eva	O
##ted	O
l	B
-	I
a	I
##rg	I
##ini	I
##ne	I
meta	O
##bol	O
##ites	O
in	O
plasma	O
are	O
associated	O
with	O
r	O
##he	O
##uma	O
##to	O
##id	O
art	O
##hr	O
##itis	O
incidence	O
l	O
l	O
l	O
l	O
A	O
##bb	O
##re	O
##viation	O
##s	O
:	O
AD	B
##MA	I
As	I
##ym	I
##metric	I
dim	I
##eth	I
##yla	I
##rg	I
##ini	I
##ne	I
,	O
SD	O
##MA	O
S	B
##ym	I
##metric	I
dim	I
##eth	I
##yla	I
##rg	I
##ini	I
##ne	I
,	O
A	O
##rg	O
##MI	O
A	O
##rg	O
##ini	O
##ne	O
met	O
##hyl	O
##ation	O
index	O
(	O
i	O
.	O
e	O
.	O
,	O
AD	B
##MA	I
+	O
SD	O
##MA	O
/	O
l	O
-	O
N	O
_	B
G	I
-	I
mon	I
##ome	I
##thy	I
##l	I
a	I
##rg	I
##ini	I
##ne	I
)	O
,	O
GA	O
##BR	O
Global	O
a	B
##rg	I
##ini	I
##ne	I
bio	O
##ava	O
##ila	O
##bility	O
ratio	O
(	O
i	O
.	O
e	O
.	O
,	O
ratio	O
of	O
l	B
-	I
a	I
##rg	I
##ini	I
##ne	I
to	O
l	B
-	I
or	I
##ni	I
##thin	I
##e	I
+	O
l	O
-	O
c	O
##it	O
##ru	O
##llin	O
##e	O
)	O
l	O
l	O
l	O
l	O
Ad	O
##ju	O
##sted	O
for	O
age	O
,	O
sex	O
,	O
and	O
decreased	O
re	O
##nal	O
function	O
(	O
c	O
##rea	O
##tin	O
##ine	O
>	O
1	O
.	O
4	O

Subsequently	O
,	O
produced	O
form	O
##az	O
##an	O
crystals	O
were	O
dissolved	O
in	O
D	B
##MS	I
##O	I
and	O
extinction	O
was	O
measured	O
at	O
570	O
nm	O
.	O

Sep	O
##ara	O
##tion	O
by	O
liquid	O
ch	O
##roma	O
##tography	O
was	O
performed	O
on	O
an	O
X	O
##bridge	O
_	O
®	O
B	O
##E	O
##H	O
Am	B
##ide	I
column	O
(	O
2	O
.	O
5	O
μ	O
##m	O
,	O
2	O
.	O
1	O
×	O
150	O
mm	O
;	O
Waters	O
,	O
MA	O
,	O
USA	O
)	O
at	O
40	O
°C	O
.	O

(	O
E	O
##SI	O
-	O
)	O
and	O
mobile	O
phase	O
B	O
was	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
with	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
solution	O
(	O
E	O
##SI	O
_	O
+	O
)	O
/	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
(	O
Me	O
##rc	O
##k	O
,	O
Dar	O
##ms	O
##tadt	O
,	O
Germany	O
)	O
(	O
E	O
##SI	O
-	O
)	O
.	O

Major	O
co	O
##en	O
##zy	O
##mes	O
include	O
red	O
##ox	O
co	O
##en	O
##zy	O
##mes	O
:	O
N	O
##AD	O
_	O
+	O
(	O
o	O
##xi	O
##dized	O
ni	B
##cot	I
##ina	I
##mi	I
##de	I
ad	I
##eni	I
##ne	I
din	O
##uc	O
##leo	O
##tide	O
)	O
,	O
N	B
##AD	I
##H	I
(	O
reduced	O
ni	B
##cot	I
##ina	I
##mi	I
##de	I
ad	I
##eni	I
##ne	I
din	O
##uc	O
##leo	O
##tide	O
)	O
,	O
N	O
##AD	O
##P	O
_	O
+	O
(	O
o	O
##xi	O
##dized	O
ni	B
##cot	I
##ina	I
##mi	I
##de	I
ad	I
##eni	I
##ne	I
din	I
##uc	I
##leo	I
##tide	I
phosphate	I
)	O
and	O
N	B
##AD	I
##P	I
##H	I
(	O
reduced	O
ni	B
##cot	I
##ina	I
##mi	I
##de	I
ad	I
##eni	I
##ne	I
din	I
##uc	I
##leo	I
##tide	I
phosphate	I
)	O
;	O
energy	O
co	O
##en	O
##zy	O
##mes	O
:	O
ATP	S
(	O
ad	O
##eno	O
##sin	O
##e	O
trip	B
##hos	I
##phate	I
)	O
,	O
AD	B
##P	I
(	O
ad	O
##eno	O
##sin	O
##e	O
dip	B
##hos	I
##phate	I
)	O
and	O
AM	B
##P	I
(	O
ad	O
##eno	O
##sin	O
##e	O
mon	B
##op	I
##hos	I
##phate	I
)	O
;	O
and	O
anti	O
##ox	O
##ida	O
##nts	O
:	O
G	O
##SS	O
##G	O
(	O
o	O
##xi	O
##dized	O
g	B
##lut	I
##ath	I
##ione	I
)	O
and	O
G	B
##S	I
##H	I
(	O
reduced	O
g	B
##lut	I
##ath	I
##ione	I
)	O
.	O

The	O
Li	O
##pid	O
##y	O
##zer	O
is	O
a	O
valid	O
##ated	O
platform	O
for	O
high	O
-	O
through	O
##put	O
identification	O
and	O
q	O
##uant	O
##itation	O
of	O
approximately	O
1	O
,	O
100	O
biological	O
lip	O
##ids	O
covering	O
13	O
lip	O
##id	O
classes	O
(	O
i	O
.	O
e	O
.	O
,	O
free	O
fatty	O
acids	O
,	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
,	O
ch	B
##ole	I
##ster	I
##ol	I
est	I
##ers	I
,	O
c	B
##era	I
##mi	I
##des	I
,	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
##s	I
,	O
di	B
##acy	I
##l	I
##gly	I
##cer	I
##ols	I
,	O
t	B
##ria	I
##cy	I
##l	I
##gly	I
##cer	I
##ols	I
)	O
.	O

In	O
addition	O
to	O
these	O
candidate	O
markers	O
,	O
we	O
also	O
q	O
##uant	O
##ified	O
c	B
##rea	I
##tin	I
##ine	I
which	O
is	O
required	O
for	O
normal	O
##ization	O
in	O
urine	O
.	O

However	O
,	O
we	O
found	O
decreased	O
amounts	O
of	O
ace	B
##ty	I
##l	I
##car	I
##ni	I
##tine	I
in	O
PT	O
##C	O
samples	O
compared	O
to	O
M	O
##NG	O
,	O
which	O
was	O
in	O
accordance	O
with	O
a	O
previous	O
report	O
about	O
serum	O
car	B
##ni	I
##tine	I
##s	I
content	O
in	O
thy	O
##roid	O
tumors	O
.	O

G	B
##lut	I
##ama	I
##te	I
released	O
at	O
the	O
s	O
##yna	O
##pse	O
(	O
ne	O
##uron	O
##al	O
compartment	O
)	O
activate	O
##s	O
g	B
##lut	I
##ama	I
##ter	I
##gic	I
receptors	O
,	O
and	O
it	O
is	O
then	O
taken	O
up	O
by	O
the	O
as	O
##tro	O
##cy	O
##tes	O
.	O

As	O
a	O
s	O
##cal	O
##able	O
alternative	O
,	O
we	O
used	O
a	O
per	O
##mu	O
##tation	O
-	O
based	O
method	O
to	O
estimate	O
the	O
meta	O
##bol	O
##ome	O
wide	O
significance	O
level	O
(	O
MW	O
##SL	O
or	O
α	O
′	O
)	O
in	O
which	O
the	O
outcome	O
(	B
glucose	S
levels	O
)	O
is	O
randomly	O
shuffled	O
across	O
observations	O
.	O

PC	O
##R	O
reactions	O
contained	O
2	O
–	O
3	O
ng	O
c	O
##D	O
##NA	O
per	O
well	O
,	O
based	O
on	O
normal	O
##ization	O
to	O
β	B
-	I
act	I
##in	I
and	O
0	O
.	O
1	O
μ	O
##M	O
final	O
prime	O
##r	O
concentration	O
in	O
25	O
μ	O
##l	O
.	O

C	O
##ir	O
##r	O
##hot	O
##ic	O
patients	O
have	O
significantly	O
elevated	O
levels	O
of	O
al	O
##ani	O
##ne	O
trans	O
##ami	O
##nas	O
##e	O
(	O
AL	O
##T	O
)	O
,	O
as	O
##par	O
##tate	O
trans	O
##ami	O
##nas	O
##e	O
(	O
AS	O
##T	O
)	O
,	O
c	B
##rea	I
##tin	I
##ine	I
(	O
CR	O
##EA	O
)	O
,	O
direct	O
bi	B
##li	I
##ru	I
##bin	I
(	O
DB	O
##IL	O
)	O
,	O
total	O
bi	B
##li	I
##ru	I
##bin	I
(	O
T	O
##BI	O
##L	O
)	O
and	O
total	O
bi	O
##le	O
acids	O
(	O
T	O
##BA	O
)	O
while	O
have	O
significantly	O
decreased	O
levels	O
of	O
album	O
##in	O
(	O
AL	O
##B	O
)	O
,	O
ch	B
##ole	I
##ster	I
##ol	I
(	O
CH	O
##OL	O
)	O
,	O
t	B
##rig	I
##ly	I
##cer	I
##ide	I
(	O
T	O
##G	O
)	O
,	O
high	O
density	O
lip	B
##op	I
##rote	I
##in	I
-	I
ch	I
##ole	I
##ster	I
##ol	I
(	O
HD	O
##L	O
-	O
C	O
)	O
,	O
and	O
low	O
density	O
lip	B
##op	I
##rote	I
##in	I
-	I
ch	I
##ole	I
##ster	I
##ol	I
(	O
L	O
##D	O
##L	O
-	O
C	O
)	O
as	O
compared	O
to	O
healthy	O
controls	O
in	O
both	O
discovery	O
set	O
and	O
valid	O
##ation	O
set	O
.	O

In	O
addition	O
,	O
the	O
specific	O
shape	O
of	O
its	O
profiles	O
also	O
differed	O
between	O
te	O
##rt	O
##iles	O
(	O
time	O
–	O
W	O
##BI	O
##SI	O
interaction	O
effect	O
,	O
P	O
=	O
0	O
.	O
02	O
)	O
,	O
under	O
##lining	O
group	O
differences	O
in	O
α	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
metabolic	O
processing	O
in	O
response	O
to	O
high	O
glucose	S
and	O
insulin	O
levels	O
.	O

Both	O
et	B
##hyl	I
ace	I
##tate	I
(	O
used	O
for	O
liquid	O
–	O
liquid	O
extraction	O
)	O
and	O
M	O
##T	O
##BS	O
##TF	O
##A	O
turned	O
out	O
to	O
be	O
especially	O
important	O
sources	O
of	O
contamination	O
as	O
they	O
contained	O
both	O
o	B
##xa	I
##late	I
and	O
g	B
##ly	I
##cola	I
##te	I
.	O

For	O
example	O
,	O
ATP	S
,	O
d	O
##G	O
##TP	O
,	O
and	O
Z	O
##D	O
##V	O
-	O
T	O
##P	O
have	O
the	O
same	O
molecular	O
weight	O
(	O
50	O
##7	O
g	O
/	O
m	O
##ol	O
)	O
and	O
similar	O
fragment	O
##ation	O
pattern	O
in	O
negative	O
ion	O
##ization	O
mode	O
,	O
and	O
therefore	O
,	O
can	O
interfere	O
with	O
respective	O
measurements	O
.	O

AU	O
##C	O
values	O
of	O
C	B
##18	I
:	I
2	I
CE	O
and	O
SM	O
22	O
:	O
0	O
for	O
S	O
##q	O
##CC	O
prediction	O
in	O
the	O
training	O
and	O
valid	O
##ation	O
co	O
##hor	O
##ts	O
.	O

El	O
##eva	O
##tions	O
in	O
a	O
##romatic	O
(	B
t	B
##yr	I
##os	I
##ine	I
)	O
and	O
branched	O
chain	O
amino	O
acids	O
,	O
and	O
try	B
##pt	I
##op	I
##han	I
breakdown	O
products	O
(	B
ant	B
##hra	I
##ni	I
##lic	I
acid	I
,	O
k	O
##yn	O
##uren	O
##ines	O
)	O
have	O
been	O
strongly	O
correlated	O
with	O
elevated	O
body	O
mass	O
and	O
insulin	O
resistance	O
p	O
##hen	O
##otype	O
##s	O
(	O
,	O
,	O
)	O
.	O

Sub	O
##jects	O
with	O
h	O
##yper	O
##tens	O
##ion	O
,	O
diabetes	O
,	O
high	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
m	O
##or	O
##bid	O
o	O
##besity	O
,	O
history	O
of	O
card	O
##iovascular	O
events	O
,	O
chronic	O
re	O
##nal	O
failure	O
,	O
liver	O
c	O
##ir	O
##r	O
##hos	O
##is	O
,	O
thy	O
##roid	O
diseases	O
,	O
history	O
of	O
significant	O
head	O
trauma	O
,	O
ma	O
##ln	O
##utrition	O
,	O
pregnancy	O
,	O
cigarette	O
smoking	O
,	O
alcohol	O
and	O
substance	O
abuse	O
,	O
chronic	O
ne	O
##uro	O
##log	O
##ic	O
illness	O
##es	O
,	O
including	O
e	O
##pile	O
##psy	O
,	O
Parkinson	O
’	O
s	O
disease	O
,	O
Huntington	O
’	O
s	O
disease	O
,	O
Alzheimer	O
’	O
s	O
disease	O
,	O
Wilson	O
’	O
s	O
disease	O
were	O
excluded	O
from	O
both	O
groups	O
.	O

These	O
data	O
may	O
suggest	O
that	O
especially	O
breast	O
cancer	O
patients	O
should	O
avoid	O
red	O
c	O
##lover	O
and	O
is	B
##of	I
##lav	I
##one	I
based	O
B	O
##DS	O
##s	O
when	O
making	O
choices	O
for	O
men	O
##op	O
##aus	O
##al	O
s	O
##ym	O
##pt	O
##om	O
relief	O
.	O

Mass	O
s	O
##pect	O
##rome	O
##try	O
was	O
used	O
to	O
ass	O
##ay	O
select	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
and	O
amino	O
acids	O
,	O
as	O
previously	O
described	O
in	O
detail	O
.	O

L	O
##C	O
–	O
MS	O
grade	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
,	O
met	B
##han	I
##ol	I
,	O
and	O
water	O
were	O
purchased	O
from	O
B	O
##ur	O
##dick	O
and	O
Jackson	O
(	O
V	O
##WR	O
International	O
,	O
West	O
Chester	O
,	O
PA	O
,	O
USA	O
)	O
.	O

The	O
significance	O
of	O
this	O
finding	O
remains	O
obscure	O
,	O
as	O
su	O
##lf	O
##ated	O
s	O
##tero	O
##ids	O
as	O
such	O
are	O
proposed	O
to	O
act	O
as	O
a	O
s	O
##tero	O
##id	O
reservoir	O
in	O
blood	O
plasma	O
,	O
with	O
no	O
ability	O
as	O
h	B
##ydro	I
##phi	I
##lic	I
molecules	O
to	O
penetrate	O
target	O
cell	O
membrane	O
and	O
to	O
interact	O
with	O
s	O
##tero	O
##id	O
receptors	O
[	O
,	O
]	O
.	O

Select	O
##ivity	O
and	O
specific	O
##ity	O
were	O
evaluated	O
by	O
analyzing	O
six	O
different	O
lots	O
of	O
un	O
-	O
pool	O
##ed	O
blank	O
human	O
plasma	O
matrix	O
samples	O
with	O
t	B
##rig	I
##ly	I
##cer	I
##ide	I
levels	O
of	O
52	O
–	O
103	O
mg	O
/	O
d	O
##L	O
.	O
The	O
same	O
six	O
lots	O
were	O
spike	O
##d	O
with	O
t	B
##rig	I
##ly	I
##cer	I
##ide	I
mixture	O
(	O
to	O
reach	O
35	O
##2	O
to	O
40	O
##3	O
mg	O
/	O
d	O
##L	O
)	O
,	O
and	O
the	O
select	O
##ivity	O
and	O
specific	O
##ity	O
were	O
assessed	O
in	O
the	O
presence	O
of	O
high	O
t	B
##rig	I
##ly	I
##cer	I
##ide	I
levels	O
.	O

Met	O
##S	O
-	O
mediated	O
increases	O
in	O
these	O
meta	O
##bol	O
##ites	O
suggest	O
altered	O
amino	O
acid	O
metabolism	O
,	O
which	O
may	O
play	O
a	O
path	O
##ogenic	O
role	O
in	O
the	O
transition	O
from	O
o	O
##bes	O
##e	O
non	O
-	O
Met	O
##S	O
to	O
Met	O
##S	O
.	O
l	B
G	I
##lu	I
##cos	I
##e	I
and	O
energy	O
metabolism	O
are	O
well	O
established	O
to	O
be	O
altered	O
in	O
o	O
##besity	O
in	O
both	O
animal	O
and	O
human	O
studies	O
.	O

The	O
d	B
##18	I
:	I
1	I
and	O
d	O
##17	O
:	O
1	O
s	O
##phi	O
##ngo	O
##sin	O
##e	O
-	O
derived	O
fragment	O
ions	O
were	O
detected	O
at	O
m	O
/	O
z	O
264	O
.	O
26	O
##8	O
##9	O
and	O
m	O
/	O
z	O
250	O
.	O
253	O
##3	O
,	O
respectively	O
.	O

Following	O
a	B
##rsen	I
##ic	I
trio	I
##xi	I
##de	I
administration	O
,	O
a	O
portion	O
of	O
As	O
_	O
III	O
can	O
be	O
transformed	O
into	O
met	O
##hyl	O
##ated	O
a	O
##rsen	O
##ical	O
##s	O
in	O
the	O
body	O
of	O
AP	O
##L	O
patients	O
through	O
the	O
processes	O
of	O
biological	O
met	O
##hyl	O
##ation	O
[	O
,	O
]	O
.	O

Low	O
serum	O
car	O
##nos	O
##inas	O
##e	O
1	O
activity	O
increases	O
circulating	O
car	B
##nos	I
##ine	I
in	O
humans	O
.	O

R	O
##R	O
##M	O
##2	O
is	O
a	O
key	O
gene	O
in	O
p	B
##yr	I
##im	I
##id	I
##ine	I
metabolism	O
and	O
has	O
been	O
earlier	O
shown	O
to	O
be	O
elevated	O
in	O
aggressive	O
BC	O
##a	O
.	O

Also	O
,	O
mice	O
exposed	O
pre	O
##nat	O
##ally	O
to	O
MI	O
##A	O
triggered	O
by	O
p	O
##oly	O
(	O
I	O
:	O
C	O
)	O
injected	O
at	O
E	O
##12	O
.	O
5	O
and	O
E	O
##17	O
.	O
5	O
show	O
an	O
excess	O
of	O
u	O
##rina	O
##ry	O
in	B
##os	I
##ine	I
.	O

A	O
significant	O
amount	O
of	O
ace	B
##ty	I
##l	I
-	I
Co	I
##A	I
entered	O
the	O
K	O
##re	O
##bs	O
cycle	O
,	O
although	O
less	O
than	O
in	O
controls	O
,	O
as	O
indicated	O
by	O
the	O
decreased	O
c	B
##it	I
##rate	I
,	O
su	B
##cci	I
##nate	I
and	O
a	B
##con	I
##itate	I
levels	O
.	O

Di	B
##thi	I
##oth	I
##re	I
##ito	I
##l	I
,	O
I	B
##od	I
##oa	I
##ce	I
##tam	I
##ide	I
,	O
and	O
β	B
-	I
case	I
##in	I
-	I
90	I
%	I
+	I
were	O
all	O
purchased	O
from	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
(	O
St	O
.	O
Louis	O
,	O
M	O
##O	O
)	O
.	O

Due	O
to	O
the	O
high	O
concentrations	O
of	O
four	O
BR	O
##B	O
ant	B
##ho	I
##cy	I
##ani	I
##ns	I
in	O
the	O
early	O
time	O
point	O
samples	O
,	O
these	O
samples	O
were	O
di	O
##lut	O
##ed	O
with	O
water	O
to	O
ensure	O
their	O
final	O
concentrations	O
fell	O
within	O
the	O
linear	O
concentration	O
range	O
(	O
1	O
–	O
1000	O
ng	O
/	O
m	O
##L	O
)	O
of	O
the	O
corresponding	O
standard	O
curve	O
.	O

More	O
studies	O
of	O
the	O
levels	O
of	O
c	B
##era	I
##mi	I
##des	I
and	O
other	O
pro	O
##ather	O
##ogenic	O
meta	O
##bol	O
##ites	O
in	O
P	O
##L	O
##W	O
##H	O
will	O
help	O
to	O
answer	O
this	O
question	O
.	O

Conversely	O
,	O
low	O
basal	O
levels	O
of	O
2	B
-	I
h	I
##ydro	I
##xy	I
##vale	I
##ric	I
acid	I
exhibit	O
a	O
highly	O
significant	O
correlation	O
to	O
L	O
##D	O
##L	O
-	O
C	O
reduction	O
in	O
good	O
and	O
poor	O
respond	O
##ers	O
.	O

We	O
measured	O
serum	O
or	O
plasma	O
24	B
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
concentrations	O
in	O
five	O
co	O
##hor	O
##t	O
studies	O
and	O
clinical	O
trials	O
:	O
the	O
Di	O
##abe	O
##tes	O
Control	O
and	O
Co	O
##mp	O
##lication	O
##s	O
Trial	O
(	O
DC	O
##CT	O
)	O
,	O
the	O
Multi	O
-	O
Ethnic	O
Study	O
of	O
At	O
##her	O
##os	O
##cle	O
##rosis	O
(	O
ME	O
##SA	O
)	O
,	O
the	O
Card	O
##iovascular	O
Health	O
Study	O
(	O
CH	O
##S	O
)	O
,	O
the	O
Seattle	O
Kid	O
##ney	O
Study	O
(	O
SK	O
##S	O
)	O
,	O
and	O
the	O
He	O
##mo	O
##dial	O
##ys	O
##is	O
(	O
H	O
##EM	O
##O	O
)	O
Study	O
.	O

G	B
##ly	I
##cer	I
##in	I
:	O
This	O
is	O
a	O
G	O
##RA	O
##S	O
compound	O
that	O
is	O
used	O
as	O
an	O
anti	O
##mic	O
##ro	O
##bial	O
,	O
pre	O
##ser	O
##vat	O
##ive	O
em	O
##oll	O
##ient	O
.	O

In	O
this	O
study	O
,	O
c	B
##era	I
##mi	I
##des	I
other	O
than	O
C	B
##18	I
:	I
0	I
were	O
not	O
different	O
between	O
groups	O
.	O

b	O
percentage	O
of	O
glucose	S
consumed	O
converted	O
to	O
secret	O
##ed	O
la	B
##ct	I
##ate	I
(	O
c	O
##f	O
.	O
text	O
)	O
.	O

Ser	O
##um	O
T	O
##NF	O
##α	O
was	O
negatively	O
associated	O
with	O
try	B
##pt	I
##op	I
##han	I
(	O
P	O
<	O
0	O
.	O
00	O
##1	O
)	O
,	O
but	O
was	O
not	O
significantly	O
associated	O
with	O
any	O
of	O
its	O
k	B
##yn	I
##uren	I
##ine	I
meta	O
##bol	O
##ites	O
.	O

S	O
##pi	O
##king	O
experiments	O
using	O
authentic	O
compounds	O
were	O
used	O
to	O
confirm	O
the	O
identity	O
of	O
peaks	O
wherever	O
there	O
was	O
overlap	O
such	O
as	O
for	O
a	B
##rg	I
##ini	I
##ne	I
and	O
se	B
##rine	I
(	O
see	O
Figure	O
S	O
##1	O
in	O
the	O
Supporting	O
Information	O
)	O
.	O

The	O
intermediate	O
##s	O
of	O
the	O
t	B
##rica	I
##rb	I
##ox	I
##yl	I
##ic	I
acid	I
cycle	O
(	O
T	O
##CA	O
)	O
show	O
significant	O
differences	O
between	O
the	O
G	O
##DM	O
-	O
group	O
and	O
the	O
control	O
-	O
group	O
.	O

Co	O
##rrel	O
##ations	O
are	O
shown	O
for	O
the	O
different	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
in	O
primary	O
PC	O
##a	O
cases	O
(	O
a	O
)	O
and	O
controls	O
(	O
b	O
)	O
.	O

Further	O
investigations	O
of	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##ome	I
are	O
crucial	O
to	O
better	O
describe	O
the	O
shifts	O
in	O
meta	O
##bol	O
##ite	O
composition	O
occurring	O
in	O
lung	O
cancer	O
patients	O
.	O

Among	O
resulting	O
pathways	O
,	O
one	O
-	O
carbon	O
metabolism	O
,	O
and	O
g	B
##ly	I
##cine	I
,	O
se	B
##rine	I
,	O
al	B
##ani	I
##ne	I
,	O
and	O
th	B
##re	I
##oni	I
##ne	I
metabolism	O
were	O
represented	O
by	O
at	O
least	O
three	O
meta	O
##bol	O
##ites	O
.	O

Although	O
the	O
Z	O
-	O
score	O
range	O
of	O
the	O
at	O
##rial	O
app	O
##end	O
##age	O
samples	O
was	O
smaller	O
,	O
the	O
plots	O
were	O
more	O
di	O
##ff	O
##use	O
,	O
and	O
the	O
difference	O
between	O
the	O
A	B
##F	I
and	O
non	O
-	O
A	O
##F	O
groups	O
was	O
more	O
obvious	O
,	O
suggesting	O
that	O
the	O
levels	O
of	O
meta	O
##bol	O
##ites	O
in	O
the	O
at	O
##rial	O
app	O
##end	O
##age	O
samples	O
varied	O
more	O
widely	O
than	O
those	O
in	O
the	O
plasma	O
samples	O
.	O

The	O
urine	O
sample	O
extracted	O
from	O
the	O
cotton	O
wool	O
after	O
squeezing	O
had	O
a	O
much	O
higher	O
concentration	O
of	O
ace	B
##tone	I
,	O
te	B
##rt	I
-	I
but	I
##ano	I
##l	I
,	O
and	O
is	B
##ob	I
##ut	I
##yl	I
alcohol	I
than	O
the	O
urine	O
obtained	O
via	O
cent	O
##ri	O
##fu	O
##gation	O
,	O
suggesting	O
that	O
manual	O
squeezing	O
of	O
cotton	O
wool	O
results	O
in	O
greater	O
destruction	O
of	O
the	O
cotton	O
wool	O
fibers	O
and	O
therefore	O
greater	O
release	O
of	O
con	O
##tam	O
##ina	O
##nts	O
into	O
the	O
urine	O
sample	O
.	O

The	O
cap	O
##illa	O
##ry	O
voltage	O
was	O
2	O
k	B
##V	I
and	O
the	O
extract	O
##or	O
voltage	O
was	O
set	O
to	O
2	O
V	O
.	O

After	O
systematic	O
metabolic	O
pathway	O
analysis	O
combined	O
with	O
multi	O
##var	O
##iate	O
statistical	O
analysis	O
,	O
we	O
found	O
the	O
home	O
##ost	O
##asis	O
of	O
re	B
##tino	I
##l	I
metabolism	O
pathway	O
mediated	O
regulation	O
of	O
L	O
##MCA	O
##D	O
pattern	O
as	O
a	O
crucial	O
mechanism	O
.	O

Moreover	O
,	O
as	O
already	O
reported	O
in	O
adults	O
with	O
I	O
##B	O
##D	O
[	O
,	O
,	O
]	O
,	O
the	O
u	O
##rina	O
##ry	O
ex	O
##cre	O
##tion	O
of	O
hip	B
##pura	I
##te	I
was	O
decreased	O
in	O
children	O
with	O
I	O
##B	O
##D	O
as	O
compared	O
to	O
healthy	O
controls	O
.	O

(	O
A	O
&	O
B	O
)	O
Pro	O
##life	O
##ration	O
of	O
L	O
##NC	O
##a	O
##P	O
and	O
PC	O
-	O
3	O
##cell	O
##s	O
treated	O
with	O
different	O
concentrations	O
of	O
AL	O
##A	O
or	O
Ethan	B
##ol	I
(	O
solvent	O
control	O
)	O
measured	O
by	O
using	O
count	O
##ess	O
in	O
cell	O
via	O
##bility	O
analyze	O
##r	O
(	O
In	O
##vi	O
##tro	O
##gen	O
)	O
over	O
72	O
h	O
.	O
(	O
C	O
&	O
D	O
)	O

Fast	O
##ing	O
blood	O
glucose	S
(	O
F	O
##B	O
##G	O
)	O
was	O
determined	O
using	O
the	O
he	O
##x	O
##oki	O
##nas	O
##e	O
method	O
.	O

For	O
males	O
the	O
negative	O
relationship	O
of	O
test	B
##osterone	I
with	O
age	O
was	O
weaker	O
and	O
did	O
not	O
remain	O
significant	O
after	O
adjustment	O
for	O
body	O
mass	O
index	O
.	O

Unlike	O
previous	O
meta	O
##bon	O
##omi	O
##c	O
studies	O
including	O
our	O
own	O
N	O
##MR	O
study	O
,	O
the	O
current	O
study	O
introduced	O
a	O
three	O
-	O
step	O
strategy	O
to	O
identify	O
potential	O
bio	O
##mark	O
##ers	O
of	O
F	B
##D	I
.	O

These	O
findings	O
are	O
consistent	O
with	O
animal	O
models	O
,	O
where	O
PC	O
##s	O
and	O
other	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
were	O
found	O
to	O
be	O
lower	O
in	O
heart	O
tissues	O
from	O
Syrian	O
ha	O
##ms	O
##ters	O
with	O
hereditary	O
card	O
##io	O
##my	O
##op	O
##athy	O
compared	O
to	O
normal	O
ha	O
##ms	O
##ters	O
.	O

In	O
addition	O
,	O
higher	O
expression	O
of	O
p	B
##yr	I
##im	I
##id	I
##ine	I
metabolism	O
genes	O
,	O
correlated	O
well	O
with	O
PA	O
##M	O
##50	O
,	O
defined	O
basal	O
-	O
like	O
,	O
Her	O
-	O
2	O
–	O
en	O
##rich	O
##ed	O
,	O
and	O
l	O
##umi	O
##nal	O
B	O
tumor	O
sub	O
##type	O
##s	O
whereas	O
being	O
lower	O
in	O
l	O
##umi	O
##nal	O
A	O
tumors	O
(	O
G	O
)	O
.	O

This	O
change	O
also	O
resulted	O
in	O
further	O
2	O
-	O
fold	O
signal	O
increase	O
from	O
the	O
14	O
%	O
am	B
##mon	I
##ium	I
flu	I
##ori	I
##de	I
mobile	O
phase	O
,	O
which	O
is	O
equivalent	O
to	O
at	O
least	O
a	O
10	O
-	O
fold	O
signal	O
increase	O
,	O
indicating	O
the	O
impact	O
of	O
higher	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
content	O
on	O
the	O
ion	O
##ization	O
efficiency	O
of	O
these	O
compounds	O
.	O

These	O
were	O
plasma	O
##log	O
##en	O
(	O
20	O
:	O
4	O
/	O
p	O
##18	O
:	O
1	O
)	O
and	O
ta	B
##uri	I
##ne	I
.	O

However	O
,	O
direct	O
measurements	O
of	O
glucose	S
concentrations	O
in	O
AD	O
brain	O
tissue	O
have	O
hit	O
##her	O
##to	O
been	O
lacking	O
.	O

Based	O
on	O
multiple	O
log	O
##istic	O
re	O
##gression	O
models	O
,	O
odds	O
of	O
re	O
##cu	O
##rrence	O
increased	O
5	O
.	O
79	O
fold	O
(	O
95	O
%	O
C	O
##I	O
:	O
1	O
.	O
65	O
to	O
20	O
.	O
29	O
,	O
p	O
=	O
0	O
.	O
00	O
##6	O
)	O
when	O
c	B
##ys	I
##tein	I
##e	I
levels	O
increased	O
from	O
34	O
##3	O
(	O
lower	O
q	O
##ua	O
##rt	O
##ile	O
,	O
hence	O
##forth	O
Q	O
##1	O
)	O
to	O
43	O
##6	O
(	O
upper	O
q	O
##ua	O
##rt	O
##ile	O
,	O
hence	O
##forth	O
Q	O
##3	O
)	O
.	O

This	O
supports	O
previous	O
studies	O
which	O
have	O
demonstrated	O
the	O
production	O
of	O
la	B
##ct	I
##ate	I
from	O
glucose	S
metabolism	O
in	O
ad	O
##ip	O
##ocytes	O
.	O

)	O
,	O
and	O
there	O
was	O
a	O
moderate	O
correlation	O
between	O
try	B
##pt	I
##op	I
##han	I
and	O
k	B
##yn	I
##uren	I
##ine	I
(	O
R	O
=	O
0	O
.	O
56	O
,	O
P	O
<	O
0	O
.	O
01	O
)	O
.	O

The	O
increased	O
a	B
##rg	I
##ini	I
##ne	I
in	O
AP	O
##S	O
patients	O
might	O
be	O
induced	O
by	O
the	O
physiological	O
condition	O
of	O
AP	O
##S	O
and	O
be	O
positive	O
on	O
the	O
body	O
.	O

Some	O
p	B
##hos	I
##ph	I
##och	I
##olin	I
##es	I
aid	O
in	O
cancer	O
cell	O
growth	O
by	O
activation	O
of	O
some	O
G	O
-	O
coupled	O
receptors	O
on	O
cell	O
surfaces	O
.	O

[UNK]	B
=	I
[UNK]	B
=	I
1	I
##β	I
##st	I
##x	I
##s	I
##x	I
##t	I
+	I
[UNK]	B
=	I
1	I
##α	I
##s	I
##x	I
##s	I
describes	O
conditional	O
depend	O
##encies	O
between	O
two	O
continuous	O
variables	O
x	O
_	O
s	O
and	O
x	O
_	O
t	O
,	O
corresponding	O
to	O
the	O
probability	O
density	O
function	O
of	O
a	O
G	O
##aus	O
##sian	O
Graphic	O
##al	O
Model	O
(	O
G	O
##GM	O
)	O
.	O

Four	O
samples	O
were	O
analyzed	O
independently	O
in	O
each	O
sample	O
group	O
(	O
black	O
bars	O
,	O
d	B
_	I
6	I
1	I
##α	I
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
;	O
gray	O
bars	O
,	O
d	O
_	O
6	O
25	O
(	O
OH	O
)	O
D	O
_	O
3	O
;	O
white	O
bars	O
,	O
ca	O
##l	O
##ci	O
##pot	O
##rio	O
##l	O
)	O
.	O

In	O
addition	O
and	O
in	O
contrast	O
to	O
glucose	S
(	O
50	O
%	O
)	O
,	O
the	O
ex	O
##ogen	O
##ous	O
contribution	O
to	O
the	O
meta	O
##bol	O
##ite	O
pools	O
of	O
la	B
##ct	I
##ate	I
(	O
35	O
%	O
)	O
and	O
al	B
##ani	I
##ne	I
(	O
20	O
%	O
)	O
is	O
smaller	O
and	O
therefore	O
,	O
the	O
effect	O
of	O
g	O
##ua	O
##r	O
gum	O
might	O
be	O
counter	O
##bal	O
##ance	O
##d	O
more	O
easily	O
for	O
la	B
##ct	I
##ate	I
and	O
al	B
##ani	I
##ne	I
.	O

Pat	O
##ients	O
with	O
lung	O
meta	O
##sta	O
##ses	O
who	O
had	O
not	O
taken	O
NSA	O
##ID	O
##s	O
,	O
pro	O
##to	O
##ty	O
##pic	O
inhibitor	O
##s	O
of	O
CO	O
##X	O
activity	O
,	O
in	O
the	O
seven	O
days	O
before	O
urine	O
collection	O
had	O
the	O
highest	O
P	O
##GE	O
-	O
M	O
levels	O
(	O
median	O
7	O
.	O
4	O
ng	O
/	O
mg	O
c	B
##rea	I
##tin	I
##ine	I
;	O
range	O
1	O
.	O
8	O
–	O
43	O
.	O
4	O
)	O
.	O

Try	B
##pt	I
##op	I
##han	I
(	O
a	O
)	O
,	O
k	B
##yn	I
##uren	I
##ine	I
(	O
b	O
)	O
,	O
k	B
##yn	I
##uren	I
##ine	I
/	O
try	O
##pt	O
##op	O
##han	O
ratio	O
(	O
c	O
)	O
,	O
k	B
##yn	I
##uren	I
##ic	I
acid	I
(	O
K	O
##Y	O
##NA	O
)	O
(	O
d	O
)	O
,	O
q	B
##uin	I
##olin	I
##ic	I
acid	I
(	O
Q	O
##UI	O
##N	O
)	O
(	O
e	O
)	O
,	O
and	O
Q	O
##UI	O
##N	O
/	O
K	O
##Y	O
##NA	O
ratio	O
(	O
f	O
)	O
,	O
in	O
the	O
plasma	O
of	O
healthy	O
controls	O
(	O
n	O
=	O
14	O
)	O
and	O
patients	O
with	O
MD	O
##D	O
(	O
n	O
=	O
19	O
)	O
.	O

Auto	O
##mated	O
den	O
##si	O
##tom	O
##et	O
##ry	O
was	O
used	O
to	O
q	O
##uant	O
##ify	O
the	O
levels	O
of	O
m	O
##TO	O
##R	O
substrate	O
protein	O
expression	O
relative	O
to	O
β	B
-	I
act	I
##in	I
using	O
a	O
Ko	O
##dak	O
Image	O
Station	O
440	O
##CF	O
with	O
Ko	O
##dak	O
1	O
##D	O
Image	O
Analysis	O
Software	O
(	O
Eastman	O
Ko	O
##dak	O
Company	O
,	O
Rochester	O
,	O
NY	O
)	O
.	O

Most	O
enzymes	O
connected	O
with	O
le	B
##uc	I
##ine	I
metabolism	O
and	O
other	O
meta	O
##bol	O
##ites	O
detected	O
here	O
have	O
not	O
been	O
found	O
in	O
large	O
-	O
scale	O
genome	O
-	O
wide	O
association	O
studies	O
(	O
G	O
##WA	O
##S	O
)	O
of	O
o	O
##besity	O
.	O

b	O
PS	O
##A	O
progression	O
-	O
free	O
survival	O
calculated	O
by	O
the	O
Kaplan	O
Mei	O
##er	O
method	O
for	O
ace	B
##ty	I
##l	I
##car	I
##ni	I
##tine	I
(	O
C	O
##2	O
)	O
.	O

203	O
.	O
06	O
corresponding	O
to	O
the	O
Na	O
_	O
+	O
glucose	S
add	O
##uc	O
##t	O
.	O

al	O
.	O
developed	O
an	O
HP	O
##LC	O
-	O
Q	O
##IT	O
-	O
MS	O
_	O
2	O
method	O
to	O
q	O
##uant	O
##ify	O
8	B
-	I
OH	I
-	I
P	I
##d	I
##G	I
and	O
6	B
-	I
OH	I
-	I
P	I
##d	I
##G	I
in	O
human	O
auto	O
##psy	O
brain	O
tissues	O
using	O
a	O
high	O
capacity	O
Q	O
##IT	O
in	O
2005	O
.	O

From	O
the	O
tissue	O
extract	O
,	O
we	O
obtained	O
an	O
upper	O
layer	O
containing	O
[UNK]	O
50	O
%	O
Me	B
##OH	I
.	O

Super	O
##nat	O
##ants	O
were	O
transferred	O
to	O
tubes	O
and	O
dried	O
by	O
cent	O
##ri	O
##fu	O
##gal	O
e	O
##va	O
##por	O
##ation	O
,	O
and	O
the	O
p	O
##elle	O
##ts	O
were	O
re	O
##sus	O
##pen	O
##ded	O
in	O
600	O
μ	O
##L	O
of	O
N	O
##MR	O
phosphate	S
buffer	O
(	O
92	O
##8	O
.	O
6	O
mg	O
an	B
##hy	I
##dr	I
##ous	I
mon	I
##oso	I
##dium	I
phosphate	I
and	O
320	O
.	O
9	O
mg	O
di	B
##so	I
##dium	I
phosphate	I
were	O
dissolved	O
in	O
80	O
m	O
##L	O
D	O
_	O
2	O
O	O
,	O
after	O
which	O
333	O
.	O
3	O
μ	O
##L	O
of	O
01	O
.	O
M	O
DS	O
##S	O
-	O
D	O
##6	O
stock	O
solution	O
was	O
added	O
,	O
pH	O
was	O
adjusted	O
to	O
7	O
.	O
0	O
,	O
and	O
the	O
final	O
volume	O
was	O
brought	O
to	O
100	O
m	O
##L	O
with	O
D	O
_	O
2	O
O	O
)	O
.	O

The	O
meta	O
##bol	O
##ite	O
standard	O
compounds	O
,	O
ad	B
##eno	I
##sin	I
##e	I
3	O
′	O
,	O
5	B
′	I
-	I
c	I
##yclic	I
mon	I
##op	I
##hos	I
##phate	I
(	O
c	O
##AM	O
##P	O
)	O
,	O
que	B
##rc	I
##eti	I
##n	I
,	O
t	B
##yra	I
##mine	I
,	O
and	O
u	B
##ro	I
##can	I
##ic	I
acid	I
were	O
purchased	O
from	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
(	O
St	O
.	O
Louise	O
,	O
M	O
##O	O
,	O
USA	O
)	O
.	O

Both	O
UC	O
and	O
CD	O
have	O
an	O
impact	O
on	O
amino	O
acid	O
metabolism	O
showing	O
increased	O
levels	O
of	O
is	B
##ole	I
##uc	I
##ine	I
(	O
and	O
its	O
first	O
degradation	O
product	O
3	B
-	I
met	I
##hyl	I
-	I
2	I
-	I
o	I
##x	I
##ova	I
##ler	I
##ate	I
)	O
,	O
met	B
##hi	I
##oni	I
##ne	I
,	O
l	B
##ys	I
##ine	I
,	O
g	B
##ly	I
##cine	I
,	O
a	B
##rg	I
##ini	I
##ne	I
,	O
and	O
pro	B
##line	I
and	O
decreased	O
levels	O
of	O
v	B
##ali	I
##ne	I
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
and	O
se	B
##rine	I
as	O
compared	O
to	O
the	O
control	O
co	O
##hor	O
##t	O
.	O

N	O
##MR	O
-	O
based	O
post	O
##pra	O
##ndi	O
##al	O
behaviour	O
of	O
t	B
##yr	I
##os	I
##ine	I
(	O
a	O
)	O
,	O
v	B
##ali	I
##ne	I
and	O
is	B
##ole	I
##uc	I
##ine	I
(	O
b	O
)	O
,	O
and	O
3	B
-	I
h	I
##ydro	I
##xy	I
##is	I
##ob	I
##ut	I
##yra	I
##te	I
(	O
c	O
)	O
after	O
cheese	O
intake	O
(	O
blue	O
)	O
when	O
compared	O
to	O
milk	O
(	O
orange	O
)	O
and	O
so	O
##y	O
drink	O
(	O
green	O
)	O
intake	O
.	O

O	O
##xy	O
##gen	O
consumption	O
rates	O
(	O
O	O
##CR	O
)	O
and	O
extra	O
##cellular	O
acid	O
##ification	O
rates	O
(	O
EC	O
##AR	O
)	O
were	O
measured	O
before	O
and	O
after	O
treatment	O
with	O
2	B
-	I
de	I
##ox	I
##y	I
##g	I
##lu	I
##cos	I
##e	I
(	O
2	O
-	O
D	O
##G	O
)	O
(	O
55	O
m	O
##M	O
,	O
Sigma	O
)	O
,	O
using	O
a	O
Sea	O
##horse	O
X	O
##F	O
##24	O
analyze	O
##r	O
(	O
Sea	O
##horse	O
B	O
##ios	O
##cie	O
##nces	O
)	O
.	O

Therefore	O
,	O
we	O
ultimately	O
h	O
##y	O
##pot	O
##hes	O
##ized	O
that	O
f	B
##uma	I
##ric	I
acid	I
was	O
associated	O
with	O
di	O
##abe	O
##tic	O
re	O
##tino	O
##pathy	O
,	O
and	O
that	O
it	O
might	O
be	O
a	O
new	O
bio	O
##mark	O
##er	O
and	O
potential	O
therapeutic	O
target	O
for	O
DR	O
.	O

Lower	O
base	O
##line	O
levels	O
of	O
x	B
##ant	I
##hine	I
(	O
p	O
<	O
0	O
.	O
000	O
##1	O
,	O
q	O
<	O
0	O
.	O
000	O
##6	O
##8	O
)	O
,	O
2	B
-	I
h	I
##ydro	I
##xy	I
##vale	I
##ric	I
acid	I
(	O
p	O
<	O
0	O
.	O
000	O
##1	O
,	O
q	O
<	O
0	O
.	O
00	O
##13	O
)	O
,	O
su	B
##cci	I
##nic	I
acid	I
(	O
p	O
<	O
0	O
.	O
000	O
##9	O
,	O
q	O
<	O
0	O
.	O
01	O
##7	O
)	O
and	O
s	B
##te	I
##ari	I
##c	I
acid	I
(	O
p	O
<	O
0	O
.	O
00	O
##39	O
,	O
q	O
<	O
0	O
.	O
03	O
##7	O
)	O
were	O
all	O
significantly	O
correlated	O
with	O
greater	O
L	O
##D	O
##L	O
-	O
C	O
response	O
.	O

A	O
higher	O
level	O
of	O
la	B
##ct	I
##ate	I
in	O
patients	O
who	O
did	O
not	O
receive	O
any	O
neo	O
##ad	O
##ju	O
##vant	O
ch	O
##em	O
##otherapy	O
showed	O
that	O
survival	O
of	O
PA	O
was	O
highly	O
dependent	O
on	O
L	O
##D	O
##HA	O
activity	O
in	O
a	O
h	O
##y	O
##pox	O
##ic	O
environment	O
.	O

The	O
MR	O
##M	O
transition	O
responses	O
for	O
the	O
S	O
##IL	O
internal	O
standard	O
of	O
c	B
##it	I
##ru	I
##llin	I
##e	I
spike	O
##d	O
into	O
,	O
and	O
extracted	O
from	O
,	O
both	O
plasma	O
and	O
serum	O
were	O
23	O
.	O
5	O
%	O
and	O
18	O
.	O
4	O
%	O
,	O
respectively	O
,	O
when	O
compared	O
with	O
the	O
values	O
for	O
the	O
spike	O
##d	O
di	O
##lue	O
##nt	O
blank	O
.	O

V	O
##eno	O
##us	O
blood	O
samples	O
were	O
collected	O
for	O
population	O
p	O
##har	O
##ma	O
##co	O
##kin	O
##etic	O
(	O
P	O
##K	O
)	O
modeling	O
from	O
all	O
patients	O
in	O
the	O
a	B
##rip	I
##ip	I
##raz	I
##ole	I
,	O
o	B
##lan	I
##za	I
##pine	I
,	O
and	O
que	B
##tia	I
##pine	I
co	O
##hor	O
##ts	O
at	O
8	O
scheduled	O
times	O
within	O
the	O
dos	O
##ing	O
interval	O
.	O

This	O
had	O
an	O
effect	O
of	O
de	O
##tun	O
##ing	O
the	O
try	B
##pt	I
##op	I
##han	I
transition	O
for	O
sensitivity	O
with	O
the	O
benefit	O
of	O
ne	O
##gating	O
the	O
effect	O
of	O
in	O
-	O
source	O
sat	O
##uration	O
,	O
resulting	O
in	O
linear	O
##ity	O
of	O
the	O
ca	O
##li	O
##bra	O
##tion	O
over	O
the	O
desired	O
range	O
(	O
Figure	O
S	O
##3	O
)	O
.	O

Ch	O
##roma	O
##tography	O
parameters	O
of	O
N	O
##RT	O
##I	O
-	O
T	O
##P	O
represented	O
by	O
the	O
symbols	O
:	O
+	O
,	O
3	O
##TC	O
-	O
T	O
##P	O
;	O
×	O
,	O
D	O
##X	O
##G	O
-	O
T	O
##P	O
;	O
[UNK]	O
,	O
T	O
##F	O
##V	O
-	O
D	O
##P	O
;	O
[UNK]	O
,	O
CB	O
##V	O
-	O
T	O
##P	O
;	O
[UNK]	O
,	O
(	O
−	O
)	O
-	O
F	O
##TC	O
-	O
T	O
##P	O
;	O
and	O
[UNK]	O
,	O
Z	O
##D	O
##V	O
-	O
T	O
##P	O
:	O
(	O
a	O
)	O
tail	O
##ing	O
factor	O
(	O
T	O
##f	O
)	O
at	O
five	O
different	O
HM	O
##A	O
concentrations	O
;	O
0	O
,	O
3	O
,	O
6	O
,	O
9	O
,	O
and	O
12	O
m	O
##M	O
.	O
(	O
b	O
)	O
Effect	O
##ive	O
plate	O
number	O
(	O
N	O
##e	O
)	O
at	O
four	O
different	O
buffer	O
compositions	O
;	O
1	O
and	O
2	O
m	O
##M	O
am	B
##mon	I
##ium	I
phosphate	I
;	O
10	O
and	O
20	O
m	O
##M	O
am	B
##mon	I
##ium	I
hydrogen	I
carbon	I
##ate	I
.	O

Our	O
studies	O
showed	O
that	O
se	O
##ra	O
of	O
subjects	O
after	O
12	O
weeks	O
of	O
diet	O
intervention	O
exhibited	O
slight	O
reduction	O
##s	O
in	O
the	O
levels	O
of	O
both	O
total	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
and	O
percent	O
body	O
fat	O
though	O
those	O
of	O
l	O
##ys	O
##o	O
##PC	O
##s	O
did	O
not	O
show	O
a	O
definite	O
trend	O
and	O
were	O
shown	O
to	O
be	O
dependent	O
on	O
the	O
types	O
of	O
fatty	O
acid	O
chains	O
est	O
##eri	O
##fied	O
to	O
the	O
g	B
##ly	I
##cer	I
##ol	I
m	O
##oi	O
##ety	O
.	O

Higher	O
level	O
of	O
ho	B
##mo	I
##cy	I
##stein	I
##e	I
,	O
caused	O
by	O
the	O
def	O
##ici	O
##encies	O
in	O
ho	O
##mo	O
##cy	O
##stein	O
##e	O
re	O
-	O
met	O
##hyl	O
##ation	O
co	O
##fa	O
##ctors	O
vitamin	B
B	I
##12	I
and	O
B	O
##9	O
(	O
f	O
##olate	O
)	O
,	O
has	O
found	O
to	O
be	O
directly	O
associated	O
with	O
decreased	O
cognitive	O
performance	O
in	O
the	O
elderly	O
,	O
which	O
is	O
consistent	O
with	O
our	O
results	O
.	O

K	O
##lo	O
##mp	O
et	O
al	O
.	O
demonstrated	O
the	O
ability	O
to	O
detect	O
in	O
breast	O
cancer	O
patients	O
the	O
various	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
meta	O
##bol	O
##ites	O
like	O
PC	O
##ho	O
,	O
GP	B
##C	I
,	O
p	B
##hos	I
##ph	I
##oe	I
##than	I
##ola	I
##mine	I
,	O
GP	O
##E	O
and	O
N	O
##TP	O
##s	O
using	O
in	O
v	O
##ivo	O
localized	O
_	O
31	O
P	O
MR	O
##SI	O
at	O
7	O
T	O
.	O

S	O
t	O
##udi	O
##es	O
have	O
shown	O
that	O
a	B
##rg	I
##ini	I
##ne	I
in	O
plasma	O
can	O
cross	O
the	O
blood	O
-	O
brain	O
barrier	O
(	O
B	O
##BB	O
)	O
into	O
the	O
brain	O
(	O
,	O
)	O
,	O
and	O
that	O
there	O
is	O
a	O
high	O
correlation	O
between	O
serum	O
a	B
##rg	I
##ini	I
##ne	I
and	O
a	B
##rg	I
##ini	I
##ne	I
in	O
c	O
##ere	O
##bro	O
##sp	O
##inal	O
fluid	O
(	O
CS	O
##F	O
)	O
in	O
stroke	O
patients	O
.	O

Po	O
##ten	O
##tial	O
mechanisms	O
included	O
reduced	O
processing	O
of	O
ace	B
##ty	I
##l	I
-	I
Co	I
##A	I
via	O
the	O
t	B
##rica	I
##rb	I
##ox	I
##yl	I
##ic	I
acid	I
(	O
T	O
##CA	O
)	O
cycle	O
due	O
to	O
the	O
in	O
##hibition	O
of	O
c	B
##it	I
##rate	I
formation	O
and	O
/	O
or	O
changes	O
in	O
the	O
N	O
##AD	O
##H	O
/	O
N	O
##AD	O
_	O
+	O
ratio	O
due	O
to	O
e	O
##ff	O
##lux	O
of	O
as	B
##par	I
##tate	I
.	O

When	O
applied	O
to	O
urine	O
,	O
we	O
were	O
able	O
to	O
identify	O
and	O
q	O
##uant	O
##ify	O
a	O
total	O
of	O
127	O
meta	O
##bol	O
##ites	O
or	O
meta	O
##bol	O
##ite	O
species	O
,	O
including	O
34	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
,	O
21	O
amino	O
acids	O
,	O
15	O
bio	O
##genic	O
am	O
##ines	O
,	O
c	B
##rea	I
##tin	I
##ine	I
,	O
he	B
##x	I
##ose	I
,	O
35	O
p	B
##hos	I
##pa	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
,	O
15	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
##s	I
and	O
5	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
.	O

In	O
HC	O
##C	O
vs	O
.	O
DC	O
,	O
p	B
##yr	I
##og	I
##lut	I
##am	I
##yl	I
##gly	I
##cine	I
and	O
g	B
##ly	I
##cy	I
##l	I
##val	I
##ine	I
trend	O
##ed	O
1	O
.	O
95	O
and	O
1	O
.	O
48	O
times	O
higher	O
,	O
and	O
of	O
the	O
only	O
four	O
meta	O
##bol	O
##ites	O
that	O
were	O
significantly	O
down	O
##re	O
##gu	O
##lated	O
in	O
HC	O
##C	O
vs	O
.	O
DC	O
,	O
three	O
were	O
dip	O
##eptide	O
##s	O
:	O
Ph	B
##en	I
##yla	I
##lan	I
##yl	I
##try	I
##pt	I
##op	I
##han	I
,	O
p	B
##hen	I
##yla	I
##lan	I
##yl	I
##ser	I
##ine	I
and	O
le	B
##uc	I
##yl	I
-	I
al	I
##ani	I
##ne	I
.	O

These	O
findings	O
have	O
clinical	O
implications	O
,	O
as	O
can	B
##na	I
##bino	I
##ids	I
may	O
have	O
an	O
im	O
##mu	O
##nological	O
benefit	O
and	O
non	O
##psy	O
##cho	O
##active	O
cannabis	S
derivatives	O
could	O
be	O
investigated	O
as	O
novel	O
therapeutic	O
##s	O
to	O
be	O
used	O
in	O
conjunction	O
with	O
AR	O
##T	O
to	O
aid	O
in	O
reduction	O
of	O
persistent	O
inflammation	O
.	O

We	O
previously	O
developed	O
a	O
unique	O
methodology	O
based	O
on	O
the	O
use	O
of	O
[	B
p	B
##yr	I
##id	I
##ine	I
-	I
D	I
_	I
4	I
]	O

Multiple	O
studies	O
suggested	O
that	O
re	O
##nal	O
involvement	O
,	O
SL	O
##E	O
disease	O
activity	O
and	O
the	O
presence	O
of	O
anti	B
##ph	I
##os	I
##ph	I
##oli	I
##pid	I
antibodies	O
are	O
associated	O
with	O
AP	O
##O	O
during	O
SL	O
##E	O
pregnancy	O
.	O

It	O
should	O
also	O
be	O
noted	O
that	O
g	B
##ly	I
##cer	I
##ol	I
-	I
3	I
-	I
P	I
and	O
F	O
##6	O
##P	O
could	O
not	O
be	O
un	O
##am	O
##bi	O
##guous	O
##ly	O
assigned	O
in	O
_	O
1	O
H	O
and	O
_	O
13	O
C	O
-	O
edited	O
experiments	O
due	O
to	O
their	O
low	O
abundance	O
and	O
/	O
or	O
spectral	O
crowd	O
##ing	O
(	O
c	O
##f	O
.	O
)	O
.	O

Although	O
BA	O
and	O
F	O
##N	O
increased	O
est	B
##rogen	I
metabolism	O
,	O
it	O
is	O
important	O
to	O
note	O
that	O
they	O
are	O
not	O
bio	O
##ava	O
##ila	O
##ble	O
and	O
are	O
rapidly	O
meta	O
##bol	O
##ized	O
to	O
G	O
##N	O
and	O
D	O
##Z	O
in	O
v	O
##ivo	O
.	O

After	O
adjustment	O
for	O
traditional	O
at	O
##her	O
##os	O
##cle	O
##rosis	O
risk	O
factors	O
,	O
in	B
##do	I
##le	I
(	O
odds	O
ratio	O
[	O
OR	O
]	O
,	O
.	O
84	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
C	O
##I	O
]	O
,	O
.	O
75	O
–	O
.	O
95	O
;	O
P	O
=	O
.	O
00	O
##4	O
)	O
,	O
try	B
##pt	I
##op	I
##han	I
(	O
OR	O
,	O
<	O
.	O
00	O
##1	O
;	O
95	O
%	O
C	O
##I	O
,	O
<	O
.	O
00	O
##1	O
–	O
.	O
00	O
##3	O
;	O
P	O
<	O
.	O
00	O
##1	O
)	O
,	O
in	B
##do	I
##le	I
-	I
3	I
-	I
prop	I
##ion	I
##ic	I
acid	I
(	O
OR	O
,	O
.	O
27	O
;	O
95	O
%	O
C	O
##I	O
,	O
.	O
01	O
##9	O
–	O
.	O
91	O
;	O
P	O
=	O
.	O
02	O
)	O
,	O
and	O
in	B
##do	I
##le	I
-	I
3	I
-	I
al	I
##de	I
##hy	I
##de	I
(	O
OR	O
,	O
.	O
12	O
;	O
95	O
%	O
C	O
##I	O
,	O
.	O
01	O
##4	O
–	O
.	O
92	O
;	O
P	O
=	O
.	O
04	O
)	O
negatively	O
associated	O
with	O
advanced	O
at	O
##her	O
##os	O
##cle	O
##rosis	O
,	O
while	O
the	O
k	O
##yn	O
##uren	O
##ine	O
/	B
try	B
##pt	I
##op	I
##han	I
ratio	O
(	O
OR	O
,	O
61	O
.	O
7	O
;	O
95	O
%	O
C	O
##I	O
,	O
1	O
.	O
9	O
–	O
>	O
99	O
##9	O
;	O
P	O
=	O
.	O
02	O
)	O
was	O
positively	O
associated	O
.	O

The	O
three	O
major	O
classes	O
of	O
e	B
##ico	I
##san	I
##oids	I
are	O
pro	B
##stan	I
##oids	I
,	O
products	O
of	O
c	O
##y	O
##c	O
##lo	O
##ox	O
##y	O
##gen	O
##ases	O
,	O
5	O
,	O
12	O
,	O
15	O
-	O
H	O
##ET	O
##Es	O
and	O
le	O
##uk	O
##ot	O
##rien	O
##es	O
products	O
of	O
lip	O
##ox	O
##y	O
##gen	O
##ases	O
,	O
and	O
E	O
##ET	O
##s	O
and	O
H	O
##ET	O
##Es	O
products	O
of	O
C	O
##YP	O
mon	O
##o	O
-	O
oxygen	O
##ases	O
.	O

Con	O
##cent	O
##rations	O
can	O
be	O
converted	O
from	O
ng	O
/	O
m	O
##l	O
to	O
nm	O
##ol	O
/	O
l	O
by	O
multi	O
##p	O
##lying	O
by	O
3	O
.	O
12	O
and	O
3	O
.	O
08	O
for	O
met	B
##had	I
##one	I
-	I
d	I
_	I
0	I
and	O
met	B
##had	I
##one	I
-	I
d	I
_	I
5	I
,	O
respectively	O
.	O

(	O
c	O
)	O
G	B
##lut	I
##ama	I
##te	I
levels	O
were	O
significantly	O
higher	O
in	O
MD	O
##D	O
patients	O
than	O
in	O
control	O
subjects	O
(	O
F	O
##DR	O
q	O
=	O
3	O
.	O
7	O
×	O
10	O
_	O
−	O
##7	O
)	O
.	O

Both	O
se	B
##rot	I
##oni	I
##n	I
and	O
its	O
major	O
meta	O
##bol	O
##ite	O
5	B
-	I
h	I
##ydro	I
##xy	I
##ind	I
##ole	I
##ace	I
##tate	I
were	O
significantly	O
decreased	O
in	O
CS	O
##F	O
of	O
pre	O
##c	O
##lini	O
##cal	O
AD	O
patients	O
.	O

A	O
synthetic	O
standard	O
for	O
this	O
compound	O
was	O
obtained	O
by	O
o	O
##xi	O
##di	O
##zing	O
N	B
-	I
ace	I
##ty	I
##l	I
-	I
S	I
-	I
[	I
1	I
-	I
(	I
5	I
-	I
h	I
##ydro	I
##xy	I
-	I
5	I
-	I
car	I
##box	I
##ype	I
##nt	I
##yl	I
)	I
-	I
1	I
##H	I
-	I
p	I
##yr	I
##rol	I
-	I
3	I
-	I
y	I
##l	I
]	I
-	I
L	I
-	I
c	I
##ys	I
##tein	I
##e	I
(	O
17	O
)	O
with	O
p	B
##yr	I
##id	I
##ini	I
##um	I
di	O
##ch	O
##roma	O
##te	O
followed	O
by	O
reaction	O
with	O
met	B
##ho	I
##xy	I
##amine	I
.	O

In	O
addition	O
,	O
two	O
signals	O
of	O
some	O
meta	O
##bol	O
##ites	O
were	O
statistical	O
##ly	O
not	O
relevant	O
,	O
such	O
as	O
is	B
##ole	I
##uc	I
##ine	I
and	O
H	B
##y	I
##pox	I
##ant	I
##hine	I
(	O
Table	O
)	O
,	O
g	B
##lut	I
##ath	I
##ione	I
(	O
Table	O
)	O
,	O
which	O
should	O
be	O
verified	O
in	O
better	O
meta	O
##bol	O
##omi	O
##cs	O
platform	O
.	O

So	B
##fo	I
##s	I
##bu	I
##vir	I
and	O
rib	B
##avi	I
##rin	I
were	O
efficiently	O
meta	O
##bol	O
##ized	O
in	O
primary	O
human	O
he	O
##pa	O
##to	O
##cy	O
##tes	O
in	O
##cu	O
##bate	O
##d	O
in	O
v	O
##it	O
##ro	O
.	O

The	O
top	O
two	O
P	O
##LS	O
-	O
derived	O
factors	O
combined	O
explained	O
7	O
%	O
of	O
the	O
outcome	O
,	O
with	O
one	O
composed	O
of	O
several	O
meta	O
##bol	O
##ites	O
including	O
C	O
##i	O
##4	O
-	O
DC	O
/	O
C	O
##4	O
-	O
DC	O
and	O
c	B
##it	I
##ru	I
##llin	I
##e	I
(	O
two	O
of	O
the	O
“	O
u	O
##rea	O
cycle	O
factor	O
”	O
meta	O
##bol	O
##ites	O
from	O
the	O
original	O
paper	O
)	O
,	O
and	O
the	O
second	O
one	O
composed	O
of	O
the	O
BC	O
##AA	O
,	O
a	O
##romatic	O
amino	O
acids	O
(	B
met	B
##hi	I
##oni	I
##ne	I
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
)	O
,	O
g	O
##lut	O
##ama	O
##te	O
/	O
g	O
##lut	O
##amine	O
and	O
C	O
##3	O
and	O
C	O
##5	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
,	O
all	O
of	O
which	O
are	O
meta	O
##bol	O
##ites	O
which	O
composed	O
the	O
“	O
BC	O
##AA	O
factor	O
”	O
identified	O
from	O
our	O
previous	O
work	O
.	O

The	O
G	O
##R	O
,	O
as	O
compared	O
to	O
PR	O
patients	O
,	O
are	O
characterized	O
by	O
overall	O
lower	O
concentrations	O
of	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
and	O
ch	B
##ole	I
##ster	I
##ol	I
associated	O
to	O
almost	O
all	O
classes	O
of	O
lip	O
##op	O
##rote	O
##ins	O
assigned	O
by	O
_	O
1	O
H	O
N	O
##MR	O
(	O
Figure	O
S	O
##4	O
)	O
.	O

These	O
results	O
suggest	O
an	O
altered	O
pattern	O
of	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##lino	I
##si	I
##to	I
##l	I
metabolism	O
in	O
smoke	O
##rs	O
.	O

In	O
o	O
##bes	O
##e	O
youth	O
with	O
d	O
##ys	O
##gly	O
##ce	O
##mia	O
,	O
D	O
##I	O
correlated	O
with	O
C	O
##5	O
a	O
##cy	O
##lar	O
##ni	O
##tine	O
(	O
r	O
=	O
0	O
.	O
35	O
;	O
P	O
=	O
0	O
.	O
00	O
##5	O
)	O
,	O
met	B
##hi	I
##oni	I
##ne	I
(	O
r	O
=	O
0	O
.	O
44	O
;	O
P	O
=	O
0	O
.	O
00	O
##2	O
)	O
,	O
al	B
##ani	I
##ne	I
(	O
r	O
=	O
0	O
.	O
31	O
;	O
P	O
=	O
0	O
.	O
02	O
)	O
,	O
g	B
##ly	I
##cine	I
(	O
r	O
=	O
0	O
.	O
30	O
;	O
P	O
=	O
0	O
.	O
03	O
)	O
,	O
his	B
##ti	I
##dine	I
(	O
r	O
=	O
0	O
.	O
35	O
;	O
P	O
=	O
0	O
.	O
00	O
##5	O
)	O
,	O
and	O
c	B
##it	I
##ru	I
##llin	I
##e	I
(	O
r	O
=	O
0	O
.	O
30	O
;	O
P	O
=	O
0	O
.	O
03	O
)	O
.	O

Two	O
features	O
that	O
were	O
over	O
-	O
abundant	O
in	O
cancer	O
tissue	O
were	O
put	O
##ative	O
##ly	O
identified	O
as	O
car	B
##ni	I
##tine	I
##s	I
(	O
14	O
,	O
15	O
)	O
.	O

For	O
individual	O
amino	O
acids	O
such	O
as	O
l	B
##ys	I
##ine	I
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
and	O
c	B
##ys	I
##tein	I
##e	I
,	O
in	O
which	O
cases	O
the	O
side	O
-	O
chain	O
functional	O
groups	O
also	O
react	O
##s	O
,	O
four	O
-	O
fold	O
excess	O
of	O
ace	B
##tic	I
an	I
##hy	I
##dr	I
##ide	I
was	O
used	O
.	O

(	O
E	O
)	O
Co	O
##mp	O
##aris	O
##on	O
of	O
the	O
s	B
##te	I
##arate	I
mon	O
##ois	O
##oto	O
##pic	O
signal	O
for	O
2	O
.	O
5	O
nm	O
##ol	O
of	O
s	B
##te	I
##ari	I
##c	I
acid	I
when	O
mixed	O
with	O
2	O
.	O
5	O
nm	O
##ol	O
of	O
the	O
4	O
matrices	O
.	O

Additionally	O
,	O
a	O
combination	O
of	O
the	O
di	B
##hy	I
##dr	I
##o	I
and	O
the	O
o	O
##x	O
##o	O
meta	O
##bol	O
##ite	O
was	O
found	O
.	O

C	O
##K	O
##D	O
##2	O
–	O
3	O
,	O
C	O
##K	O
##D	O
stages	O
2	O
and	O
3	O
;	O
C	O
##K	O
##D	O
##4	O
–	O
5	O
,	O
C	O
##K	O
##D	O
stages	O
4	O
and	O
5	O
;	O
AA	O
,	O
amino	O
acid	O
;	O
AD	B
##MA	I
,	O
as	B
##ym	I
##metric	I
dim	I
##eth	I
##yla	I
##rg	I
##ini	I
##ne	I
;	O
SD	O
##MA	O
,	O
symmetric	B
dim	I
##eth	I
##yla	I
##rg	I
##ini	I
##ne	I
.	O

Total	O
ho	B
##mo	I
##cy	I
##stein	I
##e	I
is	O
therefore	O
the	O
sum	O
of	O
all	O
ho	B
##mo	I
##cy	I
##stein	I
##e	I
obtained	O
from	O
the	O
reduction	O
of	O
these	O
di	B
##sul	I
##fi	I
##de	I
bonds	O
;	O
this	O
also	O
applies	O
to	O
total	O
c	B
##ys	I
##tein	I
##e	I
.	O

The	O
s	B
##phi	I
##ng	I
##hom	I
##ye	I
##lin	I
SM	I
(	I
32	I
:	I
0	I
)	I
level	O
at	O
1	O
month	O
was	O
significantly	O
associated	O
with	O
C	O
-	O
p	O
##eptide	O
levels	O
(	O
Table	O
)	O
.	O

For	O
example	O
,	O
both	O
the	O
S	O
##y	O
##va	O
EMI	O
##T	O
and	O
the	O
CE	O
##DI	O
##A	O
op	O
##iate	O
im	O
##mu	O
##no	O
##ass	O
##ays	O
will	O
recognize	O
the	O
presence	O
of	O
h	B
##ydro	I
##co	I
##don	I
##e	I
and	O
h	B
##ydro	I
##mor	I
##phone	I
at	O
approximately	O
600	O
ng	O
/	O
m	O
##L	O
drug	O
concentrations	O
,	O
or	O
at	O
twice	O
the	O
300	O
ng	O
/	O
m	O
##L	O
m	B
##or	I
##phine	I
cut	O
off	O
concentrations	O
.	O

A	O
representative	O
kinetic	O
profile	O
of	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
metabolism	O
to	O
h	B
##ydro	I
##xy	I
##ana	I
##stro	I
##zo	I
##le	I
in	O
H	O
##LM	O
##s	O
is	O
shown	O
in	O
.	O

The	O
definition	O
of	O
this	O
sampling	O
period	O
was	O
based	O
on	O
abnormal	O
changes	O
in	O
serum	O
c	B
##rea	I
##tin	I
##ine	I
and	O
B	O
##UN	O
concentrations	O
in	O
the	O
me	O
##lo	O
##xi	O
##cam	O
-	O
treated	O
cats	O
.	O

Drug	O
-	O
na	O
##ï	O
##ve	O
patients	O
were	O
treated	O
with	O
40	O
mg	O
/	O
day	O
si	B
##m	I
##vas	I
##tat	I
##in	I
for	O
6	O
weeks	O
in	O
the	O
Cho	B
##les	I
##tero	I
##l	I
and	O
Ph	O
##arma	O
##co	O
##gene	O
##tics	O
(	O
CA	O
##P	O
)	O
study	O
;	O
meta	O
##bol	O
##omi	O
##cs	O
by	O
gas	O
ch	O
##roma	O
##tography	O
-	O
time	O
-	O
of	O
-	O
flight	O
mass	O
-	O
s	O
##pect	O
##rome	O
##try	O
(	O
G	O
##C	O
–	O
TO	O
##F	O
–	O
MS	O
)	O
was	O
performed	O
on	O
plasma	O
pre	O
and	O
post	O
treatment	O
on	O
148	O
of	O
the	O
94	O
##4	O
participants	O
.	O

L	O
##CA	O
##T	O
is	O
a	O
serum	O
enzyme	O
that	O
cat	O
##aly	O
##zes	O
the	O
trans	O
##acy	O
##lation	O
of	O
the	O
s	O
##n	O
-	O
2	O
fatty	O
acid	O
of	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
to	O
the	O
free	O
3	O
-	O
h	O
##ydro	O
##xy	O
##l	O
group	O
of	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
generating	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
(	O
L	O
##ys	O
##o	O
##PC	O
)	O
and	O
ch	B
##ole	I
##ster	I
##yl	I
est	I
##ers	I
.	O

In	O
the	O
current	O
study	O
,	O
I	O
##CI	O
182	O
,	O
78	O
##0	O
(	O
1	O
μ	O
##M	O
)	O
potent	O
##iated	O
T	O
##CD	O
##D	O
-	O
induced	O
C	O
##YP	O
##1	O
##A	O
##1	O
and	O
C	O
##YP	O
##1	O
##B	O
##1	O
expression	O
(	O
C	O
,	O
D	O
)	O
and	O
also	O
increased	O
C	O
##YP	O
##1	O
##A	O
##1	O
expression	O
after	O
is	B
##of	I
##lav	I
##one	I
treatments	O
(	O
A	O
,	O
C	O
)	O
.	O

Here	O
,	O
we	O
developed	O
a	O
novel	O
method	O
for	O
the	O
comprehensive	O
analysis	O
of	O
th	B
##iol	I
##s	I
in	O
5	O
types	O
of	O
cancer	O
urine	O
.	O

Media	O
##n	O
concentrations	O
of	O
g	B
##lut	I
##ama	I
##te	I
and	O
2	B
-	I
o	I
##x	I
##og	I
##lut	I
##arate	I
were	O
significantly	O
higher	O
in	O
infectious	O
diseases	O
than	O
patients	O
with	O
no	O
infectious	O
disease	O
,	O
and	O
there	O
was	O
a	O
trend	O
towards	O
higher	O
c	B
##it	I
##rate	I
concentrations	O
in	O
the	O
infectious	O
disease	O
group	O
(	O
p	O
=	O
0	O
.	O
07	O
)	O
.	O

Thanks	O
to	O
the	O
high	O
mass	O
accuracy	O
of	O
the	O
Or	O
##bit	O
##rap	O
analyses	O
,	O
we	O
identified	O
the	O
peak	O
detected	O
before	O
GM	B
##3	I
in	O
the	O
op	O
##tic	O
nerve	O
and	O
brain	O
,	O
previously	O
revealed	O
in	O
HP	O
##TL	O
##C	O
,	O
as	O
GM	O
##4	O
,	O
a	O
gal	O
##a	O
-	O
series	O
G	O
##G	O
.	O

P	B
##yr	I
##im	I
##id	I
##ines	I
are	O
vital	O
bio	O
##mo	O
##le	O
##cule	O
##s	O
that	O
participate	O
in	O
a	O
wide	O
range	O
of	O
biological	O
functions	O
,	O
including	O
s	O
##ynth	O
##ese	O
##s	O
of	O
DNA	O
,	O
RNA	O
,	O
lip	O
##ids	O
,	O
and	O
car	O
##bo	O
##hy	O
##dra	O
##tes	O
and	O
p	B
##yr	I
##im	I
##id	I
##ine	I
derivatives	O
are	O
already	O
being	O
used	O
as	O
anti	O
##dia	O
##bet	O
##ic	O
medications	O
.	O

After	O
the	O
diagnosis	O
of	O
21	O
##OH	O
##D	O
was	O
confirmed	O
,	O
h	B
##ydro	I
##cor	I
##tis	I
##one	I
treatment	O
was	O
initiated	O
.	O

After	O
treatment	O
,	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
,	O
plasma	O
##log	O
##ens	O
,	O
and	O
other	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
increased	O
(	O
P	O
<	O
0	O
.	O
05	O
after	O
the	O
F	O
##DR	O
procedure	O
)	O
.	O

The	O
relatively	O
increased	O
c	B
##rea	I
##tine	I
levels	O
that	O
were	O
also	O
seen	O
in	O
our	O
previously	O
described	O
DS	O
##S	O
mouse	O
model	O
of	O
UC	O
may	O
indicate	O
the	O
need	O
of	O
ATP	S
and	O
fatty	O
acids	O
as	O
energy	O
supply	O
during	O
the	O
states	O
of	O
the	O
disease	O
.	O

The	O
increased	O
c	B
##rea	I
##tine	I
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
le	B
##uc	I
##ine	I
,	O
and	O
v	B
##ali	I
##ne	I
levels	O
in	O
RC	O
##C	O
patients	O
as	O
well	O
as	O
the	O
reduced	O
ch	B
##olin	I
##e	I
levels	O
could	O
be	O
responsible	O
for	O
cell	O
proliferation	O
.	O

The	O
HP	O
##LC	O
solvent	O
##s	O
,	O
water	O
and	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
(	O
AC	O
##N	O
)	O
,	O
were	O
of	O
high	O
purity	O
and	O
purchased	O
from	O
B	O
##ur	O
##dick	O
and	O
Jackson	O
(	O
Mu	O
##ske	O
##gon	O
,	O
MI	O
)	O
.	O

m	O
Analysis	O
of	O
β	B
-	I
a	I
##po	I
-	I
13	I
-	I
car	I
##ote	I
##non	I
##e	I
in	O
human	O
plasma	O
by	O
HP	O
##LC	O
/	O
MS	O
.	O

Although	O
further	O
study	O
is	O
still	O
needed	O
,	O
s	B
##phi	I
##ngo	I
##sin	I
##e	I
1	I
-	I
phosphate	I
will	O
probably	O
become	O
a	O
new	O
target	O
for	O
treatment	O
of	O
ul	O
##cer	O
##ative	O
co	O
##lit	O
##is	O
.	O

Using	O
q	O
##PC	O
##R	O
,	O
we	O
am	O
##plified	O
two	O
stable	O
m	O
##t	O
##D	O
##NA	O
sequences	O
(	O
mitochondrial	O
##ly	O
encoded	O
N	O
##AD	O
##H	O
de	O
##hy	O
##dr	O
##ogen	O
##ase	O
1	O
(	O
M	O
##T	O
-	O
N	O
##D	O
##1	O
)	O
and	O
mitochondrial	O
forward	O
prime	O
##r	O
from	O
n	O
##uc	O
##leo	O
##tide	O
321	O
##2	O
and	O
reverse	O
prime	O
##r	O
from	O
n	O
##uc	O
##leo	O
##tide	O
33	O
##19	O
(	O
M	O
##TF	O
##32	O
##12	O
/	O
R	O
##33	O
##19	O
)	O
and	O
one	O
reference	O
nuclear	O
gene	O
(	O
acidic	O
rib	O
##oso	O
##mal	O
p	B
##hos	I
##ph	I
##op	I
##rote	I
##in	I
P	O
##0	O
(	O
R	O
##PL	O
##P	O
##0	O
)	O
.	O

Ethan	B
##ol	I
(	O
1	O
m	O
##l	O
)	O
was	O
added	O
to	O
each	O
tube	O
,	O
and	O
the	O
samples	O
were	O
son	O
##ica	O
##ted	O
using	O
an	O
Ultra	O
##sonic	O
Di	O
##sm	O
##em	O
##bra	O
##tor	O
(	O
model	O
150	O
##E	O
,	O
Fisher	O
Scientific	O
)	O
.	O

The	O
upper	O
organic	O
layer	O
was	O
isolated	O
and	O
dried	O
by	O
cent	O
##ri	O
##fu	O
##gal	O
vacuum	O
e	O
##va	O
##por	O
##ation	O
and	O
dissolved	O
in	O
is	B
##op	I
##rop	I
##ano	I
##l	I
:	O
met	B
##han	I
##ol	I
:	O
ch	B
##lor	I
##of	I
##orm	I
(	I
4	I
:	I
2	I
:	I
1	I
)	I
containing	O
7	O
m	O
##M	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
.	O

Is	O
##olate	O
##d	O
e	O
##pit	O
##hel	O
##ial	O
cells	O
were	O
counted	O
using	O
Co	O
##ulter	O
Counter	O
model	O
Z	O
##M	O
(	O
Beck	O
##man	O
Co	O
##ulter	O
,	O
Fuller	O
##ton	O
,	O
CA	O
,	O
USA	O
)	O
and	O
stored	O
in	O
1	O
m	O
##l	O
of	O
met	B
##han	I
##ol	I
at	O
-	O
20	O
##°	O
##C	O
until	O
further	O
analyses	O
.	O

(	O
1	O
m	O
##M	O
)	O
in	O
ace	B
##tone	I
(	O
0	O
.	O
1	O
%	O
v	O
/	O
v	O
)	O
to	O
in	O
##hibit	O
s	O
##tero	O
##id	O
5	B
##α	I
red	I
##uc	I
##tase	I
##19	I
.	O

Future	O
work	O
following	O
on	O
from	O
this	O
study	O
should	O
make	O
use	O
of	O
samples	O
dedicated	O
for	O
_	O
1	O
H	O
N	O
##MR	O
analysis	O
,	O
collected	O
into	O
lit	B
##hium	I
-	I
he	I
##par	I
##in	I
tubes	O
(	O
in	O
order	O
to	O
avoid	O
the	O
relatively	O
large	O
,	O
interfering	O
E	O
##D	O
##TA	O
resonance	O
##s	O
)	O
and	O
o	O
##mit	O
##ting	O
the	O
his	O
##top	O
##aque	O
separation	O
step	O
.	O

Principal	O
components	O
analysis	O
(	O
PC	O
##A	O
)	O
scores	O
plots	O
of	O
_	O
1	O
H	O
N	O
##MR	O
standard	O
1	O
##D	O
and	O
R	B
##P	I
UP	O
##LC	O
-	O
MS	O
(	O
E	O
##SI	O
+	O
)	O
data	O
evaluating	O
variation	O
among	O
serum	O
and	O
plasma	O
samples	O
.	O

Col	O
##um	O
##ns	O
were	O
maintained	O
at	O
40	O
°C	O
and	O
el	O
##uted	O
with	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
–	O
a	O
##que	O
##ous	O
form	B
##ic	I
acid	I
(	O
0	O
.	O
1	O
%	O
v	O
/	O
v	O
)	O
using	O
a	O
series	O
of	O
linear	O
gradient	O
##s	O
over	O
either	O
15	O
,	O
7	O
.	O
5	O
or	O
3	O
min	O
(	O
depending	O
on	O
column	O
length	O
)	O
at	O
600	O
μ	O
##L	O
/	O
min	O
starting	O
at	O
2	O
%	O
AC	O
##N	O
and	O
,	O
after	O
a	O
hold	O
of	O
either	O
1	O
min	O
,	O
0	O
.	O
5	O
##min	O
or	O
0	O
.	O
2	O
min	O
##s	O
at	O
this	O
composition	O
,	O
rising	O
first	O
to	O
15	O
,	O
then	O
50	O
and	O
finally	O
to	O
95	O
%	O
AC	O
##N	O
at	O
the	O
end	O
gradient	O
(	O
for	O
column	O
/	O
run	O
-	O
specific	O
details	O
see	O
)	O
.	O

After	O
v	O
##ortex	O
##ing	O
,	O
250	O
μ	O
##L	O
of	O
ch	B
##lor	I
##of	I
##orm	I
were	O
added	O
and	O
the	O
tubes	O
were	O
agitated	O
for	O
15	O
min	O
at	O
700	O
rpm	O
.	O

The	O
mass	O
difference	O
between	O
9	O
and	O
this	O
new	O
meta	O
##bol	O
##ite	O
(	O
28	O
Da	O
)	O
is	O
consistent	O
with	O
the	O
o	O
##xi	O
##da	O
##tive	O
de	O
##car	O
##box	O
##yla	O
##tion	O
of	O
9	O
to	O
yield	O
N	B
-	I
ace	I
##ty	I
##l	I
-	I
S	I
-	I
[	I
1	I
-	I
(	I
4	I
-	I
car	I
##box	I
##y	I
##but	I
##yl	I
)	I
-	I
1	I
##H	I
-	I
p	I
##yr	I
##rol	I
-	I
3	I
-	I
y	I
##l	I
]	I
-	I
L	I
-	I
c	I
##ys	I
##tein	I
##e	I
su	I
##lf	I
##oxide	I
(	O
13	O
)	O
.	O

For	O
the	O
internal	O
standard	O
,	O
no	O
el	O
##uti	O
##ng	O
peaks	O
with	O
areas	O
of	O
>	O
5	O
%	O
of	O
the	O
normal	O
response	O
of	O
D	B
_	I
6	I
-	I
en	I
##zal	I
##uta	I
##mi	I
##de	I
were	O
observed	O
.	O

In	O
addition	O
,	O
significantly	O
different	O
meta	O
##bol	O
##ites	O
(	O
P	O
<	O
0	O
.	O
05	O
)	O
were	O
observed	O
in	O
I	O
##BS	O
,	O
including	O
g	B
##lu	I
##copy	I
##rano	I
##se	I
and	O
h	B
##ydro	I
##cin	I
##nam	I
##ic	I
acid	I
;	O
however	O
,	O
these	O
meta	O
##bol	O
##ites	O
were	O
not	O
comparable	O
to	O
the	O
currently	O
available	O
gut	O
micro	O
##bio	O
##ta	O
due	O
to	O
insufficient	O
literature	O
on	O
gut	O
bacteria	O
and	O
its	O
meta	O
##bol	O
##ites	O
.	O

Similar	O
to	O
u	O
##rina	O
##ry	O
ta	B
##uri	I
##ne	I
levels	O
,	O
we	O
documented	O
a	O
decrease	O
in	O
u	O
##rina	O
##ry	O
levels	O
of	O
AD	B
##MA	I
between	O
V	O
##1	O
and	O
V	O
##3	O
in	O
the	O
E	O
##G	O
.	O

Feature	O
13	O
at	O
m	O
/	O
z	O
304	O
.	O
09	O
##0	O
##5	O
yielded	O
one	O
hit	O
in	O
M	O
##MC	O
##D	O
,	O
namely	O
N	B
-	I
ace	I
##ty	I
##lasp	I
##art	I
##yl	I
##g	I
##lut	I
##ama	I
##te	I
(	O
N	O
##AA	O
##G	O
)	O
.	O

While	O
the	O
IS	O
-	O
normal	O
##ized	O
M	O
##F	O
for	O
s	B
##pi	I
##ron	I
##ola	I
##cton	I
##e	I
lie	O
in	O
a	O
very	O
reasonable	O
range	O
of	O
97	O
.	O
3	O
–	O
102	O
.	O
3	O
%	O
,	O
the	O
signal	O
of	O
the	O
other	O
two	O
anal	O
##yte	O
##s	O
appears	O
to	O
be	O
am	O
##plified	O
in	O
the	O
plasma	O
.	O

5	O
%	O
v	O
/	O
v	O
water	O
in	O
met	B
##han	I
##ol	I
,	O
20	O
m	O
##M	O
am	B
##mon	I
##ium	I
format	I
##e	I
in	O
met	B
##han	I
##ol	I
,	O
0	O
.	O
2	O
%	O
v	O
/	O
v	O
form	B
##ic	I
acid	I
in	O
met	B
##han	I
##ol	I
and	O
7	O
%	O
v	O
/	O
v	O
water	O
in	O
is	B
##op	I
##rop	I
##ano	I
##l	I
.	O

R	B
##iba	I
##vir	I
##in	I
levels	O
did	O
not	O
drop	O
to	O
the	O
extent	O
that	O
so	B
##fo	I
##s	I
##bu	I
##vir	I
levels	O
did	O
in	O
patients	O
who	O
had	O
been	O
off	O
treatment	O
prior	O
to	O
liver	O
transplant	O
##ation	O
,	O
a	O
finding	O
consistent	O
with	O
the	O
fact	O
that	O
rib	B
##avi	I
##rin	I
and	O
its	O
p	O
##hos	O
##ph	O
##ory	O
##lated	O
meta	O
##bol	O
##ites	O
have	O
half	O
-	O
lives	O
of	O
approximately	O
9	O
to	O
14	O
days	O
in	O
plasma	O
,	O
serum	O
,	O
red	O
blood	O
cells	O
(	O
RB	O
##C	O
)	O
,	O
and	O
peripheral	O
blood	O
mon	O
##on	O
##uc	O
##lea	O
##r	O
cells	O
(	O
P	O
##BM	O
##C	O
)	O
(	O
,	O
)	O
.	O

In	O
addition	O
to	O
a	O
relative	O
higher	O
α	O
and	O
β	B
-	I
glucose	I
content	O
that	O
characterized	O
T	O
##2	O
##DM	O
-	O
NC	O
patients	O
with	O
respect	O
to	O
C	O
##G	O
,	O
a	O
relative	O
decrease	O
of	O
al	B
##ani	I
##ne	I
,	O
c	O
##rea	O
##tine	O
/	O
c	O
##rea	O
##tin	O
##ine	O
,	O
g	B
##lut	I
##amine	I
,	O
g	B
##lut	I
##ama	I
##te	I
,	O
le	B
##uc	I
##ine	I
,	O
l	B
##ys	I
##ine	I
,	O
met	B
##hi	I
##oni	I
##ne	I
,	O
N	B
-	I
ace	I
##ty	I
##l	I
##gly	I
##co	I
##p	I
##rote	I
##ins	I
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
and	O
t	B
##yr	I
##os	I
##ine	I
was	O
observed	O
in	O
T	O
##2	O
##DM	O
-	O
NC	O
patients	O
with	O
respect	O
to	O
the	O
C	O
##G	O
(	O
C	O
)	O
.	O

Analysis	O
of	O
metabolic	O
profile	O
of	O
raw	O
CS	O
##F	O
and	O
their	O
lip	O
##id	O
extract	O
shows	O
decreased	O
levels	O
of	O
many	O
compounds	O
and	O
led	O
to	O
the	O
conclusion	O
that	O
MS	O
patients	O
could	O
have	O
a	O
disturbance	O
in	O
many	O
metabolic	O
pathways	O
perhaps	O
leading	O
to	O
the	O
decreased	O
level	O
of	O
ace	B
##ty	I
##l	I
-	I
Co	I
##A	I
and	O
/	O
or	O
inflammation	O
.	O

The	O
car	B
##ni	I
##tine	I
system	O
in	O
cancer	O
##s	O
has	O
also	O
been	O
explored	O
in	O
previous	O
studies	O
examining	O
other	O
diseases	O
_	O
,	O
.	O

With	O
respect	O
to	O
urine	O
,	O
inverse	O
associations	O
with	O
VA	O
##T	O
included	O
s	O
##tero	O
##ids	O
,	O
like	O
co	B
##rt	I
##is	I
##ol	I
,	O
and	O
other	O
fatty	O
acids	O
,	O
e	O
.	O
g	O
.	O
se	B
##ba	I
##cate	I
,	O
members	O
of	O
the	O
u	B
##rea	I
cycle	O
,	O
e	O
.	O
g	O
.	O
u	B
##rea	I
itself	O
,	O
as	O
well	O
as	O
pu	B
##rine	I
##s	I
and	O
p	B
##yr	I
##im	I
##id	I
##ines	I
,	O
like	O
u	B
##rac	I
##il	I
,	O
g	B
##uan	I
##ine	I
or	O
u	B
##rate	I
.	O

The	O
levels	O
of	O
four	O
(	B
se	B
##rine	I
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
g	B
##lut	I
##amine	I
,	O
and	O
a	O
##rac	O
##hi	O
##don	O
##ic	O
acid	O
)	O
of	O
these	O
meta	O
##bol	O
##ites	O
increased	O
striking	O
##ly	O
in	O
positive	O
group	O
compared	O
with	O
the	O
negative	O
group	O
,	O
while	O
three	O
(	O
p	O
##yr	O
##u	O
##vate	O
,	O
al	B
##ani	I
##ne	I
,	O
g	B
##lut	I
##amine	I
)	O
of	O
these	O
meta	O
##bol	O
##ites	O
decreased	O
marked	O
##ly	O
(	O
t	O
test	O
,	O
p	O
<	O
0	O
.	O
05	O
with	O
a	O
signed	O
t	O
value	O
of	O
“	O
1	O
”	O
)	O
.	O

Q	O
##uant	O
##ification	O
of	O
neon	B
##ico	I
##tino	I
##id	I
meta	O
##bol	O
##ites	O
was	O
performed	O
only	O
for	O
AM	O
-	O
2	O
,	O
because	O
standard	O
compounds	O
were	O
not	O
available	O
for	O
im	O
##ida	O
##c	O
##lop	O
##rid	O
or	O
cloth	B
##ian	I
##id	I
##in	I
,	O
i	O
.	O
e	O
.	O
I	O
##M	O
-	O
1	O
,	O
I	O
##M	O
-	O
3	O
,	O
I	O
##M	O
-	O
7	O
or	O
C	O
##M	O
-	O
1	O
.	O

The	O
SP	O
##E	O
-	O
cartridge	O
was	O
conditioned	O
with	O
1	O
m	O
##L	O
of	O
70	O
:	O
30	O
v	O
/	O
v	O
H	O
_	O
2	O
O	O
/	O
AC	O
##N	O
,	O
and	O
0	O
.	O
1	O
M	O
HC	O
##l	O
,	O
followed	O
by	O
1	O
m	O
##L	O
of	O
50	O
m	O
##M	O
sodium	B
phosphate	I
pH	O
10	O
.	O

Moreover	O
,	O
we	O
found	O
evidence	O
to	O
support	O
the	O
notion	O
that	O
the	O
path	O
##op	O
##hy	O
##sio	O
##logy	O
of	O
children	O
and	O
adolescent	O
##s	O
with	O
MD	O
##D	O
was	O
different	O
from	O
that	O
of	O
adults	O
,	O
especially	O
in	O
the	O
metabolism	O
of	O
try	B
##pt	I
##op	I
##han	I
.	O

Q	O
##uant	O
##itative	O
analyses	O
of	O
relevant	O
p	B
##yr	I
##im	I
##id	I
##ines	I
and	O
meta	O
##bol	O
##ites	O
in	O
urine	O
was	O
performed	O
by	O
G	O
##C	O
–	O
MS	O
.	O

While	O
less	O
well	O
studied	O
,	O
the	O
a	B
##cy	I
##l	I
-	I
g	I
##ly	I
##cine	I
##s	I
represent	O
a	O
growing	O
class	O
of	O
“	O
orphan	O
”	O
end	O
##ogen	O
##ous	O
lip	O
##ids	O
which	O
are	O
candidate	O
l	O
##igan	O
##ds	O
for	O
a	O
variety	O
of	O
orphan	O
G	O
-	O
protein	O
coupled	O
receptors	O
.	O

The	O
resulting	O
ma	B
##late	I
then	O
participates	O
in	O
the	O
p	B
##yr	I
##u	I
##vate	I
-	I
ma	I
##late	I
shuttle	O
as	O
shown	O
in	O
.	O

Doc	B
##osa	I
##pent	I
##aen	I
##oi	I
##c	I
acid	I
was	O
up	O
##re	O
##gu	O
##lated	O
in	O
a	O
previous	O
study	O
of	O
mild	O
cognitive	O
imp	O
##air	O
##ment	O
and	O
also	O
at	O
the	O
pre	O
##sy	O
##mpt	O
##oma	O
##tic	O
stage	O
in	O
a	O
lip	O
##ido	O
##mic	O
analysis	O
of	O
brain	O
tissues	O
and	O
plasma	O
from	O
a	O
mouse	O
model	O
of	O
AD	O
,	O
which	O
con	O
##ver	O
##ges	O
with	O
the	O
present	O
observations	O
.	O

These	O
include	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
(	O
C	O
##9	O
:	O
OH	O
)	O
,	O
u	O
##rid	O
##ine	O
/	O
pseudo	O
##uri	O
##dine	O
,	O
g	B
##lu	I
##cos	I
##amine	I
-	I
6	I
-	I
phosphate	I
and	O
certain	O
bi	O
##le	O
acids	O
.	O

Ace	B
##tam	I
##ino	I
##phe	I
##n	I
use	O
has	O
been	O
associated	O
with	O
ne	O
##ph	O
##rop	O
##athy	O
,	O
as	O
##th	O
##ma	O
,	O
and	O
other	O
lung	O
conditions	O
(	O
–	O
)	O
,	O
while	O
i	B
##bu	I
##p	I
##ro	I
##fen	I
use	O
has	O
been	O
linked	O
to	O
increased	O
risk	O
of	O
stroke	O
and	O
card	O
##iovascular	O
events	O
(	O
,	O
)	O
.	O

The	O
crude	O
met	B
##han	I
##ol	I
extract	O
of	O
T	O
.	O
ha	O
##rz	O
##ian	O
##um	O
strain	O
E	O
##S	O
##39	O
was	O
di	O
##lut	O
##ed	O
to	O
90	O
%	O
(	O
vol	O
/	O
vol	O
)	O
met	B
##han	I
##ol	I
by	O
adding	O
a	O
##que	O
##ous	O
0	O
.	O
1	O
%	O
HC	O
##O	O
##OH	O
before	O
fraction	O
##ation	O
by	O
reversed	O
-	O
phase	O
high	O
-	O
performance	O
liquid	O
ch	O
##roma	O
##tography	O
(	O
HP	O
##LC	O
)	O
(	O
Smart	O
System	O
,	O
Am	O
##ers	O
##ham	O
B	O
##ios	O
##cie	O
##nces	O
,	O
Up	O
##ps	O
##ala	O
,	O
Sweden	O
)	O
.	O

Ace	O
##ty	O
##lation	O
of	O
the	O
amino	O
acid	O
after	O
an	O
N	O
-	O
terminal	O
met	B
##hi	I
##oni	I
##ne	I
occurs	O
as	O
part	O
of	O
protein	O
cat	O
##ab	O
##olis	O
##m	O
.	O

It	O
is	O
known	O
that	O
la	B
##ct	I
##ate	I
is	O
increased	O
under	O
both	O
a	O
##ero	O
##bic	O
and	O
an	O
##ae	O
##ro	O
##bic	O
conditions	O
in	O
many	O
cancer	O
##s	O
relative	O
to	O
normal	O
tissue	O
.	O

Is	O
##oto	O
##pe	O
di	O
##lution	O
mass	O
s	O
##pect	O
##rome	O
##try	O
was	O
used	O
to	O
q	O
##uant	O
##ify	O
the	O
u	O
##rina	O
##ry	O
ex	O
##cre	O
##tion	O
of	O
the	O
me	O
##rca	O
##pt	O
##uri	O
##c	O
acids	O
of	O
ben	B
##zen	I
##e	I
,	O
a	B
##c	I
##rol	I
##ein	I
,	O
and	O
c	B
##rot	I
##onal	I
##de	I
##hy	I
##de	I
from	O
the	O
eight	O
overnight	O
12	O
-	O
hour	O
urine	O
samples	O
collected	O
from	O
each	O
participant	O
over	O
the	O
12	O
-	O
week	O
intervention	O
period	O
.	O

Re	B
##s	I
##ver	I
##at	I
##rol	I
(	I
3	I
,	I
5	I
,	I
4	I
′	I
-	I
h	I
##ydro	I
##xy	I
##st	I
##il	I
##ben	I
##e	I
)	I
,	O
present	O
in	O
grapes	O
and	O
other	O
plants	O
,	O
has	O
several	O
anti	O
-	O
car	O
##cin	O
##ogenic	O
properties	O
.	O

H	B
##ydro	I
##gen	I
per	I
##oxide	I
was	O
added	O
to	O
the	O
cultures	O
at	O
a	O
final	O
concentration	O
of	O
100	O
μ	O
##M	O
to	O
trigger	O
o	O
##xi	O
##da	O
##tive	O
stress	O
and	O
cell	O
death	O
in	O
the	O
R	O
##GC	O
-	O
5	O
cells	O
.	O

The	O
correlation	O
##s	O
between	O
MR	O
##S	O
measured	O
and	O
laboratory	O
measured	O
of	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
,	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
L	O
##D	O
##L	O
and	O
HD	O
##L	O
were	O
r	O
=	O
0	O
.	O
98	O
,	O
0	O
.	O
97	O
,	O
0	O
.	O
95	O
and	O
0	O
.	O
97	O
,	O
respectively	O
.	O

An	O
an	O
##ion	O
-	O
exchange	O
column	O
(	O
PR	O
##P	O
-	O
X	O
##100	O
,	O
50	O
mm	O
×	O
4	O
.	O
6	O
mm	O
,	O
10	O
μ	O
##m	O
;	O
Hamilton	O
,	O
Reno	O
,	O
N	O
##V	O
,	O
USA	O
)	O
was	O
used	O
for	O
separation	O
,	O
with	O
the	O
mobile	O
phase	O
comprising	O
50	O
%	O
met	B
##han	I
##ol	I
and	O
5	O
m	O
##M	O
am	B
##mon	I
##ium	I
format	I
##e	I
(	O
pH	O
6	O
)	O
at	O
a	O
flow	O
rate	O
of	O
1	O
m	O
##L	O
/	O
min	O
.	O

The	O
output	O
CS	O
##V	O
files	O
are	O
provided	O
in	O
the	O
data	O
record	O
(	B
ad	B
##ni	I
##1	I
-	I
lip	I
##ido	I
##mic	I
##s	I
-	I
e	I
##ics	I
.	I
z	I
##ip	I
)	O
in	O
Data	O
Citation	O
3	O
.	O

The	O
absolute	O
concentration	O
(	O
ng	O
/	O
m	O
##L	O
)	O
of	O
each	O
PC	O
was	O
calculated	O
based	O
on	O
the	O
peak	O
area	O
of	O
the	O
PC	O
identified	O
in	O
the	O
sample	O
and	O
the	O
peak	O
area	O
of	O
the	O
internal	O
standard	O
of	O
PC	B
(	I
15	I
:	I
0	I
/	I
18	I
:	I
1	I
)	I
corresponding	O
to	O
the	O
sample	O
(	O
the	O
formula	O
was	O
shown	O
in	O
Figure	O
_	O
S	O
##1	O
)	O
.	O

Blood	O
was	O
collected	O
from	O
the	O
arm	O
,	O
usually	O
the	O
cu	O
##bit	O
##al	O
vein	O
,	O
into	O
purple	O
topped	O
containers	O
(	O
containing	O
et	B
##hyl	I
##ened	I
##iam	I
##ine	I
##ace	I
##tic	I
acid	O
)	O
.	O

C	O
##n	O
,	O
c	B
##rea	I
##tin	I
##ine	I
;	O
C	O
##r	O
,	O
c	B
##rea	I
##tine	I
;	O
D	O
##HT	O
,	O
di	B
##hy	I
##dr	I
##oth	I
##ym	I
##ine	I
;	O
D	B
##MG	I
,	O
N	O
,	O
N	B
-	I
dim	I
##eth	I
##yl	I
##gly	I
##cine	I
;	O
EA	O
,	O
ethanol	B
##amine	I
;	O

p	B
##yr	I
##im	I
##id	I
##ine	I
n	O
##uc	O
##leo	O
##tide	O
##s	O
(	O
19	O
.	O
19	O
%	O
)	O
,	O
amino	O
acids	O
,	O
p	O
##eptide	O
##s	O
,	O
and	O
analogue	O
##s	O
(	O
7	O
.	O
56	O
%	O
)	O
and	O
others	O

_	O
–	O
Co	O
##mm	O
##uta	O
##bility	O
of	O
SR	O
##M	O
97	O
##2	O
##a	O
was	O
evaluated	O
as	O
part	O
of	O
the	O
Vita	B
##min	I
D	I
Standard	O
##ization	O
Program	O
(	O
V	O
##DS	O
##P	O
)	O
,	O
an	O
international	O
effort	O
to	O
standard	O
##ize	O
the	O
assessment	O
of	O
vitamin	B
D	I
status	O
.	O

In	O
the	O
controls	O
(	O
n	O
=	O
9	O
)	O
,	O
the	O
a	O
##que	O
##ous	O
and	O
v	O
##it	O
##re	O
##ous	O
concentrations	O
of	O
G	O
##SS	O
##S	O
##G	O
,	O
c	B
##ys	I
##tine	I
,	O
Cy	O
##s	O
,	O
and	O
Cy	O
##s	O
##SS	O
##H	O
were	O
not	O
correlated	O
(	O
upper	O
)	O
.	O

Tri	B
##met	I
##hyl	I
##amine	I
-	I
N	I
-	I
oxide	I
(	O
T	O
##MA	O
##O	O
)	O
concentrations	O
in	O
human	O
c	O
##ere	O
##bro	O
##sp	O
##inal	O
fluid	O
(	O
CS	O
##F	O
)	O
.	O

This	O
correlation	O
was	O
already	O
described	O
in	O
1999	O
,	O
although	O
treatment	O
with	O
an	O
antagonist	O
of	O
g	B
##lu	I
##co	I
##cor	I
##tic	I
##oid	I
receptors	O
could	O
not	O
a	O
##bro	O
##gate	O
de	O
##tri	O
##mental	O
wasting	O
of	O
muscle	O
.	O
43	O
Nevertheless	O
,	O
higher	O
co	B
##rt	I
##is	I
##ol	I
levels	O
in	O
cache	O
##ctic	O
patients	O
has	O
not	O
always	O
been	O
detected	O
,	O
because	O
Cha	O
##uh	O
##an	O
et	O
al	O
.	O
44	O
in	O
a	O
pilot	O
study	O
with	O
nine	O
cache	O
##ctic	O
patients	O
found	O
only	O
non	O
‐	O
significant	O
differences	O
versus	O
nine	O
healthy	O
controls	O
.	O

Many	O
analytical	O
methods	O
have	O
been	O
developed	O
for	O
the	O
analysis	O
of	O
th	B
##iol	I
##s	I
from	O
biological	O
fluids	O
,	O
such	O
as	O
high	O
-	O
performance	O
liquid	O
ch	O
##roma	O
##tography	O
(	O
HP	O
##LC	O
)	O
and	O
cap	O
##illa	O
##ry	O
electro	O
##ph	O
##ores	O
##is	O
(	O
CE	O
)	O
with	O
ultra	O
##vio	O
##let	O
(	O
UV	O
)	O
_	O
,	O
,	O
flu	O
##ores	O
##cence	O
(	O
FL	O
##D	O
)	O
_	O
,	O
,	O
electro	O
##chemical	O
detection	O
(	O
E	O
##D	O
)	O
_	O
,	O
and	O
mass	O
s	O
##pect	O
##rome	O
##try	O
(	O
MS	O
)	O
detection	O
_	O
,	O
_	O
,	O
_	O
,	O
.	O

In	O
r	O
##umi	O
##nant	O
##s	O
diet	O
##ary	O
ch	B
##olin	I
##e	I
is	O
extensively	O
de	O
##graded	O
in	O
the	O
r	O
##ume	O
##n	O
,	O
,	O
which	O
may	O
explain	O
the	O
low	O
and	O
constant	O
levels	O
of	O
free	O
ch	B
##olin	I
##e	I
in	O
plasma	O
during	O
la	O
##ct	O
##ation	O
in	O
the	O
present	O
study	O
.	O

Also	O
,	O
RB	O
##C	O
have	O
a	O
reservoir	O
of	O
g	B
##lut	I
##ath	I
##ione	I
,	O
the	O
most	O
prevalent	O
anti	O
-	O
o	O
##xi	O
##dant	O
in	O
humans	O
and	O
one	O
that	O
is	O
essential	O
for	O
the	O
protection	O
of	O
hem	O
##og	O
##lo	O
##bul	O
##in	O
(	O
,	O
)	O
.	O

In	O
neither	O
case	O
could	O
9	O
-	O
H	O
##SA	O
be	O
detected	O
,	O
suggesting	O
that	O
significant	O
oxidation	O
of	O
o	B
##le	I
##ic	I
acid	I
to	O
9	O
-	O
H	O
##SA	O
is	O
not	O
attain	O
##able	O
non	O
-	O
en	O
##zy	O
##matical	O
##ly	O
.	O

Then	O
,	O
a	O
sample	O
was	O
extracted	O
with	O
300	O
μ	O
##L	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
,	O
shaken	O
for	O
10	O
min	O
and	O
cent	O
##ri	O
##fu	O
##ged	O
at	O
1500	O
##0	O
rpm	O
at	O
4	O
##°	O
##C	O
for	O
15	O
min	O
.	O

P	O
##las	O
##ma	O
samples	O
(	O
250	O
µ	O
##l	O
)	O
were	O
in	O
##cu	O
##bate	O
##d	O
for	O
18	O
h	O
with	O
20	O
µ	O
##l	O
of	O
1000	O
units	O
m	O
##l	O
_	O
−	O
##1	O
β	O
-	O
g	O
##lu	O
##cu	O
##ron	O
##idas	O
##e	O
,	O
200	O
µ	O
##l	O
of	O
200	O
mm	O
ace	B
##tate	I
buffer	O
and	O
10	O
µ	O
##l	O
of	O
600	O
mm	O
sodium	O
a	O
##zi	O
##de	O
.	O

These	O
effects	O
could	O
be	O
contributing	O
factors	O
in	O
m	O
##od	O
##ulating	O
ch	B
##ole	I
##ster	I
##ol	I
home	O
##ost	O
##asis	O
,	O
and	O
as	O
such	O
,	O
may	O
be	O
part	O
of	O
the	O
explanation	O
of	O
the	O
elevation	O
of	O
L	B
##D	I
##L	I
ch	I
##ole	I
##ster	I
##ol	I
by	O
a	O
T	O
##FA	O
-	O
rich	O
diet	O
which	O
was	O
demonstrated	O
by	O
N	O
##MR	O
.	O

The	O
GM	B
##3	I
concentration	O
differences	O
between	O
PD	O
and	O
controls	O
were	O
stronger	O
in	O
males	O
than	O
in	O
females	O
(	O
Males	O
:	O
1	O
.	O
288	O
##±	O
##0	O
.	O
05	O
##2	O
pm	O
##ol	O
/	O
μ	O
##l	O
versus	O
1	O
.	O
53	O
##9	O
##±	O
##0	O
.	O
04	O
##7	O
pm	O
##ol	O
/	O
μ	O
##l	O
for	O
controls	O
and	O
PD	O
respectively	O
;	O
p	O
-	O
value	O
=	O
0	O
.	O
00	O
##38	O
;	O
q	O
-	O
value	O
=	O
0	O
.	O
03	O
##8	O
;	O
when	O
normal	O
##ized	O
to	O
total	O
lip	O
##id	O
:	O
p	O
-	O
value	O
=	O
1	O
.	O
47	O
##2	O
##E	O
-	O
04	O
;	O
q	O
-	O
value	O
=	O
1	O
.	O
41	O
##2	O
##E	O
-	O
02	O
.	O

a	O
fall	O
into	O
the	O
out	O
##lier	O
area	O
,	O
which	O
is	O
due	O
to	O
the	O
increased	O
k	B
##eton	I
##e	I
bodies	O
,	O
Fi	O
##g	O
.	O

During	O
the	O
SP	O
##E	O
loading	O
cycle	O
,	O
the	O
analytical	O
pump	O
(	O
binary	O
pump	O
#	O
2	O
,	O
)	O
was	O
e	O
##qui	O
##li	O
##bra	O
##ting	O
the	O
analytical	O
column	O
with	O
30	O
%	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
(	O
mobile	O
phase	O
A	O
=	O
0	O
.	O
1	O
%	O
ace	B
##tic	I
acid	I
in	O
water	O
,	O
B	O
=	O
100	O
%	O
ace	O
##ton	O
##it	O
##ril	O
##e	O
)	O
at	O
1	O
m	O
##L	O
min	O
_	O
−	O
##1	O
and	O
column	O
temperature	O
of	O
35	O
°C	O
.	O

Fun	O
##ctional	O
##ly	O
,	O
they	O
facilitate	O
transfer	O
of	O
L	O
##CF	O
##As	O
into	O
the	O
mit	O
##och	O
##ond	O
##ria	O
for	O
ß	O
‐	O
oxidation	O
.	O
52	O
Although	O
typically	O
short	O
‐	O
lived	O
,	O
L	O
##CA	O
##C	O
a	O
##cc	O
##um	O
##ulate	O
in	O
states	O
of	O
in	O
##ef	O
##ficient	O
fatty	O
acid	O
oxidation	O
(	O
FA	O
##O	O
)	O
,	O
which	O
may	O
be	O
attributed	O
to	O
(	O
1	O
)	O
defects	O
in	O
mitochondrial	O
FA	O
##O	O
enzymes	O
or	O
(	O
2	O
)	O
increased	O
FA	O
##O	O
relative	O
to	O
t	B
##rica	I
##rb	I
##ox	I
##yl	I
##ic	I
acid	I
(	O
T	O
##CA	O
)	O
flux	O
;	O
this	O
leads	O
to	O
a	O
bottle	O
##neck	O
of	O
carbon	O
substrates	O
at	O
the	O
T	O
##CA	O
cycle	O
.	O
53	O
,	O
54	O
Such	O
defects	O
can	O
be	O
caused	O
or	O
ex	O
##ace	O
##rb	O
##ated	O
by	O
I	O
##R	O
,	O
which	O
has	O
,	O
in	O
turn	O
,	O
been	O
associated	O
with	O
elevations	O
in	O
plasma	O
L	O
##CA	O
##C	O
.	O
54	O
,	O
55	O
,	O
56	O
,	O
57	O

Similarly	O
,	O
GP	O
-	O
tag	O
##ged	O
3	B
-	I
o	I
##x	I
##och	I
##ole	I
##st	I
-	I
4	I
-	I
en	I
-	I
26	I
-	I
o	I
##ic	I
acid	I
(	O
CA	O
_	O
4	O
-	O
3	O
-	O
one	O
)	O
was	O
only	O
identified	O
following	O
treatment	O
with	O
bacterial	O
ch	B
##ole	I
##ster	I
##ol	I
o	O
##xi	O
##das	O
##e	O
and	O
thus	O
must	O
originate	O
from	O
end	O
##ogen	O
##ous	O
3	B
##β	I
-	I
h	I
##ydro	I
##xy	I
##cho	I
##les	I
##t	I
-	I
5	I
-	I
en	I
-	I
26	I
-	I
o	I
##ic	I
acid	I
.	O

Although	O
,	O
a	O
direct	O
relationship	O
between	O
re	B
##tina	I
##l	I
g	I
##lut	I
##ami	I
##c	I
acid	I
and	O
plasma	O
g	B
##lut	I
##ami	I
##c	I
acid	I
has	O
not	O
been	O
well	O
studied	O
,	O
we	O
could	O
carefully	O
suggested	O
that	O
plasma	O
g	O
##lut	O
##amine	O
/	B
g	B
##lut	I
##ami	I
##c	I
acid	I
level	O
may	O
have	O
close	O
relation	O
with	O
insulin	O
secret	O
##ion	O
and	O
re	O
##tina	O
accumulation	O
.	O

Ph	B
##en	I
##yla	I
##lani	I
##ne	I
is	O
an	O
essential	O
amino	O
acid	O
absorbed	O
from	O
food	O
that	O
can	O
be	O
meta	O
##bol	O
##ized	O
primarily	O
in	O
the	O
liver	O
into	O
t	B
##yr	I
##os	I
##ine	I
,	O
which	O
is	O
then	O
used	O
in	O
do	B
##pa	I
##mine	I
(	O
D	O
##A	O
)	O
,	O
nor	B
##ep	I
##ine	I
##ph	I
##rine	I
(	O
NE	O
)	O
and	O
e	B
##pine	I
##ph	I
##rine	I
synthesis	O
in	O
the	O
nervous	O
system	O
and	O
the	O
ad	O
##rena	O
##l	O
me	O
##du	O
##lla	O
.	O

The	O
fact	O
that	O
we	O
can	O
only	O
sample	O
human	O
my	O
##oc	O
##ard	O
##ial	O
tissues	O
at	O
a	O
single	O
time	O
-	O
point	O
has	O
limited	O
our	O
analysis	O
to	O
cross	O
-	O
section	O
##al	O
comparison	O
between	O
failing	O
and	O
non	O
-	O
failing	O
hearts	O
regarding	O
the	O
relative	O
amounts	O
of	O
production	O
(	O
PR	O
##MT	O
-	O
1	O
)	O
and	O
degradation	O
(	O
DD	O
##A	O
##H	O
-	O
1	O
and	O
DD	O
##A	O
##H	O
-	O
2	O
)	O
enzymes	O
rather	O
than	O
true	O
kinetic	O
##s	O
of	O
AD	B
##MA	I
at	O
the	O
level	O
of	O
the	O
my	O
##oc	O
##ard	O
##ium	O
.	O

Among	O
the	O
key	O
findings	O
were	O
the	O
lower	O
levels	O
of	O
a	B
##rg	I
##ini	I
##ne	I
with	O
Met	O
##S	O
risk	O
factors	O
in	O
women	O
and	O
the	O
higher	O
levels	O
with	O
A	O
##EE	O
/	O
kg	O
_	O
DL	O
##W	O
and	O
PA	O
##L	O
_	O
DL	O
##W	O
in	O
both	O
Met	O
##S	O
_	O
any	O
and	O
Met	O
##S	O
_	O
zero	O
women	O
.	O

The	O
first	O
characteristic	O
assessed	O
in	O
this	O
study	O
was	O
the	O
library	O
coverage	O
,	O
i	O
.	O
e	O
.	O
the	O
percentage	O
of	O
library	O
meta	O
##bol	O
##ites	O
that	O
produced	O
an	O
id	O
##ent	O
##ifiable	O
MS	O
peak	O
after	O
separation	O
with	O
methods	O
A	O
–	O
G	O
.	O
,	O
The	O
bench	O
##mark	O
R	B
##P	I
method	O

The	O
lower	O
level	O
of	O
pro	B
##line	I
was	O
believed	O
to	O
be	O
an	O
indication	O
of	O
over	O
##uti	O
##li	O
##zation	O
of	O
amino	O
acids	O
in	O
the	O
tumor	O
tissue	O
as	O
suggested	O
previous	O
studies	O
.	O

Det	O
##ailed	O
analysis	O
,	O
including	O
the	O
disease	O
p	O
##hen	O
##otype	O
and	O
clinical	O
activity	O
,	O
showed	O
that	O
patients	O
with	O
active	O
CD	O
had	O
the	O
lowest	O
a	B
##rg	I
##ini	I
##ne	I
concentrations	O
,	O
significantly	O
so	O
as	O
compared	O
to	O
healthy	O
controls	O
and	O
active	O
UC	O
.	O

A	O
recent	O
study	O
has	O
in	O
##fa	O
##ct	O
associated	O
altered	O
g	B
##lut	I
##amine	I
and	O
g	B
##lut	I
##ama	I
##te	I
levels	O
to	O
end	O
##ome	O
##tri	O
##osis	O
-	O
associated	O
p	O
##el	O
##vic	O
pain	O
.	O

Some	O
of	O
the	O
markers	O
were	O
unique	O
to	O
a	O
set	O
(	B
su	B
##cci	I
##nate	I
for	O
set	O
1	O
,	O
p	B
-	I
c	I
##res	I
##ol	I
for	O
set	O
2	O
)	O
but	O
the	O
majority	O
showed	O
a	O
consistent	O
trend	O
of	O
increased	O
or	O
decreased	O
levels	O
in	O
both	O
sets	O
,	O
although	O
for	O
each	O
c	O
##ir	O
##cum	O
##stance	O
the	O
meta	O
##bol	O
##ite	O
had	O
a	O
non	O
-	O
significant	O
p	O
value	O
in	O
one	O
of	O
the	O
sets	O
.	O

Also	O
,	O
we	O
used	O
the	O
IS	O
##s	O
and	O
the	O
FA	O
##ME	O
##s	O
R	B
##I	I
standards	O
to	O
evaluate	O
the	O
R	O
##T	O
shift	O
.	O

Interest	O
##ingly	O
,	O
we	O
found	O
higher	O
levels	O
of	O
the	O
fur	B
##oi	I
##c	I
acid	I
meta	O
##bol	O
##ite	O
in	O
urine	O
to	O
be	O
associated	O
with	O
a	O
lower	O
risk	O
of	O
lung	O
cancer	O
.	O

The	O
standards	O
were	O
extracted	O
with	O
2	O
m	O
##L	O
of	O
an	B
##hy	I
##dr	I
##ous	I
diet	I
##hyl	I
et	I
##her	I
in	O
glass	O
tubes	O
.	O

Ser	O
##um	O
levels	O
of	O
l	B
##ys	I
##ine	I
decreased	O
from	O
control	O
subjects	O
to	O
T	O
##2	O
##DM	O
patients	O
at	O
an	O
early	O
stage	O
and	O
to	O
T	O
##2	O
##DM	O
complicated	O
patients	O
.	O

Consequently	O
,	O
we	O
might	O
have	O
under	O
##est	O
##imated	O
the	O
capacity	O
of	O
meta	O
##bol	O
##ites	O
to	O
predict	O
g	B
##ly	I
##ce	I
##mic	I
control	O
.	O

A	O
decrease	O
in	O
met	B
##hi	I
##oni	I
##ne	I
levels	O
may	O
be	O
related	O
to	O
the	O
low	O
level	O
of	O
se	B
##rine	I
in	O
the	O
serum	O
of	O
HC	O
##C	O
patients	O
that	O
has	O
also	O
been	O
reported	O
previously	O
.	O

(	O
E	O
)	O
In	O
##tra	O
##cellular	O
ATP	S
levels	O
of	O
the	O
groups	O
indicated	O
in	O
(	O
B	O
)	O
.	O

This	O
analysis	O
indicated	O
that	O
the	O
set	O
of	O
meta	O
##bol	O
##ites	O
,	O
including	O
c	B
##rea	I
##tin	I
##ine	I
(	O
p	O
value	O
4	O
.	O
0	O
×	O
10	O
_	O
−	O
##0	O
##7	O
)	O
,	O
3	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
(	O
p	O
-	O
value	O
2	O
.	O
9	O
×	O
10	O
_	O
−	O
##0	O
##2	O
)	O
,	O
o	B
##xa	I
##lo	I
##ace	I
##tate	I
(	O
p	O
-	O
value	O
2	O
.	O
7	O
×	O
10	O
_	O
−	O
##0	O
##2	O
)	O
,	O
and	O
met	B
##hyl	I
##mal	I
##ona	I
##te	I
(	O
p	O
-	O
value	O
2	O
.	O
6	O
×	O
10	O
_	O
−	O
##0	O
##6	O
)	O
disc	O
##rim	O
##inate	O
##s	O
between	O
healthy	O
controls	O
and	O
N	O
##MO	O
##SD	O
patients	O
.	O

For	O
example	O
,	O
der	O
##eg	O
##ulation	O
of	O
ch	B
##ole	I
##ster	I
##ol	I
has	O
been	O
associated	O
with	O
altered	O
levels	O
of	O
some	O
s	O
##tero	O
##id	O
hormones	O
and	O
development	O
psychiatric	O
disorders	O
including	O
autism	O
,	O
altered	O
metabolism	O
of	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
such	O
as	O
c	B
##era	I
##mi	I
##de	I
has	O
been	O
observed	O
in	O
some	O
cases	O
of	O
depression	O
and	O
patients	O
with	O
ps	O
##ych	O
##osis	O
often	O
show	O
sub	O
##c	O
##lini	O
##cal	O
d	O
##ys	O
##lip	O
##ide	O
##mia	O
.	O

The	O
only	O
amino	O
acid	O
that	O
showed	O
marked	O
##ly	O
decreased	O
t	O
-	O
values	O
after	O
prolonged	O
blood	O
in	O
##cu	O
##bation	O
was	O
a	B
##rg	I
##ini	I
##ne	I
,	O
which	O
was	O
probably	O
due	O
to	O
the	O
a	O
##rg	O
##inas	O
##e	O
activity	O
of	O
er	O
##yt	O
##hr	O
##ocytes	O
.	O

Thus	O
,	O
the	O
increased	O
GA	B
##BA	I
in	O
the	O
H	O
##LP	O
subjects	O
might	O
have	O
been	O
a	O
stress	O
response	O
to	O
am	O
##eli	O
##ora	O
##te	O
or	O
prevent	O
high	O
post	O
##pra	O
##ndi	O
##al	O
o	O
##xi	O
##da	O
##tive	O
stress	O
in	O
H	O
##LP	O
individuals	O
.	O

L	O
##CM	O
##S	O
samples	O
were	O
prepared	O
from	O
stool	O
ho	O
##mo	O
##gen	O
##ates	O
(	O
10	O
μ	O
##L	O
)	O
via	O
protein	O
precipitation	O
with	O
the	O
addition	O
of	O
nine	O
volumes	O
of	O
74	B
.	I
9	I
:	I
24	I
.	I
9	I
:	I
0	I
.	I
2	I
v	I
/	O
v	O
/	O
v	O
ace	O
##ton	O
##it	O
##ril	O
##e	O
/	O
met	O
##han	O
##ol	O
/	O
form	O
##ic	O
acid	O
containing	O
stable	O
is	O
##oto	O
##pel	O
##abe	O
##led	O
internal	O
standards	O
(	B
v	B
##ali	I
##ned	O
##8	O
,	O
Is	O
##ote	O
##c	O
[UNK]	O
and	O
p	B
##hen	I
##yla	I
##lani	I
##ned	O
##8	O
,	O
Cambridge	O
Is	O
##oto	O
##pe	O
Laboratories	O
[UNK]	O
And	O
##over	O
,	O
MA	O
)	O
.	O

The	O
triple	O
play	O
(	O
Full	O
Sc	O
##an	O
,	O
Zoo	O
##m	O
Sc	O
##an	O
and	O
Col	O
##lis	O
##ion	O
-	O
induced	O
Di	O
##sso	O
##ciation	O
Product	O
ion	O
Sc	O
##an	O
)	O
L	O
##C	O
-	O
MS	O
analysis	O
for	O
the	O
synthetic	O
pro	B
##to	I
##cate	I
##chu	I
##ic	I
acid	I
O	O
-	O
g	O
##lu	O
##cu	O
##ron	O
##ide	O
(	O
PC	O
##A	O
##O	O
##G	O
)	O
standard	O
and	O
samples	O
was	O
conducted	O
using	O
an	O
L	O
##C	O
##Q	O
system	O
(	O
The	O
##rm	O
##o	O
)	O
equipped	O
with	O
Shi	O
##mad	O
##zu	O
Class	O
10	O
##V	O
##p	O
HP	O
##LC	O
.	O

=	O
0	O
.	O
53	O
,	O
adjusted	O
P	O
=	O
0	O
.	O
02	O
##9	O
)	O
while	O
accumulation	O
of	O
la	B
##ct	I
##ate	I
,	O
an	O
end	O
product	O
of	O
g	O
##ly	O
##co	O
##lysis	O
(	O
FC	O
=	O
1	O
.	O
64	O
,	O
adjusted	O
P	O
=	O
0	O
.	O
000	O
##8	O
##9	O
)	O
indicated	O
a	O
War	O
##burg	O
effect	O
.	O

experimental	O
##ly	O
confirmed	O
the	O
m	O
##G	O
##WA	O
##S	O
driven	O
hypothesis	O
of	O
SL	O
##C	O
##16	O
##A	O
##9	O
being	O
a	O
car	B
##ni	I
##tine	I
transport	O
##er	O
.	O

Given	O
the	O
e	B
##uri	I
##co	I
##yl	I
-	I
s	I
##phi	I
##ngo	I
##my	I
##elin	I
-	I
25	I
(	I
OH	I
)	I
D	I
association	O
observed	O
here	O
,	O
these	O
studies	O
warrant	O
follow	O
-	O
up	O
,	O
including	O
with	O
respect	O
to	O
biological	O
mechanisms	O
.	O

In	O
that	O
regard	O
,	O
3	B
-	I
p	I
##hen	I
##yl	I
##la	I
##ctic	I
acid	I
,	O
a	O
bacterial	O
product	O
of	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
f	O
##er	O
##mentation	O
in	O
dairy	O
products	O
,	O
was	O
exclusively	O
detected	O
after	O
cheese	O
ing	O
##est	O
##ion	O
in	O
the	O
urine	O
and	O
serum	O
samples	O
of	O
this	O
study	O
.	O

After	O
treatment	O
,	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
,	O
plasma	O
##log	O
##ens	O
,	O
and	O
other	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
increased	O
(	O
P	O
<	O
0	O
.	O
05	O
after	O
the	O
F	O
##DR	O
procedure	O
)	O
.	O

Here	O
we	O
combined	O
met	B
##han	I
##ol	I
precipitation	O
with	O
M	B
##T	I
##BE	I
extraction	O
in	O
order	O
to	O
achieve	O
a	O
higher	O
degree	O
of	O
extraction	O
for	O
lip	O
##ids	O
.	O

Food	O
components	O
including	O
trim	B
##eth	I
##yla	I
##mine	I
,	O
trim	B
##eth	I
##yla	I
##mine	I
N	I
-	I
oxide	I
,	O
le	B
##ci	I
##thin	I
and	O
ch	B
##olin	I
##e	I
have	O
been	O
found	O
to	O
increase	O
u	O
##rina	O
##ry	O
ex	O
##cre	O
##tion	O
of	O
D	B
##MA	I
and	O
in	O
particular	O
after	O
the	O
consumption	O
of	O
fish	O
and	O
sea	O
##food	O
an	O
u	O
##rina	O
##ry	O
D	B
##MA	I
rise	O
was	O
observed	O
[	O
,	O
]	O
.	O

Lower	O
levels	O
of	O
try	B
##pt	I
##op	I
##han	I
[	O
OR	O
:	O
0	O
.	O
58	O
(	O
95	O
%	O
C	O
##I	O
0	O
.	O
35	O
–	O
0	O
.	O
93	O
,	O
p	O
value	O
:	O
0	O
.	O
03	O
)	O
]	O
and	O
X	O
##A	O
[	O
0	O
.	O
56	O
(	O
0	O
.	O
22	O
–	O
0	O
.	O
91	O
,	O
0	O
.	O
02	O
)	O
]	O
as	O
well	O
as	O
higher	O
levels	O
of	O
rib	B
##of	I
##lav	I
##in	I
[	O
2	O
.	O
13	O
(	O
1	O
.	O
32	O
–	O
3	O
.	O
54	O
,	O
0	O
.	O
00	O
##3	O
)	O
]	O
and	O
higher	O
K	O
##TR	O
[	O
1	O
.	O
65	O
(	O
1	O
.	O
02	O
–	O
2	O
.	O
71	O
,	O
0	O
.	O
04	O
)	O
]	O
were	O
significantly	O
associated	O
with	O
the	O
age	O
34	O
–	O
40	O
group	O
(	O
N	O
=	O
36	O
)	O
.	O

A	O
##cc	O
##ura	O
##te	O
mass	O
measurements	O
of	O
Ph	O
##IP	O
-	O
SA	O
add	O
##uc	O
##ts	O
formed	O
with	O
L	O
##ys	O
,	O
Ty	O
##r	O
,	O
and	O
Ty	O
##r	O
*	O
-	O
T	O
##hr	O
-	O
L	O
##ys	O
The	O
product	O
ion	O
s	O
##pect	O
##ra	O
of	O
add	O
##uc	O
##ts	O
(	O
[	O
M	O
+	O
H	O
]	O
_	O
+	O
at	O
m	O
/	O
z	O
32	O
##9	O
.	O
2	O
and	O
33	O
##4	O
.	O
2	O
)	O
of	O
the	O
second	O
pair	O
of	O
add	O
##uc	O
##ts	O
(	O
t	O
_	O
R	O
=	O
13	O
.	O
9	O
min	O
are	O
identical	O
to	O
the	O
s	O
##pect	O
##ra	O
that	O
we	O
reported	O
previously	O
for	O
des	B
##ami	I
##no	I
-	I
Ph	I
##IP	I
-	I
C	I
add	O
##uc	O
##t	O
,	O
where	O
the	O
th	B
##iol	I
group	O
of	O
Cy	O
##s	O
_	O
34	O
displaced	O
the	O
ni	O
##tro	O
m	O
##oi	O
##ety	O
of	O
Ph	O
##IP	O
.	O

By	O
mixing	O
appropriate	O
amounts	O
from	O
is	O
##oto	O
##pe	O
-	O
labeled	O
standards	O
and	O
de	O
##con	O
##ju	O
##gation	O
standards	O
in	O
1	O
:	O
1	O
(	O
v	O
/	O
v	O
)	O
met	O
##han	O
##ol	O
/	O
water	O
,	O
the	O
s	O
##pi	O
##king	O
solution	O
of	O
is	O
##oto	O
##pe	O
-	O
labeled	O
standards	O
and	O
de	O
##con	O
##ju	O
##gation	O
standards	O
mixture	O
was	O
prepared	O
,	O
so	O
that	O
a	O
100	O
-	O
μ	O
##L	O
spike	O
to	O
400	O
μ	O
##L	O
of	O
urine	O
would	O
result	O
in	O
10	O
ng	O
m	O
##L	O
_	O
−	O
##1	O
concentration	O
of	O
the	O
individual	O
labeled	O
compounds	O
,	O
750	O
ng	O
m	O
##L	O
_	O
−	O
##1	O
of	O
4	B
-	I
met	I
##hyl	I
##um	I
##bell	I
##ifer	I
##yl	I
g	I
##lu	I
##cu	I
##ron	I
##ide	I
,	O
and	O
150	O
ng	O
m	O
##L	O
_	O
−	O
##1	O
of	O
_	O
13	O
C	B
_	I
4	I
-	I
4	I
-	I
met	I
##hyl	I
##um	I
##bell	I
##ifer	I
##one	I
.	O

Over	O
3	O
times	O
more	O
17	O
:	O
0	O
Ce	O
##r	O
and	O
17	O
:	O
0	O
P	O
##E	O
were	O
extracted	O
using	O
the	O
met	B
##han	I
##ol	I
-	I
ethanol	I
method	O
compared	O
to	O
the	O
met	B
##han	I
##ol	I
method	O
.	O

One	O
significant	O
difference	O
among	O
the	O
anal	O
##yte	O
peak	O
profiles	O
of	O
the	O
samples	O
were	O
the	O
high	O
levels	O
of	O
glucose	B
T	I
##MS	I
derivatives	O
tentatively	O
identified	O
in	O
samples	O
A	O
,	O
E	O
,	O
and	O
H	O
.	O

S	O
##1	O
##P	O
and	O
s	B
##phi	I
##ngo	I
##sin	I
##e	I
kinase	O
,	O
have	O
been	O
implicated	O
in	O
many	O
cellular	O
processes	O
including	O
cell	O
growth	O
,	O
proliferation	O
,	O
survival	O
,	O
and	O
migration	O
.	O

In	O
a	O
previous	O
paper	O
,	O
we	O
have	O
already	O
discussed	O
the	O
goodness	O
of	O
this	O
approach	O
in	O
studying	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
in	O
serum	O
samples	O
of	O
Mu	O
##S	O
patients	O
,	O
even	O
in	O
pregnancy	O
.	O

This	O
different	O
profile	O
could	O
be	O
related	O
to	O
a	O
different	O
exposure	O
pattern	O
for	O
children	O
and	O
adults	O
,	O
with	O
a	O
higher	O
exposure	O
to	O
diet	B
##hyl	I
p	I
##ht	I
##hala	I
##te	I
due	O
to	O
higher	O
use	O
of	O
personal	O
care	O
products	O
by	O
adults	O
compared	O
to	O
children	O
.	O

A	O
total	O
of	O
six	O
patients	O
were	O
using	O
a	O
typical	O
and	O
at	O
##y	O
##pical	O
anti	O
##psy	O
##cho	O
##tic	O
medication	O
combination	O
regime	O
##n	O
:	O
five	O
were	O
using	O
flu	B
##phe	I
##na	I
##zine	I
and	O
one	O
was	O
using	O
ha	O
##lop	O
##eri	O
##do	O
##l	O
,	O
in	O
addition	O
to	O
an	O
AA	O
##P	O
.	O

Met	O
##ab	O
##oli	O
##tes	O
extracted	O
from	O
plasma	O
using	O
AC	O
##N	O
represent	O
primarily	O
h	B
##ydro	I
##phi	I
##lic	I
compounds	O
that	O
are	O
poorly	O
retained	O
on	O
standard	O
C	O
_	O
18	O
reversed	O
phase	O
(	O
R	O
##P	O
)	O
ch	O
##roma	O
##tography	O
columns	O
,	O
such	O
as	O
those	O
used	O
during	O
our	O
L	O
##C	O
-	O
EC	O
pro	O
##fi	O
##ling	O
experiments	O
.	O

Previous	O
findings	O
by	O
others	O
showed	O
that	O
plasma	O
concentrations	O
of	O
ta	B
##mo	I
##xi	I
##fen	I
and	O
its	O
meta	O
##bol	O
##ites	O
increase	O
with	O
age	O
,	O
_	O
46	O
which	O
,	O
according	O
to	O
our	O
findings	O
,	O
may	O
be	O
explained	O
at	O
least	O
in	O
part	O
by	O
patient	O
ad	O
##herence	O
behavior	O
.	O

We	O
additionally	O
used	O
the	O
multi	O
-	O
meta	O
##bol	O
##ite	O
model	O
built	O
in	O
the	O
SAT	B
##IN	I
data	O
##set	O
(	O
Fi	O
##g	O
.	O
)	O
to	O
explore	O
whether	O
it	O
might	O
be	O
useful	O
to	O
predict	O
changes	O
in	O
H	O
##OM	O
##A	O
-	O
I	O
##R	O
in	O
both	O
the	O
G	O
##L	O
##Y	O
##ND	O
##IE	O
##T	O
(	O
6	O
months	O
length	O
)	O
and	O
SAT	B
##IN	I
(	O
2	O
months	O
length	O
)	O
studies	O
.	O

Figure	O
S	O
##6	O
##b	O
)	O
,	O
indicating	O
that	O
the	O
intervention	O
induced	O
changes	O
on	O
the	O
conversion	O
rates	O
of	O
downstream	O
meta	O
##bol	O
##ites	O
and	O
did	O
not	O
simply	O
follow	O
the	O
kinetic	O
##s	O
of	O
glucose	S
,	O
but	O
were	O
rather	O
independent	O
of	O
glucose	S
appearance	O
.	O

Inc	O
##reased	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
species	O
,	O
which	O
are	O
an	O
important	O
reservoir	O
of	O
ch	B
##olin	I
##e	I
for	O
ace	B
##ty	I
##l	I
##cho	I
##line	I
synthesis	O
and	O
ch	B
##olin	I
##ergic	I
signaling	O
,	O
have	O
also	O
been	O
reported	O
in	O
the	O
brains	O
of	O
mouse	O
models	O
of	O
G	O
##WI	O
.	O

Similarly	O
,	O
in	O
negative	O
MS	O
mode	O
,	O
100	O
%	O
of	O
the	O
lip	O
##ids	O
identified	O
in	O
FF	O
##A	O
,	O
Ce	O
##r	O
##P	O
,	O
LP	O
##E	O
,	O
S	O
##4	O
##E	O
,	O
PA	O
,	O
PC	O
,	O
P	B
##G	I
,	O
P	O
##I	O
,	O
p	O
##P	O
##E	O
,	O
and	O
PS	O
lip	O
##id	O
classes	O
of	O
the	O
samples	O
prepared	O
by	O
the	O
UC	O
method	O
are	O
also	O
detected	O
in	O
samples	O
prepared	O
by	O
the	O
SP	O
-	O
A	O
##F	O
##4	O
method	O
in	O
both	O
the	O
L	O
##D	O
##L	O
and	O
HD	O
##L	O
fraction	O
##s	O
.	O

Both	O
CP	O
##MG	O
score	O
plots	O
(	O
a	O
)	O
and	O
LED	O
score	O
plots	O
(	O
b	O
)	O
show	O
plasma	O
meta	O
##bol	O
##ites	O
of	O
F	B
##D	I
patients	O
##are	O
different	O
from	O
those	O
of	O
control	O
subjects	O
(	O
)	O
.	O

HM	O
##PM	O
##A	O
di	O
##aster	O
##eo	O
##mers	O
were	O
collected	O
by	O
HP	O
##LC	O
using	O
the	O
S	O
##yne	O
##rg	O
##i	O
column	O
described	O
above	O
with	O
el	O
##ution	O
by	O
is	O
##oc	O
##ratic	O
95	O
%	O
15	O
m	O
##M	O
NH	O
_	O
4	O
O	O
##A	O
##c	O
,	O
5	O
%	O
met	B
##han	I
##ol	I
.	O

Also	O
,	O
Vega	O
et	O
al	O
.	O
,	O
showed	O
that	O
plasma	O
concentrations	O
of	O
24	O
-	O
OH	O
##C	O
and	O
7	O
-	O
OH	O
##C	O
but	O
not	O
27	O
-	O
OH	O
##C	O
were	O
higher	O
in	O
dem	O
##ent	O
##ia	O
than	O
in	O
healthy	O
controls	O
and	O
may	O
be	O
reduced	O
by	O
si	B
##m	I
##vas	I
##tat	I
##in	I
,	O
,	O
,	O
.	O

Moreover	O
,	O
a	O
study	O
comparing	O
sa	O
##liva	O
##ry	O
co	B
##rt	I
##is	I
##ol	I
after	O
a	O
##wa	O
##king	O
revealed	O
no	O
differences	O
between	O
11	O
women	O
in	O
the	O
l	O
##ute	O
##al	O
phase	O
and	O
12	O
women	O
in	O
the	O
f	O
##oll	O
##icular	O
phase	O
of	O
the	O
men	O
##st	O
##ru	O
##al	O
cycle	O
and	O
in	O
another	O
study	O
it	O
was	O
consciously	O
avoided	O
to	O
record	O
the	O
phase	O
of	O
men	O
##st	O
##ru	O
##al	O
cycle	O
because	O
previous	O
unpublished	O
analyses	O
did	O
not	O
reveal	O
an	O
impact	O
on	O
u	O
##rina	O
##ry	O
g	B
##lu	I
##co	I
##cor	I
##tic	I
##oid	I
and	O
and	O
##rogen	O
meta	O
##bol	O
##ites	O
.	O

We	O
##ak	O
negative	O
relationships	O
between	O
age	O
and	O
11	B
-	I
de	I
##ox	I
##y	I
##cor	I
##tis	I
##ol	I
or	O
test	B
##osterone	I
were	O
only	O
apparent	O
with	O
multi	O
##var	O
##iate	O
models	O
adjusting	O
for	O
age	O
and	O
body	O
mass	O
index	O
.	O

The	O
average	O
amount	O
of	O
Ph	O
##e	O
-	O
te	O
##tra	O
##ols	O
5	O
plus	O
21	O
in	O
26	O
urine	O
samples	O
from	O
c	O
##re	O
##oso	O
##te	O
workers	O
analyzed	O
in	O
a	O
previous	O
study	O
was	O
83	O
##7	O
±	O
69	O
##2	O
pm	O
##ol	O
/	O
m	O
##L	O
urine	O
,	O
whereas	O
levels	O
of	O
Ph	O
##e	O
-	O
te	O
##tra	O
##ols	O
5	O
plus	O
21	O
in	O
smoke	O
##rs	O
’	O
urine	O
averaged	O
4	O
.	O
60	O
pm	O
##ol	O
/	O
m	O
##L	O
.	O
Based	O
on	O
this	O
ratio	O
,	O
we	O
might	O
expect	O
only	O
about	O
1	O
/	O
200	O
_	O
th	O
the	O
amount	O
of	O
the	O
su	B
##lf	I
##oxide	I
meta	O
##bol	O
##ites	O
in	O
smoke	O
##rs	O
’	O
urine	O
as	O
in	O
c	O
##re	O
##oso	O
##te	O
workers	O
’	O
urine	O
which	O
may	O
explain	O
our	O
inability	O
to	O
detect	O
them	O
in	O
smoke	O
##rs	O
’	O
urine	O
.	O

The	O
study	O
demonstrates	O
that	O
serum	O
meta	O
##bol	O
##omi	O
##c	O
profiles	O
might	O
play	O
a	O
clinical	O
role	O
in	O
H	O
##ER	O
##2	O
‐	O
positive	O
patients	O
in	O
detect	O
##ing	O
activity	O
of	O
the	O
targeted	O
anti	O
‐	O
H	O
##ER	O
##2	O
therapy	O
lap	B
##ati	I
##ni	I
##b	I
plus	O
p	O
##ac	O
##lit	O
##ax	O
##el	O
.	O

Inc	O
##rea	O
##sing	O
T	B
##G	I
levels	O
were	O
positively	O
associated	O
with	O
changes	O
of	O
several	O
meta	O
##bol	O
##ites	O
including	O
v	B
##ali	I
##ne	I
,	O
se	B
##rine	I
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
c	B
##rea	I
##tine	I
as	I
##par	I
##agi	I
##ne	I
and	O
t	B
##yr	I
##os	I
##ine	I
(	O
all	O
p	O
<	O
0	O
.	O
05	O
)	O
,	O
while	O
HD	O
##L	O
-	O
c	O
was	O
negatively	O
associated	O
with	O
six	O
meta	O
##bol	O
##ites	O
in	O
response	O
to	O
the	O
O	O
##G	O
##TT	O
,	O
i	O
.	O
e	O
.	O
,	O
v	B
##ali	I
##ne	I
,	O
is	B
##ole	I
##uc	I
##ine	I
,	O
c	B
##rea	I
##tin	I
##ine	I
,	O
dim	B
##eth	I
##yl	I
##gly	I
##cine	I
,	O
as	B
##par	I
##agi	I
##ne	I
and	O
t	B
##yr	I
##os	I
##ine	I
(	O
all	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

Ser	O
##um	O
est	B
##rad	I
##iol	I
and	O
pro	B
##ges	I
##tero	I
##ne	I
were	O
assessed	O
using	O
electro	O
-	O
ch	O
##em	O
##il	O
##umi	O
##nes	O
##cence	O
(	O
Abbott	O
diagnostic	O
##s	O
,	O
Abbott	O
Ireland	O
)	O
.	O

Therefore	O
,	O
the	O
massive	O
in	O
sit	O
##u	O
c	O
##y	O
##c	O
##li	O
##zation	O
of	O
g	B
##lut	I
##amine	I
within	O
the	O
E	O
##SI	O
source	O
represents	O
an	O
additional	O
major	O
challenge	O
for	O
the	O
analysis	O
of	O
blood	O
g	B
##lut	I
##amine	I
using	O
MS	O
.	O

This	O
demonstrated	O
en	O
##rich	O
##ment	O
of	O
nine	O
metabolic	O
pathways	O
,	O
five	O
of	O
which	O
(	O
metabolism	O
of	O
al	B
##ani	I
##ne	I
and	O
as	B
##par	I
##tate	I
,	O
a	B
##rg	I
##ini	I
##ne	I
and	O
pro	B
##line	I
,	O
as	B
##par	I
##tate	I
and	O
as	B
##par	I
##agi	I
##ne	I
,	O
ni	B
##ac	I
##in	I
,	O
and	O
u	B
##rea	I
cycle	O
/	O
amino	O
group	O
)	O
are	O
related	O
to	O
a	B
##rg	I
##ini	I
##ne	I
metabolism	O
.	O

In	O
each	O
sample	O
,	O
the	O
co	B
##rt	I
##is	I
##ol	I
meta	O
##bol	O
##ites	O
were	O
measured	O
by	O
G	O
##C	O
/	O
MS	O
in	O
S	O
##IM	O
.	O

It	O
is	O
considered	O
that	O
one	O
of	O
the	O
possible	O
reasons	O
for	O
this	O
beneficial	O
effect	O
of	O
em	B
##pa	I
##gli	I
##f	I
##lo	I
##zin	I
is	O
due	O
to	O
a	O
function	O
of	O
3	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yric	I
acid	I
as	O
alternative	O
fuel	O
for	O
the	O
energy	O
metabolism	O
of	O
cells	O
.	O

These	O
11	O
pathways	O
included	O
those	O
that	O
describe	O
metabolism	O
of	O
pu	B
##rine	I
,	O
p	B
##yr	I
##im	I
##id	I
##ine	I
,	O
g	B
##lut	I
##ama	I
##te	I
,	O
al	B
##ani	I
##ne	I
-	I
as	I
##par	I
##tate	I
,	O
g	B
##ly	I
##cine	I
-	I
se	I
##rine	I
-	I
th	I
##re	I
##oni	I
##ne	I
,	O
but	B
##ano	I
##ate	I
,	O
β	B
-	I
al	I
##ani	I
##ne	I
,	O
ta	B
##uri	I
##ne	I
-	I
h	I
##y	I
##pot	I
##au	I
##rine	I
,	O
v	B
##ali	I
##ne	I
-	I
le	I
##uc	I
##ine	I
-	I
is	I
##ole	I
##uc	I
##ine	I
bio	O
##sy	O
##nt	O
##hesis	O
,	O
pan	B
##to	I
##the	I
##nate	I
-	I
Co	I
##A	I
bio	O
##sy	O
##nt	O
##hesis	O
,	O
and	O
l	B
##ys	I
##ine	I
degradation	O
(	O
Su	O
##pp	O
##lement	O
##ary	O
Figure	O
2	O
)	O
.	O

We	O
have	O
developed	O
a	O
fast	O
,	O
sensitive	O
and	O
specific	O
quantitative	O
L	O
##C	O
-	O
MS	O
/	O
MS	O
,	O
multiple	O
reaction	O
monitoring	O
(	O
MR	O
##M	O
)	O
method	O
to	O
target	O
five	O
o	B
##xy	I
##ster	I
##ols	I
in	O
human	O
plasma	O
with	O
anal	O
##yte	O
recover	O
##ies	O
between	O
72	O
%	O
and	O
82	O
%	O
and	O
se	O
##ns	O
##iti	O
##vi	O
##ties	O
between	O
5	O
and	O
135	O
p	O
##g	O
/	O
m	O
##l	O
.	O

However	O
,	O
vitamin	B
E	I
supplement	O
##ation	O
was	O
inverse	O
##ly	O
associated	O
with	O
F	O
_	O
2	O
-	O
Is	O
##o	O
##P	O
-	O
M	O
,	O
but	O
not	O
F	O
_	O
2	O
-	O
Is	O
##o	O
##Ps	O
.	O

Take	O
100	O
μ	O
##L	O
of	O
plasma	O
sample	O
and	O
add	O
600	O
μ	O
##L	O
of	O
met	B
##han	I
##ol	I
(	O
containing	O
1	O
m	O
##M	O
but	B
##yl	I
##hy	I
##dr	I
##ox	I
##yt	I
##ol	I
##uen	I
##e	I
)	O
was	O
for	O
5	O
min	O
ultra	O
##sonic	O
processing	O
.	O

Met	O
##hyl	O
##ation	O
is	O
one	O
of	O
the	O
mechanisms	O
for	O
regulating	O
cell	O
growth	O
and	O
differentiation	O
;	O
S	B
-	I
ad	I
##eno	I
##sy	I
##l	I
-	I
L	I
-	I
met	I
##hi	I
##oni	I
##ne	I
is	O
a	O
met	O
##hyl	O
donor	O
which	O
is	O
generated	O
by	O
the	O
conversion	O
of	O
met	B
##hi	I
##oni	I
##ne	I
;	O
therefore	O
the	O
level	O
of	O
met	B
##hi	I
##oni	I
##ne	I
was	O
down	O
-	O
regulated	O
during	O
the	O
process	O
of	O
tumor	O
occurrence	O
and	O
development	O
.	O

Tri	O
##met	O
##hop	O
##rim	O
(	O
50	O
µ	O
##m	O
)	O
in	O
##hibit	O
##ed	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
metabolism	O
by	O
only	O
11	O
.	O
3	O
%	O
and	O
at	O
100	O
µ	O
##m	O
by	O
only	O
22	O
%	O
(	O
data	O
not	O
shown	O
)	O
.	O

Studies	O
that	O
examine	O
gut	O
taxa	O
may	O
el	O
##uc	O
##ida	O
##te	O
the	O
contribution	O
of	O
bacteria	O
-	O
host	O
interaction	O
to	O
circulating	O
se	B
##rot	I
##oni	I
##n	I
levels	O
.	O

Less	O
abundant	O
flour	O
car	O
##bo	O
##hy	O
##dra	O
##tes	O
included	O
su	B
##c	I
##rose	I
and	O
r	B
##af	I
##fin	I
##ose	I
.	O

In	O
contrast	O
,	O
q	O
##PC	O
##R	O
revealed	O
that	O
the	O
quantity	O
of	O
la	B
##ct	I
##ob	I
##ac	I
##ill	I
##i	I
was	O
lower	O
in	O
n	O
##IB	O
##S	O
patients	O
than	O
in	O
the	O
normal	O
gut	O
,	O
but	O
it	O
was	O
higher	O
in	O
I	O
##BS	O
patients	O
,	O
and	O
it	O
has	O
been	O
suggested	O
that	O
la	B
##ct	I
##ob	I
##ac	I
##ill	I
##i	I
and	O
the	O
secret	O
##ed	O
organic	O
acids	O
may	O
cause	O
I	O
##BS	O
symptoms	O
.	O

N	B
-	I
form	I
##yl	I
##ky	I
##nu	I
##ren	I
##ine	I
,	O
an	O
intermediate	O
in	O
try	B
##pt	I
##op	I
##han	I
cat	O
##ab	O
##olis	O
##m	O
,	O
was	O
found	O
to	O
be	O
increased	O
in	O
RC	O
##C	O
compared	O
with	O
that	O
in	O
ben	O
##ign	O
controls	O
.	O

We	O
observed	O
inverse	O
associations	O
between	O
HD	B
##L	I
p	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
and	O
Ki	O
##6	O
##7	O
(	O
β	O
-	O
0	O
.	O
25	O
,	O
p	O
=	O
0	O
.	O
00	O
##8	O
)	O
,	O
and	O
in	O
particular	O
between	O
HD	O
##L	O
##1	O
’	O
s	O
contents	O
of	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
,	O
a	O
##poli	O
##pop	O
##rote	O
##in	O
-	O
A1	O
,	O
a	O
##poli	O
##pop	O
##rote	O
##in	O
-	O
A2	O
and	O
Ki	O
##6	O
##7	O
.	O

There	O
are	O
reports	O
of	O
d	O
##ys	O
##re	O
##gu	O
##lation	O
in	O
G	B
##lu	I
##cos	I
##e	I
and	O
amino	O
acid	O
metabolism	O
in	O
HIV	O
patients	O
,	O
and	O
reducing	O
plasma	O
viral	O
load	O
improve	O
##s	O
muscle	O
amino	O
acid	O
metabolism	O
.	O

Diet	O
##ary	O
intake	O
of	O
α	B
-	I
l	I
##ino	I
##len	I
##ic	I
acid	I
was	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
h	O
##yper	O
##p	O
##lastic	O
p	O
##oly	O
##ps	O
in	O
men	O
(	O
P	O
-	O
trend	O
=	O
0	O
.	O
03	O
)	O
,	O
which	O
was	O
not	O
seen	O
in	O
women	O
.	O

Box	O
plots	O
shown	O
in	O
Figure	O
B	O
suggest	O
that	O
levels	O
of	O
t	B
##rig	I
##one	I
##llin	I
##e	I
might	O
be	O
significantly	O
lower	O
in	O
urine	O
samples	O
of	O
I	O
##C	O
patients	O
compared	O
to	O
those	O
of	O
controls	O
.	O

A	O
previous	O
m	B
##uri	I
##ne	I
study	O
demonstrated	O
that	O
can	B
##na	I
##bino	I
##id	I
treatment	O
could	O
directly	O
induce	O
B	O
-	O
cell	O
class	O
switching	O
from	O
im	O
##mu	O
##no	O
##g	O
##lo	O
##bul	O
##in	O
M	O
to	O
im	O
##mu	O
##no	O
##g	O
##lo	O
##bul	O
##in	O
E	O
;	O
thus	O
,	O
it	O
is	O
possible	O
that	O
cannabis	S
use	O
could	O
directly	O
influence	O
B	O
-	O
cell	O
functionality	O
.	O

The	O
levels	O
of	O
all	O
mon	O
##ou	O
##ns	O
##at	O
##ura	O
##ted	O
FF	O
##As	O
(	O
M	O
##U	O
##FA	O
##s	O
)	O
and	O
p	O
##oly	O
##uns	O
##at	O
##ura	O
##ted	O
FF	O
##As	O
(	O
P	O
##U	O
##FA	O
##s	O
)	O
were	O
significantly	O
lower	O
in	O
A	B
##F	I
patients	O
.	O

Keys	O
:	O
1	O
-	O
M	O
##H	O
,	O
1	B
-	I
met	I
##hyl	I
##his	I
##tide	I
##ne	I
;	O
3	O
-	O
H	O
##B	O
,	O
3	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
;	O
3	O
-	O
M	O
##H	O
,	O
3	B
-	I
met	I
##hyl	I
##his	I
##tide	I
##ne	I
;	O
AA	O
,	O
ace	B
##to	I
##ace	I
##tate	I
;	O
Ace	O
,	O
ace	B
##tate	I
;	O
Act	O
,	O
act	O
##one	O
;	O
Al	O
##a	O
,	O
al	B
##ani	I
##ne	I
;	O
As	O
##c	O
,	O
as	B
##cor	I
##bate	I
;	O
Cho	O
,	O
ch	B
##olin	I
##e	I
;	O
C	O
##i	O
,	O
c	B
##it	I
##rate	I
;	O

We	O
describe	O
the	O
development	O
,	O
valid	O
##ation	O
and	O
application	O
of	O
a	O
stable	O
is	O
##oto	O
##pe	O
di	O
##lution	O
liquid	O
ch	O
##roma	O
##tography	O
electro	O
##sp	O
##ray	O
ion	O
##ization	O
selected	O
reaction	O
monitoring	O
mass	O
s	O
##pect	O
##rome	O
##try	O
(	O
S	O
##ID	O
-	O
L	O
##C	O
/	O
E	O
##SI	O
/	O
SR	O
##M	O
/	O
MS	O
)	O
method	O
for	O
q	O
##uant	O
##ification	O
of	O
serum	O
k	B
##eto	I
-	I
and	I
##rogen	I
##s	I
and	O
their	O
su	B
##lf	I
##ate	I
and	O
g	B
##lu	I
##cu	I
##ron	I
##ide	I
con	O
##ju	O
##gate	O
##s	O
using	O
G	O
##ira	O
##rd	O
-	O
T	O
o	B
##xi	I
##me	I
derivatives	O
.	O

In	O
the	O
six	O
patients	O
in	O
this	O
study	O
who	O
received	O
diet	O
##ary	O
supplement	O
##ation	O
with	O
gal	B
##act	I
##ose	I
,	O
some	O
potentially	O
important	O
clinical	O
changes	O
were	O
seen	O
.	O

We	O
did	O
not	O
find	O
a	O
significant	O
association	O
between	O
the	O
classes	O
of	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
and	O
the	O
risk	O
of	O
bone	O
progression	O
.	O

The	O
plasma	O
insulin	O
levels	O
at	O
1	O
,	O
3	O
and	O
5	O
minutes	O
after	O
the	O
glucose	S
injection	O
and	O
the	O
first	O
-	O
phase	O
insulin	O
response	O
(	O
F	O
##PI	O
##R	O
,	O
sum	O
of	O
1	O
+	O
3	O
minutes	O
)	O
were	O
significantly	O
reduced	O
in	O
carriers	O
of	O
the	O
T	O
##CF	O
##7	O
##L	O
##2	O
risk	O
all	O
##ele	O
compared	O
to	O
the	O
control	O
group	O
,	O
whereas	O
no	O
significant	O
differences	O
in	O
the	O
second	O
-	O
phase	O
insulin	O
response	O
were	O
observed	O
.	O

A	O
majority	O
of	O
the	O
meta	O
##bol	O
##ites	O
were	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
including	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##line	I
(	I
l	I
##ys	I
##o	I
##PC	I
)	I
16	I
:	I
0	I
,	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
(	I
PC	I
)	I
16	I
:	I
1	I
/	I
18	I
:	I
2	I
,	O
20	O
:	O
3	O
/	O
18	O
:	O
0	O
and	O
O	B
-	I
20	I
:	I
0	I
/	I
22	I
:	I
4	I
,	O
and	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##let	I
##han	I
##ola	I
##mine	I
(	I
P	I
##E	I
)	I
(	I
O	I
-	I
18	I
:	I
2	I
/	I
20	I
:	I
4	I
)	I
which	O
were	O
higher	O
in	O
plasma	O
than	O
serum	O
.	O

Val	B
##ine	I
,	O
al	B
##ani	I
##ne	I
and	O
β	B
-	I
al	I
##ani	I
##ne	I
differ	O
significantly	O
between	O
patients	O
with	O
and	O
without	O
G	O
##DM	O
.	O

P	O
##las	O
##ma	O
samples	O
were	O
obtained	O
at	O
1	O
,	O
6	O
,	O
and	O
12	O
months	O
after	O
starting	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
intake	O
.	O

The	O
anti	O
-	O
pro	O
##life	O
##rative	O
effect	O
of	O
met	B
##ho	I
##xy	I
##est	I
##rogen	I
##s	I
has	O
not	O
yet	O
been	O
demonstrated	O
in	O
relation	O
to	O
the	O
pro	O
##state	O
but	O
it	O
was	O
shown	O
that	O
in	O
breast	O
cancer	O
cells	O
the	O
effect	O
can	O
occur	O
independently	O
of	O
ER	O
##α	O
and	O
ER	O
##β	O
.	O

To	O
prepare	O
our	O
SF	O
-	O
rich	O
powder	O
,	O
the	O
a	O
##que	O
##ous	O
extract	O
was	O
filtered	O
,	O
cooled	O
to	O
37	O
##°	O
##C	O
,	O
and	O
treated	O
with	O
my	O
##ros	O
##inas	O
##e	O
,	O
an	O
enzyme	O
released	O
from	O
a	O
small	O
amount	O
of	O
da	O
##iko	O
##n	O
(	O
Rap	O
##han	O
##us	O
sat	O
##iv	O
##us	O
)	O
s	O
##p	O
##rout	O
##s	O
,	O
for	O
4	O
hours	O
in	O
order	O
to	O
h	O
##ydro	O
##ly	O
##ze	O
the	O
g	B
##lu	I
##cos	I
##ino	I
##lates	I
to	O
is	B
##oth	I
##io	I
##cy	I
##ana	I
##tes	I
.	O

For	O
our	O
study	O
group	O
fifty	O
individuals	O
having	O
fast	O
##ing	O
blood	O
glucose	S
levels	O
between	O
4	O
.	O
5	O
and	O
6	O
.	O
5	O
mm	O
##ol	O
/	O
l	O
(	O
mean	O
:	O
5	O
.	O
3	O
##±	O
##0	O
.	O
53	O
mm	O
##ol	O
/	O
l	O
)	O
which	O
are	O
all	O
below	O
the	O
current	O
diagnostic	O
criteria	O
of	O
the	O
WHO	O
for	O
type	O
2	O
diabetes	O
,	O
were	O
recruited	O
.	O

H	B
##ydro	I
##xy	I
##ana	I
##stro	I
##zo	I
##le	I
was	O
q	O
##uant	O
##ified	O
using	O
the	O
ratio	O
of	O
area	O
under	O
the	O
curve	O
(	O
AU	O
##C	O
)	O
of	O
the	O
meta	O
##bol	O
##ite	O
to	O
AU	O
##C	O
of	O
the	O
internal	O
standard	O
,	O
Con	O
##cent	O
##rations	O
of	O
the	O
meta	O
##bol	O
##ite	O
were	O
measured	O
by	O
standard	O
curves	O
obtained	O
with	O
an	B
##ast	I
##ro	I
##zo	I
##le	I
,	O
as	O
authentic	O
samples	O
of	O
the	O
synthetic	O
meta	O
##bol	O
##ite	O
were	O
not	O
available	O
to	O
us	O
.	O

Changes	O
in	O
levels	O
of	O
these	O
three	O
meta	O
##bol	O
##ites	O
were	O
significantly	O
correlated	O
with	O
each	O
other	O
in	O
samples	O
from	O
individuals	O
across	O
the	O
full	O
range	O
of	O
si	B
##m	I
##vas	I
##tat	I
##in	I
response	O
.	O

In	O
all	O
,	O
1	O
,	O
82	O
##8	O
molecular	O
features	O
were	O
found	O
in	O
the	O
M	B
##T	I
##BE	I
extracted	O
lip	O
##id	O
fraction	O
,	O
and	O
1	O
,	O
410	O
features	O
were	O
found	O
when	O
met	B
##han	I
##ol	I
alone	O
was	O
used	O
in	O
conjunction	O
with	O
R	O
##PC	O
.	O

Although	O
the	O
P	O
##EM	O
##T	O
ratio	O
has	O
not	O
been	O
used	O
to	O
predict	O
P	O
##EM	O
##T	O
activity	O
in	O
the	O
ma	O
##mma	O
##ry	O
g	O
##land	O
,	O
our	O
results	O
may	O
suggest	O
that	O
ma	O
##mma	O
##ry	O
end	O
##ogen	O
##ous	O
bio	O
##sy	O
##nt	O
##hesis	O
of	O
ch	B
##olin	I
##e	I
dropped	O
from	O
early	O
to	O
late	O
la	O
##ct	O
##ation	O
and	O
this	O
was	O
consistent	O
with	O
increasing	O
plasma	O
PC	O
concentrations	O
as	O
la	O
##ct	O
##ation	O
progressed	O
.	O

The	O
experimental	O
(	O
red	O
)	O
spectrum	O
over	O
##laid	O
with	O
a	O
mathematical	O
fit	O
(	O
black	O
)	O
from	O
a	O
composite	O
of	O
log	O
##nor	O
##mal	O
(	O
pink	O
)	O
and	O
Lo	O
##rent	O
##zia	O
##n	O
(	O
green	O
)	O
lines	O
##ha	O
##pes	O
after	O
sub	O
##traction	O
of	O
the	O
base	O
##line	O
in	O
the	O
beta	B
##ine	I
region	O
.	O

(	O
a	O
)	O
G	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
metabolism	O
;	O
(	O
b	O
)	O
s	B
##phi	I
##ngo	I
##lip	I
##id	I
metabolism	O
;	O
(	O
c	O
)	O
et	O
##her	O
lip	O
##id	O
metabolism	O
;	O
(	O
d	O
)	O
g	B
##ly	I
##cer	I
##oli	I
##pid	I
metabolism	O
.	O

However	O
,	O
when	O
comparing	O
the	O
high	O
-	O
ET	O
##S	O
subgroup	O
with	O
the	O
other	O
two	O
(	O
i	O
.	O
e	O
.	O
non	O
-	O
and	O
low	O
ET	O
##S	O
)	O
there	O
are	O
statistical	O
##ly	O
significant	O
differences	O
at	O
the	O
p	O
<	O
0	O
.	O
05	O
level	O
for	O
2	B
-	I
h	I
##ydro	I
##xy	I
##phe	I
##nant	I
##hren	I
##e	I
,	O
3	B
+	I
4	I
-	I
h	I
##ydro	I
##xy	I
##phe	I
##nant	I
##hren	I
##e	I
and	O
1	B
-	I
h	I
##ydro	I
##xy	I
##py	I
##rene	I
.	O

Prime	O
##d	O
continuous	O
(	O
prime	O
/	O
hourly	O
dose	O
)	O
_	O
13	O
C	B
_	I
2	I
-	I
o	I
##xa	I
##late	I
and	O
1	O
-	O
_	O
13	O
C	B
-	I
g	I
##ly	I
##cola	I
##te	I
in	O
##fusion	O
##s	O
were	O
then	O
started	O
.	O

Six	O
##ty	O
patients	O
underwent	O
R	B
##P	I
for	O
localized	O
C	O
##a	O
##P	O
in	O
which	O
59	O
were	O
determined	O
to	O
be	O
high	O
risk	O
per	O
the	O
D	O
’	O
Am	O
##ico	O
criteria	O
,	O
with	O
six	O
upgraded	O
from	O
low	O
risk	O
.	O

Several	O
ant	O
##hr	O
##op	O
##ometric	O
##al	O
parameters	O
and	O
bio	O
##chemical	O
analyses	O
including	O
glucose	S
,	O
high	O
-	O
density	O
lip	O
##op	O
##rote	O
##ins	O
(	O
HD	O
##L	O
)	O
,	O
low	O
-	O
density	O
lip	O
##op	O
##rote	O
##ins	O
(	O
L	O
##D	O
##L	O
)	O
,	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
(	O
T	O
##G	O
)	O
,	O
the	O
B	O
##MI	O
,	O
waist	O
,	O
insulin	O
,	O
and	O
the	O
home	O
##ost	O
##asis	O
model	O
assessment	O
of	O
insulin	O
resistance	O
(	O
H	O
##OM	O
##A	O
-	O
I	O
##R	O
)	O
were	O
measured	O
.	O

[	O
]	O
In	O
this	O
work	O
,	O
we	O
demonstrated	O
that	O
blocking	O
en	O
##zy	O
##matic	O
steps	O
downstream	O
of	O
C	O
##YP	O
##51	O
,	O
leads	O
to	O
a	O
decline	O
of	O
er	B
##gos	I
##tero	I
##l	I
and	O
/	O
or	O
accumulation	O
of	O
the	O
end	O
-	O
products	O
and	O
metabolic	O
intermediate	O
##s	O
in	O
##com	O
##pa	O
##tible	O
with	O
N	O
.	O

In	O
other	O
words	O
,	O
these	O
bio	O
##mark	O
##ers	O
of	O
est	B
##rogen	I
metabolism	O
may	O
provide	O
new	O
information	O
about	O
mechanisms	O
of	O
breast	O
car	O
##cin	O
##ogen	O
##esis	O
.	O

The	O
second	O
generation	O
product	O
ion	O
spectrum	O
of	O
the	O
ion	O
at	O
m	O
/	O
z	O
34	O
##3	O
.	O
2	O
for	O
des	B
##ami	I
##no	I
-	I
Ph	I
##IP	I
-	I
Y	I
*	I
T	I
##K	I
and	O
at	O
m	O
/	O
z	O
34	O
##8	O
.	O
2	O
for	O
des	B
##ami	I
##no	I
[	I
_	I
2	I
H	I
_	I
5	I
]	I
-	O
Ph	O
##IP	O
-	O
Y	O
*	O
T	O
##K	O

Interest	O
##ingly	O
,	O
supplement	O
##ation	O
of	O
cell	O
culture	O
media	O
with	O
la	B
##ct	I
##ate	I
led	O
to	O
a	O
recovery	O
of	O
m	O
##ot	O
##ility	O
and	O
invasive	O
##ness	O
of	O
M	O
##UC	O
##16	O
knock	O
##down	O
cells	O
.	O

A	O
spot	O
urine	O
sample	O
of	O
about	O
50	O
m	O
##l	O
was	O
collected	O
from	O
each	O
participant	O
and	O
1	O
mg	O
m	O
##l	O
_	O
−	O
##1	O
as	B
##cor	I
##bic	I
acid	I
was	O
added	O
to	O
prevent	O
oxidation	O
of	O
the	O
cat	B
##ech	I
##ol	I
m	O
##oi	O
##eti	O
##es	O
in	O
the	O
various	O
est	B
##rogen	I
compounds	O
.	O

A	O
-	O
C	O
.	O
Class	O
##ifier	O
and	B
##ros	I
##tan	I
##ed	I
##iol	I
.	O

The	O
ions	O
m	O
/	O
z	O
of	O
31	O
##9	O
and	O
32	O
##7	O
were	O
monitored	O
for	O
end	O
##ogen	O
##ous	O
and	O
de	O
##uter	O
##ium	O
(	O
d	O
##8	O
)	O
-	O
labeled	O
E	O
##ET	O
##s	O
,	O
the	O
ions	O
m	O
/	O
z	O
of	O
39	O
##1	O
and	O
39	O
##7	O
were	O
monitored	O
for	O
20	B
-	I
H	I
##ET	I
##E	I
,	O
and	O
the	O
ions	O
m	O
/	O
z	O
of	O
48	O
##1	O
and	O
48	O
##9	O
were	O
monitored	O
for	O
D	O
##H	O
##ET	O
##s	O
.	O

The	O
derived	O
beta	B
##ine	I
signal	O
amplitude	O
##s	O
were	O
converted	O
to	O
µ	O
##M	O
units	O
using	O
a	O
factor	O
that	O
was	O
empirical	O
##ly	O
determined	O
by	O
plotting	O
data	O
from	O
dial	O
##y	O
##zed	O
serum	O
samples	O
spike	O
##d	O
with	O
known	O
amounts	O
of	O
beta	B
##ine	I
and	O
relating	O
the	O
beta	B
##ine	I
signal	O
area	O
to	O
the	O
expected	O
concentrations	O
.	O

Pro	B
##line	I
beta	I
##ine	I
(	O
A	O
)	O
is	O
,	O
for	O
instance	O
,	O
highly	O
correlated	O
,	O
the	O
Pass	O
##ing	O
–	O
Ba	O
##b	O
##lo	O
##k	O
re	O
##gression	O
having	O
slope	O
of	O
1	O
.	O
05	O
and	O
B	O
##land	O
–	O
Alt	O
##man	O
plot	O
showing	O
good	O
agreement	O
between	O
the	O
results	O
obtained	O
by	O
the	O
two	O
MS	O
-	O
methods	O
(	O
mean	O
difference	O
centered	O
at	O
zero	O
)	O
.	O

Ethan	B
##ol	I
affected	O
the	O
CS	O
##F	O
sample	O
matrix	O
at	O
concentrations	O
above	O
~	O
9	O
.	O
4	O
m	O
##M	O
and	O
obscured	O
a	O
significant	O
part	O
of	O
the	O
_	O
1	O
H	O
-	O
N	O
##MR	O
spectrum	O
.	O

The	O
lowest	O
variations	O
were	O
obtained	O
for	O
the	O
s	B
##phi	I
##ngo	I
##lip	I
##id	I
and	O
fatty	O
a	O
##cy	O
##ls	O
families	O
with	O
an	O
average	O
RS	O
##D	O
of	O
3	O
.	O
9	O
and	O
5	O
.	O
8	O
%	O
,	O
respectively	O
,	O
whereas	O
the	O
highest	O
variations	O
were	O
found	O
for	O
neutral	O
lip	O
##id	O
families	O
with	O
20	O
.	O
1	O
and	O
16	O
.	O
9	O
%	O
for	O
D	O
##G	O
and	O
T	B
##G	I
species	O
,	O
respectively	O
.	O

Ace	B
##tam	I
##ide	I
has	O
diet	O
##ary	O
sources	O
.	O

The	O
mobile	O
phase	O
A	O
and	O
B	O
was	O
water	O
/	O
met	O
##han	O
##ol	O
/	O
ace	O
##ton	O
##it	O
##ril	O
##e	O
(	O
21	O
:	O
20	O
:	O
60	O
,	O
v	O
/	O
v	O
/	O
v	O
)	O
supplemented	O
with	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
and	O
10	O
m	O
##M	O
am	B
##mon	I
##ium	I
format	I
##e	I
,	O
and	O
water	O
/	O
met	O
##han	O
##ol	O
/	O
ace	O
##ton	O
##it	O
##ril	O
##e	O
(	O
1	O
:	O
10	O
:	O
90	O
,	O
v	O
/	O
v	O
/	O
v	O
)	O
supplemented	O
with	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
and	O
10	O
m	O
##M	O
am	B
##mon	I
##ium	I
format	I
##e	I
,	O
respectively	O
.	O

Ex	O
##tensive	O
expression	O
of	O
G	O
##L	O
##UT	O
-	O
5	O
,	O
a	O
f	B
##ru	I
##ct	I
##ose	I
transport	O
##er	O
,	O
has	O
been	O
implicated	O
in	O
different	O
types	O
of	O
cancer	O
##s	O
,	O
including	O
CR	O
##C	O
,	O
presumably	O
in	O
response	O
to	O
their	O
heightened	O
energy	O
consumption	O
.	O

G	B
##ly	I
##cy	I
##l	I
##p	I
##rol	I
##ine	I
is	O
a	O
dip	O
##eptide	O
and	O
part	O
of	O
the	O
primary	O
structure	O
of	O
co	O
##lla	O
##gen	O
.	O

After	O
cheese	O
intake	O
,	O
four	O
amino	O
acids	O
were	O
disc	O
##rim	O
##inating	O
based	O
on	O
an	O
O	O
##PL	O
##S	O
-	O
D	O
##A	O
analysis	O
of	O
their	O
6	O
##h	O
-	O
i	O
##A	O
##UC	O
(	O
see	O
Figure	O
S	O
##4	O
)	O
and	O
their	O
subsequent	O
targeted	O
q	O
##uant	O
##ification	O
,	O
namely	O
met	B
##hi	I
##oni	I
##ne	I
,	O
pro	B
##line	I
,	O
le	B
##uc	I
##ine	I
,	O
and	O
g	B
##lut	I
##ami	I
##c	I
acid	I
.	O

Although	O
the	O
duration	S
of	O
in	O
##patient	O
showed	O
difference	O
between	O
groups	O
,	O
the	O
average	O
years	O
of	O
each	O
group	O
was	O
above	O
one	O
year	O
.	O

Cat	B
##ech	I
##ola	I
##mine	I
bio	O
##sy	O
##nt	O
##hesis	O
had	O
the	O
highest	O
en	O
##rich	O
##ment	O
(	O
15	O
.	O
6	O
-	O
fold	O
)	O
,	O
but	O
there	O
were	O
also	O
other	O
highly	O
en	O
##rich	O
##ed	O
meta	O
##bol	O
##ite	O
sets	O
:	O
g	B
##ly	I
##cine	I
,	O
se	B
##rine	I
,	O
and	O
th	B
##re	I
##oni	I
##ne	I
metabolism	O
(	O
9	O
.	O
0	O
-	O
fold	O
)	O
,	O
am	O
##monia	O
recycling	O
(	O
8	O
.	O
7	O
-	O
fold	O
)	O
,	O
g	B
##lut	I
##ath	I
##ione	I
metabolism	O
(	O
11	O
.	O
8	O
-	O
fold	O
)	O
,	O
and	O
his	B
##ti	I
##dine	I
metabolism	O
(	O
10	O
.	O
6	O
-	O
fold	O
)	O
.	O

The	O
relative	O
expanded	O
uncertainty	O
for	O
3	B
-	I
e	I
##pi	I
-	I
25	I
(	I
OH	I
)	I
D	I
_	I
3	I
in	O
Level	O
3	O
is	O
>	O
10	O
%	O
,	O
and	O
we	O
elected	O
to	O
make	O
this	O
a	O
reference	O
value	O
.	O

A	O
number	O
of	O
differential	O
##ly	O
expressed	O
meta	O
##bol	O
##ites	O
involved	O
in	O
try	B
##pt	I
##op	I
##han	I
metabolism	O
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
and	O
t	B
##yr	I
##os	I
##ine	I
metabolism	O
,	O
bi	O
##le	O
acid	O
metabolism	O
,	O
and	O
ch	B
##olin	I
##e	I
metabolism	O
,	O
which	O
are	O
linked	O
to	O
gut	O
micro	O
##bial	O
-	O
host	O
comet	O
##ab	O
##olis	O
##m	O
,	O
were	O
observed	O
in	O
the	O
CR	O
##C	O
serum	O
metabolic	O
profile	O
.	O

For	O
example	O
,	O
ID	O
##H1	O
mutant	O
cells	O
can	O
secret	O
##e	O
enough	O
2	B
-	I
h	I
##ydro	I
##xy	I
##g	I
##lut	I
##arate	I
into	O
the	O
cell	O
culture	O
medium	O
to	O
achieve	O
a	O
two	O
m	O
##olar	O
concentration	O
within	O
24	O
h	O
(	O
,	O
)	O
.	O

In	O
our	O
previous	O
study	O
investigating	O
the	O
association	O
of	O
diet	O
##ary	O
ch	B
##olin	I
##e	I
intake	O
and	O
P	O
##LC	O
risk	O
,	O
we	O
found	O
that	O
red	O
meat	O
was	O
an	O
important	O
source	O
of	O
diet	O
##ary	O
ch	B
##olin	I
##e	I
,	O
which	O
implied	O
high	O
diet	O
##ary	O
L	B
-	I
car	I
##ni	I
##tine	I
intake	O
of	O
the	O
participants	O
.	O

1	O
mg	O
/	O
m	O
##l	O
of	O
(	O
A	O
)	O
normal	O
o	O
##vary	O
and	O
(	O
B	O
)	O
human	O
o	O
##vary	O
cancer	O
tissue	O
ho	O
##mo	O
##gen	O
##ates	O
was	O
in	O
##cu	O
##bate	O
##d	O
with	O
ex	O
##ogen	O
##ous	O
AA	O
(	O
40	O
μ	O
##M	O
)	O
,	O
1	O
m	O
##M	O
N	B
##AD	I
##P	I
##H	I
and	O
2	O
μ	O
##M	O
in	B
##dom	I
##eth	I
##ac	I
##in	I
for	O
1	O
h	O
at	O
37	O
##°	O
##C	O
in	O
the	O
presence	O
of	O
100	O
%	O
O	O
_	O
2	O
.	O

mild	O
cognitive	O
imp	O
##air	O
##ment	O
,	O
urine	O
,	O
a	B
##rg	I
##ini	I
##ne	I
,	O
bio	O
##mark	O
##er	O
,	O
early	O
diagnosis	O

A	O
recent	O
report	O
demonstrated	O
that	O
reactive	O
oxygen	O
species	O
(	O
R	O
##OS	O
)	O
may	O
increase	O
end	O
##oth	O
##eli	O
##al	O
injury	O
and	O
subsequent	O
release	O
of	O
RNA	O
##SE	O
##1	O
(	O
rib	O
##on	O
##uc	O
##lea	O
##se	O
A	O
family	O
1	O
)	O
,	O
which	O
then	O
de	O
##grade	O
##s	O
extra	O
##cellular	O
rib	O
##on	O
##uc	O
##le	O
##ic	O
acid	O
and	O
leads	O
to	O
an	O
increase	O
in	O
pu	B
##rine	I
and	O
p	B
##yr	I
##im	I
##id	I
##ine	I
degradation	O
products	O
.	O

From	O
our	O
data	O
,	O
N	B
-	I
G	I
##ly	I
##co	I
##loy	I
##l	I
##gan	I
##gli	I
##os	I
##ide	I
GM	I
##2	I
(	O
G	O
##GM	O
)	O
,	O
a	O
gang	B
##lio	I
##side	I
,	O
was	O
abundant	O
in	O
advanced	O
cases	O
.	O

Fr	O
##action	O
2	O
was	O
found	O
to	O
contain	O
another	O
add	O
##uc	O
##ted	O
p	O
##eptide	O
of	O
NO	O
_	O
2	O
-	O
Ph	O
##IP	O
at	O
a	O
l	B
##ys	I
##ine	I
residue	O
(	O
t	O
_	O
R	O
=	O
5	O
.	O
7	O
min	O
)	O
.	O

Changes	O
in	O
l	B
##ys	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
levels	O
are	O
suggested	O
to	O
result	O
from	O
their	O
activation	O
of	O
specific	O
cell	O
-	O
surface	O
G	O
protein	O
coupled	O
receptors	O
that	O
initiate	O
cell	O
growth	O
,	O
proliferation	O
,	O
and	O
survival	O
pathways	O
(	O
;	O
)	O
,	O
properties	O
characteristic	O
of	O
cancer	O
growth	O
.	O

Anti	O
##bo	O
##dies	O
included	O
anti	O
-	O
CP	O
##T	O
##1	O
##A	O
,	O
anti	O
-	O
c	O
##lea	O
##ved	O
ca	O
##sp	O
##ase	O
9	O
,	O
anti	O
-	O
M	O
##L	O
##K	O
##L	O
(	B
p	B
##hos	I
##ph	I
##o	I
S	O
##35	O
##8	O
)	O

The	O
ni	B
##cot	I
##ine	I
is	O
an	O
ex	O
##ogen	O
##ous	O
compound	O
and	O
not	O
really	O
in	O
the	O
same	O
class	O
as	O
the	O
end	O
##ogen	O
##ous	O
meta	O
##bol	O
##ites	O
normally	O
of	O
interest	O
in	O
meta	O
##bol	O
##omi	O
##cs	O
.	O

Lin	B
##ole	I
##ic	I
acid	I
(	O
LA	O
)	O
levels	O
were	O
elevated	O
in	O
severe	O
CH	O
##D	O
patients	O
compared	O
with	O
control	O
subjects	O
in	O
our	O
study	O
.	O

The	O
AM	B
##P	I
,	O
which	O
can	O
be	O
transformed	O
to	O
ATP	S
as	O
energy	O
donor	O
,	O
and	O
N	B
##AD	I
,	O
an	O
important	O
co	O
##en	O
##zy	O
##me	O
,	O
were	O
down	O
##re	O
##gu	O
##lated	O
in	O
es	O
##op	O
##hage	O
##al	O
cancer	O
tissues	O
,	O
suggesting	O
a	O
great	O
quantity	O
of	O
energy	O
consumption	O
due	O
to	O
accelerated	O
cell	O
proliferation	O
in	O
es	O
##op	O
##hage	O
##al	O
cancer	O
.	O

an	O
S	O
/	O
N	O
of	O
<	O
2	O
in	O
the	O
full	O
MS	O
scan	O
of	O
d	B
_	I
4	I
-	I
16	I
:	I
0	I
FA	I
an	O
##ion	O
at	O
5	O
f	O
##mo	O
##l	O
/	O
μ	O
##L	O
)	O
;	O
and	O
(	O
2	O
)	O
an	O
improvement	O
in	O
analytical	O
specific	O
##ity	O
through	O
elimination	O
of	O
interference	O
##s	O
from	O
background	O
ions	O
,	O
con	O
##tam	O
##ina	O
##nts	O
,	O
or	O
low	O
mass	O
fragment	O
ions	O
em	O
##ana	O
##ting	O
from	O
a	O
variety	O
of	O
mechanisms	O
that	O
only	O
become	O
evident	O
in	O
the	O
low	O
abundance	O
regime	O
.	O

For	O
proof	O
of	O
linear	O
##ity	O
,	O
two	O
different	O
spot	O
urine	O
samples	O
were	O
separated	O
in	O
specimens	O
of	O
0	O
.	O
25	O
m	O
##L	O
,	O
0	O
.	O
5	O
m	O
##L	O
,	O
1	O
m	O
##L	O
,	O
2	O
m	O
##L	O
and	O
4	O
m	O
##L	O
.	O
Each	O
sample	O
was	O
spike	O
##d	O
with	O
50	O
μ	O
##L	O
internal	O
standard	O
and	O
mixed	O
with	O
9	O
m	O
##L	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
solution	O
(	O
0	O
.	O
25	O
m	O
##M	O
,	O
pH	O
8	O
.	O
8	O
)	O
to	O
give	O
a	O
sample	O
volume	O
of	O
10	O
m	O
##L	O
.	O
The	O
obtained	O
solutions	O
were	O
proceeded	O
as	O
described	O
.	O

We	O
evaluated	O
serum	O
c	B
##rea	I
##tin	I
##ine	I
,	O
urine	O
protein	O
,	O
g	O
##lo	O
##mer	O
##ular	O
fi	O
##ltration	O
rate	O
(	O
MD	O
##RD	O
G	O
##F	O
##R	O
)	O
and	O
Body	O
Mass	O
Index	O
at	O
base	O
##line	O
and	O
after	O
six	O
months	O
of	O
follow	O
up	O
.	O

H	B
##ydro	I
##xy	I
##cho	I
##les	I
##tero	I
##ls	I
may	O
also	O
be	O
called	O
bi	O
##le	O
alcohol	O
##s	O
,	O
as	O
many	O
are	O
intermediate	O
##s	O
in	O
the	O
bio	O
##sy	O
##nt	O
##hesis	O
of	O
bi	O
##le	O
acids	O
from	O
ch	B
##ole	I
##ster	I
##ol	I
.	O

Co	O
##mpo	O
##unds	O
were	O
el	O
##uted	O
from	O
a	O
Z	O
##or	O
##ba	O
##x	O
Eclipse	O
X	O
##D	O
##B	O
-	O
C	O
##18	O
column	O
(	O
2	O
.	O
1	O
×	O
50	O
mm	O
×	O
5	O
µ	O
##m	O
,	O
with	O
guard	O
column	O
)	O
using	O
an	O
is	O
##oc	O
##ratic	O
mobile	O
phase	O
of	O
55	O
%	O
met	B
##han	I
##ol	I
in	O
0	O
.	O
05	O
%	O
T	O
##FA	O
(	O
pH	O
3	O
.	O
6	O
)	O
at	O
0	O
.	O
25	O
m	O
##l	O
min	O
_	O
−	O
##1	O
,	O
and	O
detected	O
by	O
selected	O
ion	O
monitoring	O
(	B
met	B
##had	I
##one	I
m	O
/	O
z	O
310	O
.	O
1	O
,	O
E	O
##D	O
##DP	O
m	O
/	O
z	O
278	O
.	O
1	O
,	O
E	O
##MD	O
##P	O
m	O
/	O
z	O
264	O
.	O
1	O
,	O
and	O
internal	O
standard	O
m	O
/	O
z	O
32	O
##4	O
.	O
1	O
)	O
.	O

The	O
changes	O
in	O
metabolic	O
gene	O
expression	O
profiles	O
in	O
the	O
11	O
respond	O
##ers	O
to	O
I	O
##ER	O
resembled	O
changes	O
in	O
women	O
undertaking	O
a	O
60	O
%	O
CE	B
##R	I
for	O
one	O
men	O
##st	O
##ru	O
##al	O
cycle	O
from	O
our	O
previous	O
study	O
whilst	O
the	O
9	O
non	O
-	O
respond	O
##ers	O
resembled	O
the	O
non	O
-	O
diet	O
##ing	O
controls	O
in	O
this	O
study	O
.	O

A	O
volume	O
of	O
1	O
m	O
##L	O
urine	O
was	O
spike	O
##d	O
with	O
50	O
μ	O
##L	O
of	O
internal	O
standard	O
solution	O
(	O
0	O
.	O
1	O
m	O
##M	O
is	O
##og	O
##uan	O
##os	O
##ine	O
in	O
water	O
)	O
,	O
mixed	O
with	O
9	O
m	O
##L	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
solution	O
(	O
0	O
.	O
25	O
m	O
##M	O
,	O
pH	O
8	O
.	O
8	O
)	O
and	O
then	O
put	O
on	O
the	O
column	O
following	O
pre	O
##con	O
##dition	O
##ing	O
with	O
45	O
m	O
##L	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
solution	O
(	O
0	O
.	O
25	O
m	O
##M	O
,	O
pH	O
8	O
.	O
8	O
)	O
.	O

The	O
pen	B
##tos	I
##e	I
phosphate	I
pathway	O
(	O
PP	O
##P	O
)	O
produces	O
ni	B
##cot	I
##ina	I
##mi	I
##de	I
ad	I
##eni	I
##ne	I
din	I
##uc	I
##leo	I
##tide	I
phosphate	I
,	O
a	O
necessary	O
co	O
##fa	O
##ctor	O
for	O
the	O
reduction	O
of	O
g	B
##lut	I
##ath	I
##ione	I
di	I
##sul	I
##fi	I
##de	I
(	O
marker	O
of	O
reduction	O
in	O
o	O
##xi	O
##da	O
##tive	O
stress	O
)	O
.	O

H	B
##ydro	I
##gen	I
su	I
##lf	I
##ide	I
(	O
H	O
_	O
2	O
S	O
)	O
is	O
a	O
gas	O
##ot	O
##ran	O
##sm	O
##itte	O
##r	O
involved	O
in	O
v	O
##as	O
##od	O
##ilation	O
,	O
ne	O
##uro	O
##mo	O
##du	O
##lation	O
,	O
and	O
inflammation	O
.	O

For	O
the	O
PC	O
##A	O
,	O
196	O
N	O
##MR	O
s	O
##pect	O
##ra	O
were	O
bin	O
##ned	O
to	O
0	O
.	O
04	O
pp	O
##m	O
in	O
the	O
region	O
of	O
0	O
.	O
5	O
–	O
9	O
pp	O
##m	O
,	O
with	O
the	O
water	O
and	O
u	B
##rea	I
peaks	O
excluded	O
(	O
6	O
.	O
0	O
–	O
4	O
.	O
5	O
pp	O
##m	O
)	O
,	O
yielding	O
177	O
bin	O
##s	O
,	O
un	O
-	O
normal	O
##ized	O
bin	O
##s	O
were	O
scaled	O
to	O
unit	O
variance	O
and	O
the	O
first	O
4	O
PC	O
##s	O
were	O
calculated	O
,	O
with	O
PC	O
##1	O
and	O
PC	O
##2	O
explaining	O
>	O
96	O
%	O
of	O
variance	O
.	O

Our	O
previous	O
observations	O
that	O
CD	O
##39	O
_	O
+	O
CD	O
##7	O
##3	O
_	O
+	O
T	O
##EX	O
signaling	O
via	O
the	O
A	O
_	O
2	O
##A	O
R	O
rapidly	O
induce	O
ad	B
##eno	I
##sin	I
##e	I
production	O
by	O
T	O
##re	O
##g	O
are	O
now	O
extended	O
to	O
illustrate	O
that	O
prolonged	O
exposure	O
to	O
T	O
##EX	O
up	O
##re	O
##gu	O
##lates	O
the	O
production	O
of	O
in	B
##os	I
##ine	I
in	O
T	O
##re	O
##g	O
.	O

Pat	O
##ients	O
with	O
inactive	O
UC	O
had	O
significantly	O
higher	O
c	B
##it	I
##ru	I
##llin	I
##e	I
than	O
controls	O
and	O
patients	O
with	O
active	O
disease	O
and	O
higher	O
D	B
##MA	I
than	O
controls	O
.	O

This	O
route	O
requires	O
not	O
only	O
an	O
active	O
K	O
##re	O
##bs	O
cycle	O
in	O
these	O
cells	O
,	O
but	O
also	O
a	O
functioning	O
mitochondrial	O
electron	O
transport	O
chain	O
,	O
as	O
a	O
critical	O
u	B
##rac	I
##il	I
bio	O
##sy	O
##nt	O
##hetic	O
enzyme	O
,	O
di	O
##hy	O
##dr	O
##oor	O
##ota	O
##te	O
de	O
##hy	O
##dr	O
##ogen	O
##ase	O
,	O
is	O
a	O
mitochondrial	O
enzyme	O
.	O

Lac	B
##tate	I
is	O
also	O
an	O
important	O
precursor	O
of	O
g	O
##lu	O
##con	O
##eo	O
##genesis	O
.	O

(	O
2007	O
)	O
also	O
showed	O
that	O
among	O
all	O
the	O
compounds	O
isolated	O
from	O
F	O
.	O
o	B
##xy	I
##sp	I
##orum	I
end	O
##op	O
##hy	O
##te	O
of	O
E	B
##phe	I
##dra	I
f	O
##as	O
##ci	O
##culate	O
,	O
only	O
be	B
##au	I
##ver	I
##ici	I
##n	I
(	O
21	O
)	O
in	O
##hibit	O
##ed	O
the	O
meta	O
##static	O
pro	O
##state	O
cancer	O
(	O
PC	O
-	O
3	O
##M	O
)	O
and	O
breast	O
cancer	O
(	O
MD	O
##A	O
-	O
MB	O
-	O
231	O
)	O
cells	O
and	O
also	O
showed	O
anti	O
##ang	O
##io	O
##genic	O
activity	O
in	O
H	O
##U	O
##VE	O
##C	O
-	O
2	O
cells	O
at	O
sub	O
-	O
lethal	O
concentrations	O
.	O

In	O
details	O
,	O
a	O
negative	O
correlation	O
was	O
found	O
for	O
SM	O
##s	O
,	O
AA	O
##s	O
,	O
C	O
##0	O
,	O
ACC	O
##s	O
,	O
and	O
LP	O
##Cs	O
,	O
while	O
a	O
positive	O
correlation	O
was	O
observed	O
for	O
Sa	O
and	O
c	B
##era	I
##mi	I
##des	I
.	O

Other	O
major	O
differences	O
between	O
cell	O
culture	O
media	O
were	O
found	O
in	O
the	O
met	B
##hi	I
##oni	I
##ne	I
content	O
,	O
appearing	O
to	O
be	O
present	O
in	O
larger	O
amounts	O
in	O
the	O
Co	O
##m	O
.	O

Except	O
from	O
C	B
##24	I
:	I
1	I
##C	I
##er	I
and	O
C	B
##24	I
:	I
1	I
##D	I
##HC	I
,	O
the	O
respective	O
un	O
##sat	O
##ura	O
##ted	O
derivatives	O
of	O
C	O
##24	O
##C	O
##er	O
and	O
C	O
##24	O
##D	O
##HC	O
,	O
all	O
Ce	O
##r	O
'	O
s	O
and	O
D	O
##HC	O
'	O
s	O
analyzed	O
showed	O
a	O
highly	O
significant	O
accumulation	O
in	O
HC	O
##C	O
as	O
compared	O
to	O
c	O
##ir	O
##r	O
##hos	O
##is	O
(	O
Figure	O
##s	O
and	O
and	O
,	O
P	O
<	O
0	O
.	O
00	O
##1	O
)	O
.	O

[	O
,	O
]	O
)	O
in	O
relatively	O
high	O
concentrations	O
(	O
~	O
40	O
μ	O
##M	O
in	O
urine	O
in	O
this	O
study	O
)	O
,	O
which	O
suggests	O
sources	O
beyond	O
gasoline	S
for	O
this	O
meta	O
##bol	O
##ite	O
(	O
e	O
.	O
g	O
.	O
micro	O
##bio	O
##ta	O
or	O
medication	O
)	O
.	O

A	O
common	O
hypothesis	O
implies	O
impaired	O
degradation	O
of	O
is	B
##ole	I
##uc	I
##ine	I
,	O
le	B
##uc	I
##ine	I
,	O
and	O
v	B
##ali	I
##ne	I
in	O
peripheral	O
tissues	O
,	O
such	O
as	O
skeletal	O
muscle	O
,	O
as	O
responsible	O
mechanism	O
.	O

A	O
comparison	O
of	O
individual	O
q	O
##uant	O
##ified	O
meta	O
##bol	O
##ites	O
demonstrated	O
that	O
trauma	O
patients	O
had	O
lower	O
levels	O
of	O
o	O
##xi	O
##da	O
##tive	O
substrates	O
relative	O
to	O
healthy	O
volunteers	O
(	O
mean	O
[	O
I	O
##Q	O
##R	O
]	O
,	O
ni	B
##ac	I
##ina	I
##mi	I
##de	I
concentrations	O
:	O
0	O
.	O
95	O

E	B
##thy	I
##l	I
##hy	I
##dr	I
##ox	I
##yla	I
##mine	I
was	O
tested	O
with	O
both	O
water	O
and	O
p	B
##yr	I
##id	I
##ine	I
in	O
the	O
reaction	O
medium	O
.	O

Consequently	O
,	O
GA	B
##BA	I
plays	O
an	O
important	O
protective	O
role	O
both	O
in	O
o	O
##besity	O
and	O
as	O
##th	O
##ma	O
which	O
may	O
lead	O
to	O
new	O
therapeutic	O
strategies	O
for	O
the	O
management	O
of	O
o	O
##bes	O
##e	O
as	O
##th	O
##ma	O
.	O

Accordingly	O
,	O
t	B
##yr	I
##os	I
##ine	I
up	O
##re	O
##gu	O
##lation	O
in	O
AR	O
##DS	O
has	O
been	O
correlated	O
to	O
port	O
##ending	O
AR	O
##DS	O
incidence	O
prior	O
to	O
disease	O
development	O
for	O
its	O
para	O
##mount	O
role	O
as	O
NO	O
_	O
2	O
Ty	O
##r	O
in	O
BA	O
##L	O
.	O

It	O
is	O
possible	O
that	O
these	O
beneficial	O
outcomes	O
in	O
HIV	O
/	O
S	O
##I	O
##V	O
infection	O
are	O
due	O
to	O
the	O
im	O
##mu	O
##no	O
##mo	O
##du	O
##lator	O
##y	O
capabilities	O
of	O
cannabis	S
,	O
including	O
decreasing	O
cellular	O
proliferation	O
and	O
reducing	O
c	O
##yt	O
##oki	O
##ne	O
production	O
.	O

a	O
H	O
##b	O
##A	O
##1	O
##c	O
was	O
expressed	O
in	O
National	O
G	B
##ly	I
##co	I
##hem	I
##og	I
##lo	I
##bin	I
Standard	O
##ization	O
Program	O
(	O
N	O
##GS	O
##P	O
)	O
unit	O
(	O
%	O
)	O
;	O
it	O
would	O
be	O
82	O
±	O
26	O
in	O
T	O
##2	O
##DM	O
and	O
36	O
±	O
18	O
in	O
control	O
in	O
International	O
Federation	O
of	O
Clinical	O
Chemistry	O
(	O
IF	O
##CC	O
)	O
unit	O
(	O
mm	O
##ol	O
/	O
m	O
##ol	O
)	O
.	O

Indeed	O
,	O
its	O
reduction	O
may	O
also	O
indicate	O
S	B
-	I
ad	I
##eno	I
##sy	I
##lm	I
##eth	I
##ion	I
##ine	I
de	O
##ple	O
##tion	O
due	O
to	O
its	O
red	O
##ire	O
##ction	O
to	O
help	O
re	O
##ple	O
##nish	O
reduced	B
g	I
##lut	I
##ath	I
##ione	I
(	O
G	O
##S	O
##H	O
)	O
levels	O
,	O
an	O
important	O
cellular	O
anti	O
##ox	O
##ida	O
##nt	O
molecule	O
,	O
believed	O
to	O
be	O
associated	O
with	O
increased	O
production	O
of	O
reactive	O
oxygen	O
species	O
(	O
R	O
##OS	O
)	O
in	O
cancer	O
cells	O
.	O

curve	O
analysis	O
of	O
la	B
##ct	I
##ate	I
,	O
ch	B
##ole	I
##ster	I
##ol	I
and	O
la	B
##ct	I
##ate	I
to	O
ch	B
##ole	I
##ster	I
##ol	I
ratio	O
in	O
relation	O
with	O
30	O
-	O
day	O
mortality	O
)	O
,	O
AU	O
##C	O
=	O
0	O
.	O
76	O
(	O
95	O
%	O
C	O
##I	O
,	O
0	O
.	O
65	O
##−	O
##0	O
.	O
85	O
,	O
p	O
<	O
0	O
.	O
000	O
##1	O
)	O
.	O

This	O
suggests	O
that	O
the	O
impact	O
of	O
test	B
##osterone	I
on	O
lip	O
##id	O
metabolism	O
in	O
PC	O
##OS	O
differs	O
from	O
control	O
women	O
with	O
normal	O
pre	O
-	O
treatment	O
and	O
##rogen	O
levels	O
.	O

St	O
##oud	O
##er	O
and	O
Paolo	O
##ni	O
-	O
G	O
##iac	O
##ob	O
##ino	O
also	O
reported	O
del	O
##eter	O
##ious	O
effects	O
of	O
the	O
end	O
##oc	O
##rine	O
disrupt	O
##ors	O
v	B
##in	I
##c	I
##lo	I
##zin	I
(	O
fungi	O
##cid	O
##e	O
)	O
and	O
met	B
##ho	I
##xy	I
##ch	I
##lor	I
(	O
insect	O
##icide	O
)	O
at	O
the	O
level	O
of	O
imprint	O
##ed	O
genes	O
in	O
sperm	O
of	O
mice	O
[	O
,	O
]	O
.	O

s	O
##CD	O
##40	O
##L	O
has	O
been	O
implicated	O
in	O
increasing	O
plate	O
##let	O
–	O
mon	O
##oc	O
##yte	O
complexes	O
,	O
which	O
are	O
normally	O
activated	S
only	O
during	O
inflammatory	O
conditions	O
–	O
.	O

Cy	B
##stein	I
##e	I
metabolism	O
partly	O
fed	O
into	O
increases	O
in	O
h	B
##y	I
##pot	I
##au	I
##rine	I
and	O
ta	B
##uri	I
##ne	I
in	O
SC	O
##C	O
samples	O
.	O

One	O
of	O
the	O
key	O
physiological	O
functions	O
of	O
try	B
##pt	I
##op	I
##han	I
is	O
to	O
serve	O
as	O
nitrogen	O
source	O
for	O
the	O
growth	O
of	O
some	O
micro	O
##bes	O
(	O
e	O
.	O
g	O
.	O
E	O
##scher	O
##ichi	O
##a	O
co	O
##li	O
and	O
K	O
##le	O
##bs	O
##iel	O
##la	O
pneumonia	O
##e	O
)	O

Figure	O
shows	O
a	O
representative	O
experiment	O
where	O
rat	O
V	O
##SM	O
##Cs	O
were	O
in	O
##cu	O
##bate	O
##d	O
with	O
or	O
without	O
90	O
μ	O
##mo	O
##l	O
/	O
l	O
l	B
##ino	I
##lea	I
##te	I
.	O

In	O
this	O
study	O
,	O
we	O
were	O
able	O
to	O
construct	O
standard	O
curves	O
from	O
standards	O
prepared	O
in	O
BS	O
##A	O
solution	O
and	O
in	O
human	O
plasma	O
,	O
and	O
the	O
de	O
##viation	O
of	O
the	O
standard	O
curves	O
were	O
less	O
than	O
3	O
%	O
for	O
Ce	B
##r	I
(	I
22	I
:	I
0	I
)	I
and	O
Ce	B
##r	I
(	I
24	I
:	I
0	I
)	I
.	O

G	B
##lu	I
##cos	I
##e	I
and	O
lip	O
##id	O
profile	O
was	O
measured	O
in	O
blood	O
samples	O
obtained	O
with	O
a	O
mean	O
of	O
3	O
hours	O
fast	O
##ing	O
(	O
range	O
0	O
–	O
17	O
)	O
.	O

The	O
t	B
##yr	I
##os	I
##ine	I
level	O
is	O
associated	O
with	O
the	O
risk	O
of	O
T	O
##2	O
##DM	O
in	O
different	O
ethnic	O
peoples	O
,	O
and	O
the	O
relationship	O
was	O
robust	O
by	O
ethnicity	O
and	O
study	O
designs	O
[	O
,	O
]	O
.	O

B	O
##rief	O
##ly	O
,	O
H	O
##NS	O
##CC	O
cells	O
(	O
U	O
##M	O
-	O
SC	O
##C	O
-	O
14	O
##A	O
)	O
were	O
try	O
##ps	O
##ini	O
##zed	O
and	O
washed	O
with	O
PBS	O
,	O
and	O
then	O
the	O
Al	B
##de	I
##f	I
##lu	I
##or	I
substrate	O
was	O
added	O
to	O
1	O
×	O
10	O
_	O
6	O
cells	O
/	O
m	O
##L	O
suspended	O
in	O
Al	B
##de	I
##f	I
##lu	I
##or	I
ass	O
##ay	O
buffer	O
and	O
in	O
##cu	O
##bate	O
##d	O
at	O
37	O
°C	O
for	O
45	O
min	O
.	O

G	B
##lu	I
##cos	I
##e	I
-	I
1	I
-	I
P	I
:	O
G	B
##lu	I
##cos	I
##e	I
-	I
1	I
-	I
Ph	I
##os	I
##phate	I

In	O
adults	O
,	O
a	O
previous	O
study	O
showed	O
a	O
small	O
reduction	O
of	O
α	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
levels	O
after	O
a	O
glucose	S
challenge	O
(	O
−	O
##1	O
.	O
17	O
-	O
fold	O
change	O
)	O
and	O
a	O
positive	O
correlation	O
between	O
greater	O
α	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
ex	O
##cursions	O
and	O
higher	O
2	O
-	O
hour	O
glucose	S
concentrations	O
(	O
β	O
,	O
23	O
.	O
4	O
;	O
standard	O
de	O
##viation	O
,	O
8	O
.	O
7	O
;	O
P	O
=	O
0	O
.	O
00	O
##8	O
)	O
.	O

For	O
urine	O
samples	O
,	O
meta	O
##bol	O
##ite	O
concentrations	O
were	O
adjusted	O
to	O
the	O
c	B
##rea	I
##tin	I
##ine	I
concentration	O
because	O
spot	O
urine	O
measurements	O
,	O
rather	O
than	O
24	O
h	O
urine	O
samples	O
,	O
were	O
used	O
in	O
this	O
study	O
.	O

The	O
C	O
##18	O
method	O
utilized	O
an	O
is	O
##oc	O
##ratic	O
mobile	O
phase	O
of	O
93	O
%	O
met	B
##han	I
##ol	I
,	O
7	O
%	O
water	O
,	O
column	O
temperature	O
15	O
°C	O
;	O
the	O
C	O
##N	O
method	O
utilized	O
an	O
is	O
##oc	O
##ratic	O
mobile	O
phase	O
of	O
68	O
%	O
met	B
##han	I
##ol	I
,	O
32	O
%	O
water	O
,	O
column	O
temperature	O
45	O
°C	O
;	O
the	O
P	O
##FP	O
##P	O
method	O
used	O
an	O
is	O
##oc	O
##ratic	O
mobile	O
phase	O
of	O
74	O
%	O
met	B
##han	I
##ol	I
,	O
26	O
%	O
water	O
and	O
a	O
column	O
temperature	O
of	O
15	O
°C	O
.	O

A	O
ca	O
##li	O
##bra	O
##tion	O
curve	O
was	O
used	O
to	O
calculate	O
the	O
absolute	O
q	O
##uant	O
##itation	O
of	O
GP	O
##C	O
##ho	O
concentration	O
(	B
1	B
-	I
O	I
-	I
Oct	I
##ade	I
##cy	I
##l	I
-	I
2	I
-	I
O	I
-	I
met	I
##hyl	I
-	I
s	I
##n	I
-	I
g	I
##ly	I
##cer	I
##o	I
-	I
3	I
-	I
p	I
##hos	I
##ph	I
##ory	I
##l	I
##cho	I
##line	I
,	O
Sigma	O
,	O
09	O
##26	O
##2	O
)	O
.	O

In	O
our	O
study	O
,	O
we	O
determined	O
u	O
##rina	O
##ry	O
meta	O
##bol	O
##ites	O
of	O
DB	B
##P	I
,	O
B	O
##z	O
##B	O
##P	O
,	O
and	O
DE	O
##HP	O
as	O
those	O
p	O
##ht	O
##hala	O
##tes	O
most	O
prevalent	O
in	O
Central	O
and	O
Eastern	O
European	O
populations	O
.	O

Studies	O
demonstrate	O
that	O
serum	O
u	B
##ric	I
acid	I
can	O
be	O
a	O
sensitive	O
bio	O
##mark	O
##er	O
for	O
blood	O
pressure	O
elevation	O
.	O

To	O
estimate	O
relative	O
hazards	O
from	O
Cox	O
models	O
,	O
est	B
##rogen	I
and	O
est	B
##rogen	I
metabolism	O
measures	O
were	O
log	O
-	O
transformed	O
and	O
the	O
following	O
co	O
##var	O
##iate	O
##s	O
were	O
included	O
:	O
age	O
at	O
study	O
entry	O
:	O
55	O
–	O
59	O
,	O
60	O
–	O
64	O
,	O
65	O
–	O
69	O
,	O
70	O
–	O
74	O
years	O
;	O
period	O
of	O
blood	O
collection	O
:	O
January	O
26	O
,	O
1994	O
,	O
to	O
September	O
29	O
,	O
1997	O
,	O
September	O
30	O
,	O
1997	O
,	O
to	O
October	O
17	O
,	O
2001	O
;	O
age	O
at	O
men	O
##ar	O
##che	O
:	O
<	O
12	O
,	O
12	O
–	O
13	O
or	O
missing	O
,	O
≥	O
14	O
years	O
;	O
combined	O
par	O
##ity	O
and	O
age	O
at	O
birth	O
of	O
first	O
child	O
:	O
null	O
##ip	O
##aro	O
##us	O
,	O
≥	O
1	O
live	O
birth	O
and	O
age	O
<	O
20	O
years	O
,	O
1	O
–	O
2	O
live	O
births	O
and	O
age	O
20	O
–	O
29	O
years	O
,	O
≥	O
3	O
live	O
births	O
and	O
age	O
20	O
–	O
29	O
years	O
or	O
missing	O
par	O
##ity	O
or	O
missing	O
age	O
,	O
≥	O
1	O
live	O
birth	O
and	O
age	O
≥	O
30	O
years	O
;	O
age	O
at	O
natural	O
men	O
##op	O
##aus	O
##e	O
:	O
<	O
45	O
,	O
45	O
–	O
49	O
,	O
50	O
–	O
54	O
,	O
≥	O
55	O
years	O
,	O
missing	O
;	O
type	O
of	O
men	O
##op	O
##aus	O
##e	O
:	O
natural	O
men	O
##op	O
##aus	O
##e	O
,	O
surgical	O
men	O
##op	O
##aus	O
##e	O
with	O
both	O
o	O
##var	O
##ies	O
removed	O
,	O
other	O
or	O
missing	O
;	O
first	O
-	O
degree	O
family	O
history	O
of	O
breast	O
cancer	O
:	O
yes	O
,	O
no	O
or	O
missing	O
;	O
personal	O
history	O
of	O
ben	O
##ign	O
breast	O
disease	O
:	O
yes	O
,	O
no	O
or	O
missing	O
;	O
previous	O
use	O
of	O
men	O
##op	O
##aus	O
##al	O
hormone	O

The	O
anal	O
##ytic	O
method	O
for	O
determination	O
of	O
u	O
##rina	O
##ry	O
co	B
##tin	I
##ine	I
was	O
previously	O
described	O
in	O
detail	O
.	O

Interest	O
##ingly	O
,	O
p	B
##oly	I
##amine	I
##s	I
,	O
such	O
as	O
put	B
##res	I
##cine	I
and	O
ca	B
##da	I
##ver	I
##ine	I
,	O
which	O
showed	O
a	O
higher	O
abundance	O
in	O
the	O
CR	O
##C	O
group	O
than	O
in	O
the	O
H	O
group	O
,	O
have	O
been	O
previously	O
implicated	O
in	O
cancer	O
.	O

In	O
the	O
full	O
range	O
participants	O
,	O
meta	O
##bol	O
##ites	O
that	O
co	O
##rrel	O
##ate	O
with	O
L	O
##D	O
##L	O
-	O
C	O
response	O
to	O
si	B
##m	I
##vas	I
##tat	I
##in	I
included	O
di	O
##bas	O
##ic	O
amino	O
acids	O
that	O
are	O
substrates	O
for	O
the	O
c	O
##ys	O
##tin	O
##uria	O
-	O
related	O
transport	O
##er	O
,	O
potentially	O
indicating	O
changes	O
in	O
transport	O
.	O

Of	O
the	O
33	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
species	O
tested	O
,	O
8	O
molecular	O
species	O
,	O
particularly	O
those	O
containing	O
long	O
al	B
##ip	I
##hat	I
##ic	I
chains	O
such	O
as	O
22	O
and	O
24	O
carbon	O
atoms	O
,	O
were	O
significantly	O
lower	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
in	O
AD	O
compared	O
to	O
controls	O
.	O

1	O
m	O
##l	O
of	O
2	O
%	O
potassium	B
chloride	I
was	O
added	O
and	O
the	O
contents	O
were	O
mixed	O
as	O
previously	O
described	O
.	O

Finally	O
,	O
our	O
observation	O
about	O
the	O
consistent	O
negative	O
association	O
of	O
cluster	O
10	O
with	O
several	O
risk	O
factors	O
of	O
C	O
##VD	O
indicates	O
a	O
likely	O
genetic	O
explanation	O
for	O
the	O
reported	O
association	O
of	O
reduced	O
levels	O
of	O
plasma	O
l	B
##ys	I
##op	I
##hs	I
##op	I
##hat	I
##idy	I
##l	I
##cho	I
##line	I
with	O
o	O
##besity	O
and	O
type	O
2	O
diabetes	O
.	O

We	O
found	O
that	O
the	O
CS	O
##F	O
my	B
##o	I
-	I
in	I
##os	I
##ito	I
##l	I
levels	O
decrease	O
,	O
whereas	O
ch	B
##ole	I
##ster	I
##yl	I
su	I
##lf	I
##ate	I
level	O
increases	O
linear	O
##ly	O
respect	O
to	O
tumor	O
size	O
as	O
measured	O
by	O
T	O
##ga	O
##d	O
and	O
FL	O
##A	O
##IR	O
according	O
to	O
the	O
Macdonald	O
'	O
s	O
criteria	O
.	O

Tri	B
##met	I
##hyl	I
##si	I
##ly	I
##l	I
##p	I
##rop	I
##ion	I
##ic	I
acid	O
-	O
d	O
##4	O
sodium	O
salt	O
(	O
T	O
##SP	O
)	O
was	O
bought	O
from	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
(	O
USA	O
)	O
.	O

Analysis	O
of	O
human	O
breast	O
cancer	O
tissue	O
samples	O
reveals	O
that	O
relative	O
composition	O
changes	O
of	O
C	B
##18	I
:	I
1	I
Δ	O
##9	O
and	O
Δ	O
##11	O
is	O
##omer	O
pairs	O
in	O
PC	O
##s	O
and	O
P	O
##Es	O
provide	O
reliable	O
parameters	O
for	O
tracing	O
path	O
##ological	O
conditions	O
.	O

Additional	O
adjustment	O
for	O
health	O
status	O
(	O
Su	O
##pp	O
##lement	O
##ary	O
Figure	O
S	O
##6	O
)	O
and	O
intake	O
of	O
medication	O
(	O
Su	O
##pp	O
##lement	O
##ary	O
Figure	O
S	O
##7	O
,	O
available	O
as	O
Su	O
##pp	O
##lement	O
##ary	O
data	O
at	O
I	O
##J	O
##E	O
online	O
)	O
resulted	O
in	O
additional	O
constituents	O
of	O
V	O
##LD	O
##L	O
sub	O
##c	O
##lass	O
##es	O
being	O
associated	O
with	O
25	O
(	O
OH	O
)	O
D	O
at	O
P	O
<	O
1	O
.	O
20	O
x	O
10	O
_	O
−	O
##4	O
,	O
whereas	O
the	O
association	O
with	O
is	B
##ob	I
##ut	I
##yr	I
##yl	I
##car	I
##ni	I
##tine	I
(	O
M	O
)	O
,	O
is	B
##ova	I
##ler	I
##yl	I
##car	I
##ni	I
##tine	I
(	O
M	O
)	O
,	O
p	B
##yr	I
##ido	I
##xa	I
##te	I
(	O
M	O
)	O
,	O
c	B
##rea	I
##tin	I
##ine	I
(	O
N	O
)	O
and	O
u	B
##rea	I
(	O
M	O
)	O
disappeared	O
.	O

Path	O
##way	O
analysis	O
was	O
done	O
through	O
MP	O
##P	O
software	O
using	O
thirty	O
two	O
significantly	O
different	O
##ia	O
##tive	O
meta	O
##bol	O
##ites	O
which	O
reveals	O
disturbance	O
in	O
several	O
pathways	O
including	O
p	B
##yr	I
##u	I
##vate	I
metabolism	O
and	O
c	B
##it	I
##ric	I
acid	I
(	O
T	O
##CA	O
)	O
cycle	O
,	O
fatty	O
acid	O
t	O
##ria	O
##cy	O
##l	O
##gly	O
##cer	O
##ol	O
and	O
k	B
##eton	I
##e	I
body	O
metabolism	O
,	O
bi	O
##le	O
acid	O
and	O
bi	O
##le	O
salt	O
metabolism	O
,	O
ATP	S
Bin	O
##ding	O
Cass	O
##ette	O
(	O
ABC	O
)	O
family	O
protein	O
mediated	O
transport	O
and	O
G	O
-	O
Pro	O
##tein	O
Co	O
##up	O
##led	O
Re	O
##ceptor	O
(	O
GP	O
##CR	O
)	O
downstream	O
signaling	O
pathways	O
.	O

In	O
the	O
cancer	O
cell	O
proliferation	O
,	O
besides	O
g	B
##lut	I
##amine	I
,	O
the	O
fatty	O
acids	O
are	O
required	O
for	O
the	O
membrane	O
lip	O
##ids	O
synthesis	O
due	O
to	O
accelerated	O
cell	O
proliferation	O
.	O

To	O
account	O
for	O
potential	O
con	O
##found	O
##ing	O
effects	O
of	O
demographic	O
or	O
clinical	O
differences	O
between	O
DR	O
patients	O
and	O
di	O
##abe	O
##tic	O
controls	O
,	O
we	O
performed	O
linear	O
re	O
##gression	O
analyses	O
for	O
each	O
of	O
the	O
236	O
disc	O
##rim	O
##inator	O
##y	O
features	O
with	O
meta	O
##bol	O
##ite	O
intensity	O
as	O
the	O
dependent	O
variable	O
and	O
DR	O
status	O
,	O
age	O
,	O
sex	O
,	O
diabetes	O
duration	S
,	O
and	O
H	O
##b	O
##A	O
##1	O
##c	O
levels	O
as	O
independent	O
variables	O
in	O
the	O
model	O
.	O

Among	O
these	O
,	O
we	O
highlight	O
pen	B
##tad	I
##eca	I
##ne	I
-	I
2	I
-	I
one	I
and	O
de	B
##cano	I
##ic	I
acid	I
,	O
which	O
were	O
significantly	O
increased	O
in	O
PC	O
##a	O
compared	O
to	O
normal	O
cells	O
,	O
and	O
c	B
##y	I
##c	I
##lo	I
##he	I
##xa	I
##non	I
##e	I
,	O
4	B
-	I
met	I
##hyl	I
##he	I
##pta	I
##n	I
-	I
2	I
-	I
one	I
,	O
2	B
-	I
met	I
##hyl	I
##pent	I
##ane	I
-	I
1	I
,	I
3	I
-	I
di	I
##ol	I
,	O
4	B
-	I
met	I
##hyl	I
##ben	I
##zal	I
##de	I
##hy	I
##de	I
,	O
1	B
-	I
(	I
3	I
,	I
5	I
-	I
dim	I
##eth	I
##yl	I
##fu	I
##ran	I
-	I
2	I
-	I
y	I
##l	I
)	I
et	I
##han	I
##one	I
,	O
met	B
##hyl	I
ben	I
##zo	I
##ate	I
and	O
non	B
##ano	I
##ic	I
acid	I
,	O
which	O
were	O
significantly	O
decreased	O
in	O
PC	O
##a	O
cells	O
.	O

Moreover	O
,	O
k	B
##yn	I
##uren	I
##ine	I
is	O
an	O
end	O
##ogen	O
##ous	O
l	O
##igan	O
##d	O
of	O
the	O
human	O
a	B
##ryl	I
h	I
##ydro	I
##car	I
##bon	I
receptor	O
(	O
A	O
##H	O
##R	O
)	O
and	O
plays	O
an	O
important	O
role	O
in	O
suppress	O
##ing	O
immune	O
responses	O
.	O

Cy	B
##sta	I
##thi	I
##oni	I
##ne	I
was	O
not	O
correlated	O
with	O
PA	O
##SI	O
scores	O
prior	O
to	O
treatment	O
(	O
Table	O
3	O
)	O
,	O
which	O
may	O
explain	O
the	O
lack	O
of	O
response	O
and	O
suggests	O
a	O
distinct	O
mechanism	O
.	O

In	O
2011	O
,	O
the	O
Taiwan	O
FDA	O
disclosed	O
illegal	O
di	B
(	I
2	I
-	I
et	I
##hyl	I
##he	I
##xy	I
##l	I
p	I
##ht	I
##hala	I
##te	I
)	I
(	O
DE	O
##HP	O
)	O
and	O
di	B
##but	I
##yl	I
p	I
##ht	I
##hala	I
##te	I
(	O
DB	O
##P	O
)	O
use	O
in	O
beverage	O
and	O
nutrition	O
supplement	O
##s	O
.	O

_	O
*	O
*	O
C	O
,	O
healthy	O
control	O
;	O
R	B
##L	I
,	O
re	O
##lap	O
##se	O
;	O
R	B
##M	I
,	O
Re	O
##mission	O
_	O
*	O
*	O
*	O
F	O
##DR	O
was	O
calculated	O
by	O
Benjamin	O
##i	O
-	O
Ho	O
##ch	O
##berg	O
method	O
.	O
_	O
*	O
*	O
*	O
*	O

Among	O
these	O
features	O
,	O
g	B
##lut	I
##amine	I
was	O
positively	O
correlated	O
with	O
CS	O
##F	O
t	O
‐	O
Tau	O
and	O
p	O
‐	O
Tau	O
_	O
181	O
levels	O
and	O
the	O
number	O
of	O
A	O
##po	O
##E	O
ε	O
##4	O
risk	O
all	O
##ele	O
##s	O
,	O
and	O
pipe	B
##rine	I
and	O
m	O
/	O
z	O
246	O
.	O
95	O
##50	O
correlated	O
negatively	O
and	O
positively	O
with	O
p	O
‐	O
Tau	O
_	O
181	O
levels	O
,	O
respectively	O
(	O
Table	O
)	O
.	O

A	O
single	O
,	O
fast	O
##ing	O
measurement	O
of	O
these	O
meta	O
##bol	O
##ites	O
may	O
provide	O
additional	O
information	O
over	O
standard	O
risk	O
markers	O
of	O
v	O
##is	O
##cer	O
##al	O
fat	O
(	O
B	O
##MI	O
,	O
fast	O
##ing	O
glucose	S
,	O
waist	O
c	O
##ir	O
##cum	O
##ference	O
,	O
and	O
serum	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
)	O
.	O

High	O
levels	O
of	O
g	B
##lut	I
##ama	I
##te	I
in	O
the	O
present	O
study	O
can	O
be	O
associated	O
with	O
an	O
activation	O
of	O
g	O
##lut	O
##ami	O
##no	O
##lysis	O
through	O
an	O
increased	O
activity	O
of	O
the	O
mitochondrial	O
enzyme	O
g	O
##lut	O
##ami	O
##nas	O
##e	O
.	O

De	O
##ion	O
##ized	O
water	O
was	O
pu	O
##rified	O
to	O
18	O
.	O
2	O
[UNK]	O
-	I
cm	I
resist	O
##ivity	O
using	O
an	O
E	O
##L	O
##GA	O
P	O
##UR	O
##EL	O
##AB	O
Ultra	O
laboratory	O
water	O
pu	O
##rification	O
system	O
(	O
Wood	O
##ridge	O
,	O
IL	O
)	O
.	O

The	O
SP	O
##E	O
showed	O
good	O
recover	O
##ies	O
(	O
over	O
80	O
%	O
)	O
for	O
CA	O
##D	O
,	O
GA	B
##BA	I
,	O
L	O
##Y	O
##S	O
,	O
OR	O
##N	O
,	O
P	O
##UT	O
,	O
and	O
SPD	O
,	O
but	O
the	O
other	O
anal	O
##yte	O
##s	O
did	O
not	O
have	O
better	O
recover	O
##ies	O
than	O
those	O
from	O
the	O
LL	O
##E	O
.	O

D	B
##A	I
-	I
3	I
-	I
O	I
-	I
S	I
was	O
clearly	O
detected	O
in	O
all	O
the	O
samples	O
and	O
D	B
##A	I
-	I
4	I
-	I
O	I
-	I
S	I
in	O
only	O
one	O
sample	O
,	O
which	O
indicated	O
that	O
the	O
D	B
##A	I
-	I
3	I
-	I
O	I
-	I
S	I
re	O
##gio	O
##is	O
##omer	O
pre	O
##dom	O
##inate	O
##s	O
in	O
the	O
human	O
brain	O
.	O

In	O
our	O
study	O
we	O
showed	O
that	O
en	B
##zal	I
##uta	I
##mi	I
##de	I
and	O
N	B
-	I
des	I
##met	I
##hyl	I
##en	I
##zal	I
##uta	I
##mi	I
##de	I
are	O
stable	O
in	O
whole	O
blood	O
for	O
24	O
hours	O
,	O
and	O
that	O
patient	O
plasma	O
samples	O
are	O
stable	O
at	O
ambient	O
temperature	O
for	O
23	O
days	O
.	O

(	B
Z	I
)	I
‐	I
end	I
##ox	I
##ife	I
##n	I
plasma	O
levels	O
were	O
in	O
the	O
range	O
of	O
those	O
reported	O
by	O
others	O
,	O
_	O
15	O
,	O
_	O
17	O
and	O
,	O
as	O
expected	O
,	O
C	O
##YP	O
##2	O
##D	O
##6	O
p	O
##oly	O
##mor	O
##phism	O
only	O
partially	O
predicted	O
its	O
var	O
##iability	O
.	O
_	O
19	O
Po	O
##ten	O
##tial	O
con	O
##found	O
##ers	O
,	O
such	O
as	O
D	O
##ME	O
p	O
##oly	O
##mor	O
##phism	O
##s	O
or	O
strong	O
C	O
##YP	O
##2	O
##D	O
##6	O
inhibitor	O
##s	O
,	O
do	O
not	O
play	O
a	O
significant	O
role	O
as	O
the	O
former	O
showed	O
no	O
effect	O
and	O
the	O
latter	O
were	O
in	O
##f	O
##re	O
##quent	O
##ly	O
used	O
by	O
our	O
patients	O
given	O
the	O
low	O
prescription	O
rates	O
at	O
our	O
hospital	O
.	O

Pittsburgh	O
,	O
Pennsylvania	O
,	O
and	O
Corpus	O
Christi	O
,	O
Texas	O
(	O
non	O
-	O
Hispanic	O
participants	O
)	O
showed	O
the	O
highest	O
prevalence	O
of	O
anal	O
##ges	O
##ic	O
use	O
,	O
with	O
ace	B
##tam	I
##ino	I
##phe	I
##n	I
and	O
/	O
or	O
i	B
##bu	I
##p	I
##ro	I
##fen	I
meta	O
##bol	O
##ites	O
being	O
detected	O
in	O
more	O
than	O
20	O
%	O
of	O
the	O
first	O
and	O
second	O
urine	O
collections	O
.	O

Indeed	O
,	O
la	B
##ct	I
##ate	I
might	O
be	O
a	O
predict	O
##ive	O
marker	O
for	O
assessing	O
the	O
response	O
of	O
tumor	O
cells	O
to	O
neo	O
##ad	O
##ju	O
##vant	O
ch	O
##em	O
##otherapy	O
.	O

The	O
un	O
##iva	O
##ria	O
##te	O
tests	O
demonstrated	O
that	O
11	O
meta	O
##bol	O
##ites	O
were	O
per	O
##tur	O
##bed	O
,	O
of	O
which	O
L	B
-	I
D	I
##OP	I
##A	I
,	O
x	B
##ant	I
##hine	I
,	O
op	O
##ht	O
##hal	O
##mate	O
,	O
c	B
##rea	I
##tin	I
##ine	I
,	O
t	B
##yr	I
##os	I
##ine	I
,	O
5	B
-	I
h	I
##y	I
##p	I
##ro	I
##xy	I
##try	I
##pt	I
##op	I
##han	I
,	O
ad	B
##eno	I
##sin	I
##e	I
and	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
remained	O
significant	O
after	O
correct	O
##ing	O
for	O
multiple	O
comparisons	O
.	O

Met	O
##ab	O
##oli	O
##tes	O
involved	O
in	O
d	O
##ys	O
##re	O
##gu	O
##lation	O
of	O
these	O
pathways	O
are	O
palm	B
##itic	I
acid	I
,	O
la	B
##ctic	I
acid	I
,	O
su	B
##c	I
##rose	I
,	O
t	B
##rie	I
##than	I
##ola	I
##mine	I
,	O
g	B
##ly	I
##cer	I
##ol	I
and	O
et	B
##hyl	I
##ene	I
g	I
##ly	I
##co	I
##l	I
.	O

These	O
observations	O
suggests	O
a	O
der	O
##ang	O
##ement	O
in	O
t	B
##yr	I
##os	I
##ine	I
metabolism	O
and	O
more	O
specifically	O
in	O
the	O
do	O
##pa	O
##mine	O
##rg	O
##ic	O
pathway	O
in	O
HD	O
,	O
even	O
though	O
the	O
role	O
is	O
still	O
not	O
well	O
understood	O
and	O
previous	O
findings	O
have	O
been	O
in	O
##con	O
##clusive	O
,	O
as	O
reviewed	O
by	O
Byrne	O
and	O
Wild	O
.	O

These	O
types	O
of	O
p	B
##hos	I
##ph	I
##ory	I
##lation	I
##s	I
may	O
cause	O
changes	O
in	O
the	O
function	O
of	O
the	O
protein	O
.	O

A	O
##c	O
##quire	O
##d	O
immune	O
deficiency	O
syndrome	O
;	O
BA	O
##P	O
##T	O
:	O
C	O
-	O
13	O
p	B
##hen	I
##yl	I
##p	I
##rop	I
##ano	I
##id	I
side	O
chain	O
-	O
Co	O
##A	O
a	O
##cy	O
##lt	O
##ran	O
##s	O
##fer	O
##ase	O
;	O
C	O
##a	O
##B	O
##r	O
##2	O
:	O
Cal	B
##ci	I
##um	I
br	I
##omi	I
##de	I
;	O
DB	O
##AT	O
:	O
10	O
-	O
de	O
##ace	O
##ty	O
##l	O
##ba	O
##cca	O
##tin	O
III	O
-	O
10	O
-	O
O	O
-	O
ace	O
##ty	O
##l	O
transfer	O
##ase	O
;	O
DNA	O
:	O
De	B
##ox	I
##yr	I
##ib	I
##on	I
##uc	I
##le	I
##ic	I
acid	I
;	O
E	O
##I	O
-	O
MS	O
:	O

Po	O
##ten	O
##tial	O
contributors	O
to	O
in	O
##tra	O
##oral	O
ant	B
##ho	I
##cy	I
##ani	I
##n	I
metabolism	O
include	O
oral	O
tissues	O
,	O
sa	O
##liva	O
,	O
and	O
oral	O
micro	O
##f	O
##lora	O
.	O

Therefore	O
,	O
anti	O
##ba	O
##cter	O
##ial	O
(	O
MI	O
##C	O
12	O
.	O
5	O
–	O
100	O
##μ	O
##g	O
/	O
m	O
##L	O
)	O
compounds	O
,	O
(	B
1	I
##R	I
,	I
2	I
##S	I
,	I
3	I
##R	I
)	I
-	I
3	I
-	I
(	I
(	I
S	I
)	I
-	I
2	I
-	I
h	I
##ydro	I
##xy	I
-	I
6	I
-	I
met	I
##hyl	I
##he	I
##pt	I
-	I
5	I
-	I
en	I
-	I
2	I
-	I
y	I
##l	I
)	I
-	I
1	I
,	I
2	I
-	I
dim	I
##eth	I
##yl	I
##cy	I
##c	I
##lop	I
##ent	I
##an	I
-	I
1	I
-	I
o	I
##l	I
(	O
35	O
)	O
,	O
in	B
##do	I
##l	I
-	I
3	I
-	I
ace	I
##tic	I
acid	I
(	O
36	O
)	O
,	O
met	B
##hyl	I
in	I
##do	I
##ly	I
##l	I
-	I
3	I
-	I
ace	I
##tate	I
(	O
37	O
)	O
,	O
bass	B
##ia	I
##tin	I
(	O
38	O
)	O
,	O
be	B
##au	I
##ver	I
##ici	I
##n	I
(	O
21	O
)	O
,	O
epic	O
##y	O
##c	O
##lone	O
##rod	O
##iol	O
oxide	O
(	O
39	O
)	O
,	O
3	B
##β	I
-	I
h	I
##ydro	I
##xy	I
-	I
β	I
-	I
a	I
##core	I
##no	I
##l	I
(	O
40	O
)	O
,	O
f	O
##usa	O
##p	O
##rol	O
##ifer	O
##in	O
(	O
41	O
)	O
,	O
5	B
-	I
O	I
-	I
met	I
##hyl	I
##sol	I
##ani	I
##ol	I
(	O
42	O
)	O
,	O
5	B
-	I
O	I
-	I
met	I
##hyl	I
##ja	I
##vani	I
##cin	I
(	O
43	O
)	O
,	O
met	B
##hyl	I
et	I
##her	I
f	O
##usa	O
##ru	O
##bin	O
(	O
44	O
)	O
,	O
and	O
an	B
##hy	I
##dr	I
##oja	I
##vani	I
##cin	I
(	O
45	O
)	O
were	O
isolated	O
from	O
extract	O
of	O
F	O
.	O
pro	O
##life	O
##rat	O
##um	O
A	O
##F	O
-	O
04	O
,	O
end	O
##op	O
##hy	O
##te	O
of	O
the	O
green	O
Chinese	O
on	O
##ion	O
(	O
Jiang	O
et	O
al	O
.	O
2019	O
)	O
.	O

We	O
identified	O
as	O
major	O
factors	O
:	O
(	O
i	O
)	O
so	O
##lub	O
##ility	O
in	O
formal	B
##in	I
solution	O
,	O
(	O
ii	O
)	O
co	O
##valent	O
bonding	O
to	O
cellular	O
component	O
(	O
e	O
.	O
g	O
.	O
,	O
protein	O
,	O
DNA	O
/	O
RNA	O
)	O
,	O
and	O
(	O
ii	O
##i	O
)	O
so	O
##lub	O
##ility	O
in	O
ethanol	S
and	O
x	B
##yle	I
##ne	I
.	O

Finally	O
,	O
u	O
##rina	O
##ry	O
3	B
-	I
me	I
-	I
His	I
and	O
PA	B
##G	I
levels	O
decreased	O
in	O
F	O
##S	O
##GS	O
patients	O
,	O
which	O
indicated	O
the	O
decreased	O
cat	O
##ab	O
##olis	O
##m	O
of	O
muscle	O
protein	O
and	O
lip	O
##id	O
.	O

Ty	O
##r	O
_	O
41	O
##1	O
is	O
a	O
major	O
site	O
for	O
co	O
##valent	O
add	O
##uc	O
##t	O
with	O
ni	B
##tro	I
##phe	I
##ny	I
##l	I
ace	I
##tate	I
,	O
organ	O
##op	O
##hos	O
##ph	O
##orous	O
p	O
##est	O
##icides	O
,	O
and	O
nerve	O
agents	O
(	O
ta	O
##bu	O
##n	O
,	O
sa	O
##rin	O
,	O
c	O
##y	O
##c	O
##los	O
##ari	O
##n	O
,	O
V	O
##X	O
)	O
;	O
secondary	O
add	O
##uction	O
sites	O
with	O
many	O
of	O
these	O
toxic	O
##ants	O
occurs	O
at	O
Ty	O
##r	O
_	O
148	O
,	O
Ty	O
##r	O
_	O
150	O
and	O
Ty	O
##r	O
_	O
161	O
of	O
SA	O
.	O

In	O
addition	O
,	O
it	O
was	O
reported	O
that	O
the	O
administration	O
of	O
as	B
##pi	I
##rin	I
and	O
ho	O
##rmon	O
##al	O
agents	O
reduced	O
the	O
risk	O
of	O
color	O
##ec	O
##tal	O
cancer	O
[	O
,	O
]	O
.	O

Previous	O
studies	O
showed	O
that	O
car	B
##nos	I
##ine	I
supplement	O
##ation	O
can	O
regulate	O
brain	O
function	O
in	O
some	O
patients	O
and	O
el	O
##eva	O
##te	O
plasma	O
co	B
##rt	I
##ico	I
##ster	I
##one	I
concentrations	O
via	O
the	O
h	O
##y	O
##pot	O
##hala	O
##mic	O
‐	O
pit	O
##uit	O
##ary	O
‐	O
ad	O
##rena	O
##l	O
axis	O
.	O
29	O

Ten	O
differential	O
meta	O
##bol	O
##ites	O
responsible	O
for	O
disc	O
##rim	O
##inating	O
PS	O
##D	O
subjects	O
from	O
healthy	O
control	O
(	O
HC	O
)	O
and	O
stroke	O
subjects	O
were	O
found	O
,	O
and	O
five	O
of	O
these	O
meta	O
##bol	O
##ites	O
were	O
identified	O
as	O
potential	O
bio	O
##mark	O
##ers	O
(	B
la	B
##ct	I
##ate	I
,	O
α	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
format	B
##e	I
,	O
and	O
a	O
##rab	O
##ini	O
##to	O
##l	O
)	O
.	O

High	O
concentrations	O
(	O
10	O
,	O
000	O
ng	O
/	O
g	O
)	O
of	O
cocaine	O
meta	O
##bol	O
##ites	O
,	O
e	O
##c	O
##gon	O
##ine	O
et	B
##hyl	I
est	I
##er	I
,	O
e	B
##c	I
##gon	I
##ine	I
met	I
##hyl	I
est	I
##er	I
,	O
and	O
an	B
##hy	I
##dr	I
##oe	I
##c	I
##gon	I
##ine	I
met	I
##hyl	I
est	I
##er	I
were	O
chosen	O
to	O
far	O
exceed	O
observed	O
me	O
##con	O
##ium	O
concentrations	O
.	O

All	O
-	O
ions	O
C	O
##ID	O
at	O
this	O
retention	O
time	O
confirms	O
the	O
a	O
##cy	O
##l	O
chain	O
composition	O
of	O
the	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
as	O
PC	B
18	I
:	I
0	I
_	I
18	I
:	I
1	I
,	O
and	O
the	O
observation	O
of	O
two	O
pairs	O
of	O
Oz	O
##ID	O
product	O
ions	O
reveals	O
a	O
mixture	O
of	O
the	O
double	O
bond	O
is	B
##omer	I
##s	I
PC	I
18	I
:	I
0	I
_	I
18	I
:	I
1	I
(	I
n	I
-	I
7	I
)	I
and	O
PC	B
18	I
:	I
0	I
_	I
18	I
:	I
1	I
(	I
n	I
-	I
9	I
)	I
.	O

The	O
dried	O
samples	O
from	O
each	O
protein	O
removal	O
method	O
were	O
mixed	O
with	O
100	O
μ	O
##L	O
solution	O
of	O
phosphate	S
buffer	O
(	O
100	O
m	O
##M	O
)	O
in	O
D	O
_	O
2	O
O	O
containing	O
66	O
.	O
17	O
μ	O
##M	O
T	O
##SP	O
,	O
made	O
up	O
to	O
550	O
μ	O
##L	O
with	O
phosphate	S
buffer	O
in	O
D	O
_	O
2	O
O	O
and	O
transferred	O
to	O
5	O
mm	O
N	O
##MR	O
tubes	O
.	O

The	O
library	O
solutions	O
were	O
di	O
##lut	O
##ed	O
in	O
Me	O
##OH	O
/	O
H	O
_	O
2	O
O	B
(	I
50	I
:	I
50	I
,	I
v	I
/	I
v	I
)	I
for	O
R	B
##P	I
measurements	O
and	O
in	O
AC	O
##N	O
/	O
H	O
_	O
2	O
O	B
(	I
80	I
:	I
20	I
)	I
for	O
H	O
##IL	O
##IC	O
injection	O
##s	O
.	O

This	O
is	O
an	O
observation	O
##al	O
,	O
prospective	O
,	O
single	O
-	O
site	O
,	O
cross	O
-	O
section	O
##al	O
study	O
with	O
a	O
pre	O
-	O
set	O
duration	S
of	O
1	O
year	O
involving	O
the	O
recruitment	O
of	O
47	O
patients	O
.	O

For	O
instance	O
,	O
the	O
Re	O
##lative	O
In	O
##tens	O
##ity	O
%	O
(	O
Re	O
##l	O
.	O
In	O
##t	O
.	O
%	O
)	O
of	O
P	B
##E	I
39	I
:	I
4	I
(	O
mon	O
##ois	O
##oto	O
##pic	O
molecular	O
mass	O
:	O
78	O
##1	O
.	O
56	O
##22	O
Da	O
,	O
m	O
/	O
z	O
78	O
##2	O
.	O
6	O
)	O
was	O
less	O
than	O
2	O
%	O
of	O
the	O
most	O
abundant	O
species	O
in	O
the	O
sub	O
##c	O
##lass	O
(	O
P	O
##E	O
38	O
:	O
4	O
,	O
m	O
/	O
z	O
76	O
##8	O
.	O
6	O
)	O
(	O
Fi	O
##g	O
.	O

For	O
human	O
blood	O
plasma	O
samples	O
,	O
H	O
##IL	O
##IC	O
-	O
L	O
##C	O
-	O
MS	O
was	O
performed	O
on	O
a	O
Luna	O
H	O
##IL	O
##IC	O
Di	B
##ol	I
HP	O
##LC	O
column	O
(	O
150	O
×	O
3	O
m	O
##M	O
,	O
3	O
µ	O
##M	O
particle	O
size	O
,	O
Ph	O
##eno	O
##men	O
##ex	O
,	O
Tor	O
##rance	O
,	O
CA	O
,	O
USA	O
)	O
.	O

While	O
th	B
##ios	I
##ulf	I
##ate	I
,	O
produced	O
at	O
levels	O
around	O
0	O
.	O
1	O
%	O
of	O
total	O
u	O
##rina	O
##ry	O
sulfur	O
,	O
could	O
also	O
be	O
considered	O
as	O
an	O
indicator	O
of	O
hydrogen	B
su	I
##lf	I
##ide	I
levels	O
,	O
it	O
can	O
originate	O
from	O
other	O
substrates	O
(	O
e	O
.	O
g	O
.	O
the	O
sulfur	O
transfer	O
from	O
me	B
##rca	I
##pt	I
##opy	I
##ru	I
##vate	I
to	O
su	B
##lf	I
##ite	I
)	O
,	O
rendering	O
it	O
non	O
-	O
specific	O
to	O
hydrogen	B
su	I
##lf	I
##ide	I
levels	O
.	O

Moreover	O
,	O
end	O
##ogen	O
##ous	O
as	B
##ym	I
##metric	I
dim	I
##eth	I
##yla	I
##rg	I
##ini	I
##ne	I
(	O
AD	O
##MA	O
)	O
,	O
known	O
as	O
inhibitor	O
of	O
ni	B
##tric	I
oxide	I
(	O
NO	O
)	O
synthesis	O
,	O
can	O
be	O
directly	O
de	O
##grade	O
by	O
dim	O
##eth	O
##yla	O
##min	O
##oh	O
##ydro	O
##lase	O
(	O
DD	O
##A	O
##H	O
)	O
to	O
the	O
re	O
##nal	O
##ly	O
cleared	O
products	O
D	B
##MA	I
and	O
c	B
##it	I
##ru	I
##llin	I
##e	I
[	O
–	O
]	O
.	O

We	O
measured	O
base	O
##line	O
serum	O
vitamin	B
D	I
meta	O
##bol	O
##ites	O
using	O
a	O
case	O
-	O
co	O
##hor	O
##t	O
design	O
.	O

Table	O
presents	O
the	O
associations	O
between	O
continuous	O
and	O
q	O
##ua	O
##rt	O
##ile	O
models	O
of	O
u	O
##rina	O
##ry	O
para	B
##ce	I
##tam	I
##ol	I
bio	O
##mark	O
##ers	O
and	O
T	O
##TP	O
for	O
partner	O
-	O
specific	O
analyses	O
.	O

All	O
participants	O
consumed	O
bread	O
fortified	O
with	O
f	B
##olic	I
acid	I
on	O
a	O
daily	O
basis	O
.	O

C	O
##13	O
k	B
##eton	I
##e	I
.	O

(	O
A	O
)	O
Ethan	B
##ol	I
present	O
in	O
the	O
l	O
##yo	O
##phi	O
##li	O
##zed	O
Mia	O
##P	O
##a	O
##C	O
##a	O
-	O
2	O
samples	O
only	O
.	O

A	O
di	O
##aper	O
’	O
s	O
absorb	O
##ent	O
core	O
is	O
predominantly	O
derived	O
from	O
polymer	O
##s	O
made	O
from	O
very	O
small	O
particles	O
of	O
a	B
##c	I
##ryl	I
##ic	I
acid	I
derivatives	O
,	O
giving	O
it	O
its	O
highly	O
absorb	O
##ent	O
properties	O
.	O

P	O
##las	O
##ma	O
k	B
##yn	I
##uren	I
##ine	I
was	O
found	O
to	O
negatively	O
co	O
##rrel	O
##ate	O
to	O
MA	O
##DR	O
##S	O
score	O
in	O
patients	O
with	O
MD	O
##D	O
before	O
treatment	O
with	O
EC	O
##T	O
(	O
ρ	O
=	O
−	O
##0	O
.	O
67	O
;	O
P	O
=	O
0	O
.	O
00	O
##2	O
,	O
Fi	O
##g	O
.	O

Blood	O
samples	O
were	O
obtained	O
and	O
used	O
for	O
the	O
determination	O
of	O
glucose	S
,	O
insulin	O
,	O
H	O
##b	O
##A	O
##1	O
##c	O
,	O
al	O
##ani	O
##ne	O
amino	O
##tra	O
##ns	O
##fer	O
##ase	O
(	O
AL	O
##T	O
)	O
,	O
as	O
##par	O
##tate	O
amino	O
##tra	O
##ns	O
##fer	O
##ase	O
(	O
AS	O
##T	O
)	O
,	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
(	O
T	O
##G	O
)	O
,	O
high	O
-	O
density	O
lip	O
##op	O
##rote	O
##in	O
(	O
HD	O
##L	O
)	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
and	O
low	O
-	O
density	O
lip	O
##op	O
##rote	O
##in	O
(	O
L	O
##D	O
##L	O
)	O
ch	B
##ole	I
##ster	I
##ol	I
.	O

When	O
the	O
k	B
##eton	I
##e	I
bodies	O
level	O
is	O
very	O
low	O
in	O
the	O
serum	O
,	O
they	O
only	O
provide	O
a	O
very	O
small	O
part	O
of	O
the	O
energy	O
required	O
by	O
the	O
my	O
##oc	O
##ard	O
##ium	O
.	O

We	O
found	O
that	O
heavy	O
cannabis	S
use	O
was	O
associated	O
with	O
decreased	O
frequencies	O
of	O
activated	S
T	O
cells	O
and	O
inflammatory	O
anti	O
##gen	O
-	O
presenting	O
cell	O
(	O
AP	O
##C	O
)	O
subset	O
##s	O
,	O
suggesting	O
a	O
potential	O
im	O
##mu	O
##no	O
##log	O
##ic	O
benefit	O
of	O
can	B
##na	I
##bino	I
##ids	I
through	O
decreased	O
immune	O
activation	O
in	O
HIV	O
-	O
infected	O
individuals	O
.	O

Numbers	O
indicate	O
the	O
following	O
meta	O
##bol	O
##ites	O
:	O
[UNK]	O
-	O
met	O
##hyl	O
su	O
##lf	O
##ola	O
##ne	O
;	O
[UNK]	O
-	O
he	O
##xa	O
##non	O
##e	O
;	O
[UNK]	O
-	O
pen	O
##tano	O
##ne	O
;	O
[UNK]	O
-	O
h	O
##ydro	O
##xy	O
-	O
2	O
-	O
pen	O
##tano	O
##ne	O
;	O
5	O
:	O
ally	B
##l	I
met	I
##hyl	I
##sul	I
##phi	I
##de	I
;	O
6	O
:	O
dim	B
##eth	I
##yl	I
di	I
##sul	I
##fi	I
##de	I
;	O
[UNK]	O
-	O
he	O
##pta	O
##non	O
##e	O
;	O
[UNK]	O
-	O
met	O
##hyl	O
##cy	O
##c	O
##lo	O
##he	O
##xa	O
##no	O
##l	O
;	O
9	B
;	I
2	I
-	I
he	I
##xa	I
##non	I
##e	I
;	O
[UNK]	O
,	O
4	O
-	O
dim	O
##eth	O
##yl	O
##thi	O
##op	O
##hen	O
##e	O
;	O
11	O
:	O
dial	B
##ly	I
##l	I
su	I
##l	I
##phi	I
##de	I
;	O
[UNK]	O
-	O
met	O
##hyl	O
-	O
2	O
-	O
he	O
##xa	O
##non	O
##e	O
;	O
[UNK]	O
,	O
3	O
-	O
di	O
##thi	O
##o	O
c	O
##y	O
##c	O
##lo	O
##he	O
##xa	O
##ne	O
;	O
14	O
:	O
dim	B
##eth	I
##yl	I
t	I
##ris	I
##ulf	I
##ide	I
;	O
15	O
:	O
p	B
##hen	I
##ol	I
;	O
16	O
:	O
o	B
-	I
c	I
##yme	I
##ne	I
;	O
17	O
:	O
p	B
-	I
c	I
##yme	I
##ne	I
;	O
18	O
:	O
m	B
-	I
c	I
##yme	I
##ne	I
;	O
[UNK]	O
,	O
4	O
-	O
c	O
##ine	O
##ol	O
;	O
20	O
:	O
p	B
-	I
c	I
##res	I
##ol	I
;	O
21	O
:	O
l	B
##inal	I
##ool	I
oxide	I
;	O
22	O
:	O
is	O
##o	O
-	O
men	O
##th	O
##ol	O
;	O
23	O
:	O
Alpha	B
-	I
p	I
-	I
dim	I
##eth	I
##yl	I
##sty	I
##rene	I
;	O
24	O
:	O
L	B
-	I
men	I
##th	I
##ol	I
;	O
25	O
:	O
und	B
##eca	I
##ne	I
;	O
26	O
:	O
led	B
##ene	I
oxide	I
(	O
II	O
)	O
;	O
27	O
:	O
sa	B
##lic	I
##yl	I
##ic	I
acid	I
met	O

Total	O
plasma	O
ch	B
##ole	I
##ster	I
##ol	I
was	O
measured	O
by	O
the	O
CH	O
##OD	O
-	O
PA	O
##P	O
method	O
with	O
kit	O
A1	O
##1	O
##A	O
##01	O
##6	O
##34	O
(	O
H	O
##OR	O
##IB	O
##A	O
AB	O
##X	O
Di	O
##ag	O
##nos	O
##tic	O
,	O
Mont	O
##pel	O
##lier	O
,	O
France	O
)	O
.	O

Our	O
findings	O
,	O
which	O
highlight	O
ace	B
##ty	I
##l	I
##gly	I
##co	I
##p	I
##rote	I
##ins	I
,	O
branched	O
‐	O
chain	O
amino	O
acids	O
,	O
la	B
##ct	I
##ate	I
,	O
g	B
##lut	I
##amine	I
(	O
inverse	O
##ly	O
associated	O
)	O
,	O
and	O
an	O
at	O
##her	O
##ogenic	O
d	O
##ys	O
##lip	O
##ide	O
##mic	O
profile	O
(	O
high	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
and	O
V	O
##LD	O
##L	O
and	O
low	O
HD	O
##L	O
)	O
from	O
hundreds	O
of	O
meta	O
##bol	O
##ites	O
ass	O
##ay	O
##ed	O
,	O
are	O
noteworthy	O
in	O
the	O
context	O
of	O
experimental	O
and	O
clinical	O
data	O
suggesting	O
that	O
certain	O
meta	O
##bol	O
##ites	O
may	O
be	O
both	O
markers	O
and	O
media	O
##tors	O
of	O
adverse	O
health	O
outcomes	O
related	O
to	O
v	O
##is	O
##cer	O
##al	O
o	O
##besity	O
.	O

The	O
correlation	O
##s	O
of	O
24	B
,	I
25	I
(	I
OH	I
)	I
_	I
2	I
D	O
_	O
3	O
and	O
25	O
(	O
OH	O
)	O
D	O
_	O
3	O
were	O
strongest	O
in	O
DC	O
##CT	O
and	O
ME	O
##SA	O
(	O
r	O
=	O
0	O
.	O
88	O
and	O
r	O
=	O
0	O
.	O
84	O
,	O
respectively	O
)	O
and	O
weaker	O
in	O
CH	O
##S	O
and	O
SK	O
##S	O
(	O
r	O
=	O
0	O
.	O
78	O
and	O
r	O
=	O
0	O
.	O
64	O
,	O
respectively	O
)	O
.	O

Different	O
##ial	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
classes	O
such	O
as	O
PA	O
,	O
P	O
##E	O
and	O
PC	O
have	O
been	O
reported	O
in	O
breast	O
cancer	O
.	O

Following	O
re	O
##sus	O
##pen	O
##sion	O
in	O
150	O
µ	O
##L	O
of	O
buffer	O
(	O
150	O
m	O
##M	O
potassium	B
phosphate	I
at	O
pH	O
7	O
.	O
4	O
,	O
1	O
m	O
##M	O
trim	B
##eth	I
##yl	I
##si	I
##ly	I
##l	I
prop	I
##ion	I
##ate	I
(	O
T	O
##SP	O
)	O
,	O
0	O
.	O
01	O
%	O
sodium	O
a	O
##zi	O
##de	O
in	O
100	O
%	O
de	O
##uter	O
##ium	O
oxide	O
(	O
the	O
buffer	O
was	O
first	O
prepared	O
in	O
100	O
%	O
H	O
##2	O
##O	O
,	O
l	O
##yo	O
##phi	O
##li	O
##zed	O
,	O
and	O
then	O
re	O
##con	O
##stituted	O
in	O
100	O
%	O
D	O
##2	O
##O	O
)	O
)	O
,	O
cell	O
line	O
extract	O
##s	O
were	O
combined	O
in	O
the	O
following	O
manner	O
:	O
ten	O
were	O
combined	O
to	O
generate	O
a	O
representative	O
sample	O
for	O
l	O
##yo	O
##phi	O
##li	O
##zed	O
samples	O
for	O
2D	O
N	O
##MR	O
experiments	O
needed	O
for	O
confirmation	O
of	O
meta	O
##bol	O
##ite	O
assignments	O
,	O
another	O
ten	O
were	O
combined	O
and	O
used	O
as	O
a	O
representative	O
sample	O
for	O
speed	O
vacuum	O
##ed	O
samples	O
for	O
2D	O
N	O
##MR	O
experiments	O
needed	O
for	O
confirmation	O
of	O
meta	O
##bol	O
##ite	O
assignments	O
,	O
and	O
the	O
last	O
forty	O
were	O
used	O
to	O
create	O
ten	O
replica	O
##te	O
samples	O
(	O
two	O
samples	O
combined	O
for	O
each	O
N	O
##MR	O
sample	O
to	O
increase	O
the	O
extract	O
concentration	O
for	O
N	O
##MR	O
analysis	O
)	O
per	O
drying	O
method	O
for	O
1	O
##D	O
N	O
##MR	O
experiments	O
.	O

Dr	O
##ied	O
extract	O
##s	O
were	O
a	O
##cc	O
##lim	O
##ated	O
at	O
room	O
temperature	O
for	O
10	O
min	O
,	O
dissolved	O
in	O
20	O
μ	O
##l	O
solution	O
of	O
40	O
mg	O
/	O
m	O
##l	O
met	B
##ho	I
##xy	I
##amine	I
h	I
##ydro	I
##ch	I
##lor	I
##ide	I
(	O
CH	O
##3	O
##ON	O
##H	O
##2	O
_	O
*	O
HC	O
##L	O
)	O
in	O
p	B
##yr	I
##id	I
##ine	I
and	O
in	O
##cu	O
##bate	O
##d	O
for	O
90	O
min	O
at	O
30	O
##°	O
##C	O
on	O
a	O
the	O
##rm	O
##o	O
shake	O
##r	O
(	O
550	O
rpm	O
)	O
.	O

This	O
crossover	O
point	O
with	O
high	O
p	B
##yr	I
##u	I
##vate	I
and	O
low	O
ma	B
##late	I
and	O
low	O
c	B
##it	I
##rate	I
is	O
consistent	O
with	O
a	O
block	O
at	O
the	O
PC	O
reaction	O
[	O
,	O
]	O
.	O

The	O
s	O
##pect	O
##ra	O
were	O
manually	O
corrected	O
for	O
phase	O
and	O
base	O
##line	O
distortion	O
##s	O
and	O
were	O
referenced	O
to	O
the	O
te	B
##tra	I
##met	I
##hyl	I
##si	I
##lane	I
(	O
T	O
##MS	O
)	O
signal	O
(	O
δ	O
=	O
0	O
.	O
00	O
pp	O
##m	O
)	O
.	O

The	O
levels	O
of	O
g	B
##ly	I
##cine	I
and	O
hip	B
##pura	I
##te	I
were	O
significantly	O
increased	O
in	O
AS	O
urine	O
.	O

The	O
four	O
most	O
abundant	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
in	O
seminal	O
plasma	O
were	O
C	O
##0	O
,	O
C	O
##2	O
,	O
but	B
##yr	I
##yl	I
-	I
L	I
-	I
car	I
##ni	I
##tine	I
(	O
C	O
##4	O
)	O
and	O
prop	B
##ion	I
##yl	I
-	I
L	I
-	I
car	I
##ni	I
##tine	I
(	O
C	O
##3	O
)	O
.	O

Lower	O
beta	B
##ine	I
levels	O
were	O
associated	O
with	O
increased	O
risk	O
of	O
developing	O
T	O
##2	O
##DM	O
even	O
after	O
adjusting	O
for	O
clinical	O
characteristics	O
as	O
well	O
as	O
typical	O
risk	O
factors	O
for	O
T	O
##2	O
##DM	O
such	O
as	O
B	O
##MI	O
,	O
lip	O
##ids	O
,	O
and	O
F	O
##P	O
##G	O
.	O

The	O
anal	O
##yte	O
standards	O
(	O
listed	O
in	O
Table	O
1	O
)	O
were	O
purchased	O
from	O
Sigma	O
-	O
Al	O
##dric	O
##h	O
(	O
Gill	O
##ingham	O
,	O
U	O
.	O
K	O
.	O
)	O
except	O
for	O
neo	B
##pt	I
##eri	I
##n	I
,	O
N	O
##AD	O
_	O
+	O
,	O
and	O
q	B
##uin	I
##olin	I
##ic	I
acid	I
,	O
which	O
were	O
purchased	O
from	O
C	O
##ayman	O
Chemical	O
##s	O
(	O
Ann	O
Arbor	O
,	O
MI	O
,	O
U	O
.	O
S	O
.	O
A	O
.	O
)	O
,	O
and	O
ni	B
##cot	I
##ini	I
##c	I
rib	I
##os	I
##ide	I
,	O
which	O
was	O
purchased	O
from	O
Toronto	O
Research	O
Chemical	O
##s	O
(	O
Toronto	O
,	O
Canada	O
)	O
.	O

The	O
reduced	O
u	B
##rea	I
concentration	O
can	O
be	O
either	O
explained	O
by	O
reduced	O
amino	O
acid	O
breakdown	O
or	O
by	O
nitrogen	O
im	O
##bal	O
##ance	O
with	O
increased	O
disposal	O
of	O
N	O
,	O
.	O

Un	O
##iva	O
##ria	O
##te	O
analysis	O
of	O
6	O
##h	O
-	O
i	O
##A	O
##UC	O
##s	O
for	O
la	B
##ct	I
##ose	I
,	O
gal	B
##act	I
##ose	I
,	O
and	O
gal	B
##act	I
##ona	I
##te	I
resulted	O
in	O
significant	O
differences	O
between	O
their	O
post	O
##pra	O
##ndi	O
##al	O
response	O
after	O
the	O
intake	O
of	O
milk	O
,	O
cheese	O
,	O
and	O
so	O
##y	O
drink	O
.	O

Beta	B
##ine	I
is	O
required	O
for	O
re	O
##met	O
##hyl	O
##ation	O
of	O
ho	B
##mo	I
##cy	I
##stein	I
##e	I
to	O
met	B
##hi	I
##oni	I
##ne	I
,	O
a	O
precursor	O
of	O
the	O
universal	O
met	O
##hyl	O
donor	O
SA	O
##M	O
[	O
,	O
]	O
.	O

In	O
the	O
valid	O
##ation	O
co	O
##hor	O
##t	O
,	O
plasma	O
concentrations	O
of	O
la	B
##ct	I
##ate	I
and	O
total	O
ch	B
##ole	I
##ster	I
##ol	I
were	O
independently	O
determined	O
on	O
the	O
day	O
the	O
blood	O
was	O
drawn	O
at	O
the	O
Ra	O
##ng	O
##ue	O
##il	O
hospital	O
B	O
##io	O
##chemistry	O
department	O
.	O

(	O
P	O
##m	O
/	O
R	O
##p	O
&	O
T	O
##i	O
:	O
3	O
.	O
8	O
%	O
,	O
R	O
##p	O
/	O
P	O
##m	O
&	O
T	O
##i	O
:	O
3	O
.	O
2	O
%	O
,	O
T	O
##i	O
/	O
P	O
##m	O
&	O
R	O
##p	O
:	O
3	O
.	O
4	O
%	O
)	O
,	O
ben	B
##zoic	I
acid	I
and	O
derivatives	O
(	O
P	O
##m	O
/	O
R	O
##p	O
&	O
T	O
##i	O
:	O
3	O
.	O
5	O
%	O
,	O
R	O
##p	O
/	O
P	O
##m	O
&	O
T	O
##i	O
:	O
3	O
.	O
2	O
%	O
,	O
T	O
##i	O
/	O
P	O
##m	O
&	O
R	O
##p	O
:	O
2	O
.	O
2	O
%	O
)	O
,	O
fl	B
##av	I
##ono	I
##ids	I
(	O
P	O
##m	O
/	O
R	O
##p	O
&	O
T	O
##i	O
:	O
3	O
.	O
3	O
%	O
,	O
R	O
##p	O
/	O
P	O
##m	O
&	O
T	O
##i	O
:	O
4	O
.	O
2	O
%	O
,	O
T	O
##i	O
/	O
P	O
##m	O
&	O
R	O
##p	O
:	O
3	O
.	O
6	O
%	O
)	O
,	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
(	O
P	O
##m	O
/	O
R	O
##p	O
&	O
T	O
##i	O
:	O
3	O
.	O
0	O
%	O
,	O
R	O
##p	O
/	O
P	O
##m	O
&	O
T	O
##i	O
:	O
2	O
.	O
9	O
%	O
,	O
T	O
##i	O
/	O
P	O
##m	O
&	O
R	O
##p	O
:	O
2	O
.	O
2	O
%	O
)	O
,	O
p	O
##hen	O
##ols	O
(	O
P	O
##m	O
/	O
R	O
##p	O
&	O
T	O
##i	O
:	O
3	O
.	O
0	O
%	O
,	O
R	O
##p	O
/	O
P	O
##m	O
&	O
T	O
##i	O
:	O
4	O
.	O
5	O
%	O
,	O
T	O
##i	O
/	O
P	O
##m	O
&	O
R	O
##p	O
:	O
4	O
.	O
7	O
%	O
)	O
,	O
fatty	O
alcohol	O
##s	O
(	O
P	O
##m	O
/	O
R	O
##p	O
&	O
T	O
##i	O
:	O

O	O
##xi	O
##dation	O
of	O
this	O
compound	O
with	O
m	B
-	I
ch	I
##lor	I
##oper	I
##ben	I
##zoic	I
acid	I
led	O
to	O
the	O
formation	O
of	O
the	O
anticipated	O
su	B
##lf	I
##oxide	I
product	O
,	O
8	O
.	O

In	O
multiple	O
re	O
##gression	O
,	O
c	B
##it	I
##ru	I
##llin	I
##e	I
was	O
an	O
independent	O
predict	O
##or	O
of	O
serum	O
a	B
##rg	I
##ini	I
##ne	I
concentrations	O
in	O
active	O
(	O
r	O
_	O
p	O
=	O
0	O
.	O
50	O
,	O
p	O
=	O
0	O
.	O
00	O
##1	O
)	O
and	O
inactive	O
CD	O
(	O
r	O
_	O
p	O
=	O
0	O
.	O
64	O
,	O
p	O
=	O
0	O
.	O
04	O
##5	O
)	O
,	O
explaining	O
,	O
respectively	O
,	O
25	O
%	O
(	O
R	O
_	O
2	O
=	O
0	O
.	O
253	O
;	O
F	O
=	O
12	O
.	O
5	O
,	O
p	O
=	O
0	O
.	O
00	O
##1	O
)	O
and	O
41	O
%	O
(	O
R	O
_	O
2	O
=	O
0	O
.	O
41	O
##4	O
;	O
F	O
=	O
5	O
.	O
7	O
,	O
p	O
=	O
0	O
.	O
04	O
##5	O
)	O
in	O
its	O
var	O
##iability	O
.	O

Cox	O
proportional	O
hazard	O
analysis	O
for	O
3	O
-	O
year	O
major	O
adverse	O
clinical	O
events	O
for	O
a	O
##rg	O
##ini	O
##ne	O
met	O
##hyl	O
##ation	O
and	O
global	O
a	B
##rg	I
##ini	I
##ne	I
bio	O
##ava	O
##ila	O
##bility	O
,	O
adjusted	O
for	O
re	O
##nal	O
function	O
and	O
cardiac	O
risk	O
factors	O
as	O
well	O
as	O
s	O
##tra	O
##ti	O
##fied	O
according	O
to	O
primary	O
and	O
secondary	O
prevention	O
co	O
##hor	O
##ts	O
.	O

There	O
are	O
conflicting	O
reports	O
,	O
with	O
other	O
studies	O
ill	O
##ust	O
##rating	O
increases	O
or	O
no	O
alter	O
##ation	O
in	O
plasma	O
lip	O
##op	O
##rote	O
##in	O
levels	O
.	O
_	O
,	O
Inc	O
##rease	O
##s	O
in	O
the	O
concentration	O
of	O
is	B
##ole	I
##uc	I
##ine	I
,	O
v	B
##ali	I
##ne	I
,	O
glucose	S
and	O
my	O
##o	O
-	O
in	O
##os	O
##ito	O
##l	O
were	O
observed	O
in	O
plasma	O
samples	O
from	O
patients	O
with	O
high	O
end	O
##os	O
##copic	O
activity	O
[	O
UC	O
##EI	O
##S	O
≥	O
3	O
]	O
.	O

A	O
similar	O
observation	O
was	O
reported	O
by	O
Dal	O
##li	O
et	O
al	O
.	O
,	O
where	O
higher	O
plasma	O
concentrations	O
of	O
SP	O
##Ms	O
including	O
R	O
##v	O
##D	O
##1	O
,	O
R	O
##v	O
##D	O
##5	O
,	O
and	O
(	O
N	O
)	O
PD	O
##1	O
and	O
pathway	O
marker	O
17	B
-	I
HD	I
##HA	I
in	O
se	O
##psis	O
non	O
-	O
survivors	O
were	O
found	O
.	O

Ace	B
##tate	I
is	O
the	O
final	O
product	O
of	O
lip	O
##id	O
metabolism	O
and	O
it	O
can	O
be	O
cat	O
##aly	O
##zed	O
to	O
ace	B
##ty	I
##l	I
-	I
co	I
##en	I
##zy	I
##me	I
A	O
(	B
ace	B
##ty	I
##l	I
-	I
Co	I
##A	I
)	O
by	O
ace	B
##ty	I
##l	I
-	I
Co	I
##A	I
s	O
##ynth	O
##eta	O
##se	O
.	O

G	B
##lu	I
##cos	I
##e	I
(	O
A	O
)	O
,	O
un	O
##sat	O
##ura	O
##ted	O
FA	B
18	I
:	I
1	I
(	O
B	O
)	O
and	O
18	O
:	O
2	O
(	O
C	O
)	O
,	O
shown	O
as	O
carbon	O
:	O
double	O
bond	O
ratio	O
.	O

The	O
administration	O
of	O
a	O
##que	O
##ous	O
leaf	O
extract	O
at	O
a	O
concentration	O
of	O
200	O
mg	O
/	O
kg	O
B	O
##W	O
share	O
almost	O
the	O
same	O
pattern	O
of	O
blood	O
glucose	S
reduction	O
as	O
Solo	O
##sa	O
,	O
with	O
a	O
pronounced	O
%	O
reduction	O
of	O
70	O
.	O
76	O
±	O
17	O
.	O
4	O
%	O
within	O
0	O
.	O
5	O
h	O
after	O
introduction	O
of	O
the	O
a	O
##que	O
##ous	O
leaf	O
extract	O
.	O

In	O
general	O
,	O
the	O
level	O
of	O
circulating	O
V	O
##LC	O
##FA	O
in	O
R	O
##R	O
##MS	O
tended	O
to	O
increase	O
with	O
their	O
disease	O
duration	S
(	O
data	O
not	O
shown	O
)	O
.	O

These	O
data	O
indicate	O
that	O
hydrogen	B
su	I
##l	I
##phi	I
##de	I
could	O
be	O
an	O
important	O
factor	O
in	O
the	O
progress	O
,	O
development	O
and	O
diagnosis	O
of	O
color	O
##ec	O
##tal	O
cancer	O
.	O

We	O
proposed	O
that	O
the	O
o	B
##xy	I
##lip	I
##in	I
meta	O
##bol	O
##ites	O
con	O
##stituting	O
T	O
##GR	O
##L	O
are	O
bio	O
##active	O
and	O
can	O
in	O
part	O
account	O
for	O
the	O
relative	O
at	O
##her	O
##ogenic	O
##ity	O
of	O
these	O
particles	O
by	O
altering	O
end	O
##oth	O
##eli	O
##al	O
inflammation	O
.	O

Following	O
application	O
of	O
the	O
samples	O
,	O
the	O
plate	O
was	O
washed	O
with	O
additional	O
volumes	O
of	O
phosphate	S
buffer	O
and	O
he	B
##xa	I
##nes	I
,	O
3	O
m	O
##L	O
each	O
,	O
before	O
el	O
##ution	O
with	O
1	O
.	O
25	O
m	O
##L	O
et	B
##hyl	I
ace	I
##tate	I
into	O
a	O
T	O
##ru	O
-	O
Ta	O
##per	O
96	O
-	O
well	O
collection	O
plate	O
(	O
Ana	O
##ly	O
##tical	O
Sales	O
and	O
Services	O
,	O
Cat	O
.	O

An	O
over	O
##load	O
of	O
SF	O
##A	O
in	O
response	O
to	O
the	O
test	O
meal	O
was	O
also	O
evident	O
as	O
a	O
decrease	O
in	O
the	O
ratio	O
of	O
M	O
##U	O
##FA	O
to	O
SF	O
##A	O
,	O
particularly	O
M	O
##U	O
##FA	O
##s	O
derived	O
from	O
palm	B
##itic	I
and	O
s	O
##te	O
##ari	O
##c	O
acids	O
.	O

In	O
c	O
##KO	O
mouse	O
the	O
N	B
##AD	I
##H	I
concentration	O
increased	O
relative	O
to	O
W	O
##T	O
mouse	O
,	O
which	O
results	O
in	O
increased	O
N	B
##AD	I
##H	I
/	O
N	O
##AD	O
_	O
+	O
ratio	O
relative	O
to	O
W	O
##T	O
.	O

L	B
##D	I
##L	I
ch	I
##ole	I
##ster	I
##ol	I
was	O
measured	O
using	O
en	O
##zy	O
##matic	O
color	O
##ime	O
##tric	O
methods	O
(	O
Roche	O
,	O
Mann	O
##heim	O
,	O
Germany	O
)	O
.	O

In	O
the	O
sum	O
of	O
the	O
ratios	O
of	O
de	O
##pur	O
##inating	O
add	O
##uc	O
##ts	O
to	O
est	B
##rogen	I
meta	O
##bol	O
##ites	O
and	O
con	O
##ju	O
##gate	O
##s	O
,	O
the	O
pre	O
##po	O
##nder	O
##ant	O
role	O
is	O
played	O
by	O
the	O
N	O
##3	O
##A	O
##de	O
and	O
N	O
##7	O
##G	O
##ua	O
add	O
##uc	O
##ts	O
of	O
4	O
-	O
OH	O
##E	O
_	O
1	O
(	O
E	O
_	O
2	O
)	O
,	O
whereas	O
the	O
add	O
##uc	O
##ts	O
of	O
2	O
-	O
OH	O
##E	O
_	O
1	O
(	O
E	O
_	O
2	O
)	O
play	O
a	O
very	O
minor	O
role	O
.	O

Data	O
regarding	O
body	O
weight	O
,	O
height	O
,	O
serum	O
car	O
##cin	O
##oe	O
##mb	O
##ryo	O
##nic	O
anti	O
##gen	O
(	O
CE	O
##A	O
)	O
,	O
Car	O
##bo	O
##hy	O
##dra	O
##te	O
anti	O
##gen	O
19	O
-	O
9	O
(	O
CA	O
19	O
-	O
9	O
)	O
,	O
pre	O
##al	O
##bu	O
##min	O
,	O
album	O
##in	O
,	O
c	B
##rea	I
##tin	I
##ine	I
,	O
t	B
##rig	I
##ly	I
##cer	I
##ide	I
,	O
total	O
ch	B
##ole	I
##ster	I
##ol	I
(	O
Total	O
-	O
C	O
)	O
,	O
high	O
-	O
density	O
lip	O
##op	O
##rote	O
##in	O
ch	B
##ole	I
##ster	I
##ol	I
(	O
HD	O
##L	O
-	O
C	O
)	O
,	O
low	O
-	O
density	O
lip	O
##op	O
##rote	O
##in	O
ch	B
##ole	I
##ster	I
##ol	I
(	O
L	O
##D	O
##L	O
-	O
C	O
)	O
,	O
lip	O
##op	O
##rote	O
##in	O
,	O
transfer	O
##rin	O
,	O
and	O
CR	O
##P	O
levels	O
were	O
collected	O
from	O
medical	O
records	O
.	O

The	O
demand	O
for	O
N	B
##AD	I
##P	I
##H	I
is	O
met	O
by	O
flux	O
through	O
various	O
pathways	O
in	O
multiple	O
cellular	O
compartment	O
##s	O
.	O

Small	O
molecules	O
have	O
been	O
identified	O
as	O
potential	O
diagnostic	O
bio	O
##mark	O
##ers	O
,	O
including	O
meta	O
##bol	O
##ites	O
,	O
fatty	O
acids	O
,	O
and	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
.	O

[	O
unpublished	O
]	O
,	O
have	O
higher	O
ni	B
##cot	I
##ine	I
dependence	O
scores	O
(	O
F	O
##T	O
##ND	O
2	O
.	O
0	O
vs	O
.	O
1	O
.	O
8	O
,	O
H	O
##ON	O
##C	O
4	O
.	O
5	O
vs	O
.	O
3	O
.	O
7	O
)	O

P	O
##las	O
##ma	O
total	O
and	O
high	O
‐	O
density	O
lip	O
##op	O
##rote	O
##in	O
(	B
HD	I
##L	I
)	I
‐	I
ch	I
##ole	I
##ster	I
##ol	I
,	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
and	O
glucose	S
concentrations	O
were	O
measured	O
from	O
ve	O
##nous	O
blood	O
samples	O
with	O
an	O
auto	O
##mat	O
##ized	O
en	O
##zy	O
##matic	O
ass	O
##ay	O
.	O

This	O
partition	O
##ing	O
is	O
attributed	O
to	O
the	O
diversion	O
of	O
upper	O
g	B
##ly	I
##co	I
##ly	I
##tic	I
intermediate	O
##s	O
towards	O
the	O
pen	B
##tos	I
##e	I
phosphate	I
pathway	O
for	O
the	O
synthesis	O
of	O
rib	B
##ose	I
-	I
5	I
-	I
phosphate	I
and	O
N	B
##AD	I
##P	I
##H	I
and	O
the	O
lower	O
intermediate	O
towards	O
the	O
T	O
##CA	O
cycle	O
or	O
one	O
-	O
carbon	O
metabolism	O
.	O

Dr	O
##ied	O
samples	O
were	O
re	O
##con	O
##stituted	O
in	O
3	O
m	O
##M	O
am	B
##mon	I
##ium	I
format	I
##e	I
(	O
pH	O
5	O
.	O
0	O
)	O
with	O
10	O
m	O
##M	O
dim	O
##eth	O
##yl	O
he	O
##xy	O
##l	O
am	O
##ine	O
(	O
D	O
##M	O
##HA	O
)	O
in	O
water	O
for	O
analysis	O
.	O

Despite	O
being	O
at	O
least	O
as	O
potent	O
as	O
AD	B
##MA	I
(	O
Su	O
##pp	O
##lement	O
##ary	O
Fi	O
##g	O
.	O

The	O
commercial	O
standard	O
mixture	O
consisted	O
of	O
50	O
μ	O
##M	O
car	B
##box	I
##yme	I
##thy	I
##l	I
##cy	I
##stein	I
##e	I
,	O
10	O
μ	O
##M	O
ni	B
##cot	I
##ini	I
##c	I
acid	I
,	O
8	O
μ	O
##M	O
ad	B
##eno	I
##sin	I
##e	I
,	O
80	O
μ	O
##M	O
ben	B
##zoic	I
acid	I
,	O
100	O
μ	O
##M	O
N	B
-	I
ben	I
##zo	I
##yl	I
##ty	I
##ros	I
##ine	I
,	O
20	O
μ	O
##M	O
g	B
##lut	I
##ari	I
##c	I
acid	I
,	O
20	O
μ	O
##M	O
glucose	B
-	I
c	I
##ys	I
##tein	I
##e	I
,	O
20	O
μ	O
##M	O
le	B
##uc	I
##ine	I
,	O
p	B
##hen	I
##yla	I
##lani	I
##ne	I
,	O
20	O
μ	O
##M	O
pan	B
##to	I
##the	I
##nic	I
acid	I
and	O
20	O
μ	O
##M	O
met	B
##hyl	I
-	I
2	I
-	I
amino	I
##ben	I
##zoic	I
acid	I
,	O
in	O
water	O
.	O

The	O
enzyme	O
T	O
##P	O
##H1	O
,	O
which	O
is	O
involved	O
in	O
the	O
production	O
of	O
se	B
##rot	I
##oni	I
##n	I
,	O
was	O
down	O
-	O
regulated	O
in	O
[UNK]	O
%	O
of	O
the	O
patient	O
samples	O
(	O
B	O
)	O
.	O

Form	B
##ic	I
acid	I
,	O
met	B
##han	I
##ol	I
and	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
were	O
obtained	O
from	O
Me	O
##rc	O
##k	O
(	O
Me	O
##rc	O
##k	O
K	O
##G	O
##a	O
##A	O
,	O
Dar	O
##ms	O
##tadt	O
,	O
Germany	O
)	O
.	O

p	B
(	I
x	I
,	I
y	I
;	I
Θ	I
)	I
p	I
(	I
x	I
,	I
y	I
;	I
Θ	I
)	I
p	I
(	I
x	I
,	I
y	I
;	I
Θ	I
)	I
p	I
(	I
x	I
,	I
y	I
;	I
Θ	I
)	I

Therefore	O
,	O
a	B
##rg	I
##ini	I
##ne	I
de	O
##p	O
##ri	O
##vation	O
may	O
offer	O
a	O
potential	O
treatment	O
method	O
for	O
lung	O
cancer	O
.	O

Once	O
at	O
room	O
temperature	O
,	O
the	O
samples	O
were	O
mixed	O
on	O
an	O
E	O
##ppe	O
##ndo	O
##rf	O
Mix	O
##M	O
##ate	O
and	O
50	O
μ	O
##l	O
of	O
plasma	O
was	O
transferred	O
into	O
a	O
2	O
-	O
m	O
##l	O
p	B
##oly	I
##p	I
##rop	I
##yle	I
##ne	I
E	O
##ppe	O
##ndo	O
##rf	O
tube	O
.	O

Port	O
##ion	O
of	O
a	O
typical	O
800	O
MHz	O
_	O
1	O
H	O
N	O
##MR	O
spectrum	O
of	O
a	O
mouse	O
heart	O
tissue	O
showing	O
characteristic	O
peaks	O
for	O
the	O
co	O
##en	O
##zy	O
##mes	O
:	O
N	O
##AD	O
_	O
+	O
(	B
ni	B
##cot	I
##ina	I
##mi	I
##de	I
ad	I
##eni	I
##ne	I
din	O
##uc	O
##leo	O
##tide	O
,	O
o	O
##xi	O
##dized	O
)	O
,	O
N	B
##AD	I
##H	I
(	I
ni	I
##cot	I
##ina	I
##mi	I
##de	I
ad	I
##eni	I
##ne	I
din	I
##uc	I
##leo	I
##tide	I
,	I
reduced	I
)	I
,	O
N	O
##AD	O
##P	O
_	O
+	O
(	B
ni	B
##cot	I
##ina	I
##mi	I
##de	I
ad	I
##eni	I
##ne	I
din	O
##uc	O
##leo	O
##tide	O
phosphate	S
,	O
o	O
##xi	O
##dized	O
)	O
,	O
N	B
##AD	I
##P	I
##H	I
(	I
ni	I
##cot	I
##ina	I
##mi	I
##de	I
ad	I
##eni	I
##ne	I
din	I
##uc	I
##leo	I
##tide	I
phosphate	I
,	I
reduced	I
)	I
;	O
ATP	S
(	O
ad	O
##eno	O
##sin	O
##e	O
trip	B
##hos	I
##phate	I
)	O
,	O
AD	B
##P	I
(	O
ad	O
##eno	O
##sin	O
##e	O
dip	B
##hos	I
##phate	I
)	O
and	O
AM	B
##P	I
(	O
ad	O
##eno	O
##sin	O
##e	O
mon	B
##op	I
##hos	I
##phate	I
)	O
.	O

For	O
separation	O
of	O
the	O
PS	O
derivatives	O
,	O
solvent	O
A	O
was	O
water	O
containing	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
,	O
and	O
solvent	O
B	O
was	O
met	O
##han	O
##ol	O
/	O
ace	O
##ton	O
##it	O
##ril	O
##e	O
(	O
40	O
:	O
60	O
,	O
v	O
/	O
v	O
)	O
.	O

Red	O
##uce	O
##d	O
K	O
##re	O
##bs	O
cycle	O
activity	O
and	O
g	B
##ly	I
##cer	I
##ol	I
shut	O
##tling	O
induced	O
reduced	O
production	O
of	O
N	B
##AD	I
##H	I
(	O
a	O
)	O
in	O
h	O
##y	O
##po	O
##gon	O
##adi	O
##sm	O
,	O
as	O
well	O
as	O
that	O
of	O
ATP	S
(	O
b	O
)	O
,	O
both	O
of	O
which	O
were	O
parallel	O
##ed	O
by	O
increase	O
concentrations	O
of	O
N	B
##AD	I
and	O
AM	B
##P	I
.	O

Two	O
of	O
the	O
five	O
characteristic	O
meta	O
##bol	O
##ites	O
,	O
u	B
##ric	I
acid	I
and	O
x	B
##ant	I
##hine	I
,	O
are	O
linked	O
metabolic	O
##ally	O
and	O
are	O
both	O
involved	O
in	O
the	O
pu	B
##rine	I
degradation	O
pathway	O
.	O

Sub	O
##jects	O
were	O
excluded	O
if	O
taking	O
s	B
##tat	I
##ins	I
or	O
other	O
medication	O
or	O
diet	O
##ary	O
supplement	O
##s	O
that	O
may	O
affect	O
lip	O
##ids	O
.	O

The	O
mobile	O
phases	O
were	O
(	O
A	O
)	O
100	O
%	O
water	O
and	O
(	O
B	O
)	O
100	O
%	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
with	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
.	O

In	O
addition	O
to	O
their	O
role	O
in	O
energy	O
metabolism	O
,	O
g	B
##ly	I
##cer	I
##oli	I
##pid	I
##s	I
have	O
roles	O
in	O
cellular	O
signaling	O
for	O
many	O
biological	O
processes	O
,	O
.	O

Based	O
on	O
L	O
##C	O
-	O
MS	O
metabolic	O
pro	O
##fi	O
##ling	O
methods	O
,	O
nine	O
meta	O
##bol	O
##ites	O
were	O
identified	O
in	O
this	O
study	O
:	O
pro	B
##sta	I
##g	I
##land	I
##in	I
C	O
##1	O
,	O
r	B
##ici	I
##no	I
##le	I
##ic	I
acid	I
,	O
o	B
##le	I
##ic	I
acid	I
amid	I
##e	I
,	O
et	O
##hyl	O
do	O
##cos	O
##ah	O
##ex	O
##aen	O
##oi	O
##c	O
,	O
h	O
##ulu	O
##pa	O
##pe	O
##pt	O
##ide	O
,	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##let	I
##han	I
##ola	I
##mine	I
0	I
:	I
0	I
/	I
22	I
:	I
4	I
,	O
c	B
##ys	I
##tein	I
##yl	I
-	I
l	I
##ys	I
##ine	I
,	O
met	B
##ha	I
##cho	I
##line	I
,	O
and	O
vitamin	B
K	I
##2	I
,	O
which	O
were	O
used	O
to	O
make	O
up	O
a	O
receiver	O
operating	O
characteristics	O
(	O
R	O
##OC	O
)	O
curve	O
,	O
a	O
model	O
for	O
predict	O
##ing	O
ch	O
##em	O
##otherapy	O
response	O
.	O

Cho	B
##les	I
##tero	I
##l	I
est	I
##er	I
(	O
CE	O
)	O
species	O
were	O
corrected	O
for	O
response	O
factors	O
determined	O
for	O
each	O
species	O
.	O

Is	O
##oto	O
##pe	O
labeled	O
AD	B
##MA	I
(	I
2	I
,	I
3	I
,	I
3	I
,	I
4	I
,	I
4	I
,	I
5	I
,	I
5	I
-	I
D	I
##7	I
-	I
AD	I
##MA	I
,	I
98	I
%	I
)	I
,	O
and	O
L	O
-	O
a	O
##rg	O
##ini	O
##ne	O
:	O
h	O
##ydro	O
##ch	O
##lor	O
##ic	O
acid	O
(	B
D	B
##7	I
-	I
a	I
##rg	I
##ini	I
##ne	I
,	O
98	O
%	O
)	O
were	O
purchased	O
from	O
Cambridge	O
Is	O
##oto	O
##pe	O
Laboratories	O
(	O
Te	O
##w	O
##ks	O
##bury	O
,	O
MA	O
,	O
USA	O
)	O
.	O

It	O
is	O
therefore	O
worth	O
noting	O
that	O
groups	O
2	O
and	O
3	O
have	O
higher	O
u	O
##rina	O
##ry	O
levels	O
of	O
PA	B
##G	I
and	O
try	B
##pt	I
##op	I
##han	I
,	O
compared	O
to	O
healthy	O
subjects	O
.	O

This	O
results	O
in	O
the	O
accumulation	O
of	O
ace	B
##ty	I
##l	I
-	I
Co	I
##A	I
and	O
se	O
##quential	O
##ly	O
alter	O
##s	O
the	O
T	O
##CA	O
cycle	O
,	O
and	O
pu	B
##rine	I
,	O
p	B
##yr	I
##u	I
##vate	I
metabolism	O
##s	O
[	O
,	O
]	O
.	O

Thus	O
,	O
in	O
our	O
study	O
,	O
we	O
observed	O
decreased	O
levels	O
of	O
g	B
##ly	I
##cine	I
and	O
dim	B
##eth	I
##yl	I
##gly	I
##cine	I
when	O
the	O
u	O
##rina	O
##ry	O
meta	O
##bol	O
##omi	O
##c	O
profiles	O
of	O
PC	O
##a	O
patients	O
and	O
individuals	O
diagnosed	O
with	O
BP	O
##H	O
were	O
compared	O
.	O

This	O
is	O
known	O
to	O
be	O
the	O
source	O
of	O
L	B
-	I
gamma	I
-	I
g	I
##lut	I
##am	I
##yl	I
-	I
L	I
-	I
is	I
##ole	I
##uc	I
##ine	I
which	O
is	O
newly	O
identified	O
here	O
as	O
u	O
##rem	O
##ic	O
and	O
of	O
ho	B
##mo	I
##ci	I
##tr	I
##ull	I
##ine	I
,	O
pro	B
##ly	I
##l	I
##hy	I
##dr	I
##ox	I
##y	I
##p	I
##rol	I
##ine	I
,	O
and	O
C	B
-	I
man	I
##nos	I
##yl	I
##try	I
##pt	I
##op	I
##han	I
.	O

The	O
auto	O
##sa	O
##mple	O
##r	O
stability	O
(	O
2	O
–	O
8	O
##°	O
C	O
)	O
for	O
a	B
##bir	I
##ater	I
##one	I
was	O
demonstrated	O
to	O
de	O
##via	O
##te	O
no	O
more	O
than	O
±	O
##2	O
.	O
2	O
%	O
after	O
192	O
hours	O
,	O
and	O
was	O
therefore	O
considered	O
stable	O
for	O
at	O
least	O
8	O
days	O
.	O

Furthermore	O
,	O
we	O
noted	O
increased	O
levels	O
of	O
various	O
di	B
##sa	I
##cc	I
##hari	I
##des	I
and	O
t	O
##ri	O
sa	B
##cc	I
##hari	I
##des	I
,	O
possibly	O
resulting	O
from	O
amino	O
acid	O
cat	O
##ab	O
##olis	O
##m	O
during	O
se	O
##psis	O
.	O

The	O
latter	O
clearly	O
indicates	O
an	O
independent	O
influence	O
of	O
low	O
‐	O
ad	O
##herence	O
resulting	O
in	O
sub	O
##op	O
##ti	O
##mal	O
concentrations	O
of	O
active	O
ta	B
##mo	I
##xi	I
##fen	I
meta	O
##bol	O
##ites	O
.	O

Met	B
##yra	I
##po	I
##ne	I
is	O
a	O
drug	O
used	O
for	O
the	O
diagnosis	O
of	O
ad	O
##rena	O
##l	O
ins	O
##uff	O
##iciency	O
and	O
occasionally	O
for	O
treatment	O
of	O
C	O
##ushing	O
'	O
s	O
syndrome	O
.	O

Using	O
available	O
databases	O
,	O
this	O
compound	O
was	O
put	O
##ative	O
##ly	O
assigned	O
to	O
di	O
##f	O
##ru	O
##ct	O
##ose	O
an	O
##hy	O
##dr	O
##ide	O
,	O
a	O
non	O
-	O
dig	O
##est	O
##ible	O
di	B
##sa	I
##cc	I
##hari	I
##de	I
which	O
stimulate	O
##s	O
calcium	O
absorption	O
in	O
rat	O
and	O
human	O
in	O
##test	O
##ine	O
.	O

Multiple	O
R	O
##OC	O
curve	O
analyses	O
were	O
performed	O
to	O
evaluate	O
the	O
importance	O
of	O
disc	O
##rim	O
##inating	O
meta	O
##bol	O
##ites	O
;	O
we	O
chose	O
ta	B
##uri	I
##ne	I
,	O
al	B
##ani	I
##ne	I
,	O
and	O
BA	O
##IB	O
as	O
key	O
contributing	O
metabolic	O
markers	O
based	O
on	O
them	O
.	O

When	O
compared	O
to	O
previous	O
studies	O
conducted	O
in	O
human	O
CS	O
##F	O
samples	O
using	O
E	O
##SI	O
mass	O
s	O
##pect	O
##rome	O
##try	O
,	O
most	O
of	O
the	O
major	O
lip	O
##id	O
families	O
such	O
as	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
(	O
Mu	O
##dler	O
et	O
al	O
.	O
;	O
Ko	O
##si	O
##ce	O
##k	O
et	O
al	O
.	O
;	O
Ko	O
##si	O
##ce	O
##k	O
et	O
al	O
.	O
;	O
F	O
##onte	O
##h	O
et	O
al	O
.	O
)	O
,	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
##s	I
,	O
s	O
##tero	O
##ls	O
and	O
free	O
fatty	O
acids	O
(	O
Tour	O
##tel	O
##lot	O
##te	O
)	O
,	O
that	O
are	O
usually	O
analyzed	O
by	O
several	O
complementary	O
targeted	O
methods	O
,	O
were	O
detected	O
in	O
a	O
single	O
experiment	O
thanks	O
to	O
our	O
global	O
approach	O
.	O

This	O
compound	O
was	O
identified	O
as	O
2	B
-	I
amino	I
-	I
3	I
,	I
7	I
-	I
dim	I
##eth	I
##yl	I
##im	I
##ida	I
##zo	I
[	I
4	I
,	I
5	I
-	I
g	I
]	I
q	I
##uin	I
##ox	I
##ali	I
##ne	I
(	O
7	O
-	O
Me	O
##I	O
##g	O
##Q	O
##x	O
,	O
t	O
_	O
R	O
=	O
7	O
.	O
9	O
min	O
)	O
,	O
a	O
recently	O
discovered	O
linear	O
t	B
##ric	I
##yclic	I
ring	O
is	O
##omer	O
of	O
Me	O
##I	O
##Q	O
##x	O
.	O

P	O
##las	O
##ma	O
concentrations	O
of	O
all	O
ta	B
##mo	I
##xi	I
##fen	I
meta	O
##bol	O
##ites	O
were	O
affected	O
by	O
C	O
##YP	O
##2	O
##D	O
##6	O
p	O
##hen	O
##otype	O
with	O
a	O
strongest	O
effect	O
for	O
(	B
Z	I
)	I
‐	I
end	I
##ox	I
##ife	I
##n	I
(	O
Table	O
)	O
.	O

GA	B
##BA	I
is	O
an	O
important	O
inhibitor	O
##y	O
ne	O
##uro	O
##tra	O
##ns	O
##mit	O
##ter	O
.	O

A	B
##cy	I
##l	I
-	I
Co	I
##A	I
is	O
transformed	O
to	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
and	O
shuttle	O
##d	O
into	O
the	O
mitochondrial	O
matrix	O
for	O
degradation	O
via	O
the	O
β	O
-	O
oxidation	O
system	O
by	O
car	O
##ni	O
##tine	O
palm	O
##ito	O
##yl	O
##tra	O
##ns	O
##fer	O
##ase	O
1	O
(	O
CP	O
##T	O
##1	O
)	O
and	O
car	O
##ni	O
##tine	O
-	O
a	O
##cy	O
##l	O
##car	O
##ni	O
##tine	O
trans	O
##loc	O
##ase	O
(	O
CA	O
##CT	O
)	O
.	O

Sub	O
##jects	O
further	O
followed	O
the	O
trial	O
protocol	O
,	O
which	O
will	O
be	O
described	O
elsewhere	O
along	O
with	O
data	O
on	O
additional	O
bio	O
##mark	O
##ers	O
including	O
c	B
##rea	I
##tin	I
##ine	I
.	O

(	O
H	O
)	O
Q	O
##uant	O
##ification	O
of	O
I	O
##HC	O
for	O
TD	O
##O	O
##2	O
,	O
T	O
##P	O
##H1	O
,	O
and	O
se	B
##rot	I
##oni	I
##n	I
.	O

The	O
significant	O
fold	O
change	O
was	O
LP	B
##C	I
(	I
20	I
:	I
0	I
)	I
(	O
fold	O
-	O
change	O
=	O
4	O
.	O
08	O
)	O
.	O

While	O
the	O
c	B
##era	I
##mi	I
##de	I
family	O
included	O
both	O
increased	O
and	O
decreased	O
meta	O
##bol	O
##ites	O
;	O
only	O
increased	O
levels	O
of	O
meta	O
##bol	O
##ites	O
belonging	O
to	O
Cho	O
##E	O
,	O
PC	O
,	O
P	O
##E	O
and	O
SM	O
families	O
were	O
found	O
in	O
the	O
case	O
group	O
.	O

[	B
2	I
,	I
3	I
,	I
4	I
-	I
_	I
13	I
C	I
_	I
3	I
]	I
-	I
16	I
##α	I
-	I
OH	I
-	I
E	I
##2	I
(	B
[	B
_	I
13	I
C	I
_	I
3	I
]	I
-	I
16	I
##α	I
-	I
OH	I
-	I
E	I
##2	I
)	O
,	O
[	B
13	I
,	I
14	I
,	I
15	I
,	I
16	I
,	I
17	I
,	I
18	I
-	I
_	I
13	I
C	I
_	I
6	I
]	I
-	I
4	I
-	I
Me	I
##O	I
-	I
E	I
##2	I
(	B
[	B
_	I
13	I
C	I
_	I
6	I
]	I
-	I
4	I
-	I
Me	I
##O	I
-	I
E	I
##2	I
)	O
,	O
[	B
13	I
,	I
14	I
,	I
15	I
,	I
16	I
,	I
17	I
,	I
18	I
-	I
_	I
13	I
C	I
_	I
6	I
]	I
-	I
2	I
-	I
Me	I
##O	I
-	I
E	I
##2	I
(	B
[	B
_	I
13	I
C	I
_	I
6	I
]	I
-	I
2	I
-	I
Me	I
##O	I
-	I
E	I
##2	I
)	O
,	O
and	O
[	B
13	I
,	I
14	I
,	I
15	I
,	I
16	I
,	I
17	I
,	I
18	I
-	I
_	I
13	I
C	I
_	I
6	I
]	I
-	I
2	I
-	I
OH	I
-	I
E	I
##2	I
(	B
[	B
_	I
13	I
C	I
_	I
6	I
]	I
-	I
2	I
-	I
OH	I
-	I
E	I
##2	I
)	O
with	O
an	O
is	O
##oto	O
##pic	O
purity	O
of	O
99	O
%	O
were	O
purchased	O
from	O
Cambridge	O
Is	O
##oto	O
##pe	O
Laboratories	O
(	O
Cambridge	O
,	O
MA	O
)	O
.	O

First	O
##ly	O
,	O
133	O
meta	O
##bol	O
##ites	O
including	O
g	B
##ly	I
##cer	I
##oli	I
##pid	I
##s	I
,	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
,	O
s	O
##tero	O
##l	O
lip	O
##ids	O
and	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
were	O
selected	O
as	O
candidate	O
bio	O
##mark	O
##ers	O
for	O
initial	O
analysis	O
f	O
##ae	O
##ces	O
samples	O
from	O
advanced	O
neo	O
##p	O
##lasia	O
cases	O
,	O
color	O
##ec	O
##tal	O
cancer	O
and	O
cancer	O
-	O
free	O
controls	O
(	O
Discovery	O
Phase	O
)	O
.	O

Interest	O
##ingly	O
,	O
method	O
E	O
afforded	O
similar	O
results	O
at	O
neutral	O
pH	O
.	O
Both	O
z	O
##wi	O
##tter	O
##ion	O
##ic	O
methods	O
provided	O
a	O
favorable	O
,	O
relatively	O
uniform	O
peak	O
distribution	O
across	O
the	O
run	O
time	O
But	O
the	O
absence	O
of	O
ion	O
##ic	O
interactions	O
in	O
the	O
neutral	O
M	O
##M	O
and	O
amid	B
##e	I
methods	O
C	O
/	O
D	O
and	O
F	O
reduced	O
coverage	O
to	O
32	O
%	O
(	O
D	O
)	O
,	O
10	O
%	O
(	O
C	O
)	O
and	O
even	O
<	O
7	O
%	O
for	O
method	O
F	O
.	O
On	O
z	O
##wi	O
##tter	O
##ion	O
##ic	O
columns	O
,	O
retention	O
times	O
increased	O
in	O
the	O
order	O
c	O
##X	O
##MP	O
<	O
X	O
##MP	O
<	O
X	O
##DP	O
<	O
X	O
##TP	O
(	O
X	O
…	O
n	O
##uc	O
##leo	O
##base	O
,	O
c	O
…	O
c	O
##yclic	O
)	O
.	O

However	O
,	O
the	O
inclusion	O
of	O
the	O
S	O
##IL	O
analogue	O
as	O
an	O
internal	O
standard	O
in	O
the	O
ass	O
##ay	O
protocol	O
should	O
compensate	O
for	O
these	O
matrix	O
effects	O
when	O
q	O
##uant	O
##ifying	O
c	B
##it	I
##ru	I
##llin	I
##e	I
in	O
these	O
bio	O
##f	O
##lu	O
##ids	O
.	O

This	O
is	O
consistent	O
with	O
high	O
activity	O
of	O
both	O
bio	O
##sy	O
##nt	O
##hetic	O
(	B
ch	B
##olin	I
##e	I
kinase	O
)	O
and	O
cat	O
##ab	O
##olic	O
(	O
p	O
##hos	O
##pha	O
##ti	O
##dy	O
##l	O
##cho	O
##line	O
-	O
P	O
##LC	O
/	O
P	O
##LD	O
)	O
enzymes	O
observed	O
in	O
o	O
##var	O
##ian	O
car	O
##cin	O
##oma	O
contributing	O
to	O
the	O
observed	O
ch	O
##olin	O
##e	O
-	O
containing	O
compounds	O
accumulation	O
in	O
CR	O
##C	O
tumor	O
.	O

Finally	O
,	O
Shah	O
##am	O
and	O
associates	O
have	O
reported	O
that	O
BC	O
##AA	O
##s	O
are	O
among	O
a	O
cluster	O
of	O
meta	O
##bol	O
##ites	O
that	O
change	O
more	O
significantly	O
in	O
insulin	O
resistant	O
vs	O
normal	O
participants	O
during	O
a	O
glucose	S
tolerance	O
test	O
.	O

In	O
addition	O
,	O
an	O
early	O
diagnostic	O
model	O
for	O
G	O
##CA	O
was	O
established	O
based	O
on	O
the	O
relative	O
levels	O
of	O
four	O
key	O
bio	O
##mark	O
##ers	O
,	O
including	O
p	B
##hos	I
##ph	I
##ory	I
##l	I
##cho	I
##line	I
,	O
g	B
##ly	I
##co	I
##cho	I
##lic	I
acid	I
,	O
L	B
-	I
ace	I
##ty	I
##l	I
##car	I
##ni	I
##tine	I
and	O
a	B
##rac	I
##hi	I
##don	I
##ic	I
acid	I
.	O

Only	O
one	O
meta	O
##bol	O
##ite	O
α	B
-	I
Ke	I
##to	I
##g	I
##lut	I
##ari	I
##c	I
acid	I
followed	O
the	O
pattern	O
of	O
increased	O
concentration	O
in	O
ID	O
##C	O
compared	O
with	O
ben	O
##ign	O
and	O
control	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
aimed	O
to	O
identify	O
unique	O
metabolic	O
signatures	O
for	O
C	B
##IN	I
##s	I
and	O
c	O
##er	O
##vic	O
##al	O
cancer	O
##s	O
using	O
global	O
and	O
targeted	O
meta	O
##bol	O
##omi	O
##c	O
pro	O
##fi	O
##ling	O
.	O

In	O
contrast	O
,	O
my	O
##o	O
-	O
in	O
##os	O
##ito	O
##l	O
,	O
a	B
##rab	I
##ito	I
##l	I
,	O
is	B
##oc	I
##it	I
##ric	I
acid	I
,	O
g	B
##lu	I
##cu	I
##ronic	I
acid	I
,	O
l	B
-	I
or	I
##ni	I
##thin	I
##e	I
,	O
T	B
##MA	I
##O	I
,	O
SM	B
C	I
##16	I
:	I
1	I
,	O
l	B
-	I
t	I
##yr	I
##os	I
##ine	I
,	O
hip	B
##pur	I
##ic	I
acid	I
,	O
ch	B
##olin	I
##e	I
,	O
pseudo	B
##uri	I
##dine	I
,	O
and	O
potassium	O
show	O
positive	O
weights	O
and	O
therefore	O
tend	O
to	O
have	O
a	O
higher	O
concentration	O
in	O
older	O
men	O
.	O

We	O
found	O
that	O
the	O
total	O
abundance	O
of	O
t	B
##rig	I
##ly	I
##cer	I
##ide	I
(	O
T	O
##G	O
)	O
increased	O
significantly	O
in	O
b	O
##v	O
##FT	O
##D	O
,	O
whereas	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##ls	I
##eri	I
##ne	I
and	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##gly	I
##cer	I
##ol	I
decreased	O
significantly	O
in	O
b	O
##v	O
##FT	O
##D	O
.	O

In	O
parallel	O
to	O
the	O
reduction	O
of	O
le	B
##uc	I
##ine	I
,	O
we	O
observed	O
an	O
increase	O
in	O
circulating	O
levels	O
of	O
2	O
-	O
K	O
##IC	O
,	O
which	O
is	O
the	O
first	O
step	O
in	O
le	B
##uc	I
##ine	I
degradation	O
.	O

These	O
findings	O
,	O
combined	O
with	O
the	O
observation	O
of	O
decreased	O
T	O
##MA	O
and	O
met	B
##han	I
##ol	I
in	O
Group	O
3	O
subjects	O
,	O
suggest	O
a	O
potential	O
role	O
for	O
micro	O
##bio	O
##ta	O
co	O
-	O
metabolism	O
in	O
the	O
development	O
of	O
C	O
##MR	O
##F	O
##s	O
in	O
our	O
population	O
.	O

U	O
##rina	O
##ry	O
c	B
##rea	I
##tin	I
##ine	I
is	O
considered	O
as	O
a	O
“	O
house	O
-	O
keeping	O
meta	O
##bol	O
##ite	O
”	O
,	O
integral	O
##s	O
of	O
bin	O
##s	O
in	O
every	O
sample	O
were	O
sub	O
##tracted	O
by	O
the	O
level	O
of	O
bin	O
including	O
the	O
u	O
##rina	O
##ry	O
c	B
##rea	I
##tin	I
##ine	I
.	O

Ser	O
is	O
involved	O
in	O
de	O
no	O
##vo	O
c	B
##era	I
##mi	I
##de	I
synthesis	O
,	O
through	O
a	O
pathway	O
cat	O
##aly	O
##sed	O
by	O
se	O
##rine	O
-	O
palm	O
##ito	O
##yl	O
transfer	O
##ase	O
and	O
m	O
##od	O
##ulated	O
by	O
inflammatory	O
stimuli	O
such	O
as	O
IN	O
##F	O
##γ	O
and	O
T	O
##NF	O
##α	O
,	O
according	O
to	O
Mu	O
##S	O
inflammatory	O
path	O
##ogen	O
##esis	O
.	O

A	O
portion	O
of	O
each	O
individual	O
lip	O
##id	O
extract	O
(	O
approximately	O
100	O
µ	O
##l	O
)	O
was	O
treated	O
with	O
Li	O
##OM	O
##e	O
and	O
followed	O
by	O
being	O
washed	O
with	O
he	B
##xa	I
##ne	I
as	O
previously	O
described	O
.	O

We	O
have	O
successfully	O
q	O
##uant	O
##ified	O
u	O
##rina	O
##ry	O
D	O
##IM	O
after	O
up	O
##take	O
of	O
I	O
##3	O
##C	O
from	O
food	O
,	O
and	O
demonstrated	O
that	O
differences	O
in	O
g	B
##lu	I
##co	I
##bra	I
##ssi	I
##cin	I
exposure	O
are	O
reflected	O
in	O
u	O
##rina	O
##ry	O
D	O
##IM	O
levels	O
.	O

In	O
addition	O
,	O
a	O
subset	O
of	O
patients	O
were	O
also	O
subjected	O
to	O
ch	O
##em	O
##otherapy	O
with	O
the	O
following	O
distribution	O
:	O
AC	O
(	B
Ad	B
##ria	I
##my	I
##cin	I
+	I
Cy	I
##c	I
##lop	I
##hos	I
##pha	I
##mi	I
##de	I
(	O
AC	O
)	O
(	O
Sigma	O
,	O
St	O
Louis	O
,	O
M	O
##O	O
,	O
USA	O
)	O
)	O

The	O
s	B
##phi	I
##ngo	I
##lip	I
##id	I
(	O
m	O
/	O
z	O
=	O
74	O
##2	O
.	O
98	O
##86	O
##9	O
)	O
could	O
be	O
a	O
bio	O
##mark	O
##er	O
in	O
monitoring	O
patients	O
with	O
CR	O
##C	O
.	O

B	O
##ile	O
acids	O
and	O
s	B
##tat	I
##ins	I
share	O
transport	O
##ers	O
in	O
the	O
liver	O
and	O
in	O
##test	O
##ine	O
;	O
we	O
observed	O
that	O
increased	O
plasma	O
concentration	O
of	O
si	B
##m	I
##vas	I
##tat	I
##in	I
positively	O
co	O
##rrel	O
##ates	O
with	O
higher	O
levels	O
of	O
several	O
secondary	O
bi	O
##le	O
acids	O
.	O

Note	O
that	O
co	B
##rt	I
##ico	I
##ster	I
##one	I
concentrations	O
are	O
displayed	O
using	O
a	O
log	O
##ari	O
##th	O
##mic	O
scale	O
compared	O
to	O
linear	O
scales	O
for	O
the	O
other	O
s	O
##tero	O
##ids	O
.	O

Ser	O
##um	O
concentrations	O
of	O
g	B
##lut	I
##ami	I
##c	I
acid	I
were	O
significantly	O
lower	O
in	O
HC	O
##C	O
-	O
C	O
than	O
in	O
HC	O
##C	O
-	O
B	O
,	O
whereas	O
those	O
of	O
met	B
##hi	I
##oni	I
##ne	I
and	O
γ	B
-	I
G	I
##lu	I
-	I
G	I
##ly	I
-	I
G	I
##ly	I
were	O
significantly	O
higher	O
in	O
HC	O
##C	O
-	O
C	O
than	O
in	O
HC	O
##C	O
-	O
B	O
(	B
g	B
##lut	I
##ami	I
##c	I
acid	I
:	O
47	O
##5	O
.	O
4	O
±	O
206	O
.	O
7	O
vs	O
182	O
.	O
6	O
±	O
71	O
.	O
7	O
,	O
P	O
<	O
0	O
.	O
000	O
##1	O
;	O
met	B
##hi	I
##oni	I
##ne	I
:	O
37	O
.	O
1	O
±	O
36	O
.	O
1	O
vs	O
52	O
.	O
6	O
±	O
29	O
.	O
2	O
,	O
P	O
=	O
0	O
.	O
01	O
##6	O
;	O
γ	B
-	I
G	I
##lu	I
-	I
G	I
##ly	I
-	I
G	I
##ly	I
:	O
0	O
.	O
03	O
##5	O
±	O
0	O
.	O
05	O
##2	O
vs	O
0	O
.	O
109	O
±	O
0	O
.	O
106	O
,	O
P	O
=	O
0	O
.	O
00	O
##1	O
,	O
HC	O
##C	O
-	O
B	O
vs	O
HC	O
##C	O
-	O
C	O
,	O
mean	O
±	O
SD	O
)	O
(	O
Figure	O
-	O
C	O
)	O
.	O

The	O
independent	O
variables	O
were	O
:	O
study	O
group	O
(	O
controls	O
or	O
workers	O
)	O
,	O
age	O
(	O
years	O
)	O
,	O
log	O
_	O
10	O
c	B
##rea	I
##tin	I
##ine	I
(	O
g	O
/	O
L	O
)	O
,	O
log	O
_	O
10	O
co	B
##tin	I
##ine	I
(	O
µ	O
##g	O
/	O
L	O
)	O
,	O
presence	O
of	O
ho	O
##bb	O
##ies	O
at	O
home	O
involving	O
exposure	O
during	O
the	O
last	O
3	O
days	O
(	O
no	O
or	O
yes	O
)	O
.	O

It	O
is	O
noteworthy	O
that	O
the	O
exposure	O
time	O
am	O
##p	O
##li	O
##fies	O
the	O
toxicity	O
of	O
N	O
##N	O
in	O
bees	O
,	O
i	O
.	O
e	O
.	O
micro	O
-	O
colonies	O
of	O
b	O
##umble	O
##bee	O
##s	O
fed	O
with	O
im	O
##ida	O
##c	O
##lop	O
##rid	O
showed	O
a	O
phenomenon	O
:	O
at	O
one	O
tenth	O
of	O
the	O
concentration	O
of	O
the	O
to	B
##xin	I
in	O
feed	O
,	O
it	O
took	O
twice	O
as	O
long	O
to	O
produce	O
100	O
%	O
mortality	O
in	O
a	O
b	O
##umble	O
##bee	O
micro	O
colony	O
,	O
and	O
at	O
a	O
100	O
times	O
lower	O
dose	O
,	O
it	O
took	O
about	O
four	O
times	O
longer	O
to	O
produce	O
100	O
%	O
mortality	O
.	O

No	O
##menclature	O
:	O
1	O
,	O
lip	O
##id	O
;	O
2	O
,	O
beta	B
-	I
h	I
##ydro	I
##xy	I
but	I
##yra	I
##te	I
;	O
3	O
,	O
branched	O
amino	O
acids	O
;	O
4	O
,	O
al	B
##ani	I
##ne	I
;	O
5	O
,	O
g	O
##lut	O
##ama	O
##te	O
/	O
g	O
##lut	O
##amine	O
;	O
6	O
,	O
c	B
##rea	I
##tine	I
;	O
7	O
,	O
glucose	S
;	O
8	O
,	O
t	B
##yr	I
##os	I
##ine	I
;	O
9	O
,	O
his	B
##ti	I
##dine	I
.	O

The	O
associations	O
between	O
g	B
##ly	I
##co	I
##chen	I
##ode	I
##ox	I
##ych	I
##olate	I
,	O
a	O
secondary	O
bi	O
##le	O
acid	O
,	O
and	O
color	O
##ec	O
##tal	O
cancer	O
did	O
not	O
material	O
##ly	O
change	O
when	O
the	O
models	O
were	O
also	O
adjusted	O
for	O
history	O
of	O
gal	O
##l	O
##bla	O
##dder	O
disease	O
,	O
or	O
hormone	O
therapy	O
use	O
among	O
women	O
.	O

The	O
inhibitor	O
##y	O
influence	O
of	O
v	B
##al	I
##p	I
##roi	I
##c	I
acid	I
and	O
v	O
##al	O
##p	O
##roy	O
##l	O
‐	O
Co	O
##A	O
on	O
the	O
g	B
##ly	I
##cine	I
c	O
##lea	O
##vage	O
enzyme	O
complex	O
resulting	O
in	O
elevated	O
amounts	O
of	O
g	B
##ly	I
##cine	I
in	O
serum	O
has	O
been	O
known	O
since	O
1980	O
.	O

Nat	O
##rol	O
me	B
##lat	I
##oni	I
##n	I
,	O
2	O
.	O
5	O
mg	O
liquid	O
,	O
was	O
obtained	O
from	O
Botanical	O
Laboratories	O
(	O
Fe	O
##rn	O
##dale	O
,	O
WA	O
,	O
USA	O
)	O
.	O

Un	O
##ique	O
product	O
ions	O
were	O
observed	O
for	O
E	B
##2	I
,	I
16	I
##α	I
-	I
OH	I
-	I
E	I
##2	I
,	O
is	O
##omer	O
##ic	O
4	B
-	I
OH	I
-	I
E	I
##2	I
and	O
2	B
-	I
OH	I
-	I
E	I
##2	I
derivatives	O
at	O
m	O
/	O
z	O
36	O
##4	O
.	O
2	O
,	O
380	O
.	O
2	O
and	O
37	O
##9	O
.	O
2	O
,	O
respectively	O
.	O

Met	B
##han	I
##ol	I
and	O
is	B
##op	I
##rop	I
##ano	I
##l	I
(	O
gradient	O
grade	O
)	O
were	O
purchased	O
from	O
Me	O
##rc	O
##k	O
(	O
Dar	O
##ms	O
##tadt	O
,	O
Germany	O
)	O
.	O

The	O
Cy	O
##s	O
##34	O
residue	O
of	O
Al	O
##b	O
co	O
##valent	O
##ly	O
binds	O
a	O
wide	O
number	O
of	O
end	O
##ogen	O
##ous	O
l	O
##igan	O
##ds	O
,	O
metal	O
ions	O
,	O
and	O
ni	O
##tric	O
oxide	B
.	I
_	I
−	I
Because	O
of	O
its	O
high	O
abundance	O
,	O
metal	O
-	O
binding	O
capacity	O
,	O
and	O
red	O
##ox	O
properties	O
,	O
the	O
Cy	O
##s	O
##34	O
of	O
Al	O
##b	O
is	O
the	O
predominant	O
anti	O
##ox	O
##ida	O
##nt	O
in	O
plasma	O
.	O

An	O
Atlantic	S
d	O
##C	O
_	O
18	O
3	O
-	O
μ	O
##m	O
column	O
(	O
4	O
.	O
6	O
[	O
inside	O
diameter	O
]	O
by	O
150	O
mm	O
;	O
Waters	O
Corp	O
.	O
)	O
was	O
used	O
.	O

Next	O
,	O
the	O
+	O
E	O
##SI	O
R	B
##P	I
L	O
##C	O
-	O
MS	O
analysis	O
of	O
newly	O
-	O
prepared	O
a	O
##que	O
##ous	O
and	O
organic	O
layers	O
obtained	O
after	O
M	B
##T	I
##BE	I
extraction	O
found	O
that	O
a	O
##que	O
##ous	O
extract	O
##s	O
had	O
repeat	O
##ability	O
similar	O
to	O
that	O
of	O
met	B
##han	I
##ol	I
(	O
median	O
RS	O
##D	O
of	O
15	O
.	O
7	O
%	O
for	O
M	B
##T	I
##BE	I
a	O
##que	O
##ous	O
)	O
versus	O
16	O
.	O
0	O
%	O
RS	O
##D	O
for	O
met	B
##han	I
##ol	I
obtained	O
during	O
this	O
follow	O
-	O
up	O
experiment	O
.	O

(	O
A	O
)	O
Tri	B
##gly	I
##cer	I
##ide	I
(	O
T	O
##G	O
)	O
was	O
significantly	O
increased	O
in	O
F	O
##T	O
##D	O
serum	O
(	O
N	O
=	O
40	O
)	O
compared	O
to	O
controls	O
(	O
N	O
=	O
22	O
)	O
.	O

Long	O
-	O
chain	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
seemed	O
to	O
be	O
risk	O
factors	O
for	O
c	O
##ir	O
##r	O
##hos	O
##is	O
.	O

This	O
number	O
exceeded	O
common	O
work	O
##flow	O
##s	O
such	O
as	O
shotgun	O
lip	O
##ido	O
##mic	O
##s	O
(	O
250	O
in	O
S	O
.	O
c	B
##er	I
.	O
)	O
and	O
HP	O
##LC	O
analysis	O
(	O
ca	O
.	O
200	O
in	O
P	O
.	O
pastor	O
##is	O
[	O
,	O
]	O
)	O
Without	O
SF	O
##C	O
pre	O
##fra	O
##ction	O
##ation	O
,	O
only	O
150	O
lip	O
##ids	O
(	O
purple	O
and	O
white	O
bar	O
)	O
were	O
identified	O
in	O
Pi	O
##chia	O
pastor	O
##is	O
using	O
R	O
##P	O
-	O
H	O
##R	O
##MS	O
in	O
this	O
work	O
.	O

However	O
,	O
the	O
mean	O
diet	O
##ary	O
is	B
##of	I
##lav	I
##ones	I
intake	O
was	O
much	O
lower	O
(	O
0	O
.	O
3	O
mg	O
/	O
day	O
)	O
than	O
in	O
previous	O
reports	O
.	O

Cho	O
:	O
ch	B
##olin	I
##e	I
;	O
C	O
##re	O
:	O
c	B
##rea	I
##tin	I
##ine	I
;	O
P	O
##yr	O
:	O
p	B
##yr	I
##u	I
##vate	I
;	O
Al	O
##a	O
:	O
al	B
##ani	I
##ne	I
;	O
2	O
##H	O
##i	O
##B	O
:	O
2	B
-	I
h	I
##ydro	I
##xy	I
##is	I
##ob	I
##ut	I
##yra	I
##te	I
;	O
Lac	O
:	O
la	B
##ct	I
##ate	I
;	O
2	O
##H	O
##B	O
:	O
2	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
.	O

Of	O
the	O
meta	O
##bol	O
##ites	O
associated	O
with	O
the	O
7	O
lo	O
##ci	O
,	O
5	O
meta	O
##bol	O
##ites	O
(	O
B	O
##io	O
##crates	O
C	O
##8	O
,	O
C	O
##6	O
,	O
C	O
##0	O
,	O
C	O
##4	O
,	O
and	O
g	B
##ly	I
##cine	I
)	O
had	O
at	O
least	O
moderate	O
her	O
##ita	O
##bility	O
(	O
h	O
_	O
2	O
>	O
0	O
.	O
26	O
)	O
and	O
correlation	O
(	O
>	O
0	O
.	O
38	O
)	O
on	O
both	O
platforms	O
,	O
confirming	O
that	O
these	O
profiles	O
are	O
stable	O
and	O
re	O
##p	O
##rod	O
##uc	O
##ible	O
across	O
platforms	O
.	O

The	O
sample	O
was	O
loaded	O
onto	O
the	O
SP	O
##E	O
cartridge	O
,	O
washed	O
,	O
el	O
##uted	O
,	O
and	O
concentrated	O
;	O
was	O
re	O
##con	O
##stituted	O
in	O
met	O
##han	O
##ol	O
:	O
water	O
(	O
1	O
:	O
1	O
)	O
;	O
and	O
ultra	O
##per	O
##form	O
##ance	O
liquid	O
ch	O
##roma	O
##tography	O
/	O
tandem	O
mass	O
s	O
##pect	O
##rome	O
##try	O
(	O
UP	O
##LC	O
/	O
MS	O
-	O
MS	O
)	O
was	O
used	O
to	O
separate	O
and	O
analyze	O
the	O
32	O
est	B
##rogen	I
meta	O
##bol	O
##ites	O
and	O
DNA	O
add	O
##uc	O
##ts	O
in	O
urine	O
.	O

Area	O
under	O
the	O
curves	O
(	O
AU	O
##Cs	O
)	O
among	O
normal	O
,	O
C	B
##IN	I
##s	I
,	O
and	O
c	O
##er	O
##vic	O
##al	O
cancer	O
##s	O
.	O

According	O
to	O
two	O
previous	O
studies	O
conducted	O
in	O
healthy	O
and	O
T	O
##2	O
##D	O
Japanese	O
subjects	O
,	O
several	O
AA	O
##s	O
such	O
as	O
al	B
##ani	I
##ne	I
(	O
Al	O
##a	O
)	O
,	O
is	B
##ole	I
##uc	I
##ine	I
(	O
Il	O
##e	O
)	O
,	O
G	O
##lu	O
,	O
Pro	O
and	O
v	B
##ali	I
##ne	I
(	O
Val	O
)	O
displayed	O
a	O
positive	O
association	O
with	O
H	O
##OM	O
##A	O
-	O
I	O
##R	O
in	O
our	O
study	O
.	O

A	O
100	O
,	O
000	O
-	O
ng	O
/	O
m	O
##L	O
stock	O
solution	O
(	O
20	O
,	O
000	O
ng	O
/	O
m	O
##L	O
for	O
B	O
##UP	O
and	O
N	O
##B	O
##UP	O
)	O
was	O
created	O
in	O
met	B
##han	I
##ol	I
and	O
stored	O
at	O
−	O
##20	O
°C	O
.	O

For	O
cab	B
##oz	I
##anti	I
##ni	I
##b	I
total	O
extraction	O
recovery	O
was	O
additionally	O
determined	O
for	O
Q	O
##C	O
##X	O
##L	O
in	O
du	O
##plicate	O
.	O

Our	O
observations	O
might	O
suggest	O
that	O
the	O
level	O
of	O
total	O
4	B
-	I
Me	I
##O	I
-	I
E	I
##2	I
could	O
be	O
a	O
potential	O
bio	O
##mark	O
##er	O
for	O
breast	O
cancer	O
cases	O
.	O

We	O
selected	O
the	O
five	O
most	O
important	O
meta	O
##bol	O
##ites	O
as	O
metabolic	O
bio	O
##mark	O
##ers	O
of	O
the	O
V	O
.	O
SC	O
group	O
,	O
including	O
L	B
-	I
met	I
##hi	I
##oni	I
##ne	I
,	O
the	O
ratio	O
of	O
L	B
-	I
as	I
##par	I
##agi	I
##ne	I
to	O
L	B
-	I
as	I
##par	I
##tic	I
acid	I
,	O
g	B
##lut	I
##ari	I
##c	I
acid	I
,	O
L	B
-	I
so	I
##rb	I
##ose	I
and	O
van	B
##ill	I
##yl	I
##mand	I
##eli	I
##c	I
acid	I
(	O
Fi	O
##g	O
.	O
c	O
)	O
.	O

The	O
O	O
##PL	O
##S	O
-	O
D	O
##A	O
model	O
disc	O
##rim	O
##inating	O
between	O
control	O
and	O
w	B
##hey	I
(	O
(	O
b	O
)	O
)	O
points	O
to	O
the	O
higher	O
intensity	O
of	O
the	O
lip	O
##id	O
signals	O
from	O
CH	O
##3	O
groups	O
at	O
0	O
.	O
80	O
-	O
0	O
.	O
86	O
pp	O
##m	O
and	O
CH	O
##2	O
groups	O
at	O
1	O
.	O
18	O
-	O
1	O
.	O
28	O
pp	O
##m	O
.	O

Su	O
##pp	O
##ression	O
of	O
PC	O
resulted	O
in	O
the	O
de	O
##ple	O
##tions	O
of	O
ma	B
##late	I
and	O
c	B
##it	I
##rate	I
levels	O
as	O
expected	O
(	O
and	O
)	O
.	O

Moreover	O
,	O
increased	O
muscle	O
BC	O
##AA	O
oxidation	O
has	O
been	O
reported	O
to	O
improve	O
muscle	O
glucose	S
up	O
##take	O
in	O
metabolic	O
syndrome	O
by	O
enhancing	O
the	O
recycling	O
of	O
glucose	S
via	O
the	O
glucose	B
-	I
al	I
##ani	I
##ne	I
cycle	O
.	O

For	O
both	O
,	O
total	O
and	O
free	O
o	O
##xi	O
##dis	O
##ed	O
lip	O
##ids	O
,	O
the	O
extraction	O
was	O
performed	O
by	O
the	O
same	O
et	B
##hyl	I
ace	I
##tate	I
liquid	O
-	O
liquid	O
extraction	O
(	O
LL	O
##E	O
)	O
procedure	O
.	O

It	O
may	O
be	O
produced	O
in	O
reasonable	O
amounts	O
in	O
the	O
co	O
##lon	O
through	O
degradation	O
of	O
fiber	O
p	B
##ec	I
##tin	I
(	O
which	O
is	O
contained	O
in	O
fruit	O
,	O
vegetables	O
,	O
j	O
##elli	O
##es	O
,	O
milk	O
products	O
,	O
etc	O
.	O
)	O
and	O
taken	O
up	O
by	O
the	O
circulation	O
.	O

Additionally	O
,	O
a	O
further	O
significant	O
concentration	O
reduction	O
of	O
L	O
##ys	O
##o	O
##PC	O
##s	O
,	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dic	I
acid	I
and	O
increase	O
of	O
de	B
##hy	I
##dr	I
##op	I
##hy	I
##tos	I
##phi	I
##ngo	I
##sin	I
##e	I
in	O
the	O
L	O
##MCA	O
##D	O
group	O
might	O
be	O
responsible	O
for	O
the	O
L	O
##MCA	O
##D	O
group	O
suffering	O
more	O
severe	O
my	O
##oc	O
##ard	O
##ial	O
ne	O
##c	O
##rosis	O
than	O
the	O
non	O
-	O
L	O
##MCA	O
##D	O
group	O
after	O
ST	O
##EM	O
##I	O
episode	O
.	O

The	O
injected	O
samples	O
were	O
e	O
##qui	O
##li	O
##bra	O
##ted	O
with	O
water	O
containing	O
0	O
.	O
1	O
%	O
form	B
##ic	I
acid	I
.	O

B	O
##rief	O
##ly	O
,	O
the	O
ni	O
##tro	O
derivative	O
of	O
Ph	O
##IP	O
was	O
reduced	O
to	O
H	O
##ON	O
##H	O
-	O
Ph	O
##IP	O
with	O
h	B
##yd	I
##raz	I
##ine	I
and	O
P	O
##d	O
/	O
C	O
(	O
,	O
)	O
,	O
followed	O
by	O
pu	O
##rification	O
of	O
H	O
##N	O
##OH	O
-	O
Ph	O
##IP	O
with	O
a	O
Baker	O
C	O
##18	O
SP	O
##E	O
re	O
##sin	O
.	O

Various	O
reports	O
on	O
the	O
best	O
solvent	O
composition	O
for	O
meta	O
##bol	O
##ite	O
extraction	O
suggests	O
80	O
%	O
Me	B
##OH	I
in	O
H	O
_	O
2	O
O	O
[	O
,	O
]	O
;	O
however	O
,	O
50	O
%	O
Me	B
##OH	I
is	O
also	O
used	O
for	O
meta	O
##bol	O
##ite	O
extraction	O
of	O
ad	O
##here	O
##nt	O
cells	O
grown	O
under	O
10	O
%	O
FC	O
##S	O
.	O

Moreover	O
,	O
each	O
meta	O
##bol	O
##ite	O
has	O
significance	O
in	O
different	O
sample	O
types	O
–	O
he	B
##xa	I
##noy	I
##l	I
##car	I
##ni	I
##tine	I
in	O
oral	O
wash	O
and	O
2	O
-	O
H	O
##G	O
in	O
tumor	O
tissue	O
.	O

Some	O
so	O
##lut	O
##es	O
,	O
such	O
as	O
van	B
##ill	I
##ic	I
acid	I
and	O
in	B
##do	I
##le	I
-	I
3	I
-	I
met	I
##hyl	I
ace	I
##tate	I
,	O
are	O
themselves	O
found	O
in	O
plants	O
and	O
can	O
presumably	O
be	O
absorbed	O
intact	O
from	O
plant	O
foods	O
[	O
,	O
]	O
.	O

Three	O
sets	O
of	O
Q	O
##C	O
samples	O
in	O
pool	O
##ed	O
human	O
serum	O
displayed	O
97	O
.	O
3	O
%	O
,	O
98	O
.	O
5	O
%	O
,	O
and	O
96	O
.	O
8	O
%	O
average	O
pro	B
##line	I
amount	O
remaining	O
after	O
4	O
,	O
8	O
,	O
or	O
24	O
h	O
,	O
respectively	O
.	O

During	O
sleep	O
de	O
##p	O
##ri	O
##vation	O
,	O
27	O
meta	O
##bol	O
##ites	O
(	O
try	O
##pt	O
##op	O
##han	O
,	O
se	B
##rot	I
##oni	I
##n	I
,	O
ta	B
##uri	I
##ne	I
,	O
8	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
,	O
13	O
g	B
##ly	I
##cer	I
##op	I
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
,	O
and	O
3	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
)	O
exhibited	O
significantly	O
increased	O
levels	O
compared	O
with	O
during	O
sleep	O
.	O

G	O
##rad	O
##ient	O
el	O
##ution	O
was	O
performed	O
with	O
mobile	O
phase	O
A	O
)	O
10	O
m	O
##M	O
am	B
##mon	I
##ium	I
ace	I
##tate	I
in	O
water	O
and	O
B	O
)	O
15	O
%	O
met	B
##han	I
##ol	I
in	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
at	O
a	O
flow	O
rate	O
of	O
0	O
.	O
5	O
m	O
##L	O
/	O
min	O
.	O

Multi	O
##var	O
##iable	O
linear	O
re	O
##gression	O
models	O
were	O
adjusted	O
for	O
age	O
,	O
sex	O
,	O
body	O
-	O
mass	O
-	O
index	O
,	O
H	O
##b	O
##A	O
##1	O
##c	O
,	O
low	O
-	O
density	O
lip	O
##op	O
##rote	O
##in	O
ch	B
##ole	I
##ster	I
##ol	I
and	O
s	O
##ys	O
##to	O
##lic	O
blood	O
pressure	O
.	O

As	O
listed	O
in	O
,	O
X	O
differential	O
##ly	O
expressed	O
meta	O
##bol	O
##ites	O
in	O
liver	O
c	O
##ir	O
##r	O
##hos	O
##is	O
and	O
he	O
##pa	O
##titis	O
condition	O
including	O
in	B
##os	I
##ito	I
##l	I
,	O
2	B
,	I
2	I
′	I
-	I
bi	I
##py	I
##rid	I
##ine	I
,	O
met	B
##hi	I
##oni	I
##ne	I
,	O
a	B
##rg	I
##ini	I
##ne	I
,	O
s	B
##te	I
##ari	I
##c	I
acid	I
,	O
palm	B
##itic	I
acid	I
,	O
c	B
##it	I
##ric	I
acid	I
,	O
2	B
-	I
pipe	I
##rid	I
##ine	I
car	I
##box	I
##yl	I
##ic	I
acid	I
,	O
5	B
-	I
h	I
##ydro	I
##xy	I
-	I
try	I
##pt	I
##op	I
##han	I
,	O
and	O
t	B
##yr	I
##os	I
##ine	I
were	O
obtained	O
by	O
comparison	O
among	O
healthy	O
controls	O
,	O
ben	O
##ign	O
liver	O
tumor	O
patients	O
with	O
liver	O
c	O
##ir	O
##r	O
##hos	O
##is	O
and	O
he	O
##pa	O
##titis	O
,	O
HC	O
##C	O
with	O
liver	O
c	O
##ir	O
##r	O
##hos	O
##is	O
and	O
he	O
##pa	O
##titis	O
,	O
and	O
HC	O
##C	O
without	O
liver	O
c	O
##ir	O
##r	O
##hos	O
##is	O
and	O
he	O
##pa	O
##titis	O
.	O

We	O
find	O
little	O
or	O
no	O
evidence	O
to	O
support	O
the	O
assumption	O
,	O
inherent	O
in	O
many	O
of	O
these	O
studies	O
,	O
that	O
car	O
##cin	O
##ogenic	O
bay	O
region	O
di	B
##ol	I
e	I
##pox	I
##ides	I
of	O
PA	O
##H	O
are	O
de	O
##to	O
##xi	O
##fied	O
by	O
G	B
##S	I
##H	I
con	O
##ju	O
##gation	O
in	O
un	O
##ad	O
##ulter	O
##ated	O
human	O
cells	O
.	O

Therefore	O
,	O
we	O
took	O
the	O
ratio	O
of	O
S	B
-	I
ad	I
##eno	I
##sy	I
##l	I
-	I
l	I
-	I
met	I
##hi	I
##oni	I
##ne	I
and	O
N	B
-	I
ace	I
##ty	I
##ls	I
##per	I
##mi	I
##dine	I
as	O
argument	O
to	O
character	O
##ize	O
liver	O
and	O
lung	O
cancer	O
##ous	O
urine	O
.	O

Finally	O
,	O
pre	O
-	O
cooled	O
met	B
##han	I
##ol	I
was	O
added	O
for	O
fix	O
##ation	O
.	O

A	O
##bb	O
##re	O
##viation	O
##s	O
:	O
Ah	O
##r	O
:	O
a	B
##ryl	I
h	I
##ydro	I
##car	I
##bon	I
receptor	O
;	O
BP	O
##A	O
:	O
bi	B
##sp	I
##hen	I
##ol	I
A	O
;	O
CT	O
##R	O
:	O
controls	O
;	O
S	O
##IL	O
:	O
si	O
##ly	O
##bin	O
;	O
p	O
-	O
ER	O
##K	O
:	O
p	O
##hos	O
##ph	O
##ori	O
##li	O
##zed	O
extra	O
##cellular	O
signal	O
-	O
regulated	O
kinase	O
;	O
ER	O
##K	O
:	O
extra	O
##cellular	O
signal	O
-	O
regulated	O
kinase	O
;	O
AK	O
##T	O
:	O
protein	O
kinase	O
B	O
;	O
Si	O
##l	O
:	O
si	O
##ly	O
##bin	O
.	O

In	O
the	O
present	O
subset	O
of	O
1	O
,	O
208	O
men	O
,	O
only	O
one	O
had	O
a	O
border	O
##line	O
-	O
def	O
##icient	O
serum	O
re	B
##tino	I
##l	I
value	O
(	O
i	O
.	O
e	O
.	O
,	O
192	O
µ	O
##g	O
/	O
L	O
)	O
.	O

In	O
contrast	O
,	O
there	O
were	O
no	O
clear	O
associations	O
of	O
concentrations	O
of	O
any	O
of	O
the	O
lip	O
##op	O
##rote	O
##in	O
particles	O
or	O
their	O
ch	B
##ole	I
##ster	I
##ol	I
or	O
T	B
##G	I
constituents	O
with	O
I	O
##CH	O
.	O

Val	B
##ine	I
belongs	O
to	O
the	O
branched	O
amino	O
acids	O
group	O
(	O
BC	O
##CA	O
)	O
,	O
for	O
which	O
a	O
role	O
in	O
the	O
path	O
##op	O
##hy	O
##sio	O
##logy	O
of	O
liver	O
diseases	O
has	O
been	O
established	O
.	O

For	O
example	O
,	O
the	O
sensitivity	O
for	O
p	B
##yr	I
##u	I
##vic	I
acid	I
detected	O
in	O
positive	O
ion	O
mode	O
after	O
_	O
15	O
N	B
-	I
ch	I
##ola	I
##mine	I
tag	O
##ging	O
was	O
enhanced	O
by	O
a	O
factor	O
of	O
about	O
1500	O
when	O
compared	O
to	O
that	O
detected	O
for	O
the	O
same	O
meta	O
##bol	O
##ite	O
without	O
the	O
_	O
15	O
N	B
-	I
ch	I
##ola	I
##mine	I
tag	O
,	O
in	O
negative	O
ion	O
mode	O
.	O

In	O
addition	O
,	O
the	O
absorption	O
of	O
ch	B
##olin	I
##e	I
from	O
the	O
G	O
##I	O
tract	O
may	O
be	O
decreased	O
and	O
altered	O
G	O
##I	O
micro	O
##f	O
##lora	O
may	O
result	O
in	O
altered	O
metabolism	O
of	O
ch	B
##olin	I
##e	I
within	O
the	O
gut	O
.	O

(	O
D	O
)	O
C	B
##af	I
##fe	I
##ine	I
metabolism	O
.	O

A	O
complete	O
valid	O
##ation	O
was	O
performed	O
for	O
the	O
quantitative	O
analysis	O
of	O
3	O
-	O
O	O
-	O
G	O
##lu	O
##c	O
,	O
7	O
-	O
O	O
-	O
G	O
##lu	O
##c	O
,	O
and	O
3	B
,	I
7	I
-	I
O	I
-	I
Di	I
##g	I
##lu	I
##c	I
from	O
plasma	O
;	O
a	O
summary	O
of	O
results	O
is	O
presented	O
in	O
Table	O
.	O

Furthermore	O
,	O
G	O
##SS	O
##S	O
##G	O
,	O
c	B
##ys	I
##tine	I
,	O
and	O
Cy	O
##s	O
##SS	O
##H	O
levels	O
were	O
correlated	O
in	O
the	O
a	O
##que	O
##ous	O
and	O
v	O
##it	O
##re	O
##ous	O
humor	O
##s	O
.	O

Data	O
are	O
shown	O
as	O
percentage	O
of	O
_	O
13	O
C	O
_	O
16	O
-	O
C	O
##16	O
,	O
_	O
13	O
C	O
_	O
14	O
-	O
C	O
##14	O
,	O
or	O
_	O
13	O
C	O
_	O
12	O
-	O
C	O
##12	O
to	O
the	O
total	O
pool	O
of	O
each	O
corresponding	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
.	O

Whether	O
the	O
addition	O
of	O
l	O
##ys	O
##o	O
##PC	O
C	B
##22	I
:	I
5	I
and	O
try	B
##pt	I
##op	I
##han	I
to	O
s	O
##F	O
##lt	O
-	O
1	O
/	O
P	O
##l	O
##G	O
##F	O
may	O
enhance	O
the	O
performance	O
of	O
the	O
prediction	O
model	O
even	O
further	O
is	O
not	O
known	O
.	O

X	O
##RE	O
-	O
l	O
##uc	O
##ifer	O
##ase	O
reporter	O
activity	O
analyzed	O
after	O
24	O
h	O
treatment	O
with	O
is	B
##of	I
##lav	I
##ones	I
(	O
10	O
μ	O
##M	O
)	O
,	O
BA	O
,	O
F	O
##N	O
,	O
G	O
##N	O
,	O
and	O
D	O
##Z	O
,	O
in	O
(	O
A	O
)	O
HC	O
-	O
04	O
cells	O
and	O
(	O
B	O
)	O
in	O
MC	O
##F	O
-	O
7	O
cells	O
.	O

Another	O
meta	O
##bol	O
##ite	O
from	O
m	B
-	I
t	I
##yr	I
##os	I
##ine	I
,	O
3	B
-	I
h	I
##ydro	I
##xy	I
##phe	I
##ny	I
##l	I
##p	I
##rop	I
##ion	I
##ic	I
acid	I
,	O
converts	O
into	O
HP	O
##HP	O
##A	O
and	O
3	B
-	I
h	I
##ydro	I
##xy	I
##ben	I
##zoic	I
acid	I
in	O
order	O
as	O
reported	O
by	O
Shaw	O
;	O
the	O
latter	O
product	O
then	O
con	O
##ju	O
##gate	O
##s	O
with	O
g	B
##ly	I
##cine	I
and	O
forms	O
3	O
##H	O
##HA	O
.	O

Normal	O
##ized	O
fold	O
activation	O
relative	O
to	O
vehicle	O
-	O
treated	O
cells	O
is	O
shown	O
for	O
all	O
-	O
trans	O
-	O
re	O
##tino	O
##ic	O
acid	O
(	O
far	O
left	O
bar	O
in	O
each	O
his	O
##to	O
##gram	O
)	O
or	O
the	O
β	B
-	I
a	I
##po	I
##car	I
##ote	I
##no	I
##ids	I
resulting	O
from	O
c	O
##lea	O
##vage	O
at	O
the	O
“	O
a	O
”	O
,	O
“	O
b	O
”	O
,	O
“	O
c	O
”	O
,	O
or	O
“	O
d	O
”	O
sites	O
from	O
top	O
to	O
bottom	O
,	O
respectively	O
.	O

Changes	O
in	O
plasma	O
and	O
/	O
or	O
u	O
##rina	O
##ry	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
profiles	O
are	O
used	O
to	O
detect	O
disorders	O
in	O
fatty	O
acid	O
and	O
amino	O
acid	O
oxidation	O
[	O
,	O
]	O
.	O

C	B
##is	I
##p	I
##lat	I
##in	I
is	O
a	O
radios	O
##ens	O
##iti	O
##zing	O
agent	O
widely	O
applied	O
in	O
clinical	O
therapy	O
for	O
N	O
##PC	O
_	O
,	O
.	O

Previous	O
reports	O
have	O
shown	O
that	O
increased	O
se	B
##rine	I
and	O
th	B
##re	I
##oni	I
##ne	I
pathway	O
are	O
considered	O
to	O
be	O
an	O
important	O
sign	O
of	O
poor	O
pro	O
##gno	O
##sis	O
in	O
cancer	O
[	O
,	O
]	O
.	O

Closing	O
the	O
needle	O
valve	O
resulted	O
in	O
a	O
similarly	O
pro	B
##mpt	I
return	O
to	O
the	O
signal	O
in	O
##tens	O
##ities	O
prior	O
to	O
oz	O
##one	O
introduction	O
.	O

Conversely	O
,	O
high	O
my	B
##oi	I
##nos	I
##ito	I
##l	I
levels	O
have	O
been	O
noted	O
in	O
R	O
##R	O
##MS	O
and	O
clinical	O
##ly	O
isolated	O
syndrome	O
compared	O
with	O
controls	O
using	O
_	O
1	O
H	O
MR	O
##S	O
of	O
normal	O
-	O
appearing	O
white	O
matter	O
,	O
indicating	O
as	O
##tro	O
##cy	O
##tosis	O
and	O
as	O
##tro	O
##gli	O
##osis	O
.	O

For	O
instance	O
,	O
n	B
-	I
met	I
##hyl	I
-	I
α	I
-	I
amino	I
##is	I
##ob	I
##ut	I
##yric	I
acid	I
was	O
present	O
in	O
the	O
l	O
##yo	O
##phi	O
##li	O
##zed	O
samples	O
but	O
und	O
##ete	O
##cted	O
in	O
speed	O
-	O
vacuum	O
dried	O
samples	O
in	O
cell	O
extract	O
##s	O
prepared	O
from	O
all	O
three	O
cell	O
lines	O
.	O

Pre	O
##valence	O
of	O
Ana	O
##lge	O
##si	O
##c	O
Use	O
According	O
to	O
Det	O
##ec	O
##tion	O
of	O
U	O
##rina	O
##ry	O
Ace	B
##tam	I
##ino	I
##phe	I
##n	I
and	O
I	B
##bu	I
##p	I
##ro	I
##fen	I
Met	O
##ab	O
##oli	O
##tes	O
and	O
According	O
to	O
Self	O
-	O
Reports	O
Among	O
Male	O
Part	O
##ici	O
##pants	O
,	O
by	O
Country	O
and	O
Age	O
Group	O
,	O
International	O
Study	O
of	O
Mac	O
##ro	O
-	O
/	O
Micro	O
-	O
N	O
##ut	O
##rient	O
##s	O
and	O
Blood	O
Press	O
##ure	O
,	O
1996	O
–	O
1999	O
A	O
##bb	O
##re	O
##viation	O
:	O
_	O
1	O
H	O
N	O
##MR	O
,	O
hydrogen	B
-	I
1	I
nuclear	O
magnetic	O
resonance	O
.	O

Human	O
he	O
##pa	O
##to	O
##cellular	O
car	O
##cin	O
##oma	O
cells	O
(	O
He	O
##p	O
##G	O
##2	O
,	O
H	O
##B	O
-	O
80	O
##65	O
)	O
were	O
obtained	O
from	O
the	O
American	O
Type	O
Culture	O
Collection	O
(	O
AT	O
##CC	O
,	O
Man	O
##ass	O
##as	O
,	O
VA	S
,	O
USA	O
)	O
.	O

Met	O
##ab	O
##oli	O
##tes	O
significantly	O
associated	O
with	O
B	O
##MI	O
(	O
numbered	O
according	O
to	O
spectral	O
position	O
)	O
were	O
as	O
follows	O
:	O
1	O
:	O
k	B
##eto	I
##le	I
##uc	I
##ine	I
,	O
2	O
:	O
le	B
##uc	I
##ine	I
,	O
3	O
:	O
v	B
##ali	I
##ne	I
,	O
4	O
:	O
2	O
-	O
h	O
##ydro	O
##xy	O
##is	O
##ob	O
##ut	O
##yra	O
##te	O
,	O
5	O
:	O
al	B
##ani	I
##ne	I
,	O
6	O
:	O
l	B
##ys	I
##ine	I
,	O
7	O
:	O
N	O
-	O
ace	O
##ty	O
##l	O
signals	O
from	O
u	O
##rina	O
##ry	O
g	B
##ly	I
##co	I
##p	I
##rote	I
##ins	I
,	O
8	O
:	O
N	B
-	I
ace	I
##ty	I
##l	I
ne	I
##ura	I
##minate	I
,	O
9	O
:	O
p	B
##hen	I
##yla	I
##ce	I
##ty	I
##l	I
##g	I
##lut	I
##amine	I
,	O
10	O
:	O
g	B
##lut	I
##amine	I
,	O
11	O
:	O
pro	B
##line	I
beta	I
##ine	I
,	O
12	O
:	O
4	O
-	O
c	O
##res	O
##yl	O
su	O
##lf	O
##ate	O
,	O
13	O
:	O
su	B
##cci	I
##nate	I
,	O
14	O
:	O
c	B
##it	I
##rate	I
,	O
15	O
:	O
dim	B
##eth	I
##yla	I
##mine	I
,	O
16	O
:	O
T	O
##MA	O
,	O
17	O
:	O
dim	B
##eth	I
##yl	I
##gly	I
##cine	I
,	O
18	O
:	O
c	B
##rea	I
##tin	I
##ine	I
,	O
19	O
:	O
ethanol	B
##amine	I
,	O
20	O
:	O
O	B
-	I
ace	I
##ty	I
##l	I
car	I
##ni	I
##tine	I
,	O
21	O
:	O
glucose	S
,	O
22	O
:	O
3	O
-	O
met	O
##hyl	O
##his	O
##ti	O
##dine	O
,	O
23	O
:	O
g	B
##ly	I
##cine	I
,	O
24	O
:	O
hip	B
##pura	I
##te	I
,	O
25	O
:	O
pseudo	B
##uri	I
##dine	I
,	O
26	O
:	O
N	O
##M	O
##NA	O
,	O
27	O
:	O
3	O
-	O
h	O
##ydro	O
##xy	O
##mand	O
##ela	O
##te	O
,	O
28	O
:	O
t	B
##yr	I
##os	I
##ine	I
,	O
29	O
:	O
4	O
-	O
h	O
##ydro	O
##xy	O
##mand	O
##ela	O
##te	O
,	O
30	O

In	O
addition	O
,	O
while	O
measurement	O
of	O
the	O
cannabis	S
meta	O
##bol	O
##ites	O
was	O
a	O
strength	O
of	O
our	O
study	O
,	O
it	O
still	O
does	O
not	O
provide	O
information	O
about	O
route	O
of	O
cannabis	S
intake	O
(	O
i	O
##e	O
,	O
smoking	O
,	O
v	O
##ap	O
##ing	O
,	O
eating	O
)	O
,	O
nor	O
what	O
type	O
or	O
strain	O
of	O
cannabis	S
was	O
used	O
,	O
which	O
could	O
contribute	O
to	O
differences	O
in	O
inflammation	O
and	O
health	O
.	O

These	O
compounds	O
were	O
obtained	O
by	O
a	O
simple	O
reaction	O
between	O
Te	O
##m	O
or	O
4	B
,	I
4	I
′	I
-	I
th	I
##io	I
##di	I
##phe	I
##no	I
##l	I
with	O
sodium	B
h	I
##y	I
##po	I
##ch	I
##lor	I
##ite	I
or	O
potassium	O
period	O
##ate	O
,	O
and	O
were	O
characterized	O
by	O
I	O
##R	O
,	O
N	O
##MR	O
,	O
and	O
UP	O
##LC	O
-	O
H	O
##RE	O
##SI	O
##MS	O
.	O

Di	B
##os	I
##met	I
##in	I
obtained	O
after	O
en	O
##zy	O
##matic	O
dig	O
##est	O
##ion	O
,	O
both	O
from	O
plasma	O
and	O
urine	O
samples	O
,	O
was	O
ch	O
##roma	O
##to	O
##graph	O
##ed	O
on	O
an	O
amid	B
##e	I
column	O
(	O
As	O
##cent	O
##is	O
R	B
##P	I
-	I
Am	I
##ide	I
150	O
×	O
2	O
.	O
1	O
mm	O
,	O
5	O
μ	O
##m	O
,	O
Su	O
##pel	O
##co	O
,	O
Belle	O
##fo	O
##nte	O
,	O
USA	O
)	O
el	O
##uted	O
with	O
a	O
mobile	O
phase	O
gradient	O
(	O
Method	O
1	O
)	O
.	O

Similarly	O
,	O
s	B
##phi	I
##ngo	I
##sin	I
##e	I
-	I
1	I
-	I
phosphate	I
levels	O
were	O
not	O
affected	O
by	O
treatment	O
and	O
remained	O
70	O
%	O
elevated	O
in	O
the	O
treated	O
group	O
(	O
Table	O
2	O
)	O
.	O

500	O
µ	O
##l	O
of	O
ace	B
##ton	I
##it	I
##ril	I
##e	I
was	O
added	O
and	O
mixed	O
on	O
a	O
v	O
##ortex	O
shake	O
##r	O
for	O
3	O
min	O
,	O
then	O
cent	O
##ri	O
##fu	O
##ged	O
at	O
10	O
000	O
rpm	O
/	O
min	O
for	O
10	O
min	O
.	O

4	O
-	O
,	O
7	O
-	O
,	O
14	O
-	O
and	O
17	B
-	I
h	I
##ydro	I
##xy	I
-	I
do	I
##cos	I
##ah	I
##ex	I
##aen	I
##oi	I
##c	I
acid	I
(	O
4	O
-	O
HD	O
##HA	O
,	O
7	O
-	O
HD	O
##HA	O
,	O
14	O
-	O
HD	O
##HA	O
,	O
17	O
-	O
HD	O
##HA	O
)	O
,	O

In	O
order	O
to	O
assess	O
its	O
clinical	O
useful	O
##ness	O
,	O
the	O
analytical	O
performance	O
of	O
the	O
N	O
##MR	O
-	O
based	O
beta	B
##ine	I
ass	O
##ay	O
was	O
evaluated	O
.	O

*	O
indicates	O
p	O
≤	O
0	O
.	O
05	O
between	O
Me	B
##OH	I
:	O
CH	O
##C	O
##l	O
_	O
3	O
pp	O
##t	O
versus	O
Me	B
##OH	I
:	O

The	O
major	O
u	O
##rina	O
##ry	O
ex	O
##cre	O
##tion	O
products	O
of	O
IT	O
##Cs	O
in	O
humans	O
are	O
N	B
-	I
ace	I
##ty	I
##l	I
c	I
##ys	I
##tein	I
##e	I
con	O
##ju	O
##gate	O
##s	O
,	O
which	O
are	O
rapidly	O
eliminated	O
in	O
urine	O
within	O
24	O
h	O
.	O

In	O
N	O
##MR	O
and	O
G	O
##C	O
-	O
MS	O
,	O
these	O
meta	O
##bol	O
##ites	O
clearly	O
include	O
sugar	O
##s	O
such	O
as	O
glucose	S
,	O
as	O
evidenced	O
by	O
the	O
PC	O
##A	O
loading	O
##s	O
in	O
and	O
.	O

Ser	O
##um	O
and	O
per	B
##ito	I
##nea	I
##l	I
dial	O
##ys	O
##ate	O
e	O
##ff	O
##lue	O
##nt	O
samples	O
from	O
per	B
##ito	I
##nea	I
##l	I
dial	O
##ys	O
##is	O
(	O
PD	O
)	O
patients	O
from	O
the	O
Han	O
##nov	O
##er	O
Medical	O
School	O
PD	O
out	O
##patient	O
clinic	O
were	O
obtained	O
after	O
written	O
informed	O
consent	O
according	O
to	O
the	O
declaration	O
of	O
Helsinki	O
,	O
and	O
local	O
ethics	O
board	O
approval	O
(	O
M	O
##H	O
##H	O
2014	O
/	O
66	O
##17	O
)	O
.	O

These	O
findings	O
are	O
also	O
in	O
accordance	O
with	O
our	O
previous	O
report	O
in	O
breast	O
cancer	O
,	O
where	O
an	O
increase	O
in	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
with	O
un	O
##sat	O
##ura	O
##ted	O
fatty	O
acid	O
composition	O
is	O
reported	O
.	O

The	O
level	O
of	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##lino	I
##si	I
##to	I
##l	I
(	O
P	O
##I	O
)	O
and	O
plasma	O
##log	O
##ens	O
did	O
not	O
differ	O
between	O
all	O
groups	O
(	O
F	O
,	O
G	O
)	O
.	O

In	O
general	O
,	O
cancer	O
cells	O
produce	O
abundant	O
p	B
##oly	I
##amine	I
##s	I
that	O
are	O
associated	O
with	O
increased	O
cell	O
proliferation	O
.	O

The	O
first	O
step	O
consists	O
of	O
the	O
im	O
##mers	O
##ion	O
of	O
the	O
tissue	O
in	O
the	O
formal	B
##in	I
solution	O
.	O

This	O
pattern	O
bears	O
an	O
interesting	O
resemblance	O
to	O
the	O
excess	O
of	O
u	O
##rina	O
##ry	O
in	B
##os	I
##ine	I
and	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
detected	O
in	O
F	O
##m	O
##r	O
##1	O
knock	O
-	O
out	O
mice	O
,	O
an	O
animal	O
model	O
of	O
fragile	O
-	O
X	O
syndrome	O
.	O

The	O
meta	O
##bol	O
##omi	O
##cs	O
data	O
set	O
contains	O
he	B
##x	I
##ose	I
,	O
14	O
amino	O
acids	O
,	O
free	O
car	B
##ni	I
##tine	I
(	O
C	O
##0	O
)	O
,	O
40	O
a	B
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
,	O
h	B
##ydro	I
##xy	I
##la	I
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
and	O
di	B
##car	I
##box	I
##yla	I
##cy	I
##l	I
##car	I
##ni	I
##tine	I
##s	I
,	O
15	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
##s	I
,	O
77	O
p	B
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
,	O
and	O
15	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
(	O
complete	O
list	O
of	O
the	O
anal	O
##ys	O
##ed	O
meta	O
##bol	O
##ites	O
is	O
shown	O
in	O
)	O
.	O

Gene	O
expression	O
level	O
in	O
in	O
##f	O
##lam	O
##ed	O
tissue	O
from	O
UC	O
patients	O
correlated	O
with	O
clinical	O
disease	O
activity	O
index	O
R	B
##I	I
in	O
case	O
of	O
AR	O
##G	O
##1	O
(	O
ρ	O
=	O
0	O
.	O
66	O
,	O
p	O
=	O
0	O
.	O
01	O
##9	O
,	O
n	O
=	O
12	O
)	O
,	O
AR	O
##G	O
##2	O
(	O
ρ	O
=	O
0	O
.	O
86	O
,	O
p	O
<	O
0	O
.	O
00	O
##1	O
,	O
n	O
=	O
12	O
)	O
,	O
DD	O
##A	O
##H1	O
(	O
ρ	O
=	O
0	O
.	O
75	O
,	O
p	O
=	O
0	O
.	O
00	O
##5	O
,	O
n	O
=	O
12	O
)	O
,	O
PR	O
##MT	O
##1	O
(	O
ρ	O
=	O
0	O
.	O
59	O
,	O
p	O
=	O
0	O
.	O
04	O
##3	O
,	O
n	O
=	O
12	O
)	O
,	O
and	O
PR	O
##MT	O
##2	O
(	O
ρ	O
=	O
0	O
.	O
64	O
,	O
p	O
=	O
0	O
.	O
02	O
##4	O
,	O
n	O
=	O
12	O
)	O
.	O

PC	O
was	O
visual	O
##ized	O
with	O
in	O
##cu	O
##bation	O
in	O
a	O
secondary	O
anti	O
-	O
rabbit	O
anti	O
##body	O
linked	O
to	O
horse	O
##rad	O
##ish	O
per	O
##ox	O
##idas	O
##e	O
(	O
H	O
##RP	O
)	O
(	O
The	O
##rm	O
##o	O
Scientific	O
,	O
Rock	O
##ford	O
,	O
IL	O
)	O
,	O
followed	O
by	O
reaction	O
with	O
ch	O
##em	O
##il	O
##umi	O
##nes	O
##cent	O
H	O
##RP	O
substrates	O
(	O
Super	O
##sign	O
##al	O
_	O
®	O
West	O
Du	O
##ra	O
Extended	O
Du	B
##ration	I
substrate	O
,	O
The	O
##rm	O
##o	O
Scientific	O
)	O
,	O
and	O
exposure	O
to	O
X	O
-	O
ray	O
film	O
.	O

Co	O
##mp	O
##aring	O
highest	O
and	O
lowest	O
te	O
##rt	O
##iles	O
of	O
select	O
K	O
##Y	O
##NA	O
/	O
T	O
,	O
B	O
)	O
Co	O
##mp	O
##aring	O
highest	O
and	O
lowest	O
te	O
##rt	O
##iles	O
K	B
##P	I
m	O
##RNA	O
expression	O
.	O

Ad	O
##sor	O
##ption	O
of	O
a	B
##bir	I
##ater	I
##one	I
to	O
glass	O
materials	O
was	O
addressed	O
by	O
using	O
p	B
##oly	I
##p	I
##rop	I
##yle	I
##ne	I
throughout	O
the	O
method	O
.	O

Most	O
s	B
##phi	I
##ngo	I
##lip	I
##ids	I
were	O
decreased	O
in	O
lean	O
NAS	O
##H	O
patients	O
as	O
compared	O
to	O
individuals	O
diagnosed	O
with	O
s	O
##te	O
##ato	O
##sis	O
,	O
with	O
the	O
most	O
significant	O
changes	O
being	O
observed	O
amongst	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
species	O
.	O

Specifically	O
,	O
the	O
median	O
P	O
##GE	O
-	O
M	O
was	O
6	O
.	O
7	O
##ng	O
/	O
mg	O
c	B
##rea	I
##tin	I
##ine	I
(	O
range	O
0	O
.	O
7	O
–	O
43	O
.	O
4	O
)	O
among	O
patients	O
with	O
lung	O
meta	O
##sta	O
##ses	O
,	O
which	O
was	O
significantly	O
higher	O
than	O
4	O
.	O
6	O
##ng	O
/	O
mg	O
c	B
##rea	I
##tin	I
##ine	I
(	O
range	O
0	O
.	O
7	O
–	O
26	O
.	O
8	O
)	O
in	O
patients	O
with	O
no	O
known	O
lung	O
meta	O
##sta	O
##ses	O
(	O
p	O
=	O
0	O
.	O
00	O
##3	O
)	O
and	O
4	O
.	O
2	O
##ng	O
/	O
mg	O
c	B
##rea	I
##tin	I
##ine	I
(	O
range	O
0	O
.	O
9	O
–	O
62	O
.	O
6	O
)	O
in	O
controls	O
(	O
p	O
<	O
0	O
.	O
00	O
##1	O
)	O
.	O

Un	O
##sat	O
##ura	O
##ted	O
lip	O
##ids	O
and	O
t	B
##rig	I
##ly	I
##cer	I
##ides	I
are	O
elevated	O
in	O
intact	O
tissues	O
of	O
c	O
##er	O
##vic	O
##al	O
car	O
##cin	O
##oma	O
during	O
tumor	O
##ige	O
##nes	O
##is	O
or	O
the	O
transition	O
from	O
non	O
##in	O
##vasive	O
to	O
invasive	O
c	O
##er	O
##vic	O
##al	O
cancer	O
.	O

We	O
examined	O
the	O
association	O
of	O
S	O
##1	O
##P	O
and	O
s	B
##phi	I
##ngo	I
##sin	I
##e	I
with	O
H	O
##LA	O
-	O
DB	O
##P	O
##1	O
*	O
03	O
##01	O
and	O
C	O
##Y	O
##SL	O
##TR	O
##1	O
-	O
63	O
##4	O
##C	O
>	O
T	O
p	O
##oly	O
##mor	O
##phism	O
in	O
89	O
as	O
##th	O
##matic	O
patients	O
comprising	O
of	O
44	O
patients	O
with	O
A	O
##ER	O
##D	O
and	O
45	O
with	O
AT	O
##A	O
(	O
Table	O
E	O
##3	O
)	O
.	O

We	O
placed	O
an	O
e	O
##pis	O
##oma	O
##l	O
copy	O
of	O
P	O
##f	O
##N	O
##M	O
##NA	O
##T	O
into	O
the	O
na	O
##d	O
##D	O
del	O
##eti	O
##on	O
strain	O
under	O
the	O
control	O
of	O
the	O
a	B
##rab	I
##ino	I
##se	I
promoter	O
,	O
which	O
is	O
induced	O
in	O
the	O
presence	O
of	O
a	B
##rab	I
##ino	I
##se	I
and	O
re	O
##pressed	O
in	O
the	O
presence	O
of	O
the	O
competitive	O
inhibitor	O
f	B
##uc	I
##ose	I
.	O

Therefore	O
,	O
it	O
was	O
decided	O
not	O
to	O
include	O
D	B
##MA	I
.	O

Do	B
##se	I
-	I
response	I
relationships	O
between	O
workplace	O
air	O
measures	O
of	O
ben	B
##zen	I
##e	I
and	O
u	O
##rina	O
##ry	O
ex	O
##cre	O
##tion	O
of	O
SP	O
##MA	O
have	O
been	O
reported	O
.	O

This	O
results	O
in	O
AD	B
##P	I
to	O
be	O
s	O
##hun	O
##ted	O
to	O
the	O
production	O
of	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
which	O
is	O
associated	O
with	O
an	O
increase	O
of	O
u	B
##ric	I
acid	I
,	O
as	O
observed	O
in	O
ST	O
##EM	O
##I	O
patients	O
.	O

We	O
previously	O
discussed	O
in	O
the	O
context	O
of	O
I	O
##B	O
##D	O
[	O
]	O
,	O
that	O
car	B
##ba	I
##my	I
##l	I
phosphate	I
s	O
##ynth	O
##eta	O
##se	O
(	O
CA	O
##D	O
)	O
-	O
rate	O
-	O
limiting	O
enzyme	O
for	O
the	O
u	B
##rea	I
cycle	O
-	O
was	O
identified	O
as	O
negative	O
regulator	O
of	O
NO	O
##D	O
##2	O
and	O
might	O
be	O
a	O
p	O
##har	O
##ma	O
##co	O
##log	O
##ic	O
target	O
for	O
CD	O
the	O
##rap	O
##ies	O
[	O
]	O
.	O

That	O
all	O
the	O
patients	O
were	O
well	O
-	O
controlled	O
under	O
met	B
##form	I
##in	I
therapy	O
could	O
also	O
affect	O
other	O
results	O
of	O
the	O
study	O
.	O

Two	O
patients	O
were	O
reported	O
with	O
serious	O
adverse	O
events	O
(	O
SA	O
##Es	O
)	O
,	O
one	O
of	O
whom	O
was	O
a	O
screen	O
failure	O
who	O
was	O
reported	O
with	O
SA	O
##Es	O
of	O
psychiatric	O
disorder	O
and	O
con	O
##vu	O
##ls	O
##ions	O
,	O
and	O
the	O
other	O
(	B
p	B
##ali	I
##per	I
##ido	I
##ne	I
co	O
##hor	O
##t	O
)	O
was	O
reported	O
with	O
an	O
event	O
of	O
ps	O
##ych	O
##otic	O
disorder	O
2	O
days	O
after	O
the	O
completion	O
of	O
the	O
study	O
.	O

Regardless	O
,	O
speed	O
,	O
efficiency	O
,	O
and	O
the	O
low	O
induced	O
variance	O
due	O
to	O
sample	O
handling	O
make	O
Me	B
##OH	I
:	O

Based	O
on	O
this	O
study	O
,	O
one	O
could	O
s	O
##pec	O
##ulate	O
that	O
mini	O
##mizing	O
the	O
formation	O
of	O
cat	B
##ech	I
##ol	I
est	I
##rogen	I
q	I
##uin	I
##ones	I
and	O
/	O
or	O
their	O
reaction	O
with	O
DNA	O
(	O
,	O
,	O
,	O
,	O
,	O
)	O
should	O
reduce	O
the	O
risk	O
of	O
developing	O
NHL	O
.	O

Thus	O
,	O
it	O
cannot	O
be	O
ruled	O
out	O
that	O
an	O
increased	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
up	O
##take	O
by	O
other	O
,	O
non	O
-	O
muscle	O
tissues	O
under	O
##lay	O
the	O
observed	O
decrease	O
in	O
resting	O
u	O
##rina	O
##ry	O
h	B
##y	I
##pox	I
##ant	I
##hine	I
concentration	O
.	O

Four	O
of	O
the	O
11	O
“	O
new	O
”	O
B	O
##MI	O
-	O
associated	O
meta	O
##bol	O
##ites	O
were	O
amino	O
acids	O
:	O
2	B
-	I
h	I
##ydro	I
##xy	I
##but	I
##yra	I
##te	I
(	O
discussed	O
above	O
)	O
,	O
alpha	B
-	I
h	I
##ydro	I
##xy	I
##is	I
##ova	I
##ler	I
##ate	I
,	O
n	B
-	I
ace	I
##ty	I
##l	I
##gly	I
##cine	I
,	O
and	O
his	B
##ti	I
##dine	I
.	O

Therefore	O
,	O
the	O
diagnostic	O
potential	O
of	O
g	B
##lut	I
##ama	I
##te	I
as	O
a	O
single	O
marker	O
was	O
further	O
evaluated	O
by	O
a	O
R	O
##OC	O
curve	O
.	O

Then	O
,	O
the	O
plate	O
was	O
washed	O
with	O
0	O
.	O
7	O
m	O
##L	O
of	O
2	O
%	O
a	O
##que	O
##ous	O
form	B
##ic	I
acid	I
,	O
which	O
was	O
discarded	O
.	O

The	O
blank	O
controls	O
showed	O
no	O
peaks	O
co	O
-	O
el	O
##uti	O
##ng	O
with	O
a	B
##bir	I
##ater	I
##one	I
and	O
D	B
_	I
4	I
-	I
a	I
##bir	I
##ater	I
##one	I
.	O

Alternatively	O
,	O
the	O
negative	O
relationship	O
between	O
the	O
levels	O
of	O
these	O
meta	O
##bol	O
##ites	O
and	O
G	O
##F	O
##R	O
may	O
con	O
##ce	O
##iva	O
##bly	O
be	O
a	O
consequence	O
of	O
their	O
opposite	O
regulation	O
by	O
the	O
H	O
##F	O
path	O
##op	O
##hy	O
##sio	O
##logy	O
,	O
which	O
most	O
likely	O
also	O
explains	O
the	O
negative	O
correlation	O
##s	O
of	O
both	O
c	B
##it	I
##rate	I
and	O
t	B
##yr	I
##os	I
##ine	I
with	O
various	O
serum	O
lip	O
##ids	O
,	O
B	O
##MI	O
,	O
and	O
MA	O
##P	O
,	O
which	O
are	O
frequently	O
decreased	O
in	O
H	O
##F	O
.	O

It	O
has	O
already	O
been	O
reported	O
that	O
amino	O
acids	O
such	O
as	O
se	B
##rine	I
,	O
g	B
##lut	I
##amine	I
,	O
as	B
##par	I
##tic	I
acid	I
,	O
and	O
pro	B
##line	I
metabolism	O
play	O
an	O
important	O
role	O
in	O
cancer	O
progression	O
and	O
contribute	O
to	O
tumor	O
metabolic	O
re	O
##p	O
##rog	O
##ram	O
##ming	O
.	O

Our	O
study	O
was	O
designed	O
to	O
compare	O
levels	O
of	O
o	B
##xy	I
##ster	I
##ols	I
before	O
and	O
after	O
tumor	O
removal	O
.	O

Another	O
investigation	O
was	O
for	O
a	O
possible	O
association	O
between	O
Δ	O
##UP	O
##DR	O
##S	O
##2	O
+	O
3	O
and	O
the	O
CS	O
##F	O
concentration	O
of	O
the	O
do	B
##pa	I
##mine	I
meta	O
##bol	O
##ite	O
ho	B
##mo	I
##vani	I
##lla	I
##te	I
.	O

In	O
contrast	O
,	O
R	O
##R	O
##MS	O
patients	O
had	O
significantly	O
elevated	O
levels	O
of	O
these	O
molecules	O
,	O
compared	O
to	O
controls	O
and	O
levels	O
tended	O
to	O
decrease	O
with	O
advancing	O
disease	O
duration	S
.	O

This	O
is	O
supported	O
by	O
the	O
fact	O
that	O
no	O
significant	O
differences	O
were	O
observed	O
in	O
total	O
ch	B
##ole	I
##ster	I
##ol	I
,	O
L	B
##D	I
##L	I
-	I
ch	I
##ole	I
##ster	I
##ol	I
,	O
HD	B
##L	I
-	I
ch	I
##ole	I
##ster	I
##ol	I
,	O
or	O
t	B
##rig	I
##ly	I
##cer	I
##ide	I
concentrations	O
and	O
c	O
##lar	O
##ifies	O
why	O
a	O
standard	O
lip	O
##id	O
panel	O
is	O
unable	O
to	O
disc	O
##rim	O
##inate	O
between	O
these	O
three	O
diseases	O
.	O

Prior	O
to	O
the	O
analysis	O
,	O
a	O
volume	O
of	O
400	O
μ	O
##L	O
of	O
met	B
##han	I
##ol	I
was	O
added	O
to	O
100	O
μ	O
##L	O
of	O
plasma	O
.	O

The	O
mean	O
±	O
SD	O
of	O
total	O
PC	O
##D	O
##D	O
/	O
PC	O
##DF	O
body	O
burden	O
##s	O
was	O
13	O
.	O
6	O
±	O
5	O
.	O
1	O
p	B
##g	I
WHO	O
-	O
T	O
##E	O
##Q	O
/	O
g	O
lip	O
##id	O
,	O
of	O
which	O
2	O
.	O
9	O
p	B
##g	I
was	O
due	O
to	O
di	O
##ox	O
##in	O
-	O
like	O
PC	O
##B	O
##s	O
.	O

In	O
addition	O
,	O
c	O
##i	O
##P	O
##TE	O
##C	O
were	O
also	O
exposed	O
for	O
48	O
h	O
to	O
1	O
m	O
##M	O
1	B
-	I
met	I
##hyl	I
##his	I
##ti	I
##dine	I
,	O
3	B
-	I
met	I
##hyl	I
##his	I
##ti	I
##dine	I
(	O
both	O
as	O
negative	O
control	O
)	O
or	O
in	B
##dox	I
##yl	I
su	I
##l	I
##phate	I
as	O
a	O
positive	O
control	O
.	O

Unlike	O
normal	O
pool	O
##ed	O
human	O
serum	O
,	O
Me	B
##OH	I
pp	O
##t	O
+	O
U	O
##F	O
was	O
not	O
a	O
clearly	O
superior	O
method	O
for	O
mac	O
##rom	O
##ole	O
##cule	O
removal	O
for	O
pool	O
##ed	O
human	O
serum	O
that	O
was	O
acquired	O
from	O
se	O
##psis	O
patients	O
.	O

Control	O
samples	O
from	O
individuals	O
not	O
exposed	O
to	O
any	O
as	B
##pi	I
##rin	I
,	O
NSA	O
##ID	O
,	O
or	O
anti	O
-	O
plate	O
##let	O
drug	O
for	O
the	O
previous	O
7	O
days	O
were	O
run	O
using	O
the	O
same	O
re	O
##age	O
##nts	O
and	O
methodology	O
within	O
24	O
h	O
of	O
study	O
subject	O
testing	O
.	O

Some	O
high	O
molecular	O
weight	O
meta	O
##bol	O
##ites	O
such	O
as	O
lip	O
##op	O
##rote	O
##ins	O
,	O
fatty	O
acids	O
and	O
p	B
##hos	I
##ph	I
##oli	I
##pid	I
##s	I
were	O
also	O
observed	O
.	O

Our	O
sample	O
of	O
the	O
general	O
Taiwanese	O
population	O
provided	O
some	O
evidence	O
of	O
decreasing	O
DE	O
##HP	O
and	O
DB	B
##P	I
levels	O
after	O
enacted	O
restrictions	O
and	O
regulations	O
.	O

L	O
##C	O
-	O
P	O
##B	O
–	O
MS	O
/	O
MS	O
of	O
e	O
P	B
##E	I
17	I
:	I
0	I
_	I
22	I
:	I
4	I
(	O
R	O
##T	O
:	O
5	O
.	O
2	O
min	O
,	O
m	O
/	O

AL	O
##T	O
,	O
al	O
##ani	O
##ne	O
amino	O
##tra	O
##ns	O
##fer	O
##ase	O
;	O
AS	O
##T	O
,	O
as	O
##par	O
##tate	O
amino	O
##tra	O
##ns	O
##fer	O
##ase	O
;	O
B	O
##MI	O
,	O
body	O
mass	O
index	O
;	O
F	O
:	O
female	O
;	O
γ	B
-	I
GT	I
,	O
gamma	O
-	O
g	O
##lut	O
##am	O
##yl	O
transfer	O
##ase	O
;	O
m	O
:	O
male	O
;	O
N	O
##AF	O
##L	O
,	O
non	O
##al	O
##co	O
##hol	O
##ic	O
fatty	O
liver	O
;	O
N	O
##AF	O
##LD	O
,	O
non	O
##al	O
##co	O
##hol	O
##ic	O
fatty	O
liver	O
disease	O
;	O
NAS	O
##H	O
,	O
non	O
##al	O
##co	O
##hol	O
##ic	O
s	O
##te	O
##ato	O
##he	O
##pa	O
##titis	O
.	O

However	O
,	O
no	O
differential	O
meta	O
##bol	O
##ites	O
in	O
serum	O
and	O
P	O
##BM	O
##Cs	O
were	O
statistical	O
##ly	O
related	O
with	O
F	O
##E	O
##V	O
##1	O
%	O
or	O
F	O
##E	O
##V	O
##1	O
/	O
F	O
##VC	O
%	O
except	O
for	O
is	B
##ole	I
##uc	I
##ine	I
in	O
P	O
##BM	O
##Cs	O
that	O
positively	O
correlated	O
to	O
F	O
##VC	O
%	O
(	O
r	O
=	O
0	O
.	O
37	O
;	O
P	O
=	O
0	O
.	O
04	O
##6	O
)	O
.	O

The	O
re	O
##current	O
A	B
##F	I
group	O
was	O
defined	O
as	O
those	O
with	O
documented	O
A	B
##F	I
on	O
the	O
12	O
-	O
lead	O
EC	O
##G	O
,	O
and	O
the	O
sin	O
##us	O
rhythm	O
group	O
(	O
non	O
-	O
re	O
##current	O
A	B
##F	I
group	O
)	O
was	O
defined	O
as	O
those	O
on	O
sin	O
##us	O
rhythm	O
at	O
the	O
1	O
-	O
month	O
follow	O
-	O
up	O
.	O

Val	B
##ine	I
and	O
is	B
##ole	I
##uc	I
##ine	I
are	O
two	O
of	O
the	O
main	O
amino	O
acids	O
in	O
case	B
##in	I
and	O
their	O
concentrations	O
increase	O
during	O
ripe	O
##ning	O
.	O

A	O
reduction	O
of	O
levels	O
of	O
T	O
##AG	O
##s	O
with	O
long	O
chain	O
FA	O
##s	O
in	O
patients	O
with	O
high	O
para	O
##si	O
##ta	O
##emia	O
could	O
also	O
result	O
from	O
increased	O
consumption	O
of	O
these	O
FA	O
##s	O
in	O
the	O
a	B
##cy	I
##l	I
-	I
car	I
##ni	I
##tine	I
pathway	O
indicating	O
a	O
p	O
##au	O
##city	O
of	O
the	O
substrates	O
needed	O
for	O
beta	O
-	O
oxidation	O
in	O
the	O
high	O
para	O
##si	O
##ta	O
##em	O
##ic	O
patients	O
.	O

A	O
possible	O
explanation	O
would	O
be	O
that	O
H	O
##B	O
##V	O
,	O
alcohol	O
consumption	O
,	O
smoking	O
and	O
presence	O
of	O
Mets	O
induced	O
changes	O
in	O
gut	O
flora	O
composition	O
and	O
normal	O
function	O
[	O
–	O
]	O
,	O
which	O
consequently	O
affected	O
the	O
generation	O
of	O
T	B
##MA	I
##O	I
.	O

Cal	O
##ib	O
##ration	O
curves	O
were	O
constructed	O
using	O
1	O
ng	O
/	O
µ	O
##L	O
[	O
_	O
13	O
C	O
_	O
3	O
]	O
3	O
-	O
HP	O
##MA	O
,	O
1	O
–	O
5	O
ng	O
/	O
µ	O
##L	O
3	O
-	O
HP	O
##MA	O
,	O
and	O
1	O
ng	O
of	O
N	B
-	I
ace	I
##ty	I
##l	I
-	I
[	I
_	I
2	I
H	I
_	I
3	I
]	I
-	I
S	I
-	I
(	I
3	I
-	I
h	I
##ydro	I
##xy	I
##p	I
##rop	I
##yl	I
-	I
1	I
-	I
met	I
##hyl	I
)	I
-	I
l	I
-	I
c	I
##ys	I
##tein	I
##e	I
.	O

The	O
amino	O
acid	O
meta	O
##bol	O
##ite	O
sa	B
##rc	I
##os	I
##ine	I
,	O
an	O
N	O
-	O
met	O
##hyl	O
derivative	O
of	O
g	B
##ly	I
##cine	I
,	O
fit	O
these	O
criteria	O
.	O

Con	O
##cent	O
##rations	O
of	O
the	O
identified	O
bucket	O
##s	O
The	O
mean	O
±	O
standard	O
de	O
##viation	O
of	O
the	O
concentration	O
of	O
the	O
identified	O
bucket	O
##s	O
are	O
given	O
in	O
mm	O
##ol	O
/	O
mm	O
##ol	O
u	O
##rina	O
##ry	O
c	B
##rea	I
##tin	I
##ine	I
for	O
each	O
groups	O
of	O
patients	O
(	O
a	O
##A	O
##IP	O
and	O
PC	O
##T	O
)	O
for	O
the	O
discovery	O
(	O
2014	O
)	O
and	O
the	O
valid	O
##ation	O
(	O
2015	O
)	O

(	O
1	O
.	O
07	O
±	O
1	O
.	O
57	O
and	O
1	O
.	O
06	O
±	O
1	O
.	O
31	O
vs	O
0	O
.	O
53	O
±	O
0	O
.	O
78	O
and	O
0	O
.	O
61	O
±	O
1	O
.	O
11	O
)	O
for	O
Lac	B
##to	I
##ba	I
##ci	I
##llus	I
/	O
En	O
##tero	O
##co	O
##cc	O
##us	O
s	O
##pp	O
.	O

Only	O
three	O
meta	O
##bol	O
##ites	O
(	B
ch	B
##olin	I
##e	I
,	O
v	B
##ali	I
##ne	I
,	O
and	O
c	O
##rea	O
##tin	O
##ine	O
)	O
passed	O
this	O
filter	O
,	O
and	O
the	O
p	O
-	O
values	O
,	O
fold	O
changes	O
,	O
N	O
##MR	O
chemical	O
shifts	O
and	O
multi	O
##p	O
##licit	O
##ies	O
for	O
these	O
three	O
meta	O
##bol	O
##ites	O
are	O
listed	O
in	O
.	O

There	O
was	O
a	O
significant	O
increase	O
in	O
serum	O
saturated	O
(	B
my	B
##rist	I
##ic	I
,	O
cap	O
##ryl	O
##ic	O
,	O
palm	B
##itic	I
,	O
palm	B
##ito	I
##le	I
##ic	I
,	O
o	O
##le	O
##ic	O
and	O
e	B
##ico	I
##san	I
##oi	I
##c	I
)	O
and	O
un	O
##sat	O
##ura	O
##ted	O
(	O
l	O
##ino	O
##le	O
##ic	O
,	O
l	O
##ino	O
##len	O
##ic	O
,	O
gamma	O
-	O
l	O
##ino	O
##len	O
##ic	O
and	O
a	O
##rac	O
##hn	O
##ido	O
##nic	O
)	O
fatty	O
acids	O
post	O
-	O
r	O
##if	O
##ax	O
##im	O
##in	O
.	O

The	O
mixture	O
was	O
pre	O
##in	O
##cu	O
##bate	O
##d	O
with	O
al	B
##ame	I
##thi	I
##cin	I
(	O
50	O
μ	O
##g	O
/	O
mg	O
protein	O
)	O
on	O
ice	O
for	O
15	O
min	O
.	O

2	O
##G	O
,	O
presented	O
on	O
the	O
left	O
is	O
a	O
graph	O
of	O
the	O
relationship	O
between	O
fast	O
##ing	O
C	B
##14	I
:	I
2	I
and	O
the	O
fast	O
##ing	O
Ra	O
##FF	O
##A	O
(	O
taken	O
at	O
−	O
##2	O
##h	O
)	O
.	O

The	O
E	O
##L	O
##IS	O
##A	O
kit	O
,	O
which	O
is	O
a	O
combined	O
platform	O
for	O
AD	B
##MA	I
and	O
a	B
##rg	I
##ini	I
##ne	I
,	O
declares	O
cross	O
react	O
##ivity	O
(	O
%	O
)	O
of	O
AD	B
##MA	I
with	O
a	B
##rg	I
##ini	I
##ne	I
(	O
0	O
.	O
03	O
)	O
,	O
SD	O
##MA	O
(	O
0	O
.	O
05	O
)	O
and	O
L	B
-	I
N	I
##MM	I
##A	I
(	O
1	O
.	O
93	O
)	O
and	O
of	O
a	B
##rg	I
##ini	I
##ne	I
with	O
AD	B
##MA	I
(	O
<	O
0	O
.	O
37	O
)	O
,	O
ho	B
##mo	I
##ar	I
##gin	I
##ine	I
(	O
2	O
.	O
92	O
)	O
and	O
SD	O
##MA	O
(	O
0	O
.	O
8	O
)	O
.	O

L	B
##ys	I
##o	I
##P	I
##E	I
(	I
18	I
:	I
0	I
)	I
and	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dic	I
acid	I
(	I
l	I
##ys	I
##o	I
##PA	I
)	I
(	I
20	I
:	I
0	I
)	I
were	O
higher	O
in	O
serum	O
than	O
plasma	O
.	O

HC	O
##A	O
positively	O
correlated	O
with	O
49	O
meta	O
##bol	O
##ites	O
at	O
F	O
##DR	O
p	O
<	O
0	O
.	O
05	O
,	O
including	O
se	B
##do	I
##he	I
##pt	I
##ulos	I
##e	I
7	I
-	I
phosphate	I
(	O
S	O
##7	O
##P	O
;	O
r	O
=	O
0	O
.	O
43	O
;	O
p	O
=	O
0	O
.	O
02	O
##8	O
)	O
,	O
in	B
##os	I
##ito	I
##l	I
(	O
r	O
=	O
0	O
.	O
41	O
;	O
p	O
=	O
0	O
.	O
03	O
##5	O
)	O
,	O
car	B
##ba	I
##mo	I
##yl	I
phosphate	I
(	O
r	O
=	O
0	O
.	O
40	O
;	O
p	O
=	O
0	O
.	O
03	O
##6	O
)	O
.	O

3	B
-	I
(	I
N	I
-	I
ace	I
##ty	I
##l	I
##cy	I
##stein	I
##yl	I
)	I
p	I
##hen	I
##ant	I
##hren	I
##e	I
(	O
14	O
)	O
.	O

In	O
addition	O
,	O
plasma	O
c	B
##rea	I
##tine	I
-	I
a	O
nitrogen	O
##ous	O
compound	O
synthesized	O
from	O
the	O
amino	O
acids	O
a	O
##rg	O
##ini	O
##ne	O
,	O
g	B
##ly	I
##cine	I
,	O
and	O
met	B
##hi	I
##oni	I
##ne	I
-	I
was	O
elevated	O
when	O
sleep	O
was	O
cu	O
##rta	O
##iled	O
.	O

In	O
other	O
analyses	O
of	O
ST	O
##EM	O
##I	O
patients	O
,	O
l	B
##ys	I
##op	I
##hos	I
##pha	I
##ti	I
##dy	I
##l	I
##cho	I
##lines	I
,	O
ca	B
##ffe	I
##ine	I
,	O
g	O
##ly	O
##co	O
##lysis	O
,	O
try	B
##pt	I
##op	I
##han	I
and	O
s	B
##phi	I
##ngo	I
##my	I
##elin	I
metabolism	O
and	O
minerals	O
were	O
found	O
to	O
be	O
disrupted	O
compared	O
to	O
healthy	O
controls	O
.	O

Dec	O
##reased	O
G	O
##S	O
##K	O
##3	O
##β	O
_	O
t	O
##yr	O
##21	O
##6	O
and	O
increased	O
G	B
##S	I
##K	I
##3	I
##β	I
_	I
se	I
##r	I
##9	I
levels	O
have	O
been	O
reported	O
in	O
c	O
##er	O
##vic	O
##al	O
cancer	O
tissues	O
,	O
which	O
indicates	O
that	O
activated	B
G	I
##S	I
##K	I
##3	I
##β	I
may	O
play	O
some	O
roles	O
in	O
the	O
in	O
##hibition	O
of	O
tumor	O
##ige	O
##nes	O
##is	O
.	O

Am	B
##mon	I
##ium	I
h	I
##ydro	I
##xi	I
##de	I
(	O
NH	O
_	O
4	O
OH	O
)	O
,	O
form	B
##ic	I
acid	I
(	O
FA	O
)	O
and	O
ace	B
##tic	I
acid	I
(	O
H	O
##OA	O
##c	O
)	O
were	O
obtained	O
from	O
Fisher	O
Scientific	O
(	O
Springfield	O
,	O
NJ	O
,	O
USA	O
)	O
.	O

IL	O
-	O
13	O
level	O
to	O
3	B
-	I
h	I
##y	I
##gro	I
##xy	I
##but	I
##yric	I
acid	I
(	O
r	O
=	O
0	O
.	O
59	O
##3	O
;	O
P	O
=	O
0	O
.	O
02	O
##5	O
)	O
.	O

Pre	O
##tre	O
##at	O
##ment	O
concentrations	O
of	O
two	O
bi	O
##le	O
acids	O
,	O
CD	O
##CA	O
and	O
DC	O
##A	O
,	O
were	O
positively	O
correlated	O
with	O
on	O
-	O
treatment	O
plasma	O
si	B
##m	I
##vas	I
##tat	I
##in	I
acid	I
concentrations	O
in	O
the	O
F	O
##R	O
subjects	O
.	O

Health	O
##y	O
individuals	O
taking	O
as	B
##pi	I
##rin	I
typically	O
have	O
11	B
-	I
de	I
##hy	I
##dr	I
##o	I
-	I
T	I
##x	I
##B	I
_	I
2	I
concentrations	O
<	O
500	O
p	O
##g	O
/	O
mg	O
c	B
##rea	I
##tin	I
##ine	I
when	O
measured	O
by	O
these	O
methods	O
.	O

PR	O
##MT	O
,	O
a	O
##rg	O
##ini	O
##ne	O
N	O
-	O
met	O
##hyl	O
##tra	O
##ns	O
##fer	O
##ase	O
;	O
PM	O
,	O
plasma	O
membrane	O
;	O
CA	O
##T	O
##s	O
,	O
cat	O
##ion	O
##ic	O
amino	O
acid	O
transport	O
##ers	O
;	O
DD	O
##A	O
##H	O
,	O
dim	O
##eth	O
##yla	O
##rg	O
##ini	O
##ne	O
dim	O
##eth	O
##yla	O
##min	O
##oh	O
##ydro	O
##lase	O
;	O
D	B
##MA	I
,	O
dim	B
##eth	I
##yla	I
##mine	I
;	O
AD	B
##MA	I
,	O
as	B
##ym	I
##metric	I
dim	I
##eth	I
##yla	I
##rg	I
##ini	I
##ne	I
;	O
SD	O
##MA	O
,	O
symmetric	B
dim	I
##eth	I
##yla	I
##rg	I
##ini	I
##ne	I
;	O
NO	O
##S	O
,	O
ni	B
##tric	I
oxide	I
s	O
##ynth	O
##ase	O
;	O
NO	O
,	O
ni	B
##tric	I
oxide	I
;	O
AR	O
##G	O
,	O
a	O
##rg	O
##inas	O
##e	O
;	O
O	O
##DC	O
,	O
or	O
##ni	O
##thin	O
##e	O
de	O
##car	O
##box	O
##yla	O
##se	O
;	O
protein	O
-	O
CH	O
_	O
3	O
,	O
met	O
##hyl	O
##ated	O
proteins	O
.	O

From	O
cu	O
##rs	O
##ory	O
examination	O
of	O
the	O
metabolic	O
profile	O
,	O
presence	O
and	O
identification	O
of	O
E	O
_	O
1	O
(	B
E	I
_	I
2	I
)	I
-	I
9	I
-	I
N	I
-	I
Ad	I
##e	I
in	O
the	O
breast	O
tissue	O
extract	O
##s	O
appears	O
to	O
be	O
most	O
significant	O
.	O

The	O
decreased	O
concentration	O
of	O
other	O
compounds	O
(	B
th	B
##re	I
##oni	I
##ne	I
,	O
v	B
##ali	I
##ne	I
,	O
a	B
##rg	I
##ini	I
##ne	I
,	O
g	B
##lut	I
##ama	I
##te	I
,	O
met	B
##han	I
##ol	I
)	O
is	O
primarily	O
associated	O
with	O
organ	O
d	O
##ys	O
##function	O
and	O
/	O
or	O
higher	O
u	O
##til	O
##ization	O
of	O
these	O
meta	O
##bol	O
##ites	O
in	O
the	O
disease	O
conditions	O
[	O
-	O
]	O
.	O

U	B
##ric	I
acid	I
,	O
another	O
pu	B
##rine	I
meta	O
##bol	O
##ite	O
,	O
showed	O
higher	O
levels	O
in	O
C	O
##LL	O
and	O
M	O
##M	O
,	O
and	O
lower	O
in	O
DL	O
##BC	O
##L	O
and	O
H	B
##L	I
when	O
compared	O
to	O
the	O
controls	O
.	O

For	O
instance	O
,	O
e	B
##ico	I
##san	I
##oids	I
,	O
signaling	O
molecules	O
participating	O
in	O
the	O
initiation	O
of	O
the	O
early	O
events	O
in	O
acute	O
inflammation	O
,	O
are	O
derived	O
from	O
oxidation	O
of	O
20	O
carbon	O
fatty	O
acids	O
(	O
Le	O
##i	O
et	O
al	O
.	O
)	O
.	O

Third	O
,	O
the	O
ratio	O
of	O
many	O
meta	O
##bol	O
##ites	O
to	O
ch	B
##olin	I
##e	I
was	O
low	O
in	O
the	O
pre	O
-	O
pro	O
##state	O
##ct	O
##omy	O
u	O
##E	O
##Vs	O
compared	O
to	O
other	O
groups	O
,	O
which	O
suggests	O
increased	O
ch	B
##olin	I
##e	I
levels	O
.	O

The	O
di	O
##lution	O
steps	O
en	O
##tail	O
##ed	O
by	O
N	O
##MR	O
sample	O
preparation	O
(	O
in	O
particular	O
,	O
addition	O
of	O
water	O
,	O
phosphate	S
buffer	O
and	O
de	O
##uter	O
##ium	O
oxide	O
)	O
were	O
taken	O
into	O
account	O
and	O
the	O
meta	O
##bol	O
##ite	O
concentrations	O
included	O
here	O
##in	O
are	O
representative	O
of	O
the	O
concentration	O
in	O
the	O
original	O
serum	O
samples	O
.	O

The	O
plasma	B
-	I
sa	I
##line	I
mixture	O
was	O
left	O
to	O
stand	O
at	O
room	O
temperature	O
for	O
10	O
min	O
and	O
was	O
then	O
cent	O
##ri	O
##fu	O
##ged	O
at	O
10	O
,	O
000	O
rpm	O
for	O
10	O
min	O
.	O

Of	O
the	O
media	O
tested	O
,	O
2	O
%	O
ma	O
##lt	O
extract	O
a	O
##gar	O
was	O
the	O
best	O
medium	O
for	O
the	O
production	O
of	O
to	B
##xin	I
.	O

The	O
ch	O
##em	O
##otherapy	O
regime	O
##ns	O
were	O
drawn	O
up	O
according	O
to	O
the	O
neo	O
##ad	O
##ju	O
##vant	O
/	O
ad	O
##ju	O
##vant	O
therapy	O
regime	O
##ns	O
of	O
NC	O
##C	O
##N	O
guidelines	O
breast	O
cancer	O
version	O
2	O
.	O
2013	O
including	O
(	O
regime	O
##n	O
I	O
)	O
:	O
EC	O
-	O
T	O
(	B
do	B
##x	I
##or	I
##ubi	I
##cin	I
90	O
mg	O
/	O
m	O
_	O
2	O
plus	O
c	O
##y	O
##c	O
##lop	O
##hos	O
##pha	O
##mi	O
##de	O
600	O
mg	O
/	O
m	O
_	O
2	O
IV	O
day	O
1	O
every	O
21	O
days	O
for	O
4	O
cycles	O
followed	O
by	O
do	O
##ce	O
##ta	O
##xe	O
##l	O

Super	O
SE	O
##SI	O
uses	O
a	O
flow	O
of	O
clean	O
nitrogen	O
(	O
filtered	O
through	O
a	O
built	O
-	O
in	O
activated	S
charcoal	O
filter	O
)	O
to	O
sweep	O
the	O
ion	O
##izer	O
when	O
there	O
is	O
no	O
sample	O
input	O
.	O

The	O
altered	O
ch	B
##olin	I
##e	I
metabolism	O
we	O
observed	O
is	O
possibly	O
due	O
to	O
an	O
over	O
##ex	O
##press	O
##ion	O
of	O
Ch	O
##k	O
-	O
α	O
.	O

We	O
assessed	O
vitamin	O
B	O
-	O
12	O
and	O
f	B
##olate	I
status	O
,	O
peripheral	O
nerve	O
conduct	O
##ivity	O
,	O
and	O
targeted	O
and	O
un	O
##tar	O
##get	O
##ed	O
meta	O
##bol	O
##omi	O
##cs	O
profiles	O
at	O
base	O
##line	O
and	O
4	O
m	O
##o	O
after	O
injection	O
.	O

Co	O
##mp	O
##aris	O
##on	O
of	O
the	O
est	B
##rogen	I
metabolic	O
profiles	O
of	O
these	O
two	O
groups	O
clearly	O
shows	O
that	O
the	O
median	O
4	O
-	O
O	O
##CH	O
_	O
3	O
E	O
_	O
1	O
(	O
E	O
_	O
2	O
)	O
and	O
4	O
-	O
OH	O
##E	O
_	O
1	O
(	B
E	I
_	I
2	I
)	I
-	I
th	I
##iol	I
con	O
##ju	O
##gate	O
(	O
G	O
##S	O
##H	O
,	O
Cy	O
##s	O
,	O
N	O
##A	O
##c	O
##C	O
##ys	O
)	O
values	O
were	O
higher	O
in	O
healthy	O
controls	O
compared	O
with	O
NHL	O
cases	O
.	O

